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Basal Insulin peglispro (BIL) demonstrates hepato-preferential
action vs insulin Glargine (GL) in patients with type 1 diabetes
mellitus
S. Mudaliar1; R.R. Henry1; T.P. Ciaraldi1,2; D. A. Armstrong1;
P. M. Burke1; J. H. Pettus2; P. Garhyan3; S. L. Choi4; S.J. Jacober3;
M. P. Knadler3; E. C. Q. Lam4; M.J. Prince3, N. Bose2, N.K. Porksen3,
H. Linnebjerg3
1VA San Diego Healthcare System, San Diego, 2University of California
San Diego, USA, 3Eli Lilly and Company, Indianapolis, USA, 4Lilly-
National University of Singapore Centre for Clinical Pharmacology,
Singapore.
Background and aims: BIL, a novel, long-acting basal insulin analog,
has previously been shown to demonstrate hepato-preferential action in
healthy subjects. This analysis evaluated the effects of therapeutic con-
centrations of BIL and GL and supratherapeutic concentrations of BIL on
liver (endogenous glucose production [EGP]) and peripheral tissues (glu-
cose disposal rate [GDR] and lipolysis) in patients with T1DM.
Materials and methods: This was a randomised, open-label, 4-period,
crossover study in patients with T1DM (n=14; 22 - 48 years). Each
patient had 4 euglycemic clamp assessments of 8-10 hours duration with
primed, continuous infusions of BIL (15.3 and 74.1 mU/min) and GL (10
and 20 mU/m2/min). D-[3-3H]-glucose infusion was administered to as-
sess EGP and GDR.To correct for differences in insulin receptor binding,
equivalent human insulin concentrations (EHIC) were calculated by di-
viding each insulin concentration by its Ki (binding constant) and multi-
plying by the Ki of human insulin.
Results:At both low and high doses, BIL showed similar effects on EGP
suppression (endpoint EGP) compared toGL, but had an attenuated effect
on GDR (endpoint GDR) (Table). Lipolysis, assessed by serum concen-
trations of free fatty acids (FFA) and glycerol, was suppressed at low and
high GL doses but only at the high BIL dose (Table).
Conclusion: BIL has similar hepatic activity (EGP suppression) but less
peripheral activity (GDR stimulation, lipolysis suppression) at clinically
relevant concentrations compared to GL, confirming hepato-preferential
action.
Clinical Trial Registration Number: NCT01654380
Supported by: Eli Lilly and Company
2
Reduced intra-subject variability of Basal Insulin peglispro (BIL)
compared to insulin Glargine (GL) in patients with type 1 diabetes
mellitus
E. Lam1, P. Garhyan2, H. Linnebjerg2, S. Choi1, M.P. Knadler2,
V.P. Sinha3, B.M. Sassenfeld4, L. Nosek4, T. Heise4;
1Lilly-NUS Centre for Clinical Pharmacology Pte Ltd, Singapore, 2Eli
Lilly and Company, Indianapolis, USA, 3Food and Drug Administration,
Silver Spring, USA, 4Profil, Neuss, Germany.
Background and aims:BIL is a novel PEGylated basal insulin that has a
flat pharmacokinetic (PK) and glucodynamic (GD) profile which has a
hepato-preferential action resulting from reduced peripheral effects. This
study compared the variability in the PK andGD of BIL and GL at steady
state.
Materials and methods: In this randomised, open-label, parallel study,
75 patients received either 0.5 U/kg BIL or GL subcutaneously once daily
after a transition from pre-study basal insulin. On Days 8, 11 and 14,
serial blood samples were collected to assess PK and 24-hour automated
euglycaemic clamps were performed to assess GD. Intra-subject variabil-
ity, expressed as CV, was estimated using a linear mixed model on log-
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transformed PK and GD parameters and compared using an F-test at 10%
significance level.
Results: BIL showed a flatter time-action profile than GL (figure) with a
more even distribution of the GD effect over the 1st and 2nd 12 hours of
the clamp (total amount of glucose infused [Gtot] during the 1st 12 hours/
Gtot during the 2nd 12 hours, expressed as percentage of Gtot during the
whole clamp: 47%/53% for BIL, 61%/39% for GL at Day 8; 55%/45%
for BIL, 61%/39% for GL at Day 11; and 57%/43% for BIL, 63%/37%
for GL at Day 14). Intra-subject CV was statistically significantly lower
by 41% (11% vs 19%), 55% (13% vs 28%) and 35% (41% vs 64%) with
BIL vs GL for PK and GD parameters AUC0-24,ss, Cmax,ss and Gtot,
respectively.
Conclusion: BIL has both a flatter and more predictable time-action
profile with less day-to-day intra-subject PK and GD variability com-
pared to GL. This may result in improved glycaemic control and reduced
hypoglycaemia.
Clinical Trial Registration Number: NCT01784211
Supported by: Eli Lilly and Company
3
GreaterHbA1c reduction with basal insulin peglispro (BIL) vs insulin
glargine (GL) in an open-label, randomised study in type 1 diabetic
patients: IMAGINE 1
S. Garg1, H. Jinnouchi2, M. Dreyer3, J. Mou4, M.L. Hartman4,
M. Rosilio5, E.J. Bastyr III4, for the IMAGINE 1 Study Group;
1Barbara Davis Center for Childhood Diabetes, University of Colorado
Denver, Aurora, USA, 2Diabetes Care Center, Jinnouchi Hospital,
Kumamoto, Japan, 3Zentrum für Innere Medizin, Hamburg, Germany,
4Eli Lilly and Company, Indianapolis, USA, 5Lilly France, Neuilly sur
Seine, France.
Background and aims: Basal insulin peglispro (BIL) is a novel basal
insulin with a flat pharmacokinetic profile which has a hepato-preferential
action resulting from reduced peripheral effects.
Materials and methods: We compared BIL with GL in a Phase 3, 78-
week study (primary endpoint 26 weeks) in 455 patients (51% female)
with T1D (HbA1c <12% [<108mmol/mol]). Patients were randomised to
bedtime BIL (N=295) or GL (N=160) with prandial insulin lispro. An
electronic diary was used for data capture and insulin dosing decisions.
Results: At Week 26, HbA1c reduction was greater with BIL compared
with GL (baseline: 7.8% [62 mmol/mol]; treatment difference -0.37% [-
4.0 mmol/mol]; 95% CI: -0.50%, -0.23% [-5.5, -2.5 mmol/mol]). More
patients taking BIL reached HbA1c targets. Glucose variability was re-
duced in the BIL group, and nocturnal hypoglycaemia rate was 36%
lower. Total hypoglycaemia rate was 29% higher with BIL, and severe
hypoglycaemia rate was also higher. Basal insulin dose was higher, but
bolus and total insulin dosages were lower in the BIL group. Patients on
BIL had a significant weight loss. Triglycerides (TG) increased from
baseline with BIL; no treatment differences were seen in LDL-C or
HDL-C. In the BIL group, ALT increased from baseline. More patients
taking BIL had ALT ≥3× ULN (4.5% vs 0.7%, p=.041) elevations, with
no cases of Hy’s law. Liver fat content (LFC), assessed byMRI in a subset
of T1D patients in 2 studies of BIL vs GL, also increased with BIL. More
patients taking BIL had injection site reactions (25% vs 0%, p<.001).
Conclusion: Treatment with BIL compared with GL resulted in lower
HbA1c, reduced nocturnal hypoglycaemia, and weight loss, with higher
levels of TG, ALT, and LFC, and injection site reactions in patients with
T1D.
Clinical Trial Registration Number: NCT01481779
Supported by: Eli Lilly and Company
4
Sustained glycaemic control and less nocturnal hypoglycaemia with
new insulin glargine 300U/ml versus glargine 100U/ml over 1 year in
Japanese people with type 1 diabetes mellitus (EDITION JP 1)
M. Matsuhisa1, M. Koyama2, X. Cheng3, M. Sumi2, T. Hirose4, on
behalf of the EDITION JP 1 Study Group;
1Tokushima University, Tokushima, 2Sanofi, Tokyo, Japan, 3Sanofi,
Beijing, China, 4Toho University School of Medicine, Tokyo, Japan.
Background and aims: In EDITION JP 1, Japanese people with T1DM
receiving new insulin glargine 300 U/ml (Gla-300, n=122) showed com-
parable glycaemic control and less hypoglycaemia over 6 months com-
pared with glargine 100 U/mL (Gla-100, n=121).
Materials and methods: Participants continued to receive Gla-300 or
Gla-100 for an additional 6 months.
Results: The 12-month study period was completed by 228 participants;
114 (93.4%) receiving Gla-300 and 114 (94.2%) receiving Gla-100.
HbA1c and FPG levels decreased from baseline to month 12 with Gla-
300 (mean [SD] change −0.20 [0.80] % and −0.8 [4.8] mmol/l) and Gla-
100 (mean [SD] change −0.25 [0.72] % and −0.4 [5.2] mmol/l). At month
12, mean daily Gla-300 dose was 24 U/day (0.36 U/kg/day) and Gla-100
dose was 18 U/day (0.28 U/kg/day), with little change in dose observed
betweenmonths 6 and 12. Daily mealtime insulin doses were comparable
in the Gla-300 (29 U/day [0.45 U/kg/day]) and Gla-100 (29 U/day [0.47
U/kg/day]) groups at the end of the study period. Over 12 months, rates
(events per participant-year) and percentage of participants experiencing
≥1 nocturnal confirmed (≤3.9 mmol/l [≤70 mg/dl]) or severe
hypoglycaemic event were comparable between groups. At the lower
(<3.0 mmol/l [<54 mg/dl]) threshold, a reduction in event rate was ob-
served with Gla-300 compared with Gla-100 during the night (2.39 vs
3.85; rate ratio 0.62; 95% CI: 0.39 to 0.97). Consistently, the percentage
of participants experiencing ≥1 nocturnal event at this threshold was also
reduced with Gla-300 compared with Gla-100 (52.5 vs 66.1; relative risk
0.79; 95%CI: 0.64 to 0.98). Severe hypoglycaemia occurred in 12 and 11
participants receiving Gla-300 and Gla-100, respectively. Similar num-
bers of adverse events were reported for each treatment group.
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Conclusion: Japanese people with T1DM achieved sustained glycaemic
control with less nocturnal confirmed (<3.0 mmol/l [<54 mg/dl]) or se-
vere hypoglycaemia over 12 months with Gla-300 vs Gla-100. Gla-300
was well tolerated over the 12-month study perio.
Clinical Trial Registration Number: NCT01689129
Supported by: Sanofi
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Switching basal insulin treatment to insulin degludec in patients with
type 1 diabetes having an unsatisfactory HbA1c: a clinical follow-up
L. Landstedt-Hallin;
Karolinska Institutet (KI DS), Stockholm, Sweden.
Background and aims: Insulin degludec, a basal insulin, with an ultra-
long duration of action became available in Sweden from July 2013. The
diabetes team at Danderyd Hospital decided to conduct a simple, pro-
spective, clinical follow-up of patients with type 1 diabetes who switched
basal insulin to degludec. Since this evaluation was a part of the quality
assurance regarding routine patient care, permission from the ethics com-
mittee was not necessary and no written consent was obtained but all
patients were informed about the follow-up and agreed to be part of it.
Materials andmethods: FromAugust 2013 all consecutive patients with
type 1 diabetes, who switched to insulin degludec, were registered in a
simple form which included data on (1) most recent HbA1c, (2) type of
insulins before switching, (3) insulin doses, (4) self-reported
hypoglycaemias - defined as hypoglycaemic symptoms ameliorated by
carbohydrate treatment or a self-measured plasma glucose <3.5 mmol/L -
during the previous four weeks and (5) the reason/indications for
switching. Four major indications were predefined: (i) currently admin-
istering basal insulin twice daily; (ii) having unacceptable HbA1c (in
relation to the patient’s individual goal); (iii) experiencing repeated
hypoglycaemic events and/or unstable glucose; and (iv) having an irreg-
ular daily schedule making fixed-time administration difficult. For an
individual patient one or more of these indications could be present.
The switch was decided in conjunction with professional judgment by
the healthcare professional. After 4-6 months data on HbA1c, insulin
doses and self-reported hypoglycaemias were collected again. Around
one year after the change in basal treatment a second HbA1c was re-
trieved from medical records in order to assess the long-term effect of
the switch on glycaemic control as it was recognized that an initial im-
provement in HbA1c could be due to factors such as patients increasing
their self-monitoring of blood glucose when switching to a novel insulin
and/or being more conscientious about their diabetes management. In
60% of all patients who switched basal insulin to insulin degludec an
unacceptable HbA1c was given as one of the indications for changing
treatment. Data from the follow-up in this subgroup are presented here.
Results:At the end ofMarch 2015we had follow-up data on 239 patients
in this poorly controlled subgroup. Median time to follow-up was
21 weeks [IQR 18 to 24] and mean [SD] HbA1c decreased from 78.0
[13.3] to 72.2 [13.7] mmol/mol, p<0.0001. In 138 patients a second
HbA1c had been retrieved after median 50 weeks [IQR 44 to 54] showing
a sustained improvement in HbA1c. This was achieved using lower doses
of insulin, median reduction of basal dose was 13% (IQR -22% to -0%)
while total dose (basal + prandial) was reduced by 11% (IQR -19% to -
1%). The total number of self-reported hypoglycaemic events was un-
changed but there was a reduction in nocturnal events, from 1.3 [2.3] at
baseline to 0.6 [2.0] at follow-up, p<0.0001. No validated measurement
of patient satisfaction was used. However, spontaneous comments made
by patients suggested that they felt as though blood glucose was much
more stable with insulin degludec but also that their prandial insulin
seemed to have a better effect.
Conclusion: Due to the improvement in glycaemic control, reduction of
insulin dose and less nocturnal hypoglycaemias, we concluded that insu-
lin degludec was clinically useful for our patients with type 1 diabetes.
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BIOD-531 demonstrates superior prandial glucose control, post-meal
dosing flexibility, and less insulin "stacking" compared to marketed
prandial/basal insulins
L. Morrow1, L. Canney2, P. Pichotta2, A. Krasner2, M. Hompesch1,
E. De Souza2;
1Profil Institute for Clinical Research, Chula Vista, 2Biodel, Danbury,
USA.
Background and aims: Subcutaneous (SC) injection of BIOD-531, a
400 U/ml formulation of human insulin, EDTA, citrate and magnesium
sulfate is associated with ultra-rapid absorption and a basal duration of
glucose lowering action. This study was designed to assess the pharma-
cokinetic (PK) and postprandial glycemia (PD) profiles associated with
breakfast and dinner time doses of BIOD-531 vs. marketed comparators
in patients with insulin resistant diabetes.
Materials and methods: Twelve patients with type 1 or type 2 diabetes
who use insulin at doses of≥150 U/day or≥100 U/injection were ran-
domized into this 4-period crossover trial. Each subject underwent in
random order one of the following treatments on separate days: (a)
BIOD-531 immediately before meals (pre-meal); (b) Humalog® Mix
75/25 (HMix) pre-meal; (c) Humulin® R U-500 (U-500) pre-meal; and
(d) BIOD-531, 20 min after the start of the meals (post-meal). After
baseline glucose normalization, test insulins (1.2 U/kg) were adminis-
tered by SC injection with a standardized breakfast (921 kcal) followed
by a second dose (0.8 U/kg) 11 hours later with a standardized dinner
(963 kcal). Subjects also received a standardized lunch (669 kcal)
5.5 hours after breakfast without additional insulin. The primary endpoint
was average glucose concentration in the breakfast to lunch interval.
Results:Mean baseline characteristics for the patients evaluated were as
follows: insulin dose 205 U/day, 55.4 years old, 117 kg, 25% female. The
Figure shows PK and PD profiles. The absorptive phase of BIOD-531
was significantly more rapid than either HMix or U-500 (time to half-
maximal insulin concentrations (11.7±1.2, 42.2±2.6, and 41.7±9.8 min,
respectively, p<0.001 for both comparisons). Peak insulin levels after
BIOD-531 injections were similar after breakfast and dinner. The post-
dinner:post-breakfast peak insulin concentration ratio was significantly
higher for HMix (1.21) and U-500 (1.19) compared to BIOD-531
(0.97, p<0.05 for both comparisons). Pre-meal BIOD-531 resulted in
mean post-breakfast period glucose concentration (mg/dl) of 164.6±
11.8 compared to 179.9±10.0 with HMix (p=0.009) and 178.0±7.3 with
U-500 (p=0.019). Over the entire 24 hours of observation, pre- and post-
meal BIOD-531 resulted in lower glucose concentrations compared to
pre-meal HMix and comparable to pre-meal U-500. The frequency of
adverse events was similar between treatments.
Conclusion: Ultra-rapid absorption of BIOD-531 was associated with
superior prandial control compared to HMix and U-500 in insulin-
resistant diabetes patients. Post-meal dosing of BIOD-531 resulted in
superior or comparable overall glycemic control compared to pre-meal
treatment with HMix and U-500. The duration of exposure of BIOD-531
is suitable for twice-daily dosing with evidence for less insulin “stacking”
after a second dose.
Clinical Trial Registration Number: NCT02324309
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Diabetes and cause-specificmortality: evidence from 55 000 deaths in
700 000 adults in 44 studies from the Prospective Studies
Collaboration
L. Gnatiuc, J. Halsey, J. Emberson, S. Lewington, The Prospective Stud-
ies Collaboration;
CTSU, Oxford University, UK.
Background and aims: While the association of diabetes with macro-
vascular mortality has been well-studied, evidence for the effect of dia-
betes on mortality from other causes is more equivocal.
Materials and methods: Information from 44 prospective studies was
obtained on 54,855 deaths among 690,700 adults with no previous vas-
cular or other chronic disease recorded at baseline. We assessed the asso-
ciations of DM with cause-specific mortality using Cox proportional-
hazards models adjusted for age at risk, gender, smoking, body mass
index and cohort.
Results: During 13 million person-years of follow-up there were 21 762
ischaemic, 5 386 non-ischaemic vascular, 18 658 neoplastic and 9 048
other deaths between ages 35-89. Diabetes was associated with about a
2.5-fold increased risk of death from ischaemic heart disease (HR 2.37;
95%CI 2.23-2.52), ischaemic stroke (2.75; 2.29-3.31) and cardiac ar-
rhythmia (2.47; 1.80-3.38), but was more weakly associated with non-
ischaemic vascular mortality (1.57; 1.34-1.85). There was about a 2-fold
increased risk of renal (1.90; 1.40-2.58) and hepatic (1.75; 1.36-2.26)
mortality among people with diabetes, while the increased risk for mor-
tality from any cancer was small (1.13; 1.06-1.21), andwas largely driven
by cancer of the mouth (1.81; 1.17-2.81), liver (1.80; 1.26-2.58) and
pancreas (1.57; 1.21-2.03).
Conclusion: Diabetes was associated with a substantial increased risk of
mortality from selected ischaemic and non-ischaemic diseases. Under-
standing these associations should help reduce the excess mortality
among people with diabetes.
8
Causal effects of cardiometabolic traits on cardiovascular and total
mortality: a Mendelian randomisation study
G. Rukh, G. Hindy, P. Almgren, C.-A. Schulz, U. Ericson, O. Melander,
M. Orho-Melander;
Department of Clinical Sciences in Malmö, Lund University, Malmö,
Sweden.
Background and aims: Epidemiological studies have shown associa-
tions between cardio-metabolic traits and increased risk of mortality, yet
the underlying causal relationships remain unclear. We aimed to under-
stand the causal nature of the associations of common cardio-metabolic
traits with cardiovascular (CVD)mortality and/or all-cause total mortality
using Mendelian randomization analyses.
Materials and methods:Our study included 28589 participants from the
population based Malmö Diet and Cancer study with a mean follow-up
period of 15.4 years. We conducted Mendelian randomization analyses
by using trait specific weighted genetic risk scores (GRS) for BMI (com-
prising of 31 SNPs), systolic blood pressure (SBP;29 SNPs), HDL-
cholesterol (HDL-C; 41 SNPs), LDL-cholesterol (LDL-C; 32 SNPs),
triglycerides (TG; 26 SNPs) and fasting plasma glucose (FPG; 15 SNPs)
as instrumental variables to investigate the causal role of these traits in
CVD-mortality (1913 deaths) and total mortality (5708 deaths). We per-
formed a 2-stage regression instrumental variable analysis. First, each
cardio-metabolic trait was regressed on its respective GRS creating in-
strumental variables and second, the instrumental variables were used as
predictor variables for CVD- and total mortality in Cox proportional
hazards models. The analyses were adjusted for age and sex. Lipid-
lowering and antihypertensive medications were added to the model
when lipid traits or SBP were used as outcome or predictor variables,
respectively. Finally, we performed multivariable Mendelian randomiza-
tion analyses using the effect estimates of each SNP first on all cardio-
metabolic traits and second, on CVD-mortality and total mortality to
adjust for potential pleiotropic effects of the SNPs.
Results: Higher baseline levels of SBP and FPG, and lower levels of
HDL-C associated with increased risk of both CVD- and total mortality
while higher BMI and TG associated only with increased risk of CVD-
mortality. The variances explained by GRSs for BMI, SBP, LDL-C,
HDL-C, TG and FPG were 0.8, 0.5, 7.2, 5.7, 4.3 and 2.2%, respectively,
in association with their respective traits (P<10-15 for all). The instru-
mental variable analyses indicated that aone standard deviation (1SD) of
genetically elevated BMI (HR: 1.82, 95% CI: 1.09-3.03; P: 0.02), LDL-C
(1.20, 1.02-1.42; 0.03) and TG (1.28, 1.05-1.57; 0.02) associated with
increased risk of CVD-mortality and a 1SD of genetically elevated HDL-
C (0.78, 0.65-0.93; 0.006) associated with decreased risk of CVD-mor-
tality. Additionally, a 1SD of genetically elevated TG associated with
increased risk of total mortality (1.18, 1.05-1.33, 0.005) and 1SD of
genetically elevated HDL-C associated with decreased risk of total mor-
tality (0.89, 0.80-0.99; 0.03). Adjusting for pleiotropic effects in the mul-
tivariable Mendelian randomization analyses proposed a direct causal
association of TG (P=0.02) and an inverse association of HDL-C (P=
0.035) with CVD-mortality.
Conclusion:While randomized clinical trials and Mendelian randomiza-
tion studies have only provided evidence for causality of higher LDL-C
and TG but not of lower HDL-C in coronary disease development, our
results suggest a causal role of HDL-C in addition to TG in CVD-mor-
tality. However, whether other cardiometabolic traits causally impact
mortality requires further evidence.
Supported by: VR, HLF, NNF, SDF, PF, KAWF, LF
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Value of genetic risk score in personalised risk prediction of type 2
diabetes: analysis of 10273 individuals of the Estonian Biobank
Cohort
K. Fischer1, K. Läll1,2, R. Mägi1, A. Metspalu1;
1Estonian Genome Center, University of Tartu, 2Institute ofMathematical
Statistics, University of Tartu, Estonia.
Background and aims: Large-scale genome-wide association studies
(GWAS) have revealed more than 80 geneic loci associated with preva-
lent Type 2 Diabetes (T2D), improving the understanding of molecular
pathways leading to the disease. However, practical usefulness of such
results in T2D prevention is still heavily disputed. Our aim is to assess the
association of the genetic risk score (GRS) for T2D with both prevalent
and incident T2D and cardiovascular mortality in a large population-
based cohort of European Origin.
Materials and methods: The GRS is computed as a weighted sum of
allele counts of 7500 markers identified by genome-wide genotyping of
the cohort. The selection of markers and their weights is based on a large-
scale GWAS meta-analysis (Morris et al, 2012). Predictive ability of the
GRS is validated in 10,273 individuals of the Estonian Biobank cohort
(1181 prevalent and 386 incident T2D cases, median follow-up time
5.5 years).
Results: The odds for T2D prevalence are 2.20 times higher (95% CI
1.82-2.65) in the highest GRS quintile compared to the rest of the cohort
and 3.66 times higher (95% CI 2.72-4.91) compared to the lowest GRS
quintile. For individuals in the highest GRS quintile, the estimated hazard
of developing T2D during the follow-up is 1.78 times higher (95% CI
1.41-2.24) compared to the rest of the cohort and 2.72 times higher
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(95%CI 1.94-3.81) compared to the lowest GRS quintile. From the avail-
able risk factors, GRS was the second strongest predictor for T2D (after
BMI), increasing the area under the receiver operator characteristic curve
for overweight individuals from 0.706 to 0.756 (p=5.4*10-13). In addi-
tion, we detected that individuals in the highest GRS quintile for T2D
have significantly higher risk for cardiovascular mortality (adjusted haz-
ard ratio=1.25, 95%CI 1.06-1.48, p=0.009).
Conclusion:Our results indicate that implementation of genetic testing in
routine risk assessment could greatly improve the accuracy of T2D risk
assessment in general population.
10
Glycaemic control and incidence of dementia in 363,573 patients with
type 2 diabetes: an observational study
A. Rawshani, A. Rawshani, A.-M. Svensson, S. Gudbjörnsdottir;
Clinical andMolecularMedicine, Inst ofMedicine, Gothenburg, Sweden.
Background and aims: A growing body of evidence indicates that dia-
betes increases the risk of cognitive impairment. This has prompted in-
terest in delineating predictors of cognitive decline and dementia in dia-
betes. Cohort studies relating glycated haemoglobin (HbA1c) to risk of
dementia are lacking. We evaluated extensive clinical data to explore the
association between HbA1c and the risk of hospitalization for dementia
among persons with type 2 diabetes.
Materials and methods: We identified all patients with type 2 diabetes
and no known hospitalization for dementia who were registered in the
Swedish National Diabetes Registry between January, 2004, and Decem-
ber, 2012. These patients were followed up until hospital admission for
dementia, death, or end of follow-up on Dec 31, 2012. We used Cox
regression to assess the association between patients’ characteristics, in-
cluding HbA1c, and dementia. All covariates were modelled as time-
dependent predictors.
Results: In a cohort of 395,173 patients (contributing 2,981,247 registra-
tions) with mean age of 64.6 years (SD 12.5) at baseline, 9,175 patients
(2.3%) were admitted to hospital with a primary or secondary diagnosis
of dementia during a mean (SD) follow-up of 4.6 (2.5) years. In a Cox
regression analysis - with adjustment for age, sex, duration of diabetes,
marital status, income, education, smoking status, systolic blood pressure,
body mass index, estimated glomerular filtration rate, statins, albumin-
uria, type of glucose lowering treatment, atrial fibrillation, stroke and
antihypertensive medications - the hazard ratio for hospitalization for
dementia was 2.36 (95% CI 2.00-2.78) in patients with HbA1c of
10.5% or higher, compared with a reference group of patients with
HbA1c of less than 6.5%. Statins and antihypertensive medications ap-
peared to be protective from hospitalization for dementia. Stroke was
associated with a hazard ratio of 7.69 (95% CI 7.22-8.18) for developing
dementia. Albuminuria was also associated with increased risk of demen-
tia. Refer to Figure 1.
Conclusion: The positive association between HbA1c and risk of demen-
tia in fairly young patients with type 2 diabetes indicates a potential for
prevention of dementia with improved glycaemic control.
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The risk of developing diabetes and other diseases 10-17 years after
pregnancy
U. Moll1, H. Olsson2, M. Landin-Olsson1;
1Department of Endocrinology, 2Department of Oncology, Lund,
Sweden.
Background and aims: A high pre pregnancy BMI and excessive
maternal weight gain has negative implications for pregnancy and
delivery but has also negative long term effects since these con-
ditions have been acknowledged as risk factors for post gestation-
al weight retention and obesity later in life. The aim of this study
was to analyze if a high maternal BMI at start of pregnancy and a
high or low maternal weight gain during pregnancy were associ-
ated with diseases later in life.
Materials and methods: We used a population based cohort of 23,524
women from southern Sweden. Data regarding these women were
merged with the Swedish Medical Birth Register (SMBR). 15014 of
theses women were found to have at least one registered delivery at least
10 years before answering a health questionnaire. The women were di-
vided into groups based on their BMI (≤25 and >25; n=2415 and 347)
and weight gain (≤15 and >15 kg; n=2228 and 1302).
Results: The mean pre pregnancy BMI was 21.84±2.9 kg/m2 and the
mean weight gain was 14.5±4.6 kg. There was a positive association
between BMI >25 and the risk of developing obesity, diabetes, cardiac
disease, endocrine diseases and overall/other morbidity (OR 21.9, 6.1,
2.6, 2.1, 1.2; p-value <0.001, <0.001, 0.001, <0.001, 0.012 respectivly).
There was a positive correlation between low maternal weight gain and
the risk of developing psychiatric diseases (OR 1.6; p<0.001). There was
however no significant association between a high weight gain and the
risk of developing diabetes, cardiac or endocrine diseases 10-17 years
after delivery.
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Conclusion:A high pre pregnancy BMI significantly increases the risk of
several diseases later in life, including diabetes and cardiac disease. A
high weight gain during pregnancy did not have any implications on
metabolic diseases within ten years in our study.
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Use of antibiotics and risk of type 2 diabetes: a population-based case
control study
K.H. Mikkelsen1, M.F. Nielsen2,3, F.K. Knop4, J. Hallas5, A. Pottegård5;
1Center for Diabetes Research, Department Medicine, Copenhagen Uni-
versity Hospital Gentofte, Hellerup, 2Department of Medicine, Kolding
Hospital, Kolding, 3Endocrine Research Unit, University of Southern
Denmark, Odense, 4Center for Diabetes Research, Department of Medi-
cine, CopenhagenUniversity Hospital Gentofte, Hellerup, 5Clinical Phar-
macology, Department of Public Health University of Southern Denmark,
Odense, Denmark.
Background and aims: There is accumulating evidence that bacteria in
the human gut may influence nutrient metabolism. In rodent models, it is
possible to manipulate insulin sensitivity, glucose tolerance and nutrient
deposition through antibiotics-induced alterations in the gut microbiota.
Further, associations between use of antibiotics and obesity have been
reported in recent observational studies. We investigated whether use of
antibiotics influences the risk of developing type 2 diabetes, and if so, if
the effect can be attributed to specific types of antibiotics.
Materials and methods: The analysis was conducted as a population-
based case-control study of incident type 2 diabetes cases in Denmark
(population 5.5 million) during the period January 1st 2000 to December
31st 2012. Data from the DanishNational Registry of Patients, the Danish
National Prescription Registry and the Danish Person Registry were com-
bined. The crude and adjusted odds ratios for the association between
antibiotic exposure and risk of developing type 2 diabetes were estimated
using conditional logistic regression, controlling for potential
confounders.
Results: The study included 170,504 patients with type 2 diabetes and
1,364,008 matched controls. An increased odds ratio for risk of type 2
diabetes was seen with increasing exposure to antibiotics of any type with
an odds ratio of 1.53 (95% CI 1.50-1.55) with redemption of 5+ vs 0-1
prescriptions. While no individual group of antibiotics was specifically
associated with type 2 diabetes risk, slightly higher odds ratios for type 2
diabetes were seen with narrow-spectrum and bactericidal antibiotics
compared to broad-spectrum and bacteriostatic types of antibiotics. The
increased use of antibiotics in patients with type 2 diabetes was found up
till 15 years before diagnosis of type 2 diabetes, as well as after the
diagnosis.
Conclusion: These findings may represent an increased demand for an-
tibiotics due to increased risk of infections in patients with yet undiag-
nosed diabetes, pre-diabetes or manifest type 2 diabetes. However, the
possibility that antibiotics exposure increases diabetes risk cannot be
excluded.
OP 03 Incretin-based therapy: on and
off conventional targets
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Treatment with liraglutide leads to an important reduction in liver fat
content, assessed bymagnetic resonance spectroscopy, in people with
type 2 diabetes
B. Vergès1,2, B. Bouillet1, B. Guiu1, P. Buffier1, S. Baillot-rudoni1, M.-C.
Brindisi1, E. Crevisy1, C. Fourmont1, J.-P. Cercueil1, J. Petit1,2;
1Hôpital du Bocage, 2INSERM CRI866, Dijon, France.
Background and aims:Most studies found that 60-75% of patients with
type 2 diabetes have Non-Alcoholic Fatty Liver Disease. Unfortunately,
there is no treatment of NAFLD in people with diabetes besides weight
loss and increased physical activity. Some animal studies have shown that
GLP-1 receptor agonists may reduce liver lipogenesis. The effect of the
GLP-1 receptor agonist, liraglutide on liver fat remain unknown in pa-
tients with type 2 diabetes. This prompted us to perform a prospective
study on the effect of liraglutide on liver fat content, in type 2 diabetes.
Materials and methods: A total of 43 patients with type 2 diabetes
mellitus were included in this study. Liver fat was measured by 1H-
magnetic resonance spectroscopy (gold-standard method for liver fat
measurement) before and after 6 months of liraglutide therapy (1.2 mg/j).
Results: Thirty-five (81.3%) patients had steatosis at baseline (hepatic
triglyceride content greater than 5.5%). At inclusion, liver fat content was
correlated with fasting serum triglycerides (r=0.33; p=0.02) and alanine
aminotransferase (ALAT) (r=0.46; p=0.002). Treatment with liraglutide
was associated with a mean weight loss of 4.4 kg (p<0.001), a mean
HbA1C reduction of 2.6% (p<0.001) and an important reduction in liver
fat content (from 19.1% to 12.7%, p<0.001) corresponding to a relative
decrease of 33.3%. Reduction in liver fat was correlated with weight
reduction (r=0.49, p=0.001), ALAT reduction (r=0.49, p=0.001), base-
line liver fat content (r=0.33, p=0.031) and borderline significant with
HA1c reduction (r=0.29, p=0.057). In multivariate analysis, reduction in
liver fat was independently associated with weight reduction (p<0.0001)
and baseline liver fat (p<0.0001) (r2=0.62). In the subgroup of patient
who showed a relative weight reduction below themedian value (3.3%), a
significant 19.6% decrease was observed (p=0.029) whereas the mean
body weight remained unchanged.
Conclusion: Our data indicate that liraglutide is an effective treatment to
decrease liver fat content, in patients with type 2 diabetes. Although
weight reduction induced by liraglutide appears to be an important factor
promoting reduction in liver fat content, we cannot exclude a direct action
of liraglutide on lipogenesis since a significant decrease in liver fat was
observed in patients without significant weight reduction. Further studies
are needed to explore the mechanisms involved in liver fat content reduc-
tion linked with liraglutide treatment.
Clinical Trial Registration Number: EudraCT: 2012-000375-16
Supported by: NovoNordisk Grant
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Adipose tissue response to GLP-1 analogue-induced weight loss
K. Kos1, L.J. McCulloch1, R. Ward1, S. Joshi1, K. Sjoholm2, A. Pitt3,
K.M. Gooding4, A.C. Shore4, L.M.S. Carlsson2;
1Diabetes and Obesity Research, University of Exeter Medical School,
Exeter, UK, 2Molecular and Clinical Medicine, University of Gothen-
burg, Sweden, 3NIHR Exeter Clinical Research Facility, University of
Exeter Medical School, 4Diabetes and Vascular Research Group, Univer-
sity of Exeter Medical School, Exeter, UK.
Background and aims: Glucagon like peptide-1 (GLP-1) analogues in
the treatment of Type 2 diabetes are used for the control of HbA1c and
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have the additional benefit of weight loss. Weight loss is considered to
reduce obesity-associated adipose tissue inflammation, however, little is
known about the effect of GLP-1 on adipose tissue, which is known to
express GLP-1 receptors. The aim of the study was to assess the effect of
weight loss on adipose tissue inflammatory and fibrotic responses
achieved either by 1) treatment with the GLP-1 analogue Liraglutide 2)
sustainable calorie reduction and 3) very low calorie dieting.
Materials and methods: Age and BMI matched subjects with well
controlled Type 2 diabetes were randomised toLiraglutide (at a
dose of 0.6 mg for the first 4 weeks and if tolerated continued
at 1.2 mg), or to dietetic counselling and follow up to allow for
similar weight loss. Independently, subjects with and without in-
sulin resistance underwent a very low calorie diet (VLCD) of
450 kcal/ day to achieve best possible non-surgical weight loss.
Assessments included a subcutaneous abdominal adipose tissue
biopsy at baseline and after 4 months. Fat samples were analysed
for inflammatory and profibrotic markers by microarray and
Taqman low density array based analysis. For statistical compar-
ison Wilcoxon Signed Rank Test for paired analysis was used.
Results: Subjects who completed 4 months treatment with
Liraglutide lost 3.2±1.08 kg (mean ± SD, age: 61.4±5.48 years,
baseline HbA1c: 59.6±5.28 mmol/mol, BMI: 30.06±4.85 kg/m2,
n=9) and lost 5.84±3.27 kg in the diet arm (age: 57.0±9.6 years,
baseline HbA1c: 56.4±6.54 mmol/mol; BMI: 32.4±3.67 kg/m2,
n=6). The mean weight loss after VLCD was 28±3.7 kg (baseline
HOMA-IR: 4.4±2.7, baseline BMI: 37.6±4.9 kg/m2, BMI at
4 months: 28.6±4.1 kg/m2, n=24). After Liraglutide treatment,
adipose tissue expression increased for the chemoattractant mono-
cyte chemotactic protein-1 (1.01±0.13 AU (mean ± SE) versus
1.54±0.24 AU, p<0.05), the inflammatory adipokine tumor necro-
sis factor alpha (1.05±0.16 AU versus 1.63±0.21 AU, p=0.01)
and the fibrotic cytokine transforming growth factor (TGF) beta-1
(0.91±0.07 AU versus 1.25±0.11 AU, p<0.05); whereas expres-
sion of these genes did not change in the diet arm. In contrast,
we observed a trend in lower macrophage marker CD14 expres-
sion with a diet only induced weight loss of 5.84±3.27 kg (1.1±
0.18 AU versus 0.67±0.11 AU, p=0.08). Unlike with Liraglutide
treatment and similar to sustained dieting we observed no change
in TGFbeta-1 expression with VLCD, whereas there was a ten-
dency for increased expression 2 weeks after refeeding (0.83±
0.04 AU versus 0.86±0.05 AU at 4 months and 0.97±0.07 AU
with refeeding p=0.1).
Conclusion: Unlike with calorie induced dieting, Liraglutide treatment
appears to induce an inflammatory and fibrotic response in adipose tissue
with increased expression of inflammatory markers and fibrotic factors
not otherwise found with dieting and typical of overfeeding. It remains to
be shown whether Liraglutide treatment could accelerate adipose tissue
dysfunction in the long term.
Supported by: EFSD/GlaxoSmithKline
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Upper and/or lower GI adverse events with long- vs short-acting
GLP-1 receptor agonists: incidence, co-incidence, effects on HbA1c
and weight
M. Horowitz1, V. Aroda2, J. Han3, E. Hardy4, C. Rayner1;
1University of Adelaide, Australia, 2MedStar Health Research Institute,
Hyattsville, 3Pharmapace, San Diego, 4AstraZeneca, Gaithersburg, USA.
Background and aims: In direct comparative clinical trials, long- and
short-acting glucagon-like peptide-1 receptor agonists (GLP-1RA) for
T2DM appeared to have different efficacy and tolerability profiles. Early
transient gastrointestinal adverse events (GI AE) are characteristic of
GLP-1RA, but may differ in type and frequency for long- vs short-
acting GLP-1RA. Our objective was to evaluate differences in GI
tolerability with long- versus short-acting GLP-1 RA (specifically
exenatide once weekly [ExQW], exenatide twice daily [ExBID] or
liraglutide once daily [LiraQD]) according to location (upper, lower)
and co-incidence. We also investigated whether GI AE were associated
with differences in HbA1c or weight reductions.
Materials and methods: Intent to treat analyses of patient-level
data from direct comparative trials of 2 GLP-1RA were conduct-
ed. Data from 3 studies of ExQW vs ExBID were pooled. Data
comparing ExQW with LiraQD (DURATION-6) were analysed
separately. GI events were identified according to MedDRA ter-
minology and classified as upper or lower GI. Incidences of upper
GI AE, lower GI AE, and combinations of upper and lower GI
AE were determined for individual GLP-1RA. Changes in HbA1C
and body weight from baseline at study endpoint were assessed
according to occurrence of GI AE.
Results: The most common upper GI AE were nausea or
vomiting; the most common lower GI AE were diarrhoea or
constipation. Incidences of upper GI AE appeared less for
ExQW than short-acting GLP-1RA (Table), while lower GI AE
appeared comparable across GLP-1RA. Diarrhoea was found to
be accompanied by upper GI AE, and mainly occurred within
10 days of an upper GI AE for all GLP-1RA. Although 55% of
patients overall were male in both analyses, the majority with
upper GI AE were female (57-58%). Few patients discontinued
GLP-1RA due to GI AE, but discontinuation was more frequent
with short-acting GLP-1 RA than ExQW (Table). Reductions
from baseline in HbA1C were similar for patients with no GI
AE and those with upper, lower, or combined GI AE for short
or long-acting GLP-1RA. Reductions in body weight from base-
line were observed in patients without GI AE (-2.0, -2.0 kg for
ExQW, ExBID; -2.4, -3.5 kg for ExQW, LiraQD) but reductions
were greater for those with upper + lower GI AE compared
with no GI AE (-3.5 vs -2.0 kg) for ExBID, and for upper GI
AE compared with no GI AE for ExQW (-3.9 vs -2.4 kg) in
DURATION-6.
Conclusion: Pooled patient-level data from direct comparative tri-
als indicate that upper GI AE occur more frequently with short-
vs long-acting GLP-1RA. Lower GI AE are less common and do
not differ between GLP-1 RA. Upper GI AE and diarrhoea were
often reported by the same patients, suggesting some may be
susceptible to upper and lower GI AE with GLP-1 RA. Presence
or absence of GI AE did not affect HbA1c reductions but may
influence weight reductions in some patients.
Supported by: AstraZeneca
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Differential effects of GLP-1 receptor agonists on 24-hour averaged
heart rate in healthy volunteers and patients with type 2 diabetes
M. Lorenz1, D. Owens2, D. Raccah3, C. Roy-Duval4, F. Lawson5,
A. Lehmann6, R. Perfetti7, L. Blonde8;
1R&DDiabetes Division, Sanofi-Aventis Deutschland GmbH, Frankfurt am
Main, Germany, 2Institute of Life Sciences College of Medicine, Swansea
University, Swansea, UK, 3University Hospital Sainte-Marguerite,
Marseille, 4Sanofi R&D, Chilly-Mazarin, France, 5R&D Global Diabetes
Division, Sanofi US, Bridgewater, USA, 6R&D Clinical Sciences &
Operations, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main,
Germany, 7Global Medical Affairs, Sanofi, Paris France, 8Department of
Endocrinology, Ochsner Medical Center, New Orleans, USA.
Background and aims: Heart rate (HR) increases have been reported in
studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The
present analysis compares data from 24 h time-averaged HR monitoring
with GLP-1 RAs.
Materials and methods: A review of studies that report 24 h
time-averaged HR monitoring with GLP-1 RAs, including an un-
published QT/QTc study of lixisenatide in healthy subjects, pub-
lished data for lixisenatide, exenatide, liraglutide, albiglutide and
dulaglutide, and a head-to-head comparison of lixisenatide and
liraglutide.
Results: Shorter-acting GLP-1 RAs, such as exenatide BID and
lixisenatide QD, are associated with a smaller and shorter increase
in HR (1-3 bpm, 1-12 h) compared with longer-acting GLP-1
RAs, such as liraglutide, albiglutide and exenatide QW, which
induce a greater and more prolonged diurnal and nocturnal effect
(6-9 bpm). The HR increase with dulaglutide is relatively small
but persists at night (Table). In the head-to-head comparison,
smaller LS mean HR increases from baseline were observed with
shorter-acting lixisenatide versus longer-acting liraglutide, and the
treatment difference was significantly more pronounced at night
(Table).
Conclusion: Shorter-acting GLP-1 RAs induce a smaller and
transient HR increase; most longer-acting GLP-1 RAs are asso-
ciated with a more pronounced diurnal and nocturnal HR in-
crease. The clinical consequences of these differential effects
are not known.
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Risk of pancreatic cancer associated with use of incretin-based ther-
apy and other glucose-lowering agents: a nationwide case-control
study in Denmark
R.W. Thomsen1, D.H. Christensen2, J. Kahlert1, S.T. Knudsen3, L. Pedersen1,
H. Nørrelund1, O.M. Dekkers4, I. Douglas5, G. Marchesini6, L. Smeeth5,
N. Møller3, H. Beck-Nielsen7, J.O. Jørgensen3, H.T. Sørensen1;
1Department of Clinical Epidemiology, Aarhus University Hospital, 2De-
partment of Clinical Epidemiology and Medical Department M (Endo-
crinology & Diabetes), Aarhus University Hospital, 3Medical Depart-
ment M (Endocrinology & Diabetes), Aarhus University Hospital, Aar-
hus, Denmark, 4Leiden University Medical Center, Leiden, Netherlands,
5London School of Hygiene and TropicalMedicine &University College
London, UK, 6AlmaMater Studiorum University of Bologna & Bologna
University Hospital, Italy, 7Danish Centre for Strategic Research in T2D
(DD2), Dept. of Endocrinology, Diabetes Research Centre, Odense Uni-
versity Hospital, Denmark.
Background and aims: Incretin-based drugs (glucagon-like peptide 1
(GLP-1) mimetics and dipeptidyl peptidase 4 (DPP-4) inhibitors) have
been suspected to increase risk of pancreatic cancer. We examined if use
of incretin-based drugs was associated with risk of pancreatic cancer and
compared with other glucose-lowering agents.
Materials and methods: Using population-based medical databases this
analysis was carried out as an age-, gender- and residence-matched (1:10)
case-control study from 2005 to 2012 (6,036 pancreatic cancer cases and
60,360 controls). Odds ratios (ORs) for pancreatic cancer associated with
use of incretin-based drugs and other glucose-lowering agents were com-
puted, using conditional logistic regression, and we adjusted for other
pancreatic cancer risk factors.
Results:A total of 122 incident pancreatic cancer patients (2.0%) vs. 400
controls (0.7%) had used incretin-based drugs at least once, whereas
20.8% cases vs. 8.6% controls had used any glucose-lowering agent.
Patients with pancreatic cancer more often than controls had a hospital
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history of chronic pancreatitis (3.6% vs. 0.3%), gallstone (10.7% vs.
5.3%), obesity (4.0% vs. 2.9%), alcoholism (6.5% vs. 3.9%), and chronic
pulmonary disease (21.2% vs. 17.9%). Compared with non-users of any
glucose-lowering agents, the adjusted risk of pancreatic cancer was in-
creased for DPP-4 inhibitor users (adjusted OR=3.87, 95% CI 3.06-4.89)
and GLP-1 mimetic users (adjusted OR=2.70, 95% CI 1.82-4.00), and
furthermore for ever users of metformin (adjusted OR=2.65, 95% CI
2.44-2.88), sulfonylureas 2.65 (2.41-2.91) and insulin (adjusted OR=
3.61, 95% CI 3.24-4.03). The highest cancer ORs were observed among
new initiators of each glucose-lowering agent and in those with fewer
than 3 prescriptions filled, suggesting a non-causal or reverse causal
association.
Conclusion: The risk of pancreatic cancer was increased to similar levels
for all glucose-lowering agents. This suggests that diabetes is a risk factor
for pancreatic cancer independent of a specific drug effect, yet warrants
further investigation.
Supported by: the Clinical Epidemiological Research Foundation,
Denmark
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DPP4 inhibitor can protect TZD induced bone loss via sclerostin
expression in obese diabetic rat
B.-J. Kim, A.-R. Gwon, K. Kwak, Y. Eom, K. Lee, S. Yu, S. Lee, Y. Kim,
I. Park, K.-W. Kim;
Endocrinology andMetabolism, Gachon University, School ofMedicine,
Incheon, Republic of Korea.
Background and aims: Thiazolidinediones (TZDs) are widely pre-
scribed drugs in T2DM. However, recent studies, including large-scale
randomized controlled trials and observational studies, suggests that long-
term use of thiazolidinediones is associated with bone loss and an in-
creased risk of fractures in women with Type 2 diabetes. Incretin based
drugs (glucagon-like-peptide-1 agonist and dipeptidylpeptidase-4 inhibi-
tor) have been added to a new treatment option for glucose control in
T2DMandmany beneficial effects on beta cell including insulin secretion
and beta cell mass. Beyond pancreas, Incretins affect bone mass through
stimulating bone remodeling. We already reported exendin-4 might in-
crease BMD by decreasing the expression of SOST/sclerostin in osteo-
cytes in T2DM animal model. This experiment, we evaluate protective
effects of DPP-4 inhibitor on TZD induced bone loss in T2DM animal
model.
Materials and methods: 12 week old male Zucker Diabetic Fatty (ZDF)
rats were randomized with control, vildagliptin, pioglitazone, vildagliptin
and pioglitazone treated group and treated for 5 weeks. We performed
IPGTT, ITT before and after treatment and measure bone mineral density
(BMD) by DEXA and trabecular volume by micro CT at the end of
treatment. Also, we assayed circulating levels of GLP-1, GIP, sclerostin,
osteocalcin, and tartrate-resistant alkaline phosphatase (TRAP) 5b by
ELISA.
Results: Pioglitazone treated group decreased blood glucose and in-
creased body weight. Also, this group decreased BMD in DEXA and
decreased trabecular bone volume and thickness in micro CT.
Vildagliptin, DPP4 inhibitor, treatment increased BMD and trabecular
bone volume and thickness compared with control. Also, combination
treated group showed significant increase in BMD and trabecular thick-
ness compared to pioglitazone group. Pioglitazone treatment increased
sclerostin, but add vildagliptin to pioglitazone suppressed sclerostin.
Conclusion: Vildagliptin, DPP4 inhibitor, increased bone mass in type 2
diabetes animal model. Also, Vildagliptin can protect bone loss in TZD
treated Type 2 diabetes through reducing sclerostin from osteocyte at least
in T2DM animal model.
Supported by: NRF-2013R1A1A2011278
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Postprandial brown adipose tissue fatty acid metabolism in lean and
obese subjects
T. Saari, J. Raiko, N. Savisto, M. Haaparanta-Solin, P. Nuutila, K.A.
Virtanen;
University of Turku, Finland.
Background and aims:Brown adipose tissue (BAT) is activated by cold
exposure, increasing its glucose uptake, blood flow and fatty acid uptake
(FAU). In animals BAT has thermogenic activity also in pursuance of
eating (meal-induced thermogenesis) but this is poorly studied in humans.
As fatty acids are the main fuel source for BATwe aimed to quantify FAU
in lean and obese subjects during cold exposure and after eating, in post-
prandial state.
Materials and methods: FAU was quantified in lean (n=11, 8 F/3 M,
age 33.4±11.8 years, BMI 25.2±1.5 kg/m2) and obese subjects (n=6,
5 F/1M, age: 41.5±11.0 years, BMI 31.5±2.7 kg/m2) using 18 F-FTHA,
a palmitate analog and PET/CT. Tissue specific perfusion was measured
with 15O-H2O-PET/CT. Each subject was imaged twice, once during
cold exposure in fasting conditions and once in ambient temperature
postprandially. Tissue specific NEFA uptake and perfusion was calculat-
ed for supraclavicular adipose deposits, deltoid muscles and subcutane-
ous white adipose tissue (WAT).
Results: In lean subjects cold-induced FAU in BAT was 3-fold higher
than postprandial FAU (2.05±1.66 vs. 0.66±0.64 μmol/100 g/min,
P=0.004). Cold stimulated FAU also in WAT 2-fold (0.42±0.12 vs.
0.19±0.13 μmol/100 g/min, P=0.003) and in muscle 3-fold (1.06±0.40
vs. 0.32±0.20, P=0.0005) when compared to postprandial FAU, howev-
er, these FAU rates were clearly lower than in BAT. In obese subjects,
both cold-stimulated and postprandial FAU rates were lower than in lean
subjects but FAUwas higher in cold than after meal (1.19±0.60 vs. 0.38±
0.40 μmol/100 g/min, P=0.001, cold vs postprandial). Muscle FAU rate
was similar in obese and lean subjects being 2-fold higher in cold than
postprandial state (0.98±025 vs. 0.38±0.31 μmol/100 g/min, P=0.02) in
obese subjects. Postprandial BAT perfusion was higher in lean than in
obese subjects (20.00±16.74 vs. 4.85±1.63ml/100 g/min, P=0.03). BAT
FAU in cold correlatedwith postprandial BAT FAU (r=0.84, P=0.00002)
but in WAT or muscle no such correlation was found. Serum FFA
levels were similar in lean and obese subjects during cold expo-
sure (0.89±0.18 vs 0.89±0.15 mmol/L) and after meal (0.29±0.22
vs 0.43±0.37 mmol/L).
Conclusion: Fatty acid uptake rate after meal in BAT is lower than during
cold stimulus both in lean and obese subjects. However, obesity seems to
be related with lowered FAU and perfusion in BAT. This data suggest that
in addition to blunted cold-induced FAU obese subjects have impaired
postprandial lipid metabolism in the supraclavicular area.
Supported by: AoF, EU FP7 DIABAT, TDRF, FCF
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Cold increases brown fat temperature and decreases fat content:
measured using MRS in humans
K. Koskensalo1, J. Raiko1, T. Saari1, V. Saunavaara1, O. Eskola1,
P. Nuutila1,2, R. Parkkola3, K.A. Virtanen1;
1Turku PET Center, 2Department of Endocrinology, Turku University
Hospital, 3Department of Radiology, Turku University Hospital, Finland.
Background and aims: The role of brown adipose tissue (BAT) is to
dissipate stored energy as heat. The aim of this study was to investigate
whether the temperature and the proportion of fat (expressed as the proton
density fat fraction (PDFF)) of brown and white adipose tissue (WAT) is
related to BAT metabolic activity.
Materials and methods: Magnetic resonance spectroscopy (MRS) and
18 F-FDG PET in BAT and subcutaneous WAT were performed for 9
healthy subjects (4 F/5 M, ages 26 - 44 years, BMI 24.6±2.2 kg/m2)
using Philips Ingenuity 3 T PET/MR. MRS was obtained with PRESS
sequence (TR/TE=2000/35 ms, NSA=72, voxel volume: 1.0 cm3). The
voxel was placed in the supraclavicular and subcutaneous adipose tissue.
The measurements were obtained during 2-hour non-shivering cold ex-
posure and in ambient room temperature (RT). The chemical shift differ-
ence between the CH2 peak of the lipid chain and H2O peak was deter-
mined with iNMR software (Mestrelab Research, 2014) and converted to
temperature. The proton density fat fraction (PDFF) was calculated by
dividing the sum of all LCModel fitted fat peaks by the sum of both water
and fat peaks. Fat and water were corrected for T2 and T1 relaxation
effects. The dynamic 18 F-FDG PET data was analyzed using graphical
analyses with Carimas 2.8.
Results: All study subjects had functionally active BAT based on cold-
induced glucose uptake (17.7±8.4 μmol/100 g/min). The PDFF of BAT
in cold and RTwere 68±12% and 80±14% (P=0.03), respectively, and in
WAT 76±18% and 86±6% (NS). The temperature of BAT was higher
during cold exposure (34.1±3.0°C in cold and 32.6±4.7°C in RT,
P=0.03) while in WAT there was no difference in temperature between
cold and RT (31.1±3.8°C and 29.8±2.8°C, NS). All subjects had normal
plasma lipid profiles ((HDL 1.94±0.50, and LDL 2.23±0.66mmol/l) and
whole-body insulin sensitivity (M-value 44.4±10.5 μmol/kg/min. BAT
temperature in RT correlated strongly with M-value (r=0.86, p=0.0027)
and in cold BAT temperature was associated with BAT glucose uptake
(r=0.69, p=0.041). In cold, PDFF of BAT correlated significantly with
plasma LDL (r=0.76, p=0.016) and inversely with plasma HDL
(r=-0.69, p=0.040).
Conclusion: The increment of BAT temperature during cold exposure
can be measured with MRS during cold exposure in humans. BAT tem-
perature in room temperature associates with M-value. Further, MRI-
derived PDFF during cold associates with plasma lipid values. Our find-
ings suggest that BAT has an important role in whole-body insulin sen-
sitivity and lipid metabolism.
Supported by: UTU Foundation, Academy of Finland, S.W.
Finland Medical Dist. state grant
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Impact of caloric restriction on initial age-associated metabolic alter-
ations and browning effect in mice
P. Corrales-Cordon1, Y. Vivas1, D. Horrillo1, A. Izquierdo1, P. Seoane2,
C. Martinez-Garcia1, M. Lopez2, M. Ros1, M. Obregon3, G. Medina-
Gomez1;
1Universidad Rey Juan Carlos, Madrid, 2Universidade Santiago de
Compostela, 3Instituto de Investigaciones Biomédicas Alberto
Sols/CSIC-UAM, Madrid, Spain.
Background and aims: Changes in the distribution and function of dif-
ferent deposits of white adipose tissue (WAT) and brown adipose tissue
(BAT) occur during ageing. These changes are usually associated to met-
abolic alterations like Insulin Resistance (IR) andMetabolic Syndrome. It
is also known that caloric restriction (CR) reduces the metabolic changes
associated with age. Nevertheless, it is difficult to establish when age-
associated alterations start. Similarly, the severity and the time-extent to
CR are variables under debate. The aim of this work is to investigate the
impact of the CR iniciated sind 3 months of age and maintained until
12months of age, in the development of IR and other metabolic disorders.
Materials and methods: 3 and 12-month-old male mice fed ad libitum
and 12-month-old mice under CR (20%) from 3 months of age were used
(n=10-12 animals/group). For in vivo studies, we performed glucose
(1 g/kg body weight) and insulin (0.75 U/kg body weight) tolerance test
in mice. Serum concentration values of glucose, insulin and different
cytokines were quantified by Bio-plex ProTM Diabetes Assays. Gen
expression involved in lipid metabolism was measured in BAT and
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epididimal (eWAT) and subcutaneous (scWAT) WAT. Immunohisto-
chemistry and mRNA expression of UCP-1 was also detected. Total
triiodothyronine (T3) and thyroxine (T4) concentrations were determined
by radioimmunoassay (RIA) in serum and BAT. Protein levels of
lipogenic enzymes in the Central Nervous System (CNS) were also
measured.
Results: Our data showed age-associated IR significantly (p<0.05; t-
Student) appeared at maturity and is prevented with CR (AUC mean +
-SE: 1536.64+-115.94 in 12-month old mice compared to 1587+-151.23
in animals fed with CR). These findings were in agreement with serum
concentration values quantified. Cytokines serum levels were measured.
Adiponectin level significantly (p<0.05) decreased with ageing (5.57+-
0.47 ug/ml) and increased with CR (13.62+-2.53 ug/ml), while the leptin
serum levels significantly (p<0.05) increased with ageing (10.5+-
3.095 ng/ml) but decreased with CR (2.61+-0.74 ng/ml). Furthermore,
CR restored initial age-associated alterations in lipid metabolism and
markers of macrophage infiltration, such as MCP-1 (2.00+-0.38 with
ageing; 1.32+-0.16 with CR), only in scWAT. Remarkably, brown like
adipocytes or browning effect was detected in scWAT in old animals
subject to CR. The lower browning process associated to ageing was
accompanied by a significant (p<0.05) decrease in the expression of
some brown fat-selective genes (such as UCP-1, PRDM16, FGF21),
but restored with CR. T3 and T4 levels in BAT were significantly (p<
0.05) decreased with ageing but restored by CR. In addition, serum T3
levels were significantly (p<0.05) decreased with ageing. Finally, we also
found significantly (p<0.05) changes in lipogenic enzymes such as ACC
and AMPK in the hypothalamic AMPK pathway during the first stages of
agein.
Conclusion: Long-term CR prevents the morphological and initial aged-
related metabolic changes in WAT and BAT. The browning effect ob-
served in scWAT and the activation of BAT could be explained by im-
proved thyroid hormones status and function of CNS.
Supported by: MINECO, FSEEN, Fundacion Maphre, URJC-Banco
Santander, CAM
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Identification of compounds inducing UCP1 in differentiating human
white preadipocytes
J. Boucher, S. Eng, E. Carlsson, B. Magnusson, A. Sabirsh,
S. Bartesaghi, M. Andersson, A. Hogner, A. Forslöw, O. Engkvist,
A. Paunovic, G. O'Mahony, X.-R. Peng, S. Hallen;
AstraZeneca, Mölndal, Sweden.
Background and aims: While white adipose tissue is the major energy
storage tissue in the body, brown adipose tissue dissipates energy in the
form of heat, due to the unique presence of the mitochondrial uncoupler
protein UCP1. Converting white into brown-like adipocytes, expressing
high levels of UCP1 with increased oxidative and energy wasting capac-
ity, is a promising therapeutic strategy to counter insulin resistance and
type 2 diabetes. Our goal is to identify small molecules that increase
UCP1 expression and function, and induce the “browning” of white fat.
Materials and methods: We developed a screening strategy using hu-
man adipose derived stem cells (hASCs) isolated from subcutaneous fat.
hACSs were differentiated for up to 15 days in the presence or absence of
compounds and UCP1 mRNA levels were measured. UCP1 qPCR assay
was run in a 384 well format, and compounds were tested at 0.5 and
10 μM.We tested ~3000 small molecules covering more than a thousand
targets.
Results: We identified small molecule compounds that robustly induce
UCP1 mRNA in hASCs (3% hit rate). Top UCP1 inducers were con-
firmed by measuring both UCP1 protein and β-adrenergic/free fatty acid
stimulated uncoupled respiration using the Seahorse XF Analyzer. High
content imaging demonstrated that UCP1 protein is evenly distributed in
the lipid droplet-containing adipocytes and co-localizes with
mitochondria. In addition to UCP1, other brown fat genes such as Dio2,
PGC1α and PRDM16 or beige fat markers (TMEM26), were also in-
creased in treated cells, while white fat markers leptin and Hoxc8 were
decreased, confirming the switch of white adipocytes to a brown-like
phenotype. PPARγ agonists, such as rosiglitazone, are currently among
the most potent inducers of a brown-like phenotype in cultured primary
adipocytes. The metabolic modulators described here were increasing
UCP1 protein levels to a greater extent than rosiglitazone and other PPAR
agonists.
Conclusion:We have identified novel and potent UCP1 inducers using a
qPCR based screening assay in human preadipocytes. TheUCP1 increase
was confirmed at the protein level, and drives uncoupled respiration after
activation. Hence, the observed step jump in UCP1 expression level in-
duced by these novel small molecules opens the prospect of bringing
white precursor cells one step closer to the true brown adipocyte pheno-
type.
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The β3-adrenoceptor agonist CL316,243 increases in vivo free fatty
acid uptake and utilisation in interscapular and perirenal brown fat
but not inguinal fat in high-fat fed rats
A. Warner1, A. Kjellstedt1, A. Carreras2, P. Seale3, N. Oakes1,
D. Lindén1;
1CVMD iMed, AstraZeneca AB, 2Discovery Sciences, Transgenics,
AstraZeneca AB, Mölndal, Sweden, 3University of Pennsylvania,
Philadelphia, USA.
Background and aims: Activation of brown adipose tissue (BAT) and
browning of white adipose tissue present potential new therapies for
metabolic diseases such as Type 2 diabetes and obesity. Through the
partitioning of substrates for mitochondrial uncoupling, energy is used
for the production of heat rather than ATP. Here we investigate the effects
of β3-adrenergic stimulation on glucose tolerance and whole-body met-
abolic parameters, and for the first time determine tissue-specific uptake
and storage of free fatty acids (FFA) and its implications for whole-body
FFA metabolism using a multi-radiotracer technique.
Materials and methods: For whole-body energy metabolism, male
C57BL/6 mice were fed 60% (kcal) high fat diet for a total of 20 weeks
and during the last 4 weeks administered β3-agonist CL316,243
(1 mg/kg/day) or saline via osmotic minipumps. After 14 days an oral
glucose tolerance test was performed. After 21 days the mice were re-
corded inmetabolic cages for 24 hours at ambient room temperature (22±
0.2°C), and 24 hours at thermoneutrality (30±0.2°C). For the study of
tissue-specific FFA metabolism, male Wistar rats were fed 45% (kcal)
high fat diet for 12weeks in total and during the last 3 weeks administered
β3-agonist CL316,243 (1 mg/kg/day) or saline via osmotic minipumps.
At the end of the study, the rats were fasted and acutely infused with a
tracer mixture (14C-palmitate and the partially-metabolised 3H-R-
bromopalmitate) under anaesthesia.
Results: In mice, CL316,243 (CL) infusion decreased body weight (BW
change, CL=-1.80±0.63 g vs. saline 1.27±0.45 g, p<0.01, t-test), im-
proved glucose tolerance (glucose AUC CL=1110.0±100.1 vs. saline
1459.0±106.9, p<0.05; insulin AUC CL=427.4±46.1 vs. saline=
762.5±78.0, p<0.01, t-tests), and attenuated the reduction of oxygen
consumption seen in the transition of environmental temperature from
22 to 30°C (thermoneutrality) seen in saline controls (p<0.0001 for infu-
sion, two-way ANOVA). In the rats, CL infusion decreased body weight
and fasting plasma glucose levels (BW change CL=17.3±7.3 vs. saline=
34.9±4.3 g, p<0.05, t-test; glucose CL=4.53±0.09 vs. saline=5.13±
0.20 mM, p<0.05), while there was no effect on food intake. Using
infrared thermo-imaging, an increase in tail heat dissipation was seen in
the CL-infused rats (CL=33.6±0.6 vs. saline=29.8±0.3°C, p<0.01, t-
test). Whole-body FFA clearance and appearance were unchanged while
CL administration markedly increased both FFA storage (p<0.0001, t-
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test) and utilisation (p<0.0001, t-test) in the interscapular and perirenal
BAT. Surprisingly, CL did not influence FFA uptake or utilisation in the
inguinal fat depot.
Conclusion: In summary, β3-agonism improved glucose tolerance and
increased oxygen consumption in mice. In rats, β3-agonism robustly
increased FFA flux to BAT coupled with an enhanced utilisation, which
was not the case in inguinal fat. Enhanced BATactivationwas most likely
driving the increased heat dissipation through the tail in order to maintain
thermostasis. Our results emphasise the quantitative role of brown fat as
the functional target of β3-agonism.
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Effect of metformin on glucose and fatty acid utilisation in brown
adipose tissue
J. Trnovska, V. Skop, H. Malinska, L. Kazdova;
Center for Experimental Medicine, Institute for Clinical and Experimen-
tal Medicine, Prague, Czech Republic.
Background and aims:Metformin is the first-line drug for the treatment
of type 2 diabetes. Its main action is the inhibition of glucose synthesis and
gluconeogenesis in the liver. In addition to its antihyperglycemic properties,
growing evidence indicates that metformin also affects lipid metabolism
and reduces body weight and abdominal fat mass. However, the mecha-
nisms are still unclear. These effects might be mediated by lowered pro-
duction of VLDL-TG in the liver or by increase in VLDL-TG clearance in
peripheral tissues. Recently, brown adipose tissue (BAT) was identified as
an important organ involved in clearing plasmatic VLDL-TG for thermo-
regulation and thus could prevent obesity, ectopic fat accumulation and
associated metabolic disturbances. The aim of this study was to investigate
if metformin increases glucose and fatty acid utilization in BAT, and ame-
liorate related parameters of metabolic syndrome.
Materials and methods: Male Wistar rats (age: 8 months) were fed a
standard diet (SD) or SD enriched by metformin in the following dose:
300 mg/kg b.wt./day for 4 weeks. Plasma levels of selected parameters
were measured using commercially available kits: triglycerides, insulin,
high molecular weight (HMW) adiponectin and C-reactive protein
(CRP). BAT activity was determined ex vivo by oxidation of 14C-U-
palmitic acid and 14C-U-glucose into CO2 in BAT and incorporation of
14C-U-palmitic acid and 14C-U-glucose into BAT lipids after 2-hour in-
cubation at 37°C.
Results: Metformin treatment significantly decreased body weight from
527±20 g at the beginning to 431±16 g at the end of treatment (p<
0.001), whereas body weight of controls was not significantly affected
(559±16 vs. 575±22 g; N.S.). Compared to controls, metformin de-
creased the weight of visceral adipose tissue: epididymal adipose tissue
(0.422±0.025 vs. 1.087±0.078 g/100 g b.wt; p<0.002) and perirenal
adipose tissue (0.073±0.009 vs. 0.616±0.092 g/100 g b.wt; p<0.01).
Plasma levels of triglycerides were decreased by metformin treatment
(0.560±0.060 vs. 1.360±0.180 mmol/l; p<0.01). Metformin also re-
duced ectopic fat accumulation in selected tissues: the liver (2.718±
0.201 vs. 9.594±1.564 μmol/g; p<0.02), heart (0.989±0.276 vs. 2.880
±0.533μmol/g; p<0.03), aorta (4.482±0.866 vs. 8.659±0.434μmol/g; p
<0.01) and diaphragm (3.551±1.100 vs. 17.360±2.769 μmol/g; p<
0.01). Metformin increased palmitic acid oxidation in BAT (106±15 vs.
58±10 nmol palm./g/2 h; p<0.03) and palmitic acid incorporation into
BAT lipids (2443±129 vs. 1797±111 nmol palm./g/2 h; p<0.01). Glu-
cose incorporation into BAT lipids were higher after metformin treatment
(basal: 1141±117 vs. 448±61 nmol gl./g/2 h; p<0.01 and insulin-stimu-
lated: 4876±345 vs. 1945±583 mnol gl./g/2 h; p<0.01), whereas basal
and insulin-stimulated glucose oxidationwere not influenced. In addition,
metformin also reduced plasma insulin levels (0.182±0.008 vs. 0.469±
0.003 nmol/l; p<0.001), increased HMW adiponectin plasma levels
(1.365±0.105 vs. 0.952±127 μg/ml; p<0.04) and decreased CRP plasma
concentration (238±33 vs. 502±127 μg/ml; p<0.015).
Conclusion: Results indicate that metformin-induced increase of lipid
and glucose utilization in BAT may participate in the mechanism of
improving metabolic syndrome and related disorders.
Supported by: GACR P305/13-04420S and MH CZ - DRO IKEM, IN
00023001
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The peripherally restricted CB1 receptor antagonist AM6545 reverts
experimental diabetic nephropathy
F. Barutta, S. Grimaldi, G. Gruden;
Medical Sciences, University of Turin, Italy.
Background and aims: Diabetic nephropathy (DN) is characterised by
increased glomerular permeability to proteins and excessive extracellular
matrix accumulation in the mesangium. The endocannabinoid system has
been implicated in the pathogenesis of DN as the cannabinoid receptor of
type 1 (CB1R) is overexpressed by podocytes and CB1R blockade with
AM6545 prevents the onset of both albuminuria and renal structural
abnormalities in an animal model of streptozotocin-induced diabetes.
AM6545, a peripherally restricted CB1R antagonist, is devoid of behav-
ioural side effects as it does not across the blood-brain barrier and may
thus represent a novel tool for DN treatment. Our aim was to perform a
reversal study to establish if AM6545, either alone or in combinationwith
a ACE-inhibitor, reverts charactheristic features of DN in diabetic mice
with established proteinuria.
Materials and methods: Male C57Bl6 mice were made diabetic by
intraperitoneal (i.p.) injection of streptozotocin (55mg/kg in citrate buffer
delivered in 5 consecutive days). Control mice (ND) were injected with
citrate buffer alone. Eight weeks after diabetes onset, diabetic mice (DM)
were further randomised to receive treatment with either vehicle (n=4),
AM6545 (DM-A: 10 mg/kg i.p. daily; n=4), enalapril (DM-E: 2 mg/kg
gavage daily; n=4) or both (DM-A+E, n=4). After six weeks of treat-
ment, mice were individually placed in metabolic cages for urine collec-
tions and blood samples taken for blood glucose and glycated
haemoglobin measurements. Then, mice were sacrificed, kidneys re-
moved, weighed, and analysed. Urinary albumin excretion was measured
by enzyme-linked immunosorbent assay. Expression of slit-diaphragm
proteins (nephrin and podocin) was assessed by immunofluorescence.
Markers of fibrosis (fibronectin, collagen I) were assessed by immuno-
fluorescence and/or real-time PCR on total renal cortex.
Results: Diabetes was associated with reduced body weight and an in-
crease in both blood glucose and glycated haemoglobin levels. Systolic
blood pressure was unaltered by AM6545, but reduced by enalapril.
Albuminuria was significantly (p<0.001) increased in the diabetic
[DM:429.9 (382.7-513.7) μg/18 hrs, geometric mean (25th-75th percen-
tile)] as compared to NDmice [ND:118.4 (110.7-124.6)] and ameliorated
by treatment with either AM6545 [DM-A:242.6 (213.2-297.9); p<0.05
DM-AM6545 vs DM] or enalapril [DM-E: 235.1 (217.4-267.9); p<0.05
vs DM]. Combination therapy with AM6545 and enalapril further re-
duced albuminuria and the difference as compared to ND mice was no
longer statistically significant [DM-A+E: 144.8 (112.3-204.5); p<0.05
DM-A+E vs DM-A and DM-E]. In DMmice the increase in albuminuria
was paralleled a significant reduction in both podocin and nephrin ex-
pression. This was significantly reduced by treatment with either
AM6545 or enalapril and completely prevented by the combination ther-
apy. Diabetes-induced overexpression of fibronectin and collagen was
abolished by single therapy and hence administration of both compounds
did not result in further benefit.
Conclusion: Treatment with AM6545 ameliorated experimental DN and
combination therapy with AM6545 and enalapril abolished diabetes-
induced both albuminuria and slit diaphragm protein loss.
Supported by: EFSD/Sanofi
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Age-related carbonylation in glomeruli of diabetic mice influences
anti-oxidative defense mechanisms
T.J. Wiedenmann1, C. Sultan1, N. Dietrich2, T. Fleming3, L.E.
Deelman4, R.H. Henning4, P. Nawroth3, H.-P. Hammes2, M. Hecker1,
A.H. Wagner1;
1Division of Cardiovascular Physiology, University of Heidelberg, 2Uni-
versity Hospital Mannheim, 3Department of Medicine I and Clinical
Chemistry, University Hospital Heidelberg, Germany, 4Department
of Clinical Pharmacy and Pharmacology, University of Groningen,
Netherlands.
Background and aims: Increased levels of reactive oxygen species
(ROS) greatly contribute to the development of diabetic complications
such as nephropathy. They induce carbonylation of proteins, which in
high amounts impedes normal cell function. However, physiological
amounts of ROS might have protective effects as they are involved in
cellular signaling pathways. This study aims to analyze the influence of
age-dependent protein carbonylation on the expression and activity of the
cytosolic anti-oxidative selenoenzyme GPx in the context of diabetic
nephropathy in mice.
Materials and methods: In addition to standard methods,
dinitrophenylhydrazine (DNPH) derivatization has been used to detect
carbonylated proteins in kidney homogenates and tissue sections of dia-
betic Ins2Akita mice of different ages and 18 week old db/db mice. GPx
activity was determined using a luminescent activity assay.
Results: Protein carbonylation was found to be increased in the
kidneys of both db/db and Ins2Akita mice compared to non-
diabetic control mice. Carbonylation increased with age in
Ins2Akita mice and carbonylated proteins co-localized with
podocytes and mesangial cells in glomeruli. In line, GPx1 and
GPx4 expression were found to be increased in those cell types
in diabetic Ins2Akita mice compared to non-diabetic animals. In
addition, GPx activity was augmented in kidneys of Ins2Akita
mice, especially in young (1 month) diabetic animals that did
not show a simultaneous upregulation of GPx on the protein lev-
el. In these young animals, immunoprecipitated GPx1 was found
to be carbonylated. Using a recombinant GPx1 protein, an in-
creased activity after mild in vitro carbonylation could be proved.
In podocytes cultured under high glucose conditions (25 mM for
7 days), GPx protein expression was increased as well, whereas
its activity was found to be decreased.
Conclusion: GPx carbonylation in the kidney is associated with an in-
crease in its activity at early stages of diabetes whereas this effect was
absent in animals with end-stage disease and cultured podocytes demon-
strating the role of protein carbonylation in the mechanism of ROS sig-
naling. These results indicate that there might be a threshold for beneficial
carbonylation-dependent redox signaling during the progression of dia-
betic nephropathy.
Supported by: GRK 1874 DIAMICOM, DFG
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Loss of ALCAM/CD166 partially protects against diabetic
nephropathy
A. Sulaj1, R. von Bauer2, S. Kopf1, E. Gröne3, H.-J. Gröne3, S. Hoff-
mann4, E. Schleicher5, H.-U. Häring5, V. Schwenger6, S. Herzig7, P.P.
Nawroth1, T. Fleming1;
1Department of Internal Medicine I and Clinical Chemistry, University of
Heidelberg, 2Department of Internal Medicine, SRH Klinikum Karlsbad-
Langensteinbach, Karlsbad, 3Division of Cellular and Molecular Pathol-
ogy, German Cancer Research Center, Heidelberg, 4Medical Research
Center, Medical Faculty Mannheim, University of Heidelberg, Mann-
heim, 5Department of Internal Medicine, University of Tübingen, 6De-
partment of Nephrology, University of Heidelberg, 7Joint Research Divi-
sion, Molecular Metabolic Control, German Cancer Research Center
DKFZ, Network Aging Research, ZMBH, Heidelberg, Germany.
Background and aims: Activated leukocyte cell adhesion molecule
(ALCAM/CD166) has been shown to function as a pattern recognition
receptor, analogue to the receptor of advanced glycation endproducts, and
has been implicated in the development and progression of diabetic ne-
phropathy (DN). In this study the role of ALCAM inDNwas investigated
in patients with type 2 diabetes, suffering from DN, and further investi-
gated in vitro and in vivo using homozygous knock-out mice for
ALCAM (ALCAM-/-).
Materials and methods: Serum concentration of soluble ALCAM
(sALCAM) and the expression of ALCAM and its ligand S100B in the
kidney of patients with type 2 diabetes were determined by ELISA and
histology, respectively. In vivo, diabetes was induced by low-dose
streptozotocin in wild-type and ALCAM-/- mice. Diabetes was main-
tained for six months, after which time, the mice were assessed for symp-
toms of DN, as well expression of ALCAM. In vitro isolated tubular
epithelial cells from wild-type and ALCAM-/- mice were studied.
Results: Serum concentration of sALCAMwas significantly increased in
patients with type 2 diabetes (59.85±14.99 ng/ml vs. 126.88±
66.45 ng/ml, P<0.0001), and correlated positively with HbA1c (R=
0.45, P<0.001), as well as the extent of chronic kidney disease but neg-
atively correlated with estimated GFR (R=-0.3, P<0.01). In the kidneys
of patients with type 2 diabetes, the expression of ALCAM was signifi-
cantly up-regulated in both the glomeruli and proximal and distal tubules.
In contrast, the expression of S100B was significantly increased in the
glomeruli, especially in the podocytes, but not in the tubules. In mice, the
expression of ALCAM was also localized to the glomeruli and tubules.
However, expression of S100B was only localized to the tubules. It was
found that diabetic ALCAM-/- mice had no increase in albuminuria as
well as no changes in either creatinine/body weight ratio or kidney-to-
body weight ratio. Furthermore, glomerular and tubular damage were
significantly lower than in the wild-type diabetic mice. In vitro it was
found that S100B-induced expression of TGF-beta was dependent on
ALCAM under diabetes conditions.
Conclusion: This study identifies ALCAM as a novel mediator in the late
complications of diabetes in the kidney.
Supported by: DZD, SFB1118, Dietmar-Hopp-Stiftung
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Soluble Nogo-B ameliorate angiogenesis in vitro in an experimental
model of diabetic nephropathy
J. Pan1, J. Karalliedde1, N. Fountoulakis1, A.E. Hayward1, L. Ashraf1,
A. Kahlon1, K.E. White2, D.A. Long3, L. Gnudi1;
1Cardiovascular Division, King's College London, 2Electron Microscopy
Research Services, University of Newcastle, 3Developmental Biology
and Cancer, University College London, UK.
Background and aims: We recently explored the role of neurite out-
growth inhibitor (Nogo)-B, in the pathophysiology of diabetic
nephropathy (DN). Nogo-B and its soluble form (sNogo-B) have been
implicated in the regulation of cell survival, cell migration and vascular
remodelling - known to be altered in diabetic glomerulopathy. Both
Nogo-B (at the cellular level) and sNogo-B (systemically) bind to NgBR
(expressed mainly in endothelial cells), and promote vascular remodel-
ling. In earlier work we have demonstrated that Nogo-B and NgBR are
expressed in glomeruli and that Nogo-B is downregulated in glomeruli of
experimental animal model of diabetes. The role of Nogo-B and sNogo-B
in diabetic glomerulopathy is unknown, therefore our aims were to inves-
tigate: i) the role of high glucose and VEGF-A on Nogo-B and sNogo-B
expression in human glomerular endothelial cells (GECs) in vitro; ii)
in vitro, whether sera obtained from patients with type-1 diabetes and
DN (T1DM/DN+) is paralleled by altered angiogenesis when compared
to sera from T1DM without DN (T1DM/DN-); iii) whether overexpres-
sion of sNogo-B could modulate angiogenesis.
Materials and methods: Conditionally immortalised GECs were incu-
bated with high (HG: 25 mM) or normal (NG: 5 mM+20 mM mannitol)
glucose, with or without VEGF-A (50 ng/ml), for 72 h. Serum was ob-
tained from patients with T1DM/DN+ (n=18) or T1DM/DN- (n=17); the
two groups had similar age, sex, HbA1c, duration of diabetes, BP, lipid
profile, renal function, urine albumin/creatinine ratio, sNogo-B serum
levels and only differed in that the DN+ had history of albuminuria and
were all treated with inhibitors of the renin-angiotensin-system. Angio-
genesis assay with human umbilical vein endothelial cells (HUVEC) was
conducted in the presence of the patient sera (4%vol/vol) onMatrigel and
tube formation assessed after 24 h under light microscopy and quantified
with image analysis. sNogo-B overexpression was achieved by transfec-
tion with adenoviral vector. ELISA was utilised to quantify sNogo-B
levels in cell supernatant and patients’ sera.
Results: HG and VEGF-A resulted in Nogo-B downregulation in GEC
(p<0.05), no additive effect was seen with their combination. The down-
regulation of full length Nogo-B was always paralleled by an increase of
sNogo-B in the cells supernatant (p<0.05). HUVEC cultured in
T1DM/DN+ sera displayed a 50% reduction in tube formation (total loop
number), when compared to cells cultured in T1DM/DN- sera (p<0.05).
HUVEC transfection with sNogo-B vector achieved a 4-5 folds increase
in sNogo-B in the cell supernatant when compared to control vector (p<
0.001). Overexpression of sNogo-B improved the impaired tube forma-
tion observed in cells incubated with T1DM/DN+ sera (p<0.05). No
significant effect of the overexpression was seen within the group incu-
bated with T1DM/DN- sera.
Conclusion:High glucose and VEGF-A downregulate Nogo-B, an event
paralleled by upregulation of sNogo-B. Overexpression of sNogo-B im-
proves the impaired angiogenesis seen in cells incubated with sera from
patients with T1DM/DN+. Circulating sNogo levels may influence the
progression of kidney disease in diabetes and future work will address
this question in experimental model of diabetes and in the clinical setting.
Supported by: Heart Research UK
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The renal protective effects of induction of heme oxygenase-1 com-
bined with increased adiponectin on the glomerular VEGF-NO axis
in obese rats
F. Han1, X. Liu2, N. Hou2, X. Sun2;
1Department of Pathology, Affiliated Hospital of Weifang Medical
University, 2Department of Endocrinology, Affiliated Hospital of Wei-
fang Medical University, China.
Background and aims: The uncoupling of glomerular vascular endothe-
lial growth factor (VEGF) - nitric oxide (NO) axis is an important mech-
anism of obesity-related nephropathy. The beneficial effects of heme
oxygenase-1(HO-1) induction in metabolic disease are mediated via its
effects on adiponectin-dependent pathways, which is called the HO-1/
adiponectin axis This study aimed to investigate whether induction of
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heme oxygenase-1 (HO-1) can reduce microalbuminuria and provide
renal protective effects by improving endothelial dysfunction and
uncoupling of glomerular VEGF-NO axis through increasing the
adiponectin levels in obese rats.
Materials and methods: Rats received high-fat diets and were injected
with either cobalt protoporphyrin (CoPP) to induce HO-1, or stannous
protoporphyrin to inhibit HO-1. Blood and urine samples were collected.
Endothelial function was determined by measuring endothelium-
dependent vasodilatation of the aorta. Renal tissues were collected for
CD34 immunohistochemistry. Glomerular NO levels were measured by
the Griess reaction. Glomerular AMPK, Akt and eNOS protein were
measured by western blot.
Results: Obese rats exhibited a significant increase in body weight, vis-
ceral fat, albumin-to-creatinine, plasma FFA levels, and serum levels of
triglyceride, hs-CRP, TNF-α and malondialdehyde when compared with
the control rats (P<0.01). Induction of HO-1 by CoPP resulted in a sig-
nificant decrease in the above index in obese rats when compared with
untreated obese rats (body weight, 579.7±66.5 g vs 702.3±94.4 g; vis-
ceral fat, 24.8±10.3 g vs 54.90±14.18 g; albumin-to-creatinine, 49.25±
14.93 mg/g vs 94.1±16.27 mg/g; FFA, 0.74±0.31 mmol/L vs 1.29±
0.36 mmol/L; hs-CRP, 1.04±0.41 mg/L vs 2.28±0.61 mg/L; TNF-α,
56.8±8.9 pg/ml vs 92.5±0.2 pg/ml; malondialdehyde, 2.28±0.51 umol/L
vs 3.92±0.51 umol/L, P<0.01). Serum adiponectin levels were reduced
in obese rats compared with control rats(12.77±2.77 mg/g vs 20.34±
2.76 mg/g, P<0.01), which increased after induction of HO-1 (19.35±
2.67 mg/g vs 12.77±2.77 mg/g, P<0.01). Severe endothelium-dependent
vasodilatation impairment was observed in the obese rats, which was
partially improved by HO-1 induction. CD34 expression in the glomeruli
was also enhanced in obese rats, indicating increased proliferation of
glomerular endothelial cells [mean optical density (IOD/area): 0.123±
0.015 vs. 0.094±0.010, P<0.05]. However, Induction of HO-1 improved
the increased proliferation of endothelial cells in glomeruli in obese rats
(IOD/area: 0.101±0.009 vs. 0.123±0.015, P<0.05). Obese rats showed
increased glomerular VEGF expression and reduced NO levels (P<0.05).
This uncoupling of the VEGF-NO axis was partially improved by induc-
tion of HO-1, with enhancement of phosphorylation of glomerular
AMPK, AKT and eNOS in obese rats (P<0.05)
Conclusion: Induction of HO-1 with CoPP, paralleled by an increase in
serum adiponectin levels, reduces the degree ofmicroalbuminuria and has
renal protective effects by improving endothelial dysfunction and regu-
lating the uncoupled glomerular VEGF-NO axis in diet-induced obese
rats. The mechanism may be related to increased activation of the HO-1/
adiponectin axis.
Supported by: NSFC (NO. 81300688 and 81400829)
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Cellular hypoxia and mitochondrial reactive oxygen species may
promote hyperglycaemic damage in a coordinated manner
S. Kiminori1, T. Nishikawa2, D. Kukidome1, N. Kajiwara1, H.
Motoshima1, T. Matsumura1, E. Araki1;
1Metabolic Medicine, Kumamoto University, 2Molecular Diabetology,
Kumamoto University, Japan.
Background and aims: We previously proposed that hyperglycemia-
induced mitochondrial reactive oxygen species (mtROS) production is a
key event in the development of diabetic complications. However, “leg-
acy effect” and “metabolic memory”, which are reported in DCCT/EDIC
and UKPDS, respectively, cannot be explained by the theory. Interesting-
ly, there are some common points between hyperglycemia and hypoxia-
induced phenomena such as apoptosis and fibronectin production. There-
fore, we suspect that hyperglycemia may induce cellular hypoxia, which
can produce mtROS without hyperglycemia.
Materials and methods: Bovine aortic endothelial cells (BAEC),
C57BL6 mice, and eMnSOD-Tg mice (which express manganese
superoxide dismutase (MnSOD) specifically in vascular endothelial cells)
were used for analysis. Cellular hypoxia was evaluated by hypoxia-
sensing probes, pimonitazol and LOX-1. mtROS was measured by the
reduced MitoTracker Red probe. Apoptosis was evaluated by TUNEL
assay. Fibronectin mRNAwas measured by quantitative RT-PCR.
Results: 1) In BAEC, cellular hypoxia evaluated by pimonitazol and
LOX-1 increased 1.9 and 2.0 times, respectively, after 3 hours incubation
with hyperglycemic condition (25 mM glucose) compared to that with
normoglycemic condition (5.5 mM glucose), and this phenomenon was
also observed after 24, 72 or 168 hours incubation with hyperglycemic
condition. Hypoxia was also observed in the glomeruli of STZ-induced
diabetic mice compared to those of control non-diabetic mice. 2) In
BAEC, mtROS production was increased in both hyperglycemic and
hypoxic condition (1, 3, 5 or 10% oxygen). The hypoxia-induced mtROS
production was reduced by Bis-2-(5-phenylacetamido-1, 3, 4-thiadiazol-
2-yl) ethyl sulfide (BPTES), which can inhibit glutamine incorporation
into mitochondria, whereas hyperglycemia-induced mtROS production
was not reduced by BPTES. 3) Rotenone and antimycin, both of which
can reduce oxygen consumption in mitochondria, ameliorated
hyperglycemia-induced cellular hypoxia. Interestingly, the
hyperglycemia-induced cellular hypoxia was also reduced by the overex-
pression of MnSOD in BAEC and in eMnSOD-Tg mice. 4) The overex-
pression of aquaporin-1, which is a water and gas channel, ameliorated
hyperglycemia-induced cellular hypoxia, apoptosis and fibronectin
mRNA induction in BAEC.
Conclusion: The findings of this study demonstrate that hyperglycemia
can induce cellular hypoxia, and the hypoxia can increase mtROS pro-
duction without hyperglycemia. In addition, increased oxygen consump-
tion and overproduction of mtROS are involved in hyperglycemia-
induced cellular hypoxia. Ameliorating cellular hypoxia by the overex-
pression of aquaporin-1 can inhibit apoptosis and fibronectin production
by hyperglycemia. Therefore, hyperglycemia-inducedmtROS production
and cellular hypoxia may develop diabetic complications in a coordinated
manner, and these phenomennamay be one of the mechanisms of “legacy
effect” and “metabolic memory”.
Supported by: the Japan Society for the Promotion of Science
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Weight loss improves impaired muscle capillary recruitment in
overweight/obese men: effects on metabolic insulin resistance
Y.H.A. Kusters1,2, C.G. Schalkwijk1,2, A.J.H. Houben1, J. Op 't
Roodt1,2, P.J. Joris3,2, R.P. Mensink3,2, E.J. Barrett4, C.D.A. Stehouwer1;
1Department of Internal Medicine, MUMC, Maastricht, 2Top Institute
Food and Nutrition, Wageningen, 3Department of Human Biology,
MUMC,Maastricht, Netherlands, 4Department of Medicine, Endocrinol-
ogy and Metabolism, University of Virginia, Charlottesville, USA.
Background and aims: Overweight and obesity are associated with
metabolic insulin resistance, and an increased risk of type 2 diabetes
(T2DM) and cardiovascular diseases (CVD). In skeletal muscle, insulin
normally increases the number of perfused capillaries, enhancing its own
delivery and that of glucose to myocytes. Impairments in insulin-induced
muscle capillary recruitment may be responsible for the metabolic insulin
resistance in obese individuals. It is, however, unknown whether weight
loss can restore capillary recruitment and whether this improves metabol-
ic insulin sensitivity. Therefore, we compared healthy lean men to
overweight/obese men and subsequently studied the effect of weight loss
in the latter.
Materials and methods: In a randomized controlled trial with blinded
analyses, 53 non-smoking, overweight/obese men (waist circumference
102-110 cm; aged 18-65; no CVD or T2DM) underwent either an 8-week
weight loss program (6 weeks low calorie diet (LCD), 2 weeks weight
stable) or maintained their usual diet for 8 weeks and were compared to
25 lean men (waist circumference <94 cm). During a 1 mU/kg/min
euglycaemic insulin clamp, we estimated metabolic insulin sensitivity
from the glucose infusion rate (GIR) and forearm muscle capillary re-
cruitment as the change in microvascular blood volume (ΔMBV) using
contrast-enhanced ultrasound. Overweight/obese men were studied at
baseline and after completion of their 8-week program, whereas lean
men were studied at baseline only.
Results:All 25 lean men and 50 overweight/obese men completed the
study. Baseline BMI was 23.3±1.8 kg/m2 in lean men, 29.9±2.5 kg/
m2 in the usual-diet group, and 30.0±1.7 kg/m2 in the LCD group.
LCD reduced BMI by 3.0±0.8 kg/m2 (p<0.001), whereas BMI in the
usual-diet group did not change (+0.1±0.4 kg/m2). Insulin-induced
ΔMBV at baseline was 44.4±41.2% in lean men; in both the usual-
diet (0.7±27.6%) and the LCD group (-5.6±26.2%) capillary recruit-
ment was blunted (p<0.001). LCD was able to restore part of this
response, to 33.4±39.6% (p<0.001), whereas ΔMBV remained un-
changed in the usual-diet group (0.4±25.4%). Baseline metabolic in-
sulin sensitivity was 6.76±1.79 mg/kg/min in lean men, 4.03±
1.39 mg/kg/min in the usual-diet group, and 4.06±1.28 mg/kg/min
in the LCD group. LCD increased insulin sensitivity by 1.31±
1.19 mg/kg/min (p<0.001), whereas insulin sensitivity remained unal-
tered in the usual-diet group. At baseline, ΔMBV was associated with
both BMI (r=-0.414; p<0.001) and GIR (r=0.577; p<0.001). More-
over, changes in ΔMBV were accompanied by changes in GIR (r=
0.499; p<0.001).
Conclusion: We conclude that both insulin-induced muscle capil-
lary recruitment and metabolic insulin sensitivity are impaired in
overweight/obese men. LCD-induced weight loss was associated
with improved insulin-induced muscle capillary recruitment and
insulin sensitivity. Furthermore, these changes were related to
one another. These findings support the hypotheses that impaired
vascular actions of insulin contribute to metabolic insulin resis-
tance in overweight/obese individuals and that weight loss im-
proves both.
Clinical Trial Registration Number: NCT01675401
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Impaired metabolism and transcriptional profile in cultured muscle
stem cells from individuals born with low birth weight
N.S. Hansen1, L. Hjort1, C. Broholm1, L. Gillberg1, M. Schrölkamp1, B.
Mortensen2, S.W. Jørgensen3, M. Friedrichsen4, J.F.P. Wojtaszewski4,
B.K. Pedersen5, A. Vaag1;
1Department of Endocrinology, Rigshospitalet, Copenhagen, 2Center for
Diabetes Research, Gentofte Hospital, 3Steno Diabetes Center A/S, Gen-
tofte, 4Department of Nutrition, Exercise and Sports, University of Co-
penhagen, The August Centre, Copenhagen, 5Centre of Inflammation and
Metabolism, Rigshospitalet, Copenhagen, Denmark.
Background and aims: Individuals born with low birth weight (LBW)
have an increased risk of developing type 2 diabetes (T2D) later in life.
We hypothesized that immature muscle stem cell functions including
abnormal differentiation potential and metabolic function could link
LBW with risk of developing T2D.
Materials and methods: We recruited 23 young men with LBW
(mean birth weight 2.7±0.2 kg) and 16 age-matched control sub-
jects (mean birth weight 3.7±0.2 kg) with normal birth weight.
Biopsies were obtained from vastus lateralis and muscle stem
cells were isolated and cultured into fully differentiated myotubes.
We studied glucose uptake, insulin signaling, myokine secretion,
selected site specific DNA methylation and key transcriptional
markers of cell maturity as well as mitochondrial gene expression
throughout cell differentiation.
Results: In the cultured LBW cells, we found significantly reduced glu-
cose uptake, decreased glucose transporter-4 gene expression and de-
creased levels of Akt substrate of 160 kDa compared to NBW cells.
Additionally, interleukine-6 release was increased during myoblast differ-
entiation and the expression levels of a selected set of mitochondrial
OXPHOS genes including the peroxisome proliferator-activated recep-
tor-γ coactivator-1α (PGC-1α), as well as the sarcomere gene myosin
heavy chain 2, were down regulated in LBW cells. Decreased gene ex-
pression was not explained by changes in DNA methylation levels in
gene promoter regions.
Conclusion: Our findings of transcriptional and metabolic changes in
cultured muscle stem cells from LBW subjects support the idea of altered
muscle stem cells function potentially contributing to increased risk of
developing T2D in these subjects.
Clinical Trial Registration Number: H-A-2009-040 and H-D-2008-127
Supported by: EFSD/Lilly, Rigshospitalet and Danish Strategic Research
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Maternal obesity and telomere length associate with skeletal muscle
insulin resistance which is reversed by exercise training in elderly
womenM. Bucci1, V. Huovinen1,2, M.A. Guzzardi3, S. Koskinen1, J.
Raiko1, H. Lipponen1, R.M. Badeau1, N. Sarja1, M. Salonen4, J.
Andersson5, J. Kullberg5, S. Sandboge4, P. Iozzo3, J.G. Eriksson4,6, P.
Nuutila1,7;
1Turku Pet Centre, 2Department of Radiology, Medical Imaging Centre
of Southwest Finland, Turku University and Turku University Hospital,
Finland, 3PET Centre, Institute of Clinical Physiology, National Research
Council, Pisa, Italy, 4Folkhälsan Research Centre, Helsinki, Finland, 5De-
partment of Radiology, Uppsala University, Sweden, 6University of Hel-
sinki, 7Department of Medicine, University of Turku and Turku Univer-
sity Hospital, Finland.
Background and aims:Maternal obesity during pregnancy predisposes
for subsequent morbidities in the offspring, including type 2 diabetes.
T2DM and insulin resistance have been associated with shortening of
leucocyte telomere length (LTL). Effects of resistance training (RT) on
whole body and skeletal muscle glucose disposal are not known in elder-
ly. The aims of this study were to test insulin sensitivity in elderly frail
S16 Diabetologia (2015) 58 (Suppl 1):S1–S607
women with maternal obesity and test the effects of RTon muscle insulin
sensitivity and masses.
Materials and methods:We recruited 48 women with the mean age of
72 years, of which 11 were non-frail controls (CTR), 20 frail offspring of
lean/normal weight mothers (OLM) (BMI≤26.3 kg/m2) and 17 frail off-
spring of obese mothers (OOM) (BMI≥28.1 kg/m2). The frail women
were studied before and after a 4 mo RT intervention, and controls once
using FDG-PET during hyperinsulinemic euglycaemic clamp and MRI
for the measurement of skeletal muscle mass. Glucose uptake (GU/kg)
and accounting for masses (GU(depot)) were calculated for the skeletal
muscles of the thigh. LTL was assessed from peripheral blood mononu-
clear cells.
Results: The OOM group had a lower thigh muscle insulin sensitivity
compared to the OLM group (p=0.048). Significant positive correlations
were found in the OOM group between LTL and thigh muscle GU(/kg
and depot) (R≥0.53, p≤0.05). Training increased whole body (p=0.004)
and skeletal muscle insulin sensitivity both per volume and per total
muscle mass (p=0.013 and p=0.004, respectively). Quadriceps muscle
mass increased by intervention in both groups (p=0.008 and p=0.001,
OLM and OOM respectively).
Conclusion:Maternal obesity during pregnancy and telemere length are
associated with insulin resistance in the adult offspring. RT helps to re-
verse the insulin resistance in elderly women with maternal obesity. RT is
equally effective in increasing muscle mass in elderly women regardless
of their maternal BMI.
Clinical Trial Registration Number: NCT01931540
Supported by: DORIAN (FP7/2007-2013) GA n° 278603
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Impaired PI 3-kinase signalling in a mouse model of SHORT
syndrome
M.H. Solheim1,2, J.N. Winnay1, A. Molven2,3, P.R. Njølstad2,4, C.R.
Kahn1;
1Joslin Diabetes Center, Harvard Medical School, Boston, USA, 2KG
JebsenCenter for Diabetes Research, Dept of Clinical Science, University
of Bergen, 3Gade Laboratory for Pathology, Dept of Clinical Science,
University of Bergen, 4Dept of Pediatrics, Haukeland University Hospi-
tal, Bergen, Norway.
Background and aims: The phosphatidylinositol 3-kinase (PI3K) path-
way regulates a range of cellular functions involving glucose metabolism,
cell growth, differentiation and apoptosis. A key factor regulating this
pathway is the p85α regulatory subunit of PI3K, encoded by the PIK3R1
gene. We recently identified a heterozygous missense mutation in
PIK3R1 resulting in an Arg649Trp substitution in patients with SHORT
syndrome, characterized by short stature, partial lipodystrophy and insu-
lin resistance. To investigate whether the Arg649Trp mutation alone is
sufficient to replicate characteristic features of SHORT syndrome in vivo
and to explore the function of the mutant protein at a mechanistic level,
we generated knock-in mice harboring this mutation.
Materials and methods: Body weight was assessed longitudinally at the
indicated time-points. Body composition, length, blood glucose, serum
insulin insulin- and glucose tolerance tests were performed on animals at
the indicated ages. Insulin signaling was assessed in adipose tissue, liver
and skeletal muscle, snap frozen ten minutes following intra venous admin-
istration of vehicle or insulin.Western blottingwas performed onwhole cell
lysates isolated from brown preadipocyte cell lines or primary hepatocytes.
Results: Heterozygous knock-in mice demonstrated multiple features of
SHORT syndrome including a reduction in body weight and length, a
Rieger like abnormality in the iris and a reduction in subcutaneous adi-
pose tissue. By 8 weeks, knock-in mice were hyperglycemic in the fed
state compared to controls (17.7±1.4 vs. 11.8±0.9 mmol/l). An assess-
ment of insulin levels at the same age revealed marked hyperinsulinemia
in mutant animals (fed insulin 107.9±12.9 vs. 8.9±1.2 pmol/l). Mutant
mice also demonstrated a clear impairment in glucose tolerance and a
reduced response to exogenous insulin. At a molecular level, this was
caused by reduced activation of the PI 3-kinase pathway in adipose tissue
and liver in response to insulin assessed by the phosphorylation of AKT.
Brown preadipocyte cell lines and primary hepatocytes from control and
heterozygous mutant mice showed a distinct reduction in insulin-
dependent phosphorylation of AKT. Primary hepatocytes demonstrated
a reduction in phosphorylation of AKT upon stimulation with additional
growth factors including IGF-1 and EGF, suggesting resistance to multi-
ple growth factors. The reduced capacity of the mutant protein to link the
upstream activation of the insulin signaling pathway with the downstream
activation of AKT is due to a failure of the mutant protein to bind to IRS-1
following insulin stimulation.
Conclusion:Mice heterozygous for the Arg649Trp mutant allele pheno-
copy multiple aspects of the human SHORT syndrome, including a re-
duction in weight and length, partial lipodystrophy associated with a
selective reduction in subcutaneous adipose tissue and insulin resistance.
At a mechanistic level, we have demonstrated that the mutant protein fails
to interact with IRS-1 in response to insulin, leading to impaired activa-
tion of AKT.
Supported by: NIH, U of Bergen, RCN, KG Jebsen, NES, E. Eckbo, T.
Wilhelmsen
35
HIF-1alpha transcription factor: a molecular link between exercise
and insulin action
S.W. Görgens1, K. Eckardt1, M. Hjorth2, F. Norheim2, T. Holen2, S.
Lee2, T.M. Langleite2, K.I. Birkeland2, H.L. Gulseth2, C.A. Drevon2,
J. Eckel1;
1German Diabetes Center, Düsseldorf, Germany, 2Department of
Nutrition, University of Oslo, Oslo, Norway.
Background and aims: Skeletal muscle insulin resistance is the hallmark
of type 2 diabetes, and develops long before the onset of the disease. It is
well accepted that regular physical activity improves glycemic control but
the knowledge on underlying mechanisms mediating the protective ef-
fects remains incomplete. Exercise is accompanied by a reduction in
intra-muscular oxygen tension resulting in enhanced HIF-1α protein ex-
pression. HIF-1α is a master regulator of gene expression and might play
an important role in skeletal muscle function and metabolism. Thus, we
examined the role of oxygen tension in insulin- and contraction-
stimulated glucose metabolism in primary human skeletal muscle cells
(HSkMC). Furthermore, we analyzed the impact of acute and long-term
exercise on skeletal muscle HIF-1α expression in healthy control and
dysglycemic subjects.
Materials andmethods:HSkMCwere in vitro differentiated and electrical
pulse stimulation (EPS) was applied at different oxygen tensions. Insulin
action was measured by the phosphorylation of kinases of the insulin sig-
naling pathway and glucose uptake. Sedentary individuals for the human
study were divided in two groups; controls (n=13) with normal glucose
metabolism and dysglycemic subjects (pT2D; n=11). All participants were
subjected to a training program for 12weeks. An acute exercise sessionwas
performed before and after the 12 weeks of training intervention. Muscle
biopsies were taken before, directly after, and 2 h after the acute exercise
before as well as after 12 weeks of training. Whole body insulin sensitivity
was assessed by euglycemic-hyperinsulinemic clamp.
Results: Reduced O2 tension in combination with EPS strongly en-
hanced the insulin action at the level of Akt and AS160 phosphorylation
as well as glucose uptake. Furthermore, the combination of 7% O2 and
EPS resulted in an enhanced IL-6 production and secretion as well as
HIF-1α and GLUT4 protein expression. In contrast, knockdown of
HIF-1α totally inhibits the insulin- and contraction-induced glucose up-
take as well as insulin-stimulated signaling. Furthermore, GLUT4 and
GLUT1 protein expression were decreased. In addition, human skeletal
muscle HIF-1α mRNA expression was enhanced after acute and long-
term exercise, and positively correlated with glucose infusion rate (p=
Diabetologia (2015) 58 (Suppl 1):S1–S607 S17
0.03; r=0.47) and negatively with fasting glucose (p=0.02; r=-0.49).
Interestingly, the induction of exercise-mediated HIF-1α mRNA expres-
sion was reduced in the pT2D group.
Conclusion: We have demonstrated that the reduction of oxygen to 7%
and the combination with muscle contraction improved insulin action in
primary human skeletal muscle cells. Furthermore, we showed that HIF-
1α is an important determinant in insulin- and contraction-induced glu-
cose uptake. Muscle HIF-1α mRNA expression was up-regulated by
acute and long-term exercise, and positively correlated with whole body
insulin sensitivity in subjects with normal glucose metabolism. Thus, we
suggest that muscle HIF-1α is a key regulator of insulin- and exercise-
stimulated glucose metabolism in human skeletal muscle.
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The influence of hyperinsulinaemia and circulating NEFA elevation
on sirtuin 1 expression in human skeletal muscle
M. Stefanowicz1,2, N. Matulewicz1,2, A. Nikołajuk2, M. Strączkowski1,2,
M. Karczewska-Kupczewska1,2;
1Department of Metabolic Diseases, Medical University of Białystok,
2Department of Prophylaxis of Metabolic Diseases, Polish Academy of
Sciences, Olsztyn, Poland.
Background and aims: Sirtuin 1 (SIRT1), belonging to the family of
sirtuins (Sir2, silent information regulator 2 protein) is involved in the
regulation of glucose and lipid metabolism. SIRT1 has been proposed to
be an important regulator of insulin sensitivity. SIRT1 stimulates a
glucose-dependent insulin secretion from pancreatic β cells and may
influence directly or indirectly on insulin signaling pathway in insulin
sensitive cells. Furthermore, SIRT1 in interaction with PGC1α could
increase fatty acid oxidation and glucose uptake in muscle, which also
can prevent insulin resistance. The aim of our study was to estimate the
relationship between muscle SIRT1 and insulin signaling and the effects
of hyperinsulinemia and NEFA elevation on skeletal muscle SIRT1 ex-
pression in humans.
Materials and methods:We examined 108 apparently healthy men
with normal glucose tolerance (age: 23.30±2.7 years; BMI: 25.7±
4.0 kg/m2). In all subjects insulin sensitivity was evaluated by the
2 h euglycemic-hyperinsulinemic clamp. Additionally, in 20 sub-
jects, clamp was prolonged to 6 hours. After one week, another
6 h clamp combined with Intralipid/heparin infusion was per-
formed in 20 volunteers. In all subjects before the clamp muscle
biopsy was performed. In 20 individuals with prolonged clamps,
muscle biopsy were taken before and after 6 h clamp with and
without Intralipid/heparin infusion. Tissue mRNA expression of
SIRT1 and IRS1, IRS2, PIK3R1, PIK3CA, Akt2, SLC2A4,
PGC1α was analyzed with Real Time PCR.
Results: Intralipid/heparin infusion caused 4-fold concentration NEFA in
serum (p<0.001). Insulin sensitivity was decreased by about 40% after
6 h Intralipid/heparin infusion(p<0.001). Hyperinsulinemia increased
muscle SIRT1 expression (p=0.016), whereas in the presence of
Intralipid/heparin infusion this stimulatory effect of hyperinsulinemia
was abolished. Hyperinsulinemia resulted in a significant increase in the
expression of PIK3R1 (p<0.001), Akt2 (p=0.007), SLC2A4 (p=0.02)
and PGC1α (p<0.001). Intralipid/heparin infusion abolished most of
these changes. We observed a positive correlation between the expression
of SIRT1 and expression of IRS2 (r=0.31, p<0.001), PIK3R1 (r=0.26,
p=0.007), PIK3CA (r=0.26, p=0.008), Akt2 (r=0.45, p<0.001),
SLC2A4 (r=0.24; p=0.011) and PGC1α (r=0.21; p=0.03) in the base-
line state. Increase in muscle SIRT1 expression in response to
hyperinsulinemia was related to the concurrent change in PGC1α (r=
0.46, p=0.049) and SLC2A4 (r=0.52, p=0.02).
Conclusion: Our results indicate that insulin increases muscle SIRT1
expression and this effect is abolished by circulating NFEA elevation.
Thus, muscle SIRT1 may be involved in lipid- induced insulin resistance.
Supported by: UDA-POIG.01.03.01-00-128/08-00
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Pharmacokinetics, pharmacodynamics and tolerability of a novel
glucokinase activator TMG-123, after single oral ascending doses in
Japanse healthy subjects
T. Kimura, K. Sakurai, K. Morino, M. Shimizu, T. Ishikawa,
K. Shiobara, S. Suzuki, M. Taneda, M. Yamamoto;
Teijin Pharma Limited, Tokyo, Japan.
Background and aims:TMG-123 is a novel glucokinase activator with a
postulated liver dominant mechanism of action and with the potential to
deliver effective glucose-lowing in Type 2 diabetes mellitus. Two Phase I
studies were conducted to evaluate the pharmacokinetics (PK), pharma-
codynamics (PD) and tolerability of TMG-123 in Japanese healthy male
subjects after single oral ascending doses.
Materials and methods: Two, double-blinded, randomized, placebo-
controlled studies were conducted. Gradually increasing single oral doses
of 1 mg up to160 mg TMG-123 or placebo were administered during
fasting conditions. Each subject participated once, either on TMG-123 or
on placebo, with the exception of one dose group in the second study.
Subjects in this group participated on 2 occasions, once on TMG-123 /
placebo given in fasting conditions and once on TMG-123 / placebo
given in combination with a standardized breakfast. Eight dose levels
were evaluated in the first study and four in the second study. The PK
and PD variables were calculated by non-compartmental analyses.
Results: In total, 96 Japanese healthy male volunteers aged from 20 to
34 years were participated, and from 1 mg to 160 mg of TMG-123 or
placebo were administered. TMG-123 was well tolerated up to 160 mg
dose without serious adverse event or hypoglycemia, and most adverse
events were mild. No clinically significant changes in ECG, vital signs,
or safety laboratory assessments were observed. Following TMG-123 dos-
ing in fasting conditions, TMG-123 was rapidly absorbed at all dose levels
studied. The maximum concentration of TMG-123 in plasma (Cmax) was
generally reached within 1 hour after dosing. In the first study, Cmax and
AUC were increasing in dose up to 40 mg, whereas Cmax / AUC were
increasing in dose up to 80 / 160 mg in the second study. TMG-123 dosing
in 30 minutes after the standardized breakfast had no effect on Cmax, while
AUC was slightly increased and the time reached Cmax was delayed com-
pared to fasting conditions. The plasma TMG-123 concentration dependent
serum glucose decrease was observed up to around 200 ng/mL of plasma
TMG-123 level, whereas plasma TMG-123 level was reached around
500 ng/mL in the studies. A serum glucose lowering effect was maintained
during a fasting period. A serum insulin level was transiently increased at
0.5 hours post-dose to around 15 μU/mL over 80 mg dosing. No dose
dependent serum glucagon changes were observed.
Conclusion: TMG-123 was well tolerated in single doses up to 160 mg,
and no safety concerns were raised. TMG-123 was rapidly absorbed in
fasting conditions and no significant food effect on Cmax and AUC were
observed. The PK / PD result suggests a liver dominant glucokinase
activation of TMG-123 in humans.
Supported by: Teijin Pharma Limited
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ISIS PTP-1BRx, a novel PTP-1B antisense inhibitor, improves HbA1c
and body weight in patients with type 2 diabetes on metformin±
sulphonylurea
A. Digenio, L. Watts, B. Jung, R. Geary, S. Bhanot;
Clinical Development, Isis Pharmaceuticals, Inc., Carlsbad, USA.
Background and aims: Protein-tyrosine phosphatase 1B (PTP-1B) is a
negative modulator of insulin and leptin signaling. Inhibition of PTP-1B
S18 Diabetologia (2015) 58 (Suppl 1):S1–S607
action could address both diabetes and obesity, making it an attractive
target for drug development. This study evaluated the safety, tolerability
and efficacy of 6-month treatment with a PTP-1B antisense inhibitor
(ISIS PTP-1BRx) in a double-blind placebo-controlled, Phase 2 study in
overweight patients with Type 2 diabetes inadequately controlled on met-
formin with or without sulphonylurea (SU).
Materials and methods: Patients, mean age 57, 63% female, 53% Black,
with a hemoglobin A1c ≥7.5% and a mean BMI of 34 kg/m2 were ran-
domized to ISIS PTP-1BRx 200 mg or placebo administered as once week-
ly subcutaneous injections for 26 weeks. Patients had to be on a stable dose
of metformin (≥1000 mg/day) alone or in combination with SU (≥10 mg/
day). Seventy- five patients completed treatment and 69 were evaluated for
the primary endpoint based on protocol specified criteria.
Results:Data are Mean ± SD; #Mean Change (Δ) from Baseline toWeek
36 ISIS-PTP-1BRx was well-tolerated and did not cause severe hypogly-
cemia, gastrointestinal side effects or clinically significant changes in
hepatic or renal function.
Conclusion: In this study, ISIS PTP-1BRx treatment was generally
safe and well tolerated and resulted in significant reductions in
HbA1c and body weight that continued after cessation of treat-
ment. ISIS PTP-1BRx showed an attractive profile that includes
improved glycemic control without severe hypoglycemia and with
the additive benefit of weight loss, supporting future development
in patients with Type 2 diabetes.
Clinical Trial Registration Number: NCT01918865
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Improved postprandial glycaemic control with faster-acting insulin
aspart in individuals with type 1 diabetes using CSII
B.W. Bode1, L. Hyveled2, S.C. Tamer2, P. Ybanez1, M. Demissie2;
1Atlanta Diabetes Associates, Atlanta, USA, 2NovoNordiskA/S, Søborg,
Denmark.
Background and aims: This double-blind, randomised, crossover,
active-controlled trial compared 14 days of continuous subcutaneous in-
sulin infusion (CSII) of two formulations of faster-acting insulin aspart
(faster aspart) with CSII of insulin aspart (IAsp) in 43 adults with type 1
diabetes. Only data for the faster aspart formulation undergoing further
development are presented.
Materials and methods: The primary endpoint was the mean change in
postprandial glucose response 2 h after a standardised meal test
(individualised insulin dosing by bolus calculator), as evaluated by mean
change in plasma glucose (ΔPGav,0-2h). Subjects had blinded continuous
glucose monitoring (CGM) during the trial.
Results: Faster aspart provided statistically significant lower
ΔPGav,0-2h, compared with IAsp (3.03 vs 4.02 mmol/L; mean dif-
ference [95% CI]: -0.99 [-1.95; -0.03]; Table). The greater
glucose-lowering effect demonstrated at meals with faster aspart
vs IAsp was confirmed by interstitial glucose (IG) profiles, with
the largest differences at breakfast (Table). The duration of low
IG (≤3.9 mmol/L per 24 h) was significantly longer for IAsp
(2.45 h) than faster aspart (2.03 h; mean difference [95% CI]: -
0.42 [-0.72; -0.11]. No new safety findings were observed with
faster aspart compared with IAsp.
Conclusion: In summary, faster aspart had significantly greater glucose-
lowering effect than IAsp after a standardised meal, with findings con-
firmed by CGM for all meals, and less time spent with low glucose levels,
as measured by IG.
Clinicla Trial Registration Number: NCT01682902
Supported by: Novo Nordisk
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Basal insulin peglispro is superior to insulin glargine in reducing
HbA1c in insulin-naïve patients with type 2 diabetes treated with oral
antihyperglycaemic drugs: IMAGINE 2
M.J. Davies1, D. Russell-Jones2, J.-L. Selam3, T.S. Bailey4, Z. Kerényi5,
J. Luo6, J. Bue-Valleskey6, T. Iványi7, M.L. Hartman6, J.G. Jacobson6,
S.J. Jacober6;
1University of Leicester Diabetes Research Centre, Leicester, 2Royal Sur-
rey County Hospital, Guildford, UK, 3Diabetes Research Center, Tustin,
4AMCR Institute, Inc., Escondido, USA, 5Csepel Health Service, Buda-
pest, Hungary, 6Eli Lilly and Company, Indianapolis, USA, 7Eli Lilly and
Company, Budapest, Hungary.
Background and aims: Basal insulin peglispro (BIL) is a novel basal
insulin with a flat activity profile which has a hepato-preferential action
resulting from reduced peripheral effects. The primary objective of this
Phase 3, double-blind, treat-to-target study was to assess whether BIL
was non-inferior (margin=.4%) to insulin glargine (GL) at 52 weeks in
reducing HbA1c when added to prestudy oral antihyperglycaemic med-
ications in patients with type 2 diabetes.
Materials and methods: Patients were randomised to evening dosing of
BIL (N=1003) or GL (N=535); 168 patients underwent magnetic reso-
nance imaging to assess liver fat content. Testing of the primary objective
for superiority was pre-specified with adjustment for multiplicity.
Results: BIL-treated patients had statistically superior HbA1c change at
week 52 compared to GL-treated patients (-1.6 vs -1.3%;Δ=-.3% [95%
CI: -.40, -.19]), with lower HbA1c (6.9 vs 7.2%, p<.001) and more at
goal (HbA1c ≤6.5%: 36 vs 24%, p<.001; HbA1c <7.0%: 58 vs 43%, p
<.001). Within-day glycaemic variability using standard deviation (SD)
of SMBG profiles was lower for BIL (1.7±.03 vs 1.9±.04 mmol/L [31
±.5 vs 34±.7 mg/dL], p=.003), as was between-day fasting glycaemic
variability (SD of the prior 7 days) (.9±.02 vs 1.0±.03 mmol/L [16±.4 vs
17±.5 mg/dL], p=.02). Total hypoglycaemia rates were similar (BIL vs
GL: 1.16±.06 vs 1.21±.07 events/patient/30 days) as was incidence of
severe hypoglycaemia (.4 vs .6%). Nocturnal hypoglycaemia rates were
lower with BIL (.30±.02 vs .40±.03 events/patient/30 days, p<.001).
More patients had HbA1c <7% without nocturnal hypoglycaemia
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(LOCF) with BIL (26%) than with GL (15%), p<.001. At week 52, weight
gain was less with BIL (2.1±.2 vs 2.6±.2 kg, p=.046), but insulin dose was
higher (.45±.01 vs .42±.01 U/kg, p=.022). Thus BIL was titrated to a
higher dose than GL with similar total hypoglycaemia, lower HbA1c,
and less weight gain. At week 52, triglycerides increased with BIL and
decreasedwithGL (.12±.03mmol/L [11±2mg/dL] vs -.08±.04mmol/L [-
7±3 mg/dL], p<.001). HDL- and LDL-cholesterol did not differ between
groups. Adjudicated cardiovascular events were similar between BIL and
GL. ALT increased 4.1 IU/L with BIL and decreased 2.0 IU/L with GL (p
<.001). More BIL patients had ALT ≥3X ULN (2.3% vs .6%, p=.012) but
nonemet Hy’s law criteria for acute, severe drug-induced liver injury. Liver
fat content was unchanged with BIL (-.6±.5% p=.232) but decreased 3.1
±.7% with GL (p<.001; BIL vs GL, p=.002). Injection site reactions were
more common with BIL (3.5% vs .6%, p<.001) and the majority of these
were lipohypertrophy (2.1 vs .4%, p=.007).
Conclusion: At 52 weeks in this double-blind, treat-to-target study of
insulin-naïve patients with type 2 diabetes, BIL provided greater reduc-
tion in HbA1c, less nocturnal hypoglycaemia, less weight gain, and
higher triglycerides compared to GL, consistent with reduced peripheral
insulin action and a hepato-preferential effect of BIL. Liver fat content
was unchanged from baseline with BIL but decreased with GL.
Clinical Trial Registration Number: NCT01435616
Supported by: Eli Lilly and Company.
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Unique profile of the weekly insulin HM12470: very slow onset of
action, rapid off-rate similar to insulin, and absence of insulin recep-
tor downregulation
N. Wronkowitz1, T. Hartmann1, S.W. Görgens1, D. Dietze-Schröder1, I.
Choi2, S. Park2, Y. Lee2, S. Kwon2, Y. Kang3, M. Hompesch3, J. Eckel1;
1Paul-Langerhans Group for Integrative Physiology, German Diabetes
Center, Düsseldorf, Germany, 2Hanmi Pharmaceuticals Inc., Seoul, Re-
public of Korea, 3Profil Institute for Clinical Research, Chula Vista, USA.
Background and aims: The novel long-acting basal insulin HM12470
consists of an insulin analog (Insulin 115) conjugated to the non-
glycosylated FC region of a human immunoglobulin fragment via non-
peptidyl linker and is developed for once-weekly administration. Previ-
ously, extended pharmacokinetics and prolonged glucose lowering effi-
ciency of HM12470 have been shown in rodents. The aim of the present
study was to characterize the early steps of HM12470 signaling at the
receptor and post-receptor level and to assess themetabolic andmitogenic
potency of this analog in vitro.
Materials and methods: The off-rate of HM12470 was measured in
H9C2-E2 cells by a competition binding assay with 125I-labelled
regular insulin. The impact of HM12470, Insulin 115, AspB10 and
regular insulin on the insulin signaling cascade was assessed in
H9C2-E2, primary human vascular smooth muscle cells (hVSMC)
and primary human skeletal muscle cells (hSkMC) by Western Blot
analysis. To address functional endpoints, we analysed proliferation
in hVSMC by BrdU incorporation and glucose uptake in hSkMC
using 14C-labelled 2-deoxy-glucose.
Results: In H9C2-E2 cells overexpressing the human insulin receptor, we
observed an off-rate for HM12470 very similar to regular insulin. At the
receptor level, HM12470 and Insulin 115 showed no differences in the
phosphorylation pattern of tyrosine 1146, 1150/1151 and 972 in compar-
ison to insulin. HM12470 did not acutely activate Akt or MAPK signal-
ing pathways in human skeletal (hSkMC) and human vascular smooth
muscle cells (hVSMC). However, upon long-term stimulation we could
detect a significant Akt phosphorylation after 24 or 48 h exposure to
HM12470 in hSkMC and hVSMC, respectively. Remarkably, in the
chronic treatment HM12470 did not induce downregulation of the insulin
receptor in both hVSMC and hSkMC. Under these conditions, both reg-
ular insulin and AspB10 insulin completely abrogated the insulin recep-
tor. At 100 nM, HM12470 did not induce proliferation of hVSMC in
sharp contrast to AspB10 insulin (2-3 fold stimulation). Acute stimulation
of glucose uptake in hSkMCwas obtained at EC50 values of 36.1 nM and
154.9 nM for regular insulin and HM12470, respectively. However, after
24 h exposure the HM12470-induced glucose uptake was similar to
insulin.
Conclusion: In conclusion, the long-acting basal insulin HM12470
shows a flat profile of action without increased mitogenic potency and
downregulation of the insulin receptor in vitro. Thus, HM12470 appears
safe and it does not desensitize target cells under conditions of chronic
exposure and therefore represents an excellent candidate for a weekly
basal insulin.
Supported by: Hanmi Pharmaceuticals Inc.
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Glucagon nasal powder: an effective alternative to intramuscular
glucagon in youth with type 1 diabetes
J.L. Sherr1, K.J. Ruedy2, N.C. Foster2, C. Piché3, H. Dulude3, M.R.
Rickels4, W.V. Tamborlane1, K.E. Bethin5, L.A. DiMeglio6, L.A. Fox7,
R. Wadwa8, D.A. Schatz9, B.M. Nathan10, S.M. Marcovina11, R.W.
Beck2;
1Yale School ofMedicine, NewHaven, 2Jaeb Center for Health Research,
Tampa, USA, 3Locemia Solutions ULC, Montreal, Canada, 4University
of Pennsylvania Perelman School of Medicine, Philadelphia, 5School of
Medicine andBiomedical Sciences at the University of Buffalo, The State
University of New York, Buffalo, 6Indiana University School of Medi-
cine, Indianapolis, 7Nemours Children's Clinic, Jacksonville, 8Barbara
Davis Center for Childhood Diabetes, Aurora, 9University of Florida,
Gainesville, 10University of Minnesota, Minneapolis, 11Northwest Lipid
Metabolism and Diabetes Research Laboratories, Seattle, USA.
Background and aims: Intramuscular glucagon (IM), in weight adjusted
0.5 and 1.0 mg doses, is the only currently available pharmacologic
treatment for severe hypoglycemia in children and adolescents outside
of the hospital setting. Unlike current IM emergency kits, needle-free dry-
powder intranasal glucagon (IN) does not require reconstitution prior to
administration. Having demonstrated that a 3 mg IN dose of glucagon
effectively reverses hypoglycemia in adults with T1D, this study exam-
ined the dose response relationships of 2 mg and 3 mg IN glucagon in
youth 4-<17 years of age.
Materials and methods: 45 youth with T1D were studied at 7 centers
participating in the T1D Exchange. The two youngest cohorts (4-<8; 8-<
12 yrs) were randomized to receive either IN administrations, of 2 mg and
3 mg IN on two separate days in double blind, random order or a single
weight based-dose of IM glucagon. Subjects 12-<17 yrs received in
random order, 1 mg IM at one session and 3 mg IN at another session.
Glucagon was given after blood glucose was lowered to <80 mg/dL and
the primary outcome was a ≥25 mg/dL rise in plasma glucose from nadir.
Results: The primary efficacy outcome was met after all IM and IN doses
of glucagon within 10-20minutes (Table) with one exception- a 6 yo who
immediately blew his nose following a 2-mg dosage. Lack of absorption
of the intranasal dose is supported by his low peak glucagon (324 pg/mL).
Time to peak and peak glucagon levels were similar in both IM and IN
conditions. Transient nausea (with or without vomiting) occurred with
67% of IM sessions vs. 42% of IN sessions (P=0.06).
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Conclusion: These data support the efficacy of a novel glucagon nasal
powder delivery system for treatment of hypoglycemia in youth with
T1D. Given the transient nature of adverse effects when they occur, we
conclude that a single 3 mg IN dose can be safely used across the 4-<17-
year range of pediatric patients.
Clinical Trial Registration Number: NCT01997411
Supported by: the Leona M. and Harry B. Helmsley Charitable Trust and
Locemia Solutions
OP 08 The calm before the storm:
predicting metabolic disease
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Longitudinal trajectories of insulin sensitivity and beta cell function
before the development of type 2 diabetes in Japanese individuals
Y. Heianza1, Y. Arase2, S. Kodama1, H. Tsuji2, S. Tanaka3, T.
Kobayashi2, S. Hara2, H. Sone1;
1Department of Internal Medicine, Niigata University Faculty of Medi-
cine, 2Health Management Center, Toranomon Hospital, Tokyo, 3Depart-
ment of Pharmacoepidemiology, Graduate School of Medicine and Pub-
lic Health, Kyoto University, Niigata, Japan.
Background and aims: Evidence is limited about long-term trajectories
revealed through detailed assessments of insulin and glucose concentra-
tions before the development of type 2 diabetes (T2D). We aimed to
clarify the time point of deteriorating insulin sensitivity and beta-cell
function that could be observed during the development of T2D among
Japanese individuals.
Materials and methods:We investigated data on 474 Japanese individ-
uals without T2D (T2D indicated by a self-report of clinician-diagnosed
diabetes, fasting glucose concentrations of ≥7.0 mmol/L, HbA1c ≥6.5%
or 2-h glucose concentrations of ≥11.1 mmol/L) who had available data
on glucose and insulin concentrations. We assessed glucose and insulin
concentrations during a 75-g oral glucose tolerance test over a 10-y fol-
low-up. The homeostasis model assessment of insulin resistance
(HOMA-IR), insulinogenic index (IGI) and the Matsuda index of whole
body insulin sensitivity were calculated. The insulin secretion⁄insulin re-
sistance index (disposition index, DI) was calculated as the product of the
Matsuda index and IGI. Stumvoll first-phase and second-phase insulin
release during OGTTwere also evaluated.
Results: Individuals who did not develop T2D (n=420) had consistently
low mean fasting values (<5.3 mmol/L) and postprandial glucose con-
centrations at 30 min (<8.6 mmol/L), 60 min (<8.4 mmol/L), 90 min
(<7.3 mmol/L) and 120 min (<6.7 mmol/L) over 10 y. Those who later
developed T2D (n=54) had higher glucose concentrations at 0 to 120min
even 10 y before diagnosis than those who did not develop T2D; incident
cases of T2D also experienced a sharp increase in these glucose measures
3 y before diagnosis. A large difference between cases and non-cases was
observed for glucose measurements at 60 min over the total observational
period while glucose concentrations at 180 min specifically deteriorated
only 1-2 y before diagnosis. Glucose concentrations at 60 min was sig-
nificantly predictive of future T2D independently of glucose concentra-
tions at 0 min and at 120 min. Interestingly, those who later developed
T2D had constantly reduced IGI values, reduced Stumvoll insulin release
levels and reduced DI values. These values remained low and did not
markedly increase in the late stage before diagnosis. A sharp increase in
the HOMA-IR in the late stage before diagnosis predicted T2D. Stumvoll
insulin sensitivity index levels were also deteriorated in the late stage of
the disease course.
Conclusion: Japanese individuals who later developed T2D had clearly
elevated glucose concentrations at 60 min rather than other glucose mea-
surements even 10 y before diagnosis. Those who developed T2D also
had consistently reduced beta-cell function over 10 y before diagnosis,
values similar to those observed at diagnosis.
Supported by: JSPS
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Factors affecting the risk for the first appearance of an islet autoan-
tibody in The Environmental Determinants of Diabetes in the Young
(TEDDY) study
A. Lernmark1, H. Elding Larsson2, H.-S. Lee3, J. Krischer3, K. Vehik3,
K.F. Lynch3, M. Haller4, W.A. Hagopian5, M.J. Rewers6, J.-X. She7,
O.G. Simell8, J. Toppari8, A.-G. Ziegler9, B. Akolkar10, TEDDY Study
Group;
1University Hospital MAS, Lund University, 2University Hospital SUS,
Lund University, Malmö, Sweden, 3Department of Pediatrics, University
of South Florida, Tampa, 4Department of Pediatrics, University of
Gainesville, 5Pacific Northwest Diabetes Research Institute, Seattle,
6University of Colorado, Aurora, 7Center for Biotechnology and Geno-
mic Medicine, Georgia Regents University, Augusta, USA, 8Department
of Pediatrics, Turku University Hospital, Finland, 9Forschergruppe Dia-
betes e.V., Institute of Diabetes Research, Helmholtz Zentrum München,
and Klinikum rechts der Isar, Neuherberg, Germany, 10University Hospi-
tal MAS, National Institute of Diabetes & Digestive & Kidney Diseases,
Bethesda, USA.
Background and aims: Autoantibodies against Insulin (IAA), GAD65
(GADA) and IA-2 (IA-2A) are detectable for a variable period of time
prior to diabetes onset. In the TEDDY study the incidence of IAA only
peakedwithin the first year of life and declined over the following 5 years.
GADA only increased till the second year and remained relatively con-
stant. IA-2A only was rare. GADA only were more common than IAA
only among HLA-DQ2/2 but less common among HLA-DQ4/8 children.
The aim was to study prenatal factors that may affect the risk for HLA-
dependent autoantibody appearance.
Materials and methods: Children (n=8676) with HLA-DQ high risk
genotypes (DQ2/8, DQ8/8, DQ4/8 and DQ2/2) were enrolled at 3-
4.5 months of age and followed with standardized autoantibody assess-
ments quarterly through the first 4 years of life and then semiannually
thereafter. Non-diabetic mothers of singleton infants (n=6,947) filled out
a questionnaire 3-4.5 months after pregnancy. Lower birth weight was
defined as the lower 25% of the TEDDY children's birth weights.
Results: The risk for IAA only (n=197) was increased in Finland and
Sweden but not in Germany compared to the US but not for GADA only
(n=192). The risk for both autoantibodies was increased among first degree
relatives and IAA only among boys.Maternal smoking was associated with
country (Europe), maternal BMI, drinking during the 3rd trimester (>2
drinks/month), and maternal infections (lower respiratory tract infection,
skin infection or rash, genital infection). After adjusting for country, type
1 diabetes in a first degree relative, HLA genotypes and gender, none of
these maternal factors were associated with an islet autoantibody. However,
lower birth weight, but not maternal smoking, was independently associat-
ed with a decreased risk for GADA only but not for IAA only.
Conclusion: Prenatal factors may affect the risk for HLA-associated first
appearance of either IAA or GADA.
Supported by: NIH, NIDDK, JDRF
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Using genomic information to differentiate diabetes aetiology in
young-adult onset diabetes
F.K. Kavvoura1,2, L. Moutsianas3, A. Bennett1, A. Mahajan3, N. Rob-
ertson3, N.W. Rayner3,4, C.J. Groves1, K.R. Owen1,2, M.I. McCarthy1,2;
1Oxford Centre for Diabetes, Endocrinology & Metabolism (OCDEM),
2Oxford National Institute for Health Research (NIHR) Biomedical Cen-
tre, 3Wellcome Trust Centre for Human Genetics, Oxford, 4Wellcome
Trust Sanger Institute, Hinxton, Cambridge, UK.
Background and aims: Establishing the aetiology in young adult-onset
diabetes can be challenging, in view of the overlapping features between
common diabetes types. Current tools include clinical parameters and
laboratory tests but are often inadequate to allow firm clinical decisions
to be made. The recent discovery of a large number of variants associated
with increased risk both for type 1 (T1D) and type 2 diabetes (T2D),
offers a potential adjunct in the differential diagnosis of common diabetes
types. We assessed whether individual genetic risks using known T1D
and T2D risk variants offer useful diagnostic discrimination between T1D
and T2D diagnosed in early adulthood.
Materials andmethods:North European subjects (n=715) with diabetes
onset <45 years were provisionally classified as T1D (n=293), T2D (n=
370) and LADA (n=52), based on the presence of pancreatic antibodies,
time to insulin use from diagnosis, and c-peptide level. We used common
risk variants for T1D (47 variants) and T2D (65 variants), plus high risk
and protective variants for T1D in theMajor Histocompatibility Complex
(23 variants) to calculate weighted Genetic Risk Scores (GRS) for T1D
(T1DGRS) and T2D (T2DGRS). Differences in GRS between clinical
parameters, diabetes subtypes and progression to insulin were estimated
with parametric and non-parametric tests. The area under the receiver
operator curve (AUC) was calculated for discriminating T1D and T2D
using the T1DGRS and T2DGRS.
Results:Higher T1DGRSwas associated with diagnosis <18 years (p=2×
10−13), undetectable c-peptide (p=2×10−9) and insulin vs. tablets as initial
or current treatment (both p<10−22), features consistent with T1D. Higher
T2DGRS was observed with diet (p=0.002) or tablet use (p=0.04) vs.
insulin therapy at diagnosis and with current oral therapy (p=0.0002), char-
acteristics suggestive of T2D. The difference in T1DGRS and T2DGRS
between clinically defined T1D vs. T2D cases was highly significant (both
p<10−22), as was the difference between T2D vs. LADA labelled subjects
(p<10−22 and p=0.0001 respectively). Non-T1D cases starting insulin
within 1 year from diabetes diagnosis had higher T1DGRS compared to
the remainder (p=0.0004), therefore estimating T1DGRS at diagnosis
could aid in tailoring management. The AUC for clinically defined T1D
and T2D patients using the T1DGRS and T2DGRS were 80% and 64%,
respectively, indicating that T1DGRS on its own can contribute to the
discrimination between clinically labelled T1D and T2D.
Conclusion: Genetic Risk Scores correlate well with traditional diabetes
classification parameters and the clinically defined diabetes diagnosis.
T1DGRS may also predict early progression to insulin in non-T1D indi-
viduals. In summary, genomic information could be a useful adjunct in
the differential diagnosis and management of young adult onset diabetes
from diagnosis.
Supported by: NIHR, BRC
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A signal near TMEM170A is associated with coronary artery disease
and SNPs near IL15RA/IL2RA and THY1 may interact with diabe-
tes status to modify the risk of CAD
N.R. van Zuydam1, B. Voight2, C. Ladenvall3, R. Strawbridge4, S.
Willems5, E. van Iperen6, J. Hartiala7, E. Vlachopoulou8, E. Mihailov9,
L. Kwee10, C. Nelson11, M. Kleber12, L. Qu2, A. Goel1, S. Kanoni13;
1University of Oxford, UK, 2University of Pennsylvania, Philadelphia,
USA, 3Lund University, Malmo, 4Karolinska Institute, Stockholm, Swe-
den, 5Erasmus University, Rotterdam, 6Academic Medical Center, Am-
sterdam, Netherlands, 7University of Southern California, Los Angeles,
USA, 8University of Helsinki, Finland, 9University of Tartu, Estonia,
10DUKE University, Durham, USA, 11University of Leicester, UK,
12LURIC study, Freiburg imBreisgau, Germany, 13Wellcome Trust Sang-
er Institute, Cambridge, UK.
Background and aims: Subjects with type 2 diabetes (T2D) are three or
four times more likely to suffer from coronary artery disease (CAD) than
non-diabetic individuals. Subjects with T2D have accelerated and a larger
burden of atherosclerosis compared to non-diabetic individuals. We
hypothesise that there may be different genetic factors that contribute
towards these differences.
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Materials and methods:We combined summary statistics from 1000G
imputed, HapMap 2 imputed and CardioMetabochip genotypes from
24,257 subjects with T2D (10.012 CAD cases and 14,245 CAD free
controls) and 42,384 non diabetic individuals (17,694 CAD cases and
24,690 CAD free controls) in a fixed effects variant weighted meta-
analysis and performed a test for interaction with diabetes status. Six
hundred and eighty six independent SNPs (distance>100Kb/R2<0.3)
analyses based on p value of association <1E-4 for replication from the
diabetes stratified and interaction analysis. These associations were rep-
licated in 11,537 patients with T2D (3,706 CAD cases and 7,831 CAD
free controls) and 106,250 non-diabetic individuals (12,988 CAD cases
and 93,262 CAD free controls).
Results: A known CAD SNP, rs4977574 in the 9p21.3 region, was the
top signal for CAD in non-diabetic individuals (P=7.7E-41) and was also
genome-wide significant for CAD in subjects with T2D (P=3.9E-9).
Rs11072811, a known CAD SNP near ADAMTS7, was the top signal
for CAD in subjects with T2D (OR (95%CI)=1.05 (1.02-1.09), EAF=
0.52, P=9.7E-11) but was not genome wide significant for CAD in non-
diabetic individuals (OR (95%CI)=1.02 (0.99-1.05), EAF=0.52, P=
2.8E-3). There was some evidence for interaction (P=4.5E-3) that was
not significant after correction for multiple testing. We identified a ge-
nome wide significant hit near TMEM170A that had been previously
reported (not at genome wide significance) for CAD and carotid intima
thickness (cIMT). Rs6564261 (R2 with rs4888378>0.8) was associated
with CAD in non-diabetic individuals (OR (95%CI)=1.04 (1.01-1.07),
EAF=0.62, P=2E-10) with no evidence of interaction with diabetes sta-
tus (P=8E-2). Two SNPs did show evidence for interaction with diabetes
status, with the same direction of effect in the discovery and replication
analyses and an interaction p<0.05 in the replication. Rs79705396, near
IL15RA and IL2RA (P=5.2E-6), and rs7952366, near THY1 (P=1.6E-5).
Conclusion: We reported a locus for CAD near TMEM170A at genome
wide significance that has been associated with cIMT, and two SNPs that
may interact with diabetes status to modify the risk of CAD near genes
that may have a biological role in the atherosclerosis.
Supported by: IMI, European Commission’s FP7 (the SUMMIT consor-
tium, IMI-2008/115006)
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Serum lipidome as an independent predictor of progression to type 2
diabetes: the METSIM study
M. Oresic1, I. Bondia Pons1, H. Cederberg2, A. Stančáková2, T.
Suvitaival1, J. Kuusisto2, J. Nolan1, T. Hyötyläinen1, M. Laakso2;
1Steno Diabetes Center A/S, Gentofte, Denmark, 2Institute of Clinical
Medicine, University of Eastern Finland and Kuopio University Hospital,
Kuopio, Finland.
Background and aims: There is a need for early markers to track progres-
sion from a state of normal glucose tolerance through pre-diabetes (impaired
fasting glucose and/or impaired glucose tolerance) to type 2 diabetes (T2D).
Several diabetes risk models and scores have been developed as prognostic
tools. However, these aremainly based on established risk factors of T2D and
they lack the specificity required for clinical practice.
Materials and methods:We applied global lipid profiling based on ultra-
high performance liquid chromatography (UHPLC) coupled to quadrupole
time-of-flight (QTOF) mass spectrometry (MS) at baseline and at 5-year
follow-up plasma samples of well phenotyped male participants (107 T2D
progressors, 216 matched normoglycemic controls; dataset 1) from the
longitudinal study METSIM (METabolic Syndrome In Men) to identify
lipidomic profiles of progression to T2D, and to develop a lipid-based
predictive model for T2D. The selection of progressors was based on fastest
progression to T2D and greater glucose AUC at follow-up. Age-matched
controls were selected as non-progressors. In addition, we performed global
lipidomic profiling at baseline of a larger subset of the previous cohort
(dataset 2), which was characterized by a wide distribution in terms of
glucose tolerance (n=640), including non-progressors with a high percent-
age of subjects with impaired fasting glucose (IFG; 60%), subjects with
HbA1C between 5.7-6.4% (11%), subjects with impaired glucose tolerance
(IGT; 2%), both IFG+IGT (6%), and subjects with normal glucose tolerance
(21%). 20 subjects in dataset 2 progressed to T2D during the follow-up.
Results: A total of 280 lipids were analyzed. The global lipidome was
first surveyed by clustering the baseline data from dataset 1 using Bayes-
ian model-based clustering. By applying linear mixed models to the
resulting 13 clusters, eight of them showed significant differences in their
lipid mean levels between progressors and non-progressors at baseline,
after adjusting for BMI. Four clusters consisting only of triglyceride spe-
cies (grouped by different carbon chain lengths and number of double
bounds in their structures) and a cluster consisting mainly of phospho-
lipids were upregulated in T2D progressors (adjusted p-value <0.05).
Two clusters containing sphingomyelins and ether phospholipids were
downregulated. A similar pattern was observed when dataset 2 was sur-
veyed. Those non-progressors classified as subjects with IFG at baseline
showed similar yet less pronounced lipid changes at the cluster level as
progressors to T2D. Selected lipids were then considered to build a lipid-
based predictive model of T2D with the dataset 1, by using stepwise
logistic regression. We compared the candidate models with the Finnish
Diabetes Risk Score (FINDRISC) based-model applied to our data. The
candidate lipid marker was an independent predictor of T2D and im-
proved the predictive model based on FINDRISC.
Conclusion: Our study indicates that a lipid molecular signature predic-
tive of diabetes is present already years before the diagnosis of diabetes,
independent of other risk factors
Supported by: EU FP7 DEXLIFE (279228)
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Non-coding RNA biomarkers of diabetes complications
M.V. Joglekar1, A.A. Hardikar1, R.J. Farr1, A. Januszewski1, T. Evans2,
S. Satoor1, W. Wong1, J.D. Best2, C.S. Yajnik3, S. Blankenberg2, R.
Scott2, A. Jenkins1, A.C. Keech1, on behalf of the FIELD investigators;
1NHMRC Clinical Trials Centre, University of Sydney, 2C/O NHMRC
Clinical Trials Centre, University of Sydney, Australia, 3Diabetes Unit
KEM Hospital, Pune, India.
Background and aims: Type 2 Diabetes (T2D) increases the risk of
cardiovascular disease (CVD), and other vascular complications includ-
ing retinopathy and neuropathy and is now well-accepted to be an out-
come of intra-uterine programming and exposure to environmental
(lifestyle) factors during post-natal life. It is essential and timely to iden-
tify early biomarkers of T2D and its complications. In recent years
microRNAs (miRNAs), a subset of small non-coding (nc) RNAs, have
been detected in circulation and demonstrated as promising biomarkers,
mostly in cancer research. We aim to validate circulating ncRNA and
DNA methylation signatures for T2D and its vascular complications
using two unique longitudinal cohorts i) the Pune Maternal Nutrition
study (PMNS) comprising of 18 year follow up study of undernourished
children and their parents from preconception period, 20% of whom have
now developed insulin resistance at 18 years of age ii) the FIELD study,
which demonstrated that, relative to placebo, long-term fenofibrate im-
proved some CVD and all microvascular complications with 9,795 sub-
jects enrolled in study and analysed at baseline, 1 and 5 years and in 1,744
of these individuals at 12 years. We present epigenetic (DNA methyla-
tion) and ncRNA signatures for T2D and its complications over lifetime
and response to therapy, enabling early management of at-risk individuals
and facilitating development of novel therapeutics.
Materials and methods: Circulating miRNAs in plasma were
assessed from i) PMNS study subjects at 18, 12 and 6 years as well
as at their birth and from their parents (at conception) and ii) T2D
subjects in the FIELD cohort (Fenofibrate Intervention and Event
Lowering in Diabetes) with retinopathy, neuropathy, low eGFR,
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ACR, non-fatal stroke or non-fatal myocardial infarction and were
compared to individuals without complications using ultra-high
throughput qPCR profiling. DNA methylation in both study cohorts
was assessed on Illumina 450 K DNA methylation arrays.
Results:We observed that circulating miRNAs in five T2D complication
groups Vs no complications were differentially expressed as seen in vol-
cano plot (Figure 1A). Some of the miRNAs identified in the initial high
throughput analysis (+/- 2-fold change and P<0.05) were also found to be
significantly different in multiple samples when validated using low-
throughput high sensitivity quantitative (q)PCR. We also found serum
levels of four candidate microRNAs related to vascular health to be lower
in FIELD T2D subjects at visit 20 (5 years) Vs visit 1 (baseline).
Conclusion:miRNAs are found to be differentially expressed in individ-
uals with diabetic complications, which could allow early identification
of at risk individuals, thereby providing a vital opportunity to improve
heath prior to clinical onset.
Supported by: National Health and Medical Research Council
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The economic consequences of clinical inertia in treatment intensifi-
cation for type 2 diabetes mellitus in the UK
M. Willis1, C. Neslusan2, P. Johansen1, A. Nilsson1, C. Asseburg1;
1The Swedish Institute for Health Economics, Lund, Sweden, 2Janssen
Global Services, LLC, Raritan, USA.
Background and aims: Chronic hyperglycemia may lead to severe and
debilitating micro- and macrovascular complications and an elevated risk
of premature mortality. While there is no cure for T2DM, current treat-
ment recommendations suggest treating patients with agents to maintain
near normal HbA1c levels. Despite many available treatments, T2DM
gradually worsens over time and treatment intensification is required to
meet HbA1c goals. Recent evidence confirms clinical inertia in treatment
intensification in everyday UK practice; patients taking 1 or 2 oral
antihyperglycemic drugs (OADs) waited a median of 1.5 and 7.2 years,
respectively, after exceeding a treatment goal of HbA1c <7.5% before
being prescribed rescue therapy. Reducing clinical inertia is expected to
lead to better health outcomes, but these benefits occur over long time
horizons. This analysis usedmodeling techniques to estimate the potential
magnitude of the health benefits associated with reducing clinical inertia
in terms of treatment intensification for patients with T2DM receiving
mono- or dual therapy in the UK.
Materials and methods: The Economic and Health Outcomes Model of
T2DM (ECHO-T2DM), a val idated, long-term stochast ic
microsimulation model, was used to estimate the potential health benefits
over 30 years of reducing clinical inertia in the treatment of T2DM for
patients taking 1 OAD (monotherapy) and for those taking 2 OADs (dual
therapy) in the UK. For the monotherapy simulation, patients were
assigned metformin (MET) at baseline and sulphonylurea (SU) was
added as the 2nd line treatment. For 3rd line, SU was discontinued and
basal insulin was added. Prandial insulin was specified as the add-on in
4th line. For the dual therapy simulation, patients in both arms were
assignedMET plus SU at baseline; the same insulin rescue sequence with
basal and then prandial was used. In each of these simulations, patients
were separated into 2 arms based on assumptions about the delay in
treatment intensification. In the “NoDelay” arm, treatment intensification
was triggered immediately when HbA1c >7.5% (in line with UK norms).
In the “Delay” arm, intensification at each step was postponed based on
mean values derived from the recent UK real world evidence study; add-
on with SU was delayed by 2.16 years and add-on with basal insulin by
10.63 years. Baseline patient characteristics were sourced from The
Health Improvement Network (THIN) database in the UK, separately
for patients starting on mono- and dual therapy. Treatment effects for
the OADs were obtained from published clinical trials.
Results:With mono- and dual therapy, discounted life-years (LYs) were
0.123 and 0.180 larger over 30 years, respectively, in the No Delay arm
compared with the Delay arm, in line with modest relative risk reductions
(RRRs) in the occurrence of myocardial infarctions and stroke (4.7% and
4.6% for monotherapy and 6.3% and 5.7% for dual therapy, respectively).
There were sizable RRRs in the occurrence of retinopathy and neuropathy
outcomes. For example, RRRs for proliferative diabetic retinopathy and
severe vision loss were ~50% for monotherapy and more than 55% for
dual therapy; the RRRs for lower extremity amputation were 10.6% for
monotherapy and 14.0% for dual therapy.
Conclusion: These simulation results suggest that reducing clinical iner-
tia in the UK, and likely elsewhere, has the potential to improve long-run
patient outcomes.
Supported by: Janssen Global Services, LLC
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A regimen-based measure of adherence and its association with
healthcare costs in patients with type 2 diabetes and patients with
both cardiovascular disease and type 2 diabetes mellitus
G.S. Carls1, R.-D. Tan1, C. Frois2, E. Tuttle1;
1Analysis Group, Menlo Park, 2Analysis Group, Boston, USA.
Background and aims: In order to achieve recommended HbA1c tar-
gets, many patients require multidrug regimens, but these regimens pres-
ent increased hurdles to patient adherence. Adherence may be particularly
important for T2DM patients with cardiovascular disease (CVD) due to
increased risks associated with poor HbA1c control for these patients. A
commonmeasure of adherence, proportion of days covered (PDC) ≥80%
by any diabetes medication, may overestimate adherence to multidrug
regimens if patients fill each drug inconsistently but have some drugs
on hand most of the time. This study develops a refined regimen-based
measure of adherence that accounts for drug regimen changes for patients
with T2DM and a subset of patients with both T2DM and cardiovascular
disease.
Materials and methods: A retrospective cross-sectional study was con-
ducted using data from Optum-Humedica for adult patients with T2DM
that included person-linked claims, electronic medical records (EMR),
and vital records for the period 1/2007-3/2014. PDC and health care costs
(medical, pharmacy, and total) were assessed over the most recent one
year period with continuous enrollment and at least 1 diabetes drug fill.
Patients were also required to be continuously enrolled for at least
3 months prior so that drugs on hand at the start of the year could be
accurately assessed. Patients with both T2DM and CVD were identified
based on diagnosis codes. Adherence was measured based on regimen-
based PDC≥80% accounting for initiation, switching, discontinuation,
and stockpiling at the class level and compared with the standard adher-
ence measure based on the percent of days with any diabetes drugs on
hand. Healthcare costs were estimated using data on estimated allowed
amount for each claim. Generalized linear models (log link and Poisson
distribution) were used to estimate excess costs related to non-adherence
after adjusting for demographic and health plan characteristics.
Results: 26,063 patients met study criteria and had a mean age of
61 years, 52% male, mean HbA1c of 7.3% and mean healthcare cost of
$18,047. 26% of patients (N=6,652) had CVD. Non-adherent patients
were younger (mean age 59 vs. 64, p<0.001) and had higher mean
HbA1c (7.5% vs. 7.1%, p<0.001). Non-adherent patients (N=13,666,
52%) cost 29% more than adherent patients ($20,297 vs. $15,761, p<
0.001) using the regimen-based measure. Among patients with CVD and
T2DM, non-adherent patients cost 35% more than adherent patients
($40,413 vs. $29,859 p<0.001) and nearly twice the cost vs. all patients
with T2DM. 52% of all patients filled multiple drug classes. The fraction
of multidrug patients classified as non-adherent increased to 57%
(regimen-based) from 36% (standard). The excess healthcare cost of
non-adherent multidrug patients was 20% higher compared to adherent
patients ($4,508 [regimen-based] vs. $3,750 [standard] p<0.001). A par-
simonious model with only age categories as control variables yielded
similar results.
Conclusion: A measure of PDC which more closely approximates
T2DM medication regimen shows that standard measures have
misclassified non-adherent multidrug patients and consequently
underestimated the burden of non-adherence. Estimates of medication
adherence in T2DM should be based on the patient’s regimen and not
simply any diabetes medication on hand. Among T2DM patients with
CVD, the economic burden of non-adherence is higher than in other
T2DM patients.
Supported by: Intarcia Therapeutics, Inc.
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Post-prandial hyperglycaemia (PPH): missed work time and reduced
productivity among people with type 1 and type 2 diabetes in the US,
UK and Germany
A. Nikolajsen1, M. Brod2, J. Weatherall3, K.M. Pfeiffer2;
1Novo Nordisk A/S, Søborg, Denmark, 2The Brod Group, Mill Valley,
3Novo Nordisk, Inc., Plainsboro, USA.
Background and aims: Post-prandial hyperglycaemia (PPH) is a persis-
tent challenge for diabetes management. Unfortunately, the impact of
PPH episodes onwork absenteeism and functioning while at work among
people with diabetes is not well understood. The purpose of this study
was to investigate the impact of PPH episodes on missed work time and
work productivity among people with type 1 (T1DM) and type 2 (T2DM)
diabetes in the US, UK, and Germany.
Materials and methods: Data were collected in a web survey of 906
adults diagnosed with T1DM (39%) or T2DM (61%) and treated with
self-administered bolus insulin in the US (40%), UK (26%), and Germa-
ny (34%). Experience of PPH and missed work time/work productivity
issues due to PPH were respondent-reported.
Results: A total of 519 respondents (57%) reported working for pay,
working an average of 35.2 hours per week. Inadequate post-prandial
glucose (PPG) control among both working and non-working respon-
dents was common. Among respondents who worked for pay, 68% ex-
perienced difficulty getting their blood glucose (BG) stable after eating
during the past week, and 27% experienced PPH episodes 3 or more
times in the past week. Among working respondents, 27% reported miss-
ing at least some work the last time they experienced a PPH episode. A
total of 10% of working respondents indicated that they missed a full day
of work the last time they experienced a PPH episode, while 14% report-
ed being late to work and/or 19% left work early. On average, respondents
reported missing 168 minutes of work time in the previous week due to
their BG being out of range after eating. Furthermore, 71% of working
respondents indicated that they had work productivity issues the last time
they experienced a PPH episode; 54% of respondents reported that they
experienced difficulty focusing at work, 45% indicated that they were less
productive at work, 44% reported needing to take a break at work, 28%
indicatedmakingmore mistakes at work, 11%had to cancel or reschedule
a work meeting/appointment, and 10% missed meetings at work. There
were no significant differences in missed work time due to PPH by dia-
betes type or by country. Compared to those with T1DM, respondents
with T2DM were significantly more likely to report experiencing any
work productivity issues due to PPH (77.0% vs. 62.6%, p<.05), finding
it difficult to focus at work due to PPH (62.8% vs. 43.5%, p<.01), and
being less productive at work due to PPH (50.0% vs. 37.4%, p<.05). The
association between PPH and work productivity also differed somewhat
by country. German respondents were significantly more likely than those
in the US and UK to report any work productivity issues due to PPH
(Germany, 83.5%; US, 64.5%; UK, 61.6%, p<.01), making more mis-
takes at work due to PPH (Germany, 37.1%; US, 24.7%; UK, 19.2%, p
<.05), and finding it difficult to focus due to PPH (Germany, 64.9%; US,
46.2%; UK, 50.7%, p<.05).
Conclusion: The results indicate that the experience of PPH episodes
among people with T1DM and T2DM treated with bolus insulin is com-
mon and significantly associated with missed work time and reduced
work productivity. The findings highlight the need for better clinical
management of PPH, particularly for people with T1DM or T2DM treat-
ed with self-administered bolus insulin and engaged in the workforce.
The results also suggest that PPHmay be associated with economic costs
related to missed work time and reduced work productivity.
Supported by: Novo Nordisk
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The importance of appropriately incorporating the effects of
hypoglycaemia within a health economic model when hypoglycaemia
rates are high
E. Lovato1, M. Warburton1, P. McEwan2, M. Lamotte3, V. Foos4;
1IMS Health, London, 2Health Economics & Outcomes Research Ltd,
Cardiff, UK, 3IMS Health, Vilvoorde, Belgium, 4IMS Health, Basel,
Switzerland.
Background and aims: Hypoglycaemia is an important determinant of
health utility and thus the cost-effectiveness of blood glucose lowering
therapies in people with diabetes. Standard health economic evaluations
typically attribute a per-event disutility (PED) to clinical outcomes in-
cluding hypoglycaemia. Increasingly in diabetes sources of real-world
data are being used to conduct health economic evaluations in which
patients may have very high rates of hypoglycaemia. Importantly, there
is growing evidence of the diminishing marginal effects (DME) of
hypoglycaemia on health utility as frequency increases. The objective
of this study was to compare PED versus DME on predicted quality
adjusted life expectancy (QALE) using an established diabetes model.
Materials and methods: This study used the CORE Diabetes Model
(CDM) and published real-world audit data for patients with type 1 dia-
betes switching to insulin degludec (ID) from either insulin glargine or
detemir (IGD). Mean (± SD) baseline profiles were age 35.0 years
(±11.4); diabetes duration 18.2 years (±7.5); HbA1c 9.4% (±0.8); weight
77.0 kg (±10.7) and 3.9 hypoglycaemia (severe and non-severe) events
per week (±0.9). Mean change in clinical variables was HbA1c -0.5%
(±0.3); weight +0.8 g (±1.6) and hypoglycaemia events/week -3.6 (±0.9).
A baseline cohort was projected over a lifetime using the CDM using
published PED disutility (-0.0052) and published DME disutility
(0.0141*[number of events]^0.3393) with and without treatment effects
applied to calculate life expectancy (LE) and QALE associated with the
pre and post-switch profiles. Results were discounted at 3.5%.
Results: Overall discounted LE was 18.8 years and 19.06 years
for IGD and ID profiles respectively and discounted QALE (ig-
noring the impact of hypoglycaemia) was 12.13 and 12.4 for IGD
and ID respectively. Discounted QALE was reduced by 1.85
(IGD) and 0.849 (ID) using the DME approach applied to
hypoglycaemia rates of 3.9 and 0.4 events/week respectively.
Using the PED approach discounted QALE was reduced by
22.96 (IGD) and 2.355 (ID). The PED approach resulted in a
QALE prediction less than zero for IGD.
Conclusion: Failure to adequately accommodate the relationship be-
tween hypoglycaemia frequency and quality of life within health econom-
ic evaluations may lead to misleading predictions and estimates of QALE
that lack face validity; this is particularly so when hypoglycaemia event
rates are high.
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A first evaluation of the cost-effectiveness of CSII versusMDI in type
2 patients: projection of clinical and economic benefits in the
Netherlands
S. Roze1, S. de Portu2, Y. Reznik3, B.F.E. de Brouwer4, H.W. de Valk5;
1HEVA HEOR, Lyon, France, 2Medtronic International, Tolochenaz,
Switzerland, 3Department of Endocrinology, University of Caen Côte
de Nacre Regional Hospital Center, Caen, France, 4Medtronic NL, Heer-
len, 5Dept. Internal Medicine, University Medical Centre Heidelberglaan,
Utrecht, Netherlands.
Background and aims: Literature in type 1 patients demonstrated that
CSII was often cost-effective over MDI in uncontrolled patients and in
various countries. However, this question remained unaddressed so far for
type 2 patients. The present study is the first investigating and reporting
health economic outcomes for CSII versus MDI in type 2 patients based
on improvements in glycemic control since new clinical data were pub-
lished in type 2 patients in 2014.
Materials and methods: We published the results of the OpT2mise ran-
domized controlled trial, during which they followed 331 people with type
2 diabetes who were on MDI with at least 3 injections per day and uncon-
trolled HbA1c. Mean HbA1c at baseline was 9% with average age of
56 years. At 6 months, mean HbA1c had decreased by 1.1% in the CSII
group and by 0.4% in the MDI group. The CORE Diabetes Model (CDM)
was used in order to project the long-term clinical and economic benefits of
these interventions in type 2 patients. The CDM has been widely published
and validated. For type 2 patients, it is based on the published UKPDS risk
equations amongst others published sources. The CDM uses the baseline
risk factors combined with the impact of CSII and MDI to assess annually
the risk of developing complications and mortality. Unit costs are attached
to each individual diabetes-related complication. Dutch costs (complica-
tions and interventions) come from various published and official sources.
To reflect the decrement in quality of life due to diabetes, a specific utility
value was also associated to each complication. These utilities are taken
from a published systematic literature review. Costs and clinical outcomes
were discounted at 4% and 1.5% p.a. respectively. The health economic
analysis has been conducted from a Dutch third party payer perspective.
Sensitivity analyses were also conducted to test the robustness of the results.
Results: Undiscounted life expectancies were improved for CSII versus
MDI by 0.785 years. Total QALYs were 9.38 and 8.95 respectively for
CSII and MDI.. The breakdown of costs indicated that around 50% of
these costs were attributable to diabetes related complications. Extra ac-
quisition costs of CSII versus MDI were partially offset by the reduction
in complications. The ICER has been estimated (in EUR/QALY) at
62,895 and at 60,474 when indirect costs were included.
Conclusion: These results indicate that accordingly to commonly accept-
ed threshold CSII could be considered a cost-effective intervention com-
pared toMDI in uncontrolled type 2 patients in the Netherlands. CSII also
increased the life expectancy of uncontrolled patients as well as reduced
morbidity and improved their quality of life.
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Weight change over time and its link to healthcare costs among
newly-diagnosed type 2 diabetes patients in Sweden
U. Sabale1, J. Bodegard1, J. Sundström2, B. Svennblad2, C. Östgren3,
P.M. Nilsson4, G. Johansson2, M. Ekman1;
1AstraZeneca, Södertälje, 2Uppsala University, Uppsala, 3LinköpingUni-
versity, Linköping, 4Lund University, Malmö, Sweden.
Background and aims: Weight control is an important parameter in
management of patients with type 2 diabetes (T2DM), however actual
knowledge on the impact of weight changes in relation to health care
resource use is scarce. The aim was to comprehensively describe relative
weight (body mass index, BMI) change pathways by using repeated BMI
measurements in newly diagnosed type T2DM patients and link that to
healthcare resource utilization costs from primary and hospital care.
Materials and methods: Between 1999-2009, all newly diagnosed
T2DM patients in 84 primary care centers (almost 10% of all primary
care centers in Sweden) were extracted. Patients eligible for the study had
BMImeasurement at diagnosis and subsequent BMImeasurements at 12,
24, and 36 months were identified. Patients with BMI<18, cancer and
heart failure at T2DM diagnosis were excluded from the analysis due to
the risk of unintentional weight loss. Three BMI change categories were
defined based on BMI change over a period of one year: weight gain (≥1
BMI unit increase), weight stable (<1 BMI unit change), and weight loss
(≥1 BMI unit decrease). Based on the observed individual BMI change
sequence over three consecutive years, patients were assigned to one of
totally 27 possible BMI change pathways (P1-P27, Figure). The most
common pathways were identified by estimating a conditional probability
of a patient moving between BMI categories over a period of one year.
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Mean three year healthcare costs for each pathway were estimated by
applying Swedish unit costs to the healthcare resource data extracted from
electronic patient journals and the Swedish National Patient register.
Results: Of the 16,158 newly diagnosed T2DM patients, 8,295 had a
BMI measurement at baseline and year 1; 4,888 at year 1 and 2; and
3,116 at all three years. Patients eligible for BMI change calculations in
the 1st year were 44%women, mean age 61 years, hadmeanHbA1c 6.8%
and BMI 30.8 kg/m2. The most frequently observed BMI change path-
way was associated with weight stability over 3 years (P14, €5,207). The
second and third most common pathways were associated with weight
loss or gain in year 1 and weight stability in subsequent years (P23,
€5,369 and P5, €5,845, respectively). Over 3 years, the highest healthcare
costs were observed among individuals with weight gain in year 1
(€8,335, average costs of P1-P9) whereas patients whose remained
weight stable or had weight loss in year 1 on average incurred €6,907
(average costs of P7-18) and € 6,810 (average costs of P19-P27),
respectively.
Conclusion: In newly diagnosed diabetes, an initial moderate weight
gain leads to increased healthcare costs. Costs of interventions that main-
tain weight in patients with diabetes should be considered in the context
of costs associated with weight gain.
Supported by: AstraZeneca
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Impaired sensitivity to incretins and adaptation of the incretin re-
sponse in type 2 diabetes
A. Mari1, A. Tura1, J.I. Bagger2, E. Ferrannini3,4, J.J. Holst5, F.K.
Knop2,5, T. Vilsbøll2;
1CNR Institute of Neuroscience, Padova, Italy, 2Center for Diabetes Re-
search, Gentofte Hospital, University of Copenhagen, Hellerup, Den-
mark, 3Department of Internal Medicine, University of Pisa School of
Medicine, 4CNR Institute of Clinical Physiology, Pisa, Italy, 5The NNF
Center for Basic Metabolic Research and Department of Biomedical Sci-
ences, Faculty of Health and Medical Sciences, University of Copenha-
gen, Denmark.
Background and aims: In type 2 diabetes (T2D), the sensitivity to
incretin hormones, determined by exogenous hormone infusion, is re-
duced. Whether this holds true under more physiological conditions,
e.g. during an OGTT, has not been determined. In addition, the relation-
ship between sensitivity to incretins and the incretin response has not
been explored.
Materials and methods: We used 25, 75, and 125 g OGTT and
isoglycaemic glucose infusions in patients with T2D (n=8) and matched
(n=8) normal glucose tolerant (NGT) subjects (3males; age: 57±1 (mean
± SE) years; BMI: 29±0.3 kg/m^2), and a beta cell mathematical model
to assess the time course of incretin potentiation (Pincr) of insulin secre-
tion. Total glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) were also measured, thus allowing eval-
uation of the relationships between the time course of incretin hormones
and Pincr.
Results: Pincr increased dose-dependently during the OGTTs and then
returned to baseline. As expected, the Pincr increase was markedly
blunted in T2D. Across all glucose doses Pincr was linearly correlated
in every subject with GLP-1 and GIP concentrations; the correlation was
stronger in NGT (average r=0.64 and 0.61, for GLP-1 and GIP) than in
T2D (r=0.46 and 0.47), due to the flatter Pincr response in T2D. The
slope of the individual relationships was used as an index of beta cell
sensitivity to GLP-1 and GIP. Of note, this assessment of incretin sensi-
tivity is not intrinsically related to the magnitude of the incretin response.
The sensitivities to GLP-1 and GIP were correlated (r=0.66, p<0.006).
GLP-1 sensitivity was impaired in T2D (0.008±0.002 l/pmol) vs. NGT
(0.020±0.006 l/pmol, p<0.027). However, there was a wide overlapping
between the two groups (range: 0.007-0.045 l/pmol in NGT vs. 0.002-
0.015 l/pmol in T2D). Using all OGTT data, the GLP-1 AUC was in-
versely related to GLP-1 sensitivity, with the glucose dose as a factor
increasing AUC, and a steeper slope in NGT vs. T2D (r=0.81, p<
0.0001). Similar results were obtained for GIP (GIP sensitivity: 0.003±
0.001 and 0.013±0.006 l/pmol in T2D and NGT, respectively, p<0.030).
This relationship suggests the existence of a compensation mechanism
that upregulates incretin secretion in presence of decreased sensitivity to
incretins; this compensation is impaired in T2D.
Conclusion: This analysis indicates that relative incretin insensitivity is
partly compensated for by higher incretin secretion, both in NGT and
T2D. In T2Dwe found both a moderate impairment in incretin sensitivity
and a defective compensation of the incretin secretion.
Clinical Trial Registration Number: NCT00529048
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HNF-4 gamma and HNF-4 alpha have opposite effects on diet-
induced diabetes
S. Ayari1,2, F. Baraille1,2, V. Carrière1,2, C. Osinski1,2, A. Leturque1,2, P.
Serradas1,2, A. Ribeiro1,2;
1Inserm UMR-S 1138, Centre de Recherche des Cordeliers, Sorbonne
Universités, UPMC Univ Paris 06, Université Paris Descartes, Sorbonne
Paris Cité, 2Institut de Cardiométabolisme et Nutrition ICAN, Hôpital
Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France.
Background and aims: Transcription factors, HNF-4α and HNF-4γ
belong to nuclear receptor superfamily whose ligands are fatty acids.
HNF-4α plays pleiotropic roles in liver functions. In Human, heterozy-
gous mutations in HNF4A gene lead to Maturity Onset Diabetes of the
Young Type I (MODY I). In intestine, our team showed that HNF-4α
controls epithelium homeostasis and HNF-4γ impacts the glucose ho-
meostasis through a decreased incretin effect. Furthermore, HNF-4α
and HNF-4γ have opposite effect on abundance and differentiation of
enteroendocrine cells producing incretin hormones. We test thus the hy-
pothesis that HNF-4α and HNF-4γ have opposite effects in susceptibility
to diet induced type 2 diabetes (T2D).
Materials and methods:We used 2 mouse models: 1- a constitutive and
total Hnf4g gene invalidation and 2-an inducible and intestine specific
Hnf4a gene invalidation, fed high-fat/high-fructose diet for 4 weeks. We
performed oral and intraperitoneal glucose tolerance tests and measured
insulin and enterohormone plasma concentrations to evaluate the T2D
susceptibility. GLP-1-positive cell number was measured by
immunohistology. The expression of transcription factors involved in
the differentiation of enteroendocrine cells (Ngn3, NeuroD1, PAX6 and
PAX4, ISL1, FOXA1 and FOXA2, NKX2.2, ARX, PDX1) and of some
enterohormones (CCK, PYY, GIP and GCG) was studied by RT-qPCR.
Results:We show that the invalidation of Hnf4g gene protects mice from
weight gain and glucose intolerance, induced by 4 weeks of diet rich in
lipids and fructose, that is observed in control mice. Contrary to intestinal
HNF-4a invalidation, Hnf4g invalidation improves oral glucose tolerance
but not intraperitoneal glucose tolerance. The high-fat/high-fructose diet
does not further modify the impact of Hnf4g invalidation on the abun-
dance of GLP-1 cell number and the transcription factor expression in-
volved in enteroendocrine lineage.
Conclusion:We demonstrate for the first time that HNF-4γ increases the
susceptibility to diet induced T2D. This occurred in part through intestine
action: a decrease of incretin hormone secretion mediated by lower
enteroendocrine cell differentiation. Targeting the enteroendocrine cell
differentiation through nuclear receptors HNF-4 might be a new thera-
peutic approach in DT2.
Supported by: INSERM, UPMC, ICAN Foundation Curie, Paris, France
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Differentiation and abundance of enteroendocrine cells are impaired
in obese and diabetic obese subjects
A. Ribeiro1,2, E.L. Hubert1,2, C. Osinski1,2, J. deToro Martin1,2, V.
Moreira1,2, L. Hedjazi3,2, D.A. Tregouët3,2, K. Clement3,2, C. Poitou3,4,
E. Brot-Laroche1,2, A. Leturque1,2, P. Serradas1,2;
1UMRS 1138, Paris, 2Institut de Cardiométabolisme et Nutrition ICAN,
Paris, 3UMRS ICAN 1166, Paris, 4Nutrition and Endocrinology Depart-
ment and CRNH-Ile de France, Assistance Publique-Hôpitaux de Paris,
France.
Background and aims: A worldwide obesity and diabetes epidemic is
spreading in humans since two decades. Gastric bypass, the most effective
treatment for morbid obesity, is leading to diabetes improvement or resolu-
tion. This occurs partly through changes in gut hormone secretions, which
can rely on differentiation, number and function of enteroendocrine (EE)
cells. However, it is not known if an alteration of EE cell differentiation
could explain the lower level of enterohormone in obese subjects. This
study evaluates the impact of obesity and type 2 diabetes (T2D) on the
expression of genes coding for enterohormones and for transcription factors
responsible for the commitment of EE cell subtypes in obese and obese-
diabetic subjects.
Materials and methods: Jejunum samples were obtained from gastric
bypass of obese (n=37) and obese-diabetic subjects (n=21) or from a set
of non-diabetic normal weight individuals (lean) obtained through collab-
oration with surgeons (n=22). We used an integrated strategy combining
immunohistological phenotyping of EE cell types and gene expression
studies on isolated jejunal epithelial cells by RT-qPCR using Taqman®
Arrays Cards. Expression of transcription factors involved in the differ-
entiation of EE cells (Ngn3,NeuroD1, PAX6 and PAX4, ISL1,FOXA1 and
FOXA2, NKX2.2, ARX, PDX1) and of some enterohormones (CCK, PYY,
GIP and GCG) were studied. The statistic tests were a non-parametric
Kruskal-Wallis test (lean/obese status) or an ANOVA test (lean/obese/
obese-diabetic status).
Results:We have shown that the number of EE L-cells (GLP-1), K-cells
(GIP) and I-cells (CCK) in the jejunum of obese subjects is lower than in
lean control subjects (50%, 30%, and 30% respectively, p<0.05), in ac-
cordance with reported low levels of plasma hormones. We then evaluat-
ed EE cell differentiation by low density arrays according to the obese/
lean status. We showed that PAX6 gene expression was significantly
decreased (p<0.001) between obese and lean subjects. Moreover,
PAX6, NKX2, ARX, CCK, GCG genes were found to be differentially
expressed (p<0.001) between the three groups of subjects, obese,
obese-diabetic and lean subjects. We showed that obesity impacted sig-
nificantly the EE GLP-1 cell lineage whereas T2D in obesity impacted
preferentially on CCK cell lineage.
Conclusion: Our study highlights differences on gene expression profile
according to the metabolic status of individuals. Obesity and T2D mod-
ulate the EE lineage in humans by limiting the abundance of EE cell type
in the absorptive segment of the intestine. Deregulation of the EE differ-
entiation could cause alterations in enterohormone secretions observed in
obese and obese diabetic subjects.
Supported by: INSERM, UPMC, ICAN Foundation
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Neuromedin U is a mammalian decretin hormone suppressing insu-
lin secretion through NmuR1
C.F. Jacovetti, S. Park, R.W. Alfa, H. Peiris, Y. Liu, X. Gu, G.H. Diaz,
S.K. Kim;
Developmental Biology, Howard Hughes Medical Institute, Stanford
University, Palo Alto, USA.
Background and aims: Decretins are enteroendocrine hormones postu-
lated from classical studies of starvation in humans and other mammals to
suppress insulin secretion and provoke ‘starvation diabetes’. We recently
identified a decretin in Drosophila called Limostatin (Lst) that is induced
by carbohydrate restriction and suppresses insulin output by signaling
through the G-protein coupled Limostatin Receptor (LstR). Our work
on isolated human islets suggested that the hormone Neuromedin U
(Nmu) and its islet β-cell receptor NmuR1 might be mammalian
orthologues of Lst/LstR. To test this hypothesis, we investigated in vivo
Nmu signaling in mice.
Materials and methods: We used mice homozygous for a null NmuR1
allele and Nmu-eGFP transgenic mice to investigate Nmu regulation and sig-
naling in vivo. We also generated novel sensitive enzyme linked
immunosorption assays (ELISA) tomeasureNmu inmouse and human serum.
Results: Nmu mRNA and protein were produced abundantly in mouse
stomach and intestinal enteroendocrine cells. We detected a two-fold
increase of serumNmu levels in mice after 72 hours fasting, accompanied
by increased Nmu mRNA expression in Nmu-EGFP+ cells. In this set-
ting, oral glucose challenge evoked hyperglycemia accompanied by
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relative hypoinsulinemia, effects not observed after overnight fasting or in
mice lacking NmuR1. Glucose-stimulated insulin secretion by isolated
mouse islets revealed that Nmu inhibits insulin release, an effect
abolished in NmuR1 mutant islets. Unexpectedly, we discovered that
during the latter phases of standard oral glucose tolerance testing after
overnight fasting, serum Nmu concentration increased as insulin levels
declined in control mice. By contrast, insulin levels at this stage remained
elevated in NmuR1 mutant mice, revealing that Nmu may suppress insu-
lin secretion in physiological states distinct from starvation. Consistent
with this view, in mice fasted 24 hours we found Nmu injection that
increased serum Nmu levels two-fold led to reduced insulin levels, in-
creased glucagon levels, and hyperglycemia. Nmu administered in this
way during oral glucose challenge was also sufficient to impair glucose-
stimulated insulin secretion and glucose tolerance. Thus, a small increase
of serumNmu levels in physiological settings had a marked impact on the
output of insulin and glucagon, and metabolic homeostasis.
Conclusion: Here we show that, in pathological settings like prolonged
fasting, Nmu functions as a decretin to suppress insulin output through
NmuR1 and provokes starvation diabetes. Our studies also unexpectedly
revealed how inter-organ Nmu signaling between the gastrointestinal tract
and endocrine pancreas may be regulated to coordinate changes in secre-
tion of insulin and other hormones during physiological feeding. This
previously unidentified function of Nmu suggests that drugs modulating
this entero-insular axis may be useful in physiological and disease states,
including diabetes mellitus.
Supported by: SVCF-H.L Snyder Medical Foundation-HHMI-SNSF
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Incretin effects of branched-chain amino acids
J. Gojda, R. Strakova, A. Havlova, J. Potockova, P. Tuma, M. Andel;
Centre for Diabetes, Metabolism and Nutrition, 3rd Faculty of Medicine,
Prague, Czech Republic.
Background and aims: Incretin effect described first in 1986 by Nauck
describes different insulin response to glucose load after oral vs. intrave-
nous administration. Intestinal hormones incretins, namely GLP-1 and
GIP, are responsible for this augmented insulin secretion after oral admin-
istration. Other nutrients than glucose are capable of stimulating insulin
secretion in the same glucose-independent incretin way. Branched chain
amino acids (BCAA) are known to exert insulinogenic effect. Whether
this effect is also mediated by incretins has not been well addressed in
literature. The aim of this study is to show that oral administration of
BCAA elicits higher insulin and incretin response when compared to
intravenous route of the same dose of BCAA.
Materials and methods: Twenty four healthy, male Caucasian subjects
were recruited, mean age was 25.5 years, and mean weight was 76.2 kg.
Two tests were performed on a different day after an over-night fast. First
test (IV test) comprised of intravenous application of BCAA solution
(Nutramin VLI, Fresenius Kabi) in total dose of 0,4 g/kg in a 2 hours
infusion (mean total dose of BCAA 30.5 g). Second test (PO test) com-
prised of oral ingestion of BCAA capsules (BCAA Nutrend) in a single
dose of 0.4 g/kg. Plasma levels of glucose, insulin, GLP-1 and GIP were
measured at time intervals for up to 240 minutes. Insulin secretion re-
sponse was assessed as incremental area under the curve (iAUC) and was
calculated using the trapezoid model.
Results: Oral administration of BCAA induced higher insulin response
than intravenous (iAUC 0-240 min PO 22.48±29.3 vs. IV 7.91±21.8
mIU/L, p<0, 05). The peak plasma insulin concentration were observed
at 60minute in PO test (PO 4.85±3.88 vs. IV 1.92±2.92mIU/L, p<0, 05)
and at 90minutes in IV test respectively (PO 4.49±4.37 vs. IV 2.65±3.48
mIU/L, p=0, 14). PO test induced considerably higher GLP-1 (iAUC 0-
90 min PO 9.03±5.7 vs. IV 0.97±3.45 pmol/l, p<0,001) and GIP re-
sponse (iAUC 0-90min PO 36.72±52.59 vs. IV-16.27±56.18 pg/ml, p<
0,005). The plasma GLP-1 peak was at 60 minute (GLP-1 max 2.94±
2.25 pmol/l) and GIP peak at 30minute (GIPmax 13.79±18.03 pg/ml) in
PO test. Plasma glucose levels declined in the same pattern during both
tests (iAUC 0-240 min PO -8.94 mmol/L, IV -8.49 mmol/L) reaching its
minimum at 210 minute in PO test (3.86±0.24 mmol/L) and 120 minute
in IV test respectively (3.78±0.24 mmol/L).
Conclusion: We found that oral administration of BCAA elicits signifi-
cantly higher insulin and incretin response when compared to intravenous
application. We conclude therefore that BCAA effect on insulin secretion
is at least partially incretin dependent.
Supported by: IGA NT/14416
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NHE3 blockade ameliorates glucose intolerance via its inhibitory
action on SGLT1-mediated intestinal glucose absorption in diabetes
L. Chan1, T. Wong1, E. Ng2, P. Leung1;
1School of Biomedical Sciences, Faculty ofMedicine, The Chinese University
ofHongKong, 2Department of Surgery, Prince ofWalesHospital,HongKong.
Background and aims: Na+-glucose cotransporter 1 (SGLT1) plays
a pivotal role in regulating intestinal glucose uptake and has a
profound impact on glucose homeostasis and type 1 and 2 dia-
betic states. Interestingly, we have previously shown that angio-
tensin II (AngII), via its receptor AT1R, has an inhibitory action
on SGLT1 function. In light of these findings, investigation is
warranted to identify additional modulators of SGLT1. Therefore,
the present study aimed to unravel a previously unknown role of
sodium-hydrogen exchanger 3 (NHE3), a critical transporter for
sodium homeostasis, in the regulation of SGLT1-mediated intesti-
nal glucose absorption, and to elucidate its downstream signaling
cascades, as well as further exploring a potential interaction of the
“AT1R-NHE3-SGLT1” signaling axis in the control of intestinal
glucose uptake and glucose homeostasis, and thus its consequence
on diabetes.
Materials and methods: 14C-glucose absorption in human and mouse
(m+/db & db/db) jejunums, and human Caco2 cells after incubation with
EIPA (NHE3 blocker)wasmeasured by liquid scintillation counting. Changes
in plasma levels of fasting blood glucose of mice after gastric gavage with
EIPA were studied by OGTT. NHE3 was also downregulated by siRNA-
mediated transient knockdown and overexpressed in Caco2 cells. Intracellular
pH (pHi) and its recovery rate after incubation with AngII, L162313 (non-
peptide AT1R agonist), losartan (AT1R blocker) and KT5823 (PKG blocker)
were measured using the fluorescent dye, BCECF-AM.
Results:NHE3 blockade inhibited SGLT1-mediated glucose uptake
in a GLUT2-independent manner across the 3 study models con-
sistently, i.e. human jejunum (1.0 mM EIPA: -41.6%, p<0.0001),
human Caco2 cells (1.0 mM EIPA: -40.5%, p<0.0001), and
mouse jejunum (1.0 mM EIPA: m+/db, -76.1%, p<0.0001; db/
db, -44.1%, p<0.0001). In parallel, knockdown of NHE3 in
Caco2 cells significantly reduced SGLT1-mediated glucose uptake
(-29.1%, p<0.0001) and mRNA levels of SGK1 (-34.5%, p<
0.001) and SGLT1 (-63.0%, p<0.0001); whereas overexpression
of NHE3 reversely upregulated SGLT-1 mediated glucose uptake
(+52.1%, p<0.001) and mRNA levels of SGK1 (+161.3%, p<
0.001) and SGLT1 (+89.8%, p<0.001). For the effect on glucose
metabolism, NHE3 blockade did not significantly alter the blood
glucose levels in m+/db mice (0.5 mM EIPA: -9.2%, p>0.05) but
remarkably reduced those of db/db mice (0.5 mM EIPA: -33.7%,
p<0.0001), as shown by OGTT. For the study of AT1R, AngII
inhibited NHE3-mediated pHi recovery (1 μM: -34.6%, p<0.01),
of which its effect was abolished by blockade of AT1R (1 μM
losartan: -3.93%, p>0.05) and PKG (1 μM KT5823: -4.61%, p>
0.05). Activation of AT1R attenuated protein expressions of
NHE3, as revealed by Western blot (10 μM L162313: -51%,
p<0.0001).
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Conclusion: Collectively, our data reveal for the first time that NHE3
blockade reduces glucose intolerance in diabetes by inhibiting SGLT1-
mediated intestinal glucose absorption, probably via SGK1 mediation.
Such an interaction may be modulated by an upstream inhibitory action
of AT1R-PKG activation on NHE3. Our study provides a perspective of
counteracting hyperglycemia by targeting intestinal glucose uptake, and
opens an avenue for the potentially clinical use of NHE3 blockade in the
regulation of post-prandial hyperglycemia for diabetic patients.
Supported by: RGCHK (#14110314)
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Incidence and predictors of ulceration and amputation in a Dutch
type 2 diabetes mellitus population
A.A.W. van der Heijden, T.E. Crezee, B.C. van der Zwaard, P. Elders,
G. Nijpels;
The EMGO Institute for Health and Care Research, VU University Med-
ical Center, Amsterdam, Netherlands.
Background and aims: Ulceration and amputation are burdensome
complications of type 2 diabetes (T2DM). A reliable method that predicts
these outcomes would help in the identification of patients at risk of
ulceration and amputation. We therefore aimed to identify predictors of
ulceration and amputation.
Materials and methods: This study was conducted in 5,466 patients
whocwere treated by the Diabetes Care System (DCS) in the West-
Friesland region of the Netherlands between 2011 andc2013. In these
patients, a general foot inspection was performed, in linecwith the
SIMM’s classification, to check for foot deformities or local pressure
points. Patients were examined to obtain information on peripheral neu-
ropathy, vibration sensation, peripheral arterial disease and limited joint
mobility. Diabetic foot ulceration was defined as a skin lesion distal to the
ankle. Information of foot ulceration and amputation in the last year, was
obtained by self-report during the annual screening. According to this
examination, patients were categorized according to the SIMM’s risk
classification. The primary outcome of this study was the incidence of
ulceration or amputation (SIMM’s category 3). Potential predictors of
ulceration and amputation, other than SIMM’s category 1 and 2 were also
determined during the annual screening including age, sex, diabetes du-
ration, smoking status, BMI, blood pressure, HbA1c, lipid levels. The
prevalence of the different SIMM’s risk categories and the 2-year inci-
dence ulceration and amputation was determined. Predictors for ulcera-
tion and amputation were identified out of easily available clinical mea-
surements performed at baseline, using backward logistic regression anal-
yses using the Akaike information criterion, with a significance level of
15.7% (p<0.157).
Results: Two-year incidence of ulceration and amputation was 1.9%.
SIMM’s risk classification 1 (OR 4.03 (95% CI 2.34-6.92)) and 2 (OR
3.92 (95% CI 2.50-6.15)) Current smoking (OR 1.81 (95% CI 1.14-
2.88)), BMI (OR 1.03 (95% CI 1.00-1.07)) and HbA1c (OR 1.02 (95%
CI 1.00-1.03)) were identified as predictors for ulceration and amputation
(Table).
Conclusion: This study identified risk factors for the prediction of ulcer-
ation and amputation. The predictors are factors routinely measured dur-
ing usual diabetes care, which will allow for a translation to clinical care.
Using this classification system, it provides a method to select patients at
higher risk for ulceration and amputation and distribute medical care to
those at most need.
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Magnetic resonance imaging shows wide-spread bone marrow oede-
ma in the acute Charcot foot and this can be quantitated by a novel
scoring system
N.L. Petrova1, A.N. Donaldson1, L. Meacock2, A. Isaac2, D. Elias2,
M.E. Edmonds1;
1Diabetic Foot Clinic, King's College Hospital, 2Department of Radiolo-
gy, King's College Hospital, London, UK.
Background and aims: Magnetic resonance imaging (MRI) is an
established modality in the diagnosis of acute Charcot foot. It shows the
extent of bone and joint damage not only in areas presenting with radio-
logical changes but also in areas which appear “normal” on standard foot
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and ankle radiographs. We devised a novel semi-quantitative bone mar-
row oedema (BMO) score that can be used on foot and ankle MRI scans
in patients with acute Charcot foot. The aim of this study was to investi-
gate the extent of BMO onMRI scans in patients with acute Charcot foot
and to determine the inter- and intra-observer reliability of the BMO
score.
Materials and methods: We studied 45 patients presenting to a single
centre with a recent onset of acute Charcot foot. All bones (proximal
phalanges, medial and lateral sesamoids, metatarsals, tarsals, distal tibial
plafond, medial and lateral malleoli) were scored individually by three
observers for the extent of oedema (BMO score: 0- no oedema; 1-oede-
ma50% on two planes) on a non-contrast MRI scan (Siemens Avanto
1.5 T, dedicated foot and ankle coil). Zones of involvement were assessed
using Sanders and Frykberg’s classification (pattern I - metatarsal-pha-
langeal joints; pattern II - metatarsal-tarsal joint; pattern III - tarsal joints;
pattern IV- ankle joint and pattern V- calcaneum). The inter-observer and
intra-observer reliability for assessing the total BMO score and identify-
ing the zones of involvement were also determined.
Results: The MRIs showed extensive bone marrow oedema throughout
the foot involving several combinations of patterns and only 2 cases
presented with a classical single pattern of involvement - pattern II (1
case, 2.2%) and pattern IV (1 case, 2.2%). The two most common pre-
sentations were the combination of patterns I+ II+III, whichwas observed
in 13 cases (28.9%) and the combination of patterns II +III, which was
observed in 12 cases (26.7%). Five cases presented with a combination of
patterns I+II (11.1%) and further 5 cases presented with a combination of
patterns I+II+III+IV (11.1%). Less frequent presentations included a
combination of patterns II+III+IV noted in 3 cases (6.7%) and patterns
I+II+IV noted in 2 cases (4.4%). The remaining presentations were noted
only in single cases. These included a combination of patterns I+III (1
case, 2.2%), patterns I+II+IV (1 case, 2.2%), patterns I+II+III+IV+V (1
case, 2.2%). The total BMO score showed no significant difference be-
tween the three observers (Interclass Correlation Coefficient 78% (95%CI
60% to 95%), p=0.47) and there was good intra-observer reliability (2
replications of 10 scans - mean difference -0.179 (95%CI -2.031 to
1.674), p=0.21). There was very good intra-observer reliability for the
identification of patterns I, II and III (Kappa coefficients 75%, 100%,
79% respectively) andmoderate for patterns IVandV (Kappa coefficients
43% and 47%, respectively).
Conclusion: We report an extensive distribution of BMO on foot and
ankle MRI scans in diabetic patients with acute Charcot foot, which has
not been previously noted. The total BMO score has very good intra- and
inter-observer reliability. MRI imaging of the whole foot should be con-
sidered when Charcot foot is suspected to allow full appreciation of the
extent of bone and joint damage. The proposed semi-quantitative BMO
score can become a novel tool in the assessment of the acute Charcot foot.
Supported by: Diabetes UK
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Improved 6-year survival in patients with chronic diabetic foot ulcers
after hyperbaric oxygen therapy: outcome from a randomised
double-blind study
M. Löndahl1, K. Fagher1, A.L. Nilsson2, P. Katzman1;
1Endocrinology, Clinical Sciences, Lund, Sweden, 2Internal Medicine,
Angelholm Hospital, Angelholm, Sweden.
Background and aims: Presence of a chronic diabetic foot ulcer (DFU) is
associated with increased mortality. Hyperbaric Oxygen Therapy (HBO), a
medical treatment for chronic DFU in selected patients, increases tissue
oxygenation, stimulates angiogenesis and restores stem cell mobilization
from bone marrow. We have previously shown, beside improved healing
rates, an increased 3-year survival in DFU patients receiving HBO com-
pared to placebo (89.5 vs. 70.3%, p=0.04). The aim of this study was to
evaluate whether this plausible effect persists in a 6-year perspective.
Materials and methods: Patients with chronic DFU were included in a
prospective randomized double-blind placebo-controlled study evaluat-
ing the effect of 40 treatment sessions with HBO (2.5 ATA, 90 mi-
nutes) compared to hyperbaric air (placebo). Patients receiving >35
treatment sessions (per-protocol requirement) were included in the
analysis. Mortality data were received from the Swedish National
Death Registry. Non-parametric statistics were used to assess differ-
ences between groups. Survival was estimated with Kaplan-Meier
curves and Log-rank test. Data are given as median and percentages.
A two-tailed p-value <0.05 was taken as statistically significant.
Results: 75 patients (38 HBO and 37 placebo) with a median age of 67
and 71 years (HBO and placebo, respectively, n.s) and a diabetes duration
of 22 and 21 years (n.s) were included in the analysis. Baseline co-
morbidities were similar between groups, as were prescription patterns
of antidiabetic and cardiovascular protective drugs. Baseline QTc time on
ECGwere similar between groups. The 6-year survival rate was higher in
HBO compared to placebo treated patients (63.2 vs. 40.5%, p<0.05). The
deceased patients were 68.2 years old at baseline in the HBO group
compared to 73.3 years in placebo group (p=0.18). Since age could be
a plausible confounding factor, a subgroup analysis excluding patients
<50 years, was performed (Figure). In this analysis of 69 patients (33
HBO and 36 placebo) aged 71.2 and 71.0 years respectively (n.s.), the
difference in 6-year survival persisted (63.2% in HBO vs. 40.5% in pla-
cebo, p<0.05) and no difference in baseline age of non-survivors was
found (71.9 vs. 73.3 years). QTc time between survivors and non-
survivors at time of inclusion, did not differ in the HBO-group (425 vs.
432 ms, p=0.85), whereas a difference was seen in the placebo group
(419 vs. 434 ms, p=0.02), with a longer QTc time among non-survivors.
Similar outcome was found in the subgroup analysis excluding patients
<50 years of age.
Conclusion: Our study indicates that HBO may improve 6-year survival
in patients with chronic diabetic foot ulcers.Whether this finding is due to
improved healing rates and thus less co-morbidity or whether the effect
might be mediated by an improved cardiac microcirculation and perhaps
a protective effect against further QTc prolongation needs to be further
evaluated.
Clinical Trial Registration Number: NCT00953186
Supported by: T Zoegas foundation, Krapperup Foundation, ALF Med
Fac LU
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Capsaicin 8% patch in painful diabetic peripheral neuropathy: a
randomised, double-blind, placebo-controlled study
M. Stoker1, N. Katz2,3, J. Van4, R. Snijder1, H. Jacobs1, S. Long1, D.
Schregardus1, B. Lambourg5, J. Robinson-Papp6, D. Simpson6;
1Astellas Pharma Europe B. V., Leiden, Netherlands, 2Analgesic Solu-
tions, Natick, 3Tufts University School of Medicine, Boston, 4Diabetes
Research Center, Tustin, 5Helix Biomedics, Boynton Beach, 6Icahn
School of Medicine at Mount Sinai, New York, USA.
Background and aims: The capsaicin 8% patch has demonstrated anal-
gesic efficacy over 12 weeks in patients with post-herpetic neuralgia and
HIV-associated distal sensory polyneuropathy, as well as non-inferior
efficacy to pregabalin in peripheral neuropathic pain, with a faster onset
of action, fewer systemic side effects and greater treatment satisfaction.
STEP evaluated the efficacy and safety of the capsaicin 8% patch versus
placebo in patients with painful diabetic peripheral neuropathy (PDPN).
Materials and methods: STEP was a Phase III, multicentre, double-
blind, placebo-controlled, 12-week study. Patients with painful, distal,
symmetrical, sensorimotor diabetic polyneuropathy of at least 1 year’s
duration, glycosylated haemoglobin ≤11% and average daily pain score
≥4 (question 5 of Brief Pain Inventory-Diabetic Neuropathy [BPI-DN]),
were randomised (1:1) to either capsaicin 8% patch or placebo patch to
painful areas of the feet for 30 minutes. The primary endpoint was per-
centage change in average daily pain score from baseline to between
Weeks 2-8. Secondary endpoints included weekly average daily pain,
30% responder rates, BPI-DN sleep interference score and weekly sleep
interference score.
Results: Overall, 369 patients with mean [SD] duration of PDPN 5.8
[4.0] years, glycosylated haemoglobin 7.3% [1.3] and average daily pain
6.5 [1.4], were randomised to capsaicin 8% patch (n=186) or placebo
patch (n=183). In the primary analysis, a statistically significant greater
mean reduction in average daily pain score was observed for capsaicin
8% patch versus placebo from baseline to between Weeks 2-8 (-27.4%
versus -20.9%; p=0.025). Greater reductions in weekly average daily
pain score were observed from Week 3 onwards with capsaicin versus
placebo (p<0.05 each week, except at Week 6). A greater proportion of
the capsaicin versus placebo group achieved at least a 30% reduction in
average daily pain score from baseline to between Weeks 2-8 (39.8%
versus 32.8%; p=0.108), and also Weeks 2-12 (40.9% versus 31.7%;
p=0.05). Greater improvements in sleep interference score were observed
with capsaicin versus placebo from baseline to between Weeks 2-8 (p=
0.030), and also Weeks 2-12 (p=0.020). In addition, greater improve-
ments in weekly sleep interference score were observed with capsaicin
versus placebo fromWeek 6 onwards (p<0.05 eachweek, except atWeek
10). Apart from transient application site reactions, treatment-emergent
adverse events (TEAEs) in the capsaicin and placebo arms were very
similar, and no discontinuations due to drug-related TEAEs occurred in
either arm.
Conclusion: The capsaicin 8% patch provided statistically significant
improvements in pain relief and sleep quality compared with placebo in
patients with PDPN, with no new safety issues. The STEP study extends
the range of peripheral neuropathic pain aetiologies for which the capsa-
icin 8% patch has demonstrated efficacy and safety.
Clinical Trial Registration Number: NCT01533428
Supported by: Astellas Pharma Europe B. V.
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Impact of chronic renal failure on the clinical outcome of stem cell
therapy in diabetic patients with critical limb ischaemia
M. Dubský1, A. Jirkovská1, R. Bem1, A. Nemcová1, V. Fejfarová1, L.
Pagacová2, K. Navrátil3, E. Syková4;
1Diabetes Centre, Institute for Clinical and Experimental Medicine, 2Au-
totransfusion Unit, Institute for Clinical and Experimental Medicine,
3Clinic of Transplant Surgery, Institute for Clinical and Experimental
Medicine, 4Institute for Experimental Medicine, Czech Academy of Sci-
ences, Prague, Czech Republic.
Background and aims: Therapeutic vasculogenesis by autologous stem
cell therapy is a new treatment method for diabetic patients with critical
limb ischemia (CLI). Chronic renal failure (CRF) can be one of the main
factors that influence the prognosis and amputation rates in patients with
diabetic foot disease, especially with CLI. The aim of our study was to
assess the impact of CRF on the outcomes of stem cell therapy in diabetic
patients with CLI.
Materials and methods: Sixty-two patients with CLI persisting after
unsuccessful standard revascularization, treated by autologous stem cells
in our foot clinic from January 2008 to October 2014 were included in the
study. Patients were divided in a CRF group (17 patients) and a non-CRF
group (42 patients). Patients with the same inclusion criteria treated con-
servatively in the same period and diagnosed to have CRF formed a
control group (21 patients). CRF was defined as chronic kidney disease
stages 4-5 (glomerular filtration rate<29 ml/min/1.73 m2). Mean follow-
up was 17.9±13.1 months. Death and major amputation were assessed
during the follow-up; the changes in transcutaneous oxygen pressure
(TcPO2) were evaluated at 6 months the after cell treatment.
Results: The increase of TcPO2 after 6 months was significantly higher in
the non-CRF group (25.7±12.5 mmHg) in comparison with the CRF group
(16.1±11.3 mm Hg, p=0.032) and control group (9.2±5.4 mm Hg, p=
0.002). TcPO2 was significantly increased in both cell therapy groups after
6 moths compared to baseline (p=0.0008, p=0.0002), we observed no
change in control group. No significant difference in mortality rates during
the follow-up between CRF and control groups was observed (5/17 vs. 6/21,
NS), non-CRF group revealed significantly lowermortality (6/42, p=0.039);
all deaths were without a casual link to cell treatment. The major amputation
rate in surviving patients was significantly lower in the non-CRF group
compared to the control group (10/36 vs 8/15, p=0.0034), comparison of
CRF and control groups revealed no difference (5/12 vs 8/15, NS).
Conclusion: Our study showed that stem cell therapy of patients with
CLI and chronic renal failure significantly improved ischemia in compar-
ison with chronic renal patients treated conservatively, but did not influ-
ence the mortality and rates of major amputation. Patients with normal
renal function treated by stem cells had significantly lower mortality,
amputation rate and higher improvement of ischemia. The therapeutic
vasculogenesis by autologous stem cells should always be considered
in patients on hemodialysis.
Supported by: grant MZO 00023001
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Local application of human stem cells accelerated wound healing in
diabetic rat model
R. Bem1, M. Dubský1, J. Kříž1, Z. Kočí2,3, K. Turnovcová2,3, A.
Němcová1, Š. Kubínová2, V. Fejfarová1, J. Skibová1, E. Syková2,3, A.
Jirkovská1;
1Diabetes Centre, Institute for Clinical and Experimental Medicine, 2De-
partment of Neuroscience, Institute of Experimental Medicine, 3Depart-
ment of Neuroscience, 2nd Faculty of Medicine, Prague, Czech Republic.
Background and aims:Wounds associated with diabetes are recalcitrant
to healing due to many cellular and molecular aberrations as a result of
diabetic complications such as neuropathy, immune impairment and
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ischemia. There is increasing evidence that bone marrow mononuclear
cells (BM-MNC), their subpopulation - mesenchymal stem cells (BM-
MSC) and adipose tissue derived mesenchymal stem cells (AT-MSC) can
differentiate into haematopoietic and non-haematopoietic cells, that can
be related to wound healing. The aim of our study was to compare the
process of wound healing in diabetic rats treated with the various types of
stem cell suspensions of human BM-MNC, BM-MSC and AT-MSC ob-
tained from diabetic and nondiabetic donors.
Materials and methods: Human BM-MNC, BM-MSC and AT-MSC
were isolated from diabetic and nondiabetic donors by standard methods.
BM-MNC concentrate, BM-MSC and AT-MSC in the 2nd passage were
divided in aliquots and cryopreserved till application to rats. Diabetes in
56 Wistar rats was induced by a single intraperitoneal injection of
streptozotocin 64 mg/kg bw and confirmed 48 h later by a blood glucose
level higher than 15mmol/l. 14 days later, the animals were divided into 7
groups of 8 rats. In each animal, one full thickness skin wound 0.8 cm in
diameter was created by a punch biopsy device in the area of the back.
The cell suspension from diabetic or non-diabetic donors was injected
into the base of the wound, and its close surroundings: 1) 0.5 ml of BM-
MNC concentrate; 2) 1 million of BM-MSC in a volume of 0.5 ml or 3) 1
million of AT-MSC in volume of 0.5 ml. The seventh group (Controls) of
8 rats undergone all the procedures except the application of cell suspen-
sion. All animals had a wound covered with silicon dressing and also
were treated daily with subcutaneous long acting insulin and immuno-
suppression. Photographs andmeasurements of thewound has been taken
for the assessment of the effect of cell therapy on wound healing after 3, 7
and 14 days of the appropriate therapy.
Results: The sizes of the wounds before treatment were comparable in all
groups. After 3, 7 and 14 days, there was a significant reduction of wound
size in all groups, including controls (p<0.05). After 7 days, a significant
acceleration of healing in all BM-MNC and BM-MSC groups in compar-
ison with the controls (all p<0.05) was seen, but acceleration in both AT-
MSC groups was not significant. After 14 days, there was a significant
acceleration of wound healing in all cells groups in comparison with
controls, the average area reduction was 99.2% and 94.4% in diabetic
and nondiabetic BM-MNC groups; analogous 97.8% and 98.6% in BM-
MSC; 96.6% and 95% in AT-MSC; but only 83.8% in controls (all p<
0.05).
Conclusion: In our experiment, the local application of human stem cells
derived from bone marrow and adipose tissue accelerated wound healing
in diabetic rats compared with controls receiving only standard therapy; a
significant difference between the diabetic and nondiabetic cell suspen-
sions was not found. AT-MSC were slower to improve healing after
7 days, but after 14 days, there were not significant differences between
the types of used stem cells. Topical treatment of wounds by stem cells
could be a promising therapy for patients with diabetes.
Supported by: GACR 14-03540S
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Dipeptidyl peptidase-4 inhibitor anagliptin alleviates lipotoxicity-
induced hepatic insulin resistance and steatohepatitis in mice
Y. Sakai, M. Nagashimada, N. Nagata, Y. Ni, S. Kaneko, T. Ota;
Brain/Liver Interface Medicine Research Center, Kanazawa University,
Kanazawa, Japan.
Background and aims: Nonalcoholic fatty liver disease (NAFLD) is a
form of a lipotoxic liver injury that can impair systemic insulin resistance
and progress to nonalcoholic steatohepatitis (NASH). We previously dem-
onstrated that excessive hepatic lipid accumulation promotes the activation
of macrophages/Kupffer cells, resulting in exacerbated insulin resistance
and hepatic inflammation. However, there are few promising treatments
targeting lipotoxicity-mediated hepatic activation/polarization of macro-
phages in NASH. Dipeptidyl peptidase-4 (DPP-4) is widely expressed,
including in immune cells such as monocytes/macrophages. In this study,
to test the hypothesis that DPP-4 plays a role in immune cell-mediated
insulin resistance and NAFLD progression to NASH, we examined the
effect of anagliptin, a DPP-4 inhibitor, on diet-induced NAFLD.
Materials andmethods: Eight-week-old C57BL/6mice were fed a high-
cholesterol/high-fat (CL) diet with or without 0.3% anagliptin (CL+Ana)
for 14 weeks. The liver histology, insulin sensitivity, and DPP-4 activity
were examined. Next, we quantified intrahepatic immune cells using a
fluorescence-activated cell sorter (FACS).
Results: After 14 weeks of feeding, histological examination revealed he-
patic steatosis and inflammation inmice fed the CL diet. Themice exhibited
hyperinsulinemia and glucose intolerance, indicating that mice fed the CL
diet developed NASH associated with insulin resistance. Anagliptin admin-
istration improved the hepatic steatosis by decreasing TG and FFA levels by
23% and 50%, respectively. Anagliptin also inhibited the development of
hepatic inflammation and fibrosis, lowering F4/80+ macrophage/Kupffer
cell infiltration and the hydroxyproline content in the liver. Importantly,
hepatic DPP-4 protein expression was increased in mice fed the CL diet
compared with mice fed normal chow (NC), while anagliptin significantly
suppressed DPP-4 expression. Moreover, in the CL group, the DPP-4 ac-
tivity increased 2.2-fold and 1.4-fold in the plasma and liver, respectively,
compared with the NC group, whereas anagliptin markedly reduced the
DPP-4 activity in both plasma and liver by 88% and 65%, respectively (p
<0.01). Anagliptin administration in mice fed the CL diet led to improved
glucose intolerance and hyperinsulinemia and enhanced insulin signal
assessed by IRβ and Akt phosphorylation in the liver. These findings were
associated with endoplasmic reticulum stress reduction (GRP78/CHOP and
phospho-eIF2α) and MAPK (JNK/p38MAPK) and NFkB attenuation in
the liver. To assess the effect of anagliptin on hepatic inflammation further,
intrahepatic leukocytes were quantified using FACS. Hepatic macrophages
identified as CD45+CD11b+F4/80+ cells were decreased in the CL + Ana
group by 26% compared with mice fed the CL diet. In addition to a slight
reduction of the total macrophage content in the liver, mice fed CL + Ana
had 38% fewer CD11c+CD206- (M1)-type macrophages, but 24% more
CD11c-CD206+ (M2)-type macrophages than mice fed the CL diet,
resulting in a predominance of M2 over the M1 macrophage population.
Conclusion: DPP-4 activity in both liver and plasma is increased signif-
icantly in the dietary model of NAFLD associated with insulin resistance.
Anagliptin suppresses lipotoxicity-induced aberrant activation of DPP-4
and attenuates hepatic insulin resistance and steatohepatitis by regulating
M1/M2 status in hepatic macrophages.
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Dipeptidyl peptidase-4 inhibitor suppresses inflammation in U937
monocytes by inhibiting phosphorylation of caveolin-1 through
CD26
M. Hiromura1, K. Nohtomi1, M. Terasaki1, Y. Mori1, H. Kuwata2, T.
Hirano1;
1Diabetes, Metabolism, and Endocrinology, Showa University School of
Medicine, 2Oral Microbiology and Immunology, Showa University
School of Dentistry, Tokyo, Japan.
Background and aims: We reported that dipeptidyl peptidase-4 inhibi-
tors (DPP-4i) confer an anti-atherosclerotic effect in apolipoprotein-E null
mice by incretin-dependent and -independent manner. To elucidate the
molecular mechanisms, we focused on the effect of DPP-4i on expression
of proinflammatory cytokines in monocytes.
Materials and methods: Cultured U937 human monocytes were treated
with or without 10 ug/ml of Lipopolysaccharide (LPS) and teneligliptin
(1-10 nM). Treated cells lysates, and RNA were collected for Western
blotting and real-time reverse transcription polymerase chain reaction.
Some cells were treated with teneligliptin (5 and 10 nM) or vehicle with
LPS, and RNAwas subjected to microarray analysis.
Results: Teneligliptin (1-10 nM) widely suppressed the expression of
inflammatory molecules, such as IL-1β, IL-6, TNF-α, NF-κB, TLR-4,
MCP-1, CCR2, IL-8, IP-10, and RANTES induced by LPS without af-
fecting cell proliferation. Treatments with antibody (Ab) or small inter-
fering (si) RNA against CD26 mimicked anti-inflammatory effect of
teneligliptin. Microarray analysis failed to detect a specific molecule to
explain anti-inflammatory action of teneligliptin, suggesting posttransla-
tional mechanisms. We nominated caveolin (Cav)-1, a signaling protein
associated with caveolae, as a candidate molecule because it has been
reported that Cav-1 binds to CD26 via DPP-4 catalytic site, which medi-
ates inflammatory signals. Anti-Cav-1 polyclonal antibody [H97] recog-
nizing 82-178 amino acids of Cav-1 significantly suppressed IL-1β, IL-6,
TNF-α, and NF-κB mRNAs, whereas anti-Cav-1 monoclonal antibody
[7c8] reacts epitope between residue 32 and the C-terminus of Cav-1 did
not. Cav-1 gene expression was not altered by LPS or teneligliptin, how-
ever, Cav-1 was phosphorylated by LPS and teneligliptin attenuated LPS-
induced p-Cav-1 generation. Likewise, anti-CD26Ab suppressed p-Cav-
1generation. Anti-Cav-1Ab [7c8] suppressed slightly but anti-Cav-1Ab
[H97] strongly suppressed p-Cav-1 generation by LPS. Induction of
siRNAs into CD26 and Cav-1 genes successfully suppressed gene ex-
pression of CD26 and Cav-1, which resulted in significantly suppression
of LPS-induced expression of IL-1β, IL-6, TNF-α, and NF-κB mRNAs.
CD26siRNA and Cav-1siRNA tended to suppressCD86mRNA, a down-
stream of NF-κB signal. ERK1/2 was phosphorylated by LPS, and
teneligliptin, Anti-CD26Ab and anti-Cav-1Ab [H97] all suppressed p-
ERK1/2 generation. Likewise CD26siRNA and Cav-1siRNA suppressed
p-ERK1/2 generation. IRAK-4, a master molecule of downstream of
TLR-4 signaling, was phosphorylated by LPS. Teneligliptin significantly
suppressed LPS-induced p-IRAK-4 generation. Anti-CD26Ab and anti-
Cav-1Ab[H97] tended to suppress p-IRAL-4 expression.
Conclusion: The present study suggests that a DPP-4i suppresses LPS-
induced inflammation in human monocytes by inhibiting interaction of
CD26 and Cav-1, which resulted in suppressed TLR4/ IRAK-4 mediated
NF-kB and MAPK pathways.
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Dipeptidyl peptidase 4 inhibition by gemigliptin prevent abnormal
vascular remodelling mediated by Nrf2 activation
A. Khang1, S. Choi2, S. Park3, Y.-K. Choi1, J.-H. Jeon1, K.-H. Bae1, G.-
S. Jung1, M.-K. Kim4, E.-H. Kim5, K.-G. Park1, I.-K. Lee1;
1Kyungpook National University School of Medicine, 2Department of
Biomedical Science, Kyungpook National University School of Medi-
cine, 33Leading-edge Research Center for Drug Discovery and Develop-
ment for Diabetes and Metabolic Disease, Kyungpook National Univer-
sity School of Medicine, 4Department of Internal Medicine, Keimyung
University School ofMedicine, 5Department of InternalMedicine, Daegu
Fatima Hospital, Daegu, Republic of Korea.
Background and aims: Dipeptidyl peptidase-4 (DPP-4) inhibitors exert
a potent anti-hyperglycemic effect and reduce cardiovascular risk in type
2 diabetic patients. Several experimental studies have shown that in ad-
dition to glucagon-like peptide-1 augmentation, DPP-4 inhibitors includ-
ing sitagliptin and anagliptin have a beneficial effect in cardiovascular
diseases such as atherosclerosis and cardiac infarction that involves reac-
tive oxygen species. Here, we show that gemigliptin, a new DPP-4 inhib-
itor, can directly attenuate the abnormal proliferation and migration of
vascular smooth muscle cells (VSMCs) via enhanced NF-E2-related fac-
tor 2 (Nrf2) activity.
Materials and methods: The carotid artery ligation model was per-
formed for the assessment of neointimal hyperplasia in male C57BL/
6 N mice treated with different concentrations of gemigliptin in a normal
chow diet (0, 0.04, 0.09, and 0.27% in diet). VSMCs were isolated from
the thoracic aortas of four-week-old SD rats and the cells from the third to
fifth passages were used for in vitro experiments: WST-1 assay, FACS
analysis, RT-PCR and Western blotting, and wound healing assay. The
expression of DPP-4 in VSMCs was knockdown by small interfering
RNA (siRNA) using Lipofectamine® RNAiMAX .
Results: Gemigliptin significantly prevented the neointimal hyperplasia
induced by ligation injury in mouse carotid arteries, in vivo. Likewise, the
proliferation of rat primary VSMCs stimulated by 20% FBS was signifi-
cantly attenuated by gemigliptin in a dose dependent manner, confirmed by
the decreased phospho-Rb leading to G1 cycle cell arrest, conse-
quently. We found that gemiglitin enhanced Nrf2 activity by not
only its mRNA expression but also increased Keap1 proteosomal
degradation by p62, resulting in the induction of Nrf2 target genes
such as NAD(P)H quinone oxidoreductase 1 and heme oxygenase
1. The anti-proliferative role of gemigliptin disappeared in VSMCs
with DPP4 siRNA knockdown, indicating that the endogenous
DPP4 in VSMCs mediated the effect of gemigliptin. Besides,
gemigliptin diminished TNF-α-mediated cell adhesion molecules
such as MCP-1, VCAM-1 and MMP2 activity in VSMCs.
Conclusion: Taken together, our data indicate that gemigliptin exerts a
prohibitory effect on the proliferation and migration of VSMCs via Nrf2
activity for the prevention of cardiovascular diseases.
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Effects of DPP-4 inhibition on glomerular and tubular function in a
rat model of ischaemia-reperfusion injury
C. Reichetzeder1, K. von Websky1, O. Tsuprykov1, V. Antonenko1, A.
Mohagheghi Samarin1,2, B. Hocher1;
1University of Potsdam, Germany, 2University of South Bohemia, České
Budějovice, Czech Republic.
Background and aims: Dipeptidyl peptidase (DPP)-4 inhibitors have
protective effects in ischaemia-reperfusion injury (IRI) of the heart and
lung. DPP-4 shows strong renal expression and its substrates are present
in the kidney. Therefore, we studied the effects of the DPP-4 inhibitors
linagliptin, vildagliptin and sitagliptin on the outcome of IRI-induced
acute kidney injury in uninephrectomised rats.
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Materials and methods: Male Wistar rats obtained from Charles River
(Germany) weighing 150–170 g were subjected to uninephrectomy. Two
weeks later, the remaining kidney was exposed to IRI by clamping the renal
artery for 30 min; sham surgery was performed without clamping. The rats
(n=10–14/group) receivedDPP-4 inhibitor treatment once-daily with either
linagliptin (1.5 mg/kg/day), vildagliptin (8 mg/kg/day), sitagliptin
(30 mg/kg/day) or vehicle via gavage on the 3 consecutive days prior to
IRI. An additional groupwas treated with sitagliptin until study end in order
to inhibit DPP-4 activity during the entire experiment. This group was
initially treated with sitagliptin 30 mg/kg/day; after induction of IRI, the
dose was adjusted to 15 mg/kg/day because of renal failure.
Results: Levels of active glucagon-like peptide-1 increased 3–4 fold in
all DPP-4 inhibitor treatment groups versus placebo up to 24 h after
clamping (p<0.05 for all comparisons). Plasma cystatin C, a marker of
glomerular filtration rate, peaked 48 h after clamping and increased from
1454±320 ng/ml in the sham-operated group to 1728±323 ng/ml in the
placebo-treated group (p=0.059). However, this increase was unaffected
by treatment with either linagliptin, vildagliptin, or sitagliptin. In contrast,
DPP-4 inhibitor treatment elicited beneficial effects on tubular regenera-
tion. The tubular dilatation score, assessed 1 week after induction of IRI,
was significantly reduced in all treatment groups compared with placebo.
Conclusion: In rats with acute IRI of the kidney, DPP-4 inhibition does
not alter glomerular function but may enhance tubular regeneration.
Supported by: Boehringer Ingelheim
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The neuroprotective efficacy of the DPP-4 inhibitor linagliptin
against stroke is not mediated by GLP-1 receptor activation
V. Darsalia1,M. Larsson1, D. Nathanson1, D.J. Drucker2, T. Nyström1, T.
Klein3, C. Patrone1;
1Karolinska Institutet, Department of Clinical Science and Education,
Södersjukhuset, Internal Medicine, Stockholm, Sweden, 2Department of
Medicine, Mount Sinai Hospital and the Lunenfeld-Tanenbaum Research
Institute, University of Toronto, Canada, 3Boehringer Ingelheim Pharma
GmbH & Co. KG, Biberach, Germany.
Background and aims: Diabetes and obesity are strong risk factors for
premature and severe stroke. Inhibition of dipeptidyl peptidase (DPP)-4 is
a treatment for type 2 diabetes that prevents the inactivation of glucagon-
like peptide (GLP)-1 and therefore increases levels of active GLP-1. In
addition to their glycaemic actions, DPP-4 inhibitors have been shown to
have neuroprotective effects in several experimental models. Specifically,
our research group has shown that the DPP-4 inhibitor linagliptin is effi-
cacious against stroke in normal and type 2 diabetic and obese mice.
However, the mechanism of action of DPP-4 inhibitor-mediated neuro-
protection remains largely unknown. The aim of this study was to deter-
mine whether the efficacy of linagliptin against stroke is mediated by
GLP-1 receptor (GLP-1R) activation by performing stroke efficacy stud-
ies in normal versus knockout mice lacking the GLP-1R (Glp1r−/−mice).
Materials and methods: Adult male mice with or without functional
disruption of GLP-1R were treated orally with linagliptin 10 mg/kg/day
or vehicle for 7 weeks. There were 4 experimental groups: Glp1r−/− plus
linagliptin, n=9; Glp1r−/− plus vehicle, n=8; wild type plus linagliptin,
n=9; wild type plus vehicle, n=9. After 4 weeks of treatment, the mice
were subjected to 30 min of transient middle cerebral artery occlusion to
induce ischaemic stroke. Drug treatment was continued for 3 additional
weeks until sacrifice. The severity of the ischaemic damage wasmeasured
by evaluating the stroke volume and by stereological counting of NeuN-
positive surviving neurons in the striatum and cortex.
Results: Linagliptin treatment resulted in a strong trend, albeit not statis-
tically significant, towards a reduction of ischaemic volume in wild type
mice (mean linagliptin=6.5 mm3 vs mean vehicle=11.8 mm3). In the
Glp1r−/− mice, the effect of linagliptin on the reduction of ischaemic
volume reached significance (mean linagliptin=18.8 mm3 vs mean
vehicle=7.9 mm3; p<0.001). The results also showed that linagliptin
treatment resulted in a significant reduction of stroke damage in both wild
type (mean linagliptin=2.27×106 vs mean vehicle=1.62×106; p<0.05)
and Glp1r−/− mice (mean linagliptin=2.07×106 vs mean vehicle=1.18×
106; p<0.0005) as measured by the number of surviving neurons in the
striatum and cerebral cortex.
Conclusion: These results indicate that linagliptin-induced neuroprotec-
tion is mediated by a GLP-1R-independent mechanism. Because DPP-4
inhibitors can also increase the levels of other DPP-4 substrates that may
have beneficial effects in the brain, our results should provide a strong
rationale for identifying these factors.
Supported by: Boehringer Ingelheim
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Amelioration of hyperglycaemia with SGLT2i prevents atherosclero-
sis through suppression of macrophage form cell formation in dia-
betic mice independent of insulin action
M. Terasaki1,2, M. Hiromura1, K. Kohashi1, H. Kushima1, M.
Nagashima1, Y. Mori1, T. Hirano1;
1Department ofMedecine, Showa University School ofMedicine, 2Ebara
Hospital, Tokyo, Japan.
Background and aims: Although diabetes is one of the leading
causes of atherosclerosis, it is poorly understood the direct associa-
tion between hyperglycaemia and atherosclerosis independent of
insulin action. A SGLT2i is a recently developed oral anti-diabetic
agent, which reduces plasma glucose levels by increasing urinary
glucose excretion without affecting insulin secretion and action. We
investigated how amelioration of glycaemia by SGLT2i is associated
with macrophage-driven atherosclerosis in mouse models of type 1
and type2 diabetes.
Materials and methods: Male Apoe-/- mice receiving injection of
streptozotocin (50 mg/kg i.p x 5 days,n=34) or saline (n=31) were ran-
domly assigned to SGLT2i treatment (dapagliflozin, 1.0 mg/kg/day) or
vehicle. Male db/db diabetic mice were maintained on the food contain-
ing SGLT2i (ipragliflozin, 1.0 mg/kg/day, n=14) or none (n=30). After
4 weeks, the peritoneal macrophages (Mφ) migrated by an i.p. injection
of thioglycolate were collected to evaluate foam cell formation measured
by incorporation of [3H]-oleate into [3H]-cholesteryloleate in the presence
of ox-LDL. In the Apoe-/- mice, The atherosclerosis was assessed as en
face atherosclerotic plaque area determined by oil red O staining. In the
diabetic mice, gene expressions related to foam cell formation in Mφ
were examined by RT-PCR.
Results: In the type1 diabetic Apoe-/- mice, the SGLT2i decreased the
fasting blood glucose (FBG) , HbA1c, and glucose-AUC after oral glu-
cose tolerance test (OGTT) compared to vehicle. The body weight, daily
food intake, systolic blood pressure, or insulin and lipids were not
changed by treatment with the SGLT2i in the diabetic and non-diabetic
mice. In the diabetic Apoe-/- mice, the atherosclerotic lesions and foam
cell formation were accelerated compared to the non-diabetic counter-
parts (2-3 folds, p<0.01), and significantly suppressed by the SGLT2i
administration (33-34%, p<0.01). The atherosclerotic lesions was highly
correlated to the degree of foam cell formation (r=0.95, p<0.01, n=15)
and the HbA1c levels (r=0.86, p<0.01, n=15), but insignificantly to the
cholesterol levels (r=0.31, p=0.12). In the db/db type 2 diabetic mice
with hyperinsulinemia, the SGLT2i decreased the body weight, levels of
plasma triglycerides, FBG, and HbA1c, and the glucose AUC with in-
creased water intake by 3 times and doubled urine volume. Foam cell
formation was suppressed by the SGLT2i (34%, p<0.01), which corre-
lated to the HbA1c levels (r=0.88, p<0.01, n=36), but insignificantly to
lipid levels (r=-0.46, p=0.06) or insulin (r=-0.15, p=0.56). Gene expres-
sions of scavenger receptors, CD36 and Lox-1, and ACAT-1, a rate lim-
iting enzyme for cholesterol esterification were up-regulated, while
ABCA1, a key molecule for cholesterol efflux was down-regulated in
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Mφ obtained from both diabetic mice. The SGLT2i decreased expres-
sions of scavenger receptors and ACAT-1 by approximately 30 to 40%
and increased ABCA1 by 42%.
Conclusion: The SGLT2is exert anti-atherogenic effects by normaliza-
tion of blood glucose levels in both type1 and type2 diabetic mice through
preventing foam cell formation of Mφ, which is independent of insulin
action. Our results suggest that the foam cell formation regulated by
scavenger receptors, ACAT-1, and cholesterol efflux is highly sensitive
to glycaemia ex.vivo.
OP 13 Growing experience
with GLP-1 receptor agonists
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Endogenous GLP-1 and treatment with liragluitde affect activation
in reward and satiety related brain areas in response to palatable
food
J.S. tenKulve1, D.J. Veltman2, L. van Bloemendaal3, P.F.C. Groot4, H.G.
Ruhé5, F. Barkhof6, M. Diamant3, R.G. IJzerman3;
1Diabetes Centre / Internal Medicine, VU Universtiy Medical Centre,
2Psychiatry, VU University Medical Centre, 3Diabetes Centre / Internal
Medicine, VU Universtiy Medical Centre, 4Radiology, Academic Medi-
cal Center, Amsterdam, 5Psychiatry, University of Groningen, University
Medical Centre Groningen (UMCG), Groningen, 6Radialogy & Nuclear
Medicine, VU University Medical Centre, Amsterdam, Netherlands.
Background and aims: Central nervous system (CNS) activation in
response to food cues may play an important role in the regulation of
food intake. Obesity is associated with a deficit in responsivity to palat-
able food in reward areas of the CNS, which may lead to an increase in
food intake, as a means to compensate for understimulation of the CNS
reward system. It is suggested that alterations in these CNS responses
may contribute to the development of obesity and type 2 diabetes
(T2DM). The gut-derived hormone glucagon-like peptide-1 (GLP-1)
and GLP-1 receptor agonists (GLP-1RA) reduce appetite and body
weight. It has been suggested that these effects are, at least to some extent,
mediated by effects on the CNS. We hypothesized that, in humans, en-
dogenous GLP-1 and treatment with a GLP-1RA influence activation in
reward and satiety related areas in the CNS in response to intake of
palatable food.
Materials and methods: Using functional magnetic resonance imaging
(fMRI), we determined the effects of endogenous GLP-1 and treatment
with the GLP-1 analogue liraglutide on acute CNS activation to the re-
ceipt of chocolate milk. In the first study, infusion of the GLP-1 receptor
antagonist exendin 9-39, was used to block endogenous GLP-1 effects in
healthy lean individuals (n=20, mean ± SD age 56.3±6.2 yrs, BMI 22.5±
1.7 kg/m2, 10 males) and obese patients with T2DM (n=20, mean ± SD
age 59.3±4.1 yrs, BMI 32.0±4.7 kg/m2, 11 males). Infusion with
exendin 9-39 was compared to placebo infusion, which were performed
on two separate test visits. In the second study, in a cross-over designwith
only the T2DM patients, we compared CNS activation between treatment
with liraglutide 1.8 mg and insulin glargine at two time points, i.e. after
10 days and 12 weeks of treatment.
Results: Reduced activation in response to the receipt of chocolate milk
was observed in T2DM patients, compared to lean individuals, in right
insula (p=0.04). Blockade of endogenous GLP-1 effects blunted the ac-
tivation to chocolate milk receipt in healthy lean individuals in bilateral
insula (right p=0.01, left p=0.03). Increased activations in response to
chocolate milk were observed after 10 days of treatment with liraglutide,
compared to insulin, in right insula (p=0.03) and right caudate nucleus
(p=0.01), but these effect ceased to be significant after 12 weeks of
treatment.
Conclusion: We found effects of GLP-1 and liraglutide in the insula and
caudate nucleus, areas implicated in CNS reward and the central regulation
of food intake. Our results indicate that endogenous GLP-1 contributes to
the central regulation of feeding. Furthermore, compared to insulin, short-
term treatment with the GLP-1 analogue liraglutide may improve the ob-
served deficit in the responsivity of the CNS to palatable food in obese
T2DM patients, which may contribute to the induction of weight loss ob-
served during this treatment. However, there were no long-term effects of
liraglutide on CNS activation. This may explain why weight loss does not
proceed after the initial treatment period with liraglutide 1.8 mg.
Clinical Trial Registration Number: NTC 01363609
Supported by: Novo Nordisk
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A randomised double-blind trial of liraglutide to control HbA1c in
subjects with type 2 diabetes treated with multiple daily insulin in-
jections (MDILiraglutide trial)
M. Lind1,2, I. Hirsch3, J. Tuomilehto4, S. Dahlqvist1, B. Ahrén5, O.
Torffvit5, S. Attvall2, M. Ekelund5, K. Filipsson5, B.-O. Tengmark6, S.
Sjöberg7, N.-G. Pehrsson8;
1NU Hospital Group, Uddevalla, 2University of Gothenburg, Sweden,
3University of Washington, Seattle, USA, 4Helsinki University, Helsinki,
Finland, 5Lund University, Lund, 6Citydiabetes, Stockholm, 7Karolinska
Institutet, Stockholm, 8Statistiska Konsultgruppen, Gothenburg, Sweden.
Background and aims:Multiple daily insulin injections (MDI) are gen-
erally a final treatment option in subjects with type 2 diabetes (T2D) and
poor glycemic control, but are often associated with weight gain and
increased risk of hypoglycemia. Many individuals also have significantly
reduced insulin production and do not reach glycemic targets. Random-
ized controlled trial data are lacking on whether adjunctive glucose low-
ering agents can improve glycemic control in these individuals.
Materials andmethods: In total, 124 subjects with T2D treated withMDI
at 14 hospitals in Sweden were randomized to liraglutide (L) or placebo (P)
for 24 weeks. The primary endpoint was change in HbA1c from baseline to
week 24 estimated by ANCOVA, adjusted for baseline HbA1c.
Results: Mean age at baseline was 63.8 and 63.6 years, HbA1c
74.6 mmol/mol (9.0%) and 74.4 mmol/mol (9.0%), BMI 33.7 and
33.5 kg/m2 and total insulin dose 105.3 and 105.6 units in the L and P
groups, respectively. In the Intention to Treat Analysis, HbA1c was re-
duced by 16.9 mmol/mol (1.5%) in the L group, compared to 4.6 mmol/
mol (0.4%) in the P group, difference -12.3 mmol/mol (-1.1%, p<
0.0001). There were more in the L group (42.9%) than in the P group
(5.1%), who reached HbA1c <53 mmol/mol=7.0% (p<0.0001). Body
weight was reduced by 3.8 kg in L but not P subjects, +0.0 kg, difference -
3.8 kg (p<0.0001). Total insulin dose was reduced by 18.1 U with L and
2.3 U with P, difference -15.8 U (p<0.0001). Fasting and postprandial
glucose levels were lower in the L than P group, difference -1.5 and -
2.0 mmol/l, respectively (p<0.01 for both). The mean glucose levels (p<
0.001) and standard deviation of glucose levels (p=0.001) estimated by
masked continuous glucose monitoring were significantly lower in the L
than P group, -1.9 and -0.5 mmol/l, respectively. There were no severe
hypoglycaemia in either group. No significant difference existed in symp-
tomatic or asymptomatic non-severe hypoglycaemias with values <4.0 or
<3.0 mmol/l between the L and P groups. The most common type of
hypoglycaemia was non-severe symptomatic hypoglycaemia
<4.0 mmol/l, mean number during follow-up 1.29 and 1.24 in the L
and P Groups respectively (p=0.96).
Conclusion: Adding liraglutide to individuals with T2D treated with
MDI improves glycemic control without increased risks of
hypoglycaemia, reduces weight and patients can lower their insulin doses.
Clinical Trial Registration Number: NCT02113332
Supported by: Research initiated trial partly funded by Novo Nordisk
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Once-daily liraglutide vs lixisenatide as add-on to metformin in type
2 diabetes: a 26-week randomised controlled clinical trial
M.A. Nauck1, M. Rizzo2, V. Pirags3, H. Bosch-Traberg4, J. Madsen4, B.
Cariou5;
1Division of Diabetology, St. Josef Hospital, Ruhr University Bochum,
Germany, 2University of Palermo, Italy, 3Pauls Stradins Clinical Univer-
sity Hospital, University of Latvia, Riga, Latvia, 4Novo Nordisk, Søborg,
Denmark, 5Hôpital Nord-Laënnec, Saint Herblain, France.
Background and aims: Liraglutide (lira) and lixisenatide (lixi) are GLP-1
receptor agonists for the treatment of type 2 diabetes mellitus (T2DM), both
to be injected once daily. The aim of the trial was to compare the efficacy
and safety of lira vs lixi, as add-on to metformin (MET) in patients with
T2DM not achieving adequate glycaemic control on MET alone.
Materials and methods: This was a 26-week, randomised, parallel group,
open label trial. Patients (age ≥18 years, HbA1c 7.5−10.5% [58−91 mmol/
mol], BMI≥20 kg/m2)with T2DMwere randomised 1:1 to lira 1.8mg or lixi
20 μg as add-on to MET (maximum tolerated dose, 1000−3000 mg daily).
Dose escalation and administration of lira and lixi were according to the
approved label for both drugs at the time of the trial. Lira was administered
once daily at any time of the day irrespective ofmeals. Lixi was administered
once daily, within an hour prior to the morning or evening meal.
Results: 404 patients (mean age 56 years, male/female 60%:40%, BMI
35 kg/m2, HbA1c 8.4% [68 mmol/mol], T2DM duration 6.4 years) were
randomised. AtWeek 26, lira reducedmeanHbA1c significantly more than
lixi did (estimated treatment difference: −0.62%, 95%CI: −0.80 to −0.44; p
<0.0001), with more patients reaching HbA1c goals of <7% and ≤6.5%,
compared to lixi (Table). Lira was associated with greater improvement in
the HOMA-B index. As HOMA-B was measured in the fasting state, the
improvement was possibly determined by differences in drug exposure due
to different half-lives of lira and lixi. Lira reduced fasting plasma glucose
more than lixi. Greater reduction in mean 9-point self-measured plasma
glucose was seen with lira. However, lixi had smaller post-prandial incre-
ments for the meal following injection compared to lira. Both drugs pro-
moted similar body weight decrease (−4.3 kg for lira and −3.7 kg for lixi;
p=ns). Systolic and diastolic blood pressure similarly decreased in both
groups. The safety profile was overall similar between the two groups.
The most common adverse events were gastrointestinal disorders (nausea:
21.8% for lira and lixi; diarrhoea: 12.4% for lira and 9.9% for lixi). Con-
firmed hypoglycaemic episodes (severe hypoglycaemia or PG <3.1 mmol/
L) were rare (4 events in 3 patients for lira, and 8 events in 5 patients for lixi,
p=ns), with no severe hypoglycaemic episodes.
Conclusion: Liraglutide was more efficacious than lixisenatide as add-on
to MET in achieving glycaemic control, and may be associated with
greater improvement in beta-cell function in patients with T2DM. Body
weight and blood pressure reductions were similar, and both treatments
were well-tolerated with low risk of hypoglycaemia and similar gastroin-
testinal adverse events profiles.
Clinical Trial Registration Number: NCT01973231
Supported by: Novo Nordisk
Diabetologia (2015) 58 (Suppl 1):S1–S607 S37
76
Continuous glucose monitoring in type 2 diabetes patients treated
with once weekly dulaglutide or once daily glargine, both combined
with insulin lispro (AWARD-4 substudy)
J. Jendle1, M. Testa2, S. Martin3, H. Jiang3, Z. Milicevic4;
1Endocrine and Diabetes Center, Örebro University, Örebro, Sweden,
2Harvard T.H. Chan School of Public Health, Boston, 3Eli Lilly and
Company, Indianapolis, USA, 4Eli Lilly and Company Regional Opera-
tions, Vienna, Austria.
Background and aims: Since higher glycaemic variability may predict
potentially greater risk for both hypo- and hyperglycaemia, we compared
continuous glucose monitoring (CGM) metrics during treatment with
1.5 mg and 0.75 mg doses of once weekly GLP-1 receptor agonist
dulaglutide (DU) vs daily glargineGLA), bothwith prandial lispro (±met-
formin), in a subset of patients with type 2 diabetes (T2D) enrolled in the
AWARD-4 trial.
Materials and methods: The study population comprised patients with
T2D uncontrolled on conventional insulin regimens. Participants (n=
144) had mean baseline age of 59.9 y, HbA1c of 8.57% [70.2 mmol/
mol], and a BMI of 32.9 kg/m2. A CGMS® iPro™ was used for 3 days,
at baseline and 26 (primary endpoint) and 52 weeks after randomisation,
to estimate between-group differences in 24 h glycaemic ranges, thresh-
olds, and variability. Study participants also performed 8-point self-mon-
itored blood glucose (SMBG).
Results: The mean decreases from baseline to 26 weeks in CGM glucose
(see Table) were similar to those from 8-point SMBG (LSM±SE; DU
1.5 mg -3.3±0.4 mmol/L; DU 0.75 mg -3.1±0.3 mmol/L; GLA -2.8±
0.3 mmol/L), with no significant differences between treatments. These
results were similar at 52 weeks. Increases in % time within the 3.9-
7.8 mmol/L range were not different between treatments; however, DU
1.5 mg increased % time within the 3.9-10.0 mmol/L range significantly
more than GLA at 26 weeks. Treatment effect on % time <3.9 mmol/L at
26 weeks were not different, but at 52 weeks treatment with GLA signif-
icantly increased % time <3.9 mmol/L versus both DU doses. DU 1.5 mg
had a greater reduction in glycaemic variability as measured by within-
patient standard deviation at 26 weeks versus GLA with no significant
differences between treatments at 52 weeks. Total mean amplitude of
glucose excursions (MAGE) was not different between treatments.
Conclusion: At primary endpoint, after 26 weeks, DU 1.5 mg compared
to GLA resulted in greater increase in % time with CGM glucose in the
3.9-10.0 mmol/L range and with lower glycaemic variability. Both
dulaglutide doses were associated with smaller increase in % time
<3.9 mmol/L at final endpoint (52 weeks). These results are consistent
with reported lower risk of clinical hypoglycaemia with DU 1.5 mg ver-
sus GLA in the overall AWARD-4 but further investigations are need to
evaluate potential causal relationship between the observed changes in
glucose variability and episodes of hypoglycaemia.
Clinical Trial Reigstration Number: NCT01191268
Supported by: Eli Lilly and Company
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Onceweekly dulaglutide does not increase the risk for cardiovascular
(CV) events in type 2 diabetes: a prespecified meta-analysis of pro-
spectively adjudicated CV events
K.C. Ferdinand1, P. Sager2, C.M. Atisso3, F.T. Botros4;
1Tulane University SOM, New Orleans, 2Sager Consulting, San
Francisco, 3Statistics, Eli Lilly and Company, 4Diabetes Development,
Eli Lilly and Company, Indianapolis, USA.
Background and aims: Patients with type 2 diabetes have a 2- to 4-fold
greater risk for cardiovascular disease than those without diabetes.
Dulaglutide is a once weekly glucagon-like peptide-1 receptor agonist
recently approved for treatment of type 2 diabetes. This meta-analysis
evaluates the cardiovascular risk in type 2 diabetes patients treated with
dulaglutide in 9 randomised safety and efficacy trials (mean [median]
treatment duration was 333 [358] days).
Materials and methods: Reported cardiovascular events were indepen-
dently adjudicated by a blinded clinical endpoint committee. The primary
endpoint was a composite of death due to cardiovascular causes, nonfatal
MI, nonfatal stroke, or hospitalisation for unstable angina (4-component
major adverse cardiovascular event or MACE). Additional prespecified
endpoints, composite and individual, included adjudicated coronary
revascularisations, hospitalisation for heart failure, or all-cause mortality.
Cox proportional hazards regressionmodel stratified by studywas used to
estimate the hazard ratio (HR) and confidence interval (CI); the model
included treatment as a fixed effect with 2 levels for the factor
(dulaglutide or control).
Results: The analysis included 6010 randomised patients (dulaglutide:
3885; all comparators [active or placebo]: 2125); cumulative exposure to
dulaglutide or control was 3941 and 2223 patient-years, respectively. The
demographic and baseline cardiovascular disease characteristics were
well-balanced across groups. Twenty-six (0.67%) patients in the
dulaglutide group vs 25 (1.18%) in the all comparators group experienced
a primary MACE-4 event. Treatment with dulaglutide was not associated
with an increase in the risk of experiencing a MACE-4 endpoint com-
pared with control therapies (HR: 0.57; multiplicity-adjusted (98.02%)
CI: 0.30, 1.10) (Table). Results for the 3- and 6-component MACE, and
all-cause mortality were consistent with the primary analysis (HR <1.0 for
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all). In the dulaglutide group, 23 (0.59%) patients experienced a 3-
component MACE event (composite of death from CV causes, nonfatal
MI, or nonfatal stroke) compared to 21 (0.99%) in the all comparators
group (HR: 0.60; 95% CI: 0.33, 1.08).
Conclusion: These results suggest that dulaglutide does not increase the
risk of MACE events in type 2 diabetes patients. The ongoing cardiovas-
cular outcomes study, REWIND, will further assess cardiovascular safety
of dulaglutide.
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Advancing basal insulin glargine with prandial lixisenatide QD vs
insulin glulisine QD or TID in type 2 diabetes: the GetGoal-Duo2
evidence-based trial
C. Roy-Duval1, M. Hanefeld2, S. Gentile3, R. Aronson4, F.J.
Tinahones5,6, B. Guerci7,8, E. Souhami1, M. Wardecki9, J. Ye10, S. Hell-
er11, J. Rosenstock12, on behalf of the GetGoal-Duo2 study investigators;
1Sanofi, Paris, France, 2GWT-TUD, Study Centre Prof. Hanefeld, Dres-
den Technical University, Dresden, Germany, 3Department of Clinical
and Experimental Medicine, Second University of Naples, Italy, 4LMC
Diabetes & Endocrinology, Toronto, Canada, 5CIBER de Fisiopatalogía
de la Obesidad y Nutrición (CIBEROBN), Insituto de Salud Carlos III,
6Hospital Virgen de la Victoria, Malaga, Spain, 7University of Lorraine,
8Department of Diabetology, Metabolic Diseases and Nutrition, Brabois
Adult Hospital, Vandoeuvre Lès Nancy, France, 9Sanofi, Warsaw, Poland,
10Sanofi, Bridgewater, USA, 11Department of Human Metabolism, Univer-
sity of Sheffield, UK, 12Dallas Diabetes and Endocrine Center, Dallas, USA.
Background and aims: To provide evidence on how to advance basal
insulin (BI).
Materials and methods: We explored treatment options in poorly con-
trolled, BI-treated (≥6 mo±1-3 OADs), predominantly obese adults with
type 2 diabetes mellitus (T2DM) randomized to lixisenatide 20 μg QD
(LIXI), insulin glulisine QD (GLU-1) or GLU TID (GLU-3), all added to
insulin glargine (IG)±metformin, if HbA1c remained ≥7-≤9% after a 12-
week IG optimization run-in period after stopping other OADs. Co-
primary endpoints at 26 weeks were (1) non-inferiority (95% CI upper
bound <0.4%) in HbA1c reduction with LIXI vs GLU-1 and (2) for LIXI
vs GLU-3, either non-inferiority in HbA1c reduction (2a) OR superiority
(one-sided α=0.025) in body weight change (2b). FPG, PPG, IG dose,
AEs and hypoglycaemia were assessed. Each arm randomized 298 pts
(T2DM duration 12 yrs, BI duration 3 yrs, weight 89 kg).
Results: All co-primary endpoints were met as LIXI was non-inferior to
GLU-1 and GLU-3 for HbA1c reductions and statistically superior to both
for body weight loss (Table). Documented hypoglycaemia was numerically
and significantly lower with LIXI than with GLU-1 andGLU-3, respectively.
Conclusion: BI plus LIXI may become a preferred option to advance BI,
attaining meaningful glycaemic targets with less hypoglycaemia and with-
out negative impact on weight vs prandial insulin as Basal Plus or Basal
Bolus for uncontrolled, BI-treated T2DM.
Clinical Trial Registration Number: NCT01768559
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Adverse impact of visceral fat on lipid and metabolic profile in fatty
liver disease
C. Saponaro1, M. Gaggini1, C. Rosso2, E. Buzzigoli1, F. Carli1, D.
Ciociaro1, L. Mezzabotta2, E. Vanni2, F. Saba2, M. Abate2, A. Smedile2,
M. Rizzetto2, E. Bugianesi2, A. Gastaldelli1;
1Institute of Clinical Physiology, CNR, Pisa, 2Division of Gastroenterol-
ogy and Hepatology and Lab. of Diabetology, Dept. ofMedical Sciences,
University of Turin, Italy.
Background and aims: Abdominal/visceral (VF) adiposity is a major
risk factor for metabolic syndrome and type 2 diabetes and could be
implicated in onset and development of non alcoholic fatty liver disease
(NAFLD). However, the relative role in the progression of liver damage
and dysfunction is still unknown. Insulin resistance, lipotoxicity and in-
flammation are the main events that occur in FLD. The aim of this work
was to evaluate the impact of visceral fat on histological liver damage,
lipid profile and metabolic alterations in patients with proven NAFLD.
Materials and methods: In 34 non diabetic subjects with biopsy proven
non alcoholic FLD and 8 controls (CT) we measured visceral, subcuta-
neous and hepatic fat by MRI, plasma concentrations of triglycerides
(TG), total cholesterol, free fatty acids (FFA), and GGT. Gas chromatog-
raphy mass spectrometry was used to assess FFAs composition. From
plasma FFA we calculated the de novo lipogenesis index (DNL=
palmitic/linoleic acid) and unsaturated to saturated fat ratio (PUFA/SFA).
By use of tracers we evaluated lipolysis and endogenous glucose produc-
tion (EGP) and calculated adipose tissue insulin resistance (Adipo-IR=
Lipolysis x Insulin) and hepatic insulin resistance (Hep-IR=EGP x Insu-
lin). Histology was scored according to Kleiner.
Results:Of the 34 recruited patients 10 were without fibrosis (F0), 24 with
fibrosis score 1 to 4 (F1-4). Fibrosis was associated with a worse metabolic
profile, with increased both adipo-IR (8.3±4.3 vs 7.4±6.0 vs 3.6±1.4) and
HOMA index (3.2±1.9 vs 2.6±1.2 vs 1.3±0.4) in F1-4 vs F0 vs CT (all p<
0.05 for F1-4 vs CT). In addition patients with F1-4, compared to F0 and
CT, had higher VF (2.9±1.1 vs 2.1±0.6 vs 0.7±0.4 kg, p<0.03). VF and
hepatic fat correlated with Adipo-IR (r=0.42, r=0.64) and HOMA index
(r=0.42, r=0.52) and with increased plasma levels of TG (r=0.53, r=0.52)
and DNL (r=0.46, r=0.52) all p<0.05. Also alterations in FFA composi-
tion, in particular reduced PUFA/SFA ratio, were associated with higher VF
(r=-0.41) and hepatic fat (r=-0.57 p<0.005). Moreover, VF and hepatic fat
correlated positivelywithMCP-1 (r=0.52, r=0.55) and oxLDL (r=0.37, r=
0.25) and negatively with adiponectin (r=-0.49, r=-0.53), all p<0.05,
documenting a pro-inflammatory profile.
Conclusion: In patients with NAFLD, hepatic fat is associated with met-
abolic derangements and HOMA, but Adipo-IR and visceral fat accumu-
lation appear to provide a major contribution to liver damage and is
associated with an adverse lipid and inflammatory profile.
Supported by: FP7-FLIP - Health-F2-2009- 241762; Flagship
Interomics Project
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In massively obese patients with a metabolically healthy phenotype
the prevalence of non alcoholic fatty liver disease is high and associ-
ated with sympathetic overactivity
S. Chiheb, N. Helmy, B. Merioud, A. Rezki, M. Ziol, C. Barrat, C. Vons,
P. Valensi;
Jean Verdier Hospital, Bondy, France.
Background and aims:Metabolically healthy obese (MHO) individuals
are relatively insulin sensitive, normotensive and have favourable glucose
and lipid profiles. Obesity andmetabolic syndrome (MS)were reported to
be associated with sympathetic nervous system overactivity. Non alco-
holic fatty liver disease (NAFLD) is considered as the hepatic component
of MS. The role of inflammation in the development of steatohepatitis
(NASH) and the relation with sympathetic activity and metabolic disor-
ders has been suggested. This study aimed to determine whether in mas-
sively obese patients with MHO phenotype inflammatory markers, insu-
lin resistance, cortisol and sympathetic activity are associated with
NAFLD.
Materials and methods: In a prospective study of patients undergoing
bariatric surgery, liver biopsies were obtained peroperatively. We includ-
ed 66 patients (54 women) aged 36.4±9.6 years, body mass index 44.7±
0.9 kg/m2. All of them were free of other liver disease. Liver changes
were classified by histological analysis into 3 groups: normal liver, simple
steatosis and steatohepatitis (NASH). MHO phenotype was defined as no
or only one feature of the metabolic syndrome (IDF criteria). Biological
measurements included plasma liver enzymes, lipids, glucose, cortisol,
inflammatory markers (C-reactive protein (CRP), fibrinogen) and
HOMA-IR. Sympathetic activity was assessed by plasma epinephrine
and norepinephrine at fasting and 2 hours after an oral glucose challenge.
Results: Among the 66 patients 34 had steatosis and 16 NASH. Twenty-
two patients had definite MHO status, including 8 with histologically
normal liver, 11 with steatosis and 3 NASH. AmongMHO patients, those
with steatosis or NASH had higher post-glucose norepinephrine, after-
noon cortisol levels and CRP levels (p=0.04, 0.01, 0.05 respectively). No
other significant difference was detected between these patients and those
with normal liver.
Conclusion: The prevalence of liver disease is high in massively obese
patients withMHO phenotype. Those with NAFLD exhibit a more marked
cluster of inflammation, hypercortisolism and sympathetic activity.
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The link between obesity and insulin resistance by hepassocin
C.-J. Chang1, H.-T. Wu1,2, H.-Y. Ou3, F.-H. Lu1, H.-C. Hung3, Y.-C.
Yang1, J.-S. Wu1;
1Department of Family Medicine, College of Medicine, National Cheng
Kung University and Hospital, 2Research Center of Herbal Medicine,
New Drugs, and Nutritional Supplements, National Cheng Kung Univer-
sity, 3Department of Internal Medicine, College of Medicine, National
Cheng Kung University and Hospital, Tainan, Taiwan.
Background and aims: The prevalence of obesity has increased in most
of the world over the past few decades, and the excess of body fat is
associated with adverse health consequences. Numerous studies indicated
that inflammation-mediated adipokines or hepatokines release led to the
development of insulin resistance, the relationship among these factors
was still obscure. Hepassocin was previously discovered as a hepatokine
that exerted a lipogenic activity and led to insulin resistance. A recent
study indicated that hepassocin also expressed in the adipose tissue. How-
ever, the role of hepassocin between obesity and insulin resistance is still
obscure
Materials and methods: A total of 150 subjects with normal weight,
overweight, and obesity (n=50 for each group) were enrolled. Serum
hepassocin concentrations were measured by enzyme-linked immunosor-
bent assay. Overexpression or knockdown of hepassocin in the adipose
tissue of high fat diet-fed mice was achieved by lenti-viral vector trans-
fection to evaluate the effects of hepassocin in fat pad. In addition, 3 T3-
L1 adipocytes were used to investigate the possible mechanisms in
hepassocin-induced lipogenesis, and to clarify the role of hepassocin in
obesity. Moreover, HepG2 cells were treated with hepassocin recombi-
nant protein to evaluate the effect of hepassocin on hepatic insulin
sensitivity.
Results: The serum concentrations of hepassocin were significantly in-
creased in subjects with overweight, or obesity as compared with normal
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weight group (P for trend <0.01). The expression of hepassocin was
detected in the epididymal fat, and the epididymal hepassocin expression
was increased in high fat fed mice, as compared with chow group.
Interleukin-6 treatment induced the expression of hepassocin in 3 T3-
L1 adipocytes. In addition, treatment with hepassocin in 3 T3-L1 adipo-
cytes significantly increased the lipogenesis through an ERK1/2-depen-
dent pathway. Overexpression of hepassocin in epididymal adipose tissue
significantly increased the size of the fat pad in mice. Furthermore,
hepassocin disrupted insulin signaling to increase glucose production in
HepG2 hepatocytes.
Conclusion: Inflammation in adipose tissue increased the expression of
hepassocin and the elevated hepassocin in circulation further led to the
insulin resistance in liver, and affected hepatic glucose production. In
addition, hepassocin increased lipogenesis in adipocytes to induce obesi-
ty. Thus, we provided a novel mechanism of obesity-induced insulin
resistance by hepassocin.
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Glucagon-Like Peptide-1 (GLP-1) and its receptor agonist, exendin-
4, affect cholesterol metabolism by regulating SREBP2 in hepatocyte
Y. Hasegawa1,2, M. Hori2, T. Nakagami1, M.H. Shiba2, Y. Uchigata1;
1Diabetes Center, Tokyo Women's Medical University School of Medi-
cine, Tokyo, 2Department ofMolecular Innovation in Lipidology, Nation-
al Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.
Background and aims: Type2 diabetes mellitus (T2DM) causes dyslip-
idemia characterized by enhance of production of very low-density lipo-
protein (VLDL) and LDL, and decrease of high-density lipoprotein
(HDL). Glucagon-like peptide-1 (GLP-1) has been implicated in decreas-
ing postprandial Apo-B48, chylomicron, triacylglycerol in animal models
and patients with T2DM, by reducing intestinal lipoprotein production.
To date, GLP-1 has some effects on cholesterol metabolism, but it re-
mains to be completely elucidated. In this study, we investigated the effect
of GLP-1 on cholesterol metabolism in liver of mice and Huh7
hepatocytes.
Materials and methods: (1) in vivo study, ten-weeks-old male C57BL/
6J mice (n=16) were treated with the agonist of GLP-1 receptor, exendin-
4 (ex-4, 10 nmol/kg body weight) or saline (control) by intraperitoneal
injection for 5 days. Serum biological analysis was performed. Hepatic
cholesterol contents were determined by Folch method. Protein levels and
mRNA expressions involved with cholesterol metabolism in mice liver
and small intestine were analyzed by western blotting and quantitative
real-time PCR, respectively. (2) In vitro study, cultured Huh7 hepatocytes
were treated with 0, 100, or 500 nM GLP-1(7-36) amide and LDL
(100 μg/mL) in medium containing 10% lipoprotein derived serum
(LPDS). Cellular protein and mRNA levels were analyzed described
above.
Results: (1) The change in body weights did not differ between ex-4
treated mice and control mice. Serum VLDL- and LDL-cholesterol levels
were significantly decreased in ex-4 treated mice than control mice (9.2±
1.4 vs. 6.3±1.8 mg/dL, 11.6±2.3 vs. 8.8±2.0 mg/dL, p<0.05). Hepatic
protein levels of sterol regulatory element-binding protein (SREBP2) and
LDL receptor (LDLR) were significantly increased by ex-4 treatment. Ex-4
increased hepatic mRNA expression levels of hydroxymethylglutaryl-CoA
synthase and reductase, which are related to cholesterol synthesis, by 2.0-
(p=0.03) and 1.5-folds (p=0.005), respectively. It decreased those of ATP-
binding cassette transporters-G5/8 (ABCG5/8), which are related to choles-
terol excretion, by 0.6- (p=0.02) and 0.7-folds (p=0.01), respectively. Ex-4
did not change hepatic cholesterol contents and the mRNA expression
levels of cholesterol metabolism-related genes in small intestine. (2) In
Huh7 cells, 500 nM GLP-1 increased the protein levels of SREBP2 and
LDLR. 100 nM GLP-1 significantly increased mRNA expression of
SREBP2 and LDLR by 1.5- (p=0.01) and 2.5- (p=0.01) folds while it
significantly decreased those of ABCG5/8 by 0.3- (p=0.02) and 0.5- folds
(p=0.04), respectively. 100 or 500 nM GLP-1 enhanced phosphorylated
Erk1/2 associated with activation of insulin signal pathway.
Conclusion: Ex-4 decreased serum levels of VLDL- and LDL-
cholesterol by increasing the hepatic expression of SREBP2 and LDLR
in C57BL/6J mice. In culture hepatocytes, GLP-1 also increased the
SREBP and LDLR expression, suggesting that ex-4/GLP-1 increases
the uptake of VLDL and LDL in liver and reduce serum cholesterol
independent of insulin.
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Hepatic FGF21 protects mice against diet-induced lipid dysregula-
tion and insulin resistance
Z. Huang, T.-H. Lee, C.-M. Wong, K.-L. Lam, A. Xu;
Medicine, The University of Hong Kong, Hong Kong.
Background and aims: Fibroblast growth factor 21 (FGF21) is a potent
metabolic hormone produced by a number of organs. It has been shown to
confer multiple metabolic benefits on obesity and diabetes. Therapeutic
administration of FGF21 or its analog protects against diet-induced obe-
sity and hyperglycemia in both rodents and humans. However, the phys-
iological roles of FGF21 remain ambiguous. Since the liver is the major
site of production for circulating FGF21, we propose that the endocrine
actions of FGF21 derived from the liver may account for its metabolic
effects on lipid metabolism.
Materials and methods:We therefore generated the liver-specific FGF21
KO (LiverKO) mouse strain by crossbreeding transgenic mice bearing a
conditional FGF21 allele with the exons 2 and 3 flanked by LoxP sites with
mice expressing Cre under the control of the albumin promoter. LiverKO
mice and their age-matched wild-type (WT) littermates were fed a high fat
diet (HFD) for 20 weeks and assessed for the metabolic phenotypes.
Results: Circulating FGF21 was significantly elevated in WT mice dur-
ing fasting or HFD feeding. However, this elevation of circulating FGF21
level was completely abolished in LiverKO mice, suggesting the liver is
the major source of circulating FGF21. LiverKO mice treated with HFD
showed a significant reduction in body fat mass when compared to WT
mice, as revealed by NMR body composition analyzer suggesting resis-
tance to obesity was mainly attributed to the loss of hepatic FGF21.
Interestingly, although LiverKO mice had lean phenotype, they devel-
oped more severe glucose intolerance and insulin resistance after HFD
feeding as shown by GTT and ITT, respectively. In addition, LiverKO
mice had higher serum triglyceride and free fatty acid (FFA) levels sug-
gesting that lipid homeostasis is impaired. It is possible that hepatic
FGF21 inhibits lipolysis while promotes lipid uptake in adipocytes.
Conclusion: These data collectively suggest that circulating FGF21 is
mainly derived from the liver. Hepatic FGF21 regulates lipid metabolism
in adipocytes, and therefore protects mice against diet-induced hypergly-
cemia and insulin resistance possibly via reducing ectopic lipid accumu-
lation in non-adipose tissues such as the liver and skeletal muscles.
Supported by: Collaborative Research Fund, Hong Kong
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Monounsaturated fatty acid enriched high fat diets attenuate obesity
induced hyperinsulinaemia concurrent with an altered hepatic
lipidome
A.M.Murphy1, M. Morine2, O. Finucane1, C. Reynolds1, C. Lyons1, N.
Healy1, L. Brennan3, F. McGillicuddy1, H. Roche1;
1UCD Conway Institute for Biomolecular and Biomedical Science, Uni-
versity College Dublin, Ireland, 2The Microsoft Research, University of
Trento Centre for Computational and Systems Biology Rovereto, Italy,
3UCD Institute of Food and Health, University College Dublin, Ireland.
Background and aims: Altered lipid metabolism underlies many meta-
bolic disorders such as obesity and Type 2 Diabetes Mellitus (T2DM).
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Excess lipids and their metabolites act as metabolic stressors to induce
inflammation and promote insulin resistance (IR). Lipidomics represents
a novel tool to identify lipid biomarkers of disease. A lipidomic approach
sought to investigate the differential effect of saturated fatty acid (SFA)
versus monounsaturated fatty acid (MUFA) high-fat diet (HFD) chal-
lenges on the hepatic lipidome and an IR profile.
Materials and methods: C57BL/6 mice were fed SFA-HFD (45% palm
oil), MUFA-HFD (45% olive oil) or chow diet for 24 weeks. GTT, ITT
and an insulin secretory response determined insulin sensitivity. The he-
patic lipidome of 36 mice was quantified by Biocrates Austria.
Electrospray ionization-MS/MS screened glycerophospholipids and
sphingolipids. The lipidomic database was combined with phenotypic
data. Multivariate principle component analysis (PCA) and regression
analysis were performed using SPSS. A novel visualization approach,
manually superimposed liver lipidomic data onto the online LipidMaps
sphingolipid biosynthesis pathway using a BioPAX level 3 format to
differentiate the synthesis of these lipids between diets.
Results: MUFA-fed mice had reduced hyperinsulineamia compared to
SFA-fed mice despite equivalent obesity. PCA combined with regression
analysis highlighted that a high-SFA/high-ceramide/low-PE cluster was
predictive of an IR phenotype. Hepatic sphingolipid synthesis was down-
regulated following a MUFA-HFD compared to chow and SFA-HFD.
Conclusion: Dietary intake of MUFA, can attenuate obesity-induced
hyperinsulinaemia concurrent with an altered hepatic lipidome. A novel
visualization of LipidMaps illustrated that MUFA-HFD prevented
sphingomyelin or ceramide synthesis, which were associated with IR.
Further work is required to determine the mechanistic basis of the altered
hepatic lipidome, wherein to what extent can replacement of dietary SFA
with MUFA, prevent IR by modifying hepatic lipid biology.
Supported by: Science Foundation Ireland 11/PI/1119
OP 15 In vivo veritas
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Pancreatic beta cell function, insulin sensitivity and metabolic phe-
notypes in type 2 diabetes at the time of diagnosis. The Verona newly
diagnosed type 2 diabetes study
M. Dauriz1, R.C. Bonadonna2, M. Trombetta1, L. Boselli1, L. Santi1, C.
Brangani1, I. Pichiri1, C. Bianchi3, R.Miccoli3, S. Del Prato3, E. Bonora1;
1Department of Medicine, Division of Endocrinology, Diabetes and Me-
tabolism, University of Verona School of Medicine and AOUI Verona,
2Division of Endocrinology, Department of Clinical and Experimental
Medicine, University of Parma School of Medicine and Azienda
Ospedaliera Universitaria of Parma, 3Department of Endocrinology and
Metabolism, Section of Diabetology and Metabolic Disease, University
of Pisa School of Medicine, Pisa, Italy.
Background and aims: Presence and frequency of beta cell (BC) dys-
function (BCD) and insulin resistance (IR) in patients with newly diag-
nosed type 2 diabetes mellitus (NDT2D) are imperfectly known, because
previous studies used small cohorts and/or only surrogate indexes of BC
function and IR.We sought to assess BC function and IR with state-of-art
methods in the VNDS.
Materials and methods: In 712 GADA-negative, drug naïve, consecu-
tive Italian NDT2D patients we assessed: 1. standard parameters; 2. in-
sulin sensitivity (IS) by the euglycaemic insulin clamp); 3. BC function
by state-of-art modeling of prolonged (5 hours) OGTT-derived glucose/
C-peptide curves. Thresholds for BCD and IR were the 25th percentiles
of BC function and IS assessed with the same methods of the VNDS in
Italian subjects with normal glucose regulation of the GENFIEV (n=340)
and GISIR (n=386) studies, respectively.
Results: In the VNDS, 89.8% [95% C.I.: 87.6 - 92.0%] and
87.8% [85.4 - 90.2] patients had BCD and IR, respectively. Pa-
tients with only one defect were 19.7% [16.8 - 22.6]. Isolated
BCD and isolated IR were present in 10.9% [8.6 - 13.2] and
8.9% [6.8 - 11.0] patients, respectively. Coexistence of BCD
and IR was observed in 78.9% [75.9 - 81.9] of the patients.
1.4% [0.5 - 2.3] of the patients had no detectable alterations in
BC function and IS. Patients (19.7%) with only one metabolic
defect had lower BMI, fasting glucose, HbA1c, triglycerides and
BC function, and higher HDL-cholesterol and IS than patients
with both BCD and IR (p<0.01 or less after Bonferroni’s
correction).
Conclusion: In conclusion, in NDT2DM patients: 1. at least 75.9% have
both BCD and IR; 2. At least 87.6% and 85.4% have BCD and IR,
respectively; 3. At least 16.8% have only one defect and a significantly
different (milder) metabolic phenotype compared to patients with both
defects. These findings may be relevant to therapeutic strategies centered
on the metabolic phenotype of the patient.
Clinical Trial Registration Number: NCT00879801; NCT01526720
Supported by: University of Verona
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Cardio-vascular changes associated with impaired as compared with
normal glucose tolerance in obese patients. Role of sympathetic
activity
A. Rezki, M. Fysekidis, B. Merioud, S. Chiheb, I. Banu, E. Cosson, P.
Valensi;
Department of Endocrinology-Diabetology-Nutrition, CRNH-IdF,
CINFO, AP-HP, Jean Verdier Hospital, Bondy, France.
Background and aims: An increase in cardiac output and alterations in
cardio-vascular autonomic activity are clearly demonstrated in obese pa-
tients. Glucose intolerance is associated with more marked alterations of
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cardiac autonomic function. This study aimed to compare cardio-vascular
autonomic activity and hemodynamic parameters in obese patients with
normal (NGT) or impaired glucose tolerance (IGT).
Materials and methods: Sixty-six obese patients were included and
classified according to OGTT as NGT (n=38) or IGT (n=28). NGT and
IGT patients were similar for sex ratio, age andBMI (38.4±4.1 and 37.4±
4.3 kg/m2, respectively). All were normotensive or had well-controlled
hypertension and were free of cardio-vascular history. Arterial stiffness
(carotid-to-femoral pulse wave velocity), central and peripheral blood
pressure and left ventricular ejection time (LVET) were assessed by
applanation tonometry (SphygmoCor®). Cardiac sympathetic activity
(LF-HR) and sympatho-vagal balance (LF/HF-HR) were determined by
spectral analysis of heart rate variations (Task Force Monitor® digital
plethysmography). Cardiac output, stroke volume (SV), cardiac index
(CI) and thoracic fluid content (TFC) were measured by thoracic imped-
ance. The stroke volume to pulse pressure ratio (SV/PP, an index of total
arterial compliance) was calculated from SphygmoCor® aortic and pe-
ripheral blood pressure measurements.
Results: Blood pressures and pulse wave velocity were similar in both
groups. Compared with NGT, IGT patients had higher CI (2.3±0.5 vs 1.8
±0.7 l/min*m2), SV (68±19 vs 55±17 ml) and TFC and longer LVET
(317±25 vs 304±25 ms), and lower total peripheral resistance index (p<
0.04 to p<0.002). The SV/PP ratio derived from aortic (1.1±0.4 vs 2.2±
0.8) and peripheral (0.8±0.2 vs 1.7±0.5) pulse pressure were significant-
ly higher in IGT patients (p=0.002, p<0.0001). In the overall population,
plasma glucose at fasting and 2 hours after the oral glucose challenge
correlated with LF/HF-HR (r=0.27, p=0.02; r=0.26, p=0.03), even after
adjusting for age and BMI.
Conclusion: In obese patients, IGT is accompanied by an increase in left
ventricular output and ejection duration and hypervolemia, all probably
favoured by higher sympathetic activity. IGT patients also have a better
total arterial compliance, in line with lower peripheral resistance.
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Influence of replacement therapy on metabolic profile in male pa-
tients with type 2 diabetes mellitus and androgen deficiency
M. Rabijewski, P. Piątkiewicz;
Department of Internal Medicine, Diabetology and Endocrinology, War-
saw Medical University, Warsaw, Poland.
Background and aims: Low testosterone levels are observed in about
40% of men with diabetes mellitus type 2 and are associated with meta-
bolic disorders, abnormalities of body composition and glycemic control.
The aim of our study was to investigate the influence of testosterone
replacement therapy on lipids, anthropometric parameters and HbA1c
level in patients with diabetes mellitus type 2 and testosterone deficiency
Materials and methods:We investigated 102 male patients with diabetes
mellitus type 2, aged 53 to 68 years, with BMI from 27.5 to 38.5 kg/m2.We
assessed total (TT) and free testosterone (fT) levels, lipids, HbA1c, body
mass index (BMI), waist-to-hip ratio (WHR) and waist circumstances
(WC). Patients were divided into two groups: 1) treatment group, where
we used diet, antidiabetic therapy and testosterone replacement therapy
during 12 months; 2) control group where we used diet and antidiabetic
therapy. IN treatment group PSA and prostate volume were controled.
Results: In treatment group baseline mean TT and fT levels were
8.24 nmol/l and 0,256 nmol/l, respectively and in control group
8.45 nmol/l and 0.265 nmol/l respectively, and did not differ significantly
between groups. During testosterone replacement therapy mean TT and
fT levels increased to 16.45 nmol/l and 0.567 nmol/l, respectively. After
12 months of treatment we observed significant improvement of lipids
profile in both groups (decreasing of total cholesterol from mean
256.4 mg/dl to 221.8 mg/dl in treatment group and from 249.4 mg/dl to
238.2 mg/dl in control group and decreasing of LDL-cholesterol from
179.3 mg/dl to 147.4 mg/dl in treatment group and from 175.5 mg/dl fo
163.3 mg/dl in control group) but changes in testosterone group were
higher (p<0.05 and p<0.02, respectively). We observed also decreasing
of HbA1c levels in testosterone group (8,3 vs. 7.2%; p<0,001) and in
control group (8,4 vs. 7,6%; p<0.001) but there were also significant
differences between both groups (p<0,02). BMI values decreased but
changes between groups did not differ significantly. WHR and WC
values also decreased in both groups (p<0.002 and p<0,01; respectively),
but changes in testosterone group were higher (p<0,02 and p<0,05;
respectively). The method of antidiabetic therapy (oral or insulin) had
not significant impact on changes of lipids, HbA1c and anthropometric
indexes during study. PSA and prostate volume did not changes signifi-
cantly during treatment.
Conclusion: Testosterone replacement therapy in men with diabetes
mellitus type 2 and androgen deficiency testosterone influenced positive-
ly on lipids, body composition and HbA1c. This treatment is safe and
routine testosterone measurement should be taken under consideration in
diabetic men with testosterone deficiency.
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The impact of TSH increment on incident type 2 diabetes mellitus in
euthyroid subjects
J. Jun, Y.-B. Lee, S.-E. Lee, W. Hong, Y. Hong, S.-M. Jin, M.-K. Lee, J.
Kim;
Samsung Medical Center, Seoul, Republic of Korea.
Background and aims: It is widely known that thyroid function influ-
ences glucose metabolism. However, there have been no longitudinal
studies to determine the association between thyroid function and diabe-
tes. Therefore, the objective of this study was to investigate the incidence
of type 2 diabetes mellitus (T2DM) according to the change of TSH level.
Materials and methods:A total of 23,063 participants had taken thyroid
function tests (thyroid-stimulating hormone [TSH], total or free thyroxine
[T4] and triiodothyronine [T3]) between 2006 and 2012 through a yearly
health check-up program. Among them, 16,921 euthyroid subjects with-
out diagnosed T2DM were enrolled in the study. Euthyroid was defined
as having normal total T4 (4.7 to 12.5 ng/dL) or free T4 (0.78 to 1.85 ng/
dL) and normal total T3 (76 to 190 ng/dL) with normal TSH level (0.4 to
4.2 μIU/L). TSH changes were calculated from TSH ratio as dividing
TSH level at the end of follow-up or until a year before the last date of
diabetes diagnosis into baseline TSH level.
Results: During 86,010 person-years of follow-up, there were 726 inci-
dent cases of T2DM. In cox proportional hazards models, the higher TSH
ratio was significantly associated with the increased risk of incident
T2DM (HR=1.10, 95% CI : 1.02-1.18, p=0.011) after adjusting baseline
HbA1c, fasting glucose, age, sex, BMI, TG , HDL and LDL. In compar-
ison with subjects in the lowest tertile (0.6±0.2), the subjects in the
highest tertile of TSH ratio (1.9±1.0) also had a greater risk of incident
T2DM (HR=1.39, 95% CI : 1.16-1.66, p for trend<0.001). Most of the
subjects (4814, 83.0%) in the hightest tertile of TSH ratio maintained an
euthyroid status. However, either baseline TSH level or tertiles were not
associated with the risk of incident T2DM.
Conclusion: This study demonstrated that TSH increment, rather than
baseline TSH level itself, can be an additional risk factor of incident
T2DM even in the subjects with preserving euthyroidism.
Diabetologia (2015) 58 (Suppl 1):S1–S607 S43
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Apelin administration improves insulin sensitivity: proof of concept
study in overweight healthy men
P. Gourdy1, L. Cazals2, C. Thalamas3, E. Lami2, A. Sommet4, F. Calvas3,
M. Galitzky3, I. Castan-Laurell5, P. Valet5;
1Diabetology Department, Toulouse University Hospital and INSERM
U1048/I2MC, 2Diabetology Department, Toulouse University Hospital,
3Clinical Investigation Center, Toulouse University Hospital, 4Depart-
ment of Clinical Pharmacology, Toulouse University Hospital, 5Team 3,
INSERM U1048/I2MC, Toulouse, France.
Background and aims: Apelin is a recently identified adipokine that
influences various biological systems through the activation of its G
protein-coupled receptor (APJ). This adipokine is thought to exert bene-
ficial actions on glucose metabolism since apelin administration has been
demonstrated to improve glucose tolerance in various murine models by
enhancing insulin sensitivity in peripheral tissues such as skeletal muscles
and white adipose tissues. The aim of the present “APELINS” proof of
concept study was to determine the influence of apelin administration on
insulin sensitivity in humans.
Materials and methods:We designed a Phase I, double-blind, placebo-
controlled, cross-over study which included non diabetic overweight
male volunteers to successively assess the efficacy and the tolerance of
two doses of (pyr1)-Apelin-13 versus placebo. A first group of subjects
received 9 nmol/kg (n=8), and, after safety data review by an independent
expert committee, a second group received 30 nmol/kg (n=8). Each vol-
unteer participated in two hyperinsulinemic (1 mU.Kg-1.min-1)
euglycemic clamps spaced from 7 to 21 days. The primary endpoint
(ΔGIR) was the difference between the glucose infusion rate (GIR) mea-
sured during the steady state ending the “investigational product” perfu-
sion (GIRperfusion 210th-240th min) and the GIR measured during the
first steady state ending the “basal” phase (GIRbasal 90th -120th min).
Results:Main clinical characteristics of male volunteers were as follows:
32.8±6.8 yr, BMI: 27.6±1.4 kg/m2, waist circumference: 99.3±4.7,
fasting plasma glucose: 94±8 mg/dl, A1c: 5.4±0.3%. Mean concentra-
tions of total plasma apelin were similar and stable in the different groups
during the “basal” phase and placebo administration (from 277±106 to
305±59 pg/ml), but raised to 1332±1525 pg/ml and 4815±1874 respec-
tively during the steady states ending the perfusion of low dose and high
dose apelin. At low dose (9 nmol/kg), apelin administration induced a non
significant increase in ΔGIR versus placebo (+2.21±0.54 vs+1.57±
0.53 mg/kg/min, p=0.06). A significant improvement in insulin sensitiv-
ity was observed with the dose of 30 nmol/kg (ΔGIR: + 1.72±
0.47 mg/kg/min with apelin administration versus + 0.89±0.62 mg/kg/
min with placebo, p=0.03). Cardiovascular monitoring and safety reports
did not reveal any specific side effect of apelin administration.
Conclusion: The present data provide the first demonstration of the in-
sulin sensitizing action of apelin in humans, as recently suggested by
animal studies, and thus open new therapeutic perspectives. The apelin/
APJ pathway shoud now be considered for the development of alternative
strategies aiming to fight against insulin resistance in type 2 diabetic
subjects.
Clinical Trial Registration Number: 2013-002759-13
Supported by: Société Francophone du Diabète and Région Midi-
Pyrénées
90
Insulin sensitivity to glucose uptake is similarly changed across insu-
lin sensitive tissues: evidence from a positron emission tomography
study
M.-J. Honka1, M. Bucci1, J.C. Hannukainen1, K.K. Kalliokoski1, K.A.
Virtanen1, P. Nuutila1,2, M. Laakso3;
1Turku PET Centre, University of Turku, 2Department of Endocrinology,
Turku University Hospital, Turku, 3Institute of Clinical Medicine, Inter-
nal Medicine, University of Eastern Finland, Kuopio, Finland.
Background and aims: Insulin resistance is the major pathophysiologi-
cal feature of type 2 diabetes. Skeletal muscle, liver, and adipose tissue are
the key insulin sensitive tissues in humans. Impaired effect of insulin is
reflected by reduced glucose uptake (GU) into these tissues. No previous
study has investigated whether insulin sensitivity to GU differs across the
insulin sensitive tissues in the same individual. To investigate this ques-
tion, we measured GU in skeletal muscle, liver, and adipose tissue in a
single session using positron emission tomography (PET) and
euglycemic-hyperinsulinemic clamp.
Materials and methods: The study population consisted of 141 subjects
without type 2 diabetes, who had previously participated in PET studies.
PET-studies included the measurement of GU in the liver, quadriceps
femoris muscle, and intra-abdominal and abdominal subcutaneous adi-
pose tissue during the euglycemic-hyperinsulinemic clamp using
fluorine-18 labelled deoxyglucose and PET. Principal component analy-
sis (PCA) was used to analyze the rates of GU across the different tissues.
Eigenvalue 1 was used as a threshold for component extraction.
Results: In PCA analysis, skeletal muscle, intraperitoneal adipose tissue
and liver GU loaded on one single principal component indicating that the
rates of GU were similarly changed across the tissues. The model ex-
plained 53% of the variance of GU. When intraperitoneal adipose tissue
was substituted by abdominal subcutaneous adipose tissue the results
remained almost unchanged, and the model explained 55% of the vari-
ance of GU. PCA resulted in one principal component even after the
inclusion of BMI and age into the model.
Conclusion: PCA analysis showed that over half of the variance in the
insulin stimulated GU in skeletal muscle, liver, and adipose tissue was
explained by a single principal component. Our results indicate that the
insulin sensitivity to GU is similarly changed across the insulin-sensitive
tissues, independently of obesity and age.
Supported by: Finnish Cultural Foundation, Yrjö Jahnsson Foundation
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TYK2, a candidate gene for type 1 diabetes, modulates apoptosis and
the innate immune response in human pancreatic beta cells
L. Marroqui1, R.S. Dos Santos1, T. Fløyel2, I. Santin3,4, A. Op de
beeck1, L. Marselli5, P. Marchetti5, F. Pociot2, D.L. Eizirik1;
1ULB Center for Diabetes Research, Brussels, Belgium, 2Department of
Pediatrics, Herlev University Hospital, Herlev, Denmark, 3Endocrinology
and Diabetes Research Group, BioCruces Health Research Institute,
Barakaldo, Spain, 4Spanish Biomedical Research Centre in Diabetes
and Associated Metabolic Disorders (CIBERDEM), Spain, 5Department
of Clinical and Experimental Medicine, Pancreatic Islet Laboratory, Uni-
versity of Pisa, Pisa, Italy.
Background and aims: Type 1 diabetes (T1D) is a chronic autoimmune
disease characterized by the specific destruction of pancreaticβ-cells. Link-
age and genome-wide association studies have identified >50 loci across
the human genome associated with risk of T1D, including two SNPs in the
TYK2 gene. These SNPs are predicted to decrease TYK2 function and are
associated with a decreased risk to develop T1D. TYK2 is a member of the
JAK family of tyrosine kinases that play a critical role in the interferons
(IFN) signaling via phosphorylation and activation of STAT proteins. We
presently evaluated whether TYK2 plays a role in human pancreatic β-cell
apoptosis and production of pro-inflammatory mediators.
Materials and methods: Human β-cell line EndoC-βH1 cells and dis-
persed human islets were transfected with small interfering (si)RNA
targeting TYK2 (inhibition of >50%) and subsequently exposed to intracel-
lular polyinosinic-polycitidilic acid (PIC; a synthetic viral double-stranded
RNA) or IFNα. Activation of the IFN signaling pathway was evaluated by
Western blot of P-STAT1/STAT1 and P-STAT2/STAT2. Expression and
release of IFNα, IFNβ and the chemokine CXCL10 were determined by
RT-PCR and ELISA, respectively. Viability assays were performed by
Hoechst/Propidium Iodide staining. Expression of MHC class I proteins
was evaluated by RT-PCR, immunofluorescence and flow cytometry.
Results: Pathway analysis of candidate genes expressed in human islets
identified a central role for interferon-regulated pathways. TYK2 knock-
down (KD) decreased by 50-70% (p 0.05) PIC-induced STAT1/2 activation
in human β-cells. Both mRNA expression and release of IFNα, IFNβ and
CXCL10 were increased by 2-400 fold in human β-cells after PIC transfec-
tion, which was partially prevented by TYK2 KD in the case of IFNα and
CXCL10, but not IFNβ (p<0.001; n=3-4). Expression of MHC class I
proteins, a hallmark of early β-cell inflammation, was prevented by TYK2
silencing after both PIC or IFNα treatments. This decreased type I IFN
response was paralleled by prevention of PIC-induced apoptosis in TYK2-
silenced β-cells (36% and 26% of protection in EndoC-βH1 and dispersed
human islets, respectively; p 0.05; n=4-5). Protection against apoptosis was
confirmed by lower expression of cleaved caspase 3 in TYK2-inhibited cells.
Conclusion: The present findings suggest that the T1D candidate gene
TYK2 regulates apoptotic and pro-inflammatory pathways in human pan-
creatic β-cells via modulation of IFN signaling and expression of MHC
class I proteins. TYK2 may play a key role in the “dialog” between β-
cells and the immune system in early T1D.
Supported by: L.M. is supported by a FNRS post-doctoral fellowship
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The hepatokine fetuin-A has TLR4 dependent and independent ef-
fects in islets
F. Gerst1,2, G. Kaiser1,2, T. Sartorius1, N. Stefan1,2, H.-U. Häring1,2, S.
Ullrich1,2;
1Internal Medicine IV, Endocrinology, Diabetology, Angiology,
Nephrolo, University Hospital Tübingen, 2Institute for Diabetes Research
andMetabolic Diseases of the Helmholtz Center Munich at the Eberhard-
Karls-University of Tübingen, Germany.
Background and aims:An increased level of plasma fetuin-A in humans
strongly predicts the incidence of T2DM. In adipocytes, fetuin-A aug-
ments fatty acid-induced inflammation in a TLR4-dependent manner. We
previously showed that in mouse islets fetuin-A increased the mRNA
levels of pro-inflammatory cytokines (IL-1β, MCP-1) in a TLR2/4-de-
pendent manner. In spite of increased cytokine production and JNK phos-
phorylation, chronic exposure to fetuin-A did not augment apoptosis. In
contrast, palmitic acid induced JNK phosphorylation and apoptosis with-
out stimulation of cytokine production. The present study aims to deci-
pher the signalling pathways activated by fetuin-A and its contribution to
the lipotoxic effect of palmitic acid.
Materials and methods: Isolated islets from WT and TLR4 KO mice
were cultured in medium supplemented with palmitic acid (60 μmol/l) in
the presence of either serum albumin (0.6 mg/ml) or fetuin-A (0.6 mg/ml)
for 1 h to 48 h. Protein phosphorylations were analyzed on western blots.
Changes in gene expression were quantified by RT-PCR. Apoptosis was
estimated by TUNEL staining of isolated islet cells and subcellular
localisation of proteins by confocal microscopy.
Results: In agreement with observations made in other tissues, fetuin-A
induced stimulation of cytokine production was mediated through TLR4,
since the effect was absent in islets of TLR4 KOmice. When the islets of
WT mice were treated with clodronate (0.5 mg/ml) in order to deplete
them from immune cells, the effect of fetuin-A on cytokine production
was abrogated. Furthermore, fetuin-A did not induce nuclear accumula-
tion (i.e. activation) of the transcription factor NFkB in isolated islet cells,
suggesting that the endocrine cells were not the source of cytokines.
Surprisingly, fetuin-A stimulated phosphorylation of the pro-apoptotic
JNK in isolated islets ofWT but also of TLR4 deficient islets. In contrast,
palmitic acid stimulated JNK in a TLR4 dependent manner. Consequent-
ly, in TLR4 KO islet cells palmitic acid-induced apoptosis was inhibited,
while addition of fetuin-A restored the cytotoxic effect of palmitic acid.
Conclusion: These results suggest that in islets fetuin-A may worsen
lipotoxicity through TLR4-dependent stimulation of cytokine production in
immune cells and TLR4-independent activation of JNK in endocrine cells.
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Loss of the pro-apoptotic BH3-only protein BIM results in increased
beta cell mass in a mouse model of type 2 diabetes
J.A.Wali1, J. Ge1, E. Mathieson1, C. Varanasi1, L. Jones2, R. Laybutt3, I.
Smyth2, E.N. Gurzov1, T.W. Kay1, H.E. Thomas1;
1St Vincent's Institute, Melbourne, 2Monash University, Melbourne,
3Garvan Institute of Medical Research, Sydney, Australia.
Background and aims: Loss of beta cell mass is a feature of type 2
diabetes, and evidence suggests that this is the result of apoptosis. We
identified that the high concentrations of glucose induce ER and oxidative
stress, which results in islet cell apoptosis mediated by pro-apoptotic
BH3-only molecules BIM and PUMA. Islets isolated from organ donors
with type 2 diabetes had increased expression of BIM and PUMA com-
pared with non-diabetic donors, suggesting these factors are also impor-
tant in loss of beta cells in humans. We hypothesized that blocking beta
cell apoptosis in type 2 diabetes would improve glucose homeostasis, and
tested this by examining the effects of BIM deficiency in the leptin re-
ceptor mutant Leprdb/db mouse model of type 2 diabetes.
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Materials and methods: BIM-deficient mice were crossed with Leprdb/
db mice to generate three groups of male and female mice: Leprdb/dbBIM+/
+, Leprdb/dbBIM+/- and Leprdb/dbBIM-/- mice. Corresponding non-diabetic
Leprdb/+ mouse groups were used as controls. Fasting blood glucose
(FBG) was measured at 6, 10, 14 and 18 weeks of age. Intraperitoneal
glucose tolerance test was performed in 16-week-old mice and serum
insulin was quantified by ELISA. Islet morphology was studied in
H&E, insulin and TUNEL stained pancreatic sections. To quantify islet
volume, we performed optical projection tomography (OPT), 3-
dimensional imaging of whole pancreas stained with anti-insulin antibod-
ies. Abdominal fat was quantified after micro-CT scanning.
Results: Deficiency of BIM significantly protected Leprdb/db mice from
development of hyperglycaemia. FBG in female Leprdb/dbBIM-/- mice
was in the non-diabetic range (FBG in 18 week old mice: Leprdb/
dbBIM-/-=10.1±1.5 vs Leprdb/dbBIM+/+=26.2±0.7 mmol/l). Compared
to Leprdb/dbBIM+/+ mice, Leprdb/dbBIM-/- mice also had improved glu-
cose tolerance. Leprdb/db mice heterozygous for BIM (Leprdb/dbBIM+/-)
had an intermediate phenotype. We observed a striking increase in islet
size in BIM-deficient Leprdb/db mice by histology, while the beta cell size
was similar between Leprdb/dbBIM+/+ and Leprdb/dbBIM-/- mice. This
suggests that increase in islet size was due to an increase in number of
beta cells. Quantification of islet volume with OPT revealed a significant
increase in islet volume in BIM-deficient compared with wild-type
Leprdb/db mice (4.2±0.7×106 vs 2.1±0.4×106 μm3). The increased islet
volume was accompanied by a two-fold increase in serum insulin con-
centration (19.3±2.1 vs 9.7±2.3 μg/L). We detected reduced number of
TUNEL positive cells in BIM-deficient compared with wild-type Leprdb/
db islets indicating that the islet phenotype is secondary to apoptosis
inhibition. Further, compared to Leprdb/db mice wild-type for BIM,
Leprdb/db mice deficient in BIM gained more weight (20-week old female
body weights: 66.2±1.6 vs 60.8±0.8 grams) and had increased abdomi-
nal fat (% abdominal fat volume: 73.9±4.1 vs 42.2±3.5). These changes
in body weight could be due to increased circulating insulin concentration
in Leprdb/dbBIM-/- mice.
Conclusion: Our data suggest that BIM has a direct role in beta cell
apoptosis in vivo in type 2 diabetes, and indicate that inhibition of beta
cell apoptosis can prevent the loss of islet cell mass, allowing the islet to
compensate for the increasing insulin demand caused by insulin resis-
tance and obesity.
Supported by: NHMRC, Diabetes Australia, University of Melbourne
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Thrombospondin 1: a master regulator of the anti-oxidant defence in
pancreatic beta cells
D.A. Cunha1, P.-O. Carlsson2, J.D. Molkentin3, M. Bugliani4, P.
Marchetti4, D.L. Eizirik1, M. Cnop1;
1ULB Center for Diabetes Research, Université Libre de Bruxelles, Brus-
sels, Belgium, 2Department ofMedical Cell Biology, Uppsala University,
Uppsala, Sweden, 3Department of Pediatrics, Cincinnati Children's Hos-
pital Medical Center, Cincinnati, USA, 4Department of Endocrinology
and Metabolism, University of Pisa, Italy.
Background and aims:Western diets rich in saturated fats contribute to
the increasing prevalence of type 2 diabetes. Saturated fatty acids, such as
palmitate, induce endoplasmic reticulum (ER) stress and cause lipotoxic
beta-cell death. Thrombospondin 1 (THBS1) is a glycoprotein expressed
in the ER and secreted to the intercellular space. THBS1 has been shown
in other tissues to promote adaptive ER stress signaling. THBS1-/- mice
have impaired glucose tolerance and glucose-stimulated insulin release.
In this study we interrogated the putative role of THBS1 in lipotoxic beta-
cell death.
Materials and methods: Apoptosis was evaluated using nuclear dyes,
mRNA expression by qPCR, and protein expression/phosphorylation by
Western blot. Gene silencing and overexpression were achieved by RNA
interference and adenoviral vectors, respectively. The data are based on 3-
5 independent experiments.
Results: Palmitate reduced THBS1 protein expression in human islets by
73±3% (p<0.05) and in rat beta-cells by 71±3% (p<0.05). THBS1
knockdown (KD) sensitized beta-cells to palmitate-induced apoptosis
(from 24±2 to 48±2% apoptosis, p<0.05), while its overexpression
was protective (from 24±2 to 18±2% apoptosis, p<0.05). Different from
previous findings in cardiomyocytes, THBS1 KD or overexpression did
not modulate ATF6 signaling in beta-cells. Reactive oxygen species were
induced by THBS1 KD (by 43±9%, p<0.05) and reduced by THBS1
overexpression (by 38±4%, p<0.05) in palmitate-treated cells. The anti-
oxidant enzymes glutathione s-transferase M1 (GSTM1) and catalase
were induced by palmitate (by 5.3±0.7 and 3.3±0.3-fold, respectively,
p<0.05) and further increased by THBS1 overexpression (by 44±9% and
48±2% compared to palmitate, p<0.05). GSTM1 expression was re-
duced in islets from THBS1-/- mice (by 55±7% compared to wild-type
mice, p<0.05), showing that THBS1 also regulates the anti-oxidant re-
sponse in vivo. THBS1 overexpression increased by 75±9% (p<0.05)
the activity of an anti-oxidant response element (ARE) reporter. The
transcription factor NRF2 is known to bind to ARE. NRF2KD in THBS1
overexpressing cells resulted in decreased GSTM1 and catalase mRNA
expression (by 5.6±1.3 and 3.5±0.5-fold, p<0.05), showing that NRF2
mediates the THBS1-dependent induction of anti-oxidant stress enzymes.
The PERK inhibitor GSK2606414 reduced NRF2 activation in THBS1
overexpressing cells by 2.5±0.5-fold and down-regulated GSTM1 and
catalase mRNA by 60±9% and 57±3% (p<0.05), indicating that THBS1
activates NRF2 via the ER stress transducer PERK. Importantly, THBS1
KD induced JNK phosphorylation (by 75±16%, p<0.05) and expression
of the proapoptotic BCL-2 family member PUMA (51±8%, p<0.05),
providing a mechanistic explanation for the increase in beta-cell apoptosis
following THBS1 inhibition.
Conclusion: THBS1 activates NRF2 via PERK, thus orchestrating a
protective anti-oxidant defense mechanism against lipotoxicity in beta-
cells. These data contribute to a better understanding of the mechanisms
leading to beta-cell failure during metabolic stress and point to THBS1 as
an interesting target to prevent oxidative stress in type 2 diabetes.
Supported by: BetaBat Framework Program 7, FNRS Belgium
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The hippo kinase LATS2 impairs pancreatic beta cell survival and
function
T. Yuan1, S. Awal1, J. Kerr-Conte2, A. Ardestani1;
1Center for Biomolecular Interactions, Bremen, Germany, 2Thérapie
Cellulaire du Diabète, Lille, France.
Background and aims: Both type 1 and type 2 diabetes mellitus result
from an absolute or relative decline in pancreatic β-cell function and/or
mass. Apoptosis and loss of function are hallmarks of β-cell failure and
the fundamental cause of diabetes. Large-tumor suppressors 2 (LATS2), a
core component of the Hippo signaling pathway, is a ubiquitously
expressed serine/threonine kinase and involved in multiple cellular pro-
cesses such as proliferation, stress responses, and apoptosis. So far, the
role of LATS2 in the β-cell is not known. Our aim was to investigate
whether LATS2 is activated in the β-cell under diabetic conditions and
whether its hyper-activation or inhibition would regulate β-cell death and
insulin secretion.
Materials and methods: Rat β-cell line INS-1E and isolated human
islets were exposed to a diabetic milieu (IL-1β/IFNγ or increased glucose
concentration (22.2 mM)). Phospho-LATS1/2, LATS2,MOB1 andβ-cell
apoptosis (Caspase 3 & PARP cleavage) were analyzed by Western blot-
ting. β-cell apoptosis was also analyzed by TUNEL staining and insulin,
Pdx1, Nkx2.2, Nkx6.1, Neurod1, MafA, GCK, Slc2a2, KCNG11 and
Abcc8 mRNA expression by real-time PCR (RT-PCR). LATS2 was
overexpressed by plasmid transfection or adenovirus infection, LATS2
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inactivation was performed by overexpressing dominant-negative LATS2
(dn-LATS2) or specific siRNA to LATS2 in both INS-1E cells and human
islets. Insulin secretion in response to glucose (GSIS at 2.8 mM and
16.7 mM glucose), Glibenclamide (1 uM) and KCl (35 mM) in human
islets in vitro were examined by ELISA.
Results: LATS1/2 phosphorylation (at S909/872 for LATS1 and LATS2)
was increased in INS-1E cells exposed to pro-inflammatory cytokines:
IL-1β/IFNγ or increased glucose concentration, indicating higher activity
of LATS kinases under diabetic conditions. This correlated with MOB1
(LATS2-associated protein) up-regulation and increasedβ-cell apoptosis.
LATS2 overexpression increased the number of TUNEL-positive β-cells
in human islets and induced caspase-3 and PARP cleavage in human and
rodent β-cells. Inhibition of endogenous LATS2 activity by siRNA
knockdown or overexpression of dominant negative LATS2 protected
INS-1E cells and human islets from chronically elevated glucose- and
cytokines-induced apoptosis. LATS2 silencing abolished diabetic
milieu-induced MOB1 up-regulation suggesting LATS2-dependent reg-
ulation of MOB1 in β-cells. Consistently, MOB1 knockdown blocked
LATS2- and glucotoxicity-induced caspase-3 and PARP cleavage in INS-
1E cells indicating a major role of MOB1 in LATS2-induced β-cell ap-
optosis. Also, LATS2 overexpression impaired GSIS in human islets
without significant changes neither on insulin content and gene expres-
sion nor on genes involved in glucose sensing (Slc2a2 and GCK), insulin
transcription (Pdx1, NeuroD, MafA) and ATP-dependent K+ channel
subunits (Kcnj11 and abcc8). LATS2 overexpression also abolished in-
sulin secretion stimulated by the insulin secretagogues KCl and
glibenclamide, suggesting that the insulin secretory defect may occur at
a step down-stream of calcium influx.
Conclusion: Our results show that LATS2 hyper-activation leads to β-
cell death and loss of function and its inhibition protects from apoptosis.
Blocking of LATS2 may be a successful strategy to improve β-cell sur-
vival and function in diabetes.
Supported by: DFG
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Metabolic stress induces aberrant G-protein prenylation in pancre-
atic beta cells
A. Kowluru1, M. Goalstone2, V. Sidarala1, K. Syeda1, R.A. Kowluru3;
1Pharmaceutical Sciences, Wayne State University, Detroit, 2Medicine,
University of Colorado, Denver, 3Ophthalmology, Anatomy and Cell
Biology, Wayne State University, Detroit, USA.
Background and aims: Activation of specific small G-proteins [Arf6,
Cdc42 and Rac1] is implicated in glucose-stimulated insulin secretion
[GSIS] in clonal β-cells, normal rodent and human islets. We recently
demonstrated requisite roles for G-protein prenylation in GSIS. We iden-
tified three classes of prenylating enzymes in pancreatic β-cells.
Farnesyltransferase [FTase] and geranylgeranyltransferases [GGTase-I]
prenylate Ras and Rho G-proteins, respectively. GGTase-II mediates
prenylation of Rab G-proteins. The aim of the current study is to assess
alterations, if any, in FTase/GGTase-I signaling in pancreatic β-cells in
in vitro and in vivo models of metabolic stress, impaired insulin secretion
and T2DM.
Materials and methods: Normal rat islets or INS-1 832/13 β-cells were
exposed to glucotoxic [20 mM; 24 hr], lipotoxic [0.3 mM palmitate;
24 hr] or thapsigargin [0.25 μM; 24 hr] conditions. FTase and GGTase-
I activities were assayed by radiometric methods. Caspase-3 activation
and FTase/GGTase-α degradation were quantified by Western blotting.
Results: Exposure of INS-1 832/13 β-cells to gluco- or lipotoxic condi-
tions markedly attenuated [~50%] FTase and GGTase activities. A sig-
nificant increase in caspase-3 activity and degradation of the common α-
subunit of FTase/GGTase [FTase/GGTase-α] were also seen under these
conditions. Thapsigargin, a known inducer of endoplasmic reticulum
[ER] stress, promoted caspase-3 activation, FTase/GGTase-α degradation
and reduction [~70%] of FTase and GGTase activities. Compatible with
our in vitro findings, caspase-3 activity and FTase/GGTase-α degradation
were markedly increased in islets derived from the Zucker diabetic fatty
[13 weeks] rats compared to those from the age-matched Zucker lean
controls. Consequentially, a significant increase in the abundance of
unprenylated Rap1, a geranylgeranylated protein, was noted in pancreatic
β-cells exposed to gluco or lipotoxic conditions. In addition, forced in-
activation of G-protein prenylation [via depletion of endogenous pools of
mevalonic acid] using simvastatin also resulted in accumulation of
unprenylated Rap1 in these cells. Lastly, glucotoxic conditions promoted
sustained activation of Rac1, a geranylgeranylated protein, activation of
stress kinase [p38MAPK], nuclear lamin-B degradation and inhibition of
GSIS in rat islets and INS-1 832/13 cells.
Conclusion: Based on our findings we propose that metabolic stress
induces aberrant G-protein prenylation signaling events leading to stress
kinase activation and loss in β-cell function including GSIS.
Supported by: Department of VA and NIH
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Unravelling the effects of endogenous incretin hormones on glucose
metabolism after Roux-en-Y gastric bypass surgery
M.S. Svane1,2, K.N. Bojsen-Møller1,2, S. Nielsen1, N.B. Jørgensen1,2, C.
Dirksen1,2, V.B. Kristiansen3, B. Hartmann2, J.J. Holst2, S. Madsbad1,2;
1Dept. of Endocrinology, Hvidovre Hospital, Hvidovre, 2NNF Center of
Basic Metabolic Research, Copenhagen, 3Dept. of Surgical Gastroenter-
ology, Hvidovre Hospital, Hvidovre, Denmark.
Background and aims: Roux-en-Y gastric bypass (RYGB) induces
weight loss and diabetes remission. Exaggerated meal-induced secretion
of glucagon-like peptide-1 (GLP-1) is important for enhanced postpran-
dial insulin secretion and improved glucose metabolism after surgery, but
the role of glucose-dependent insulinotropic polypeptide (GIP) is debat-
ed. Administration of a DPP-4 inhibitor as sitagliptin (sita) prevents the
degradation of the active forms of GLP-1 and GIP, while it is possible to
block the effect of GLP-1 with the GLP-1 receptor antagonist exendin 9-
39 (Ex9). We investigated the individual and combined effects of DPP-4
inhibition and GLP-1 receptor blockade to understand the relative impor-
tance of the endogenous incretin hormones on glucose metabolism after
RYGB.
Materials and methods: In a placebo-controlled, single-blinded, cross-
over design, twelve glucose tolerant patients (age 35.4±7 (mean±SEM)
years, gender (f/m) 8/4, BMI 33.5±6 kg/m2) were studied 5.3±1 month
after RYGB. On four separate experimental days patients underwent a
standard 4 h mixed meal test (356 kcal, 53E% carbohydrate, 33E% fat,
14E% protein) with either 1) placebo (plac); 2) sita (100 mg 12 h and 2 h
before study start); 3) Ex9 infusion (900 pmol×kg-1×min-1); or both 4)
sita and Ex9 (Ex9/sita) in a randomized order. Pre-hepatic insulin secre-
tion rates (ISR) were calculated from deconvolution of C-peptide and
beta-cell glucose sensitivity (beta-GS) was used to characterize the
dose-response relationship between glucose concentration and ISR. Re-
sults were analysed by linear mixed effects models.
Results: GLP-1 receptor antagonism by Ex9 infusion increased glucose
excursions compared with placebo while no effect of DPP-4 inhibition
was seen (incremental (i)-AUC glucose: plac 92±44 mmol/L×min, Ex9
192±44 p<0.01, sita 112±43 p=0.47). Ex9 and Ex9/sita had comparable
effects on glucose concentrations (iAUC glucose: Ex9 192±44 vs. Ex9/
sita 163±39, p=0.27). Insulin secretion evaluated by iAUC ISR and beta-
GS decreased during Ex9 infusion, whereas no significant effect of sita
was seen compared with placebo (iAUC ISR: plac 933±96 pmol×kg-1,
Ex9 713±83 p<0.01, sita 963±123 p=0.95. Beta-GS: plac 4.8±0.8
(pmol×kg-1×min-1)/mmol/L, Ex9 3.8±0.7 p=0.01, sita 5.7±1.2 p=
0.26). Both measures of beta-cell function deteriorated equally during
Ex9 infusions with and without sita (iAUC ISR: Ex9 713±83 vs. Ex9/
sita 660±53, p=0.65 and beta-GS: Ex9 3.8±0.7 vs. Ex9/sita 3.1±0.5 p=
0.09). Total AUC of intact GLP-1 increased 3-fold (p<0.01) and intact
GIP 1.6-fold (p<0.01) on sita days, thereby indicating an effective DPP-4
inhibition.
Conclusion: After RYGB, infusion of the GLP-1 receptor antagonist,
Ex9, induced deteriorated glucose tolerance and impaired postprandial
insulin secretion, whereas DPP-4 inhibition had no effect on glucose
tolerance or insulin secretion. DPP-4 inhibition also failed to improve
beta-cell function when the GLP-1 receptor was blocked. This finding
underscores the importance of the exaggerated GLP-1 secretion for im-
proved glycaemic control after RYGB, but does not support a major role
of GIP for improved glucose tolerance and beta-cell function after RYGB.
Clinical Trial Registration Number: NCT02336659
Supported by: University of Copenhagen
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The expression of genes involved in intestinal gluconeogenesis is al-
tered in morbidly obese subjects with higher insulin resistance
C. Gutiérrez Repiso1, S. García Serrano1,2, F. Rodríguez Pacheco1,2, J.
García Arnés1, S. Valdés1,2, F. Soriguer1,2, F.J. Moreno Ruíz3, A.
Rodríguez Cañete3, G. AlcaínMartínez4, L. Vázquez Pedreño5, E. García
Fuentes1,6;
1UGC de Endocrinología y Nutrición.Instituto de Investigación
Biomédica de Málaga (IBIMA). Hospital Regional Universitario,
2CIBERDEM, Instituto de Salud Carlos III, 3UGC de Cirugía General,
Digestiva y Trasplantes, Instituto de Investigación Biomédica de Málaga
(IBIMA), Hospital Regional Universitario, 4UGC de Aparato Digestivo,
Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital
Universitario Virgen de la Victoria, 5UGC deAparato Digestivo, Hospital
Regional Universitario, 6CIBERDEM. CIBEROBN, Instituto de Salud
Carlos III, Málaga, Spain.
Background and aims: It has been suggested that small intestine might
possess the capacity to produce glucose, being induced in insulin resis-
tance states. It has been shown that genes involved in gluconeogenesis are
expressed in human small intestine. However, there is little information
about intestinal gluconeogenesis in humans and the alterations that high
insulin resistance may produce. The aim of this study is to evaluate the
expression of genes involved in intestinal gluconeogenesis in morbidly
obese subjects in states of insulin resistance and also to evaluate the effect
of metformin in their expression.
Materials andmethods:The studywas undertaken in 45morbidly obese
subjects who underwent to Roux-en-Y gastric bypass. The morbidly
obese subjects were classified in subjects with homeostasis model assess-
ment of insulin resistance (HOMA-IR) value lower than 4.7 (MO-low-
IR), subjects with HOMA-IR value higher than 4.7 (MO-high-IR) (both
groups without treatment for T2D) and subjects with T2D who were only
receiving metformin treatment (MO-metf-T2D). The jejunal biopsy sam-
ples used to evaluate the mRNA expression levels were obtained during
the bariatric surgery, 40 cm from the ligament of Treitz.
Results: In MO-high-IR group, glutaminase (GLS) (p=0.034), phospho-
enolpyruvate carboxykinase (PEPCK) (p=0.027) and glucose 6-
phosphatase (G6Pase) (p=0.024) mRNA expression levels were signifi-
cantly higher than inMO-low-IR group. InMO-metf-T2D group, G6Pase
(p=0.014) and GLS (p=0.049) mRNA expression levels were signifi-
cantly higher than in MO-low-IR group, whilst PEPCK mRNA expres-
sion levels were significantly lower (p=0.001). In MO-metf-T2D group,
PEPCK (p=0.001) mRNA expression levels were significantly lower
than in MO-high-IR group. Weight, BMI and waist circumference corre-
lated positively with PEPCK mRNA expression levels (r=0.416; p=
0.025; r=0.398; p=0.033; r=0.446; p=0.043, respectively). Insulin levels
correlated positively with PEPCK (r=0.347; p=0.045), fructose 1,6-
bisphosphatase (FBPase) (r=0.319; p=0.046) and G6Pase (r=0.461;
p=0.005) mRNA expression levels. HOMA-IR value correlated positive-
ly with G6Pase (r=0.424; p=0.010) mRNA expression levels. GLS
mRNA expression levels correlated positively with FBPase mRNA ex-
pression levels (r=0.683; p<0.001). G6Pase mRNA expression correlat-
ed positively with GLS (r=0.703; p<0.001) and FBPase (r=0.654; p<
0.001) mRNA expression levels.
Conclusion: The mRNA expression of most of the genes involved in
gluconeogenesis is increased in the jejunum of morbidly obese subjects
with higher insulin resistance. This altered jejunal mRNA expression is
attenuated in those morbidly obese subjects treated with metformin.
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CD163+ and CD206+ adipose tissue immune cells in obese subjects
with type 2 diabetes mellitus: the effect of gastric plication and
duodenal-jejunal bypass liner implantation
A. Cinkajzlova, Z. Lacinova, J. Klouckova, P. Kavalkova, P. Trachta, M.
Mraz, M. Haluzik;
3rd Department of Medicine, Charles University, Prague,
Czech Republic.
Background and aims: CD163 and CD206 are considered the main
markers of alternatively activated (M2)macrophages which are suggested
as one of the main players in the resolution of adipose tissue low-grade
inflammation. The aim of our study was to examine changes in CD163+
and CD206+ cells in subcutaneous adipose tissue (SCAT) of obese sub-
jects with type 2 diabetes mellitus (T2DM) in the context of global met-
abolic improvements after selected bariatric procedures.
Materials and methods: Twenty-two obese subjects with T2DM under-
going either GP or DJBL were included into the study. Anthropometric
and biochemical parameters were measured and SCAT samples from the
abdominal region were taken at baseline, 1 and 6 (GP) or 10 months
(DJBL) after intervention. M2 macrophage subpopulations were identi-
fied using flow cytometry and a combination of antigens including CD14,
HLA-DR, CD163 and CD206.
Results: At baseline 2 different subsets of CD163+ (CD163+HLA-
DR+CD14+ and CD163+HLA-DR+CD14-) and CD206+ cells
(CD206+HLA-DR+CD14+ and CD206+HLA-DR+CD14-) were identi-
fied in SCATaccording to the presence of CD14. Both interventions result-
ed in decreased body weight (BMI 43.2±1.8 vs. 36.0±2.1 kg/m2, p<0.001
for GP and 42.6±1.2 vs. 39.0±1.5 kg/m2, p<0.001 for DJBL) and im-
proved glucose control (HbA1C 64.8±6.3 vs. 45.0±2.9 mmol/mol, p=
0.004 for GP and 74.2±5.6 vs. 53.8±5.0 mmol/mol, p<0.001 for DJBL).
In SCAT, both GP and DJBL significantly decreased CD163+HLA-
DR+CD14+ (20.4±2.7 vs. 11.3±1.0%, p=0.010 for GP and 19.9±1.9
vs. 12.6±0.6%, p=0.025 for DJBL) and increased CD163+HLA-
DR+CD14- cells (3.5±0.3 vs. 7.3±1.1%, p=0.001 for GB and 3.4±0.4
vs. 5.3±0.5%, p=0.029 for DJBL). CD206+HLA-DR+CD14+ cells also
decreased (21.0±3.3 vs. 11.6±0.8%, p=0.013 for GB and 18.1±1.4 vs.
11.9±1.3%, p=0.039 for DJBL), while the CD206+HLA-DR+CD14- sub-
set remained unchanged in both groups (2.0±0.2 vs. 2.7±0.3, p=0.43 for
GP and 2.3±0.3 vs. 2.0±0.2, p=0.62 for DJBL).
Conclusion: Human adipose tissue immune cells with M2 macrophage
phenotype seem to consist of several subpopulations which react differ-
ently to weight reduction. These changes might contribute to positive
effects of GP and DJBL on metabolic control in obese T2DM subjects.
Supported by: RVO VFN64165, IGA NT13299-4 and SVV260019/2014
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Effects of ursodeoxycholic acid and chenodeoxycholic acid on insulin
secretion after Roux-en-Y gastric bypass
S. Nielsen1,2, M.S. Svane1,2, K.N. Bojsen-Møller1,2, V. Kristiansen3, J.J.
Holst2,4, S. Madsbad1,2;
1Department of Endocrinology, Hvidovre University Hospital, Hvidovre,
2The Novo Nordisk Foundation Center for Basic Metabolic Research,
University of Copenhagen, 3Department of Surgical Gastroenterology,
Hvidovre University Hospital, Hvidovre, 4Department of Biomedical
Sciences, University of Copenhagen, Denmark.
Background and aims: Roux-en-Y gastric bypass (RYGB) induces
weight loss and improved glycaemic control. Bile acids have been proposed
as an important contributor to the improved glycaemic control postopera-
tively since the plasma bile acid concentration increases substantially after
RYGB. However, causality between increased plasma bile acids and effects
on the glucose-regulatory pathways remain to be demonstrated. In healthy
subjects and type 2 diabetic patients intragastric, intraduodenal and
intrarectal infusions with bile acids increase secretion of glucagon-like pep-
tide-1 (GLP-1), an important insulinotropic hormone. After RYGB,
intraluminal bile acids may thus also contribute to increased postprandial
GLP-1 secretion and thereby to increased postprandial insulin secretion.
RYGB changes the gastrointestinal anatomy and makes it possible to reach
the GLP-1 producing L-cells in the distal part of the intestine by an oral
route. Therefore, we evaluated the effects of oral administration of
ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) on
insulin secretion in RYGB-operated patients.
Materials and methods: In a placebo-controlled, crossover study, we
examined insulin secretion and glucose concentration in 10 RYGB-
operated patients with normal glucose tolerance (age (mean±SEM)
37.9±3.4 years, BMI 29.2±1.3 kg/m2, fasting plasma glucose 4.96±
0.13 mmol/litre) at 32.6±1.1 months postoperatively. On three different
days the patients ingested either 1) UDCA (750 mg); 2) CDCA
(1250 mg) suspended in 150 mL water; or 3) 150 mL water alone (pla-
cebo). Blood samples were drawn for the following 180 minutes. Insulin
secretion was evaluated using delta C-peptide0-peak and positive incre-
mental AUC (pi-AUC, i.e. AUC above fasting concentration). Linear
mixed-effects models were used for statistical analysis.
Results: Oral intake of CDCA increased insulin secretion slightly, but
significantly, compared with placebo (delta C-peptide0-peak: placebo: 45±
13 pmol/L, CDCA: 140±27 pmol/L, p=0.0012; pi-AUC: placebo: 1900
±643 pmol/L×min, CDCA: 7094±1447 pmol/L×min, p=0.02)). UDCA
did not affect insulin secretion compared with placebo (UDCA: delta C-
peptide0-peak: 72±13 pmol/L, p=0.23; pi-AUC: 3119±1234 pmol/L×
min, p=0.47). Plasma glucose was not affected by oral intake of neither
UDCA nor CDCA.
Conclusion: In RYGB-operated patients with normal glucose tolerance,
oral administration of CDCA increased insulin secretion significantly
compared with placebo, whereas no effect was seen after oral adminis-
tration of UDCA. However, the effect was small and no effect on glucose
concentration was observed questioning a major role of bile acids for the
improved glycaemic control after RYGB.
Clinical Trial Registration Number: NCT02340247
Supported by: Copenhagen Medical Society
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Roux-en-Y gastric bypass improves gastrointestinal-mediated glu-
cose disposal in type 2 diabetes whereas gastric banding and caloric
restriction do not
T. Jorsal1, B. Mortensen1, M. Hansen1, R. Dutia2, B. Laferrere2, F.K.
Knop1;
1Department of Medicine, Center for Diabetes Research, Hellerup, Den-
mark, 2New York Obesity Nutrition Center, New York, USA.
Background and aims: The mechanisms by which Roux-en-Y gastric
bypass surgery (RYGB) mediates its glucose-lowering effect in type 2
diabetes are debated. The two predominant hypotheses include 1) im-
proved glucose handling driven by gastrointestinal (GI) factors elicited
by rerouting of nutrients through the GI tract, and 2) post-surgery caloric
restriction promoting beneficial effects on glucose metabolism (indepen-
dent of the altered GI anatomy/physiology). We evaluated the impact of
RYGB vs laparoscopic adjustable gastric banding (LAGB) and surgery-
matched caloric restriction alone (CAL), respectively, on GI-mediated
glucose disposal (GIGD) in patients with type 2 diabetes.
Materials and methods: GIGD was calculated by comparing glucose
amounts utilised during 50 g-OGTT and isoglycaemic i.v. glucose infu-
sion (IIGI) (using variable glucose infusion rates), respectively
(100%×(glucoseOGTT- glucoseIIGI / glucoseOGTT)), in obese patients
with type 2 diabetes before and 1 month after either RYGB (n=40),
LAGB (n=16) or CAL (n=11).
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Results: As previously reported, all groups showed a significant and
similar degree of weight loss, and AUC for plasma glucose during OGTT
improved in all groups with RYGB eliciting the most robust improve-
ment. We observed a significantly increased GIGD following RYGB
(Δ13.0±4.8%, p<0.01), whereas GIGD changes were insignificant after
LAGB (Δ-1.7±9.5%, p=0.86 and CAL (Δ9.5±9.1%, p=0.32).
Conclusion: These data suggest that the improved glucose tolerance
observed after RYGB is mainly driven by nutrient-rerouting through the
GI tract rather than surgery-induced caloric restriction and ascribe im-
proved GIGD a key role in remission of the diabetic state often observed
in patients with type 2 diabetes undergoing RYGB.
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Bariatric surgery normalises splanchnic vascular responses to a
mixed-meal and to GIP infusion
H. Honka1, J. Koffert1,2, S. Kauhanen3, N. Kudomi4, J. Linden1, J.
Teuho1, A. Lindqvist5, N. Wierup5, L. Groop5, P. Nuutila1,6;
1Turku PET Centre, University of Turku, 2Department of Gastroenterol-
ogy, Turku University Hospital, 3Division of Digestive Surgery and Urol-
ogy, Turku University Hospital, Turku, Finland, 4Department of Medical
Physics, Kagawa University, Kagawa, Japan, 5Lund University, Lund,
Sweden, 6Department of Endocrinology, Turku University Hospital, Tur-
ku, Finland.
Background and aims: Splanchnic vasculature regulates intermediary
metabolism by facilitating nutrient delivery from intestine into systemic
circulation and pancreas, and by affecting hepatic insulin clearance. Re-
cent studies have suggested that disturbances in splanchnic vascular func-
tions are associated with dysglycemia predisposing to development of
type 2 diabetes. The present study was conducted to investigate the
splanchnic vascular responses to a mixed-meal test, and to glucose-
dependent insulinotrophic polypeptide (GIP) infusion before and after
bariatric surgery.
Materials and methods: Ten morbidly obese (40.8±5.9 kg m-2) diabetic
subjects and 10 age-matched, lean (22.9±2.1 kg m-2) subjects were recruit-
ed. Small intestinal, pancreatic and hepatic blood flow (BF) and volume
(BV) before and after 300-kcal mixed-meal, and during GIP infusion (2
pmol kg-1 min-1) were measured using radiotracers [15O]H2O and
[15O]CO, and PET. A standard 75-g oral glucose tolerance test was per-
formed, and during imaging studies blood was continuously drawn to
measure glucose, insulin, and incretin hormones (GIP andGLP-1). In obese
subjects, these procedures were repeated six weeks after bariatric surgery.
Results: Compared to controls, obese diabetic subjects were slightly
hyperglycemic (fasting plasma glucose 6.8±0.8 vs. 5.0±0.4 mM,
P<0.0001) prior to surgery. In both groups, meal ingestion provoked
significant increases in small intestinal BF (+61.8 and +92.2% vs. base-
line, for lean and obese subjects, respectively, both P<0.05). While pan-
creatic BF was increased in lean subjects (1.9±0.6 vs. 1.6±0.4 ml ml-
1 min-1, P<0.05), this was not observed in obese subjects (NS). During
GIP infusion, small intestinal BF was increased in both groups (+141 and
+112% vs. baseline, for lean and obese subjects, respectively, both
P<0.05). In contrast, pancreatic BF was decreased (1.2±0.3 vs. 1.6±
0.4 ml ml-1 min-1, P=0.01) only in lean subjects, whereas no response
was observed in obese subjects (NS). Hepatic BV was decreased after
meal ingestion and during GIP infusion in both groups (from -6.3 to -
11.9%, P<0.05). Six weeks after bariatric surgery, 12% excess body
weight loss was observed (-13.9 kg, P<0.01), and diabetes remission rate
of 80% was reached. Postoperatively, small intestinal vascular responses
to meal and to GIP infusion (+167 and +93.6% vs. baseline, respectively,
both P<0.05) were unchanged when compared with the preoperative
state. However, after surgery pancreatic vascular responses to meal (1.4
±0.2 vs. 1.0±0.3 ml ml-1 min-1, P<0.01) and to GIP infusion (0.9±0.3 vs.
1.1±0.3 ml ml-1 min-1, P<0.05) were normalized and essentially similar
to those of lean subjects.
Conclusion: Bariatric surgery in morbidly obese diabetic patients nor-
malizes splanchnic vascular responses. Further studies are needed and
should focus on investigating the many factors that affect splanchnic
blood flow kinetics after a meal, and their association to insulin secretion,
systemic delivery and hepatic clearance rate.
Clinical Trial Registration Number: NCT01880827
Supported by: Academy of Finland, The Finnish Medical Foundation
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Sequencing of 12,940 exomes identifies additional coding variants in
G6PC2 which influence fasting glucose levels through effects on pro-
tein stability or activity
H.J. Ng1, A. Mahajan2, H. Highland3, X. Sim4, A. Manning5, M. Rivas2,
A. Locke4, N. Grarup6, N.L. Beer1, J.K. Rundle1, A. Raimondo1, A.P.
Morris2, C.M. Lindgren2,5, A.L. Gloyn1,2, T2D-GENES and GoT2D
Consortia;
1OCDEM, University of Oxford, 2Wellcome Trust Centre for Human
Genetics, University of Oxford, UK, 3The University of Texas Health
Science Center, Houston, 4University of Michigan, Ann Arbor, 5Broad
Institute, Cambridge, USA, 6University of Copenhagen, Denmark.
Background and aims:We recently identified coding variants inG6PC2
(encoding the islet-specific glucose-6-phosphatase catalytic subunit)
influencing fasting glucose (FG) levels in non-diabetic Europeans and
demonstrated that these variants affected protein stability. In addition to
single variant associations, gene-based analyses also revealed a robust
association driven by multiple low-frequency/rare variants in the exome
array analysis. To achieve a comprehensive assessment of the impact of
coding variation in G6PC2 on FG levels, especially that of rare variants
not captured on the array, we combined exome sequence data with array
data to identify additional coding variants. We coupled genetic analyses
with functional characterisation to identify nonsynonymous G6PC2 var-
iants altering protein function, thus impacting on FG levels.
Materials and methods: Exome sequence data from 12,940 individuals
consisting of type 2 diabetes cases and controls from fivemajor ancestries
was used to catalogue coding variants in G6PC2. For analysis of glyce-
mic traits, 5,132 non-diabetic exome sequences were combined with pre-
viously published exome array data from 33,407 non-diabetic Europeans.
Single variant analyses were performed within each ethnic group then
combined in a trans-ethnic meta-analysis. G6PC2 variants were
characterised by assessing effects on protein expression (western blot)
and/or activity (phosphatase assay).
Results:We identified 69 coding variants in G6PC2 in our exome
array and sequence data, including 3 previously reported function-
al variants that were shown to influence FG levels (H177Y,
Y207S, V219L). We selected 10 further variants, all rare (minor
allele frequency [MAF]<0.005), for functional follow-up based on
either evidence of association with FG levels (S30F, I171T,
S324P; single variant P<0.05), or biological relevance (variant
maps to conserved active site). All the variants studied except
for I171T-G6PC2 had significantly reduced protein levels (mean
12.1% of wild type [WT]; P<0.001) due to enhanced proteasome-
mediated degradation. I171T-G6PC2 was expressed at levels sim-
ilar to WT-G6PC2, however its position within the active site
suggested an alternative mechanism. This was confirmed by ac-
tivity assays which showed that the missense substitution affected
protein activity. Using a glucose-6-phosphatase homologous mod-
el, phosphatase activity of the variant was decreased by 38.9% at
2.5 mM glucose-6-phosphate compared to WT (P<0.05). Both
S324P and I171T are rare functional variants (MAF=0.0044 and
0.0012 respectively) that contributed to the gene-based signal at
G6PC2 in the exome array analysis.
Conclusion: We identified additional coding variants in G6PC2,
mostly rare, providing a more complete inventory of genetic var-
iation in this key regulator of beta cell function. Functional in-
vestigation demonstrated that many of these result in marked pro-
tein instability whilst one variant alters protein activity, consistent
with a role in modulating FG levels.
Supported by: Wellcome Trust
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Role of the type 2 diabetes genome-wide association studies gene
SLC30A8 in the pancreatic alpha cell
A.M. Solomou1, G. Meur1, E.A. Bellomo1, D.J. Hodson1, P.L. Herrera2,
S. Migrenne3, C. Magnan3, G.A. Rutter1;
1Imperial College London, UK, 2Genetic Medicine and Development,
University of Geneva, Switzerland, 3University Paris, France.
Background and aims:Genome-wide association studies have revealed
>90 loci in the human genome with a significant impact on type 2 diabe-
tes risk. One such locus encodes a non-synomymous single nucleotide
polymorphism in the SLC30A8 gene encoding the zinc transporter ZnT8,
expressed almost exclusively in pancreatic islets. Changes observed in
humans containing risk alleles and animals lacking ZnT8 have previously
been attributed to alterations in insulin secretion from beta-cells. Though
the role of the ZnT8 transporter in beta-cells has been studied extensively
its role on glucagon secretion is largely unknown. Here, we investigate
the role of ZnT8 in the alpha-cell by generating animals deleted for
slc30a8 selectively in these cells.
Materials andmethods: Slc30a8 was inactivated in alpha-cells by cross-
ing animals bearing a floxed Slc30a8 gene with mice expressing Cre
recombinase under a 1.6 kB fragment of the pre-proglucagon promoter,
plus tdRFP expressed at the Rosa26 locus distal to a LoxP-STOP-LoxP
cassette. Deletion was confirmed by qPCR on FACS-sorted alpha-cells.
Glucose homeostasis was assessed by glucose tolerance and insulin tol-
erance test and by hypoglycaemic clamp studies. Intracellular free Ca2+
and Zn2+ were measured in tdRFP-labelled alpha-cells within the intact
islet using the trappable fluorescent probes Fluo-2 and Fluozin-3,
respectively.
Results: Glucose and insulin tolerance were normal in αSlc30a8KO
mice. However, female KO mice required lower glucose infusion rates
(KO 18.8±1.62 mg/min/kg vs control 28±1.27 g/min/kg, P<0.001, n=4-
6) during hypoglycaemic clamps, and displayed enhanced glucagon re-
lease. Correspondingly, isolated islets from KO mice released more glu-
cagon at 1 mMglucose thanWT islets (0.18±0.009 vs 0.1±0.03 as a% of
total, P<0.01, n=5) despite unchanged intracellular Ca2+ responses to
glucose withdrawal (1 vs 17 mM). Additionally there was a tendency
towards a higher α:β cell area in KO mice (0.2±0.015 vs 0.16±0.01, P
<0.5, n=7). Cytoplasmic free Zn2+ concentrations were significantly
lower in αSlc30a8KO alpha-cells (KO 1.14±0.007 vs control 1.33±
0.02 F1/Fmin, P<0.0001, n=4).The expression of other ZnT family
members was unchanged.
Conclusion: ZnT8 deletion from the mouse alpha-cell results in de-
creased intracellular zinc levels and increased glucagon secretion from
isolated islets in vitro at low glucose conditions and in vivo during
hypoglycaemia. These findings suggest that altered ZnT8 expression
may affect glucagon levels in carriers of SLC30A8 variants in man, and
may thus contribute to diabetes risk.
Supported by: Diabetes UK studentship
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A genome wide association study of IVGTT based measures of first
phase insulin secretion reveals new physiology of known and novel
variants
N. van Leeuwen1, A.R. Wood2, A. Jackson3, A. Jonsson4, N. Wang5, U.
Smith6, L. Boquete Vilarino2, A. Stancakova7, M. Walker8, R. Hanson9,
T.M. Frayling2, GUINNESS consortium;
1Molecular Cell Biology, LUMC, Leiden, Netherlands, 2Institute of Bio-
medical and Clinical Sciences, University of Exeter Medical School,
Exeter, UK, 3Department of Biostatistics and Center for Statistical Ge-
netics, University ofMichigan School of Public Health, AnnArbor, USA,
4Faculty of Health andMedical Science, University of Copenhagen, Den-
mark, 5Department of Preventive Medicine, Keck School of Medicine of
USC, Los Angeles, USA, 6Sahlgrenska Academy and Lundberg Labora-
tory for Diabetes Research, University of Gothenburg, Sweden, 7Institute
of Clinical Science, Internal Medicine, University of Eastern Finland and
Kuopio University Hospital, Kuopio, Finland, 8Institute of Cellular Med-
icine, Newcastle University, Newcastle upon Tyne, UK, 9Phoenix Epide-
miology and Clinical Research Branch, The National Institute of Diabetes
and Digestive and Kidney Diseases, Phoenix, USA.
Background and aims: Deterioration of insulin secretory capacity plays
an important role in the development of type 2 diabetes yet the mecha-
nisms underlying the process are not fully understood. As part of the
GUINNESS consortium we meta-analysed 8 GWAS and 2 metabochip
studies where first phase insulin secretion has been investigated through
intravenous glucose tolerance tests (IVGTT) in an attempt to identify the
genetic factors involved.
Materials and methods: The meta-analysis included 5 European (n=
2090) and 3 non-European (n=1655) studies with GWAS data and 2
European studies with metabochip data (n=741). First phase insulin se-
cretion was assessed with an IVGTT or hyperglycemic clamp and three
different traits were defined in all cohorts: Acute Insulin Response to
glucose (AIR), Peak Insulin (PeakIns) and Disposition Index (DI) (n=
4486), all accounting for fasting glucose levels. GWAS studies were
imputed using the 1000G reference panel. Variants were tested for asso-
ciation using linear regression adjusting for age and sex. In sub-analyses,
BMI and Insulin Sensitivity Index (SI) were also used as additional
covariates.
Results: Of known common type 2 diabetes variants, 7 were associated
with both PeakIns and AIR at p<0.01, two MTNR1B and CDKAL1 at
genome wide significance for both traits (PeakIns p=8×10-16, p=6×10-
13; AIR p=1×10-12, p=1×10-9). Comparing these associations to type 2
diabetes risks and measures based on oral glucose tolerance tests (OGTT)
revealed some interesting patterns. The variant at TCF7L2 is only mod-
estly associated with first phase insulin despite having the strongest effect
on diabetes risk. Whereas the diabetes variants at HNF1A (p=4×10-5
PeakIns) and ZFAND6 (p=8×10-4 PeakIns) showed much stronger sig-
nals despite being unclassified in previous studies of diabetes intermedi-
ate traits using OGTT. Adjustments for BMI and SI did not substantially
influence results. Putative novel associations for AIR were observed in
population-specific analyses on chromosome 2 and 11 (both P<5×10-8)
but these low frequency variants need further validation.
Conclusion: Our genome wide analysis was performed on the largest
dataset for intravenously measured first phase insulin secretion. Common
type 2 diabetes risk alleles at the MTNR1B and CDKAL1 loci were the
most strongly associated with our measures. For other variants, including
those in HNF1A and ZFAND6 our analyses provide new insight into
physiological mechanisms of diabetes risk.
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The impact of known type 2 diabetes associated variants on circulat-
ing levels of GLP-1, GIP and glucagon during an oral glucose toler-
ance test
A. Jonsson1, S.S. Torekov1,2, T. Schnurr1, C.T. Have1, Y. Mahendran1,3,
N. Grarup1, N.B. Johansen3,4, K. Færch4, D.R.Witte3,5, T. Lauritzen5, J.J.
Holst1,2, M.E. Jørgensen4, O. Pedersen1, T. Hansen1;
1NNF Center for Basic Metabolic Research, Faculty of Health and Med-
ical Sciences, University of Copenhagen, 2Department of Biomedical
Sciences, Faculty of Health and Medical Sciences, University of Copen-
hagen, 3The Danish Diabetes Academy, Odense, 4Steno Diabetes Center,
Gentofte, 5Institute of Public Health, University of Aarhus, Denmark.
Background and aims: Large-scale genome wide association studies
(GWAS) have currently identified 68 genetic determinants of type 2 dia-
betes. Formany of those variants, it is unclear throughwhichmechanisms
they exert their effect and little is known about whether these genes also
affect incretin hormone levels and/or alpha-cell function. Our aim is to
examine the impact of known type 2 diabetes associated variants on
circulating levels of glucagon-like peptide-1 (GLP-1), glucose-
dependent insulinotropic polypeptide (GIP) and glucagon during an oral
glucose tolerance test (OGTT).
Materials and methods: Plasma levels of GLP-1, GIP and glucagon
were examined in samples obtained during an OGTT in 1,547 individuals
from the ADDITION-PRO cohort. Participants were given a standard
75 g OGTT after an overnight fast of ≥7 hours and blood samples were
drawn at 0, 30 and 120 min for assessment of plasma GLP-1, GIP and
glucagon levels. The incremental area under the curve of plasma GLP-1,
GIP and glucagon were calculated from 0-30 minutes and from 0-120
minutes during the OGTT. Associations between 68 genetic variants and
plasma levels of GLP-1, GIP and glucagon were studied using a linear
mixed model (EMMAX) implemented in the EPACTS software package
by the use of inverse-normalized residuals of the traits adjusted for age,
sex and BMI.
Results: None of the associations of the 68 known type 2 diabetes risk
variants with circulating plasma levels of GLP-1, GIP or glucagon during
the OGTTwere significant after correction for multiple testing. However,
nominally associated (P<0.05) variants are reported in Table 1.
Conclusion:Known type 2 diabetes risk variants seem not to be strongly
associated with altered secretion of GLP-1, GIP or glucagon. Large-scale
genome-wide association studies of incretin hormone and glucagon re-
lease as well as studies of incretin hormone and glucagon action are
needed in order to explain the genetic influence on these traits.
Supported by: EFSD/Novo Nordisk, Lundbeck Foundation, FP7-PEO-
PLE-2013-IEF, DFF
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Effect of 36 hours fasting on genome-wide muscle gene expression in
low and normal birth weight men
L. Gillberg1, S.W. Jørgensen1, A. Perfilyev2, T. Rönn2, A. Vaag1, C.
Ling2;
1Department of Endocrinology, Rigshospitalet, Copenhagen, Denmark,
2Department of Clinical Sciences, Lund University Diabetes Centre,
Malmö, Sweden.
Background and aims: An adverse fetal environment might cause low
birth weight (LBW) that is associated with increased risk of metabolic
diseases. We recently showed that healthy young LBW men cope in a
metabolically preferential way with 36 hours of fasting compared to nor-
mal birth weight (NBW) men. We hypothesized that fasting might un-
mask differential metabolic and molecular changes in insulin sensitive
tissues from LBW individuals. Therefore, we analyzed genome-wide
gene expression in skeletal muscle from 20 young LBWand 17 matched
NBW men during 36 h fasting, and after overnight fast in 8 LBW and 8
NBW men.
Materials and methods: Gene expression of more than 99% RefSeq
genes was analyzed with Affymetrix HumanGene 1.0 ST arrays. The
effect of fasting and LBW was analyzed with non-parametric tests and
false discovery rate (FDR) was applied to correct for multiple testing.
Results: The fasting intervention caused increased lipolysis and FFA
levels as well as whole-body insulin resistance in the young healthy
men. Gene expression of 28,829 transcripts was examined in skeletal
muscle. After FDR correction, we did not find any significant transcrip-
tional differences in muscle from LBW versus NBWmen. Therefore, we
combined the groups when investigating the fasting induced mRNA re-
sponse. Interestingly, 1,706 (6% of all) transcripts changed significantly
in response to 36 h fasting with mTOR signaling, Wnt signaling and
cancer related KEGG pathways being up-regulated whereas metabolic
pathways including fatty acid synthesis and citrate cycle were down-
regulated during 36 h fasting.
Conclusion: The genome-wide transcriptional profile in skeletal muscle
in young healthy LBW men was not significantly different than in
matched NBW men. In response to 36 h fasting, widespread mRNA
changes were observed in skeletal muscle in the combined group of
LBWand NBWmen. Up-regulation of genes involved in mTOR signal-
ing and Wnt signaling may contribute to beneficial metabolic effects of
fasting.
Supported by: Danish Strategic Research Council, Swedish Research
Council, Region Skåne
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Selective metabolite biomarkers of isolated IFG (iIFG) and isolated
IGT (iIGT)
J.E. Cobb1, A. Eckhart1, A. Motsinger2, B. Carr3, E. Ferrannini4;
1Metabolon, Durham, 2North Carolina State University, Raleigh, USA,
3Vhi Healthcare, Dublin, Ireland, 4CNR Institute of Clinical Physiology,
Pisa, Italy.
Background and aims: IFG and IGTare distinct prediabetic states which
may be characterized by different metabolite profiles. This work focused
on identifying metabolites selective for the non-overlapping conditions of
iIFG and iIGT.
Materials and methods: A targeted metabolomic analysis of fasting
plasma samples taken at time=0 of an OGTT was performed. Quantita-
tive measurements for a panel of 23 metabolites previously associated
with prediabetes and type 2 diabetes were made using the isotope dilution
method. The data was rank normalized using the GenAbel package in R
to create a normal distribution. The associations of metabolites for normal
(normal glucose tolerance & normal fasting glucose) vs iIFTor iIGTwere
made using logistic regressions controlling for age, sex, and BMI. Odds
ratios for a one SD change in the metabolite level, 95% confidence inter-
vals and p values were calculated for eachmetabolite and reported as (OR
(95% CI) p value). P values were adjusted with a false discovery rate of
0.1. Candidate biomarkers were identified using samples from the obser-
vational RISC study 3 year follow-up (normal n=623, iIFG n=220, iIGT
n=56). The resulting candidate biomarkers were then validated in a sec-
ond cohort, the DMVhi study (part of the DEXLIFE project), comprised
of subjects at risk for type 2 diabetes (iIFG, iIGT, or FINDRISC score
>12; normal n=485, iIFG n=104, iIGT n=31).
Results: In the RISC samples, 2-oxoleucine was associated with iIFG
(1.36 (1.1-1.7) 3E-3) and had no significant association with iIGT. 2-
Oxovaline was associated with iIFG (1.45 (1.2-1.7) 4E-5) and less so
with iIGT (1.49 (1.1-2.0) 9E-3). alpha-Hydroxybutyric acid (AHB) was
associated with iIGT (2.54 (1.9-3.5) 5E-9) and was not significantly as-
sociated with iIFG. Similar results were found in the DMVhi samples.
Both 2-oxoleucine (1.65 (1.3-2.2) 0.001) and 2-oxovaline (1.58 (1.2-2.0)
0.001) were associated with iIFG and were not significantly associated
with iIGT. AHB was associated with iIGT (2.75 (1.8-4.2) 4E-5) but less
so with iIFG (1.31 (1.0-1.7) 0.05). In both cohorts, all three metabolites
are associated with subjects having combined IFG and IGT.
Conclusion: Two branched-chain 2-oxoacids, 2-oxoleucine and 2-
oxovaline, were found to be selective biomarkers for iIFG and AHB
was found to be a selective biomarker for iIGT. The former are associated
with elevated fasting glucose and the latter with impaired glucose dispos-
al and may reflect different pathophysiological aspects of prediabetes.
These biomarkers of different prediabetic states may have utility in iden-
tifying and stratifying subjects at risk for type 2 diabetes. Finally, these
findings were seen in two different European cohorts having a total of
1519 subjects.
Supported by: DEXLIFE project (EU FP7 programme, Grant agreement
no: 279228)
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Efficacy and safety of gemigliptin/metformin initial combination
therapy versus either as monotherapy in drug-naïve patients with
type 2 diabetes
S. Lim1, K. Min2, J.-M. Yu3, P. Chamnan4, E. Kim5, K.-H. Yoon6, S.
Kwon7, M.Moon8, K. Lee9, D.-J. Kim10,M. Kim11, M.Wongtanate12, E.
Kim13, S.-H. Kim13, M.-K. Lee14;
1Seoul National University Bundang Hospital, Seongnam, 2Eulji Univer-
sity Medical Center, Seoul, 3Kangnam Sacred Heart Hospital, Seoul,
Republic of Korea, 4Sunpasitthiprasong Hospital, Ubon Ratchathani,
Thailand, 5Ulsan University Hospital, Ulsan, 6The Catholic University
of Korea, Seoul St. Mary’s Hospital, Seoul, 7Samsung Changwon Hos-
pital, Changwon, 8Seoul National University Boramae Medical Center,
Seoul, 9Ajou University Hospital, Suwon, 10Inje University Ilsan Paik
Hospital, Goyang, 11Inje University Haeundae Paik Hospital, Busan, Re-
public of Korea, 12Nan Hospital, Nan, Thailand, 13LG Life Sciences,
Seoul, 14Samsung Medical Center, Sungkyunkwan University, Seoul,
Republic of Korea.
Background and aims: This study evaluated the efficacy and safety of
initial combination therapy with gemigliptin and metformin vs. gemigliptin
or metformin monotherapy in drug-naïve patients with type 2 diabetes.
Materials and methods: In this randomized, double-blind, active-con-
trolled, Phase III trial, eligible patients with HbA1c greater than 7.5%
were randomized to gemigliptin 50 mg q.d + metformin GR q.d
(GEMI/MET, n=141), gemigliptin 50 mg q.d (GEMI, n=142), or met-
formin GR q.d (MET, n=150). From weeks 2-6, metformin GR was up-
titrated in 500 mg/day increments to 2000 mg/day maximum in the
gemigliptin/metformin and metformin groups. The primary endpoint
was change from baseline in HbA1c after 24 weeks.
Results: Baseline demographics and clinical characteristics were generally
well balanced across treatment groups (meanHbA1c 8.68%; age 53.9 years;
BMI 25.9 kg/m2, duration of T2DM 3.92 years). Mean daily metformin
doses at week 24 were 1699 mg and 1868 mg for GEMI/MET and MET
respectively. All treatment groups showed statistically significant reduc-
tions in HbA1c from baseline at week 24. Mean change in HbA1c from
baseline was -2.06% for GEMI/MET versus -1.24% for GEMI and -1.47%
for MET respectively (p<0.0001 for all comparisons of combination ther-
apy vs. monotherapy). The differences in proportions achieving an HbA1c
<7 or <6.5% were also statistically significant (p<0.0001) between the
combination therapy and the respective monotherapy groups. After
24 weeks, FPG decreased in all treatment groups, to the greatest extent with
GEMI/MET (Table). Adverse events (AEs) were reported in 61.0%, 53.5%
and 58% of subjects on GEMI/MET, GEMI and MET, respectively. The
GEMI group had the lowest incidence of drug-related adverse events rela-
tive to other groups. The incidence of hypoglycemia was very low (0.0~
2.13%) and similar among treatment groups.
Conclusion: Initial combination therapy with gemigliptin and metformin
was more effective in glycemic control than their monotherapy and was
well tolerated in patients with type 2 diabetes.
Clinical Trial Registration Number: NCT01787396
Supported by: LG Life Sciences
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Omarigliptin, a once-weekly DPP-4 inhibitor, provides similar
glycaemic control to sitagliptin in patients with type 2 diabetes
mellitus inadequately controlled on metformin
I. Gantz, E. Lai, S. Suryawanshi, P. Andryuk, S.S. Engel;
Merck & Co., Inc., Kenilworth, USA.
Background and aims: Omarigliptin (OMARI; MK-3102) is a potent,
oral, once-weekly, dipeptidyl peptidase-4 (DPP-4) inhibitor in develop-
ment for the treatment of patients with type 2 diabetes mellitus (T2DM).
The convenience of an effective, well-tolerated, weekly oral drug may
improve medication adherence. This global study compared the efficacy
of OMARI 25 mg once weekly (q.w.) with that of sitagliptin (SITA)
100 mg daily (q.d.) in patients with T2DM and inadequate glycemic
control on metformin monotherapy. The study also assessed the safety
and tolerability of OMARI.
Materials and methods: This was a randomised, double-blind, non-
inferiority study. Patients on metformin 1500 mg and an A1C ≥6.5% to
≤9.0%who met all other enrollment criteria entered a 2-week, single-blind,
placebo run-in period, and were then randomised 1:1 to OMARI 25 mg
q.w. or SITA 100 mg q.d. The primary efficacy analyses used the Full
Analysis Set (FAS) population: patients who received at least one dose of
study therapy and had a baseline or at least one post-randomization mea-
surement. The primary hypothesis of non-inferiority (using an upper bound
of 0.3%) of OMARI versus SITA in decreasing A1C at Week 24 was
assessed using a constrained longitudinal data analysis model.
Results: Baseline characteristics were balanced across the two groups;
baseline A1C was approximately 7.5%. At Week 24, OMARI and SITA
both reduced A1C and FPG from baseline (Table). The upper bound of
the two-sided 95% confidence interval for the between-group difference
in reduction of A1Cwas 0.08% confirming non-inferiority. Changes from
baseline in A1C were greater in subgroups with higher baseline A1C
(Table). The percentage of patients with one or more adverse event was
36.3% and 40.6% in the OMARI and SITA groups, respectively, with no
notable differences in specific adverse events. The incidences of serious
adverse events, drug-related adverse events and discontinuations were
similar between treatment groups. The incidences of hypoglycemia were
3.7% and 4.7% in the OMARI and SITA groups, respectively, with 1
severe hypoglycemia event reported in the OMARI group.
Conclusion: In patients with T2DM and inadequate glycemic control on
metformin, once-weekly OMARI 25 mg provided similar improvement
in glycemic control compared to SITA 100 mg q.d. Treatment with both
agents was associated with a low incidence of hypoglycaemia and both
agents were well-tolerated.
S54 Diabetologia (2015) 58 (Suppl 1):S1–S607
Clinical Trial Registration Number: NCT01841697
Supported by: Merck & Co., Inc.
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Improved glucose control without increased hypoglycaemia risk with
insulin glargine/lixisenatide fixed-ratio combination (LixiLan) vs in-
sulin glargine alone
R. Berria1, B. Guerci2,3, S. Paranjape1, E. Souhami4, V. Aroda5,6, J.
Rosenstock7;
1Sanofi, Bridgewater, USA, 2Brabois Hospital, Vandoeuvre Lès Nancy,
3CIC INSERM ILCV, University Hospital of Nancy, Vandoeuvre Lès
Nancy, 4Diabetes Division Clinical Development Department, Sanofi,
Chilly-Mazarin, France, 5Medstar Health Research Institute, Hyattsville,
6Georgetown University Medical School, Washington, 7Dallas Diabetes
and Endocrine Center, Dallas, USA.
Background and aims: In a 24-week, proof-of-concept study in insulin-
naïve patients with type 2 diabetes on metformin (N=323; mean baseline
HbA1c 8.0%, age 56.7 yrs, diabetes duration 6.7 yrs), once-daily LixiLan
demonstrated greater HbA1c reductions than insulin glargine alone, with a
change from baseline of -1.8% vs -1.6%, respectively (p=0.01); endpoint
HbA1c of 6.3% vs 6.5%, respectively, and 84% vs 78% of patients
achieved HbA1c <7%. The rate of symptomatic hypoglycaemia was sim-
ilar (~25%) in both groups. This post hoc exploratory analysis was con-
ducted to determine whether the risk of symptomatic hypoglycaemia was
impacted by the magnitude of HbA1c reductions.
Materials and methods: Hypoglycaemia rates were assessed in sub-
groups based on achieving HbA1c categories (<6%; ≥6 - <6.5%; ≥6.5 -
<7%; ≥7%) and reduction in HbA1c from baseline (≤1%; >1 - ≤1.5%;
>1.5 - ≤2%; >2%) at Week 24, last observation carried forward. Cochran-
Armitage Trend Tests (2-sided) and a regression analysis assessing non-
homogeneous rates of hypoglycaemia across groups were performed.
Results:Neither test showed a relationship between hypoglycaemia rates
and HbA1c (p>0.1; Table).
Conclusion: Reaching lower near-normal HbA1c levels and achieving
greater HbA1c reductions with LixiLan vs insulin glargine alone did not
increase rates of hypoglycaemia at any level of glucose control.
Clinicla Trial Registration Number: NCT01476475
Supported by: Sanofi
112
A randomised, double-blind, placebo-controlled, 39 week trial of
ITCA 650 as add-on therapy in type 2 diabetes
M.A. Baron1, J. Buse2, R. Azeem1, L. Kjems1, J. Rosenstock3;
1Intarcia Therapeutics, Inc., Boston, 2University of North Carolina
School of Medicine, Chapel Hill, 3Dallas Diabetes and Endocrine Center
at Medical City, Dallas, USA.
Background and aims: ITCA 650, an injection-free glucagon-like
peptide-1 (GLP-1) receptor agonist delivers continuous subcutaneous
(SC) exenatide for up to 12 months from a single sub-dermal placement
of the osmotic minipump.
Materials and methods: This first pivotal Phase 3 study randomized
(1:1:1) type 2 diabetes (T2DM) subjects with HbA1c ≥7.5 to ≤10% on
diet and exercise or oral antidiabetics to ITCA 650 40 or 60 mcg/d or
placebo (PBO), starting with 20 mcg/d for 13 weeks, then 40 or 60 mcg/d
for 26 wks. HbA1c, body weight, and % achieving HbA1c <7% were
tested hierarchically.
Results: Baseline characteristics were similar in the 3 groups (n=460):
mean HbA1c 8.5%; BMI 33.5 kg/m2, diabetes duration 9 years. Efficacy
endpoints were statistically significant for both doses vs PBO. Mean
reduction in HbA1c from baseline was -1.1% (97.5% CI: -1.29, -0.71)
and -1.2% (97.5% CI: -1.37, -0.80) with 40 and 60 mcg/d (p=0.001 vs
PBO) atWeek 39 (last observation carried forward). Greater reductions in
HbA1c (-1.7%) occurred in subjects not taking sulfonylureas (SUs), most
of whom were on metformin monotherapy. Progressive weight loss was
dose dependent (Figure). ITCA 650 60 mcg/d resulted in greater weight
loss, more subjects achieving HbA1c <7%, and less need for rescue
therapy. Gastrointestinal adverse events consistent with the GLP-1 class
were most common and decreased over time. ITCA 650 was well toler-
ated with a low rate of discontinuation for adverse events.
Conclusion: ITCA 650 ensured consistent SC delivery of exenatide over
39 weeks and resulted in meaningful reductions in HbA1c and body
weight in inadequately controlled T2DM.
Clinical Trial Registration Number: NCT01455857
Supported by: Intarcia Therapeutics, Inc.
Diabetologia (2015) 58 (Suppl 1):S1–S607 S55
113
Once a month treatment with HM11260C improves glycaemic con-
trol in type 2 diabetes mellitus: interim data from a 16-week study
S. Del Prato1, J. Kang2, S. Choi2, W. Lee2, O. Han2, S. Kil2, K. Gee2, I.
Choi2, S. Kwon2, M. Trautmann3, M. Hompesch3;
1Department of Clinical and Experimental Medicine, University of Pisa,
Italy, 2Hanmi Pharmaceutical, Co., Ltd., Seoul, Republic of Korea, 3Profil
Institute for Clinical Research, Inc., Chula Vista, USA.
Background and aims: HM11260C (HM) is a novel ultra-long acting
GLP-1R agonist with a T1/2 of~158 hrs. This 16-week, randomized,
placebo (PBO) controlled, double-blind parallel group study was de-
signed to investigate efficacy, safety, and tolerability of a range of once
monthly (QM) HM doses in subjects with T2DM.
Materials and methods:We report interim data from 86 patients (mean age
56 yrs, BMI 32.1 kg/m2, T2DMduration 95.4months) out of 209 patients with
unsatisfactoryglycemiccontrolwhileona stabledoseofmetformin (≥3months)
before entering this study. Patients were randomized to one of three HM QM
doses (8, 12 and 16 mg) or PBO, followed by a 4-week titration period.
Results: Overall, all HM doses produced remarkable reductions in
HbA1c, fasting plasma glucose, and 7-point daily glucose (Table 1). Per-
centage of patients on HM achieving A1c Target<7% was 73.3% (8 and
16mg) and 64.3% (12mg) vs. 22.2% on PBO.With HM, the reduction in
body weight ranged from 2.16% to 2.80% vs. 1.24% on PBO. The most
frequent AEs in HM-treated patients were mild or moderate gastrointes-
tinal events. No increase in heart rate was recorded.
Conclusion: All QM doses of HM demonstrated clinically meaningful
improvement in blood glucose and body weight loss. The current results
will have to be confirmed upon completion of the trial and warrant further
studies to evaluate the long-term efficacy and safety of a monthly regimen
with HM in T2DM.
Clinical Trial Registration Number: NCT02081118
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Efficacy and safety of liraglutide added to insulin therapy in patients
with type 1 diabetes: the Lira-1 study
T.F. Dejgaard1,2, C.S. Frandsen2, F.K. Knop3,4, L. Tarnow5, T.S.
Hansen1, T.P. Almdal3, U. Pedersen-Bjergaard5, S. Urhammer6, T.J.
Jensen7, J.J. Holst4, S. Madsbad2, H.U. Andersen1;
1Steno Diabetes Center, Gentofte, 2Hvidovre Hospital, University of Co-
penhagen, Hvidovre, 3Gentofte Hospital, University of Copenhagen,
Gentofte, 4The NNF Center for Basic Metabolic Research, University
of Copenhagen, Copenhagen, 5Nordsjællands Hospital, University of
Copenhagen, Hillerød, 6Frederiksberg Hospital, University of Copenha-
gen, Frederiksberg, 7Rigshospitalet, University of Copenhagen, Copen-
hagen, Denmark.
Background and aims: Weight gain and hypoglycaemia are common
side effects to insulin therapy in type 1 diabetes (T1D). The combination
of insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) ther-
apy has proven effective in reducing weight gain and insulin dose in type
2 diabetes and may have similar effects in patients with T1D.
Materials and methods: This 26-week trial is the first randomised, dou-
ble-blinded, placebo controlled study to evaluate efficacy and safety of
GLP-1RA treatment in poorly controlled, overweight patients with T1D.
In total 100 patients with T1D, HbA1c>64 mmol/mol and BMI>25 kg/
m2, were randomised to liraglutide 1.8 mg once daily or placebo added to
intensive insulin therapy.
Results: Mean baseline characteristics were similar between groups
(liraglutide±SD;placebo±SD) age 47±13;49±12 years (p=0.355),
HbA1c 73±8;73±8 mmol/mol (p=0.827), total daily insulin dose 60±
23;61±21 IU/day (p=0.813) and bodyweight 93.4±14.2;94.0±12.5 kg
(p=0.828) except diabetes duration 20±12;25±12 years (p=0.049). After
12 weeks of treatment, liraglutide reduced HbA1c, bodyweight and daily
insulin dose compared with placebo. At the end of treatment no difference
in HbA1c between groups was found. Bodyweight and daily insulin dose
remained reduced in the liraglutide group compared to placebo. Frequen-
cy of hypoglycaemia did not differ between groups. Heart rate increased
with liraglutide treatment, while no differences in systolic or diastolic
blood pressure was found by 24-hour ambulatory blood pressure moni-
toring (table). Gastrointestinal AEs occurred more frequently with
liraglutide than placebo, i.e. nausea (48% vs.7%).
Conclusion: In conclusion, liraglutide added to insulin treatment in over-
weight and poorly controlled patients with T1D reduced bodyweight and
daily insulin dose, but increased heart rate and did not improve HbA1c
compared with placebo at end of treatment.
Clinical Trial Registration Number: NCT01612468
Supported by: An unrestricted grant from Novo Nordisk A/S
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A reduced incretin effect can be detected in non-diabetic women with
previous gestational diabetes even before the development of diabetes
S. Foghsgaard1,2, L. Vedtofte1, E. Bahne1, E.S. Andersen1, C.
Andreasen1, T.D. Clausen3, J.A. Svare4, J.J. Holst2, E.R. Mathiesen5, P.
Damm6, F.K. Knop1, T. Vilsbøll1;
1Center for Diabetes Reseach, Gentofte Hospital, University of Copen-
hagen, Hellerup, 2NNFCenter for BasicMetabolic Research, Department
of Biomedical Sciences, Faculty of Health and Medical Sciences, Uni-
versity of Copenhagen, Copenhagen, 3Department of Gynaecology and
Obstetrics, Nordsjællands Hospital, University of Copenhagen, Hillerød,
4Department of Gynaecology and Obstetrics, Herlev Hospital, University
of Copenhagen, Herlev, 5Center for Pregnant Women with Diabetes,
Department of Endocrinology, Rigshospitalet, University of Copenha-
gen, Copenhagen, 6Center for Pregnant Women with Diabetes, Depart-
ment of Obstetrics, Rigshospitalet; University of Copenhagen, Copenha-
gen, Denmark.
Background and aims: The incretin effect is decreased in patients with
type 2 diabetes, which prompted us to study whether reduced incretin
effect can be detected in high-risk individuals such as women with pre-
vious gestational diabetes mellitus (GDM).
Materials andmethods:One hundred and two non-diabetic womenwith
previous GDMwere examined on two separate occasions: 1) 4-hour 75 g
OGTT and 2) isoglycaemic i.v. glucose infusion (IIGI). Based on the
fasting plasma glucose (FPG) and the 2-hour plasma glucose concentra-
tions of the OGTT, the women were classified as having normal glucose
tolerance (NGT) or prediabetes (impaired fasting glucose and/or impaired
glucose tolerance) (WHO 2006).
Results: Sixty three of the women (62%) were diagnosed with prediabe-
tes (age: 38±5 years (mean ± SD); BMI: 32±4 kg/m2; waist:hip ratio: 0.9
±0.1; HbA1c: 34±4 mmol/mol; insulin resistance according to homeo-
static model assessment 2 (HOMA2IR): 1.8±0.8), and 39 (38%) had NGT
(age: 39±5 years; BMI: 31±5 kg/m2; waist:hip ratio: 0.9±0.1; HbA1c: 33
±4mmol/mol; HOMA2IR: 1.9±1.1).Womenwith prediabetes had higher
FPG (5.5±0.5 vs. 5.2±0.4 mmol/l, p=0.002) and 2-hour plasma glucose
during OGTT (9.2±1.1 vs. 7.0±0.8 mmol/l, p<0.0001) as well as lower
insulin sensitivity measured by Matsuda Index (2.6±1.3 vs. 3.3±1.8
p<0.005) compared to women with NGT. The incretin effect was calcu-
lated from insulin responses during the two experimental days
[100%×(AUCinsulin,OGTT - AUCinsulin,IIGI) / AUCinsulin,OGTT] and
amounted to 41±18% and 54±13% in women prediabetes and NGT,
respectively (p=0.0003) (Figure). The groups were similar with respect
to age, BMI, waist:hip ratio, HbA1c, HOMA2IR, fasting insulin (110±58
vs. 96±60 pmol/l, p=0.078), number of previous GDM-pregnancies (1.2
±0.4 vs. 1.1±0.3, p=0.448) and duration since index pregnancy (5.2±2.7
vs. 4.9±2.5 years, p=0.658).
Conclusion: Our results show that prediabetes is prevalent in women
with previous GDM, and alterations in the incretin effect can be detected
in these high-risk individuals even before the development of type 2
diabetes.
Clinical Trial Registration Number: EudraCT 2012-001371-37
Supported by: Unrestricted grant from Novo Nordisk
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Insulin resistance and large amounts of visceral fat characterise
women with previous gestational diabetes and non-alcoholic fatty
liver disease
L. Vedtofte1, S. Foghsgaard1,2, C. Andreasen1, E.S. Andersen1, E.
Bahne1, C. Strandberg3, T. Buhl4, J.J. Holst2, J.A. Svare5, T.D. Clausen6,
E.R. Mathiesen7, P. Damm8, L.L. Gluud1, F.K. Knop1,9, T. Vilsbøll1;
1Center for Diabetes Research, Gentofte Hospital, University of Copen-
hagen, Hellerup, 2University of Copenhagen, NNF Center for Basic Met-
abolic Research, Section for Translational Metabolic Physiology, Copen-
hagen, 3Department of Radiology, Gentofte Hospital, University of Co-
penhagen, Hellerup, 4Department of Nuclear Medicine, Gentofte Hospi-
tal, University of Copenhagen, Hellerup, 5Department of Obstetrics and
Gynaecology, Herlev Hospital, University of Copenhagen, Herlev, 6De-
partment of Gynaecology and Obstetrics, Nordsjællands Hospital, Uni-
versity of Copenhagen, Hillerød, 7Center for Pregnant Women with Di-
abetes, Department of Endocrinology, Rigshospitalet, University of Co-
penhagen, Copenhagen, 8Center for Pregnant Women with Diabetes, De-
partment of Obstetrics, Rigshospitalet, University of Copenhagen, 9NNF
Center for BasicMetabolic Research, Section for Translational Metabolic
Physiology, Faculty of Health and Medical Sciences, Faculty of Health
and Medical Sciences, University of Copenhagen, Denmark.
Background and aims: Non-alcoholic fatty liver disease (NAFLD), a
condition with fat accumulation in the liver in the absence of significant
Diabetologia (2015) 58 (Suppl 1):S1–S607 S57
alcohol consumption, is the most common liver disease in Western coun-
tries. The disease spectrum spans from simple steatosis to liver cirrhosis.
In type 2 diabetes, NAFLD is linked to cardiovascular disease and hepa-
tocellular carcinoma, which can occur in patients with or without cirrho-
sis. Because of their high risk of type 2 diabetes, women with previous
gestational diabetes (GDM)may have a high risk of developing NAFLD.
Materials and methods: Non-diabetic women with previous GDM (n=
98, age: 38±5 years) underwent 75 g OGTT, dual energy X-ray absorp-
tiometry whole body scan and ultrasound scan and elastography of the
liver to evaluate steatosis (NAFLD). Elastography is a novel, non-
invasive way of measuring steatosis. The median of ten representative
elastographic measurements is provided as the E-median index. Insulin
resistance was evaluated by the HOMA2-IR. Values are mean ± SD for
age and BMI and mean±SEM for the remaining variables.
Results: Twenty-six (27%) women had NAFLD based on the ultrasound
scan and 72 (73%) were without steatosis. None had cirrhosis. When
comparing the two groups, women with NAFLD had significantly higher
BMI (34±5 vs. 31±4 kg/m2, p=0.001) and android-to-gynoid fat-ratio
(1.2±0 vs. 1.1±0, p=0.021). Women with NAFLD also had larger vis-
ceral fat mass (1,488±136 vs. 1,009±60 g, p=0.003), were more insulin
resistant (2.5±0 vs. 1.7±0, p=0.019), had higher fasting C-peptide (672±
61 vs. 496±21 pmol/l, p=0.011), E-median index (1.7±0 vs. 0.9±0, p=
0.001), and liver enzyme levels (alanine aminotransferase: 34±4 vs. 23±
1 U/l, p=0.017; aspartate aminotransferase: 31±2 vs. 26±1 U/L, p=
0.018) and lower plasma high density lipoprotein cholesterol (1.1±0 vs.
1.3±0 mmol/l, p=0.019). Multivariable logistic regression analysis
showed that visceral fat mass (p=0.0011) and the aspartate aminotrans-
ferase level (p=0.001) were independent predictors of NAFLD.
Conclusion: The results show that a large proportion of women with
previous GDM and insulin resistance have NAFLD at a young age. We
have identified predictors to be used for early identification of these
women for best possible management of comorbidities in order to prevent
future liver disease and cardiovascular events.
Clinical Trial Registration Number: EUCTR2012-001371-37-DK
Supported by: Unrestricted financial support from Novo Nordisk
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Decreased gene expression of leptin, adiponectin and resistin in sub-
cutaneous adipose tissue biopsies from adult offspring of womenwith
diabetes in pregnancy
A. Houshmand-Oeregaard1,2, N.S. Hansen1,3, L. Kelstrup2,3, L.
Hjort1,3, C. Broholm1, E.R. Mathiesen2,3, T.D. Clausen3,4, P. Damm2,3,
A.A. Vaag1,3;
1Department of Endocrinology, Rigshospitalet, 2Center for Pregnant
Women with Diabetes, Department of Obstetrics and Gynecology,
Rigshospitalet, 3Faculty of Health and Medical Sciences, University of
Copenhagen, 4Department of Obstetrics and Gynecology, Hilleroed Hos-
pital, Copenhagen, Denmark.
Background and aims: Offspring exposed to intrauterine
hyperglycaemia are at increased risk of developing adiposity and type 2
diabetes (T2D). Adipose tissue secretes adipokines such as leptin,
adiponectin, and resistin, all of which play important roles in lipid and
carbohydrate metabolism, as well as in the development of adiposity and
T2D. We hypothesized that the plasma levels, and/or expression levels of
the genes encoding these adipokines in subcutaneous adipose tissue
(SAT), may be altered in adult offspring of women with diabetes in
pregnancy compared to unexposed controls.
Materials and methods: We obtained a total of 166 biopsies from sub-
cutaneous adipose tissue (SAT) in adult offspring of womenwith gestation-
al diabetes mellitus (O-GDM (n=60)) or type 1 diabetes in pregnancy (O-
T1D (n=63)), and offspring of women (controls) from the background
population (O-BP (n=43)). All subjects were born between 1978 and
1985 and data was collected in 2012-2013. The subjects underwent clinical
examinations with anthropometric measurements and 2-hour 75 g oral
glucose tolerance tests (OGTT’s), as well as a dual energy x-ray absorp-
tiometry (DEXA) whole-body scanning. Women with T1D were charac-
terized by increased average plasma glucose levels during pregnancy
compared with women with GDM during pregnancy. Gene expression
of leptin, adiponectin and resistin in SATwas examined by real-time PCR
and plasma levels were measured by Meso Scale Discovery.
Results: No significant differences were found in average BMI, waist-hip
ratio, or body composition between the three groups. Compared to O-BP, 2-
hour plasma glucose was significantly higher in O-GDM (p=0.019) and O-
T1D (p=0.001). Plasma levels of leptin were increased in O-GDM and in
O-T1D compared to O-BP, but only the difference between O-T1D and O-
BP reached statistical significance (p=0.05). Measurement of plasma
adiponectin and resistin levels are ongoing. Interestingly, significantly low-
er levels of gene expression of all three adipokines were found in O-GDM
compared with O-BP: leptin (1.18 vs. 1.63; p=0.003), adiponectin (1.32 vs.
1.99; p=0.0003) and resistin (1.07 vs. 7.01; p<=0.0001). Similarly, in O-
T1D compared with O-BP, significantly decreased levels of adiponectin
(1.56 vs. 1.99; p=0.03) and resistin (3.56 vs. 7.01; p=0.001) were found.
The gene expression of leptin in O-T1D was similar to that in O-BP.
Conclusion: Despite borderline increased plasma leptin levels, the gene
expression of leptin in SATwas markedly reduced in O-GDM compared
with O-BP controls. Furthermore, the gene expression of the two other
adipokines, adiponectin and resistin, was also significantly reduced in O-
GDM compared with O-BP. O-T1D was exposed to a higher degree of
intrauterine hyperglycaemia, yet the adipokine gene expression differ-
ences in O-T1D compared with O-BP were quantitatively less pro-
nounced, indicating that the quantitatively more pronounced changes
seen in O-GDM comparedwith O-BP cannot be explained by intrauterine
hyperglycaemia alone.
Supported by: The Danish Strategic Research Council
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DNAmethylation and gene expression of PPARGC1A in muscle and
fat biopsies from adult offspring of women with diabetes in
pregnancy
L. Kelstrup1, L. Hjort2, A. Houshmand-Oeregaard1, T.D. Clausen1,3,
N.S. Hansen2, C. Broholm2, L. Borch-Johnsen1, E. Mathiesen4,5, A.A.
Vaag2,5, P. Damm1,5;
1Department of Obstetrics, Center for Pregnant Women with Diabetes,
2Department of Endocrinology, Diabetes and Metabolism, Copenhagen,
3Department of Obstetrics and Gynecology, Hilleroed Hospital, Hillerød,
4Department of Endocrinology, Center for Pregnant Women with Diabe-
tes, Copenhagen, 5Faculty of Health and Medical Siences, University of
Copenhagen, Denmark.
Background and aims: Fetal exposure to intrauterine hyperglycemia is
associated with increased risk of type 2 diabetes (T2DM) later in life, but
the underlying mechanisms are unknown. Epigenetics has been proposed
as a link between environmental exposures and the phenotype. Methyla-
tion of CpG-sites in the DNA is the most studied epigenetic marker.
Increased CpGmethylation and reduced gene expression of themetabolic
regulator peroxisome proliferator-activated receptor gamma co-activator
1 alpha (PPARGC1A) in skeletal muscle and subcutaneous adipose tissue
(SAT) has been reported in patients with T2DM. We aimed to investigate
DNAmethylation and gene expression of PPARGC1A in skeletal muscle
and SAT from adult offspring of women with diet-treated gestational
diabetes (O-GDM, N=83) or with type 1 diabetes (O-T1DM, N=67)
and from the background population (O-BP, N=58) (Total N=208).
Materials andmethods: The adult offspring (26-35 year) underwent a 2-
hour 75 g OGTTand tissue sampling from the vastus lateralis muscle and
abdominal SAT. PPARGC1A promoter DNAmethylation was studied by
pyrosequencing at three CpG sites. PPARGC1A gene expression was
assessed using real-time quantitative PCR.
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Results: Plasma glucose during OGTTwas significantly higher for both
groups exposed to intrauterine hyperglycemia compared to O-BP (O-
GDM: [30 min: p=0.005] and [120 min: p=0.019]; O-T1DM: [30 min:
p=0.001]). Average PPARGC1A promoter DNAmethylation was higher
in O-GDM in muscle (p=0.05) and SAT (p=0.02) compared to O-BP,
while no differences neither in muscle or SAT was found between O-
T1DM and O-BP. PPARGC1A gene expression in muscle was signifi-
cantly lower in O-GDM compared to O-BP (p=0.0003), while no differ-
ence was found between O-T1DM and O-BP. PPARGC1A gene expres-
sion in SATwas similar in all three groups.
Conclusion: Both groups of adult offspring of women with diabetes in
pregnancy had elevated glucose levels during OGTT. O-GDM presented
significantly altered DNAmethylation in both skeletal muscle and SATand
decreased PPARGC1A gene expression in skeletal muscle. The findings in
O-GDMmay contribute to the increased risk of developing T2DM, but our
negative findings in O-T1DM despite fetal exposure to more severe hyper-
glycemia indicate that other mechanisms than only exposure to intrauterine
hyperglycaemia or other mechanisms in terms of epigenetic markers may
be involved in fetal programming of adult adverse metabolic health.
Supported by: The Research Found of Rigshospitalet
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Effects of a hyperglycaemic intrauterine environment on offsprings
epigenome and risk of cardio-metabolic disease later in life
L. Hjort1, L. Groth Grunnet1, A. Olsson1, D. Martino2, F. B Hu3, C.
Zhang4, R. Saffery2, S. Olsen5, A. Vaag1;
1Copenhagen University Hospital, Copenhagen, Denmark, 2Murdoch Chil-
drens Research Institute, Parkville, Australia, 3Harvard Medical and Public
Health School, Boston, 4National Institute of Child Health and Human De-
velopment, Bethesda, USA, 5Statens Serum Institut, Copenhagen, Denmark.
Background and aims: Offspring of women with Gestational Diabetes
Mellitus (GDM) are at high risk of developing Type 2 Diabetes (T2D)
later in life, but the putative epigenetic mechanisms underlying this asso-
ciation remain unknown. Using an epigenome-wide approach in a
subcohort of the Danish National Birth Cohort, we aimed to explore
whether DNA methylation in blood differed in 9-14 year old offspring
of GDM women versus matched controls.
Materials and methods: We recruited 623 GDM- and 617 control off-
spring. DNA from 95 GDM offspring and 95 controls were analyzed for
genome-wide DNA methylation profiles using the Infinium
HumanMethylation450 BeadChip.
Results: BMI, fat percentage, fasting glucose, insulin and c-peptide levels
were higher amongGDMoffspring compared to controls (P≤0.04).We did
not find any differentially methylated positions at the genome-wide signif-
icance level (Bonferroni adjusted), but identified 1,828 sites potentially
differentially methylated between the groups (P≤0.01, unadjusted). When
performing a differential methylated region (DMR) analysis, we identified a
small non-coding RNA, VTRNA2-1, that reached genome-wide signifi-
cance, covering 16 CpG sites overall presenting lower methylation in the
GDM group (P=0.02, adjusted). Multiple examples of differential methyl-
ation within the same gene were noted, suggesting a coordinated change in
methylation, and several localized to genes previously associated with
DNA methylation changes, in earlier studies of GDM cord blood and
placenta samples. From the top ten probes based on P-value, PTCH1 was
identified with decreased methylation in GDM offspring and associated
with increased glucose levels among the offspring (P=0.02).
Conclusion: Our data suggests that offspring of GDM women exhibit
pre-diabetes traits at preadolescent age. A substantial proportion of meth-
ylation differences observed in previous GDM cord blood/placenta stud-
ies are likely to resolve during childhood, thus, the persistent marks iden-
tified in this study may serve as interesting sites in investigation of causal
relation to the increased T2D risk later in life. Validation studies of the
identified 1,828 sites are in progress in the entire cohort of 1,240 children.
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Epigenetic effects of maternal type 1 diabetes: placental DNA meth-
ylations, miRNAs and their effect on gene expression
A.M. Wägner1,2, D. González García-Cano3, B. Vega-Guedes3, P.
Lorente-Arencibia4, T. Figueras-Falcón3, Y. Brito-Casillas1,2, M.
Armas-Roca3, C. Pérez-Matos3, C. Fleitas-Ojeda3, S. Correa-González3,
A. Nimptsch3, J.S. Álvarez-Cuenod3, A.B.. Junco-Acosta5, M. Andújar-
Sánchez6, J.C. Wiebe1,2;
1Endocrinology, Complejo Hospitalario Universitario Insular Materno-
Infantil (CHUIMI), 2Instituto Universitario de Investigaciones
Biomédicas y Sanitarias, Universidad de Las Palmas de Gran Canaria
(ULPGC), 3Gynaecology and Obstetrics, CHUIMI, 4Research Unit,
CHUIMI, 5ULPGC, 6Pathology, Complejo Hospitalario Universitario In-
sular Materno-Infantil, Las Palmas de Gran Canaria, Spain.
Background and aims:Offspring of mothers with type 1 diabetes (T1D)
have a lower risk of T1D than offspring of fathers with T1D. This could
be explained by intrauterine, epigenetic effects, detectable already at the
time of birth. Our aim was to assess the effect of maternal T1D on the
placental expression of miRNAs and DNA methylation and their effect
on gene expression.
Materials and methods: Samples of the maternal and foetal sides of the
placenta were obtained fromwomenwith T1D and type 2 diabetes (T2D),
women whose partner had T1D and controls matched for age and gesta-
tional age. Five "pools" of 8-10 samples of maternal and 5 of foetal
placenta were analysed. DNA methylation patterns (Methylation-
specific digital karyotyping) were analysed and compared. Genes in
which high methylation (fold-change of tags<-1) levels coincided with
a reduction in the mRNA expression level (fold-change<-1.5) were iden-
tified. Massive sequencing of miRNAs was performed. Potential target
genes of novel miRNAs were sought (simulation, miRDB). We selected
miRNAs that showed a difference in expression between groups (p<0.1)
and a difference (in the opposite direction) in the expression levels of the
target mRNA (fold-change below-0.5/above0.5). We report the changes
identified in the foetal side of the placentas in T1D
Results: A total of 38 women with T1D and 32 with T2D, 15 women
whose partners had T1D and 59 controls have been included [age 32.3(5.9),
32.3(5.8), 28.4(5.1) and 29.8 (5.8), years; gestational age 38.7(1.6),
38.5(1.5), 38.4(1.3) and 39.5 (1.4) weeks, respectively); pregestational
HbA1c in the women with diabetes 7.3(1.9) and 7.0(1.2)% and third tri-
mester HbA1c 6.4(0.9) and 6.1(0.7) %]. We identified 13 genes with rele-
vantly different methylation in the foetal placenta of mothers with T1D, as
well as 5 new and 8 known miRNAs (See table). The latter have conse-
quences on the expression of genes involved in immune response,
aminoacid and protein metabolism and insulin signalling.
Conclusion: Epigenetic effects of maternal T1D can be detected at birth
and the most relevant seem to be due to hyperglycaemia, rather than
autoimmunity, as suggested by a lack of difference with the T2D group.
The implications of these preliminary findings are still to be clarified.
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The risk of severe hypoglycaemia events in working-age adults and
use of basal insulins NPH, glargine and detemir: a nationwide regis-
ter study in Finland
A.Y. Strandberg1, T.E. Strandberg2, H. Khanfir3, S. Mäkimattila4, T.
Saukkonen4, F. Hoti3;
1Aava Medical Centre, Kerava, 2Institute of Health Sciences/Geriatrics,
University of Oulu, 3EPID Research, Espoo, 4Novo Nordisk Farma, Es-
poo, Finland.
Background and aims: Hypoglycaemia is a common and costly side
effect of insulin treatment. The risk of hypoglycaemia increases with the
duration of treatment andwith advancing age. In comparison to the earlier
generation basal insulin NPH, modern, longer acting basal insulins
glargine and detemir have shown a lower incidence of hypoglycaemia
in clinical studies. In real-life care the benefits have not been fully dem-
onstrated, especially among the working-age population, for whom the
target levels of glucose control are strict than for older persons. We eval-
uated the risk of severe hypoglycaemia events among new users of NPH,
glargine and detemir in a real-world setting among working-age adults in
Finland.
Materials and methods: Persons aged 18-65 years with diabetes and
recently prescribed with basal insulin (NPH, glargine, detemir) during
2006-2009 were identified from the Finnish national prescription register.
During this period all three insulins were fully reimbursed for patients
with diabetes. The study patients were followed up until the first event of
severe hypoglycaemia or death by the end of 2009, utilizing the nation-
wide hospital discharge register and cause of death register. The Poisson
model was used to evaluate the absolute risk (with 95% confidence inter-
vals) for severe hypoglycaemia events for new users of NPH, glargine or
detemir during follow-up. The risk between the study insulins was com-
pared with Cox’s proportional hazards model adjusting for age, gender,
type of diabetes, use of sulfonylurea, use of other than study insulin,
history of hospitalizations due to severe hypoglycaemia, and switch of
study insulin. Several sensitivity analyses were performed to test the
robustness of the results with respect to the exposure definitions and
possible confounders.
Results: During the follow-up of up to four years, (mean 1.8 years) there
were 16,985 persons (2,604with type 1, 13,254with type 2, and 1,127 with
unclassified diabetes mellitus) who initiated basal insulin treatment. 5,586
patients initiated NPH, 7,499 glargine, and 3,900 detemir. During the
27,815 person-years of follow-up, 2,730 (16%) people switched insulin at
least once, and 536 (3%) people were hospitalized due to an event of severe
hypoglycaemia with 190, 222 and 76 during exposure to insulin NPH,
glargine or detemir, respectively. The type of insulin in use was not spec-
ified for 48 events. The absolute rate (per 1000 patient-years) of severe
hypoglycaemia was 20.6 (95% CI 17.9, 23.8) for NPH, 17.8 (15.6, 20.3)
for glargine, and 12.4 (9.9, 15.5) for detemir initiators. With NPH as refer-
ence, the adjusted hazard ratio (HR) for the risk was 0.92 (95% CI 0.74,
1.15, p=0.47) for glargine, and significantly lower 0.70 (0.52 0.94, p<0.05)
for detemir. The corresponding risk was also significantly lower (HR 0.76
[0.58, 0.99, p <0.05]) for detemir compared to glargine.
Conclusion: We observed significant differences in the risk of severe
hypoglycaemia between different basal insulins among working-aged
adults with diabetes in Finland. Use of insulin detemir was associated with
a significantly lower risk of severe hypoglycaemia requiring hospital care
compared to glargine and NPH. The results suggest that in routine practice
the burden of hypoglycaemiamay be reduced by the choice of basal insulin.
Supported by: Novo Nordisk, Gustaf V and Queen Victoria
Frimurarestiftelse
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Reactive hypoglycaemia after Roux-en-Y gastric bypass in type 2
diabetic subjects
M. Nannipieri1, D. Guarino1, M. Seghieri1, E. Rebelou1, A. Mari2, D.
Colligiani1, D. Moriconi1, S. Baldi1, M. Anselmino3, E. Ferrannini4;
1Dpt Clinical and Experimental Medicine, University of Pisa, 2Biomed-
ical Engeneering of Padua, CNR Institute, Padua, 3Bariatric Surgery Unit,
Azienda Ospedaliera Universitaria Pisana, Pisa, 4Clinical Physiology,
CNR Institute, Pisa, Italy.
Background and aims: Reactive hypoglycaemia (Hypo) is a well-
recognised complication of RYGB surgery in non-diabetic subjects. In
type 2 diabetes (T2DM), RYGB improves glucose metabolism, but
whether this improvement is related to the later development of reactive
hypoglycaemia is not known. Our aim was to investigate presence and
mechanisms of postprandial Hypo in T2DM undergoing RYGB.
Materials and methods: 32 obese T2DM subjects treated with RYGB
received a 5-hr OGTT before and 12-18 months after surgery. Hypo was
defined as a plasma glucose ≤3.3 mmol/L in subjects off hypoglycaemic
agents. Insulin sensitivity was assessed by Matsuda index and ß-cell
function by modelling analysis of the C-peptide response to the OGTT.
Results:Hypo occurred in 10 of 32 RYGB patients. Age did not discrim-
inate Hypo from non-Hypo (NH) subjects. Presurgery BMI was lower in
Hypo than NH (42.8±6.4 vs 46.0±5.9 kg/m2, p=0.03). Pre-surgery
fasting glycaemia was similar in both groups, as was mean plasma glu-
cose duringOGTT (11.0±2.1 vs 10.4±2.0 mM, p=ns). Pre-surgery mean
insulin during OGTT and insulin secretion rate (basal and total) were
similar in both groups. Post-surgery, mean insulin was reduced to a sim-
ilar extent in both groups (p=0.003), whereas insulin secretion was un-
changed. Baseline peripheral insulin sensitivity was higher in Hypo than
NH and after surgery it improved more in Hypo than in NH (4.3±2.3 vs
9.0±3.1 and 2.8±1.1 vs 5.5±2.6 mL.min-1.m-2, p<0.0001 for time, p=
0.05 for interaction time*Hypo). Baseline ß-cell glucose sensitivity was
similar in the two groups (29±22 vs 25±34 pmol.min-1.m-2.mM-1), but
after surgery it increased more in Hypo than NH (82±49 vs 34±23
pmol.min-1.m-2.mM-1, p=0.0018 for interaction time*Hypo). Baseline
insulin clearance was similar, but post-surgery it improved in Hypo (p=
0.004 interaction time*Hypo). No differences in fasting or postglucose
GLP1 and glucagon were found between Hypo and NH, whereas fasting
plasma PYY concentrations before surgery were significantly higher in
Hypo compared to NH (p=0.04). In logistic regression, presurgery insu-
lin sensitivity (positive, p=0.03) and fasting PYY (positive, p=0.04) were
the only predictors of reactive hypoglycaemia after surgery.
Conclusion: A better insulin sensitivity and higher fasting PYY concen-
trations before surgery are associated with a higher risk of post-surgery
reactive hypoglycaemia in T2DM subjects. Independently of diabetes
remission, improvement in ß-cell glucose sensitivity in association with
peripheral insulin sensitivity is responsible for postprandial
hypoglycaemia after RYGB.
Supported by: EFSD
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Hypoglycaemia association with hospitalisation and mortality in
older patients with type 2 diabetes mellitus initiating Basal Insulin
(BI) in a US medicare advantage population
J. Escalada1, L. Liao2, C. Pan3, H. Wang2, M. Bala4;
1Department of Endocrinology and Nutrition, Clinica Universidad de
Navarra, Pamplona, Spain, 2Sanofi, Bridgewater, 3ProUnlimited, Boca
Raton, 4Sanofi, Cambridge, USA.
Background and aims: Hypoglycemia has been associated with an in-
creased risk of cardiovascular (CV) events and all-cause mortality. Older
patients initiating basal insulin are at particular risk of experiencing severe
hypoglycemic events given the observed increase in hypoglycemic rates
in this population, and the established risk between insulin and hypogly-
cemia.We performed a retrospective US health insurance claims database
study to assess the current burden of hypoglycemia in older patients
initiating basal insulin treatment, investigating whether there is an asso-
ciation between hypoglycemia, hospitalization, and all-cause mortality.
Materials and methods: The Clinformatics® Data Mart Medicare Ad-
vantage database was used to identify patients with T2DM who initiated
Basal insulin between January 2007 and December 2013. All patients had
a minimum of one year continuous health coverage prior to and after
basal insulin initialization. A Cox proportional hazard model was
employed to evaluate the risk of all-cause hospitalization and death, with
medically attended hypoglycemia (HG) as a time-varying covariate
adjusting for demographic, comorbidities and medication history.
Results:Of the total 31,035 patients analyzed, 16,534 (53%) experienced
hospitalization and 4414 (14%) died during a mean follow-up of 2.9 year.
A greater proportion of patients with HG recorded during the first-year
post BI initiation required hospitalization than those without HG (75.6%
vs 50.8%), experiencing 1.43 and 0.65 hospitalization episodes/patient-
year, respectively. Patients with HG were more likely to die than those
without HG (21.1% vs 13.4%). After accounting for other risk factors,
HG was associated with an elevated risk of all-cause hospitalization (HR
1.60; 95%CI: 1.53-1.65) and death (HR 1.50; 95%CI: 1.40-1.60). (Fig-
ure: Hazard ratio analysis for all-cause hospitalization and death)
Conclusion: In a large US Medicare Advantage population with T2DM,
HG is a strong independent risk factor for hospitalization and death fol-
lowing BI initiation, suggesting the need for a new BI with a favorable
HG profile in this older population.
Supported by: Sanofi
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Reduced cognitive function in people with type 1 diabetes and im-
paired awareness of hypoglycaemia
M.R. Bjørgaas1, T.I. Hansen2, E.C.D. Haferstrom3, S.E. Olsen4, A.K.
Håberg2;
1Department of Endocrinology, Trondheim University Hospital, 2Depart-
ment of Neuroscience, Norwegian University of Science and Technology
(NTNU), 3Department of Medical Imaging, Trondheim University Hospi-
tal, 4Department of Cancer Research and Molecular Medicine, Norwegian
University of Science and Technology (NTNU), Trondheim, Norway.
Background and aims: Impaired awareness of hypoglycaemia (IAH) im-
plies an increased risk of severe hypoglycaemia (SH) in type 1 diabetes
(T1D). Recurrent SHs may impair brain function, and the hippocampus is
especially vulnerable. We aimed to investigate whether T1D patients with
IAHhave reduced cognitive function compared toT1Dpatientswithout IAH.
Materials and methods: In total 105 participants (33 T1D with IAH
(Gold score≥4), 35 T1D with normal awareness (NAH; Gold score≤2),
and 37 healthy controls) completed a web-based neuropsychological test
battery assessing verbal-, spatial-, and working memory, executive func-
tion, processing speed and pattern separation. Raw scores were trans-
formed to z-scores using the results of the healthy controls as reference.
Results:As shown in Table 1, age (~47 years) and gender distribution was
similar in the IAH, NAH and healthy control groups. In the IAH and NAH
subjects, diabetes duration (~30 years), mean HbA1c (~8%), and percent-
age of subjects with no retinopathy (48.% vs. 45.7%) did not differ between
groups (Student t-test and Chi square tests p-values 0.984-0.194). No par-
ticipant had severe hypoglycaemia the day before testing or biochemical
hypoglycaemia during testing (Table 1). IAH-subjects had lower z-scores
than NAH-subjects in tests of verbal memory delayed recall (t(62) =2.4, p=
0.018, d=0.60), spatial memory immediate recall (t(57.5) =2.1, p=0.043,
d=0.51), pattern separation (t(59) =2.8, p=0.007, d=0.72), and in process-
ing speed and executive function (t(60) =2.2, p=0.032, d=0.57).
Conclusion: T1D participants with IAH had lower performance in neu-
ropsychological tests than NAH participants. These differences were
most pronounced in tests associated with hippocampal function.
Supported by: NTNU and Norwegian Extra Foundation for Health abd
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Interim results on the relationship between mild-moderate and se-
vere hypoglycaemia and cardiovascular disease in a cohort of sulfo-
nylurea users
A.P. Nunes1, J. Yang1, K. Tunceli2, K. Kurtyka2, L. Radican2, S.S.
Engel2, S. Yu2, M.C. Doherty1, D.D. Dore1;
1Optum Epidemiology, Waltham, 2Merck Sharp & Dohme Corp., Kenil-
worth, USA.
Background and aims: Severe hypoglycemia is associated with higher
risk for cardiovascular disease (CVD), but most hypoglycemic events are
non-severe. Little is known about the CVD effects of mild-to-moderate
hypoglycemia, which is less likely to be encoded in administrative data-
bases. We used electronic health records (EHR) to identify a large cohort
of sulfonylurea (SU) users and examine the association between baseline
hypoglycemia by severity and CVD outcomes at follow-up.
Materials and methods: Patients with type 2 diabetes prescribed SUs
were identified from the Humedica Research Database from January
2009 to March 2014. This database includes EHRs on over 30 million
patients throughout the United States. Hypoglycemia occurrence was
identified using an algorithm incorporating International Classification
of Diseases, Ninth Revision (ICD-9) diagnostic codes and natural lan-
guage processing (NLP) of free text clinical notes to improve capture of
non-severe hypoglycemic events. We identified mentions of hypoglyce-
mia and synonyms within the free text from note sections likely to indi-
cate the patient’s current status/experience (History of Present Illness,
Diagnoses, Problems, and Patient Complaints) and did not include re-
cords of patient counseling about the risk of hypoglycemia or other
false-positive scenarios. Mentions of hypoglycemia associated with ne-
gations or a non-confirmatory sentiment (e.g. denies hypoglycemia) were
not considered. We categorized hypoglycemic events as serious, mild-
moderate, or unknown based on descriptors within the free text and by
site of care, treatments, and comorbidities. Frequency of hypoglycemia
events, by seriousness, was assessed as a determinant of CVD outcomes,
acute myocardial infarction (AMI) and congestive heart failure (CHF),
identified from diagnoses within the EHR.We compared the relative rates
(RR) and 95% confidence intervals (CI) of CVD across categories of
baseline hypoglycemia with adjustment for baseline covariates via
Poisson regression models.
Results: Of the 82,321 eligible patients, 4,922 (6%) had at least one
hypoglycemia event in the year before cohort entry. In the follow-up
period (Median: 164 days; 25th and 75th percentiles: 20 days, 601 days),
47% had an observed diagnosis for any CVD, 2% had a diagnosis for
AMI, and 15% had a diagnosis for CHF. Severe hypoglycemia frequency
was positively associated with CHF (RR per episode: 1.69, CI 1.55-1.84)
and AMI (RR 1.66, CI 1.31-2.09). Mild-moderate hypoglycemia and
hypoglycemia of unknown seriousness were more strongly associated
with CHF (Mild-Moderate RR 1.48, CI 0.93-2.34; Unknown Seriousness
RR 1.43, CI 1.37-1.48) relative to AMI (Mild-Moderate RR 0.96, CI
0.15-6.3; Unknown Seriousness RR 1.19, CI 1.06-1.35). Restricting to
patients with active sulfonylurea use at the time of hypoglycemia assess-
ment yielded comparable results.
Conclusion: The association between hypoglycemia and CVD may be
dependent on the subtype of CVD and the seriousness of hypoglycemia.
Hypoglycemia characterized as mild-moderate or unknown had attenuat-
ed associations with AMI. Limitations of this study include differential
documentation of hypoglycemia, lack of validation of the NLP algorithm,
incomplete capture of non-serious hypoglycemic events and residual
confounding.
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Cardiac autonomic regulation during experimental hypoglycaemia
in type 1 diabetes with impaired awareness of hypoglycaemia
E. Walkinshaw1, S.A. Little2, A. Bernjak1, A. Lubina-Solomon1, E.
Chow1, J.A.M. Shaw2, S.R. Heller1;
1Human Metabolism, University of Sheffield, 2Institute of Cellular Med-
icine, Newcastle University, Newcastle Upon Tyne, UK.
Background and aims: Impaired awareness of hypoglycaemia (IAH)
affects 25% of patients with type 1 diabetes (T1DM) and increases the
risk of severe hypoglycaemia (SH). Previous studies report decreased
vagal outflow during hypoglycaemia in T1DM, potentially increasing
vulnerability to cardiac arrhythmias. Our aim was to investigate the effect
of experimental hypoglycaemia on cardiac autonomic regulation in pa-
tients with IAH.
Materials and methods: Ten participants with T1DM and intact
hypoglycaemia awareness, eight with IAH (Gold score≥4), six with pre-
viously impaired but restored awareness (Gold score<4) and ten without
diabetes underwent a stepped hyperinsulinaemic hypoglycaemic clamp
study. Glucose was stabilised at 5 mmol/l at time 20 minutes (T20) and
reduced step-wise to a nadir of 2.4 mmol/l at time 180 minutes (T180).
Heart rate variability was measured during each glucose step.
Results: An increase in heart rate (HR) and a corresponding reduction in
high frequency (HF) power, suggesting vagal withdrawal was seen in
participants without diabetes with recovery by T180 (HR at T20 65.3;
T100 68.7, p=0.057; T180 62.8). HR increased in subjects with diabetes
and intact awareness of hypoglycaemia without signs of recovery by
T180 (HR T20 72.2; HR T180 80.7, p=0.008). Increases in normalised
low frequency (LFnorm), indicating elevated sympathetic contribution,
were higher in participants with diabetes than subjects without diabetes.
Participants with IAH had a peak heart rate at T100 with evidence of
recovery by T180 (HR T20 79.43, T100 83.61, T180 81.70 p=0.041).
This was accompanied by small, non-significant reductions in HF power
and increases in LFnorm which recovered by T180. Participants with
restored awareness showed early changes in heart rate variability with a
peak in heart rate at time 60 minutes (T60) and recovery by 140 minutes.
Reductions in HF power (p=0.02) and LFnorm (p=0.013) peaked at T60
with similar patterns of recovery. Rises in plasma metanephrine were
lower in participants with IAH and restored awareness of hypoglycaemia
(Table 1).
Conclusion:Changes in cardiac autonomic regulation during experimen-
tal hypoglycaemia are time dependent and differ according to self-
reported awareness of hypoglycaemia in T1DM. In subjects with IAH,
hypoglycaemia had a diminished effect on sympathetic activation,
blunting hypoglycaemia recognition through autonomic symptoms but,
potentially providing cardiovascular protection against arrhythmias. This
corresponds to a reduction in metanephrine response to hypoglycaemia.
Clinical Trial Registration Number: 52164803
Supported by: Diabetes UK
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Therapeutic inertia for glycaemic and blood pressure control in pa-
tients with type 2 diabetes mellitus and the cardiovascular
consequences
S. Paul1, J. Shaw2, K. Klein1;
1Clinical Trials and Biostatistics Unit, Brisbane, 2Baker IDI, Melbourne,
Australia.
Background and aims: The delay or failure to intensify treatment for
better glycaemic and blood pressure (BP) control (therapeutic inertia, TI)
in patients with poor glucose and BP control, the risk burden and the
effects of TI on cardiovascular (CV) risk in newly diagnosed T2DM
patients have not been explored. The aims of this longitudinal cohort
study were to evaluate the prevalence of TI, the extent of potentially
avoidable glycaemic and BP burden, and the association of TI and TI-
associated glycaemic and BP burden with the risk of composite of myo-
cardial infarction (MI), heart failure (HF) and stroke.
Materials and methods: A cohort of 1,145,979 patients, aged≤70 yrs
with diagnosis of T2DM from 2000 were selected from the Centricity
EMR Database of USA, with follow-up data available till September
2014. CEMR provides longitudinal patient-level data on over 38 million
insured and non-insured patients from about 35,000 care providers (70%
primary care providers) derived from clinical practices across 49 US
states. Longitudinal follow-up data on HbA1c, BP, prescriptions and
doses for anti-diabetes drugs (ADDs) and anti-hypertensive drugs
(AHDs), and CV events with dates of events were extracted. TI for glu-
cose and BP control were defined as failure to take at least 2 ADDs
(ADD2) and at least 2 AHDs (AHD2), respectively, in patients with
HbA1c and BP persistently above target for 2 years. 474,429 patients
had a minimum of 2 yrs of follow-up data post diagnosis of diabetes.
Results: Patients were 49% male, mean (SD) age 58 (11) yr, HbA1c 8.4
(2)%, SBP 132 (18)mmHg, 59% hadHbA1c≥7.5%, and 29% had SBP≥
140 mmHg at diagnosis. The proportions of patients with ischemic heart
disease, hypertension and chronic kidney disease prior to diagnosis of
diabetes were 1.2%, 12 .3% and 0.8% respectively. In patients with
HbA1c≥7.5% at diagnosis, more than 47%/29% had HbA1c consistently
above 7%/7.5% during 2 yrs post diagnosis. In patients with HbA1c
consistently above 7%/7.5% over 2 yrs, 40%/36% never received
ADD2, only 46%/51% received ADD2within 2 yrs, and the median time
to intensification with ADD2 in these patients were 15/13 months. Only
7%patients had SBP≥140mmHg consistently over 2 yrs, 9% of these did
not receive AHD2, and the median time to intensification by AHD2 was
7 months. During 4 yrs of median follow-up, 0.82% had MI , 0.67% had
HF, 1.72% had stroke, and 3.1% experienced at least one of these events.
Adjusting for age, sex, ethnicity, smoking status, renal diseases, stratified
by year of diagnosis of diabetes , in patients without history of CVD, TI
for glycaemia and blood pressure was associated with 38% (95% CI of
HR: 1.14, 1.66) and 20% (95% CI of HR: 1.05, 1.38) increased risk of a
composite of MI, HF and stroke, respectively. Those with HbA1c con-
sistently above 7.5% over 2 yrs, independently had 80% (95% CI of HR:
1.69, 1.93) increased risk of composite CV events, compared to those
with HbA1c below 7.5%.
Conclusion: This study shows that in a large population of people with
newly diagnosed diabetes, aged≤70 yrs, and with minimal prior CVD,
there was a high prevalence of TI, a significant glycaemic burden over
two years even with intensified treatment , and an association of TI with
an increased CV risk over 4 years. Greater efforts are needed to under-
stand, identify and appropriately manage this group of patients.
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Increased risk of cardiovascular-related events associated with sulfo-
nylureas compared to other antihyperglycaemic drugs: a Bayesian
meta-analysis of survival data
C.A. Baxter1, R. Das1, H. Langerman1, E.J. Mills2, E. Druyts2, G.
Siliman2, C. Balijepalli2, K. Thorlund2;
1MSD Ltd, Hoddesdon, UK, 2Redwood Outcomes, Vancouver, Canada.
Background and aims: Studies suggest different glucose-lowering treat-
ments can have different, and even divergent, effects on cardiovascular
risk and mortality. We conducted a systematic review involving studies
that compared sulfonylurea to placebo/no intervention or other anti-
diabetic drugs.
Materials and methods: Since events occur at differing time points
among included studies, we employed a complementary-log-log link
model in the Bayesian framework to obtain comparative hazard ratios
(HR) between interventions. Conventional pairwise meta-analyses were
used to pool adjusted hazard ratios for observational studies.
Results:We identified 91 RCTs including 36,573 patients and 26 obser-
vational studies including 1,553,856 patients. Analyses of RCT data dem-
onstrated an increased risk of all-cause mortality and cardiovascular-
related mortality for sulfonylureas compared to all treatments combined
(HR 1.26 [1.10; 1.44] and 1.46 [1.21; 1.77], respectively). These results
were confirmed in the analyses of the observational studies. The risk of
myocardial infarction was significantly higher for sulfonylureas com-
pared to DPP-4 inhibitors (HR 2.54 [1.14; 6.57]) and elevated compared
to SGLT-2 inhibitors HR 41.80 [1.64; 360.4]), but not other classes of
treatments. Observational studies confirmed an increased risk of myocar-
dial infarction for sulfonylureas compared to all other treatments com-
bined. The RCTs showed that the risk of stroke was significantly higher
for sulfonylureas compared to DPP-4 inhibitors, GLP-1 agonists, TZDs
and insulin (HR 9.40 [3.27; 41.9], 45.40 [1.99; 362.7], 1.75 [1.20; 2.69],
and 1.46 [1.01; 2.14], respectively). No observational evidence was avail-
able on the risk of stroke.
Conclusion: Our findings in RCTs demonstrate a higher risk of
cardiovascular-related events associated with sulfonylureas compared to
other anti-diabetic drugs that increases over time. The analyses on the
observational studies confirmed our results. These findings should inform
guidelines for patients with elevated risk of CVevents.
Supported by: MSD Ltd
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Second-line treatment with sulfonylurea compared to DPP4 inhibi-
tors is associated with risk of cardiovascular disease, all-cause mor-
tality and severe hypoglycaemia
J.W. Eriksson1, J. Bodegard2, A. Norhammar3, D. Nathanson3, M.
Thuresson4, T. Nyström3, A. Norhammar3;
1Uppsala University, 2AstraZeneca, Södertälje, 3Karolinska Institutet,
Stockholm, 4Statisticon, Uppsala, Sweden.
Background and aims: To compare the risk of cardiovascular disease
(CVD), all-cause mortality and severe hypoglycaemia in type 2 diabetes
(T2DM) patients who initiate second-line treatment with either sulfonyl-
urea (SU) or DPP4 inhibitors (DPP4i).
Materials andmethods: T2DM patients whowere treated with one non-
insulin antidiabetic drug (NIAD) and that added a second glucose lower-
ing drug during 2006_2013 were identified in the Swedish Prescribed
Drug Register and linked with National Patient-, and Cause of Death
registers. Index date was defined as the date of patients second NIAD
dispense after monotherapy on NIAD. Cox survival models, adjusted for
age, gender, time on first-line treatment, previous CVD and fragility (3 or
more days in hospital the year prior to index) were used to estimate event
risks during follow-up. Cardiovascular disease was defined as hospitali-
zation due to unstable angina, myocardial infarction or embolic stroke, or
cardiovascular related death; severe hypoglycemia as any hospitalisation
with diabetic hypoglycemia diagnosis.
Results: In the 68,351 patients whowere started on dual NIAD treatment;
the two most frequent dual-combination were metformin+SU (64%)
followed by metformin+DPP4i (15%). Metformin+SU vs
metformin+DPP4 were similar in age (65 vs 61 years), gender (59 vs
62% were men), had similar history of cardiovascular-, (32 vs 28%)
and microvascular disease (18 vs 15%). Blood pressure-, lipid lowering
and low dose aspirin treatment were also similar in the two groups. Add-
on with SU compared with DPP4 in second-line treatment was associated
with higher risk of subsequent fatal/nonfatal CVD-, all-cause mortality
and severe hypoglycemia; hazard ratios (95% CI): 1.11 (1.00-1.22), 1.20
(1.07-1.33) and 1.62 (1.11-2.36) respectively.
Conclusion: In T2DM patients, second-line treatment with sulfonylurea
compared to DPP4i was associated with an increased risk of subsequent
cardiovascular events, all-cause mortality and, severe hypoglycemia. On-
going and future randomized trials will be important to elucidate possible
causal relationships between treatments and the reported complications.
Supported by: AstraZeneca
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Treatment characteristics and outcomes associated with
sulphonylurea versus metformin therapy in incident type 2 diabetes
mellitus patients: results of the German CREST study
B. Berg1, T.Wilke1, A. Groth1, S.Müller1, S. Stephens2, N. Hammar3, A.
Fuchs4, K. Tsai5, U. Maywald4;
1Institut für Pharmakoökonomie und Arzneimittellogistik, University of
Wismar, Germany, 2Pharmerit International, York, UK, 3AstraZeneca UK
and Institute of Environmental Medicine, Karolinska Institute, Stock-
holm, Sweden, 4AOK Plus, Dresden, Germany, 5AstraZeneca US, Gai-
thersburg, USA.
Background and aims: The aim of this study was to analyse (1) charac-
teristics of incident T2DM-patients having started either a MET or SU
monotherapy and (2) whether these therapies are associated with different
mortality, T2DM-related hospitalizations and macrovascular events
(MACE).
Materials and methods: This was a cohort study using a German AOK
PLUS-claims data set covering the years 2010-12. Incident T2DM pa-
tients having started either aMET/SUmonotherapy between 01/07/2010-
31/12/2011 without having received any prior antidiabetic medication
during the preceding 180 days were included. Observation started with
the first MET/SU prescription. Follow-up-time for each patient was at
least 12 months, or, in case of death or therapy discontinuation (treatment
gap>180 days or prescription of another agent), until that date. Event
rates per 1,000 patient years were compared between the two patient
groups using incidence rate ratios (IRR), Kaplan Meier curves, and Log
S64 Diabetologia (2015) 58 (Suppl 1):S1–S607
Rank tests. Furthermore, a Upropensity score matched (PSM) compari-
son of event rates between the two groups and a multivariate Cox regres-
sion analysis were carried out.
Results: We observed 35,661 incident T2DM- patients. Of them, 904
(2.5%)/7,874 (22.1%) started a SU/MET monotherapy, respectively. A
mean age of 70.1/61.4 years (p<0.001), 54.6%/50.3% (p<0.001) female
gender and a mean Charlson Comorbidity Index excluding age factor of
2.23/1.44 (p<0.001) were observed in the respective SU/MET groups. In
the unmatched patient sample comparisons, the mortality rate (all rates
per 1,000 patient-years) in the SU/MET groups was 82.5/25.5, respec-
tively (IRR=3.24, p<0.001), for MACE 94.3/56.9 (IRR=1.66, p<
0.001), and for T2DM-hospitalizations 32.1/11.2, respectively (IRR=
2.87, p<0.001). In the PSM comparison which included 1,460 patients
(730 patients per group), the mortality rates in the SU/MET groups were
56.3/40.3, respectively (IRR=1.40, p>0.100), for MACE/T2DM-related
hospitalizations they were 82.5/61.1 (IRR=1.35, p>0.100), and 30.1/6.9
(IRR=4.34, p<0.005), respectively. In the multivariate Cox regression
analysis, SU monotherapy was associated with higher T2DM-
hospitalization risk (HR 2.822; p<0.001), higher MACE risk (HR
1.342; p<0.050), higher T2DM-related hospitalization risk (HR 2.014;
p<0.001), and higher composite event risk (HR 1.776; p<0.001).
Conclusion: Among incident T2DM patients initiating first line treat-
ment, those receiving SU therapy are older, more likely to be female,
more comorbid, and discontinue their monotherapy earlier than patients
treated with MET; a substantial number may also face MET contraindi-
cations. Taking these differences in patient characteristics into account,
patients treated with SU seem to be at increased risk of death, MACE and
T2DM-hospitalization compared to MET treated patients in Germany.
Residual confounding cannot be excluded as at least a partial explanation
to these findings.
Supported by: AstraZeneca US
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Dual antiplatelet therapy after acute coronary syndrome in patients
with and without diabetes: a Swedish nationwide population-based
cohort study
A. Deleskog1, O.Ö. Braun2, P. Hasvold1, M. Thuresson3, O. Angerås4;
1AstraZeneca, Nordic-Baltic, Södertälje, 2Department of Cardiology,
University, Lund, 3Statisticon AB, Uppsala, 4Department of Cardiology,
Sahlgrenska University Hospital, Gothenburg, Sweden.
Background and aims: Diabetes mellitus confers a high risk for recur-
rent ischemic events, including death, in patients with acute coronary
syndromes (ACS). Patients with diabetes have platelet hyper-reactivity,
as well as impaired platelet inhibition, in response to clopidogrel, sug-
gesting that they might receive a greater benefit from more potent anti-
platelet regimens. To characterize patients with ACS with and without
diabetes and describe the dual antiplatelet therapy (DAPT; P2Y12 antag-
onist and acetylsalicylic acid) regimen in these populations.
Materials and methods: This observational cohort study linked morbid-
ity, mortality, and medication data from Swedish national registries from
patients with ACS alive after discharge from the hospital in 2013. Patients
were categorized by diagnosis of diabetes or not. Chi-squared test was
used to test for statistically significant differences between groups.
Results: In total, 17,135 patients with ACS were identified, 4122 with
diabetes and 13,013 without diabetes, with a median age of 72 vs.
71 years, respectively. Patients with diabetes more frequently had a his-
tory of more than one myocardial infarction than non-diabetics (20% vs.
11%). Patients with diabetes underwent revascularization less often com-
pared with patients without diabetes (61% vs. 66%). Among patients with
diabetes, 50% were treated with percutaneous coronary intervention
(PCI) vs. 59% of patients without diabetes. However, 11% of patients
with diabetes were treated with coronary artery bypass graft (CABG)
surgery vs. 7% of patients without diabetes. In total, 71% of patients with
diabetes received DAPT vs.76% of patients without diabetes. Among
patients receiving DAPT, a larger proportion of patients with diabetes
were treated with clopidogrel (44%), compared with patients without
diabetes (36%). Consequently, 56% of patients with diabetes received a
newer P2Y12 antagonist (prasugrel or ticagrelor) vs. 64% of diabetic
patients without diabetes. All reported differences between groups were
statistically significant. There was no difference in DAPT duration be-
tween patients with and without diabetes.
Conclusion: Patients with ACS and diabetes were less often
revascularized and less often prescribed DAPT, compared with ACS
patients without diabetes. Among patients receiving DAPT, patients with
diabetes less often received newer P2Y12 antagonists. Possibly, patients
with diabetes could benefit from more frequent revascularization and
from receiving more potent DAPT to prevent future ischemic events.
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No difference in Major Adverse Cardiovascular Events (MACE+)
with Basal Insulin peglispro (BIL) vs comparator insulins in patients
with type 1 or type 2 diabetes
R.M. Bergenstal1, A.M. Lincoff2, Á. Rodríguez3, L. Chen4, Y. Qu4, M.J.
Prince4, B.J. Hoogwerf4;
1International Diabetes Center, Minneapolis, 2Cardiovascular Medicine,
C5 Research, Cleveland, USA, 3Lilly Spain, Avda. Industria 30, Spain,
4Eli Lilly and Company, Indianapolis, USA.
Background and aims: Diabetes mellitus is associated with an
increased risk for cardiovascular disease (CVD). Whether insulin
use contributes to CVD risk is still uncertain. In order to iden-
tify possible differences in CV risk among different insulin ther-
apies, we performed pre-specified meta-analyses across the clin-
ical program for BIL, in which patients were randomised to
treatment with either BIL or comparator insulin (glargine [GL]
or NPH).
Materials and methods: One Phase 2 (12-week) and 6 Phase 3
(26–78-week) studies of BIL compared to GL or NPH were in-
cluded, where more patients were randomised to BIL. The partic-
ipants were diverse with respect to demographics, baseline
glycaemic control, and concomitant disease or medications. For
any potential CV or neurovascular event, relevant medical infor-
mation was collected and provided to an external clinical events
committee, where each instance was prospectively adjudicated by
blinded, independent experts. Cox regression analysis was used to
calculate the estimated risks. The primary endpoint was a com-
posite of adjudicated MACE+ (CV death, nonfatal MI, nonfatal
stroke, or hospitalization for unstable angina).
Results: The pooled population included 5872 patients. Mean age
(SD) was 54.1 (13.3) years; 56% were male, 16% were Hispanic
or Latino, and 5%, 5%, and 88% were Asian, black, or white,
respectively. Baseline demographic and clinical characteristics, in-
cluding use of statins or other lipid-lowering drugs, were compa-
rable between BIL and comparators. A total of 83 patients expe-
rienced at least 1 MACE+ and 70 patients experienced at least 1
MACE (CV death, nonfatal MI, or nonfatal stroke). Overall, there
were no treatment-associated differences in time to MACE+ (haz-
ard ratio [HR] for BIL vs comparator insulin [95% CI]: 0.82
[0.53, 1.27]) or MACE (HR [95% CI]: 0.83 [0.51, 1.33]). Al-
though there were only 12 MACE+ in patients with T1D, the
HR favoring BIL was statistically significant (table). There were
no differences in the incidence rates for MACE+, MACE and all-
cause death between BIL and comparators. Sub-group analyses
did not identify any population with increased treatment-
associated risk.
Conclusion: Treatment with BIL vs comparator insulin in patients with
T1D or T2D was not associated with increased risk for major CVevents.
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Clinical Trial Registration Number: NCT01027871, NCT01435616,
NCT01790438, NCT01468987, NCT01481779, NCT01454284,
NCT01582451
Supported by: Eli Lilly and Company
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Recruitment of beta cells during glucose stimulation in mouse pan-
creas tissue slices
D. Jurij1, M. Skelin Klemen1, M. Slak Rupnik2, A. Stožer1;
1Institute of Physiology, Medical Faculty, Maribor, Slovenia, 2Medical
University Vienna, Austria.
Background and aims: Beta cells in the islet of Langerhans respond to
glucose with a tonic increase in intracellular calcium concentration
([Ca2+]i), with superimposed high frequency [Ca2+]i oscillations. The
pattern of activity is aligned across different cells due to gap-junctional
coupling between cells. We recently introduced functional multicellular
[Ca2+]i imaging (fMCI) to study [Ca2+]i changes in a large number of
beta cells from all layers of an islet in acute pancreas tissue slices. In the
present paper, we describe how stimulus strength (i.e., glucose concen-
tration) modulates parameters of the [Ca2+]i response in populations of
beta cells in islets of Langerhans of NMRI mice.
Materials and methods: [Ca2+]i patterns in beta cells were obtained
using confocal fMCI imaging in acute mouse pancreas tissue slices. Islets
of Langerhans were loaded with the fluorescent calcium indicator Oregon
Green 488 BAPTA-1 and stimulated with different concentrations of
glucose in the form of pulses of a single stimulatory concentration and
staircase stimulations with increasing or decreasing concentrations. Re-
gions of interest were selected based on cell morphology and further
analyzed for cell activity off-line.
Results: Glucose dependence of the [Ca2+]i response is very steep. Beta
cells in an islet start to activate at 7 mM glucose and all cells are active at
10 mM glucose (EC50=8 mM glucose). The onsets of [Ca2+]i responses
are delayed relative to the beginning of stimulation and this delay depends
on glucose concentration. During stimulationwith 7mMglucose, all cells
that become active at this concentration are recruited over a period of
25 minutes. Increasing the concentration improves the synchrony of the
response onsets. At 12 mM glucose, the last cells that respond to this
concentration responded 7 minutes after stimulation onset. Similarly to
the increase in basal [Ca2+]i, the superimposed high frequency oscilla-
tions depend on concentration of glucose. Two crucial parameters of the
superimposed oscillatory behavior, namely frequency and duration of
oscillations, respond to an increasing concentration of glucose such that
the former gradually increases from 7 to 12 mM glucose and declines
beyond this concentration (16 mM), whereas the latter continuously in-
creases with increasing glucose concentrations.
Conclusion: Combining fMCI and the acute tissue slice technique, we
were able to study the reponses of large populations of beta cells to
different stimulatory concentrations of glucose in situ. Glucose modulates
both the basal [Ca2+]i response and the superimposed [Ca2+]i oscilla-
tions. Increasing glucose concentrations recruit cells within an islet in a
concentration and time dependent manner. The dose-response curve is
very steep, with an EC50 of 8 mM. In addition the frequency of
superimposed [Ca2+]i oscillations as well as the duration of oscillations
increase across the physiological range of concentrations (7-12 mM).
Taken together, this indicates that at low levels of stimulation (7-
9 mM), recruitment of beta cells significantly contributes and is arguably
the most important mechanism of response to increasing concentrations
of glucose, whereas at higher concentrations (9-16), the increased fre-
quency and duration of oscillations are the predominate. Our findings
might have important implications for responsiveness under pathological
conditions when concentrations of glucose progressively increase.
Supported by: ARRS, COREUM
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Porcine neonatal islets with eGFP-labeled beta cells as novel tool in
diabetes research
E. Kemter1, A. Wolf2, A. Wuensch1, M. Kurome1, B. Kessler1, V.
Zakhartchenko1, M. Loehn2, Y. Ivashchenko2, A. Schulte2, E. Wolf1;
1Chair for Molecular Breeding and Biotechnology, GeneCenter, LMU
München, Munich, 2Diabetes Division, Sanofi-Aventis, Frankfurt, Ger-
many.
Background and aims: Due to the easy availability of pancreata of pigs
and high similarity between porcine and human islets, porcine islets
might be of great interest for studying beta-cell biology and for screening
compounds affecting beta-cell proliferation and function. Further, avail-
ability of efficient tools of genetic modification in pigs enables specific
labeling of beta-cells by fluorescent reporter gene expression for in vivo
imaging of islets and FACS sorting of beta-cells.
Materials andmethods:We established a routine procedure for isolation
of porcine neonatal islet cell clusters (NICCs). Briefly, pancreata of pig-
lets (<8 days old) wereminced and shortly digestedwith collagenase. The
suspension was sieved through a 500-μm mesh and exocrine cells were
removed within the first three days in culture. Best culture conditions
proved to be recovery media of Ham’s F12/M199 with additives of pro-
tease inhibitors, antioxidants and additional nutrients for the first three
post-isolation days followed by maturation media of Ham’s F10 with
IBMX. After in vitromaturation, NICCs were characterized by immuno-
fluorescence (IF) analysis, glucose stimulated insulin secretion (GSIS)
assays, and proliferation assays. To generate islets donor pigs with eGFP
labeled beta-cells, porcine kidney cells were transfected with a porcine
INS promoter-eGFP expression vector, pools of stable transfected cell
clones were used for somatic cell nuclear transfer (SCNT), and cloned
embryos were transferred to recipient gilts. Offspring were genotyped by
PCR and Southern blot analysis and characterized for reporter gene
expression.
Results: Our isolation protocol facilitated a yield of 10-30 thousand
NICCs per donor piglet (culture day 5). IF analysis demonstrated that
NICCs contained similar proportions of insulin- and glucagon-positive
cells. GSIS assays revealed on average 3.2-fold increased insulin secre-
tion in high- vs. low-glucose medium. NICC derived beta-cell prolifera-
tion was significantly (p<0.001) increased by a GSK3β inhibitor and
significantly (p<0.001) impaired by a CDK4 inhibitor. A total of 12 live
INS-eGFP transgenic founder piglets were born, with a total of 10 differ-
ent transgene integration patterns. Fluorescence microscopy and immu-
nohistochemistry for GFP in sections of pancreas and a panel of other
tissues demonstrated islet-specific transgene expression. Consistent with
these results, isolated NICCs of the transgenic founder pigs showed dif-
ferent levels of eGFP fluorescence (1 strong, 1 weak, all others interme-
diate). Double-immunofluorescence analysis identified eGFP expression
specifically in the beta-cells; eGFP was neither detected in glucagon
positive alpha-cells nor in somatostatin positive delta-cells. Two founders
with high and intermediate beta-cell specific eGFP expression were suc-
cessfully reproduced by SCNT to set up breeding lines of donor pigs for
large-scale NICC isolation.
Conclusion: Porcine islets expressing beta-cell specific eGFP marker
protein will enable in vivo imaging of islets, e.g. in the setting of islet
transplantation. Further, eGFP-labeled beta-cells enable efficient and spe-
cific FACS sorting of beta-cells which may provide a useful screening
system for compounds affecting beta-cell proliferation and function.
Supported by: Sanofi-Aventis
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Electrophysiological characterisation of the human beta cell line
EndoC-βH2
B.Hastoy1, M. Chibalina1, M. Godazgar1, R. Scharfmann2, P. Rorsman1;
1Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford
University, Headington, UK, 2INSERM U1019, Cochin Institute,
Universite Paris Descartes, Paris, France.
Background and aims: We have characterised the novel human beta
cell- line EndoC-βH2 in terms of glucose-induced insulin secretion
(GISS), depolarization-evoked exocytosis and properties of voltage-
gated ion channels.
Materials and methods: Insulin secretion was tested by static incuba-
tions. Secretion rates have been normalised to insulin content. Cytosolic
calcium levels ([Ca2+]i) were monitored in cells transfected with the ge-
netically encoded calcium sensor GCaMP5. Exocytosis was assessed by
whole-cell capacitance measurement. Membrane potential and currents
were recorded using the perforated patch or standard whole-cell config-
uration of the patch-clamp technique. Membrane currents were isolated
using specific blockers.
Results: Basal insulin secretion at 1 mmol/l glucose amounted to 2%.
Glucose (6 or 20 mmol/l) stimulated insulin secretion 1.5- (p<0.05) to 2-
fold (p<0.01), respectively. This was associated with initiation of action
potential firing and elevation of [Ca2+]i. The effects of glucose on insulin
secretion, electrical activity and [Ca2+]i were mimicked by tolbutamide
(0.5 mmol/l) and reversed by diazoxide (0.2 mmol/l), consistent with a
key role of ATP-regulated potassium channels. Forskolin potentiated
GISS evoked by 6 mmol/l glucose ~3-fold. Exocytosis, evoked by a train
of ten 500 ms depolarizations, was biphasic with the largest responses
occurring during the initial 3 depolarizations with subsequent depolariza-
tions eliciting progressively smaller responses. The cumulative increase
of capacitance is of 15fF.pF-1 (increase in cell capacitance normalized to
cell size, n=9). The contribution of different voltage-gated calcium chan-
nels to calcium entry was evaluated using an action potential-like voltage-
clamp command (based on spontaneous glucose-induced action poten-
tials recorded in EndoC-βH2 cells). The inward current evoked by the
action potential waveform amounted to 8pA.pF-1 (n=7) of which 10%
was due to tetrodotoxin (TTX)-sensitive sodium channels, 10% due to
SNX482-sensitive R-type calcium channels with the remaining 80% at-
tributable to isradipine-sensitive and ω-agaotoxin-sensitive L- and P/Q-
type calcium channels.
Conclusion: The complement of voltage-gated ion channels in EndoC-
βH2 is very similar to that seen in primary human beta-cells.We conclude
that EndoC-βH2 cell line is good glucose-sensitive model of insulin
secretion and electrical activity of primary human beta-cells.
Supported by: MRC and the Wellcome Trust
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Human pancreatic microislets as a standardised model for glucose-
stimulated insulin and glucagon secretion
E.-M. Andersson, I. Ahlstedt, M. Sörhede-Winzell, C. Ämmälä;
Diabetes Bioscience, AstraZeneca R&D, Mölndal, Sweden.
Background and aims: Isolated human pancreatic islets represent a use-
ful tool to study islet function and hormone secretion in vitro. Neverthe-
less, insulin response to glucose is known to vary considerable between
different donor preparations, and glucagon secretion is challenging to
measure in primary human islets. In addition to this, both donor charac-
teristics and isolation procedures add inconsistency regarding islet size
and function. The aim of this study was to evaluate InSight™microislets
from InSphero as an alternative model to primary human islets for the
assessment of insulin and glucagon secretion.
Materials and methods: The assay-ready 3D InSight™ Human Pancre-
atic Microislets are produced from dispersed human islets using the
hanging-drop technique and delivered with one microislet per well in a
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96-well GravityTRAP™ plate. Three different lots/donors were evaluat-
ed with the focus on insulin and glucagon secretion. The microislets’
ability to regulate insulin and glucagon release in response to glucose
was measured at different occasions up to three weeks after delivery.
The possibility to re-use the microislets was also evaluated. Insulin and
glucagon levels were measured after two hours of stimulation with dif-
ferent glucose concentration (2.8-22.2 mM), with or without addition of
the glucagon-like peptide 1 (GLP-1) analogue Exendin-4 (10 nM), and
measured using hormone specific ELISA kits (Mercodia). In order to
expose the islets to a diabetogenic milieu, high glucose (22.2 mM) and
interleukin 1β (IL-1β, 20 ng/ml) were added. Glucose-stimulated insulin
secretion (GSIS) was measured after 24 hours of incubation in high glu-
cose conditions. In parallel experiments human primary islets were ex-
posed to the same conditions and GSIS measured. Briefly, five islets/well
were transferred into a 96 well plate and insulin secretion was measured
after 1 h incubation in 2.8 or 11.1 mM glucose.
Results: Both insulin and glucagon secretion could be readily measured
in all three lots of microislets. The half maximal effect of glucose (EC50)
in stimulation of insulin secretion was 7.1 mM (n=6) while the EC50 for
inhibition of glucagon secretion was 2.1 mM (n=3). The microislets
responded to Exendin-4 with a modest but stable 1.4±0.05 fold increase
in insulin secretion (11.1 mM glucose). The microislet plates could be re-
used for hormone secretion experiments at least two times during the
three week period tested, with similar insulin and glucagon responses to
glucose. Diabetogenic culture conditions reduced the insulin secretion
stimulation index (11.1 mM glucose/2.8 mM glucose) from 16.6±1.4 in
microislets cultured at 5.8 mM glucose, to 1.9±0.3 after cultured in high
glucose (22.2 mM) and to 1.6±0.3 in microislets with high glucose + IL-
1β pre-treatment. This was comparable to a similar experiment using
primary human islets with corresponding stimulation indices; 17.4, 1.7
and 1.5. In both preparations, the decreased stimulation index was a
consequence of both increased basal secretion (2.8 mM) and decreased
capacity to secrete insulin upon glucose stimulation (11 mM).
Conclusion: The human pancreatic microislets constitute a robust and
reproducible tool for islet research where both insulin and glucagon se-
cretion can easily be measured in a 96-well plate format in the same
experiment. There was no apparent difference in GSIS between the
microislets compared to primary human islets.
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Defining the islet ‘GPCR peptidome’: quantification and functional
modelling of all GPCR peptide ligand signalling pathways in human
and mouse islets
S. Amisten, R. Hawkes, P. Atanes, G. Huang, S. Persaud;
King's College London, UK.
Background and aims: Human islets express 293 G-protein coupled
receptors (GPCRs), and 110 of these GPCRs (37.5%) have polypeptides
(‘peptides’) as ligands. Autocrine GPCR signaling in islets, where islet
cells express both a receptor and its cognate ligand, plays an important
role in regulating islet function. Some islet autocrine signaling pathways
are well characterised (e.g. glucagon/glucagon receptor, serotonin/
serotonin receptors) but no systematic study has been undertaken to de-
fine the human and mouse islet ‘GPCR peptidomes’ and to define how
similar the human and mouse GPCR peptidomes are. The aim of this
study is to quantify the expression of all known human GPCR peptide
ligands and their mouse orthologs and to create an atlas describing all
known islet GPCR/peptide ligand signaling pathways in human and
mouse islets.
Materials and methods: Human islets were isolated from heart beating
donors at our islet isolation centre.Mouse isletswere isolated from 8week
old male ICR mice using collagenase digestion and handpicked. mRNA
was extracted from islets using the TRIzol method and reverse transcribed
into cDNA. Peptide ligand mRNA expression was quantified relative
GAPDH by quantitative real-time PCR. An atlas of all GPCR/peptide
ligand signaling pathways was constructed by manually extracting data
from guidetopharmacology.org and PubMed.
Results: The expression of 138 GPCR peptide ligand genes (encoding
212 mature GPCR peptide ligands) was quantified in human islets, and
mRNAs of 114 (82.6%) GPCR peptide ligand genes (encoding 173 ma-
ture GPCR peptide ligands) were found to be expressed in human islets.
Mouse equivalents exist of 126 (91.3%) of the 138 human GPCR peptide
ligands, as the remaining 12 (8.7%) GPCR peptide ligand genes are
absent from the mouse genome. mRNAs of 102 (81%) GPCR peptide
ligand genes, encoding 163 different GPCR peptide ligands, were
expressed in mouse islets. The 10 most abundant GPCR peptide ligand
mRNAs in human islets are: glucagon (GCG)>somatostatin (SST)>
amylin (IAPP)>pancreatic polypeptide (PPY) >>neuropeptide Y
(NPY)>interleukin-8 (CXCL8)>ghrelin (GHRL)>Wnt protein 4
(WNT4)>Complement 3a (C3)>angiotensin (AGT). In mouse islets,
the 10 most abundant GPCR peptide ligand mRNAs are: glucagon
(Gcg)>amylin (Iapp)>somatostatin (Sst)>pancreatic polypeptide (Ppy)
>>peptide YY (Pyy)>urocortin 3 (Ucn3)>R-spondin-4 (Rspo4)>
dynorphin (Pdyn)>neuropeptide Y (Npy)>Wnt protein 4 (Wnt4). A de-
tailed islet pathway atlas outlining all auto- and exocrine signaling path-
ways involving GPCRs and peptide ligand in human and mouse islets
was constructed. 323 GPCR/peptide signaling pathways were identified
in human islets, consisting of 239 (74%) autocrine and 84 (26%) exocrine
signaling pathways. In mouse islets, 283 GPCR/peptide signaling path-
ways were identified, made up of 249 (88%) autocrine and 34 (12%)
exocrine pathways.
Conclusion: Human and mouse islets express a large number of
peptide ligands of G-protein coupled receptors. Although the hu-
man and mouse islet GPCR peptide ligand repertoires seem sim-
ilar at a first glance, there are fundamental differences in both
peptide mRNA expression levels and auto- and exocrine signaling
pathways. These differences are very likely to influence islet
function, so great caution is warranted when translating mouse
islet functional data to a human islet context.
Supported by: EFSD/Boehringer Ingelheim
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Reduced glucose-stimulated insulin release from human type 2 dia-
betic islets associates with multiple metabolomic changes in the
secretome
M. Suleiman1, M. Bugliani1, L. Marselli1, J. Cobb2, M. Occhipinti1, P.
Marchetti1, E. Ferrannini3;
1University of Pisa, Italy, 2Metabolon, Inc., Durham, USA, 3CNR Insti-
tute of Clinical Physiology, Pisa, Italy.
Background and aims: Beta cell insulin secretory failure is the hallmark
of type 2 diabetes (T2D). The associated molecular changes are still
largely unclear in the beta cell.
Materials and methods: We evaluated glucose-stimulated insulin re-
lease (by the batch sequential incubation method - 45 min), metabolomic
features in the secretome (using a screening metabolomic platform), and
gene expression profiles (with beta cells obtained by laser capture micro-
dissection) of islets from 17 non-diabetic (ND; 10 males/7 females; age:
68±17 yrs; BMI: 26.0±3.4 Kg/m2) and 14 T2D (12 males/2 females;
age: 74±7 yrs; BMI: 26.0±3.1 Kg/m2) organ donors.
Results: Insulin release (μU/ml) at 3.3 mmol/l glucose was 35±19 with
ND and 41±42 with T2D islets (NS), and increased respectively to 188±
95 and 47±52 in response to 16.7mmol/l glucose (p<0.01). Accordingly,
stimulation index was 5.6±1.4 with ND and 1.1±0.1 with T2D islets (p<
0.01). Compared to ND islets, T2D islets showed a significant (p≤0.05)
retention of glucose and release of aminoacids (glycine, alanine, phenyl-
alanine, serine). Furthermore, T2D islets released significantly (p=0.02)
more citrate into the incubation medium. Array data from ND and T2D
beta cells, showed significantly decreased expression of enolase 1, mito-
chondrial aconitase 2, ATP citrate lyase, and dihydrolipoamide
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dehydrogenase, and increased expression of aldolase B, lactate dehydro-
genase A, phosphoenolpyruvate carboxykinase and oxoglutarate
dehydrogenase.
Conclusion: Taken together, these results are compatible with metabolic
overload and alterations of the late glycolytic and TCA cycle pathways in
human T2D beta cells. If corrected, these changes could lead to improved
glucose-stimulated insulin secretion.
OP 24 Brain reward and satiety
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Brain reward-system activation in response to anticipation and con-
sumption of palatable food is altered byGLP-1 receptor activation in
humans
L. van Bloemendaal1, D.J. Veltman2, J.S. ten Kulve1, P.F.C. Groot3,
H.G. Ruhé4, F. Barkhof5, J.H. Sloan6, M. Diamant1, R.G. IJzerman1;
1Diabetes Centre/Internal Medicine, 2Department of Psychiatry, VU Uni-
versity Medical Centre, 3Department of Radiology, Academic Medical
Center, 4Department of Psychiatry, Academic Medical Center, 5Depart-
ment of Radiology & Nuclear Medicine, VU University Medical Centre,
Amsterdam, Netherlands, 6Lilly Research Laboratories, Eli Lilly and
Company, Amsterdam, USA.
Background and aims: It has been suggested that obese individuals have
increased brain reward system activation while anticipating food intake,
which may lead to cravings for food, and decreased reward system acti-
vation during actual food consumption, which may induce overeating.
Gut-derived hormones, such as glucagon-like peptide-1 (GLP-1), are
likely involved in the regulation of food intake. GLP-1 receptor agonists
improve glycaemic control and reduce food intake and body weight. We
hypothesised that food intake reduction following GLP-1 receptor acti-
vation is mediated through brain areas regulating anticipatory and con-
summatory food reward.
Materials andmethods:Obese T2DMpatients (n=16; mean ± SD; BMI
34±4 kg/m2; HbA1C 6.9±0.9%, 8 males), age- and gender-matched
normoglycaemic obese (n=16; BMI 33±3 kg/m2) and lean individuals
(n=16; BMI 23±1 kg/m2) were studied in a randomised, crossover,
placebo-controlled trial. Using functional MRI, we determined the acute
effects of GLP-1 receptor activation on brain responses to anticipation
and receipt of chocolate milk vs. tasteless solution. All subjects
underwent three functional MRI sessions at separate visits with intrave-
nous infusion of A) the GLP-1 receptor agonist exenatide, B) exenatide
with prior GLP-1 receptor blockade by exendin 9-39 or C) placebo;
during somatostatin pituitary-pancreatic clamps (glucose 5 mmol/L).
We assessed the effects of BMI and GLP-1 receptor activation on brain
responses in areas regulating reward, appetite and motivation (putamen,
caudate nucleus, amygdala, insula and orbitofrontal cortex).
Results: BMI was negatively correlated with brain responses to receipt of
chocolate milk and positively correlated with anticipation of receipt of
chocolate milk in brain areas regulating reward, appetite and motivation
(P<0.005). Exenatide vs. placebo increased brain responses to receipt of
chocolate milk and decreased anticipation of receipt of chocolate milk (P<
0.005). Exenatide vs. placebo reduced caloric intake during a subsequent
choice buffet by 23% in lean subjects, by 24% in obese subjects and by
14% in obese T2DM patients. The exenatide-induced effects on brain ac-
tivations and caloric intake were largely prevented by exendin 9-39.
Conclusion: GLP-1 receptor activation decreased anticipatory food re-
ward, which may reduce cravings for food, and increased consummatory
food reward, which may prevent overeating. Our findings provide novel
insights into the mechanisms by which GLP-1 regulates food intake and
how GLP-1 receptor agonists induce weight loss.
Clinical Trial Registration Number: NCT01281228
Supported by: Eli Lilly / BMS / AstraZeneca
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Insulin sensitisation normalises brain processing of satiation in non-
obese insulin resistant men
Y.S. Cheah1,2, S. Lee1,3, F.O. Zelaya3, S.A. Amiel1,2;
1Diabetes Research, King's College London, 2Diabetes Centre, King's
College Hospital NHS Foundation Trust, 3Department of Neuroimaging,
Institute of Psychiatry, Psychology & Neuroscience, King's College Lon-
don, UK.
Background and aims: Altered activity of brain networks involved in
appetite regulation are implicated in the aetiology of diabetes and obesity,
conditions associated with insulin resistance. We characterised the effects
of early systemic insulin resistance and the impact of insulin sensitisation
on pre- and post-prandial brain activity in non-obese men.
Materials and methods: 16 healthy right-handed insulin resistant (IR)
and 17 insulin sensitive (IS) men (HOMA2-IR 1.6±0.3, 0.5±0.1, age
34.9±10.2, 33.3±7.1 years, BMI 26.2±2.3, 24.2±1.9 kg/m2, respective-
ly) were studied twice in random order. Regional cerebral blood flow
(CBF), a surrogate marker of resting neuronal activity, was measured
using continuous arterial spin labelling magnetic resonance imaging in
a 1.5 T MRI scanner before (-14 to -8 minutes) and after (0 to +6, +8 to
+14, and +34 to +40 minutes) consuming 50 ml water or 630 kcal mixed
meal after an overnight fast. Subjective measures of appetite were col-
lected on a visual analogue scale after each scan. IR then completed
3 months metformin therapy with lifestyle advice before repeating MRI
studies. Statistical parametric analysis of whole-brain CBF was per-
formed using SPM-8. A cluster-forming uncorrected threshold of Z>
2.31 was used, with clusters surviving statistical significance (p<0.05),
corrected for multiple comparison.
Results: Within-group analyses showed no differences between pre-
water and pre-meal CBF. Compared to water, food reduced CBF in cen-
tres that provide inhibitory control of eating (dorsolateral prefrontal cor-
tex, DLPFC) in IR and in visual processing centres (lingual gyrus) in IS.
Between-group analyses showed greater CBF in regions involved in he-
donic processing (orbitofrontal, anterior cingulate cortices) in IR than IS
before the meal and throughout the water study. After food, IR showed
lower CBF in the default mode network (precuneus) and greater CBF in
regions involved in processing interoceptive awareness (insula) than IS.
In IR, insulin sensitisation improved HOMA2-IR (1.34±0.46, vs pre-
treatment p=0.02) and increased fullness (p=0.02). Post-treatment, IR
no longer showed a fall in DLPFC CBF post-meal compared to post-
water. Compared to pre-treatment, the intervention was associated with
decreased pre-ingestion CBF in the default mode network (posterior cin-
gulate cortex) and in regions involved in memory and energy regulation
(hippocampus) and increased it in lingual gyrus and reward processing
centres (striatum), with similar findings post-water, whilst post-meal CBF
decreased in insula and increased in striatum. Regression analyses
showed a negative association between changes in HOMA-IR and post-
meal CBF in striatum, where greatest improvements in insulin sensitivity
were associated with greatest increases in striatal CBF.
Conclusion: In non-obese men with systemic insulin resistance, altered
responses of brain regions involved in reward processing and hedonic eval-
uation, inhibitory control and interoception in anticipation of and in re-
sponse to meal ingestion may promote excessive eating behaviours. Strat-
egies that improve systemic insulin resistance ameliorate these alterations in
ways that could improve satiation, enhancing appetite control. This mech-
anism may offer a target for preventing weight gain and diabetes.
Supported by: Diabetes UK, King's College Hospital Charity
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Differences in brain responses to visual food stimuli among monozy-
gotic twins discordant for BMI
S. Doornweerd1, R.G. IJzerman1, L. van Bloemendaal1, F. Barkhof2,
D.J. Veltman3, E.J. de Geus4;
1Diabetes Centre / Internal Medicine, 2Department of Radiology and
Nuclear Medicine, 3Department of Psychiatry, 4Biological Psychology,
Amsterdam, Netherlands.
Background and aims: It has been suggested that increased central
reward and satiety responses to food stimuli play an important role in
the development of obesity. Since our genetic variation has not changed
substantially in the past decades, the recent increase in obesity rates is
assumed to be driven by changes in the environment. Therefore, we
aimed to investigate to what extent the previously observed increases in
central reward and satiety responses to food cues in obese individuals are
influenced by environmental factors.
Materials andmethods:Monozygotic twins discordant for BMI provide
a unique opportunity to investigate the effects of environmental factors on
obesity, since these subjects share an identical genetic background. We
included fifteen rare female monozygotic twin pairs from the Netherlands
Twin Register, with a mean age of 49.0±9.7 and a mean BMI difference
of 4.18±1.9 kg/m2 in a cross-sectional study. We measured neural activ-
ity in reward and satiety related brain areas in response to visual food
stimuli, using functional magnetic resonance imaging (fMRI), after an
overnight fast. Subjects were presented pictures of high-calorie food,
low-calorie food and non-food items. Imaging data were analysed using
SPM8 and activation contrasts were computed (food versus non-food and
high-calorie food versus non-food).
Results: In all subjects the viewing of food versus non-food pictures and
high-calorie versus non-food pictures resulted in activation of limbic
brain areas, such as amygdala, insula and orbitofrontal cortex, measured
as changes in blood oxygen level dependent (BOLD) signal. When com-
paring leaner and heavier co-twins, no differences in brain activation were
found when watching food versus non-food pictures. However, when
watching high-calorie food versus non-food pictures, the heavier co-
twins showed decreased, not increased, brain activation compared to their
leaner co-twins within right orbitofrontal cortex, left insula and left cau-
date nucleus.
Conclusion: Contrary to previous studies in singletons, we found no
increased brain activation in response to food versus non-food pictures
in heavier compared to leaner individuals as measured with fMRI in a co-
twin control study using monozygotic twins discordant for BMI. Indeed,
in response to high-calorie food versus non-food pictures a decreased, not
increased activation was found in heavier versus leaner co-twins. The
increased activation in obese individuals observed in previous studies
may reflect an influence of genetic factors on brain responses to food.
The contradictory higher activation in leaner versus heavier co-twins in
responses to high-calorie versus non-food pictures may be explained by
an acquired higher attention to foods that are consciously being avoided
in lean individuals in attempt to remain thin despite one’s inherited risk of
weight gain. Future studies should investigate the influence of genetic
factors on previously observed increased brain responses to food in obese
individuals.
Clinical Trial Registration Number: NCT02025595
Supported by: Netherlands Organisation Scientific Research
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Leptin-substitution increases connectivity in reward-related brain
areas in patients with congenital lipodystrophy
H. Schlögl1, K. Müller2, A. Horstmann2, K. Miehle1, B. Pleger2, H.
Möller2, A. Villringer2, M. Faßhauer1, M. Stumvoll1;
1University of Leipzig, Faculty of Medicine, 2Max-Planck-Institute for
human Cognitive and Brain Sciences Leipzig, Germany.
Background and aims: In patients with congenital lipodystrophy (LD)
leptin serum concentrations are reduced, serum triglycerides high and pa-
tients often suffer from a severe diabetes with high insulin demands. Fur-
thermore, LD patients can develop a disturbed hunger/satiety regulation:
after the consumption of a meal, satiety lasts only a short period of time,
leading to short intervals between meals. To assess long term effects of
leptin substitution on eating behavior and related brain connectivity in treat-
ment naïve patients with congenital LD, we performed resting-state func-
tional MRI (fMRI) before and during the initial 52 weeks of treatment.
Materials andmethods: The study included eight leptin-treatment naïve
LD patients (six females, age 36±4 y, BMI 27±2 kg/m2). MRI scannings
were performed before leptin supplementation, and after one, four, 12, 26,
and 52 weeks of treatment. In each session, patients consumed a meal
consisting of 20% of their daily energy requirements. Before and after the
meal, patients rated satiety feelings using 100 mm visual analog scales
(VAS, 0 mm=no satiety; 100 mm=extreme satiety).
Results: Glycated haemoglobin (HbA1c) decreased by 17.1% after
52 weeks of leptin treatment (before leptin treatment 8.3±0.6%, after
52 weeks 6.7±0.5%, p=.13). Satiety ratings after the standard meal in-
creased from 65±10 mm to 93±2 mm, p=.04 after 26 weeks and 71±
11mm, p=.55 after 52weeks. FMRI analysis showed connectivity increases
in nucleus accumbens bilaterally (T=4.17/4.38), medial frontal gyrus (T=
4.77), and hypothalamus (T=4.85) over the 52 weeks of treatment (Figure).
Conclusion: After leptin substitution, patients anecdotically described
longer periods of satiety and reduced meal frequencies. Consistently,
leptin treated patients showed increased satiety ratings in the VAS after
a meal. Under leptin treatment, we also observed an increase of functional
connectivity in nucleus accumbens, an important player in the dopami-
nergic reward system, suggesting a modulation of this network by leptin.
Furthermore, we found an increased connectivity of the hypothalamus,
the homeostatic control center of the brain, where humoral information
from the body converges (Figure).
Supported by: DFG (SFB 1052), BMBF (IFB Adiposity diseases)
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Specific deletion of lipoprotein lipase in ventromedian hypothalamus
induces obesity and impairment of glucose homeostasis in mice
E. Laperrousaz, V.S. Moullé, N. Kassis, R.G. Denis, S. Luquet, C.
Magnan, C. Cruciani-Guglielmacci;
University Paris Diderot, France.
Background and aims: The Lipoprotein Lipase (LPL) is the key enzyme
of triglycerides (TG) hydrolysis of chylomicrons and VLDL, allowing the
storage of the TG in the adipose tissue. It also has a crucial role in the
Central Nervous System (CNS) in the control of the energy balance: a
neuronal deletion of LPL leads to the onset of obesity and a modification
of locomotor activity and energy expenditure. We studied here its specific
deletion in the ventro-median hypothalamus (VMH), an area known to
control food intake and peripheral glucose homeostasis via the autono-
mous nervous system.
Materials and methods:We injected in the VMH of LPL lox/lox mice
(and controls) an Adeno Associated Virus, expressing the fusion protein
Cre-GFP, to get a specific and localized deletion of LPL. We measured
food intake, time course of body weight, body composition, and meta-
bolic parameters ( by indirect calorimetry) and performed glucose and
insulin tolerance tests. Tests and tissues sampling were performed at
10 days post injection (10d, before the onset of obesity) or 12 weeks post
injection (12w, massive obesity).
Results:Compared toWT, LPLVMH -/- mice have a significant increase
of body weight 15 days post injection, without any hyperphagia. Obesity
is massive at 12w and associated with insulin resistance and glucose
intolerance. They show already at 10d post injection a significant de-
crease of locomotor activity, a decreased respiratory quotient during
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24 h of fasting, and an increased food intake during refeeding. Early
deregulation of insulin sensitivity is also present at 10d. Analysis of gene
expression shows an early modulation of enzymes of ceramides metabo-
lism and of FATP1 transporter.
Conclusion: A decrease of LPL hypothalamic activity leads to obesity
associated with deregulation of glucose homeostasis. This phenotype is
not linked to hyperphagia but likely to a modulation of locomotor activity
and energy metabolism. Fine modulations of hypothalamic nervous ac-
tivity (potentially due to intracellular variations, quantitative or qualita-
tive, of cerebral ceramides content) could explain this phenotype.
Supported by: EFSD/Lilly Fellowship
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GLP-1R activation by exendin-4 prevents neuronal loss in the
piriform cortex of type 2 diabetic rats
G. Lietzau1,2, V. Darsalia1, C.-G. Östenson3, T. Nyström1, C. Patrone1;
1Department of Clinical Science and Education, Karolinska Institutet,
Södersjukhuset, Internal Medicine, Stockholm, Sweden, 2Department of
Anatomy andNeurobiology,Medical University of Gdansk, Poland, 3De-
partment of Molecular Medicine and Surgery, Karolinska Institutet,
Stockholm, Sweden.
Background and aims: Type 2 diabetes (T2D) accelerates the progres-
sion of cognitive decline and neurodegenerative diseases such as
Alzheimer’s (AD) and Parkinson’s (PD). Impaired olfactory function,
which is an early symptom of AD and PD has also been associated with
T2D. The piriform cortex is a crucial area involved in the regulation of
olfaction that has been shown to be vulnerable in AD and PD. However,
olfactory dysfunction in T2D has not been previously linked to a specific
brain neuropathology on histological and quantitative level. Aim of this
study was to determine potential neuronal cell loss in the piriform cortex
of T2D rats along aging. Others and we have recently shown that antidi-
abetic drugs targeting the Glucagon-like receptor 1 (GLP-1) are neuro-
protective and can counteract neurodegeneration. Thus, we determined
whether GLP-1R agonist Exendin-4 was able to counteract the T2D-
induced neuronal loss.
Materials and methods: Young 3-month-old and middle-aged 13-
month-old T2D Goto-Kakizaki (GK) rats were compared to age-
matched Wistar rats (n=6 in each group). Additional groups of GK rats
have been treated with Exendin-4 or vehicle for 4 weeks before sacrifice.
Neuropathological assessments have been performed in the piriform cor-
tex using stereology methods after immunohistochemistry of the specific
neuronal marker NeuN and of the specific interneuronal marker
Calbindin 28 KDa.
Results: The results show a significant decrease of the total neuronal
number in the piriform cortex of GK versus Wistar rats along aging as
assessed by NeuN staining (mean=48,207.4 in GK middle-aged vs.
mean=66,256.9 in Wistar middle-aged; p≤0.01). We also demonstrate
that interneurons positive for Calbindin 28 KDa are particularly vulnera-
ble to the neuronal loss induced by T2D (mean=2,866.5 in GK middle-
aged vs. mean=6,165.2 in Wistar middle-aged; p≤0.001). Interestingly,
the GLP-1R agonist Exendin-4 substantially counteracted the neuronal
loss observed in the piriform cortex of T2D animals as assessed by both
NeuN (mean=47,560.6 in vehicle vs. mean=60,184.0 in Ex-4; p≤0.001)
and Calbindin 28KDa (mean=3,890.2 in vehicle vs. mean=7,439.2 in
Ex-4; p≤0.0001) staining.
Conclusion: Our results indicate neuronal pathology in the piriform cor-
tex of the T2D brain along aging. These results could provide the neural
anatomical basis of olfactory deficits in T2D. In addition, our results
reveal a potentially novel finding at the basis of the detrimental effect of
T2D in neurodegenerative diseases. Finally, by showing that neuronal
loss in the piriform cortex can be pharmacologically counteracted by
GLP1-R activation, our findings support recent research promoting the
use of GLP-1R agonists against neurodegeneration.
Supported by: Diabetesfonden, DRWF, EFSD/Lilly, Frimurarestiftelse,
Hjärt-Lungfonden
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Prepregnancy care for a region: exploring the clinical and economic
effects
A.M. Egan1, A. Danyliv1,2, L. Carmody1, B. Kirwan1, F.P. Dunne1;
1Galway Diabetes Research Centre, 2School of Business and Economics,
National University of Ireland Galway, Ireland.
Background and aims: Prepregnancy care (PPC) has the potential to
reduce the risk of adverse pregnancy outcomes in the setting of
pregestational diabetes. Our aims were to implement and examine the
effectiveness of a regional PPC program on pregnancy outcomes and to
determine whether the additional costs of delivering the program are
balanced against potential savings from averted complications.
Materials and methods: This prospective cohort study included 414
women with type 1 and type 2 diabetes attending five antenatal centers
along the Irish Atlantic Seaboard between January 2006 and December
2014. PPC was offered to all women age 18-40 years via a diabetes
register. Primary outcomes included: neonatal outcomes [shoulder dysto-
cia, congenital malformation, stillbirth/neonatal death, admission to the
neonatal intensive care unit (NICU)], hypertensive disorders of pregnan-
cy, cesarean delivery, use of prepregnancy folic acid and glycemic control
in pregnancy. Comparisons were made between those that did and did not
attend PPC. A cost analysis took into account the direct cost of PPC and
antenatal care delivery along with management of infant complications
during the first 6 months post delivery.
Results: A total of 149 (36%) women attended and 265 (64%) did not
attend PPC. Those women who attended were more likely to take
preconceptual folic acid (97.3% vs 57.7%, p<0.001), have a lower 1st
trimester HbA1c (6.8% vs 7.7%, p<0.001) and not smoke during pregnan-
cy (91.3% vs 83.4%, p=0.03). Their offspring had lower rates of congenital
malformations (0.81% vs 5.24%, p=0.04) and fewer admissions to the
NICU (44.3% vs 62%, p=0.02). There were no significant differences
between groups in relation to the other primary outcomes. Table 1 demon-
strates the difference in average cost of complication treatment for those
who did and did not attend PPC. A delivery in the PPC group was associ-
atedwith an average saving of €3251. Although themajor component of the
difference is that associated with malformations, exclusion of any single
component still yields a significant difference in total cost on the rank-
sum test. When adjusted for age, ethnicity, BMI, smoking and parity, PPC
remains significantly associated with a reduced total cost of €2578. This
fully offsets the average cost of PPC delivery per pregnancy of €449.
Conclusion: A successful regional PPC program was implemented.
Women who attended were better prepared for pregnancy and their off-
spring experienced significantly lower rates of congenital anomalies and
NICU admissions. A significant cost saving is expected per pregnancy,
even in the short-term.
Supported by: Health Research Board of Ireland
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The prevalence and prognosis of gestational diabetes mellitus after
assisted reproductive technology
E. Cosson1, A. Diallo2, B. Merioud1, I. Cédrin1, D. Sandre-Banon1, Y.
Jaber1, I. Banu1, C. Cussac-Pillegand1, P. Valensi1, L. Carbillon1;
1AP-HP, Jean Verdier hospital, 2AP-HP, Lariboisière hospital, Bondy,
France.
Background and aims: Pregnancies after assisted reproductive technol-
ogy (ART) are associated with poor prognosis, includingmore gestational
diabetes mellitus (GDM), perhaps due to confounding factors as age or
twin pregnancies. Whether ART confers a worse prognosis for GDM is
unknown.
Materials and methods: We analyzed the prevalence of GDM and of
GDM-related events (preeclampsia or birth weight ≥4000 g or shoulder
dystocia) in the 18.305 women without known diabetes who delivered in
our hospital between January 2002 and December 2010 after natural
pregnancies (n=17.697) or ART (n=608: 155 ovulation inductions, 453
procedures).
Results: The greater rate of GDM after ART than after natural pregnan-
cies (17.6 vs 14.2%, p<0.05) was driven by ART procedures (18.3%)
rather than by ovulation inductions (15.5%). In multivariate analysis tak-
ing into account the parameters associated with GDM in univariate anal-
yses (French risk factors for GDM including age, body mass index, fa-
milial history of diabetes, history ofGDMormacrosomic child; history of
miscarriage; multi-parity; smoking before pregnancy; hypertension; twin
pregnancy; origin/ethnicity), pregnancies after ART procedures as com-
pared with pregnancies after natural pregnancies or ovulation induction
were still associated with more GDM (odds ratio 1.32 [95% confidence
interval 1.03-1.69], p<0.05). In women without twin pregnancies, the
rate of GDM-related events were different across groups: no GDM
9.0%; natural pregnancies with GDM 14.8%; GDM after ovulation in-
duction 13.0%; GDM after ART procedure 11.4% (p<0.001); as the rate
of caesarian deliveries: 20.3; 27.7; 21.7 and 28.8%, respectively (p<
0.001).
Conclusion: Independently of confounding factors, GDM is more usual
during pregnancies following ART procedures. However, prognosis of
GDM appears to be similar or even better after ovulation induction and
ART procedures as/than after natural pregnancies.
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Predictors of need for insulin therapy in gestational diabetes mellitus
K.A. Scheuneman1, S.H. Koning1, K. Hoogenberg2, M.G. Baas2, B.J.
Schering1, P.P. van den Berg3, K.M. Sollie3, A.J. van Loon4, F.J.
Korteweg4, H.L. Lutgers1, B.H.R. Wolffenbuttel1;
1Department of Endocrinology, University of Groningen, University
Medical Center Groningen, 2Department of Endocrinology, Martini Hos-
pital, 3Department of Gynaecology and Obstetrics, University of Gro-
ningen, University Medical Center Groningen, 4Department of Gynae-
cology and Obstetrics, Martini Hospital, Groningen, Netherlands.
Background and aims: The incidence of Gestational Diabetes Mellitus
(GDM) is increasing, due to an increase in obesity in pregnant women
and more stringent guidelines for screening and detection.
Hyperglycaemia during pregnancy may cause peri- and postnatal compli-
cations for both mother and newborn. This risk may be reduced by
achieving adequate glycaemic control with dietary intervention and/or
insulin therapy. The aim of this study was to identify relevant factors
which predict the necessity of additional insulin therapy during
pregnancy.
Materials and methods: Retrospective cohort study of singleton preg-
nancies of all women with GDM between January 2011 and September
2014 in a teaching and an academic hospital. Patients underwent an 75-
gram OGTT if they had risk factors for GDM or symptoms suggestive of
GDM (e.g. polyhydramnion, large for gestational age). GDM was
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diagnosed if fasting plasma glucose was ≥7.0 mmol/l and/or 2-hour glu-
cose ≥7.8 mmol/l. After GDM diagnosis, instruction for self-
measurement of blood glucose (SMBG) and dietary advice was provided.
Insulin therapy was started if with SMBG fasting glucosewas≥5.3 mmol/
l or if 1-hour postprandial glucose values were≥7.8 mmol/l, despite die-
tary intervention.
Results: A total of 820 women with GDM were referred for treatment.
Their mean (±SD) age was 32±5 years, BMI was 27.7 [IQR 24.0-31.9]
kg/m2. Of them, 460 women (56%) were able to maintain adequate
glycaemic control with dietary restrictions only, while 360 (44%) required
exogenous insulin. Of the women who required exogenous insulin, 142
women (39%) received thrice daily pre-prandial rapid-acting insulin, 164
women (46%) received basal-bolus insulin therapy and 39 women (11%)
received NPH insulin once daily at bedtime. Insulin dose varied from 2 to
80U (median 22 [IQR 12-42]U). Logistic regression analysis showed the
following significant predictors for the need of insulin therapy: history of
GDM, a previous newborn with birthweight>4500 gram or>P95, first-
degree relative with type 2 diabetes, multiparity, mediterranean ethnicity,
pre-pregnancy BMI≥30, and both increased fasting and 2-hour blood
glucose during OGTT. The strongest predictor for insulin therapy was a
fasting blood glucose of≥5.5 mmol/l (RR 6.81 (CI 4.03-11.5, p<0.001).
Maternal age, smoking during pregnancy, history of IUFD, chronic hy-
pertension and other ethnic groups did not predict insulin need. The
prediction model had an explained variance of 16%.
Conclusion: This study developed a prediction model to identify GDM
patients with an increased likelihood for the need for exogenous insulin
therapy. In GDM, fasting glucose≥5.5 mmol/l is the strongest predictor
for the need of insulin therapy.
Supported by: Novo Nordisk Netherlands provided an unrestricted re-
search grant
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Pregnancy outcomes of women with untreated GDM (according to
the WHO 2013 diagnostic criteria)
A. Kun1, J. Tornoczky2, Z. Sudar3, Z. Kerenyi4, A.G. Tabak5,6;
1Department Obstetrics and Gynecology, 2Diabetes Outpatient Clinic,
33rd Department of Internal Medicine, Tolna County Balassa Janos Hos-
pital, Szekszard, 4Diabetes Outpatient Clinic, Toth Ilona Health Service,
Csepel, 51st Department of Medicine, Diabetes Unit, Semmelweis Uni-
versity Faculty of Medicine, Budapest, Hungary, 6Department of Epide-
miology and Public Health, University College London, UK.
Background and aims: Based on the HAPO (Hypoglycemia and Ad-
verse Pregnancy Outcomes) study results, WHO issued new recommen-
dations for the diagnosis of gestational diabetes mellitus (GDM) in 2013.
While the use of the new diagnostic criteria (not yet applied in Hungary)
approximately doubles the prevalence of GDM, there are no Hungarian
data on the pregnancy outcomes of untreated WHO 2013 GDM women.
We aimed to compare pregnancy outcomes of women with untreated
GDM (according to WHO 2013, WHO-GDM) and women with normal
glucose tolerance (NGT).
Materials and methods: During a universal screening program in a
Western Hungarian region 4677 pregnant women (age: 29.6±5.6 years;
mean ± SD) had a 75 g OGTT with the determination of fasting, 60-
minute and 120-minute glucose determination between 16/JAN/2009
and 10/APR/2013. NGT was diagnosed in n=4113, untreated WHO-
GDM in n=445 cases.
Results:UntreatedWHO-GDMwomen were older (1.6, SE 0.3 yrs), had
higher fasting (difference: 1.0, SE 0.02), 60-minute (1.4, SE 0.11), and
120-minute (0.8, SE 0.07 mmol/l) blood glucose, and blood pressure (2.2,
SE 0.5 / 1.4, SE 0.4 mmHg). No difference in marital status, education,
and residency was found (all p>0.05). While weight gain was similar in
both groups (13.1, SE 0.3 vs. 13.0, SE 0.1 kg, p=0.90), GDM newborns
had a higher birthweight (116, SE 26 g). Hypertension during pregnancy
was more frequent in the GDM group (OR 1,44, 95%CI 1,02-2,03), as
well as induced delivery(OR 1.34, 95%CI 1.10-1.64), forceps or vacuum
use (OR 1.31, 95%CI 1.08-1.60), acute cesarian section (OR 1.34, 95%CI
1.10-1.64), and macrosomia (>4000 g, OR 1.64, 95%CI 1.23-2.20). No
difference in the risk of preeclampsia and malformations (p>0.25) was
found.
Conclusion: According to the present analysis, the pregnancy outcomes
of women diagnosed with GDM according to the novel WHO criteria
were worse compared to normal glucose tolerant women. Randomized
controlled trials are required to prove that the treatment of these women
would improve their outcomes.
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The effect of professional continuous glucose monitoring on
glycaemic control and hypoglycaemia in insulin-requiring gestational
diabetes mellitus
S.S. Paramasivam1, A.T.B. Tan1, S.P. Chan1, K. Chinna2, J.
Ratnasingam1, L. Ibrahim1, L.L. Lim1, P. Tan3, S.Z. Omar3, S.R.
Vethakkan1;
1Endocrinology, 2Julius Centre, 3Obstetrics and Gynaecology, University
Malaya Medical Centre, Kuala Lumpur, Malaysia.
Background and aims: Good glycaemic control in gestational diabetes
mellitus (GDM) improves pregnancy outcomes and reduces perinatal
morbidity. Continuous Glucose Monitoring (CGM) is ideal for monitor-
ing glucose levels where tight glycaemic control without hypoglycaemia
is required for short periods of time. CGM has been shown to improve
glycaemic control and pregnancy outcomes in women with pre-
gestational diabetes. However the same has not been established in
GDM. Aim: To determine if professional CGM improves glycaemic con-
trol with less hypoglycaemia in insulin-requiring GDM.
Materials and methods: In this prospective, open-label trial , women
with insulin-requiring GDM, gestation <28 weeks, were randomized to 2
groups. Group 1(CGM) (n=25) underwent professional CGM using the
iPro2 Enlite 6-day sensor at 28, 32 and 36 weeks gestation while Group
2(control)(n=25) did not. Patients in both groups performed 7 point
finger-stick glucose profiles 3×/week, recorded hypoglycaemic
events(symptoms without glucose readings or finger-stick fasting glu-
cose<3.5/non-fasting glucose<4.0 mmol/l) and were reviewed at 1-
2 week intervals. In Group 1, both CGM and finger-stick data were used
to manage diabetes while women in Group 2 were managed based on
finger-stick data alone. HbA1c was measured at weeks 28, 33 and 37.
Euglycaemia on CGMS was defined as 3.5-6.7 mmol/l.
Results: No significant difference was seen in mean age, pre-pregnancy
BMI, HbA1c and total insulin dose between groups at baseline.The con-
trol group had a significant rise in mean HbA1c from week 28(5.27±
0.52%) to 37(5.57±0.57%), while mean HbA1c in the CGM group did
not significantly change fromweek 28(5.08±0.32%) to 37(5.17±0.41%).
The control group also showed a significantly higher mean HbA1c at 33
and 37 weeks compared with the CGM group (5.42±0.58 vs 5.08±
0.37%; 5.57±0.57 vs 5.17±0.41%). There was a significant difference
in mean change in HbA1c between the groups from week 28 to 37(CGM
+0.09%, control +0.31%, p=0.027). 87.5% of patients in the CGM group
had HbA1c <5.6% at 37 weeks compared to only 52% of controls (p=
0.012). Although 58.8% of patients in the CGM group had increased
frequency of hypoglycaemia from week 28 to 37 compared to 37.5% in
controls, mean increase in hypoglycaemia frequency was negligible (<1
in CGM group, not significantly different from control group).Within the
CGM group, mean time spent in euglycaemia significantly rose from the
1st to 3rd CGM (84.6±9.3 vs 88.8±7.0, p=0.016) with significant de-
crease in time spent in hyperglycaemia (12.7±9.9 vs 8.3±6.3, p=0.017).
This was not accompanied by an increase in mean time spent in
hypoglycaemia(2.7±5.0 vs 2.9±3.2, p=NS). There was no significant
difference in mean total insulin dose at 37 weeks between the groups.
Offspring from the CGMgroup had lowermean birth weight compared to
controls (2842.4±448.6 vs 2976.0±473.5, p=NS).
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Conclusion: Women who underwent CGM had significantly better
glycaemic control compared to those who received usual antenatal care
based on finger-stick glucose alone. Our findings suggest that use of
CGM is associated with improvement in maternal glycemic control and
may prove beneficial in management of GDM.
Clinical Trial Registration Number: NCT02204657
Supported by: Endocrine research grant
150
Characteristics and risk factors for large-for-gestational age infants
in a large cohort of pregnant women with type 1 diabetes
A.Morrens1, J. Verhaeghe2, C. Vanhole3, R. Devlieger2, C. Mathieu1, K.
Benhalima1;
1Department of Endocrinology, 2Department of Obstetrics & Gynecolo-
gy, 3Department of Pediatrics, UZ Gasthuisberg, KU Leuven, Belgium.
Background and aims: In women with type 1 diabetes (T1DM) the
prevalence of large-for-gestational age infants (LGA) remains high, de-
spite strict glycaemic control and intensive obstetrical follow-up. Our aim
was to evaluate the prevalence and risk factors for LGA in T1DM in our
university hospital during the last 3 decades.
Materials and methods: Retrospective analysis of the medical files of
pregnant women with T1DM attending our hospital form 01-01-1992 till
31-07-2014. Clinical and biochemical characteristics associated with
LGA were analyzed. Excessive weight gain during pregnancy was de-
fined according to the 2009 Institute of Medicine recommendations. Lip-
id levels were measured before pregnancy or in the first trimester. The
generalized mixed model was used to adjust for several pregnancies over
time in the same women and to adjust for confounders such as weight,
weight gain and Hba1c in de different trimesters.
Results: Over a 22-year period, 259 pregnancies in 180 T1DM women
were identified. Mean diabetes duration of women was 13.7±7.1 years,
with a mean age at delivery of 29.5±5.2 years. Of these women, 33.9%
were overweight, 10.9% were obese before pregnancy and 35.1% had
excessive weight gain. Despite an active policy of pregnancy planning,
10.0% of women had unplanned pregnancies. HbA1c before pregnancy
was 6.9±0.9%, dropping to 6.6% ±0.8, 5.9% ±0.7 and 6.1% ±0.6 in the
first, second and third trimester respectively. Insulin pumps were used by
84.6% of women. Comparing the first versus third decade, diabetes du-
ration at conception increased (15.4±8.39 vs. 11.7±5.8, p=0.002), wom-
en were older (30.4±4.9 vs. 28.7±3.9, p=0.03), more women were over-
weight (29.3% vs. 23.3%, p=0.009) and more women had excessive
weight gain (37.7% vs. 20.3%, p=0.019). Macrosomia (>4 Kg) was
present in 16.2% of women, LGA was present in 45.2% and 67.2%
received a cesarean section. These numbers did not change over time
(resp. p=0.92, p=0.19 and p=0.70). Compared to women with a non-
LGA baby, women with a LGA baby had a higher weight at delivery
(84.1±11.1 vs. 80.4±10.8, p=0.016), had more often excessive weight
gain (45.3% vs. 25.2%, p=0.003) and were more often multiparous
(61.3%vs.46.2% , p=0.01). Glycaemic control was also less strict in the
first and third trimester in women with a LGA baby (resp. 6.7% ±0.9 vs.
6.5% ±0.8, p=0,01 and 6.2% ±0.5 vs. 6.0% ±0.6, p=0.01), without dif-
ference in the frequency of non-planned pregnancies (9.4% vs. 10.6%,
p=0.65). No differences in BMI before pregnancy (25.2±3.7 kg/m2 vs.
25.3±3.8 kg/m2, p=0.80), duration of diabetes (13.7±6.7 years vs. 13.7±
7.4 years, p=0.99), age at delivery (29.5±4.1 years vs. 29.6±4.3 years,
p=0.92), triglycerides levels (79±36 mg/dl vs. 85±41 mg/dL, p=0.60),
HDL cholesterol (66±16 mg/dL vs. 67±17 mg/dl, p=0.47) and LDL
cholesterol (87±28 mg/dl vs. 91±28 mg/dL, p 0.70) were seen between
LGA and non-LGA groups. In the forward multivariate analysis, exces-
sive weight gain (p=0.013) and HbA1c level in the first trimester (p=
0.006) remained independent predictors for LGA, after adjustment for
confounders.
Conclusion: LGA remains a frequent complication in T1DM. Excessive
weight gain and HbA1c in early pregnancy are important risk factors for
LGA in our population.
Supported by: Scholarship of FWO Vlaanderen for KB and RD
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Basal insulin peglispro in combination with oral agents provides sim-
ilar glycaemic control when given once daily in the morning or at
bedtime in insulin naïve type 2 diabetic patients
Á. Rodríguez1, F.J. Tinahones2, L. Chen3, G. Grunberger4, S.J. Jacober3,
J. Bue-Valleskey3;
1Eli Lilly and Company, Alcobendas, 2Hospital Virgen de la Victoria,
Malaga, Spain, 3Eli Lilly and Company, Indianapolis, 4Grunberger Dia-
betes Institute, Bloomfield Hills, USA.
Background and aims: Basal insulin peglispro (BIL) is a novel basal
insulin with a flat profile which has a hepato-preferential action resulting
from reduced peripheral effects. In clinical trials BIL treatment consis-
tently improved glycaemic control and reduced nocturnal hypoglycaemia
(hypo) compared to insulin glargine or NPH. Since the other BIL Phase 3
comparator trials were conducted using bedtime administration, this pre-
specified secondary objective was intended to evaluate if administration
of BIL in the morning (AM) was non-inferior (margin=0.4%) to bedtime
administration (PM) in reducing HbA1c after 26 weeks of treatment.
Materials and methods: This secondary objective was part of a 26-
week, Phase 3, open-label, treat-to-target study to compare the safety
and efficacy of BIL to NPH when added to prestudy oral agents in 641
patients with type 2 diabetes mellitus. Changes to prestudy oral agents
and doses were not permitted during the study. This analysis involves the
428 patients treated with BIL who were randomised to either AM (n=
213) or PM (n=215) administration.
Results: After 26 weeks both AM and PM BIL administration signifi-
cantly reduced HbA1c, with no significant difference between the AM
and PM treatment groups (AM: 6.7 vs PM: 6.8%; treatment difference
[95% CI]:
-0.13% [-0.29, 0.03%]; p=0.109). A similar proportion of patients in both
groups achieved HbA1c <7.0%. No significant differences were found in
fasting glucose, weight gain, or insulin dose between groups. However,
significantly greater reductions in self-monitored blood glucose (BG)
values were observed for the AM group at midday pre-meal (p=0.038),
evening pre-meal (p=0.003), and bedtime (p=0.048) compared to the
PMgroup (see table). There was no significant difference between groups
in the percentage of patients reporting missed treatment doses. Total hypo
rates (events/patient/30 days) were similar for AM vs PM dosing, as were
rates of nocturnal hypo. A similar proportion of patients achieved HbA1c
<7.0% without nocturnal hypo. However, there were higher rates of non-
nocturnal (daytime) hypo in the AM group compared to the PM group
(AM: 1.32 vs PM: 1.01; p=0.048). There was one case of severe hypo in
each group.
Conclusion: These analyses showed that glycaemic control, as measured
byHbA1c and fasting glucose, was similar regardless of whether BILwas
administered in the morning or at bedtime, with no significant difference
in mean insulin dose. However, morning administration of BIL was as-
sociatedwith lower daytime BG and a tendency formore daytime hypo in
the absence of OAM adjustment, suggesting that individualised manage-
ment of insulin and/or oral agents may be warranted.
Clinical Trial Registration Number: NCT01790438
Supported by: Eli Lilly and Company
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Assessment of real-world efficacy and safety of basal insulin plus
rapid-acting insulin vs basal insulin treatment among patients with
type 2 diabetes in the UK
J. Lin1, M. Jhaveri2, L. Liao2, B. Kitio-Dschassi3, M. Lingohr-Smith1;
1Novosys Health, Green Brook, 2Sanofi, Bridgewater, USA, 3Sanofi,
Paris, France.
Background and aims: Basal insulin alone and basal insulin plus rapid-
acting insulin (RAI) are commonly used as add-on therapies for patients
with type 2 diabetes (T2DM) who have inadequate glycemic control with
oral antidiabetic drugs. The objectives of this study were to evaluate the
real world efficacy and safety of basal insulin plus RAI (basal+RAI)
therapy and basal insulin alone therapy.
Materials and methods: Patients with a diagnosis of T2DM and a claim
for basal insulin and/or RAI, regardless of daily dosing frequency (index
event) were identified during 1/1/2004 to 12/31/2012 from The Health
Improvement Network (THIN) U.K. database. T2DM patients were
grouped into 2 cohorts; one treated with basal+RAI and the other treated
with basal insulin alone. Patient characteristics, clinical outcomes, and
healthcare resource use were evaluated and compared during a 12-
month baseline period. Generalized linear models were used to control
for key patient characteristics and evaluate adjusted treatment outcomes.
Results: Using THIN database, 3,186 T2DM patients were identified
with basal+RAI usage and 7,277 were identified with basal alone usage.
At baseline the mean age of the basal+RAI cohort was less than the basal
alone cohort (61 vs. 67 years, p<0.001). Also, the basal+RAI cohort had
a greater mean baseline weight (92.4 vs. 88.3 kg, p<0.001) and a higher
mean HbA1c level (9.24% vs. 8.36%, p<0.001). After controlling for key
patient characteristics, the mean change in HbA1c was -0.29% (greater
reduction) (p<0.001) for the cohort treated with basal+RAI compared to
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the cohort treated with basal alone. The frequency of hypoglycemia did
not significantly differ among study cohorts. Using the regression adjust-
ment, the incremental number of healthcare utilizations (4.1, p<0.0001)
and number of outpatient only healthcare utilizations (3.0, p<0.001) for
all causes during the follow-up period were greater for the cohort treated
with basal+RAI in comparison to the cohort treated with basal alone.
Conclusion: In the real-world setting, while basal+RAI treatment is ef-
fective in reducing Hb HbA1c, the additional change in HbA1c (-0.29%)
associated with basal+RAI vs. basal alone treatment was relatively low.
Titration of RAI remains one of the challenges of treatment of patients
with T2DM.
Supported by: Sanofi US, Inc.
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Effectiveness of intensification therapy in patients with type 2 diabe-
tes who used basal insulin only
H. Nørrelund1, L.M. Baggesen1, M. Søgaard1, L. Pedersen1, E.S. Buhl2,
C.L. Haase2, S.P. Johnsen1, R.W. Thomsen1;
1Department of Clinical Epidemiology, Aarhus University Hospital, Aar-
hus, 2Novo Nordisk Scandinavia AB, Copenhagen, Denmark.
Background and aims: Limited data exist on the glycemic benefit of
different intensification therapies in type 2 diabetes (T2D) patients who
use basal insulin only in a routine clinical setting. We examined the effect
of different intensification therapies on glycemic control among T2D
patients who received basal insulin only therapy.
Materials and methods:We identified a cohort of all individuals with a
first basal insulin only prescription in Northern Denmark, 2000-2012 and
identified all add-on intensification therapy with bolus insulin, premixed
insulin, or GLP-1 receptor agonists. We used Poisson regression to com-
pute adjusted relative risks (aRRs) of reaching a HbA1c target value of
<7.0% adjusted for age, gender, comorbidities, and baseline HbA1c.
Results:We included 6,114 patients with a first basal insulin prescription
and HbA1c measurements. Of these 2,156 (35.3%) received intensifica-
tion therapy after a median of 11 months: 59.2% (n=1276) were intensi-
fied with premixed insulin, 27.5% (n=592)with bolus insulin, 11.8% (n=
255) with GLP-1 agonists, and only 1.5% (n=33) received more than one
add-on regimen simultaneously. Overall, 25.9% attained an HbA1c target
of <7% within 3-6 months after intensification. Reductions in median
HbA1c were 0.9 percentage points (pp) for premixed insulin, 0.4 pp for
bolus insulin, 0.9 pp for GLP-1 agonists, and 1.1 pp for patients with >1
intensification drug. Compared with the large group of premixed insulin
intensification as reference, aRRs of attaining an HbA1c <7% were 1.01
(95% CI 0.84-1.21) for bolus insulin, and 1.28 (95% CI 1.02-1.60) for
GLP-1 agonists.
Conclusion: In this population-based study one fourth of T2D patients
reached a target HbA1c <7% within 3-6 months after intensification of
their basal insulin only therapy. GLP-1 agonists were associated with
higher target attainment than premixed insulin intensification.
Supported by: research grant from Novo Nordisk to Aarhus University
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The significance of obtaining single patient evidence for the best in-
sulin treatment in patients with type 1 diabetes with recurrent severe
hypoglycaemia
B. Thorsteinsson1, P.L. Kristensen1, H. Beck-Nielsen2, K. Nørgaard3, H.
Perrild4, J.S. Christiansen5, T. Jensen6, H.-H. Parving6, L. Tarnow1,7, U.
Pedersen-Bjergaard1;
1Endocrinology Section, Nordsjællands Hospital Hillerød, 2Odense Uni-
versity Hospital, 3Hvidovre University Hospital, 4Bispebjerg Hospital,
Copenhagen, 5Aarhus University Hospital, 6Rigshospitalet, Copenhagen,
7Steno Diabetes Center, Gentofte, Denmark.
Background and aims: The scientific evidence for the benefit of insulin
analogues on a single patient level in type 1 diabetes is sparse. We made a
post-hoc analysis of data from the HypoAna cross-over trial to test the
hypothesis that obtaining single-patient evidence for the superior treat-
ment can improve overall treatment outcomes compared to grouped treat-
ment approach, based on either human insulin or analogue insulin.
Materials and methods: In a two-year, multicentre, prospective,
randomised, open, blinded endpoint (PROBE) trial, 114 patients with
type 1 diabetes and recurrent severe hypoglycaemia were treated with
basal-bolus therapy based on analogue (detemir/aspart) and human
(NPH/regular) insulin in a balanced cross-over design aiming at mainte-
nance of baseline HbA1c. For each patient the superior treatment was
considered that resulting in fewest events of severe hypoglycaemia de-
fined by ADA criteria, or in case of similarity, that eventually resulting in
a more than 0.4% lower HbA1c.
Results: A higher proportion of the patients (n=56; 49%) had superior
outcome with analogue insulin compared with equal outcome (n=30;
26%) and better outcome on human insulin (n=28; 25%) (p=0.0016).
The overall rate of severe hypoglycaemia during the superior treatment
for each patient of 0.67 episode per patient-year was lower compared to
the 1.1 and 1.6 episode per patient-year with analogue insulin and with
human insulin, respectively (p<0.0001). There was no clinically signifi-
cant difference in HbA1c between the three groups.
Conclusion: In patients with type 1 diabetes and recurrent severe
hypoglycaemia insulin treatment selected according to single-patient ev-
idence may result in clinically significant improvement of outcomes com-
pared to a grouped treatment approach based on either human or analogue
insulin.
Clinical Trial Registration Number: NCT00346996
Supported by: Novo Nordisk
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Insulin pump in difficult to control type 2 diabetes mellitus
P. Singh, D. Pandey, N. Trivedi;
Internal Medicine, Saint Vincent Hospital, Worcester, USA.
Background and aims: The prevalence of type 2 diabetes mellitus is
increasing worldwide. Despite the availability of a number of anti-
hyperglycemic agents, large percentage of diabetics remains poorly con-
trolled. Due to the progressive loss of beta-cell functions, most type 2
diabetics eventually require intensification of insulin therapy. Delivering
high doses of insulin by multiple daily injections present a therapeutic
challenge. Continuous subcutaneous insulin infusion (CSII) through an
insulin pump has been successfully used in type 1 diabetics; however,
long term data is lacking in type 2 diabetes. OpT2mise trial tested CSII in
type 2 diabetics, and showed a decrease of mean glycated hemoglobin
(HbA1c) by 1·1% in the pump treatment group compared to 0·4% in the
multiple daily injections (MDI). Nevertheless, all the previous trials in-
cluding OpT2mise have a very short experience with the insulin pump (6-
12 months). The long-term efficacy and safety of CSII in patients with
type 2 diabetes has not been reported. We hereby, aim to present our five
years experience with the use of insulin pumps in type 2 diabetics.
Materials and methods: Our study was single centered, outpatient-
based, retrospective, un-blinded, and non-randomized chart review of
all the patients with type 2 diabetes treated via insulin pump between
2005 and 2013. Inclusion criteria were, age between 18-75 years, with
type 2 DM,HbA1c of more than 7% at initiation, and on insulin pump for
more than 5 years. Additionally, all patients had one of the problems with
the insulin therapy: dose more than 100 units, more than 4 injections,
wide glycemic excursions, and/or intractable hypoglycemia. Exclusion
criteria were type 1diabetics. A total of 13 patients were identified. The
primary endpoint was change in HbA1c from baseline to five years.
HbA1c was assessed at baseline, at 3 months, 6 months, 9 months,
12 months, and at 5 years. We also reviewed the change in body mass
index (BMI), basal insulin requirement, and hypoglycemia from baseline
to one year. All oral anti-diabetic agents were discontinued with the ex-
ception of metformin. Data are presented as the mean (SD) and were
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analyzed using unpaired t test. A p-value of less than 0.05 was considered
statistically significant.
Results: At baseline, mean HbA1c was 8.89±1.15 (Range 6.6-10.8). At
3, 6, 9, and 12 months the mean HbA1c was 7.58%, 7.55%, 8.33%, and
7.96% respectively. The HbA1c at 5 years was 7.7231 compared to base-
line HbA1c of 8.89 (p value equals 0.007). These results were encourag-
ing as in historical data from patients on multiple daily injections; there is
a progressive increase of HbA1c. However, in our data after initial in-
crease the patients have sustained decrease in HbA1c even at five years of
follow up. Furthermore, we did not find any documented episode of
severe hypoglycaemia. Moreover, CSII was not associated with signifi-
cant increase in BMI, or basal insulin requirements.
Conclusion: The use of insulin pumps in patients with difficult to treat
type 2 diabetes is safe and effective, with the beneficial effects persisting
for five years of follow-up.
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The dual-wave bolus provides better glycaemic control of the high-
protein meal in type 1 diabetic children treated with insulin pumps:
randomised cross-over study
K. Piechowiak, K. Dżygało, A. Szypowska;
Warsaw Medical University, Poland.
Background and aims: Insulin pumps apart from normal boluses have
also the ability to deliver the insulin over a time by use of a dual-wave or
square-wave bolus. It is well known that carbohydrates need to be cover
with normal boluses as well as the fat content meals need dual-wave
boluses. There is a lack of studies estimating the need for additional
insulin for high-protein (H-P) meals. The aim of the study was to assess
the differences in the postprandial glycemic excursions following a high-
protein, low-fat meal after administration of insulin by normal versus
dual-wave bolus.
Materials and methods: We performed a randomized, double-blind,
two-way crossover study. There were 38 patients included,14 (37%) boys
and 24 (63%) girls, aged 15.1±1.7 years (range 11-18) with mean diabe-
tes duration 9.2±2.7 years, mean HbA1c 8.3±1.1%, mean daily insulin
dose 0.75±0.26 u/kg. Subjects were randomly assigned into two groups:
group A consisted of patients who applied normal bolus or group B
included subjects who applied dual wave bolus. All patients had a stan-
dardized (H-P) breakfast for 2 subsequent days. Insulin in normal bolus
was calculated based on the number of carbohydrate units. One carbohy-
drate unit was defined as 10 grams of carbohydrate. Insulin in dual-wave
bolus was calculated based on the number of carbohydrate units and
protein-fat units. One protein-fat unit was defined as a 100 kcal from
protein and/or fat. The same insulin-ratio was for one carbohydrate unit
and one protein-fat unit. The primary outcome was postprandial glycemia
(PPG) based on continuous glucose monitoring system and self-blood
glucose measurements assessed in 60, 120 and 180 minutes after the meal
bolus. Secondary outcome was the frequency of hypoglycemia (<65 mg/
dl) during 3-h follow-up.
Results: Postprandial glycemia assessed in 180 min was significantly
higher in group A compared to group B: 157 vs 115 mg/dl (p<0.0001).
There were no statistically significant differences in blood glucose levels
between both groups during first 2 h after the meal bolus: 109 vs 104 mg/
dl at the baseline (p=0.35); 152 vs 151 mg/dl in 60 min (p=0.57); and
177 vs 168 mg/dl (p=0.43) in 120 min. 3 hours after the meal bolus we
observed 1 (2%) hypoglycemic episode in the group A and 6 (15%)
hypoglycemic episodes in the group B (p=0.2).
Conclusion:We demonstrated that applying the dual wave bolus for high
protein meal improve postprandial glycemic profile compared to normal
bolus in type 1 diabetic children treated with insulin pumps. Reduction of
postprandial hyperglycemia was not associated with increased risk of
hypoglycemia.
Clinical Trial Registration Number: NCT02276859
Supported by: Medtronic
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Evaluation of the one-year efficacy, safety and glycaemic effects of
evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at
low risk for, diabetes mellitus
N. Sattar1, D. Preiss1, D. Blom2, C.S. Djedjos3, M. Elliott4, A.
Pellacani3, S.M. Wasserman3, M. Koren5, R. Holman6;
1University of Glasgow, UK, 2Division of Lipidology, Department of
Medicine, University of Cape Town, South Africa, 3Amgen Inc., Thou-
sandOaks,USA, 4Amgen Limited, Cambridge, UK, 5Jacksonville Center
for Clinical Research, Jacksonville, USA, 6Diabetes Trials Unit,
OCDEM, University of Oxford, UK.
Background and aims: Statins reduce cardiovascular risk but increase
the risk of developing diabetes. We investigated the effects of the PCSK9
inhibitor evolocumab (AMG 145), a fully human monoclonal antibody to
PCSK9, on measures of glycaemia and adverse event (AE) rates in sub-
jects stratified by glycaemic status.
Materials and methods: In two open-label trials (OSLER-1 and OS-
LER-2), 4,802 subjects completed one of 13 phase 2 or 3 parent studies
of evolocumab andwere randomly assigned in a 2:1 ratio to receive either
evolocumab 140 mg every 2 weeks or 420 mg monthly plus standard of
care (SoC) or SoC alone. SoC included statin use for some patients.
Changes in fasting plasma glucose (FPG), HbA1c, and AEs were evalu-
ated over 48 weeks in three subject groups: 852 with type 2 diabetes
mellitus (T2DM), 2,432 at high risk of developing T2DM (defined as
metabolic syndrome, IFG, HbA1c >6% or BMI >30 kg/m2), and 1,518 at
low risk of developing T2DM.
Results: LDL-C reductions for evolocumab + SoC compared with SoC
were comparable across the 3 subgroups (57% to 60%). No notable dif-
ferences were seen in median (SE) change in FPG from baseline to
48 weeks in patients on evolocumab + SOC compared with SoC alone
(see Figure). Mean (SE) HbA1c changes at week 48 in patients on
evolocumab + SoC and in patients on SoC alone were +0.16 (0.05) and
+0.23 (0.06)% in patients with diabetes; +0.05 (0.01) and +0.06 (0.01)%
in patients at high diabetes risk; and +0.06 (0.01) and +0.07 (0.01)% in
patients at low risk of diabetes. Results were similar irrespective of
parent-study drug assignment. Rates of AEs in patients on evolocumab
+ SoC vs. SoC alone were: 64% and 63% (T2DM); 69% and 64% (high
diabetes risk); and 69% and 63% (low diabetes risk).
Conclusion: Evolocumab showed encouraging safety with no mea-
surable effect on glycaemic parameters despite reducing LDL-C
levels markedly.
Clinical Trial Registration Number: NCT01439880, NCT01854918
Supported by: Amgen Inc.
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Efficacy and safety of alirocumab in individuals with diabetes: anal-
yses from the ODYSSEY LONG TERM study
H.M. Colhoun1, H.N. Ginsberg2, L.A. Leiter3, U. Chaudhari4, C.
Lorenzato5, R. Pordy6, J.G. Robinson7;
1University of Dundee, UK, 2Columbia University, New York, USA, 3Li
Ka Shing Knowledge Institute and Keenan Research Centre for Biomed-
ical Science, St. Michael's Hospital, University of Toronto, Canada,
4Sanofi, Bridgewater, USA, 5Sanofi, Chilly-Mazarin, France, 6Regeneron
Pharmaceuticals, Inc., Tarrytown, 7University of Iowa, USA.
Background and aims: Diabetes (DM) increases risk for cardiovascular
disease (CVD) and is often complicated by dyslipidaemia. The efficacy
and safety of the PCSK9 inhibitor alirocumab (ALI) for lowering LDL-C
in individuals with DM vs those without DM is unknown. We compared
the effects of ALI in individuals with and without DM according to
medical history at baseline in ODYSSEY LONG TERM.
Materials and methods: LONG TERM included 2341 individuals (832
with DM; 35.5%) at high CVD risk and LDL-C ≥70mg/dL onmaximally
tolerated statin±other lipid-lowering therapy, randomized (2:1) to ALI
150 mg or placebo (PBO) Q2W (as 1 mL injection) for 78 weeks. We
report prespecified efficacy analyses at Week 24 and safety including all
available data from baseline to Week 78 (all individuals to at least Week
52). Final study data will be presented at EASD.
Results:At baseline, mean LDL-C andHDL-C levels were slightly lower
in individuals with DM than those without; individuals with DM also had
higher TGs than those without DM (Table). LS mean (95% CI), PBO-
corrected, reductions in LDL-C of 59% (63.2 to 54.8) were observed in
ALI-treated individuals with DM at Week 24 (Table); LDL-C was re-
duced by 63.4% (66.5 to 60.3) in individuals without DM. Decreases in
TGs and increases in HDL-C levels were also seen with ALI compared
with PBO. These treatment effects were similar in individuals with or
without DM. Adverse events occurring in ≥5% of individuals in all sub-
groups were nasopharyngitis, URI and UTI, including those treated with
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both ALI and PBO. In individuals with DM, injection site reactions
(ISRs) occurred in 3.4% of ALI individuals vs 3.2% in PBO; myalgia
occurred in 3.1% vs 2.9%, respectively. In those without DM, ISRs oc-
curred in 7.0% (ALI) vs 4.9% (PBO); myalgia occurred in 5.9% vs 3.1%,
respectively. Treatment-emergent CVevents were positively adjudicated
in 5.1% (ALI) and 7.2% (PBO) of individuals with DM; for those without
DM, CV event rates were 3.4% (ALI) and 2.9% (PBO). In post-hoc
analyses, rates of major CV events were 1.8% (ALI) and 4.3% (PBO)
for those with DM and 1.2% (ALI) and 2.4% (PBO) for those without
DM; hazard ratios (95% CI) vs PBO were 0.41 (0.18-0.96) [with DM]
and 0.51 (0.23-1.13) [without DM].
Conclusion: Significant LDL-C reductions with ALI vs PBO were seen
in individuals with DM; these reductions were similar to individuals
without DM. ISRs and myalgia occurred more frequently with ALI than
PBO in individuals without DM; in those with DM, rates were similar for
ALI and PBO. Treatment with ALI for potential reduction of CVevents is
under evaluation in the large ongoing ODYSSEY OUTCOMES study
which will include a sizeable proportion of individuals with DM.
Clinical Trial Registration Number: NCT01507831
Supported by: Funded by Sanofi and Regeneron Pharmaceuticals, Inc.
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Efficacy of one year of treatment with the PCSK9 inhibitor
evolocumab (AMG 145) in 4,802 subjects with or without type 2
diabetes
D. Preiss1, N. Sattar1, J.G. Robinson2, C.S. Djedjos3, M. Elliott4, A.
Pellacani3, S.M. Wasserman3, D. Blom5, F. Raal6;
1University of Glasgow, UK, 2Departments of Epidemiology and Medi-
cine, University of Iowa, 3Amgen Inc., Thousand Oaks, USA, 4Amgen
Limited, Cambridge, UK, 5Department of Medicine, University of
Cape Town, South Africa, 6Department of Medicine, University of Wit-
watersrand, Johannesburg, South Africa.
Background and aims: Lipid-lowering therapy is a mainstay of treat-
ment for subjects with type 2 diabetes mellitus (T2DM), who are at
elevated risk for cardiovascular disease. In a pooled analysis of subjects
with T2DM from 2 open-label extension trials, we evaluated the efficacy
of one year of subcutaneous evolocumab (AMG 145) treatment added to
standard of care (SoC) in subjects with or without T2DM at baseline.
Materials and methods: In total, 4,802 subjects completed one of 13
phase 2 or 3 studies and continued into OSLER-1 (phase 2 extension) or
OSLER-2 (phase 3 extension). Subjects were randomly assigned 2:1 to
either evolocumab 140mg biweekly or 420mgmonthly plus SoC or SoC
alone; randomization was irrespective of parent-study assignment.
Changes in LDL-C (calculated) and other lipids were evaluated at week
48 in subjects with or without T2DM. LDL-C changes within T2DM
subgroups (including low-, moderate-, or high-intensity statin; insulin
or no insulin treatment; presence or absence of CVD; HbA1c≥or<
8.0%; and eGFR≥or<60 mL/min/1.73 m2) were also evaluated.
Results: In total, 563 subjects with and 2,637 without T2DM (defined by
history, glycemic criteria, or baseline diabetes medication) received
evolocumab plus SoC in the open-label extension phase of the study. In
subjects on evolocumab plus SoC, mean percent changes in LDL-C from
baseline versus SoC at one year were -60% and -58% in those with and
without T2DM, respectively. Similar changes in LDL-C were observed
between treatment arms in T2DM subgroups (Figure). Changes in lipo-
protein (a) (-30% and -29%) and TG (-14% and -11%) were also compa-
rable in evolocumab plus SoC-treated subjects with and without T2DM,
respectively, compared with SoC alone.
Conclusion: One year of treatment with evolocumab resulted in marked
and comparable reductions in LDL-C in subjects with and without
T2DM, and these changes were similar across T2DM subgroups, irre-
spective of baseline characteristics. Beneficial changes in other lipids
were also observed in those receiving evolocumab plus SoC.
Clinical Trial Registration Number: NCT01439880 and NCT01854918
Supported by: Amgen Inc.
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Lipid changes during 26-week treatment with the novel basal insulin
peglispro (BIL) vs insulin glargine or NPH insulin in 6 IMAGINE
Trials
B.J. Hoogwerf1, H. Ginsberg2, B. Cariou3, T. Orchard4, L. Chen1, J.
Luo1, E.J. Bastyr III1, J. Bue-Valleskey1, A.M. Chang1, S.J. Jacober1,
J.G. Jacobson1, T. Iványi5;
1Eli Lilly and Company, Indianapolis, 2Irving Institute for Clinical and
Translational Research, New York, USA, 3L’institut du Thorax, Nantes
University Hospital, Nantes, France, 4GSPH, University of Pittsburgh,
Pittsburgh, USA, 5Eli Lilly and Company, Budapest, Hungary.
Background and aims: Basal insulin peglispro (BIL) is a novel basal
insulin with a flat activity profile which has a hepato-preferential action
resulting from reduced peripheral effects. Lipid changes observed with
BIL in Phase 3 studies differ from those observed with the comparators
insulin glargine and NPH insulin. To better understand these differences,
we analysed fasting lipid data from the first 26 weeks of treatment from 6
Phase 3 trials of BIL. Five of these trials had subgroups from which
apolipoproteins and free fatty acid data were collected.
Materials and methods: Trials were divided into 4 categories for analysis:
trials of a basal insulin regimen in insulin-naïve patients with type 2 diabetes
(T2D); trials of a basal insulin regimen in patients with T2D previously
treated with insulin; trials of a basal-bolus insulin regimen in patients with
T2D previously treated with insulin; and trials of a basal-bolus insulin reg-
imen in patients with type 1 diabetes (T1D) previously treated with insulin.
Results: By week 26, in insulin-naïve patients with T2D, triglycerides
decreased with glargine and NPH (-.12 mmol/L [-11 mg/dL] and -
.17 mmol/L [-15 mg/dL], p<.05) but were unchanged from baseline with
BIL (range: -.02 mmol/L [-1 mg/dL] to .04 mmol/L [4 mg/dL], p=NS). In
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patients with T1D or T2Dpreviously treatedwith insulin, triglycerides were
stable with glargine (p=NS) and increased .21 to .27 mmol/L (19 to 24 mg/
dL; 15 to 25%) with BIL (p<.001). After BIL discontinuation triglycerides
decreased to pre-study levels. In all trials, with BIL, HDL-cholesterol (C)
changed 0 to -.12 mmol/L (0 to -5 mg/dL); LDL-C changed 0 to .17 mmol/
L (0 to 7 mg/dL). With glargine, HDL-C and LDL-C changed 0 to -
.04 mmol/L (0 to -1 mg/dL) and .03 to .12 mmol/L (1 to 5 mg/dL), respec-
tively. Apolipoproteins A1 and B were mostly unchanged with BIL.
Among patients previously treated with insulin, there were no treatment
differences in free fatty acids (p=NS); in insulin-naïve patients with T2D,
free fatty acids decreased more with glargine than BIL (p=.003).
Conclusion: Lipids, free fatty acids and apolipoproteins A1 and B had
little or no change with BIL in insulin-naïve patients with T2D; in con-
trast, GL and NPH lowered triglycerides. When BIL replaced conven-
tional insulin treatments, increases in triglycerides were observed. In-
creased hepatic de novo lipogenesis, increased adipose tissue release
and hepatic flux of free fatty acids, or decreased adipose tissue lipoprotein
lipase activity, either alone or in combination, may also be the basis for
differences in triglyceride concentrations between BIL and other insulins.
Clinical Trial Registration Number: NCT01435616, NCT01790438,
NCT01468987, NCT01481779, NCT01454284, NCT01582451
Supported by: Eli Lilly and Company
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RESEARCH: superior effect of ezetimibe was sustained on LDL-C
level and the rate of achievement of target value in a 52-week analysis
M. Kawamura1, T. Watanabe2, K. Sakamoto3, K. Ashidate4, T. Kohro5,
A. Tanaka6, Y. Mori7, M. Tagami8, T. Hirano9, T. Yamazaki10, T. Shiba3,
RESEARCH Study Group, Tokyo, Japan, Yokohama, Japan;
1Endocrinology and Meatabolism, Tokyo Teishin Hospital, 2Internal
Medicine, Yokohama City Minato Red Cross Hospital, 3Department of
Diabetes and Metabolism, Toho University Ohashi Medical Center, To-
kyo, 4Internal Medicine, Kudanzaka Hospital, Tokyo, 5Clinical Informat-
ics / Cardiology, Jichi Medical University, Shimono, 6Nutrition Clinic,
Kagawa Nutrition University, Tokyo, 7Endocrinology and Meatabolism,
Toranomon Hospital, Tokyo, 8Life-style related Disease Clinic, Sanraku
Hospital, Tokyo, 9Diabetes,Endocrinology and Meatabolism, Showa
University, Tokyo, 10Clinical Research Support Center, The University
of Tokyo Hospital, Japan.
Background and aims: Lowering cholesterol levels decreases the
risk of atherosclerotic diseases. Low-density lipoprotein cholester-
ol (LDL-C), other atherogenic lipid parameters, especially small
dense LDL-C (sd-LDL) have been shown to increase the risk of
coronary artery diseases(CAD). We evaluated long-term ezetimibe
add-on therapy in type 2 diabetic (DM) patients with hypercho-
lesterolemia not achieving LDL-C target value.
Materials and methods: A total of 109 DM patients not attaining
LDL-C target value despite usual-dose statin therapy in Japan
were recruited. We investigated the difference in cholesterol low-
ering effect between ezetimibe add-on statin (E) group and
double-dose statin (S) group. Changes of lipid parameters were
assessed in a randomized, multicenter, 52 weeks and open label
study. We determined sd-LDL levels by the precipitation method.
The participants were randomly assigned to 2 groups, E group
(n=31) with ezetimibe 10 mg + atorvastatin 10 mg or pitavastatin
1 mg combination and S group (n=38) with atorvastatin 20 mg or
pitavastatin 2 mg.
Results: At the baseline(0 week), there was no difference between the
groups in age, body mass index (BMI), sex ratio, HDL-C, triglyceride
(TG), hemoglobin A1c (A1c) and high-sensitivity C-reactive protein (hs-
CRP) . However, sd-LDL and nonHDL-C were significantly higher in D
group than in E group. Then, both of the groups showed significant
decrease in LDL-C, sd-LDL and non HDL-C during the study. LDL-C,
sd-LDL and non HDL-C were significantly lower in the E group than in
the S group at the end of the study.
Conclusion: In the present 52-week long-term period, ezetimibe add-on
therapy showed a robust advantage in lowering LDL-C and in attaining
target LDL-C values compared with the doubling of statin dose.
Moreover,it's meaningful that sd-LDL, powerfully atherogenic lipopro-
tein, was decreased prominently by ezetimibe add-on therapy. DM pa-
tients with hypercholesterolemia are at high risk for CAD, and adding
ezetimibe onto usual-dose statin treatment in Japan has been suggested as
the first-line therapy for those DM patients who failed to attain the target
LDL-C value.
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Efficacy and safety of liraglutide versus sulphonylurea both in com-
bination with metformin during Ramadan in subjects with type 2
diabetes (LIRA-Ramadan): a randomised trial
S. Azar1, A. Echtay2, W. Wan Bebakar3, S. Al Araj4, A. Berrah5,
M. Omar6, A. Mutha7, K. Tornøe8, M. Kaltoft8, N. Shehadeh9;
1American University of Beirut, 2Lebanese University Medical School,
Rafik Hariri University Hospital, Beirut, Lebanon, 3Universiti Sains Ma-
laysia, Pulau Pinang, Malaysia, 4Ras-Alkhaimah Medical and Health
Sciences University, Ras-Alkhaimah, United Arab Emirates, 5University
Hospital Bab El Oued, Algiers, Algeria, 6University of Kwazulu-Natal,
Durban, South Africa, 7diabetes Care and Research Centre, Maharashtra,
India, 8Novo Nordisk, Søborg, Denmark, 9Meyer Children's Hospital of
Haifa at Rambam Medical Center, Rambam, Israel.
Background and aims: There are approximately 50 million Muslims
worldwide with diabetes who fast during Ramadan, 79% of which are esti-
mated to have type 2 diabetes (T2D). Fasting during Ramadan leads to a 5-
and 7.5-fold increased risk of severe hyper- and hypoglycaemia, respective-
ly. Furthermore, adjustment of glucose-lowering medication and closer
follow-up during Ramadan may be necessary. The effect of liraglutide vs
sulphonylurea (SU), both + metformin (Met), on change in glycaemic con-
trol in subjects with T2D who fasted during Ramadan was examined.
Materials and methods: In this up to 33-week, open-label trial, adults
(HbA1c 7-10%; BMI >20 kg/m2; stable SU + Met; intent to fast during
Ramadan) were randomised to either switch to once-daily liraglutide
1.8 mg (N=172) or continue pretrial SU (N=171), both + Met. After 3-
week dose escalation, a 6-19-week maintenance period preceded Rama-
dan. Primary endpoint was change in fructosamine from start to end of
Ramadan (liraglutide N=151; SU N=165) (Table).
Results: During Ramadan, despite lower fructosamine and HbA1c at start
of Ramadan in the liraglutide arm, a similar reduction in fructosamine and
HbA1c with liraglutide and SU was seen. Confirmed hypoglycaemic epi-
sodes appeared to be lower with liraglutide and fewer subjects withdrew
during Ramadan (liraglutide 3, SU 11). At end of Ramadan, more subjects
reached the composite endpoint of HbA1c <7%, no weight gain and no
confirmed hypoglycaemia with liraglutide (51.3% vs 17.7%; odds ratio
4.90; 95% confidence interval 2.79-8.62; p<0.0001). For changes in blood
pressure during Ramadan, reduction in systolic blood pressure was greater
with liraglutide than SU (estimated treatment difference: -4.01 mmHg; p=
0.0061); there was no difference for diastolic blood pressure. AE frequen-
cies appeared at similar levels: liraglutide 23.7%; SU 20.9%. Gastrointesti-
nal AEs were more common for liraglutide (10.5%; SU 3.7%). A low
incidence of SAEs was observed (liraglutide 1.3%; SU 0%).
Conclusion: During Ramadan, liraglutide showed similar improvements
in glycaemic control from lower fructosamine and & HbA1c levels com-
pared to SU with a similar number of AEs, fewer confirmed
hypoglycaemic episodes and better weight control.
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Clinical Trial Registration Number: NCT01917656
Supported by: Novo Nordisk
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SGLT2 inhibitor dapagliflozin ameriorates diabetic nephropathy by
inhibiting high-glucose-induced oxidative stress in a mouse model of
type 1 diabetes
T. Hatanaka, D. Ogawa, N. Terami, N. Nishii, A. Nakatsuka, J. Eguchi,
J. Wada;
Departments of Medicine and Clinical Science, Okayama University
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Japan.
Background and aims: Previously, we demonstrated that dapagliflozin,
a sodium glucose cotransporter 2 (SGLT2) inhibitor, protects against
diabetic nephropathy; however, it was unclear whether it is mediated by
a direct action on kidney. Therefore, we investigated the effect of
dapagliflozin on early stage of diabetic nephropathy using a mousemodel
of type 1 diabetes and cultured murine proximal tubular epithelial cells.
Materials and methods: Eight-week-old Akita mice were treated with
1.0 mg/kg of dapagliflozin (n=5) or 10-20 unit/kg/day of insulin (n=5)
for 12 weeks. Control C57BL/6 mice (n=6) and Akita mice (n=6) re-
ceived saline for 12weeks.Murine proximal tubular epithelial (mProx24)
cells were cultured and treated with dapagliflozin and transfected with
Slc5a2 (encoding SGLT2) siRNA.
Results: Compared with control Akita mice, dapagliflozin and insulin
equally decreased blood glucose and hemoglobin A1c levels
(dapagliflozin: 6.8±0.2%; insulin: 6.4±0.2%; Akita: 9.2±0.2%). Urinary
albumin excretion (UAE) was higher in Akita group compared with that
in the C57BL/6 group, and was significantly lower in both dapagliflozin
and insulin groups. Moreover, dapagliflozin was more effective than in-
sulin in reducing UAE. ROS production, which was detected by
dihydroethidium, was higher in the cortex of Akita group than in that of
C57BL/6 group, and it was suppressed by insulin and more efficiently by
dapagliflozin. Similarly, Nox4, a subunit of NADPH oxidase, was upreg-
ulated in the cortex of Akita group compared with the C57BL/6 group,
but it was attenuated in the dapagliflozin group and in the insulin group,
though less effectively by the latter. As demonstrated by qRT-PCR anal-
ysis of kidney tissue, expression of Nox4 was significantly suppressed by
dapagliflozin, but not by insulin. Moreover, Western blotting showed that
dapagliflozin, but not insulin, suppressed the Nox4 protein expression.
Collectively, oxidative stress induced by diabetes was suppressed by gly-
cemic control using insulin, and was more strongly suppressed by
dapagliflozin. These data indicate that dapagliflozin directly reduced ox-
idative stress in diabetic kidney. To further investigate the effect of
dapagliflozin on high-glucose-induced ROS production in kidney, we
performed dichlorofluorescin diacetate staining and FACS analysis using
cultured mProx24 cells. High-glucose medium increased ROS produc-
tion in mProx24 cells, which was significantly attenuated by
dapagliflozin treatment in a dose-dependent manner. To evaluate whether
or not the suppressive effect of dapagliflozin depends on the inhibition of
SGLT2, we performed RNAi against Slc5a2 in mProx24 cells. Knock-
down of Slc5a2 also suppressed the expression of these inflammatory
genes to similar levels as dapagliflozin did. These results show that
dapagliflozin inhibited oxidative stress by inhibiting SGLT2 in proximal
tubular epithelial cells.
Conclusion: In conclusion, our study demonstrated that inhibition of
SGLT2 by dapagliflozin improved hyperglycemia and ameliorated dia-
betic nephropathy directly by inhibiting oxidative stress in Akita mice.
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The effect of SGLT-2 inhibitor, tofogliflozin on the urinary albumin
excretion rate by the degree of albuminuria in Japanese type 2
diabetes
K. Nunoi1, Y. Sato1, K. Kaku2, H. Suganami3;
1Division of Endocrinology &Metabolism, St.Mary's Hospital, Kurume,
2Department of Internal Medicine, Kawasaki Medical School, Okayama,
3Clinical Data Science Dept., Kowa Co.,Ltd., Tokyo, Japan.
Background and aims: Diabetic nephropathy is a major microvascular
complication of diabetes characterized by albuminuria and progressive
loss of kidney function. The renal sodium glucose transporter-2 (SGLT2)
is specifically expressed on the proximal tuble as well as on themesangial
cells in the literature. However, there were a few reports that showed that
SGLT2 inhibitors improved albuminuria. The aim of this study was to
investigate the effect of the SGLT2 inhibitor, tofogliflozin (TOFO), on the
urinary albumin excretion rate (UACR) by the degree of albuminuria in
not so obese Japanese type 2 diabetic patients from TOFO phase 3
studies.
Materials and methods: Total number of subjects was 1044 type 2
diabetics(male:698, female:346, age:mean 58.3 years, duration of
DM:6.9 years, BMI:25.6 kg/m2) who were rolled from TOFO phase 3
four studies except two subjects with eGFR less than 30. They were
divided into three groups by the degree of UACR. Normal albuminuria
group(G1:UACR<30 mg/gCr) was 701 subjects(placebo:40,
TOFO:661). Microalbuminuria group(G2:UACR;30 to <300) was 290
s ub j e c t s ( p l a c e bo : 1 2 , TOFO : 278 ) . Ma c r o a l b um i n u r i a
group(G3:UACR≧300) was 53 subjects(placebo:4, TOFO:49). Glucose
and physiological parameters were followed with urinary
indexes(UACR, urinary beta-2 microglobulin to creatinine ratio[u-MG]
and urinary N-acetyl-beta-D-glucosaminidase to creatinine ratio[u-
NAG]). The changes of variables from baseline to week 24 (last obser-
vation carried forward [LOCF] procedure) were analyzed by Wilcoxon
sign rank test. Urinary indexes were log-transformed in the correlation
analysis.
Results: TOFO made significant reduction in HbA1c(mean:-0.76 to -
0.89%) and weight(-2.72 to -2.85 kg) similarly in the three groups. A
little reduction in UACR(median) was observed in G1(-0.60 mg/gCr, p
<.05 vs baseline), but its clinical significance was obscure. On the con-
trary, clinical significant reduction in UACR was observed in G2(-26.10,
p<.0001) and G3(-323.30, p<.0001). UACR reduction was positively
correlated with the changes in fasting plasma glucose(r=0.30), u-
MG(r=0.28), u-NAG(r=0.27), weight(r=0.19) and diastolic blood
pressure(r=0.17) in G2. On the contrast, UACR reduction in G3 was
prominent and correlated only with urinary indexes, u-MG(r=0.60) and
u-NAG(r=0.32).
Conclusion: SGLT2 inhibitor, TOFO, reduced UACR in Japanese type 2
diabetic patients preserved renal function with micro- and
macroalbuminuria. Although UACR reduction might be attributed to
improvement of glucose and physiological parameters by SGLT2 inhibi-
tion in microalbuminuric stage, other direct mechanism, for example,
inhibition of SGLT2 on tubule or mesangial cells was considered in the
cases with macroalbuminuria.
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Linagliptin decreases the growth of immortalised human podocytes
through the SDF-1-CXCR4/CXCR7 axis
G. Miglio1, G. Vitarelli1, R. Fantozzi1, T. Klein2, E. Benetti1;
1Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin,
Italy, 2Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach,
Germany.
Background and aims:Linagliptin is a potent and selective dipeptidyl
peptidase (DPP)-4 inhibitor, approved as an oral treatment for patients
with type 2 diabetes mellitus. In contrast to its effects on glucose
homeostasis, the effects of linagliptin on diabetic nephropathy have
been less well investigated, although mounting data indicate a thera-
peutic potential. Stromal cell-derived factor (SDF)-1 is a physiologi-
cal substrate of DPP-4, and has been postulated to mediate the effects
of DPP-4 inhibitors. However, due to complex interactions involving
two chemokine receptors (CXCR4 and CXCR7), the role of SDF-1
remains controversial. The aims of this study were to evaluate whether
linagliptin exerts direct effects on human glomerular cells, and deter-
mine the role of the SDF-1-CXCR4/CXCR7 axis in mediating these
effects.
Materials and methods: Expression of DPP-4, SDF-1α, CXCR4, and
CXCR7 was evaluated in human immortalised podocytes and mesangial
cells at themRNA (RT-PCR analysis) and protein levels (western blot and
ELISA). DPP-4 activity was assessed in cell extracts by measuring the
c leavage of the DPP-4 subs t ra te H-Ala-Pro-7-amido-4-
trifluoromethylcoumarin. Cell growth wasmeasured using anMTTassay.
The role of SDF-1-CXCR4/CXCR7 signalling pathways was investigat-
ed by analysing the effects of the bicyclam AMD3100, which is a non-
peptide CXCR4 competitive antagonist and CXCR7 allosteric modulator.
Results: Compared with mesangial cells, the expression and activity of
DPP-4 was significantly higher in podocytes (p<0.001). The DPP-4 ac-
tivity in podocyte extracts was abolished by linagliptin (0.01–100 nM;
pIC50=8.9). Moreover, podocyte growth, which is a pathophysiological
feature of activated podocytes, was decreased by linagliptin in a time- and
concentration-dependent manner; maximal effect (mean±SEM) at 5 days
was 25.1±1.6% (p<0.01 vs cells exposed to vehicle alone, and pEC50=
8.8). CXCR4 and CXCR7were expressed in podocytes, and mean±SEM
levels of SDF-1α increased from 0.82±0.18 ng/ml (day 0) to 7.76±
0.17 ng/ml (day 5; p<0.001). The effects of linagliptin on podocyte
growth were mimicked by AMD3100, and a synergistic interaction was
observed when linagliptin and AMD3100 were combined.
Conclusion: Our in vitro data suggest that linagliptin could exert direct
effects on human podocytes. In particular, it may promote the mainte-
nance of a more favourable quiescent phenotype of this cell type, which is
essential for preserving the integrity of the glomerular filtration barrier.
These effects may depend on inhibiting DPP-4-mediated processing of
SDF-1.
Supported by: Boehringer Ingelheim
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Comparable effectiveness of real-world dual combination therapies
across different levels of renal function in patients with type 2
diabetes
M.C. Thomas1, P.M. Paldánius2;
1Baker IDI Heart and Diabetes Institute, Melbourne, Australia, 2Novartis
Pharma AG, Basel, Switzerland.
Background and aims: Dipeptidyl Peptidase-4 (DPP-4) inhibitors are
widely used in themanagement of type 2 diabetes mellitus (T2DM). They
have demonstrated utility in patients with normal renal function, but have
additional advantages for patients with renal impairment (RI). These in-
clude reduced need for complex dose titration and lack of increased risk
of hypoglycaemia. Another advantagemay be comparable efficacy across
all levels of renal function, ages and duration of diabetes that may not be
seen with other drug classes, and especially in comparison vs.
sulphonylureas (SUs). To further explore this hypothesis in a ‘real-world’
setting, we compared the effectiveness and glycaemic response of a DPP-
4 inhibitor, vildagliptin vs. SUs as add-on second-line dual therapy in
patients with different degrees of RI enrolled in an observational, non-
interventional study, EDGE, which included T2DM patients with failing
antidiabetes monotherapy, worldwide.
Materials and methods: In this exploratory post-hoc analysis we used
descriptive statistics and adjusted multivariate analysis to assess the ef-
fectiveness by the absolute change in HbA1c and the proportion of pa-
tients responding to treatment (HbA1c <7%) without tolerability issues
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such as weight gain (≥3%) or hypoglycaemia for 12 months. The esti-
mated glomerular filtration rate (eGFR) values were available for a sub-
set of EDGE patients (optional as per original study protocol) in whom
vildagliptin or SU for treatment intensification was chosen by the inves-
tigators based on clinical judgment.
Results: MDRD-eGFR values were available for 20,822 patients; 2,532
of whom (1,649 in vildagliptin vs. 883 in SU group) had an eGFR value
<60 ml/min/1.73 m2 denoting the presence of RI. Participants with RI
were older (65 vs. 57 years), had a lower BMI or absolute body weight
and had a longer duration of diabetes (7 vs. 5 years) than those with an
eGFR>60ml/min/1.73m2. Inmultivariate analysis, the change inHbA1c
in response to add-on therapy was associated with baseline HbA1c,
weight, and assignment to receive vildagliptin (all p<0.001). However,
the HbA1c response to either vildagliptin or SUs was not significantly
influenced by the presence or absence of renal impairment (p=0.7). Over-
all, patients treated with vildagliptin reached their glycaemic targets more
often without weight gain or hypoglycaemia vs. those treated with SUs
(OR 1.766, 95%CI 1.646, 1.896, p<0.001). The response rates (HbA1c
<7% without tolerability issues) were modestly lower in those patients
with an eGFR <60 vs. those with an eGFR >60 ml/min/1.73 m2 in both
patients receiving vildagliptin (36 vs. 38%) vs. SUs (22 vs. 26%), respec-
tively. In patients with an eGFR <60 ml/min/1.73 m2, weight gain ap-
peared to be the main reason for the reduced tolerability (p=0.002), and
this issue was greater with SU add-on therapy.
Conclusion: Diabetes management is complicated and costly in an ever
increasing number of patients with RI. This exploratory analysis from
EDGE suggests that, DPP-4 inhibitors may have the potential to retain
and simplify glycaemic control even in a heterogeneous, ‘real-life’ set-
ting, without tolerability issues such as hypoglycaemia.
Supported by: Novartis
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LEADER-6: variation of renal function status and risk markers
across geographic origin, race and ethnicity in a high CV risk type
2 diabetic population: baseline results of the trial
I. Satman, on behalf of the LEADER investigators;
Div. Endocrinology and Metabolism, Dept. Internal Medicine, Istanbul
University, Turkey.
Background and aims: Cardiovascular disease (CVD) correlates with
the risk of chronic kidney disease (CKD) in patients with type 2 diabetes
(T2D) but it is not clear whether ‘prior CVD’ or having multiple risk
factors for CVD increase the risk of CKD, i.e. the direction of causality
is unclear. Also ethnic, racial, geographical or demographic differences of
CKD have not been extensively studied. Our objective was to examine
prevalent CKD and potential risk factors in a study designed to evaluate
the long-term cardiovascular safety of liraglutide in a multi-racial and
multi-ethnic T2D population with high CVD risk.
Materials and methods: The Liraglutide Effect and Action in Diabetes:
Evaluation of cardiovascular outcome Results (LEADER) trial included
9,340 participants with T2D from 32 countries. The majority of the partic-
ipants (81.3%, n=7,592) had ‘prior CVD’. In this group, CKD at baseline
was estimated by calculation of glomerular filtration rate (eGFR) using the
MDRD formula and CKDwas defined as eGFR <60mL/min/1.73m2 and/
or an albumin-to-creatinine ratio (ACR) >2.0 mg/mmol. We used descrip-
tive statistics and the association of baseline characteristics with prevalent
CKD was examined using multivariable logistic regression analysis.
Results: Of the LEADER participants with prior CVD, 34.5% had nor-
mal renal function (eGFR ≥90 mL/min/1.73 m2). For the remaining par-
ticipants with renal impairment, there were 38.8%, 24.4%, and 2.3%with
mild (eGFR 89-60 mL/min/1.73 m2), moderate (eGFR 59-30 mL/min/
1.73 m2), and severe (eGFR <30 mL/min/1.73 m2), respectively. The
prevalence of CKD differed between regions and was highest in partici-
pants fromAsia (80%), lowest in patients fromEurope or theMiddle East
(47.5% and 47.6%, respectively) and 60% in participants from Australia
and the Americas. In multivariate logistic regression analysis, the preva-
lence of CKD in participants with prior CVDwas associated with increas-
ing age (OR per SD: 1.40, p<0.0001), increasing HbA1c (1.30, p<
0.0001), diabetes duration (1.23, p<0.0001), systolic BP (1.34, p<
0.0001), heart rate (1.10, p=0.0290) and serum triglycerides level (1.21,
p<0.0001). Furthermore, number of antihypertensive medications (1.54,
p<0.0001); region of living being Asia (4.78, p<0.0001), N. America
(1.50, p<0.0001), Australia (1.48, p=0.0211), Africa (1.47, p=0.0176)
and S. America (1.40, p=0.0004) were associated with CKD at baseline
(reference region Europe). In addition, male gender (1.28, p=0.0001),
current smoking (1.33, p=0.0010), being on insulin only (1.71, p=
0.0002), no history of angina (1.71, p<0.0001), myocardial infarction
(1.41, p<0.0001), and stroke (1.39, p<0.0001) were factors that in-
creased the likelihood of having CKD at baseline. In contrast, diastolic
BP (0.91, p=0.0121) and no diuretic treatment (0.75, p<0.0001) was
associated with a reduced likelihood of prevalent CKD.
Conclusion: The prevalence of CKD is high among T2D patients with
‘prior CVD’. Particularly, Asian patients are at highest risk. Age, diabetes
control, comorbidities and medications used are the most important fac-
tors associated with prevalence of CVD. However, these data do not infer
causality. Nonetheless, screening for CKD in T2D patients with prior
CVD or high risk of CVD and priority inclusion of patients at high risk
of CKD into preventive programs may be of great importance.
Clinical Trial Registration Number: NCT01179048
Supported by: Novo Nordisk
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Albumin creatinine ratio and cardiovascular outcomes in the
SAVOR-TIMI 53 trial
O. Mosenzon1, A. Cahn1, B. Hirshberg2, M. Sjöstrand3, R.C. Ma4,
G. Jermendy5, R.G. Bretzel6, I. Yanuv1, A. Rozenberg1, C. Wei7, B.M.
Scirica8, D.L. Bhatt8, I. Raz1;
1The Diabetes Unit, Hadassah Hebrew University Medical Center, Jeru-
salem, Israel, 2CVMD, Astrazeneca, Gaithersburg, USA, 3CVMD
GMed, AstraZeneca R&D Molndal, Gothenburg, Sweden, 4Department
of Medicine and Therapeutics, The Chinese University of Hong Kong,
China, 5Medical Department, Bajcsy-Zsilinszky Hospital, Budapest,
Hungary, 6St. Josefs Hospital Balserische Stftung, Giessen, Germany,
7Biometrics & Information Sciences, AstraZeneca Phamaceuticals,
Gaithersburg, 8Brigham and Women's Hospital, Boston, USA.
Background and aims: Amongst type 2 diabetic patients (pts) albumin
creatinine ratio (ACR) is an important marker both for the risk of renal
function deterioration and for cardiovascular adverse (CV) events. How-
ever, the exact threshold of ACR at which CV risk is increased is
unknown.
Materials and methods: We studied the CV outcomes of the 9,696
(58.8%) pts with ACR<30 mg/G, 4,426 (26.8%) pts with micro-
albuminuria (30≤ACR<300 mg/g) and 1,638 (9.9%) pts with macro-
albuminuria (ACR≥300 mg/g) at baseline that participated in the
SAVOR-TIMI 53 trial. We further subdivided ACR groups into ACR<
15 [N=7,445 (45.1%)], 15≤ACR<30 [N=2,251 (13.7%)], 30≤ACR<
100 [N=2,893 (17.5%)] and 100≤ACR<300 [N=1,533 (9.3%)] mg/g.
Pts. were followed prospectively for a median of 2.1 years. Cox propor-
tional hazard ratio for time to first CVevent was calculated with stratifi-
cation for baseline eGFR and CV risk group and for treatment arm, ACR
category, sex, age, diabetes duration, smoking, hypertension, hyperlipid-
emia, BMI and HbA1c as model terms.
Results: ACR>15 mg/g was associated with increased risk for most
adverse CVevents (figure). In the ACR≤15 mg/g group, every increase
in ACR by 1 mg/g was associated with increased HRadj for the primary
composite endpoint (1.06 (95% CI 1.02-1.09)) and its components: CV
death (1.05 (95%CI 1.00-1.11)) and myocardial infarction (1.05 (95%CI
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1.00-1.10)) (p<0.05). Such an association could not be demonstrated in
the 15≤ACR<30 mg/G group.
Conclusion:Within the normoalbuminuric range, higher ACR is associ-
ated with increased CV risk. The risk for CV events increases rapidly in
the ACR≤15 mg/dl range and continues to increase gradually thereafter.
Clinical Trial Registration Number: NCT01107886
Supported by: AstraZeneca / Bristol Myers Squibb
OP 29 The complex world of beta cell
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Stimulation of insulin secretion by cannabinoid ligands LH-21 and
Abn-CBD in mouse and human islets: evaluation of the role of
GPR55
I. Ruz Maldonado1,2, A. Pingitore2, B. Liu2, G.C. Huang2, D. Baker3,
F.J. Bermúdez-Silva1, S.J. Persaud2;
1Unidad de Gestion Clínica Intercentros de Endocrinología y Nutrición,
Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Re-
gional Universitario de Málaga, Spain, 2Division of Diabetes & Nutri-
tional Sciences, Diabetes Research Group, King's College London,
3Blizard Institute, Barts and The London School of Medicine
and Dentistry, London, UK.
Background and aims: The cannabinoid receptors CB1 and GPR55
belong to the highly specialised G-protein coupled receptor (GPCR) fam-
ily, and we and others have reported that ligands for these receptors
regulate insulin secretion from islet beta cells. This study aims to inves-
tigate the effect on insulin secretion of the CB1 neutral antagonist LH-21
and the GPR55-selective agonist Abn-CBD to gain new insights into the
signaling pathways operating downstream of CB1 and GPR55 in human
and mouse islets.
Materials and methods: Islets isolated fromWT C57BL6/J and GPR55
KO mice and from human pancreas were perifused with a physiological
salt solution supplemented with 2 mM glucose followed by 20 mM glu-
cose in the absence or presence of LH-21 or Abn-CBD at 37°C, and
insulin secretion was quantified by radioimmunoassay. For assessment
of downstream signalling mouse and human islets and MIN6 beta-cells
were treated with Abn-CBD and/or LH-21 (0.1-10 μM) at 20 mM glu-
cose for 30 min, after which phosphoCREB, total CREB and β-actin
expression were evaluated by electrophoresis and western blotting with
specific antibodies.
Results: Abn-CBD (1 μM) had no significant effect on glucose-
stimulated insulin secretion from WT mouse islets, but it unexpectedly
increased insulin secretion from GPR55 KO mice islets (control: 8±
1.5 pg/islet/min, Abn-CBD: 14±0.9, n=3-4, p<0.0001). In contrast,
LH-21 at 0.1 and 1 μM increased insulin secretion fromWTmouse islets,
but no changes in secretion were observed with 10 μMLH-21 (control: 9
±1.7 pg/islet/min; 0.1 μMLH-21: 25±5.6, p<0.0001; 1 μMLH-21: 15±
0.2, p<0.01; 10 μM LH-21: 10±2.1, p>0.2). The stimulatory effects of
0.1 μM LH-21 on insulin secretion were abolished in islets from GPR55
KO mice (WT: 27±5.4 pg/islet/min, KO: 11.4±7.4, n=3-4, p<0.01).
1 μM LH-21 also potentiated glucose-induced insulin secretion from
isolated human islets (188±16.7 pg/islet/min vs 124±9.3 pg/islet/min at
20 mM glucose, n=3-4, p<0.0001) as did 0.1 and 1 μMAbn-CBD (225
±14.1 and 230±8.7 pg/islet/min, respectively, p<0.0001 vs 20 mM glu-
cose alone). 10 μMAbn-CBD increased CREB phosphorylation by 20%
in WT mouse islets and in MIN6 beta-cells, as revealed by densitometry
analysis of the western blot signals, but it did not alter phosphoCREB
expression in human islets. 0.1 μM LH-21 also promoted CREB phos-
phorylation in MIN6 beta-cells.
Conclusion: Our results indicate that LH-21 potentiates glucose-
stimulated insulin secretion from mouse and human islets and the data
obtained using islets from GPR55 KO mice imply that it exerts these
stimulatory effects by activating GPR55. In contrast, the apparently se-
lective GPR55 agonist Abn-CBD stimulated insulin secretion in a
GPR55-independent manner. Both ligands were capable of inducing
small increases in CREB phosphorylation, suggesting a potential role in
beta-cell mass expansion. A broader knowledge of these novel mecha-
nisms of action of LH-21 and Abn-CBD might offer new approaches to
treat type 2 diabetes.
Supported by: ISCIII PFIS FI11/00363
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Diet-derived short chain free fatty acids stimulate insulin secretion
from mouse and human islets
A. Pingitore, T. Hill, J.E. Bowe, G.C. Huang, S.J. Persaud;
Diabetes Research Group, Division of Diabetes&Nutritional Sciences,
King's College London, UK.
Background and aims: Short chain fatty acids (ScFA) are saturated 2-6
carbon fatty acids originating from fermentation of undigested carbohy-
drates and fibre by gut microbiota, which act as endogenous ligands of G-
protein coupled receptors FFA2 and FFA3. Diets rich in fermentable
carbohydrates improve glucose homeostasis, but it is not known if direct
action of ScFA at islets via FFA2 and FFA3 contributes to this. FFA2
couples to Gi and Gq, while FFA3 is Gi-coupled.
Materials and methods: We have studied the effects of sodium acetate
(SA; C2) and sodium propionate (SP; C3), the main circulating ScFAs, on
insulin secretion from human (HI) and mouse islets (MI) via dynamic
insulin profiling, with quantification of secreted insulin by radioimmuno-
assay. Changes in intracellular Ca2+ in Fura-2-loaded islet cells following
ScFA treatment were measured by single cell calcium microfluorimetry.
Results: Perifused human islets (HI) responded with a significant and
reversible increase in insulin secretion upon exposure to SA (0.1-
1 mM) in the presence of 20mM glucose, with 0.1 mM being as effective
as 1 mM (20 mM glucose: 25.9±3.4 pg/islet/min; +0.1 mM SA: 110.7±
25; +1 mM SA: 118.0±12.9, n=5, p<0.001). Insulin secretion from
human islets was also potentiated by 1 mM SP, albeit to a lesser extent
than with 1 mM SA (20 mM glucose: 24.8±1.9 pg/islet/min; +1 mM SP:
40.3±6.4, n=5, p<0.05). Potentiation of glucose-induced insulin secre-
tion was also observed in response to SA and SP in perifusion experi-
ments using mouse islets (MI), although the magnitude of response was
lower than that seen in human islets (20 mM glucose: 8.0±0.7 pg/ islet/
min; +1 mMSA: 11.5±1.6, n=3, p<0.01; +1mMSP: 25.2±4.8, n=4 p<
0.001 ). Despite the reversible potentiation of insulin secretion observed
upon exposure to SA and SP in perifused human andmouse islets, neither
ScFA significantly affected insulin secretion during one hour static incu-
bation experiments of both HI and MI (HI, 20 mM glucose: 1.8±0.2 ng/
islet/h; +1 mM SP: 1.9±0.2, n=8, P>0.2; MI, 20 mM glucose: 1.0±
0.3 ng/islet/h; +1 mM SP: 1.0±0.1, n=8, P>0.2). Dispersed MI loaded
with Fura-2 responded with reversible increases in free intracellular Ca2+
concentrations in the presence of 20 mM glucose upon exposure to SA or
SP (SA basal to peak difference 0.069±0.025 n=10, p<0.05; SP basal to
peak difference 0.033±0.015, n=12 p<0.05)
Conclusion: Despite reports of an inhibitory role for ScFAs on insulin se-
cretion via FFAs, our dynamic insulin and calcium profiling experiments
depict a different picture, with a stimulatory role of SA and SP, possibly acting
via theGq-coupled FFA2. These data implicate the ScFA receptor system as a
potential pharmacological target in the treatment of type 2 diabetes.
Supported by: European Commission - Marie Curie IEF - FP7
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Potentiation of glucose-stimulated insulin secretion by GPR40-PLC-
TRPC pathway in pancreatic beta cells
H. Yamada1, M. Yoshida1, K. Ito1, K. Dezaki2, M. Kawakami1, S.-E.
Ishikawa1, T. Yada2, M. Kakei1;
1First Department of Comprehensive Medicine, Jichi Medical University
Saitama Medical Center, 2Department of Physiology, Jichi Medical Uni-
versity, Shimotsuke, Tochigi, Japan.
Background and aims: G-protein coupled receptors (GPCRs) are
expressed in pancreatic beta cells. G protein-coupled receptor 40
(GPR40) contributes to medium- or long-chain fatty acids-induced am-
plification of glucose-stimulated insulin secretion (GSIS). Thus, its ago-
nists are promising therapeutic target in type 2 diabetes. Recently we
demonstrated that GLP-1, a ligand of pancreatic GPCR, activates a class
of nonselective cation channel (NSCC) and enhances GSIS. The aim of
the current study is to determine whether GPR40 signal interacts to
NSCCs and to identify what type of channel is related to the NSCC.
Materials and methods: Islets of Langerhans were isolated by collage-
nase digestion from male Wister rats. Measurement of insulin secretion
was performed with static incubations. Perforated whole-cell clamped
currents were recorded at the holding potential of -70 mV in the presence
of 100 μM tolbutamide or at -80 mV without tolbutamide. The latter
potential was used to exclude the influence of KATP-channel current on
NSCC-current changes induced by GPR40 agonist.
Results: GPR40 agonist (fasiglifam 10 μM) potentiated GSIS at
16.7 mM glucose(control vs. fasiglifam 10 μM; 19±0.3 vs. 26.2±
0.8 ng/mL/10 islets/hour), but not at 2.8 mM glucose (5.0±0.1 vs. 6.1±
0.2). NSCC current was activated by fasiglifam at 5.6 mM glucose with
100 μM tolbutamide at the holding potentialof -70 mV(control vs.
fasiglifam 10 μM; -1.8±0.3 pA/pF vs. -3.8±1.2 pA/pF, p=0.016, n=6)
and the consistent results were obtained at 5.6 mM glucose without tol-
butamide at -80 mV. The current increase was prevented by the presence
of 2-APB (a nonspecific NSCCs blocker) or BTP2 (transient receptor
potential canonical; a TRPC channel blocker). Then we examined the
relationship between GPR40 stimulation and phospholipase C (PLC)
downstream of the GPR40 signal. A PLC inhibitor U73122 inhibited
the increase in GSIS of 16.7 mM glucose (fasiglifam vs.
fasiglifam+U73122; 29.7±1.7 vs. 22.9±0.7 ng/mL/10 islets/hour, p<
0.05) and the NSCC-current (fasiglifam vs. fasiglifam+U73122; -1.4±
0.3 pA/pF vs. -1.4±0.9 pA/pF, p=0.99). Fasiglifam did not increase
cytosoic cyclic adenosine 3′,5′-monophosphate (cAMP) concentration
of islets. Protein kinase A inhibitor H89 did not affect the potentiation
of GSIS by fasiglifam at 16.7 mM glucose.
Conclusion: The present study demonstrates a novel mechanism under-
lying potentiation ofGSIS byGPR40 in pancreatic beta-cells. Stimulation
of GPR40-PLC-TRPC channel pathway potentiates GSIS by depolariza-
tion of the beta-cell plasma membrane.
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Extracellular ATP affects stimulus-secretion coupling of mouse pan-
creatic beta cells by activating Ca2+-dependent K+ channels
C. Bauer1, P. Krippeit-Drews1, M. Düfer2, G. Drews1;
1Pharmacology, University of Tuebingen, 2Pharmacology, University of
Muenster, Germany.
Background and aims: ATP acts as an autocrine signal in beta-cells
which affects stimulus-secretion coupling. The signalling cascade down-
stream the activation of purinergic receptors that modulates electrical
activity and the cytosolic Ca2+ concentration ([Ca2+]c) as well as the
consequences for insulin secretion are still a matter of debate.
Materials and methods: Membrane potential (Vm) and Ca
2+ currents
(ICa) were measured using the perforated patch-clamp technique;
[Ca2+]c was determined by fluorescence technique. Experiments were
carried out with clusters of beta-cells from C57Bl/6N wild type and BK
knockout mice.
Results: In 10 mM glucose ATP (100 μM) led to a hyperpolarization of
Vm (Δ-24±4 mV, n=7, p≤0.05) which was reduced by blocking SK4
channels or knock-out of BK channels (Δ-12±1 mV, n=5 and Δ-10±
1 mV, n=9, respectively, p≤0.05). ATP caused a transient peak in
[Ca2+]c after blocking L-type Ca
2+ channels with D600 (100 μM) (Δ24
±2 nM, n=31, p≤0.05). This transient Ca2+ release was inhibited by
either the P2x/y antagonist suramin (200 μM) or emptying Ca
2+ stores
of the endoplasmic reticulum with thapsigargin (1 μM). Surprisingly,
ATP (100 μM) only transiently decreased glucose-induced (10 mM)
Ca2+ oscillations for (235±32 sec, n=24, p≤0.05) to basal values. This
effect was not altered by preincubation with thapsigargin (1 μM). The
time interval of the transient decrease was reduced by blocking SK4
channels or knock-out of BK channels (149±21 sec, n=17, 128±
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21 sec, n=37, respectively, p≤0.05). Moreover, ATP induced a decline in
the maximum amplitude of the Ca2+ oscillations ([Ca2+]cMax) (Δ-285±
47 nM, n=24, p≤0.05). Both ATP effects on [Ca2+]c described above
were blocked by suramin (400 μM) and the effect on [Ca2+]cMax was
mimicked by the P2X agonist α,β-Methylene ATP (100 μM) (Δ-340±
34 nM, n=16, p≤0.05). The reduction in [Ca2+]c) is probably owing to an
ATP-induced decrease in voltage-dependent Ca2+ currents (ICa) (Δ-13±4
pA, n=9, p<0.05) which were elicited by voltage steps from -70 mV to
0 mV.
Conclusion: ATP appears to act as a negative autocrine signal in beta-
cells and seems to exert this effect through ionotropic purinergic P2X
receptors. Obviously, this leads to activation of SK4 and BK channels
as well as a direct inhibition of ICa through L-Typ Ca
2+ channels culmi-
nating in changes of beta-cell electrical activity and [Ca2+]c.
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The calcium sensor sorcin lowers G6PC2 expression to protect
against obesity-induced beta cell failure
A.P. Marmugi, L. Carmichael, G.A. Rutter, I. Leclerc;
Department of Medicine, Imperial College London, UK.
Background and aims: Pancreatic beta cell dysfunction is central to the
pathogenesis of Type 2 diabetes. We have recently reported that the
calcium-sensor sorcin (SRI) prevents glucose-induced nuclear shuttling
of the transcription factor ChREBP (Carbohydrate-responsive element-
binding protein).Moreover, SRI overexpression in pancreatic beta cells in
transgenic mice preserves whole body glucose homeostasis during high
fat feeding, and alleviates endoplasmic reticulum (ER) stress. Here, we
demonstrate a role in SRI signalling for G6pc2 (Glucose-6-phosphatase
2), a regulator of fasting blood glucose in human.
Materials and methods: Transgenic male mice bearing one (SRI-1) or
ten (SRI-10) copies of SRI cDNA, resulting in SRI overexpression spe-
cifically in beta cells, and their littermate controls (CTRL), were main-
tained on a high-fat diet (60%; HFD). Glucose-stimulated insulin secre-
tion (GSIS) was assessed in vivo and ex vivo. Real-time intracellular
calcium imaging was measured using Fura-2 for cytosolic calcium
([Ca2+]cyt) and D4ER for ER calcium ([Ca
2+]ER), and changes in gene
expression was assessed by quantitative RT-PCR on isolated islets.
Results: SRI-10 mice displayed enhanced GSIS in vivo (30 min plasma
insulin (mmol/L): 0.60±0.06 for SRI-10, 0.43±0.04 for CTRL, n=5-7
mice, p<0.05) and ex vivo (% secreted insulin, high glucose condition:
0.57±0.06 for SRI-10, 0.37±0.02 for CTRL, n=3 mice, p<0.01). Con-
comitantly, SRI-1 and SRI-10 islets displayed higher [Ca2+]cyt in response
to high glucose than control islets (AUC (a.u.): 499.1±7.3 for SRI-1,
471.4±7.8 for CTRL, n=3 mice, p<0.05; 165.6±7.1 for SRI-10, 144.3
±5.4 for CTRL, n=3 mice, p<0.05). Moreover, as assessed using acetyl-
choline to fully deplete the ER calcium stores, SRI-10 islets had a greater
[Ca2+]ER compared to controls (fall (%) : -6.1±0.5 for SRI-10, -4.2±0.3
for CTRL, n=3-4 mice, p<0.01). Furthermore, islets from both
SRI-1 and SRI-10 mice showed lowered expression of G6pc2
with respect to those from littermate controls (fold-change nor-
malised to beta-actin: 0.6±0.06 for SRI-1, n=3 mice, p<0.05;
0.4±0.05 for SRI-10, n=5 mice, p<0.01). G6PC2 is a negative
regulator of GSIS whose inactivation in mice leads to increased
[Ca2+]cyt and decreased fasting blood glucose. Similar changes in
fasting blood glucose were observed in our SRI-10 mice on a
HFD (0 min glycaemia (mmol/L): 8.7±0.4 for SRI-10, 10.9±0.8
for CTRL, n=9-11 mice, 8-week-old, p<0.05).
Conclusion: SRI appears to preserve beta cell function during high fat
feeding at least in part by lowering G6pc2 expression. This is likely to
increase glucose 6-phosphate levels, elevate ER calcium, lower ER stress,
and potentiate GSIS. Such changes may avert or delay the decline in
insulin secretion which underlies progression towards Type 2 diabetes.
Supported by: Diabetes UK, Wellcome Trust, EFSD/MSD, BBSRC and
MRC
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CAMTA1 - Calcium-Calmodulin Transcriptional Activator 1, a new
player in the regulation of microRNAs and insulin secretion
I.G. Mollet, H.A. Malm, A. Wendt, M. Orho-Melander, L. Eliasson;
Clinical Sciences, Malmö, Lund University, Malmö, Sweden.
Background and aims: CAMTAs are calmodulin-binding transcription-
al activators highly conserved across a wide range of multicellular eu-
karyotes, involved in cell differentiation in response to environmental
stresses. Mammalian CAMTA1 and CAMTA2 came to our attention as
putative transcription factors involved in miR-212/132 expression, a clus-
ter which responds to glucose and cyclic AMP in rat insulin secreting β-
cells and is upregulated in islets of the diabetic Goto-Kakizaki (GK) rat
model. Our aim was to examine the role of CAMTAs in insulin secretion
and the regulation ofmiR-212/132 expression in islets and the INS-1 832/
13 insulin secreting beta-cells.
Materials and methods: Human and rat islets and INS-1 832/13 cells
were conditioned for hours or days at various glucose concentrations,
cyclic AMP stimulation and/or alpha-2 adrenergic stimulation. Insulin
secretion was determined by radioimmunoassay. Gene knockdowns were
performed with siRNA. Gene expression was determined by qPCR. Lu-
ciferase assaywas performed using a construct containing the promoter of
miR-212/132.
Results: In GK rat islets incubated for 24 h at 16.7 mM glucose or 6 days
at 5 mM glucose CAMTA1 and CAMTA2 expression was markedly
reduced compared to Wistar control: 24 h at 16.7 mM glucose (n=4),
CAMTA1 (p=6.7E-4), CAMTA2 (p=6.9E-3); six days at 5 mM glucose
(n=4), CAMTA1 (p=5.4E-4), CAMTA2 (p=0.028). In human islets
CAMTA1 and CAMTA2 are both upregulated after 72 h at 16.7 mM
glucose compared to 5 mM glucose (n=7): CAMTA1 (p=4.0E-4);
CAMTA2 (p=0.023). Knockdown of CAMTA1 reduced insulin secre-
tion (p=9.0E-3, n=3) in INS-1 832/13 cells and upregulated miR-132
(p=0.032, N=3). Luciferase expression frommiR-212/132 promoter was
upregulated after knockdown of CAMTA1 (p=7.0E-4, n=3). In
INS-1 832/13 cells expression of CAMTA1 was reduced after
2 h in Forskolin/IBMX (p=9.8E-3, n=3) and after 48 h of
50 nM clonidine (p=4.1E-3, n=3).
Conclusion: This data show that CAMTA1 expression is modulated not
only by glucose and cyclic AMP in beta-cells but also by alpha-2 adren-
ergic stimulation and is involved in the regulation of insulin secretion and
expression from the miR-212/132 promoter. We believe that CAMTA1 is
therefore a new player involved in the pathways that lead to reduced
insulin secretion in the diabetic GK model.
Supported by: Vetenskapsrådet, EXODIAB/LUDC, Albert Påhlsson,
Svenska Diabetesförbundet
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Elucidating the role of protein-coding variants in type 2 diabetes
susceptibility
A. Mahajan, on behalf of ExT2D Exome Chip Consortium, for
PROMIS, CHARGE and T2D-GENES/GoT2D;
Wellcome Trust Centre for Human Genetics, Oxford, UK.
Background and aims: Changes in protein-coding sequence have been
hypothesised to be particularly enriched for variants of large-effect on
complex human diseases. Such variants are more likely to have functional
impact and support more direct biological interpretation than non-coding
alleles. To evaluate the contribution of coding variants to type 2 diabetes
(T2D) risk, we combined exome array data from 208,465 individuals
(50,760 cases and 157,705 controls) in 39 studies from five ancestry
groups: European (78.1%), South Asian (11.7%), African American
(5.6%), Hispanic (3.0%), and East Asian (1.5%).
Materials and methods:Within each study, we tested single variants for
association with T2D, with/without body-mass index (BMI) adjustment,
using a linear mixed model to account for relatedness and population
structure. We combined association summary statistics across studies in
a fixed-effects z-score effective sample size weighted meta-analysis. In
established genome-wide association study (GWAS) loci, we investigated
the relationship between coding variants and previously reported lead
SNPs (where available on the exome array) through approximate condi-
tional analyses implemented in RareMetal.
Results: A total of 36 coding variants, mapping to 22 loci, were associ-
ated with T2D at exome-wide significance (P <5×10-7) in European only
or trans-ethnic meta-analysis. All but three were common, with minor
allele frequency (MAF) >5% in the ancestry driving the association.
Eleven variants were located outside established T2D GWAS loci. These
included common variants in ZZEF1 (L1972P, P=4.6×10-9 and I2014V,
P=1.3×10-8), POC5 (H36R, P=3.4×10-7), PNPLA3 (I148M, P=5.7×
10-8), and a low-frequency variant (MAF=1%) in FAM63A (Y285N, P=
6.1×10-8). Of these, POC5 maps to a known BMI GWAS locus and the
PNPLA3 variant has been implicated in fatty liver disease. The other 25
variants mapped to established T2D susceptibility loci. These included
nine variants in SLC30A8, MACF1, GCKR, PPARG, KCNJ11-ABCC8,
and PAM-PPIP5K2, which were confirmatory of previously-reported
coding alleles that drive GWAS association signals. However, the 16
remaining variants have not previously been directly implicated in T2D
susceptibility, and not reported to drive the non-coding association signal.
Amongst novel variants that were distinct from the GWAS signal was
GIPR E354Q, for which T2D association observed only after BMI ad-
justment (P=2.4×10-8), but which was not eliminated after conditioning
on the previously reported inter-genic lead SNP (Pcond=3.6×10-6).
Conversely, at the CILP2 locus, a coding variant in TM6SF2 (E167K;
P=1.0×10-10) was indistinguishable from the previously reported lead
SNP (Pcond=0.11), suggesting that the GWAS signal is mediated
through this gene.
Conclusion: Our results indicate that low-frequency and rare coding
variants of large effect do not make a major contribution to T2D risk.
However, these analyses implicate several novel genes in T2D pathogen-
esis, and provide direct insight into the underlying biology of the disease.
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A meta-analysis of Japanese genome-wide association studies identi-
fied seven novel susceptibility loci to type 2 diabetes
M. Imamura1, S. Maeda1,2, T. Yamauchi3, K. Hara4, M. Iwata5, H.
Hirose6, K. Yasuda7, H. Watada8, H. Maegawa9, C. Ito10, Y. Tanaka11,
K. Tobe5, K. Kaku12, R. Kawamori8, T. Kadowaki3;
1Laboratory for Endocrinology,Metabolism andKidney Disease, RIKEN
Center for Integrative Medical Sciences, Yokohama, 2University of the
Ryukyus, Nakagami-gun, 3The University of Tokyo, 4Tokyo Medical
University, , 5University of Toyama, 6Keio University, Tokyo, 7National
Center for Global Health and Medicine, Tokyo, 8Juntendo University,
9Shiga University of Medical Science, Otsu, 10Grand Tower Medical
Court, Hiroshima, 11St. Marianna University School of Medicine, Kawa-
saki, 12Kawasaki Medical School, Kurashiki, Japan.
Background and aims:Genome-wide association studies (GWAS) have
been extensively performed in diverse ethnic groups, and have identified
over 80 loci for susceptibility to type 2 diabetes; ~50 loci from European
GWAS and ~30 loci from non-European or trans-ethnic GWAS meta-
analysis. Although many loci have been shown to be common loci for
conferring susceptibility to type 2 diabetes across different ethnic groups,
the joint effects of these variants could explain only less than 10% of the
heritability for type 2 diabetes. To identify novel genetic loci associated
with susceptibility to type 2 diabetes further, we expanded Japanese
GWAS by combining a new Japanese GWAS data (Stage-1; 9,817
cases and 6,763 controls, BioBank Japan) with a GWAS data in previ-
ously reported case-control samples (Stage-2; 5,646 cases and 19,420
controls, BioBank Japan).
Materials and methods: We analyzed ~7.5 million single nucleotide
polymorphisms (SNPs) data obtained from genotype imputation per-
formed by mini-mac using directly genotyped data (Study-1; Omni-
express exome, Study-2; Illumina 610 K SNP array) and reference data
in the 1000 genomes (JPT+CHB+CHS, n=275), and combined the re-
sults of the 2 GWAS with a meta-analysis using the inverse variance
method. As a result, we have identified 17 novel loci showing suggestive
evidences for the association with type 2 diabetes (p<1×10-6) in Japanese
populations. These loci were further evaluated in an independent Japa-
nese case-control study (Stage-3; 7,936 cases and 6,478 controls, multi-
center) using de novo genotyping data obtained by the multiplex PCR-
invader assay.
Results: After combining all the association data (Stage-1, Stage-2 and
Stage-3) for the 17 loci by a meta-analysis, the association of 7 loci
reached to a genome-wide significant level (p<5×10-8); rs1116357 on
chromosome (Ch) 2: p=9.20×10-11, OR (95%CI)=1.10 (1.07-1.13),
rs147538848 on Ch12: p=2.96×10-10, OR (95%CI)=1.11 (1.08-1.15),
rs1575972 on Ch9: p=1.14×10-9, OR (95%CI)=1.19 (1.13-1.26),
rs67839313 on Ch15: p=2.05×10-9, OR (95%CI)=1.09 (1.06-1.13),
rs9309245 on Ch2: p=4.21×10-9, OR (95%CI) =1.11 (1.07-1.14),
rs7107784 on Ch11: p=5.97×10-9, OR (95%CI)=1.15 (1.10-1.20),
rs67156297 on Ch1: p=4.30×10-8, OR (95%CI)=1.13 (1.08-1.18). The
effect sizes (odds ratio) of these 7 SNPs were similar before and after
adjusting for age, sex, and BMI.
Conclusion: By performing the largest Japanese GWAS meta-analysis,
we have identified 7 new loci associated with susceptibility to type 2
diabetes in the Japanese population.
Supported by: Japan MEXT Leading Project
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High-density imputation and trans-ethnic association analysis re-
veals a novel locus for type 2 diabetes susceptibility
A.P. Morris;
Department of Biostatistics, University of Liverpool, UK.
Background and aims: The Resource for Genetic Epidemiology Re-
search on Adult Health and Aging (GERA) is a large multi-ethnic
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population-based cohort, created for investigating the genetic and envi-
ronmental basis of common age-related diseases, including type 2 diabe-
tes (T2D). Participants were genotyped using one of four custom arrays,
designed to maximise coverage of common and low-frequency variants
in non-Hispanic white, East Asian, African-American and Latino ethnic-
ities. With these data, this study aimed to discover loci for T2D suscep-
tibility through high-density imputation and trans-ethnic association anal-
ysis and to evaluate the evidence for heterogeneity in allelic effects on the
disease between ancestry groups.
Materials and methods: After quality control, 71,604 unrelated partici-
pants, including 9,747 T2D cases, were retained for analysis and imputed
up to the multi-ethnic reference panel (Phase 3, October 2014 release)
from the 1000 Genomes Project Consortium. High-quality imputed var-
iants were tested for association with T2D in a logistic regression model,
after adjustment for sex and eigenvectors from principal components
analysis to account for trans-ethnic and ancestry-specific population
structure.
Results:Common lead SNPs at ten loci attained genome-wide significant
evidence (p<5×10-8) of association with T2D, including a novel signal
mapping to TOMM40 (p=2.8x10-9). This gene has been previously im-
plicated in Wolfram Syndrome, a neurodegenerative disorder
characterised by diabetes mellitus. Across lead SNPs for the ten loci,
nominal evidence of heterogeneity in allelic effects between ethnicities
was observed only at TCF7L2 (pHET=0.012), where the risk allele had the
lowest T2D odds-ratio for participants of East Asian ancestry.
Conclusion: This study provides further evidence for the homogeneity of
allelic effects of common T2D risk variants across diverse populations,
and highlights the benefits of trans-ethnic analysis for the discovery of
novel loci associated with the disease.
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Genome-wide association study imputed to 1000 Genomes Project
reference panels reveals 17 novel associations with type 2 diabetes
R. Mägi1, R.A. Scott2, A.P. Morris3, L. Marullo4, K. Galton5, M.
Boehnke6, J. Dupuis7, M.I. McCarthy5, L.J. Scott6, I. Prokopenko8, DI-
AGRAM consortium;
1Estonian Genome Center, Tartu, Estonia, 2MRC Epidemiology Unit,
University of Cambridge School of Clinical Medicine, 3Department of
Biostatistics, University of Liverpool, UK, 4Department of Life Sciences
and Biotechnology, University of Ferrara, Italy, 5Wellcome Trust Centre
for Human Genetics, Oxford, UK, 6Center for Statistical Genetics and
Dept of Biostatistics, University ofMichigan, Ann Arbor, 7Department of
Biostatistics, Boston University School of Public Health, USA, 8Geno-
mics of Common Disease, Imperial College London, UK.
Background and aims: Genome-wide association studies (GWAS)
using imputation based on the HapMap 2 reference panel (analysis of
2.5 M single nucleotide variants (SNVs)), have identified more than 70
loci associated with type 2 diabetes (T2D). These loci are exclusively
common, with minor allele frequency (MAF)>5%. The aim of current
work was to detect additional common (MAF≥5%) and low-frequency
(0.5%≤MAF<5%) T2D associated loci using the denser 1000 Genomes
(1000G) Project imputation reference panel.
Materials andmethods:Weperformed imputation using theMarch 2012
release of the 1000G “all ancestries” reference panel in 26,676 T2D cases
and 132,532 controls from 18 European GWAS. The 1000G panel pro-
vides more comprehensive coverage than HapMap for imputation of both
common and low frequency variants. Amongst more than 12 million
SNVs in meta-analysis of which 2.9 M were low frequency, we followed
up those achieving p<5×10-5 in an additional 14,545 cases and 38,994
controls of European ancestry genotyped with Metabochip.
Results: In combined meta-analysis, we identified 17 novel loci achieving
genome-wide significant (p<5×10-8) associationswith T2D.All lead SNVs
were commonwithMAF>10%, including loci mapping to/near PLEKHA1
(p=1.8×10-12), APOE (p=1.5×10-10), andCENPW (p=5.9×10-10). On the
basis of the meta-analysis, we defined 99% credible sets of variants that
weremost likely to drive the association signal in established and novel loci.
The 99% credible set contained fewer than 20 SNVs at 17 loci.Within these
17 credible sets, we were able to find coding variants for three genes
(HNF1A, CTRB2, ADCY5), which were not present in HapMap2.
Conclusion: Our results highlight the potential for the identifica-
tion of novel T2D loci through imputation up to 1000G reference
panels, and highlight functional mechanisms driving association
signals at three loci through coding variants that were not present
in HapMap2.
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Genome-wide association studies on kidney complications in patients
with type 1 diabetes
N. Sandholm1,2, E. Ahlqvist3, H. Deshmukh4, N. Van Zuydam5, N.W.
Rayner5, V. Harjutsalo1,6, M.L. Marcovecchio7, J. Cooper7, A.J.
McKnight8, R.M. Salem9, M. Lajer10, D. Tregouet11, L.T. Hiraki12, M.
Pezzolesi13, C. Forsblom1,2;
1Folkhälsan Institute of Genetics, Folkhälsan Research Center, 2Abdom-
inal Center Nephrology, University of Helsinki and Helsinki University
Hospital, 3Skåne University Hospital, Lund University, Malmö, Sweden,
4University of Dundee, 5Wellcome Trust Centre for Human Genetics,
Oxford, UK, 6National Institute for Health and Welfare, Helsinki, Fin-
land, 7University of Cambridge, 8Queen’s University of Belfast, UK,
9Broad Institute, Cambridge, USA, 10Steno Diabetes Center, Gentofte,
Denmark, 11INSERM UMR_S 1166, Paris, France, 12Hospital for Sick
Children, Toronto, Canada, 13Joslin Diabetes Center, Boston, USA.
Background and aims: Diabetic nephropathy is a common and serious
complication of type 1 diabetes (T1D), but few genetic risk factors have
been identified. Our aim was to detect genetic risk factors by performing
genome-wide association studies (GWAS) on a variety of renal pheno-
types in four European studies with 5,156 T1D patients from the SUM-
MIT Consortium.
Materials and methods:We employed seven different case-control def-
initions based on the severity of diabetic nephropathy (DN; micro-/mac-
ro-albuminuria and/or end stage renal disease (ESRD)), chronic kidney
disease (CKD; estimated glomerular filtration rate (eGFR) <60 ml/min),
or a combination. The proportion of phenotypic variance explained by the
GWAS SNPs, the narrow-sense heritability, was estimated in
3,415 Finnish patients (GCTA). Genotype imputation with the
1000 Genomes (March 2012) resulted in 8,578,867 variants (mi-
nor allele frequency ≥0.01) found in at least two studies. Associ-
ation analysis with an additive model was adjusted for sex, dia-
betes duration, age at diabetes onset, and kinship matrix
(EMMAX). Meta-analyses were performed using a sample size
weighted method (METAL). Associations with p<5×10-6 were
in silico replicated in six additional GWAS with 7,041 T1D pa-
tients and data on renal complications.
Results: Heritability of DN was estimated to be 35% (p=0.006), or 50%
after adjusting for sex, duration of T1D, and age at T1D onset (p=2.5×
10-4). Strongest heritability was estimated for the combined CKD andDN
vs. no CKD and normal AER phenotype (59%, p=0.0011). A total of 101
loci reached p<5×10-6 in GWAS meta-analyses. After joint meta-
analysis with the in silico studies, no locus reached genome-wide signif-
icance, but three reached a suggestive p<10-6: on chromosome (chr)
7q36.1 near CNTNAP2 for the combination of DN and CKD (p=6×10-
7); on chr4q21.3 near PTPN13 for ESRD (p=6×10-8); and on chr2q11.2
in AFF3 for ESRD (p=3×10-7). In a look-up from the SUMMIT meta-
analysis of 5,717 patients with type 2 diabetes (T2D), only the AFF3
signal showed any corroboration for kidney phenotypes (CKD+DN:
T2D p=0.002, T1D+T2D p=2×10-7). These three SNPs, and a SNP near
NRG3with p<0.05 for DN in replication, were further genotyped in up to
1,800 T1D patients. However, the associations were not significant and
did not improve the overall p-values.
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Conclusion: Although no locus was robustly associated with renal com-
plications in T1D, these analyses support the role of AFF3, and suggest a
notable genetic contribution, especially for the more extreme phenotypes.
Supported by: EU's 7th Framework Program (FP7, IMI/115006 (the
SUMMIT Consortium))
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Synergistic effect of genetic susceptibility and poor glycaemic control
on renal decline in patients with type 1 diabetes and proteinuria
J. Skupien1,2, A.M. Smiles2, A.T. Galecki3, J.C. Mychaleckyj4, M.G.
Pezzolesi2, A.S. Krolewski2;
1Department of Metabolic Diseases, Jagiellonian University Medical
College, Krakow, Poland, 2Section on Genetics and Epidemiology, Joslin
Diabetes Center, Boston, 3University of Michigan, Ann Arbor, 4Univer-
sity of Virginia, Charlottesville, USA.
Background and aims: The key phenotype of diabetic nephropathy, the
renal decline, is a progressive loss of glomerular filtration rate that even-
tually leads to end-stage renal disease (ESRD). Its genetic background is
not well understood. Glycemic control may be an important modifier of
genetic susceptibility to renal decline.
Materials and methods: As a part of search for genes determining time
to onset of ESRD in type 1 diabetes (T1D) patients with proteinuria we
sought for common genetic variants associated with renal decline, whose
effect on the slope of renal decline is modified by glycemic control. We
examined 544 patients with T1D and proteinuria, followed for up to
24 years. Serial serum creatinine determinations were obtained during
the follow-up. We used a joint longitudinal-survival model, which ac-
counts for informative censoring in those who rapidly progress to ESRD.
We tested for an interaction with HbA1c in strata below and above values
of 8.0% or 63.9 mmol/mol (1st quartile), 9.1% or 76.0 mmol/mol
(median) and 10.5% or 91.3 mmol/mol (3rd quartile). The patients were
genotyped with the Illumina HumanCoreExome Beadarray 1.0.
Results: We identified two variants associated with renal decline with
genome-wide significant effect modification by HbA1c. A minor allele of
rs10997250 polymorphism (minor allele frequency 7.2%) in patients with
fair glycaemic control (HbA1c<10.5%) was not associated with a signif-
icant change in the slope of renal decline (1.0 ml/min/1.73 m2/year less
decline per one additional minor allele, p=0.24), while in patients with
poor glycaemic control (HbA1c≥10.5%) an additional minor allele was
associated with a 9.1 ml/min/1.73 m2/year steeper renal decline than in
those with fair glycaemic control (p=2.2×10-8 for the interaction). Sim-
ilarly, a minor allele of rs12877579 (minor allele frequency 14.8%) in
patients with fair glycaemic control was associated with 0.8 ml/min/
1.73 m2/year less decline (p=0.20), but in patients with poor glycaemic
control an additional minor allele resulted in a 6.9 ml/min/1.73 m2/year
steeper renal decline than in the patients with fair glycaemic control (p=
4.2×10-8 for the interaction). This gene-environment interaction can be
also presented as estimated mean slopes for each genotype and HbA1c
stratum. For the variant rs10997250 the mean slopes of renal decline in
patients with fair glycemic control in major homozygotes, heterozygotes
and minor homozygotes were -5.7, -4.5 and -7.5 ml/min/1.73 m2/year,
respectively. In those with poor glycemic control they were -8.9, -17.2
and -23.8 ml/min/1.73 m2/year. The respective means for the rs12877579
variant were -5.8, -4.7, -5.7 and -8.3, -15.0, -17.7 ml/min/1.73 m2/year.
No significant interactions were found for HbA1c strata formed by thresh-
olds 8.0% and 9.1%.
Conclusion: The minor alleles of variants rs10997250 on chromosome
10 and rs12877579 on chromosome 13 have strong deleterious effect on
renal decline only in patients with poor glycaemic control. Genetic sus-
ceptibility and poor glycemic control seem to have synergistic effect on
the risk of renal decline. This phenomenon should be accounted for in
studies of genetics of diabetic nephropathy.
Supported by: JDRF grant 17-2013-8 (A.S.K.) and JDRF grant 3-2009-
397 (J.S.).
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Empagliflozin reduces HbA1c with lower insulin doses in patients
with type 1 diabetes: a 4-week placebo-controlled trial (EASE-1)
T.R. Pieber1, S. Famulla2, J. Eilbracht3, J. Cescutti4, N. Soleymanlou5,
O. Johansen6, H.J. Woerle7, U.C. Broedl7, S. Kaspers7;
1Medical University of Graz, Austria, 2Profil, Neuss, 3Boehringer
Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 4Boehringer
Ingelheim France, Reims, France, 5Boehringer IngelheimCanada Ltd./Ltee,
Burlington, Canada, 6Boehringer Ingelheim Norway K.S, Asker, Norway,
7Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Background and aims: In the EASE-1 study, we investigated the phar-
macodynamics, efficacy and safety of empagliflozin (EMPA) as adjunct
to insulin in patients with type 1 diabetes.
Materials andmethods: In this Phase II, double-blind trial, patients with
type 1 diabetes were randomized to placebo (PBO; n=19), EMPA 2.5 mg
(n=19), EMPA 10 mg (n=19) or EMPA 25 mg (n=18) as adjunct to
insulin (multiple daily injections) for 28 days. Insulin dose was to be kept
as stable as possible for 7 days and was freely adjustable thereafter. The
primary exploratory endpoint was change from baseline in 24-h urinary
glucose excretion (UGE) at day 7.
Results: EMPA significantly increased 24-h UGE vs PBO at days 7 and
28. At day 28, EMPA significantly reduced HbA1c vs PBO, with reduc-
tions in fasting plasma glucose, and a significant reduction in recorded
total daily insulin use. EMPA significantly reduced weight vs PBO at day
28. Adverse events (AEs) were reported in 94.7%, 89.5%, 78.9% and
100.0% of patients on PBO, EMPA 2.5 mg, 10 mg and 25 mg, respec-
tively. AEs consistent with urinary tract infection were reported in one
patient (on EMPA 25 mg). No AEs consistent with genital infection were
reported. In PBO, EMPA 2.5 mg, 10 mg and 25 mg groups, respectively,
19, 8, 10, and 13 symptomatic hypoglycemic episodes with glucose
≤54 mg/dL not requiring assistance were reported. One hypoglycemic
episode requiring assistance was reported (on PBO).
Conclusion: In patients with type 1 diabetes, EMPA for 28 days as
adjunct to insulin increased UGE, improved HbA1c and reduced weight
with lower insulin doses vs PBO and was well tolerated. EMPA is not yet
approved for use in patients with type 1 diabetes.
Clinical Trial Registration Number: NCT01969747
Supported by: Boehringer Ingelheim and Eli Lilly and Company
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Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improves
glycaemic control in type 1 diabetes mellitus in a randomised, place-
bo-controlled, double-blind study
W. Cefalu1, A.T. Sands2, J. Rosenstock3, P. Lapuerta2, B.W. Bode4, S.K.
Garg5, J.B. Buse6, P. Banks2, R. Heptulla7,M. Rendell8, B. Zambrowicz2,
P.S. Strumph2;
1Pennington Biomedical Research Center, Baton Rouge, 2Lexicon Phar-
maceuticals, Inc., The Woodlands, 3Dallas Diabetes and Endocrine Cen-
ter, 4Atlanta Diabetes Association, 5University of Colorado Denver/
Barbara Davis Center for Childhood Diabetes, Aurora, 6University of
North Carolina Diabetes Care Center, Chapel Hill, 7Albert Einstein Col-
lege of Medicine/Montefiore Medical Center, Bronx, 8Creighton Diabe-
tes Center, Omaha, USA.
Background and aims: Dual inhibition of both SGLT1 and SGLT2 may
provide additional benefit above that achieved with SGLT2 inhibition
alone when used as adjunctive therapy to insulin in T1DM. Sotagliflozin
(LX4211) is a dual inhibitor of sodium-glucose cotransporters SGLT1
and SGLT2. In T1Dwe hypothesized that inhibition of SGLT1, the major
intestinal glucose transporter, would reduce glucose absorption in the
gastrointestinal tract, with an increase in incretins. SGLT2 inhibition re-
duces renal glucose reabsorption.
Materials and methods: This 29-day study evaluated 33 subjects with
T1D (ages 21-57 years, duration of diabetes 3-42 years) with screening
A1C of 7.0%-9.0%, treated with insulin pump or multiple daily injection
therapy who were randomized to double-blind treatment with
sotagliflozin 400 mg or placebo once daily.
Results: All participants completed the study. Raw means are displayed;
p-values for change from baseline and between group effects are based on
least squares means, unless otherwise noted.
Conclusion: Sotagliflozin a next generation SGLT inhibitor, significantly
reduced A1C levels, daily bolus and total daily insulin dose, postprandial
blood glucose, and body weight, and increased PYY in T1D with no
increase in hypoglycemia risk. Larger studies of a longer duration are
needed to confirm these findings.
Clinical Trial Registration Number: NCT01742208
Supported by: The Robert and Janice McNair Foundation, Houston, TX,
USA
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Dapagliflozin modulates SGLT1 and GLUT2 expression and gluca-
gon secretion in a SGLT2-independent manner in murine alpha cells
A. Solini1, L. Nigi2, E. Santini1, G. Sebastiani2, B. Astiarraga1, C. Rossi1,
F. Dotta2;
1Dept of Clinical and Experimental Medicine, University of Pisa, 2De-
partment of Medicine, Surgery and Neuroscience, University of Siena,
Italy.
Background and aims: SGLT2 inhibitors reduce plasma glucose levels
via a forced glycosuria through inhibition of glucose uptake by the kid-
ney, with a fully insulin-independentmechanism. However, recent studies
show increased glucagon concentrations after acute or chronic adminis-
tration of SGLT2 inhibitors. Whether or not such effect is consequence of
a series of systemic metabolic variations rather than due to a direct effect
on pancreatic α-cells is unclear.
Materials and methods:We tested this hypothesis by treating for differ-
ent times (30, 45, 60 min and 12 h) murine pancreatic α-cell line (alpha-
TC1) with 100 ng/ml dapagliflozin (Dapa), and measuring its effect on
the expression of glucose transporters, molecular mediators of hormone
secretion and glucagon and GLP-1 release.
Results: SGLT2 was not detectable in these cells even by digital PCR
technique. SGLT1, was quite abundantly represented and was significant-
ly increased by Dapa at 30’ and 45’(+65±21% and + 16±3% vs untreat-
ed, p<0.001 and 0.05, respectively). GLUT1 expression was substantial-
ly unaffected by Dapa (-5% at 30’and -7% at 45’), while GLUT2 was
down-regulated (-24±60% at 30’ and -19±23% at 45’, both p<0.005). At
12 h, the expression of both glucose transporters returned to baseline
levels. Similarly, Dapa did not induce variations in the expression of
several molecules involved in the modulation of glucagon release or α-
cell phenotype (fold induction at Dapa 30’ vs untreated=CHGA: 1.10±
0.17; PAX6 1.13±0.14; PCSK2: 1.20±0.18; PCSK1: 0.99±0.18; SYP:
1.14±0.23, all p=ns).Moreover, GLP-1 receptor expression did not differ
in α-cells treated or untreated with Dapa. Accordingly, glucagon release
minimally changed in cells pretreated with Dapa (at 30’: 822±76 vs 828±
85; at 45’: 1198±127 vs 1515±112 pg/ml/μg protein, both p=ns). Of
note, at 12 h, glucagon release was significantly lower in Dapa-treated
cells (3524±254 vs 2446±157 pg/ml/μg protein, p<0.005). GLP-1 did
not significantly change after Dapa (at 30’: 610±76 vs 640±52; at 45’:
842±96 vs 1000±118pmol/ml/μg protein, both p=ns). At 12 h, GLP-1
was 3533±216 in untreated cells and 3604±270 pmol/ml/μg in Dapa-
treated cells (p=ns). Low (5.5 mM) or high (25 mM) glucose pulses did
not affect SGLT1, GLUT1 or GLUT2 expression, while glucagon (2210
±125vs 1725±117 pg/ml/μg protein, p<0.05) and GLP-1 release (2671±
139 vs 2090±154 pmol/ml/μg protein, p<0.01) secretion were slightly
but significantly reduced by high glucose.
Conclusion: Dapa acutely upregulates SGLT1 and downregulates
GLUT2 expression in pancreatic α-cells, while SGLT2 was not detect-
able in these cells. In addition, glucagon release was significantly reduced
after long-term (12 h) treatment with Dapa. These data suggest that the
glucagon raise reported in type 2 diabetes patients treated with Dapa does
not reflect the direct action of this molecule on pancreatic α-cells.
Supported by: AZ International
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Dapagliflozin potentiates glucagon secretion at high glucose: experi-
mental findings and mathematical simulation
I. Ahlstedt1, M. Gram Pedersen2, E.-M. Andersson1, S.O. Göpel1;
1Bioscience, AstrazenecaR&D, Mölndal, Sweden, 2Information Engi-
neering, Univ. Padua, Italy.
Background and aims: Inhibiting glucose re-absorption in the kidney by
blocking the Na+/glc co-transporters SGLT has been proven to be a safe
and effective treatment for diabetes. However, recently it was discovered
that SGLT inhibition raises hepatic glucose output and plasma glucagon
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levels. It is plausible that the former is caused by the latter and we thus
attempted to investigate the direct effect of the SGLT2 blocker
Dapagliflozin on glucagon secretion from pancreatic islets.α-cells re-
spond to low glucose levels with increased glucagon secretion which is
directly regulated by the electrical activity of the cell. The current gener-
ated by the electrogenic SGLT-transporters is thus expected to affect
glucagon secretion by changes of the membrane potential. We construct-
ed a mathematical model of α-cell electrical activity based on data from
human α-cells which is able to explain our experimental findings.
Materials and methods:Mice islets were prepared by pancreas collage-
nase digestion and for human islets assay ready 3D InSight™ plates were
used. Islets were kept for 1 h under the indicated conditions and glucagon
levels determined using ELISA-kits from Merocodia. For each prepara-
tion secretion was measured in 6-8 wells and median secretion calculated.
Values were normalized to secretion at 1 mMglc and data are presented as
average from indicated number of preperations. A Hodgkin-Huxley type
model of electrical activity was constructed including KATP, Nav, T-, L-
and P/Q-type Cav, A-type and delay-rectifier Kv-channels based on pub-
lished human A-cell electrophysiological data. A previously published 6-
state model of SGLT Na+/glc co-transport was included to analyze the
effect of SGLT currents on α-cell electrophysiology. Simulations were
performed in XPPAUT using the cvode solver.
Results: In mouse islets raising the glucose concentration to 11 mM glc
reduced glucagon secretion to 17 +/- 2.6% (n=16) compared to 1 mM
glc. Dapagliflozin (10 nM) had no effects at 1 mM glc but increased
secretion from 17% to 59.1 +/-22% (n=13) at high glucose. In human
islets Dapagliflozin had similar effects (19.2+/-3.5% at 11 mM glc, 32.7
+/- 7.3% with 11 mM glc + Dapagliflozin n=5). We then simulated the
effects of glucose and Dapagliflozin on the membrane potential. High
(11 mM) and low (1 mM) glucose was simulated by changing the extra-
cellular glucose concentration (Go) in the SGLT submodel and varying
the KATP-channel conductance (G-KATP) between 0.19 nS and 0.17 nS,
which resulted in action potentials reaching 10 mV and -12 mV, respec-
tively. Inhibition of SGLT2 at Go and G-KATP corresponding to low
glucose had almost no effect whereas at high glucose it increased action
potential peaks from -12 mV to 15 mV.
Conclusion:Ourα-cell model reproduces the effects of glucose on action
potential firing seen in membrane potential recordings in rodent α-cells.
Dapagliflozin directly stimulates glucagon secretion from pancre-
atic islets at high glucose. Since glucagon secretion is strongly
dependent on the maximal depolarization reached during an action
potential, the increased action potential height upon SGLT2 inhi-
bition in our model fits well to our secretion data. These findings
potentially explain the observation that diabetic subjects treated
with SGLT-blockers experience elevated glucagon levels and in-
creased hepatic glucose output.
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Dapagliflozin reduces albuminuria on top of renin-angiotensin sys-
tem blockade in hypersensitive patients with diabetes
H. J. Lambers Heerspink1, E. Johnsson2, I. Gause-Nilsson2, C.
Sjöström2;
1Dept of Clinical Pharmacology, University Medical Center Groningen,
Netherlands, 2AstraZeneca, Mölndal, Sweden.
Background and aims: Hypertension (HTN) and albuminuria are risk
factors for cardiovascular (CV) and renal disease in patients with type 2
diabetes mellitus (T2DM). Glycaemic, blood pressure (BP) and albumin-
uria control are critical to reducing CV and renal risk. Dapagliflozin
(DAPA) reduces HbA1c and BP in patients with T2DM. The aim of the
study was to characterise the effect of DAPA on albuminuria and estimat-
ed glomerular filtration rate (eGFR).
Materials and methods: Data was pooled from 2 studies for patients
with T2DM, micro- or macroalbuminuria and HTN, who were assigned
to DAPA 5 mg (n=87), 10 mg (n=167) or placebo (PBO; n=189). All
patients were on stable angiotensin-converting enzyme inhibitor or an-
giotensin receptor blocker therapy.
Results:At 12 weeks, DAPA resulted in greater reductions from baseline
vs PBO in albuminuria (as assessed by albumin:creatinine ratio [ACR]).
Reductions in HbA1c and systolic BP (SBP) vs PBO were also observed
(Table). There was a decrease in eGFR with DAPA vs PBO, which was
readily reversed 1 week after the last dose. DAPA’s ACR-reducing effect
was also present after adjusting for changes in HbA1c, SBP and eGFR.
There were no increases in serum creatinine≥1.5×baseline for DAPA 5
or 10 mg vs PBO (0%, 1.2%, 1.1%, respectively). Potassium≥6 mEq/L
values were also similar for DAPA 5 or 10 mg vs PBO (1.2%, 2.4%,
2.2%, respectively). There were no serious renal-related adverse events
(AEs) in any group.
Conclusion: DAPA reduces ACR in T2DM patients with HTN using
renin-angiotensin system blockade without increasing serious renal AEs.
Clinical Trial Registration Number: NCT01137474, NCT01195662
Supported by: AZ
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Canagliflozin reduces both HbA1c and body weight in patients with
type 2 diabetes on background dipeptidyl peptidase-4 inhibitors or
glucagon-like peptide-1 agonists
V. Woo1, C. Wysham2, C. Mathieu3, F. Vercruysse4, G. Capuano5,
G. Fulcher6;
1Endocrinology Section, Department of Internal Medicine, University of
Manitoba, Winnipeg, Canada, 2Washington State University, Spokane,
USA, 3Laboratory of Experimental Medicine and Endocrinology, KU
Leuven, 4Janssen Research & Development, Beerse, Belgium, 5Janssen
Research & Development, LLC, Raritan, USA, 6The Royal North Shore
Hospital and University of Sydney, Australia.
Background and aims: Canagliflozin (CANA), a sodium glucose co-
transporter 2 (SGLT2) inhibitor approved for the treatment of type 2
diabetes mellitus (T2DM), has been shown to provide reductions in
HbA1c and body weight (BW) compared with placebo (PBO) over
18 weeks in subgroups of patients on background dipeptidyl peptidase-
4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) agonists from
the CANagliflozin cardioVascular Assessment Study (CANVAS), an on-
going, randomised, double-blind, study in patients with T2DM and a
history or high risk of cardiovascular disease; this post hoc analysis eval-
uated the proportion of patients who had decreases in both HbA1c and
BW with CANAversus PBO at Week 18.
Materials andmethods:Of the 4,330 patients enrolled in CANVAS, 316
patients were taking DPP-4 inhibitors (mean baseline HbA1c, 8.1%; BW,
90.7 kg) and 95 were taking GLP-1 agonists (mean baseline HbA1c,
8.1%; BW, 108.8 kg). Patients were randomised to receive CANA 100
or 300 mg or PBO. Using individual patient data, the proportion of pa-
tients achieving both change from baseline in HbA1c <0% and BW<0 kg
was assessed at Week 18.
Results: At Week 18, least squares (LS) mean changes in HbA1c with
CANA 100 and 300 mg and PBO were -0.46%, -0.64%, and 0.10%,
respectively, in patients taking DPP-4 inhibitors; LS mean percent
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changes in BW were -3.2%, -3.9%, and -0.9%, respectively. In patients
taking GLP-1 agonists, LS mean changes in HbA1c at Week 18 with
CANA 100 and 300 mg and PBO were -0.83%, -0.89%, and 0.17%,
respectively; LS mean percent changes in BW were -3.0%, -3.7%, and -
0.4%, respectively. In the DPP-4 inhibitor subgroup, a greater proportion
of patients had reductions in both HbA1c and BW at Week 18 with
CANA 100 and 300 mg versus PBO (65.3%, 78.1%, and 29.2%, respec-
tively; PBO-subtracted differences [95% confidence interval (CI)] of
36.2% [22.2, 50.2] and 48.9% [35.9, 62.0]). A greater proportion of
patients in the GLP-1 agonist subgroup also had reductions in both
HbA1c and BW at Week 18 with CANA 100 and 300 mg versus PBO
(82.4%, 85.7%, and 24.1%, respectively; PBO-subtracted differences
[95% confidence interval (CI)] of 58.2% [34.9, 81.6] and 61.6% [37.8,
85.3]). CANA was generally well tolerated in both subgroups with a
safety profile similar to that seen in previous Phase 3 studies of CANA.
Conclusion: CANA provided greater attainment of reduction in both
HbA1c and BW versus PBO at Week 18 and was generally well tolerated
in patients with T2DM as add-on to DPP-4 inhibitors or GLP-1 agonists.
Clinical Trial Registration Number: NCT01032629
Supported by: Janssen Research & Development, LLC
OP 32 Insights into lifestyle
and diabetes
187
Is access to the outdoors associated with childhood overweight and
obesity?
B.C. van der Zwaard1,2, A. Schalkwijk1,2, P.J.M. Elders1,2,
G. Nijpels1,2, L. Platt3;
1General practice and elderly care medicine, VU medical center,
2EMGO+ Institute for Health and Care research, Amsterdam, Nether-
lands, 3Social Policy, London School of Economics and Political Science,
London, UK.
Background and aims: Overweight and obese children are at increased
risk of becoming overweight and obese adults and therefore an important
risk factor for developing type 2 diabetes. Being overweight or obese is
associated with environmental, parental and socioeconomic status (SES)
characteristics. The aims of this study were to assess the association of
environmental characteristics during ages 3-5 on being overweight or obese
at age 7. Furthermore we assessed if parental behaviors moderate or medi-
ate this influence. In the final stage of our analysis we assessed if the
influence of SES on the derived model the previous aims was assessed.
Materials andmethods: The analysis used theMillenniumCohort Study;
a nationally representative study of around 19,000 children born in the UK
between 2000-2001who are followed over time.We use measures from the
surveys carried out at age 9 months, 3 years, 5 years and 7 years. Logistic
regression was used to test the initial association between the outcome
measure overweight/obese (according to the age specific Cole criteria)
and determinants: amount of green space in the neighborhood, having
access to a garden and the condition (i.e. shabbiness) of the neighborhood.
Subsequently, parental determinants consisting of variables summarizing:
food consumption, physical activity, rules and regularity were evaluated as
moderators or mediators of the initial association. Lastly SES related vari-
ables, namely education level, housing tenure and poverty were tested as
moderators or mediators of the associations.
Results: Statistically significant associations (p≤0.05) were found be-
tween low levels green space, not having access to a garden, shabbiness
of the neighborhood and childhood obesity (OR (95% CI) respectively:
1,14 (1,02-1,27), 1,35 (1,16-1,58), 1,22 (1,05-1,42)). Parental determi-
nants were related to the environmental determinants and childhood
overweight/obese but did not moderate or mediate the association be-
tween the latter two. Therefore no parental variables were left in the
model. For SES, the highest level of education in the household did
diminish the magnitude of the associations found between the environ-
mental determinants and being overweight/obese. In the final model the
remaining significant associations with childhood overweight/obese were
no garden access for lower educated households and shabbiness of the
neighborhood for higher educated households (OR (95% CI) respective-
ly: 1,41 (1,09-1,84), 1,38 (1,12-1,70)).
Conclusion:Not having access to a garden at age 3 - 5 for lower educated
households increased childhood overweight/obesity at age 7. Also the
combination of a more dilapidated neighborhood and higher education
increased childhood overweight/obesity. To conclude, we showed that
limits on access to outdoors space is associated with future childhood
overweight/obesity although moderated by education level. More re-
search is needed to see how we can deploy these findings in the preven-
tion of type 2 diabetes.
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Body mass index during early adulthood in relation to risk of diabe-
tes in later life among Chinese men and women
H. Du1, L. Li2, D. Bennett1, Y. Guo3, M. Holmes1, Z. Bian4, A. Iona1, L.
Yang1, I. Millwood1, Y. Chen1, R. Collins1, R. Peto1, Z. Chen1;
1CTSU, University of Oxford, UK, 2PekingUniversity, Beijing, 3Chinese
Academy of Medical Sciences, 3Chinese Academy of Medical Sciences,
Beijing, China.
Background and aims: Although adiposity has been established as a
strong risk factor for diabetes, the independent effects of bodymass index
(BMI) in early adulthood on risk of diabetes in middle and older age
remains unclear, particularly in China.
Materials and methods: The study population includes 430,074 partici-
pants (57% women, mean baseline age 51 years) enrolled into the China
Kadoorie Biobank between 2004-8 from 10 diverse localities across China,
for whom self-reported data on weight at 25 years old (weight25) were
available. Information on socio-demographics, lifestyle and personal &
family disease history was collected using an electronic questionnaire. Data
on diabetes incidence was collected through electronic linkage with mortal-
ity andmorbidity registries and the national health insurance system. Height
at 25 years old (height25, in meters) was estimated according to the age
trend of baseline measured height, and body mass index (BMI) at 25 years
(BMI25) was calculated using the standard formula. The Pearson correla-
tion coefficient of weight25 recalled at baseline and at resurvey (~3 years
after baseline, n=14,452) was calculated to assess its reproducibility. Cox
regression models were used to yield hazard ratios (HRs) relating BMI25 to
risk of incident diabetes (between 35-79 years of age), adjusting for age, sex,
region, smoking, alcohol consumption, education, income, baseline values
of BMI and waist circumference, and family history of diabetes.
Results: The correlation coefficient of weight25 reported at baseline and
resurvey was 0.80. Mean (SD) BMI25 was ~2.5 kg/m2 lower [21.4 (2.5)
kg/m2] than BMI at baseline [23.8 (3.4) kg/m2] and the correlation coeffi-
cient between the two was 0.32. During approximately 7-years of follow-
up, 17,105 incident diabetes cases were documented. A J-shaped associa-
tion was observed between BMI25 and diabetes, with risk lowest at BMI25
around 20 (19.5-20.5) kg/m2. Between 20 and 25 kg/m2, diabetes risk
increased by 3-6% per unit BMI25 increase. However, at BMI25>25 kg/
m2 the HR of diabetes increased substantially to 1.61 (95% CI: 1.54-1.68)
(Figure). BMI25 lower than 19.5 was also associated with a 6-9% elevated
risk of diabetes. Although a similar J-shaped association was observed in
both genders and different age groups, stronger associations were observed
in men than in women, and in younger than in older people.
Conclusion: Among Chinese, overweight in early adulthood is associat-
ed with a greatly elevated risk of diabetes in late adulthood. This associ-
ation is independent of family history of diabetes and adulthood adiposity,
highlighting the importance of lifelong body weight control.
Supported by: Kadoorie Charitable Foundation, UK Wellcome Trust,
Chinese National Natural
189
Objectively measured sedentary behaviour patterns according to di-
abetes status: The Maastricht Study
J.D. van der Berg1, C.D.A. Stehouwer2,3, H. Bosma1, J.H.P. van der
Velde4,3, P.J.B. Willems4, H.H.C. Savelberg4, M.T. Schram2,3, S.J.S.
Sep2,3, C.J.H. van der Kallen2,3, R.M.A. Henry2,3, P.C. Dagnelie5,6,
N.C. Schaper3,5, A. Koster1;
1Social Medicine/CAPHRI School for Public Health & Primary Care,
2Cardiovascular Research Institute Maastricht (CARIM), 3Department
of Internal Medicine, 4Dep Human Movement Sciences; School for Nu-
trition and Translational Research in Metabolism (NUTRIM), 5CAPHRI
School for Public Health & Primary Care; Cardiovascular Research In-
stitute Maastricht (CARIM), 6Department of Epidemiology, Maastricht
University, Netherlands.
Background and aims: Studies have shown that physical activity (PA)
plays a role in the development and management of type 2 diabetes
mellitus (T2DM). Next to the role of PA, there has been growing interest
in the role of sedentary behaviour. However, large-scale studies with
objectively measured sedentary behaviour in a population with T2DM
are scarce. Therefore, we examined differences in objectively assessed
sedentary behaviour patterns between participants with T2DM, with pre-
diabetes (impaired glucose metabolism) and without T2DM.
Materials and methods: We included 2,529 participants (aged 40-
76 years) of The Maastricht Study who wore an activPAL accelerometer
24 h/day for 7 consecutive days on the front right thigh. We calculated
percentage sedentary time (ST) of waking time, mean number of breaks
in ST per day (≥1 minute of ST followed by ≥1 minute activity), and
mean step frequency per day (measure for PA). To determine glucose
metabolism status, all participants underwent an oral glucose tolerance
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test. Associations between glucose metabolism status and percentage ST
were examined using linear regression analysis.
Results: 726 participants (28.7%) had T2DM, 391 (15.5%) had predia-
betes, and 1,412 (55.8%) had no T2DM. Participants provided on average
6.4 valid days (defined as ≥14 h of monitoring), and 91%wore the device
6 or more days. Participants with T2DM spent on average (mean ± SD)
10.2±1.8 hours per day sedentary, as compared to on average 9.5±1.8 in
participants with prediabetes and 9.1±1.6 in participants without T2DM
(P<0.001). Mean number of sedentary breaks per day was 35.8±9.3
among participants with T2DM, and 37.4±8.8 and 38.0±8.5 among par-
ticipants with prediabetes and participants without T2DM (P<0.001).
After adjustment for demographic factors (sex, age, level of education),
health factors (smoking status, body mass index, mobility limitation,
history of cardiovascular diseases and chronic obstructive pulmonary
disease), and mean step frequency, participants with T2DM had on aver-
age 22.5 minutes more ST per day (95%CI=16.8 - 28.2; P<0.001) com-
pared to those without T2DM.
Conclusion:Having T2DMwas significantly associated with on average
22.5 sedentary minutes more per day. The results suggest that next to PA,
sedentary behaviour could be an important determinant of the develop-
ment and management of T2DM.
Supported by: EFRO, MUMC+
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Overall dietary characteristics of individuals with high consumption
of beverages previously associated with risk of type 2 diabetes
L. Brunkwall, S. Hellstrand, M. Orho-Melander, U. Ericson;
Diabetes and Cardiovascular Disease, Genetic Epidemiology, Lund Uni-
versity, Clinical Sciences, Malmö, Sweden.
Background and aims: Consumption of several beverages has been
associated with risk of type 2 diabetes; high coffee and tea consumption
has been associated with a decreased risk and high consumption of sugar-
sweetened beverages (SSB) with an increased risk. Regarding juice and
artificially sweetened beverages (ASB), the results are inconclusive. As
beverages are part of our overall diet and lifestyle we hypothesized that
high consumption of these beverages (SSB, ASB, juice, coffee and tea)
may be associatedwith certain characteristics of the overall diet that could
be difficult to take into account when analysing associations between
beverage consumption and disease.
Materials and methods: Analyses were performed among 25 112 indi-
viduals (60% women, 45-74 years, mean BMI=25.6) without prevalent
diabetes, cardiovascular disease or cancer from the population based
Swedish Malmö Diet and Cancer Cohort. Intake of beverages, macronu-
trients and 24 food groups were obtained from a modified diet history
method including a 7-day food record and a 168-item questionnaire. To
examine food intakes across five intake groups of the different beverages,
we used linear regression adjusted for age, sex, season, method, BMI,
leisure time physical activity, total energy intake, smoking, education and
alcohol intake. Bonferroni correction was applied to handle multiple test-
ing and therefore statistical significance was assumed at p<0.002 (0.05/
28=0.002).
Results: We observed a high consumption of SSBs to be significantly
associated with lower intakes of foods generally perceived as healthy; the
largest intake differences between high and low consumers of SSBs were
seen for fruits, vegetables, yoghurt, breakfast cereals, fiber rich bread and
fish (all p-values for trend<0.002). In contrast, high consumption of both
tea and juice was significantly associated with higher intakes of foods
perceived as healthy; largest differences were seen for fruits, vegetables
and yoghurt (all p-values for trend<0.002). High consumption of ASBs
was significantly associated with higher intakes of low fat products; low
fat milk and margarines (both p-values for trend<0.002). High consump-
tion of coffee associated with higher intakes of meat and high fat marga-
rine and a lower intake of breakfast cereals (all p-values for trend<0.002).
Conclusion:We observed that high consumption of beverages that have
previously been associated with risk of type 2 diabetes strongly associates
with characteristics of the overall diet. This might be of importance when
interpreting future studies investigating beverage-disease associations.
Supported by: Swedish Research Council, Swedish Heart and Lund
Foundation, The Novo Nordi
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Maternal smoking during pregnancy is associated with poorer aero-
bic fitness of offspring in young adulthood
M.P. Hagnäs1,2, I. Mikkola2, J. Jokelainen1, H. Cederberg3, U. Rajala1,
S. Keinänen-Kiukaanniemi1;
1Department of Medicine, Center for Life Course Epidemiology and
Systems Medicine, Oulu, 2Rovaniemi Health Centre, 3Department of
Medicine, Kuopio University Hospital, Finland.
Background and aims: In Finland pregnant women are offered a cost-
free health care at municipal maternity welfare clinics and health counsel-
ling is being given incl. adequate/excessive gestational weight gain
(GWG) andmaternal smoking. Our aim was to investigate the association
of maternal pre-pregnancy body mass index (BMI), GWG and maternal
smoking with aerobic fitness and weight in young men aged 19-28.
Materials and methods: Data consisted of 508 mothers and their off-
spring in the Northern Finland Birth Cohort (NFBC 1986) who entered
military service at the Sodankylä Jaeger Brigade in 2005. The associa-
tions of weight, 12-minute running test result (Cooper test),smoking
among offspring on entry to military service were evaluated with antena-
tal factors including maternal smoking, pre-pregnancy BMI and GWG in
this prospective cohort study. Physical activity at the 15-16 years age was
evaluated from questionnaires.
Results: Weight of conscripts whose mothers were overweight and
gained excessive weight during pregnancy was higher (84.4 kg, SD
18.1) than those of overweight mothers whose weight gain was consid-
ered appropriate (73.5 kg, SD 12.5) (p=0.005). Offspring of mothers who
smoked>10 cigarettes / day during pregnancy also had a lower Cooper
test result (2237 m, 95% CI 1930-2544) compared to the offspring of
mothers did not smoke during pregnancy (2537 m, 95% CI 2499-
2574). Multivariate linear regression analysis showed that maternal
smoking, low level of physical activity at 15-16 years age, conscripts
own smoking and own BMI, however not maternal pre-pregnancy BMI
or GWG, were independently associated with worsening of Cooper test
result. According to mediation analysis, conscript’s own BMI mediated
the association of maternal pre-pregnancy BMI and GWG with the Coo-
per test result. Direct effect ofmaternal pre-pregnancy BMI on theCooper
test result of the offspring was 28% (regression coefficient of direct effect
- 4.07, p=0.394) and that of GWG was 60% (regression coefficient of
direct effect - 5.51, p=0.092). No association of birth weight and the
Cooper test result was observed.
Conclusion:Maternal smoking during pregnancy had a long-term nega-
tive impact on the aerobic fitness of the offspring, observed during a 19-
year follow-up. This study highlights the need of health-counsel for preg-
nant women concerning non-smoking and appropriate weight gain during
pregnancy. Supervised exercise and smoking cessation groups for preg-
nant women via maternity clinics could be one way for attaining benefi-
cial circumstances for pregnancy.
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The association between sleep duration and insulin sensitivity: the
EGIR-RISC study
F. Rutters1, H. Besson2, M. Walker3, A. Mari4, B. Balkau5, J.M. Dek-
ker1, on behalf of the EGIR-RISC Study group;
1Department of Epidemiology and Biostatistics, VUmc, Amsterdam,
2PHARMO Institute for Drug Outcome Research, Utrecht, Netherlands,
3Medical School Newcastle University, UK, 4Institue of Biomedical En-
gineering, Padova, Italy, 5EpReC: Renal and Cardiovascular Epidemiol-
ogy UVSO, Inserm U1081 Centre for Research in Epidemiology and
Population Health, Villejuif, France.
Background and aims: In the past 10 years, over three-dozen studies
reported a relationship between short sleep and disturbed glucose metab-
olism. Studies with insulin sensitivity assessed according to the gold
standard hyperinsulinemic-euglycemic clamp are however still missing.
We therefore aimed to evaluate the cross-sectional association between
sleep duration and insulin sensitivity in the European Relationship be-
tween Insulin Sensitivity and Cardiovascular Disease (EGIR-RISC)
study.
Materials and methods:We used data from the baseline measurements
of the European, multi-centre EGIR-RISC study, which included 1259
clinically healthymen and women. Sleep and physical activity were mea-
sured objectively using a single-axis accelerometer, which was worn for
at least 3 days and up to 8 days. Insulin sensitivity was measured by
hyperinsulinemic-euglycemic clamp (M/I). Other markers of metabolic
syndrome included levels of fasting plasma glucose, insulin, 2-h plasma
glucose and insulin as well as BMI, waist circumference and blood
pressure.
Results: In our current analysis, we included 797 participants (57%wom-
en, age 44±8 years). AweakU-shaped association between hours of sleep
and M/I was observed: after adjustment for age and sex, M/I was 10.7 (-
4.4- 25.9),3.6 (-10.2-17.4), -0.8 (-15.9-14.3) and 4.7 (-14.3-23.9)
μmolmin-1kgffm-1nM-1 higher for the 6-7 hour group, 7-8 hour group,
8-9 and the >9 hour group, respectively, compared to the<6 h group.
Additionally, we observed a J-shaped association for basal glucose: after
adjustment for age and sex, glucose levels were 0.13 (0.02-0.24), 0.12
(0.02-0.22), 0.16 (0.05-0.27) and 0.19 (0.05-0.33) mmol/l higher for the
6-7 hour group, 7-8 hour group, 8-9 and the >9 hour group, respectively,
compared to the<6 h group. Similar J-shaped associations were observed
for basal insulin levels and 2-h glucose and insulin levels. No associations
were observed for BMI, waist circumference or blood pressure.
Conclusion: Short and long sleep duration are weakly associated with
insulin sensitivity and markers of glucose homeostasis in a healthy pop-
ulation. Prospective studies are needed to study the temporal associations
in a healthy population.
Supported by: EU grant QLG1-CT-2001-01252
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Six year follow-up after CSII initiation: HbA1c is significantly re-
duced without weight gain
H.U. Andersen, S. Hangaard, E.E. Hommel, M. Ridderstråle;
Steno Diabetes Center, Gentofte, Denmark.
Background and aims:Meta analyses show that treatment with contin-
uous subcutaneous insulin infusion (CSII) lowers HbA1c by 0.3% com-
pared tomulitiple daily injections (MDI) in adult populations. The longest
observation period in the included RCTs was one year. An observational
study included 331 patients that were observed for 5.5 years in ten clinics.
In CSII treated patients, HbA1c decreased 0.42% after 1 and 2 years, but
only 0.2% after 5 years, when compared to time-matched MDI patients.
In our clinic, we have previously found that the HbA1c of 505 patients
was reduced by 0.7% (females) and 0.5% (males) one year after CSII
initiation. In the present study, our aim was to investigate the long term
effect of shift from MDI to CSII on HbA1c and weight.
Materials and methods: All patients were analysed for age, T1D dura-
tion, weight (kg), and HbA1c (IFCCmmol/mol and DCCT%) four years
before and six years after initiation of CSII. Data are mean±standard
deviation. A p-value below 0.05 was considered statistically significant.
Results: Since 2002, 856 patient initiated CSII at our center. Mean age
and T1D duration at CSII initiation were 39±14 years and 21±13 years.
622 patients that had data two years before CSII were included in the
analysis. There was no significant change in weight or in HbA1c prior to
minus 2 years (Fig. 1). HbA1c decreased by 1.6 mmol/mol during the
ensuing period prior to initiation (1.1 mmol/mol between minus 2 years
and minus 1 year (p<0.0002), and 0.5 mmol/mol between minus 1 year
and initiation (p<0.02)). This reduction was concomitant to the patients
receiving education on carbohydrate counting. The total reduction in
HbA1c from minus 2 years to one year after initiation was 8.3 mmol/
mol (p<0.0001). The reduction in HBA1c from initiation to six years
after was 7.8 mmol/mol (n=183, p<0.0001). There was no significant
rise or decline in HbA1c between one and six years after CSII initiation.
Conclusion:Our one year data show a significant HbA1c reduction after
CSII initiation which is comparable, or better, than results from RCTs.
Previous studies have suggested a diminishing effect of CSII on HbA1c
over time. By contrast, here we found a stable reduction of HbA1c in the
six year follow-up period after CSII initiation. Importantly, contrasting
the effect of most other effective glucose-lowering strategies the effect
was obtained without an increase in body weight.
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Effects on glycaemic variability and glyco-metabolic control of an
insulin pump integrated with continuous glucose monitoring system
in type 1 diabetic patients
P. Maffioli, D. Romano, A. D'Angelo, G. Derosa;
Internal Medicine and Therapeutics, University of Pavia, IRCCS
Policlinico S.Matteo, Italy.
Background and aims: Often, insulin pump therapy is not enough to
reach an adequate glycemic control; this is particularly true in type 1
diabetic patients, where glycemic fluctuations are very high. For this
reason, in the latest years, continuous glucose monitoring system
(CGMS) has become available. The aim of this study was to evaluate
the effects of an insulin pump integrated with continuous glucose moni-
toring system (CGMS) compared to insulin pump alone on glycemic
control, and blood glucose variability in type 1 diabetic patients, in a
case-control clinical trial. We also evaluated the degree of patients’ satis-
faction to treatment.
Materials andmethods:We enrolled 38 type 1 diabetic subjects, with an
inadequate glycemic control (glycated hemoglobin >7.5%), with an insu-
lin pump from at least three months. At baseline, patients were instructed
to use a CGMS able to communicate with an insulin pump in an integrat-
ed system. The function of suspension of insulin delivery, in case of
hypoglycemia, was activated. We evaluated: anthropometric measure-
ments, glycated hemoglobin, fasting plasma glucose (FPG), post-
prandial glucose (PPG). These parameters were recorded at baseline, at
3 and 6 months after the placement of the device. Diabetes Treatment
Satisfaction Questionnaire (DTSQ) was used to assess patients' satisfac-
tion toward treatment. The primary analyzed variable was glucose mea-
sured byCGMS and evaluated using area under curve. Percentage of time
spent (based on CGMS records) in different ranges of glucose was also
analyzed. These two variables were analyzed usingWilcoxon signed rank
test, and stepdown Bonferroni (Holm’s) correction of p-values was ap-
plied to adjust p-values for multiple testing. The following variables were
analyzed using Wilcoxon signed rank test: M value, glycated hemoglo-
bin, mean blood glucose, number of hypoglycemia during CGMS (blood
glucose≤70mg/dL), and standard deviation (SD) of glucose measured by
CGMS. Mean amplitude of glycemic excursions (MAGE) measured by
CGMS was analyzed using t-test.
Results: After 6 months since the placement of the integrated system,
there was a decrease of glycated hemoglobin, FPG and PPG compared to
baseline (p<0.05 after 3 months, and p<0.01 after 6 months). The daily
blood glucose variability, expressed as MAGE, was reduced after the
placement of the integrated system. Mean blood glucose, as calculated
from CGMS values, was significantly higher with insulin pump alone
compared to insulin pump + CGMS (172.4±60.4 vs 153.1±51.3, p<
0.05). M value with insulin pump + CGMS was lower compared to
insulin pump alone between 7-8, 10-11, 17-18, and 23-24 h. The SD,
and the MAGE values were significantly lower with insulin pump +
CGMS compared to insulin pump alone (p<0.05). The MODD value at
7-8, and 10-11 h was lower with insulin pump + CGMS compared to
insulin pump alone (p<0.05). Insulin pump + CGMS gave less time spent
with glycemia<70 mg/dl and more time with glycemia between 70 and
180 mg/dL compared to insulin pump alone. There was a greater degree
of satisfaction for the insulin pump integrated with CGMS according to
the DTSQ.
Conclusion: The insulin pump integrated with CGMS better improved
glycemic control, glycemic variability and patients’ satisfaction in type 1
diabetic patients compared to insulin pump alone.
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Medical imaging for performance characterisation of a novel contin-
uous subcutaneous insulin infusion set
R.J. Pettis1, N.G. Bolick1, D.E. Sutter2, B. Pflug3, B.W. Bode4, L.J.
Hirsch3;
1Parenteral & Translational Sciences, 2Corporate Clinical Development,
BD Technologies, Research Triangle Park, 3Medical Affairs, BD, Frank-
lin Lakes, 4Atlanta Diabetes Associates, USA.
Background and aims: Insulin pump therapy for Continuous Subcutane-
ous Insulin infusion (CSII) is a highly effective method of glycemic control
for diabetic patients. However, CSII set performance is often characterized
as the “Achilles heel” of an otherwise sophisticated control system. An
investigational flow-stabilizing infusion set with 28G, 6 mm side-ported
polymer catheter has been designed to reduce infusion delivery pressures,
stabilize flow performance, and minimize insulin flow stoppages that may
occur without triggering pump alarms (e.g. “silent occlusions”). Medical
imaging can be highly informational but is not a routine testing procedure
for delivery devices. The objective of this study was to utilize various
imaging techniques to characterize the in vivo flow and deposition perfor-
mance of the investigational CSII set against control 6 mm and 9 mm
commercial polymer sets in both animal and human studies.
Materials and methods: In vivo fluoroscopy was performed using both
static and dynamic imaging during bolus (10U) infusion of iodinated
contrast media on anesthetized swine from the investigational set and
commercial controls. Images were analyzed for location of device place-
ment in the tissue, bolus depot patterning, and occurrence of delivery
faults such as incomplete insertion and leakage. A corollary human
MRI study with saline placebo was performed in 8 non-diabetic subjects
across multiple bolus volumes (2-20U) and various routine insulin infu-
sion sites (arm, thigh, abdomen, and gluteus). The addition of MR con-
trast enhancers was not required for effective depot visualization.
Results: For each imaging modality, contrast-filled polymer catheters were
visible in situ. Depotswere clearly visible after bolus administration, even at
low bolus volumes. The investigational ported set typically exhibited more
diffuse subcutaneous (SC) depot patterns in contrast to denser more local-
ized depots observed frommarketed sets. Side-port flowwas typically most
readily observed during stepwise boluses of increasing volume (Figure 1).
The investigational set demonstrated effective SC placement and placebo
delivery at all anatomical sites tested sites during the human trial.
Conclusion: Both fluoroscopic and MR imaging techniques provide ef-
fective characterization of CSII set insertion and bolus delivery perfor-
mance at relevant anatomical sites and may enable better comparative
device performance assessment. The investigational catheter set porting
appears to create an auxiliary tissue flow pathway that may reduce occlu-
sion and stabilize flow.
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Effect of sensor augmented pump treatment on fear of
hypoglycaemia and quality of life in subjects with dysregulated type
1 diabetes
H.-C. Andersen, H. Andersen, E. Hommel, M. Ridderstråle;
Steno Diabetes Center, Gentofte, Denmark.
Background and aims: To investigate the one year effect of sensor
augmented pump (SAP) treatment on glycaemic control and quality of
life of subjects with dysregulated type 1 diabetes (DT1D) and/or prob-
lematic hypoglycaemia.
Materials and methods: As part of quality assurrance we studied 64
patients on insulin pump (32 male and 32 female) with DT1D (HbA1c
>69 mmol/mol for >12 months), or problematic hypoglycaemia (un-
awareness or≥one severe episode during the preceding year) who were
offered SAP. Primary endpoints were decrease in HbA1c and effect on
quality of life as evaluated by the Hypo Fear Scale (HFS), ProblemAreas
in Diabetes (PAID), andWHO5. Non-parametric statistical analyses were
used to compare responses before and one year after SAP was initiated.
Data are expressed as mean±sem.
Results: The average age was 44±1.7 years. Baseline HbA1c was 75.3±
1.5 mmol/mol (n=64), HFS 38±3 (n=53), PAID 26.6±2.6 (n=54); 19.4±
2.7 and 35.0±4.1 for males (n=29) and females (n=25), respectively (p=
0.004), and WHO5 15.1±0.7 (n=59). More than five episodes of severe
hypoglycaemia had been experienced by 33%. Any degree of
hypoglycaemia unawareness was significantly more common in this group
(p=0.02). After one year 48 patients (75%) were still using SAP. These
were significantly older than those who stopped (45±2 vs. 39±3, p=0.04)
but there was no difference in duration of diabetes or time on pump. Aver-
age sensor use was 9.0±0.6 out of 12months; 34 patients (71%) reporting a
use greater than 2/3 of the time. HbA1c decreased in both SAP users and in
those who stopped using SAP (from 73.8±1.6 to 66.1±1.7 [n=48;
p<0.0001] and 80.3±3.5 to 72.9±3.2 [n=14; p=0.001], in users and
non-users, respectively). There was no correlation between time on SAP
andHbA1c lowering. By 12months HFS had decreased significantly (from
38.1±3.2 to 28.9±3.4; n=39, p=0.001), as had PAID (from 25.2±2.6 to
20.9±2.6; n=41, p=0.007), whereas there was no difference in WHO5.
PAID>30, a level indicating high diabetes related distress, was found in
62% of those who stopped using sensor, compared to 31% for the SAP
users, (p=0.047). The influence of SAP on the top three PAID score ques-
tions at baseline are shown in Table 1. WHO5 score<13, indicating de-
clined wellbeing, was found in 16% of the SAP users and 43% of patients
who stopped using sensor (p=0.035).
Conclusion: Additional to a significant improvement in HbA1c, SAP
seems to offer specific support concerning the fear of hypoglycaemia
and diabetes related distress to subjects with T1D who are prone to
hypoglycaemia with no negative impact on overall wellbeing of the pa-
tients from the use of sensors.
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HbA1c improvement with less hypoglycaemia in patients with type 1
diabetes wearing an artificial pancreas for two months from dinner
to breakfast
J.H. DeVries1, J. Place2, J. Kropff1, S. del Favero3, F. di Palma4, G.
Lanzola4, A. Farret2, F. Boscari5, A. Avogaro5, S. Galasso5, D.
Bruttomesso5, E. Renard2, C. Cobelli3, L. Magni4, AP@home
consortium;
1Internal Medicine F4-222, Academic Medical Center, Amsterdam,
Netherlands, 2Endocrinology, Diabetes, Nutrition,Montpellier University
Hospital, France, 3Information Engineering, University of Padova, 4Civil
Engineering and Architecture, University of Pavia, 5Internal Medicine,
University of Padova, Italy.
Background and aims:Wearable artificial pancreas (AP) at home from
dinner to breakfast appears a safe concept for first routine use in patients
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with Type 1 diabetes (T1D). We explored this concept in the first AP trial
with sufficient length to assess HbA1c.
Materials and methods: Thirty-five adult T1D patients with insulin
pumps and an HbA1c between 7.5 and 10% were enrolled in a random-
ized crossover trial comparing AP use from dinner to wake-up time and
sensor augmented pump (SAP) during day-time vs. all day SAP under
free-living conditions. The design included a run-in of 2 weeks with SAP
and a wash-out of 4 weeks between 2 periods of 2 months. AP was
achieved by connecting a continuous glucose monitor (CGM) and insulin
pump to a smart-phone which ran a Model Predictive Control algorithm.
CGM data from the last 6 weeks of each period were analyzed on an
intention-to-treat basis with % time in target [70-180 mg/dL] from 20:00
to 08:00 as primary endpoint. HbA1c change was analysed with an
ANOVA model with patient, period and treatment as factors.
Results: Three patients dropped out, 1 before and 2 shortly after random-
ization, due to poor system acceptance. 18 (56%) of 32 analysed patients
were female, HbA1c was 8.2±0.6% and age 47.0±11.2 years. From 20:00
to 08:00, time in target was higher with AP: 67.0 vs. 57.8% (paired
difference 8.2%, IQR 5.0-14.4, p<0.0001), through a reduction in %time
both >180 mg/dL and <70 mg/dL: 31.8 vs. 38.6% (paired difference
6.7%, 95%CI 3.7-9.8, p<0.0001) and 1.7 vs. 3.0% (paired difference
1.3%, IQR 0.5-3.0, p<0.0001). Also over 24 hrs, higher time in target
was seen with AP (63.7 vs. 58.9%, paired difference 5.0%, IQR 1.7-7.8,
p=0.00017), again through a reduction in %time both >180 mg/dL (33.5
vs. 36.9% paired difference 4.3% IQR 0.7-7.4, p=0.00179) and <70 mg/
dL (2.2 vs. 3.0%, paired difference 1.0% IQR 0.3-1.7, p=0.00013).
HbA1c was reduced 0.18% more on AP (95%CI 0.00 to 0.36, p=0.047).
Conclusion: AP from dinner to wake-up time increases % time in target
range during this time period and also over 24 hours, due to a decrease in
time both above and below target and with a significant decrease in
HbA1c. These results support AP from dinner to breakfast as a safe and
beneficial option for moving to the market.
Clinical Trial Registration Number: NCT02153190
Supported by: FP7-ICT-2009-4 grant number 247138
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Delivery of exenatide by subdermal placement of ITCA 650 in a
nonclinical model demonstrates 1 year of continuous exposure and
tolerability
D.T. Zane1, L. Thorner1, M. Baron2, M. Charan1, T. Zoetis3, R. Fiel-
ding4, C. Papagiannis5, T. Alessi1;
1Product Development, Intarcia Therapeutics, Hayward, 2Clinical Re-
search, Intarcia Therapeutics, Boston, 3SciLucent, Herndon, 4Biologistic
Services, Boulder, 5MPI Research, Mattawan, USA.
Background and aims: ITCA 650 is a mini osmotic pump designed to
deliver exenatide as a continuous zero-order subdermal infusion. In an
ongoing 2-year carcinogenicity study, rats received ITCA 650 at
exenatide doses of 0, 3, 10 (females), 20 (males) and 40 mcg/d. The
low and high doses were selected to provide approximately 4-fold and
25-fold exposure multiples of the anticipated clinical dose (60 mcg/d).
Materials and methods: On Day 1, an ITCA 650 osmotic minipump or
placebowas placed subdermally in each rat. At 6-month intervals, devices
were removed and replaced with another of the same dose at the same site
to provide continuous exposure during the 2-year study. Plasma exenatide
was measured by a validated ECL assay in toxicokinetic group animals
on Day 365/366.
Results: There was no evidence of systemic toxicity and survival was not
adversely affected by treatment. As expected from the pharmacology of
exenatide, a decrease in body weight gain (up to 40% vs control) was
noted in ITCA 650-treated groups. Macroscopic evaluation of tissues
local to the placement site revealed a minimal tissue response to the
device. Despite repeated removal and replacement of devices during the
study, microscopic observations were minimal to mild in all groups, with
minimal inflammation in some animals. Exenatide exposures increased as
the dose increased from 3 mcg/d to 40 mcg/d. Comparing Day 365
AUC24h with human AUCs at the clinical dose (60 mcg/d) showed that
this study achieved exposure multiples of at least 7.3-fold at the mid dose
and 18.1-fold at the high dose.
Conclusion: These results are relevant to the human experience as
prolonged exposure and repeat minipump placements did not result in
any local or systemic toxicologic differences between the active and
control groups.
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Non-invasive determination of the beta cell mass with 111In-exendin-3
in rodent models for spontaneous type 1 diabetes
L. Joosten1, M. Brom1, D. Bos1, C. Frielink1, H. Peeters2, E. Himpe3, L.
Bouwens3, O.C. Boerman1, M. Gotthardt1;
1Department of Radiology and Nuclear Medicine, Radboud university
medical center, Nijmegen, 2Radiation Oncology, GROW mumc, Maas-
tricht, Netherlands, 3Cell differentitation, Vrije Universiteit, Brussel,
Belgium.
Background and aims:The beta cell mass (BCM) plays a key role in the
development and progression of diabetes, but the onset of beta cell loss
and the relationship between loss of beta cell mass and beta cell function
still needs to be unraveled. A non-invasivemethod to determine the BCM
in vivo allows measurement of the BCM over time during the develop-
ment and progression of type 1 and 2 diabetes. Exendin-3 is a stable
analogue of glucagon-like peptide 1 (GLP-1) and has high affinity for
the GLP-1 receptor, which is specifically expressed on beta cells. Recent-
ly, targeting of the GLP-1 receptor on beta cells was proven to be a
successful method to determine the beta cell mass in vivo in a rat model
of chemically induced beta cell loss. Furthermore, in a first clinical proof-
of-principle study these preclinical data were confirmed. In this study we
investigated the potential of 111In-exendin-3 to determine the BCM
in vivo in a mouse and rat model that closely mimic the development of
type 1 diabetes in humans: Non-obese Diabetic (NOD) mice and
BioBreeding Diabetes Prone (BBDP) rats. In these models the potential
of SPECT, the relationship between the BCM, exendin uptake in the
pancreas and insulitis were investigated.
Materials and methods: NOD mice (n=78) of 7-21 weeks old and
BBDP rats (n=45) of 4-18 weeks of age were injected intravenously with
15 MBq 111In-exendin-3. SPECT/CT Images were acquired 1 h p.i. and
the animals were euthanized after SPECT/CT acquisition. The pancreas
and relevant organs were dissected, weighed and the radioactivity in the
organs was measured in a gamma counter. The pancreas was fixed in
formalin, embedded in paraffin and sections were used for histology,
determination of the beta cell mass by morphometric analysis and degree
of insulitis.
Results: With SPECT the pancreas in both rats and mice was visualized.
Biodistribution showed high uptake of 111In-exendin in the pancreas in
healthy mice of 7 weeks of age (15.1±2.5%ID/g) and a significantly re-
duced uptake in diabetic mice of 21 weeks old (10.1±3.8%ID/g, p=
0,0379). In BBDP rats a reduction in pancreatic uptake of more than ninety
percent was found. In BBDP rats and NOD mice the correlation (Pearson)
between the BCM (mg) and pancreatic uptake (%ID) was 0.80 (p<0,0001)
and 0.42 (p<0,0002), respectively. Ex vivo autoradiography showed high
uptake in the exocrine pancreas inmice, but not in rats, whichmight explain
the difference in correlation between BCM and uptake between both
models. In severely diabetic rats, with no insulin-positive cells, the pancreas
was undetectable by autoradiography. Furthermore, insulitis did not have an
influence on the uptake of exendin in the pancreas.
Conclusion: In conclusion, the BCM can be determined after injection of
111In-exendin-3 in a mouse and rat model for type 1 diabetes, closely
mimicking the human development of type 1 diabetes. Furthermore, the
pancreas can be visualized with SPECT in both models. These results
indicate that 111In-exendin-3 is a promising tracer to determine the BCM
during the development of type 1 diabetes, without interference of severe
insulitis or insulin treatment. However, due to exocrine uptake of exendin
in mice, rat models would be more suitable than mouse models when
studying the GLP-1R in diabetes.
Supported by: JDRF
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Immune subsets profile through disease onset, remission phase and
final establishment in type 1 diabetic children
C. Martins1, A.L. Fitas2, G. Nunes1, R. Pina2, L. Lopes2, S. Lenzen3,
L.M. Borrego1, C. Limbert2;
1CEDOC-NMS, 2HDE - CHLC, Lisbon, Portugal, 3MHH, Hannover,
Germany.
Background and aims: Type 1 diabetes (T1D) is an autoimmune disease
with regulatory/effector T cell imbalance. Its autoinflammatory nature
makes it possible to develop new therapies based on immune-modulatory
strategies. Immunologic characterization along the natural history of the
disease (onset, remission and established T1D) is essential for better
targeting the immune treatment and to identify key immunological markers
that will allow monitoring future interventions towards immune balance
restoration. The aim of this study was to evaluate the dynamics of T cell
subsets from T1D onset to final establishment, in children.
Materials and methods: T1D children (n=24) were followed along 3
time points of the disease (t1 - onset, t2 - remission, t3 - establishment).
Peripheral blood (PB) samples from patients and matched controls were
analyzed by flow cytometry. Treg were identif ied as the
CD4+CD25+CD127dim subset within CD3+T cells. Th1, Th17, Tc1
and Tc17 cells were identified through the production of IFN-γ and
IL17 within CD4 and CD8 T cells, after a 5 h stimulation with
PMA+Ionomycin, at 37°C, 5% CO2.
Results:Compared to controls, in t1, T1D children presented a tendency for
lower % of Treg, recovering in t2. At t3, Treg % and absolute counts were
significantly impaired, also compared to t1 and t2 (p<0.05). Again in t1, a
significantly lower % of IFN-γ secreting cells (Th1 and Tc1) was observed
(p<0.05) compared to t2 and t3. Despite this tendency for higher values in
the final t2 and t3 evaluations, none of the time points significantly differ
from controls. In contrast, compared to controls, Th17 cells were significant-
ly impaired in all time points (p<0.05), in particular t1. Tc17 present the
same profile, but their % recover to levels similar to controls in t3.
Conclusion: To our knowledge, this is the first study evaluating the
immune profile throughout T1D stages. Our data points to a more pro-
inflammatory profile as the disease evolves, with loss of Treg, and in-
creasing IFN-g, as well as Il-17, producing Tcells. Although the status of
Treg in T1D onset is controversial, our study shows a significant Treg
imbalance only after disease establishment. The normal values of Treg in
remission may be related to the apparent control of the immune response
at this stage. The increasing Th1/Tc1 compartments observed in T1D
establishment are in accordance with the less effective presence of sup-
pressive Treg. Also, remission corresponds to regeneration of β-cells and
normalization of glycaemia, which can lead to new inflammatory events
with subsequent Th1/Tc1 differentiation and activation. A more promi-
nent Th17 response in T1D has been suggested. We report lower circu-
lating Th17 cells in T1D patients, though recovering at established dis-
ease. Accordingly, recent studies report increased Th17 cells in pancreatic
lymph nodes (PLN), but not in PB, speculating the migration of Th17 to
target organs later in the disease. In our study, circulating Th17 and Tc17
were impaired in early stages of T1D, when massive destruction of pan-
creatic tissue occurs, which suggests an early migration of Th17 into
target tissues, associated with tissue damage events. The chemotactic
capacity of Th17 towards neutrophils can reinforce our data, as PB neu-
trophils were impaired in T1D patients, mostly in t1 and t2. PLN immune
profile evaluation would help the interpretation of our data on the quest
for immune markers and therapeutic targets for T1D.
Supported by: Sanofi
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Relationship between islet specific autoantibodies at the diagnosis
and the first autoantibody marking initiation of the autoimmune
process in children with type 1 diabetes
J. Ilonen1, J. Lempainen2, A. Hammais2, T. Härkönen3, J. Toppari1, R.
Veijola4, M. Knip3;
1University of Turku, 2Immunogenetics Laboratory, University of Turku,
3University of Helsinki, 4University of Oulu, Finland.
Background and aims: Serum autoantibodies specific for islet antigens
characterize the onset of type 1 diabetes and also predict development of
the disease. Demographic and genetic associations with the presence of
specific autoantibodies have been described suggesting immunological
heterogeneity in the immunology of the disease. Prospective follow-up
studies collecting samples from children at genetic risk starting from birth
on have recently made it possible in many cases to detect the first islet
autoantibody to appear. This has revealed patterns associated with the
specificity of this autoantibody. In the present study we aimed to compare
islet autoantibodies detected at the diagnosis of overt diabetes with the
first autoantibodies initiating the diabetes associated autoimmunity.
Materials andmethods:Antibody data from the children participating in
the follow-up cohort of the Finnish Diabetes Prediction and Prevention
(DIPP) study who had developed clinical type 1 diabetes were analysed.
A single first islet autoantibody out of three (IAA, GADA and IA-2A)
could be identified in 135 of 233 (57.9%) children who had developed
type 1 diabetes.
Results: The results are summarized in the Table. The most common
initializing autoantibody was IAA followed by GADA and IA-2. How-
ever, when the presence of various antibodies was compared at diagnosis,
IA-2A was the autoantibody most often detected followed by IAA and
GADA.
Conclusion: These results can be used to estimate to what extent the
presence of various autoantibodies at diagnosis reflects the initiating au-
toantibody. Because of antigen spreading and disappearance of some
autoantibodies (especially in the case of IAA), during the prediabetic
period autoantibody status at diagnosis gives limited information on the
development of islet autoimmunity. In addition antibody status at diag-
nosis is largely affected by the variable proportion of different first auto-
antibodies at various ages.
Supported by: SA, SJF, JDRF
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Functional defects of regulatory T cells and the influence of age in
naïve and memory T cells in new-onset type 1 diabetes and first
degree relatives
G. Treiber1, B. Prietl1, E. Fröhlich-Reiterer2, M. Tauschmann2, A.
Ribitsch1, E. Lechner1, W. Graninger3, T.R. Pieber1;
1Devision of Endocrinology and Metabolism, 2Devision of Diabetes and
Endocrinology, 3Devision of Rheumatology and Immunology, Medical
University Graz, Austria.
Background and aims: T cells are key mediators of autoimmune dis-
eases like type 1 diabetes (T1D) and regulatory T cells (Tregs) are a
critical subset that plays an indispensable role in maintaining
immunotolerance. In the present study, we aimed to assess number and
function of Tregs as well as naïve and memory T cell population in
children and adults with new-onset T1D compared to first degree relatives
(FDR) and heathy controls and we evaluated age effects on Tcell subsets.
Materials and methods: Peripheral blood cells from 14 adult T1D (age:
35±12ys), 29 juvenile T1D patients (age: 12±4ys), agematched FDR (20
children, 38 adults) and healthy controls (17 children, 55 adults) were
quantified by a multi-parameter FACS analysis. Apoptosis and suppres-
sive capacity of Tregs were measured in vitro with FACS sorted Tregs and
stimulated autologous effector T cells.
Results: The suppressive capacity of Tregs was decreased in children
with T1D (mean±SEM; 20.6±6.6% vs 39.4±4.2% vs 43.8±6.4% p=
0.024) and adult T1D patients (7.5±8.1% vs 34.5±3,6% vs 39.7±2.0%
p<0.001) in comparison to FDR and healthy. Apoptosis of Tregs was
only significantly increased in children with T1D (2.83±0.68% vs 1.24±
0.31% vs 0.67±0.19%, p=0.026) but apoptosis of effector T cells were
increased (p=0.001) in adults with T1D. Number and function of Tregs
did not change with age within the group of new onset T1D, FDR or
healthy controls but naïve CD4+CD25hi decreased and memory
CD4+CD25hi T cells increased with age in each group.
Conclusion: Our data show that Tregs function is impaired in juvenile
and adult new-onset T1D, which is already seen in FDR. Furthermore age
influences the frequencies of naïve and memory CD4+CD25hi T cells and
the functional differences in peripheral Tregs suggest an age dependent
defect of Tregs function in the pathogenesis of T1D.
Supported by: BioPersMed (COMET K-project 825329), EFSD/MSD
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Autoantibodies to posttranslationally modified insulin in type 1
diabetes
R. Strollo1,2, C. Vinci1, M.H. Arshad1, D. Perrett3, C. Tiberti4, F.
Chiarelli5, N. Napoli2, P. Pozzilli2,6, A. Nissim1;
1Centre for Biochemical Pharmacology, Queen Mary University of Lon-
don, UK, 2Endocrinology & Diabetes, University Campus Bio-Medico,
Rome, Italy, 3BioAnalytical Science, Queen Mary University of London,
, 4Department of Experimental Medicine, Sapienza University of Rome,
Italy, 5Department of Pediatrics, University of Chieti, Italy, 6Centre for
Diabetes, Queen Mary University of London, London, UK.
Background and aims: Insulin is themost specific antigen for pancreatic
beta-cells and a primary potential autoantigen in type 1 diabetes. Al-
though insulin autoantibodies (IAA) are the earliest marker of beta-cell
autoimmunity only half of children with newly-diagnosed type 1 diabetes
and fewer patients diagnosed in adult age are positive to IAA. The aim of
this investigation was to determine if insulin, posttranslationally modified
by reactive oxidants (oxPTM) present within the inflamed beta-cells mi-
croenvironment, could generate neoantigenic epitopes.
Materials and methods: oxPTM of insulin were induced by incubation
with reactive oxidants such as ribose and various reactive oxygen species
(ROS). Modifications were analysed by polyacrylamide gel
elecrophoresis, 3-dimensional fluorescence and mass spectrometry. Re-
activity to posttranslationally modified insulin by ROS (oxPTM-INS)
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was measured by ELISA, radioimmunoassay andWestern blotting, using
sera from 114 patients with newly-diagnosed type 1 diabetes and 113
healthy controls.
Results:Mass spectrometry mapped oxPTM of insulin to chlorination of
Tyr16 and 26; oxidation of His5, Cys6 and Phe24 and glycation of Lys29
and Phe1 in B-chain. Significantly higher binding to oxPTM-INS vs
native-insulin was observed in type 1 diabetic individuals (P<0.0001).
oxPTM-INS autoantibodies showed better sensitivity than IAA (79 vs.
60% with the same 99% specificity) and were able to detect 31% of IAA-
negative patients. The combined measurement of IAA and oxPTM-INS
autoantibodies raised the detection of insulin autoimmunity to 91% of
subjects with new-onset type 1 diabetes. Binding to oxPTM-INS did
not correlate with blood glucose or age and was directed toward
oxPTM-INS fragments with slower mobility than native insulin.
Conclusion: These data suggest that oxPTM-INS is an autoantigen in
type 1 diabetes and that antibodies to oxPTM-insulin are present in the
largemajority of new-onset type 1 diabetes patients. Overall, over 90% of
individuals with new-onset type 1 diabetes presented autoimmunity to
insulin, either IAA or oxPTM-INS autoantibodies.
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Delivery of recombinant human soluble receptor for advanced
glycation end products delays autoimmune diabetes in the NOD
mouse model
D.J. Borg1, S. Leung1,2, A. Zhuang1, A. Fotheringham1, D. McCarthy1,
J. Di Trapani2, P.-H. Groop3, M. Knip3, J. Forbes1,4;
1Mater Research Institute- University of Queensland, Brisbane, 2School
of Natural Sciences, Griffith University, Brisbane, Australia, 3University
of Helsinki, Helsinki, Finland, 4Mater Clinical School, The University of
Queensland, Brisbane, Australia.
Background and aims: Like other autoimmune diseases in developed
nations, the risk of developing type 1 diabetes (T1D) is increasing, which
remains unexplained, and is postulated to occur as a result of environ-
mental triggers. Recently, circulating advanced glycation end products
(AGEs) and their receptor, receptor for AGEs (RAGE), have been shown
to be altered in children prior to T1D diagnosis. The soluble RAGE
(sRAGE) isoform is thought to bind RAGE ligands within the circulation.
We aimed to reduce AGEs early in life in the NOD mouse model by
delivering a short pulse of recombinant human sRAGE, and to determine
the therapeutic effect on diabetes incidence, beta cell function and im-
mune cell infiltration.
Materials and methods:Groups of female NOD mice were randomized
to either vehicle (PBS) or recombinant human sRAGE (25 μg twice
daily) via intraperitoneal injection from day 50-64 of life. To determine
the effect of sRAGE therapy on the immune system, glucose homeostasis
and diabetes incidence, mice were followed until 0 (n=6), 2 (n=14) or 22
(n=15) weeks post-treatment, respectively.
Results: Twoweeks of sRAGE therapy afforded protection from diabetes
at day 221 of life compared to mice given the vehicle control only (13%
vs 53%; p=0.01). This reduction in diabetes associatedwith a progressive
decrease in non-fasted (p<0.0001) and fasted blood glucose levels (p=
0.02) after 22 weeks post sRAGE treatment compared to vehicle control.
Although oral glucose tolerance tests revealed no change in the area under
the glucose curve between groups (835 vs 899 mmol/L.120 min; p=
0.19), there was an increase in the area under the insulin curve demon-
strating an increase in insulin secretion (29.8 vs 37.1 ng/mL.120 min; p=
0.02). Flow cytometry analysis confirmed an increase in splenic numbers
of CD11b+CD11c+CD8-RAGE+ dendritic cells (2.7-fold; p=0.008), as
well as classical (F4/80+CD11c-Ly6C+; 2-fold; p=0.04) and non-
classical (F4/80+CD11c-Ly6C-; 1.9-fold; p=0.02) macrophages directly
after sRAGE therapy compared to vehicle alone.
Conclusion: These results demonstrate for the first time that short-term,
recombinant human sRAGE therapy prediabetes, has long lasting effects
that improve insulin secretion and autoimmune diabetes incidence. The
mechanism responsible for these improvements by sRAGE remain to be
elucidated, but may involve changes to antigen presenting cells such as
macrophages and dendritic cells.
Supported by: JDRF Innovative Grant
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Intrinsic depot-specific differences in the angiogenic potential of ASC
M. Azorin-Ortuño, B. Oñate, G. Vilahur, L. Badimon;
Cardiovascular Research Center, CSIC-ICCC,Hospital de la Santa Creu I
Sant Pau, Barcelona, Spain.
Background and aims: Fat body distribution is known to be an impor-
tant factor for the development of metabolic and cardiovascular diseases.
Regional differences include variation in the residing cell populations and
the vasculature. Fat cell progenitors (adipose-derived stem cells, ASC)
are considered one of the most abundant (15-50% of total cells) and
important cellular population within adipose tissue (AT) because their
active role in the modulation of tissue expansion and homeostasis, pro-
ducing paracrine factors and metabolic signals. The expansion of AT is
closely associated with the development of its vasculature and the regu-
lation of ATangiogenesis is emerging as a promising therapeutic target in
obesity. Our objective was to explore the role of ASC isolated from the
two main adipose depots, subcutaneous and omental visceral fat, in the
modulation of AT angiogenesis.
Materials andmethods:ASCwere isolated from omental (omASC) and
subcutaneous (subASC) fat paired samples obtained from metabolically-
healthy morbidly obese (ob, n=13, 6 M/7 F, BMI=43.3±5.1 kg/m2, age:
33.4±9.5 years) and metabolically-healthy control individuals (n-ob, n=
6, 5 M/1 F, BMI=28.7±2.7 kg/m2, age: 43.7±10.5 years). ASC were
in vitro expanded, and gene expression and protein levels were evaluated
by real-time PCR and WB, respectively.
Results: The gene expression level of a set of pro-angiogenic and anti-
angiogenic molecules was analyzed: VEGFA, VEGFB, VEGFC, TSP1,
and TGFβ1. The genes encoding for VEGFB, TSP1 and TGFβ1 showed
a similar expression pattern and expression levels in ob and n-ob individ-
uals, being significantly up-regulated in subASC compared with omASC,
with fold-changes ranging from 2 to 3 for VEGFB and TGFβ1, and
reaching 10-fold up-regulation for TSP1, further confirmed at protein
level. For VEGFA and VEGFC, we only observed depot-specific differ-
ences in ob individuals. The expression of VEGFA in subASC was 2.4-
fold higher than in omASC, and 2-fold higher than in the counterpart
form n-ob individuals. Moreover, correlation analysis revealed that the
expression levels of VEGFA in omASC, but not in subASC, negatively
correlated with serum cholesterol levels (r=-0.454, p=0.05). VEGFCwas
the only angiogenic factor with higher expression in omASC than in
subASC, showing a slight (1.2-fold up-regulation) but significant (p=
0.012) differential expression. A range of endothelial cell (EC) markers
(CD105, vWF, VEGFR1, and VEGFR2) was explored. We did not find
depot-specific differences in the expression of CD105 and vWF. Interest-
ingly, high significant differences, and opposite pattern, were observed in
the expression of VEGFR1 and VEGFR2, in both ob and n-ob. The
expression of VEGFR1 was higher in subASC compared with omASC
(2.55±1.96 arbitrary units (AU) vs 0.22±0.18 AU, p<0.001, ob; 1.33±
0.57 AU vs 0.29±0.22 AU, p<0.01, n-ob), whereas VEGFR2 showed
the opposite trend, moderate gene expression in omASC (1.76±1.40 AU,
ob; 1.45±1.39 AU, n-ob) and almost undetectable expression in subASC,
further confirmed at protein level. Unexpectedly, omASC did not show
in vitro EC differentiation capacity.
Conclusion: The results show a more active role of subASC producing
pro and anti-angiogenic paracrine factors than omASC. VEGFA and
VEGFC appear as important factors in obesity. Due to the differential
expression of VEGFR2 and VEGFR1, there is a depot-specific role for
VEGFA in ASC that is independent of EC differentiation potential.
Supported by: ISCIII
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The role of BMP2 in the pathophysiology of obesity
M. Unthan1, E. Guiu- Jurado2, T. Wohland1, D. Schleinitz1, K.
Ruschke3, M. Kern4, B. Gutsmann1, N. Klöting1, A. Tönjes4, M.
Stumvoll1,4, M. Scholz5,6, M. Blüher1,4, P. Kovacs1;
1IFB Adiposity Diseases, University of Leipzig, Germany, 2Department
of Medicine and Surgery, University Rovira i Virgili, Tarragona, Spain,
3Institute for Chemistry and Biochemistry, Freie Universität Berlin, 4De-
partment of Medicine, University of Leipzig, 5Institute of Medical Infor-
matics, Statistics and Epidemiology, University of Leipzig, 6LIFE Re-
search Center, University of Leipzig, Germany.
Background and aims: Besides its known functions in the embryonic
development the Bone Morphogenetic Protein 2 (BMP2) may affect ad-
ipogenesis. Our aim was to investigate the potential role of BMP2 in the
pathophysiology of obesity and related traits and to uncover genetic var-
iants determining the variability in circulating BMP2 levels.
Materials and methods: Circulating BMP2 levels were measured by
commercially available ELISA in serum samples from subjects derived
from two phenotypically well characterized cohorts: the Sorbs (n=638)
and the Leipzig cohort (n=489). We measured BMP2 mRNA expression
by qRT-PCR in 632 paired samples of human subcutaneous and visceral
adipose tissue. We also conducted a Genome Wide Association Study
(GWAS) for circulating BMP2 in the Sorbs using the GenAbel Package
of R for HapMap imputed genotypes generated by Affymetrix Gene chip
arrays (500 K and 6.0) (n=580).
Results: BMP2 serum levels were significantly lower in obese (BMI>
30 kg/m2, n=248) compared to lean subjects (BMI<25 kg/m2, n=250; p
<0.05 adjusted for age and sex). Consistently, they correlated negatively
with waist circumference, Waist- to Hip- Ratio (WHR) and Waist- to-
Height- Ratio (WHtR) (adj. p<0.05). Furthermore,BMP2mRNA expres-
sion in visceral and subcutaneous adipose tissue correlated positivelywith
BMI (n=620; adj. p<0.001) and related traits like waist circumference
(adj. p<0.001) and circulating blood lipids (n=110; adj. p<0.05). After
adjusting for sex, age, BMI and inflation factor, 45 single nucleotide
polymorphisms (SNPs) showed association with circulating BMP2 at p
<1×10-5, including rs918604 (p=1.77×10-7) in RGS7BP (Regulator of
G-Protein Signalling 7 Binding Protein), rs17111592 (p=6.5×10-7) in
USP24 (Ubiquitin Specific Peptidase 24) and rs7799603 (p=1.75×10-
6) in CNTNAP2 (Contactin-associated Protein-like 2) locus.
Conclusion: Our data suggests that BMP2 is related to the pathophysi-
ology of obesity and highlights the role of genetic variation in the regu-
lation of circulating BMP2 levels.
Supported by: SFB 1052 Obesity mechanisms
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Reduced SIRT1 and SIRT2 expression in visceral adipose stem cells
may promote visceral fat expansion in human obesity
S. Perrini, P. Nigro, S. Porro, A. Cignarelli, C. Caccioppoli, A.
Natalicchio, R. Ficarella, L. Laviola, F. Giorgino;
Endocrinology & Metabolic Diseases, University of Bari, Italy.
Background and aims: Adipose tissue expands as a consequence of
hypertrophy of preexisting fat cells and hyperplasia by recruitment of
adipose stem cells (ASC) into the adipogenic program. SIRT1 and SIRT2
have been involved in regulation of adipocyte differentiation in rodent
cells. In this study, we investigated the role of SIRT1 and SIRT2 in human
adipocyte differentiation in obesity.
Materials andmethods: Subcutaneous (Sc)- and visceral (V)-ASCwere
isolated from fat biopsies of 30 obese (Ob) and 30 non-obese (n-Ob)
donors and differentiated in vitro. Cell cultures were analyzed by immu-
nofluorescence with Nile Red/DAPI to quantify triglyceride-containing
cells (adipogenesis) and Oil-Red-O staining followed by spectrophotom-
etry to measure accumulated triglycerides (lipogenesis). mRNA
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expression of marker genes for early (PPARγ, SREBP1c, C/EBPalpha)
and terminal (FAS and adiponectin) phases of adipogenesis was evaluated
after selective overexpression of SIRT1 or SIRT2 by adenoviral-mediated
gene transfer in V-ASC. Assessment of SIRT1 and SIRT2 mRNA levels
in human Sc and V fat biopsies from 149 donors with a wide BMI range
was also carried out.
Results: No differences in either adipogenesis or lipogenesis were found
in Sc-ASC from Ob vs. n-Ob donors. By contrast, both the number of
triglyceride-containing cells and extent of triglyceride accumulation were
~2.0-fold higher in V-ASC from Ob compared to n-Ob donors (p<0.05).
These cellular phenotypes correlated with changes in SIRT1 and SIRT2
mRNA and protein levels, whichwere not different in Sc-ASC from n-Ob
and Ob, and 50% lower in V-ASC fromOb compared to n-Ob subjects (p
<0.05). Noteworthy, the selective overexpression of SIRT1 or SIRT2 in
Ob V-ASC resulted in downregulation of genes involved in early adipo-
genesis, such as PPARγ, SREBP1c, C/EBPalpha (p<0.05), as well as
genes marking terminal adipocyte differentiation, such as FAS and
adiponectin (p<0.05), and in a significant 45% decrease in both lipogen-
esis and adipogenesis (p<0.05). Finally, assessment of SIRT1 and SIRT2
mRNA levels in human Sc and V fat biopsies from 149 donors with a
wide BMI range showed a significant negative relationship between
SIRT1/SIRT2 expression in V fat and BMI, both in males (R=-0.448, p
<0.05) and females (R=-0.535, p<0.05), while no correlation was found
between SIRT1/SIRT2 expression in Sc fat and BMI.
Conclusion: Reduced SIRT1 and SIRT2 expression in V-ASC from
obese individuals promotes enhanced lipogenesis and adipogenesis,
representing a new mechanism for expansion of V fat in human obesity.
208
TMEM18 is a regulator of adipogenesis and involved in PPARG
signalling in vivo
K. Landgraf1,2, J.T. Schwartze1, D. Rockstroh1, W. Kiess1, A. Körner1,2;
Center for Pediatric Research Leipzig (CPL), 2Medical Center
AdiposityDiseases (IFB), Leipzig, Germany.
Background and aims: Polymorphisms in TMEM18 are associated with
obesity in children and adults.We have reported previously that TMEM18 is a
regulator of human adipogenesis in vitro. The aim of this study was to inves-
tigate the role of TMEM18 during adipose tissue (AT) accumulation in vivo.
Materials and methods:We used the zebrafish as an in vivo model for
AT development. In addition, we analysed TMEM18 expression in whole
AT samples, isolated adipocytes and cells of the stroma-vascular fraction
(SVF) from lean and obese children of our Leipzig Childhood ATcohort,
and addressed associations with PPARG expression and measures of obe-
sity and glucose homeostasis.
Results: Using whole mount in situ hybridisation on 9 day old zebrafish
larvae, we showed co-expression of tmem18 and pparg in a visceral region
where also first adipocytes are detectable by nile red staining. Morpholino-
mediated inhibition of tmem18 expression resulted in a reduction in the
number of visceral adipocytes but did not affect zebrafish development
per se. There was no effect of tmem18 knockdown on eating behaviour
suggesting that the inhibition of adipocyte formation was not mediated by a
central effect. Tmem18-mediated inhibition of adipogenesis was accompa-
nied by a significant down-regulation in pparg expression. Using luciferase
reporter assays in 3 T3-L1 cells, we detected a significant activation of the
PPARG promoter in presence of Tmem18 indicating that Tmem18 is an
upstream regulator of PPARG signalling. In line with these data,
TMEM18 expression correlated with PPARG expression in whole
AT and isolated adipocytes but not in SVF cells of children in-
cluded in our Leipzig AT cohort. Similar to PPARG, TMEM18
expression was down-regulated in adipocytes of obese children
compared to lean children and correlated with adipocyte diameter,
macrophage infiltration, serum adiponectin levels and HOMA-IR
as a measure of insulin resistance.
Conclusion: Our findings may indicate a potential role of TMEM18 as a
regulator of PPARG-driven adipogenesis and obesity progression in vivo.
Clinical Trial Registration Number: NCT02208141
Supported by: BMBF IFB AdiposityDiseases
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The impact of birth weight on epigenetic and transcriptional regula-
tion of adipose-derived stem cells
A.H. Olsson1, C. Broholm1, A. Perfilyev2, N.S. Hansen1, A. Ali3, B.
Mortensen4, S.W. Jørgensen1,4, C. Ling2, A. Vaag1,4;
1Department of Endocrinology, Diabetes and Metabolism,
Rigshospitalet, Copenhagen, Denmark, 2Department of Clinical Sci-
ences, Epigenetics and Diabetes, 3Department of Clinical Sciences, Ge-
netic and Molecular Epidemiology, Lund University, Malmö, Sweden,
4Steno Diabetes Center A/S, Gentofte, Denmark.
Background and aims: Low birth weight (LBW) is associated with
dysfunctions of adipose tissue contributing to an elevated risk of devel-
oping metabolic diseases in adulthood. We hypothesized that altered epi-
genetic and transcriptional regulation of adipose-derived stem cells
(ADSCs) could play a role in programming adipose tissue dysfunctions
in LBW subjects.
Materials andmethods:ADSCs were isolated from adipose tissue of 13
normal birth weight (NBW) and 13 LBW adult males. Global DNA
methylation and gene expression patterns were analysed in cultured
ADSCs during proliferation and after differentiation into mature
adipocytes.
Results: Immature ADSC from LBW subjects exhibit differential expres-
sion of 506 gene transcripts after correction for multiple testing, including
genes involved in spliceosomal function and cell cycle regulation. Prin-
cipal component analyses confirmed that the transcriptional and epige-
netic profiles differed more between the birth weight (BW) groups in the
immature ADSC compared with only subtle differences in the mature
adipocytes. Although differentiation of ADSCs into matures adipocytes
was associated with multiple and within the BW groups converging
changes in gene expression and DNA methylation, the dynamics of spe-
cific gene groups varied. Construction of gene interaction networks sug-
gest a key role for the transcription factor CCNT2 in the diverse gene
regulation patterns seen between BW groups during adipocyte
differentiation.
Conclusion: Our findings support the notion that the differential epige-
netic and transcriptional changes in LBW subjects are most pronounced
in immature ADSCs that in turn may program more permanent structural
and physiological characteristics of the mature adipocytes influencing
risk of metabolic diseases.
Supported by: DFF, the Novo Nordisk Foundation, EFSD/Lilly, Aase and
Ejnar Danielsens Fond
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Increased brown fat and insulin sensitivity in obesemice overexpress-
ing WISP2 in the adipose tissue
J.R. Grünberg1, J.M. Hoffmann1, S. Hedjazifar1, A. Nerstedt1, L.
Jenndahl1, J. Castellot2, L. Wei3, S. Movérare Skrtic4, F. Bäckhed1, I.
Syed5, A. Saghetelian6, B. Kahn5, A. Hammarstedt1, U. Smith1;
1Molecular and Clinical Medicine/Diabetes, Medicine, Göteborg, Swe-
den, 2Department of Integrative Physiology and Pathobiology, Tufts Uni-
versity School of Medicine, 3Massachussetts General Hospital, 4Medi-
cine, Göteborg, Sweden, 5Harvard Medical School, Boston, 6Salk Insti-
tute, San Diego, USA.
Background and aims: WISP2 is highly expressed in, and secreted by,
mesenchymal precursor cells. It is an important early regulator of mesen-
chymal precursor cell commitment to the adipogenic lineage through dual
effects; by forming a BMP4-regulated complex with the PPARγ
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transcriptional activator ZFP423 in the cytosol preventing its nuclear
translocation and; as a secreted protein activating the canonical WNT
pathway and inhibiting differentiation of the precursor cells. To examine
the in vivo effect of secreted WISP2 by the adipose tissue we generated a
transgenic (Tg) mouse overexpressing WISP2 under an aP2 promoter.
Materials and methods: The mice were fed a control or high fat diet
(HFD) for 17 weeks. Metabolic phenotyping included hyperinsulinemic
euglycemic clamps combined with [C14] 2-deoxyglucose uptake and
body composition analysis with DEXA. Samples were collected for
blood chemistry and several tissues were analyzed with immunohisto-
chemistry, protein and gene profiling. Conventional statistical methods
were used to analyse results.
Results: Tg mice on HFD showed unchanged body weight compared to
wildtype (wt) mice but had markedly increased and hypercellular brown
adipose tissue (BAT) (weight increased≈100%, p<0.05), hypercellular
white adipose tissue with smaller cells (42% increase in number of cells;
p<0.05) and increased lean body mass (≈8% p<0.05). In spite of same
body weight, Tg mice were markedly more insulin-sensitive, verified by
hyperinsulinemic euglycemic clamps (GIR +237% at steady-state, p<
0.01) and had increased glucose uptake by the adipose tissue and skeletal
muscle, increased adipose tissue adiponectin mRNA and circulating
levels (150%, p<0.01) and increased GLUT4 in both adipose tissue and
skeletal muscles (≈140% p<0.05). Insulin-stimulated glucose uptake
ex vivo was also increased in adipose cells and skeletal muscle
(≈160%, p<0.05). Interestingly, de novo lipogenesis, known to be elevat-
edwhenGLUT4 is increased in the adipose tissue, and serum levels of the
novel fatty acid-hydroxy fatty acids (FAHFAs) were also increased in Tg
compared to wt mice on HFD (≈175% p<0.05). The mesenchymal tissue
hypercellularity suggests that WISP2 increases mesenchymal precursor
cell growth and this was also verified in vivo in BAT. Furthermore, serum
from Tg mice increased the proliferation of both BAT precursor cells and
the mesenchymal stem-like CH3T101/2 cells and this effect was inhibited
by adding specific anti-WISP2 monoclonal antibodies to the serum.
Conclusion:WISP2 is a novel circulating adipokine which targets mes-
enchymal precursor cells leading to increased lean body mass,
hypercellular BAT and hyperplastic healthy white adipose tissue with
increased GLUT4 and circulating levels of adiponectin. Lipogenesis is
increased leading to higher serum levels of the novel FAHFAs and im-
proved insulin sensitivity. Thus WISP2 is a promising target to prevent
obesity-related complications and Type 2 diabetes.
Supported by: Research Council, Torsten Söderberg, Novo Nordisk
Foundation, EFSD
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A multi-national normative dataset for corneal nerve morphological
parameters with using corneal confocal microscopy for early diag-
nosing diabetic neuropathy
M. Tavakoli1, M. Ferdousi1, I. Petropoulos1, J. Morris2, N. Pritchard3, A.
Zhivov4, D. Ziegler5, D. Pacaud6, K. Romanchuk6, B. Perkins7, V. Bril7,
G. Smith8, A. Boulton1, N. Efron9, R. Malik1;
1Center for Endocrinology and Diabetes, University ofManchester, 2Uni-
versity of Manchester, Manchester, UK, 3Institute of Health Biomedical
Innovation, QUT, Brisbane, Australia, 4University of Rostock, 5Univer-
sity Hospital, Düsseldorf, Germany, 6University of Calgary, Canada,
7University of Toronto, Canada, 8University of Utah, Salt Lake City,
USA, 9QUT, Brisbane, Australia.
Background and aims: Corneal confocal microscopy (CCM) is a novel
diagnostic technique for the detection of nerve damage and repair in a
range of peripheral neuropathies, in particular diabetic neuropathy. To
enable clinical translation and wider use of this technique, normative
reference values need to be defined. We have therefore undertaken a
multicenter collaboration to provide worldwide age adjusted normative
values of corneal nerve fibre parameters.
Materials and methods: 1965 corneal nerve images from 343 healthy
volunteers were pooled from six clinical academic centers across the
world (Manchester, Brisbane, Calgary, Düsseldorf, Utah and Toronto).
All subjects underwent examination with the Heidelberg Retina
Tomograph corneal confocal microscope. Images of the sub-basal nerve
plexus were acquired by each centre using a standard protocol and ana-
lyzed bymanually with using Semi-automated software (CCMetrics) and
also by automated software (ACCMetrics). Age-trends were established
using simple linear regression, and normative corneal nerve fiber density
(CNFD), corneal nerve fiber branch density (CNBD), corneal nerve fiber
length (CNFL) reference values were calculated using quantile regression
analysis for each method of measurements.
Results: There was a significant linear age-dependent decrease in CNFD
(-0.164 no/mm2 per year for men, P<0.01 and -0.161 no/mm2 per year
for women, P<0.01) that determined with both analysing systems. There
was no change with age in CNBD (+0.192 no/mm2 per year for men, P=
0.26 and -0.050 no/mm2 per year for women; P=0.78). CNFL decreased
in men (-0.045 mm/mm2 per year, P=0.07) and women (-0.060 mm/
mm2 per year, P=0.02). Height, weight and BMI did not influence the
5th percentile normative values for any corneal nerve parameter. Signif-
icant correlations for CNFL, CNBD, CNFL were observed between 2
methods of measurements.
Conclusion: This study provides robust worldwide normative reference
values for corneal nerve parameters to be used in research and clinical
practice in the study of diabetic and other peripheral neuropathies.
Supported by: NIH/ JDRF
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Obesity related neuropathy and the effects of bariatric surgery
S. Azmi1, M. Ferdousi1, G. Ponirakis2, I. Petropoulos2, J. Schofield1, H.
Fadavi1, M. Tavakoli1, H. Soran1, R.A. Malik1,2;
1Diabetes and Endocrinology, University ofManchester, UK, 2Weill Cor-
nell Medical College in Qatar, Doha, Qatar.
Background and aims: Obese subjects have risk factors for the devel-
opment of neuropathy. Bariatric surgery normalises these risk factors,
however its benefits on neuropathy have not been assessed.
Materials and methods: 50 morbidly obese subjects and 30 age-
matched controls underwent assessment of: sural nerve conduction ve-
locity (SNCV) and amplitude (SNAP), peroneal nerve conduction veloc-
ity (PMNCV) and amplitude (PNA), Vibration Perception
Threshold(VPT), cold(CT) and warm(WT) threshold, corneal nerve fibre
density(CNFD), branch density (CNBD) and fibre length(CNFL). 19
subjects were re-assessed 6 months post-bariatric surgery
Results: Obese subjects had a higher BMI (50.5±2.2 v 27.9±1.9, P<
0.000), HbA1c (55.1±4.4 v 38.5±0.8, P=0.002) with no difference in
blood pressure (mmHg)(133.2±4.7/73.0±2.6 v 125.8±2.9/74.1±2.4, P=
0.69/0.37). They had a significant reduction in SNAP (mV)(11.4±1.4 v
20.5±1.9, P<0.001), PNA (mV)(3.65±0.3 v 5.5±0.42, P<0.001),
PMNCV (m/s)(45.7±0.8 v 47.8±2.0, P=0.005) and CT (0C)(24.1±1.4
v 28.7±0.3, p=0.02) with an increase inWT (0C)(40.0±0.7 v 36.7±0.79,
P=0.02). CNFD (no/mm2)(23.3±1.3 v 37.7±2.0,p<0.000), CNBD(no/
mm2)(32.0±3.1 v 37.9±2.6, p<0.000) and CNFL (mm/mm2)(14.2±0.6
v 26.9±2.0,p<0.000) were significantly reduced. Paradoxically, CNBD
(38.5±5.7 v 23.9±2.8, p=0.03) and CNFL (15.1±1.1 v 13.2±0.5,p=
0.05) were significantly lower in the non-diabetic (n=35) compared to
the diabetic (n=14) group. In the 19 subjects assessed post-operatively at
6 months, BMI (52.2±3.5 v 34.6±2.1, P=0.004), BP (112±2.3/71.5±
0.4, P=0.03), CIP (7.3±1.6 v 16.5±4.0, P=0.05) and CNFD (23.0±1.6 v
25.3±0.9, P=0.05) and (CNFL (14.3±1.0 v 16.0±1.0, P=0.005) im-
proved with no change in other parameters
Conclusion: Obese subjects have large and small fibre neuropathy. Par-
adoxically those with diabetes have less severe small fibre damage, pre-
sumably driven by factors other than hyperglycaemia. Bariatric surgery
improves small fibre neuropathy as shown by CCM within 6 months.
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Disrupted resting-state attentional networks in type 2 diabetes
mellitus patients
W. Xia1,2, S. Wang1, H. Rao2, A. Spaeth2, P. Wang1, Y. Yang1, R.
Huang1, H. Sun1;
1affiliated Zhongda Hospital of Southeast University, Nanjing, China,
2Center for functional Neuroimaging, University of Pennsylvania, Phila-
delphia, USA.
Background and aims: Although Type 2 diabetes mellitus (T2DM) is a
well-recognized risk factor for dementia, the neural mechanisms that
underlie cognitive impairment in T2DM remain unclear. In addition to
memory deficits, attention is compromised in patients with T2DM. Our
study aims to examine attentional network alterations in T2DM patients
and their relationships to impaired cognitive performance using resting-
state functional magnetic resonance imaging (fMRI).
Materials andmethods: For the first time, data-driven independent com-
ponent analysis was applied to resting-state fMRI data from 38 T2DM
patients and 32 healthy controls to identify the dorsal attention network
(DAN) and ventral attention network (VAN). Correlations were then de-
termined among the resting-state functional connectivity (rsFC), clinical
data, and neuropsychological scores.
Results: Typical significant spatial patterns of the DAN and VAN in both
the controls and T2DMpatients were revealed (p<0.01, corrected;figure).
When compared with the healthy controls, the T2DM patients exhibited
decreased rsFC in the left middle frontal gyrus (MFG) and bilateral infe-
rior parietal lobe (IPL) of the DAN, as well as the left IPL and rightMFG/
IFG of the VAN. In addition, the rsFC of the left MFG was inversely
correlated with the Trail Making Test-B scores (r=-0.533, p=0.001); the
rsFC of the left IPL was positively correlated with the Digit Span Test
scores but negatively correlated with HbA1c (r=0.403, p=0.012; r=-
0.370, p=0.022, respectively).
Conclusion: T2DM patients exhibit disrupted functional integration
within attention-related brain networks. Several core regions in the
DAN, especially the IPL, likely underlie the attentional deficits in
T2DM patients. We suggest T2DM affects resting-state attentional net-
works, which may be related to reduced attention and a hyperglycemic
state. Our data may potentially support resting-state fMRI as a promising
tool to detect attentional changes in T2DM and provide new insights into
the neural deficits present in T2DM patients.
Clinical Trial Registration Number: ChiCTR-ONRC-13003095
Supported by: WS; XW
214
Thalamic neuronal dysfunction and patterns of sensory loss in dia-
betic neuropathy: a proton magnetic resonance spectroscopy study
M. Greig1,2, D. Selvarajah1,2, P. Shillo1,2, G. Rao2, I.D. Wilkinson1, S.
Tesfaye2;
1University of Sheffield, 2Sheffield Teaching Hospitals, UK.
Background and aims:Although we have previously demonstrated tha-
lamic neuronal dysfunction in diabetic neuropathy (DN) using proton
magnetic resonance spectroscopy (1H-MRS), the relationship between
quantitative sensory testing of large and small fibre function (QST) and
thalamic neuronal dysfunction is not known.
Materials and methods: 37 subjects with T1DM (12 No-DN and 25
DN) and 14 healthy volunteers (HV) underwent QST using the German
DFNS protocol. All subjects were right handed and aged between 45 and
60 years (with no significant difference between the groups).1H-MRS
examination was performed at 3 T (Ingenia, Phillips Netherlands). Single
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voxel spectra were obtained from a 2.25 cm3 (15×10×15mm) cubic
volume of interest within the L. thalamus. TE=135 ms, TR=1600 ms,
NSA=256 using point resolved (PRESS) technique. Fitted metabolite
area ratios were calculated for choline (Cho) at 3.2 ppm, Creatine (Cr)
at 3.0 ppm, and N-Acetyl Aspartate (NAA) at 2.02 ppm, and mean area
under the curve values were compared. ANOVAwas performed for group
means and correlations between QST parameters and 1H-MRS ratios
were calculated using Pearson’s correlation.
Results: Subjects with DN had significantly lower NAA:Cr [1.74(0.22)]
compared to HV [1.96(0.3)] and No-DN [1.90(0.26); ANOVA p=0.036].
There was a significant negative correlation between NAA:Cr and small
fibre assessments of heat pain threshold r=-0.287(p=0.04) and warm
detection thresholdr=-0.289 (p=0.043). There was no significant corre-
lations between assessments of large fibre dysfunction and NAA:Cr.
Conclusion: The thalamus plays an important role in processing ascend-
ing somatosensory inputs to the cerebral cortex. Reduction in NAA:Cr as
assessed using 1H-MRS indicates abnormal thalamic neuronal function
in DN. In this preliminary study we have demonstrated that thalamic
neuronal dysfunction relates to abnormalities of small fibre function on
detailed QST. NAA ratios associated with changes in the thalamus may
be linked to specific patterns of sensory abnormalities. Further investiga-
tion of the relationship between these findings and underlying structural
and perfusion abnormalities, may provide a physiological mechanism for
this novel finding.
Supported by: EFSD/Novo Nordisk
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Vibration sensitivity violation evaluation for diabetic distal
polyneuropathy early diagnosis in patients with type 2 diabetes
A.P. Shepelkevich1, I.K. Bilodid1, A.V. Sosedkova1, S.S. Korytko2,
L.M. Pedchenec3, L.P. Kovshik4, M.I. Tylypova5, N.V. Karlovich6,
A.S. Grigorovich7, O.G. Zalesskaya8, V.N. Selivanov9;
1Belarusian state medical university, 2Centre for Medical Rehabilitation
and Balneotherapy, Minsk, 3Vitebsk Regional Endocrinological Dispen-
sary, 4Grodno Regional Endocrinological Dispensary, 5Gomel Regional
Endocrinological Dispensary, 6City Endocrinological Dispensary of
Minsk, 7Brest Regional Endocrinological Dispensary, Brest, 8Minsk Re-
gional Clinical Hospital of the Order of the Red Banner of Labour, Minsk,
9Mogilyov Regional Diagnostic and Treatment Centre, Mogilyov, Bela-
rus.
Background and aims:Distal sensorimotor polyneuropathy (DSPN) is a
severe complication of type 2diabetes. According to the GermanNational
Disease Management Guidelines for neuropathy adults with type 2 dia-
betes mellitus (T2DM) should be screened for distal sensorimotor
polyneuropathy (DSPN) at diagnosis set up and yearly thereafter. This
study aimed to assess the prevalence of vibration sensitivity disorders in
T2DM patients using Vibratip device which can be used as an alternative
test for vibration sensation evaluation for DSPN early diagnosis.
Materials and methods: 4303 patients with T2DM (2757 women, 1546
men, average age: 59,2±10,4 years, average bodymass index (BMI) 32,2
±5,6 kg / m2) were examined. The study was conducted within the
framework of the campaign "Approach Optimization in Diabetic
polyneuropathy Early Diagnostics and Prevention Improvement”. All
participants with inclusion criteria (T2DM duration≤1 year with average
duration of DM: 0,8±0,3 years) had a clinical examination and were
examined with Vibratip on both feet. Vibratip is new device using stan-
dardized vibration for DSPN detection. Vibratip is applied to the patients
feet, testing 2 sites on both feet (1st metatarsal head on the plantar surface
and hallux pump)-once whilst non-vibrating and once whilst vibrating
and the patient (with their eyes closed) is asked to indicate when they
feel the vibration. Vibration sensitivity disorder was defined in condition
when patients were answering twice “yes” to the question, “Are you able
to feel vibration on any site of both feet during the test?”
Results: Clinical symptoms of DSPN were prevalent in 3781 (88%)
participants with T2DM, 775 (18%) of whom were suffered from pain,
706 (16.4%) - from burning, 1144 (26.6%) - numbness, 921 (21.4%) -
feeling of pins and needles, 235 (5.5%) - feeling of electric shock. Patients
with clinical symptoms such as numbness (26.6%) and feeling of pins and
needles (21.4%) had the highest prevalence of clinical impairment of feet.
Vibration sensitivity disorders feet were found in 24,1% (1036) of dia-
betic patients: 15,3% (656) women, 8,8% (380) men using Vibratip
device.
Conclusion: Our findings showed a high prevalence of vibration sensi-
tivity disorders among patients with T2DMwith disease duration≤1 year
using Vibratip device, suggesting inadequate attention to diabetic foot
prevention practice.
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Oxidative and carbonyl stress in relation to polyneuropathy in sub-
jects with recently diagnosed type 1 and type 2 diabetes
D. Ziegler1, A. Strom1, K. Kaul1, I. Rokitta1, T.H. Fleming2, S. Püttgen1,
J. Brüggemann1, I. Ziegler1, B. Ringel1, J. Szendrödi1, P.P. Nawroth2, M.
Roden1, for the German Diabetes Study Group;
1Institute for Clinical Diabetology, German Diabetes Center at Heinrich
Heine University, Düsseldorf, 2Department of Medicine I and Clinical
Chemistry, University of Heidelberg, Germany.
Background and aims: Oxidative stress resulting from enhanced free-
radical formation, reduced antioxidative defense, and reactive carbonyls
which react with proteins to form advanced glycation endproducts
(AGEs) have been implicated in the pathogenesis of diabetic neuropathy.
We sought to determine whether biomarkers of systemic oxidative stress,
defective antioxidative defense, and carbonyl stress are altered in relation
to diabetic sensorimotor polyneuropathy (DSPN) in recently diagnosed
diabetes patients.
Materials and methods:We assessed serum concentrations of thio-
barbituric acid reactive substances (TBARS) as a marker of oxi-
dative stress, extracellular superoxide dismutase (SOD3) and re-
duced glutathione (GSH) as markers of antioxidative defense, and
methylglyoxal as a marker of carbonyl stress in 111 type 1 and
223 type 2 diabetic subjects from the baseline cohort of the Ger-
man Diabetes Study (GDS) (type 1/type 2 diabetes (T1D/T2D):
age: 34.3±13.0/52.8±11.0 [SD] years; male: 57/65%; BMI: 24.6±
4.1/31.7±6.0 kg/m2, diabetes duration: 7.2±3.2/6.1±3.0 months;
HbA1c: 6.8±1.4/6.5±1.0% [50.5±15.2/47.3±10.4 mmol/mol])
and 52 healthy control subjects (age: 40.3±16.4 years; male:
56%). Neurophysiological and clinical measures included motor
and sensory nerve conduction velocity (MNCV, SNCV), Neurop-
athy Symptom Score (NSS), and Neuropathy Disability Score
(NDS). DSPN was defined by electrophysiological and clinical
criteria (Toronto Consensus, 2011). All comparisons were adjusted
for sex, age, and BMI.
Results: TBARS levels were higher in T1D (3.1±2.0 μM) and T2D
(3.2±1.8 μM) than in controls (0.9±0.3 μM) as was methylglyoxal
(T1D: 404±150, T2D: 412±160, controls: 154±69 nM, while
SOD3 concentrations were reduced in T1D (38.9±14.9 ng/ml) and
T2D (32.7±16.3 ng/ml) compared to controls (52.4±16.6 ng/ml) as
was GSH (T1D: 1.6±0.6, T2D: 1.7±0.8, controls: 2.7±1.2 μM) (P<
0.0001 for T1D and T2D vs controls for all markers). Subclinical
and clinical DSPN confirmed by nerve conduction studies were
present in 21% of subjects with T1D and 29% of those with T2D.
Multiple linear regression analysis revealed that low SOD3 levels
were associated with the presence of DSPN in both T1D subjects
(ß=-0.319, P=0.002) and those with T2D (ß=-0.151, P=0.030),
while low methylglyoxal concentrations were associated with DSPN
in T2D subjects (ß=-0.153, P<0.022). No association with DSPN
was noted for TBARS and GSH.
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Conclusion: Patients with recently diagnosed T1D and T2D show evi-
dence of systemic oxidative and carbonyl stress despite good glycaemic
control, but only lower SOD3 concentrations in both T1D and T2D and
lower methylglyoxal levels in T2D were linked to the presence of
polyneuropathy. The predictive value of these markers for the develop-
ment and progression of diabetic neuropathy remains to be determined in
prospective studies.
Clinical Trial Registration Number: NCT01055093
Supported by: Ministry of Science/Research NRW (MIWF NRW), Ger-
man BMG, BMBF to DZD e.V.
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Sulfonylurea is still useful in type 2 diabetic patients with sulfonyl-
urea failure
T. Kunavisarut, R. Lertwattanarak, S. Sriussadaporn;
Mahidol University, Bangkok, Thailand.
Background and aims: A large number of type 2 diabetic patients can-
not achieve good glycemic control with maximumdosage of sulfonylurea
(SU), so called sulfonylurea failure (SUF). Some guidelines suggest to
continue SU whereas some suggest to stop SU once insulin therapy is
started in patients with SUF. This study was aimed to evaluate whether
SU is still useful in patients with SUF.
Materials and methods: Type 2 diabetic patients who had A1c≥8%
while receiving recommended maximum dosage of SU and metformin
were studied. Beta-cell function and insulin resistance status were
assessed by plasma glucose and insulin response to oral glucose tolerance
(OGTT) method. OGTTwere performed 3 times including while receiv-
ing maximum dose of SU (max-SU), after discontinuation of SU for
4 weeks (discont-SU), and at 2 weeks after restarting the same SU at
25% of max-SU (25%-SU). During each OGTT, plasma insulin and glu-
cose levels were measured at 0, 30, 60, 90 and 120 minutes. Beta-cell
function was assessed by area under the curve (AUC) of plasma insulin
divided by AUC of plasma glucose. Insulin sensitivity and insulin resis-
tance were assessed by Matsuda index and HOMA-IR, respectively. The
patients were assigned to continue the same dosage of metformin
throughout the study and to measure fasting capillary blood glucose at
home (CBG) at least 3 times per week to assess glycemic control and for
safety monitoring during the intervals between OGTT.
Results: Twenty-five patients with SUF were recruited. Median duration
of diabetes was 12 years (range, 4-38). Beta-cell function during max-SU
(median 0.1, range 0.02-0.56) was significantly higher than that of during
discont-SU (0.06, range 0.01-0.22), (p<0.001) and also higher but not
significant (p=0.269) than that of during of 25%-SU (0.09, range 0.01-
0.32). Beta-cell function was also higher during 25%-SU (0.09, range
0.01-0.32) compared with during discont-SU (0.06, range 0.01-0.22),
(p<0.001), suggesting that SU is still able to stimulate insulin secretion
in SUF in dose dependent manner. Among the 3 OGTT, there was no
significant different inMatsuda index (OGTT-11.97±1.14, OGTT-2 1.93
±1.1 and OGTT-3 1.98±1.31, p=0.759) and HOMA-IR (OGTT-1 11.48
±8.17, OGTT-2 12.13±6.7 and OGTT-3 11.24±7.42, p=0.179), suggest-
ing that SU has no significant effect on insulin sensitivity or insulin
resistance. For the glycemic control, the mean CBG measured during
max-SU and 25%-SU were lower than that of during discont-SU (186.2
±43.5 vs. 222.3±60.6 vs.256.1±66.7 mg/dL, respectively, p<0.05).
Conclusion: Discontinuation of SU results in a decrease in insulin secre-
tion and worsening glycemic control. The findings lead to the clinical
implication that SU is still useful and should be continued, if not contra-
indicated, in diabetic patients with SUF who need insulin therapy.
Supported by: Siriraj Research Development Fund (Managed by Routine
to Research: R2R)
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The OCT1 reduced-function polymorphisms are associated with
common metformin-induced gastrointestinal side-effects
T. Dujic1, A. Causevic1, T. Bego1, M. Malenica1, Z. Velija-Asimi2, E.R.
Pearson3, S. Semiz4,1;
1Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy,
University of Sarajevo, 2Clinic for Endocrinology, Diabetes and Metabo-
lism Diseases, University Clinical Centre of Sarajevo, Bosnia and Herzego-
vina, 3Division of Cardiovascular & Diabetes Medicine, Medical Research
Institute, University of Dundee, UK, 4Faculty of Engineering and Natural
Sciences, International University of Sarajevo, Bosnia and Herzegovina.
Background and aims:Metformin is the first-line drug for treatment of
type 2 diabetes, and the most widely used antidiabetic agent. However,
20-30% patients treated with metformin develop gastrointestinal (GI)
side-effects, which may result in suboptimal drug dosage and non-adher-
ence. About 5% of patients are not able to tolerate metformin due to
severity of these GI symptoms. Themechanism of GI side-effects, as well
as their considerable interindividual variability, is unknown. We have
recently shown that organic cation transporter 1 (OCT1) polymorphisms
are associated with severe intolerance to metformin, namely the discon-
tinuation of metformin and switching to another oral hypoglycaemic
agent in the first months of metformin treatment. The aim of this study
was to examine the association OCT1 reduced-function alleles with com-
mon metformin-induced GI adverse effects in T2D patients.
Materials and methods: This prospective observational study included
92 newly diagnosed T2Dpatients whowere prescribedmetformin as their
initial hypoglycaemic therapy. Patients weremonitored during the first six
months of metformin treatment for development of adverse GI outcomes.
Two common loss-of-function variants in the OCT1 gene (SLC22A1),
R61C (rs12208357) and M420del (rs72552763) were genotyped using
TaqMan genotyping assays. The association of OCT1 reduced-function
diplotypes with GI side-effects was analysed using logistic regression.
Age, gender, weight, and the concomitant use of medications known to
inhibit OCT1 activity, were added as covariates.
Results: A total of 43 patients (47%) experienced GI side-effects during
first six months of metformin treatment. The effects were ranging from
mild/moderate to severe GI symptoms. The most frequent symptom was
diarrhoea. Female gender and lower weight showed a trend of association
with the presence of adverse effects. Interestingly, the number of OCT1
reduced-function alleles was significantly associated with over two-fold
higher odds of metformin-induced GI side-effects (OR=2.31, 95% CI
1.07-5.01, p=0.034).
Conclusion: In this study we showed for the first time the association of
OCT1 reduced-function variants with the incidence of common
metformin-induced GI side-effects in T2D patients. Our results confirm
the recent findings related to the severe cases of metformin intolerance,
and suggest that a high interindividual variability seen in mild to moder-
ate, as well as severe GI intolerance, share common underlying mecha-
nism, despite considerably different intensity and duration of GI symp-
toms. Importantly, our data could lead to more personalised and safer
treatment with metformin.
Supported by: Federal Ministry of Education and Science B&H, EFSD
Albert Renold Fellowship
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The acute glucose-lowering effect of metfomin in patients with type 2
diabetes is partly glucagon-like peptide-1-dependent
M. Hansen1,2, E. Bahne1, D.P. Sonne1,2, J.F. Rehfeld3, J.J. Holst2, T.
Vilsbøll1, F.K. Knop1,2;
1Center for Diabetes Research, Gentofte Hospital, Hellerup, 2NNFCenter
for Basic Metabolic Research and Department of Biomedical Sciences,
Faculty of Health and Medical Sciences, University Copenhagen, 3De-
partment of Clinical Biochemistry, Rigshospitalet, Copenhagen, Den-
mark.
Background and aims: Metformin has been suggested to increase
glucagon-like peptide-1 (GLP-1) secretion. By the use of the GLP-1
receptor antagonist exendin 9-39 (Ex9-39), we evaluated whether the
acute effect of metformin on postprandial glucose excursions is GLP-1-
dependent.
Materials and methods: Twelve patients with type 2 diabetes (age: 60.8±
8.8 years (mean ± SD); BMI: 29.8±3.0 kg/m2; HbA1c: 6.5±0.5% (48±
6 mmol/mol)) were included in this placebo-controlled, double-blinded
study. On 4 separate days, after 1-week washout of antidiabetic drugs, the
patients received metformin (1.5 g) or placebo suspended in a 302-kcal
liquid meal with 1.5 g paracetamol (for evaluation of gastric emptying)
with i.v. infusion of Ex9-39 (450 pmol×kg body weight-1×min-1) or saline.
At baseline and during 240 min blood was sampled, gallbladder volume
was evaluated by ultrasound and appetite was evaluated by visual analogue
scale. At the end of each day ad libitum food intake was measured.
Results: On the 2 days of Ex9-39 infusion, mean basal concentrations of
plasma glucose were higher compared with the 2 days of saline infusion
(9.8±0.58 mmol/l vs. 8.7±0.52 mmol/l, p<0.05). Metformin + saline
increased plasma GLP-1 incremental AUC (iAUC) compared with pla-
cebo + saline (1985±365 pmol/l×min vs. 1156±244 pmol/l×min,
p<0.05). Ex9-39 increased GLP-1 iAUC after both metformin and pla-
cebo, but GLP-1 iAUC remained significantly higher with metformin
compared to placebo (3218±563 pmol/l×min vs. 1798±333 pmol/l×
min, p<0.05). Metformin + saline reduced the postprandial plasma glu-
cose iAUC by 58% vs. placebo + saline (145±68 mmol/l×min vs. 350±
73 mmol/l×min, p<0.05), and while the difference was still significant,
metformin + Ex9-39 only reduced iAUC by 25% vs. saline + Ex9-39
(467±112 mmol/l×min vs. 614±124 mmol/l×min, p<0.05). C-
peptide:glucose ratios were significantly higher after metformin + saline
vs. placebo + saline (18225±2703 pmol/mmol × min vs. 12345±1766
pmol/mmol×min, p<0.05) whereas the difference was no longer signif-
icant with Ex9-39 infusions (13233±3243 pmol/mmol×min vs. 9863±
2505 pmol/mmol×min, p=0.07). Metformin did not affect gastric emp-
tying, plasma cholecystokinin concentrations and gallbladder contraction
vs. placebo, irrespective of Ex9-39. None of the interventions affected
appetite perceptions or ad libitum food intake.
Conclusion: We show that acute administration of metformin increases
plasma GLP-1 secretion and reduces postprandial plasma glucose excur-
sions vs. placebo, and that a substantial part of the glucose-lowering effect
appears to be GLP-1-dependent.
Clinical Trial Registration Number: NCT02050074
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Metformin, methylmalonic acid and the risk of neuropathy: a
randomised placebo-controlled trial
M. Out1,2, A. Kooy1,2, P. Lehert3, C.G. Schalkwijk4, C.D.A. Stehouwer5;
1Internal Medicine, location Bethesda, Treant Care Group, 2Bethesda
Diabetes Research Center, Hoogeveen, Netherlands, 3Faculty of Eco-
nomics, Louvain Academy, Belgium, 4Faculty of Health, Medicine and
Life Sciences, Maastricht University Medical Center, 5Internal Medicine,
Maastricht University Medical Center, Netherlands.
Background and aims:Metformin lowers serum vitamin B12 (B12) and
increases serum methylmalonic acid (MMA), the gold standard
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biomarker for tissue B12 deficiency. However, the clinical relevance of
metformin-associated decreases in B12 is still controversial, since rele-
vant clinical outcomes are lacking. Current guidelines mention B12 de-
ficiency as a disadvantage of metformin, but do not yet give recommen-
dations on the detection and prevention of B12 deficiency, waiting for
more clinical evidence. Therefore, we studied whether the increase in
MMAwas associated with the onset or deterioration of neuropathy.
Materials and methods: In the HOME trial, 390 insulin-treated patients
with type 2 diabetes were treated with 850mgmetformin or placebo up to
three times daily for 52 months. We analyzed the association between
metformin and changes in HbA1c, MMA and the Valk Score, a validated
neuropathy score. We used structural equation modeling (SEM) analysis
to estimate the mediation effects ofMMA andHbA1c in the total effect of
metformin on neuropathy score. We excluded patients with B12 deficien-
cy at baseline or with B12 supplementation (n=15).
Results: In mixed model analysis, metformin, as compared to placebo,
was associated with an increase of MMA at the end of the study
(0.04 μmol/L, 95%CI 0.02 - 0.06, p=0.001). There was no significant
difference in neuropathy score after 52months between placebo (increase
from 0.8±2.2 to 2.2±1.6) and metformin (1.1±2.1 to 3.7±1.3;
ANCOVA: 0.03; 95% CI -0.03 - 0.08, p=0.41). However, SEM analysis
showed that the effect of metformin on the neuropathy score consisted of
a beneficial effect through lowering HbA1c (-0.02 per gram year of met-
formin) and an adverse effect through increasing MMA (0.04 per gram
year). The model satisfied the goodness-of-fit test (χ2=4.0; df=2, p=
0.13; normated fit index=0.98). In addition, during the study, MMA
did not differ significantly between treatment groups when stratified for
B12 concentration, showing that metformin did not affect the biological
relation between B12 and MMA.
Conclusion: Metformin not only reduces B12, but also progressively
increases MMA. The increase of MMA in metformin users was associ-
ated with significant worsening of the neuropathy score. Furthermore,
metformin did not affect the biological relation between B12 and
MMA. These results indicate that metformin-related B12 deficiency is
clinically relevant. Monitoring of B12 and, when available, MMA, in
users of metformin should be considered.
Clinical Trial Registration Number: NCT00375388
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Differential adaptation of human gut microbiota to weight loss and
diabetes remission achieved by gastric bypass versus sleeve
gastrectomy
R. Murphy1, P. Tsai2, L. Plank3, M. Booth4;
1Department of Medicine, 2Bioinformatics Institute, 3Department of Sur-
gery, University of Auckland, Auckland, 4Department of Surgery,
Waitemata District Health Board, Auckland, New Zealand.
Background and aims: Bariatric surgery achieves weight loss and re-
mission of type 2 diabetes through many mechanisms, potentially includ-
ing modification of gut microbiota. By comparing human gut microbiota
changes after two types of bariatric surgery: gastric bypass (GBP) and
sleeve gastrectomy (SG), with similar metabolic outcomes and food in-
take at 1 year, we aim to examine the gut microbiota changes which differ
by type of surgery and those that correlate with diabetes remission status
achieved by both surgeries.
Materials and methods:Whole-metagenome shotgun (WMS) sequenc-
ing of genomic DNA fragments using Illumina HiSeq2000 was obtained
from stool samples collected from 14 obese patients with type 2 diabetes
pre-operatively and 1 year after either SG (n=7) or GBP (n=7) as part of a
randomised, blinded clinical trial in which metabolic outcomes, including
body composition, resting energy expenditure (REE), glycaemia, inflam-
matory markers, and food diaries were collected. Post-operative diabetes
status was defined as partial remission (PR) or complete remission (CR) if
HbA1c was <48 mmol/mol or <38 mmol/mol respectively and off glu-
cose lowering therapy. Resulting shotgun readswere annotated with Kyo-
to Encyclopaedia of Genes and Genomes (KEGG).
Results: There were similar reductions in body weight (27.4 kg [SEM
5.3] v 23.5 kg [SEM 5.4], p=0.48), BMI (9.9 [SEM 1.8] v 7.6 [SEM 1.6],
p=0.29) and REE (240 kcal [SEM 44] v 198 kcal [SEM 72], p=0.57)
after GBP compared to SG. Estimated caloric intake and dietary compo-
nents (fibre, fat, carbohydrate, protein) were similar betweenGBP and SG
at baseline and 1 year. Diabetes remission occurred to a greater extent
after GBP (4 CR, 1 PR) than after SG (1 CR, 4 PR). A greater change in
taxonomy of gut microbiota was observed after GBP (3 major phyla
differences) than after SG (no major phyla difference, only increase in
Bacteroidia species). A significant increase in Roseburia species was
found among those achieving diabetes remission after both GBP and
SG. Functional analysis of gut microbiota metabolism by KEGG
Orthology revealed a greater number of significant changes in KEGG
gene function among those achieving diabetes remission after GBP (15
higher and 13 lower) than after SG (9 lower and 9 higher), and similarly
for KEGG pathways (9 altered after GBP and 4 altered after SG). There
were no common KEGG gene functions or pathways that were signifi-
cantly altered among those achieving diabetes remission after both SG
and GBP.
Conclusion:A greater proportion of gut microbiota are altered following
GBP than SG surgery, likely reflecting the greater alteration to the gut
ecological system achieved by GBP. The association of greater Roseburia
species among those achieving diabetes remission after both GBP and SG
supports a causal link with metabolic benefits.
Clinical Trial Registration Number: NCT01486680
Supported by: Maurice Wilkins Centre
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Does experimental metabolic endotoxaemia worsen high-fat diet-in-
duced insulin resistance and obesity?
L. Lebrun1, S. Mandard1, N. Le Guern1, J.-P. Pais de Barros1, J. Petot1,
V. Deckert1, D.J. Drucker2, L. Lagrost1,3, J. Grober1;
1Faculté de médecine, INSERM UMR866, Dijon, France, 2Department
of Medecine, Samuel Lunenfeld Research Institute, Toronto, Canada,
3Centre Hospitalier Universitaire, Dijon, France.
Background and aims: Obesity and type 2 diabetes are metabolic dis-
eases which have reached epidemic proportions worldwide. According to
World Health Organization, about 347 million adults have diabetes and
around 1.6 billion are overweight (400 million of them are obese). These
metabolic disorders are associated with a low grade inflammation whose
molecular origin is still unknown. Previous studies have highlighted the
involvement of the gut microbiota and lipopolysaccharides (LPS), which
are components of the cell wall of Gram (-) bacteria. It has been shown
that a slight increase of LPS plasma levels, metabolic endotoxemia, could
mimic the effect of a very high-fat diet and initiate insulin resistance and
obesity. We have recently shown that LPS increase glucagon-like peptide
1 (GLP-1) plasma levels, a hormone which is known to stimulate insulin
secretion. Our present work deals with i) the molecular mechanisms in-
volved in this newly described pathway and ii) the physiological conse-
quences of this LPS/GLP-1/Insulin cascade during an obesogenic diet.
Materials and methods: Molecular mechanisms are investigated
through in vivo, ex vivo and in vitro experiments to study the effects of
LPS on synthesis/secretion/degradation of GLP-1. The long-term out-
comes of the induced metabolic endotoxemia are explored by a continu-
ous infusion of LPS (300 μg/kg/day). Osmotic pumps are implanted
intraperitoneally in high-fat fed mice for one or two months.
Results: In vivo, measurements of total and active GLP-1 plasma levels
show that the increase of GLP-1 upon LPS stimulation is due to enhanced
secretion (x3.91 compared to NaCl control group, p<0.001) rather than
inhibition of its degradation. Stimulation of ileum explants or
enteroendocrine cultured cells by LPS leads to an increased GLP-1 se-
cretion suggesting a direct effect of LPS. This effect is mediated through
toll-like receptor 4 (TLR4). Indeed, pharmacological (TLR4 antagonist)
and genetical (TLR2/TLR4 KO mice) experiments suppress GLP-1 se-
cretion. Very surprisingly, experimental metabolic endotoxemia induced
by a continuous infusion of LPS for 30 days leads to improved metabolic
consequences of an obesogenic diet. Compared to NaCl control mice,
LPS-infused mice show a significant reduced fat mass measured by
EchoMRI® (NaCl: 16.9%±1.3% ; LPS: 9.7%±0.8%, p<0.001). Hepatic
lipid content estimated by Oil Red O staining indicate a significant de-
crease in LPS-treated mice (p<0.001). Finally, glucose metabolism and
insulin sensitivity are also improved in LPS-treated mice as shown by an
oral glucose tolerance test (aera under curve: NaCl: 819.7±22.2; LPS:
698.6±39.5, p<0.01) and an insulin tolerance test (aera under curve:
NaCl: 216.5±10.1; LPS: 184±7.3, p<0.05).
Conclusion:We demonstrate for the first time that LPS modulate the secre-
tion ofGLP-1 through a direct regulation of enteroendocrine cells by a TLR4
pathway. In addition, our data suggest that 30 days of experimentalmetabolic
endotoxemia does not worsen high-fat diet-induced insulin resistance and
obesity but rather seem to improve it. Nevertheless further experiments are
currently ongoing to test the effect of a longer infusion of LPS (60 days) and
pharmacological approaches will define the specific involvement of GLP-1.
Supported by: French National Research Agency, “Investissements
d’Avenir”, LipSTIC LabEx
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Clc-5-deficient mice, a novel murine model for investigating the role
of gut microbiota in obesity and metabolic syndrome
Y. Dong, H. Zhai, S. Jin, J.E. Maria, X. Li;
Medicine, Johns Hopkins University School of Medicine, Baltimore,
USA.
Background and aims:Clc-5 (chloride channel 5) functions primarily as
an electrogenic 2Cl-/1H+exchanger. Mice deficient in Clc-5 exhibit a
phenotype strikingly similar to human Dent’s disease. We have identified
Clc-5 knockout (Clc-5KO) mice as a completely novel animal model of
obesity and metabolic syndromes. The aim of this study is to characterize
this new phenotype and identify the molecular mechanisms involved.
Materials and methods: We extensively characterized the obesity phe-
notype and molecular features of Clc-5KO mice using various technolo-
gies including QNMR, MRI, PCR, ELISA, and Western blot.
Results:We have identified a previously unrecognized and highly unique
phenotype of Clc-5KO mice: they are all (100%) markedly obese on
regular chow diet, with a body weight 25-35% higher than that of age-
matched WT mice. QNMR analysis showed that Clc-5KO mice were
constituted of 21% of total body fat compared to only 7% inWTcontrols.
MRI analysis indicated a dramatic increase in both subcutaneous and
visceral (abdominal) fats. All Clc-5KO exhibited glucose intolerance
and 3-4-fold elevated levels of systemic proinflammatory IL-6 and
MCP-1 (than WT), remarkably similar to those in human obesity. More-
over, the Clc-5KO mice exhibit a 3- to 10-fold increase in the expression
of a panel of diabetes/obesity-related genes in the liver, including PPARγ,
LXRα, RXRα, CD36 (a lipoprotein scavenger receptor), SRA (class A
scavenger receptor), leptin-R, SREBP2, AMPKβ, and GHRP-R, all of
which are the hallmarks of metabolic syndrome. More surprisingly, Clc-
5KO mice had similar food assumption as the age-matched WT mice,
suggesting that Clc-5KO mice acquire a more efficient dietary energy
harvesting mechanism. We found a weakened bacterial killing capacity
of the Clc-5KO macrophages compared to WT macrophages. Co-caging
littermate WT with Clc-5KO mice led to a marked improvement of glu-
cose intolerance and decreased body fats in Clc-5KO mice while im-
paired glucose intolerance in WT.
Conclusion: Our data clearly indicate that it is the altered intestinal flora
that enable the Clc-5KO mice a higher energy-harvesting efficiency from
dietary foods, while the WT microbiota can diminish this efficiency. We
conclude that Clc-5 plays a critical and previously unrecognized role in
lipid and glucose metabolism via modulating gut flora, and Clc-5KO
mice can be used as a novel model of obesity, diabetes or metabolic
syndromes.
Supported by: NHI/NIDDK
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Diet interacts with host NOD2 genotype to control blood glucose and
the gut microbiota
K.P. Foley, E. Denou, T.C. Lau, J.F. Cavallari, B.D. Henriksbo, B.M.
Duggan, Y.E. Li, J.D. Schertzer;
Biochemistry and Biomedical Sciences, McMaster University, Hamilton,
Canada.
Background and aims: Obesity is associated with inflammation, which
is critical in causing insulin resistance. Sensing of bacterial components
via Pattern Recognition Receptors (PPRs) contribute to this metabolic
inflammation during obesity. The gut microbiome has also emerged as
a mediator of metabolic inflammation and insulin resistance during obe-
sity. However, familial transmission of microbiota during long term
breeding can confound associations between immunity and taxonomy
of the microbiota. Recently, our lab showed that deletion of Nucleotide
Oligerization Domain 2 (NOD2) in mice promotes diet-induced inflam-
mation, dysbiosis, and insulin resistance. The dysbiosis caused by NOD2
deletion was an independent factor that transmits insulin resistance. Here
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we aim to circumvent issues associated with familial transmission of
microbiota by generating WT and NOD2 KO littermates and tracking
changes in metabolism, inflammation, and microbiome across the first 3
generations of breeding.We hypothesized that the dysbiosis phenotype of
NOD2 deletion would first manifest in F2 generation NOD2 KO mice
and that inflammation and insulin resistance would be exacerbated in
these mice when comparted to F1 generation mice.
Materials and methods: See Fig. 1
Results:We confirmed that after 14 weeks of HFD Fx generation NOD2
KO mice (2556+/-105) were glucose intolerant relative to WT mice
(2005+/-112) as measured by GTT AUC (p<0.01). In contrast, F1 gen-
erationWT (2265+/-113) and NOD2KO (2150+/-145) littermates did not
differ in GTT AUC (p=0.55). The role of NOD2 in regulating glucose
during a HFD emerged in the F2 generation, with NOD2 KO mice
(3168+/-115) being significantly more glucose intolerant than F2 WT
mice (2596+/-115) on HFD (p<0.01). F2 NOD2 mice also trended to-
wards having higher fasting blood glucose (FBG) (p=0.069, 12.7 vs
14.2 mM). F2 generation WT and NOD2 KO mice were then used as
donors for microbiota transfer to germ-free WT mice. After 4 weeks of
colonization while on HFD NOD2 KO recipient germ-free mice had
significantly higher FBG than WT recipient germ-free counterparts (p<
0.01, 11.6 vs 14.0mM). Glucose intolerance (WT=1991+/-132 vsNOD2
KO=2688+/-142, p<0.01) and increased FBG (WT=10.8 vs NOD2
KO=12.3, p=0.096) characteristics persisted in F3 generation mice.
Chow-fed WT versus NOD2 KO mice did not have altered glucose tol-
erance in any generation.
Conclusion: Our data shows an interaction between deletion of host
NOD2 and lipid content in the diet that alters blood glucose. The gut
microbes that thrive in the absence of NOD2 during a HFD promote
hyperglycemia independent of host genetics. Data from F2 generation
mice demonstrate that the divergence in microbiota between WT and
NOD2 KO mice that drives glucose intolerance is not due to prolonged
familial transmission during successive breeding of mice. Ongoing anal-
ysis will determine taxomic microbial markers and effects of the diet-
microbiome interaction on inflammation in the gut and metabolic tissues.
Supported by: CIHR, NSERC, CDA
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Frailty and the relationship between HbA1c and mortality in elderly
patients with type 2 diabetes
L.C. Hartog1, H. van Hateren1, K.H. Groenier2, H. Bilo1, N. Kleefstra1;
1Diabetes Centre, Isala, Zwolle, 2General Practice, University, Medical
Center Groningen, Netherlands.
Background and aims: In patients with type 2 diabetes mellitus, poor
glycemic control is associated with an increased risk of all-cause and
cardiovascular mortality. Frailty influences the relationship between
blood pressure and mortality in old age. We hypothesized that the rela-
tionship between HbA1c and mortality may also be influenced by the
level of frailty.
Materials and methods: Patients with type 2 diabetes mellitus partici-
pating in a prospective observational cohort study in theNetherlands were
included. Patients aged 60 years and older were selected from this cohort
of primary care treated patients. Frailty was defined as a score less than 80
on the subscale ‘physical functioning’ of the RAND-36 questionnaire.
After median follow-up for 14 years, multivariate Cox regression analy-
ses were performed to evaluate the association between HbA1c and mor-
tality, adjusted for age, sex, BMI, duration of diabetes, systolic blood
pressure, serum creatinine level, total cholesterol-HDL ratio,
macrovascular complications, albuminuria, and the use of insulin. Anal-
yses were performed in strata according to the frailty level (‘physical
functioning’ score<80 and>80 ) and diabetes duration.
Results: Approximately 60% of our study population was female. Medi-
an age (interquartile range) at baseline was 72 (67-77) years and median
diabetes duration was 6 (3-12) years. Frailty was highly prevalent in our
study population: 629 out of 858 patients (73%). Hazard ratios (95%
confidence interval) of an increase in HbA1c for all-cause and cardiovas-
cular mortality in frail patients were 1.11 (1.02-1.21) and 1.19 (1.05-
1.34), respectively (table 1). For the non-frail patients no significant as-
sociations were observed. When stratified according to diabetes duration,
all confidence intervals were comparable between frail and non-frail pa-
tients, except for non-frail patients with a diabetes duration <5 years.
Within this group no significant association was observed.
Conclusion: Higher HbA1c was significantly related to increased all-
cause and cardiovascular mortality in frail patients but outcomes were
more or less comparable to the non-significant relationships in the non-
frail population. Therefore, we conclude that frailty does not modify the
relationship between HbA1c and mortality in elderly patients with type 2
diabetes mellitus very much. Within non-frail patients with a diabetes
duration less than 5 years, HbA1c was not significantly related to mortal-
ity. Perhaps the positive relationships in frail patients with short diabetes
duration reflect underlying morbidity.
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Optimum level of glycaemic control for the lowest mortality in very
old adults with type 2 diabetes mellitus
T. Wongviriyawong, A. Sriwijitkamol, V. Srinonprasert;
Medicine, Faculty of medicine, Siriraj hospital, Bangkok, Thailand.
Background and aims: The complexity of care for diabetes patients
increases substantially with age. Older adults with diabetes have higher
rates of major diabetic complication and mortality. There are few studies
conducted in the very old (age≥75 years) diabetic patients to investigate
on optimal care for the very old adults, particularly glycemic target for
this group of population. The aims of this study were to primarily explore
which level of HbA1c is associated with the lowest mortality and secondly
for HbA1c level with lowest diabetic-related complications in the very old
diabetic patients.
Materials and methods: We conducted a retrospective cohort study of
1,000 participants with T2DM age≥75 years being treated in a university
hospital during January 2007 to December 2013. Data collected were
baseline characteristics including HbA1c level, and geriatric syndromes
such as dementia and frailty, a progressive decline in multiple organ
systems and function which leads to vulnerability to complications and
mortality. Primary outcome was analyzed in using Cox proportional haz-
ard models and binary logistic regression for secondary outcomes.
Results: Included population had median age of 77(75-100) years with
median HbA1c of 7.0 (4.3-17.3) % and diabetic microvascular complica-
tions of 24.8%. Median follow-up time was 5.0(1.6-7.0) years. Overall
mortality rate was 47.5/1000 person-year. HbA1c had a U-shaped rela-
tionship with mortality; the lowest mortality was at HbA1c of 6.0-6.9%
and the highest at≥8.0% (hazard ratio [HR] 1.59; 95% confidence inter-
val [CI] 1.04-2.45; P=0.034). Other factors influencing mortality were;
GFR<30mL/min/1.73m2 (HR 3.52; 95%CI 2.05-6.04; P<0.001), age≥
85 year (HR 2.91; 95%CI 1.91-4.43; P<0.001), frailty (HR 2.52; 95%CI
1.76-3.61; P<0.001), presence of coronary artery disease (CAD) (HR
2.02; 95% CI 1.39-2.93; P<0.001), male sex (HR 1.82; 95% CI 1.27-
2.61; P=0.001), having both diabetic nephropathy and retinopathy (HR
1.95; 95% CI 1.10-3.43; P=0.021). While attending a special clinic (DM
or geriatric) was a protective factor (HR 0.56; 95% CI 0.39-0.79; P=
0.001). Higher level of HbA1c was related to more hypoglycemia espe-
cially in patients using insulin and having impaired renal function; and
also more stroke events when HbA1c≥8%. Moreover, frailty was signif-
icantly associated with stroke (odd ratio [OR] 2.92; 95% CI 1.58-5.38;
P=0.001). Patients using beta blockers were more likely to develop CAD
(OR 2.00; 95% CI 1.17-3.41; P=0.012) and heart failure (OR 2.28; 95%
CI 1.20-4.31; P=0.011).
Conclusion:Optimum level of HbA1c in the very old adults aimed for the
lowest mortality should be less than 8%. However, attention should be
drawn to other risk factors, such as reduced renal function, extreme age
and frailty, which appeared to show more influence on mortality in older
diabetic patients. In order to provide good care of diabetes for the very
old, optimal goal should not focus only on glycemic level.
Supported by: Siriraj research fund, Mahidol university
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Serum levels of advanced glycation end products and their receptor
in the elderly diabetic patients with mild cognitive impairment
M. Gorska-Ciebiada1, M. Saryusz-Wolska1, A. Borkowska1, M.
Ciebiada2, J. Loba1;
1Department of Internal Medicine and Diabetology, 2Department of Gen-
eral and Oncological Pneumology, Medical University of Lodz, Poland.
Background and aims: Type 2 diabetes (T2DM) is a risk factor for
Alzheimer’s disease and mild cognitive impairment (MCI) in the elderly.
The cause of cognitive impairment in diabetes is unknown, but it is most
likely multi-factorial. Advanced glycation end products (AGEs) and their
receptor (RAGE) play crucial roles in the pathogenesis of T2DM and
associated complications, but RAGE is also an important cell-signaling
receptor involved in cognitive impairment. The aim of the study was to
evaluate serum levels of AGEs, RAGE and C-reactive protein (CRP) in
elderly patients with T2DM with and without MCI and to determine the
predictors (including AGEs, RAGE and CRP levels) of having MCI in
elderly patients with T2DM.
Materials and methods: According to the criteria proposed by the MCI
Working Group of the European Consortium onAlzheimer’s Disease 276
elderly subjects with T2DM were screened for MCI (using the Montreal
Cognitive Assessment: MoCA score) and selected into groups: 87 pa-
tients with MCI and 189 patients without MCI as a control. Data of
biochemical parameters and biomarkers were collected. The serum levels
of AGEs, RAGE and CRP were assessed using ELISA kit.
Results: In MCI patients serum levels of AGEs (2.19±1.12 ng/ml),
RAGE (4.24±1.89 ng/ml) and CRP (7.6±2.7 mg/L) were significantly
increased compared to controls (AGEs 1.04±0.82 ng/ml; RAGE 1.94±
0.91 ng/ml; CRP 3.9±2.0mg/L; p<0.001). In group of subjects withMCI
serum RAGE level was positively correlated with AGEs level (r=0.85; p
<0.001) and with CRP level (r=0.54; p<0.001). RAGE, AGEs and CRP
concentrations were positively correlated with HbA1c levels (RAGE: r=
0.78, p<0.001; AGEs: r=0.71, p<0.001; CRP: r=0.63, p<0.001) and
negatively correlated with MoCA score (RAGE: r=-0.61, p<0.001;
AGEs: r=-0.5, p<0.001; CRP: r=-0.37, p<0.001). The univariate logistic
regression models revealed that variables which increased the likelihood
of diagnosis of MCI in elderly patients with T2DMwere: higher levels of
HbA1c, RAGE, AGEs, CRP, triglicerydes, lower level of HDL choles-
terol, previous cardiovascular disease (CVD), hypertension (HA) or use
of antihypertensive drugs, hiperlipidaemia, retinopathy, nephropathy, in-
creased number of co-morbidities, older age and less years of formal
education. HA or use of anti-HA drugs (OR 3.48, 95% CI: 1.56-7.76,
p=0.002), previous CVD (OR 3.34, 95%CI: 2.06-5.41, p<0.001), higher
level of RAGE (OR 1.95, 95% CI: 1.24-3.06, p=0.004), and CRP (OR
1.55, 95% CI: 1.21-1.99, p=0.001), older age (OR 1.11, 95% CI: 1.0-
1.23, p=0.039), and less years of formal education (OR 0.64, 95% CI:
0.5-0.82, p<0.001), are the factors increasing the likelihood of having
MCI in elderly patients with T2DM in multivariable analysis.
Conclusion: In summary, serum levels of AGEs, RAGE and CRP are
increased in MCI elderly diabetic patients compared to controls. A larger
population-based prospective study needs to be performed to further con-
firm the relationship between AGEs, RAGE and the cognitive decline or
progress to dementia. As an option, targeting the AGEs-RAGE system in
diabetes especially with cognitive impairments through specific pharma-
cologic interventions might result in a clinical benefit for these patients.
Supported by: grant of Medical University of Lodz
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Protection from diabetic retinopathy, but not nephropathy
K.A. Hillary1, M. Khamaisi1, L.J. Tinsley1, S.M. Hastings1, S. D'Eon1,
D. Pober1, J.K. Sun2, G.L. King1;
1Vascular Cell Biology, , 2Beetham Eye Institute, Joslin Diabetes Center,
Boston, USA.
Background and aims: Diabetic patients with nephropathy (DN) most
often develop retinopathy (DR) as well, but those with DR frequently do
not have DN suggesting that causal and protective factors may differ.
Amongst the Joslin 50-Year Medalist we identified a cohort with DN,
but not DR, providing the unique opportunity to characterize this unusual
phenotype and possibly identify protective factors.
Materials and methods: This is a cross-sectional study of individuals
with 50 or more years of type 1 diabetes, the Joslin 50-Year Medalists.
The cohort was grouped into four categories by DN (eGFR lt 45 mL/min/
1.73 m2) and proliferative DR (PDR, ETDRS gt 53) status. We compared
groups of Medalists with DN and PDR (+DN/+PDR; n=63), DN and no
PDR (+DN/ -PDR; n=30), no DN and with PDR (-DN/ + PDR; n=345),
and no DN and no DR (-DN/-PDR; n=326).
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Results: Of those with DN (+DN/-PDR and +DN/+PDR) the mean
eGFR, serum creatinine and ACR in the groups were 37.5±8.5 v 33.9±
8.8 mL/min/1.73 m2, 1.7±0.5 v 1.9±0.7 mg/dL,median [Q1, Q3] were
18.8 [8.0, 57.9] v 49.7 [14.0, 127.1] mcg/mg, respectively. Post-mortem
pathology in +DN/-PDR (n=4) confirmed classic clinical DN with
mesangial expansion and advanced glomerulosclerosis (DN class IIB
and III). Those in the +DN/-PDR group were older at diagnosis (15.0±
7.5, 10.4±5.5, 11.6±6.6, 10.5±5.9 years, p<0.01) and at study partici-
pation (72.1±7.2, 66.3±6.8, 66.1±7.3, 64.6±7.0 years, p<0.01). Surpris-
ingly, those in the +DN/-PDR group had lower rates of cardiovascular
disease (CVD) than expected for those with renal disease, 34.5% in the
+DN/-PDR compared to 71.0% in the +DN/+PDR, 43.8% in -DN/+PDR,
and 29.3% in -DN/ -PDR , p<0.05. Interestingly, the highest proportion
of detectable c-peptide was in the +DN/ -PDR group (56.7% v. 30.7%
+DN/+PDR, 37.4% -DN/-PDR, 32.2% -DN/+PDR, p=0.03). In addition,
vascular endothelial growth factor (VEGF) response to stimulation (insu-
lin and hypoxia) in fibroblasts was almost twice as high amongst those
+DN/ -PDR (n=4) compared to those +DN/+PDR (n=6) (insulin 29% v
15%; hypoxia 40% v 29%). Those without DN or PDR (n=6) had the
highest response to stimulation (insulin 94% and hypoxia 128%) over
baseline. The VEGF response to stimulation mirrored the prevalence of
CVD across the four DN/DR groups.
Conclusion: Among Medalists, the absence of PDR with DN is associ-
ated with a relative decreased prevalence of CVD, retention of beta cell
function and higher VEGF response compared to the other +DN group
indicating possible common protective factors against hyperglycemic
toxicity for CVD and PDR.
Supported by: NIH NIDDK, JDRF
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Effects of quiescent and activated mesenchymal stromal cells on islet
secretory functions
A.A. Arzouni, A.E. Vargas, P.K. Dhadda, A. King, P.M. Jones;
Diabetes Research group, Divison of Diabetes and Nutritional Sciences,
King's College London, UK.
Background and aims: Pre-culturing of islets in a direct co-culture with
mesenchymal stromal cells (MSCs) has been shown to enhance islet
function in vitro and to the outcome of islet transplantation in vivo. This
study aimed to determine whether activation ofMSCs by exposure to pro-
inflammatory cytokines affects their ability to influence islet function.
Materials and methods: Adipose-derived MSCs and pancreatic islets
were isolated from C57B1/6 and ICR mice. To determine the optimum
time of co-culture required forMSCs to improve islet function, islets were
co-cultured with quiescent MSCs in a direct-contact configuration and
islets function was assessed by measuring glucose-stimulated insulin se-
cretion (20 mmol/l; GSIS) at 24, 48 and 72 hours. Activation of MSCs
was achieved by incubation (37C, 8 h) in the presence of the inflamma-
tory cytokines TNF-α and IFN-γ (20 ng/ml each), and confirmed by
measuring the relative expression of mRNAs for nitric oxide synthase-2
(NOS2) and chemokine C-X-C motif ligand 9 (CXCL9). Islets were
cultured alone or in a direct-contact configuration with either quiescent
or activated MSCs for 48 hrs before assessment of GSIS.
Results:Co-culture incubation time:GSISmeasured from islets alone vs.
islets co-cultured on MSCs at different time points revealed that a mini-
mum of 48 hrs incubation time was needed for the MSCs to exert their
beneficial effect on islets: islets-MSCs (2 mmol/l: 0.91±0.08 ng/islet/h;
20 mmol/l: 6.20±0.50) vs. islets-alone (2 mmol/l: 0.333±0.05 ng/islet/h;
20 mmol/l: 2.08±0.30, p <0.001, n=3 experiments, each of 10 observa-
tions). Activation of MSCs: Culturing MSCs for 8 h in the presence of
TNF-α and IFN-γ was sufficient to activate MSCs as assessed by in-
creased mRNA expression levels of NOS2 (quiescent MSCs 0.0001 vs.
activated MSCs 0.1 relative expression) and CXCL9 (quiescent MSCs
3.4×10-5 vs. activated MSCs 0.6 relative expression). The activation of
MSCs was maintained for 72 hours after removal of cytokines. Islets
cultured alone (IA) for 48 hours responded to a stimulatory concentration
of glucose with increased insulin secretion (2 mmol/l: 0.07±0.05 ng/islet/
h; 20 mmol/l: 0.73±0.14). Glucose-induced insulin secretion was poten-
tiated from islets that had been co-cultured with quiescent or activated
MSCs compared to IA (quiescent-MSCs 20 mmol/l 4.99±1.1, activated
MSCs 20 mmol/l 3.50±0.82 p<0.05). However, activated MSCs did not
further enhance insulin secretion above that induced by co-culture of
islets with quiescent MSCs.
Conclusion: Both quiescent and activated MSCs enhanced glucose-
induced insulin secretion from islets when co-cultured in a direct co-
culture configuration in vitro. MSCs activation by cytokine treatment
did not further enhance insulin secretion above that induced by quiescent
MSCs, but activated MSCs may also influence islet cell survival.
Supported by: MRC
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Activation of pancreatic progenitors during isolation of porcine neo-
natal pancreatic cell clusters
J.-H. Juang1, C.-Y. Chen1, W.-J. Chang2, C.-Y. Chen2, C.-H. Kuo3, W.-
C. Li2;
1Division of Endocrinology and Metabolism, Department of Internal
Medicine, Chang Gung Memorial Hospital, Taoyuan, 2Institute of Oral
Biology, School of Dentistry, Taipei, 3Biomedical Technology and De-
vice Research Laboratories, Industrial Technology Research Institute of
Taiwan, Hsinchu, Taiwan.
Background and aims:Generation ofβ cells ex vivo that are suitable for
transplantation paves the way to correct beta-cell deficit in diabetic pa-
tients. While multiple step-wise protocols to differentiate human stem
cells into functional β cells were proposed and early commitment of
pluripotent cells into pancreatic progenitors is fairly efficient, the β cell
maturation triggers are still largely unknown. Previous studies showed
that in vitro cultivated porcine neonatal pancreatic cell clusters (NPCCs)
exhibited primarily epithelial progenitor-like phenotype in vitro and could
successfully ameliorate hyperglycemia in diabetic mice revealing a useful
tool to explore islet maturation promoters.
Materials and methods: Current study sought to identify molecular
profile of NPCCs upon isolation to better define their cellular properties.
The NPCCs from 1-3 day new-born pigs were isolated using collagenase-
based protocol and maintained in vitro for up to 4 days after dissociation.
The mRNA and protein expression for insulin, glucagon, exocrine en-
zymes amylase and carboxypeptidase B, proliferation indicator Ki67 as
well as the progenitor markers Pdx1 and Sox9 in time-course NPCC
cultures were examined using semi-quantitative RT-PCR and immuno-
fluorescence staining analysis, respectively.
Results: Histological analysis showed 3.4%, 7.6%, 8.6% and 11.4% of
NPCCs are insulin+ in 1-,2-,3- and 4-day cultures, respectively, whereas
semi-quantitative RT-PCR detected increased insulin and decreased exo-
crine enzyme carboxypeptidase B (CPB) mRNA expression over 4-day
cultivation implying gradual enrichment of β cell population in culture.
Strikingly, highly proliferating (30.1% Ki67+ cells in first 4-day cultures
compared to 16.1% Ki67+ cells in 1-day old pig pancreas) pancreatic
progenitors stained for Pdx1 (83.7%, 72.7%, 77.3% and 77.1% in 1-,2-
,3- and 4-day cultures, respectively, compared to 51.9% in 1-day old pig
pancreas) and Sox9 (respect 78.0%, 79.7%, 80.0% and 81.3% in 1-,2-,3-
and 4-day cultures compared to 6.8% in 1-day old pig pancreas) were
quickly induced after isolation indicating the pancreatic precursors could
be propagated in vitro.
Conclusion: In summary, our results showed that islet precursors could
be simply activated during NPCC isolation. NPCC-derived progenitors
maintain their pluripotency in culture providing a useful platform to ex-
amine insulintropic and maturation-promoting effects of candidate mole-
cules to direct human pluripotent cells into functional β cells.
Supported by: Ministry of Science and Technology (NSC102-2314-B-
182A-012 -MY3)
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A small molecule that facilitates the differentiation into pancreatic
endocrine cells from human ES/iPS cells
Y. Kondo1,2, T. Toyoda1, M. Funato1, Y. Hosokawa1, T. Sudo1, X.
Zhuang2, A. Ohta1, N. Inagaki2, K. Osafune1;
1Center for iPS Cell Research and Application (CiRA), 2Department of
Diabetes, Endocrinology and Nutrition, Kyoto University, Japan.
Background and aims: Type 1 diabetes is an autoimmune disease char-
acterized by the destruction of β-cells in the pancreas, absolute insulin
deficiency and persistent high levels of blood glucose. Cases with diffi-
cult blood glucose control exist even using intensive insulin therapy.
Although pancreas and pancreatic islet transplantation is established as
the radical treatment of type 1 diabetes, problems of the transplantation
therapies include shortage of donors and immune rejection. Generation of
pancreatic β cells from embryonic stem (ES) cells or induced pluripotent
stem (iPS) cells would lead to the development of a promising replace-
ment therapy for insulin-dependent diabetes, such as type 1 diabetes.
Researchers have aimed to differentiate pancreatic β cells from stem or
progenitor cells for the goal. However, the induction efficiency of insulin-
producing (INS(+)) cells from humanES/iPS cells has been low (less than
10%) inmost reports. Aims: To establish an efficient differentiation meth-
od of INS(+) cells from human ES/iPS cells by identifying novel small
molecule inducers.
Materials and methods: Based on the previously-reported differentia-
tion protocol (Kunisada Yet al, 2012), human iPS cells were first induced
into PDX1(+) pancreatic progenitors through SOX17(+) definitive endo-
derm, and then 4 factors (Nicotinamide, Forskolin, Dexamethasone and
ALK5 inhibitor; 4Fs) and/or small molecules were added on the PDX1(+)
cells. We used High-Throughput Screening (HTS) system to examine
thousands of compounds from various libraries. Anti-insulin immuno-
staining was performed and the induction rate of INS(+) cells was quan-
titatively evaluated. Small molecules that more efficiently induce INS(+)
cells than the previous protocol with 4Fs were defined as primary hits.
Then, we evaluated the insulin secretory function of the INS(+) cells
generated with the hit compounds. Finally, we established the
INSULIN-GFP human iPSC reporter line to monitor and isolate the
INS(+) cells and evaluated the function and gene expression of INS(+)
cells differentiated from human iPSCs.
Results: Out of about 1,250 small molecules that we screened, one hit
compound(compound SC)was identified. When the compound SC was
combined with the previously-reported protocol with 4Fs, the induction
rate of INS(+) cells was increased up to 15-20%. We found that com-
pound SC facilitates the differentiation of endocrine cells including
INS(+) cells both in vitro and ex vivo by expanding the NEUROG3(+)
endocrine precursor cells. The INS(+) cells generated with compound SC
showed the ability to secrete C-peptide in vitro. We then successfully
established the INSULIN-GFP human iPSC reporter line, and are cur-
rently examining the mechanisms of action of compound SC to induce
the pancreatic endocrine differentiation, based on the information of its
target molecules and by gene expression analyses of purified INS(+) cells
generated with compound SC.
Conclusion: We have identified one small molecule that facilitates the
differentiation of human iPS/ES cells into pancreatic endocrine cells in-
cluding insulin-producing β-like cells in vitro.
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Endocrine cell plasticity in human islets of Langerhans in type 2
diabetes
C. Perego1, S.Moretti1, C. Santi1, S. LaRosa2, F. Bertuzzi3, F. Folli4, E.S.
Di Cairano5;
1DiSFB Dept of Pharmacological and Biomolecular Sciences, University
of Milano, 2Ospedale di Circolo, Varese, 3Niguarda Cà Granda Hospital,,
Milano, Italy, 4University of Texas Health Science Center, San Antonio,
USA, 5DiSFeB Dept of Pharmacological and Biomolecular Sciences,
University of Milano, Italy.
Background and aims: Studies in the last years indicate that the adult
pancreas has an inherent regenerative capacity to produce new β-cells in
response to increased metabolic demand or injury. Different mechanisms
of beta cell regeneration in the adult pancreas have been proposed: 1)rep-
lication from endogenous β-cell, 2)neogenesis from non-β-cells precur-
sors and 3)β-cell formation by transdifferentiation. The last mechanism
consists in the conversion of one endocrine non-beta cell into beta by
lineage reprogramming. It has been clearly identified in animal models;
its existence and relevance in humans has never been demonstrated. Aim
of this study was to examine the islet composition and architecture in
control and diabetic subjects and to verify the existence of a
transdifferentiation process in diabetic islets.
S116 Diabetologia (2015) 58 (Suppl 1):S1–S607
Materials and methods: We collected human pancreatic sections from
12 normal (7 M/5 F, mean age 69±7 years) and 14 diabetic donors (8 M/
6 F; mean age 66.4±10.3 years). Sections were double/triple stained with
antibodies directed against hormones (insulin,glucagon,somatostatin) and
samples were analysed by confocal microscopy. Total islet area, β/α/δ-
cell area, frequency of heterologous/homologous contacts among differ-
ent endocrine populations, and the % of endocrine cells co-expressing
insulin and glucagon (indicative of transdifferentiation) were quantita-
tively analyzed with the image-Pro 3D analyser software.
Results: In pancreatic sections derived from diabetic subjects there is a
significant decrease of the total islet area (27±5% reduction; p=0.01) and
cell density (15±7.9% reduction) compared to healthy controls, due to b-
cell death and amyloid accumulation. In particular, we detected a 49±7%
(p<0.0001) reduction in b-cell area of T2D subjects compared to healthy
controls (particularly evident in the islet core). No significant modifica-
tion of a-cell area was observed. The overlap coefficient between insulin
and glucagon stainings (co-localization index) was significantly increased
in diabetic subjects compared to controls (T2D 0.36±0.03; CTR 0.20±
0.04; p<0.05), suggesting a transdifferentiation process. No correlation
was found between the overlap coefficient and subjects’ age, sex, diabetes
duration, islet area. Interestingly, subjects with the highest overlap coef-
ficient were under insulin treatment, suggesting that the phenomenon
correlates with severe islet dysfunction.
Conclusion:The validation of transdifferentiation as an alternativemech-
anism occurring in adult diabetic pancreases and the understanding of
how this event can be manipulated may lead to the design of new treat-
ments aimed at promoting the survival of residual β-cell and preventing
diabetes progression.
Supported by: PUR
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Cumulative excess HbA1c index may substantially predict retinopa-
thy in type 1 diabetes patients, if we use HbA1c data of total diabetes
duration - a DCCT/EDIC subgroup analysis
A. Hirose1, A. Goto2, N. Yamaguchi2, S. Kitano1, Y. Uchigata3;
1Diabetic Ophthalmology, Diabetes Center, 2Public Health, 3Diabetes
Center, Tokyo Women's Medical University, Japan.
Background and aims: We found that an index, cumulative excess
HbA1c value (CueA1C), may substantially predict retinopathy, if we
use HbA1c data covering total diabetes duration, which may reflect the
whole effect of metabolic memory in our type 1 diabetes mellitus
(T1DM) patients who had only a short period (≤12 months) between
diabetes onset and the beginning of observation. We also found that the
longer the period without HbA1c data following onset, the lower the
capacity for prediction in our cohort. To confirm these results, we exam-
ined the public data of DCCT/Epidemiology of Diabetes Interventions
and Complications (EDIC).
Materials and methods: To examine only selected cases of
DCCT/EDIC, those who had HbA1c data during nearly their entire
period of hyperglycemia, we included 55 T1DM patients of primary
prevention with the shortest diabetes duration (≤12 months) at
DCCT baseline. We developed a window which we named ‘half-
yearly visit (HV)’ to integrate HbA1c data and retinopathy steps of
the final Early Treatment Diabetic Retinopathy Study (ETDRS) se-
verity scale for persons. HV00 was DCCT baseline, and HV24 was
at DCCT year 12. During DCCT, HbA1c values of an even number
of quarterly visits (QVs) were applied to those of HVs: for example,
the value of QV00 (DCCT baseline) was applied to HV00, QV02 to
HV01, and so on. During EDIC, HbA1c values were applied to the
corresponding HVs according to their data collection dates from
DCCT baseline: for example, 11.75≤X<12.25 years’ data to
HV24. Missing values were estimated by time-weighted averaging
from the HbA1c values of preceding and succeeding HVs. CueA1C
was calculated by adding the values of (HbA1c -6.5)(%)x1/2(year)
of all the HVs from onset to a given HV, supposing each case had
one-year duration at HV00, keeping the same HbA1c value during
that period. Simulated 3-, 6- and 9-year masked CueA1Cs were
calculated in the same way but masking HbA1c data for 3, 6 and
9 years following onset respectively. Retinopathy was defined as
DR+ at ETDRS step≥4, otherwise as DR- at a given HV. The pre-
diction capacities of CueA1Cs for retinopathy between HV16 and
HV24 (DCCT years 8 and 12, respectively) were examined by re-
ceiver operating characteristic (ROC) analysis and were compared
by the method of DeLong. P<0.05 was considered significant.
Results:Of the 132 HVs which had retinopathy data between HV16
and HV24, 36 were DR+ and 96 were DR-. The area under the
curve (AUC) for retinopathy was 0.885, 0.875, 0.777 and 0.653 in
CueA1C, 3-, 6- and 9-year masked CueA1Cs respectively. The dif-
ference of AUC compared to CueA1C was not significant for 3-year
masked CueA1C (P=0.39), but it was significant for 6-year (P=
0.0002) and 9-year (P<0.0001) CueA1Cs. It seemed that CueA1C
had a substantial capacity to predict retinopathy, and that the longer
the period without A1C data, the lower the capacity for retinopathy
prediction. The results in our previous study of Japanese patients
seemed to be confirmed in the patients of the current DCCT/EDIC
subgroup.
Conclusion: CueA1C index may have a substantial capacity to predict
retinopathy in T1DM, if we use HbA1c data of total diabetes duration
insofar as possible. We should consider information from the entire du-
ration of diabetes in order to study the relation between hyperglycemia
and retinopathy accurately.
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Cardiac autonomic function in relation to diabetic retinopathy devel-
opment and progression in type 1 diabetic patients: a prospective
observational study
K. Blaslov1,2, S. Vučković Rebrina1, M. Tomić1, L. Duvnjak1,2;
1University hospital Merkur, 2School of Medicine, University of Zagreb,
Zagreb, Croatia.
Background and aims:Denervation of the cardiovascular system is one
of the earliest manifestations of diabetic autonomic neuropathy (DAN).
Various studies have shown that it is strongly associated with microvas-
cular complications of diabetes, microalbuminuria and diabetic retinopa-
thy (DR). In this longitudinal observational study we aimed to determine
whether cardiac autonomic fuction contributes to risk of DR development
and progression in normoalbuminuric type 1 diabetic (T1DM) without
syptomiatic DAN .
Materials and methods: One hundred fifty four normoalbuminuric
T1DM patients were included in the study. Urine albumin excretion
(UAE) was measured from two 24-h urine samples and determined as
the mean of 24-h urine collections to minimize variability.
Photodocumented retinopathy statuswas made according to EURODIAB
protocol. Normoalbuminuria was defined as a UAE<30 mg/24 h. The
battery of cardiovascular autonomic function (AFT) tests included: heart
rate variation at rest (HRV-CV), HRV-CV during deep breathing
(dbHRV-CV), Valsalva manoeuvre and active orthostatic test and blood
pressure response to standing. In the frequency domain we measured
high-frequency power (HF), and low frequency power (LF) using a fast
Fourier transformation in order to calculate the power spectral density
curve. Participants were reexamined after 18 months to update their
glycaemic control, UAE and retinopathy status.
Results: The results of AFT in T1DM patients with NPDR and 107 free
of DR are given in Table 1. Patients with NPDR showed significantly
lower HRVat rest, HRV during deep breathing as well as deep breathing
E/I ratio compared to group of patients without DR. There was a signif-
icant attenuation for both LF and HF Power in the NPDR group. In-
between groups diabetes duration was significantly different although
long-term glycaemic control assessed by glycated haemoglobin A1c
(HbA1c) was similar. Six (3.89%) patients developed albuminuria during
18 months follow up period while 21 (13.36%) developed NPDR or
progressed from NPDR to PDR. A Cox regression model adjusted for
age, gender, disease duration, HbA1c, hypertension prevalence, ACE
inhibitor use and smoking status showed that higher HRV-CV, dbHRV-
CVas well as LF Power reduce the risk of DR incidence and progression
(HR 0.664 (0.514 to 0.866), p=0.002; 0.873 (0.784 to 0.972), p=0.013
and 0.909 (0.892 to 0.964), p=0.014, resepectively).
Conclusion: In this prospective, longitudinal, observational cohort study,
we demonstrated that AFT results might serve as an independent prog-
nostic factor for the future development or progression of DR in T1DM
patients even in the DAN absence.
235
Effects of baseline haemoglobin A1c and on-treatment blood pressure
on outcomes in the VIVID-DME and VISTA-DME studies
M. Evans1, T.A. Katz2, M. Crane2, VIVID-DME and VISTA-DME
Study Investigators;
1Diabetes Resource Centre, Llandough Hospital, Cardiff, UK, 2Bayer
HealthCare Pharmaceuticals, Whippany, USA.
Background and aims: The VIVID-DME and VISTA-DME studies
evaluated intravitreal aflibercept (IVT-AFL) vs. laser for diabetic macular
edema (DME). The current subanalyses analyse associations between
haemoglobin A1c (HbA1c) and blood pressure (BP) and visual and ana-
tomic outcomes in these studies.
Materials and methods: In the VIVID-DME and VISTA-DME studies,
865 patients with diabetic macular edema (DME) were treated with IVT-
AFL (2 mg every 4 weeks [2q4] or 2 mg every 8 weeks following 5
monthly doses [2q8]) or laser. In the current subanalyses, data from both
studies have been integrated. The IVT-AFL treatment arms were pooled
to increase the power of the analysis. HbA1c quartiles were defined using
all available baseline data. On-treatment BP was calculated as ([mean
systolic BP+mean diastolic BP]/2) using the average of measurements
obtained every 4 weeks from baseline to week 52. Values were then
divided into quartiles.
Results:Mean changes in best corrected visual acuity (BCVA) and central
retinal thickness (CRT) by mean baseline HbA1c quartiles and by mean
on-treatment BP quartiles are shown in the table. The most frequent ocular
serious adverse event in a pooled analysis of VIVID-DME and VISTA-
DME was cataract (2.4% and 1.0% vs. 0.3% for 2q4 and 2q8 vs. laser).
Conclusion: In the laser group but not the IVT-AFL group, visual and
CRT improvements were less with increasing baseline HbA1c. There was
no apparent correlation between increasing on-treatment BP and vision or
CRT in either group. Visual benefits were consistently greater with IVT-
AFL vs. laser, regardless of baseline HbA1c or on-treatment BP.
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Topical administration of GLP-1 receptor agonists prevents retinal
neurodegeneration in experimental diabetes
R. Simó1, P. Bogdanov1, L. Corraliza1, C. Solà-Adell1, A.I. Arroba1,
A.M. Valverde2, C. Hernández1;
1Diabetes and Research Unit, Institut de Recerca Hospital Universitari
Vall d'Hebron and CIBERDEM, Barcelona, 2Instituto de Investigaciones
Biomédicas Alberto Sols and CIBERDEM, Madrid, Spain.
Background and aims: Retinal neurodegeneration is an early event in
the pathogenesis of diabetic retinopathy (DR). Since glucagon-like pep-
tide-1 (GLP-1) exerts neuroprotective effects in the central nervous sys-
tem and the retina is ontogenically a brain-derived tissue. The aims of the
present study were: 1) To examine the expression and content of GLP-1R
in human and db/db mice retinas. 2) To determine the retinal neuropro-
tective effects of systemic and topical administration (eye drops) of
GLP-1R agonists in db/db mice. 3) To examine the underlying neuropro-
tective mechanisms.
Materials and methods: Human study: retinas were obtained from the
Tissue Bank of our Centre. A total of 8 diabetic donors and 8 non-diabetic
donors matched by age and gender were included in the study. GLP-1R
expression and content were analyzed by RT-PCR, Western-blot and im-
munohistochemistry. Animal studies: after 15 days of treatment by using
subcutaneous or topical GLP-1R agonists the neurodegenerative features
were examined. Functional abnormalities were assessed by electroretinog-
raphy and neurodegeneration was assessed by measuring glial activation
and the apoptotic rate. In addition, several representative mediators of
apoptotic (Fas/FasL, caspase 8, Bax, p53), anti-apoptotic (BclxL),
neuroinflammatory (iNOS), and insulin signaling (pAKT/AKT) pathways
were also analyzed byWestern blot. Glutamate (HPLC) and its main trans-
porter GLAST (glutamate/aspartate transporter) were also determined.
Results: We have found abundant expression of GLP-1R in the human
retina and retinas from db/db mice. Moreover, we have demonstrated that
systemic administration of a GLP-1R agonist (liraglutide) prevents retinal
neurodegeneration (glial activation, neural apoptosis and
electroretinographical abnormalities). This effect can be attributed to a
significant reduction of extracellular glutamate due to the prevention of
the down-regulation of GLAST induced by diabetes. In addition, an
increase of prosurvival signaling pathways was observed. We have found
a similar neuroprotective effect using topical administration of native
GLP-1 and several GLP-1R agonists (liraglutide, lixisenatide and
exenatide). Notably, this neuroprotective action was observed without
any reduction in blood glucose levels.
Conclusion: These results suggest that GLP-1R activation itself prevents
retinal neurodegeneration. Our results should open up a new approach in
the treatment of the early stages of DR.
Supported by: SAF2012-35562, SAF2012-33283, PI13/00603
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Bioactive lipids dissociate steatosis and insulin resistance in the hu-
man liver in non-alcoholic fatty liver disease
P. Luukkonen1,2, Y. Zhou1, S. Sädevirta1,2, M. Leivonen3, J. Arola4, M.
Oresic5, T. Hyötyläinen5, H. Yki-Järvinen1,2;
1Minerva Foundation Institute for Medical Research, 2Department of
Medicine, University of Helsinki, 3Department of Surgery, University
of Helsinki, 4Department of Pathology, University of Helsinki, Helsinki,
Finland, 5Steno Diabetes Center, Gentofte, Denmark.
Background and aims: ‘Metabolic NAFLD’ is characterized by hepatic
insulin resistance (IR) and the features of metabolic syndrome, while
NAFLD due to the common (40% of Europeans) PNPLA3 I148M gene
variant at rs738409 (‘PNPLA3 NAFLD’) is not. We used these two
models to determine in the human liver whether i) NEFA or triglyceride
(TG) composition; ii) bioactive lipids; iii) pathways of ceramide synthesis
differ between ‘Metabolic NAFLD’ and ‘PNPLA3NAFLD’. The latter is
of interest as recent studies in mice have identified 16:0-ceramide formed
via the de novo ceramide synthetic pathway as the key mediator of he-
patic insulin resistance.
Materials andmethods: Liver biopsies from 125 subjects, characterized
with respect to metabolic features and PNPLA3 genotype, were taken for
profiling of molecular lipids using UHPLC-MS and liver histology. Sub-
jects were divided into groups based on median HOMA-IR (‘High
HOMA-IR’, n=62, vs. ‘Low HOMA-IR’, n=63) and the PNPLA3
genotype (PNPLA3148MM/MI, n=61 vs. PNPLA3148II, n=64). The
groups were similar with respect to BMI and gender.
Results: Histologic liver fat was similarly 3-fold increased in ‘High
HOMA-IR’ (15 [5 - 33]) vs. ‘Low HOMA-IR’ (5 [0 - 20], p<0.002)
group, and in ‘PNPLA3148MM/MI (15 [5 - 30]) vs. the ‘PNPLA3148II‘
(5 [0 - 28], p<0.04) group. By definition, the ‘High HOMA-IR’ group
was insulin-resistant vs. the ‘Low HOMA-IR’ group (HOMA-IR 4.8
[3.9-5.8] vs. 1.8 [1.3-2.7], p<0.0001), and also had decreased serum
adiponectin (6.0 [4.0-8.7] vs. 9.5 [6.1-12.1] ng/ml, p<0.0001), while no
changes were observed in PNPLA3148MM/MI vs. PNPLA3148II group
(HOMA-IR 3.2 [1.7-5.1] vs. 3.2 [1.9-4.5], NS). The liver in ‘High
HOMA-IR’ vs. ‘Low HOMA-IR’ was markedly enriched in saturated
and monounsaturated TGs, dihydroceramides (34:0 and 36:0, reflecting
de novo ceramide synthesis from 16:0 palmitate and 18:0 stearate,
Figure), other ceramides (Figure) and in 16:0 and 18:0 but not 18:2 or
20:4 intrahepatic NEFA. Markers of other ceramide synthetic pathways
were unchanged. In PNPLA3148MM/MI vs. PNPLA3148II, the increase
in liver fat was due to polyunsaturated TGs while other TGs, diacylglyc-
erols, ceramides (Figure) and intrahepatic NEFAwere unchanged.
Conclusion: Equal increases in liver fat due to ’Metabolic NAFLD’ and
’PNPLA3 NAFLD’ are characterized by strikingly different hepatic
lipidomes. Bioactive IR causing lipids, particularly ceramides from de
novo synthesis from saturated fatty acids, are increased in ‘Metabolic
NAFLD’ but not ‘PNPLA3 NAFLD’. These differences imply measure-
ment of liver fat allows diagnosis of NAFLD but not insulin resistance or
its metabolic consequences.
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Gene therapy with insulin receptor isoform a as an approach for the
treatment of type 2 diabetes
S. Diaz-Castroverde1,2, O. Escribano1,2, M. Luque1, A. Gómez-
Hernández1,3, S. Fernández1,3, G. García-Gómez1,3, G. González-
Aseguinolaza4, M. Di Scala4, N. Beneit1, L. Perdomo1, M. Benito1,2;
1Biochemistry and Molecular Biology II, Complutense University of
Madrid, 2Mechanism of Insulin Resistance Consortium, 3Spanish Bio-
medical Research Centre in Diabetes and Associated Metabolic Disor-
ders, Madrid, 4Center for applied medical research, University of Navar-
ra, Pamplona, Spain.
Background and aims: Type 2 diabetes mellitus is a complex metabolic
disease and its pathogenesis involves abnormalities in both peripheral
insulin action and insulin secretion by pancreatic beta cells. There are
many proteins involved in insulin resistance and one of the most impor-
tant is the insulin receptor (IR). Our laboratory has generated iLIRKO
mice (inducible Liver Insulin Receptor KnockOut) that develops Type 2
diabetes in a very similar way to what happens in humans. Moreover,
previous experiments in our laboratory found that IRA isoform, but not
IRB, plays a direct role in the regulation of basal glucose uptake/transport
through its specific association with endogenous glucose transporters
(GLUT1 and GLUT2) in murine hepatocytes. With this background,
we hypothesized that the expression of IRA in iLIRKOmice using AAVs
(Adenoassociated virus) as a gene therapy approach could be a good
option in order to reverse the diabetic phenotype. Thus, reconstitution
of iLIRKO with IRA in the liver might increase glucose consumption,
ameliorate hyperglycaemia and therefore impair the compensatory mech-
anisms through beta cell hyperplasia/hypertrophy that finally lead to beta
cell failure.
Materials and methods: Recombinant hepatospecific AAV vectors
(serotype 8) were constructed with a transgene cassette encoding either
the IRA or IRB or the reporter gene GFP. Twenty-week-old mice were
injected intravenously with the AAV viruses. Glucose and insulin toler-
ance tests were performed to evaluate insulin sensitivity and glucose
clearance and follow the diabetic phenotype. In addition, insulin plasma
levels were also measured by ELISA.
Results: The physiological effects of the disruption of insulin signaling in
liver in iLIRKOmice were apparent 5 weeks after the induction of the IR
deletion. By 3 months of age, male iLIRKO displayed pronounced glu-
cose intolerance and insulin resistance. The expression of IRA in
20-week-old mice, but not IRB, was able to restore glucose tolerance
and reverted insulin resistance about 8 weeks after the treatment. More-
over, plasma insulin levels were recovered in injected IRA iLIRKO mice
as compared with IRB-injected or reporter gene-injected mice.
Conclusion: Our data demonstrate that the expression of IRA by gene
therapy improves hyperglycemia by promoting an increased glucose up-
take by the liver. The decrease on glucose plasma levels ameliorates the
compensatory hyperinsulinemia that finally lead to beta cell failure and
overt diabetes. Therefore, hepatic expression of IRA could be a therapeu-
tic approach for Type 2 diabetes treatment.
Supported by: SAF2011-22555, CAM S2010/BMD-2423, CIBERDEM,
ISCIII, MCINN
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Metabolic reprogramming in male offspring in a non-dietary model
of liver insulin resistance
D.F. De Jesus1,2, R.N. Kulkarni1;
1Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard
Medical School, Boston, USA, 2GABBA - Graduate Program in Areas
of Basic and Applied Biology, Abel Salazar Biomedical Sciences Insti-
tute, University of Porto, Portugal.
Background and aims: Several studies have focused on investigating
the effects of early nutritional insults that increase the likelihood of de-
veloping type 2 diabetes in the offspring. Virtually none include the use
non-dietary models manifesting hyperglycemia and hyperinsulinemia.
We aimed to determine the effects of paternal versusmaternal liver insulin
resistance on the developmental programming in the offspring of the
liver-specific insulin receptor knockout (LIRKO) mice.
Materials and methods: Male control offspring from 12 weeks of age
LIRKO father (LF) and control mother, LIRKO mother (LM) and control
father, and control mothers and fathers (C) were weaned at 3 weeks of age
on a chow (21%) or high-fat diet (HFD) (60%) and followed for 12 weeks.
Body weights and blood glucose levels were measure weekly. Insulin sen-
sitivity, glucose tolerance, in vivo glucose-stimulated insulin secretion was
assessed between 9 and 12 weeks of age in randomly selected mice from a
least 3 different offsprings in each group. Mice were sacrificed at 15 weeks
of age, blood, pancreases and liver were harvested for further analysis.
Results: As previously reported, 8 week-old LIRKO males and females
exhibited insulin resistance and glucose intolerance compared to their
respective controls. On a chow diet, LF (LF: 14.1±0.5; C: 17.5±0.5 g;
LF vs C: p<0.001, 4 weeks of age): and LM (LM: 15.1±0.5; C: 17.5±
0.5 g; LM vs C: p<0.001; 4 weeks of age) exhibited lower body weights
until 9 weeks of age and compensated by gaining weight with age com-
pared to controls. After 3 weeks on HFD, LM (LM: 27.7±1.0; C: 23.7±
0.7 g; LM vs C: p<0.01; 6 weeks of age) but not LF gained more weight
compared to C. LF and LM exhibited insulin resistance compared with C
on both chow (LF vs C: p(area under the curve - AUC)<0.01 and LM vs
C: p(AUC)<0.01; n=5-8) and HFD (LF vs C: p(AUC)<0.05 and LM vs
C: p(AUC)<0.01, n=4-5) cohorts at 9 weeks of age. LF and LM main-
tained insulin resistance with age and after 8 weeks on HFD became
hyperglycemic (LF, 110.2±6.2; LM, 107.2±4.1; C, 78.3±6.9 mg/dL;
LF vs C and LM vs C: p<0.01; n=4) and LM hyperinsulinemic (LM,
2.63±0.66; LF, 1.62±0.67; C, 0.52±0.11 ng/ml; LM vs C: p<0.05; n=4)
during fasting. LF and LM presented an augmented acute insulin secre-
tion response to glucose (LF: 374.95±4.4; LM: 502.41±39.5; C: 223.65
±36.4% of initial insulin levels; LF vs C: p<0.001; LM vs C: p<0.001;
n=3; 2 minutes after stimulation) on chow. On HFD this response was
abrogated in both groups. LF and LM had increased beta-cell
S120 Diabetologia (2015) 58 (Suppl 1):S1–S607
proliferation (LF: 0.42±0.06; LM: 0.44±0.02; C: 0.23±0.04% KI67+/
Insulin+ cells; LF vs C: p<0.05; LM vs C: p<0.01; n=3-4) on chow
comparing with C. After 12 weeks of HFD, LF and LM presented prom-
inent hepatic steatosis. Analysis of genes involved in the regulation of
liver glucose and fatty acid metabolism revealed LM and LF on chow diet
exhibited downregulation of Glut2, Gpase, Cpt1, CD36, Elovl2, PPARα
and PPARγ genes while the same groups on HFD showed upregulation
of CD36, PPARα, PPARγ, Fas and Scd1.
Conclusion: Together these data suggest that prenatal hyperinsulinemia and
hyperglycemia have detrimental effects on beta-cell adaptation and transcrip-
tional regulation of hepatic metabolism in the offspring that may contribute
to their impaired growth and metabolic response to dietary challenges.
Supported by: DFDJ: FCT SFRH/BD/51699/2011; RNK: NIH RO1 DK
67536
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Liver insulin sensitivity is linked with resting sympathetic nervous
activity in non-diabetic obese men
D.L.T. Chen1, D. Chisholm1, R. Brown2, V. Macefield2, D. Samocha-
Bonet1,3, J. Greenfield1,4;
1Garvan Institute ofMedical Research, 2Integrative Physiology School of
Medicine, University of Western Sydney, 3School of Medical Sciences,
University of New South Wales,4Department of Endocrinology and Dia-
betes Center, St. Vincent’s Hospital, Sydney, Australia.
Background and aims: Sympathetic nervous system activity may play a
role in the aetiology of insulin resistance in humans. Obesity is associated
with peripheral and hepatic insulin resistance and with basal sympathetic
nervous hyperactivation. However, whether sympathetic nervous activation
is more closely aligned with peripheral or hepatic insulin resistance in
obesity remains unclear. We aimed to compare resting muscle sympathetic
nervous activity (MSNA) between non-diabetic obese insulin-sensitive and
insulin-resistant subjects stratified by liver and muscle insulin sensitivity.
Materials andmethods: Forty-five non-diabetic obese subjects (22men,
23 women) aged 51±11 years were studied. Two-step (low-dose [15] and
high-dose [80] mU/m2/min) hyperinsulinaemic-euglycaemic clamps
with deuterated glucose were performed. Subjects in the top tertile of
endogenous glucose production (EGP) suppression were deemed
Liversen; those in the bottom two tertiles were deemed Liverres. Subjects
in the top tertile of glucose infusion rate (GIR) during the high-dose
insulin clamp were deemed Musclesen; the bottom two tertiles were
deemed Muscleres. Clinical and metabolic parameters were assessed.
MSNAwas measured by microneurography.
Results: MSNA did not differ between insulin-sensitive and insulin-
resistant groups stratified by either liver or muscle insulin sensitivity.
However, when men and women data were analysed separately, Liversen
men had lower MSNA burst frequency compared to Liverres men
(27±14 vs. 38±7 units; P=0.03). Musclesen men had lowerMSNA burst
frequency compared to Muscleres men (24±9±12.0 vs. 38±9 units;
P=0.004). No differences in MSNA were observed in parallel analyses
in women.MSNA burst incidence correlated positively with age (r=0.48,
P<0.01) and visceral fat (r=0.3, P=0.05) in total cohort. In men, MSNA
burst frequency correlated with the hepatokines high-sensitivity C-reac-
tive protein (hsCRP) and fibroblast growth factor (FGF)19 (r=0.57,
P=0.006; r=-0.47, P=0.03 respectively) and correlated negatively with
liver insulin sensitivity (EGP suppression, r=-0.53, P=0.02).
Conclusion: MSNA burst frequency is lower in obese insulin-sensitive
men compared to their insulin-resistant counterparts, when stratified by
either muscle or liver insulin-sensitivity. Basal sympathetic nervous ac-
tivity is related to liver insulin sensitivity and circulating hepatokines,
suggesting a potential hepato-endocrine-sympathetic axis. Future studies
are needed to clarify the influence of sympathetic nervous activity on liver
insulin sensitivity in men.
Supported by: NHMRC
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Non-invasive in vivo monitoring of pancreatic beta cell insulin
resistance
M. Paschen, T. Moede, B. Leibiger, S. Jacob, G. Bryzgalova, I.B.
Leibiger, P.-O. Berggren;
Karolinska Institutet, Stockholm, Sweden.
Background and aims: Pancreatic β-cell dysfunction is central to the
development of type 2 diabetes (T2DM) which has reached epidemic
proportions. Because the pancreatic β-cell itself is a target for insulin
action, β-cell insulin resistance can contribute to β-cell dysfunction.
While in vivo tests are available to measure overall body or liver insulin
resistance, there is currently no test to evaluate insulin resistance at the
pancreatic islet/β-cell level in the living organism. In the present study we
present a technique to report on insulin resistance in pancreatic β-cells
in vivo .
Materials and methods:We transplant pancreatic islets into the anterior
chamber of the eye (ACE) that express a fluorescent biosensor in their
β-cells and monitor insulin resistance non-invasively and longitudinally
by fluorescence microscopy at single-cell resolution in the living mouse.
The biosensor is based on the different subcellular localization of FoxO1-
GFP, i.e. cytosolic in insulin responsive cells and nuclear at insulin
resistance.
Results: In vitro experiments inMIN6 cells and islets of Langerhanswere
performed to validate the function of the biosensor. In these experiments
wemonitored insulin resistance induced by pharmacological inhibitors as
well as by the free fatty acid palmitate. The leptin deficient ob/ob mouse
was used to validate the biosensor in vivo. At 3 and 10 months of age,
lean control mice did not develop either whole-body insulin resistance
(AUC (3 months)=845±56; AUC (10 months)=907±67) or β-cell insu-
lin resistance (3 months of age: 1.1±0.6% insulin-resistant β-cells;
10 months of age: 1.8±0.9% insulin-resistant β-cells). In contrast,
ob/ob mice were β-cell insulin resistant at 3 months of age (12.1±2.8%
insulin-resistant β-cells, p<0.001 compared to ob-control (3 months) and
p<0.01 compared to ob/ob (10months)) and insulin responsive at old age
(3.7±1.4% insulin-resistant β-cells). The β-cell insulin resistance was
paralleling the whole-body insulin resistance (AUC (3 months)=1914±72;
AUC (10 months)=827±89; p<0.001: 3 months compared to 10 months
old ob/ob; p<0.001: 3 months old ob/ob compared to 3 months old
ob-control). The in vivo imaging data were complemented with and con-
firmed by data from immunohistochemistry and Western blot analysis of in
situ pancreatic islets.
Conclusion: Our technique will allow monitoring longitudinally and
non-invasively at single cell resolution the dynamics of pancreatic
β-cell insulin sensitivity/resistance in the context of overall insulin resis-
tance, hepatic insulin resistance and glucose tolerance during progression
and intervention of experimental T2DM in a ‘personalized’ medicine
approach.
Supported by: KID, NovoNordiskFonden,Erling-Persson Found.,VR
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Glucagon is a key factor in circadian glucose rhythm and clock gene
regulation
S. Malmgren, B. Ahrén;
Department of Clinical Sciences in Lund, Lund University, Sweden.
Background and aims:Metabolic regulation of glucose homeostasis is
partly controlled by oscillations in the transcription of concurrent
CLOCK genes. On the tissue level, these transcription patterns are strong-
ly affected by nutritional intake and subsequent hormone release. Shift
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work and/or an altered sleeping pattern are lifestyle factors that increase
the risk of diabetes and other disturbances in glucose metabolism. Since
dysregulation of glucagon accompanies disrupted insulin secretion in
type 2 diabetes, we asked if glucagon signalling is involved in the circa-
dian rhythm of clock genes and glucose homeostasis and whether gluca-
gon secretion is regulated by circadian rhythm.
Materials and methods: To assess the effects of disrupted glucagon
signalling on circadian glucose rhythm, we performed oral challenges
using a mixed meal (60/20/20E% Glucose/Protein/Lipid) in wt and glu-
cagon receptor knock-out mice (GCGR-/-) and measured glucose and
insulin in plasma at zeitgeber times (ZT) 3 (3 h after start of 12 h/12 h
light/dark cycle; light phase) and ZT15 (dark phase). To assess the effect
of disrupted glucagon signalling on molecular clocks we analysed core
clock gene expression in islets at ZT 3, 9, 15 and 21 using qPCR. To
further examine circadian rhythm in glucagon dynamics, glucagon
response following a meal challenge or a hyperinsulinaemic,
hypoglycaemic clamp was measured in wt mice.
Results:During light phase (ZT3), we found a marked difference in basal
(4.2±0.2 vs. 7.4±0.3 mmol/l, p<0.0001) and peak glucose (8.0±0.4 vs.
13.5±0.6 mmol/l, p<0.0001), and glucose-stimulated insulin peak (837±
174 vs. 2250±347 pmol/l, p<0.0001) in GCGR-/- compared to wt ani-
mals. In contrast, there was little difference in glucose levels and no
difference in insulin levels between groups at the dark phase (ZT15).
When applying the quantitative insulin sensitivity check index
(QUICKI), we found that GCGR-/- differ greatly from wt in insulin sen-
sitivity at ZT3 (0.90±0.07 vs. 0.51±0.02, p<0.0001) but not at ZT15.
GCGR-/- mice displayed disrupted expression of clock genes Bmal1,
Clock, Rev-Erbα and Per1 at the mRNA level compared to wt. The
glucagon response to a meal challenge did not differ between the ZT:s,
however, the glucagon response to hypoglycaemia (4.8±1.2 vs. 1.9±0.5,
p=0.035) and the insulin sensitivity measured using clamp (4.8±0.9 vs.
1.5±0.2, p=0.0034) was greater at ZT15 in wt animals.
Conclusion: In conclusion, this study shows that glucagon signalling is
important for circadian glucose rhythm, as is highlighted by the fact that
GCGR-/- mice differs in insulin dynamics from wt animals only during
the light phase. This is further emphasized by the concurrent altered
expression pattern of core clock genes in GCGR-/- mouse islets that
suggests that altered glucagon signalling disrupts islet clock gene
transcription.
Supported by: Kungl. Fysiografiska Sällskapet i Lund
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Hyperglucagonaemia after oral glucose and suppression of glucagon
following i.v. glucose in totally pancreatectomised patients
A. Lund1,2, J.I. Bagger1,2, M. Christensen1, M. Grøndahl1, N.W.
Albrechtsen2, E.R. Mathiesen3, C.P. Hansen4, J.H. Storkholm4, G.V.
Hall5, S. Larsen1, J.J. Holst2, T. Vilsbøll1, F.K. Knop1,2;
1Center for Diabetes Research, Gentofte Hospital, 2NNF Center for Basic
Metabolic Research, Faculty of Health and Medical Sciences, 3Center for
Pregnant Women with Diabetes, Department of Endocrinology,
Rigshospitalet, 4Department ofGastrointestinal surgery,Rigshospitalet, 5Clin-
ical Metabolomics Core Facility, Rigshospitalet, Copenhagen, Denmark.
Background and aims: Glucagon is believed to be a pancreas-
specific hormone and postabsorptive hyperglucagonaemia is thought
to contribute to the hyperglycaemic state of patients with diabetes.
This hyperglucagonaemia has been thought to arise as a consequence
of alpha cell insensitivity to the glucagon suppressive effects of glu-
cose and insulin combined with reduced insulin secretion. We
hypothesised that postabsorptive hyperglucagonaemia represents a
gut-dependent phenomenon occurring independently of plasma glu-
cose and insulin concentrations. Therefore, we evaluated plasma
levels of glucagon during OGTT and isoglycaemic i.v. glucose
infusion (IIGI) - bypassing the gastrointestinal tract - in totally
pancreatectomised patients.
Materials and methods: Ten totally pancreatectomised patients (PX)
(age: 59.8±3.1 years [mean±SEM]; BMI: 21.5±1.3 kg/m2; HbA1c:
67.3±3.5 mmol/mol) and 10 healthy control subjects (CTRL) (age:
58.4±1.6 years; BMI: 22.9±0.8 kg/m2; HbA1c: 34.6±2.0 mmol/mol)
underwent a 75 g-OGTT and a corresponding IIGI on two separate days.
Analysis of plasma glucagon was carried out using a newly developed
sandwich ELISA specific for fully processed human 29-amino acid
glucagon.
Results: Significantly larger amounts of glucose were needed during the
IIGI (in order to copy the 75 g-OGTT plasma glucose curve) in the PX
group than in the CTRL group (83±3 g vs. 28±2 g, p<0.001). The PX
group tended to have lower fasting levels of plasma glucagon compared to
the CTRL group (5.4±0.2 pmol/l vs. 8.3±1.5 pmol/l, p=0.064), but ex-
hibited a significant hyperglucagonaemic response during OGTT (Fig. 1).
In contrast, IIGI suppressed plasma glucagon levels in both groups.
Conclusion: We demonstrate that fully processed 29-amino acid gluca-
gon circulates in patients without a pancreas and that glucose stimulation
of the gastrointestinal tract elicits significant hyperglucagonaemia where-
as i.v. glucose administration results in suppression of plasma glucagon
levels. These findings emphasise that gut-derived glucagon may play an
important role in diabetic pathophysiology - also in diabetes secondary to
total pancreatectomy.Figure 1.Time courses of plasma glucagon [mean±
SEM] following OGTT and isoglycaemic i.v. glucose infusion (IIGI) in
totally pancreatectomised patients (PX) and healthy control subjects
(CTRL).
Clinical Trial Registration Number: NCT02006459
Supported by: EFSD/Novo Nordisk
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A role for glucokinase in pancreatic alpha cell stimulus-secretion
coupling
T. Moede, B. Leibiger, P. Vaca Sanchez, E. Daré, M. Köhler, T.P.
Muhandiramlage, P.-O. Berggren, I.B. Leibiger;
Department of Molecular Medicine and Surgery, Karolinska Institutet,
Stockholm, Sweden.
Background and aims: One of the remaining controversial issues of
glucose-regulated glucagon secretion is the identity of the glucose sensor
linking glucose metabolism to hormone secretion. To strengthen the
argument that glucokinase (GK) is this sensor in pancreatic alpha cells
we decided on the following two aims: 1. Which hexokinases are
expressed in pancreatic alpha cells? 2. Does manipulation of GK activity
by inhibitors, activators or knockdown lead to a change in stimulus-
secretion coupling in alpha cells?
Materials and methods: Primary pancreatic alpha cells were purified by
FACS sorting from islets of 3 months old Wistar rats. Single cells RT-
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PCR was performed for ca. 100 cells using primer sets for insulin, gluca-
gon, somatostatin and pancreatic polypeptide to verify cell identity and to
determine the expression patterns of glucose phosphorylating enzymes
(GK and hexokinase I to III). 5’race combined with cloning and sequenc-
ing was performed to identify the isoforms of glucokinase mRNAs pres-
ent in pancreatic alpha cells. For glucagon secretion studies the cells were
seeded onto 25 mm cover glasses and transduced with an adenovirus
expressing glucagon-pHluorin under the control of the glucagon promot-
er. 72 h after transduction the cover glasses were moved to a ZEISS
Axiovert TIRF microscope and glucagon release events were imaged,
analyzed and quantified. GK inhibitors and a GK activator were used
acutely while knockdown of GK expression was achieved by treatment
with siRNA. To verify the glucagon release measurements performed by
TIRF microscopy, glucagon secretion from isolated primary alpha cells
was measured by glucagon RIA.
Results: Single cell RT-PCR showed that >90% of analyzed pancreatic
alpha cells were positive for glucokinase mRNA (>90 analyzed cells). All
analyzed cells were negative for hexokinase I-III. 5’Race and sequence
analysis revealed that 63% of the analyzed mRNAs (45/71) were the full
length neuroendocrine GK form, resulting in a functional protein while
37% had deletions resulting in non-functional proteins. Primary alpha
cells show a twofold difference in glucagon release at 3 mM vs 4 mM
glucose (22.4±6 release events/minute and 100 μm2 (RE) vs. 11,2±2
RE; p<0.001). The same difference in release at these two glucose con-
centrations was observable using RIA (3%±0.5 of content released at
3 mM glucose vs 1.5%±0.1 at 4 mM; p<0.05). Treatment with glucoki-
nase inhibitors 5-thioglucose and deoxyglucose led to an increased re-
lease at 4 mM glucose concentration (22±3 RE or 24±4 RE respectively;
P<0.001 vs 4 mM glucose) while treatment with the activator
RO0281675 led to a decreased release at 3 mM glucose (9,68±2RE; p
<0.001 vs 3 mM glucose). 80% knockdown of glucokinase mRNA,
which was verified by RT-PCR, led to a loss of glucose sensitivity
resulting an increased release at 4 mM glucose (14.4±0.9 RE) and a
decreased release at 3 mM glucose (16.2±1 RE).
Conclusion: Rat alpha cells express the functional neuroendocrine form
of glucokinase. Single rat alpha cells respond to an increase of glucose
concentration with a decrease in glucagon release with a set point be-
tween 3 and 4 mM glucose. Activation of glucokinase lowers this set
point while inhibition of Glucokinase raises it. Knockdown of glucoki-
nase leads to a loss of glucose responsiveness. Taken together these data
indicate that glucokinase is indeed the glucose sensor linking glucose
concentration to glucagon secretion in pancreatic alpha cells.
Supported by: KI,VR, Novo Nordisk Fonden, Family Erling-Persson
Foundation
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A systematic review of educational, psychosocial, behavioural and
health service organisational interventions to improve outcomes for
young adults with type 1 diabetes
M. O'Hara1,2, L. Hynes3, M. O'Donnell1, N. Nery1, M. Byrne3, S.F.
Dinneen1,2, for the Irish Type 1 Diabetes Young Adult Study Group;
1School of Medicine, NUI Galway, 2Endocrinology and Diabetes Centre,
Galway University Hospitals, 3School of Psychology, NUI Galway,
Ireland.
Background and aims: Many young adults (YA) with type 1 diabetes
(T1D) experience poor outcomes as a result of their condition. Reasons
may include poor knowledge and self management skills, poor clinic
attendance, poor adherence with treatment recommendations and engag-
ing in high risk behaviours. The aim of this systematic review was to
identify, describe and synthesise the evidence regarding the effectiveness
of any educational, psychosocial, behavioural and health service
organisational interventions to improve outcomes for YAwith T1D.
Materials and methods: Five electronic databases were searched
between June and September 2014. Expert groups were contacted to
identify relevant grey literature. Any studies that addressed interventions
related to patient education and/ or support, behaviour, lifestyle change,
or health service organisational change for YA between 15-30 years old
with T1D were included. Interventions which aimed to improve out-
comes by purely pharmacological or physiological means were excluded.
A narrative synthesis of all relevant studies was undertaken.
Results: Papers (n=1,700) were screened by 2 authors (a 3rd author
screened if there were discrepancies), 19 quantitative studies published
between 1991 and 2013 met the inclusion criteria. Four major categories
were identified; Health Services Organisation (n=4), Technology (n=9),
Support (n=2) and Education (n=4). Quality of the studies was variable,
1 randomised controlled trial (RCT), 3 retrospective, 7 feasibility/ accept-
ability studies and 8 studies with a pre/ post designwere identified. All the
studies were of relatively short duration (3 days - 12 months, 1 study was
36 months), 12 had convenience/ opportunistic samples (often with small
sample sizes) and 10 had no/ inappropriate controls. Outcome measures
included HbA1c (n=14), frequency of episodes of hypoglycaemia/ dia-
betic ketoacidosis, diabetes knowledge, clinic attendance, telephone con-
tact time with diabetes nurse, insulin administration, treatment satisfac-
tion, self care activities, attitudes and behaviours towards intervention,
number of blood glucose (BG) tests, BG cue awareness and compliance.
The majority reported weak evidence for the intervention improving the
outcomes of interest and where significance was reported, it often deteri-
orated over time. The use of E-health (text messaging and internet), newer
insulin administration devices and smarter BG self monitoring devices in
the review highlighted the importance of Technology. Papers in the
Health Services Organisation category mainly aimed at impacting on
diabetes management/ engagement by the introduction of a structured/
coordinated approach to transition, some incorporated educational ele-
ments (n=2), and technology (n=1). Papers in both the Education and
Support categories aimed to improve management of diabetes, specifical-
ly glycemic control and 2 aimed to enhance awareness of BG cues.
Conclusion: This systematic review and narrative synthesis has
highlighted a lack of well designed and well described interventions, in
particular RCTs, aimed at improving health outcomes for YAwith T1D.
Further high quality research is warranted in this area.
Supported by: HRB, Ireland
Diabetologia (2015) 58 (Suppl 1):S1–S607 S123
246
Patients education focusing on physical activity - impact on habitual
activity levels, exercise tolerance, metabolic control and life quality
A.V. Petrov, L.G. Strongin, D.V. Shokareva;
Dpt. of Endocrinology and internal medicine, Nizhny Novgorod State
Medical Academy, Russian Federation.
Background and aims: The aim of study was to evaluate physical ac-
tivity changes in T2DM patients after standard education and educational
program with specific target of its increase and influence on metabolic
control and patients life quality.
Materials and methods: Prospective randomized unblinded study was
performed with 79 T2DM patients randomized to standard educational
program consisting of 5 sessions and similar program with addition of
15 minute simple physical exercises during each session, use of pedom-
eter (“standard” and “active” education groups correspondingly). Physi-
cal activity was evaluated by IPAQ questionnaire and average number of
steps per day by pedometer. 6-minute walk test (6-MWT) distance was
used for assessment of exercise tolerance, SF-12 v.2 questionnaire for life
quality. HbA1c and body weight changes characterized metabolic con-
trol. Patients were observed for 6 months after finishing education pro-
gram. Data are presented as M(SD) format, Mann-Whitney U-test was
used for statistical analysis.
Results: 39 patients were randomized to standard and 38 to active group.
At baseline groups were comparable for age, diabetes duration, HbA1c,
BMI, IPAQ score, 6-MWTdistance, number of steps per day and physical
component score of SF-12 (see Table). For mental component score of
SF-12 there was statistically significant difference in favor of standard
group. As it is shown in data table, in 6 months patients of active group
had increase in physical activity and 6-MWTdistance, increase in number
of steps per day compared to standard education. Also they had signifi-
cantly larger decrease of HbA1c, improvement of PCS and trend for
improvement of MCS scores of SF-12. Then both standard and active
group were evaluated together higher self-reported activity (METs/wk
>1500) was associated with significantly more weight loss compared to
baseline (-1.9(2.4) vs. -0.7(2.7) kg p=0.04), larger 6-MWT distance
(460(62) vs. 415(81) m p=0.01), better life quality on physical compo-
nent score (42(7.2) vs. 37(7.9) p=0.006).
Conclusion: In T2DM patients education can lead to significant increase
in physical activity together with improvement of metabolic control and
life quality. Its effectiveness was significantly enhanced by introducing
practical physical exercises and patients’ participation in physical activi-
ties together with use of pedometers with minimal additional time and
costs. Not only daily patients activities but also their tolerance to physical
exercise was increased which can improve patients’ attitude and capacity
for habitual exercise. Higher habitual exercise levels were associated with
better weight control and life quality thus improving health care for dia-
betic patients.
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Study on efficacy of long-term education for achieving compensation
of type 1 diabetes mellitus in children and adolescents
A.B.. Tashmanova1,2, S.I. Ismailov3,4, G.N. Rakhimova3,5;
1Diabetology, Center for the Scientific and Clinical Study of Endocrinol-
ogy, 2Endocrinology, Tashkent PediatricMedical Institute, 3Center for the
Scientific and Clinical Study of Endocrinology, 4Tashkent Pediat-
ric Medical Institute, 5Tashkent Institute of Physicians’ Post-
Graduate Study, Uzbekistan.
Background and aims:Today education is a basic component in therapy
of patients with diabetes mellitus in most countries. It was interesting to
assess achievement of compensation in children and adolescents with
type 1 diabetes mellitus within a 5-year period after training. The work
was initiated to assess level of knowledge and compensation degree in
children and adolescents with type 1 diabetes mellitus in “Type 1 Diabe-
tes School”.
Materials and methods: A five-day training course was conducted in
“Type 1 Diabetes School” at our Center. The training was conducted by
means of a structured program containing all appropriate sections. Before
and after training course all participants were tested with a questionnaire
containing 30 key questions for self-control. On the basis of the findings
children and adolescents with type 1 diabetes mellitus were divided into
groups, trained and untrained. 54 of 80 children and 38 of 57 adolescents
were preliminary trained, 26 children and 19 adolescents got no training.
DS5 Glycomat (USA) was used to measure glycated hemoglobin
(НbА1с) by means of high pH anion-exchange liquid chromatography.
Certified by the National Glycohemoglobin Standardization Program this
method became the reference one. It helps demonstrate the predicting role
of НbА1с level as a criterion for assessment of compensation.
Results: Before training children gave right answers to 20% of questions
only. In 5 years they could give right answers to 85% of questions, mean
НbА1с in trained and untrained children was 7.8% and 10.8%, respec-
tively. Children who got no training, those with low level of knowledge
and motivation both in them and their parents were hospitalized at the
intensive care units more frequently both before and after training.Within
follow-up period they gave right answers to 15% of questions only. The
trained adolescents with type 1 diabetes mellitus initially could give right
answers to 30% of questions, in 5 years there were 70% of right answers.
In the untrained adolescents, level of knowledge remained as low as it
was before and after 5-year follow-up, mean НbА1с level was 8.1% and
10.1% in the trained and untrained adolescents, respectively.
Conclusion: In the group of children trained for 5 years НbА1с mean
level was 7.8%, in those untrained it was 10.8%. In the groups of trained
and untrained adolescents meanНbА1сwas 8.1% and 10.1%, respective-
ly. Better compensation and level of knowledge in children as compared
with those among adolescents confirm the role of family in the type 1
diabetes mellitus control.
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Effectiveness of nurse-led telecoaching in optimising diabetes con-
trol: results of a randomised controlled trial in patients with type 2
diabetes
I. Odnoletkova1, G. Goderis1, F. Nobels2, B. Aertgeerts1, L. Annemans3,
D. Ramaekers1;
1Public Health and Primary Care, University of Leuven, Brussel, 2Endo-
crinology, OLV Hospital Aalst, 3Public Health, Ghent University, Bel-
gium.
Background and aims: About a half of people with type 2 diabetes do
not reach their treatment targets, increasing the risk of future complica-
tions. Patient education has been shown to contribute to a better
glycaemic control. Diabetes education by phone may improve patient
inclusion and increase efficiency, however the effectiveness of telephone
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education in type 2 diabetes is uncertain. The objective was to study the
effect of “The COACH Program”, a well-established Australian
telecoaching program for patients with chronic conditions, on
glycohemoglobin and other modifiable risk factors in patients with type
2 diabetes in primary care.
Materials andmethods:Randomized controlled trial in Belgium where-
in people between 18 and 75 years were selected on hypoglycaemic agent
consumption, recruited by their sickness fund and randomized to
telecoaching or usual care. The intervention was delivered by diabetes
nurse educators and consisted of five telephone sessions spread over
6 months, aimed at achievement of guideline-recommended diabetes
treatment targets. The primary outcomewas change inHbA1c at 6months
in the entire study group and the subgroup with HbA1c≥7% at baseline
(further “subgroup”). The secondary outcomes were: total cholesterol
(TC), LDL, HDL, triglycerides, BP and BMI at 6 and 18 months fol-
low-up. The measurements were performed by trial nurses and the blood
samples analyzed in a single lab. Linear mixed-effect model was used to
compare the change in outcomes within and between groups.
Results: 574 eligible patients were randomized to the telecoaching
(N=287) or the control group (N=287). Their median age was 64 years,
62% were men, 86% on oral antidiabetics therapy. The mean (SD) base-
line HbA1c,% was 7.0 (1.0) and 7.9 (0.9) in the subgroup, TC: 176 (38)
mg/dl, BP: 133 (17)/75 (10) mmHg, BMI: 30 (5) kg/m2. 85% of patients
in the telecoaching group attended the intervention as planned. The attri-
tion rate was 11% and 16% in the intervention group and 9% and 14% in
the control group at 6 months and 18 months respectively. At 6 months,
the reduction in HbA1c,% (95% CI) in the intervention group was -0.2
(-0.3 to -0.1, p=.000) and in the subgroup -0.5 (-0.7 to -0.3, p=.000); in
the control group 0.0 (-0.1 to 0.1, p=.703) and -0.1 (-0.3 to 0.1, p=.411)
in the respective subgroup. The between-group difference in HbA1c was
0.2 (0.1 to 0.3, p=.003) and 0.4 (0.1 to 0.7, p=.002) in the subgroup.
Other between group differences at 6 months were observed only in BMI
(kg/m2): 0.4 (0.1 to 0.7, p=.003) and TC (mg/dl): 6 (2 to 11, p=.011), in
favor of the intervention. At 18 months, the sustained between-group
difference in HbA1c was 0.1 (0.0 to 0.3, p=.065) and 0.3 (0.0 to 0.6,
p=.033) in the subgroup. No between-group difference in other outcomes
was observed at 18 months.
Conclusion: The COACH Program improved the glycaemic control,
total cholesterol and body mass index at 6 months in people with type 2
diabetes in Belgian primary care. Overall, the differences between groups
did not sustain at 18 months. In patients with HbA1c≥7% at baseline, the
clinically relevant difference in glycaemic control slightly declined but
stayed significant at 18 months follow-up. Nurse-led telecoaching in type
2 diabetes is an effective alternative to face-to-face patient education.
Clinical Trial Registration Number: NCT01612520
Supported by: EFRO, MSD, Abbott
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The effect of a short-term high-fat overfeeding on plasma levels of
acylcarnitines in young, healthymenwith low or normal birth weight
A. Ribel-Madsen1,2, R. Ribel-Madsen2,3, C. Brøns2, C.B. Newgard4,
A.A. Vaag2, L.I. Hellgren1;
1Department of Systems Biology, Technical University of Denmark,
Kongens Lyngby, 2Department of Endocrinology, Copenhagen Universi-
ty Hospital, 3Danish Diabetes Academy, Odense, , 4Sarah W. Stedman
Nutrition and Metabolism Center, Duke University, Durham, USA.
Background and aims: Low birth weight (LBW) subjects have an in-
creased risk of developing type 2 diabetes later in life compared with
normal birth weight (NBW) subjects. Also, an impaired oxidation of fatty
acids and a subsequent accumulation of lipid species have been implicat-
ed in the pathogenesis of type 2 diabetes. Acylcarnitines are markers of an
incomplete beta-oxidation in mitochondria. Here, we investigated wheth-
er LBWand NBW subjects had different plasma levels of acylcarnitines
after a control diet and a high-fat, high-calorie diet and whether they
changed these levels in response to overfeeding. Also, we examined
whether the levels were related to insulin secretion and/or sensitivity.
Materials and methods: Twenty LBW (0-10th percentile) and twenty-
six NBW (50-90th percentile) young, healthy men were in a random
order given a three-day control diet and a five-day high-fat, high-calorie
diet. After these challenges, we measured fasting plasma levels of forty-
five acylcarnitine species by tandem mass spectrometry and assessed
differences in these levels between birth weight groups or diets by un-
paired or paired t-tests, respectively, or Wilcoxon signed rank tests. Also,
we performed intravenous glucose tolerance tests and hyperinsulinaemic
euglycaemic clamps to assess insulin secretion and sensitivity and eval-
uated associations between levels of acylcarnitines and these measures by
regression analyses adjusted for age, body mass index, and birth weight.
Results: LBW subjects had higher plasma levels of eight acylcarnitine
species, of these five hydroxyl- (OH)/dicarboxyl- (DC) species, as well as
of total acylcarnitines and total OH-/DC-acylcarnitines after the control
diet compared to NBW subjects, but no differences were seen after the
high-fat, high-calorie diet. Furthermore, LBW and NBW subjects
decreased levels of twelve species and increased levels of three or four
species, respectively, and additionally decreased the level of total
acylcarnitines in response to overfeeding. Also, the level of total
OH-/DC-acylcarnitines was inversely associated to the serum level of
insulin and hepatic insulin resistance after the control diet.
Conclusion: LBW subjects had a higher plasma level of total
acylcarnitines after the control diet compared to NBW subjects, which
indicates that they have an incomplete beta-oxidation of fatty acids in
mitochondria. Also, their higher level of total OH-/DC-acylcarnitines
suggests that they have a higher omega-oxidation of fatty acids in endo-
plasmic reticulum and/or an incomplete beta-oxidation of OH-/DC-fatty
acids. LBWand NBW subjects decreased the level of total acylcarnitines
in response to overfeeding, which may be a normal response to an acute
overfeeding followed by an overnight fast with a minor release and oxi-
dation of fatty acids in this less fasted state. Acylcarnitines do not seem to
adversely affect insulin secretion or action. On the contrary, the level of
total OH-/DC-acylcarnitines was inversely associated to insulin resis-
tance, which suggests that omega-oxidation may be a scavenger pathway
for oxidation of fatty acids that could accumulate as lipid species that
impair insulin signalling.
Supported by: Danish Innovation Foundation, EFSD/Lilly, EU 6th
Framework EXGENESIS
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Suppression of plasma free fatty acids similarly reduces myocardial
lipid content and left ventricular systolic function in type 2 diabetic
patients as in controls
P. Wolf1, Y. Winhofer1, S. Smajis1, J. Harreiter1, L. Kosi-Trebotic1, C.
Fürnsinn1, C. Anderwald1, S. Baumgartner-Parzer1, S. Trattnig2, A. Lug-
er1, M. Krssak1, M. Krebs1;
1Internal Medicine III, Medical University of Vienna, 2Biomedical Imag-
ing and Image-guided Therapy, Centre of Excellence - High Field MR,
Medical University of Vienna, Austria.
Background and aims: Type 2 diabetes (T2DM) is closely associated
with the development of heart failure, which could in part be due to
impaired substrate metabolism and accumulation of myocardial lipids
(MYCL). To better understand substarte metabolism of the diabetic
heart,this study investigated the impact of an acute pharmacological in-
hibition of adipose tissue lipolysis leading to reduced availability of cir-
culating FFA on MYCL and heart function in T2DM.
Materials and methods: 8 T2DM (Age:56±11a;BMI:28±3.5 kg/
m2;HbA1c:7.29±0.88%) were investigated on two study days in random
order, following administration of Acipimox /Placebo and compared to
previously assessed data in healthy controls. MYCL and heart function
was measured by 1H-magnetic-resonance-spectroscopy and tomography
at baseline, at 2 and at 6 hours.
Results: Acipimox reduced MYCL by -39±41% as well as systolic heart
function significantly (Ejection Fraction (EF): -13±8 and cardiac index: -
16±15% compared to baseline) to the same extent than in healthy controls.,
FFA strongly correlated with changes inMYCLΔMYCLMR1vsMR3: r=
0.707; p=0.002) and EF (ΔEFMR1vsMR3: r=0.651; p=0.006). Diastolic
heart function remained unchanged.
Conclusion: Inhibition of adipose tissue lipolysis is associated with a
rapid depletion of MYCL-stores and reduced systolic heart function in
T2DM. These changes were comparable to those previously found in
insulin sensitive controls. MYCL thus likely serves as a readily available
energy source to cope with short-time changes in FFA availability in the
diabetic state.
Clinical Trial Registration Number: NCT01980524
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Saturated fatty acids increase intramuscular lipid by activation of
lipogenic pathways dependent on SREBP-1c with no modification
of fatty acid transport or lipid oxidation
E. Rubio-Martin1, R. Monastero1, N. Colomo1, J. Gomez-Zumaquero2,
S. García-Serrano1, A. Lago-Sampedro1, E. García-Fuentes1, G. Rojo-
Martinez1, E. García-Escobar1;
1UGCEndocrinología y Nutrición. IBIMA, 2ECAI de Genomica IBIMA,
Malaga. Spain.
Background and aims: Dietary saturated fatty acids induce insulin
resistance in muscle with the increment in intramuscular lipid accu-
mulation (IMLA). The mechanism by which dietary fatty acids mod-
ulate IMLA are not clear. The aim of this study is evaluate the mech-
anism that could be regulating the IMLA under different dietary fatty
acid composition.
Materials and methods: A group of rats was assigned to an
isoenergetic and normocaloric diet, each with a significantly different
composition of saturated (SD), monounsaturated (MD) and polyun-
saturated (PD) fatty acids and they were feed for a month. Samples of
muscle tissue were taken to determine tissue lipid accumulation and
to study the gene expression levels of fatty acids transports FATP1,
FATP4, FAT/CD36 and FABPpm, muscle lipid oxidation marker
CPT1 and the lipogenic markers SREBP-1c, ACC1 and SCD1. Ad-
ditionally, L6 cells were differentiated and then treated with Palmitic,
Oleic, and Linoleic fatty acid for 24 h. Fatty acid cytotoxicity was
evaluated by the gene expression levels of BCL2, P53 and Casp3.
After treatment lipid accumulation and the same genetic markers as
in muscle tissue samples were studied. Analysis of differences be-
tween groups was performed using Kruskal-Wallis or U of Mann-
Witney test. Associations between variables were evaluated by
Spearman corretation test. A P value <0.05 was considered statisti-
cally significant.
Results: Animal weights did not vary according to diets. Muscle lipid
accumulation were significantly higher in animals feed with CD
(p=0.01). The expression levels of CPT1 and fatty acid transport proteins
FATP1, FATP4, FAT/CD36 were no different between diets, however
FABPpm gene expression levels were significantly lower in animals fed
with SD (p<0.01), with an inverse correlation with the IMLA (r=-0.59,
p<0.01). SD raised muscle lipogenic markes with the increment of
SREBP-1c , ACC1 and SCD1gene expression levels (p<0.01, p=0.05
and p=0.03 respectively); a direct association between these gene expres-
sion levels and the IMLA was found (r=0.54, p=0.02; r=0.59; p<0.01
and r=0.52, p=0.03 respectively). Fatty acids did not induce apoptosis.
L6 lipid content (CLC) was higher in cells treated with any of the fatty
acids than in control group, with no differences between the fatty acid
treatment. None of the measured gene expression levels were different
according to the control group nor to fatty acids treatment. However,
FATP1 and FABPpm gene expression were negative associated with the
lipid content (r=-0.64, p<0.01 and r=-0.62, p<0.01 respectively), while
lipogenic markers SREBP-1c, ACC1 and SCD1 gene expression levels
were directly correlated with CLC (r=0.44, p=0.04; r=0.46, p=0.03 and
p=0.54, r=0.01 respectively).
Conclusion: The elevated levels of IMLA in the presence of saturated
fatty acids are associated with the induction of SREBP-1c gene expres-
sion and its regulated lipogenic pathways with the increment of ACC1
and SCD1 gene expression levels, rather than the modification in the fatty
acid transport or the muscle lipid oxidation.
Supported by: Fondo de Investigación Sanitaria of the ISCIII and the
Fondo FEDER, (PI11/0
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Role of Rab-GTPases in the regulation of fatty acid metabolism in
skeletal muscle
T. Benninghoff1,2, Z. Zhou1,2, A. Chadt1,2, H. Al-Hasani1,2;
1Institute for Clinical Biochemistry and Pathobiochemistry, German Di-
abetes Center (DDZ), Leibniz-Center for Diabetes Research at the
Heinrich-Heine University Düsseldorf, 2German Center for Diabetes Re-
search (DZD e.V.), Partner Düsseldorf, Neuherberg, Germany.
Background and aims:Besides glucose, fatty acids play a central role
in the energy metabolism of skeletal muscle. Deficiency of the Rab
GTPase-activating protein (Rab-GAP) TBC1D1 leads to an increase
of fatty acid uptake and fatty acid oxidation accompanied by a shift in
skeletal muscle energy substrate preference from glucose towards
fatty acids. It is the aim of this project to find the underlying mech-
anisms that drive the shift towards fatty acid metabolism under con-
ditions of Tbc1d1-deficiency.
Materials and methods: Cell culture experiments were performed using
differentiated C2C12 myoblasts. Selected Rab GTPases (Rab8a, 10, 14,
28)that function as potential substrates of TBC1D1 were silenced via
siRNA technology. Subsequently, fatty acid uptake was determined mea-
suring the incorporation of 3H-Palmitic acid. In addition, siRNA oligos
for Rab-GTPase knock-down (KD) were transfected into Extensor
digitorum longus (EDL) and Soleus muscle of 12 - 15 week old
C57BL/6 males via in vivo Electrotransfection (IVE). Seven days after
electrotransfection intact EDL and Soleus muscle were dissected and 3H-
Palmitic Acid oxidation was measured.
Results: In cultured C2C12 myotubes the Knock-down (KD) of
Tbc1d1 led to a significant increase in fatty acid uptake (+41%,
SEM±21%). KD of Rab8a, Rab10 and Rab14 reduced fatty acid
uptake (Rab8a: -43%, SEM±13%; Rab10: -41%, SEM±9%;
S126 Diabetologia (2015) 58 (Suppl 1):S1–S607
Rab14: - 23%, SEM±20%). In contrast to this Rab28 KD did not
affect fatty acid uptake in these cells. In both, glycolytic EDL and
oxidative Soleus muscle the siRNA-mediated KD of Rab8a caused a
significant reduction of fatty acid oxidation (EDL: -35%, SEM±9%;
Soleus: -42%, SEM±8%). KD of Rab10, however, did not alter fatty
acid oxidation in EDL or Soleus muscle.
Conclusion: We showed that Rab8a, Rab10 and Rab14 influence fatty
acid uptake in cultured C2C12 myotubes in a similar fashion, while
knock-down of Rab28 did not lead to changes in fatty acid uptake in
these cells. Ex vivo experiments revealed that the siRNA-mediated KD
of Rab8a led to a significant reduction of the ex vivo fatty acid oxidation
of intact isolated EDL and Soleus muscle. In contrast to the cell culture
experiments, KD of Rab10 did not affect ex vivo fatty acid oxidation in
both, EDL and Soleus muscle.
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Rabs and RIM are differentially involved in docking and tethering of
insulin granules
N.R. Gandasi, S. Barg;
Institute of Medical cell biology, Box 571, Husargatan 3, Uppsala Uni-
versity, Sweden.
Background and aims: Glucose dependent insulin release is markedly
reduced in the islets obtained from type 2 diabetic subjects. Insulin is
released by regulated exocytosis and docking of insulin granules at the
plasma membrane, followed by the assembly of the secretory machinery
is a prerequisite for insulin release. We have recently shown that central
elements of the secretory machinery assemble after granule docking, but
it remains unclear whether granule docking sites can exist before arrival
of a granule. Current models propose that docking of the granules occurs
through binding to either raft-like clusters of SNARE proteins or to struc-
tural proteins such as RIM1, in all cases implying at least partial assembly
of the secretory machinery prior to docking. However, direct evidence for
this is lacking.
Materials and methods: Dual-color TIRF microscopy of INS1 cells
832/13 combined with quantitative image analysis was used to study
the association of GFP-labeled proteins with granules labelled with
NPY-mCherry at the plasma membrane.
Results:We show that the insulin granule transits to stably docked state
from a loosely tethered state a few seconds after the arrival of the granule.
This transition is induced by recruitment of syntaxin and munc18-1, and
that recruitment of munc13 and SNAP25 was delayed further. Here we
extend on this work and present quantification of several exocytosis pro-
teins including rab3 and 27, rabphilin, granuphilin, RIM1, tagged with
EGFP at the insulin granule release site during insulin granule docking,
priming and exocytosis. We find that the Rab3 interacting protein RIM1
and Rabphilin were enriched at docking sites prior to granule tethering
and docking. A slow but significant increase of RIM1 fluorescence was
seen during granule maturatrion into the releasable pool (priming), sug-
gesting roles for RIM1 in both docking and priming. None of the other
proteins were present before granule arrival, but they were instead recruit-
ed during docking or even later during priming. Granules that docked
successfully carried Rab3 and Rabphilin, whereas those that only tempo-
rarily tethered did not. In contrast, Rab27 and its effector Granuphilin
were present on both types of granules.
Conclusion: We conclude that sites enriched with RIM1 at the plasma
membrane act as tethers for incoming granules. The likely binding part-
ners on the granule for this weak interaction are rab27/granuphilin. Con-
version into the stably docked state that is required for exocytosis occurs
only when rab3/rabphilin are also present on the granule. Successful
docking coincides with acute clustering of syntaxin/munc18, and we
propose that this cluster then nucleates assembly of the exocytosis ma-
chinery. It may thus underlie the docking defect observed with reduced
expression of SNARE and accessory proteins during type 2 diabetes.
Supported by: Swedish Research Council, Diabetesfonden, Albert
Påhlsson Foundation, LUDC
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Clustering of L-type CA2+-channels promotes exocytosis of individ-
ual secretory granules
P. Yin1, N.R. Gandasi1, M. Riz2, G. Cortese3, M. Chibalina4, P.
Rorsman4, A. Sherman5, M.G. Pedersen2, S. Barg1;
1Institute of Medical cell biology, Box 571, Husargatan 3, Uppsala Uni-
versity, Sweden, 2Department of Information Engineering,3Department
of Statistics, University of Padua, Italy, 4Oxford center for diabetes, En-
docrinology and Metabolism, University of Oxford, UK, 5NIDDK, NIH,
Bethesda, USA.
Background and aims: Ca2+ entry through voltage gated L-type calci-
um channels triggers release of insulin-containing secretory granules, and
is required for 1st phase insulin secretion. Indirect electrophysiological
and biochemical evidence suggest that L-type channels functionally cou-
ple to the exocytosis machinery by binding of the α1 subunit of L-type
channels to SNARE proteins through its synaptic protein interaction site
(synprint). Clustering of L-type channels near docked granules is thought
to facilitate exocytosis by generating local domains where Ca2+ is suffi-
ciently elevated. However, direct evidence for channel clustering and
localized Ca2+ influx near granules is lacking.
Materials andmethods: EGFP-labeled Ca2+-channel subunits (Cav1.2)
were imaged together with a granule marker in human islet cells and Ins1
cells using TIRF-microscopy. Local Ca2+ domains were visualized using
Fluo 5 F-am or membrane-targeted lyn-R-GECO. Ca2+-currents were
recorded using whole cell patch clamp.
Results: Cav1.2-EGFP formed clusters on a hazy background that par-
tially colocalized with a subset of the docked granules. Image analysis
indicated specific binding of Cav1.2-EGFP to granules, which was con-
firmed by single molecule imaging demonstrating reduced mobility of
CaV1.2-EGFP near docked granules. This binding was not detectable
when the synprint fragment was coexpressed, suggesting that the peptide
competes with and uncouples Cav1.2 from the exocytosis machinery.
Ca2+-channel clusters formed at granules at least 60 s after their arrival
at the plasma membrane, and rapidly dispersed after exocytosis. In
depolarized cells, docked granules that exocytosed (responders) carried
significantly more CaV1.2-EGFP than those that failed to do so (failures).
Endogenous Ca2+-channels were visualized functionally as Ca2+ micro-
domains; these measurements indicated localized and more rapid Ca2+-
entry at responder granules compared with failures or random sites.
Modeling of Ca2+-influx confirmed that the observed rates of Ca2+-entry
and distribution are consistent with localized Ca2+-influx near granules.
Statistical analysis indicates that the probability of exocytosis is at least
1000-fold higher when a channel is bound to the granule than when it is
500 nm away.
Conclusion:Using high resolution microscopy we identify in human and
rat insulin secreting cells a granule pool where localized Ca2+ influx
leads to exocytosis with high release probability and minimal latency,
corresponding to the immediately releasable pool (IRP). Prior to exocy-
tosis these granules slowly recruit on average L-type Ca2+-channels
through an interaction that involves the channels’ synprint site. When this
interaction is interrupted by expression of exogenous synprint or when
Ca2+ is raised by release from intracellular stores, rapid exocytosis is
absent. This arrangement leads focal Ca2+ influx that supports rapid
and selective exocytosis of the associated granules with minimal require-
ments for Ca2+-influx. Thus, IRP granules are docked at the plasma
membrane and associated with L-type Ca2+-channels.
Clinical Trial Registration Number: C113/13
Supported by: Swedish Research Council, Diabetesfonden, Albert
Påhlsson Foundation, LUDC
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MiR-335 regulates exocytotic proteins and affects glucose-stimulated
insulin secretion through decreased Ca2+-dependent exocytosis in be-
ta cells
V.A. Salunkhe1, J. Ofori1, N.R. Gandasi2, S.A. Salö1,3, S. Hansson1,
M.E. Andersson1, A. Wendt1, S. Barg2, J.L.S. Esguerra1, L. Eliasson1;
1Islet Cell Exocytosis, Lund University Diabetes Centre, Clinical Re-
search Centre Malmö, Lund University, Malmö, 2Department of Medical
Cell Biology, BMC, Uppsala University, Sweden, 3Department of Sci-
ence, Systems and Models, Roskilde University, Denmark.
Background and aims: Ca2+-induced exocytosis is essential for insulin
to be secreted from beta-cells, and in islets from type-2 diabetic (T2D)
donors the expression of several genes coding for exocytotic proteins is
reduced. Largely this phenomenon cannot be explained by polymor-
phism; rather it is likely due to epigenetic factors like microRNAs
(miRNAs). Indeed, previous studies have identified a number ofmiRNAs
with differential expression in the islets from T2D donors and the Goto-
Kakizaki (GK) rat. One of the upregulated miRNAs in the GK rat is miR-
335, predicted to target several exocytotic genes amongst those Stxbp1 is
a validated target. Here we aim to investigate whether miR-335 regulates
the expression of exocytotic genes and affects insulin secretion and exo-
cytosis in beta-cells.
Materials and methods: Insulin secretion was measured by radio
immuno assay. Exocytosis and docking of insulin granules was studied
by capacitance measurements using the patch-clamp technique and by
TIRF microscopy. Rat miR-335 was overexpressed using chemically-
modified mature microRNA mimic in INS-1 832/13 beta-cells by trans-
fection. Gene knockdownwas performedwith RNAi. Protein and mRNA
levels were analysed with Western Blot and RT-qPCR, respectively.
Results: Overexpression of miR-335 (OE335) in INS-1 832/13 cells
reduced insulin secretion at 16.7 mM glucose compared to control cells
(SCR) (n=3; p<0.01). This was not due to reduced insulin content (n=3)
or voltage-dependent Ca2+ currents (n=15-17) but rather a direct effect on
second phase exocytosis; the measured increase inmembrane capacitance
was extensively decreased inOE335 cells (42±23 f. vs 128±18 fF; n=11-
14; p<0.01). In agreement, exocytotic events measured by TIRF micros-
copy were reduced in OE335 cells (0.032±0.001 min-1 μm-2; n=8) com-
pared to SCR cells (0.049±0.003 min-1 μm-2; n=8; p<0.001). However,
TIRF microscopy revealed similar density of docked granules in both
OE335 and SCR cells (n=51-53). The exocytotic genes coding for
Snap25, Stxbp1 and Synaptotagmin 11 (Syt11), known to have reduced
expression in T2D islets, are putative targets of miR-335. In accordance,
protein levels of Snap25, Stxbp1 and Syt11 were decreased in OE335
cells compared to SCR cells (p≤0.05; n=4 for each protein). Snap25 and
Stxbp1 have previously been proven essential in insulin exocytosis, but
the role of Syt11 is still uncertain. Interestingly, Syt11 silencing in INS-1
832/13 cells resulted in decreased first phase exocytosis measured as
increase in membrane capacitance (161±22 f. vs 251±34 f. in control
cells; n=9-13; p<0.05).
Conclusion: We suggest that miR-335 is crucial in the regulation of
glucose-stimulated insulin secretion. It functions by reducing the exocy-
totic proteins Snap25, Stxbp1 and Syt11 which modulates Ca2+ depen-
dent exocytosis in beta-cells. The progression of T2D is facilitated by
failure of beta-cell adaptations to secret more insulin. We believe our
study contributes with novel insights as to how single dysregulated
miRNA may affect pancreatic beta-cell function.
Supported by: SRC, Diabetesfonden, A. Påhlsson Foundation,
EXODIAB, DRWF, NNF, EFSD/MSD
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Effects of high glucose andK+ depolarisation on secretion and insulin
granule mobility in MIN6 cells and mouse beta cells
D. Brüning1, K. Schumacher1, M. Matz2, K. Baumann2, I. Rustenbeck1;
1Institute of Pharmacology, Toxicology and Clinical Pharmacy, 2Institute
of Medicinal and Pharmaceutical Chemistry, University of Braun-
schweig, Germany.
Background and aims: To further characterize the differences between
nutrient- and depolarization-induced insulin secretion, we compared in-
sulin secretion and parameters of insulin granule mobility in MIN6 cells
and MIN6 pseudo-islets and in normal mouse beta-cells and islets.
Materials andmethods: Insulin granules were labeled by transient trans-
fection with insulin-EGFP in MIN6 cells and by adenoviral transduction
in primary mouse beta-cells. The granules present in the submembrane
space of the cell footprint were imaged by TIRF microscopy. The cells
were continuously perifused at 37°Cwith oxygenatedmedium containing
the respective stimuli. The image files (1 sequence=200 images=25 sec-
onds) were evaluated by an in-house written program to achieve an
observer-independent quantification. The insulin secretion of MIN6
pseudo-islets and mouse islets was measured by perifusion with ELISA
of the fractionated efflux.
Results: The perifused islets and pseudo-islets were stimulated by
40 mM K+ for 10 min and, after a wash-out period, by 30 mM glucose
for 10 min. In MIN6 pseudo-islets 30 mM glucose was much less effec-
tive than 40 mM K+. When the K+ depolarization preceded the glucose
stimulus, glucose was entirely ineffective. In mouse islets glucose was
about equi-effective with K+ depolarization. When the K+ depolarization
preceded the glucose stimulus, the glucose-induced secretion had a slug-
gish onset, but still reached the same maximal level. Under control con-
dition, the number of granules in the first image of the sequences was 337
±34 per MIN6 cell but only 68±15 per beta cell. In both cell types this
parameter remained essentially stable during imaging. Due to continuous
arrivals at and departures from the evanescent field the total number of
granules under this condition were 6972±873 per sequence inMIN6 cells
and 1439±281 in beta-cells. In MIN6 cells about 5720 granules per
sequence were classified as short-term resident granules (residence
time≤1 s) and about 118 granules were long-term residents (residence
time≥25 s). The corresponding values for beta-cells were 1334±247 and
15±5, respectively. Apparently, the proportion of long-term resident
granules is lower in beta cells than in MIN6 cells. The stimulation pattern
in beta cells differed from that of MIN6 cells, in that only K+, but not
glucose increased the number of arriving granules and diminished the
number of long-term resident granules.
Conclusion: The insulinotropic efficacy of nutrient stimulation is much
higher in beta-cells than in MIN6 cells, while both have comparable
responses to K+ depolarization. This may be related to the proportionally
lower number of tethered granules in beta-cells. Unexpectedly, the gran-
ule mobility in beta cells was less influenced by insulinotropic stimulation
than that in MIN6 cells.
Supported by: DDG, DFG
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Lack of association between plasma PCSK9 and LDL-cholesterol in
patients with controlled type 1 diabetes
S. Laugier-Robiolle1, B. Verges2, S. Hadjadj1, B. Cariou3;
1Médecine Interne, Endocrinologie, Maladies Métaboliques, C.H.U. Poi-
tiers, 2Médecine Interne, Endocrinologie, Maladies Métaboliques,
C.H.U. du Bocage, Dijon, 3Clinique d'Endocrinologie, Institut du thorax,
C.H.U. de Nantes, France.
Background and aims: Pro-protein convertase subtilisin/kexin type 9
(PCSK9) is a post-transcriptional inhibitor of LDL-receptor (LDLR).
PCSK9 impairs LDL clearance by promoting the LDLR degradation.
PCSK9 is secreted by hepatocytes and binds to the extracellular domain
of the LDLR, causing degradation in the lysosomes. Previous studies
have shown that, in non-diabetic population, PCSK9 was positively cor-
related to the circulating plasma concentrations of total cholesterol and
especially LDL cholesterol (LDL-C). In case of good glycemic control,
lipid profile of patients with type 1 diabetes mellitus (T1DM) is different
fromwhat is observed in case of poor glycemic control; it can be observed
an increase in plasma triglycerides and higher LDL-C levels in case of
poor glycemic control. A previous study has shown that PCSK9-LDL
association was lost in patients with type 2 diabetes mellitus with poor
glycemic control. Here, we aimed to determine the relationship between
circulating levels of PCSK9 and LDL-C in subjects with T1DM depend-
ing on glycemic control.
Materials and methods: A multicentric study of PCSK9 plasma levels
was performed in 202 patients with T1DM whose diagnosis was made
before age 40 and insulin treatment initiated within 12 months after di-
agnosis. They were free of any hypolipidemic agent. Fasting blood sam-
ples were obtained from a biological collection. Plasma concentrations of
PCSK9 were mesured using a sandwich ELISA assay (CycLex).
Results: The mean age was 38 years and diabetes duration 18 years. The
mean HbA1c was 8.3%. Plasma PCSK9 concentrations ranged from 85
to 868 ng/ml (mean 314 ng/ml). A positive correlation was found be-
tween PCSK9 and age and systolic blood pressure. Plasma PCSK9 was
positively correlated with total cholesterol, triglycerides, LDL-C, apoB
(Table 1). There was a tendency for a positive association between
PCSK9 and HbA1C. In multivariate analysis, PCSK9 (log) was indepen-
dently associated with LDL-C (p=0,04) and HbA1c (p=0,03). However,
the association between PCSK9 and LDLC seemed to be limited to the
patients with "uncontrolled" diabetes: PCSK9 was still correlated with
LDL-C (p=0.0004) in “uncontrolled” diabetics (HbA1c≥8%) while this
correlation was lost (p=0.52) in “controlled” diabetics. Plasma PCSK9
levels were significantly higher in “uncontrolled” diabetes subgroup than
in “controlled” diabetics (p=0.001).
Conclusion: This first study evaluating PCSK9 in patients with T1DM
shows a positive correlation between PCSK9 and total cholesterol, LDL
and triglycerides; this correlation is lost in patients with good glycemic
control in contrast to patients with poor glycemic control.
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Dysfunctional endothelial progenitor cells in diabetes: establishing a
link between epigenetics and metabolic memory
V. Bianchessi, M. Toia, M. Pesce, M. Vinci;
Unit of Cardiovascular Tissue Engineering, Centro Cardiologico
Monzino IRCCS, Milan, Italy.
Background and aims: Endothelial progenitor cells (EPCs) have regen-
erative capacities and play an important role in vessel wall homeostasis by
promoting angiogenesis and maintaining endothelial integrity. The EPCs
dysfunction, observed in type I and II diabetes mellitus, contributes to the
insurgence of vascular complications in diabetic patients. These compli-
cations persist and progress even after good long-term glycemic control, a
phenomenon termed “metabolic memory”, suggesting that EPC dysfunc-
tion might also last even after glycemia normalization. We investigated
whether the exposure to pathologic glucose concentrations affected hu-
man cord blood-derived CD34+ cell functions and whether these defects
persisted after glucose normalization.
Materials and methods: CD34+ cells were purified from cord blood of
healthy donors and expanded in normal-glucose (NG; with 30 mM man-
nitol for osmotic control) or high-glucose (HG; 30 mM) serum-free me-
dium plus cytokines (FLT3 50 ng/ml, SCF 50 ng/ml, IL3 20 ng/ml and
IL6 20 ng/ml) for up to 30 days. The proliferative capacity of CD34+ cells
was assessed by producing a growth curve over 30 days and performing
doubling time analyses. Telomere length was evaluated by quantitative
real-time PCR. Migration ability toward stromal cell-derived factor-1
(SDF-1) was determined using a modified Boyden chamber. CXCR4
protein and mRNA expression were assessed by flow cytometry and
quantitative real-time PCR, respectively. The methylation status of
CXCR4 gene was assessed by methylation-sensitive restriction enzyme
digestion followed by quantitative real-time PCR.
Results:We previously showed that after 20 days hyperglycemia dramat-
ically impaired CD34+ cell proliferation, migration and differentiation
into pro-angiogenic cells. Here we demonstrated that high glucose affect-
edCD34+ proliferation by inducing cell senescence. Indeed, after 20 days
HG-CD34+ cells presented a significant telomere shortening when com-
pared to the NG-CD34+ cells (p≤0.05 vs NG). In addition, we also
showed that the reduced migration toward SDF-1 in HG-CD34+ cells
was associated to a down-regulation of CXCR4 receptor, both in terms
of protein (p≤0.001 vs NG) and mRNA (p≤0.05 vs NG). Importantly,
this defect was maintained even after 72 hours of relief from hyperglyce-
mia (p≤0.05 HG and exHG vs NG). To address whether epigenetic reg-
ulation contributed to defective CXCR4 expression in HG-CD34+ cells,
we investigated the methylation status of the CXCR4 gene using
methylation-specific restriction enzymes. We found that after 20 days
HG-CD34+ cells presented a significant (p≤0.05 vs NG) hypermethyla-
tion of CpG island I, IV and Vof CXCR4 gene when compared to NG-
CD34+ cells.
Conclusion: These data suggest that hyperglycemia negatively affects
CD34+ stem cell function by promoting premature senescence and re-
ducing migration ability towards SDF-1 via CXCR4 gene methylation.
Interestingly, this latter defect, which persists after glucose normalization,
provides the first evidence of an epigenetic contribution to the establish-
ment of “metabolic memory” in CD34+ cells, paving the way to new
pharmacological targets.
Supported by: Italian NHS/Grant
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FDG-PET-CT assessed subclinical arterial inflammation is associat-
edwith glycaemic control, central obesity, and systolic blood pressure
in type 2 diabetes patients
S.A. de Boer1, M.C. de Boer2, J.D. Lefrandt1, A.J. Smit1, H.L. Lutgers3,
A.W.J. Glaudemans4, H.J. Lambers Heerspink5, R.H.J. Slart4, D.J.
Mulder1;
1Vascular Medicine, University Medical Center, Groningen, 2Radiology
& Nucleair Medicine, Meander Medical Center, Amersfoort, 3Endocri-
nology, 4Nucleair Medicine and Moleculair Imaging, 5Department of
Clinical Pharmacy and Pharmacology, University Medical Center, Gro-
ningen, Netherlands.
Background and aims: In type 2 diabetes mellitus (T2DM), subclinical
atherosclerotic changes occur early in its course. We investigated the
association of arterial inflammation and calcification assessed with 18-
Fluorodeoxyglucose positron emission tomography-computed tomogra-
phy (FDG-PET-CT) with atherosclerotic risk factors, skin advanced
glycation end products (AGEs)), and microalbuminuria in early T2DM.
Materials and methods: 34 patients with treatment naïve T2DM, with-
out cardiovascular disease , were studied (age 63 [IQR, 55-66] yrs, 65%
male, BMI 31.5 [28.6-36.8] kg/m2, HbA1c 6.4±0.4% (46±4.3 mmol/
mol), 17% microalbuminuria. A whole body FDG-PET-CT scan was
performed to assess arterial inflammation. Standardized uptake value
(SUV)max was calculated according to EARL guidelines and CT was
used to score arterial calcification (AC: visual score: 0(no calcification) to
4(>50% calcified plaque)). SUVmax and AC were measured in 4 seg-
ments (carotid arteries, ascending aorta and aortic arch, descending and
abdominal aorta, and iliac and femoral arteries) and calculated for the total
aortic tree (aSUVmax, mean of 4 segments). Clinic and 24-hour ambu-
latory blood pressure (ABPM) was assessed. Skin AGEs were measured
as skin autofluorescence.
Results: aSUVmax and AC were not associated. aSUVmax was associat-
ed with BMI (r=0.64, P<0.001), HbA1c (figure 1A), waist circumference
(1B), systolic BP(1C) and pulse pressure (r=0.39,P=0.025; comparable
results for ABPM), urinary albumin/creatinine ratio (r=0.38, P=0.031),
and not with SAF, age, gender, smoking, and lipids. After multivariate
adjustment (r2=0.73, P<0.001), only HbA1c, (β=0.50, P<0.001), waist
circumference (β=0.45, P<0.001), and SBP (β=0.40, P<0.001) remained
significant. AC was associated with male gender (r=0.48, P=0.004), age
(r=0.51, P=0.002), BMI (r=-0.43, P=0.011), and SAF (r=0.37, P=0.036)
and not with other mentioned risk factors. After multivariate adjustment
(r2=0.39, P=0.001) only male gender (β=0.49, P=0.003) and SAF
(β=0.34, P=0.033) remained significant.
Conclusion: These results show that in treatment naïve T2DM, glycemic
control, central obesity, and SBP are independent determinants of FDG-
PET-CT assessed subclinical arterial inflammation. Interessingly, while
the extent of arterial calcification did not show any relation with arterial
inflammation, it was independently associated with skin AGEs, suggest-
ing discordant pathways at different stages of atherosclerotic disease.
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Clinical Trial Registration Number: NCT02015299
Supported by: Boehringer Ingelheim
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RVX-208 acts via an epigenetic mechanism to lower Major Adverse
Cardiovascular Events (MACE) in patients with atherosclerosis and
especially in those with diabetes mellitus
N.C.W.Wong1, E. Kulikowski1, L. Tsujikawa1, D. Gilham1, S. Wasiak1,
C. Halliday1, K. Lebioda1, J.O. Johansson2, M. Sweeney2;
1Clinical Development, Resverlogix Corporation, Calgary, Canada,
2Clinical Development, Resverlogix Corporation, San Francisco, USA.
Background and aims: RVX-208 binds selectively to the second ligand
domain of Bromodomain and Extra-Terminal (BET) proteins and inhibits
their activity. Each BET protein has two bromodomains that bind acety-
lated lysines in histones. When a BET protein binds ligand, it recruits
transcriptional machinery to DNA and thereby modifies gene activity.
Analysis of pooled data from two phase 2b trials; SUSTAIN and AS-
SURE revealed a 55% relative risk reduction (RRR) of MACE in RVX-
208 treated patients (n=331) vs. placebo (n=168). But in those with
diabetes mellitus (DM) RVX-208 treatment lead to a 77%RRR ofMACE
vs. placebo. RVX-208 increased production of ApoA-I yielding more
high-density lipoprotein (HDL) particles. While these effects should low-
er MACE, the magnitude was more than expected, prompting studies to
identify properties of RVX-208 beyond its effects on ApoA-I/HDL.
Materials and methods: Plasma biomarkers from SUSTAIN and AS-
SURE trials were analyzed. Microarray data from RVX-208 treated pri-
mary human hepatocytes (PHH) or human whole blood (HWB) were
used to identify differentially expressed genes, and guide measurements
of specific proteins in clinical samples to confirm key findings.
Results: Biomarkers from the trials showed significant increases
(p<0.05, unless specified) between RVX-208 vs. placebo in: HDL-
c (+3 mg/dL), ApoA-I (+7.5 mg/dL), large HDL (+0.7 umol/L), HDL
size (+0.1 nm), and total HDL particles (+1.8 umol/L, p<0.07). Glu-
cose in all patients (n=499) or in those with DM (n=192) given
RVX-208 or placebo was unchanged vs baseline. In patients with
DM (n=119) and low HDL (<40 mg/dL), RVX-208 reduced glucose
by -0.3 mmol/L but in placebo it increased +0.9 mmol/L. These
modest changes do not predict the MACE reductions. Thus microar-
rays were used to survey PHH and HWB exposed to RVX-208. In
PHH, RVX-208 decreased expression of genes in pathways for cho-
lesterol & fatty acid synthesis, innate immunity and glucose process-
ing. Most profound were effects on complement and coagulation
pathways, where RVX-208 downregulated expression of 19/26 and
20/33 genes respectively. These data were confirmed by RT-PCR of
key mRNAs. Furthermore, specific complement and coagulation pro-
teins were found to be decreased in plasma from the trials (range 7-
12% vs. baseline). Microarrays from HWB exposed ex-vivo to RVX-
208 identified pathways with known roles in atherogenesis including:
pro-inflammatory signaling, cell-cell interactions and extracellular
matrix organization. RVX-208 significantly downregulated several
pro-atherogenic genes (43/56) but upregulated anti-atherogenic
genes (9/17), that control monocyte recruitment, migration and acti-
vation, macrophage function, inflammatory signaling and plaque sta-
bility to suggest an overall anti-atherosclerotic benefit.
Conclusion: RVX-208 treatment is associated with marked MACE
reductions in SUSTAIN and ASSURE patients and especially in
those with DM. RVX-208 modifies cellular epigenetics to impact
multiple biological processes that underlie CVD. Combined effects
of RVX-208 on reverse cholesterol transport, vascular inflammation,
innate immunity, atherosclerosis and thrombosis may explain its ef-
ficacy in reducing MACE.
Clinical Trial Registration Number: NCT01423188, NCT01067820
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A trans-ethnic meta-analysis of genome wide association studies re-
veals new loci associated with childhood obesity
J.P. Bradfield1, J.F. Felix2, V.W.V. Jaddoe2, S.F.A. Grant1, Early Growth
Genetics Consortium;
1Center for Applied Genomics, Children's Hospital of Philadelphia, Phil-
adelphia, USA, 2The Generation R Study Group, Erasmus Medical Cen-
ter, Rotterdam, Netherlands.
Background and aims: Childhood obesity has more than doubled in the
last 30 years. Children who are obese are more likely to be obese as adults
and are more at risk for several adult health problems such as type 2
diabetes and heart disease. To search for genetic variants that are associ-
ated with childhood obesity, we performed a trans-ethnic meta-analysis of
22 genome wide association studies with European, African, South
American, and East Asian ancestry.
Materials and methods: The discovery stage of the meta-analysis has
10,668 cases, defined as greater than the 95th percentile of BMI between
2 and 18 years old, and 12,647 controls, defined as less than the 50th
percentile all throughout childhood.
Results: Using the MANTRA algorithm, we meta-analyzed approxi-
mately 19 million SNPs, and found 14 loci that attained genome wide
significance (P<5×10-8). 10 of these loci (FTO, TMEM18, FAIM2,
MC4R, SEC16B, ADCY3, TNNI3K, GNPDA2, FHIT, and TFAP2B)
have been previously discovered, while 4 (PHLDA1, METTL15,
RBMS3, and COTL1) are novel. More than 100 loci were found to be
suggestive of association (P<5×10-6), 7 of which (HOXB3, ADCY9,
NEGR1, PTPB2, OLFM4, LINGO2 and SULT1A2) have previously
been found to be associated with BMI or Obesity. All of these loci will
be carried over into our replication effort, which will narrow down the list
even more.
Conclusion: In summary, should these loci survive our replication effort,
we will have implicated new pediatric obesity loci.
Supported by: R01 HD056465
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CReP loss-of-function causes beta cell failure and diabetes
B. Abdulkarim1, M. Nicolino2,3, M. Igoillo-Esteve1, M. Daures4,5, S.
Romero4,5, A. Philippi4,5, V. Senée4,5, M. Lopes1, D.A. Cunha1, H.P.
Harding6, N. Bendelac2, A.T. Hattersley7, D. Ron6, M. Cnop1, C.
Julier4,5;
1ULB Center for Diabetes Research, Université Libre de Bruxelles, Bel-
gium, 2Hôpital Femme-Mère-Enfant, Division of Pediatric Endocrinolo-
gy, Hospices Civils de Lyon, Lyon1 University, 3Inserm U870, Lyon,
4Inserm UMR-S 958, Faculté de Médecine Paris Diderot, 5University
Paris 7 Denis–Diderot, France, 6Cambridge Institute for Medical Re-
search (CIMR),Department of Medicine, University of Cambridge, 7Uni-
versity of Exeter Medical School, University of Exeter, UK.
Background and aims: A well balanced endoplasmic reticulum (ER)
function is crucial for insulin release and survival of pancreatic β-cells.
Deficient as well as excessive/prolonged ER stress can cause β-cell
dysfunction/death and diabetes. Phosphorylation of the α subunit of eu-
karyotic translation initiation factor 2 (eIF2α) is key for protein folding
homeostasis in the ER. CReP is a cofactor for protein phosphatase 1
(PP1), which is required for eIF2α de-phosphorylation. Here we report
on the first mutation in PPP1R15B, encoding CReP, in two siblings with
young-onset diabetes.
Materials and methods: Exome sequencing was performed in the index
case. PP1 binding was examined in HEK293T cells expressing wild type
or mutant CReP. CReP, PUMA, DP5 and Bim were silenced by RNA
interference in INS-1E and FACS-purified primary rat β-cells. Insulin
secretion wasmeasured by ELISA. eIF2α phosphorylationwas examined
by Western blot and gene expression by qPCR. Apoptosis was assessed
by Hoechst 33342/propidium iodide staining and by Western blot for
caspases and cytochrome c release.
Results: Two siblings, born to unaffected parents, had early-onset insulin
treated diabetes (autoantibody negative, with low but detectable C-
peptide levels) diagnosed at 15 and 28 years. This was associated with
short stature and microcephaly. Exome sequencing identified a homozy-
gous R658C mutation in PPP1R15B in the index case, which was con-
firmed by Sanger sequencing in the two siblings. Introducing the R658C
mutation in a CReP plasmid diminished the ability of CReP to bind PP1
in vitro and de-phosphorylate eIF2α. CReP silencing in INS-1E cells
increased eIF2α phosphorylation. CReP-deficient β-cells had reduced
insulin content and reduced glucose-induced insulin secretion. CReP si-
lencing induced apoptosis in INS-1E cells (14±3% apoptosis with
siCReP vs 4±0% with control siCT, p<0.05, n=4-5) and primary β-
cells (siCReP 22±3% vs siCT 15±2%, p<0.05, n=5). CReP silencing
induced caspase-9 cleavage and cytochrome c release from the mitochon-
dria, indicating activation of the intrinsic pathway of apoptosis. CReP
deficiency induced a 2-3-fold increase in mRNA expression of the pro-
apoptotic BH3-only proteins PUMA and DP5 (p<0.05, n=6). Silencing
of PUMA, DP5 and Bim partially protected CReP-deficient β-cells
against apoptosis (11-13% apoptosis vs 16%, p<0.05, n=3-4).
Conclusion: We have identified a homozygous missense mutation in
PPP1R15B leading to a syndrome that includes young-onset diabetes
and microcephaly. The mutation diminishes the ability of CReP to bind
PP1 and de-phosphorylate eIF2α, leading to β-cell dysfunction and ap-
optosis. Our findings support the concept that dysregulated eIF2α phos-
phorylation, decreased in Wolcott-Rallison syndrome or increased by the
PPP1R15B mutation, is deleterious to β-cells and leads to diabetes.
Supported by: FNRS FRIA
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Characterisation of rapid progressors to type 1 diabetes among chil-
dren with HLA-conferred disease susceptibility
P.M. Pöllänen1,2, H. Siljander1,3, J. Lempainen4, A.-P. Laine4, R.
Veijola5, J. Toppari6,7, J. Ilonen4,8, M. Knip1,2;
1University of Helsinki and Helsinki University Hospital, Children's Hos-
pital, 2Research Programs Unit, Diabetes and Obesity, Helsinki, 3Tampe-
re University Hospital, Department of Paediatrics, 4University of Turku,
Immunogenetics Laboratory, 5University of Oulu, Department of Paedi-
atrics, PEDEGO Research Unit, MRC Oulu, 6University of Turku, De-
partment of Paediatrics, 7University of Turku, Department of Physiology,
8University of Eastern Finland, Department of Clinical Microbiology,
Kuopio, Finland.
Background and aims: To assess the characteristics of rapid progressors
to type 1 diabetes (T1D) among children with HLA-conferred disease
risk.
Materials and methods:We followed from birth 7410 children (52.6%
males) with HLA-conferred disease risk for development of islet autoim-
munity and progression to T1D over a median follow-up time of
13.2 years (range 0.9-18.2). Islet cell autoantibodies (ICA), autoanti-
bodies to insulin (IAA), to glutamic acid decarboxylase (GADA), and
islet antigen 2 (IA-2A) were analyzed for screening for β-cell autoimmu-
nity. Disease progression was considered rapid when T1Dwas diagnosed
within 1.5 years after the seroconversion to autoantibody positivity. We
analyzed the association between rapid progression and 25 non-HLA
single nucleotide polymorphisms (SNPs) predisposing to T1D.
Results: Among the 7410 children, 1563 (21.1%) tested positive for
diabetic autoantibodies, and 221 (14.1%) of the seroconverted children
progressed to T1D by the end of 2012. The median time from serocon-
version to diagnosis was 0.35 (0.02-1.46) years in rapid progressors (n=
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46, 20.8%) and 4.3 (1.5-15.8) years in slower progressors. Compared to
slower progressors, rapid progressors had higher frequency of
multipositivity (76 vs. 54%; P=0.008), higher titers of ICA (10.0 vs.
5.0 JDFU; P=0.003) and IAA (9.1 vs. 6.6 RU; P=0.02) at seroconver-
sion, and higher prevalence of a single nucleotide polymorphism (SNP)
in the FUT2 gene (major allele G homozygotes, 74 vs. 25%; P<0.001)
among individuals carrying the high risk HLA genotype. Furthermore,
rapid progressors carried more frequently a combination of ≥3 of these
risk SNPs in comparison to slower progressors (74 vs. 57%; P=0.04).
Compared to autoantibody-positive non-progressors, rapid progressors
were younger at seroconversion (1.6 vs. 5.5 years; P<0.001), carried
more often the high risk HLA-DQB1*02/*0302 genotype (48 vs. 26%;
P=0.001), had higher frequency of IAA (80 vs. 13%; P<0.001), GADA
(58 vs. 13%; P<0.001), and IA-2A positivity (31 vs. 3%; P<0.001), and
higher titers of ICA (10.0 vs. 4.0 JDFU; P<0.001), IAA (9.1 vs. 0.3 RU;
P<0.001), GADA (6.9 vs. 0.1 RU; P<0.001), and IA-2A (0.11 vs. 0.08
RU; P<0.001) at seroconversion. In comparison to autoantibody-positive
non-progressors, rapid progressors with a high risk HLA genotype carried
more often the predisposing SNP in the FUT2 gene (74 vs. 32%;
P=0.001).
Conclusion: At seroconversion, individuals with rapid progression to
T1D are characterized by young age, high-risk HLA genotype, higher
autoantibody titers, positivity for multiple autoantibodies, higher preva-
lence of the predisposing SNP in the FUT2 gene and a higher number of
risk SNPs per individual. Such children should be considered as a target
for careful monitoring and aggressive intervention.
Supported by: Finska Läkaresällskapet
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Prevalence of monogenic diabetes in the Norwegian childhood dia-
betes registry estimated by targeted deep sequencing
B.B. Johansson1,2, H.U. Irgens1,3, J. Molnes1,2, P. Sztromwasser2, O.
Søvik1,3, S. Levy4, I. Aukrust2,1, D.E. Undlien5, T. Skrivarhaug6, G.
Joner6,7, A. Molven1,8, P.R. Njølstad1,3, S. Johansson1,2;
1Department of Clinical Science, KG Jebsen Center for Diabetes Re-
search, 2Center for Medical Genetics and Molecular Medicine, 3Depart-
ment of Paediatrics, Bergen, Norway, 4Hudson Alpha Institute for Bio-
technology, Huntsville, USA, 5Department ofMedical Genetics, 6Depart-
ment of Paediatrics, 7Institute of Health and Society, Oslo, 8Gade Labo-
ratory for Pathology, Bergen, Norway.
Background and aims: 10-15% of children with diabetes do not have
auto-antibodies at diagnosis, and it is unknown how many of these who
have an underlying monogenic form of diabetes. We therefore screened
all auto-antibody negative patients in the Norwegian Childhood Diabetes
Registry for five monogenic diabetes genes. Our aim was to estimate the
prevalence of common forms of monogenic diabetes in childhood diabe-
tes in Norway.
Materials and methods: The Norwegian Childhood Diabetes Registry
includes 95% of all children with newly diagnosed diabetes from 2002.
By 17.03.2015, the registry contained clinical data (onset of diabetes,
family history and treatment) for 3882 children, as well as serum and
DNA samples. 469 negative as well as 469 GAD and IA-2 antibody
positive individuals were screened for HNF1A, HNF4A, GCK, HNF1B,
and INS sequence variants using TruSeq Custom Amplicon sequencing.
Classification of DNA variant pathogenicity was performed blindly to
auto-antibody status.
Results: Mean coverage was 488X with 97% of the target covered at
>20X. We found 58 rare exonic and splice variants and classified them
according to clinical criteria for pathogenicity (class 1-5). 6.7% of auto-
antibody negative patients had a sequence variant classified from unknown
to pathogenic (class 3-5) compared to 2.8% of the auto-antibody positive
patients (P=0.005, OR=2.51). For the stricter classification (class 4-5), the
corresponding numbers were 3.9% and 0.2%, respectively. Interestingly,
4.1% of the auto-antibody negative patients showed an enrichment of
HNF1A variants of pathogenicity class 3-5; compared to 0.8% of the
auto-antibody positive patients (P=0.001, OR=4.99).
Conclusion: This is a population-based study screening all the auto-
antibody negative patients for five monogenic diabetes genes. Our results
suggest that the prevalence of monogenic diabetes in the Norwegian
Childhood Diabetes Registry is in the range of 3.9 - 6.7% among GAD-
and IA-2 antibody negative patients. Molecular screening in all auto-
antibody negative patients should now be considered for routine
diagnostics.
Supported by: The Norwegian Diabetes Association
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Gender difference in diabetes related excess risk of cardiovascular
events: When does the ‘risk window’ open?
G. Seghieri1, L. Policardo1, R. Anichini2, P. Francesconi1;
1Epidemiology, Agenzia Regionale Sanità, Florence, 2Epidemiology, Di-
abetes Unit, Ospedale S.Jacopo, Pistoia, Italy.
Background and aims: Diabetic women have a significantly higher
excess risk of cardiovascular events than diabetic men, when compared
with their respective non diabetic counterparts. However, whether this is
evident along the entire period of life or whether this gender driven ‘risk
window’ opens only in some life’s periods, remains still uncertain. This
study has retrospectively followed up, along a period of eight years (from
2005 to 2012) a cohort of diabetic patients living in Tuscany, a region of
centre of Italy, comparing between genders the effect of age on diabetes
related excess risk of hospitalization for acute myocardial infarction
(AMI), ischemic stroke (IS), and congestive heart failure (CHF).
Materials and methods: The database used for this investigation was
obtained from linking three datasets: the first concerning hospital dis-
charges with main diagnosis of AMI (ICD-9-CM:410.xx), IS (ICD-9-
CM:430.xx, 431.xx, 432.xx, 434.xx or 436.xx) or CHF (ICD-9-CM:
402 to 428), from all Tuscan hospitals over the period 2005 to 2012,
the second was the general population registry of all inhabitants of Tus-
cany and the third a dataset containing the registry of all known diabetic
patients from Tuscany. The effect of diabetes, identified by hospital dis-
charge with ICD-9-CM code: 250.xx, and/or by the presence in the re-
gional diabetes registry, on hospitalization for AMI, IS, CHF, was sepa-
rately measured in men and in women according to a Cox regression
analysis model, along the entire period 1st January 2005 to 31st Decem-
ber 2012.
Results: On a total of 3,192,203 inhabitants aged more than 16 yr (47%
males), we counted 24,605 hospitalizations for AMI (16,251 in men and
8,354 in women), 26,953 for IS (14,848 in men and 12,105 in women),
17,628 for CHF (8,403 in men and 9,225 in women). After adjusting for
age, the diabetes related excess risk, expressed as hazard ratio
(HR:95%CI), was, overall, significantly higher in women than in men
hospitalized for AMI [2.629(2.484-2.781) vs. 1.963 (1.877-2.053); p<
0.05], but similar between genders for those hospitalized for IS
[2.103(2.000-2.209) vs. 2.131(2.041-2.224); p=ns] and CHF
[2.631(2.499-2.769) vs. 2.550(2.418-2.688); p=ns]. After stratifying the
population by age decades, however, diabetic women hospitalized for
AMI had a significantly higher excess risk than diabetic men, along the
entire age interval between decade 45-54 yr up to age class 75-84 yr, with
the highest difference found in age class 45-54 yr [5.827(4.299-7.720) in
women vs. 2.879(2.493-3.304) in men; p<0.05]. In patients hospitalized
for IS and CHF diabetic women had an excess risk higher than men from
age class 55-64 yr up to class 75-84 yr, with the highest difference in age
decade 55-64 yr in both [4.139(3.594-4.745) vs. 3.044(2.769-3.339) and
6.828(5.683-8.156) vs. 4.109(3.611-4.663) respectively; p<0.05 for
both].
Conclusion: In this cohort of Tuscan population the excess risk of car-
diovascular events linked with diabetes, is significantly different between
genders. With respect to AMI, diabetic women are more disadvantaged,
compared to diabetic men, with a gender driven ‘risk window’ which
mostly opens in the perimenopausal age. As to IS and CHF, it opens later,
in the postmenopausal age, and at a lesser extent. All this prompts atten-
tion to a timely, gender oriented, prevention of cardiovascular events in
people with diabetes.
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N-terminal prohormone of brain natriuretic peptide is a predictor of
heart failure complicating type 2 diabetes: the Fremantle Diabetes
Study Phase II
W.A. Davis1, K.E. Peters1, P. Chubb2, D.G. Bruce1, T.M.E. Davis1;
1School ofMedicine and Pharmacology, University ofWestern Australia,
Fremantle, 2Fiona Stanley Hospital, Department of Clinical Biochemis-
try, PathWest Laboratory Medicine WA, Murdoch, Australia.
Background and aims:N-terminal prohormone of brain natriuretic pep-
tide (NT-proBNP) predicts incident heart failure in the general population
but can be influenced by factors such as renal disease and obesity that are
common in type 2 diabetes. The aim of this study was to determine the
prognostic utility of NT-proBNP for hospitalisation or death due to heart
failure in type 2 diabetes.
Materials and methods: We used baseline data and incident outcomes
from the Fremantle Diabetes Study Phase II, a community-based longi-
tudinal observational study. Patients were recruited between 2008 and
2011 and heart failure events were obtained from validated linked data
up to end-June 2013. Plasma NT-pro BNP was measured by commercial
assay with inter-day imprecision ≤4.0% at concentrations up to 406 pg/
mL and limit of detection 5 pg/mL. The optimum plasma NT-pro BNP
cut-points for prevalent and incident heart failure were identified from the
area under the receiver operating characteristic curve (AUC) and
Youden’s Index. Cox regression with age as time-scale identified inde-
pendent predictors of heart failure.
Results: Of 1,551 type 2 diabetes participants (mean age 66 years, 52%
male, median diabetes duration 9 years), 101 (6.5%) had a prior
hospitalisation for heart failure. The geometric mean (SD range) NT-
proBNP was greater in those with vs without prior heart failure (456
(99-2098) vs 75 (19-291) pg/mL, P<0.001). In those <75 years, the
AUC for NT-proBNP for identifying prevalent heart failure was 0.83
(0.77-0.89) with an optimum cut-off of 122 pg/mL, and 0.74 (0.65-
0.83), with an optimum cut-off of 275 pg/mL, in those ≥75 years. During
amean ± SD 3.6±1.1 years’ follow-up (5,153 patient-years), 80 (5.5%) of
the remaining 1,450 patients were hospitalised with/died from heart fail-
ure, an unadjusted incidence of 15.5 (95%CI 12.3-19.3) per 1000 patient-
years. NT-proBNP was greater in those with vs without incident heart
failure (424 (107-1685) vs 68 (19-246) pg/mL, P<0.001). The NT-
proBNP AUC for incident heart failure was 0.79 (0.71-0.88) with an
optimum cut-point of 114 pg/mL in those aged <75 years (sensitivity,
specificity, PPV and NPV: 72.4%, 76.4%, 8.3% and 98.9%), and 0.78
(0.71-0.85) and 282 pg/mL for those aged ≥75 years (sensitivity, speci-
ficity, PPV and NPV: 76.3%, 74.0%, 30.2% and 95.5%). Significant
independent predictors of incident heart failure were longer diabetes du-
ration, insulin use and ln(NT-proBNP).
Conclusion: NT-proBNP cut-offs for predicting incident hospitalisation
with/death from heart failure in our contemporary type 2 diabetes cohort
were similar to those for defining prevalent heart failure. For those
≥75 years, NT-proBNP cut-offs for both prevalent and incident heart
failure were lower than for diagnosis of heart failure in the general pop-
ulation (>450 pg/mL).
Supported by: NHMRC Project Grant APP1042231; Novo Nordisk Dia-
betes Support Scheme 2015
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Fructosamine is a risk factor for myocardial infarction and all-cause
mortality: longitudinal experience from the AMORIS cohort
H. Malmström1, G. Walldius1, V. Grill2, I. Jungner1,3, N. Hammar1,4;
1Institute of Environmental Medicine, Karolinska Institutet, Stockholm,
Sweden, 2Department of Cancer Research andMolecular Medicine, Nor-
wegian University of Science and Technology, Trondheim, Norway,
3CALAB Research, Stockholm, 4Department of Epidemiology,
AstraZeneca R&D, Mölndal, Sweden.
Background and aims: Glycation is linked to microvascular complica-
tions of diabetes and also to macrovascular events. Fructosamine is a
biomarker of glycation but its associations to macrovascular complica-
tions are not well documented. The aim of this study was to evaluate
fructosamine as a risk factor of myocardial infarction and all-cause mor-
tality in a large population based cohort.
Materials and methods: Information on glucose and fructosamine was
obtained from subjects of the large AMORIS cohort between 1985 and
1996 (n=338,443) who were followed for 19 years on average. None of
the subjects were hospitalized at the time of blood sampling and samples
were collected either at routine health check-ups or in primary care. Inci-
dent cases of myocardial infarction and death from any cause were iden-
tified from national patient and cause of death registers respectively with
no loss to follow-up. Cox regression with censored data was used to
estimate hazard ratios between relevant clinical groups of glycemic status.
Results: The incidence of myocardial infarction (n=21,526 cases) and
all-cause mortality (n=73,458 deaths) increased at fructosamine levels
above 2.30 mmol/L indicating prediabetes. For myocardial infarction,
the sex- age- fasting- and entry period adjusted hazard ratio in subjects
above 2.70 mmol/L vs reference subjects with normal glucose tolerance
was 2.9 (95% CI: 2.7-3.1) (Figure 1). The corresponding hazard ratio for
all-cause mortality was 2.3 (95% CI: 2.2-2.4). These associations
remained basically unchanged after adjustment for total cholesterol, tri-
glycerides, albumin and social class. When additional adjustment for
glucose was performed the associations were attenuated but remained.
Furthermore, the associations remained stable when smoking and hyper-
tension were accounted for in a subset of the cohort (n=3,178). In a
proportion of the subjects with simultaneous measurements of
fructosamine, HbA1c and fasting glucose respectively (n=9,746), similar
associations across the biomarkers were observed with somewhat lower
hazard ratios for fasting glucose.
Conclusion: There is a strong association between increased
fructosamine levels and myocardial infarction and death from any cause
whenmajor cardiovascular risk factors are accounted for. This association
could only partly be explained by glucose levels and fructosamine may
add or complement to risk assessment in this setting.
Supported by: Jungner Foundation for laboratory medicine
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Single nucleotide polymorphisms at the Niemann-Pick C1-Like 1
gene locus significantly predict cardiovascular events in coronary
patients with type 2 diabetes
A. Muendlein1, A. Leiherer1, C.H. Saely1,2, E. Kinz1,3, P. Rein1,4, A.
Vonbank1,4, P. Fraunberger5, H. Drexel1,4;
1VIVIT Institute, 2cDepartment of Medicine and Cardiology, Academic
Teaching Hospizal Feldkirch, Feldkirch, Austria, 3Private University of
the Principality of Liechtenstein, Triesen, Liechtenstein, 4Department of
Medicine and Cardiology, Academic Teaching Hospital Feldkirch, 5Med-
ical Central Laboratories, Feldkirch, Austria.
Background and aims: Niemann-PickC1-like1 (NPC1L1) protein is
critically involved in intestinal cholesterol absorption. Recently, genetic
variation at NPC1L1 locus has been linkedwith cardiovascular event risk.
The association of NPC1L1 variants with cardiovascular events in pa-
tients with type 2 diabetes (T2DM) is unknown and is addressed in the
present study.
Materials and methods: We prospectively investigated the impact of
NPC1L1 tagging single nucleotide polymorphisms (SNPs) rs3187907,
rs10264715, rs4720470, rs217420, rs17655652, and rs17725246 on the
incidence of vascular events in 943 patients undergoing coronary angi-
ography for the evaluation of stable coronary artery disease. Furthermore,
variants rs217434, rs2072183 and rs41279633 were included based on
previously published associations.
Results: As is shown in the table, variants rs3187907, rs10264715,
rs217420, rs17725246 as well as rs217434, rs2072183 and rs41279633
significantly predicted cardiovascular events both in the total study pop-
ulation and specifically in patients with T2DM after multivariate adjust-
ment including statin use. Tagging variants rs4720470 and rs17655652
neither in the total study population nor among T2DM patients predicted
cardiovascular events.
Conclusion: We conclude that common NPC1L1 variants significantly
predict cardiovascular events, particularly in patients with T2DM.
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Diabetes as a risk factor for acute coronary syndrome in women
compared with men: a systematic review and meta-analysis
X. Dong, R. Cai, J. Sun, R. Huang, P. Wang, H. Sun, S. Tian, S. Wang;
Department of Endocrinology, The Affiliated ZhongDa Hospital of
Southeast University, Nanjing, China.
Background and aims: Diabetes mellitus is a significant cause of
death and disability worldwide and is a strong risk factor for
acute coronary syndrome. Whether diabetes confers the same ex-
cess risk of acute coronary syndrome between the sexes is un-
known. Therefore, we undertook a systematic review and meta-
analysis to estimate the relative risk for acute coronary syndrome
associated with diabetes in men and women.
Materials and methods: We systematically searched PubMed,
Embase, and Cochrane Library databases for both case-control
and cohort studies published between Jan 1, 1966, and Dec 3,
2014. Studies were included if they reported sex-specific esti-
mates of the relative risk (RR), hazard ratio (HR), or odds ratio
(OR) for the association between diabetes and acute coronary
syndrome, and its associated variability. We pooled the sex-
specific RR and their ratio (RRR) between women and men,
using a random-effects model with inverse-variance weighting.
Results: We included 9 case-control and 10 cohort studies with
data for 10856279 individuals and at least 106703 fatal and non-
fatal acute coronary syndrome events. The pooled maximum-
adjusted RR of acute coronary syndrome associated with diabetes
was 2.46(95%CI 1.92-3.17) in women and 1.68(95%CI 1.39-2.04)
in men. In patients with diabetes compared with no diabetes,
women therefore had a significantly greater risk of acute coronary
syndrome_the pooled women-to-men RRR was 1.38(95%CI 1.25-
1.52, p<0.001), with no evidence of publication bias.
Conclusion: Women with diabetes have a roughly 40% greater excess
risk of acute coronary syndrome, compared with men with diabetes.
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Concordance of glucose based and of HbA1c based diagnoses of dia-
betes in patients with established coronary atherosclerosis: a compar-
ison between men and women
E. Kinz1,2, C.H. Saely1,3, D. Zanolin1,4, P. Rein1,5, A. Vonbank1,5, A.
Leiherer1, G. Naerr2, A. Muendlein1, H. Drexel1,5;
1VIVIT Institute, Feldkirch, Austria, 2Private University of the Principal-
ity of Liechtenstein, Triesen, Liechtenstein, 3Academic TeachingHospital
Feldkirch, Feldkirch, 4Private University of the Principality of Liechten-
stein, Triesen, 5Department of Medicine and Cardiology, Academic
Teaching Hospital Feldkirch, Austria.
Background and aims: Concordance between glucose based and
HbA1c based diagnoses of diabetes differ between populations. Here,
we aimed at investigating their concordance in men and in women with
stable coronary artery disease (CAD).
Materials and methods: We measured fasting glucose as well as
HbA1c and performed standard 75 g oral glucose tolerance tests
in a consecutive series of 711 patients, 513 men and 198 women,
who had angiographically proven coronary artery disease (CAD)
but not previously diagnosed diabetes. Based on glucose values,
diabetes was diagnosed with a fasting plasma glucose (FPG)
≥126 mg/dl or a postchallenge glucose ≥200 mg/dl 2 hours after
the oral glucose load; based on HbA1c values diabetes was diag-
nosed with an HbA1c ≥6.5%.
Results: Among men, 33 had diabetes based on fasting or postchallenge
glucose values, of whom 26 also had diabetes according to the HbA1c
criterion. Of the 480 men who did not have diabetes based on glucose
values, 446 also did not have diabetes according to HbA1c criteria;
among women, 3 had diabetes based on glucose values, of whom 2 also
had diabetes according to the HbA1c criterion. Of the 195 women who
did not have diabetes based on glucose values, 185 also did not have
diabetes according to HbA1c criteria. Concordance of Glucose and
HbA1c criteria was similar in men and women (92% and 94%; p=
0.335). Applying glucose criteria as a standard, sensitivity, specificity,
positive predictive value (PPV) and negative predictive value (NPV) of
the HbA1c criterion for men were 78.8%, 92.9%, 43.3%, and 98.5%,
respectively. For women, sensitivity, specificity, PPV and NPV of the
HbA1c criterion were 66.7%, 94.9%, 16.7%, and 99.5%, respectively.
Conclusion: We conclude that concordance of glucose and HbA1c
criteria among patients with stable CAD is high and is similar in men
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and women with CAD. However, for both sexes the sensitivity of the
HbA1c criterion is poor in this patient population.
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Glycaemic control and excess mortality in patients with type 2
diabetes
M. Tancredi1, A. Rosengren2, A.-M. Svensson3, M. Kosiborod4, A.
Pivodic5, S. Gudbjornsdottir2, S. Dahlqvist6, H. Wedel7, M. Lind8;
1Medicine, NU-Hospital Organization, Trollhattan, 2Medicine, Universi-
ty, 3Registercentrum, Gothenburg, Sweden, 4Heart Institute, University of
Missouri, Kansas, USA, 5Statistiska Konsultgruppen, Gothenburg, 6NU
hospital Organization, Uddevalla, 7Nordic School of Public Health, Goth-
enburg, 8Medicine, NU-Hospital Organization, Uddevalla, Sweden.
Background and aims: The excess risk of all-cause and cardiovascular
mortality in individuals with type 2 diabetes and various levels of glyce-
mic control and renal complications has not been evaluated.
Materials and methods: Individuals with type 2 diabetes registered in
the Swedish National Diabetes Registry after 1/1/1998 were included in
this study. For each patient, 5 controls were randomly selected from the
general population andmatched by age, sex, and county. All were follow-
ed until 31/12/2011 through the Swedish cause-specific death registry.
Results:Over a mean follow-up of 4.6 and 4.8 years respectively, 77,117
(17.7%) of 435,369 patients with diabetes and 306,097 (14.5%) of
2,117,483 controls died; corresponding rates for cardiovascular mortality
were 7.9% vs 6.1% (adjusted hazard ratio (HR) 1.15 (95% confidence
interval (CI): 1.14-1.16) and 1.14 (1.13-1.15), respectively. The excess
risk of all-cause and cardiovascular mortality increased with younger age,
worse glycemic control, and severity of renal complications. In patients
younger than 55 years having hemoglobin A1c (HbA1c), ≤6.9%
(≤52 mmol/mol), the HR for all-cause mortality was 1.92 (1.75-2.11),
which decreased to 0.95 (0.94-0.96) in those older than 75 years. If
normoalbuminuria coexisted the corresponding hazard ratios were 1.60
(1.40-1.82) and 0.76 (0.75-0.78) respectively, with a significant risk re-
duction also in those 65-75 years old, hazard ratio 0.87 (0.84-0.91).
Conclusion: Although there is evidence suggesting that the overall ex-
cess risk of mortality among individuals with type 2 diabetes has dropped
to historically low levels of around 15%, our study shows that remains
high in certain patient groups, and is still substantially increased in indi-
viduals younger than 55 years even among those with glycemic control
within target ranges and normoalbuminuria. Our study highlights the
important need to continue efforts to improve life expectancy in people
with diabetes type 2. This appears to be particularly important for younger
middle-aged people.
Supported by: SIMSAM
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Evaluation of aldehyde dehydrogenase from human erythrocytes of
patients with type 2 diabetes mellitus
A. Picazo1, A.S. Jiménez-Osorio22, J. Pedraza-Chaverri2, E. Ramirez-
Arellano3, A. Monroy4, D. Barrera-Oviedo1;
1Facultad de Medicina, UNAM, Mexico, Mexico, 2Departamento de
Biología, Facultad de Química, 3Hospital “Lic. Adolfo Lopez Mateos,
UNAM, 4Hospital General de México, Mexico.
Background and aims: Type 2 diabetes (DM2) is a complex disease that
is typically diagnosed in midlife and is characterized by progressive de-
fects due to insulin secretion decreased or insulin action accompanied by
changes in the metabolism of carbohydrates, lipids and proteins. There is
evidence that oxidative stress (OS) plays a major role in the insulin resis-
tance and in the pathogenesis of DM2, then the oxidative stress associa-
tion has been described for several years. As one of the consequences of
oxidative stress is lipid peroxidation (LP) levels increase where the
aldehyde dehydrogenase (ALDH) enzymes are involved in the detoxifi-
cation of aldehydes formed during this LP increase.
Materials and methods: In this study one of the proposals was to eval-
uate, how the activity ALDH is changed in patients suffering from insulin
resistance and DM2 as well, a full evaluation of anti-oxidant and oxidant
systems in human erythrocytes was performed with the aim of analyzing
their activity and association with DM2, via absorbance and fluorescence
techniques.The study subjects consited of a total of 542 patients, aged 35-
88 years. Groups were classified based on HOMA-IR, the cut off was 2.6
being 232 subjects showed no insulin resistance, 133 subjects showed
insulin resistance and 177 patients with DM2. The average time the pa-
tients were diabetes diagnosis was 9.2±7.2 years. Also, the DM2 patients
were categorized by glycemic control DM2CT (DM2-HbA1c 6.9, n=82)
and without control DM2 NCT (DM2-HbA1c 7, n=95).
Results: Interestingly, increased ALDH activity was observed in the di-
abetic group, it seems to be associated with the severity of the disease and
might be a compensatory effect against oxidative stress (noticed in con-
trolled and uncontrolled patients).The antioxidant enzymes activity
(SOD,CAT,GPx), bilirrubin and stress oxidative markers levels (ROS,
lipid and protein oxidation) are modified during the development of
DM2. Previous studies have shown that this could probably occur during
the beginning of a certain pathology causing the increase in the antioxi-
dant capability to diminish the oxidative stress and finally the oxidative
damage. Additionally, associations between phenotypic characteristics
with the antioxidant and oxidant systems were noticed between age,
gender, glucose, HbA1c and HOMA-IR, probably for the oxidative stress
severity of the diabetes.
Conclusion: Our findings suggest that glycemic control and insulin re-
sistance have an influence on the oxidative stress in DM2 . DM2 present-
ed more oxidative stress than HOMA-IR>2.6 and HOMA-IR<2.7.
Therefore, our obtained data suggest that oxidative stress play a role in
the DM2 pathology and the evaluation of these antioxidants enzymes as
ALDH and oxidative markers could help in the severity of the type 2
diabetes and improving redox status.
Supported by: PAPPIT IN2117, UNAM
Diabetologia (2015) 58 (Suppl 1):S1–S607 S137
PS 002 Complications in type 1
diabetes
273
The epidemiology of diabetes, diabetes related mortality, complica-
tions, obesity and target HbA1c in Russian Federation: the national
diabetes register
O.K. Vikulova, M.V. Shestakova, Y.I. Suntsov, I.I. Dedov;
Endocrinology Research Center, Moscow, Russian Federation.
Background and aims: Due to the progressive growth of diabetes
mellitus (DM) and diabetic complications and the rising costs of their
treatment the data of diabetes registers are important for planning of
healthcare system. The aim of our study was to evaluate the trends in
epidemiology of DM, DM-related mortality, complications, obesity and
target HbA1c in Russian Federation (RF).
Materials and methods: The study summarized the data of National
diabetes register based on medical records of DM patients in more than
2000 clinics of primary care in 31 regions of RF. Primary care is provided
by DM specialists (mostly) or general practitioners, the data entered man-
ually in online diabetes register, powered by Microsoft Dynamics CRM
platform let data export/import to/from MS Excel. Statistics was per-
formed by IBM SPSS Statistics version 19.
Results: In 31 regions of RF in 2014 have been registered 1984791 DM
patients compared with 1882483 in 2013 (+5.4%): type 2 (T2DM)
92.2%, type 1 (T1DM) 5.6%, other types 2.2%; 99.4% adults (≥18 yr.),
0.4% children, 0.2% adolescents; gender M/F T1DM 52.5/47.5%, T2DM
28.1/71.9%. The average prevalence of T1DMwas 1.56 cases/1000 pop-
ulation, T2DM 25.72 cases/per 1000 population with the wide range of
variability among regions from 0.19 to 2.66 and 6.47 to 34.97/1000
population, respectively. The incidence of DM: in 2014 registered
103277 new DM cases, 30.9% less compared to 2013 (T2DM 92.1%,
T1DM 3.3%, other types 4.6%). In 2014 registered 26 450 DM-related
deaths, the rate of mortality compared to 2013 also decreased by 27.7%.
The leading cause was cardiovascular disease: cumulatively heart failure,
stroke and myocardial infarction - 50.7% of deaths in T2DM and 34.5%
in T1DM, the third leading cause in T1DM - kidney failure (7.9%), in
T2DM - oncology (7.5%). Mortality rate due to diabetic coma remains
fairly high in T1DM (2.1%). The most frequent complications in
T1DM/T2DM: diabetic neuropathy 38.4/19.0%, retinopathy 34.7%/
15.3%, hypertension 18.8/37.6%, nephropathy 20.2/4.9%, CKD as
GFR<60 9/17%, macroangiopathy 16.7/8.3%. Only 9% of T2DM pa-
tients had normal body weight, 33.7% were overweight and 57% had
obesity; in T1DM 51%, 26% and 11%, respectively. HbA1c in 2014
T2DM: 35.8% of patients <7.0% and another 35.7% <8.0%, that in some
T2DM cases can be considered as suboptimal target achieved; in T1DM
the situation was somewhat poorer: 26.1% had HbA1c <7.0% and 30.3%
of patients <8.0% (2013: 38.0/37.4%; 24.2/33.7% for T1/T2DM,
respectively).
Conclusion: The data of National diabetes register have shown increased
DM prevalence in RF over 2013-14 years that is clearly in concordance
with the global worldwide trends, but decrease in DM incidence. Appar-
ently, we are dealing not with true reduction but rather with inappropriate
registration of new DM cases in primary care. With the general trend of
DM-related mortality decrease the cardiovascular pathology remain the
main cause of death both in T1 and T2DM. The registered in primary care
frequency of complications looks rather underestimated, especially com-
pared with the data of epidemiology studies with active screening. The
data demonstrated a very high level of overweight and obesity in DM
population that raises the issue of crucial importance for preventive mea-
sures. Based onHbA1c level, we consider the situation as fairly stable but
need the further efforts for the better DM control.
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Glycaemic control and prevalence of complications in adolescents
and young adults with type 1 diabetes: longitudinal data from to
Norwegian diabetes quality registers
S. Carlsen1, J.G. Cooper1,2, T. Skrivarhaug3, G. Thue2, S. Sandberg2,4;
1Medical department, Stavanger University Hospital, 2The Norwegian
Diabetes Register for Adults, Bergen, 3Norwegian Childhood Diabetes
Registry, Oslo, 4Department of Public Health and Primary Health Care,
Bergen, Norway.
Background and aims: Good glycemic control delays the onset and
progression of microvascular complications, but this can be difficult to
achieve, particularly in young people with type 1 diabetes.The aim of this
study was to assess glycemic control and the prevalence of complications
in a contemporary cohort of adolescents and young adults in Norway.
Materials and methods: Data was obtained by linking the Norwegian
Diabetes Register for Adults and the Norwegian Childhood Diabetes
Registry. We identified 874 patients with type 1 diabetes (diagnosed
before age 14) who were aged between 18-30 in 2013. All available
HbA1c data from the age of 14 until the age of 30 were obtained from
the two registers. We calculated updated median HbA1c for each patient,
together with median HbA1c for each year (14-30). The patients were
grouped according to glycemic control. Good control was defined as
HbA1c<7.5% (58 mmol/mol) for patients<18 years of age and<7.0%
(53 mmol/mol) for patients aged 18-30, and poor control as HbA1c>
9.0% (75 mmol/mol). The last available data on retinopathy, nefropathy,
blood pressure, lipid profile, smoking habits, weight and insulin device
was obtained from the adult register.
Results: Median age of the cohort was 23, median age at diabetes onset
9 years and diabetes duration was 15 years. 51%weremales, 18%were ex-
smokers or current smokers and 40% were treated with continuous subcu-
taneous insulin infusion. Median HbA1c rose during adolescence to peak at
9.3% (78 mmol/mol) at age 17 in females and 9.1% (75 mmol/mol) at age
19 in males thereafter decreasing steadily in both genders. Females had a
higher HbA1c result compared to males at ages 16-18 years (p<0.01). The
proportion of patients achieving good glycemic control was worst at
18 years of age (3%) and only 18% of patients achieved good glycemic
control in their late twenties. 26% of the patients had retinopathy and/or
nephropathy with no gender differences. 72% of patients with poor glyce-
mic control both as teenagers and young adults had complications. In a
binary logistic GEE model updated median HbA1c, smoking habits, diabe-
tes duration and age at diagnosis predicted complications (p<0.05).
Conclusion: Longitudinal data from two Norwegian diabetes quality
registers show that glycemic control is still far from satisfactory in ado-
lescents and young adults, females have higher HbA1c than males in their
middle teens. The prevalence of microvascular complications was 26%
for both genders and 72% in the group with sustained poor glycemic
control.
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Long-term trends in cardiovascular risk factors in type 1 diabetes:
nationwide monitoring of 38,169 patients from 1996 to 2014
A. Rawshani1, A.-M. Svensson1, A. Rosengren1, S. Franzén2, B.
Eliasson1, S. Gudbjörnsdottir1;
1Clinical and Molecular Medicine, Inst of Medicine, 2Västra
Götalandsregionen, Centre of Registers, Gothenburg, Sweden.
Background and aims: The last decades have witnessed remarkable ad-
vances in the management of type 1 diabetes. The risk of complications has
presumably been reduced by intensive insulin therapy, improved insulin
delivery and glucose monitoring, blood pressure control and lipid lowering
therapy. Yet long-term trends in risk factor control has not been examined.
We aimed to examine trends in six cardiovascular risk factors from 1996 to
2014, in the overall cohort and in relation to socioeconomic categories.
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Materials and methods: We included all patients with type 1 diabetes
entered in the Swedish National Diabetes Register from 1996 to 2014 (n=
38,169 contributing 457,577 appointments). We calculated adjusted esti-
mates of glycated haemoglobin (HbA1c), systolic blood pressure (SBP),
LDL cholesterol (LDL-C), body mass index (BMI), physical activity and
smoking.
Results: HbA1c declined from 68.1 mmol/mol to 64.0 mmol/mol from
1996 to 2007 and then reversed to 66.8 in 2012, declining slightly in the
remaining two years. By the end of the study period there was no im-
provement in HbA1c since the turn of the millennium (Figure 1). Indi-
viduals with a college/university degree had 4 mmol/mol lower HbA1c
than individuals with 9 years or less education and there was no trend
towards reduced differences. Overall LDL-C declined from 2.85 in 2002
to 2.59 in 2014, which was, however, not significantly lower than LDL-C
in 2006. Higher education, but not higher income, was associated with
lower LDL-C. BMI increased linearly, from 24.7 kg/m2 to 26.1 kg/m2
from 1996 to 2014. SBP decreased from 131.2 mmHg in 1996 to
125.9 mmHg in 2014. Odds ratio for being a smoker in 2014, compared
with 1999, was 0.75 (95% CI 0.69 to 0.82); there were staggering differ-
ences in relation socioeconomic status, with no tendencies towards re-
duced gaps. Smoking rates declined more in the background population
than among persons with type 1 diabetes. Physical activity doubled be-
tween 2004 and 2007 and then remained unchanged for the remaining
seven years. Odds ratio for being physically active in 2014, compared
with 2001, was 5.25 (95% CI 5.05 to 5.45).
Conclusion: Blood pressure control has been successful. Smoking rates
have declined but smoking cessation has been less less successful among
persons with type 1 diabetes, as compared with persons without diabetes.
Promotion of physical activity has been successful. Less stable improve-
ments are noted for HbA1c and LDL-C. BMI is increasing steadily. So-
cioeconomic differences are pronounced.
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Gender aspects in type 1 diabetes patients undergoing angiography:
a registry report
C. Hero1, V. Ritsinger2,3, A.-M. Svensson4, N. Saleh2, B. Lagerqvist5, A.
Norhammar2, K. Eeg-Olofsson1;
1Department ofMedicine, SahlgrenskaUniversity Hospital, University of
Gothenburg, 2Department of Medicine, Karolinska institute Cardiology
unit, Karolinska University Hospital, Stockholm, 3Department of Re-
search and Development, Region Kronoberg, 4Centre of Registers, The
National Diabetes Register, Region of Västra Götaland, Gothenburg,
5Uppsala University Hospital, Department of Medical Sciences, Cardiol-
ogy, Sweden.
Background and aims: In patients without diabetes, widespread coro-
nary artery disease (CAD) is more common among men compared to
women. This difference is often attenuated if diabetes is present. Few
studies have addressed type 1 diabetes (T1D) in this context. The aim
of this study was to describe angiographic findings and assess long term
mortality also by affected coronary vessels in women and men with T1D.
Materials andmethods:All patients undergoing coronary angiography in
Sweden 2001-2012, included in the Swedish Coronary Angiography and
Angioplasty Registry (SCAAR) and registered in the Swedish National
Diabetes Registry (NDR) with T1D were included. T1D was defined both
with an epidemiological definition and also using the clinicians’ diagnosis
and onset age before 50 years. Coronary angiogramwas visually judged by
the local coronary interventionist and divided into normal (including
atheromatosis/stenosis <50%), one-, two-, three-, and left main-vessel dis-
ease. Patients were followed for mortality until 31 December 2012.
Results: We included 1180 women and 1664 men undergoing coronary
angiography. Mean age 57.5±11 years in both women and men. Mean dia-
betes duration 37.0±14.1 years in women, vs. 33.5±14.0 years in men
(p<0.0001). Mean HbA1c 67±14 vs. 66±14 mmol/mol (p=0.26), LDL
2.7±0.9 vs. 2.6±0.9 mmol/L (p=0.83), HDL 1.65±0.49 vs. 1.43±
0.47mmol/L (p<0.0001), systolic bloodpressure 136±18vs. 136±17mmHg
(p=0.33) in women and men respectively. Men had more albuminuria 51%
vs. 42% (p<0.0001) and women more retinopathy 68% vs. 64% (p<0.05).
Main indications for coronary angiography were stable coronary artery
disease (CAD) 36 vs. 34%, unstable acute CAD 39 vs. 37% and ST-
elevation myocardial infarction (STEMI) 9 vs.12%, other indications 18
vs. 16% in women and men respectively. CAD findings by gender are
presented in Figure 1. Normal angiography was more common in women
(24% vs. 19%). The mean follow-up period was 7.2 (SD 2.2) years and
total mortality did not differ (unadjusted) in women compared to men. In
women diagnosed with 2- and 3-vessel disease crude mortality seemed
higher compared to men.
Conclusion: In patients with T1D admitted for coronary angiography
women more often had a normal angiogram whereas men more often
had 3- vessel and left main vessel disease. Thus the advantage related
to female gender seen in the general population is not completely atten-
uated by the presence of T1D. Despite less widespread angiographic
findings in women, total mortality did not differ, which might be ex-
plained by longer diabetes duration in women.
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What makes a survivor? Description of patients with very long du-
ration of type 1 diabetes with and without a history of micro- or
macrovascular complications
B. Eliasson1, S. Adamsson Eryd2, A.-M. Svensson2, S. Franzén2, P.M.
Nilsson3, S. Gudbjörnsdottir2;
1University of Gothenburg, Department of Medicine, 2Region of Västra
Götaland, The National Diabetes Register, Gothenburg, 3Lund Universi-
ty, Department of Clinical Medicine, Malmö, Sweden.
Background and aims: Type 1 diabetes (T1D) is associated with an
increased risk of micro- and macrovascular disease. Some individuals
with T1D develop such complications very early, while others may never
experience them, despite long diabetes duration. The aim of this study
was to describe the risk factor distribution in subjects with very long
duration of T1D, with and without micro- and macrovascular
complications.
Materials and methods: The study included individuals with T1D
registered in the Swedish National Diabetes Registry (NDR) be-
tween 2002 and 2004. The distribution of biological, lifestyle- and
socioeconomic factors were compared between subjects with and
without a history of cardiovascular disease (CVD), and also between
subjects with and without a history of renal impairment or severe
retinopathy.
Results: Of those with a diabetes duration >50 years (n=583), 290
subjects had a history of CVD and 240 subjects had a history of
kidney disease or severe retinopathy, while 180 individuals were
free of these diagnoses. Detailed risk factor distributions in these
groups are given in Table 1. Factors that differed significantly
between subjects with and without CVD were age, HbA1c, body
mass index (BMI), HDL-cholesterol, LDL-cholesterol, albuminuria,
antihypertensive- as well as lipid-lowering medication, and income.
The same factors differed significantly between subjects with and
without history of renal impairment or severe retinopathy, except for
BMI, HDL-cholesterol and income.
Conclusion: Individuals with T1D who have survived >50 years without
either micro- or macrovascular complications have significantly lower
age, HbA1c, and triglyceride levels compared to patients with a history
of such complications. They also have higher LDL-cholesterol levels, less
albuminuria and less antihypertensive and lipid-lowering medication. Al-
though these differences in risk factor burden may contribute to explain
the presence of diabetic complications, unknown protective factors may
be present.
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Determinants of HbA1c in patients with type 1 diabetes in seven
Swedish county councils
M. Lilja1, B. Julin2, G. Andersson3, I.-L. Andersson4, M. Axelsen4, M.
Ek5, R. Kristiansson6, J. Lekell7, A. Lindberg8, P. Lindgren2, F. Löndahl9,
K. Looström Muth10, A.-M. Svensson11, T. Dahlström12;
1Public Health and Clinical Medicine, Östersund unit, Umeå University,
2Ivbar, Stockholm, 3The Swedish Society of Diabetes Nursing, 4Swedish
Association of Clinical Dietitians, 5Stockholm county council, 6Uppsala
county counsil, Uppsala, 7Department of Medical Scieces, Uppsala Uni-
versity, 8Region Skåne, Malmö, 9Swedish Diabetes Association, Stock-
holm, 10Region Västra Götaland, Gothenburg, 11Swedish National Dia-
betes Register, Gothenburg, 12Public Health and Caring Science, Uppsala
University, Sweden.
Background and aims: In order to make fair comparisons between the
results of different health care providers, proper consideration of the case-
mix of the populations they serve is important. HbA1c is often used as a
metric to indicate the quality of diabetes care, it is therefore of value to
determine what patient characteristics affect this outcome. As part of the
ongoing National Collaboration for Value Based Reimbursement and
Monitoring Systems, we therefore set out to investigate what factors are
associated with HbA1c in a large retrospective cohort of persons with
type 1 diabetes.
Materials and methods: This was a retrospective register study where
we analyzed persons 18 years or older, with a health care contact and a
diagnosis of diabetes during 2010-11 in the administrative systems of
seven Swedish county councils (Dalarna, Jämtland Härjedalen, Skåne,
Stockholm, Uppsala, Västra Götaland and Östergötland), covering
~70% of the Swedish population and linked this data to data from the
National Diabetes Register, socioeconomic data from Statistics Sweden
and data on filled prescriptions from the Prescribed Drug Register. We
estimated a random effect model on HbA1c after one year of follow-up,
including socioeconomic, demographic and clinical factors.
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Results: Based on a complete case approach, 13 396 patients were ana-
lyzed. Women had on average higher HbA1c than men. Blood sugar
control seemed to be better with higher age. Of the socioeconomic fac-
tors, higher education was associated with lower levels of HbA1c, as was
being married. By contrast, we found no association between HbA1c and
being born outside the EU. A history (previous 2 years) of diabetes related
complications were associated with higher levels of HbA1c, which is
likely due to high levels of HbA1c being an indicator of what is causing
the complications in the first place. The exception to this pattern was
patients with renal failure.
Conclusion: Apart from obvious demographic factors such as age and
gender as well as disease history, educational and civil status are impor-
tant factors to take into consideration when comparing obtained HbA1c
levels between health care providers. This also raises the question of the
need for additional focus on education directed towards these groups to
facilitate improved diabetes management.
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HbA1c and incidence ofmicro- andmacrovascular disease in patients
with very long duration of type 1 diabetes
S. Adamsson Eryd1, A. Rawshani2, A.-M. Svensson1, S. Franzén1, B.
Eliasson2, P.M. Nilsson3, S. Gudbjörnsdottir1;
1Region of Västra Götaland, The National Diabetes Register, 2University
of Gothenburg, Department of Medicine, Gothenburg, 3Lund University,
Department of Clinical Medicine, Malmö, Sweden.
Background and aims: Type 1 diabetes (T1D) is associated with an
increased risk of micro- and macrovascular disease. Glycemic control is
a strong predictor of these complications. The aim of this study was to
explore whether HbA1c is associated with incidence of micro- and
macrovascular disease in subjects with very long duration of T1D.
Materials and methods: Individuals with T1D included in the Swedish
National Diabetes Registry (NDR) between 2002 and 2004 without a
history of cardiovascular disease (CVD) and albuminuria (n=7081) were
followed until the first event of CVD, death or until December 31, 2012.
Furthermore, subjects without a history of renal impairment, severe reti-
nopathy and albuminuria (n=6577) were followed until the first event of
renal impairment, severe retinopathy, death or until December 31, 2012.
Cox proportional hazards regression was used to study the relation be-
tween HbA1c and incidence of CVD, renal impairment and severe reti-
nopathy. The models were adjusted for age, sex, systolic blood pressure,
body mass index, total cholesterol, HDL-cholesterol, triglycerides, albu-
minuria, antihypertensive medication, lipid-lowering medication, educa-
tion level, civil status and income. The analyses were stratified into five
levels of diabetes duration: 0-19 years, 20-29 years, 30-39 years, 40-
49 years, and >50 years.
Results: During a mean follow-up time of 9 years 480 individuals were
diagnosed with CVD (7.3 per 1000 person-years). In addition, 1232 sub-
jects were diagnosed with renal impairment or severe retinopathy (21.7
per 1000 person-years). After adjusting for potential confounding factors,
incidence of CVD was significantly associated with HbA1c levels in all
duration strata (Figure 1). Hazard ratios decreased with longer diabetes
duration. A similar relationship was observed with incidence of micro-
vascular disease. HbA1c levels were not associated with incidence of
microvascular disease in patients with >50 years duration.
Conclusion: HbA1c is a predictor of micro- and macrovascular disease
independent of duration of T1D. The results suggest that HbA1c is a
weaker risk factor in persons with very long diabetes duration, indicating
the importance of other known and unknown protective factors in this
very selected group of patients.
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Application of a validated prognosticmodel to identify type 1 diabetic
patients at high risk for major outcomes
M. Garofolo, E. Russo, D. Lucchesi, L. Giusti, V. Sancho Bornez, R.
Bellante, R. Miccoli, G. Penno, S. Del Prato;
Clinical and Experimental Medicine, University of Pisa, Italy.
Background and aims:A prognostic model for assessing individual risk
for major outcomes (CHD, stroke, ESRD, amputation, blindness and all-
cause death) in type 1 diabetes (T1DM) has been developed from the
EURODIAB PCS and tested in three other prospective cohorts. The
model uses routinely available features: age, HbA1c, waist-hip ratio, uri-
nary ACR and HDL. It identifies three groups of T1DM at low- (LR,
score lower than 16), intermediate- (IR, score 16-20) and high- (HR, score
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higher than 20) absolute risk. This model has been applied to a cohort of
774 T1DM (367 F, 47%; 407 M, 53%) attending our outpatients clinic.
Materials and methods: Mean age and diabetes duration (DD) were
40.2±11.7 years and 19.3±12.2 years; HbA1c 7.8±1.2% (range 5.2-
15.1%); urinary ACR (median) 0.49 mg/mmol (0.03-142.6); HDL 62.5
±15.2 mg/dl (8-103 mg/dl), WHR 0.92±0.06 (0.74-1.14). Risk distribu-
tion was evaluated in the entire cohort and after exclusion of 41 T1DM
subjects (5.3%) with major outcomes.
Results:Risk distribution was LR n. 466 (60.2%), IR n. 205 (26.5%) and
HR n. 103 (13.3%) in the whole cohort, and LR n. 461 (62.9%), IR n. 195
(26.6%) and HR n. 77 (10.5%) after exclusion of T1DM with major
outcomes. Major outcomes were more frequent in HR (26/103; 25.2%)
and IR (10/205; 4.9%) than in LR (5/466; 1.1%; p<0.0001). Mean abso-
lute risk at 3, 5, 7 and 10 years in the 733 subjects with no previous
outcomes were, respectively, 1.4, 2.4, 3.4 and 4.9% for LR; 3.8, 6.5,
9.2 and 13.1% for IR; 11.7, 18.9, 25.4 and 33.9% for HR. Distribution
of risk was similar inM and F: LR 58.7 vs. 61.9%, IR 25.5 vs. 27.5% and
HR 15.7 vs 10.6% (p=0.113), but HR was more common in M (p=
0.037). IR and HR increased with quartiles of DD: DD lower than 9 years
16.6 and 1.6%; 10-18 years 24.8 and 4.9%; 19-28 years 24.7 and 13.9%;
higher than 28 years 40.9 and 34.8% (p<0.0001). Bymultiple regression,
main factors associated with IR&HR were age (r2=0.801), logACR
(Δr2=0.097) and HbA1c (Δr2=0.039; p<0.0001 for all). Other recog-
nized prognostic factors (not included in the model because of weak
additional effects) were strictly correlated with those included in the mod-
el; indeed, these risk factors increased from LR to HR: sBP 120±14, 132
±17 and 145±20 mmHg; dBP 72±8, 75±9 and 75±10 mmHg; LDL
cholesterol 113±29, 122±30 and 120±29 mg/dl; non-HDL cholesterol
120±32, 131±35 and 132±33 mg/dl; triglycerides 69 (55-91 IQR range),
82 (63-106) and 101 (69-137) mg/dl; fibrinogen 320±64, 353±63 and
376±67 mg/dl; uric acid 3.6±1.0, 3.8±1.9 and 4.8±4.7 mg/dl; on the
other hand, eGFR (CKD-EPI) decreased progressively: 108±15, 99±13
and 83±20 ml/min/1.73 m2 (p<0.001 for all).
Conclusion: In our cohort of T1DM, 30-40% of subjects had high (about
10%) or intermediate risk (about 25%) for major outcomes. Subjects at IR
and some at HR are also present among T1DM with short DD. This
model allows to trace for each T1DM an exact risk profile to be used in
the clinical practice with the aim of improving treatment for all risk
factors.
Supported by: Regione Toscana, Italy - CUP D55E11002680005
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SNP x SNP interactions in the VPS13C/C2CD4A/C2CD4B locus
modulate diabetes risk
R. Wagner1,2, M. Heni1,2, J. Machann3, F. Schick4, E. Hatziagelaki5, F.
Machicao1,2, H. Staiger1,2, H.-U. Häring1,2, A. Fritsche1,2;
1Division of Endocrinology, Diabetology, Nephrology, Vascular Disease
and Clinical Chemistry, University Hospital of Tübingen, 2Institute for
Diabetes Research and Metabolic Diseases of the Helmholz Centre Mu-
nich at the University of Tübingen (IDM), 3Department of Diagnostic and
Interventional Radiology, Section on Experimental Radiology, University
Hospital of Tübingen, 4Department of Diagnostic and Interventional Ra-
diology, Section on Experimental Radiology, Eberhard Karls University
Tübingen, Germany, 52nd Department of Internal Medicine, Research
Institute and Diabetes Center, UniversityMedical School, “Attikon”Uni-
versity Hospital, Athens, Greece.
Background and aims: Single nucleotide polymorphisms (SNPs) in the
VPS13C/C2CD4A/C2CD4B locus have been found to be associated with
type 2 diabetes, fasting plasma glucose, 2-hour plasma glucose and insu-
lin secretion in genome-wide association studies (GWAS). Some of the
weakly linked SNPs demonstrate opposing effect directions. The func-
tional impact of these genetic variants is unknown. Our objective was to
examine a broad panel of intermediary traits in our extensively
phenotyped cohort.
Materials and methods: We genotyped 21 tag SNPs in the locus. Met-
abolic traits from oral glucose tolerance tests conducted in 2273 partici-
pants and MR-based body fat distribution parameters in a subgroup were
jointly examined using region-based analyses. Key variants were identi-
fied by iterative leave-one-out tests and single SNP association tests.
Haplotype-association tests and linear regression tests with interaction
models were conducted. Insulin secretion and insulin sensitivity were
additionally examined in subgroups with hyperglycemic and
hyperinsulinemic-euglycemic clamps, respectively.
Results: Joint tests confirmed the previously established association with
post-challenge glucose and insulin secretion. After adjustment for sex,
age and BMI, region-wide analysis indicated an association with insulin
clearance (p=0.01), fasting non-esterified fatty acids (NEFA, p=0.009 ),
glycerol (p=4•10-4 ), and subcutaneous abdominal adipose tissue volume
(p=10-5 ). For rs11629596 and rs1425270, a near genome-wide level of
significance was detected for fasting glycerol and insulin clearance (p=
4•10-7 and p=7•10-7, respectively). We demonstrated SNP×SNP interac-
tions on metabolic traits centered around rs72752005. This SNP also
augmented the association of the GWAS-SNP rs7172432 with diabetes
(adjusted per-A-allele OR of rs7172432 on diabetes: 1.03 [CI 0.48-2.19],
1.44 [CI 0.98-2.11] and 2.63 [1.07-6.55] for strata of the A/A, A/G and
G/G genotypes of rs72752005, respectively).
Conclusion: In the VPS13C/C2CD4A/C2CD4B locus, we demonstrate
pleiotropic metabolic effects with strong SNP x SNP interactions affect-
ing multiple metabolic traits and association with diabetes. Specific SNP
combinations in this locus could bear a much higher diabetes risk than
SNP effect estimates from GWAS that originally identified this genetic
region.
S142 Diabetologia (2015) 58 (Suppl 1):S1–S607
282
Genome-wide multi-phenotype rare variant association analysis de-
tects effect of ZNF259 on fasting insulin and triglyceride levels
M. Kaakinen1, R. Mägi2, K. Fischer2, M.-R. Järvelin1,3, A.P. Morris4, I.
Prokopenko1;
1Imperial College London, UK, 2Estonian Genome Center, Tartu, Esto-
nia, 3University of Oulu, Finland, 4University of Liverpool, UK.
Background and aims: Individuals with type 2 diabetes (T2D) have
increased risk of coronary heart disease (CHD), suggesting shared path-
ogenesis. While adverse fasting insulin (FI) levels have a central role in
T2D development, CHD is causally related to dyslipidaemia and triglyc-
erides (TG), in particular. For common variants (minor allele frequency,
MAF>5%), single-trait analyses have shown an enrichment of FI asso-
ciations among SNPs preselected on Metabochip for TG and waist phe-
notypes. However, novel associations could be detected via i) multi-
phenotype analysis by accounting for the correlation between traits, and
ii) analysis of low-frequency and rare variants (MAF≤5%, both denoted
by RVs).
Materials and methods:We have developed a method and software tool
for Multi-phenotype Analysis of RVs (MARV), and have applied it to
jointly analyse FI, TG and WHR using data from 4788 individuals from
the Northern Finland Birth Cohort 1966. Individuals were genotyped on
the Illumina370CNVarray and imputed to the 1000 Genomes Project all
ancestries reference panel (March 2012). FI/TG/WHR were adjusted for
sex, BMI and three principal components to control for population struc-
ture. The following transformationswere applied: natural logarithm for FI
and inverse normal for the residuals of TG and WHR.
Results: We identified RV associations, at genome-wide significance
(p<1.7×10-6, Bonferroni correction for 30,000 genes) in ZNF259, which
maps to a common variant GWAS locus for TG and CHD. Based on BIC,
the model with TG and FI provided the best fit (pmodel=2.2×10
-9), and
stronger associations than in univariate analyses (pTG=1.1×10
-7; pFI=
0.22). ZNF259 included 18 rare variants with MAF ranging from
0.01% to 4.9%, including three missense SNPs.
Conclusion: Common variants at ZNF259 have previously been associ-
ated with lipid levels and CHD but not FI. Using the MARV method and
tool, we demonstrate for the first time a role of ZNF259 RVs in T2D/
CHD-related trait variability, suggesting shared pathophysiology.
Supported by: EU FP7 project MARVEL (WPGA-P48951)
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SNPS in FGF5 and ZNF652 show parent-of-origin specific effects on
blood pressure in families from the Botnia study
A. Lessmark1, R.B. Prasad1, P. Almgren1, G. Kovacs2, M. Vitai2, T.
Tuomi3,4, L. Koranyi2, O. Melander1, L. Groop1,5;
1Department of Clinical Science, Lund University, Malmö, Sweden,
2Heart Center Foundation, DRC, Balatonfüred, Hungary, 3Folkhälsan
Research Centre, 4Department of Medicine, Helsinki University Central
Hospital, 5Finnish Institute of Molecular Medicine, Helsinki University,
Helsinki, Finland.
Background and aims: Hypertension affects ~1 billion people and
causes ~9.4 million deaths worldwide each year. There is a strong heri-
table component; however the genetic variants identified so far explain
only ~1% of the heritability. There are differences in disease
expression between the genders that cannot be fully explained
by hormonal differences alone, and some genetic basis for the
sex-specific effects has been suggested in previous studies. Fur-
ther, Lascaux-Lefebvre et al (Diabetes Metab. 2001) and others
have suggested the impact of parental histories and specifically, a
stronger maternal influence on blood pressure. Parent-of-origin
effects (POE) could explain some of these biases, but they would
not be detected in a case-control setting. Our study aims to ex-
plore these effects in two of the largest family based cohorts.
Materials andmethods: Families from the Botnia cohort (n=4189, 1083
families) were genotyped on the Sequenom mass array for 13 SNPs that
has previously shown an association with blood pressure in GWAS stud-
ies and Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)
andMean Arterial Pressure (MAP) were measured. Correlations between
the parent and offspring phenotypes were analysed, and tests for associ-
ation and parent-of-origin effects were performed using a family based
linear regression model (qTDT). SNPs showing parent-of-origin effects
will be replicated in families from the Hungarian Transdanubian Biobank
(n=9279, 1022 families).
Results: The correlation between SBP, DBP and MAP were stronger
between mothers and offspring (rMAT) than between fathers and offspring
(rPAT) (SBP: rMAT=0.222 rPAT=0.140 pDIFF=0.002, DBP: rMAT=0.215
rPAT=0.120 pDIFF=0.001, MAP: rMAT=0.245 rPAT=0.137 pDIFF=
<0.001). The SNP rs16998073 in fibroblast growth factor 5 (FGF5),
showed the strongest POE.. The A-allele, previously associated with low-
er DBP, showed a trend for lower DBP when inherited from the father
(Pat_effect=-0.021, pPAT=0.07), but higher DBP when inherited from the
mother (Mat_effect=+0.020, pMAT=0.08), with the total test for POE
reaching significance (pPOE=0.005). The POE test also reached signifi-
cance forMAP (Pat_effect=-0.019,Mat_effect=+0.020, pPOE=0.006) and
SBP (Pat_effect=-0.019, Mat_effect=+0.015, pPOE=0.04). The SNP
rs16948048 near zinc finger protein 652 (ZNF652) reached significance
for POE (pPOE=0.03) on DBP, with the A allele, previously associated
with lower DBP, associated with lower DBP when inherited maternally
(Mat_effect=-0.029, pMAT=0.03) but neutral when inherited paternally
(Pat_effect=+0.003, pPAT=0.79) in the current study.
Conclusion: We show here for the first time parent-of-origin specific
effects of SNPs previously associated with blood pressure. This could
explain some of the gender specific effects in traits and the correlation
between individual parents and offspring observed and highlights the
need to consider parent-of-origin effects while investigating genetic asso-
ciations for blood pressure traits. Studies to replicate this parent-of-origin
effect in families from Hungary are underway.
Supported by: ERC Advanced Researcher Grant
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Heritability of human serum lysophospholipids and ether
phospholipids
T. Frahnow1, M.A. Osterhoff1,2, A.-C. Seltmann1, S. Hornemann1, M.
Kruse1, S. Sales3, J.L. Sampaio4, K. Simons4,3, A.F.H. Pfeiffer1,2;
1Clinical Nutrition, German Insitute for Human Nutrition Potsdam-
Rehbrücke, Nuthetal, 2Charité - University of Medicine Berlin, 3Max
Planck Institute of Molecular Cell Biology and Genetics, Dresden,
4Lipotype GmbH, Dresden, Germany.
Background and aims: Although lipidomics, the study of lipids, have a
great potential as clinical tool for monitoring metabolic changes in health
and disease, hardly anything is known about the heritability of lipids. We
therefore use the cohort of our intervention study in twins to investigate
similarities and differences in the lipid profile of mono- and dizygotic
twins.
Materials and methods: In the NUGAT (NUtriGenomic Analysis in
Twins) study, 46 healty twin pairs (34 monozygotic, 12 dizygotic) were
standardized for their nutritional behavior due to a period of six weeks on
a high-carbohydrate, low-fat diet. This standardization was followed by
an interventional low-carbohydrate, high-fat diet for another six weeks.
Extensive characterization of the metabolic responses was performed
after the low fat (LF) and after 1 (HF1) and 6 (HF6) weeks of high fat
diet (HFD) to evaluate rapid and long-term effects. A lipid profile of 307
lipids out of 18 classes were part of the examination including 2 classes of
lysophospholipids (n=27) and 2 classes of ether phopholipids (n=39).
For the study of heritability, the ACE model was applied. This model is
based on a correlation analysis of themono- and dizygotic twins, in which
the proportion of variance is determined that can be traced back to
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additive genetics (A), common environment (C) and individual environ-
ment (E) of the twins. The ACE model was also checked against the AE
model.
Results:Both classes of lysophospholipids showed stable and high
proportions of heritability (A≥0.5) for the screening (Scr) and
during the study. Although both classes didn't differ very much
a n d s h o w e d t h e s a m e r e a c t i o n p a t t e r n , t h e
lysophosphatidylcholines (LPC) had slightly higher inheritance
(Scr: 0.72, LF: 0.60, HF1: 0.80, HF6: 0.66) than the
lysophosphatidylethanolamines (LPE; Scr: 0.70, LF: 0.55, HF1:
0.75, HF6: 0.51). The single members of LPC (n=18) and LPE
also showed these high A-values with the solitary exception of
the LPCs with 19 C-atoms and different number of double bonds
(0≤A≤0.46). In contrast the concentrations of the ether phospho-
lipid classes seemed much more environmentally determined (0≤
A≤0.46). Moreover the reaction pattern differed between the
ethers of phosphatidylcholine (PC-O; Sc: 0.00, LF: 0.00, HF1:
0.46, HF6: 0.00) and the ethers of phosphatidylethanolamine
(PE-O; Sc: 0.24, LF: 0.40, HF1: 0.41, HF6: 0.00). Their single
members also varied in their heritability. For the PC-Os (n=26)
the length of their fatty acids seemed to have the strongest im-
pact. The longer the fatty acids, the less heritable they were.
Conclusion:Although we understand more and more, how lipids act and
interact under different environmental conditions, it is necessary to clarify
how and how much we can affect these progresses in individuals (e.g by
nutrition). There is evidence that especially lipids with odd fatty acids
were able to reduce the diabetes risk. Our data showed strong differences
in the heritability of lipid classes and also that classes like
lysophospholipids, which can be associated with inflammation, seemed
to be genetically determined. These findings may be part of an explana-
tion for phenomena like metabolically healthy obesity and the ability to
compensate the unfavorable effects of HFDs.
Clinical Trial Registration Number: NCT01631123
Supported by: BMBF, DZD
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Use of Danish National Registers to identify parental history of type 2
diabetes for gene-environment interaction and association studies
D.R. Witte1,2, M.E. Jørgensen3, I. Brandslund4,5, B. Carstensen3, N.
Grarup5, T. Hansen5, T. Jørgensen6, A. Linneberg6,7, O. Pedersen5, J.
Wohlfahrt8, A. Kurbasic3,9;
1Department of Public Health, Aarhus University, 2Danish Diabetes
Academy, Odense, 3Clinical Epidemiology, Steno Diabetes Center, Gen-
tofte, 4Department of Clinical Biochemistry, Vejle Hospital, Vejle, 5The
Novo Nordisk Foundation Center for Basic Metabolic Research, Univer-
sity of Copenhagen, 6Research Centre for Prevention and Health, The
Capital Region of Denmark, Glostrup, 7Department of Clinical Experi-
mental Research, Rigshospitalet Glostrup, 8Department of Epidemiology
Research, Statens Serum Institut, Copenhagen, Denmark, 9Lund Univer-
sity Diabetes Centre, Lund University, Malmö, Sweden.
Background and aims: Family history is one of the major independent
risk factors for type 2 diabetes, reflecting both a shared underlying genetic
susceptibility and environment. The study of interactions between genetic
variants and family history of diabetes is a powerful way of examining
gene-environment interactions as it investigates whether the over-all level
of known and unknown genetic and environmental factors which cluster
in families, modifies the genetic associations. We aimed (1) to assess
whether it is feasible to obtain systematic data concerning parental history
of diabetes (PHD) through linkage between several Danish National Reg-
isters (DNR) and (2) to enrich a composite genetic study of diabetes (The
LuCAMP study) with register-derived PHD data in order to examine the
modifying effect of PHD on known genetic markers of diabetes risk.
Materials and methods: We obtained records of diabetes diagnosis for
the parents of the 5447 LuCAMP participants (968 with T2DM) by
record linkage in the DNR. Logistic regression was used to assess the
interaction between PHD and 30 known genetic variants associated with
diabetes risk, adjusting for age and sex.
Results: Among participants with diabetes, 42% (n=409) had PHD,
while only 28% of participants without diabetes had PHD (n=1236);
OR for diabetes by PHD: 1.92 (95%CI: 1.66;2.22). Four SNPs
(rs5945326, rs7957197, rs340874 and rs7578597) showed nominally
statistically significant (p<0.05) interaction with PHD (either parent).
For three of these (rs5945326, rs7957197, and rs7578597) the diabetes
risk associated with the risk allele was lower among people with PHD
(ORint:0.77, 0.69 and 0.63 respectively), while for rs340874 the risk was
higher (ORint:1.24). Odds ratios were broadly consistent when examining
maternal PHD, paternal PHD and PHD from both parents separately for
these fours SNPs, although not all sub-analyses were statistically signif-
icant. Five further SNPs (rs8042680, rs13266634, rs896854, rs7961581
and rs10010131) showed nominally statistically significant interactions
with maternal PHD, paternal PHD or PHD from both parents without
showing a significant interaction for PHD from either parent. None of
the interaction p-values remained statistically significant after Bonferroni
correction for multiple comparisons.
Conclusion: We showed that it is possible to use the Danish National
Registers to enrich extant genetic studies in Denmark with parental his-
tory of diabetes data. Our approach can be used to discover signals of
modification of some genetic determinants of diabetes by parental history
of diabetes.
Supported by: Lundbeck Foundation, Novo Nordisk Foundation, Danish
Diabetes Academy
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Familial clustering of Japanese patients with adult-onset type 1 dia-
betes mellitus from the database of “Tokai Clinical Study Group of
Diabetes”
K. Hosokawa1, S. Tsunekawa1, Y. Seino2, Y. Hamada2, Y. Oiso1;
1Department of Endocrinology and Diabetes, 2Department of Metabolic
Medicine, Nagoya University Graduate School of Medicine, Japan.
Background and aims: The prevalence of Type 1 diabetes mellitus
(T1DM) in Japanese is known to be much lower than in Caucasians.
Meanwhile, previous studies reported that the λsibling(λs), which repre-
sents the ratio of the risk of T1DM in siblings of patient with T1DM to
that of general population, was much higher in Japanese than in Cauca-
sians(15 in Caucasians and 65-271 in Japanese, respectively). However,
those studies were based on the data of subjects whose onset of T1DM
was under the age of 20 years old, and showed the risk only in siblings.
The aim of this study is to investigate familial clustering of T1DM in
Japanese subjects with adult-onset T1DM.
Materials and methods: This cross sectional study was performed with
737 subjects with T1DM from the database of “The Tokai Clinical Study
Group of Diabetes” enrolled from 28 hospitals. Assuming the subjects as
probands, the familial clustering was investigated using questionnaires
regarding the family history, including parents, siblings, and children,
of T1DM. In addition, we classified the probands into the different groups
according to the subtypes of T1DM development; slowly progressive,
acute, and fulminant-onset, or their onset-age; 0-12 , 13-19 , 20-39 ,
and 40≦ years old.
Results: The mean age of probands was 53.6 years old, and the onset of
T1DM in 85.3% of them was above the age of 20 years old. 6.2% of the
probands had at least one T1DM family member. The prevalence of
T1DM was 2.3% in siblings, 1.2% in parents and 0.8% in children. The
risk of T1DM in the siblings, parents, and children of proband was re-
spectively 164, 89, and 59 times higher than the general population in
which the prevalence is 0.014% in Japanese. Among 3 subtypes of
T1DM, the acute-onset group showed the highest familial risk (acute-
onset; 2.4%, slow progressive-onset; 1.0%, fulminant-onset; 1.1%).
Meanwhile, the one-way Cochran-Armitage trend test demonstrated that,
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among 4 groups of their onset-age, the earlier-onset group showed the
significantly higher risk of T1DM in their siblings and fathers, but not
mothers. Furthermore, among 17 families in which both parents and their
children had T1DM, the onset-age of T1DM of children in 16 families
was earlier than that in their parents’.
Conclusion: In this study, the risk of T1DM in the family of Japanese
patients with adult-onset T1DM was much higher than that of Cauca-
sians, even though the prevalence of T1DM is much lower in Japan.
Furthermore, families of acute-onset and early-onset probands showed
the highest risk of developing T1DM, suggesting that the high familial
clustering could be attributed to genetic factors. This study also demon-
strated that the parental risk in early-onset proband was associated to
father, but not mother, and this finding might support EURODIAB study
that showed the high risk in children of fathers with T1DM. The children
of probands in 16 out of 17 families were observed to develop T1DM
earlier than their parents, supporting that the incidence of T1DM espe-
cially in young children is worldwide increasing. However, further study
is needed to elucidate the genetic susceptibility contributing the most to
the high familial clustering in Japanese.
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Family history of diabetes and cardiovascular disease is associated
with cardiometabolic markers in offspring at age 12: the PIAMA
study
A.M.W. Spijkerman1, N.E. Berentzen1,2, L. van Rossem2, U. Gehring3,
J.C. de Jongste4, A.H. Wijga1;
1Centre for Nutrition, Prevention and Health Services, National Institute
for Public Health and the Environment, Bilthoven, 2Julius Center for
Health Sciences and Primary Care, University Medical Center Utrecht,
3Institute for Risk Assessment Sciences (IRAS), Division of Environ-
mental Epidemiology, Utrecht University, 4Department of Pediatrics,
Erasmus University Medical Center, Sophia Children's Hospital, Rotter-
dam, Netherlands.
Background and aims: The associations of family history of type 2
diabetes and cardiovascular disease (CVD) with cardiometabolic markers
in offspring have been well documented. Type 2 diabetes and CVD share
risk factors and often co-occur. We investigated cardiometabolic risk
factors in children with a (combined) family history of diabetes and
CVD (myocardial infarction (MI) and stroke).
Materials and methods: We used data of 1379 children of the Dutch
Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth
cohort, for whom family history of diabetes, MI and stroke were parent-
reported, and cardiometabolic markers (waist circumference (WC), cho-
lesterol, blood pressure (BP), glycated haemoglobin (HbA1c)) were mea-
sured at age 12. The following categories were created for each child: ‘no
family history’; ‘moderate family history’ (1-2 grandparent(s) with late
disease onset); or ‘strong family history’ (parent(s) with disease; grand-
parent(s) with early disease onset; or 3-4 grandparents with late disease
onset). Differences in cardiometabolic markers between children with no
family history and children with a moderate or strong family history were
assessed by multiple linear regression analyses.
Results:Children with a strong family history of diabetes, (N=146, 11%)
had 2.02 cm higher WC (95%CI 0.91-3.13), 0.19 mmol/l higher total
cholesterol (TC) (95%CI 0.06-0.32), 0.18 higher total-to-high-density-
lipoprotein cholesterol ratio (TC/HDLC ratio) (95%CI 0.004-0.36) and
0.68 mmol/mol higher HbA1c (95%CI 0.17-1.20) than children with no
family history of diabetes. Children with a strong combined family his-
tory of diabetes and CVD (N=414, 30%) had 0.13 mmol/l (95%CI 0.03-
0-23) higher TC and 0.17(95%CI 0.03-0.31) higher TC/HDLC ratio than
children with no family history. Moderate family history of diabetes or
moderate combined family history were not associated with any of the
cardiometabolic markers.
Conclusion: At age 12, children with a strong family history of diabetes
and a strong combined family history of diabetes and CVD had
significantly higher levels of cardiometabolic markers compared to chil-
dren without family history. Family history of these diseases, in particular
family history of diabetes, is a useful tool to identify children at high risk
for the development of future cardiometabolic diseases in order to offer
preventive interventions.
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The identification of wrist circumference cut off for insulin resistance
prediction in a population of children/adolescents
G. Campagna1, M. Spoletini1, M. Calanchini2, S. Zampetti1, L.
Marandola1, G. Leto1, F. Lucantoni1, L. Pacifico3, E. Di Benedetto2, A.
Fabbri2, R. Buzzetti1;
1Experimental Medicine, Sapienza, University of Rome, 2Medicina dei
Sistemi, Tor Vergata University, 3Pediatrics, Sapienza, University of
Rome, Rome, Italy.
Background and aims: Insulin resistance plays a central role in the
pathogenesis of the metabolic syndrome and its prevalence in the paedi-
atric population is increasing, particularly among obese children/adoles-
cents. In a previous study we observed a close relationship among wrist
circumference, its bone component, and insulin resistance in overweight/
obese children/adolescents. The aim of this study was to identify the wrist
circumference cut off for the prediction of insulin resistance in a popula-
tion of children/adolescents.
Materials and methods: We recruited n=1134 (M=583, F=551; mean
age: 10.3±2.9) overweigh/obese children/adolescents in the Department
of Pediatrics of our University and n=114 (M=58, F=56; mean age: 11.8
±2.9) normal weight controls in a hospital. We evaluated the following
anthropometric and biochemical parameters: body weight (kg), height
(cm), wrist circumference (cm), BMI-z score, fasting glucose (ml/dl),
fasting insulin levels (μU/ml). The wrist circumference was measured
using a tension-gated tape measure positioned over the Lister tubercle
of the distal radius and over the distal ulna. The subjects were divided
into two groups according to Tanner stage (TS): prepubertal (TS 1),
pubertal (TS from 2 to 5). Insulin resistance was estimated according to
the homeostasis model assessment of insulin resistance (HOMA-IR).
HOMA-IR cut off values for insulin resistance in the pre-pubertal period
were: 2.22 in females and 2.67 in males; in the pubertal period were: 3.82
in females and 5.22 in males. The data were analyzed through logistic
regression and ROC curves, with SAS software 9.3.
Results: We observed that the cut-off of wrist circumference to predict
insulin resistance in the pre-pubertal subjects were: ≥15.8 cm in males
(sensitivity 0.70, specificity 0.73), ≥15.4 cm in females (sensitivity: 0.36,
specificity: 0.82); in the pubertal subjects were ≥17.7 cm in males (sen-
sitivity: 0.52, specificity: 0.84) and ≥15.2 cm in females (sensitivity: 0.85,
specificity: 0.40). The linear regression demonstrated a positive correla-
tion between wrist circumference and HOMA-IR (R2=0.09, p<0.0001).
Conclusion: The wrist circumference, an easy method to detect anthro-
pometric parameter, could be utilized to identify children/adolescents
with increased risk for insulin resistance, thus avoiding testing the entire
population of overweight/obese children.
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Ratio of waist-to-calf circumference is associated with NAFLD and
hepatic fibrosis in type 2 diabetes independently of obesity and insu-
lin resistance
Y. Lee1, E. Han1, G. Kim1, S. Kim1, B.-W. Lee1, E. Kang1, C. Ahn1, H.
Lee1, K. Huh2, B.-S. Cha1;
1Department of Internal Medicine, Yonsei University College of Medi-
cine, 2Huh’s Diabetes Center and the 21st Century Diabetes and Vascular
Research Institute, Seoul, Republic of Korea.
Background and aims: Although the term sarcopenic obesity refers to
the loss of skeletal muscle mass with increased body fat that occurs with
ageing, assessment of sarcopenic obesity is not feasible due to the require-
ment of specific imaging modalities such as dual-energy X-ray
absorptiometry. For a clinical practice, we previously validated waist-
to-calf circumference ratio (WCR) as a simple index to assess the dispro-
portion between abdominal obesity and legmuscle leanmass, which were
significantly associatedwith carotid atherosclerosis in patients with type 2
diabetes (Diabetes Care. 2011;34:2067-71). Sarcopenic obesity is closely
linked to various cardiometabolic disorders, while its influence on non-
alcoholic fatty liver disease (NAFLD) or steatohepatitis has not been fully
determined in type 2 diabetes. Therefore, we aimed to investigate whether
WCR is associated with NAFLD and hepatic fibrosis in patients with type
2 diabetes.
Materials and methods: This was an observational study performed in
5,806 consecutively enrolled patients with type 2 diabetes. Hepatic
steatosis was diagnosed using ultrasonography. Insulin resistance was
assessed using the insulin tolerance test (ITT). NAFLD fibrosis scores
(NFS) and FIB-4 scores were calculated to define advanced fibrosis in
subjects with NAFLD.
Results: The prevalence of NAFLD and obesity (BMI≥25 g/m2, Asian
definition) were 44.6% and 38.9%, respectively, in the whole study pop-
ulation of type 2 diabetes. The proportion of NAFLD was higher in
subjects with increasing WCR tertiles regardless of gender (the lowest
WCR tertile vs. the highest WCR tertile, 32.6% vs. 52% in men, 24.1%
vs. 58.0% in women, both Ps<0.0001). This relationship between WCR
tertiles and NAFLD appeared significant even after stratification with
obesity or insulin resistance status assessed by ITT (Ki values). Multiple
logistic regression analysis also demonstrated this independent associa-
tion between WCR tertiles and NAFLD after adjusting for confounding
factors related to obesity or insulin resistance (ORs=1.32 to 1.36 in men,
Ps<0.01 and ORs=1.14 to 1.24 in women, Ps<0.05). Serum levels of
liver enzymes (ASTandALT) and an inflammatorymarker, CRPwere all
elevated with increasing WCR tertiles in both men and women (All Ps<
0.001). Furthermore, among the NAFLD population, subjects with the
highest WCR tertile were likely to have advanced fibrosis compared with
other individuals regardless of obesity (hepatic fibrosis assessed by NFS
and FIB-4: ORs=2.27 and 2.15, respectively; both Ps<0.001).
Conclusion: WCR is associated with increased risks of NAFLD and
advanced hepatic fibrosis in type 2 diabetes independently of obesity or
insulin resistance. This suggests that WCR which indirectly reflects
sarcopenic obesity may be a useful and practical anthropometric index
to predict fatty liver and its fibrosis in type 2 diabetes.
Supported by: Korea Health Technology R&D Project
290
Associations between type 2 diabetes-related genetic scores and
OGTT derived traits, in obese children and normal weight controls
A. Morandi1, A. Bonnefond2,3, L. Yengo2,3, S. Lobbens2,3, C. Lévy-
Marchal4, J. Weill5, A. Grandone6, L. Perrone6, E. Miraglia del Giudice6,
C. Maffeis1, P. Froguel2,3;
1Unit of Pediatric Diabetes and Metabolic Disorders, University of Vero-
na, Italy, 2CNRS-UMR8199, Lille Pasteur Institute, 3Lille University,
4Inserm CIE 05 – Department of Clinical Epidemiology, Paris, 5Pediatric
Endocrine Unit, Lille University Hospital, France, 6Department of Wom-
an, Child and of General and Specialized Surgery, Second University of
Naples, Italy.
Background and aims: A total of 62 single nucleotide polymorphisms
(SNPs) have been associated with type 2 diabetes (T2D) and pooled
together into an additive T2D genetic risk score (GRS-T2D) in European
adults. Of these SNPs, 21 have been recognized to affect β-cell function
and 10 to affect insulin resistance (IR), and have been pooled into aβ-cell
function GRS (GRS-β) and an IR GRS (GRS-IR) respectively. Here, we
aim to investigate the associations between these GRSs and OGTT de-
rived traits in obese and normal-weight adolescents and young adults.
Materials andmethods: In a sample of 1,076 obese children/adolescents
(11.4±2.8 years old) and 1,265 normal weight adolescents and young
adults (21.1±4.4 years old) of European ancestry, we performed a
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standard OGTT to assess fasting glucose homeostasis traits, i.e. fasting
plasma glucose [FPG] (mmol/l), fasting insulin [FI] (mU/l), HOMA-B
(20*FI/[FPG-3.5]) and HOMA-IR (FPG*FI/22.5), post-load glucose ho-
meostasis traits, i.e. insulinogenic index [II] (ΔInsulin30’/ΔGlucose30’),
insulin sensitivity index [ISI] (k/sqrt[Glucose0’*Insulin0’*Average-
Glucose*Average-Insulin]), disposition index [DI] (ISI*100*Insulin30’/
[glucose30’*(glucose30’-3.89)]) and 2-hours plasma glucose [2-hG]
(mmol/l), and the presence of pre-diabetic conditions, i.e. impaired glu-
cose tolerance [IGT], and impaired fasting glucose [IFG]. The genotyping
of SNPs was performed with Metabochip arrays (Illumina). We assessed
the associations of T2D-related traits with GRS-T2D, GRS-β and GRS-
IR using linear or logistic regression models adjusted for gender, age and
BMI. Here, we only report associations that were significant after
Bonferroni multiple test correction (i.e. with a p<0.0015).
Results:TheGRS-IRwas not associated with any variable either in obese
children or in normal weight controls, while the GRS-T2Dwas associated
with only II (-0.02 per allele) and DI (-0.02 per allele) in normal weight
young adults but with no variable in obese children. GRS-β was associ-
ated with HOMA-B (-0.02 per allele), II (-0.04 per allele) and DI (-0.03
per allele) in normal weight children, with FPG (+0.02 per allele) and DI
(-0.03 per allele) in obese children, and with FPG (+0.01 per allele),
HOMA-B (-0.02 per allele), II (-0.03 per allele) and DI (-0.03 per allele)
in meta-analyzed data. None of the scores was associated with any binary
trait.
Conclusion: Among T2D related genetic scores, only GRS-β shows
significant associations with glucose homeostasis traits in both obese
children/adolescents and in normal weight controls. These associations
highlight that GRS-β influences both fasting and post-load glucose ho-
meostasis. The fact that GRS-T2D is associated with II and DI only in
normal weight participants, may be explained by a higher influence of
non genetic factors in obese compared to non obese subjects.
Supported by: CNRS
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Age associated DNA methylation changes in adipose tissue is linked
to type 2 diabetes
T.S. Rönn1, P. Volkov1, L. Gillberg2, A. Perfilyev1, P.-A. Jansson3, A.
Vaag2, L. Groop4, E. Nilsson1, C. Ling1;
1Epigenetics & Diabetes, Clinical Sciences, Malmö, Sweden, 2University
of Copenhagen, Denmark, 3Sahlgrenska University Hospital, Gothen-
burg, Sweden, 4Diabetes and Endocrinology, Clinical Sciences, Malmö,
Sweden.
Background and aims: Ageing is a risk factor for several common
diseases, including type 2 diabetes, and has been suggested to contribute
to increased epigenetic variability. Epigenetic factors, e.g. DNA methyl-
ation, provide a link between genetic and non-genetic factors, and could
be involved in phenotype transmission and disease development. The
current aim was to investigate the effect of age on DNA methylation in
human adipose tissue.
Materials and methods: The Infinium HumanMethylation450
BeadChip was used to analyse the genome-wide DNA methylation pat-
tern in adipose tissue from 96 healthy men with an age span between 23
and 80 years. The association between age and DNA methylation of
individual CpG sites was tested using a random effect mixed model,
including cohort as the random effect variable and age, BMI, and HbA1c
as fixed factors.
Results: DNA methylation data was obtained for 456,800 CpG sites in
the 96 men. Age was positively correlated with the average level of DNA
methylation in adipose tissue (p=1.1×10-5). After correction for multiple
testing, we found 31,567 individual CpG sites significantly associated
with age. Among these sites, 90.6% showed a positive whereas only
9.4% showed a negative relation between age and the level of DNA
methylation, in agreement with the result of average DNA methylation.
Of the CpG sites significantly associated with age, 24,514 are annotated
to 11,036 unique genes, whereas 7,053 of the CpG sites are intergenic.
We proceeded to test if the age-associated methylation differences also
can be identified in diseased subjects, by comparing our results with a
recently published case-control study identifying 15,627 CpG sites with
differential DNA methylation in adipose tissue from subjects with type 2
diabetes compared with non-diabetic age-matched controls. We found an
overlap of 1,278 differentially methylated CpG sites, 90% of which
changed in the same direction due to age and type 2 diabetes. These
CpG sites include many novel loci, but also established diabetes suscep-
tibility genes such as JAZF1. To obtain further biological insight into the
significant associations between DNA methylation and age, we used
WebGestalt to perform a KEGG pathway analysis on the 11,036 genes
with one or more CpG sites significantly associated with age. Significant
enrichment was found for 31 pathways, including e.g. the MAPK and
Wnt signaling pathways, pathways in cancer and type 2 diabetes mellitus.
Conclusion: We have shown extensive epigenetic alterations in adipose
tissue due to ageing, some which previously also have been shown to be
present in type 2 diabetic patients. Our study supports a role for epigenetic
mechanisms in the development of age related diseases such as type 2
diabetes.
Supported by: VR, ALF, Wallenberg, NNF, EFSD/Lilly,Påhlsson,
DCSR,Danish Diabetes Academy
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Lower risk for obesity among adolescents living at higher altitudes: a
cross-sectional analysis in the Peruvian population
O.O. Woolcott1, C. Gutierrez2, O.A. Castillo3, R.M. Elashoff4, D.
Stefanovski1, R.N. Bergman1;
1Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center,
Los Angeles, USA, 2Instituto de Medicina Tropical Daniel A. Carrión,
3Instituto Nacional de Biología Andina, Universidad Nacional Mayor de
San Marcos, Lima, Peru, 4Department of Biomathematics, University of
California, Los Angeles, USA.
Background and aims: A significant inverse association between
obesity and altitude has been reported in the adult population of the
United States, adjusting for multiple covariates. However, whether
this relationship extends to the pediatric populations remains un-
known. The aim of the present study was to determine the association
between altitude and obesity among adolescents, adjusting for sever-
al factors.
Materials and methods: We explored the association between altitude
and obesity in the adolescent population of Peru, a country with topo-
graphic, socio-economic, cultural, and ethnic features differing from
those of the United States and Europe. We utilized data publicly available
online from the Food and Nutrition National Center of Peru, CENAN,
for 2009-2010, the last period for which data relevant for a model analysis
are available. The CENAN used a nationally representative sample
selected by the National Home Survey. An important feature of this sur-
vey is the on-site measurements of body weight and height using stan-
dardized methods. Final analysis included 7,618 adolescent subjects
(14-19 years old). Obesity was defined as the BMI-for-age in months
at or above 95th percentile for sex. Percentiles were estimated using
the Centers for Disease Control and Prevention 2000 growth charts.
Multilevel mixed-effects Poisson regression was used to estimate the
relative risk for obesity, adjusting for several factors including age,
sex, physical activity, out-migration rate, urbanization, and latitude,
accounting for nested data (region level) and the random effects
between subjects.
Results: The crude prevalence of obesity among adolescents was 3.7%
between 0−1,499 m and 0.9% at high altitude (≥1,500 m). Boys had
substantially less crude prevalence of obesity at high altitude as com-
paredwith girls living at high altitude (0.86%and0.93%, respectively).
Overall, the relative risk for obesity, adjusted for age, sex, physical
activity, out-migration rate, urbanization, and latitude was as follows:
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1.00 between 0−499 meters (reference category), 1.63 (95% confi-
dence interval 1.05 to 2.53) between 500−1,499 m, 0.59 (0.33 to 1.07)
between 1,500−2,999 m, and 0.28 (0.14 to 0.56) at ≥3,000 m.
Conclusion: Among Peruvian adolescents, the risk for obesity was lower
at altitudes above 3,000 m. These findings suggest that geographical ele-
vation is an important factor linked to obesity not only among adults but
also in the pediatric population. Exploring the underlying mechanisms of
this association could provide new insights in the pathogenesis of obesity.
Supported by: NIH, Alexander von Humboldt Foundation, UCLA-CTSI
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Metabolic syndrome in elderly women: Is waist circumference the
correct 'entrance criteria'?
K. Dragsbæk, J.S. Neergaard, M. Karsdal, C. Christiansen;
Nordic Bioscience, Herlev, Denmark.
Background and aims:More than 20% of the world’s adult population
is considered having metabolic syndrome (MetS). MetS is used to iden-
tify patients at greater risk of developing cardiovascular diseases (CVD)
and type II diabetes (T2DM). The consensus definition set out by the
International Diabetes Federation (IDF) defines largewaist circumference
as the ‘entrance criteria’ for identifying MetS and thereby high risk pa-
tients. This study aimed to investigate the risk of developing CVD based
on number of MetS risk factors rather than waist circumference. Subjects
were further stratified based on body weight and body composition in
order to determine rate ratios (RR) and incidence within the specified
groups.
Materials and methods: Demographics, DEXA scans and serum
samples were collected from 1999-2001 on 5855 women aged
73.1±6.3. CVD diagnoses were collected from Danish National
Disease Registries primo 2015. Subjects with a preexisting CVD
event at baseline were excluded from analysis. Presence of MetS
and number of abnormalities were assessed by the IDF criteria for
triglycerides, HDL-cholesterol, blood pressure, and fasting glucose.
Initially, RR for a CVD event was determined in subjects with ≥2
MetS risk factors (corrected for age and BMI) by Poisson regression
analysis. Thereafter, RR for development of CVD was determined
based on BMI (corrected for age and number of MetS risk factors).
Lastly, stratification was made based on BMI (underweight (UW):
<18.5, normal weight (NW): 18.5-24.9, overweight (OW): 25.0-
29.9, fat: ≥30) and body composition defined as central/peripheral
(C/P) fat mass ratio stratified into quartiles (Q1-Q4) in order to
determine RR and incidence in the specific groups.
Results: An increase in CVD risk of 27% was found throughout the
cohort solely by number of MetS risk factors (≥2 vs. <2), RR=1.27
(1.14-1.42). Moreover, the risk for developing CVD was increased
with increasing BMI (UW: RR=0.88 (95% CI: 0.52-1.47), NW:
RR=1 (ref), OW: 1.18 (1.04-1.32), FAT: RR=1.29 (1.11-1.50)). This
indicates that both number of MetS risk factors and BMI is associated
with CVD events. However, within all groups, regardless of stratifi-
cation (BMI or body composition), a significant increase in risk of
CVD event was found for subjects having ≥2 MetS risk factors (Ta-
ble 1). This indicates that number of risk factors, rather than BMI or
body composition, are the underlying denominator for CVD out-
come. The CVD incidence increased between groups highlighting
that increasing BMI and central fat mass increase the risk of a CVD
event.
Conclusion: Number of risk factors and BMI are both of importance in
defining subjects at risk of developing CVD. However, the risk of devel-
oping a CVD event was increased with ≥2 MetS risk factors regardless of
BMI or body composition in elderly women. It is proposed that number
of risk factors should be used for optimal identification of patients at
increased risk of CVD. Large waist circumference or BMI >30 should
be employed as an individual risk factor rather than the ‘entrance criteria’
for MetS in elderly women.
Supported by: The Danish Research Foundation (Den Danske
Forskningsfond)
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Different relationship between body fat distribution and diabetes
mellitus: analysis of the 2008-2010 Korean national health and nu-
trition examination surveys
J. Huh, J. Lim, M. Lee, J. Shin, C. Chung;
Internal medicine, Yonsei University, Wonju College of Medicine,
Wonju-Si, Republic of Korea.
Background and aims: The aim of this study was to investigate the
association between the regional body fat distribution, especially leg fat
mass and the presence of diabetes mellitus (DM) in older populations.
Materials and methods:A total of 3,027 men and 3,548 postmenopaus-
al women aged 50 years or older were analyzed from Korea National
Health and Nutrition Examination Surveys (2008-2010). Body composi-
tions including muscle mass and regional fat mass were measured using
dual-energy X-ray absorptiometry.
Results: Obesity indices such as body weight, body mass index (BMI),
waist circumference, total body fat (%) and truncal/arm fat mass were
higher in diabetes patients compared with those non-diabetes patients.
However, leg fat mass was lower in postmenopausal women with diabetes
but not in men (Table 1). In multiple logistic regression analysis, a 1-
kilogram increase in trunk fat mass was associated with 15% increase in the
presence of DM in men and 19% increase in women after adjustment for
confounding factors. Conversely, each kilogram increase in leg fat mass
was significantly associated with 51% reduction of DM in men and 44%
reduction in women. In partial correlation analysis adjusted for age, leg fat
mass was positively correlated with appendicular skeletal muscle mass and
HOMA-β. There was significant negative association between leg fat mass
and glycated hemoglobin in both genders and fasting glucose in women
(Table 2). When the participants were classified four groups according to
sex-specific leg fat mass quartiles, the odds ratios (OR) for the presence of
DM significantly decreased gradually as leg fat mass increased in both
sexes (men: Quartile 1 vs. Quartile 2 vs. Quartile 3 vs. Quartile 4 : OR
[95% CI]=1 vs. 0.43 [0.31-0.60] vs. 0.32 [0.23-0.46] vs. 0.13 [0.09-0.21];
women: Quartile 1vs. Quartile 2 vs. Quartile 3 vs. Quartile 4 : OR [95%
CI]=1 vs. 0.41 [0.30-0.57] vs. 0.32 [0.22-0.46] vs. 0.13 [0.08-0.21], respec-
tively) after adjustment for potential confounding factors (Table 3). To
define the relative importance of leg fat mass and leg muscle mass on
DM, we categorized subjects into four groups: HF-LM, HF-HM, LF-LM,
and LF-HM based on the median values of leg fat mass and leg muscle
mass. As a result, higher leg fat mass significantly lowered the risk of DM
regardless of leg muscle mass status in both genders (p <0.001).
Conclusion: In conclusion, our study demonstrated that, in contrast to
trunk and arm adiposity, there is a favorable association of leg adiposity
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with DM in Korean adults aged 50 years or older. We also found the
contributory effects of lower extremity fat on DM are more dominant
than those of lower extremity muscle. Our findings support the notion
that subcutaneous fat and glucose metabolism are intimately interlinked.
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Predictors of severe obesity and associated morbidity in the Malmö
Preventive Project: a population-based cohort study
P.M. Nilsson1, B. Zöller2, J. Sundquist1, K. Sundquist1;
1Deptartment of Clnical Sciences, 2Deptartment of Clinical Sciences,
Lund University, Malmö, Sweden.
Background and aims: Severe obesity represents an increasing medical
problem of relevance for type 2 diabetes. This study aimed to evaluate
risk markers for developing severe obesity as well as the prospective
morbidity risk associated with severe obesity in a population-based
screening and intervention programme.
Materials and methods: In total, 18,200 individuals from a population-
based cohort underwent a baseline examination in 1972-1991 and were re-
examined in 2002-2006 in Malmö, Sweden. In total, 809 (4.4%) patients
with severe obesity (BMI ≥35 kg/m2) were found at re-examination, and
predictive risk factors from baseline were identified. Total and cause-specific
morbidity were followed in national registers in all severely obese patients,
as well as in age- and sex-matched normal weight controls (n=1618).
Results:Men and women developing severe obesity differed significant-
ly from matched controls in baseline variables associated with the meta-
bolic syndrome (BMI, triceps skinfold, blood pressure, fasting-glucose,
triglycerides), as well as in fasting-insulin, liver enzymes, cholesterol, and
uric acid. Both male and female obese subjects were on average shorter
than controls (p<0.001). Female but not male severe obesity was associ-
ated with family history of hypertension. Abstaining from alcohol was
more common in female severely obese subjects (p<0.001), but not
among male subjects (p=0.324), compared with normal-weight controls.
Incident cancer (p=0.002), coronary events (p=0.022), stroke (p=0.002),
heart failure (p<0.001), atrial fibrillation (0<0.001), and diabetes (p<
0.001) during follow-up was higher among severely obese persons com-
pared to normal-weight controls.
Conclusion: Variables associated with the metabolic syndrome are sig-
nificant predictors for development of severe obesity after a long-term
follow-up. Severe obesity is associated with cardiovascular morbidity,
cancer and incident diabetes. This calls for improved weight control in
persons with certain predictors of this condition, as well as better risk
factor control in patients with severe obesity.
Supported by: Heart- and Lung Foundation, Sweden
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Maternal exposure of autoantibodies protects the child from islet
autoimmunity in early childhood if the mother does not have type 1
diabetes (TEDDY)
C. Torn1, Å. Lernmark1, K. Vehik2, E. Bonifacio3, M. Rewers4, O.
Simell5, J. Toppari5, A. Ziegler6, B. Akolkar7, W. Hagopian8, D. Schatz9,
J.-X. She10, J. Krischer2, the TEDDY Study Group;
1Department of Clinical Sciences, Lund University, Malmo, Sweden,
2Pediatric Epidemiology Center, University of South Florida, Tampa,
USA, 3Faculty of Medicine, Technische Universität, Center for Regener-
ative Therapies, Dresden, Germany, 4Department of Pediatrics, Universi-
ty of Colorado at Denver and Health Sciences Center, USA, 5Department
of Pediatrics, University of Turku, Finland, 6Department of Pediatrics,
Diabetes Research Institute, Munich, Germany, 7National Institutes of
Diabetes and Digestive and Kidney Disorders, Bethesda, , 8Pacific North-
west Institute, Seattle, 9Department of Pediatrics, University of Florida,
Gainesville, 10Medical College of Georgia, Atlanta, USA.
Background and aims: Maternal islet autoantibodies transferred via
placenta indicate presence of type 1 diabetes (T1D) or an increased risk
of T1D in the mother. However, little is known concerning the child´s risk
of islet autoimmunity (IA) or T1D. The aim was to explore whether
exposure of maternal autoantibodies in absence of maternal T1D affects
the child´s risk to develop IA in early childhood.
Materials andmethods:Children with an increased genetic risk for T1D
were followed from birth in The Environmental Determinants of Diabetes
in the Young (TEDDY-study). Maternal venous blood sample was col-
lected at the child´s age of 9 months if: the mother had T1D (n=297), of a
child of a mother without T1D that was positive for any islet autoanti-
bodies at age 3-6 months or if the mother had any other type of diabetes
(type 2, gestational or maturity onset of diabetes in the young (MODY)
(n=538).
Results:During the follow-up for a median of 65months (IQR 49-86) IA
developed in 14.1% (42/297) of children born to a mother with T1D and
in 12.8% (69/538) of children born to a mother without T1D. Children
exposed to maternal islet autoantibodies from non-T1Dmothers were less
likely to develop IA (HR=0.26; 95%CI 0.08-0.84; p=0.0236) as com-
pared with un-exposed children. In contrast, children exposed to maternal
autoantibodies and born to mothers with T1D had similar risk of IA as
compared with un-exposed children. (HR=1.08; 95%CI 0.58-2.0; p=
0.8137).
Conclusion: Exposure of maternal autoantibodies indicated decreased
risk for IA in early childhood in children without a mother with T1D,
but not for children to mothers with T1D as compared with un-exposed
children.
Supported by: NIDDK, NIAID, NICHD, NIEHS, JDRF, CDC
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Identification of potential circulating beta cell biomarkers
S.F. Hansson1, P. Vachet1, M. Hammar1, O. Korsgren2,3, P. Davidsson1;
1Translational Science, AstraZeneca, R&D Mölndal, Mölndal, 2Immu-
nology, Genetics and Pathology, Uppsala University, 3The Nordic Net-
work for Clinical Islet Transplantation, Uppsala, Sweden.
Background and aims: Therapies to promote the preservation and res-
toration of functional pancreatic β-cell mass are essential for the treatment
of type 2 diabetes (T2D). A major challenge for the development of such
therapies is the lack of adequate biomarkers to assess changes in β-cell
health with theraputic interveniton and disease stage. Monitoring β-cell
mass and function during the disease progression could lead to a better
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understanding of pathogenesis and an improved treatment. In this study,
proteomic analysis of human islets of Langerhans was carried out in order
to search for such biomarkers.
Materials and methods: Human islets and exocrine pancreatic tissue
were provided by the Nordic Network for Clinical Islet Transplantation.
One and two dimensional (2D) SDS-PAGE was used for separation of
islet and exocrine tissue extracts and the entire 1D gel lanes or the 2D gel
spots with two fold increased expression in islets, were subjected to in-gel
digestion. The resulting peptides were analyzed by liquid chromatogra-
phy FTICR mass spectrometry. Proteins were identified by searching
against the Swiss-Prot database using Mascot, requiring at least two
unique peptides, at 95% level of confidence for a valid protein identifi-
cation. Following in silico filltering for islet enriched expression using the
Human Protein Atlas, candidates were further investigated using Western
blotting (WB) and immunohistochemistry (IHC). Quantification of
Secretagogin (SCGN) levels in human plasma from age, body mass in-
dex, and gender matched T2D patients and healthy control subjects, pro-
vided by Uppsala University Hospital,was enabled by ELISA
(BioVendor).
Results: In the islet protein extracts, 1700 proteins were identified and
following in silico filltering for islet enriched expression, one of the can-
didate proteins, SCGN, were highly expressed in human islets both on
mRNA and protein level. Furthermore, WB also showed that the protein
was secreted into the culturing media with an indication that high glucose
(16.5 mM) exposure for 1 h resulted in higher intracellular levels and
reduced SCGN levels in the cell media. Double staining of human pan-
creatic tissue with SCGN and insulin showed co-localisation of the two
proteins, indicating that SCGN was predominantly expressed in β-cells.
Finally, ELISA allowed for the quantification of SCGN in plasma of T2D
patients (n=15) as well as in healthy subjects (n=16). Significantly in-
creased SCGN levels (p=0.03) could be observed in the diabetic patients.
Conclusion: To identify a circulating biomarker of β-cell mass offers a
challenge since the dispersed islets constitutes only 1-2% of the total
pancreatic mass, and the insulin producing β-cells even a smaller fraction
within the islets. This demands that a suitable biomarker must be highly
expressed and secreted mainly from the β-cells in order to reflect their
health, functional status or mass. SCGNmet these criterias and could also
be quantified in human plasma, suggesting a potential of SCGN as a β-
cell biomarker. However further studies will be required to determine
whether the increase of plasma SCGN reflects the mass of β-cells present
in the islets of T2D patients.
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Altered lipid metabolism preceding onset of islet autoimmunity and
type 1 diabetes
T. Marinkovic1, T. Hyötyläinen1, I. Mattila1, P. Pöhö2, M. Knip3, M.
Oresic1;
1SystemsMedicine, Steno Diabetes Center, Gentofte, Denmark, 2Univer-
sity of Helsinki, 3Children's Hospital, University of Helsinki and Helsinki
University Central Hospital, Finland.
Background and aims: Dysregulation of lipid and amino acid metabo-
lism has been shown to take place already prior to the first seroconversion
to islet autoimmunity in progression to Type 1 diabetes (T1D). Previously
we also observed by lipidomic analysis of cord blood that lipid dysregu-
lation is found in newborn infants who developed T1D early in life while
it is not associated with development of beta-cell autoimmunity in gen-
eral. In order to gain a global view of metabolome in progression to islet
autoimmunity and T1D, here we studied serum metabolome in children
from the DIABIMMUNE cohort, who seroconverted to one or more
autoantibodies and matched controls.
Materials and methods: Children were divided into four groups accord-
ing to the number of autoantibodies they developed during the follow-up:
12 children progressed to two or more islet autoantibodies (≥2 Aab)
group, 8 children developed one Aab persistently (1pAb), 21 children
developed one Aab transiently (1tAb). 81 children were controls matched
for gender, HLA genotype, country (Finland, Estonia) and date of birth.
Among the 12 children from ≥2 Aab group, four progressed to T1D. The
study included a longitudinal series of samples (cord blood, 3, 6, 12, 18,
24, 36 months of age) from three case groups and controls. Metabolomic
analysis of serum samples was performed by applying two global analyt-
ical platforms to study molecular lipids and polar metabolites, respective-
ly. The two metabolomics datasets (876 molecular lipids and 355 polar
metabolites) were clustered using the model-based clustering, which re-
sulted in 18 and 13 clusters of molecular lipids and polar metabolites,
respectively. Linear mixed effect models were applied at cluster level to
further analyze the metabolomics data. The fixed effects accounted for in
themodels were group effects at different time points, effect of age as well
as the effect of age of seroconversion to islet autoantibodies.
Results: The significant differences were mainly observed for the ≥2 Aab
and 1pAb groups, while 1tAb group tended to have very similar metab-
olite profiles as the controls. Specifically, in ≥2 Aab group, triglycerides
were downregulated at early age and lysophosphatidylcholines were up-
regulated, as compared to controls. In contrast, in the 1pAb group triglyc-
erides were upregulated while lysophosphatidylcholines were downreg-
ulated. No significant changes were observed for major membrane lipids
such as phosphatidylcholines (PC). Regarding metabolites, in ≥2 Aab and
1 Aab groups the cluster containing TCA cycle metabolites and metabo-
lites of branched chain amino acid (BCAA) metabolism (excluding
BCAAs themselves) was downregulated in cord blood. In ≥2 Aab group
this cluster remained downregulated while in the 1Aab group became
upregulated at about 2 years of age.
Conclusion:The childrenwho seroconvert to two ormore autoantibodies
(as well as to T1D) have markedly different metabolic profile from those
children who progress to a single islet autoantibody. Identification of the
underlying pathwaysmay lead to improved disease detection and to novel
clues for disease prevention.
Supported by: EU FP7 (202063), JDRF (2-SRA-2014-159-Q-R), Acade-
my of Finland (250114)
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Antigen-based immunotherapies do not prevent progression of auto-
immune diabetes: a systematic review and meta-analysis
E. Bekiari1, C. Rizava1, A. Liakos1, M. Sarigianni1, G. Nikolaidis1, M.
Rika2, P. Boura2, D.R. Matthews3, A. Galli-Tsinopoulou4, A. Tsapas1,3;
1Clinical Research and Evidence-Based Medicine Unit, Second Medical
Department, 2Second Medical Department, Aristotle University of
Thessaloniki, Greece, 3Harris Manchester College, University of Oxford,
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Background and aims: Antigen-based immunotherapies aim to attenu-
ate the destructive autoimmune process against pancreatic β-cells in pa-
tients with recent-onset autoimmune diabetes. We performed a systematic
review and meta-analysis to assess their efficacy and safety in tertiary
prevention of autoimmune diabetes.
Materials and methods: We searched in major bibliographic databases
(MEDLINE, COCHRANE, EMBASE), trial registries, conference pro-
ceedings and reference lists of included studies and relevant reviews, for
randomized controlled trials of antigen-based immunotherapies (GAD-
alum, Diapep277, oral insulin, nasal insulin, NBI-6024, insulin B-chain
fragment) in patients with recent-onset autoimmune diabetes (less
than 60 months after diagnosis or C-peptide levels after mixed
meal stimulation more than 0.2 nmol/L). Our primary outcome
was residual β-cell function by means of fasting and stimulated
(both glucagon and mixed meal) C-peptide. We also synthesised
data for change in HbA1c and daily insulin dose, incidence of any
and severe hypoglycaemic events, and incidence of severe adverse
events. Finally, we assessed risk of bias and graded the quality of
the body of evidence.
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Results:We identified 22 eligible studies, 15 of which were included in
the meta-analysis. Risk of bias was deemed high in 14 of them, while in
the remaining two it was unclear or low. Overall, there were no differ-
ences in fasting [weighted mean difference (WMD) 0.01 nmol/L; 95% CI
-0.09 to 0.11; I2=73%] or mixed meal stimulated (WMD 0.02 nmol/L/
min; 95% CI -0.08 to 0.12; I2=50%) C-peptide compared with placebo.
Glucagon stimulated C-peptide was maintained higher (WMD
0.13 nmol/L/min; 95% CI 0.05 to 0.21; I2=0%) in patients treated with
Diapep277. Moreover, there was no change in daily insulin dose (WMD
0.02 IU/kg; 95% CI -0.04 to 0.09; I2=51%) or HbA1c (WMD -0.06%;
95% CI -0.35 to 0.23; I2=42%) versus placebo. Finally, antigen-based
immunotherapies were not effective in reducing the incidence of severe
hypoglycaemic events. Nonetheless, there was no increase in the inci-
dence of severe adverse events (risk ratio 0.87; 95% CI 0.53 to 1.44;
I2=0%). The overall quality of the body of evidence was very low.
Conclusion: Antigen-based immunotherapies are not effective in
preventing the progression of autoimmune diabetes in newly-diagnosed
patients.
300
Residual beta cell function in diabetes children followed and diag-
nosed in the TEDDY study compared to controls
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Background and aims: Participation in prospective follow-up studies is
associated with a reduction in symptoms and ketoacidosis at diabetes
onset, but it is not known whether this close monitoring also leads to
better outcomes beyond diagnosis. We hypothesize that children diag-
nosed with type 1 diabetes through The Environmental Determinants of
Diabetes in the Young (TEDDY) study are diagnosed earlier in the time
course of diabetes and that they will have a higher level of C-peptide at
diagnosis compared with control children diagnosed through the
community.
Materials andmethods:TEDDY childrenwere enrolled at 3-4.5 months
of age and followed every 3 months for autoantibodies against insulin,
GAD65 and IA-2 and for the development of clinical diabetes. Control
subjects are matched to diabetic TEDDY subjects by age of diagnosis
within one year and have at least one islet autoantibody at diagnosis. After
diagnosis of type 1 diabetes, all participants undergo visits at diabetes
onset and then at 3, 6, 12, 18 and 24 months and annually thereafter. The
primary outcome measure is the AUC of C-peptide in response to a
Mixed Meal Tolerance Test (MMTT) over time. The goal is to follow
all subjects until the loss of detectable endogenous C-peptide.
Results: A preliminary analysis of 46 TEDDY and 43 control children
revealed that TEDDY children diagnosed with diabetes often had no
symptoms (58%) at onset and none had ketoacidosis (DKA) compared
to 100% with diabetes symptoms and 18% DKA in the controls. Mean
HbA1c was lower in TEDDY (6.4%) than control (7.6%) children (p<
0.0001). The TEDDY children had significantly higher residual C-
peptide AUC than the controls analyzed by a generalized linear model
with repeated measures (p=0.0062). The decrease in residual C-peptide
during follow up did not differ between TEDDYand control children (p=
0.1976).
Conclusion: The earlier diagnosis of type 1 diabetes in TEDDY children
studied so far appears to be associated with higher MMTT levels of
residual C-peptide. Although the loss of C-peptide may be parallel, it
remains to be determined whether early symptom-free diagnosis of dia-
betes has a long term benefit.
Supported by: NIDDK, JDRF
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Serum microRNAs as novel biomarkers for diagnosis of type 1 dia-
betes mellitus
L. Liu, D. Yang, J. Yan, H. Xu, W. Xu, B. Yao, J. Weng;
Department of Endocrinology,The Third Affiliated Hospital,Sun Yat-sen
University, Guangzhou, China.
Background and aims: New Strategies and biomarkers for early detec-
tion of type 1 diabetes mellitus (T1DM) are sorely needed. We aimed to
explore the diagnostic value of serum microRNAs (miRNAs) in newly
diagnosed patients with T1DM.
Materials and methods: Serum miRNA expression was investigated in
patients with T1DM (duration of diabetes≤1 year) and age-, gender-
matched healthy individuals recruited between August 2011 and
June 2014. Firstly, microarray was used to screen 2006 miRNAs in 6
T1DM patients and 6 healthy controls. Quantitative reverse-
transcriptase polymerase chain reaction assay (qRT-PCR) was then ap-
plied to evaluate the expression of differentially altered miRNAs. A lo-
gistic regression model was developed using a training cohort (character-
istics as shown in table). Area under the receiver operating characteristic
curve (AUC) was used to assess diagnostic accuracy. Finally, the model
was validated by leave-one-out cross-validation and another independent
validation cohort (characteristics as shown in table).
Results: Microarray analysis discovered that thirty-one serum miRNAs
were significantly different between T1DM patients and healthy controls
(fold expression change≥2, P<0.05). Six miRNAs (miR-642a-3p, miR-
320c, miR-1225-5p, let-7b-5p, miR-26b-5p, miR-144-3p) were verified
by qRT-PCR in the training cohort (P<0.05 for each). A logistic regres-
sion model combining miR-320c, miR-1225-5p, age and body mass in-
dex (BMI) was developed, which provided a high diagnostic accuracy of
T1DM (AUC=0.817 for training data set, 95% confidence interval 0.732-
0.904, P=0.000). The cross-validation error rate based on logistic regres-
sion models was 18.3%. The satisfactory diagnostic performance of the
model persisted in the validation cohort (AUC=0.804, 95% confidence
interval 0.688-0.921, P=0.000).
Conclusion: Our results identified a panel based on the expression of
serum miRNAs with considerable diagnostic value for T1DM. Further
research is necessary to explore whether these have clinical implications
for early detection of disease.
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Predicting islet cell death using miRNAs: small molecules giving big
insights
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Background and aims: Death of insulin-producing beta cells is a com-
mon feature of type 1 diabetes (T1D), including after islet transplantation
as well as Latent Autoimmune Diabetes of Adults (LADA) and type 2
diabetes (T2D). The death of these islet beta cells is a slow process that
commences several months-years prior to clinical onset of T1D. We cur-
rently lack tools to quantitatively detect islet cell loss prior to the clinical
onset of diabetes, or to predict the progression of established T1D.
MicroRNAs (miRNAs), a subset of small non-coding (nc)RNAs, are
promising biomarkers as i) some of these are significantly altered
in circulation between individuals with or without diabetes, ii)
show high stability in blood, iii) offer ease of detection and iv)
are resistant to freeze-thaw degradation. We identified a set of
ncRNAs that are either enriched in islet beta cells or differentially
expressed in individuals with diabetes. This set of ncRNAs, which
we refer to as the RAPID signature (RNA-based Analysis for
Predicting Islet Death) can potentially predict islet beta cell death
during diabetes progression.
Materials and methods: Next Generation Sequencing (NGS) and quan-
titative (q)PCR profiling studies were conducted on developing human
pancreases and adult islets. MicroRNAs in plasma from individuals with
newly diagnosed or established T1D, compared to age and gender
matched controls, were profiled on the OpenArray™ (OA) platform
followed by validation on ViiA7 platform.
Results: To determine the most reproducible high-throughput qPCR plat-
form on which to assess the RAPID signature, we undertook a robust
comparison of multiple nano- and micro-fluidics platforms (OA, Dynam-
ic Array® (DA), TaqMan Low Density Arrays/TLDAs and the standard
96-well (low throughput) platform on the ViiA7 system). Data from OA
was more reproducible (median assay CV 2.1%) than DA and best cor-
related with the 96-well platform (R2=0.88). We therefore used OA
platform for future assays. NGS and qPCR studies identified 20 miRNAs
that are enriched during pancreas development and remain highly
expressed in adult islets. Twenty four other miRNAs were identified to
be differentially expressed (fold change >2, P-value <0.05) in individuals
with T1D, compared to age and gender matched controls (see Fig. 1).
Validation of the above selected miRNAs in multiple T1D individuals (vs
controls) will lead to refining the RAPID signature into a minimal set of
miRNAs that can reliably measure the death of islet beta cells and diabe-
tes progression.
Conclusion: Our studies will inform medical researchers and clinicians
as to how to predict the development of T1D, and monitor response to
interventions such as islet transplantation, vaccines and drugs that aim to
retard beta cell loss or promote beta cell regeneration, and also guide the
development of new treatments to lessen the burden of diabetes.
Supported by: Funding to AAH from NHMRC and JDRF Clinical Trials
Network, Australia.
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A toddler with type 2 diabetes
M. Yafi, K. Collins;
Pediatric Endocrinology, The University of Texas, Houston, USA.
Background and aims: Type 2 Diabetes Mellitus continue to be a major
health problem related to pediatric obesity. Early identification of pediat-
ric patients at risk, prompt diagnosis and early therapy are major factors to
partial reversal of the disease.
Materials and methods:We present a case report of early onset of Type
2 Diabetes in a 3 year-old child with description of the clinical course.
Results: A 3 ½year-old Hispanic female presented to the pediatric endo-
crinology clinic for evaluation of obesity. She had symptoms of polyuria
and polydipsia. Her past medical history was unremarkable. She was born
full term. Birth weight was 3.2 kg. Her family history is significant for
obesity in parents with no history of diabetes. Diet review revealed poor
family nutritional habits with uncontrolled counting of calories and fat.
On physical examination, weight was 35 kg (>95 percentile) and height
was 95% percentile. Her BMI was also 95% for age. The patient had no
cushinoid features, no thyromegaly and her Tanner Stage was I.
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Laboratory tests revealed: Fasting plasma glucose 230 mg/dl (12.6 mmol/
l) hemoglobin A1C 7.2% insulin 48.8 ulu/ml (339 pmol/L )(normal range
0-29.1uiu/ml, 0- 202 pmol/L) C-peptide 6.9 ng/nl 2.2 nmol/L (normal
range 0-3.3, 0- 1.09 nmol/L). Lipid and liver panels were normal. Im-
mune markers for Type 1 Diabetes were negative. Based on symptoms,
physical findings of obesity and laboratory results the diagnosis of Type 2
Diabetes was made. The patient was started on liquid Metformin 500 mg
daily. Diabetes and nutritional education were performed. We asked the
family to implement lifestyle modification by controlling their food por-
tions, total caloric intake and increased physical activities. The patient
made significant improvement in weight reduction that lead to normali-
zation of blood glucose levels. The Metformin therapy was decreased by
50% each month, and then stopped. Six months after diagnosis, the pa-
tient was at 75% of weight, had normal blood glucose levels, hemoglobin
A1C of 5.3% and was off therapy.
Conclusion: Reversal of type 2 diabetes in children is possible by:
1. Early screening of obese children
2. Early diagnosis
3. Appropriate therapy
4. Lifestyle modification
PS 006 Physical activity and other life
style factors affecting glycaemia
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Physical activity in a large cohort of insulin-treated type 2 diabetes
patients: PROGENS ARENA study
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Background and aims: Data from multiple studies present a consistent
picture indicating that regular physical activity substantially reduces the risk
of type 2 diabetes mellitus (T2DM). Additionally, in subjects with a diagno-
sis of T2DM, exercise helps to increase insulin sensitivity, control weight,
and improve cardiovascular risk profiles. Unfortunately, the level of physical
activity seems to be low among T2DM individuals. Moreover, it was sug-
gested that starting insulin therapy may be associated with an even further
decrease in physical activity. We aimed to estimate the level of physical
activity in a large cohort of insulin-treated T2DM patients. All of them were
participants of the PROGENS ARENA study which was designed to assess
the role of behavior-oriented educational intervention in T2DM.
Materials andmethods: There were 2500 insulin treated T2DM patients
(55.41% women) included into the study. The mean age of the study
participants was 64.92±9.31 years, mean BMI 31.44 kg/m2±4.49, mean
diabetes duration 12,43±6.86 years, mean baseline HbA1c 8.46% ±1.21.
All the patients used both prandial and basal insulins. The proportion of
subjects using prandial short acting human insulin was 50.27%, others
used rapid acting insulin analogues (in the model of multiple daily injec-
tions or as a component of a pre-mixed regimen). At the study onset all
the patients filled out a questionnaire concerning health-oriented behav-
iors including physical activity.
Results: Only 57.4% of examined T2DM patients (51.79% women and
64.36% men) declared any form of deliberate physical activity. Most of
the group (82.33%) reported a minimal level of exercise, such as walk or
seasonal garden activities. Only 17.4% of patients declared moderate
physical activity (swimming, jogging, biking); it is of note that this level
of activity was declared more often by men than women (24.88% vs
11.37%). Intense exercise (including participation in sport competitions)
was reported only by 0.27% of the study participants. The majority of
T2DM patients declared undertaking any form of deliberate physical
activity only 1-2 times per week, exercise was performed on daily basis
only by 22.26% of T2DM patients.
Conclusion: Insulin-treated T2DM patients are characterized by a very
low level of physical activity. The subject of exercise should be consid-
ered a very important target in diabetes education.
Supported by: Bioton company
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Physical activity in patients with type 2 diabetes and hypertension:
insights into motivations and barriers from the MOBILE study
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Background and aims:While Physical Activity (PA) is key in the man-
agement of type 2 diabetes (T2DM) and hypertension, it is difficult to
implement in practice and many patients do not achieve recommended
levels of PA.
Materials and methods: Cross sectional, observational study conducted
in 2014 in France. Participating physicians (cardiologists and diabetolog-
ists) were asked to recruit two physically-active and four inactive patients,
screened with the Ricci-Gagnon self-questionnaire (active if score ≥16).
Patients subsequently completed the validated IPAQ-SF self-question-
naire, as well as all the physicians to assess their own level of PA. The
objective was to evaluate the achievement of an individualized HbA1c
target and blood pressure goal (<140/90 mmHg) in the active vs. inactive
cohort, to explore the correlates for meeting both targets by multivariate
analysis, and to examine the barriers and motivations to engage in PA as
expressed by active and inactive patients.
Results: 1766 patients were analyzed. Active (n=628) vs. inactive (n=
1138) patients were more often male, younger, less obese, had shorter
durations of diabetes, fewer complications and other health issues, such as
osteo-articular disorders (p <0.001 for all). Their diabetes and hyperten-
sion control was better and obtained despite a lower treatment burden.
The biggest difference in PA between the active vs. inactive patients was
the percentage of patients who declared engaging in regular leisure-type
PA (97.9% vs. 9.6%), also reflected in the percentage with vigorous
activities in IPAQ-SF (59.5% vs. 9.6%). Target glycemic and blood pres-
sure control was achieved by 33% of active and 19% of inactive patients
(p<0.001). In multivariate analysis, active patients, those with fewer bar-
riers to PA, with lower treatment burden, and with an active physician,
were significantly more likely to reach the combined glycemic and blood
pressure goal. Having an active physician was the strongest correlate:
participants were 4 times more likely to be at targets vs. those with an
inactive physician. The physician’s role also emerged in the motivations
(reassurance on health issues, training on hypoglycemia risk, and direct
prescription and monitoring of the PA by the physician). A negative self-
image was the highest ranked barrier for the inactive patients, followed by
lack of support and encouragement, and by medical concerns and fear of
injury.
Conclusion: Physicians should consider PA prescription as seriously as
any drug prescription, with the same need to monitor compliance and the
response-effect, and take into account motivations and barriers to PA to
tailor advice to patients’ specific needs and reduce their perceived
constraints.
Supported by: Novartis
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Physical activity and the incidence of diabetes: evidence from the
China Kadoorie Biobank study
D.A. Bennett1, L. Li2, H. Du1, Y. Gou3, Z. Bian3, J. Chen4, Z. Chen1;
1Nuffield Department of Population Health, University of Oxford, UK,
2Department of Epidemiology and Biostatistics, Peking University, 3Chi-
nese Academy of Medical Sciences, 4China National Center for Food
Safety Risk Assessment, Beijing, China.
Background and aims: The estimated prevalence of diabetes in China is
high and increasing. Higher physical activity is associated with decreased
risk of diabetes in Western populations, but evidence from Chinese pop-
ulations is limited.Moreover, most previous studies have assessedmainly
recreation- related physical activity rather than total activity from different
domains.
Materials and methods:We analysed prospective data of over 0.5 mil-
lion people aged 30-79 years who were recruited into the China Kadoorie
Biobank Study from 10 areas in China. Information about the frequency,
duration and type of activity was collected via a questionnaire and an
estimate of intensity in metabolic equivalent of task (MET) was assigned
to each activity based on the literature. Physical activity was calculated as
MET hours per day (MET-h/d) spent on work, commuting, housework,
and non-sedentary recreational activities. Data on diabetes incidence was
collected via linkage with mortality and morbidity registries and the na-
tional health insurance system. After excluding individuals with a prior
history of cardiovascular disease or diabetes (including screen detected) at
baseline, Cox regression models were used to yield hazard ratios (HRs)
relating physical activity to diabetes risk adjusting for age, sex, study area,
body mass index and other potential confounding factors. The HRs were
corrected for ‘regression dilution bias’ using a self-correlation (~0.52) for
MET-h/d ascertained from a re-survey of about 20,000 individuals con-
ducted on average 3 years later to ascertain the association with “usual”
physical activity.
Results: The study population included 463,347 participants (59%
female; mean age 51 years; mean physical activity 21.8 MET-h/
d). During 7-years of follow-up there were 8866 incident diabetes
events recorded. There was a strong inverse association of “usual”
physical activity with risk of incident diabetes with a log-linear
dose-response relationship. Comparing the highest (≥40 MET-h/d)
with the lowest (<8 MET-h/d) physical activity group, there was a
27% lower (95% CI: 18%, 36%) risk of diabetes. Each usual 4
MET-h/d increase, (approximately an hour of brisk walking per
day), was associated with 2.7% (95%CI: 1.4%, 4.1%) risk reduc-
tion. The associations did not change materially after exclusions
of individuals with other prior chronic diseases, exclusion of the
first two years of follow-up, and varied little across different
subgroups of participants.
Conclusion: In Chinese adults, higher usual physical activity was asso-
ciated with a lower risk of diabetes. These findings suggest that targeted
strategies to increase levels of physical activity in China could have a
major health impact.
Supported by: MRC, BHF
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Evolution of physical activity patterns and subsequent type 2 diabe-
tes risk: results from the E3N-EPIC cohort study
G. Fagherazzi1, G. Gusto1, A. Affret1, S. Neqqache1, B. Balkau2, F.
Clavel-Chapelon1, F. Bonnet1,3;
1Lifestyle, genes and health, Inserm, 2Inserm, VILLEJUIF, 3CHU,
Rennes, France.
Background and aims: Physical activity (PA) is themainmodifiable risk
factor to prevent or postpone type 2 diabetes mellitus (T2DM). However,
the association between the evolution of PA and subsequent risk of
T2DM is not well known. The aim of this study was to evaluate the
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association between 5-year changes in patterns of PA and T2DM inci-
dence in the large E3N-EPIC cohort study.
Materials andmethods: The study population was constituted of 60,992
women followed from 1997 to 2008. During the follow-up, 1,982 cases if
T2DMwere observed. Mutually exclusive patterns of PAwere construct-
ed using latent class analysis (LCA) and latent transition analysis (LTA).
The associations between the 5-year evolutions (from 1993 to 1997) of
PA patterns and incident T2DM were assessed by multivariate Cox
models. Results were expressed as risk ratios (RR) and 95% confidence
intervals.
Results: Four PA patterns were identified: «high PA level», «moderate
PA level», «gardening/do it yourself» and «low PA level». Between 1993
and 1997, a total of 10,952 women (18%) increased somehow their levels
of PA. After adjustment for established risk factors of T2DM and strati-
fication on body mass index (BMI), maintaining a high level of PAwas
associated with a decrease of T2DM incidence when compared to women
who stayed at a low level of PA (RR=0.77 (0.60-0.99) and 0.71 (0.58-
0.87) for women with a BMI lower than or higher than 25 kg/m2 respec-
tively). Increasing the level of PA between 1993 and 1997 was associated
with a borderline decreased risk in both strata of BMI (RR=0.89 (0.73-
1.10) and 0.89 (0.77-1.03) for women with a BMI lower than or higher
than 25 kg/m2 respectively).
Conclusion: Using an innovative method in T2DM epidemiology, asso-
ciations between evolutions of PA patterns and T2DMwere quantified for
the first time in such a large population.We have found that maintaining a
high level of PA over time was associated with a decreased risk of T2DM,
independently of BMI.
Supported by: Fondation Coeur et Artères, VITADIAB Project
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Lower mortality with physical activity in type 1 diabetes of extreme
duration: Joslin 50-Year Medalist study
S.A. D'Eon, D.M. Pober, L.J. Tinsley, S.M. Hastings, G.L. King, H.A.
Keenan;
Vascular Cell, Joslin Diabetes Center, Boston, USA.
Background and aims: Physical activity (PA) is often discussed as a
crucial aspect of type 1 diabetes management, however, very little is
understood about the effect of PA on mortality in those with the disease.
This analysis examines the association in a unique group of individuals
who have had type 1 diabetes for 50 or more years (the Joslin 50-Year
Medalists).
Materials and methods:All Medalists (n=955, 54.1% female) provided
documentation of 50 years of insulin dependence, resided in the US, and
were examined at the Joslin Diabetes Center. The median HbA1c was
7.1%, age 65.0y, duration of diabetes 53.0y, age at onset 11.0y, with a
median BMI of 25.6 kg/m2 and daily insulin dose of 0.4 U/kg. PA was
assessed by self-report and validated by the Paffenbarger Questionnaire.
Results: Medalists who reported being physically active (77.5%) had a
significantly lower HbA1c (7.1 v 7.2%, p<0.01), BMI (25.3 v 27.4 kg/
m2, p<0.0001),) and triglycerides (64.0 v 73.5 mg/dL, p<0.001). Addi-
tionally, those reporting PA had higher eGFR (72.7 v 66.4 mL/min/
1.73 m2, p<0.01) and HDL-C (64.0 v 57.0 mg/dL, p<0.0001) levels.
The rates of cardiovascular disease (CVD) (37.1 v 48.9%) and nephrop-
athy (10.3 v 21.0%) were significantly different in the active group com-
pared to the inactive group (p<0.01 and p<0.0001, respectively). Prolif-
erative diabetic retinopathy and neuropathy were not significantly differ-
ent (p>0.05). Ten percent (n=99, 42.4% female) of Medalists have
passed away, 61 (61%) of whom reported being physically active. Among
these individuals median age (74.0 v 64.0y, p<0.0001), age at diagnosis
(12.0 v 11.0y, p<0.01), duration (57.0 v 52.0y, p<0.0001), HbA1c (7.2 v
7.1%, p=0.05), and eGFR (53.5 v 73.7 mL/min/1.73 m2, p<0.0001),
were significantly different than the rest of the cohort. Prevalence of
neuropathy, nephropathy, and CVD were higher in the deceased group
(p<0.05). The most frequent cause of death was CVD (n=42), followed
by cancer (n=9), end-stage renal disease (n=5), and accidents (n=5). We
investigated the influence of PA onmortality byCox proportional hazards
regression. The group crude hazard ratio (HR)=0.47, (95%CI 0.31, 0.72)
for PA compared to non-PA indicates a substantial protective effect. After
adjusting for potential covariates including, age, sex, HbA1c, history of
CVD, nephropathy, and use of antihypertensives, PA remained indepen-
dently associated with protection from all-cause mortality (HR=0.50,
95%CI 0.31, 0.78). To counter the possibility of reverse causality we
duplicated analyses without subjects who passed awaywithin 1 or 3 years
of enrollment into the study and found similar results.
Conclusion: This longitudinal analysis confirms that PA is associated
with increased survival probability independent of other factors in an
aging population of older type 1 diabetic individuals, providing evidence
of PA as an important means of reducing the burden of mortality in this
population.
Supported by: NIH JDRF
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Skin autofluorescence is related to tobacco smoke and nicotine
exposure
R.P. van Waateringe1, M.J. Mook-Kanamori2,3, S.N. Slagter1, M.M.
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Medical College, Doha, Qatar, 3Department of Biostatistics, Epidemiol-
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cialist Hospital and Research Center, Riyadh, Saudi Arabia, 4Bioinfor-
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Background and aims: Tobacco smoke has been found to be an exog-
enous source of reactive glycation products. Skin autofluorescence
(SAF), reflecting advanced glycation endproducts (AGE) accumulation
in the skin, has been shown to predict diabetes-related cardiovascular
complications and is higher among smokers compared to non-smokers.
In the present study, we examined the association of different smoking
behaviors and nicotine exposure with SAF using both epidemiological
and metabolomics data.
Materials and methods: We used a large population-based dataset
from the LifeLines Cohort Study and metabolomics data from the
Qatar Metabolics Study of Diabetes (QMDiab). Smoking behavior
and exposure to tobacco smoke from others (secondhand smoking
(SHS)) were assessed in a questionnaire in 9,009 individuals in-
cluding 314 individuals (3.5%) with type 2 diabetes (T2DM) par-
ticipating in the LifeLines Cohort Study. In QMDiab nicotine
exposure was measured in saliva, plasma and urine in 374 indi-
viduals of whom 190 individuals (51%) with type 2 diabetes.
SAF was measured non-invasively in all individuals using the
AGE Reader.
Results: Urinary cotinine N-oxide, a marker of nicotine exposure, was
found to be positively associated with SAF in QMDiab (p=0.03). HbA1c
(p=0.010) and type 2 diabetes (p<0.0001) were most strongly associated
with higher SAF levels among former and current smokers participating
in the LifeLines Cohort Study. We observed a gradual increase in SAF
with the number of hours being exposed to SHS. SAF levels of former
smokers decreased to levels of never smokers after 15 years of smoking
cessation (Figure 1).
Conclusion: We have demonstrated that tobacco smoke exposure,
assessed by questionnaire as well as by cotinine N-oxide in urine, is
significantly associated with SAF. Both active smoking and exposure to
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secondhand smoking are associated with higher SAF levels. Smoking
cessation has beneficial effects on SAF levels.
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Association between diabetes and exposure to pesticides: a systematic
review and meta-analysis
G. Ntritsos1, F.K. Kavvoura2,3, M. Chondrogiorgi1, E.E. Ntzani1,4, I.
Tzoulaki5,1, E. Evangelou1,5;
1Department of Hygiene and Epidemiology, University of Ioannina,
School ofMedicine, Greece, 2Oxford Centre for Diabetes, Endocrinology
&Metabolism (OCDEM), 3Oxford National Institute for Health Research
(NIHR) Biomedical Centre, UK, 4Centre for Evidence-Based Medicine,
Brown University, Providence, USA, 5Department of Biostatistics and
Epidemiology, Imperial College London, UK.
Background and aims: Diabetes mellitus is a worldwide epidemic, cur-
rently affecting more than 350 million people and expected to reach 550
million by 2050. It represents a major global public health challenge.
Diabetes aetiology is considered to be an interplay between genetic and
environmental factors. Emerging evidence suggests that environmental
contaminants, including pesticides play an important role in the patho-
genesis of diabetes. We performed a systematic review of observational
studies that assessed the association between exposure to pesticides and
diabetes.
Materials and methods: A comprehensive literature search of peer-
reviewed original research pertaining to pesticide exposure and any health
outcome, published until December 2014, with no language restriction,
was conducted. The association between exposure to any pesticide and all
types of diabetes was examined. Separate analyses for studies that recruit-
ed only Type 2 diabetes (T2D) participants were performed. Odds ratios
(OR) using fixed and random-effects models were calculated. Random
effects are reported in view of the presence of heterogeneity. Risk esti-
mates were transformed in order to be comparable across studies. Hetero-
geneity was assessed using the I2 (0-100%).
Results:We identified 21 studies assessing the association between pes-
ticides and diabetes, in a total of 66,714 individuals (5,066 cases/ 61,648
controls). Most studies did not report the specific diabetes type. The
summary OR for the association of the exposure to any type of pesticide
and diabetes was 1.61 (95% CI: 1.33-1.95, p=9×10−7), with large het-
erogeneity (I2=68.2%). Studies evaluating T2D only (n=12 studies),
showed a similar summary effect 1.64 (95% CI 1.39-1.92, p=2×10−9)
however heterogeneity disappeared (I2=0%). Analysis by type of pesti-
cide showed an increased risk with less heterogeneity (I2=0-87%). The
summary effects ranged from 1.19 (95%CI: 1.05-1.35, p=0.007, I2=0%)
for the exposure to chlordane, up to 2.34 (95%CI: 1.53-3.59, p=9×10−5,
I2=43.7%) for exposure to trans-nonanchlor. The study type and the
measurement of the exposure did not affect the effect estimate. Egger’s
test was significant suggesting the presence of small-study effects. High
heterogeneity was attributed mainly to the synthesis of observational
studies.
Conclusion: This systematic review supports the hypothesis that expo-
sure to various types of pesticides increases the risk of diabetes. Subgroup
analyses did not reveal any differences in the risk estimates based on the
type of studies or the measurement of the exposure. Analysing each
pesticide separately reduces heterogeneity and the different effect sizes
suggest that some pesticides are more likely to contribute to the develop-
ment of diabetes than others.
Supported by: EFSA, NIHR
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Diabetes mellitus as a risk factor for community-acquired pneumo-
nia in hospital admissions
M. Martins1,2, J.M. Boavida2, J.F. Raposo1,2, F. Froes3, B. Nunes4, R.T.
Ribeiro1,2, M. Macedo1,2, C. Penha-Gonçalves5;
1NOVA Medical School / Faculdade de Ciências Médicas (MEDIR
Group), Universidade NOVA de Lisboa, CEDOC, Chronic Diseases Re-
search Center, 2APDP - Diabetes Portugal (Education and Research Cen-
tre/APDP-ERC), 3Service of Pneumology, Hospital Pulido Valente,
Centro Hospitalar Lisboa Norte, , 4Department of Epidemiology, Instituto
Nacional de Saúde Dr. Ricardo Jorge, Lisbon, 5Instituto Gulbenkian de
Ciência, Oeiras, Portugal.
Background and aims: Respiratory infections are frequently associated
with diabetes mellitus (DM). Health Authorities and Medical Societies
recommend several general measures (e.g., smoking cessation and con-
trol of chronic illnesses), as well as flu and pneumococcal vaccination of
people with DM. Portugal has one of the highest prevalence rates of DM
within the European context. We have therefore, carried out a retrospec-
tive, nation-wide register analysis of hospitalized patients that aimed to
estimate the prevalence of DM among community-acquired pneumonia
(CAP) patients and evaluate the impact of DM in hospital length of stay
and in-hospital mortality.
Materials and methods: Anonymized data from 157,291 CAP adult
patients referring to the period 2009-2012 were extracted from the Na-
tional Hospital Discharge Database of DRGs (Diagnostic-Related
Groups). Patients included in the study had CAP as main diagnosis on
admission within the age range 20-79 that matched the PREVADIAB -
National Prevalence Study. Data for analysis were clean from double
entries, day cases and hospitalizations >90 days. We also excluded indi-
viduals with HIV and with iatrogenic immunosuppression. Nation-wide
DM statistics from 2009 to 2012 were collected from the PREVADIAB
study.
Results: Within the 74,175 CAP episodes that matched the inclusion
criteria we found a high burden of DM that tended to increase over time,
from 23.7% in 2009 to 28.1% in 2012. Importantly, the DM prevalence in
CAP patients was significantly higher when compared to the national DM
prevalence (P<0.0002), particularly in women.We found that episodes of
CAP in DM patients had in average 0.8 days longer hospital stay as
compared to patients without DM (P<0.0001) totalling an estimated
15,370 days of stay attributable to DM in 19,212 CAP admissions. In-
hospital mortality was also significantly higher in CAP patients that have
DM (15.2%) vs without DM (13.5%) (P=0.002).
Conclusion: Taken together, our data show a significant increase in the
prevalence of DM in subjects hospitalized with CAP reinforcing the
relevance of DM as a risk factor for CAP. This longitudinal study pro-
vides indications that DM patients acquiring CAP are older, have longer
hospitalization time and have higher mortality rates than CAP patients
without DM. Importantly, our study also highlights that the relative im-
pact of diabetes was greatest in younger adults (20-39 years) and in
women. Thus, this nation-wide study identified people with DM as a
priority group for adoption of general measures to prevent CAP, and more
specifically for flu and prophylactic pneumococcal vaccination. These
results have informative value for strategies of patient awareness and
future healthcare guidance, particularly for people with diabetes under
40 years and for DM women.
Supported by: a Pfizer Grant to Ernesto Roma Foundation
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Influenza in patients with diabetes and obesity: vaccine effectiveness
against hospitalised influenza and complications after hospitalised
influenza-like illness
F. Galtier1,2, P. Loulergue3,2, P. Vanhems4,2, X. Duval5,2, S. Jouneau6,2,
D. Postil7,2, F. Letois1, N. Lenzi2, C. Merle8,2, F. Carrat9,2, O. Launay3,2;
1CIC 1411, CHRU & Inserm, Montpellier, 2Inserm, FCRIN I-REIVAC,
3CIC 1417, APHP & Inserm, Paris, 4GH Edouard Herriot, Lyon, 5CIC
1425, APHP & Inserm, Paris, 6CIC 1414, CHRU & Inserm, Rennes,
7CIC 1435, CHRU & Inserm, Limoges, 8MIT, CHRU, Montpellier,
9Inserm, UMR-S 707, Paris, France.
Background and aims: Diabetic subjects are at risk for influenza com-
plications, and vaccination has long been recommended in this population
in France. Recent data show that the same applies to obese subjects, and
recent French recommendations are to vaccinate subjects with a BMI≥
40. Since 2012-13, we have conducted multicentre test negative case
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control studies to estimate influenza vaccine effectiveness (IVE) against
hospitalized laboratory confirmed influenza in Europe. A sub-analysis
performed on the data from 6 hospitals in France considered the results
among subjects with diabetes (DM) and obesity (Ob).
Materials and methods: During the 2012-13 and 2013-14 seasons, we
swabbed all patients hospitalized for influenza related illness, aged≥18,
and reporting an influenza-like illness (ILI) within 7 days before admis-
sion (cases: PCR positive for influenza; controls: negative for any influ-
enza virus). Influenza vaccination was recorded. By logistic regression
we calculated IVE by influenza subtype (adjusted for age, sex and num-
ber of children) and risk factors for complications (adjusted for age, sex,
influenza infection, vaccination, DM and Ob).
Results: Among the 848 patients included, influenza was confirmed in
253. IVE was 69% (95% IC: 38-84, P<0.001) and 40% (95% IC: 01-64,
P<0.05) in the 2012-13 and 2013-14 seasons, resp. DM or Ob was pres-
ent in 286 subjects (DM: 197; Ob: 152; both: 63), influenza was con-
firmed in 85/286, and vaccine coverage was 54%, 45% and 44% in DM,
Ob and other subjects, resp. (P=0.05). Subjects with DM were older
(DM: 71±17; Ob: 61±18; both: 69±12; other: 65±20, P=0.001). Overall
adjusted IVE in subjects with DM or Ob was 55% (95%CI: 19-75, P<
0.01). Table 1 shows IVE according to virus subtype, metabolic disease
and season. Complications during hospitalizations for ILI were respirato-
ry failure (N=160), heart failure (N=100), renal failure (N=79) and death
(N=27). In multivariate analysis, renal failure was associated with DM
(OR 2.57, 95%CI: 1.55-2.48, P <0.001) and Ob (OR 1.73, 95%CI: 0.99-
3.03, P=0.05). Heart failure was associated with age (65-74: OR 2.57,
95%CI: 1.28-5.16, P=0.008); ≥75: OR 4.15, 95%CI: 2.26-7.64, P=
0.0001), Ob (OR 1.76, 95%CI: 1.04-3.00, P=0.03) and DM (OR 1.55,
95%CI: 0.99-2.51, P=0.07). Respiratory failure, death and length of in-
patient stay were not associated with DM or Ob.
Conclusion: In patients with DM or Ob, IVE is similar to that reported in
general population. However vaccine coverage is insufficient, especially
in Ob. DM and Ob increase the risk of cardiac and renal complications in
subjects hospitalized with ILI.
Clinical Trial Registration Number: NCT01764152 & NCT02027233
Supported by: Sanofi-Pasteur MSD
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Direct medical costs of severe hypoglycaemic events amongst type 2
diabetes patients in the UK: a retrospective database study
K. Tunceli1, T. Holbrook2, J. Williams1, R. Shankar1, J. Chen1, L.
Radican1, J. Piercy2;
1Merck & Co. Inc, Kenilworth, USA, 2Adelphi Real World, Manchester,
UK.
Background and aims: Hypoglycaemia is a common complication in
type 2 diabetes mellitus (T2DM) patients. Treatments raising insulin
levels independently of blood glucose, such as oral insulin secretagogues
(sulfonylureas and glinides) and exogenous insulin, can increase the risk
of hypoglycaemia. This study aims to provide an up to date estimate of
the direct medical costs of severe hypoglycemic events amongst T2DM
patients to the UK healthcare system.
Materials and methods: A retrospective cohort design was undertaken
with linked UK Clinical Practice Research Datalink (CPRD) and Hospital
Episodes Statistics (HES) databases, selecting patients initiated on any
mono, dual, or triple combination therapies for treatment of T2DM be-
tween 2008 and 2012, and observing severe hypoglycemic events and
costs estimated up to end of regimen +90 days, or end of recorded data
(minimum of 1 day, maximum 6 years). All patient characteristics were
described at treatment initiation for mono, dual, or triple combination ther-
apies. Severe events were defined as events requiring hospital treatment
with hypoglycaemia-specific diagnosis or procedure code. Costs were es-
timated using Healthcare Resource Groups (HRGs version 4) and tariffs
derived from the National Tariff 2013-14, and primary care follow-up
appointment costs using Personal Social Services Research Unit
(PSSRU) 2014, and drug prescription costs using Prescription Cost Anal-
ysis for England 2008-13. Results from the linked sample were extrapolat-
ed using the full HES census dataset to provide national cost estimates.
Results: There were 857 severe events observed, with a mean observa-
tion period of 510; 522; 503 days (mono, dual, triple therapy respectively,
regardless of regimen), among 60,335; 31,610; 10,298 patients identified
in the linked sample. 56; 58; 61% of admitted patients were male, with a
mean age of 63.8; 62.4; 61.2 years in three groups. Mean diabetes dura-
tion at admission was 3.0; 5.6; 7.3 years in the three groups, with a mean
HbA1c of 7.7%; 8.3%; 8.8%. The event rate was 5.3; 7.0; 6.6 per 1000
patient-years in the three groups with a mean per-event secondary care
cost of £3,558; £3,477; £2,989, and primary care follow-up cost of £56
per event in each group. Extrapolating to national data (17,622 episodes
observed in full 2013-14 HES data), estimated national cost to the NHS
per year was £61,193,413.
Conclusion: Severe hypoglycemic events impose a substantial burden
upon the NHS. Further research is required to quantify the extent to which
events could be prevented, and the associated potential cost savings to
NHS budgets.
Supported by: Merck & Co. Inc.
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Towards a better understanding of acute post-prandial
hyperglycaemic episodes: a patient perspective
S. Heller1, C.E. Kosmas2, N. Kragh3, A. Nikolajsen3, A.J. Lloyd2;
1School of Medicine and Biomedical Sciences, University of Sheffield,
2Patient Reported Outcomes, ICON plc, Oxford, UK, 3Novo Nordisk,
Bagsvaerd, Denmark.
Background and aims: Prolonged or severe episodes of hyperglycaemia
have been associated with the development of micro- and macrovascular
long term complications such as neuropathy and atherosclerosis. Previous
studies have demonstrated comparable effects of acute hyperglycaemia
on cognitive function and mood to hypoglycaemia. This study aimed to
explore the impacts of acute post-prandial hyperglycaemia (PPHG) on
health-related quality of life in people with insulin-dependent diabetes
mellitus.
Materials and methods: Twenty-four adults (≥18 yrs) with Type 1 (n=
14) and Type 2 (n=10) insulin-dependent diabetes took part in a qualita-
tive study. Data were collected via one-to-one telephone interviews in the
US (n=10) and two focus groups in the UK (n=14). The study was
reviewed and approved by an independent ethics board and participants
provided written informed consent. Interviews and focus groups were
audio-recorded and transcribed verbatim. Anonymised transcripts were
analysed using a thematic analysis approach, supported by qualitative
software (MAXQDA).
Results: A number of common themes were identified associated with
participants’ awareness and experience of acute PPHG (such as variabil-
ity, frequency and duration). Some participants felt that the food eaten and
activities undertaken had an effect on the speed with which glucose rose
and the time taken for glucose levels to return within normal range.
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Increased thirst and frequency/urgency of urination, tiredness, feeling
lethargic and suddenly hot and sweaty were consistent symptoms when
discussing PPHG. Other symptoms included dizzy spells and “foggi-
ness”, impaired concentration and difficulty thinking quickly. Some par-
ticipants worried about these symptoms and found them “unnerving”.
Participants’ perceived physical and cognitive impacts of acute PPHG
could affect their work and perceived ability to drive. Experiences of
acute PPHG episodes also prompted changes in behaviour including
avoiding social events, leaving early or avoiding them altogether, arrang-
ing with employers to take breaks in the working day and constant worry
that resulted in restrictive diets. Anxieties about PPHG episodes were
most frequently related to concerns that repeated episodes could have
on long term health. Some participants expressed particular fears that
severe and long lasting episodes (compared to short lived “routine” pe-
riods of PPHG) would lead to diabetic complications.
Conclusion: This study advances our understanding of the every-day
impact of acute PPHG on individuals with diabetes, which to the authors’
knowledge has not been previously explored using qualitative methods.
Analysis of the interview transcripts provided rich insight into partici-
pants’ experiences of PPHG. The data will be used to guide development
of a self-reported outcome measure of the impact of PPHG, to allow a
more systematic and quantitative study involving a larger sample.
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Hospital incidental diagnosis of diabetes: a population study
P. Francesconi1, F. Profili1, L. Policardo1, R. Anichini2, G. Seghieri1;
1Epidemiology, Agenzia Regionale Sanità, Florence, 2Diabetes Unit,
Ospedale S.Jacopo, Pistoia, Italy.
Background and aims: Uncertainty remains on how the diagnosis is
being made of new, not previously identified, incident diabetes. Newly
diagnosed diabetes, has been, indeed, mainly identified after admission to
intensive care units or after hospitalizations due to acute cardiovascular
events and seems to bring about, in such conditions, an excess risk of fatal
events. Purpose of this study was to present a new method apt to identify
incidentally diagnosed diabetes (IDD) among a large population of hos-
pital discharged patients, determining, moreover, their risk ofmortality, as
compared with that of subjects with known diabetes (KD).
Materials and methods:Among 214,991 individuals discharged in year
2011 from both medical and surgical wards of all hospitals of Tuscany,
Italy we identified IDD when all these conditions were satisfied: a.: ab-
sence in the regional diabetes registry, b.: no previous hospital discharge
with main or secondary diagnosis of diabetes (ICD-9-CM 250.xx), c.: no
past prescriptions of glucose lowering drugs (GLD) (ATC class A10A or
A10B), d.: no evidence of legal certifications including those enabling
patients to free prescriptions of consumables, clinical chemistry tests,
specialists’ consultations related to the diabetic condition. Diagnosis of
incidental diabetes also required e.: record for at least two GLD prescrip-
tions, with the first prescription occurring within 30 days after the index
discharge and the second over the next six months. In addition, two-year
(2012-2013) adjusted mortality risk, expressed as hazard ratio (HR), was
tested through a Cox regression analysis, comparing IDD subjects and
KD patients having had at least one hospital admission in 2011 and alive
at 1st January 2012 (n=865 and 31,715 respectively).
Results: IDD was found in 974 patients in one year, corresponding to
375.6 per 100,000 hospitalized people. The great majority of IDD pa-
tients were discharged bymedical wards (88%). The adjusted relative risk
[RR(95%CI)] of IDD, as evaluated in hospitalized population, exponen-
tially increased with age and was three-fold higher in migrants of non-
Italian ancestry; RR: 3.18 (1.87-5.42). Furthermore IDD risk was associ-
ated with male gender; RR: 1.24 (1.09-1.41) and with greater burden of
existing co-morbidities, as evaluated by Charlson Co-morbidity index in
previous hospitalizations; [(RR:63.51 (49.78-81.03) in those with
Charlson Co-morbidity index≥2], while was reduced among patients of
general practitioners adhering to shared guidelines resulting in a proactive
model of care delivery RR: 0.75(0.63-0.91). In the cohort of IDD patients
alive at 1st January 2012, (n=865) the hazard ratio(HR) of two-year-
mortality, adjusted for main confounders, was not different from that of
matched KD subjects (HR=1.08; 95%CI: 0.92-1.26; p=NS).
Conclusion: IDD is relatively common among hospitalized individuals
and, in our population, occurs more commonly in older male subjects,
migrants of non-Italian ancestry, and in patients of physicians non-
adhering to a shared care model of diabetes care. Finally, people with
IDD have similar mortality risk compared with matched KD individuals.
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Normoalbuminuric male but not female patients with type 2 diabetes
have a normal life expectancy after 14 years of follow-up (ZODIAC-
50)
N. Kleefstra1,2, S.H. Hendriks1, K.J.J. van Hateren1, K.H. Groenier3,
G.W.D. Landman1, A.H.E. Maas4, H.J.G. Bilo1,2;
1Diabetes Centre, Isala Clinics, Zwolle, Netherlands, 2Department of In-
ternal Medicine, 3Department of General Practice, University of Groning-
en and University Medical Center Groningen, 4Department of Cardiolo-
gy, Radboud University Medical Center, Nijmegen, Netherlands.
Background and aims: When compared to the general population, the
relative risk for cardiovascular mortality in patients with type 2 diabetes
(T2DM) has been described to be substantially higher in women com-
pared to men. To what extend gender influences mortality risk in the
Netherlands is unclear as it is known from previous studies that overall
mortality in patients with diabetes in the Netherlands is low compared to
many other countries. The aim of the present study was to investigate
gender differences in life expectancy in primary care treated patients with
type 2 diabetes in the Netherlands.
Materials and methods: Patients with T2DM participating in a prospec-
tive observational cohort study (ZODIAC) in the Netherlands were in-
cluded. Inclusion in this cohort took place in 1998, 1999 and 2001. Vital
status was assessed in 2013 and life expectancy was calculated using
relative survival analysis. Using the Hakulinen method, the relative sur-
vival was expressed as the ratio of observed survival of patients observed
divided by the survival of the general population in the Netherlands with
the same age (data available from Statistics Netherlands). Analyses were
performed for men and women separately and for subgroups of patients
with and without albuminuria.
Results:A total of 1791 patients was included of which 56%was female.
Mean age was 67 (SD 12) years and the median diabetes duration was 4
(ICR: 2-9) years. Microalbuminuria was present in 29% and
macroalbuminuria in 9% of patients at baseline. After 14 years 49%
(874) patients died, of which 43% from cardiovascular causes. The rela-
tive survival was 0.87 (95%CI: 0.80 - 0.93) for men and 0.81 (95%CI:
0.75 - 0.87) for women with T2DM. In the subgroup of patients without
microalbuminuria the relative survival was 0.99 (95%CI: 0.90 - 1.05) for
men and 0.91 (95%CI: 0.84 - 0.98) for women. In the subgroup of pa-
tients with albuminuria the relative survival was 0.70 (95%CI: 0.58 -
0.81) for men and 0.63 (95%CI: 0.54 - 0.74) for women (figure 1).
Conclusion: In primary care treated T2DM patients, the life expectancy
of men and women was 13% and 19% lower after 14 years of follow-up
compared to men and women in the general population, respectively. In
the subgroup of patients without albuminuria, male patients had the same
life expectancy compared to the general population, while the life expec-
tancy in women still was lower. These results confirm that overall, pa-
tients with T2DM, have a lower life expectancy compared to the general
population, but that the absence of albuminuria increases this expectancy
considerably, even to normal in men.
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Fruit and vegetable consumption and risk of prediabetes and type 2
diabetes in a Swedish prospective study
A.A. Barouti, A. Hilding, C.-G. Östenson, A. Björklund;
Department of Molecular Medicine and Surgery, Karolinska Institutet,
Stockholm, Sweden.
Background and aims: Fruit and vegetable intake has been proposed for
the prevention of type 2 diabetes (T2D) but the evidence from observa-
tional studies is inconclusive or even scarce when it comes to other glu-
cose tolerance abnormalities, like prediabetes. Therefore, we investigated
the association between fruit, vegetable or combined fruit and vegetable
intake and the risk of deterioration in glucose tolerance (to prediabetes or
T2D), in a prospective population-based cohort study.
Materials andmethods: Subjects were 2296men and 3180women aged
35-56 years old at baseline, without previously diagnosed diabetes, who
participated in the Stockholm Diabetes Prevention Program and were
followed for 8-10 years. For all participants, anthropometric and clinical
measurements, an OGTT for the assessment of prediabetes (impaired
fasting glucose and/or impaired glucose tolerance) or type 2 diabetes,
an extensive questionnaire on lifestyle factors and a food frequency ques-
tionnaire were carried out at both baseline and follow-up. Men and wom-
en differed in fruit and vegetable consumption, so we used sex-specific
tertiles of intake for our analyses.
Results: Median intake of fruit and vegetables at baseline was higher
among women compared to men: 185 vs 103 g/day for fruit (p<0.001)
and 163 vs 117 g/day for vegetables (p<0.001). Higher intake of fruit
(>148 compared to <64 g/day) was associated with a 27% lower risk of
deteriorating glucose tolerance in men, after adjusting for age, family
history of diabetes, BMI, physical activity, smoking, education and blood
pressure (OR: 0.73, 95% CI: 0.55-0.98); more specifically the risk of
developing prediabetes from normal glucose tolerance (NGT) decreased
by 26% (OR: 0.74, 95% CI: 0.52-1.05). Vegetable consumption in men
was inversely but not significantly associated with the risk of prediabetes
or T2D. In women, vegetable consumption appeared protective, and es-
pecially the middle tertile of total vegetable intake was significantly as-
sociated with a lower risk of developing T2D from NGT (OR: 0.42, 95%
CI: 0.20-0.90). Intake of a specific vegetable subgroup (green leafy veg-
etables) reduced also the risk of developing T2D in women. The multi-
variate adjusted OR for the highest (>42 g/day) compared to the lowest
(<12 g/day) intake of green leafy vegetables was 0.33 (95% CI: 0.16-
0.68). The consumption of fruit and vegetables combined showed no
significant associations.
Conclusion: Higher consumption of fruit was associated with a reduced
risk of deteriorating glucose tolerance in men, especially for the progres-
sion fromNGT to prediabetes, whereas in women vegetable consumption
and specifically higher intakes of green leafy vegetables, reduced the risk
of developing T2D from NGT. Overall, the findings from this Swedish
study population add to the evidence of a beneficial effect of fruit and
vegetables on T2D risk, and provide new insight for the prevention of
prediabetes.
Supported by: KI, SthlmCountyCouncil, Forte, Sw.ResearchCouncil,
Sw.Diab.Assoc, NovoNordisk
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Exposure to persistent organic pollutants in early pregnancy and risk
of gestational diabetes mellitus
L. Chatzi1, M. Vafeiadi1, T. Roumeliotaki1, G. Chalkiadaki1, P.
Rantakokko2, H. Kiviranta2, E. Fthenou1, S.A. Kyrtopoulos3, M.
Kogevinas4;
1Department of Social Medicine, Faculty of Medicine, University of
Crete, Heraklion, Greece, 2Department of Environmental Health, Nation-
al Institute for Health and Welfare, Kuopio, Finland, 3National Hellenic
Research Foundation, Institute of Biology, Medicinal Chemistry and Bio-
technology, 4National School of Public Health, Athens, Greece.
Background and aims: Persistent Organic Pollutants (POPs) are a group
of diverse substances, including polychlorinated biphenyls (PCBs) and
organochlorine pesticides that are resistant to biodegradation and ubiqui-
tously present in our environment. Exposure to endocrine disrupting
chemicals such as POPs has been linked to type 2 diabetes and metabolic
disturbances in epidemiological and animal studies, but little is known
about POPs exposure during pregnancy and the development of gesta-
tional diabetes mellitus (GDM). The purpose of this study was to deter-
mine the extent to which, exposure to current low levels of different POPs
in the first trimester of pregnancy is associated with GDM risk in 639
women from the RHEA pregnancy cohort in Crete, Greece.
Materials and methods: Concentrations of several PCBs,
dichlorodiphenyldichloroethene (DDE), and hexachlorobenzene (HCB)
were determined in first trimester maternal serum by triple quadrupole
mass spectrometry. POPs were treated as continuous variables on a log10
scale. We defined total PCBs as the sum of all congeners, non dioxin-like
PCBs as the sum of PCB 153, 138, 170 and 180, and dioxin-like PCBs as
the sum of PCB 118 and 156. Pregnant women were screened for gesta-
tional diabetes mellitus (GDM) between 24 and 28 weeks of gestation,
and GDM was defined by the criteria proposed by Carpenter and
Coustan. Adjusted odds ratios (ORs) and 95% confidence intervals
(CIs) were estimated using multivariable logistic regression models.
Results:Geometric mean HCB, DDE and PCBs serum concentrations in
pregnant women were 88, 2043 and 295 pg/ml respectively. 68 (7%)
women had GDM. On multivariable regression analyses, a 10-fold in-
crease in total PCBs was associated with increased risk of GDM (OR=
4.44; 95% CI: 1.17, 16.79) after adjusting for pre-pregnancy BMI and
several other confounders. The association was more pronounced for non
dioxin-like PCBs (OR=4.42; 95% CI: 1.19, 16.43). Prenatal DDE and
HCB exposure were not significantly associated GDM risk.
Conclusion: These findings suggest that women with high PCBs levels
in early pregnancy had higher risk for GDM. Further studies are needed to
replicate these results and to evaluate potential biological mechanisms
underlying the observed associations.
Supported by: EU FP7-2008-ENV-1.2.1.4 Envirogenomarkers
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Comparison of glycaemic outcome and relation to changes in liver fat
content in low-carb vs low-fat dietary regimes for prediabetic subjects
U. Kaiser1, S. Kabisch1,2, M. Kemper1, C. Honig1, C. Gerbracht1, A.F.H.
Pfeiffer1,2;
1Clinical Nutrition, German Institute of Human Nutrition, Potsdam, 2Ger-
man Center for Diabetes Research, Munich, Germany.
Background and aims: Very low carb diets (LCD) were reported to
rapidly reduce liver fat and to improve glucose metabolism more effec-
tively than low fat diets (LFD) in metabolic syndrome subjects. However,
this observation is confounded by small sample sizes and could not be
replicated by others. The aim of this study was to investigate the effect of
a sequential short-term very low carb hypocaloric vs. low fat hypocaloric
diet followed by an isocaloric moderately low carb or low fat dietary
intervention on glycemic parameters, intrahepatic lipids (IHL) and risk
factors for cardiovascular disease in prediabetic subjects.
Materials and methods: In a subcohort of the Prediabetes Lifestyle
Intervention Study (PLIS; n=99) we conducted a two-step dietary inter-
vention with two different regimes. The initial 3 wk-phase was
hypocaloric (ca. 1500 kcal/day), the second phase (11 months) represent-
ed the maintenance period. We compared a 3 week very low-
carbohydrate diet followed by moderate carb diet (short term: < 40 g
carbohydrates/day, long term: < 40% of daily energy intake) and a low-
fat diet (fat intake<30% of daily energy intake). Metabolic assessment
took place after 3 weeks, 6 and 12 months and was based on 2-hour oral
glucose tolerance tests and magnetic resonance spectroscopy (for IHL).
Results: While both interventions showed similar significant short-term
reduction and long-term maintenance of reduced glucose levels and liver
fat content (LCD vs LFD; relative change in IHL after 6 months: -42,2±
29,2% vs -24,6±65,8%, p=0,382), short-term reductions in mean (± SD)
fasting glucose levels were significantly greater in the LCD-group (-11,1
±12,1 mg/dl vs -3,7±10,9 mg/dl, p=0,002). After 3 weeks, reduction of
blood pressure was greater in LCD (systolic: -12±13 mmHg vs -4±
15 mmHg, p=0,002; diastolic: -7±8 mmHg vs -4±9 mmHg, p=0,019),
whereas in triglycerides the LCD-improvement reached only a trend ef-
fect (p=0,073). In the LFD-group, reductions in C-reactive protein (CRP:
0,1±3,6 mg/dl vs -0,7±2,2 mg/dl, p=0,017) and high density lipoprotein
(HDL: -0,8±10,6 mg/dl vs -6,2±6,2 mg/dl, p=0,001) could be observed,
but did not sustain in the maintenance period. The same long-term atten-
uation applied to blood pressure and triglycerides. No short-term diet-
specific effect on low density lipoprotein (LDL) was observed (p=
0,263) after 3 weeks, whereas a significant reducing LCD-effect was
assessed after 6 months (-19,1±20,8 mg/dl vs -9,9±18,3 mg/dl, p=
0,003). Correlation analysis showed, that despite similar magnitude of
metabolic changes, liver fat reduction under low-fat diet is tightly linked
to weight loss (p=0,003), but not in the low-carb group (p=0,170).
Conclusion: Low-carb and low-fat diets are similarly effective to reduce
glycemic parameters and liver fat content, whereas the improvement in
other cardiovascular risk parameters was more pronounced under the
low-carbohydrate diet. The underlying mechanisms appear to differ re-
garding dietary composition suggesting an individualization of dietary
strategies.
Clinical Trial Registration Number: NCT01947595
Supported by: EFSD
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Association of dairy foods with impaired glucose metabolism and
diabetes mellitus in The Maastricht Study
S.J.P. Eussen1, M.J.C. van Dongen1, N.W. Wijckmans1, N.W.
Wijckmans1, L. den Biggelaar1, S.J.W. Oude Elferink2, C.M. Singh-
Povel2, M.T. Schram3, S.J.S. Sep3, C.J. van der Kallen3, A. Koster4, N.
Schaper3, R.M.A. Henry3, C.D.A. Stehouwer3, P.C. Dagnelie1;
1Depa r tmen t o f Ep idemio logy, Maas t r i ch t Un ive r s i t y,
2FrieslandCampina, Wageningen, 3Department of Internal Medicine,
Maastricht University Medical Center, 4Department of Social Medicine,
Maastricht University, Netherlands.
Background and aims: Observational studies suggest an inverse
association between total dairy intake and diabetes risk. However,
there is a lack of information on the relation of specific dairy
products with impaired glucose metabolism (IGM) and type 2
diabetes (T2DM).
Materials andmethods: Individuals aged 40-75 y were recruited for The
Maastricht Study. All participants filled out a 254-food item food frequen-
cy questionnaire (FFQ), covering 41 specific dairy items that captured
differences between full fat, semi-skimmed, and skimmed products, as
well as fermented and non-fermented products. Glucose metabolism sta-
tus was assessed by an oral glucose tolerance test and participants were
informed on their glucose metabolism status after returning the FFQ.
2,508 Individuals were available to estimate odds ratios (ORs (95%CI))
for IGM (n=501) and newly diagnosed (ND) T2DM (n=129), with
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adjustment for BMI, physical activity, smoking, education, energy intake,
and intake of vegetables, fruits, meat, and fish.
Results: For IGM, fully adjusted analyses revealed inverse associations,
with ORs (95%CI) comparing the highest with the lowest tertile of intake
of 0.73 (0.55 - 0.96) for skimmed products and 0.74 (0.54 - 0.99) for
fermented products. These dairy products were not associated with ND
T2DM. In contrast, full fat products were positively associated with ND
T2DM (OR (95%CI): 2.01 (1.16-3.47)), whereas total dairy intake was
inversely associated with ND T2DM (OR (95%CI): 0.46 (0.24-0.86)).
Conclusion: Individuals with a high consumption of skimmed and
fermented products had a lower odds of having IGM, and individuals
with a high consumption of total dairy products had a lower odds of
having ND T2DM. High intake of full fat products was not related to
IGM, but increased the odds of ND T2DM.
Supported by: European Regional Development Fund, Economic
Affairs(NL), CARIM, NUTRIM, FC
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Adherence toMediterranean diet reduces ten-year diabetes risk. The
role of TNF-a and homocystein as potential mediators
E . Ko l o v e rou 1 , D . P a n a g i o t a k o s 1 , C . Ch r y s o h oou 2 ,
E. Georgousopoulou1, V. Metaxa2, I. Skoumas2, D. Tousoulis2,
C. Stefanadis2, C. Pitsavos2;
1Department of Nutrition and Dietetics, School of Health Science and
Education, Harokopio University, 2First Cardiology Clinic, School of
Medicine, University of Athens, Athens, Greece.
Background and aims: Beyond its cardioprotective effects, Mediterra-
nean diet has been reported to offer an anti-diabetic protection. The aim of
this study was to investigate the effect of long term adherence to Medi-
terranean diet on ten-year diabetes incidence, and examine inflammatory
and oxidative stress biomarkers as candidate mediators of this
relationship.
Materials and methods: At baseline (2001-2), a random sample of
1514 men and 1528 women (>18 years) without any clinical
evidence of cardiovascular disease, were enrolled in the study.
Several socio-demographic, clinical, biochemical and other vari-
ables were studied in relation to diabetes development (i.e.,
fasting blood glucose >125 mg/dL or the use of antidiabetic med-
ication, WHO, ICD-10 criteria). Adherence to Mediterranean diet
was evaluated using MedDietScore (range 0-55) and score tertiles
(low, moderate and high adherence to the diet) were calculated. In
2011-2012 the ten-year follow up was performed.
Results: 191 new diabetes cases were recorded. The ten-year incidence of
diabetes was calculated 13.4% and 12.4% among men and women respec-
tively. Moderate and high adherence to Mediterranean diet were found to
reduce the risk of diabetes by 49% (95%CI: 0.30, 0.88) and 62% (95% CI:
0.16, 0.88) respectively, compared with low adherence, taking into consid-
eration age, sex, years of education, family history of diabetes, hypercho-
lesterolemia, hypertention, smoking habits, physical activity and central
obesity (waist circumference≥94/80 for men and women respectively).
Trend analysis revealed a logarithmic relationship (p=0.042). Men with
waist circumference >94 cm and women >80 cm were found to benefit the
most. Whole grains, fruits and legumes were found to exert the greatest
predictive ability. When various biomarkers were entered in the fully ad-
justed model, the antidiabetic effect of Mediterranean diet was found to be
mediated by TNF-a and homocysteine levels.
Conclusion: The present work demonstrates the beneficial role of Med-
iterranean dietary pattern against type 2 diabetes development, which
extends Mediterranean diet’s therapeutic potential to other cardio-
metabolic disorders. The possible participation of TNF-a and
homocystein in this pathway is proposed. The components of Mediterra-
nean which are responsible for this protection require more investigation.
Supported by: Hellenic Cardiological Society, Hellenic Atherosclerosis
Society
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A high diet quality based on dietary recommendations does not
reduce the incidence of type 2 diabetes in theMalmoDiet and Cancer
cohort
E. Sonestedt, E. Mandalazi, I. Drake, E. Wirfält, M. Orho-Melander;
Department of Clinical Sciences Malmö, Lund University, Malmö,
Sweden.
Background and aims: A high diet quality index based on the Nordic
nutrition recommendations and Swedish dietary guidelines has previous-
ly been associated with reduced risk of cardiovascular disease and mor-
tality in the Malmö Diet and Cancer cohort. The aim was to investigate if
this diet quality index was associated with risk of type 2 diabetes.
Materials andmethods:Out of 26,172 participants (44 to 74 years) from
the Malmö Diet and Cancer cohort study, 2,829 type 2 diabetes incident
cases were identified from registers during 18 years of follow-up. A
modified diet history method was used to estimate dietary intakes. A diet
quality index was constructed based on adherence to the recommended
intakes of saturated fat, polyunsaturated fat, fish and shellfish, dietary
fiber, fruit and vegetables, and sucrose.
Results: After adjustments for potential confounders, we observe no
significant association between diet quality index and type 2 diabetes risk.
Hazard ratio for highest vs. lowest index category were among men 1.05
(95% CI: 0.88, 1.25; P-trend=0.94) and among women 1.03 (95% CI:
0.87, 1.22; P-trend=0.34). Exclusion of individuals reporting a substan-
tial diet change in the past and energy mis-reporters did only marginally
affect the results.
Conclusion: This study found no significant association between a high
diet quality index based on the current dietary recommendations and
reduced incidence of type 2 diabetes. Further investigation is needed to
better understand how overall diet quality and individual dietary compo-
nents are associated with the development of type 2 diabetes.
Supported by: Swedish Medical Research Council, Heart and Lung
Foundation
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Paternal chronic high-fat diet consumption reprogrammes the
gametic epigenome and induces transgenerational inheritance of
metabolic disorder
T. de Castro Barbosa1,2, S. Versteyhe2, P. Alm1, L.R. Ingerslev2, J.
Massart3, M. Rasmussen2, I. Donkin2, K. Qian2, R. Sjögren3, J.M.
Mudry3, L. Vetterli3, S. Gup4, A. Krook1, J.R. Zierath2,3, R. Barrès2;
1Department of Physiology and Pharmacology, Karolinska Institutet,
Stockholm, Sweden, 2The Novo Nordisk Foundation Center for Basic
Metabolic Research, Faculty of Health and Medical Sciences, University
of Copenhagen, Copenhagen, Denmark, 3Department of Molecular Med-
icine and Surgery, Karolinska Institutet, Stockholm, Sweden, 4Depart-
ment of Veterinary Disease Biology, University of Copenhagen, Den-
mark.
Background and aims:Genetic and non-genetic (environmental) factors
are strongly implicated in obesity. Increasing evidence indicate that pa-
ternal obesity is associated with epigenetic inheritance of metabolic dis-
orders in the next generations. However, a direct evidence of the molec-
ular carriers remains elusive. We hypothesized that paternal chronic high-
fat diet (HFD) consumption transgenerationally alters the gametic epige-
nome, affecting the metabolism of the offspring.
Materials and methods: F0-male rats fed either HFD or chow diet for
12 weeks were mated with chow-fed dams to generate F1 and F2 off-
spring. Motile spermatozoa were isolated from F0 and F1 breeders to
determine DNA methylation and small non-coding RNA (sncRNA) ex-
pression pattern by deep sequencing.
Results: Newborn offspring of HFD-fed founders had reduced body
weight and decreased beta-cell mass when compared to offspring from
chow-fed breeders. F1 and F2 adult females from F0 founders fed a HFD
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were glucose intolerant and resistant to HFD-induced weight gain. No
major phenotype was observed in male offspring, suggesting sex-specific
responses. HFD-fed F0 and their F1 male offspring presented similar
changes in the epigenome of spermatozoa, showing altered DNA meth-
ylation and sncRNA expression profile when compared to respective
controls. Altered expression of the miRNA let-7c in sperm of F0 and
F1 breeders was also observed in the white adipose tissue of female
offspring, leading to a transcriptomic shift in let-7c putative target genes.
Conclusion: Our results indicate that chronic HFD consumption
transgenerationally reprograms the gametic epigenome, which may be
the molecular mechanism involved in the transmission of
environmentally-induced metabolic dysfunction to the next generations.
Supported by: Novo Nordisk Foundation, Swedish Research Council,
European Res Council
PS 009 Diet and drug interventions in
type 2 diabetes
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The effect of haptoglobin polymorphism and PPAR-γ agonists on
carotid artery intima-media thickness in type 2 diabetic patients:
seven years follow-up
M. Káplár1, B. Cogoi1, J. Kulcsár1, R. Esze1, Z. Karányi1, L. Oláh2, K.
Szabó2, R.K. Czuriga-Kovács2, T. Magyar2, H.P. Bhattoa3, J. Hársfalvi4,
G. Paragh1;
1Institute of Internal Medicine, 2Department of Neurology, 3Department
of Laboratory Medicine, University of Debrecen, 4Department of Bio-
physics and Radiation Biology, Semmelweis University, Budapest, Hun-
gary.
Background and aims: Patients with Type 2 diabetes mellitus are
predisposed to accelerated atherosclerosis. Subclinical atherosclerosis
can be measured by carotid artery intima-media thickness (cIMT), which
predict cardiovascular and all-cause mortality independently. Lately the
role of non traditional risk factors such as haptoglobin polymorphism,
elevated homocysteine levels, inflammatory factors, etc. have emerged in
the pathogenesis of diabetic vascular complications. Haptoglobin (Hp)
plays an important role in iron metabolism and additionally modulates
atherosclerosis given its antioxidant effect. Hp (1-1) provides a stronger
antioxidant effect as compared to Hp (1-2) and Hp (2-2) polymorphisms.
A strong association between haptoglobin polymorphism and coronary
sclerosis, as well as carotid artery intima-media thickness (cIMT) has
been reported previously. Peroxisome proliferator-activated receptor-γ
(PPAR-γ) agonists (rosiglitazone and pioglitazone) are oral antidiabetic
agents with insulin sensitizer properties. These bind to nuclear PPAR-γ
receptor and have pleiotropic effects, some of which are independent of
their glucose lowering action. There are no data available in the literature
regarding the long term effect of these agents on cIMT and their associ-
ation with haptoglobin polymorphism. Our aim was to investigate the
effect of haptoglobin polymorphism on cIMT in Type 2 diabetic patients
during a 7 years follow-up with respect to the applied treatment (antidi-
abetic agents, aspirin) as well as metabolic and conventional cardiovas-
cular risk factors.
Materials and methods: We recruited 114 patients in 2005 and 2006,
and Hp polymorphism, CRP level, HbA1c and lipid parameters were
determined. Seven years later control examinations were performed and
we tried to find any association between Hp polymorphism and changes
in cIMT. During the follow-up period 29 patients were treated with
rosiglitazone for 46±23 months on average. Following rosiglitazone re-
striction, treatment of 11 patients was continued with pioglitazone for 12
±5 months.
Results: Our results showed a decrease in cIMT of patients treated with
PPAR-γ agonists compared to those having been on other medications. In
the latter group, an increase in cIMT was noticed and the difference
between the two groups was significant (p=0.003). Regarding PPAR-γ
treatment and Hp polymorphism significant improvement of cIMT in
Hp(1-1 1-2) patients (p=0.016), and moderate, non-significant increase
of cIMT in Hp(2-2) group was found, respectively. There was no signif-
icant difference in lipid parameters and HbA1c between the groups, nor
aspirin treatment and smoking influenced significantly the changes in
cIMT.
Conclusion: In patients with Hp(1-1 1-2) polymorphism PPAR-γ ago-
nists significantly decreased the subclinical atherosclerosis in Type2 dia-
betics during the seven years follow-up.
Supported by: TÁMOP-4.2.2.A-11/1/KONV-2012-0031 project, co-
financed by EU and ES Fund
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Effect of exercise on Pharmacokinetics (PK) of Basal Insulin
peglispro (BIL) and insulin Glargine (GL) in type 1 diabetes mellitus
patients
H. Linnebjerg1, E. Lam2, S. Choi2, M.P. Knadler1, N. Porksen1, V.P.
Sinha3, P. Garhyan1, O. Klein4, L. Nosek4, T. Heise4;
1Eli Lilly and Company, Indianapolis, USA, 2Lilly-NUS Centre for Clin-
ical Pharmacology Pte Ltd, Singapore, 3Food and Drug Administration,
Silver Spring, USA, 4Profil, Neuss, Germany.
Background and aims: BIL is a novel basal insulin that has a prolonged
duration of action related to a delay in insulin absorption and a reduction
in clearance. As exercise may potentially affect insulin absorption, this
study investigated the effect of exercise on PK of BIL and GL.
Materials and methods: Forty patients with T1DM received 0.5-U/kg
subcutaneous doses of either BIL or GL once daily in the thigh for
20 days. In each treatment arm, patients were randomised to 1 of 2 se-
quences, providing an intra-subject comparison: a 45-minute exercise
challenge at 50%-70% VO2 max (17 hours postdose; ~6 hours after a
meal) on Day 17 and no exercise on Day 20, or vice versa. On both days,
PK samples were collected for 24 hours after insulin dosing. Frequent
blood sampling for PK and blood glucose (BG) was conducted from 17 to
20 hours postdose (0-3 hours after start of the exercise).
Results: Mean BIL concentrations increased with exercise, reaching a
peak at 1 hour and returning to pre-exercise levels within 3 hours after
starting exercise. BIL AUC during a dosing interval at steady state
(AUC0-24,ss) was increased by 13% with exercise compared to no exer-
cise. BIL AUC for 3 hours after the start of exercise (AUC0-3) and max-
imum observed concentration at steady state (Cmax,ss) were increased by
63% and 64%, respectively, with exercise compared to no exercise. These
differences were statistically significant. In contrast, for GL, these PK
parameters were not affected by exercise. Mean baseline (pre-exercise)
BG levels were 138 mg/dL (7.7 mmol/L) with exercise vs 122 mg/dL
(6.8 mmol/L) without exercise in the BIL treatment arm, and 145 mg/dL
(8.0 mmol/L) with exercise vs 148 mg/dL (8.2 mmol/L) without exercise
in the GL arm. Over the 3-hour period after exercise start, mean (±SD)
BG levels were similar with or without exercise following BIL or GL
dosing (BIL: 86.0±26.5 mg/dL [4.8±1.5mmol/L] with exercise vs 90.7±
30.2 mg/dL [5.0±1.7 mmol/L] without exercise; GL: 113±31.8 mg/dL
[6.3±1.8 mmol/L] with exercise vs 125±48.9 mg/dL [6.9±2.7 mmol/L]
without exercise).
Conclusion:While exercise transiently increased systemic exposure fol-
lowing BIL but not GL dosing, the mean glucose concentration appeared
comparable. With the reduced receptor binding affinity and attenuated
peripheral glucose uptake of the hepato-preferential drug BIL, further
research is warranted to delineate the hypoglycaemia risk with exercise.
Clinical Trial Registration Number: NCT01784211
Supported by: Eli Lilly and Company
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Improvement in hepatic metabolism is associated with reduced con-
version to diabetes in IGT subjects treated with pioglitazone (ACT
NOW study)
A. Gastaldelli1,2, D. Tripathy2, M. Gaggini1, N. Musi2, R.A. DeFronzo2;
1MetabolismUnit, CNR Institute of Clinical Physiology, Pisa, Italy, 2Uni-
versity of Texas Health Science Center, San Antonio, USA.
Background and aims: Increased liver enzymes are markers of fatty
liver disease (FLD) and of progression to type 2 diabetes (T2DM). Pio-
glitazone has been shown not only to delay onset of T2DM, but also to
ameliorate fatty liver and improve hepatic function. We recently have
shown that subjects with FLD have increased plasma amino acid concen-
trations and that the ratio of glutamate/( serine+glycine) (GSG index) was
associated with degree of hepatic fibrosis measured by liver biopsy. The
aim of this study was to evaluate the changes observed in parameters of
hepatic function after 2.4 year of pioglitazone treatment in subjects with
impaired glucose tolerance (IGT) and the relationship with onset of
T2DM.
Materials and methods: 441 IGT subjects who participated in the ACT
NOW Study and had complete end-of-study metabolic measurements
were randomized to receive pioglitazone (45 mg/day) or placebo and
were observed for a median of 2.4 years. Indices of insulin sensitivity
(Matsuda index [MI]), lipid profile (triglycerides, HDL, LDL), liver en-
zymes, plasma amino acid concentrations, adipose tissue IR (FFA x Ins),
hepatic IR index (Glu 0-30 min x Ins 0-30 min), and index of hepatic
damages, ie GSG index and AST/ALT score were measured.
Results: Pioglitazone reduced IGT conversion to diabetes by 72%
(P<0.0001) and decreased AST (from 26 to 22 U/l), ALT (from 30 to 24
U/l) and TG (from 123 to 106 mg/dl) concentrations compared to placebo
(p<0.001). Pioglitazone, compared to placebo, markedly decreased hepatic
IR (-2637 vs -259mMxpM), AST/ALT (+0.08 vs -0.08) and the GSG index
(-0.6 vs +0.9), all p<0.0001 documenting improved hepatic metabolism.
Changes in GSG index correlated with changes in hepatic IR (r=0.26),
adipose tissue IR (r=0.29) and matsuda index (r=-0.28, all p<0.0001). In
the pioglitazone group, after 2.4 year, fewer subjects converted to T2DM
(n=15 vs 45). New T2DM subjects showed increased or no change (rather
than decrease) in GSG index, hepatic IR, AST, ALTand TG concentrations.
Conclusion: Reduced conversion of IGT to T2DM after pioglitazone
treatment is strongly related to the improvement in hepatic function.
Clinical Trial Registration Number: NCT00220961
Supported by: Funded by Takeda Pharmaceuticals
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Effectiveness of shared decision making using a support decision tool
to achieve treatment targets in type 2 diabetes mellitus patients. A
randomised trial (OPTIMAL)
H. Den Ouden, R.C. Vos, G.E.H. Rutten;
UniversityMedical Centre Utrecht, Julius Centre for Health Sciences and
Primary Care, Netherlands.
Background and aims: No more than 15% of type 2 diabetes mellitus
(T2DM) patients achieve all treatment goals regarding glycaemic control,
lipids and blood pressure. Shared decision making (SDM) may increase
that percentage; however, not all support decision tools are appropriate.
Because the ADDITION-Europe study demonstrated two (almost) equal-
ly effective treatments but with slightly different intensities, it may be a
good starting point to discuss with the patients their diabetes treatment,
taking into account both the intensity of treatment, clinical factors and
patients’ preferences. We aimed to evaluate whether such an approach
increased the proportion of patients that achieve all three treatment goals.
Materials and methods:Cluster-randomised trial in 35 general practices
that participated from 2002-2009 in the ADDITION study. Both ADDI-
TION and non-ADDITION T2DM patients, 60-80 years, known with
T2DM for 8-12 years, were included. GPs from the intervention group
were trained in SDM with the decision support tool. During the first visit
the intensity of treatment, personalised targets and treatment priorities
were established. Participants underwent 3-monthly check-ups as usual
and a yearly rearrangement of priorities and discussion of treatment tar-
gets with the repeated use of the decision tool. The control group contin-
ued treatment as before. Follow-up: 24 months. Primary outcome: the
proportion of patients who achieve all three treatment goals (intensive
treatment: HbA1c 45-53 mmol/mol (6.5-7%), BP <135/85 mmHg, total
cholesterol<3.5 mmol/mol; less intensive treatment: Hba1c <53 mmol/
mol, BP<140 mmHg, total cholesterol <4.5 mmol/mol). Intention-to-
treat analyses (ITT). To analyse the proportion of achieved treatment
goals for blood pressure, lipids andHbA1 relative risks will be calculated,
with the control group as reference. P <0.05 is considered statistically
significant.
Results: In total 157 participants. In the intervention group 25 patients
decided to continue less intensive treatment and 10 patients continued
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intensive treatment. 34 patients (61.1%) switched from less intensive to
intensive treatment and 3 the other way round. After one year, mean
values of HbA1c, BP and total cholesterol had not changed in both
groups. Compared to the control group, the proportion of patients achiev-
ing treatment targets in the intervention group did not improve (table 1).
Two-years results will be available in Mai 2015 and presented during
EASD Annual meeting 2015.
Conclusion: After shared decision making more than 60% of type 2 dia-
betes patients decided to choose stricter treatment targets. This led to a non-
significant decrease in achieved treatment targets after 1 year, without a
change in mean values for HbA1c, blood pressure and cholesterol levels.
Clinical Trial Registration Number: NCT02285881
Supported by: Nuts OHRA
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The effect of a vegetarian vs conventional hypocaloric diet on serum
concentrations of persistent organic pollutants in patients with type 2
diabetes
J. Veleba1, H. Kahleova1, S. Tonstad2, J. Rosmus3, A. Mari4, P. Fišar3,
M. Hill5, T. Pelikanova1;
1Departement of Diabetoology, Institute of Clinical and Experimental
Medicine, Prague, Czech Republic, 2Department of Endocrinology, Mor-
bid Obesity and Preventive Medicine, Oslo University Hospital, Norway,
3State Veterinary Institute, Prague, Czech Republic, 4C.N.R. (National
Research Council), Padua, Italy, 5Institute of Endocrinology, Prague,
Czech Republic.
Background and aims: Emerging evidence suggests that environmental
factors described as persistent organic pollutants (POPs) are involved in the
development of type 2 diabetes (T2D). POPs may be present especially in
fatty fish, fish and seafood, meat and dairy products. The aim of this study
was to explore the effect of a vegetarian vs. conventional diet on serum
levels of POPs in T2D patients after 12 weeks of a dietary intervention.
Materials and methods: 74 subjects with T2D were randomly assigned
to either follow a vegetarian diet without fish or meat (n=37) or a control
group who followed an isocaloric conventional diabetic diet (n=37). Both
diets were calorie restricted (-500 kcal/day). To measure insulin sensitiv-
ity, the hyperinsulinemic (1 mU.kg-1.min-1) isoglycemic clamp was con-
ducted. β-cell function was assessed using a mathematical model after a
test meal. Magnetic resonance imaging of the abdomen was performed to
measure the amount of visceral fat. We measured serum levels of 44
POPs. Dioxins and dioxin-like POPs were analyzed by isotope dilution
high resolution gas chromatography andmass spectrometry after clean up
on silica and carbon columns. Non-dioxin-like POPs were analyzed by
gas chromatography with electron capture detector. All measurements
were performed at 0 and 12 weeks. For statistical analysis we used re-
peated measures ANOVA and a multivariate regression model. Correla-
tions were calculated using Pearson's correlations.
Results:We did not observe any difference between the groups in serum
levels of most POPs in response to both hypocaloric diets. In the groups
combined, changes in serum concentrations of the POPs were correlated
to changes in HbA1c (r=+0.34; p<0.01), fasting plasma glucose
(r=+0.41; p<0.01) and β-cell function measured as insulin secretion at
a reference glucose level (r=-0.37; p<0.01), independent of changes in
body weight and volume of visceral fat.
Conclusion: Our findings support the relationship between POPs and
diabetes, especially β-cell function.
Clinical Trial Registration Number: NCT00883038
Supported by: IGA MZCR NT/14250-3; MZCR 00023001
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Differential effects of a two-year insoluble cereal fiber intervention in
prediabetic subjects (the OPTImal FIber Trial - OPTIFIT)
C. Honig1, S. Kabisch1, C. Gerbracht1, M. Kemper1, S. Hornemann1,
A. Fischer2, A.F.H. Pfeiffer1,3;
1Department of Clinical Nutrition, German Institute of Human Nutrition,
Potsdam-Rehbrücke, 2J. Rettenmaier & Söhne GmbH + Co KG, Rosen-
berg, 3Department of Endocrinology, Diabetes and Nutrition, Campus
Benjamin Franklin, Charité Universitätsmedizin, Berlin, Germany.
Background and aims: The development of type 2 diabetes is
believed to be associated with some dietary factors including po-
tential beneficial effects of dietary fibre. Epidemiological studies
have highlighted their putative preventive role and especially in-
soluble fibre seems to improve insulin sensitivity and therefore
reduce the risk of type 2 diabetes. On this behalf a prospective
2-year-study was performed to investigate whether a fibre supple-
mentation can delay or inhibit the increase in blood glucose in
subjects with prediabetes. Aim of the program was an increased
intake of dietary fibre through change of diet (lifestyle interven-
tion course) additionally to fibre supplementation.
Materials and methods:We performed a 24-months randomized, place-
bo-controlled, double-blind study involving 180 adults with impaired
glucose tolerance. They were randomized into two groups receiving dif-
ferent types of fibre supplement. All subjects started with a one-year
lifestyle program including group-based consultations and 4-day food
records at regular intervals. During the second year of study they only
received their study supplement and were asked to continue their regular
intake twice daily. Blinded fibre supplement was either enriched with
insoluble oat fibre adding 15 g of fibre per day to the normal nutrition
or served as a placebo. Every 6 months anthropometric data and serum
markers were assessed. In total 136 participants completed the first study
year and 108 subjects completed the whole trial.
Results: The 2-h-OGTT glucose levels improved significantly in
both intervention groups after the first study year (placebo-group:
Δ -10,5 mg/dL, p=0.020 vs. fiber-group: Δ - 17,3 mg/dL, p<
0.001) as well as markers of insulin sensitivity (HOMAIR,
OGIS180, ISIFFA), weight (p<0.001), waist (p<0.001) and hip
circumference (p<0.001). In the fiber-group visceral and subcutaneous
adipose tissue were significantly reduced (p 19 g fiber/day, Δ -17,0 mg/
dL, non-adjusted p=0.002) compared to the lowest fiber consumption
(<15 g fiber/day, Δ -10,6 mg/dL, non-adjusted p=0.102). Several fea-
tures of metabolic syndrome were significantly improved in both groups
at the end of the study. Due to the supplementation the subjects in the fibre
group effectively enhanced their fibre intake by approx. 13,4 g per day
(placebo-group: 1,5 g per day), revealing good and continuous compli-
ance of the study participants
Conclusion: The OPTIFIT-study showed that also in Germany a lifestyle
intervention can significantly improve risk factors for type 2 diabetes. An
increased intake of dietary fibre can significantly improve parameters of
glucose levels and insulin sensitivity. Fat metabolism, anthropometric
data and the extent of fatty liver disease were positively affected by the
intervention.
Clinical Trial Registration Number: NTC01681173
Supported by: Deutsche Diabetes Stiftung
Diabetologia (2015) 58 (Suppl 1):S1–S607 S165
330
Identifying people at high risk for type 2 diabetes: preliminary re-
sults from the Kerala Diabetes Prevention Programme
B. Oldenburg1, T. Sathish1, K.R. Thankappan2, S. Balachandran2,
F. D'esposito1, E. Mathews2, P. Lorgelly3, P. Absetz4, P.Z. Zimmet5,
J. Shaw5, R.J. Tapp1;
1The University of Melbourne, Australia, 2Sree Chitra Tirunal Institute
for Medical Sciences and Technology, Trivandrum, India, 3Monash Uni-
versity, Melbourne, Australia, 4University of Tampere, Finland, 5Baker
IDI Heart and Diabetes Institute, Melbourne, Australia.
Background and aims: The majority of people with type 2 diabetes
mellitus (T2DM) live in low- and middle- income countries. Limited
longitudinal studies among Asian Indians have assessed the performance
of diabetes risk scores in identifying those at high risk for T2DM. We
evaluated the performance of a diabetes risk score to recruit participants
into a diabetes prevention program and determined the one-year change
in glucose metabolism.
Materials and methods: The Kerala Diabetes Prevention Program is a
cluster randomised controlled trial of a peer-led, group-based lifestyle
intervention on reducing the incidence of T2DM in rural Kerala, India.
The present analyses were limited to those in the control arm, with pre-
liminary data available. At baseline, the Indian Diabetes Risk Score
(IDRS), with a cut-point ≥60 was used to identify those at high risk for
T2DM among 1306 participants. Participants with an IDRS cut-point ≥60
and without known T2DM attended a mobile clinic and underwent an
oral glucose tolerance test (OGTT). Pre-diabetes and diabetes were de-
fined using the World Health Organisation criteria.
Results: The mean (standard deviation) age of participants in the control
arm was 47.1 (7.4) years and 47% were females. The IDRS risk factors
were age ≥35 years (97.9%), family history of diabetes (51.9%), physical
inactivity (79.4%) and central obesity (72.4%). At baseline, 47.1%
(n=615) of participants screened were identified as being at high risk
for T2DM, using the IDRS and of those 54.5% (n=335) had normal
glucose tolerance (NGT), 29.1% (n=179) had pre-diabetes and 16.4%
(n=101) had diabetes, based on OGTT. Of those with NGT at baseline,
26% progressed to pre-diabetes and 3.2% progressed to T2DM, by one
year. Among those with pre-diabetes at baseline, 27.6% reverted to NGT
and 19% progressed to T2DM by one year.
Conclusion: This is one of the first diabetes prevention programs in a
developing country to use a diabetes risk score to identify people at high
risk for T2DM. This study identified a large proportion of people with NGT
who progressed to pre-diabetes or diabetes within one year, these partici-
pants would normally be excluded from diabetes prevention programs.
These findings provide evidence to support the usefulness of a diabetes risk
score to identify people at high risk for T2DM, among Asian Indians.
Clinical Trial Registration Number: ACTRN12611000262909
Supported by: NHMRC, Australia
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Implementation and preliminary outcomes of the Madrid city coun-
cil diabetes prevention program (ALAS, High Risk Strategy) applied
to workers
M. Martinez1, C. Martín2, O. Borrego3, F.J. Sobrino4, C. Segador2,
M. Darna2, I. Bordel4, N. Calle2, L. Lobato4, J. Moreno3, P. García5;
1Prevention and Promotion Health Service of Madrid City Council,
2Diabetes Unit, 3Healthy Habits, 4Health Workers Unit, 5Madrid Salud,
Prevention and Promotion Health Service of Madrid City Council, Spain.
Background and aims: In people with prediabetes, lifestyle interven-
tions directed at weigth lossand increasing physical activity are effective
in preventing the progression to type 2 diabetes. TheMadrid City Council
Diabetes Prevention Program (ALAS, High Risk Strategy), has beeb
implemented among its employees. Aims: 1 -To achieve 5%-7% weight
reduction ; 2- To improve glycemic control.
Materials and methods: During a medical examitation, Madrid City
Council workers are encouraged to complete the Findrisc test. Those with
positive results, that means, puntuation>15 are asked to undergo Oral
glucose tolerance test (OGTT). When they fulfill criteria for prediabetes,
they are invited to participate in the ALAS program. It is delivered over
6 months and consits of 10 group sessions in a Workshop format. There
are 6 weekly core sessions the main content of which are: healthy diet,
physical activity and emotional management, and 4 more sessions direct-
ed at maintenance.
Results: 852workers fulfilled Findrisc test. 76 people got positive results,
from these, 53 (69,73%) underwent (OGTT). Up to February 2015, 43
participants have completed the Madrid City Council Diabetes Preven-
tion Program (ALAS, High Risk Strategy), 30 had Prediabetes (70%) and
13 Normoglycemic at high risk (30%). Participants ages ranged from 37
to 68 ( mean 53.6 SD=7,6), 20males (46,5%) and 23 females (53,5%). At
program completion, participants lost a mean of 4,73 Kg or 5,03% of
body weight and 23% have normalized the glycemic control; 35%
achieved 5% or more weight loss; 56% people attended 6 or more ses-
sions.Weight loss was negatively associatedwith age, and positively with
male gender and attendance. Factors contributing to program success are
their implementation in the setting of work health screening, given the
employees busy schedules and family responsabilities.
Conclusion: In people with prediabetes, lifestyle interventions are effec-
tive to achieve weight loss and to improve glycemic control. It should be
encouraged to pass the Findrisc Test during health examinations in the
workplace. Such a program could be introduce as part of the health
screening examination that companies provide. It could be relevant to
the health of employees to implement Diabetes Prevention Program in
the workplace.
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The prevalence of gestational diabetes largely increases if the WHO-
1999 cut-off values of the 75-gram oral glucose tolerance test are
replaced with the WHO-2013 criteria
J.J. van Zanden1, B.J. Schering2, S.H. Koning2, K. Hoogenberg3,
B.H.R. Wolffenbuttel2, H.L. Lutgers2;
1Laboratory of Clinical Chemistry, Certe, Medical Laboratory North,
2Endocrinology and Metabolism, University of Groningen, University
Medical Center Groningen, 3Internal Medicine, Martini Hospital Gro-
ningen, Netherlands.
Background and aims:The prevalence of gestational diabetes (GDM) is
rising and contributes to a growing burden to global obstetric health care.
In 2013, the WHO adopted the stricter cut-off glucose values for diagno-
sis of GDM of the IADPSG-2010 criteria. In the Netherlands, we have
used the WHO 1999 criteria for GDM so far. In this study, we evaluated
the prevalence of GDM applying the currently used WHO-1999 criteria
compared to the new WHO-2013 criteria.
Materials and methods: Retrospective evaluation of blinded laboratory
results of all 75-gram OGTTs performed between January 2011 and Au-
gust 2014 by Certe, a regional primary- and secondary healthcare labo-
ratory which covers a large rural area and urban area in northern Nether-
lands of approximately 550,000 inhabitants. Women could be referred by
their midwife or gynaecologist to perform an outpatient OGTT if they had
risk factors for GDM or symptoms suggestive of GDM (e.g.
polyhydramnion). From this database, GDM prevalence was determined
using the current national guidline based on the diagnostic WHO-1999
criteria: positive if fasting plasma glucose is ≥7.0 mmol/l and/or 2-h
glucose value ≥7.8 mmol/l after a 75-gram OGTT. GDM prevalence
was also determined using the WHO-2013 cut-off values: fasting plasma
glucose ≥5.1 mmol/l and/or 2-h glucose value ≥8.5 mmol/l after a 75-
gram OGTT.
Results:A total of 6130 OGTTs were carried out in the study period, 193
(3%) were incomplete (0.6% failed because of intolerance caused by
nausea/vomiting, for the remaining 2.4% there was no registration of
the cause of failure). Mean (±SD) age of the women was 30.3±5 years.
The prevalence of GDM in this cohort was 19% using the WHO-1999
cut-off values and 30% using the WHO-2013 cut-off values (+58%).
GDM was diagnosed solely on fasting glucose in 64% by WHO-2013
criteria contrasting to 1% by WHO-1999 cut-off values where the 2-h
glucose value was the major determinant of GDM-diagnosis. Prevalence
of GDM increased with maternal age category (WHO1999/WHO2013):
18-25 years 14%/23%; 25-30 years 14%/24%; 30-35 years 21%/33%;
35-40 years 24%/35%; >40 years 30%/48%.
Conclusion: Adjusting our national guideline to the new WHO-2013
criteria will have a major impact on the prevalence of GDM, a 1.5 fold
increase mainly because a larger proportion of GDM based on abnormal
fasting glucose levels. This will lead to a higher referral rate to secondary
obstetric care, necessitating a shared-care model for obstetric and diabetes
care between primary and secondary obstetric care facilities. Furthermore
it remains to be seen whether the WHO-1999 GDM-negative but WHO-
2013 GDM-positive screeners have better maternal and neonatal
outcomes.
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Prevalence and risk factors for thyroid pathology in patients with
diabetes mellitus
M.V. Arnaudova, I.K. Daskalova, T.T. Totomirova;
Military Medical Academy, Sofia, Bulgaria.
Background and aims: The aim of this study was to assess the preva-
lence and risk factors for thyroid pathology among patients with type 1
and type 2 diabetes mellitus
Materials and methods: The study was conducted in our clinic during
the period of January 2012 - December 2013. It was a retrospective study.
The total study population included 829 patients with type 1 (14.8%) and
type 2 diabetes ( 85.2%). The study group consisted of 532 women
(64.2%) and 297 men (35.8%).
Results: Thyroid pathology was found in 78 (63.4%) of patients with
type 1 diabetes and 507 (71.8%) of patients with type 2 DM. In type 1
diabetes group with established thyroid pathology the most common
disorder was autoimmune thyroid disease - 45 (36.5%), while nodules
were diagnosed in 31 patients (25.2%). In type 2 DM group the most
common disorder were nodules - 332 (47.0%), while patients with auto-
immune thyroid disease were 152 (21.5%). In type 2 DM group the risk
of developing thyroid pathology increased by 1,074 times in comparison
to type 1 diabetes. The risk of developing nodules increased by 1,142
times accordingly, and the risk of auto-immune thyroid disease decreased.
The comparative analysis of patients with single and multiple nodules
showed a statistically significant difference in terms of age - patients with
multiple nodules were older - 61,35±10,78 years and those with single
nodules 57,7±12,45 years. In type 1 diabetes mellitus a statistically sig-
nificant correlation between age and presence of nodular formations was
found. This correlation was not established in terms of auto-immune
thyroid disease. In patients with type 2 diabetes mellitus statistically sig-
nificant correlation was established between age and thyroid pathology in
general as well as between age and the presence of nodular formations. In
terms of AITD such correlation was not found.
Conclusion: Data comparison in type 1 and type 2 diabetes mellitus
showed that aging increases the risk of nodular changes in both type 1
and type 2 diabetes, i.e., age can be perceived as an absolute risk factor for
developing thyroid pathology, namely nodular pathology. According to
our data in type 1 and type 2 diabetes, female sex is a risk factor for the
development of nodular pathology and AITD.
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Plasma lipids at type 1 diabetes onset predicts residual beta cell func-
tion after 6 and 12 months
A. Overgaard1, S. Porksen1, M.-L.M. Andersen1, S. Fredheim1, H.B.
Mortensen1, P. Meikle2, F. Pociot1;
1Herlev Hospital, Copenhagen, Denmark, 2Baker IDI Heart and Diabetes
Institute, Melbourne, Australia.
Background and aims: The exact mechanisms triggering and regulating
progression towards beta-cell failure in type 1 diabetes (T1D) are poorly
understood. It is generally acknowledged, however, that both genetic and
environmental components are involved. A detailed understanding of the
pathogenesis of T1D is a criterion for the development of preventive
strategies. In particular, the identification of earlymetabolic modifications
is promising in the study of etiological pathways. Recent research indi-
cates that modulations of multiple plasma phospholipids precedes the
presence of autoantigens in the development of T1D. These observations
suggests the potential of metabolomic biomarker panels in monitoring
health and potential decline in beta-cell function before T1D symptoms
appear. Thus, we hypothesize that new biomarkers in the form of metab-
olite panels, and in particular lipids, in plasma from children with recent
onset T1D will reflect the remaining beta cell function. This could lead to
the development of new biomarker panels for decline in beta-cell function
before T1D manifests itself clinically.
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Materials and methods: For this study we used a total of 129 patients
<15 years of age followed in the Danish Remission Phase Study. The
patients were followed for 12 months (n=40 additionally returned at
60months) from the diagnosis of T1D. Demographic and anthropometric
data, insulin therapy as well as blood samples for centralized measure-
ment of Hemoglobin A1c and meal-stimulated C-peptide were collected
prospectively 1, 3, 6, 12 and 60 months after diagnosis. Multiple reaction
monitoring lipidomics were used to characterize the lipid profiles of the
participants of the cohort at each time point.
Results: Seven diacylglycerols (DG) and total amount of DG all of them
carrying either 16:1 or 18:1 fatty acids, or both, were significantly asso-
ciated, after Benjamini-Hochberg correction, to a decrease in stimulated
C-peptide after six months, and three of these: DG 16:1/16:1, DG 18:1/
18:1 and DG16:1/ 18:1 and total DGwere also associated to a decrease in
stimulated C-peptide after 12 months. Six triacylglycerols (TG) and total
TG were also associated to a decrease in stimulated C-peptide after six
months, and three of these and total TGwere also associated to a decrease
in stimulated C-peptide after 12 month. All of the TGs contained at least
one 16:1 or 18:1 fatty acid. Six cholesterol ester (CE) and total CE were
associated to a decrease in stimulated C-peptide at six months, of these
three and total CE were associated to stimulated C-peptide decrease at
12 months. CE 24:0 were only associated to a decrease in stimulated C-
peptide after 12 months. Oxidated PC (OxPC) and PC 36:4a were signif-
icantly associated to an increase in stimulated C- peptide after 6 and
12 month. Another phospholipid, sphingomyelin 34:2 were also associ-
ated to a decrease in stimulated C-peptide after 12 months.
Conclusion: These observations provide evidence that lipid disturbances
predicts decline in beta cell function, and could by closer examinations
lead to better classification of patients and the progression of the disease
as well as to the identification of new pharmaceutical drug targets.
Supported by: JDRF
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A comparison of diabetes type 1 in South Asian and Caucasian pa-
tients in the UK: the Type 1 in Minority Ethnic populations (TIME)
study
K.N. Sarwar1, S.M.R. Gillani2, B.M. Singh2, P. Saravanan3,
P. Narendran1;
1Endocrinology, Queen ElizabethHospital Birmingham, 2Endocrinology,
Royal Wolverhampton NHS Trust, 3Endocrinology, University of
Warwick, UK.
Background and aims: Diabetes type 2 (T2D) is up to six times more
common in people of South Asian origin than in white Caucasians in the
UK. Furthermore, onset is earlier with higher morbidity and mortality.
Diabetes type 1 (T1D) has not previously been characterised in this
group, despite South Asians comprising over 7% of the UK population.
Recent reports suggest the prevalence of T1D is similar across South
Asian and white Caucasian ethnicities. The aim of the TIME study was
to characterise and compare T1D between South Asian and background
white Caucasian populations.
Materials and methods:We performed a case controlled analysis of 417
patients across two centres in theWest Midlands, UK (a region in the UK
with one of the highest South Asian populations) matching for age and
gender (one South Asian patient matched to two white Caucasian). Data
for 177 patients was analysed from the Queen Elizabeth Hospital (QEH)
and 240 patients from New Cross Hospital (NCH).
Results: The results are shown in Table 1. Values are median (interquar-
tile range) with * indicating a p value <0.05.
Conclusion: In conclusion, we found that South Asians with T1D pre-
sented at a later age, and had more significant macrovascular risk factors
than white Caucasians. Interestingly, there was no difference in glycaemic
control or prevalence of microvascular complications. As for T2D, these
findings have important implications for service delivery and
personalised healthcare.
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National childhood diabetes register: disease onset, diabetes control
and therapeutic data in the Czech Republic
K. Picková1, J. Venháčová2, J. Škvor3, P. Konečná4, J. Chudáčková4,
D. Neumann5, J. Vosáhlo6, J. Strnadel7, S. Koloušková1, O. Cinek1,
Z. Šumník1, ČENDA Project Group;
1Department of Pediatrics, 2nd Faculty of Medicine, Charles University
in Prague andMotol University Hospital, 2Department of Pediatrics, Fac-
ulty of Medicine, Palacky University, Olomouc, 3Department of Pediat-
rics, Masaryk Hospital, Ústí nad Labem, , 4Department of Pediatrics,
University Hospital, Brno, , 5Department of Pediatrics, University Hos-
pital, Hradec Kralove, 6Department of Pediatrics, 3rd Faculty of Medi-
cine, Charles University in Prague, 7Clinic of Pediatrics, University Hos-
pital, Ostrava, Czech Republic.
Background and aims: The Czech National Childhood Diabetes Data-
base (ČENDA) is a centralized web-based national database that stores
treatment and outcome data in children and adolescents with diabetes,
allowing for anonymous comparison among diabetes clinics. The goals of
the ČENDA database are to provide longitudinal data of childhood dia-
betes control and to identify strengths and weaknesses in the system of
care. Here we present the first two years of the database.
Materials and methods: Since 2013, the database collects data on every
patient treated by 48 participating pediatric diabetes outpatient clinics.
Importantly, a prerequisite for participation is to report every patient cared
for. Data include characteristics of the disease onset and annual summa-
ries of clinical care, including every tested HbA1c value. Protocols have
been implemented ensuring complete anonymization and patient data
protection.
Results: The database contains data of 2192 children and young people
with diabetes; this is estimated to be 70% of all Czech pediatric patients
according to the highly accurate national incidence register. In 2013, com-
plete annual data were available for 1972 patients (1025 boys and 947 girls)
up to the age of 18. Of these, 95% had type 1 diabetes, 3% had genetically
proven monogenic diabetes, 1% had type 2 diabetes and 1%were stated as
other type of diabetes. Median HbA1c was 66.3 (average 69.3; IQR 57-78)
mmol/mol. The proportion of children reaching target therapeutic goal of
59 mmol/mol declines from 34% in 0-4 years old children to 25% in 15-18
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the years old. Out of children treated by insulin, 75% were on multiple
daily injections (MDI), 24% were on continuous subcutaneous insulin
infusion (CSII) and 1% were on conventional therapy. The proportion of
children treated by CSII rises significantly with age, being 6.8% in
0-4 years old children and 33% in the 15-18 years old. HbA1c values do
not differ between children on MDI and CSII therapy. The total daily
insulin dose varied by age and diabetes duration; the lowest dose was
observed in children younger than 4 years (0.65 U/kg/day), the highest
dose was in adolescents 15-18 years old (0.84 U/kg/day). Celiac disease
was reported in 11.5%, and 18.3% of childrenwere treated for autoimmune
thyroid disease. Significant differences have been noted between clinics in
almost all of the observed parameters.
Conclusion: With a coverage over 70%, the ČENDA database offers a
representative view of childhood diabetes in the Czech Republic. The com-
parison of pediatric diabetes clinics shows large differences in treatment
processes, complications and outcomes, notably in the proportion of pa-
tients reaching therapeutics targets. Detailed data analyses will help identify
key areas for further improvement of the system of pediatric diabetes care.
Supported by: Czech Diabetes Society, MZČR National action plans and
concepts
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Rising incidence of childhood type 1 diabetes inWielkopolska province,
Poland
E. Niechciał1, B. Skowrońska1, I. Krzyśko1, A. Gertig-Kolasa1,
W. Stankiewicz1, M. Michalak2, P. Fichna1;
1Department of Paediatric Diabetes and Obesity, 2Department of Infor-
matics and Statistics, Poznan University of Medical Sciences, Poznan,
Poland.
Background and aims: Over the past decades, a rapidly increasing in-
cidence of childhood type 1 diabetes has been reported in many parts of
the world. In Poland, the first epidemiological register was conducted in
Wielkopolska between 1970-1985, where the estimated average inci-
dence rate was 4.4/105 for the age group 0-16 years. In 80s and early
90s of the 20th century according to data from epidemiological programs
EURODIAB and DiaMond, Poland was included to a very low incidence
of type 1 diabetes countries with an incidence rate estimated around 6.6 /
105. This study aims to assess the current incidence of type 1 diabetes
among children in Wielkopolska.
Materials and methods: The analysis involved cases of new onset type 1
diabetes that were recorded in Wielkopolska Register of Childhood Diabe-
tes from 2008 to 2013. The degree of completeness of the registry overall
has been estimated at 95.0% The denominator for the analysis were chil-
dren≤14 years with residency in the study area, which was defined geo-
graphically to correspond with administrative and census boundaries of
Wielkopolska. Diabetes was diagnosed based on WHO criteria and first
day of insulin administrationwas assumed the time of diagnosis. Total, sex-
, and age-specific incidence rates per 100,000 person-years were calculated
for each calendar year. A direct standardization method was used to esti-
mate age and sex standardized rates, assuming a reference population com-
prising equal numbers in each of the sex- and age-specific groups (0-4, 5-9,
and 10-14 years). The 95% CI was calculated using the Gaussian approx-
imation to the Poisson log-likelihood. The demographic date was obtained
from the Statistical Office in Poznan.
Results: 571 new cases of type 1 diabetes: 259 girls and 312 boys were
identified during the period January 2008 - December 2013. The mean
age at diagnosis was 9.0±4.3 years. The trend for increased incidence of
type 1 diabetes has been observed in children aged 0-14 (2008: 15.6/105,
95% CI: 8.6-22.4; 2013: 24.3/105, 95% CI: 20.2-28.4). The highest an-
nual incidence was reported among those aged 5-9 years (2008 - 22.8/
105- 95%CI: 15.6-30.0; 2013 - 27.2/105- 95%CI: 19.7-34.6). The fastest
incidence increase was found in the youngest age group (2008 - 7.1/105,
95% CI: 3.2-11.0; 2013 - 17.4/105 , 95% CI: 11.5-23.2). Diabetes has
occurred more often in autumn and winter months comparing to spring/
summer months, except for 2012 when the seasonality was not observed
Conclusion: Incidence rate of type 1 diabetes is rising in Wielkopolska.
Such rapid increase in very short period rather is associated with environ-
mental factors than changing in genetic background. Seasonality of the
disease is not a regular occurrence, which suggests increasing role of non-
seasonal factors in the growing incidence. The fastest increase of type 1
diabetes incidence was noticed among the youngest children. The peak
incidence is steadily moving towards younger age groups of children
which indicates that paediatric diabetes health care will be extended and
there is a higher risk of developing chronic complications in younger
patients. The accelerating trend needs to be well monitored due to the
search for its causes, prevention and the possibility of customizing med-
ical care.
338
Effect of ethnicity on clinical presentation with type 1 diabetes and on
humoral autoimmunity, within ADDRESS-2 (After Diagnosis Diabe-
tes Research Support System)
V. Bravis1, A. Kaur1, H. Walkey1, I. Godsland1, C. Dayan2,
M. Peakman3, P. Bingley4, D. Dunger5, N. Oliver1, D.G. Johnston1;
1Dpt of Endocrinology, Diabetes & Metabolism, Imperial College,
London, 2Institute of Molecular & Experimental Medicine, Cardiff
University School of Medicine, 3Dpt of Clinical Immunology, King’s
College, London, 4Dpt of Diabetes & Metabolism, University of Bristol,
5Dpt of Paediatrics, University of Cambridge, UK.
Background and aims: In type 1 diabetes (T1D), most comparisons
across the literature are within and between countries, but not by ethnicity
per se. That is, in part, due to the fact that many of the countries are
relatively homogenous with regards to ethnicity. Here, we examined the
effect of ethnicity on the clinical presentation and humoral autoimmunity,
within people with incident T1D recruited to ADDRESS-2.
Materials and methods: ADDRESS-2 comprises of a multi-ethnic co-
hort of people with incident T1D, aged 5-60 years old, characterized on
the basis of clinical and demographic features and, in many, islet-specific
antibodies (Ab) (GAD65, IA-2, ZnT8). From 01/09/2011 to 28/02/2014,
patients with T1D were recruited to ADDRESS-2, within 6 months of
diagnosis, from 134 recruiting sites in the UK.
Results: 1,580 patients were recruited (1,453 White-Europeans
(WE); 909 male; 867 children). Of the non-WE patients, 52 were
Asian (A), 20 Black (B), 55 Mixed/Other (MO). Osmotic symptoms
(95%), weight loss (84%), fatigue (84%) were the main presenting
symptoms and occurred in comparable frequency in all ethnic
groups (p>0.05). Symptom duration was greater in WE people
(p=0.002). 42% presented with diabetic ketoacidosis. Ketoacidosis
rates were similar in WE (43%) and non-WE (38%) (p>0.05). Eth-
nicity did not independently predict symptom duration or mode of
clinical presentation. Family history of diabetes (FHDM) was re-
ported at comparable frequencies between ethnic groups (p>0.05).
A ethnicity was a strong, independent predictor of FHDM (OR=1.9;
p=0.03). Ethnicity did not predict HbA1c or insulin dose require-
ments at the time of presentation. Of all patients, 926 (59%) pro-
vided a blood sample for Ab testing. 84% (774/926) had at least one
Ab present. Ab positive status was associated with WE (85%) more
than non-WE (67%) ethnicity (p=0.001). WE ethnicity was a
strong, independent predictor of Ab presence in children (5-16 years;
OR=4.1; p=0.01) and adults (17-60 years: OR=2.3; p=0.02). A
(OR<5; p=0.01) and B (OR<5; p=0.04) ethnicities strongly and
independently predicted Ab absence. MO ethnicities less strongly
predicted that (OR<0.5; p=0.08). None of the potential confound-
ing variables that may explain the effect of ethnicity increased the
OR above 0.5 for non-WE ethnicities, on multiple regression anal-
yses. WE patients were significantly more likely to have multiple
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(versus single) Ab present compared to non-WE patients (RR=1.9;
p=0.01).
Conclusion: ADDRESS-2 is a registry-based recruitment study of repre-
sentative patients with a clinical diagnosis of T1D, over a wide age range
andmultiple ethnicities. It offers important information on the clinical and
anthropometric characteristics of patients presenting with T1D. Although
T1D is a condition that mostly affects people of WE ethnicity, there were
no major differences in presentation across different ethnicities. Presence
of islet cell Ab was much higher in WE patients compared with non-WE.
Ethnicity was a strong, independent predictor of Ab status and frequency
in children and adults presenting with T1D.
Supported by: Diabetes UK, JDRF
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Characteristics of newly diagnosed adults with type 1 diabetes in the
UK and their evolution over the first 5 years
S. Ramtoola1, U.J. Ploug2, N. Kragh2, M.E. Nyeland2;
1Royal Blackburn Hospital, Blackburn, UK, 2Novo Nordisk, Søborg,
Denmark.
Background and aims: The aim of this study was to ascertain the
weight, BMI characteristics and comorbidities of adults with newly diag-
nosed type 1 diabetes (T1D) in the UK and assess the impact of initiating
insulin therapy on their glycaemic control and weight profile over the first
5 years after diagnosis.
Materials and methods: This study was a non-interventional, retrospec-
tive, cohort study utilising data from the UK Clinical Practice Research
Datalink (CPRD) database between 2001 and 2013. Patients were selected
based on a recorded diagnosis (C10* read codes) of T1D or fulfilling the
NHS criteria for T1D, in whom onset of continuous insulin treatment was
within 12 months of diagnosis. Patients included were aged 18-85 years,
with a body mass index (BMI) of 11-50 kg/m2 and a full medical history of
at least 12 months prior to diagnosis (n=2430). Using this dataset, HbA1c
and BMI levels were compared at baseline and 12, 24, 36 and 60 months
after insulin therapy was initiated.
Results:At baseline, patients (63.3%male, 36.7% female) had a mean ± SD
age of 40.8±16.1 years, HbA1c of 10.8%±3.0, and a BMI of 25.3±5.5.
Mean BMI and BMI distribution of study patients were comparable to that
of the UK general population. Following initiation of insulin therapy, mean
HbA1c statistically significantly (only taking inter-subject variation into con-
sideration) declined from 10.8%±3.0 to 7.7%±2.0 at 12 months (P<0.01),
but subsequently statistically significantly increased to 8.1%±2.0 at
24 months, remaining stable thereafter at 8.2%±1.9 and 8.2%±1.7 at 3 and
5 years, respectively (Figure 1). Mean BMI consistently increased from 25.3
±5.5 at baseline, to 27.2±5.8, 27.4±5.7, 27.5±5.6, and 27.9±5.5 kg/m2 at 1,
2, 3 and 5 years, however, only the increase in the first 12 months was
statistically significant (only taking inter-subject variation into consideration).
Conclusion: Whilst insulin therapy exerted an initial reduction in
HbA1c at 12 months, mean HbA1c at 12 months was still above
the NICE targets, and further deteriorated soon after, stabilizing
between 2 and 5 years after initiation of treatment. After beginning
insulin therapy, T1D patients were susceptible to long-term cumu-
lative weight gain and increase in BMI, with deeper entrenchment
into pathophysiological BMI weight categories. This study sup-
ports the concept of “glycaemic streaming” and suggests that fur-
ther intensification of efforts is required right from diagnosis and
initiation of insulin therapy to support patients with T1D to
achieve and maintain glycaemic control targets. Currently weight
control is a side issue in UK T1D patient education and treatment
strategies which focus primarily if not almost exclusively on the
titration of insulin to achieve HbA1c targets. This study illustrates
the need for greater emphasis on weight management in national
T1D education programmes.
Supported by: Novo Nordisk
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Obesity associated variants within FTO are functionally connected to
multiple genes in the locus
I. Aneas, D. Sobreira, M. Rodriguez-Oquendo, M. Nobrega;
University of Chicago, USA.
Background and aims: Several studies directly implicated FTO as the
obesity gene. Genome-wide association studies have linked non-coding
variants within FTO introns with increased risk for obesity and type 2-
diabetes. Recently, our group has discovered that the obesity-associated
elements within fto interact with Irx3, a distant gene on the genome that
appeared to be the functional obesity gene. Our data showed that FTO
obesity-associated region contain enhancers that drive Irx3- like expres-
sion, whereas Fto expression is primarily regulated by regions proximal
to its promoter. eQTL mapping showed altered Irx3 expression (not Fto)
in the human brain and null mice demonstrated that Irx3 is also a regulator
of bodymass and composition. However, involvement of Fto gene and/or
other genes in the phenotype couldn’t be rejected.
Materials and methods: To identify all possible genomic interactions
between the 47 kb obesity-associated interval and promoters of genes
located within a megabase window downstream FTO locus, we per-
formed circular chromosome conformation capture followed by high
throughput sequencing (4C-seq) in adult mouse brain (8 weeks). In order
to determine a potential role for Irx5 expression (and exclude IRX6) in the
regulation of body mass index and metabolism, we used the CRISPR-
Cas9 system to create Irx5 and Irx6 Knock-out mice.
Results: Using 4C-seq, we observed strong long -range interaction be-
tween the obesity-associated FTO intron not only with Irx3, but also Irx5.
No interaction was observed with IRX6 promoter. Mice homozygous for
an Irx5 and Irx6 null allele are viable and fertile, with no evidence of
embryonic lethality. Irx5KOmice showed a significant reduction in body
weight. Importantly, the percentage of fat mass was significantly reduced
without marked change of the lean mass ratio, due to an increase in
browning of white adipose tissue. Similar phenotype was observed for
Irx3KO mice. After the mice were subjected to 45% high fat diet (HFD)
for 10 weeks, Irx5KO showed improved glucose intolerance and insulin
resistance compared to control littermates. Irx6KOmice did not show any
weight loss phenotype and HFD lead to glucose intolerance similar to
observed in WT controls. Compound animals Irx3/Irx6 and Irx3/Irx5 are
being generated and heterozygote animals are being evaluated for meta-
bolic phenotypes.
Conclusion: These results strongly suggest that Irx5, together with Fto
and Irx3, is also responsible for controlling body mass, body composition
and energy metabolism. Our data shows that obesity-associated SNPs
within FTO are functionally connected with multiple genes and that
misregulation of Irx3 and Irx5 expression, but not with Irx6, that is indeed
located in another transcription activation domain (TAD), might lead to
obesity in mice.
Supported by: NIH
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Identification of novel susceptibility genes for diabetes- and obesity-
related traits in two backcross populations of obese and lean mice
T. Schallschmidt1, S. Lebek1, A. Chadt1, Y. Schulte1, M. Damen1, T.
Stermann1, C. de Wendt1, B. Knebel1, A. Schürmann2, H. Al-Hasani1;
1Institute for Clinical Biochemistry and Pathobiochemistry, German Di-
abetes Center, Leipniz Center for Diabetes Research, Heinrich-Heine-
University; German Center for Diabetes research (DZD), Duesseldorf,
Germany, 2Department of Experimental Diabetology, German Institute
of Human Nutrition (DIfE), Nuthetal, Germany.
Background and aims: Type 2 diabetes (T2D) in humans is influenced
by a combination of numerous adipogenic and diabetogenic alleles. In
outcross experiments of obese and lean mouse strains, several QTL
(Quantitative Trait Loci) for obesity and hyperglycemia were separated.
Mouse models could therefore help to identify several key obesity and
diabetes modifier genes. In order to find further disease genes we per-
formed two new crossbreeding approaches and subsequent QTL analysis.
The obese New Zealand Obese (NZO) mouse which represents a poly-
genetic model for the human metabolic syndrome and T2D, was crossed
with the two lean mouse strains C3HeB/FeJ and 129/OlaHsd.
Materials and methods:We measured phenotypic traits associated with
obesity and T2D in two backcross populations of 600 individuals each
(300 males, 300 females). Animals were fed a high-fat-diet (45% fat/cal.)
throughout the experiment. Body weight, body composition, plasma glu-
cose and insulin concentrations during fasted and fed states were mea-
sured at different time points. At 21weeks of life mice were sacrificed and
tissues were harvested for the analysis of metabolic regulators. We geno-
typed both N2 populations with the help of a genome-wide high-density
SNP panel. Linkage analysis was performed by in silico calculation of
phenotype-genotype associations. Moreover, differential gene expression
between the parental strains in liver, skeletal muscle, WAT, BAT and
pancreatic islets was analysed by Affymetrix microarrays.
Results: Genetic linkage analysis revealed several highly significant QTL
for metabolic traits in both backcross populations. In the NZOxC3HeB/FeJ
backcross, major QTL for blood glucose were identified on chromosomes 4
(32 cM, logarithm of odds (LOD) 8.4), 7 (12 cM, LOD 14.0) and 15
(13 cM, LOD 7.5). Interestingly, a QTL for blood glucose at 32 cM on
Chr. 4 was detected in both backcrosses (NZOx 129/OlaHsd and
NZOxC3HeB/FeJ), indicating the contribution of an NZO allele. However,
the largest effects were contributed by Chromosome 7, where maximum
LOD scores overlapped for blood glucose, body weight, lean mass, final
plasma insulin and BMI. Moreover, this locus appeared to be responsible
for almost 80% of the total prevalence of hyperglycaemia in the male
NZOxC3HeB/FeJ backcross population. Using microarray data we were
able to detect several candidate genes within the loci with tissue-specific
differential expression between the strains.
Conclusion: We identified novel QTL associated with obesity and T2D
through a mouse genetics approach. Moreover, we were able to determine
promising candidate genes for the diabetogenic effect of the most striking
QTL on chromosome 7. Sequencing and functional assays of these candi-
dates will help to identify the causal genes. Furthermore, interval-specific
congenic introgression of 129, C3H and NZO into diabetes-resistant
C57BL/6J will be performed to narrow down the candidate region and
therefore serve as a second approach to identify novel diabetes genes.
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Obesity modulates Ankrd26 gene expression by inducing epigenetic
changes of its promoter
G.A. Raciti1, R. Spinelli1, A. Desiderio1, M. Campitelli1, L. Parrillo1,
M. Longo1, F. Zatterale1, V. Vastolo1, P. Ungaro1, C. Miele1, I. Pastan2,
F. Beguinot1;
1CNRResearchUnit at the Department of TranslationalMedical Sciences
(DiSMeT), “Federico II” University of Naples, Italy, 2National Cancer
Institute (NCI), National Institute of Health (NIH), Bethesda, USA.
Background and aims: Ankyrin repeat domain 26 (Ankrd26) gene is a
novel actor in the pathogenesis of obesity and T2D. This gene indeed plays
an important role in the control of food intake, fat mass and glucose toler-
ance in vivo in mice. Based on ourMeDIPseq data, Ankrd26 gene seems to
be a target sensitive to environmental exposure and to epigenetic modifica-
tions. Here, we aimed to investigate whether obesity in vivo impacts on
Ankrd26 gene transcription by causing epigenetic modifications
Materials and methods: Obesity was induced by feeding 8 weeks (w)
old male C57BL/6mice with a high fat diet (HFD; ~60% energy from fat)
up to 22 w. Gene expression was evaluated by Real-time qPCR in tissues
from obese mice and lean mice (STD). DNA methylation of Ankrd26
promoter was investigated by MeDIP-qPCR and bisulfite sequencing
analysis in both lean and obese mice
Results: HFD-fed mice are heavier than STD-fed mice already upon 8 w
of obesogenic treatment reaching a 50% increase of body weight com-
pared with lean mice at the end of the treatment. Obese mice exhibit also
increased fasting blood glucose, impaired glucose tolerance and reduced
insulin sensitivity at 8 and 22w compared with controls (Table 1). Upon 8
w of treatment Ankrd26 mRNA expression is slightly decreased in the
epididymal white adipose tissue (WAT) from obese mice compared with
lean mice (STD 0.544±0.036 AU vs. HFD 0.521±0.021 AU). By con-
trast, 22 w of treatment leads to a significant decrease of Ankrd26mRNA
in WAT from obese mice (STD 0.509±0.011 AU vs. HFD 0.483±
0.008 AU, p<0.001). Similar to WAT, Ankrd26 mRNA levels are de-
creased in the tibialis skeletal muscle (STD 0.578±0.019 AU vs. HFD
0.558±0.011 AU, p<0.01), but not in the liver (STD 0.492±0.023 AU
vs. HFD 0.500±0.028) from obese mice upon 22 w of HFD compared to
controls. Consistent with the lower Ankrd26 expression in obese mice,
MeDIP-qPCR analysis shows a 2-fold increase in DNA methylation en-
richment of a region covering the Ankrd26 promoter (-462 bp to -193 bp)
in pooledWAT genomic DNA from 22 wHFD-fed obese mice compared
with lean mice (STD IP=0.407±0.171% vs. HFD IP 0.814±0.047%, p<
0.05). Bisulfite sequencing also reveals in obese mice a consistent and
specific hyper-methylation of 2 cytosine residues at -436 bp (% of meth-
ylation: STD 62% vs. HFD 90%, p<0.001), and -431 bp (% of methyl-
ation: STD 38% vs. HFD 83, p<0.001) from Ankrd26 Transcription
Starting Site. By contrast, no differences in the methylation state of these
two specific CpG sites were observed between lean and obese mice upon
8 w of treatment (% of methylation -436 bp: STD 71% vs. HFD 83%; %
of methylation -431 bp: STD 65% vs. HFD 58%)
Conclusion: Obesity regulates in a time dependent manner the expres-
sion of the Ankrd26 gene by inducing methylation of specific CpG sites
on Ankrd26 promoter
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New animalmodels reveal that two genes are candidates for the onset
of type 2 diabetes associated with obesity in rats
D. Sasaki, J. Koto, R. Watadani, Y. Seto, A. Tanida, K. Honda,
K. Matumoto;
Kyoto Sangyo University, Japan.
Background and aims: Obesity is a major factor for the onset of type 2
diabetes. However, little is known how obesity induces the onset of type 2
diabetes. So far, many genes responsible for obesity and type diabetes
were identified by genome-wide association studies, but only few genes
are common between obesity and type 2 diabetes. Since it is difficult to
directly search for diabetogenic genes associated with obesity, the use of
double congenic rats introgressing both fa/fa obese and diabetogenic gene
is an essential component of genetic investigation. In this study, we in-
vestigate to identify diabetogenic gens associated with obesity using new
obese animal models.
Materials and methods:We generated several congenic strains: (1) sin-
gle lean congenic introgressed Nidd2 QTL derived from OLETF rat into
F344 (F.O-Nidd2/of), (2) single obese congenic introgressed Lepr-/- lo-
cus into F344 (F.ZF-Lepr) and (3) double congenic rats having obese and
Nidd2 QTL region (F.ZF-Lepr&Nidd2/of). Each strain was phenotyped
for plasma glucose, insulin levels and insulin resistance by insulin toler-
ance test (ITT). In 25 weeks of age, they were sacrificed and then liver,
skeletal muscle and abdominal fat tissues were dessected and stored at -
80°C until use. RNA and protein levels were determined using reverse
transcription-quantitative PCR and western blotting analyses,
respectively.
Results: The double congenic strain, F.ZF-Lepr&Nidd2/of (Lepr−/− and
Nidd2/of) showed significantly higher glucose levels (60, 90, 120 min
after glucose loading : p<0.001 vs F.ZF-Lepr), and significantly lower
hypoglycemic response to insulin than those of the obese control strain,
F.ZF-Lepr (Lepr−/−) (30, 60, 90, 120 min after insulin injection : p<0.05
vs F.ZF-Lepr). These phenotypes were observed specifically in the obese
strains, but not in the lean strains. These results indicate that the Nidd2/of
locus harbours a diabetogenic gene associated with obesity. We measured
the expression of 60 genes in the Nidd2/of QTL region between the
strains and found that the levels of the mRNA expression of five genes
were significantly different between the strains under condition of obesi-
ty. Three genes among the five genes were differentially expressed both in
obese and lean rats, while the other two genes, Coq2 and Plac8 were
differentially expressed specifically only in the obese rats, suggesting that
these genes are candidates for the onset of type 2 diabetes associated with
obesity in rats (Coq2 : P=0.00387 and Plac8 : p=0.00122)
Conclusion: Our data show that Coq2 and Plac8 were candidate genes
for the onset of type 2 diabetes associated with obesity in rats.
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Nicotinamide nucleotide transhydrogenase and the glucose regula-
tion of mitochondrial glutathione oxidation, NADPH concentration
and insulin secretion in mouse islets
L.R.B. Santos, C. Muller, A.H. Souza, H.K. Takahashi, J.-C. Jonas;
UCL, Brussels, Belgium.
Background and aims: Changes in glutathione redox state (EGSH) were
recently measured with the redox-sensitive GFP2 probe fused to
glutaredoxin 1 (GRX1-roGFP2) and its mitochondrial form (mt-GRX1-
roGFP2) in rat islet cell clusters and human islets. We found an inverse
correlation between 1) the acute glucose-mediated reduction in EGSH and
2) the acute rise in NAD(P)H autofluorescence and glucose stimulation of
insulin secretion (GSIS). Nicotinamide nucleotide transhydrogenase
(NNT) is one of several NADPH-producing enzymes in mitochondria
that could contribute to these acute glucose effects. Its spontaneous
inactivating mutation in C57BL6/J mice was shown to reduce the GSIS
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due to reductions in ATP production, β-cell depolarization and Ca2+
influx. Here, we tested the impact of a lack of NNT on the acute glucose
regulation of mitochondrial EGSH and its role in GSIS and key stimulus-
secretion coupling events by comparing islets from C57BL6/J mice with
islets from closely-related C57BL6/N mice that express wild-type NNT
(J vs. N islets).
Materials and methods: Islets were isolated from 8-16 week-old female
C57BL6/J and /N mice. After isolation, the islets were (co)infected with
adenoviruses coding (mt-)GRX1-roGFP2, NNT+mCherry (to express
wild-type NNT in J islets) or mCherry alone as control, and cultured for
2-4 days. The mitochondrial and cytosolic EGSH, the reduced and oxi-
dized forms of NADP and NAD, ATP and the sum ATP+ADP, the intra-
cellular Ca2+ concentration, and insulin secretion were measured after 30-
60 min incubation or during perifusion at increasing glucose concentra-
tions from 0.5 (G0.5) to 30 mmol/L (G30) in the presence of 4.8 or
30 mmol/L extracellular K+ (K4.8 or K30).
Results: In N islets, glucose acutely and significantly reduced mitochon-
d r i a l E G S H a s i n r a t s a n d h uman s wh i l e i n c r e a s i n g
NADH/(NADH+NAD+) (G30 0.22±0.03 vs. G0.5 0.05±0.01, p<
0.01), NADPH/(NADPH+NADP+) (G30 0.72±0.08 vs. G0.5 0.48±
0.06, p<0.05) and ATP/(ATP+ADP) ratios (G30 0.83±0.003 vs. G0.5
0.69±0.003), p<0.001), Ca2+ and insulin secretion in K4.8 or K30 (p<
0.05). In J islets, the glucose-induced rises in NADH/(NADH+NAD+)
(0.21±0.04 vs. 0.04±0.01, p<0.01), ATP/(ATP+ADP) (0.85±0.01 vs.
0.71±0.02, p<0.001) and [Ca2+]i were similar to those in N-islets. There
were also no significant differences between mice for their lack of cyto-
solic EGSH response to glucose. In contrast to N islets, mitochondrial
EGSH was low at all glucose concentrations and NADPH/
(NADPH+NADP+) was not increased in G30 compared to G0.5 (0.83±
0.03 vs. 0.78±0.03) and not decreased by 10 μM of mitochondrial un-
coupler FCCP in G30 (0.83±0.02). The GSIS in K4.8 and K30 was 66%
lower (p<0.05) in J vs. N islets, but the relative amplifying action of
glucose in K30 was preserved (fold-increase vs. G0.5). Importantly,
adenovirus-mediated expression of NNT in J islets restored the glucose
regulation of mitochondrial EGSH and the glucose (G30 0.84±0.01 vs.
G0.5 0.52±0.04, p<0.001) and FCCP (0.64±0.05, p<0.05 vs. G30) reg-
ulation of the NADPH/(NADPH+NADP+) ratio as observed in N islets,
and significantly increased GSIS in both K4.8 and K30 conditions.
Conclusion:NNT is responsible for the glucose-induced rise in NADPH/
(NADPH+NADP+) ratio and reduction in mitochondrial EGSH in pancre-
atic islets, and increases the GSIS by acting at a site distal to Ca2+ influx.
The results also suggest that NNTworks in the reverse mode of operation
in islets exposed to a low glucose concentration or to FCCP.
Supported by: FRS/FNRS/ARC/CFB
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Mitochondrial mutations affect cellular calcium homeostasis in the
aging organism and could support development of type 2 diabetes
mellitus
J. Niemann, C. Johne, M. Tiedge, S. Baltrusch;
Institute of Medical Biochemistry and Molecular Biology, University
Rostock, Germany.
Background and aims: It was postulated that mutations in the mitochon-
drial genom (mtDNA) which accumulate in age can contribute to the
pathogenesis of type 2 diabetes mellitus (T2DM). In mice there is a
maximum value in ROS generation in liver at the age of 9 months. At
an advanced age there is a decreased value in ROS generation and a
reduced membrane potential in C57BL/6NTac-mice (control). However,
in conplastic C57BL/6NTac-mtNOD/LtJ-mice (mtNOD) carrying a point
mutation in complex IVof the respiratory chain ROS generation remains
constantly high and membrane potential increased in age. The aim of this
study was to examine if an altered calcium homeostasis contributes to this
adaption in the mtNOD mouse strain.
Materials and methods: Hepatocytes of 3, 6, 9 and 12 months old
control- and mtNOD mice were isolated and transfected with the
cyto(plasmatic)-CAR-GECO and the mito(chondrial)-GEM-GECO vec-
tor. Fluorescence intensity of the resulting proteins depends on calcium
binding. Cells were analysed after starvation and subsequent glucose
supply (25 mmol/l) by means of fluorescence microscopy. In addition,
RNAwas isolated from hepatocytes and gene expression of uncoupling
protein 2 (UCP2) and the mitochondrial calcium uniporter (MCU) were
investigated by quantitative Real-Time PCR.
Results: Cytosolic Calcium influx after glucose supply was comparable
at the age of 3 months in both strains. At the age of 6 months this influx
was reduced in controls and mtNOD mice. The cytosolic calcium influx
was highest in 12 months old controls with a significant increase com-
pared to 6 months old mice. In contrast, in mtNOD mice cytosolic calci-
um influx in 9 and 12 months old animals was comparable to 3 months
old animals. Interestingly, the age dependent pattern of glucose-induced
cytosolic calcium influx was in line with the gene expression of UCP2
suggesting a relationship of both parameters. At the age of 3 months
mitochondrial calcium influx was significantly higher in mtNOD mice
compared to controls. A slight increase of the mitochondrial calcium
influx was observed in controls during aging, whereas there is a strong
and significant decrease in mtNOD mice. Notably, the age dependent
decline of the glucose-induced mitochondrial calcium influx after fasting
occurred inversely to the increase in the mitochondrial membrane poten-
tial in hepatocytes. Gene expression of the MCU was comparable in
3 month old animals. It remained unchanged during aging in controls,
whereas a significant increase was observed in 9 and 12 versus 3 months
old mtNOD mice.
Conclusion: The mitochondrial calcium influx declined at the age of
9 months in both strains compared to the cytosolic calcium influx in
hepatocytes. However, control and mtNOD mice adapted in a different
manner. Control mice increased the cytosolic calcium influx, whereas
mtNOD up-regulated MCU gene expression. Our data suggest reduced
sensitivity to external triggers including insulin in mtNOD mice in age.
Thus, the C57BL/6NTac-mtNOD/AtJ mouse strain represents an inter-
esting model to study trigger effects of age dependent mitochondrial
regulation in the pathogenesis of T2DM.
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Deletion of the type 2 diabetes-associated gene product STARD10 in
mice impairs insulin secretion and action
G.A. Rutter, G.R. Carrat, M.-S. Nguyen-tu, P. Chabosseau;
Dept. Cell Biology, Div. Diabetes, Endocrinology & Metabolism,
Imperial College, London, UK.
Background and aims: Genome-wide association studies have identi-
fied more than 90 loci associated with type 2 diabetes risk. Recently-
identified common genetic variants in the ARAP1/STARD10 locus affect
fasting proinsulin levels (rs11603334) and glucose-induced insulin secre-
tion (rs1552224) in man. The implicated single nucleotide polymor-
phisms (SNPs) are located in the 5’UTR of the ARAP1 gene and
~40 kb downstream of the STARD10 gene. The product of the latter gene,
StAR-related lipid transfer (START) domain containing 10, is involved in
the intracellular transport of phospholipids. Here, we show that global
deletion of the StarD10 gene in mice leads to marked defects in both
insulin secretion and insulin sensitivity.
Materials and methods: Null alleles of StarD10 (Tm1a), bearing a
LacZ-neo-STOP cassette downstream of exon 2, were provided through
the International Mouse Phenotyping Consortium (IMPC) and main-
tained on a C57BL6 background. Loss of StarD10 mRNA from liver
and islets was confirmed by qRT-PCR. Transgenic mice were generated
by pronuclear injection of DNA encoding FLAG-tagged StarD10 under
tetracycline-regulated promoter control. Crossing with RIP7-rtTA mice,
expressing the reverse tetracycline transactivator under the control of the
rat insulin promoter, allowed ß-cell-specific, tetracycline-inducible ex-
pression in adult mice, and was confirmed by qRT-PCR analysis and
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Western (immuno-) blotting. Measurement of glycemic parameters
in vivo, islet isolation, intracellular Ca2+ imaging and insulin secretion,
were performed using standard protocols.
Results: Compared to wild type (WT) littermates, mice deleted globally
for StarD10 (KO), and assessed at 14-16 weeks of age, displayed in-
creased fed glycemia (WT, 8.1±0.1 mmol/L vs KO, 9.7±0.3, p<
0.001), intraperitoneal glucose (1 g/kg; AUC: WT, 1169±34 WT vs
KO, 1274±30 mmol/l*min., p=0.034) and insulin (0.75 U/kg; AUC:
WT, 875±62 vs KO, 670±34 pM*min., p<0.01) tolerance. Glucose-
(3 g/kg) stimulated insulin secretion was also sharply reduced in vivo in
knockout mice (AUC: WT, 50.37±22.53 vs KO, 40.57±6.65 pM*min.,
p=0.026). Correspondingly, glucose- (17 vs 3 mM) induced insulin se-
cretion (WT, 0.86±0.05%; KO, 0.21±0.03% p<0.001) and cytoplasmic
Ca2+ increases, assessed using the entrappable fluorescent probe fluo-2,
and confocal imaging of whole islets (fold-change: WT, 23.5%±1.7 fold
change vs KO, 15.4%±1.9, p<0.001) were reduced in islets from KO
mice versus those from WT littermates. Transgenic StarD10 male mice
displayed a tendency towards reduced glucose tolerance (AUC: WT,
1251±36; Tg: 1397±69 mmol/l*min., p=0.076) at 16 weeks, but were
otherwise normoglycemic. Correspondingly, adenovirus-mediated over-
expression of StarD10 in mouse islets exerted no effect on insulin secre-
tion stimulated by glucose (17 vs 3 mmol/L) or KCl (30 mM/L). How-
ever, overexpression of StarD10 potentiated apoptosis induced by
staurosporine (1 μM) in mouse islets, as assessed by Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining
(control: 1.85±0.23%; StarD10: 4.60±0.62%; p<0.0001).
Conclusion:These data indicate that lowered expression of StarD10 gene
in risk allele carriers may contribute to exaggerated disease risk, and may
act both via changes in insulin secretion and action.
Supported by: MRC (UK), Wellcome Trust, SFD (Fr), Royal Society
347
A novel gene, R3h domain containing-like, might play a role
in muscle regeneration
K. Sakamoto, M. Takemoto, T. Ishikawa, R. Ishibashi, P. He, A. Hattori,
M. Yamaga, M. Shoji, S. Ide, K. Ide, H. Kawamura, K. Kobayashi, H.
Tokuyama, Y. Maezawa, K. Yokote;
Department of Clinical Cell Biology and Medicine, Chiba University
Graduate School of Medicine, Japan.
Background and aims: Skeletal muscles are fundamentally important
not only for physiological activities but also for maintaining normal glu-
cose homeostasis. Sarcopenia, a loss of muscle mass that is often seen in
the elderly patients with type 2 diabetes, might be caused by the disability
of muscles to regenerate, thus inducing frailty and insulin resistance.
Although the number of geriatric patients with type 2 diabetes has in-
creased worldwide, the mechanisms underlying sarcopenia and muscle
regeneration have not yet been understood. We previously reported that
the R3h domain containing-like (R3hdml) gene, a podocyte-specific tran-
script, inhibited TGF-β-induced p38 MAPK signaling. Furthermore, it
has been reported that TGF-β-induced p38 MAPK signaling is important
for muscle regeneration. In addition, a meta-analysis of genome-wide
association studies has identified a gene locus including the R3hdml gene
as a risk allele for type 2 diabetes in East Asians. Therefore, we have
begun investigating the function of R3hdml in skeletal muscle, particu-
larly focusing on muscle regeneration.
Materials and methods: R3hdml expressions in skeletal muscle regener-
ation model mice [10 mM cardiotoxin (CTX) was injected in the tibialis
anteriormuscle or quadriceps] were evaluated by real-time polymerase chain
reaction (qPCR) andwestern blotting (WB). C2C12 cells, amousemyoblast
cell line, were differentiated into myotubules in the presence of 2% horse
serum for 5 days; thereafter, the expressions of R3hdml as well as transcrip-
tion factors that related to muscle differentiation were examined by qPCR
and WB. R3hdml was then silenced with small interfering RNA (siRNA)
and the effects of R3hdml on the formation of myotubules were examined.
The expressions of R3hdml in skeletal muscle were also studied in wild-type
control mice, db/db mice fed or not fed a high-fat diet for 7 weeks.
Results:R3hdml was not detected in skeletal muscle under physiological
conditions. However the expressions of R3hdml were increased upon
injury of skeletal muscle with CTX indicating that R3hdml expressions
were induced by skeletal muscle regeneration. Neither R3hdml mRNA
nor protein were detected in undifferentiated C2C12 cells, however their
expressions increased along with differentiation of C2C12 cell. The ex-
pression of Pax 7, a marker for early muscle differentiation, was de-
creased and myotubule formation was attenuated by 26.1% when the
R3hdml gene was silenced by siRNA in C2C12 cell. Finally, the expres-
sions of R3hdml were also increased in skeletal muscle under diabetic
conditions where chronic inflammation and muscle regeneration took
place to a lesser extent compared to CTX model.
Conclusion: Since the disability of muscles to regenerate were often
observed in geriatric patients with type 2 diabetes, R3hdml, a novel skel-
etal muscle expressed gene, may play a role not only in glucose metab-
olism but also in sarcopenia development through the modulation of
skeletal muscle regeneration.
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Evaluation of clinical risk factors for diabetes screening in a large
cohort of subjects in a primary care setting
L. Czupryniak1, M.T. Małecki2, K. Strojek3, E. Szymańska-Garbacz1, P.
Bijoś4, J. Loba1;
1Medical University of Lodz, 2Collegium Medicum, Cracow, 3Silesian
Medical University, Lodz, 4TEVA Pharmaceuticals, Kutno, Poland.
Background and aims: Timely diagnosis of diabetes remains a global
challenge as many subjects with diabetes are unaware of their condition.
A simple diagnostic strategy which could help decrease the rate of undi-
agnosed diabetes is needed. The aim of this study was to evaluate the
performance of classical clinical risk factors in screening for diabetes in a
large group of individuals in a primary care settings.
Materials and methods: In 2014 we conducted a primary care
physician-based nationwide screening programme aiming at identifying
individuals with undiagnosed diabetes or prediabetes. A total of 561
primary care physicians (PCPs) took part in the programme, and 21 726
subjects were enrolled. The inclusion criteria were following: no earlier
diagnosis of diabetes or prediabetes (i.e. IFG and/or IGT) and the pres-
ence of at least one classical risk factor: age>45 yrs, family history of
diabetes, sedentary lifestyle, smoking, presence of fatty liver disease,
hypertension, hyperlipidemia, coronary artery disease, peripheral artery
disease, obstructive sleep apnoea syndrome, polycystic ovary syndrome,
history of stroke, gestational diabetes or having a child with birth weight>
4 kg as well as BMI>25 kg/m2 or waist circumference>80 cm in women
or 94 cm in men. All subjects underwent fasting plasma glucose (FPG)
measurement, and those individuals in whom its value exceeded 125 mg/
dl were referred to have second FPG measured at least one week later,
while those in whom the initial FPG measurement was between 100 and
125 mg/dl had an oral 75 g glucose tolerance test (OGTT) performed.
Results: The prevalence of all risk factors assessed in the examined
cohort is presented in Table 1. In the whole group diabetes was diagnosed
in 4221 (19.4%), and prediabetes in 5829 (26.8%) of the subjects, thus 10
050 (46.3%) of the individuals in the studywere found to have any degree
of glucose metabolism abnormalities. The majority of diabetes cases
(2825/4221, i.e. 66.9% of the diagnosed group) were diagnosed based
on two FPG measurements >125 mg/dl. In 6265 (28.8%) of the subjects
the concomitant presence of three main unmodifiable risk factors, which
are also simply identified in PCP setting, i.e.: age>45 years, family his-
tory of diabetes and BMI>25 kg/m2 were found. In this subgroup 1989
(31.7%) individuals were found to have diabetes and 2101 (33.5%) to
have prediabetes, thus, the rate of glucose metabolism abnormalities
reached 65.2% in these subjects. The odds ratio for diabetes in this sub-
group was 2.757 (95% CI 2.57-2.957), and for diabetes or prediabetes it
was 2.998 (2.818-3.189), as compared to those with only one or two co-
existing features.
Conclusion: Our data support the use of classical clinical risk factors in
screening for diabetes in a primary care setting. Particular effort should be
put into testing individuals older than 45 years who have a family history
of diabetes and are overweight.
Supported by: TEVA Pharmaceuticals
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One in four subjects above the age of 20 years could have diabetes in
Bangalore
S.M. Rajbhandari1,2, Diabetacare Screening Team;
1Diabetes Dept, Chorley & South Ribble Hospital, Chorley, UK,
2Diabetacare, Bangalore, India.
Background and aims: The number of people with diabetes in India is
increasing due to population growth and aging, urbanization, increasing
prevalence of obesity and physical inactivity. Despite this, there are no
good studies on the prevalence of diabetes and risk factors associated with
it. This cross-sectional population survey was undertaken to determine
the prevalence of diabetes and impaired glucose in an urban population of
Bangalore, India and its association with dietary habits.
Materials and methods: Subjects were invited to attend screening for
blood glucose, blood pressure, dietary history and anthropometric mea-
surement at various venues across the city of Bangalore. Local publicity
in and around the venue were done few days prior to the event. It was a
free event and people could come anytime without appointment.
Results: 3882 subjects were screened over a period of 15 months at 32
venues. Out of this 29 subjects below the age of 20 years and 133 subjects
without blood glucose data were excluded from analysis. Diabetes (DM)
was defined as history of self-reported condition or random blood glucose
of 11.1 mmol/L (200 mg%) or more. Impaired glucose (IG) was defined
as those subjects with diabetes or random blood glucose of 7.8 mmol/L
(140 mg%) or more. Out of 3720 patients the prevalence of DM was
24.5% (n=913) and that of IG was 30.5% (n=1134). Out of these 846
(21.8%) subjects were already known to have diabetes. Of the remaining
2874 people, 67 (2.3%) had possible diabetes and 288 (10.0%) had IG,
which were discovered on the day. Prevalence of both diagnosed and
undiagnosed diabetes was high in older subjects (Table 1). There were
no relation (p>0.05) in blood pressure (BP), weight and Body Mass
Index (BMI) in this population between subjects with or without diabetes.
Regarding dietary habvit, there was no difference in BP, weight, BMI and
blood glucose between vegetarian and non-vegetarian subjects. Interest-
ingly there were significantly moremales in non-vegetarian group (53.1%
vs 60.4; p=0.01).
Conclusion:Our data suggest that DM& IG is present in about a quarter
of the urban Indian population. 10% of population above the age of
20 years have glucose abnormalities of which they are not aware. There-
fore regular screening from the general population in urban area is nec-
essary to avert or delay the progression toDMand reduce diabetes-related
morbidity and mortality.
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The prevalence of hypothyroidism is gender-neutrally increased by
autoimmune diabetes but unaffected by type 2 diabetes: the
population-based HUNT study in Norway
H.F. Fleiner1, B.O. Åsvold2, V. Grill1;
1Department of Cancer Research and Molecular Medicine, 2Department
of Public Health and General Practice, Norwegian University of Science
and Technology, Trondheim, Norway.
Background and aims:Associations between autoimmune diabetes and
hypothyroidism are known, but insufficiently characterized. Some previ-
ous studies suggest that type 2 diabetes is associated with hypothyroid-
ism. The aims were to analyse the impact of autoimmune diabetes on the
prevalence of hypothyroidism specifically with regard to gender, and to
test for associations between type 2 diabetes and hypothyroidism.
Materials and methods: Cross-sectional population-based studies of adults
in two surveys of the HUNT Study. Data were available for 34,287 partici-
pants of HUNT2 (1995-97) and 48,598 participants of HUNT3 (2006-08).
Prevalence of hypothyroidism was assessed by self-report, TSH measure-
ments and, for HUNT3, linkage with the Norwegian Prescription Database.
Results: In HUNT2, the prevalence of hypothyroidism was in nondia-
betics 2.7 fold higher among women (8.3%) than in men (3.1%). Auto-
immune diabetes increased the prevalence inwomen to 15.8% and inmen
to 10.9%. Thus, compared with having no diabetes, autoimmune diabetes
was associated with a 64% higher age-adjusted prevalence of hypothy-
roidism among women (prevalence ratio [PR] 1.64, 95% confidence in-
terval [CI] 1.15-2.34) but an almost three times higher age-adjusted prev-
alence of hypothyroidism amongmen (PR 2.93, 95%CI 1.90-4.52). Type
2 diabetes was not associated with the prevalence of hypothyroidism. In
HUNT3 the associations were broadly similar to those in HUNT2.
Conclusion: 1) The enhancing effect of autoimmune diabetes on the prev-
alence of hypothyroidism was gender neutral, thus decreasing the difference
in prevalence between women and men, 2) type 2 diabetes did not incur
increased risk of hypothyroidism, thus contradicting the notion that increased
surveillance for hypothyroidism is necessary in patients with type 2 diabetes.
Supported by: Norwegian Research Council of Norway
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Prevalence of diabetes mellitus and its associated risk indicators in a
peripheral region of Bangladeshi population
F. Jasmine1, K. Fatema2,3, L. Ali4;
1Department of Health Promotion and Health Education, 2Department of
Epidemiology, Bangladesh University of Health Sciences, Dhaka, Ban-
gladesh, 3The School of Public Health and CommunityMedicine, Faculty
of Medicine, The University of New South Wales, Sydney, Australia,
4Department of Molecular and Cell Biology, Bangladesh University of
Health Sciences, Dhaka, Bangladesh.
Background and aims:A large racial heterogeneity in diabetes suggests
that there is a need of conducting epidemiological studies in different
communities. There is scarcity of such studies in Bangladesh, particularly
in remote rural areas. The objectives of this study were to estimate the
prevalence of diabetes and to identify its associated risk indicators in a
rural population of Bangladesh.
Materials andmethods: In 2008, a large cohort was initiated that follow-
ed up in 2011 where we screened a proportion (subset of 63708
participants, aged 31-74) of this cohort for cardiovascular disease related
risk factors using WHO CVD Risk Management Package 2002’ under a
cross-sectional design. The study participants (n=1732, male=834 and
female=898) were randomly selected from the subset and screened in a
camp setting. Diabetes was diagnosed based on WHO study group
Criteria after a 2-hr OGTT, body mass index (BMI), waist-hip ratio
(WHR), blood pressure and lipid profile were also estimated.
Results: The prevalence of diabetes was found to be 14.2% (95%CI 12.6-
15.9) and that of impaired glucose tolerance (IGT) and impaired fasting
glucose (IFG) was 7.9 (95%CI 6.7-9.3) and 4.3 (95%CI 3.4-5.3) respec-
tively. The prevalence of diabetes and impaired glucose regulation dif-
fered between males and females (p<0.005), but, both increased with age
in males as well as in females. After adjusting for potential confounders
WHR, hypertension, smoking, triglyceride and cholesterol were found as
significant independent risk indicators for the occurrence of diabetes in
this population.
Conclusion: Fairly a high prevalence of diabetes was observed in this
remote rural Bangladeshi population. Preventive programs, particularly
targeted to WHR management, lipid profile control through lifestyle
modification should be strengthened in rural areas.Most of the existing
research conducted in Bangladeshi rural settings has been in rural areas
adjacent to urban spaces, whereas a remote rural area is one geographi-
cally and behaviorally distinct from urban influences.
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Nation-wide estimated prevalence of diabetes in Greece: identifica-
tion of patients with prescribed pharmacological treatment among
94.5% of the total Greek population
S. Liatis1, G. Dafoulas1, N. Tentolouris1, A. Kokkinos1, M. Arvanitis1, E.
Diakoumopoulou1, C. Kani2, A. Politi2, P. Litsa2, P.P. Sfikakis1, K.
Makrilakis1;
1First Department of Propaedeutic Medicine, Diabetes Center, Athens
University Medical School Laiko Hospital, 2Medicines Department, Na-
tional Organization for the Health Care Services Provision, Athens,
Greece.
Background and aims: The prevalence of diabetes in Greece is virtually
unknown, despite several regional, small-scale epidemiological studies.
Since Greece is among the first countries that developed a nationwide
electronic drug prescription system, we aimed to identify all patients with
prescribed pharmacological treatment for diabetes.
Materials and methods: The Business Intelligence database system of
the Greek National Organization for Healthcare Services Provision
(EOPYY), which includes big data from e-prescriptions and handwritten
prescriptions, was used to provide analytics on these patients (date of
birth and gender, based on the unique citizens’ social security numbers
and the relevant ICD-10 codes). Permission for use of anonymized data
was obtained by the administration of EOPYY together with the positive
recommendation of the General Secretariat for Public Health of the Greek
Ministry of Health, in accordance to the national legislation on Personal
Data Protection.
We defined people with diabetes as those who received at least two
prescriptions with an ICD-10 code relevant to diabetes (E10, E11 or
O24), dispensed by Greek pharmacies between January 1st 2014 and
December 31st 2014.
Results: This analysis included 10,222,778 individuals (5,012,226
(49.03%) males and 5,210,552 (50.97%) females, representing 94.5%
of the total Greek population, according to the 2011 national census)
S176 Diabetologia (2015) 58 (Suppl 1):S1–S607
and revealed that the prevalence of drug-prescribed diabetes is 7.21%
(736,900 individuals). There is no difference between males and females
(360,335 vs. 376,565; 7.19% vs. 7.23%, respectively). There is a strong
positive association with age, increasing from 0.12% at the age group of
5-14 years, to 3.45% at the age group of 45-54 years and up to 32.11% in
those older than 75 years (p for trend<0.001).
Conclusion: In this first nation-wide analysis of data for the prevalence of
drug-prescribed diabetes in Greece, it was found that its prevalence is
7.21%, one of the highest in Europe. It is presumed that these data provide
reliable estimates of descriptive epidemiology of diabetes, since the anal-
ysis of such big databases largely overrides incorrect diagnosis-associated
limitations that an electronic prescription system may have.
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Trends in diabetes mellitus in Greece from 2003 to 2014 with a future
projection. The SALAMINA study
O. Apostolou1, A. Koutsovasilis1, P. Stamataki2, M. Pappa1,
D. Kraniou1, S. Pappas1, A. Sotiropoulos1;
13rd Internal Medicine Department & Diabetes Center, General Hospital
of Nikaia-Piraeus, 2Salamina Navy Hospital, Athens, Greece.
Background and aims: Diabetes mellitus (DM) is becoming a world-
wide epidemic. The International Diabetes Federation (IDF) recently
readjusted its estimations on DM, predicting a higher prevalence, and,
according to is data, the prevalence in Greece should be 10.2% for 2013.
The aim of the present study is to examine DM prevalence in the adult
population of Salamina island, where relevant studies have been carried
out in 2003 and 2006 with the same methodology, as well as to estimate
DM prevelance in Greece for 2032 according to most recent data.
Materials and methods: Data was derived from three consecutive
population-based surveys conducted in Salamina, during three election
days (13 October 2002, 15 October 2006 and 25 May 2014). In all three
surveys the same selection procedure was used and data was collected
using the same questionnaire, completed by almost the same team of
interviewers. There were 2805 randomely selected adults (> or =20 years)
in 2002, 3478 in 2006 and 2527 in 2014 of similar age and sex distribu-
tion to the target population. Demographic and anthropometric data rele-
vant to DM (duration, medication, family history) as well as presence of
cardiovascular risk factors or other comorbidities were recorded. Statisti-
cal analysis was carried out with SPPS v21.0 (Chicago, Ilinois, USA).
Results: There was no stastistically signifficant difference in age in all
three surveys (p=0.251).The overall crude prevalence of diabetes in-
creased significantly, from 245 (8.7%) in 2002 to 358 (10.3%) in 2006
and to 318 (12.6%) in 2014 (p=0.028). The rates per age group for the
2002, 2006 and 2014 surveys were: 0.4%, 0.6% and 0.3% (p=0.128) in
individuals aged 20-29, 3.6%, 3.7% and1.9% (p=0.048) in individuals
aged 30-39%, 7.3%, 7.2% and 9.4% (p=0.033) in individuals aged 40-
49, 21.6%, 21.2% and 26.4% (p=0.026) in individuals aged 50-59,
31.8%, 31.2% and 30.2% (p=0.214), in individuals aged 60-69, and
35%, 36% and 31.8% (p=0.030) in individuals aged over 70. The mean
age for diabetes diagnosis was 57.6±11.9 while the mean diabetes dura-
tion was 12.3 years for 2014 comparable with the other two surveys (p=
0.086). Only 3.2% of participants reported they were under dietary treat-
ment in 2014 (p=0.016), while more diabetes patients were under insulin
treatment (26.4%) compared to those in 2002 and 2006 (p=0.012). 79.7%
of the individuals who answered the questionnaire had had laboratory
tests for glucose levels and lipids during the last 12months in 2014which
is a signifficantly higher rate compared to higher the rest of the surveys
(p=0.022). Using a Markov model to estimate the future diabetes preva-
lence, a dramatic increase in diabetes prevalence was predicted for 2032
(19.8%)
Conclusion:DMprevalence is higher than the one predicted according to
older studies, basically confirming IDF's predictions. An increase of prev-
alence is observed in younger ages and, according to the prediction for
2032, approximately one out of five people in Greece will have diabetes
which indicates a dramatic increase in diabetes prevalence among Greek
adults.
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Screening for prediabetes in adults aged 45-55 years in primary care
setting should be universal rather than risk-factors based
J. Loba, E. Szymanska-Garbacz, M. Pawlowski, M. Saryusz-Wolska,
L. Czupryniak;
Medical University of Lodz, Poland.
Background and aims: Current guidelines recommend yearly screening
towards glucose metabolism disturbances in individuals aged >45 years,
in whom risk factors for diabetes development are present. However, as
prediabetes is a clinically silent condition, its early diagnosis remains a
challenge. Middle aged professionally active adults are particularly non-
compliant with screening procedures. We conducted a study aiming at
assessing the use of risk factors-based screening for impaired fasting
glucose (IFG) in primary care setting.
Materials and methods: 5276 diabetes-free individuals (2963 women;
56% women) aged 45-55 years, who had at least one risk factor for
diabetes development took part in a nationwide diabetes screening pro-
gramme conducted at primary care level.The participants underwent full
medical examination and had their fasting plasma glucose (FPG) assessed
during a visit at their primary care physician office.
Results:Normal FPG (>100mg/dl) was found in 1421 (27%), while IFG
(100-125 mg/dl) in 1860 (35%) persons. FPG>125 mg/dl was found in
1995 (38%) individuals, and they were excluded from further anaysis.
The prevalence of well established risk factors for glucose metabolism
disturbances in IFG and NFG individuals is presented in the Table. Sed-
entary lifestyle, family history of diabetes and newly diagnosed hyper-
tension were similarly prevalent in both studied groups, however even
when differences in prevalence of other risk factors reached statistical
significance, the actual difference was relatively small, with the exception
of the history of IFG as it was found almost twice as often in persons with
IFG as compared to those with normal fasting plasma glucose.
Conclusion: In conclusion, the prevalence of IFG in adults aged 44-
55 years with risk factors is high. Prediabetes screening programmes
conducted in high risk population in this age group should be universal
rather than risk factors based. In particular, they must not be based on
family history of diabetes or sedentary lifestyle as these factors are equal-
ly often present in persons with IFG as well as normal fasting glucose.
Supported by: Bayer Diabetes Care
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Racial differences in glycaemic marker levels among individuals
without diabetes: the coronary artery risk development in young
adults study
A.P. Carson1, P. Muntner1, E. Selvin2, M.R. Carnethon3, M.D. Gross4,
W.T. Garvey1, C.E. Lewis1;
1University of Alabama at Birmingham, 2Johns Hopkins University,
Baltimore, 3Northwestern University, Chicago, 4University ofMinnesota,
Minneapolis, USA.
Background and aims: Prior studies have reported that glycemic marker
levels vary by race and ethnicity among individuals without diabetes.
However, it is unclear whether these racial differences occur among both
individuals at high-risk for diabetes (i.e., prediabetes) and those with
normal glycemic levels and, if so, whether these differences are clinically
meaningful. The aim of this study was to assess glycemic marker levels
(i.e., fasting glucose, 2-hour post-challenge glucose from OGTT, HbA1c,
glycated albumin, fructosamine, and 1,5-anhydroglucitol) by race among
individuals with and without prediabetes in a cohort study of adults in the
United States.
Materials and methods: The Coronary Artery Risk Development in
Young Adults (CARDIA) Study is a prospective cohort study of 5,115
African American and white adults, age 18-30 years at baseline (1985-
86), from four field centers. This analysis included 2,465 participants who
attended the year 20 examination (2005-06), had glycemic marker data
available, and did not have diabetes (defined as fasting glucose ≥126 mg/
dL, 2-hour post-challenge glucose≥200 mg/dL, HbA1c≥6.5%, or use of
diabetes medications). Prediabetes was defined as a fasting glucose of
100-125 mg/dL, 2-hour post-challenge glucose of 140-199 mg/dL, or
HbA1c of 5.7-6.4%. Multiple regression models were used to assess the
association of race with each glycemic marker, stratified by prediabetes
status.
Results: The mean age of participants was 45 years. Overall, 42% of
participants were African American, 55% were female, and 39% had
prediabetes. Among those with prediabetes, African Americans had low-
er fasting glucose (-1.59 mg/dL), but higher HbA1c (0.26%), glycated
albumin (0.82%), and fructosamine (8.96 μmol/L) compared with whites
after multivariable adjustment. No racial differences were observed for 2-
hour post-challenge glucose or 1,5-anhydroglucitol among those with
prediabetes (Table). Similarly, among normoglycemic individuals, Afri-
can Americans had lower fasting glucose (-2.24 mg/dL) and 1,5-
anhydroglucitol (-0.66 μg/mL), but higher HbA1c (0.04%), glycated al-
bumin (0.61%), and fructosamine (5.97 μmol/L) compared with whites.
No racial difference was observed for 2-hour post-challenge glucose
among normoglycemic individuals (Table).
Conclusion: Racial differences in glycemic marker levels were observed
across the glycemic spectrum, among both individuals with prediabetes
or normal glycemia. These differences were small and not clinically di-
vergent, although African Americans tended to have slightly more ad-
verse glycemic levels than whites for most glycemic markers. Further
investigation of the potential prognostic implications, if any, are
warranted.
Supported by: NIH NIDDK and NIH NHLBI
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Changes in the use of antidiabetic, antihypertensive, and hypolipid-
aemic drugs within 30 months after Roux-en-Y gastric bypass
surgery
S.B. Gribsholt1, E. Svensson2, R.W. Thomsen2, H.T. Sørensen2, D.K.
Farkas2, B. Richelsen1;
1Department of Endocrinology and Internal Medicine, 2Department of
Clinical Epidemiology, Aarhus University Hospital, Denmark.
Background and aims: In the majority of patients undergoing Roux-en
Y gastric bypass (RYGB) surgery, obesity-related complications such as
diabetes and hypertension may improve or remit, with concomitant re-
duction or discontinuation ofmedications. Relapse of these complications
may occur in some patients after a few years, but studies with long-term
follow-up are sparse. We investigated long-term changes in use of anti-
diabetic, antihypertensive, and hypolipidemic drugs among patients, who
underwent RYGB surgery. Furthermore, we compared changes in use of
these drugs among RYGB patients with that in a matched comparison
cohort of persons without RYGB.
Materials and methods: The study included all 9,908 individuals under-
going RYGB in Denmark during 2006-2010 and a 10:1 matched general
population comparison cohort of 99,080 persons, using age, gender, and
RYGB/index date as matching variables. We ascertained complete data
on medication use from population-based medical databases. All subjects
were followed from 6 months prior to the RYGB/index date until
30 months following this date. We computed the proportion of subjects
in each cohort with current drug use and prevalence ratios (PRs) compar-
ing use 6 months before and 30 months after the RYGB/index date, using
Poisson regression analysis.
Results: The mean age in both cohorts was 40.6 years; 21.7%were male.
Figure 1 shows changes in drug use prior to and following the
RYGB/index date. Among the RYGB patients 16.5% used antidiabetic
drugs 6 months before surgery, while 4.7% were on antidiabetic drugs
30 months after surgery [PR=0.27 (95% confidence interval (CI); 0.27,
0.27)]. In the comparison cohort 2.0% used antidiabetic drugs 6 months
before the index date and 2.4% used them 30 months after the index date
[PR=1.25 (95% CI; 1.24, 1.25)]. Like antidiabetic drugs, use of hypolip-
idemic drugs decreased in the RYGB cohort: 14.4% used them 6 months
prior to surgery vs. 7.3% 30 months after surgery [PR=0.49 (95% CI;
0.48, 0.49)]. In the comparison cohort 3.8% used hypolipidemic drugs
6 months before the index date, while 5.4% used them 30 months later
[PR=1.41 (95% CI; 1.41, 1.42)]. For antihypertensives, 43.2% of RYGB
patients were users prior to their surgery compared with 26.1% 30months
after surgery [PR=0.67 (95% CI; 0.67-0.67)]. In the comparison cohort
10.1% used antihypertensives 6 months before and 11.9% 30 months
after the index date [PR=1.22 (95% CI; 1.22 -1.22)].
Conclusion: In this nationwide population-based study, we observed
large reductions in use of antidiabetic, hypolipidemic, and antihyperten-
sive drugs occurring rapidly after RYGB surgery. This reduction was
maintained over 30 months of follow up, with little indication of relapse
as indicated by drug use. Nonetheless, use of these drugs remained higher
among RYGB patients than in the matched comparison cohort.
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Supported by: Grant from the Central Denmark Region and from the
Novo Nordisk Foundation
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Impact of pre-existing cardiovascular disease on treatment initiation
with SU in Denmark: a registry based population study
J. Rungby1, N. Lassota2, A.D. Jørgensen2, R. Ibsen3, J. Kjellberg4;
1Gentofte University Hospital andDept. Biomedicine, Aarhus University,
Gentofte and Aarhus, 2MSD Danmark, Ballerup, 3I2Minds, Aarhus,
4KORA - Danish Institute for Local and Regional Government Research,
Copenhagen, Denmark.
Background and aims: Uncertainties about the cardiovascular (CV)
safety of sulphonylureas (SU) are reflected in package labels and treat-
ment guidelines. Utilizing Danish national registries, we examined
whether this has affected the prescription patterns for SU in Denmark.
Materials and methods:We analysed the development of new SU users
(initiation of SU monotherapy or SU supplementation to any other anti-
diabetic drugs) from 2006 to 2012. History of CV disease (ICD-10: I00-
I99) 0-13 years prior to initiating SU treatment was assessed in this pop-
ulation and among new users of any other oral anti-diabetic drug (OAD).
Since there has been speculation that gliclazide might be associated with a
more benign CV profile than other SU´s an additional analysis was con-
ducted where gliclazide was excluded from the SU group. Furthermore
the analysis was done separately for two sub-groups of CV disease,
namely of coronary heart disease (ICD-10: I20-I25, I46) and myocardial
infarct (ICD-10: I21-I22).
Results:We observed a reduction in the number of new SU users during
the period from 10.530 to 3.876, representing a decrease of 63.2% (figure
1). The relative proportion of new SU users with pre-existing CV disease
increased numerically from 2006 to 2012 (46.9% vs. 48.7%; p=0.06).
During the entire period the proportion of new SU users with pre-existing
CV disease remained higher than the corresponding proportion for other
OAD´s (figure 1, P<0.001 all years). It did not alter the result to exclude
the new users of gliclazide (8-12% of the new users of SU). The propor-
tion of new SU users with pre-existing coronary heart disease was also
found to be higher than the corresponding proportion for other OAD´s (P
<0.05 all years). For patients with pre-existing myocardial infarction the
proportion was higher all years although not significant in years 2009 and
2012.
Conclusion: In Denmark the initiation of SU treatment declined from
2006 to 2012. The proportion of new SU users with pre-existing CV
disease remained high, approaching 50% over the entire period and was
larger than the corresponding proportion for new users of other OADs.
Irrespective of definitions of SU group and type of CV disease, we found
that initiation of SU therapy was more common among patients with CV
disease compared to patients without history of CV disease. This
indicates that pre-existing CV disease did not negatively impact clini-
cians’ usage of SU.
Supported by: MSD Denmark
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Medication persistence and adherence in type 2 diabetes patients
using fixed- versus loose-dose combination products
E. Sorstadius1, T. Lokhandwala2, W. Lee3, N. Smith4, C. Sternhufvud1,
J. Mukherjee5;
1Global payer evidence and pricing, AstraZeneca, Molndal, Sweden,
2Xcenda, Palm Harbor, 3Xcenda, San Francisco, 4Bristol-Myers Squibb,
Lawrenceville, 5Bristol-Myers Squibb, Wallingford, USA.
Background and aims: To compare medication persistence and adher-
ence between type 2 diabetes mellitus (T2DM) patients using fixed-dose
combination (FDC) and loose-dose combination (LDC) products.
Materials andmethods:A retrospective cohort study design using Unit-
ed States’ administrative claims data from Jan 1, 2009 through Dec 31,
2013 was employed. Patients with a prescription for at least 1 FDC or 2
LDC medications filled (on the same date) between Jan 1, 2010 and
Dec 31, 2012 were identified as the target population, with the index date
defined as the fill date. The identified population was restricted to patients
with a T2DM diagnosis (non-diagnostic medical claim with ICD-9 CM
codes of 250.x0, 250.x2) and at least 1 additional oral anti-diabetic pre-
scription (of the same regimen [FDC/LDC] as the index prescription)
within 12 months following the index date. A 12-month pre-index period
was used to obtain baseline characteristics. Persistence (no ≥30 day gap)
and adherence (medication possession ratio [MPR]) were assessed while
the patients were on the index regimen up to a maximum of 1-year
(follow-up period) starting on (and including) the index date. Patients
on triple therapy over follow-up were excluded. The odds of persistence
and adherence [MPR ≥0.8] to therapy were assessed using logistic regres-
sion after adjusting for baseline covariates and the hazard of non-
persistence was similarly assessed using a Cox proportional hazards
model.
Results: Of the 23,361 patients identified, 12,590 (53.9%) were on FDC
therapy and 10,771 (46.1%) were on LDC therapy. The majority of pa-
tients were male (62.4%) with a mean (SD) age of 54.9 (11.2) years. The
mean (SD) number of unique prescription classes was 2.6 (2.9). A statis-
tically significantly greater proportion of FDC patients were persistent
(32.1% vs 26.6%, p<0.0001) and adherent to therapy (57.0% vs
50.7%, p<0.0001) when compared to LDC patients. Average duration
of persistence was significantly longer among the FDC patients when
compared to the LDC patients (207.1 [±136.3] vs 186.3 [±130.0] days,
p<0.0001). After adjusting for baseline characteristics, the odds of non-
persistence in therapy were 21% lower among T2DM patients on FDC
therapy when compared to those on LDC therapy (OR=0.79, 95% CI
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[0.74, 0.85], p<0.0001). The odds of being adherent to therapy (MPR/
DTMPR ≥0.8) were 28% higher among T2DM patients on FDC therapy
when compared to those on LDC therapy (OR=1.28, 95% CI [1.20,
1.36], p<0.0001). Furthermore, T2DM patients on FDC therapy had a
12% lower risk of being non-persistent at any point in time compared to
those on LDC therapy (HR=0.88, 95% CI [0.84, 0.91], p<0.0001).
Conclusion: Management of T2DM using FDC therapies provides a
compliance benefit to patients when compared to LDC therapies, most
likely due to reduced medication burden. This compliance benefit may
translate to better glycemic control and possible reduction in healthcare
utilization and costs due to improved disease management.
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Use of sodium-glucose co-transporter 2 inhibitors among US patients
with type 2 diabetes
S. Rajpathak1, S. Yu1, S.S. Engel1, Z. Li2, C.-P.S. Fan2, J. Tang2,
B. Hanna2, J. Williams1, A. McNeill1;
1Merck & Co., Inc., Kenilworth, 2Asclepius Analytics LLC, Brooklyn,
USA.
Background and aims: Sodium-glucose co-transporter 2 inhibitors
(SGLT-2i) are a new class of oral antihyperglycemic agents (AHA) used
to manage hyperglycemia in patients with type 2 diabetes mellitus
(T2DM). A retrospective study was conducted using MarketScan data-
base to assess treatment patterns and characteristics of patients using
SGLT-2i compared to other oral AHAs.
Materials andmethods: Patients initiating oral AHA between 3/29/2013
and 6/30/2013 (index period) qualified for the study. The index date was
set as the first oral AHA prescribed in the index period. Included were
patients ≥18 years who had continuous enrollment of ≥1 year before and
≥90 days after the index date. Those with T1DM, gestational or second-
ary diabetes, pregnancy, or metformin use for polycystic ovarian syn-
drome were excluded. Patients were assigned to SGLT-2i and non-
SGLT-2i cohorts based on their index drug. Between-group differences
were assessed using Wilcoxon rank-sum tests for continuous variables
and χ2 tests for categorical variables.
Results: Of the 69,511 patients in the study, 2.8% (n=1,917) initiated a
SGLT-2i (canagliflozin was the only available SGLT-2i during the study
period), and the rest were initiated on other oral AHAs. 30.2% patients
were initiated on a 300 mg dose of canagliflozin and of the 68.4% who
initiated 100 mg dose, 9.5% escalated to higher dose within 90 days.
Compared to patients on other oral AHAs, canagliflozin patients were
younger (55.1 vs. 56.1 years, p<0.01) and had a higher proportion of
males (56.1% vs. 51.0%, p<0.01). In addition, canagliflozin patients used
more concomitant medications during baseline (anti-hypertensive: 77.7%
vs. 64.1%; lipid-lowering: 72.8% vs. 49.4%; NSAID: 26.8% vs. 22.8%;
beta-blockers: 27.2% vs. 25.0%, all p<0.01) and already had more ad-
vanced antihyperglycemic treatment regimens compared to those on other
oral AHAs. Furthermore, canagliflozin patients were also more likely to
have micro-vascular complications (23.6% vs. 12.7%, p<0.01), including
nephropathy (4.4% vs. 2.5%, p<0.01), as well as hypertension (62.0% vs.
56.5%, p<0.01) and hyperlipidemia (62.9% vs. 50.9%, p<0.01).
Conclusion: US patients initiating SGLT-2i were already on multiple
AHAs and higher prevalence of comorbidities at baseline compared to
patients initiating other AHAs.
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Patient characteristics, treatment and prevalence/incidence of the
type 2 diabetes population in Sweden: a nationwide study from
2006 to 2013
D. Nathanson1, A. Norhammar1, T. Nyström1, M. Thuresson2, J.W.
Eriksson3, J. Bodegard4;
1Karolinska Institutet, Stockholm, 2Statisticon, Uppsala, 3Uppsala
University, 4AstraZeneca, Södertälje, Sweden.
Background and aims: In a modern nation-wide setting characterise
patterns of glucose lowering treatment and prevalence and incidence of
type 2 diabetes (T2DM) in Sweden.
Materials and methods: Patients who dispensed any glucose-lowering
drug (GLD) between 2006 and 2013 were identified in the Swedish
Prescribed Drug Register and linked with the Swedish National Patient
Register and the Cause of Death Register. Patients with type 1 diabetes
and gestational diabetes were excluded. Information on comorbidities and
medical events were collected from main and secondary diagnoses at
discharge.
Results: In 2013 the prevalence of GLD- treated T2DM was 4.4% (n=
355 114) and incidence 368 per 100 000 patients (28 023). Prevalence of
T2DM patients with GLD treatment increased during 2006-2013 by 51%
while the incidence remained stable. Themean age was 67 years and 56%
were male. Previous cardiovascular disease was present in 34%, micro-
vascular disease in 26%, cancer in 19% and 4% had chronic kidney
disease. Treatment with statin, antihypertensives and low dose aspirin
was present in 56%, 70% and 35% respectively. The most frequently
used GLDs were metformin (69%;), insulin (28%) and SU (17%).
Incretin based GLDs were used in low proportions (DPP4; 6% and
GLP-1; 3%). During 2006-2013 the use of SU decreased by 55% while
insulin use increased by 29%. After direct age adjustment, the standard-
ized risk ratio for myocardial infarction, stroke and all-cause mortality
was 1.9, 1.6 and 1.4-fold respectively in T2DM patients (Figure).
Conclusion: The number of T2DM patients on glucose lowering drugs in
Sweden has increased by 51% the last seven years despite stable T2DM
incidence. The incidence of drug treated T2DM was more than twice as
high as previously reported which illustrates the general problem to report
on true incidence of T2DM accurately with high risk for underestimation.
Despite improved medical care the last decade individuals with T2DM
still have increased risk of cardiovascular disease and death compared to
the general population. The use of SU is declining and seems to be
replaced by insulin and less by incretin based glucose lowering drugs.
Supported by: AstraZeneca
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First-line and intensified treatment with glucose lowering drugs in
the Swedish type 2 diabetes population
T. Nyström1, J. Bodegard2, D. Nathanson1, M. Thuresson3, J.W.
Eriksson4, A. Norhammar1;
1Karolinska Institutet, Stockholm, 2AstraZeneca, Södertälje, 3Statisticon,
4Uppsala University, Sweden.
Background and aims: To investigate initiation of first-line glucose
lowering drug (GLD) treatment, and subsequent GLD treatment, and
prior cardiovascular disease (CVD) for all type 2 diabetes (T2DM) pa-
tients in Sweden.
Materials and methods: T2DM patients who were GLD naïve and ini-
tiated on their first-line GLD treatment during 2006-2013 were identified
in the Swedish Prescribed Drug Register. Patients with type 1 diabetes or
gestational diabetes were excluded. Patients were linkedwith the Swedish
National Patient- and Cause of Death registry. Index date was defined as
date of patients first GLD dispense. Definition of a non-insulin antidia-
betic drug (NIAD) start was any dispense recorded whereas insulin start
was defined when treatment duration exceeded 6 months. From 1987 to
index date, baseline information on CVDs (coronary heart disease, heart
failure, stroke and peripheral artery disease) was collected from the Swed-
ish National Patient Register. Cox survival models adjusted for age, gen-
der, first-line GLD treatment time and any history of CVDs were used to
estimate likelihood of early treatment intensification during up to 7 years
of follow-up.
Results: In 232,749 T2DM patients, first-line GLD treatment were
initiated with either mono NIAD, insulin (alone or in combination
with NIAD), or dual NIAD (86%, 13% and 2% respectively).
Insulin treated patients, in comparison to mono- and dual NIAD
groups were slightly older (64, 63 and 59 years) and had more
CVD (36%, 29% and 21%). Despite higher CVD burden, insulin
treated patients had significantly less CVD preventive treatment
with statin, antihypertensive and low dose aspirin, compared to
NIAD groups. Among 199,562 patients initiated on mono NIAD,
metformin was most common (90%) followed by sulfonylurea
(SU 8%), and other NIADs (2%). Patients initiated with SU were
older (72 vs. 62 years), had more CVDs (43% vs. 27%) and were
more often treated with low dose aspirin and less with statins,
compared to the metformin group. Initiation with SU was associ-
ated with earlier intensification to a second and a third-line
NIAD, or insulin, compared with metformin; hazard ratio (95%
CI): 1.74 (1.69-1.79), 1.76 (1.65-1.88) and 1.72 (1.65-1.80).
Conclusion: In Sweden newly diagnosed T2DM patients are treat-
ed much in concordance to diabetes guidelines, beginning with
metformin. Noteworthy, patients initiated with SU were associated
with earlier insulin treatment intensification. One third of GLD
naïve patients had a history of CVD, clearly demonstrating the
burden in T2DM patients.
Supported by: AstraZeneca
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Patient-related predictors for attaining early glycaemic control in
type 2 diabetes: a population-based study
E. Svensson1, L.M. Baggesen1, R.W. Thomsen1, T. Lyngaa1, L. Pedersen1,
H. Nørrelund2, E.S. Buhl3, C.L. Haase3, S.P. Johnsen1;
1Department of Clinical Epidemiology, Aarhus University hospital, ,
2Aarhus University hospital, 3Novo Nordisk Scandinavia AB, Copenhagen,
Denmark.
Background and aims: Early glycaemic control in type 2 diabetes
(T2DM) may reduce the risk of microvascular and possibly
macrovascular complications. However, data on patient-related predictors
for achieving HbA1c targets is sparse. We examined predictors of early
glycaemic control with particular emphasis on the effects of age and
comorbidity.
Materials and methods: We included all individuals registered with a
first-time glucose-lowering drug prescription in Northern Denmark be-
tween 2000 and 2012. We obtained data on glycated hemoglobin
(HbA1c) levels at baseline and within 3 to 6 months after treatment start,
comorbidities, and medications from population-based medical data-
bases. Success in reaching HbA1c target (less than 7%) one year after
treatment start was examined by Poisson regression analysis, comparing
T2DM patients who were frail (i.e., over 65 years with comorbidities)
with healthy T2DM patients (less than or equal to 65 years and no co-
morbidity). Individual patient-related predictors included age, gender,
marital status, and presence of non-psychiatric comorbidities (Charlson
Comorbidity Index (CCI) level). We adjusted all analyses for age, gender,
pre-treatment HbA1c, diabetes duration, and micro-and macrovascular
complications at baseline. In a sub-sample, we had information on
BMI. We repeated all analyses in this sample.
Results: We identified 38,418 eligible T2DM patients (median age
63 years). Of these, 27,545 (72%) achieved HbA1c target of less than
7% at three to six months after drug initiation. After adjustment for po-
tential confounders mentioned above, there was no difference in achieve-
ment of an early glycaemic target of 70 years vs. 60-70 years) or marital
status (adjusted RR=0.98 [95% CI 0.96-1.00] comparing widowers with
married individuals). Female gender (adjusted RR=0.97 [95% CI 0.96-
0.98] for females vs. males) and presence of comorbidity at baseline
(adjusted RR=0.94 [95% CI: 0.90-0.97] for patients with CCI≥3 com-
pared to CCI=0) were weakly associated with non-achievement of
HbA1c target. The strongest predictor of early glycemic control was the
pre-treatment HbA1c level (adjusted RR=0.63 [95% CI: 0.61-0.64] for
baseline HbA1c of 7.5-8.9%, and 0.58 [95% CI: 0.57-0.59] for baseline
HbA1c of over or equal to 9%, respectively, compared with HbA1c less
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than 7.5%). In a sub-cohort with available BMImeasurements (n=4,166),
results were consistent after additional adjustment for BMI, and BMI per
se was not associated with the chance of successful early glycaemic
control.
Conclusion: In this large population-based study of incident treated
T2DM patients in Denmark, older frail patients had a similar chance of
achieving early glycaemic control as 65 years and younger patients with-
out comorbidity. The strongest predictor of reaching HbA1c target less
than 7% was the pre-treatment HbA1c level.
Supported by: research grant from Novo Nordisk A/S to Aarhus
University
PS 014 Risk marker of type 2 diabetes
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Using diabetes risk scores to select high-risk individuals for diabetes
prevention in the United States: a cost-effectiveness analysis
K. Mühlenbruch1, X. Zhou2, B. Bardenheier3, P. Zhang3, E. Gregg3,
M.B. Schulze1;
1Molecular Epidemiology, German Institute of HumanNutrition Potsdam
Rehbruecke, Nuthetal, Germany, 2Merck, North Wales, 3Division of Di-
abetes Translation, Centers for Disease Control and Prevention, Atlanta,
USA.
Background and aims: Several scoring systems have been developed
for predicting future risk of type 2 diabetes within the past years. While
the performance of these risk scores has been evaluated in detail, few
studies have evaluated the application of those scoring systems to identify
the targeting population for diabetes prevention. This study aimed to
apply the framework of cost-effectiveness analysis to determine the opti-
mal threshold of two previously developed risk scoring algorithms, the
German Diabetes Risk Score (GDRS) and the Atherosclerosis Risk in
Communities (ARIC) 2009 score while using them for identifying high
risk individuals with which to intervene.
Materials and methods: To determine the performance of the two risk
scores in a US population, receiver operating characteristic (ROC) anal-
ysis was performed combining data from the Atherosclerosis Risk in
Communities (ARIC) study and the Cardiovascular Health Study
(CHS)(N combined=17,291; aged 44 to 91 years). Survival analysis
was applied to determine diabetes incidence rates according to a broad
range of risk thresholds (5% to 20% by 1% increments; 25%, 30% and
35%) for the two risk scores. The threshold-specific incidences were
incorporated into a Markov-based simulation model. Two scenarios were
simulated wherein the 1-stage scenario included stratification by the risk
score only and the 2-stage scenario additionally included a glucose test
(threshold 100 mg/dl) in the identified high-risk group. Identified high-
risk individuals were assumed to receive a low-cost community-based
intervention with a risk reduction of 12.5% per year. Simulation samples
were obtained from the 2001-2004 National Health and Nutrition Exam-
ination Survey (NHANES). Incremental cost per quality adjusted life year
gained was calculated by progressively increasing the score threshold.
Results: The area under the ROC curve (ROC-AUC) for the GDRS and
the ARIC 2009 score were 0.691 (0.677-0.704) and 0.720 (0.707-0.732),
respectively. The incremental cost-effectiveness ratios (ICER) in a 1-stage
scenario ranged from $36,447 (GDRS) and $33,404 (ARIC 2009 score)
for 35% risk to $51,318 (GDRS) and $60,170 (ARIC 2009 score) for the
lowest risk cut-off of 5% risk. The selected risk cut-off for an ICER
<$50,000 would be 7% for the GDRS and 9% for the ARIC 2009 score.
In the 2-stage scenario with an additional glucose test in the selected high-
risk group, ICERS for all cut-offs were below $50,000.
Conclusion: The results of this study suggest that a non-invasive diabetes
risk score can be a valuable tool to identify high-risk individuals for a
lifestyle intervention. The optimal thresholds of the GDRS and the ARIC
2009 score were 7% and 9%, respectively when using a 1-stage screening
with the risk scores only and 5% for both scores when using an additional
glucose test with 100mg/dl threshold in the identified high-risk group in a
2-stage screening.
Supported by: DZD
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A comparison of different glucometabolic markers for prediction of
future type 2 diabetes in young and middle-aged subjects: a 20-year
follow-up study
M.L. Nielsen1, M. Pareek1, M. Leósdóttir2, K. Højlund1, P.M. Nilsson2,
M.H. Olsen1;
1Department of Endocrinology, Odense University Hospital, Denmark,
2Department of Cardiology, Skåne University Hospital, Malmö, Sweden.
Background and aims: Risk prediction models for type 2 diabetes
mellitus (T2DM) often incorporate a few common risk factors (RF) in-
cluding fasting blood glucose (FBG). Further addition of other
glucometabolic risk markers (GRM) incl. multiple measurements during
OGTTmay improve prediction, but superiority of one over other at long-
term follow-up remains unproven. The purpose of this study was to assess
the added predictive value of various GRM (fasting plasma insulin, ho-
meostatic model assessment derived insulin sensitivity (HOMA-%S) and
beta-cell function (HOMA-%B), and 40 and 120 min BG and plasma
insulin during OGTT) to a model with RF (age, BMI, systolic blood
pressure, total cholesterol, triglycerides, family history) and FBG.
Materials and methods: We assessed improvement in the prediction of
incident T2DM (through re-examination and registries) during 20-year
follow-up in a random population sample of 3576men free from DM and
cardiovascular disease at baseline, using the above-mentioned GRM.
Their additive value to a model with RF and FBG was evaluated using
Cox proportional hazards regression, receiver-operating characteristic
(ROC) analysis, and integrated discrimination improvement (IDI).
Results: Median age at inclusion was 48 (IQR 47-48) years. During
follow-up (median 20 (IQR 20-20) years), 300 new cases of DM devel-
oped. The ROC-curves are depicted in figure 1. Addition of FBG to a
model with RF alone resulted in significant improvement (likelihood-
ratio X2=106.62 (p<0.0001); AUC 0.773 vs. 0.741, X2=10.26 (p=
0.001); IDI 0.04 (p<0.0001)). All models with an additional GRM per-
formed significantly better than the model with RF+FBG (AUC 0.780-
0.800 vs. 0.773, p<0.05 for all comparisons). The largest improvement
was seen for 40 min BG (likelihood-ratio X2=72.47 (p<0.0001); AUC
0.800, X2=11.84 (p<0.0001); IDI 0.03 (p<0.0001)), which performed
non-significantly better than 120 min BG (p=0.2) and 120 min insulin
(p=0.3) and significantly (p<0.05) better than all other GRM. The opti-
mal prediction model (AUC 0.823) included RF, FBG, fasting insulin,
BG and insulin at both 40 and 120 min and performed significantly better
than themodels with RF+FBG+40minBG and insulin (AUC 0.812, X2=
4.77 (p = 0.03); likelihood-ratio X2= 48.62 (p< 0.0001)) and
RF+FBG+120 min BG and insulin (AUC 0.793, X2=16.14 (p=
0.0001); likelihood-ratio X2=81.04 (p<0.0001)), respectively. The mod-
el with 40 min BG and insulin further performed significantly better than
the model with 120 min measurements only (AUC X2=4.14, (p=0.04)).
Conclusion: GRM provided a significantly better prediction of future
DM risk during long-term follow-up than knowledge of RF and FBG
alone. Although multiple measurements during OGTT possessed incre-
mental predictive value, the addition of 120 BG and insulin was associ-
ated with limited benefit beyond measurements at 0 and 40 min only.
Supported by: DDA
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The association between GAD65 antibody levels and incident diabe-
tes in a population-based cohort: the Hoorn study
A.D.M. Koopman1,2, E. Voerman1,2, F. Rutters1,2, S.P. Rauh1,2, C.D.A.
Stehouwer3, P.J. Elders2,4, G. Nijpels2,4, J.M. Dekker1,2;
1Department of Epidemiology and Biostatistics, 2EMGO+ Institute for
health and care research, VU University medical centre, Amsterdam,
3Department of Internal Medicine and Cardiovascular Research, Maas-
tricht University medical centre, Maastricht, 4Department of General
Practice, VU University medical centre, Amsterdam, Netherlands.
Background and aims: GAD antibodies are autoantibodies against the
enzyme glutamic acid decarboxylase (GAD). Up until now it is not clear
whether GAD antibody positivity is predictive for the development of dia-
betes. Prospective studies on whether the presence of GAD antibodies pre-
dicts diabetes are rare and provide contradicting results. Therefore, the aim of
this study was to assess the association between levels of GAD65 antibodies
and incident diabetes after 6.5 years in the general Dutch population.
Materials and methods: We assessed the association in 1302 men and
women of the Hoorn study, a population-based cohort. Participants with
prevalent diabetes at baseline were excluded. Diabetes status at baseline
and follow-up was defined according to WHO criteria 2011, including
fasting plasma glucose levels, 2 h post load plasma glucose and HbA1c
values. GAD65 antibody levels were measured in serum by means of a
standardized radioligand assay and subsequently were expressed as indexes.
GAD65 antibody positivity was defined as indexes equal or above the 99th
percentile point. Logistic regression analysis was performed to compare
GAD antibody positive participants to GAD antibody negative participants.
Results:Of the 1302 participants (age 60.3±7y, 45.8%male), 11.1% had
developed diabetes after 6.5 years. For GAD65 antibody positive partic-
ipants the Odds Ratio (OR) for developing diabetes was 7.09 (95% con-
fidence interval (CI): 2.35-21.40), compared to GAD65 antibody nega-
tive participants. After adjustment for age, sex, follow-up duration and
glucose metabolism status at baseline, the OR for developing diabetes
was 4.86 (95% CI: 1.45-16.29). In sensitivity analyses, the adjusted stan-
dardized regression coefficients for HbA1c levels, fasting glucose levels
and 2 h post load plasma glucose levels were 0.141 (p<0.001), 0.149 (p<
0.001) and 0.058 (p=0.015) in GAD65 antibody positive participants,
compared to GAD65 antibody negative participants.
Conclusion:Within our population-based cohort, GAD65 antibody pos-
itivity was strongly and independently of glucose metabolism status at
baseline associated with an increased risk of developing diabetes during
6.5-year follow-up.
Supported by: Dutch Diabetes Research Foundation
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Continuous glucose monitoring at the early phases of type 2 diabetes
L.H. Hakaste1, F. Sambo2, A. Facchinetti2, C. Cobelli2, L.C. Groop3,
T. Tuomi1;
1Folkhalsan Research Centre, Helsinki, Finland, 2University of Padova,
Italy, 3Lund University Diabetes Centre, Malmo, Sweden.
Background and aims: Little is known about glucose variability in the
early phases of type 2 diabetes (T2D). In an effort to improve the risk
prediction of T2D, we studied whether a particular pattern of glucose
excursion in subjects with impaired glucose tolerance (IGT) would be
associated with a decrease in insulin secretion, increase in glucose excur-
sions and/or diabetes after 1.5 (or 5) years follow-up.We also compared a
single capillary glucose measurement at 2 hours (2 h) after a standardized
test-meal eaten at home with a 2 h oral glucose tolerance test (OGTT) in
diagnosis of T2D.
Materials andmethods: 36 subjects with IGTand 25 with T2D from the
Botnia Study participated in a 2 h OGTT and a one-week continuous
glucose monitoring (CGM), during which they ate two test meals at home
after 10-12 hours fasting and measured capillary glucose at 0, 60 and
120 minutes after the meal. They filled in a questionnaire and kept a food
and exercise diary during the CGM. A follow-up visit will be completed
1-1.5 years after the first visit in March-June 2015, with a similar study
protocol except for one of the test meals eaten at the study center with
blood sampling. Subjects with known diabetic complications, HbA1c
>8% (63.9 mmol/mol), fasting plasma glucose (PG) >10mmol/l, or treat-
ed with insulin, GLP1-analogues, or sulphonylureas were excluded. Met-
formin was stopped two days before the CGM. None of the participants
was on glitazone, gliptine or acarbose medication.
Results: At the first visit, the IGTand T2D groups had similar age, BMI,
waist and hip circumference and blood pressure, but fasting PG, 2 h
glucose at OGTT and B-HbA1c were significantly higher in those with
T2D (6.86 mmol/l and 5.84 mmol/l; 11.44 mmol/l 9.29 mmol/l;
37.7 mmol/mol and 44.7 mmol/mol, respectively) (table). The glucose
excursions were significantly larger in the T2D subjects compared with
IGT subjects estimated as area under curve above 6 mmol/l (52.58 vs.
84.35, p=0.0041), or as mean or largest amplitude of excursion (p=
0.047) (table). As the 2 h glucose was significantly lower after test meal
than after OGTT, both insulin and incretin responses will be analyzed
during the follow-up visit. Longitudinal changes in glucose excursions,
insulin secretion and glucose tolerance will be analyzed in August 2015.
Conclusion: Glucose variability during the CGM was significantly
higher in subjects with T2D compared to those with IGT. It will be
interesting to see whether a subgroup of IGT subjects with a higher risk
for deterioration of glucose tolerance can be identified based on glucose
excursions.
Clinical Trial Registration Number: NCT02294370
Supported by: Folkhalsan research Foundation, Sigrid Juselius Founda-
tion, EC
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Incremental value of a past fasting glucose for the prediction of type 2
diabetes mellitus. The Whitehall II study
A.G. Tabák1,2, M. Kivimäki2, T.N. Akbaraly2,3, E.J. Brunner2, D.R.
Witte4, A. Hulman5, D. Vistisen6, K. Færch6, G.D. Batty2, M.J. Shipley2;
11st Department of Medicine, Semmelweis University, Faculty of Medi-
cine, Budapest, Hungary, 2Epidemiology and Public Health, University
College London, UK, 3Inserm U 1061, Montpellier, France, 4Aarhus
University, Denmark, 5University of Szeged, Hungary, 6Steno Diabetes
Centre, Gentofte, Denmark.
Background and aims: Lifestyle interventions can reduce the risk of
type 2 diabetes by more than 50% in high risk populations. In order to
effectively identify such high-risk individuals, current diabetes prediction
models require improvement. Accordingly, we examined the impact of
adding a previous fasting glucose measurement to the Framingham Off-
spring Diabetes Risk Score (FOS-DRS).
Materials and methods: In an cohort of British government workers
taking part in 5-yearly clinical examinations, 338 incident cases of type
2 diabetes were observed (75 g OGTTs or self-report of diabetes or use of
antidiabetic medication) in two 5-year baseline-follow-up data cycles (n=
3550 and n=4140). FOS-DRS was re-estimated with Weibull regression
using baseline data on age, sex, parental history of diabetes, body mass
index, systolic blood pressure, hypertensive medication, HDL-cholester-
ol, triglyceride, and fasting glucose. Then, we added fasting glucose
values measured 5 years earlier to the existingmodel. The value of adding
past fasting glucose was examined by C-statistics, net reclassification
improvement (NRI), and integrated discrimination improvement (IDI);
calibration by the Hosmer-Lemeshow test.
Results: As anticipated, previous fasting glucose concentration was an
independent predictor of type 2 diabetes (OR 1.98, 95% CI: 1.56-2.52).
Its addition to the FOS-DRS significantly improved discrimination (FOS-
DRS vs. additional glucose, C-statistic: 0.774 vs. 0.783, p=0.031; 3-
category NRI: 4.7%, 95%CI 0.6-8.8%, IDI: 0.007, P<0.0001); however,
calibration was imperfect for both models (both p<0.05). Most of the
improvement of NRI was related to an increase in the predicted risk of
incident diabetes cases.
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Conclusion: In the present study, the addition of a routinely available past
clinical measure (fasting glucose) to an optimized clinical diabetes risk
score improved its prediction.
Supported by: the MRC, BHF, NHLBI, and the NIA.
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Predicting risk of progression to diabetes from prediabetes defined
by HbA1c or fasting plasma glucose in Koreans
C.-H. Kim1, E.-H. Kim2, S.-J. Bae2, H.-K. Kim2;
1InternalMedicine, SoonchunhyangUniversity, Bucheon, 2AsanMedical
Center, Seoul, Republic of Korea.
Background and aims: Although both HbA1c and fasting plasma glu-
cose (FPG) criteria have been recommended as screening tests for predi-
abetes, the performance of these tests in predicting future risk of diabetes
remains to be established. We assessed 5-year progression rate to diabetes
in individuals identified as having prediabetes byHbA1c and FPG criteria
in a large cohort of Koreans.
Materials and methods:We analyzed data of 17,971 Korean adults (age
20-79 years, 39% women) who underwent routine medical check-ups in
2007-2008 (baseline) and followed up in 2012-13 with a median 5.1-year
(range 3.1-6.7 years) interval. Patients who had diabetes at baseline were
excluded. Prediabetes at baseline was defined as FPG 5.6-6.9 mmol/l or
HbA1c 39-46 mmol/mol [5.7-6.4%]. Diagnosis of diabetes at follow-up
was based on FPG ≥7.0 mmol/l, HbA1c ≥48 mmol/mol [6.5%], or use of
antihyperglycemic medications. Odds ratios (ORs) for developing diabe-
tes were estimated using multiple logistic regression analysis.
Results: Among the 17,971 participants who did not have diabetes at
baseline, the prevalence of prediabetes was 30.6% (n=5495) by FPG
and 20.4% (n=3664) by HbA1c criteria. A total of 723 subjects (4.0%)
developed diabetes during the 5-year follow-up. Only 0.4% of subjects
who had normoglycemia (FPG <5.6 mmol/l and HbA1c <39 mmol/mol)
at baseline developed diabetes. Individuals with prediabetes identified by
HbA1c test had a higher 5-year rate of progression to diabetes compared
to those by FPG test (14.7% vs. 10.4%, P <0.001). This trend was con-
sistent regardless of age, sex, BMI, and family history of diabetes. Among
individuals diagnosed as prediabetes discordantly by the two tests, sub-
jects diagnosed by HbA1c only had a higher risk of progression to dia-
betes compared to those by FPG alone (6.0% vs. 3.9%, P <0.001) (Table).
Individuals diagnosed as prediabetes by both criteria had much higher
rate of progression to diabetes (22.3%). Receiver operating characteristic
curve analysis showed that area under the curve was greater for HbA1c
(0.855, 95% CI 0.840-0.870) compared to that for FPG (0.830, 0.813-
846) (P=0.006). The OR of developing diabetes adjusted for convention-
al risk factors was also higher for prediabetes by HbA1c (9.91, 95% CI
8.24-11.9) compared with that by FPG (7.29, 5.97-8.89) (P=0.026).
When we subdivided the prediabetes group, individuals with higher
FPG (6.1-6.9 mmol/l) and HbA1c (42-46 mmol/mol) had substantially
higher risk of progression to diabetes compared to those with FPG 5.6-
6.0 mmol/l and HbA1c 39-41 mmol/mol, respectively (Table).
Conclusion: Although the HbA1c test identified fewer individuals with
prediabetes than did FPG test, the predictive power for progression to
diabetes assessed by HbA1c was stronger than that assessed by FPG.
However, these two tests could independently and additively predict risk
of progression to diabetes, and combined use of both tests could more
efficiently identify individuals at risk for diabetes.
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FINDRISC score and glycaemic measures, better than HbA1c, as
predictor and monitor of diabetes incidence within 5 years
R.T. Ribeiro1,2, J.F. Raposo1,3, J.M. Boavida4, M. Macedo1,3,
I. Correia1,2, R. Andrade1,3, A. Silva1, R. Duarte1,2, J.L. Medina2,
L. Gardete-Correia1,2;
1APDP - Diabetes Portugal (Education and Research Centre -
APDP/ERC), 2SPD - Portuguese Society of Diabetology,
3CEDOC-NOVA Medical School, 4National Programme for Diabetes,
Lisbon, Portugal.
Background and aims: Diabetes is a rising epidemic, with increasing
social and economic impact. PREVADIAB, the first Portuguese nation-
wide study on the prevalence of diabetes, showed that 11.7% of the
general population has diabetes; while nearly 25% already showed pre-
diabetes (IFG, IGT, or both). Five years after, we aimed to evaluate the
role of diabetes incidence predictors in a non-diabetic cohort of the initial
study.
Materials and methods: From the 5167 individuals recorded on the
database of the first PREVADIAB, people evaluated as non-diabetics
(either designated with “normal” or “prediabetes” based on both fasting
glycemia and/or 2 h post-load challenge) were called for reassessment.
Thus, people aged between 23 and 83 years, taken from 73 of the original
122 locations, were recruited 5 years after the initial call, being represen-
tative of the non-diabetic distribution observed on the first study. An
OGTTwas again performed and HbA1c quantified to evaluate glycemic
control. WHO criteria were used for the diagnosis of diabetes. For diabe-
tes risk assessment, we applied the Finnish Diabetes Risk Score
(FINDRISC) to information from the original study,specific to this
subgroup.
Results: The present cohort consisted of 1024 participants. In relation to
the deterioration of glycemic control with time, 3.8% of individuals were
diagnosed with diabetes in the intervening 5 years, while an additional
5.0% were shown here to have undiagnosed diabetes. In terms of
matching the initial diabetes risk score categories to the incidence of
diabetes, while no individual initially characterized with the lower
FINDRISC score (below 7) progressed to diabetes, 25.9% of individuals
initially characterized with the higher risk score (above 20) developed a
diagnosis of diabetes within these 5 years. Initial HbA1c was also shown
to be related to diabetes incidence, but with a similar sensitivity only at
≥6.3%. In terms of diabetes detection, applying HbA1c diagnostic criteria
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(≥6.5%) did not add significantly to criteria based on OGTT measures,
while on the other hand merely 25.5% of participants found with undi-
agnosed diabetes were detected by the HbA1c criteria cut-off.
Conclusion: Primary prevention strategies targeted to high risk popula-
tions are usually more cost-effective than the ones targeted to general
populations. Initial HbA1c showed to be strongly related to 5 years dia-
betes incidence only already at a high range, while it was shown to
perform poorly in detecting undiagnosed diabetes. Thus, this 5-year pro-
spective analysis argues in favor of the FINDRISC, a non-invasive inex-
pensive tool, as adequate to evaluate risk of diabetes development in the
general population. More, it also argues for the necessity of glycemic
measures, and not solely HbA1c, to monitor diabetes incidence in high-
risk individuals.
Supported by: DGS - Portuguese General Directorate of Health
PS 015 DPP4-inhibitors:
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Risk of hospitalisation for heart failure between dipeptidyl peptidase
4 inhibitors vs sulfonylureas and saxagliptin vs sitagliptin in a U.S.
claims database
J.J. Sheehan1, K. Tsai2, S. Johnston3, A. Ghannam1, K. Cappell3,
R. Fowler3, I. Kalsekar1, A. Fu4;
1Medical Affairs, AstraZeneca, Fort Washington, 2Epidemiology,
AstraZeneca, Gaithersburg, 3Truven Health Analytics, Bethesda, 4Popu-
lation Sciences, Georgetown University, Washington D.C., USA.
Background and aims: In the SAVOR trial, the risk of hospitalization
for heart failure (hHF), a component of the secondary endpoint, was
increased with saxagliptin compared to placebo. This observational co-
hort study used a large U.S. insurance claims database to compare the risk
of hHF between patients with type 2 diabetes mellitus (T2DM) treated
with dipeptidyl peptidase-4 inhibitors (DPP-4is) vs. sulfonylureas (SUs)
and between those treated with saxagliptin vs. sitagliptin.
Materials and methods: Methods followed the U.S. Food and Drug
Administration’s Mini-Sentinel protocol for active surveillance of antidi-
abetic agents. Patients initiated treatment between Aug-1-2010 and Aug-
30-2013 and had no use of the comparator treatments in the 12 months
before treatment initiation (baseline). Each comparison consisted of pa-
tients matched 1:1 on a propensity score (nearest neighbor; caliper=0.01)
based on demographics, general clinical characteristics, and hHF risk
factors measured at baseline. The primary study outcome was time to
hHF, defined as the number of days from treatment initiation until hHF
or censoring at cessation of the initiated treatment, use of the alternative
comparator treatment, loss to follow-up, or 8/30/2013, whichever was
earlier. Time to hHF was compared between the matched groups using
Cox proportional hazards models. Analyses were stratified by presence of
baseline cardiovascular disease (CVD).
Results: The table shows the main study results. The propensity score
matches achieved balance on all patient characteristics included within
the propensity score models; across the 4 models, the standardized dif-
ferences for matched covariates ranged from 0%-2.3%; values <10% are
considered to be indicative of adequate balance.Within the comparison of
DPP-4i vs. SU among patients with no baseline CVD, those who were
treated with a DPP-4i had significantly (P=0.013) lower hazards of hHF
compared to those who were treated with an SU. In all other comparisons
there were no statistically significant differences in the risk of hHF be-
tween DPP-4i and SU or between saxagliptin and sitagliptin. Sensitivity
analyses on subgroups (patients with no baseline use of loop diuretics,
patients with no baseline or follow-up use of thiazolidinediones, and
patients with characteristics similar to those included in the SAVOR trial)
and using alternative assumptions of time at risk produced consistent
results (not shown).
Conclusion: In this analysis of U.S. patients with T2DM in a real-world
setting, there was no evidence of increased risk of hHF for DPP-4is
relative to SUs or for saxagliptin relative to sitagliptin.
Supported by: AstraZeneca Pharmaceutical LP
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Pharmacological treatment changes in 4.143 patients with dysregu-
lated type 2 diabetes referred to a tertiary diabetes center
N. Safai, M. Ridderstråle;
Patient Care, Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Changes to the pharmacological treatment are
commonwhen addressing dysregulated type 2 diabetes (DT2D).We have
previously described improvements in such patients referred from prima-
ry care. Our aim here was to describe the most common pharmacological
treatment changes implemented in these subjects.
Materials and methods: Pharmacological treatment data before and
after a six to nine month treatment program for all patients re-
ferred to a tertiary diabetes center between Jan 1st 2001 and
Jan 1st 2013 were extracted from the electronic medical records
(n=4.143). Patient population and metabolic control data have
been described previously; e.g. proportion with HbA1c
<53 mmol/mol improved from 25% to 47%; blood pressure
<140/<85 mmHg from 41% to 52%, and LDL cholesterol
<2.6 mmol/l from 56% to 74%. Only between treatment class
comparisons were performed, and non-parametric analysis was
used throughout.
Results: 61% of patients were on metformin (Met) on referral: 18%
prescribed Met alone, 28% a combination of Met and sulphonyl urea
(SU), and 14% of Met and insulin (Ins). Any other Met combination,
including triple therapy, was virtually non-existent (about 1%). SU alone
was seen in 10% of the patients, and 7% of patients were on Ins mono-
therapy. The combination of SU and Ins was less common at 2%. Total
daily insulin dose at referral was 55±47 IE/day (n=924). At discharge the
dose in all subjects on insulin was 54±44 IE/day (n=1.462), was in-
creased to 61±50 IE/day in those already on Ins at baseline (n=914;
p<0.0001), and 43±31 IE/day (n=548) in those put on Ins. Only 1%
was on GLP1-analogue alone and 0.2% on DPP4-i alone at baseline. 9
out of 10 patients who were on Met at referral remained so, and in total
67% were on Met at discharge (Figure 1): Met alone 19%; Met/SU 20%;
Met/Ins 18%; and 11% on other combinations: Met/GLP-1 4.2%; Met/
GLP-1/Ins 2.1%; Met/DPP4-i 1.3%; Met/SU/Ins 1.1%; Met/SU/GLP-1
1.0%;Met/SU/DPP4-i 0.9%;Met/DPP4-i/Ins 0.4%. SUs were withdrawn
more commonly than Met (39%), whereas Ins was rarely discontinued
(6%).The HbA1c lowering effect differed significantly between patients
receiving different treatment alternatives and was particularly beneficial
when including a GLP-1 analogue in triple therapy (-18 vs. -12 mmol/
mol, p=0.0001). In addition to medication controlling glycaemia we ob-
served increases in the use of antihypertensive drugs (from 63% to 75%),
and lipid-lowering drugs (from 55% to 76%), and antithrombotic therapy
(from 53% to 75%; p<0.001 for all changes).
Conclusion: When patients are referred from primary care to a tertiary
center for DT2D, Ins andMet are the most likely drugs to be continued or
newly prescribed, whereas SUs are more likely to be discontinued. The
role for newer agents and triple combinations merit further investigation.
Even if there are many different drugs available for glycemic control this
remains a major task in comparison to the management of lipids and
blood pressure where goal attainment is achieved in greater proportions
of patients, even with DT2D.
Supported by: Innovation Fund Denmark
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Longitudinal changes in type 2 diabetic patient medication treatment
patterns from 2006 to 2012
W. Weng, Y. Liang, E. Kimball, T. Hobbs, S. Kong, B. Sakurada, J.
Bouchard;
Clinical, Medical & Regulatory Affairs, Novo Nordisk Inc., Plainsboro,
USA.
Background and aims: It is important to understand changes in diabetes
treatment patterns over time in order to optimize treatment paradigms.
This was a longitudinal study of real-world claims data from a single
cohort (N=35017) of patients newly diagnosed in 2006 with Type 2
Diabetes (T2D) which followed changes in their treatment patterns and
costs from 2006 to 2012.
Materials andmethods: The Truven HealthMarketScan®Database was
used, from which claims data for only US-based newly diagnosed T2D
patients were examined. Inclusion criteria were: at least 2 diagnoses ac-
cording to ICD-9 codes for T2D, or 1 T2D diagnosis and at least 1 OAD
claim, and allowing 1 diagnosis for T1D, >18 years of age, continuous
enrolment starting from 2006 (index year) to 2012 in a plan with pre-
scription benefits, and with at least 1 anti-diabetic drug prescription dur-
ing the study. Data were analyzed for drug treatment patterns, and for
costs of inpatient and outpatient services, emergency department use, and
medications and supplies.
Results: Approximately 28% of newly diagnosed patients had no pre-
scriptions for anti-diabetic drugs in 2007, and this decreased to 22% in
2012. The percentage of patients who received only OADs, but no inject-
ables, during the enrollment period remained between 65% and 69%.
Among these patients, the percent receiving 1 OAD fell from approxi-
mately 70% to 60%, those receiving 2 OADs rose from 25% to 31%, and
patients prescribed 3 OADs increased from 4.5% to 8%. Less than 1%
received 4 or more OADs. Monotherapy with Metformin (Met) progres-
sively fell from 35% to 31% of patients. Monotherapy with SUs fell from
7% to 6%, and for TZDs fell from 5% to 1.8% of patients. Dual OAD
combinations were used by 17.8% of patients in 2007, progressively
rising to 20% in 2012. Insulin monotherapy was initiated by only 0.2%
of patients in 2007, rising to 1.7% in 2012. Patients using combined
insulin and OAD therapy grew from <1% in 2007 to 6.5% in 2012.
Combined GLP-1 agonist/OAD therapy grew from 2.3% to 3.3% of
patients in 2012. From 2007 to 2012, total Met use (single and multiple
therapy) grew from 56% to 62% of patients. Similarly, total SU use grew
from 20% to 27%, TZD use fell from 18% to 10%, and DPP-4 inhibitor
use grew from 2% to 15% of patients in the cohort. The total percent of
patients using insulin or GLP-1, with and without OADs, rose to 7% and
4% of patients, respectively, in 2012. Total annual costs/T2D patient rose
from $9817 to $12551 (based on 2012 levels), with the largest contribu-
tion coming from outpatient costs ($4140 to $5485), followed by costs for
all drugs ($2897 to $3275), for inpatient services ($1421 to $1695) and
emergency department use ($960 to $2096).
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Conclusion: From 2006 to 2012, OAD monotherapy in this cohort of
newly diagnosed patients declined and dual OAD therapy rose. Costs for
all forms of resource utilization increased, resulting in net overall cost
increases of $2734 per T2D patient/year.
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DISCOVERing treatment of type 2 diabetes in real world settings
using electronic medical record databases
N. Hammar1, B. Charbonnel2, P. Fenici3, L. Garcia-Alvarez4, M.B.
Gomes5, K. Hashigami6, J. Hiller4, L. Ji7, K. Khunti8, A. Nicolucci9, S.
Pocock10, M.V. Shestakova11, I. Shimomura12, F.A. Surmont13, J.
Medina14;
1AstraZeneca (AZ), Södertälje, Sweden, 2Univ of Nantes, France, 3AZ,
Melbourn, UK, 4IMS Health, London, UK, 5Rio de Janeiro State Univ,
Brazil, 6AZ, Tokyo, Japan, 7Diabetes Center, Peking Univ People's Hos-
pital, Beijing, China, 8Univ of Leicester, UK, 9Ctr for Outcomes Res and
Clinical Epidemiology, Pescara, Italy, 10London School of Hygiene &
Tropical Med, UK, 11Endocrinology Res Ctr, Moscow, Russian Federa-
tion, 12Osaka Univ, Japan, 13AZ, Shanghai, China, 14AZ, Madrid, Spain.
Background and aims: Despite evidence of improved long term com-
plications with risk factor control in patients (pts) with type 2 diabetes
mellitus (T2DM), there is a lack of comparative global data on T2DM
treatments (tx) and control from different regions. The availability of
existing electronic medical records (EMR) in some countries offers the
opportunity to gain insights into the disease, pt characteristics and man-
agement patterns, as well as clinical evolution. This study aims to provide
descriptive EMR data from the real-world clinical setting on second and
further line anti-diabetic tx use among T2DM patients in Canada (CAN),
France (FR), Germany (DE), specifically those treated by general practi-
tioners (DE GPs), and the United Kingdom (UK). The main outcomes of
interest were changes in T2DM tx, glycaemic control in response to
second-line tx and proportion of pts reaching A1c<7% during the
follow-up period.
Materials and methods: Retrospective multi-country non-intervention-
al, cohort study utilising longitudinal EMR data from pre-existing data-
bases. Pts with T2DM aged ≥18 years, initiating a second line anti-
diabetic tx at baseline, and with a minimum follow-up of 6 months, were
included.
Results: A total of 22,272 T2DM pts initiating second-line tx were iden-
tified from May 2011 to April 2014. Of these pts, 805 were from CAN,
432 from FR, 8,140 from DE and 12,895 from the UK. Mean A1c at
initiation of second-line tx was >7.5% in all countries (CAN: 8.8%; FR:
7.83%; DE GPs: 8.01%; UK: 9.0%). The most common first-line mono-
therapies were metformin (CAN: 81.7%; FR: 91.7%; DE GPs: 79.40%;
UK: 88.6%), and sulphonylureas (SU) (CAN: 13.4%; FR: 4.9%; DEGPs:
12.14%; UK: 10.7%). The most frequently initiated second-line therapies
were combination tx: metformin and DPP4 combination (CAN: 38.6%;
FR: 38.4%; DE GPs: 45.2%; UK: 21.4%) and metformin and SU com-
bination (CAN: 25.7%; FR: 15.7%; DE GPs: 21.28%; UK: 53.2%). Re-
ductions in A1c were observed from baseline throughout the follow up
period in all countries (mean A1c at 6 months in CAN: 7.4%; FR: 6.94%;
DE GPs: 7.03%; UK: 7.6%).
Conclusion: Despite availability of guidelines, all countries studied had
high A1c at baseline with many pts failing to achieve A1c <7% with
second-line therapy. There are large intercountry variations in glycaemic
control and second-line tx initiated. After failure of metformin monother-
apy, the most common drugs added by physicians were DPP4 inhibitors
and SU. Although reductions in A1c were achieved, mean values
remained mostly above the recommended target of 7%. Data derived
from real-world analyses such as this, where EMR sources are exploited
to fill in gaps in evidence, may be useful to inform on the clinical utility of
different tx applied in routine practice. The long term glycaemic control in
the real world on micro and macrovascular outcomes is being investigat-
ed in the DISCOVER program.
Clinical Trial Registration Number: NCT02322762
Supported by: AstraZeneca
374
Characteristics and prescription behaviour of insulin glargine users
among patients with type 2 diabetes mellitus
X. Huang1, C.-P.S. Fan2, Z. Li2, B. Hanna2, J. Tang2, J. Williams1;
1Merck & Co., Inc, Kenilworth, 2Asclepius Analytics LLC, Brooklyn,
USA.
Background and aims: Type 2 Diabetes Mellitus (T2DM) is a progres-
sive disease and treatment intensification is often required. When oral
antidiabetic drugs (OAD) fail to maintain glycemic control, initiating
insulin therapy is recommended by the ADA and EASD. Published anal-
yses of randomized controlled trials suggest advantages of initiating in-
sulin therapy with long-acting basal insulin (e.g. insulin glargine or insu-
lin determir) compared to conventional intermediate-acting human basal
insulin (e.g. NPH). However, target treatment populations and real-world
patterns of insulin glargine use have not been well documented. This
study examined the characteristics and prescription behavior of patients
(pts) initiating insulin glargine in Germany.
Materials and methods: A retrospective cohort study utilized a sample
from the Germany IMS Disease Analyzer data. Included were pts with
T2DM who initiated any basal insulin (i.e. intermediate-acting or long-
acting insulin) in 2009-2013, ≥18 years (yrs), with continuous medical
records. Eligible pts were classified into glargine or non-glargine cohort,
depending on their index insulin. Between-cohort differences in 1-yr
baseline patient characteristics, 1-yr post-index cumulative insulin dose
and 1-yr post-index concomitant OAD use were assessed usingWilcoxon
rank-sum tests for continuous and χ2 tests for categorical variables. Mul-
tivariable linear regression was used to compare the cumulative insulin
dose in the glargine vs. non-glargine cohort, adjusting for baseline HbA1c
and other characteristics.
Results: 14,886 basal insulin initiators were included, 47.0% and 53.0%
were in the glargine cohort and non-glargine cohort, respectively. Among
the glargine cohort, 85.3% initiated glargine only and 14.7% initiated
glargine with short-acting insulin. Among the non-glargine cohort,
31.2% initiated NPH only, 16.3% initiated insulin detemir only, and
52.5% initiated either NPH or insulin detemir with short-acting insulin.
Compared to the non-glargine cohort, the glargine cohort had higher
HbA1C (8.7% vs. 8.6%), and a greater proportion had diabetes-related
macro-vascular complications (17.0% vs. 7.7%), hypertension (32.6%
vs.15.1%) and hyperlipidemia (15.4% vs. 7.6%) at baseline. Post insulin
initiation, compared to the non-glargine cohort, a higher proportion of the
glargine cohort used concomitant OADs (DPP-4: 21.3% vs. 11.7%), but
they had a lower cumulative insulin dose (9,753 vs. 10,288 IU) (all p<
0.01). Regression analysis demonstrated that among pts with baseline
HbA1c<8% and between 8-9%, the glargine cohort used 124 IU and
963 IU less insulin over 1 year compared to the non-glargine cohort,
respectively.
Conclusion: Almost 1/2 of basal insulin initiators initiated insulin
glargine. Pts initiating insulin glargine had more comorbidities and
T2DM related macro-vascular complications at baseline. In the 1-yr
post-initiation, the insulin glargine cohort had higher use of concomitant
OAD, but a lower cumulative insulin dose.
Supported by: Merck & Co., Inc.
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Second-line treatment with sulfonylurea compared to DPP4 inhibi-
tors demonstrated associations with earlier treatment intensification
with insulin
J. Bodegard1, D. Nathanson2, T. Nyström3, M. Thuresson4, A.
Norhammar5, J.W. Eriksson6;
1AstraZeneca, Södertälje, 2Department of Clinical Science and Educa-
tion, Karolinska Institutet, 3Karolinska Institutet, Stockholm, 4Statisticon
AB, Uppsala, 5Department ofmedicine, Karolinska Institutet, Stockholm,
6Department of Medical Sciences, Uppsala University, Sweden.
Background and aims: To investigate the initiation of second-line blood
glucose lowering drug (GLD) treatment, patient characteristics and sub-
sequent drug intensification for type 2 diabetes (T2DM) patients.
Materials andmethods:T2DMpatients who were onmonotherapy with
non-insulin antidiabetic drug (NIAD) and initiated on their second-line
GLD treatment during 2006-2013 were identified in the Swedish Pre-
scribed Drug Register and linked with the Swedish National Patient and
Cause of Death registries. Index date was defined as the date of patients
second GLD dispense after monotherapy on NIAD. Definition of a non-
insulin antidiabetic drug (NIAD) start was any dispense recorded whereas
insulin start was defined when treatment duration exceeded 6 months.
From 1987 to index date, baseline information on comorbidity was col-
lected from the Swedish National Patient Register. Cox survival models
adjusted for age, gender, first line duration and prior cardiovascular dis-
ease were used to estimate risk of early treatment intensification during up
to 7 years of follow-up.
Results: Of the 102,085 T2DM patients initiated on second-line
treatment, 73% were on metformin, 22% on SU, 3% on
metiglinid and 2% on other treatments in first line. Second-line
was initiated by add-on of either one or more NIAD (67%) or
switch to insulin (33%). Insulin patients, compared to the NIAD
combinations, were older (70 vs. 64), had more history of
cardiovascular- (50% vs. 31%) and microvascular disease (29%
vs. 17%). In the 68,351 patients (on NIAD only); the most fre-
quent dual-combination was metformin+sulfonylurea (SU) (64%)
followed by metformin+DPP4i (15%). Metformin+SU vs
metformin+DPP4 were older (65 vs 61 years), less frequently
men (59 vs 62%), whereas the history of cardiovascular-, (32 vs
28%) and microvascular disease (18 vs 15%) were similar. Blood
pressure-, lipid lowering and low dose aspirin treatment were also
similar in the two groups. Compared with metformin+DPP4,
metformin+SU was associated with earlier treatment with insulin,
hazard ratio (95% CI): 1.06 (1.01-1.11).
Conclusion: In type 2 diabetes patients in Sweden, approximately
70% of second-line treatment was initiated with dual NIADs and
more than 30% with insulin. Metformin+SU was the most fre-
quent second-line combination, and demonstrated associations
with ear l ier t reatment with insul in compared with the
metformin+DPP4 combination.
Supported by: AstraZeneca
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The beta cell and insulin resistance in polycystic ovary syndrome:
new insights into the origins and prevention of type 2 diabetes
J. Tomlinson1, A. Mari2, A. Tura2, K. Bond3, E. Stenhouse4, R.P.
Vincent5, J. Pinkney6;
1Pool Health Centre, Redruth, Cornwall, UK, 2Institute of Biomedical
Engineering of the Italian National Research Council, University of Pad-
ua, Italy, 3Research and Development, Royal Cornwall Hospital, Truro,
4School of Nursing and Midwifery, University of Plymouth, 5Clinical
Biochemistry, King's College Hospital, London, 6Peninsula Schools of
Medicine and Dentistry, University of Plymouth, UK.
Background and aims: Polycystic Ovary Syndrome is a risk factor for
type 2 diabetes (T2D) and cardiovascular disease (CVD) but the mecha-
nisms are poorly understood. The aim of this study was to investigate how
the interplay of insulin secretion and action results in glucose dysregula-
tion in PCOS.
Materials and methods: 48 non-diabetic lean and obese women with
PCOS (Rotterdam criteria) and 53 BMI-matched controls were studied.
Insulin secretion was calculated by a model of insulin secretion and beta
cell function from glucose and C-peptide levels, and Insulin Sensitivity
Index (ISI) by the method of Matsuda, from a 6-point, 2 hour, 75 g oral
glucose challenge. Adiposity was measured by bioimpedance and
anthropometry.
Results: 1) Women with PCOS and controls were well matched for BMI
(mean [SD]28.83 [6.98] vs 29.42 [7.17] kg/m2; p=0.68) and there was no
difference in Beta Cell Glucose Sensitivity (BCGS), which is the mean
slope of the dose-response function, representing the static relationship
between glucose and insulin secretion (median [IQR] 83.3 [62.2-131.9]
vs 102.4 [64.1-145.8] pmol/min/mL/mmol; p=0.57). 2) ISI was strongly
related to BMI category (<25, 25-29.9, 30-34.9, >35) (ANOVA; p<
0.001), and waist circumference (WC) and visceral fat (VF) (r=0.50-
0.58; p<0.001). Although ISI did not differ in PCOS vs controls, Insulin
at 2 hrs was higher in PCOS (371.63 [261.14-578.07] vs 263.91 [150.01-
488.93] pmol/l; p=0.03) and strongly associated with VF (r=0.52; p<
0.001) and 2 hr glucose (r=0.66; p<0.001). In both groups, WC and VF
correlated strongly with HDL cholesterol (r=-0.42 to -0.64; all p<0.004),
systolic blood pressure (r=0.24-0.71; p=0.09-<0.001) and C-reactive
protein (r=0.49-0.56; all p<0.002). 3) Women with PCOS and 2 hr glu-
cose >7.5 vs <7.5 mmol/l, had lower BCGS (43.5 [23.6] vs 109.0 [68.5]
pmol/min/mL/mmol; p=0.04), higher WC (116.8 (15.8) vs 93.5(15.9)
cm; p<0.01) and VF (14.6 (4.2) vs 10.3 (4.6); p=0.05), and despite
non-significantly lower ISI (0.42 [0.25-0.96] vs 0.94 [0.53-1.36];p=
0.29) levels of insulin at 2 hrs were much higher (964.0 (579.2-1214.7)
vs 328.2 (242.2-475.7) pmol/l; p=0.01). In PCOS, WC was strongly
associated with increasing 2 hr glucose, but this was only present in
women in the lowest quartile of BCGS (r=0.80; p=0.003).
Conclusion: PCOS predisposes to T2D and CVD as a result of insulin
resistance (IR) which is exacerbated by central obesity. Although neither
PCOS nor central obesity impair BCGS per se, women who also have
poor BCGS possess the critical defect that renders them unable to com-
pensate for increasing IR, and therefore predisposes to T2D. These results
show that the pathogenesis of T2D in women with PCOS conforms to the
models postulated by DeFronzo and Reaven, in which glucose levels are
determiend by an interplay of insulin secretion and resistance, with adi-
posity being a dominant influence on IR. The findings suggest that waist
circumference and 2 hr glucose could be used to stratify risk, and high-
light the importance of healthy weight to reduce the risks of T2D and
CVD in women with PCOS.
Supported by: Duchy Health Charity, Cornwall Endocrinology and Di-
abetes Centre
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The shape of plasma insulin and insulin-to-glucose ratio curves dur-
ing an oral glucose tolerance test and prediction of future risk of type
2 diabetes
H. Yang, S.-H. Lee, B. Kang, Y.-R. Yang, J. Cho, B. Cha, K.-H. Yoon;
Endocrinology and Metabolism, The Catholic University of Korea,
School of Medicine, Seoul, Republic of Korea.
Background and aims: The pattern of glucose curve during oral
glucose tolerance test (OGTT) is known to be associated with
degree of insulin sensitivity and secretory function as well as with
the risk of type 2 diabetes development in adults and adolescents.
However little is known about the patterns of insulin or insulin-
to-glucose (I/G) ratio curves. In this prospective follow-up study,
we aimed to evaluate the risk for future diabetes development
according to the shape of plasma insulin and I/G ratio during
75 g OGTT.
Materials and methods: Among subjects enrolled in a community-
based cohort named Chungju Metabolic disease Cohort, those
who performed OGTT during 2007-2010 and repeated the test
during 2011-2014 were included. Subjects with diabetes at base-
line were excluded. Blood samples were obtained at 0-, 30-, and
120-min to measure glucose and insulin levels and I/G ratio was
calculated for each time points. Compared to the insulin or I/G
ratio value at 30-min, those showing lower value at 120-min was
classified as having downward-slope, while those with higher val-
ue was classified as having upward-slope of insulin or I/G ratio
curve, respsectively.
Results: Among 1126 subjects, 117 (10.39%) developed type 2
diabetes after 4 years. Compared to the baseline value, the
AUC(0-30 min) of insulin and I/G ratio curves, insulinogenic
index and Stumvoll index increased in diabetes-nonconverters af-
ter follow-up, which was not shown in diabetes-converters.
HOMA-beta and Matsuda index did not show significant change,
while BMI and HOMA-IR increased in both groups. Among sub-
jects with downward (n=482) and upward (n=644) slope of in-
sulin curve, 3.9% and 15.2% developed diabetes, respectively. .
Among subjects with downward (n=328) and upward (n=798)
slope of I/G ratio curve, 3.0% and 13.4% developed diabetes,
respectively. Those showing upward slope of insulin curve dem-
onstrated crude odds ratio (OR) of 4.924 (95% CI, 2.541-9.542)
and adjusted OR of 3.804 (2.276-6.538) for development of dia-
betes. Similarly, subjects showing upward slope of I/G ratio curve
demonstrated crude OR of 4.924 (2.541-9.542) and adjusted OR
of 3.804 (2.276-6.358) for future diabetes.
Conclusion: The shape of insulin or I/G ratio curve during OGTT
may help to identify subjects who are at risk of diabetes devel-
opment. Further studies in different ethnicities are required to
confirm out study results.
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Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but
not pre-diabetes, in Xi’an, China: a 5-year cohort study
B. Gao1, J. Ming2, S. Xu2, Y. Fang2, Q. Ji2;
11.Department of Endocrinology, Xijing Hospital, Fourth Military Med-
ical University, The Key Laboratory of Biomedical Information Engi-
neering of Ministry of Education, Xi’an Jiaotong University School of
Life Science and Technology, 2Department of Endocrinology, Xijing
Hospital, Fourth Military Medical University, Xi'an, China.
Background and aims: Emerging studies have focused the association
between non-alcoholic fatty liver disease (NAFLD) and the risk of type 2
diabetes mellitus (T2DM) but the results were inconsistent. In addition,
few studies have put focus on the association between NAFLD and the
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risk of pre-diabetes. We aimed to investigate whether NAFLD diagnosed
by ultrasonography could predict the risk of T2DM and pre-diabetes in
Chinese population.
Materials and methods: The population-base cohort study, which
was held in Xi’an, Northwestern China, was based on China
National Diabetes and Metabolic Disorders Survey ( 2007 -
2008 ). During a follow-up of 5 years, 508 healthy subjects were
included as study sample. NAFLD was determined by abdominal
ultrasonography. T2DM and pre-diabetes were diagnosed based on
oral glucose tolerance test. Cox proportional hazard regression
was utilized to examine the association between NAFLD and
the development of diabetes and pre-diabetes.
Results: Of 508 subjects, 97 (19.1%) were diagnosed as NAFLD
and 411 (80.9%) were as non-NAFLD; 20 (3.9%) developed dia-
betes and 85 (16.7%) developed pre-diabetes during follow-up.
The incidence of diabetes and pre-diabetes in the NAFLD group
was 20.6 and 51.6 per 1000 person-years, respectively, whereas
that in non-NAFLD group was 4.9 and 29.2 per 1000 person-
years, respectively. Cox proportional hazard regression showed
that the multivariable-adjusted relative risk (RR) of T2DM and
pre-diabetes in the NAFLD group was 4.462 [95% confidence
interval (CI): 1.855-10.734, P<0.001] and 1.642 (95% CI:
0.965-2.793, P=0.067), respectively, compared with non-NAFLD
group.
Conclusion: NAFLD was a significant predictor for T2DM, but not for
pre-diabetes, in Xi’an, China. More future cohort studies are needed to
confirm the present findings.
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Serum uric acid predicts incident type 2 diabetes mellitus only in
women after adjusting body compositions
Y. Hong, Y.-B. Lee, S.-E. Lee, J. Jun,W. Hong, T. Yu,M.-K. Lee, J. Kim;
Samsung Seoul Hospital, Republic of Korea.
Background and aims: Serum uric acid (SUA) level has been reported
to be associated with incident type 2 diabetes mellitus (T2DM) and body
composition. However, several previous studies reported combined re-
sults for men and women after adjusting for sex and there were no studies
that body compositions were taken into account. Thus, we designed this
longitudinal sex-specific follow-up study to elucidate the association of
SUA levels with incident T2DM including body compositions as an
adjusting factor with large scale.
Materials and methods: A retrospective longitudinal study was per-
formed to evaluate the association between SUA levels and the develop-
ment of T2DM. A total of 21,714 participants (12,307 men and 9,407
women) taking a medical health check-up program without diagnosed
T2DM at baseline were enrolled. Separate analyses were performed for
men and women including body compositions as a confounding factor.
Cox proportional hazards models were used to quantify the independent
association between SUA levels and incident T2DM.
Results: During 109,438 person-years of follow-up, there were
1,768 (1,269 in men, 499 in women, respectively) incident cases
of T2DM between 2006 and 2012. After full adjustment for mul-
tiple associated confounders including body compositions, SUA
levels were significantly associated with incident T2DM in wom-
en (per 1 mg/dl, hazard ratio (HR)=1.125, 95% confidence inter-
val (CI): 1.005-1.260, p=0.041). In men, however, this associa-
tion lost statistical significance after adjusting for multiple associ-
ated confounders (per 1 mg/dl, HR=1.009, 95% CI: 0.952-1.069,
p=0.762).
Conclusion:This study demonstrated that SUA levels are associated with
incident T2DM only in women and do not predict incident T2DM in men
after adjusting body compositions. Abbreviations: T2DM, type 2 diabetes
mellitus; SUA, serum uric acid; BMI, body mass index; BP, blood pres-
sure; LDL, low density lipoprotein; HDL, high density lipoprotein; FFM,
fat-free mass; FM, fat mass.
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High triglycerides, low HDL cholesterol and a low LDL cholesterol
per apolipoprotein B ratio predict incident diabetes in patients with
established CAD
C.H. Saely1,2, P. Rein3, A. Vonbank3, D. Zanolin2, G. Naerr1, A.
Leiherer2, A. Muendlein2, H. Drexel4,3;
1Private University of the Principality of Liechtenstein, Triesen, Liech-
tenstein, 2VIVIT Institute, Feldkirch, 3Academic Teaching Hospital
Feldkirch, Austria, 4Drexel University, Philadelphia, USA.
Background and aims: Patients with type 2 diabetes mellitus
(T2DM) exhibit a typical pattern of dyslipidemia with low
HDL cholesterol, high triglycerides and a low LDL cholesterol
per apolipoprotein B (LDL-C/apoB) ratio reflecting small LDL
particles. We hypothesized that high triglycerides, low HDL cho-
lesterol and a low LDL-C/apoB ratio predict incident T2DM
among non-diabetic patients with established coronary artery dis-
ease (CAD).
Materials and methods: We enrolled 655 non-diabetic patients
with angiographically proven stable CAD. Prospectively, the in-
cidence of T2DM was recorded over a mean follow-up period of
6.1±3.7 years. Diabetes was diagnosed according to ADA
criteria.
Results: From our non-diabetic coronary patients, 358 (54.7%) at
baseline had normal fasting glucose (NFG) <100 mg/dl, and 297
(45.3%) had impaired fasting glucose (IFG) ≥100 mg/dl. During
follow-up, T2DM was newly diagnosed in 17.4% of our patients.
Baseline IFG compared to NFG was associated with a strongly
increased risk of T2DM (26.6% vs. 9.8%; adjusted OR 3.34
[2.17-5.16]; p<0.001). Low HDL cholesterol, high triglycerides,
and a low LDL-C/apoB ratio after multivariate adjustment includ-
ing fasting glucose significantly predicted incident diabetes in the
total study cohort (OR 0.65 [0.49-0.86]; p=0.003, 1.40 [1.13-
1.74]; p=0.002 and 0.54 [0.41-0.71]; p<0.001, respectively) and
also when we separately analyzed patients with IFG (OR 0.67
[0.46-0.97]; p=0.032, 1.42 [1.03-1.96]; p=0.032 and 0.56 [0.39-
0.79]; p=0.001, respectively) and NFG (OR 0.62 [0.40-0.96]; p=
0.034, 1.38 [1.03-1.86]; p=0.033 and 0.49 [0.32-0.76]; p=0.001,
respectively).
Conclusion: We conclude that among patients with angiographically
proven stable CAD the incidence of diabetes is high, particularly among
those with IFG. Importantly, high triglycerides, low HDL cholesterol and
a low LDL-C/apoB ratio significantly predict incident diabetes indepen-
dently from baseline glycemia.
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A mathematical disease progression model for the effect of diet and
exercise in subjects with impaired glucose tolerance in the Finnish
Diabetes Prevention Study (FDPS)
S.M.S. Ghadzi1,2, M.O. Karlsson1, V.D. de Mello3, M. Uusitupa3, M.C.
Kjellsson1, Finnish Diabetes Prevention Study Group;
1Department of Pharmaceutical Biosciences, Uppsala University, Swe-
den, 2School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pe-
nang, Malaysia, 3Institute of Public Health and Clinical Nutrition, Uni-
versity of Eastern Finland, Kuopio Campus, Finland.
Background and aims: Mathematical modelling is frequently used to
characterize and quantify underlyingmechanisms of complicated physiolog-
ical responses. For this purpose, Silber et al developed an integrated glucose-
insulin (IGI) model describing dynamic glucose and insulin after glucose
provocations in healthy and type 2 diabetic subjects. Although being able to
describe the two populations, the progression from healthy to diabetic is
missing in the IGI model. The aim of this project was to develop the IGI
model to include disease progression for a population with impaired glucose
tolerance (IGT), quantifying the effect of diet and exercise intervention.
Materials and methods: Data derived from the randomized Finnish
Diabetes Prevention Study (FDPS) and consisted of yearly OGTTs (from
baseline, year 0 to the fourth year), one IVGTT at the start of the study
(baseline) and one IVGTT at the end of the study (fourth year). One
hundred and one out of 552 subjects with impaired glucose tolerance
who were randomly assigned to a lifestyle intervention group (diet and
exercise) or a control group were studied. Subjects who developed dia-
betes were excluded from the study at the time of diagnosis. All longitu-
dinal measurements of glucose and insulin after IVGTT and OGTTwere
used to fit the IGI model with mixed-effect methodology (NONMEM
version 7.3). Disease progression was investigated on the
pathophysiologically most reasonable parameters of themodel. The effect
of diet and exercise was investigated on the parameters identified to be
involved in disease progression.
Results: Disease progression was found to affect the first phase insulin
secretion, the maximal effect of incretin on insulin release and the insulin
sensitivity, represented as insulin-dependent glucose elimination (p value
<0.001); only the maximal effect of incretin on insulin release was unaf-
fected by changes in lifestyle. For the control group, decreases of 7.5%/
year and 4.7%/year were observed on first phase insulin secretion and
insulin-dependent glucose elimination. With diet and exercise interven-
tion, the decrease in the first phase insulin secretion was only 1.3%/year
and the insulin-dependent glucose elimination increased by 3.1%/year.
These values represent patients in the pre-diabetic state as occurrence of
diabetes was an exclusion criterion for the study.
Conclusion: The disease progression was successfully included in the
IGI model to describe changes in glucose provocation data from subjects
with IGT, independent of lifestyle intervention program.
This Supported by: DDMoRe (www.ddmore.eu) project
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Circulating concentrations of endothelin-1 predict impaired glucose
tolerance and type 2 diabetes in women but not in men: a prospective
study in the Vara-Skövde cohort
J. Olausson1, B. Daka2, M.I. Hellgren2, C.A. Larsson2,3, U. Lindblad2,
P.-A. Janssson1;
1Molecular and Clinical Medicine, Medicine, Sahlgrenska Academy,
2Department of Public Health and Community Medicine/Primary Health
Care, Sahlgrenska Academy, Medicine, Sahlgrenska Academy, Gothen-
burg, 3Department of Clinical Sciences, Social Medicine and Global
Health, Lund University, Malmö, Sweden.
Background and aims: Endothelial dysfunction is mechanistically
coupled to insulin resistance and is characterised by an imbalance
between nitric oxide and endothelin-1 (ET-1). Although ET-1 expression
is increased in insulin resistance and type 2 diabetes (T2D) it is unclear
whether ET-1 may be a forerunner of these conditions. Our current aim
was to investigate whether circulating ET-1 levels may predict the inci-
dence of impaired glucose tolerance (IGT) and T2D in a population based
prospective study.
Materials andmethods:During 2002-2005, 2816 adult participants (age
30-74 years) were randomly selected from two municipalities in south-
western Sweden. At baseline circulating ET-1 levels and metabolic risk
factors were measured while glucose metabolism was assesssed by
performing an oral glucose tolerance test (OGTT, 75 g). Moreover, blood
sampling, including OGTT, being performed in 1338 participants at base-
line was repeated at the follow-up between 2012-2014. After excluding
participants with IGT, T2D or missing information on ET-1 at baseline,
1152 participants were left for further analysis. General linear models
(GLM) were employed to estimate differences in ET-1 levels in partici-
pants with or without impaired glucose metabolism. In addition, logistic
regressions were used to estimate the odds ratio (OR) for incident IGT or
T2D by 1 pg/ml difference in ET-1 level at baseline. All analyses were
performed using SPSS 21.
Results: Age- and municipality-adjusted GLM showed that circulating
baseline ET-1 levels were significantly higher in women who developed
incident IGT and T2D compared with women with normal glucose me-
tabolism at the follow-up (2.8±1.2, n=67 vs 2.4±1.3 pg/ml, n=518, p=
0.013). In contrast, we observed no difference in ET-1 levels in men
comparing participants with or without IGT/T2D at the follow-up (2.2±
1.3, n=83 vs 2.3±1.2 pg/ml, n=483 p=0.589). There was a significant
age-independent interaction term between sex and ET-1 (p=0.027). Fur-
ther, sex-stratified logistic regression was significant in women (OR: 1.3,
95%CI: 1.1-1.6, p=0.013), but not in men (OR: 0.9, 95%CI: 0.8-1.4, p=
0.513). Finally, the predictive value of ET-1 for IGT/T2D at the follow-up
in women remained significant after further adjustment for age, munici-
pality, waist-hip ratio, CRP, smoking, leisure time physical activity, and
systolic blood pressure (OR: 1.3, 95% CI: 1.1-1.7, p=0.010).
Conclusion: This longitudinal population-based study shows that higher
circulating ET-1 levels predict development of incident IGT and T2D in
women but not in men. ET-1 might be an early marker for increased T2D
risk in women, and, thus, a target for future treatment and prevention
strategies.
Supported by: ALF-agreement, Swedish Research Council
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Increment of serum bilirubin affects incident type 2 diabetes
S.-E. Lee, T.Y. Yu, Y. Hong, W.J. Hong, J.E. Jun, Y.-B. Lee, M.-K. Lee,
J.H. Kim;
Internal Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Background and aims: Bilirubin is not only the byproduct of heme
catabolism but also an important antioxidant in vivo. Serum bilirubin
level has been reported to be associated with incident type 2 diabetes
mellitus (T2DM). However, there have been no longitudinal studies to
determine the association between changes of serum bilirubin levels and
incident T2DM. The aim of current study was to investigate the relation-
ship between baseline serum bilirubin (BB) levels and percentage chang-
es in serum bilirubin (PCB) levels and incident T2DM in a large-scale
longitudinal study.
Materials and methods: A total of 24185 participants taking annual
medical health check-up program between 2006 and 2012 were enrolled.
Multivariable-adjusted Cox regression models were fitted to assess the
relative risk of incident T2DM by baseline and percentage change during
follow-up in bilirubin levels. PCB levels were defined as follows; chang-
es in serum bilirubin levels were calculated from baseline to the end of
follow-up or until a year before the last date of diabetes diagnosis, divided
by BB, and multiplied by 100.
S192 Diabetologia (2015) 58 (Suppl 1):S1–S607
Results:After exclusion of subjects with T2DM at the baseline and at the
first visit of follow-up, liver disease, and missing data, 20233 participants
were investigated and median follow-up duration was 60.23 months.
1275 new cases of T2DM occurred during follow-up. There was no
significant difference in BB levels between the group with incident
T2DM and the group without incident T2DM (P>0.05), while PCB
levels of those groups were significantly different (P<0.001). When di-
viding BB and PCB levels into quartiles, the proportions of participants
observed to develop T2DM were not different among BB quartiles
(P>0.05), however, the proportions of incident T2DM significantly in-
creased across quartiles of PCB (from the lowest to the highest quartile,
3.9% in the first, 4.2% in the second, 7.0% in the third, and 9.7% in the
fourth; P<0.001). After adjusting multiple potential confounders includ-
ing fasting blood glucose level and HbA1c, the HR of incident T2DM in
the highest quartile of PCB was more than two times that of the lowest
quartile group (HR 2.038 [95% CI 1.722 - 2.412]; P for trend<0.001).
This association was still significant when PCB was analyzed as a con-
tinuous variable, per 1% increase, the HR of incident T2DM was 1.006
(95% CI 1.005 - 1.007; P<0.001). In subgroup analysis (n=13394) with
fasting insulin levels, the result remained significant (HR 1.006 [95% CI
1.005-1.008]; P<0.001) after additional adjustment of fasting insulin lev-
el and homeostasis model assessment of insulin resistance (HOMA-IR).
Conclusion: This study demonstrated that an increase in serum bilirubin
level, rather than baseline serum bilirubin level itself, can be associated
with incident T2DM.
PS 017 Monogenic diabetes
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A novel insulin mutation in autosomal dominant diabetes
C.M. Reinauer1, S. Kummer1, K. Förtsch1, C. Bergmann2, E.
Mayatepek1, T. Meissner1;
1Department of General Pediatrics, Neonatology and Pediatric Cardiolo-
gy, Heinrich-Heine-University Düsseldorf, 2Center for Human Genetics
Bioscientia, Ingelheim, Germany.
Background and aims:Diabetes caused by insulin (INS) gene mutations
is a rare form of neonatal diabetes, prevalence is estimated at 1 of 200.000
live births in Europe. We report a German female patient with a novel
form of permanent neonatal diabetes mellitus.
Materials and methods: The second child of non-consanguineous Ger-
man parents was born at 40 weeks of gestation; BW 3260 g. At the age of
8 days the girl presented with polyuria, sweating and frequent vomiting.
Blood glucose showed significant hyperglycaemia >200 mg/dl without
ketosis. Insulin (6.9 mU/l) and C-peptide (1.8 μg/l) were detectable and
there were no clinical or laboratory signs of exocrine pancreatic insuffi-
ciency. Transabdominal ultrasound showed a normal pancreatic structure.
No other symptoms or dysmorphic features were evident. Her father had
been treated for diabetes mellitus since the age of 3 months, so far clas-
sified as type 1 diabetes, while there was no other case of DM in the
family history. Genetic testing identified a novel heterozygous INS gene
mutation (c.128G>A) in both father and daughter. Themissensemutation
causes an amino acid exchange of the highly conserved position 43
cystein (p.Cys43Tyr), resulting in the loss of one disulfide bond. Bioin-
formatic tools predict an impairment in protein function (MutationTaster,
PolyPhen2, SIFT, AlignGVGD).
Results:We considered that the novel mutant insulin might cause ß-cell
toxicity through endoplasmatic reticulum (ER) stress as described for
other INS mutations. Low dose insulin therapy was started using contin-
uous subcutaneous insulin infusion (CSII) with insulin U10 dilution at the
age of 4 weeks in combination with continuous subcutaneous glucose
monitoring (CGMS). Significant hypoglycaemia did not occur, blood
glucose could be kept in the range between 100 and 170 mg/dl within
the first year of life. Bolus insulin was not introduced until the age of
18months. At the current age of 24months, the child is thriving well with
HbA1c stable between 60-65 mmol/mol under low dose CSII with
0.3 IU/kg/d without hypoglycaemia. The father shows poor glucose con-
trol (HbA1c 111 mmol/mol) due to incompliance, and low but significant
C-peptide release even after three decades of diabetes.
Conclusion: This novel INS mutation leads to a loss of one disulfide
bond. Its phenotype has not yet been described. Low dose CSII was used
without overt hypoglycaemia aiming to decrease endogenous insulin pro-
duction and therefore reduce ER stress to minimize progressive loss of
beta cell mass. Follow up will show whether low dose insulin infusion
will help to maintain ß-cell function due to reduction of ER stress.
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miRNA 224 is readily detectable in urine of individuals with diabetes
mellitus and a potential indicator of beta cell demise
S. Bacon1, B. Engelbrecht2, J. Schmid3, S. Pfeiffer2, C.G. Concannon2,
A. McCarthy1, M. Burke1, J.H.M. Prehn3, M.M. Byrne1;
1Endocrinology & Diabetes, Mater Misericordiae University Hospital,
2Department of Physiology & Medical Physics, Royal College of Sur-
geons in Ireland, 3Centre for Systems Medicine, Royal College of Sur-
geons in Ireland, Dublin, Ireland.
Background and aims:MicroRNA (miRNA) are a class of non-coding,
19-25 nucleotide RNA critical for network-level regulation of gene ex-
pression. HNF1A-maturity-onset diabetes of the young (HNF1A-
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MODY) is a monogenic form of diabetes resulting from mutations in the
gene encoding the pancreatic transcription factor hepatocyte nuclear fac-
tor 1α (HNF1A). We recently demonstrated that induced suppression of
endogenous HNF1A function in INS-1 cells, a cellular model of HNF1A-
MODY increased the levels of two miR-224 and miR-103. Using abso-
lute quantitative PCR analysis, we demonstrated that miR-224 and miR-
103 levels were significantly elevated in the serum of HNF1A-MODY
carriers when compared to controls. miR-224 is a novel miRNA in the
field of diabetes. The aim of this current study was to obtain proof-of-
concept that miR-224 and miR-103 are also detectable in the urine of
HNF1A-MODY carriers, and to determine whether these diabetes-
associated miRNA are also elevated in the urine of patients with type 1
and type 2 diabetes mellitus.
Materials and methods: Absolute levels of miR-224 and miR-103
were determined in the urine of n=144 individuals including
HNF1A-MODY carriers, participants with type 1, type 2 diabetes
mellitus and normal controls. We also correlated urinary levels of
miRNA with serum levels and with clinically relevant indices of
renal disease.
Results: miR-224 was significantly elevated in the urine of HNF1A-
MODY carriers and participants with type 1 diabetes mellitus (see figure
1). miR-103 was highly expressed in urine across all diabetes cohorts
when compared to controls. For both miRNA-224 and-103 we found a
significant correlation between serum and urine levels (p<0.01). miR-
224 and miR-103 levels in HNF1A-MODY, type 1 or type 2 diabetes
mellitus cohorts did not correlate with the renal indices; albumin creati-
nine ratio (ACR) or estimated Glomerular Filtration Rate (eGFR).
Conclusion: We here provide the first proof-of-concept study that
miRNA can be readily detected in the urine of participants with
diabetes. The utilization of urine as a biofluid has multiple ad-
vantages in the clinical setting. Urine sampling is non-invasive
and not subject to haemolysis. This is important, as blood con-
tamination and haemolysis are the most common artefacts encoun-
tered in miRNA detection in fluids. miR-224 is a novel diabetes-
associated miRNA which is highly expressed in the urine of
HNF1A-MODY carriers and a type 1 diabetes mellitus cohort.
We surmise that the differential expression levels of miR-224 in
both insulin deficient states may be an attempt to compensate for
beta- cell demise. A further novel finding of the current study is
the detection of the well-established diabetes-associated miRNA;
miR-103 in urine.
Supported by: Health Research Board of Ireland awarded to S.B. Grant
number; HP
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Permanent neonatal diabetes: new hopes for a dreadful disease
S. Ioacara1,2, C. Toader1, A. Oprea1, A. Reghina1,2, O. Georgescu1, S.
Martin1,2, A. Sirbu1,2, S. Fica1,2;
1Endocrinology and diabetes, "Elias" University Emergency Hospital,
2"Carol Davila" University of Medicine and Pharmacy, Bucharest, Ro-
mania.
Background and aims: Of the many possible mutations in the KCNJ11
gene, the Q52R is responsible for a severe form of permanent neonatal
diabetes (PND) associated with developmental delay and epilepsy
(DEND syndrome). None of the previously 3 cases detected worldwide
was successfully switched to sulphonylurea (SU). One of them had only a
few months survival and the long-term insulin treatment in the other two
patients was associated with poor disease control and persistence of de-
velopmental deficits.
Materials and methods: A one year and three months old boy was
admitted on 28th July 2014 in our emergency university hospital, for a
scheduled attempt on switching from insulin to SU for his PND. He was
diagnosed with PND at age 2 months, testing negative for major islet
autoantibodies. As switching to SU resulted in ketoacidosis, he has since
remained on insulin, currently needing 6 U/day. Recent genetic testing
performed in Exeter laboratories (Welcome Trust fund), UK revealed an
acquired, rare, but severe point mutation (Q52R) in KCNJ11 gene.
Results: On admission, he had moderate-severe developmental deficit,
with moderate hypotonia, but no other significant symptoms. He was just
staying horizontally in his bed, without the possibility of rolling over by
himself. His weight was 13 Kg, for a 75 cm length, showing no clinical
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significant biochemical results except for HbA1c=9.5% (80 mmol/mol),
LDH=352U/L (Normal range: 125-220U/L), andC-peptide=0.02 ng/ml
(intermediate DEND syndrome). He was successfully switched on
glibenclamide alone, given every 3-6 h, with a rapid escalation of doses
due to lack of initial response. He was discharged from the hospital on 6th
August 2014, with a total SU dose around 0.8 mg/Kgc/day. A significant
improvement in both metabolic control and developmental deficits was
registered after one month. The patient was able to walk and HbA1c was
6.5% at 6 months of SU treatment. Insulin secretion appears to be strong-
ly nutrient dependent, with glucose values dropping after food intake and
rising with food deprivation.
Conclusion: This is the first worldwide report of a successful transition
from insulin to SU treatment in a patient suffering from PND associated
with intermediate DEND syndrome due to Q52R mutation in the
KCNJ11 gene. The dramatic improvement in neurologic deficits gives
new hopes for what was once considered a dreadful disease.
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The clinical management of hyperglycaemia in pregnancy complicat-
ed by maturity onset diabetes of the young
M.M. Byrne1, J. Schmid2, A.McCarthy1, J. Edwards3, A. Fleming3, B.T.
Kinsley4, R.G. Firth5, B. Byrne6, C. Gavin5, S. Bacon1;
1Endocrinology & Diabetes, Mater Misericordiae University Hospital,
2Centre for Systems Medicine & Department of Physiology and Medical
Physics, Royal College of Surgeons in Ireland, 3Diabetes, Rotunda Ma-
ternity Hospital, 4Endocrinology & Diabetes, Mater Misericordiae Uni-
versity Hospital and Coombe Women & Infants Hospital, 5Endocrinolo-
gy&Diabetes, National Maternity Hospital, 6Endocrinology&Diabetes,
Coombe Women & Infants University Hospital, Dublin, Ireland.
Background and aims: Women with Maturity Onset Diabetes of the
Young (MODY) are often first identified and diagnosed with diabetes
during pregnancy. Genetics and hyperglycemia play an important role
in determining fetal size in MODY pregnancies .Observational data on
glycemic control and fetal outcomes in pregnancies complicated by glu-
cokinase (GCK) and (hepatocyte nuclear factor-1 alpha) HNF-1αMODY
mutations are lacking. The aim of the current study was to determine the
outcomes and clinical management of hyperglycemia using home blood
glucose monitoring (HBGM) in MODYpregnancies.
Materials and methods:A retrospective chart review of 37 women with
a GCK or a HNF-1α mutation was conducted. There were 132 pregnan-
cies in these women. Data on variables such as birth weight, mode of
delivery and the treatment of hyperglycaemia was recorded. Complica-
tions which included congenital anomaly, birth injury, admission to neo-
natal intensive care unit (NICU) and prolonged neonatal hypoglycemia
were recorded. Genotyping of 36 offspring was known. The HBGM
recordings of a subset of these women, who were all managed according
to our current guidelines for diabetes in pregnancy, with a GCK or HNF-
1α mutation referred to one of the three tertiary centres were analysed.
The median of the highest and lowest blood glucose value for each day, at
each time point, was averaged over a seven day period. This was per-
formed for each trimester.
Results: The birth weight in non-effected GCK offspring was significant-
ly higher than in the effected GCK offspring (4.8 kg (4.1-5.2) vs. 3.2 kg
(3.1-3.7), p=0.01). Seven point home blood glucose monitoring
(HBGM) over a seven day period in each trimester demonstrated higher
fasting and post prandial glycemic excursions in the 1st trimester of GCK
pregnancies when compared to HNF-1α pregnancies (Fasting; 5.8 mmol/
l (5-6.4) vs 4.7 mmol/l (4.3-4.9), p=0.01 and Post-prandial: 8.6 mmol/l
(7.5-10.9) vs 6.2 mmol/l (5.6-7.3), p=0.04) despite insulin treatment.
There was a higher percentage of miscarriages in the GCK group when
compared to the HNF1A-MODY group (33.3% vs 14%, p=0.07) which
was similar to the background population. Insulin initiated at an early
gestation appeared to lower the incidence of macrosomia in GCK non-
effected offspring.
Conclusion: To date, this is the largest study performed specifically
looking at glycemic excursions in pregnancies complicated by GCK
and HNF-1α MODY. This study demonstrates that the current manage-
ment of HNF-1α pregnancies appears to be appropriate. In GCK preg-
nancies, however, the glycaemic variability that we have clinically noted
warrants attention. There was an increased percentage of both
macrosomia and miscarriages in GCK pregnancies highlighting the im-
portance of a diagnosis of GCK-MODY in women prior to conception
and the necessity for pre-conception care.
Supported by: HRB to SB, HPF-2013-459
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Identification and clinical characteristics of a family with the
ARG103PROmutation in the NEUROD1 gene detected by new gen-
eration sequencing
A. Ludwig-Galezowska, M. Szopa, J. Machlowska, J. Skupien, P.
Radkowski, M.T. Malecki;
Jagiellonian University Medical College, Krakow, Poland.
Background and aims: Until now there have been only a few families
with early onset autosomal diabetes due to mutations in the NEUROD1
gene identified. Moreover, only two of them seemed to meet strict
MODY criteria. The introduction of next-generation sequencing (NGS)
provides a new opportunity to detect more pathogenic mutations in this
gene. The aim of this study was to evaluate a segregation of the
Arg103Pro mutation in the NEUROD1 gene detected by NGS in the
proband from family and to describe the clinical characteristics of muta-
tion carriers.
Materials and methods: We selected 96 diabetic probands of MODY
families, among which 42 patients were earlier tested GCK-MODY and
HNF1A-MODY by Sanger sequencing with negative results. Genetic
testing was performed by the targeted NGS sequencing using a panel of
29 genes in which mutations have been reported to cause monogenic
diabetes. This panel included the NEUROD1 gene.
Results: Among genetic variants detected by NGS, one patient had a
missense mutation in the gene NEUROD1. It was the Arg103Pro (CGC
/ CCC) missense mutation. This mutation affected the DNA binding
domain of the NEUROD1 transcription factor. We confirmed this se-
quence difference by Sanger sequencing. The family with the mutation
was included into our MODY registry in 1999 and had previously been
tested with negative results for mutations in GCK and HNF1A. 17 family
members were invited for further genetic testing. In 11 subjects we con-
firmed the presence of the mutation. Seven adult mutation carriers (all but
one) from three generations have been already diagnosed with diabetes
and were treated with different therapeutic models. There were 3 individ-
uals with the Arg103Pro mutation diagnosed before the age of 30 years in
the family. The range of age of unaffected mutation carriers was 4-
48 years. Interestingly, there was a history of neonatal severe hypoglyce-
mia in a pediatric patient who is also a carrier of the mutation. The clinical
course reminded episodes typical for HNF4A-MODY.
Conclusion: The use of the NGS method will likely allow for more
frequent identification of rarer forms of MODY. The identified MODY
family seems to be just the third NEUROD1 family meeting the criteria of
MODY.
Supported by: "Iuventus Plus", No. 0545 / IP1 / 2011/71
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Reuptake of secreted carboxyl-ester lipase (CEL) variants, a role in
diabetes and exocrine pancreatic disease?
I.M.K. Lavik1,2, M. Dalva1,2, S.J. Steine1,3, P.R. Njølstad1,4, A.Molven3,
5, K. Fjeld1,2, B.B. Johansson1,2;
1Department of Clinical Science, KG Jebsen Center for Diabetes Re-
search, 2Center for Medical Genetics and Molecular Medicine, 3Depart-
ment of Clinical Medicine, Gade Laboratory for Pathology, 4Department
of Paediatrics, 5Department of Pathology, Bergen, Norway.
Background and aims: CEL is a digestive enzyme involved in hydro-
lysis and absorption of cholesterol and lipid-soluble vitamin esters. We
have previously described a syndrome of diabetes and exocrine pancre-
atic dysfunction caused by mutations in the CEL gene. The mutant pro-
tein (CEL-MUT) has a higher tendency to aggregate and undergo endo-
cytosis as compared to the wild-type CEL protein (CEL-WT). Here, we
compare the cellular reuptake of CEL-MUT and CEL-WT in HEK293
cells and pancreatic cell lines.We also investigated the intracellular fate of
the two protein variants, their effect on viability, as well as their impact on
insulin secretion from endocrine cells.
Materials and methods: HEK293 cells stably expressing CEL protein
variants were grown for 24 h toward confluence. Conditioned media were
added to untransfected cell lines (HEK293, embryonic kidney; INS-1E,
insulinoma; 266-6, acinar; PANC-1, ductal) for various durations. Immu-
nostaining and confocal microscopy were performed to investigate endo-
cytosis and degradation of CEL. Cell viability was monitored by quanti-
tation ofATP generated bymetabolically active cells and insulin secretion
was determined by ELISA.
Results: In HEK293, acinar and INS-1E cells we observed increased
uptake of the CEL-MUT protein variant as compared to CEL-WT. After
endocytosis the mutant protein was present as intracellular puncta co-
localizing with the lysosomal marker LAMP1. The same tendency was
noted for CEL-MUT in PANC-1 cells. Exposure to the CEL-MUT pro-
tein negatively affected the viability of the investigated cell lines. Prelim-
inary results indicated that long-time exposure of INS-1E cells to the
mutated protein leads to a reduced glucose-stimulated insulin secretion
compared to when these cells are grown in the presence of the wild-type
protein.
Conclusion: Our data indicate that mutated CEL negatively affects insu-
lin secretion. We suggest that extracellular CEL-MUT aggregates are
toxic and removed by cell-mediated uptake and degraded by the cells.
Taken together, these findings could be relevant for howCEL-MUTcause
a disease affecting both the exocrine and endocrine pancreas.
Supported by: KG Jebsen Foundation
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Serum metabolome changes in healthy subjects with different geno-
types of NOS1AP in the Chinese population
W. Congrong1, Y. Zhang2, W. Jia1;
1Shanghai 6th people's hospital, Shanghai, China, 2Center for Transla-
tional Medicine, Shanghai 6th people's hospital, Shanghai, China.
Background and aims: Nitric oxide synthase 1 adaptor protein
(NOS1AP), regulates the neuronal nitric oxide synthase (nNOS)
activity and has an effect on nitric oxide (NO) release by binding
N-methyl-d-aspartate receptors. One functional study showed that
rs12742393 could affect NOS1AP gene expression through
influencing transcription factor binding. Our previous study
showed evidence that rs12742393 in NOS1AP was involved in
type 2 diabetes susceptibility in the Chinese population, with C
allele as the risk allele (OR 1.17, 95% CI 1.07-1.26; P =0.0005).
In this study, we report a comprehensive metabonomic study of
different genotypes (AA and CC) of rs12742393 using two com-
plementary analytical platforms, gas chromatography time-of-flight
mass spectrometry (GC-TOFMS) and ultra-performance liquid
chromatography quadrupole time-of-flight mass spectrometry
(UPLC-QTOFMS).
Materials and methods: Fifty-five healthy participants with normal glu-
cose regulation were selected for metabolomic investigation, including
twenty-seven CC homozygote and twenty-eight AA homozygote indi-
viduals. All the individuals for the metabolomic analysis were matched
strictly with age, sex, BMI, glucose, and lipid related parameters. For all
the subjects, venous blood samples were obtained after overnight fasting
for at least 10 h and subjected to GC-TOFMS and UPLC-QTOFMS. The
GC-TOFMS data was analyzed by ChromaTOF software, the UPLC-
QTOF-MS ES+ and ES- raw data were analyzed by the MarkerLynx
Applications Manager version 4.1 (Waters, Manchester, U.K.) and then
metabolites were identified by comparing the accurate mass, mass frag-
ments, characteristic ions with the available reference standards and pub-
lished reports, in addition to the web-based resources such as the Human
Metabolome Database. The data sets were then analyzed and validated by
uni- and multi-variate statistical methods, separately. Principle compo-
nent analysis (PCA) and orthogonal partial least squares-discriminant
analysis (OPLS-DA) were carried out (SIMCA-P 12.0, Umetrics, Umeå,
Sweden) and Wilcoxon-Mann-Whitney test was selected to measure the
significance of each metabolite.
Results: A total 258 metabolites were identified and seven significantly
altered serum metabolites identified in AA carriers relative to CC carriers
were selected according to the VIP threshold (VIP>1) in OPLS-DA
model coupled with the Mann-Whitney U test (p<0.05). These including
Malic acid, Inosine, maltose, adonitol, ribitol, serine and glycine.
Conclusion: We detected seven metabolites showing significant differ-
ences between CC and AA carriers of rs12742393 in NOS1AP. These
metabolites might associate with the development of type 2 diabetes in
subgroup of patients through the crosstalk with NOS1AP protein, which
might provide us a new perspective to the mechanism of type 2 diabetes.
Supported by: National Natural Science Foundation of China (Grant No.
81170760)
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Integrated analysis of oxidative phosphorylation changes and char-
acteristic metabolic profiles on diabetes with the mitochondrial DNA
3243 (A>G) mutation
Y. Zhang1, C. Wang2, W. Jia2;
1Center for Translational Medicine, Shanghai 6th people's hospital,
Shanghai, China, 2Department of Endocrinology and Metabolism,
Shanghai 6th people's hospital, China.
Background and aims: An A-to-G transition at position 3243 of mito-
chondrial DNA (A3243G) can result in maternally inherited diabetes and
deafness (mitochondrial diabetes). The relationship among mutation
heteroplasmy, mitochondrial oxidative phosphorylation(OXPHOS) and
metabolic profiles are largely unknown, making great challenges for dis-
ease prevention and control.
Materials and methods: Five mitochondrial DNA 3243 (A>G) muta-
tion patients, three of them belong to one family linage, were included in
this project. The participants’ body mass index scores, blood pressures,
blood glucose and insulin levels at 0, 30, 60, 120 and 180 min were
measured in response to a 75 g oral glucose tolerance test. Also they were
undergone pure tone test, brain MRI, visual evoked potential, electrocar-
diogram. A quantitative method based on pyrosequencing was used to
analyze the heteroplasmy of these patient. Quantitative reverse
transcription-PCR analysis was used to analysis the expression of all
the 13 OXPHOS genes. The serum of five mitochondrial DNA 3243
(A>G) mutation patients, five type 2 diabetes patients, five latent auto-
immune diabetes in adult and five normal controls were analyzed using
gas chromatography time-of-flight mass spectrometry platform.
Results: We found a variety of clinical conditions in association with
mitochondrial DNA 3243A>Gmutation, even in asymptomatic subjects.
Levels of the mutation heteroplasmy varied among the different sampled
blood, buccal cells and urinary sediment of the mutation carriers. In
addition, defects in subunits of the OXPHOS complexes and respiratory
chain assembly were observed in the mutation carriers. Using GC-MS
profiling methods, we found significant changed metabolites that were
associated with mitchodrial DNA 3243A>G mutation.
Conclusion: The metabolic profile of mitochondrial DNA 3243 (A>G)
mutation was quiet unique. There are some significant changed metabo-
lites were associated with neurotransmitter and energy transfer. The met-
abolic profile together with the oxidative phosphorylation changes can
partly explain the clinical symptoms of mitochondrial DNA 3243 (A>G)
mutation.
Supported by: National Natural Science Foundation of China
(81170760)
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Prevalence of retinopathy in adult patients with GCK-MODY and
HNF1A-MODY
M. Szopa1, J. Wolkow1, B. Matejko1, J. Skupien1, T. Klupa1, I.
Wybranska1, M. Borowiec2, M.T. Malecki1;
1Jagiellonian University Medical College, Krakow, 2Medical University
of Lodz, Poland.
Background and aims:Maturity onset diabetes of the young (MODY) is
a heterogeneous group of monogenic disorders that result in hyperglyce-
mia of various degree and pattern. It constitutes up to 1 million of patients
in Europe. Thus, it is very important to understand the consequences of
MODY diagnosis, including the risk of vascular complications. Diabetic
retinopathy (DR) is a complication considered to be particularly closely
related to the duration and degree of hyperglycemia. We aimed to assess
the prevalence of DR in adult patients with GCK-MODY and HNF1A-
MODY in Poland and to identify biochemical and clinical risk factors
associated with its occurrence.
Materials and methods: We examined 74 GCK mutation carriers, 51
with diabetes and 23 with prediabetes, respectively, and 63 patients with
HNF1A-MODY. Retinal photographs, twelve for each patient, were done
by a fundus camera. Signs of DR were graded according to the DR
disease severity scale. Statistical tests were performed to assess differ-
ences between the groups and logistic regression was done for the asso-
ciation with DR.
Results: The mean age at examination was 34.5±14.8 and 39.9±15.2 in
the GCK-MODY and HNF1A-MODY groups, respectively. Mild
nonproliferative DR (NPDR) was found in one patient with the GCK
mutation and likely concomitant type 1 diabetes, whereas DR was diag-
nosed in 15 HNF1A-MODYpatients: 9 with proliferative, 3 with moder-
ate NPDR and 2 with mild NPDR. The strongest independent predictors
of DR in HNF1A-MODY were markers of glucose control: HbA1c (OR:
2.05, CL%95: 1.2-3.83, p=0.01) and glucose (p=0.006, OR: 1.40,
CL%95: 1.12-1.83) analyzed in two separated models. Additionally, ar-
terial hypertension independently predicted DR (OR: 9.06, CL%95: 1.19-
98.99, p=0.04) in the model with HbA1c as glycaemic control marker.
Conclusion: In conclusion, DR of any degree was not present in our
GCK-MODY group, while in spite of young age almost every fourth
subject with HNF1A-MODY showed signs of this complication.
Supported by: Polish National Research Center, No ODW-5224/B/P01/
2011/40
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Variants of the SLC30A8 gene associated with anti-ZNT8 antibody
and predisposition to type 1 diabetes
C. Semzezem, K.F.B. Gomes, A.S. Santos, R.T. Fukui, M.R.S. Correia,
R. Batista, M.E.R. Silva;
Laboratório de Carboidratos e Radioimunoensaio–LIM18. Hospital das
Clínicas da Faculdade de Medicina, University of São Paulo, Brazil.
Background and aims: The SLC30A8 gene encodes the zinc transporter
protein (ZnT8), present in the membrane of insulin granules and
expressed mainly in pancreatic beta cells. The ZnT8 protein was identi-
fied as an autoantigen in T1D and the rs2466293 and rs16889462 variants
were associated with susceptibility to type 1 diabetes (T1D) in Cauca-
sians, but there are few data in Latin-America and in the multi-ethinic
Brazilian population. The objective was to evaluate the influence of the
variants rs2466293 and rs16889462 in the predisposition to T1D and in
the frequency of anti-ZnT8 autoantibody (Ab) which was previously
found to be 48.3% in 479 T1D patients living in Sao Paulo city.
Materials and methods: We evaluated 623 patients T1D (age: 25±
12.7 years; 367 F / 257 M, 80% white) and 650 controls (age: 29±
11.2 years; 243 F / 407 m, 63.4% white). The variants rs2466293 and
rs16889462 were genotyped by the Vera Code Golden Gate (Illumina)
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methodology. Autoantibodies against zinc transporter (anti-ZnT8) were
determined by ELISA (Kronus, USA CVof <7%) and against glutamic
acid decarboxylase (anti-GAD65) and tyrosine phosphatase (anti-IA2) by
radioimmunoassay (RSR Limited, UK, CV <7%). The genotypic associ-
ationswere analyzed using the chi-square test or Fisher exact test. P <0.05
was considered significant.
Results: The frequencies of genotypes of rs2466293 and rs16889462
variants were in Hardy-Weinberg Equilibrium , were similar in patients
and controls and were independent of gender. However, in non-whites,
the rs2466293 AA genotype conferred protection to T1D, prevailing in
controls (57.1%) compared to T1D patients (43.7%); p=0.0233; OR=
0.5821; CI=.3716 to .9117. The rs1688946 AG genotype , although rare,
was associated with higher frequency of anti-ZNT8 Ab (75%) when
compared to GG (48%); p=0.0415; OR=3.245; CI=1.023 to 10.288.
None of SLC30A8 variants influenced on age at diagnosis of T1D or
on anti-GAD65 and anti-IA2 Abs frequency .
Conclusion: The rs2466293 and the rs16889462 variants in SLC308A
gene were related to T1D predisposition and to anti-ZnT8 Ab frequency
respectively in our population.
Supported by: FAPESP
PS 018 Genetic diversity in type 1
and type 2 diabetes
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GWAS-implicated in type 1 and type 2 diabetes loci: insight into their
relative roles in the pathogenesis of Latent Autoimmune Diabetes in
Adults (LADA)
D.R.G. Leslie1, A. Chesi2, V.C. Guy2, M.I. Hawa1, J.P. Bradfield3, H.
Hakonarson3, C. Thivolet4, D. Mauricio5, N. Schloot6, K.B.
Yderstraede7, S. Schwartz8, B.O. Boehm9, S.F.A. Grant2;
1Department of Immunology and Infectious Disease, Blizard Institute,
London, UK, 2Division of Human Genetics, 3Division of Human Genet-
ics, The Childrens Hospital of Philadelphia, USA, 4Grenoble University
Hospital, France, 5Department of Endocrinology and Nutrition, Hospital
Univesitari Germans Trias i Pujol, Badalona, Spain, 6German Diabetes
Center, Dusseldorf, Germany, 7Department of Medical Endocrinology,
Odense University Hospital, Odense, Denmark, 8Main Line Health Sys-
tem, Wynnewood, USA, 9University of Ulm, Nanyang technology Uni-
versity, Singapore, Malaysia.
Background and aims: The genetic etiology of adult-onset autoimmune
diabetes, including ‘latent autoimmune diabetes in adults’ (LADA), re-
mains unresolved. LADA exhibits clinical features of both type 1 (T1D)
and type 2 (T2D) diabetes. LADA cases present initially as adult-onset
diabetes, but not requiring insulin, yet with circulating T1D-associated
islet autoantibodies and comprise 5-10% of all adult-onset diabetes in
Europe and China.
Materials and methods: Leveraging existing genome-wide SNP
genotyping data generated on the Illumina Infinium II OMNI Express
platform, we assessed the association of all GWAS-implicated T1D and
T2D loci reported to date in 965 LADA subjects and 1134 healthy control
subjects recruited from a European multicenter study. Through strict phe-
notyping criteria, diagnosis was defined by subjects aged 30-70 years,
positive for glutamic acid decarboxylase autoantibodies without initial
insulin therapy.
Results: The MHC region was strongly associated with LADA (sentinel
SNP rs1063355; odds ratio (OR)=1.58; P=3.24×10-10). Strong evi-
dence of association was also observed for other T1D-associated loci,
including SH2B3 (rs3184504 and rs1265564, OR=1.45; P=1.18×10-
6), IL7R (rs6897932, OR=1.31; P=4.34×10-5 & rs1445898; OR=
1.23; P=2.94×10-4), PTPN22 (rs2476601 and rs6679677, OR=0.71;
P=2.62×10-4) and INS (rs689, OR=1.45; P=3.46×10-4). Despite these
observations, it was interesting to note that there was no association with
the strong T1D-associated locus, CLEC16A or, contrary to previous re-
ports, the key T2D TCF7L2 locus. However, when we constrained the
dataset on positivity for the IA2 antibody, the TCF7L2 locus did yield
nominal evidence of a paucity of the T2D-associated rs7903146 T allele
(n=367 cases; OR=0.78; P=0.014). Conversely, also in the IA2 con-
straint setting, the HNF1A locus yielded significant (including survival
for multiple correction) evidence of an excess of the T2D-associated
rs7957197 T allele (OR=1.55; P=1.04×10-4). These novel observations
require follow-up studies to elucidate the mechanism of action in this
setting.
Conclusion: In conclusion, LADA, the major form of adult-onset auto-
immune diabetes as defined here, reveals a genetic etiology very similar
to childhood-onset T1D, with the striking exception of CLEC16A. Ab-
sence of the genetic locus CLEC16A could account for a later age at
presentation of T1D, notably LADA.
Supported by: R01 HD58886
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Genes previously associated with Polycystic Ovary Syndrome
(PCOS) in the Asian population and variability in PCOS population
from central Europe
R. Attaoua1, S. Haydar1, D. Fakih1, L. Andreasen1, M. Vintila2, A.
Bensalem1, N. Baculescu2, C. Normand1, P. Poucheret3, M. Coculescu2,
F. Grigorescu1;
1Molecular Endocrinology Laboratory, UMR204 NUTRIPASS,
Université de Montpellier 1 (IURC), France, 2Department of Endocrinol-
ogy, University of Medicine and Pharmacy “Carol Davila”, Bucharest,
Romania, 3Pharmacology and Experimental Physiology Laboratory. Fac-
ulty of Pharmacy, Montpellier, France.
Background and aims: Recent investigations by genome-wide associa-
tion approach in an Asian population identified many genes associated
with polycystic ovary syndrome (PCOS), as LHCGR (luteinizing
hormone/choriogonadotropin receptor), DENND1A (DENN/MADD do-
main containing 1A), YAP1 (Yes-associated protein 1), TOX3 (TOXhigh
mobility group box family member 3) and insulin receptor (INSR) genes.
In this context we explored variation of these genes and that of KLF14
(Kruppel-like factor 14) gene in PCOS in a population of 401 cases and
143 controls from Central Europe well characterized at the endocrine and
metabolic levels, aiming to test gene association to PCOS in a population
of Caucasian origin.
Materials and methods: Genetic markers used in the study were the
SNPs rs2479106 A/G, rs1894116 A/G, rs4784165 T/G, rs2059807
(A/G) and rs1562398 for DENND1A, YAP1, TOX3 and INSR, respec-
tively. Genotyping of SNPs was carried-out by KASPar technology while
genetic association and genotype-phenotype correlations were calculated
by logistic regression and ANOVA, respectively using StatView and
GoldenHelix programs, respectively.
Results: We observed gene-dose effect of LHCGR (rs1340572) with
diastolic blood pressure (P=0.014; GG (n =1) 100 mmHg, AG: (n=33)
73,8±3.2 mmHg, AA: (n=224) 69.7±0.8 mmHg) while DENND1
(rs2479106) displayed a trend of gene-dose effect with plasma insulin
at 120 minutes during the OGTT test (P=0.053; AA (n=84): 73.8±
7.2 mU/L, AG (n=101): 102.0±10.9 mU/L, GG (n=22) 128.3±
39.2 mU/L). However none of genes were associated with PCOS pheno-
type in our investigation.
Conclusion: This study allowed observing the association of genes with
metabolic components of PCOS with some variability from data previ-
ously reported in the Asian population, which highlights one more time
the necessity of considering differences between populations when study-
ing the genetic susceptibility to complex disorders.
Supported by: EC MEDIGENE FP7 project
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Haplotype mapping of GCKR gene indicates the association with
PCOS and reveals the role of BCAA metabolism
S. Haydar1, R. Attaoua1, M. Coculescu2, M. Vintila2, D. Fakih1, A. Ben
Salem1, N. Baculescu2, P. Poucheret3, F. Grigorescu1;
1Molecular Endocrinology Laboratory, Nutrition & Genomes, UMR-204
NUTRIPASS, IURC, Montpellier, France, 2Department of Endocrinolo-
gy, University of Medicine and Pharmacy "Carol Davila", Bucharest,
Romania, 3Pharmacology and Experimental Physiology Laboratory, Fac-
ulty of Pharmacy, Montpellier, France.
Background and aims: Polycystic ovary syndrome (PCOS) is one of the
most common endocrine disorders characterized by reproductive and
metabolic disorders including insulin resistance (IR) and metabolic syn-
drome (MetS). It has been shown that dysregulated branched-chain amino
acids (BCAA) metabolism may be associated with IR. High plasma level
of BCAA was also noted in women with PCOS. At the genetic level,
some genes were correlated to BCAA plasma variation, type 2 diabetes
(T2D), IR and obesity, among which the GCKR (glucokinase regulatory
protein) is one of the candidates. The aim of this work was to investigate
the potential association of GCKR with PCOS and its components.
Materials and methods: We studied a population from Central Europe
(401 cases and 143 controls) with PCOS diagnosed according to Rotter-
dam criteria, using the leader SNP (Single nucleotide polymorphism)
rs1260326 (C/T) as well as 200 SNPs at this locus. The leader SNP was
genotyped in all population byKASPAR technology. Haplotype mapping
was performed in a nested study to determine the Linkage Disequilibrium
(LD) pattern in population. The locus of GCKR gene was screened with
200 SNPs in 55 cases and 48 controls by Affymetrix technology. LD
pattern and haplotypes reconstruction were carried-out by HAPLOVIEW
4.2 and PHASE 2.1, respectively while gene association and genotype-
phenotype correlations were assessed by logistic regression and ANOVA
using StatView and GoldenHelix.
Results: We found an association of the leader SNP rs1260326 TT ge-
notype with protective effect against PCOS (P<0.03, OR 0,49 95%CI
[0.25 - 0.96]). This result was specifically observed in lean PCOS women
(P=0.036) and PCOS without metabolic complications or MetS (P=
0.045). The nested study showed a block of LD including SNPs
rs2293572, rs2293571, rs1260326 and rs3817588 while reconstruction
of haplotypes in population revealed 7 haplotypes, among which 5 were
more frequent: H3 (CGTT) (49%), H5 (GACT) (27.7%), H2 (CGCC)
(15.0%), H1 (CGCT=ancestral haplotype) (4.9%) and H6 (GACC)
(2.4%). The T variant of rs1260326 was found in the most frequent
haplotype.
Conclusion: Our finding indicates that GCKR is a good candidate for
PCOS and is in accordance with some previous studies albeit with some
variations and reinforces the interest in BCAA and our approach in study-
ing SNPs variation in ethnic groups in Europe.
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Impact of known type 2 diabetes associated variants on circulating
levels of branched-chain amino acids during an oral glucose toler-
ance test
Y. Mahendran1,2, A. Jonsson1, T. Schnurr1, C.T. Have1, N. Grarup1,
N.B. Johansen2,3, D.R. Witte2,4, T. Lauritzen4, M.E. Jørgensen3, O. Pe-
dersen1, T. Hansen1;
1NNF Center for Basic Metabolic Research, University of Copenhagen,
2The Danish Diabetes Academy, Odense, 3Steno Diabetes Center, Gen-
tofte, 4Department of Public Health, University of Aarhus, Denmark.
Background and aims:Adetailed understanding of the pathophysiology
of type 2 diabetes (T2D) and identification of early metabolic alterations
is essential for identifying individuals at high risk of this disease. Our aim
is to investigate the branched-chain amino acids (BCAAs; that is leucine,
isoleucine, valine) level in various stages of pre-diabetes and their asso-
ciation with known T2D risk variants.
Materials and methods: ADDITION-PRO is a population based longi-
tudinal cohort study of individuals at low to high risk for diabetes, nested
in the ADDITION-Denmark study. A stratified sub-sample of individuals
were invited to a follow-up health examination (2009-2011) and 2,082
participants attended. A total of 1,490 participants without known diabe-
tes were given a standard 75 g oral glucose tolerance test (OGTT) after an
overnight fast of ≥8 hours. The blood samples were drawn at 0, 30 and
120 min for assessment of serum insulin, plasma glucose, and plasma
BCAAs concentrations. Plasma BCAA levels were measured by NMR
spectroscopy. Previously reported 68 T2D risk SNPs were genotyped
using the Illumina Infinium HumanCoreExome Bead chip or imputed
with high quality into a 1000 genomes phase 3 panel. Genotype-
phenotype correlations were studied using the linear mixed model test
implemented in the EPACTS software package.
Results: Circulating BCAA levels decreased during an OGTT (30,
120minutes) compared to fasting (0minutes) levels. Additionally, fasting
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and stimulated BCAA levels were higher in men compared to women (P
<0.001), higher in obese compared to lean subjects (P<0.001), and
higher in individuals with impaired fasting glucose (IFG) (P<0.04) and
impaired glucose tolerance (IGT) (P<0.001) compared to normal glucose
tolerance. BCAA levels were positively correlated with sex, BMI, insulin
levels, HOMA-IR and negatively correlated with Matsuda indices. Ge-
netic association with fasting and/or stimulated BCAA levels (after
adjusting for age, sex and BMI) suggested that the known T2D risk
variants in JAZF1 (rs864745, effect size -2.7%), DUSP9 (rs5945326,
effect size +2.6%), IGF2BP2 (rs1470579, effect size +2.4%) and GCKR
(rs780094, effect size -2.4%) were associated significantly (P<0.05) with
Isoleucine levels. PPARG (rs1801282, effect size +3.0%), JAZF1
(rs864745, effect size +1.9%), DUSP9 (rs5945326, effect size +2.2%),
PAM (rs35658696, effect size +3.5%) variants were significantly (P<
0.05) associated with leucine levels. And the variants in ADAMTS9
(rs4607103, effect size +7.6%), DUSP9 (rs5945326, effect size +5.9%),
IGF2BP2 (rs1470579, effect size +2.8%), andGRB14 (rs3923113, effect
size -2.2%) were significantly (P<0.05) associated with valine levels.
Conclusion: Our large population-based study shows that BCAA levels
were significantly higher in individuals with impaired glucose regulation.
Several T2D risk SNPs were significantly associated with BCAA levels;
however, biological functions of these associated variants are largely
unknown. Further investigations are needed to find the casual relation
of the T2D risk variants with BCAA levels.
Supported by: DDA, EFSD/J&J, DFF, Lundbeck Foundation
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Genome-wide association studies of diabetic kidney disease in pa-
tients with type 2 diabetes
N.W. Rayner1, E. Ahlqvist2, H. Deshmukh3, N. Van Zuydam1, N.
Sandholm4, C. Ladenvall2, M. Lajer5, L. Marcovecchio6, E. Rurali7,
SUMMIT Collaborators, SUMMIT Consortium;
1Wellcome Trust centre for Human Genetics, University of Oxford, UK,
2Lund University, Malmo, Sweden, 3University of Dundee, UK,
4Folkhalsan Research Center, Helsinki, Finland, 5Steno Diabetes Center,
Gentofte, Denmark, 6University of Cambridge, UK, 7IRCCS - Istituto di
Ricerche Farmacologiche, Bergamo, Italy.
Background and aims: Diabetes mellitus is associated with a range of
chronic complications including diabetic kidney disease (DKD), a lead-
ing cause of end-stage renal disease (ESRD). To date few robustly asso-
ciated genetic factors for these traits have been identified. As part of the
SUMMIT consortium we performed a meta-analysis of genome-wide
association studies (GWAS) in patients with type 2 diabetes (T2D) from
European backgrounds to identify genetic determinants of DKD.
Materials and methods: GWAS were performed on 7 case control phe-
notypes based on the severity of diabetic nephropathy (DN). DN was
characterised by micro-albuminuria, macro-albuminuria, end stage renal
disease (ESRD), or chronic kidney disease (CKD; eGFR <60 ml/min) in
4 European studies with type 2 diabetes comprising up to 3,345 cases and
2,372 controls.We analysed 9,213,894 single nucleotide polymorphisms,
imputed based on the 1000 Genomes (March 2012) reference panel,
using EMMAX, adjusting for sex, age at onset, duration of diabetes and
kinship matrix. Meta-analyses were performed using a fixed effects mod-
el and SNPs with p<5×10-6, from any of the binary phenotypes, were
selected for in silico replication in 2 European cohorts comprising 3,247
cases and 906 controls.
Results: From the meta-analyses we identified 139 SNPs for in silico
replication. After joint analysis of the discovery and replication cohorts
9 SNPs showed nominal replication (p<0.05 with same direction of ef-
fect), however no loci reached genome wide significance (p<5×10-8).
The strongest joint signals were rs4977388 (ESRD vs all other pheno-
types, p=2.25×10-7, nearMLLT3), rs7916840 (DN, p=6.2×10-7 intronic
to GP158), rs9942471 (DN, p=9.8×10-7, near GABRR1), rs6865390
(Macro-albuminuria + ESRD, p=2.05×10-7, near RAI14) and
rs2206136, (CKD, p=5.42×10-7, intronic to PLCB4).
Conclusion: To follow up on these findings we are now performing de
novo genotyping in 3,867 additional individuals with T2D. In additionwe
are also integrating these data with T1D data from SUMMIT and the
JDRF DNCRI, T2D data from FIND and other sources, as well as exome
sequence data. By combining and comparing these different analyses we
hope to gain a broader picture of the biology of DKD.
Supported by: IMI, European Commission’s FP7 (the SUMMIT consor-
tium, IMI-2008/115006).
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The protective effect of cathepsinH on beta cell apoptosis is mediated
through the Jak-STAT and NFkappaB signalling pathways
T. Floyel, A.H. Mirza, S. Kaur, F. Pociot;
Copenhagen Diabetes Research Center, Pediatric Department, Herlev
University Hospital, Denmark.
Background and aims: In type 1 diabetes (T1D) the pancreatic β-cells
are specifically destroyed by the immune system. Genome-wide associa-
tion studies have identified >50 loci that are associated with the risk of
T1D, however, only little is known about how these variants modify
disease risk. We recently showed that T1D-associated single nucleotide
polymorphisms (SNPs) in CTSH (lysosomal protease cathepsin H) affect
the expression level of CTSH. By combining in vitro and in vivo exper-
iments with clinical studies we demonstrated that CTSH regulates β-cell
function and disease progression in children with newly-diagnosed T1D.
Interestingly, overexpression of CTSH protected insulin-secreting INS-1
cells against cytokine-induced apoptosis, which was associated with de-
creased activation of phospho-JNK and phospho-p38, reduced expression
of the pro-apoptotic factors Bcl2l11 (Bim), Myc and Hrk (DP5), and
increased insulin transcription. The aim of this study was to identify the
mechanisms through which CTSH mediates its protective effect.
Materials and methods: INS-1 cells (n=3) stably transfected with a
plasmid encoding CTSH (pCTSH) or an empty control vector (pcDNA)
were left untreated or stimulated with 150 pg/ml recombinant mouse IL-
1β and 5 ng/ml recombinant rat IFN-γ for 6 h or 16 h. RNAwas extracted
and microarray analysis performed using the Affymetrix Rat Genome
230 array. Data was analyzed in R using the Bioconductor affy package
and normalized using the RMA method. Comparisons between pCTSH
and pcDNA cells were done usingmoderated t-statistic and p-values were
adjusted to control the false discovery rate using the Benjamini-Hochberg
procedure. Genes were considered differentially expressed when the ad-
justed p-value was below 0.05 and the fold change was below -1.2 or
above 1.2.
Results: 39 genes were differentially expressed between the pCTSH and
the pcDNA cells in the untreated condition, whereas 46 and 38 genes
were differentially expressed between the pCTSH and the pcDNA
cells after cytokine treatment for 6 h and 16 h, respectively. The
top candidate genes are involved in the KEGG pathways: apopto-
sis, Jak-STAT signaling, NFκB signaling, insulin signaling, and
chemokine signaling. Among the most interesting candidates is
Trib3 which previously has been implicated in endoplasmic retic-
ulum stress-induced β-cell apoptosis. The expression of Trib3 was
decreased by 1.48 fold in pCTSH cells compared to pcDNA cells
after 6 h of cytokine treatment (p=1.68×10-4).
Conclusion: The current data support our previous findings that CTSH
protects against cytokine-induced apoptosis by regulating apoptotic sig-
naling pathways in the β-cell, such as the Jak-STAT and NFκB signaling
pathways. Our data indicate that higher CTSH levels in β-cells may
protect against immune-mediated damage and preserve β-cell function,
thereby representing a possible target for β-cell therapy in T1D.
Supported by: EFSD/JDRF/Novo Nordisk
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Generation of epigenetic and transcriptome maps for insulin-
producing cells in pancreas, gallbladder and the brain
W. Wong1, M. Joglekar1, S. Satoor1, S. Sahu1, E. Stanley2, A. Elefanty2,
T. Kay3, T. Loudovaris3, H. Thomas3, D. Liuwantara4, W. Hawthorne4, P.
O'Connell4, D. Martin5, A. Hardikar1;
1NHMRC CTC, Sydney, 2MCRI, 3SVI, Melbourne, 4WMI, 5RPA Hos-
pital, Sydney, Australia.
Background and aims: Islet transplantation is currently the only
established cell-based therapy for treatment of diabetes. However due to
the limited availability of pancreas and low yield of islets isolated
- it is important to find alternate sources of potential insulin-
producing cells. We’re the first to identify insulin-producing cells
in adult human gallbladder epithelium. Although, the levels of
pro-insulin gene transcripts in gallbladder are thousand-fold less
than in pancreatic islets, it is still significantly higher than the
reported levels in differentiated stem cells. Insulin-producing cells
have been also identified in brains of fruit-flies, mice and a clin-
ical case of insulinoma from a patient with congenital brain mal-
formation. The aim of this research is to generate epigenetic and
transcriptome maps of the insulin-producing cells in pancreas,
gallbladder and the brain. This will help understand the lineage
commitment and function of insulin in different tissues.
Materials and methods: We implemented a range of molecular tech-
niques including Next Generation Sequencing (NGS), Ultra high
throughput TaqMan-based real-time mRNA and miR PCR, immunocy-
tochemistry, single cell PCR, Chromatin IP (ChIP) and DNAmethylation
to map the transcriptome and epigenome expression of mouse and human
islets, gallbladder and brain cells.
Results: Our analyses using NGS indicate similarities between the tran-
scriptome in the brain, gallbladder and pancreatic islets (Figure 1). Insulin
transcript is detected in the human gallbladders, but at several million-fold
lower than in islets. Similar levels were found for glucagon in the gall
bladder and brain in comparison to the higher levels in islets. Somatostat-
in is lower by an order of magnitude in the brain while expression of Pdx1
in the gallbladder is at ~50% of the abundance seen in human islets.
Expression of the glucose transporter Glut1 is significantly higher in
human islets than Glut2- at comparable levels in human gallbladder.
Urocortin3, a recently described candidate associated with maturation
of insulin -producing cells was seen at ~8-fold lower in gallbladder than
human islets and around 20-fold lower in human brain. miRNAs impor-
tant in islet beta-cell function were found in the human gallbladder epi-
thelium (correlation, R2=0.716). ChIP data indicates progenitors of gall-
bladder epithelial cells continue to retain open chromatin conformation at
the insulin promoter region, with H3K4 trimethylation- significantly
higher compared to the insulin promoter conformation in the negative
control (cord-blood cells).
Conclusion: Similarities and differences in transcriptome and epigenome
maps of human gallbladder and pancreas samples are identified through
NGS, real-time PCR technologies and DNA methylation epigenetics.
Supported by: JDRF, DART, NHMRC and the University of Sydney
PS 019 Multiple organs influence
complication risk
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Risk factors of new-onset diabetes after liver transplantation and
whether the interleukin-2 receptor antagonists can reduce its
incidence
M. Yu1, M. Xue1, X. Chen1,2, X. Huang3, C. Lv1, J. Gao4, J. Zhou3, J.
Fan3, X. Gao1;
1Department of Endocrinology and Metabolism, Zhongshan hospital af-
filiated to Fudan University, Shanghai, 2Department of Endocrinology
and Metabolism, Hainan Provincial Nong Ken Hospital, Haikou City,
3Department of Liver Surgery, 4Evidence Base Medicine Center,
Zhongshan hospital affiliated to Fudan University, Shanghai, China.
Background and aims:To investigate risk factors for new-onset diabetes
after transplantation (NODAT) in patients undergoing a liver transplanta-
tion and whether interleukin-2 receptor antagonists (IL-2Ra) can reduce
the incidence of NODAT.
Materials and methods: We retrospectively analyzed the preoperative
and postoperative clinical data of patients aged >18 years who underwent
a liver transplantation in our hospital between April 2001 and December
2013. Patients with diabetes mellitus or taking glucocorticoids before
transplantation, with incomplete data, or undergoing the second trans-
plantation or being died within 3 months after transplantation were ex-
cluded. Finally, 705 non-diabetic patients who underwent a liver trans-
plantation were included for analysis. The incidence of NODAT was
analyzed according to the fasting plasma glucose (FPG) after live trans-
plantation. All the patients were divided into 2 groups (NODAT and N-
NODAT groups)and the possible risk factors of NODAT were analyzed
with One-WayANOVA and also with logistic regression analysis, includ-
ing age, gender, hepatitis virus infection, living donor, preoperative FPG
level, BMI, preoperative liver function, the severity of liver cirrhosis,
acute rejection (AR), postoperative immunosuppressant regimen, meta-
bolic factors, especially the effect of IL-2Ra on NODAT. Statistical anal-
ysis was done by SPSS 19.0.
Results: Of the 705 eligible study patients, 224 patients suffered from
NODAT while 481 patients did not. The incidence of NODAT was
31.77%. One hundred and four patients (46.4%) in the NODAT group
received IL-2Ra, while 276 patients(57.4%) in the N-NODAT group
received IL-2Ra. Single factor analysis indicated that age, preoperative
FPG were positive related to NODAT (P <0.05), while living donor, IL-
2Ra were negative related to NODAT (P <0.05). Logistic regression
analysis indicated that age (OR=1.025, P =0.006), preoperative FPG
(OR=1.305, P =0.012) can increase the risk of NODAT, while IL-2Ra
(OR=0.555, P=0.001) and living donor (OR=0.121, P=0.041) can re-
duced the risk of NODAT.
Conclusion: Age and preoperative FPG level was independent risk fac-
tors for NODAT, while the IL-2Ra and living donor can reduce the risk of
NODAT after liver transplantation.
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Low cumulative incidence of end-stage renal disease in young pa-
tients with type 1 diabetes in Sweden: a population based study
C. Toppe1, A. Möllsten2, S. Schön3,4, G. Dahlquist2;
1Department of internal medicine, Länssjukhuset Ryhov, Jönköping, 2De-
partment of Clinical scineces, Pediatrics, Umeå University, 3Swedish Re-
nal Registry, Jönköping, Sweden, 4Diaverum Renal Services Group,
Lund, Sweden.
Background and aims: A previous study from our group showed a low
cumulative incidence of end-stage renal disease (ESRD) in a Swedish
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cohort of type 1 diabetes (T1D) patients withmedian duration of 20 years.
We speculated that a good diabetes health care system might have post-
poned the peak incidence of ESRD and that young age at onset of T1D
can postpone the development of diabetic nephropathy (DN) and ESRD.
Moreover, diabetes onset during puberty may promote the development
of diabetic complications. Our previous study also indicated differences
by sex in ESRD development and a possible interaction with age at onset.
Female patients who developed T1D after puberty had similar risk of
ESRD as those with onset before 10 years of age. Male patients had the
same high risk with onset during puberty and after puberty, those with
onset before 10 years had the lowest risk. The aims of the present study
are to assess the cumulative incidence of ESRD due to DN in a large
prospective population-based cohort of T1D patients at maximum
36 years of diabetes duration and to study the effects of sex and age at
onset of T1D.
Materials andmethods: Since 1977 all incident cases of T1D in the ages
0-14 years are recorded in the Swedish Childhood Diabetes Register
(SCDR). The Swedish Renal Registry (SRR) started in 1991 and collects
data on all patients with active uraemia treatment, ESRD. We decided to
include patients with diabetes duration ≥14 years. In total 9381 patients
from the SCDR were included. We have recently received permission to
include data from the Swedish National Diabetes Register, a national
quality register, and are awaiting data to include patients with age at onset
15-34 years.
Results: For the childhood onset cases the median diabetes duration was
23.8 years, maximum 36.7 years, and 154 patients had developed ESRD
due to diabetes. The cumulative incidence was 4.5%. There was no sta-
tistical difference between male and female patients with age at diabetes
onset before 15 years of age, males 5.0%, females 3.8%. We confirm that
onset of diabetes before 10 years of age postpones the development of
ESRD when compared to onset during 10-14 years, HR 2.3 (95% CI=
1.7-3.3). Further analyses will be available for presentation in September.
Conclusion: The cumulative risk of ESRD due to diabetic nephropathy
in Swedish T1D patients at maximum 36 years of diabetes duration is still
exceptionally low. There is no difference in the development of ESRD
between male and female patients with onset of diabetes before 15 years
of age.
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Sarcopenia is associated with micro- and macro-albuminuria inde-
pendently of hypertension and diabetes: nationwide surveys
(KNHANES 2008-2011)
B.-S. Cha, Y.-H. Lee, G. Kim, E. Han, S. Kim, B.-W. Lee, E. Kang, C.
Ahn, H. Lee;
Yonsei University College of Medicine, Seoul, Republic of Korea.
Background and aims: Sarcopenia is known to be associated with
obesity-related comorbidities such as hypertension and diabetes. Howev-
er, its influence on albuminuria or nephropathy has not been determined.
Therefore, the aim of this study was to identify the relationship between
sarcopenia and albuminuria or nephropathy in the general population.
Materials and methods: This was a population-based, cross-sectional
study using nationally representative samples of 2,326 subjects aged≥
20 years from the Korea National Health and Nutrition Examination
Surveys (KNHANES) 2008-2011. The nephropathy was defined more
than 30 μg/mg of a urinary albuminuria-to-creatinine ratio (UACR) in
spot urine or more than one positive for proteinuria in urine dip stick tests.
The skeletal muscle index (SMI) [SMI(%)=total appendicular skeletal
muscle mass (kg) / weight (kg) x 100] measured by dual-energy X-ray
absorptiometry was used to diagnose sarcopenia with cut points of 32.2%
for men and 25.5% for women according to the previous study (J Clin
Endocrinol Metab. 2014;99:3879-3888).
Results: A total of 385 (16.5%) subjects were classified as having a
micro- or macro-albuminuria. Individuals with sarcopenia showed a
higher proportion of albuminuria compared to subjects with non-
sarcopenia (22% vs. 8%, odds ratio [OR]=3.26, 95% confidential inter-
vals [CI]=2.32-4.58, P<0.001). Sarcopenic subjects had a higher risk of
albuminuria, after stratification with hypertension (all ORs=2.32, all Ps<
0.05) or diabetes (ORs=1.76 to 2.71, all Ps<0.05), which are known as
established risk factors for albuminuria (Figure 1). Multiple logistic re-
gression analysis also demonstrated that sarcopenia was independently
associated with micro- or macro-albuminuria after adjusting for con-
founding factors related to albuminuria and renal function (OR=1.70,
95% CI=1.11-2.59, P=0.014).
Conclusion: Sarcopenia is associated with increased risks of micro- and
macro-albuminuria independently of hypertension or diabetes. This sug-
gests that sarcopenia may be considered as a novel risk factor for albu-
minuria.
Supported by: Korea Health Technology R&D Project
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The mortality risk in post transplantation diabetes mellitus is better
predicted by glucose than HbA1c based diagnostic criteria
I.A. Eide1, T.A.S. Halden1, A. Hartmann1,2, A. Åsberg3, D.O. Dahle1,
A.V. Reisæter4,1, T. Jenssen5,1;
1Department of Transplant Medicine, Oslo University Hospital, 2Institute
of Clinical Medicine, 3Department of Pharmaceutical Biosciences, Uni-
versity of Oslo, 4The Norwegian Renal Registry, Oslo University Hospi-
tal, 5Metabolic and Renal Research Group, The Arctic University of
Norway, Tromsø, Norway.
Background and aims: Current diagnostic criteria for posttransplanta-
tion diabetes mellitus (PTDM) are either a fasting plasma glucose (fPG)≥
7.0 mmol/L (≥126 mg/dL) or a 2-hour post-challenge plasma glucose≥
11.1 mmol/L (≥200mg/dL) during an oral glucose tolerance test (OGTT).
Recently the diagnostic criteria for type 2 diabetes of glycosylated
haemoglobin (HbA1c)≥6.5% (≥48 mmol/mol) was proposed also for
PTDM. We examined HbA1c based criteria compared with conventional
glucose criteria in the early phase after transplantation as a predictor of
mortality.
Materials and methods: In this retrospective cohort study of 1996 renal
transplant recipients, transplanted between 1999 and 2011, we estimated
mortality hazard ratios for patients diagnosed with PTDM. The study
participants underwent weekly fPG measurements during the first
10 weeks after transplantation, followed by an OGTT and HbA1c mea-
surements at 10 weeks post-transplant.
Results:During a median follow-up of 5.4 years, 314 patients died. Both
PTDM detected by an OGTT (OGTT criteria) and persistent
hyperglycaemia throughout the first 2 months post-transplant (manifest
PTDM) were associated with mortality (OGTT criteria: adjusted hazard
ratio [HR] 1.64, 95% confidence interval [CI] 1.02 - 2.63, p=0.04.
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Manifest PTDM: adjusted HR 2.21, 95% CI 1.40 - 3.49, p=0.001).
PTDM detected by HbA1c≥6.5% (≥48 mmol/mol) was not associated
with mortality (adjusted HR 0.96, 95% CI 0.61 - 1.51, p=0.86).
Conclusion: Our findings confirmed that, in the early phase after renal
transplantation, PTDM diagnosed by conventional glucose criteria, as
opposed to the HbA1c criterion, predicted mortality.
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Impact of renal transplantation on glucose tolerance in Japanese
recipients with impaired glucose tolerance
A. Nakamura1, D. Iwami1, H. Miyoshi1, K. Morita1, N. Shinohara1, Y.
Terauchi2, T. Atsumi1;
1Graduate School of Medicine, Hokkaido University, Sapporo, 2Graduate
School of Medicine, Yokohama City University, Japan.
Background and aims: New-onset diabetes after transplantation
(NODAT) is a serious and frequent complication related with renal trans-
plantation. Insulin resistance and impaired insulin secretion could con-
tribute to the pathogenesis of glucose intolerance after renal transplanta-
tion, but it has been controversial which component of them is more
relevant. In the current study, we investigated the natural history of glu-
cose tolerance, insulin secretion and insulin sensitivity by analyzing the
results of oral glucose tolerance test (OGTT) in Japanese recipients before
and one year after renal transplantation.
Materials andmethods:We performed a retrospective study of Japanese
recipients without diabetes who received renal transplantation at our hos-
pital. A 75-g OGTTwas performed before and one year after renal trans-
plantation. NODATwas defined according to the OGTT result (2-h glu-
cose≥200 mg/dL; fasting glucose≥126 mg/dL). Normal glucose toler-
ance (NGT), impaired fasting glucose (IFG) and impaired glucose toler-
ance (IGT) were defined according to the World Health Organization
Expert Committee. Insulin sensitivity was estimated by the use of the
Matsuda index and homeostasis model assessment of insulin resistance
(HOMA-IR). Insulin secretion was evaluated based on the insulinogenic
index and oral disposition index.
Results: Of the 62 recipients, 31 were diagnosed as NGT, while the
remaining 31 were diagnosed as IGT before renal transplantation. In the
NGT group, 9.7% of the recipients developed NODAT, 32.3% developed
IFG and/or IGT, and 58.1% remained NGTone year after renal transplan-
tation. In the IGT group, after one year, 12.9% developed NODAT and
29.0% remained IGT. Unexpectedly, 58.1% of the IGT group turned to
NGT. When the patients in the IGT group were classified into an amelio-
ration group (the changes in area under the curve of the glucose excursion
during the OGTT (ΔAUCglu)<0) and a non-amelioration group
(ΔAUCglu>0), there were no differences in parameters reflecting insulin
secretion and insulin sensitivity between the two groups before transplan-
tation. After one year of renal transplantation, Matsuda index was signif-
icantly increased, with no significant changes in insulinogenic index or
oral disposition index in the amelioration group. By contrast,
insulinogenic index and oral disposition index were significantly reduced,
with no significant changes in atsuda index or HOMA-IR in the non-
amelioration group. To reveal the factors influencing glucose tolerance
before and after renal transplantation in the IGT group, we examined the
association between ΔAUCglu and the changes in parameters reflecting
insulin secretion and insulin sensitivity. The changes in Matsuda index
(r=-0.5580, p=0.0014), insulinogenic index (r=-0.4674, p=0.0092) and
oral disposition index (r=-0.7788, p<0.0001) had a significant negative
correlation with ΔAUCglu.
Conclusion: More than half of Japanese recipients with IGT turned to
NGT after one year follow-up of their renal transplantation. Our results
suggested that the increase of insulin sensitivity without decreased insulin
secretion is associated with the improvement of glucose tolerance in these
recipients. Further studies are needed to elucidate the mechanism of the
increase of insulin sensitivity and maintaining of insulin secretion after
renal transplantation.
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Coronary artery disease as a risk for developing type 2 diabetes
mellitus
D. Zanolin1, C. Saely2,3, A. Vonbank3, P. Rein3, A. Leiherer1, A.
Muendlein1, H. Drexel4,3;
1VIVIT Institute, Feldkirch, Austria, 2Private University of the Principal-
ity of Liechtenstein, Triesen, Liechtenstein, 3Academic TeachingHospital
Feldkirch, Austria, 4Drexel University, Philadelphia, USA.
Background and aims: Diabetes mellitus is a major risk factor for cor-
onary artery disease (CAD); whether conversely CAD confers an in-
creased risk for diabetes is unclear.
Materials and methods: We prospectively recorded incident diabetes
over 6.1±3.7 years in 829 consecutive non-diabetic Caucasian patients
undergoing coronary angiography for the evaluation of stable CAD, cov-
ering 5057 patient years.
Results: During follow-up, diabetes was newly diagnosed in 133 pa-
tients, i.e. in 16% of the study population or in 2.6% per year. Patients
with significant CAD (n=444) when compared to subjects who did not
have significant CAD at the baseline angiography were at a strongly
increased diabetes risk (20.3 vs. 11.2%; p<0.001). The relationship be-
tween CAD and incident diabetes was confirmed after multivariate ad-
justment including metabolic syndrome status (OR 1.85 [1.23-2.79], p=
0.003).
Conclusion:We conclude that the presence of CAD indicates a strongly
increased risk for incident diabetes. Repeated diabetes screening of coro-
nary patients and targeted programs to prevent diabetes in these high-risk
patients are warranted.
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Fatal complications and causes of death in patients with type 2 dia-
betes mellitus comparing with general population by results of
autopsies
A.L. Terekhova, A.V. Zilov;
Department of Endocrinology, I.M. Sechenov the First Moscow State
Medical University, Moscow, Russian Federation.
Background and aims: To assess the frequency of fatal complications
and the risks of death from different causes in patients with type 2 diabe-
tes mellitus (DM) comparing with general population.
Materials and methods: On the basis of autopsy of 439 patients with
type 2 diabetes mellitus had died in the Clinical Hospital№50 ofMoscow
during 2006-2009 we studied the main causes of their death and fatal
complications. We compared our results with similar data from the Mos-
cow City Statistics for the general population: autopsies of all dead
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patients in hospitals of Moscow during 2007-2009. Сhi-square test was
used and relative risk (RR) with 95% confidence interval [95% CI] was
calculated. Differences were considered statistically significant at p
<0.05.
Results: Patients with type 2 DM significantly were more likely to die
from diseases of circulatory system compared to general population: 338
subjects (77,0%) vs.45586 subjects (57,7%), р<0,001, RR 1,33 [1,26-1,
40]. Diabetics more often died from ischemic heart disease - 211 subjects
(48.1%) vs.20007 subjects (25.3%), p <0,001 RR 1,89 [1,71-2,09], from
myocardial infarction - 83 subjects (18.9%) vs.10739 subjects (13.6%),
p=0,001 RR 1,39 [1,13-1,69], from cerebrovascular disease - 154 sub-
jects ( 35.1%) vs.20084 subjects (25.4%), p <0,001 RR 1,38 [1,20-1,56]
and from ischemic stroke - 89 subjects (20.3%) vs.11725 subjects
(14.8%), p=0,001 RR 1,36 [1,12-1,65]. Patients with type 2 DM had a
greater risk (р 0,001) of death also from ischemic bowel disease 19 sub-
jects (4,3%) vs.1287 subjects (1,6%), RR 2,65 [1,65-4,19], cholelithiasis -
12 subjects (2.7%) vs.469 subjects (0,59%), RR 4,60 [2,48-8,25], chronic
pancreatitis - 5 subjects (1.14%) vs.104 subjects (0,13%), RR 8,65 [3,12-
21,78], and pyelonephritis - 18 subjects (4.1%) vs.1034 subjects (1,3%),
RR 4.1 [1,92-5,00]. The groups (diabetics and general population) did not
differ (р 0,05; RR≈1) in frequency of such causes of death as hemorrhag-
ic stroke (26 subjects (5.9%) vs.4971 subjects (6.3%)), cancer (67 sub-
jects (15, 3%) vs.10240 subjects (13.0%)), chronic obstructive pulmonary
disease (8 subjects (1.8%) vs.1264 subjects (1.6%)), gastric or duodenal
ulcer (3 subjects (0.6%) vs.938 subjects (1.2%)) and non-alcoholic cir-
rhosis (9 subjects (2.0%) vs.1565 subjects (2.0%)). Patients with type 2
DM were more likely to develop fatal complications: pneumonia - 138
subjects (31,4%) vs.4023 subjects (7,37%), р 0,001 RR 4,26 [3,67-4,9];
pulmonary embolism - 100 subjects (22,8%) vs.3481 subjects (6,38%),
р=0,000 RR 3,53 [2,93-4,21]; gastrointestinal bleeding - 36 subjects (8,
2%) vs.2801 subjects (5,14%), р=0,005 RR 1,59 [1,14-2,19]; peritonitis -
28 subjects (6,37%) vs.1462 subjects (2,68%), р 0,001 RR 2,38 [1,62-3,
44].
Conclusion: In comparison with general population the patients with
type 2 DM more often died not only from diseases of circulatory system,
but also from a number of diseases of gastrointestinal tract and pyelone-
phritis. Diabetics had a greater risk of severe complications such as pneu-
monia, pulmonary embolism, gastrointestinal bleeding and peritonitis.
Along with the appropriate management of DM and the correction of
cardiovascular risk factors, the timely diagnostics and treatment of non-
cardiovascular comorbidities are necessary. An autopsy is an objective
method of obtaining reliable information on the structure of mortality.
PS 020 Progenitor cells and pancreas
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Use of epigenetic inhibitors to modulate endocrine differentiation
M. Fontcuberta-Pi-Sunyer1, S. Cervantes1,2, A. Garcia1,2, L. Sanchez1,
R. Gomis1,2, R. Gasa1,2;
1Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
2Centro de Investigación biomédica en Red de Diabetes y Enfermedades
Metabólicas Asociadas (CIBERDEM), Barcelona, Spain.
Background and aims: In the developing pancreas, the endocrine dif-
ferentiation program is initiated in multipotent pancreatic progenitors by
expression of the basic helix-loop-helix (bHLH) transcription factor
Neurogenin3 (Neurog3). Posttranscriptional modifications of histones
constitute an epigenetic mechanism that is closely linked to both gene
silencing and activation events. A key mark in differentiation processes is
the trimethylation of Histone3 at lysine 27 (H3K27me3), which is asso-
ciated with transcriptional repression. Previously, we showed that ectopic
Neurog3 promoted the removal of H3K27me3 marks at promoter regions
of some of its target genes, suggesting a functional interaction between
Neurog3 and regulators of this chromatin mark. In the present study, we
aimed to specifically evaluate the contribution of these epigenetic regu-
lators to the proendocrine activity of Neurog3. To this objective, we used
chemical inhibitors for the H3K27 methyltransferase EZH2 and the
H3K27 demethylases Jmjd3/UTX and studied their effects in the activa-
tion of the pancreatic endocrine differentiation program in several in vitro
models.
Materials and methods: We used the mouse pancreatic duct cell line
mPAC as a Neurog3-dependent endocrine differentiation model. Mouse
embryonic fibroblasts (MEFs) were obtained from E12.5-E14.5 mouse
embryos. To activate endocrine differentiation, we used a recombinant
adenovirus expressing Neurog3 in mPAC cells and a recombinant adeno-
virus expressing Pdx1+MafA+Neurog3 in MEFs. Chemical inhibitors
used were: EI-1/GSK-126 (EZH2) and GSK-J4 (UTX/JMJD3). Total
H3K27me3 mark levels were analyzed byWestern blotting, gene expres-
sion was quantitated by Real Time PCR and chromatin marks were
assessed by chromatin immunoprecipitation assays (ChIP).
Results: In mPAC cells, GSK-J4 treatment led to marginal increases in
total levels and enrichment of H3K27me3 marks at key endocrine gene
promoters. By contrast, EI-1 treatment significantly reduced total levels
and enrichment of H3K27me3 at promoter regions. Remarkably, this
decrease was accompanied by enrichment in acetylated H3K27
(H3K27ac) but not by transcriptional activation of these genes. Upon
ectopic expression of Neurog3, GSK-J4 dramatically blocked whilst EI-
1 improved transcriptional activation of the endocrine program. However,
pre-treatment with EI-1 (before Neurog3 expression) was not sufficient to
impact Neurog3 function, suggesting functional interaction between
EZH2 and Neurog3. Lastly, in MEFs, chemical inhibition of EZH2 also
resulted in a higher level of activation of selected endocrine genes
(NeuroD1, Nkx2-2, Pax6, Insulin) in response to combined ectopic ex-
pression of Pdx1, Neurog3 and MafA.
Conclusion: These results demonstrate the participation of epigenetic
regulators of the H3K27me3 mark in the activation of the endocrine
transcriptional cascade promoted by Neurog3. Inhibition of EZH2 activ-
ity may be a useful strategy to improve the efficiency of endocrine dif-
ferentiation and beta cell transdifferentiation protocols in vitro.
Supported by: Fundació La Marató de Tv3: 97/C/2012
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Examination of sorted ALDHhi and ALDHhi/CD133+ cells in the
developing human pancreas
A.M. Oakie1,2, J. Li1,2, G. Grewal1,2, G.F. Fellows2, R. Wang1,2;
1Children's Health Research Institute, 2Western University, London, Can-
ada.
Background and aims: The enzyme aldehyde dehydrogenase (ALDH)
has been previously determined to regulate endocrine differentiation via
retinoic acid signaling in the developing human pancreas. CD133, a sur-
face membrane protein associated with the ductal cells in the fetal and
adult human pancreas, has also been used in prior studies to identify and
isolate stem cells. However, the separation of cells with high ALDH
activity (ALDHhi) and the analysis of putative stem cell markers associ-
ated with ALDH expression has not yet been reported. This study aims to
characterize transcription factors and stem cell surface markers in sorted
ALDHhi cells in the human fetal pancreas, and examines the differenti-
ation potential of ALDHhi or ALDHhi/CD133+ cells in vitro.
Materials and methods:Human fetal pancreata (18 to 22 weeks of fetal
age), composed mainly of undifferentiated epithelial cells, were dissoci-
ated for fluorescence-activated cell sorting (FACS). Cells sorted based on
ALDH activity alone (ALDHhi and ALDHlo populations) or ALDH co-
localization with CD133 (ALDHhi/CD133+ and ALDHlo/CD133- pop-
ulations) were examined for transcription factors (TFs), hormones, and
pancreatic cell lineage markers immediately after cell sort, after in vitro
expansion culture, or following differentiation of cluster formation using
immunohistological and qRT-PCR approaches.
Results: FACS demonstrated that CD133 was highly expressed in
ALDHhi cell populations, while CD34was expressed mainly in ALDHlo
cells (p<0.001). The sorted ALDHhi population cells contained higher
levels of islet-associated TFs (SOX9, PDX-1, and NKX6.1, p<0.01)
compared to ALDHlo sorted cells, as well as hormones insulin and so-
matostatin (p<0.05), but not glucagon. It was also noted that vimentin +
and CD31+ cells were predominantly observed in ALDHlo population
immediately after cell sorting. Expanded culture of sorted ALDHhi or
ALDHhi/CD133+ cells resulted in loss of nuclear endocrine TFs, except
SOX9, and displayed mesenchymal-like structure. The loss of ductal cell
phenotype in ALDHhi cells and increased vimentin+ staining in both
expanded cell cultures may indicate that sorted cells enter epithelial-to-
mesenchymal (EMT) transition. A similar result was observed in sorted
ALDHlo or ALDHlo/CD133- cells during the expanding culture. Differ-
entiation of expanded ALDHhi or ALDHhi/CD133+ cells led to formed
islet-like clusters, restored CK19 ductal cell marker, and increased endo-
crine TFs gene expression; however, no endocrine hormones were detect-
ed in the clusters.
Conclusion: This study demonstrated that ALDHhi cells contain a
CD133 enriched endocrine progenitor cell pool in the developing human
pancreas, indicating that sorted ALDHhi/CD133+ cells may be fated
towards islet cell commitment. However, future experiments require op-
timal culture environments for inducing progenitors to differentiate into
insulin-producing islet cells.
Supported by: Canadian Diabetes Association
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MicroRNA expression dynamics during human induced pluripotent
stem cells differentiation into insulin-producing cells
G. Sebastiani1,2, M. Valentini1,2, G.E. Grieco1,2, G. Ventriglia1,2, S.
Pellegrini3, V. Sordi3, L. Piemonti3, F. Dotta1,2;
1Diabetes Research Unit, University of Siena, 2Fondazione Umberto di
Mario ONLUS, Toscana Life Sciences, Siena, 3Diabetes Research Insti-
tute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Background and aims: In a previous study we demonstrated that human
induced pluripotent stem cells (HiPSCs) are able to differentiate into
insulin-producing cells following the stages of pancreatic organogenesis.
Moreover, mice transplanted with differentiated HiPSCs secreted human
C-peptide in response to glucose, suggesting that these differentiated cells
can engraft and secrete insulin in-vivo. MicroRNAs (miRNAs) are a class
of small non-coding RNA molecules, which control gene expression by
inhibition of messenger RNA translation. MiRNAs are involved in the
control of several biological processes such as cell differentiation or in-
sulin secretion.
Here, we aim at characterizing miRNA expression profiles during differ-
entiation of HiPSC into insulin-producing cells
Materials and methods: HiPSC were derived from fibroblast prepara-
tions from adult healthy donors and from human fetal fibroblast cell line
IMR90, using a retroviral cocktail of reprogramming factors. HiPSC
differentiation into insulin-producing cells lasted 18 days and was per-
formed following Viacyte protocol with slight modifications. Total RNA
was extracted using miRvana Kit at different stages during differentiation
(day 0-native HiPSCs, day 4-definitive endoderm, day 10-posterior fore-
gut, day 18-endocrine pancreas). Gene expression was analyzed by RT
Real Time PCR using Taqman assays. The expression of 768 miRNAs
was analyzed using Taqman human microRNA array cards PanelA+B
and normalized using small RNAs RNU48 and RNU6. Differentially
expressed miRNAs were further analyzed by RT-stem loop Real Time
PCR.MiRNA predicted target genes were identified using Targetscan 6.2
and Gene Ontology classification was performed using online software
DAVID 6.7
Results: A progressive upregulation of islet hormonal genes (insulin,
glucagon, somatostatin) and of endocrine/beta-cell specific transcription
factors NGN3, MAFA, MAFB, NeuroD1 and ISL-1 was detected at day-
4, -10 and -18 of differentiation vs native HiPSC, paralleled by increased
expression of glucose sensing apparatus genes GCK and GLUT2.
MiRNA expression profiles analysis of native HiPSC during differentia-
tion into insulin-producing cells revealed that 347/768 miRNAs were
expressed at least at one time point of all samples; in addition, 19
miRNAs resulted as differentially expressed during differentiation: 12
upregulated (miR-9, miR-9#, miR-10a, miR-99a#, miR-124a, miR-
135a, miR-138, miR-149, miR-211, miR-224, miR-342-3p and miR-
375) and 7 downregulated (miR-31, miR-127, miR-143, miR-302c#,
miR-373, miR-518b and miR-520c-3p). Following Targetscan 6.2 anal-
ysis of predicted target genes of differentially expressed miRNAs, Gene
Ontology classification revealed that such target genes belong to catego-
ries of major significance in pancreas organogenesis such as cell morpho-
genesis at day 4, organ/tissue development at day 10 or pancreas devel-
opment and exocytosis at day 18
Conclusion: We detected a specific miRNA signature in HiPSC during
their differentiation into insulin producing cells and demonstrated that
differentially expressed miRNAs putatively control the expression of
genes involved in pancreas organogenesis
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The role of miRNAs in adult cells reprogramming along the endo-
crine pancreatic lineage
A. Osnis1,2, I. Meivar-Levy2, S. Ferber2,1;
1Human Genetics and Biochemistry, Tel Aviv University, 2Sheba Regen-
erative Medicine, Stem cells and Tissue engineering Center, Sheba Med-
ical Center, Tel-Hashomer, Ramat Gan, Israel.
Background and aims: Cell replacement therapy may offer a cure for
diabetes as long as new sources of insulin producing cells (IPCs) are
found. Transdifferentiation of liver cells to IPCs may offer a new thera-
peutic source for diabetic patients. We have reported that ectopic expres-
sion of pancreatic transcription factors (pTFs) in the liver induces insulin
production, both in vivo and in vitro. The key transcription factor is
Pancreatic-duodenal-homeobox-1 (PDX1) which plays a dual and central
role in regulating pancreas organogenesis in embryo and β-cell function
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in adults. Regardless to the use of several pTFs combined with specific
growth and soluble factors, transdifferentiation efficiency could be further
improved. MicroRNAs (miRNAs) are short non-coding RNAs (20-25
nucleotides) that regulate gene expression. miRNAs have been shown
to participate in almost every cellular process investigated so far. Several
specific miRNAs involved in β-cells' development and function and also
with the upkeep of insulin transcription have been identified. It was
shown that miRNAs are indeed involved in the transdifferentiation pro-
cess between several tissues. The present study is designed to analyze the
role of miRNAs in the transdifferentiation process of extra-pancreatic
tissues along the pancreatic ß-cell lineage.
Materials and methods: Primary human liver and fibroblast cultures are
generated from>10 separate donors. Transdifferentiation induction is per-
formed by ectopic expression of pTFs sub-cloned in adenoviral vectors.
Soluble factors are used to increase transdifferentiation efficiency.
Transdifferentiation is evaluated at the molecular, cellular and functional
levels.
Results: Using global analyses in miRNA arrays (QuantiMir™,
NanoString) our data suggest that pTFs induced transdifferentiation is
associated with alterations in the expression profile of miRNAs in both
human fibroblasts and liver cells. IPCs originated from fibroblasts exhib-
ited numerous changes in the miRNA profile, substantial activation of 9
miRNAs and the suppression of more than 100 miRNAs. Many of the β-
cell specific miRNAs including miR-375 expression was not increased,
possibly suggesting that not all the transcriptional repressors have been
removed from the IPC cells. Ectopic complementation of miR-375, the
major miRNA in the pancreas, indeed increased insulin gene
expression.A potential role of miRNA in the transdifferentiation process
is further exemplified by increases in Dicer expression; Pdx-1 but none of
the other pancreatic pTFs used, specifically activated Dicer expression.
The increased activation of Dicer expression during transdifferentiation
may suggest a crucial role for miRNA biogenesis during reprogramming
and the alteration in cells’ fate.
Conclusion: Our data suggest that pTFs induced reprogramming alters
the profile of the miRNA expression in part by increasing Dicer expres-
sion. Although it is well known that Dicer is ubiquitously expressed
among many cell types, its activation during transdifferentiation poten-
tially suggest an important role of controlling miRNA biogenesis during
the reprogramming process.MiRNAsmay lead profound insights into the
underlying molecular and cellular pathways which regulate cell-fate tran-
sitions, to be used in regenerative medicine approaches.
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Epithelial to mesenchymal transition process is a frequent event
in vitro in all pancreatic endocrine cell types
J. Moreno-Amador1, M. Nacher1,2, C. García1, N. Téllez1, E.
Montanya1,2;
1IDIBELL, CIBERDEM, University of Barcelona, 2University Hospital
of Bellvitge, Barcelona, Spain.
Background and aims: The concept of epithelial to mesenchymal tran-
sition (EMT) of cultured pancreatic beta cells has been carefully demon-
strated by lineage tracing. In vitro, adult human beta cells transition into a
highly proliferative mesenchymal cell population. The presence of EMT
in other pancreatic endocrine cell populations is unknown. The aim of this
study was to determine the EMT process in endocrine pancreatic cells.
Materials and methods: Human islets were isolated from pancreas of 6
multiorgan donors (age 47±7 y.o; BMI 27±2; islet purity 67±6%). Islets
were dissociated into single cells by enzymatic and mechanical disrup-
tion. Single endocrine cells (34±7% endocrine cell purity) were purified
by magnetic cell sorting using PSA-NCAM antibody. The resulting cell
fraction (74±6% endocrine cell purity) was seeded for monolayer culture
and split 1:2 weekly. Expression of the mesenchymal marker vimentin
(determined by immunofluorescence) in human endocrine cells was used
to evaluate EMT from day 0 to passage 4 (P4). Gene expression was
determined by quantitative real time PCR. Beta cell apoptosis was quan-
tified by double-staining using TUNEL assay and insulin antibody.
Results: A progressive reduction of cells expressing endocrine markers
(insulin, glucagon, somatostatin and pancreatic polypeptide (PP)) was
found along the four passages of culture. PP positive cells were identified
up to P2 (0.3±0.2%), and the presence of insulin (0.6±0.2%), glucagon
(0.2±0.1%), and somatostatin (0.2±0.1%) positive cells was residual at
P4. The percentage of apoptotic beta cells was low (day 0: 0.56±0.26%;
day 4: 0.04±0.01%; day 8: 0.03±0.02%; day 12: 0.05±0.04%; P2: 0.06±
0.06%) suggesting that the reduction in insulin expressing cells was not
due to increased beta cell death. Co-expression of endocrine and mesen-
chymal markers was detected after 4 days in culture and increased sub-
sequently (insulin+vim+ 6±4% at P1; 58±4% at P4). Other endocrine
populations were also found to co-express vimentin (glucagon+vim+ 62
±4% and 93±4%, somatostatin+vim+ 18±6% and 95±5%, at P1 and P4
respectively; PP+vim+ 81±9% at P1 and 92±8% at P2). Changes in gene
expression were also suggestive of EMT process with a significant in-
creased expression of mesenchymal markers (cdh2, snai2, vim, nt5e and
acta2) and reduction of cdh1.
Conclusion: All four types of adult human pancreatic endocrine cells
underwent EMT in vitro. Lineage tracing will be used to quantify the
contribution of the different endocrine cell populations to the proliferative
mesenchymal pool.
Supported by: Fundació La Marató de TV3 (Ref.121130); CIBERDEM;
ISCIII (PI13/00108)
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Haematopoietic CD34+ stem-cell differentiation to insulin-producing
cells: possible role of betatrophin
R. Lupi1, E. Selvaggi2, S. Del Guerra2, S. Del Prato2;
1Medical Area, 2Clinical and Experimental Medicine, Metabolic Unit,
Pisa, Italy.
Background and aims: Though human pancreatic islet transplantation
has raised great expectation, the shortage of pancreas donors remains a
main limitation. Stem cell therapy is, therefore, being a matter of contin-
uous investigation. We have investigated the potential of betatrophin to
improve generation of insulin-producing cells (IPCs) from circulating
hematopoietic CD34+ stem-cell of normal subjects as well as type 1
(T1DM) and type 2 diabetic (T2DM) patients.
Materials and methods: Hematopoietic CD34+ stem cells were isolated
by immunomagnetic technique from the blood of 15 non-diabetic (ND:
46±4 yrs; 5 M/10 F; BMI 24.7±1.5 Kg/m2), 10 T1DM (45±5 yrs; 7 M/
3 F; 23.7±1.6 Kg/m2) and 15 T2DM (62±4 yrs; 8 M/7 F; 26.5±1.4 Kg/
m2) subjects. Differentiation into insulin-producing cells was obtained by
a protocol, modified in our laboratory, in presence or absence of
betatrophin (10 μmol/l). Insulin-producing cells were identified by col-
orimetric staining and immune-fluorescence technique. Real-Time R-
PCR was used for assessment of insulin gene expression and telomere
length (TL) as a marker of cell senescence. Insulin was measured in
culture media by IRMA assay.
Results: The number (ND: 2.71E+4±5.19E+3; T1DM: 3.26E+4±
1.43E+4; T2DM 4.21E+4±1.16E+4 cell/ml) and viability (ND 42.38
±6.68%; T1DM 43.29±6.18%; T2DM 44.55±7.09%) of CD34+ stem
cells was similar in the 3 groups andwas not affected by age. After 10-day
culture in vitro expansion (ND 1.12E+5±2.03E+4, T1DM 3.08E+5±
9.22E+4, and T2DM 1.31E+5±1.92E+4 cell/ml; all p<0.05 vs. day 1)
and viability remained comparable among the 3 groups. TL was lower in
T2DM (4.62E+1±3.44 bp) as compared to ND (2.78E+7±1.15E+7 bp)
and T1DM (9.58E+7±6.18E+7 bp; both p<0.05) at baseline and it did
not change after 10 day cell replication. Insulin gene expression in
CD34+ stem cells increased in all groups being higher in T2DM (15.91
±4.44 2^-ΔCt) than in ND (2.30±1.25 2^-ΔCt) and T1DM (1.84±0.77
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2^-ΔCt; both p<0.05). The increase in insulin mRNA expression was
associated with a mild increase in insulin concentration in the medium.
Addition of betatrophin to the culture medium further increased insulin
mRNA expression in all groups (ND 13.9±2.93 2^-ΔCt, T1DM 9.12±
3.41 2^-ΔCt, and T2DM 50.63±2.17 2^-ΔCt; all p<0.05 vs. no
betatrophin) with no effect on insulin release in the medium.
Conclusion: Although circulating stem cells from normal and diabetic
subjects can be manipulated to increase insulin mRNA expression, insu-
lin release remains insufficient. Betatrophin enhances mRNA expression
without affecting insulin release. Although our results support a hypothet-
ical generation of insulin producing cells from circulating stem cells, the
relevance of this approach remains questionable.
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Elucidating the role of Pancreatic Stellate Cells (PaSCs) during islet
cell development in the human foetal pancreas
J. Li1, B. Chen1, G.F. Fellows2, R. Wang1;
1Physiology& Pharmacology, 2Obstetrics andGynecology,Western Uni-
versity, London, Canada.
Background and aims: Pancreatic stellate cells (PaSCs) are non-endo-
crine, mesenchymal-like cells that reside within the peri-pancreatic tissue
of the rodent and human pancreas. PaSCs regulate extracellular matrix
(ECM) turnover in maintaining the integrity of pancreatic tissues archi-
tecture. Although there is evidence indicating that PaSCs are involved in
islet cell survival and function, its role in islet cell differentiation during
pancreatic development remains unclear. In the present study, the expres-
sion pattern and functional role of PaSCs was examined in the early to
mid-gestation human fetal endocrine pancreas.
Materials and methods: The presence of PaSCs in the human fetal (8-
22 weeks fetal age) pancreas was characterized by quantitative RT-PCR,
western blotting, and ultrastructural and immunohistological approaches.
Isolated human fetal islet-epithelial cell clusters (17-21 weeks fetal age)
were directly and indirectly co-cultured with active or inhibited PaSCs to
examine the developmental effects of PaSC on islet cell differentiation
in vitro.
Results: Using microarray, qRT-PCR, and western blot approaches,
we found PaSCs to be highly proliferative, with significantly higher
gene and protein levels for PaSC markers during the 1st trimester of
pregnancy compared to the 2nd. Ultrastructural and immunofluores-
cence analysis of PaSCs demonstrated a population of PaSCs near
ducts and newly formed islets. A subset of PaSCs co-localized with
transcription factors (PDX-1, SOX9, and NKX6.1) that are critical for
maintenance of the pancreatic progenitor pool and endocrine differ-
entiation. Human fetal PaSCs were isolated from pancreata collected
during the 2nd trimester of pregnancy and identified by expression of
stellate cell markers and associated products. Inhibition of PaSC ac-
tivation using ATRA resulted in reduced PaSC proliferation and pro-
duction. Co-culture of human fetal islet-epithelial cell clusters direct-
ly on PaSCs or indirectly using Millicell® Inserts showed a signifi-
cant reduction in NGN3, NKX6.1, and insulin expression, while
PDX-1 and SOX9 expression remained unchanged. Interestingly,
high levels of Notch signalling, significantly increased PTF1A
mRNA and the number of amylase+ cells were observed during the
co-culture.
Conclusion:We have investigated the expression and potential function
of PaSCs in the early to mid-gestation human fetal pancreas, and have
determined that PaSCs are abundant during early stages of pancreatic
development around ductal and islet structures. Direct and indirect co-
culture of islet-epithelial cell clusters with PaSCs suggests that PaSCs are
required for maintaining pancreatic progenitor pool. However, over-
activation of PaSCs plays a negative role with respect to endocrine cell
differentiation in the developing human fetal pancreas.
Supported by: CDA
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The core trithorax protein Wdr5 is essential for specification of pan-
creas progenitors into endocrine and exocrine cell lineages
S.A. Campbell1,2, B.R. Tennant1,2, C.J. Whiting2, B.G. Hoffman1,2;
1Cell and Developmental Biology, University of British Columnia, 2Sur-
gery, Child and Family Research Institute, Vancouver, Canada.
Background and aims:All cells of the pancreas arise from Pdx1+Sox9+
pancreas progenitors that begin differentiation into endocrine, exocrine
and ductal cells starting at around embryonic day 12.5 (E12.5). Various
transcription factors are critical for this process; for example, Ngn3 is
essential for specification of endocrine cells, which will mature into the
islet cell types, including insulin-producing beta-cells. However, exactly
how these transcription factors are appropriately regulated during pancre-
as development is still largely unknown. We have previously compared
the chromatin state of mouse pancreatic islets and ES cells using chroma-
tin immunoprecipitation sequencing data and found that cis-regulatory
regions associated with pancreas critical transcription factors need to gain
activating marks to become expressed; however, when and how this
occurs is still not clear. Trithorax group (TrxG) complexes promote gene
activation by catalyzing histone methylation via Mll/Set1 methyltransfer-
ases and we hypothesized that these complexes are necessary for induc-
tion of factors critical to progenitor cell specification during pancreas
development.
Materials and methods: To test this hypothesis, we used lentiviral short
hairpin RNA-mediated knockdown of the core TrxG protein Wdr5
(shWdr5) in an in vitro model of mouse pancreas development where
E13.5 Pdx1+Sox9+Ngn3- progenitor cells are expanded into spheroids
and then differentiated for seven days.
Results: We first examined the expression of select TrxG complex pro-
teins, Wdr5, Dpy30, Mll1 and Mll3, at E12.5 and E14.5 of mouse devel-
opment by immunohistochemistry. These proteins were widely expressed
in the mouse embryonic pancreas and were co-expressed with both
Pdx1+ and Ngn3+ cells. Suppressing Wdr5 using our in vitro pancreas
progenitor sphere differentiation model, we found that shWdr5 treatment
significantly reduced the number of spheres generated per pancreas (n=4,
p<0.001) as well as the diameter of the spheres produced (n=4, p<0.01).
Interestingly, shWdr5 also almost completely prevented expression of
markers of endocrine cell lineages, including Ngn3, Ins1, Ins2 and Gcg
(n>4, p<0.01). This effect was confirmed by experiments in mouse in-
sulin promoter-GFP spheres, which had significantly reduced production
of GFP+ cells in shWdr5-treated spheres (n=4, p<0.01). To determine
the effect of shWdr5 on the other pancreas lineages, we performed RNA-
seq on pancreas spheres treated with shScramble and shWdr5. Consistent
with our gene expression data, the RNA-seq results confirmed that knock-
down of Wdr5 impairs endocrine cell specification. To our surprise, exo-
crine cell specification was also impaired, but development of ductal cells
was not.
Conclusion: These results suggest that the core TrxG complex protein
Wdr5 is essential for pancreas progenitors to be specified into endocrine
and exocrine, but not duct, cell lineages. This implies that in pancreas
progenitors, factors necessary for duct cell specification and differentia-
tion have already attained histone methylation at their cis-regulatory re-
gions, while factors necessary for endocrine and/or exocrine specifica-
tion, such as Ngn3, have not.
Supported by: CFRI Canucks for Kids Fund
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Induction of selective unresponsiveness to glucose but not nutrient
secretagogues in general by depolarisation in the absence of nutrients
T. Schulze, K. Schumacher, M. Morsi, U. Panten, I. Rustenbeck;
Institute of Pharmacology and Toxicology, Braunschweig, Germany.
Background and aims: The mechanisms underlying the metabolic sig-
nals which amplify glucose-induced insulin secretion while
circumventing plasma membrane depolarization are still poorly under-
stood in spite of considerable research efforts. Here, an experimental
protocol is presented which may prove useful to identify the relevant
metabolites.
Materials and methods: All parameters were measured in freshly iso-
lated mouse islets. Insulin secretion was measured by ELISA of the frac-
tionated perifusion efflux, the oxygen consumption rate (OCR) was mea-
sured by a fluorescence quench technique, and the ATP/ADP ratio by the
luciferase technique.
Results: A 60 min perifusion of isolated islets with 500 μM tolbutamide
in the absence of glucose abolished the insulinotropic effect of 30 mM
glucose but not of 10 mM alpha-ketoisocaproic acid (KIC). The same
dissociation was seen when 15 mM K+ was used instead of 500 μM
tolbutamide. When the perifusion period prior to the glucose stimulation
was 40 min instead of 60 min, the loss of the insulinotropic efficacy of
30 mM glucose was incomplete. Similarly, when the KATP channel ac-
tivity was only partially inhibited by 50 μM tolbutamide, a gradual in-
crease of secretion resulted in response to 30 mM glucose. This pattern
resembled the effect of glucose after 60 min perifusion in the absence of
glucose (control). In SUR1 KO islets the moderate insulinotropic efficacy
of glucose and KIC remained unaffected by 60 min perifusion with
500 μM tolbutamide in the absence of glucose. The loss of the
insulinotropic efficacy of glucose was paralleled by the inability of glu-
cose to raise the OCR. Under the same condition KIC increased OCR in
parallel with secretion. Under control condition glucose increased the
OCR, even faster than it increased secretion. The discrepancy between
the preserved insulinotropic efficacy of KIC and the loss of efficacy of
glucose was not due to different ATP/ADP ratios.
Conclusion: These observations suggest that the combination of moder-
ate depolarization, either byKATP channel closure or 15mMK+, and the
absence of basal nutrient supply decreases the concentration of one or
several metabolites critical for glucose-induced secretion, but leaves the
exocytotic machinery of the beta cell unimpaired. This situation should
facilitate the identification of the relevant amplifying metabolites.
Supported by: DDG, DFG
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Beta cell action potentials and Ca2+ currents during K+
depolarisation
N. Görgler1, M. Willenborg1, K. Schumacher1, A. Welling2, I.
Rustenbeck1;
1Institute of Pharmacology and Toxicology, University of Braunschweig,
2Institute of Pharmacology and Toxicology, University of Munich, Ger-
many.
Background and aims: The concept of the amplifying pathway of insu-
lin secretion is mainly based on experimental observations where the
nutrient-induced depolarization via KATP channel closure is replaced by
K+ depolarization. Additionally, diazoxide is used to clamp the K+ con-
ductance at a constant level, thus precluding insulinotropic effects via
changes in the activity of voltage-dependent ion channels. Earlier,
diazoxide was described to exert direct effects on the mitochondrial mem-
brane potential; recently, discrepancies were described that exist between
depolarization via KATP channel closure and K
+ depolarization.
Materials and methods: Using mouse islets insulin secretion was mea-
sured by batch perifusion and ELISA and the free cytosolic Ca2+ concen-
tration ([Ca2+]i) by the Fura technique. Primary mouse beta cells were
used for electrophysiological experiments. The membrane potential was
measured by utilizing the perforated patch mode. Simultaneous measure-
ments of [Ca2+]i were performed by loading with Fluo 4. To specifically
investigate currents through voltage-dependent Ca2+ channels in voltage-
clamp experiments using the conventional whole cell configuration K+
channel blockers were added to the bath solution and intracellular KCl
was replaced by CsCl in the pipette solution.
Results: Raising the extracellular K+ concentration of perifused islets to
15 and 40mM led to a strong further increase of the insulin secretion even
if the beta cells were already depolarized by KATP channel closure. This
effect of high K+ was accompanied by an increase of [Ca2+]i, which could
be shown by simultaneous measurements of the plasma membrane po-
tential. It could completely be antagonized by application of L-type Ca2+
channel blockers. In voltage-clamp experiments the Ca2+ influx appeared
as nifedipine-inhibitable inward action currents when outward K+ cur-
rents were blocked. Under these conditions 15mMK+ induced prolonged
action currents and 40 mMK+ transformed the action current pattern into
a continuous inward current. Under current-clamp conditions the increase
of the K+ concentration to 15 mM in the presence of 500 μM tolbutamide
led to a broadening of the action potentials. This was due to the fusion of
several action potentials, separated by prolonged phases of electrical si-
lence. A similar pattern of fused action potentials was caused by 1 μM
BayK8644, an opener of L-type Ca2+ channels. In contrast to BayK8644
high extracellular K+ did not affect the current-voltage relation when
conditions were used to selectively measure currents through voltage-
dependent Ca2+ channels.
Conclusion: High extracellular K+ concentrations do not simply activate
Ca2+ influx via voltage-dependent Ca2+ channels, they also affect the
pattern of Ca2+ influx as becomes visible in the presence of K+ channel
blockers. In contrast to the action of Ca2+ channel openers this effect does
not result from a direct interference with channel function.
Supported by: DDG, DFG
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Pancreatic beta cell dedifferentiation involves the voltage-gated cal-
cium channel subunit gamma4
C. Luan1, E. Ganic2, I. Artner2, E. Zhang1, E. Renström1;
1Lund University, Malmö, 2Lund University, Sweden.
Background and aims: Voltage-gated Ca2+ channels (CaV) are funda-
mental for insulin secretion. They are heteromeric complexes comprised
of the pore-forming alpha1 subunits, and the accessory modulatory sub-
units beta, alpha2delta and gamma. The impact of gamma subunits in the
pancreatic beta-cell is unexplored, especially the gamma4 (CaVγ4) iso-
form, which has been widely detected in many tissues. Importantly,
CaVγ4 exhibits differential down-regulation in human diabetic islets
and was therefore investigated in detail. The aim of this study is to inves-
tigate the physiological mechanism through which CaVγ4 influences
beta-cell function.
Materials and methods: Roles of CaVγ4 in INS-1 cells, rat islets, hu-
man islets and beta-cell specific MafA knockout mice (MafAΔβcell)
islets were identified by systems biology approaches in combination with
physiological validation experiments: microarray, siRNA silencing, real-
time quantitative PCR, western blot, patch clamp, immunostaining and
radioimmunoassay.
Results: In human diabetic islets, CaVγ4 exhibits differential 15% down-
regulation (by microarray collected from 113 donors, P<0.05). The gene
and protein expression of CaVγ4 were also reduced by gluco-/lipotoxic
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conditions (35% and 34v respectively, n=3). CaVγ4 exerted surprisingly
strong effects on beta-cell Ca2+ signaling, by an action specific to L-type
CaV channels. Silencing of CaVγ4 reduced expression of L-type Cav1.2
and Cav1.3 (28% and 32% respectively, n=3), and also suppressed
voltage-gated Ca2+ entry (888.5 ± 49.8A.U.C. vs. 1084.5 ±
48A.U.C.(negative control); n=3) and insulin exocytosis (389±35fF
n=14 vs. 997±206fF(negative control); n=15). This is reminiscent of a
dedifferentiated diabetic beta-cell phenotype. Interestingly, microarray
analysis of co-regulated genes identified the transcription factor MafA
that is responsible for the final steps of beta-cell differentiation, as a
potential regulator of CaVγ4 (r=0.649, P<0.001, from 128 donors). This
was verified by MafA silencing and in MafAΔβcell (55% reduction of
CaVγ4 protein levels, n=3).
Conclusion: In conclusion, gamma4 affects beta-cell function stronger
than expected. CaVγ4 is important for maintaining a normal differentiat-
ed beta-cell phenotype, and is down-regulated by glucose, palmitate and
in human diabetes. Treatment aiming at restoring CaVγ4 may contribute
to correcting the dedifferentiated beta-cell phenotype in diabetes.
Supported by: Diabetes Wellness foundation
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The type 2 diabetes associated K+ channel TALK-1 modulates pan-
creatic beta cell electrical excitability and 2nd-phase insulin secretion
N. Vierra, P.K. Dadi, I. Jeong, D.A. Jacobson;
Molecular Physiology and Biophysics, Vanderbilt University, Nashville,
USA.
Background and aims: Glucose-stimulated insulin secretion (GSIS) re-
quires Ca2+ influx through voltage-dependent Ca2+ channels (VDCCs).
VDCC activity is modulated by the plasma membrane potential (Vm),
which is tuned by K+ channels. The two-pore domain K+ (K2P) channel
TALK-1 is linked to type-2 diabetes risk through a non-synonymous
polymorphism (TALK-1 A277E), however, its physiological function
has remained elusive. The aim of this study was to assess the role of β-
cell TALK-1 channels on electrical excitability, Ca2+ influx, GSIS, and
glucose homeostasis.
Materials and methods:Whole-cell or single channel electrophysiolog-
ical recordings were used to assess TALK-1 currents and electrical excit-
ability of mouse and human β-cells. TALK-1 currents were inhibited by
expression of a dominant negative (DN) TALK-1 channel variant or
eliminated via a knockout mouse model (TALK-1 KO). Islet Ca2+ levels
were determined with the Ca2+ dye Fura-2. Insulin secretion was mea-
sured from pancreatic islets and serum. Blood glucose was monitored for
changes in glucose tolerance.
Results:Genetic ablation of TALK-1 reduces mouseβ-cell K2P currents
(11.7±1.0 pA/pF, n=25) compared to controls (18.3±1.2, n=23). Human
β-cells also express functional TALK-1 channels (36.7±4.5 pA/pF, n=
10) and their K2P currents are significantly attenuated following expres-
sion of a TALK-1 DN (22.1±2.3 pA/pF, n=11; P=0.008). Interestingly,
we find that TALK-1 A277E channels show increased open probability
(PO; 0.15±0.01, n=6) compared to TALK-1 A277 (0.09±0.01, n=5; P<
0.05), suggesting that TALK-1 A277E may hyperpolarize the β-cell Vm
and limit GSIS. This is supported by our finding that TALK-1 KOβ-cells
are depolarized by 6.2±1.4 mV in low glucose (2 mmol/l) and 5.2±
1.1mVin high glucose (14mmol/l) compared to controls (n=7/genotype;
P<0.03). The plateau fraction (the fraction of time spent in the electrically
active phase) is also increased in TALK-1 KO β-cells by 0.13±0.02
compared to controls (P=0.03; n=7/genotype). Furthermore, we observe
a 0.28±0.06 peak/minute increase in the frequency of Ca2+ oscillations in
TALK-1-deficient islets relative to controls (n>125 islets/genotype; P
<0.005). Consistent with these findings, we observe augmented 2nd-phase
insulin secretion from TALK-1 KO islets, which secrete more insulin
(4.02±1.07 ng/100 islet equivalents) than control islets stimulated with
11 mmol/l glucose (P<0.05; n=4 islet preparations/genotype). Ablation
of TALK-1 channels modestly increases serum insulin levels in chow-fed
mice but does not alter glucose tolerance. However, after three weeks on a
high-fat diet, fasting blood glucose is significantly reduced in TALK-1
KO mice (169.5±5.6 mg/dl) relative to control mice (221.3±8.4 mg/dl;
n=10 mice/genotype; P<0.0005), revealing that beta-cell TALK-1 plays
a critical role in adapting to metabolic stress.
Conclusion: TALK-1 channels hyperpolarize the β-cell Vm, modulating
2nd-phase GSIS by limiting the plateau fraction and reducing the frequen-
cy of Ca2+ oscillations. Furthermore, TALK-1 channels impact glycemia
under environmental conditions that promote diabetes. As we find that
TALK-1 A277E channels have increased activity, this suggests that
TALK-1 A277E may exacerbate hyperglycemia and accelerate diabetes
pathogenesis under metabolically stressful states.
Supported by: NIH Grants DK081666, DK097392, and P60 DK20593
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Ca2+-dependent expansion of cortical ER in insulin-secreting beta
cells
B. Xie, O. Idevall-Hagren;
Medical Cell Biology, Uppsala University, Sweden.
Background and aims: The endoplasmic reticulum (ER) is responsible
for protein and lipid synthesis and Ca2+ homeostasis. Dysfunctional ER is
associated with β-cell failure and death in diabetes. The ER morphology
is complex with numerous domains making contacts with other membra-
nous organelles, including the plasma membrane (PM). It is becoming
increasingly clear that such membrane contact sites are important for the
normal function of the ER. The ER-PM contacts are generated by the ER-
localized protein family Extended-Synaptotagmins (E-Syts), which con-
tains multiple C2-domains with Ca2+ and lipid-binding properties. The
aim of this study was to investigate the distribution and dynamics of E-
Syt-generated ER-PM contacts in β-cells.
Materials and methods: TIRF and confocal microscopy was used to
study subcellular distribution kinetics of fluorescently tagged E-Syt1, E-
Syt2, E-Syt1 mutants and the cytosolic fragment of Synaptotagmin-1
(Syt-1) together with the cytosolic Ca2+ concentration in intact or perme-
abilizedMIN6 cells. An optogenetic approachwas used to rapidly deplete
the PM of the lipid PI(4,5)P2 by light-induced PM recruitment of a 5’-
phosphatase.
Results: Immunoblotting showed high expression of both E-Syt1 and E-
Syt2 in MIN6 β cells and mouse islets. Fluorescence-tagged E-Syt1
localized to the reticular ER and was rapidly recruited (t1/2 21±2 s) to
the PM upon depolarization-induced Ca2+ influx. When overexpressed
alone, E-Syt2 was constitutively bound to the PM but showed
depolarization-induced PM binding after co-expression with E-Syt1,
demonstrating E-Syt1/2 heterodimer formation. Elevation of the glucose
concentration from 3 to 20mM resulted in oscillatory binding of E-Syt1/2
heterodimers to the PM and expansion of cortical ER. Both responses
were completely inhibited by the omission of extracellular Ca2+ and by
blocking L-type Ca2+ channels with 100 μM verapamil. Experiments in
permeabilized cells revealed half-maximal binding of the E-Syt1/2 het-
erodimer to PI(4,5)P2 in the PM at 1.3±0.2 μM Ca
2+. Deletion studies
showed that the central C2C domain and the C-terminal C2E domain of
E-Syt1 function as an intramolecular coincidence detector. Both domains
were thus required for efficient PM binding within the physiological Ca2+
range (1-10μM). E-Syt1 and the cytosolic fragments of Syt1, which is the
Ca2+-sensor for insulin granule exocytosis, showed nearly identical Ca2+-
induced PM-binding with half-maximal effects at 7.6±0.9 μMand 10.2±
0.7 Ca2+, respectively, in permeabilizedMIN6β cells. The PMbinding of
the proteins was reduced by 95±4% (E-Syt1) and 79±9% (Syt1) after
light-induced PI(4,5)P2 depletion, demonstrating a role of this lipid for
PM-binding of both ER and insulin granules.
Conclusion: The ER undergoes expansions in the cortical regions during
glucose-stimulation of insulin secreting cells. The expansion is driven by
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Ca2+-induced interactions between the ER-localized proteins E-Syt1/2
and PI(4,5)P2 in the PM. The lipid- and Ca
2+-binding properties of E-
Syt1/2 strongly resembles those of granule-localized Syt1, indicating ER
expansion at sites for insulin granule exocytosis.
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Activation-dependent translocation of Epac2 to granule docking sites
at the beta cell plasma membrane
I. Alenkvist, N.R. Gandasi, S. Barg, A. Tengholm;
Department of Medical Cell Biology, Uppsala University, Sweden.
Background and aims: Epac2 is an important mediator of cAMP-
dependent processes in pancreatic β-cells. Activation of Epac2 results
in its translocation from the cytoplasm to the β-cell plasma membrane,
but it is not known how the membrane interaction is mediated. Epac2
consists of multiple domains organized in a regulatory and a catalytic
region. The regulatory region contains a low- and a high- affinity
cAMP-binding domain (CNB1 and CNB2) and a DEP (disheveled,
Egl-10 and pleckstrin) domain. The catalytic region contains, apart from
the catalytic domain, a Ras association domain that previously has been
found to interact with the plasmamembrane. The aim of the present study
was to elucidate how different domains in the regulatory region contribute
to membrane localization of Epac2 in β-cells and to investigate how
localization of Epac2 is related to insulin secretory granule docking and
exocytosis.
Materials and methods: Epac2 binding to the plasma membrane was
monitored with total internal reflection fluorescence (TIRF) microscopy
of intact or α-toxin-permeabilized MIN6 β-cells co-expressing wildtype
and mutant versions of Epac2 tagged with the fluorescent proteins GFP
and mCherry, respectively. Secretory granules and exocytosis were visu-
alized by TIRF imaging of cells expressing fluorescent protein-tagged
neuropeptide Y (NPY) as granule marker along with Epac2.
Results: Addition of cAMP to permeabilized β-cells evoked
concentration-dependent translocation of Epac2 to the plasma membrane
with half-maximal and maximal translocation at ~30 μM and >100 μM,
respectively. Removal of the CNB1 domain reduced the maximal trans-
location amplitude to 45% of the wildtype control, but markedly in-
creased the cAMP sensitivity (half-maximal translocation at 5.6 μM).
After removal of the DEP domain, a protein module often involved in
membrane targeting, the cAMP-induced translocation was reduced by
more than 90%. Epac2 translocation was also investigated in intact cells
during stimulation with the cAMP-elevating hormone glucagon-like pep-
tide-1 (GLP-1). At 1 nM, GLP-1 triggered pronounced translocation of
wildtype Epac2 to the plasma membrane. The translocation response was
significantly increased by CNB1 deletion (274% of wildtype), or a point
mutation preventing cAMP-binding to the CNB1 domain (133%). In
contrast, translocation was decreased by a point mutation preventing
cAMP-binding to the CNB2 domain (28%), as well as by DEP deletion
(46%). The cAMP-increasing agent forskolin induced clustering of
Epac2 at sites of docked insulin secretory vesicles in 40% of the β-cells
and this clustering required an intact CNB1 domain. When cells were
depolarized with 75 mM K+, exocytosis events were seen as disappear-
ance of granular NPY-mCherry fluorescence immediately after onset of
the stimulation. The Epac2 signal was significantly elevated at granules
undergoing exocytosis, but indistinguishable from background at gran-
ules that failed to release.
Conclusion: cAMP-induced translocation of Epac2 to the plasma mem-
brane requires nucleotide binding to the high-affinity CNB2 domain and
presence of an intact DEP-domain. The low-affinity cAMP-binding
CNB1 domain is not required for membrane targeting, but modulates
the cAMP-sensitivity of the membrane interaction and contributes to
the specific association of Epac2 with granule docking sites. The data
indicate that Epac2 translocation to the plasma membrane promotes se-
cretory granule priming and exocytosis.
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Eriodictyol stimulates insulin secretion through cAMP/protein ki-
nase a signalling pathway in mice pancreatic islets
A. Hameed1, R. Hafizur1, S. Raza1, N. Hossain2, I. Choudhary2;
1Dr. Panjwani Center for Molecular Medicine and Drug Research, 2H. E.
J. Research Institute of Chemistry, University of Karachi, Pakistan.
Background and aims: Very recently our group has undertaken a long-
term program to identify new insulin secretagogue(s) using in-house
compounds available at a ‘Compound Bank’. Among 179 tested com-
pounds, eriodictyol (ED), a flavanoid, isolated fromLyonia ovalifolia was
found as a potent insulin secretagogue in in-vitro assay. In the present
study, we explored possible mechanism(s) of insulin secretory activity of
ED in isolated mice islets and MIN6 cells.
Materials andmethods: Islets were isolated from BALB/c mice pancre-
as by collagenase digestion followed by hand picking. Batches of three
size matched islets or MIN6 cells (passages 23 - 26) were incubated in
KRB buffer containing 3 or 16.7 mM glucose in the presence or absence
of test substance(s). Secreted insulin from islets and MIN6 cells were
measured by mouse insulin ELISA kit.
Results: ED stimulated insulin secretion frommice islets andMIN6 cells
only at stimulatory glucose concentrations distinctly different from sulfo-
nylurea. At 16.7 mM glucose, ED significantly induced insulin secretion
from isolated islets at 50-200 μM concentrations, maximum effect at
200 μM. At 3 mM glucose when islets were incubated with 200 μM
ED and 50 μM diazoxide to keep K-ATP channels open, ED-induced
insulin secretion was not affected; however, at 16.7 mM glucose ED-
induced insulin secretion was inhibited significantly by diazoxide (ng/
islet/h; M±SEM; 1.75±0.32 vs. 39.76±2.71, P<0.001). When islets
were depolarized by 25 mM KCl in the presence of diazoxide, insulin
secretory ability of ED was enhanced at both 3 mM (ng/islet/h; M±SEM;
21.5±1.42 vs 7.37±1.6, P<0.001) and 16.7 mM (ng/islet/h; M±SEM;
70.51±1.83 vs. 24±1.64, P<0.001) glucose. In the presence of 200 μM
verapamil, an L-type Ca2+ channels blocker, ED-induced insulin secre-
tion was not affected at 3 mM but inhibited at 16.7 mM (ng/islet/h; M±
SEM; 5.2±0.54 vs. 50.55±3.61, P<0.001) glucose. In the Ca2+ free
media, ED-induced insulin secretion was significantly inhibited at
16.7 mM (ng/islet/h; M±SEM; 10.13±0.88 vs 50.62±3.61, P<0.001)
glucose. IBMX, a phosphodiesterase inhibitor, at 100 μM significantly
(P<0.001) enhanced ED-induced insulin secretion (70.22±2.91 ng/islet/
h) at 16.7 mM glucose in comparison to ED (41.61±2.06 ng/islet/h) and
IBMX (50.22±2.04 ng/islet/h) alone. H-89, a protein kinase A (PKA)
inhibitor, at 30 μM almost completely inhibited ED-induced insulin se-
cretion at 16.7 mM glucose (ng/islet/h; M±SEM; 13.81±0.61 vs. 41.13±
1.96, P<0.001). Calphostin-C, a protein kinase C (PKC) inhibitor, at
2.5 μM partially inhibited ED-induced insulin secretion at 16.7 mM glu-
cose (ng/islet/h; M±SEM; 29.74±1.37 vs. 41.13±1.97). When islets
were pretreated with pertussis toxin (100 ng/ml), ED-induced insulin
secretion was not affected at both 3 and 16.7 mM glucose.
Conclusion: ED, a novel insulin secretagogue, exerts an exclusive
glucose-dependent insulinotropic effect in isolated mice islets and
MIN6 cells. ED-induced insulin secretion seems to be mediated through
cAMP/PKA signaling pathway, distal to the K-ATP channels and L-type
Ca2+ channels, coupled with stimulatory glucose.
Supported by: HEC, Pakistan
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Chronic exposure to fructose exaggerates glucose-stimulated insulin
secretion in INS-1E beta cells and human islets
T. Brun1, C. Bartley1, D. Bosco2, T. Berney2, P. Maechler1;
1Cell Physiology and Metabolism, University of Geneva, 2Surgery, Cell
Isolation and Transplantation Center, Geneva University Hospital, Swit-
zerland.
Background and aims: Fructose massively appeared as an additive in
theWestern diet in the late 70’s, preceding high incidences of obesity and
type 2 diabetes and raising questions regarding putative mechanistic
links. Upon fructose administration, energy sensing mediated by AMPK
activation is impaired in the hypothalamus, increasing feeding behaviour
in rodents. In pancreatic beta-cells, AMPK is activated in conditions of
nutrient deprivation and renders the beta-cell more sensitive to glucose.
Although fructose does not acutely stimulate insulin secretion, we decid-
ed to investigate the effects of chronic exposure to fructose on beta-cell
function.
Materials and methods: INS-1E cells and freshly isolated human islets
from different donors (n=10, each donor provided written informed con-
sent) were exposed for 4 days to 5.5 mM fructose. Culture at standard
11.1 mM (INS-1E) and 5.6 mM glucose (human islets) served as control
culture condition. At the end of the 4-day pre-treatment period, we per-
formed immunodetections of Kir6.2 and P2Y1, measured AMPK phos-
phorylation, ATP levels, and insulin secretion.
Results:Chronic exposure of INS-1E cells and human islets for 4 days to
fructose potentiated insulin secretion in response to intermediate 8.3 mM
glucose (1.6-fold, p<0.05). Paradoxically, fructose pre-treatment reduced
intracellular ATP levels by 20% and induced AMPK phosphorylation
(1.3-fold, p<0.05). The latter effect was mimicked by the stable cell
permeant ADP analogue 2-methyl-S-ADP, although not additive to fruc-
tose. Correlating with intracellular energy deprivation and AMPK activa-
tion, fructose caused translocation of K+-ATP Kir6.2 channels to the cell
membrane, exhibiting starving-like phenotype. Upon glucose stimula-
tion, ATP and ADP are co-secreted with insulin and may activate
purinergic receptors on the plasma membrane. Western blot and immu-
nofluorescence analyses showed the presence of the calcium-mobilizer
P2Y1 receptor in INS-1E cells. Accordingly, in the fructose-treated cells,
higher intracellular calcium oscillations were observed. Addition of P2Y1
agonists potentiated insulin secretion stimulated by 8.3 mM glucose on
control INS-1E cells and human islets, mimicking the effects of fructose
pre-treatment. Conversely, the P2Y1 antagonist MRS2179 reversed the
potentiated secretory response induced by fructose exposure. Moreover,
clearance of extracellular ATP and ADP by apyrase also inhibited
fructose-potentiating effects.
Conclusion: Fructose treatment induced starving-like phenotype in INS-
1E cells and human islets, resulting in the potentiation of glucose-
stimulated insulin secretion. This effect was mediated by activation of
purinergic P2Y1 receptor through increased release of cellular ATP/ADP.
Supported by: Swiss National Science Foundation to P.M.
PS 022 Islet GPCRs
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Of mice and men: a comparative analysis of G-protein coupled re-
ceptor expression in mouse and human islets of Langerhans
R.G. Hawkes, P. Atanes, G. Huang, S.J. Persaud, S. Amisten;
Diabetes Research Group, King's College London, UK.
Background and aims: G-protein coupled receptors (GPCRs) have
proven to be very successful drug targets and are responsible for the
actions of approximately 30% of all prescribed therapeutics. The attrac-
tiveness of GPCRs as drug targets can be attributed to their involvement
in numerous biological processes including the regulation of islet func-
tion. However, despite the large pool of potential GPCR targets only a
small proportion of these are the targets of current type 2 diabetes clinical
projects (GLP1R, GPR119, FFAR1). This can partly be attributed to the
lack of knowledge of GPCR expression homology in translation models
required to assess the suitability of such potential targets. The aim of this
study was to compare the expression of GPCR mRNAs in mouse and
human islets to evaluate to what degree studies on mouse islet GPCR
function are translatable to human islet physiology.
Materials and methods: GPCR mRNA expression in isolated mouse
and human islets was quantified relative to GAPDH using quantitative
SYBR green based real-time PCR (qPCR). Human islets were isolated
from heart beating donors at the islet isolation centre at King’s College
London.Mouse islets were isolated from 8week oldmale ICRmice using
collagenase digestion and handpicked. mRNAwas extracted from islets
using the TRIzol method and reverse transcribed into cDNA for qPCR
screening.
Results: 327 functional GPCRs present in both human and mouse ge-
nomes were included in the study. GPR56 was the most abundant GPCR
mRNA in human islets (15.6±1.6% of GAPDH, n=3), while the most
highly expressed GPCR in mouse islets was Cckar (78.4±12.4% of
Gapdh, n=4). 99 GPCRs (30.3%) were absent or expressed at trace levels
in both mouse and human islets. 114 GPCR mRNAs (34.9% of GPCRs
studied) were expressed above trace levels in both mouse and human
islets. 62 of these (54.4%) showed >200% higher mRNA expression
relative to Gapdh in mouse islets compared to their human counterparts,
including 9 GPCRs (S1PR3, GALR1, OXTR, VIPR2, TACR3, CCKAR,
GABBR2, TAAR1, PTGER3) whosemRNA expressionwas greater than
5000% more abundant in mouse islets than in human islets. On the other
hand, mRNAs encoding 18 GPCRs were at least twice as abundant in
human islets compared to mouse islets, including 3 GPCRs (SCTR,
GPR135 and C5AR1) which were over 500% more abundant in human
islets compared to mouse islets. The remaining 34 GPCRs were
expressed at similar levels in both human and mouse islets. Of particular
interest, 80 GPCRs (25.2%) were expressed only in human islets (e.g.
HTR1F, GPR63) and 34 GPCRs (10.3%) were present only in mouse
islets (e.g. GALR3, LPAR6). Additionally, 4 GPCRs (GPR148, OXER1,
CCRL1, P2RY8) which are not present in the mouse genome, were
expressed above trace levels in human islets.
Conclusion: This study found that approximately one third of GPCR
mRNAs are expressed at similar levels in mouse and human islets, while
the rest show significant differences in expression between mouse and
man. These clear species differences in GPCR expression are relevant to
appropriate interpretation of functional studies using mouse islets, as they
indicate whether results obtained usingmouse islets are relevant to human
physiology.
Supported by: Diabetes UK
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Insulin secretion from human and rodent islets is modulated by ad-
renergic alpha2A receptor-selective antagonists
K. Bokvist1, X. Peng1, D. Scheuner1, D.B.Wainscott1, X.-S. Wang1, F.F.
Willard1, N. Calvert1, N. Diaz2, A. Castaño2;
1Eli Lilly & Co, Indianapolis, USA, 2Eli Lilly & Co, Alcobendas, Spain.
Background and aims: Insulin secretion from the pancreatic islet is
regulated by a plethora of neurotransmitters and hormones including
catecholamines such as adrenaline. Recently, the adrenergic alpha 2A
receptor (AdrA2A) has been associated to type 2 diabetes risk with a
phenotype of reduced insulin secretion and receptor overexpression at
cellular levels in human islets. In this study we therefore evaluated to
which extent an AdrA2A-selective antagonist modulates insulin secretion
from human and rodent islets in the absence or presence of
catecholamines.
Materials and methods: The in vitro pharmacology of a novel
carboxamide (Cpd250) was first evaluated in functional and binding as-
says that assess its AdrA2 receptor family subtype specificity. After
confirming that Cpd250 was a >50× selective AdrA2A antagonist com-
pared to AdrA2B and AdrA2C, we evaluated its effects on insulin secre-
tion in human and rat islets in the presence of catecholamines aswell as its
pharmacokinetic properties.
Results: Cpd250 reversed receptor activation by 300 nM noradrenaline
in a cell line overexpressing human AdrA2A with a relative IC50 of
57 nM. In binding assays using membranes from cells overexpressing
human AdrA2A, AdrA2B or AdrA2C, Cpd250 bound to AdrA2A with
64× higher affinity than the closest family member. Binding Ki:s were
23 nM, 9220 nM and 1480 nM for AdrA2A, AdrA2B and AdrA2C
receptors, respectively. Binding Ki:s for human AdrA1A or AdrA1B
were both >25000 nM. Cpd250 had a slight affinity for human 5HT2B
(Ki=3390 nM) but the Ki:s for all other 5HT receptors tested were
>5000 nM. In rat islets 300 nM noradrenaline inhibits insulin secretion
elicited by 11.2 mM glucose by 50-70%, an inhibition that is fully re-
versed by Cpd250 at doses of 3000 nM or higher. Similar observations
were made in human islets; inclusion of 1000 nM noradrenaline sup-
pressed insulin secretion induced by 11.2 mM glucose by 60%, an effect
which was fully reversed by Cpd250 with an approximate EC50 of
1000 nM Cpd250. We next evaluated the pharmacokinetics of Cpd250
in rats; however, we failed to observe any measurable plasma exposure.
Cpd250 had very poor stability in rodent plasma, suggesting that Cpd250
is a useful in vitro tool but cannot be used to evaluate AdrA2A receptor
function in vivo.
Conclusion: Here we show that adrenergic inhibition in rodent and hu-
man islets can be reversed by an AdrA2A specific antagonist which
further validates previously published data on the importance of the
AdrA2A receptor in the regulation of insulin secretion. We have also
shown that it is possible to identify compounds that show selectivity for
AdrA2A. However, Cpd250 will require further optimization to be a
useful tool for in vivo studies.
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G-protein coupled receptor dynamics in insulin secreting cells
E.I. Kay, S. Barg;
Uppsala University, Sweden.
Background and aims: The alpha 2A adrenergic receptor (ADRA2A) is
a G-protein coupled receptor (GPCR) whose activation has multiple ef-
fects on signalling processes inside the pancreatic β cell, ultimately lead-
ing to reduced insulin exocytosis. Polymorphisms in ADRA2A are also
associated with reduced insulin secretion and the development of type II
diabetes.We aimed to identify proteins that interact with ADRA2A and to
characterise the movement of ADRA2A single molecules in the mem-
brane of insulin secreting cells.
Materials and methods: Insulin secreting INS-1 cells were co-
transfected with ADRA2A-GFP and potential interacting proteins tagged
with mRFP or mCherry and imaged using TIRF microscopy. For single
particle tracking, INS-1 cells were transfected with ADRA2A-PAtagRFP
and imaged using PALM microscopy.
Results: ADRA2A-GFP was observed as bright spots in the INS-1 cell
membrane which did not associate with docked secretory granules ex-
pressing NPY-mCherry. However, membrane associated ADRA2A-GFP
did colocalise with caveolin-1-mRFP, a marker of caveolae. ADRA2A-
GFP colocalisation with caveolin-1-mRFP was reduced following stim-
ulation of INS-1 cells with the ADRA2A agonist norepinephrine
(10 μM). ADRA2A-PAtagRFP was observed both as single molecules
and forming larger brighter clusters in the INS-1 cell membrane. The
fluorescence intensity distribution of ADRA2A-PAtagRFP molecules
changed following stimulation with 10 μM norepinephrine, with two
peaks observed for stimulated cells compared to a single peak for
unstimulated control cells. Mean squared displacement analysis of
ADRA2A-PAtagRFP tracks revealed that fractions of ADRA2A-
PAtagRFPmolecules exhibited normal, anomalous or corralled diffusion.
This indicates that while some ADRA2A-PAtagRFP molecules move
freely in the membrane, others are impeded in their range of motion.
Overall ADRA2A-PAtagRFP single molecules moved rapidly, with a
median speed of 0.075 μm2/s, however the peak speed was 0.025 μm2/
s, indicating the presence of a slower moving receptor population. Fol-
lowing stimulation with 10 μM norepinephrine, ADRA2A-PAtagRFP
speed was slightly increased to a median value of 0.083 μm2/s.
Conclusion:ADRA2A exhibits a range of dynamics in the membrane of
insulin secreting cells, which we predict are under the control of agonist
stimulation and/or interaction with other membrane proteins, such as
caveolin-1. ADRA2A association with caveolae may stabilise the recep-
tor and influence its ligand stimulated interactions with G-proteins and
downstream effectors. Norepinephrine stimulates ADRA2A movement
away from caveolae, most likely into the cell via endocytosis, which
would control the amount of membrane bound receptor available for
further stimulation.
Supported by: DRWF Sweden, Novo Nordisk Foundation, VR Sweden,
EFSD/Boehringer Ingelheim
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GPR75 stimulation to insulin secretion: identification of a signalling
pathway in beta cells
Z. Hassan, P.M. Jones, S.J. Persaud;
Diabetes Research Group, Kings College London, UK.
Background and aims: We have previously identified that the atypical
chemokine G-protein coupled receptor GPR75 is the most abundantly
expressed chemokine receptor in mouse and human islets, is localized
to beta cells, and is activated by the pro-inflammatory chemokine ligand 5
(CCL5). Furthermore, we have also found that the conventional CCL5
receptors, CCR1, CCR3 and CCR5, are expressed at very low levels in
islets. We have previously demonstrated that CCL5-induced elevations in
intracellular calcium ([Ca2+]i) and insulin secretion are significantly di-
minished upon GPR75 down-regulation. However, identification of fur-
ther downstream GPR75 signalling pathways in rodent beta cells remains
unknown. Therefore, this study aimed to identify components of this
pathway in MIN6 beta cells.
Materials and methods: Changes in [Ca2+]i were measured by single
cell microfluorimetry of Fura-2 (5 μM) loaded MIN6 beta cells (50,000
cells per coverslip). Insulin secretion from MIN6 beta cells (30,000 cells
per well) was determined in static incubation experiments and quantified
by radioimmunoassay.
Results: Phospholipase C (PLC) inhibition in MIN6 beta cells dimin-
ished CCL5-induced elevations in [Ca2+]i (0.25 nM CCL5: 149±33%
of tolbutamide response; +10 μMU73122: 65±16%, n=29, P<0.05) and
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insulin secretion (20 mM glucose: 6.75±0.58 ng/30,000cells/h; +10 nM
CCL5: 8.88±0.57; +10 nM CCL5+10 μM U73122: 6.90±0.11, P>0.2
vs 20 mM glucose). Blockade of L-type Ca2+ channels with nifedipine
abolished CCL5-induced elevations in [Ca2+]i inMIN6 beta cells (P>0.2
vs basal), and inhibited CCL5-induced insulin release (20 mM glucose:
3.57±0.25 ng/30,000cells/hr; +10 nM CCL5: 6.35±0.37, P<0.001; +
10 nM CCL5+10 μM nifedipine: 4.93±0.43). Depletion of DAG-
sensitive PKC isoforms by 24 hour exposure to 200 nM 4-beta PMA
inhibited the stimulation of insulin secretion by CCL5 (Control: 20 mM
glucose: 7.54±0.41 ng/30,000cells/hr; +25 nM CCL5: 9.12±0.50, P<
0.05: PKC-depleted: 20 mM glucose: 3.13±0.11; +25 nM CCL5: 3.42
±0.12, P>0.2 n=6-8). Furthermore, CCL5-induced insulin secretion was
also inhibited upon CAMK II inhibition (20 mM glucose: 6.75±0.58 ng/
30,000cells/hr; +10 nM CCL5: 8.88±0.57; +10 nM CCL5+10 μM
KN62: 5.07±0.43, P<0.001 vs 10 nM CCL5).
Conclusion: These data indicate that activation of the GPR75 signalling
pathway by CCL5 in MIN6 beta cells permits Ca2+ influx via L-type
voltage operated Ca2+ channels by activating PLC and subsequent acti-
vation of DAG-sensitive PKC isoforms. Furthermore, the identification
of a calcium influx component upon GPR75 activation likely promotes
the exocytosis of insulin secretory granules by activating CAMK II. This
novel role for CCL5 in improving beta cell function via the GPR75
signalling pathway provides further insight into its therapeutic potential
for improving insulin secretion in type 2 diabetes.
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The adhesion receptors GPR56 and GPR126 and their ligands are
expressed by islets and regulate beta cell function
O.E. Olaniru, P.M. Jones, S.J. Persaud;
Division of Diabetes and Nutritional Sciences, King's College London,
UK.
Background and aims: GPR56 and GPR126 are members of the adhe-
sion class of G-protein coupled receptors that play key roles in organ
development. Collagen III is the agonist of GPR56 and we have shown
that GPR56 is one of the most abundant GPCRs in human islets. Collagen
IV increases cAMP in GPR126 transfected HEK293 cells and stimulates
an increase in [Ca2+]i in tumour cells. The roles of GPR56 and GPR126
in islets is not known, so the aim of this study was to investigate their
expression and functions in islets.
Materials and methods: Expression of GPR56, GPR126, collagens III
and IV was determined by RT-PCR, Western blotting, and immunohisto-
chemistry of mouse and human pancreases. The effects of 100 nM col-
lagens on insulin gene expression and β-cell adhesion were determined
by qPCR and adhesion assay respectively. Insulin secretion was quanti-
fied by radioimmunoassay after 3 days exposure of mouse islets to col-
lagens III and IV. Changes in [Ca2+]i of Fura-2 loaded MIN6 β-cells on
exposure to 100 nM collagens III and IV were measured by single cell
microfluorimetry.
Results: GPR56, GPR126, collagens III and IV were detected in mouse
and human islets. GPR56 was abundantly expressed by β-cells but was
absent from glucagon-secreting α-cells of mouse islets. Unlike collagen
IV, collagen III was not expressed by β-cells, but was confined to islet
capillaries. Collagens III and IV significantly increased insulin gene ex-
pression (by 178.7±5.9% and 211.5±5.3% respectively, p<0.001) and
enhanced β-cell adhesion (control: 0.08±0.01 absorbance units; +Col III:
0.13±0.02; +Col IV: 0.23±0.03, p<0.01, n=5). Pre-exposure of isolated
mouse islets to 100 nM collagens III and IV for 3 days led to significantly
enhanced glucose-induced insulin secretion (20 mM glucose: 5.91±
1.22 ng/islet/h; +Col III: 10.30±0.94; +Col IV: 13.26±0.99, p<0.01,
n=7-8). Chronic exposure to collagen III did not increase basal insulin
release (2mMglucose: 0.24±0.02 ng/islet/h; +Col III: 0.20±0.01, p=0.1,
n=7), but islets exposed to collagen IV for 3 days did show significantly
increased basal insulin release (2 mMglucose: 0.24±0.02 ng/islet/h; +Col
IV: 0.38±0.05, p<0.05, n=7). Collagen IV induced elevations in β-cell
[Ca2+]i at 2 mM glucose (100 nMCol IV: 60±4% tolbutamide response,
n=24) and it also had a small stimulatory effect at 20 mM glucose
(100 nM Col IV: 133±10% 20 mM glucose response). Collagen III was
without effect on [Ca2+]i in Fura 2-loaded β-cells at 2 mM glucose (n=
32).
Conclusion: Mouse and human islets express the adhesion receptors
GPR56 and GPR126 and their ligands, collagen III and IV, suggesting
that these receptors may be activated in a paracrine/autocrinemanner. Our
data further suggest that these receptors may be the mechanism through
which extracellular matrix collagens regulate β-cell adhesion, insulin
synthesis and insulin secretion.
Supported by: Commonwealth Scholarship
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Characterisation of the sweet taste receptor electrophysiology in pan-
creatic beta cells
J.V. Sanchez-Andres1, W.J. Malaisse2;
1Medicine, Universitat Jaume I, Castellon, Spain, 2Medicine, Brussels
Free University, Brussels, Belgium.
Background and aims:According to the so-called "fuel hypothesis" the
stimulation of insulin release by glucose and other nutrient secretagogues
may be attributed to their catabolism resulting inter alia in an increased
generation of ATP. However, recent work based among others on the
effects in beta cells of non-metabolizable agents, such as sucralose, has
revived interest on a "receptor hypothesis", apparently involving the ac-
tivation of the sweet taste receptor T1R3. The present study aimed at
characterizing the electrophysiological effects of sucralose in mouse
insulin-producing cells.
Materials and methods: The beta cell membrane potential was recorded
in isolated mouse pancreatic islets fixed with micropins to the bottom of a
perifusion chamber. The superfusion medium contained, as required, glu-
cose and/or sucralose.
Results:When tested in the absence of glucose, sucralose (5 to 10 mM)
did not affect membrane potential. At a substimulatory glucose concen-
tration (3 to 5 mM), sucralose evoked a biphasic electrophysiological
response. The first phase lasted for a few minutes and consisted of a
depolarizing wave with overimposed bursting activity. No obvious dif-
ference was found between bursting induced by either glucose or sucra-
lose. Incidentally, the response to sucralose displayed some heterogeneity.
Thus, 15% of the cells were unresponsive. Moreover, In the 85% respon-
sive cells, a second phase of electrical activity was only apparent in 11 out
of 17 cells. Interestingly, when the sucralose concentration was increased
during the second phase initially evoked by a lower concentration of the
artificial sweetener, the cells displayed an unresponsive behavior, sug-
gesting an apparent desensitization. At a suprastimulatory glucose con-
centration (5 to 10 mM), sucralose also excited the cells in a dose-
dependent manner. Lower sucralose concentrations increased bursting
duration at the expense of hyperpolarized periods. Higher glucose con-
centrations are able to drive the cell into continuous activity. The effect
reverted immediately after sucralose withdrawal even for high sucralose
concentrations (30 mM).
Conclusion: The present findings reveal that sucralose exerts a stimula-
tory effect on beta cell electrical activity. This effect is closely related to
the glucose concentration. Thus, sucralose is unefficient in the absence of
glucose, while potentiating the electrical response recorded in the pres-
ence of the latter hexose. These data support the view that the activation
of a sweet taste receptor may stimulate and modulate glucose responses.
The similarities between glucose and sucralose actions may suggest a
distal convergence in their mode of action. The data presented constitutes
a strong evidence of the receptor hypothesis as far as sucralose, an agonist
of the homodimeric T1R3 taste receptor in the pancreatic beta cell, is able
to induce an excitatory effect of the pancreatic beta cell electric activity.
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Palmitate stimulates insulin secretion by enhancing mitochondrial
respiration via intracellular metabolism and FFAR1 signalling
H. Kristinsson, P. Bergsten, E. Sargsyan;
Medical Cell Biology, Uppsala University, Sweden.
Background and aims: Free fatty acids (FFAs) play an important role in
the regulation of insulin secretion. At high glucose, FFAs enter
glycerolipid/free fatty acid cycle and generate insulinotropic metabolic
coupling factors such as long-chain acyl CoAs, phosphatic acids, diacyl-
glycerol, etc. FFAs enhance insulin secretion also by interacting with G-
protein coupled receptors (GPCRs) on the plasma membrane. One of the
GPCRs highly expressed in beta cells is the free fatty acid receptor 1
(FFAR1 or GPR40). We have reported that palmitate potentiates insulin
secretion via a synergistic action of intracellular metabolism and FFAR1
signalling. Given the importance of mitochondria in insulin secretion, we
investigated the effects of fatty acid metabolism and FFAR1 signaling on
mitochondrial function.
Materials and methods: Study was performed on mouse insulinoma
MIN6 cells. Cells were treated for 1 hour with XF assaymedia containing
25 mM glucose and 0.5 mM palmitate in the absence or presence of
FFAR1 antagonist, ANT203. Cells were also exposed to FFAR1 agonist
TAK875. During treatment, insulin secretion and mitochondrial oxygen
consumption rate (OCR) were measured. Insulin was measured by
ELISA whereas OCR was measured by Extracellular Flux Analyzer
XF96e. Palmitate oxidation and glucose utilization were determined by
including during culture [3H]palmitate and d-[5-3H]glucose,
respectively.
Results: MIN6 cells cultured in the presence of palmitate secreted 50%
more insulin than in the absence of the fatty acid. This was accompanied
by a 35% rise in OCR. Inhibition of the FFAR1 pathway with ANT203
prevented the palmitate-induced rise in insulin secretion. The effect was
associated with a significant reduction in OCR to levels close to those
observed in control cells. Stimulation of another Gαq-coupled receptor,
M3 muscarinic acetylcholine receptor, with agonist carbachol in the pres-
ence of ANT203 reverted OCR back to levels observed in the presence of
palmitate alone. Stimulation of FFAR1 with TAK875 in the absence of
extracellular palmitate did not enhance OCR. By inhibiting fatty acid or
glucose oxidation we showed that the increase in OCR in palmitate-
treated cells was largely due to increased glucose oxidation. In line with
this, glucose utilization in the presence of palmitate was increased com-
pared to control cells. However, FFAR1 antagonist did not reduce
palmitate-induced glucose utilization. Also, FFAR1 agonist TAK875 in
the absence of extracellular palmitate did not elevate glucose utilization.
Conclusion: During short-term exposure palmitate stimulates insulin se-
cretion by enhancing mitochondrial respiration via complementary action
of intracellular metabolism and Gαq-dependent signaling of FFAR1
Supported by: FP7 Contract 279153
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Kisspeptin and the adaptation of islets to pregnancy: a role for islet
serotonin
T.G. Hill, P.M. Jones, J.E. Bowe;
Diabetes and Nutritional Sciences, King's College London, UK.
Background and aims: During pregnancy, the pancreatic islets of
Langerhans undergo adaptive changes in order to compensate for the
normal progression of insulin resistance that occurs during gestation.
These adaptive changes include both increased glucose-stimulated insulin
release and increased beta-cell mass. The signals underlying these chang-
es are not fully understood, however it is established that prolactin and
placental lactogen play an important role. Recently beta-cell serotonin (5-
HT) has been found to mediate the effects of lactogenic hormones on
beta-cell proliferation and glucose-stimulated insulin release via autocrine
or paracrine effects at the Htr2b receptor. We have previously shown that
placental kisspeptin (KP), and its G-protein coupled receptor, GPR-54,
may also play a key contributory role in mediating the adaptation of
rodent islets to pregnancy. However, the downstream mechanism by
which KP causes these compensatory changes is not understood. We
therefore investigated a possible role of the islet serotonin system, as well
as the involvement of key pro-proliferative genes, in mediating the effects
of KP.
Materials and methods: Islets were isolated from female ICR mice and
cultured in either 2 mmol/L or 20 mmol/l glucose RPMI, with or without
KP-10 (1 μmol/l) for 48 hrs. Islet samples were then taken and mRNA
expression of key genes investigated using quantitative RT-PCR analysis.
Results: KP treatment dramatically increased the mRNA expression of
the 5-HT synthesis enzyme Tph-1 within islets cultured in stimulatory
glucose concentrations (20 mmol/l glucose: 0.4±0.06×10-3, 20 mmol/l
glucose + 1 μmol/l KP-10: 1.5±0.2×10-3; relative to Gapdh; n=4; p=
0.063), but no change was observed for Tph-2 expression (20 mmol/l
glucose: 0.032±0.004, 20 mmol/l glucose+1 μmol/l KP-10: 0.053±
0.006; relative to Gapdh; n=4). Additionally no change in expression
of the 5-HT receptor Htr2b was observed in islets treated with KP-10 at
either glucose concentration (20 mmol/l glucose: 0.2±0.01×10-3,
20mmol/l glucose+1 μmol/l KP-10: 0.2±0.009×10-3; relative toGapdh;
n=4). Exposure of isolatedmouse islets to KP-10 had no effect onmRNA
expression levels for the proliferative genemarkersCyclin E1,Cyclin D1,
and Ki67 (20 mmol/l glucose: 3.27±0.74, 69.1±4.35, 1.3±0.2×10-3;
20 mmol/l glucose+1 μmol/l KP-10: 5.21±0.97, 94.0±1.48, 1.4±0.2×
10-3; expression levels of Cyclin E1, Cyclin D1 and Ki67 relative to
Gapdh respectively; n=3) or the pro-survival gene marker, Birc5
(20 mmol/l glucose: 0.8±0.3×10-3, 20 mmol/l glucose+1 μmol/l KP-
10: 0.8±0.2×10-3; relative to Gapdh; n=3).
Conclusion: These results suggest that in addition to an established role
mediating the effects of the lactogenic hormones, KP signalling may also
bemediated through beta-cell 5-HT. Specifically KP increases the expres-
sion of the 5-HT synthesis enzyme Tph-1, but not Tph-2, suggesting an
increase in 5-HT production. However, contrary to previous studies, there
was no change in expression levels of the 5-HT receptor Htr2b. Further-
more, at present these data do not show which proliferative or pro-
survival genes may be involved in mediating effects of KP on beta-cell
mass, further measurements are required to determine the downstream
signalling pathways involved in these effects.
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Foetal endocannabinoids orchestrate the organisation of pancreatic
islet microarchitecture
K. Malenczyk1,2, V. Di Marzo3, A. Dobrzyn4, T. Harkany1,2;
1Center for Brain Research, Wien, Austria, 2Medical Biochemistry &
Biophys ics , Karo l inska Ins t i tu t e t , S tockholm, Sweden ,
3Endocannabinoid Research Group, Institute of Biomolecular Chemistry,
Naples, Italy, 4Nencki Institute of Experimental Biology, Warsaw, Po-
land.
Background and aims: 2-Arachydonoylglycerol (2-AG) and ananda-
mide, major endocannabinoids are implicated in the control of glucose
utilization and energy homeostasis by orchestrating pancreatic hormone
release. Moreover, in many cell niches, endocannabinoids regulate cell
proliferation, fate determination and migration. Nevertheless,
endocannabinoid contributions to the development of the endocrine pan-
creas and, consequently, to long-lasting changes in hormone release post-
natally remain unknown.
Materials and methods: To dissect the role of endocannabinoid signal-
ing during endocrine pancreas development we combined the genetic
ablation of main components of endocannaboinoid signaling, (e.g., CB1
cannabinoid receptor (CB1R), monoacylglycerol lipase (MAGL) or tran-
sient receptor potential vanilloid 1 channels (TRPV1) knock-out models),
modifications to the maternal diet during pregnancy (enrichment in ω-3
polyunsaturated fatty acids) and pharmacological probing of
endocannabinoid signaling in ‘pseudoislets’, α/β cell aggregates that
model cell sorting in pancreatic islets in vitro.
Results: Our results show that α cells produce 2-AG in mouse fetuses
and human pancreatic islets, which primes the recruitment of β cells by
CB1R engagement. By using subtractive pharmacology we extend these
findings since exogenous anandamide, a promiscuous endocannabinoid/
endovanilloid ligand, impacts both the determination of islet size by cell
proliferation and α/β cell sorting by differential activation of transient
receptor potential TRPV1 channels and CB1Rs. Accordingly, genetic
disruption of TRPV1 channels increases islet size, while CB1R knockout
augments cellular heterogeneity by inducingα/β cell ‘mixing’ and favors
insulin over glucagon release. Dietary enrichment in ω-3 fatty acids
during pregnancy and lactation in mice, which permanently reduces
endocannabinoid levels in the offspring, phenocopies CB1R
-/- islet mi-
crostructure and improves coordinated hormone secretion. This is signif-
icant since both CB1R
-/- andω-3 fatty acid-exposed offspring are lean.
Conclusion: Our study ident i f ies fundamental roles for
endocannabinoids acting at CB1R and TRPV1s in determining cellular
diversity, structural complexity and life-long plasticity of the endocrine
pancreas. Furthermore, it highlights that maternal dietary choices during
pregnancy can program fetal pancreas development by altering
endocannabinoid bioavailability which prospectively determines the off-
spring’s sensitivity to metabolic stressors.
Supported by: SRC, Petrus and Augusta Hedlunds Foundation, Novo
Nordisk Foundation. NCN
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The PIN protein participates in and modulates exocytosis of insulin
secretory granules in the INS-1 cell line
J. Leroy1, K. Mezghenna1, P. Yin2, S. Barg2, M. Séveno3, C. Assaillit3, J.
Azay-Milhau1, S. Péraldi-Roux1, R. Gross1, A.-D. Lajoix1;
1Faculte de Pharmacie, EA 7288, Montpellier, France, 2Medical Cell
Biology, University of Uppsala, Sweden, 3Functional proteomics plat-
form, Institute of Functional Genomics, Montpellier, France.
Background and aims: PIN (Protein Inhibitor of Neuronal NO synthase)
or LC8 (Light Chain 8) is a hub protein able to interact with multiple
partners including neuronal NO synthase (nNOS) and cytoskeletal pro-
teins like myosin Vand dynein. We have previously shown that PIN is a
positive modulator of glucose-induced insulin secretion. In order to better
understand the role of PIN, we developed an inhibitory peptide, able to
block interactions between PIN and its proteic partners and rendered cell-
permeant by coupling with the Tat-peptide.
Materials and methods: Glucose-induced insulin secretion was mea-
sured in INS-1 β-cells in the presence of the Tat-peptide alone
( G R K K R R Q R R R ) , - t h e i n h i b i t o r y p e p t i d e
(GRKKRRQRRRGGIDVGIQVDWD) or - an irrelevant one
(GRKKRRQRRRGGKAVDLSHQPS). For Western blotting, monoclo-
nal anti-α-tubulin (SigmaAldrich) or anti-PIN (BDBiosciences) antibod-
ies were used. Immunoprecipitation was performed using a polyclonal
anti-PIN (Santa Cruz) or the monoclonal anti-α-tubulin antibody. GST-
pull down was performed using recombinant GST-PIN as bait on INS-1
extracts. Potential partners of PIN were identified by Orbitrap XL mass
spectrometry thanks to the Functional proteomics platform of Montpel-
lier. For TIRF microscopy experiments, cells were transfected with NPY-
EGFP reporter and continuous perifused at 32°C with KRB buffer con-
taining 75 mM KCl to stimulate insulin secretion. Cells were imaged
using a custom-built lens-type TIRF microscope based on an Axiovert
135 microscope with a 100×/1.45 objective (Carl Zeiss).
Results: In the INS-1 cell line, the inhibitory peptide decreased insulin
secretion induced by 2.8, 5.6 and 8.3 mM glucose, by 33% at 20μM, and
by 58% at 40 μM (p<0,001). Such an inhibitory effect has also been
observed using a PIN siRNA, which decreased PIN expression and re-
duced 5.6 and 8.3 mM glucose-insulin secretion by respectively 16 and
20% in response to (p<0,001). Surprisingly, in the presence of the inhib-
itory peptide, we observed, by Western blotting, a decreased level of
soluble α-tubulin (-22% at 20 μM and -95% at 40 μM), suggesting an
increased polymerization of tubulin. Interestingly, using GST-pull down
with PIN as bait, revealed an interaction of PINwithα1C-tubulin andβ5-
tubulin. Direct interaction of PIN and α-tubulin was confirmed by immu-
noprecipitation experimentations. Finally, in TIRF microscopy experi-
ments, we found the average release time of insulin granules, during
single exocytosis event, increased by 3.5 fold in the presence of the
inhibitory peptide.
Conclusion: Interaction of PIN with cytoskeletal proteins appears to be
involved in the control of insulin granules exocytosis, possibly via mod-
ulation of α-tubulin polymerization.
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LKB1 is required for normal glucose-signalling, but not insulin se-
cretion, in pancreatic beta cells
S. Sayers1, D.J. Hodson1, P. Spegel2, H. Mulder2, A. Swisa3, Y. Dor3,
G.A. Rutter1;
1Imperial College London, UK, 2Lund University Diabetes Center, Swe-
den, 3School ofMedicine-IMRC, HebrewUniversity of Jerusalem, Israel.
Background and aims: Liver kinase B1 (LKB1/STK11), a tumour sup-
pressor inactivated in Peutz-Jeghers syndrome, exerts its biological
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effects largely by the direct phosphorylation of AMP-activated protein
kinase (AMPK) and AMPK-related kinases. Deletion of LKB1 from
pancreatic beta cells using a variety of Cre deleter strains has previously
been shown to improve insulin content and secretion in mice. Here, we
explore the impact of LKB1 deletion in beta cells on glucose-induced
changes in mitochondrial metabolism and Ca2+ signalling using islet
imaging approaches.
Materials and methods: Mice deleted selectively in the beta cell for
LKB1were generated by breeding animals bearing flox’d alleles at exons
3-6 with the novel and highly beta cell-selective Ins1Cre deleter line.
Total and released insulin was measured by radioimmunoassay. Changes
in intracellular ATP/ADP ratio ([ATP/ADP]cyt) and Ca
2+ ([Ca2+]cyt) were
measured by confocal microscopy of whole islets expressing the recom-
binant GFP-based probe Perceval, or loaded with the fluorescent Ca2+
dye, fluo-2, respectively. An LKB1-encoding adenovirus (Vector Biolab),
titred using qPCR to assess LKB1 overexpression, was used to rescue the
effects of LKB1 deletion. Metabolite profiling was performed on isolated
islets after extraction in 16.7 mM glucose on an Agilent 6890 N gas
chromatograph coupled with a Leco Pegasus III TOFMS electron impact
time of-flight mass spectrometer.
Results:Whereas insulin secretion in response to elevated glucose (11 vs
3 mM) was largely unaffected (4 mice/ genotype, 6 size matched islets/
well, p>0.05), glucose-stimulated increases in [ATP/ADP]cyt (12 islets/
genotype, p<0.05) and [Ca2+]cyt (12 islets/4 mice/genotype, p<0.01)
were severely impaired in islets from LKB1 KO mice, as was the per-
centage of islets responsive to glucose-stimulation (n=12 islets, p<0.05,
p<0.01, respectively). [Ca2+]cyt signalling was largely rescued after
LKB1 over-expression in Ins1Cre::LKB1flox/flox islets (12 islets, 3
mice/genotype, p>0.05), excluding developmental effects of LKB1 de-
letion as responsible for the observed signalling abnormalities.
Metabolomic profiling showed that fatty acids (C12, C16, C18), glycerol
and glycerol-3-phosphate were lowered in LKB1 null islets, as were
lactate and fumerate (n=3 mice/genotype, P<0.05).
Conclusion: Despite the improvement of glucose tolerance previously
observed in this model, and preserved insulin secretion, deletion of LKB1
significantly impairs normal glucose-induced [ATP/ADP]cyt and [Ca
2+]cyt
signalling in beta cells. Our findings suggest that LKB1 deficiency stim-
ulates metabolic changes in beta cells which activate a robust amplifying
pathway. This appears to override defects in the classical triggeringmech-
anisms of insulin secretion that rely on oxidative metabolism of glucose
towards ATP.
Supported by: EU (IMIDIA), BBSRC (UK), MRC (UK), Royal Society,
Diabetes UK
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S561f cdkal1 variant, identified by whole exome sequencing of con-
genital hyperinsulinismpatients, affects insulin content and release in
ins1-e cells
C. Cosentino1,2, E.S. Di Cairano3, M.C. Proverbio4, E. Mangano5, S.
Moretti3, C. Perego3, C. Battaglia2,5;
1Molecular and translational medicine, Milan, Italy, 2Department ofMed-
ical Biotechnology and Translational Medicine, 3Department of Pharma-
cological and Biomolecular Sciences, 4Department of Pathophysiology
and Transplantation, 5Institute of biomedical technologies, National Re-
search Council (ITB-CNR), Milan, Italy.
Background and aims: Congenital hyperinsulinism (CHI) is a rare dis-
order (MIM#256450), characterised by inappropriate insulin secretion
that is responsible of hypoglycaemia, which can lead to neurological
damage. In a previous work conducted in our laboratories 17 patients of
Congenital Hyperinsulinism were recruited for aWhole Exome Sequenc-
ing (WES) study. We selected all the genes presenting rare or novel
potentially damaging single nucleotide variants to perform candidate
gene prioritization analysis. We found that CDK5 Regulatory Subunit
Associated Protein 1-Like 1 (CDKAL1) was one of the most significantly
enriched genes by the bioinformatics analysis. CDKAL1 is a methylthio-
transferase anchored to the endoplasmic reticulum membrane, that mod-
ifies the tRNALys (UUU) ensuring the correct translation of the codons
AAA,AAG into Lysine residue. A Lysine residue is crucial for the correct
cleavage of pro-insulin and the folding of mature insulin protein. Differ-
ent studies have previously associated CDKAL1 to type 2 diabetes de-
velopment risk and to impaired glucose homeostasis phenotype in knock-
out (cdkal1 -/-) mice. The S561F-CDKAL1 variant identified in our study
results in the substitution of a residue of serine by a phenylalanine, more
hydrophobic residue at the level of the transmembrane domain. The aim
of this work is to understand the consequences of the CDKAL1 variant
S561F on the protein itself and on the insulin content and release of
pancreatic beta cells.
Materials and methods: Clonal INS1-E cells expressing Wild Type
(WT) or S561F CDKAL1 were generated and used as model to charac-
terise S561F-CDKAL1 impact on beta cell function. The localisation of
the mutated protein was monitored by immunofluorescence and insulin
content and release was measured with ELISA assays.
Results:Wild type CDKAL1 overexpressed in INS1-E cells localized as
expected in the reticular compartment, diffused in the cell cytoplasm. The
genetic variant S561F was similarly confined in the reticular compart-
ment, although its localization was enriched in vesicular-like structures
distributed in the perinuclear region. Insulin content was increased by
overexpression of WT CDKAL (2 fold over INS1E, p<0.05) while it
was decreased by S561F-CDKAL1 variant, thus suggesting a different
insulin processing in the mutant CDKAL1. Insulin release measured in
overnight culture medium in basal conditions showed that S561F-
CDKAL1 overexpression increased the constitutive insulin release (2 to
4 fold over INS1E in clones 3 and 7, respectively; p<0,05, p<0,005 vs
WT).
Conclusion: The S561F-CDKAL1 variant leads to an abnormal
localisation of the protein. An increase of insulin release was observed
as consequence of the overexpression of the mutated CDKAL1 protein.
Our findings support the importance of CDKAL1 in insulin release and
propose novel mechanisms leading to beta cells dysfunction that can
participate to the development of congenital hyperinsulinism.
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Protein disulfide isomerase ameliorates beta cell function in pancre-
atic islets overexpressing human islet amyloid polypeptide
J.Montane1,2, M. Obach1,2, L. Cadavez1,2, S. De Pablo1,2, C. Castaño1,2,
G. Alcarraz-Vizán1,2, J. Rodriguez-Comas1,2, J. Servitja1,2, A. Novials1;
1Diabetes and Obesity Laboratory, Institut d’Investigacions Biomèdiques
August Pi i Sunyer (IDIBAPS), 2Centro de Investigación Biomédica en
Red de Diabetes y EnfermedadesMetabólicas ASociadas (CIBERDEM),
Barcelona, Spain.
Background and aims:Human islet amyloid polypeptide (hIAPP) is the
major component of amyloid deposits in pancreatic islets of patients with
type 2 diabetes. The process of hIAPP misfolding and aggregation is one
of the factors that may lead to beta-cell dysfunction and death. Endoge-
nous chaperones have been described to be important for the folding and
proper function of proteins. Here, we examine the effect of the endoplas-
mic reticulum chaperone protein disulfide isomerase (PDI) on insulin and
IAPP secretion in hIAPP Tg mouse islets.
Mater i a l s and methods : Human i s l e t l y s a t e s w e r e
immunoprecipitated for hIAPP and interaction with major chaper-
ones was analyzed. hIAPP Tg islets were transduced with an
adenovirus encoding for the chaperone PDI and cultured with
16 mM glucose and 400 μM palmitate (HG+PA) for 24 hours.
Islet function was determined by glucose-stimulated insulin and
IAPP secretion and gene expression and protein levels of PDI
and apoptosis marker caspase 3 were determined by real-time
RT-PCR and immunohistochemistry, respectively.
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Results: Immunoprecipitation of human islet lysates indicated that,
among the most important chaperones of the ER (BiP, CCT4, TCP1a
and PDI), only PDI was interacting with hIAPP. Islet transduction with
an adenoviral vector encoding for chaperone PDI demonstrated that PDI
could be overexpressed in mouse pancreatic islets. PDI overexpression at
a dose of 20 MOI had no effect in glucose-stimulated insulin secretion in
untreated wild-type islets. When PDI was overexpressed in hIAPP Tg
islets, PDI was able to restore beta cell dysfunction associatedwith hIAPP
overexpression by increasing insulin secretion levels. Furthermore, treat-
ment of islets with HG+PA for 24 hours decreased glucose stimulated
insulin and hIAPP secretion in hIAPP Tg mice. Nevertheless, PDI over-
expression was able to counteract the decrease in insulin and hIAPP
secretion in hIAPP Tg islets.
Conclusion: Overexpression of chaperone PDI was able to rescue HG+
PA-induced beta cell dysfunction. This approach could reveal a new
therapeutic target and aid in the development and evaluation of strategies
to decrease beta cell dysfunction in type 2 diabetic patients.
Supported by: FIS (PI11/00674 and PI14/00447)
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Generation of the transgenic INS-SNAP (SOFIA) pig for the high-
throughput high-content study of insulin granule biogenesis and
turnover in isolated islets
A. Ivanova-Cederström1, N. Klymiuk2, E. Kemter2, C. Andree3, A.
Wuensch2, M. Kurome2, B. Kessler2, D. Richter1, A. Müller1, T. Kurth4,
M. Bickle3, E. Wolf2, M. Solimena1;
1Paul Langerhans Institute Dresden of the Helmholtz Center Munich at
the Univ. Clinic of TU Dresden, 2Inst. Molecular Animal Breeding and
Biotechnology LMU, Munich, 3Max Planck Institute of Molecular Cell
Biology and Genetics, Dresden, 4BIOTEC, TU Dresden, Germany.
Background and aims: Age-distinct pools of insulin secretory granules
(SGs) display different propensity for exocytosis, with newly synthesized
SGs being preferentially secreted. Recently we exploited an insulin-
SNAP chimera (Ins-SNAP) as a reporter for conditional fluorescent la-
belling and imaging of SGs generated at different times in insulinoma
cells and mINS2-SNAP knocked-in SOFIA (Study OF Iinsulin Aging)
mice.With this approach we provided formal evidence for the preferential
exocytosis of young SGs and their progressive loss of mobility with
ageing. These findings are relevant for the understanding of type 2 dia-
betes, in which reduction of the 1st phase of insulin secretion and in-
creased proinsulin release point to deficits in SG biogenesis and turnover.
Here we report the generation of an INS-SNAP transgenic pig (SOFIA
pig) as a large animal model for studying in greater detail the biogenesis
and turnover of insulin SGs through the performance of high-throughput
high-content (HTHC) screenings of compounds affecting these
processes.
Materials and methods: Pools of stably INS-SNAP transfected porcine
kidney cells were used for somatic cell nuclear transfer (SCNT), and
reconstructed embryos were transferred to recipient gilts. The resulting
progeny was examined for transgenic status by PCR and southern blot-
ting and then for INS-SNAP protein expression in β-cells by immunocy-
tochemistry on pancreatic tissue sections. Correlative light-electron mi-
croscopy (CLEM) was performed on pancreatic tissue sections of a ma-
ture founder pig. Pseudoislets obtained from hINS-SNAP insulinoma
INS-1 cells were used to optimize a semi-automated HTHC pipeline in
a 384-well format. Neonatal islet-like cell clusters (NICC) isolated from
newborn SOFIA pigs were used for a pilot HTHC screening for com-
pounds affecting SG biogenesis and turnover.
Results: A 2-year-old SOFIA founder pig was sacrificed to verify the
expression of INS-SNAP protein in situ and the β-cell ultrastructure.
Electron microscopy did not reveal morphological alterations of the ER,
SGs or other β-cell compartments. The restricted expression of INS-
SNAP protein in β-cells and its correct targeting to SGs were confirmed
by CLEM. Optimization of the HTHC platform allowed for the homog-
enous dispensing of ~50 hINS-SNAP INS-1 pseudoislets or NICC/well in
384-well plates and their retention throughout the SNAP labelling and
immunolabelling procedures. Parameters for automated confocal imag-
ing, recognition and analysis of fluorescently labelled INS-SNAP+ SGs
were validated, thus enabling a first pilot screen for compounds affecting
the turnover of age-defined SGs.
Conclusion: The successful generation of a transgenic SOFIA pig shall
enable for the first time the performance of HTHC studies on the biogen-
esis and age-dependent turnover of insulin SGs within islets, hence pro-
viding novel insight into the biology of β-cells and treatment opportuni-
ties for type 2 diabetes.
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ERK7: a novel regulator of insulin secretion and lipid metabolism in
Drosophila
K. Hasygar, R. Hynynen, V. Hietakangas;
Department of Biosciences/Institute of Biotechnology, University of Hel-
sinki, Helsinki, Finland.
Background and aims: Mitogen Activated Protein Kinases (MAPKs)
are Ser/Thr kinases which regulate a wide variety of cellular processes.
Although this family is very well studied, some of the members like
ERK7 (ERK8/MAPK15) are poorly characterized. ERK7 is an atypical
MAP kinase which was shown to be activated by amino acid and serum
starvation inDrosophila S2 cells. We have developed in vivo Drosophila
models to further characterize its physiological functions.
Materials andmethods: dILP2-Gal4; UAS-GFP driver linewas used for
Insulin Producing Cells (IPC) specific genetic manipulations. CG-Gal4
was used for fat body specific experiments. RNAi lines and p53 overex-
pression lines were obtained from VDRC, Austria and Bloomington
Stock Center, USA. qRT-PCR assays were used to measure mRNA levels
of insulin like peptides and lipogenic genes. Immunostainings using anti-
dILP2 antibody were used to assess secretion of insulin like peptides. Gas
chromatography was used for quantitative lipidomics.
Results:We hereby show that ERK7 is an important regulator of growth
and lipid metabolism in Drosophila. We observed that upon starvation,
ERK7 is expressed in median neurosecretory cells (IPCs) which regulate
larval growth by secreting insulin-like peptides (dILPs) in diet-dependent
manner. We demonstrate that overexpression of ERK7 in IPCs strongly
inhibits dILP secretion which consequently leads to reduced body size
and a delay in larval development. We also identify p53 as an upstream
activator of ERK7 in IPCs. Further, we establish that ERK7 function in
IPCs is necessary for efficient starvation response. Finally, we also show
that ERK7 has important metabolic functions outside IPCs.We show that
ERK7 function in lipogenic tissues ofDrosophila is important for normal
lipid homeostasis. Overexpression of ERK7 in these tissues caused qual-
itative and quantitative changes in lipid levels. We are currently generat-
ing ERK7 mutants to try and decipher the pathways it regulates by using
RNA-seq analysis.
Conclusion: ERK7 regulates starvation response by inhibiting insulin
secretion from insulin producing cells. It also has a role outside IPCs in
regulation of lipid homeostasis.
Supported by: Sigrid Juselius
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Reciprocal changes in glucose tolerance after pancreatic beta cell
selective deletion or over-expression of Slc30a8/ZnT8 in mice
R.K.Mitchell1, M. Hu1, G. Meur1, E.A. Bellomo1, P.L. Chabosseau1, R.
Carzaniga2, L.M. Collinson2, D.J. Hodson1, G.A. Rutter1;
1Section of Cell Biology & Functional Genomics, Imperial College Lon-
don, 2Electron Microscopy Unit, London Research Institute, UK.
Background and aims: The incorporation of two zinc (Zn2+) ions into
the insulin hexamer is fundamental for insulin maturation. Zinc Trans-
porter 8 (ZnT8, encoded by SLC30A8) is highly, and almost exclusively,
expressed within pancreatic beta and alpha cells where it facilitates the
importation of cytosolic zinc into secretory granules. Co-secretion of
Zn2+ from secretory granules is an important paracrine regulator of islet
hormone secretion and has also been shown to regulate insulin bioavail-
ability. Moreover, a common polymorphism (R325W) within SLC30A8,
which lowers transporter activity, is associated with higher risk of devel-
oping type 2 diabetes (T2D). Recently, however, rare inactivating muta-
tions in SLC30A8 have been described which appear to protect against
T2D development. Here, we explore the effects of either ZnT8 deletion or
over-expression specifically in the beta cell in mice.
Materials and methods: Beta cell specific deletion of ZnT8 was
achieved by crossing mice harbouring LoxP sites either side of exon 1
of Slc30a8 with an Ins1Cre deleter strain. Transgenic mice were generat-
ed by pronuclear injection of DNA encoding c-myc tagged ZnT8 down-
stream of a tetracycline regulated promoter. Beta cell overexpression of
ZnT8 was achieved by crossing transgenic mice with mice containing the
tetracycline transactivator gene under the control of the insulin promoter.
Glucose tolerance was assessed using glucose tolerance tests and insulin
granule structure by electron microscopy.
Results: Beta cell selective deletion: Male Ins1Cre+/-::ZnT8 fl/fl mice
displayed significant impairments in glucose tolerance at 10 weeks of
age vs Ins1Cre-/-::ZnT8 fl/fl littermate controls (13.6±0.74 mmol/L vs
11.5±0.59 mmol/L at 30 min. respectively; P<0.05; n=8/11). Granule
morphology was dramatically altered following ZnT8 deletion, with an
increased percentage of granules from Ins1Cre+/-::ZnT8 fl/fl mice lacking
dense cores (36.3±2.48 vs 85.6±1.37, Ins1Cre+/-::ZnT8 fl/fl vs Ins1Cre-/
-::ZnT8 fl/fl, P<0.001, n=8 beta-cells/genotype) or having ‘rod-like’ struc-
tures (31.9±3.42 vs 0.6±0.28, Ins1Cre+/-::ZnT8 fl/fl vs Ins1Cre-/-::ZnT8 fl/
fl, P<0.001, n=8 beta-cells/genotype), insulin granule diameter was also
increased in ZnT8 null mice (377.467 ± 5.12 nm vs 328.09 ± 5.46 nm,
Ins1Cre+/-::ZnT8 fl/fl vs Ins1Cre-/-::ZnT8 fl/fl, P<0.001, n=204/226
granules). Beta cell selective overexpression: Female mice
overexpressing ZnT8 (Rip7rTTa+/-::ZnT8Tg+/-; doxycycline treated
from 5 weeks) showed significant improvements in glucose tolerance
compared to Rip7rTTA+/-::ZnT8Tg-/- littermate controls at both 10 (12.2
±0.51 mmol/L vs 13.9±1.1 mmol/L; respectively; P<0.05; n=6) and
14 weeks of age (8.84±0.59 mmol/L vs 11.7±1.01 mmol/L;
respectively; P<0.01; n=6). Overexpression of ZnT8 also caused a
significant reduction in glucose-stimulated insulin secretion in isolated
islets (0.40±0.05 ng/mL vs 0.94±0.21 ng/mL, Rip7rTTa+/-::ZnT8Tg+/-
vs Rip7rTTa+/-::ZnT8-/- respectively; p<0.05; n=10-13).
Conclusion: Using in vivo models to manipulate gene expression we
show that down- or up-regulation of ZnT8 in the beta cell respectively
worsens and improves glucose tolerance in the mouse. These studies
support the view that ZnT8 activation may be therapeutically useful in
T2D treatment.
Supported by: Diabetes UK, Wellcome Trust, The MRC, Royal Society &
EFSD/MSD
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A pre-obese state accelerates beta cell dysfunction in patients with
type 2 diabetes: a glucagon stimulation test-based cross-sectional
study
Y. Kondo1,2, S. Satoh2, U.N. Osada3, Y. Terauchi1;
1Endocrinology and Metabolism, Yokohama City University, 2Endocri-
nology andMetabolism, ChigasakiMunicipal Hospital, , 3Endocrinology
and Diabetes, Saiseikai Yokohama-shi Nanbu Hospital, Kanagawa, Ja-
pan.
Background and aims: Type 2 diabetes (T2D) is a progressive disease in
which β-cell function declines. The loss of β-cell function results in poor
glucose control in T2D patients, and it accelerates the progression of
diabetic complications. Some preclinical studies have shown links be-
tween obesity and β-cell dysfunction. Therefore, we aimed to investigate
the relationship between obesity and the progress ofβ-cell dysfunction in
T2D patients.
Materials and methods: We conducted a cross-sectional study on T2D
patients whose β-cell function were assessed using 1-mg intravenous
glucagon stimulation test (GST) from June 2010 through March 2015.
Their BMI and known diabetes duration were also collected. After
reviewing their medical records, the onset of diabetes was primarily de-
fined as the time of a new T2D diagnosis after a 75-g oral glucose toler-
ance test (75 g-OGTT) was performed. In cases with missing 75 g-OGTT
data, we defined the onset as the first finding of an HbA1c level
≥48 mmol/mol. The β-cell function was assessed using the area under
the curve for serum C-peptide immunoreactivity (AUC-CPR) during the
GST. Patients were stratified into the following groups: non-obese (BMI,
<25 kg/m2), pre-obese (BMI, 25-29.9 kg/m2), and obese (BMI, ≥30 kg/
m2). Univariate regression analysis was performed to determine the rela-
tionship between the AUC-CPR and diabetes duration for each group.
The primary endpoint was to assess the effect of obesity on the annual
declining rate of the AUC-CPR.
Results: After screening, 256 consecutive T2D patients were included in
our analysis. Of those, 120 patients (47%) were non-obese, 88 (34%)
were pre-obese, and 48 (19%) were obese. The obese group showed the
highest AUC-CPR levels (non-obese: 8.25±4.48 ng/mL•min, pre-obese:
9.81±5.48 ng/mL•min, obese: 13.83±9.11 ng/mL•min; p <0.001). Each
group had a negative regression between the AUC-CPR and diabetes
duration (non-obese: β=-0.11, 95% confidence interval [CI]: -0.20 to -
0.02, p=0.02; pre-obese: β=-0.22, 95% CI: -0.36 to -0.02, p=0.002;
obese: β=-0.87, 95% CI: -1.30 to -0.44, p <0.001). However, as shown
in figure 1, the annual declining rate of the AUC-CPR was significantly
accelerated in the pre-obese group (-1.84% per year, p=0.02 vs. non-
obese group) and the obese group (-4.37% per year, p <0.001 vs. non-
obese group) compared to the non-obese group (-1.17% per year).
Conclusion: In this cross-sectional study, negative regression was con-
firmed between β-cell function and diabetes duration according to the
AUC-CPR. The annual declining rate of β-cell function was already
accelerated in the pre-obese state prior to reaching the obese state. These
findings suggest that antidiabetic therapy aimed at body weight reduction
should be chosen from the pre-obese state in order to preserve β-cell
function in T2D patients.
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Deletion of PKCε in islet-associated macrophages improves beta cell
function
L. O'Reilly, J. Cantley, V. Turner, R. Brink, C. Schmitz-Peiffer, T.J.
Biden;
Garvan Institute of Medical Research, Darlinghurst, Australia.
Background and aims: Islet inflammation is an increasingly accepted
contributing factor to β-cell dysfunction in the context of Type 2 Diabe-
tes. This is thought to involve the actions of macrophages which are
increased in islets of animals fed a high-fat diet (HFD), as well as multiple
models of diabetes. Whole body deletion of the serine/threonine kinase
PKCε in HFD mice improves β-cell function in vivo. PKCε is important
in toll-like receptor signalling, and is involved in macrophage function
and activation. We hypothesise that PKCε is an important regulator of
macrophage function in islet-associated macrophages and is a target to
alleviate macrophage-mediated β-cell dysfunction in HFD mice.
Materials and methods: To study the specific actions of PKCε we de-
veloped a floxed PKCεmouse (PKCεf). This was crossedwith Pdx-cre or
Rip-cre mice for β-cell specific deletion and LysMcre mice for macro-
phage specific deletion . Control mice were the corresponding cre alone,
or PKCεf mice. Bone marrow chimeras were generated by irradiation of
congenic donor mice, which then received bonemarrow cells from PKCε
WT or null mice.
For all models mice were fed normal chow or HFD for varying times and
glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) were
performed. Insulin and c-peptide excursions were also monitored during
GTTs, using ELISA. Circulating cytokines, islet gene expression, and
islet morphology were characterised in LysMcrePKCεf mice. Addition-
ally, primary peritoneal and bone marrow-derived macrophages from
PKCε WT and null mice were isolated to characterise the role of PKCε
in macrophage function and activation in vitro.
Results: β-cell specific PKCε deletion did not improve glucose tolerance
or β-cell function in HFD mice compared to controls. Bone marrow
chimera mice reconstituted with PKCε null bone marrow exhibited im-
proved glucose tolerance (p<0.05, two-way ANOVA), and insulin and c-
peptide excursions (p<0.05, two-way ANOVA) during the GTT at
20 weeks of high fat feeding, but not before. At 12 weeks of high fat
feeding LysMcrePKCεf mice exhibited significantly improved glucose
tolerance (p<0.05, two-way ANOVA), an elevated insulin profile (p<
0.05, two-way ANOVA) and significantly improved c-peptide response
(p<0.05, t-test) during the GTT. This effect was not seen in chow-fed
mice. Islets from HFD fed LysMcrePKCεf mice showed improved
glucose-stimulated insulin secretion ex vivo (p<0.05, one-way ANOVA).
Insulin resistance as measured by an ITT was not altered, and no gross
changes in circulating cytokines or inflammatory gene expression were
observed. β-cell area was not changed in LysMcrePKCεf mice. In vitro
stimulation of primary PKCε null macrophages with common activators
(e.g. LPS, IFNγ, palmitate) showed no obvious alteration in macrophage
activation as measured by production of nitric oxide and release of IL-1β,
IL-1α, TNFα, IL-6, MCP-1, IL-12, IL-23, IL-10 and PGE2.
Conclusion: Deletion of PKCε in the haematopoietic compartment, and
more specifically macrophages, improves β-cell function in HFD mice.
This improvement occurs after increased macrophage accumulation and
does not appear to be due to any gross alterations in canonical activation
pathways. These results suggest that a subtle alteration in macrophage
biology independently of currently known mediators can preserve β-cell
function under a HFD stress.
Supported by: NHMRC
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TLR4 triggered inflammation involves an interplay between macro-
phages, alpha and beta cells in human pancreatic islets
W. He1, J. Kerr-Conte2, K. Maedler1;
1Centre for Biomolecular Interactions, University of Bremen, Germany,
2U859 INSERM University of Lille 2, France.
Background and aims: Inflammatory signals are strong mediators of
metabolic failure in fat, liver, brain, muscle as well as in pancreatic islets.
Toll-like receptor-4 (TLR-4) signaling is one of the major pro-
inflammatory pathway; its ligands as well as downstream products, i.e.
cytokines and chemokines are increased systemically in patients with
T2D as well as in at-risk individuals. TLR4 knockout mice are protected
from the metabolic consequences of a high fat diet. In the present study
we investigated the mechanism of TLR4 induced inflammation in isolat-
ed human islets.
Materials and methods: Isolated human islets from healthy donors were
plated onto ECM-coated dishes and exposed to the natural TLR4 ligand
Lipopolysaccharide (LPS) for 3 days. Depletion of islet resident macro-
phages was achieved by treatment with clodronate liposome. Expression
and secretion of pro-inflammatory cytokines/chemokines was evaluated
by qRT-PCR and ELISA. Glucose-stimulated insulin secretion(GSIS)
from islet supernatants and insulin content from human islets were exam-
ined by insulin ELISA. Beta cell apoptosis and IL-8 localization were
determined by double labeling for the TUNEL assay or by anti-IL-8 and
anti-insulin or anti-glucagon antibodies. Human monocytes were
enriched from human PBMCs and used for the migration assay through
a Boyden chamber.
Results: Treatment of isolated human islets with LPS reduced GSIS by
71.6% and insulin content by 76.6% and increased beta cell apoptosis by
2.5-fold, compared to untreated control. In parallel, mRNA levels of pro-
inflammatory cytokines/chemokines, including IL-1alpha, IL-1beta, IL-
6, TNFalpha, CCL2 and IL-8, were elevated by LPS. Depletion of resi-
dent macrophages in human islets by clodronate showed that LPS-
induced IL-1beta and IL-1alpha expression was macrophage dependent,
while IL-6, TNFalpha, CCL2 and IL-8 expression remained unchanged,
suggesting the endocrine cells themselves were the major source of these
cyto-/chemokines. Immunohistochemical staining showed intra-islet pro-
duction of IL-8 from alpha cells. In contrast, human macrophages differ-
entiated from human primary monocytes produced high levels of IL-8 as
well as IL-1beta in response to LPS. Migration of primary human mono-
cytes was induced by supernatants from LPS-treated human islets; this
was highly dependent on IL-8, since an IL-8 neutralizing antibody
completely blocked the migration.
Conclusion: Our results show that TLR4 activation leads to beta cell
dysfunction, beta cell apoptosis and islet inflammation.This depends on
the interplay between islet-associated resident macrophages, alpha cells
and beta cells, while recruited islet macrophages may exacerbate inflam-
mation and amplify islet damage.
Supported by: the European Research Council
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An emerging role for autophagy in the regulation of beta cell survival
by glucagon-like peptide-1
F.P. Zummo, K.S. Cullen, P.E. Lovat, J.A. Shaw, C. Arden;
Institute of Cellular Medicine, Newcastle University, Newcastle upon
Tyne, UK.
Background and aims: Loss of pancreatic beta- cell mass is central to
the development of Type 2 diabetes. Autophagy is a self-degradative
process, important for recycling cell components in response to stress
and, under most conditions, is considered a cell survival mechanism.
However, deregulation of autophagic flux can lead to cell death. Whether
beta-cell autophagy has a protective or detrimental role in the
development of T2D is contentious. Glucagon-like peptide-1 (GLP-1)
improves glycaemic control through multiple actions including
preventing beta cell loss, although the mechanisms are not well under-
stood. The aim of the current study was to determine whether the protec-
tive effect of the GLP-1 analog exendin-4 on glucolipotoxic-induced cell
death is due to alterations in autophagic flux.
Materials and methods: INS-1E cells were treated with glucolipotoxic
stress (25 mM glucose, 0.5 mM palmitate) in the absence or presence of
100 nM exendin-4 and/or 10 μM BAPTA, 10 μM ESI-09 for 6-16 h.
Immunohistochemical staining of p62 both in fixed INS-1E and pancreas
sections from control and T2DM donors was used to assess autophagy
impairment. Autophagic flux was assessed by LC3-I to LC3-II conver-
sion and by using a mCherry-GFP-LC3 construct.
Results: Treatment of INS-1E cells with glucolipotoxic stress increased
cell death as evident by increased PI staining (3.7-fold±0.4 n=3, p<
0.001) and also increased LC3-I to LC3-II conversion (2.5-fold±0.1 n=
3, p<0.01), a distinct marker of autophagy. Glucolipotoxicity increased
p62 puncta accumulation (2.0-fold±0.2 n=6, p<0.01), which indicates
defective autophagy. In accordance, further studies using mCherry-GFP-
LC3 showed that treatment of INS-1Ewith glucolipotoxic stress leaded to
accumulation of autophagosomes and impaired autophagic flux. An in-
crease in p62 puncta accumulation was also found in pancreatic beta cells
from Type 2 diabetic donors, indicating that autophagy may also be
impaired in human diabetes. Co-treatment with exendin-4 protected
INS-1E cells from glucolipotoxic induced cell death (37.3% decrease
n=3, p<0.01). Exendin-4 further exacerbated LC3-I to LC3-II conver-
sion (4.1-fold±0.2 n=3, p<0.01), while reducing p62 puncta accumula-
tion (17.9% decrease n=6, p<0.05) suggesting further stimulation and, at
least partial, restoration of autophagic flux. The Ca2+ chelating agent
BAPTA and ESI-09, an Epac inhibitor, suppressed the increase in LC3-
I to LC3-II conversion driven by exendin-4 (59.0% decrease n=3, p<
0.05 and 64.7% decrease n=4, p<0.05, respectively), suggesting a role
for calcium in the exendin-4 regulation of autophagy.
Conclusion: Glucolipotoxicity causes impairment in autophagic flux in
beta cells, resulting in accumulation of autophagosomes inside the cells.
Co-treatment with exendin-4 causes partial restoration in autophagosome
clearance through an EPAC/calcium-dependent mechanism.
Supported by: Diabetes UK (project grant 12/0004544)
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Modulation of beta cell function by the atrial natriuretic peptide
S. Undank1, P. Krippeit-Drews1, M. Düfer2, G. Drews1;
1Pharmacology, University of Tuebingen, 2Pharmacology, University of
Muenster, Germany.
Background and aims: Recent studies suggest that the cardiac hormone
ANP (atrial natriuretic peptide) is an important regulator of metabolism. It
may provide a link between cardiovascular and metabolic dysregulation
in obesity and (pre)diabetes. The aim of the present study was to inves-
tigate the effect of ANP on beta-cell stimulus-secretion coupling.
Materials and methods: Ion currents and the membrane potential (Vm)
of mouse beta-cells were measured with the patch-clamp technique. Mi-
tochondrial membrane potential (ΔΨ) was determined with Rh-123 fluo-
rescence. Protein expression in pancreatic islet lysates was assessed by
Western blotting. For insulin secretion measurements, batches of 5 islets
were incubated for 60 minutes at 37°C with the indicated substances.
Insulin was determined by radioimmunoassay.
Results: ANP (10 nM) decreased the open probability of the KATP chan-
nel in beta-cells of GC-Aflox/flox mice to 29±11% (n=6, p≤0.01). This
effect was absent in mice with specific deletion of the GC-A receptor in
beta-cells (Rip-Cre+/- GC-Aflox/flox) (119±15%, n=6, n.s.). A membrane-
permeable analog of the second messenger cGMP, 8-Br-cGMP
(250 μM), mimicked the effect of ANP on the KATP channel in beta-
cells of GC-Aflox/flox mice (reduction to 72±8% open probability vs.
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100% control, n=7, p≤0.05), indicating that ANP acts in a cGMP-
dependent manner. Determination of specific current density (GC-Aflox/
flox: 21±2 pA/pF, n=33 vs. Rip-Cre+/- GC-Aflox/flox: 23±1 pA/pF, n=34,
n.s.) as well as Western blotting (n=6, n.s.) revealed no significant dif-
ference in the number of KATP channels or protein expression in beta-cells
of Rip-Cre+/- GC-Aflox/flox mice and their wild type littermates. ANP
(10 nM) did not influence mitochondrial membrane potential (15 mM
glucose: 1232±35 a.u. vs. +ANP: 1240±32 a.u., n=60, n.s.), indicating
that it does not affect ATP production. In accordance with closure of KATP
channels, ANP increased glucose-induced electrical activity measured as
fraction of plateau phase (FOPP=percentage of time with spike activity)
(ANP: 65±5% vs. glucose 10 mM: 47±5%, n=6, p≤0.05). Insulin se-
cretion was increased by ANP at a subthreshold glucose concentration
(6 mM glucose) in islets of GC-Aflox/flox mice (ANP: 0.33±0.07 ng insu-
lin/(islet*h) vs. 6 mM glucose: 0.24±0.06 ng insulin/(islet*h), n=4, p≤
0.05), whereas the effect was absent in islets of Rip-Cre+/- GC-Aflox/flox
mice (ANP: 0.23±0.06 ng insulin/(islet*h) vs. 6 mM glucose: 0.24±
0.04 ng insulin/(islet*h), n=4, n.s.).
Conclusion: These results provide evidence that ANP exerts cGMP-
dependent specific actions in the endocrine pancreas via activation of
the GC-A receptor and that the hormone is involved in the regulation of
beta-cell function.
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Ghrelin has a direct inhibitory effect on insulin secretion in human
islets from both healthy subjects and type 2 diabetic patients
R.G. Fred, L. Shcherbina, M. Abels, N. Wierup;
Lund University Diabets Centre, Lund University, Malmö, Sweden.
Background and aims: Ghrelin is an insulinostatic hormone expressed
in the gastro-intestinal tract and in islet ghrelin cells. In rodents most of
the circulating ghrelin originates from the fundus but in humans a larger
portion originates from the islets and intestine, demonstrating the neces-
sity of experimental data from humans in addition to other experimental
models. The effect of ghrelin is well documented in several experimental
models, as well as in vivo in humans. However, the direct effect of ghrelin
on human islets is not well known. Although IVGTTs have shown de-
creased insulin-, as well as C-peptide release after ghrelin infusion it has
hitherto not been clarified if this is a primary response. Thus, our aim was
to perform in vitro secretion assays to study the direct effect of ghrelin on
human islet insulin secretion in islets from normoglycemic and type 2
diabetes (T2D) donors. Furthermore it is not known how islet expression
of ghrelin and its receptor GHS-R1a are affected by T2D. We aimed to
investigate ghrelin and GHS-R1a expression levels to establish the effects
of prolonged hyperglycemia on ghrelin signaling. This was to be done
using microarrays on islets from healthy subjects and T2D patients.
Materials and methods: Human islets from the Nordic Network for
Clinical Islet Transplantation, delivered through the Human Tissue Lab
(LUDC), were considered being from normoglycemic (HbA1c<6.0) or
T2D (diagnosed or HbA1c>6.0) donors. The islets were incubated in 2.8
or 16.7 mMglucose for 1 hour with or without different concentrations of
ghrelin. Insulin secretion was determined by ELISA (Mercodia). Micro-
array data was collected from 128 donors using the Affymetrix GeneChip
Human Gene 1.0 ST array.
Results: 1 hour incubation of human islets fromT2D donors (HbA1c>6.0
with 1, 10 and 100 nM ghrelin at 16.7 mM glucose dose-dependently
decreased insulin secretion with a 31.2±15.7% reduction at 10 nM (p=
0.042 for n=3). At 2.8 mM glucose ghrelin did not effect insulin secre-
tion. In islets from normoglycemic donors the same pattern was seen with
a dose dependent decrease in insulin secretion at 16.7 mM glucose with
31.5±7.27% at 100 nM (p=0.022 for n=6). Thus indicating that the
in vivo effect of ghrelin on insulin secretion is predominantly due to a
direct effect on the beta-cells. The micro-array data from human islets
revealed that islet ghrelin expression was negatively correlated with
HbA1c (p=0.007 for n=128) and that ghrelin expression was lower in
T2D islets (p=0.03). Islet ghrelin also correlated positively with insulin,
glucagon and somatostatin expression (p=1*10-10, p=0.001 and p=
2*10-5 respectively for n=128. The ghrelin receptor (GHS-R) expression
did not correlate significantly with known diabetes risk-factors such as
BMI, insulin secretion index or HbA1c. Nevertheless, GHS-R correlated
with PDX-1 expression (p=3*10-13 for n=128) and somatostatin (p=
1.6*10-16 for n=128) indicating a previously unknown connection to
both beta-cell transcription and delta-cell function.
Conclusion: We conclude that: 1) ghrelin directly inhibits insulin secre-
tion in islets from both healthy subjects and T2D patients. 2) ghrelin
expression levels correlate negatively with both HbA1c and diagnosed
T2D and positively with insulin, glucagon and somatostatin. 3) the ghrel-
in receptor also correlates positively with somatostatin. These findings
suggest that inhibition of ghrelin signaling may be a therapeutic avenue
for treatment of T2D.
Supported by: Swedish Research Council
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The role of Epac2 in bile acid-mediated modulation of insulin
secretion
E. Heider1, P. Krippeit-Drews1, M. Düfer2, G. Drews1;
1Pharmacology, University of Tuebingen, 2Pharmacology, University of
Muenster, Germany.
Background and aims:We have shown recently that bile acids enhance
glucose-stimulated insulin secretion via activation of the farnesoid X
receptor (FXR). FXR activation leads to closure of KATP channels, how-
ever, the underlying mechanism is still unknown. The aim of the present
study was to test whether Epac2 (exchange protein directly activated by
cAMP 2) plays a role in the bile acid-mediated regulation of glucose
homeostasis via FXR.
Materials and methods: Experiments were performed with beta-cells
from wild-type (WT) and Epac2-knockout (KO) mice. Ion currents were
measured with the patch-clamp technique; the cytosolic Ca2+ concentra-
tion [Ca2+]c was determined by fura-2.
Results: Chenodeoxycholate (CDC, 500 nM) and the synthetic
FXR agonist GW4064 (500 nM) enhanced [Ca2+]c in beta-cells
of WT mice to 130±12%, n=12, p≤0.05 and 119±5%, n=18, p≤
0.01, respectively. Interestingly, both substances did not alter
[Ca2+]c in beta-cells of Epac2-KO mice (CDC: n=41, GW4064:
n=22). The Epac-selective cAMP analog Sp8 (1 μM) evoked an
elevation of [Ca2+]c in WT beta-cells (122±4%, n=22, p≤0.001)
but not in Epac2-KO beta-cells (n=17) indicating that Epac acti-
vation augments [Ca2+]c in beta-cells. We further tested whether
the KATP channel density is altered in beta-cells of Epac2-KO
mice. Whole-cell KATP current measurements were performed
without ATP in the pipette solution to induce maximum KATP
current. The experiments revealed a significant decrease in KATP
channel density in beta-cells lacking Epac2 (WT: 26±2 pA/pF, n=
15 vs. Epac2-KO: 18±2 pA/pF, n=22, p≤0.05). To investigate
whether the ATP sensitivity of the KATP channel is modified by
FXR activation, we tested different ATP concentrations in the
pipette solution in the absence and presence of GW4064. The
FXR agonist increased ATP sensitivity of the channels in WT
beta-cells by about 40% (14±1 pA/pF n=7 vs. 8±1 pA/pF, n=
6, p≤0.01 for 1 mM ATP and 11±1 pA/pF, n=9, vs. 6±1 pA/pF,
n=9, p≤0.01 for 2 mM ATP with and without GW4064, respec-
tively). The FXR agonist did not affect ATP sensitivity of KATP
channels in Epac2-KO beta-cells (n=5-8).
Conclusion: The experiments provide evidence for a link between bile
acid signaling and the activation of Epac2 which seems to increase KATP
channel sensitivity towards ATP. It is suggested that FXR stimulation
activates Epac2 which in turn decreases KATP channel activity.
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Decorin: A new positive component of skeletal muscle to beta cell
communication?
T. Haider, C. Arous, A. Zoso, P.A. Halban, K. Bouzakri;
GEDEV, centre médical universitaire, Genève, Switzerland.
Background and aims: Inter-organ crosstalk including possible commu-
nication between skeletal muscle and beta cells is an important compo-
nent of normal physiology that may contribute towards the pathophysi-
ology of type 2 diabetes. Indeed, skeletal muscle cells secrete different
sets of soluble proteins (myokines) which could act positively or nega-
tively (in health and disease respectively) on the function of distant tissues
including pancreatic islets. We have observed that conditioned medium
from skeletal muscle of healthy individuals has positive effects on beta
cell function. Decorin, a chemokine that has been shown to be a compo-
nent of the extracellular matrix of a variety of connective tissues, was
identified as a myokine regulated by muscle fiber type. The major aim of
this study was to explore the impact of decorin on primary sorted beta
cells under control conditions and after exposure to TNF-α or cytomix.
Materials and methods: All studies were performed using sorted rat
primary beta cells exposed to decorin for 24 h. Glucose-stimulated insulin
secretion (GSIS) was measured by radioimmunoassay after 1 h at
2.8 mmol/l (basal) and 1 h at 16.7 mmol/l (stimulated) glucose. Confocal
immunofluorescence microscopy was used to study focal adhesion and
actin remodeling (after 15 min glucose stimulation). Cell death and pro-
liferation were measured by TUNEL assay and BrdU incorporation re-
spectively. To study the potential beneficial/protective effects of decorin,
beta cells were exposed to decorin for 24 h alone or with addition of
cytomix (20 ng/ml each TNFα, IFNγ, IL1-β) or 20 ng/ml TNF-α alone.
Data are mean±SE for 5-8 independent experiments.
Results: Decorin treatment of rat primary beta cells for 24 h increased
GSIS (control: 12.4±3.2% content/h; 1 μg/ml decorin: 15.08±3.8%*;
10 μg/ml decorin: 14.1±1.8%*; *p<0.05 vs. control) and decreased cell
death (TUNEL-positive beta cells control: 0.7±0.2%; 1 μg/ml decorin:
0.38±0.1%*; 10 μg/ml decorin: 0.4±0.1%*; *p<0.05 vs. control).
Decorin had no effect on beta cell proliferation. Confocal microscopy
showed a modification of glucose-induced formation of focal adhesions
containing paxillin and actin after 24 h decorin (1 μg/ml). Decorin
(100 μg/ml) induced a slight increase of paxillin phosphorylation and
presented a denser actin network in both basal and stimulated conditions
depending on the decorin concentration (1 μg/ml-100 μg/ml). Decorin
protected against the adverse effects of TNF-α on GSIS (control: 10.20±
0.8% content/h; TNF-α: 8.6±0.8%*; TNF-α + 1 μg/ml decorin: 11.03±
0.9%**; *p<0.05 vs. control; **p<0.05 vs. TNF-α alone) and blocked
the effects of cytomix on apoptosis (control: 0.75±0.1%TUNEL-positive
beta cells; cytomix: 5.9±0.12%; cytomix + 1 μg/ml decorin: 0.95±
0.35%).
Conclusion:We demonstrate for the first time that decorin has a positive
effect on beta cells, increasing glucose-stimulated insulin secretion and
decreasing cell death in the basal state. The myokine affects also beta cell
focal adhesion and actin remodeling. Moreover, decorin protects beta
cells from the adverse effects of TNF-α and cytomix, indicating the
potential for a specific impact of decorin on cytokine signaling pathways
in beta cells.
Supported by: SNF:31-135645; 31003A-144092/1
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Impact on beta cells of myokines secreted by skeletal muscle of dif-
fering insulin sensitivity and fiber type
K. Bouzakri1, P. Plomgaard2, C. Howald1, E.T. Dermitzakis1, B.K. Pe-
dersen2, P.A. Halban1;
1Department of Genetic Medicine and Development, CMU, Geneva,
Switzerland, 2Department of Infectious Diseases and CMRC, University
of Copenhagen, Denmark.
Background and aims: Decreased beta-cell functional mass and insulin
resistance are hallmarks of type 2 diabetes (T2D). We have studied
crosstalk between skeletal muscle of different insulin sensitivity and be-
ta-cells, and suggested that myokines secreted by insulin-resistant skeletal
muscle could contribute towards decreased beta-cell function/mass in
T2D. In obese and T2D individuals, the distribution of muscle fiber types
is shifted toward faster, more glycolytic fibers. We have now explored the
impact on beta-cells of secreted products from human myotubes of dif-
ferent fiber type with varying insulin sensitivity.
Materials and methods: Human skeletal muscle biopsies of different
fiber type where collected from soleus (S; slow twitch fiber) and triceps
(T; fast twitch fiber); cells were expanded in culture and differentiated into
myotubes. mRNA expression were measured by unbiased RNA sequenc-
ing on biopsies and corresponding cell preparations. Human myotubes
where treated for 24 h with or without (control) 20 ng/ml TNF-α to
induce insulin resistance. Glucose uptake was measured in response to
insulin. Conditioned media (CM) from the fiber types (test: TNF-α-CM-
S or T; control: C-CM-S or T) were collected and analyzed to identify
their myokine composition by protein arrays. Sorted rat and human pri-
mary beta-cells were used to test effects of exposure to CM for 24 h on
death (TUNEL), proliferation (BrdU) and glucose-stimulated insulin se-
cretion (GSIS). Data are mean+/-SE with p<0.05 considered significant
for all indicated differences.
Results: Biopsies from soleus and triceps revealed a unique gene signa-
ture with 2497 genes (S vs.T; p<0.01) differentially expressed in these 2
groups, while primary cells derived from soleus and triceps showed 1682
differentially expressed genes (S vs.T; p<0.01). Moreover, cells isolated
from triceps and soleus secreted a different panel of myokines in control
condition and after treatment with TNF-α allowing for identification of
fiber specific, TNF-α and fiber/TNF-α dependent myokines. Interesting-
ly, TNF-α failed to induce insulin resistance in cells isolated from triceps.
CM-S and -T increased whereas TNF-α-CM-S but not -T decreased
GSIS. Beta-cells treated with TNF-α-CM-S showed increased death
(11+/-2-fold increased TUNEL-positive cells) and decreased proliferation
(1.1+/-0.4 vs. 7.3+/-1.7% BrdU positive cells vs. C-CM-S) whereas
TNF-α-CM-T treatment had no impact on these parameters vs. C-CM-
T treatment. Finally, CM from either fiber type without prior exposure to
TNF-α increased beta-cell proliferation (Control: 4.7+/-0.3; CM-S: 7.3+/
-0.6*; CM-T: 8.6+/-1.1* % BrdU positive cells; *p<0.05 vs. Control).
Conclusion: Taken together these results show that skeletal muscle cells
from biopsies with different fiber composition present unique gene ex-
pression and myokine signatures. Moreover the impact on pancreatic
beta-cells of human skeletal muscle cells is fiber specific, with both pos-
itive and negative effects depending on different insulin sensitivity. The
identification of the fiber specific myokines and their molecular targets on
beta-cells may lead to new therapeutic strategies for preservation of func-
tional beta-cell mass in T2D.
Supported by: SNF:31-135645; 31003A-144092/1
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Identification of novel targets of the miR-212/132 cluster involved in
Wnt-signalling and regulation of insulin secretion in the pancreatic
beta cell
H.A. Malm, J.L.S. Esguerra, M. Orho-Melander, L. Eliasson, I.G.
Mollet;
Dept Clinical Sciences in Malmö, Lund University Diabetes Centre,
Malmö, Sweden.
Background and aims:We have recently shown the miR-212/132 clus-
ter to be highly overexpressed in diabetic Goto-Kakizaki (GK) rat islets.
In the present study we aimed to validate targets of miR-212 andmiR-132
and investigate their effects on insulin secretion.
Materials and methods: Conservation of microRNA 3’UTR target pre-
dictions was evaluated using TargetScan. Rat miR-212 andmiR-132were
overexpressed using mirVana Mimics in INS-1 832/12 clonal beta-cells
by transfection and analysed with RT-qPCR and Western Blot.
Results: In silico analysis of 249 predicted miR-212 and miR-132 target
genes conserved in human, rat and mouse revealed several genes of
interest to the study of type-2 diabetes mellitus (T2DM). Among these
wereMAPTand two transcription factors (TFs) targets ofWnt-signalling,
ISL1 and SOX6. ISL1 binds to the enhancer region of the insulin gene
and is a primary target of TCF7L2; SOX6 is known to function in tran-
scriptional regulation through interaction with beta-catenin and is down-
regulated in human islets from donors with high HbA1c; and MAPT,
which is understood to be hyper-phosphorylated in neurofibrilar tangles
in insulin deficient mice, to a large extent by glycogen synthase kinase 3
beta (GSK-3beta), a central kinase that is inactivated by canonical Wnt-
signalling. Moreover, clustering of miR-212/miR132 predicted targets
shows enrichment within the Wnt-signalling pathway. We have con-
firmed down-regulation of MAPT (p=0.0118, N=3), ISL1 (p=0.0057,
N=3) and SOX6 (p=0.0287, N=3) at the mRNA level in the insulin
secreting cell line INS-1 832/13 when miR-212 are overexpressed. Like-
wise, after overexpression of miR-132 mRNA expression of SOX6 (p=
0.0008, N=3), ISL1 (p=0.0009, N=3) andMAPT (p=0.0001, N=3) was
reduced. We have also obtained preliminary Western blot data showing
down regulation of MAPT at the protein level.
Conclusion: These results give evidence that MAPT, SOX6 and ISL1, all
three genes relevant to type-2 diabetes, are likely to be targets of miR-212
andmiR-132. In addition, these results indicate that these microRNAs are
involved in the translational regulation of genes affected by canonical
Wnt-signalling. We are currently aiming to investigate the effect of these
targets on insulin secretion and to verify additional targets of miR-212/
132 involved or affected byWnt-signalling by using an Argonaute-2/RIP
(Ago2-RIP) approach.
Supported by: Swedish research council, EXODIAB/LUDC, A Påhlsson
foundation, Diabetesfonden
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Circulating levels of microRNAs predict residual beta cell function
and glycaemic control the first 12 months after diagnosis in children
with type 1 diabetes mellitus
N. Samandari, S. Pörksen, L.B. Nielsen, M.M. Andersen, S. Fredheim,
J. Johannesen, J. Svensson, H.B. Mortensen, F. Pociot;
Paediatrics, Herlev University Hospital, Denmark.
Background and aims: MicroRNAs have gained intensive research fo-
cus in order to explain pathophysiological processes leading to many
complex disorders including autoimmune diseases. Type 1 diabetes
mellitus is the final result of T-cell driven beta-cell loss leading to lifelong
insulin treatment and regular control of metabolic status. In this study it is
hypothesized that miRNA expression profile over time predicts residual
beta-cell function andmetabolic control in newly diagnosed children with
type 1 diabetes mellitus.
Materials andmethods:Children and adolescents with newly diagnosed
type 1 diabetes mellitus from The Danish Remission Cohort (N=129)
were intensively followed with blood samples the first 12 months after
diagnosis. A subset of 40 children from this cohort were followed up
5 years after diagnosis. In this subgroup RNAwas extracted from serum
samples obtained at 1, 3, 6, and 12 months. At the same time points meal
stimulated C-peptide and HbA1cwere measured and IDAA1c calculated.
miRNA profiling was performed using a predefined panel of 179 human
miRNAs. Normalization is based on the global mean of all expressed
miRNAs. Statistical analysis ofmiRNA prediction on disease progression
with stimulated C-peptide, HbA1c and IDAA1c as endpoint was per-
formed by multiple linear regression analysis adjusted for age and sex.
Comparisons were further adjusted for multiple testing by the Benjamini-
Hochberg approach for the 172 miRNAs at all time points.
Results: miRNA profiling was performed in a total of 182 serum
samples. 172 different miRNAs were identified and further ana-
lyzed. Stimulated C-peptide at 12 months was predicted by hsa-
mir-197-3p at 3 months . A doubl ing in miRNA level
corresponded to a 3.5 fold higher stimulated C-peptide level (p=
0.03). In addition a doubling of hsa-mir-24-3p and hsa-mir-146a-
5p levels at 3 months corresponded to a 4.2% and 3.5% decrease
in IDAA1c 12 months after diagnosis, (p=0.01) (p=0.02) respec-
tively. A doubling in hsa-mir-375 at 3 months corresponded to a
0.75 fold lower stimulated C-peptide level at 6 months (p=0.02).
Furthermore a doubling of hsa-mir-301a-3p at 3 months
corresponded to a 1.1% decrease in HbA1c at 6 months (p=0.02).
Conclusion: A combination of circulating novel miRNAs expressed in
sera from children newly diagnosed with type 1 diabetes mellitus can
predict beta-cell function and metabolic control 12 months after disease
onset. miRNAs could potentially be used as predictive biomarkers in
attempt to individualize the beta-cell regenerative treatment at a crucial
timepoint in this group of patients.
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Modulation of long non-codingRNAs in islets of high fat diet induced
obesity mice
A. Motterle1, S. Gattesco1, M.L. Peyot2, M. Prentki2, R. Regazzi1;
1Department of Fundamental Neuroscience, University of Lausanne,
Switzerland, 2University of Montreal, Montreal Diabetes Research Cen-
ter, Canada.
Background and aims: The genome transcribes a great number of long
non-coding RNAs (lncRNAs). Despite being involved in diverse gene-
regulatory mechanisms and their dysregulation being implicated in many
diseases, only few lncRNAs have been functionally characterized and
little is known about their contribution to type 2 diabetes. Type 2 diabetes
is characterised by a combination of beta-cell failure and insulin resis-
tance. The mechanisms leading to beta-cell dysfunction are complex and
still largely unknown. The aim of this project is to identify novel
lncRNAs, study their deregulation in the islets of mice fed a high fat diet
and to investigate their role in the regulation of beta-cell functions.
Materials andmethods: Islets were isolated from 13 weeks old C57Bl/6
mice after being fed a standard (SD) or a high fat (HFD) diet for 8 weeks.
100 nucleotide pair end sequencing was performed on cDNA libraries
prepared from rRNA-depleted islet RNA using the Illumina platform.
Reads were mapped with TopHat software version 2.0.8 to UCSC mm9
mouse genome. Ab initio transcript reconstruction was performed using
Cufflinks version 2.1.1 and novel lncRNAs transcripts were classified
from known lncRNAs and protein-coding mRNAs using Cuffmerge ver-
sion 2.1.1. Differential lncRNAs of selected novel lncRNAs was con-
firmed by quantitative real-time PCR.
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Results: RNA sequencing yielded around 500.000.000 reads par sample
of which on average 75% were mapped to the mouse genome. We iden-
tified a total of 14874 protein-coding transcripts of which 1366 were
upregulated and 396 downregulated in HFD mice. Functional annotation
of the differentially expressed protein-coding genes showed a strong en-
richment for endoplasmic reticulum, mitochondrion, protein biosynthesis
and transport processes. We also detected 1761 previously annotated
lncRNAs, of which 23 were upregulated and 104 downregulated. Finally,
de novo annotation identified around 1805 novel lncRNAs, 39 of which
were upregulated and 107 downregulated. Amongst the 1805 novel
lncRNAs, only 237 overlapped with previously published transcripts. In
agreement with previous studies, the expression of lncRNAs was lower
than that of protein-coding genes, with the majority displaying an expres-
sion below an FPKM of 5. Amongst the differentially expressed genes,
we confirmed in additional samples the upregulation and downregulation
of two selected lncRNAs. XLOC_010971 was 35±21 (p=0.0205) fold
higher in HFD versus SD while XLOC_013310 was 50% lower (p=
0.0051) in HFD versus SD.
Conclusion: We used high throughput sequencing to study the differ-
ences in gene expression in islets of a well characterized model of diet-
induced obesity and glucose intolerance. We detected many changes in
protein-coding genes and previously annotated lncRNAs. Furthermore,
we identified a new set of novel lncRNAs, a group of which displayed
changes in expression between islets of lean and diet induced obesity
mice, suggesting that lncRNAs could play an important role during the
pathogenesis of type 2 diabetes. These data provide the basis for future
studies on the contribution of lncRNAs to beta-cell dysfunction during
the development of type 2 diabetes.
Supported by: EFSD/Lilly Fellowship, FFRD, FNS
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Influence of environmental factors on the repression of "disallowed"
genes in mouse islets
K. Lemaire, M. Granvik, L. Goyvaerts, L. Van Lommel, A. Schraenen,
F. Schuit;
Cellular and Molecular Medicin, KU Leuven, Belgium.
Background and aims: The concept of "disallowed” genes - a special
group of housekeeping genes that is expressed in all tissues except one -
was introduced in the context of low Km hexokinases and monocarbox-
ylate transporters, genes that would interfere with normal glucose-
induced insulin release when expressed in the beta cell. Subsequent
mRNA analysis using freshly isolated islets and a panel of tissues from
the same mice indicated that a small set of "disallowed” genes is part of
the phenotype of adult mouse islets as a result of repressive changes of
chromatin structure and the finetuning influence of microRNA's. This
phenotype is established during the neonatal period when beta cells ma-
ture. It is unknown to what extent environmental factors can reverse this
epigenetic signature so that "disallowed” genes are induced in beta cells.
The aim of the present study was to examine the potential influence of
important environmental factors (age, diet, pregnancy) on the expression
of the “disallowed” genes in mouse islets.
Materials and methods: For the ageing experiment, we compared
mRNA signals in collagenase isolated islets from male C57Bl6/J
mice (Janvier) of 1 month, 2 months, 6.5 months, 16.5 months and
26 months of age. We next studied mRNA from islets of male
mice fed a high fat diet (45% fat) or standard diet (9% fat) for
16 weeks, starting at 6 weeks of age. Islets from female mice (age
10-12 weeks) were analysed at day 0, 9.5 and 15.5 of pregnancy.
Via quantitative RT-PCR (N=4 per tested condition) we quantified
islet mRNA expression signals of a signature of 14 genes consid-
ered “disallowed” in islets. Chromatin immunoprecipitation was
used to test histone-3 epigenetic markers for activation (H3K9ac)
and repression (H3K27me3) of gene expression.
Results: Age-dependent repression of the 14 "disallowed” genes follows
two patterns with significant correlations between genes within each
group (e.g. R2=0.98 between Zyx and Ldha; R2=0.96 between Pdgfra
and Itih5). Expression of the largest group (Arghdib, Cat, c-Maf, Ldha,
Lmo4, Smad3, Zfp36l1 and Zyx) was independent of age in animals of
1 month or older. In the second group (Itih5, Oat, Pdgfra, Cxcl12, Igfbp4
and Slc16a1) mRNA expression signals decreased significantly in func-
tion of age (e.g. 1 vs 6.5 months, Pdgfra: 0.91±0.22 vs 0.09±0.03; p=
0.004; Itih5: 1.1±0.34 vs 0.2±0.02, p=0.04). For none of the 14
“disallowed” genes, the repression was weakened when comparing
2 yrs old with 1 month old mice. In line with this result, the epigenetic
H3K9ac H3K27me3 marks were well preserved in function of age. High
fat diet feeding for 16 weeks led to small alterations of expression of three
genes: Itih5 (0 vs 16 weeks HFD; 1.43±0.32 vs 2.1±0.36, p=0.03) and
Zyx (0.97±0.11 vs 1.3±0.19, p=0.02) and Ldha (1.01±0.32 vs 0.57±
0.1, p=0.04). At day 15.5 of pregnancy we observed between 1.5 and 2.4
times more repression of Cxcl12 (p=0.01), Igfbp4 (p=0.003), Itih5 (p=
0.01) and Oat (p=8.10-5); genes associated with the control of prolifera-
tion of cells.
Conclusion:With some minor exceptions, the phenotypic islet signature
of 14 “disallowed” islet genes appears stable during ageing, after high fat
diet and during pregnancy indicating that maintenance of an epigenetic
repressive signature is very effective in islets against the influence of
environmental factors.
Supported by: FWO
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DBP and Nfil3/E4BP4 play pivotal roles in circadian regulation of
beta cell function
Y. Tanizawa1, Y. Ohta1, A. Taguchi1, M. Akiyama1, H. Nakabayashi1, T.
Matsumura1, R. Suetomi1, A. Yanai2, K. Shinoda2;
1Department of Bio-Signal Analysis, 2Department of Neuroscience,
Yamaguchi University, Graduate School of Medicine, Ube, Japan.
Background and aims: Disturbances in circadian rhythm regulation
have been implicated in the development of metabolic disorders, includ-
ing diabetes mellitus. The most convincing evidence has emerged from
the study in mice with tissue-specific ablation of Bmal1, one of the core
clock components. However, the detailed links between circadian regu-
lators and downstream targets are poorly understood. Recently, we re-
ported that the expression level of Dbp was decreased and E4bp4 was
increased simultaneously in the islets of Wfs1-/- Ay/a mice, a model of
diabetes. Dbp and E4bp4 are clock-controlled output genes. DBP acti-
vates, whereas E4BP4 reciprocally suppress downstream target genes by
competing the same binding site, D-box. Here, we investigated the roles
of Dbp and E4bp4 in the circadian regulation of ß-cell function.
Materials and methods: We investigated the circadian expression of
Dbp and E4bp4 in pancreatic islets under normal, and restricted feeding
(RF). We generated transgenic mice with beta-cell specific E4bp4 over-
expression (MIP-E4BP4), and examined islet morphological changes and
ß-cell function.
Results: RF caused 6-h phase advances in Bmal1 and Clock expression
and a 12-h phase advance inDbp expression and the bathyphase of E4bp4
expression. The higher sensitivity of the Dbp and E4bp4 to RF compared
with Bmal1 and Clock suggests a role of the Dbp transactivity in the
adjustment in pancreatic ß-cells to changes in food availability. In MIP-
E4BP4 ß-cells, E4BP4 should suppress the expression of targets of the
DBP.We generated 2MIP-E4BP4 lines, TG-C and TG-D. TG-C and TG-
D have 10 and 3 transgene copies, respectively. Real-time RT-PCR con-
firmed 150- or 50- fold up-regulation of E4bp4 in the isolated islets, with
increased corresponding nuclear protein levels. Circadian expression of
Bmal1 and Clock was not altered. Glucose tolerance test revealed mark-
edly impaired glucose tolerance in both of the TG mice with severely
diminished insulin secretion. Glucose excursion in TG-C was higher than
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that in TG-D, suggesting gene-dose dependent effect. We then analyzed
insulin secretion in perfused pancreas. TG-C had markedly reduced and
delayed insulin secretion to 17 mM glucose. MIP-E4BP4 mice were
indistinguishable in body weight from control littermates. We confirmed
a 50% reduction in insulin content in TG-C. The ratio of beta to alpha
cells was significantly decreased and the proportion of islets with alpha-
cells in center was obviously increased in TG-C. Electron microscopy
revealed the total number of insulin granules to be reduced in TG-C ß-
cells. RNA expression of several genes involved in insulin secretion rises
around the beginning of the feeding period and sustains during that peri-
od. In contrast, circadian RNA expression of these genes was diminished
in TG-C islets during the same period. Increase in those RNA transcrip-
tionmight get beta-cells ready to rapidly release insulin preceding feeding
time.
Conclusion: Findings from this genetic model support the premise that
DBP/E4BP4, downstream of the core clock genes, plays essential role in
the regulation of beta-cell function, and therefore occupies a pivotal po-
sition in beta-cell failure following circadian misalignment.
Supported by: Grants from MEXT of Japan
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Glucose-dependent expression of Alx3 in alpha cells inhibits gluca-
gon gene expression via interactions with Pax6
M. Vallejo, M. Mirasierra;
Instituto de Investigaciones Biomedicas Alberto Sols, Madrid, Spain.
Background and aims: The regulation of glucose homeostasis to main-
tain normoglycaemia requires the coordinated activity of insulin and its
counter regulatory hormone glucagon. Defects in insulin synthesis, secre-
tion and/or function resulting in hyperglycaemia have been at the centre
of diabetes research since its discovery. However, the notion that abnor-
mally increased glucagon production and secretionmay play an important
role in the etiopathogenic mechanisms of this disease has gained recog-
nition in recent years. Although glucagon secretion in response to fluctu-
ations in the concentrations of glucose has been widely studied, relatively
less attention has been paid to investigate how changes in glucose levels
regulate glucagon gene transcription. The regulation of glucagon gene
expression in alpha cells involves the binding of several transcription
factors to at least four regulatory elements, named G1-G4, located in
the proximal promoter. Among these transcription factors the paired-
like homeoprotein Pax6 plays a prominent role as a key factor for alpha
cell function. In addition, Alx3, another paired-like homeoprotein known
to be important for glucose homeostasis, appears to regulate glucagon
gene transcription because glucagon expression is decreased Alx3-
deficient mice. In the present study, we aimed to determine the mecha-
nism by which Alx3 regulates glucagon gene expression in alpha cells.
Materials and methods: Isolated mouse islets and alphaTC1 cells were
used. Protein-DNA binding was tested by chromatin immunoprecipita-
tion (ChIP) and electrophoretic mobility shift assays (EMSA). Quantita-
tive RT-PCR and siRNAwere used for expression studies. Student's t test
was used for statistical analysis.
Results: ChIP assays and EMSA demonstrated that Alx3 binds the glu-
cagon promoter at the G3 but not at the G1 element, whereas Pax6 binds
both elements as previously reported. Immunoprecipitations from
alphaTC1 cells as well as GST-pull down assays showed that Alx3 inter-
acts and forms heterodimers with Pax6 via the homeodomain. Alx3-Pax6
heterodimers bind G3, although Alx3 alone is unable to bind this site. In
contrast, Alx3-Pax6 heterodimers cannot bind G1, so that Alx3 inhibits
Pax6 binding to this site. Consistent with this, overexpression of Alx3 in
transfected alphaTC1 cells resulted in decreased glucagon promoter ac-
tivity and inhibition of Pax6-dependent transactivation. Expression of
Alx3 in mouse islets and alphaTC1 cells increased after raising the con-
centration of glucose. This was accompanied by decreased binding of
Pax6 to G1. In cultured islets from wild type mice, glucagon expression
was lower in the presence of 16 mM glucose than in the presence of
2.8 mM glucose. In contrast, changes in glucose concentration had no
effect on glucagon expression in islets from Alx3-deficient mice. In
alphaTC1 cells in which Alx3 expression was silenced by siRNA, ex-
pression of glucagon in the presence of 2.8 mMglucose was lower than in
controls, but in the presence of 16 mM glucose the effect was reversed so
that glucagon mRNA levels were higher than in controls, reflecting avail-
ability of Alx3-free Pax6 for binding to G1.
Conclusion: Our data indicate that glucose stimulates the expression of
Alx3 in alpha cells, resulting in glucose-dependent inhibition of glucagon
gene expression via Alx3-Pax6 interactions on the G1 element. Thus,
Alx3 contributes as a key component to the mechanisms that regulate
glucose-dependent glucagon expression in pancreatic islets.
Supported by: MINECO (BFU2011-24245) and CIBERDEM
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Regulation of glucose-stimulated TXNIP expression by histone ace-
tyltransferase (HAT) p300 and histone deacetylases (HDACs) in pan-
creatic islet cell
Y. De Marinis1,2, P. Bompada1, J. Wright3, D. Atac1, L. Groop1;
1Dept of Clincal Sciences Malmö, 2Diabridge, Malmo, Sweden, 3The
Broad Institute of Harvard and MIT, Cambridge, USA.
Background and aims: Uncontrolled hyperglycemia has been consid-
ered a main reason for beta-cell deterioration over time and referred to as
glucotoxicity. It has been suggested that glucose through epigenetic
mechanisms, i.e. effect on histone marks, influences gene expression.
Here we have used the TXNIP gene as a candidate to study such mech-
anisms as it is known to be upregulated by glucose in islets where it can
induce beta cell apoptosis. We tested whether glucose induced TXNIP
expression by stimulating activating histone mark but also if these effects
of glucose on TXNIP expression could be prevented by a HAT inhibitor
or by mutating the HAT by CRISPR.
Materials and methods:We applied qPCR to determine Txnip mRNA
expression and chromatin immunoprecipitation (ChIP) to study acetyla-
tion at histone 3 lysine 9 (H3K9ac). We also used CRISPR with
sequence-specific gRNAs to mutate HAT p300 in an insulin-producing
rat beta cell line INS1 832/13 cells as an attempt to prevent the effect of
glucose on histone acetylation.
Results: Treatment of INS1 832/13 cells with high glucose (25 mM) for
24 hours resulted in a 30-fold increase in Txnip mRNA expression, and
accordingly a 20% increase of H3K9ac at the 5’-coding region of Txnip.
We then tried to prevent the effect of glucose on Txnip expression by
using the HAT p300 inhibitor C646 to reduce acetylation. Txnip expres-
sion was significantly inhibited by C646 at both 5 mM (by ~40%) and
25 mM glucose (by ~75%). The involvement of HAT p300 in Txnip
expression was further confirmed by ChIP-qPCR using primers flanking
the 5’-coding region of Txnip and showed a 70% down-regulation of
H3K9ac by C646 at 5 mM glucose. However, no reduction in H3K9ac
by C646 was detected at 25 mM glucose. This suggests that high glucose
may also elevate H3K9ac by inhibiting HDACs. To confirm this hypoth-
esis, we mutated p300 in INS1 832/13 cells by creating an indel deletion
at exon1 of the p300 gene (Ep300) using CRISPR/Cas9. Compared to the
wild-type INS1 cells, the Ep300 knockout cells showed almost abolished
Txnip expression (96% reduction) at 5 mM glucose (see Fig), which
correlated with a 70% reduced acetylation at H3K9ac Txnip, indicating
direct involvement of p300 in glucose-induced Txnip expression and
histone acetylation. Furthermore, in these cells Txnip expression was
partially recovered by the HDAC inhibitor CI994 or high glucose with
elevated H3K9ac to the same levels as in wildtype cells. This suggests
that in the absence of p300, glucose-stimulated H3K9ac and thereby
Txnip expression can also be achieved by inhibition of HDACs.
Conclusion:Wedemonstrate that glucose can stimulate Txnip expression
in beta-cells by stimulating an activating histone mark, H3K9ac, involves
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activity of both HAT p300 and HDAC. This study thus points at the
potential of reversing adverse effects of glucose on gene expression by
treatments that can modify these histone effects.
Supported by: ERC, Swedish VR
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Beta cell serotonin during pregnancy: Fact or artifact?
L.Goyvaerts1, K. Lemaire1, J. Van Schoors2, G. Vodjdani3, I. Smolders2,
P. in 't Veld4, A. Schraenen1, F. Schuit1;
1Cellular and Molecular Medicine, KU Leuven, 2Pharmaceutical Chem-
istry and Drug analysis, VUB, Brussels, Belgium, 3Centre de Recherche
de l’Institut du Cerveau et de la Moelle épinière, CNRS, INSERM,
Université Pierre et Marie Curie, Paris, France, 4Diabetes Research Cen-
ter, VUB, Brussels, Belgium.
Background and aims: In pregnant mice, placental lactogen induces
Tph1, the rate-limiting enzyme of serotonin biosynthesis, in a subpopu-
lation of pancreatic beta cells. This physiological process is recapitulated
in non-pregnant mice by the artificial expression of the human growth
hormone (hGH) minigene in many commonly used transgenic driver
lines for islet and diabetes research. hGH has lactogenic effects in the
mouse, by binding to prolactin receptors on beta cells. The physiological
process during pregnancy and the common artifact in genetically modi-
fied mouse models raises the question what the function is of beta cell
serotonin. It was suggested (but not confirmed) that serotonin acts locally
on beta cell proliferation and insulin release. In order to find an answer,
we examined the phenotype of Tph1-deficient mice.
Materials and methods: Beta cell-specific Tph1 knockout mice
(Tph1betaKO) were generated by crossing Tph1fl/fl mice (Dr. Yadav,
Cornell University, US) with Rip-creERR26LacZ mice that do not ex-
press hGH. Second, we re-analysed the total body Tph1KO mice which
have serotonin-negative islets during pregnancy. Quantitative PCR was
performed for islet transcripts encoding Ki-67 and for the 12 most in-
duced genes during pregnancy (“islet pregnancy gene signature”). Islet
serotonin was measured using HPLC and normalized for islet GABA
content. Pancreas sections were used for serotonin immunohistochemis-
try and quantification of Ki-67/insulin double positive cells as an index
for beta cell proliferation.
Results: To our surprise, the Tph1betaKO line maintained high islet
[serotonin]/[GABA] ratios during pregnancy (Tph1betaKO versus Cre-
control p=0.74, Flox-control p=0.27), despite an efficient and islet-
specific recombination of the gene. The underlying mechanism is that
genetic recombination in islets removes exons 2 and 3 of the gene, but
leaves a downstream methionine codon in the correct reading frame for
initiation of translation. Thus, Tph1betaKO beta cells produce a truncated
but catalytically active TPH1. Taking a step back, we therefore used total
Tph1KO mice for further studies. mRNA analysis in pregnant mice
showed that Tph1 was not induced during pregnancy and there was no
compensatory increment in Tph2 in WTmice. All but one of the genes of
the islets pregnancy gene signature remained unchanged in islets from
pregnant Tph1KO mice, the exception being the gene encoding
isovalerate dehydrogenase (Ivd) an enzyme needed for the catabolism
of leucine. Importantly, neither Ki-67 mRNA signal, nor the percentage
Ki-67 positive beta cells was decreased in pregnant Tph1KO mice.
Conclusion: The Tph1betaKO mouse which has already been used in
literature, still has islet serotonin production during pregnancy and there-
fore cannot be used to investigate a serotonin-deficient islet phenotype
during pregnancy. Total body Tph1KO mice with complete disappear-
ance of islet serotonin production during pregnancy were statistically the
same asWTmice in terms of islet Ki-67 mRNA signal and number of Ki-
67-positive beta cells. Together, our data do not support the idea that islet
serotonin stimulates beta cell proliferation during pregnancy.
Supported by: FWO JDRF
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Proinflammatory cytokines disrupt islet gap junction channels and
calcium homeostasis early in development of diabetes in NOD mice
R.K.P. Benninger1, N.L. Farnsworth2, J. St.Clair1;
1Bioengineering, University of Colorado, 2University of Colorado, Au-
rora, USA.
Background and aims: Pro-inflammatory cytokines mediate β-cell de-
cline and islet dysfunction in type1 and type2 diabetes. Cytokines disrupt
islet Ca2+, and disruption to islet Ca2+,are observed in models of type 1
diabetes. In addition, there is a strong Ca2+ dependence to apoptosis
mechanisms. Gap junction channels between islet β-cells regulate
Ca2+, and studies in models of type2 diabetes have indicated their dis-
ruption during disease progression. The goal of this study was to under-
stand the role of altered Cx36 gap junction coupling in islet dysfunction
during the progression of type1 diabetes and how pro-inflammatory cy-
tokines may disrupt coupling.
Materials and methods: Ca2+ signaling, insulin secretion, cell viability
and Cx36 gap junction coupling and Cx36 phosphorylation were mea-
sured in mouse and human islets treated with a cocktail of pro-
inflammatory cytokines (10 ng/mL TNF-α, 5 ng/mL IL-1β,100 ng/mL
IFN-γ), or in islets from NOD and NOD-RAG1ko mice at >6 weeks of
age. Glucose tolerance tests (GTT) were administered in these mice.
Genetic modulators of Cx36 and pharmacological modulators of Cx36,
KATP, PKCδ, iNOS and NO donors/scavengers were also applied. Sta-
tistical significance was determined using ANOVAwith Tukey’s post-hoc
analysis (α=0.05).
Results: Low levels (up to 1/100 dilution) of pro-inflammatory cytokines
disrupted Ca2+ signaling in terms of disrupted oscillations and increased
basal activity (p<0.005). Cx36 gap junction coupling was also reduced
under these conditions in mouse and human islets (p<0.05). This disrup-
tion was dependent on nitric oxide generation, PKCδ activation and
phosphorylation of Cx36 (all p<0.005). Altered Ca2+ signaling (p<
0.05) and decreased Cx36 gap junction coupling (p<0.05) was similarly
observed as early as 6 weeks of age in NOD mice prior to the emergence
of diabetes but in the presence of disruptions to glucose tolerance. Gap
junction coupling, Ca2+ dynamics and glucose tolerance further declined
with increasing age, prior to the onset of diabetes. Increased gap junction
coupling in mouse and human islets reduced cytokine-induced disrup-
tions to insulin release andβ-cell death (p<0.05). Decreased gap junction
coupling inmouse islets increased cytokine-induced disruptions to insulin
release and β-cell death (p<0.05). This increase was reversed through
inhibiting depolarization-induced Ca2+ elevations by KATP activation
(p&gt0.1).
Conclusion: This study shows that gap junction coupling and Ca2+
regulation is highly-sensitive to disruption by conditions associated with
the development of type1 diabetes, and discovers the mechanisms under-
lying its disruption in mouse and human models. This study also suggests
this loss of gap junctions exacerbates cytokine-induced islet dysfunction
and β-cell death later in disease progression through Ca2+ dependent
mechanisms. As elevated gap junctions protects against this, this may
provide a therapeutic target for delaying the onset of diabetes. Defining
themechanisms underlying gap junction disruption, may provide a means
to modulate gap junctions for such a therapeutic strategy.
Supported by: NIH R00 DK085145, NIH F32 DK102276, JDRF 5-CDA-
2014-198-A-N
458
Overexpression of Fis1 leads dose-dependently to alterations of mi-
tochondrial morphology and impairment of glucose-stimulated insu-
lin secretion in INS1E beta cells
J. Schultz, T. Kantowski, R. Waterstradt, S. Baltrusch;
Institut of Medical Biochemistry and Molecular Biology, Rostock, Ger-
many.
Background and aims: Mitochondria in living cells exist as a dynamic
network that continuously cycle through fusion and fission events. Mito-
chondrial fission is mainly regulated by three proteins, the fission protein
1 (Fis1), the dynamin-related protein 1 (Drp1) and the mitochondrial
fission factor (Mff). Numerous studies indicate that Fis1 is the key regu-
lator for mitochondrial dynamics and, thus, essential to maintain mito-
chondrial function. Recent data questioned the need of Fis1 for mitochon-
drial network integrity and eventually proper insulin secretion in pancre-
atic beta cells. Therefore, the aim of this study was to investigate changes
in the mitochondrial network structure and cellular function after overex-
pression of Fis1 in INS1E cells.
Materials and methods: Overexpression of Fis1 in INS1E cells was
achieved by the pLUX lentiviral vector system. Scrambled lentiviral par-
ticles were used as control. Gene expression of Fis1 was carried out by
quantitative Real-Time PCR and the protein level of Fis1 was determined
using western blot and immunofluorescence analyses. The ATP content
was measured using the ATPlite assay and glucose-stimulated insulin
secretion by ELISA. The mitochondrial membrane potential and mito-
chondria morphology was analyzed bymeans of TMRE andMitoTracker
Green, respectively.
Results: Lentiviral Fis1 overexpression of resulted in significantly en-
hanced gene and protein expression of Fis1 compared to control infected
cells.We observed an impairment of ATP content andGlucose-stimulated
insulin secretion was significantly impaired after enhancement of Fis1 in
INS1E cells, whereas the control cells respond to the glucose stimulus.
The ATP content was markedly reduced in Fis1 overexpressing cells
compared to control infected cells. Likewise, the mitochondrial mem-
brane potential and glucose content was significantly reduced in cells
overexpressing Fis1 compared to control infected cells. INS1E cells as
well as control infected cells showed an interconnected mitochondrial
network with a homogenous structure. In contrast, a 10-fold overexpres-
sion of Fis1 resulted in fragmentation of mitochondria. Higher level of
overexpression evoked dose-dependently formation of mitochondrial
perinuclear clusters. In addition, we observed enhanced loop formation
of mitochondria in cells with overexpression of Fis1.
Conclusion: Our results suggest that Fis1 is certainly important for beta
cell metabolism and proper glucose-stimulated insulin secretion. Because
the enhanced expression of Fis1 evoked a strong change in the mitochon-
drial morphology of INS1E cells, we propose to further characterize the
role of Fis1 in regulation of mitochondrial dynamics and function in
pancreatic beta cells in healthy and type 2 diabetic subjects.
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Oxidative stress induced-autophagy might involve in pancreatic beta
cells remodelling during neonatal mice through p53/pAMPK/
mTOR/ Beclin1 pathway
X. Wu1, L. Gao1, H. Zhang1, H. Shi1, J. Zhao1, X. Zhao1, K. Xu1, M.
Woo2;
1Department of Endocrinology, First Affiliated Hospital with Nanjing
Medical University, China, 2Division of Endocrinology, Department of
Medicine, Toronto General Hospital, Toronto General Research Institute,
Canada.
Background and aims: Pancreatic beta cells undergo dynamic remod-
eling during neonatal period to meet the increased physiological demands
after weaning, with decreased proliferation, neogenesis and enhanced
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apoptosis. Autophagy, a catabolic process of the lysosomal degradation of
cellular components, has been found to be crucial in beta cell survival/
function and body metabolism. However, whether autophagy involves in
neonatal beta cells remodeling is unknown. This study was designed to
explore the function and related molecular mechanisms of autophagy in
beta cells remodeling during neonatal period.
Materials and methods: Mice islets at 1-, 3-, 8-week after birth were
isolated by collagenase. The morphological structure of autophagosome
was observed by electron microscope.Double immunofluorescence stain-
ing was performed for insulin with LC3. The expression of autophgy-
related genes were detected by real-time quantitative PCR.The expression
of the p53/pAMPK/mTOR/Beclin1/LC3-II proteins was detected by
Western blotting. The expression of malondiadehyde (MDA) and nico-
tinamide adenine dinucleotide phosphate (NADPH) oxidase subunits
p22phox of islet cells were detected by lipid oxidation kit and immuno-
histochemistry respectively. Hydrogen peroxide (H2O2)- stimulated INS-
1 cells were applied as a cell model of oxidative stress on beta cells. INS-1
cells were treated with PFT-α (the inhibitor of p53), the change of protein
expression of p53/pAMPK/mTOR/Beclin1/LC3-II was detected by
Western blotting.
Results: (1) Compared with 1 w and 8 w, the typical doubled-membrane
autophagosome appeared within cytoplasm of islet cells at 3 w, the ex-
pression of p22phox , MDA and insulin+/LC3+ cells was significantly
increased (P<0.01) (2) The mRNA level of p53 was higher at 3 w than
that at 1 w and 8 w (P<0.05), while mTORwas lower than that at 1 w and
8 w (P<0.01). The mRNA expression of the autophagy-related genes
dynamically changed. Compared with 1 w and 8 w, the mRNA levels
of ULK1, Becn1 and Map1lc3b markedly increased at 3 w (P<0.05).
Compared with 1 w, the levels of pik3c3, Atg5, Map1lc3a and Atg16l1
increased at 3 w (P<0.05); the mRNA level of Atg4d was significantly
increased at 3 w and 8 w (P<0.05). At 3 w, the mRNA expression of
Atg4c was higher than that at 8 w (P<0.05). (3)Western blot showed that
compared with 1 w and 8 w,the protein levels of p53, pAMPK, Beclin1
and LC3-II were markedly increased at 3w (P<0.01), while mTOR pro-
tein significantly decreased at 3 w (P<0.01). (4) TheMDA level of INS-1
cells after H2O2 stimulation was markedly increased in a dose dependent
manner (P<0.01), along with the markedly increased expression of LC3-
II and p53. With the inhibitor of p53 to block the signaling pathway, the
protein expression of p53/pAMPK/Beclin1/ LC3II were significantly de-
creased, but the expression of mTOR increased in H2O2-stimulated INS-
1 cells (P<0.05).
Conclusion: Both autophagy and oxidative stress increase in islet cells at
3-week after birth. Oxidative stress induced-autophagy might involve in
pancreatic beta cells remodeling during neonatal mice through p53/
pAMPK/mTOR/Beclin1 pathway.
Supported by: NSFC(81261120566)
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Evidence of beta cells dedifferentiation in human type 2 diabetes
F. Cinti1, R. Bouchi2, J. Kim-Muller2, L.E. Ratner2, M. Suleiman3, M.
Masini3, L. Marselli3, P. Marchetti3, D. Accili2;
1UnivPM-Department of Experimental and Clinical Medicine, Ancona,
Italy, 2Columbia University, New York City, USA, 3University of Pisa,
Italy.
Background and aims: Diabetes is associated with a deficit of insulin-
producing β cells. Animal studies show that β cells become
dedifferentiated in diabetes, reverting to a progenitor-like stage, and partly
converting to other endocrine cell types. To determine whether similar
processes occur in human type 2 diabetes, we surveyed pancreatic islets
from 15 diabetic and 15 non-diabetic organ donors.
Materials and methods: We scored dedifferentiation, by immunohisto-
chemistry, using markers of endocrine lineage (Synaptophysin and
Chromogranin A), β cell-specific transcription factors (NKX6.1,
FOXO1,MafA), and a newly identified endocrine progenitor cell marker,
aldehyde dehydrogenase 1A3 (ALDH1A3).
Results: Dedifferentiated cells, defined as Synaptophysin-positive/hor-
mone-negative cells, accounted for 31.9% of β cells in type 2 diabetics
vs. 8.7% in controls (p<0.001). The expression and localization of tran-
scription factors required for maintenance of β cells in rodents (FOXO1,
NKX6.1, and MAFA) were altered in 84% of insulin positive cells in
diabetics (p<1×10-5) and associated with the expression of the progen-
itor cell marker ALDH1A3. Interestingly, insulin secretion in response to
glucose was inversely correlated with the dedifferentiation score (r=0.55,
p<0.05). Moreover, β cell-specific transcription factors were ectopically
found in glucagon- and somatostatin-producing cells of diabetic subjects.
Conclusion: The data support the view that pancreatic β cells become
dedifferentiated and convert to α- and δ-“like” cells in human type 2
diabetes. We envision dedifferentiation as a mechanism to protect β cells
from apoptosis by stealth, preserving them for re-differentiation under
more favorable metabolic conditions. The findings should prompt a reas-
sessment of goals in the prevention and treatment of β cell dysfunction.
Supported by: NIH, JDRF, Brehm Coalition, JPB foundation
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Palmitate-induced impairment of glucose-stimulated insulin secre-
tion by pancreatic beta cells is disconnected from concomitant mito-
chondrial respiratory defects
C. Affourtit1, J. Barlow1, V. Hirschberg Jensen1, M. Jastroch2;
1Plymouth University, UK, 2Institute for Diabetes and Obesity, Helm-
holtz Zentrum Muenchen, Germany.
Background and aims: Pancreatic beta cell mitochondria couple the
oxidative breakdown of glucose to the synthesis of ATP and are essential
for glucose-stimulated insulin secretion (GSIS). Indeed, mitochondrial
respiratory activity might prove a good indicator of functional beta cell
integrity, and insight in islet respiration may thus benefit transplantation
protocols. With this study we aimed to clarify the connection between
mitochondrial function and GSIS in pancreatic beta cells subjected to
glucolipotoxic conditions.
Materials and methods: Islets isolated from C57BL/6 mice and INS-1E
insulinoma cells were exposed for 24 or 48 hr to BSA-conjugated palmi-
tate (free concentration 20-40 nM) in the presence of 11 mM glucose.
Glucose sensitivity of oxidative phosphorylation was derived from abso-
lute oxygen uptake rates measured in a Seahorse XF24, and insulin was
quantified by ELISA. Respiratory activity and insulin secretion were
normalised to islet DNA or INS-1E cell number determined from
PicoGreen and DAPI fluorescence, respectively. Significance of palmi-
tate effects was evaluated with Student’s t-tests.
Results: Islets exposed to palmitate for 48 hr consume oxygen at a rate of
3.9±0.5 pmol oxygen x min-1×ng DNA-1 when incubated at 5.5 mM
glucose. This respiratory rate is corrected for non-mitochondrial oxygen
uptake and is indistinguishable from that exhibited by control islets ex-
posed to BSA alone. Basal mitochondrial respiration increases to 8.2±1.5
and 6.4±0.8 pmol oxygen × min-1×ng DNA-1 in control and palmitate-
exposed islets, respectively, when glucose is raised to 28 mM. Normal-
ised to basal mitochondrial oxygen uptake, palmitate lowers the islets’
respiratory response to glucose from 2.5- to 1.7-fold (P<0.05). This re-
spiratory defect is echoed by GSIS impairment: 48-hr palmitate exposure
lowers the islet insulin secretory response to glucose from 10.5-fold±1.8
to 3.4-fold±0.6 (P<0.001). GSIS impairment results from an inhibitory
palmitate effect (P<0.01) on absolute insulin secretion at 28 mM glucose
and a stimulatory effect (P<0.001) on absolute basal insulin release at
5.5 mM glucose. GSIS impairment is also apparent after 24-hr palmitate
exposure when the islet insulin secretory response to glucose has been
lowered from 6.5-fold±0.5 to 3.5-fold±0.6 (P<0.01). Importantly, after
this relatively short exposure, palmitate has not yet significantly affected
islet mitochondrial respiration. A disconnect between palmitate-induced
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respiratory defects and GSIS impairment is also seen in INS-1E cells.
After 24-hr exposure, palmitate lowers the insulin secretory response
(secretion at 28 mM glucose normalised to insulin release by nutrient-
starved cells) from 4.4-fold±1.1 to 1.2-fold±0.1 (P<0.05). This GSIS
annulment results from palmitate stimulation of basal insulin release (P
<0.05) and a small non-significant inhibition (P=0.45) of insulin secre-
tion at 28 mM glucose. Concomitantly, palmitate lowers the normalised
mitochondrial respiratory response to glucose of nutrient-starved INS-1E
cells from 1.7±0.1 to 1.2±0.1 (P<0.05). This respiratory defect is exclu-
sively caused by an inhibitory effect (P<0.01) of palmitate on absolute
respiration at 28 mM glucose.
Conclusion: Palmitate-induced GSIS impairment in pancreatic beta cells
is disconnected from mitochondrial respiratory defects.
Supported by: the Medical Research Council (UK) grant G1100165
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Improved human type 2 diabetes beta cell function and survival by
autophagy induction
M. Bugliani1, M. Masini1, F. Syed1, S. Mossuto1, M. Suleiman1, L.
Marselli1, U. Boggi1, F. Filipponi1, D.L. Eizirik2, M. Cnop2, V. De Tata1,
P. Marchetti1;
1University of Pisa, Italy, 2Universitè Libre de Bruxelles, Belgium.
Background and aims: Cells degrade and recycle their components by
autophagic processes. Autophagy alterations have been proposed to also
cause beta cell dysfunction thato lead to type 2 diabetes (T2D). We eval-
uated the effects of autophagy modulation in islets prepared from T2D
and non-diabetic (ND) human donors, studied under several different
experimental conditions.
Materials andmethods: Islets were isolated from 5 T2D (age: 77±7 yrs;
gender: 3 M/2 F; BMI: 23.9±3.7 Kg/m2) and 17 non-diabetic (ND; age:
65±21 yrs; gender: 5M/12 F; BMI: 23.4±3.3 Kg/m2) organ donors. T2D
and/or ND islets were then cultured for 1-5 dayswith 10 ng/ml rapamycin
(autophagy inducer), or 5 mM 3-methyl-adenine (3MA) and 1.0 nM
concanamycin-A (ConcA) (autophagy blockers), either in the presence
or absence of metabolic (0.5 mM palmitate) or chemical (0.1 ug/ml
brefeldin A) inducers of endoplasmic reticulum (ER) stress.
Results: Compared to untreated T2D islets, rapamycin exposed (24 h)
diabetic islets showed improved insulin secretion (glucose-induced insu-
lin stimulation index from 1.6±0.8 to 2.1±1.1, p=0.05), reduced percent-
age of β cells showing signs of apoptosis (from 6.6±1.7 to 2.0±0.8% by
electron microscopy, p<0.05) and better preserved insulin granules, mi-
tochondria and ER ultrastructure. This was associated with significant
reduction of PERK, CHOP and Bip gene expression (qRT-PCR). As
expected, in ND islets palmitate exposure (5 days) induced a 4-5 fold
increase of beta cell apoptosis (from 0.4±0.2 to 2.0±0.8%, p<0.01); this
deleterious action was prevented by rapamycin (0.3±0.3%) and signifi-
cantly exacerbated by 3-MA (7.0±1.1%) and ConcA (3.1±1.1%). Sub-
stantially similar results were observed with brefeldin treatment (24 h).
Glucose-stimulated insulin secretion from ND islets was reduced by pal-
mitate (40-50%) and brefeldin (60-70%); rapamycin prevented palmitate
cytostatic action, but affected brefeldin effects marginally. Both palmitate
and brefeldin induced PERK, CHOP andBip gene expression, whichwas
partially, but significantly prevented by rapamycin.
Conclusion: This study emphasizes the importance of autophagy in hu-
man beta cell function and survival, particularly in situations of ER stress.
Modulation of autophagy could be a tool for beta cell protection
strategies.
Supported by: IMIDIA
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Mitochondrial dysfunction and diabetes predisposition
A. Kogot-Levin, I. Raz, S.W. Zangen;
Diabetes Unit, Hadassah University hospital, Jerusalem, Israel.
Background and aims: Pancreatic β-cells couple mitochondrial oxida-
tion of glucose to ATP with insulin secretion. The Cohen diabetic sensi-
tive rat (CDs), a genetic model of diet-induced diabetes, develops hyper-
glycemia when fed a diabetogenic, high sucrose diet (HSD) but maintains
normoglycemia on regular-diet (RD). We previously demonstrated in
CDs rats reduced glucose stimulated insulin secretion (GSIS) in associa-
tion with altered mitochondrial morphology. We aim to examine islet-
mitochondrial function and biogenesis in CDs and its role in diabetes
development in CDs rats.
Materials and methods: Pancreatic islets were isolated from CDs and
non-diabetic control rats fed 30 days RD, or a HSD. Activity of islet-
mitochondrial respiratory chain enzyme, cytochrome-c oxidase (COX,
complex IV), normalized to activity of citrate-synthase (CS) was deter-
mined spectrophotometrically. Gene expression was analyzed by qRT-
PCR. Protein level was determined byWestern-blot analysis. ATP content
was measured by the luciferin-luciferase luminescence assay.
Results: Complex IVactivity was ~50% reduced (P<0.01 vs. control) in
islets isolated from normoglycemic-CDs fed RD, maintaining only small
residual activity (~15%) in islets of hyperglycemic-CDs rats fed HSD.
ATP content was 20% lower (P<0.01 vs. control) in islets of
normoglycemic-CDs markedly reducing on HSD (60%, P<0.01 vs. con-
trol). Expression of complex IV subunits; COX2, COX4 and COX5bwas
decreased (P<0.01) in islets of normoglycemic-CDs-rats, decreasing fur-
thermore on the diabetogenic-diet. Gene-expression of complex IV as-
sembly chaperones (COX10, COX11, COX17 and SCO1) was unaltered
in islets of normoglycemic-CDs rats. COX17 expression was 50% re-
duced in islets of hyperglycemic-CDs while the expression of the other
the COX assembly factors were unchanged. COX1 protein levels was
lower in islets of normaglycemic-CDs decreasing furthermore in islets
of hyperglycemic-CDs rats. CDs-islet expression of mitochondrial bio-
genesis activators (NRF1, NRF2 and TFAM) was decreased; while PGC-
1α expression and protein levels as well as islets mtDNA content were
unchanged.
Conclusion:We found a tight association between the significant reduc-
tion in islets-COX activity and GSIS in normoglycemic-CDs rats. Our
data suggest that combination between reduced COX activity and mito-
chondrial biogenesis sets a congenital low mitochondrial threshold in
islets of CDs rats. The low islet-COX threshold probably plays a critical
role in the inability of the β-cells to secrete sufficient insulin to maintain
the plasma glucose concentrations within the normoglycemic-range when
exposed to a diabetogenic diet. The Cohen diabetic rat represents an
interesting model to study molecular pathways underlying reduced GSIS
and provides a good model to examine novel therapeutic intervention
aimed at improving β-cell function.
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Coxsackievirus B5 infection and CVB5 proteases 2A and 3C both
increase caspase 3/7 activity independently from apoptosis and re-
duce insulin granule cargoes in beta cells
A. Petzold1, K.-P. Knoch1, A. Sönmez1, C. Wegbrod1, C. Münster1, A.
Friedrich1, M. Roivainen2, M. Solimena1;
1Paul Langerhans Institute Dresden of the Helmholtz Center Munich, at
University Clinic and Faculty of Medicine, TUD, Germany, 2National
Institute for Health and Welfare, Helsinki, Finland.
Background and aims: Type 1 Diabetes (T1D) results from the autoim-
mune destruction of pancreatic beta cells. Major cargoes of the beta cell
secretory granules (SGs), namely proInsulin/Insulin, ICA512/IA-2 and
ZnT8/SLC308A are dominant autoantigens of T1D, but the reason(s)
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for their preferential targeting by autoimmunity is unknown. Human En-
teroviruses (HEVs), like Coxsackievirus B (CVB) are among the candi-
date environmental agents triggering and/or accelerating the development
of T1D. However, the relationship between HEV infection and loss of
self-tolerance toward SG cargoes is unclear. We previously showed that
CVB5 infection of rodent islets and insulinoma cells inhibited the
glucose-induced rapid up-regulation of total protein biosynthesis, but
not that of SG precursor proteins, including proInsulin, proICA512,
proPC1/3, proPC2 and proChromograninA. The corresponding mature
SG cargoes and Insulin release were instead dramatically reduced. Thus,
we investigated if and how HEV infection affects the expression of SG
autoantigens that may favor their targeting by the immune system.
Materials and methods: Mouse insulinoma MIN6 cells were infected
with Faulkner (F) or MIN6 cell adapted (MCA) CVB5 serotypes and
compared to non-infected cells 96 h post-infection. Mouse pancreatic
islets were harvested 72 h post-infection with CVB5 strains. MIN6 cells
transfected with CVB5 proteases 2A and 3C were compared to mock
transfected cells 96 h post-transfection. Proteasome activities were mea-
sured by luminescence assays and protein expression by immunoblotting.
Results: The reduction of mature SG proteins upon CVB5 infection was
insensitive to proteasome inhibitors MG-115 and MG-132. However, in
CVB5-infected cells the increased Caspase-, Trypsin- and Chymotrypsin-
like proteolytic activities associated with the proteasome were insensitive
to these inhibitors. CVB5-infection increased also Caspase 3/7 activity,
which however was mostly insensitive to Caspase 3/7 inhibitor and not
associated with enhanced apoptosis, as assessed by TUNEL and Annexin
V staining, while necrosis was increased. Accordingly, cleavage of apo-
ptotic markers Caspase 3/7 and Poly (ADP-ribose) polymerase (PARP)
was not detected. Finally, the levels of Major Histocompatibility Com-
plex class I molecules (MHC class I) were unchanged in CVB5 infected
insulinoma cells, but increased in CVB5-infected mouse islets. Remark-
ably, expression of CVB5 proteases 2A and 3C, similarly to CBV5 in-
fection, was sufficient to reduce the levels of mature SG proteins inMIN6
cells. Likewise, in proteases 2A and 3C transfected cells Caspase-,
Trypsin- and Chymotrypsin-like activities associated with the proteasome
as well as Caspase 3/7 activity were increased, albeit not apoptosis.
Conclusion:Our findings suggest that CVB5 proteases 2A and 3C target
SG cargoes to massive degradation in conditions of reduced translation of
housekeeping proteins, thus poising infected beta cells for preferential
presentation of SG protein-derived peptides on MHC class I.
Supported by: German Center for Diabetes Research (DZD e.V.) - PLID
PS 027 Beta cell injury: lipotoxicity
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Role of PIAS1 in palmitate mediated beta cell dysfunction
A.I. Chowdhury1, K. Hörnaeus2, J. Bergquist2, P. Bergsten1;
1Medical cell biology, 2Chemistry Biomedical centre and SciLifeLab,
Uppsala University, Sweden.
Background and aims: Elevated circulating free fatty acid levels, in
particular palmitate, have been connected with development of type 2
diabetes mellitus (T2DM). The notion is supported by observed beta-
cell dysfunction in islets after long-term treatment with palmitate. The
protein inhibitor of activated STAT (PIAS) family consists of four mem-
bers. Initially identified as negative regulators of STAT mediated signal-
ing, they have since been implicated in regulating many transcription
factors by blocking DNA binding activity, recruiting transcriptional co-
repressors or co-activators and promoting protein sumoylation through
SUMO E3 ligase activity. In a recent study PIAS1 suppressed the tran-
scriptional activity of liver X receptor (LXR) in hepatocytes. LXR is
involved in integrating lipid metabolism and the potential role of PIAS1
in lipid metabolism made us investigate the role of PIAS1 in islet dys-
function induced by chronically elevated palmitate levels.
Materials and methods: Human islets were cultured in the presence or
absence of palmitate for 7 days. After culture, glucose-stimulated insulin
secretion was measured by ELISA and levels of various proteins by
western blot. PIAS1 interacting proteins were pulled down and identified
using LTQ-Orbitrap mass spectrometer.
Results:Glucose-stimulated insulin secretion was decreased by 50% and
apoptosis increased by 40% in human islets after long-term palmitate
treatment. PIAS1 was present at the protein level in control islets and
the level almost doubled after treatment with the fatty acid. PIAS1
interacting proteins included ATP citrate lyase (ACLY) and ATP synthase
subunit 5 beta (ATP5B). In islets treated with palmitate the two proteins
were significantly reduced. Overexpressing PIAS1 in beta-cells signifi-
cantly reduced ACLYand ATP5B. Consistent with reduced ACLY levels
in islets exposed to palmitate, levels of acetyl-CoA carboxylase (ACC)
and fatty acid synthase (FAS) were also reduced in islets treated with the
fatty acid.
Conclusion: Long-term palmitate treatment of islets increased levels of
PIAS1, which in turn decreased ACLY and ATP5B protein levels impli-
cating decreased lipogenesis as well as ATP synthesis. Elevated PIAS1
levels may thus contribute to altered lipid and energy metabolism reduc-
ing GSIS and increasing apoptosis.
Supported by: Beta-JUDO (EU FP7), Swedish Medical Research Council
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Eukaryotic translation initiation factor 2A (eIF2A) protects pancre-
atic beta cells from ER stress-induced apoptosis by selective regula-
tion of translational initiation
E. Panzhinskiy1, F. Taghizadeh1, Y. Yang1, B. Hu1, J.D. Johnson1, E.
Jan2;
1Cellular and Physiological Sciences, 2Biochemistry, University of Brit-
ish Columbia, Vancouver, Canada.
Background and aims: Endoplasmic reticulum (ER) stress plays impor-
tant role in beta cell death in diabetes. ER stress leads to activation of the
unfolded protein response (UPR), which inhibits protein translation via
phosphorylation of eIF2α, and if unresolved induces apoptosis. eIF2A
has been implicated in the translation of specific mRNAs under stress
conditions, such as viral infection, when general translation is suppressed.
Therefore, our specific hypothesis was that eIF2A plays a key role in
regulation of mRNA translation during UPR in beta cells.
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Materials and methods: Thapsigargin (Tg, 1 μmol/l), palmitate (PA,
0.5 mmol/l in BSA) were used to induce ER stress in mouse insulinoma
cells (MIN6), primary mouse and human islets. Real-time RT-PCR and
Western Blot were used to assess gene expression. Spinning disc confocal
microscopy and ER tracker Blue-White DPX (Molecular Probes) were
used for subcellular localization studies. Plasmid encoding GFP-tagged
eIF2Awas transfected using electroporation and cells were FACS sorted
72 hr later for the experiments. Apoptosis was assessed by live cell im-
aging of propidium iodide stained cells. Insulin secretion assay was per-
formed using RIA. To assess protein synthesis cells were treated with 35S
Met/Cys DMEM for 30 min, protein samples were collected and separat-
ed using SDS-PAGE, and radiation quantified.
Results:We showed that mRNA (3.7±0.5-fold, n=3) and protein (2.3±
0.3-fold, n=6) expression of eIF2Awas up regulated in MIN6 beta cells
treated with Tg, suggesting an association with the UPR. PA also in-
creased protein expression of eIF2A by 2.1±0.1 fold (n=3). The findings
were confirmed using isolated mouse and human islets treated with Tg
and PA. We found that eIF2A was predominantly localized in the ER
under basal and UPR conditions (67.1±13% n=10). We showed 94.3±
5.1% (n=3) reduction in thapsigargin-induced apoptosis in MIN6 cells
overexpressing eIF2A (4-fold). On the protein level reduced death of beta
cells was associated with 90.5±6.1% (n=3) decrease in protein expres-
sion of UPR pro-apoptotic marker CHOP. However eIF2A overexpres-
sion had no effect on induction of transcription of CHOP mRNA during
UPR, indicating specific role of eIF2A in the inhibition of stress-induced
translation of CHOP mRNA. Tg decreased insulin secretion by 54±11%
(n=3) in MIN6 cells, however it was only decreased by 21±17% in cells
overexpressing eIF2A. MIN6 cells showed decreased protein synthesis
rate by 80.2±10% (n=3) after 2 hours of Tg treatment. However protein
synthesis rate was unchanged in cells overexpressing eIF2A, despite nor-
mal induction of eIF2α phosphorylation after Tg treatment. Immunopre-
cipitation of eIF2A showed increase in the interaction of eIF2A with
eIF2α during UPR in MIN6 cells with the maximum of 5.9±1.1 fold
increase (n=3) after 24 hr of Tg treatment, which might explain
uncoupling of translational initiation from eIF2α phosphorylation in cells
overexpressing eIF2A.
Conclusion:We conclude that eIF2A improves function of beta cells and
prevents UPR-induced apoptosis.We identified a novel protective role for
eIF2A in the context of ER-stressed beta cells via the selective inhibition
of CHOP mRNA translation and prevention of global translation attenu-
ation. Thus, eIF2A may potentially serve as a new therapeutic target in
diabetes.
Supported by: CDA
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Lipotoxic stress induces pancreatic beta cell apoptosis through mod-
ulation of BCL-2 proteins by the ubiquitin-proteasome system
E.N. Gurzov, S.A. Litwak, J.A. Wali, E.G. Pappas, H. Saadi, W.J. Stan-
ley, L.C. Varanasi, T.W.C. Kay, H.E. Thomas;
Immunology and Diabetes Unit, St Vincent's Institute, Melbourne, Aus-
tralia.
Background and aims: Previous studies have shown induction of endo-
plasmic reticulum (ER) stress, increased levels of ubiquitinated proteins,
and deregulation of the Bcl-2 protein family in the pancreas of type 2
diabetic patients. Here, we evaluated the role of the saturated free fatty
acid (FFA) palmitate in modulation of the ubiquitin-proteasome system
(UPS) and β-cell apoptosis.
Materials and methods: UPS activity was assessed by immunohisto-
chemistry in lean and obese human and mouse samples. Real time PCR,
Western blot, and viability assays were performed to study the molecular
mechanism of palmitate-induced β-cell death in human and mouse islets
and MIN6 cells. β-cell function and islet apoptosis triggered by diabeto-
genic conditions were analysed in Bcl-2 transgenic mice (RIP-Bcl-2).
Results: To examine the effect of obesity on the UPS in islets, we stained
pancreatic sections of lean and obese [body mass index (BMI)>25 kg/
m2] humans with anti-ubiquitin antibody. In obese human samples, there
was an increased prevalence of ubiquitinated proteins in pancreatic islets
when compared to lean controls. Similar results were obtained in
pancreata from mice fed a high fat diet for 24 weeks. To determine
whether exposure to increased FFAs had a role in the increased ubiquitin
staining observed in obese subjects, human islets were treated with pal-
mitate and levels of ubiquitinated proteins weremeasured byWestern blot
analysis. We observed an increase in the levels of ubiquitinated proteins
after palmitate treatment in human islets. Similar results were obtained in
mouse islets andMIN6 cells (1.5 fold increase in ubiquitination, n=4, p<
0.05). Moreover, after 24 h treatment with either palmitate or the UPS
inhibitor MG132, there was a significant increase in cell death (15% cell
death in palmitate-treated cells, 28% cell death inMG132-treated cells, 1-
2% cell death in control cells, n=5, p<0.001). Palmitate or MG132 treat-
ment induced ER stress in β-cells (ATF4, Chop and Bip activation),
resulting in decreased expression of the pro-survival proteins Bcl-2 and
Bcl-XL, and upregulation of the pro-death BH3-only protein PUMA. On
the other hand, pharmacological activation of the UPS by sulforaphane
(SFN) ameliorated ER stress, upregulated anti-apoptotic Bcl-2 proteins
and protected β-cells from palmitate-induced cell death (21% cell death
in palmitate-treated cells, 7% cell death in palmitate and SFN-treated
cells, 3-4% cell death in control cells, n=5, p<0.05). Furthermore, trans-
genic overexpression of Bcl-2 protected islets from apoptosis in vitro
(45% cell death in palmitate-treated wild-type islets, 32% cell death in
palmitate-treated RIP-Bcl-2 islets, 16-22% cell death in control islets, n=
4, p<0.05) and improved glucose-induced insulin secretion in vivo.
Conclusion: Our results suggest that the FFA palmitate inhibits the UPS,
causing β-cell apoptosis, and that this effect could be reversed by activa-
tion of the proteasome. The mechanism of β-cell death involves the
deregulation of Bcl-2 proteins via activation of ER stress signaling. In
this context, overexpresison of the pro-survival protein Bcl-2 improved
β-cell function in a mouse model of obesity. Overall, our data clarify the
mechanism by which FFAs induce β-cell death and provide therapeutic
targets to improve glucose homeostasis in type 2 diabetes.
Supported by: NHMRC Grant APP1071350
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Role of Sirtuin 3 (Sirt3) in the regulation of pancreatic beta cell
function
Y. Zhou1, A.C.K. Chung1,2, H. Lee1, G. Xu1,3, J.C.N. Chan1,4, A.P.S.
Kong1,4;
1Department of Medicine and Therapeutics, The Chinese University of
Hong Kong, Shatin, 2Partner State Key Laboratory of Environmental and
Biological Analysis, The Hong Kong Baptist University, Kowloon Tong,
3School of Chinese Medicine, The Hong Kong Baptist University, Kow-
loon Tong, 4Li Ka Shing Institute of Health Sciences, The Chinese Uni-
versity of Hong Kong, Shatin, Hong Kong.
Background and aims: Pancreatic beta cells play an important role in the
pathogenesis of type 2 diabetes (T2D). Beta cells are extremely vulnera-
ble to pathological conditions such as hyperglycemia and hyperlipidemia.
Sirt3 is a mitochondrial deacetylase which regulates a series of cell met-
abolic pathways including glucose and fatty acid oxidation. We aimed to
investigate the role of Sirt3 in the regulation of beta cell function.
Materials and methods: Sirt3 mRNA and protein expression levels of
MIN6 pancreatic beta cell line and isolated mouse islets were measured
after free fatty acid (FFA) treatment. Sirt3 was overexpressed or knocked
down in MIN6 cells and primary islets to evaluate its role on beta cell
function. Sirt3 knockout (KO) mice and wild type (WT) mice were treated
with high fat diet (HFD) or standard diet (STD) for 3 months (n=7 for each
STD feed group, n=8 for each HFD feed group). Body weight and blood
glucose levels were measured every week. Oral glucose tolerance test
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(OGTT) and insulin tolerance test (ITT) were performed after mice were
fed with STD or HFD. During OGTT, blood samples were collected for
insulin level determination in addition to blood glucose measurements.
Results: Exposure of MIN6 cells and primary islets to FFA decreased
Sirt3 expression and impaired glucose stimulated insulin secretion
(GSIS). However, overexpression of Sirt3 partially rescued FFA induced
impairment on insulin secretion. This protective effect was abolished after
intervention with protein kinase A (PKA) specific inhibitor H89. Knock
down of Sirt3 in MIN6 cells attenuated glucose stimulated ATP genera-
tion (7.00±0.49 vs. 4.71±0.38 pmol/μg protein, p<0.001), CREB phos-
phorylation and PPARγ expression. Besides, the GSIS ofMIN6 cells was
also decreased after Sirt3 siRNA transfection (1.13±0.32 vs. 0.58±
0.15 ng/μg protein, p<0.05). Similar changes were observed in islets
isolated from Sirt3 KO mice. However, these impairments in beta cells
function were ameliorated after re-expression of Sirt3 in Sirt3 KO islets
via Sirt3 adenovirus infection. After 3 months of HFD feeding, glucose
tolerance of both Sirt3 KO and WT mice were impaired with a higher
magnitude observed in Sirt3 KO mice (glucose AUC: HFD feed WT vs.
KO=1102±88.42 vs. 1328.25±52.22 mmol•L-1•min-1, p<0.05). In addi-
tion, the fasting serum insulin level was decreased in Sirt3 KO mice
compared with WT mice after both STD and HFD feeding (STD feed
WT vs. KO=0.033±0.012 vs. 0.0042±0.00060 ng/ml, p<0.05. HFD
feed WT vs. KO=0.042±0.015 vs. 0.0039±0.00023 ng/ml, p<0.05).
The GSIS of Sirt3 KO mice was also significantly reduced compared
with WT mice after both STD and HFD feeding (STD feed WT vs.
KO=0.160±0.029 vs. 0.031±0.023 ng/ml, p<0.01; HFD feed WT vs.
KO=0.240±0.040 vs. 0.130±0.027 ng/ml, p<0.05).
Conclusion: Sirt3 is involved in the regulation of insulin secretion in
pancreatic beta cells under physiological condition and after HFD.
Over-expression of Sirt3 protects pancreatic beta cells from FFA induced
dysfunction possibly through a PKA/CREB dependent pathway.
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Downregulation of TxNIP under glucolipotoxic conditions in insulin
secreting cells
M. Panse1, G. Kaiser1,2, F. Gerst1,2, H.-U. Häring1,2, S. Ullrich1,2;
1Internal Medicine IV, Endocrinology, Diabetology, Angiology, Nephrol-
ogy and Clinical Chemistry, University Hospital Tübingen, 2Institute for
Diabetes Research and Metabolic Diseases of the Helmholtz Center Mu-
nich at the University of Tübingen (IDM of the DZD e.V.), Germany.
Background and aims: Glucose dependent stimulation of TxNIP is
speculated to play a role in glucotoxicity, by inhibiting the ROS scaven-
ger thioredoxin, thereby, increasing oxidative stress. Upregulation of
TxNIP by glucose occurs via ChREBP dependent transcriptional activa-
tion. This activation is negatively regulated by the transcription factor
FOXO1. The glucose dependent stimulation of TxNIP is counteracted
by fatty acids. We have previously observed that palmitic acid lowers
TxNIP mRNA levels both in a FFAR1 dependent and independent man-
ner. Although the FFAR1 dependent pathway does not involve PKCδ or
FOXO1, INS-1E cells overexpressing PKCδ contain significantly lower
TxNIP mRNA levels than control INS-1E cells. The present study at-
tempts to identify the detailed mechanisms of TxNIP mRNA regulation.
Materials and methods: INS-1E cells were cultured under standard
culture conditions (11 mmol/l glucose, 10% FCS) and protein expression
was downregulated by siRNA. After 48 h of culture, cells were treated
with palmitic acid (60 and 600 μmol/l) or the FFAR1 agonist TUG-469
(3-10 μmol/l). Inhibitors were added 1 h prior to palmitic acid. Changes
in expression were analysed by qRT-PCR and western blot.
Results: To examine the role of FOXO1 in TxNIP mRNA regulation,
INS-1E cells were incubated with the pan protein kinase B (Akt/PKB)
inhibitor Akti-1/2, which triggers dephosphorylation and nuclear accu-
mulation of FOXO1. Akti-1/2 (10 μmol/l) did not lower but rather in-
creased glucose (11 mmol/l) induced TxNIP mRNA levels. In
accordance, in PKCδ overexpressing INS-1E cells, which have low
TxNIP mRNA levels, phosphorylation of Akt/PKB and nuclear
phospho-FOXO1 was significantly higher than in control INS-1E cells.
These observations suggest that glucose induced TxNIP expressionmight
be antagonized by phosphorylated but not by dephosphorylated FOXO1.
Since palmitic acid transiently reduced Akt/PKB phosphorylation,
palmitic acid induced TxNIP downregulation is probably mediated by
other pathways. FFAR1 induced enhancement of insulin secretion de-
pends on the stimulation of phospholipase C (PLC) and protein kinase
D1 (PKD1) and therefore, we examined whether these enzymes exert
effects on TxNIP mRNA levels. While the PLC inhibitor U73122
(1 μmol/l) counteracted FFAR1 dependent reduction of TxNIP mRNA
levels, the downregulation of PKD1 by siRNA had no effect. In addition,
the inhibition of ERK1/2 by PD98059 (10 μmol/l) did not affect TxNIP
mRNA levels. Finally, the stress kinase JNK, which plays a crucial role in
palmitic acid induced β-cell death, was inhibited by SP600125 (10μmol/
l). The inhibitor did not counteract the effect of palmitic acid but itself
reduced TxNIP mRNA levels.
Conclusion: In insulin secreting cells, TxNIP mRNA levels are rapidly
and reversibly regulated by a variety of pathways including Akt/PKB,
JNK and PLC.
Supported by: GRK 1302
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Role of very long chain fatty acid elongase 2 (Elovl2) in the regulation
of pancreatic beta cell dysfunction induced by gluco-lipotoxicity
L. Bellini1, M. Campana1, A. Machet1, J. Véret1, M. Chacinska2, N.
Kassis1, A. Blachnio-Zabielska2,M. Ibberson3, C. Bernard4, B. Thorens3,
C. Cruciani-Guglielmacci1, C. Magnan1, H. Le Stunff1;
1BFA team 2, University Paris Diderot, France, 2Medical University of
Bialystok, Poland, 3University of Lausanne, Switzerland, 4Institut de
Recherches Servier, Suresnes, France.
Background and aims: The IMIDIA program (http://www.imidia.org/)
aims to identify new targets involved in ß cell dysfunctions induced by
obesity. To achieve this goal, RNAseq analyses have been performed on
isolated islets of Langerhans from mice under high fat diet and controls.
Using bioinformatical analysis, we found that expression of Elovl2 was
correlated with glucose intolerance. This enzyme is involved in the
production of poly-unsaturated fatty acids, such as decosahexaenoic acid
(DHA). Therefore, our project aimed to determine the role of Elovl2 in ß
cell dysfunction induced by saturated fatty acids and high glucose con-
centrations, a phenomenon defined as gluco-lipotoxicity.
Materials andmethods: Pancreatic cell lines (INS-1 andMIN6) or islets
of Langerhans have been incubated with 0.4 mM of palmitate and 30mM
of glucose. Elovl2 expression has been determined by real-time PCR and
Western-Blot. The role of Elovl2 has been determined using a stable cell
line over-express it or by adding its product, DHA, on the β cells. Insulin
secretion (ELISA test) and apoptosis (detection of caspase 3/7 activity
and PARP cleavage by western blot) of pancreatic β cells have been
determined. Ceramide production has been quantified through a DAG
kinase test and lipidomics.
Results:We found that gluco-lipotoxicity inhibits Elovl2 expression in β
cells. Addition of DHA to the incubation medium can partially restore
insulin secretion induced by glucose. DHA also inhibits caspases-3/7
activation and PARP cleavage induced by gluco-lipotoxicity. Interesting-
ly, stable Elovl2 over-expressing cells are partially protected from apo-
ptosis induced by glucolipotoxicity. We also found that adding DHA and
over-expressing Elovl2 inhibit ceramides production induced by gluco-
lipotoxicity.
Conclusion:Our results show that Elovl2, through DHA production, can
counteract the deleterious effects induced by gluco-lipotoxicity by
blocking ceramide synthesis.
Supported by: IMIDIA
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Enhancer of Zeste Homolog 2 (EZH2) is a molecular switch in
HDAC3-mediated glucolipotoxicity in beta cells
T. Dahlby1, M.B. Backe1, M.S. Dahllöf1, C. Simon2, E. Holson3, B.
Wagner3, M. Lundh2, T. Mandrup-Poulsen1;
1Department of Biomedical Sciences, University of Copenhagen, 2Uni-
versity of Copenhagen, Denmark, 3Broad Institute, Cambridge, USA.
Background and aims: Type 2 diabetes (T2DM) is caused by relative
insulin deficiency arising when pancreatic β-cell insulin secretion fails to
compensate for insulin resistance. Elevated blood free fatty acids and later
glucose are mediators of progressive β-cell failure in T2DM. Posttrans-
lational modifications by acetylation and methylation of the histone back-
bone in chromatin are important epigenetic modulators of gene transcrip-
tion. We previously showed that inhibition of histone deacetylase
(HDAC) 3 reverts deleterious effects of β-cell glucolipotoxicity (GLT),
but the molecular mechanisms are unclear. The aim of this study was to
investigate the mechanisms bywhichβ-cell dysfunction and apoptosis by
HDAC3-mediated glucolipotoxicity (GLT) can be reverted by HDAC3-
inhibition.
Materials and methods:mRNA microarray was performed on sam-
ples from the rat β-cell line INS-1E exposed to a diabetic milieu
(25 mM glucose and 0.5 mM palmitate) in the presence or ab-
sence of the HDAC3-selective inhibitor BRD3308 and validated
by RT-qPCR. Microarray data was analyzed by fold-change and
the 400 top scoring genes from each set and the intersecting gene
sets were analyzed to find enriched transcription factors (TF) by
employing the ENCODE ChIP-Seq Significance Tool. EZH2 in-
activation was performed by overexpression of four different
EZH2 shRNAs in INS-1E cells, confirmed by real-time PCR
and Western blotting. Empty vector (EV) served as control (ctrl).
EZH2 knock-down cells were exposed to 25 mM glucose and
0.5 mM palmitate, and β-cell apoptosis was analyzed by quanti-
tative in vitro determination of cytoplasmic histone-associated
DNA fragments (Roche). Data was analyzed by two-tailed, paired
Student’s t-test.
Results: The mRNA microarray data revealed 52 genes differentially
regulated by nutrient overload (glucolipotoxicity, GLT) with or without
specific HDAC3-inhibitor. The microarray was validated by qRT-PCR of
6 genes selected for their differential expression pattern which was con-
firmed in 5/6 cases. By unbiased bioinformatics analysis of the mRNA
microarray data we found that the histone methyltransferase (HMT) and
TF Enhancer of zeste homolog 2 (EZH2) is a key transcriptional regulator
in HDAC3 inhibitor treated insulin-producing cells exposed to GLT. We
achieved ~70% knock down of EZH2 with sh-1 and ~40% knock down
with sh-4 and somewhat lower knock-down by sh-2 and -3. Pronounced
shRNA mediated knock-down of EZH2 (sh-1) aggravated whereas par-
tial knock-down (sh-4) protected against GLT-induced β-cell apoptosis
(p-value of n=4: ** p<0.01, * p<0.05, Figure 1).
Conclusion: Our results identified EZH2 as a novel molecular switch
regulating glucolipotoxicity-induced β-cell dysfunction and apoptosis.
The possibility that the bimodal role of EZH2 on β-cell viability is con-
ferred by the dual action of EZH2 as HMTand TF is under investigation.
Supported by: UCPH Career PhD fellowship; EliteForsk Travel Grant
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PKCdelta is a key regulator of palmitate-induced beta cell death
M. Shiozaki1, K. Fujimoto1, T. Sasaki2, K. Yoshida3, K. Utsunomiya1;
1Division of Diabetes, Metabolism and Endocrinology, Department of
Internal Medicine, 2Institute of Clinical Medicine and Research, 3Depart-
ment of Biochemistry, The Jikei University School of Medicine, Tokyo,
Japan.
Background and aims: High glucose and fatty acid (FA) levels induce
beta cell dysfunction and cell death, leading to a condition known as
glucolipotoxicity. Both FAs and glucose are metabolized to diacylglycer-
ol which activates novel protein kinase C (PKC), including PKCdelta.
Although activated PKCdelta is implicated in cell death, the molecular
mechanisms involved in the role of PKCdelta in beta cells are yet to be
fully defined. The aim of this study was to elucidate PKCdelta’s molec-
ular mechanism during glucolipotoxicity in beta cell death.
Materials and methods:Mouse insulinoma (MIN6) cells were incubat-
ed with 25 mmol/l glucose with or without 0.4 μmol/l palmitate for 72 h.
Phosphorylation of PKCdelta and protein expression of Pdx1 were ana-
lyzed by Western blotting. Translocation of PKCdelta was studied by
PKCdelta staining and Western blotting. Cell death was assessed with
Annexin V and propidium iodide. PKCdelta knockdown was performed
using a lentiviral vector followed by a cell death assay. To study the
molecular mechanism in vivo, we created beta cell specific Pkcd−/−mice
(bPKCDKO) and treated them with 50 mg/kg streptozotocin (STZ) in the
neonatal period (type 2 diabetes model). These mice were fed either a
normal diet (ND) or a high fat diet (HFD). Intraperitoneal (i.p.) glucose
tolerance tests were performed after a 16-h fast. Alpha/beta cell architec-
ture and mass were assessed by insulin/glucagon staining, and beta cell
death was assessed by TUNEL staining.
Results: Palmitate phosphorylated PKCdelta, with no change in whole
PKCdelta protein expression in MIN6 cells, suggested PKCdelta activa-
tion. Although in the normal state, PKCdelta was localized in the cyto-
plasm, palmitate induced a nuclear translocation of a full length and a
catalytically active fragment of PKCdelta. During palmitate treatment, the
number of Annexin V positive cells significantly increased. Furthermore,
palmitate phosphorylated Pdx1 at T11, and reduced the expression of
Pdx1 protein, implicating PKCdelta induced MIN6 cell death via Pdx1
down regulation. To confirm the involvement of PKCdelta in palmitate
induced MIN6 cell death, PKCdelta was knocked down. PKCdelta defi-
ciency prevented the development of palmitate induced Annexin V-
positive cells by 28% (p 0.05). bPKCDKO mice treated with STZ and
HFD showed improved glucose tolerance compared with mice fed ND,
accompanied by improved insulin secretion. Although HFD-fed control
mice treated with STZ showed reduced beta cell mass and disturbed
alpha/beta cell architecture, PKCdelta deficiency in beta cells ameliorated
beta cell mass to about 70% (p<0.05) and disturbed alpha/beta cell
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architecture. PKCdelta deficiency in beta cells also showed a reduction in
beta cell apoptosis by 46% (p<0.05).
Conclusion: Under glucolipotoxic conditions, PKCdelta is activated,
followed by the downregulation of Pdx1, which results in beta cell death.
In vivo, beta cell specific PKCdelta deficiency ameliorates beta cell mass
and insulin secretion, as a result of reduced beta cell apoptosis. Our results
suggest that palmitate induces beta cell death via a PKCdelta/Pdx1 de-
pendent pathway. It may serve as fundamental knowledge pertaining to
novel approaches toward diabetes, by targeting the PKCdelta/Pdx1
pathway.
PS 028 Beta cell injury: apoptosis
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NPY Y1 receptor stimulation protects against cytokine-induced ap-
optosis in mouse islets
Z.J. Franklin, S.J. Persaud, G.A. Bewick;
Diabetes and Nutritional Sciences, King's College London, UK.
Background and aims: NPY receptor stimulation has proliferative ac-
tions and protective effects against programmed cell death in a number of
tissues, but little is known about the protective effects of NPY receptor
activation on beta cell survival. We have identified Y1 receptors as the
most abundant sub-type in mouse islets. Therefore, we investigated the
potential protective role of Y1 receptor activation in mouse islets.
Materials and methods: Isolated mouse islets were treated for 24-48 h
with the Y1 receptor agonist Leu31Pro34-NPY (1 nmol/l-1 μmol/l) alone
or in combination with the Y1 antagonist BVD10 (100 nmol/l-1 μmol/l)
or the PLC inhibitor U73122 (10 μmol/l) in the absence or presence of a
cytokine cocktail (IL-1β, 50 U/ml; TNF-α, 1000 U/ml, IFN-γ, 1000 U/
ml) for the last 24 h of incubation. Apoptosis was measured by caspase
glo 3/7 activity and insulin secretion by RIA.
Results: Treatment of mouse islets for 48 hours with Leu31Pro34-NPY
(1 nmol/l-1 μmol/l) protected against cytokine-induced apoptosis (mixed
cytokine response: 100%; 60±2%, 67±5%, 54±2%, 69±7% with
1 nmol/l, 10 nmol/l, 100 nmol/l and 1 μmol/l Leu31Pro34-NPY respec-
tively, p<0.01- p<0.001, n=8). Furthermore, pre-treatment with 1 nmol/l
Leu31Pro34-NPY for 24 h followed by cytokine exposure alone and
1 nmol/l Leu31Pro34-NPY treatment in the presence of cytokines for
24 h without pre-treatment significantly protected mouse islets against
cytokine-induced apoptosis (mixed cytokine response: 100%; pre-treat-
ment: 61±5%, p<0.001; no pre-treatment: 71±5%, p<0.01, n=8). The
selective Y1 receptor antagonist BVD10 did not inhibit islet apoptosis
induced by cytokines when administered alone (100 nmol/l BVD10: 98±
22%; 1μmol/l BVD10 139±27% of the mixed cytokine response, p>0.2,
n=8), but reversed the anti-apoptotic effect of Leu31Pro34-NPY (1 nmol/l
Leu31Pro34-NPY + 100 nmol/l BVD10: 78±13%; 10 nmol/l Leu31Pro34-
NPY + 1 μmol/l BVD10: 109±14% of the mixed cytokine response,
p<0.05-p<0.01, n=8), indicating the protective effect is likely via Y1
receptors. Inhibiting PLC activity with U73122 reversed the anti-
apoptotic effects of Leu31Pro34-NPY (10 μmol/l U73122+1 nmol/l
Leu31Pro34-NPY: 110±13% of the mixed cytokine response, p<0.01,
n=6), whilst having no protective effect on cytokine-induced apoptosis
when administered alone (10 μmol/l: 109±17% of the mixed cytokine
response, p>0.2, n=6), suggesting that the anti-apoptotic properties of
Y1 receptor activation may be mediated through a PLC signalling cas-
cade. As expected, acute exposure to Leu31Pro34-NPY inhibited glucose-
induced insulin secretion when used at 1 μmol/l (2 mmol/l glucose: 0.6±
0.05 ng islet-1 h-1; 20 mmol/l glucose: 2.5±0.5; 1 μmol/l Leu31Pro34-
NPY: 0.9±0.3, p<0.05, n=8), but it had no effect at 1 nmol/l-
100 nmol/l (all p>0.2, n=8). In addition, 48 h exposure to Leu31Pro34-
NPY (1 nmol/l-100 nmol/l) had no significant effect on glucose stimulat-
ed insulin secretion (all p>0.2, n=8).
Conclusion: These results indicate that NPYY1 receptor stimulation can
protect against cytokine-induced apoptosis in mouse islets at low concen-
trations without inhibiting glucose-stimulated insulin secretion.
Supported by: JDRF
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Hypoxia induces beta cell death by inhibiting the adaptive UPR
M. Bensellam1, E. Maxwell1, J.-C. Jonas2, J. Chan1, D.R. Laybutt1;
1Diabetes and Obesity, Garvan Institute of Medical Research, Sydney,
Australia, 2Pôle d'endocrinologie, diabète et nutrition, Université
catholique de Louvain, Brussels, Belgium.
Background and aims: Hypoxia is implicated in the loss of functional
beta cell mass in type 2 diabetes and with islet transplantation, although
the mechanisms are unknown. The adaptive unfolded protein response
(UPR) is required for endoplasmic reticulum (ER) homeostasis and beta
cell integrity. Here we investigated the influence of hypoxia on the adap-
tive UPR and the role it plays in apoptosis.
Materials and methods: Isolated mouse islets and MIN6 cells were
exposed to various O2 tensions. Ddit3 (Chop) and Hif1α were inhibited
using siRNA. Hspa5 (Bip) was overexpressed using a plasmid vector.
JNK was inhibited using SP600125. UPR and hypoxia-response gene
expression was assessed in islets from prediabetic and diabetic db/db
mice and age-matched lean control mice. mRNA and protein levels were
measured by real-time RT-PCR and western blot. Apoptosis was mea-
sured by DNA fragmentation ELISA.
Results:Deprivation of O2 (1% vs 20%) for 4-24 hmarkedly reduced the
mRNA and protein levels of adaptive UPR genes, including Hspa5,
Hsp90b1 and Fkbp11 as well as the activation of Xbp1 (splicing) and
PERK (phosphorylation). Opposing effects were observed in MEF cells
suggesting that hypoxia specifically inhibits the adaptive UPR in beta
cells. This was accompanied by upregulation of integrated stress response
(ISR) genes, including Ddit3, Atf3 and Trb3 along with increased phos-
phorylated EIF2A. Interestingly, Ddit3 knockdown significantly in-
creased adaptive UPR gene expression in association with partial protec-
tion against hypoxia-induced apoptosis (p<0.05). Moreover, Hspa5 over-
expression alone partially protected against hypoxia-induced apoptosis (p
<0.01). JNK inhibition, but not Hif1α knockdown, partially prevented
the hypoxia-mediated loss of adaptive UPR gene expression and
protected against hypoxia-induced apoptosis (p<0.01). Finally, mRNA
levels of hypoxia-response genes, including Hyou1, Tpi1, Gapdh and
Eno1, were markedly upregulated in vivo in the islets of diabetic db/db
mice, but not in prediabetic db/db mice, suggesting that islet hypoxia
correlates with beta cell failure. Interestingly, the upregulation of
hypoxia-response genes further correlate with downregulation of adaptive
UPR gene expression in diabetic db/db islets.
Conclusion: Hypoxia inhibits the adaptive UPR in beta cells partially via
Ddit3 and JNK activation, but independently of Hif1α. Downregulation of
the adaptive UPR contributes to hypoxia-induced beta cell apoptosis and
may play a role in the loss of functional beta cell mass in type 2 diabetes.
Supported by: SFD (Paris, France) and NHMRC and ARC of Australia
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The L-type calcium channel beta1 subunit is essential for preventing
apoptosis in beta cells
A. Kazim, E. Zhang, E. Renström;
Lund University, Malmö, Sweden.
Background and aims:Voltage-gate calcium channels (Cav) play a piv-
otal role as triggers of insulin secretion. Genetic variants in genes
encoding the pore-forming Cavα1 subunits determine the human beta-
cell phenotype and affect the risk of type 2-diabetes. The functions of the
auxiliary Cavβ subunits are only patchily explored, but they are proposed
to modulate of translocation and stability of the α1 subunits. Supporting
this idea, Cavβ3 was previously shown to suppress Ca2+-oscillations in
mouse beta-cells. Furthermore, Cavβ2 is subject to palmitoylation, which
could serve as a regulatory signal for α1 function. To clarify this we have
investigated gene co-expression with Cavβ in human islets and explored
the effects of all Cavβ subunits (1-4) in beta-cell function.
Materials and methods: Insulin secretion. Calcium imaging. Immuno-
blotting. Viability assay.
Results:Microarray analysis of gene expression in human islets revealed
that the different Cavβ subunit genes (CACNB1, CACNB2, CACNB3,
CACNB4) significantly correlated primarily with genes encoding other
Cav subunits, structural proteins, as well as apoptosis-regulating proteins.
For example, CACNB1, -2, -4 correlated with EIF3E that was recently
demonstrated to control translocation of Cavα1. These results support the
idea that Cavβ may interfere with beta-cell function and viability. In
addition, CACNB1 and CACNAB2 both exhibited a negative correlation
vs. HbA1c of the islet donors. Next, we investigated the effects of silenc-
ing the different Cavβ subunits on glucose-stimulated insulin secretion in
INS(832-13)cells. Gene silencing (72 h) was efficient as verified on the
protein level by immunoblotting and for e.g. Cavβ1 it amounted near
>95%. Interestingly, silencing of Cavβ2, Cavβ3 and Cavβ4 failed to
affect insulin release under either basal or stimulatory conditions. By
contrast, reduced Cavβ1 expression resulted in increased insulin release
under both basal and stimulated conditions. Based on these results, we
next focused on Cavβ1 and explored depolarization-evoked increases in
cytoplasmic Ca2+ concentration ([Ca2+]i) in Cavβ1-silenced cells. Sur-
prisingly, this resulted in a 76% decrease in [Ca2+]I evoked by high K+
(9.8±1.09 vs. 2.3±0.23 fluorescence intensity; P<0.001), whilst not af-
fecting basal [Ca2+]I. This result contrasts with the observed increased
insulin release. In an attempt to explain this we next investigated cell
viability (EthD-1 & Calcein AM) and found that this was severely com-
promised in Cavβ1-silenced cells (0.46±0.21 vs. 7.8±0.098 percentage
cells; P<0.001). This was due to increased apoptosis as assessed by
immunoblotting of cleaved caspase 3, which increased by 300% in
Cavβ1-silenced cells.
Conclusion: Cavβ1 affects Ca2+-homeostasis in the beta-cell, but is
essential for beta-cell viability. Silencing of Cavβ1 results in increased
apoptosis in a non-Ca2+ dependent fashion.
Supported by: Swedish Research Council, Swedish Diabetes Society,
EXODIAB Human TissueLab
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A dual approach with Siglec-7: it inhibits macrophage infiltration
into human islets and restores beta cell function and survival
M. Hauke1, G. Dharmadhikari1, K. Stolz1, S. Kelm1, J. Kerr-Conte2, K.
Maedler1;
1Centre for Biomolecular Interactions, University of Bremen, Germany,
2Thérapie Cellulaire du Diabète, University of Lille 2, France.
Background and aims: In both, type 1 and type 2 diabetes mellitus
cytokine and chemokine production and infiltrating immune cells are
hallmarks of islet inflammation. Siglecs (Sialic-acid binding
immunoglobulin like lectins) are cell surface receptors expressed on
haematopoietic cells, they balance immune responses by immunoreceptor
tyrosine-based inhibitory motifs (ITIMs), which recruit tyrosine phospha-
tases and eventually inhibit activation signals transduced from pattern
recognition receptors. Siglec-7 was found to be downregulated in diabetic
islets as well as in activated PBMCs. Here, we aimed to investigate
whether such changes in Siglec-7 expression directly modulate islet im-
mune cell infiltration, β-cell function and survival.
Materials and methods: To investigate the role of Siglec-7 in β-cell
function and survival, over-expression was carried out in isolated human
islets with or without diabetic stimuli (glucose/palimitic acid, cytokine
mixture IL-1β/IFNg/TNFα), followed by glucose stimulated insulin se-
cretion (GSIS) and TUNEL assay. Cytokine secretion was analyzed by
theMeso Scale Discovery®multi array technology. To ascertain its role in
immune cells, Siglec-7 expressionwas analyzed byRT-PCR and FACS in
freshly isolated PBMCs from non-diabetic individuals cultured with the
same diabetogenic conditions or 100 ng/ml Lipopolysaccharide (LPS) for
12 hours.
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Results: Siglec-7 mRNAwas markedly down-regulated in islets isolated
from patients with T2D and in pancreases from autopsy from patients
with T2D. Over-expression of Siglec-7 improved β-cell function and
survival in human islets isolated from patients with T2D. The overexpres-
sion also prevented glucolipotoxicity- and cytokine-induced β-cell apo-
ptosis. In isolated human islets from patients with T2D, Siglec-7 overex-
pression caused a reduction in basal IL-1β (40%) and TNFα (50%)
expression. In human monocytes, LPS, glucose/palmitic acid, as well as
the cytokine mixture IL-1β/IFNg/TNFα induced their activation as seen
by the induction of IL-6 mRNA and CD25 expression; a simultaneous
decrease was observed in Siglec-7 mRNA levels. Induced migration of
enriched monocytes was observed under conditions of elevated glucose/
palmitate as well as by islets from patients with T2D. This demonstrates
the triggering of inflammation in islets under diabetogenic conditions.
Conditioned media from islets overexpressing Siglec-7 majorly inhibited
cell migration of immune cells.
Conclusion: Our data suggest that Siglec-7 is regulated in islets and
immune cells under diabetogenic conditions and influences immune cell
migration, β-cell function and survival.
Supported by: ERC
477
Reduced expression of the transcription factor, STAT6, in beta cells
may contribute to their loss in human type 1 diabetes
M.A. Russell, K. Taniguchi, S.J. Richardson, N.G. Morgan;
University of Exeter Medical School, UK.
Background and aims: It is widely accepted that immune cells infiltrate
the pancreatic islets in human type 1 diabetes and contribute to beta-cell
loss by releasing pro-inflammatory cytokines. In addition, the production
and influence of anti-inflammatory cytokines (e.g. IL-4 or IL-13) is cor-
respondingly down-regulated in this disease, which may also contribute
to beta cell loss. IL-4 and IL-13 each signal via their cognate cell surface
receptor to induce the phosphorylation and activation of the transcription
factor, STAT6; which then mediates their effects. In the current study we
have evaluated the extent to which STAT6 acts as a regulator of beta-cell
viability and have studied whether islet STAT6 expression is altered in
human type 1 diabetes.
Materials and methods: An archival collection of formalin fixed paraf-
fin embedded (FFPE) pancreas samples from both healthy controls and
individuals with type 1 diabetes was interrogated using STAT6 antisera.
Both immunofluorescence (IF) and immunohistochemical (IHC) staining
approaches were employed. Cell culture studies were also undertaken to
explore STAT6 phosphorylation and beta-cell viability by Western blot-
ting and flow cytometry respectively.
Results: IF staining of FFPE human pancreas tissue revealed a robust
expression of STAT6 within the endocrine pancreas in non-diabetic indi-
viduals. Importantly, STAT6 was found at high levels in insulin-
containing beta-cells but expression was negligible in other islet endo-
crine cell types. To assess the role of STAT6 in the beta-cell, IL-4 and IL-
13 were employed as stimuli in INS-1E cells and isolated human islets.
Treatment of these with IL-4 or IL-13 induced a rapid, time-dependent
rise in STAT6 phosphorylation at Tyr641, indicating increased STAT6
activation. In accord with this, the anti-inflammatory cytokines potently
protected the cells against a range of cytotoxic insults including serum
starvation, saturated fatty acids and pro-inflammatory cytokines (10%
foetal calf serum: 11.3±0.9%; no serum: 35.5±1.3% cell death; no serum
plus 20 ng/ml IL-13: 23.8±0.8%; p<0.001). Pharmacological inhibition
of Janus kinases (which act immediately upstream of STATs) prevented
cytokine-induced STAT6 phosphorylation and reversed the improved cell
viability caused by IL-4 or IL-13 (no serum: 30.0±1.3% cell death, IL-13:
16.9±0.8%, IL-13+P6: 30.3±1.3%; p<0.001). Finally, we investigated
whether the expression of STAT6 is altered within the islets of pancreases
of patients with type 1 diabetes compared to controls. Pancreas sections
from six healthy and six age- and sex-matched patients with recent-onset
type 1 diabetes were immunostained for STAT6 and islet hormones. Im-
ages of five islets per section were captured at identical microscope and
camera settings. The mean fluorescence intensity of STAT6 expression
within each islet was calculated and analysis of these data revealed that
total STAT6 levels were significantly decreased in the islets of individuals
with recent-onset diabetes (MFI for STAT6; healthy control 14.22±1.23,
T1D 2.31±0.64; p<0.001).
Conclusion: STAT6 is expressed in human beta-cells and its activation
improves the viability of these cells in response to various cytotoxic
insults. Expression of STAT6 is reduced in the beta cells of individuals
with type 1 diabetes and this may contribute to the enhanced vulnerability
of these cells in the face of the pro-inflammatorymilieu found in inflamed
islets.
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Robust amyloid deposition with M1 macrophage infiltration in the
islets in super-elderly Japanese type 2 diabetic subjects
H. Mizukami, W. Inaba, A. Xing, T. Yoshida, Y. Takeuchi, S. Yagihashi;
Pathology and Molecular Medicine, Hirosaki University, Japan.
Background and aims: Dramatic increase in elderly type 2 diabetic
patients (T2DM) is a serious problem in modern society. Although path-
ogenesis of elderly T2DM can be distinct from that in younger ones based
on their different energy metabolism, differences in the islet pathology
between elderly and less old diabetic patients are yet to be addressed. In
this study, we attempted to characterize the islet changes in elderly T2DM
patients.
Materials and methods: Pancreata from 13 young non-diabetic (Y-ND)
(mean 25.8 y.o.), 22 middle-aged non-diabetic (M-ND) (61.3), 23
middle-aged diabetic (M-DM) (59.4; onset of DM 48.8),30 super-
elderly non-diabetic (SE-ND) (89.5), and 10 super-elderly diabetic sub-
jects (SE-DM) (88.5; onset of DM 80.3) were investigated. On the tetra
immunostained sections, morphometric analysis was conducted on each
endocrine cell as to their volume density, mass and occupancy in the islet.
Immunohistochemical expressions of insulin transcriptional factors (TFs)
such as PDX1 and MafA or in situ hybridization for (pro)insulin mRNA,
and infiltration of macrophages positive for CD68 (M1-M) and CD163
(M2-M) were assessed for insulin transcriptional activity and inflamma-
tory changes, respectively .
Results: Pancreas weight (PW) was comparable among groups except for
SE-DMwhich showed 50% decrease compared to SE-ND. In accordwith
this result, pancreatic parenchyma of SE-DMdisplayed severe atrophy. In
addition, we found a high frequency of amyloid deposition (amyloid
volume density>0.1%) in SE-DM (70%) compared to M-DM (27%)
and SE-ND (3%). Compared to M-ND, volume density of β cells (Vβ)
was reduced ca 30% in M-DM. In contrast, there was a significant in-
crease in volume density of α cells (Vα in M-DM. Vβ in SE-ND was
increased to 130% of M-ND accompanied by an increase in islet volume
density (Vi). Vβ in SE-DM was dramatically reduced 35% compared to
SE-ND (p<0.01). There were no significant changes in either δ or PP cell
volume densities among all cohorts. The expressions of PDX1 andMafA
were the most prominent in Y-ND and preserved inM-ND, whereas those
in M-DM, SE-ND, and SE-DM were all suppressed to similar extents to
those in M-ND, together with reduced insulin mRNA expression (p<
0.05). Both M1-M and M2-M infiltrated into the islets of M-DM and
further M1-M infiltrates were conspicuous in SE-DM, while M2-M infil-
trates in SE-DM were less marked compared to that of M-DM.
Conclusion: This study disclosed that the islet pathology in SE-DM is
distinct from those inM-DM, characterized by pancreas atrophy, amyloid
deposition, macrophage infiltrates, and less implication of TFs. Thus,
environmental insults may more strongly be implicated in the onset of
SE-DM compared to usual M-DM.
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A role for the Nrf2-antioxidant pathway in intrinsic beta cell repair
after resolution of hyperglycaemia
R. Robertson1, T. Abebe1, S. Hahn1, J. Mahadevan2, E. Oseid1, F.
Urano2;
1Medicine, Pacific Northwest Diabetes Research Institute, Seattle, ,
2Medicine, Washington University, St. Louis, USA.
Background and aims: It is well established that sustained hyperglyce-
mia causes beta cell necrosis and apoptosis. However, very little infor-
mation exists about whether damaged beta cells can undergo intrinsic
repair once treatment resolves the hyperglycemic state, and if so, what
mechanisms might be involved. To address these issues, we studied
euglycemic ZDF rats that become hyperglycemic when fed a high fat diet
(HFD). Observations were made during a baseline non-HFD period, dur-
ing a HFD, and after returning to a non-HFD with particular emphasis on
Nrf2, a protein that binds to the promoter elements of genes involved with
synthesis of antioxidant proteins.
Materials and methods: 3 groups (n=12 each) of normoglycemic ZDF
female rats were fed non-HFD (16.5% fat) for 2 weeks. Thereafter, one
group each was fed the HFD (48% fat) for 9, 18, and 28 days, respec-
tively. Animals (n=4) from each of the groups were sacrificed for pan-
createctomy at 3 time periods: at baseline; on the 9th, 18th, and 29th day
of HFD; and at the end of a 3 week return to non-HFD. Non-fasting blood
samples were taken throughout the study for glucose and insulin.
Pancreases were used for insulin immunostaining and beta cell mass as
well as for immunoflourescent staining for Ki67, apoptosis, PDX-1, su-
peroxide dismutase (SOD-1), catalase (CAT), glutathione peroxidase-1
(GPx-1), hemoxygenase-1 (HO-1) and nuclear factor erythroid-derived
2-related factor (Nrf-2).
Results: 9 days HFD caused hyperglycemia (348 +/- 16 mg/dl ) and
during the remaining weeks after return to non-HFD, elevated glucose
levels returned to baseline levels (147 +/- 10 vs 135 +/- 3 baseline, mg/dl;
p=ns). After 18 days HFD and hyperglycemia (513+/- 34), elevated
glucose values partially returned to baseline levels (215 +/- 37 vs 144
+/- 6 baseline; p=ns). After 28 days HFD and hyperglycemia (546 +/- 63)
and during the remaining weeks after return to non-HFD, elevated glu-
cose levels failed to return to baseline levels 294 +/- 69 vs 133 +/9; p<
0.03). Corresponding insulin levels failed to respond to the higher glucose
levels by the end of the experiments: 18 day study=20 +/- 4 vs. 38 +/- 4
microU/ml baseline; 28 day study=14 +/- 2 vs. 26 +/- 4 baseline. Insulin
immunostaining revealed beta cell damage after 9, 18, and 28 days of
HFD. However, islets were healthy-appearing after a return to non-HFD
in the 9 day HFD study. Nonetheless, there was a lesser improvement in
beta cell imagery during return to non-HFD after 18 days HFD and very
little improvement in beta cell imagery after return to non-HFD after
28 days HFD. Nrf2, HO-1, and SOD-1 were prominent in the nucleus
during HFD in the 9 day study compared to pre-HFD images, although
less so in the 18 and 28 day experiments. No changes in apoptosis, Ki67,
GPx-1, or catalase were observed.
Conclusion: These data demonstrate that HFD in female ZDF rats causes
hyperglycemia and associated beta cell damage that is reversible after a
return to non-HFD in a time-related fashion wherein longer exposure to
HFD is accompanied by lesser recovery of beta cell mass. The immediate
appearance of intranuclear Nrf2 and antioxidant proteins that accompany
the recovering beta cell morphology after the shortest but not the longest
exposure to HFD suggests an early response role of the Nrf2-antioxidant
pathway in beta recovery from hyperglycemia-induced damage.
Supported by: NIH RO1 DK 38325-35
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Protection against inflammatory beta cell damage by lysine
deacetylase inhibition and microRNA expression
A.L. Vestergaard1, E.M.H. Pallesen1, G. Novotny1, D.N. Rasmussen1,
R. Regazzi2, M. Lundh1, T. Mandrup-Poulsen1;
1Department of Biomedical Sciences, University of Copenhagen, Den-
mark, 2Department of Fundamental Neurosciences, University of Lau-
sanne, Switzerland.
Background and aims: Pro-inflammatory cytokines contribute to pan-
creatic β-cell apoptosis in type 1 and 2 diabetes mellitus. The detrimental
effects resulting from cytokine-induced signaling in the β cell can be
reduced by inhibition of class I classical lysine deacetylases (KDACi),
especially HDAC1 or HDAC3, and is associated with down-regulation of
inflammatory gene expression, only in part through hyperacetylation of
NFκB.We therefore hypothesize that HDACi-mediated hyperacetylation
of histones and/or other proteins upregulate expression of microRNAs
(miR), which repress translation of oxidative stress proteins responsible
for β-cell death. The aim of the study is to identify novel and specific
therapeutic targets for β-cell protection by mapping the miR profile of β
cells rescued from inflammatory assault by inhibition of lysine
deacetylation, thereby identifying miR that repress cytokine-induced mi-
tochondrial and oxidative β-cell stress.
Materials and methods: Stable INS-1 knockdown (KD) clones of
HDAC1, -2, and -3 (class 1 KDACs) or empty vector were generated
by Lentiviral shRNA transduction. The cells were incubated 6 h with or
without cytokines (150 pg/mL IL-1β + 5 ng/mL IFNγ), and RT-qPCR-
based miR array was performed. Regulation of several miR was verified
by TaqMan RT-qPCR, and medium nitrite was determined with Griess’
reagent.
Results: Following systematic analysis using NormFinder, miR-103 was
chosen for normalization of the qPCR array data. Constitutive expression
of 103 miR, and cytokine-induced expression of 84 miR were up- or
down-regulated more than 3-fold by KD of HDAC1, -2, and/or -3 (see
figure). MiR-146a, -146b, -21 and -34a were chosen for further analysis,
and their expression was assessed by RT-qPCR normalized to U6. Cyto-
kine exposure induced a 15-fold expression of miRNA-146a, which was
reduced by 65% in HDAC1- but not in HDAC2- or HDAC3-deficient
INS-1 cells (p<0.05, n=5). Expression of miRNA-146b, miR-21 and
miR-34a were unaffected by HDAC1-3 deficiency, while cytokine-
induced NO production was reduced by 27% and 44% in the HDAC1
(n=8) and HDAC2 (n=5) but not HDAC3 deficient clones respectively.
The qPCR array analysis revealed several additional novel miR poten-
tially important for understanding the beneficial effects of KDAC inhibi-
tion, which are currently being functionally validated.
Conclusion: The interesting association between HDAC1 KD-mediated
protection against cytokine-induced INS-1 cell destruction, and the inhib-
itory effect of HDAC1 knockdown on the β-cell pro-apoptotic miR-146a
and other miR under investigation, warrants further investigations aiming
to show a causal role of miR in HDAC inhibitor-mediated protection of
pancreatic β cells. The perspective of this study is to develop novel anti-
diabetic drugs targeting HDAC1 and/or associated miR.
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Graft revascularisation is essential for non-invasive monitoring of
transplanted islets with radiolabeled exendin
W.A. Eter, D. Bos, C. Frielink, O.C. Boerman, M. Brom, M. Gotthardt;
Radiology and Nuclear Medicine, Radboud University Medical Center,
Nijmegen, Netherlands.
Background and aims: Pancreatic islet transplantation provides insulin
independence for type 1 diabetes patients. However, the clinical outcome
is still poor due to decline of islets survival in response to inflammatory
and non-inflammatory processes. Clearly, development of non-invasive
imaging tools visualizing islet transplants would improve the therapy by
predicting islets survival. 111In-exendin-3 is a promising tracer to non
invasively visualize β-cells by SPECT (Single Photon Emission Com-
puted Tomography). However, after isolation, islet vasculature is
disrupted and therefore, delivery of the radiotracer to islet grafts early
after transplantation may depend on their revascularization. Here we in-
vestigated the role of islet revascularization dynamics in promoting
exendin-3 delivery to islet grafts and to image them after transplantation
by SPECT.
Materials and methods: Syngeneic transplantation was performed in
calf muscle of C3Hmice with 800 islets. Mice were injected intravenous-
ly with 15 MBq of 111In-exendin and scanned 1 h post-injection. SPECT
was acquired at 3 days, 1, 2, 3 or 4, 5, 6 weeks. Exendin uptake was
determined by SPECT quantitative analysis and immunostaining was
performed against insulin and VEGFR-2 to confirm presence of β-cells
and to quantify intra-islet vascular density, respectively. Data were
expressed as means ± SEM.
Results: After 3 days, 0.013±0.003 kBq of the tracer accumulated in the
transplants, which significantly increased up to 0.06±0.005 kBq at
4 weeks (p<0.001) and remained similar up to 6 weeks after transplan-
tation (0.07±0.003 and 0.07±0.002 kBq, for week 5 and 6, respectively).
First signs of revascularization coincidedwith low exendin-3 uptake by 3-
day old grafts and increase in islets vascular density between 3 days and
3 weeks (p<0.001) correlated with the uptake of exendin-3 by the islets
(Pearson Correlation coefficient r=0.85)
Conclusion: Islet revascularization is a key physiological process when
monitoring islet transplants after in-vivo targeting of the β-cells with
radiotracers. Stable and reproducible uptake of exendin was achieved
starting 4 weeks post-transplantation, indicating that longitudinal assess-
ment of islet survival by SPECTcan reproducibly be performed after this
time point.
Supported by: The People Programme (Marie Curie Action)
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Re-routing of insulin signalling in response to knockdown of PI3K-
C2alpha promotes pancreatic beta cell proliferation
B. Leibiger1, T. Moede1, M. Paschen1, N.-O. Yunn2, J.-H. Im2, S.H.
Ryu2, P.-O. Berggren1, I.B. Leibiger1;
1The Rolf Luft Research Center for Diabetes and Endocrinology,
Karolinska Institutet, Stockholm, Sweden, 2PohangUniversity of Science
and Technology, Republic of Korea.
Background and aims: Signaling via insulin receptor B-type (IR-B) and
PI3K-C2α is required for glucose-stimulated insulin secretion and keeps
the beta cell in a glucose-sensitive, differentiated state. We have recently
observed that knock-down of PI3K-C2α in pancreatic beta cells, in con-
trast to most other cells, leads to increased proliferation and survival. The
aim of this study was to evaluate the mechanism underlying the increased
beta cell proliferation and survival after knockdown of PI3K-C2α.
Materials and methods: MIN6 cells, primary mouse and human beta
cells were treated with control siRNA or siRNA against PI3K-C2α. Cell
proliferation was measured by incorporation of labeled DNA precursors
into nuclei. Protein expression and phosphorylation were evaluated by
Western blot. Apoptosis rate was determined by triple staining with
Hoechst 33342, propidium iodide and AlexaFluor488-annexinV. IR-B/
Shc interaction was evaluated by FRET analysis and co-
immunoprecipitation.
Results: Knockdown of PI3K-C2α led to increased cell proliferation of
MIN6 cells (1.48±0.11fold), mouse (1.88±0.24fold) and human (1.92±
0.21fold) primary beta cells. Cells treated with PI3K-C2α siRNA were
more resistant to apoptotic stimuli (48.4±4.9% less apoptotic MIN6 cells
when treated with 20 μM H2O2 and 32±2.9% less apoptotic MIN6 cells
when treated with 6 μM staurosporine). The positive effect of PI3K-C2α
knockdown on cell proliferation was insulin-dependent and was
abolished both by IR-B-blocking antibodies (p≤0.01) and IR-B-
blocking aptamers (p≤0.01). Knockdown of PI3K-C2α led to increased
IR-B/Shc interaction (1.8±0.3fold). Knockdown of PI3K-C2α led to
decreased signaling via the IR-B/PKBα-pathway resulting in a less glu-
cose-sensitive/differentiated phenotype and to increased signaling via the
IR-B/Shc/ERK-pathway resulting in enhanced proliferation.
Conclusion: Insulin resistance in the signaling cascade via IR-B/PI3K-
C2α leads to partial loss of the differentiated, glucose-responsive state of
the beta cell but at the same time promotes beta cell proliferation via a
different signaling cascade involving Shc/ERK. PI3K-C2α represents a
key regulatory element allowing the beta cell to switch between IR-B
signaling leading to differentiation respective proliferation in response
to insulin.
Supported by: KI, VR, NovoNordisk Fonden, JDRF, Family Erling-
Persson Foundation
483
Beta cell amount, function and turnover in non-diabetic obese vs lean
subjects
L. Marselli, M. Suleiman, M. Occhipinti, F. Olimpico, F. Syed, M.
Bugliani, P. Marchetti;
Department of Clinical and Experimental Medicine, Islet Cell Laboratory,
University of Pisa, Italy.
Background and aims: To better understand the relative roles of beta
cell amount, function and turnover in the maintainance of glucose ho-
meostasis in non-diabetic (ND) obese subjects (OB), we compared sev-
eral beta cell characteristics in 13 OB (age 66±13 yrs; 4 M/9 F; BMI:
32.0±3.3 kg/m2) and 14 lean [LEAN; 64±15 yrs; 4 M/10 F; 22.5±
1.8 kg/m2 (p<0.01 vs OB)] ND organ donors.
Materials and methods: Immunofluorescence staining was performed
with pancreatic sections; glucose stimulated insulin secretion was
assessed from isolated islets by the batch incubationmethod; laser capture
microdissection (LCM) was used to acquire beta cell enriched samples
from frozen specimens.
Results: Pancreatic insulin (INS) and glucagon (GLUC) areas were 0.71
±0.34% and 0.27±0.25% in OB, and 0.85±0.50% and 0.22±0.15% in
LEAN, with the respective INS/GLUC values of 3.0±1.1 and 4.1±1.3
(p=0.06). Cells positive for both INS and GLUC were 10.5% in OB and
7.0% in LEAN islets. Beta cell clusters (<4 cells) per mm2 were 7.8±4.9
in OB and 7.6±7.0 in LEAN (>90% in acinar tissue, the remaining in/
close to ducts); similar proportions of OB and LEAN clusters contained
only INS+ (around 60%) or GLUC+ (around 35%) cells; costained INS+
andGLUC+ cells were seen in 7.6 and 3.9%of clusters in OB and LEAN,
respectively. TUNEL or Ki67 positive beta cells were similarly rare in the
two groups. Glucose stimulated (16.7 mMglucose) INS release (μU/islet/
min) was 0.093±0.048 from OB and 0.058±0.031 from LEAN (both p<
0.01 vs basal) islets; INS stimulation index was higher with OB islets (3.4
±1.2 vs 2.3±1.1, p=0.03), with a similar effect also seen with
glibenclamide (3.4±1.1 vs 2.5±1.2) but not with arginine (2.4±0.9 vs
2.2±1.0). LCM was applied to islets and acinar or duct clusters. RIN
values were >6 for islet beta cells and >4 for cluster beta cells, with
respective concentrations of >4 ng/μl and approximately 100 pg/μl.
Conclusion: Beta cells in ND OB show greater insulin secretion to glu-
cose and glibenclamide, but not arginine; the morphometric fetures of OB
vs LEAN beta cells requires further studies; LCM use could allow de-
tailed molecular investigation of OB beta cell properties.
Supported by: JDRF and IMIDIA
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In vitro imaging of GLP-1R as an approach to non-invasive in vivo
pancreatic islet imaging
V. Chellakudam, K. Janikowska, A. Babic, E. Allémann, N. Lange;
Pharmaceutical Technology, School of Pharmaceutical Sciences, Univer-
sity of Geneva - University of Lausanne, Geneva, Switzerland.
Background and aims: Recently, exendin-4 derivatives targeting gluca-
gon like peptide -1 receptor (GLP-1R) are emerging as promising candi-
dates for the imaging of pancreatic β cell mass. Our project aims at
developing and evaluating 1) multimodality imaging probes with exendin
as the targeting ligand; 2) multivalent probes with 1 to 4 exendin to
increase the avidity of the probe to receptor; and 3) inclusion of short
and long PEG linkers to reduce the kidney uptake and enhance circulation
half-lives for in vivo studies. In our studies, a defined cyclopeptidic scaf-
fold was selected as delivery vehicle for these probes. All probes were
labeled with Cy5 for fluorescence imaging.
Materials and methods: Dose response assays were carried out to de-
termine the binding affinity (IC50) of exendin derivatives. Then, compe-
tition binding assays were designed to study the specificity to the GLP-
1R. Finally, cell imaging experiments at 37°C and 4°C were conducted to
visualize internalization of the probes. Assays were performed in CHL/
hGLP-1R cells that ectopically express hGLP-1R and compared to the
GLP-1R negative native CHL cell line.
Results: Dose response assays: All compounds showed affinities in the
nanomolar range to CHL/hGLP-1R cells. The cyclopeptide carrying 2
exendins and short PEG linker showed the lowest IC50 values (1.0±
0.1 nM) in CHL/hGLP-1R cells (see table below)No bindingwas observed
in GLP-1R negative CHL cell line or other human control cell lines (HeLa,
Panc-1). Competition binding assays: At high concentrations of unlabeled
exendin, tagged exendin derivatives were unable to displace the untagged
ligand. Cell imaging experiments: At 37°C Internalization of the probes
into the cytoplasm was observed. However, at 4°C was mostly confined to
the cell membrane indicating an active transport of the probes.
Conclusion: GLP-1R targeting cyclopeptide carrying multiple exendin
copies show high binding affinities to the GLP-1R similar to exendin-4
(39aa). The competition assays and fluorescence imaging confirm the spec-
ificity of the probes to the receptor for receptor-mediated internalization
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Cathelicidin antimicrobial peptide: a novel regulator of islet function
and beta cell regenerative capacity
L.D. Pound, C. Patrick, C.E. Eberhard, G.-S. Wang, R.N. Vandenbeek,
F.W. Scott;
Ottawa Hospital Research Institute, Ottawa, Canada.
Background and aims: Cathelicidin antimicrobial peptide (CAMP) is a
naturally-occurring secreted peptide primarily expressed in immune cells
and in epithelia that are in contact with the environment. CAMP has
numerous pleiotropic roles in immunomodulation, wound healing and
cell growth. We have previously demonstrated that Camp expression is
up-regulated in the gut when type 1 diabetes (T1D)-prone BBdp rats are
protected from diabetes development. Unexpectedly, we identified
CAMP expression in the pancreatic β-cell, a previously unreported find-
ing. Thus, we sought to characterize the novel roles of CAMP in the
pancreatic islet and investigate its potential as a novel therapeutic for
the treatment of diabetes.
Materials and methods: Immunohistochemistry was used to detect
CAMP expression in the pancreatic islet. Changes in Camp gene were
analysed by qRT-PCR in diabetes-prone BBdp and control BBc rats.
Dispersed islets were loaded with an intracellular calcium indicator,
FURA-2 AM, to assess calcium mobilization following treatment with
the CAMP peptide (LL-37). Glucose-stimulated insulin secretion and
glucagon secretion were evaluated under high or low glucose conditions,
respectively, in the presence or absence of the CAMP peptide. Finally, a
cohort of BBdp rats was treated daily for one week with either the CAMP
peptide or saline control and duct-associated insulin+ cells were quanti-
fied to assess β-cell regenerative processes.
Results: CAMP expression colocalizes with insulin+ but not glucagon+
cells, indicative of the novel expression of CAMP in theβ-cell but not the
α-cell. Camp gene expression was significantly down-regulated in the
islets of young diabetes-prone BBdp rats compared with control BBc rats
prior to the onset of insulitis, suggesting early involvement in T1D path-
ogenesis. CAMP treatment of dispersed islets from both BBc and BBdp
rats resulted in a significant increase in intracellular calcium levels. This
effect was both delayed and blunted in the absence of extracellular calci-
um, indicating that CAMP promotes the mobilization of both extracellu-
lar and intracellular calcium stores. Consistent with the critical role of
calcium mobilization in islet hormone secretion, CAMP treatment simi-
larly promoted both insulin and glucagon secretion from islets isolated
from BBc and BBdp rats. Daily treatment with the CAMP peptide for
7 days resulted in enhanced β-cell neogenesis. In addition, we identified
changes in the gut microbiota in BBdp rats compared with BBc rats.
In vivo CAMP treatment alleviated this gut microbiota dysbiosis and
resulted in a shift in abundance in specific bacterial populations towards
control BBc levels.
Conclusion: Our data indicate for the first time that CAMP is expressed
in the islet β-cell and demonstrate a novel role for CAMP in pancreatic
islet function and β-cell regenerative capacity. Importantly, by stimulat-
ing both insulin and glucagon secretion, CAMP may be promoting islet
paracrine signalling thereby enhancing overall islet function and
glucoregulation. Furthermore, changes in expression in diabetes-prone
BBdp rats indicate that CAMP could play an important role in T1D
pathogenesis. Taken together, these findings strongly suggest that CAMP
could be used as a novel therapeutic target for diabetes.
Supported by: CIHR
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GCN2, a type 2 diabetes mellitus susceptibility gene, is associated
with the regulation of pancreatic beta cell mass
K. Masuda1, A. Kanno2, S.-I. Asahara2, R. Yoshitomi1, T. Matsuda2, M.
Kimura-Koyanagi2, Y. Shibutani2, N. Yokoi3, M. Kasuga4, S. Seino3, Y.
Kido1;
1Kobe University Graduate School of Health Sciences, 2Division of Di-
abetes and Endocrinology, 3Division of Molecular and Metabolic Medi-
cine, Kobe University Graduate School of Medicine, 4Research Institute
National Center for Global Health and Medicine, Tokyo, Japan.
Background and aims: Single-nucleotide polymorphism (SNP) analysis
of Japanese diabetes patients has revealed a significant correlation be-
tween a general control nonderepressible 2 (GCN2) SNP and type 2
diabetes mellitus (T2DM). GCN2 is a molecule activated by amino acid
deficiency. Amino acid deprivation leads to accumulation of uncharged
transfer RNAs (tRNAs), which induce the activation of GCN2. A com-
parison of GCN2 expression in different mouse tissues showed that
GCN2 was prominently expressed in pancreatic islets. We analyzed the
role of GCN2 in pancreatic β-cells and its involvement in the onset of
T2DM.
Materials and methods: We generated generalized GCN2 knockout
mice (GCN2-/-mice), analyzed their metabolic parameters and histology.
We also investigated changes in intracellular signaling by using islets
from GCN2-/-mice and INS-1 cells. Using isolated islets from wild-type
mice fed a normal-chow diet (NCD) and a high-fat diet (HFD), we ana-
lyzed amino acid levels and relative charging levels of tRNAs.
Results:GCN2-/- mice fed a NCD did not exhibit any changes in glucose
tolerance or pancreatic β-cell mass. However, GCN2-/- mice fed an HFD
exhibited significant aggravation in glucose tolerance and reduction in
pancreatic β-cell mass. Islets isolated from GCN2-/- mice showed signif-
icant increase in mTORC1 activity and decrease in insulin signaling. We
also found elevated phosphorylation of TSC2 in islets from GCN2-/-
mice, considered that chronic activation of mTORC1 resulted in reduc-
tion of insulin signaling through the negative-feedback mechanism,
which is consistent with our previous findings on TSC2-/- mice. As
GCN2-/- mice displayed reduction in pancreatic β-cell mass only when
fed an HFD, we compared the activity of GCN2 in islets from wild-type
mice, and found that GCN2 was markedly activated in islets from mice
fed an HFD. Next, we investigated the conditions which activate GCN2
in pancreatic β-cells. In INS-1 cells, GCN2 was activated by glucose
load, but not by other insulin secretagogues. Because insulin translation
was enhanced in islets of mice fed an HFD, we constructed a hypothesis
that amino acids were decreased by its consumption and GCN2 was
activated when translation of insulin is enhanced. To verify our hypoth-
esis, we compared amino acid levels in islets from wild-type mice fed a
NCD with those fed an HFD, and found that a lot of amino acids are
decreased in islets frommice fed an HFD. Moreover, we found decreases
in charging level of tRNAs in islets from mice fed an HFD.
Conclusion: Our results showed that chronic activation of mTORC1
activity is one of the causes of reduction in pancreatic β-cell mass in
GCN2-/- mice. During HFD load, insulin translation is enhanced, amino
acids are decreased, and uncharged tRNAs accumulate in islets, which
leads to the activation of GCN2. From our data, we consider that activated
GCN2 contributes to the maintenance of pancreatic β-cell mass. We
expect that GCN2-/- mice could be one of the models of the pathogenesis
of T2DM in patients who have a SNP in GCN2.
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Calculation of radiation doses to the islets of Langerhans due to
radionuclide imaging with exendin
I. van der Kroon1, W.Woliner-van derWeg1, M. Brom1, C. Frielink1, L.
Joosten1, M.W. Konijnenberg2, E.P. Visser1, M. Gotthardt1;
1Radiology and Nuclear Medicine, Radboud university medical center,
Nijmegen, 2Nuclear Medicine, Erasmus Medical Center, Rotterdam,
Netherlands.
Background and aims:Recently, radiolabeled exendinwas developed to
non-invasively image the beta cells in the islets of Langerhans by Single
Photon Emission Computed Tomography (SPECT) or Positron Emission
Tomography (PET), aiming at increasing our insight into the pathophys-
iology of diabetes. The use of radiolabeled exendin could lead to concern
about radiation-induced damage to the islets because it is known from
literature that high doses of radiation ( >10 Gy) can lead to islet death.
Estimation of the potential radiation-induced damage requires a method
for calculation of the radiation dose to the islets. Commonly used whole
organ dosimetry methods do not contain the islets of Langerhans as a
separate compartment and therefore do not provide the radiation dose to
single islets. Due to high accumulation of the radiolabeled tracer in the
islets as compared to the exocrine pancreas, whole pancreas radiation
dose estimation will underestimate the actual radiation dose to single
islets, while overestimating the dose in the exocrine pancreas. Therefore,
the islets of Langerhans need to be treated as a separate compartment. In
our work, whole organ dosimetry is combined with the islets of
Langerhans as a separate compartment to calculate the islet radiation dose
resulting from imaging of beta cells with radiolabeled exendin. Using this
model, the islet radiation dose was calculated for different conditions (i.e.
different radionuclides, healthy and diabetic patients, different islet sizes).
Materials and methods: The model includes the compartments that
contribute to the islet radiation dose. The contribution of the pancreas
and kidneys to the islet radiation dose was S-value based, while the
self-dose of the islets was calculated using Monte Carlo simulations for
a small sphere model (diameter: 50-400 μm). As input for the model both
data from a clinical study (organ distribution of the tracer) and data from a
preclinical study with Biobreeding Diabetes Prone (BBDP) rats (endo-
crine-exocrine uptake ratio, intra-pancreatic tracer distribution and beta
cell mass), was used.
Results: The islet radiation dose was found to be small with a maximum
of 74.3 mGy for the SPECT tracer 111In-exendin (150 MBq injected
activity per patient) and a maximum of 2.35 mGy for the PET tracer
68Ga-exendin (75 MBq injected activity per patient). The activity in the
islets contributes up to 45% to the total islet radiation dose for 111In-
exendin and up to 22% for 68Ga-exendin. Due to the high accumulation
of radiolabeled exendin in the kidneys, the kidneys have the largest con-
tribution to the total islet radiation dose (49-81%).
Conclusion:The resulting islet radiation doses suggest that even repeated
exendin imaging will not lead to islet death, since the maximum islet
radiation dose is smaller by a factor of 130 - 4000 than the one known
to cause serious islet damage ( >10Gy). Further reduction of the total islet
radiation dose may be achieved by reducing the activity in the kidneys,
for example by co-injection with gelofusin or injection of lower amounts
of activity.
Clinical Trial Registration Number: NCT01825148
Supported by: IGMD
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Effects of obesity and diabetes on alpha and beta cell mass in surgi-
cally removed human pancreas
J. Inaishi1, Y. Saisho1, K. Kou1, S. Sato1, R.Murakami1, T. Yamada2, M.
Kitago3, Y. Kitagawa3, H. Itoh1;
1Department of Internal Medicine, 2Department of Pathology, 3Depart-
ment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Background and aims: The physiological and pathophysiological
changes in beta cell mass (BCM) and alpha cell mass (ACM) in humans
in the face of obesity and diabetes (DM) remain unclear. We have previ-
ously reported that there was no increase in BCM in Japanese obese
individuals compared with lean subjects, however, the study was based
on autopsy pancreas where we were not able to exclude the possibility of
various confounding factors. The aim of this study was that, by using
surgically removed pancreas samples, to clarify 1) effect of obesity or
duration of obesity on ACM and BCM, 2) relationship between the gly-
cemic markers (HbA1c and glycated albumin (GA)), beta cell function
and ACM or BCM, and 3) relationship between postoperative glycemic
control and ACM or BCM in humans.
Materials and methods:We obtained human pancreas samples from 69
individuals (41 men, body mass index (BMI) 22.2±2.9 kg/m2, age 66±
12 years (mean±S.D)) who underwent pancreatic surgery between the
years 2000 and 2012. Twenty-nine patients were diabetic before opera-
tion. Pancreatic sections were stained for insulin or glucagon, and frac-
tional beta (%BCA) or alpha cell area (%ACA) was measured, respec-
tively. In addition, we evaluated the history of obesity by questionnaires
to the patients.
Results: 1) In the non-diabetic (NDM) group (N=40), there was no
significant correlation between BMI and %BCA or %ACA. Cases in
NDM were divided into lean and obese groups (mean BMI 21.6±2.0
vs. 26.4±1.3 kg/m2). Either %BCA or %ACA in obese group was not
significantly increased compared with lean group. Cases in NDM were
also divided into two groups according to the duration of obesity (less
than 10 years and 10 years of more). However, there was no significant
difference in%BCA or%ACA between the two groups. 2) In the patients
with DM (type 2 or pancreatic DM, N=29, 66±8 years, BMI 21.6±
3.1 kg/m2), %BCAwas significantly decreased by 56% compared with
age- andBMI-matchedNDMgroup (P <0.01), while there was no change
in%ACA.%BCA, but not %ACAwas significantly negatively correlated
with HbA1c orGA (r=-0.44, P=0.04 and r=-0.46, P <0.01, respectively).
Furthermore, there was a significant positive correlation between %BCA
and serum C-peptide to plasma glucose ratio before operation (r=0.37,
P=0.03). 3) To clarify the relationship between postoperative glycemic
control and %ACA or %BCA, five cases who underwent total pancrea-
tectomy were excluded. There was no significant correlation between
HbA1c at 6 months after operation and either %BCA or %ACA. How-
ever, %BCA, but not %ACAwas significantly negatively correlated with
GA at 3 and 6 months after operation (r=-0.60, P <0.01 and r=-0.59, P=
0.01, respectively).
Conclusion: We confirmed that there was no increase in either BCM or
ACM in Japanese nondiabetic obese individuals who undertook pancreas
surgery, supporting the hypothesis that beta cell regenerative capacity is
limited in Japanese population. BCM was decreased by 56% in patients
with diabetes, while there was no change in ACM in those individuals.
BCM, but not ACM was associated with preoperative and postoperative
glycemic control. These findings further support the concept that BCM
rather than ACM has a major role in regulating blood glucose level.
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The importance of Zinc transporter 8 autoantibody (ZNT8A) in the
diagnosis of type 1 diabetes in the Brazilian population
K.F.B. Gomes, C. Semzezem, R.T. Fukui, A.S. Santos, R.F. Santos,
M.E.R. Silva;
Laboratório de Carboidratos e Radioimunoensaio–LIM18. Hospital das
Clínicas da Faculdade de Medicina, University of São Paulo, Brazil.
Background and aims: Recently, the Zinc transporter-8 (ZnT8), an islet
cell secretory granule membrane protein, was identified as an autoantigen
in T1D. Autoantibodies to ZnT8 (ZnT8A) complement the established
antibodies to insulin (IAA), to GAD65 (65 glutamic acid decarboxylase,
GAD65A), and to protein tyrosine phosphatase (insulinoma-2 antigen,
IA2A) in Caucasians, but there are few data in Latin-America and in the
very heterogenous Brazilian population, with diverse patterns of
admixture.
Materials andmethods: For this purpose, we analyzed 479 T1D patients
(12.3±7.7 yrs., diabetes duration 10.9±11.5 yrs.) and 329 controls (27.2
±10.6 yrs). Serum levels of GAD65A and IA2A were determined by
radioimmunoassay (RSR limited, UK; CV <7%). Serum levels of Znt8A
were obtained by ELISA (Kronus, USA CV <7). Chi- square test, Fisher
exact test and Mann-Whitney test were used in statistical analysis. P≤
0.05 was considered significant.
Results: The Znt8A frequency of all patients analyzed (48.3%) was sim-
ilar to that of GAD65A (47.7%) and IA2A (45.4%), but GAD65A fre-
quency was slighted greater than that of IA2A (OR=1.25; CI: 1.016-
1.559; p=0.04). All three autoantibodies frequencies declined in a similar
way following years after diagnosis, being more intense after the first
year. The three autoantibody titers also declined with diabetes duration,
being much more faster to ZnT8A. There was a negative correlation
among ZnT8A titers with age of blood collection (r=-0.369; p<0.0001)
and diabetes duration (r=–0.439; p<0.0001), but not with age at diabetes
onset (r=-0.006; p=0.91), even when considering only those patients
with new onset T1D (less than two years of diagnosis). Titers and fre-
quency of ZnT8A and IA-2A did not differ with respect to gender and
ancestry, whereas GAD65A titers were greater in females (12.0±23.9×
6.8±14.9 IU/mL; p=0.003) and in those of European ancestry (10.6±
22.2×6.4±12.6 IU/mL; p=0.01). Among patients with only one islet
autoantibody, ZnT8A, GAD65A and IA-2A corresponded to 10.1%,
10.1% and 4.3% respectively. So, the determination of ZnT8A allowed
the additional diagnosis of DM1 in 10.1% of patients and, only 3.8% of
recent-onset T1 D patients, (until 2 year after diagnosis) remained three
autoantibodies negative The CTLA4 +46A/G was slighted associated
with greater frequency of ZNT8A (80.4%×66.7; OR 2.048, CI=1.138-
3.685; p=0.023). ZnT8A was rare in controls, being the only autoanti-
body observed in seven control subjects (1,5%) who were GAD65A and
IA-2A negative, and its frequency was similar to that GAD65A (1.6%)
and IA2-A (1.6%) in controls.
Conclusion: The prevalence of Znt8A in a Brazilian population (Sao
Paulo city) was higher than previously reported in Asiatic patients with
T1D, but similar to that reported in Caucasians. Therefore, ZnT8A can be
considered a marker for T1D autoimmunity even in heterogenous
populations.
Supported by: FAPESP
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In situ detection of components of innate immune response in human
insulitis
L. Nigi1, F. Mancarella1, G. Ventriglia1, G. Sebastiani1, A. Pugliese2,
G.W. Burke2, M. Battaglia3, F. Dotta1;
1Diabetes Unit, Department of Medicine, Surgery and Neuroscience,
University of Siena, Italy, 2Diabetes Research Institute, Depts. of Medi-
cine and Surgery, University of Miami-Miller School of Medicine, USA,
3Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Insti-
tute, Milan, Italy.
Background and aims: Type 1 diabetes (T1D) is an autoimmune disease
in which both adaptive and innate immune responses are involved in
target organ destruction and dysfunction. The aim of the present study
was to analyze pancreatic expression of components of innate immune
system (neutrophils; CCL2 and its receptor CCR2; CXCL10 and MICA)
in human T1D.
Materials and methods: We analyzed pancreatic specimens obtained
from 4 T1D, 4 autoantibody-positive non-diabetic (AAb+) and 6
autoantibody-negative non-diabetic (CTR) organ donors from the nPOD
cohort, as well as from pancreatic biopsies obtained from 4 T1D
transplanted patients from the nPOD-Transplantation (nPOD-T) cohort.
Formalin-fixed and paraffin embedded sections were used in immunohis-
tochemical investigations to analyze the expression of neutrophils, CCR2
and CXCL10. In addition, triple and/or double immunofluorescence with
confocal microscopy analysis, was performed to identify islet cells sub-
set(s) expressing CCL2 chemokine and MICA protein (a ligand for NK
and CD8 T-cells). Colocalization between CCL2 and MICAwith insulin
and glucagon was performed by using Las AF software.
Results: Immunohistochemical experiments revealed that neutrophils
were detectable in pancreatic exocrine tissue at higher frequency in
T1D and in AAb+ vs CTR (p:0,0095 and p:0,038 respectively). Neutro-
phils were also found in pancreatic exocrine tissue of T1D transplanted
patients. CCR2+ cells were scattered in exocrine tissuewith the following
trend: T1D> AAb+>CTR. The expression of CXCL10 was found in all
insulin containing islets of T1D patients and in several islet cells from
AAb+ donors, while was virtually undetectable in CTR islets. In nPOD-T
donors the expression of CXCL10 was found in several islets. Immuno-
fluorescence analysis revealed that CCL2 was expressed almost exclu-
sively by beta cells in islets of T1D, AAb+ and CTR, as well as of nPOD-
T subjects. The same result was detected in islets of transplanted
pancreata of nPOD-T subjects. Finally, MICA was expressed in few in-
sulin containing islets with inflammatory infiltrates, exclusively in beta
cells in pancreata from transplanted patients of the nPOD-Tcohort but not
of other nPOD organ donors.
Conclusion:Our findings strengthen the hypothesis that: 1 Innate immu-
nity is indeed involved in T1D pathogenesis. 2 Residual presence of
insulin containing cells is associated with ongoing islet inflammation. 3
Immune infiltration affects the whole pancreas and not only pancreatic
islets.
Supported by: JDRF- nPOD initiative
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Increased leucocytic infiltration of islets and exocrine tissue in organ
donors with prolonged duration of life support
S. Smeets, G. Stangé, L. Zhidong, P. in't Veld;
Diabetes Research Center, Vrije Universiteit Brussel (VUB), Brussels,
Belgium.
Background and aims: Leucocytic infiltration of the human endocrine
pancreas is considered to be the hall-mark of recent onset type 1 diabetes
in young patients. Recently, it has been proposed that a more general
infiltration of both endocrine and exocrine pancreas can be found in most
type 1 and type 2 diabetic patients. To interpret these findings, it is
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important to have insight into the variability of leucocytic infiltration in
the normal pancreatic gland in function of the clinical characteristics of
the patient. This study assesses the correlation between the duration of life
support and the presence of a leucocytic infiltrate in human donor pan-
creas. It extends our previous observations, using immunophenotyping to
identify and quantify the infiltrating leucocytes, study the kinetics of the
infiltration in a series of organ donors with increasing duration of life
support, and differentiate between infiltration in the exocrine tissue and
in the endocrine pancreas.
Materials and methods: Pancreas biopsy specimens from non-diabetic
organ donors with different duration of life support (0, 3, 6, 9 and
≥12 days) were used (n=10 per time point). Sections were double-
stained for CD68, CD45, CD3, CD8 and CD20 in combination with
insulin and digitally imaged to quantify the number of leucocytic cells
in total pancreas and islets of Langerhans.
Results: Donor pancreata from patients with a short duration of life sup-
port (0-3 days) showed low levels of infiltrating leucocytic cells. Infiltra-
tion levels strongly increased from 6 - ≥12 days of life support onwards:
CD68+ cells were found to increase 10-fold between day 0 and day 6 (p<
0.0125), remaining at elevated levels at day 9 and ≥12 (p<0.0025), with
up to 9% of total cells found to be CD68+ in some donors (Figure 1).
CD45+, CD3+, CD8+ and CD20+ cells were less markedly increased,
with a significant (p<0.0125) 5-fold increase for CD45 and a significant
(p<0.0125) 2-fold change for CD8 and CD20 between day 0 and day 9.
The number of CD68+ cells in the islets showed a significant 2.5-fold
increase between 0 and ≥12 days (p<0.05), whereas other leucocyte cell
types were present in low numbers and did not show significant changes
between the two groups.
Conclusion: These results show that increased duration of life support is
associated with increased leucocytic infiltration in the endocrine and exo-
crine human donor pancreas from day 6 of life support onwards, affecting
15-33% of pancreatic organ donors. The effect is strongest for CD68+
cells. Clinical conditions around the time of organ retrieval should there-
fore be taken into account when studying inflammatory lesions in the
diabetic pancreas and necessitate adequate matching of patient samples.
Supported by: FWO
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STZ treatment causes immediate depletion of immune cells in sciatic
nerve and dorsal root ganglion
T. Fleming, A. Hidmark, S. Vittas, P.P. Nawroth;
Internal Medicine I and Clinical Chemistry, University of Heidelberg,
Germany.
Background and aims: Streptozotocin (STZ) treatment is common
method for the induction of type 1 diabetes in rodent models. However,
it has been shown that STZ induces thermal hyperalgesia in mice, inde-
pendently of hyperglycemia, and is neurotoxic in vitro by induction of
oxidative stress. These findings bring into question the limitations of
STZ-induced diabetes as a model for diabetic neuropathy. Tissue resident
macrophages constitute the first line of response to toxic challenges by
clearing debris from apoptotic cells via their scavenger receptors. In this
study, the effect STZ treatment on macrophages resident in sciatic nerve
(SN) and dorsal root ganglions (DRG) and determine whether the ob-
served thermal hyperalgesia was associated with neuronal inflammation.
Materials and methods: Healthy, wild-type mice were sacrificed 5 days
after three consecutive treatments of STZ (50 mg/kg/day; i.p.,n=5) or
after 1 week, 3 weeks or 3 months after five consecutive treatments.
Following sacrifice, peritoneal cavity lavage was collected, along with
the DN and DRGs, which were digested and stained with antibodies
against CD45, MHC class II, CD68, CD11b, Ly-6C, mannose receptor
CD206 and activated NFkB and analysized by flow cytometry. Thermal
hyperalgesia was measured by Hargreaves. Statistical significance was
tested with two-tailed student’s T-test.
Results: Transient hyperalgesia was detected 4 days after initiation of
treatment with STZ (resonse times was decreased by 1.3 secs, p<0.01)
before significant difference in blood glucose levels had developed. Ther-
mal hyperalgesia was also evident at 6 days (-0.9 secs, p<0.01) but had
disappeared by 3weeks. The number of CD68+macrophages in the DRG
was significantly reduced at 5 days after treatment (from 9% of all nucle-
ated cells to 2%, p<0,001). The number of CD68+macrophages were not
significantly reduced in the SN at this point, but SN macrophages
displayed increased activation of NFkB (1.9 fold increase of flouresence
intensity p<0.01 and 1.7. fold increase of number of positive cells p<
0.05). At 1 and 3 weeks, CD68+ cells in SN of STZ-treated mice were
reduced to 54% and 39% respectively, as compared to control (p<0.05),
and in particular macrophages expressing CD206 were depleted (from
constituting 70% to 50% of CD68+ macrophages after 1 week, p<0.01).
None of these changes were evident in macrophages obtained by perito-
neal lavage at any of the studied time points, excluding the explanation of
direct effects of STZ on macrophages. There were no signs of STZ-
induced immediate inflammation in the nerve. MHC class II was at no
point up-regulated on macrophages and there was no evidence of inflam-
matory infiltration of CD45+CD11b+LY6C+ monocytes at 1 week. As a
result of the CD68+macrophage depletion, number of intraneural CD45+
cells was significantly reduced (to 64% and 41% of control at 5 days and
1 week respectively, p<0.05 and <0.001). STZ-induced lymphopenia of
peripheral nerve gradually normalized over the course of 12 weeks.
Conclusion: Our findings are consistent with a non-inflammatory innate
immune response in the peripheral nervous system due to a toxic injury
induced by STZ. Depletion ofM2 macrophages by STZ in SNmay affect
the regenerative capacity of the nerve in response to further injury. Symp-
toms of neuropathy observed during the first three months of STZ-
induced diabetes may therefore be indirectly affected by the neurotoxic
effects of STZ.
Supported by: SFB118, DZD/BMBF, Dietmar-Hopp-Stiftung
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Functional silencing of CD4+ T-cells by the modulating RIB5/2 anti-
body prevents islet autoimmunity and systemic prediabetic inflam-
mation in the LEW.1AR1-IDDM rat model
T. Schoeppe, H. Weiss, S. Baltrusch, M. Tiedge;
IBIO, University of Rostock, Germany.
Background and aims: The LEW.1AR1-iddm rat is an animal model of
spontaneous autoimmune diabetes. Islet infiltration occurs within a nar-
row time range between 40 and 60 days after birth with proinflammatory
cytokine peaks in blood PBMCs. The rat-specific anti-CD4 antibody
RIB5/2 confers temporal internalization of the T-cell receptor complex
without depletion of T cells. It was the aim of this study to investigate if
RIB5/2 treatment can ameliorate the proinflammatory state in prediabetic
LEW.1AR1-iddm rats.
Materials and methods: Normoglyceamic LEW.1AR1-iddm rats were
treated between the age of 40 and 50 days with the monoclonal anti-CD4
antibody RIB5/2 (5×5 mg ab/kg b.w. i.p.). 200 μl blood were collected at
day 40 (before antibody application), day 50 and day 60. RNA was
purified from peripheral blood mononuclear cells (PBMCs) that were
isolated by Ficoll density-gradient centrifugation. The RNA was used
for gene expression analysis of proinflammatory (TNFα, IFNγ, IL-1β)
and antiinflammatory cytokines (IL-4, IL-10), T-cell markers (CD25,
CTLA4, NRP1), L-Selectin, TGF-β andFoxP3 by real-time RT-PCR. Rats
were monitored until the age of 120 days. Serial pancreatic sections were
stained with Haematoxylin-Eosin (HE) to document the islet infiltration
process.
Results: All 12 treated LEW.1AR1-iddm rats remained normoglycaemic
and developed no diabetes until age of 120 days. In the control cohort the
diabetes incidence was 60% after 70 days. In comparison to untreated rats
the antibody treated animals revealed by HE- and T-cell staining no lym-
phocytic infiltrations in pancreatic sections. Treatment with the anti-CD4
antibody RIB5/2 resulted in significantly (P<0.05) reduced gene expres-
sion levels of TNFα, INF-γ, IL-4, NRP1 (1.4 - 8-fold) at most 12 days
after the last administration of RIB5/2 (age 60 days) compared with
infiltrated animals. The treatment led to significantly higher expression
of the regulatory genes TGF-β, FoxP3 and L-Selectin (1.2 - 3-fold) but
also significant high levels of the T-cell silencer signal CTLA4 (6-fold)
with an age of 50 and 60 days in compared with infiltrated animals.
Conclusion: The anti-CD4 antibody RIB5/2 treatment conferred tempo-
ral functional CD4 T-cell silencing without significant immunosuppres-
sive side effects in the LEW.1AR1-iddm rats. The treatment induced
permanent tolerance against beta cell autoimmunity with downregulation
of proinflammatory gene signatures in PBMCs. Moreover, this strategy
effectively prevented islet infiltration and beta cell destruction. The data
indicate that CD4+ T-cells play a key-role within systemic inflammatory
processes of islet autoimmunity. T-cell silencing by modulating antibod-
ies may be an attractive option for prevention of human T1DM.
Supported by: EFSD/GSK
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The dependence of the insulin-induced cytokine levels production by
basic genetic markers in the patients with autoimmune diabetes
E.A. Repina1, E.N. Stepanova2, M.N. Boldyreva3, M.V. Shestakova1, I.I.
Dedov1;
1Endocrinology Research Centre, 2Russian medical academy of post-
graduate education, 3FGBU “Institute of Immunology” FMBA of Russia,
Moscow, Russian Federation.
Background and aims: Numerous studies in different countries have
been proven association of some single nucleotide polymorphisms
(SNP) of the gene CTLA-4 with the development of autoimmune diabe-
tes (T1DM). Its protein product expressed by natural T regulatory cells
that control autoimmune inflammation. br />The aim of this study was to
investigate the dependence on the insulin-induced cytokine levels pro-
duction by genotype polymorphisms options rs 231775 and rs 3087243
CTLA-4 gene.
Materials and methods:We examined polymorphisms rs 231775 and rs
3087243 CTLA-4 gene. These two SNPs of CTLA-4 gene were analyzed
in 134 patients with T1DM. The control group consisted of 108 blood
donors without autoimmune disease and family history on them. Allele
identification was performed with Real-Time PCR technique. Associa-
tion of genetic markers with pathology was considered statistically sig-
nificant when p-value<0,05. At the same time we examined cytokines’
levels in 30 patients with T1DM and 10 healthy people. Mononuclear
leukocytes were isolated by centrifugation in the ficoll-verographin den-
sity gradient. The cells thus obtained were resuspended in the complete
nutritient medium reducing their concentration to 2,0×10^6/ml. Phyto-
hemagglutinin (PHA-P) (10 mcg/ml) and insulin (insulin human) (10
mcg/ml) were added to the samples to stimulate mononuclear leukocytes;
cell suspensions were further incubated for 36 hours. Initial, PHA-
induced and insulin-induced levels of interleukin-1 (IL-1), IL-2, IL-4,
IL-6, IL-7, IL-8, IL-10, IL-12, gamma interferon (IFN-γ) and tumor
necrosis factor alpha (TNF-α) in supernatants of cell cultures were mea-
sured by solid phase immunoassay at 450 nm. Statistical analysis was
performed by analysis of variance adjusted for sex and age. It was calcu-
lated the exact two-sided Fisher's test and p-value.
Results: 1) Insulin-induced levels of IL-1, IL-2, IL-4, IL-6, IL-7, IL-12
and IFN-γ were significantly higher in patients with G/G genotype of
polymorphism rs 231775 CTLA-4 gene in comparison with genotypes
A/A andA/G of the same polymorphism (IL-1 - p=0,0042/p=0,0005; IL-
2 - p=0,0025/p=0,0002; IL-4 - p=0,0036/p=0,0036; IL-6 - p=0,0004/
p=0,0004; IL-7 - p=0,0176/0,0070; IL-12 - p=0,0573/0,0097 and IFN-γ
- p=0,0043/p=0,0004).
2) At the same time, insulin-induced levels of IL-1 and IL-6 were signif-
icantly higher in the patients with G/G genotype of polymorphism rs
3087243 CTLA-4 gene in comparison with genotype A/G of the same
polymorphism (IL-1 - p=0,0357 and IL-6 - p=0,0080).
3) Insulin-induced levels of IL-6, IL-8, IL-10, IFN-γ and TNF-α were
significantly higher in the patients with T1DM in comparison with
healthy people (IL-6 - p=0,0215, IL-8 - p=0,0002, IL-10 - p=0,0033,
IFN-γ - p=0,0228 and TNF-α - p=0,0034).
Conclusion: The high levels of IL-6, IL-8, IL-10, IFN-γ and TNF-α
testify quite aggressive autoimmune inflammation in the patients with
T1DM. G/G genotypes of rs 231775 and rs 3087243 CTLA-4 gene poly-
morphisms are the markers of natural T regulatory cells insufficiency,
which is reflected in the levels of insulin-induced cytokine production
in the patients with T1DM.
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Betatrophin in newly diagnosed type 1 and 2 patients: preliminary
results
R. Maciulewski, K. Siewko, A. Zielińska, D. Lipińska, G. Kozłowska,
M. Górska, M. Szelachowska;
Department of Endocrinology, Diabetology and Internal Medicine, Med-
ical University of Bialystok, Poland.
Background and aims: Betatrophin is a factor produced in the liver and
white adipose tissue, regulating the metabolism of lipids, especially tri-
glycerides. There is limited data about this recently discovered molecule.
It has been shown that in mice, betatrophin significantly improves beta
cell function. Preliminary studies in humans suggest that elevated
betatrophin concentration may be associated with an increased risk for
type 2 diabetes (T2D) and cardiovascular diseases. Elevated concentra-
tion of this molecule was also observed in the longitudinal type 1 diabetes
(T1D). The aim of the study was to compare the concentration of
betatrophin in newly diagnosed patients with autoimmune diabetes (AD
- type 1 and LADA), type 2 diabetes and in the control group.
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Materials and methods: The study enrolled 80 patients with newly
diagnosed diabetes: 28 patients with AD (mean age 36±1.98; mean
BMI 23.8±0.94 kg/m2), 26 patients with T2D (mean age 37.7±1.7; mean
BMI 29.5±0.93 kg/m2) and 26 healthy controls (mean age 39.5±2.25;
mean BMI 25.5±0.94 kg/m2). All subjects were measured also C-peptide
concentrations in the glucagon test, the presence of antibodies against
beta cells (GADA, IA-2A, IAA), concentration of interleukin 15 (IL15)
and lipids profile with free fatty acids (FFA). Concentrations of
betatrophin, IL15, FFA, C-peptide, anti-islet antibodies were measured
by ELISA and lipid profile-by Cobas analyser.
Results: Serum betatrophin concentrations were higher in the newly di-
agnosed AD and T2D compared with healthy controls with significant
difference between AD and the control group (p=0.02). C-peptide con-
centration was significantly lower in AD in comparison to the control
group (p<0.001). We found significantly lower total cholesterol concen-
tration in AD group vs T2D (p=0.036), HDL-cholesterol concentration in
T2D vs control group (p=0.04), LDL cholesterol concentration in AD vs
control group (p=0.02), significantly higher triglycerides concentration in
T2D vs AD (p=0.003) and in T2D vs control group (p=0.01). Concen-
tration of betatrophin in T2D correlated negatively with the patient’s
weight (r=-0.4; p=0.04), C-peptide (r=-0.44; p=0.03) and IL15 level
(r=-0.47; p=0.01).
Conclusion: Higher betatrophin concentration in newly diagnosed AD
and T2D in comparison to the control group, may suggest potential role of
betatrophin in the pathogenesis of diabetes, in particular AD. Although Il-
15 seems to be important in the pathogenesis of T1D, we found the
association between betatrophin and IL15 in T2D. A further research
are needed. For that reason, we are going to check the above-mentioned
parameters in another 170 subjects soon.
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Liquefied pancreatic ECM: a novel encapsulation platform for dia-
betes therapy
S. Krishtul, D. Chaimov, L. Baruch, M. Machluf;
Biotechnology and Food Engineering, Technion, Haifa, Israel.
Background and aims: Despite the large potential of beta cells encap-
sulation for diabetic therapy, and the extensive knowledge gained in the
field, severe hurdles impede their clinical application. Those include the
limited longevity of encapsulated beta cells, and the polymers used,
which provide immunological and mechanical protection, but do not
mimic the cell biological niche. Extracellular matrix (ECM) plays a vital
role in the function of mature tissue. Not only it provides a physical niche
for cellular attachments, the ECM is also responsible for transmitting
signals, which affect cellular differentiation, maintenance, and biological
function. Particularly, ECM based materials were demonstrated to im-
prove beta cells culture and insulin secretion. Therefore, the aim of this
study was to develop a unique cell microencapsulation platform, which is
based on isolated natural pancreatic ECM hydrogel, and entraps cells that
are induced to transdifferentiate into insulin producing cells and to pro-
vide a pre-clinical evidence for its applicability for diabetes therapy.
Materials and methods: Insulin-secreting human transduced mesenchy-
mal stem cells and liver cells were encapsulated in gelled
ECM―produced by enzymatic decellularization and liquefaction of por-
cine pancreatic tissue―and injected into diabetic mice.
Results: The newly-developed ECM-microencapsulation system provid-
ed the cells with a natural fibrous niche that supports cell viability, and
significantly improves differentiation and insulin secretion (up to 5-fold
increase comparing to transduced non-encapsulated cells, p 0.001).
Moreover, the ECM-encapsulated cells were immunologically silent, as
concluded from the negligible levels of pro-inflammatory cytokines in the
peripheral blood, the normal values of complete blood count and the
viability of the cells within ECM-capsules even four weeks following
subcutaneous transplantation to mice. Most importantly, transplantation
of approximately 5.5×105 ECM-encapsulated transduced cells to
streptozotocin induced diabetic mice significantly ameliorated hypergly-
cemia for up to four weeks. This was demonstrated in reduced blood
glucose levels which were maintained less than 300 mg/dl through all
the experiment, comparing to the blood glucose levels of the untreated
group (approximately 350 mg/dl). Further, fructosamine concentration
test and glucose tolerance test were performed two weeks post transplan-
tation. The treatment with encapsulated transduced cells had reduced the
fructosamine levels of the diabetic mice to levels of healthy, non-diabetic
mice (p 0.005). Similarly, treatedmice responded to glucose tolerance test
with a clearance rate that paralleled that of healthy mice, whereas in the
untreated group no glucose clearance was evident.
Conclusion: Our results indicate that ECM-microcapsules not only pro-
vide the transdifferentiated cells with immunological and mechanical
protection, but also support cell function by mimicking their natural
niche. Thus, transplantation of the ECM-encapsulated cells, even in min-
imal quantities, to diabetic mice results with a significant amelioration of
their condition. Altogether, the advantages of this ECM-encapsulation
system, clearly point at our ECM-based microencapsulation platform as
a promising prospective cell-based therapy for the treatment of diabetes.
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Bioactive nanocoatings: the integration of active anti-coagulant and
anti-inflammatory therapeutics in multilayer nanocoatings to im-
prove survival of pancreatic islets
A.L.F. Austin, Z.-L. Zhi, A.J.F. King, P.M. Jones;
Diabetes and Nutritional Sciences Division, King's College London, UK.
Background and aims: There are still many obstacles to successful islet
transplantation, the main one being the loss of the functional beta cell
mass in the early post-transplantation period, where up to 70% of the islet
cells become functionally impaired due to the instant blood mediated
inflammatory response (IBMIR). Conformal nanocoating may be one
way in which to protect islets in this early time period by providing a
nano-thin, protective shield around the islet without changing the islet
volume. This would allow transplantation to the clinically relevant
intraportal site whilst still providing protection against cell interactions
and the hostile microenvironment. Importantly, this coating also has the
advantage of being able to incorporate therapeutically active molecules
which can target this IBMIR effect. We have developed a novel
nanocoating scheme using incorporated anti-IBMIR agents to protect
the islets and reduce islet cell destruction in the immediate post-
transplantation period.
Materials and methods: Islets were isolated from ICR mouse pancreata
by collagenase digestion and Histopaque®-1077 gradient. The
nanocoatings were constructed using an anti-coagulant heparin
polyaldehyde and glycol chitosan alternating layering scheme and incor-
porated the anti-inflammatory protein α1-antitrypsin with differing den-
sities of aldehyde groups to alter layering capacity. Anti-coagulant activ-
ity, islet viability and function in vitro and in vivo were assessed.
Results: By controlling aldehyde density generated on heparin at below
5%, the cell viability was greater than 99% in both groups and nanocoated
islets had similar dynamic insulin secretion to non-coated islets. Mice
transplanted with with nanocoated islets had comparable blood glucose
concentrations compared to those transplanted with non-coated islets.
The nanocoating incorporating α1-antitrypsin exhibited significant anti-
coagulant activities in an in vitro clotting assay (strand formation time:
276±6 s vs 235±15 s, control, P<0.05, n=5).
Conclusion: The anti-coagulant and anti-inflammatory activities of our
nanocoating have shown that therapeutic molecules can be successfully in-
corporated. These results demonstrate the potential of this approach for re-
ducing donor cell induced inflammatory responses especially at the crucial
early post-transplantation time points, thus improving transplant outcome.
Supported by: JDRF
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Levels of insulin antibodies negatively associate with insulin sensitiv-
ity in autoantibody-positive adults with newly diagnosed diabetes
V. Burkart1, B. Nowotny1, F. Zivehe1, M.-C. Simon1, K. Strassburger1,
C. Herder1, K. Muessig1, J. Szendroedi1, M. Roden1,2;
1German Diabetes Center, 2Department of Endocrinology and
Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf,
Germany.
Background and aims: Increasing evidence indicates that the pathogen-
esis of type 1 diabetes (T1D) is not only driven by beta cell-directed
autoreactivity but also by insulin resistance (IR). Autoimmunity in T1D
is characterized by the presence of antibodies against beta cell-associated
molecules, such as islet cell antigen (ICA), glutamic acid decarboxylase
(GAD) and insulin, the dominant target autoantigen in T1D. Autoanti-
bodies typically emerge in the prediabetic phase and persist after disease
onset. The link between IR and autoimmunity might be relevant for
monitoring diabetes progression and adaptation of therapeutic strategies,
particularly in the early phase following disease diagnosis. In our current
study we therefore hypothesized that IR associates positively with circu-
lating beta cell-directed autoantibodies in patients with newly diagnosed
T1D.
Materials and methods: From the German Diabetes Study, 156 patients
(97 male, 59 female; mean age 36±11 years; diabetes duration 196±
94 days, A1c 48.6±8.8 mmol/mol) who were positive for at least one
antibody against ICA (immuno fluorescence), GAD or insulin
(radioimmunoassay) were selected. Insulin sensitivity (M-value) of the
patients was determined by hyperinsulinemic-euglycemic clamp tests.
Results: In the patients circulating insulin-directed antibodies (IAA)were
found to be correlated with M-values. The levels of IAA had a median of
0.9 U/ml with an interquartile range of 0.2 to 7.4 U/ml. The clamp studies
yielded M-values with a median of 8.2 mg * kg-1 * min-1 with an
interquartile range of 6.4 to 10.4 mg * kg-1 * min-1. Correlation analyses
by applying an unadjusted model revealed that doubling of IAA levels
decreased the M-value by 2.6% (p=0.023). After adjustment for age, sex
and body mass index (BMI), doubling the IAA level resulted in a 3.9%
lowering of the M-value (p<0.001). Additional adjustment for the pa-
tients´ C-peptide concentration and fasting blood glucose levels as well as
for their daily insulin dose did not affect the correlation between IAA and
M-value (p=0.009). In contrast, levels of antibodies against GAD or ICA
did not correlate with insulin sensitivity.
Conclusion: From our results we conclude that in patients with newly
diagnosed T1D expressing at least one beta cell-directed antibody, insulin
sensitivity negatively relates to IAA, but not to other autoantibodies. This
finding may be of clinical relevance for monitoring the course of the
disease and for optimizing the treatment of T1D in the early phase after
disease onset.
Supported by: DZD
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Autoimmune diseases in children and adults with type 1 diabetes
from the type 1 diabetes exchange clinic registry
J.B. McGill1, T.D. Riddlesworth2, J. Hughes1, L.A. DiMeglio3, K.M.
Miller2, R.W. Beck2;
1Washington University School of Medicine, St. Louis, 2Jaeb Center for
Health Research, Tampa, 3Indiana University School of Medicine, Indi-
anapolis, USA.
Background and aims: Type 1 diabetes (T1D) is often associated with
other autoimmune diseases (AD), but screening guidelines for these ADs
in T1D patients are not well characterized or evidence based. To better
understand the factors associated with and the prevalence of AD in people
with T1D, we analyzed the frequency of AD and associated factors in all
individuals in the T1D Exchange Clinic Registry database.
Materials and methods: Diagnoses of AD, represented as ordinal cate-
gories: 1) no AD, 2) 1 AD, or 3) >1AD based on the list of diseases in the
Table, were obtained from medical record review of 25762 T1D Ex-
change Clinic Registry participants diagnosed with type 1 diabetes
(50% female, 82% non-Hispanic white, mean age 23 yrs, mean duration
of diabetes 11 yrs). Ordinal logistic regression was used to identify de-
mographic and clinical factors associated with the diagnosis of AD.
Results: Of 25762 people diagnosed with T1D, 6588 (26%) were diag-
nosed with at least 1 additional AD: 5054 (20%) with 1 AD and 1534
(6%) with>1 AD. The Table displays the percent diagnosed by specific
AD. Of the most common ADs, 4871 (19%) were thyroid diseases, with
Hashimoto’s disease /hypothyroidism being the most common of the
thyroid diseases, and 1428 (6%) were celiac disease. When comparing
>1 ADwith one AD and noAD, subjects with>1 ADwere more likely to
be slightly older (mean 29 yrs vs 28 yrs vs 21 yrs; p<0.001), female (71%
vs 62% vs 45%; p<0.001), non-Hispanic White (89% vs 88% vs 80%; p
<0.001), and have a longer T1D duration (mean 15 yrs vs 14 yrs vs 9 yrs;
p&lt0.001). Mean HbA1c was similar between AD groups: 8.1% for &gt
1 AD, 8.2% for 1 AD and 8.3% for 0 AD.
Conclusion: In the T1D Exchange Clinic Registry, diagnosis of one or
more AD in addition to T1D is common, particularly in women, older
participants, and non-Hispanic whites. Autoimmune thyroid disease and
celiac disease are the most common associated ADs. Further studies are
needed to better understand contributing factors and the prevalence of
new diagnosis of AD to aid in the development of AD screening recom-
mendations for patients with T1D.
Supported by: the Leona M. and Harry B. Helmsley Charitable Trust
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The role of IL-7 and IL-7/IL-2 receptor isoforms in the development
of the autoimmune T cells of children with type 1 diabetes
K. Förtsch, T. Meissner, B. Ueberberg, C.M. Reinauer, E. Mayatepek,
M. Jacobsen;
Department of General Pediatrics, Neonatology, and Pediatric Cardiolo-
gy, University Children's Hospital, Heinrich Heine University,
Düsseldorf, Germany.
Background and aims: Autoantigen specific CD4+ T cells of a TH1
phenotype support the development of autoimmune diseases and play a
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key role in the pathogenesis of type-1 diabetes. Regulatory T cells can
prevent development and progress of type 1 diabetes. IL-7 has multifac-
eted effects on T cells including induction of effector T cells of a TH1
phenotype and suppressing the development of regulatory T cells. The
crucial role of IL-7 and its receptor for type 1 diabetes was shown in type
1 diabetes animal models and by functional analyses of IL-7 receptor
signalling in patient's material. Association of a polymorphism in the
IL-7 receptor with type-1 diabetes indicated a role of genetic components.
In contrast to IL-7, IL-2 primarily supports the development of regulatory
Tcells, which in principle can prevent the development of type 1 diabetes.
Notably, both IL-7 and IL-2 receptors are strongly regulated during early
T cell activation and polarization. The influence of IL-2 and IL-7 receptor
expression pattern on the T cell response to IL-7 and IL-2 and how this
effects T cell polarization remains unclear. The aim of this study was to
determine cellular and soluble IL-7 and IL-2 receptor expression and to
examine the influence of IL-7/IL-2 in vitro on the generation, polariza-
tion, and regulation on T cell immunity and to identify possible dysreg-
ulation of T cell functions in type 1 diabetes.
Materials and methods: Children with type 1 diabetes were recruited
and classified according to the manifestation age (below or above 5 years)
and disease duration. T cell activation in the presence or absence of IL-7
dependent T cell response is characterized in vitro. Flow cytometry was
applied to determine activation markers, cytokine profile, and IL-7/IL-2
receptor expression. Concomitantly soluble IL-7 and IL-2 receptor iso-
form expression was quantified in plasma and culture samples using
cytometric bead array technology. Immunological results were correlated
with clinical data (including autoantibody status and HLA type).
Results: Initial results showed significant differential IL-7 and IL-2 re-
ceptor expression during T cell activation with and without IL-7. In ad-
dition, we detected increased proportions of IFNγ/TNFα expressing T
cells in the presence of IL-7 and remarkably IL-10 expression was also
enhanced by IL-7. Notably, IL-7 and IL-2 receptor concentrations in
serum samples varied markedly between individual patients with newly
diagnosed diabetes.
Conclusion: Functional in vitro analyses of IL-7/IL-2 receptor expres-
sion during T cell activation and effector cytokine expression may pro-
vide insight into relevant events in the development of type 1 diabetes
autoimmunity. Soluble cytokine receptors in serum are biomarker candi-
dates for disease manifestation and severity.
Clinical Trial Registration Number: DRKS00007397
Supported by: BMBF
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Relationship betweenHashimoto's thyroiditis, autoimmune andmet-
abolic markers in adult onset autoimmune diabetes
L. Duvnjak1,2, D. Majić Milotić1, M. Senta3, K. Blaslov1,2, J. Knežević
Ćuća1;
1University Hospital Merkur, Zagreb, 2School of Medicine, University of
Zagreb, 3University Hospital Center Zagreb, Croatia.
Background and aims: Hashimoto’s thyroiditis and juvenile type 1 di-
abetes mellitus (T1DM) are the most common combination of autoim-
mune (AI) disorders. It was recently proposed that besides genetic sus-
ceptibility central obesity might contribute to unknown mechanisms un-
derlying the thyroid-antibody production. Latent AI diabetes in adults
(LADA) is characterized by clinical presentation resembling type 2 dia-
betes but with T1DM autoimmune markers, primarily glutamic acid au-
toantibody (GADAb). Little is known about the presence of Hashimoto’s
thyroiditis in LADA and adult onset T1DM. We aimed to investigate the
relationship between Hashimoto's disease presence, AI markers and met-
abolic features in patients with LADA and adult-onset T1DM.
Materials and methods: Four hundred and seven patients diagnosed
with AI diabetes over the age of 30 years were divided according to Ab
positivity into three groups: GAD single positive group (representing
LADA); islet cell Ab (ICA)+GAD positive and ICA+GAD+protein
thyrosine phosphatase Ab (IA2) positive group representing adult-onset
T1DM. ICA Ab was measured by indirect immunofluorescence. GAD
and IA2 Abs were detected by enzyme like immunoadsorbent assay
(ELISA). Hashimoto’s thyroiditis was diagnosed by thyroid ultrasound
guided needle biopsy and serologic tests for thyreoiglobulin and tissue
peroxidase Abs by chemiluminescent immunoassay (CLIA). Body mass
index (BMI), waist circumference, arterial hypertension (AH), THS, fT3,
fT4, triglycerides, HDL cholesterol and statin use were also evaluated.
Results: Patients characteristics are shown in Table 1. LADA group
showed significantly higher Hashimoto's thyroiditis presence compared
to the groups of adult-onset T1DM. Althought all patients had TSH and
peripheral thyroid hormone levels within the normal range, TSH was
significantly higher in the LADA group compared to other two groups.
Higher BMI, waist circumference, statin use and AH presence were more
common in the LADA group. In the regression analysis including Ab
status, BMI, waist circumference, the use of statins and the presence of
AH adjusted for gender and age at diagnosis, single GAD positivity was
significantly associated with Hashimoto's thyroiditis (OR 1.977 (1.174-
3.328), p=0.001). The association was also significant for waist circum-
ference and statin use (OR 1.038 (1.003-1.072), p=0.031; OR 1.525
(1.171-1.716), p=0.008).
Conclusion: Hashimoto's thyroiditis is more prevalent in patients with
LADA compared to other forms of AI diabetes in adults. The possible
association of both GAD positivity and waist circumference with the
presence of Hashimoto's thyroiditis in LADA patients was found. These
results might indicate the potential contribution of central obesity in
Hashimoto's pathogenesis which needs to be clarified in further studies.
502
Islet cell associated autoantibodies in Ethiopians with diabetes
mellitus
E.S. Siraj1, M. Gupta2, H. Yifter3, A. Ahmed3, T. Kebede3, A. Reja3;
1Temple University School ofMedicine, Philadelphia, 2Cleveland Clinic,
Cleveland, USA, 3Addis Ababa University, Faculty of Medicine,
Ethiopia.
Background and aims: Our understanding of the role of autoimmunity
in the pathogenesis of diabetes in African population is limited. This
study aims to evaluate the prevalence of 4 different islet cell associated
antibodies in Ethiopian patients with diabetes as well as non-diabetic
controls. In addition, the study intends to assess the utility of a combi-
assay for the simultaneous detection of antibodies against glutamic acid
decarboxylase (GADA) and the protein tyrosine phosphatase like IA-2
(IA-2A) as a first-line screening test for antibodies.
Materials andmethods:A total of 187 subjects from a Diabetic Clinic at
an Ethiopian Hospital were evaluated in a cross sectional study. Fifty five
patients had type 1 diabetes mellitus (T1DM), 86 patients had type 2
diabetes mellitus (T2DM) and 46 were non-diabetic controls. In addition
to clinical information, blood samples well collected. Islet cell associated
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antibodies were measured by using 4 different assays for: islet cell anti-
bodies (ICA), GADA, insulin autoantibodies (IAA) and the IA-2A.
Results: The mean age of studied subjects was 29 years in T1DM,
51 years in T2DM and 29 years in controls. The mean duration of diabe-
tes was 7 years in T1DM and 9 years in T2DM. The results of the
antibody studies [no. positive/no. tested (% positive)] are shown in the
Table below. Testing with individual assays revealed that the combi-assay
positivity was entirely due to GADA and none due to IA-2A. The GADA
assay had a concordance rate of 95% when compared with ICA assay. In
subjects with T2DM, GADA positivity was associated with insulin re-
quirement (P=0.022), lower BMI (P=0.039) and lower basal C-peptide
levels (P=0.005).
Conclusion: 1- Ethiopian patients with T1DM have a higher prevalence
of islet cell associated autoantibodies than patients with T2DM. 2-GADA
seems to be significantly present in Ethiopians whereas IA-2A seems to
be absent. 3-Because of its simplicity and its good diagnostic accuracy,
GADA should replace the ICA as the assay of choice. 4-Subjects with
T2DM, who are GADA+, have some features of T1DM, supporting the
notion that a subset of T1DM patients may exist within the group of
Ethiopians with T2DM.
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Proinsulin peptide immunotherapy in type 1 diabetes: safety data of
a first in new-onset type 1 diabetes phase 1b trial
M. Alhadj Ali1, Y.-F. Liu2, R. Stenson1, G. Clifford1, L. Adams3, J.
Powrie3, D. Kyne4, N. Leech4, K. Green5, R. Andrews5, M. Peakman2,
C. Dayan1;
1Cardiff University School ofMedicine, 2Department of Immunobiology,
King’s College London, 3Department of Diabetes and Endocrinology,
Guy’s and St. Thomas’ Foundation Trust, London, 4Department of Dia-
betes and Endocrinology, Victoria Royal Infirmary, Newcastle upon
Tyne, 5Joint Clinical Research Unit, Bristol Royal Infirmary, UK.
Background and aims: In Type 1 Diabetes, nonclinical studies have
shown that Antigen Specific Therapy (ASI) strategies have been highly
effective in disease prevention, and some of them have worked in the
much more stringent setting of close to, or at, disease onset. Furthermore,
they have demonstrated that the ASI strategies may be effective when the
relevant autoantigen is delivered as a short peptide, representing a key
target (termed an epitope) of the pathological T lymphocyte response that
is characteristic of the disease. Clinical trials of ASI as applied to Type 1
Diabetes have predominantly focused on insulin as the autoantigen, ad-
ministered by a variety of routes, in the setting of secondary prevention.
Aims and objectives: We aimed to examine the safety of intradermal
administration of the naturally processed proinsulin peptide C19-A3
(PPI C19-A3) at a dose of 10 μg every 14 days or every 28 days for a
total of 12 doses (Group B) and 6 doses (Group C), respectively, to
patients with new-onset Type 1 diabetes.
Materials and methods: The trial was a multi-centre, randomised; dou-
ble-blind, placebo-controlled, 3-arm study of 10 μg of PPI C19-A3 pep-
tide administered every 14 or every 28 days, with follow-up for 48weeks.
27 patients aged 18-45 with new-onset Type 1 Diabetes, HLA-
DRB1*0401 genotype, antibody positivity and a stimulated c-peptide
level >0.2pmol/ml were recruited to the trial within 100 days of diagnosis.
TAll subjects received injections at bi-weekly intervals, and in the case of
the placebo group (Group A) (n=8) this was normal saline only; for the
low frequency dosing group (Group C) (n=10) this was alternate study
drug and normal saline only; and for the high frequency dosing group
(Group B) (n=9) this was the study drug on every occasion.
Results: The trial injections have been generally well tolerated and all
recruited patients completed the trial follow up with no withdrawal. No
events of systemic hypersensitivity (type 1) have been reported in the
trial, therefore; it has been shown that administration of Proinsulin peptide
was safe. Only 5 serious adverse events (SAEs) were reported and clas-
sified as mild or moderate in severity (either unrelated or unlikely related
to the randomisation drug). Local trial investigators did not report any
SUSAR. More than 75% of adverse events (AEs) have been reported as
hypoglycaemic episodes unlikely related to the randomisation drug, how-
ever; local skin reaction at the injection site has been reported as an AE
that is likely related to the trial drug with no systemic complications.
Conclusion: Proinsulin peptide immunotherapy in the dosing regimen
used is well tolerated and free from the risk of systemic hypersensitivity
and serious adverse reactions. The safety from hypersensitivity reaction
was clearly seen in the repeated dosing up to 12 doses in the same patient.
This phase 1 trial will pave the route for future phase 2 trials in new-onset
Type 1 Diabetes which aim to examine the effectiveness of Proinsulin
peptide immunotherapy on T cell autoimmunity and preservation of β
cell function.
Clinical Trial Registration Number: EudraCT Number: 2007-003759-35
Supported by: DVDC (Diabetes Vaccine Development Centre
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Prevalence of latent autoimmune diabetes in young, non obese, adult
onset diabetes patient with poor response to oral insulin
secretagogues
A. Shrivastav, S. Mukhopadhyay, S. Chowdhury;
Institute of Post GraduateMedical Education& Research, Kolkata, India.
Background and aims:Latent autoimmune diabetes in adults (LADA) is
defined as adult-onset diabetes with circulating islet antibodies but not
requiring insulin initially. Diagnosing LADA has treatment implications
because of the high risk of progression to insulin dependency. This study
was done to observe the prevalence of LADA in young (25-40 years),
adult onset ( >20 years) and non obese (BMI<23) diabetic patients having
poor glycemic control with Oral insulin secretagogues
Materials andmethods:Three hundred young (25-40 years), adult onset
(>20 years) and non obese (BMI<23 )diabetic with poor glycemic control
with optimal dosage of Oral insulin secretagogues (Sulphonylureas) were
included in the study. None of the patient had e/o Ketoacidosis. Detailed
clinical History, family history and Anthropometric measurements were
taken. Ultrasound screening of pancreas was done for every patient.
HbA1c, fasting C peptide, 1 hour post meal C peptide, Anti Glutamic
acid decarboxylase antibodies (GADA) and Islet Cell Autoantigen 512
Antibodies (AntiIA2) were estimated for every patient.
Results: The mean age of patients was 33 years and they had diabetes for
an average of 6 years. On Autoantibody screening, 134 patients came out
to be Autoantibody positive. 122 patients (40.67%) were positive for
GADA and 21 patients were positive for Anti IA2 antibodies. 9 of the
21 Anti IA2 positive patients were also having Anti GAD Antibodies.
Patients who were Antibody positive had lower BMI , more complica-
tions and worse glycemic control. Family history of Diabetes was most
predictive of absence of Antibodies.
Conclusion: The high prevalence of LADA (44.67%) in our study is
among a selected subclass of diabetic with higher pretest probability for
LADA. The prevalence in general diabetics will bemuch lower. However
we can say that Antibody screening in this select group of diabetic
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(young, non obese, no family history) is warranted and will lead to better
standards of care. The low positivity of Anti IA2 Antibody as compared
to GADA has also been observed in other Indian studies and may be due
to lower prevalence of HLA DR4. Young, non obese diabetes patients
with adultonset diabetes, no family history and poor response to oral
insulin secretagogues should be screened for Autoimmune Diabetes.
Fasting / Stimulated C peptide is a good screening test with a poor re-
sponse leading to a higher pre test probability for testing positive for
LADA. A high C peptide rules out Autoimmune Diabetes.
Supported by: RSSDI WEST BENGAL
505
Misclassification of outcomes of pancreas transplantation
T. Bawa1, S. Clarke-Swaby2, M. Drage2, P. Choudhary3;
1King's College London, 2Guy's Hospital, London, 3Diabetes Research
Group, King's College London, UK.
Background and aims: Success rates for pancreas transplantation have
been steadily improving, with 5-year survival rates over 70% for simul-
taneous pancreas kidney transplants. Currently, graft failure is defined as
the re-introduction of insulin, which has some limitations. Different cli-
nicians have different thresholds to introduce insulin, and some choose to
start oral therapies first in some cases. Alternatively, some patients may
still have residual C-peptide despite being on insulin therapy, providing
important protection against hypoglycaemia. As a result, current graft
survival rates may not provide an accurate picture of graft success - i.e.
restoration of the patient to the non-diabetic state. Our hypothesis is that a
clinically relevant proportion of patients may be misclassified. Our aim
was to identify the number of patients with misclassified graft function
who had had a pancreas transplant at our transplant unit between 2008
and 2012.
Materials and methods:We were able to obtain latest available HbA1c,
fasting glucose [FG], C-peptide, and current therapy for 103/124 pancreas
transplant recipients at Guy’s hospital between 2008 and 2012, of which
90 were simultaneous pancreas kidney and 13 were solitary pancreas
transplantations. We classified pancreas grafts using current definitions
of function based on insulin use and compared this to a modified classi-
fication based around definitions of diabetes. We categorised grafts using
the following criteria: 1] Functioning: HbA1c<6% or FG <6.1 mmol/L,
and on no diabetes medication; 2] Partial function: HbA1c≥6% or FG≥
6.1 mmol/L, and on basal insulin alone/oral therapy/no therapy, or having
C-peptide>300pmol/L. 3] Failure: Pancreatectomy or C-peptide<
300pmol/L. If C-peptide was unavailable, HbA1c≥6.5% or FG≥7.0,
and full insulinisation was considered graft failure.
Results: Of the 103 transplants, there were 10 early technical failures
[<1 month post transplantation]. 71 are currently classified functioning
and 22 as late failure, after a mean follow up of 4.0±1.7 years. Of 71
functioning grafts, 7 met our criteria of partial function, with 2 patients on
oral therapy and 5 with raised HbA1c on no therapy. Of the 22 with late
failure [mean time to failure 1.7±1.4 years], 2 met our criteria of partial
function; 1 had residual function with preserved C-peptide, the other on
basal insulin only. In the 20 that met our criteria of failure, 45% [n=9]
failed after experiencing a period of partial function. In total, 9/103 grafts
[8.7%] were misclassified according to our criteria. C-peptide data was
incomplete and some patients classified as having late failure may still
have some measurable C-peptide.
Conclusion: Our new classification system would reclassify 8.7% of
grafts as having partial function. Almost half of the grafts that developed
late failure were documented as having a period of partial graft function
for some time before complete graft failure, and identifying these patients
early may represent an opportunity to understand mechanisms of graft
failure and intervene to prolong graft survival.
PS 032 Improving transplantation
outcomes
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Protein tyrosine phosphatase 1B is a novel target on the improvement
of islet graft's revascularisation
H. Figueiredo1, A.L. Castillo Figueroa1, A. Garcia1,2, R. Fernandez-
Ruiz1,2, H.S.M. Farghaly1,3, R. Malpique1, R. Gomis1;
1Diabetes and Obesity Research Laboratory, IDIBAPS-Hospital Clínic,
University of Barcelona, 2CIBERDEM, Barcelona, Spain, 3Faculty of
Medicine, Assiut, Egypt.
Background and aims:One of the main limitations encountered in pan-
creatic islet transplantation, leading to islet loss and graft failure is poor
revascularization. Protein tyrosine phosphatase 1B (PTP1B) is known to
negatively mediate several signaling pathways by maintaining phospho-
tyrosine levels in key proteins. Recently PTP1B was described as a neg-
ative regulator of angiogenesis through vascular endothelial growth factor
(VEGF) signaling. In this sense, our main aim is to investigate if PTP1B
ablation contributes to the improvement of graft revascularization and
survival.
Materials and methods: Diabetic BALB/c mice (single injection of
streptozotocin - 160 mg/Kg) were transplanted, with 200 islets, isolated
from PTP1B-/- or PTP1B +/+ mice, into the anterior chamber of the eye.
Four groups of animals were constitute (n=12 animals/group): Non
transplanted; Control - transplanted with PTP1B+/+ islets; PTP1B-/- -
transplanted with PTP1B-/- islets; and not diabetic group. Animals were
followed for 28 days during which weight and glycemic levels were
measured. Graft revascularization was evaluated, in vivo, at day 7, 15
and 28. Post-mortem morphometric analysis was conducted on graft-
containing eyes. Gene expression (qRT-PCR), and protein detection
(ELISA), were performed in islet samples.
Results: After 28 days the PTP1B-/- group showed normalization of
glycemic levels when compared with the not diabetic group (PTP1B-/-:
161±32 mg/dL vs not diabetic: 140±22, not significant) and a dramatic
decrease when compared with the control (472±52 mg/dL, 66% de-
crease, p<0.05) and non transplanted groups (528±22, 70% decrease, p
<0.01). Graft functional vascularization was accessed, in vivo, after 7, 15
and 28 days post-transplant. In all moments, PTP1B-/- group, showed
increased vascular density (day 7: PTP1B-/-: 0.0187±0.002% vs Control:
0.0130±0.001%, p<0.05/ day 15: PTP1B-/-: 0.0290±0.005% vs Control:
0.0188±0.002%, p<0.05/ day 28: PTP1B-/-: 0.0297±0.004% vs Control:
0.0187±0.005%; p<0.05) and increased vascular area (day 7: PTP1B-/-:
11.3±3% vs Control: 5.8±2%, p<0.001/ day 15: PTP1B-/-: 21.4±2% vs
Control: 10.8±2%, p<0.001/ day 28: PTP1B-/-: 23.180±2% vs Control:
10.027±3%; p<0.001). Grafts from both groups reached maximum re-
vascularization by day 15. Morphometric analyses of the graft-containing
eyes (recovered at day 28) revealed a 5-fold increase on the percentage of
ß-cell expressing VEGF on PTP1B-/- grafts when compared with the
control (PTP1B-/-:89.9±9% vs control: 17.86±3%; p<0.001). Moreover,
when compared with PTP1B+/+ islets, PTP1B-/- islets show a 3 fold in-
crease in VEGF expression (p<0.05) and, at the protein level, a 1.8 fold
increase in relative VEGF secretion by VEGF islet content (PTP1B-/-:
1.95±0.45 vs PTP1B+/+: 1.05±0.1, p<0.05).
Conclusion: Our results reveal PTP1B as a particular key player on the
revascularization of islet grafts, suggesting this as a potential novel target
for an improved therapeutic treatment in islet transplantation. Further
investigation is being conducted to decipher the signaling mechanism
behind these findings.
Supported by: MICINN SAF2010-19527;GenCat. 2009SGR1426;Beca
Recerca Bàsica2014 L'Academia
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The co-transplantation of islets with dental pulp stem cells improved
survival and function of transplanted beta cells in streptozotocin-
induced diabetic mice
I.-A. Takako1,2, T. Shin1, I. Atsushi1, H. Kaori1, N. Yasuhiro1, M.
Ryuya1, S. Yusuke3, H. Yoji3, O. Yutaka1;
1Endocrinology and Diabetes, 2Oral and Maxillofacial Surgery, 3Meta-
bolic Medicine, Nagoya University Graduate School of Medicine, Japan.
Background and aims: Pancreatic islet transplantation is an attractive
treatment option for Type 1 diabetes mellitus (T1DM). Islet transplanta-
tion has some issues, however, such as the required administration of
immuno-suppressant drugs and the low rate of insulin withdrawal due
to a short survival rate of transplanted islets. Therefore, it is critical how to
protect the viability of transplanted islets in recipient. Recent studies
reported that co-transplantation of Mesenchymal Stem Cells (MSC) with
pancreatic islets improved glycemic control more than that of pancreatic
islets alone. Meanwhile, we have reported that secreted factors from stem
cells, especially Dental pulp stem cells from human exfoliated deciduous
teeth (SHED) rather thanMSC, has beneficial effects in paracrine manner
on viability of pancreatic islets. SHED have received considerable atten-
tion because of requiring a less invasive collection method and their
applicability to autologous treatment. Therefore, we examined the effect
of co-transplantation of islets with SHED on glycemic control in
streptozotosin (STZ) diabetic mice.
Materials and methods: Islets were isolated from 10 week-old male
C57Bl/6J. STZ (150 mg/kg body weight) was intraperitoneally injected
into 10 week-old male C57Bl/6J mice one time only. Three days after this
single STZ injection, the mice were divided into six transplanted groups:
Sham (CTL), transplantation of SHED alone (a-SHED: 5×105 cells),
MSC alone (a-MSC: 5×105 cells), islet alone (a-Isl: 75 islets), islets with
MSCs (co-MSC: 75 islets and 5×105 cells) or islets with SHED (co-
SHED: 75 islets and 5×105 cells). The cells were transplanted into the
kidney capsule of C57Bl/6J. An intraperioneal glucose tolerance test
(IPGTT) and insulin content were examined 28 days after the
transplantation.
Results: Co- SHED ameliorated glucose intolerance and reduction of
body weight in STZ-diabetic mice and the effects continued for 28 days
after transplantation, although all other groups did not show any benefi-
cial effect. Only Co- SHED also suppressed the elevated level of blood
glucose and enhanced the insulin secretion during IPGTT. These data
suggested that the improved viability of transplanted islets possibly con-
tributed to the improvement in glycemic regulation, thus we next inves-
tigated the state of insulin preservation in transplanted islets. Co- SHED
and co-MSC preserved the insulin content of transplanted islets in the
kidney capsule more than a-Isl, and the level of insulin content in co-
SHEDwas much higher than in co-MSC. Interestingly, histological study
showed that transplanted SHED survived for 28 days after transplanta-
tion, even though any immuno-suppressant drug was not administrated.
Conclusion: This study demonstrated that co-transplantation of islets
with SHED had much more beneficial effects on the survival of
transplanted islets than transplantation of islet alone and co-
transplantation with MSC. Furthermore, the result of their long survival
of SHED after transplantation suggested that SHED might modulate the
immune reaction. The co-transplantation of islets with SHED has poten-
tial as practical strategy for T1DM treatment.
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A newly developed non-haematopoietic erythropoietin analogue pre-
vents damages to transplanted islets and inhibits macrophage
activation
M. Kumagai-Braesch1, M. Watanabe1, A. Cerami2, M. Brines2, C.-G.
Östenson3, T. Lundgren1;
1CLINTEC, Transplantation Surgery, Karolinska Institutet, Stockholm,
Sweden, 2Araim Pharmaceticals, Tarrytwon, USA, 3Molecular Medicine,
Karolinska Institutet, Solna, Sweden.
Background and aims: Pancreatic islet transplantation (PITx) efficiency
has been hampered by islet damage during isolation and inflammatory
reactions at transplantation. Erythropoietin (Epo) exerts anti-inflammato-
ry, anti-apoptotic and cyto-protective effects in addition to its hematopoi-
etic property. We’ve investigated if a newly developed non-
haematopoietic epo analogue, ARA 290, would protect islets and ame-
liorate inflammatory responses following PITx.
Materials and methods: Effects of ARA 290 on pancreatic islets of
C57BL/6J (H-2b) mice and on murine macrophage were investigated
in vitro in a culture model. As a marginal PITx, 175 islets were
transplanted intraportally to STZ-induced diabetic mice (H-2b). ARA
290 (120 μg/kg) was given intraperitoneally just before and at 0, 6 and
24 hours after PITx. Liver samples were obtained at 12 hours after PITx,
and expression levels of pro-inflammatory cytokines were assessed.
Results: ARA 290 protected islets from cytokine-induced damage and
apoptosis. Pro-inflammatory cytokine secretions (IL-6, IL-12 and
TNF-α) were significantly inhibited by ARA 290. In the transplantation
sutdy, ARA 290 treatment significantly improved metabolic control of
recipients after marginal mass PITx. Intra peritoneal glucose tolerance test
(IPGTT) performed at day 14, showed significantly lower area under the
curve (AUC) in the ARA 290 treated group (Figure 1). Up-regulation of
MCP-1,MIP-1β, IL-1β and IL-6mRNA expressionwithin the liver were
suppressed by ARA 290 treatment.
Conclusion:ARA 290 protected pancreatic islets from cytokine-induced
damage and apoptosis in vitro and ameliorated the inflammatory response
following PITx. It appears to be a promising candidate for improvement
of PITx.
Supported by: ALF (Stockholm), svenska barndiabetesfonden, SRP in
DM at KI
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Quantitative imaging of intramuscular transplanted islets of
Langerhans with SPECT by dopamine 2 receptor targeting
S.M.A.Willekens, I. van der Kroon, D. Bos, L. Joosten, C. Frielink, O.C.
Boerman, M. Brom, M. Gotthardt;
Radiology and Nuclear Medicine, Radboud university medical center,
Nijmegen, Netherlands.
Background and aims: Besides insulin therapy, islet transplantation is
considered one of the most promising therapies for type 1 diabetic pa-
tients with poor glycemic control. Despite improvements in immunosup-
pressive therapy, islet transplantation still results in short term insulin
independence. A non-invasive imaging method to, longitudinally and
quantitatively, monitor the viable transplanted islets might provide insight
in the faith of the islets after transplantation. Furthermore, it would offer
the possibility to evaluate potential interventions that might improve long
term transplantation outcome. Dopamine (D2) receptors are expressed on
beta cells and are therefore a suitable target to monitor islet grafts. Here,
we inves t iga ted the use of the D2 recep to r an tagon i s t
[123I]Iodobenzamide ([123I]IBZM) for the quantification of viable graft
volume.
Materials andmethods: Sixweeks after rats were transplanted intramus-
cularly with 1000, 2000 or 3000 islets, they received 50MBq [123I]IBZM
intravenously and one hour post injection SPECT images were acquired.
Afterwards, animals used for ex vivo autoradiography were injected with
[125I]IBZM, euthanized 1 h post-injection, and the graft containing mus-
cles were dissected for ex vivo SPECT, autoradiography and histological
analysis. Viable graft volume was calculated histologically by multiply-
ing insulin-positive area by interslice distance.
Results: Six weeks after transplantation, a clear signal of all grafts was
observed by SPECT. Moreover, the intensity of the SPECT signal corre-
lated linearly with the calculated viable graft volume (Pearson r=0,73 ;
p=0,005). The SPECT signal observed in the calf muscle ex vivo corre-
lated with the SPECT signal observed in the calf muscle in vivo. Further-
more, ex vivo autoradiography confirmed specific tracer accumulation
and co-localization with the grafts location, as determined histologically.
These observations confirm that the SPECTsignal observed in vivo orig-
inates from specific targeting of the D2 receptor, expressed on the graft.
Conclusion: In conclusion, [123I]IBZM can successfully be applied for
non-invasive, quantitative graft observation in vivo. Especially in combi-
nation with other beta cell specific tracers, such as exendin, it might
provide a strong tool to obtain detailed complementary information by
non-invasive molecular imaging and to predict islet graft metabolic state
and transplantation outcome.
Supported by: EU FP7/2007-2013/ under grant agreement n° 289932
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Comparative biology of porcine and human islets in situ and after
xenotransplantation in vivo
J.K. Stertmann, C.M. Cohrs, C. Chen, H. Chmelova, M. Solimena, S.
Speier;
Paul Langerhans Institute Dresden of Helmholtz Centre Munich at the
University Clinic Carl Gustav Carus of the Technische University Dres-
den, Germany.
Background and aims: Islet transplantation is a successful experimental
clinical approach for the treatment of brittle diabetes. However, its wide
application is limited by the shortage of human organ donors. Pig to
human xenotransplantation may serve as a potential alternative approach.
Sparse previous work on isolated islets and dispersed cells suggested that
porcine islet endocrine cell composition and architecture differs from
human islets, potentially affecting the regulation of islet cell function.
However, detailed information about the physiology of porcine islets as
well as the vascular network is still limited. To further increase our knowl-
edge and to circumvent the enzymatic stress during islet isolation, we
utilize acute pancreas tissue slices to compare the three-dimensional mor-
phology of porcine and human islets in situ. This approach allows the
analysis of endocrine cells and intact intra-islet vascular network within a
conserved anatomical environment under near physiological conditions.
Furthermore, we evaluated the ability of porcine and human islets to
rebuild their distinct vascular network after transplantation, by three-
dimensional analysis of transplanted islets in vivo.
Materials and methods: We here used a combinational approach of
pancreas tissue slices and the anterior chamber of the mouse eye platform
to assess three-dimensional islet architecture of human and porcine islets
in the endogenous pancreas in situ and after xenotransplantation in vivo.In
situ analysis of endogenous islet architecture was performed on pancreas
tissue slices prepared from slaughterhouse pigs and human tissue obtain-
ed after partial pancreatectomy. The tissue was stained for insulin, gluca-
gon for endocrine cell composition and the vascular network was visual-
ized by fluorescently labeled lectin. In vivo, intra-islet vascular network
was assessed in fully engrafted porcine and human islets transplanted to
the anterior chamber of the mouse eye by i.v. injection of a fluorescent
tracer.
Results: Three-dimensional analysis of human and porcine pancreatic
tissue slices revealed cell compositional differences of the insulin (55%
±6.95 for human vs. 67.4%±6.10 for porcine, p-value <0.05) and gluca-
gon fraction (24.7%±7.73 human vs. 6.2%±2.66 porcine, p-value
<0.01). Additionally fractional blood volume displayed significant differ-
ences between the species (7.97%±2.65 vs. 10.26%±2.94, p-value
<0.05).
After xenotransplantation into the anterior chamber of the mouse eye, the
vascular network of porcine donor islets was similar to the in situ situation
(8.78%±3.63). In contrast, human islets displayed a reduced potential to
revascularize under xenogenic conditions (2.32%±1.10).
Conclusion: In conclusion, the three-dimensional in situ analysis reveals
interspecies differences of islet architecture which are potentially impor-
tant for islet function. Additionally, our in vivo approach could show that
porcine islets have the potential to rebuild their endogenous vascular
network under xenogenic conditions which might be crucial for therapeu-
tic islet transplantation.
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The effect of transplanted pancreatic islets on recipient liver mor-
phology: rat animal study
J. Kriz1, E. Fabryova2, Z. Papackova2, D. Jirak3, E. Sticova4, M.
Cahova2, T. Koblas2, F. Saudek1;
1Diabetes Center, 2Center of Experimental Medicine, 3MRI unit, 4Trans-
plant Center, Institute for Clinical and Experimental Medicine, Prague,
Czech Republic.
Background and aims: The permanent hyperinsulinemia in Type-2 di-
abetic patients is considered a likely risk factor for development of pri-
mary liver tumor. Pancreatic islets are commonly transplanted into the
hepatic portal vein and the liver tissue is subsequently exposed to insulin
in locally high concentration. There were published several articles pro-
nouncing the hypothesis of a direct influence of transplanted islets on
formation and subsequent progression of morphological changes in liver
tissue (tumors, cysts). Therefore our study was focused on monitoring of
liver changes during 10 months follow up after transplantation of pancre-
atic islets in rat animal model.
Materials and methods: Isolated pancreatic islets were transplanted into
diabetic (streptozotocin) or healthy recipients in isogeneic manner. Group
A (n=5) - healthy Brown Norway recipients, transplantation of 450 islets
into the portal vein; Group B (n=17) - STZ (50 mg/kg) diabetic Brown
Norway recipients, transplantation of 450 islets into the portal vein;
Group C (n=8) - STZ (50 mg/kg) diabetic Brown Norway recipients,
transplantation of 1000 islets under the left kidney capsule; Group D
(n=8) - STZ (60mg/kg) diabetic PragueHereditary Hypertriglyceridemic
recipients, transplantation of 1200 islets into the portal vein; Blood glu-
cose levels, weight, IVGTTwasmonitored in all recipients for 10months.
The morphology of liver was examined by magnetic resonance imaging
(MRI) 5 and 8 weeks after islet transplantation. At the end of study all
recipients liver were excised, fixed in formalin and examined by
histology.
Results: Injection of streptozotocin induced severe diabetes (glycaemia
over 25 mmol/l) in all animals. Transplantation of pancreatic islets in
suboptimal number normalized fasting blood glucose levels but did not
normalize glucose assimilation in IVGTT in all diabetic recipients. In
healthy recipients transplanted islets did not modify blood glucose levels.
While liver of Group A recipients remained intact, in animals of Group B
and C the substantial part of liver tissue was cystically changed. Multiple
voluminous cystic complexes with cholangiocyte cubic epithelium lining
were detected in these animals irrespective of transplantation site. In
insulin resistant animals of Group D, the transplanted islets caused just
formation of focal steatosis until the end of study. The total volume of
hepatic cysts detected in animals of group B by MRI was 0.42±0.92 ml
and 4.68±9.57 ml five and eight months after transplantation, respective-
ly. This represented 4.3% and 29.3% of total liver volume.
Conclusion: The injection of diabetogenic agent streptozotocin and sub-
sequent transplantation of isogeneic pancreatic islets can induce liver
morphological changes, which were different in relation to the strain.
Further research is needed to identify the differences in Brown Norway
and hHTG rats, which are substantial for kind of liver reaction.
Supported by: IGACMHNT14240-3, CSF 14-03305S, MHCZ Inst. supp.
00023001
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Human IAPP impairs the success of islet transplantation
A. Hara1,2, Y. Fujitani1, T. Ogihara1, T. Miyatsuka1, H. Watada1,2;
1Department of Metabolism & Endocrinology, 2Center for Therapeutic
Innovations in Diabetes, Juntendo University Graduate School of Medi-
cine, Tokyo, Japan.
Background and aims: ß-cell replacement by islet transplantation has
been explored as a potential curative therapy for type 1 diabetes. Despite
advancements in islet manipulation and immune suppression that have
increased the survival of transplanted islets, the progressive decline of
graft function remains a problem, and many recipients return to being
insulin dependent within a few years after the transplant. However, the
molecular mechanisms underlying the loss of function of grafted islets
have not been fully elucidated. Islet amyloid polypeptide (IAPP)-derived
amyloid deposits were observed in approximately half of the implanted
islets in a recipient with type 1 diabetes. We therefore hypothesized that
human IAPP (hIAPP) in transplanted islets contributes to loss of islet
function and impairs the success of islet transplantation. The aim of this
studywas to elucidate the role of hIAPP during islet transplantation, using
knock-in mice that express a physiological level of hIAPP.
Materials and methods: Islet donors were 16-week-old hIAPP-KI male
mice and C57BL/ 6J (control) male mice. Mice with a plasma glucose
level>400 mg/kg 7 days after streptozotocin treatment that were fed a
high-fat diet (60% fat) were used as recipients. Recipients were implanted
under the kidney capsule with 150 hIAPP- KI or control islets. Following
transplantation, blood glucose levels and body weight were measured for
8 weeks. Thereafter, metabolic parameters were measured, and the graft-
bearing kidney was subjected to both histological and biochemical anal-
ysis. To assess glucose level-dependent cell death, islets were cultured for
4 days in medium containing 200, 300, or 400 mg/dL glucose, and
oligonucleosomes released into the cultured cell lysate were quantified.
Results: Plasma glucose levels were significantly higher in mice im-
planted with hIAPP-KI islets (hIAPP group) than control islets from
3 days after transplantation. Normalized scores, which reached
normoglycemic levels (<200 mg/dL) after transplantation, were lower
in the hIAPP group than the control group. HbA1c levels were well
controlled in the control group (4.8%) but not in the hIAPP group
(6.7%) after 8 weeks of transplantation (P<0.005). The insulin content
of kidneys from the hIAPP group were significantly lower than the con-
trol group. The ratio of cleaved caspase 3 (cell death marker)-positive
cells to insulin-positive cells was significantly higher in the hIAPP group
than in the control group. Culturing of hIAPP-KI islets for 4 days in
400 mg/dL glucose increased the production of cell death marker,
oligonucleosomes was significantly increased by 1.8 times compared
with control islets.
Conclusion: In summary, we showed that the physiological level of
hIAPP is associated with an increase in ß-cell apoptosis, and inhibits
the amelioration of hyperglycemia by islet transplantation.
Supported by: Grant-in-Aid for Young Scientists (B) (25860757) from
Ministry of Education
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5 year safety and effectiveness of islet transplantation in subjects with
eGFR <60: retrospective observational study
R.A. Oram, T. Olateju, Y. Ling, S. Imes, A. Malcolm, A.M.J. Shapiro,
P.A. Senior;
Clinical Islet Transplant, University of Alberta, Edmonton, Canada.
Background and aims:Kidney-pancreas transplant is optimal treatment
for Type 1 diabetes (T1D) with end-stage renal disease (ESRD)while islet
transplantation (ITx) has been reserved for subjects with adequate renal
reserve. Since renal impairment increases the risk of severe
hypoglycaemia, the short term risks of severe hypoglycemia may justify
the potential renal risks of ITx with calcineurin inhibitor (CNI) based
immunosuppression in T1D with moderate, stable renal impairment.
Materials and methods: We compared the safety and effectiveness of
ITx in T1D subjects with or without renal impairment (eGFR<60 ml /
min) in a single centre, 5 year, retrospective study. The primary end points
were a) safety: progression to ESRD, doubling of serum creatinine, or
death from any cause; and b) effectiveness: proportion maintaining good
glycemic control (a1c <7%) and protection from hypoglycemia (HYPO
score<423, Clarke score<4 and LI<329) at 5 years.
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Results: 118 ITx recipients with at least 5 years of follow up (transplanted
between 1999-2009) were included. Maintenance immunosuppression
was with sirolimus plus tacrolimus or tacrolimus plus mycophenolate.
29/118 (25%) subjects had eGFR<60 ml/min at baseline. Subjects with
eGFR<60 were older (mean ± sd: 52±10 v 44±10 years, p=0.0001),
female gender 69 v 52% (p=0.1), median(IQR) eGFR was 81(71-92) v
54 (48-58). The proportion of subjects reaching the safety end point was
3/28 (11%) v 7/86 (8%) (p=0.7). The proportion reaching the efficacy
end point was 14/29 (48%) v 37/82 (45%) (p=0.8). Average yearly GFR
decline was slightly greater with higher starting gfrs (r=0.15, p<0.0001).
Conclusion: ITx appears to be equally safe and effective to provide good
glycemic control and protection from hypoglycaemia over 5 years in
carefully selected subjects with moderate renal impairment. These data
help guide the risk benefit assessment for T1D subjects with both severe
hypoglycemia and renal impairment.
Supported by: Alberta Health Services Transplant Fellowship
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Efficacy of autologous stem cells transplantation in patients with type
2 diabetes mellitus: a randomised placebo-controlled study
S. Bhansali1, V. Kumar2, V. Jha2, N. Marwaha3, N. Khandelwal4, A.
Bhansali1, P. Dutta1;
1Endocrinology, 2Translational and Regenerative Medicine, 3Transfusion
Medicine, 4Radiodiagnosis, PGIMER, Chandigarh, India.
Background and aims: T2DM is characterized by two major defects:
insulin resistance and insulin deficiency. Current therapies in T2DM
targeting β-cells are insulin, glitazones and GLP-1 analogs. These thera-
pies have demonstrated glycemic durability over a prolonged period of
time but their role in β-cells regeneration is elusive. Therefore, this has
led to the emergence of novel β-cells regenerative therapies like hemato-
poietic stem cell (HSCs), mononucleated stem cells (MNCs) and mesen-
chymal stem cells (MSCs). This study evaluates the efficacy of autolo-
gous bone marrow derived-stem cell transplantation (ABMSCT) and au-
tologous bone marrow derived-mesenchymal stem cell transplantation
(ABM-MSCT) in patients with T2DM.
Materials and methods: This prospective, randomized, single-blinded
placebo controlled study enrolled 30 patients with triple oral hypoglyce-
mic drug failure and requiring insulin ≥0.4 Units/Kg/day for achieving
euglycemia (HbA1c ≤7.5%). They were randomly assigned to MSCs
group (n=10), MNCs group (n=10), who received ABM-MSCT and
ABMSCT through targeted approach respectively, while control arm
(n=10) underwent sham procedure and were followed for 6 months.
The efficacy of intervention was assessed by gold standard method “hy-
perglycemic clamp” to estimate C-peptide response and insulin sensitiv-
ity index. The primary end-point was a reduction in insulin requirement
by ≥50% from baseline, while maintaining HbA1c ≤7%.
Results: Six out of 10 (60%) patients in the ABM-MSCTand 9 out of 10
(90%) patients in the ABMSCT, while one (10%) in the control group
achieved the primary endpoint (p=0.001). There was a modest but not
significant decrease in HbA1c in ABM-MSCT from 6.9% (6.6-7.0%) to
6.8% (6.4-7.3%) (p=0.441) , ABMSCT from 6.7% (6.4-7.3%) to 6.9%
(6.5-7.0%) (p=0.575) as well as in controls from 6.5% (6.2-6.8%) to
6.2% (6.0-6.2%) (p=0.262). There was a significant increase in C- pep-
tide response in ABMSCT (p=0.046), while improvement in insulin
sensitivity index (p=0.04) in ABM-MSCT group during hyperglycemic
clamp. There was a significant decrease in HOMA-IR (p=0.028) in
ABM-MSCT, while HOMA - β function were remain unaltered (p=
0.445) in ABMSCT.
Conclusion: The ABMSCT and ABM-MSCT results in reduction in
insulin dose while maintaining target HbA1c. MSCs improves insulin
sensitivity index and MNCs improves β cell function. A combined ther-
apy with these two types of stem cells remains to be explored.
Clinical Trial Registration Number: NCT01759823
PS 033Clinical studies on insulin action
515
Effect of pioglitazone, exenatide and combination of pioglitazone and
exenatide on plasma alpha-hydroxybutyrate in type 2 diabetes
D. Tripathy, A. Chavez-Velazquez, R. Martinez, A. Hansis, R.
DeFronzo;
Diabetes, Medicine, University of Texas Health Science Center, San
Antonio, USA.
Background and aims:Alpha-hydroxybutyrate has been shown to be an
early marker of insulin resistance in recent studies. Pioglitazone is known
to reduce plasma alpha-hydroxybutyrate in IGT subjects. The aim of this
study was to examine the effect of Pioglitazone, Exenatide(Byetta) and a
combination of these two on plasma metabolites in subjects with T2DM.
Materials and methods:We randomized thirty T2DM subjects (age=55
±3 yrs; BMI=34.9±5; FPG=167±10 mg/dl; HbA1c=8.3±0.4%) to re-
ceive the following: (i) Exenatide (EXE 10ug bid, n=11), (ii) pioglitazone
(PIO, 45 mg/d, n=10), or (iii) PIO+EXE (n=9) for 24 weeks. Subjects
also participated in an OGTT and 2-step hyperglycemic (+125 and +
400 mg/dl) clamp followed by IV arginine (5 g) bolus prior to treatment
and again at week 24 of treatment. Plasma alpha-hydroxybutyrate,
linoleoyl-GPC (LGPC), and oleic acid were measured before and after
treatment.
Results: At baseline there was no significant difference in the concentra-
tions of the measured metabolites between subjects. Combined Pioglita-
zone+Exenatide yielded the greatest reduction in fasting plasma glucose,
2-hr glucose and HbA1c compared to treatment with individual medica-
tions (all p<0.05). Combined treatment increased Matsuda Index (MI) of
insulin sensitivity from 2.7±0.5 to 5.9±0.6 (p<0.05). Pioglitazone alone
improvedMatsuda Index of insulin sensitivity (MI) from 4.9±0.8 to 7.9±
1.5 (p<0.05). Pioglitazone treatment alone decreased the fasting FFA
(0.643±0.06 to 0.376±0.07 μM, p=0.001) and 2-hour FFA (0.252±
0.09 to 0.09±0.01 μM, p=0.009). Pioglitazone therapy led to a signifi-
cantly lower alpha-hydroxybutyrate (6.31±0.8 vs 4.8±0.7 μg/mL, p=
0.04) and oleic acid (72±5.4 vs 53.7±6.8 μg/mL, p=0.03), however
Pioglitazone did not affect plasma LGPC levels. Alpha-hydroxybutyrate
correlated with insulin secretion insulin sensitivity index in Pioglitazone
treated subjects (r=0.643, p=0.04). Combined Pioglitazone+Exenatide
treatment showed a trend to reduced plasma alpha-hydroxybutyrate
(6.31±0.8 vs 4.8±0.7 μg/mL, p=0.058). There were no significant
changes in plasma metabolites seen in patients treated with Exenatide
alone.
Conclusion: Pioglitazone reduces novel metabolites related to lipid me-
tabolism and oxidative stress. This could represent a novel mechanism by
which TZDs improve insulin sensitivity. Plasma alpha-hydroxybutyrate
was not affected by Exenatide suggesting that the mechanism of im-
proved glycemic control seen with Exenatide is primarily by improve-
ment in insulin secretion.
Clinical Trial Registration Number: NCT00845182
Supported by: Takeda Pharmaceuticals
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Chronic caffeine intake restores insulin sensitivity in high-sucrose
diet rats through adaptations in adipose tissue metabolism
J.C. Coelho1, B.F. Melo1, T. Rodrigues2, P. Matafome2, J.F. Sacramen-
to1, M.J. Ribeiro1, M.P. Guarino1,3, R. Seiça2, S.V. Conde1;
1CEDOC, NOVA Medical School, Faculdade de Ciências Médicas,
Universidade NOVA de Lisboa, 2Laboratório de fisiologia, IBILI,
Faculdade de Medicina, Universidade de Coimbra, 3UIS-Unidade de
Investigação em Saúde- Escola Superior de Saúde de Leiria- Instituto
Politécnico de Leiria, Portugal.
Background and aims: Several epidemiological studies have described
beneficial effects of chronic coffee intake on type 2 diabetes and meta-
bolic syndrome. Our group has previously shown that chronic caffeine
(caff) intake both prevents and reverses insulin resistance in prediabetes
animal models, being the time needed to restore insulin sensibility in-
versely correlated with the caff concentration administrated. It is known
that obesity is associated with insulin resistance and that alterations in
adipose tissue (AT) metabolism contribute to the development and main-
tenance of insulin resistance. Therefore, the aim of this work was to
investigate if the enhancement of insulin sensitivity induced by chronic
caff intake is due to alterations in AT metabolism, namely in fat deposi-
tion, lipid profile and insulin signaling pathway in this tissue.
Materials and methods:All experiments were performed in 8-13 weeks
Wistar rats of both genders (250-450 g). Two groups of rats were used: the
high sucrose (HSu) group and a control group. The HSu model was
obtained by submitting animals to a 35% sucrose diet in drinking water
during 28 days. After the 28 days, the 2 groups were divided and submit-
ted to different caff concentration in drinking water: 0, 0.5, 0.75 and 1 g/L
during 12 weeks. Insulin sensitivity and glucose tolerance were moni-
tored during all the experimental period. Afterwards rats were anaesthe-
tized with pentobarbitone (60 mg/Kg) and blood was collected by heart
puncture. Abdominal fat was collected and weighted and plasma choles-
terol, HDL, LDL and triglycerides were measured. Western blots of pro-
teins involved in insulin signaling pathway in AT were performed.
Results: HSu diet did not change weight gain in relation to controls,
however both visceral and total fat weight increased by 47% and 49%
respectively (visceral fat control=5.29±0.86 g; total fat control=23.59±
4.30 g). Chronic caff intake did not modify daily weight gain either in
control or in the HSu group. Caff did not promote changes in total or
visceral fat in the control group, however in the HSu group, visceral fat
deposition was inhibited by caff in all concentrations tested and total fat
deposition was inhibited by caff concentrations of 0.75 and 1 g/L. Hsu
diet, as well as caff intake, did not significantly modify cholesterol, LDL
and HDL plasma levels. Nevertheless, HSu diet increased triglycerides
levels to 77.58±5.89mg/dl (control=42.69±5.17mg/dl) and caff showed
a trend to decrease triglycerides in this group, in a dose dependent man-
ner. Although caff did not change AT insulin receptor (IR), protein kinase
B (Akt) and Glut4 total expression, it increased the expression of the
phosphorylated forms of the IR and Akt in the Hsu animal model.
Conclusion: Chronic caff administration avoids visceral and total fat
accumulation in a concentration dependent manner in HSu animals, with-
out altering animal’s weight. Although caff did not directly affect IR
expression in the AT, it stimulated insulin signaling cascade, suggesting
that this may be one of the mechanisms for caffeine-induced improve-
ment of insulin sensitivity in HSu rats.
Supported by: EXPL/NEU-SCC/2183/2013 (Portugal)
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The rapid subcutaneous injection of heparin plus insulin lispro im-
proved dramatically blood glucose of a patient with subcutaneous
insulin resistance
T. Sumita1, T. Hosaka2, T. Iuchi1, G. Sakai1, S. Yasuda1, S. Katayama1, I.
Inoue1;
1Saitama Medical University, 2Kyorin University, Tokyo, Japan.
Background and aims: Subcutaneous insulin resistance (SIR) is a syn-
drome, which is caused by increased insulin inactivation or proteolytic
degradation in the dermal tissue and by impaired transport of injected
insulin from subcutaneous tissue into the circulation. The blood glucose
levels of 48 year-old male with type 2 diabetes, who injected insulin about
200 U per day, were still high. Interestingly, his blood glucose levels were
improved near normal after direct infusion of insulin into vein. Thus, he
was considered to be a state of SIR. In this report, we evaluate the suc-
cessful treatment of this SIR case.
Materials and methods: The dimethyl-isopropyl-azulene ointment in-
cluding 0.1% nafamostat mesilate (NAF) as a protease inhibitor was
treated with the case, which is expected to prevent insulin degradation
at the injection skin spot. Heparin modulates vascular endothelial growth
factor and is expected to accelerate subcutaneous diffusion of insulin into
the blood stream. And insulin lispro mixed with heparin (Hepalis)
consisted of the concentrations of 500 U heparin and 50 U insulin per
one mL respectively. And Hepalis was injected by syringe or continuous
subcutaneous infusion (CSII) capillary. The blood glucose level (7 times
in a day), serum C-peptide and serum insulin was examined.
Results: The blood glucose levels after lispro insulin injection at the skin
spot with NAF contain ointment (310±17 mg/dL) were not significantly
changed compared to those without NAF’s one (351±22 mg/dL). Next,
Hepalis was tried to inject as the continuous basal insulin injection by
CSII. The blood glucose levels with Hepalis after replaced similar
amounts of lispro insulin were a little decreased (327±16 mg/dL), but
not significant (p=0.05), compared to those with lispro alone (360±
12 mg/dL). And then, although the Hepalis treatment by CSII was tried
as basal-bolus insulin, the blood glucose levels were still not decreased
under 300 mg/dL. Finally, we tried to inject as bolus insulin by syringe at
the short time. The activity of Hepalis was suspected to impair due to
slowly infusion by CSII because an injection time of Hepalis by CSII was
took about ten minutes. Basal hepalis infusion was continued by CSII.
Drastically, the blood glucose levels after Hepalis infusion by syringe
were decreased significantly (P<0.001) and reached the levels under
200 mg/dL with gradual Hepalis elevation, followed by the significant
increasing serum levels of insulin lispro.
Conclusion: In this SIR case, Injection of Hepalis rapidly into subcuta-
neous tissue was more effective to circulate the insulin lispro and to
improve the blood glucose levels. Though the precise mechanism of this
SIR has not been cleared, our repot will be a clue to discover the patho-
physiology of the SIR.
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Acetic acid enhances insulin-stimulates glucose uptake by the fore-
arm muscle in patients with type 2 diabetes
E. Petsiou1, P. Mitrou2, E. Papakonstantinou1, E. Maratou2, V.
Lambadiari1, F. Spanoudi1, S.A. Raptis1,2, G. Dimitriadis1;
12nd Department of Internal Medicine, Attikon University Hospital,
2Hellenic National Center for Reasearch, Prevetion and Treatment of
Diabetes Mellitus and its Complications (H.N.D.C), Athens, Greece.
Background and aims:Acetic acid, the main constituent of vinegar, has
been shown to have a glucose-lowering effect in patients with glucose
abnormalities. However, the mechanisms of this effect are still obscure.
The aim of this randomised, cross-over study was to investigate the effect
of vinegar on 1) muscle glucose uptake and blood flow rates and 2)
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circulating plasma glucose, insulin and lipid levels, in patients with type 2
diabetes, using the arteriovenous difference technique across the forearm
muscles.
Materials and methods: Eleven subjects with DM2 (age 53+4 years,
BMI 25+1, HbA1c 6.8+0.3%) consumed vinegar (30 ml containing
6% acetic acid, 20 ml water) or placebo (50 ml water), at random
order on two separate days (a week apart), before a mixed meal
(557 kcal; 75 g carbohydrates, 26 g protein, 17 g fat). Plasma glucose,
insulin, triglycerides, non-esterified fatty acids (NEFA) and glycerol
were measured preprandially and at 30-60 min for 300 min
postprandialy from the radial artery and from a forearm vein. Muscle
blood flow was measured with strain-gauge plethysmography. Glu-
cose flux was calculated as the arteriovenous difference of glucose
multiplied by the blood flow rates.
Results: Vinegar compared to placebo: 1) increased forearm glucose
uptake (765+87 vs 579+63 μmol/100 ml tissue, p=0.0357) 2) decreased
plasma glucose (2834+134 vs 3005+149 mM*min, p=0.0279), insulin
(16136+3397 vs 20473+4185 mU/L*min, p=0.0457) and triglycerides
(371+34 vs 409+38 nmol/L*min, p=0.0439) 4) did not change muscle
blood flow, plasma NEFA and glycerol.
Conclusion: In DM2 vinegar reduces postprandial hyperglycaemia,
hyperinsulinaemia and hypertriglyceridaemia without affecting lipolysis.
Vinegar’s effect on carbohydrate metabolismmay be partly accounted for
by an increase in glucose uptake, demonstrating an improvement in in-
sulin action in skeletal muscle.
Clinical Trial Registration Number: NCT02309424
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The in vitro pharmacology of LY IGlar (LY2963016): a new insulin
glargine product
J.S. Moyers, S.D. Kahl, X. Ruan, C. Zhang, M.W. Farmen, M.D. Mi-
chael, R.A. Owens;
Eli Lilly and Company, Indianapolis, USA.
Background and aims: Basal insulin analogs, with durations of action
sufficient for coverage over the course of 24 hours, are important for the
proper management of glycemic control in the patients with diabetes. LY
IGlar (LY2963016, insulin glargine), an insulin analog with the same
amino acid sequence as insulin glargine (Sanofi-Aventis; IGlar), differs
from human insulin due to the addition of two arginine residues to the C-
terminus of the B-chain and due to the replacement of asparagine at
position A21 with a glycine. These changes shift the isoelectric point such
that the insulin glargine analog is soluble at an acidic pH but then precip-
itates after injection at the neutral physiological pH.
Materials and methods: The pharmacological properties of six indepen-
dent lots of LY IGlar were compared to IGlar using a panel of in vitro
biological assays. The receptor binding affinity of LY IGlar for the human
insulin receptor isoform A (hIR-A), hIR isoform B (hIR-B), and human
IGF-1 receptor (hIGF-1R) was determined by competitive radioligand
binding using cell membranes prepared fromHEK-293 cells overexpress-
ing the cloned receptors. Functional activation of hIR signaling was de-
termined in cells by quantitation of receptor phosphorylation by ELISA
using 293 cells expressing hIR-A or hIR-B, de novo lipogenesis from
[14C]-glucose in 3 T3-L1 adipocytes, and cell proliferation by [3H]-thy-
midine incorporation in human Saos-2 cells. Statistical comparisons were
determined for the Ki/EC50 responses from each assay using the Sidak
and Holm-Bonferroni multiple comparison adjustment methods with the
significance level set at α=0.05.
Results: The receptor binding affinity, Ki, of LY IGlar was determined to
be 0.41±0.01, 0.45±0.03, and 16.0±0.4 nM for hIR-A, hIR-B, and
hIGF-1R, respectively. The affinities were comparable to those observed
for IGlar at 0.40±0.02, 0.45±0.04, and 15.5±0.6 nM, respectively. To
determine whether LY IGlar and IGlar stimulated similar functional acti-
vation of hIR, we used 293 cells expressing hIR-A or hIR-B to determine
the half-maximal concentrations, EC50, of each ligand required to stimu-
late receptor tyrosine phosphorylation. The EC50 values for LY IGlar
were 3.7±0.2 and 2.1±0.1 nM for hIR-A and hIR-B, respectively. The
EC50 values for IGlar were 4.5±0.2 and 2.5±0.1 nM for hIR-A and hIR-
B, respectively. Using 3 T3-L1 adipocytes to assess ligand stimulation of
metabolic activity, we found that LY IGlar and IGlar were maximally
efficacious with comparable EC50 values for stimulation of de novo lipo-
genesis from glucose. The EC50 of LY IGlar was 0.97±0.09 nM and the
EC50 of IGlar was 0.87±0.08 for stimulation of de novo lipogenesis. The
mitogenic potential of LY IGlar and IGlar was determined by [3H]-thy-
midine incorporation in the hIGF-1R dominant human cell line, Saos-2.
The EC50 values for stimulation of cell proliferation by LY IGlar and
IGlar were 0.53±0.03 and 0.53±0.03 nM, respectively.
Conclusion: Results showed that the in vitro pharmacological properties
of LY IGlar were not different from IGlar, supporting LY IGlar as an
alternative therapy for patients with diabetes.
Supported by: Eli Lilly and Company/Boehringer Ingelheim
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D-chiro-inositol improves metabolic control in overweight patients
with type 1 diabetes
A. Maurizi, R. Del Toro, M. Menduni, A. Lauria Pantano, S. Kyanvash,
S. Manfrini, P. Pozzilli;
Endocrinology and Diabetes, University Campus Bio-Medico, Rome,
Italy.
Background and aims: With the increase of obesity in childhood and
adolescence, insulin resistance is now occurring more frequently in pa-
tients with type 1 diabetes (T1D). Consequently, insulin doses are often
increased causing weight gain and poor glycaemic control in these pa-
tients. Therefore, to achieve optimal glycaemic control and to improve
insulin sensitivity, insulin sensitizing drugs such as metformin are com-
monly used in addition to insulin therapy in overweight and obese T1D
patients. Similarly to metformin, studies in vitro and in animal models
have shown that D-Chiro-Inositol (DCI), as putative mediator of intracel-
lular insulin action can accelerate glucose disposal and act as insulin
sensitizer. In recent clinical trials significant reduction of DCI plasma
levels and a linear relationship between its decreased urinary excretion
and the degree of insulin resistance were observed. In these conditions
oral supplementation with DCI seems to improve glucose metabolism
reducing insulin resistance status. The aim of this prospective, random-
ized controlled trial was to evaluate the efficacy of DCI oral supplemen-
tation on glycaemic control as assessed by HbA1c in patients with T1D
undergoing intensive insulin therapy.
Materials and methods:A total of 25 patients affected by T1D aged 17-
50 years (12 males, 13 females) with disease duration>1 year and BMI
>25, were enrolled in the study. Patients were randomised to 1 g DCI plus
400 mcg folic acid once daily (treated group) or to 400 mcg folic acid
only once daily (control Group). HbA1c and BMI were evaluated at entry
into the trial and at 3 and 6 months follow-up. The sample size for the
study has been calculated taking into account 80% power and a difference
of HbA1c of 0.3% at the end of the study period. Paired t test (two tailed)
and analysis of variance were used to evaluate differences in HbA1c and
BMI at different time points.
Results: HbA1c at entry was 8.3%±0.14 (SD) in DCI treated group and
7.9%±0.28 (SD) in control patients (p:NS). After 3 months follow-up a
statistically significant reduction of HbA1c levels were observed in DCI
treated group vs. control group (7.4%±0.8 vs. 7.7%±1.0, respectively,
p:<0.05). At the end of the study period HbA1c reduction in DCI treated
group vs. control group was statistically confirmed. BMI at entry was
25.6±1.8 (SD) in DCI treated group and 27.1±2.2 (SD) in control pa-
tients (p:NS). After 3 and 6 months follow-up there was a tendency for a
reduction in BMI in the DCI treated group vs. control group (25.2±1.5 vs.
26.9±1.5, respectively, p:NS)
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Conclusion: Insulin therapy is the mainstay of treatment for patients with
T1D. This trial demonstrated for the first time that the oral supplementa-
tion of DCI to insulin treatment in T1D patients improves glycaemic
control as shown by a significant reduction of HbA1c levels.
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The role of a fixed Berberis aristata/Silybummarianum combination
in the treatment of type 1 diabetic patients
G. Derosa, D. Romano, A. D'Angelo, P. Maffioli;
Internal Medicine and Therapeutics, University of Pavia, IRCCS
Policlinico S.Matteo, Italy.
Background and aims:Berberis Aristata is available in a fixed dosewith
SylibumMarianum, in order to increase its low bioavailability. Even if the
effects of Berberis Aristata in type 2 diabetic patients have been already
reported, nothing has been published about Berberis Aristata use in type 1
diabetic patients. For this reason, the aim of this study was to evaluate if
the addition of Berberis Aristata/Sylibum Marianum leads to a reduction
of insulin dose and to an improvement of glycemic control in type 1
diabetic patients.
Materials and methods: We enrolled 85 type 1 diabetic patients and
randomized them to add, to their usual insulin therapy, placebo or Ber-
beris Aristata/Silybum Marianum 588/105 mg, 1 tablet during the lunch
and 1 tablet during the dinner, for six months. We evaluated if there was a
reduction of insulin dose necessary to reach an adequate glycemic con-
trol. We also evaluated at baseline, and after 6 months: body mass index
(BMI), glycated hemoglobin, fasting plasma glucose (FPG), post-
prandial glucose (PPG), total cholesterol (TC), low density lipoprotein-
cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), tri-
glycerides (Tg). The null hypothesis that the expected total dose of insulin
used from randomization would did not differ significantly between pla-
cebo, and Berberis Aristata/SilybumMarianum was tested using analysis
of variance and analysis of covariance (ANCOVA) models. Similar anal-
yses were applied to the other variables. The statistical significance of the
independent effects of treatments on the other variables was determined
using ANCOVA. A 1-sample t test was used to compare values obtained
before and after treatment administration; 2-sample t tests were used for
between-group comparisons. Statistical analysis of data was performed
using the Statistical Package for Social Sciences software version 11.0
(SPSS Inc., Chicago, Illinois, USA). For all statistical analyses, p<0.05
was considered statistically significant.
Results: We observed a reduction of total insulin dose necessary to
achieve an adequate glycemic control in Berberis Aristata/Silybum
Marianum, both compared to baseline and to placebo (p<0.05 for both).
Regarding insulin administration at meals, we recorded that the group
treated with Berberis Aristata/Silybum Marianum used less insulin at
meals, both compared to baseline and placebo (p<0.05 for breakfast,
and p<0.01 for lunch and dinner). The same can be said for insulin at
bedtime (p<0.05 for both vs baseline and vs placebo). We observed a
decrease of glycated hemoglobin with Berberis Aristata/Sylibum
Marianum compared to baseline (p<0.05), but not compared to placebo.
There was a decrease of FPG, and PPG with Berberis Aristata/Sylibum
Marianum both compared to baseline and to placebo (p<0.05 for both).
We recorded a decrease of TC, Tg and LDL-C and an increase of HDL-C
with Berberis Aristata/SylibumMarianum both compared to baseline and
to placebo (p<0.05 for both).
Conclusion: The addition of Berberis Aristata/Sylibum Marianum to
insulin therapy in type 1 diabetic patients leads to a reduction of the
insulin dose necessary to achieve an adequate glycemic control.
522
Resveratrol improves glucose homeostasis in diabetic rats: Potential
involvement of the hepatic glucose handling
C.Y. Yonamine, E.P. Machado, J.V.D. Esteves, H.S. Freitas, M.M.
Okamoto, U.F. Machado;
Physiology and Biophysics, University of São Paulo, Brazil.
Background and aims: The polyphenol resveratrol is a powerful activa-
tor of the sirtuin 1 (SIRT1), a histone deacetylase that plays an important
role in the cellular homeostasis. It has been described that resveratrol
improves the metabolic profile of obese subjects; however, the mecha-
nisms by which this effect occurs remain obscure. Glycemic homeostasis
involves a balance between glucose uptake and delivery, respectively in
skeletal muscle and liver. These glucose fluxes are impaired in diabetes
mellitus (DM), and have been related to decreased GLUT4 protein
(encoded by the Slc2a4 gene) in muscle and increased GLUT2 protein
(encoded by the Slc2a2 gene) and phosphoenolpyruvate carboxykinase
(Pepck) expression in liver. Despite evidence that resveratrol improves
the metabolic profile, it is not established if it could contribute to improve
glycemic homeostasis in DM. We hypothesized that resveratrol could
revert the DM-induced alterations in the expression of glucose trans-
porters, thus contributing to improve glycemic homeostasis. Therefore,
the present study investigated, in insulin-treated diabetic rats, if resvera-
trol improves glycemic homeostasis, and regulates gene expression of the
glucose transporters in muscle and liver as well.
Materials and methods: Male Wistar rats were rendered diabetic by
streptozotocin injection (50 mg/Kg of body weight); citrate buffer-
injected rats were used as non-diabetic controls (ND). Twenty days later,
the diabetic rats were divided into 3 groups: placebo-treated diabetic
(DP), insulin-treated diabetic (DI, 6 U/day insulin) and insulin+resvera-
trol treated diabetic (DIR) (6 U/day insulin + 10mg/Kg resveratrol). After
30 days of treatment, glycemia, 24-hour glycosuria and plasma
fructosamine were evaluated, and soleus muscle and liver were sampled
for analysis of Slc2a4, Slc2a2 and Pepck mRNAs (qPCR), and GLUT4,
GLUT2 and p-AMPK (phosphorylated AMP-activated protein kinase)
proteins (Western blotting). Results were analyzed by one-way ANOVA,
followed by Bonferroni post-test.
Results: As expected, DP rats showed increased glycemia, 24-hour gly-
cosuria and plasma fructosamine. DI and DIR showed similar decrease in
glycemia and glycosuria; however, only DIR restored completely the
fructosamine concentration (P<0.01 vs DP and DI). In soleus, diabetes
decreased Slc2a4 (by 60%, P<0.001), GLUT4 (by 53%, P<0.05) and p-
AMPK (by 48%, P<0.05); and all these parameters were similarly recov-
ered in DI and DIR rats. On the other hand, in liver, diabetes increased the
Slc2a2 (by 3.6 folds, P<0.001), GLUT2 (by 30%, P<0.05) and Pepck
(by 80%, P<0.01); and insulin alone was not able to significantly alter
these parameters. However, the addition of resveratrol to insulin treatment
restored the Slc2a2 (P<0.001 vs DP and P<0.05 vsDI), GLUT2 (P<0.05
vs DP and DI) and Pepck (P<0.001 vs DP, P<0.05 vs DI) expression to
the non-diabetic values.
Conclusion: Addition of resveratrol to insulin treatment of diabetic rats
improved long-term glycemic homeostasis, as evinced by plasma
fructosamine levels. Resveratrol also decreased Slc2a2 and Pepck in liver,
indicating reduction in hepatocyte gluconeogenic activity and glucose
efflux as well. No evidence of resveratrol effect in skeletal muscle was
observed. In summary, the results reveal that resveratrol, as coadjuvant in
the insulintheraphy of diabetic rats, improves glycemic homeostasis, and
that involves reduced hepatic glucose production.
Supported by: CNPq #142187/2013-5 and FAPESP #2012/04831
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Stearoyl-CoA desaturase and its regulation in human skeletal muscle
by exercise
K. Eckardt1, S. Lee1, T.M. Langleite1, T. Holen1, J. Jensen2, K.I.
Birkeland3,4, C.A. Drevon1;
1Department of Nutrition, University of Oslo, 2Norwegian School of
Sport Sciences, Oslo, 3Department of Endocrinology, Oslo University
Hospital, 4Institute of Clinical Medicine, University of Oslo, Norway.
Background and aims: Stearoyl-CoA desaturase 1 (SCD1) catalyzes the
rate-limiting step in the synthesis of monounsaturated fatty acids (FA),
which are required for de novo triacylglycerol synthesis. In this way
SCD1 also converts FAwith a high lipotoxic potential into FAwith lower
lipotoxic potential, e.g. palmitic acid (PA) to palmitoleic acid. Recently, a
muscle-specific SCD1-overexpressing mouse model was described with
elevated glucose uptake, FA oxidation and exercise capacity. Hence, a
high SCD1 level in skeletal muscle might be beneficial for its metabolic
function. Here, we investigated the regulation of SCD1 in human skeletal
muscle.
Materials and methods: Healthy sedentary men categorized either as
control (BMI=23.5±2.0 kg/m2, normal fasting and 2 h serum glucose
levels, n=13) or dysglycemic (pT2D; BMI=28.9±2.5 kg/m2, fasting glu-
cose≥5.6 mmol/L and/or 2 h serum glucose≥7.8 mmol/L, n=11) partic-
ipated in a combined strength and endurance training for 12 weeks. In
addition, an acute endurance test was performed before and after the
intervention. Biopsies fromm. vastus lateraliswere taken before, directly
after, and 2 h post exercise, before and after intervention. RNA was
isolated and analyzed by high throughput mRNA sequencing followed
by differential gene expression analysis. Primary human skeletal muscle
cells (SkMC)were exposed to electrical pulse stimulation (EPS) to induce
contraction, low dose of PA or a combination of both followed by anal-
yses using qRT-PCR.
Results:At baseline SCD1 mRNA expression was 50% lower in skeletal
muscle of pT2D compared to control group (p<0.001). After the inter-
vention SCD1 expression was enhanced significantly both in pT2D (1.8-
fold, p<0.001) and control subjects (1.5fold, p<0.001). Both groups also
had increased VO2max (13%, p<0.001) and insulin sensitivity (pT2D
29%, p<0.01; control 36%, p<0.001). At baseline acute exercise in-
creased SCD1 mRNA expression in the pT2D group directly after the
acute bout (1.3fold, p<0.05). After intervention the pT2D group exhibit-
ed a significant 1.9-fold increase in SCD1 mRNA expression p<0.001)
2 h post exercise, which then reached a similar level as in the controls.
During in vitro differentiation of SkMC SCD1 mRNA expression in-
creased significantly (3.7-fold, n=5-6) in parallel with up-regulation of
myogenin (4-fold) and MHCIIa (10-fold). Stimulation of contraction by
EPS (1 Hz, 2 ms, 11.5 V) for 24 h significantly promoted SCD1 mRNA
expression (1.5-fold, p<0.05, n=7) in parallel with induction of PGC1a
(1.8-fold, p<0.01) and IL-6 (2.8-fold, p<0.01). Incubation of SkMCwith
PA increased SCD1 mRNA expression significantly at a concentration as
low as 20 μM (1.2-fold, p<0.05). Maximum induction of 2-fold was
observed at 100 μM (p<0.001, n=8), and higher concentrations of PA
up to 300 μM had no additional effect. The combination of EPS and PA
for 24 h increased SCD1 mRNA expression 3.8-fold (p<0.001, n=7)
compared to control cells.
Conclusion: Given the important role of SCD1 in lipid metabolism its
lower expression in skeletal muscle of overweight dysglycemic subjects
may be linked to metabolic impairments observed in similar groups of
participants. Moreover, the up-regulation of SCD1 by long-term exercise
may be associated with increased insulin sensitivity.
Clinical Trial Registration Number: NCT01803568
Supported by: DFG, JohanThrone-Holst Foundation, Helse Sør-Øst,
NutriTech
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Does the energy cost of walking explain why patients with diabetic
peripheral neuropathy walk more slowly?
M. Petrovic1, F. Bowling2, K. Deschamps3, S. Verschueren3, C.
Maganaris4, A. Boulton2, N. Reeves1;
1Manchester Metropolitan University, 2University of Manchester, UK,
3Katholieke Universiteit Leuven, Belgium, 4Liverpool JohnMoores Uni-
versity, UK.
Background and aims: It is has previously been shown that patients with
diabetes and especially those with diabetic peripheral neuropathy (DPN)
choose to walk more slowly (self-selected speed) and display a number of
other gait alterations compared to age-matched healthy controls. It has
been suggested that patients with diabetes and DPN have a lower self-
selected walking speed to lower the physical demands of walking. How-
ever, there are a number of physiological alterations with diabetes that
would increase the energy cost of walking (CoW). We therefore
hypothesise that the CoW will be higher in patients with diabetes and
DPN compared to controls when walking at the same speed, and will
dictate the choice of a slower self-selected walking speed in patients with
diabetes and DPN. The aim of this study was to investigate the CoW in
patients with diabetes and neuropathy at different speeds.
Materials and methods: Participants were allocated into one of the three
groups: healthy controls (Ctrl; mean age: 56, n=31), patients with diabe-
tes but no neuropathy (DM; mean age: 51, n=22) and patients with
diabetes and moderate-severe peripheral neuropathy (DPN; mean age:
66, n=14). Participants walked at a range of control speeds on a treadmill
while expired air was measured to determine oxygen uptake and the CoW
calculated. Participant’s self-selected walking speed was measured in a
gait laboratory using motion analysis. Group differences were tested
using an ANOVA and LSD post-hoc test.
Results: Self-selected walking speed was lower in DM and DPN patients
compared to controls, albeit not reaching significance (Ctrl: 1.45; DM:
1.38; DPN: 1.35m·s−1; P>0.05) but the CoWwas not different between
groups. At standardised speeds, patients with DPN walked with a higher
CoW compared to the Ctrl and DM group and this was mostly evident at
the speeds of 0.6, 0.8, 1.0, 1.2 and 1.6 m·s−1 (Figure 1).
Conclusion:When walking at the same controlled speeds, the CoW was
significantly higher in people with DPN compared to controls, people
with DPN chose to walk more slowly than controls, but there were no
differences in the CoW between groups at this self-selected speed. There
are a number of physiological mechanisms such as stiffer tendons that
cause a higher CoW in people with DPN when they are ‘forced’ to match
the walking speed of controls. We suggest that the CoW is a major factor
in determining why people with DPN choose to walk more slowly, since
they seek to minimise the energy CoW. This will likely have implications
for the level physical activity and amount of walking people with DPN
choose to perform, which might impact upon glycaemic control.
Supported by: Erasmus Mundus doctoral program ‘Move-Age’ and
EFSD
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Energy expenditure from daily physical activity and risk of develop-
ing diabetes and change in cardiovascular risk factors
M. Kurita1, T. Nakagami1, J. Oya1, C. Isago1, Y. Tanaka1, Y. Hasegawa1,
A. Ito1, Y. Endo2, Y. Uchigata1;
1Tokyo Women’s Medical University School of Medicine, 2Health and
Community Medicine, Saitama-ken Saiseikai Kurihashi Hospital,
Saitama, Japan.
Background and aims: Prior studies have shown that leisure time phys-
ical activity decreased the risk of incidence of diabetes and hypertension,
and increasing daily steps ameliorated lipid metabolism in Japanese.
However, very few studies used the information of energy expenditure
(EE) estimated from time and intensity during daily physical activity.
Here, we examined the association between daily EE estimated by vali-
dated questionnaires and risk of developing diabetes and change in car-
diovascular risk factors.
Materials and methods: We registered 1,532 Japanese health checkup
examinees at SSK hospital who were neither previously diagnosed dia-
betes, or medicated hypertension or dyslipidemia. They completed the
Japan Arteriosclerosis Longitudinal Study Physical Activity Question-
naire, which examined usual patterns of physical activity during the pre-
vious month. Of those, 1,096 (746 men, average age: 55±8 years) were
followed for 5 years. Incidence of diabetes was defined when HbA1c
≥6.5% or fasting plasma glucose (FPG) ≥126 mg/dl was observed at least
once during the follow-up period. The relation between total (tertile) or
leisure time (0 or >0 ) EE at baseline and 5-year change in waist circum-
ference (Wc), body mass index (BMI), FPG, blood pressures, lipids, and
high-sensitivity C-reactive protein (CRP) were analyzed. Cox’s propor-
tional hazard model was used to calculate hazard ratios (HRs) and their
95% confidence intervals (CIs) for incidence of diabetes from total or
leisure time EE at baseline.
Results: In men, total EE had negative relations with FPG and triglycer-
ide (TG) at baseline, and leisure time EE had a positive relation with
HDL-cholesterol (HDL-c) and negative relations with TG and CRP at
baseline (all p‹0.05). In women, total EE had negative relations with Wc
and BMI at baseline and a positive relation with HDL-c, and leisure time
EE had no relation with cardiovascular risk factors at baseline. Increasing
total EE (tertile1→3) increased 5-year change of HDL-c (3.0→5.0%, p=
0.037) in men. Men with leisure time EE›0 showed lower 5-year change
in TG and higher 5-year change in HDL-c compared with men with
leisure time EE=0 (25 vs 14% and 1.5 vs 6.3% respectively, all
p‹0.05). In comparison with the 1st tertile of total EE, HRs (95% CI)
for the risk of developing diabetes in the 2nd and 3rd tertiles were 0.71
(0.32-1.61) and 0.73 (0.33-1.65) for men, and 1.33 (0.30-5.96) and 0.32
(0.03-3.04) for women, respectively. The HRs (95%CI) for the risk of
developing diabetes in leisure time EE›0 in comparison to leisure time
EE=0 were 0.78 (0.34-1.78) for men and 0.54 (0.13-2.27) for women.
Conclusion: Increasing total EE, especially leisure time EE, ameliorated
lipid metabolism during five years in Japanese men. The non-significant
effect of EE on the development of diabetes may in part reflect the het-
erogeneity of pathophysiology of diabetes.
Supported by: Japan Diabetes Society
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Reduced and adverse metabolic response to supervised 8-week en-
durance exercise in a group at high risk for type 2 diabetes
A. Böhm1,2, G. Schnauder1, P. Schneeweiß1, J. Hudemann1, A. Nieß1, C.
Hoffmann1,2, C. Weigert1,2, J. Machann2,3, H. Staiger1,2, A. Fritsche1,2,
N. Stefan1,2, H.-U. Häring1,2;
1Internal Medicine, Eberhard Karls University Tübingen, 2Institute for
Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Cen-
ter Munich at the University Tübingen, 3Radiology, Eberhard Karls Uni-
versity Tübingen, Germany.
Background and aims: Increase in physical activity is essential for the
prevention of type 2 diabetes. However, there is evidence that people
differ in their individual response to exercise and there is little information
available about potential pathomechanisms involved.
Materials and methods: In our study center in Tübingen, a group of 20
middle-aged individuals (13 women, 7 men), at high risk for type 2
diabetes, completed an 8-week supervised endurance training (3×1h/
week) on sub-maximal intensity (80% VO2max). Individual anaerobic
threshold (IAT) was determined by lactate measurements during incre-
mental exercise, peak aerobic capacity (VO2max) by spiroergometer at
exhaustion. Pre and post intervention, insulin sensitivity wasmeasured by
a 75 g frequently sampled oral glucose tolerance test. Body fat mass and
distribution were determined by magnetic resonance imaging, liver fat
content by 1H magnetic spectroscopy.
Results: Despite the relative short time of the intervention, an increase in
VO2max (from 22.9±5.1 to 25.4±5.8; p=0.0442) and IAT (from 1.1±0.3
to 1.3±0.3; p<0.0001), a decrease in BMI (from, 32.5±4.7 to 32.2±4.8,
p=0.0309), percent body fat (from 39.0±10.7 to 36.9±10.7; p=0.0320),
total adipose tissue mass (from 35.4±10.4 to 34.6±10.6; p=0.0234),
RRdiastolic(from 92±10 to 88±9; p=0.0324), heart ratio (from 76±13 to
70±9; p=0.0200), triglycerides (from 114±36 to 98±38, p=0.0176), and
LDL cholesterol (from 117±28 to 111±25; p=0.0268) was observed.
Unexpectedly, insulin sensitivity, did not change significantly (8.3±6.4
vs. 9.5±7.8; p=0.1). We found a high variability in the change of insulin
sensitivity, ranging from 0.6 - to 2.7-fold during the intervention. Insulin
sensitivity did not improve in 20 percent of the participants; in 40 percent
of the subjects a negative effect on insulin sensitivity was seen. Between
the two groups with the largest changes of insulin sensitivity (8 responder
versus 8 non-responder) there were no differences in baseline parameters.
However, after adjustment for sex, age and BMI, transaminases (GOT: 28
±6 vs. 24±8, padj=0.0082; GPT: 32±13 vs. 30±16; padj=0.0080; γ-GT:
38±14 vs. 21±15; padj=0.05) and intrahepatic lipids (8.4±6.6 vs. 7.8±
8.5, padj=0.03) were higher in the responders, pointing to a possible
impact of intrahepatic lipids on the increase of insulin sensitivity during
a supervised exercise training.
Conclusion:We found that, although mean body fat mass and cardiore-
spiratory fitness improved during a supervised exercise intervention, in-
sulin sensitivity did not increase in 60 percent of these individuals. High
liver fat content and elevated liver enzymes may predict a larger increase
in insulin sensitivity during exercise training.
Supported by: BMBF to DZD, MSD
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IL6 mediates the reduction of insulin secretion in exercise-trained
mice
F.M.M. de Paula, N.C. Leite, P.C. Borck, C.C. Zoppi, A.C. Boschero;
Structural and Functional Biology, University of Campinas, Brazil.
Background and aims: Exercise training reduces glucose-induced insu-
lin secretion (GIIS) in lean and obese rodents. Despite higher insulin
sensitivity and blood glucose clearance capacity, some intracellular mech-
anisms have been proposed to explain the lowered insulin secretion.
However, it is still unknown how this signal reaches pancreatic beta cells
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activating the intracellular pathways. IL6 is highly released by skeletal
muscle cells and it was reported to mediate the crosstalk between
contracting muscles and pancreatic beta cells. Thus, our aim was investi-
gating the role of IL6 on GIIS modulation of exercise-trained mice.
Materials and methods: After weaning, 21 days old male C57BL-6
mice were randomly assigned into the control group (C) remaining un-
trained, limited only to cage movement and the trained group (TRE).
Mice were submitted to an endurance training 5× per week, during 1 h,
at 70% VO2 max for 8 weeks. After training, pancreatic islets were
isolated and the blood collected. GIIS was measured in islets from trained
mice. In addition, islets from non-trained mice were incubated with serum
from trained animals with or without IL6 inhibitor. It was also quantified
UCP2 expression and ATP production. Insulin content was measured by
radioimmunoassay.
Results: Isolated islets from TRE mice displayed 50% lower GIIS under
stimulatory glucose concentration. CTL islets incubated with serum from
TRE animals showed the same magnitude of insulin secretion decrease,
reported in the islets from trained mice. When the islets from CTL ani-
mals were pre-incubated with IL6 inhibitor, before incubating with serum
from TRE mice, the effect of exercise-induced reduction on GIIS was
lost. Although UCP2 expression was increased in TRE, ATP production
did not differ between the groups.
Conclusion: Exercise-induced GIIS modulation seems to be an endo-
crine signaling through plasma factors, being IL6 among them. Higher
islets UCP2 content was associated with reduced GIIS. However, ATP
production was not altered.
Supported by: FAPESP, CNPq, CAPES
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Synergistic mtDNA point mutations of OXPHOS complexes resulted
in reduced fat mass, improved genetic fitness in a conplastic mouse
strain
S. Schröder1, J. Brenmoehl2, M. Tiedge1, S. Baltrusch1;
1Institute of Medical Biochemistry and Molecularbiology, Rostock,
2Leibniz Institute for Farm Animal Biology (FBN), Dummerstorf, Ger-
many.
Background and aims:Mutations in complexes of the respiratory chain,
which are encoded in the mitochondrial genome (mtDNA), can alter
cellular energy metabolism during aging. Due to mitochondrial dysfunc-
tion mtDNA mutations may result in a reduced physiological fitness and
metabolic diseases such as adipositas and type 2 diabetes mellitus. Previ-
ous studies indicate that multiple mutations in the OXPHOS system pre-
dispose to hepatosteatosis. It was the aim of this study to investigate the
fitness, muscle and fat mass from conplastic mice carrying a single
mtDNA point mutation in the cytochrome c oxidase (complex IV) or a
combined mutation in the cytochrome c oxidase (complex IV) and the
NADH dehydrogenase (complex I).
Materials and methods: The genetic fitness was quantified by a computer-
controlled treadmill in conplastic mouse strains C57BL/6NTac-mtBPL/1J
(NADH dehydrogenase mutation und cytochrome c oxidase mutation,
mtBPL), C57BL/6NTac-mtNOD/LtJ (cytochrome c oxidase mutation,
mtNOD) and C57BL/6NTac-mtAKR/J (control; mtAKR) at the age of
6months. In addition, we analyzed blood glucose levels.Muscle and fatmass
was quantified by weighting femoral muscle, gonadal and brown adipose
tissue, respectively. Data are expressed as percentage of total body weight.
Results: At the age of 6 months mtBPL mice (7.2 mmol/l) showed sig-
nificantly higher blood glucose levels compared to mtNOD mice
(6.1 mmol/l) and mtAKR control mice (6.2 mmol/l). mtBPL (70 m) mice
moved over longer distances on a treadmill than mtAKR control mice
(28 m). Furthermore, mtBPL mice showed a significantly higher muscle
mass (1.3% vs. 1.0%) and a significantly lower fat mass for both gonadal
fat (2.9% vs. 4.2%) and brown fat (0.2% vs. 0.3%) compared to mtAKR
control mice.
Conclusion: Double mtDNA point mutations in the NADH dehydroge-
nase and cytochrome c oxidase resulted in higher blood glucose levels in
6 month old mtBPL mice without manifestation of diabetes. However,
mtBPLmice showed a better physiological aerobic fitness, higher muscle
mass and lower fat deposition. Apparently, OXPHOS mutations induce
tissue-specific adaptations of mitochondrial dynamics and energy metab-
olism. The reduced fat stores in adipose tissue may favor hepatic steatosis
and subsequent insulin insensitivity as observed in older mtBPL mice.
Thus, mtDNA mutations in humans may also play a causative role for
disproportional fat distribution between fat tissue and liver in adipose
patients.
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Moderate intensity exercise training rapidly increases insulin stimu-
lated intestinal glucose uptake in sedentary individuals
K.K. Motiani, A. Savolainen, J. Eskelinen, K.A. Virtanen, R. Parkkola,
J. Knuuti, P. Nuutila, K.K. Kalliokoski, J.C. Hannukainen;
Turku PET Center, University of Turku, Finland.
Background and aims: Recently it has been shown that insulin is a
potent stimulator of glucose uptake (GU) in intestine and that intestinal
insulin resistance manifests in obesity and type 2 diabetes. Exercise train-
ing improves whole body glycaemia and insulin stimulated skeletal mus-
cle GU. Thus, we aimed to study the tissue specific effects of exercise
training on insulin-stimulated intestinal GU.
Materials and methods: Healthy individuals (n=26, aged=48 [SD 5]
yrs, BMI=26.1 [SD 2.4] kg·m-2, VO2peak=34.2 [SD 4.1] ml·kg
-1·min-
1) and patients with IFG/IGT/T2D (n=20, aged=49 [SD 4] yrs, BMI=
30.1[SD 2.7] kg·m-2, VO2peak=28.3[SD 4.6] ml·kg
-1·min-1) were ran-
domized into high intensity interval training (HIT) and moderate intensity
training (MIT) groups. The groups were studied before and after two
weeks and six sessions of HIT (4-6×30 s all out sprints on cycle ergom-
eter with 4 minutes of recovery) or MIT training (40-60 min cycling with
ergometer at 60% of VO2max). Intestinal GU was measured during
euglycemic hyperinsulinemic clamp using positron emission tomography
and 18F-FDG.
Results: In healthy individuals, VO2peak and whole body insulin sensi-
tivity improved and visceral fat decreased similarly in both groups (all p<
0.05), following intervention. Training increased GU in colon and tended
to increase in small intestine in MIT group, whereas opposite was ob-
served in HIT group [colon: MIT 30%, HIT - 2% (p=0.02) and small
intestine: MIT 10%, HIT - 9% (p=0.08), respectively]. The GU in the
small intestine correlated positively with the VO2peak [Pre: r=0.46 p=
0.03; Post: r=0.45 p=0.03] and negatively with visceral fat mass [Pre:
r=-0.42 p=0.05; Post: r=-0.45 p=0.03]. The results for IFG/IGT/T2D
group are under analysis and will be presented in the congress.
Conclusion: This study suggests that MIT rapidly enhances insulin stim-
ulated intestinal GU already after two weeks of training in sedentary
individuals.
Clinical Trial Registration Number: NCT01344928
Supported by: EAS,EFSD/Novo Nordisk,EVO,COE,ORION
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Effect of individualised physical activity treatment on drug naïve
type 2 diabetic patients
T.N. Nguyen1,2, H.T.T. Vu1,2, T. Pham1, I. Van de Ploeg3, C.J.
Sundberg3;
1National Geriatric Hospital, Hanoi, 2Hanoi Medical University, Viet
Nam, 3Physiology and Pharmacology, Karolinska Institutet, Stockholm,
Sweden.
Background and aims: Exercise is considered a corner stone of diabetes
management, along with diet and medication since long. The benefits of
exercise are determined by its type, duration, frequency and intensity. The
aim of this study was to evaluate the health effect of physical activity on
prescription in newly diagnosed type 2 diabetes (T2D) patients in
Vietnam.
Materials and methods: Twenty-three newly diagnosed T2D patients
were randomized in two groups: 12 patients received a 12week - program
of individualized physical activity (IPA group) (at least 30 minutes/day of
moderate-to-vigorous intensity activity, face-to-face education each
week, guided to use pedometer Yamax 500, physical activity diaries);
11 patients received standard care (SC group) according to WHO guide-
lines. Fasting plasma glucose (FPG) was measured before, every second
week and after twelve weeks. HbA1c, insulinemia, liver enzymes, serum
creatinine, BUN, lipid profile, oral glucose tolerance test, blood pressure,
weight, waist and hip circumference were measured before and after
12 weeks.
Results:During the treatment period, all patients in IPA group kept walk-
ing: mean 5.3±0.9 days/week, 8317±1962 steps/day (67.3±25.9 mi-
nutes/day). In IPA group, FPG decreased and achieved the treatment goal
after 4 weeks (from 8.8±1.0 to 7.1±0.8 mmol/L, p<0.001), which was
sustained during the treatment course. Over the twelve weeks, the FPG
level decreased by 1.6±0.9 mmol/L in the IPA group and by 0.4±
1.2 mmol/L in the SC group (from 8.7±1.9 to 8.3±1.0 mmol/L) (p<
0.05). HbA1c in the IPA group was reduced by 16.3±7.3 mmol/mol
(from 66.8±5.1 to 50.5±5.5 mmol/mol, p<0.001) and by 1.3±
6.8 mmol/mol in the SC group. In addition, triglyceride levels decreased
more (p<0.05) in the IPA group (1.1±1.6 mmol/L) between baseline and
twelfth week than in the SC group (0.6±1.1 mmol/L). There was no
difference between the two groups in homeostasis model assessment of
insulin resistance (HOMA - IR), blood pressure, weight, waist and hip
circumference.
Conclusion: Individualized physical activity of sufficient frequency, du-
ration and intensity shows a promising improvement of glycemia and
lipid profile in drug naïve type 2diabetes.
Supported by: SIDA, Sweden
PS 035 New insights on old therapies:
experimental studies
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Insulin increases the expression of the genes associated with glyco-
protein 130 signalling in human skeletal muscle and this effect is
reversed by NEFAs
M. Straczkowski1,2, M. Stefanowicz1,2, N. Matulewicz1,2, A.
Nikolajuk1, M. Karczewska-Kupczewska1,2;
1Department of Prophylaxis of Metabolic Diseases, Institute of Animal
Reproduction and Food Research, Polish Academy of Sciences, Olsztyn,
2Department of Metabolic Diseases, Medical University of Bialystok,
Poland.
Background and aims: Glycoprotein 130 (gp130) cytokines, including
interleukin 6 (IL-6), act through plasmamembrane receptors consisting of
2 glycoproteins: a cytokine binding subunit (like IL-6R) and gp130, re-
sponsible for signal transduction. IL-6 may induce insulin resistance,
however, in some conditions it may exert insulin-sensitizing effect in
skeletal muscle. The aim of the present study was to assess the effect of
insulin and NEFAs on the expression of the genes associated with gp130
signaling in skeletal muscle of healthy humans and in cultured human
myotubes.
Materials and methods: In experiment 1, we examined 20 healthy male
subjects with normal glucose tolerance (mean age 25.2±3.2 years, mean
BMI 26.5±4.6 kg/m2). The biopsy of vastus lateralis muscle was per-
formed before and after 6-hour clamps without or with Intralipid/heparin
infusion. In experiment 2, we performed muscle biopsy in 8 healthy male
subjects with similar characteristics and then satellite cells were differen-
tiated into myotubes. We treated myotubes with insulin and palmitate
separately and in combination. In both experiments, the expression of
IL-6R, gp130 and associated genes was analyzed with Real Time PCR.
Results: In experiment 1, serum IL-6 increased and soluble forms of IL-
6R and gp130 decreased similarly during both clamps (all p<0.05). In-
sulin infusion resulted in an increase in muscle expression of IL-6R (p<
0.001) and JAK2 (p=0.041) in the entire group and in gp130 (p=0.043)
in normal-weight individuals. Concurrent Intralipid heparin infusion,
which reduced insulin sensitivity by approx. 40%, abolished all these
insulin’s effects. In experiment 2, incubation with insulin increased the
expression of IL-6R, gp130 and SOCS3 (all p<0.05). Incubation with
palmitate reversed all these changes and decreased JAK1 (p=0.041).
Conclusion: Our data show that the regulation of genes associated with
gp130 signaling in skeletal muscle may be important for lipid-induced
insulin resistance.
Supported by: Grant 2011/01/B/NZ5/05380 from National Science Cen-
ter, Poland
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Metformin action on cell cycle arrest and insulin resistance condition
in hepatocarcinoma cells
A.Montesano1, P. Senesi2, G.Mollica1, F. Vacante3, S. Paini1, L. Luzi1,2,
I. Terruzzi3;
1Department of Biomedical Sciences for Health, University of Milan,
2Metabolism Research Center, San Donato Hospital and Scientific Insti-
tute, 3Diabetic Research Institute, Metabolism, Nutrigenomics and Cel-
lular Differentiation Unit, San Raffaele Scientific Institute, Milan, Italy.
Background and aims: Nutrient overload is associated with the devel-
opment of obesity, insulin resistance and type 2 diabetes (T2DM). Insulin
resistance is a characteristic feature of T2DM and is characterized by
defects in insulin signaling. However, the underlying mechanisms for
developing insulin resistance in the presence of excess nutrients are
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incompletely understood. In recent decades, global changes in dietary
habits have led to an increase in added sugar consumption, which has
been linked to increased trends in obesity and type 2 diabetes (T2DM).
T2DM is associated with a higher risk of liver diseases frequently
degenerating in hepatocellular carcinoma (HCC). Fructose (FR) has been
reported to be responsible for the metabolic disturbances, liver fat depo-
sition and HCC. Unfortunately, most HCC seem to be resistant to con-
ventional chemotherapy and radiotherapy. The poor efficacy of antitumor
agents is also due, at least in part, to the inefficient drug delivery and
metabolism exerted by the steatotic/cirrhotic liver that host the tumor.
Excessive IGFs signaling is a characteristic feature of liver tumors. Re-
cent studies suggest that downregulation of IGFI together with upregula-
tion of IGFII and overactivation of IGFI receptor and insulin receptor
isoform A are important events in HCC development. These alterations
cause a higher cell proliferation. Metformin (METF), the most commonly
prescribed drug for T2DM that inhibits hepatic gluconeogenesis and de-
creases glycogenolysis, has been found to lower HCC risk. We investi-
gated molecular effects of METF on in vitro human hepatoma cell lines
(HepG2), an useful insulin resistance cell model.
Materials and methods: HepG2 cells were treated with METF
(400 μM) in association or not with 5 mM FR for 24 or 48 hours. METF
action on cell cycle progression and signaling pathways involved in me-
tabolism regulation was evaluated by Immunofluorescence and Western
Blot assay.
Results: Since assessing HepG2 cell viability, METF seemed to decrease
growth cell capacity, we performed western blot and immunofluores-
cence studies to investigate cell cycle regulators. METF showed to induce
expression of cyclin D3 and p21 protein. In addition, METF increased
ratio retinoblastoma (Rb)/pRb. These data suggest that METF could ar-
rest the cell cycle at G0/G1 phase without inducing apoptosis as support-
ed by p53 unmodified levels. Furthermore, studying PPARs modulation,
target signaling of FR action on liver fatty acid metabolism, we observed
that METF seemed to increase PPAR γ levels, confirming that METF
could reduce cellular lipid drops accumulation caused by FR, as showed
by Red Oil staining. Besides, METF showed to improve insulin resis-
tance increasing pIRS1tyr/pIRSser ratio, principal molecular marker of
IR condition, and GSK activation.
Conclusion: In conclusion, our data shows that METF could suppress
HepG2 proliferation, through induction of cell cycle arrest at G0/G1
phase. Also, METF effect on fatty acid metabolism and on insulin resis-
tance leads to the development of new METF therapeutic use in liver
diseases associated with insulin resistance.
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Bone/BodyMorphogenetic Proteins (BMPS) act as insulin-sensitisers
via upregulation of PPARgamma expression in mature 3T3-L1
adipocytes
I. Schreiber1,2, P. Knaus1,2, K. Ruschke1;
1Biochemistry, FU Berlin, 2BSRT, Berlin, Germany.
Background and aims: Antidiabetic drugs like Metformin and
thiazolidinediones improve insulin sensitivity of muscle and adipose tis-
sue, but can cause severe side effects in type-2-diabetes patients. There-
fore, the identification of new insulin sensitizers and a detailed under-
standing of their functionality is of great interest. Bone/Body morphoge-
netic proteins are secreted growth factors clinically used because of their
bone healing properties. Beside their classical role in development, BMPs
are now seen as metabologens. They have been found to regulate adipo-
genesis, iron metabolism in liver and the formation and thermoregulatory
activity of BAT, but their metabolic functions in adult tissues need to be
further investigated.
Materials and methods: Fully differentiated 3 T3-L1 adipocytes were
stimulated with insulin, BMP-2, BMP-6 or both. To generate insulin-
resistant adipocytes, the cells were kept in medium containing insulin
for 8 h prior to stimulation. Adipocytes stably expressing a GLUT-
4_GFP_7myc-construct were stimulated as described, stained for myc-
tag-translocation and analyzed via flow cytometry. Uptake of 3H-2-
deoxyglucose was measured after short or long-term stimulations. Protein
expression levels were analyzed by qRT-PCR and Western Blot or via
flow cytometry.
Results: Previous work showed that overnight stimulation with BMPs in
combination with a short-term insulin stimulation significantly increases
glucose uptake rates compared to controls (F=25.998, p<0.05). Further-
more in vitro generated insulin resistant adipocytes show elevated glucose
uptake upon 18 h of BMP2 treatment independent of an additional insulin
stimulus (F=9.365, p<0.05). The magnitude of this effect is comparable
to the known insulin sensitizer Rosiglitazone that served as positive con-
trol. The BMP-mediated effect is not caused by enhanced translocation of
GLUT-4 vesicles as shown with a GLUT-4_GFP_7myc-translocation
assay and time resolved glucose uptake assays. The insulin sensitizing
effect of BMP-2 and BMP-6 was observed earliest 4 h after stimulation.
Canonlical Smad 1/5/8 as well as MAP kinase signaling was triggered by
BMPs in mature adipocytes. Sequential alteration of PPARgamma,
RXRalpha, GLUT-4 and GLUT-1 mRNA expression indicates a tran-
scriptional effect of BMPs on glucose uptake.
Conclusion: Long-term BMP stimulation has an insulin sensitizing effect
on mature adipocytes. We suggest that this effect is mediated by activa-
tion of PPARgamma expression and not via direct glucose transporter
translocation. Phospho-Smads activating the PPARgamma promoter via
known Smad-binding elements might mediate this effect on glucose me-
tabolism. The impact of MAP kinase signaling on this effect will be
further investigated using selective inhibitors. PPARgamma is a nuclear
receptor and its upregulation via BMP signaling could lead to a higher
sensitivity of the nuclear surface for natural ligands like polyunsaturated
fatty acids. Therefore, PPARgamma together with RXRalpha can act as a
transcription factor and initiate transcription of a defined set of down-
stream targets likeGLUT-1 andGLUT-4. To investigatemetabolic chang-
es in BMP stimulated adipocytes extracellular flux measurements will be
performed. Further work needs to determine if BMPs could serve as a
new antidiabetic treatment strategy with reduced side effects, especially
beneficial for osteoporosis patients.
Supported by: DFG RU 155/1-1, DDG, office of the research committee
FU Berlin
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Effect of the long-acting insulin analogues glargine and degludec on
cardiac cell function
T. Hartmann1, N. Wronkowitz1, S. Greulich2, M. Ouwens2, P.
Wohlfart3, N. Tennagels3, J. Eckel1;
1Paul-Langerhans Group for Integrative Physiology, 2Institute for Clini-
cal Biochemistry and Pathobiochemistry, German Diabetes Center,
Düsseldorf, 3Sanofi-Aventis Deutschland GmbH, Frankfurt am Main,
Germany.
Background and aims: Long acting insulin analogues are designed to
mimic the physiological pattern of endogenous insulin secretion resulting
in a better glycaemic control while reducing the risk of hypoglycaemia.
One important aspect for their long-term use is cardiovascular safety data:
Insulin glargine (IGla) has proven to be safe in the cardiovascular out-
come ORIGIN trial; for Insulin degludec (IDeg), the outcome trial DE-
VOTE is ongoing. The aim of this study was to investigate IGla, its active
metabolite M1 (IGla-M1) and IDeg on signaling and contractility in three
pre-clinical cardiovascular cellular models (mouse atrial cell line HL-1,
primary rat cardiomyocytes (ARVM) and iPS-cell derived human
cardiomoycytes (Cor.4U)).
Materials and methods: Adult rat ventricular cardiomyocytes were iso-
lated from Lewis rats and incubated with 100 nM regular insulin (Ins),
IGla, IGla-M1 or IDeg to compare the positive inotropic effect of each
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insulin. To examine the role of Akt, we preincubated ARVM for 30 min
with the Akt inhibitor triciribine. Additionally, ARVM and HL-1 cells
were used to investigate the insulin signaling pathway by Western Blot
analysis. To determine the impact of insulins on cardiotoxicity and effi-
cacy in human Cor.4U cells, beating rate was monitored with an
impedance-based device (xCelligence Cardio) for up to 24 h.
Results: In HL-1 cells, IDeg stimulation results in a significantly lower
Akt (Ser473) phosphorylation compared with Ins, IGla and IGla-M1 after
5- and 10-min incubation. Nonetheless, after 60-min treatment the phos-
phorylation was comparable with Ins and IGla M1. In ARVM we ob-
served similar increases in pAkt (Ser473) phosphorylation with Ins, IGla-
M1 and IDeg (7.4-, 8.2- and 7.8-fold, respectively) after a single
timepoint (10 min). Incubation of electrically paced ARVM with the
different analogues resulted for all insulins in a significantly increased
sarcomeric shortening (2.5-2.8 fold) and similarly increased contractility
(2.1-2.4 fold) and relaxation velocities (2.6-3.5 fold). The positive inotro-
pic effect of Ins and long-acting analogues could be totally abrogated by
the specific Akt inhibitor triciribine. In human Cor.4U cells, all insulins
displayed no obvious cardiotoxicity and slightly increased the rate of
spontaneous beating 1.1-1.2-fold.
Conclusion: In conclusion, we demonstrated similar efficacy under
steady-state-conditions in regard to insulin signaling, positive inotropy
and beating rate for the insulin analogues tested compared with regular
insulin. In HL-1 cells, IDeg exhibited a slower on-set of action on AKT
phosphorylation. Whether the observed kinetic difference plays a role in
more complex tissue models may need to be investigated.
Supported by: Sanofi-Aventis Deutschland GmbH
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Insulin glargine and (A21Gly,DiD-Arg) insulin do not promote
breast cancer growth in a mouse model
E. Gallagher1, N. Tennagels2, U. Werner2, D. LeRoith1;
1Department of Medicine, Mount Sinai School of Medicine, New York,
USA, 2Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.
Background and aims: Since it was found that the insulin analog
AspB10 led to mammary tumors in rats, there have been concerns over
the potential mitogenicity of insulin analogs. As insulin analogs and de-
livery systems continue to be developed, there is a need to understand the
mitogenic mechanisms of certain analogs.Previous studies have reported
that insulin analogs that activate the insulin-like growth factor receptor
(IGF-1R) may be more mitogenic, while others have suggested that
prolonged activation of the insulin receptor (IR) may be responsible for
the tumor promoting effects. Insulin glargine has greater affinity for the
IGF-1R than human insulin (HI) in vitro, but in vivo it is metabolized to
an M1 metabolite that has similar affinity to the IR and IGF-1R as HI.
(A21Gly,DiD-Arg) Insulin is a modified form of insulin glargine that is
resistant to in vivometabolism and has higher affinity for the IGF-1R than
HI.The aim of our study was to determine if insulin glargine and the non-
metabolizable insulin (NMI) glargine analog (A21Gly,DiD-Arg) promote
the growth and metastasis of breast cancer in a mouse model.
Materials and methods:We used female MKRmice on an FVB/n back-
ground for these studies.TheMKRmouse is a model of insulin resistance,
due to muscle specific (M) overexpression of a mutant (K to R mutation)
kinase dead IGF-1R. At 8 weeks of age, the 4th mammary fat pad of
MKR mice was injected with murine Mvt-1 breast cancer cells, derived
from a c-myc/vegf overexpressing model. Tumor bearing mice were di-
vided into 3 groups (n=8 per group) and injected with insulin glargine
(12.5 IU/kg twice daily), NMI (12.5 IU/kg twice daily) or an equal vol-
ume of vehicle for 3 weeks. Tumors were measured twice weekly for
3 weeks. At the end of the study tumors were weighed, and pulmonary
macrometastases were quantified.
Results: There was no difference in tumor size (vehicle 234.3±
39.5 mm3, glargine 237.4±33.8 mm3, NMI 265.5±21.8 mm3) at the
end of the study. Similarly, tumor weight and the number of metastases
were not significantly different between the insulin glargine, NMI and
control groups at the end of the study.
Conclusion: These data demonstrate the lack of mitogenic effect of in-
sulin glargine or the non-metabolizable form of insulin glargine in a
mouse model of breast cancer.
Supported by: Sanofi
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GLP-1 agonist induces transdifferentiation of pancreatic alpha cells
dedifferentiated by FOXO signalling
M.-K. Kim1,2, J. Park1, M. Park3, H. Jung2, E. Lee1, T. Kim1, T. Kim1,
M. Kwon1, S. Lee1, B. Rhee1, J. Park1,2;
1Division of Endocrinology and Metabolism, College of Medicine, 2Mo-
lecular Therapy Lab, Inje University, 3Division of Endocrinology and
Metabolism, Dong-A University College of Medicine, Busan, Republic
of Korea.
Background and aims: Pancreatic alpha cell has been more empha-
sized in pathophysiology of diabetes by glucagoncentric explanation
and transdifferentiation to beta cell. One recent study reported that
GLP-1 directly increased intrinsic GLP synthesis in alpha cell line
and changed alpha cell specific gene transcription. FOXO signaling
under glucotoxic injury is related to dedifferentiation of pancreatic beta
cell and delta cell.We investigated FOXO signaling in pancreatic alpha
cell under hyperglycemia and GLP-1 effect on transdifferentiation of
alpha cell.
Materials and methods: α-TC1-6 cell line was cultured in hyperglyce-
mia or FOXO inhibitor. And then GLP-1 agonist, Exendin-4 was applied
to them. We measured FOXO transcription factor, Pax6 levels and MafB
gene, glucagon gene (Gcg) and protein expression after hyperglycemia or
FOXO inhibitor treatment. PDX1, Pax4 levels, Pax6 levels, MafA and
MafB gene, glucagon gene (Gcg) and protein expression were checked
after Exendin-4 treatment.
Results: Hyperglycemia induced FOXO nuclear localization in pancre-
atic alpha cell. Hyperglycemia and FOXO inhibitor decreased Maf B,
glucagon gene and Pax 6. Exendin-4 increased Maf A, Pax 4 and
PDX1 in FOXO inhibitor affected alpha cells
Conclusion: GLP-1 agonist treatment can induce transdifferentiation of
pancreatic alpha cell dedifferentiated by FOXO signaling and hypergly-
cemia
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Effects of glucose concentration on AMPK activation and activity of
metformin and berberine
J. Yin, Y. Xiao, L. Wei, W. Jia;
Shanghai Clinical Center for Diabetes, Department of Endocrinology and
Metabolism, Shanghai Key Labo, Shanghai Jiao Tong University Affili-
ated Sixth People’s Hospital, China.
Background and aims: Both metformin and berberine are well-known
hypoglycemic agents for treatment of type 2 diabetes. Underlying mech-
anisms involves activation of AMP-activated protein kinase (AMPK)
pathway. However, theoretically excess nutrient such as hyperglycemia
may inactivate AMPK. This study aimed to examine whether metformin
and berberine were able to exert hypoglycemic effects under high glucose
condition via AMPK activation.
Materials and methods: Glucose consumption was used to evaluate the
glucose-lowering effect of metformin and berberine on HepG2 hepato-
cytes and C2C12 myotubes. AMPK phosphorylation and ACC phos-
phorylation were measured with western blot to assess the activity of
AMPK pathway. Anaerobic glycolysis was evaluated through determin-
ing lactate concentration in the medium.
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Results: In this study, we found that in HepG2 hepatocyte and C2C12
myotubes, metformin and berberine significantly increased glucose con-
sumption in a dose-dependent manner. In different glucose concentra-
tions, e.g. 5.6 mmol/L, 15 mmol/L and 30 mmol/L, metformin and ber-
berine exerted similar glucose-lowering effects. On the other hand, the
lactate production was largely enhanced by metformin or berberine in the
cells in the same way as they affect glucose consumption. Meanwhile,
AMPK and ACC phosphorylation was stimulated by 5 mmol/L metfor-
min or 10 μmol/L berberine in the presence of 5.6 mmol/L glucose
concentration. Nevertheless, in 15 mmol/L glucose concentration, met-
formin and berberine failed to activate AMPK pathway. In 30 mmol/L
glucose concentration, metformin and berberine even reduced phosphor-
ylation of AMPK and ACC. Surprisingly, more phosphorylation of
AMPK and ACC was observed in high glucose concentration compared
with low glucose concentration.
Conclusion: These results suggest: 1) Metformin and berberine promote
glucose metabolism by stimulation of glycolysis, which is independent of
glucose concentration. 2) Metformin and berberine activate AMPK path-
way in low glucose concentration other than in high glucose concentra-
tion. 3) High glucose concentration is able to activate AMPK pathway by
itself.
Supported by: NSFC of China (31171128)
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Glucagon receptor siRNA is not as effective at normalising glycaemia
and lipid metabolism as leptin treatment in streptozotocin-diabetic
mice
U.H. Neumann1, J.S.S. Ho1, S. Chen2, Y.Y.C. Tam2, P.R. Cullis2, T.J.
Kieffer1;
1Cellular and Physiological Sciences, 2Biochemistry and Molecular Bi-
ology, University of British Columbia, Vancouver, Canada.
Background and aims: The hormone leptin can reverse hyperglycemia
in rodent models of type 1 diabetes. Supraphysiological levels of leptin
dramatically reduce the counter-regulatory hormone glucagonwhich may
be one mechanism by which leptin acts to reduce glycemia. However,
leptin therapy can also improve hyperglycemia prior to normalization of
glucagon and can reverse hyperglucagonemia without restoring
normoglycemia. Therefore, the contribution of glucagon suppression to
the metabolic actions of leptin remains unclear. To investigate this we
compared the metabolic effects of leptin with hepatic glucagon receptor
(GCGR) knockdown using GCGR siRNA encapsulated in liposomal
nanoparticles (LNPs) in streptozotocin (STZ)-treated mice.
Materials and methods: To find an effective GCGR siRNA, 3 GCGR
siRNAs, and factor VII (FVII) siRNA as a control, were encapsulated into
LNPs and delivered via the tail-vein at a dose of 5mg/kg to wildtypemice
and subsequent glucose homeostasis was assessed for 7 days. To compare
the effect of glucagon suppression in type 1 diabetes to that of leptin
treatment, STZ diabetic mice were administered either 5 mg/kg GCGR
siRNA or FVII siRNA as a control, then half of the animals from each
group were implanted with a pump delivering 20 μg/day leptin resulting
inmice that received FVII siRNA,GCGR siRNA, leptin+FVII siRNA, or
both GCGR siRNA and leptin treatments. Various metabolic parameters
were assessed over 7 days to compare the therapies.
Results:Two of threeGCGR siRNAs appeared towork in wildtypemice;
the most effective GCGR siRNAwas capable of reducing fasting blood
glucose (5.6±0.1 mM vs 8.1±0.3 mM, p<0.05), enhancing oral glucose
tolerance (10.8±0.6 mM vs 19.2±0.8 mM, 20min post gavage, p<0.05),
and elevating plasma glucagon levels (140±30 pg/mL vs 14±3 pg/mL, p
<0.05) compared to controls given FVII siRNA. This GCGR siRNAwas
then used in mice with STZ-diabetes to compare with leptin treatment. As
expected, glucagon levels were suppressed by leptin treatment, and in-
creased by GCGR siRNA treatment. In addition, this dose of leptin in-
duced supraphysiological levels of leptin that were unaltered by GCGR
siRNA treatment. Blood glucose levels were significantly reduced by
GCGR siRNA treatment, however, not as dramatically as with leptin
treatment (29.5±0.6 mM FVII siRNA, 19.4±1.2 mM GCGR siRNA,
9.9±0.7 mM leptin+FVII siRNA, p<0.05). Plasma β-hydroxybutyrate
was similarly normalized by both treatments compared to FVII siRNA
treatment (2.67±0.22 mM FVII siRNA, 0.56±0.04 mM GCGR siRNA,
0.38±0.03 mM leptin+FVII siRNA, p<0.05). Conversely, plasma cho-
lesterol, triglycerides, fatty acids, and glycerol were all significantly re-
duced by leptin treatment, but were unaffected by GCGR siRNA treat-
ment. For all parameters, the addition ofGCGR siRNA to leptin treatment
did not further improve metabolism compared to leptin treatment alone.
Conclusion: Compared to leptin treatment, GCGR siRNA was equally
effective at reducing plasma ketones, partially effective at reducing gly-
cemia, and ineffective at reducing cholesterol, triglycerides, fatty acids,
and glycerol. Therefore our results suggest that the glucagon suppression
by leptin only accounts for a portion of the metabolic actions of leptin.
Supported by: CIHR
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Fibroblast growth factor-21 is secreted by skeletal muscle in vivo and
correlates withmuscle glucose uptake in humans with type 2 diabetes
P. Mitrou1, E. Maratou1, E. Petsiou2, V. Lambadiari2, S.A. Raptis1,2, G.
Dimitriadis2;
1Hellenic National Center for Research, Prevention and Treatment of
DiabetesMellitus and its Complications (H.N.D.C), Athens, 22nd Depart-
ment of Internal Medicine and Research Institute, Athens University
Medical School, “Attikon” University Hospital, Greece.
Background and aims: Fibroblast growth factor-21 (FGF-21) belongs to
the fibroblast growth factor family, and serves as an endocrine hormone,
which was originally identified to increase glucose uptake in fat cells. In
rodents, FGF-21 is highly expressed in the liver and regulates hepatic
glucose production. The physiological role of circulating FGF-21 in the
regulation of carbohydrate metabolism in-vivo in skeletal muscle which
is the most important tissue for insulin-stimulated glucose uptake, still
remains to be clarified. The aim of this study was to investigate the
association of circulating FGF-21 levels with glucose uptake by the skel-
etal muscle in humans with type 2 diabetes (DM2), using the arterio-
venous difference technique across the forearm muscle.
Materials and methods: A mixed meal (557 kcal; 75 g carbohydrates,
26 g protein, 17 g fat) was given to 11 newly diagnosed subjects with
DM2 (age 53±4 years, BMI 25±1, HbA1c 6.8±0.3%) and 10 control
subjects (age 48±4 yrs, BMI 24±1 kg/m2). Plasma FGF-21, glucose [G]
and insulin were measured preprandially and at 60 min intervals for
300 min postprandialy from the radial artery (A) and from a deep forearm
vein (V). Muscle blood flow [BF] was measured with strain-gauge pleth-
ysmography. Calculations: Glucose flux: [G(A-V)]x[BF]; Glucose
clearance:[G(A-V)]x[BF]/[G(A)].
Results: 1) FGF-21 concentrations were increased in the forearm vein
compared to the artery throughout the whole 5-h period in both DM2
(poverall=0.0028) and control (poverall=0.0146) subjects 2) FGF-21
levels were changed after the mixed meal in both DM2 (poverall=
0.0008) and control (poverall=0.0092) subjects, reaching a peak at
120 min (following the postprandial glucose and insulin increase) 3)
Fasting FGF-21was increased in patients withDM2 compared to controls
(157±30 vs 82±12 pg/ml respectively, p=0.0146) (3) Fasting FGF-21
was positively correlated with muscle glucose flux (r=0.87, p=0.0004)
and glucose clearance (r=0.07, p=0.0127) in patients with DM2.
Conclusion: FGF-21 is secreted by human skeletal muscle in-vivo. In
type 2 diabetes FGF-21 is increased and positively correlated with glu-
cose flux and glucose clearance by the forearm muscle. Therefore, FGF-
21 may be considered as a beneficial myokine for improving muscle
glucose metabolism in type 2 diabetes.
540
AS160 vs Tbc1d1: cooperative determination of insulin-responsive
GLUT4 trafficking activity after exercise-mimetic stimuli
H. Hatakeyama1,2, M. Kanzaki2;
1Frontier Research Institute for Interdisciplinary Sciences, 2Graduate
School of Biomedical Engineering, Tohoku University, Sendai, Japan.
Background and aims:AS160 and Tbc1d1, proteins of the TBC1DRab
GTPase-activating (RabGAPs) family, emerged as the key nexus
deciphering biochemical phosphorylation signals into physical processes
of GLUT4 translocation. Unlike adipocytes which express only AS160,
skeletal muscle cells express both RabGAPs and their relative abun-
dances vary among different skeletal muscles. With our novel GLUT4
nanometry combined with cell-based reconstitution model, we clearly
determined the respective functional roles of the RabGAPs in GLUT4
behavior (MBoC 24: 806, 2013), i.e. AS160 mediates insulin-responsive
GLUT4 release from its static storage sites and, in contrast, Tbc1d1 tem-
porally acquires insulin-responsiveness which triggers GLUT4 release
only after exercise-mimetic stimuli (AICAR-pretreatment and transient
cytosolic Ca2+ increases). We herein analyzed their combinatorial regu-
lator y mechanisms employing our methodology with varied relative
abundances of the two RabGAPs.
Materials and methods: All experiments were performed in 3T3L1
fibroblasts exogenously expressing myc-GLUT4, HA-sortilin, AS160-
enhanced yellow fluorescent protein (EYFP) and HaloTag-Tbc1d1, and
relative abundances of AS160 and Tbc1d1 were estimated by relative
fluorescence intensities of EYFP to those of HaloTag TMR ligand. Intra-
cellular myc-GLUT4was labeledwith Quantum dot-conjugated anti-myc
antibodies, and the movement of individual Quantum dot signals was
tracked with positional precision at 6 nm.
Results: First, Tbc1d1 inhibited AS160-mediated insulin-dependent
GLUT4 release in a relative abundance-dependentmanner, indicating that
Tbc1d1 functionally dominates AS160. Detailed functional assessments
with varied relative abundances of AS160 and Tbc1d1 revealed that
AS160 modulates sensitivity to external stimuli in Tbc1d1-mediated ac-
tivation of GLUT4 trafficking. For example, GLUT4 release induced by
transient cytosolic Ca2+ increases in the presence of insulin with abundant
AS160 occurred much faster (~30 s) than that in cells with little or no
AS160 (~10 min). In addition, acquired insulin responsiveness after
AICAR-pretreatment is more obvious in cells with both Tbc1d1 and
AS160 even after acute (5 min) stimulation than in cells expressing only
Tbc1d1. Importantly, this modulatory action of AS160 was completely
abolished by an obesity-related Tbc1d1 mutant (R125W) with an im-
paired phosphotyrosine-binding 1 (PTB1) domain.
Conclusion: Our GLUT4 nanometry combined with cell-based reconsti-
tution model revealed that AS160 potentiates insulin sensitivity in
Tbc1d1-mediated GLUT4 releasing activity after exercise-mimetic stim-
uli, apparently mediated through functional interaction with the PTB1
domain of Tbc1d1. This modulatory action could be involved in the
differences in insulin sensitivity among skeletal muscles and beneficial
effects of exercise on muscle insulin sensitivity. To further verify this
notion, we currently examine GLUT4 behavior in isolated skeletal mus-
cle and in vivo using several imaging techniques.
541
Alpha-lipoic acid increases "exercise-mimetic" effects of the
PPARbeta/delta pathway in skeletal muscle
A.-S. Rousseau, B. Sibille, J. Murdaca, I. Mothe-Satney, J. Neels, P.A.
Grimaldi;
University of Nice Sophia Antipolis/INSERM U1065/C3M, France.
Background and aims: The quality of the acute and adaptive response to
physical exercise depends on exercise-induced molecular signals and
signaling pathways, the activation of which varies with redox status. α-
lipoic acid (α-LA), a powerful antioxidant, is independently involved in
some exercise-signaling pathway activation driven by PPARβ/δ, a tran-
scription factor known to mimic the phenotypic adaptation to aerobic
exercise training. We validated the hypothesis that α-LA interacts with
PPARβ/δ genic effects in skeletal muscle, identified the molecular mech-
anisms involved in those effects, and determined their potential physio-
logical implications.
Materials and methods: Differentiated C2C12 myotubes and C2C12
expressing a negative-dominant form of PPARβ/δ, were treated during
48 hwith various concentrations ofα-LA (50 to 250μmol/l) and PPARβ/
δ agonist GW0742 (0.3 to 300 nmol/l). Different inhibitors were used (eg.
the non-competitive inhibitor of PPARβ/δ GSK3787 (1 μmol/l) and the
inhibitor of the c-Jun N-terminal (JNK) pathway, SP600125 (30μmol/l)).
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The agonist activity of α-LA on PPARβ/δ was measured in a reporter
assay. In vivo studies with 3-month C57Bl6 mice (minimum 6 per group)
were conducted.Mice performed a one bout of stressful treadmill exercise
(35 cm/s, 1 h) and/or one night or 7-weeks voluntary wheel running
training. Analyses were done by qPCR andWestern-Blot. Statistical anal-
yses were performed using parametric or non-parametric tests depending
on cases.
Results: Treatment of C2C12 with α-LA (250 μmol/l) induces (p<0.05)
a pattern of gene expression (PDK4, CPT1a, Catalase, Prkag3) similar to
those observed in response to GW0742 in C2C12 myotubes. In the re-
porter assay, treatment with α-LA did not lead to an increase in luciferase
activity, suggesting that α-LAwas not an agonist of PPARβ/δ. However,
the inhibition of PPARβ/δ activity, in C2C12 PPARβ/δ-DN or in C2C12
treated with GSK3787, led to a loss of α-LA effect on PPARβ/δ target
gene expressions, suggesting that this pathway had to be active to allow
α-LA effects. Both PPARβ/δ mRNA levels and protein expression were
increased in response to α-LA treatment (2-fold; p<0.05). Moreover, co-
treating cells with α-LA and GW0742, maximized the effect of GW0742
on PDK4 expression for lower concentration (3 nmol/l) than those usually
used (300 nmol/l) to induce this effect. Under physiological conditions,
PPARβ/δ expression was decreased (p<0.05) in vastus lateralis in re-
sponse to one bout of stressful treadmill exercise whereas it was increased
(p<0.05) when lowering oxidative stress exposition in response to vol-
untary exercise training (2-fold). We evidenced in C2C12 that the JNK
pathway activity was decreased with α-LA treatment. The inhibition of
the JNK pathway with SP600125 induced a 2-fold (p<0.05) increase in
PPARβ/δ mRNA level and protein expression and a significant response
on its target-genes, similar to α-LA treatment.
Conclusion:We have evidenced a novel potential mechanism of regula-
tion of the adaptation to stress involving the JNK pathway on the level of
expression of PPARβ/δ in skeletal muscle. This mechanism could be
relevant when the JNK pathway is chronically active in skeletal muscle
such in diabetic or obese patients and/or in conditions where PPARβ/δ
expression in skeletal muscle is known to be particularly low, such aswith
aging and/or physical inactivity. Furthermore, treatment withα-LAmight
be beneficial in these conditions.
Supported by: AFLD/ANTADIR
542
Fractalkine (CX3CL1) a novel myokine protecting skeletal muscle
from insulin resistance in humans
A. Zoso1, P. Plomgaard2, J.S. Hansen2, C. Brandt2, C. Howald1, E.T.
Dermitzakis1, B.K. Pedersen2, P.A. Halban1, K. Bouzakri1;
1Department of Genetic Medicine and Development, Geneva University,
Switzerland, 2Department of Infectious Diseases and CMRC, University
of Copenhagen, Denmark.
Background and aims: Fractalkine (CX3CL1) is a chemokine produced
as a membrane-bound protein shed to the circulation through enzymatic
cleavage by Adam 10 and 17 and regulated by exercise. Recently it has
been shown to be associated with Type 2 Diabetes and we showed that its
mRNA expression is increased in human primary skeletal muscle cells
with TNF-α induced insulin resistance. However, the impact of CX3CL1
on primary human skeletal muscle cells exposed to TNF-α remains to be
explored.
Materials and methods: CX3CL1 mRNA and protein levels were mea-
sured in plasma and muscle biopsies from healthy volunteers performing
either 3 h of bicycling exercise or 2 h of one legged knee extensor exer-
cise. Plasma CX3CL1 levels were also measured in healthymales infused
for 4 h with TNF-α or placebo. Human skeletal muscle cells were ob-
tained from abdominal muscle and cultured with CX3CL1 for 48 h alone
or with TNF-α 20 ng/ml for the last 24 h to induce insulin resistance. We
investigated insulin induced-deoxyglucose uptake, insulin and NFkB sig-
naling pathways using western blot and ER and mitochondrial alterations
by immunostaining. Deeper investigation of CX3CL1 effects onmyotube
gene expression was conducted by RNAseq.
Results: Plasma CX3CL1 increased rapidly after the beginning of exer-
cise, reaching a maximum by 3 h (1.4±0.4 μg/l; p<0.01 vs starting
condition). In the one-legged knee extensor model, mRNA content of
CX3CL1 in the exercising leg (EL) was higher compared to the resting
leg (RL). During exercise CX3CL1 plasma levels increased in all vessels
(arterial, RL femoral vein and EL femoral vein), even if its release did not
increase significantly from the EL compared to RL. 24 h post exercise,
CX3CL1 protein content in the EL was decreased (1.08±0.07 vs 0.31±
0.04; p<0.05), while ADAM10 mRNA expression was not increased.
Human volunteers infused with TNF-α showed an increase of plasma
CX3CL1 with a maximum after 4 h (8.2±0.8 μg/l; p<0.001 vs placebo).
In vitro, myotubes treated with CX3CL1 showed an increase of basal
glucose uptake (190±8 vs. 120±18 cpm/mg protein/min; p<0.05) and
were protected from the impact of TNF-α on insulin stimulated-glucose
uptake (TNF-α+CX3CL1: 245±9 vs. TNF-α: 146±25 cpm/mg protein/
min; p<0.05). CX3CL1 moreover prevented the negative effect of
TNF-α on Akt and AS160 phosphorylation and IRS1 expression, restor-
ing control levels. Phosphorylation of ERK, NFkB and p38 induced by
TNF-α was blunted in the presence of CX3CL1. In addition, confocal
imaging highlighted that CX3CL1 in the face of TNF-α reorganized a
proper structure of ER and increased considerably the number of mito-
chondria measured by cytochrome C staining. Although TNF-α modu-
lated the expression of 5276 genes (CTR vs TNF-α), CX3CL1 failed to
reverse the vast majority of these changes (TNF-α vs TNF-α+CX3CL1).
Conclusion: Our study demonstrates that CX3CL1 is expressed by hu-
man skeletal muscle and regulated by exercise and TNF-α infusion. We
also show that this novel myokine protects human myotubes from the
negative impact of TNF-α. This suggests that its autocrine role might
have important implications inmodulating the effects of insulin resistance
on skeletal muscle function including glucose uptake. Ongoing studies
are underway to determine more precisely any possible impact of
CX3CL1 on human muscle gene expression.
Supported by: SNF: 31-135645; 31003A_144092/1
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Regulation of skeletal muscle energy metabolism and insulin action
by perilipin 5
C. Laurens1,2, P.-M. Badin1,2, K. Louche1,2, D.R. Joanisse3, D. Langin1,
2, V. Bourlier1,2, C. Moro1,2;
1Institute of Metabolic and Cardiovascular Diseases, INSERM, 2Paul
Sabatier University, Toulouse, France, 3Département de Médecine et de
Kinésiologie, Centre de Recherche Institut Universitaire deCardiologie et
de Pneumologie de Québec, Canada.
Background and aims: Intramuscular triglycerides lipid droplets can
fuel muscle contraction during exercise but also promote insulin resis-
tance when in excess. Recent work indicates that perilipin 5 (PLIN5) may
play a gatekeeper role at the lipid droplet surface. The aim of the present
work was to characterize the role of PLIN5 in the regulation of skeletal
muscle lipid and glucose metabolism.
Materials and methods:We measured PLIN5 protein content in differ-
ent mouse skeletal muscles and in lean sedentary, endurance trained and
obese glucose intolerant (IGT) subjects. We also overexpressed PLIN5
using an adenoviral approach in human skeletal muscle cells primary
culture to characterize its functional role in the regulation of energy me-
tabolism and insulin action.
Results: PLIN5 is highly expressed in oxidative compared to glycolytic
muscles. PLIN5 protein content strongly correlates with insulin sensitiv-
ity (r2=0.42, p<0.0001), is elevated in endurance-trained subjects, and
reduced in obese IGT. PLIN5 overexpression in human skeletal muscle
cells slows down triglyceride depletion (-53%, p=0.0025), as well as
lipolysis-derived fatty acids mobilization and oxidation (-46%, p=
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0.0035). This is accompanied by an increase in glucose oxidation and
glycogen synthesis, concomitant with a decrease of pyruvate dehydroge-
nase kinase 4 gene expression. Finally, PLIN5 overexpressing cells are
partly protected from palmitate-induced lipotoxicity and insulin
resistance.
Conclusion:Collectively, our data indicate that PLIN5 plays a key role in
the regulation of skeletal muscle energy metabolism. PLIN5 could con-
tribute to maintain insulin sensitivity by modulating fatty acid trafficking
in and out of the lipid droplet in skeletal muscle.
Supported by: National Research Agency ANR-12-JSV1-0010-01 and
SFD
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p300 is essential for the full effect of calorie restriction to enhance
skeletal muscle insulin sensitivity
S. Schenk1, S. LaBarge1, O. Osborn2, C.E. McCurdy3, C. Migdal1, S.
Nalbandian1;
1Orthopaedic Surgery, 2Medicine, University of California, San Diego,
La Jolla, 3Human Physiology, University of Oregon, Eugene, USA.
Background and aims: The E1A binding protein, p300, is a transcrip-
tional co-activator and acetyltransferase (KAT), that along with its
paralog, CREB binding protein (CBP), interacts physically and function-
ally with 2000 or more transcriptional regulators and other proteins, many
of which play an integral role in regulating metabolism. Surprisingly,
however, very little is known regarding the contribution of p300, and
KATs in general, to skeletal muscle metabolism. Our objective was to
determine the contribution of p300 to skeletal muscle insulin action,
including calorie restriction (CR)-induced enhancement of skeletal mus-
cle insulin sensitivity.
Materials and methods:Mice with knockout of p300 (mKO) in skeletal
muscle were generated using Cre Recombinase methodology. Beginning
at 10 weeks old, individually housed male, mKO and floxed/wildtype
(WT) littermates continued on an ad libitum (AL) diet, or were switched
to a CR (20 d at 60% of AL) diet. At 12 weeks old, an oral glucose
tolerance test (OGTT; 2 g/kg) was performed, and at 13 weeks old, basal
and insulin-stimulated 2-deoxyglucose uptake (2DOGU) was measured
in isolated extensor digitorum longus (EDL) and soleus muscles using a
physiological insulin concentration (60 μU/mL). Before the 2DOG ex-
periments, body composition was assessed in all mice by magnetic reso-
nance imaging.
Results: As expected, CR decreased fat, lean and total body mass com-
pared to AL fed mice, with no genotype differences observed. Interest-
ingly, while CR significantly reduced the glucose response to an OGTT
by ~60% in WT mice, this improvement was ~25% lower in mKO vs.
WT mice, suggesting that p300, in skeletal muscle, is required for the full
effect of CR to improve glucose tolerance. Supporting this, insulin-
stimulated 2DOGU (insulin 2DOG basal 2DOGU) in the EDL and
soleus of WT-CR mice was ~3-5-fold higher as compared to WT-AL
mice, but this CR-induced improvement was ~40-60% lower in mKO
mice.
Conclusion: These results demonstrate while loss of p300 does not alter
skeletal muscle insulin sensitivity in youngAL-fedmice, p300 is essential
for the full effect of CR to enhance skeletal muscle insulin sensitivity.
Supported by: R01 AG043120, R24 HD050837
545
Dysregulated iron metabolism in human skeletal muscle cells are
associated with free fatty acid-induced insulin resistance
K.-W. Lee1, T. Kim2, S.-E. Choi3, S.-A. Lee1, J. Jeon1, S. Ock4, S.-Y.
An5, Y. Kang3, S. Han1, H. Kim1, D. Kim1;
1Endocrinology and Metabolism, Ajou University Hospital, Suwon, 2Di-
vision of Endocrine and Metabolism, Department of Internal Medicine,
Seoul Medical Center, 3Physiology, Ajou University Hospital, Suwon,
4Endocrinology and Metabolism, Kosin University Gospel Hospital, Bu-
san, 5Endocrinology and Metabolism, Hongik Hospital, Seoul, Republic
of Korea.
Background and aims:Although iron is an important component of the
respiratory system in mitochondria, the relationship between iron metab-
olism and insulin resistance (IR) in skeletal muscles has not been well
studied.
Materials and methods: In this study, we investigated the relationship
between iron metabolism and palmitate-induced insulin resistance in hu-
man skeletal muscle cells. We measured cellular iron levels in palmitate-
induced insulin resistant skeletal muscle cells using calcein-AM. In addi-
tion, we tested the effects of a variety of chemical iron chelators such as
deferoxamine (DFO), deferasirox (DS), FeCl3, and FeSO4 in palmitate-
induced insulin resistant skeletal muscle cells using the glucose uptake
method. Because iron is a critical factor for respiratory metabolism, the
current study was initiated to determine whether abnormal iron metabo-
lism is involved in palmitate-induced insulin resistance.
Results: Palmitate treatment reduced insulin-induced Akt phosphoryla-
tion and glucose uptake but increased the intracellular iron content in
skeletal muscle cells compared with control cells. When palmitate-
treated skeletal muscle cells were treated with iron chelators, insulin-
stimulated phosphorylated Akt levels and glucose uptake were recovered.
However, iron supplementation by treatment with FeCl3 and FeSO4 aug-
mented palmitate-induced insulin resistance. Interestingly, iron supple-
mentation in normal skeletal muscle cells reduced insulin-stimulated
phosphorylated Akt and glucose uptake and evoked insulin resistance.
Similarly, treating skeletal muscle cells with TNF-α elicited similar
effects.
Conclusion: The current study revealed that iron overload in skeletal
muscle cells induced insulin resistance, whereas reduced intracellular iron
levels protected palmitate-induced insulin resistance. Therefore, these
data provide a therapeutic strategy for the treatment of insulin resistance.
546
Muscle glucose uptake and insulin signalling do not correlate over
the feeding/fasting cycle in high fat fed rats
L.B. Small, A. Brandon, E. Suryana, G.J. Cooney;
Diabetes and Metabolism, The Garvan Institute of Medical Research,
Sydney, Australia.
Background and aims:Many studies investigating mechanisms of diet-
induced insulin resistance impose controlled experimental conditions
(constant insulin stimulation, constant glucose and/or fatty acid availabil-
ity) designed to make interpretation of results simpler. These models may
alter important parameters such as insulin or glucose to levels that are not
ever experienced physiologically by the animal during normal feeding or
fasting. We examined glucose uptake and markers of insulin action in
muscle of high fat diet-fed (HFD) rats during the normal diurnal cycle.
Materials and methods:Male Wistar rats were fed a high fat diet (45%
calories as fat) for 4 weeks. After 3 weeks of fat feeding rats were
anaesthetised, implanted with a single chronic jugular cannula and
allowed to recover. One week after surgery the cannula was used to
sample blood and deliver 14C-glucose and 3H-2-deoxyglucose to mon-
itor in vivo glucose uptake at several timepoints along the feedings/
S266 Diabetologia (2015) 58 (Suppl 1):S1–S607
fasting axis (4 pm, 9 pm, 12 am and 8 am). Tissues were collected for
further analysis.
Results: Plasma insulin levels were the same in Chow and HFD rats in
the basal state and after feeding. However glucose uptake into skeletal
muscle was impaired in the tibialis anterior (TA) muscle of HFD rats at
12 am and 8 am (12 am Chow=19.3±2.8, HFD=7.7±0.9, 8 am Chow=
10.4±1.2, HFD=5.6±0.6, umol/min/100 g, p<0.05). There was no dif-
ference in the phosphorylation state of canonical signalling proteins AKT,
GSK3ß and TBC1D4 in TA muscle from Chow and HFD rats at any of
the time points studied. In contrast, pyruvate dehydrogenase (PDH) ac-
tivity in the TA was dramatically lower in HFD rats at both 12 am and
8 am (12 am Chow=4.26±1.73 HFD=0.96±0.17, 8 am Chow=6.46±
0.97 HFD±1.05±0.18, mU/g, p<0.01).
Conclusion: These data suggest that reduced glucose uptake in muscle of
HFD rats assessed during the normal diurnal cycle of energy metabolism
relates more to changes in glucose metabolism than altered canonical
insulin signalling.
Supported by: NHMRC
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Effect of glucagon-like peptide-1 on glucagon secretion, endogenous
glucose production and whole body lipolysis in patients with non-
alcoholic liver disease
A.E. Junker1, L. Gluud2, G.V. Hall3, J.J. Holst4, F.K. Knop1, T.
Vilsbøll1;
1Center for Diabetes Research, Hellerup, 2Department of Gastroenterol-
ogy, Hvidovre, 3Clinical Metabolomics Core Facility, 4NNF Centre for
Basic Metabolic Research and Department of Biomedical Science, Co-
penhagen, Denmark.
Background and aims:We evaluated the glucagon-suppressive effect of
glucagon-like peptide-1 (GLP-1) and its potential effects on endogenous
glucose production andwhole body lipolysis in non-diabetic patients with
non-alcoholic fatty liver disease (NAFLD).
Materials and methods: Ten non-diabetic patients with biopsy-verified
NAFLD (NAFLD activity score 2.5±1.0) and 10 matched controls
underwent a 2-hour intravenous GLP-1 (0.8 pmol×kg-1×min-1) and
placebo infusion on separate days. Since GLP-1-mediated glucagon sup-
pression is glucose-dependent, plasma glucose was clamped at fasting
level during the first hour, then raised and clamped at ‘postprandial level’
(fasting plasma glucose level plus 3 mmol/l) for the remaining hour. We
evaluated plasma levels of glucagon, endogenous glucose production and
whole body lipolysis rates with stable isotopes, and respiratory quotient
using indirect calorimety. Data are presented as median±interquartile
range and groups are compared using non-parametric analysis of
variance.
Results: Compared to controls, patients with NAFLD were more insulin
resistant (HOMA-IR: 3.8±2.2 vs 1.6±1.5, p=0.003) and had higher
fasting glucagon (7.5±5.3 vs 5.8±1.5 mmol/l, p=0.045). Similar relative
glucagon suppression was seen in both groups during GLP-1 infusion at
fasting (-97±75 vs -93±41 pmol/l×min-1 p=0.566) and ‘postprandial’
plasma glucose levels (-108±101 vs -97±53 pmol/l×min-1, p=0.196).
Patients with NAFLD had impaired GLP-1-induced suppression of en-
dogenous glucose production at fasting and ‘postprandial’ glucose levels
and impaired elevation of respiratory quotient during ‘postprandial’ glu-
cose levels.
Conclusion: Patients with NAFLD are insulin resitant and exhibit fasting
hyperglucagonaemia, but intact GLP-1-mediated glucagon suppression
independently of plasma glucose concentrations. Preserved
glucagonostatic effect of GLP-1 in patients with NAFLD may be impor-
tant to sustain normoglycaemia.
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Glucagon suppression is, besides hyperinsulinaemia, an adaptation
to reduced insulin sensitivity in individuals with normal and im-
paired glucose regulation
G. Pacini1, B. Ahrén2, D. Vistisen3, S.S. Torekov4, N.B. Johansen3,5,
D.R. Witte6, A.E. Jonsson4, O. Pedersen4, T. Hansen4, T. Lauritzen6,
J.J. Holst4, M.E. Jørgensen3, K. Færch3;
1Metabolic Unit, IN-CNR, Padova, Italy, 2Lund University, Lund, Swe-
den, 3Steno Diabetes Center, 4University of Copenhagen, 5Danish Dia-
betes Academy, Copenhagen, 6Aarhus University, Denmark.
Background and aims: Hyperinsulinaemia is an important adaptive
mechanism to insulin resistance to maintain normoglycaemia. The aim
of this study was to assess whether also glucagon is involved in the islet
adaptation to insulin resistance.
Materials and methods:We evaluated 1,433 individuals (762 men/671
women) with normal or impaired glucose regulation from the Danish
ADDITION-PRO study. All underwent 75 g oral glucose tolerance tests
Diabetologia (2015) 58 (Suppl 1):S1–S607 S267
with sampling of glucose, insulin and glucagon at 0, 30 and 120 min.
Mean (SD) age was 66.1 (7.1) years, BMI 27.1 (4.5) kg/m2 and HbA1c
5.7 (0.4) % or 38 (4) mmol/mol. Total areas under the curves (AUCs) for
glucose, insulin and glucagon were calculated. Glucagon suppression (%)
was calculated as (1 - (AUCglucagon/(fasting concentration×120min)) ×
100). The insulin sensitivity index (ISI0-120) was calculated using fasting
and 120 min glucose and insulin concentrations as well as information on
body weight. The study participants were divided into two groups de-
pending on glucagon suppression: 1) No suppression (≤0%; n=287); 2)
Suppression (>0%; n=1146).
Results: Median (IQR) of glucagon suppression was 22% (6-34%).
While AUC for glucose did not differ between the groups, AUC for
insulin was higher and insulin sensitivity was lower in individuals with
glucagon suppression (Table 1). When quantifying the effect of insulin
sensitivity on glucagon suppression, adjusting for age, sex, BMI, AUC
insulin and AUC glucose, we found that a doubling in ISI0-120 resulted
in 13.0% less glucagon suppression (95%-CI: 8.1-18.2%, P<0.001). Glu-
cagon suppression was lower in individuals with screen-detected diabetes
(median (IQR): 17% (3-30%)) than in individuals with pre-diabetes (13%
(7-34%)) or normal glucose tolerance (13% (5-36%); P<0.001). Howev-
er, glucose tolerance status (P=0.745) or obesity (P=0.505) did not mod-
ify the association between glucagon suppression and ISI0-120.
Conclusion: The results suggest that glucagon suppression, together with
increased insulin secretion, is an adaptation to reduced insulin sensitivity
in individuals with normal or impaired glucose regulation. Therefore,
preservation of glucose tolerance in the presence of insulin resistance
may depend not only on an individual’s ability to secrete more insulin
but also on their ability to suppress glucagon.
Supported by: ADDITION-PRO funded by EFSD/Novo Nordisk &DCSR
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Distinct roles of somatostatin in the control of glucagon secretion by
glucose and KATP channel blockers from the perfused mouse
pancreas
H. Chae1, A. Gómez-Ruiz1, B. Lai1, N. Antoine1, S. Seino2, P. Gilon1;
1Pôle d’endocrinologie, diabète et nutrition, Institut de recherche
expérimentale et clinique, Université catholique de Louvain, Brussels,
Belgium, 2Kobe Biotechnology Research and Human Resource Devel-
opment Center, Kobe University, Japan.
Background and aims: The mechanisms by which glucose controls
glucagon release are hotly debated. In particular, it is unclear whether it
acts directly on α-cells or indirectly through a paracrine factor released
from non-α-cells within the islet. One of the reasons for the controversies
might be linked to the different experimental models used in which para-
crine and endocrine interactions might be altered (fresh or cultured tissue,
single cells or isolated islets). To be as close as possible to the physiolog-
ical situation, we used the in situ perfused mouse pancreas which pre-
serves endocrine and paracrine interactions, and we investigated the role
of somatostatin (SST) in the control of glucagon secretion by glucose and
KATP channel modulators.
Materials and methods: The effects of glucose and KATP channel mod-
ulators were tested on glucagon secretion of the in situ perfused pancreas
of Sst+/+ and Sst-/- (to address the role of SST) and of C57BL/6 and Sur1-/-
orKir6.2-/-mice (to address the role of KATP channels, the last two mouse
models lacking a major functional subunit of the KATP channels). The
effluent from the portal vein was collected every 4 min. The experiments
were performed in the presence of a 6 mmol/l mixture of amino acids or a
2 mmol/l mixture of various amino acids present at physiological
concentrations.
Results: Glucagon release of C57BL/6 or Sst+/+ mice was inhibited by a
rise of the glucose concentration of the medium from 1 to 7 mmol/l, or by
the addition of the KATP channel blocker tolbutamide (100 or 500 μM) or
the KATP channel opener diazoxide (100 μM) to a medium containing
1 mmol/l glucose. Glucagon release of Sur1-/- or Kir6.2-/- mice was also
inhibited by 7 mmol/l glucose but it was, as expected, unaffected by
tolbutamide or diazoxide. This suggests that glucose can inhibit glucagon
release independently of KATP channels. In Sst
-/-mice, glucagon secretion
was inhibited by a rise of the glucose concentration of the medium from 1
to 7 mmol/l, but it was stimulated by tolbutamide. Because it has been
suggested that tolbutamide might stimulate exocytosis by activating
Epac2, we tested the effect of another sulfonylurea, gliclazide, which is
ineffective on Epac2. Gliclazide (10 μM) mimicked the glucagonostatic
effect of tolbutamide in Sst+/+ mice and the glucagonotropic effect of
tolbutamide in Sst-/- mice.
Conclusion: Using the preparation of the in situ perfused mouse pancre-
as, we confirmed key observations previously obtained on perifused
mouse islets. Glucose can inhibit glucagon release independently of KATP
channels. SST is responsible for the glucagonostatic effect of sulfonyl-
ureas since ablation of SST transformed their glucagonostatic effect into a
glucagonotropic effect. This suggests that sulfonylureas modulate gluca-
gon secretion by two distinct mechanisms: a direct stimulatory effect of
α-cells (independent of Epac2 activation and observed in the absence of
SST influence) and an indirect inhibition via SST released from δ-cells
which counteracts the direct stimulation.
Supported by: ARC 13/18-051, FNRS and EFSD/Boehringer Ingelheim
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Paradoxical Ca2+ kinetics in islet-located glucagon-releasing alpha
cells
Q. Yu, J. Li, P. Ahooghalandari, A. Tengholm, E. Gylfe;
Department of Medical Cell Biology, Uppsala University, Sweden.
Background and aims: Insulin and glucagon are the principle hormones
that maintain blood glucose homeostasis. Previous studies have shown
that insulin and glucagon are secreted in pulses with opposite phase from
glucose-stimulated islets. Also secretion of somatostatin is pulsatile in
opposite phase to glucagon. Since Ca2+ is regarded as the main trigger
of both insulin and glucagon release, we compared glucose-induced cy-
toplasmic Ca2+ dynamics in α- and β-cells within pancreatic islets.
Materials and methods:Mouse islets were loaded with the fluorescent
Ca2+ indicator Fluo-4 and the Ca2+ concentration in the sub-plasmamem-
brane space ([Ca2+]pm) was monitored with total internal reflection fluo-
rescence microscopy. Discrimination between α- and β-cells was based
on transgenic α-cell expression of red fluorescent protein and cell-
characteristic Ca2+ responses. Glucagon and insulin secretion was mea-
sured from batch-incubated islets with immunoassays.
Results: At 3 mM glucose, RFP-positive α-cells showed non-
synchronized irregular spikes of [Ca2+]pm, whereas RFP-negative β-cells
showed low and stable [Ca2+]pm. Introduction of 20 mM glucose induced
pronounced [Ca2+]pm elevation with oscillations that were perfectly syn-
chronized among β-cells whereas there was often temporary interruption
of [Ca2+]pm signaling in the α-cells. However, the recurring [Ca
2+]pm
oscillations tended to synchronize among the islet α-cells, and cross-
correlation analysis revealed unexpected synchronization between the
[Ca2+]pm oscillations in α- and β-cells. This synchronization was neither
affected by addition of 400 nM somatostatin, nor by 100 nM insulin. The
somatostatin receptor SSTR2 antagonist PRL 2903 (5 μM) had only
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subtle effects on [Ca2+]pm signaling inα-cells despite potently stimulating
glucagon secretion at both 3 and 20 mM glucose without preventing the
inhibitory effect of glucose. Moreover, the [Ca2+]pm synchronization be-
tween α-cells and β-cells exposed to 20 mM glucose remained after 18 h
treatment of the islets with pertussis toxin, which prevents somatostatin
receptor signaling via Gαi. The insulin receptor antagonist S961 (20 nM)
lacked significant effects on [Ca2+]pm in α- and β-cells, as well as on
insulin and glucagon release at 20 mM glucose.
Conclusion: Synchronization of [Ca2+]pm oscillations between α-cells
and β-cells at 20 mM glucose surprisingly indicates that pulsatile gluca-
gon release is not generated by α-cell oscillations of [Ca2+]pm. Since
somatostatin receptor antagonism potently stimulated glucagon release
with little effects on [Ca2+]pm, pulsatile glucagon release is probably
generated by inhibitory somatostatin pulses overriding the stimulatory
effect of Ca2+.
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Calcium activated potassium channels modulate pancreatic alpha
cell electrical excitability and glucagon secretion
D.A. Jacobson1, K.R. Verlage2, G. Amarnath1, P.K. Dadi1;
1Molecular Physiology and Biophysics, Vanderbilt University, Nashville,
2School of Medicine, Texas Tech University Health Sciences Center,
Lubbock, USA.
Background and aims: Ca2+ influx into pancreatic alpha-cells through
voltage-dependent Ca2+ channels (VDCCs) is required for glucagon se-
cretion and regulatory mechanisms of this process become defective dur-
ing the pathogenesis of diabetes. Potassium channels are the primary
regulators of membrane potential, and thus, regulate the activity of
VDCCs. However, the roles of Ca2+ activated potassium channels
(KCa
2+) during alpha-cell Ca2+ entry and glucagon secretion have not
been determined. The aim of this study was to determine the influence
of alpha-cell KCa
2+ channels on electrical excitability, Ca2+ entry and
glucagon secretion.
Materials and methods: Whole cell current clamp and voltage clamp
electrophysiological recordings were used to measure KCa
2+ currents and
electrical excitability from human and mouse alpha-cells. Cells were con-
firmed as alpha-cells with either glucagon staining or via expression a red
fluorescent protein in glucagon positive islet cells. Ca2+ imaging was
performed on mouse and human pancreatic islets and single cells with
and without inhibitors of small conductance (SK) or intermediate con-
ductance (IK) KCa
2+ channels (apamin and TRAM34 respectively); glu-
cagon secretion was assayed under similar conditions. Immunofluores-
cent imaging was used to detect IK expression in mouse and human
pancreatic sections.
Results:Mouse pancreatic alpha-cells have KCa
2+ currents (13.3 +/- 1.78
pA, n=19), which were elicited byCa2+ entry following 26 voltage ramps
that resembled action potentials. The alpha-cell KCa
2+ currents were par-
tially inhibited by SK channel blockade with apamin (37.87 +/- 5.7%, n=
8) or IK channel blockade with TRAM34 (25.75 +/- 4.4%, n=11).The
membrane potential of alpha-cells was depolarized in response to SK or
IK channel inhibition (1.61 +/- 0.49 mV with apamin, n=5; 1.94 +/-
0.32 mV with TRAM34, n=6) under elevated glucose (11 mM) condi-
tions. Inhibition of SK channels also enhanced alpha-cell Ca2+ influx
under both low and high glucose conditions, increasing Ca2+ levels by
36.18% (p<.01) and 17.15% (p<.0001) respectively. Moreover, SK
channels limited glucose induced Ca2+ influx into alpha-cells within clus-
ters of islet-cells and when inhibited increased Ca2+ influx by 23.72% (p
<.05). IK channels are also expressed in pancreatic islets and we find that
mouse and human pancreatic sections show IK channel expression in
glucagon positive alpha-cells. Inhibition of IK channels caused a
41.76% (p<.001) increase of mouse alpha-cell Ca2+ influx in low glucose
and a 28.76% (p<.05) increase of Ca2+ influx in high glucose. Human
alpha-cells mirrored this behavior in response to IK channel inhibition,
showing a 31.66% (p<.05) increase in Ca2+ influx in low glucose and a
33.28% (p .05 vs. apamin treated islets); whereas IK channel blockade
with TRAM34 caused an insignificant trend toward increased glucagon
secretion.
Conclusion: In conclusion, this study suggests that SK channels play a
role limiting glucagon secretion under high glucose conditions. SK and
IK channels hyperpolarize the alpha-cell membrane potential, decreasing
excitability and Ca2+ influx during glucose stimulation, which reduces
glucagon secretion. Thus, KCa
2+ channel activity helps to modulate
glucose-dependent inhibition of alpha-cell glucagon secretion.
Supported by: DK096122; DK081666; DK20593
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Direct effects of anti-diabetic drugs on glucagon secretion in rat pan-
creatic islets
M. Yang, R. Chu, Y. Ge, A.K. Dhalla.;
Biology, Gilead Sciences, Fremont, USA.
Background and aims: Glucagon secreted by pancreatic α-cells plays
an important role in maintaining glucose homeostasis via its ability to
increase hepatic glucose production. Patients with type 2 diabetes exhibit
fasting and paradoxical postprandial hyperglucagonemia, suggesting dys-
function of the pancreatic α-cell may contribute to hyperglycemia. Thus,
suppression of inappropriate glucagon secretion is potentially an effective
treatment strategy for patients with type 2 diabetes. We have previously
shown that Na+ channel blockers directly inhibit glucagon secretion from
pancreatic islets and have glucose lowering properties, without effecting
hypoglycemia-stimulated glucagon release. Various glucose lowering
therapeutics have been shown to modulate glucagon levels and action
in both clinical and non-clinical studies, but it is unclear which of these
therapies have a direct effect on glucagon secretion at the level of the
pancreatic islet. The present study was carried-out to determine the direct
effects of different classes of glucose lowering medications on glucagon
secretion from rat pancreatic islets.
Materials and methods: Pancreatic islets were isolated from SD rats.
Glucagon secretion was measured in equal sized isolated islets incubated
with agents in Kreb-ringer buffer with 0.1% BSA, in 3 or 11 mM glucose
for 1 h. Glucagon levels were measured by an ELISA kit.
Results: In the presence of 3 mM glucose, insulin at 10 or 100 nM
significantly reduced glucagon secretion by 48±8 or 36±11% compared
to vehicle control, respectively. Exendin-4 at 100 nM also significantly
decreased glucagon secretion in the presence of 3 or 11 mM glucose, by
41±11 or 62±5% compared to control, respectively. In addition, exendin-
4 significantly increased (154±24%) insulin secretion in the presence of
11 mM glucose compared to control. Tolbutamide (10-100 μM),
sitagliptin (0.003-3 μM), canagliflozin (0.1-30 μM) and metformin (1-
100 μM) had no significant effect on glucagon secretion. Veratridine, a
Na+ channel activator, significantly increased glucagon secretion with 8-
fold induction at 30 μM, suggesting a direct role of Na+ channels in
glucagon secretion. Accordingly, glucagon secretion was significantly
and concentration-dependently reduced by Na+ channel blockers TTX
or GS-458967, with a 47±6 or 53±8% reduction at 100 nM or 3 μM,
respectively.
Conclusion: Data show that insulin at high concentrations directly in-
hibits glucagon secretion in rat islets. GLP-1R agonist exendin-4 directly
inhibits glucagon secretion from α-cells as well as through paracrine
effect on β-cells by stimulating insulin secretion. The sulfonylurea tolbu-
tamide, DPP-IV inhibitor sitagliptin, SGLT2 inhibitor canagliflozin and
metformin do not directly regulate glucagon secretion in rat islets. Na+
channel blockers directly inhibit glucagon secretion in isolated pancreatic
islets and present a potential new strategy for the treatment of diabetes.
Diabetologia (2015) 58 (Suppl 1):S1–S607 S269
553
Sodium-glucose transporter 1 and 2 are involved in the GLP-1 re-
lease from pancreatic alpha cells
V. Sancho Bornez, R. Lupi, S. Paparo, G. Penno, S. Del Prato;
Dept of Clinical and Experimental Medicine, Section of Diabetes and
Metabolic Diseases, University of Pisa, Italy.
Background and aims: It has been recently reported that human alpha
cells express sodium-glucose co-transporters (SGLT) and that the diabetic
condition is associated with reduced expression of SGLT2 and a concom-
itant increase in the expression of SGLT1 and glucagon genes. Moreover,
SGLT2 silencing or functional inhibition with dapagliflozin was associ-
ated with increased expression of the glucagon gene. We have tested
whether this system also is involved in the recently reported regulation
of GLP-1 secretion by the alpha cell. Moreover, since glucagon/GLP-1
secretion by the alpha cell has been claimed to be under the control of the
TCF7L2 signaling pathway, we have also evaluated the interaction of the
two systems in the alpha cell.
Materials and methods:We have studied a murine alpha cell line (TC1/
6) in the presence of low (LG, 5.5 mM) or high (HG, 16.7 mM) glucose
concentrations. Experiments were repeated with and without phloridzin
(50 μM), a non-selective SGLT inhibitor. SGLT1, SGLT2 and TF7L2
mRNA and protein expression were determined by RT-PCR andWestern
blot. Glucagon and total GLP-1 secretion in culture medium was mea-
sured by ELISA. Cell viability was determined by MTT method, Reac-
tive Oxigen Species (ROS) by H2DCFDA fluorescence and apoptosis by
Annexin staining and Propidium Iodine (PI) fluorescence.
Results: At LG, mRNA and protein expressions of SGLT1 and 2, and
TCF7L2 were all detectable. HG incubation was associated with an in-
crease of both mRNA and protein expression of TCF7L2 (protein: +46±
10%, p<0.001; mRNA 2.79±0.47 folds, p<0.001). Concomitantly,
SGLT1 mRNA expression increased (2.31±0.49 folds, p<0.001) while
SGLT2 decreased (0.48±0.09, p<0.001). Changes in mRNA expressions
were associated with -34±11% (p<0.01) reduction in SGLT1 protein
expression with no significant changes for SGLT2 protein. GLP-1 con-
centration in the medium increased by 25±3% (p<0.001) as compared to
LG. SGLT1/2 inhibition by phloridzin did not affect GLP-1 release at LG
(-10±6%, p=NS), while it was associated with a 30±3% reduction
(p<0.001) as compared to LG, and also with an increment in glucagon
secretion as compared toHG (HG: -16±5%vs. LG, p<0.03; HG+Phl: 1±
5% vs. LG, p<0.05 vs. HG) and PC2 expression (HG+Phl: 1.40±0.12,
p<0.02 vs. LG). The presence of phloridzin did not modify TCF7L2
expression, at both low and high glucose concentrations. The presence
of the SGLT inhibitor also modulates cellular state. When added to LG,
phloridzin produced an increment in cell viability (+13±2%, p<0.001 vs.
LG), a decrement in ROS production (-11±3%, p<0.001 vs. LG) with no
modification of apoptosis rate. On the contrary, addition of phloridzin to
cell incubated at HGwas associated with reduced cell viability (-23±5%,
p<0.001) and increased apoptosis (+19±2%, p<0.001 vs. LG).
Conclusion: These data suggest that GLP-1 and glucagon release from
alpha cells in response to high glucose could be mediated by SGLT
expression independently of TCF7L2 activation.
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Enteroendocrine secretion after meal challenge is preserved across
glucose tolerance spectrum: lack of correlationwith beta cell function
M. Gebauer1, H. Ruetten1, R.H. Raymond2, R.P. Robertson3, P.J. Sav-
age4, S.S. Shankar5, D. Stefanovski6, M.T. Vassileva7, A. Vella8, K.F.
Wright9, D.A. Fryburg9, For the Foundation for the NIHBeta Cell Project
Team;
1Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany,
2RSquared Solutions, Skillman, 3Pacific Northwest Diabetes Research
Institute, Seattle, 4NIH-NIDDK, Bethesda, 5Eli Lilly and Co, Indianapo-
lis, 6U. Pennsylvania, Philadelphia, 7Foundation for the NIH, Bethesda,
8Mayo Clinic, Rochester, 9ROI BioPharma Consulting, East Lyme, USA.
Background and aims: Although it is known that meal ingestion stim-
ulates gut enteroendocrine secretion (ES) and beta cell function (BCF),
the relationship between ES and BCF is not known across GT
populations.
Materials and methods: In studies examining BCF in subjects with
normal glucose tolerance (NGT), prediabetes (PDM), and type 2 DM
(T2DM), total and active GLP-1, GIP, PYY, and glucagon (glgn) were
measured before and after a mixed meal (MTT). We hypothesized that
these responses were associated with BCF. ES was assessed in overnight
fasted subjects before and 30, 60 and 120 min after 470 kCal MTT.
Results: Table summarizes responses pre- and 30-min post MTT. Param-
eters of insulin secretion (Φtot) and sensitivity (SI) and disposition index
(DItot) were estimated using minimal model. BCF: ES association was
conducted using Spearman’s Rank correlations. Before the MTT, ES was
generally higher for T2DM versus NGT and PDM. MTT increased total
and active GLP-1, GIP and PYY at 30 min. Changes were generally
comparable across GT populations except glgn which showed increases
across the GT Populations NGT<PDM<T2DM (ANOVA p<0.001).
Corr analysis revealed no strong relationships between ES at baseline or
30 min post-MTT, with SI, Φtot or DItot (to be shown in poster).
Conclusion: ES is not impaired after MTT in PDM and T2DM, yet there
is no apparent correlation between ES and BCF, suggesting a defect in
BCF rather than the ES in PDM and T2DM.
Clinical Trial Registration Number: NCT01454973
Supported by: FNIH
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Renal extraction and acute effects of glucagon-like peptide-1 on cen-
tral and renal haemodynamics in patients with type 2 diabetes
A. Asmar1, L. Simonsen1, M. Asmar1, S. Madsbad2, J.J. Holst3,4, E.
Frandsen5, C. Moro6, T. Jonassen4, J. Bülow1,4;
1Clinical Physiology and Nuclear Medicine, Bispebjerg University Hos-
pital, 2Department of Endocrinology, Hvidovre University Hospital,
3NNF Center for Basic Metabolic Research, University of Copenhagen,
4Department of Biomedical Sciences, University of Copenhagen, 5De-
partment of Diagnostics, Clinical Physiology and Nuclear Medicine,
Glostrup University Hospital, Copenhagen, Denmark, 6Institute of Met-
abolic and Cardiovascular Diseases, Paul Sabatier University, Toulouse,
France.
Background and aims: During acute administration of native GLP-1,
we previously demonstrated central hemodynamic effects in healthy
males, whereas renal hemodynamics, despite renal extraction of GLP-1,
were unaffected. In the present study, we elucidated hemodynamic effects
of GLP-1 in type 2 diabetic subjects (n=8) under fixed sodium intake.
Materials and methods: During a 3-hour infusion of GLP-1 (1.5 pmol
kg-1 min-1) or saline, cardiac output was continuously estimated by pulse
contour analysis, concomitantly with intra-arterial blood pressure and
heart rate. Renal plasma flow, glomerular filtration rate, and uptake/
release of hormones and ions were measured using Fick’s Principle after
catheterization of a renal vein. Urine collectionwas conducted throughout
the experiments at voluntary voiding, and subjects remained supine.
Results: During GLP-1 infusion, systolic and diastolic blood pressure
remained unchanged. Heart rate increased significantly, whereas cardiac
output remained unchanged. GLP-1 was extracted significantly in the
kidneys, however, renal plasma flow and glomerular filtration rate as well
as renal sodium and lithium excretion were not affected.
Conclusion: In conclusion, like in healthy subjects, acute administration
of GLP-1 in type 2 diabetic subjects led to a positive chronotropic effect,
but in contrast to healthy subjects, cardiac output did not increase in type
2 diabetic subjects. Renal hemodynamics and sodium excretion were not
affected by GLP-1 infusion.
Clinical Trial Registration Number: H-2-2013-099
Supported by: Danish Heart Foundation
556
Preserving expression of GLP-1 receptor in beta cells of db/db mice
increases insulin secretion
F. Kubo1, T. Miyatsuka1,2, S. Sasaki1, M. Takahara1, Y. Yamamoto1, N.
Shimo1, H. Kaneto3, T.-A. Matsuoka1, I. Shimomura1;
1Department of Metabolic Medicine, Osaka University Graduate School
of Medicine, 2Department of Medicine, Metabolism and Endocrinology,
Juntendo University Graduate School of Medicine, Tokyo, 3Department
of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School,
Okayama, Japan.
Background and aims:GLP-1 signaling has been shown to play impor-
tant roles in maintainingβ-cell functions, such as insulin secretion andβ-
cell proliferation. While expression levels of GLP-1 receptor (Glp1r) and
GIP receptor (Gipr) are compromised in the islets of diabetic rodent
models, it remains unclear at which stage of glucose intolerance the
incretin receptors are downregulated and whether preserving expression
of Glp1r and/or Gipr affects the phenotypes of diabetic model mice.
Materials and methods: To address the first question, we investigated
expression levels of Glp1r, Gipr, and other β-cell specific genes in the
islets of db/db mice at 4, 8, and 12 weeks of age. Then, we generated a
transgenic mouse model “CAG-CAT-Glp1r -IRES-eGFP” that
conditionally and specifically expressed Glp1r in β cells, and evaluated
their glucose tolerance.
Results: The expression levels of Glp1r and Gipr in db/db islets were
comparable to those in control (db/misty) mice at the age of 4 weeks, and
significantly decreased at the age of 8 and 12 weeks. When CAG-CAT-
Glp1r -IRES-eGFP mice were crossed with Pdx1-CreER mice, eGFP
expression was detected exclusively in β cells of Pdx1-CreER; CAG-
CAT-Glp1r -IRES-eGFP (βGlp1r). Oral glucose tolerance test (OGTT)
after 4-week treatment of Exendin-4 (0.1 mg/kgBW/day) revealed that
the glucose profiles were comparable between βGlp1r; db/db and control
db/dbmice, whereas serum insulin levels duringOGTTwere significantly
higher in βGlp1r; db/db than control db/db mice.
Conclusion: The expression levels of Glp1r and Gipr in db/db mice were
significantly downregulated with aging. Activation of Glp1r signaling in
β cells of db/db mice increased insulin secretion.
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Changes in postprandial glucagon-like peptide-1 secretion during the
development of diet-induced obesity in rats
T. Hira, A. Kanehira, H. Hara;
Hokkaido University, Sapporo, Japan.
Background and aims: Diet-induced obesity is a major cause of meta-
bolic syndrome such as diabetes. Incretins including glucagon-like pep-
tide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
are secreted from entoroendocrine cells in response tomeal ingestion, and
contribute to preventing postprandial hyperglycemia by enhancing insu-
lin secretion. It is unclear whether postprandial GLP-1 secretory response
is affected (increased or decreased) during the development of diet-
induced obesity. In the present study, meal tolerance test (MTT) was
conducted in rats fed normal or high-fat/high-sucrose diet, and postpran-
dial GLP-1, insulin and glycemic response were monitored.
Materials and methods:Male Sprague Dawley rats (5 weeks age) were
fed control diet (AIN-93G, n=8) or high-fat/high-sucrose diet (HF/HS,
n=8) containing 30% fat and 40% sucrose for 5 weeks. MTT was con-
ducted every week for 4 weeks. In MTT, all rats were fed the control diet
(5 or 10 g/kg) for 15 min after overnight fasting. Tail vein blood was
collected before and after the meal feeding until 120 min, and plasma
glucose, insulin and GLP-1 levels were measured. After 5 weeks feeding
period, rats were killed and intestinal tissue samples (jejunum, ileum,
cecum and colon) were collected for measurement of mRNA expressions
by real-time PCR.
Results: Body weigh was significantly higher in HF/HS rats than control
rats (423.4 g vs 380.8 g, P<0.05) at the end of experiment (5 week).
Fasting glucose levels were higher in HF/HS rats (94.7 mg/dL vs
75.0 mg/dL, P<0.05) after week 3 until the end of experiment. However,
postprandial glycemia did not differ between control and HF/HS rats
throughout the experimental period, suggesting some protective adapta-
tions occurred in HF/HS rats. Postprandial GLP-1 secretion was signifi-
cantly larger (P<0.05) in HF/HS rats than control rats at week 2 and 4,
and this was reflected by increased insulin response in HF/HS rats. In the
intestinal mucosa, among various nutrient sensing receptors and trans-
porters evaluated, one of fatty acid receptors, FFAR1 had higher mRNA
expression (150% increment against control rats, P<0.05) in the upper
small intestine of HF/HS rats compared to that of control rats.
Conclusion: The present study demonstrates that postprandial GLP-1
secretion is increased in the early period of developing diet-induced obe-
sity. These results suggest that increased postprandial GLP-1 response
contributes to normalize postprandial glycemic response by enhancing
insulin secretion. Increased expression of a fatty acid receptor may be
involved in the protective adaptation against induction of glucose
intolerance.
Supported by: JSPS25450159
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Farnesoid X receptor inhibits glucagon-like peptide-1 production by
enteroendocrine L-cells
S. Lestavel1,2, M.-S. Trabelsi1,2, M. Daoudi1, S. Ducastel1,2, V. Touche1,
2, O. Briand1,2, S.I. Sayin3, A. Perino4, C.A. Brighton5, J. Kluza6,2, G.
Baud7,2, A. Tailleux1,2, B. Staels1,2;
1INSERM U1011, Lille, 2Université Lille, France, 3Wallenberg laborato-
ry, Gothenburg, Sweden, 4Ecole Polytechnique Fédérale de Lausanne,
Switzerland, 5Cambridge Institute for Medical Research, UK, 6INSERM
U837, 7INSERM U859, Lille, France.
Background and aims: Bile acids (BA) are signalling molecules which
activate the transmembrane receptor TGR5 and the nuclear receptor FXR.
BA sequestrants (BAS) complex BA in the intestinal lumen and decrease
intestinal FXR activity. The BAS-BA complex also induces Glucagon-
Like Peptide-1 (GLP-1) production by L-cells which potentiates beta-cell
glucose-induced insulin secretion. Whether FXR is expressed in L-cells
and controls GLP-1 production is unknown.
Materials and methods: Glucose homeostasis and Proglucagon/GLP-1
production were studied in different in vitro-ex vivo models (GLUTag
cell line and human jejunal biopsies) and in different mouse strains (Wild-
type mice, mice invalidated for FXR or TGR5, conventional-raised and
germ-free mice). FXR was activated by a synthetic ligand.
Results:We show that FXR activation in L-cells decreases proglucagon
expression by interfering with the glucose-responsive factor
Carbohydrate-Responsive Element Binding Protein (ChREBP) and
GLP-1 secretion by inhibiting glycolysis. In vivo, FXR-deficiency in-
creases GLP-1 gene expression and secretion in response to glucose
hence improving glucose metabolism.Moreover, treatment of ob/ob mice
with the BAS colesevelam increases intestinal proglucagon gene expres-
sion and improves glycemia in a FXR-dependent manner.
Conclusion: These findings identify the FXR/GLP-1 pathway as a new
mechanism of BA control of glucose metabolism and a pharmacological
target for type 2 diabetes.
Clinical Trial Registration Number: NCT01129297
Supported by: French MER, FRM, ANR FXREn, EGID ANR-106LABX-
46, LMCU
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The glucose lowering effect of small molecule GPR120 agonists is
driven by glucagon-like peptide
M.S.Winzell, S. Myhre, L. Sundström, A. Ahnmark, A.-C. Nyström, M.
Sundqvist, M. Någård;
Cardiovascular and metabolic diseases, AstraZeneca R&D, Mölndal,
Sweden.
Background and aims: GPR120 is a fatty acid receptor suggested to
have anti-diabetic effects throughmultiple effects on different organs. It is
also known that GPR120 is expressed in many tissues, including
enteroendocrine cells in the gut, where it has been suggested to be in-
volved in mediating the fatty acid effect on GLP-1 secretion. Whether
GLP-1 plays a role in the glucose lowering effect observed after GPR120
activation by small molecule compounds in vivo is not completely un-
derstood. Here, we examine the the acute mechanism of action of
GPR120 agonism in lean mice.
Materials and methods: Insulin secretion was studied in lean female
mice, following oral administration with a specific GPR120 agonist prior
to an intravenous glucose tolerance test (IVGTT, 0.35 g/kg), with and
without addition of a GLP-1 receptor antagonist, exendin 9-39 (30 nmol/
kg). In a second experiment, the combination of a GPR120 agonist and a
DPP-4 inhibitor, sitagliptin (15 mg/kg), to reduce the degradation of
GLP-1, was examined. Insulin and glucose were measured after 0, 1, 5,
10, 20 and 40 min following the intravenous glucose administration. In a
separate experiment, total GLP-1 levels were measured in plasma follow-
ing oral administration with the GPR120 agonist.
Results: The GPR120 agonist significantly increased insulin secretion in
the IVGTT in leanmice, where the acute insulin response (AIR) was 0.9±
0.09 ng/ml versus 1.4±0.21 ng/ml after GPR120 agonist administration
(p=0.001). This increase in insulin secretion resulted in improved glucose
elimination (K G1-20min 2.5±0.24%/min versus 3.3±0.28%/min after
GPR120 agonist administration (p=0.004). Exendin 9-39, a GLP-1 re-
ceptor antagonist, completely blocked this effect, while the DPP-4 inhib-
itor sitagliptin, induced a significantly increased insulin response com-
pared to GPR120 agonist (AIR 2.0±0.22 ng/ml, p<0.05 compared to
GPR120 agonist alone) or sitagliptin alone. Circulating total GLP-1 levels
were measured and found to be increased after administration of the
GPR120 agonist comapred to vehicle (58±6 pM versus 69±6 pM, p=
0.02.
Conclusion: This study clearly demonstrates that administration of a
GPR120 agonist to lean mice resulted in increased insulin secretion,
and it is suggested to be the main mechanism behind the acute glucose
lowering effect of GPR120 agonists. The increased insulin secretion was
mediated through increased circulatingGLP-1 levels. The combination of
GPR120 agonists and DPP-4 inhibition may be an attractive combination
to improve glycemic control in diabetic individuals.
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CART regulates GIP and GLP-1 expression and secretion in vitro
and in vivo
L. Shcherbina, A.-H. Thoren Fischer, N. Wierup;
Lund University Diabetes Centre, Malmo, Sweden.
Background and aims: Cocaine- and amphetamine-regulated transcript
(CART) is a brain-gut peptide with several functions including regulation
of islet hormone secretion and beta-cell survival. We have recently re-
ported that CART is a constituent of human incretin-producing L- and K-
cells in the duodenum and jejunum. The aim of the present study was to
examine whether CART regulates secretion and expression of glucose-
dependent insulinotropic peptide (GIP) and glucagon-like peptide 1
(GLP-1) in vitro and in vivo.
Materials and methods: To test the effect of CART on GIP and GLP-1
secretion in vivo in mice, CART was administered i.v. during an oral
glucose-tolerance test (OGTT). Effects of siRNA-mediated CARTsilenc-
ing on incretin expression and secretion in vitro were studied in GLUTag
and STC-1 cells, used as L- and K-cell models respectively. Gene expres-
sion was assessed with qPCR, protein content and secretion with ELISA
Results: In both GLUTag and STC-1 cells silencing of CARTaugmented
incretin gene and protein expression. In GLUTag cells GLP-1 mRNA and
protein (active) levels were increased by 133.7±12.5% and 230±80%
respectively (p<0.001 and p<0.05). In STC-1 cells silencing of CART
increased mRNA levels of both GLP-1 and GIP by 147±7.1% and 125±
8% respectively (p<0.001). There were also trends towards increased
GLP-1 and GIP protein content (128±10%, P =0.06 and 117±8%, P
=0.06). Moreover, silencing of CART provoked robustly increased
GLP-1 (active) secretion in GLUTag cells stimulated with 2.8 mM glu-
cose, 16.7 mM glucose and10 μM IBMX and 16.7 mM glucose (3.79±
0.15, 3.78±0.32 and 4.45±0.32-fold respectively, p<0.001). CART si-
lencing in STC-1 provoked 1.5-fold increase in GLP-1 secretion in cells
stimulated with 16.7 mM glucose and 10 μM IBMX (p<0.05).
Intravenous administration of CART 54-102 during an OGTT in mice
provoked elevated glucose-stimulated GIP secretion at 10 and 20 min (P
<0.01 and P<0.001), greater AUC for GIP and GLP-1 at 0-60 min (P<
0.05) and higher acute GIP release (P<0.01).
Conclusion:We conclude that CART in L- and K-cells acts as an endog-
enous inhibitor of GIP and GLP-1 expression and secretion. On the other
hand, in vivo in mice CART stimulates GIP and GLP-1 secretion.
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Whether this latter effect is direct or a consequence of altered insulin and
glucagon secretion needs further investigation.
Supported by: EFSD/MSD, The Novo Nordisk foundation , The Swedish
Research Council
561
Intestinal GLUT2 invalidation leads to glucose malabsorption and
reduces enteroendocrine cell density
C. Schmitt1, T. Aranias1, V. Carrière1, A. Ribeiro1, K. Garbin1, M. Le
Gall2, E. Brot-Laroche1, A. Leturque1, A. Grosfeld1, P. Serradas1;
1Inserm UMR_S 1138, Centre de Recherche des Cordeliers; Sorbonne
universités, UPMC Univ Paris 06; Sorbonne Cités, UPD Univ Paris 05,
2InsermUMR_S 1149, DHUUnity; Sorbonne Cités, UPDUniv Paris 05,
France.
Background and aims: In western countries, diet has been considerably
enriched in readily absorbable sugars. The absorption of sugars in the
small intestine is mediated by several transporters. GLUT2, a very effi-
cient glucose and fructose facilitative transporter, is located at the apical
membrane of enterocytes, transiently during sugar-rich meals but consti-
tutively in insulin resistant states. At the basal membrane of enterocytes,
GLUT2 mediates glucose and fructose exit to the bloodstream. Our team
have shown that GLUT2 is also present in another intestinal cell type: the
enteroendocrine cells. Those cells produce Glucagon-Like Peptide-1
(GLP-1) andGlucose-dependent Insulinotropic Polypeptide (GIP), strong
activators of glucose-induced insulin secretion. This study aims to eluci-
date the role of intestinal GLUT2 in enterocytes and enteroendocrine cells
on glucose homeostasis in mice.
Materials and methods: To address this question, we generated an in-
ducible GLUT2 deficient mouse model specifically in intestinal epithelial
cells (GLUT2ΔIEC) by CreLox strategy. Body weight gain, oral glucose
tolerance tests and plasma insulin measurements were performed at dif-
ferent time points after intestinal GLUT2 invalidation. GLP-1 and GIP
positive cells were quantified in jejunum and colon by immunostaining.
Results:GLUT2ΔIECmice have a lower body weight gain compared to
control mice (7.5 g±0.2 vs. 5.2±0.3 g, P<0.01, 11 weeks post invalida-
tion). This result could be explained by a slower glucose absorption in
invalidated mice compared to their littermate controls from 4 weeks post
invalidation (12.7±2.9 vs. 4.3±1.9 mg of glucose/dL/min, P<0.05) up to
12 weeks post invalidation (18.7±1.1 vs. 13.5±1.3 mg of glucose/dL/
min, P<0.01). Nevertheless, glucose malabsorption is affecting neither
oral glucose tolerance nor plasma insulin levels. Interestingly, there is a 6-
fold decrease of GLP-1-producing cell density in jejunum of
GLUT2ΔIEC compared to control mice (9.3±2.2 vs. 1.4±0.4 GLP1+
cells/mm2, P<0.01). Intestinal GLUT2 invalidation reduces to a lesser
extent (by 2-fold) GIP-producing cell abundance in this small intestine
segment (19.2±6.3 vs. 8.9±1.2 GIP+ cells/mm2, P=0,06), suggesting a
preferential effect of GLUT2 on GLP-1-producing cells. Moreover,
enteroendocrine cell density is not affected by intestinal GLUT2 invali-
dation in the colon (16.7±5.8 vs. 8.2±1.7 GLP1+ cells/mm2, P=0.1135
and 12.2±5.3 vs. 12.8±1.8 GIP+ cells/mm2, P=0,8747), probably be-
cause GLUT2 expression is low in the large intestine.
Conclusion: Our data highlight crucial roles of intestinal GLUT2 in
glucose absorption and enteroendocrine cell density in the absorptive
segment of the intestine. The impact of reduced enteroendocrine cell
density on diabetes remains to be challenged by metabolic perturbations.
The reduction of enteroendocrine cell number could be a consequence of
the absence of GLUT2 either in enteroendocrine cells or in neighbouring
enterocytes. To discriminate which GLUT2 expressing cell is involved in
enteroendocrine cell plasticity, we are studying a new mouse model with
specific GLUT2 invalidation in enteroendocrine cells.
Supported by: INSERM, UPMC, ICAN Foundation
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Mechanisms regulating gastrointestinal somatostatin secretion
A.E. Adriaenssens1, B. Lam1, L. Billing1, K. Skeffington1, S. Sewing2,
F. Reimann1, F. Gribble1;
1Clinical Biochemistry, University of Cambridge, UK, 2Roche Innova-
tion Center, Basel, Switzerland.
Background and aims: Beginning with the control of acid secretion and
gastric emptying, entero-endocrine cells (EECs) in the gastrointestinal
tract shape post-prandial glucose excursions and nutrient delivery to pe-
ripheral tissues. Somatostatin (Sst)-producing D-cells are of particular
interest because they exert profound inhibitory control over other EECs,
particularly in the stomach where they regulate gastric acid secretion. The
objective of this study was to identify molecular pathways underlying Sst
release from D-cells.
Materials and methods: We generated transgenic mice expressing Cre
driven by the Sst promoter. Upon crossing with Cre reporter strains, mice
expressed red fluorescent protein (tdRFP), enhanced yellow fluorescent
protein (EYFP), or a genetically encoded calcium indicator, GCaMP3, in
Sst-expressing cells. RNA sequencing of gastric D-cells purified by fluo-
rescence activated cell sorting identified the D-cell transcriptome. Molec-
ular targets were verified by quantitative RT-PCR (qPCR). Primary gas-
tric cultures were used in Sst secretion assays and to monitor calcium
responses to test stimuli in D-cells by fluorescence imaging.
Results: By qPCR, sst message was enriched 690-fold (p<0.001) in the
EYFP positive population, confirming D-cell specificity of transgene
expression. RNA sequencing showedD-cells expressedmRNA encoding
peptideYY (pyy), albeit at 14-fold lower levels than sst. RNAseq and
qPCR found G-protein coupled receptors enriched in D-cells included
glucose-dependent insulinotropic peptide (GIP) receptor (gipr), musca-
rinic receptor-4 (chrm4), calcitonin gene related polypeptide (CGRP)
receptor (calcrl/ramp1), trace amine associated receptor (taar1) and calci-
um sensing receptor (casr) (fold-enrichment vs neighbouring cells of
1300, 98, 110, 42, 13, and 78, respectively; p<0.01 each). D-cells also
expressed receptors for glucagon-like peptide-1 (GLP-1: glp1r) and cho-
lecystokinin (CCK: cckar but not cckbr). In gastric cultures Sst secretion
was stimulated 1.9-fold by GLP-1, 1.5-fold by GIP and 1.8-fold by CCK
(p<0.01 each). Acetylcholine decreased secretion 2-fold (p<0.001),
whereas vasoactive intestinal polypeptide (VIP) and CGRP increased
Sst release 2.3-fold and 4.6-fold, respectively (p<0.001 each).
Oligopeptides and the TAAR1 agonist Ro5166017 stimulated Sst secre-
tion 1.9-fold and 4.5-fold (p<0.001 each) suggesting that D-cells can
sense ingested luminal factors. CCK and oligopeptides elicited increases
in intracellular calcium in imaging experiments, consistent with the cou-
pling of CCK-A receptors and CaSR to Gq signalling pathways.
Conclusion: Sst secretion from gastric D-cells is directly inhibited by the
vagus nerve via muscarinic M4 receptors, and stimulated by the enteric
neurotransmitters CGRP and VIP. Luminal factors like oligopeptides and
trace amines stimulate Sst release via CaSR and TAAR1. Feedback stim-
ulation of Sst by small intestinal hormones including CCK, GIP and
GLP-1 likely provides a mechanism to tune the termination of acid se-
cretion according to the nutrient content of a meal. Our data provide a first
transcriptomic analysis and functional characterization of gastric D-cells,
and indentify regulatory pathways that underlie the direct detection of
stimuli by this cell type which is intricately linked to rates of food intake
and absorption, and the coordination of post-prandial digestion.
Supported by: EFSD/Boehringer Ingelheim
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Impaired beta cell function and insulin secretion in non-diabetic pa-
tients with extrahepatic cholestasis
T. Mezza1, V.A. Sun1, S. Moffa1, G. Sorice1, C. Conte1, C.M.A. Cefalo1,
A. Mari2, A. Giaccari1;
1Università Cattolica del sacro cuore, Rome, 2National Research Council,
Padua, Italy.
Background and aims: Several studies have shown the inverse correla-
tion between serum bilirubin levels and the risk of diabetes, suggesting
that bilirubin acting as antioxidant and cytoprotectant could antagonize
oxidative stress-induced beta cell damage. Whereas, in both human and
animal models, cholestasis is associated with altered glucose tolerance.
However, the relationship between cholestasis and beta cell function has
not been fully evaluated in the clinical setting. To investigate whether
cholestasis, as evidenced by hyperbilirubinemia, affects β cell function
and insulin secretory response, we performed oral glucose tolerance tests
and hyperglycemic clamps (HC) followed by arginine stimulation in 44
patients (27 F/17 M, 51±15 yrs) scheduled for pancreatoduodenectomy
for periampullary diseases, all without known history of diabetes.
Materials andmethods:Based on bilirubin levels, subjects were divided
into 2 groups: with resolved cholestasis and/or normal bilirubin levels
(NChol, n=21, Bil: 0.29±0.03 mg/dl) and with active extrahepatic cho-
lestasis (Chol, n=23, Bil: 4.30±0.69 mg/dl). Amylasemia was similar
between the two groups (76.6±15.8 vs. 86.9±10.3 UI/L). To evaluate β
cell function, β cell glucose sensitivity (GS) during hyperglicemic clamp
was calculated as the ratio of insulin secretion (IS) and glucose
increments.
Results: Cholestatic subjects displayed a significantly lower
Insulinogenic index (II) (0.46±0.06 vs. 0.76±0.11, p=0.01), while no
differences were detected in the Matsuda index (5.89±0.88 vs. 4.66±
0.67, p=NS). The incremental first phase (p=0.01), second phase insulin
secretion (p=0.02) and GS (57.5±10.5 vs. 92.3±11.3 pmol·min-1·m-2·
mM-1, p=0.03) were significantly lower in Cholestatic subjects. Analysis
of the entire group revealed an inverse correlation between bilirubin
levels and Insulinogenic index (r=-0.40; p<0.05), and Arginine-
stimulated Insulin Secretion (AIS) (r=-0.51; p<0.01).
Conclusion:Our data indicate that cholestasis associates with impairedβ
cell function and possibly reduced β cell mass (as estimated by AIS). We
speculate that, in subjects with extrahepatic cholestasis, impaired β cell
glucose sensitivity could represent a major determinant of the observed
insulin secretory defect in response to both glucose and arginine stimulus.
Further investigation of this mechanism might improve our understand-
ing of the pathogenic events leading to altered insulin secretion in type 2
diabetes.
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No effect of high-dose vitamin D treatment on beta cell function,
insulin sensitivity or glucose homeostasis in subjects with abnormal
glucose tolerance: a RCT
H. Wagner1, M. Alvarsson1, B. Mannheimer2, M. Degerblad1, C.-G.
Östenson1;
1Endocrinology and Diabetes Unit, Molecular Medicine and Surgery,
2Department of Clinical Science and Education, Södersjukhuset,
Karolinska Institutet, Stockholm, Sweden.
Background and aims: There has been conflicting evidence regarding
the potential role of vitamin D in glucose homeostasis. This study was
designed to investigate the effect of high-dose vitamin D treatment on
beta cell function, insulin sensitivity and glucose tolerance in middle-
aged subjects with pre-diabetes or diet treated type 2 diabetes.
Materials andmethods: Subjects were randomised to 30 000 IU vitamin
D3 once weekly or placebo for eight weeks. Hyperglycaemic clamp
assessed first- (0-12 min) and second-phase (12-120 min) insulin re-
sponse, insulin sensitivity and disposition index. Oral glucose tolerance
test andHbA1c assessed glycaemic control. Data are presented as medians
(interquartile range) and non-parametric tests were used for the outcome
assessments.
Results: 21 (vitamin D) and 22 (placebo) subjects completed the study,
respectively. Baseline characteristics did not differ significantly between
the two groups. Season-adjusted 25-OH-vitamin D level was doubled in
the vitamin D group (+42 (32-50) nmol/l) and remained unchanged in the
placebo group (0 (-7-11) nmol/l). No effect of vitamin D treatment, com-
pared to placebo, was seen on first-phase insulin secretion, second-phase
insulin secretion, insulin sensitivity or disposition index. There was a
small reduction in median HbA1c in the vitamin D group of 1 (-3-1)
mmol/mol (P=0.06), but with no significant difference versus placebo
(P=0.84). No other measurements of glycaemia showed any changes.
Sub-group analyses of those with the lowest basal vitamin D values did
not change these results. No hypercalcemia or other adverse effects of
vitamin D treatment were seen compared to placebo.
Conclusion: This study gives no support for any substantial effect of
high-dose vitamin D treatment for eight weeks in pre-diabetes or diet
treated type 2 diabetes on beta cell function, insulin sensitivity or
glycaemic control.
Clinical Trial Registration Number: NCT01497132
Supported by: EFSD, Swe. Res. Council, Swe. Diab. Assoc., Renapharma
AB, Merck KGaA
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Early insulin secretion defect characterisesmaleswith type 2 diabetes
of Yemenite origin
M. Blaychfeld– Magnazi1,2, T. Zornitzki3, M. Ulman4, Z. Madar2, H.
Knobler1;
1Diabetes and Metabolic Disease Unit, Kaplan Medical Center, 2Hebrew
University, Faculty of Agriculture Food and Environment, 3Endocrinol-
ogy Unit, 4Endocrinology Laboratory, Kaplan Medical Center, Rehovot,
Israel.
Background and aims:Yemenites who immigrated to Israel demonstrat-
ed within 6 decades a dramatic 20-fold increase in the prevalence of
diabetes but the underlying mechanisms remain obscure. The aim of the
current study was to compare parameters of β-cell function and insulin
sensitivity in patients with new-onset Type 2 diabetes of Yemenite (Y-
DM) and non-Yemenite origin (NY-DM) treated by diet with or without
oral antihyperglycemic monotherapy.
Materials and methods: A 180-minutes meal tolerance test (MTT) was
performed in 121 GAD negative patients: 59 Y-DM (57% males) and 62
NY-DM (48% males). Based on the MMT we calculated indexes of
insulin resistance (Matsuda index, HOMA2IR) indexes of insulin secre-
tion including the insulinogenic index [Δ insulin (30-0 min)/ Δ glucose
(30-0)], and the disposition index that indicates the hyperbolic relation-
ship between insulin sensitivity and insulin response.
Results:Age, sex, DMduration, BMI, HbA1c and lipid profile were with
no significant differences. A significant difference was found in family
history: 63% of Y-DM had maternal inheritance compared with 35% in
NY-DM (p<0.001), but no difference was found in paternal inheritance.
Y-DM had increased hyperglycemia manifested by a significantly higher
area under the curve (AUC) of glucose during MTT compared with NY-
DM (p=0.005) but there was no difference in insulin and C-peptide AUC.
There were no difference in insulin sensitivity but both the insulinogenic
index and the disposition index were significantly lower in Y-DM com-
pared with NY-DM (0.68±0.5 vs. 0.95±0.8, p=0.04; 2.25 vs. 3.3, p=
0.03, respectively). When females and males were analyzed separately
the difference in maternal inheritance remained significant in both (p<
S274 Diabetologia (2015) 58 (Suppl 1):S1–S607
0.005). The difference in β-cell function however remained significant
only in males, with Y-DM having a lower insulinogenic index (0.56±0.4
vs.1.02±1.12 p=0.02) and a shift to the left and downward of the curve
describing the hyperbolic relationship between insulin sensitivity and
insulin secretion (Figure).
Conclusion:Y-DMhave a significantly higher maternal inheritance com-
pared with NY-DM. Males of Yemenite origin have a significant reduc-
tion of β-cell function and reduced ability to compensate for insulin
resistance compared with NY-DM. These data suggest different underly-
ing mechanisms leading to early loss of β-cell function in Y-DM ob-
served in males.
Supported by: Novo Nordisk, IMRIC & KMC
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Exploring the role of secreted frizzled related protein 4 as a novel
biomarker of beta cell dysfunction, insulin resistance and type 2
diabetes
K. Gokulakrishnan1, V. Sudha2, A. Kaviya1, I. Lasrado2, G.K. Pandey1,
A. Amutha1, H. Ranjani1, R.M. Anjana3, V. Mohan3;
1Research Biochemistry, Madras Diabetes Research Foundation, Chen-
nai, 2KasturbaMedical College, Manipal, 3Diabetology,Madras Diabetes
Research Foundation, Chennai, India.
Background and aims: There is emerging data to indicate that secreted
frizzled-related protein 4 (SFRP4) is highly expressed in islets. SFRP4 is
associated with increased risk of type 2 diabetes mellitus [T2DM] but the
physiological role of SFRP4 remains poorly understood.We report on the
systemic levels of SFRP4 and its association with insulin resistance, beta
cell dysfunction, prediabetes and type 2 diabetes in Asian Indians.
Materials and methods: Individuals with normal glucose tolerance
[NGT; n=90], impaired glucose tolerance [IGT; n=50] and T2DM [n=
90] were recruited from a large tertiary diabetes center and a medical
college hospital in southern India. Insulin resistance was calculated using
the homeostasis assessment model (HOMA-IR) and beta cell function by
oral disposition index (DIo). SFRP4 levels were measured by the
enzyme-linked immunosorbent assay.
Results: Circulatory age adjusted SFRP4 levels were highest in T2DM
(246±99 ng/ml) followed by IGT (167±62 ng/ml) and NGT (101±
45 ng/ml; p<0.001). Patients with older age onset T2DM had higher
levels of SFRP4 compared to youth onset T2DM (286 vs 165 ng/ml, p
<0.001]. However, no differences in SFRP4 levels were seen between
males and females (158±60 vs. 169±64 ng/mL, respectively; p>0.05).
SFRP4was positively correlatedwith HOMA-IR (p<0.01), C- Peptide (p
<0.01) and inversely with DIo (p<0.01). In linear regression analysis,
SFRP4 was significantly associated with insulin resistance (β=1.592; p<
0.001) and DIo (β=- 0.353; p<0.05) after adjusting for age, gender and
waist circumference. In standardized polytomous regression models,
higher levels of SFRP4 were independently associated with T2DM [odds
ratio (OR) per standard deviation: 2.867, 95% CI 1.189 - 4.343; p<
0.001]. Adjustment for age, gender, waist circumference and insulin re-
sistance, did not substantially change the association between SFRP4 and
T2DM [OR per standard deviation: 2.185, 95% CI: 1.309 - 3.649, p=
0.003].
Conclusion: In Asian Indians, the circulatory levels of SFRP4 showed a
significant association with glucose intolerance, insulin resistance, beta
cell dysfunction and T2DM and could serve as a biomarker for early beta
cell dysfunction and glucose intolerance.
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The impact of family history of young-onset type 2 diabetes on met-
abolic profile and beta cell function in euglycaemic young-to-middle
age Chinese individuals in Hong Kong
Y. Zhang;
Medicien& Therapeutics, The Chinese University of HongKong, Shatin,
China.
Background and aims: The prevalence of young-onset type 2 diabetes
(YOD) is increasing globally. Family history of type 2 diabetes is asso-
ciated with defect in insulin sensitivity and/or beta-cell function. We
investigated the impact of family history of YOD (defined as age at
diagnosis <40 years) on the metabolic traits, insulin sensitivity and
beta-cell function in young-to-middle aged Chinese individuals with
euglycemia in Hong Kong.
Materials and methods: 415 participants with normal glucose tolerance
(fasting plasma glucose [PG]<5.6 mmol/L and 2-hour PG <7.8 mmol/L
during the 75-gram OGTT test) were studied. Among them, 220 individ-
uals did not have family history of diabetes (FH-), 122 individuals had
family history of late-onset type 2 diabetes (age at diagnosis ≥40 years,
FH+LOD) and 73 had family history of YOD (FH+YOD). Insulin sen-
sitivity was measured by Matsuda insulin sensitivity index (ISI) and
early-phase insulin response was measured by insulinogenic index
(IGI). Disposition index (DI) was used to measure beta-cell function.
Metabolic data were compared between groups with adjustment for
age, sex, body mass index and waist-to-hip ratio.
Results: The mean age was 35.5±7.2 [SD] years in FH+YOD group,
lower than those with FH+LOD (43.0±7.2 years) and without family
history of diabetes (42.2±7.6 years, p trend <0.001). Individuals with
FH+YOD and FH+LOD had higher BMI, waist circumference (in
men), LDL-cholesterol, and lower HDL-cholesterol compared to those
without family history (all p trend <0.05, table). The FH+YOD group had
highest 1-hour PG (p trend=0.001, table), while fasting and 2-hour PG
during OGTTwere similar between the 3 groups. Subjects with positive
family history had lower DI than the FH- group (p trend=0.005), al-
though DI did not differ between FH+LOD and FH+YOD groups. ISI
was similar between all 3 groups. There was a tendency for IGI to be
lower in the FH+YOD group with borderline significance between FH+
YOD and FH- groups (post-hoc p=0.078, table).
Conclusion: Normal glucose-tolerant first-degree relatives of patients
with type 2 diabetes, especially those with family history of YOD, exhibit
reduced beta-cell function and increased obesity. The disease burden of
YOD calls for early detection and intervention program in subjects with
family history of diabetes, especially YOD.
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Active GLP-1 but not insulin, glicentin or glucagon predicts the 2-
hour OGTT glucose value in obese children
H. Ohlsson1,2, J. Staaf1,2, L. Manukyan1, J. Cen1,2, A. Forslund2, P.
Bergsten1;
1Department of Medical Cell Biology, 2Department of Women's and
Children's Health, Uppsala University, Sweden.
Background and aims: Proglucagon is post-translationally processed to
glucagon, glucagon-like peptide 1 (GLP-1) and glicentin, among other
peptides. Despite the fact that glucagon and GLP-1 are well-known reg-
ulators of glucose metabolism, little is known of them in the context of
childhood obesity and early stages of impaired glucose metabolism.
Glicentin is less studied than other proglucagon peptides but functions
described to date are inhibition of gastric acid secretion and gastrointes-
tinal motility. The aim of this study was to investigate the levels of GLP-1,
glicentin and glucagon in childhood obesity and their importance for the
development of impaired glucose tolerance in this patient group.
Materials and methods: Obese (n=50) and lean (n=19) children, 10-
18 years of age, were recruited from the Uppsala Longitudinal Study of
ChildhoodObesity cohort between June 2012 andOctober 2014. After an
overnight fast, subjects underwent a standard OGTT. Classification of
normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/
or impaired fasting glucose (IFG) and type 2 diabetes (T2DM) was done
according to WHO criteria. Fasting plasma active GLP-1 was quantified
by electrochemi-luminescent immunoassay (Meso Scale Discovery, MD,
USA). Fasting plasma insulin, glicentin and glucagon levels were quan-
tified by ELISA (Mercodia AB, Uppsala, Sweden). Differences among
groups were analysed by one-way ANOVAwith Bonferroni post hoc test.
Results: Of the obese children, 25 had NGT, 21 had IGT (including 9
children with IFG) and 4 met the criteria for T2DM. All lean children had
NGT. As the number of subjects with T2DM was limited, these were
excluded from the data analysis. Lean controls had lower fasting GLP-1
levels than obese children with NGT (0.37±0.05 vs 0.58±0.07 pmol/l)
and lower fasting glucagon levels than obese children with IGT (8.1±0.5
vs 14.1±1.4 pmol/l). Fasting GLP-1 levels were lower in obese children
with IGT than in those with NGT (0.34±0.03 vs 0.58±0.07 pmol/l) and
the same was true for glicentin levels (16.1±1.6 vs 26.5±2.4 pmol/l).
Fasting glucagon levels were higher in obese children with IGT than in
those with NGT (14.1±1.4 vs 10.8±0.7 pmol/l). In addition, multiple
regression analysis was performed with 2-hour glucose as the dependent
parameter and age, sex, age-adjusted BMI, fasting insulin, GLP-1,
glicentin and glucagon as independent parameters. Only fasting GLP-1
levels were significantly correlated to the two-hour blood glucose values
(parameter estimate -1.91; SE 0.9; p<0.05).
Conclusion: Obese children with IGT are characterized by increased
fasting glucagon and decreased fasting glicentin and GLP-1 levels. In
obese children, fasting plasma active GLP-1 is correlated to the 2-hour
OGTT glucose value independent of age, sex, BMI, and fasting levels of
insulin, glicentin and glucagon.
Supported by: EU-FP7 (Beta-JUDO), SMRC, RFR Uppsala-Örebro,
Selander's Foundation, UU
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Combined N-terminal and C-terminal truncations of Glucose depen-
dent Insulinotropic Polypeptide (GIP) are potent and efficient GIP
receptor antagonists
L.S. Hansen1, A.H. Sparre-Ulrich2, B. Svendsen3, M. Christensen1, B.
Hartmann3, F.K. Knop1, J.J. Holst3, M.M. Rosenkilde2;
1Center for Diabetes Research, Gentofte Hospital, Hellerup, 2Department
of Neuroscience and Pharmacology, University of Copenhagen, 3Depart-
ment of Biomedical Sciences, University of Copenhagen/Novo Nordisk
Foundation, Denmark.
Background and aims: The intestinal hormone glucose‐dependent
insulinotropic polypeptide (GIP) exhibits several functions within lipid,
bone, and glucose homeostasis. The GIP receptor (GIP R) is a family B 7‐
transmembrane receptor with the most established signaling pathway
being GαS. It is expressed in the pancreas, brain, bone, cardiovascular
system, and gastrointestinal tract. High affinity ligands are needed to
explore the role of GIP in adiposity, osteogenesis, and glucose homeosta-
sis in vivo. hGIP(1-30) is naturally occurring in humans. Here we report a
pharmacological characterization of eigth N-truncated GIP analogs of
hGIP(1-30): hGIP(2- to 9-30).
Materials and methods: COS‐7 cells were transiently transfected with
the human GIP R for all assays. We used radiolabeled 125I‐hGIP(1-42),
125I‐hGIP(1-30), 125I‐hGIP(2-30) and 125I‐hGIP(3-30) for competitive
binding analyses and an enzyme fragment-based cyclic AMP‐
accummulation assay. Pancreas perfusions in rats were performed with
a single-pass system (10 mmol/l glucose) through arteries and collected
effluent from the portal vein.
Results: hGIP(1-30) displaced 125I-GIP(1-42) with similar affinity as
native GIP(1-42) (Ki of 0.75 nmol/l). The eight truncated analogs
displaced 125I‐GIP(1-42) with lower affinities (Ki from 2.3 to
347 nmol/l) following the truncation lengths with the highest affinities
identified for GIP(3-30) and GIP(5-30) (Ki of 2.6 and 6.1 nmol/l, respec-
tively). GIP(1-30) acted as a full agonist (EC50 9.8 pmol/l), whereas
GIP(2-30), as the only one of the truncations, displayed potent partial
agonistic properties (20% efficacy of hGIP(1-30) and an EC50 of
1.8 nmol/l). GIP(2- to 9-30) displayed length-dependent antagonistic
properties (IC50 from 12 to 450 nmol/l) and resulted in right‐shifts of
the hGIP(1-42) dose-response curve in a dose-dependent manner. Schild
plot analysis concluded that GIP(3-30) and GIP(5-30) were competitive
antagonists with equal pA2 values of 15 nmol/l and Hill-slopes of 0.93±
0.02 and 1.1±0.04 respectively. Homologous binding studies revealed
different binding confirmations that corresponded to the functional prop-
erties of the agonist GIP(1-30), the partial agonist GIP(2-30) and com-
petitive antagonist GIP(3-30). In pancreas perfusion studies 100 nmol/l
GIP(3-30) significantly reduced somatostatin secretion induced by
1 nmol/l GIP(1-42), and stimulated de novo and potentiated 1 nmol/l
GIP(1-42)-induced insulin secretion. GIP(3-30) did not affect GIP(1-42)
induced glucagon secretion nor stimulated de novo secretion.
Conclusion: Human GIP(3-30) and GIP(5-30) were highly potent com-
petitive antagonists of the humanGIP R. GIP(3-30), a presumed naturally
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occurring degradation product, showed diverse effects on somatostatin
and insulin release in vivo (rat). These antagonists could serve as tool
compounds for further elucidation of the human GIP physiology and
thereby in turn for future pharmacological interventions.
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Translation of predictive in vitro GIP receptor assays to in vivo acute
efficacy
D.C. Hornigold1, J. Naylor1, A.T. Suckow2, A.T. Suckow2, N.
Bhagroo2, H. Salari2, D.J. Baker1;
1CVMD, MedImmune, Cambridge, UK, 2CVMD, MedImmune, Gai-
thersburg, USA.
Background and aims: Glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide 1 (GLP-1), both Gs-coupled GPCRs, are
incretin hormones whose primary role is to potentiate glucose-stimulated
insulin secretion from pancreatic beta-cells. Dual agonism of the GIP and
GLP-1 receptors has recently been speculated as being advantageous in
treating type 2 diabetes. Drug discovery projects tasked with identifying
agonists at these incretin receptors require high throughput in vitro func-
tional assays to drive structure activity relationship hypothesis testing. It
is imperative that these assays translate to biological effect assays in
disease relevant cell lines and are predictive of the effects seen in preclin-
ical in vivo models. In this study we show that potency and efficacy
translates from transfected receptor cell line second messenger assays to
endogenous receptor second messenger and insulin secretion assays, and
also to acute efficacy in vivo in glucose tolerance tests.
Materials and methods: A panel of GIP peptides palmitoylated at dif-
ferent positions along the length of the peptide were tested in vitro for
potency and intrinsic activity in transfected CHO-humanGIPR, clonal rat
beta cell (INS-1E) and mouse adipocyte (3T3L1) cell line cAMP accu-
mulation assays. Cells were incubated with peptides for 30 min prior to
lysis and detection of cAMP levels. A subset of potent peptides was then
tested for glucose-stimulated insulin secretion in glucose-responsive INS
832/3 cells. Cells were cultured in the presence of low glucose (2.8 mM)
for 1 hr at 37°C prior to incubation of peptides in the presence of high
glucose (8.3 mM) for 1 h. Insulin secretion was quantified using Meso-
scale Discovery ECL detection. Key peptides were then further profiled
in vivo using glucose tolerance tests in C57Bl/6J mice. Fasted C57BL/6J
male mice were dosed SC with either Na2+phosphate buffer or
palmitoylated GIP ligands 2 h prior to intraperitoneal 2 g/kg glucose
(ipGTT) challenge. Blood glucose was measured from tail vein samples
at -120, 0, 15, 30, 45, 60 and 90 mins.
Results: The palmitoylated GIP molecules were all full agonists in CHO-
human GIPR transfected receptor cAMP assays with potencies spread
over a 1000-fold range. The peptide EC50 from the transfected human
GIPR correlated well with EC50 determinations from both rat INS-1E and
mouse 3T3L1 cAMP assays. Six peptides with potencies spanning 40 pM
to 60 nM in the INS1E cAMP assaywere shown to have robust activity in
glucose stimulated insulin secretion (GSIS) assay in INS 832/3. There
was also positive correlation for peptide potency in the INS 832/3 be-
tween cAMP and GSIS assays (slope =0.92, r2=0.94). Key molecules
with a broad range of potencies in the INS GSIS assay were profiled in a
lean mouse ipGTT study. There was consistent correlation between INS
GSIS pEC50 and AUC for ipGTTand peptide rank order was maintained
with a good correlation (r2=0.91).
Conclusion: Here we show correlation of potency from transfected re-
ceptor in vitro assays to endogenous receptor assays at the level of cAMP
accumulation. These potencies directly correlate with biological effect
readouts of insulin secretion in rat beta cells. Furthermore we showed
translation of these in vitro potencies and rank order to in vivo efficacy
through glucose disposal in ipGTT studies. Based on these results we
have the tools to successfully interrogate GIPR potency in a drug discov-
ery screening cascade.
PS 040 New experimental models of
insulin secretion
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Enhancement of beta cell function by combination treatment with
stromal derived factor 1 alpha (SDF-1) and the DPP-4 inhibitor
vildagliptin in streptozotocin diabetic mice
B. Omar, B. Ahrén;
Clinical Sciences, Lund University, Lund, Sweden.
Background and aims: In both type 1 and type 2 diabetes, there is a
decline in the mass and function of beta cells resulting in insulin insuffi-
ciency and hyperglycemia. In type 1 diabetes this is relatively rapid
whereas in type 2 diabetes this occurs over a longer period of time.
Recently it has been reported that the pancreatic islet alpha cells of type
2 diabetic humans and mouse models produce elevated amounts of the
incretin hormone glucose dependent insulinotropic polypeptide 1 (GLP-
1). In genetic mouse models of type 2 diabetes, alpha cell GLP-1 produc-
tion appears to increase as diabetes develops. Additionally, it has been
demonstrated that alpha cell production of GLP-1 is enhanced by the
chemokine stromal derived factor 1 (SDF-1).We hypothesized that chem-
ically induced beta cell loss would lead to a compensatory increase in
alpha cell GLP-1 which could be enhanced by intervention with SDF-1
leading to preserved beta cell function. We therefore treated
streptozotocin diabetic mice with a combination of recombinant stromal
derived factor 1 and the DPP-4 inhibitor Vildagliptin to determine wheth-
er it could preserve and enhance beta cell function at an early stage of
diabetes development.
Materials and methods: Four month old female C57BL6JBomTac mice
were given interperitoneal injections of streptozotocin (50 mg/kg) or ve-
hicle daily for 5 days. Three days after the final injection mice were
subjected to a baseline oral glucose tolerance test (OGTT) and immedi-
ately placed on a regimen of daily injections with recombinant mouse
SDF-1 alpha (1 μg/mouse) or vehicle for 5 days. Mice were concurrently
treated with either a background of Vildagliptin (3 umol/mouse per day)
or water. Mice remained on a background of Vildagliptin or water for an
additional 3 weeks and OGTTs were performed mid-study and at termi-
nation (4 weeks). Bodyweight was monitored weekly. Plasma glucose
and insulin were measured at multiple time points during the OGTTs
and beta cell function was calculated using the insulinogenic index. Beta
cell mass was determined from histological sections of whole pancreas
stained with insulin specific antibodies.
Results: After an initial decline the first week of the intervention,
bodyweight was maintained throughout the final 3 weeks of the study.
Diabetic mice that did not receive treatment saw a decline in beta cell
function (insulinogenic index) by the end of the four week study period.
Diabetic mice that were treated exclusively with a background of
Vildagliptin saw a 2 fold improvement in insulinogenic index after four
weeks compared to baseline (57±14 vs. 29±6 pmol/mmol, p=0.043).
Diabetic mice that were treated with SDF-1 injections in week 1 com-
bined with backgroundVildagliptin saw a 4-fold improvement in beta cell
function after four weeks compared to baseline (53±6 vs. 14±4
pmol/mmol, p=0.0003). In addition, the SDF-1-vildagliptin treated group
displayed significantly greater glucose elimination rates than untreated
diabetic controls (1.02±0.07 vs. 0.79±0.07%/min, p=0.028). Immuno-
histochemical analysis of pancreata after the study revealed that all dia-
betic groups have significant reductions in beta cell mass with no signif-
icant differences in beta cell mass between treated and untreated diabetic
mice.
Conclusion: The combination of SDF-1 alpha and vildagliptin represents
a novel treatment concept which improves beta cell function and glucose
elimination in an insulin deficient mouse model of diabetes.
Supported by: VR, LU, ALF
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Calcium independent functional compensation of beta cells predom-
inates islet mass adaptation in diet induced insulin resistance
S. Speier, H. Chmelova, J.A. Chouinard, C.M. Cohrs, S. Jahn, C. Chen;
Paul Langerhans Institute Dresden of Helmholtz Centre Munich at the
University Clinic Carl Gustav Carus of the Technische Universität Dres-
den, Germany.
Background and aims: Pancreatic islets have been suggested to com-
pensate in both mass and function to meet the increased insulin demand
during obesity and insulin resistance (IR). However, the dynamics and
relative contribution of these two forms of compensation are not well
understood. In addition, the mechanisms underlying compensation
in vivo remain to be elucidated. Here, we longitudinally in vivo assessed
the adaptation of islet cell mass and function in correlation to glucose
homeostasis during diet-induced obesity and IR in mice.
Materials and methods: Mice were transplanted with MIP-GFP or
Pdx1CreER-GCaMP islets into the anterior chamber of the mouse eye.
After engraftment period, the recipient mice were fed with HFD (60%)
for 17 weeks before switching back to normal chow. Several parameters
of glucose homeostasis were assessed and in parallel transplanted islets
repetitively monitored noninvasively in vivo. Islet morphology and dy-
namics of cytosolic calcium were visualized by GFP and GCaMP
expression.
Results: HFD feeding induced obesity, IR and impaired glucose toler-
ance. Total islet mass (1.92±0.50 fold increase, p<0.001; 16wk) and beta
cell volume (1.91±0.39 fold increase, p<0.001; 16wk) continuously in-
creased over the entire experimental time course. Intra-islet vessels
adapted by dilation in response to HFD feeding. Glucose stimulated in-
sulin secretion during an intraperitoneal glucose tolerance test (IPGTT)
increased until 10 weeks HFD and reached a plateau thereafter. The
functional efficacy of islets in relation to islet mass was initially increased
(3.17±1.78 fold increase, p<0.05; 8wk) but slowly declined, indicating
an initial functional compensation, followed by decompensation. To eval-
uate the mechanisms of functional beta cell compensation we measured
beta cell calcium dynamics ([Ca2+]i) in vivo., Basal [Ca2+]i increased
shortly after HFD onset in association with elevated fasting plasma insu-
lin. In contrast glucose-stimulated [Ca2+]i decreased throughout the time
course of HFD feeding (388±256 vs 853±230, p<0.01, 16wk), while
insulin release remained increased. This indicates an early calcium inde-
pendent compensatory mechanism, followed by a calcium dependent
dysfunction of beta cells in response to long-term HFD. Interestingly,
even after 17 weeks HFD feeding the detected changes were rapidly
reversible after by 2 weeks normal diet feeding.
Conclusion: Our results demonstrate that the beta cell functional re-
sponse outweighs mass adaptation in the compensation for insulin resis-
tance. In addition, our data indicate that the observed functional compen-
sation and dysfunction of beta cells are based on diverse mechanisms.
Supported by: BMBF and KKNDM
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Regulation of GPR40 gene expression in pancreatic islets of non-
obese and obese glucose-intolerant rat models, Goto-Kakizaki rat
and Koletsky rat
Y. Kira1, T. Tomita1, S. Odori1, J. Fujikura1, K. Hosoda1, K. Nakao2, N.
Inagaki1;
1Department of Diabetes, Endocrinology and Nutrition, 2Medical Inno-
vation Center, Kyoto University Graduate School of Medicine, Japan.
Background and aims:G protein-coupled receptor 40 (GPR40; FFAR1)
is a Gq-coupled receptor for middle- to long-chain fatty acids. GPR40 is
highly expressed in pancreatic beta cells in rodents and we have reported
that GPR40 is probably highly expressed in pancreatic beta cells also in
humans. GPR40 is reportedly involved in the regulation insulin secretion
and is a potential therapeutic target in diabetes mellitus. However, little is
known about the regulation of its gene expression. This study was de-
signed to elucidate the regulation of GPR40 gene expression in glucose
intolerance and to explore the pathophysiological implication of GPR40.
Materials and methods: As a non-obese glucose-intolerant model, we
used Goto-Kakizaki (GK) rat, a Wistar substrain that develops Type 2
diabetes. As an obese glucose-intolerant model, we used Koletsky rat, a
genetically obese model whose nonsense mutation in the Ob-R gene was
reported by us. Six-week-old GK rat and 14-week-old Koletsky rat with
established glucose intolerance were subjected to intraperitoneal glucose-
tolerance tests (IPGTT, 2 g/kg), and compared with age-matched control
rats (6-week-oldWistar rat and 14-week-old lean littermate, respectively).
Blood glucose levels were determined by the glucose oxidase method.
Plasma insulin levels were measured by EIA. Pancreatic islets were iso-
lated from these rats and GPR40 mRNA expression was measured by
quantitative PCR.
Results: In 6-week-old GK rats, blood glucose levels were markedly
elevated at all time points during IPGTT. Serum insulin levels at 15 and
30min after glucose load were significantly lower in GK rats compared to
those in Wistar rats, though there was no significant difference at fasting,
and at 60 and 120 min after glucose load. GPR40 mRNA levels in pan-
creatic islets of GK rats were markedly decreased compared to those of
Wistar rats (43% vs Wistar rats, p<0.05). In 14-week-old Koletsky rats,
blood glucose levels were significantly elevated after glucose load com-
pared to lean littermates, while there was no significant difference at
fasting between two groups. Serum insulin levels in Koletsky rats were
approximately ~7 times higher than those in lean littermates at all time
points during IPGTT, however, at 15 minutes after glucose load it was
rather decreased vs before glucose load in Koletsky rats. GPR40 mRNA
levels in pancreatic islets of Koletsky rats were markedly decreased com-
pared to those of lean littermates (39% vs lean littermates, p<0.05).
Conclusion: We demonstrate that GPR40 mRNA levels in pancreatic
islets are markedly decreased in both non-obese and obese model rats,
suggesting decreased GPR40 gene expression in pancreatic beta cells in
glucose intolerance. In both models, increment of insulin secretion after
glucose load was attenuated, suggesting impaired early insulin response.
GPR40 is implicated in the augmentation of glucose stimulated insulin
secretion (GSIS), so the possible link between decreased GPR40 gene
expression in pancreatic beta cells and impaired early insulin response
in vivo seems plausible. Further investigations are now in progress.
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Limited impact on glucose homeostasis of highly beta or alpha cell-
selective disruption of leptin signalling
H. Soedling1, D. Hodson1, A. Adriaenssens2, F. Reimann2, F. Gribble2,
S. Trapp3, G. Rutter1;
1Medicine, Imperial College London, 2Clinical Biochemistry, Cambridge
University, 3Neuroscience, University College London, UK.
Background and aims:The adipose tissue-derived hormone leptin plays
an important role in maintenance of body weight and glucose homeosta-
sis. Leptin mediates its effects by interaction with leptin receptors (LepR),
which are highly expressed in the hypothalamus and reportedly at low
levels in pancreas. Previous studies have used relatively promiscuous Cre
deleter strains to explore the role of LepR in pancreatic beta and alpha
cells, with conflicting results. Here, we investigate the role of LepR in
these cells using more selective Cre deleter strains.
Materials and methods: Mice lacking leptin signalling specifically in
beta and alpha cells respectively were generated by Ins1-Cre or
iGlu[proglucagon promoter]-Cre-mediated recombination of LoxP sites
within exon 17 of the leptin receptor gene. Highly purified beta and alpha
cells were prepared by fluorescence-activated cell sorting (FACS) of islets
from mice expressing YFP selectively in the latter. LepR expression was
quantified by massive parallel sequencing (RNASeq) of purified islet
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cells. In vivo glucose homeostasis, pancreatic histology and hormone
secretion were monitored by standard techniques. Intracellular Ca2+ dy-
namics were assessed by confocal microscopy of the entrapped fluores-
cent probe, Fluo-2, in intact islets.
Results: Expression of LepR mRNA was undetectable or vanishingly
low (0.2 reads per kilobase per million mapped reads, RPKM) in purified
mouse pancreatic alpha and beta cells, respectively. Whereas male mice
lacking the leptin receptor in beta cells mice exhibited no evident abnor-
malities in glucose tolerance up to 16 weeks of age, females displayed
slightly improved glucose tolerance at 8 weeks (AUC=865.1±31.21 for
WT, 937.7±32.38, Ins1Cre::LepRF/F; n=9-13 per genotype; mice, P=
0.0292), but not at 12 weeks. No differences were seen between geno-
types in body weight, fasting glucose or beta/alpha cell ratio. No differ-
ences were observed in glucose- (16.7. vs 3 mM) induced Ca2+ changes
betweenWTand Ins1Cre::LepRF/F (AUC=1191±105.4 forWT, AUC=
1024±148.3, Ins1Cre::LepRF/F, NS) mouse islets. Deletion of LepR
from alpha-cells, a minority of beta cells, and a subset of proglucagon-
expressing cells in the brain, exerted no effects on body weight, glucose
or insulin tolerance, nor on pancreatic hormone secretion assessed in vivo
and in vitro.
Conclusion: In contrast to earlier reports, the use here of a highly cell
type-selective Cre recombinase indicates that leptin signalling plays a
relatively minor, age- and sex-dependent role in the control of beta cell
function in the mouse, consistent with low levels of LepR on these cells.
No in vivo role for leptin receptors on alpha cells, nor in other
proglucagon-expressing cells, was detected in this study. These studies
suggest that the roles of leptin signalling in the endocrine pancreas may
need to be re-evaluated.
Supported by: MRC, IMIDIA
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Role of TGF-beta superfamily receptor ALK7 in the regulation of
glucose-induced insulin secretion
K. Mezghenna, C.F. Ibáñez;
Neuroscience, Karolinska Institut, Stockholm, Sweden.
Background and aims: Activin ligands of the TGF-β superfamily are
important regulators of adult pancreatic endocrine function. We have
previously shown that mice lacking globally activin B or its receptor
ALK7 (activin receptor-like kinase 7) display fasting hyperinsulinemia
in early stages and increased glucose-stimulated insulin secretion (GSIS).
The aim of our study is to determine whether ALK7 functions cell-
autonomously in islets to negatively regulate insulin secretion.
Materials and methods: To address this issue, we generated the mouse
line Alk7fx/fx::Ptf1aCre/+ that displays a conditional invalidation of
Akl7 gene in pancreatic progenitors. The Cre recombinase activity was
checked by immunohistochemistry using the Cre reporter strain, RO-
SA26-stop-YFP. ALK7 expression was analysed by q-PCR. Metabolic
parameters were assassed in 8-10 week-old mice. Fasting intraperitoneal
glucose tolerance test (IPGTT, 2 g/kg) and in vivo GSIS were assassed in
mutant mice and their control littermates fed a standard chow diet or a
60% calorie high-fat diet for 2 weeks. Ex vivo GSIS was also assassed in
isolated islets from conditional knock-out mice and their controls fed a
standard chow diet.
Results: Using the Cre reporter strain ROSA26-stop-YFP, we first con-
firmed the Cre mediated-recombination occurred in different islet cell
types such as alpha and beta cells in Alk7fx/fx::Ptf1aCre/+ mice. In
addition, ALK7 deletion in islets has been confirmed by q-PCR with a
70% decrease (P<0.001) in ALK7 mRNA levels. In Alk7fx/
fx::Ptf1aCre/+ mice, we showed a 60% significant increase (P<0.01) in
fasting insulinemia compared to controls (Alk7fx/fx). Islets derived from
Alk7 mutants fed a standard chow diet significatively (P<0.05) increase
in vitro GSIS by 36%. in vivo GSIS and IPGTT performed in mice fed a
chow diet showed that Alk7mutant mice tended to secrete more insulin in
response to glucose (N.S) and displayed a slightly impaired glucose tol-
erance. However, when mice were fed a high-fat diet for 2 weeks, in vivo
GSIS was highly enhanced (P<0.05) in Alk7fx/fx::Ptf1aCre/+ mice al-
though their glucose tolerance is not improved compared to controls.
Interestingly, the conditional loss of ALK7 expression is associated to a
significant (P<0.01) increase in mRNA level of the ATGL (adipose tri-
glyceride lipase) lipase in islets of Alk7fx/fx::Ptf1aCre/+ mice.
Conclusion: Our study suggests that ALK7 may regulate glucose-
induced insulin secretion in a cell autonomous manner in islets. Moreover
we have recently shown that ALK7 inhibition in adipocytes enhances
lipolysis. Thus, ALK7 deletion could promote lipolysis in islets through
lipases upregulation, thereby potentiating insulin secretion in response to
glucose.
Supported by: ERC, SRC, KAW, SRP Diabetes KI
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CART is a novel glucose-dependent peptide with antidiabetic actions
in humans
M. Abels1, M. Riva1, W. Poon1, H. Bennet1, V. Nagaraj1, O. Dyachok2,
B. Isomaa3,4, T. Tuomi3,5, B. Ahrén6, A. Tengholm2, M. Fex1, E.
Renström1, L. Groop1, V. Lyssenko1, N. Wierup1;
1Lund University Diabetes Centre, Malmö, 2Department of Medical Cell
Biology, Uppsala, Sweden, 3Folkhälsan Research Center, Helsinki, 4De-
partment of Social Services and Health Care, Jacobstad, 5Department of
Medicine, Helsinki, Finland, 6Lund University Diabetes Centre, Lund,
Sweden.
Background and aims: Cocaine- and amphetamine-regulated transcript
(CART) is necessary for islet function in mice, but information from
humans is lacking. We examined CART expression and function in hu-
man healthy and T2D islets, as well as the effect of genetic variations in
the CARTPT gene. We also aimed to dissect the mechanisms by which
CART affects islet hormone secretion using rodent models.
Materials and methods: Human islets from healthy and T2D cadaver
donors and rodent islets were used to study CART expression by immu-
nohistochemistry, qPCR and western blot. Islets from 64 human donors
were subjected to Affymetrix GeneChip Human Gene 1.0ST array. Insu-
lin and glucagon secretion was studied in vivo in mice and in human and
mouse islets. Ca2+ oscillations and islet single cell exocytosis was studied
in mouse islets. 22132 non-diabetic individuals were selected from 2
population-based cohorts (Malmö Preventive Project and the Prevalence,
Prediction and Prevention of diabetes Botnia study) and genotyped for
CARTPT gene variants.
Results: CART was expressed in human beta cells, alpha cells, and in
cholinergic pancreatic neurons. CART mRNAwas higher in hyperglyce-
mic donors (p<0.015) and CART mRNA (p<0.009) and protein expres-
sion (p<0.008) were 3-times higher in islets of T2D patients compared to
controls. Islet CART expression was several-fold increased in 4 diabetic
rodent models and up regulated by glucose in vivo in rats (p<0.03).
CART increased insulin secretion by 25% in human control- and T2D
islets (p<0.02). Administration of CART i.v. and beta cell specific over-
expression of CART provoked a 2-fold increased first phase insulin re-
lease (p<0.01), as well as improved glucose elimination in vivo inmice (p
<0.02). The effect of CART on first phase insulin secretion was compa-
rable to that of GLP-1 and notably, CART caused a 30% further increase
in insulin secretion on top of that achieved by GLP-1 alone (p<0.02).
Furthermore, CART augmented beta cell exocytosis 2-fold (p<0.05),
triggered slowwave Ca2+ oscillations and synchronized oscillations with-
in the islets. In addition, glucagon secretion was reduced by CART in vivo
in mice (p<0.001) and CART diminished alpha cell exocytosis (p<0.05).
Genetic variants in the CARTPT gene were associated with increased
glucose levels (p<0.03), reduced insulin (p<0.04) and elevated glucagon
secretion (p<0.008), and a BMI-dependent 1.5-1.7 fold increased T2D
risk (p=0.001).
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Conclusion:We conclude that CART is a novel glucose-dependent pep-
tide with potential as a future anti-diabetic therapy. This is based upon its
properties to stimulate insulin- and inhibit glucagon secretion, as well as
the demonstration that genetic variants in the CARTPT gene increase risk
of T2D in obese individuals.
Supported by: EFSD/MSD, Novo Nordisk Foundation, Swedish research
council
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Involvement of Rab3B in the regulation of beta cell insulin secretion
C. Johne, S. Baltrusch;
Institute of Medical Biochemistry and Molecular Biology, University
Rostock, Germany.
Background and aims: Trafficking and exocytosis of insulin granules in
pancreatic beta cells is a sophisticated process in which the coordinated
interplay of many different proteins is essential. Rab proteins which be-
long to the Ras superfamily are crucial factors within this scene. Research
in the past 2 decades mainly focused onRab3A andRab27A and revealed
both as key regulators of late stages of exocytosis. Recent studies pro-
posed that another member of the Rab family, Rab3B, has a pivotal
function in coordination of beta cell insulin secretion. Therefore the aim
of this study was to explore the role of Rab3B in beta cells.
Materials and methods: Mouse islets, murine tissues and MIN6 beta
cells were analyzed for Rab3 expression by RT-PCR, Western Blot and
immunofluorescence analyses. The influence of different culture condi-
tions on Rab3 expression in MIN6 cells and isolated islets was followed
by RT-PCR. For overexpression of Rab3A and Rab3B, cells were tran-
siently transfected. Down regulation of Rab proteins was evoked by
lentiviral shRNA transduction. Glucose-induced insulin secretion was
measured by ELISA.
Results: Expression of both, Rab3A and Rab3B was detected in mouse
islets, brain, liver and pancreas as well as in MIN6 beta cells. RT-PCR
analysis showed that the two other isoforms Rab3C and Rab3Dwere only
expressed at a low level in beta cells. But equal amounts of Rab3A and
Rab3B were detectable in isolated islets, indicating the pivotal role of
Rab3B in endocrine tissue. Immunofluorescence analyses of Rab3A
and Rab3B in MIN6 cells and in primary beta cells revealed a vesicle-
like distribution with, surprisingly, only little colocalization with each
other. Rab3A displayed a higher degree of colocalization with insulin
granules than Rab3B. Endogenous Rab3B protein expression was addi-
tionally detected in glucagon containing alpha cells. Investigating the
effects of glucose and palmitic acid onRab3 gene expressionwe observed
a decrease in Rab3A and B expression in MIN6 cells but a significant
increase in the expression levels of both isoforms in islets. To explore the
functional impact of Rab3B on insulin excocytosis glucose-induced in-
sulin secretion was studied. Neither Rab3A nor Rab3B overexpression in
MIN6 beta cells modified insulin secretion. In contrast, knocking down
Rab3A or Rab3B protein expression in MIN6 cells resulted in a signifi-
cant reduction of glucose-induced insulin secretion. This result was also
obtained after downregulation of Rab3A in mouse islets.
Conclusion: Besides the well known Rab3Awe could determine Rab3B
as an additional crucial factor of the insulin exocytosis machinery: 1)
Rab3B is expressed in primary murine beta cells; 2) expression is altered
upon exposure to high glucose and palmitic acid and 3) reduced protein
expression impaired insulin secretion. Thus, both Rab3B and Rab3A are
essential factors in beta cell function and a balanced expressionmight be a
prerequisite to prevent the development of type 2 diabetes mellitus.
Supported by: DDG
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Knock-down of the alpha subunit (PDHA1) of pyruvate dehydroge-
nase E1 in insulin-secreting cells reduces glucose-induced respiration
J.K. Ofori, V.A. Salunkhe, A. Bagge, H. Mulder, L. Eliasson, J.L.S.
Esguerra;
Department of Clinical Sciences, Lund University, Malmö, Sweden.
Background and aims: It has been reported that tight coupling between
cytosolic and mitochondrial metabolism increases glucose-stimulated in-
sulin secretion (GSIS). In β-cells, metabolism of pyruvate is critical for
metabolic coupling, and hence the mitochondrial pyruvate dehydroge-
nase complex (PDC) may play an important role in β-cells in control of
GSIS and regulation of blood glucose levels.We have previously reported
that GSIS is regulated by miR-130a/b and miR-152 via PDHA1, which is
a component of PDC enzyme complex. We showed that PDHA1 knock-
down by siRNA reduced GSIS by 40%. Here, we aim to investigate the
bioenergetics underlying the actions of PDHA1 in insulin-secreting cells.
Materials and methods:We silenced PDHA1 by siRNA in INS-1 832/
13 cells .We measured the knock-down efficiency at both mRNA and
protein levels by RT-qPCR and western blot, respectively. Basal respira-
tion, glucose-induced respiration, non-mitochondrial respiration, maxi-
mal mitochondrial respiration capacity and maximal respiration were
measured by the Seahorse Extracellular Flux Analyzer, XF24.
Results:We observed an approximately 70% knock-down of PDHA1 at
both mRNA and protein levels (n=3; p<0.01). Glucose-induced respira-
tion decreased by ~25% (n=3, p<0.05), non-mitochondrial respiration
decreased by ~20% (n=3, p<0.05) and maximal respiration reduced by
~15% (n=3; p<0.01) in insulin-secreting cells upon PDHA1 knock-
down. We found no significant difference in the proton leak, but there
was a trend of decreased basal respiration and a decreased maximal mi-
tochondrial respiration capacity.
Conclusion: PDHA1, a component of pyruvate dehydrogenase complex
potentially involved in metabolic coupling in insulin-secreting beta cells,
may contribute to beta cell dysfunction.
Supported by: Swedish RC, Diabetic Wellness, Diabetesfonden, Albert
Påhlsson Foundation
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Larger glucagon response to OGTT compared to isoglycaemic i.v.
glucose infusion translates into increased endogenous glucose pro-
duction in patients with type 2 diabetes
J.I. Bagger1,2, A. Lund1,2, M. Christensen1,2, G. Van Hall3, J.J. Holst2, T.
Vilsbøll1, F.K. Knop1,2;
1Gentofte University Hospital, Hellerup, 2NNF Center for Basic Meta-
bolic Research, 3Clinical Metabolomics Core Facility, University of Co-
penhagen, Denmark.
Background and aims: OGTT induces less suppression of glucagon
than isoglycaemic i.v. glucose infusion (IIGI) in healthy subjects and this
difference is exaggerated in patients with type 2 diabetes (T2D). The
impact of this difference on plasma glucose levels is not clear. We eval-
uated glucose clearance and endogenous glucose production (EGP) dur-
ing OGTT and IIGIs with and without simulated lack of glucagon sup-
pression in patients with T2D and healthy control subjects (CTRLs).
Materials and methods: Ten patients with T2D (age: 57±2 years [mean
±SEM]; BMI: 29.0±1.4 kg/m2; HbA1c: 53.8±3.5 mmol/mol) and 10
matched CTRLs (age: 56±3 years; BMI: 29.8±0.9 kg/m2; HbA1c:
33.8±1.7 mmol/mol) underwent three investigations, day A: 75 g-
OGTT labelled with [U-13C]glucose, day B: [6,6D-2]-labelled IIGI cor-
responding to day A, and day C: IIGI as day B with glucagon infusion
(0.8 ng/kg/min from 0-25 min).
Results: Isoglycaemia was obtained during all three study days in both
groups. As expected, larger glucagon responses were observed in the
initial phase of the OGTT (0-90min) compared to the IIGI in both groups
(Table 1). The IIGI with concomitant glucagon infusion resulted in sim-
ilar glucagon AUCs (0-90 min) compared to the T2D OGTT response
(Table 1). In both groups more glucose was infused during day B com-
pared to day C (P=0.01 for healthy and P=0.14 for T2D; Table 1). In the
T2D group, EGP was higher during day A compared to day B and C,
whereas no difference in EGP between days were seen in the CTRL
group. Peripheral glucose disappearance was higher during day A com-
pared to day B and C among CTRLs, but similar on all days in the T2D
group.
Conclusion: These findings suggest that glucagon release arising from
glucose stimulation of the gastrointestinal tract may stimulate EGP and
that exaggerated glucagon release during OGTT in patients with T2D
may contribute to reduced glucose tolerance characterising these patients.
Table 1. Glucose and glucagon following OGTT and isoglycaemic i.v.
glucose infusions (IIGIs) in patients with type 2 diabetes (T2D) and
healthy control subjects (CTRL). Data are mean±SEM values. P values
are from paired sample t test or repeated-measurement ANOVA. Signif-
icant differences (P≤0.05) between days (derived from post hoc analysis)
are indicated by asterisks (*) followed by the letter of the day compared
with.
Clinical Trial Registration Number: NCT02010827
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Identification of secreted factors linking hepatic steatosis to insulin
resistance
R.C.R. Meex1, A.J. Hoy2, A. Morris1, R.D. Brown1, M. Burke1, R.
Goode3, S.S. Rensen4, B.A. Kingwell5, G.I. Lancaster6, M. Kraakman6,
M.A. Febbraio6, P.J. Meikle7, M.P. Molloy8, C.R. Bruce1, M.J. Watt1;
1Physiology, Monash University, Clayton, 2Physiology, University of
Sydney, 3Biochemistry and Molecular Biology, Monash University,
Clayton, Australia, 4Internal Medicine, Maastricht University, Nether-
lands, 5Metabolic & Vascular Physiology, 6Cellular and Molecular Me-
tabolism, Baker IDI, Melbourne, 8Chemistry & Biomolecular Sciences,
Macquarie University, Sydney, Australia.
Background and aims: Non-alcoholic fatty liver disease (NAFLD) is a
common health problem that is associated with obesity. Liver steatosis is
an early manifestation in the aetiology of NAFLD, which usually pre-
cedes the development type 2 diabetes. We tested the hypothesis that
protein and lipid signals originating from the fatty hepatocyte induce
‘cross-talk’ with other tissues to modulate metabolic phenotypes.
Materials and methods: Male C57Bl/6J mice were fed a chow diet
(Chow) or high-fat diet (HFD) for 6-8 weeks to induce simple steatosis.
Hepatocytes were isolated and cultured, and the secreted products were
collected in protein and lipid free media for analysis (=conditionedmedia,
CM).
Results: HFD CM but not Chow CM induced insulin resistance and
inflammation in cultured cells. Quantitative analysis of the CM detected
17 lipid classes and >200 lipid species, and showed increased secretion of
11 lipid classes in HFD CM compared with Chow CM (including cho-
lesterol esters, ceramides, diacylglycerols, phosphatidylcholine and triac-
ylglycerol). Isobaric tag for relative and absolute (iTRAQ) labelling and
mass spectrometry quantification of the CM detected 538 proteins. Of
these proteins, 115 were identified as ‘classically secreted’, 31 of which
were upregulated, and three that were downregulated in HFD CM. Fetuin
B was increased in the CM of HFD hepatocytes and subsequent studies
showed that fetuin B was elevated in patients with liver steatosis com-
pared with weight-matched patients without steatosis, and fetuin B cor-
related with insulin resistance. Further studies in lean mice showed that
acute injection of fetuin B decreased glucose tolerance, whereas adeno-
associated virus administration of fetuin B shRNA in obese mice reduced
plasma fetuin B by 33% and improved glucose tolerance.
Conclusion: Hepatic steatosis invokes changes in the protein and lipid
secretory profile that in turn causes inflammation and insulin resistance,
and targeted profiling identified fetuin B as a steatosis responsive protein
that was shown to cause glucose intolerance. Further interrogation of the
secreted proteins may be a useful strategy for understanding the develop-
ment of impaired glucose metabolism.
Supported by: NHMRC, DART
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Metabolic assessment of cirrhotic patients before liver transplanta-
tion: relation between impaired glucose homeostasis, liver function
and HCC
V. Grancini, M.E. Lunati, E. Palmieri, V. Resi, M. Smiraglia, E. Orsi;
Endocrinology and Diabetology Unit, Fondazione IRCCS Ca' Granda -
Ospedale Maggiore Policlinico di Milano, Italy.
Background and aims: Impaired glucose tolerance (IGT) and Diabetes
Mellitus (DM) are common in patients with liver cirrhosis. DM develop-
ment has been associated to advanced liver disease (LD) and HCV infec-
tion, but the relative roles played by these factors are still somewhat
unclear. Moreover, it has been demonstrated that Insulin Resistance
(IR), is related to increased risk of developing Hepatocellular Carcinoma
(HCC), the first cause of death in patients with cirrhosis. Aim of the study
is to assess, in cirrhotic patients candidate to organ transplantationwith no
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history of glucose abnormalities: a) prevalence of altered glucose homeo-
stasis and its relation to liver function; b) IR and its relationship with
HCC.
Materials and methods: 204 patients, aged 54.3±8.4, with liver cirrho-
sis and candidate to organ transplantation underwent an anthropometric
and metabolic evaluation and an OGTT. IR was assessed with HOMA-IR
(a cut off of 3 was utilized to identify insulin-resistant patients) andOGIS.
Results: 35 patients had normal glucose tolerance (NGT), 68 had IGT,
101 had DM. Diabetic patients were older than patients showing IGT or
NGT (age 56.2±6.9 vs 53.3±8.4 vs 50.9±11.1, respectively, P<0.01).
Glucose tolerance worsened with worsening of liver function: DM was
diagnosed in 24.6% of patients in stage A and 65.4% of those in stage B
or C, according to Child Pugh classification. Moreover, diabetes was
related to lower levels of total cholesterol (128.3±44.9 vs 132.2±45.1
vs 160.0±73.5, P<0.01), LDL-cholesterol (65.1±35.1 vs 68.9±35.5 vs
96.2±65.4, P<0.01), albumin (3.4±0.5 vs 3.5±0.6 vs 3.7±0.5, P=0.01),
pseudocholinesterase (2683.2±1673.2 vs 3720.3±2472.9 vs 3534.5±
2169.8, P<0.01) and platelets count (73.1±35.9 vs 102.8±67.9 vs
124.8±105.3, P<0.01) if compared to patients with IGTand NGT, show-
ing worse hepatic synthetic capacity and liver function in patients with
altered glucose homeostasis. HOMA-IR steadily increased with declining
of glucose tolerance (2.85±0.34 vs 4.66±0.59 vs 5.9±0.70 from NGT to
DM, P<0.05), and it was higher in presence of HCV: 68% of HCV+
patients showed IR vs 44.8% of HCV- patients (P<0.01). OGIS level
decreased from NGT to IGT to DM (425.5±78.0 vs 372.5±82.2 vs
352.9±80.2, P<0.01). Finally, prevalence of HCC was significantly
higher in patients with IR vs cirrhotic patients without IR (45.1% vs
27.9%, P<0.01).
Conclusion: In cirrhotic patients, DM is related to the severity of LD.
HCV infection might play a role in deteriorating glucose homeostasis via
IR. Moreover HOMA, a reliable index to identify insulin-resistant pa-
tients, allows to characterize a class of patients at highest risk of devel-
oping HCC.
Clinical Trial Registration Number: NCT02038517
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Selenoprotein-P as marker of insulin sensitivity in prediabetes and
diabetes
M.Kumar1, S. Mondal2, D. Dutta3, S. Chowdhury1, S.Mukhopadhyay1;
1Department of Endocrinology, 2Department of Biochemistry,
IPGME&R SSKM Hospital, Kolkata, 3Department of Endocrinology,
Post Graduate Institute of Medical Education & Research & Dr. Ram
Manohar Lohia Hospital, Delhi, India.
Background and aims: Initial reports have suggested selenprotein-P
(SeP), a novel hepatokine, to modulate insulin resistance (IR) and energy
metabolism in animals and humans. This study evaluated the relation
between SeP, anthropometric parameters, IR, systemic inflammation
and vitamin-D across the spectrum of glycemia, viz. normoglycemia
(NGT), prediabetes (preDM) and newly diagnosed treatment naïve
type-2 diabetes (T2DM) patients.
Materials and methods: Anthropometric parameters (waist circumfer-
ence, hip circumference, neck circumference (NC)], Serum selenoprotein,
fasting blood glucose (FBG), 2 h post 75gram glucose blood glucose
(2hPGBG), HbA1c, fasting insulin, lipids, inflammatory cytokines [inter-
leukin (IL)-6, IL1β, soluble tumor necrosis factor receptor (sTNFR)-1,
sTNFR2] and 25-hydroxy-vitamin-D (25OHD) were evaluated in 34
NGT, 64 preDM and 38 T2DM patients, selected from the eastern India
vitamin-D in prediabetes study. Serum insulin was estimated using CLIA
(Immunite-1000, Gwynedd, UK). Human SeP was estimated using sand-
wich ELISA, (Cat No. MBS2515309, MyBioSource, USA), detection
range 0.156-10 ng/ml, sensitivity 0.094 ng/ml with intra and interassay
coefficient of variation of <10%. 25OHD was measured using 125I ra-
dioimmunoassay kit (REF 68100E, Diasorin, USA). IL6, IL1b, sTNFR1
and sTNFR2 were estimated using sELISA. Insulin sensitivity was esti-
mated using QUICKI (Quantitative Insulin Sensitivity Check Index).
Results: NGT (age: 50.29±13.2 years), prediabetes (age: 46.9±
12.3 years) and T2DM (age: 49.73±13.4 years) had significantly different
BMI (24.7±2.75, 24.6±4.28, 27.29±5.08 kg/m2, P=0.035), waist-height
ratio(0.55±0.04, 0.55±0.06, 0.59±0.07, P=0.009), NC (34.72±3.19,
35.33±2.9, 37.3±2.68 cm, P=0.003),triglycerides (126.7±60.1, 115.9±
63, 200.9±62.6 mg/dl, P=0.031), IL6 (4.93±0.44, 4.74±2.65, 5.7±
1.6 pg/ml, P=0.08), sTNFR1 (2863.77±1106.72, 3371.89±1102.4,
3830.41±1529.65 pg/ml, P=0.021), 25OHD (30.50±18.37, 31.95±
23.25, 42.07±20.23 ng/ml, P=0.075) and SeP (848.35±220.21,
1002.93±279.50, 826±240.59 ng/ml, P=0.011). SeP had very strong
inverse correlation with insulin sensitivity (QUICKI) in NGT (r=-0.94,
P<0.001), prediabetes (r=-0.92, P<0.001) and diabetes (r=-0.96, P<
0.001). SeP was persistently the strongest predictor of QUICKI in NGT,
prediabetes and T2DM at baseline (β=-1.124, P<0.001; β=-1.003, P<
0.001;β=-0.957, P<0.001, respectively) and after adjusting for age, BMI
and waist circumference (Model-1) (β=-1.11, P<0.001; β=-1.006; P<
0.001; β=-0.942, P<0.001, respectively).
Conclusion: SeP is elevated across the spectrum of dysglycemia with
lowest in normoglycemia. SeP is a very good predictor of insulin sensi-
tivity and may be considered as a biomarker of insulin sensitivity.
Clinical Trial Registration Number: CTRI/2011/091/000192
Supported by: DST West Bengal [853(Sanc.)/ST/P/S&T/9G-2/2011]
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Phosphorylated serum IGFBP-1 as a non-invasive predictor of liver
fat in NAFLD
E.M. Petäjä1,2, Y. Zhou2, M. Havana3, J. Ihalainen3, A. Kotronen1,2, H.
Yki-Järvinen1,2;
1Department of Medicine, University of Helsinki, 2Minerva Foundation
for Medical Research, Helsinki, 3Medix Biochemica, Kauniainen, Fin-
land.
Background and aims: Non-alcoholic fatty liver disease (NAFLD) is
currently the most common chronic liver disease and it strongly associ-
ates with metabolic syndrome, insulin resistance, and type 2 diabetes.
There is a need to develop non-invasive tools for diagnosis of NAFLD.
Insulin is the major regulator of the hepatospecific insulin-like growth
factor binding protein 1 (IGFBP-1). The majority of serum IGFBP-1 is
phosphorylated. IGFBP-1 inversely correlates with liver fat content. Of
all subjects 30-50% carry an I148M variant allele in PNPLA3, which
increases the risk of NAFLD but not insulin resistance. The aim of the
study is to determine whether measurement of fasting serum
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phosphorylated IGFBP-1 (fS-pIGFBP-1) helps in prediction of liver fat
compared to routinely available clinical parameters and PNPLA3 geno-
type at rs739409.
Materials andmethods:A cross-sectional study comprised 378 subjects
(62% women, age 43 (30-54) years, BMI 32.7 (28.1-39.7) kg/m2, 46%
with NAFLD) of whom liver fat content was determined by proton mag-
netic resonance spectroscopy (1H-MRS). fS-pIGFBP-1 was determined
with an immunoenzymometric assay with an in-house monoclonal anti-
body as the detecting antibody. Subjects were randomly divided into
discovery (2/3) and validation (1/3) groups that matched with respect to
clinical and biochemical parameters and PNPLA3 genotype. Univariate
analysis was used to evaluate correlations between liver fat content and
measured parameters. To create a model for prediction of liver fat, vari-
ables identified by univariate analysis in the discovery group were select-
ed for multiple linear regression analysis using backward stepwise regres-
sion based on Akaike Information Criteria. Random Forest modeling was
used to evaluate relationships between liver fat predictors.
Results: fS-pIGFBP-1 inversely correlated with liver fat content (r=-
0.21, p=0.0009). The final model, the ‘% Liver Fat Equation’, included
age, fS-pIGFBP-1, an interaction term (age times fS-pIGFBP-1), S-ALT,
waist-to-hip ratio, fP-Glucose and fS-Insulin, adjusted R2=0.44, p<
0.0001 (adjustedR2=0.49 in the validation group and 0.47 in all subjects)
(Table 1). The model was significantly better than S-ALT (adjusted R2=
0.25) or S-AST (adjusted R2=0.15) (p<0.0001). Exclusion of fS-
pIGFBP-1 significantly reduced the variation explained (p=0.03). Ran-
dom Forest modeling identified the same predictors (adjusted R2=0.39, p
<0.0001). Correlation coefficient between measured liver fat% (1H-
MRS) and estimated liver fat% with ‘%Liver fat equation’ was r=0.62,
p<0.0001.
Conclusion: fS-pIGFBP-1 is significantly inversely correlates with liver
fat content in NAFLD and independently contributes to prediction of liver
fat even when its known associates are considered.
Supported by: Sigrid Juselius Foundation, Academy of Finland, EVO
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Metabolomics profiling identifies potential pathways involved in the
interaction of iron homeostasis with insulin resistance
L. Stechemesser1, T. Felder2, A. Stadlmayr3, S. Auer2, S. Eder1, M.
Strasser1, W. Patsch4, C. Datz3, E. Aigner1;
1Internal Medicine 1, 2Laboratory Medicine, Paracelsus Medical Univer-
sity Clinic, Salzburg, 3Internal Medicine, Hospital Oberndorf, 4Institute
of Pharmacology and Toxicology, Paracelsus Medical University Clinic,
Salzburg, Austria.
Background and aims: Elevated serum ferritin has been linked to type 2
diabetes and adverse outcomes in subjects with the Metabolic Syndrome
(MetS). As the mechanisms underlying the negative impact of excess iron
have so far remained elusive, we aimed to identify potential metabolic
pathways using a metabolomics analysis.
Materials and methods: Metabolomics profiling was performed in pa-
tients with MetS with (n=56) and without iron overload (n=54) and a
lean, healthy control group (n=53) in a targeted metabolomics approach
utilizing the AbsoluteIDQ™ p180 kit (BIOCRATES Life Sciences AG).
Results: Clinically, subjects with MetS and high ferritin had higher indi-
ces of impaired glucose homeostasis as assessed by fasting glucose and
HOMA-IR compared to subjects matched for components of the MetS
without iron overload. Several differences between MetS and healthy
controls confirmed previous studies, i.e. branched-chain amino acids,
kynurenin, and alpha AA. However, significant differences between
MetSwith high and low ferritin were detected in the serum concentrations
of sarcosine and methionine, citrulline and particularly long-chain
phosphatidylcholines.
Conclusion: Our data confirm that high serum ferritin concentrations are
linked to impaired glucose homeostasis. Additionally, our study identifies
novel associations of iron excess in MetS subjects with distinct subsets of
phosphatidylcholines as well as a pathway involving methionine,
sarcosine and citrulline. These metabolic pathways may be involved in
iron-induced augmentation of IR.
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Gender specific association of serum leptin and insulinaemic indices
with nonalcoholic fatty liver disease in prediabetic subjects
A. Rouf, I.A. Hossain, L. Ali;
Biochemistry and Cell Biology, Bangladesh University of Health Sci-
ences (BUHS), Dhaka, Bangladesh.
Background and aims: Adipose tissue-derived hormone leptin play a
functional role in glucose tolerance through its effects on insulin secretion
and insulin sensitivity which also the risk factors for nonalcoholic fatty
liver disease (NAFLD). The present study explored the gender specific
association of serum leptin with insulinemic indices in Bangladeshi pre-
diabetic subjects having NAFLD.
Materials andmethods:Under a cross-sectional analytical design a total
of 110 prediabetic subjects diagnosed by WHO Group Study criteria,
aged 35-68 years consisting of 57.3% male (55.6% non NAFLD and
44.4% NAFLD) and 42.7% female (57.4% non NAFLD and 42.6%
NAFLD), were investigated. NAFLD was diagnosed by liver ultrasound
to assess serum (S) glucose by glucose-oxidase method, S lipid profile by
enzyme colorimetric method and glycated hemoglobin (HbA1c) by high
performance liquid chromatography (HPLC) method. S insulin and and
leptin were measured by enzyme-linked immunosorbent assay (ELISA).
Insulin secretory function (HOMA%B) and insulin sensitivity
(HOMA%S) were calculated from homeostasis model assessment
(HOMA).
Results: On Pearson’s correlation analysis, S leptin showed significant
positive correlation with fasting insulin (r=0.530, p=0.004), postprandial
insulin (r=0.384, p=0.042) and HOMA-IR (r=0.541, p=0.003) as well
as significant negative correlation with HOMA%S (r=-0.388, p=0.046)
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and HOMA%B (r=-0.356, p=0.039) in male prediabetic subjects having
NAFLD. On multiple regression analysis, S leptin showed significant
positive association with HOMA-IR (β=0.706, p<0.001) after adjusting
the effects of major confounders of body mass index (BMI), triglyceride
(TG) and HOMA%B inmale subjects havingNAFLD. On binary logistic
regression analysis, only S leptin [odds ratio (OR)=1.296] in male sub-
jects as well as HOMA%B (OR=0.942), HOMA-IR (OR=3.305) and
leptin (OR=1.106) in female subjects were found to be independent de-
terminants of NAFLD after adjusting the effects of potential confounders
of BMI and TG.
Conclusion: Elevated levels of serum leptin seems to have an association
with NAFLD both in male and female prediabetic subjects and this asso-
ciation in turn, is mediated by insulin secretory dysfunction and insulin
resistance among these subjects.
Supported by: BUHS
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Insulin pulse amplitude and frequency do not determine rates of
endogenous glucose production in nondiabetic subjects
R.T. Varghese1, J.C. Andrews2, M. Shah1, F. Piccinini3, C. Dalla Man3,
R.A. Rizza1, C. Cobelli3, A. Vella1;
1Endocrinology, Diabetes, Metabolism and Nutrition, 2Vascular and In-
terventional Radiology, Mayo Clinic, Rochester, USA, 3Department of
Information Engineering, University of Padova, Italy.
Background and aims: Diabetes, obesity and aging cause changes in
insulin pulse amplitude and frequency, which affects the pulsatile secre-
tion of insulin into the portal circulation. Insulin concentrations in the
hepatic sinusoids in turn affect glucose production. In dogs, partial pan-
createctomy decreases inter-digestive insulin pulsatility and results in
decreased hepatic insulin action. Whether this mechanism is extant in
humans remain unknown.
Materials andmethods: 30 non diabetic subjects (Age 43±2 years, BMI
29.0±0.8 Kg/M2) were studied on 2 occasions. Endogenous glucose
production (EGP) was measured on one occasion using an intravenous
infusion of [3-H3] glucose after an overnight fast prior to a euglycemic
clamp. On a separate study day a hepatic vein catheter was placed to
allow sampling of hepatic venous insulin concentrations at 2 minute in-
tervals. Samples were obtained during fasting conditions and after periph-
eral glucose concentrationswere raised to 8.5 mmol/L. Indocyanine green
was used to measure splanchnic blood flow.
Results:Under fasting conditions, Peak andNadir insulin concentrations,
(53±9 and 21±4, respectively) and mean pulse amplitude and pulse fre-
quency (30±6pmol/L and 11±1 pulses/hr respectively) were measured.
The relationship of insulin pulse frequency and amplitude to fasting EGP
(14.3±0.6 μmol/kg/min) was also examined. Under fasting basal condi-
tions EGP did not correlate with peak (R2<0.01, p=0.80), and Nadir
(R2=0.01, p=0.72) insulin, pulse frequency (R2=0.08, p=0.30) or pulse
amplitude (R2=0.04, p=0.52). The mean rates of insulin appearance
calculated by multiplying mean insulin concentrations in the hepatic vein
(35±6 pmol/L) with splanchnic blood flow (1439±95 ml/min) however
correlated inversely with EGP (R2=0.36, p=0.03).
Conclusion: The current experiment demonstrates that in in nondiabetic
individuals, it is mean insulin concentrations that determine EGP during
fasting, rather than pulse frequency or pulse amplitude.
Supported by: NIH- DK 078646
PS 042 Type 1 diabetes: new insights
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Presence of remission after onset of type 1 diabetes predicts higher
insulin sensitivity at 7 years
S. Pilacinski, P. Niedzwiecki, A. Uruska, D. Zozulinska-Ziolkiewicz;
Department of Internal Medicine and Diabetology, Poznan University of
Medical Sciences, Poland.
Background and aims: After onset of type 1 diabetes some patients
experience remission of the disease. This phenomenon is associated with
regeneration of beta cells and preserved insulin secretion, but also with
increased insulin sensitivity. It was not evaluated whether presence of
remission may be of value in predicting the degree of insulin sensitivity
in the later course of disease. Aim of the study was to determine the
association between presence or absence of remission after onset of type
1 diabetes and insulin resistance after 7 years from diagnosis of disease.
Materials and methods: We followed prospectively 240 consecutive
adult patients (77 women and 143 men) hospitalized with new onset type
1 diabetes (NOT1DM) in the Department of Internal Medicine and
Diabetology in the years 2004-2007. The presented analysis is a part of
POZREM Study. Inclusion criteria were: new diagnosis of autoimmune
type 1 diabetes (specific autoantibody-positive), age 18-35 years and
informed consent to participate in the study. Adult patients with
NOT1DM from the catchment area (the majority of Great Poland region)
are referred to our department on a routine basis, independently from the
severity of presentation. In the follow-up time of onset and duration of
diabetes remissionwere registered. Presence of remissionwas determined
in the third month after diagnosis of diabetes. Remission was defined as
the time when the patients met all of the the following criteria: HbA1c<
6.5%, daily dose of exogenous insulin <0.3 U/kg body weight and serum
C-peptide concentration >0.5 ng/ml. Patients were divided into groups
with and without remission. Insulin sensitivity was assessed using
normoglycemic-hyperinsulinemic clamp with measurement of glucose
disposal rate (GDR [mg/kg/min]). The test was performed after 7 years
from diagnosis of diabetes. We excluded seven patients still fulfilling
remission criteria.
Finally 74 patients [24 women and 50 men, median age at diagnosis
26 years (IQR 22-31)], in whom insulin sensitivity at 7 years was mea-
sured, were included into analysis. Patients were divided into groups with
GDR<4 (lower insulin sensitivity) and GDR≥4 (higher insulin sensitiv-
ity). In the statistical analysis Mann-Whiney U test, Spearman correlation
and logistic regression were used. The calculations were performed using
Statistica 10.
Results: In the study group GDR value <4mg/kg/minwas observed in 23
(31%) patients. Comparison of GDR between groups with and without
remission showed higher insulin sensitivity in the remission group [GDR
6.2 (IQR 4.2-7.0) vs 3.8 (IQR 3.0-4.8); p=0.01]. Furthermore, in the
group with GDR≥4 duration of remission was longer than in the group
with lower insulin sensitivity: [351 days (IQR 206-561) vs 70 days (0-
289); p=0.002]. Duration of remission correlated positively with GDR
value (Rs 0.42; p=0.002). In multivariate logistic regression analysis
presence of remission was associated with higher odds of GDR≥4 at
7 years (OR 4.14; 95%CI: 1.08-15.88; p=0.03), independently from
age, sex and BMI at 7 years.
Conclusion: Patients with type 1 diabetes who entered remission, despite
its completion, have higher insulin sensitivity at seven years after diag-
nosis than nonremitters.
Clinical Trial Registration Number: NCT02220257
Supported by: Grant of the Polish Society of Diabetology (PTD)
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Inverse association of HbA1c with faecal elastase 1 in people without
diabetes
W. Rathmann1, B. Haastert2, J. Oscarsson3, N. Berglind3, N.J.
Wareham4;
1Institute for Biometrics and Epidemiology, German Diabetes Center,
Düsseldorf, 2mediStatistica, Neuenrade, Germany, 3AstraZeneca,
Mölndal, Sweden, 4MRC Epidemiology Unit, Cambridge, UK.
Background and aims: Faecal elastase 1 (FE1) concentrations, a marker
of pancreatic exocrine function, are lower in type 2 diabetes than in non-
diabetic controls. FE1 is also inversely correlated with glycated hemoglo-
bin and diabetes duration in type 2 diabetes. The association of FE1 and
HbA1c has not been investigated in people without diabetes.
Materials and methods: Patients with type 2 diabetes (oral antidiabetic
drugs or insulin: n=391; medically untreated: n=145) and matched (age,
sex, practice) controls without diabetes (n=529) from general practices
were included. FE1 measurements (μg/g stool) were performed centrally.
Linear mixed regression models were fitted using FE1 as dependent var-
iable and HbA1c, diabetes diagnosis (no, yes-untreated, yes-treated) and
interactions as independent variables. Potential confounders were age,
sex, body mass index, alcohol consumption, smoking, triglycerides, and
amylase. Univariate regression models were stratified by diabetes groups,
multivariate models were fitted on the whole study population.
Results: In univariate linear regression models, HbA1c was significantly
inversely related to FE1 in non-diabetic controls (ß-coefficient: -108.74, p
<0.0001), whereas no significant associations were found for the diabetes
groups. The inverse relationship of HbA1c with FE1 concentrations in
patients without diabetes persisted after adjusting for potential con-
founders in multivariate regression (ß-coefficient of HbA1c: -109.18, p
<0.0001). In people without diabetes, there were lower FE1 concentra-
tions among those with increased diabetes risk (HbA1c 5.7%-6.4% [39-
46 mmol/mol]: 395±204 μg/g vs. HbA1c ≤5.6% [≤38 mmol/mol]: 476±
219 μg/g (p<0.0001). The prevalence of FE1<100 μg/g was significant-
ly increased among non-diabetic controls with an HbA1c of 5.7%-6.4%
(39-46 mmol/mol) compared with those with a normal HbA1c ≤5.6%
(≤38 mmol/mol) (6.1% vs. 1.4%; p=0.004).
Conclusion: The present study suggests that pancreatic exocrine dys-
function might be an early disturbance in prediabetes that develops in
parallel with hyperglycemia.Whether it is a consequence or a determinant
of hyperglycaemia requires further investigation.
Supported by: Unrestricted grant fromAstraZeneca, Sweden for the anal-
yses.
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A parsimonious model of a mixed-meal test in patients with type 1
diabetes in insulin pump therapy
C. Brangani1, M. Dauriz1, L. Boselli1, F. Reali2, L. Marchetti2, G.
Ceradini1, I. Rubbo1, M. Trombetta1, C. Priami2, R.C. Bonadonna3;
1Department of Medicine, Division of Endocrinology, Diabetes and Me-
tabolism, University of Verona School of Medicine and AOUI Verona,
2TheMicrosoft Research - University of Trento Centre for Computational
and Systems Biology (COSBI), Rovereto, 3Division of Endocrinology,
Department of Clinical and Experimental Medicine, University and Uni-
versity Hospital of Parma, Verona, Italy.
Background and aims: Currently available closed-loop insulin delivery
systems stem from sophisticated models of the glucose-insulin (G/I) sys-
tem mostly based on complex studies employing glucose tracer technol-
ogy. We asked the question whether simpler studies based on the minimal
modeling approach (Bergman, 1981; Cobelli, 2007) could likewise reli-
ably describe the G/I system during a mixed meal test (MMT) in patients
with type 1 diabetes (T1D). If effective, this approach would expedite the
creation of large bio-banks of virtual patients to develop robust models
“to close the loop”. To this end, we tested the performance of a minimal
model of the G/I system to characterize the glucose (G) and insulin (I)
dynamics during MMT in T1D patients on insulin pump therapy (CSII).
Materials and methods: In six T1D patients on CSII enrolled in the
MMT-T1D Pilot Study we assessed on three separate days: (1) insulin
sensitivity, by the hyperinsulinemic euglycemic clamp (HEC); (2) the G/I
time-courses during a standardized 5 h-MMT (MMT1: 292 Kcal; 38.9 g
complex CHO, 8.9 g lipids, 14 g proteins); (3) the G/I time-courses during
a second identical (3 patients) or double-sized (3 patients) MMT
(MMT2). The parameters estimated by modeling of the HEC were used
to cast a comprehensiveMMTmodel (GLUKINSLOOP.2), including the
insulin delivery system and the metabolic G/I system of each patient.
GLUKINSLOOP.2 was implemented and run in the SAAM 2.1 software.
Results: The GLUKINSLOOP.2 model identified the G/I system param-
eters (among others: insulin sensitivity, SI; glucose effectiveness, SG;
glucose distribution volume, Vd; time of oral carbohydrate appearance
in the peripheral circulation, expressed as ICMTT, Intestinal Carbohy-
drate Mean Transit Time) and provided a good fit of the G/I time-
courses in all studies, as proved by the analysis of mean weighted resid-
uals (WR, mean ± SD; MMT1: WR(G)=-0.03±0.71; WR(I)=0.33±
1.04; MMT2: WR(G)=0.09±0.86; WR(I)=0.01±1.37). Both the identi-
cal and double-sized repeated MMT2s showed good reproducibility of
the G/I system parameters (mean±SEM; MMT1: SI=0.57±0.12
(mL˙min-1)/(pmol˙L-1); SG=15.6±10.1 mL˙min-1; Vd=11,482±1,
131 mL; ICMTT=105±14 min; MMT2: SI=0.57±0.13; SG=38.2±
13.6; Vd=11,609±1,031; ICMTT=101±11).
Conclusion: The GLUKINSLOOP.2model herein presented can provide
a fairly good and reproducible description of the G/I system in T1D
patients on CSII and it may be used to build a bank of “virtual patients”.
Our results might be relevant to strategies directed to improve the archi-
tecture of upcoming closed-loop CSII systems.
Clinical Trial Registration Number: NCT01800734
Supported by: EFSD/Novo Nordisk
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Partial recovery of insulin secretion in type 1 diabetes?
A.S. Januszewski1, Y. Cho2, Y. Loh1, D.N. O'Neal3, M. Craig2, K.
Donaghue2, A.J. Jenkins1;
1NHMRC Clinical Trials Centre, University of Sydney, Camperdown,
2Childrens Hospital at Westmead, 3Department of Medicine, University
of Melbourne, Fitzroy, Australia.
Background and aims: Even long-term Type 1 diabetes (T1D) can be
associated with low level insulin production. Residual C-peptide may
reduce risk of vascular complications and hypoglycaemia.
Materials and methods: Plasma C-peptide levels were measured in a
cross-sectional study of 249 healthy controls (CON) and 365 T1D pa-
tients (F/M=198/167), aged 10-80 y, (mean ± SD) 30±16 y, with T1D
duration of 16±12 y. Of the T1D patients 129 had microvascular com-
plications (CX+). HbA1cwas 8.4±1.6% and 5.1±0.4% in T1D andCON
respectively (p=0.00001). C-peptide levels were measured by ultra-
sensitive ELISA (Mercodia, Sweden), with a low detection limit of 1.25
pmol/L (0.0038 ng/mL). C-peptide levels below OD of the lowest cali-
brator were expressed as ¼ of the concentration of the assay’s lowest
calibrator as per manufacturer’s instructions (Technical Note 34-0144).
Results: C-peptide in CON and T1D were 547.1±1.2 pmol/L and 3.6±
1.2 pmol/L respectively; p=0.0001. Undetectable C-peptide level fre-
quency did not differ between CX+ and CX- groups. For T1D subjects
with detectable levels C-peptide levels were lower in those with vs. with-
out complications: 2.7±0.9 pmol/L and 4.4±0.6 pmol/L respectively, p=
0.04. Subjects were divided into cohorts by age of T1D diagnosis (≤10,
10 to ≤20 and >20 y) and T1D duration (≤10, 10 to ≤20 and >20 y). C-
peptide levels are shown in the table. Young age diagnosis (≤10 y.o.) was
associated with higher rates of undetectable C-peptide, p=0.0001 vs.
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combined age T1D diagnosis 10 to ≤20y.o. and >20y.o. For T1D diag-
nosed in early childhood C-peptide levels are higher in those with longer
T1D duration, whilst for those diagnosed >20 y longer T1D duration is
associated with lower C-peptide.
Conclusion:Although cross-sectional, our results are supportive of more
complete beta cell loss in younger onset T1D, and potential beta cell
regeneration. Residual C-peptide levels are higher in T1D subjects with-
out vs with complications. Longitudinal studies are merited.
Supported by: 2013 DART
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Endogenous C-peptide secretion in patients with long-duration type
1 diabetes
S.L. Prior1, S.D. Luzio1, G.J. Dunseath1, G.V. Gill2, S.C. Bain1;
1Diabetes Research Group, Swansea University, 2Department of Diabetes
& Endocrinology, University of Liverpool, UK.
Background and aims: Classically, Type 1 diabetes is thought to pro-
ceed to absolute insulin deficiency; however, recent reports suggest that
some Type 1 patients secrete low levels of endogenous insulin. It is
thought that even small amounts of residual β-cell function may result
in fewer complications including lower rates of hypoglycaemia and lower
incidences of retinopathy and nephropathy. We aimed to assess amounts
of detectable C-peptide in the Golden Years cohort who have had Type 1
diabetes for over 50 years, and to assess whether this had a bearing on the
presence/absence of complications.
Materials andmethods:Random serum C-peptide was measured in 334
samples from the Golden Years cohort, using a commercially available
immunometric C-peptide assay. Subjects were divided into ‘no secretor’
and ‘secretor’ groups based on the detection limit of the C-peptide assay
(5.0 pmol/L).
Results: A substantial proportion (15.9%) of the Golden Years
patients continued to secrete detectable levels of C-peptide (5.1
- 245.2 pmol/L) despite having been diagnosed with Type 1 dia-
betes for ≥50 years. Both ‘no secretor’ and ‘secretor’ groups were
well matched, with no significant difference in age, age at diag-
nosis, duration of diabetes, BMI, HbA1c or lipid levels (Table 1).
There was however, a significant difference in insulin dose (‘no
secretor’ vs ‘secretor’: 34.4 v 26.7 U/24 hr; p=0.002) between
the groups, which appeared to be clinically significant. With re-
spect to complications, there was no difference in UACR, or
prevalence of diabetic retinopathy, IHD or hypertension.
Conclusion: In common with recent reports, our results confirm that
some level of endogenous C-peptide production is evident in Type 1
diabetes and this persists for decades after disease onset, allowing a pos-
sible route for therapeutic intervention to preserveβ-cell function, even in
a population of patients with long-duration diabetes, such as the Golden
Years cohort. However, the presence of detectable C-peptide did not
appear to confer protection against diabetes related complications such
as retinopathy, IHD or nephropathy.
592
Glucose metabolism under differing exercise conditions in type 1
diabetes
L. Bally1, T. Zueger1, C. Speck1, D. Paganini1, N. Pasi1, H. Loher1, K.
Feller1, T. Buehler2, A. Dokumaci2, M. Fiedler3, L. Tappy4,M.Wilhelm5,
C. Boesch2, C. Stettler1;
1Div of Endocrinology, Diabetes and Clinical Nutrition, 2Dept of Clinical
Research, MR-Spectroscopy & -Methodology, 3Center for Laboratory
Medicine, University Hospital, Bern, 4Institute of Physiology, University,
Lausanne, 5Div of Cardiovascular Prevention, Rehabilitation and Sports
Cardiology, University Hospital, Bern, Switzerland.
Background and aims: The combination of aerobic exercise with inter-
spersed high-intensity activity (intermittent high intensity exercise IHE)
may be a strategy to attenuate exercise-related glucose fluctuations in
diabetic patients not willing or unable to reduce insulin in the context of
exercise. The present study comprehensively investigated glucose metab-
olism during IHE compared to isoenergetic continuous exercise (CONT)
in individuals with T1DM.
Materials and methods: In a prospective, randomized cross-over
study, 12 male, well controlled, complication-free patients with
T1DM (mean ± SD age 26±4 y, HbA1C 7.0±0.6%, diabetes
duration 14±6 y) injected their usual morning insulin and had a
standardized breakfast. In the postabsorptive phase they performed
90 min of cycling at 50% VO2peak with (IHE) and without
(CONT) 10 s maximal sprints every 10 min. Blood glucose,
counter-regulatory hormones, lactate and acid-base parameters
were measured at regular intervals. Euglycemia was maintained
using a 10% oral glucose solution labelled with [U-13C] glucose
following a pre-specified algorithm. Analysis of glucose kinetics
was based on dual labelling stable isotope technique ([6,6-
2H2]glucose and [U-13C] glucose). Intramyocellular glycogen
was measured using MR spectroscopy.
Results: Mean±SE glucose was 6.8±0.1 and 7.2±0.2 mM in IHE and
CONT (n.s.). Insulin levels were 21.0±0.5 and 20.7±0.2 mU/l (n.s.).
Exogenous glucose requirements in IHE were significantly lower com-
pared with CONT (13.4±5.2 g vs 39.8±7.6 g, p<0.004). Catecholamine
and growth hormone (GH) levels were significantly higher in IHE when
compared to CONT (p<0.05) while cortisol and glucagon levels did not
differ between groups. Lactate was significantly higher in IHE compared
with CONT (7.3±0.4 vs 2.6±0.3 mM, p<0.01) and was paralleled by
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significantly lower pH (p<0.001) and bicarbonate (p<0.001). Analysis of
glucose fluxes revealed higher total Ra in CONTcompared with IHE (p<
0.01) but similar hepatic glucose output (Ra from liver) and a trend to-
wards lower Rd (glucose utilization) in IHE (p=0.054). Relative changes
in intramyocellular glycogen were -41.0±3.7 and -38.6±5.3% for IHE
and CONT (n.s.).
Conclusion: The present findings suggest that IHE is associated with
lower requirements of exogenous glucose for maintenance of euglycemia
in patients with T1DM compared with isoenergetic CONTover 90 min if
insulin is not reduced. IHE elicits a strongmetabolic response with higher
levels of catecholamines, GH and lactate. Kinetic analyses suggest that
hepatic glucose production is similar in IHE and CONT. Consumption of
intramyocellular glycogenwas also comparable between conditions. The-
se findings implicate that the metabolic difference between IHE and
CONTmainly relates to higher lactate levels in IHE, potentially providing
an alternative carbohydrate source to the working muscle.
Clinical Trial Registration Number: NCT02068636
Supported by: Swiss National Science Foundation
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Regional cerebral haemodynamic response to incremental exercise is
blunted in poorly controlled patients with uncomplicated type 1
diabetes
S. Tagougui1, P. Fontaine2, E. Leclair3, J. Aucouturier1, R. Matran4, K.
Oussaidene1, A. Descatoire5, F. Prieur6, P. Mucci1, A. Vambergue2, G.
Baquet1, E. Heyman1;
1University of Lille, URePSSS, ‘Physical Activity, Muscle, Health’ Re-
search Team, 2Department of Diabetology, Lille University Hospital, EA
4489, France, 3School of Kinesiology and Health Science, Faculty of
Health, York University, Toronto, Canada, 4Department of Physiology,
EA 2689 and IFR 22, Lille, 5Regional Hospital Centre of Roubaix, 6Uni-
versity Paris Sud-University of Orléans, EA 4532 ‘CIAMS’, France.
Background and aims: Cerebral vasoreactivity to pharmacologically
induced hypercapnia is impaired in poorly controlled patients with type
1 diabetes but otherwise free from microangiopathy. However, whether
this response is also compromised during exercise, a daily-life physiolog-
ical condition challenging regional cerebral hemodynamics, is unknown.
We aimed to investigate prefrontal cortex hemodynamics incremental
maximal exercise in patients with uncomplicated type 1 diabetes, taking
into account long-term glycemic control as well as exercise- and diabetes-
influenced vasoactive stimuli.
Materials and methods: Two groups of patients (type 1 diabetes with
adequate glycemic control [T1D-A], n=8, HbA1c 6.8±0.7% [51±
7.7 mmol/mol]; type 1 diabetes with inadequate glycemic control [T1D-
I], n=10, HbA1c 9.0±0.7% [75±7.7 mmol/mol]) were compared with 18
healthy control subjects (CON-A and CON-I) matched for physical ac-
tivity and body composition. Throughout exercise, near-infrared spectros-
copy allowed investigation of changes in oxyhemoglobin (O2Hb),
deoxyhemoglobin (HHb), and total hemoglobin (THb) in the prefrontal
cortex. Venous and arterialized capillary blood was sampled during exer-
cise to assess for factors that may alter prefrontal cortex hemodynamics
and oxygenation.
Results:No differences were observed between T1D-A and CON-A, but
VO2max was impaired (P<0.05) and cerebral blood volume (THb) in-
crease blunted (P<0.05) in T1D-I compared with CON-I. Nonetheless,
O2Hb appeared unaltered in T1D-I probably partly due to blunting of
simultaneous neuronal oxygen extraction (i.e., a lower HHb increase; P<
0.05). There were no intergroup differences in arterial oxygen content,
PACO2, pH, [K+], and free insulin levels.
Conclusion:Maximal exercise highlights subtle disorders of both hemo-
dynamics and neuronal oxygenation in the prefrontal cortex of poorly
controlled patients with type 1 diabetes. These findings may warn
clinicians of brain endothelial dysfunction occurring even before overt
microangiopathy during exercise.
Clinical Trial Registration Number: NCT02051504
Supported by: SFD (Société Francophone du Diabète)
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Imbalance of muscular carnosine and fatty acids assessed by 1H
MRS in subjects with type 1 diabetes
L. Brugnara1,2, A. García3, S. Murillo1,2, M. Rodriguez4,2, M. Vinaixa4,
2, T. Casserras5, S. Kalko5, J. Pomes3, X. Correig4,2, A. Novials1,2;
1Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
Hospital Clínic de Barcelona, 2Spanish Biomedical Research Centre in
Diabetes and Associated Metabolic Disorders (CIBERDEM), 3Depart-
ment of Radiology – Hospital Clínic de Barcelona, 4Metabolomics Plat-
form – Universitat Rovira i Virgili, Reus, 5Institut d'Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS), Bioinformatics Core Facil-
ity, Barcelona, Spain.
Background and aims: Skeletal muscle represents one of themost active
organs in glucose metabolism and is directly involved in insulin resis-
tance and sensitivity. In subjects with type 1 diabetes (T1D), there is little
information about muscle particularities and specific metabolism.
Carnosine is a dipeptide with antioxidant activity that reflects the content
of muscular type II fibers (glycolitic). Imbalances in muscular lipid me-
tabolism may be estimated by intramyocellular lipids (IMCL),
representing saturated fatty acids (FA), but also some unsaturated FA
(UFA) components. The aim of this study was to analyze muscle alter-
ations in T1D patients by estimating muscle carnosine, IMCL, UFA and
unsaturation index (UI) by proton magnetic resonance spectroscopy (1H
MRS), and to investigate the influence of physical activity and clinical
variables on these parameters.
Materials and methods: 18 men with T1D (10 athletes and 8 sedentary)
with 41.3±7.2 years of age, 18.8±9.4 years of T1D evolution, were
matched with 14 control (CT) men (9 athletes and 5 sedentary). Clinical
data were registered, body fat was obtained by iDXA, VO2peak was
estimated by ergoespirometry test, basic biochemical parameters were
analysed and 1H MRS were performed in the tibialis anterior, soleus
and vastus intermedius in a 3 T unit. The spectra were processed in
jMRUI for obtaining the concentrations of carnosine (C2-H peak at
8 ppm), IMCL (methylene protons at 1.2 ppm) and UFA (olefinic protons
at 5.2 ppm) content, and UI was obtained from UFA/IMCL ratio. Differ-
ences between groups (Kruskal-Wallis and U-Mann Whithey), influence
of exercise and diabetes (Anova with covariates) and the pearson’s cor-
relation for clinical and muscle lipid variables were analysed (p<0.05).
Results: T1D athletes presented a VO2peak of 41.3±10.4 mL/kg/min,
and sedentary T1D subjects 20.2±6.7, confirming the differences be-
tween groups (p=0.01). T1D patients presented an increase in carnosine
(p=0.045) in the soleusmuscle after adjustments for age, physical activity
and the presence of dyslipidemia, when compared to the CT group. So-
leus carnosine was positively correlated with total body fat by iDXA (R=
0.577) and serum triglycerides (R=0.501) and negatively correlated with
VO2peak (R=-0.579) and UI UFA/IMCL in soleus (R=-0.473). In the
CT group, carnosine of soleus muscle presented a positive correlation
with waist (R=0.848), waist/hip ratio (R=0.836), total body fat (R=
0.699), abdominal body fat (R=0.578), BMI (R=0.674) and soleus
IMCL (R=0.795). There was no difference in carnosine estimations be-
tween athletes and sedentary subjects, in both T1D and CT groups.
Conclusion: Carnosine (marker of glycolytic fibers) is increased in mus-
cles with a predominance of oxidative fibers (soleus) in T1D patients.
These findings could indicate a dysfunction in oxidative muscle fibers,
thus requiring the increased function of glycolytic fibers, a circumstance
also associated with poorer clinical parameters.
Supported by: CIBERDEM-METADIAB 12/12/2009
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Effect of renal sympathetic denervation on hepatic glucose metabo-
lism and blood pressure in a rat model of insulin resistance
M. Tian1,2, L. Li1,2, G. Yang3;
1Key Laboratory of Diagnostic Medicine (Ministry of Education) &De-
partment of Clinical Biochemistry, 2College of Laboratory Medicine,
3Department of Endocrinology, The Second Affiliated Hospital, Chong-
qing Medical University, China.
Background and aims: Hypertension and diabetes are associated with
impaired glucose metabolism and insulin resistance. Chronic activation
of the sympathetic nervous system may contribute to either condition.
However , the effects of RD on glucose metabolism and insulin sensitivity
have also not been systematically examined.The purpose of this study
was to investigate the effect of renal sympathetic denervation (RD) on
glucose kinetics and insulin signal pathways in high fat diet (HFD) fed
rats.
Materials and methods: Mainly,we used 12-week-old male Sprague-
Dawley rats as research object .We examined the effects of RD on glucose
kinetics and insulin sensit ivity in HFD-fed rats with the
hyperinsulinemic-euglycemic clamp technique combined with [3-
3H]glucose and [U-14C]-lactate as a tracer. We also analyzed the
in vivo flux through glucose-6-phosphatase (G6Pase) and the relative
contribution of gluconeogenesis and glycogenolysis in RD rats. In addi-
tion, Western blotting was used to identify the activities of insulin signal-
ing proteins.
Results: RD in HFD-fed rats markedly decreased blood pressure and
hepatic glucose production (HGP). HGP reduction in RD-treated rats
was due to an 18.2% decrease for left RD and a 31.9% decrease for
bilateral RD in glycogenolysis and a 16.3% decrease for left RD and a
42.8% decrease for bilateral RD in gluconeogenesis. These changes were
accompanied by decreased hepatic expression of glucose-6-phosphatase
(G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK). Important-
ly, RD increased phosphorylation of insulin receptors, insulin receptor
substrate-1 (IRS-1) and Akt kinase in HFD-fed rats.
Conclusion:These data provide evidence for a mechanism of the RD role
and corroborate the notion that RD potentiates hepatic insulin sensitivity.
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Distinct contributions of hepatic insulin and IGF-1 signalling in met-
abolic alterations induced by liver-specific PTEN deletion in mice
D. Portius1, C. Sobolewski1, N. Calo1, J.-L. Pitetti2, A.-S. Ay1, F.
Berthou1, M. Fournier1, C. Maeder1, S. Nef2, M. Foti1;
1Cell Physiology and Metabolism, 2Genetic Medicine and Development,
Faculty of Medicine, Geneva, Switzerland.
Background and aims: PTEN is a lipid/protein phosphatase that coun-
teracts insulin and IGF1 signalling in hepatocytes by antagonizing the
activity of PI3K. Hepatic Pten deletion in mice triggers the development
of steatosis and liver to muscles and adipose tissue crosstalks resulting in
increased muscle insulin sensitivity, a reduced fat mass and browning of
white adipose tissue. Here, we investigated the specific contributions of
hepatic insulin and IGF1 signalling in the deregulated liver metabolism
and inter-organ communication triggered by liver-specific Pten deletion
in mice.
Materials and methods:Mice with liver-specific deletions of the insulin
receptor, the IGF1 receptor, or both, in addition to deletion of Pten were
generated and metabolically phenotyped. Histological and molecular
analyses were performed on explanted tissues.
Results: Suppression of both insulin receptor (IR) and IGF1 receptor
(IGF1R) signalling was required in liver-specific PTEN knockout mice
to completely prevent hepatomegaly and steatosis development. Surpris-
ingly, the improved systemic glucose tolerance and impaired hepatic glu-
coneogenesis induced by PTEN deficiency in hepatocytes were reverted
by suppressing hepatic IGF1R signalling. In contrast, the decreased adi-
posity observed in liver-specific PTEN KO mice was prevented in mice
lacking hepatic expression of the IR.
Conclusion: Although they share important similarities, hepatic insulin
and IGF-1 signaling exacerbated by PTEN deficiency in hepatocytes
distinctly affect liver metabolism and communication with peripheral
tissues including muscles and white adipose tissues.
Supported by: Suisse National Science Foundation
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Induction of hepatic de novo lipogenesis impairs hepatic but not
muscle insulin sensitivity and associates with increased adiposity
T. Jelenik1,2, K. Kaul1,2, U. Flögel3, G. Séquaris1, J. Kotzka4, G.I.
Shulman5,6, J. Szendroedi1,7, M. Roden1,7;
1Institute for Clinical Diabetology, German Diabetes Center, 2German
Center for Diabetes Research, 3Department of Molecular Cardiology,
Medical Facul ty, HHU, 4Ins t i tu te for Biochemis t ry and
Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany, 5De-
partment of Internal Medicine, 6Howard Hughes Medical Institute, Yale
University School of Medicine, New Haven, USA, 7Department of En-
docrinology and Diabetology, Medical Faculty, HHU, Düsseldorf, Ger-
many.
Background and aims: Non-alcoholic fatty liver (NAFL) has been as-
sociated with insulin resistance, however, the causal relationships be-
tween NAFL, hepatic and muscle insulin sensitivity as well as underlying
mechanisms are yet unclear. The aim of this study was to determine the
effects of NAFL on the tissue-specific insulin sensitivity in mice with
genetically induced hepatic de novo lipogenesis.
Materials and methods: We examined 36-weeks-old female mice with
primary NAFL due to liver-specific overexpression of the sterol
regulatory-element binding protein-1c (Alb-SREBP-1c: PRIM; n=7-8)
and compared to wild-type C57BL/6 controls (CON; n=6-7). All mice
were maintained on chow diet. Intracellular lipids and body fat distribution
were assessed with proton magnetic resonance spectroscopy. Fatty acid
composition of ceramides and diacylglycerols (DAG) was analyzed with
HPLC-MS. Insulin sensitivity was measured with hyperinsulinemic-
euglycemic clamp. Protein expression was assessed by western blot and
gene expression by qRT-PCR. Redox potential in serum and hydrogen
peroxide production in tissues were assessed to estimate oxidative stress.
Data were statistically analysed by one-wayANOVAwith Tukey post-hoc.
Results: Body weight (BW) was unchanged in PRIM vs. CON mice,
while visceral and subcutaneous fat depots were enlarged by 225% (p<
0.001) and 275% (p<0.001), respectively. Liver weight to BW ratio was
unchanged, however, hepatic lipid content was increased by 87% (p<
0.01) and expression of fatty acid synthase (fas) by 217% (p<0.001) in
PRIM mice. While total ceramides and DAG were unchanged, the cyto-
solic DAG containing two oleic fatty acids (C 18:1) were increased by
61% (p<0.05) in the liver of PRIM mice. Insulin suppression of hepatic
glucose production was decreased by 43% in PRIM mice (p<0.01). The-
se results were in accordance with 63% lower tyrosine phosphorylation of
IRS (pIRS2-Tyr; p<0.001) and lack of insulin stimulation of protein
kinase B (Akt) in the liver of PRIM mice. No differences in serum redox
potential and hydrogen peroxide production from the liver were observed
in the PRIMmice. Intramyocellular lipid content of the soleus and tibialis
muscles as well as ceramide and DAG levels were similar to CON mice.
Furthermore, insulin-stimulated glucose disposal (Rd) as well as translo-
cation of GLUT4 remained unimpaired in PRIM mice. No changes in
muscle hydrogen peroxide production were observed.
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Conclusion: Increased hepatic de novo lipogenesis per se leads to hepatic
insulin resistance, even in the absence of obesity. This associates with
increased accumulation of specific DAG species containing two oleic
fatty acids. Furthermore, de novo lipogenesis does not necessarily result
in impairedmuscle insulin sensitivity, potentially due to increased storage
of inert lipids in adipose tissue.
Supported by: MIWFNRW; BMG; BMBF to DZD; DFG (SFB1116,B05);
Schmutzler Stiftung, Germany
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Up-regulation of selenoprotein P, a diabetes-associated hepatokine,
and HIP/PAP, a mitogenic factor for the liver, in hepatocytes by
intermittent hypoxia
H. Ota1, A. Itaya-Hironaka2, A. Yamauchi2, S. Sakuramoto-Tsuchida2, T.
Fujimura2, H. Tsujinaka2, K. Tomoda1, M. Yoshikawa1, H. Kimura1, S.
Takasawa2;
1Second Department of Internal Medicine, 2Department of Biochemistry,
Nara Medical University, Kashihara, Japan.
Background and aims: Sleep apnea syndrome (SAS) is characterized by
recurrent episodes of oxygen desaturation during sleep, the development
of daytime sleepiness, and deterioration in the quality of life. Accumulat-
ing evidence suggests that SAS is associated with glucose intolerance and
insulin resistance independently age, gender, smoking status, body mass
index, and waist circumference. The progression to type 2 diabetes is
dependent on the development of glucose intolerance and insulin resis-
tance. However the direct effects of intermittent hypoxia (IH), a hallmark
of SAS, on insulin resistance have obscured. Recently, several proteins
that are exclusively or predominantly secreted from the liver are known to
directly affect glucose and lipid metabolism and are named as
hepatokines. In the present study, using rat and human hepatocytes, we
investigated the direct effect of IH on gene expression of hepatokines.
Materials and methods: Human JHH5, JHH7, and rat H4IIE hepato-
cytes were exposed either to 64 cycles/24 h of IH (5 min hypoxia (1%
O2)/10 min normoxia (21% O2)), mimicking hepatocytes of SAS pa-
tients, or normoxia for 24 h. After the treatment, mRNA levels of
selenoprotein P, fibroblast growth factor (FGF) 21, alpha2-HS glycopro-
tein (AHSG), angiopoietin-like protein (ANGPTL) 6, sex horomone-
binding globulin (SHBG), leukocyte cell-derived chemotaxin (LECT) 2,
Lipasin, which are diabetes-associated hepatokines, and regenerating
gene (Reg) family genes, were measured by real-time RT-PCR. The con-
centrations of selenoprotein P in the culture medium were also measured
by an ELISA kit.
Results: The mRNA levels of selenoprotein P were significantly in-
creased in IH-treated H4IIE (1.31 fold vs normoxia, P=0.0057), JHH5
(2.25 fold, P=0.0477), and JHH7 (2.17 fold, P=0.0027) cells whereas
mRNA levels of FGF21, AHSG, ANGPTL6, SHBG, LECT2 and Lipasin
were not increased by IH. The concentrations of selenoprotein P in the
culture medium were significantly increased in all IH-treated hepatocytes
(H4IIE (3.33±1.24 vs 6.15±0.545 ng/mL, P=0.048), JHH5 (1.57±0.464
vs 11.20±3.09 ng/mL, P=0.037), and JHH7 cells (2.24±1.65 vs 8.68±
1.92 ng/mL, P=0.043)). In addition, mRNA levels of hepatocarcinoma-
intestine-pancreas (HIP)/pancreatitis-associated protein (PAP) were sig-
nificantly increased in IH-treated JHH5 (P=0.0022) and JHH7 cells (P=
0.0016) whereas mRNA levels of the other REG familymembers (REG I
alpha, REG I beta, REG III and REG IV) were not increased by IH.
Conclusion: These results indicate that IH stress up-regulates expression
of selenoprotein P as well as HIP/PAP in hepatocytes. It is quite possible
that the cyclic changes of hypoxia-reoxygenation, which occurs in SAS
patients, up-regulate HIP/PAP to proliferate hepatocytes and
selenoprotein P, accelerating insulin resistance in SAS patients.
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The novel TRPVI antagonist, AZV1, improves insulin sensitivity in
ob/ob mice
M. Fritsch Fredin, A. Kjellstedt, D.M. Smith, N. Oakes;
CVMD, Bioscience, AstraZeneca R&D Mölndal, Sweden.
Background and aims: Transient receptor potential cation channel sub-
family V member 1 (TRPV1) is a ligand gated non-selective cation chan-
nel and the receptor for capsaicin on primary sensory nerves. Capsaicin
treatment, which ablates these sensory nerves, has been shown to increase
insulin secretion and improve insulin sensitivity in animal models. Func-
tional TRPV1 antagonism might have an equivalent effect. AZV1 is a
novel TRPV1 antagonist originally developed as an approach to suppress
nociceptive pain (IC50 of ~100 nM in cells overexpressing rodent
TRPV1). The aim of this study was to test the ability of AZV1 to ame-
liorate aspects of themetabolic syndrome (diabetes, insulin resistance and
dyslipidemia) in the ob/ob mouse.
Materials and methods: Nine week old male ob/ob mice on a C57BlJ/6
background (B6.V-Lepob/OlaHsd) were orally gavaged daily for 12 days
with either vehicle or the TRPV1 antagonist at 30 mg/kg/day. Body
weight and food intake were recorded. At termination, blood was collect-
ed under anaesthesia, 3 h following final dosing for the measurement of
AZV1 content, plasma glucose, insulin, fructosamine and triglycerides
(TG). In addition, liver TG content was determined.
Results: AZV1 was well tolerated with no apparent reductions of food
intake or body weight gain over the dosing period. The AZV1 plasma
concentration achieved 3 h following the final dosing was approximately
6-fold the in vitro potency consistent with robust TRPV1 antagonism.
AZV1 treatment lowered plasma glucose and fructosamine levels com-
pared to controls (20.7±2.1 to 13.0±0.6 and 95.0±2.5 to 76.0±6.8, p<
0.01, t-test), consistent with a substantial treatment induced reduction in
average diurnal blood glucose levels. This effect was achieved without
any significant alteration in the 3 h fasted plasma insulin levels, indicating
a treatment induced increase in glucose metabolic insulin sensitivity.
AZV1 had no apparent effect on fasting plasma FFA, TG or liver TG
content.
Conclusion: In conclusion, AZV1 was well tolerated and exerted a sub-
stantial antidiabetic action in the ob/ob mouse. Our data suggests that the
improvement in glucose control was at least partially mediated by an
enhancement in insulin sensitivity.
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Insulin resistance impairs human liver progenitor cell function
in vitro: Consequences for liver injury and tumorigenesis in meta-
bolic disease and type 2 diabetes?
L.A. Noon1, F. Manzano Núñez1, C. Acosta Umanzor1, A. Leal Tassias1,
A. Corlu2, D.J. Burks1;
1Metabolic growth signals and regenerative medicine, Centro de
Investigacion Principe Felipe (CIPF), Valencia, Spain, 2Foie,
Métabolisme et Cancer, Inserm UMR 991, Rennes, France.
Background and aims: Insulin promotes liver growth and the prolifera-
tion of hepatocytes following injury, whereas insulin resistance is associ-
ated with chronic liver damage and the increased risk of hepatocellular
carcinoma. However, the precise effects of aberrant insulin signalling on
regenerative processes in the liver remain unclear. In this study, we set out
to explore the role of insulin signalling in de novo human hepatogenesis
by modelling insulin resistance during the differentiation of bipotent liver
progenitor cells using; (1) hepatoma derived HepaRG progenitor cells
and (2) hepatoblast-like cells derived from pluripotent human embryonic
stem cells (hESCs).
Materials and methods: Insulin resistance was modelled by stable
knockdown of the insulin receptor (IR-beta), IRS1 and IRS2 using
shRNA-lentivirus. Enhanced insulin sensitivity was conferred by
Diabetologia (2015) 58 (Suppl 1):S1–S607 S289
overexpression of lentiviral mouse (m)IRS2, whereas the direct effects of
insulin were assessed by inclusion/exclusion of supplemented insulin
(0.88 uM) in the differentiation medium. High-content “IN Cell” cytom-
etry was used to quantify relevant aspects of hepatocyte differentiation.
Results: Insulin was required for the differentiation of bipotent human
liver progenitor cells to hepatocytes as well as for the cell-specific prolif-
eration of hepatocyte precursors expressing albumin and ApoA2 within
the cultures, whereas insulin resistance, induced by knockdown of either
IR-beta, IRS1 or IRS2, significantly blocked differentiation without
diminishing the proliferation of undifferentiated cells. Conversely, over-
expression of mIRS2, which mimicked hyperinsuliaemia by increasing
insulin/IRS signalling, significantly enhanced the number and percentage
of progenitors that differentiated to hepatocyte-like cells, whilst in long-
term experiments excessive signalling blocked maturation and promoted
steatosis in the differentiating fraction. Finally, we demonstrate that insu-
lin sensitivity is dynamically regulated by IRS expression in a time de-
pendent manner such that dampening of insulin/IRS signalling in imma-
ture hepatocytes leads to cell cycle exit, maturation and CYP3A4 expres-
sion. Insulin/IRS signalling therefore plays a dual role in promoting de
novo hepatogenesis and transient amplification of immature hepatocytes
whilst impairing normal maturation and promoting steatosis.
Conclusion: Our results demonstrate that insulin/IRS signalling has pro-
hepatogenic actions in both tumour derived HepaRG, as well as non-
transformed hESC derived hepatic progenitor cells, thus highlighting a
potential role for IRS proteins in both regenerative and tumorigenic
mechanisms in the liver. Chronic activation of this pathway, by sustained
exogenous IRS expression in the presence of insulin had pathogenic
effects in differentiating cells including steatosis, whereas, by limiting
differentiation, insulin resistance maintained cells in a progenitor-like
state - which if observed in vivo could have adverse consequences for
regenerative pathways whilst simultaneously perpetuating a more aggres-
sive undifferentiated state in liver cancer stem cells in insulin resistant
patients.
Supported by: CIBER, Spanish Ministerio SAF2011-28331 & Subpro-
gram Ramón y Cajal RYC2012
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Liver glutamate dehydrogenase knockout mice display impaired glu-
coneogenesis and altered feeding behaviour
M. Karaca, M. Grimaldi, J. Martin, P. Maechler;
Cellular Physiology andMetabolism, University of Geneva, Switzerland.
Background and aims: Glutamate dehydrogenase (GDH, encoded by
Glud1 gene) is mainly expressed in the liver, pancreas, kidney and the
brain. In mammals, this enzyme is a homohexamer located in the mito-
chondrial matrix where it catalyzes the reversible oxidative deamination
of glutamate to alpha-ketoglutarate and ammonia. GDH catalyzes the
same reaction in every tissue, although direction of the predominant flux
might be tissue specific. Moreover, physiological function of GDH varies
greatly according to specific organs. GDH is of major importance for
ammonia detoxification through nitrogen metabolism and urea synthesis
in the liver and kidney. Hepatic GDH is also involved in the metabolism
ofmost amino acids, in particular glutamine and alanine being transported
from skeletal muscle during periods of active gluconeogenesis. The im-
portance of GDH activity is witnessed by the severity of disorders where
GDH function is inappropriate, such as hyperinsulinemia/
hyperammonemia syndrome. Here, we have generated inducible liver-
specific GDH knockout mice (HepGlud1-/-) to investigate consequences
of the lack of hepatic GDH on metabolic homeostasis in basal and energy
challenging conditions.
Materials andmethods:The in vivo deletion ofGDH in hepatocytes was
induced at 8 weeks of age by subcutaneous implantation of tamoxifen
pellets in Glud1lox/lox mice (generated in our laboratory) carrying the
Albumin-Cre-ERT2 construct (provided by P Chambon). Metabolic
parameters were investigated by ip challenges (glucose, pyruvate, gluta-
mine, alanine), monitoring in metabolic cages, EchoMRI and commer-
cially available kits.
Results: Three weeks after in vivo induction of recombination by tamox-
ifen, deletionwas successful and specific for the liver inHepGlud1-/-mice
(<5% remaining of immunoreactive GDH). We also observed abrogation
of GDH enzymatic activity in liver homogenates (-67%, p<0.01). In
isolated primary hepatocytes, we measured the half-life of GDH lasting
for about 2-3 days. In non-hepatic tissues of HepGlud1-/- mice, GDH
expression was fully preserved as revealed by immunoblotting. Immuno-
histochemical analyses of HepGlud1-/- livers did not showmorphological
abnormalities. Intra-peritoneal glucose tolerance tests revealed normal
glucose homeostasis in HepGlud1-/- mice upon standard conditions and
both body weight and fat/lean mass ratio were similar between control
and HepGlud1-/- mice. Remarkably, the food intake profile was changed
by the absence of liver GDH, knockout animals exhibiting a shift in the
circadian rhythm of feeding. Moreover, lipids were favored over carbo-
hydrates as energy fuel in HepGlud1-/- mice. Finally, we tested the
gluconeogenic capacity of HepGlud1-/- mice in response to substrates
specific for situation of energy imbalance, such as fasting, i.e. glutamine
and alanine. Control mice could increase glycemia in response to both
glutamine and alanine challenge. However, the alanine response was
abrogated in HepGlud1-/- mice, while its deaminated product pyruvate
could induce gluconeogenesis.
Conclusion: Liver-specific GDH deletion induced substrate-specific im-
pairment of liver gluconeogenesis, higher lipid consumption, and a shift
in the circadian rhythm of feeding. These results highlight the central role
of hepatic GDH in energy metabolism.
Supported by: SNSF
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Phenotyping of the mitochondrial phosphoenolpyruvate
carboxykinase (PEPCK) knockout mouse
R. Stark, M.W.Y. Cheung, Z.B. Andrews;
Physiology, Monash University, Melbourne, Australia.
Background and aims: The GTP-dependent enzyme phosphoenolpyr-
uvate carboxykinase (PEPCK) is the key enzyme that provides phospho-
enolpyruvate (PEP) for gluconeogenesis (de novo glucose production)
and glyceroneogenesis (de novo glycerol production to store free fatty
acids in form of triglycerides). Although, there are two isoforms, a cyto-
solic (PEPCK-C) and a mitochondrial (PEPCK-M) form, most research
focused on the function and regulation of PEPCK-C, probably due to its
hormonal regulation and the suggested absence of PEPCK-M in rodent
metabolism. In contrast to PEPCK-C, in which transcription is strongly
inhibited by insulin, PEPCK-M is constitutively expressed and therefore
PEP is synthesized according to fuel supply and mitochondrial GTP
(mtGTP). Although, previous reports suggest that rodents do not have
significant PEPCK-M activity, we aimed to confirm the existence and
importance of PEPCK-M in rodent metabolism.
Materials and methods: To assess the role of PEPCK-M in rodent me-
tabolism we created PEPCK-M knockout mice on a C57Bl6 background
(PCK2-/-). At the age of 6 weeks we fedmice either a normal chowdiet or
a high fed diet up to 15 weeks long and performed metabolic tests to
assess glucose homeostasis, including glucose tolerance test, insulin tol-
erance test and measurement of energy expenditure using a controlled
animal monitoring system (CLAMS).
Results: There was no difference in body weight gain for PCK2-/- on a
normal chow diets and high fat diet compared to wild-type animals (wt).
PCK2-/- mice on a normal chow diet had higher fasting blood glucose
levels (9.33±0.29 mmol/l versus 7.97±0.31 mmol/l; P=0.0031) but
showed normal glucose tolerance. After 4 weeks on a high fat diet
PCK2-/- mice showed glucose intolerance, measured by glucose and
insulin tolerance test (GTT-area under the curve 1796±80.14 versus
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1444.46±82.64; ITT-area under the curve 913.35±163.97 versus 607.91
±61.8). The difference in glucose intolerance disappeared with increase
of age. Thus, we targeted further experiments to investigate why knock-
out mice are prone to become glucose intolerant. Interestingly, we noticed
higher heat production and activity with PCK2-/- mice on a normal chow
diet using CLAMS. However, PCK2-/- mice on high fat diet showed no
difference in heat production or activity but had significant lower energy
expenditure.
Conclusion: Despite previous reports that deletion of PCK2 would be
insignificant, we confirm that PCK2 does have a role in rodent glucose
metabolism and PCK2-/- mice on a high fat diet are prone to develop
glucose intolerance.
Supported by: NHMRC Early Career Fellowship
PS 044Mousemodels of type 2 diabetes
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The role of TBC1D1 and TBC1D4 in contraction-induced glucose
uptake in mouse skeletal muscle
C. deWendt1,2, A. Chadt1,2, J. Loffing3, D. Loffing-Cueni3, H.-G. Joost4,
2, H. Al-Hasani1,2;
1Institute for Clinical Biochemistry and Pathobiochemistry, German Di-
abetes Center (DDZ), Duesseldorf, 2German Center for Diabetes Re-
search (DZD e.V.), Neuherberg, Germany, 3Institute of Anatomy, Univer-
sity of Zurich, Switzerland, 4German Institute of Human Nutrition Pots-
dam Rehbruecke (DIfE), Nuthetal, Germany.
Background and aims: The RabGTPase-activating proteins TBC1D1
and TBC1D4 (AS160) are key players in AKT- and AMP-dependent
protein kinase (AMPK) regulated glucose metabolism. The aim of this
study is to analyze the contribution of these two homologous proteins to
the contraction-mediated glucose uptake and metabolism in skeletal
muscle.
Materials andmethods:Tbc1d1-deficient mice (RCS.B6.SJL-Nob1.10)
were crossbredwith conventional Tbc1d4 knockoutmice to yield double-
deficient mice (D1/4KO) on a C57BL/6J background. Ex vivo muscle
contraction of male 12-16 wk old knockout mice and wildtype controls
(WT) was conducted using isolated Extensordigitorum longus (EDL) and
Soleus muscles in a myograph chamber. Contraction force and time for
half-capacity were measured. Subsequently, contraction- and insulin-
induced 3H-2-deoxyglucose uptake and glycogen levels were
determined.
Results: We could previously demonstrate that D1/4 knockout muscles
show substantially reduced GLUT4 protein abundance in EDL and
Soleusmuscle (~50% of WT). Consistently, contraction-induced glucose
uptake was similarly reduced in both, glycolytic EDL and oxidative
Soleus muscle from D1/4KO mice (WT vs. D1/4KO; EDL: 4.45±0.25
vs. 2.00±0.14; p<0.001 and Soleus: 4.14±0.32 vs. 2.86±0.26 nmol/mg/
20 min; p<0.05). Combined stimulation of the muscles with ex vivo
contraction and insulin further increased glucose uptake in wildtype con-
trols. In skeletal muscle fromD1/4KOmice this effect was blunted (Contr
vs. Ins+Contr; EDL, WT: 11.24±0.81 vs. 14.45±0.731, p<0.05; D1/
4KO: 8.02±0.66 vs. 8.48±1.08 and Soleus, WT: 16.83±1.05 vs. 21.76
±1.45, p<0.05; D1/4KO: 12.71±1.40 vs. 13.57±2.01 nmol/mg/20 min).
Moreover, contraction force and time for half-capacity were unchanged
between the genotypes. Glycogen levels were increased in skeletal mus-
cle of D1/4KOmice (WT vs. D1/4KO: 1.53±0.30 vs. 2.74±0.31 μg/mg;
p<0.05) whereas liver showed decreased glycogen content (WT vs. D1/
4KO: 9.35±1.50 vs. 3.07±0.44 μg/mg; p<0.001).
Conclusion: Contraction-induced glucose uptake is severely reduced but
not completely eliminated inEDL and Soleusmuscle fromD1/4KOmice,
suggesting that a TBC1D-independent pathway also contributes to
contraction-mediated GLUT4 translocation. Elevated glycogen levels
may enable muscles of D1/4KO mice to develop the same contraction
forces and times for half-capacity as wildtype controls.
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Uncoupling protein 1 is required for fibroblast growth factor 21 me-
diated improvements in glucose tolerance but is dispensable for body
weight loss in diet-induced obese mice
M.M. Kwon, S. O'Dwyer, R.K. Baker, T.J. Kieffer;
Department of Cellular and Physiological Sciences, University of British
Columbia, Vancouver, Canada.
Background and aims: Fibroblast growth factor 21 (FGF21) has
emerged as a metabolic regulator with therapeutic potential for the treat-
ment of diabetes. Administration of FGF21 to rodent models of type 2
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diabetes reduces body weight and improves lipid and glucose homeosta-
sis. FGF21 treatment also increases uncoupling protein 1 (Ucp1) mRNA
and protein levels in brown and white adipose tissues. We sought to
determine whether the anti-diabetic and anti-obesity effects of FGF21
therapy require UCP1.
Materials and methods:Mice with a genetic deletion of Ucp1 (Ucp1-/-)
and wildtype controls (Ucp1+/+) were fed either a low-fat diet or rendered
obese with high-fat diet feeding. Next, we administered a vehicle
(controls) or plasmid encoding the human FGF21 gene by hydrodynamic
delivery to high-fat fed mice and body weight and fasting blood glucose
levels were tracked for 4 months. In addition, we performed glucose
tolerance tests (days 6 and 22) and an insulin sensitivity test (day 14).
Results: High-fat diet resulted in excess body weight gain in both
Ucp1+/+ and Ucp1-/- mice. Hydrodynamic delivery of the human
FGF21 gene increased plasma human FGF21 to supraphysiological
levels by day 3 compared to vehicle controls (42.6±7.8 ng/ml Ucp1+/+,
51.2±12.7 ng/ml Ucp1-/-, <0.05 ng/ml in both vehicle groups). On day
30, FGF21 treated Ucp1+/+ and Ucp1-/- mice lost comparable body
weight (-19.6±8.7% and -19.5±5.2%) whereas control Ucp1+/+ and
Ucp1-/- mice gained weight (9.4±1.4% and 4.8±1.1%). Despite mainte-
nance of supraphysiological plasma human FGF21 levels, body weight
reducing effects of FGF21 therapy waned in both Ucp1+/+ and Ucp1-/-
mice between days 22 and 30, and body weights returned to near pre-
treatment values in most mice by day 95. FGF21 treated Ucp1+/+ mice
had improved glucose tolerance at day 6 compared to vehicle (AUC 446
±63 mM and 1253±31 mM, p<0.05), even beyond that of low-fat diet-
fed Ucp1+/+ mice (AUC 713.4±61 mM, p<0.05). In contrast, FGF21
treatment did not improve glucose tolerance relative to vehicle in Ucp1-/-
mice (AUC 2174±37 mM vs 1892±174 mM). Similarly, glucose toler-
ance was also improved at day 22 with FGF21 treatment relative to
vehicle in Ucp1+/+ mice (AUC 550±54 vs 1574±123, p<0.05) but not
inUcp1-/-mice (AUC 1246±108 vs 1329±86). Glucose stimulated insu-
lin secretion at 15 minutes post-glucose delivery in FGF21 treated
Ucp1+/+ mice tended to be higher than vehicle on days 6 (2.8±0.8 fold
vs 1.7±0.05 fold, p=0.1) and 22 (2.9±0.9 fold vs 1.9±0.3 fold, p=0.4).
Similarly, FGF21 treated Ucp1-/- mice had improved glucose stimulated
insulin secretion at 15 minutes post-glucose delivery compared to vehicle
on days 6 (5.2±1.9 fold vs 1.9±0.1 fold, p<0.05) and 22 (3.6±0.4 fold vs
1.9±0.2 fold, p<0.05). FGF21 treated Ucp1+/+ and Ucp1-/- mice had
improved insulin sensitivity compared to vehicle, and the degree of blood
glucose lowering by insulin was similar between FGF21 treated Ucp1+/+
and Ucp1-/- mice (AUC 3778±132 and 4006±581).
Conclusion: Genetic ablation of UCP1 does not prevent FGF21 mediat-
ed lowering of body weight but prevents improvements in glucose toler-
ance despite improvements in glucose stimulated insulin secretion and
insulin sensitivity by FGF21 therapy. These data suggest that UCP1 de-
pendent thermogenesis in brown or white adipose tissue is not required
for body weight reduction but required for improvements in glucose
tolerance by FGF21 therapy.
Supported by: CIHR
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Validation of the intraperitoneal insulin tolerance test for the mea-
surement of insulin sensitivity in mice
R. Codella1, D. Gabellini2, L. Luzi1, A. Caumo1;
1Department of Biomedical Sciences for Health, University of Milan,
2Diabetes Research Institute, San Raffaele Scientific Institute, Milan,
Italy.
Background and aims:Mouse models are helpful in clarifying the path-
ophysiological mechanisms by which insulin resistance contributes to the
development of obesity and diabetes. Thus, the ability to accurately and
easily quantify insulin resistance in mice is of interest. The reference
standard for measuring insulin sensitivity is the glucose clamp, but
simpler methods previously developed in humans are frequently adopted
in mouse studies. Here, we focused on the intraperitoneal insulin sensi-
tivity test (IPIST). The domain of validity of the insulin sensitivity index
derived from IPIST is unknown since no direct validation against the
clamp is available in mice. Aim of this study was to compare the indeces
of insulin sensitivity derived from IPISTand the clamp in a group of wild-
type mice.
Materials andmethods: Six CB57BL6 12-week oldmice underwent the
IPIST first, and the euglycemic clamp two weeks later. In the IPIST, after
a 30-min stabilization period, a bolus of human insulin (0.5 U/kg) was
administered by an intraperitoneal injection at t=0. Blood samples (~5μl)
for the determination of glucose concentration were collected at 0, 5, 10,
15, 30, 60, 90, 120 min. The IPIST-based index of insulin sensitivity,
SI(IPIST), was calculated as the slope of the regression line between
the logarithm of glucose concentration vs. time in the interval 0-15 min
(i.e., when the linearity hypothesis was tenable). In the hyperinsulinemic-
euglycemic clamp, after a 30-min stabilization period, a primed-
continuos infusion of human insulin (2.5 mU/kg/min) was begun at t=0
and maintained constant for 120 min. Concurrently, 20% glucose was
infused at a variable rate to maintain glucose at basal concentration.
The clamp-based index of insulin sensitivity, ISI(clamp), was calculated
as the ratio between the levels of the glucose infusion rate and insulin
concentration measured at the end of the clamp. The relationship
ISI(IPIST) vs. ISI(clamp) was investigated by linear regression and the
coefficient of determination, R2, was evaluated to assess the goodness of
the fit. Results were expressed as Mean ± SD and the level of statistical
significance was 0.05.
Results: During IPIST, the glucose decay curve achieved a nadir (69.2±
14.4 mg/dl) at 60 min (Figure, left panel). At the end of the clamp, insulin
concentration was 50.3±2.0 μU/ml. ISI(IPIST) was 3.36±0.95 10-2 mg/
dl per min. ISI(clamp) was 10.41±1.20 10-1 mg/kg min per μU/ml. The
association between the two indices was excellent and R2 was 0.96, p=
0.001 (Figure, right panel).
Conclusion: IPIST is simple and calculation of ISI(IPIST) from glucose
data collected during the initial 15 min of the test is straightforward. The
findings of this preliminary report are encouraging since ISI(IPIST) re-
sulted extremely well correlated with ISI(clamp). If confirmed in a larger
sample of mice, IPIST may constitute a cost-effective and validated ap-
proach to measure insulin sensitivity in mice.
Supported by: University of Milan, Department of Biomedical Sciences
for Health, Project B
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Acyl-carnitines induce insulin resistance in high fat diet-fed and dia-
betic db/db mice
M. Dambrova1,2, M.Makrecka-Kuka1,2, K. Volska1, E. Sevostjanovs1, I.
Konrade2, E. Liepinsh1;
1Latvian Institute of Organic Synthesis, 2Riga Stradins University, Riga,
Latvia.
Background and aims: The important pathological consequences of
diabetes arise from the detrimental effects induced by fatty acids and their
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metabolites. The aim of this study was to test the role of long chain
acylcarnitines in the development of insulin resistance. In addition, we
tested whether pharmacological decreasing of the content of long chain
acylcarnitines represents an effective strategy to improve insulin sensitiv-
ity in diabetes.
Materials and methods: In this study acylcarnitine content was
measured in plasma and muscles of high fat diet-fed animals,
as well as diabetic db/db and control db/L mice in fasted and
fed states. Palmitoylcarnitine administration was used to study
the detrimental effects of long chain acylcarnitines. To test
whether the decreased content of acylcarnitines in skeletal mus-
cle improves insulin sensitivity, we administered a novel com-
pound, 4-[ethyl(dimethyl)ammonio]butanoate (methyl-GBB),
which effectively decreases contents acylcarnitines in plasma
and muscle.
Results: Pronounced accumulation of long chain acylcarnitines
was detected in the fed state of high fat diet-fed and diabetic
db/db mice (Fig.A). In addition, even single administration of
palmitoylcarnitine induced decrease in 2-deoxy-glucose uptake in
skeletal muscles by 47%. Long term administrat ion of
palmitoylcarnitine resulted in the insulin resistance equal to high
fat diet-induced changes in insulin sensitivity. Methyl-GBB ad-
ministration both improved glucose utilisation in tissues and insu-
lin sensitivity, and thus significantly reduced blood glucose level
in fed and fasted db/db mice (Fig.B).
Conclusion: The reduction of long chain acylcarnitine content represents
an effective strategy to improve insulin sensitivity. Methyl-GBB de-
creases contents of carnitine and acylcarnitine, significantly reduces
blood glucose concentration and improves insulin and glucose tolerance
in db/db mice.
Supported by: BIOMEDICINE, RSU
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The roles of heat shock protein 72 in hepatic glucose metabolism in
mice model of type 2 diabetes
T. Kondo1, R. Matsuyama1, S. Kitano1, R. Goto1, K. Ono1, M. Igata1,
J. Kawashima1, H. Motoshima1, T. Matsumura1, H. Kai2, E. Araki1;
1Metabolic Medicine, 2Molecular Medicine, Kumamoto University,
Japan.
Background and aims: Cell stress, such as endoplasmic reticulum stress
or oxidative stress is one of the key mediators in pathophysiology of type
2 diabetes. Molecular chaperone, which modulate protein folding and/or
assembly and protect cells from those stresses, may be a favorable target
for diabetic treatment. Heat shock protein (HSP) 72 is a major inducible
heat shock protein against heat, ultraviolet, heavy metals or infection, and
works as a molecular chaperone to protect cells from inflammatory stress-
es or apoptotic signals. Induction of HSP72 by pharmacologic agent or
mild electrical stimulation with heat shock improves glucose intolerance
in diabetic model mice. In this study, we investigated glucose metabolism
in whole body HSP72 deficient (KO) mice to explore the roles of HSP72
in diabetes.
Materials andmethods:Male HSP72KOmice or control (C) mice were
subjected to a high-fat diet (HFD) regimen for 16 weeks. Several meta-
bolic parameters and cellular stress markers were evaluated.
Results: KO mice showed significantly higher body weight after
10 weeks of HFD (KO: 36.9 g v.s. C: 33.4 g). Fasting blood glucose
was significantly elevated after 11 weeks of HFD (KO: 143.3 mg/dL
v.s. C: 115.5 mg/dL). Random fed blood glucose and food intake were
comparable. Upon glucose challenge, blood glucose levels at any time
points measured were higher in KO mice. On insulin tolerance test, KO
mice exhibited insulin resistant phenotype. Epididymal, mesenteric and
retroperitoneal fat masses were all increased in KO. Hepatic steatosis was
obvious in KO liver. Upon insulin stimulation from inferior vena cava,
phosphorylation of Akt was decreased by approximately 50% inKO liver
extracts, with increased activation of c-jun N-terminal kinase. Hepatic
gluconeogenesis was not suppressed in KO mice.
Conclusion: In summary, deficiency ofHSP72 leads to increased visceral
adiposity, hepatic insulin resistance, glucose intolerance and fatty liver.
As induction of HSP72 is beneficial to treat diabetes, our observations
strongly indicate the abundance of HSP72 is critical in diabetic
pathophysiology.
Supported by: MEXT KAKENHI JAPAN
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Western diet intervention modulates regulation of IGFBP-1 protein
in C57/Bl6 mice
I. Ansurudeen1, T. Daraio1, C. Kolonelou2, C. Bark1, K. Brismar1,
I. Valladolid-Acebes1;
1Department of Molecular Medicine and Surgery (MMK), 2Department
of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Background and aims: High calorie diet has a negative impact on glu-
cose homeostasis, insulin responsiveness and liver function, especially
during the development of adolescence. Growing evidence supports the
concept that diet-induced metabolic disturbances lead to impairments
both in the peripheral and brain insulin responsiveness, glucose utilization
and energy metabolism. However, the mechanism by which diet inter-
ventions provokes tissue-specific insulin resistance is unclear. Insulin-like
growth factor binding protein-1 (IGFBP-1), produced in the liver, modu-
lates the distribution, bioactivity and bioavailability of the IGF-I and IGF-
II proteins. Insulin is the predominant inhibitor if IGFBP-1 secretion
under normal conditions. IGFBP-1 is regulated by acute changes in nu-
trition and cellular stress. Under stress and/or intensive exercise this neg-
ative feedback between insulin and IGFBP-1 is lost possibly due to he-
patic insulin resistance or due to factors that directly stimulate IGFBP-1.
In the current study we explored in mice the effect of short-term inter-
vention with high-fat/high-sucrose diet (Western Diet, WD) during ado-
lescence and its effect in the regulation on IGFBP-1.
Materials and methods:We subjected adolescent 5-week old male and
female C57Bl/6CRmice to a 7-week diet intervention with high fat / high
sucrose (WD) or regular chow diet (CD) and studied body weight during
the diet intervention. After 7 weeks on diet we analyzed the glucagon,
insulin, glucose and IGFBP-1 plasma levels during different metabolic
conditions (starvation, after sleep phase 7 PM andwake phase 7 AM) and
performed intraperitoneal insulin tolerance tests (ipITT) and morpholog-
ical studies of the liver.
Results: After the diet intervention, we observed that the WD mice had
developed overweight, dyslipidemia, hyperglycemia and presented sig-
nificantly higher serum insulin and glucagon levels as compared to the
CD mice. The insulin levels were increased at all the metabolic condi-
tions. The IGFBP-1 fasting levels were decreased in the males but not in
the females in the WD mice. Insulin and glucose homeostasis impair-
ments detected in the WD mice were concomitant with a significant
increase in IGFBP-1 levels in spite of increased insulin levels both in
the sleep phase and wake phase. Furthermore, animals on WD
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experienced insulin intolerance in the ipITT together with an evident
deterioration of liver morphology.
Conclusion: Altogether these results suggest that high calorie diet can
increase the levels of IGFBP-1 independently of circulating insulin. He-
patic insulin resistance as well as increased glucagon may explain the
IGFBP-1 induction. These factors may also explain the increase in glu-
cose levels. It is not excluded that the increase in IGFBP-1 secretion is
secondary to WD activation of the central nervous system.
Supported by: Family Erling-Persson Foundation
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Aonlteratis in insulin signalling in insulin-sensitive tissues contribute
to insulin resistance induced by chronic intermittent hypoxia in rats
M.J. Ribeiro1, J.F. Sacramento1, T. Rodrigues2, P. Matafome2, L.N.
Diogo1, R.M. Seiça2, M.P. Guarino1,3, S.V. Conde1;
1CEDOC, Centro de Estudos de Doenças Crónicas, NOVA Medical
School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa,
2Laboratório de Fisiologia, IBILI, Faculdade de Medicina, Universidade
de Coimbra, 3UIS-Unidade de Investigação em Saúde- Escola Superior
de Saúde de Leiria- Instituto Politécnico de Leiria, Portugal.
Background and aims: Chronic intermittent hypoxia (CIH) and sleep
fragmentation are consequences of obstructive sleep apnea (OSA) that is
characterized by recurrent obstruction of the upper airways. In last year’s
several clinical studies have demonstrated that OSA is associated with an
increased prevalence of type 2 diabetes and it was recently shown to be a
risk for incident in diabetes. In fact, evidence from animal models of CIH,
that mimics OSA, shows its association with insulin resistance and dys-
lipidemia, however, the mechanisms underlying metabolic effects of CIH
are still unknown. The aim of the present work was to investigate the
effect of CIH on insulin sensitivity, exploring the time frame necessary to
induce insulin resistance and the alterations in the insulin signaling path-
ways in skeletal muscle and adipose tissue.
Materials and methods: Experiments were performed in male Wistar
rats (280-440 g). Control animals were maintained in room air atmo-
sphere and CIH rats were submitted for 28 and 35 days during their
sleeping period to a CIH paradigm: 5.6 hypoxic (5%O2) cycles/h,
10.5 h/day. At the end of CIH paradigm the animals were anaesthetized
(pentobarbitone 60 mg/Kg) and insulin sensitivity was evaluated by an
insulin tolerance test. Mean arterial pressure (MAP), plasma catechol-
amines (norepinephrine plus epinephrine) levels and adrenal catechol-
amines content were evaluated. Skeletal muscle and adipose tissue ex-
pression were collected to quantify, by western blot, alterations in the
expression of proteins involved in insulin signaling pathways.
Results: CIH during 28 and 35 significantly increased MAP. CIH Insulin
sensitivity decreased by 20.84 and 35.92% (p<0.01) with 28 and 35 days
of CIH, respectively, but not modify fasting glycemia. Plasma catechol-
amines doubled at 28 days of CIH and more than triple after 35 days of
CIH. 35 days of CIH, but not 28, decreased insulin receptor
phosphorilation by 54.94% (p<0.01) in skeletal muscle, without altering
Glut4 expression. Also, in adipose tissue, 35 days of IH, but not 28,
decreased: Akt expression by 36.25 (p<0.01), AKt phosphorilation by
36.09% (p<0.05) and insulin receptor expression by 32.49% (p<0.001).
Conclusion: We have shown that insulin resistance induced by CIH is
positively correlated with the period of time of CIH exposure. Also, our
results demonstrated that insulin resistance induced by CIH is mediated
by alterations in insulin signaling pathways in skeletal muscle and adi-
pose tissue as well as in plasma catecholamines.
Supported by: FCT-EXPL/NEU-SCC/2183/2013; PTDC/SAU-TOX/
112264/2009;Pest-C/SAU/UI3282/2011
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Changes in the adenosine / nitric oxide signalling pathways are asso-
ciated skeletal muscle insulin resistance
C.R.S. Ferreira1, I.B. Martins1, B.F. Melo1, J.F. Sacramento1, M.P.
Guarino2, S.V. Conde1;
1CEDOC, Centro de Estudos de Doenças Crónicas, NOVA Medical
School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa,
, 2UIS-Unidade de Investigação em Saúde- Escola Superior de Saúde de
Leiria- Instituto Politécnico de Leiria, Portugal.
Background and aims: Endothelial nitric oxide (NO) production is
known to be positively co-related with insulin sensitivity. It is well
established that adenosine induces NO release via A1, A2A and A2B
receptors and our group has recently described that adenosine increases
insulin sensitivity in vivo through an NO-mediated effect. The aim of the
present work was to investigate if adenosine modulates NO production in
insulin-sensitive tissues, like the skeletal muscle, the liver and adipose
tissue and if an altered interaction between adenosine andNO is present in
insulin-resistant states. Additionally, adenosine receptors responsible for
NO production in insulin-sensitive tissues were also characterized.
Materials and methods: Experiments were performed in 10-20 weeks
Wistar rats (250-450 g). Two groups of rats were used: a high-sucrose
diet-group (Hsu, 35% sucrose in drinkingwater for 28 days) and a control
group. The liver, soleus muscle and visceral adipose tissue were dissected
and incubated in Tyrode-Bicarbonate solution during 10, 30 and 60 mi-
nutes in the absence or in the presence of different concentrations of the
following adenosine agonists: Bay-60-6583 (A2B agonist), CPA (A1
agonist) and CGS-21680 (A2A agonist). Tissues were weighted and ho-
mogenized and NO in the homogenate was determined by
chemiluminescence.
Results: NO in soleus muscle was 22.86±2.54 nmol/g tissue, 20.06±
1.76 nmol/g tissue and 25.79±4.41 nmol/g tissue after 10, 30 and 60 mi-
nutes of incubation in the absence of adenosine agonists, respectively.
The HSu diet did not change NO levels either in the liver or in adipose
tissue, but in soleus muscle the NO levels were significantly increased by
35.89%, 50.42% and 41.37% when incubated during 10, 30 and 60 mi-
nutes, respectively. In control animals: CPA (3 nM) significantly increase
NO production in liver by 54,2% and 58.75% after 30 and 60 min of
incubation and in soleus muscle by 5.11%, 34.74% and 67.81% after 10,
30 and 60 minutes of incubation; CGS (30 nM) increased by 93.87%,
18.91% and 71.84% in soleus 100.64%, 68.17% and 6.81% and in adi-
pose tissue after 10, 30 and 60 min of incubation respectively, without
affecting the liver; and BAY (1 μM) did not modify NO production in
soleus muscle but decreased NO production in the liver by 53.2%, 32.0%
and 55.9% after 10, 30 and 60 min of incubation. In HSu insulin-resistant
animals: CPA (30 nM) did not alter soleus muscle NO production; BAY
(1μM) decreased NO production by 43.6%, 53.6% and 15.2% in the liver
and by 47.0%, 37.9% and 46.8% in the soleus muscle after 10,30 and
60 min of incubation.
Conclusion: In a physiological state adenosine modulates NO production
in insulin sensitive tissues via an action on A1 receptors in soleus muscle,
A2B in the liver and A2A in adipose tissue. In HSu insulin resistant
animals, NO production increases only in the soleus muscle and there is
a switch between A1 andA2B receptor in the control of NO production in
this tissue.We conclude that an altered interaction between adenosine and
NO in soleus muscle is associated with insulin resistant states.
Supported by: EXPL/NEU-SCC/2183/2013
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Role of circular dorsal ruffles in the internalisation of the insulin
receptor
M. Araújo-Correia1, A. Portelinha1, D.C. Barral1, M.P. Macedo1,2;
1Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical
School | Faculdade de Ciências Médicas, Universidade Nova de Lisboa,
2Associação Protectora dos Diabéticos de Portugal - Centro de Educação
e Investigação (APDP - ERC), Lisboa, Portugal.
Background and aims: Upon insulin binding, the insulin receptor is
rapidly internalized in clathrin-coated pits. After being endocytosed, the
clathrin coat disassembles and the activated receptors are concentrated in
endosomes to further stimulate pathways that regulate metabolism and
mitogenesis. The uncoupling of the insulin-insulin receptor complex
leads to signal termination. The receptors can then be degraded, recycled
back to the surface or translocated to the nucleus. However, the number of
receptors undergoing each pathway, how the cell decides the pathway that
receptors take and how many rounds of recycling undergo each receptor
before degradation, is currently unknown. The insulin receptor’s fate
influences peripheral insulin levels, as 50-70% of portal insulin is cleared
during the first pass in the liver. Since insulin receptor trafficking is
critical for normal development andmaintenance of homeostasis, control-
ling the magnitude and specificity of the cell’s response, it is crucial to
determine the mechanisms involved in this process, both in physiology
and pathophysiology. Our hypothesis is that alterations in the internaliza-
tion and trafficking of the insulin receptor in hepatocytes impair insulin
clearance.
Materials and methods: We used Hepa 1-6 and HUH-7 mouse and
human hepatoma cell lines, respectively, to characterize the trafficking
of the insulin receptor, in physiological conditions. For this, cells were
stimulated with various insulin concentrations (50, 75 and 100 nM), dur-
ing different time points, and processed for immunofluorescence, using
phalloidin to label the actin cytoskeleton and antibodies against the
receptor.
Results: Our results suggest that after insulin stimulation, hepatocytes
form ring-shaped actin-rich structures known as Circular Dorsal Ruffles
(CDRs). CDRs are dynamic and transient, forming exclusively on the
dorsal surface of the cell, upon growth factor stimulation. The main func-
tion of these membrane-bound structures is the rapid internalization by
macropinocytosis of tyrosine kinase receptors, like the insulin receptor.
After this step, the receptors can be recycled back to the surface, follow-
ing the recycling pathway or degraded in lysosomes. We observed that
CDRs form as soon as 1 min after insulin stimulation. Furthermore, we
found that the insulin receptor localizes to CDRs, suggesting it is inter-
nalized via this pathway.
Conclusion: Thus, our results suggest that the insulin receptors are rap-
idly internalized and recycled back to the plasma membrane through
CDRs. This fast recycling might be crucial for the liver to fulfill its
functions, especially the insulin clearance.
Supported by: FCT - PD/BD/52427/2013; PTDC/DTP-EPI/0207/2012
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Lack of CD2AP disrupts Glut4 trafficking and attenuates glucose
uptake
T.A. Tolvanen, S.N. Dash, Z. Polianskyte, V. Dumont, S. Lehtonen;
Department of Pathology, University of Helsinki, Finland.
Background and aims: Glucose transporter 4 (Glut4) is the primary
insulin responsive glucose transporter. In the absence of insulin, Glut4
resides in intracellular vesicles, and undergoes exocytosis upon insulin
stimulation. CD2-assosiated protein (CD2AP) is a ubiquitously expressed
cytoplasmic protein, which is necessary for the formation of slit dia-
phragms and glomerular ultrafiltration. Interestingly, CD2AP gene vari-
ants associate with end-stage renal disease in patients with type 1
diabetes. CD2AP functions as a scaffolding protein in different signaling
and vesicle trafficking pathways, but it is not known whether it regulates
glucose uptake into cells. In this study we investigated the role of CD2AP
in insulin-dependent Glut4 trafficking and glucose uptake.
Materials and methods: Glucose uptake was measured in immortalized
wildtype (WT) and CD2AP-/- podocytes, and in HIRC and L6 cells
transfected with CD2AP and control siRNAs, using tritium-labeled 2-
deoxyglucose in basal, serum starved and insulin stimulated conditions.
CD2AP-/- and WT podocytes stably expressing HA-Glut4-GFP were
surface-labelled with an antibody against HA to quantify the amount of
Glut4 on the plasma membrane. HA-Glut4-GFP expressing podocytes
were also used to study the trafficking of Glut4 by live cell imaging,
and to quantify the circulation of Glut4 between the intracellular com-
partment and the plasma membrane in a time-dependent manner.
Results: In the basal state lack of CD2AP attenuated glucose uptake into
podocytes by 20% compared to WT cells (p<0.05). Also knockdown of
CD2AP in HIRC and L6 cells by siRNA reduced glucose uptake by 25%
(p<0.05). Insulin stimulation induced glucose uptake into WT podocytes
by 20% (p<0.05), whereas CD2AP-/- podocytes failed to respond. In line
with this, insulin stimulation increased the amount of HA-Glut4-GFP on
the plasma membrane by 50% in WT podocytes (p<0.01), whereas no
difference was observed in CD2AP-/- podocytes. In WT podocytes, live
cell imaging revealed dynamic trafficking of HA-Glut4-GFP in response
to insulin, whereas in CD2AP-/- podocytes HA-Glut4-GFP formed dense
insulin unresponsive clusters. Quantification of HA-Glut4-GFP on the
plasma membrane in a time-dependent manner after insulin stimulation
revealed that in WT podocytes the amount of Glut4 on the plasma mem-
brane increased by 30% after 5 minutes (p<0.01), and by 270% after
30 minutes (p<0.001). In CD2AP-/- podocytes, however, there was no
difference in the amount of HA-Glut4-GFP on the plasma membrane
after insulin stimulation for 5 minutes. After 15 minutes, there was a
50% increase (p<0.001), which did not significantly increase by 30 mi-
nutes (p<0.22).
Conclusion: Our results indicate that CD2AP is essential for regulating
glucose uptake into podocytes and other insulin responsive cells. CD2AP
appears to be vital for sorting of endocytosed Glut4 to correct insulin
sensitive compartments and insulin-responsive trafficking of Glut4 to
the plasma membrane in podocytes.
Supported by: ERC, DPBM craduate shcool
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MicroRNAs potentially regulators of GLUT4
J.V.D. Esteves1, C.Y. Yonamine1, F. Gerlinger-Romero1, D.C. Pinto-Ju-
nior1, M.M. Okamoto1, F.J. Enguita2, U.F. Machado1;
1Physiology and Biophysics, University of São Paulo, Brazil, 2University
of Lisbon, Portugal.
Background and aims:Diabetes is a metabolic disease characterized by
hyperglycemia associated with impaired glucose uptake, in which re-
duced GLUT4 protein expression (encoded by the SLC2A4 gene) plays
an important role. The recently described microRNAs (miRNAs), which
are small RNAs involved in gene regulation at the post-transcription
level, usually by affecting the stability and degradation of mRNAs, have
been described as involved in the pathophysiology of diabetes. However,
the miRNAs participation in the reduction of GLUT4 expression, conse-
quently in impaired glucose uptake, especially in skeletal muscle, remains
unclear. Thus, the objective of this study was to investigate the expression
of miRNAs potentially involved in the regulation of Slc2a4/GLUT4 ex-
pression in skeletal muscle of diabetic rats.
Materials and methods: Male Wistar rats (70-day old) were rendered
diabetic by receiving streptozotocin (50 mg/kg, i.v.), After 13 days, 3
groupswere formed: non-diabetic (ND), and diabetic treated with placebo
(DP) or insulin (DI) (NPH insulin, 6U/day). Treatment was conducted for
7 days, totalizing 21 days of diabetes. At the end of the experimental
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period, the animals were anesthetized, blood was collected and the soleus
muscle was removed for evaluation of mRNA and protein expression. In
silico analysis was used to select miRNAs predicted as potential regula-
tors of Slc2a4/GLUT4 in rat. After that, based on previous description of
diabetes-induced modulation of the miRNAs, and/or their participation in
the skeletal muscle cell homeostasis, some miRNAs were selected for
validation. The Slc2a4 mRNA and the miRNAs were analyzed by qPCR.
The GLUT4 protein was assessed by Western blotting. The comparison
among groupswas performed by analysis of variance (ANOVA) followed
by Bonferroni post-test.
Results: Diabetic rats developed hyperglycemia, glycosuria and in-
creased plasma fructosamine; insulin treatment improved these parame-
ters. Diabetes reduced (P<0.01) by 60% and 40% the Slc2a4 mRNA and
GLUT4 protein; insulin treatment was able to restore these parameters
completely. In silico analysis scored 32 miRNAs, predicted by at least 3
algorithms, as potential regulators of Slc2a4/GLUT4 expression. From
these, 10 miRNAs were selected for validation: miR-1, miR-29a, miR-
29b, miR-31, miR-93, miR-106b, miR-133a, miR-133b, miR-199a and
miR-206. Four of these miRNAs were modulated by diabetes in skeletal
muscle: MiR-1 and miR-29b were upregulated by 28% and 119%, re-
spectively (P<0.05 and P<0.01), and miR-93 and miR-199a were down-
regulated by 39% and 30%, respectively (P<0.05). Insulin treatment was
able to fully restore the expression of the miR-29b, miR-93 and mir-199,
but had no effect upon miR-1.
Conclusion: This study shows that diabetes represses the Slc2a4/GLUT4
expression in soleus muscle, and that may be related to enhanced miR-1
and miR-29b and repressed miR-93 and miR-199 activity. Except by
miR-1 overexpression, insulin treatment was able to reverse all the
diabetes-induced regulations, which can be fundamental to improve the
skeletal muscle glucose uptake in diabetes.
Supported by: FAPESP #2012/20432-0 and #2012/04831
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APPL1 promotes mechanical stretch induced glucose uptake
through PKCζ-Myosin IIa pathway in C2C12 myotubes
T. Saito, Y. Shimoda, Y. Tagaya, A. Osaki, E. Yamada, S. Okada, M.
Yamada;
Molecular Science and Internal Medicine, Gunma University, Maebashi,
Japan.
Background and aims: Adaptor protein, phosphotyrosine interaction,
PH domain and leucine zipper containing 1 (APPL1) promotes insulin
or adiponectin induced glucose uptake via protein kinase B (PKB/Akt) or
5' adenosine monophosphate-activated protein kinase (AMPK) depen-
dent pathway. We have reported that APPL1 also promotes mechanical
stretch induced glucose uptake through PKCζ dependent pathway in
C2C12 myotubes, but the mechanism was unknown. Therefore, this
study aimed to investigate the mechanism of PKCζ dependent pathway
involved in glucose uptake stimulated by mechanical stretch.
Materials and methods: C2C12 myoblasts were grown on an elastic
silicone chamber and induced differentiation. Differentiated C2C12
myotubes were stimulated by cyclic uniaxial stretch (10% of initial
length, 10 cycle/min) for 5 hours. Plasmid DNA was transfected into
C2C12 myoblasts by electroporation. Glucose uptake was measured by
enzymatic assay and the localization of PKCζ was examined by immu-
nofluorescence. To find the binding partner of PKCζ, PKCζ was
immunoprecipitated from cell lysates and analyzed by MS/MS.
Results: Mechanical stretch statistically increased PKCζ phosphoryla-
tion by 30% and translocation to plasma membrane in APPL1 over-
expressed myotubes compared to control cells. To investigate PKCζ
pathway, we have tried to find PKCζ binding partner. Mass spectrometry
analysis revealed non-muscle myosin IIa binds phosphorylated PKCζ by
immunoprecipitation in APPL1 over-expressed cells. This interaction
was confirmed by western blotting. Furthermore, blebbistain, myosin
IIa ATPase inhibitor, suppressed PKCζ phosphorylation, translocation
and glucose uptake to the basal level.
Conclusion: These results suggest that APPL1 promotes stretch induced
glucose uptake through PKCζ-myosin IIa pathway.
Supported by: JSPS KAKENHI
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Favorable actions of Insulin-like Growth Factor Binding Protein
(IGFBP)-1 and its RGD domain in insulin sensitivity and glucose
regulation
N. Haywood, P. Cordell, N. Yuldasheva, J. Smith, M. Kearney, S.
Wheatcroft;
LIGHT LABS, The University of Leeds, UK.
Background and aims: In prospective studies, low circulating levels of
IGFBP1 predict the development of type 2 diabetes. We have previously
shown that in vivo over expression of IGFBP1 improves insulin sensitiv-
ity and protects against atherosclerosis. IGFBP1 can impact on cellular
functions via an RGD (α5β1 integrin binding) motif independent of IGF
binding. However, whether IGFBP1 is causally implicated in insulin
sensitivity and glucose regulation and could be exploited therapeutically
remains unexplored.
Materials and methods: C2C12 myotubes, 3 T3 adipocytes, HepG2
hepatocytes and INS823/13 pancreatic β-cells, were used to investigate
the effects of acute treatment of rIGFBP1 and the synthetic hexapeptide
GRGDTP (which binds α5β1-integrin) on the insulin sensitivity and glu-
cose regulation, through several complimentary in vitro assays. To exam-
ine whether the RGD motif of IGFBP1 is mechanistically implicated in
glucose regulation, we administered GRGDTP peptide to both C57BL/6
mice with diet-induced obesity and KKAy diabetic Mice.
Results: Treatment of C2C12 myotubes with rIGFBP1 or GRGDTP,
enhanced insulin stimulated IRS1, AKT phosphorylation and insulin
stimulated glucose uptake (P≤0.05, ≤0.02 and P≤0.01 respectively). En-
hanced insulin sensitivity is mediated through integrin engagement and
focal adhesion kinase. Co-incubation with glucose and IGFBP1 or
GRGDTP, increased glucose stimulated insulin secretion in INS823/13
pancreatic β-cells (P≤0.01 and ≤0.05 respectively) and is dependent up-
on integrin linked kinase. Acute administration of GRGDTP significantly
improved glucose clearance and insulin sensitivity in mice with diet-
induced obesity and KKAy diabetic mice (P≤0.05). Long term adminis-
tration of GRGDTP had no detrimental effect.
Conclusion: We have shown that the RGD integrin-binding domain of
IGFBP1 may play an important role in insulin sensitivity and glucose
regulation and representsa potential novel therapeutic agent in the field
of type 2 diabetes that requires further investigation.
Supported by: The authors would like to acknowledge the support of the
BHF and ERC
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Transcriptome profiling in lympho-monocytes of healthy subjects
identifies a biomarker of early insulin resistance with potential im-
plications in chronic heart failure
E. Derlindati1, A. Matone2, V. Spigoni1, L. Marchetti2, D. Ardigò1, V.
Curella1, A. Dei Cas1, I. Zavaroni1, C. Priami2, R.C. Bonadonna1;
1Dept. of Clinical and Experimental Medicine, University of Parma,
2Centre for Computational and System Biology (COSBI), The Microsof
Research-University of Trento, Rovereto, Italy.
Background and aims: Gene expression profile (GEP) of peripheral
blood mononuclear cells (PBMCs) is significantly affected by various
diseases and may serve as biomarker of pathological changes occurring
in other tissues. The aim of our study was to investigate whether insulin
resistance (IR) per se is characterized by a specific pattern of GEP.
Materials and methods: 150 healthy young adults, were recruited in a
cardiovascular risk assessment study (Multi-Knowledge project).Two
groups of 10 subjects with extreme HOMAIR indices (High
HOMA:4.0±2.8; Low HOMA:0.5±0.1), but with normal, similar BMI
(22.2±2.6 vs 22.5±2.2 kg/m2), and comparable age (33.9±6.2 vs 40.2±
11.3 years) and gender (7 M and 3 F in both groups) were selected.
Standard anthropometric, hemodynamic, and metabolic variables were
assessed. GEP of PBMCs from all subjects was evaluated using Agilent
whole genome oligonucleotide mRNA microarrays. Data were analyzed
with a novel ad-hoc rank-based classification method, optimized to ex-
tract a gene expression signature with highest power and statistical sig-
nificance (p at least<0.005) to discriminate the two groups. Gene enrich-
ment analysis was applied on the significant differentially expressed list
of genes. All analyses were performed with R and Matlab.
Results:We identified a set of 512 probes corresponding to 321 annotat-
ed genes which summarize the characteristics of each sample and allow
distinguishing Low HOMA and High HOMA subjects with an accuracy
of 100%, according to a 5-fold cross-validation approach. Gene enrich-
ment analysis of the 321 genes showed significant enrichment for the
KEGG pathway “Adrenergic signaling in cardiomyocytes”, in which
differentially expressed genes were compatible with a cluster of alter-
ations, including increased intracellular cAMP and Ca2+ and accelerated
apoptosis in the High HOMA group. We hypothesized that this pathway
should biomark chronic heart failure (CHF), of which IR is a known risk
factor. In two publicly available gene expression data sets (GSE21125
and GSE9128) we investigated whether the genes in the pathway of
interest could differentiate between patients with CHF and controls.
Two biomarkers (length 41 and 22, respectively) were found with high
discriminant accuracy (95%), at a significant p value (p<0.02), overlap-
ping with the “adrenergic signaling in cardiomyocytes” pathway.
Conclusion: GEP of the “adrenergic signaling pathway in
cardiomyocytes” in lymphomocytes is a fingerprint of IR and is implicat-
ed also as a biomarker of patients with CHF. This may be a major mo-
lecular platform linking IR to CHF.
Supported by: "Multi-Knowledge project”, reference: FP6-IST–2004-
027106
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Mitochondrial respiratory capacity of peripheral bloodmononuclear
cells associates with insulin resistance
K. Kaul1, T. Jelenik1, B. Menart1, R. Rütter1, B. Nowotny1, J.
Szendrödi1,2, M. Roden1,2;
1Institute of Clinical Diabetology, 2Department of Endocrinology and
Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf,
Germany.
Background and aims: Subclinical inflammation contributes to the de-
velopment of insulin resistance. In adipose tissue, infiltration by pro-
inflammatory M1 macrophages has been linked to insulin resistance
through release of tumor necrosis factor alpha and enhanced reactive
oxygen and nitrogen intermediates. Pro-inflammatory M1 macrophages
have higher non-oxidative respiration at resting stage, coupled with
higher generation of reactive oxygen species. We aimed to study the
association between whole-body insulin resistance and mitochondrial
respiration in monocytes in circulation and systemic oxidative stress.
Materials and methods: Recently diagnosed type 2 diabetes patients
(T2D) and lean individuals (CON) were recruited from the German Dia-
betes Center Study (GDS), and underwent thorough metabolic and blood
analysis, including hyperinsulinemic-euglycemic clamps to assess whole-
body insulin sensitivity (M-value). Leukocytes were isolated from fasting
blood samples using density gradient centrifugation. Mitochondrial res-
piration was measured in isolated leukocytes using multiple substrate
protocols and high-resolution respirometry. Tricarboxylic acid cycle ac-
tivity was assessed by using saturating concentrations of malate, gluta-
mate, succinate and adenosine diphosphate. Beta-oxidation was mea-
sured in response to octanoyl carnitine. Finally, maximal respiration ca-
pacity in the uncoupled state u was investigated using the uncoupler
carbonyl cyanide-4-trifluoromethoxy phenylhydrazone (FCCP). Leak
respiration was measured in response to ATPase inhibitor, oligomycin.
The coupling efficiency of the mitochondrial complexes was assessed as
the ratio of leak respiration to maximal respiration, known as the leak
control ratio. Mitochondrial content was assessed by citrate synthase
activity (CSA) in the leukocytes. Heparinized blood was used for the
quantification of the ratio of CD11 positive M1 and CD 206 positive
M2 macrophage subsets. Lipid peroxidation measured by thiobarbituric
acid reactive substances assay (TBARS) was performed to assess system-
ic oxidative stress.
Results: Rates of oxygen consumption by leukocytes were markedly
lower in patients with T2D than in CON (State u: 4.0±1 vs 8.3±1.3
pmol/s/mg protein, P<0.05). Maximal beta-oxidation was also lower in
leukocytes of T2D (3.9±0.7 vs 6.2±0.6 pmol/s/mg protein, P<0.05).
CSA did not differ between groups. The leak control ratio was higher in
T2D indicating lower mitochondrial coupling efficiency and thus a source
of reactive oxygen species (0.5±0.07 vs 0.2±0.04, P<0.05). The ratio of
M1:M2 expression was also higher in leukocytes of T2D (0.2±0.01 vs
0.1±0.01, P<0.05) in line with a pro-inflammatory phenotype. TBARS
in plasma was higher in T2D compared to CON (2±0.2 vs. 1±0.2 μM).
Leukocyte state u respiration associated positively to whole-body insulin
sensitivity (M-value: R=0.45, P<0.05) and negatively with TBARS
(R=-0.49, P<0.005). Beta-oxidation also related positively to M-value
(R=0.57, P<0.05) and negatively to total blood cholesterol (R=-0.47, P<
0.05).
Conclusion: Lower mitochondrial respiration in circulating leukocytes
may influence pro-inflammatory polarization of leukocytes and contrib-
ute to oxidative stress, which have been related insulin resistance.
Clinical Trial Registration Number: NCT01055093
Supported by: Ministry of Science/Research NRW (MIWF NRW), Ger-
man BMG, BMBF to DZD e.V.
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Sclerostin and insulin resistance in prediabetes. Evidence of a cross-
talk between bone and glucose metabolism
G. Daniele1, D. Winnier1, A. Mari2, J. Bruder3, M. Fourcaudot1, Z.
Pengou1, D. Tripathy1, C. Jenkinson1, F. Folli1;
1Medicine/Diabetes, UTHSCSA, San Antonio, USA, 2Medicine/Diabe-
tes, Institute of Neuroscience, Padova, Italy, 3Medicine/Endocrinology,
UTHSCSA, San Antonio, USA.
Background and aims: Sclerostin is a peptide inhibiting Wnt/β-catenin
signaling. Impaired glucose regulation (IGR), which includes impaired
fasting glucose (IFG) and/or impaired glucose tolerance (IGT), is charac-
terized by insulin resistance and altered insulin secretion, two key patho-
physiological features preceding the development of type 2 diabetes. Our
aims were to evaluate serum sclerostin levels in IGR subjects and to
analyze its relationship with insulin-resistance and β-cell function
Materials and methods: In a cross-sectional study, 43 healthy normal
glucose tolerant (NGT) individuals (12 male and 31 women; age=44.0±
1.9 years; BMI=31.1±1.1 Kg/m2) and 79 individuals with impaired glu-
cose regulation (IGR) (22 male and 57 women; age=46.0±1.4 years;
BMI=31.9±1.2 Kg/m2) which included subjects with IFG (n=27), IGT
(n=18) and combined IFG/IGT (n=34), underwent OGTT and DXA.
Serum sclerostin levels were measured at fasting. β-cell function param-
eters were calculated using C-peptide deconvolution. Dynamic indexes of
insulin sensitivity were calculated from OGTT. A subgroup (n=18 with
NGTand n=30 with IGR) underwent to an euglycemic hyperinsulinemic
clamp with 3-3H-glucose to estimate the endogenous glucose production
(EGP) and the rate of insulin-mediated total body glucose disposal (TGD/
SSPI)
Results: Sclerostin levels were higher in IGR as compared to NGT (50.8
±2.4 vs. 38.7±2.3 pmol/l; p=0.01). IFG and combined IFG-IGT mani-
fested higher sclerostin levels compared to NGT (55.8±2.9 and 50.8±5.1
vs. 38.7±2.3 pmol/l; p=0.02, respectively) while no difference was found
between isolated IGTandNGT. Inwhole population serum sclerostin was
correlated with HOMA-IR (r=0.62), OGIS (r=-0.38), Matsuda Index
(r=-0.42), adipose tissue insulin resistance index (ATIRI) (r=0.61) and
TGD/SSPI (r=-0.40) (all p<0.001) although subjects with isolated IFG
were mostly accountable for the correlations with insulin sensitivity in
skeletal muscle (r=0.63 HOMA-IR; r=- 0.55; Matsuda Index; r=- 0.64
OGIS; r=- 0.57 TGD/SSPI), liver (r=0.61; fasting EGP) and adipose
tissue (r=0.71 ATIRI) (all p<0.05). EGP, hepatic insulin resistance and
ATIRI were correlated with sclerostin levels (r=0.48 and r=0.62; r=0.61;
p<0.001). Fasting and OGTT insulin clearance were correlated with
sclerostin serum levels (r=-0.52 and r=-0.44; both p<0.001) but no cor-
relations were found with β-cell function parameters. In multiple linear
regression analysis, sclerostin levels improved the r2 associated to
HOMA-IR (r2=0.192 to 0.247) to TGD/SSPI (r2=0.518 to 0.577).
Sclerostin levels were positively correlated with fasting plasma glucose
(r=0.22; p=0.01), fasting and 2-hours plasma insulin (r=0.63 and r=0.45
respectively; p<0.001) and HbA1c (r=0.18; p=0.04). IFG and combined
IFG-IGT were accountable for the correlation between sclerostin levels
and fasting plasma insulin (r=0.64 and r=0.52; p<0.01) and 2-hours
plasma insulin (r=0.72; p<0.01 and r=0.29; p=0.08)
Conclusion: Sclerostin levels are increased in IGR individuals and cor-
related with insulin-resistance in skeletal muscle, liver and adipose tissue.
These data suggest that sclerostin might play a role in determining insulin
resistance possibly acting on insulin clearance and degradation
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Elevated circulating microRNA-143-3p is associated with insulin re-
sistance in the metabolic syndrome
X. Lin, D. Yu, Z. Xu, Q. Pan, X. Yin, J. Zhou, F. Zheng, H. Li;
Department of Endocrinology,The Affiliated Sir Run Run ShawHospital,
Zhejiang University, Hangzhou, China.
Background and aims:Metabolic syndrome (MetS) is a cluster of car-
diovascular risk factors that includes obesity, diabetes, and
dyslipidemia.Insulin resistance(IR) is the most accepted unifying theory
e x p l a i n i n g t h e p a t h o p h y s i o l o g y o f t h e m e t a b o l i c
syndrome.Accumulating evidence implies that circulating microRNAs
(miRNAs) are involved in the regulation of MetS,but existing studies
have yielded inconclusive results. Examining the associations of circulat-
ing miRNAs levels with MetS and insulin sensitivity in human may lead
to improved insight.
Materials and methods: The genome-wide circulating miRNA profiles
were detected via microarray in serum samples from 4 patients withMetS
and 4 control without MetS. Elevated miR-143-3p was selected and val-
idated in individual serum and urine samples from 50 MetS pa-
tients(52.0% men) and 50 control (48.0% men) subjects. Associations
between circulating miR-143-3p levels and parameters related to adipos-
ity, insulin resistance, lipid profiles and hepatic enzymes were further
assessed.
Results: Eleven miRNAs were found to be expressed differently in the
sera of MetS patients compared to control subjects (p<0.001). Further
qRT-PCR analyses confirmed that circulating miR-143-3p was increased
significantly in MetS compared with controls (p<0.001) both in the se-
rum and urine samples. Serum and urine miR-143-3p levels were corre-
lated with homeostasis model assessment of insulin resistance (HOMA-
IR) (r=0.726,0.624), high density lipoprotein-cholesterol (r=-0.321,-
0.473) and percentage of body fat(Fat%)(r=0.307,0.392,all p<0.001).
After controlling for confounding factors, miR-143-3p remained an inde-
pendent risk factor for insulin resistance (OR=10.500, 95% CI=1.329 -
24.93 for surem, OR=3.225, 95% CI=1.073 - 9.687 for urine,both p<
0.001).
Conclusion: Elevated circulating miR-143-3p is positively associated
with MetS and insulin resistance. These findings provide a better under-
standing regarding the role of circulating miRNAs in insulin sensitivity.
Supported by: NSFC (81270924)
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Bone turnover markers and prediabetes in humans
D. Winnier1, G. Daniele1, A. Mari2, J. Bruder3, M. Fourcaudot1, Z.
Pengou1, D. Tripathy1, C. Jenkinson1, F. Folli1;
1Medicine/Diabetes, UTHSCSA, San Antonio, USA, 2Medicine/Diabe-
tes, Institute of Neuroscience, Padova, Italy, 3Medicine/Endocrinology,
UTHSCSA, San Antonio, USA.
Background and aims: Recent studies have suggested a link between
bone remodeling and glucose metabolism. The aim of the study was to
examine the relationship between hormones involved in bone remodeling
and glucose metabolism alterations in subjects with impaired glucose
regulation (IGR), which is known to lead to type 2 diabetes mellitus
Materials andmethods:We performed a cross-sectional study including
43 healthy normal glucose tolerant (NGT) individuals (12 male and 31
women; age=44.0±1.9 years; BMI=31.1±1.1 Kg/m2) and 79 individ-
uals with impaired glucose regulation (IGR) (22 male and 57 women;
age=46.0±1.4 years; BMI=31.9±1.2 Kg/m2) which included subjects
with IFG (n=27), IGT (n=18) and combined IFG/IGT (n=34), undergo-
ing OGTT and DXA. Osteopontin, Osteocalcin, Osteoprotegerin and
PTH were measured at fasting. β-cell function parameters were calculat-
ed using C-peptide deconvolution. Dynamic indexes of insulin sensitivity
were calculated fromOGTT (SI, OGIS and Stumvoll). A subgroup (n=18
with NGT and n=30 with IGR) underwent in addition to an euglycemic
hyperinsulinemic clamp with 3-3H-glucose to estimate the endogenous
glucose production (EGP) and the rate of insulin-mediated total body
glucose disposal (TGD/SSPI)
Results:Osteopontin levels were higher in IGR as compared toNGT (5.3
±0.5 vs. 3.3±0.2 μg/ml; p=0.008) while osteocalcin, osteoprotegerin and
PTH were similar in both groups. Osteopontin levels were higher in
isolated IGT as compared to isolated IFG and IFG/IGT (6.3±0.5 vs. 4.5
±0.3 and 5.4±0.5 μg/ml; p=0.02). Osteocalcin levels were similar be-
tween IFG and NGT (8.0±0.5 vs. 8.3±0.3 ng/ml; p=0.74) but lower in
isolated IGTand IFG/IGTas compared to NGT (7.2±0.3 and 5.4±0.2 vs.
8.3±0.3 ng/ml; p<0.01). Osteoprotegerin and PTH levels were similar
between glucose tolerance subgroups in IGR subjects. Osteopontin levels
positively correlated with HbA1c, fasting and 2 h plasma glucose and
PTH (r=0.20; r=0.21; r=0.26 and r=0.26; all p<0.05). Conversely,
osteocalcin levels were negatively correlated with body fat, 2 h plasma
glucose, insulin (r=- 0.25; r=- 0.18; r=- 0.21, all p<0.05) and positively
correlated with Stumvoll index (r=0.21; p<0.05). Osteoprotegerin levels
correlated with TGD/SSPI (r=-0.29; p<0.05) and with EGP and Hepatic
Insulin Resistance Index in IGR subjects (r=0.51 and r=0.43; p<0.01).
PTH did not correlate with insulin sensitivity and β-cell function
parameters
Conclusion: Osteopontin and osteocalcin were inversely correlated with
glucose metabolism parameters. Interestingly, in IGR subjects osteopro-
tegerin levels were strongly associated with increased EGP and increased
insulin resistance in skeletal muscle and liver. In prediabetes, hormone
known to be involved in bone remodeling may directly affect glucose
metabolism before overt type 2 diabetes occurs
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The adipokine Zinc-α2-Glycoprotein (ZAG) is downregulated with
insulin sensitivity in polycystic ovary syndrome
Y. Chang1,2, L. Li1,2, G. Yang3;
1Key Laboratory of Diagnostic Medicine (Ministry of Education) &De-
partment of Clinical Biochemistry, 2College of Laboratory Medicine,
3Department of Endocrinology, the Second Affiliated Hospital, Chong-
qing Medical University, China.
Background and aims: Zinc-alpha2-glycoprotein(ZAG) is a novel
adipokine,which can act locally to influence adipocyte metabolism. Re-
cent studies have shown that ZAG decreases in type 2 diabetes mellitus,
which suggest that ZAG is likely to associate with insulin
resistance(IR).Meanwhile,polycystic ovary syndrome (PCOS) character-
ized by androgen eccess is also linked to IR. Currently, no report has
demonstrated any relationships between ZAG and IR in a relative large
population of PCOS. The aim of the current study is to investigate wheth-
er ZAG correlates with IR in PCOS women.
Materials andmethods: 99 PCOSwomen and 100 healthy age-matched
control subjects were recruited. Euglycemic- hyperinsulinemic clamps
(EHCs) were performed to assess their insulin sensitivity, which was
expressed as M-value. Circulating ZAG was measured with ELISA kit.
Plasma glucose and HbA1c were measured by the glucose oxidase meth-
od and HPLC,respectively. Plasma insulin was detected by radioimmu-
noassay. Plasma TC, HDL, LDL, and TG were analyzed enzymatically
using an autoanalyzer. The percentage of body fat (FAT%) was deter-
mined by bioelectrical impedance. HOMA-IR=fasting insulin (FIns,
mU/L)×fasting blood glucose (FBG, mmol)/22.5. The area under the
curve for glucose (AUC glucose) and insulin (AUC insulin) during the
OGTTwas calculated geometrically using the trapezoidal rule.The ROC
curves of ZAG was analyzed to investigate the predictive value of ZAG
for PCOS.
Results: Circulating ZAG and M-value were much lower in PCOS than
in controls (35.3±18.3 vs. 53.9±15.3 mg/L for ZAG; 5.9±2.9 vs. 10.1±
2.6 mg/kg/min for M-value, both P <0.01). Pearson correlations showed
that in PCOS , ZAG correlated positively with M-value and negatively
with BMI, FAT%, TG, FIns, HbA1c, HOMA-IR, AUCglucose and
AUCinsulin. Multiple linear regression analysis revealed that only M-
value and AUCglucose were independently related factors to ZAG in
PCOS. Multivariate logistic regression analysis showed that ZAG was
associated significantly with PCOS even after controlling for anthropo-
metric variables, blood pressure, lipid profile and hormones. The ROC
curve analyses revealed that the best cutoff value for ZAG to diagnose
PCOS was 42.6 mg/L(sensitivity 84.0%, specificity 77.8%).
Conclusion: Circulating ZAG is reduced in PCOS and is associated with
IR,which suggests that ZAG may play a role in the pathogenesis of IR in
PCOS ,and even become a marker of insulin resistance that predicts
outcomes and therapeutic responses to assist clinical management of
PCOS.
Clinical Trial Registration Number: ChiCTR-OCS-13003185
Supported by: National Natural Science Foundation of China
(81100567, 813006)
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Acute exercise impacts kynurenine metabolism in type 2 diabetic and
healthy people
J.M. Mudry1, J.L. Ruas2, S. Erhardt2, K. Caidahl1, J.R. Zierath1, A.
Krook2, H. Wallberg-Henriksson2;
1Molecular medicine and surgery, 2Physiology and Pharmacology,
Karolinska Institutet, Stockholm, Sweden.
Background and aims: Tryptophan (Trp) is an essential amino acid and
a primary source for the synthesis of neurotransmitters and signalling
peptides such as serotonin and kynurenine (KYN). KYN is the substrate
for two different neuro-active metabolites with opposing effects:
kynurenic acid (KYNA) or quinolinic acid (QUIN). Kynurenine amino-
transferase (KATs) enzymes catalyse the conversion of KYN intoKYNA.
In contrast to KYN, KYNA does not cross the brain blood barrier. KYN
entry into to the brain is associated with psychiatric disorders such as
schizophrenia or depression. Reductions in circulating KYN coupled to
resistance to depression. Exercise and PGC1α overexpression in skeletal
muscle increases skeletal muscle KATs mRNA expression, thus enhanc-
ing conversion of KYN into KYNA in the periphery. Given that type 2
diabetic (T2D) patients are prone to depression, we determined whether
resting and exercise-induced KATs expression and circulating KYN and
KYNA concentration are altered compared to people with normal glucose
tolerance (NGT).
Materials and methods: We recruited sedentary T2D age- and BMI-
matched NGT volunteers. Subjects underwent clinical phenotyping and
VO2max testing. Subjects performed a 30minute exercise bout on a cycle
ergometer at 80% of VO2max. A vastus lateralis muscle biopsies and
plasma sample was collected at rest, after exercise and during recovery
(3 hours post-exercise). Skeletal muscle mRNA expression of KATs and
metabolism-related genes, as well as plasma measurement of Trp, KYN
and KYNA were determined. Statistical analysis was performed using
repeated measures two-way ANOVAwith Bonferroni post-tests.
Results: Exercise increased PGC1α mRNA expression in skeletal mus-
cle as expected. Skeletal muscle mRNA expression of KAT1 and KAT2
was reduced in T2D, while acute exercise altered KAT4 expression in
both NGT and T2D subjects. Plasma concentrations of Trp and KYN
were decreased and KYNA increased in response to exercise.
Conclusion: mRNA expression of KATs is reduced in skeletal muscle
from T2D patients. However, KATs mRNAwas not correlated with acute
variations in plasma levels of KYN or KYNA. Acute exercise (30 min)
reduces plasma level of Trp and KYN and increases KYNA over 3 hours,
indicating that exercise directly alters KYN/KYNA balance in the
circulation.
Supported by: Swedish Research Council; Novo Nordisk Foundation
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Analysis of anti-insulin receptor antibody in two patients with rheu-
matoid arthritis and systemic lupus erythematosus
K. Fujioka1, M. Asano1, T. Ishizuka1, H. Okada2, I. Mori3, K. Kajita3, H.
Morita3;
1General Internal Medicine, Gifu Municipal Hospital, 2General Internal
Medicine, Gifu Prefectual General Medical Center, 3General Internal
Medicine, Gifu University Graduate School of Medicine, Gifu City, Ja-
pan.
Background and aims: Type B insulin resistance syndrome (IRS) pro-
posed by Flier et al in 1976, is a rare autoimmune disease characterized by
the presence of autoantibodies against the insulin receptor. The majority
of the patients present marked hyperglycemia and compensated
hyperinsulinemia, but some patients may present with hypoglycemia
caused by an insulin-like effect of the receptor autoantibodies. A common
feature of type B IRS is the co-occurrence of autoimmune disorders, such
as systemic lupus erythematosus (SLE) and rheumatoid arthritis(RA). We
have reported here 2 cases of novel type B IRS presented with hypogly-
cemia and unstable diabetes control in a patient with SLE and RA,
respectively.
Materials and methods: Two Japanese woman were examined. One
women have RA and the another woman have SLE. We examined an
insulin receptor antibody by immunoprecipitation method.
Results: Case1. 17 years old Japanese woman had both shoulders and
cubital arthralgia, butterfly rash, stomatitis, photoallergy, and proteinuria
were presented, suggesting SLE with lupus nephritis (WHO classII) di-
agnosed by renal biopsy. Moreover, hypoglycemia (less than 60 mg/dl)
were appeared with hyperinsulinemia (IRI90.7 μ l /ml and
CPR11.5 ng/ml). We examined an insulin receptor antibody by immuno-
precipitation method. We identified the 95 kDa band which showed anti-
insulin receptorβ subunit antibody using patient’s serum.When we treat-
ed with mycophenolate mofetil and predonisolone (30 mg/day), the hy-
poglycemia and pyrexia had been disappeared. Case2. 52 years old Jap-
anese woman have been suffered with rheumatoid arthritis treated with
salazosulfapyridine, methotrexate and tacrolimus. General fatigue and
hyperglycemia (300 mg/dl) appeared. When intensive insulin therapy
had been started, her glycemic control was poor with hyperglycemia
(>400 mg/dl) and hypoglycemia (<40 mg/dl). We identified the
135 kDa band which showed anti-insulin receptor α subunit antibody.
Etanercept treatment improves rheumatoid arthritis and glucose control in
accodance with amelioration of insulin resistance and vanishing of
hypoglycemia.
Conclusion: When hypoglycemia and unstable control of diabetes oc-
curred in autoimmune disease such as SLE and rheumatoid arthritis, we
should be suspicious of type B insulin resistance syndrome.
Supported by: A-15-1027-EASD
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Association of faecal elastase 1 with non-fasting triglycerides in type 2
diabetes
J. Oscarsson1, W. Rathmann2, B. Haastert3, N. Berglind1, B. Lindkvist4,
N. Wareham5;
1AstraZeneca R&D, Mölndal, Sweden, 2Institute for Biometrics and Ep-
idemiology, Dusseldorf, 3mediStatistica, Neuenrade, Germany,
4Sahlgrenska Academy, Göteborg, Sweden, 5MRC Epidemiology Unit,
Cambridge, UK.
Background and aims:Morphological alterations and moderate impair-
ment of exocrine pancreatic function are present in patients with type 2
diabetes. Despite the fact that decreased pancreas lipase activity is a
hallmark for pancreatic exocrine insufficiency, little is known about the
impact of exocrine pancreatic function on plasma triglycerides. More-
over, studies specifically investigating the metabolic importance of a mild
impairment of pancreatic exocrine function demonstrated as a low fecal
elastase-1 (FE1) levels in patients with diabetes are lacking. We investi-
gated the association between FE1 and non-fasting triglycerides in pa-
tients with type 2 diabetes and controls.
Materials and methods: Data from 544 patients with type 2 diabetes
(age: 63±8 years) randomly selected from diabetes registers, and 544
matched controls (age, sex, practice) without diabetes were retrospective-
ly analysed. FE1 (μg/g stool) measurements were performed centrally.
Non-fasting plasma triglycerides were centrally determined. Linear re-
gression models were fitted using FE1 as dependent and log-
triglycerides as independent variable adjusting for sex, age, body mass
index, alcohol consumption, serum lipase, HbA1c, and smoking.
Results: FE1 concentrations were lower (mean ± sd: 337±204 vs. 437±
216 μg/g, p<0.05) and plasma triglycerides were higher (geometric mean
*/: standard deviation factor: 2.2*/:1.9 vs. 1.6*/:1.8 mmol/l, p<0.05) in
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patients with type 2 diabetes vs. controls, respectively. In type 2 diabetes,
a 10% increase in plasma triglycerides was associated with 4.5 μg/g
higher FE1 concentrations (p=0.001) after adjusting for confounders.
The model in controls comprised triglycerides (+10% increase: +
4.5 μg/g FE1, p=0.005), age, heavy alcohol drinking, HbA1c, serum
lipase, and current and ex-smoking. Triglyceride levels and the con-
founders explained about 10% of the variance in FE1 in both groups. In
contrast, patients with diabetes and controls with pathological FE1
(<100 μg/g) showed an inverse relation: low FE1 levels were associated
with high plasma triglycerides, but the association was statistically sig-
nificant only in controls (p=0.012 for controls, n=20, and p=0.135 for
patients with type 2 diabetes, n=65).
Conclusion: Non-fasting triglycerides were positively related to FE1 in
both patients with type 2 diabetes and control subjects, suggesting that
impairment of exocrine pancreatic function is influencing plasma triglyc-
erides. Marked loss of exocrine pancreatic function is associated with an
opposite effect, resulting in higher plasma levels of plasma triglycerides.
Supported by: Unrestricted grant fromAstraZeneca, Sweden for the anal-
yses
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Balance between innate immunity pathways (MYD88/TRIF) is asso-
ciated with insulin sensitivity in muscle and adipose tissue of obese
post-menopausal women
C. Amouzou1, C. Breuker1, K. Lambert1, F. Galtier2, J. Cristol2, A.
Avignon2, J. Mercier1, A. Sultan1,2, C. Bisbal1;
1INSERM U1046, 2CHU Lapeyronie, Montpellier, France.
Background and aims: During obesity, innate immune Toll like recep-
tors (TLRs) activation in insulin dependent tissues such as adipose tissue
(AT) and skeletal muscle (SM) is one of the key mechanisms involved in
insulin resistance (IR) development. In fact, in obese subjects, the excess
of free fatty acids (FFA) and lipopolysaccharides (LPS) at systemic level
induced TLRs activation such as TLR4. TLR4 activation occurs via two
pathways: - The myeloid differentiation primary response gene 88
“MYD88 pathway” which induces IR by activating nuclear factor κB
(NFκB) transcription factor, inflammatory cytokines (TNFα, IL6) and
inflammatory kinases. - The toll/interleukin-1-receptor-domain-contain-
ing adapter-inducing interferon β “TRIF pathways” which is less studied
than “MYD88 pathway”, and involved interferon β (IFNβ) production,
and proteins such as oligoadenylate synthetase 2 (OAS2), the latent
endoribonuclease (RNase L) and TLR3. The aim of this study was to
identify the role of “TRIF pathway” in early mechanisms leading from
obesity to IR in AT and SM of grade I obese women.
Materials and methods:We recruited 30 post-menopausal women (50-
65 years old), with no personal or familial history of diabetes and any
treatment that could interfere with IS. Among these subjects 10 were
normal-weight control (CT) and 20 were grade I obese subjects. IS/IR
was first assessed by HOMAIR index in order to classify grade I obese
volunteers as obese insulin-sensitive OIS ( n=11) or obese insulin-
resistant OIR (n=9), and the accuracy of these method was then con-
firmed by glucose infusion rate (GIR) measurement determined by a
hyperinsulinemic euglycemic clamp test. SM and AT of all volunteers
were obtained respectively from biopsies in the vastus lateralis and ab-
dominal subcutaneous adipose tissue.We analyzed tissues insulin re-
sponse, inflammatory state at systemic level and innate immune
MYD88 and TRIF pathways at tissues level (SM and AT).
Results: Our results show that at systemic level, there is no difference in
cytokines levels between OIS and OIR. In AT, IS (measured by Phospho
Akt/Akt ratio) was comparable in CT, OIS and OIR while it was signif-
icantly decreased in OIR’s SM compare to CT (P=0.002) and OIS (P=
0.002). The preservation of IS in AT is associated with activation of
“TRIF pathway” (up- regulation of OAS2, RNase L and TLR3 mRNA
level and increase in IRF3 phosphorylation). On the other hand, alteration
of IS in OIR’s SM is associated with “MYD88 pathway” activation.
In grade I obese subjects, IR occurs only in OIR’s SM. This muscular
IR appears without any systemic inflammation but is associated with
“MYD88 pathways activation”. On the other hand, preservation of IS
in AT is associated with “TRIF pathway” activation. These results
show that “TRIF pathways” activation seems to have positive effects
on IS.
Conclusion: Further, the balance between MYD88 and TRIF pathways
seems to be important for IS regulation.
Clinical Trial Registration Number: N°:2011.01.04, ANSM: B110204-20
Supported by: SFD, AOI CHU Montpellier
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The prevalence of pre-diabetes, insulin sensitivity indices and glucose
levels are increased in patients with autoimmune thyroiditis
G. Boutzios1, K. Alexandraki1, S. Liatis2, K. Makrilakis2, E.
Lampropoulou1, G. Nikolopoulos1, K. Paradeisi1, G. Kaltsas1;
1Pathophysiology, 2First Department of Propaedeutic Medicine, National
University of Athens, Greece.
Background and aims: The prevalence of thyroid autoimmunity in
general population (positive tests for thyroglobulin antibodies
(TgAb) and/ or thyroperoxidase antibodies (TPOAb) is increased
up to 14.8% in men and 23.4% in women without palpable goiter.
The prevalence of pre-diabetes is also increased and it is estimated up
to 14.6%.The aim of the study was to investigate whether there is an
association between thyroid autoimmunity and β-cell secretion in
patients with impaired fasting glucose (IFG) and/ or impaired glucose
tolerance (IGT).
Materials and methods: 609 patients (457 females) 46.8±14.5 years
studied for pre-diabetes (defined as IGT either IFG or HbA1c≥5.7%)
and autoimmune thyroiditis (AIT, TgAb and/or TPOAb positive) were
included in the study. Characteristics recorded were age, gender, waist
circumference (cm), BMI (Kg/m2). Fasting glucose (mg/dl) and insulin
levels (μIU/ml), glucose 120 min post-oral glucose tolerance test
(OGTT), HbA1c (%), HOMA and QUICKI insulin-resistance (IR) indi-
ces, and IR status as HOMA >2.16 and QUICKI <0.34 were also
assessed. In 291 patients who had an oral glucose tolerance test
(OGTT) with glucose and insulin measurement in five different time
points, first, second phase insulin sensitivity index (ISI) and ISI were also
assessed. Patients with hypothyroidism and DM2were excluded from the
study.
Results: Patients (n=311) who had AIT compared to non-AIT patients
(n=293) were older [49.2±13.9 vs. 44.2±14.7 (p<0.001)], had larger
waist [96±15.3 vs. 91.7±15.3 (p=0.002)], higher glucose levels [99.6±
12 vs. 95.6±12.2 (p<0.001)], and higher pre-diabetes rates (71.2%) (chi-
square=21.5, p<0.001) but similar rates of IR (44.6%). Pre-diabetic (n=
221) patients with AIT had first phase ISI (1470.9±458.2), and ISI (0.1±
0.03) higher to non-AIT (first phase ISI:1262.8±596.4, p<0.001;
ISI:0.09±0.05, p<0.001).
Conclusion: Patients with AIT and impaired β-cell secretion had
higher HbA1c levels with similar rate of insulin resistance and
higher prevalence of pre-diabetes compared to non-AIT. Thyroid
autoimmunity could be eventually a possible factor modifying
β-cell secretion. Nevertheless further studies are needed to confirm
these findings.
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Insulin sensitivity with reactive hypoglycaemia: a metabolic subtype
of polycystic ovary syndrome with reduced risks of type 2 diabetes
and cardiovascular disease
J. Pinkney1, A. Mari2, A. Tura2, K. Bond3, E. Stenhouse4, R.P. Vincent5,
J. Tomlinson6;
1Centre for Clinical Trials and Population Studies, Plymouth University,
Peninsula Schools of Medicine and Dentistry, UK, 2Italian National Re-
search Council Institute of Biomedical Engineering, University of Padua,
Italy, 3Research and Development, Royal Cornwall Hospital, Truro,
4School of Nursing and Midwifery, Plymouth, 5Clinical Biochemistry,
King's College Hospital, London, 6Pool Health Centre, Redruth, UK.
Background and aims: Polycystic Ovary Syndrome (PCOS) is associ-
ated with insulin resistance (IR) and is a risk factor for type 2 diabetes
(T2D) and cardiovascular disease (CVD). However, Reactive
Hypoglycaemia (RH) in PCOS has received little attention. This study
aims to identify the frequency of RH in PCOS, its potential mechanisms
and clinical significance.
Materials and methods: 48 women with PCOS (Rotterdam criteria) and
53 BMI-matched controls underwent a 6-point, 2-hour 75 g oral glucose
tolerance test to identify beta cell function (computermodelling from glucose,
insulin and C-peptide data) and Insulin Sensitivity Index (ISI) (Matsuda
method). Central adiposity was measured by bioimpedance and anthropom-
etry. Biochemical RH was defined as 2-hour glucose less than fasting.
Results: (1) There were no signjificant differences between PCOS and
controls in beta cell glucose sensitivity (BCGS) (103.8 [69.1] vs 105.1
[54.9]pmol/min/mL/mmol; p=0.91) or ISI (0.94 [0.57] vs 1.17 [0.77];
p=0.11) but ISI was strongly associated with adiposity (BMI categories
<24.9, 25-29.9, 30-34.9, >35 kg/m2; PCOS and controls, ANOVAboth p<
0.001). (2) RH was common in both PCOS (37%) and controls (52%)
(Chi-square; p=0.48). Compared to women without RH, those with RH
had lower increases in insulin levels from 0-120 mins (PCOS 171.6 [28.5-
243.8] vs 340.6 [228.8-429.5] pmol/l; p=0.005: Controls 66.7 [8.7-122.1]
vs 250.8 [165.8-504.4] pmol/l; p<0.001), and controls with RH also had
higher ISI (1.68 [0.98] vs 0.89 [0.46]); (p<0.001). (3) In women with
PCOS, glucose at 120 mins correlated with waist circumference (r=0.40,
p=0.008), triglycerides (r=0.33, p=0.03), systolic (r=0.32, p=0.03) and
diastolic blood pressure (r=0.35, p=0.02) and C-reactive protein (r=0.31,
p=0.04), but these relationships were not present in controls. (4) Women
with PCOS and poor insulin secretion (lowest quartile of BCGS), lowwaist
circumference (r=0.81, p=0.001), low visceral fat (r=0.82, p=0.001) and
high ISI (r=-0.60, p=0.01) were associated with lower 2 hour glucose
levels. Women with PCOS in the lowest waist tertile (<87 cm) also had
significantly lower 2 hour glucose (5.29 [1.07]mmol/l) vs) than those in the
middle and upper tertiles (6.12 [1.85] mmol/l) (p=0.005). Finally, (5)
women with PCOS who self-reported regular hypoglycaemic symptoms
such as shakiness had higher ISI (1.14 [0.63] vs 0.77 [0.46]; p=0.03).
Conclusion: These new findings identify a common subtype of PCOS in
which lower visceral fat and increased insulin sensitivity are associated
with normal blood glucose despite poor insulin secretion. Waist circum-
ference less than 87 cm and 2 hour glucose less than baseline, sometimes
accompanied by symptoms of RH, identifies women with PCOS who
may have lower risks of future T2D and CVD. These findings have
significant implications for patient education, screening and prevention.
Supported by: Duchy Health Charity, Cornwall Centre for Endocrinolo-
gy and Diabetes
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Metabolic flexibility and oxidative capacity independently predict
insulin sensitivity in newly diagnosed patients with type 2 diabetes
M. Apostolopoulou1,2, K. Strassburger2,3, B. Knebel2,4, J. Kotzka2,4, J.
Szendroedi1,2, M. Roden1,2;
1Institute for Clinical Diabetology, German Diabetes Center, 2German
Center for Diabetes Research, 3Institute for Biometrics and Epidemiolo-
gy, 4Institute for clinical biochemistry and pathobiochemistry, German
Diabetes Center, Duesseldorf, Germany.
Background and aims: Inherited and acquired insulin resistance have
been related to abnormal muscle mitochondrial function. Mitochondrial
function should be reflected by maximal oxygen uptake (VO2max) and
metabolic flexibility, defined as the difference between fasting and
insulin-stimulated respiratory quotient (ΔRQ). However it is unclear,
whether impaired ΔRQ results from impaired mitochondrial function or
decreased glucose uptake due to insulin resistance. We hypothesized that
VO2max andΔRQ correlate with each other and with insulin sensitivity
and that gender, genetic variations associated with higher insulin sensi-
tivity or VO2max in peroxisome proliferator-activated receptors and co-
factors (PPARγ, PPARδ, PGC-1α), NADH dehydrogenase 1 ß
subcomplex 6 (NDUFB6) or ß-adrenergic receptor (ADRB) genes, gly-
cemia or lipidemia would mediate such relationships.
Materials and methods: A total of 121 patients (85 males, 36 females),
all participants of the GDS, within the first year of type 2 diabetes (T2D)
diagnosis were included. The patients underwent comprehensive pheno-
typing including hyperinsulinemic-euglycemic clamps, indirect calorim-
etry and cycling spiroergometry as well as genotyping for PPARγ,
NDUFB6, PGC-1α, PPARδ and ADRB2 genes.
Results:Males and females had comparable age (51±10 vs 52±11 years)
but different body mass (BMI; 30.3±5.5 vs 33.8±7.6 kg.m-2, p=0.01) and
VO2max (29±5 vs 27±4 ml.min-1.(kg fat free mass)-1, p=0.05). Insulin
sensitivity (M: 9.7(7.3,12.2) vs 9.7(7.1, 11.9) mg.(kg fat free mass)-1.min-
1) and ΔRQ (0.11±0.06 vs 0.11±0.05, p=0.99) were nearly identical
between males and females. ΔRQ and VO2max did not correlate with
each other, but both parameters associated with insulin sensitivity in both
males and females (ΔRQ: males: β=1.91, p=0.002, females: β=2.46, p=
0.014, VO2max: males: β=0.04, p<0.0001, β=0.04 females: p=0.02).
When we examined also the effect of body mass index, age, fat mass and
waist-to-hip ratio performing multiple regression analysis, ΔRQ and
VO2max were remained independent predictors of insulin sensitivity in
male (β=1.56, p=0.004 and β=0.02, p=0.006 respectively), but not in
female participants. There was no association of the examined parameters
with glycemic control, free fatty acids or tested gene variations.
Conclusion: The absence of a relationship between VO2max and ΔRQ
despite their independent association with insulin sensitivity suggest that
metabolic flexibility and oxidative capacity are different features of mus-
cle mitochondrial function.Moreover, neither glycemia and lipidemia nor
variants in genes related to oxidative metabolism affected the relationship
between VO2max and ΔRQ in T2D patients.
Clinical Trial Registration Number: NCT01055093
Supported by: DZD e.V
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Excess in haemoglobin glycation and glucose variability in obese
patients without known dysglycaemia
P. Valensi, M. Fysekidis, A. Rezki, I. Banu, C. Pillegand, S. Chiheb, E.
Cosson;
Department of Endocrinology, Diabetology, Nutrition, Paris Nord Uni-
versity, France.
Background and aims: We previously showed that, in obese patients
without known dysglycemia, age was a determinant of hemoglobin
glycation. A mathematical relation has been proposed between mean
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glucose given by continuous glucose monitoring (CGM) and HbA1c
levels. This study aimed to explore in overweight or obese patients the
difference between themeasured HbA1c level and HbA1c level predicted
by this relation (ΔHbA1c), and the factors associated with this difference.
Materials and methods: We included 70 patients (46.5±14.3 years,
BMI 35.2±6.8 kg/m2) without known dysglycemia. CGM was per-
formed during 24 hours. Mean glucose and mean amplitude glycemic
excursion (MAGE) were calculated. Predicted HbA1c level was calculat-
ed using the following formula (ADAG): mean glucose=1.649×HbA1c-
2.645, and the difference between measured and predicted HbA1c was
calculated (ΔHbA1c). An OGTTwas performed.
Results: Measured HbA1c was 5.1% to 7.4%. According to OGTT, 24
patients had prediabetes (fasting hyperglycemia and/or glucose intoler-
ance) and 13 had diabetes whereas 49 patients had an HbA1c ≥5.7%. The
population was separated in quartiles of measuredHbA1c (Q1 toQ4). For
every quartile, measured HbA1c was higher than predicted value of
HbA1c (p<0.01 to <0.0001), and ΔHbA1c increased significantly from
Q1 to Q4 (0.60±0.23/0.77±0.34/0.85±0.25/1.13±0.31%; p<0.008). In
the overall population, ΔHbA1c correlated with age (r=0.536, p<0.0001)
and MAGE (r=0.494, p<0.0001). In multivariate analysis, ΔHbA1c
remained associated independently with age, MAGE and HbA1c quar-
tiles (p=0.002, 0.017, 0.006; adjusted r2 for the model=0.43).
Conclusion: In obese patients with dysglycemia detected on OGTT in
half of them, measured HbA1c is higher than HbA1c predicted by mean
glucose given by CGM. This possible excess in hemoglobin glycation is
noticeably determined by 24-hour glucose variability in addition to age
and higher measured HbA1c. This may partly explain why the sensitivity
of HbA1c is greater than OGTT to detect dysglycemia in this population.
PS 048 Food intake and
weight regulation
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Body composition, insulin resistance, and the effectiveness of orlistat
versus metformin added to dietary treatment in obese premenopaus-
al women
M. Łuczak1, K. Musialik2, M. Szulińska2, E. Swora-Cwynar3, A.
Kargulewicz3, M. Grzymisławski3, D. Pupek-Musialik1, P. Bogdański2;
1Department of Internal Medicine, Metabolic Disorders, and Hyperten-
sion, 2Department of Education and Obesity Treatment and Metabolic
Disorders, 3Department of Internal Medicine, Metabolic Disorders and
Dietetics, University of Medical Sciences, Poznań, Poland.
Background and aims: Clinical studies have determined a strong corre-
lation between insulin resistance and the amount of total and
intraabdominal fat. We aimed to evaluate the effects of treatment with
metformin and orlistat on body composition with a focus on glucose-
insulin homeostasis in obese premenopausal women.
Materials and methods: 73 obese premenopausal women aged 31.9±
9.4 years were randomized to open label treatments: diet + metformin
1000 mg/d (n=37); or diet + orlistat 360 mg/d (n=36). Anthropometric
measurements, dual-energy X-ray absorptiometry, oral glucose tolerance
test, insulin resistance by the homeostasis model assessment (HOMA-
IR), and insulin sensitivity by the Matsuda Index (ISI) were evaluated
at the baseline and after 3 months.
Results: Treatment with orlistat was superior to metformin regarding
weight loss (-9.4±2.3 vs. -4.9±1.3 kg), fat mass (-5.41±3.02 vs. -3.49
±0.68 kg) , as well as an increase in the lean body mass (2.39±1.87 vs.
0.09±1.10 kg), improving the body composition. Similar reductions in
the % of android and gynoid fat were achieved in both groups, with the
greater decreases in android (-0.10±0.06 vs. -0.69±0.19 kg) and trunk fat
(-3.83±0.73 vs. -0.72±0.68 kg), seen in the metformin group. Orlistat
and metformin similarly improved the ISI (18.6±10.3 vs. 17.5±47.4) and
postchallenge insulin (-19.0±50.5 vs. -18.8±40.2 nmol/L). High initial
postload insulin and low ISI - though not HOMA-IR - correspond with
reductions in total fat, trunk fat, waist in both groups as well as with the
decrease in android fat in metformin group (table).
Conclusion: Orlistat treatment resulted in a greater weight loss and im-
provement in body composition, metformin - in a additional visceral fat
reduction. Orlistat and metformin produced a comparable improvement
in insulin/glucose homeostasis. High initial postload insulin and low ISI
predict greater effects of treatment.
Supported by: Polish Ministry of Science and Higher Education NN
40412743
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The effect of laparoscopic greater curvature plication andRoux-en-Y
gastric by-pass on metabolic control in obese subjects with type 2
diabetes mellitus: a 2-year follow-up
P. Trachta1,M.Mraz1, P. Kavalkova1, K. Dolezalova2, J. Klouckova1, A.
Cinkajzlova1, M. Kosak1, D. Haluzikova3, J. Krizova1, Z. Lacinova1, M.
Matoulek1, M. Fried2, S. Svacina1, M. Haluzik1;
13rd Department of Medicine, Charles University, 2OB Klinika, 3Depart-
ment of Sports Medicine, Charles University, Prague, Czech Republic.
Background and aims: Bariatric surgery is considered one of the most
effective options in the treatment of obesity and its co-morbidities, in-
cluding type 2 diabetes mellitus (T2DM). The aim of our study was to
assess the effect of laparoscopic greater curvature plication (LGCP) and
Roux-en-Y gastric by-pass (RYGB) on antropometric and biochemical
parameters and metabolic control in obese subjects with T2DM.
Materials and methods: Forty-four subjects undergoing LGCP and 8
patients scheduled for RYGBwere included into the study. Anthropomet-
ric, biochemical and hormonal examinations were performed before and
1, 6, 12 and 24 months after the procedure. In a selected subgroup of
LGCP patients the postprandial incretin effect was assessed using a 2-
hour liquid meal test (LMT - Fresubin Original 200 ml, Fresenius Kabi,
Germany).
Results: Both LGCP and RYBP lead to a significant decrease in body
weight that was sustained throughout the whole 24 months (BMI 42.4±
0.9 vs. 37.1±1.8 kg/m2, p<0.05 for LGCP and 50.3±4.2 vs. 37.1±
3.6 kg/m2, p<0.05 for RYGB). The same was true for glucose control
(HbA1c 51.9±2.6 vs. 44.7±3.2 mmol/mol, p<0.05 for LGCP and 54.0±
7.7 vs. 41.7±4.7 mmol/mol, p<0.05 for RYGB). Both procedures also
partially improved the lipid profile (HDL cholesterol 1.17±0.04 vs. 1.27
±0.07mmol/l, p<0.05 for LGCP and 1.15±0.09 vs. 1.45±0.16mmol/l, p
<0.05 for RYGB). Additionally, LGCP was accompanied by a reduction
in systemic low-grade inflammation (hsCRP 3.2±0.6 vs. 1.3±0.3 mg/l, p
<0.05). The incretin effect was temporarily restored 1 month after LGCP
(GLP-1 at min 30 of LMT: 10.37±3.77 vs. 26.48±7.70 pM, p<0.05).
Conclusion: Laparoscopic greater curvature plication as well as Roux-
en-Y gastric by-pass rapidly and sustainably reduce body weight and
improve glucose control during the first 24 months after surgery. Partial
restoration of the incretin effect might play a role in these processes.
Supported by: RVO VFN64165, IGA NT/13299-4, IGA NT/14083-3 and
SVV260019/2014.
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Insulin sensitivity indices derived from oral glucose tolerance tests:
Are they valid after Roux-en-Y gastric bypass?
K.N. Bojsen-Møller1,2, C. Dirksen1,2, N.B. Jørgensen1,2, V.B.
Kristiansen3, J.J. Holst4,2, E.A. Richter5, S. Madsbad1;
1Department of Endocrinology, Hvidovre Hospital, 2NovoNordisk Foun-
dation Center for Basic Metabolic Research, University of Copenhagen,
3Department of Surgical Gastroenterology, Hvidovre Hospital, 4Depart-
ment of Biomedical Sciences, 5Department of Nutrition, Exercise and
Sports Sciences, University of Copenhagen, Denmark.
Background and aims: Insulin sensitivity indices obtained from oral
glucose tolerance tests (OGTTs) are frequently used in diabetes research
and provide an easily obtained surrogate measure of insulin sensitivity.
Roux-en-Y gastric bypass (RYGB) induces extensive weight loss and
improvements in insulin sensitivity when evaluated by the
hyperinsulinaemic clamp. Insulin sensitivity indices obtained from
OGTTs have not been validated after RYGB and may be inaccurate due
to surgical alterations of the gut resulting in accelerated glucose absorp-
tion and increased insulin secretion.
Materials and methods:We investigated insulin sensitivity in 20 obese
subjects (10 with type 2 diabetes and 10 with normal glucose tolerance)
before, 3 months (mo) and 1 year (y) after RYGB using a 4 h
hyperinsulinaemic (40 mU/m2/min) euglycaemic (5.5 mmol/L) clamp
combined with [6,6-2H2]-glucose tracer infusion as well as a 2 h 75 g
OGTT. Fat free mass (ffm) was assessed by DEXA. Matsuda, Gutt and
Oral Glucose Insulin Sensitivity (OGIS) indices were calculated from
OGTTs and compared to the clamp-derived Rate of disappearance (Rd)
of [6,6-2H2]-glucose (in mg/min/kg ffm). Pearson test was used to eval-
uate correlations.
Results: Before RYGB, the three OGTT-based insulin sensitivity indi-
ces correlated significantly with Rd (Matsuda vs Rd: r=0.63, p<0.001,
Gutt vs Rd: r=0.56 p=0.012 and OGIS vs Rd: r=0.62, p=0.005). After
RYGB, the relative improvements in Matsuda and Gutt were substan-
tially larger than improvements in Rd at 3 months (Rd: +36±13%,
Matsuda: +86±17% p<0.05, Gutt: +91±9.7% p<0.01) and 1 year
(Rd: +57±14%, Matsuda: +164±28% p<0.01, Gutt: +145±18%
p<0.01). Furthermore, the relative changes in Matsuda and Gutt did
not correlate significantly to the relative changes in Rd (%Matsuda vs
%Rd: 3 mo: r=0.23, p=0.35, 1y: r=0.46, p=0.07; %Gutt vs %Rd: 3
mo: r=0.35, p=0.16, 1 y: r=0.46, p=0.06). In contrast, the relative
changes in OGIS were comparable to the relative changes in Rd
both at 3 mo (Rd +36±13%, OGIS +31±5.9%, p=0.34) and 1 year
(Rd: +57±14%, OGIS: +46±5.9%, p=0.36) and correlations be-
tween the relative change in OGIS and Rd were significant (%OGIS
vs %Rd: 3 mo: r=0.61, p=0.007; 1 y: r=0.50, p=0.04).
Conclusion: Insulin sensitivity indices obtained from oral tests may be
inaccura te af te r RYGB. Compared to the gold s tandard
hyperinsulinaemic euglycaemic clamp, OGIS seems to perform better
than Matsuda and Gutt indices in assessing changes in insulin sensitivity
within the first year after RYGB.
Clinical Trial Registration Number: NCT01202526
Supported by: UNIK
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Metabolic improvements observed in subjects receiving
EndoBarrier: a pooled analysis of clinical trials
J. Teare1, C.W. Le Roux2, E. Chiquette3, D. Maggs3, I. Janssen4;
1Imperial College London, UK, 2Diabetes Complications Research Cen-
tre, Conway Institute, University College Dublin, Ireland, 3GI Dynamics,
Lexington, USA, 4Rijnstate Hospital Arnhem Netherlands, Netherlands.
Background and aims: EndoBarrier therapy (EBT) involves the revers-
ible endoscopic placement of an impermeable liner that anchors in the
duodenum and bypasses the first two feet of the upper bowel, thus repli-
cating features of bariatric surgery.
Materials and methods: EBT in obese subjects with≥1 comorbidity
(diabetes, hypertension, hyperlipidemia) or morbidly obese with or
without comorbidities from 6 clinical trials (n=211, age 46 yrs, BMI
38.9 kg/m2) was evaluated.
Results: Significant metabolic improvements were observed with EBT
(Table). At 12 months, 57% of subjects achieved ≥10% weight loss
while 55% of those with T2DM reached an A1C of ≤7%. The improve-
ment in glycemic control occurred despite a shift to decreased concom-
itant anti-diabetic medication use. Moreover, 37% of T2DM subjects
achieved both a ≥0.5% A1C reduction and ≥10% weight loss at
12 months.Reported AEs were mild (event rate 85.0%) or moderate
(event rate 14.5%) in severity and mostly GI in nature. Hypoglycemia
was observed in patients on insulin or sulfonylurea, but no severe hypo-
glycemia occurred. EBT did not induce hypoglycemia in non-diabetic
subjects, suggesting no innate hypoglycemia potential. Early device re-
moval was due to anchor migration, GI distress, liner obstruction, or GI
bleed; all resolved w/o permanent sequelae. SAEs were reported infre-
quently at a rate of 3%.
Conclusion: EBT elicits metabolic benefits, with an acceptable safety
profile, in obese subjects with comorbidities.
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Clinical Trial Registration Number: 00985491, 00985114, 00986349,
01114438, 00985491, 01372501
Supported by: GI Dynamics
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Associations of glucagon-like peptide 1 with food processing in the
brain are present in lean and obese humans
M. Heni1,2, S. Kullmann3,2, B. Gallwitz1, H.-U. Häring1,3, H. Preissl3,2,
A. Fritsche1,3;
1Department of Internal Medicine IV, 2German Center for Diabetes Re-
search (DZD e.V.), 3Institute for Diabetes Research and Metabolic Dis-
eases of the Helmholtz Center Munich at the University of Tübingen,
Germany.
Background and aims: Glucagon-like peptide 1 (GLP-1) is a peptide
hormone that is released into the bloodstream after food intake. In addi-
tion to stimulating insulin release, it introduces satiety and contributes to
the termination of food intake as indicated by research in animals and
exogenous administration in humans. Here, we investigated whether en-
dogenous GLP-1 associates with food-related brain activity and hunger.
Materials and methods: Twenty-four human volunteers underwent a
75 g oral glucose tolerance test that promotes GLP-1 secretion as part
of another study. Food-cue induced brain activity was assessed by func-
tional magnetic resonance imaging (fMRI) and GLP-1 concentrations
were measured before and after glucose intake.
Results: The significant increase in GLP-1 levels negatively correlated
with change in food-cue induced brain activity in the orbitofrontal cortex,
a major reward area. This association was independent of concurrent
alterations in insulin and glucose concentrations. Furthermore, GLP-1
was negatively correlated with hunger ratings. Both associations were
present in lean and overweight participants. In contrast, postprandial in-
sulin associated with orbitofrontal response only in lean individuals.
Conclusion: The postprandial release of GLP-1 alters reward processes in
the orbitofrontal cortex and might thereby support the termination of food
intake and reduce hunger. While obese persons showed brain insulin resis-
tance, noGLP-1 resistancewas observed. Our study provides novel insights
in the central regulation of food intake by the incretin hormone GLP-1.
Supported by: BMBF to the DZD, Helmholtz Alliance ICEMED, DDG
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Luminal trans,trans-2,4-decadienal reduces gastric emptying in rats
A. Yahagi1, T. Hira2, S. Nishimura3, M. Sakaino3, T. Yamashita3, H.
Hara2;
1Division of Applied Biosciences, Graduate School of Agriculture, 2Di-
vision of Applied Biosciences, Research Faculty of Agriculture, Hokkai-
do University, Sapporo, 3Fundamental Research Laboratory, Research
and Development Division, J-Oil Mills, Inc, Yokohama, Japan.
Background and aims: Postprandial glycemia and lipidemia are strong-
ly affected by the rate of gastric emptying, and slowing of gastric
emptying contributes to reducing postprandial hyperglycemia and hyper-
lipidemia. Gut hormones including cholecystokin (CCK) are major en-
dogenous factors for reducing postprandial gastric emptying. We recently
demonstrated that unsaturated aldehydes stimulated CCK secretion from
murine enteroendocrine cell line, STC-1. Among various aldehydes test-
ed, trans,trans-2,4-decadienal (decadienal) had a potent CCK-releasing
activity, however, its effect in vivo has not been studied. In the present
study, we investigated whether oral administration of decadienal affects
the rate of gastric emptying (one of CCK-related physiological effects) in
rats, by using the acetaminophen absorption test and the phenol red re-
covery method.
Materials and methods: In fasted Male Sprague-Dawley rats, test liq-
uids containing acetaminophen with or without decadienal (50-
100 mg/kg) were orally administered. Tail vein blood was collected with
time until 120 min, and plasma acetaminophen concentration was mea-
sured. In separated experiments, decadienal was orally administered to-
gether with phenol red. Luminal contents in the stomach, the proximal
and the distal small intestine were respectively collected 15 min after the
administration. Amounts of luminal phenol red were measured and the
rate of gastric emptying was calculated. By using the methods above, we
compared various aliphatic compounds having the same chain length
(C10) with decadienal, and further investigated the effect of an intraper-
itoneal administration of decadienal, on the rate of gastric emptying.
Results: Oral administration of decadienal dose-dependently reduced the
appearance of acetaminophen in the peripheral blood. Luminal phenol red
recovered from the stomach was greater in decadienal-treated rats than
control rats, which resulted in lower gastric emptying rate in decadienal-
treated rats (13%) compared to control rats (57%) (n=7, P<0.01). This
was reflected by smaller amount of phenol red collected from the small
intestine in decadienal-treated rats compared to control rats. Oral admin-
istrations of aliphatic compounds (decanal, decanol and decanoic acid)
having the same chain length with decadienal, and an intraperitoneal
administration of decadienal did not reduce the rate of gastric emptying,
respectively.
Conclusion: These results demonstrate that orally administered
decadienal has inhibitory effect on gastric emptying through acting in
the intestinal lumen, possibly on enteroendocrine cells.
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Mice on high fat diet or normal diet have different metabolic re-
sponses to rosuvastatin treatment
L. Eliasson1, V.A. Salunkhe1, T. Reinbothe1,2, I.G.Mollet1, A.Wendt1, J.
Vikman1;
1Dept Clinical Sciences Malmö, Lund University Diabetes Center, 2De-
partment of Physiology, University of Gothenburg, Sweden.
Background and aims: Rosuvastatin (Ros) is a member of the choles-
terol lowering statin family prescribed to reduce the risk of cardiovascular
disease. The beneficial effects of statin treatment are well documented.
However, several reports have also indicated diabetogenic effects of
statins. The underlying mechanisms are poorly understood. Here we
aim to investigate the effects of rosuvastatin on glucose homeostasis
and insulin secretion in mice on high fat diet (HFD) or normal diet (ND).
Materials and methods: C57BL/6 mice were put on ND or HFD for
12 weeks. 4 weeks into the experiment a subset of the mice were given
rosuvastatin (Ros) in the drinking water (0.2 mg/mice/day; 15 mice per
group). Every 4 weeks the mice were subjected to an oral glucose toler-
ance test (OGTT) and samples were taken for in vivo measurements of
glucose and insulin. In agreement with earlier studies HFD mice had
higher blood glucose levels than ND mice and comparison was per-
formed ND vs ND+Ros and HFD vs HFD+Ros. Every second week it
was verified that Ros treatment resulted in lowered blood cholesterol
levels. At the termination of the experiment tissues were collected for
in vitro experiments. Insulin secretion was measured with RIA. Exocyto-
sis was recorded as changes in membrane capacitance using the patch
clamp technique. Intracellular calcium was monitored with fura-2.
Results: After 4 weeks of Ros treatment the OGTT revealed a glucose
lowering effect of Ros in ND mice (delta15 min(glucose) was reduced
~50%; p≤0.01 and total AUC(glucose) was reduced ~20%; p≤0.05; N=
14ND;N=15ND+Ros), but this was not accompanied by any changes in
insulin response. In the HFD mice, that already had high blood glucose
compared to the ND mice, total AUC or delta15 min for glucose was not
altered after 4 weeks or 8 weeks of Ros treatment. However, acute insulin
response during the OGTT was significantly decreased after Ros treat-
ment for 8 weeks in the HFD group (delta15 min (insulin) was reduced
~65%; p≤0.01; n=15 HFD; n=13 HFD+Ros). On a cellular level, Ros
treatedmice, regardless of diet, had a ~20% (p≤0.01; n=24) lower insulin
content. In vitro insulin secretion at 16.7 mM glucose was reduced by
~40% (n=4; p≤0.05) with Ros treatment in the ND mice. However, the
insulin release relative to insulin content was not changed. No significant
difference in insulin secretion by Ros from the HFD islets was detected.
The exocytotic response from single beta-cells did not differ between the
ND+Ros andND (n=7). However, elevating glucose concentrations from
2.8 mM to 16.7 mM in isolated ND islets resulted in a delayed increase in
intracellular calcium in the Ros treated group compared to ND alone. In
addition, the dip in intracellular calcium preceding the increase in calcium
was less prominent (p<0.001; N=3) in ND+Ros islets, indicating a re-
duced uptake of calcium into the ER.
Conclusion: The integrated physiological response to glucose is intact
after 8 weeks of rosuvastatin treatment. Interestingly, the acute insulin
response to glucose in HFD mice is more vulnerable to rosuvastatin
treatment than it is in ND mice. Taken together, our data suggests that
the metabolic state of the individual could influence the effects of
rosuvastatin treatment on glucose homeostasis. On a cellular level
rosuvastatin reduced insulin content and disturbed calcium handling in
the islets, which may perturb insulin secretion in the long term.
Supported by: SRC, ALF- Skåne, Albert Påhlssons foundation,
Diabetesfonden, EXODIAB
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Adverse effect of ovariectomy on substrate utilisation in brown adi-
pose tissue and on liver dicarbonyl stress in rats
H. Malinska, J. Trnovska, V. Skop, L. Kazdova;
Center for Experimental Medicine, Institute for Clinical and Experimen-
tal Medicine, Prague 4, Czech Republic.
Background and aims: Ovariectomy leads to increase in body weight,
visceral adiposity, insulin resistance, fatty liver and other disorders of
lipid and glucose metabolism. However, the underlying mechanism of
these disorders remains unclear. Increasing evidence indicates that brown
adipose tissue (BAT) modulates energy balance. It also suggests that
increased accumulation of dicarbonyls in the liver may increase oxidative
stress, activate the inflammatory pathway and can play a key role in the
development of other metabolic disorders. In this study, we examined the
effect of ovariectomy on the utilization of energetic substrate in
interscapular brown adipose tissue and liver dicarbonyl and oxidative
stress.
Materials and methods: Female Wistar rats were ovariectomized
(OVX) or sham-operated (controls) at 8 weeks of age and fed a standard
diet for 4 month, in order to fully develop disorders associated with
ovariectomy. BAT activity was determined ex vivo according to the utili-
zation of 14C-U-palmitic acid and 14C-U-glucose for oxidation (incorpo-
ration into CO2) and incorporation of
14C-U-palmitic acid and 14C-U-
glucose into BAT lipids. Lipolysis in BAT was measured by the release
of free fatty acids. The concentrations ofmethylglyoxal and glutathione in
the liver were determined using the HPLC-method with fluorescence
detection.
Results: Compared with sham-operated control rats, OVX rats exhibited
markedly increased body weight (+10%, p<0.05) and visceral adipose
tissue weight (+10%, p<0.05). Insulin sensitivity of white visceral adi-
pose and muscle tissue, measured according to 14C-U-glucose incorpora-
tion into lipids and glycogen, were significantly decreased (p 0.01) in
OVX rats compared to controls. However, plasma glucose, insulin and
triglycerides were not different between OVX and control rats. Severe
hepatic triglycerides accumulation (12.76±1.10 vs 5.44±0.85 μmol/g, p
<0.001) in OVX rats associated with significantly elevated level of
methylglyoxal (12.78±2.7 vs 5.49±0.41 nmol/mg, p 0.01) may have
contributed to the development of liver steatosis. Ovariectomy led to
impaired balance in the reduced and oxidised forms of glutathione in
the liver (GSH/GSSG: 15.4±1.3 vs 28.4±1.4, p 0.01), which may have
increased oxidative and carbonyl stress. BAT of OVX rats exhibited a
reduced fatty acid oxidation (-72%, p<0.05), lipogenesis (-26%, p<0.05)
and decreased lipolysis (-25%, p<0.05), despite the fact that BATweight
was significantly increased (p<0.05) in OVX rats compared to controls.
Conclusion: Results indicate that reduced fatty acid and glucose utiliza-
tion, together with lower lipolysis in brown adipose tissue in response to
ovariectomy, may contribute to the development of obesity in the post-
menopausal period. Severe liver steatosis induced by ovariectomy was
associated with excessive formation of methylglyoxal and the reduced
ratio of GSH/GSSG, which could participate in oxidative stress. Both low
metabolic activity in BAT and liver dicarbonyls formation may be in-
volved in the development of postmenopausal metabolic syndrome.
Supported by: GACR P303/13-10813S and MZ CR - DRO (IKEM, IN
00023001)
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Interspecies scaling of dynamic glucose and insulin using a mathe-
matical model approach
O. Alskär, M.O. Karlsson, M.C. Kjellsson;
Department of Pharmaceutical Biosciences, Uppsala University, Sweden.
Background and aims:Mathematical models are useful tools in under-
standing complex relationships such as glucose homeostasis. The
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integrated glucose insulin (IGI) model is a mathematical model that de-
scribes dynamic glucose and insulin concentrations in humans during
glucose tolerance tests. The aim of this work was to investigate if the
model can be scaled to describe intravenous glucose tolerance test
(IVGTT) data from several preclinical species.
Materials and methods: Glucose and insulin concentrations from
IVGTTs performed in healthy individuals of rats (n=16), mice (n=24),
dogs (n=11), pigs (n=11) and humans (n=24) was available for analysis.
In the first step allometric scaling based on individual body weights was
investigated. The most suitable value for the allometric exponent was
investigated for all parameters in the model, based on objective function
value, parameter uncertainty and model complexity. In the second step
species adaptations was investigated by scaling parameters with the
weight of organs relevant to that parameter in each species. In the third
step remaining species adaptations that could not be described by allo-
metric scaling was investigated.
Results: Estimating one allometric exponent for clearances (0.85), one
exponent for volumes (0.9) and fixing the exponent of rate constants to -
0.25 described the data well and kept the scaling complexity low. Esti-
mating the allometric exponent is of importance to be able to describe
rodents well, since their body weights are far from humans. Of the inves-
tigated scaling relationships with species specific organ weights no rela-
tionship improved the fit for all animals. Dogs and pigs showed lower
first phase secretion and stronger second phase secretion of insulin than
the model predicted and these two parameters were estimated for dogs
and pigs. Pigs also showed a slower first phase secretion and this param-
eter was also estimated for pigs. The model predicted slower glucose
elimination in pigs than the data showed and insulin dependent glucose
clearance was estimated separately for pigs. The result of the final model
describing IVGTT in rats, mice, dogs and pigs is displayed in figure 1 (the
solid line is the median based on the observed data. Shaded area is the
95% confidence interval around the median based on the simulated data).
Conclusion: The allometrically scaled IGI model developed in this pro-
ject can accurately predict preclinical IVGTT data. In general glucose
scales better than insulin, as insulin is a protein the kinetics are more
complex and the amino acid sequence is not identical in the different
species. When investigating animal models of diabetes it is of most im-
portance that glucose scales well since insulin secretion often is dimin-
ished. The allometrically scaled IGI model can be used in drug develop-
ment to facilitate better translations of preclinical research into clinic.
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Moderate exercise prevents pituitary dysfunction induced by a su-
crose rich diet
M.E. Mercau1, E. Repetto1, P. Arias2, C.V. Finkielstein3, C.B.
Cymeryng1;
1Dpto de Bioquímica Humana. FMED, UBA, CEFYBO-CONICET,
Buenos Aires, 2Departamento de Fisiología. Facultad de Medicina.
Universidad Nacional de Rosario, Argentina, 3Department of Biological
Sciences. Virginia Polytechnic Institute and State University, Blacksburg,
USA.
Background and aims: Increased consumption of sucrose, a major con-
stituent of western diet, has been associated with the development of
obesity and insulin resistance (IR). Altered hypothalamic-pituitary-
adrenal axis function has been linked to to IR, in animal models and
patients. Studies from our group have shown morphological and func-
tional changes in the adrenal cortex of rats fed a sucrose-rich diet (SRD).
The aim of this study was to evaluate the effects of SRD on basal activity
of the pituitary gland, the underlying cellular processes, and the effect of
exercise (E) on these parameters.
Materials and methods: Adult male Wistar rats were randomized into 4
groups (n=5), two of which received 30% w/v sucrose in the drinking
water (SRD) for 15 weeks. A subset of each dietary group was subjected
to E protocol (C-E and SRD-E) (treadmill walk, 15 min/day, 5 day/week,
for 15 weeks, at 0.8 km/h speed). The sedentary (C-S and SRD-S) subset
of each dietary group did not perform any physical activity. Insulin sen-
sitivity was assessed at the 7th week of treatment by i.p. ITT. Statistical
analyses were performed using Student’s t test or ANOVA and significant
differences were studied with Tukey’s post hoc test.
Results: Our results showed that serum metabolites (fasting glucose,
triglycerides and free fatty acids (FFA)) were increased in SRD-S animals
by the end of the 15th week of treatment. Animals from the SRD-S group
showed significantly lower plasma levels of ACTH (C-S: 96.9±2.6,
SRD-S: 52.6±0.5, pg/ml), decreased pituitary POMC mRNA levels (C-
S: 1.02±0.04, SRD-S: 0.64±0.03, fold induction), and lower serum cor-
ticosterone concentrations (C-S: 13.61±2.66, SRD-S: 2.66±0.33, ng/ml)
than those from the C-S group. Analysis of pituitary levels of antioxidant
enzymes and autophagymarkers suggested the activation of these cellular
pathways in the SRD-S group. E was able to prevent the induction of
autophagy and antioxidant defense systems in the pituitary gland of SRD-
E animals. Analysis of POMC mRNA (C-E: 1.46±0.06, SRD-E: 1.43±
0.18, fold induction), plasma ACTH levels (C-E: 142.0±8.6, SRD-E:
130.6±20.2, pg/ml) and of serum corticosterone concentrations (C-E:
28.05±4.8, SRD-E: 50.40±3.33, ng/ml) showed that E prevented the
effects of SRD on HPA axis basal activity. Regarding the analyzed serum
biochemical parameters, E was able to prevent the increase in serum FFA
levels. Given this, we analyzed the effects of palmitic acid (PA) on
POMC-ACTH production in AtT-20 corticotroph cell-line. Cells were
transiently transfectedwith a POMC-luciferase reporter plasmid, and then
incubatedwith 4%BSA±PA.Our results showed that 24 h treatment with
1 mM PA significantly inhibited POMC promoter activity (4% BSA:
1.00±0.07, 4%BSA + 1mMPA: 0.75±0.04, A.U.), and induced autoph-
agy and oxidative stress. Similar results on POMC promoter activity were
obtained incubating the cells with Rapamycin or H2O2, suggesting a role
for these cellular processes on POMC regulation.
Conclusion: Administration of a SRD shows a significant effect on cel-
lular mechanisms that influence POMC transcription and ACTH produc-
tion in corticotroph cells. We also hypothesize that sustained elevated
FFA serum levels could contribute to the observed pituitary dysfunction.
Supported by: PICT 2008-1034; CONICET PIP 2013-2015, UBACYT
2011-2014
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A disrupted rhythm of appetite-regulating hormone is relevant to
abnormal feeding behaviour in high fat diet induced obese mice
H. Mifune1, Y. Tajiri2, K. Hara2, S. Iwata2, Y. Nishi3, M. Kojima4, K.
Yamada2;
1Institute of Animal Experimentation, 2Department of Internal Medicine,
Division of Endocrinology and Metabolism, 3Department of Physiology,
Kurume University School of Medicine, Japan, 4Kurume University, Ja-
pan.
Background and aims:A number of appetite-regulating molecules have
been identified and discussed in obese subjects and animals. Ghrelin is a
representative orexigenic gut hormone produced in the stomach. Patho-
physiological roles of ghrelin in obesity is, however, largely unknown
together with its diurnal dynamics. Neuromedin U (NMU) is distributed
in the brain and gut, including supra-chiasmic nucleus (SCN) in the hy-
pothalamus, a master biological clock. In contrast to ghrelin, NMU acts as
an anorexigenic peptide. Because these two antagonistic peptides have
never been discussed simultaneously, the aim of the present study is to
explore the relevance of these peptides in the formation and progression
of obesity, especially in relation to a diurnal rhythm of feeding and
activity.
Materials and methods: Male C57BL/6J mice at 4 weeks old were
housed in a control room under a 12 h light-dark cycle (light on 0700-
1900) with ad libitum access to either control diet (CD: 10 kcal% fat) or
high fat diet (HFD: 60 kcal% fat) for 12 weeks. At 16 weeks old, an
individual mouse was transferred to a metabolic chamber (ARCO sys-
tems), and respiratory quotient (RQ), food consumption and locomotor
activity (ACT) was measured on a minute by minute basis for 2 days.
Then mice were sacrificed at 4 different time points (7:00, 13:00, 19:00,
25:00), and plasma for the determination of ghrelin by RIA and hypo-
thalamus for NMU and stomach for clock genes such as BMAl1 and
PER2 by RT-PCR were retrieved. To further elucidate a role of ghrelin
for the regulation of feeding and ACT, 16 weeks old ghrelin knockout
(GKO) mice fed CD were housed in ARCO systems for 2 days same as
wild type (WT) mice.
Results: Body weight in HFD group was significantly higher than that in
CD group at 16 weeks old. Food consumption and ACT in CD group
were mainly observed during dark phase (D) with a very small ACT
during light phase (L). RQ in CD group showed a clear diurnal rhythm
with being low during L and high during D. In contrast, these distinct
diurnal rhythms of food consumption, ACT and RQ were severely
disrupted in HFD group with an increase of these parameters during L.
Although plasma ghrelin concentration revealed a bimodal rhythm with a
zenith at 7:00, 19:00 and a nadir at 13:00, 25:00 in CD group, a complete-
ly reverse rhythm was observed in HFD group. On the other hand, NMU
expression in the hypothalamus showed a diurnal rhythm with being high
during L and low during D in CD group, and a completely reverse rhythm
was observed in HFD group. Furthermore, a diurnal phase of stomach
BMAl1 expression shifted backward and PER2 shifted forward in HFD
group compared to CD group. It is of interest that GKO mice fed CD
showed indistinct rhythms of ACT and RQ, which are quite similar to
those in WT mice fed HFD.
Conclusion:An indistinct rhythms of ACTand feeding observed in HFD
group evokes abnormal binge eating in human obese subjects. Ghrelin
may act as an initiator of feeding behavior from the results in GKOmice,
and NMU may control circadian rhythms of clock genes taking its local-
ization in SCN into account. It is suggested that abnormal diurnal rhythms
of both appetite-regulating peptides in HFD group is quite relevant to the
formation and progression obesity.
Supported by: Grant-in-Aid for Scientific Research (C) (No. 25504019 &
25350914)
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Dose-dependent stimulatory effect of leptin on Leydig cell steroido-
genesis in leptin-deficient obese mice
S. Kralisch-Jäcklein1,2, I.V. Wagner1,3, G.M. Manjowk1, A. Hoffmann2,
N. Klöting1,2, T. Ebert1,2, B. Jessnitzer2, U. Loessner1,2, R. Burkhardt4,
M. Stumvoll2, O. Söder3, K. Svechnikov3, M. Fasshauer1,2;
1IFBAdiposityDiseases, 2Department of Endocrinology and Nephrology,
University of Leipzig, Germany, 3Department of Women and Child
Health, Karolinska Institutet, Stockholm, Sweden, 4Institute of Laborato-
ry Medicine, University Leipzig, Germany.
Background and aims: Over the last decade, the evidence linking obe-
sity to impaired male reproductive function has grown. Leptin is a known
mediator and modulator of the hypothalamus-pituitary-testes axis, dys-
regulated in obesity; however, data have been inconsistent. The aim of the
study was to elucidate the dose-dependent impact of leptin on male re-
productive function and Leydig cell steroidogenesis in a mouse model of
obesity.
Materials and methods: Leptin-deficient obese (ob/ob) male mice on a
C57BL/6J LDLR-/- background were treated with 0.1, 0.5, or 3 mg/kg
body weight/d murine recombinant leptin or saline for 12 weeks starting
at 8 weeks of age. The effect of leptin on testicular weight, spermatogen-
esis, intratesticular testosterone, Leydig cell morphology, and macro-
phages was elucidated.
Results: Testis weight which is mostly indicative of overall spermatogen-
ic activity was significantly and dose-dependently up-regulated between
control (saline-treated; 1.69 mg/g bodyweight (BW)) and leptin-treated
animals (2.56, 2.76, and 3.28 mg/g BW at 0.1, 0.5, or 3 mg/kg body
weight/d, respectively) (p<0.001). Moreover, intratesticular testosterone
content was restored dose-dependently after leptin treatment (314.4,
497.2, and 526.3 ng/g tissue at 0.1, 0.5, or 3 mg/kg body weight/d,
respectively) compared to saline-treated mice (212.7 ng/g tissue) (p<
0.001). Restoration of intratesticular testosterone in leptin-treated animals
was associated with a significant up-regulation of the steroidogenic en-
zymes Cyp11a1 and Cyp17. Testicular histology indicated that Leydig
cells dose-dependently regain their usual morphology and clustering
characteristic after leptin-treatment as compared to saline-treated animals.
In contrast, macrophagemarkers were not different between leptin-treated
and control mice.
Conclusion: The adipokine leptin might play an important role in the
regulation of Leydig cell function and testicular physiology.
Supported by: SFB 1052/1, C06; BMBF FKZ 01EO1001, K7-58; DDS;
ESPE
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BACE2 suppression protects from High Fat Diet (HFD)-induced
metabolic effects
G. Alcarraz-Vizán, C. Castaño, M. Visa, J. Montane, M. Obach, J.-M.
Servitja, A. Novials;
Diabetes & Obesity Laboratory, IDIBAPS, Barcelona, Spain.
Background and aims: BACE2 (β-site APP-cleaving enzyme 2) is a
protease that has been found in the brain, where it is thought to play a role
in the development of Alzheimer’s disease (AD). It has also been local-
ized in the pancreas, where it seems to play a physiological role, since
BACE2-deficient mice elicit better glucose tolerance than control litter-
mates. However, despite the potential link between AD and glucose
homoeostasis deregulation in humans and rodents, the involvement of
BACE2 in other metabolic disturbances, such as insulin resistance and
obesity, has not been explored. Thus, the aim of the present study was to
investigate the effect of BACE2 on whole-body glucose metabolism.
Materials and methods: BACE2-KO mice and their respective controls
were used to analyze their phenotype after 16 weeks of high-fat diet
(HFD) feeding. Insulin tolerance test (ITT) and glucose tolerance test
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(GTT) were performed to evaluate metabolic phenotype, and the area
under the curve (AUC) of the GTTwas calculated as a measure of glucose
homeostasis. The ability to secrete insulin in response to glucose (GSIS)
was quantified with an ELISA kit. β-cell mass was analyzed by insulin
immunostaining. mRNA expression of relevant genes from pancreatic
islets, white adipose tissue and hypothalamus was analyzed by quantita-
tive PCR.
Results: BACE2-KO mice fed with HFD showed a 32% reduction in
body weight (p<0.05), with respect to their wild type counterparts,
whereas no changes in food intake were observed. Moreover, BACE2-
KO mice fed with HFD presented better glucose homeostasis (28% de-
crease in AUC of GTT) and did not exhibit insulin resistance when
compared to wild type animals with the same feeding. Interestingly, white
adipose tissue from these animals presented a weight reduction of 25% (p
<0.01) and a lower expression of the inflammation marker ccl2. Further-
more, while wild type animals presented a remarkable decrease in the
levels of hypothalamic anorexigenic markers pomc and cartpt when fed
with HFD (65% reduction in the case of pomc, p<0.01), BACE2-KO
animals did not show changes in any of the neuropeptides studied with
respect to the animals fed with a regular diet.
Conclusion: Altogether, these results indicate that the inhibition of
BACE2 seems to protect against HFD. Thus, targeting BACE2 may
represent a good therapeutic strategy to ameliorate the pathological ef-
fects of obesity.
Supported by: FIS (PI11/00679 PI14/00447)
PS 050 GLP-1 based therapies
for obesity
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Significant effects of HM11260C on body weight over 20 weeks in
obese subjects without diabetes: a randomised, double-blind, placebo
controlled study
R. Pratley1, J. Kang2, P. Kim2, E. Kwak2, O. Han2, S. Kil2, K. Gee2, I.
Choi2, S. Kwon2, M. Trautmann3, M. Hompesch3;
1Florida Hospital Diabetes Institute, Orlando, USA, 2Hanmi Pharm. Co.,
Ltd., Seoul, Republic of Korea, 3Profil Institute for Clinical Research,
Inc., Chula Vista, USA.
Background and aims: HM11260C (HM) is a novel long acting GLP-
1R agonist with a T1/2 of~158 hrs resulting in a flat PK profile. This 20-
week, randomized, double-blind, placebo (PBO) controlled, parallel
group study was designed to evaluate the efficacy, safety, and tolerability
of once a week (QW) or every other week (Q2W) doses of HM in obese
subjects without diabetes.
Materials and methods: 297 subjects (mean age 43.4 yrs and BMI
35.5 kg/m2) were randomized to one of four HM doses (4 mg QW,
6 mg QW, 6 mg Q2W, or 8 mg Q2W) or to PBO. HM was administered
subcutaneously for 20 weeks. The diet and exercise regimens remained
unchanged during the study.
Results: The body weight loss with HM4mgQW, 6mgQW, 6mgQ2W
and 8 mg Q2W was 6.2 kg, 7.8 kg, 7.0 kg and 7.1 kg (LS Mean, p<
0.0001 all HM treatment groups), whereas the body weight gain was
observed with PBO (0.8 kg). More subjects in the HM treatment groups
achieved significant body weight loss ≥5% or ≥10%, and the mean re-
ductions in BMI from baseline were greater, compared with PBO. Chang-
es from baseline in waist circumference were -6.00 cm, -9.45 cm, -
7.11 cm, -8.00 cm and -0.21 cm (LS Mean) with HM 4 mg QW, 6 mg
QW, 6 mg Q2W, 8 mg Q2Wand PBO. The most frequent adverse events
were gastrointestinal events which were observed relatively frequently
and increased injection site reactions which were less common (Table 1).
Conclusion: All doses of HM meaningfully reduced body weight and
werewell tolerated. These results warrant further studies to assess titration
schemes as well as the long-term efficacy and safety of HM in obesity.
Clinical Trial Registration Number: NCT02075281
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MEDI0382 a novel GLP1/glucagon co-agonist induces profound
body weight loss and improves metabolism in rodents and non-
human primates
A. Konkar1, P. Ambery2, M. Bednarek2, M. Fritsch-Fredin3, J. Grims-
by1, S. Henderson2, D. Hornigold2, R. Jackson2, C. Rondinone1, J.
Trevaskis1, L. Jermutus2;
1MedImmune, Inc., Gaithersburg, USA, 2MedImmune, Inc., Cambridge,
UK, 3Astrazeneca, Molndal, Sweden.
Background and aims: Oxyntomodulin (OXM), the endogenous GLP-
1/Glucagon co-agonist peptide, is secreted from intestinal L-cells in re-
sponse to meals. OXM reduces body weight in obese subjects and pro-
duces direct acute glucoregulatory effects in type 2 diabetic patients. Due
to its short lifetime in circulation, the clinical utility of this hormone is
limited. We synthesized stable, lipidated analogs of OXM that possessed
the in silico selected ratios of GLP-1:glucagon activity ideal for clinical
utility.
Materials and methods: Chinese hamster ovary cells stably expressing
human GLP-1 and glucagon receptors were used to evaluate the ability of
MEDI0382 to stimulate cAMP production. C57Bl/6 mice fed a 60%
high-fat diet, diabetic db/db mice and cynomolgus monkeys were used
to evaluate the metabolic effects of subcutaneously injected MEDI0382.
Results: The lead molecule, MEDI0382, is a highly potent agonist of
GLP-1 and glucagon receptors. Once-daily subcutaneous dosing with
MEDI0382 (10 and 30 nmol/kg) reduced body weight by 24.5% and
32.5% in male diet-induced obese (DIO) mice, as compared with
vehicle-treated DIO mice. The effect was superior to liraglutide
(40 nmol/kg). Liraglutide had a greater effect on cumulative food intake
than both doses of MEDI0382, suggesting that the effect of MEDI0382
on body weight may be partly mediated by increased energy expenditure.
A significant improvement in glucose tolerance was observed in drug-
treated mice in an intraperitoneal glucose tolerance test. In diabetic db/db
mice, a single dose of MEDI0382 reduced glucose excursion following
an intraperitoneal glucose challenge. Repeated daily dosing of
MEDI0382 for 2 months in cynomolgus monkeys resulted in dose-
dependent reductions in body weight of 5% to 12% compared to starting
bodyweights at the end of the treatment period.
Conclusion: In summary, our data indicate that MEDI0382 shows sig-
nificant promise as a weight loss drug in overweight and obese subjects
and the potential to lower glucose in people with type 2 diabetes.
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Early weight loss with liraglutide 3.0 mg is good predictor of clinical-
ly meaningful weight loss after 56 weeks
M. Blüher1, K. Hermansen2, F. Greenway3, K. Fujioka4, M. Donsmark5,
C.B. Jensen5, J.P.H. Wilding6;
1University of Leipzig, Germany, 2AarhusUniversity Hospital, Denmark,
3Pennington Biomedical Research Center, Baton Rouge, 4Scripps Clinic,
La Jolla, USA, 5Novo Nordisk, Søborg, Denmark, 6University of Liver-
pool, UK.
Background and aims: Early identification of responders to weight loss
(WL) medications is important in order to discontinue those unlikely to
achieve WL targets; EU regulators are especially interested in identifying
those unlikely to achieve ≥10% WL at 1 yr. This subgroup analysis of
SCALE Obesity and Prediabetes and SCALE Diabetes trials reports key
efficacy and safety outcomes in adults achieving ≥5%WL from baseline at
Week (W) 16 on liraglutide (lira) 3.0 mg (early responders; ER), compared
to those who did not (early non-responders; ENR). AWL target of ≥5% at
W16 demonstrated the best balance between negative predictive value and
sensitivity in identifying those unable to achieve ≥10% WL at W56.
Materials and methods: 2910 adults were randomized to lira as adjunct
to diet & exercise (D&E): 2487 without T2D (BMI ≥30 or 27-29.9 kg/
m2+≥1 comorbidity; 45 yr; 21% male; BMI 38 kg/m2; 61% with predi-
abetes), and 423 with T2D (BMI ≥27 kg/m2; 55 yr; 52% male; BMI
37 kg/m2); 2159 and 365 adults without and with T2D respectively com-
pleted 16 W of treatment. Lira was increased weekly by 0.6 mg to a
3.0 mg maintenance dose. Efficacy data are for 56 W completers. Mean
and categorical WL was estimated by ANCOVA or logistic regression
model respectively. Efficacy data are LS means or estimated proportions,
safety data are observed proportions.
Results: 67.5% ofW16 completers without T2D were ER to lira 3.0 mg,
with a mean WL of 11.5% at W56. Proportions of ER with ≥5%, >10%
and >15% WL at W56 with lira were 88.2%, 54.8% and 24.2%, respec-
tively. ENR without T2D achieved mean WL of 3.8% at W56, and
36.9%, 8.3% and 1.8% had achieved ≥5%, >10% and >15%WL, respec-
tively. 50.4% of W16 completers with T2D were ER to lira 3.0 mg, with
mean WL of 9.3%W56. Proportions of ER with ≥5%, >10% and >15%
WL at W56 with lira were 80.1%, 44.6% and 11.6%, respectively. ENR
with T2D achieved mean WL of 3.6% at W56, at which time 33.3%,
5.8% and 1.3% had achieved ≥5%, >10% and >15% WL, respectively.
Pooled across trials 93.4% of ENR failed to achieve ≥10% WL at W56.
Across both trials, greater improvements in CV risk factors were seen in
ER than ENR, consistent with greater WL. The overall safety profile was
generally comparable between ER and ENR (Table). In those without
T2D rates of hepatobiliary disorders appeared higher in ER than ENR.
In patients with T2D rates of severe hypoglycaemia (ADA Criteria) were
low in both ER and ENR (1.1% v 0.6%; all on SU) and the overall hypo
rates (ADA criteria, documented symptomatic) were generally compara-
ble between ER (28.3%) and ENR (21.0%).
Conclusion: Those failing to reach ≥5%WL atW16 are unlikely to reach
≥10% atW56. By contrast, ER to lira 3.0 mg as adjunct to D&E with and
without T2D achieve a meanWL at W56 of 9.3% and 11.5%, respective-
ly, with improvements in cardiometabolic markers with a similar safety
profile to NR.
Clinical Trial Registration Number: NCT01272219; NCT01272232
Supported by: Novo Nordisk
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Liraglutide 3.0 mg efficacy and safety by baseline BMI in the SCALE
Diabetes trial: post-hoc analysis
J. Udden Hemmingsson1, J. Rosenstock2, M. Davies3, H. Bays4, A.-P.
Cancino5, T.V. Skjøth5, V. Aroda6;
1Capio St Gorans Hospital, Stockholm, Sweden, 2Diabetes & Endocrine
Center, Dallas, USA, 3University of Leicester, UK, 4L-MARC Research
Center, Louisville, USA, 5Novo Nordisk, Søborg, Denmark, 6MedStar
Health Research Institute, Hyattsville, USA.
Background and aims: This analysis from the SCALE Diabetes trial
compared efficacy and safety results for individuals with baseline BMI
<or ≥35 kg/m2 treated with liraglutide 3.0 mg for weight management or
placebo.
Materials and methods: 846 adults were randomised (age 54.9 y, male
50%, BMI 37 kg/m2, A1C 7.9%, T2D duration 7.3 years) 2:1:1 to
liraglutide 3.0 mg, 1.8 mg, or placebo as adjunct to diet and exercise
for 56 weeks. Data are LS means (efficacy) or observed means (LOCF).
Results: Overall withdrawals rates were 23.4% for liraglutide 3.0 mg vs
34.0% for placebo. At 56 weeks, greater mean and categorical weight
loss, and greater improvements in glycaemic parameters, SBP, and
IWQoL-Lite physical function score were seen with liraglutide 3.0 mg
vs placebo in both subgroups. Treatment effects were independent of
baseline BMI subgroup (p>0.05) (Table). BMI subgroups had broadly
comparable adverse events (AEs). In both liraglutide 3.0 mg subgroups
(BMI<or ≥35 kg/m2) a greater proportion of subjects had nausea (34 vs
32%) and vomiting (11% vs 20%) than placebo (nausea: 12 vs 15%;
vomiting: 8% vs 4%). Documented symptomatic hypoglycaemia (FPG
≤3.9 mmol/L) rates were similar with liraglutide 3.0 mg in both BMI
subgroups (1.07 vs 0.70 events/PYE), as was severe hypoglycaemia, seen
in three subjects with concomitant sulphonylureas.
Conclusion: In summary, effects of liraglutide 3.0 mg, as adjunct to diet
and exercise, on weight loss, associated metabolic effects and safety pro-
file were consistent across predefined baseline BMI subgroups.
Clinical Trial Registration Number: NCT01272232
Supported by: Novo Nordisk
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The impact of gastrointestinal adverse events on weight loss with
liraglutide 3.0 mg as adjunct to a diet and exercise programme
C. le Roux1, D.C.W. Lau2, K. Fujioka3, I.D. Caterson4, A.-P. Cancino5,
C.B. Jensen5, M.E.J. Lean6;
1Diabetes Complications Research Centre, University College Dublin,
Ireland, 2University of Calgary, Canada, 3Scripps Clinic, La Jolla, USA,
4University of Sydney, Australia, 5Novo Nordisk, Søborg, Denmark,
6University of Glasgow, UK.
Background and aims: To explore any associations between gastroin-
testinal adverse events (GI AEs) and weight loss with liraglutide 3.0 mg/
day in addition to a diet and exercise programme in individuals without
type 2 diabetes who had obesity (BMI ≥30 kg/m2) or overweight (BMI
27-29.9 kg/m2) with at least one comorbidity.
Materials andmethods:The SCALEObesity and Prediabetes trial was a
randomised, double-blind, multi-centre trial in which individuals (mean
age 45.1 years, 78.5% female, meanweight 106.2 kg, mean BMI 38.3 kg/
m2, 61% with prediabetes) were enrolled in a long-term weight manage-
ment programme and randomised to liraglutide 3.0 mg (n=2487) or pla-
cebo (n=1244). These data are from an exploratory analysis based on
groups of individuals defined by occurrence of GI AEs (0-16 weeks, 0-
56 weeks). Weight loss at week 56 is presented as least squares means
using LOCF, with p-values denoting whether or not GI AEs had a signif-
icant effect on treatment.
Results: Overall, liraglutide 3.0 mg was associated with a greater weight
loss from baseline than placebo (8.0% vs. 2.6%, respectively, p<0.0001).
As expected, more individuals on liraglutide 3.0 mg (68.3%) compared
with placebo (40.3%) reported GI AEs; the most prevalent GI AEs were
nausea (40.2 vs. 14.7%), diarrhoea (20.9 vs. 9.3%), constipation (20.0 vs.
8.7%) and vomiting (16.3 vs. 4.1%), occurring mostly within the first
16 weeks of treatment. There was no significant difference in weight loss
between individuals who did or did not experience ≥1 episode of nausea/
vomiting during 0-56 weeks, regardless of treatment (liraglutide 3.0 mg:
nausea/vomiting, -7.8%, no nausea/vomiting, -8.1%; placebo: nausea/
vomiting -2.5%, no nausea/vomiting -2.6%, p=0.81). Similar results
were seen if all other types of GI AE combined were included. Moreover,
no significant differences were observed at week 56 for weight loss in
individuals who experienced 0, 1, 2-3, or ≥4 GI AEs in the first 16 weeks
(7.7-8.2%with liraglutide 3.0 mg vs. 2.3-3.0%with placebo, p=0.24), or
during the entire 56 weeks of treatment (7.7-8.4%with liraglutide 3.0 mg
vs. 2.4-3.2% with placebo, p=0.55). Although those experiencing 0 GI
AEs appeared to perform slightly better than the other groups, this may be
explained by the higher withdrawal rate as the number of GI AE increase.
These results were further supported by comparable mean weight loss
profiles over time across the 0, 1, 2-3, or ≥4 GI AE groups.
Conclusion: The weight loss observed with liraglutide 3.0 mg is not
explained by the occurrence of GI AEs, including nausea/vomiting.
Clinical Trial Registration Number: NCT01272219
Supported by: Novo Nordisk
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GLP-1 andGLP-2 responses to a fat-richmeal correlate to postpran-
dial triglyceride-rich lipoproteins in obese men
N. Matikainen1,2, S. Söderlund2, C. Borén3, B. Eliasson3, K.H.
Pietiläinen1,2, L.H. Bogl2, A. Rivellese4, G. Riccardi4, J.-P. Després5, N.
Alméras5, J.J. Holst6, C.F. Deacon6, J. Borén3, M.-R. Taskinen2;
1Endocrinology, Helsinki University Hospital, 2Research programs Unit,
Diabetes and Obesity, University of Helsinki, Finland, 3Department of
Molecular and Clinical Medicine/Wallenberg Laboratory, University of
Gothenburg, Sweden, 4Department of Clinical Medicine and Surgery,
Federico II University, Naples, Italy, 5Institut Universitaire deCardiologie
et de Pneumologie de Québec, Québec City, Canada, 6NNF Centre for
Basic Metabolic Research, and Department of Biomedical Sciences, Fac-
ulty of Health and Medical Sciences, Copenhagen, Denmark.
Background and aims: Nutrients, mainly glucose and lipids stimulate
the gut incretin hormones glucagon-like peptide (GLP) 1, GLP-2 and
glucose-dependent insulinotrophic peptide (GIP) that in animal models
or if given in pharmacologic doses to humans regulate chylomicron se-
cretion from the enterocytes. However, the effect of these gut incretins on
human postprandial lipid metabolism is not fully clarified. We aimed to
explore the responses of GLP-1, GLP-2 and GIP after glucose tolerance
test (OGTT) or fat-rich meal, and the relationships between responses of
incretins and postprandial triglyceride (TG)-rich lipoprotein after fat-rich
meal.
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Materials and methods:Glucose, insulin, GLP-1, GLP-2 and GIP were
measured during OGTT (75 g glucose) and fat-rich meal (63 g carbohy-
drates, 56 g fat and 40 g protein) in 75 healthy obese (BMI 26-40 kg/m2)
male subjects with mean age of 49 years, LDL-cholesterol 3.3 mmol/L,
HDL-cholesterol 1.2 mmol/L and TG 1.6 mmol/l. TG, apoB48 and
apoB100 in TG-rich lipoproteins(chylomicrons, VLDL1 and VLDL2)
were measured after fat-rich meal. We measured postprandial responses
[area under curve (AUC)] for glucose, insulin, GLP-1, GLP-2, GIP in
plasma, and TG, apoB48 and apoB100 in plasma and TG-rich lipopro-
teins separated by gradient density ultracentrifugation.
Results: The GLP-1, GLP-2 and GIP responses after fat-rich meal and
OGTT correlated strongly (r=0.73, p<0.0001; r=0.46, p<0.001 and r=
0.69, p<0.001, respectively). Glucose and insulin AUCs were lower, but
the AUCs for GLP-1, GLP-2 and GIP were significantly higher after fat-
rich meal than OGTT. The peak value for all hormones appeared at
120 minutes after fat-rich meal, compared to 30 minutes after OGTT.
After fat-rich meal, the AUCs for GLP-1, GLP-2 and GIP correlated
significantly with TG, apoB48 and apoB100 in chylomicrons.
Conclusion: In obese males, GLP-1, GLP-2 and GIP responses to a fat-
rich meal are greater than following an OGTT. The balance between
responses of GLP-1 and GLP-2 to a fat-rich meal may be involved in
regulating postprandial responses of TG-rich lipoproteins.
PS 051 Obesity: emerging concepts in
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Effects of weight loss and long-term weight maintenance with diets
varying in protein and glycaemic index on atrial natriuretic peptide
in the Diet, Obesity, and Genes study
N.N. Rudovich1,2, W. Bernigau3, O. Pivovarova1,2, V. Murahovshi1,2,
M.A. Osterhoff1, M.A. van Baak4, S.A. Jebb5, A. Valsesia6, J. Hager6,
N. Viguerie7, D. Langin7, W.H.M. Saris4, A. Astrup8, A.F.H. Pfeiffer1,2,
DiOGenes Study Group;
1Clinical Nutrition, DIFE Potsdam-Rehbrücke, Nuthetal, 2Charite´
Universitätsmedizin, Berlin, 3Epidemiology, DIFE Potsdam-Rehbrücke,
Nuthetal, Germany, 4NUTRIM School for Nutrition, Toxicology, and
Metabolism, Maastricht University Medical Centre, Netherlands, 5Med-
ical Research Council HumanNutrition Research, ElsieWiddowson Lab-
oratory, Cambridge, UK, 6Nestlé Institute of Health Sciences SA, Lau-
sanne, Switzerland, 7Obesity Research Laboratory, Institute of Metabolic
and Cardiovascular Diseases, Inserm, Paul Sabatier University, Toulouse,
France, 8Faculty of Science, University of Copenhagen, Denmark.
Background and aims: Low atrial natriuretic peptide (ANP) concentra-
tions are independently associated with risk of cardiovascular diseases
and type 2 diabetes in obesity, while high natriuretic peptide levels appear
to be protective. We tested the hypothesis that circulating ANP may be
regulated by weight loss and dietary interventions.
Materials andmethods:DiOGenes is a pan-European controlled dietary
intervention study in overweight adults who first lost body weight on an
8-week low-calorie diet and were then randomized to 1 of 5 ad libitum
diets for 26 weeks. The diets were either high (HPI) or low (LPI) protein
or high (HGI) or low (LGI) glycemic index in 4 combinations or control.
The concentrations of adiponectin and ANP (measured as mid-regional
pro-atrial NP (MR-proANP)), were measured and analyzed together with
anthropometrical and physiological parameters.
Results: Weight loss after 8-week low-calorie diet (mean±s.e.m; 11.2±
3.5 kg; p<0.001) increasedMR-proANP (from 49.7±20.3 pmol/l to 53.0
±19.3 pmol/l; p<0.001) in the whole cohort and was pronounced in male
subjects (n=173; 44.6±18.2 pmol/l vs. 52.5±21.0; p<0.001) than in
women (n=336; 52.0±20.1 pmol/l vs. 52.8±18.2 p=0.39). During the
26-week weight maintenance period, MR-proANP decreased among the
male subjects assigned to HGI diets (53.0±19.0 pmol/l vs. 47.0±19.0 p=
0.002) as well as in groups with LGI diets (50.3±22.1 pmol/l vs. 45.2±
19.4 p=0.003, p=0.69 for group comparison). A similar effect was ob-
served in male subjects during HPI and LPI interventions (50.3±19.2
pmol/l vs. 45.6±16.6, p=0.006 for HPI; 53.5±22.3 pmol/l vs. 46.8±
22.4, p<0.001 for LPI; p=0.418 for group comparison). No changes of
MR-proANPwere observedwith all three types of diets in women (51.2±
14.5 pmol/l vs. 49.7±15.8, p=0.18 for HGI; 54.3±21.4 pmol/l vs. 53.6±
21.9, p=0.63 for LGI; p=0.63 for group comparison and 52.1±17.1
pmol/l vs. 51.0±19.9, p=0.37 for HPI; 53.7±20.1 pmol/l vs. 52.7±
18.7, p=0.45 for LPI; p=0.95 for group comparison). Changes in circu-
lating MR-proANP after weight loss correlated inversely with fasting
insulin (r=-0.12, p=0.01), fasting glucose (r=-0.18, p<0.0001), waist
circumferences (r=-0.11, p=0.01 and positively with adiponectin (r=
0.16, p=0.0004) in the whole cohort.
Conclusion:Weight loss effectively increases circulatingMR-proANP in
male but not female subjects. The different types of diets were unable to
prevent a decrease of ANP during the weight maintaining phase. Gender
differences in the regulation of endogenous ANP may be causally asso-
ciated with higher cardiovascular risk in males and could have implica-
tions for personalized medicine.
Clinical Trial Registration Number: NCT00390637
Supported by: FP6-2005-513946 and FOOD-CT-2005-513946
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Impact of obesity on bone mass throughout adult life: influence of
gender and severity of obesity
A. Sultan1,2, A. Avignon1,2, D. Mariano-Goulart1, T. Mura1, L.
Maimoun3,2;
1CHU Lapeyronie, 2INSERM U1046, 3CHU, Montpellier, France.
Background and aims: Cross-sectional studies have demonstrated that
obesity improves areal bone mineral density (aBMD). However, it is not
known if gender, aging or severity of obesity could modulate this effect
and if bone sites are similarly impacted. The main aim of the study was to
model the aBMD variation in obese patients from peak bone mass period
until elderly age according to gender, bone localisation and severity of
obesity. The secondary aim was to identify the relationship between
aBMD and body composition during obesity.
Materials and methods: Obese patients were recruited in the Nutrition
Clinic where they had been addressed for metabolic and physical assess-
ment of their obesity. DXA (Hologic QDR-4500A, Hologic, Inc., Wal-
tham,MA) measured the areal bone mineral density (BMD; g/cm2) of the
whole body and at specific bone sites: the antero-posterior lumbar spine
(L1-L4), the dominant arm radius and the hip. The soft tissue body com-
position , percentage of body fat mass and leanmass was derived from the
whole body scan. We first estimated Z-scores of aBMD adjusted for age
according to bone sites and gender using a linear mixed model. We then
customized statistical tests to compare (1) the estimated value of Z-score
(and change in Z-score with age) to 0 for each bone site for men and
women, (2) the estimated value of Z-score (and change in Z-score with
age) between men and women for each bone site, (3) the estimated value
of Z-score (and change in Z-score with age) between each bone site for
men and women. The effect of obesity grades was analyzed separately for
men and women using the same type of linear mixed model and custom-
ized statistical tests. The relations between aBMD and age have also been
studied for each bone site according to gender and grades of obesity using
thin plate regression spline models. Statistical analyses were performed at
the conventional two-tailed α level of 0.05 using SAS version 9.2
Results: Five hundred and four french obese patients (363 women and 141
men) with a mean BMI of 38.5±6.0 kg/m2, aged from 18.1 to 81.9 years
(mean age 49.6±14.6 years) were enrolled.Excepted at L1-L4 in men, Z-
scores were significantly increased, above the age- and gender-related
mean, both for women and men at WB (respectively 0.79 SD and 0.31
SD), hip (1.09 SD and 1.05 SD), radius (1.42 SD and 0.25 SD) and L1-L4
(0.85 SD for women only). The improvement of Z-scores appeared signif-
icantly more marked in women that in men in all bone sites, hip excepted.
Further, differences with normal values were significantly accentuated by
aging, without any depend-effect of gender. In women, whatever the BMI
or the bone site, Z-scores were significantly higher than normal values, but
difference appeared more marked at WB, L1-L4 and hip for those patients
with a BMI above 40 kg/m2. Lean mass, but not fat mass appeared an
independent predictor of aBMD in men and women.
Conclusion: This study demonstrated for the first time that obesity in-
duces an improvement of aBMD, which is however modulated by bone
site localisation, severity of obesity, age and gender. The accentuation of
peak bone combined to reduction of bone loss related to aging may
explain that obese patients do present a lower prevalence of osteoporosis.
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Visceral fat obesity and metabolic syndrome increase serum DPP-4
levels in type 2 diabetes mellitus
S. Tanaka, I. Kanazawa, M. Notsu, T. Sugimoto;
Shimane University Faculty of Medicine, Izumo City, Japan.
Background and aims:Dipeptidyl peptidase-4 (DPP-4) is a ubiquitously
expressed transmembrane glycoprotein and separates N-terminal dipep-
tides from a variety of substrates including incretin such as glucagon-like
peptide 1 (GLP-1) and gastric inhibitory polypeptide. Recently, it has
been shown that DPP-4 is one of adipokines expressed and secreted from
adipose tissue, and that DPP-4 expression in visceral fat is greater than in
subcutaneous fat. Previous studies showed that serum DPP-4 levels were
significantly elevated in obese subjects compared to non-obese. However,
it remains unclear whether or not serum DPP-4 levels are associated
specifically with visceral fat mass and metabolic syndrome (Mets) in type
2 diabetes mellitus (T2DM). Therefore, the aim of this study was to
examine the association of serum DPP-4 with visceral fat accumulation
and the presence of Mets in patients with T2DM.
Materials and methods: This is a cross-sectional study with 135 Japa-
nese male patients with T2DM. None of them had hepatic or renal dys-
function and had taken DPP-4 inhibitors or GLP-1 receptor agonists so
far. Visceral and subcutaneous fat areas were evaluated by performing
computed tomography scan at the level of the umbilicus. Serum DPP-4
concentration was measured by using commercially available ELISA
kits. We defined more than 100 cm2 of visceral fat area as visceral fat
obesity as well as dyslipidemia (triglyceride≥150 mg/dL, HDL <40 mg/
dL, or usage of statins and fibrates) and/or hypertension (systolic blood
pressure (BP)≥140 mmHg, diastolic BP≥90 mmHg, or usage of anti-
hypertensive drugs) accompanied by visceral fat obesity as Mets. We
analyzed the relationships between serum DPP-4 levels and various pa-
rameters by multiple regression analyses and logistic analysis.
Results: Means of age and duration of T2DM were 57.4 years old and
9.8 years, respectively. Mean serum DPP-4 level was 809.1 ng/mL. Of
135 patients, 78 and 74 were visceral fat obesity and Mets, respectively.
In multiple regression analysis adjusted for age, duration of T2DM, body
mass index, serum creatinine, and HbA1c, DPP-4 was significantly and
positively associated with visceral fat area (β=0.15, p=0.01), but not
subcutaneous fat area (β=-0.09, p=0.14). Un-paired Student t-test
showed that serum DPP-4 was marginally higher in patients with visceral
fat obesity than without it (832 ng/mL vs 778 ng/mL, p=0.09), and that
serum DPP-4 was significantly higher in patients with Mets than without
it (838 ng/mL vs 775 ng/mL, p=0.04). In logistic analyses adjusted for
the confounding factors described above, serum DPP-4 was significantly
and positively associated with visceral fat obesity and Mets [odds ratio
(OR)=1.34, 95% confidence interval (CI)=1.04-1.72 per standard devi-
ation (SD) increase, p=0.02; OR=1.87, 95%CI=1.17-2.98 per SD in-
crease, p<0.01, respectively].
Conclusion: Although it is previously reported that serum DPP-4 levels
were increased in obese patients, the present study showed for the first
time that serum DPP-4 levels were associated positively and specifically
with accumulation of visceral fat, which is evaluated by CTscan, in male
patients with T2DM. In addition, serum DPP-4 levels were significantly
increased in patients with Mets, suggesting that serum DPP-4 may be
involved in not only glucose metabolism but also lipid metabolism and
blood pressure.
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Analysis of the intestinal microbiota composition and its relationship
with type 2 diabetes in patients with overweight and obesity in level II
C. Taddei1, J. McCulloch1, T.B. Petry2, M. Martinez1, R. Cohen2, J.
Salles3;
1University of São Paulo, 2Hospital Alemão Oswaldo Cruz, 3School of
Medical Sciences Santa Casa, São Paulo, Brazil.
Background and aims: It is estimated that 11 million people are diabetic
in Brazil, with a prevalence of T2DM. In recent years, studies indicate the
gut microbiota as an important modulator of the disease. Environmental
and genetic factors interact to control the host intestinal microbiota, trig-
gering metabolic disorders such as obesity and insulin resistance. The
objective of this study was to identify the fecal microbiota in adult dia-
betic patients and to evaluate changes in its composition after bariatric
surgery. Two groups of eleven patients each were enrolled in this study.
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Materials and methods: Group 1 were submitted to the Reducing
gastroplasty in Roux-Y and fecal sample were collected before the sur-
gery and after 6 and 12 months. Group 2 were followed through 6 and
12 months without surgery intervention and fecal samples were collected
at inclusion in the trial and after 6 and 12 months. Fecal microbiota was
analyzed using high throughput sequencing in MiSeq (Illumina) with v3-
v4 16S rRNA primers.
Results: The fecal microbiota in a surgery group has an increase in
bacterial abundancy and diversity when compared with non-surgery
group. This data was observed with the genera belonging to the Phylum
Bacteroidetes, with a remarkable increase of Bacteroides, and
Actinobacteria, with an increase of Bifidobacterium in surgery group.
Conclusion: This data could contribute to a better understanding of the
role of the microbiota in T2DM regulation.
Clinical Trial Registration Number: 1298/13
Supported by: CNPq
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Gliadin intake alters intestinal microbiota, glucose and lipid metab-
olism, and adipose tissue and liver immune cells
D. Andersen1, L. Zhang2, H.M. Roager2, N. Danneskiold-Samsøe3,
C.H.F. Hansen4, M.I. Bahl2, A.K. Hansen4, S. Brix1, L.I. Hellgren1,
T.R. Licht2;
1Systems Biology, 2National Food Institute, Technical University of Den-
mark, Copenhagen, 3Department of Biology, University of Copenhagen,
4Department of Veterinary Disease Biology, University of Copenhagen,
Denmark.
Background and aims: Dietary gluten induces type 1 diabetes and in-
testinal inflammation in celiac disease patients. Likewise, gluten has ef-
fects on intestinal inflammation andmicrobiota composition in non-celiac
disease subjects. However, the effect of dietary gluten on metabolic per-
formance in non-celiac disease conditions is still largely uncharacterised.
Therefore, we aimed to elucidate the mechanisms involved in the devel-
opment of gluten-induced metabolic dysregulation in obesity.We hypoth-
esized that intake of the gluten component, gliadin, induces changes in the
intestinal ecology compared to a gluten-free diet. This subsequently af-
fects host physiology via changes in glucose and lipid metabolism, as
well as leukocyte subsets in liver and adipose tissue, thus leading to a
metabolic syndrome phenotype.
Materials and methods: Forty C57BL/6 mice were fed a high-fat diet
with or without 4% gliadin for 22 weeks.
Results:Among the gliadin-fedmice, HbA1c levels andHOMA-IRwere
significantly higher, suggesting gliadin-dependent changes in glucose
metabolism and development of insulin resistance. Analysis of RNA
expression showed that the gluconeogenic enzyme Glucose-6-
phosphatase (G6Pase) was upregulated in the liver, indicating that the
increased blood glucose level was at least partly explained by increased
hepatic glucose output. Principal coordinate analysis (PCoA) of intestinal
content showed that gliadin-fed mice have an altered intestinal microbi-
ota, which also was manifested as higher acetate and total levels of short-
chain fatty acids in cecum. Since gliadin is known to be immune-
regulating and obesity-induced insulin resistance rely strongly on im-
mune cell signaling in metabolic organs, such as adipose tissue and the
liver, we performed a deep-phenotyping of the immune cells in these
tissues using flow cytometry. Monocyte subsets in blood showed no
differences in systemic inflammation between treatments. However, sig-
nificant alterations of the immune cell composition were evident in the
epididymal adipose tissue and the liver. Total numbers of macrophages
and T cells increased significantly in the adipose tissue of gliadin-fed
mice. Furthermore, various T cell subsets in the adipose tissue exhibited
a more pronounced inflammatory phenotype. Likewise, based on the
major immune cells detected in the liver, gliadin-fed mice displayed
alterations in their immune cell composition allowing for a gliadin-
dependent segregation using a principal component analysis (PCA).
Conclusion: Gliadin intake caused significant changes in glucose regu-
lation, intestinal microbiota, and in the leukocyte phenotypes of adipose
tissue and liver. Collectively, this suggests that gliadin-intake affects sev-
eral of the systems involved in regulating insulin sensitivity. The exacer-
bation of an insulin resistant phenotype in obese mice by gliadin indicates
that excessive gluten intake might increase the severity of metabolic syn-
drome. Further analyses of the relationship between these gliadin pheno-
types are needed to identify the mechanisms mediating a response to
gluten in the host.
Supported by: 3G Center
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Elevated plasma pigment epithelium-derived factor is reduced by
metformin treatment
P. Zhang, Y. Bi, S. Shen, D. Zhu;
Endocrinology department, DrumTower Affiliated to Nanjing University
Medical School, China.
Background and aims: Pigment epithelium-derived factor (PEDF) was
recently found to be closely associated with metabolic syndrome and
insulin resistance. However, there is a lack of evidence quantitating PEDF
levels in different glucose tolerance state and whether metformin treat-
ment could influence it remains unknown.We aimed to investigate serum
PEDF levels in subjects with different glucose tolerance and the effect of
metformin treatment on PEDF levels in type 2 diabetic patients.
Materials andmethods:Circulating PEDF levels and metabolic profiles
were assessed in 517 Chinese participants with normal glucose tolerance
(NGT), impaired glucose regulation (IGR) and type 2 diabetes mellitus
(T2DM), based on the guideline of International Diabetes Federation.
Body mass index (BMI) classification was according to the World Health
Organization, underweight (BMI <18.5 kg/m2), normal weight (18.5≤
BMI<25 kg/m2 ), overweight (25≤BMI <30 kg/m2), and obesity (BMI
≥30 kg/m2).63 diabetic patients were treated with metformin (Bristol-
Myers Squibb) for a period of 24 weeks, initially administered at
500 mg once daily and gradually titrated every two weeks to meet glyce-
mic targets (fasting plasma glucose ≤6.1 mmol/L) up to a maximum daily
dose of 1500mg. If the target was not achievedwith maximum dose, then
metformin was maintained as the maximum dose until the end of the
24weeks. PEDF levels after 24-weeks metformin treatment in 63 patients
with T2DM were also analyzed. Serum estradiol levels were determined
in females.
Results: In all participants (42.6%men and 57.4%women,mean age was
49.7±14.5 years), 186 had NGT, 216 had IGR and 169 had newly diag-
nosed diabetes. Serum PEDF level was significantly higher in subjects
with IGR [9.51 (7.6 - 11.4) ug/ml] and T2DM [9.7 (7.9 - 11.7) ug/ml],
compared with the controls [8.5 (7.1 - 10.7) ug/ml, p=0.010] and met-
formin treatment significantly decreased PEDF levels in T2DM patients
with weight loss (p=0.027).Spearman correlation analysis demonstrated
that PEDF levels were positively and significantly correlated with risk
factors regarding metabolic syndrome and visceral obesity such as body
mass index, waist circumference, waist-to-hip ratio, fasting and 2 h glu-
cose (p<0.001). Multiple stepwise regression analysis revealed that
PEDF was associated with alanine aminotransferase (p<0.001), triglyc-
erides (p=0.002) and diastolic blood pressure (p=0.002) after adjustment
for age and gender. Subjects with a higher tertile of PEDF concentration
exhibited a higher prevalence of overweight or obesity than those in the
lower tertile (p<0.001). Furthermore, men exhibited remarkably higher
serum PEDF levels [9.58 (7.92-11.92) ug/ml] than women [8.88 (7.35-
10.77) ug/ml, p=0.003] and this difference still existed even after
adjusting for BMI, waist circumference and waist-to-hip ratio (p=
0.009). We found that in post-menopause females, serum estradiol level
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was negatively associated with PEDF (r=-0.216, p=0.013) and was an
independent determinant of PEDF
Conclusion: PEDF concentration is significantly elevated in patients
with IGR and could be reduced after metformin treatment in T2DM
patients with weight loss. We for the first time identifying decreased
estradiol level was an independent risk factor for the elevated PEDF
and may contribute to the occurrence of T2DM in post-menopause
females.
Supported by: NSFC 81270906, 81370947
PS 052 The future of
obesity management?
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Effects of a novel potent and specific melanin-concentrating hormone
receptor 1 antagonist, AZD1979, on bodyweight homeostasis inmice
and dogs
D. Lindén1, L. Benthem1, D. Kakol-Palm1, P. Gennemark1,
L. Andersson1, M. Bjursell2, J. Börjesson2, L. Kärrberg1, M. Antonsson1,
A. Johansson1, S. Iverson3, A. Turnbull1, K. Ploj1;
1Cardiovascular & Metabolic Diseases iMed, 2Disovery Sciences, Trans-
genics, 3Drug Safety & Metabolism, AstraZeneca, Mölndal, Sweden.
Background and aims: Melanin-concentrating hormone (MCH) exerts
an orexigenic response and while rodents express one receptor for MCH
(Mchr1), humans, non-human primates and dogs express twoMCH recep-
tors (MCHR1 andMCHR2).MCHR1 antagonists have been developed for
the treatment of obesity and they generally lower body weight in rodents.
However, the relative contribution of the effect on food intake and energy
expenditure as well as if MCHR1 antagonists can lower body weight in
species expressing both MCH receptors are not fully understood. We have
discovered a novel potent small molecule MCHR1 antagonist, AZD1979,
and the aims of this study were to investigate the mechanism for weight
loss in diet-induced obese (DIO) mice and to study the effect of AZD1979
on body weight in dogs expressing both MCH receptors.
Materials andmethods:The effect of AZD1979 (20-60μmol/kg by oral
gavage twice daily for up to 3 weeks) on food intake and bodyweight was
compared to vehicle in DIO wildtype and mchr1 knock-out (KO) mice.
The importance of food intake and energy expenditure for the effects was
analyzed using continuous pair-feeding based on 30 min intervals in an
automated system and by indirect calorimetry (CLAMS system). The
effect of AZD1979 (22-216 μmol /kg by oral gavage once daily for
4 weeks) on body weight was also studied in dogs.
Results: AZD1979 dose-dependently reduced body weight (-17.1±1%
vehicle adjusted, p<0.001 at 60 μmol/kg), body fat mass (60 μmol/kg,
19.2±1.5 g vs. vehicle, 27.7±1.7 g, p<0.001) and improved homeostasis
model assessment (HOMA)-index of insulin sensitivity (mMglucose x nM
insulin) (60 μmol/kg, 4.9±0.9 vs. vehicle, 9.8±1.8, p<0.01). Importantly,
AZD1979 had no effect on food intake or body weight in Mchr1 KOmice.
AZD1979 (60 μmol/kg) and pair-fed vehicle dosed DIO mice showed
similar body weight reduction up to 11 days. Thereafter, AZD1979 dosed
DIOmice had lower bodyweights compared to pair-fed vehicle dosedDIO
mice (41.5±1 g vs. 44.2±1 g, p<0.001 dosing day 17), indicating a pre-
served energy expenditure. In line with this, AZD1979 (60 μmol/kg) had
no effect on energy expenditure day 0-3 post initial dose but elevated
energy expenditure during the light periods day 7-10 post initial dose (p
<0.05). Finally, AZD1979 also dose-dependently reduced body weight in
dogs (-5.2±1.6% vehicle adjusted, p<0.01 at 216 μmol /kg).
Conclusion: We have discovered a novel potent and specific MCHR1
antagonist, AZD1979 that affects both food intake and energy expendi-
ture leading to body weight loss in species expressing one or two MCH
receptors.
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FGF21 improves the adipocyte dysfunction related to seipin-
deficiency
L. Dollet1, T. Coskun2, C. Levrel1, C. Le May1, A.C. Adams2, R.
Gimeno2, J. Magré1, B. Cariou1, X. Prieur1;
1UMR 1087, Nantes, France, 2Lilly, Indianapolis, USA.
Background and aims: Berardinelli and Seip Congenital Lipodystrophy
(BSCL) is a rare genetic disease characterized by an almost complete lack
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of adipose tissue. Bi-allelic mutations in BSCL2, encoding seipin, are
responsible for the most severe form of BSCL. Seipin function remains
largely unknown, however, previous studies have shown that seipin de-
ficiency affects adipogenesis.
Materials and methods:We used seipin knock-out (SKO) mice and we
developed a new inducible seipine knock-down cell line (SKD). We use
the FGF21 analog from LY2405319.
Results: SKO mouse model displays severe lipodystrophy with residual
dysfunctional adipose tissues. Interestingly, by comparing the profile of
these residual fat pads in 4 and 12-week-old mice, we highlighted a
decrease in adiponectin mRNA and plasma levels with aging (3,25±0,
41 vs 0,64±0,12 μg/mL in 4 vs 12-week-old mice), suggesting that be-
yond adipogenesis, seipin is involved in adipocyte maintenance. Aiming
to prevent this impairment, we treated 6-week old SKO mice with an
FGF21 analog (LY2405319, Eli-Lilly) known to target adipose tissue
and to increase adiponectin secretion. FGF21 treatment during 28 days
improved random fed glycemia (256±49 vs 147±28 mg/dL in control vs
treated SKO), normalised insulin sensitivity, and increased adiponectin
expression in adipose tissue and secretion (0,64±0,12 vs 1,53±0,47 μg/
mL). To further decipher the molecular pathways altered by seipin defi-
ciency in mature adipocytes, we developed a unique SKD cell-line from
3 T3-L1, with inducible expression of a shRNA targeting seipin mRNA.
shRNA expression was induced after differentiation, and at day 9, the
SKD cells and control cells exhibited similar Oil red O staining and
mature adipocyte gene expression with a 60% decrease in seipin mRNA
levels. At day 21, SKD cells displayed a strong decrease in Oil red O-
positive cells and in mRNA levels of mature adipocytes markers. Impor-
tantly, FGF21 treatment significantly prevented this phenotype.
Conclusion: This study highlights an essential role of seipin in the main-
tenance of the mature adipocyte integrity, and identifies FGF21 as a
potential therapeutic target for BSCL2. Our new cellular model is a useful
tool to distinguish seipin function in the mature adipocyte as opposed to
its established role in adipocyte differentiation.
Supported by: SFD
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Dose dependent effect of all-trans retinoic acid on weight and glucose
homeostasis
S. Hasan1, R. White2, F.G. Hamel3, C.V. Desouza1, R.G. Bennett3;
1Diabetes, Endocrinology and Metabolism, University Of Nebraska
Medical Center, Omaha, 2University Of Nebraska Medical Center, Oma-
ha, 3VA Nebraka-Western Iowa Health Care System, Omaha, USA.
Background and aims:All-trans retinoic acid (ATRA) is a potent deriv-
ative of VitaminA. In recent years, the importance of vitaminA in obesity
and type 2 diabetes has become apparent. We previously showed that
treatment (tx) of db/db mice with ATRA promoted the remodeling of
WAT and attenuated inflammation by reducing macrophage infiltration.
The objective of this study was to determine the effects of different doses
of ATRA onweight, glucose homeostasis and body composition in obese,
diabetic db/db mice.
Materials andmethods: Three month old female mice were divided into
4 groups: high dose group was treated with 0.6 mg/mouse (ATRA-H),
median dose group-0.2 mg/mouse (ATRA-M), low dose group-0.06 mg/
mouse (ATRA-L) and control grp was treated with corn oil. Tx was
5 days/week for 12 weeks by voluntary oral feeding. Body weight and
random glucose levels were determined weekly, and body composition
analysis was performed at baseline, at week 6 and 12.
Results: Baseline body weights were similar in the 3 groups (46.3±0.8 g
(ATRA-H) vs 46.4±0.8 g (ATRA-M) vs 46.8±0.9 g (ATRA-L). High
dose group lost 4.6±1.9 g, with a significant difference at wk 10 (41.6
±1.4 g (ATRA-H) vs 43.6±2.2 g (ATRA-M), 47.7±2.8 g (ATRA-L), p
<.05), whereas no weight loss was observed in low dose group. After
10 weeks of tx, random glucose levels significantly decreased in the high
dose grp (239.5±32 mg/dL (ATRA-H) vs 407.8±32 mg/dL (ATRA-M)
vs 418.5±28 mg/dL (ATRA-L), p<.05). High dose ATRA treatment
significantly decreased fasting glucose levels at week 6 (277.3±32 mg/
dL (ATRA-H) vs 445.6±17 mg/dL (ATRA-M) vs 420.7±46 mg/dL
(ATRA-L), p<.05). Baseline % body fat was similar in all the groups,
which significantly reduced after 6 wks of high dose ATRA treatment
(56.6±0.9 (ATRA-H) vs 54.7±1. 7 (ATRA-M) vs 57.1±1.5 (ATRA-L).
The db/dbmice developed hepatic steatosis, which wasmarkedly reduced
with high dose of ATRA. This change was reflected in the liver triglyc-
eride content, which decreased significantly with ATRA (48.9±6.1 ug
Triglycerides/mg Liver control vs 23.4±3.2 1 ug Triglycerides/mg Liver
ATRA, p<0.05). Obesity is accompanied by downregulation of adipose
PPAR-δ expression and activity, leading to weight gain and insulin resis-
tance. ATRA increased PPAR-δ gene expression in visceral white adipose
whichwas statistically significant (1.1±0.1 control vs 6.7±3.4 ATRA, p<
0.001).
Conclusion:We have shown that ATRApromotedweight loss, improved
glucose homeostasis and reduced hepatic steatosis by upregulating
PPAR-δ expression suggesting that it may be an effective treatment for
obesity-associated diabetes.
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Role of cannabinoid receptor type 1 in glucocorticoid-induced lipol-
ysis, insulin resistance and central obesity in human adipose tissue
C.O. Sidibeh1, M.J. Pereira1, J.L. Börjesson1, P.G. Kamble1, P.
Katsogiannos1, M. Sundbom2, M.K. Svensson3, J.W. Eriksson1;
1Department of Medical Sciences, 2Department of Surgery, Uppsala Uni-
versity, 3Department of Molecular and Clinical Medicine, University of
Gothenburg, Sweden.
Background and aims: Glucocorticoids and the endocannabinoid sys-
tem are both involved in the regulation of energy balance. Cannabinoid
receptor type 1 (CNR1) is highly expressed in the central nervous system.
However, it is also expressed in adipose tissue. CNR1 antagonistic drugs
such as rimonabant have previously been developed and marketed in
efforts to treat obesity and metabolic comorbidities. However, psychiatric
side-effects, notably depression, lead to its withdrawal from the market.
We recently showed that CNR1 is upregulated in human adipose tissue by
the synthetic glucocorticoid dexamethasone. Here, we study the involve-
ment of CNR1 in glucocorticoid-induced lipolysis and insulin resistance
in human adipose tissue.
Materials and methods: Human subcutaneous (sc) and omental (om)
adipose tissue, obtained from non-diabetic volunteers (13 M/30 F, 24-
66 yr, BMI 20.7-55.5 kg/m2) undergoing kidney donation or bariatric
surgery, was incubated with or without dexamethasone (0.003-3 μM,
24 h). In addition, sc adipose tissue acquired from non-diabetic volunteers
(5 M/17 F, 23-72 yrs, BMI 21.3-32.8 kg/m2) by needle biopsies from the
lower abdomen was incubated with or without dexamethasone (0.3 μM,
24 h) in the presence or absence of the CNR1 antagonist/inverse agonist
AM281 (1 μM) during the last 4 h of incubation. In adipose tissue, CNR1
expression as well as sc adipocyte lipolysis and glucose uptake was
assessed following the incubations above.
Results: Dexamethasone increased CNR1 expression dose-dependently
in adipose tissue (p<0.001 sc: by 14-fold, om: by 29-fold). CNR1 gene
expression was higher in sc than om adipose tissue in overweight-obese
subjects, while levels were similar between depots in normal-weight sub-
jects. Furthermore, CNR1 gene expression in both depots correlated pos-
itively with markers of insulin resistance and central obesity such as
fasting plasma levels of insulin (sc: r=0.52, p<0.001; om: r=0.40, p<
0.05), HOMA-IR (r=0.56, p<0.001; r=0.38, p<0.05) and waist circum-
ference (r=0.62, p<0.001; r=0.44, p<0.01). In subcutaneous adipose
tissue, pre-treatment with dexamethasone (0.3 μM) for 24 h increased
the rate of isoprenaline-stimulated lipolysis by about 50%, comparedwith
control (p<0.01), whereas AM281 prevented this effect (p<0.01).
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Moreover, incubation of subcutaneous adipose tissue for 24 h with only
the CNR1-specific agonist ACEA (1 μM), increased isoproterenol-
stimulated lipolysis in adipocytes by about 20% (p< 0.01).
Dexamethasonealso reduced the rate of basal glucose uptake in sc by
about 40% (p<0.001) and insulin-stimulated glucose uptake by about
24% (p<0.01). However, treatment with AM281 did not prevent these
effects.
Conclusion: Our findings suggest that CNR1 is upregulated in states of
insulin resistance and central obesity. Its expression may therefore be
associated with the metabolic syndrome. Furthermore, CNR1 may be a
mediator involved in glucocorticoid-regulated lipid metabolism in human
adipose tissue. This study gives further support for a role of the peripheral
endocannabinoid system in central obesity and insulin resistance. It sup-
ports the potential of peripherally restricted CNR1 antagonists for future
treatment of type 2 diabetes.
Supported by: AZ R&D, GU/SUH, PFCT, FoU-VG, SH-LF, SDA
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Peripheral oxytocin administration activates vagal afferent nerves to
suppress feeding, ameliorating hyperphagia and obesity in diabetic
db/db mice
T. Yada1,2, Y. Iwasaki1, Y. Maejima1, S. Suyama1, M. Yoshida3, T. Arai1,
K. Katsurada1, P. Kumari1, M. Kakei3;
1Physiology, Jichi Medical University, Tochigi, 2Developmental Physiol-
ogy, National Institute for Physiological Sciences, Aichi, 3Saitama Med-
ical Center, Jichi Medical University, Saitama, Japan.
Background and aims: Hyperphagia and obesity cause type 2 diabetes
and hamper dietetic treatment. Oxtytocin (Oxt) is produced in the
paraventricular nucleus and supraoptic nucleus of hypothalamus and, as
a classic neurohypophysial hormone, promotes labor and lactation. Oxt is
also released as a neurotransmitter within various brain regions and plays
a critical role in regulation of food intake and body weight, as well as
social behavior and stress responses. Peripheral administration of Oxt, as
well as central administration, suppresses feeding and ameliorates obesity
and metabolic syndrome in high fat diet-induced obese mice. However,
peripheral Oxt reportedly little enters the brain through blood-brain bar-
rier. Hence, the route through which peripheral Oxt informs the brain is
unclear. In this study, we aimed to clarify whether vagal afferents mediate
the sensing and anorexigenic effect of peripherally injected Oxt in healthy
and diabetic db/db mice.
Materials and methods: To evaluate the direct action of Oxt on vagal
afferents, we measured the cytosolic Ca2+ concentration ([Ca2+]i) in sin-
gle nodose ganglion neurons isolated from mice, by using fura-2
ratiometoric analysis. To examine the involvement of vagal afferents in
Oxt-induced anorexigenic effect, we measured food intake after intraper-
itoneal injection of Oxt in the mice received systemic capsaicin treatment,
subdiaphragmatic vagotomy or sham-operation.
Results: Oxt evoked membrane depolarization, increased action po-
tential firings, and increased [Ca2+]i in single nodose ganglion neu-
rons. The Oxt-induced [Ca2+]i increases were inhibited by Oxt recep-
tor antagonist. Majority of Oxt-responsive nodose ganglion neurons
also responded to cholecytokin-8, a postprandial gastrointestinal hor-
mone known to reduce food intake via direct interaction with vagal
afferents. Moreover, around 80% of Oxt-responsive nodose ganglion
neurons contained cocaine- and amphetamine-regulated transcript
(CART) as the neurotransmitter. Intraperitoneal injection of Oxt sup-
pressed food intake and induced c-Fos expression in the nucleus
tractus solitarius (NTS) of medulla, to which vagal afferents project.
This feeding suppression and c-Fos expression in NTS were blunted
by subdiaphragmatic vagotomy or capsaicin treatment. In obese dia-
betic db/db mice, leptin failed to but Oxt increased [Ca2+]i in nodose
ganglion neurons. Moreover, sub-chronic administration of Oxt de-
creased feeding and body weight gain.
Conclusion: Peripheral injection of Oxt suppresses food intake by direct
activation of vagal afferents. Oxt exerts these effects in leptin-resistant
obese diabetic db/db mice, and its sub-chronic administration suppresses
feeding and body weight gain. This “vagal afferent-mediated peripheral
Oxt signaling to brain” may provide a novel effective route to treat hy-
perphagia and obesity in diabetes.
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A monoclonal anti-aP2 antibody treats diabetes and fatty liver dis-
ease in obese mice
M.F. Burak1,2, K. Inouye1, A. White1, C. Doyle3, D. Lightwood3, L.
Howells3, G. Odede3, H. Hailu3, S. West3, A. Clargo3, H. Neale3, R.
Garlish3, A. Moore3, G.S. Hotamisligil1;
1Department of Genetics & Complex Diseases and Sabri Ülker Center,
Harvard T. H. Chan School of Public Health, Boston, 2Medicine, Mount
Auburn Hospital, Harvard Medical School, Cambridge, USA, 3UCB
Pharmaceuticals, Slough, UK.
Background and aims: The lipid chaperone aP2/FABP4 has been im-
plicated in the pathology of many immunometabolic diseases, such as
diabetes and atherosclerosis. While multiple lines of evidence also sup-
ports its involvement in human disease, targeting aP2 for therapeutic
applications have not yet been accomplished. Recent studies in our lab-
oratory have shown that aP2 is not simply an intracellular protein binding
lipids but an active adipokine that contributes to hyperglycemia by pro-
moting hepatic gluconeogenesis and interfering with peripheral insulin
action. Multiple groups have now demonstrated that serum aP2 levels are
markedly elevated in mouse models of obesity, and human serum aP2
levels strongly correlate with BMI, insulin resistance, dyslipidemia, and
cardiovascular risk. Importantly, blocking aP2 in preclinical models
showed strong anti-diabetic activity. These observations raised an excit-
ing new strategy for targeting serum aP2 to treat metabolic disease with a
monoclonal anti-aP2 antibody.Here, we report the identification of a high-
ly effective, anti-aP2 mAb, CA33, and the characterization of its effects
in vivo.
Materials and methods: In hyperinsulinemic-euglycemic clamp studies,
we found that the anti-diabetic effect of CA33 was predominantly linked
to the regulation of hepatic glucose output and peripheral glucose utiliza-
tion. We also examined the properties of this antibody by structural and
biochemical studies, identified its target epitopes, and demonstrated its
target specificity.
Results: Treatment of mice with dietary or genetic obesity with CA33
lowered fasting blood glucose levels, improved glucose metabolism, in-
creased systemic insulin sensitivity and reduced fat mass and liver
steatosis.
Conclusion: We conclude that development of an anti-aP2 monoclonal
antibody-mediated therapeutic is a feasible approach and would consti-
tute a strong candidate for the treatment of diabetes and fatty liver disease.
Supported by: UCB Pharmaceuticals
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Prevention of progression from prediabetes to diabetes in 109
hypogonadal men treated with testosterone for up to 8 years
F. Saad1,2, A. Haider3, A. Yassin4, G. Doros5, A. Traish6;
1GlobalMedical Affairs Andrology, Bayer PharmaAG,Berlin, Germany,
2GulfMedical University School ofMedicine, Ajman, United Arab Emir-
ates, 3Private Urology Practice, Bremerhaven, 4Institute for Urology and
Andrology, Norderstedt, Germany, 5Boston University School of Public
Health, 6Boston University School of Medicine, USA.
Background and aims: While short-term studies using testosterone re-
placement therapy (TRT) in hypogonadal men with type 2 diabetes
mellitus (T2DM) have yielded mixed results, long-term treatment has
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shown beneficial effects of TRT. There is no information, however,
whether TRT has benefits in hypogonadal men with prediabetes.
Materials and methods: Men presenting to urological offices with var-
ious complaints were screened for the presence of hypogonadism and, if
found hypogonadal, offered TRT. Those who had received at least 1 year
of treatment with TU were entered into two independent, prospective,
observational, cumulative registry studies. 109 men with prediabetes,
defined as a baseline HbA1c from 5.7 to 6.4%, were analysed. TU was
administered in 3-month intervals for up to 8 years. At each or each other
visit, anthropometric and metabolic parameters were measured. Patients
whose TRTwas temporarily interrupted were excluded from the analysis.
Results:Mean age was 57.37±8.99 years. Mean weight decreased from
96.15±13.05 to 84.14±6.98 kg. Change from baseline was -14.58±
0.68 kg, percent change from baseline -14±0.65%. Waist circumference
decreased from 103.8±6.88 to 94.32±4.53 cm. Change from baseline
was -9.62±0.44 cm. BMI decreased from 30.55±4.35 to 27.04±
2.55 kg/m2, change from baseline -4.66±0.23 kg/m2. Waist-to-height
ratio decreased from 0.58±0.04 to 0.53±0.03. All anthropometric mea-
sures were statistically significant vs. baseline (p<0.0001) and improved
progressively with statistical significance compared to the previous year
for 6 to 7 years. Fasting glucose decreased from 5.43±0.68 to 4.63±
0.6723 mmol/L (p<0.0001), change from baseline -0.94±0.11 mmol/L
reaching a plateau after 1 year. HbA1c decreased from 5.9±0.21 to 5.38±
0.26% (p<0.0001), change from baseline -0.59±0.04% with statistical
significance compared to the previous year for the first 3 years. The
triglyceride to HDL ratio, considered a surrogate parameter of insulin
resistance, declined from 5.62±2.61 to 2.6±0.74 (p<0.0001). The prod-
uct of fasting glucose and triglycerides (TyG Index), another surrogate for
insulin resistance, improved from 4.04±0.17 to 3.81±0.14. No patient
progressed from prediabetes to T2DM. All but 4 patients’ last measured
HbA1c was <5.7%. Lipid patterns as well, blood pressure, liver transam-
inases and C-reactive protein all improved significantly. 3 patients
dropped out, 2 due to relocation to a different city, 1 was lost to follow-
up. There were no major adverse cardiovascular events during the full
observation time.
Conclusion: Hypogonadal men with prediabetes defined by HbA1c from
5.7 to 6.4% showed clinically meaningful and sustainable weight loss as
well as improvements in glycaemic control when receiving long-term
treatment with testosterone. No patient advanced from prediabetes to
overt T2DM. TRT seems to be effective to improve anthropometric and
metabolic parameters in hypogonadal men and in preventing progression
from prediabetes to T2DM, thereby potentially reducing cardiometabolic
risk.
Supported by: Data entry and statistical analyses were partially funded
by Bayer Pharma
662
Effect of apelin on duodenal contraction: consequences on the gut-to
brain axis in the control of glucose metabolism
A. Fournel1, A. Drougard1, T. Duparc2, A. Marlin1, N. Cenac3, N.
Vergnolle3, P. Valet1, P. Cani2, C. Knauf1;
1INSERM U1048, I2MC / Neuromicrobiota, European Associated Lab-
oratory (EAL), Toulouse, France, 2Université catholique de Louvain,
Louvain Drug Research Institute / Neuromicrobiota, European Associat-
ed Laboratory (EAL), Brussels, Belgium, 3INSERMU1043, CPTP, Tou-
louse, France.
Background and aims: In the gut, the enteric nervous system (ENS)
controls intestinal contractility allowing postprandial absorption of nutri-
ents. In diabetic human and mice, ENS function is profoundly altered
resulting in intestinal hyper-contractility. Our original concept is that
“ENS/intestinal contraction” coupling, could also permit to modulate
central nervous system activity (via afferent nervous messages), and in
particular the hypothalamus, a key area able to control glucose utilization
in peripheral tissues. In this study, we aim at demonstrating that apelin, a
bioactive peptide present in the intestinal lumen, could target ENS neu-
rons and so control activity of “ENS/intestinal contraction” coupling.
These potential modifications could have consequences on hypothalamic
Nitric Oxide release (NO, a neurotransmitter strongly involved in the
control of glucose metabolism) leading to variations of glucose utilization
in peripheral tissues.
Materials and methods: Animals were handled in accordance with the
principles and guidelines established by the National Institute of Health
and Medical Research. Male C57BL6/J mice are fed on normal or high-
fat diet. ENS neurons expressing APJ, the apelin receptor, are identified
by immunohistochemistry. Effects of apelin on duodenal contractility are
measured ex vivo with an isotonic transducer (Krebs-Ringer is used as
control), and in vivo by telemetry (water is used as control). Hypothalam-
ic release of NO in response to apelin infusion in the digestive tract, is
recorded in vivo via specific amperometric NO probe implanted in the
hypothalamus (water is used as control). Peripheral glucose utilization is
assessed following oral gavage of apelin coupled with tritiated glucose
(water is used as control).
Results: Immunohistochemistry experiments reveal that APJ is
expressed in ENS neurons. In normal mice, low-dose of apelin stimulates
ex vivo duodenal mechanical activity (151±15,55% of basal contraction
amplitude vs 90±11, 14 for control; P<0,05) and in vivo duodenal elec-
trical activity (123±0,67 (fold increase) vs 114±0,56 for control; P<0,
001). Average frequency of NO hypothalamic release is significantly
reduced following infusion of low-doses of apelin in the digestive tract
(0,11±0,003 Hz vs 0,12±0,002 for control; P<0.001) associated with a
significant decrease in muscle glucose utilization (158±17,3 Log10[dpm/
g tissue] vs 267±33,1 for control; P<0.05). In contrast, higher concen-
trations of apelin inhibit in vivo duodenal electrical activity, restore hy-
pothalamic NO release and improve glucose utilization and tolerance in
normal and obese/diabetic mice.
Conclusion:We demonstrate that apelin could target the ENS activity in
order to modify hypothalamic NO release and then to control muscle
glucose entry. Decrease the activity of the duodenum by acting on ENS
neurons via bioactive peptides could be considered as a new therapeutic
strategy for metabolic diseases.
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PS 053 Adipokines and novel proteins
in adipose tissue
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siRNA-mediated silencing of DPP4 improves insulin sensitivity of
human primary adipocytes
D. Röhrborn, H. Sell, J. Eckel;
German Diabetes Center, Düsseldorf, Germany.
Background and aims: DPP4 is a ubiquitously expressed cell surface
protease which is also released to the circulation as soluble DPP4
(sDPP4). DPP4 is able to clip numerous substrates e.g. the incretin hor-
mones, and therefore represents an important drug target for the treatment
of type 2 diabetes. Recently, we identified DPP4 as a novel adipokine
oversecreted in obesity and thus potentially linking obesity to the meta-
bolic syndrome. Furthermore, we could show that sDPP4 impairs insulin
signaling in an autocrine and paracrine fashion in different cell types.
However, it is still unknown which functional role DPP4 plays within
adipose tissue. The aim of this study was to elucidate the influence of
siRNA-mediated knockdown of DPP4 on differentiation and functional-
ity of adipocytes.
Materials andmethods: Primary human adipocytes were silencedwith a
specific DPP4 siRNA one day prior to start of differentiation. Markers of
differentiation, inflammation and adipocyte functionality were measured
by Western Blot, qRT-PCR and ELISA. Furthermore adipokine profiler
arrays were performed with supernatants from day 14 of differentiation to
monitor changes in the secretome. In these arrays the relative level of 58
human adipokines can be determined simultaneously. On day 14 of dif-
ferentiation, cells were stimulated with 100 nM insulin and parameters of
insulin signaling were monitored.
Results:Very high silencing efficiency was achieved at the DPP4mRNA
level (68±15%) which remained stable over the whole differentiation.
DPP4 protein expression was diminished substantially to about 50% at
day 14 of differentiation. DPP4 knockdown had no effect on protein or
mRNA expression of the differentiation marker PPARγ. Functional adi-
pocyte markers like HSL and Glut4 were slightly but not significantly
reduced at the level of protein expression on day 14. Of the 58 adipokines
spotted on the membrane of the profiler arrays, 31 proteins were detect-
able. Most of them were unaffected by DPP4 silencing in adipocytes.
Slight changes were found in the secretion of Cathepsin L, MIF and
IGFBP-6, which seemed to be decreased whereas IL-10 secretion seems
to be upregulated. mRNA expression and release of adiponectin and
MCP-1 were unchanged by silencing, whereas mRNA expression of
IL-6 was significantly reduced in adipocytes with reduced DPP4 expres-
sion. Most interestingly, at the level of insulin signaling DPP4 knock-
down affected the insulin-stimulated phosphorylation of the insulin re-
ceptor (Tyr1150/1151) and expression of the insulin receptor substrate
1(IRS1) which are increased by about 60% and 40%, respectively. In
accordance to that, silencing induced a significant 1.7 -fold higher
insulin-stimulated phosphorylation of Akt (Ser473) compared to control
whereas basal levels remained similar. Further experiments to elucidate
the underlying mechanisms and consequences of altered insulin signaling
are ongoing at the moment.
Conclusion: In conclusion, knockdown of DPP4 improves the respon-
siveness towards insulin in primary human adipocytes without affecting
adipocyte differentiation and secretory function. Taken together with our
previous observation that sDPP4 induces insulin resistance in adipocytes
and higher adipose DPP4 levels in obese insulin-resistant patients, DPP4
might be a potential marker of adipose tissue insulin sensitivity.
664
A new role for GLP-2 in human adipose tissue: effects on differenti-
ation and adipocyte metabolism
M. Ejarque, C. Serena, C. Nuñez-Roa, K. Roche, J.J. Vendrell, S.
Fernandez-Veledo;
Institut d´Investigacions Sanitaries Pere Virgili (IISPV), Tarragona,
Spain.
Background and aims: Glucagon-like peptide-2 (GLP-2) is a
proglucagon-derived peptide structurally related to GLP-1 that is released
by enteroendocrine L cells, which plays an important role in the regula-
tion of intestinal growth and function. Unlike GLP-1, GLP-2 has not been
reported to modulate insulin secretion, however, meal-related GLP-2 se-
cretion suggests a putative role for GLP-2 in metabolism regulation be-
yond its well-established intestinal function. The GLP-2 receptor (GLP-
2R) shows significant homology with GLP-1R, but its expression has
been described largely restricted to intestine, lungs and hypothalamus.
Interestingly, our group has observed GLP-2R expression in human adi-
pose tissue. This work aims to gain insight into the molecular function of
GLP-2/GLP-2R axis on energetic metabolism, focusing on its potential
modulatory function on adipose tissue.
Materials and methods: Clinical studies. Visceral (VAT) and subcuta-
neous (SAT) adipose tissue samples from lean and obese individuals with
different degrees of insulin resistance were obtained during a scheduled
surgical procedure (27 women and 21 men, aged 42,4±11,3 years and
BMI range 23,3 to 42,4 kg/m2). Stroma-vascular (SVF) and adipocyte
fractions were also obtained. Gene and protein expression studies were
performed. in vitro studies. SGBS cell line was used as a model of human
subcutaneous pre-adipocytes. Human adipocytes (hADSC) were isolated
from adipose tissue from lean and obese patients. Effects of GLP-2 on
proliferation, viability, gene expression and adipocyte metabolism were
analysed.
Results: GLP-2R is expressed in SAT and VAT of lean and obese indi-
viduals mainly in the adipocyte fraction. Patient classification according
to HOMA-IR shows a GLP-2R down-regulation in SAT on high-IR in-
dividuals, with independence on BMI, suggesting a putative relationship
between insulin sensitivity and GLP-2R expression on AT. Accordingly,
GLP-2R expression is down regulated at mRNA and protein level on
adipocytes derived from hADCS isolated from obese patients. In vitro
studies demonstrate no effects on adipocytes proliferation and viability
during differentiation, but GLP-2 administration produce an increase on
lipids accumulation with an up-regulation of lipogenic genes in differen-
tiated adipocytes.
Conclusion:Our data suggest that adipose tissue may be a new target for
GLP-2 activity, influencing the adipogenic and functional capacity of
human adipocytes. Understanding the role of GLP-2 in the metabolic
events that take place in AT my help to define more precisely new poten-
tial indications of clinical usefulness in metabolic imbalance.
Supported by: IISPV postdoctoral grant; MINECO- ISCIII
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Adiponectin is required for adaptive thermogenesis by enhancing the
browning of white adipose tissues in mice
A. Xu, X.-Y. Hui, P. Gu;
State Key Laboratory of Pharmaceutical Biotechnology, The University
of Hong Kong, China.
Background and aims: Adiponectin is a major adiocyte-secreted
adipokine with multiple protective effects against a cluster of obesity-
related cardiometabolic diseases. Plasma levels of adiponectin are in-
versely associated with obesity and insulin sensitivity. However, its role
in adaptive thermogenesis remains unclear. This study aims to investigate
whether adiponectin regulates thermogenic activity of adipose tissues in
mice.
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Materials and methods: Adiponectin-knockout mice and wild-type lit-
termates were exposed to cold temperature to induce thermogenesis. The
browning phenotypes of different adipose depots were analyzed by im-
munocytochemistry and real-time PCR. The thermogenic activity of ad-
ipose tissues was measured with the Seahorse analyzer.
Results:Chronic cold exposure caused a dramatic and selective elevation
of adiponectin in stromal vascular fraction of subcutaneous white adipose
tissue (scWAT),but not in classical brown adipose tissue. In scWAT,
adiponectin co-localized with alternatively-activated M2 macrophages
in response to cold challenge. Chronic cold exposure-induced accumula-
tion of M2 macrophages, activation of biege cells and thermogenesis
were obviously impaired in scWAT of adiponectin-knockout mice,
whereas these impairments were reversed by replenishment with recom-
binant adiponectin. Further analysis found that adiponectin bound to the
cell surface of M2 macrophages via its co-receptor T-cadherin and pro-
moted the cell proliferation by activation of Akt, thereby leading to beige
cell activation by secreting catecholamines.
Conclusion: Adiponectin is a key mediator for cold-induced browning
and adaptive thermogenesis of white adipose tissue, by facilitating the
crosstalk between adipocytes and immune cells.
Supported by: Hong Kong RGC GRF 14124174 and CRF C7055-14G
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FNDC5 (irisin) expression is increased in subcutaneous adipose tissue
in obese patients with type 2 diabetes one year after bariatric surgery
J. Muenzker1, A. Harger1, A. Tuca1, L. Lindheim1, V. Zachhuber1, E.
Svehlikova1, O. Freisinger2, J. Fruhmann2, F. Tadler3, B. Obermayer-
Pietsch1, T.R. Pieber1;
1Division of Endocrinology and Metabolism, 2Department of Surgery,
Medical University of Graz, 3Department of Surgery, Krankenhaus der
Elisabethinen Graz, Austria.
Background and aims:Gastric bypass surgery improves glycaemic con-
trol, but the underlying mechanisms including potential changes in
adipoinsular axis are incompletely understood. The aim of this study
was to investigate potentially causal or associated alterations in gene
expression of adipokines, myokines and hormones in the subcutaneous
adipose tissue of diabetic and non-diabetic obese patients before and after
gastric bypass.
Materials and methods: Biopsy specimens from the subcutaneous adi-
pose tissue of 12 diabetic and 12 non-diabetic patients at and one year
after gastric bypass were analyzed with quantitative real-time PCR for the
expression levels of various adipokines and myokines.
Results:Non-diabetic subjects were found to express significantly higher
levels of FNDC5 (irisin) in the subcutaneous adipose tissue than diabetic
subjects before gastric bypass (p=0.0167). FNDC5 expression in the
subcutaneous adipose tissue of diabetic patients was significantly in-
creased one year after surgery (p<0.001). In non-diabetic subjects, there
was no significant increase observable (p=0.158). The increase in
FNDC5 in diabetic subjects correlated with reduction in BMI (Pearson’s
r=0.718, p=0.009). No correlation was observed between FNDC5 ex-
pression and early insulin response or insulin sensitivity index.
Conclusion: To the best of our knowledge, this is the first study to
investigate the role of the novel myokine irisin in bariatric surgery medi-
ated weight loss in diabetic patients. The results of this study demonstrate
that exercise-independent weight loss significantly increases irisin ex-
pression levels in subcutaneous adipose tissue of diabetic subjects.
Supported by: EFSD/MSD
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Microdialysis and proteomics of the subcutaneous interstitial fluid
reveals abundance of galectin-1 in type 2 diabetes patients
E. Fryk1, J. Perman Sundelin1, L. Strindberg1, M. Pereira2, M. Federici3,
N. Marx4, P.-A. Svensson1, J.W. Eriksson2, J. Borén1, P.-A. Jansson1;
1Molecular and clinical medicine, Medicine, Gothenburg University,
2Department of Medical Sciences, Medicine, Uppsala University, Swe-
den, 3Systems Medicine, Medicine, University of Rome "Tor Vergata",
Italy, 4Division of Cardiology, Medicine, University Hospital RWTH
Aachen, Germany.
Background and aims: It is well established that adipose tissue dysfunc-
tion conveys insulin resistance and type 2 diabetes (T2D). We have pre-
viously used microdialysis for in vivo studies of adipose tissue metabo-
lism in human subjects. Our aim was to identify novel proteins in insulin
resistant adipose tissue by applying a combination of subcutaneous mi-
crodialysis and proteomics in T2D patients and healthy controls.
Materials and methods: Eight newly diagnosed male T2D patients and
7 male healthy participants were recruited. Microdialysis was performed
in the subcutaneous adipose tissue (SCAT) and the obtained dialysates
were analysed with a tandemMS. For validation of our results, dialysates
and serum samples were quantified for galectin-1 using ELISA. More-
over, isolated adipocytes were prepared from biopsies and cell size and
galectin-1 gene expression were determined. In a larger group of T2D
patients (n=31) and healthy controls (n=20) serum levels of galectin-1
were measured. Furthermore, another group of obese patients (n=24) was
subject to a very low calorie diet (VLCD) for 16 weeks and galectin-1
gene expression wasmeasured at week 0, 8, 16 and 18. In addition, SCAT
biopsies were obtained from non-diabetic participants where glucose up-
take, GLUT 1 and GLUT 4 expression were measured in the presence of
galectin-1. Finally, insulin signalling was quantified in cultured endothe-
lial cells through Western blot in the presence of galectin-1.
Results: Thirty-six different proteins differed significantly when compar-
ing dialysates obtained from SCAT in T2D patients and healthy controls.
One of these proteins showing a significant over-expression in T2D pa-
tients compared with the controls, was galectin-1. This was validated by
ELISA analyses of the dialysate samples (p<0.05) and qPCR of isolated
adipocytes (p<0.05). Moreover, circulating galectin-1 levels correlated
with subcutaneous adipocyte size and waist/hip ratio (p<0.05, respective-
ly). In the expanded groups there was also a significant difference in
circulating galectin-1 levels when comparing T2D patients and healthy
controls (p<0.05). In this larger sample, we also observed linear correla-
tions between serum galectin-1, fasting glucose and fasting insulin at
concentrations below 10 mmol/L and 10 mU/L respectively. The corre-
lations were not observed in participants with higher fasting glucose or
insulin levels. Furthermore, a VLCD diet reduced galectin-1 gene expres-
sion in adipose tissue biopsies (p<0.05). In addition, adipocytes showed a
20% reduction (p<0.05) in basal and insulin-stimulated glucose uptake
after pre-incubation with galectin-1 for 24 h and GLUT4, but not GLUT1
mRNA expression was reduced. Finally, endothelial cells pre-incubated
with galectin-1 for 24 hrs showed a significant decrease in AKT phos-
phorylation after 5 min of insulin stimulation (p<0.05).
Conclusion: Galectin-1 is an abundant protein in subcutaneous adipose
tissue of T2D patients, with effects on both insulin signalling and glucose
uptake. Circulating galectin-1 levels may be a biomarker for an insulin-
resistant adipose tissue indicating an increased diabetes risk.
Supported by: VR, Diabetesfonden, ALF och EFSD/Lilly
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Clock genes are implicated in the regulation of energy homeostasis in
humans
O. Pivovarova1,2, Ö. Gögebakan1,3, S. Sucher1, J. Groth1, V.
Murahovschi1,2, K. Kessler1,2, M. Osterhoff1, N. Rudovich1,2, A.
Kramer4, A.F.H. Pfeiffer1,2;
1Dept. of Clinical Nutrition, German Institute of Human Nutrition Pots-
dam-Rehbruecke, Nuthetal, 2Dept. of Endocrinology, Diabetes and Nu-
trition, Campus Benjamin Franklin, Charité University Medicine, 3Dept.
for Radiology and Interventional Therapy, Vivantes Klinikum Neukölln,
4Laboratory of Chronobiology, Institute for Medical Immunology,
Charité University Medicine, Berlin, Germany.
Background and aims: The circadian clock coordinates numerous met-
abolic processes to adapt physiological responses to light-dark and feed-
ing regimens. The implication of the circadian clock in the control of
energy balance, and consequently in the regulation of body weight, is
widely studied in rodents, but not in humans. Here, we investigated (1)
whether the expression of clock genes in human adipose tissue is changed
by weight loss and weight regain and (2) whether these alterations are
associated with metabolic parameters.
Materials and methods: Subcutaneous adipose tissue samples were col-
lected before and after 8 weeks of weight loss on a 800 kcal/d hypocaloric
diet (Modifast, Nutrition et Santé, France plus 200 g/d vegetables) and
again after 6 month of weight maintenance at the same time of day. Only
participants who achieved a weight loss of at least 8% after 8 weeks were
selected for the study (n=50, age 40.8±0.9 years, BMI 34.2±0.6 kg/m2,
mean +/- SEM). The expression of core clock genes, and key metabolic
and inflammatory genes was determined by quantitative real-time PCR.
Results: The mean weight loss for the group was 10.8% of initial weight
after the hypocaloric phase and 8.0% after the weight maintenance phase.
The expression of core clock genes PER2 and NR1D1 was increased in
the hypocaloric phase (p=7×10-6 and p=0.031, respectively). Expres-
sion of BMAL1 andCLOCKdid not change in the hypocaloric phase, but
decreased during the weight maintenance period (p=0.014 and p=0.012,
respectively). Clock gene expression levels and their weight loss-induced
changes strongly correlated with each other at all investigation days (p<
0.001). The expression levels of PER2, but not its weight loss-induced
alterations, negatively correlated with BMI and body fat percentage (p<
0.05). Moreover, BMAL1, CLOCK, and PER2 demonstrated a large
number of correlations with genes involved in the inflammatory response
(TLR4, NFKB, NFKBIA, NLRP3), energy metabolism (SIRT1) and fat
metabolism (FASN, CPT1A, LPL, PPARG, PGC1A), as well as with
adiponectin gene expression (ADIPOQ).
Conclusion: Clock gene expression in human subcutaneous adipose tis-
sue is regulated by the body weight changes and associated with BMI,
body fat percentage and expression of metabolic and inflammatory genes.
This suggests that clock genes are implicated in the regulation of energy
homeostasis in humans.
Clinical Trial Registration Number: NCT00390637
Supported by: DFG grant KFO218 PF164/16-1 OP, AK, AFHP; FP6-
2005-513946; FOOD-2004-513946
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Role of lipocalin 2 in human adipose tissue metabolism and
glucocorticoid-induced insulin resistance
P.G. Kamble1, M.J. Pereira1, C.O. Sidibeh1, S. Amini1, M. Sundbom2,
J.W. Eriksson1;
1Medical Sciences, 2Surgical Sciences, Uppsala University, Sweden.
Background and aims: Lipocalin 2 (Lcn2), a peptide produced by adi-
pose tissue (AT), has been reported to be linked to obesity and related
metabolic disorders. Agents promoting insulin resistance like glucocorti-
coids can induce Lcn2 expression and this can be reversed by
thiazolidinediones. However, the role of Lcn2 in glucose and lipid me-
tabolism is not fully explored in humans. We aimed to study effects of
Lcn2 on glucose and lipid metabolism in human AT.
Materials and methods: Paired samples of human subcutaneous (SC)
and omental (OM) AT obtained from non-diabetic subjects undergoing
elective surgery (12 M/29 F, 24-66 yrs, BMI 20.7-55.5 kg/m2) were
incubated with Dexamethasone (Dex), a synthetic glucocorticoid, (0.03-
3 μM, 24 hr) to measure Lcn2 gene expression. Adipose tissue samples
from non-diabetic subjects (3 M/19 F, 22-71 yrs, BMI 21.2-29.4) were
treated with recombinant human (RH) Lcn2 (100 ng/ml, 24 hr) and used
for gene (n=11) and protein expression (n=7). Isolated adipocytes were
used for glucose uptake (n=8) and lipolysis (n=11) assays. Fasting blood
samples were taken to measure the levels of plasma glucose, insulin and
lipids, and anthropometric measurements were done.
Results: When considering both males and females, Dex significantly
increased the Lcn2 gene expression in SC AT by 2.5 fold (p<0.05) in a
dose-dependent manner. However, in OM AT, there was only a tendency
to an increased Lcn2 expression by 1.4 fold (NS). Gender comparison
shows that Dex increased Lcn2 expression in SC AT from females by 3.5
fold (p<0.05), but had no effect in males. No effect on Lcn2 expression in
OM ATwas seen in either gender. RH-Lcn2 treatment reduced the basal
and insulin-stimulated (1000 μU/ml) glucose uptake in SC adipocytes by
18% and 25% respectively (p<0.01), similar in both genders. In addition,
Lcn2 reduced the protein content of the glucose transporters GLUT1 and
GLUT4 by ~40% (P<0.01) in SC AT. In paired samples, Lcn2 gene
expression in OM depot was ~7.5 fold higher than in SC depot (p<
0.001). Lcn2 expression in both SC and OM AT showed a tendency to
be correlated with BMI (NS). The basal Lcn2 expression in SC AT was
positively correlated with fasting glucose (r=0.32, p<0.05), SC adipocyte
size (r=0.509, p<0.002) and OM adipocyte size (r=0.397, p=0.017). In
OM AT, Lcn2 expression was positively correlated with fasting insulin
(r=0.359, p=0.034) and HbA1C (r=0.376, p=0.031). In a stepwise mul-
tivariate analysis, glucose (r=0.457, p<0.01) and HbA1C (r=0.377, p<
0.05) remained significant predictors of Lcn2 gene expression in SC and
OM AT, respectively. In human SC AT, Lcn2 reduced PPARγ gene ex-
pression by 24% (p<0.05) and its target gene adiponectin by 34% (p<
0.01). Finally, RH-Lcn2 did not affect basal or isoproterenol stimulated
lipolysis in adipocytes.
Conclusion: Our results suggest that glucocorticoids increase Lcn2 ex-
pression in SC AT from females, and that this inhibits glucose uptake and
reduces expression of GLUT1 and GLUT4 in adipocytes. Decreased
PPARγ expression by Lcn2 suggests a possible role in the regulation of
human adipogenesis. Lcn2 expression in AT is also positively correlated
with blood glucose levels. In conclusion, the adipokine Lcn2 can contrib-
ute to development of insulin resistance in human AT, and it may be a
mediator of metabolic adverse effects of glucocorticoid excess.
Supported by: SDA,UU, AstraZeneca R&D
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Adipose tissue miR-15b, miR-20a, miR-20b, miR-27b, miR126, miR-
130a, miR210, miR296 and Let-7f expression profile in relation to
obesity and type 2 diabetes
A.-M. Gentile1, L. Coín-Aragüez2, S. Lhamyani2, W. Oliva Olivera2, M.
Murri3, F. Tinahones2, R. El Bekay2;
1UMA/IBIMA, 2ISCIII/CIBERobn/HUVV, Málaga, 3ISCIII/
CIBERDEM/IRYCIS, Madrid, Spain.
Background and aims: Adipose tissue expandability is an important
factor determining the appearance of insulin resistance and Type 2 diabe-
tes (T2D) associated to obesity. Several studies revealed the importance
of miRNAs in the post-transcriptional regulation of adipose tissue func-
tionality. MiR-15b, miR-20a, miR20b, miR-27b, miR126, miR130a,
miR210,miR-296 and Let-7f have shown a differential expression profile
between lean and obese subjects and between metabolically healthy and
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type 2 diabete subjects in visceral adipose tissue (VAT). These
microRNAs are principally involved in adipogenic, angiogenic and apo-
ptotic regulation. Bioinformatic’s analysis highlighted 50 target genes of
these microRNAs; 16 among them:CDKN1A, E2F3, ESR1, GLUL, GPI,
HIF1A, HIST2H3A, LRIG3, MYC, MEF2D, NUP210, STAT3,
SERTAD2, UBA1, VMP1, VEGFA, showed significant expression dif-
ferences in visceral adipose tissue in relation to obesity and type 2 diabe-
tes. In summary, our data highlight the potential involvement of miR-15b,
miR-20a, miR20b, miR-27b, miR126, miR130a, miR210, miR-296 and
Let-7f in the regulation of apoptosis, adipogenesis and angiogenesis in
adipose tissues and to have an association with obesity and type 2
diabetes.
Materials and methods: MicroRNAs and mRNA were extracted from
visceral and subcutaneous adipose tissue biopsies from the following
subjects: Lean (n=10), T2D lean subjects (n10) obese (n=10), T2D obese
subjects (n=10). MicroRNAs miR-15b, miR20a, miR.20b, miR-27b,
miR-126, miR-130a, miR-210, miR-296 and Let-7 were extracted and
analyzed by qPCR from visceral and subcutaneous adipose tissues. In
silico prediction of target genes was carried out using miRTarBase, Pan-
ther and David. The network and visualization using Cytoscape software.
Results: MiR-15b, miR-20a, miR20b, miR-27b, miR126, miR130a,
miR210,miR-296 and Let-7f have shown a differential expression profile
between lean and obese subjects and between metabolically healthy and
T2D subjects in VAT. A prediction in silico by miRTarBase, Panther and
David showed that 50 target genes share connections with at least two or
three of the studied miRNA. 16 among them: CDKN1A, E2F3, ESR1,
GLUL, GPI, HIF1A, HIST2H3A, LRIG3, MYC, MEF2D, NUP210,
STAT3, SERTAD2, UBA1, VMP1, VEGFA, showed statistically signif-
icant expression differences in visceral adipose tissue in relation to obe-
sity and type 2 diabetes
Conclusion: Our data highlight the potential involvement of MiR-15b,
miR-20a, miR20b, miR-27b, miR126, miR130a, miR210, miR-296 and
Let-7f in the regulation of apoptosis, adipogenesis and angiogenesis in
adipose tissues and to have an association with obesity and type 2 diabe-
tes.
Supported by: ISCIII (PI10/01947, PI13/02628, CPII13/00041) CTS-
7895
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Hyperinsulinaemia increases proinflammatory factors genes expres-
sion in subcutaneous adipose tissue in young healthy subjects
N.Matulewicz1,2, M. Stefanowicz1,2, A. Nikołajuk2, M. Strączkowski1,2,
M. Karczewska-Kupczewska1,2;
1Medical University of Bialystok, 2Institute of Animal Reproduction and
Food Research, Polish Academy of Sciences, Olsztyn, Poland.
Background and aims: In obese and type 2 diabetic subjects adipose
tissue is characterized by a chronic low-grade inflammation witch is
correlated with an increased secretion of proinflammatory cytokines, such
as macrophage inhibitory factor (MIF), monocyte chemotactic protein-1
(MCP-1) and IL-18, which might contribute to insulin resistance.
Hyperinsulinemia, frequently present in type 2 diabetes and obesity,
might be one of the drivers of the enhanced production of proinflamma-
tory adipokines, however this issue remains controversial. It is also un-
clear if the alternations in expression of proinflammatory factors genes in
adipose tissue are already present in young subjects with increased adi-
posity but without overt metabolic disturbances. The aim of the present
study was to assess the regulation of proinflammatory factors genes ex-
pression in subcutaneous adipose tissue by hyperinsulinemia and their
relationships with adiposity and insulin sensitivity in young subjects.
Materials and methods: We examined 150 young (age 23.39±
2.93 years) apparently healthy subject with normal glucose tolerance,
83 lean (BMI<25 kg/m2 ) and 67 with overweight or obesity (BMI
between 25 and 40 kg/m2). In all subjects insulin sensitivity was evalu-
ated by the 2 h euglycemic-hyperinsulinemic clamp. Additionally, in 20
subjects, clamp was prolonged to 6 hours. Biopsy of subcutaneous adi-
pose tissue was performed before each clamp and after 6-hour clamp.
Adipose tissue mRNA expression of MIF, MCP-1, IL-18 and subunits
of nuclear factor κ B (NFκB) was analysed with Real-Time PCR.
Results: Obese subjects had higher adipose tissue MIF, MCP-1, IL-18,
NFκB1 expression (all p<0.05). 6 h hyperinsulinemia increased the ad-
ipose tissue expression of MIF by 22% (p=0.009). Furthermore, 6 h
hyperinsulinemia resulted in an increase in the expression of NFκB1 by
35%, (p=0.004) and NFκB2 by 54% (p=0.008) in subcutaneous adipose
tissue. We found positive correlations between adipose tissue MIF, MCP-
1, IL-18 expression and BMI (r=0.17, p=0.04; r=0.29, p=0.001 and r=
0.35, p<0.0001, respectively), waist circumference (r=0.21, p=0.01; r=
0.22, p=0.009 and r=0.34, p<0.0001, respectively) at baseline. Adipose
tissue MIF and IL-18 expression was negatively related to insulin sensi-
tivity (r=-0.17, p=0.04; r=-0.18, p=0.03, respectively) in the baseline
state.
Conclusion: Our data show that 6 h hyperinsulinemia resulted in an
increased expression of the proinflammatory factors in adipose tissue.
This expression is already increased in young healthy people with excess
body fat.
Supported by: UDA-POIG.01.03.01-00-128/08-00
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Plasma chemerin is elevated in type 2 diabetes, is associated with
impaired kidney function, and is predictive for cardiovascular events
A. Leiherer1,2, A. Muendlein1, P. Rein1,3, K. Geiger1, P. Fraunberger2,4,
H. Drexel3, C.H. Saely1,3;
1Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT),
Feldkirch, Austria, 2Private University of the Principality of Liechten-
stein, Triesen, Liechtenstein, 3Medicine and Cardiology, Academic
Teaching Hospital Feldkirch, 4Medical Central Laboratories, Feldkirch,
Austria.
Background and aims:The association of the novel adipokine chemerin
with cardiovascular event risk is unclear and is addressed in the present
study.
Materials and methods: We measured plasma chemerin levels in 495
patients undergoing coronary angiography for the evaluation of
established or suspected stable CAD.
Results: Chemerin was higher in patients with type 2 diabetes mellitus
(T2DM, n=111) than in non-diabetic subjects (192±73 vs.170±65 ng/ml,
p=0.001). Further, chemerin was significantly and independently associ-
ated with the glomerular filtration rate (GFR) in analysis of covariance
using age, sex, and BMI as covariates (F=49.6, p<0.001). Prospectively,
we recorded 186 cardiovascular events during a 8-year follow-up.
Chemerin both univariately and after multivariate adjustment including
baseline GFR significantly predicted cardiovascular events, with hazard
ratios of 1.72 [95%CI 1.19-2.47], p=0.004 and 1.51 [1.03-2.23], p=
0.037 for the top tertile of chemerin versus the first and second tertiles,
respectively. A cardiometabo-chip-analysis revealed an association of
two nearby located SNPs in TP53BP1 and CAPN3 rs2444030 nominal
p-value=5.2 e-9, and rs3098423 nominal p-value=9.6 e-8) with
chemerin concentration. Haplotype analysis for these two SNPs revealed
a significantly impaired GFR associated with the fully mutated haplotype
compared to all other haplotypes (OR=0.63, p=0.006).
Conclusion:We conclude that high chemerin is characteristic of T2DM,
is associated with impaired kidney function, and is predictive for cardio-
vascular events.
Supported by: ÖNB: 14159
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The role of the nuclear receptor FXR in obesity-induced adipose
tissue inflammation
A. Marino, D. Mogilenko, H. Dehondt, D. Dombrowicz, S. Caron, B.
Staels;
UMR1011, Lille, France.
Background and aims: Obesity plays a central role in the development
of metabolic syndrome and related diseases. Understanding the mecha-
nism behind the development is necessary to adopt the right clinical
approach to prevent and treat metabolic disorders. Obesity is character-
ized by a state of low-grade inflammation consisting of a progressive
infiltration of immune cells in adipose tissue. The molecular mechanisms
and the contribution of the different cell types involved are still not clear.
Recent observations suggested that adipocytes themselves may exert im-
munological functions. The nuclear receptor FXR plays major role in
regulating bile acid metabolism, but it plays also a role in maintaining
systemic glucose/lipid homeostasis. Although lower than in liver, FXR is
expressed in adipose tissue and regulates adipocyte differentiation and
function. FXR-KO mice, in the lean state, show impaired glucose toler-
ance and peripheral insulin resistance. By contrast, in mouse models of
obesity (ob/ob and high fat diet (HFD), FXR-deficiency protects from
obesity. Recently, has been shown that FXR plays a role in hepatocyte
inflammation. The aim of this study was to elucidate the role of FXR in
adipocytes on the development of obesity-induced inflammation.
Materials and methods:WTand FXR KO mice were fed a low fat diet
(LFD) or a HFD. After 12 weeks, epididymal white adipose tissue (e-
WAT) was collected and inflammatory phenotype was analyzed.
Cytofluorimetric analysis was used to evaluate number and phenotype
of immune cells infiltrating WAT. mRNA was isolated from WAT to
analyze the expression of inflammatory mediators by quantitative PCR.
In vitro differentiated primary adipocytes from WT and FXR KO mice
were stimulated with cytokines (TNFα 20 ng/ml, IFNγ 20 ng/ml), LPS
(100 ng/ml) or palmitic acid (PA, 0.5 mM). mRNA and proteins has been
isolated to evaluate the expression of genes and proteins involved in
adipocyte inflammation, respectively by quantitative PCR and western
blot. Cytokines secretion in cell culture medium was evaluated using
ELISA kits.
Results: HFD-induced accumulation of macrophages in e-WAT, mea-
sured by the number of macrophages per gram of WAT, was significantly
lower in FXR-KO mice (p<0.05) compared to WT after 12 weeks of
HFD. Moreover, gene expression of the macrophage marker EMR1
(F4/80) was lower in WAT of FXR-KO mice compared to WT on HFD
(p<0.05). HFD droveM1 polarization of e-WATmacrophages inWT but
not FXR-KO mice. Indeed, we found a significant decrease in CD11c+
M1 macrophages (p<0.001) and a significant increase in CD206+ M2
macrophages (p<0.005) in e-WAT of FXR KO mice. Gene expression
analysis revealed a significantly decreased of inflammatory marker
(TNFα, IL6, NLRP3, caspase1) (p<0.05) in WAT from HFD feeding
FXR-KO mice. Our in vitro results showed a decreased inflammatory
response of FXR-KO adipocytes. Gene expression analysis showed that
FXR deficiency impairs the inflammatory response of adipocytes, in
terms of gene expression of different cytokines (TNFα, IL-1β) (p<
0.005) and of inflammasome proteins encoding genes (NLRP3 and
caspase-1) (p<0.05). Moreover FXR-KO adipocytes did not show any
increase of SOCS3 gene expression in response to cytokines. Further-
more, FXR-KO adipocytes stimulated with LPS and PA showed de-
creased IL1β secretion compared to WT (p<0.05).
Conclusion: Our results clearly suggest a role of FXR in the inflamma-
tory response of adipocytes and in the crosstalk between adipocytes and
immune cells in adipose tissue in the context of obesity-induced inflam-
mation.
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Linagliptin-mediated DPP4 inhibition controls both macrophage mi-
gration and alternative activation and improves insulin resistance in
diet-induced obese mice
T. Ota, F. Zhuge, Y. Ni, L. Xu, M. Nagashimada, N. Nagata, S. Kaneko;
Brain/Liver Interface Medicine Research Center, Kanazawa University,
Japan.
Background and aims:Obesity activates the innate immune systemwith
subsequent recruitment of immune cells such as macrophages and T cells
into metabolic tissues, leading to the development of insulin resistance. In
particular, macrophage recruitment and polarization are pivotal in
obesity-induced inflammation and insulin resistance. Dipeptidyl
peptidase-4 (DPP4), also known as CD26, is widely expressed, including
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in immune cells. However, the role of DPP4 in macrophage-mediated
inflammation is unclear. In the present study, we showed that linagliptin,
a DPP4 inhibitor, attenuates whole-body insulin resistance by regulating
macrophage migration and alternative activation in both the adipose tis-
sue and liver of high-fat diet (HFD)-induced obese (DIO) mice.
Materials and methods: Eight-week-old C57BL/6J mice were fed a
HFD or a HFD containing linagliptin (HFD + Lina; 3 mg/kg body
weight) for 8 weeks. The histological characteristics and DPP4 activity
in the epididymal white adipose tissue (eWAT) and liver as well as insulin
sensitivity were examined. To quantify DPP4+ macrophages in lean and
obese mice, fluorescence-activated cell sorter (FACS) analysis was per-
formed on stromal vascular (SV) cells from the eWAT and liver of DIO
mice.
Results: DPP4 mRNA expression was significantly higher in the SV
fraction than in the adipocyte fraction from the eWAT of DIO mice.
Furthermore, an immunofluorescence study of eWAT in DIO mice re-
vealed that F4/80+ macrophages expressed DPP4 in crown-like struc-
tures. FACS analysis showed that only a small percentage of adipose
tissue macrophages (ATMs) and liver macrophages (LMs) co-expressed
DPP4 in wild-type (WT) mice. However, the percentage of DPP4+ cells
was significantly higher in both ATMs and LMs of DIO mice. Important-
ly, DPP4 activity in the eWAT and liver of DIO mice were 1.7-fold and
1.4-fold higher, respectively, than in WT mice (p<0.01), whereas
linagliptin markedly reduced the DPP4 activity by 89% and 88% (p<
0.01) in the eWAT and liver of DIO mice, respectively. Linagliptin ad-
ministrat ion improved HFD-induced glucose intolerance,
hyperinsulinemia (HFD, 1.1±0.3 vs. HFD + Lina, 0.5±0.08 ng/mL; p<
0.05, fasting state) and hepatic steatosis. Linagliptin also enhanced insulin
signaling assessed by IRβ and Akt phosphorylation in both the eWATand
liver of DIO mice. F4/80+ macrophage migration into eWAT and liver as
well as crown-like structure formation in eWAT were lower in HFD +
Lina mice than in HFD mice, although adiposities were similar. These
findings were associated with decreased mRNA expression of chemokine
systems (MCP-1-CCR2 and RANTES-CCR5) and proinflammatory cy-
tokines (IL-1β, IL-6, and TNFα) in eWAT and liver of HFD+Lina mice.
Furthermore, FACS analysis revealed that HFD + Lina mice had 35% and
36% fewer CD11c+CD206-(M1) ATMs and LMs, respectively, and 25%
and 164%more CD11c-CD206+(M2) ATMs and LMs, respectively, than
HFD mice, resulting in predominance of the M2 over M1 ATM and LM
population. However, the predominance of the Ly6C- over the Ly6Chi
monocyte population was not observed in the peripheral blood or bone
marrow of HFD+LY mice.
Conclusion: Linagliptin-mediated DPP4 inhibition reduces M1-
polarized macrophage migration and induces a M2 dominant shift of
macrophages within adipose tissue and liver, thereby attenuating
obesity-induced inflammation and insulin resistance.
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The SUCNR1-pathway couples obesity-induced metabolic stress to
the development of adipose tissue inflammation and diabetes
J.A. van Diepen1, J.H. Robben2, G. Hooiveld3, C. Carmone2, M.
Bekkenkamp-Grovenstein2, M.G. Netea1, C.J. Tack1, R. Stienstra1,
P.M.T. Deen2;
1Internal Medicine, 2Physiology, Radboud UMC Nijmegen, 3Nutrition,
Metabolism and Genomics Group, Wageningen University, Netherlands.
Background and aims: Adipose tissue of obese animals and humans is
characterized by adipocyte hypertrophy, oxidative stress, macrophage
infiltration and enhanced production of pro-inflammatory cytokines.
The enhanced inflammatory state of the adipose tissue significantly con-
tributes to the development of insulin resistance and development of type
2 diabetes mellitus (T2DM). However, mechanisms by which local met-
abolic disturbances in adipose tissue in obesity lead to macrophage infil-
tration and the onset of chronic inflammation are not fully understood.
The TCA cycle intermediate succinate has recently emerged as a meta-
bolic signal induced by pro-inflammatory stimulations. In the present
study, we aimed to investigate the role of succinate and its receptor
SUCNR1 in obesity-induced inflammation and insulin resistance in type
2 diabetes mellitus (T2DM).
Materials and methods: To study the role of the SUCNR1-pathway,
both animal and human studies were combined with various in vitro
approaches. Human plasma samples of T2DM patients (n=58) and
non-diabetic subjects (n=76) were used to determine circulating succi-
nate levels. In addition, adipose tissue inflammation as well as glucose
tolerance were determined in SUCNR1-/- and Wildtype (WT) mice that
were fed a high fat diet (HFD) or low fat diet (LFD) for 16 weeks.
Results: Circulating levels of succinate were elevated in humans diag-
nosed with T2DMas compared to non-diabetic subjects (+60%; P<0.01).
Interestingly, ex vivo, both hypoxia and hyperglycemia appeared to drive
the release of succinate from adipose tissue. Therefore, we set out to
evaluate the significance of the SUCNR1 in adipose tissue. Feeding mice
a high fat diet (HFD) increased expression of SUCNR1 in the stromal
vascular fraction (SVF) of the adipose tissue (4-fold; P<0.01), pointing
towards a role of the SUCNR1 in immune cell function in enlarged
adipose tissue. In response to HFD, WT and SUCNR1-/- mice had a
similar increase in total body weight and adipose tissue mass. However,
absence of the SUCNR1 in HFD-fed mice led to a reduction in total
adipose tissue macrophage numbers (-39%; P<0.05) and Crown Like
Structures (CLS; -53%: P<0.01), further confirmed by reduced F4/80
and Cd68 mRNA expression. In vitro, absence of the SUCNR1 in bone
marrow derived macrophages strongly reduced the chemotaxis potential
towards medium derived from apoptotic/hypoxic 3 T3 adipocytes (-59%;
P<0.05). In vivo, the reduced macrophage infiltration in adipose tissue of
obese SUCNR1-/- mice was accompanied by a significantly improved
glucose tolerance as compared to WT mice (AUC -28%; P<0.01).
Conclusion:Overall, our results have identified succinate and its receptor
as a driver of obesity-induced inflammation and an important contributor
to the migration of macrophages into adipose tissue leading the systemic
glucose intolerance in obesity-induced type 2 diabetes. As such, our data
put the SUCNR1 forward as a promising therapeutic target to combat
obesity-induced diabetes.
Supported by: EFSD/Lilly Fellowship
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MIP-1α ablation prevents insulin resistance induced by high-fat
feeding or leptin deficiency
M. Nagashimada, Y. Ni, L. Xu, N. Nagata, S. Kaneko, T. Ota;
Brain/Liver Interface Medicine Research Center, Kanazawa University,
Japan.
Background and aims: Monocyte chemoattractant protein-1 (MCP-1)
and its receptor CCR2 play a central role in the recruitment of adipose
tissue macrophages (ATMs) and subsequent development of insulin re-
sistance; however, a deficiency in either CCR2 or MCP-1 is insufficient
to overcome obesity-inducedATM recruitment and insulin resistance.We
have previously shown that other chemokine receptors, such as CCR5,
also promote adipose tissue inflammation and insulin resistance in obese
mice. The expression of macrophage inflammatory protein-1α (MIP-1α
or CCL3), a ligand of CCR5, is elevated markedly in the white adipose
tissue (WAT) of obese mice, although the mechanism by which MIP-1α
affects insulin resistance and glucose homeostasis remains poorly under-
stood. Here, we investigated the role of MIP-1α in obesity-induced adi-
pose tissue inflammation and whole-body insulin resistance induced by
high-fat (HF) feeding or leptin deficiency.
Materials and methods: Gene expression and the localization of
chemokines and their receptors were examined in the WATof genetically
(ob/ob) and HF diet-induced obese (DIO) mice. To determine whether
MIP-1α is required for obesity-induced ATM recruitment and insulin
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resistance in vivo, we examined the metabolic phenotype of MIP-1α-/-
mice. We also performed bone marrow transplantation (BMT) of MIP-
1α-/- mice or wild-type (WT) C57Bl/6J mice donor cells into irradiated
WT recipient mice to generate myeloid cell specific chimeric mice.
Results:MIP-1α expression was increased markedly compared to that of
MCP-1 in theWATof both DIO (MIP-1α, 5.9-fold; MCP-1, 3.2-fold; p<
0.05 vs. WT) and ob/ob mice (MIP-1α, 17.5-fold; MCP-1, 4.1-fold; p<
0.05 vs.WT) at 15weeks of age. Immunofluorescence staining ofWAT in
DIOmice revealed strongMIP-1α expression in the crown-like structures
(CLS) of F4/80+ macrophages. MIP-1α-/- mice fed normal chow had
slightly better glucose tolerance. MIP-1α-/- mice fed a HF diet showed
decreased macrophage infiltration and CLS formation in WAT compared
with WT mice at 16 weeks, although the weight gain was similar in both
groups. The HF diet-induced glucose intolerance and hyperinsulinemia
(MIP-1α-/- vs. WT; 0.6±0.1 ng/mL vs. 2.3±0.3 ng/mL, p<0.01) were
improved significantly in MIP-1α-/- mice. These findings were associat-
ed with decreased inflammatory cytokine expression (TNFα and iNOS),
attenuated endoplasmic reticulum stress evaluated by XBP-1 splicing,
and reduced hepatic steatosis. Next, we introduced a MIP-1α deficiency
into ob/ob mice to generate double-knockout (DKO) mice. The DKO
mice were strikingly resistant to the development of both insulin resis-
tance and fatty liver disease. The DKO mice also exhibited decreased
ATM recruitment and CLS formation, along with slightly reduced adipo-
cyte size compared to ob/ob littermates. Importantly, mRNA expression
of MIP-1α and other CCR5 ligands in WAT was higher in the stromal
vascular fraction relative to the adipocyte fraction from DIO mice at
16 weeks. Furthermore, chimeric mice lacking MIP-1α in myeloid cells
were protected from HF diet-induced hyperinsulinemia (MIP-1α-/-BMT
2.6±0.3 vs. WT-BMT 5.1±1.1 ng/mL, p<0.05), glucose intolerance, and
hepatic steatosis.
Conclusion: MIP-1α deficiency prevents insulin resistance caused by
either HF feeding or leptin deficiency, indicating a crucial role for MIP-
1α in ATM recruitment and the subsequent development of insulin resis-
tance independent of MCP-1/CCR2.
Supported by: MEXT, Japan
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Inflammation triggers specific microRNA profiles in human adipo-
cytes and macrophages and in their supernatants
F.J. Ortega1, M.Moreno1, J.M. Mercader2, J.M.Moreno-Navarrete1, M.
Sabater1, W. Ricart1, J.M. Fernandez-Real1;
1Department of Diabetes, Endocrinology and Nutrition (UDEN), Institut
d’Investigació Biomédica de Girona (IdIBGi), Girona, 2Joint IRB-BSC
program on Computational Biology, Barcelona Supercomputing Center,
Spain.
Background and aims: The potential relevance of microRNAs
(miRNAs) in adipose tissue is increasingly recognized, being intrinsically
linked to different pathways, including obesity-related inflammation. In
this study, we aimed to characterize the changes induced by inflammation
on the miRNA pattern of human adipocytes and macrophages.
Materials and methods: An extensive profile of 759 common miRNAs
was assessed in cells (human primary mature adipocytes, and the
macrophage-like cell line THP-1) and in their supernatants (SN) using
TaqMan low-density arrays. This profile was evaluated at the baseline
and after administration of lipopolysaccharide (LPS, 10 ng/ml) and LPS-
conditioned medium fromM1macrophages (MCM, 5%). Those miRNA
that experienced the most dramatic changes were also studied in subcu-
taneous human adipose tissue before and ~2 years after bariatric surgery-
induced weight loss.
Results: Differentiated adipocytes expressed 169 miRNAs, being 85 de-
tectable in the SN. In M1 macrophages, 183 miRNAs were detected,
being 106 present also in the SN. MCM and LPS led to increased number
of detectable miRNAs in cells and SN in both adipocytes (+8.3% and +
24.7%) and M1 macrophages (+1.4% and +5%, respectively). Under
inflammatory conditions, adipocytes and M1 macrophages shared the
expression of 147 (+9%) miRNAs, and 100 (+41%) common miRNAs
were also shared in their SN. Twelve of these “inflammatory” miRNA
were linked to inflammation in adipose tissue from obese subjects. Inter-
estingly, miR-221 (2-fold, p=0.002), miR-222 (2.5-fold, p=0.04) and
miR-155 (5-fold, p=0.015) were increased not only in inflamed adipo-
cytes but also in their SN (15, 6 and 4-fold, respectively, all p<0.001).
The expression of these specific miRNAs in human adipose tissue con-
cordantly decreased after weight loss (-51%, p=0.003, -49%, p=0.03,
and -54.4%, p=0.005, respectively).
Conclusion: Inflammation induces a specific miRNAs pattern in adipo-
cytes and M1 macrophages with impact on the physiopathology of
obesity-induced inflammation of adipose tissue. Variations regarding
the cluster miR-221/222 and the miR-155 may participate in the crosstalk
between obesity-related inflammation and AT/adipocytes impaired glu-
cose uptake.
Supported by: EFSD/Lilly, FIS2011-00214, FEDER, CIBERobn
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The transcription factor Prep1 is a molecular link between insulin-
resistance and inflammation in adipose tissue
F. Oriente1, A. Liotti1, S. Cabaro1, I. Cimmino1, S. Ricci1, G. Perruolo1,
M.Ciccarelli1, F. Ariemma1, C. Procaccini1, G.Matarese2, P. Formisano1,
F. Beguinot1;
1Department of Translational Medicine, University of Naples “Federico
II”; IEOS/CNR &URT “Genomica del Diabete”, 2University of Salerno,
Italy.
Background and aims: Mounting evidence have highlighted that the
chronic low-grade systemic inflammation accompanying obesity impairs
insulin signaling by secreting adipokines and may contribute to the de-
velopment of insulin-resistance and type 2 diabetes mellitus. We have
previously identified Prep1 as a homeodomain transcription factor, which
plays an important role in glucose homeostasis. Prep1 hypomorphic het-
erozygous mice (Prep1i/+) expressing low levels of protein are protected
from streptozotocin-induced diabetes and show improved insulin sensi-
tivity both in muscle and in liver. Moreover, these mice feature reduced
lipotoxicity and diet-induced steatohepatitis. In this study, we have fo-
cused our attention on the role of Prep1 on adipose tissue function.
Materials and methods: Adipose tissue of WT and Prep1i/+ mice have
been characterized by histological analysis and Western blot and qRT-
PCR experiments have been used to measure adipocyte protein and
mRNA expression. Adipose tissue immune-phenotyping has been per-
formed by cytofluorimetric analysis and metabolic profile of adipocytes
has been evaluated by extracellular flux analyzer.
Results: Prep1 hypomorphic heterozygous mice feature a 23% reduction
of total body lipid content compared to theWT littermates while the fresh
weight of the epididymal fat pads was found 25% lower in Prep1i/+ mice
(p<0.01). Histological analysis in adipose tissue of WT and Prep1i/+
mice revealed that Prep1 hypomorphic adipocytes feature a reduced cell
volume compared to the adipocytes of WT mice. More detailed analysis
of Prep1i/+ adipose tissue indicated increased number of small adipo-
cytes, which are more insulin responsive, and a reduction of enlarged
adipose cells that promote immune-inflammatory responses. Indeed, in-
sulin receptor tyrosine and akt/PKB phosphorylation was markedly in-
creased in Prep1 deficient mice and, in parallel, glucose uptakewas 3-fold
higher in Prep1i/+ animals (p<0.05). In addition, adipose tissue from
Prep1 hypomorphic heterozygous mice showed reduced T cells infiltra-
tion and leptin, TNF-α and IL-8 expression, while adiponectin levels
were increased.
Conclusion: All together, these data indicate that Prep1 deficiency re-
duces immune-inflammatory response improving glucose homeostasis in
adipose tissue.
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The role of tight glycaemic control on inflammation factors and
vasculoactive substances in newly diagnosed type 2 diabetes mellitus
A.A. Makina1, P. Mitrou2, M. Chrisanthakopoulou1, A. Theofanou3, P.
Georgoutsou3, T. El Xasmpan1, Z. Aleksiou1, G. Dimitriadis2;
12nd Department of Internal Medicine, General Hospital, Eleusina, 22nd
Department of Internal Medicine and Research Institute Athens Univer-
sity Medical School, General Hospital, Attikon University Hospital,
3Haematology Laboratory of General Hospital of Eleusina, Athens,
Greece.
Background and aims: In conditions with insulin resistance, a low-
grade inflammation in adipose tissue activates macrophages that together
with adipocytes produce various inflammatory adipokines, procoagulant
and vasculoactive substances. Considering the crosstalk between inflam-
matory pathways and insulin signalling cascade, these molecules may
represent a link between inflammation andmetabolic signals andmediate,
at least in part, insulin resistance in peripheral tissues. However, little is
known about the effect of intensive therapy targeting in tight glycemic
control on these factors. In our study we aimed to investigate circulating
levels of inflammatory markers including hsCRP, interleukin (IL)-6, IL-
18 and von Willebrand factor (vWF) in patients with newly diagnosed
type 2 diabetes, before and after 6-months intensive antidiabetic therapy
resulting in tight glycemic control.
Materials and methods: 52 newly diagnosed T2DM (29 males, age:
54.7+2.1 years) were selected. None of the subjects had coexistent auto-
immune or other inflammatory disease. Venous blood was obtained on
admission (1st baseline sample without any medication therapy) and
6 months later (2nd sample under antidiabetic therapy with oral agents
and/or insulin) for measurements of hsCRP, IL-6 IL-18 and vWF.
Results: After 6 months therapy (compared to baseline): 1) HbA1c de-
creased (6.01+0.1 vs 7.91±0.26, p<0.05) 2) BMI decreased (31+1 kg/
m2 vs 34.5+1 kg/m2, p=0.0001) 3) hsCRP serum levels decreased
(4.20+1.3 vs 9.29+1.51 mg/l, p<0.05) 4) IL-6 serum levels decreased
(2.44+0.41 vs 3.45+0.26 pg/ml, p<0.05) 5) IL-18 serum levels de-
creased (77.57+6.64 vs 99.54±8.0 pg/ml, p<0.05) and vWF plasma
levels decreased (97.14+8.58 vs 137.28+25.08%, p<0.69) 6) Therewere
no statistically significant differences between different therapies.
Conclusion: Tight glycemic control with oral agents and/or insulin de-
creases the inflammatory factors, with additional beneficial effects on
endothelial dysfunction wich may reduce procoagulant imbalance seen
in untreated patients with type 2 diabetes.
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Impact of glucose-loading on the variation of CD4+ and CD8+ Tcells
A. Miya1, A. Nakamura1, H. Miyoshi1, Y. Takano1, K. Sunagoya2, K.
Hayasaka2, C. Shimizu2, Y. Terauchi3, T. Atsumi1;
1Division of Rheumatology, Endocrinology and Nephrology, 2Division
of Laboratory and Transfusion Medicine, Hokkaido University, Sapporo,
3Department of Endocrinology and Metabolism, Graduate School of
Medicine, Yokohama City University, Japan.
Background and aims: Chronic inflammation is involved in the patho-
genesis of obesity and type 2 diabetes. Obesity and diabetes were asso-
ciated with the peripheral blood T cell composition as well as total pe-
ripheral white blood cell and leukocyte count. However, little is known
about the effect of acute change of glucose metabolism by glucose-
loading on the peripheral blood Tcell compartment. The aim of this study
is to examine the fluctuation of CD4+, CD8+ T cells and natural CD4+
CD25+FoxP3+ T-regulatory (Treg) cell variation following oral glucose
tolerance test (OGTT) in patients with or without type 2 diabetes and its
relation to fluctuation in glucose, insulin and free fatty acid (FFA) caused
by OGTT.
Materials and methods: Twenty Japanese patients with type 2 diabetes
(DM group) and 20 without diabetes (non DM group) were recruited into
the present study. After obtaining the approval of the institutional review
board and written informed consent from the subjects, a 75-g OGTT was
performed. The plasma glucose and insulin levels were measured after an
overnight 12-h fast and during a 75-g OGTT at 30, 60, 90 and 120 min.
Cell numbers of leucocyte, lymphocytes and T cell compartment such as
CD4+, CD8+, and Treg were calculated from their blood after an overnight
12-h fast and during a 75-g OGTT at 60 and 120 min. Insulin sensitivity
was estimated using theMatsuda index and homeostasis model assessment
of insulin resistance (HOMA-IR). Glucose-stimulated insulin secretionwas
evaluated based on the insulinogenic index and oral disposition index.
Results: Age was significantly higher, whereas insulinogenic index and
oral disposition index were significantly lower in the DM group com-
pared with those in the non DM group. There were no significant differ-
ences in sex, body mass index, Matsuda index, nor HOMA-IR between
these two groups. Before glucose-loading, there were no differences in
cell numbers of leucocyte (6466.7±2332.9/μL in the DM group vs
6290.0±1587.1/μL in the non DM group), lymphocytes (2001.2±
636.7/μL vs 2336.6±1173.7/μL), CD4+ (896.5±290.9/μL vs 1036.2±
429.0/μL), CD8+ (582.7±277.8/μL vs 622.6±290.5/μL), and Treg (78.6
±38.1/μL vs 88.9±40.2/μL) between these two groups. The proportion
of lymphocytes (DM group: 31.8±7.3% to 30.2±7.4/μL; p<0.01, and
non DM group: 37.5±16.0% to 36.9±15.5%; p<0.01) and CD8+ (DM
group: 28.4±7.4% to 26.3±6.4/μL; p<0.01, and non DM group: 27.1±
4.9% to 25.3±5.6%; p<0.01) significantly decreased, whereas the pro-
portion of CD4+ significantly increased (DMgroup: 45.2±6.1% to 47.6±
5.9/μL; p<0.01, and non DM group: 46.3±9.0% to 47.7±9.8%; p<0.01)
after 120 min of glucose-loading in both groups. The proportion of Treg
was not affected. Furthermore, significant positive correlation was ob-
served between the area under the curve for CD8+ and the change of
FFA following OGTT (r=0.40, p<0.05), but not that of glucose nor
insulin.
Conclusion: Although Treg population was not quantitatively different,
CD4+ T cells were increased and CD8+ T cells decreased after glucose
loading in both subjects with and without diabetes. These findings sug-
gest that glucose loading dynamically affects the balance of circulating T
lymphocyte subset regardless of glucose tolerance.
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Association of low-grade inflammation with early changes of
glycaemic control, insulin sensitivity and secretion in recent-onset
type 1 and type 2 diabetes
K.S. Weber1,2, B. Nowotny1,2, K. Strassburger3,2, G. Pacini4, J.
Szendroedi1,5, K. Müssig1,5, C. Herder1,2, M. Roden1,5, for the GDS
Group;
1Institute for Clinical Diabetology, German Diabetes Center at Heinrich
Heine University, Leibniz Institute for Diabetes Research, 2German Cen-
ter for Diabetes Research, Partner Düsseldorf, 3Institute for Biometrics
and Epidemiology, German Diabetes Center at Heinrich Heine Universi-
ty, Leibniz Institute for Diabetes Research, Düsseldorf, Germany, 4Meta-
bolic Unit, Institute of Biomedical Engineering, National Research Coun-
cil, Padua, Italy, 5Department of Endocrinology and Diabetology, Medi-
cal Faculty, Heinrich Heine University, Düsseldorf, Germany.
Background and aims: Low-grade inflammation affects insulin sensi-
tivity and beta-cell function already before the onset of diabetes and can
contribute to the development of both type 1 (T1D) and type 2 diabetes
(T2D). We hypothesized that biomarkers of low-grade inflammation also
associate with the early progression of recent-onset T1D and T2D.
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Materials and methods: In the prospective GDS study, new-onset T1D
(n=42) and T2D (n=94) patients underwent detailed metabolic charac-
terization within the first year after diabetes diagnosis and 2 years there-
after. Associations between changes of markers of low-grade inflamma-
tionwith changes of HbA1c, insulin sensitivity and secretion as measured
by intravenous glucose tolerance test were assessed using multivariable
linear regression analysis adjusted for age, sex, body mass index (BMI),
smoking status, as well as for 2-year changes of BMI, smoking status, and
glucose-lowering treatment.
Results: Both T1D and T2D patients exhibited good glucometabolic
control at baseline (mean HbA1c 7.1±1.6% and 6.4±1.0%) and after
2 years (mean HbA1c 7.0±1.2% and 6.6±1.1%). Two-year increases of
high-sensitive C-reactive protein, soluble E-selectin and soluble intercel-
lular adhesion molecule-1 in T2D and of interleukin-18 in T1D were
associated with absolute increases of HbA1c by +0.5%, +0.9%, 1.7%
and +1.2% (all P<0.01; changes per doubling of biomarker levels be-
tween baseline and 2-year follow-up). A comparable 2-year increase of
sE-selectin associated with a relative decrease in pre-hepatic beta-cell
function by -34.9% (P<0.05) in T2D.
Conclusion:During the initial course of disease, low-grade inflammation
relates to worsening of glycemia in both T1D and T2D, whereas endo-
thelial activation may contribute to decreasing beta-cell function in T2D.
Clinical Trial Registration Number: NCT01055093
Supported by: DZD e.V.
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Metformin decreases TLR4 expression in type 2 diabetic patients
monocytes and inhibits leptin secretion in peripheral blood mononu-
clear cells (PBMC)
A. Coppola1,2, M. Caputo1,2, D. Pastore1, B. Capuani1, F. Pacifici1, R.
Arriga1, S. Caratelli1,3, A. Bellia1,2, S. Tartaglione4, A. Galli4, M. Roma-
no4, P. Sbraccia1, D. Della Morte1,2, G. Sconocchia5, D. Lauro1,2;
1University of Rome, 2University Hospital ‘Fondazione Policlinico di Tor
Vergata’, 3Institute of Translational Pharmacology, National Research
Council,, 4University Hospital ‘Fondazione Policlinico di Tor Vergata’,
5Institute of Translational Pharmacology, National Research Council, Ro-
ma, Italy.
Background and aims: Several studies argue the importance of inflam-
mation as key component of Type 2 Diabetes Mellitus (T2D). Among
cytokines involved in T2D pathogenesis, serum levels of Leptin and High
Mobility Group Box (HMGB)1 were found increased in T2D patients:
Leptin modulates cytokines secretion in monocytes and CD4+ T-cells
while HMGB1 actives immune system by promoting T-cell and B-cell
reactivity. Moreover, HMGB1 receptors Toll like receptor 2 and 4 (TLR2
and 4) were found increased in monocytes of newly diagnosed T2D
patients. Metformin represents the T2D first lane therapy, and it can
decrease both HMGB1 and Leptin blood levels. We aimed to investigate
the effects of Metformin therapy on TLR expression in T2D patients and
to explain its anti-inflammatory mechanism.
Materials and methods: 50 Caucasian subject were recruited and divid-
ed in 3 groups: 10 healthy controls (HC), 20 T2D patients in therapy with
Metformin (MET-T2D), and 20 newly diagnosed T2D patients without
pharmacological treatment (Naïve-T2D). MET-T2D and Naïve-T2D
showed BMI≤28, glucose value <126 mg/dl and HbAC1 values were
<6%. Monocyte percentage was evaluated by flow cytometry and con-
firmed with complete blood count (CBC) analysis. TLR2 and TLR4
expression or mean fluorescence intensity (MFI) of each cohort were
evaluated by flow cytometry. PBMCs of each group were isolated by
Ficoll gradient, activated with IL-2 (200U/ml) for 72 h and treated with
HMGB1 (2 ug/ml) for 48 h. Leptin levels were evaluated by ELISA
assay. Results were analyzed with t-test and P values <0.05 were consid-
ered statistically significant.
Results: CBC analysis showed no variation in monocytes count among
our groups. We, thus, analyzed TRL2 and TLR4 expression: we found
Naïve-T2D showed an increase in amount of TLR2+/TLR4+ subpopula-
tion compared to HC. Conversely,MET-T2D showed a dramatic decrease
in TLR4 compared to Naïve-T2D and HC while TLR2 expression is not
affected by Metformin. We confirmed these data by MFI analysis. To
asses biological significance to TLR4 inhibition by Metformin, PBMCs
from HC, Naïve-T2D and MET-T2D were isolated, activated with IL-2
and treated with HMGB1. We established that HMGB1 increases Leptin
secretion in IL-2 activated HC PBMCs, whileMET-T2D PBMCs showed
no variations in Leptin secretion after HMGB1 treatment and IL-2 acti-
vation. Nevertheless, HMGB1/IL-2 tandem treatment increased Leptin
secretion only in TLR4+ PBMC in Naïve-T2D patients, in fact we found
a small percentage of Naïve-T2D in which TLR4 expression is highly
deregulated. MET-T2D and TLR4- Naïve-T2D did not show any varia-
tion in Leptin secretion after HMGB1/IL-2 treatment.
Conclusion: Our data shows that Metformin therapy is associated with
TLR4 deregulation in T2D patient’s monocytes. The lack of TLR4 sug-
gests a minor susceptibility to inflammatory stimuli in terms of Leptin
secretion, providing a potential mechanism to explain Metformin anti
inflammatory pleiotropic effect.
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Effects of empagliflozin in a murine model of diet-induced insulin
resistance: A role for NLRP3 inflammasome inhibition?
E. Benetti1, G. Vitarelli1, M. Collino1, R. Mastrocola2, J.C. Cutrin3, F.
Chiazza1, D. Nigro2, R. Fantozzi1;
1Dipartimento di Scienza e Tecnologia del Farmaco, 2Department of
Clinical and Biological Sciences, 3Department of Biotechnology and Sci-
ences for the Health - University of Turin, Italy.
Background and aims: Empagliflozin is a potent and selective inhibitor
of the sodium glucose co-transporter (SGLT)-2, approved as a new oral
treatment for type 2 diabetes. However, to date, the potential ability of
empagliflozin to affect the chronic inflammatory response associated with
diabetes and recently recognized as a primary pathogenic factor in the
development of insulin resistance, has not been investigated. Aim of this
study was to evaluate the effects of a chronic treatment with
empagliflozin in a murine model of diet-induced insulin resistance, fo-
cusing on inflammatory response in liver and kidney. In particular, as
NLRP3 (nucleotide-binding and oligomerization domain [NOD]-like re-
ceptor [NLR] pyrin domain-containing 3) inflammasome has been rec-
ognized playing a key role in insulin-resistance and obesity-induced in-
flammation, the effect of empagliflozin on diet-induced NLRP3 activa-
tion was evaluated.
Materials and methods: Male C57BL/6 mice (n=20 per group) were
provided with a standard (control group) or a high fat-high sugar (HFHS
group) diet for 4 months. Over the last 2 months, subsets of animals were
treated with empagliflozin (1-10 mg/kg) added to the diet. Body weight,
water/food intake were recorded weekly. Insulin, interleukin (IL)-1β, IL-
18, IL-6 and tumor necrosis factor (TNF) levels and albumin/creatinine
ratio (ACR) were measured by ELISA. Phosphorylation of insulin sig-
naling intermediates, NLRP3 expression and caspase-1 activation were
evaluated by western blot on tissue specimens.
Results: In comparison to mice fed with standard diet, animals provided
with HFHS diet exhibited a significantly bigger final body weight (25.2±
0.8 vs 34.6±3.0 g, p<0.001), higher fasting glycaemia (111.3±11,8 vs
171.3±21.4 mg/dl, p<0.001) and plasma total cholesterol (102.3±24.3
vs 138.9±10.9 mg/dl, p<0.05). HFHS mice shown hepatic steatosis and
tubular vacuolar degeneration in the kidney. Moreover, a 4-fold higher
liver triglyceride level (p<0.01), a 5-fold higher ACR (p<0.001) and a
marked increase of NLRP3 expression (p<0.01) in liver and kidney were
also measured in HFHS mice. A 10% reduction of body weight was
induced by 10 mg/kg empagliflozin (p<0.001), and a dose-dependent
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effect on fasting glycaemia, liver steatosis and renal tubular damage was
measured in animals treated with the drug. Interestingly, the diet-related
overexpression of NLRP3 was attenuated by empagliflozin in a dose
dependent manner, and this effect was associated with a significant de-
crease in tissue caspase-1 activation and IL-1β production. Empagliflozin
evoked a significant reduction of plasma TNF, liver IL-6 and ACR
starting from 1 mg/kg.
Conclusion: The deleterious effects of a HFHS diet were reverted by
empagliflozin in a dose-dependent manner. Our results clearly demon-
strated the ability of the drug to affect NLRP3 inflammasome signaling,
suggesting that this inhibition may contribute to the therapeutic effects
exerted by empagliflozin.
Supported by: Boehringer Ingelheim
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Hypoglycaemic episodes are associated with inflammatory status in
patients with type 1 diabetes
B. Kiec-Wilk1, B. Matejko1, U. Razny2, A. Polus2, T. Klupa1, J.
Skupien1, M.T. Malecki1;
1Metabolic Diseases Department, 2Clinical Biochemistry Department,
Jagiellonian University Medical College, Krakow, Poland.
Background and aims: It is well documented that glycemic control is
associated with inflammatory status in type 1 diabetes (T1DM) patients.
The hyperglycemia-induced oxidative stress plays a key pathophysiolog-
ical role in damaging endothelial function in diabetes. However, the in-
dividual contribution of different parameters and indices, for example
glucose variability or hypoglycemic episodes, is not clear. The aim of
the study was to examine the association of glycemic control parameters
and selected blood markers of endothelial function and inflammation in
T1DM patients.
Materials and methods:We included 101 patients with T1DM on insu-
lin pumps (mean age - 28.7+10.8 years, mean T1DM duration - 8.5 +/-
2 years). All subjects completed a standardized questionnaire. Other
sources of information included medical records, downloads from glu-
cose meters and personal pumps. The list of glycemic control parameters
included HbA1c, mean glucose level, standard deviation and four other
indices based on self-monitoring blood glucose as well as the number of
hypoglycaemias (glucose <55 mg/dL) from the period of last 7 days.
Blood was collected for 4 inflammatory markers: interleukin 6 (IL-6),
Vascular Cell Adhesion molecule 1 (VCAM), Intercellular Adhesion
Molecule 1 (ICAM), E-selectin. Appropriate statistical analyses were
performed for differences and associations. In forward stepwise multiple
linear regression analysis, inflammatory factors were dependent vari-
ables, while as independent variables we used seven glycemic control
indices and selected clinical as well as biochemical parameters.
Results: The examined cohort was characterised by good glycemic con-
trol as the mean HbA1c level was 7.1+0.8%, mean daily glucose -
141.5+27.1 mg/dL. Standard deviation reached 65.6+16.9, while num-
ber of hypos 5.6+4.0 over the observation period. In forward stepwise
multiple linear regression analysis we observed that the number of hypo-
glycemias was consistently an independent predictor of the level of all
investigatedmarkers - sICAM (p=0.0019), VCAM (p=0.021), E-selectin
(p=0.048) and IL-6 (p=0.027), respectively. None of the other glycemic
parameter turned out to independently predict the inflammatory status of
examined T1DM patients.
Conclusion: For the first time, we report the association between the
number mild hypoglycemic episodes over the period of one week and
the level of several inflammatory markers in T1DM patients with good
glycemic control.
Supported by: Scientific grants K/ZDS/003785; K/ZDS/004501
685
Characterisation of the complement system among hospitalised type
2 diabetic patients with community acquired bacterial infections
L.J. Barkai, E. Sipter, D. Csuka, Z. Nebenfuhrer, Z. Prohaszka, I. Karadi,
N. Hosszufalusi;
3rd Department of Internal Medicine, Semmelweis University, Budapest,
Hungary.
Background and aims: Infections are more frequent and severe in pa-
tients with type 2 diabetes mellitus (T2DM) than in nondiabetic popula-
tion. The complement cascade is a complex protein system, which can be
activated via different enzymatic pathways and plays an important role in
response to pathogens. The goal of our study was to determine predictive
association between increased risk of community-acquired bacterial in-
fections and lectin complement pathway member ficolin-3 among pa-
tients with type 2 diabetes mellitus.
Materials and methods: In our prospective, matched pairs study 40
subjects with T2DM according to WHO criteria and 12 nondiabetic sub-
jects were investigated. Patient inclusion criteria were clinical diagnosis
of acute community acquired bacterial infections. Immunological, hema-
tological, oncological illnesses were excluded. Activity of the ficolin- and
MBL-lectin complement pathway member ficolin-3 and mannose bind-
ing lectin (MBL), activity of the alternative complement pathway, con-
centrations of classical complement pathway member C1q and comple-
ment activation end product C4d were measured from blood samples
using standardized ELISA kits. Complement and laboratory parameters
of 26 subjects from the T2DM and 9 subjects from the nondiabetic group
were reassessed after a minimum of three-month infection-free period.
Statistical analysis and correlations between C1q/WBC, C4d/WBC, C4d/
CRP, F3/WBC and F3/CRP were performed using GraphPad Prism 5.
Results:We found higher HbA1c levels in the T2DM group (17/40 men;
median [percentile 25-75] age: 73 [66.3-80.8] years, HbA1c: 7.6 [6.2-
8.1]%, CRP: 146 [74.6-248.3] mg/l, white blood cell count (WBC): 10.2
[8.1-14] G/l; sepsis: 17/40; mortality: 8/40) than in the nondiabetic group
(8/12 men; median [percentile 25-75] age: 74.5 [59.3-82] years, HbA1c:
5.5 [5.4-6] %, CRP: 118.7 [74.7-159.7] mg/l, white blood cell count
(WBC): 10.95 [8.5-13.4] G/l; sepsis: 4/12; mortality: 1/12). Among
T2DM subjects during acute infection no change was found in the
MBL activity, however ficolin-3 activity, alternative complement path-
way activity were higher (p=0.0061 and p=0.0447, respectively), C4d
concentrations were lower (p=0.0138) than in an infection-free period.
During infection, C4d concentrations were also lower in the T2DM group
than in the nondiabetic group (p=0.025), however no difference was
found in the MBL and ficolin-3 activity, alternative complement pathway
activity, and C1q concentrations. In the absence of infection, lower C1q
levels were found in T2DM than in nondiabetic subjects (p=0.0212),
however during infection this difference could not be seen. Interestingly,
between C1q and WBC during infection-free period a positive (p=
0.0087, Spearman r=0.51), while having an infection a negative correla-
tion (p=0.0054, Spearman r=-0.53) was found.
Conclusion: Our results show that T2DM may be associated with an
alteration of not only the ficolin- and MBL-lectin, but also the classical
and the alternative complement pathways. This could be a possible cause
of the increased risk of infection among patients with T2DM.
Supported by: EFSD
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Free fatty acid uptake in different abdominal adipose tissue
compartments
P. Dadson1, L. Landini1,2, J.C. Hannukainen1, M.-J. Honka1, H.
Immonen1, M. Soinio3, P. Salminen4, J. Pihlajamäki5, P. Iozzo6, P.
Nuutila1,3;
1Turku PET Center, University of Turku, Finland, 2Institute of Clinical
Physiology, National Research Council, Pisa, Italy, 3Department of En-
docrinology, 4Acute and Digestive Surgery, Turku University Hospital,
5Clinical Nutrition and Obesity Center, University of Eastern Finland,
Kuopio, Finland, 6Institute of Clinical Physiology, National Research
Council, Pisa, Italy.
Background and aims: Abdominal adipose tissue (AT) contains subcu-
taneous (SC) deep and superficial layers and intraperitoneal and
extraperitoneal visceral AT. There is limited information about differences
and the effect of surgery in fatty acid uptake (FAU) in these compart-
ments. We therefore aimed to study tissue-specific FAU in abdominal
adipose tissue compartments before and after obesity surgery and com-
pare the results to non-obese subjects.
Materials andmethods:A total of 27 severely obese females (BMI 41.4
±4.0 kg/m2, age 42±9 yrs, 11 T2D and 16 non-T2D) undergoing bariatric
surgery and 15 age-matched non-obese healthy women (BMI 22.6±
2.8 kg/m2) were recruited into the study. FAU in superficial and deep
abdominal SC ATand extra- and intraperitoneal visceral ATwas assessed
using PET with [18 F] fluoro-6-thia-heptadecanoic acid ([18 F] FTHA).
Studies were repeated in obese subjects 6 months after surgery. The con-
trols were studied once.
Results: During the follow-up, both BMI (41.4±4.0 vs 31.8±4.2 kg/m2,
p<0.001) and body fat % (50.0±3.7 vs 42.8±4.3%, p<0.001) decreased,
but remained abnormal. Before surgery obese had higher fasting glucose
and FFA levels compared to controls, and FFA remained at the same level
postoperatively. In obese, abdominal fat FAU (μmol*min-1*100 g-1) was
higher in intraperitoneal than extraperitoneal AT (0.81±0.44 vs 0.46±
0.29, p<0.001) and in deep than superficial SC AT (0.38±0.18 vs 0.30
±0.16, p<0.001). Similarly, deep vs superficial AT (0.30±0.16 vs 0.25±
0.14, p<0.01) and intra- vs extraperitoneal AT (0.56±0.27 vs 0.43±0.25,
p<0.01) differed in controls, but no differences were found in tissue-
specific FAU between obese and controls, when FAU was expressed
per kilogram AT. The FAU per depots of AT was in obese 6-fold higher
before surgery and 4-fold higher postoperatively as compared to controls.
Surprisingly, the distribution of FAU between SC, and intra- and extra-
abdominal depots was similar in obese and controls. Baseline SC FAU
correlated with fasting glucose (r=0.41, p=0.03) and intraperitoneal FAU
with high-sensitivity C-reactive protein (r=0.47, p=0.02).
Conclusion: Fatty acid uptake in abdominal AT depots is markedly en-
hanced in obesity and remains elevated after bariatric surgery. FAU per
volume ofAT differs between different abdominal AT depots, but remains
similar in morbidly obese before and after bariatric surgery. Surgery did
not alter FAU in the metabolically distinct abdominal fat compartments.
The enhanced metabolic activity in intraperitoneal fat coupled with its
association with a marker of low-grade inflammation may be the major
contributing factor to the unfavorable glucose homeostasis observed in
obese subjects before surgery.
Clinical Trial Registration Number: NCT01373892
Supported by: Academy of Finland
687
Respective roles of ATGL and HSL on adipose tissue lipolysis-
mediated control of glucose metabolism and insulin sensitivity
E. Mouisel, L. Monbrun, P. Morigny, J. Personnaz, M. Houssier, V.
Barquissau, G. Tavernier, D. Langin;
Obesity Research Laboratory, Institute of Metabolic and Cardiovascular
Diseases, Toulouse, France.
Background and aims:We and others showed that pharmacological and
genetic inhibition of the neutral lipases, Adipose Triglyceride Lipase
(ATGL) or Hormone-Sensitive Lipase (HSL), responsible of adipose tis-
sue lipolysis, improves whole-body glucose metabolism and insulin sen-
sitivity. The underlying mechanisms are not perfectly understood. Re-
cently, our laboratory showed a potentially beneficial upregulation of
adipose de novo lipogenesis (DNL) following HSL down regulation
in vitro in human adipocytes (see abstract from Morigny et al, EASD
2015). Here, we aimed at deciphering in vivo the roles of ATGL and
HSL haploinsufficiency on insulin sensitivity.
Materials and methods: ATGL+/-HSL+/-, ATGL+/-, HSL+/- and
wildtype (WT) male C57BL/6J mice were fed 3 months either a chow
or a 60% high fat diet and phenotyped at various time points.
Results:Whole-body insulin sensitivity, measured byQUICKI, indicated
a higher sensitivity in ATGL+/-HSL+/- fed a chow diet in comparison to
WT mice (0.47±0.01 vs 0.41±0.01, respectively, p=0.02). When chal-
lenged 3 months with high fat diet, ATGL+/- (0.36±0.01, p=0.02),
HSL+/- (0.36±0.01, p<0.01) and double haploinsufficient mice (0.38±
0.01, p<0.001) showed a significantly higher insulin sensitivity in com-
parison toWTmice (0.33±0.01). Compared toWTmice fed high fat diet,
lipase haploinsufficiency resulted in an improvement of insulin signalling
pathway (AktSer473 phosphorylation) and increased expression of mas-
ter regulator genes of glucose metabolism and DNL in white adipose
tissue (WAT). The improvement was more pronounced in ATGL+/-
HSL+/- mice. There was no difference in fat mass andWAT inflammation
between genotypes. In the liver, glycogen content was increased and
hepatic steatosis was decreased. Measurements of respiratory quotient
suggested a shift from fat to glucose metabolism in the haploinsufficient
mice.
Conclusion: Altogether these results shed new light on the role of adi-
pose neutral lipase in the control of glucose metabolism and insulin sen-
sitivity. Whether the mechanisms mediating these improvements are sim-
ilar or different following ATGL and HSL inhibition is currently under
investigation.
Supported by: ANR and CLE Midi-Pyrénées
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Partial inhibition of hormone-sensitive lipase improves insulin sensi-
tivity by induction of de novo lipogenesis and elongase ELOVL6 in
human adipocytes
P. Morigny1, M. Houssier1, S. Caspar-Bauguil1, D. Beuzelin1, A.
Mairal1, E. Mouisel1, C. Postic2, H. Guillou3, D. Langin1;
1INSERM U1048 I2MC, Toulouse, 2CNRS UMR 8104, Institut Cochin,
Paris, 3INRA UMR 1331, TOXALIM, Toulouse, France.
Background and aims: Partial inhibition of Hormone-Sensitive Lipase
(HSL) improves in vivo and in vitro insulin sensitivity. In human adipo-
cytes, HSL inhibition improves glucose metabolism and increases de
novo lipogenesis (DNL). Recent studies report a close relationship be-
tween adipose DNL, under the control of the transcription factor Carbo-
hydrate Responsive Element Binding Protein (ChREBP), and insulin
sensitivity. Consequently, we hypothesized that the improvement of insu-
lin sensitivity observed during HSL inhibition is driven by an increase of
DNL.
Materials and methods: In human hMADS adipocytes (human
multipotent adipose-derived stem cells), downregulation of HSL (siHSL),
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ChREBP (siChREBP), Elongation of Very-Long-Chain Fatty Acids 6
(siELOVL6) or, as control, Green Fluorescent Protein (siGFP) expression
has been achieved by siRNA transfection. Glucose metabolism has been
measured by radiolabelled glucose. Insulin signaling has been assessed
by Western Blot. Fatty acid (FA) composition of phospholipids (PL) has
been determined by gas chromatography.
Results: siHSL adipocytes show improved glucose transport, oxidation
and DNL in parallel to an increase of ChREBP gene expression (+32%, p
<0.001). These cells also present an improved insulin signaling. All these
beneficial effects are lost with dual inhibition of HSL and ChREBP. HSL
downregulation promotes an increase in PL oleate (+18%, p<0.001)
combined with a slight decrease of PL palmitoleate whereas the opposite
profile is observed in siChREBP adipocytes. Among ChREBP-induced
genes, the elongase ELOVL6 gene expression shows the highest induc-
tion in siHSL cells (+93%, p<0.001). Inhibition of ELOVL6 decreases
PL oleate in favor of an important increase of PL palmitoleate and results
in a significant reduction of the beneficial effects of HSL inhibition on
insulin sensitivity.
Conclusion: We have demonstrated that partial inhibition of HSL im-
proves insulin sensitivity and increases DNL pathway through ChREBP
induction. ChREBP by a positive control of ELOVL6 is responsible of an
increase in oleate synthesis. Increased PL oleate by ELOVL6 could mod-
ify plasma membrane fluidity and thereby improve insulin signaling.
Supported by: ANR
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Mitochondrial oxidative pathways are downregulated in adipocytes
in obesity - a twin study
S. Heinonen1, M. Muniandy1, A. Hakkarainen2, J. Lundbom2,3, N.
Lundbom4, J. Kaprio5,6, A. Rissanen1, K. Pietiläinen1,7;
1Obesity Research Unit, Diabetes and Obesity Research Programs Unit,
2Helsinki Medical Imaging Center, University of Helsinki, Finland, 3In-
stitute for Clinical Diabetology, Leibniz Center for Diabetes Research,
Heinrich Heine University, Düsseldorf, Germany, 4University of Helsin-
ki, Helsinki Medical Imaging Center, 5Department of Health, National
Institute for Health and Welfare, Helsinki, 6Department of Public Health,
7Department of Endocrinology, Abdominal Center, University of Helsin-
ki, Finland.
Background and aims: Low mitochondrial activity in adipose tissue is
suggested to be an underlying factor in obesity and its metabolic compli-
cations. However it is still unknown whether this is due to malfunction of
adipocytes or of other cells in adipose tissue.
Materials and methods: We studied young adult monozygotic (MZ)
Finnish twin pairs discordant (n=14, ΔBMI>3 kg/m2) and concordant
(n=5, ΔBMI<3 kg/m2) for obesity, aged 22-36-years by assessing ab-
dominal body fat distribution (MRI), liver fat content (MR spectroscopy),
insulin sensitivity (OGTT) and global gene expression (Affymetrix U133
plus 2.0 chips) of isolated adipocytes, collagenase digested and washed
from subcutaneous abdominal adipose tissue biopsies.
Results: The obese (mean BMI 30.0±1.0 kg/m2) and lean (BMI 23.9±
0.8 kg/m2) co-twins of the discordant pairs had a mean 17.6±1.9 kg, p<
0.001 difference in body weight. The obese co-twins had more subcuta-
neous (6068.9±437.4 vs. 3526.1±293.6 cm3, p<0.001), intra-abdominal
(1193.1±169.4 vs. 540.5±81.9 cm3, p<0.001) and liver fat (2.93±0.79
vs. 0.62±0.07%, p<0.001), and were more insulin resistant (HOMA-
index 1.6±0.2 vs. 1.1±0.2, p<0.01; Matsuda-index 6.4±0.7 vs. 8.3±
0.9, p=0.02). The concordant pairs were very similar in their measures.
The significantly differentially expressed genes in adipocytes between the
discordant co-twins (2538 transcripts, adjusted p-value, FDR<0.05) were
related to mitochondrial oxidative phosphorylation, branched chain ami-
no acid catabolism, glucocorticoid receptor signaling and IL-8 signaling.
More than one-tenth of these transcripts (n=278) were mitochondria-
related and almost all of them downregulated (244/278, 88%) in the obese
co-twins. Pathway analysis of the mitochondria-related transcripts re-
vealed reduced oxidative phosphorylation, TCA-cycle, fatty acid beta
oxidation, branched chain amino acid degradation and ketone body pro-
duction and breakdown (all p<0.001) in the obese co-twins. These down-
regulated pathways correlated negatively with intra-abdominal and liver
fat, HOMA-index, hs-CRP and positively with adiponectin (p<0.05 all)
in individual twins.
Conclusion:We report global downregulation ofmitochondrial oxidative
pathways in obese adipocytes, associating with metabolic disturbances, in
young adult MZ twins.
Supported by: Orion, Academy of Finland, Novo Nordisk, HUCH, Dia-
betes Research F.
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The adipokine adipocyte fatty acid-binding protein in high altitude
T. Ebert1,2, J. Pichler Hefti3,4, T.M.Merz3, U. Hefti5, A. Hoffmann1,2, M.
Stumvoll1, M. Fasshauer1,2, S. Kralisch1,2;
1Department of Endocrinology and Nephrology, University of Leipzig,
2IFB AdiposityDiseases, Leipzig University Medical Center, Germany,
3Department of Intensive Care Medicine, 4Department of Pneumology,
University Hospital and University of Bern, 5Swiss Sport Clinic, Bern,
Switzerland.
Background and aims: Different adipose tissue-secreted adipokines are
dysregulated in hypoxia in vitro. However, the in vivo-effect of prolonged
hypobaric hypoxia on serum levels of the insulin resistance-inducing and
proatherogenic adipokine adipocyte fatty acid binding-protein (AFABP)
has not been comprehensively studied in humans, so far.
Materials and methods: AFABP serum levels were quantified in all
participants of the High Altitude Medical Research Expedition Himlung
2013 (N=39) byenzyme-linked immunosorbent assay. This expedition is
an observational cohort study of human adaption to hypobaric hypoxia
and has measured clinical and anthropometric data of the subjects at six
time points at different altitudes, i.e. pretest: 550 m; base camp 1: 4800m;
camp 2: 6025 m, base camp 2: 4800 m; camp 3: 7050 m; post: 550 m
(Figure 1). Associations were studied using multivariate regression
models with relative changes (ratios=parameter at maximum altitude /
parameter at start altitude) of the respective parameters.
Results: Median [interquartile range] AFABP serum concentrations in-
creased during the ascent from 11.2 [6.6] μg/l at pretest to a maximum of
34.2 [16.1] μg/l at the peak level, i.e. 7050 m (p<0.05). Barometric
pressure was the strongest and negative predictor of AFABP after adjust-
ment for age, gender, and bodymass index (p=0.003). In accordancewith
these findings, altitude was the strongest positive predictor of AFABP
when included in this multivariate model instead of barometric pressure
(p=0.004). Interestingly, serum levels of the control and obesity-
associated adipokine leptin decreased during the ascent (2.8 [4.8] μg/l
at pretest as compared to 1.1 [1.7] μg/l at 7050 m) (p=0.003) but no
independent associations with relative changes of leptin could be
demonstrated.
Conclusion: Circulating AFABP is increased during a high altitude as-
cent and is independently associated with barometric pressure, as well as
with altitude level. These data are in accordance with the hypothesis that
hypoxia could contribute to an adverse metabolic profile in humans.
Further studies need to elucidate the pathophysiological significance of
AFABP upregulation in high altitude/hypoxia.
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Supported by: DFG, SFB 1052/1, C06; BMBF, Germany, FKZ:
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Human brown adipose tissue oxygen consumption after meal is sim-
ilar to cold activated consumption
M. U Din1, J. Raiko1, T. Saari1, N. Kudomi2, R. Parkkola3, P. Nuutila1,4,
K.A. Virtanen1;
1Turku PET Centre, Turku University Hospital and University of Turku,
Finland, 2Department of Medical Physics, Faculty of Medicine, Kagawa
University, Kita-gun, Japan, 3Medical Imaging Centre of Southwest Fin-
land, 4Department of Endocrinology, Turku University Hospital, Finland.
Background and aims: Diet-induced thermogenesis in human brown
adipose tissue (BAT) has not been widely examined. Therefore, we aimed
to compare BAT oxygen consumption during cold activation and after
standardised meal.
Materials and methods: Healthy lean and obese study subjects (n=14,
age: 36.2±12.0 years, BMI range: 23.3 - 34.2 kg/m2) of both genders
(10 F/4 M) were studied at two different scanning sessions, 1) after
standardised meal (542 kcal, 58% carbohydrates, 25% fats, 17% proteins)
at room temperature (RT) and 2) after overnight fasting during acute cold
exposure, using PET-CT. Radioactive oxygen [15O]O2 and [
15O]H2O
were given to measure oxygen consumption and perfusion in BAT, re-
spectively. Indirect calorimetry was performed to assess the differences in
whole body resting energy expenditure (REE) and whole body substrate
oxidation between post-prandial state and cold exposure.
Results: Supraclavicular BAT oxygen consumption during cold was 1.7
±0.6 ml/100 g/min while after standardised meal it was 2.0±1.0 ml/
100 g/min (p=0.81). There was no relation between BAT oxygen con-
sumption measured during cold and post prandial state (r=-0.15; p=
0.66). As expected, post-prandial plasma insulin level was higher than
plasma insulin levels during fasting and cold exposure (p<0.001).
Whole body REE during cold and post-prandial state was at the
same level (7.7±1.0 MJ/day and 7.4±0.9 MJ/day, p=0.50, respec-
tively). During post-prandial state whole body glucose oxidation
was higher than in cold (p<0.001), while in cold whole body fat
oxidation was higher compared to post-prandial state (p<0.001).
Post-prandial BAT oxygen consumption correlated negatively with
waist circumference (r=-0.77; p=0.006).
Conclusion: Similar oxygen consumption in post-prandial state and in
cold suggests that human BAT has diet-induced thermogenic capacity.
However, mechanism of action and substrate utilisation responsible for
enhanced BAT oxygen consumption in these two states appear to be
different. Since BAT is insulin sensitive we speculate that BAT oxygen
consumption in post-prandial state is potentially due to insulin mediated
substrate utilisation.
Supported by: Academy of Finland, EU FP7 DIABAT, The Diabetes
Research Foundation, SRK
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Clinical and laboratory characteristics of 14 patients with
Berardinelli-Seip syndrome
R.M. Montenegro Jr1, A.D.R. Montenegro1, V.O. Fernandes1, L.A.S.
Karbage1, C.M.M. Ponte1, M.C.G. Castelo1, M.M.D. Carvalho1, D.D.
Gadelha1, M.L. Aragão1, S.C. Lopes1, A.A.M. Sales1, C.B.R. Liberato1,
L.B. Aguiar1, A.P. Moraes2, C.B. D' Alva1;
1Faculty of Medicine - Federal University of Ceara, 2São José Hospital of
Infectious Diseases, Fortaleza, Brazil.
Background and aims: Congenital generalized lipodystrophy (CGL) or
Berardinelli-Seip syndrome (BS) is a rare disease that affects 1:
10.000.000 live births. This condition is inherited in an autosomal reces-
sive pattern. These individuals have total or near total absence of subcu-
taneous tissue since birth. This condition is associated to severe insulin
resistance and, in general, these patients develop early metabolic disor-
ders such as diabetes and hypertriglyceridemia. Others clinical manifes-
tations are hepatic steatosis and hepatic cirrhosis, muscle hypertrophy and
acanthosis nigricans. The aim of this study was to describe the clinical
and laboratory characteristics of patients with BS residents in the state of
Ceara-Brazil.
Materials and methods: We studied 14 patients with BS. They per-
formed a complete clinical evaluation, image exams and collected labo-
ratory tests for metabolic evaluation. Data were analyzed in STATA 11.2
program. Results were expressed as mean±standard deviation (SD).
Results: 71.43% of patients were women; the mean age was 10.78±
8.29 years old. BS family history was present in 21.43% and inbreeding
in the family 64.29%. All patients had muscle hypertrophy, prominence
of veins, acanthosis nigricans and no clinical evidence of peripheral ad-
ipose tissue. The mean body fat percentage of these individuals, rated by
bioelectrical impedance analysis, was 8.56±3.53%. Diabetes was present
in 50% of subjects. The age mean in diabetes diagnosis was 7.73±
6.52 years old. After adjusted for sex, age and height, 88.89% had high
blood pressure; 69.23% hypertriglyceridemia; 84.62% low HDL-c and
25% hypercholesterolemia. Imaging studies showed hepatomegaly in
92.86%, hepatic steatosis in 28.57%, splenomegaly in 35.71%,
nephromegaly in 61.54% and left ventricular hypertrophy in 40% of the
subjects. Laboratory findings were: A1C: 7.06±2.30%, fasting glucose:
109.14±78.60mg / dL, insulin: 28.04±31.18μUI / mL, HOMA-IR: 3.83
±3.21, total cholesterol: 192.46±179.83 mg / dL, HDL-c: 29.84±
8.73 mg / dL, LDL-c: 80.82±28.04 mg / dL, triglycerides: 188.08±
186.09 mg / dL, leptin: 1.19±0,26 ng / mL and albumin / creatinine ratio:
85.80±113,20 mg / g.
Conclusion: The patients with BS have important metabolic disturbances
since childhood, with multiple cardiovascular risk factors. Thus, it is
necessary an early therapeutic intervention in this population to minimize
the complications inherent to these condition.
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Type 2 diabetes and a reduced risk of prostate cancer: a case for a
spurious association
E.L. Badrick1, M. Sperrin1, T. Moran2, I. Buchan1, A. Renehan1;
1Institute of Population Health, University of Manchester, 2Cancer Reg-
istry, Manchester, UK.
Background and aims: Several studies from western populations indi-
cate that men with Type 2 Diabetes (T2D) are paradoxically at reduced
risk of developing incident prostate cancer (PC), but recent data from
Asian-Pacific populations indicate that, here, there is a positive associa-
tion between T2D and PC. In addressing aetiological inference, we
hypothesise that such contrasting relationships reflect methodological
rather than biological mechanisms.
Materials and methods:We used the Salford Integrated record database
linked with the Northwest Cancer Intelligence service (UK) (1995-2010).
We identified incident male cohorts with (N=5,069) and without T2D
(N=41,812), who were matched (1: 3) by year of birth and smoking
status. We explored two broad methodological models to estimate risk:
(A) a fixed ever/never method based on prevalent T2D in 1999 (com-
monly used in the literature); and a (B) time-varying approach allowing
for date of T2D diagnosis to be a varying exposure, until the diagnosis of
PC. Risk estimates were expressed as hazard ratios (HRs) and their 95%
confidence intervals (CIs) using a split-interval approach and age as the
timescale.
Results: Using model A, there were 1,098 new diagnoses of PC, the risk
of incident PC in men with T2D was reduced (HR: 0.54, 95% CIs: 0.31,
0.94), similar to estimates reported in the literature. Using model B, mean
follow-up time was 6.80 years we observed that within 6 months follow-
ing T2D diagnosis, there was an increased ‘spike’ co-diagnosis of PC.
Analysing beyond 2 years, the association between T2D was null (HR:
0.96, 95% CIs: 71, 1.29).
Conclusion: These findings support the hypothesis that the apparent
protective association between T2D and risk of PC might be spurious,
and reflect methodological rather than true biological mechanisms. These
analyses need to be repeated in a larger independent dataset.
Supported by: MRC CRUK
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Deterioration of glycaemic control as a clue to finding occult cancer
A. Reiko, H. Eguchi, Y. Ueda, Y. Tahara, S. Kaneko;
Diabetes, Endocrinology and Life-related Disease, Takatsuki Red Cross
Hospital, Japan.
Background and aims: Hyperglycemia, insulin resistance and
hyperinsulinemia have been implicated in promoting carcinogenesis.
On the other hand, cancer associated factors worsen insulin resistance,
and glycemic control of cancer bearing diabetic patients often deterio-
rates. Either way, deteriorated glycemic control is believed to be an im-
portant clue to finding occult cancer in patients with diabetes.
Materials and methods: We tried to confirm whether deteriorated gly-
cemic control was a clue to finding occult cancer in patients with diabetes
and investigated whether it applies to every type of cancer. We investi-
gated the medical records for diabetic patients with cancer going back
over a period of 8 years. Their trends in glycemic control in relation to
types and stages of cancer were analyzed.
Results: During 8 years from 2006 to 2013, 755 diabetic patients were
newly diagnosed with cancer. Lung cancer was most common and found
in 167 patients, followed by 114 colorectal, 110 gastric, 72 prostate, 40
pancreas, 36 hepatocellular, 26 kidney or urethra-bladder, 24 breast can-
cers and 20 uterine cancers. Cancers with diagnosed patient numbers
under 20 were excluded for analysis. HbA1c significantly elevated in
gastric cancer as the stage advanced. However, gastrointestinal bleeding
causes apparent decrease in HbA1c regardless of glycemic control, and
should be given attention. HbA1c of patients with pancreatic cancer rose
significantly in stage 2. Although statistically not significant, HbA1c of
patients with hepatocellular carcinoma tended to increase as the stage
advanced. HbA1c of patients with kidney or urethra-bladder elevated in
stage 0 or 1 more significantly than stage 4. In patients with uterus cancer,
HbA1c rose significantly as the stage 0 to 1 advanced. On the other hand,
HbA1c of lung or prostate cancer-bearing patients was not elevated even
in advanced stages.
Conclusion:Deterioration of glycemic control can be a promising clue to
detect occult gastric, pancreatic, kidney or urethra-bladder, and uterus
cancers. However, lung or prostate cancers had little effect on glycemic
control. Keeping good glycemic control is not only essential for preven-
tion of diabetic complication, but also helps early detection of pancreatic
cancer, improvement of personal prognosis and the saving of medical
economics.
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p38 MAPK inhibitor suppresses diabetic pancreatic tumour growth
and epithelial-mesenchymal transition-mediated metastasis via re-
ducing inflammation
L. Wang, J. Zhou;
Department of General Surgery, Zhongda Hospital, Medical School,
Southeast University, Nanjing, China.
Background and aims: Diabetes contributes to chronic inflammation
and promotes tumor progress. p38 mitogen-activated protein kinase
(MAPK), as an essential kinase of inflammation, plays an important role
in tumor growth. However, the effects of p38 MAPK on epithelial-
mesenchymal transition (EMT)-mediated diabetic pancreatic cancer me-
tastasis remains unclear. The aim of this study was to investigate the
effects of p38 MAPK inhibitor on pancreatic cancer growth and metas-
tasis in diabetic animals.
Materials and methods: C57BL/6 mice were intra-peritoneally admin-
istered with streptozotocin for 5 days and then fed with high fat diet in
following 3 weeks to establish animal models of type 2 diabetes. p38
MAPK inhibitor, SB203580, was intravenously injected into pancreatic
cancer mice for 7 consecutive days after surgical orthotopic implantation.
Results:Glucose does-dependently increased the phosphorylation of p38
MAPK (P<0.05, Fig. A) and time-dependently increased the prolifera-
tion (P<0.05, Fig. B) of pancreatic cancer cells which were both signif-
icantly reduced by SB203580. Transwell assay showed that SB203580
significantly inhibited both high glucose and TGF-β induced cancer cell
invasion (P<0.001, Fig. C). The orthotopically implanted tumors in wild-
type controls and diabetic mice treated with SB203580 or saline were
monitored by MRI in 1, 2, 3 and 4 weeks (n=20/group, Fig. D). Tumor
volume measurement showed that the diabetic cancers grew much more
rapidly than non-diabetic controls (P<0.05, Fig. E), while SB203580
treatment significantly suppressed the tumor growth both in non-
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diabetic and diabetic mice (P<0.05, Fig. E). Survival curves showed that
SB203580 could significantly increase the survival of diabetic and non-
diabetic pancreatic cancer mice (P=0.02, n=20/group, Fig. F). In addi-
tion, Western blot analysis of tumors showed that diabetes decreased the
expression of E-cadherin while increased the expression of vimentin;
however, SB203580 treatment could reverse the above EMT process (P
<0.05, n=6/group, Fig. G). Furthermore, the pro-infammatory factors
(IL-6,TNF-α, NFκB) in diabetic pancreatic tumors were significantly
reduced in SB203580-treated groups (P<0.05, n=6/group, Fig. H).
Conclusion: Diabetes induced the phosphorylation of p38 MAPK and
inflammation, which promoted the proliferation and EMT-mediated me-
tastasis of pancreatic cancers; while SB203580 suppressed the diabetes-
induced tumor growth and EMT. Our results indicate that p38 MAPK
inhibitor may provide a novel intervention strategie for diabetic pancre-
atic cancer patients.
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Differential expression of the E2F family in the carcinogenesis accel-
erated by liver steatosis
K. Tanaka1, S. Otabe1, S. Kakino1, E. Soejima1, X. Yuan1, H.
Nakayama1, O. Nakashima2, K. Hara1, T. Ohki2, N. Wada1, T.
Hashinaga1, T. Egashira1, Y. Tajiri1, K. Yamada1;
1Endocrinology and Metabolism, 2Clinical Laboratory Medicine,
Kurume University, Japan.
Background and aims: Obesity and type 2 diabetes are major risk fac-
tors for non-alcoholic steatohepatitis (NASH) and hepatocellular carcino-
ma (HCC). Although various factors including insulin resistance and
oxidative stress have been implicated in the development of HCC, the
precise mechanism of the carcinogenesis remains to be determined. The
E2F family is a group of transcription factors that plays pivotal roles in the
regulation of cellular proliferation and apoptosis. The family is currently
divided into pro-proliferative (E2F1-E2F3) and anti-proliferative (E2F4-
E2F8) members. We tested a hypothesis that the differential regulation of
the E2F family is involved in the development of HCC associated with
steatosis.
Materials and methods: We used wild-type C57BL/6 mice, adipocyte-
specific nSREBP-1c transgenic mice that exhibit liver steatosis and insu-
lin resistance, and liver-specific cyclin D1 (Ccnd1) transgenic mice that
develop HCC at around the age of 60 weeks or later. A Ccnd1/nSREBP-
1c double transgenic mouse line was generated to assess the effect of liver
steatosis on the development of HCC. Gene expressions were measured
by DNA microarray analysis and quantitative RT-PCR. Protein expres-
sions were determined by the Western blot analysis.
Results:Wild-type mice fed a high-fat/high-sucrose diet from the age of
8weeks became obese and developed diabetes before the age of 20weeks.
The expression of E2f2 was higher in the liver compared with mice fed
normal chow, while that of E2f8 was lower. Similarly, the expressions of
E2f2 and E2f8 were increased and decreased, respectively, in the liver
from nSREBP-1c transgenic mice. However, in Ccnd1 transgenic mice
that had no liver steatosis, the expressions of E2f2 and E2f8 were com-
parable to those of wild-type mice. At the age of 52 weeks, small hepatic
tumors were detected in 10 of 48 Ccnd1 transgenic mice. In contrast,
Ccnd1/nSREBP-1c double transgenic mice that had liver steatosis devel-
oped multiple hepatic tumors with histological features corresponding
with those of human HCC (34 of 34 mice, p<0.00001). The expressions
of E2f2, Ccna2 and Ccnb1were significantly increased in the background
liver tissue, whereas the expression of E2f8 was markedly reduced. Im-
munohistochemical analysis showed that the proliferating cell nuclear
antigen was positive in the nuclei of the non-tumor tissue.
Conclusion: We demonstrated that steatosis accelerated carcinogenesis
in the liver of the cancer-susceptible mice. Both Ccna2 and Ccnb1 are
target genes of E2F2 and E2F8; E2F2 enhances the expression of the
cyclin genes whereas E2F8 represses it. Although the expression levels
of E2F members in human HCC and their association with prognosis are
still controversial, these observations suggest that the up-regulation of
E2F2 and the down-regulation of E2F8 may be involved in the develop-
ment of HCC in patients with obesity and type 2 diabetes, probably
through the modulation of cyclin gene expression.
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Glucose-induced CCL5 release by human adipocytes promotes
breast cancer invasiveness and distant metastasis
V. D'Esposito1, D. Liguoro1, M.R. Ambrosio1, M. Cantile2, F. Collina2,
G. Mosca1, A. Buonomo1, M. Lecce1, L. Albano1, F. Beguinot1, M. Di
Bonito2, R. Franco2, P. Formisano1;
1Department ofTranslational Medicine, University of Naples“Federico
II”; IEOS/CNR & URT “Genomica del Diabete”, 2National Institute of
Tumors, Foundation “G. Pascale”, Naples, Italy.
Background and aims: Type 2 diabetes (T2D) is associated with an
excess risk of several forms of cancer. In particular, women with
diabetes have a statistically significant 20% increased risk of breast
cancer. Additionally, patients with breast cancer and preexisting dia-
betes have an increased of metastasis and of all-cause mortality com-
pared with their nondiabetic counterparts. Breast cancer grows and
metastasizes to a predominantly adipocyte-dominated host environ-
ment. T2D induces adipocyte alterations leading to an imbalanced
adipokine production that in turn may promote cancer phenotypes.
We have studied the mechanisms by which adipocytes integrate in-
puts from T2D-induced alterations and promote breast cancer cell
motility and invasiveness.
Materials and methods:Human Stromal Vascular cells were isolated by
adipose tissue biopsies, differentiated in adipocytes and incubated in the
presence of different concentrations of glucose. Adipocyte conditioned
media and co- cultures were established to investigate MDA-MB-231
breast cancer cell motility and invasiveness. Adipocyte- released factors
were determined by ELISA multiplex. CCL5 and IGF1 expression in
peritumoral adipose tissue was evaluated by immunochemistry.
Results: We have obtained evidence that human adipocytes exposed to
high glucose concentration (25 mM) induce breast cancer cell prolifera-
tion, migration and invasion. Screening for several cytokines revealed
that adipocytes cultured in high glucose medium release 1.5 and 2-fold
higher amount of IGF1 and CCL5, respectively, compared to those cul-
tured in low glucose medium (5.5 mM glucose). Moreover, adipocyte-
released factors control IGF1, but not CCL5 expression in cancer cells.
Inhibition of IGF-1 pathway almost completely prevented the effect of
adipocytes on breast cancer cell growth but only slightly interfered with
cancer cell motility. At variance, inhibition of CCL5 action by specific
peptides and antibodies reduces adipocyte promoting effect on breast
cancer cell migration and invasion. Interestingly, CCL5/RANTES ex-
pression in peritumoral adipose tissue of women with Triple Negative
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Breast Cancer correlated with lymph node (p-value=0.04) and distant
metastases (p-value=0.001). A positive correlation was also observed
between CCL5 expression and T2D. Finally, Kaplan-Meier curves
showed a significant negative correlation between CCL5 staining in the
peritumoral adipose tissue and overall survival of patients (p-value=
0.039).
Conclusion: Hyperglycemia induces adipocyte release of CCL5 that, in
turn, contributes to cancer cell motility, cancer lymph node and distant
metastases, which may contribute to reduce the overall survival of
patients.
Supported by: EFSD, AIRC
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Chronic hyperglycaemia enhances the malignant molecular commu-
nication between the human pancreatic stellate and cancer cells
G. Firneisz1, K. Kiss2, K. Baghy2, S. Spisak3, S. Szanyi4, Z. Tulassay1,
A. Zalatnai2, J.-M. Löhr5, R. Jesenofsky6, I. Kovalszky2;
12nd Department of Medicine, 21st Department of Pathology and Exper-
imental Cancer Research, Semmelweis University, Budapest, Hungary,
3Children's Hospital, Harvard Medical School, Boston, USA,
4Semmelweis University, Budapest, Hungary, 5Karolinska Institutet,
Stockholm, Sweden, 6Medical Campus Mannheim, Dept. of Medicine
II,, University of Heidelberg, Mannheim, Germany.
Background and aims: The association between diabetes mellitus (DM)
and pancreatic cancer (PaC) was established by epidemiologic studies. It
was concluded that DM is not only an early manifestation, but also an
etiologic factor of PaC.We hypothesized a role for pancreatic stellate cells
(PSC) in the hyperglycemia induced deterioration of pancreatic cancer.
Therefore studied two human cell lines (RLT-PSC, T3M4) in hypergly-
cemic environment.
Materials and methods: In case of 'chronic hyperglycemia' (CHG) ex-
posure RLT-PSC cells were cultured in a medium containing 15.3 mmol/
L glucose for 21 days. Subsequently, cells were starved for 24 hours in
FBS-free medium and thereafter for 48 hours in FBS-free medium either
with or without TGFβ1. The effect of CHG on PSCs was sutided using
mRNA expression array (GeneChip PrimeView, Affymetrix) with real-
time PCR (ABI Gene Expression TaqMan®) validation and bioinformatic
pathway analysis (MetaCore, Thomson Reuters). Main results were also
confirmed using protein studies (ELISA, WB, IC). The effect of PSC-
conditioned media and hyperglycemia on T3M4 pancreatic cells was
assessed in proliferation and migration assays.
Results: The stress fiber formation (IC αSMA) indicated that PSCs tend
to trans-differentiate to a myofibroblast-like state after CHG exposure.
Glucose transporters (types-1, -2, and -3) were expressed on RLT-PSC
and T3M4 cells. The phosphorylation of p38 and ERK1/2 was increased
with a consecutive upregulation of CDC25, SP1, cFOS and p21, and with
downregulation of PPARg after PSCs were exposed to chronic
hyperglycemia.
CXCL12 levels increased significantly in PSC supernatant after cells
were exposed to CHG regardless of TGF-β1 treatment (3.09-fold with
and 2.73-fold without TGF-β1, p<0.05). Treatment of PSCs - kept in
normal glucose concentration with TGF-β1 treatment in a 2.69-fold in-
crease of CXCL12 levels. When the TGF-β1 treatment was applied sub-
sequently after that PSCs were exposed to CHG it resulted in a significant
(3.78 fold, p<0.05) IGFBP2 protein level elevation in the supernatant. In
cancer cells, hyperglycemia induced an increased expression of CXCR4,
a CXCL12 receptor that was also induced by PSC’s conditioned medium.
The receptor-ligand interaction increased the phosphorylation of ERK1/2
and p38. Conditioned medium of PSC increased pancreatic cancer cell
proliferation and this effect could be partially inhibited by a CXCR4
inhibitor (AMD3100). The PSC conditioned medium (even under normal
glucose concentration) could increase the ERK1/2 and p38
phosphorylation.
Conclusion: Hyperglycemia induces increased CXCL12 production by
the human PSCs, and its receptor, CXCR4 on cancer cells. The ligand-
receptor interaction activates MAP kinase signaling that further increases
the cancer cell proliferation and migration. The upregulation of the SP1
transcription factor in PSCs after CHG exposure may result in the in-
creased CXCL12 and IGFBP2 production.
Supported by: OTKA 100904 grant.
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Insulin and IGF-1 promote pancreatic stellate cells activation and
galectin-3 expression: potential role in promotion of pancreatic
cancer
X. Zhu1, R. Waldron2,3, A. Lugea2,3, L. Li1,3;
1Departmentof Endocrinology, affiliated ZhongDa Hospital of Southeast
University, Nanjing, China, 2Cedars-Sinai Medical Center, 3VA Greater
Los Angeles Healthcare System, University of California, Los Angeles,
USA.
Background and aims: Epidemiological studies indicate that the risk of
pancreatic cancer (PC) is increased in type 2 diabetic patients. Insulin and
insulin-like growth factor (IGF-1) play an important role in carcinogene-
sis. Insulin resistance and associated hyperglycemia, hyperinsulinemia,
and abnormalities in insulin/IGF receptor pathways have been suggested
to be the underlying mechanisms contributing to development of
diabetes-associated pancreatic cancer. Activated pancreatic stellate cells
(PSCs) are key stroma cells responsible for pancreatic fibrogenesis and
pancreatic cancer progression. The aim of this study was to elucidate
PSCs functional responses to insulin and IGF-1.
Materials and methods: In primary mouse PSCs and a novel immortal-
izedmouse pancreatic stellate cell line (imPSCs), we examined the effects
of insulin and IGF-1 on PSCs activity. Cells were stimulated with
100 nmol/L insulin or 10 nmol/L IGF-1. We determined expression of
α-smooth muscle actin (α-SMA) and galectin-3, measured matrix syn-
thesis of collagen I (Col-I) and fibronectin (FN), and analyzed the expres-
sion of insulin/IGF-1 signaling pathway components and their operation
as profibrotic and/or proliferative pathways and assessed the potential
contributions of PSCs to a procarcinogenic microenvironment.
Results: PSCs express receptors for both insulin (IR) and insulin-like
growth factor 1 (IGF-1R), and respond to insulin/IGF-1 stimulation with
increased tyrosine phosphorylation at specific autophosphorylation sites.
Akt/mTOR/p70S6K signaling were activated.α-SMA expression were
induced when PSCs were incubated with either insulin (1.75±0.06 of
control, P<0.01) or IGF-1 (8.16±0.04 of control, P<0.01). Galectin-3
production of PSC was enhanced after incubation with insulin (1.83±
0.07 of control, P<0.01) or IGF-1 (9.80±0.06 of control, P<0.01). Col-
I and FN production were also increased (P <0.05 ). IGF-1 was four to
five times more potent than insulin. Results in imPSCs were in accor-
dance with primary mouse PSCs.
Conclusion:Our study suggests that insulin and IGF-1 play an important
role in the activation of PSCs and progression of fibrosis. Increased ex-
pression of galectin-3 and abnormalities in insulin/IGF receptor signaling
network may be involved in development and progression of diabetes-
associated pancreatic cancer.
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The postprandial glucose response is not a good reflection of the
actual rate of glucose release from a starchy food: an exploratory
study using dual stable isotope technique
H.P.F. Peters1, H.M. Boers1, T.H. van Dijk2, C. Eelderink3, H.
Hiemstra1, A.R. Hoogenraad1, D.J. Mela1, M.G. Priebe3;
1Unilever R&D, Vlaardingen, 2Dept of Laboratory Medicine, University
of Groningen, UniversityMedical Center Groningen, 3Center forMedical
Biomics, University Medical Center Groningen, Netherlands.
Background and aims: We have shown that guar gum added to a flat
bread flour lowers postprandial blood glucose and insulin dose-depen-
dently, probably due to the viscosity-inducing effects of the fibre. How-
ever, the glucose influx rate from a starchy food source is not established
by measuring only total blood glucose, as this is the net result of glucose
absorption, glucose disposal into tissues and hepatic glucose production
rates. The aim of this study was therefore to measure the actual rate of
glucose release from the food and related glucose fluxes, and to obtain
more insight into the mechanism of glucose lowering, by using the dual
isotope technique and measuring incretin hormones.
Materials and methods: In a double-blind, randomized, placebo-con-
trolled, cross-over design, 12 healthy males consumed each of three
flatbread test products labelled with 13C-wheat flour: a control (C), or C
with the incorporation of 15% chickpea with either 2% (GG2) or 4%
(GG4) guar gum. By a 6 h primed-continuous infusion of D-[6,6-2H2]
glucose the appearance of exogenous glucose (RaE), endogenous glucose
production (EGP) and glucose clearance (GCR) rates could be calculated.
Plasma glucose, insulin, GIP and GLP-1 were measured for 4 h postpran-
dially. All data were calculated as 2 h and (except glucose) 4 h area-under-
the-curve (AUC). As the study was explorative, statistical significance
was assessed by comparing the confidence intervals of the changes after
GG2 and GG4 compared to C.
Results: Compared to C, GG2 reduced glucose by 14% (NS) and insulin
by 16% (P<0.05), while 4 h AUC values for RaE, GCR and EGP were
reduced slightly by 3, 5 and 3%, respectively (all NS). Changes after GG4
were more distinct and all significant (all P<0.05): glucose was reduced
by 26% and insulin by 23%, while RaE, GCR and EGP were reduced by
11, 12 and 64%, respectively. The 2 h and 4 h effect sizes were similar for
RaE and GCR, but the 2 h values for EGP were bigger, namely 36 and
80% greater suppression after GG2 and GG4 respectively (both P<0.05)
compared to C. Postprandial changes in GIP and GLP-1 did not differ
significantly between products.
Conclusion: Using the dual isotope technique, we found that the lower
glucose response to GG2 and GG4 was not clearly dominated by a re-
duced absorption rate, as might be expected for a viscous fibre, but was
perhaps even more due to post-absorptive effects (GCR and EGP). The
data suggest that small initial changes in RaE could potentially result in
larger post-absorptive effects. The lower GCRwas in accordance with the
lower insulin response after the test meals, but EGP was not. EGP was
paradoxically more suppressed after the test meals than after the control,
especially during the first 2 h, which could also not be explained by the
other incretin hormones. These data reinforce the view that the rate of
glucose release from carbohydrate-rich foods cannot be assumed from the
postprandial glucose response, but must be measured using labelled
tracers.
Clinical Trial Registration Number: NCT01734590
Supported by: Unilever
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Metabolic and molecular effects of a high-protein diet in subjects
with type 2 diabetes
M. Markova1, S. Hornemann1, S. Sucher1, O. Pivovarova1,2, A.
Pfeiffer1,2;
1Clinical Nutrition, German Institute of Human Nutrition (DIfE),
Nuthetal, 2Department of Endocrinology, Charité University Medicine,
Berlin, Germany.
Background and aims: Previous studies reported both favourable and
adverse impacts of high-protein diet in type 2 diabetes. In our clinical
study we compared effects of two isocaloric high-protein diets of animal
(AP) and plant (PP) origin on metabolic markers, liver fat content and
signalling pathways in white blood cells and adipose tissue.
Materials and methods: Individuals with type 2 diabetes (age 65±
6 years, BMI 30.5±3.6 kg/m2, HbA1c 7.0±0.6%, n=30) were random-
ized to either high-animal (meat and dairy foods) or high-plant (dietary
pulses) protein diet (30% protein, 40% carbohydrates, 30% fat) for
6 weeks. Before and after the diet intervention, magnetic resonance im-
aging, hyperinsulinemic euglycemic clamps, and meal tolerance tests
were performed, and blood and subcutaneous adipose tissue samples
were collected. Key proteins of the Akt/mTOR signalling pathway were
analysed in isolated white blood cells and adipose tissue using PathScan
Antibody Array (Cell Signaling).
Results: Levels of liver parameters (AST, ALT, GGT) in blood improved
after diet intervention in both groups. Liver fat content and HbA1c levels
were reduced in all subjects (AP: -43.6%, p<0.001; PP: -37.1%, p<
0.001, and AP: - 0.58%, p<0.05; PP: - 0.41%, p<0.001, respectively).
The clamp-derived insulin sensitivity improved significantly only in the
AP group (ΔM-value=0.88 mg/kg BW/min, p<0.05). In the PP group
there was a significant reduction of plasma creatinine (-7.79 μmol/l, p<
0.01) and improvement of the glomerular filtration rate (from 75.95 to
88.15 ml/min/1.73 m2, p<0.001) which was not found in the AP group.
We did not observe any alteration of the Akt/mTOR pathway in white
blood cells after the dietary intervention. However, in adipose tissue the
phosphorylation of AMPK, Erk1/2 and 4E-BP1 was approximately 2-
fold higher in the AP group, whereas in the PP group the phosphorylation
of Bad and PDK1 was significantly increased.
Conclusion: In diabetic subjects, the 6-week high-protein diet leads
to an improvement of glucose metabolism and decrease of liver fat
content independently from the protein origin. The high-protein diet
has no adverse effects on kidney parameters, moreover the kidney
function improved in the plant protein group. On molecular level, we
observed the dietary-induced increase of the phosphorylation of some
proteins of Akt/mTOR pathway in subcutaneous adipose tissue, but
not in blood cells, indicating a differential modulation of intracellular
signalling pathways.
Clinical Trial Registration Number: NCT02402985
Supported by: BMEL, DZD
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Effects of medium-chain saturated dairy fat on the body composition
of abdominal obese subjects (DairyHealth): a 12-week, randomised,
double-blinded, intervention study
M. Bohl1, A. Bjørnshave1, M.K. Larsen2, S. Gregersen1, K. Hermansen1;
1Department of Metabolism and Endocrinology, Aarhus University Hos-
pital, 2Department of Food Science, Aarhus University, Tjele, Denmark.
Background and aims: Obesity, reduced insulin sensitivity and hyper-
tension are important risk factors for cardiovascular disease (CVD) and
type 2 diabetes (T2D). These risk factors are influenced by the dietary
behavior. Thus the consumption of dairy products e.g. whey protein and
medium-chain saturated fatty acids (MC-SFA) may have a beneficial
impact.
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Materials and methods:We conducted a 12-week randomized, double-
blinded, parallel controlled, diet intervention study in 63 abdominal obese
subjects. Subjects were randomized into one of four diets in a 2×2 fac-
torial square design: 60 g/day of whey or casein combined with 63 g/day
of milk fat with either high (8.5 g/day) or low content of MC-SFA (6.9 g/
day). Body composition was assessed by dual-energy x-ray absorption
scan at baseline and after intervention. We estimated insulin sensitivity
using the homeostatic model assessment (HOMA-IR) and the Matsuda
Index. In addition, diurnal blood pressure (24-h BP) was measured. Two-
way ANOVA analysis was used to examine the difference between the
whey and casein supplementation and between the high and low MC-
SFA supplementation, as well as to elucidate potential interactions be-
tween the protein and the MC-SFA.
Results: Fifty-two subjects completed the intervention. We found that
lean body mass increased by 981 g (95%CI: 248, 1713; p=0.010) by
the diet supplemented with milk fat high rather than low in MC-SFA,
whereas total body fat percentage was lowered by 0.70% (95%CI: 0.10,
1.31; p=0.024). These changes were independent of the protein type. We
found no difference in HOMA-IR, the Matsuda Index, glycated hemo-
globin, or 24-h BP between protein type or fat composition.
Conclusion: In conclusion, supplementation with milk fat enriched in
MC-SFA via a feasible cattle feeding regimen resulted in increased lean
body mass and lower total body fat percentage in abdominal obese sub-
jects underlining the importance of the fat quality in dairy products.
Clinical Trial Registration Number: NCT01472666
Supported by: DSF, Arla Foods, Danish Dairy Research Foundation
703
Differential effects of carbohydrate vs fat overfeeding on liver fat
content and lipid metabolism in healthy overweight males
C. Chee1, P. Mansell2, F. Stephens1, S. Cordon1, M. Kavani3, S.
Bawden3, C. Hoad3, P. Gowland3, I. Macdonald1;
1University of Nottingham, 2Nottingham University Hospitals NHS
Trust, 3Sir Peter Mansfield MRI Centre, Nottingham, UK.
Background and aims: Ectopic fat accumulation is thought to be an
important contributor to insulin resistance and diabetes. Excess energy
consumption has been shown to increase liver fat content and reduce
insulin sensitivity, but it is unclear to what extent this is influenced by
dietary composition. We investigated the degree to which liver fat, liver
and lipid markers are affected by 2 weeks of overfeeding at 25% excess
energy given as either carbohydrate or fat.
Materials and methods: After 1 week of ingesting an isocaloric diet, 21
overweight but healthy males ( 40.3±2.5 yrs; BMI 31±1.0 kg m-2)
underwent 3 T H1Magnetic Resonance Spectroscopy (H1 MRS, Philips
Achieva) of their liver and magnetic resonance imaging (MRI) of their
abdomen to measure liver fat content and visceral fat respectively. Fasting
serum insulin, glucose, triacylglyceride (TAG), free fatty acids (FFAs),
lipoapoproteins, total cholesterol and liver function were also obtained. Sub-
jects were then randomised into 2 groups of ingesting either a hyperenergetic
(25% excess) high fat (HF) n=11, (42.2±2.4 yrs, BMI 30.5±0.9 kgm-2 ) or
high carbohydrate (HC) n=10, (38.3±2.4 yrs, BMI 31.5±1.0 kg m-2) diet
for two weeks. The diets comprised either high carbohydrate (65% CHO,
20% Fat, 15% Prot) or high fat (38% CHO,47% Fat, 15% Prot). After two
weeks, H1MRS liver, MRI abdomen and fasting bloods were repeated.
Results: After 2 weeks of excess energy consumption, there was an
overall main effect of time on liver fat content (increased by 2.2±0.8%;
p<0.05) which approached significance in the high carbohydrate group
(increased by 2.8±1.8%; p=0.06) but not in the high fat group (increased
by 1.6±1.1%; p=0.3). Fasting TAG in the whole group increased by 0.33
±0.13 mmol/l (p<0.05), and this was notably higher in the high carbo-
hydrate group where TAG increased by 0.45±0.14 mmol/l (p<0.05). In
the whole group both Apolipoprotein A and B increased by 0.08±0.01 g/
L, p<0.01 and 0.07±0.01 g/L p<0.01 respectively. The increase in
Apolipoprotein A and B was greater in the high fat group (0.13±
0.03 g/dL and 0.10±0.03 g/L; p<0.01 respectively. There were no chang-
es in body mass, visceral fat, HOMA-IR, or fasting insulin, glucose,
FFAs, total cholesterol or liver function after 2 weeks of overfeeding in
either the whole group or between dietary groups.
Conclusion: Two weeks excess energy consumption increased liver fat
content, TAG, Apolipoprotein A and B. This deleterious effect of over-
feeding on liver fat and markers of liver function and lipid appears to be
more pronounced in the high carbohydrate-fed group.
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Angiotensin converting enzyme increases in response to a high fat
diet
R. Schüler1,M.A.Osterhoff1,2, T. Frahnow1, A.-C. Seltmann1, L. Xu1, A.
Busjahn3, S. Kabisch1,2, S. Hornemann1, M. Kruse1, A.F.H. Pfeiffer1,2;
1Clinical Nutrition, German Institute of Human Nutrition Potsdam-
Rehbrücke (DIfE), Nuthetal, 2Department of Endocrinology, Diabetes
and Nutrition, Charité-University Medicine, 3HealthTwiSt GmbH, Ber-
lin, Germany.
Background and aims: Angiotensin-converting enzyme (ACE) cata-
lyzes the conversion of angiotensin I to angiotensin II which leads to
vasoconstriction. Pharmaceutical inhibition of ACE serves as effective
treatment in hypertension and cardiovascular diseases, but also improves
insulin sensitivity. On the contrary, carriage of the D-allele of the ACE
insertion/deletion (I/D) polymorphism is associated with increased ACE
serum levels and impaired glucose tolerance. ACE is not only expressed
in vascular endothelial cells but also in adipose tissue and its levels are
altered in conditions of obesity and weight loss. We aimed to investigate
effects of an isocaloric high-fat diet (HF) on ACE considering possible
nutrigenetic influences.
Materials and methods: In the NUGAT (NUtriGenomic Analysis in
Twins) study 46 healthy twin pairs went from a 6-week carbohydrate-rich
low-fat diet (LF) to a 6-weekHF diet under isocaloric conditions. Clinical
investigation days took place after 6 weeks LF and after 1 and 6 weeks of
HF (HF1, HF6). At each investigation day subcutaneous adipose tissue
biopsies were taken for gene expression analysis on Agilent 8×60K mi-
croarrays. Serum parameters were analyzed in blood samples using
ELISA. To assess insulin sensitivity intravenous glucose tolerance tests
(ivGTT) were performed and incremental areas under the curve (AUC)
calculated. Genomic DNA extracted from whole blood was genotyped
using Illumina HumanOmniExpressExome BeadChips. For heritability
estimates the ‘ACE’ structural equation model was applied.
Results: Heritability estimates >80% prove a high genetic component of
circulating ACE levels (p<0.001). After six weeks HF circulating ACE
levels increased by 15% (HF6 161±49 ng/ml vs. LF 139±41 ng/ml; p<
0.001) paralleled by an increase in adipose tissue gene expression (1.41-fold,
p<0.001). 34% of the increase in circulating ACE levels as regulatory re-
sponse to the HF diet is explained by additive genetic factors (p<0.01).
Interestingly, in homozygous carriers (GG) of the rs4343 polymorphism,
which serves as a surrogate marker for ACE I/D polymorphism, the increase
in serum levels was nearly double that of non-carriers (AA) or heterozygous
carriers (AG) (p<0.001). Whereas no change in glucose tolerance was ob-
served for AA/AG-carriers, glucose tolerance significantly declined in GG-
carriers after six weeks of HF (ΔAUCglucose, recessive model: p=0.009).
Conclusion: Despite the known strong heritable component for ACE
levels, we could show a considerable increase in ACE serum levels and
gene expression in adipose tissue in response to a high fat diet. These
results point out that ACE potentially constitutes a molecular link be-
tween dietary fat intake and cardiovascular diseases as well as impaired
glucose metabolism. The extent of this relationship seems to be
nutrigenetically modulated.
Clinical Trial Registration Number: NCT01631123
Supported by: BMBF 0315424
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High fat diet induced association of anti-inflammatory phospholipid
and CRP levels in human adipose tissue in the NUGAT study
M.A. Osterhoff1,2, T. Frahnow1, A.-C. Seltmann1, A.S. Mosig3,4, K.
Heisig3, S. Sales5, J.L. Sampaio6, S. Hornemann1, M. Kruse1, A.F.H.
Pfeiffer1,2;
1Clinical Nutrition, German Institute of Human Nutrition, Potsdam-
Rehbruecke, Nuthetal, 2Endocrinology, Diabetes and Nutrition, Charité
- University Medicine Berlin, 3Molecular Haemostaseology, 4Center for
Sepsis Control and Care, Jena University Hospital, 5Max Planck Institute
of Molecular Cell Biology and Genetics, 6Lipotype GmbH, Dresden,
Germany.
Background and aims: Lipid metabolism and signaling might be either
controlled genetically or by environmental factors. The aim of the study
was to correlate lipidomic and genomic data of human subjects to identify
specific gene-modules responsible for the regulation or connected with
the function of specific lipid metabolites.
Materials and methods: In the NUGAT-Study 46 healthy mono- and
dizygotic twin-pairs first were standardized for their nutritional behavior
by a carbohydrate-rich low-fat diet for 6 weeks (LF), immediately follow-
ed by a high-fat diet for 1 week (HF1) and additional 5 weeks (HF6). At
each CID periumbilical fat biopsies were taken for determination of gene
expression on Agilent 8×60K gene micro Arrays. Plasma was measured
for lipid metabolites and cytokines (ELISA). Weighted gene Co-
Expression Network Analysis (WGCNA) and regularized Canonical Co-
variance Analysis (rCCA) were used for identification of co-expressed
gene-networks and their correlation with lipidome data.
Results: Analysis of the 5000 strongest regulated genes revealed a gene-
module highly correlated with CRP (r=0.31; p=6×10-4) and highly as-
sociated (r=-0.32, p<0.0004) with an anti-inflammatory/anti-bacterial
lysophosphatidylethanolamine specimen (LPE18:1). Application of
rCCA showed an increasing association of a set of genes involved in
lysophosphatidic acid (LPA) receptor signaling with the decreasing con-
centrations of LPE specimen. When stratifying the cohort for individuals
with a CRP<1 or CRP≥1 at HF6, LPE18:1 levels decrease more pro-
nounced in individuals with high CRP (p=0.042). Remarkebly, in indi-
viduals with low CRP the detected inflammatory gene-module is not
associated with LPE18:1 (r=-0.04; p=0.7) while highly associated in
people with high CRP (r=-0.6; p=0.008).
Conclusion: Our data show for the first time in humans that high-fat diet
induces a gene set with inflammatory character which might be involved
in lysophosphatidic acid (LPA) receptor signaling. Specifically we iden-
tify down regulation of the anti-inflammatory phospholipid LPE and
increasing synchronization of LPE concentration with gene expression
patterns as a mediator of inflammatory processes in the adipose tissue in a
CRP associated manner.
Clinical Trial Registration Number: ClinicalTrials.gov, NCT01631123
Supported by: BMBF
706
Dysregulation of sirtuins and key metabolic genes in skeletal muscle
of pigswith intrauterine growth restriction is associated to alterations
of circulating IGF-1
L. Pirola1, S. Chriett1, I. Le Huërou-Luron2, H. Vidal1;
1Medical Faculty, INSERM Unit1060, Oullins, 2INRA - UR 1341
ADNC, Saint-Gilles, France.
Background and aims: Prenatal and early postnatal lives are important
determinants of future health, and intrauterine growth restriction (IUGR) -
associated low birth weight predisposes to the development of metabolic
and cardiovascular disease in adult life, but the mechanisms are largely
unknown. We hypothesize here that IUGR might confer gene expression
alterations, predisposing to metabolic disease.
Materials and methods: Using a porcine model of spontaneous IUGR,
we determined in utero (71, 112 days post-conception) and early-
postnatal (2 days post-birth) IGF-1, insulin and leptin levels, and in par-
allel we investigated skeletal muscle (Longissimus dorsi) gene expression
of sirtuins and key metabolic genes (IRS1, GLUT4, HK2 and GAPDH).
Results: In IUGR, we observed impaired IGF-1, insulin and leptin serum
levels. Gene expression of sirtuin 1, 5, 6, 7, GLUT4 and HK2 exhibited
significant correlations with gestational age or fetus/newborn body
weight. SIRT1 and HK2 expression displayed an age- and weight-
dependent downregulation in controls, which was lost in IUGR pigs.
Conversely, SIRT2 and GLUT4 were upregulated in IUGR pigs. Within
the set of genes studied, we found a significant correlation between IGF-1
levels and gene expression, indicating that IGF-1 is limiting in IUGR.
IUGR-dependent gene alterations were partly linked to epigenetic chang-
es on histone H3 acetylation and methylation.
Conclusion:Our observations indicate that several sirtuins and metabolic
genes display specific gene expression trajectories during fetal and early
postnatal life, which are altered in IUGR, and are related to hormonal
dysregulations observed in IUGR. Given the importance of these genes in
metabolic control, their perinatal alterations might contribute to the pre-
disposition to metabolic disease and diabetes in adulthood.
Supported by: INRA multicentric study start grant
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Association between eating rate and obesity: a systematic review and
meta-analysis
T. Ohkuma1, Y. Hirakawa2, U. Nakamura3, Y. Kiyohara2, T. Kitazono3,
T. Ninomiya1;
1Center for Cohort Studies, 2Department of Environmental Medicine,
3Department of Medicine and Clinical Science, Kyushu University, Fu-
kuoka, Japan.
Background and aims:Considering the epidemic and deleterious impact
of obesity and its complication such as type 2 diabetes, a better under-
standing of the association between diet therapy and obesity would be
beneficial from both clinical and public health care perspectives. Epide-
miological evidence has shown that diet therapy based on not only the
types and amounts of foods, but also eating behaviours play an important
role in the management of obesity. Recently, several epidemiologic stud-
ies have reported the significant association between eating rate and obe-
sity. However, the influence of eating rate on the obesity remains incon-
clusive. Therefore, we undertook a systematic review with a meta-
analysis of published epidemiological studies to provide a reliable esti-
mate of the association between eating rate and obesity.
Materials and methods: A systemic search of MEDLINE, EMBASE
and CINAHLwas conducted to identify studies that reported quantitative
estimates for indices of obesity based on the category of eating rate.
Interventional studies or those conducted for children were excluded.
The reference lists of identified articles were manually scanned to identify
other relevant studies. Two independent researchers extracted the data. A
summary estimate was calculated using a random-effects model. Sub-
group analyses were conducted to identify the sources of heterogeneity.
Results: Twenty-three published studies were eligible for inclusion, of
which 20 were cross-sectional studies, 2 were longitudinal studies and 1
provided results from both study designs. Twenty one cross-sectional
studies were included in the meta-analysis. The mean difference in BMIs
between individuals who ate quickly and those who ate slowly was
1.78 kg/m2 (95% CI, 1.53-2.04 kg/m2). The pooled odds ratio of eating
quickly on the presence of obesity was 2.15 (95% CI, 1.84-2.51). There
was evidence of significant quantitative heterogeneity in the magnitudes
of the association across studies (I2=78.4%, P value for heterogeneity<
0.001 for BMI, I2=71.9%, P value for heterogeneity<0.001 for obesity),
which may be partially explained by differences in the type of study
population (a weaker association was observed for BMI in individuals
with diabetes than in those without; mean difference 1.32 kg/m2 [95%CI,
0.90-1.74 kg/m2] versus mean difference 1.89 kg/m2 [95% CI, 1.64-
2.15 kg/m2], respectively, P value for heterogeneity=0.038). A funnel
plot showed a symmetric pattern, and formal statistical testing did not
identify the presence of publication bias. Three longitudinal studies also
showed that a faster eating rate was associated with increased BMI and a
higher risk of incident obesity over time.
Conclusion: Eating quickly is positively associated with excess body
weight. Although further studies are needed to conclude a causal relation-
ship between eating rate and obesity, more emphasis may be placed in
clinical practice on slowing the speed of eating.
Supported by: Health and Labour Sciences Research Grants: Research
on Food Safety
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The effect of meal frequency in a reduced-energy regimen on the
gastrointestinal and appetite hormones in patients with type 2 diabe-
tes: a randomised crossover study
L. Belinova, J. Veleba, H. Kahleova, H. Malinska, O. Topolcan, J.
Vrzalova, O. Oliyarnyk, L. Kazdova, M. Hill, T. Pelikanova;
Department of Diabetes, Institute for Clinical and Experimental Medi-
cine, Praha 4, Czech Republic.
Background and aims: Appetite and gastrointestinal (GI) hormones
participate in energy homeostasis, feeding behavior and regulation of
body weight. We demonstrated previously the superior effect of two
meals a day, breakfast and lunch (B2) on bodyweight, hepatic fat content,
insulin sensitivity and feelings of hunger compared to the same diet di-
vided into six smaller meals a day (A6). The aim of this secondary anal-
ysis was to investigate the effect of frequency of meals on the appetite and
GI hormones.
Materials and methods: In a randomized, crossover study, we assigned
54 patients with T2D to follow two regimens of a hypocaloric diet, each
for 12 weeks: either 6 meals (A6) or two meals (B2). The diet in both
regimens had the same macronutrient and energy content. After each
regimen participants underwent a standard meal test. The concentrations
of glucagon-like peptide-1 (GLP-1), gastric inhibitory peptide (GIP), pan-
creatic polypeptide (PP), peptide YY (PYY), amylin, leptin and ghrelin
were determined usingmultiplex immunoanalyses. For statistical analysis
2×2 crossover ANOVAwas used.
Results:Body weight decreased in both regimens (p<0.001), more in
B2 (p<0.001). Fasting leptin and GIP decreased (both p<0.05) in
response to both regimens with no difference between the treatments.
Fasting ghrelin decreased in A6 (p<0.001), with a trend toward an
increase (p=0.08) in B2 (p<0.05). Fasting PP increased in B2 (p<
0.05) with a trend toward an increase in A6 (p=0.09) with no signif-
icant difference between both regimens. Neither GLP-1 nor PYY did
change in either regimen. The decrease in body weight correlated
negatively with changes in fasting ghrelin (r=- 0.4, p<0.05) and
the postprandial suppress of ghrelin correlated positively with its
fasting level (r=0.9, p<0.001).
Conclusion: We demonstrated that a hypocaloric diet with lower meal
frequency leads to greater decrease in body weight in patients with T2D
and the changes in body weight correlated negatively with changes in
fasting ghrelin. The effect of meal frequency on other measured GI pep-
tides was not proven.
Clinical Trial Registration Number: NCT01277471
Supported by: Institutional Support MZCR 00023001
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Effect of different diurnal patterns of meal composition onmetabolic
parameters in healthy men
K. Kessler1,2, S. Hornemann1, C. Sticht3, N. Gretz3, A. Kramer4, O.
Pivovarova1,2, A.F.H. Pfeiffer1,2;
1Dept. Clinical Nutrition, German Institute of Human Nutrition Potsdam-
Rehbruecke (DIfE), Nuthetal, 2Dept. Endocrinology, Diabetes and Nutri-
tion, Charité University Medicine, Berlin, 3Center for Medical Research
(ZMF),Medical FacultyMannheim at Heidelberg University,Mannheim,
4Laboratory of Chronobiology, Institute for Medical Immunology,
Charité University Medicine, Berlin, Germany.
Background and aims: A recent animal study has shown a potential
benefit of a fat-rich diet at the beginning of the active phase and a
carbohydrate-rich diet at the end (versus the opposite order) on glucose
tolerance, beta-oxidation and bodyweight. We therefore aim to determine
the effects of two different diurnal patterns of meal composition on met-
abolic parameters and circadian gene expression in subcutaneous adipose
tissue (SAT) in humans.
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Materials and methods: In a cross-over study, 20 men (age 46.4±
14 years, BMI 27.5±4 kg/m2) consumed isocaloric carbohydrate-rich
meals in the morning and fat-rich meals in the evening (diet A) or isoca-
loric fat-rich meals in the morning and carbohydrate-rich meals in the
evening (diet B) for four weeks each. At the end of each intervention
period, two 850 kcal meal tolerance tests, a carbohydrate-rich (MTT HC)
or a fat-rich (MTT HF), were performed at 09.00 am and 03.40 pm,
respectively, according to the participant´s previous dietary regimen. In-
sulin, C-peptide, glucose, and other routine lipid, liver and kidney
markers were determined in plasma. Gene expression in SAT was mea-
sured at three time points (08.45 am, 12.15 pm and 07.00 pm) during each
investigation day using quantitative real-time PCR.
Results: Mean body weights were not affected by the diets. Both diets
decreased fasting blood glucose, insulin, and total cholesterol levels. As
expected, MTTHC induced a larger increase in glucose and insulin levels
than MTT HF. Postprandial glucose, insulin and C-peptide levels were
higher in the afternoon compared to the morning for both MTT HC and
MTT HF. In the afternoon, postprandial peak of insulin secretion was
delayed and insulin excursion pattern showed a second peak independent
of the meal composition. Postprandial NEFA levels were significantly
higher in the afternoon compared to the morning only for MTT HC.
Analysis of core clock gene expression in SAT (BMAL1, CLOCK,
PER1-3, CRY1-2, NR1D1 and RORA) revealed profound reorganization
of circadian oscillations induced by the change of the diurnal pattern of
meal composition.
Conclusion: Our results show that glucose tolerance decreases in the
afternoon independent of meal composition. Still, different diurnal pat-
terns of meal composition induce large differences in circadian oscilla-
tions in SAT underlining the important role of food composition for the
entrainment of peripheral circadian clocks in humans.
Supported by: DFG grant KFO218 PF164/16-1
710
Extension of overnight fast until noon, triggers increased postpran-
dial hyperglycaemia and reduced and delayed insulin response after
lunch and dinner in type 2 diabetes
D. Jakubowicz1, J.Wainsten1, B. Ahrén2, Z. Landau1, Y. Bar-Dayan1, O.
Froy3;
1Diabetes Unit, E.Wolfson Medical Center, Holon, Israel, 2Clinical Sci-
ence, Lund University, Sweden, 3Agriculture Food and Environment,
The Hebrew University of Jerusalem, Rehovot, Israel.
Background and aims: Reduction of postprandial hyperglycemia is a
major target in the treatment of type 2 diabetic patients. Skipping break-
fast has been consistently associated with higher HbA1c and overall
PPHG in T2D. We aimed to explore the effect of eating vs. skipping
breakfast on PPHG after subsequent isocaloric lunch and dinner.
Materials and methods: In a crossover design, 22 type 2 diabetic pa-
tients, since 7.79±2.1 yrs, aged 58.7±4.9 yrs, BMI 28.4±2.8 kg/m2 and
HbA1c 7.7±0.394%were randomly assigned to 2 meal test days: one day
with breakfast, lunch and dinner (YesB) and another day the breakfast
was omitted and only lunch and dinner were consumed (NoB). Postpran-
dial plasma glucose, insulin, free fatty acids (FFA), glucagon and intact
glucagon-like peptide-1 (iGLP-1) after isocaloric (700 kcals; %
CH:protein:fat 50:30:20) lunch and dinner were assessed and calculated
as AUC180min.
Results: Compared with YesB, AUC180 after lunch in the NoB group
was higher by 37% for glucose (41804±310 vs 30566±185 mg/dl*min,
p<0.0001), lower by 17% for insulin (5156±86 vs 6213±116 μU/
ml*min, p<0.0001) and lower by 19% for iGLP-1 (p<0.0001). Plasma
FFA and glucagon were suppressed by 41.3% and 14.8%, respectively (p
<0.0001). Insulin peaked 30 min after lunch in the YesB group vs 60 min
after lunch in the NoB group. After dinner, in the NoB vs YesB, AUC180
increased by 26.6% for glycemic response (47310±88 vs 37368±
247 mg/dl*min, p<0.0001), reduced by 7.9% for insulin (5150±99 vs
5593±147 μU/ml*min, p<0.0001) and reduced by 16.5% for iGLP-1 (p
<0.0001). Plasma FFA and glucagon were less suppressed by 29.6% and
11.5%, respectively (p<0.0001) in the NoB compared with the YesB
group. Insulin peaked 60 min after dinner in the YesB group vs 90 min
after dinner in the NoB group. Glycemic response AUC after lunch and
dinner positively correlated with AUC180 for FFA (R2=0.78, p<0.0001)
and with AUC180 for glucagon (R2=0.73, p<0.0001) and was inversely
correlated with AUC180 iGLP-1 (R2=0.79, p<0.0001).
Conclusion: Skipping breakfast increased postprandial hyperglycemia
after lunch and dinner. This was accompanied in NoB, by less iGLP-1,
lower and delayed prandial insulin release, and less suppressed plasma
FFA and glucagon. Breakfast consumption should be a strategy toward
reduction of postprandial hyperglycemia in type 2 diabetic individuals.
Clinical Trial Registration Number: NCT02287103
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Dietary habits and physical activity of Greek children in relation to
the presence of diabetes in a household member
S. Kalantzi1, G. Karamanakos1, I. Pagkalos2, A. Abrahamian3, I.
Kaklamanos3, E. Kapantais3, T. Tzotzas3, M. Hassapidou4, S. Liatis1;
1First department of Propaedeutic Internal Medicine,University Medical
School, Laiko General Hospital, Athens, 2Department of Electrical &
Computer Engineering, Aristotle University, Thessaloniki, 3Hellenic
Medical Association for Obesity, Athens, 4Alexander Technological Ed-
ucational Institute, Thessaloniki, Greece.
Background and aims: To explore the relationship between dietary
habits and amount of physical activity of Greek children aged 6-9 years
old and the presence of diabetes in a family member living in the same
household.
Materials and methods: Analysis was based on cross-sectional data
obtained from the Greek arm of the second round of the Childhood
Obesity Surveillance Initiative (COSI) study, established by the World
Health Organization. The study population was nationally representative
and consisted of primary school children aged 6-9 years old. A family
record form was used to gather information on a voluntary basis on
simple indicators of the children’s dietary intake and physical activity/
inactivity patterns, the family’s socioeconomic characteristics and the
presence of diabetes on a household member. Univariate and multivariate
relationships between variables were studied using Chi-square and logis-
tic regression tests.
Results: A total of 1821 children (884 boys and 937 girls) were
included in the analysis. There were 104 children (5.7%) reporting
a family member with diabetes in their household. Mean BMI was
similar between children of families with and without diabetes in the
household (18.8±3.4 Kg/m2 vs. 18.7±3.3 Kg/m2 respectively). The
presence of a household member with diabetes was associated with
less frequent breakfast consumption (p=0.04), lower consumption of
fresh fruits (p=0.051) and fish (p=0.053), higher consumption of diet
soft drinks (p<0.001), flavored milk (p=0.016), foods like potato
chips, corn chips, popcorn or peanuts (p=0,003) and foods like pizza,
fried potatoes, hamburger, sausage or meat pies (p=0.001). In addi-
tion, it was associated with lower participation in sport or dancing
clubs (p=0.002 and p=0.007 respectively), fewer hours spent
playing outside (p=0,008) and more hours spent on computer games
(p<0.001). The above associations remained significant after adjust-
ment for BMI and socioeconomic status.
Conclusion: The presence of diabetes in a household member is associ-
ated with several unhealthy nutritional and physical activity habits in
Greek children aged 6-9 years old, despite no difference in BMI and even
after adjustment for family socioeconomic status. These findings may be
attributed to the transition of unhealthy lifestyle choices of parents with
diabetes to their children.
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Nutritional regulation of incretin secretion in controls, impaired glu-
cose tolerance and type 2 diabetes
F. Keyhani Nejad1,2, M. Kemper1,2, R. Schueler1, O. Pivovarova1,2, N.
Rudovich1,2, A.F.H. Pfeiffer1,2;
1Department of Clinical Nutrition, German Institute of Human Nutrition,
Nuthetal, 2Department for Endocrinology, Diabetes and Nutrition,
Charité – University of Medicine, Berlin, Germany.
Background and aims: While studies suggest that excessive sugar in-
take is associated with the development of type 2 diabetes (T2DM) and
non-alcoholic fatty liver, it is unclear whether this is primarily related to
sugar metabolites such as glucose and fructose or to the postprandial
hormonal responses, particularly incretins, glucose-dependent
insulinotropic peptide (GIP) and glucagon like pepetide-1 (GLP-1). We
investigated the effects of sucrose and its isomer Palatinose ingestion on
endogenous GIP and GLP-1 release and their relation to hepatic insulin
clearance (HIC) in normal (NGT), impaired glucose tolerant (IGT) and
T2DM participants.
Materials and methods: In a randomized, within-subject crossover
study 15 NGT (control), 10 IGT and 10 T2DM subjects were studied
for 180 min consuming 50 g either Palatinose or sucrose solutions which
are dimers of glucose and fructose but resorbed either distally or proxi-
mally due to different 1,6 vs 1,2 linkage to evaluate glucose and insulin
responses. Postprandial GIP and GLP-1 levels were assessed and related
to HIC.
Results: Following oral sucrose, blood glucose levels peaked significant-
ly ~2 fold after 30 min which were 38% (p<0.001) and 26% (p<0.05)
higher than Palatinose intake in NGT and IGT subjects, respectively. In
T2DM, maximal postprandial glucose excursions after sucrose and
Palatinose intake were at 60 min and were ~20% significantly lower with
Palatinose ingestion (p<0.01). Palatinose intake resulted in similar
insuliniAUC levels in NGT, IGT and T2M (10.44±2.2, 10.9±2.3 and
11.5±3.3 nmol/l x180 min, respectively). InsuliniAUC levels after su-
crose ingestion were 88%, 32% and 55% higher than Palatinose intake
in NGT, IGT and T2DM (p<0.01, p<0.05 and p=0.1, respectively).
Following sucrose intake, plasma concentrations of GIP increased signif-
icantly with 4.1, 3.1 and 2.8 fold in NGT, IGT and T2DM subjects,
respectively. It reached its peak after 15 min sucrose load, while by
Palatinose intake GIP levels peaked at 60 min with 2 fold increase in
NGT and IGT and 1.5 fold increase in T2DM subjects compared to
baseline. Palatinose intake compared with sucrose increased secretion
of active GLP-1 (GLP-1iAUC) ~77% (p<0.01), 85% (p<0.01) and
84% (p<0.05) in NGT, IGT and T2DM groups, respectively. Sucrose
caused only minor increases. Compared with sucrose, Palatinose intake
improved HIC rate ~32% (p<0.001), 30% (p<0.05) and 37% (p<0.05) in
NGT, IGT and T2DM, respectively. Across all groups, there was an
inverse association between GIPiAUC and HIC (r=-0.44, p<0.001). In
contrast, GLP-1iAUC was positively associated with the increased HIC
(r=0.4, p=0.001).
Conclusion: Palatinose possesses a favorable profile for diabetes nutri-
tion by lowering postprandial endogenous GIP levels, increasing GLP-1
concentrations and saving insulin secretion which ultimately results in
improved management of blood glucose. Palatinose improves HIC in
IGT and T2DM subjects. An inverse relationship between HIC and post-
prandial GIP concentrations and positive association between GLP-1 nad
HIC suggest that the pattern of incretin secretions determines the rate of
HIC. In particular, modulation of GIP secretion can be considered as a
potential therapeutic target for improving hepatic glucose metabolism and
the treatment of fatty liver.
Clinical Trial Registration Number: NCT02219295
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Altered mitochondrial metabolism is involved with increased ampli-
fying pathways modulation of insulin secretion in protein malnour-
ished obese mice
C.C. Zoppi, N.C. Leite, R.C.S. Branco, F.M.M. Paula, P.C. Borck, J.F.
Vettorazzi, E.M. Carneiro;
Structural and Functional Biology, University of Campinas, Brazil.
Background and aims: Glucose-induced insulin secretion (GIIS) stim-
ulates dependent and independent mechanisms of KATP channels. Low
protein and high-fat diets, during important stages of development favor
obesity progress inducing several changes in pancreatic islets. The chang-
es on the independent mechanisms of KATP channels, also called ampli-
fying pathways, induced by the combination of these two treatments are
unknown. Our aim was investigating the role of these pathways on GIIS
modulation of malnourished obese mice.
Materials and methods: After weaning, 21 days old male C57BL-6
mice were randomly assigned into the control group (C) which received
a normo-protein diet (14% protein) during 105 days; the control-high fat
diet (HFD) (CH) received normo-protein diet for 45 days and after that
was treated with a HFD (60% fat) for 60 days. The protein restricted R
and RH groups were fed with a low protein diet (LPD) (6% protein),
receiving the same HFD treatment. Insulin tolerance was assessed by
euglycemic-hyperinsulinemic clamp. In order to investigate amplifying
pathways control of insulin secretion, we incubated islets with glucose
(G2.8; 11.1; 22.2 mM) in the presence of K+ (30 mM) and diazoxide
(250 μm). Insulin content was measured by radioimmunoassay. Protein
kinases A and C and mitochondrial metabolism were also assessed.
Results: HFD decreased glucose uptake (C=25.6±2.1/CH=15.9±2.36;
R=50.0±5.1/RH=18.18±3.9 mg/kg/min). GIIS was higher in animals
fed with HFD (G22.2 C=1.58±0.18/CH=3.0±0.3; R=1.08±0.12/RH=
1.8±0.3 ng/mL/hour/islet). The influence of amplifying pathways in in-
sulin secretion was lower in R animals (G22.2 C=0.757±0.1; R=0.33±
0.09 ng/mL/hour/islet). There were no differences among C and CH in all
glucose concentrations. Additionally, the role of amplifying pathways
was higher in RH (G22.2 R=0.33±0.09; RH=1.67±0.22). Whereas
PKA and PKC content were not altered, ATP production displayed a
trend to be reduced in RH. Basal mitochondrial membrane potential
and glutamate dehydrogenase (GDH) protein content were nearly 40
and 50% higher, respectively.
Conclusion: Higher amplifying pathway modulation of insulin secretion
of obese protein malnourished mice is associated with impaired mito-
chondrial function and GDH content. This could be one of the mecha-
nisms reprogrammed by early protein malnutrition, since this effect does
not appear in animals fed with a normal protein plus HFD.
Supported by: FAPESP, CNPq, CAPES
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Metformin associated lactic acidosis-incidence in the years of 2004-
2012
A. Aharaz1, T. Frøslev2, R. Thomsen2, H.T. Sørensen2, H. Beck-Niel-
sen1,3;
1Dpt. of Endocrinology, Odense University Hospital, 2Dpt. of Clinical
Epidemiology, Aarhus University Hospital, 3Dansk Center for strategisk
forskning i type 2 diabetes, Odense, Denmark.
Background and aims: Over the last decade Metformin has become
frontline treatment in the overwhelming majority of patients with type 2
diabetes, including in elderly patients with possible increased risk of
adverse effects. We examined if the annual incidence of lactic acidosis
(LA) overall and associated with metformin use has increased in Den-
mark over a 9-year period.
Materials and methods: We conducted a nationwide cross-sectional
study in Denmark in the period of 2004-2012, using population-based
hospital and prescription registries. We identified all people in Denmark
exposed to metformin in this period, and assessed first-time hospital con-
tacts with LA (ICD-10 diagnosis code E87.2A) from the Danish National
Patient Register. For each calendar year, we assessed the annual incidence
rate (IR) of first-time LA events per 100.000 person-years among
metformin-exposed people and among Denmark’s entire background
population.
Results:As shown in the Figure below the annual IRs for LA inDenmark
increased substantially over time, both for LA in the entire background
population (LA_IR, red graph) and for LA among metformin exposed
individuals (MELA_IR, blue graph). In the general population, the inci-
dence of LA increased from 0.01-0.1 per 100,000 person years in the
early study years 2004-2006 to 3.0 per 100,000 person years in 2012.
Among metformin users, the incidence of LA increased from 0.0-5.9 per
100,000 person years in the early study years 2004-2006 to 33,0 per 100,
000 person years in 2012, corresponding to a 11-fold higher incidence of
LA in metformin users versus the general population.
Conclusion: During the last decade, there has been a substantial rise in
the incidence of LA among metformin users in Denmark, as well as in the
background population. These finding raise concern that caregivers may
not always comply with contraindications for metformin use.
Supported by: 13/36915
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Metformin inhibits pancreatic stellate cells proliferation and
migration
C. Wu, X. Zhu, L. Li;
Department of Endocrinology, ZhongDa Hospital of Southeast Universi-
ty, Nanjing, China.
Background and aims: Metformin treatment is associated with a de-
creased risk and better prognosis of pancreatic cancer (PC) in patients
with type 2 diabetes. The effects of metformin are mediated by activation
of AMPK and a reduction in mTOR signaling in cancer cells. Activated
pancreatic stellate cells (PSCs) are key stroma cells responsible for
pancreaticfibrogenesis and PC progression. However, the impact of met-
formin on PSCs has not been studied. Assuming a protective role of
metformin, we investigated its effects on PSCs.
Materials and methods: In primary mouse PSCs and a novel immortal-
ized mouse pancreatic stellate cell line (imPSCs), cells were cultured with
different concentrations of metformin (2.5, 5, 10 mmol/L). Cell prolifer-
ation was determined by MTT assay. PSCs migration was assessed by a
wound healing assay. AMPK and mTOR, the important regulatory mol-
ecules responsible for metformin action, were investigated for their pos-
sible involvements in metformin-induced proliferation and migration.
Results: Metformin dose- and time-dependently decreased PSCs prolif-
eration (78±3% of control, P<0.01). Metformin inhibited PSCs migra-
tion (73±4% of control, P<0.01). Metformin addition induced AMPK
phosphorylation, reaching a maximum within 24 hours (4.52±0.03 of
control, P<0.01). Metformin application showed inhibition of phosphor-
ylated Akt (0.38±0.06 of control, P<0.01), mTOR (0.12±0.05 of control,
P<0.01) and P70S6K (0.18±0.02 of control, P<0.01), maximal inhibi-
tory effects were achieved at 48 hours.
Conclusion: Our findings indicated that metformin inhibited the prolif-
eration and migration of PSCs. Metformin activated AMPK and reduced
AKT/mTOR/P70S6K phosphorylation. Further studies designed to char-
acterize the possible molecular mechanisms by which metformin affects
PSCs are awaited.
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Once-daily delayed release metformin in the morning is superior in
efficacy to evening and twice-daily administration but at lower sys-
temic exposures
M. Fineman, A. Baron, C. Burns, S. Skare;
Elcelyx Therapeutics, Inc., San Diego, USA.
Background and aims: Metformin delayed-release (MetDR) is a gut-
restricted formulation designed to release drug only when it reaches the
ileum, a region of the gut where GLP-1 secreting L-cells are abundant and
absorption is poor, leading to low bioavailability. MetDR was previously
shown to have glucose-lowering activity comparable to immediate-release
and extended-release metformin (both of which are absorbed in the upper
bowel with ~50% bioavailability) but with ~40% lower doses and signif-
icantly lower (>75%) systemic exposure, consistent with the gut being
metformin’s primary site of action. As the intestine is a major site of Met
accumulation (300-1000X plasma), timing and frequency of daily metfor-
min delivery to the lower bowel may not be important with repeated dosing
(ie, at steady-state, the intestine effectively becomes a metformin reservoir
that provides sustained activity). We tested this in the present study by
comparing the pharmacokinetics (PK) and glucose-lowering efficacy of a
total daily dose of 1000 mg MetDR administered twice-daily (BID) or
once-daily (QD) in the morning (QAM) or evening (QPM).
Materials and methods: 1000 mg MetDR QAM or QPM were com-
pared to 500 mg MetDR BID in a 7-day randomized crossover design
(n=26, mean FPG 168 mg/dL) in subjects with T2D not on Met ≥2 wks
prior to dosing. All treatments were administered with meals and were
separated by a 6- to 12-day washout.
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Results: PK results indicate a diurnal effect in both the rate and extent of
metformin absorption with QAM having the fastest gut transit time and
the lowest plasma exposure compared to QPM. The time to reach the
ileum was 4.5-5.8 h for morning dosing vs 7.1-8.5 h for evening dosing.
QAM resulted in a 29% decrease in 24-h Met plasma exposure (AUC)
compared to QPM and BID (p<0.005 for both). Despite these differences
in exposure, QAM dosing resulted in the greatest reduction (9%) in plas-
ma glucose AUC0-24 from baseline (p=0.003) compared to a 5% reduc-
tion for both QPM (p=0.002) and BID (p=0.099). QAM dosing also
resulted in a 10% reduction in 24-h maximum plasma glucose (Cmax)
from baseline (p=0.0006) compared to a 9% reduction for QPM (p=
0.0007) and a 6% reduction for BID (p=0.039). All treatments were well
tolerated consistent with previous studies of MetDR.
Conclusion:MetDR delivered once-daily in the morning results in lower
Met plasma exposure but the greatest reduction in plasma glucose com-
pared to evening or BID administration. The observation that MetDR
provides 24-h glucose lowering with once daily administration supports
the previous findings that Met works predominantly in the lower bowel
and that the contribution of systemic exposure to glucose lowering is
small at best. As MetDR is being developed to limit metformin exposure
in patients with renal impairment, once-daily morning administration of
MetDR is the preferred dosing regimen.
Clinical Trial Registration Number: NCT01804842
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Optimisation of metformin discontinuation in diabetic patients ex-
plored with 18 F-FDG PET/CT
B. Pérez-Pevida1, L. Sancho Rodriguez2, E.F. Guillén Valderrama2, F.J.
Escalada San Martín1, M.J. García Velloso2, E. Pascual Corrales1, G.
Gutiérrez Buey1, M. Llavero Valero1, J.C. Galofré Ferrater1, J.A. Rich-
ter2, J. Salvador Rodríguez1;
1Endocrinology and Nutrition, 2Nuclear Medicine, Clínica Universidad
de Navarra, Pamplona, Spain.
Background and aims: It is known that metformin increases 18 F-FDG
PET/CT intestinal uptake and that it is reduced after its discontinuation for
3 days. The aim of this study was to determine if in patients with type 2
diabetes mellitus (T2D), 24 or 48 h metformin discontinuation could be
useful to reduce 18 F-FDG PET/CT intestinal uptake keeping patient’s
glucose levels (GL) in normal range and improving PET/CT quality.
Materials and methods: 101 T2D patients referred to a 18 F-FDG PET/
CTstudy were included. Drug regimen included metformin in 81 patients
(group A) and other oral antidiabetic drugs (OAD) in 20 patients (group
B). 30 patients without T2D served as the control group (group C). Group
A was divided in three subgroups: 31 patients (group A1) were taking
metformin, 21 patients (group A2) were asked to discontinue metformin
for 24 h before 18 F-FDG PET/CT and the remaining 29 patients (group
A3) were asked to discontinue metformin for 48 h. 18 F-FDG PET/CT
intestinal uptake was assessed both, qualitatively (normal, mild, moderate
or intense) and semi-quantitatively, using SUVmax values and tissue-to-
background ratio (TBR). Results were compared among the groups. GL
were assessed before PET/CT performance in all patients.
Results: Intense intestinal uptake in group A3 (17%) was significantly
lower (p<0.001) than in group A2 (32%) and A1 (68%) and comparable
to group B (15%) and C (7%). Intestinal 18F-FDG uptake in group Awas
reduced after metformin discontinuation for 24 hours (TBR A1=2,32 vs
TBR A2=3,24; p=ns) and significantly after 48 hours (TBR A3=1,82 vs
A1 y A2; p<0.001). There were no significant differences among A3
(TBR=1, 82), B (TBR=1, 69) and C (TBR=1,40). There were also no
significant differences in age and body mass index (BMI) among the
different groups. GL were higher in group A (122±19) than in groups
B (119±19) and C (95±11) (p<0. 01).
Conclusion:Metformin discontinuation for 48 hours is feasible and bet-
ter than 24 hours to reduce 18 F-FDG intestinal uptake in T2D and it
significantly improved PET/CT studies quality. Although GL increased
with discontinuation, they were in normal range according to guidelines.
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Development of oedema is associated with an improved glycaemic
response in patients initiating thiazolidinediones: a MASTERMIND
study
J.M. Dennis1, A.T. Hattersley1, M. Weedon1, C. Angwin1, L. Rodgers1,
E.R. Pearson2, W.E. Henley1, B.M. Shields1;
1University of Exeter Medical School, University of Exeter, 2Ninewells
Hospital and Medical School, University of Dundee, UK.
Background and aims: Oedema is a common and serious side effect of
thiazolidinedione therapy. A stratified medicines approach would aim to
give thiazolidinediones to patients likely to have a good glycaemic re-
sponse but to not develop oedema. We investigated whether oedema was
associated with glycaemic response to thiazolidinedione therapy.
Materials and methods:We retrospectively studied 11,459 patients ini-
tiating a thiazolidinedione from UK primary care data (Clinical Practice
Research Datalink), and identified medical records of new oedema in the
subsequent twelve months. Response was defined as change in HbA1c at
twelve months and was adjusted for baseline HbA1c, baseline BMI,
gender and compliance (medication possession ratio). In secondary anal-
yses we restricted oedema classification to patients with concomitant
weight gain. As a comparison the same analysis was performed in 13,
089 patients initiating a sulfonylurea.
Results: The 5% of patients with recorded oedema on thiazolidinediones
had a mean (CI) 2.2 (1.1-3.2)mmol/mol greater fall in HbA1c (p<0.001)
compared to thiazolidinedione patients without oedema. This improved
response increased when oedema was associated with weight gain, with a
2.5 (1.1-4)mmol/mol greater HbA1c fall when weight gain >3 kg (p<
0.001) and a 3.6 (1.8-5.4)mmol/mol greater fall when weight gain >5 kg
(p<0.001). Oedema was recorded in 3.7% of sulfonylurea patients and
was not associated with response (HbA1c fall difference 1 (-0.5-
2.5)mmol/mol, p=0.2), even when associated with weight gain >3 kg
(p=0.19).
Conclusion: Patients with Type 2 diabetes who develop oedema on ini-
tiating thiazolidinediones have an improved glycaemic response, and
more severe oedemamay be associated with greater reductions in HbA1c.
An association between oedema and glycaemic response was not ob-
served in patients initiating sulfonylureas. This supports glycaemic low-
ering and fluid retention being mediated by a common pathway of
thiazolidinedione drug action.
Supported by: MRC grant MR-K005707-1
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Combined intervention with pioglitazone and n-3 fatty acids in
metformin-treated diabetic patients
J. Kopecký1, J. Veleba1, P. Janovska2, O. Kuda2, O. Horakova2, H.
Malinska1, L. Kazdova1, J. Olza3, P. Calder3, A. Gardlo4,2, E. Fiserova4,
J. Jensen5, M. Bryhn6, J. Kopecky sr.2, T. Pelikanova1;
1Institute for Clinical and Experimental Medicine, 2Department of Adi-
pose Tissue Biology, Institute of Physiology Academy of Sciences of the
Czech Republic, Prague, Czech Republic, 3Human Development &
Health Academic Unit Faculty, Medicine University of Southampton,
UK, 4Department of Mathematical Analysis and Applications of Mathe-
matics, Faculty of Science, Palacky University in Olomouc,
Czech Republic, 5University of Oslo, Norway, 6Silentia A.S., Svelvik,
Norway.
Background and aims: Marine n-3 fatty acids eicosapentaenoic (EPA)
and docosahexaenoic (DHA) acids help in primary prevention of cardio-
vascular disease, but their impact on glucose homeostasis in type 2
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diabetic (T2D) patients remains unclear. We aimed to evaluate the effect
of a combination intervention using EPA+DHA and a suboptimal doses
of insulin-sensitizing drug pioglitazone on insulin resistance, body
weight, serum lipid concentrations and compensation of diabetes in obese
patients with T2D already treated with metformin.
Materials and methods: In a double-blind, placebo-controlled trial, 69
patients, 38-70 years of age (66% men) were randomly assigned to 24-
week-intervention using: (i) corn oil (5 g/day; Placebo), (ii) pioglitazone
(15 mg/day; Pio), (iii) EPA+DHA (2.75 g/day; Omega3), or (iv) pioglit-
azone and EPA+DHA (Pio+Omega3). The primary endpoints were the
changes from baseline in insulin sensitivity and in triacylglycerol clear-
ance assessed using hyperinsulinemic-isoglycemic clamp and a meal test.
Secondary endpoints included changes in fasting glycemia and HbA1c,
glucose and NEFA clearance and inflammatory markers and adipokines.
Results: Omega3 and Pio+Omega3 increased EPA+DHA content in
plasma phospholipids. Pio and Pio+Omega3 increased body weight and
adiponectin levels. Both fasting glycemia and HbA1c were increased by
Omega3, but unchanged by Pio + Omega3. Insulin sensitivity was im-
proved by Pio + Omega-3. Triacylglycerol and NEFA clearance were
increased by Pio+Omega3. See table.
Conclusion: Besides preventing a modest negative effects of Omega-3
on glycemic control, the combination of pioglitazone and EPA+DHA can
be used to increase insulin sensitivity and postprandial lipid clearance in
T2D patients on stable metformin therapy.
Clinical Trial Registration Number: EudraCT number 2009-011106-42
Supported by: Ministry of Health (CR) NT13763-4, NT14250-3 and IN
00023001
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Single-dose colesevelam has no effect on postprandial GLP-1 levels,
but increases CCK levels and decreases gallbladder refilling and
gastric emptying in type 2 diabetes
E. Bahne1, M. Hansen1,2, D.P. Sonne1,2, J.F. Rehfeld3, J.J. Holst2, T.
Vilsbøll1, F.K. Knop1,2;
1Center for Diabetes Research, Gentofte Hospital, University Copenha-
gen, Hellerup, 2NNF Center for Basic Metabolic Research and Depart-
ment of Biomedical Sciences, Faculty of Health and Medical Sciences,
University Copenhagen, 3Department of Clinical Biochemistry,
Rigshospitalet, University Copenhagen, Denmark.
Background and aims: The well-established antidiabetic effect of the
bile acid sequestrant, colesevelam (COL) has been proposed to be
glucagon-like peptide-1 (GLP-1)-dependent since long-term COL treat-
ment seems to increase postprandial GLP-1 levels in rodents and patients
with type 2 diabetes. We evaluated the acute effect of oral COL on post-
prandial plasma GLP-1, insulin and glucose levels as well as plasma
cholecystokinin (CCK), gallbladder volume, gastric emptying, appetite
and food intake.
Materials and methods: In this placebo-controlled, double-blinded
study we included twelve patients with type 2 diabetes (age: 60.8±
8.8 years [mean ± SD]; BMI: 29.8±3.0 kg/m2; HbA1c: 6.5±0.5% (48
±6 mmol/mol)). On 2 separate days, after 1-week washout of antidiabetic
drugs, the patients received COL (3.75 g) or placebo suspended in a
302 kcal-liquid meal with 1.5 g paracetamol (for evaluation of gastric
emptying). At baseline and during 240 min blood was sampled, gallblad-
der volume was evaluated by ultrasound and appetite was evaluated by
visual analogue scale. At the end of each day ad libitum food intake was
evaluated.
Results: Acute administration of COL did not affect postprandial plasma
responses (incremental AUCs) of GLP-1 (995±678 vs 1156±845 min×
pmol/l, p=0.78), insulin (3112±4252 vs 3115±2396 min×pmol/l, p=
0.99) or glucose (321±197 vs 350±255 min×mmol/l, p=0.91), but sig-
nificantly increased the postprandial CCK response compared to placebo
(760±262 vs 391±248 min×pmol/l, p=0.005). Meal-induced gallblad-
der emptying (AUC0-60 min for gallbladder volume) was not affected by
COL whereas gallbladder refilling (AUC60-240 min) was significantly
reduced. COL significantly reduced gastric emptying vs placebo whereas
food intake and appetite was unaffected.
Conclusion: Acute administration of COL does not seem to affect post-
prandial plasma levels of glucose, GLP-1 or insulin, appetite or food
intake in patients with type 2 diabetes, but appears to have a pronounced
stimulatory effect on postprandial CCK levels, which may explain the
reduced gallbladder refilling observed, and an inhibitory effect on gastric
emptying. Whether these changes contribute to the long-term antidiabetic
effect of COL remains to be elucidated.
Clinical Trial Registration Number: NCT02050074
Supported by: University Hospital, Gentofte, Copenhagen
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Effects of pentoxifylline on proteinuria and glucose control in pa-
tients with type 2 diabetes
S.Han1, H. Kim1, D. Kim1, C. Chung2, C. Ahn3, K. Kim4, S.-K. Kim5, S.
Park5, Y.-W. Cho5, S. Kim6, C. Kim7, J. Lee8, T. Kim9, S.-Y. An10, K.
Lee1;
1Endocrinology and metabolism, Ajou University Hospital, Suwon, 2In-
ternal Medicine, Yonsei UniversityWonju College of Medicine, 3Internal
Medicine, Gangnam Severance Hospital, Yonsei University College of
Medicine, Seoul, 4Endocrinology andmetabolism, Dongtan jeilWomen’s
Hospital, Hwasung, 5Internal Medicine, CHA Bundang Medical Center,
CHA University, Seongnam, 6Internal Medicine, Kwandong University
College of Medicine, Suwon, 7Internal Medicine, Hallym University Sa-
cred Heart Hospital, Hallym University College of Medicine, Anyang,
8Endocrinology and metabolism, Myongji Hospital, Ilsan, 9Division of
Endocrine and Metabolism, Department of Internal Medicine, Seoul
Medical center, 10Endocrinology and metabolism, Hongik Hospital,
Seoul, Republic of Korea.
Background and aims: Pentoxifylline is a methylxanthine derivative
with significant anti-inflammatory, anti-fibrotic, and anti-proliferative
properties. Some studies demonstrated that pentoxifylline might have
renoprotective effects in chronic kidney disease. However, these studies
had limitations due to the small sample sizes and the heterogeneity of
patients’ characteristics. Therefore, we investigated whether
pentoxifylline could reduce proteinuria further in patients with diabetic
nephropathy and residual proteinuria despite receiving adequate therapy
with an angiotensin-converting enzyme inhibitor (ACEI) or an angioten-
sin II receptor blocker (ARB). We also studied the effects of
pentoxifylline on glycemic control and insulin resistance.
Materials and methods: This was a prospective, randomized, double
blinded, active control, multicenter study. The ethics committee of the
Ministry of Food and Drug Safety approved the study protocol. A total of
174 patients with type 2 diabetes and albuminuria >30 mg/g of creatinine
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during treatment with ACEI or ARB were assigned randomly to receive
pentoxifylline (1200 mg, daily (n=87) or placebo (n=87). The study
endpoint was the effect of pentoxifylline on proteinuria and glucose con-
trol, renal function, and inflammatory parameters.
Results: Six months of treatment with pentoxifylline did not change the
amount of proteinuria. Although the estimated glomerular filtration rate
(eGFR) decreased in the control group, there was no significant difference
from the pentoxifylline group. However, pentoxifylline reduced fasting
plasma glucose, HbA1c, and homeostatic metabolic assessment (HOMA-
IR) significantly.
Conclusion: Although we did not find any beneficial effects regarding
reducing proteinuria or preserving renal functions when pentoxifylline
was added to ACEIs or ARBs, pentoxifylline therapy improved glucose
control and insulin resistance in patients with type 2 diabetic nephropathy.
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Implementing an optimised glucose-lowering strategy in daily medi-
cal practice with first- and second-line gliclazide MR 60 mg
N.P. Trubitsyna1, M.V. Shestakova1, M. Piletič2, I. Satman3, L.A.
Leiter4;
1Institute of Diabetes Mellitus, Moscow, Russian Federation, 2General
Hospital NovoMesto, Slovenia, 3Istanbul University, Turkey, 4University
of Toronto, Canada.
Background and aims: Intensive glucose control with gliclazide modi-
fied release (MR) has been reported to significantly reduce major
macrovascular or microvascular events in people with type 2 diabetes
(T2D). A new and convenient scored formulation (MR 60 mg) has been
developed to facilitate medication adherence. This study explored the
temporal titration profile of gliclazide MR 60 mg when used as either a
first- or second-line prescription.
Materials and methods: This was a 6-month long, international,
multicentre, non-comparative, open-label observational study. Between
7/2011 and 2/2014, 7170 individuals aged ≥35 years with T2D, HbA1c
≥7.5% and not on insulin were enrolled. At Visit 1, they were prescribed
30-120 mg once daily (QD) of the gliclazide MR 60 mg formulation as a
first line (FIRST - newly diagnosed and/or pharmacotherapy naïve), add-
on (ADD) or switch from a previous oral antihyperglycaemic treatment
strategy (SWITCH). At months 1, 2 and 3, gliclazideMR 60mg dosewas
uptitrated (≥120 mg) based on fasting plasma glucose (FPG) and at the
discretion of the investigator. The primary evaluation criterion was the
time between first gliclazide MR intake and first occurrence of optimal
glycaemic control (usually HbA1c <7%). Values are mean(SD); signifi-
cance set at P<0.05.
Results:Women comprised 58.5% of the cohort. Baseline (BL) age was
58.9(10.6) years, BMI 30.1 (5.0) kg/m2, and T2D duration 5.1(4.4) years.
FIRST (n=1911), ADD (n=2831) and SWITCH (n=1683) groups had
BL HbA1c 8.83(1.39)%, 8.77(1.25)% and 8.75(1.30)% respectively.
Probability of the entire cohort reaching optimal gliclazide MR dosing
at months 1, 2, 3 and 6 was 0.15, 0.39, 0.59 and 0.92 respectively. Similar
trends were observed in the three groups (Fig). Mean HbA1c changes
from BL to month 6 were FIRST: -1.98(1.36)%, ADD: -1.74(1.28)% and
SWITCH: -1.61(1.33)% (all P<0.01); these corresponded with 71.8%,
65.0% and 57.7% of the respective groups documenting an HbA1c ≤7%.
Overall, 65.3% achieved an HbA1c ≤7.0% with an average time to effi-
cient dose of 80.1 days. Weight loss occurred across the board (kg differ-
ences between BL and month 6 ― FIRST -1.45(4.31), ADD -1.27(5.01)
and SWITCH -1.30(4.22)). Severe hypoglycaemic incidents were rare,
with 4 (0.06%) participants experiencing an episode. The majority
(95.5%) indicated a greater likelihood of adherence with the gliclazide
MR 60 mg QD regime vs their previous therapy.
Conclusion: Within 6 months, progressive gliclazide MR 60 mg QD
titration produced a significant mean 1.78% improvement in HbA1c with
~90% optimal dose achievement. There was concomitant weight loss and
few severe hypoglycaemic incidents. In this large, real world study, pro-
gressive uptitration with gliclazide MR 60 mg QD appears to be effica-
cious and safe in people with uncontrolled T2D independent of their prior
antihyperglycaemic treatment.
S344 Diabetologia (2015) 58 (Suppl 1):S1–S607
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Supported by: Institut de Recherches Internationales Servier (France)
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Efficacy and safety of repaglinide added to sitagliptin in Japanese
patients with type 2 diabetes: a randomised 24 week open-label trial
A. Nishimura1,2, S. Usui1, N. Kumashiro1, H. Uchino1, A. Yamato2, D.
Yasuda2, M. Okubo2, Y. Mori2, T. Hirose1;
1Division of Diabetes, Metabolism and Endocrinology, Department of
Internal Medicine, Toho University School of Medicine, 2Toranomon
Hospital, Tokyo, Japan.
Background and aims: Although sitagliptin (SITA) improves glycemic
control without increasing risk of hypoglycemia and is weight-neutral,
SITA can't ameliorate postprandial glucose sufficiently in many patients
with type 2 diabetes. Repaglinide (REPA), a potent insulin secretagogue
has been reported to increase early insulin secretion and improve post-
prandial hyperglycemia, and might be effective in combination with
SITA. However, there has been no report that shows the efficacy of REPA
in combination with SITA, previously. The aim of this study is to inves-
tigate the efficacy and safety of REPA as add-on to SITA, compared with
switching to REPA in Japanese type 2 diabetes patients poorly controlled
with SITA.
Materials and methods: Thirty patients inadequately controlled with
SITA 50 mg once daily [range of glycated hemoglobin (HbA1c) was
7.0-8.5%] were randomized 1:1 to REPA as add-on therapy to SITA
(0.5 mg of REPA thrice daily and 50 mg of SITA once daily, n=15:
AD group) or switch from SITA to REPA (0.5 mg of REPA thrice daily,
n=15: SW group). A meal tolerance test was carried out at weeks 0 and
24. All data are expressed as mean±standard deviation (SD).
Results: Treatment groups were balanced at baseline (HbA1c, 7.6±0.4%
in AD group and 7.6±0.4% in SW group; fasting plasma glucose, 8.5±
1.4 mmol/L in AD group and 8.5±1.7 mmol/L in SW group; body
weight, 66.4±8.0 kg in AD group and 71.4±15.1 kg in SW group).
The mean HbA1c changes from baseline to week 24 were -0.8±0.7 and
-0.2±0.4% in AD and SW groups, respectively, and the difference be-
tween two groups was significant (P=0.008). The mean changes in area
under the curve (AUC) of glucose from 0 to 180 min from baseline to
week 24 in AD group was -271.1±200.2 mmol*min/L in AD group
compared with those in SW group (-31.2±342.6 mmol*min/L) (P=
0.032). Mean insulin secretion relative to glucose elevation (ISG) (ISG:
AUC0-180 insulin / AUC0-180 glucose) in AD group significantly in-
creased in comparison with that in baseline (P=0.020) and tended to be
higher than that in SW group, but the differences are not statistically
significant (mean changes from baseline to week 24 were 1.23±1.24
μIU/mmol in AD group and those in SW group were 0.35±1.19 μIU/
mmol; P=0.069). The mean change in AUC0-180 of glucagon decreased
in AD group and increased in SW group, but the difference was not
significant (-5485±9633 pg•min/mL in AD group and 2915±
12050 pg•min/mL in SW group; P=0.058). There was no significant
difference in changes in bodyweight between the two groups (AD group
0.4±1.6 kg, SW group 0.5±1.3 kg; P=0.807). The incidence of hypogly-
cemic events was low (three in AD group), and none of the patients
developed severe hypoglycemia or severe.
Conclusion: The combination therapy of SITA and REPA is effective
and well tolerated in Japanese type 2 diabetes without significant weight
gain and severe hypoglycemia.
Clinical Trial Registration Number: UMIN (no. R000013214)
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Within-sulfonylurea-class evaluation of the time to intensification
with insulin or triple oral therapy (ZODIAC-43)
G.W.D. Landman1,2, D. Schrijnders1, K.H. Groenier1,3, H.J.G. Bilo1,4,
N. Kleefstra1,4;
1Diabetes Centre Isala, Zwolle, 2Dept. of Internal Medicine, Gelre Hos-
pital, Apeldoorn, 3Dept. of General Practice, University Medical Center
Groningen, 4Dept. of Internal Medicine, University Medical Center Gro-
ningen, Netherlands.
Background and aims: The Dutch type 2 diabetes mellitus (T2DM)
guideline advices sulfonylureas (SUs), specifically gliclazide, as the first
intensification step after metformin and the addition of insulin as a second
intensification step. There is evidence for important within-class SU dif-
ferences, but data are lacking concerning within-class SU differences and
the time to a second intensification with either insulin or a third oral agent
in daily practice. This study aims to investigate the relationships between
three different SUs, either gliclazide, glimepiride or tolbutamide, used as
dual therapy next to metformin, and the time needed for treatment inten-
sification with either insulin or oral triple therapy in patients with T2DM.
Materials and methods: From a large prospective cohort study (the
ZODIAC cohort, n=82.167), patients were selected who used monother-
apywithmetformin for at least one year and subsequently intensified with
one out of three SUs (gliclazide, glimepiride or tolbutamide), the so called
new users. Patients with an eGFR below 30 mL/min per 1.73 m2 were
excluded. Time-dependent Cox proportional hazard analyses, adjusted
for age, gender, diabetes duration, updated mean eGFR and BMI were
used to evaluate the primary outcome, first receipt of insulin, and the
secondary outcome, first receipt of insulin or triple oral therapy.
Results: From the 3507 selected patients 47.0% were female, the mean
age (SD) 61.0(11.4), median diabetes duration (interquartile range (IQR))
6.8 years (IQR 4.5-9.4), median HbA1c 6.8 (IQR 6.4-7.4), median BMI
29.7 (IQR 26.8-33.3) and the mean eGFR 83.2 mL/min per 1.73 m2
(20.0). 2.5 and 5 years after intensification 13% and 32% of patients were
using insulin. The cumulative hazard ratio (HRs) for the primary endpoint
is shown in figure 1. Metformin/gliclazide was taken as a reference cat-
egory. HR for time to insulin or triple oral therapy (the secondary end-
point) for metformin/glimepiride was 1.042 (95% CI 0.778-1.394) and
for metformin/tolbutamide 0.845 (95% CI 0.632-1.129). There were no
significant between group differences in both primary and secondary
outcome.
Conclusion: In this study, intensification with either gliclazide,
glimepiride or tolbutamide on top of metformin, was not associated with
a difference in risk for need for a second intensification with insulin or
triple oral therapy. 87% and 68% of patients were without insulin 2.5 and
5 years, respectively, after starting a SU. In this large Dutch primary care
population, there were no within-SU-class differences concerning the
time for the need of further treatment intensification with either insulin
or a third oral agent.
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Low baseline beta cell function is associated with higher rates of
hypoglycaemia with glimepiride in elderly patients with type 2 dia-
betes inadequately controlled with metformin
S. Perl, W. Cook, C. Wei, P. Ohman, B. Hirshberg;
AstraZeneca, Gaithersburg, USA.
Background and aims: Elderly patients with type 2 diabetes (T2D) pose
a challenge for management of glycemia owing to excess fragility and
risk of adverse outcomes during hypoglycemia episodes. We therefore
sought to identify risk factors for the development of hypoglycemia (any
reported symptomatic event and events of plasma glucose concentration
<54 mg/dL regardless of symptoms) in elderly patients when saxagliptin
(SAXA) or glimepiride (GLIM) is added to metformin.
Materials and methods: A post hoc analysis of data from the GENER-
ATION trial that enrolled 720 patients aged ≥65 years was conducted. β-
cell function was assessed using HOMA-2%β.
Results: The proportion of patients experiencing any hypoglycemia
event was lower with SAXA vs GLIM (5.8% vs 34.8%). Regardless of
treatment, patients with baseline HOMA-2%β≤median value of 39.1%
had a higher event rate of hypoglycemia of 1.27 events/patient year com-
pared with patients with baseline HOMA-2%β>median, 0.82 events/
patient year (RR=1.300 [95% CI, 1.084, 1.560]). In the GLIM-treated
patients, the hypoglycemia event rate in patients with baseline HOMA-
2%β≤median was higher (2.29 events/patient year) compared with pa-
tients with baseline HOMA-2%β>median (1.60 events/patient year;
RR=1.278 [95%CI, 1.057, 1.545]); corresponding SAXA hypoglycemia
event rates were too low to draw meaningful conclusions at 0.16 vs 0.09
events/patient year (RR=1.446 [0.687, 3.043]), respectively. The associ-
ation between lower β-cell function at baseline and increased incidence
of hypoglycemia was particularly strong for patients ≥75 years (RR=
2.572 [95% CI: 1.787-3.701], P<0.001).
Conclusion: In patients with lower β-cell function, the addition of a
sulfonylurea is associated with increased risk of hypoglycemia compared
with patients with higher β-cell function. These findings are especially
relevant to elderly patients in whom hypoglycemia associated morbidity
is higher.
Clinical Trial Registration Number: NCT01006603
Supported by: AstraZeneca
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Comparative efficacy of anti-diabetic agents on nonalcoholic fatty
liver disease in patients with type 2 diabetes mellitus: a systematic
review and meta-analysis
W. Tang, Y. Bi, S. Shen, D. Zhu;
Endocrinology department, Drum Tower Hospital Affiliated to Nanjing
University Medical School, China.
Background and aims:Nonalcoholic fatty liver disease (NAFLD) has a
high prevalence in patients with type 2 diabetes mellitus (T2DM). It
deteriorates abnormal glucose and lipid metabolism, and accelerates the
development of diabetic complications. In this study, we sought to pro-
vide a comprehensive assessment regarding the effects of anti-diabetic
agents on NAFLD in patients with T2DM.
Materials and methods:MEDLINE, EMBASE and the Cochrane Cen-
tral Register of Controlled Trials were searched for both randomized and
non-randomized clinical trials focused on T2DM patients with NAFLD.
Thiazolidinediones (TZDs), glucagon-like peptide-1 receptor (GLP-1R)
agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose transport pro-
teins type 2 inhibitors, sulfonylureas, insulin and metformin were ex-
plored, regardless of comparing with placebo, each other or non-treated
controls. Observational trials were also recruited to expand exploration.
Relative changes of hepatic fat content (HFC) and liver histology were
evaluated as primary outcomes. We also assessed body composition,
glucose and lipid metabolism, and inflammatory factors. Data was col-
lected and analyzed by STATA.
Results: 1,196 participants from 19 randomized controlled trials (RCTs)
and 14 non-randomized studies were included. Evidence from RCTs and
observational studies suggested TZDs for 12-72 weeks were associated
with greater HFC reduction (WMD -22.27%, 95%CI -26.98 to -17.56,
p=0.000, as compared with placebo; WMD -27.88%, 95%CI -47.41 to -
8.35, p=0.005, as comparedwith metformin; -35.7%vs. -7.69%, p<0.05,
as compared with glibenclamide; a range of -30% to -52.1%, all p<0.05,
in observational studies) and improved liver histology (including
steatosis, ballooning necrosis, inflammation and NAFLD score as com-
pared with placebo and metformin, all p<0.05). GLP-1R agonists had
beneficial effects on HFC after 26-50 weeks intervention (-61% vs. -41%
for exenatide/pioglitazone combination vs. pioglitzone monotherapy, p<
0.05; 0.1 vs. 0 for liraglutide vs. glimepiride, p=0.045, changes from
baseline of CT value), and insulin/metformin combination with 3-
7 months improved HFC (a range of -17.6% to -48%, all p<0.05, com-
pared with baseline). Nevertheless, initiating metformin alone showed no
benefit on HFC or liver histology, at least in 16-48 weeks. Neither did
dapagliflozin for 24 weeks. Additionally, nateglinide for 18 months was
reported in a small sample-size RCT to ameliorate HFC (-27%, p value
was unavailable) and liver histology (steatosis and portal inflammation,
both p<0.05). Sitagliptin therapy of one year also provided benefit on
nonalcoholic steatohepatitis score (p=0.04) in an observational study.
What’s more, we observed the reduction of TG, improvement of HbA1c
and alleviation of inflammation all paralleled to the amelioration of
NAFLD. In spite that weight loss has been proved beneficial on NAFLD,
it is definitely not the mere factor that contributed, since TZDs could still
improve HFC and liver histology significantly with greater weight gain
than placebo and metformin.
Conclusion: For T2DM with NAFLD, administrating TZDs and GLP-
1R agonists seems providing more identified advances in attenuating
HFC. Further RCTs with high quality, long-term duration and large-size
samples are warranted to assess the efficacy of various hypoglycemic
agents on clinical outcomes associated with NAFLD in T2DM.
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A network meta-analysis to assess options for treatment intensifica-
tion for patients with type 2 diabetes inadequately controlled on dual
therapy
M. Schroeder1, V. Taieb2, M. Pacou3, S. Ho2, A.T. Nielsen4, A. Schu-
bert5, C. Neslusan6;
1Janssen UK, High Wycombe, 2Amaris, London, UK, 3Amaris, Paris,
France, 4Janssen-Cilag, Birkerød, Denmark, 5Janssen-Cilag,Warsaw, Po-
land, 6Janssen Global Services LLC, Raritan, USA.
Background and aims: Augmenting existing therapies with medicines
that have alternative modes of action in terms of glucose lowering and
benefits in terms of other micro- and macrovascular risk factors beyond
HbA1c reduction (e.g. weight loss and blood pressure reduction) may
improve outcomes. In the absence of direct evidence comparing
antihyperglycaemic agents (AHAs) in triple therapy, indirect comparisons
can be used to inform clinical and policy decisions. A network meta-
analysis (NMA) was conducted to assess the relative efficacy of
canagliflozin (CANA), an agent that inhibits sodium glucose co-
transporter 2 (SGLT2), compared to other non-insulin AHAs as add-on
to metformin plus sulphonylurea (MET+SU) and as add-on to MET plus
pioglitazone (MET+PIO).
Materials and methods: Two separate networks of evidence informed
by a systematic literature review were constructed to estimate the relative
efficacy of CANA in combination with MET+SU or MET+PIO in low-
ering HbA1c at 26±4 weeks via Bayesian NMA. After screening the
trials for appropriateness of pooling, comparisons of CANAwere feasible
versus dapagliflozin (DAPA), empagliflozin (EMPA), liraglutide (LIRA),
exenatide (EXEN), sitagliptin (SITA), linagliptin (LINA), saxagliptin
(SAXA), PIO and insulin in the MET+SU network and EMPA, EXEN,
and LINA in the MET+PIO network. Relative efficacy was evaluated
based on absolute differences (Δ) and Bayesian pairwise probabilities
(P); P ≤30% and P ≥70% were chosen to indicate a smaller and larger
effect, respectively.
Results: As add-on to MET+SU, HbA1c reductions (%) were higher for
CANA 300 mg compared to EMPA 10 and 25 mg (Δ=-0.36 to -0.41, P=
100%), DAPA 10 mg (Δ=-0.32, P=99%), EXEN 5 μg (Δ=-0.23, P=
96%), and SITA, SAXA, and LINA (Δ=-0.20 to -0.39, P=100%) and
comparable to LIRA 1.8 mg (Δ=0.08, P=31%) and EXEN 10 μg (Δ=-
0.01, P=53%). HbA1c reductions with CANA 100 mg were greater
compared to EMPA 10 and 25 mg (Δ=-0.11 to -0.16, P ≥81%), SAXA,
and LINA (Δ=-0.10 to -0.14, P ≥75%), similar compared toDAPA 10mg
(Δ=-0.07, P=68%), EXEN 5 μg, and SITA (Δ=0.02 to 0.05, P ≥33%),
and lower compared to LIRA 1.8 mg (Δ=0.33, P=3%). As add-on to
MET+PIO, CANA 300 mg was associated with greater HbA1c reduc-
tions versus all comparators: EMPA 25 and 10 mg (Δ=-0.17 to -0.27, P
≥88%), LINA (Δ=-0.20, P=84%), and EXEN 10 μg (Δ=-0.24, P=96%).
CANA 100 mg conferred HbA1c reductions greater than EMPA 10 mg
(Δ=-0.13, P=81%) and EXEN 10 μg (Δ=-0.10, P=76%), and were
deemed similar compared to EMPA 25mg (Δ=-0.03, P=58%) and LINA
(Δ=-0.06, P=62%).
Conclusion: An NMA of add-on therapies to MET+SU indicates that
glycaemic reductions at 26 weeks were greater for CANA 300 mg and at
least as large for CANA 100 mg compared to EXEN, other SGLT2
inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors. CANA
300 mg was found to be comparable to LIRA 1.8 mg in terms of HbA1c
reduction. An NMA of add-on therapies to MET+PIO indicates that CA-
NA 300 mg was associated with consistently greater HbA1c reductions
versus EMPA, EXEN, and LINA, while CANA 100 mg was deemed at
least similar. These results suggest that CANAmay be a good therapeutic
option as an add-on to common dual therapies for T2DM.
Supported by: Janssen Research & Development, LLC
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The impact of delaying treatment intensification in type 2 diabetes:
evidence from UK general practice
R. Das1, L. Watson2, R. Farquhar2, H. Langerman1, A.H. Barnett3;
1Merck Sharp & Dohme, Hoddesdon, 2EpiPharmaCo, Buxton, 3Heart of
England NHS Foundation Trust, Birmingham, UK.
Background and aims: A key objective of treating type 2 diabetes
mellitus (TD2M) is obtaining and maintaining good glycaemic control,
generally based on measurement of glycated haemoglobin (HbA1c).
Keeping HbA1c below target levels, which vary across international
and local guidelines, reduces the risk of vascular complications. Evidence
from UK, Europe and USA, however, indicates that health care profes-
sionals are commonly slow to intensify treatment in patients with poor
glycaemic control (often termed “clinical inertia”). Our study aimed to
evaluate longitudinal clinical changes and resource burden in patients
intensified at varying times after loss of glycaemic control in the UK.
Materials and methods: Adults with incident T2DM were identified in
the UK Clinical Practice Research Datalink during the period 1 January
2000 to 31 March 2014. Patients who were newly initiated on metformin
monotherapy and who had lost good glycaemic control on medication
(HbA1c>7%) were included. Patients were grouped according to time to
intensification of second line therapy: Group A, rapid intensification
within 365 days of treatment failure; Group B, delayed intensification
from day 366 to 1824 post treatment failure; Group C, never intensfied
post treatment failure. Patients were followed up from day 365 (index
date) post first treatment failure for five years, until end of study, switch to
insulin, migration or death. The study evaluated a variety of longitudinal
clinical changes including HbA1c, weight and diabetes prescribing.
Results: 6,710 patients with T2DM met the study inclusion criteria. Key
baseline characteristics of the evaluated patients are described below.
There was a delay in treatment intensification to second-line therapy or
no treatment intensification in 60.5% of patients in the 5-year follow-up
period. Group A achieved a significant decline in HbA1c from baseline
1 year post index date compared to Groups B & C (-1.13% Group A; +
0.26% Group B, +0.16% Group C). A significantly higher proportion of
patients achieved HbA1c target<7% in Group A (Group A (45.8%);
Group B (19.1%), p<0.0001). Using an adjusted hazard model, Group
Awas found to achieve the HbA1c target from the index date significantly
faster than Group B (hazard ratio 3.25 (95% CI 2.87, 3.69)). The most
commonly used second-line intensification agent was sulphonylureas in
both Groups A and B throughout the observation period but was associ-
ated with signficant weight gain (+1.3 kg per patient ) in the adjusted
models. Similar results were seen with thiazolidinediones users (+1.0 kg).
Only patients taking DPP-4 inhibitors had consistent weight loss over
5 years of -0.6 kg.
Conclusion: There was a substantial level of clinical inertia. Patients that
were rapidly intensified post treatment failure achieved a significant re-
duction in HbA1c and got to target faster. A significantly higher propor-
tion achieved theHbA1c target <7% inGroupA compared with GroupB,
despite a higher baseline HbA1c.
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Patient preferences for attributes of type 2 diabetes mellitus treat-
ments in Germany
M. Sikirica1, C. Mansfield2, A. Pugh2, C. Poulos2, A. Martin1, V.
Unmuessig1;
1GSK, King of Prussia, 2RTI, RTP, USA.
Background and aims: Understanding T2DM patients’ preferences for
attributes of T2DM treatments may help to explain how each of these
attributes differentially affect patients’ perception and behavior. Our aim
was to quantify the relative preferences of a set of attributes describing
T2DM treatments for T2DM patients in Germany.
Materials and methods:A stated-preference discrete-choice experiment
(DCE) survey was designed to elicit preferences for T2DM treatment
attributes among patients in Germany taking a prescription T2DM med-
ication for>2 years. The survey collected background characteristics and
information on respondent demographics, health history, current health
status (EQ-5D), and experience with T2DM and T2DM treatments. The
DCE included a series of 8 choices between pairs of hypothetical T2DM
treatments defined by these seven attributes: chance of reaching target
HbA1c (A1c), reduction in risk of serious heart attack or stroke, frequen-
cy of hypoglycemia, risk of gastrointestinal side effects (GI SEs), weight
change, mode of administration (MoAdmin; pill or injection), and dosing
frequency. Random-parameters logit was used to analyze the DCE data.
Interactions between patient characteristics and preference estimates were
explored and results for prespecified subgroups analyzed. A preference
for an attribute was dominant if a respondent always selected the medi-
cine with the better level of that attribute. Minimum additional benefit
(MAB) was defined as the minimum increase in probability of reaching
target HbA1c for which respondents would accept a worse level of an-
other attribute.
Results: Of 1,198 individuals that responded to the survey, 531 (44.3%)
were eligible to participate, and 474 consented and completed the survey
and were included in this analysis. Mean age was 61 years, 58% male,
and 54% with T2DM diagnosed>7 yrs ago. Based on the DCE analysis,
Figure 1 below, GI SEs were most important to patients, followed by
weight changes, MoAdmin and A1c. Eighteen percent of respondents
always selected the treatment administered by pills, 7% dominated on
weight change, and 4% on A1c. Based on the DCE, the MAB analysis
found that patients would require that the probability of reaching their
target HbA1c is 56 additional percentage points higher to change from a
0% to 30% risk of having GI SEs. Other high MAB levels were reported
by moving from 2-kg weight loss to 2-kg weight gain (MAB of 44),
moving from 0% to 20% risk of GI SEs (43) and moving from pill to
injection (42).
Conclusion: Our findings suggest that this sample of German T2DM
patients was willing to trade-off efficacy for improved GI SEs and a better
mode of administration (pills). Patients focused on reduction in the risk
ofT2DM-related GI-SEs, weight changes and mode of administration as
key attributes that they value highly. Given the variety of T2DM medi-
cations available, the results suggest that careful discussion about patient
preferences could help improve patient satisfaction with T2DM drugs.
Supported by: GSK
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Dapagliflozin decreases post-prandial glucose without an increase in
C-peptide or insulin
T. Forst1, K. Rohwedder2, E. Johnsson3;
1Profil Institute for Metabolic Research, Mainz, 2AstraZeneca, Wedel,
Germany, 3AstraZeneca, Mölndal, Sweden.
Background and aims: Control of postprandial glucose (PPG) is impor-
tant for type 2 diabetes mellitus (T2DM) management and risk reduction.
The combination of PPG, insulin and C-peptide are measures of β-cell
function, insulin resistance and success of glycaemic control.
Materials and methods: In a small subgroup of patients from a 4-year,
phase 3 trial of dapagliflozin (DAPA, ≤ 10 mg/d) vs glipizide (GLIP, ≤
20 mg/d) as add-on to metformin (MET) in patients with T2DM, PPG
was assessed by oral glucose tolerance test at 52 and 104 weeks.
Results: At 52 weeks, mean area under the curve (AUC0-180 mins) for
PPGwas reduced from baseline in both groups, but wasmore pronounced
with DAPA compared with GLIP (-636.44 [76.4] mmol/L/min vs -398.31
[82.67] mmol/L/min, respectively). Reductions were sustained at
104 weeks (DAPA, -517.12 [104.93] mmol/L/min; GLIP, -404.6
[107.0] mmol/L/min). At both time points, DAPA-mediated reductions
in PPG were not associated with an increase in AUC for circulating
insulin; this finding was the opposite for GLIP. In addition, increases in
C peptide AUC were greater with GLIP than with DAPA at both time
points (Table).
Conclusion: Compared with GLIP, DAPA is associated with a sustained
reduction in PPG and improvement in glycaemic control without an in-
crease in C-peptide or insulin over 2 years, suggestive of a potential
protective effect of β-cell function and alleviation of β-cell stress and
insulin resistance.
Clinical Trial Registration Number: NCT00660907
Supported by: AZ
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Combined treatment with saxagliptin + dapagliflozin improves beta
cell function and reduces insulin levels by increased insulin clearance
E. Ekholm1, L. Hansen2, N. Iqbal2, B. Carlsson1, H. Chen3, B.
Hirshberg3;
1AstraZeneca, Molndal, Sweden, 2Bristol-Myers Squibb, Princeton,
USA, 3AstraZeneca, Gaithersburg, USA.
Background and aims:Dapagliflozin (DAPA) alone and in combination
with saxagliptin (SAXA+DAPA) reduced, while SAXA increased, insu-
lin levels during a meal tolerance test (MTT). We asked if this was driven
by increased insulin clearance.
Materials andmethods:C-peptide/insulin ratio was used as a marker for
insulin clearance during an MTT and β-cell function was assessed by
HOMA-2 in a study testing SAXA 5 mg+DAPA 10 mg vs SAXA and
DAPA alone in patients with type 2 diabetes poorly controlled with
metformin.
Results: At week 24, SAXA+DAPA and SAXA increased mean (95%
CI) C-peptide AUC from baseline, whereas no change was observed for
DAPA (SAXA+DAPA: 40.2 [9.2, 71.3 ng/mL]; SAXA: 95.4 [63.4,
127.4] ng/mL; DAPA: 14.5 [-17.6, 46.8] ng/mL). In contrast, change
from baseline in insulin AUC was reduced with SAXA+DAPA (-
1120.4 [-1633.9, -606.9] μU/mL), and DAPA (-1018.6 (-1550.5, -
486.8), but increased with SAXA (661.2 [131.1, 1191.3]μU/mL). Curves
for C-peptide/insulin at baseline were similar between the 3 treatment
groups. At week 24, C-peptide/insulin was unaltered by SAXA but in-
creased similarly after SAXA+DAPA and DAPA (Figure), mainly due to
decreased insulin AUCwith DAPA.All treatments improvedβ-cell func-
tion compared with baseline (SAXA+DAPA: 20.6% [16.5, 24.8]; DAPA:
17.0% [12.7, 21.4]; SAXA: 11.0% [6.6, 15.5]).
Conclusion: The data suggest that at 24 weeks, SAXA+DAPA and
DAPA improved β-cell function and increased insulin clearance in pa-
tients with type 2 diabetes poorly controlled with metformin.
Clinical Trial Registration Number: NCT01606007
Supported by: AstraZeneca
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Baseline fasting plasma glucose may predict response to
dapagliflozin when added to metformin
K. Rohwedder1, E. Johnsson2;
1AstraZeneca Pharmaceuticals LP, Wedel, Germany, 2AstraZeneca Phar-
maceuticals LP, Mölndal, Sweden.
Background and aims: Dapagliflozin (DAPA) is a highly selective,
orally active sodium-glucose co-transporter 2 (SGLT2) inhibitor that in-
creases urinary glucose excretion and reduces hyperglycaemia indepen-
dently of insulin.
Materials and methods: In a 52-week, double-blind, active-controlled,
non-inferiority trial, patients with type 2 diabetes mellitus (T2DM) inad-
equately controlled on metformin were randomised to DAPA (≤10 mg/d;
n=406) or glipizide (GLIP; ≤20 mg/d; n=408). As previously reported,
the response rate (reduction in HbA1c and body weight from baseline to
52 weeks) was significantly higher in the DAPA group (66.9 vs 21.3%
[difference, 45.7%; 95% CI, 39.3-51.6%]). We report the results of a post
hoc analysis of baseline factors, whichmay predict response to DAPA (C-
peptide; fasting plasma glucose [FPG]; C-peptide:FPG ratio; estimated
glomerular filtration rate).
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Results: In both arms, response rate increased as baseline FPG increased
(Table). Differences in response rate between baseline FPG categories
were significant for DAPA categories <7.8 vs ≥9.6 mmol/L (<141 vs
≥173 mg/dL [difference, 20.0%; P<0.001]) and for ≥7.8-<9.6 vs
≥9.6 mmol/L (≥141-<173 vs ≥173 mg/dL [difference, 11.8%; P=
0.044]) but not for any GLIP categories. In both groups (full analysis
set), greater HbA1c decreases occurred with higher baseline FPG. Body
weight change showed no obvious pattern with baseline FPG.
Conclusion: These data suggest that baseline FPG may predict the like-
lihood of combined HbA1c and body weight reduction in DAPA-treated
T2DM patients.
Clinical Trial Registration Number: NCT00660907
Supported by: AZ
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Initial combinations of empagliflozin and metformin in patients with
type 2 diabetes
S. Hadjadj1,2, A. Jelaska3, S. Zhang3, T. Meinicke4, H.J. Woerle5, U.C.
Broedl5;
1Centre Hospitalier Universitaire Poitiers, 2INSERM CIC 1402, Poitiers,
France, 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USA,
4Boehringer Ingelheim PharmaGmbH&Co. KG, Biberach, 5Boehringer
Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Background and aims:Metformin (MET) is the recommended first-line
therapy for patients with type 2 diabetes (T2DM), but initial combination
therapy may provide more robust glucose-lowering efficacy.
Materials andmethods: In this Phase III study, 1364 drug-naïve patients
with T2DM were randomized to empagliflozin (EMPA) 12.5 mg bid+
MET 1000 mg bid (n=170), EMPA 12.5 mg bid+MET 500 mg bid (n=
170), EMPA 5 mg bid+MET 1000 mg bid (n=172), EMPA 5 mg bid+
MET 500 mg bid (n=170), EMPA 25 mg qd (n=168), EMPA 10 mg qd
(n=172), MET 1000 mg bid (n=171) or MET 500 mg bid (n=171). The
primary endpoint was change from baseline in HbA1c at week 24. Key
secondary endpoints were changes from baseline in fasting plasma glu-
cose (FPG) and weight.
Results: EMPA+MET bid led to statistically superior and clinically
meaningful reductions in HbA1c vs EMPA qd and MET bid doses (Ta-
ble). EMPA+MET bid led to significant reductions in FPG vs EMPA qd
and MET bid and in weight vs MET bid (Table). Adverse events (AEs)
were reported in 56.7-66.3% of patients across groups. The percentage of
patients with confirmed hypoglycaemic AEs (plasma glucose ≤70 mg/dL
and/or requiring assistance) was low in all groups (0-1.8%); none required
assistance.
Conclusion:EMPA+METbid significantly reduced HbA1c vs EMPA qd
and MET bid and was well tolerated.
Clinical Trial Registration Number: NCT01719003
Supported by: Boehringer Ingelheim and Eli Lilly and Company
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Efficacy and safety of canagliflozin monotherapy: results from 2
studies in patients with type 2 diabetes mellitus
E. Jodar1, J. Rosenstock2, L. Chuck3, M. González-Ortiz4, C. Tong5, G.
Capuano5, M. Alba5, R. Qiu5;
1Department of Endocrinology, Hospital Quiron, Madrid, Spain, 2Dallas
Diabetes and Endocrine Center at Medical City, Dallas, 3Diablo Clinical
Research Inc, Walnut Creek, USA, 4Institute of Experimental and Clini-
cal Therapeutics, Physiology Department, Health Science University
Center, University of Guadalajara, Mexico, 5Janssen Research & Devel-
opment, LLC, Raritan, USA.
Background and aims: Canagliflozin (CANA) is an SGLT2 inhibitor
approved for the treatment of type 2 diabetes mellitus (T2DM). The
efficacy and safety of CANA monotherapy was assessed in patients with
T2DM inadequately controlled with diet and exercise enrolled in 2
randomised, double-blind, Phase 3 studies.
Materials and methods: In Study 1, the efficacy and safety of
canagliflozin 100 and 300 mg versus PBO were assessed at Week 26
(N=584; mean age, 55.4 y; HbA1c, 8.0%; BMI, 31.6 kg/m2); change
in HbA1c was also assessed in a separate substudy of patients with high
baseline HbA1c (HbA1c >10.0% to ≤12.0%; N=91) that was not PBO
controlled. In Study 2, the efficacy and safety of canagliflozin 100 and
300 mg versus metformin extended release (MET XR) were assessed at
Week 26 (N=712; mean age, 55.0 y; HbA1c, 8.8%; BMI, 32.6 kg/m2);
change in HbA1c was also assessed in a subset of patients with baseline
HbA1c ≥9.0% (n=280). The proportion of patients achieving HbA1c
<7.0% was evaluated in both studies at Week 26. Safety was assessed
based on adverse event (AE) reports.
Results: In Study 1, CANA 100 and 300 mg provided significant reduc-
tions in HbA1c from baseline at Week 26 versus PBO (least squares [LS]
mean changes of -0.77% and -1.03% vs 0.14%); HbA1c reductions were
-2.13% and -2.56%with CANA100 and 300mg in patients with baseline
HbA1c >10.0% to ≤12.0% in the substudy of Study 1 (Figure). In Study
2, CANA 100 and 300 mg showed noninferiority in lowering HbA1c
versus MET XR at Week 26 (LS mean changes of -1.37%, -1.42%, and
-1.30%, respectively); HbA1c reductions were -1.94%, -2.03%, and -
1.79%, respectively, in patients with baseline HbA1c ≥9.0% (Figure).
In Study 1, a greater proportion of patients achieved HbA1c <7.0% with
CANA 100 and 300 mg versus PBO at Week 26 (44.5% and 62.4% vs
20.6%). In Study 2, the proportion of patients achieving HbA1c <7.0% at
Week 26 with CANA 100 and 300 mg and MET XRwas 38.8%, 42.8%,
and 43.0%, respectively. In Study 1, the overall AE incidence was 61.0%,
59.9%, and 52.6% with CANA 100 and 300 mg and PBO, respectively.
In Study 2, the overall AE incidence was 37.1%, 39.9%, and 37.6% with
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CANA 100 and 300 mg and MET XR, respectively. In both studies, the
incidence of serious AEs and AEs related to discontinuation was low
across groups. Rates of genital mycotic infections were higher with CA-
NA in both studies; rates of osmotic diuresis-related AEs were low overall
but higher with CANA.
Conclusion: CANA provided reductions in HbA1c and was generally
well tolerated over 26 weeks as monotherapy in patients with T2DM
inadequately controlled with diet and exercise, including those with high
baseline HbA1c.
Clinical Trial Registration Number: NCT01081834, NCT01809327
Supported by: Janssen Research & Development, LLC
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Canagliflozin is superior to sitagliptin in reducing both HbA1c and
body weight in patients with type 2 diabetes mellitus
G. Schernthaner1, L. Hieronymus2, H. Jodon3, U. Vijapurkar4, G.
Meininger4, W. Canovatchel4;
1Rudolfstiftung Hospital-Vienna, Austria, 2DiabetesCare & Communica-
tions, Lexington, 3Metabolic Disease Associates, Erie, 4Janssen Research
& Development, LLC, Raritan, USA.
Background and aims: Many patients with type 2 diabetes mellitus
(T2DM) are obese or overweight, so treatments that improve glycaemic
control and reduce body weight (BW) may be beneficial. Canagliflozin
(CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor approved
for the treatment of T2DM, inhibits renal glucose absorption by lowering
the renal threshold for glucose and increasing urinary glucose excretion,
resulting in lowered plasma glucose levels and a net caloric loss. CANA
has been shown to provide reductions in HbA1c and BW compared with
sitagliptin (SITA) in 2 studies as add-on to metformin (MET) or MET
plus sulphonylurea (SU). This analysis evaluated the proportion of pa-
tients who responded to treatment in terms of both HbA1c and BW in
these studies at Week 52.
Materials and methods: This analysis used data from two, 52-week,
randomised, double-blind, Phase 3 studies of CANA 100 and 300 mg
versus SITA 100 mg as add-on to MET (Study 1: N=1,284; mean base-
line HbA1c, 7.9%; BW, 87.2 kg) and CANA 300 mg versus SITA
100 mg as add-on to MET plus SU (Study 2: N=755; mean baseline
HbA1c, 8.1%; BW, 88.3 kg).
Results: In Study 1, least squares (LS) mean changes from baseline in
HbA1c at Week 52 were -0.73%, -0.88%, and -0.73% with CANA 100
and 300 mg and SITA 100 mg, respectively; LS mean percent changes in
BW were -3.8%, -4.2%, and -1.3%, respectively. In Study 2, LS mean
changes from baseline in HbA1c were -1.03% and -0.66% at Week 52,
and LS mean percent changes in BW were -2.5% and 0.3% with CANA
300 mg and SITA 100 mg, respectively. A greater proportion of patients
in Study 1 had reductions in both HbA1c and BW with CANA 100 and
300 mg versus SITA 100 mg (67.7%, 74.7%, and 50.6%, respectively;
differences [95% confidence interval (CI)] of 17.1% [9.7, 24.5] and
24.2% [17.1, 31.3], respectively; Figure). Similar to Study 1, a greater
proportion of patients in Study 2 had reductions in both HbA1c and BW
with CANA 300 mg (70.6%) versus SITA 100 mg (37.8%; difference
[95% CI] of 32.8% [25.7, 39.8]). The overall incidence of adverse events
(AEs) was similar across treatment groups in both studies; CANA was
associated with increased rates of genital mycotic infections and osmotic
diuresis-related AEs compared with SITA. In Study 1, the incidence of
documented hypoglycaemia (≤3.9 mmol/L) was 7%, 7%, and 4% with
CANA 100 and 300 mg and SITA 100 mg, respectively; in Study 2, the
incidence of documented hypoglycaemia was 43% and 41%with CANA
300 mg and SITA 100 mg, respectively.
Conclusion: CANA provided greater attainment of reduction in both
HbA1c and BW compared with SITA at 52 weeks and was generally well
tolerated in patients with T2DM as add-on to MET or MET plus SU.
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736
Canagliflozin provides reductions in HbA1c, body weight, and blood
pressure in patients with type 2 diabetes on metformin with or with-
out other antihyperglycaemic agents
P. Hollander1, C. Mathieu2, C. Tong3, W. Canovatchel3, G. Meininger3;
1Baylor University Medical Center, Dallas, USA, 2Clinical and Experi-
mental Endocrinology, KU Leuven, Belgium, 3Janssen Research & De-
velopment, LLC, Raritan, USA.
Background and aims: Canagliflozin (CANA) is a sodium glucose co-
transporter 2 (SGLT2) inhibitor developed for the treatment of adults with
type 2 diabetes mellitus (T2DM). This post hoc analysis evaluated the
efficacy and safety of CANA in patients with T2DM inadequately con-
trolled with metformin +/- other antihyperglycaemic agents (AHAs; ie,
sulphonylurea or pioglitazone) based on pooled data from Phase 3
studies.
Materials and methods: Data were pooled from 3 randomised, double-
blind, placebo (PBO)-controlled studies (N=1,729; mean age, 56.2 years;
HbA1c, 8.0%; body mass index, 32.2 kg/m2; estimated glomerular filtra-
tion rate, 88.5 mL/min/1.73m2). Patients received CANA 100 or 300 mg
or PBO once daily for 26 weeks. Efficacy endpoints were evaluated at
26 weeks; safety was assessed based on adverse event (AE) reports.
Results:Relative to PBO, CANA 100 and 300 mg provided least squares
(LS) mean reductions in HbA1c (-0.65% and -0.82%), body weight (-
2.2% and -2.8%), and systolic blood pressure (BP; -4.0 and -4.4 mmHg)
at Week 26 (Table). Overall AE rates were 59.9%, 59.0%, and 62.3%
with CANA 100 and 300 mg and PBO, respectively; serious AE rates
were 3.1%, 3.1%, and 4.0%, respectively. Over 26 weeks, higher rates of
genital mycotic infections in males and females and osmotic diuresis-
related AEs were seen with CANA 100 and 300 mg versus PBO. Rates
of urinary tract infections were higher with CANA 100 mg versus CANA
300 mg and PBO. Rates of volume depletion-related AEs were low and
similar across groups.
Conclusion: CANA improved glycaemic control and reduced body
weight and BP compared with PBO, and was generally well tolerated in
patients with T2DM as add-on to metformin +/- other AHAs.
Clinical Trial Registration Number: NCT01106625, NCT01106677,
NCT01106690
Supported by: Janssen Research & Development, LLC
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Changes in HbA1c and weight in type 2 diabetes patients initiating
dapagliflozin treatment in routine UK primary care
J.P.H.Wilding1, C.J. Bailey2, U. Rigney3, B. Blak3, W. Beekman4, C.E.
Emmas3;
1Diabetes & Endocrinology Research Group, Clinical Sciences Centre,
Liverpool, UK, 2Life and Health Sciences, Aston University, Birming-
ham, UK, 3RWE, AstraZeneca UK, Luton, UK, 4Medical, AstraZeneca
NL, Zoetermeer, Netherlands.
Background and aims: Dapagliflozin is a sodium-glucose co-
transporter-2 (SGLT2) inhibitor that lowers blood glucose in type 2 dia-
betes (T2DM) by reducing renal glucose reabsorption. This study
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examines the characteristics of patients initiating dapagliflozin treatment
in routine clinical care and assesses subsequent changes in HbA1c and
body weight.
Materials andmethods: This retrospective observational study was con-
ducted using the Clinical Practice Research Datalink which contains re-
cords from 684 primary care practices in the UK. The study cohort
consisted of patients with T2DM given a first prescription for
dapagliflozin between Nov 2012 and Sept 2014 who were registered
≥6 months prior to that prescription and remained registered for
≥3 months after dapagliflozin initiation. Changes in HbA1c and weight
were reported for patients with a measure pre-initiation and at least one
measure during dapagliflozin treatment (up to 12 months follow-up).
Results: Of 2401 patients with ≥1 prescription for dapagliflozin, 1732
fulfilled the inclusion criteria.Mean agewas 57.5 (SD:10.5) years, weight
was 103.1(SD:23.0) kg, HbA1c was 80.1(SD:17.9) mmol/mol and time
since T2DM diagnosis was 9.5 (SD:6.0) years: 58% of patients were
male. A history of retinopathy was present in 36.9%, nephropathy in
9.8% and neuropathy in 20.4%. The most common usages of
dapagliflozin treatment were dual therapy with metformin (435, 25%),
triple therapy (480, 28%) and add-on to insulin (332, 19%). 1091 patients
had HbA1c values and 970 had weight recorded before initiation of
dapagliflozin and on treatment. Reductions in HbA1c and weight were
observed with each of the more common treatment combinations and
overall (see table). A greater reduction was observed in patients with
higher baseline HbA1c (upper tertile, 17.8 (15.4-20.1) mmol/mol) com-
pared to those with a lower baseline (lower tertile, 2.6 (1.3-3.2)
mmol/mol) as measured 14-90 days post-initiation.
Conclusion: Reductions in HbA1c and weight observed in a routinely
treated UK T2DM population were consistent with results from the
dapagliflozin clinical trial program. Reductions were observed with
dapagliflozin in combination with metformin, two glucose-lowering
agents and insulin.
PS 063 SGLT-2 inhibitors: long-term
and advanced combination therapy
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Simultaneous reduction in both HbA1c and body weight with
canagliflozin compared with glimepiride in metformin-treated pa-
tients with type 2 diabetes mellitus over 104 weeks
G. Langslet1, L.A. Leiter2, U. Vijapurkar3,M.Davies3,W. Canovatchel3;
1Lipid Clinic, Oslo University Hospital, Norway, 2Keenan Research Cen-
tre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital,
University of Toronto, Canada, 3Janssen Research & Development,
LLC, Raritan, USA.
Background and aims: Canagliflozin (CANA), a sodium glucose co-
transporter 2 (SGLT2) inhibitor developed to treat type 2 diabetesmellitus
(T2DM), lowers the renal threshold for glucose and increases urinary
glucose excretion, leading to decreased plasma glucose levels and a net
caloric loss. Glimepiride (GLIM) is a sulphonylurea that stimulates insu-
lin secretion. In patients with T2DM on background metformin (MET),
CANA showed durable glycaemic improvements and reductions in body
weight (BW) versus GLIM over 104 weeks; this post hoc analysis eval-
uated the proportion of patients who had decreases in both HbA1c and
BW with CANAversus GLIM.
Materials andmethods: In this randomised, double-blind study, patients
with T2DM (N=1,450; mean baseline HbA1c, 7.8%; BW, 86.6 kg) re-
ceived CANA 100 or 300mg or GLIM as add-on toMETover a 52-week
core period, followed by a 52-week extension (n=1,050). Using individ-
ual patient data, the proportion of patients achieving both change from
baseline in HbA1c <0% and BW <0 kg was assessed at Weeks 52 and
104.
Results: At Week 52, least squares (LS) mean changes from baseline in
HbA1c were -0.82%, -0.93%, and -0.81% with CANA 100 and 300 mg
and GLIM, respectively; LS mean percent changes in BW were -4.2%, -
4.7%, and 1.0%. AtWeek 104, LSmean changes from baseline in HbA1c
were -0.65%, -0.74%, and -0.55% with CANA 100 and 300 mg and
GLIM, respectively; LS mean percent changes in BW were -4.1%, -
4.2%, and 0.9%. The proportion of patients with HbA1c reductions at
Week 52was 83.9%, 86.9%, and 81.9%with CANA100 and 300mg and
GLIM, respectively; 84.1%, 87.3%, and 32.3% had reductions in BW. A
greater proportion of patients had reductions in both HbA1c and BW at
Week 52 with CANA 100 and 300 mg versus GLIM (72.4%, 78.5%, and
26.8%, respectively; differences [95% confidence interval (CI)] of 45.6%
[39.7, 51.5] and 51.7% [46.0, 57.3]). The proportion of patients with
HbA1c reductions at Week 104 was 75.7%, 79.7%, and 72.6% with
CANA 100 and 300 mg and GLIM, respectively; 83.1%, 85.2%, and
34.6% had reductions in BW (Figure). A greater proportion of patients
atWeek 104 had reductions in both HbA1c and BWwith CANA 100 and
300 mg versus GLIM (65.5%, 71.1%, and 26.8%, respectively; differ-
ences [95% CI] of 38.7% [32.6, 44.7] and 44.3% [38.4, 50.2]). At Week
104, the overall incidence of adverse events was 73%, 78%, and 78%
with CANA 100 and 300 mg and GLIM, respectively. The incidence of
documented hypoglycaemia (≤3.9 mmol/L) at Week 104 was lower with
CANA 100 and 300 mg versus GLIM (7% and 8% vs 41%).
Conclusion: CANA provided greater attainment of reduction in both
HbA1c and BW compared with GLIM at 52 and 104 weeks and was
generally well tolerated in patients with T2DM as add-on to MET.
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Distribution of weight loss with canagliflozin in patients with type 2
diabetes mellitus over 104 weeks
K. Stenlöf1, L. Blonde2, A. Fung3, J. Xie3, W. Canovatchel3, G.
Meininger3;
1Clinical Trial Center, Sahlgrenska University Hospital, Gothenburg,
Sweden, 2Department of Endocrinology, Diabetes, and Metabolic Dis-
eases, Ochsner Medical Center, New Orleans, 3Janssen Research & De-
velopment, LLC, Raritan, USA.
Background and aims: Canagliflozin (CANA), a sodium glucose co-
transporter 2 inhibitor, lowers plasma glucose levels in patients with type
2 diabetes mellitus (T2DM) by increasing urinary glucose excretion. This
also results in a mild osmotic diuresis and net caloric loss, which leads to
reductions in body weight. This analysis assessed the distribution of body
weight changes in two randomised, double-blind, Phase 3 studies of
CANA.
Materials and methods: Study One assessed CANA 100 and 300 mg
versus glimepiride (GLIM) as add-on to metformin in a 52-week core
period, followed by a 52-week extension period (N=1,450; mean age,
56.2 y; HbA1c, 7.8%; body weight, 86.6 kg). Study Two assessed CANA
100 and 300 mg versus placebo (PBO) in older patients (55-80 years) on
various background antihyperglycaemic therapies in a 26-week core pe-
riod, followed by a 78-week extension period (N=714; mean age, 63.6 y;
HbA1c, 7.7%; body weight, 89.5 kg). Percent change from baseline in
body weight was a key endpoint in both studies. The cumulative distri-
bution of body weight changes for each study was determined, as well as
the proportion of patients with ≥5% and ≥10% weight loss.
Results: In Study One, body weight reductions were seen with CANA
100 and 300mg versus an increase with GLIM atWeek 52 (-4.2%, -4.7%,
and 1.0%); these changes were sustained atWeek 104 (-4.1%, -4.2%, and
0.9%). In Study Two, CANA 100 and 300 mg and PBO provided body
weight reductions atWeek 26 (-2.4%, -3.1%, and -0.1%) and atWeek 104
(-3.0%, -3.8%, and -0.6%). In both studies, a greater proportion of pa-
tients in the CANA 100 and 300 mg groups experienced weight loss
compared with those in the comparator groups (Figure). In Study One,
approximately 85% to 90% of patients treated with CANA and approx-
imately 30% to 35% of patients treated with GLIM had a reduction in
body weight at Weeks 52 and 104. The proportion of patients with ≥5%
bodyweight reduction with CANA100 and 300mg and GLIMwas 33%,
43%, and 6% atWeek 52, and 35%, 40%, and 7%, at Week 104. In Study
Two, approximately 80% to 85% of patients treated with CANA and
approximately 60% of patients treated with PBO experienced weight loss
at Weeks 26 and 104. The proportion of patients with ≥5% body weight
reduction with CANA 100 and 300 mg and PBOwas 24%, 28%, and 4%
at Week 26, and 28%, 33%, and 11% at Week 104. The proportion of
patients with weight loss ≥10%was low across groups in both studies, but
higher with CANAversus GLIM or PBO.
Conclusion:CANA 100 and 300mg provided bodyweight reductions in
a greater proportion of patients with T2DM compared with GLIM and
PBO over 104 weeks; most patients experienced body weight reductions
with CANA, and a greater proportion achieved ≥5% and ≥10% weight
loss.
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Dapagliflozin added to metformin is effective in achieving combined
improvements in HbA1c and weight without hypoglycaemia over
4 years
P. Fenici1, C. Sternhufvud2, V. Cain3, J. Mukherjee4, K. Rohwedder5;
1AstraZeneca, Melbourn, UK, 2AstraZeneca, Mölndal, Sweden,
3AstraZeneca, Wilmington, 4Bristol-Myers Squibb, Wallingford, USA,
5AstraZeneca, Wedel, Germany.
Background and aims: The goal of type 2 diabetes (T2D) management
is to achieve optimal glycaemic control whilst avoiding side effects, in-
cluding hypoglycaemia and weight gain. Dapagliflozin (DAPA) increases
glucosuria in a glucose-dependent and insulin-independent manner,
resulting in reductions in hyperglycaemia and weight, with a low risk of
hypoglycaemia. Key 4-year results (1×52 week double-blind treatment
period; 2× double-blind extension periods of 52 and 104 weeks) from a
study comparing DAPAwith the sulfonylurea, glipizide (GLIP), as add-
on to metformin (MET) in patients with inadequately controlled T2D
(HbA1c >6.5 - ≤10%) have been reported previously. The aim of this
post-hoc analysis was to investigate the proportion of patients achieving
composite outcomes including reductions in HbA1c and weight and no
hypoglycaemic episodes with DAPA compared with GLIP over 4 years.
Materials and methods: HbA1c reduction was considered to be a de-
crease ≥0.5%. Weight reduction was considered to be any decrease in
weight ≥3% or ≥5%. HbA1c and weight reductions were defined as
change from baseline and percent change from baseline, respectively, to
Week 208. Major (symptomatic episodes requiring third-party assistance
and prompt recovery after glucose or glucagon administration, and cap-
illary or plasma glucose <3.0 mmol/L [<54 mg/dL]) and minor (symp-
tomatic or asymptomatic episode, with capillary or plasma glucose
<3.5 mmol/L [<63 mg/dL] regardless of need for external assistance, that
does not qualify as a major episode) hypoglycaemic events were consid-
ered when defining “no hypoglycaemic events”. Binomial exact P-values
and 95% CI for the difference in proportions between treatment groups
were calculated using StatXact (r) PROCs (v9.0), Cytel Inc., USA.
Results: The proportion of patients achieving the composite outcomes of
interest over 4 years (Table) was consistently higher in those receiving
DAPA + MET (24.5-56.0%) compared with those receiving GLIP +
MET (2.1-12.9%). This difference was significant for all endpoints ex-
plored, but was largest when the proportion of patients experiencing no
hypoglycaemia was included in the analysis.
Conclusion:This post-hoc analysis demonstrates that over 4 years DAPA
is more effective than GLIP, when added to MET, at achieving combined
improvements of HbA1c and weight without hypoglycaemia. 27.1% of
DAPA-treated patients still benefited from both HbA1c and weight reduc-
tion (≥0.5% and ≥3%, respectively) with no hypoglycaemic events after
208 weeks compared with 2.9% of GLIP-treated patients. This suggests
that DAPA can positively impact long-term disease management in pa-
tients with T2D.
Clinical Trial Registration Number: NCT00660907
Supported by: BMS
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Triple therapy with saxagliptin and dapagliflozin add-on to metfor-
min: safety of dual add-on versus sequential add-on
R. Garcia-Sanchez1, S. Del Prato2, S. Matthaei3, N. Iqbal4, L. Hansen4,
E. Johnsson5, H. Chen1, A.J. Chin1, C. Mathieu6;
1AstraZeneca, Gaithersburg, USA, 2School of Medicine, University of
Pisa, Italy, 3Diabetes-Center, Quakenbrück, Germany, 4Bristol-Myers
Squibb, Princeton, USA, 5AstraZeneca, Mölndal, Sweden, 6Katholieke
Universiteit Leuven, Belgium.
Background and aims: Triple oral therapy with dual add-on of
saxagliptin (SAXA) plus dapagliflozin (DAPA) to metformin (MET)
was previously shown to reduce HbA1c to a greater extent than dual
therapy with either SAXA or DAPA add-on to METand was an effective
treatment option in patients with high baseline HbA1c poorly controlled
with MET. We assessed the safety and tolerability of triple therapy with
concomitant dual add-on of SAXA and DAPA to MET versus the se-
quential single add-on of SAXA to dual therapy of DAPA plus METand
the single add-on of DAPA to dual therapy of SAXA plus MET in 3
randomized trials of adults with type 2 diabetes (T2D).
Materials and methods: In the dual add-on trial, patients on stable MET
(baseline HbA1c 8.0%-12.0%) received SAXA 5 mg/d plus DAPA
10 mg/d for 24 weeks. In the sequential add-on trials, patients (baseline
HbA1c 7%-10.5%) on stable MET+SAXA 5 mg/d or stable MET+
DAPA 10 mg/d received add-on DAPA 10 mg/d or SAXA 5 mg/d,
respectively for 24 weeks. Safety results from the sequential add-on trials
were pooled and compared with the dual add-on trial.
Results: Events of hypoglycemia were uncommon and similar in the 2
groups. Overall adverse events (AEs) and serious AEs (SAEs) were sim-
ilar between treatment regimens (Table). The most common AE was
nasopharyngitis (3.9% vs 3.5% for dual vs sequential add-on, respective-
ly). Urinary tract infections were more frequent in patients receiving
sequential add-on therapy; genital infections were reported only with
the sequential single add-on of DAPA to dual therapy of SAXA plus
MET. There were no events of hypotension/dehydration/hypovolemia.
There was 1 event of hepatic cancer that was subsequently identified as
pancreatic cancer that had metastasized to the liver and was considered
unrelated to drug treatment.
Conclusion: In a cross-study comparison, dual add-on of SAXA and
DAPA toMET had a similar safety and tolerability profile compared with
single add-on of either SAXA or DAPA to existing dual therapy in pa-
tients poorly controlled on MET.
Clinical Trial Registration Number: NCT01606007, NCT01646320,
NCT01619059
Supported by: AstraZeneca
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A randomised, double-blind phase 3 trial of dapagliflozin add-on to
saxagliptin + metformin in type 2 diabetes
C. Mathieu1, A.E. Ranetti2, D. Li3, E. Ekholm4, W. Cook5, B.
Hirshberg5, L. Hansen3, N. Iqbal3;
1Katholieke Universiteit Leuven, Belgium, 2Carol Davila University of
Medicine and Pharmacy and “Dr. Carol Davila”Central University Emer-
gency Military Hospital, Bucharest, Romania, 3Bristol-Myers Squibb,
Princeton, USA, 4AstraZeneca, Molndal, Sweden, 5AstraZeneca, Gai-
thersburg, MD, USA.
Background and aims: SGLT2 and DPP-4 inhibitors have complemen-
tary mechanisms of action. We compared the efficacy and safety of
dapagliflozin (DAPA) versus placebo (PBO) as add-on to saxagliptin
(SAXA)+metformin IR (MET) in adults with type 2 diabetes (T2D).
Materials and methods: Patients on stable MET (stratum A; baseline
A1C 8.0%-11.5%) or stable MET+DPP-4 inhibitor (stratum B; A1C
7.5%-10.5%) for ≥8 weeks received open-label SAXA 5 mg/d+MET
for 16 (stratum A) or 8 weeks (stratum B, any DPP-4 inhibitor was
replaced with SAXA). At the end of the open-label period, patients with
inadequate glycemic control (A1C 7%-10.5%) were randomized to PBO
or DAPA 10 mg/d plus open-label SAXA+MET. Primary end point was
change in A1C from baseline to week 24. Secondary end points included
fasting plasma glucose (FPG), 2-hour postprandial glucose (PPG), body
weight, and the proportion of patients achieving A1C<7%.
Results: DAPA+SAXA+MET resulted in a greater A1C reduction than
PBO+SAXA+MET (-0.82% vs -0.10%) (Table). More patients achieved
A1C <7%and greater reductions in FPG, PPG, andweight were observed
with DAPA+SAXA+MET vs PBO+SAXA+MET. AEs were similar
across treatment groups with a low overall risk of hypoglycemia (~1%).
More patients developed genital infections with DAPA (5%) vs PBO
(0.6%).
Conclusion: Addition of DAPA to SAXA+MET improves glycemic
control and is well tolerated in patients with T2D inadequately controlled
with SAXA+MET.
Clinical Trial Registration Number: NCT01646320
Supported by: AstraZeneca
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Impact of canagliflozin added-on to insulin and metformin in type 2
diabetes: a substudy of the CANVAS trial
D. Matthews1, J. Rosenstock2, M. Desai3, G. Capuano3, G. Meininger3,
W. Canovatchel3;
1University of Oxford, UK, 2Dallas Diabetes and Endocrine Center at
Medical City, Dallas, 3Janssen Research & Development, LLC, Raritan,
USA.
Background and aims: Canagliflozin (CANA) is a sodium glucose co-
transporter 2 (SGLT2) inhibitor developed for the treatment of adults with
type 2 diabetes mellitus (T2DM). The CANagliflozin cardioVascular Assess-
ment Study (CANVAS) is a cardiovascular (CV) outcomes trial in patients
with T2DM and a history or high risk of CV disease. The efficacy and safety
of CANA vs. placebo (PBO) were evaluated in a subset of patients from
CANVAS who were on ≥30 IU/d of insulin and ≥2,000 mg/d of metformin.
Materials and methods: Patients on ≥30 IU/d of insulin and ≥2,000 mg/
d of metformin (N=432; mean age, 61 yrs; HbA1c, 8.2%; fasting plasma
glucose [FPG], 9.2 mmol/L; body mass index [BMI], 34.9 kg/m2; insulin
dose, 93 IU/d) were randomised to receive CANA 100 or 300 mg or PBO
once daily for 18 weeks. Efficacy endpoints were evaluated at 18 weeks;
safety was assessed by adverse event (AE) reports.
Results:Relative to PBO, CANA100 and 300mg provided significant least
squares (LS) mean reductions in HbA1c (-0.7% and -0.8%; P <0.001), FPG
(-0.9 and -1.4 mmol/L; P ≤0.001), and body weight (-1.7% and -2.7%; P
<0.001) at Week 18 (Table). PBO-subtracted LS mean reductions in systolic
blood pressure were -3.5 and -6.1 mmHg (P <0.001) with CANA 100 and
300mg. The overall incidence of AEs was 66%, 67%, and 61%with CANA
100 and 300 mg and PBO, respectively, with low rates of AE-related discon-
tinuations across groups. The incidence of hypoglycaemia (≤3.9 mmol/L)
was similar with CANA 100 and 300 mg and PBO (42%, 47%, and 46%),
with low rates of severe episodes (1%, 2%, and 3%). GenitourinaryAEswere
consistent with the reported frequency in the SGLT2 inhibitor class.
Conclusion: Short-term CANA treatment improved glycaemic control,
reduced body weight, and was generally well tolerated as add-on to in-
sulin and metformin in patients with T2DM.
Clinical Trial Registration Number: NCT01032629
Supported by: Janssen Research & Development, LLC
744
Efficacy and safety of dapagliflozin in patients with type 2 diabetes on
insulin ± metformin regimens
H. Yeh, A. Katz;
AstraZeneca, Fort Washington, USA.
Background and aims:This analysis evaluated the efficacy and safety of
dapagliflozin (DAPA) in patients with type 2 diabetes (T2D) inadequately
controlled with high doses of insulin (INS)±up to 2 oral antidiabetes
agents.
Materials and methods: In this post hoc analysis of a 24-week, placebo
(PBO)-controlled trial of DAPA in patients with T2D inadequately con-
trolled with INS±up to 2 oral antidiabetes agents, 587 patients were
stratified by INS regimen (basal, sliding scale, or basal/sliding scale)
and metformin (MET) use.
Results: Mean T2D duration was >10 years and baseline HbA1c was
8.4%-8.8% across groups. With each of the 3 INS regimens, DAPA 5 and
10 mg/d significantly reduced HbA1c (all P<0.001 vs PBO) and body
weight (BW, all P<0.01, except DAPA 5 mg/d + basal INS) from base-
line at week 24. DAPA reduced HbA1c and BW with MET (all
P<0.0001 vs PBO) or without MET (HbA1c, all P<0.0001; BW, P=
0.0439 and <0.0001 for DAPA 5 and 10 mg/d, respectively), but reduc-
tions were numerically larger with MET and significantly more patients
receiving MET had HbA1c <7% at 24 weeks (P<0.01 vs PBO). Genital
and urinary tract infections were more frequent with DAPA than PBO.
Hypoglycemia was more common with DAPA (45%, 48%) than PBO
(42%); 1 major hypoglycemia event occurred in each DAPA dose group
and 2 in the PBO group.Conclusion: In patients withT2D, including
those with progressive disease (inadequately controlled on INS, T2D
duration >10 years), DAPA was effective and well tolerated with each
INS regimen, with no increase in major hypoglycemia. The effects of
DAPA appeared greater in patients receiving MET in addition to INS.
Clinical Trial Registration Number: NCT00673231
Supported by: AstraZeneca
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Efficacy and safety of canagliflozin added to background insulin in
patients with type 2 diabetesmellitus in subgroups by baseline insulin
dose
L. Van Gaal1, R. Dumas2, D. Matthews3, M. Desai4, G. Capuano4, G.
Meininger4;
1Department of Endocrinology, Diabetology and Metabolism, Antwerp
University Hospital, Belgium, 2Laval Clinic Research Center, Montreal,
Canada, 3University of Oxford, UK, 4Janssen Research & Development,
LLC, Raritan, USA.
Background and aims: Across Phase 3 studies, canagliflozin (CANA),
an SGLT2 inhibitor, was associated with improvements in glycaemic
control and reductions in body weight and blood pressure (BP) in patients
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with type 2 diabetes mellitus (T2DM) on a range of background
antihyperglycaemic agents, including insulin. This analysis evaluated
the efficacy and safety of CANA in patients with T2DM who were on
background insulin with or without other antihyperglycaemic agents in
subgroups by baseline insulin dose.
Materials and methods: This post hoc analysis assessed efficacy and
safety in the subset of patients enrolled in the CANagliflozin cardioVas-
cular Assessment Study (CANVAS; patients with T2DM who had a
history or high risk of cardiovascular disease) who were on insulin
≥30 IU/d by tertiles based on baseline insulin dose (<54, 54-<90, and
≥90 IU/d). Patients (N=1,718; mean age, 63 y; HbA1c, 8.3%; body
weight, 97.0 kg; eGFR, 74.9 mL/min/1.73 m2; T2DM duration, 16.6 y;
insulin dose, 83 IU/d) received CANA 100 or 300 mg or placebo (PBO)
once daily over 18 weeks. Patient characteristics across tertiles were gen-
erally similar, except for baseline body weight, which increased as insulin
dose increased.
Results: During the study, 6%, 10%, and 9% of patients across treatment
groups in the <54, 54-<90, and ≥90 IU/d tertiles decreased their insulin
dose; 2%, 1%, and 2% increased their insulin dose. In general, more
patients decreased their insulin dose with CANA than PBO; the propor-
tion with increases in insulin was similar across groups. Relative to PBO,
CANA 100 and 300 mg provided reductions in HbA1c, body weight, and
fasting plasma glucose (FPG) over 18 weeks that were similar across
tertiles (Table). PBO-subtracted reductions in systolic BP (SBP) were also
observed with CANA 100 and 300 mg across tertiles. The incidence of
overall adverse events (AEs) with CANA 100 and 300 mg and PBO was
62.8%, 54.6%, and 53.5% in the <54 IU/d tertile; 57.9%, 64.7%, and
58.0% in the 54-<90 IU/d tertile; and 70.3%, 76.8%, and 65.0% in the
≥90 IU/d tertile; rates of serious AEs and AEs leading to discontinuation
were low across groups. Increased incidence of male and female genital
mycotic infections and osmotic diuresis-related AEs was seen with CA-
NA versus PBO across tertiles. The incidence of documented
hypoglycaemia episodes was higher with CANA 100 and 300 mg com-
pared with PBO across tertiles. The incidence of severe hypoglycaemia
episodes was low across groups in all tertiles.
Conclusion: Consistent with its insulin-independent mechanism of ac-
tion, CANA provided improvements in glycaemic control, as well as
body weight and SBP reductions, and was generally well tolerated com-
pared with PBO across tertiles by baseline insulin dose in patients with
T2DM over 18 weeks.
Clinical Trial Registration Number: NCT01032629
Supported by: Janssen Research & Development, LLC
PS 064 SGLT-2 inhibitors:
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Cystatin C and creatinine-based estimates of glomerular filtration
rates in dapagliflozin phase 3 clinical trials
C. Mende1, A. Katz2;
1Department ofMedicine, University of California at San Diego, La Jolla,
2AstraZeneca, Fort Washington, USA.
Background and aims: Sodium-glucose cotransporter 2 (SGLT2) inhib-
itor efficacy depends on the kidneys’ ability to filter glucose and declines
with lower glomerular filtration rate (GFR). Estimates of GFR based on
creatinine (eGFRcr) are routinely used but are affected by factors, such as
muscle mass and diet, and may be inaccurate under certain conditions.
Estimates based on cystatin C (eGFRcys) appear to correlate better with
morbidity and mortality than eGFRcr. KDIGO guidelines suggest mea-
suring eGFRcys when eGFRcr is 45-59 ml/min/1.73 m
2 with no evidence
of kidney damage and/or when eGFRcr may be unreliable. This analysis
compared the proportion of patients with type 2 diabetes (T2D) with
eGFR <60 and ≥60 mL/min/1.73 m2 in 9 dapagliflozin (DAPA) clinical
trials when GFR was estimated using creatinine versus cystatin C.
Materials and methods:Using pooled data from 9 DAPA phase 3 trials,
the proportion of patients with T2Dwith eGFR 30-<60 and ≥60mL/min/
1.73 m2 was determined using both eGFRcr and eGFRcys.
Results: The correlation between eGFRcr and eGFRcys was poor; r
2=0.25.
At least 60% of patients who had moderate renal impairment (eGFR 30-<
60) at baseline based on eGFRcr had an eGFRcys ≥60. Among patients with
eGFRcr ≥60, ≥95% remained ≥60 with eGFRcys. Decreases in HbA1c,
body weight, and systolic blood pressure with DAPAwere similar in pa-
tient subgroups defined by either eGFR estimate, and statistically signifi-
cant and clinically meaningful with DAPA 10 mg in most subgroups.
Conclusion: The data suggest that in patients with T2D, renal function as
assessed by eGFRcr may be underestimated, rendering such patients in-
eligible to receive medications limited by renal function (eg, metformin,
SGLT2 inhibitors).
Clinical Trial Registration Number: NCT00528372, NCT00528879,
NCT00680745, NCT00673231, NCT00984867, NCT00855166,
NCT01031680, NCT01042977, NCT00859898
Supported by: AstraZeneca
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Effect of longer-term canagliflozin treatment on eGFR in patients
with type 2 diabetes mellitus and various degrees of baseline renal
function
P. Fioretto1, M. Weir2, R. Gilbert3, M.J. Davies4, G. Meininger5;
1Department of Medicine, University of Padova, Italy, 2University of
Maryland School of Medicine, Baltimore, USA, 3University of Toronto,
Canada, 4Janssen Scientific Affairs, LLC, 5Janssen Research & Develop-
ment, LLC, Raritan, USA.
Background and aims: Canagliflozin (CANA), a sodium glucose co-
transporter 2 inhibitor, is associated with a small, transient reduction in
estimated glomerular filtration rate (eGFR) after treatment initiation,
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which stabilizes or attenuates towards baseline levels with continued
treatment in short-term studies (i.e. 26 weeks). This analysis evaluated
the effect of CANA on renal function in patients with type 2 diabetes
mellitus (T2DM) for up to 2 years.
Materials andmethods: eGFRover time was compared between CANA
and glimepiride (GLIM) or placebo (PBO) using data from 3 clinical
studies: Study 1, patients aged 18-80 years (mean eGFR 90.2 mL/min/
1.73 m2) received CANA 100 mg or 300 mg, or GLIM for 2 years; Study
2, patients aged 55-80 years (eGFR 77.5 mL/min/1.73 m2) received CA-
NA 100 mg or 300 mg, or PBO for 2 years; and Study 3, patients aged≥
25 years with Stage 3 chronic kidney disease (eGFR 39.4 mL/min/
1.73 m2) received CANA 100 mg or 300 mg, or PBO for 1 year.
Results: Following an initial decrease with CANA, eGFR stabilized or
attenuated toward baseline within the first 3–6 weeks and remained un-
changed for up to 2 years; eGFR progressively declined with GLIM but
not with PBO (Figure). Consistent absolute effects of CANA on eGFR
were observed in all patients across study groups, regardless of baseline
renal function. Reductions in the urine albumin to creatinine ratio were
also seen with CANA 100 mg and 300 mg, versus increases with GLIM
and PBO.
Conclusion: In summary, changes in eGFR with CANA were transient
and attenuated over time.
Clinical Trial Registration Number: NCT00968812; NCT01106651;
NCT01064414
Supported by: Janssen Scientific Affairs, LLC
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The effect of renal impairment on the pharmacokinetics and phar-
macodynamics of ertugliflozin in subjects with type 2 diabetes
mellitus
V. Sahasrabudhe1, S.G. Terra2, R.J. Fountaine1, A. Hickman1, D. Saur3,
K. Matschke4, H. Shi1, M. O'Gorman1, M.V. Chakravarthy5, D.L.
Cutler6;
1Pfizer Inc., Groton, 2Pfizer Inc., Andover, USA, 3Pfizer Inc., Paris,
France, 4Pfizer Inc., Collegeville, 5Merck & Co., Kenilworth, 6Merck
& Co., North Wales, USA.
Background and aims: Ertugliflozin is a highly selective and potent
inhibitor of Sodium Glucose co-Transporter 2 (SGLT2) that is under
development for the treatment of T2DM. Ertugliflozin inhibits renal glu-
cose reabsorption resulting in urinary glucose excretion (UGE), thereby
reducing elevated plasma glucose and HbA1c. The glycemic efficacy of
SGLT2 inhibitors depends on the amount of glucose filtered through the
kidney. As renal impairment (RI) is a co-morbidity of T2DM, this study
evaluated the effect of RI on the pharmacokinetics, pharmacodynamics
(as measured by 0 to 24 hour urinary glucose excretion [UGE24]), safety,
and tolerability of ertugliflozin in subjects with T2DM.
Materials andmethods: In this Phase 1, multi-centre, open-label study, a
single 15mg oral dose of ertugliflozin was administered in the fasted state
to healthy and T2DM subjects with normal renal function (estimated
glomerular filtration rate not normalized for body surface area [eGFR]
≥90mL/min) and in T2DM subjects with mild RI (eGFR 60-89mL/min),
moderate RI (eGFR 30-59 mL/min) and severe RI (eGFR <30 mL/min).
Serial blood samples and urine samples at specified intervals were col-
lected predose and for 96 hours post-dose for pharmacokinetic evaluation
and for measurement of UGE24.
Results: Geometric mean (CV%) values for ertugliflozin exposure pa-
rameters (area under the concentration-time curve [AUC0-inf] and peak
concentration [Cmax]) are presented in the table below. Ertugliflozin ex-
posures were similar in healthy subjects and T2DM subjects with normal
renal function. Based on an analysis of variance, the geometric mean ratio
(GMR) [90% confidence interval (CI)] for AUC0-inf in T2DM subjects
with mild, moderate, and severe RI compared to healthy and T2DM
subjects with normal renal function (pooled) was 1.56 [1.28, 1.91], 1.70
[1.39, 2.08], and 1.55 [1.24, 1.94], respectively. Regression analysis of
the change from baseline in UGE24 versus eGFR showed a decrease in
urinary glucose excretion with declining renal function.
Conclusion: Systemic exposure of ertugliflozin was increased by less
than 2-fold in subjects with varying degrees of renal impairment com-
pared to subjects with normal renal function. The observed increase in
exposure in renal impairment is not anticipated to be clinically meaning-
ful. As expected for this mechanism, UGE24 decreased with declining
renal function due to a decrease in the filtered glucose load. A single
15 mg dose of ertugliflozin was well tolerated in subjects with normal
renal function and in T2DM subjects with renal impairment.
Clinical Trial Registration Number: NCT01948986
749
Empagliflozin moderately increases LDL-cholesterol levels through
reduced LDL catabolism while it increases slightly the reverse cho-
lesterol in hamsters
F. Briand1, N. Burr1, I. Urbain1, E. Mayoux2, T. Sulpice1;
1Physiogenex S.A.S, Labège, France, 2Boehringer-Ingelheim, Biberach,
Germany.
Background and aims: The slight increase of LDL-cholesterol (LDL-C)
level described with SGLT2 inhibitors could result of the haemo-
concentration associated with glucosuria and osmotic diuresis. Because
chronic treatment with SGLT2 inhibitors shifts substrate utilization from
carbohydrate to lipid with a moderate increase of ketone bodies, we
investigated in hamster, a preclinical model with a human-like cholesterol
metabolism, whether other mechanisms could contribute to this increase
in LDL-C levels.
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Materials andmethods:Diet-induced dyslipidemic hamsters were treat-
ed orally (2 weeks) with vehicle or empagliflozin 30 mg/kg/day.
Results: Empagliflozin increased urinary glucose excretion (1200-fold, p
<0.001), reduced fasting glycemia and insulin (p<0.05), and moderately
but significantly increased ketone bodies and LDL-C levels In the liver,
empagliflozin increased HMG-CoA reductase activity and cholesterol
levels and reduced LDL-receptor protein levels by 20% (p<0.05). In line
with lower LDL-receptors in response to higher hepatic cholesterol level,
empagliflozin reduced LDL-3H-C catabolism by 20% (p<0.05), indicat-
ing that the raise in LDL-C may be due to lower LDL-C catabolism.
Interestingly, empagliflozin increased LDL-derived 3H-C fecal excretion
by 26% (p<0.05). This effect was related to a 40% reduction in intestinal
cholesterol absorption determined after oral gavage of 14C-cholesterol-
oil. We next evaluated whether the reverse cholesterol transport was af-
fected by injecting hamsters ( i.p.) with 3H-cholesterol labeled macro-
phages. Empagliflozin increased macrophage-derived 3H-tracer fecal ex-
cretion by 29% (p<0.05).
Conclusion: In conclusion, empagliflozin promotes LDL-derived choles-
terol fecal excretion and reverse cholesterol transport despite a moderate
increases in LDL-C levels possibly through lower LDL-C catabolism in
response to a moderate increase in ketone bodies and a switch in substrate
utilization.
750
Potential relevance of changes in haematocrit to changes in lipid
parameters with empagliflozin in patients with type 2 diabetes
S.S. Lund1, N. Sattar2, A. Salsali3, S. Crowe1, U.C. Broedl1, H.N.
Ginsberg4;
1Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany,
2University of Glasgow, Glasgow, UK, 3Boehringer Ingelheim Pharma-
ceuticals Inc, Ridgefield, 4College of Physicians and Surgeons of Colum-
bia University, New York, USA.
Background and aims: Empagliflozin (EMPA), when given as mono-
therapy or as add-on therapy, has consistently reduced HbA1c in patients
with type 2 diabetes (T2DM). Changes in lipid parameters have also been
observed following treatment with EMPA. To test our hypothesis that
these changes in lipids could be partly due to haemoconcentration as a
result of increased urinary volume and subsequent volume contraction
during EMPA treatment, we used pooled data from four 24-week, Phase
III, randomised trials to analyse the contributions of haematocrit (HCT)
changes, a marker of changes in plasma volume, to changes in LDL-
cholesterol (LDL-C), HDL-cholesterol (HDL-C), triglycerides (TG) and
apolipoprotein B (Apo B).
Materials and methods: Patients with T2DM received placebo (PBO),
EMPA 10 mg or EMPA 25 mg for 24 weeks as monotherapy or add-on
therapy (N=2477; mean [SD] age 55.6 [10.2] years, HbA1c 7.99 [0.85]
%, BMI 28.7 [5.5] kg/m2). Total changes in LDL-C, HDL-C, TG and
Apo B, and changes associated with (i.e., potentially contributed to by)
and independent of changes in HCT were assessed using baseline-
adjusted ANCOVA models.
Results: Increases in LDL-C, HDL-C and Apo B, and decreases in TG
were observed with EMPA 10 mg and 25 mg; although changes from
baseline in Apo B and TG at week 24 did not reach statistical significance
with both doses of EMPA and EMPA 25 mg, respectively (table). At
baseline, mean (SE) HCT was 41.9 (0.1) % in the EMPA groups and
41.5 (0.2) % in the PBO group. At week 24, the PBO-corrected adjusted
mean (SE) percentage changes from baseline in HCT were 5.2 (0.3) %
and 5.5 (0.3) % with EMPA 10 mg and EMPA 25 mg, respectively (both
p<0.001). Changes in HCTwere significantly associated with changes in
LDL-C, HDL-C, TG and Apo B (table). The contribution of changes
independent of changes in HCT varied among the lipid parameters; these
were only significant for changes in HDL-C and TG.
Conclusion: Changes in HCT were associated with changes in LDL-C,
HDL-C, TG and Apo B. As the observed increase in HCT may reflect
haemoconcentration, the changes seen in these lipid parameters following
24 weeks’ treatment with EMPA in patients with T2DM may be partly
due to haemoconcentration. Changes in HDL-C and TG that were inde-
pendent of changes in HCTweremore pronounced than for the other lipid
parameters; it may be hypothesised that improvements in metabolic con-
trol following treatment with EMPA in patients in T2DMmay drive HCT-
independent changes in HDL-C and TG.
Clinical Trial Registration Number: NCT01210001, NCT01159600,
NCT01177813
Supported by: Boehringer Ingelheim and Eli Lilly and Company
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Contrasting influences of renal function on blood pressure, body
weight and HbA1c reductions with empagliflozin: pooled analysis of
phase III trials
M.E. Cooper1, D. Cherney2, S. Crowe3, O. Johansen4, S.S. Lund3, H.J.
Woerle3, U.C. Broedl3, T. Hach3;
1Baker IDI Heart and Diabetes Institute, Melbourne, Australia, 2Toronto
General Hospital, University of Toronto, Canada, 3Boehringer Ingelheim
Pharma GmbH & Co. KG, Ingelheim, Germany, 4Boehringer Ingelheim
Norway K.S, Asker, Norway.
Background and aims: The SGLT2 inhibitor empagliflozin (EMPA)
reduces HbA1c, weight and blood pressure (BP) in patients with type 2
diabetes (T2DM). While glucose lowering with EMPA is dependent on
renal function, it is less well understood how chronic kidney disease
(CKD) influences BP modulation and weight loss with EMPA.
Materials and methods: In five randomised Phase III trials, 2286
patients with T2DM received EMPA 25 mg or placebo (PBO) for
24 weeks as monotherapy or add-on therapy. Using pooled data
from these trials, we assessed changes from baseline in systolic
BP (SBP), HbA1c and body weight with EMPA 25 mg vs PBO
in subgroups by baseline eGFR (MDRD equation), adjusting for
differences in baseline SBP (SBP analyses only), baseline body
weight (body weight analyses only), baseline HbA1c, region,
treatment, study, baseline eGFR and treatment by baseline eGFR
interaction between groups.
Results: In patients with normal renal function, or stage 2 or 3 CKD,
EMPA significantly reduced HbA1c, SBP and body weight vs PBO (Ta-
ble). As expected, PBO-corrected HbA1c reductions with EMPA de-
creased with decreasing baseline eGFR and PBO-corrected reductions
in body weight tended to decrease, with decreasing baseline eGFR. In
contrast, PBO-corrected reductions in SBP with EMPA appeared to be
maintained with decreasing baseline eGFR (Table).
Conclusion:Unlike HbA1c and possibly body weight, reductions in SBP
with EMPA in patients with T2DM appeared to be maintained in patients
with lower baseline eGFR, indicating that SBP modulation with EMPA
may involve pathways other than urinary glucose excretion such as di-
uretic effects, weight loss, reduced arterial stiffness or direct vascular
effects.
S360 Diabetologia (2015) 58 (Suppl 1):S1–S607
Clinical Trial Registration Number: NCT01210001, NCT01159600,
NCT01177813, NCT01164501
Supported by: Boehringer Ingelheim and Eli Lilly and Company
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Blood-pressure lowering effects of canagliflozin across a range of
background antihyperglycaemic treatment regimens used in patients
with type 2 diabetes mellitus
J. Ren1, M.R. Weir2, J. Yee3, U. Vijapurkar3, G. Meininger3;
1Janssen Scientific Affairs, LLC, Raritan, 2Division of Nephrology, Uni-
versity ofMaryland School ofMedicine, Baltimore, 3Janssen Research &
Development, LLC, Raritan, USA.
Background and aims: Hypertension is a common comorbidity in pa-
tients with type 2 diabetes mellitus (T2DM) and is an important risk factor
for cardiovascular disease. Therefore, lowering blood pressure in patients
with T2DM without meaningfully increasing heart rate is of benefit in
reducing the risk of cardiovascular complications. In this analysis, the
effect of the sodium glucose co-transporter 2 inhibitor canagliflozin
(CANA) on blood pressure and heart rate was studied in patients with
T2DM across a broad range of antihyperglycemic treatment regimens.
Materials and methods: In four Phase 3 clinical trials (26 weeks) and
two substudies (18 weeks), CANA 100 mg and 300 mg were compared
with: placebo (PBO) as monotherapy; dual therapy (add-on to metformin
[MET] or a sulfonylurea [SU]); triple therapy (add-on to MET + SU or
MET + pioglitazone [PIO]); and add-on to insulin (± other
antihyperglycemic agents). In three active-controlled, Phase 3 clinical
trials (52 weeks), CANAwas compared with sitagliptin (SITA) 100 mg
as dual therapy (add-on to MET; CANA 100 mg and 300 mg) or triple
therapy (add-on to MET + SU; CANA 300 mg only); and to glimepiride
(GLIM) as dual therapy (add-on to MET; CANA 100 mg and 300 mg).
Efficacy and safety endpoints reported here include change from baseline
in systolic blood pressure (SBP), diastolic blood pressure (DBP), and
heart rate. The last observation carried forward imputation method was
employed.
Results: Treatment with CANA 100 mg and 300 mg was associated with
reductions in SBP and DBP compared with PBO, with generally no
increase in mean heart rate across the range of treatment regimens eval-
uated. PBO-subtracted changes (least square [LS] mean change from
baseline and 95% CIs) are reported for each endpoint (Table). When
added to MET, CANA 100 mg and 300 mg provided greater reductions
in SBP and DBP compared with SITA (differences in LS mean change
from baseline [95% CI] with CANA 100 mg and 300 mg, respectively,
vs. SITA: SBP −2.9 mmHg [−4.5, −1.3] and −4.0 mmHg [−5.6, −2.4];
and DBP −1.4 mmHg [−2.4, −0.5] and −1.5 mmHg [−2.5, −0.5]). When
added toMET, CANA 100mg and 300mg provided greater reductions in
SBP and DBP compared with GLIM (differences in LS mean change
from baseline [95% CI] with CANA 100 mg and 300 mg, respectively,
vs. GLIM: SBP −3.5 mmHg [−4.9, −2.1] and −4.8 mmHg [−6.2, −3.4];
andDBP −1.7 mmHg [−2.6,−0.8] and −2.4mmHg [−3.3,−1.5]). As add-
on to MET + SU, CANA 300 mg lowered SBP (−5.9 mmHg [−7.6,
−4.2]) and DBP (−2.7 mmHg [−3.8, −1.7]) compared with SITA. No
clinically meaningful differences in heart rate were observed with CANA
across the studies.
Conclusion: Compared with placebo and commonly used
antihyperglycemic agents, CANA reduced SBP and DBP without chang-
ing heart rate in patients with T2DM whether used alone, in combination
with oral antihyperglycemic agents, or with insulin.
Clinical Trial Registration Number: NCT01032629; NCT01106677;
NCT00968812; NCT01137812; NCT01106625; NCT01081834;
NCT01106690
Supported by: Janssen Scientific Affairs, LLC
753
The effects of empagliflozin on blood pressure and markers of arte-
rial stiffness and vascular resistance by subgroups of age, sex and
degree of hypertension in type 2 diabetes
O. Johansen1, I. Tikkanen2, C.P. Cannon3, S. Crowe4, H.-J. Woerle5,
U.C. Broedl5, R.J. Chilton6;
1Medical Department, Boehringer-Ingelheim, Asker, Norway, 2Medical
Department, Helsinki University Central Hospital and Minerva Institute
forMedical Research, Finland, 3Harvard Clinical Research Institute, Bos-
ton, USA, 4Boehringer-Ingelheim, 5Therapeutic Area Metabolism,
Boehringer-Ingelheim, Ingelheim, Germany, 6University of Texas Health
Science Center, San Antonio, USA.
Background and aims: Empagliflozin improves glycemia and reduces
weight, blood pressure as well as central and peripheral hemodynamic
parameters. Differential effects of empagliflozin on this by age, sex and
degree of hypertension are unknown. We assessed the hypothesis that
empagliflozin would reduce blood pressure (BP), pulse pressure (PP), a
validated surrogate marker of arterial stiffness being determined by the
cardiac output and the stiffness of elastic central arteries like the aorta and
wave reflection (PP=systolic BP - diastolic BP), and mean arterial pres-
sure (MAP), a measure reflecting the cardiac cycle and is determined by
the cardiac output, systemic vascular resistance, and central venous pres-
sure (MAP = ([2 × diastolic BP] + systolic BP)/3) across these subgroups.
It was also postulated that greater reductions would be seen in those with
highest baseline systolic BP and advanced age.
Materials and methods: Overall 2477 patients were analyzed from four
24-week phase III randomized trials (on no, one or two background
glucose lowering drugs) of empagliflozin 10 mg or 25 mg (n=1652)
versus placebo (n=825). At screening, patients in these trials had type 2
diabetes, HbA1c ≥7% and ≤10%, a body mass index (BMI) ≤45 kg/m2
and were on a diet and exercise regimen.
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Results: Mean ± SD age was 55.6±10.2 years, HbA1c 7.99±0.85%,
systolic BP/diastolic BP 129.1±15.0/78.3±8.8 mmHg, heart rate 74.2±
9.6 bpm and BMI 28.7±5.5 m/kg2 for the overall population and demo-
graphics and baseline characteristics were generally balanced between
treatment groups. HbA1c was significantly reduced with empagliflozin
(pooled) compared to placebo at week 24 (adjusted mean [SE]):-0.65%
(0.03), p<0.001). The overall adjusted mean difference vs placebo in
change from baseline in systolic BP at week 24 was -3.6 mmHg (95%
CI -4.5, -2.7; p<0.001) and in DBPwas -1.3 mmHg (95%CI -1.9, -0.8; p
<0.001) and change from baseline in heart rate vs placebo was -
0.8 bpm(95% CI -1.4, -0.2; p=0.012). Systolic BP, diastolic BP, PP and
MAP were reduced in all subgroups. For systolic BP and MAP, greater
reductions were observed in those with highest systolic BP whereas PP
was reduced most in those with advanced age (Table).
Conclusion: Reductions in BP and arterial stiffness are two of the effects
of SGLT2 inhibitors that might ameliorate cardiovascular risk in patients
with type 2 diabetes. EMPA-REG OUTCOME™, reporting 2015, will
evaluate if these benefits will translate into CV risk reduction.
Supported by: Boehringer-Ingelheim and Eli Lilly
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No increased risk of cardiovascular events with dapagliflozin in el-
derly patients with type 2 diabetes mellitus, cardiovascular disease
and hypertension
I. Gause-Nilsson, C. Sonesson, P.A. Johansson, E. Johnsson;
AstraZeneca, Mölndal, Sweden.
Background and aims: Dapagliflozin (DAPA) reduces plasma glucose
in patients with type 2 diabetes mellitus (T2DM) by inhibiting renal
glucose reabsorption, leading to increased glucosuria. DAPA is also as-
sociated with blood pressure and weight reduction. In a previous pooled
analysis of 21 phase 2b/3 trials in T2DM (≤4 years), the hazard ratio (HR)
for the pre-specified primary endpoint of major adverse cardiac events
(MACE: cardiovascular [CV] death, myocardial infarction, and stroke)
plus unstable angina for DAPA (all doses [2.5, 5, 10, 20 and 50 mg]; N=
5936) versus comparator (N=3403) was 0.79 (95% CI: 0.58, 1.07). The
HR for MACE was 0.77 (95% CI: 0.54, 1.10).
Materials and methods: This post hoc pooled analysis of the data
assessed CV safety in a high-risk subgroup of elderly (≥65 years) patients
with a history of CV disease and hypertension (n=707 for DAPA; n=556
for comparator).
Results: Baseline characteristics were similar between treatment groups.
For MACE, the HR was 0.92 (95% CI: 0.51, 1.64). For MACE plus
unstable angina, the HRwas 0.82 (0.50, 1.37). Additional HRs are shown
in the figure. The overall adverse events profile was similar between
treatment groups.
Conclusion: These analyses suggest that DAPA is not associated with
increased CV risk in elderly patients with T2DM, comorbid CV disease
and hypertension. The impact of DAPA on CVevents is being prospec-
tively tested in the ongoing DECLARE-TIMI58 study.
S362 Diabetologia (2015) 58 (Suppl 1):S1–S607
Clinical Trial Registration Number: 00263276; 00357370; 00528372;
00528879; 00643851; 00663260; 00683878; 00736879; 00859898;
00976495; 00831779; 01095653; 00660907; 00680745; 00972244;
00673231; 01294423; 00984867; 00855166; 01031680; 01042977
Supported by: AstraZeneca
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Safety and tolerability of combinations of empagliflozin/linagliptin
for 52 weeks in subjects with type 2 diabetes
S. Kohler1, S. Patel2, R.A. DeFronzo3, A. Lewin4, D. Liu5, R. Kaste5, H.-
J. Woerle6, U. Broedl6;
1Boehringer IngelheimLtd., Ingelheim, Germany, 2Boehringer Ingelheim
Ltd., Bracknell, UK, 3University of Texas Health Sciences, San Antonio,
4National Research Institute, Los Angeles, 5Boehringer Ingelheim Phar-
maceuticals Inc., Ridgefield, USA, 6Boehringer Ingelheim Pharma
GmbH & Co. KG, Ingelheim, Germany.
Background and aims: Two 52-week Phase III studies evaluated the
efficacy and safety of once daily combinations of empagliflozin/
linagliptin (EMPA/LINA) as monotherapy or add-on to metformin in
subjects with type 2 diabetes (T2DM). Using pooled data from these
trials, we assessed the safety and tolerability of EMPA/LINA.
Materials and methods: A total of 1363 subjects were treated with
EMPA 25 mg/LINA 5 mg (n=273), EMPA 10 mg/LINA 5 mg (n=
272), EMPA 25 mg (n=276), EMPA 10 mg (n=275), or LINA 5 mg
(n=267). Adverse events (AEs) were assessed descriptively in subjects
who took ≥1 dose of study drug.
Results: Total exposure was 251, 255, 256, 249, and 243 patient-years in
the EMPA 25 mg/LINA 5 mg, EMPA 10 mg/LINA 5 mg, EMPA 25 mg,
EMPA 10 mg, and LINA 5 mg groups, respectively. The percentage of
subjects with any AE(s) was similar across groups (Table). The percent-
age of subjects with confirmed hypoglycaemic AEs (plasma glucose
≤70 mg/dL and/or requiring assistance) was low in all groups (1.1%-
2.2%); none required assistance. Events consistent with urinary tract in-
fection were reported in similar percentages of subjects in all groups.
Events consistent with genital infection were reported in higher percent-
ages of subjects on EMPA/LINA or EMPA than LINA 5 mg, and in a
greater proportion of female than male subjects.
Conclusion: EMPA/LINA as monotherapy or add-on to metformin for
52 weeks was well tolerated in subjects with T2DM, with safety profiles
similar to individual components, including a low risk of hypoglycaemia.
Clinical Trial Registration Number: NCT01422876
Supported by: Boehringer Ingelheim and Eli Lilly and Company.
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Efficacy and safety of canagliflozin in patients with type 2 diabetes
mellitus living in hot climates
M. John1, R. Violante2, C. Deerochanawong3, U. Vijapurkar4, W.
Canovatchel4, G. Hamilton5;
1Health and Research Centre, Trivandrum, Kerala, India, 2Centro de
Estudios de Investigacíon Metabólicos y Cardiovasculares S.C., Tampi-
co, Mexico, 3Rajavithi Hospital, Bangkok, Thailand, 4Janssen Research
& Development, LLC, Raritan, USA, 5Janssen-Cilag Ltd, High
Wycombe, UK.
Background and aims: In hot climates, patients with type 2 diabetes
mellitus (T2DM) treated with canagliflozin (CANA), an SGLT2 inhibitor,
may be at increased risk for adverse events (AEs; eg, dehydration). This post
hoc analysis assessed the efficacy and safety of CANA in a pooled popula-
tion of patients living in hot climates (ie, countries between the Tropics of
Cancer and Capricorn: Colombia, Costa Rica, Guatemala, Hong Kong,
India, Malaysia, Mexico, Peru, Philippines, Singapore, and Thailand).
Materials and methods: This analysis pooled data from 4 randomised,
placebo (PBO)-controlled, Phase 3 studies. Patients (N=611; mean age,
53.3 y; HbA1c, 8.0%; BMI, 28.9 kg/m2) received CANA 100 or 300 mg
or PBO once daily for 26 weeks.
Results:Relative to PBO,CANA100 and 300mg loweredHbA1c (-0.88%
and -0.98%), body weight (-2.2% and -3.0%), and systolic BP (-3.5 and -
5.8 mmHg) over 26 weeks. Overall AE incidence was 58.6%, 61.1%, and
57.1% with CANA 100 and 300 mg and PBO, with a similar safety profile
as the overall population (Table). The incidence of genital mycotic infections
in men and women and osmotic diuresis-related AEs was higher with both
CANA doses versus PBO.While 3.6% of patients in the hot climate dataset
were at high risk for volume-related AEs (eGFR <60 mL/min/1.73 m2, on
loop diuretic, and/or aged ≥75 y), rates of theseAEswere low across groups.
Consistent with the overall population, documented hypoglycaemia rates
were low but higher with CANA 100 and 300 mg versus PBO in patients
not on sulphonylurea (SU; n=535; 6.5%, 4.0%, 1.5%), with a higher inci-
dence across groups in those on SU (n=76; 39.1%, 18.5%, 19.2%).
Conclusion: In summary, CANA reduced HbA1c, body weight, and BP,
and was generally well tolerated in patients with T2DM living in hot
climates over 26 weeks.
Clinical Trial Registration Number: NCT01081834, NCT01106677,
NCT01106625, NCT01106690
Supported by: Janssen Research & Development, LLC
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Assessment of dehydration parameters with dapagliflozin in patients
with type 2 diabetes mellitus during Ramadan fasting month
N.Kamaruddin1,W.Wan Seman2, N. Kori1, S. Rajoo2, N.MohdNoor2,
N. Mohd Noor2, N. Mustafa1;
1Department of Medicine, University Kebangsaan Malaysia Medical
Centre, Cheras, Kuala Lumpur, 2Department ofMedicine, Putrajaya Hos-
pital, Wilayah Persekutuan Putrajaya, Malaysia.
Background and aims:The population-based Epidemiology of Diabetes
and Ramadan (EPIDIAR) study showed that 79% of the 12,243 people in
their study fasts during Ramadan.4,8 There will be changes in glycaemic,
metabolic profile and biochemistry parameters among patients who fasts
during Ramadan. Dapagliflozin is a novel class of glucose-loweringmed-
ications which acts via blocking the sodium-glucose cotransporter (SGLT
2) in the proximal renal tubule and leads to urinary glucose excretion. We
assessed the dehydration parameters in Type 2 diabetic patienst on either
Dapagliflozin or sulphonylurea during Ramadan fasting month.
Materials and methods: In this 12-weeks, randomized, open-label, two-
arm parallel group study, 119 patients with T2DM on sulphonylurea(SU)
and metformin therapy randomised to either switch to Dapagliflozin
10 mg od(n=58) or remain on pre-study therapy sulphonylurea(n=52).
The primary endpoint was to assess the proportion of patient with dehy-
dration, defined as loss of 1.8% of body weight within 13 hours period of
fasting daily; which is weight difference between after sunirise(‘sahur’)
and before sunset (‘iftar’). Other assessment of dehydration included 4
parameters; medical history questions (feeling thirsty, recent fever, recent
vomiting and diarrhoea, vigorous exercise and frequency of passing
urine), physical examination parameters (dry mucus membrane, dry
tongue, reduce skin turgor and altered mental status), blood biochemistry
(blood urea, serum creatinine, serum sodium, plasma osmolarity, uric acid
and blood ketone) and urine biochemistry analysis (urine osmolarity,
urine sodium and urine specific gravity). Data analysed via IBM SPSS
Statistics Version22.
Results: There is no difference in the proportion of patient with dehydra-
tion 73.1%(n=38) vs 81.6%(n=38); p=0.258, defined as 1.8% weight
low within 13 hours of fasting in both Dapagliflozin and sulphonylurea
group. More patients in the Dapagliflozin group, 43.1% (n=25) vs 23.1%
(n=12); p=0.026 complained of thirst sensation. Other parameters such
as BMI, postural hypotension, changes in standing heart rate, physical
examinations were similar in both groups. There is higher mean blood
ketone (0.2 (0.20) versus 0.1(0.10)mmol/L; p=0.002 ) and mean
haematocrit level ( 41.6(3.60)% versus 40.0(4.70)%;p=0.009) in
Dapagliflozin group versus sulphonylurea group respectively. There is a
significantly higher mean urine osmolarity (805(116.23) vs 652(220.19)
mOsm/L; p=0.001) and a significantly lower mean urine sodium
(85(43.0) vs 120(50) mmol/24 hr; p<0.005) in Dapagliflozin group com-
pared to sulphonylurea group, at Week 6 and Week 12. Adjustment of
1.8% of weight loss to age, gender, HbA1c, urine osmolarity and blood
ketone did not show any significant correlation via binary logistic regres-
sion analysis.
Conclusion: Clinical dehydration assessment of 1.8% loss of body
weight within 13 hours of fasting, physical examination and blood bio-
chemistry (except blood ketone and haematocrit) parameters were similar
between both groups, postulating that Dapagliflozin does not pose a
higher risk of dehydration in Ramadan fasting month. In conclusion,
Dapagliflozin is well-tolerated in diabetic patients fasting during Rama-
dan month without an increase risk of dehydration.
Supported by: AstraZeneca
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Incidence of genital mycotic infections decrease over time in patients
with type 2 diabetes mellitus treated with canagliflozin over 2 years
M. Davies1, J.D. Sobel2, R.M. Goldenberg3, K. Khunti4, U. Vijapurkar5,
G. Meininger5;
1Janssen ScientificAffairs, LLC,Raritan, 2Harper UniversityHospital, Detroit,
USA, 3LMC Diabetes and Endocrinology, Thornhill, Canada, 4University of
Leicester, UK, 5Janssen Research & Development, LLC, Raritan, USA.
Background and aims: Patients with type 2 diabetes mellitus (T2DM)
are at increased risk of genital mycotic infections (GMIs), and those with
poorly controlled diabetes have higher risks. Sodium glucose co-
transporter 2 inhibitors, such as canagliflozin (CANA), improve glycemic
control by inhibiting renal glucose reabsorption and increasing urinary
glucose excretion, a mechanism of action associated with an increased
incidence of GMIs.
Materials and methods: The incidence of GMIs was evaluated over
2 years in a pooled analysis of 2 randomized clinical studies including
2,164 patients with T2DM; patients received CANA 100 mg or 300 mg,
or glimepiride (GLIM) in Study 1 or placebo (PBO) in Study 2. The
incidence of GMIs was monitored and evaluated overall, and at 3-
month intervals.
Results: The cumulative incidence of GMIs was higher with CANA
100 mg and 300 mg versus GLIM/PBO in both females (17.2% and
16.5% vs 3.2%) andmales (8.2% and 9.7% vs 1.7%). The highest incidence
of GMIs occurred in the first 3 months of treatment in both females and
males, and then declinedwith time (Figure). GMIs were characterized by the
investigators as generally mild to moderate in intensity and responded to
standard treatment. In both CANA-treated groups, around 1% of patients (a
total of 4 men and 6 women) discontinued treatment due to GMIs.
Conclusion: In summary, in patients with T2DM, GMIs associated with
CANA occurred early in treatment, were mild to moderate in intensity,
and decreased over time.
S364 Diabetologia (2015) 58 (Suppl 1):S1–S607
Clinical Trial Registration Number: NCT01106651; NCT00968812
Supported by: Janssen Scientific Affairs, LLC
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Genital infections and relation to body mass index in patients with
type 2 diabetes mellitus treated with dapagliflozin
G. Rudofsky1, I. Baldycheva2, E. Johnsson3, K. Rohwedder4;
1Kantonsspital Olten, Olten, Switzerland, 2AstraZeneca, Gaithersburg,
USA, 3AstraZeneca, Mölndal, Sweden, 4AstraZeneca, Wedel, Germany.
Background and aims: Treatment with dapagliflozin (DAPA), a highly
selective sodium glucose co-transporter 2 (SGLT2) inhibitor, increases
glucosuria and reduces hyperglycaemia in patients with type 2 diabetes
mellitus (T2DM). Genital infections are a common side effect of treat-
ment with SGLT2 inhibitors, likely resulting from this increase in
glucosuria. Clinical trials have reported a greater frequency of vulvovag-
initis, balanitis and related genital infections with DAPA versus placebo.
In addition, patients with T2DM are generally at increased risk of genital
infections. Because obesity is a potential risk factor for some infections, it
could be speculated that patients with a higher body weight are at in-
creased risk of genital infections. DAPA has been shown to promote
modest weight loss and may therefore be a useful option when it is
desirable to avoid weight gain or induce weight loss, particularly in over-
weight or obese patients. This pooled analysis investigated whether there
was a relationship between baseline body mass index (BMI) and the
frequency of genital infections in patients with T2DM treated with
DAPA, in order to determine whether overweight or obese patients have
a clinically important increased susceptibility to this adverse event (AE).
Materials and methods: Data were pooled from 13 studies of up to
24 weeks’ duration comprising 2,360 patients treated with DAPA
10 mg and 2,295 patients treated with placebo. The frequency of genital
infections was compared between three BMI subgroups (<30, ≥30 to <35
and ≥35 kg/m2).
Results: Genital infection AEs were reported in 130 (5.5%) patients
receiving DAPA and 14 (0.6%) patients receiving placebo; none of which
were serious. Baseline HbA1c was similar in DAPA-treated patients with
and without a genital infection (8.12 and 8.18%, respectively). AEs of
genital infections were more common in females than males treated with
DAPA (64.6 and 35.4%, respectively). The frequency of genital infection
AEs in DAPA-treated patients was similar between the BMI subgroups
(4.3% [38/882], 5.9% [47/796], 6.6% [45/682] in patients with BMI <30,
≥30 to <35 and ≥35 kg/m2, respectively). Discontinuations due to genital
infections were low in DAPA-treated patients (N=5) and were similar in
all BMI subgroups (0.2% [2/882], 0.1% [1/796], 0.3% [2/682] in patients
with BMI <30, ≥30 to <35 and ≥35 kg/m2, respectively). There were
several limitations to this post hoc pooled analysis, including the low
numbers of cases of genital infection, the short duration of the analysis
and the exclusion of patients with a BMI of >45 kg/m2.
Conclusion: The frequency of genital infection was low in patients with
T2DM treated with DAPA 10 mg. Although these findings were
hypothesis-generating only, there was a trend towards a greater frequency
of genital infections in patients with a higher baseline BMI. This observed
trend is unlikely to be clinically relevant and there is currently no need to
adjust advice about the risk of genital infections in overweight or obese
patients versus lean patients.
Clinical Trial Registration Number: NCT00263276, NCT00972244,
NCT00357370, NCT00528372, NCT00528879, NCT00855166,
NCT00859898, NCT00680745, NCT00683878, NCT00984867,
NCT00673231, NCT01031680, NCT01042977
Supported by: AstraZeneca
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Low carbohydrate diet and SGLT-2 inhibitors dissimilarly influ-
enced on body weight and adiposity in normal mice
K.K. Atageldiyeva, Y. Fujita, T. Yanagimachi, J. Honjo, A. Abiko, Y.
Takiyama, Y. Makino, M. Haneda;
Devision of Metabolism and Biosystemic Science, Department of Med-
icine, Asahikawa Medical University, Japan.
Background and aims: Carbohydrate is one of major energy sources,
but its excess intake can inducemetabolic disorders including obesity and
diabetes. Low-carbohydrate diet (LCHD) has been favourably indicated
to prevent obesity, dyslipidaemia and hyperglycaemiamostly in the short-
term studies. While, a new class of glucose lowering agents, sodium-
glucose cotransporter-2 inhibitor (SGLT-2i), exerts its therapeutic activity
independently on insulin secretion by facilitating glucose excretion
through the kidneys. SGLT-2i improves glycaemic control and potentially
promotes body weight reduction. However, it is still obscure whether
dietary carbohydrate-restriction via LCHD functions similarly to urinary
glucose disposal by SGLT-2 inhibitors. Moreover, it is not clear whether
LCHD is still beneficial to long-term metabolism or not. In current study,
we investigated how differently LCHD and SGLT-2i can influence on
metabolic changes including body weight, adiposity and glycaemia using
normal mice.
Materials and methods:We conducted an eight-week study using non-
diabetic C57Bl/6 mice. Mice were fed either LCHD (carbohydrate : pro-
tein : fat (C:P:F)=16:40:44%cal) or normal diet (ND, C:P:F=
68:20:12%cal) ad libitum and treated with either SGLT-2i (ipragliflozin
3 mg/kg) or saline by daily oral gavage. Mice were randomized into four
groups (each n=5~10): LC group fed with LCHD, Ipra group treated
with ipragliflozin, LC + Ipra group combined with LCHD and
ipragliflozin and C group as controls. To evaluate metabolic changes,
we monitored body weight and glycaemia. We also compared glucose
excursions, glucose-stimulated insulin secretion and insulin sensitivity
among the groups by 2 g/kg OGTT or intraperitoneal insulin tolerance
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test (0.6 U/kg). Then, we conducted the calorie-adjusted pair-feeding (PF)
study, where mice were similarly divided to four groups: LCPF, IpraPF,
LC + IpraPF, controlPF, respectively.
Results: There was no significant difference in non-fasted glucose levels
among the groups fed ad libitum. However, not LCHD but SGLT-2i
treatment reduced glucose excursion after OGTT compared to controls
(AUC glucose, LC: 1698±77.04, Ipra*: 1190±62C: 1730±102mmol/l x
min, * p<0.0001 vs C). Both LCHD and SGTL-2i treatment enhanced
calorie-intake compared to controls (p<0.03), whereas LCHD unexpect-
edly increased bodyweight (LC*,**: 27.0±0.9, Ipra: 23.9±0.5, LC+Ipra:
22.9±0.7, C: 23.6±0.4 g, *p<0.005 vs C, **p<0.005 vs Ipra) and epi-
didymal fat mass (LC*,**: 0.90±0.09, Ipra: 0.34±0.01, LC+Ipra: 0.43±
0.01, C: 0.38±0.02 g, *p<0.0001 vs C, **p<0.0001 vs Ipra). Further-
more, insulin tolerance test indicated that LCHD induced insulin resis-
tance in mice treated with SGLT-2i. (LC+Ipra vs Ipra, p<0.05). In con-
trast, glucose-stimulated insulin secretion was increased in LC to com-
pensate glucose excursions. Finally, pair-feeding ameliorates LCHD-
induced body weight gain, fat deposition and insulin resistance by
calorie-adjustment to ND
Conclusion: Collectively, our results suggest that LCHD without calorie
restrictionmay unexpectedly induce insulin resistance and obesity in non-
diabetic mice.
Supported by: Bolashak International shcolarship
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Hypersensitivity events with dapagliflozin: a pooled analysis
A. Mellander, M. Billger, K. Johnsson, E. Johnsson;
AstraZeneca Pharmaceuticals LP, Mölndal, Sweden.
Background and aims: In patients with type 2 diabetes mellitus
dapagliflozin (DAPA) improves glycaemic control, is generally well tol-
erated, and has an adverse event (AE) profile typically related to its
mechanism of action. Hypersensitivity events have been reported in some
patients with sodium-glucose co-transporter 2 inhibitors, including a re-
port of dermatological AEs in Japan.
Materials and methods: We therefore investigated the frequency and
characteristics of hypersensitivity AEs pooled across 21 phase 2/3
comparator-controlled DAPA trials, including a subanalysis of Asian
patients.
Results: In the total population, AEs and serious AEs (SAEs) of hyper-
sensitivity were infrequent and reported in a similar proportion of patients
with DAPA or comparator (Table); the most common events were rash,
eczema, dermatitis, and urticaria. Few patients discontinued as a result of
hypersensitivity AEs. In patients of Asian descent, a lower frequency of
hypersensitivity AEs was observed with DAPA vs comparator. In the
placebo (PBO)-controlled pools hypersensitivity AEs were slightly more
frequent with DAPA vs PBO across the overall population and less fre-
quent with DAPA vs PBO in Asian patients.
Conclusion: In conclusion, hypersensitivity events with DAPAwere in-
frequent across the clinical programme and were similar between PBO
and comparator. These events rarely led to discontinuation of DAPA and
were not more frequent in Asian patients.
Supported by: AstraZeneca
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Urinary glucose excretion and insulin to carbohydrate ratio to assess
insulin dose adjustments in type 1 diabetes mellitus patients treated
with dapagliflozin
L. Hansen1, C. Sonesson2, F. Thoren2, A. Ptaszynska1, N. Iqbal1, E.
Johnsson2;
1Bristol-Myers Squibb, Princeton, USA, 2AstraZeneca, Mölndal,
Sweden.
Background and aims: Dapagliflozin is a selective sodium-glucose
co-transporter 2 inhibitor that lowers HbA1c, body weight and
systolic blood pressure in patients with type 2 diabetes mellitus
(T2DM). Dapagliflozin has previously been shown to be safe and
well tolerated in a 14-day Phase 2 study in patients with type 1
diabetes mellitus (T1DM).
Materials and methods:We hypothesised that carbohydrate (CHO)
loss, counted as 24 hour urinary glucose excretion (UGE), after
7 days of dapagliflozin treatment in patients with T1DM (Phase 2
data) or as UGE estimated from a dapagliflozin dose-response
model, could be used with the calculated insulin to CHO ratio
(I/C) to assess insulin dose adjustments needed upon initiation of
dapagliflozin treatment. Data on total daily insulin dose (TDD)
were obtained from the Phase 2 study, or arbitrarily chosen to
represent “low” or “high” insulin dose. The ‘450 rule’ i.e. I/C
(for adults on short acting insulin)=450 / TDD was applied to
derive I/C. TDD adjustment was calculated as UGE:I/C.
Results: Empirically, there was agreement between observed mean
TDD adjustments (Phase 2 data) and I/C-calculated mean TDD
adjustments using either observed mean UGE (Phase 2 data) or
estimated mean UGE from the dapagliflozin dose-response model
(Table).
Conclusion:UGE and I/C can be used to assess mean reductions
in TDD upon initiation of dapagliflozin. Further assessments are
needed to evaluate the impact of patient characteristics such as
eGFR and average plasma glucose on individual TDD adjust-
ments.
Clinical Trial Registration Number: NCT01498185
Supported by: AstraZeneca
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Empagliflozin decreases glucose exposure and variability in patients
with type 1 diabetes: continuous glucose monitoring data (EASE-1)
S. Kaspers1, S. Famulla2, T.R. Pieber3, J. Eilbracht4, D. Neubacher5, N.
Soleymanlou1, U.C. Broedl5;
1Boehringer Ingelheim Canada Ltd./Ltee, Burlington, Canada, 2Profil,
Neuss, Germany, 3Medical University of Graz, Austria, 4Boehringer
Ingelheim Pharma GmbH & Co. KG, Biberach, 5Boehringer Ingelheim
Pharma GmbH & Co. KG, Ingelheim, Germany.
Background and aims: Empagliflozin (EMPA) lowers blood glucose by
reducing renal glucose reabsorption via a mechanism independent of the
action of insulin. In the EASE-1 study, we characterised the effects of
EMPA as adjunct to insulin on glucose exposure in patients with type 1
diabetes, by analysing glucose patterns via continuous glucose monitor-
ing (CGM).
Materials andmethods: In this Phase II, double-blind trial, patients
with type 1 diabetes were randomised to placebo (PBO; n=19),
EMPA 2.5 mg (n=19), EMPA 10 mg(n=19) or EMPA 25 mg (n=
18) as adjunct to insulin for 4 weeks. Insulin dose was to be kept
as stable as possible for the first 7 days and was freely adjustable
thereafter. Markers of glucose exposure and variability were
assessed from 7-day blinded CGM periods.
Results: At week 1, all EMPA doses decreased total glucose ex-
posure (AUC) and increased time in the glucose range of
>70 mg/dL to ≤180 mg/dL vs PBO; results were sustained to
week 4 with EMPA 25 mg (Table). A similar pattern was ob-
served in nocturnal glucose exposure (00:00-05:59 h). Hours/day
with glucose ≤70 mg/dL increased with EMPA 10 mg and 25 mg
vs PBO at week 1 but there were no significant differences with
EMPA vs PBO at week 4. Hours/day with glucose ≤54 mg/dL
were not increased with EMPA vs PBO. All EMPA doses signif-
icantly reduced glucose variability, as measured by interquartile
range (IQR [Table]; ambulatory glucose profiling) and mean am-
plitude of glucose excursions (MAGE), vs PBO at weeks 1 and 4.
Conclusion: These CGM data show that EMPA as adjunct to in-
sulin therapy decreased glucose exposure and variability and in-
creased time in glucose target range over 4 weeks in patients with
type 1 diabetes. EMPA is not yet approved for use in patients
with type 1 diabetes.
Clinical Trial Registration Number: NCT01969747
Supported by: Boehringer Ingelheim and Eli Lilly and Company.
Diabetologia (2015) 58 (Suppl 1):S1–S607 S367
764
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces glucose
variability in type 1 diabetes mellitus in a randomised, placebo-con-
trolled, double-blind study
P.S. Strumph1, A.T. Sands1, J. Rosenstock2, P. Lapuerta1, B.W. Bode3,
S.K. Garg4, J.B. Buse5, P. Banks1, R. Heptulla6, M. Rendell7, W. Cefalu8,
B. Zambrowicz1;
1Lexicon Pharmaceuticals, Inc., The Woodlands, 2Dallas Diabetes and
Endocrine Center, 3Atlanta Diabetes Association, 4University of Colora-
do Denver/Barbara Davis Center for Childhood Diabetes, Aurora, 5Uni-
versity of North Carolina Diabetes Care Center, Chapel Hill, 6Albert
Einstein College of Medicine/Montefiore Medical Center, Bronx,
7Creighton Diabetes Center, Omaha, 8Pennington Biomedical Research
Center, Baton Rouge, USA.
Background and aims: Sotagliflozin (LX4211) is a dual inhibitor of
sodium-glucose cotransporters SGLT1 and SGLT2. Inhibition of SGLT1,
the major intestinal glucose transporter, reduces glucose absorption in the
gastrointestinal tract, and SGLT2 inhibition reduces renal glucose reab-
sorption. We hypothesized that sotagliflozin would increase “time in glu-
cose range” by decreasing postprandial hyperglycemia and glycemic
variability.
Materials and methods: This 29-day study evaluated 33 subjects with
T1D (age 21-57 years, diabetes duration 3-42 years) with screening A1C
7.0%-9.0%, randomized to double-blind treatment with sotagliflozin
400 mg or placebo 1×/day. All subjects wore masked continuous glucose
monitors (CGM).
Results: All 33 patients completed the study. Raw means are displayed;
p-values for change from baseline and between group effects are based on
least squares means.
Conclusion: Sotagliflozin, a next generation SGLT inhibitor, significant-
ly improved time in glucose range as measured by the following CGM
glucose indices: Mean daily glucose, % time spent between 70 and
180mg/dL, >180 mg/dL, and >250mg/dL, and glucose variability (mean
standard deviation, MAGE, and HBGI). Sotagliflozin as an adjunctive
treatment to insulin showed improved glucose control and glycemic var-
iability. Larger studies of longer duration are needed to confirm these
findings.
Clinical Trial Registration Number: NCT01742208
Supported by: The Robert and Janice McNair Foundation, Houston, TX,
USA
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Efficacy and safety of dapagliflozin in patients with type 2 diabetes
mellitus and concomitant heart failure
M. Kosiborod1, I. Gause-Nilsson2, C. Sonesson2, E. Johnsson2;
1Saint Luke's Mid America Heart Institute, Kansas City, USA,
2AstraZeneca, Mölndal, Sweden.
Background and aims: Over 40% of patients with heart failure (HF)
have type 2 diabetes mellitus (T2DM); a number that is expected to
increase due to rising prevalence of both conditions. Yet, remarkably little
is known about the optimal glycaemic management in this patient group.
Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor, pro-
motes renal glucose excretion, causing osmotic diuresis, weight loss and
decreased blood pressure (BP). These effects may provide a unique ben-
efit to patients with coexisting T2DM and HF, but have not been formally
evaluated in this group.
Materials and methods:We pooled data from 5 clinical trials, selecting
patients randomised to DAPA 10 mg or placebo that had a documented
history of HF. Using longitudinal repeated-measures models, we exam-
ined the effects of DAPAvs placebo on HbA1c, weight and BP for up to
1 year in patients with T2DM and HF. Safety was also assessed.
Results: In total, 171 patients received DAPA 10 mg and 149 patients
received placebo across the 5 studies (age 64 years, T2DM duration
13.2 years, HbA1c 8.18%, ~50% with New York Heart Association
[NYHA] class ≥2 HF). Patients receiving DAPA experienced clinically
meaningful placebo-adjusted declines in HbA1c (−0.55%; 95%CI −0.80,
−0.30), weight (−2.67 kg; 95% CI −3.88, −1.47) and systolic BP
(−2.1 mmHg; 95% CI −5.68, 1.57) over 52 weeks; there was no change
in heart rate in either group. The rates of orthostatic hypotension, syncope
and hypoglycaemia were similar between the two groups. More patients
on DAPAvs placebo had a decrease in creatinine clearance (11 [6.4%] vs
2 [1.3%]) and an increase in creatinine (7 [4.1%] vs 2 [1.3%]); however,
absolute difference in estimated GFR from baseline to 50 weeks was
minimal (−2.6 vs −1.4 mL/min/1.73 m2 with DAPA vs placebo).
Conclusion:Treatment with DAPA 10mg vs placebo produced clinically
meaningful reductions in HbA1c, weight and systolic BP in patients with
T2DM and HF, and was well tolerated. The weight and BP effects of
DAPA may lead to improvement in HF-related symptoms in this patient
population, which should be further investigated in prospective studies.
Clinical Trial Registration Number: NCT00663260, NCT00680745,
NCT00673231, NCT01031680, NCT01042977
Supported by: AstraZeneca
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Consistent weight changes irrespective of baseline HbA1c with the
combination of empagliflozin/linagliptin in subjects with type 2
diabetes
C. Lee1, A.H. Barnett2, R.A. DeFronzo3, A. Lewin4, S. Patel5, D. Liu6, R.
Kaste6, U. Broedl1;
1Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany,
2Diabetes Centre, Heart of England NHS Foundation Trust and Univer-
sity of Birmingham, UK, 3University of Texas Health Sciences, San
Antonio, 4National Research Institute, Los Angeles, USA, 5Boehringer
Ingelheim Ltd., Berkshire, UK, 6Boehringer Ingelheim Pharmaceuticals
Inc., Ridgefield, USA.
Background and aims: Two Phase III studies evaluated the efficacy and
safety of once daily combinations of empagliflozin/linagliptin
(EMPA/LINA) as initial therapy or add-on to metformin (MET) in sub-
jects with type 2 diabetes (T2DM) for 52 weeks. Change from baseline in
weight at week 24 was a key secondary endpoint in both studies. In both
studies, EMPA/LINA led to significant reductions in weight vs LINA but
not vs EMPA atweek 24. In pre-specified subgroup analyses, we assessed
the influence of baseline HbA1c on weight changes at week 24 with
EMPA/LINA vs the individual components.
Materials and methods: Changes from baseline in weight at week 24
were analysed by subgroups of baseline HbA1c (<8.5% and ≥8.5%) in
subjects randomised to EMPA 25 mg/LINA 5 mg, EMPA 10 mg/LINA
5 mg, EMPA 25mg, EMPA 10 mg, or LINA 5 mg as initial therapy or as
add-on to stable-dose MET.
Results: EMPA/LINA significantly reduced weight vs LINA in both
HbA1c subgroups as add-on to MET but only in subjects with HbA1c
<8.5% as initial therapy (Table). There were no significant differences in
changes in weight with EMPA/LINA vs EMPA as initial therapy or add-
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on toMET in either HbA1c subgroup. The treatment and baseline HbA1c
interaction was not significant, suggesting no differential treatment effect
across HbA1c subgroups (p=0.308 and p=0.649 for interaction when
EMPA/LINA was given as initial therapy and add-on to MET,
respectively).
Conclusion: The degree of glycemic control at baseline had no effect on
weight changes with EMPA/LINA given as initial therapy or add-on to
MET for 24 weeks in subjects with T2DM.
Clinical Trial Registration Number: NCT01734785
Supported by: Boehringer Ingelheim and Eli Lilly and Company.
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Efficacy of SGLT2 inhibitors on bone mineral density in Japanese
patients with type 2 diabetes
M. Kusunoki1, Y. Natsume1, D. Sato2, H. Tsutsui3, H. Sasaki2, T.
Nakamura2, T. Miyata4, Y. Oshida1;
1Research Center of Health, Physical Fitness and Sports, Nagoya Univer-
sity, 2Department of Biomedical Information Engineering, Yamagata
University, 3Department of Hygiene and Public Health, Teikyo Universi-
ty School of Medicine, 4Vascular Center, Sanno Medical Center, Tokyo,
Japan.
Background and aims: Sodium-glucose co-transporter-2 (SGLT2) in-
hibitor enhances glucose excretion in urine, and reduces blood glucose in
type 2 diabetic patients. In addition to glycemic control effects, it is
reported that SGLT2 inhibitor lowers serum lipid profile and body
weight. However, few studies have examined the effects of SGTL2 in-
hibitor on bone density. In the present study, we evaluated change of bone
mineral density in Japanese patients with type 2 diabetes treated with
SGLT2 inhibitors.
Materials and methods: The subjects were 115 type 2 diabetic outpa-
tients, consisting of 77 men and 38 women (52±9 and 54±12 years old,
respectively; mean ± SD) who were orally treated with any one of three
SGLT2 inhibitors (luseogliflozin 2.5 mg qd, dapagliflozin 5 mg qd or
tofogliflozin 20 mg qd) for 6 months. We measured BMI, hemoglobin
and HbA1c levels, serum uric acid (UA) level, renal function parameter
(serum creatinine and urine creatinine and albumin levels), and bone
mineral density (BMD) before and after the drug treatment.
Results: After the 6-month treatment, SGLT2 inhibitors significantly
reduced BMI and HbA1c level in both male and female patients (BMI
in male: from 29.2±4.9 to 28.4±4.8 kg/m2, p<0.01; in female: from 28.4
±5.1 to 27.6±5.0 kg/m2, p<0.01; HbA1c in male: from 7.1±1.2 to 6.9±
0.9%, p<0.05; in female: from 6.8±0.9 to 6.7±0.7%, p<0.05). Hemo-
globin level was significantly elevated (in male: from 14.6±1.1 to 15.6±
1.2 g/dL, p<0.01; in female: from 12.8±1.1 to 13.8±1.1 g/dL, p<0.01).
Although significant changes were not detected in serum creatinine and
urine creatinine and albumin levels, UA level was lowered (in male: from
5.6±1.3 to 5.0±1.3 mg/dL, p<0.01; in female: from 5.0±1.4 to 4.1±
1.2 mg/dL, p<0.01). BMD compared to that of a young adult mean
was raised (in male: from 87±15 to 90±15%, p<0.01; in female: from
94±15 to 97±14%, p<0.01).
Conclusion: The treatment of SGLT2 inhibitors reduced BMI and HbA1c
level. Interestingly, SGLT2 inhibitors raised BMD compared to that of a
young adult mean. Since it was reported that SGLT2 inhibitor preserves
renal function in diabetic patients, the improvement of BMD seen in this
study may be attributed to alteration of the renal function including pro-
duction of active vitamin D. In addition, SGLT2 inhibitors decreased UA
level although the detailed mechanisms were not cleared in this study.
Some of antihypertensive agents elevate UA level and reduce BMD.
Thus, SGLT2 inhibitors could also prevent such adverse effects. On the
other hand, SGLT2 inhibitors increased hemoglobin level. These changes
may derived from diuretic effects of SGLT2 inhibitors and consequent
body fluid reduction. In the present study, it is suggested that SGLT2
inhibitors are potentially useful to reduce fracture risk while the treatment
require attention to dehydration in type 2 diabetic patients.
Clinical Trial Registration Number: UMIN000016921
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Comparative persistency with newer agents to treat type 2 diabetes in
the US: canagliflozin vs dipeptidyl peptidase-4 inhibitors and
glucagon-like peptide-1 agonists
J. Diels1, C. Neslusan2;
1Janssen Research & Development, Beerse, Belgium, 2Janssen Global
Services, LLC, Raritan, USA.
Background and aims: Canagliflozin is an agent approved for the treat-
ment of type 2 diabetes mellitus (T2DM) that inhibits sodium glucose co-
transporter 2 (SGLT2), and as such, has been shown to reduce not only
HbA1c, but also weight and blood pressure with an acceptable tolerability
profile. In contrast, dipeptidyl peptidase-4 (DPP-4) inhibitors do not im-
pact weight and blood pressure, and tolerability issues have been docu-
mented with glucagon-like peptide-1 (GLP-1) agonists. As these different
treatment profiles may impact treatment persistency in the real world,
retrospective claims data were used to estimate the time to discontinuation
of canagliflozin versus these alternatives.
Materials and methods: Patients with T2DM who received a first pre-
scription for a DPP-4 inhibitor (sitagliptin, saxagliptin, linagliptin), GLP-
1 agonist (liraglutide, exenatide, exenatide long-acting), or canagliflozin
in 2013 were extracted from two United States claims databases of com-
mercially insured patients (Truven, Optum). The analytical sample in-
cluded only patients with ≥6 months of retrospective data prior to their
first paid claim. Discontinuation was defined as an observed refill gap
≥90 days (sensitivity analysis for 30/60 days) between two subsequent
prescriptions. Time to discontinuation was analysed using Kaplan-Meier
and Cox proportional hazards regression, including demographics, treat-
ment background, and diabetes-related complications/comorbidities as
covariates.
Results: 66,206 patients (mean age, 52.6 years; 50% male; median/
maximum follow-up, 10.1/19.0 months) were identified in the Truven
database. After one year, the percentage of patients still on treatment
was significantly higher with canagliflozin 100 mg (n=7,445; 64.0%)
and 300 mg (n=4,486; 65.0%) versus DPP-4 inhibitors (30.2%
[linagliptin] to 50.1% [sitagliptin]) and GLP-1 agonists (24.3%
[exenatide] to 43.0% [liraglutide]) (P <0.0001 for all comparisons). The
adjusted hazard ratio (HR) for time to discontinuation for canagliflozin
100 mg (reference) and 300 mg (HR=0.92 [0.86; 0.99]) was significantly
lower versus DPP-4 inhibitors and GLP-1 agonists: sitagliptin (n=29,
426; HR=1.28 [1.22; 1.34]); saxagliptin (n=1,566; HR=2.01 [1.86;
2.16]); linagliptin (n=1,432; HR=2.08 [1.92; 2.24]); exenatide (n=2,
376; HR=2.59 [2.41; 2.77]); exenatide long-acting (n=5,922; HR=1.46
[1.40; 1.52]); liraglutide (n=17,690; HR=1.23 [1.20; 1.27]). Being youn-
ger, male, and being onmonotherapy were associated with higher discon-
tinuation risk. HRs were stable across sensitivity analyses using
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alternative discontinuation definitions. Analyses from Optum were gen-
erally consistent with these results.
Conclusion: These analyses indicate that patients who received
canagliflozin versus DPP-4 inhibitors or GLP-1 agonists remained on
their therapy longer, which may reflect better effectiveness and/or
tolerability.
Supported by: Janssen Global Services, LLC
769
Sodium-glucose cotransporter 2 inhibitor increases circulating
zinc-α2-glycoprotein levels in patients with type 2 diabetes
Y. Chen1,2, L. Li1,2, G. Yang3;
1Key Laboratory of Diagnostic Medicine (Ministry of Education) & De-
partment of Clinical Biochemistry, 2College of Laboratory Medicine,
3Department of Endocrinology, the Second Affiliated Hospital, Chong-
qing medical University, China.
Background and aims: Zinc-α2-Glycoprotein (ZAG) has recently been
characterized as a potent metabolic regulator, but the effect of anti-
diabetic agents on circulating ZAG in humans remains unknown. Our
aim was to study the effects of Sodium-glucose cotransporter 2 inhibitors
(SGLT2) inhibitors on circulating ZAG and adiponectin (ADI) in newly
diagnosed type 2 diabetes mellitus (nT2DM).
Materials and methods: 171 subjects with nT2DM were assigned to
receive placebo or SGLT2 inhibitors for 3 months. Before and after treat-
ment, ZAG and ADI concentrations were measured by ELISA.
Results: Circulating ZAG and ADI levels in nT2DM patients were sig-
nificantly lower than in the controls (P<0.01). After 3-months of SGLT2
inhibitors therapy, HbA1c, fasting blood glucose (FBG), postprandial
glucose (2 h-PBG), free fatty acides (FFA), triglyceride (TG), blood pres-
sure, bodymass index (BMI), waist-to-hip ratio (WHR), bodyweight, the
percentage of fat in vivo (FAT%), fasting insulin (FINS), and homeostasis
model assessment of insulin resistance (HOMA-IR) in T2DM patients
decreased significantly (P<0.05 or P<0.01), whereas high- density lipo-
protein cholesterol (HDL-C) was significantly increased (P<0.05). Im-
portantly, circulating ZAG and ADI levels in nT2DM patients were also
significantly increased after SGLT2 inhibitors therapy (both P<0.01).
The change of circulating ZAG (ΔZAG) was associated with ΔTG, Δ
total cholesterol (TC), ΔHDL-C and ΔFFA, whereas ΔADI associated Δ
HDL-C, Δ2-h insulin after glucose load (2 h-INS) and ΔLDL-C.
Conclusion: These findings suggest that ZAG and ADI can be regulated
by SGLT2 inhibitors, and SGLT2 inhibitors may play a physiologic role
in enhancing insulin sensitivity.
Clinical Trial Registration Number: ChiCTR-OCS-13003185
Supported by: NSFC of China (81270913,81070640,81100567)
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Three-year efficacy and safety of exenatide once weekly: a pooled
analysis of three trials
M.E. Trautmann1, L. Van Gaal2, J. Han3, E. Hardy4;
1Diabetes Research, Hamburg, Germany, 2Antwerp University Hospital,
Edegem, Belgium, 3Pharmapace, San Diego, 4AstraZeneca, Gaithers-
burg, USA.
Background and aims: Long-term data for glucose-lowering therapies
(eg, glucagon-like peptide-1 receptor agonists) help to inform drug selec-
tion for treatment strategies.
Materials and methods: This post hoc analysis examined the efficacy
and safety of exenatide once weekly (QW) in pooled completer data (N=
329) from extensions (2.5-3 years) of three trials (DURATION-1, -2, -3);
3 year data for insulin glargine (IG) was included for reference (N=158),
as IG was a long-term comparator in one trial (DURATION-3).
Results: Baseline mean age, weight, and HbA1c were 56/58 years, 93.7/
90.3 kg, and 8.3/ 8.3%, in the exenatide QW/IG groups, respectively.
After 3 years, patients receiving exenatide QW had improvements from
baseline in HbA1c, fasting glucose, body weight, and some cardiovascu-
lar risk markers (Table). A total of 101 (30.7%) exenatide-treated patients
and 26 (16.5%) IG-treated patients achieved the stringent goal of HbA1c
≤6.5%, and 95 (28.9%) and 11 (7.0%), respectively, achieved the Com-
posite goal of HbA1c <7%, no hypoglycaemia, and no weight gain.
Diarrhoea, nausea, vomiting, and injection-site pruritus occurred in
24.0%, 22.2%, 10.6%, and 8.2% of patients, respectively, receiving
exenatide QWand in 8.2%, 2.5%, 3.2%, and 0% of patients, respectively,
receiving IG. Major and minor hypoglycaemia were more frequent with
sulphonylurea than without (exenatide QW: 32.6% vs 10.0%; IG: 70.2%
vs 45.9%, respectively).
Conclusion: Long-term exenatide QW treatment improved multiple out-
comes in a large, pooled cohort of patients. Exenatide QWwas associated
with weight loss and a lower risk of hypoglycaemia than the reference IG
treatment, but had a higher incidence of gastrointestinal and injection-site
events.
Clinical Trial Registration Number: NCT00308139, NCT00637273,
NCT00641056
Supported by: AstraZeneca
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Treatment of patients with type 2 diabetes mellitus and baseline
HbA1c ≥10% with exenatide twice daily, exenatide once weekly, or
basal insulin: a pooled analysis of 20 randomised controlled trials
R.S. Busch1, L. Ferri2, J. Ruggles3, E. Hardy2, J. Han4;
1The Endocrine Group, Albany, 2AstraZeneca, Gaithersburg,
3AstraZeneca, Fort Washington, 4Pharmapace, San Diego, USA.
Background and aims: Guidelines recommend insulin-based injectable
therapy for type 2 diabetes mellitus (T2DM) patients presenting with
HbA1c ≥10%-12%, to rapidly minimise glucotoxicity. We explored the
effects of a glucagon-like peptide-1 receptor agonist, exenatide, on
glycaemic control in patients with very high HbA1c, to determine wheth-
er options other than basal insulin may be shown to be appropriate for
such patients. In individual randomised controlled trials (RCTs) with a
mean baseline HbA1c of 8.1%-8.5%, HbA1c reduction with exenatide
twice daily (BID) was noninferior to basal insulin and with exenatide
once weekly (QW) was superior to basal insulin; however, no previous
assessment of these agents has been conducted in the subset of patients
with HbA1c ≥10%.
Materials and methods:Using pooled intention-to-treat (ITT) data from
4,340 patients treated for ≥24 weeks in 20 RCTs, we evaluated glycemic
parameters for exenatide BID, exenatide QWand basal insulin, in a sub-
population of patients with baseline HbA1c ≥10%. Most patients in this
subgroup (>80%) also used metformin-and/or sulfonylurea (SU) as back-
ground therapy.
Results:Reductions from baseline in HbA1c were significant fromWeek
2 (earliest timepoint; P<0.001) with exenatide BID, Week 4 (P<0.001)
with exenatide QW, andWeeks 12 and 10 (earliest timepoints with avail-
able patient data; both P<0.001) for the corresponding basal insulin
groups. Endpoint reductions in HbA1c (Table) were comparable between
exenatide BID and basal insulin, and numerically greater with exenatide
QW than basal insulin. Significant reductions from baseline in fasting
glucose were observed at endpoint (Table) that were greater with basal
insulin. A higher proportion of patients achieved an HbA1c of <7% or
≤6.5% with exenatide QW than with basal insulin. Weight significantly
decreased with exenatide and increased with basal insulin. Major and
minor hypoglycaemia incidence was numerically higher in SU vs non-
SU users and with basal insulin.
Conclusion: In this post-hoc analysis, exenatide BID and QW achieved
marked reductions in HbA1c in patients with T2DM and baseline HbA1c
≥10%. Exenatide BID and QWmay be appropriate treatment alternatives
to basal insulin for patients with HbA1c ≥10%.
Clinical Trial Registration Number: NCT00039013, NCT00039026,
NCT00035984, NCT00360334, NCT00359762, NCT00577824,
NCT00082381, NCT00082407, NCT00381342, NCT00603239,
NCT00434954, NCT00375492, NCT00308139, NCT00637273,
NCT00877890, NCT01003184, NCT00641056, NCT00676338,
NCT00917267
Supported by: AstraZeneca
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Responses to exenatide twice daily, basal insulin or placebo with oral
medications over different durations of type 2 diabetes mellitus: Does
diabetes duration matter?
S.L. Aronoff1, L. Ferri2, J.A. Ruggles3, J. Han4;
1Endocrine Associates of Dallas, 2AstraZeneca, Gaithersburg,
3AstraZeneca, Fort Washington, 4Pharmapace, San Diego, USA.
Background and aims: Type 2 diabetes is a progressive disease;
thus, patients with longer disease durations are usually more dif-
ficult to treat. Using the exenatide clinical development database,
we investigated whether patients with longer durations of type 2
diabetes had lesser responses to therapy, and whether certain ther-
apy combinations appeared more effective at certain type 2 dia-
betes durations.
Materials and methods: We compared the efficacy of exenatide
twice daily (BID) with basal insulin therapy or placebo in patients
with longer type 2 diabetes durations, and examined whether use
of concomitant metformin, sulfonylurea, or both, affected response
after 16-30 weeks of treatment, based on the duration of type 2
diabetes. We analysed intention-to-treat data from 14 studies of
≥16 weeks’ duration with exenatide BID (N=2792) compared
with basal insulin(N=935) or placebo (N=1092) in patients with
type 2 diabetes treated with diet and exercise with or without ≥1
oral drug(s) (mean HbA1c 8.3%, type 2 diabetes duration
7.7 years). Patients continued existing treatment (metformin, n=
1020; sulfonylurea, n=464; metformin + sulfonylurea, n=2433).
Results: Overall results from the metformin population showed
that baseline HbA1c increased with type 2 diabetes duration
(≤2 years, 7.83%; >2-≤5 years, 8.05%; >5-≤10 years, 8.14%;
>10-≤15 years, 8.45%; >15 years, insufficient sample size),
supporting concerns for loss of efficacy of metformin. However,
correlations between improvement in efficacy variables (HbA1c,
fasting glucose and weight) and type 2 diabetes duration were
weak for all drug combinations studied. The table shows HbA1c
changes and goal achievement by type 2 diabetes duration cate-
gories and concomitant oral drug(s). Responses with exenatide
BID and basal insulin were similar within each type 2 diabetes
duration category, which was particularly evident among patients
on concomitant metformin + sulfonylurea (the largest concomitant
treatment subgroup).
Conclusion:Our analysis indicated that a longer type 2 diabetes duration
was not associated with a reduced response to exenatide BID compared
with basal insulin; however, the majority of patients with longer durations
of type 2 diabetes needed multiple therapies to achieve an HbA1c of 7%.
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NCT00039013, NCT00039026, NCT00035984, NCT00360334,
NCT00577824, NCT00082381, NCT00082407, NCT00099619,
NCT00099320, NCT00324363, NCT00381342, NCT00603239,
NCT00434954, NCT00375492
Supported by: AstraZeneca
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The effect of added exenatide twice daily or bolus insulin on insulin
glargine and total insulin dose with improvedHbA1c: subgroup anal-
ysis of the 4B study
E. Hardy1, K. Brismar2, M. Davies3, J. Han4, B.H.R. Wolffenbuttel5;
1AstraZeneca, Gaithersburg, USA, 2Karolinska Institutet, Karolinska
University Hospital, Stockholm, Sweden, 3University of Leicester, Dia-
betes Research Centre, UK, 4Pharmapace, San Diego, USA, 5University
of Groningen, University Medical Center Groningen, Netherlands.
Background and aims: Persistent hyperglycaemia after insulin glargine
(IG) up-titration necessitates treatment intensification. With multiple in-
tensification options available for patients failing basal insulin, individu-
alization of therapy becomes possible. A subgroup of particular interest is
patients on high IG doses, who may respond less to additional therapies.
Materials and methods: This post hoc analysis examined responses to
exenatide twice daily (BID) or insulin lispro (IL) added to IG +metformin
in patients with type 2 diabetes mellitus (T2DM) according to IG dose
tertile at randomisation. Baseline values in the exenatide BID/IL arms for
total insulin were 33/33 U for tertile 1, 53/52 U for tertile 2 and 94/96 U
for tertile 3. Postrandomisation, the daily IG dosewas reduced by 33-50%
and converted to IL in the IL arm, and reduced by ≥10% in patients with
HbA1c ≤8.0% in the exenatide BID arm.
Results: The analysis included 627 patients. Baseline body weight with
exenatide BID and IL was 81/82 kg for tertile 1, 90/87 kg for tertile 2 and
99/98 kg for tertile 3; baseline HbA1cwas 8.2/8.0% for tertile 1, 8.2/8.1%
for tertile 2 and 8.4/8.5% for tertile 3. At Week 30, HbA1c reductions
with exenatide BID and IL were similar across tertiles (Table); fasting
glucose decreased with exenatide BID in tertiles 1 and 3. Exenatide BID
reduced body weight, while IL increased body weight. Proportions of
patients achieving HbA1c <7.0% with exenatide BID and IL were gen-
erally similar across tertiles. In each tertile, greater proportions of patients
treated with exenatide BID compared with IL achieved the composite
goal of HbA1c <7.0%, no weight gain, and no major or minor
hypoglycaemia. Tertile 3 had the numerically greatest IG dose reductions,
but still had the highest total insulin dose at endpoint. Adverse events
(AEs) were generally similar across tertiles within treatment groups. Gas-
trointestinal AEs were more common with exenatide BID compared with
IL (tertile 1: 46% vs 17%; tertile 2: 48% vs 13%; tertile 3: 46% vs 9%).
The major and minor hypoglycaemia event rate/patient-year was lower
with exenatide BID than with IL (tertile 1: 1.7 vs 5.2; tertile 2: 2.3 vs 6.0;
tertile 3: 2.6 vs 4.8).
Conclusion: Patients with the highest baseline IG doses were able to
sustain the largest reductions in the IG dose in both treatment groups,
but only those treated with exenatide BID used less total insulin, with
similar improvement in HbA1c. Adding exenatide BID or IL to patients
on low or high insulin doses improved glycaemic control to a similar
extent, with weight loss and less hypoglycaemia in the exenatide BID
group, regardless of baseline IG dose. There was a higher incidence of
gastrointestinal AEs with exenatide BID compared with IL.
Clinical Trial Registration Number: NCT00960661
Supported by: AstraZeneca
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Safety and tolerability of liraglutide versus sulphonylurea in people
with type 2 diabetes before, during and after Ramadan fasting: a
randomised trial (LIRA-Ramadan)
N. Shehadeh1, A. Echtay2, D.D. Ørsted3, M.S. Kaltoft4, S.T. Azar5;
1Pediatric Diabetes Unit, Rambam Medical Center, Haifa, Israel, 2Leba-
nese UniversityMedical School, Rafik Hariri University Hospital, Beirut,
Lebanon, 3Novo Nordisk, Søborg, France, 4Novo Nordisk, Søborg, Den-
mark, 5American University of Beirut Medical Centre, Lebanon.
Background and aims: Fasting during Ramadan is challenging for peo-
ple with diabetes due to 5- and 7.5-fold increased risks of severe hyper-
and hypoglycaemia, respectively. Data are needed to guide planning and
treatment. We report safety and tolerability data from the LIRA-Ramadan
trial, which compared liraglutide (lira) with sulphonylurea (SU) in people
with T2D during Ramadan.
Materials and methods: In this open-label trial, adults (HbA1c 7-10%;
BMI >20 kg/m2; stable SU + metformin [Met]) intending to fast during
Ramadan were randomised to switch to once daily lira 1.8 mg (N=172)
or continue pretrial SU (N=171), both + Met, then followed for
≤32 weeks. Lira was dose-escalated for 3-4-weeks then administered at
≤1.8 mg for 6-19-weeks before Ramadan (4 weeks). Changes in SU dose
and/or timing using ADA recommendations were allowed during Rama-
dan. Primary endpoint was change in fructosamine (FA) from start to end
of Ramadan (lira, N=151; SU, N=165). Treatment continued for 4 weeks
post Ramadan.
Results: There was a significantly greater reduction in FA from baseline
to end of Ramadan with lira vs SU (estimated treatment difference [ETD]
[95% CI]: -10.3 [-18.7, -1.89] μmol/L; p=0.0165). Despite lower FA and
HbA1c at start of Ramadan in the lira arm, similar FA reductions occurred
with lira and SU during Ramadan (ETD: 3.51 [-5.26, 12.28] μmol/L; p=
0.4311). Results were similar for HbA1c (data not shown). Nonetheless,
significantly fewer confirmed hypoglycaemic events (ADA defined) oc-
curred with lira vs SU over the study period (estimated rate ratio for
lira/SU: 0.2 [0.1, 0.5]; p=0.0027). No nocturnal hypoglycaemic events
occurred with lira (vs 3 with SU [42 events/1000 subject years of expo-
sure]). During the trial, 77% of people switching to lira and 57% continu-
ing on SU experienced adverse events (AEs). Few serious AEs were
observed (lira, 2.9%; SU, 1.2%). More people had GI AEs with lira than
SU, commonly nausea (generally transient; 33% vs 0%), diarrhoea (22%
vs 4%) and vomiting (21% vs 1%). There were no cases of acute pancre-
atitis. The proportion of withdrawals was similar for lira and SU (15.1%
and 14.0%, respectively). With lira, 20/26 withdrawals occurred before
Ramadan. The most common reason for withdrawal with lira was an AE:
11 participants in the lira arm (6%) withdrew due to an AE (n=10 before
Ramadan) vs 0 in the SU arm. With SU, 11/24 withdrawals occurred
during Ramadan, and the most common withdrawal reasons were fasting
plasma glucose exceeding the protocol limit (n=7), or not fasting in
Ramadan (n=3). No withdrawals during Ramadan were due to AEs.
No significant differences between lira and SU were observed for change
in overall treatment satisfaction (Diabetes Treatment Satisfaction Ques-
tionnaire [DTSQ]) or Short Form-36 Health status questionnaire scores
during Ramadan. A non-significant difference in perceived frequency of
hypoglycaemia was observed for lira vs SU (DTSQ ETD -0.297 [-0.701,
0.106]; p=0.1480).
Conclusion: A significantly lower risk of hypoglycaemic events was
seen with lira vs SU, despite lower levels of FA and HbA1c. No new
safety concerns were identified with lira during the trial, which included a
physiologically challenging fasting period during Ramadan.
Clinical Trial Registration Number: NCT01917656
Supported by: Novo Nordisk
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The addition of liraglutide 1.8 mg to insulin in type 1 diabetes does
not improve patient-reported outcome measures
R. Hinsch1, T.F. Dejgaard1, M.W. Pedersen1, B.J. von Scholten1, C.S.
Frandsen2, S. Madsbad2, H.U. Andersen1;
1Steno Diabetes Center, Gentofte, 2Hvidovre Hospital, University of Co-
penhagen, Denmark.
Background and aims: In insulin treated type 2 diabetes (T2D) the
addition of a glucagon-like peptide-1 receptor agonist (GLP-1RA) has
improved both metabolic control, and patient satisfaction with treatment.
In patients with type 1 diabetes (T1D) studies have reported positive
effects on weight and glycaemic control by adding a GLP-1 RA to insulin
treatment. However, as a potential future treatment of T1D it is important
to evaluate the patient-reported outcomes.
Materials and methods: A total of 100 patients with T1D, poor
glycaemic control, and overweight, were randomised to liraglutide
1.8 mg once daily or placebo as an add-on to intensive insulin therapy
in a double-blind, parallel design (The Lira-1 Study). To evaluate patient-
reported outcomes, we used the Diabetes Treatment and Satisfaction
(DTSQs) and Problem Areas in Diabetes (PAID) questionnaires at base-
line, after 3 weeks of treatment, and at the end of treatment (26 weeks).
The DTSQs was divided into a treatment satisfaction section and a
hypoglycaemia section.
Results: Mean baseline characteristics were similar between the
liraglutide and placebo groups (liraglutide;placebo, mean ± SD) age 46
±13;50±13 years, HbA1c 73±8;73±7 mmol/mol, total daily insulin dose
60±23;61±21 IU/day and bodyweight 93.0±14.3;93.7±13.2 kg except
diabetes duration 20±12;27±12 years (p=0.009). Patient-reported out-
comes were assessed in 73 patients (38 and 35 patients in the liraglutide
and placebo groups, respectively). The overall satisfaction score for the
DTSQs in the liraglutide group did not differ significantly from baseline
23.0±3.5 to 23.7±3.2 (p=0.18) after 3 weeks or at the end of treatment
24.1±3.4 (p=0.051). In the placebo group, themean baseline score 23.7±
4.1 showed no significant change after 3 weeks of treatment 24.3±3.1
(p=0.31), but increased to 25.5±3.3 (p=0.013) at the end of treatment.
No significant differences were observed between the groups in changes
or the overall satisfaction score at any time point (p>0.46). For the
DTSQs hypoglycaemia section, the score in the liraglutide group in-
creased from 4.7±1.4 to 5.4±1.0 (p=0.004) after 3 weeks of treatment,
but showed no significant change 5.3±1.3 (p=0.055) at the end of treat-
ment compared with baseline. In the placebo group, baseline 4.5±1.6,
and 3 weeks score did not differ significantly 5.1±1.2 (p=0.075), but
increased significantly to 5.3±0.9 (p=0.003) at the end of treatment com-
pared with baseline. No significant differences were observed in the
changes in the hypoglycaemia score between the groups at any time point
(p>0.59). In the PAID questionnaire, the mean score in the liraglutide
group decreased from 24.9±15.9 to 18.8±15.4 (p<0.0001) after 3 weeks,
and was 20.4±17.2 (p=0.029) at the end of treatment. In the placebo
group, the mean baseline score of 22.6±14.4 showed no significant
change at 3 weeks 19.3±13.3 (p=0.074) or at 26 weeks 20.7±15.8 (p=
0.21). No significant differences were observed between the groups at
any time point (p>0.21).
Conclusion: The addition of 1.8 mg liraglutide once-daily to insulin in
overweight and poorly regulated patients with T1D did not improve the
patient reported outcome measures DTSQs and PAID, during or after
26 weeks of treatment. These findings are in contrast to the improved
treatment satisfaction reported in obese insulin treated T2D patients after
add-on of the GLP-1 RA liraglutide to insulin.
Clinical Trial Registration Number: NCT01612468
Supported by: An unrestricted grant from Novo Nordisk A/S
Diabetologia (2015) 58 (Suppl 1):S1–S607 S373
776
Liraglutide as add-on to insulin in normal-weight and poorly con-
trolled patients with type 1 diabetes: the T1DMLIRA study
C.S. Frandsen1, T.F. Dejgaard2, J.J. Holst3, H.U. Andersen2, B.
Thorsteinsson4, S. Madsbad1;
1Department of Endocrinology, Hvidovre University Hospital, 2Steno
Diabetes Center, Gentofte, 3Novo Nordisk Foundation Center for Basic
Metabolic Research, Copenhagen, 4Department of Cardiology, Nephrol-
ogy and Endocrinology, Nordsjællands Hospital, Hillerød, Denmark.
Background and aims:Combination of a GLP-1 receptor agonist (GLP-
1RA) with insulin is a novel, potential treatment strategy in patients with
type 1 diabetes (T1D). Open-label and mechanistic studies indicate that
GLP-1RA treatment induces weight loss, improves PPG excursions and
reduces insulin requirements with improved or unaltered glycemic con-
trol in patients with T1D. This is the first randomized, double-blinded,
placebo-controlled study to evaluate efficacy and safety of liraglutide as
add-on to insulin treatment in normal-weight T1D patients without resid-
ual β-cell function
Materials and methods: In total 40 patients with T1D were randomized
to once-daily liraglutide 1.2 mg or placebo adjunct to pre-existing insulin
treatment for 12 weeks. Baseline characteristics were similar between
groups (liraglutide; placebo): HbA1c 73±2; 72±2 mmol/mol, BMI
24.2±0.6; 22.8±0.4 kg/m2, diabetes duration 18±2 20±2 years, basal
insulin 34±2; 34±4 IU/day, bolus insulin 28±3; 24±2 IU/day. Insulin
dose was adjusted according to a treat-to-target algorithm. Primary end-
point was mean change in HbA1c from baseline to week 12
Results: After 12 weeks, changes in HbA1c from baseline were similar
with liraglutide and placebo (table). Patients taking liraglutide had greater
reductions in body weight and bolus insulin requirements compared with
placebo (table). Changes in glycemic variability and frequency of hypo-
glycemia were similar between groups (table).Heart rate (HR) increased
with liraglutide compared with placebo (between-group difference 2.44
beats/min (CI: -1.92 to 6.81), p=0.04). Simultaneously, systolic blood
pressure (SBP) decreased with liraglutide compared with placebo-
treated patients (between-group difference 3.21 mmHg (CI: -8.31 to
1.90), p=0.04). Gastrointestinal (GI) AEs were significantly more fre-
quent with liraglutide than placebo (% pts): nausea 33; 23, dyspepsia
15; 5
Conclusion: In conclusion, liraglutide added to insulin significantly re-
duces body weight and bolus insulin requirements, but has no additional
effect on HbA1c in T1Dpatients inadequately controlled on insulin alone.
Frequency of hypoglycemia did not differ between groups. GI AEs were
more frequent with liraglutide than placebo. HR increases and SBP de-
creases significantly with liraglutide compared with placebo
Clinical Trial Registration Number: NCT02092896
Supported by: an unrestricted grant by Novo Nordisk
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Effects of liraglutide vs lifestyle changes on subcutaneous and viscer-
al fat, liver steatosis, insulin sensitivity and beta cell function after
comparable weight loss
F. Santilli1, M. Guagnano1, A. Tartaro2, P.G. Simeone1, R. Liani1, R.
Tripaldi1, M. Maccarone2, E. Zecca1, E. Angelucci3, V. Federico4, A.
Quirino3, L. Pansa4, M. Golato4, G. Davi1, A. Consoli1;
1Department of Medicine and Aging and Center of Excellence on Aging,
2Department of Neuroscience & Imaging, University of Chieti, 3Depart-
ment of Clinica Medica, Chieti Hospital, 4Department of Clinical Pathol-
ogy, Chieti Hospital, Italy.
Background and aims: Obesity, insulin resistance and beta cell deterio-
ration are key issues in the development and progression of type 2 dia-
betes (T2DM). Given the concurrent effects acknowledged for GLP-1
agonists on body weight, fat mass, insulin resistance and beta cell pres-
ervation, we hypothesized that this class of drugs may exert additional
actions on top of those anticipated for lifestyle intervention-mediated
weight loss.
Materials and methods: Twenty-nine metformin-treated obese subjects
with impaired glucose tolerance (IGT), impaired fasting glucose (IFG) or
newly diagnosed T2DM, were randomized to liraglutide treatment
(1.8 mg/d) or lifestyle counseling to assess whether changes in subcuta-
neous (SAT) and visceral (VAT) adipose tissue distribution and in degree
of non-alcoholic fatty liver disease (NAFLD) (all assessed by MRI) after
a modest and comparable weight loss (7% of initial body weight), might
affect insulin sensitivity (Matsuda Index) and β-cell performance (by
Insulin Secretion-Sensitivity Index-2 (ISSI-2)) during multiple sampling
oral glucose tolerance test.
Results: At baseline, VAT was correlated directly with HbA1c (Rho=
0.374, p=0.045) and ISSI-2 (Rho=-0.378, p=0.043), and inversely with
adiponectin (Rho=-0.470, p=0.010), whereas SATwas significantly and
directly correlated with C-reactive protein (Rho=0.466, p=0.013), leptin
(Rho=0.811, p<0.0001) and NAFLD degree (Rho=0.379, p=0.042).
VAT, SATand NAFLD grade were significantly and comparably reduced
in both treatment groups, whereas insulin sensitivity was not significantly
affected by any intervention. In contrast, the liraglutide group showed a
significantly greater reduction in median VAT (p=0.001), as compared to
the lifestyle group (-15.3% vs. -7.3% median decrease) and a greater
improvement in beta cell function (ISSI-2) (96.3% vs. 29.8%, p=
0.006), which translated into a significantly more pronounced reduction
in both fasting, 1-hour and 2-hour postprandial plasma glucose, despite
comparably reduced HbA1c in both groups (by 7.0%). In the liraglutide
arm, but not in the lifestyle arm, VAT percent decrease throughout the
intervention period was significantly related to improvement in beta-cell
function (ISSI-2, Rho=-0.60, p=0.023) and increase in adiponectin levels
(Rho=-0-589, p=0.021). SAT and leptin percent changes were instead
associated with improvement in insulin sensitivity, as reflected by
Matsuda index (Rho=-0.722,p=0.002, and Rho=-0.708, p=0.003).
Conclusion: This pilot study may help establishing a cause-and-effect
relationship between VAT inflammation, adipokine secretion, beta cell
performance and development or progression of T2DM, unraveling as
well potential mechanisms by which liraglutide may favorably impact
T2DM pathogenesis.
Supported by: MIUR
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The efficacy and safety of once-weekly, subcutaneous dulaglutide
monotherapy compared to glimepiride in Asian patients with type 2
diabetes mellitus
W. Wang1, C.-N. Huang2, M.-C. Young3, P. Li4, L. Gu4, J. Yang4;
1Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China,
2Chung Shan Medical University Hospital, Taichung City, Taiwan,
3Seoul National University Hospital, Republic of Korea, 4Lilly Suzhou
Pharmaceutical Co., Ltd, Shanghai, China.
Background and aims: This Phase 3, randomized, double-blind, parallel-
arm 26-week (wk) monotherapy study compared the efficacy and safety of
once weekly dulaglutide (DU), a long-acting glucagon-like peptide-1
(GLP-1) receptor agonist, with glimepiride in Asian patients with type 2
diabetes mellitus who had discontinued oral antihyperglycemic medication
(OAM) monotherapy or were OAM-naïve.
Materials andmethods:A total of 807 patients (all Asian; mean baseline
age, 52.8 years; mean duration of T2DM, 3.7 years; HbA1c, 7.94%;
weight, 70.0 kg) were randomly assigned to once-weekly DU 1.5 mg,
DU 0.75mg or glimepiride (1-3mg/day) in a 1:1:1 ratio. The primary and
key secondary objectives were to test the noninferiority (margin 0.4%)
and superiority of DU 1.5 and 0.75 mg versus glimepiride using a
prespecified gatekeeping method, as measured by A1C change from
baseline at Week 26.
Results: Both DU 1.5 mg and DU 0.75 mg demonstrated superiority to
glimepiride (Least-squares [LS] mean difference [%][95% CI]: -0.60% [-
0.78%, -0.41%] and -0.31% [-0.49%, -0.13%], respectively). More pa-
tients achieved HbA1c target <7.0% in both DU 1.5 mg and DU 0.75 mg
than glimepiride. LS mean decrease from baseline in fasting blood glu-
cose was significantly greater for both DU 1.5 mg and DU 0.75 mg
compared with glimepiride. Total hypoglycemia incidence was signifi-
cantly lower in both DU 1.5 mg and DU 0.75 mg than glimepiride. No
severe hypoglycemic events were reported. Weight decreased with DU
and increased with glimepiride. The most common treatment-emergent
gastrointestinal adverse events for DU 1.5 mg, DU 0.75 mg were diarrhea
(14.9%, 6.3%), nausea (8.6%, 4.1%), abdominal distension (6.0%, 2.6% )
and vomiting (6.3%, 1.1%).
Conclusion: Superiority in change from baseline HbA1c of both
dulaglutide 1.5 mg versus glimepiride and dulaglutide 0.75 mg versus
glimepiride were statistically demonstrated in this study. These results,
combined with the overall efficacy, safety, and tolerability data, support
the use of dulaglutide as one of monotherapy options in Asian patients
with T2DM.
Clinical Trial Registration Number: CT01644500
Supported by: Eli lilly and Company
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Relationship betweenweight change and glycaemic control with once
weekly dulaglutide treatment in patients with type 2 diabetes
L. Fernandez Lando1, G. Umpierrez2, K.M. Pantalone3, A. Kwan1,
A.G. Zimmermann4;
1Lilly USA, LLC., Indianapolis, 2Division of Endocrinology, Emory Uni-
versity, Atlanta, 3Department of Endocrinology, Cleveland Clinic, Cleve-
land, 4Eli Lilly and Company, Indianapolis, USA.
Background and aims: Dulaglutide, a once weekly GLP-1 receptor
agonist, was studied in the AWARD clinical trial program in adult patients
with type 2 diabetes. In 6 head-to-head phase 3 trials, dulaglutide dem-
onstrated significant HbA1c reduction and weight control effects. To
assess the relationship between weight change and glycaemic control in
dulaglutide-treated patients, HbA1c and body weight data from the 6
trials were analysed.
Materials and methods: Due to differences in design, background ther-
apy, and baseline characteristics, analyses on HbA1c and body weight
data at 26 weeks were conducted by trial rather than by pooling.
Results: Across the studies 87%-97% and 83%-95% of patients treated
with dulaglutide 1.5 mg and 0.75 mg, respectively, demonstrated HbA1c
reduction. Among the patients with HbA1c reduction, the majority of
patients receiving dulaglutide 1.5 mg experienced weight loss (55%-
83%) while 41%-79% in the dulaglutide 0.75 mg arm lost weight. Min-
imal correlation was observed between the changes in HbA1c and weight
(ІRІ <0.3, all). Baseline characteristics of gender, age, duration of diabe-
tes, HbA1c, body weight and BMI did not correlate with different weight
responses.
Conclusion: In summary, dulaglutide demonstrated a dose-dependent
effect on both weight loss and HbA1c reduction. Dulaglutide is an effec-
tive treatment option with both HbA1c reduction and weight loss ob-
served across the type 2 diabetes treatment spectrum.
Supported by: Eli Lilly and Company
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Baseline factors associated with the glycaemic response to treatment
with once weekly dulaglutide in patients with type 2 diabetes
C. Wysham1, B. Guerci2, D. D'Alessio3, N. Jia4, F.T. Botros4;
1Rockwood Center for Diabetes and Endocrinology, Spokane, USA,
2University of Lorraine and Brabois Hospital & Center of Clinical Inves-
tigation, Nancy, France, 3Duke University Medical Center, Durham, 4Eli
Lilly and Company, Indianapolis, USA.
Background and aims: Dulaglutide (DU) is a once weekly glucagon-
like peptide-1 (GLP-1) receptor agonist that has been recently approved
Diabetologia (2015) 58 (Suppl 1):S1–S607 S375
in the US and EU for the treatment of type 2 diabetes. Glycaemic efficacy
of DU has been demonstrated in six Phase 3 studies. The objective of this
analysis is to determine major baseline factors that are associated with the
reduction in glycosylated haemoglobin A1c (HbA1c) in response to treat-
ment with DU.
Materials andmethods:DUpatient (pt) covariates from across the 6 DU
Phase 3 clinical trials were analysed using gradient boosting analysis to
assess their relative contribution to the change in HbA1c at 26 weeks of
treatment. Baseline variables which were associated with the greatest
amount of influence on HbA1c change were further evaluated in univar-
iate and multivariable modeling to assess the magnitude and direction of
impact. Analysed baseline factors included age, race, ethnicity, gender,
duration of diabetes, serum glucose measures, fasting serum C-peptide
and insulin (FSI), weight, BMI, cardiovascular disease history, estimated
glomerular filtration rate (eGFR), and albuminuria.
Results: This analysis included 2806 DU treated pt with mean age 56.3±
9.8 years, duration of diabetes 7.8±6.0 years, baseline HbA1c 8.0±1.0%
(64±11 mmol/mol), BMI 32.4±5.2 kg/m2,and eGFR 89.5±16.9 mL/
min/1.73 m2. Based on gradient boosting, the top 5 baseline factors as-
sociated with reduction in HbA1c (and their relative influence) are base-
line HbA1c(48.8%), age (9.1%), fasting serum glucose (FSG) (8.2%),
FSI (6.7%), and eGFR (5.4%). The role of baseline glycaemic factors
(HbA1c, FSG, FSI) was evaluated. Univariate regression demonstrated
that higher baseline HbA1c and FSG values and lower FSI values were
associated with greater reduction in HbA1c (coefficient estimates of
HbA1c change: -0.598%, -0.101%, and 0.002%, respectively, p<
0.0001 for all). Multivariable linear regression showed similar results
for baseline HbA1c (-0.594±0.027%) and FSI (-0.197±0.045% for FSI
≤55 pmol/L), but greater baseline FSG was associated with smaller de-
crease in HbA1c when adjusted for the other 4 factors (0.047±0.010%, p
<0.0001), indicating that pts with smaller baseline FSG, while having
similar baseline HbA1c and other variables, are likely to have a greater
decrease in HbA1c in response to dulaglutide. Subgroup analysis by
baseline HbA1c (9 quantiles) confirmed that higher FSG is associated
with smaller decreases in HbA1c for pts within the same category of
baseline HbA1c. Multivariable linear regression also showed that greater
reduction in HbA1c was observed in associated pts with baseline eGFR≤
100 mL/min/1.73 m2 (coefficient estimate of HbA1c change: -0.143±
0.047%, p=0.002) and age≤65 years (coefficient estimates of HbA1c
change: -0.175±0.058%, p=0.003).
Conclusion: These data indicate that higher baseline HbA1c, reflecting
poor glycaemic status, is the major factor associated with greater reduc-
tion in HbA1c in response to treatment with DU. Other baseline factors
associated with greater decrease in HbA1c in response to dulaglutide,
albeit to a limited extent, include baseline FSG, FSI, age, and eGFR.
Supported by: Eli Lilly and Company
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Improvement inHbA1c in patients with type 2 diabetesmellitus treat-
ed with once weekly dulaglutide across baseline body mass index
(BMI) subgroups at 26 or 52 weeks
L.A. Vázquez1, E. Jódar2, C. Trescoli3, C. Nicolay4, J. Reviriego1, R.
Gentilella5;
1Eli Lilly, Alcobendas, 2Hospital Universitario Quirón, Madrid, 3Hospital
Universitario de la Ribera, Alzira, Valenzia, Spain, 4Lilly Deutschland
GmbH, Bad Homburg, Germany, 5Lilly Diabetes, Sesto Fiorentino, Italy.
Background and aims: This post-hoc analysis investigated the efficacy
of dulaglutide and active comparators across baseline BMI categories
(BMI <30, ≥30-<35 or ≥35 kg/m2) in patients with T2DM using data
from the phase 3 randomised trials AWARD-1 to -6.
Materials and methods: Patients with T2DM received dulaglutide
[1.5 mg, n=1719 (AWARD-1 to -6); 0.75 mg, n=1417 (AWARD-1 to -
5)], or exenatide (n=276), insulin glargine (n=558), metformin (n=268),
sitagliptin (n=315) or liraglutide (n=300), in addition to other concomi-
tant background treatments (Table). Analysis of covariance models
(AWARD-1 to -5) or mixed-effects model for repeat measures
(AWARD-6), including treatment-by-BMI subgroup interaction terms,
were applied by study to estimate the effect of each treatment on HbA1c
at 52 weeks (AWARD-1 to -5) or 26 weeks (AWARD-6) and to compare
dulaglutide and corresponding active comparators for patients with base-
line BMI <30, ≥30-<35 or ≥35 kg/m2 (intention-to-treat population).
Results:Baseline mean BMI in each study ranged from 31.2-33.6 kg/m2.
HbA1c reductions from baseline according to BMI subgroup are shown
for each study (Table). In all studies, dulaglutide 1.5 mg, dulaglutide
0.75 mg and all active comparators achieved statistically significant
HbA1c reductions from baseline overall and in all BMI subgroups. No
statistically significant treatment-by-BMI subgroup interactions were
found for reductions in HbA1c (Table).
Conclusion:Dulaglutide (1.5mg or 0.75mg) is an effective treatment for
patients with T2DM, regardless of baseline BMI. There was no evidence
of any treatment-by-BMI subgroup interaction for HbA1c change, sug-
gest ing that basel ine BMI had no effec t on the relat ive
antihyperglycaemic efficacy associated with dulaglutide versus compar-
ator antidiabetes agents.
Clinical Trial Registration Number: H9X-MC-GBDA; H9X-MC-GBDB;
H9X-MC-GBDC; H9X-MC-GBDD; H9X-MC-GBCF; H9X-MC-GBDE
Supported by: Eli Lilly and Company, Ltd.
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Achieving the composite endpoint ofHbA1c <7.0% (53mmol/mol), no
hypoglycaemia, and no weight gain in the once weekly dulaglutide
AWARD programme
J.L. Fahrbach1, K.M. Dungan2, I. Raz3, Z. Skrivanek1, W. Sealls1;
1Eli Lilly and company, Indianapolis, 2The Ohio State University, Co-
lumbus, USA, 3Hadassah Hebrew University Hospital, Jerusalem, Israel.
Background and aims: The 6 completed Phase 3 trials from the
dulaglutide AWARD program, a once weekly glucagon-like peptide-1
receptor agonist, demonstrated significant improvements in HbA1c and
weight, with a low risk for hypoglycaemia. Post-hoc analyses from these
data compare dulaglutide 1.5 mg and 0.75 mg with active comparator
therapies and placebo on the composite endpoint of HbA1c <7%
(53 mmol/mol), and no weight gain or hypoglycaemia.
Materials andmethods:A logistic regression analysis was performed on
the intent-to-treat population, last observation carried forward patient data
on the composite endpoint of glycated haemoglobin HbA1c <7.0%
(53 mmol/mol), no weight gain (≤0 kg) and no hypoglycaemia (glucose
<3.0 mmol/L or any report of severe hypoglycaemia) after 26 weeks of
treatment.
Results: At 26 weeks, within each study, 37 to 58% of patients on DU
1.5 mg, 27 to 49% of patients on DU 0.75 mg, and 9 to 61% on AC
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achieved the composite endpoint. Significantly more patients reached the
composite endpoint with DU 1.5 mg than with metformin, sitagliptin,
exenatide BID, and insulin glargine (odds ratio [95% CI]: 1.5 [1.0, 2.2;
p<.05], 4.5 [3.0, 6.6; p<.001], 2.6 [1.8, 3.7; p<.001], 7.4 [4.4, 12.6; p
<.001], respectively); with no difference between dulaglutide 1.5 mg and
liraglutide 1.8 mg (Figure). In addition, significantly more patients
reached the composite endpoint with DU 0.75 mg compared to sitagliptin
and insulin glargine (3.3 [2.2, 4.8; p<.001], 4.5 [2.7, 7.8; p<.001],
respectively).
Conclusion: Dulaglutide is an effective treatment option, resulting in a
similar or greater proportion of patients who reached the HbA1c target of
<7.0% (53 mmol/mol), without weight gain or hypoglycaemia compared
to active comparators.
Supported by: Eli Lilly and Company.
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Effects of once weekly dulaglutide on kidney function in clinical trials
K.R. Tuttle1, T.D. McKinney2, G. Anglin3, K.D. Harper2, F.T. Botros2;
1Providence Health Care, University of Washington, Spokane, 2Eli Lilly
and Company, Indianapolis, USA, 3Eli Lilly Canada Inc, Toronto, Can-
ada.
Background and aims:Dulaglutide is a once weekly glucagon-like pep-
tide 1 receptor agonist approved for the treatment of type 2 diabetes
(T2D). Postmarketing cases of acute decreases in kidney function related
to other incretin-based therapies have been reported. However, experi-
mental models of diabetes have not suggested harm to the kidney from
these therapies. The aim of this study was to determine effects of
dulaglutide (1.5 mg and 0.75 mg) on kidney function and adverse events
(AEs) in post hoc analyses of clinical trials with placebo (PL) and active
comparators.
Materials and methods: Serum creatinine (sCr), estimated glomerular
filtration rate (eGFR), and urine albumin-to-creatinine ratio (UACR)were
evaluated using integrated data from 9 completed Phase 2 and 3 trials.
Dulaglutide was compared to PL in 3 studies (treatment duration 16-
26 weeks) and to a combined active comparator group (sitagliptin,
exenatide [twice daily], insulin glargine, and metformin) in 5 studies
(Treatment duration 52-104 weeks). Dulaglutide was also compared to
insulin glargine alone in 2 studies (at 52 weeks).
Results: Treatment durations were comparable between dulaglutide and
comparator arms for all studies included in this analysis. No significant
differences in sCr or eGFR were observed at baseline or during treatment
between dulaglutide and PL, the combined active comparator group, or
insulin glargine alone. UACR values were slightly but significantly lower
for dulaglutide than for PL, the combined active comparators, and insulin
glargine alone during the treatment period. AE terms reflecting potential
acute kidney injury were reported at rates of 3.4, 1.7, and 7.0 events per
1000 patient years of exposure for dulaglutide (n=12; N=4006), all ac-
tive comparators (n=3; N=1541), and PL (n=2; N=703), respectively.
Conclusion: Treatment of T2D patients with dulaglutide in clinical trials
did not appear to alter kidney function when compared to PL, a group of
active comparators, or insulin glargine alone. Rates of reported AEs re-
lated to kidney disease were comparable for all groups.
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Low incidence of anti-drug antibody in type 2 diabetes patients treat-
ed with once weekly dulaglutide
Z. Milicevic1, G. Anglin2, K. Harper3, R. Konrad3, Z. Skrivanek3, W.
Glaesner4, K. Mace3;
1Eli Lilly and Company, Vienna, Austria, 2Eli Lilly Canada Inc., Toronto,
Canada, 3Eli Lilly and Company, Indianapolis, 4Eli Lilly and Company,
San Diego, USA.
Background and aims: Dulaglutide, a once weekly glucagon-like pep-
tide-1 (GLP-1) IgG4-Fc fusion protein for type 2 diabetes treatment, was
structurally modified to reduce immunogenic potential by eliminating T-
cell epitopes based on the results of the EpiVax algorithm. Immunoge-
nicity of dulaglutide was assessed in 9 clinical studies.
Materials and methods: Blood samples collected serially were assayed
for dulaglutide anti-drug antibody (ADA) using validated ELISAs. Sam-
ples with treatment-emergent ADA were tested for dulaglutide -
neutralizing antibody and native sequence GLP-1 (nsGLP-1) cross-reac-
tivity, and then neutralization of nsGLP-1. Associations between ADA
and hypersensitivity adverse events, injection site reactions, and HbA1c
changes were assessed.
Results:A total of 3907 dulaglutide and 1114 non-GLP-1 receptor
agonist comparator patients were tested. The incidence of
treatment-emergent ADA with dulaglutide was 1.6% vs 0.7% with
non-GLP-1 receptor agonist comparator. Dulaglutide-neutralizing
antibody, nsGLP-1 cross-reactivity, and nsGLP-1 neutralizing an-
tibody were observed in 0.9%, 0.9%, and 0.1% of dulaglutide
patients, respectively. There was no evidence of an effect of
ADA on HbA1c change after 26 or 52 weeks of treatment. Only
19 (0.5%) of dulaglutide patients had a hypersensitivity adverse
event, none had treatment-emergent ADA. There were 20 (0.5%)
dulaglutide-exposed patients with potentially immune-mediated in-
jection site reactions; 2 of them (0.05% of 3907) had treatment-
emergent ADA.
Conclusion: Incidence of ADA in patients exposed to dulaglutide was
low. No association between dulaglutide ADA and hypersensitivity ad-
verse events, injection site reactions, or HbA1c changes was observed.
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Supported by: Eli Lilly and Company
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Albiglutide provides effective glycaemic lowering across diabetes du-
ration subgroups
P. Home1, D. Miller2, M.C. Carr2;
1Newcastle University, Newcastle upon Tyne, UK, 2GlaxoSmithKline,
King of Prussia, USA.
Background and aims: Incretin therapies work in part by stimulating
insulin secretion, so it is important to characterize their efficacy in people
with longer-standing diabetes and less residual β-cell function. Here we
test the hypothesis that albiglutide will have a similar efficacy and safety
profile independent of diabetes duration.
Materials and methods: Pooled phase-3 data were from 1391 partici-
pants in placebo comparator studies, randomized 923 to albiglutide and
468 to placebo, ± oral agents. Efficacy analyses use the primary outcome
variable (HbA1c) and other measures pooling data 6 months from
randomization
Results:Baseline characteristics were generally well balanced vs placebo
and typical of people with T2DM (age 54 yr, HbA1c 8.1% (65.02 mmol/
mol), BMI 33.1 kg/m2). Change in HbA1c for albiglutide vs placebo
varied from a difference of -0.93 (-1.08,-0.79) %-units (-10.17 [-11.81, -
8.64] mmol/mol) in the <5-yr group to -0.70 (-0.90, -0.50) %-units (-7.65
[-9.84, -5.47] mmol/mol) in the ≥10-yr group (Table). The fasting plasma
glucose difference was -1.65 (-2.03, -1.27) mmol/L at short duration, -
1.30 (-1.75, -0.86) mmol/L in the middle group, and -1.44 (-1.97, -0.92)
mmol/L at ≥10-yr duration. Adverse events did not differ between
albiglutide groups except for injection site reactions (fewer at longer
duration). Serious adverse events were similar by duration of diabetes
for the albiglutide group.
Conclusion: Albiglutide had good efficacy independent of diabetes du-
ration with no deterioration of adverse event profile.
Supported by: GSK
PS 069 GLP-1 receptor agonists:
approaching approvability
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Efficacy and tolerability of ITCA 650 (continuous subcutaneous
exenatide) for 39 weeks in patients with poorly controlled type 2
diabetes mellitus and high baseline HbA1c (>10%)
R.R. Henry1, J. Rosenstock2, D. Denham3, P. Prabhakar4, L. Kjems4, M.
Baron4;
1University of California San Diego School ofMedicine, Veterans Affairs
San Diego Healthcare System, 2Dallas Diabetes and Endocrine Center at
Medical City, 3Clinical Trials of Texas, San Antonio, 4Intarcia Therapeu-
tics, Inc., Boston, USA.
Background and aims: ITCA 650 is an injection-free glucagon-like
peptide-1 (GLP-1) receptor agonist that provides continuous subcutane-
ous (SC) exenatide for up to 12 months from a single sub-dermal place-
ment. Open-label treatment with ITCA 650 was offered to type 2 diabetes
(T2DM) patients ineligible for a double-blind, placebo-controlled trial
because of HbA1c >10%.
Materials andmethods: Patients were 18-80 years with HbA1c >10% to
≤12%, BMI 25-45 kg/m2, on stable (≥3 months) diet and exercise or oral
antidiabetics (OADs). ITCA 650 was initiated at 20 mcg/d for 13 weeks,
then 60 mcg/d for 26 weeks. Baseline (BL) OADs were continued; sul-
fonylureas (SUs) were adjusted if medically necessary. Endpoints were
change from BL for HbA1c and body weight (BW) and % achieving
HbA1c <7% at 39 weeks.
Results: Sixty patients were enrolled. Six (10.0%) patients discontinued
for adverse events (AEs). At BL, HbA1cwas 10.8%, age 51.9 years, BMI
32.0 kg/m2, diabetes duration 9 years, OAD use 69%. At Week 39, mean
reduction of HbA1c from BL to Week 39 (last observation carried for-
ward) was -2.8% (p<0.001), and 22% achieved HbA1c <7%. Significant
A1C reductions were seen by Week 6 (Figure). The most common AEs
were nausea, vomiting, diarrhea, headache, and urinary tract infection.
Nausea, vomiting, and diarrhea rapidly decreased after Week 1. There
were no reports of pancreatitis or major hypoglycemic events; 6.7% re-
ported minor hypoglycemia, and all serious AEs were considered unre-
lated to ITCA 650.
Conclusion: ITCA 650 for 39 weeks produced significant reductions in
HbA1c, improvedBWand goal attainment andwas well tolerated in these
poorly controlled T2DM patients with high HbA1c.
Clinical Trial Registration Number: NCT01785771
Supported by: Intarcia Therapeutics, Inc.
787
Absorption, metabolism and excretion of [3H]-semaglutide following
a single, subcutaneous dose in healthy male subjects
A.F. Roffel1, L. Jensen2, J.J. van Lier1, E. Rowe3, J. Derving Karsbøl2,
M.L. Pedersen2;
1PRA Health Sciences Early Development Services, Zuidlaren, Nether-
lands, 2Novo Nordisk, Søborg, Denmark, 3Novo Nordisk Inc., Princeton,
USA.
Background and aims: Semaglutide is a human GLP-1 analogue in
clinical development for once-weekly treatment of T2D. Semaglutide
has minor modifications versus native human GLP-1 that aim to reduce
renal clearance and protect against dipeptidyl peptidase-4 degradation,
resulting in a prolonged half-life. This open-label study investigated the
absorption, metabolism and excretion of radiolabelled semaglutide in
humans.
Materials and methods:Healthy male subjects (n=7; aged 48-64 years;
bodymass index 21.7-29.7 kg/m2) received a single subcutaneous dose of
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radioactively labelled semaglutide (0.5 mg/450 μCi/16.5 MBq [3H]-
semaglutide). The [3H] label, used previously in non-clinical semaglutide
studies, was attached to the semaglutide fatty acid side chain. Radioac-
tivity was determined in the blood, plasma, urine, faeces and expired air
up to 56 days after administration. Metabolites were quantified in plasma,
urine and faeces using HPLC followed by radio detection. In addition,
routes and rates of excretion, blood-to-plasma ratio, pharmacokinetics
(PK) of [3H]-semaglutide-related material and standard PK were
assessed.
Results: Total recovery of [3H]-semaglutide-related material was 75.1%
(coefficient of variation in percentage [CV%] 5.2) of the administered
dose: urine 53.0% (8.2); faeces 18.6% (19.9); and expired air 3.2%
(9.0) (Figure). Intact [3H]-semaglutide was the major component in plas-
ma at all time points analysed, accounting for 83% of the total radioac-
tivity, based on the area under the concentration-time curve (AUC). A
total of 6 metabolites were detected in plasma, each accounting for be-
tween 0.4% and 7.7% of the total amount of radioactivity. Intact
semaglutide accounted for ~3% of the administered dose in urine. In
addition, 21 metabolites were detected in urine; the 2 most abundant each
comprised ~14% of the administered dose (all other metabolites each
≤1.8%). Intact semaglutide was not detected in faeces. In total, 7 metab-
olites were detected in faeces, each ≤1.5% of the administered dose. The
blood-to-plasma ratio of radioactivity showed that [3H]-semaglutide-re-
lated material was primarily distributed in the plasma compartment, and
was relatively constant over time. The PK properties of [3H]-semaglutide
in this study were comparable with results from previous trials with
unlabelled semaglutide. No new or unexpected safety or tolerability is-
sues were identified.
Conclusion: This study shows that, following treatment with [3H]-
semaglutide, intact semaglutide is the main component in plasma.
Semaglutide is extensively metabolised prior to elimination, and
semaglutide-related material is primarily excreted in the urine.
Semaglutide has limited renal excretion in its intact form. This supports
that semaglutide may be used without dose adjustment in subjects with
renal impairment.
Clinical Trial Registration Number: NCT02060266
Supported by: Novo Nordisk A/S
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Superagonistic mechanism of increased glucodynamic and weight
loss effects of LAPSCA-exendin-4 (efpeglenatide)
I. Choi1, S. Park1, M. Trautmann2, J. Kim1, J. Kim1, Y. Lee1, J. Kang1,
M. Hompesch2, S. Kwon1;
1Hanmi Pharm. Co., Ltd., Hwasung, Republic of Korea, 2Profil Institute
for Clinical Research, Inc., Chula Vista, USA.
Background and aims: The novel long-acting GLP-1 receptor agonist,
efpeglenatide, was developed for the treatment of type 2 diabetes and is
currently in phase II clinical trials as a weekly or monthly GLP-1 receptor
agonist (GLP-1RA). It consists of an exendin-4 analog (CA-Exendin-4)
conjugated via non-peptidyl linker to a non-glycosylated human Fc frag-
ment. Previously, CA-Exendin-4 showed greater blood glucose lowering
efficacy in db/db mice compared to native exendin-4 and it was hypoth-
esized that such a superagonistic action ofCA-Exendin-4 is due to its fast
dissociation from human GLP-1 receptor. In this study, we investigated
further the mechanism using CA-Exendin-4 and efpeglenatide.
Materials andmethods:Affinity to GLP-1 receptor (GLP-1R) wasmea-
sured by Surface Plasmon resonance (SPR) analysis. Internalization of
GLP-1R was assessed in GLP-1R/U2OS cells using the PathHunter™
eXpress Kit (DiscoveRx Corp. Ltd., UK). Surface GLP-1R level was
determined by [125I]GLP-1 binding after acid-wash of the cells. In vitro
activity after chronic treatment of GLP-1RAs was determined bymeasur-
ing intracellular cyclic AMP in GLP-1R/CHO and insulin release in
RINm5F cells. The cells were pre-treated with 10 nM of GLP-1RAs for
4 to 24 hours and followed by cAMP or insulinotropic induction by re-
treatment with 0-5,000 nM of GLP-1RAs. In order to compare in vivo
efficacy between efpeglenatide and other GLP-1RAs, change of blood
glucose and HbA1c in db/db mice by subcutaneous injection was moni-
tored during 4 weeks and body weight loss was compared in DIO rats for
4 weeks.
Results: CA-Exendin-4 elicited less internalization of GLP-1 receptors
compared to exendin-4 in human GLP-1R overexpressed U2OS, and this
was also confirmed in hGLP-1R/CHO cells by measuring the residual
surface receptors. Further, GLP-1R internalization was compared be-
tween efpeglenatide and other long-acting GLP-1RAs. Efpeglenatide
led to less GLP-1R internalization (e.g. 50% or less) than liraglutide
and dulaglutide in both hGLP-1R/U2OS and hGLP-1R/CHO cells.
Efpeglenatide also led to less receptor desensitization under chronic treat-
ment conditions in cAMP accumulation and insulinotropic assays. Final-
ly, in db/dbmice, efpeglenatide showed a greater HbA1c decrease (-3.8%
in 4 weeks) than liraglutide and dulaglutide (-2.6% and -2.8%, respec-
tively) at doses to corresponding to human use. In addition, efpeglenatide
revealed greater efficacy in body weight loss of -20.9% in DIO mice for
4 weeks,compared with -18.6% by liraglutide and -7.1% by dulaglutide.
Conclusion: Following conjugation to Fc the fast receptor dissociation
kinetics of CA-Exendin-4 were maintained in efpeglenatide (kd 4.2×10
-
3 s-1 vs. 1.0×10-3 s-1 for efpeglenatide). We also demonstrated that
efpeglenatide lead to significantly less GLP-1R internalization than
liraglutide and dulaglutide in human GLP-1R transformed U2OS cells.
This translated into more potent glucose lowering in db/db mice and
greater body weight loss in DIO mice in comparison to liraglutide and
dulaglutide. Taken together, CA-Exendin-4 even after conjugation to the
human Fc-fragment seems to achieve more pronounced GLP-1R activa-
tion due to reduced receptor internalization and consequently leads to
more potent effects. These findings may explain the observed efficacy
of efpeglenatide in clinical trials relative to liraglutide.
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CCK and GLP-1 receptor agonist co-administration ameliorates di-
abetes in mice
S. Ali1, S. Hawkins2, S. Will3, M. Feigh4, D. Hornigold3, A. Konkar3,
J.L. Trevaskis3;
1Cardiovascular and metabolic disease, Medimmune, 2Laboratory Ani-
mal Resources, Medimmune, 3Cardiovascular Metabolic Disease,
Medimmune, Gaithersburg, USA, 4Gubra, Hørsholm, Denmark.
Background and aims: GLP-1 and CCK are hormones secreted from
gut endocrine cells in response to meals that regulate metabolism. Co-
administration of CCK and GLP-1 analogs induce synergistic weight loss
in diet-induced obese rats.
Materials andmethods:We investigated the impact of selective CCK1R
(A1) or CCK2R (A2) agonists alone or in combination with a GLP-1R
agonist (AC3174) on acute inhibition of food intake in lean mice, insulin
secretion from a rat beta cell line (Ins-1 cells), and on body weight and
glycemia in obese and diabetic db/db mice.
Results: Combined AC3174 (0.3 nmol/kg, sc) and A1 (300 nmol/kg, ip)
administration had greater impact on inhibiting food intake vs. monother-
apy, whereas addition of A2 to AC3174 had no further impact on food
intake. In Ins-1 cells, glucose-dependent insulin secretion was enhanced
by incubation with AC3174, and to a lesser extent A1. Incubating Ins-1
cells with AC3174 and A1, but not A2, resulted in additive effects on
insulin secretion. These findings suggest synergy between CCK and
GLP-1 requires activation of CCK1R and not CCK2R. Diabetic db/db
mice administered AC3174 (0.3 nmol/kg, sc, qd) and A1 (300 nmol/kg,
ip, qd) for 14 days exhibited a robust reduction in body weight (-25.8%)
compared to vehicle (+8%), AC3174 alone (-4.9%) or A1 alone (-13.4%).
Weight loss was associated with reduced food intake, and combination
treatment was associated with lower glucose and a trend towards lower
HbA1C levels vs. monotherapy- or vehicle-treated groups. AC3174 did
not affect liver weight, however a significant reduction in liver weight
was observed with A1 alone and in combination with AC3174, and was
associated with reduced plasma alanine aminotransferase and triglyceride
levels.
Conclusion: In summary, our results demonstrate that co-administration
of CCK1R and GLP-1R agonists elicits synergistic weight loss and im-
provement in glucose control, potentially via improved liver function and/
or co-operative actions on pancreatic function.
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Potent weight loss mechanism and improvement of NASH by the
long-acting GLP-1/glucagon receptor dual agonist HM12525A
S. Jung1, J. Lee1, J. Kim1, Y. Lee1, Y. Kim1, J. Kang1,M. Trautmann2,M.
Hompesch2, S. Kwon1;
1Hanmi Parmaceutical, Seoul, Republic of Korea, 2Profil institute, Chula
Vista, USA.
Background and aims: Dual agonists activating the GLP-1 receptor
(GLP-1R) and the glucagon receptor (GCG-R) may represent a new ther-
apeutic approach for obesity with the potential for enhanced weight loss
beyond those of GLP-1R agonists. Oxyntomodulin, a human gut hormone
with agonism to the GLP-1R and the GCG-R, causes a significant reduc-
tion inweight by regulating both, appetite and energy expenditure, however
its clinical application is limited due to a short half-life. HM12525A is a
long-acting GLP-1/glucagon receptor dual agonist for once-weekly admin-
istration. It consists of a GLP-1/glucagon receptor dual agonist conjugated
via non-peptidyl linker to a non-glycosylated human Fc fragment. The aim
of this development was to achieve increased body weight loss (BWL)
compared to GLP-1R agonists while extending the half-life. This study
investigated the mechanism responsible for increased BWL and the effect
on nonalcoholic steatohepatitis (NASH) by HM12525A by assessing en-
ergy expenditure (EE) and lipid metabolism.
Materials and methods: To evaluate the effect on FGF21 related EE
increase, firstly, the secretion of FGF21 was investigated in primary he-
patocytes and DIO (diet induced obesity) rats after HM12525A treatment.
Next, the expression of UCP-1, a well known mediator of EE, was inves-
tigated in differentiated 3 T3-L1 adipocytes by co-treatment with FGF21.
In vivo energy intake and expenditure as well as locomotor activity were
assessed by using a combined indirect calorimetry system in DIO mice.
To evaluate the effect on lipid metabolism in the liver, liver histology and
CPT-1 expression, a marker ofβ-oxidation, were investigated in DIO rats
following chronic administration of HM12525A. To evaluate the effect
on NASH, hepatic levels of inflammation, fibrosis marker, and histolog-
ical scoring were investigated in ALIOS- (American lifestyle induced
obesity syndrome) and methionine-choline deficient (MCD) diet-mice
as NASH models.
Results: The secretion of FGF21 was significantly increased in primary
hepatocytes (2-fold vs. vehicle) as well as in DIO rats after HM12525A
treatment. HM12525A treatment induced the expression of UCP-1 (4.5-
fold vs. vehicle) which was further enhanced by co-treatment with FGF21
(13.4-fold vs. vehicle). Consistent with these in vitro results, HM12525A
increased EE without affecting locomotor activity in DIO mice. These
results suggest that the HM12525A-FGF21 axis plays an essential role in
BWL by enhancing EE. In DIO rats, the chronically administered
HM12525A ameliorated fatty livers together with the increase of CPT-1
expression (1.8-fold vs. vehicle). In ALIOS mice, HM12525A resulted in
greater effects on body weight and hepatic TG reduction compared to
liraglutide. Hepatic levels of inflammation, fibrosis marker, and histolog-
ical scoring for NASH were decreased consistently after HM12525A
administration in MCD mice.
Conclusion: Taken together, our results demonstrate that that the novel
GLP-1/glucagon receptor dual agonist HM12525A may have clinical
potential for the treatment of obesity and obesity-related liver disease.
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The ultra-long acting LAPSGLP/GCGdual agonist, HM12525A, dem-
onstrated safety and prolonged pharmacokinetics in healthy volun-
teers: a phase 1 first-in-human study
J. Kang1, J.-H. Kim1, J. Yi1, O. Han1, Y. Kim1, E. Baek1, S. Jung1, S.
Kwon1, M.E. Trautmann2, M. Hompesch2;
1Hanmi Pharmacuticals Co., Ltd, Seoul, Republic of Korea, 2Profil Insti-
tute for Clinical Research, Inc., Chula Vista, USA.
Background and aims: Glucagon-like peptide-1 (GLP-1) /glucagon
(GCG) dual agonists have potential to treat obesity and diabetes by acti-
vating both GLP-1 and GCG receptors. Once-weekly LAPSGLP/GCG
dual agonist, HM12525A, is site-specifically conjugated by
LAPSCOVERY technology for sustained duration. Combining the syn-
ergetic effects with this long-acting platform, HM12525A may improve
patient compliance and thereby treatment outcomes further. This First-in-
Human, Phase I, randomized, double-blinded, placebo-controlled single
ascending dose study evaluated the safety, tolerability, PK and PD of
HM12525A in healthy volunteers.
Materials and methods: Forty subjects (age: 48.3±10.4 years; male:
70%; BMI: 29.7±3.3 kg/m2) were randomly assigned to 5 cohorts
(0.25, 0.5, 1.0, 2.0, and 4.0 nmol/kg), and received a single subcutaneous
injection of either HM12525A or placebo (ratio, 3:1). The total duration
of the study was 56 days, including follow up.
Results:HM12525A demonstrated prolonged PK profiles with tolerance.
The observed Cmax in each cohort was ranged from 0.759 to 18.5 nmol/L
at 113.1±55.3 hr post-dose. AUC0-last (120 to 6560 hr·nmol/L) and T1/2
(112.5 to 276.2 hr) was also observed. Among the 5 cohorts, the maxi-
mum tolerated single dose was determined at a dose level of 2.0 nmol/kg.
Overall, none of the subjects exhibited any clinically significant alter-
ations in vital signs, laboratory values, and 24 hr ambulatory ECG. Dur-
ing 24 hr ambulatory blood pressure assessments, no significant change
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in heart rate (HR) was observed up to 1.0 nmol/kg dose. At 2.0 and
4.0 nmol/kg doses, mean HR was elevated by 5.77±2.30 and 8.06±
2.56 (p-value: 0.017 and 0.004) compared to the placebo, while mean
systolic and diastolic BPs had no significant changes. Anti-drug antibod-
ies were detected in 7 subjects; 3 subjects already had ADA at baseline,
while the other 4 were newly detected during the study. None of these 7
subjects had neutralizing antibodies. The most frequent treatment emer-
gent adverse events (TEAEs) were gastrointestinal disorders, such as
nausea and vomiting. No serious TEAEs were occurred.
Conclusion: In summation, this single ascending dose study demon-
strates that HM12525A was well tolerated with prolonged PK profile,
which may confirm the potential for once-weekly injections. Further in-
vestigation in T2DM patients is expected to explore further synergetic
potential of this LAPSGLP/GCG dual agonist to provide beneficial and
effective therapeutic regimens.
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LAPS-Exendin-4 (HM11260C) enhances insulin secretion and beta
cell responsiveness in subjects with type 2 diabetes
E. Watkins1, J. Kang2, M. Trautmann1, L. Morrow1, S. Choi2, O. Han2,
M. Hompesch1;
1Profil Institute for Clinical Research, Inc, Chula Vista, USA, 2Hanmi
Pharmaceutical Co., Ltd, Seoul, Republic of Korea.
Background and aims: LAPSExendin-4 (HM11260C) is a glucagon
like peptide -1 (GLP-1) receptor agonist being developed for the treat-
ment of type 2 diabetes mellitus (T2DM). In this phase 1B study the
effects of different HM11260C regimens on insulin secretion rate (ISR),
β-cell responsiveness, and gastric emptying (GE) compared to placebo
and to liraglutide were investigated.
Materials and methods: Subjects with T2DM received 6 mg
HM11260C weekly (cohort A; age: 52.8 years, HbA1c: 8.4, n=13),
16 mg HM11260C monthly (cohort B; age: 50.1 yr, HbA1c: 8.1, n=
13), 1.8 mg liraglutide daily (cohort C; age: 54.9 yr, HbA1c: 8.02 n=
13), or placebo (age: 54.1 yr, HbA1c: 8.6, n=8). Subjects in cohorts A
and C were evaluated at baseline and steady state, and cohort B was
evaluated at trough (day [d] 82) and peak (d89) drug concentration. Islet
β-cell function was assessed during a graded IV glucose infusion (GGI);
infusion steps: 2, 4, 6, 8, 12 mg/kg/min of 20% IV glucose for 30 min
each. Insulin C-peptide levels, and plasma glucose response to each GGI
step were measured. ISR were determined using a population based C-
peptide de-convolution model. AUC(insulin) and AUC(C-peptide) as
measures of ISR were determined for each treatment. β -cell responsive-
ness was assessed as the ratio of ISR/ blood glucose (BG) over the dura-
tion of the GGI, and the slope of the ISR/BG was compared between the
treatments. The rate of GE was determined for 1 g of liquid acetamino-
phen following a mixed meal and a mixed meal tolerance test (MMTT)
was performed. For GE, non-inferiority to liraglutide was tested using a
margin of 0.8 for the least squares (LS) mean ratio.
Results: Insulin secretion for all active treatments was increased
compared to placebo and for HM11260C 6 mg and 16 mg was
greater than for liraglutide (point estimates LS mean ratio:
1.765 mU/L, 90% CI: 1.331, 2.342 mU/L, one-sided p=0.0008,
and LS mean ratio: 1.440 mU/L, 90% CI: 1.080, 1.920 mU/L,
one-sided p=0.0196). Comparisons of the relationship between
ISR and plasma glucose using mixed effects modelling showed
an improvement in beta cell responsiveness relative to placebo/
baseline which was not different among treatments. In the month-
ly treatment group, there was a diminution of effect at PK trough
(d82). For postprandial glucose following the MMTT the LS
means of the Cmax, AUC0-180, and AUC0-360 parameters were
significantly (two-sided p 0.8) to liraglutide in terms of acetamin-
ophen Cmax, AUC0-120 min, and AUC0-180 min. While for
Cohort B the effect on gastric emptying appeared to be similar
or even less when compared to liraglutide, formal non-inferiority
could not be established for all parameters. GE was delayed in
cohorts A and B compared to placebo.
Conclusion: HM11260C improved measures of β-cell function signifi-
cantly compared to placebo, and for the weekly treatment regimen (cohort
A), significantly compared to liraglutide. The results of this trial suggest
that HM11260C is a safe and efficacious GLP-1 receptor agonist and that
with regard to gastric emptying it inhibited less or similarly compared to
other known GLP-1 receptor agonists.
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Dose-response improvements in glycaemic control and body weight
reduction with HM11260C, a once weekly GLP-1 receptor agonist
with liraglutide as reference, in type 2 diabetes
K.-H. Yoon1, J. Kang2, S. Choi2, O. Han2, S. Kil2, K. Gee2, I. Choi2, S.
Kwon2, M. Trautmann3, M. Hompesch3;
1Department of Endocrinology and Metabolism, Seoul St. Mary’s Hos-
pital, The Catholic University of Korea, 2Hanmi Pharmaceutical Co.,
Ltd., Seoul, Republic of Korea, 3Profil Institute for Clinical Research,
Inc., Chula Vista, USA.
Background and aims: HM11260C (HM) is a novel long acting GLP-
1R agonist with a T1/2 of~158 hrs resulting in a flat PK profile. This 12-
week, randomized, placebo (PBO) controlled, double-blind parallel
group study with an open label active control liraglutide (LIRA) arm,
was designed to investigate the dose ranging efficacy, safety, and tolera-
bility of once weekly (QW) doses of HM in subjects with Type 2 Diabetes
(T2DM).
Materials and methods: Stratified by metformin use 254 patients (mean
age 55.3 yrs, BMI 31.76 kg/m2, diabetes duration 73.08 months) were
randomized to one of five HM QW doses, PBO or to LIRA QD up-
titrated to 1.8 mg. All HM doses were not titrated.
Results: HM 0.3 to 4 mg produced dose-dependent reduction in HbA1c,
fasting plasma glucose, and 7-point daily glucose (Table 1). In addition,
HM 4 mg reached statistical significance in demonstration for non-
inferiority to LIRA by mean % change of HbA1c from baseline (Differ-
ence=-0.23, 95.1% CI=[-0.56, 0.10]). Attainment of target HbA1c<7%
with HM was 89.7% (3 mg, p<0.0001) and 89.3% (4 mg, p<0.0001) vs
26.5% (PBO), and 73.3% (LIRA). The reduction in body weight with
HM 3 mg (2.732 kg) and 4 mg (3.309 kg) was significantly greater than
that with PBO (1.290 kg, p<0.049, both). The most frequent AEs were
gastrointestinal side effects of mild or moderate severity: nausea and
vomit that subsided over time.
Conclusion: In summary, all doses of HM demonstrated clinically mean-
ingful improvements in blood glucose and body weight, with higher
doses being more effective. Safety profiles were comparable to LIRA.
The current results warrant further studies to assess the long-term efficacy
and safety of HM11260C in T2DM.
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Once weekly glucagon-like peptide 1 receptor agonists for type 2
diabetes: systematic review and meta-analysis
A. Liakos1, T. Karagiannis1, E. Bekiari1, E. Athanasiadou1, P. Paschos1,
D. Vasilakou1, M. Mainou1, M. Rika1, P. Boura2, D.R. Matthews3, A.
Tsapas1,3;
1Clinical Research and Evidence-Based Medicine Unit, Second Medical
Department, Aristotle University Thessaloniki, 2Second Medical Depart-
ment, Aristotle University Thessaloniki, Greece, 3Harris Manchester Col-
lege, University of Oxford, UK.
Background and aims: Albiglutide, dulaglutide and exenatide extended
release are injectable glucagon-like peptide 1 receptor agonists (GLP-1
RAs) administered once weekly that have recently been approved for type
2 diabetes.We performed a systematic review and meta-analysis to assess
their efficacy and safety.
Materials and methods: We searched for randomised controlled trials
with at least 12 weeks duration of treatment in Medline, Embase, the
Cochrane Library, ClinicalTrials.gov, and abstracts of major scientific
meetings through December 2014. We synthesised results regarding
change in HbA1c and body weight, and incidence of hypoglycemia, in-
jection site reactions, nausea, vomiting, serious adverse events (SAEs)
and all cause mortality. We conducted separate analyses for studies
against placebo or active comparator. We quantified heterogeneity with
the I2 statistic.
Results: We included 33 trials (16,003 participants) with a duration be-
tween 12 and 156 weeks in our systematic review. Participants’mean age
ranged from 52 to 63 years and baseline HbA1c from 7.1% to 8.7%. The
majority of albiglutide and dulaglutide trials utilised a double blind de-
sign, whilst most exenatide extended release studies were open label.
Compared with placebo, change in HbA1c was -0.66% (six studies;
95% CI -1.14 to -0.19; I2=88%) with albiglutide, -1.18% (seven studies;
95% CI -1.34 to -1.02; I2=65%) with dulaglutide, and -1.48% (two stud-
ies; 95% CI -2.61 to -0.36; I2=80%) with exenatide extended release.
Once weekly GLP-1 RAs outperformed sitagliptin, daily exenatide and
basal insulin in terms of HbA1c lowering, and were equally effective with
liraglutide (Table). Based on placebo controlled trials, treatment with
once weekly GLP-1 RAs did not result in significant body weight reduc-
tion (weighted mean difference -0.61 kg; 95% CI -1.31 to 0.09; I2=84%),
although weight sparing benefits were evident relative to sitagliptin and
basal insulin, but not versus liraglutide (Table). Risk for any
hypoglycaemia was higher compared to sitagliptin, similar to daily
GLP-1 RAs, and lower in comparison with basal insulin (Table). Main
adverse effects included gastrointestinal and injection site reactions (Ta-
ble). Incidence of SAEs and all cause mortality did not differ between
once weekly GLP-1 RAs and across all comparator arms (ORs 0.93; 95%
CI 0.82 to 1.04; I2=13% and 0.67; 95% CI 0.40 to 1.11; I2=0%
respectively).
Conclusion: Given their overall efficacy and safety profile and conve-
nient dosing scheme, once weekly GLP-1 RAs are an attractive therapeu-
tic alternative to oral antidiabetic agents, basal insulin, or twice daily
exenatide in patients inadequately controlled with metformin alone.
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Adherence with GLP-1RA therapy in Germany: exenatide once
weekly vs liraglutide once daily
Q. Qiao1, S. Grandy2, K. Kostev3;
1Medical Evidence and Observational Research Center, Global Medical
Affair, Astrazeneca Phamaceuticals, Mölndal, Sweden, 2Global Medi-
cines Development, AstraZeneca, Wilmington, USA, 3Epidemiology,
IMS Health, Frankfurt am Main, Germany.
Background and aims: The aim was to estimate the adherence of pri-
mary care patients initiating therapy with GLP-1 receptor agonist (GLP-1
RA) once weekly (exenatide) or once daily (liraglutide).
Materials and methods: Initiation of GLP-1 RA therapy documented in
statutory health insurance patients in Germany between January 1, 2011
and September 30, 2014 (date of initiation=index) were studied. The
database covers 60% of all prescriptions nationwide. A minimum 6-
month prior to and at least 6-month post-index pharmacy benefits enroll-
ment was required for eligibility of inclusion. Adherence was measured
using the ‘proportion of days covered’ (PDC) with index GLP-1RA dur-
ing the 6-month post-index period. PDCwas calculated by taking the total
number of days supply per patient during the post-index 6-month period
and dividing that by 180 days. Days supplied was calculated as follows:
pack size * pack count * 7 for exenatide; and strength * pack size * pack
count / 1.3 (median dose) for liraglutide.
Results: Overall, 5,449 patients (mean (sd) age: 59.7 (11.8) years, men
51.4%) initiating exenatide, and 24,648 patients (mean (SD) age: 59.4
(11.4) years, men 49.7%) initiating liraglutide therapy were included in
the data analysis. The median PDC was 0.88 for exenatide and 0.77 for
liraglutide (p<0.001). 53.4% of the patients receiving exenatide, and
47.7% of those receiving liraglutide had an adherence of at least 80%
(p<0.001) during the 6 months after initiating the drugs. There was no
significant gender difference in the median PDC (exenatide: male 0.85
and female 0.86; liraglutide: male 0.77 and female 0.77). The medians of
the PDC in age groups of ≤50, 51-60, 61-70 and >70 years were 0.78,
0.92, 0.92 and 0.81 for exenatide, and 0.77, 0.79, 0.79 and 0.77 for
liraglutide, respectively.
Conclusion:Over a 6-month period after initiation of GLP-1RA therapy,
patients treated with exenatide once weekly had significantly better ad-
herence compared with patients on liraglutide once daily, particularly
among patients aged 50 years or older.
Supported by: Astrazeneca
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Achieving postprandial glucose control with lixisenatide improves
glycaemic control in patients with type 2 diabetes mellitus on basal
insulin
S. Paranjape1, W. Stager1, R. Berria2, L.A. Leiter3;
1ProUnlimited@Sanofi, 2Sanofi US, Inc., Bridgewater, USA, 3Li Ka
Shing Knowledge Institute and Keenan Research Centre for Biomedical
Science, St Michael’s Hospital, University of Toronto, Canada.
Background and aims: Lixisenatide is a prandial glucagon-like peptide-
1 receptor agonist. Given the rationale for combining complementary
therapies to improve glycaemic control, we examined the impact of
lixisenatide on postprandial plasma glucose (PPG) target achievement
(measured 2 hours after a standard liquid breakfast), and subsequent
efficacy and safety in patients with type 2 diabetes mellitus (T2DM) on
basal insulin. The hypothesis was that achieving PPG targets with
lixisenatide increases the likelihood of reaching HbA1c goals.
Materials and methods: Data were analysed from the GetGoal-L,
GetGoal-Duo1, and GetGoal-L Asia studies in which patients with
T2DM were treated with lixisenatide plus basal insulin. Patients
(lixisenatide: n=587, 47% male, mean weight 82 kg, mean HbA1c
8.1%; and placebo: n=484, 50% male, mean weight 81 kg, mean HbA1c
8.1%) were categorized by baseline fasting plasma glucose (FPG) levels
of < 126 or≥126 mg/dL (<7.0 or≥7.0 mmol/L, respectively).
Lixisenatide-treated patients were grouped as PPG responders
(<180 mg/dL [<10.0 mmol/L]) or non-responders (≥180 mg/dL
[≥10.0 mmol/L]). Data were derived from a fixed effect meta-analysis
with inverse variance weights. Changes in HbA1c and body weight were
analysed using an analysis of variance using last observation carried
forward at Week 24.
Results: In both FPG categories, more lixisenatide-treated patients with
T2DM reached target PPG versus placebo (<126 mg/dL [<7.0 mmol/L]:
55% vs 18%; and≥126 mg/dL [≥10.0 mmol/L]: 48% vs 10%). Greater
reductions in HbA1c and weight were seen in lixisenatide-treated patients;
efficacy was superior in patients meeting the PPG targets for both FPG
categories (Table). Lixisenatide-treated patients were more likely to
achieve HbA1c<7.0% and had no increased risk of symptomatic
hypoglycaemia (Table).
Conclusion: These results support the hypothesis that achieving PPG
targets with lixisenatide increases HbA1c goal achievement in patients
with T2DM and uncontrolled HbA1c on basal insulin, and highlights
the importance of PPG control.
Supported by: Sanofi US, Inc.
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Glucagon-like peptide 1 receptor agonist or rapid-acting insulin as
add-on to basal insulin therapy in patients with type 2 diabetes
mellitus: a meta-analysis
L. Kuritzky1, J. Lin2, C.H. Wysham3;
1Department of Community Health and Family Medicine, University of
Florida, Gainesville, 2Novosys Health, Flemington, 3Rockwood Clinic,
Spokane, USA.
Background and aims: When patients with type 2 diabetes mellitus
(T2DM) are suboptimally controlled on oral antidiabetes agents plus
basal insulin, clinicians must choose from a variety of next-step treat-
ments. Glucagon-like peptide 1 receptor agonists (GLP) have been used
as add-on to basal insulin (BI) in patients with T2DM due to their advan-
tage in improving glycaemic control, with a lower risk of hypoglycaemia
and less weight gain compared with intensified insulin regimens. This
meta-analysis was conducted to compare add-on GLP (BI+GLP) with
add-on rapid-acting insulin (BI+RAI) in patients with T2DM whose
glycaemic control remained unoptimised with basal insulin therapy alone.
Materials and methods: Peer-reviewed literature was searched using
PubMed and EMBASE, as well as abstracts presented at the American
Diabetes Association and European Association for the Study of Diabetes
meetings from 2009-2013. Endpoints included HbA1c levels and symp-
tomatic hypoglycaemia (defined as blood glucose level <56 mg/dL); and
change in body weight and fasting plasma glucose (FPG). Three
randomised clinical trials (duration 26-44 weeks) involving 1,370 pa-
tients with T2DM (28.4-54.0% of which were female) were included.
Patients were aged 54.8-61.1 years, had baseline HbA1c levels of 7.7-
8.5%, and a BMI of 32.0-32.7 kg/m2.
Results: Compared with patients treated with BI+RAI, patients treated
with BI+GLP had significantly greater reductions in HbA1c and body
weight, and a significantly lower risk of symptomatic hypoglycaemia.
Furthermore, these patients had numerically greater FPG reductions
and, although not significant, higher odds of achieving HbA1c <7.0%
than patients treated with BI+RAI (Table).
Conclusion:GLP-1 RA therapy is a viable option to complement insulin
therapy as the addition of a GLP-1 RA to basal insulin therapy improved
glycaemic control with a lower risk of symptomatic hypoglycaemia, and
without weight gain compared with the addition of RAI to basal insulin
therapy. Therefore, this combined approach can be particularly valuable
for patients with T2DM who are treated with basal insulin and have poor
glycaemic control or issues with weight gain.
Supported by: Sanofi US, Inc.
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Real world glucose and weight control in patients treatedwithGLP-1
receptor agonists, with addition or treatment change to insulin
K. Klein1, A. Shaunik2, S. Paul1;
1Clinical Trials & Biostatistics Unit, QIMR Berghofer Medical Research
Institute, Brisbane, Australia, 2AstraZeneca, Washington DC, USA.
Background and aims: Glucose control and weight change in patients
(pts) treated with GLP-1 receptor agonists (GLP-1 RA), and the patterns
of addition or change to insulin from GLP-1 RA are not well studied in a
real world setting. The aims were to (1) evaluate the change inHbA1c and
weight over 6 months, 1- and 2-years post initiation of GLP-1 RA and (2)
evaluate the time and possible benefits of adding or change to insulin
treatment post GLP-1 RA.
Materials and methods: A cohort of 75964 T2DM pts, who initiated
GLP-1 RA treatment from May 2005, were selected for this longitudinal
cohort study from the Centricity EMR Database of USA, with follow-up
data available till September 2014. Longitudinal data on demographics,
HbA1c, weight and anti-diabetes medication before/after the GLP-RA
initiation were available. These pts did not receive insulin before GLP-1
RA initiation.
Results:At baseline, the 75964 pts were mean (SD) 61 (11) yrs old, 43%
male, with mean(SD) HbA1c, weight and BMI of 8.2 (1.5)%, 109 (26) kg
and 38 (8) kg/m2 respectively. Of these, 46353 and 29611 initiated
Exenatide and Liraglutide respectively with concomitant medications of
86% / 59% metformin/sulfonylurea (SU), while 13%/12% stopped met-
formin/SU. The proportions of pts with HbA1c>7.5% and 8% at GLP-1
RA initiation were 69% and 51% respectively. Mean (min, max) and
median (IQR) duration of treatment with GLP-1 RA were 11 (1, 121)
months and 5 (1, 14) months respectively. After GLP-1 RA treatment
for at least 6-months (n=35267), 1-year (n=23414) and 2-years (n=
10834), 30%, 32% and 33% pts reduced their HbA1c below 7% respec-
tively. The adjusted changes in body weight at these time intervals were -
2.3 (-2.4, -2.2) kg, -3.0 (-3.1, -2.9) kg and - 3.7 (-3.9, -3.5) kg respectively.
In the cohort, 44% (n=33341) and 22% (n=16726) pts added and
changed to insulin, with mean (min, max) 3 (0, 106) months and 16 (0,
111) months to adding and changing to insulin respectively. The mean /
median HbA1c levels at the time of adding and changing to insulin were
8.3/7.9% and 8.8/8.5% respectively. Pts who added insulin within 1 year
of GLP-1 RA initiation reduced the HbA1c by an additional 0.60% at
1 year, starting with a baseline HbA1c of 8.3% (Fig 1). Compared to pts
who changed to insulin within a year, those who added insulin showed an
additional HbA1c reduction by 0.34%. Compared to pts who moved to
insulin, those who added insulin within 1 year were 2.4 times (95% CI of
odds ratio: 2.2, 2.6) more likely to reduce HbA1c below 7%within 1 year.
Conclusion: Among pts with HbA1c above 8%, more than a third were
likely to achieve a guideline recommended glucose control within one
year of initiation of GLP-1 RA treatment with accompanying weight loss
during this period. In poorly controlled pts, early addition of insulin
treatment with GLP-1 RA, rather than changing to insulin, offers clini-
cally significant glycaemic benefits, while maintaining the statistically
significant weight loss.
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Non-adherence and non-persistence related to GLP-1 therapy in pa-
tients with type 2 diabetes mellitus: analysis of a large UK CPRD
dataset
T. Wilke1, B. Berg1, A. Groth1, A. Martin2, J. Logie2, M. Sikirica3;
1Institut für Pharmakoökonomie und Arzneimittellogistik, University of
Wismar, Wismar, Germany, 2GlaxoSmithKline, Uxbridge, Middlesex,
UK, 3GlaxoSmithKline, King of Prussia, USA.
Background and aims:This study describes the extent of non-adherence
(NA) and non-persistence (NP) with Glucagon-like peptide 1 agonists
(GLP-1) and oral anti-diabetic (OAD) therapy in T2DM patients in clin-
ical practice in the UK.
Materials and methods: Electronic primary health care data collected in
the CPRD (Clinical Practice Research Datalink) database from 2010-
2012 were used to identify patients with ≥1 diagnosis code for T2DM
and also at least one antidiabetic medication prescription. NA and NP
weremeasured for patients initiating new T2DMmedication (no prescrip-
tion of respective medication in prior 6 months). A patient was classified
as NP when a medication gap≥90 days was observed. Patient-specific
estimates of adherence were calculated via medication possession ratios
(MPR) for those patients maintaining their therapy (without gaps≥
90 days) during a one-year observational period. The maximum adher-
ence possible was based on the assumption that adherence to therapy is
equivalent to the drug-specific DDD (defined daily dosage). NA was
defined as MPR<80%. Descriptive analyses with percentage of patients
classified as NP and/or NAwere conducted.
Results: The persistence analysis included 1,905 and 13,387 T2DM pa-
tients initiating GLP-1 and OAD-therapy, respectively. Among GLP-1
patients, 1,083 received once-daily (OD) and 545 received twice daily
(BID) therapies, the remaining patients switched between regimens.
Mean age for GLP-1 users was 55.5 (SD 10.6) and 60.6 (SD 13.2) years
in the OAD cohort. After 12 months, the percentage of patients with NP
was 29.6% (all GLP-1 s), 27.2% (OD-GLP-1), 36.0% (BID-GLP-1), and
23.2% (OAD). The NA analysis included 1,744 GLP-1 and 11,722 OAD
patients initiating therapy with ≥1 follow-up prescription. Mean age was
55.2 (SD 10.4) and 60.2 (SD 12.9) years for the GLP and OAD cohorts,
respectively. Mean MPR was 88.6% (all GLP-1 s), 88.2% (OD-GLP-1),
89.3% (BID-GLP-1) and 64.7% (OAD). Percentage of patients affected
by NAwas 20.2% (all GLP-1 s), 20.0% (OD-GLP-1), 20.5% (BID-GLP-
1) and 68.4% (OAD).
Conclusion: In this UK dataset, we observed several patterns of patient
behaviour. Persistence with OAD therapy was numerically higher than
with GLP-1 therapy. Adherence to therapy within the GLP-1 cohort was
high, and appears to be similar between dosing frequency regimens, while
persistence rates may be higher with less frequently dosed GLP-1 s and
should be investigated further.
Supported by: GlaxoSmithKline UK
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Co-administration of a lipidated GIPR agonist with a GLP1 ana-
logue provides no additional benefit on HbA1c% over GLP1 ana-
logue in db/db mice
A. Seth1, A. Suckow2, B. Clayton1, N. Burmeister1, I. Sermadiras1, J.
Metcalfe1, J. Naylor1, A. Collinson1, D. Hornigold1, D. Baker1;
1CVMD, MedImmune, Cambridge, UK, 2CVMD, MedImmune, Gai-
thersburg, USA.
Background and aims: The incretin hormone glucose-dependent
insulinotrophic polypeptide (GIP) has well established actions in the β
cell to enhance insulin secretion in humans. In addition, variants at the
GIP receptor (GIPR) gene locus are associated with elevated glucose and
decreased insulin secretion. However, there has been controversy regard-
ing the anti-diabetic potential for GIPR agonists as many patients with
diabetes exhibit greatly reduced insulin responses to GIP. Further studies
have suggested that normalisation of glycemia in diabetics can restore
GIP sensitivity. In this study we set out to examine the anti-diabetic
potential for GIPR agonism alone, or in combination with a GLP1R
agonist in db/db mice.
Materials and methods: A total of 56 male db/db mice 9 weeks of age
were randomised into seven groups based on baseline HbA1c%. Mice
received either vehicle, low dose (LD) GLP1R agonist alone, LD GIPR
agonist alone, combination of LD GLP1R agonist plus LD GIPR agonist,
high dose (HD) GLP1R agonist alone, HD GIPR agonist alone or com-
bination of HD GLP1R agonist plus HD GIPR agonist. LD and HD were
determined by acute dose response glucose tolerance tests carried out in
lean C57BL/6J mice. The GLP1 analogue was dosed at 10 nmol/Kg and
30 nmol/Kg for LD and HD respectively. The GIPR agonist was a
lipidated GIP molecule dosed at 1 nmol/Kg and 10 nmol/Kg for LD
and HD respectively. Mice received daily s.c. injections≈3 hours before
the dark cycle for three weeks. HbA1c% was measured at the beginning
and end of the study, 6 hour fasted blood glucose was measured at weekly
intervals. Data was analysed by a one way ANOVAwith a Fisher’s LSD
post hoc test.
Results: Over the duration of the study the HbA1c% in vehicle group
increased by 2.49%, treatment with a GLP1 analogue significantly atten-
uated the increase in HbA1c% by 1.2% in HD group and by 0.79% in the
LD group, (vehicle vs HD GLP1R p<0.0001, vehicle vs LD GLP1R P<
0.001). Treatment with lipidated GIP attenuated the increase in HbA1c%
in the HD group by 0.52% (vehicle vs HD GIP1R p<0.05) and had no
significant effect in the LD group. In combination with a GLP1 analogue
the addition of GIPR agonism provided no additional benefit over
GLP1R agonism to lower HbAc1% at either dose. Initially, weekly fasted
glucose readings suggested dual GLP1R/GIPR agonism did improve glu-
cose control to a greater extent than either single agent alone in the HD
groups (Δfasted glucose 7 days: HD combination -11.96±0.91 vs HD
GLP1R -4.10±3.44 p=0.046, 14 days: HD combination -8.71±1.46 vs
HD GLP1R 0.03±3.64 p=0.054). Any differential effect between GLP1
single agent HD and the combination with GIP was lost by the end of the
study (21 days: -0.40±3.72 vs -0.53±2.24 p=n.s). These results are con-
sistent with a parallel study in which an Fc conjugated GIP molecule had
only modest effects on HbA1c% as a single agent and provided no addi-
tional benefit in combination with GLP1R agonism in db/db mice.
Conclusion: The glucose lowering actions of GIP are greatly blunted in
the diabetic db/db mouse model. In combination with a GLP1 analogue,
GIPR agonism did provide an initial additional benefit in glucose control;
however, these effects were not sustained and did not translate to an
overall improvement in HbA1c%. In summary, these data do not support
the hypothesis that combinations of GIPR/GLP1R agonists would pro-
vide a useful strategy to treat T2D.
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Do we need another consideration during incretin based therapy?
Aberrant expression of glucagon-like peptide-1 receptor in papillary
thyroid carcinomas
S. Kwon1, M. Jung2, J. Heo3, S. Kim3, S. Ock1, B. Kim1, Y. Choi1, J.
Kim4;
1Department of Internal Medicine, Kosin University College of Medi-
cine, 2Department of Pathology, Kosin University College of Medicine,
3Department of Molecular Biology and Immunology, Kosin University
College of Medicine, 4Department of Surgery, Kosin University College
of Medicine, Busan, Republic of Korea.
Background and aims: Incretin-based therapies are rapidly becoming
one of the main glucose lowering agents in diabetes. Considering the
large numbers of papillary thyroid carcinomas (PTC) and possible effects
of Glucagon-like peptide-1 (GLP-1) on cell proliferation, the expression
of GLP-1 receptor (GLP-1R) in PTC is likely to have clinical
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significance. We performed this study to evaluate the expression of GLP-
1R in PTC.
Materials and methods: Eighty-three cases of PTC and fifty-five cases
of normal thyroid tissue were selected for immunostaining for GLP-1R
by polyclonal antibody. Twenty-eight cases of PTC and twelve cases of
normal thyroid tissue were selected for immunostaining for GLP-1R by
monoclonal antibody. Total RNAwas isolated from twenty-one cases of
PTC and twelve cases of normal thyroid tissue for evaluation of GLP-1R
mRNA RT-PCR.
Results: Immunohistochemical staining for GLP-1R by polyclonal anti-
body exhibited immunoreactivity in thirty-seven of eighty-three cases
(44.6%) in PTC but, none of fifty-five cases of normal thyroid follicular
cells. Eight of twenty-one cases (38.1%) of PTC and none of twelve
normal thyroid tissues expressed GLP-1R mRNA.
Conclusion: Some of PTC tissues express GLP-1R, although normal
thyroid follicular tissues do not express GLP-1R. The clinical significance
of GLP-1R expression in PTC and long-term influence of pharmacolog-
ically increased GLP-1 to development and progression of GLP-1R
expressed PTC associated with incretin based therapy should be
evaluated.
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A randomised, double-blind trial of saxagliptin add-on to
dapagliflozin + metformin
D. Catrinoiu1, S. Matthaei2, A. Celiński3, E. Ekholm4, W. Cook5, B.
Hirshberg5, N. Iqbal6, L. Hansen6;
1Spitalul Clinic Judetean de Urgenta Constanta, Romania, 2Diabetes-
Center, Quakenbrück, Germany, 3CenterMed - Centrum Badań
Klinicznych, Kraków, Poland, 4AstraZeneca, Molndal, Sweden,
5AstraZeneca, Gaithersburg, 6Bristol-Myers Squibb, Princeton, USA.
Background and aims: DPP-4 and SGLT2 inhibitors have complemen-
tary mechanisms of action that can potentially improve glucose control
with a low risk of hypoglycemia. We compared the efficacy and safety of
saxagliptin (SAXA) vs placebo (PBO) add on to dapagliflozin (DAPA) +
metformin IR (MET) in adults with type 2 diabetes (T2D).
Materials and methods: Patients on stable MET (≥1500 mg/d) for
≥8 weeks with baseline A1C 8.0%-11.5% (mean A1C at screening
9.3%) received open-label DAPA 10 mg/d + MET for 16 weeks. At the
end of the open-label period, patients with inadequate glycemic control
(A1C 7%-10.5%) were randomized to PBO (n=153) or SAXA 5 mg/d
(n=162) in addition to background DAPA+MET. Primary end point was
change in A1C from baseline to week 24. Secondary end points included
fasting plasma glucose (FPG), 2-hour postprandial glucose (PPG), and
the proportion of patients achieving A1C<7%.
Results: There was a significantly greater reduction in A1C at 24 weeks
with SAXA+DAPA+MET vs PBO+DAPA+MET (Table). Reductions in
FPG and PPGwere similar between treatment arms. A greater proportion
of patients achieved A1C <7% with SAXA+DAPA+MET vs PBO+
DAPA+MET. AEswere similar across treatment groups, although urinary
tract infections and nasopharyngitis were higher with SAXA+DAPA+
MET. Episodes of hypoglycemia were rare.
Conclusion: Addition of SAXA to DAPA+MET is well tolerated and
produces significant improvements in glycemic control in patients with
T2D inadequately controlled with DAPA+MET.
Clinical Trial Registration Number: NCT01619059
Supported by: AstraZeneca
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Effects of gemigliptin versus sitagliptin or glimepiride on glycaemic
variability as initial combination therapy with metformin in drug-
naïve patients with type 2 diabetes
B.-W. Lee1, J. Kim2, S. Park3, C. Jung4, S.-H. Lee5, S. Suh6, W. Lee4, J.-
H. Cho5, Y. Jang7, S.-H. Kim7, C.-Y. Park3, STABLE Study;
1Severance Hospital, University of Yonsei University College of Medi-
cine, 2Samsung Medical Center, Sungkyunkwan University School of
Medicine, 3Kangbuk Samsung Hospital, Sungkyunkwan University
School of Medicine, 4Asan Medical Center, University of Ulsan College
of Medicine, 5Seoul St. Mary's Hospital, The Catholic University of Ko-
rea, Seoul, 6Dong-A Medical Center, Dong-A University College of
Medicine, Busan, 7LG Life Sciences, Seoul, Republic of Korea.
Background and aims: Glycemic variability and chronic sustained hy-
perglycemia are the main components of dysglycemia in diabetes. The
purpose of this study was to assess whether there is a difference between-
or within drug classes on glycemic variability and glucose control as
initial combination therapy with metformin in drug-naive patients with
type 2 diabetes.
Materials and methods: A multi-center, randomized, active controlled,
open-label, parallel design study was performed in 69 patients with
HbA1c greater than 7.5%. Subjects were randomized (1:1:1) to receive
gemigliptin 50 mg qd, sitagliptin 100 mg qd, or glimepiride 2 mg qd for
12 weeks. The mean amplitude of glycemic excursions (MAGE) and
standard deviation (SD) were used for assessing glucose fluctuations at
baseline and after 12weeks. Glycosylated hemoglobin (HbA1c), glycated
albumin (GA), fructosamine, C-reactive protein and other metabolic pa-
rameters were also measured. Safety and tolerability based on adverse
events (AEs) were assessed. To strengthen the reliability of the study
results, data from continuous glucose monitoring system (CGMS) was
evaluated independently by a blinded central evaluator.
Results: A total of 69 subjects were randomized to receive gemigliptin
50 mg (n=24), sitagliptin 100 mg (n=23) or glimepiride 2 mg (n=22).
Mean baseline characteristics were similar across the groups (age,
50.0 years; HbA1c, 9.4%; GA, 26.4%; fructosamine, 412.8 μmol/L).
At 12 weeks, MAGE was significantly lower in the DPP-4 inhibitor
groups, gemigliptin and sitagliptin, than in the glimepiride group (-43.1,
-38.3, and -21.7 mg/dl, respectively). Furthermore, the SD of mean glu-
cose was significantly lower in patients with gemigliptin (vs sitagliptin
p=0.01; vs glimepiride p=0.007) when compared with sitagliptin and
glimepiride. Mean HbA1c was reduced from baseline by 2.75%, 2.24%
and 2.75% for gemigliptin, sitagliptin and glimepiride, respectively. A
similar profile was also observed in other glycemic control parameters
(FPG, glycated albumin, and fructosamine). A greater decrease in total-
and LDL-cholesterol and nitrotyrosine was observed for DPP-4 inhibitor
groups versus glimepiride, although there were no significant differences
between the groups. In addition, only gemigliptin significantly decreased
C-reactive protein levels from baseline. Drug-related AEs including
symptomatic hypoglycemia were reported more frequently in glimepiride
group than in other groups.
Conclusion: In summary, gemigliptin was more effective than
glimepiride and sitagliptin in reducing glucose variability as initial com-
bination therapy with metformin in drug-naïve patients with T2DM.
Clinical Trial Registration Number: NCT01787396
Supported by: LG Life Sciences
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Efficacy and safety of gemigliptin in type 2 diabetes patients with
moderate to severe renal impairment
S. Yoon1, B. Han2, S. Kim3, S. Han4, Y.-I. Jo5, K. Jeong6, K.-H. Oh7, H.
Park8, S.-H. Park9, S.-W. Kang10, K.-R. Na11, Y. Jang12, S.-H. Kim12, D.
Cha13, GUARD Study;
1Uijeongbu St. Mary’s Hospital, 2Yonsei University Wonju College of
Medicine, 3Hallym University Sacred Heart Hospital, Anyang, 4Ilsan
Paik Hospital, Goyang, 5KonkukUniversity School ofMedicine, 6Kyung
Hee University School of Medicine, Seoul, 7Seoul National University
College ofMedicine, 8Gangnam Severance Hospital, Seoul, 9Kyungpook
National University School of Medicine, Daegu, 10Yonsei University
College of Medicine, Seoul, 11Chungnam National University College
of Medicine, Daejeon, 12LG Life Sciences, Seoul, 13Korea University
Ansan-Hospital, Republic of Korea.
Background and aims: Renal impairment in type 2 diabetes mellitus
limits the available glucose-lowering medication and requires frequent
monitoring of renal function. Gemigliptin, a potent and selective DPP-4
inhibitor, can be used without dose reduction in renal impairment. This
randomized, double blind, parallel group Phase 3b study comprised a 12-
week, placebo-controlled phase followed by a 40-week, double blind
active-controlled extension phase (placebo switched to linagliptin). This
12-week randomized trial investigated the efficacy and safety of
gemigliptin in type 2 diabetic patients with moderate to severe renal
impairment. It was also evaluated whether gemigliptin has renoprotective
effects in these patients.
Materials and methods: A total of 132 patients were randomized to
gemigliptin (n=66) or placebo (n=66). Primary endpoint was HbA1c
change from baseline at Week 12. Baseline demographics were similar
between treatment groups (mean HbA1c 8.4%; age 62.0 years; BMI
26.2 kg/m2, duration of T2DM 16.3 years; eGFR 33.3 mL/min/
1.73 m2). The predominant background therapy was insulin (63.1%).
Results: At Week 12, adjusted mean±SE change HbA1c with
gemigliptin was -0.83±0.14%(change with placebo 0.38±0.14%; differ-
ence -1.21, 95% CI -1.54 to -0.89; p<0.0001). A similar profile was also
observed in other glycemic control parameters (FPG, glycated albumin,
and fructosamine). After 12 weeks of gemigliptin treatment, albuminuria
(measured by urinary albumin creatinine ratio [UACR]) significantly de-
creased in the patients with micro- and macro-albuminuria. Furthermore,
urinary nephrin and type IV collagen in the gemigliptin were also signif-
icantly reduced compared to placebo. Drug-related AEs including hypo-
glycemia for gemigliptin was similar to placebo (15.2% and 12.1%, re-
spectively). There was no meaningful change from baseline in body
weight (gemigliptin, -0.3 kg; placebo -0.2 kg).
Conclusion: Gemigliptin improved glycemic control and provided addi-
tional renoprotection in T2DM patients with moderate to severe renal
impairment. There was no additional risk of hypoglycemia and no weight
gain.
Clinical Trial Registration Number: NCT01968044
Supported by: LG Life Sciences
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Reduced incidence of hypoglycaemia with sitagliptin used with inten-
sively titrated insulin may be due to factors other than the difference
in insulin dose
S.S. Engel1, F. Wu2, L. Xu1, R. Shankar1;
1Merck & Co., Inc., Kenilworth, USA, 2MSD R&D (China) Ltd., Bei-
jing, China.
Background and aims:Addition of sitagliptin (SITA) relative to placebo
(PBO) in patients (pts) (N=658) with type 2 diabetes who intensively
titrate insulin glargine±metformin has been shown to result in a lower
incremental insulin dose requirement (mean Δ=-4.7 units), better
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glycemic control (mean ΔA1C=-0.45%), and a lower incidence of ad-
verse events of symptomatic hypoglycemia (HYPO) (meanΔ=-11.6%).
Materials and methods: To determine if the reduced insulin dose re-
quirement with SITA accounted for the lower HYPO incidence, we con-
ducted a post hoc analysis of the incidence of HYPO in subgroups based
on quartiles (Q) of change in insulin dose from baseline for the entire
study cohort (Table).
Results: PBO-adjusted ΔA1C in Q 1-4 were -0.33%, -0.62%, -0.47%
and -0.47%, respectively. For pts with the lowest insulin dose increment
(<=6 units), no difference in incidence of HYPO was seen. For pts in the
remaining 3 Qs, the incidence of HYPO was lower with SITA. Addition-
ally, an analysis of the incidence of asymptomatic hypoglycemia showed
similar between-group results in Q1 and Q2 but lower incidences in the
SITA group in Q3 and Q4 (7.7% vs 17.9% and 1.5% vs 12.5% for SITA
and PBO, respectively).
Conclusion: These analyses suggest that the reduced incidence of hypo-
glycemia seen when sitagliptin is used in conjunction with intensively
titrated insulin may be due to factors other than the difference in insulin
dose.
Clinical Trial Registration Number: NCT01462266
Supported by: Merck & Co., Inc.
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Type 2 diabetes patients on metformin and well-controlled basal:
Can supplementary vildagliptin control residual prandial
hyperglycaemia? VIBE study results
S. Franc1,2, A. Daoudi1,2, I. Xhaard2, C. De Moura2, C. Randazzo2, G.
Charpentier1,2;
1Centre Hospitalier Sud Francilien, Corbeil-Essonnes, 2CERITD, Evry,
France.
Background and aims: In patients with type-2 diabetes (DT2) treated
with metformin and well-titrated basal insulin whose HbA1c remains
above 7%, failure to optimize glycemic control is mainly due to a persis-
tent elevation in postprandial glycaemia (PPG). Can supplementary
vildagliptin reduce HbA1c to target levels (<7.0%) vs. placebo?
Materials and methods: In the study, 34 DT2 patients receiving metfor-
min at the maximum tolerated dose together with well-titrated insulin
glargin (fasting blood glucose: <1.20 g/l), but with HbA1c persistently
between 7 and 9%, were randomised to double-blind cross-over treatment
with either vildagliptin (50 mg b.i.d.) or placebo, with the 3-month treat-
ment periods being separated by a 3-month wash-out period. Immediately
prior to the end of these two periods, patients wore a continuous glucose
monitoring device for 5 days. The amount of carbohydrates was collected
at the same time for each of the 5-day meals.
Results: 31 patients were randomised (4 F/27H) and 3 dropped out.
Baseline data were as follows: HbA1c: 7.65.±0.5%; diabetes duration:
6.1±7.9 years; age: 59.4±7.6 years; BMI: 28.6±4.3; insulin glargin dose:
39.3±36.8 u/d; metformin dose: 2.8±0.29 g/d. The proportion of patients
acheiving an HbA1c <7%with vildagliptin was 4 times as high as that of
patients treated with placebo (28.6% vs. 7.4%, p=0.007). Moreover, the
addition of vildagliptin allowed a mean HbA1c reduction of 1% in the
vildagliptin group vs placebo (vildagliptin: -0.7 (±0.9)%; placebo=+0.3
(±0.9)%; p=0.002). Glucose excursions on CGM curves at mealtime,
estimated through AUCs, were significantly lower with vildagliptin vs.
placebo. Significantly more time was spent in the range [70-180 mg/dl]
with vildagliptin vs placebo [74.8 (±18.0)% vs. 61.1 (±22.9)%]. Con-
versely the time spent above 180 mg/dl was significantly lower for
vildagliptin vs placebo (21.2 (±17.9)) vs 37.4 (±23.2). Predictors for
patient response to treatment were also studied.
Conclusion: In patients treated with metformin and well-titrated basal
insulin, uncontrolled postprandial glycemic excursions are significantly
improved by the addition of vildagliptin. By that way, 4 times more
patients achieved the HbA1c target below 7%. This improved response
involved a better control of post-prandial glycaemia, as attested by CGM
data.
Clinical Trial Registration Number: NCT01757587
Supported by: Novartis
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Efficacy and safety of linagliptin/metformin fixed-dose combination
as initial therapy in drug-naïve Asian patients with type 2 diabetes
Y. Gong1, Y. Mu2, B. Fan3, U. Hehnke1, C. Pan2;
1Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany,
2Chinese PLA General Hospital, Beijing, 3Boehringer Ingelheim (China)
Investment Co., Ltd, Shanghai, China.
Background and aims: A 24-week study investigated the efficacy and
safety of initial fixed-dose combination (FDC) therapy with linagliptin
(L) and metformin (M) immediate release in drug-naïve patients from
Asia (83.4% from China) with type 2 diabetes (T2D) and inadequate
glycemic control.
Materials and methods: In total 733 patients (initial HbA1c [%] ≥7.5-<
11) were randomized to one of five regimens (L 5mgQD,M 500mgBID,
M 1000 mg BID, L 2.5 mg/M 500 mg BID, L 2.5 mg/M 1000 mg BID).
The primary endpoint was HbA1c change from baseline to week 24.
Results: Overall mean baseline (SD) age, body mass index, HbA1c and
fasting plasma glucose (FPG) were 51.3 (10.0) years, 26.0 (3.6) kg/m2,
8.7 (1.0) % and 169.0 (39.5) mg/dL, respectively. At week 24, the FDCs
showed clinically meaningful reductions from baseline in HbA1c (Table)
and FPG. The first test of the primary HbA1c analysis (L 2.5 mg /M
1000 mg BID vs M 1000 mg BID) was borderline non-significant; how-
ever, all but one pre-defined sensitivity analysis showed that the FDCs
had significantly greater reductions in HbA1c from baseline vs their re-
spective monotherapy components. This was also shown for a pre-
defined subgroup analysis in Chinese patients. Target HbA1c (<7%, week
24) was reached in the following % of patients: L 5 mg QD (44%), M
500 mg BID (50%), M 1000 mg BID (69%), L 2.5 mg/M 500 mg BID
(72%), L 2.5 mg/M 1000 mg BID (77%). Adverse event (AE) rates were
similar across groups except for a small but expected increase in gastro-
intestinal AEs with M and FDCs particularly with M 1000 mg. Hypogly-
cemic AEs were low across groups.
Conclusion: FDCs significantly improved glycemic control and were
well tolerated.
Clinical Trial Registration Number: NCT01708902
Supported by: Boehringer Ingelheim
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Use of the Japanese health insurance claims database to assess dura-
bility of DPP-4 inhibitors in patients with diabetes: comparison with
other anti-diabetic drugs
D. Yabe1, H. Kuwata1, R. Nishikino2, M. Kaneko2, C. Ito2, K.Murotani3,
T. Kurose1, Y. Seino1;
1Center for Diabetes, Endocrinology and Metabolism, Kansai Electric
Power Hospital, Osaka, 2Japan Medical Data Center Co., Ltd, Tokyo,
3Center for Clinical Research, Aichi Medical University, Japan.
Background and aims: Dipeptidyl peptidase-4 inhibitors (DPP-4i) have
been widely used to manage type 2 diabetes (T2DM), especially in Jap-
anese who show greater HbA1c-lowering effects compared to other eth-
nicities. However, its long-term therapeutic durability remains to be
shown in actual clinical practice. The current study was initiated to eval-
uate durability of DPP-4i, GLP-1 receptor agonists (GLP-1RA) and other
oral anti-diabetic drugs (OADs) among Japanese T2DM patients.
Materials and methods: The Japan Medical Data Center Claims Data-
base, a comprehensive medical and pharmacy claims database, was used
to compare average days before prescription change (DBPC) of anti-
diabetic drugs in 1) untreated patients who received DPP-4i, GLP-1RA
or other OADs as monotherapy (n=1,918) and 2) patients who had been
on one OAD or GLP-1RA and received DPP-4i, GLP-1RA or other
OADs as either switch (n=662) or add-on therapy (n=1,113). Patients
aged 30-74 years with pharmacy andmedical claims data for a continuous
period of at least 32 months were included. This allowed a 6-month
period for baseline observations and 26 months of observation after ini-
tiation of the index medication. Patients with at least one ICD-10 code of
E11 or E14 during the observational period were subjected to further
analyses, while those with E10, E12 and E13 were excluded. Patients
on insulin injection and/or those on more than 2 OADs were excluded.
The index date was defined as the prescription date of the first claim for a
new OAD during the target period from December 1, 2009 through
May 31, 2012. An anti-diabetic drug was considered new if there were
no claims for the medication during the prior 6 months. The observation
period started on the index date and ended on the initiation of another new
OAD, GLP-1RA or insulin. The same patients were included multiple
times into different index drug groups if they met the criteria.
Results: Among untreated patients who received OAD as monotherapy,
DPP-4i (n=795) showed significantly longer DBPC compared to other
OADs (n=1,117) (DPP4i 546.9 days; and Others 433.9 days; p<0.0001).
Kaplan Meier analysis confirmed that DPP-4i showed longer DBPC than
other OADs (Log-rank test, p<0.0001). Among patients who had been on
one OAD or GLP-1RA and received OAD as switch, DPP-4i (n=397)
showed significantly longer DBPC compared to other OADs (n=261)
(DPP4i 554.5 days; and Others 367.7 days; p=0.0002). Among patients
who had been on one OAD or GLP-1RA and received OAD as add-on,
DPP-4i (n=431) showed significantly longer DBPC compared to other
OADs (n=682) (DPP4i 564.9 days; and Others 442.4 days; p<0.0001).
Among various OADs, DPP-4i add-on showed longer DBPC with α-
glycosidase inhibitors (AGI) (AGI 650.0 days; Others 555.7 days; p=
0.0004). Cox proportional hazard models revealed lower chance for pre-
scription change with DPP-4i compared to other OADs as monotherapy
or dual therapies. Limited or no patients receiving GLP-1RA as mono-
therapy (n=10) or dual therapy (n=0) did not allow meaningful analysis.
Conclusion: Despite numerous limitations, our findings indicate that
DPP-4i, as first-line or second-line therapy, has long-term therapeutic
durability superior to other OADs for Japanese T2DM in clinical practice.
Supported by: JSPS, JADEC
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Dipeptidly peptide-4 (DPP-4) inhibitors did not increase the inci-
dence of infection in immune-compromised patients under
chemotherapy
M. Morita1, M. Yamamoto1, T. Takahashi2, T. Sugimoto1;
1Internal Medicine 1, Shimane University Faculty of Medicine, 2Oncol-
ogy and Hematology, Shimane University Hospital, Izumo, Japan.
Background and aims: It is still unknown whether suppression of DPP-
4 activity, which is known as T-cell activation antigen CD26, increases
risk of infection. To clarify this issue, we compared the infection rate
between the patients with malignant lymphoma with and without admin-
istration of DPP-4 inhibitor (DPP-4I) under chemotherapy.
Materials and methods: We analyzed 815 exposure chemotherapies,
performed in 162 patients from September 2006 to December 2014
[mean (±SD) age: 66.8±13.2 years, men: 43.1%, range: 1-8 times/per-
son]. Infection was defined as a body temperature higher than 38 degrees
C except for infusion reactions of anticancer drug, or diagnosed by phy-
sician within 28 days after chemotherapy. We compared incidence of
infection between 2 groups, classified by user of DPP-4I or non-user.
Results: The numbers of infection case/total care were 11/54 (20.4%) in
user of DPP-4I, 215/761 (28.3%) in non-user. No significant increased
risk of infection was observed in DPP-4I user adjusting for age, sex, Ann
Arbor staging, performance status and serum levels of albumin [OR: 1.62
(95%CI: 0.78 - 3.33), p=0.193]. In contrast, serum levels of albumin and
hemoglobin were significant preventive factor for infection [OR: 0.37
(95%CI: 0.25 - 0.53) and OR: 0.88 (95%CI: 0.79 - 0.99), respectively].
Conclusion: This study suggested that DPP-4I treatment did not
affect the immune system even in immune-compromised patients
under chemotherapy.
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Linagliptin acutely increases endothelial progenitor cells and anti-
inflammatory monocytes in a randomised, placebo-controlled cross-
over study
G.P. Fadini, B. Bonora, M. Albiero, R. Cappellari, M. Marescotti, M.
Vedovato, A. Avogaro;
Department of Medicine, University of Padova, Italy.
Background and aims: Circulating cells, including endothelial progen-
itor cells (EPCs) and monocyte subtypes are likely involved in the path-
ogenesis of diabetic complications. We herein assessed whether the
dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin acutely modifies
EPCs and monocyte subsets in patients with type 2 diabetes.
Materials and methods: This was a randomized cross-over placebo-
controlled trial in which 46 type 2 diabetic patients with (n=18) or with-
out (n=28) chronic kidney disease (CKD) underwent a 4 day treatment
with linagliptin or placebo in random order, in 2 periods separated by a
washout of 2 weeks. Before and the day after each period of 4-day treat-
ment with linagliptin or placebo, blood samples were collected for the
determination of EPC phenotypes and monocyte subsets.
Results: Linagliptin reduced DPP-4 activity by about 70%. Compared to
placebo, linagliptin increased CD34+CD133+ progenitor cells (placebo-
subtracted effect +40.4±18.7/10^6; p=0.036), CD34+KDR+ EPCs (pla-
cebo-subtracted effect +22.1±10.2/10^6; p=0.036), and CX3CR1^bright
monocytes (placebo-subtracted effect +1.7±0.8%; p=0.027). No effect
was seen on other EPC phenotypes, M1 andM2monocyte-macrophages,
as well as traditional monocyte subsets (classical, intermediate and non-
classical). In patients with CKD, as compared to those without, CD133+
and CD34+CD133+ cells were significantly reduced, whereas CD34+
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and CD34+KDR+ cells were reduced with borderline significance (p=
0.06 for both).
Conclusion: DPP-4 inhibition with linagliptin acutely increases
vasculoregenerative and anti-inflammatory cells. These results highlight
the direct, glucose-independent, effect of DPP-4 inhibition and may be
important to lower vascular risk in diabetic patients, especially in the
presence of CKD.
Clinical Trial Registration Number: NCT01617824
Supported by: Boehringer Ingelheim
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Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal neo-
vascularisation in oxygen-induced ischaemic retinopathy and retinal
vascular leakage in db/db mice
E. Jung1, S.-H. Kim1, J. Kim2;
1LG Life Sciences Ltd., R&D Park, Daejeon, 2Korean Medicine Conver-
gence Research Division, Korea Institute of Oriental Medicine, Daejeon,
Republic of Korea.
Background and aims: Retinal vascular leakage and neovascularization
are features of diabetic retinopathy. Gemigliptin, a dipeptidyl peptidase-4
(DPP-4) inhibitor, has shown robust blood-glucose lowering effect in
type 2 diabetic patients, but its effects on diabetic retinopathy have not
been reported. This study evaluated the efficacy of gemigliptin on retinal
vascular leakage in db/db mice, an animal model for type 2 diabetes and
neovascularization in oxygen-induced retinopathy (OIR) mice, an animal
model for ischemic proliferative retinopathy.
Materials and methods: Gemigliptin (100 mg/kg/day) was orally ad-
ministered to db/db mice for 12 weeks. In OIR models, neonatal mice at
postnatal day 7 (P7) were exposed to 75% concentration of oxygen for
5 days (P7~P12), and then returned to room air from P12 to P17 to induce
retinal neovascularization. Gemigliptin (50 mg/kg/day) were adminis-
tered once per day for 5 consecutive days (P12~P16) by intraperitoneal
injection. Retinal neovascularization was measured at P17.
Results: Oral administration of gemigliptin for 12 weeks significantly
ameliorated retinal vascular leakage and tight junction protein loss in
db/db mice. Gemigliptin also ameliorated retinal neovascularization in
OIR mice. Gemigliptin also attenuated overexpression of plasminogen
activator inhibitor-1(PAI-1), monocyte chemoattractant protein-1 (MCP-
1) and vascular endothelial growth factor (VEGF) in the retinas of dia-
betic and OIR mice.
Conclusion: These results suggest that gemigliptin has a potent anti-
angiogenic activity via its ability to inhibit the pro-angiogenic PAI-1-
related signaling pathway and support the direct retinoprotective action
of gemigliptin.
Supported by: LG Life Sciences
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DPP-IV inhibitor linagliptin restores insulin-mediated vasorelax-
ation and attenuates vascular remodelling inmiddle cerebral arteries
from type 2 diabetic GK rats
A. Ergul1,2, T. Hardigan1, Y. Abdul1, M. Abdelsaid1,2, M. Coucha1,2;
1Georgia Regents University, 2Charlie Norwood Veterans Affairs Medi-
cal Center, Augusta, USA.
Background and aims: Diabetes is associated with macrovascular and
microvascular complications leading to cerebrovascular disease. Insulin
resistance in type-2 diabetes leads to impaired endothelial cell function
and vascular dysfunction characterized by decreased vasodilation and
increased vascular remodeling. It has been shown that insulin signaling
in middle cerebral arteries (MCAs) induces vasorelaxation through pro-
duction of nitric oxide in a PI3K/Akt dependent manner. The enzyme
dipeptidyl peptidase-IV (DPP-IV) degrades glucagon-like peptide 1
(GLP-1), thereby reducing insulin secretion. DPPIV inhibitors such as
linagliptin have been shown to improve insulin secretion and endotheli-
um dependent vascular function through PI3K/Akt signaling in rat aorta
and mesentery. We hypothesized that linagliptin reverses cerebrovascular
remodeling and restores vascular function via its direct and glucose low-
ering properties in type-2 diabetic GK rats.
Materials and methods: Diabetic and non-diabetic male GK rats, aged
24 weeks were used in this study, and were fed either normal chow or
linagliptin mixed with normal chow for 4 weeks at a concentration of
166 mg/kg of chow (n=5-6/group). MCA segments were mounted in an
arteriograph chamber and vascular relaxation was determined by
performing concentration response to insulin (Ins, 10-13-10-6 M), and
measurements of vascular structure were recorded. Statistical significance
was determined for multiple comparisons by ANOVA with Tukey post
hoc correction or 2-Way ANOVAwith Bonferroni post hoc correction at
p<0.05.
Results: Linagliptin treatment does not alter hyperglycemia levels (He-
moglobin A1C%, Non-diabetic Vehicle (NDV): 5.68±0.086, Diabetic
Vehicle (DV): 8.02±0.273***, Non-diabetic Linagliptin (NDL): 5.85±
0.077, Diabetic Linagliptin (DL): 8.20±0.327***, ***=p<0.001) or
body weight (grams, NDV: 404.5±13.35, DV: 411.3±16.12, NDL:
421.9±14.98, 398.8±8.656). Linagliptin restores insulin-mediated vascu-
lar relaxation in MCAs from diabetic rats (Maximum Relaxation
RMax%: NDV: 46.04±2.803, DV: 12.69±0.9657***, DL: 45.89±
2.632###, ***=p<0.001 vs. NDV, ###=p<0.001 vs. DV). Linagliptin
ameliorates pathological vascular remodeling in MCAs from diabetic
rats. Improvement was observed in cross-sectional area(μm at max
intraluminal pressure 120 mmHg: NDV: 21673±569.8, DV: 25765±
1530*, DL: 21319±664.8#, *=p<0.05 vs. NDV, #=p<0.05 vs. DV),
media thickness (μm at max intraluminal pressure 120 mmHg: NDV:
40.00±1.027, DV: 51.43±3.139*, DL: 40.50±1.067#, *=p<0.05 vs.
NDV, #=p<0.05 vs. DV) and wall:lumen ratio (at max intraluminal pres-
sure 120 mmHg: NDV: 0.1217±0.0062, DV: 0.1750±0.0184*, DL:
0.1244±0.0070##, *=p<0.05 vs. NDV, ##=p<0.01 vs. DV).
Conclusion: There was no reduction in hyperglycemia level in the dia-
betic rats. This allowed us to examine the glucose-independent effects of
DPP-IV inhibition with linagliptin. Type-2 diabetic rats have impaired
cerebrovascular response to insulin-mediated relaxation and pathological
vascular remodeling remodeling, both of which were improved following
linagliptin treatment. DPP-IV inhibition with linagliptin holds potential as
a possible therapy for diabetic vascular disease in addition to its clinical
anti-hyperglycemic use.
Supported by: Boehringer Ingelheim Pharm., Inc.
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A randomised, active- and placebo-controlled, three-period cross-
over trial to investigate short-term effects of linagliptin on endothelial
function in type 2 diabetes
T. Jax1, M. von Eynatten2, A. Stirban1, A. Terjung1, H. Esmaeili3, A.
Berk3, S. Thiemann2, R. Chilton4, N. Marx5;
1Profil, Neuss, Germany, 2Boehringer Ingelheim Pharma GmbH & Co.
KG, Ingelheim, Germany, 3Boehringer Ingelheim Pharma GmbH & Co.
KG, Biberach, Germany, 4University of Texas Health Science Center,
San Antonio, USA, 5University of Aachen, Germany.
Background and aims: Studies of dipeptidyl peptidase (DPP)-4 inhibi-
tors report heterogeneous effects on endothelial function in patients with
type 2 diabetes. This study assessed the effects of the DPP-4 inhibitor
linagliptin versus the sulphonylurea glimepiride and placebo onmeasures
of macro- and microvascular function.
Materials and methods: This study randomised type 2 diabetes patients
(n=42) with HbA1c ≤7.5%, no micro- or macrovascular disease and on
stable metformin background to linagliptin 5 mg qd, glimepiride 1-4 mg
qd or placebo for 28 days. Fasting and postprandial macrovascular
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endothelial function, measured by brachial flow-mediated vasodilation
(FMD), and microvascular function, measured by laser-Doppler, were
analysed after 28 days.
Results: Baseline mean (SD) age and body-mass index were 60.3 (6.0)
years and 30.3 (3.0) kg/m2, respectively. After 28 days, changes in fasting
FMD were similar between the 3 study arms [treatment ratio, gmean (90%
CI): linagliptin vs glimepiride, 0.884 (0.633, 1.235); linagliptin vs placebo,
0.884 (0.632, 1.235); glimepiride vs placebo, 1.000 (0.715, 1.397); all p=
not significant]. Similarly, no differences were seen in postprandial FMD.
Linagliptin significantly improved fasting, but not postprandial, microcir-
culation (figure). Linagliptin had no effect on heart rate or blood pressure.
Rates of overall adverse events with linagliptin, glimepiride and placebo
were 27.5%, 61.0% and 35.0%. Fewer hypoglycaemic events were seen
with linagliptin (5.0%) than glimepiride (39.0%).
Conclusion: Linagliptin had no effect on macrocirculation in type 2
diabetes, but significantly improved microcirculatory function in the
fasting state.
Clinical Trial Registration Number: NCT01703286
Supported by: Boehringer Ingelheim
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Safety and efficacy of linagliptin in patients with type 2 diabetes and
coronary artery disease: analysis of pooled incident investigator-
reported events from phase 3 trials
M. Lehrke1, L.A. Leiter2, U. Hehnke3, S. Thiemann3, O.E. Johansen4, A.
Bhandari5, S. Patel6, H.-J. Woerle3;
1University Hospital Aachen, Germany, 2Keenan Research Centre in the
Li Ka Shing Research Institute, St. Michael’s Hospital, University of
Toronto, Canada, 3Boehringer Ingelheim Pharma GmbH & Co. KG,
Ingelheim, Germany, 4Boehringer Ingelheim Norway KS, Asker, Nor-
way, 5Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, USA,
6Boehringer Ingelheim Ltd, Bracknell, UK.
Background and aims: Patients with type 2 diabetes (T2D) continue to
have increased coronary artery disease (CAD) morbidity and mortality.
This analysis evaluated safety and efficacy data of the dipeptidyl
peptidase-4 inhibitor linagliptin in patients with CAD.
Materials and methods: Data from T2D patients with CAD (identified
using standardised MedDRA query “embolic and thrombotic events”)
were pooled from a large clinical trial programme that included
randomised placebo-controlled trials of linagliptin 5 mg. The safety set
included patients with ≥12 weeks of treatment (19 trials: linagliptin, n=
451; placebo, n=272). The efficacy set included patients with ≥24 weeks
of treatment (12 trials: linagliptin, n=328; placebo, n=198).
Results: In the safety set, baseline mean (SD) age, body-mass index, and
HbA1c were 64.7 (9.2) years, 30.6 (4.9) kg/m
2, and 8.1 ( 0.9)%, respec-
tively. Approximately 50% of patients in each group received ≥2 addi-
tional background antidiabetes drugs. Use of cardiovascular (CV) non-
study drugs was similar between the linagliptin vs placebo groups: aspi-
rin, 74.9 vs 77.6%; beta-blockers, 60.1 vs 59.9%; angiotensin-converting
enzyme inhibitors, 46.3 vs 44.5%; statins, 62.3 vs 67.6%. Baseline mean
(SD) vital signs and lipid levels were as follows: systolic BP, 135.5 (16.1)
mmHg; pulse, 70.1 (10.5) bpm; total cholesterol, 176.6 (46.5) mg/dl.
Median (range) exposure to linagliptin and placebo was 169 (6-707) days
and 170 (1-706) days, respectively. Baseline CV risk factors/history were
well matched between the groups (Table). The overall incidence of ad-
verse events (AEs) was numerically lower with linagliptin than with
placebo (Table). Cardiac AEs were reported by 9.1% of linagliptin pa-
tients and 9.2% of placebo patients (Table). In the efficacy set [baseline
mean (SD) HbA1c was 8.2 (0.9%)], the placebo-adjusted mean HbA1c
change from baseline at week 24 with linagliptin was -0.57% (95% CI -
0.70, -0.43; p<0.0001). Although patients were more likely to achieve
HbA1c <7% with linagliptin vs placebo (OR 3.70; p<0.0001), the inci-
dence of hypoglycaemia was 20.8% with linagliptin and 24.6% with
placebo.
Conclusion: Linagliptin was well tolerated and efficacious in T2D pa-
tients with known risk factors for CAD. Ongoing CVoutcomes trials will
provide further insights into the long-term safety and efficacy of
linagliptin.
Supported by: Boehringer Ingelheim
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Hepatic fat deposition is improved more with SGLT2 inhibitor
luseogliflozin compared with sitagliptin: a randomised, crossover,
controlled study using computed tomography
N. Fushimi, T. Shibuya, S. Takeishi, S. Itou, H. Kawai, A. Mori;
Diabetes and Endocrinology, Ichinomiyanishi Hospital, Japan.
Background and aims: There are few drug therapies approved for non-
alcoholic fatty liver disease (NAFLD) based on evidence-basedmedicine.
Recently, incretin-related drugs with multiple pharmacological effects are
expected to improve NAFLD. In addition, sodium-glucose co-transporter
2 (SGLT2) inhibitors are a new class of oral hypoglycemic agents that
improve hyperglycemia and reduce body weight due to increased urinary
glucose excretion. We hypothesized that SGLT2 inhibitors have the po-
tential to improve NAFLD owing to this new mechanism. We aimed to
compare the effect of the SGLT2 inhibitor luseogliflozin with that of the
dipeptidyl peptidase-4 inhibitor sitagliptin on hepatic fat deposition.
Materials andmethods:This study was conducted in 16 Japanese type 2
diabetic outpatients (male: 9, female: 7) treated with only oral hypogly-
cemic agents, including sitagliptin (50 mg/day). Participants were ran-
domly assigned to groups that either continued with sitagliptin (S) or
switched to luseogliflozin (L). After 4 weeks, participants then switched
to the other drug for another 4 weeks. Characteristics of participants were
as follows: age, 62 (57.3-66.5) years; diabetes duration, 9.5 (5-13.5)
years; BMI, 27.7 (24.3-29.7) kg/m2; and HbA1c, 7.6% (7.2-7.9%). Other
oral agent(s) received by participants were glimepiride (4), biguanide
(12), thiazolidine (2), α-glucosidase inhibitor (2), statin (11), and angio-
tensin receptor blocker (7). The dosages of oral agents did not change in
this study. Outcomes were as follows: evaluation of liver attenuation,
liver-to-spleen attenuation ratio (L/S), and visceral fat mass area (VFA)
measured by computed tomography; body weight (BW); and fasting
plasma levels of alanine aminotransferase, aspartate aminotransferase,
γ-glutamyl transferase, glycosylated hemoglobin, glucose,
glycoalbumin, ketone bodies, immunoreactive insulin, and immunoreac-
tive C-peptide. These data were evaluated at the end of administration of
each drug.
Results: Liver attenuation and L/S in the L group were significantly
higher than in the S group (liver attenuation: 50.6 (40.6-57.8) Hounsfield
units (HU) vs. 44.2 (36.5-58.1) HU, P=0.034; L/S: 0.98 (0.73-1.04) vs.
0.90 (0.82-1.14), P=0.013, respectively). Moreover, both VFA and BW
in the L group were significant lower than in the S group (VFA: 123.0
(105.3-151.6) vs. 135.4 (104.7-156.6) cm2, P=0.007; BW: 68.5 (58.8-
76.2) vs. 69.3 (59.6-76.3) kg, P=0.049, respectively), although plasma
levels of ketone bodies in the L group were significant higher (P=0.0007)
than in the S group. There was no significant difference among other
outcomes measures, including glycemic control.
Conclusion: Based on both the reduced liver attenuation as well as L/S,
this study suggests that luseogliflozin decreased hepatic fat deposition
compared with sitagliptin. It is conceivable that increasing urinary glu-
cose excretion with luseogliflozin, independently of glycemic control
improvement, induced consumption of visceral fat and hepatic fat
deposition.
PS 073 DPP-4 inhibitors: mechanisms
and implications
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Exogenous glucagon-like peptide 1 is not fully protected by acute
dipeptidyl peptidase 1 inhibition
E.S. Andersen1,2, A. Lund1,2, C. Andreasen1, J.I. Bagger1, C.F. Deacon2,
B. Hartmann2, J.J. Holst1,2, F.K. Knop1,2, T. Vilsbøll1;
1Center for Diabetes Research, Gentofte Hospital, University of Copen-
hagen, Hellerup, 2NNFCenter forMetabolic Research and Department of
Biomedical Sciences, Faculty of Health andMedical Sciences, University
of Copenhagen, Denmark.
Background and aims: Dipeptidyl peptidase 4 (DPP-4) inhibitors limit
glucagon-like peptide-1 (GLP-1) degradation and are widely used to treat
type 2 diabetes. DPP-4 exists in soluble and membrane-bound forms. It is
unclear if plasma DPP-4 activity levels reflect the full extent of DPP-4
inhibition in all compartments. We used the selective inhibitor sitagliptin
to explore the relationship between DPP-4 activity and protection of
GLP-1.
Materials and methods: On four separate days, eight patients with type
2 diabetes (BMI: 28.8±1.4 kg/m2 [mean±SEM]; HbA1c: 43.1±
2.4 mmol/mol) and eight matched healthy controls (BMI: 28.1±1.2 kg/
m2; HbA1c: 34.4±1.2 mmol/mol) received continuous i.v. GLP-1 (1.0
pmol/kg/min) and oral sitagliptin (0 [placebo], 25, 100 or 200 mg) ad-
ministered in a double-blinded randomised order. Plasma (soluble) DPP-4
activity wasmeasured by chromogenic assay, and the degree of protection
of GLP-1 (assessed with specific RIAs) was used as a surrogate index of
inhibition of ‘total’ DPP-4 activity in all compartments of the body.
Results: At steady-state (180-360 minutes), plasma DPP-4 activity de-
creased dose-dependently (Table), but with differences between ‘total’
and plasma DPP-4 compartments. A difference between the groups was
also explored, possibly due to differences in absorption (Table). Despite
relatively high inhibition of plasma DPP-4 activity, intact GLP-1 levels
(N-terminal RIA) remained lower than total GLP-1 levels (C-terminal
RIA).
Conclusion: Our results suggest that membrane-bound DPP-4 was not
fully inhibited by single-dose sitagliptin. Furthermore, other enzymes, not
inhibitable by sitagliptin, may also have been responsible.
Clinical Trial Registration Number: H-2-2012-149
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Islet-independent mechanisms contribute to the glucose-lowering ef-
fect of acute DPP-4 inhibition in healthy non diabetic and type 2
diabetes subjects after mixed meal intake
W. Alsalim, B. Omar, B. Ahrén;
Dept of Clinical Sciences, Lund, Sweden.
Background and aims:Chronic use of DPP-4 inhibitors has been shown
to improve glycemic control in type 2 diabetic subjects (T2D) by increas-
ing levels of incretin hormones, glucagon-like peptide-1 (GLP-1) and
glucose dependent insulinotropic polypeptide (GIP), resulting in stimula-
tion of insulin secretion. It has been suggested that the insulinotropic
effect of GIP is reduced in T2D subjects with insufficient glycemic con-
trol, and therefore, that GIP may be of less importance for the early
glucose-lowering effect of DPP-4 inhibition. We therefore explored
whether an increase in intact GIP by an acute single dose of the DPP-4
inhibitor sitagliptin is associated with effects on the islet hormones after
intake of mixed meal in healthy and drug-naïve T2D subjects.
Materials and methods: After an overnight fast, twelve healthy male
(mean age 22 yrs, BMI 22 kg/m2 ) and twelve well-controlled and drug-
naïve T2D male subjects (mean age 64 yrs, BMI 27 kg/m2, HbA1c
43 mmol/mol=6.0%, diabetes duration 4 yrs) underwent two tests in
random order and ingested a standardized mixed meal with sitagliptin
(SITA; 100 mg) or placebo (PBO). Blood samples were taken for analy-
ses of glucose, insulin, glucagon and intact GIP and their suprabasal
120 min areas under the curve (AUC) were calculated. β-cell function
was estimated as insulinogenic index [IGI=AUC insulin/ AUC glucose]
calculated from the glucose and insulin levels.
Results: Plasma intact GIP levels increased after meal intake with aug-
mented effects of sitagliptin in healthy subjects (SITAvs PBO AUC GIP
5835±409, 3059±294 pmol/l x min; P<0.001) and in T2D subjects
(SITA vs PBO AUC GIP 9227±1157 vs 5891±553 pmol/l x min; p=
0.003). Sitagliptin almost completely suppressed the rise in glucose in
healthy (AUC 46±16 vs 70±15 mmol/l x min; P=0.03) and in T2D
subjects (AUC 146±28 vs 239±49 mmol/l x min; P=0.04). This was
associated with significant reduction in insulin levels in healthy (AUC
16±1 vs 21±2 nmol/l x min, P=0.02) but not in T2D subjects (AUC 29.2
±7.1 vs 29.8±6.9 nmol/l x min; P=0.3). There were increases in IGI,
however, sitagliptin treatment showed no significant increase in IGI com-
pared to the placebo both in healthy (AUC 4.6±0.4 vs 4.8±0.4 nmol/
mmol, p=0.7) and T2D subjects (AUC 3.7±1.1 vs 3.6±1.1 nmol/mmol;
P=0.4). Sitagliptin did not suppress glucagon in healthy (AUC 382±102
vs 294±88 pmo/l x min; p=0.2) or T2D subjects (AUC 643±98 vs 569±
143 pmol/l min, P=0.2).
Conclusion: The increased glycemia after meal ingestion is prevented by
sitagliptin without preceding increase in insulin or reduction in glucagon
in well controlled and drug-naïve type 2 diabetes and healthy non-
diabetic subjects. Furthermore, the β-cell function is not increased by
sitagliptin in spite of augmentation of intact GIP levels in T2D. Our
results therefore suggest that extra-islet effects contribute to the glucose-
lowering effect of a single dose of sitagliptin after standardized mixed
meal ingestion in healthy and in T2D individuals but increases in intact
GIP do not appear to contribute.
Clinical Trial Registration Number: 2012-005660-98
Supported by: VR, Region Skane
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Sitagliptin effect on lipid and glucose metabolism (SLIM) study
S. Oikawa1, M. Nagao2, T. Harada2, K. Tanimura-Inagaki2, H.
Sugihara2, S. Moritani3, J. Sasaki4, S. Kono5, STREAM Study
Investigators;
1Fukujuji Hospital, 2Department of Endocrinology, Diabetes and Metab-
olism,, Nippon Medical School, 3Moritani Clinic, Tokyo, 4International
University of Health and Welfare, Fukuoka, 5National Institute of Health
and Nutrition, Tokyo, Japan.
Background and aims: DPP4-inhibitors are expected to improve the
post-prandial hyperlipidemia in addition to improving the glycemic con-
trol. This study was designed to investigate the “Sitagliptin Effect on
Lipid and Glucose Metabolism” (SLIM Study) in the type 2 diabetic
patients.
Materials and methods: The SLIM study was a multicenter, prospec-
tive, open-labeled, randomized study from April 2010 to September
2014. The type 2 diabetic outpatients treated with sulfonylureas (SU),
who accepted the informed consent, were recruited. The inclusion criteria
were HbA1c 6.9-8.5% and serum triglyceride (TG) concentraton 120-
400 mg/dl. They were randomized to the sitagliptin group (Sita, 50 mg/
day of sitagliptin addition) and the non-sitagliptin group (non-Sita, SU
multiplication), and the goal after 6 months treatment was HbA1c<6.9%.
This study conformed to the principles out-lined in the Declaration of
Helsinki, and was approved by the ethics committees of all participating
hospitals. We monitored the fasting levels of blood glucose, HbA1c,
glycated albumin (GA), lipids (TC, TG, HDL-C), and apolipoproteins
(AI, AII, B, CII, CIII, E, and B48) before and after 3 and 6 months
treatment.
Results: There were no significant differences in the sex and age distri-
bution (n=81, 45 men, 62±13 years old and 36 women, 68±10 years old
in the sitagliptin group, and n=83, 45 men, 62±11 years old, and 38
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women, 66±9 years old in the non-sitagliptin group, mean ± SD), and
HbA1c 7.5±0.8 vs. 7.5±0.7%, GA20.2±4.0 vs. 20.5±3.6%, TC 5.4±1.0
vs. 5.4±0.9 mmol/L, TG 2.1±1.4 vs. 1.8±1.3 mmol/L, HDL-C 1.3±0.3
vs. 1.4±0.3 mmol/L, and Apo B48 6.6±5.2 vs. 5.7±4.0 μg/ml, sitagliptin
group vs. non-sitagliptin group, respectively. There were no differences in
the Apo CII (5.1±2.5 and 4.6±2.0) or CIII (11.8±4.7 and 10.4±3.6)
levels between the sitagliptin and non-sitagliptin group. The reduction
of HbA1c (-0.5±0.8%) and GA (-2±3.1%) in the sitagliptin group were
significant, but not in the non-sitagliptin group (0.1±0.9 and -0.1±3.5%,
respectively). The fasting lipids-profile was not significantly changed in
the both groups, but TG levels slightly decreased in the sitagliptin group
(-0.2±1.0 mmol/L). Apo B48, CII and CIII levels were significantly
decreased in the sitagliptin group (-1.2±4.5 μg/ml, -0.4±1.3 mg/dl, and
-1.1±2.7 mg/dl, respectively), but not in the non-sitagliptin group.
Conclusion: The SLIM Study demonstrated that the sitagliptin treatment
effectively reduced the fasting levels of Apo B48, CII and CIII, which are
related to the chylomicron and remnant metabolism, with the improved
glucose metabolism. DPP4-inhibitor, sitagliptin, will effectuate the reduc-
tion of atherogenic lipoproteins in diabetes. The further study should
elucidate the mechanism of DPP4-inhibitor effect on the lipid metabolism
through the direct effect on lipid metabolism by this agent, the inhibitory
effect on DPP4, or the improved glucose metabolism.
Clinical Trial Registration Number: UMIN000006511
Supported by: The Kidney Foundation, Japan
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Incidence of microvascular outcomes in type 2 diabetes patients
treated with vildagliptin vs sulphonylurea: a retrospective study
using German electronic medical records
W.M. Kolaczynski1, M. Hankins2, S.-H. Ong1, H. Richter3, A. Clem-
ens1, M. Toussi4;
1Novartis Pharma AG, Basel, Switzerland, 2IMS Health, London, UK,
3IMS Health, Frankfurt, Germany, 4IMS Health, Paris, France.
Background and aims: Preliminary data suggest that dipeptidyl
peptidase-4 (DPP-4) inhibitors may reduce microvascular events, but
there is little evidence to support this from adequate real-world studies.
This study aimed to compare the microvascular outcomes between pa-
tients prescribed vildagliptin and those prescribed sulphonylurea (SU).
Materials and methods: This retrospective cohort study was conducted
on a large sample from the German electronic medical records database
IMS Lifelink Disease Analyzer. We used propensity score matched sam-
ples of patients prescribed either vildagliptin or SU. Exposure was de-
fined as therapy (SU or vildagliptin); primary outcomes were a diagnosis
of retinopathy, nephropathy, neuropathy or diabetic foot ulcer over the
observation period in patients with no previous record of these outcomes.
Secondary outcome was a composite of any primary outcome occurring
during the observation period.
Results: 16321 patients prescribed SU and 4481 prescribed vildagliptin
met the inclusion criteria. After propensity score matching each sample
comprised 3015 patients. Mean age was 63.7/64.6 years for SU/
vildagliptin, respectively, with mean disease duration of 3.2/3.1 years
and mean treatment duration of 2.5/2.3 years. Treatment with vildagliptin
was associated with a significantly lower incidence of retinopathy (OR=
0.55, p=0.0004), neuropathy (OR=0.71, p=0.001) and the composite
outcome (OR=0.70, p<0.0001). Incidences of nephropathy and diabetic
foot ulcer were lower for vildagliptin, but not significantly so (OR=0.90,
p=0.3920; OR=0.76, p=0.0742, respectively). There were no significant
differences in incident rate ratios (all p>0.05).
Conclusion: Treatment with vildagliptin was associated with a reduced
incidence of microvascular complications, especially neuropathy and ret-
inopathy, compared to treatment with SU.
Supported by: Novartis
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Linagliptin, independently of blood glucose control, ameliorates cog-
nitive impairment and brain atrophy induced by transient cerebral
ischaemia in type 2 diabetic mice
S. Kim-Mitsuyama, M. Ma, N. Koibuchi, T. Nakagawa, B. Lin, Y.
Hasegawa;
Department of Pharmacology and Molecular Therapeutics, Kumamoto
University Graduate School of Medical Sciencesv, Kumamoto, Japan.
Background and aims: It is well established that type 2 diabetes is
significantly associated with cognitive decline and stroke. It remains to
be clarified whether dipeptidylpeptidase-4 (DPP-4) inhibition can coun-
teract the impairment of cognitive function and brain atrophy caused by
transient cerebral ischemia in type 2 diabetes. The present study was
performed to test our hypothesis that linagliptin, a DPP-4 inhibitor, ad-
ministration following transient cerebral ischemia can ameliorate cogni-
tive impairment and brain atrophy in diabetic mice.
Materials and methods: Eight-week-old male db/db mice, a model of
obese type 2 diabetes, were subjected to transient cerebral ischemia by
17 minutes of bilateral common carotid artery occlusion (BCCAO), and
were administered (1) vehicle or (2) linagliptin (0.083 g/kg in chow) for
8 weeks or 1 week.
Results: Linagliptin administration almost completely suppressed
the blood DPP-4 activity in db/db mice (P<0.01). However,
linagliptin did not significantly reduce blood glucose or not im-
prove glucose tolerance in old db/db mice. Linagliptin administra-
t ion following transient cerebral ischemia significantly
counteracted cognitive impairment in diabetic mice subjected to
BCCAO, as estimated by water maze test (Figure (A)) and pas-
sive avoidance test. Linagliptin administration ameliorated the de-
crease in brain weight (Figure (B)), and also alleviated the de-
crease in cerebral volume (Figure (C)) and neuron cell number
(Figure (D)) in hippocampus and cortex of diabetic mice subject-
ed to BCCAO. Linagliptin administration significantly reduced the
increase in cerebral IgG extravasation (blood brain barrier disrup-
tion) and the increase in reactive microglia caused by BCCAO in
diabetic mice. Linagliptin significantly suppressed the increase in
cerebral oxidative stress in BCCAO-subjected diabetic mice. Fur-
thermore, linagliptin significantly increased cerebral claudin-5, a
main cerebral endothelial tight junction protein, and significantly
decreased gp91phox, a major subunit of NADPH oxidase, in di-
abetic mice subjected to BCCAO.
Conclusion: DPP-4 inhibition with linagliptin counteracted cogni-
tive impairment and brain atrophy induced by transient cerebral
ischemia in type 2 diabetic mice, independently of blood glucose-
lowering effect. This cerebroprotective effect of linagliptin was
associated with the suppression of blood brain barrier disruption
and the attenuation of cerebral oxidative stress. We propose that
DPP-4 inhibition seems to be a promising therapeutic strategy for
cognitive impairment and cerebral vascular complications in type
2 diabetes.
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Supported by: Boehringer Ingelheim
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Incidence of hypoglycaemia with the dipeptidyl peptidase-4 inhibitor
linagliptin in type 2 diabetes patients with renal impairment
M. von Eynatten1, U. Hehnke1, H.-J. Woerle1, M.C. Thomas2;
1Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany,
2Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
Background and aims: Patients with type 2 diabetes (T2D) and renal
impairment (RI; eGFR <60 ml/min/1.73 m2) have a significantly in-
creased risk for hypoglycaemia. This can lead to therapeutic inertia, a
reluctance to intensify management and the compromise of less stringent
targets for glycaemic control in patients with RI. In this context, the
addition of a dipeptidyl peptidase (DPP)-4 inhibitor is a potentially attrac-
tive alternative. Therefore, we evaluated the incidence of hypoglycaemic
events in placebo-controlled trials with the DPP-4 inhibitor linagliptin
specifically in participants with RI.
Materials and methods: Participants with T2D and RI were identified
from 20 randomised placebo-controlled trials (duration 12–52 weeks) of
linagliptin 5 mg once daily as monotherapy or add-on to other glucose-
lowering drugs. The incidence of pre-defined overall and confirmed
hypoglycaemic events was determined.
Results: 1155 participants with T2D and RI were identified (linagliptin,
n=669; placebo, n=486). 80% of participants had an eGFR between 30
and <60 ml/min/1.73 m2 and 20% had an eGFR <30 ml/min/1.73 m2.
Overall, participants with T2D and RI were 66±9 years of age, had a
prolonged duration of diabetes and frequent vascular comorbidities. 44%
of participants were treated with insulin. Mean baseline HbA1c was 8.2%
and mean exposure was >6 months in both groups. In these participants,
linagliptin significantly lowered HbA1c versus placebo (−0.53%, −0.57%
and −0.53% at 12, 24 and 52 weeks, respectively; all p<0.0001). Al-
though the background incidence of hypoglycaemia was high (>30%),
lowering of glucose levels with linagliptin was not associated with an
increase in any of the pre-defined hypoglycaemic event categories (Fig-
ure). The incidence risk ratio of any confirmed hypoglycaemic event for
linagliptin versus placebo was 0.99 (95% CI 0.79–1.24). Severe
hypoglycaemia occurred in 1.3% of linagliptin participants and 1.0% of
placebo participants (p=not significant).
Conclusion: These findings support the addition of linagliptin for im-
proving glycaemic control in patients with T2D and RI without increasing
the risk for hypoglycaemia.
Supported by: Boehringer Ingelheim
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Major cardiovascular outcomes in the EXAMINE trial according to
ACE inhibitor use
W.B. White1, C.A. Wilson2, G.L. Bakris3, R.M. Bergenstal4, C.P. Can-
non5, W.C. Cushman6, P.R. Fleck2, S.R. Heller7, S. Kupfer2, C.R.
Mehta8, V. Menon9, S.E. Nissen9, A.T. Perez2, F. Zannad10;
1Calhoun Cardiology Center, University of Connecticut School of Med-
icine, Farmington, 2Takeda Development Center Americas, Inc,
Deerfield, 3Pritzker School of Medicine, The University of Chicago,
4Park-Nicollet Clinic, International Diabetes Center, Minneapolis,
5Brigham and Women’s Hospital, Harvard Medical School, Boston,
6University of Tennessee College ofMedicine, Memphis Veterans Affairs
Medical Center, USA, 7University of Sheffield, UK, 8Harvard School of
Public Health, Boston, 9Cleveland Clinic Foundation, Cleveland, USA,
10Inserm 1143, Université de Lorraine and CHU, Nancy, France.
Background and aims: Activation of the sympathetic nervous system
through substance P occurs when there is DPP-4 inhibition (DPP-4i) in
the presence of high-dose ACE inhibition (ACEi). This has led to con-
cerns of potential increases in cardiovascular (CV) events when the 2
classes of drugs are used together; hence, we evaluated CV outcomes
from the large CVoutcomes trial EXAMINE according to ACEi use.
Materials and methods: Patients with type 2 diabetes mellitus (T2DM)
with a recent acute coronary syndrome (ACS) were randomly assigned to
receive alogliptin or placebo added to existing antihyperglycemic and CV
prophylactic therapies.Major CVevents were adjudicated by a committee
blinded to treatment assignment. Risks of CV death, nonfatal MI and
stroke, and hospitalized HF (HHF) were analyzed using a Cox propor-
tional hazards model in patients with and without baseline ACEi.
Results: There were 5380 patients randomized for a median follow-up of
18 months. At baseline, 3323 (62%) EXAMINE patients were using an
ACE inhibitor (1681 on alogliptin; 1642 on placebo). The composite rates
of CV mortality, nonfatal MI, and nonfatal stroke were similar for
alogliptin vs placebo with ACEi (11.4% vs 11.8%; HR=0.97; 95% CI,
0.79-1.19) and without ACEi use at baseline (11.2% vs 11.9%; HR=0.94;
95%CI, 0.72-1.21). CV death or HHF in patients onACEi use at baseline
occurred in 6.8%of patients on alogliptin vs 7.2% on placebo (HR=0.93;
95% CI, 0.72-1.20). In addition, alogliptin showed no effect on HHF
alone in ACEi-treated patients (3.3% vs 3.1%; HR=1.09; 95% CI,
0.81-1.48) for alogliptin vs placebo, respectively. There were also no
significant differences for these endpoints in patients without ACEi use
at baseline. Subgroup analyses according to any prerandomization history
of HF and ACEi use at baseline showed the primary endpoint (CV death,
MI, and stroke) occurring in 13.9% and 16.5% of patients on alogliptin vs
placebo, respectively (HR=0.87; 95% CI, 0.63-1.19) and CV death or
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HHF in 12% and 13.2% of patients on alogliptin vs placebo, respectively
(HR=1.01; 95% CI, 0.69-1.49).
Conclusion: Cardiovascular outcomes were not different for alogliptin
compared with placebo in patients with T2DM and coronary disease
treated with ACE inhibitors.
Clinical Trial Registration Number: NCT00968708
Supported by: Takeda Development Center Americas, Deerfield, IL
PS 074 The future of diabetes
pharmacology
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RG-125 (AZD4076): clinical candidate with a novel modality to treat
insulin resistance through inhibiting miR-103/107
B.Wagner1, P. Tran1, R. Pagarigan1, S. Neben1, J. Kim2, B. Zarrouki3, P.
Andersson3, E.-L. Lindstedt3, A. Turnbull3, D. MacKenna4;
1Regulus Therapeutics Inc., San Diego, 2University of Massachusetts
Medical School, Boston, USA, 3Cardiovascular & Metabolic Diseases
Innovative Medicines, AstraZeneca, Mölndal, Sweden, 4Regulus Thera-
peutics, San Diego, USA.
Background and aims: Anti-miRs targeting the miR-103/107 family
have been shown to improve insulin sensitivity and glucose homeostasis
in diet induced obese (DIO) and db/db mice. In vitro and in vivo screen-
ing of anti-miR-103/107 oligonucleotides (anti-miRs) led to the identifi-
cation of RG-125, a GalNAc conjugated anti-miR. The goal of these
studies was to evaluate RG-125 potency and efficacy in insulin resistant
DIO and db/db mice. In addition a hyperinsulinemic-euglycemic clamp
was performed in DIO mice to examine the mechanism by which miR-
103/107 inhibition improves insulin sensitivity. RG-125 was also evalu-
ated in mouse and non-human primate (NHP) toxicology studies.
Materials and methods: DIO and db/db mice were dosed s.c. at dose
levels noted, once weekly for 3-9 weeks. Oral glucose tolerance tests and
weekly fasting glucose and insulin were performed after 6 hour fasting.
Clamp studies were performed on conscious, overnight-fasted mice using
an indwelling intravenous catheter with operator blinded to dosing group.
Exploratory toxicology studies were performed in CD-1 mice and cyno-
molgus monkeys, dosed s.c. once weekly for 5-6 weeks.
Results: RG-125 induces dose-dependent reductions in weekly fasting
blood glucose and plasma insulin in DIO mice, with significant improve-
ments in the homeostatic assessment of insulin resistance (HOMA-IR) at
doses as low as 5 mg/kg. There were no effects on body weight. RG-125
normalized glucose tolerance to that of lean controls. Clamp studies in
DIO mice confirm the insulin sensitizing effects of miR-103/107 inhibi-
tion with RG-125 administration giving clear dose-responsive improve-
ments in both glucose infusion rate and whole body glucose turnover.
Decreases in clamped hepatic glucose production along with increased
glucose uptake in brown adipose tissue and skeletal muscle indicates that
RG-125 improves hepatic and peripheral insulin sensitivity. RG-125 also
reversed the extreme hyperglycemia that develops with age in db/db
mice. Exploratory toxicology studies in mice and NHP show RG-125
was well tolerated across multiple dose levels and provided insight into
GLP study design.
Conclusion: RG-125 (AZD4076), via inhibition of miR-103/107, is a
novel insulin sensitizer with proven efficacy across a number of mouse
disease models, and good tolerability in both mouse and NHP. These data
support clinical development of RG-125 for treatment of type 2 diabetes
and associated metabolic disorders.
824
Preclinical pharmacokinetics-pharmacodynamics modelling to guide
first-time-in-human studies with the anti-miR-103/107, RG-125
(AZD4076)
M. Sundqvist1, M. Antonsson1, B. Zarrouki1, E.-L. Lindstedt1, A.
Turnbull1, T. Owen2, K. Liu2, J. Grundy2, B. Wagner2;
1Cardiovascular & Metabolic Diseases Innovative Medicines,
AstraZeneca, Mölndal, Sweden, 2Regulus Therapeutics, San Diego, USA.
Background and aims:MicroRNAs (miR) are short, non-coding RNA
sequences controlling the expression of multiple genes by mRNA
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degradation or post-transcriptional regulation. In humans, hepatic expres-
sion of miR-103/107 is increased in patients with fatty liver disease and
correlates with insulin resistance. In rodent models of insulin resistance
and diabetes, inhibition of miR-103/107 alleviates insulin resistance and
reduces hyperglycemia. RG-125, a novel anti-miR-103/107 GalNAc-
conjugated oligonucleotide, increases insulin sensitivity in the diet-
induced obesity mouse model (DIO). By using pharmacokinetic-
pharmacodynamic modelling to integrate all preclinical data we predicted
human dose and time-course of response.
Materials and methods: RG-125 was administered s.c. once weekly at
multiple dose levels to mouse (50-450 mg/kg) and non-human primate
(NHP; 5-150 mg/kg) in combined pharmacokinetic and toxicology stud-
ies. A mathematical pharmacokinetic model was fitted, describing both
plasma and liver exposure for parent drug and its metabolites in mouse
and NHP. In a separate series of studies, RG-125 was dosed once weekly
s.c. in DIO mice (1.7-45 mg/kg) and plasma glucose and insulin were
measured over time to assess potency and efficacy. The homeostatic
model assessment of insulin resistance (HOMA-IR) response in DIO
mice was calculated from glucose and insulin, and fit to a turnover model,
taking the animal disease progression into account.
Results: A pharmacokinetic model including saturated uptake into liver,
predicted observed plasma and liver concentrations of the combined RG-
125 active metabolites in the evaluated animal species well, justifying an
allometric approach to predict human pharmacokinetic parameters. The
pharmacodynamicmodel liver IC80 parameter estimate was 8.4 μM (95%
confidence interval: 6-12 μM) in DIO mice and assumed applicable to
humans. Allometric scaling was further implemented on the pharmaco-
dynamic model to predict human response over time. The observed time
to achieve 50%maximal inhibitory response in RG-125 treated DIOmice
(~5 days) was extrapolated to humans (~30 days), based on reported
glucose turnover half-life values in mouse (~3 days) and human
(~19 days) studies with thiazolidinediones. The model predicted human
therapeutic s.c. dose of RG-125 was predicted to be 70 mg once weekly
and which will need to be confirmed in clinical testing.
Conclusion: RG-125 (AZD4076) causes robust insulin sensitization in
DIO mice and is an attractive candidate to investigate effects on insulin
sensitization in man. The human PKPD model, albeit assumption-rich,
could be further used to guide the design of safety studies as well as early
clinical trials, impacting both duration and dosing regimen.
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GMC-252 Lysine Salt, a conjugate of the anti-inflammatory
diflunisal and the antioxidant N-acetylcysteine, shows anti-diabetic
effects in db/db mice
S.GarcíaVicente1, L.Marti1, M. SerranoMuñoz1, D. Pérez Cáceres2, A.
Zorzano3,4;
1Genmedica Therapeutics S.L., Esplugues de Llobregat, 2Servei
d'Experimentación Animal, Universitat de Barcelona. Facultat de
Farmàcia, 3Departament de Bioquímica i Biologia Molecular, Universitat
de Barcelona. Facultat de Biologia., Esplugues de Llobregat, 4Institute for
Research in Biomedicine (IRB Barcelona), Spain.
Background and aims: Chronic inflammation is seen to be involved in
the pathogenesis of insulin resistance and type 2 diabetes. Oxidative stress
is the common factor underlying insulin resistance, type 2 diabetes and
cardiovascular disease, which helps to explain the presence of inflamma-
tion in all these conditions. Here we investigate the anti-diabetic effects of
GMC-252, a conjugate, which allows the sustained release of the anti-
inflammatory Diflunisal and the antioxidant N-acetylcysteine, in db/db
mice.
Materials and methods: 5-weeks old BKS(D)-Leprdb/JOrlRj mice (db/
db) were administered orally daily with GMC-252 Lysine Salt (0.5 mmol/
kg/day) or vehicle (PBS-Tween 20 0.1%) for 28 days. Non-fasting gly-
cemia, body weight, food and fluid intake were measured every 2-3 days.
GTT and ITT test were performed before the end of the treatment. C-
Peptide, insulin, HbA1c, plasma lipids, pancreatic insulin content and
pancreatic morphology were analyzed at the end of the treatment.
Results: After 4 weeks of treatment, db/db mice treated with GMC-252
Lysine Salt showed an increase in glycemic control (reduction in non-
fasting glycemia and HbA1c). There was also an improvement in pan-
creatic function (increases of plasma insulin, plasma c-peptide and pan-
creatic insulin content). Pancreata morphology analysis revealed in-
creased insulin immunostaining signal (1.75 fold; P<0.05) and islet size
(1.62 fold; P<0.05) due to GMC-252 treatment. There was also a de-
crease in plasma Free Fatty Acids and plasma Triglycerides but plasma
total cholesterol was not modified (see Table 1). Moreover, GMC-252
oral chronic treatment does not affect animal weight. We observed in
GMC-252 treated mice an improvement in glucose tolerance in the glu-
cose tolerance test (P<0.05) and the action of insulin lasted longer during
the insulin tolerance test (P<0.05).
Conclusion: In conclusion, GMC-252, a conjugate formed by the anti-
inflammatory Diflunisal and the antioxidant N-acetylcysteine, showed
anti-diabetic effects in db/dbmice. This indicates that co-targeting inflam-
mation and oxidative stress could be a new terapeutic approach for the
treatment of type 2 diabetes.
Supported by: ENISA, CDTI
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Metabolic effects of dietary supplementation with Lactobacillus
reuteri DSM 17938: a randomised proof-of-concept study in type 2
diabetes
R. Mobini1, P. Kovatcheva1, V. Tremaroli1, F. Karlsson2, M. Levin3, M.
Ljungberg4, M. Sohlin4, H. Bertéus Forslund5, M. Ståhlman1, E.
Connolly6, F. Bäckhed1, P.-A. Jansson1;
1Department of Molecular and Clinical Medicine, University of Gothen-
burg, 2Department of Chemical and Biological Engineering, Chalmers
University of Technology, 3Department of Oncology, University of Goth-
enburg, 4Department of Radiation Physics, University of Gothenburg,
5Department of Internal Medicine, University of Gothenburg, 6BioGaia,
Stockholm, Sweden.
Background and aims: Growing clinical evidence bridges composition
of the human gut microbiota to metabolic diseases. However, very few
randomised controlled trials (RCT) have addressed the effect of
probiotics on metabolic outcomes in type 2 diabetes (T2D) patients. We
conducted a RCT in T2D patients and evaluated metabolic effects after
oral supplementation with Lactobacillus reuteri DSM 17938 (LR).
Materials and methods: Forty-six insulin treated T2D patients partici-
pated in a double-blind and placebo-controlled trial and were randomised
to one of three parallel groups receiving daily either placebo (n=15,
11 M/4 F, Age: 65±5 years, BMI: 31.2±4.0 kg/m2, HbA1c: 60.4±
1.5 mmol/mol and total insulin dose: 67±52 U/day, Mean ± SD), a low
dose of LR (108 Colony Forming Unit (CFU), n=16, 12M/4 F, Age: 65±
6, BMI: 31.3±4.0, HbA1c: 61.5±1.5 and total insulin dose: 41±25) or a
high dose of LR (1010 CFU, n=15, 12 M/3 F, Age: 64±6, BMI: 32.5±
3.0, HbA1c: 66.4±2.2 and total insulin dose: 51±37). We assessed met-
abolic control by HbA1c, fat distribution by CT scan, liver steatosis by
MRI, insulin sensitivity by a euglycemic hyperinsulinemic glucose clamp
(120 mU/m2/min), fat cell size by subcutaneous needle biopsy, dietary
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registration by a validated questionnaire and fecal microbiota composi-
tion by sequencing of the 16S rRNA gene at the baseline and 12 weeks
after treatment in an intention to treat analysis.
Results: The study groups differed in HbA1c at baseline but showed
similar anthropometry and pharmacological treatment (oral hypoglyce-
mic agents in addition to insulin were metformin≈80% and sulfonyl-
urea≈20%). We observed no difference in HbA1c, BMI, fat distribution,
liver steatosis, calorie intake and microbiota composition when compar-
ing baseline and follow-up after 12 weeks within or between the placebo
(P), low dose (L) or high dose (H) LR groups. However, patients treated
with the high dose LR increased the insulin sensitivity index (1.41±0.16
vs 1.76±0.24 100×mg×L×kg-1×min-1×mU-1, mean±SEM, p<0.05,
Wilcoxon signed rank test). While fat cell size increased in the placebo
group (81±2 vs 88±1 μm, mean±SEM, p<0.05, n=11), we observed a
tendency to decreased fat cell size in the high LR dose group (84±3 vs 81
±4 μm, p=0.09, n=9). Finally, we observed a trend for an increased
serum adiponectin at follow-up in the high LR dose group (7.6±1.5 vs
8.4±1.6 mg/L, mean±SEM, p=0.06, n=14).
Conclusion: Dietary supplementation with Lactobacillus reuteri DSM
17938 for 12 weeks did not improve HbA1c in insulin treated T2D pa-
tients. However, insulin sensitivity in skeletal muscle and adipose tissue
significantly increased in patients treated with the highest dose of Lacto-
bacillus reuteri.
Clinical Trial Registration Number: NCT01836796
Supported by: BioGaia, Per-Anders Jansson (SRC and ALF)
827
Effect of Gymnema sylvestre administration onmetabolic syndrome,
insulin sensitivity and insulin secretion
E. Martínez-Abundis, L.Y. Zuñiga, M. González-Ortiz;
Institute of Experimental and Clinical Therapeutics, University of Gua-
dalajara, Mexico.
Background and aims: The metabolic síndrome(MetS) is a cluster of
most dangerous heart attack risk factors: diabetes mellitus type 2 and
prediabetes, abdominal obesity, high cholesterol and high blood pressure.
A quarter of the world´s adults have MetS in Mexico 49.8%. Gymnema
sylvestre indigenous herb, belonging to the class dicotyledonous of
Ascleapidaceae. Although the herb is widely used as a naturopathic treat-
ment for diabetes, it also demonstrates promising effects in the treatment
of obesity, dyslipidemia, hypertension, insulin secretion, among others.
The above-mentioned findings show that Gymnema sylvestre has an
excellent potential for the prevention and treatment of MetS. The aim of
this study was to evaluate the effect of Gymnema sylvestre administration
on MetS, insulin sensitivity, and insulin secretion.
Materials and methods: A randomized, double-blind, placebo-
controlled clinical trial was carried out in 24 patients with a diagnosis
of MetS in accordance with the modify International Diabetes Federation
criteria. After simple random allocation using a random number list, 12
patients received Gymnema sylvestre capsules (300 mg), two times per
day before breakfast and dinner for 90 days. The remaining 12 patients
received placebo at the same dose and the same pharmacological presen-
tation. Before and after intervention we evaluated: the components of
MetS, body weight, body mass index, total cholesterol, low-density lipo-
protein, very-low-density lipoprotein.We calculated: area under the curve
of glucose and insulin, Insulinogenic index, Stumvoll index, andMatsuda
index.
Results: The placebo group showed significant increase in body weight
(78.8±16.1 vs. 80.3±18.2 kg, p=0.01), body mass index (30.3±3.2 vs.
30.7±3.8 kg/m2, p=0.03), waist circumference (98.3±13.6 vs. 100.5±
14.7 cm, p=0.01), low density lipoprotein (82±23 vs. 107±21mg/dl, p=
0.01), area under the curve of insulin (10719±5819 vs. 15136±7556 μU/
min, p=0.01), Insulinogenic index (0.61±0.33 vs. 0.95±0.66 p=0.01), as
well as an decrease in the Matsuda index (3.3±1.9 vs. 2.5±1.4, p=0.02).
After Gymnema sylvestre administration, there were significant decrease
in body weight (81.3±10.6 vs. 77.9±8.4 kg, p=0.02), body mass index
(31.24±2.55 vs. 30.43±2.23 kg/m2, p=0.02) and very low density lipo-
protein (40±13 vs. 31±13 mg/dl, p=0.05).
Conclusion: Gymnema sylvestre decreased body weight, body mass in-
dex and the low density lipoprotein in patients with MetS, likewise, in
counterpart with placebo, Gymnema sylvestre prevented decrease in in-
sulin sensitivity and compensatory hyperinsulinemia in this population.
Clinical Trial Registration Number: NCT02370121
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Insulin-sensitising effects of methysulfonlymethane (MSM), an
organosulfur compound, in insulin-resistant obese mice
I.S. Lima1, S. Park2, J. Seo1, M. Chung1, L. Moura1, M. Macedo3, Y.-B.
Kim1;
1Division of Endocrinology, Diabetes and Metabolism, Beth Israel Dea-
coness Medical Center, 2Boston Children's Hospital, Boston, USA,
3CEDOC Nova Medical School, Lisboa, Portugal.
Background and aims: Methysulfonlymethane (MSM) is an
organosulfur compound present in plants. MSM has been used as a sup-
plement to improve various metabolic-related diseases, including joint
inflammation, osteoarthritis, rheumatoid arthritis, osteoporosis, musculo-
skeletal pain, and chronic pain. However, the effects of MSM treatment
on obesity-linked metabolic disorders remaims unclear. The aim of this
work was to determine whether MSM therapy ameliorates glucose me-
tabolism and insulin resistance.
Materials and methods:Male leptin receptor-deficient (db/db, 6 weeks
of age) and control mice were treated with MSM (3-5% m/v) in drinking
water for 4 weeks. Male C57 mice (5 weeks of age) fed a high-fat diet
(HFD) were treated with MSM (2.5-5% m/v) for 10 weeks. Insulin sen-
sitivity and glucose tolerance were assessed; body weight and glucose
levels were monitored. Hepatic and serum content in triglycerides and
cholesterol and gene expression of key molecules involved in lipid me-
tabolism and inflammation were determined. Hematoxylin and eosin
stain (H&E stain) of liver sections from control, db/db and HFD mice
was performed.
Results: Four weeks of MSM treatment decreased blood glucose levels
from 516±18.79 mg/dl (before treatment) to 242.3±41.78 mg/dl (after
treatment) in db/db mice (p<0.001), suggesting effects for glucose-
lowering action. Interestingly, this effect occurred in the presence of
hyperinsulinemia (6.349±1.121 ng/mL for untreated versus 12.59±
1.204 ng/mL for treated db/db mice, p<0.001). Histological analysis
indicated that hepatic steatosis was decreased in MSM-treated db/db
mice. This was consistent with a reduction in hepatic triglyceride
(263.8±34.46mg/dL for untreated versus 137.6±10.96mg/dL for treated
db/db mice, p<0.01) and cholesterol (231.2±29.45 mg/dL for untreated
versus 144.4±9.131 mg/dL for treated db/db mice, p<0.01) levels. MSM
treatment also promoted a decrease in serum triglycerides (171.1±
12.84 mg/dL for untreated versus 105.6±4.975 mg/dL for treated db/db
mice, p<0.01) and cholesterol (109.0±3.591 mg/dL for untreated versus
79.97±15.89 mg/dL for treated db/db mice, p<0.05). In mice fed a high-
fat diet (HFD), 10 weeks of MSM treatment led to a decrease in insulin
(10.40±1.183 ng/mL for HFD versus 3.285±1.168 ng/mL for treated
HFD mice, p<0.01) and glucose 152.4±6.743 mg/dL for HFD versus
128.2±3.364 mg/dL for treated HFD mice, p<0.01) levels. Importantly,
MSM treated HFD-fed mice displayed hypersensitivity to insulin, indi-
cating that MSM has insulin-sensitizing effect. In response to MSM,
hepatic triglyceride (21.19±0.9239 mg/g of tissue for HFD versus
16.76±0.3724 mg/g of tissue for treated HFD mice, p<0.01) and choles-
terol (6.780±0.3642 mg/g of tissue for HFD versus 4.906±0.5015 mg/g
of tissue for treated HFD mice, p<0.05) contents were decreased in HFD
fed mice. This was associated with a reduction in lipogenic gene expres-
sion of FAS and ACC. In addition, gene expression of key molecules
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involved in inflammation, MCP1, TNF-alpha, and IL-6, were greatly
suppressed by MSM.
Conclusion: These data suggest that MSM has beneficial metabolic ef-
fects on hyperglycemia, insulin resistance, and hepatic steatosis, all of
which are often found in obesity and type 2 diabetes. Thus, MSM could
be the therapeutic option for the treatment of metabolic disorders.
Supported by: SFRH/BD/71021/2010
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TAZ modulator, TM-25659-induced activation of FGF21 levels
decreases insulin resistance
J. Jeon1, S.-E. Choi2, J. Jung3, S.-A. Lee3, Y. Kang2,M. Bae4, J. Ahn4, H.
Jeong5, E. Hwang5, S. Han3, H. Kim3, T. Kim6, S.-Y. An7, D. Kim3, K.-
W. Lee3;
1Endocrinology and Metabolism, Ajou University Hospital, 2Physiology,
Ajou University Hospital, Suwon, 3Endocrinology and metabolism, Ajou
UniversityHospital, Suwon, 4Korea Research Institute of Chemical Tech-
nology, University of Science & Technology, 5College of Pharmacy,
Graduate School of Pharmaceutical Sciences, and Global Top5 Research
Program, Ewha Womans University, Seoul, 6Division of Endocrine and
Metabolism, Department of Internal Medicine, Seoul Medical Center,
7Endocrinology and Metabolism, Hongik Hospital, Seoul, Republic of
Korea.
Background and aims: Transcriptional co-activator with PDZ binding
motif (TAZ) plays a key role in regulating myogenic differentiation and
muscle regeneration. In this study, we investigated the effects of TAZ on
palmitate-induced insulin resistance.
Materials and methods: The effects of TAZ on palmitate-induced insu-
lin resistance were investigated using TM-25659 to modulate TAZ, C2
myotubes, and C57BL/6J mice. And, we investigated the relationship
between the expressions of FGF21 and TM-25659 using immunoblotting
and quantitative real-time PCR. To elucidate the mechanism of action of
TM-25659, we measured the levels of the pro-inflammatory cytokines
TNF-α, IL-1-β, IL-6, and MCP-1, as well as FGF21. We also measured
the secretion of FGF21 from cells into the cytosol after treatment with
TM-25659. To determine whether TM-25659 exerted the same effects
in vivo, C57BL/6Jmice were injected intraperitoneally with either vehicle
or TM-25659 every other day for 1 week. Finally skeletal muscle cells
were transfected with FGF21 siRNA, and FGF21 levels and the effects of
TM-25659 on palmitate-induced insulin resistance were measured.
Results: Palmitate reduced the phosphorylation ofAkt, thereby impairing
insulin signaling and eventually leading to reduced glucose uptake in C2
myotubes. However, treatment with TM-25659, which stimulates TAZ,
blocked palmitate-inhibited glucose uptake and insulin signaling signifi-
cantly. Different doses of TM-25659 inhibited the production of pro-
inflammatory cytokines and induced FGF21 mRNA and protein levels.
TM-25659 increased FGF21 RNA and protein levels significantly in the
skeletal muscle. TM-25659 could not rescue cells from palmitate-induced
insulin resistance when FGF21 had been knocked down. Therefore, the
TAZ activator TM25659 protected palmitate-induced insulin resistance
via FGF21.
Conclusion: The present study suggests that TM-25659 might have ther-
apeutic potential as a treatment for insulin resistance and diabetes by
inducing FGF21 expression.
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Effect of lobeglitazone, a new PPAR-gamma agonist, on restenosis
after balloon injury in diabetic rats
K. Kim, S. Lim, J. Lee, S. Choi, K. Park, H. Jang;
Internal Medicine, Seoul National University College of Medicine,
Seongnam, Republic of Korea.
Background and aims: The ligand-activated transcription factor perox-
isome proliferator-activated receptor gamma (PPARγ) is a key factor in
adipogenesis, insulin sensitivity, and cell cycle regulation. Activated
PPARγ might also have anti-inflammatory and antiatherogenic proper-
ties. We tested whether lobeglitazone, a PPARγ agonist, might protect
against atherosclerosis.
Materials and methods: A rat model of balloon injury to the carotid
artery, and high-fat, high-cholesterol diet-fed apolipoprotein E gene dou-
ble knockout (ApoE-/-) mice were studied.
Results: After the balloon injury, lobeglitazone treatment (0.3 and
0.9 mg/kg) caused a significant decrease in the intima-media ratio com-
pared with control rats (2.2±0.9, 1.8±0.8, vs. 3.3±1.2, P<.01) (figure 1).
Consistent with this, in ApoE-/- mice fed a high-fat diet, lobeglitazone
treatment (1, 3, and 10 mg/kg) for 8 weeks reduced atherosclerotic lesion
sizes in the aorta compared with the control mice in a dose-dependent
manner. Treatment of vascular smooth muscle cells with lobeglitazone
inhibited proliferation and migration and blocked the cell cycle G0/G1 to
S phase progression dose-dependently. In response to lobeglitazone, tu-
mor necrosis factor alpha (TNFα)-induced monocyte-endothelial cell ad-
hesion was decreased by downregulating the levels of adhesion mole-
cules. TNFα-induced nuclear factor kappa-B (NF-κB) p65 translocation
into the nucleus was also blocked in endothelial cells. Insulin resistance
was decreased by lobeglitazone treatment. Circulating levels of high sen-
sitivity C-reactive protein and monocyte chemoattractant protein-1 were
decreased while adiponectin levels were increased by lobeglitazone in the
high-fat diet-fed ApoE-/- mice.
Conclusion: Lobeglitazone has antiatherosclerotic properties and has po-
tential for treating patients with diabetes and cardiovascular risk.
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PS 075 Investigational injectable
glucose-lowering therapy
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Insulin degludec/liraglutide (IDegLira) improves patient-reported
outcomes in subjects with type 2 diabetes uncontrolled on insulin
glargine + metformin: DUALV
I. Lingvay1, F.C. Pérez Manghi2, P.A. García-Hernández3, P. Norwood4,
H. Jarlov5, J.H. Kongsø5, M. Brod6;
1UT Southwestern Medical Center, Dallas, USA, 2CINME, Buenos
Aires, Argentina, 3Hospital Universitario de Monterrey, Mexico, 4Valley
Research, Fresno, USA, 5Novo Nordisk A/S, Søborg, Denmark, 6The
Brod Group, Mill Valley, USA.
Background and aims: This 26-week, open-label trial compared the
efficacy and safety of IDegLira vs insulin glargine (IGlar) in subjects with
type 2 diabetes inadequately controlled on IGlar (20–50U).
Materials and methods: Adults (n=557, HbA1c 7–10%) were
randomised to either once-daily IDegLira or continued IGlar uptitration,
both + metformin. Initial doses were 16 dose steps (16U insulin degludec
+ 0.6 mg Liraglutide; maximum 50 dose steps) for IDegLira and pre-trial
dose for IGlar (baseline mean 32U; no maximum). Fasting self-measured
blood glucose titration target was 4.0–5.0 mmol/L for both arms. Patient-
reported impact of treatment on functioning and well-being were assessed
by TRIM-D and SF-36 v2. Scores were analysed using an ANCOVA
method with treatment and region as fixed factors and baseline value as
a covariate. Missing data were imputed using last observation carried
forward.
Results: TRIM-D scores were summed from 5 subdomains and weighed
together to give total score. Change from baseline was higher with
IDegLira vs IGlar for total score (p=0.003) as well as the treatment
burden (p=0.017) and diabetes management (p<0.001) subdomains (Ta-
ble). The SF-36 validated multi-purpose questionnaire is grouped into 8
domains, including a physical component summary (PCS) score and
mental component summary (MCS) score. The improvements in PCS
(p<0.001) and 3 of the physical domain scores were significantly greater
with IDegLira vs IGlar. The MCS and the mental domain scores were
similar for both arms.
Conclusion: The statistical significant changes in the TRIM-D total score
and SF-36 PCS score, indicate that patients with type 2 diabetes treated
with IDegLira versus IGlar observed more improvement in their
treatment-related impact as well as physical functioning.
Clinical Trial Registration Number: NCT01952145
Supported by: Novo Nordisk
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Assessment of glycaemic control by continuous glucose monitoring in
patients with type 2 diabetes treated with IDegLira
T. Vilsbøll1, A. Philis-Tsimikas2, E.S. Kilpatrick3, I.H. Langbakke4, K.
Begtrup4, A.B.. King5;
1Gentofte Hospital, Copenhagen, Denmark, 2Diabetes Care Center, San
Diego, USA, 3Hull Royal Infirmary/Hull York Medical School, UK,
4Novo Nordisk A/S, Søborg, Denmark, 5Diabetes Care Center, Salinas,
USA.
Background and aims: This post-hoc analysis of the DUAL I trial ex-
amined glycaemic fluctuations and day-to-day variability with a novel,
once-daily combination of insulin degludec (IDeg) and liraglutide (Lira)
compared with IDeg or Lira alone.
Materials and methods: Seventy-two hour continuous glucose monitor-
ing (CGM) was performed in a subset of patients (type 2 diabetes [T2D]
uncontrolled on metformin±pioglitazone; oral anti-diabetic drug use bal-
anced across treatment groups; N=260) in DUAL I, a 52-week trial in
which IDegLira reduced HbA1c (1.8%) more than IDeg (1.4%, p<
0.0001) or Lira alone (1.2%, p<0.0001).
Results:Mean interstitial glucose (IG) decreased more with IDegLira vs.
Lira (p<0.0001), while IDeg produced a similar reduction (Table). Sig-
nificantly lower IG fluctuations (adjusted integrated absolute distance
from the mean profile, i.e. flatness of IG profile, p=0.0018) and postpran-
dial IG increments across all meals (p=0.0288) were observed with
IDegLira vs. IDeg. Time outside the IG target range was lower with
IDegLira vs. Lira (p=0.0072). Day-to-day IG variability (SD of daily
[24 h] mean) was similar with IDegLira vs. IDeg or Lira.
Conclusion: IDegLira shifted the glucose profile downwards compared
with Lira and flattened the profile compared with IDeg. Day-to-day
glycaemic variability was low and similar between IDegLira, Lira and
IDeg. These complementary actions on fasting and postprandial glucose
narrow the overall range of glucose excursion and produce HbA1c levels
lower than those routinely achieved in the management of T2D.
Clinical Trial Registration Number: NCT01336023
Supported by: Novo Nordisk
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Similar incidence of gastrointestinal side effects between IDegLira
and non-glucagon-like peptide-1 receptor agonist comparators
V. Aroda1, E. Jaeckel2, H. Jarlov3, T.J. Abrahamsen3, T. Vilsbøll4;
1MedStar Health Research Institute, Hyattsville, USA, 2Hannover Med-
ical School, Germany, 3Novo Nordisk A/S, Søborg, Denmark, 4Gentofte
Hospital, University of Copenhagen, Denmark.
Background and aims: IDegLira is a novel, fixed-ratio combination of
insulin degludec (IDeg), a basal insulin with an ultra-long duration of
action, and liraglutide (Lira), a glucagon-like peptide-1 (GLP-1) receptor
agonist (GLP-1RA). This combination has previously demonstrated ad-
vantages in glycaemic control compared with basal insulin and GLP-1
therapy alone. In this post-hoc analysis, gastrointestinal side effects, often
associated with GLP-1RAs during the first 12 weeks of treatment (Fig-
ure 1), were compared between IDegLira and non-GLP-1RA
comparators.
Materials and methods: This is a post-hoc analysis of two double-blind,
26-week, phase 3 trials: (DUAL IV: IDegLira vs. placebo in patients
inadequately controlled on oral antidiabetic drugs [OADs]; and DUAL
II: IDegLira vs. IDeg in patients inadequately controlled on basal insulin
and OADs) in which IDegLira was initiated at 10 and 16 dose steps,
respectively (1 dose step=1 unit of IDeg and 0.036 mg Lira). We com-
pared the proportion of patients experiencing gastrointestinal (GI) side
effects.
Results: The GI side effects are presented in Figure 1. There was no
statistically significant difference in the odds of experiencing GI side
effects for subjects on IDegLira vs. pooled comparators at weeks 4, 8,
12 or during the entire trial period (odds ratios, DUAL II: 2.0, 1.1, 1.1,
2.0; DUAL IV: 1.0, 2.0, 0.4, 0.9, respectively).
Conclusion: In double-blinded studies, a similar proportion of patients
treated with IDegLira experienced GI side effects compared with IDeg or
placebo. This may be explained by the slow and steady titration of
IDegLira which appears to improve tolerability vs. GLP-1RA therapy,
while also improving glycaemic control.
Clinical Trial Registration Number: NCT01618162 / NCT01392573
Supported by: Novo Nordisk
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Efficacy and safety of IDegLira (combination of insulin degludec +
liraglutide), in insulin-naïve patients with type 2 diabetes uncon-
trolled on GLP-1 receptor agonist (GLP-1RA) therapy
S. Linjawi1, B.W. Bode2, L.B. Chaykin3, J.-P. Courreges4, Y.
Handelsman5, L.M. Lehmann6, A. Mishra7, R.W. Simpson8;
1Coffs Endocrine&Diabetes Services, Coffs Harbour, Australia, 2Atlanta
Diabetes Associates, Atlanta, USA, 3Meridien Research, Bradenton,
USA, 4Diabetology and Vascular Disease Unit, General Hospital, Nar-
bonne, France, 5Metabolic Institute of America, Tarzana, USA, 6Novo
Nordisk A/S, Søborg, Denmark, 7Novo Nordisk A/S, Bangalore, India,
8Monash University and Eastern Health, Box Hill, Australia.
Background and aims: Due to the progressive nature of type 2 diabetes
(T2D) most patients will require treatment intensification. This phase 3
trial aimed to investigate the efficacy of IDegLira (a combination of
insulin degludec and liraglutide) in controlling glycaemia in adults with
T2D who were inadequately controlled on a glucagon-like peptide-1
receptor agonist (GLP-1RA) and oral anti-diabetic drugs (OADs).
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Materials and methods: In this 26-week open-label trial, adults with
T2D uncontrolled on maximum dose GLP-1RA therapy (liraglutide once
daily [OD] or exenatide twice daily) + metformin ± pioglitazone ±
sulphonylurea were randomised 2:1 to IDegLira OD (n=292) or continue
unchanged GLP-1RA therapy (n=146); previous OADs were continued.
Results: Mean HbA1c decreased from baseline (7.8%/7.7%) to 6.4%
(IDegLira) and 7.4% (unchanged GLP-1RA) (estimated treatment differ-
ence –0.94%, p<0.001). 75% of patients on IDegLira achieved HbA1c
<7% vs. 36% on unchanged GLP-1RA (p<0.001); 63% on IDegLira vs.
23% on unchanged GLP-1RA attained HbA1c ≤6.5% (p<0.001). Fasting
plasma glucose and 9-point self-measured blood glucose profiles im-
proved significantly more with IDegLira than unchanged GLP-1RA (Ta-
ble). Weight change was +2.0 kg with IDegLira and –0.8 kg with un-
changed GLP-1RA. Confirmed hypoglycaemia rates were low (Table)
but higher with IDegLira vs. unchanged GLP-1RA. Mean IDegLira dose
at 26 weeks was 43 dose steps (i.e. 43 U insulin degludec, 1.55 mg
liraglutide). Safety profile of IDegLira was consistent with previous find-
ings; both treatments were well tolerated.
Conclusion: Consistent with previous findings on GLP-1RA intensifica-
tion with insulin-containing therapy, IDegLira provided superior
glycaemic control vs. unchanged GLP-1RA and represents an efficacious
approach to intensifying therapy in patients with T2D uncontrolled on
GLP-1RAs.
Clinical Trial Registration Number: NCT01676116
Supported by: Novo Nordisk
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IDegLira in insulin-naïve patients with type 2 diabetes (T2D) inade-
quately controlled on sulphonylureas (SU) alone or combined with
metformin: The DUAL IV Study
H.W. Rodbard1, B.W. Bode2, S. Harris3, L. Rose4, L.M. Lehmann5, H.
Jarlov5, J. Thurman6;
1Endocrine and Metabolic Consultants, Rockville, 2Atlanta Diabetes As-
sociates, USA, 3Centre for Studies in Family Medicine, University of
Western Ontario, London, Canada, 4Institut für Diabetesforschung
Münster GmbH, Münster, Germany, 5Novo Nordisk A/S, Søborg, Den-
mark, 6SSM Medical Group, Saint Charles, USA.
Background and aims: This 26-week, multinational, double-blind
study assessed the efficacy and safety of an insulin degludec/
liraglutide combination (IDegLira) in adults (n=435) with T2D
(HbA1c 7.0–9.0%).
Materials and methods: Patients were randomised 2:1 to receive once-
daily IDegLira or placebo added to SU±metformin, and started at 10 dose
steps (10 units IDeg/0.36 mg Lira), with titration to a fasting glycaemic
target of 4.0–6.0 mmol/L.
Results: Mean HbA1c decreased from 7.9% (both groups) to 6.4% with
IDegLira and to 7.4% with placebo, (estimated difference –1.02%, p<
0.001). HbA1c <7% was achieved by 79.2% of IDegLira patients vs.
28.8% receiving placebo, odds ratio 11.95, p<0.001 (for HbA1c ≤6.5%:
64.0% vs. 12.3%, odds ratio 16.36, p<0.001). Mean fasting plasma glu-
cose decreased from 9.1 mmol/L (both groups) to 6.5 mmol/L with
IDegLira and to 8.8 mmol/L with placebo, (estimated difference –
2.3 mmol/L, p<0.001). At 26 weeks, a self-monitored 9-point blood
glucose profile showed reductions in the profile mean of 2.2 vs.
0.7 mmol/L with IDegLira and placebo, respectively (estimated differ-
ence in mean glucose of –1.6 mmol/L, p<0.001). Blood glucose was
significantly lower with IDegLira at all 9 time-points (post-hoc analysis).
Mean IDegLira dose at 26weeks was 28 dose steps (28 units IDeg/1.0 mg
Lira). Confirmed hypoglycaemia (severe or plasma glucose <3.1 mmol/
L) occurred in 41.7% and 17.1% of IDegLira- and placebo-treated pa-
tients, respectively, with rates of 3.5 vs. 1.4 events/patient year (estimated
rate ratio: 3.74, p<0.001). Mean weight change was +0.5 kg with
IDegLira vs. –1.0 kg with placebo (estimated difference 1.48 kg, p<
0.001). The rate of serious adverse events was higher in the IDegLira
group than in the placebo group (20.3 vs. 8.0 per 100 patient-years of
exposure) without any obvious patterns in the type of events.
Conclusion: IDegLira significantly improved glycaemic control in com-
bination with SU. Hypoglycaemia rates were low, but given the use of
SUs, more common than in previous trials where IDegLira was used in
combination with other oral anti-diabetic agents. Treatment was well
tolerated, with overall adverse event rates comparable to previous
IDegLira trials.
Clinical Trial Registration Number: NCT01618162
Supported by: Novo Nordisk
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Insulin degludec/liraglutide (IDegLira) is superior to insulin glargine
(IGlar) in HbA1c reduction, risk of hypoglycaemia and weight
change: DUALV study
J.B. Buse1, F.C. Pérez Manghi2, P.A. García-Hernández3, P. Norwood4,
L.M. Lehmann5, M.J. Tarp-Johansen5, I. Lingvay6;
1Endocrinology andMetabolism, University of North Carolina School of
Medicine, Chapel Hill, USA, 2CINME, Buenos Aires, Argentina, 3Hos-
pital Universitario de Monterrey, Mexico, 4Valley Research, Fresno,
USA, 5NovoNordiskA/S, Søborg, Denmark, 6UTSouthwesternMedical
Center, Dallas, USA.
Background and aims: This 26-week, open-label trial compared the
efficacy and safety of IDegLira vs IGlar in subjects with type 2 diabetes
uncontrolled on IGlar (20–50U) and metformin.
Materials and methods: Adults (n=557, HbA1c 7–10%) were
randomised to either once-daily IDegLira or continued IGlar uptitration,
both plusmetformin. Initial doses were 16 dose steps (16U IDeg + 0.6 mg
Lira; maximum 50 dose steps) for IDegLira and pre-trial dose for IGlar
(mean 32U; no maximum). Fasting self-measured blood glucose titration
target was 4.0–5.0 mmol/L for both arms.
Results:MeanHbA1c decreased from 8.4 to 6.6%with IDegLira (change
from baseline [SD] –1.81% [1.08]) and from 8.2 to 7.1% with IGlar
(change from baseline [SD] –1.13% [0.98]); estimated treatment differ-
ence (ETD) IDegLira–IGlar [95% CI] –0.59 [–0.74; –0.45], p<0.001
(Figure). Mean fasting plasma glucose decreased similarly in both arms
from 8.9 to 6.1 mmol/L with a change from baseline [SD] of –2.83mmol/
L [2.80] with IDegLira and –2.77 mmol/L [3.02] with IGlar; ETD [95%
CI] –0.01 mmol/L [–0.35; 0.33], NS. Weight decreased from 88.3 to
86.9 kg with IDegLira (change from baseline [SD] –1.4 kg [3.5]) and
increased from 87.3 to 89.1 kg with IGlar (change from baseline [SD]
1.8 kg [3.6]); ETD [95%CI] for weight change –3.20 kg [–3.77; –2.64], p
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<0.001. Significantly more subjects achieved the ADA HbA1c target and
pre-specified composite endpoints with IDegLira vs IGlar: HbA1c <7%,
71.6 vs 47.0%, estimated odds ratio (EOR) [95% CI] 3.45 [2.36; 5.05];
HbA1c <7%without hypoglycaemia, 54.3 vs 29.4%, EOR [95% CI] 3.24
[2.24; 4.70]; HbA1c <7% without hypoglycaemia and no weight gain,
38.8 vs 12.2%, EOR [95% CI] 5.53 [3.49; 8.77], respectively, all p<
0.001. IDegLira was insulin sparing; mean 26-week dose was 41 dose
steps (IDegLira) and 66U (IGlar), p<0.001.
Conclusion: IDegLira was superior to IGlar in terms of HbA1c reduction,
risk of hypoglycaemia and weight change and decreased insulin dose
requirements. Through a greater reduction in HbA1c combined with a
lower rate of hypoglycaemia, IDegLira offers meaningful clinical advan-
tages over IGlar in intensifying therapy, in subjects with type 2 diabetes
uncontrolled on IGlar.
Clinical Trial Registration Number: NCT01952145
Supported by: Novo Nordisk
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Higher early insulin exposure and greater early glucose-lowering
effect with faster-acting insulin aspart vs insulin aspart in Japanese
patients with type 1 diabetes
M. Shiramoto1, T. Nishida2, A. Hansen3, H. Haahr3;
1SOUSEIKAI Global Clinical Research Center, 2Novo Nordisk Pharma
Ltd., Tokyo, Japan, 3Novo Nordisk A/S, Søborg, Denmark.
Background and aims: Faster-acting insulin aspart (faster aspart) is a
new formulation of insulin aspart (IAsp), with faster initial absorption
following subcutaneous (s.c.) injection. This trial aimed to investigate
the pharmacokinetic (PK) and pharmacodynamic (PD) properties of
faster aspart vs IAsp following s.c. injection in Japanese patients with
type 1 diabetes.
Materials and methods: Patients (N=43; mean age±SD: 39.4±
9.4 yrs) received a single dose (0.2 U/kg s.c.) of faster aspart
or IAsp under glucose-clamp conditions (STG-22; blood glucose
target 100 mg/dL; duration 12 h post-dose) in a double-blind,
randomised, crossover design.
Results: Onset of appearance and t50%Cmax with faster aspart occurred
58% and 35% earlier than with IAsp, and faster aspart had greater early
insulin exposure during the first 2 h (2-fold greater exposure than IAsp in
the first 30 min post-dose); total exposure was similar (Table). Faster
aspart had a greater glucose-lowering effect within 2 h post-dose vs IAsp
(greatest difference in the first 30 min), and earlier onset of glucose-
lowering effect (Table). Earlier onset of action with faster aspart vs IAsp
was supported by ~10min shorter t50%GIRmax (37.5 vs 47.4min; treatment
diff. [95% CI]: -9.97 min [-12.78; -7.15]). Both treatments were well
tolerated.
Conclusion: Earlier onset and greater early insulin exposure with faster
aspart led to a greater early glucose-lowering effect vs IAsp in Japanese
patients with type 1 diabetes.
Clinical Trial Registration Number: NCT01934712
Supported by: Novo Nordisk
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A novel GIP receptor agonist enhances the body weight lowering
effect of liraglutide in diet-induced obese mice and has the potential
for once-weekly administration in humans
P. Noerregaard, M.A. Deryabina, J.U. Fog, P.T. Shelton, L. Giehm, J.R.
Daugaard;
Zealand Pharma A/S, Copenhagen, Denmark.
Background and aims: Analogs of the incretin hormone glucagon-like
peptide-1 (GLP-1) are used for the management of type 2 diabetes and are
often accompanied by modest weight loss. One approach to enhance the
efficacy of GLP-1 receptor (GLP-1R) agonists includes co-administration
with other endogenous hormones e.g. glucagon. Recently, it has been
demonstrated in animals that the incretin hormone glucose-dependent
insulinotropic peptide (GIP) enhances the weight loss induced by GLP-
1. Here we report the characterization of a novel long-acting GIP receptor
(GIP-R) incretin (I) agonist, ZP-I-98.
Materials and methods: In vitro receptor activation by ZP-I-98 was
measured as cAMP formation in HEK293 cells stably expressing human
or mouse GIP receptors or human GLP-1 or glucagon receptors. Pharma-
cokinetic (PK) characterization of ZP-I-98 was performed in mice and
monkeys and the acute pharmacodynamic effect of ZP-I-98 was investi-
gated in mice by measuring blood glucose levels during an oral glucose
tolerance test (OGTT). Sub-chronic effects of ZP-I-98, with or without
liraglutide (GLP-1 analog) co-administration, on body weight and food
intake were investigated in diet-induced obese (DIO) mice.
Results: ZP-I-98 activated the human and mouse GIP-R with EC50
values of 9 and 52 pM, respectively, while it displayed selectivity >300
fold over the GLP-1 and glucagon receptors. The terminal half-life of ZP-
I-98 in mice and monkeys, following i.v. administration, was estimated to
approximately 15 h and 57 h, respectively. Simple two species allometric
scaling of the PK indicated that the compound is suitable for once-weekly
dosing in humans.
Compared to vehicle treatment, ZP-I-98 dosed s.c. 4 h prior to an OGTT,
dose-dependently (3 and 30 nmol/kg) and significantly reduced blood
glucose levels in lean mice (p<0.001 at 30 nmol/kg, 0-180 min after
glucose administration), thus indirectly confirming the incretin effect of
the compound. Administration with liraglutide (20 nmol/kg, once-daily)
induced a transient reduction in food intake in DIO mice and 3 weeks of
treatment resulted in a mean weight loss ± SEM of 3.0±1.3%. DIO mice
treated with vehicle gained 4.3±0.95% body weight during the study. In
contrast, co-administration of liraglutide (20 nmol/kg, once-daily) and
ZP-I-98 (30 nmol/kg, once every third day) resulted in a weight loss of
9.0±1.9% over the three weeks of treatment. This weight loss was sig-
nificantly greater than the liraglutide-induced weight loss (p<0.05). Co-
treatment of liraglutide and ZP-I-98 transiently suppressed food intake to
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a similar extent as liraglutide alone. Finally, ZP-I-98 (30 nmol/kg, once
every third day) did not significantly affect the body weights of the mice
compared to vehicle.
Conclusion:Our results suggest that a combination therapy consisting of
ZP-I-98 and a GLP-1R agonist can improve the management of type 2
diabetes by inducing body weight loss superior to GLP-1R agonist alone.
The in vivo profile of ZP-I-98 further suggests that ZP-I-98 can be used as
a convenient once-weekly treatment in humans.
839
Patient characteristics and predictors of a future termination of basal
insulin supported oral therapy in the DIVE registry
T. Danne1, T. Bluhmki2, M. Kaltheuner3, W. Rathmann4, J.
Beyersmann2, P. Bramlage5;
1Kinder- und Jugendkrankenhaus “Auf der Bult”, Hannover, 2Institute of
Statistics, Ulm, 3Gemeinschaftspraxis Kaltheuner – v. Boxberg, Leverku-
sen, 4Leibniz Center for Diabetes Research at the Heinrich Heine Univer-
sity, Institute for Biometrics and Epidemiology, Düsseldorf, 5Institut für
Pharmakologie und Präventive Medizin, Mahlow, Germany.
Background and aims: The addition of a single daily injection of long-
acting insulin to oral therapy is a well-established method for treating
type-2 diabetes patients. Termed basal supported oral therapy (BOT), this
approach can greatly improve glycaemic control. However, it is not an
efficacious long term solution for every individual. The identification of
patient-related characteristics that may predict failure of BOT would be
beneficial in a clinical setting when assessing potential treatment
regimens.
Materials and methods: Data taken from the DIabetes Versorgungs-
Evaluation (DIVE) registry was analysed for patients who were younger
than 90 years and had been treated with BOT for at least 3 months. Time
origin was set to BOT-initiation. The event of interest ‘BOT failure’ was
defined as the cessation of oral therapy, the cessation of insulin therapy, or
the addition of short-acting insulin to the treatment regimen during the
observational period. Risk quantification for demographic, glycaemic,
and pharmacotherapeutic characteristics of patients was based on univar-
iate and multivariate Cox proportional hazards regression.
Results:BOT failure occurred in 2,021 patients (35.7%) of the 5,663 that
fulfilled the inclusion criteria for the study. Of these, 46.7% discontinued
oral therapy, 32.7% discontinued insulin, and 20.6% had short-acting
insulin added to their treatment. Multivariate analysis revealed that body
mass index (BMI; HR: 1.012; 95% CI: 1.001, 1.023), diabetes duration
(HR: 0.982; 95% CI: 0.976, 0.989), and HbA1c level (HR: 1.102; 95%
CI: 1.022, 1.188) were associated with BOT failure. Age, gender, fasting
plasma glucose (FPG), presence of micro- or macrovascular disease,
number of oral antidiabetic drugs (OADs), and number of concomitant
drugs were not found to be predictive of BOT failure.
Conclusion: The identification of factors that may be predictive of the
failure of BOTcould be highly useful in a clinical setting when assessing
the most appropriate treatment strategy for type-2 diabetes patients.
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A composite measure to define insulin responders: HbA1c <7% and
≥1% absolute decrease in HbA1c from baseline
J. Reviriego1, I. Conget2, M.S. Kirkman3, D. Cao4, M. Wong4, D.M.
Kendall4;
1Medical Research, Lilly Spain, 2Hospital Clinic i Universitari, Barcelo-
na, Spain, 3Medical Research, University of North Carolina School of
Medicine, Durham, 4Eli Lilly and Company, Indianapolis, USA.
Background and aims: A majority of patients with type 2 diabetes
(T2D) treated with insulin do not reach the hemoglobin A1c (HbA1c)
goal of <7% suggested by guidelines, yet they can have clinically relevant
HbA1c reductions with insulin use. Using an integrated database of 53
insulin lispro clinical trials, we propose a composite HbA1c measure to
define patients with T2D responding to therapy and report their baseline
(BL) characteristics.
Materials and methods: The analysis population included 9869 patients
with T2D treated with any insulin regimen with a BL and ≥1 post-BL
HbA1c value. Responders were defined as patients with an endpoint
HbA1c <7% and/or a ≥1% absolute (AA) decrease from BL in HbA1c.
The percentage of responders was assessed at 12 and 24 weeks, along
with the BL demographics of responders versus non-responders.
Results: Overall, only 29.6% and 40.6% of patients reached HbA1c <7%
at 12 and 24 weeks respectively, whereas the AAmodel identified greater
proportions of patients as responders (62.3% at 12 weeks and 72.6% at
24 weeks). Responders at both 12 and 24 weeks had a significantly lower
duration of diabetes and higher BL HbA1c compared to non-responders.
Compared to whites, significantly higher proportions of Hispanic patients
were responders at 12 weeks (odds ratio [OR]: 1.81; 95% confidence
interval [CI]: 1.45, 2.25) and 24 weeks (OR: 1.45; 95% CI: 1.11, 1.90).
Conversely, significantly lower proportions of Asians compared to whites
were responders at 12 (OR: 0.81; 95% CI: 0.71, 0.92) and 24 weeks (OR:
0.70; 95% CI: 0.60, 0.82). A limitation of this integrated database was
that the clinical trial population is different from a real-world treatment
population.
Conclusion: The composite HbA1c measure (AA model), which has a
≥1% absolute decrease in HbA1c from BL added to HbA1c <7%, identi-
fied more patients with clinically meaningful responses to insulin therapy
than an HbA1c target alone. Characteristics of responders by the AA
model (higher BL HbA1c, fewer years of diabetes duration) were consis-
tent with other reports. Proportions of responders by the AA model may
be significantly higher among Hispanics and lower among Asians com-
pared with Whites. Although additional validation analyses in real-world
populations are necessary, this composite model of defining insulin ther-
apy response may be useful in population management and quality
measures.
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Patient characteristics are associated with treatment response to sec-
ond line glucose lowering therapy: a MASTERMIND study
B.M. Shields1, M. Lonergan2, J. Dennis1, A. Jones1, L. Rogers1, M.
Weedon1, L. Donnelly2, R. Holman3, W. Henley1, E. Pearson2, A.
Hattersley1, The MASTERMIND Consortium;
1University of Exeter Medical School, 2University of Dundee, 3Univer-
sity of Oxford, UK.
Background and aims: The most common second-line glucose-lower-
ing agent in type 2 diabetes is a sulfonylurea (SU). Draft NICE (UK)
guidelines, currently out for consultation, propose using a
thiazolidinedione (TZD), pioglitazone, as second-line. There is no guid-
ance regarding which treatment is most effective in which patients. We
assessed whether patient clinical characteristics could be used to predict
response and aid treatment decisions.
Materials and methods: 12-month glycaemic response (HbA1c change
from baseline) was calculated for patients in the CPRD (UKprimary care)
dataset treated with SUs (n=8748) or TZDs (n=8876). Relationships
between clinical phenotype and glycaemic response were assessed using
linear regression, with adjustment for baseline HbA1c. This analysis was
repeated for the ADOPT randomised controlled trial (SUs n=1441; TZDs
n=1456).
Results: In CPRD, patients diagnosed younger had a smaller glycaemic
response to both SUs and TZDs (~2 mmol/mol greater response per 10-
year increase in age at diagnosis, p<0.0001). Female patients responded
better to TZDs (1.9 mmol/mol greater HbA1c reduction compared with
males, p<0.0001), but worse to SUs (2.4 mmol/mol smaller response, p<
0.0001). Obese patients (BMI≥30 kg/m2) responded better to TZDs
(2.1 mmol/mol greater HbA1c reduction compared with non-obese pa-
tients, p<0.0001), but non-obese patients responded better to SUs
(1.9 mmol/mol greater HbA1c response, p<0.0001). Combining catego-
ries led to greater differences (obese females: 4.4 mmol/mol greater re-
sponse to TZDs; non-obese males: 3.3 mmol/mol greater response to
SUs). Effect sizes were similar in ADOPT.
Conclusion:Clinical phenotype helps determine likely initial response to
second-line glucose lowering therapies, and could influence therapeutic
choices. Obese females have the greatest HbA1c reduction with TZDs,
and non-obese males with SUs.
Supported by: Medical Research Council
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Factors associated with type 2 diabetes mellitus treatment choice
across Europe
E.M. Heintjes1, J.A. Overbeek1, G.C. Hall2, F. Lapi3, D. Prieto-Alham-
bra4, I.D. Bezemer1;
1PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands,
2Grimsdyke House, Barnet, UK, 3Health Search, Italian College of Gen-
eral Practitioners and Primary Care, Florence, Italy, 4Idiap Jordy Gol
Primary Care Research Institute, Universitat Autònoma de Barcelona,
Spain.
Background and aims: Demographic and clinical factors associated
with choice of type 2 diabetes mellitus (T2DM) treatment at treatment
intensifications were explored using electronic health care databases in
four European countries.
Materials and methods: Antidiabetic drug prescription records were
obtained from electronic health care record databases for a 5-year study
period (2007-2011/2008-2012) in TheNetherlands (NL), Italy (IT), Spain
(ES) and the United Kingdom (UK). A standardized analytical tool
assessed treatment patterns in each database. Oral monotherapy was de-
fined as first line, oral dual therapy as second line, >2 oral treatments or
oral combined with an injectable as third line and injectables only as
fourth line therapy. Treatment intensification was defined as starting a
higher line of treatment, including start of treatment. Factors associated
with the choice of treatment were identified using multivariate logistic
regression. Potential associated factors included general characteristics,
comedication, comorbidities and clinical parameters. Missing values
were categorized as a separate category in order to avoid major loss of
data.
Results: A total of 617,346 T2DM patients were included; 48,479 from
NL, 67,751 from IT, 348,572 from ES and 152,544 from UK. Prescrip-
tion of a sulfonylurea (SU) as a first line treatment was associated with
age >75 years (RR ranged from 2.05 in ES to 3.66 in IT) and renal
comorbidity (RR ranged from 1.36 in NL to 2.65 in UK) in all countries,
while there was an inverse associationwith BMI ≥30 kg/m2 (RR 0.22 and
0.46, respectively) in UK and ES. For second line treatment, across all
countries, age >75 years was associated with receiving metformin + SU
(RR ranged from 1.05 in ES to 1.34 in IT) and renal comorbidity with
receiving SU+ dipeptidyl peptidase-4 inhibitors (DPP4) (RR ranged from
1.26 in UK to 2.31 in NL). In UK and ES, BMI ≥30 kg/m2 increased the
probability of receiving metformin + thiazolidinedione (TZD) (RR 1.44
and 1.25, respectively) and, in UK only, also the probability of receiving
metformin + DPP4 (RR 2.38). For third line treatment, age >75 years (RR
ranged from 2.49 in ES to 3.56 in UK) and renal comorbidity (RR ranged
from 1.61 in ES to 3.45 in UK) were associated with SU + insulin. BMI
≥30 kg/m2 decreased the probability of receiving metformin + SU + TZD
as third line treatment in UK (RR 0.90), but increased the risk in ES (RR
1.51). Furthermore, a BMI ≥25 kg/m2 decreased the probability to re-
ceive any third line treatment including insulin in these two countries.
Analyses of associations with fourth line treatments were not performed
for all countries because there were few treatment options. Year of index
or intensification date and prior treatment class also played a significant
role in choosing treatment when intensifying.
Conclusion: The results from this study in four different EU countries
suggest that age and renal comorbidity were the predominant factors
significantly associated with T2DM treatment choice across treatment
intensifications. Our findings might be used to investigate on appropri-
ateness of diabetes pharmacotherapy in Europe.
Supported by: BMS/AZ
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Real-life intensification of pharmacotherapy in type 2 diabetes.
ARETAEUS2 Study results
E. Placzkiewicz-Jankowska1, W. Lesniak1, M.M. Bala1, R. Topor-
Madry1, E. Szymanska-Garbacz2, P. Bijos3, J. Loba2, L. Czupryniak2;
1Jagiellonian University School of Medicine, Cracow, Poland, 2Medical
University of Lodz, Poland, 3TEVA Pharmaceuticals, Kutno, Poland.
Background and aims: Type 2 diabetes (DM2) is a progressive disease,
subsequently its pharmacotherapy requires constant intensification. Pa-
tients are also often treated for hypertension or dyslipidaemia, and these
therapies are not seen as requiring a step up approach over time. In 2012 a
cross-sectional nationwide study assessing DM2 treatment efficacy was
conducted.
Materials andmethods: Patients with DM2 (n=15,643) were enrolled at
primary care (68%) and specialist (32%) outpatient clinics, and were
analysed in three groups according to diabetes duration: up to 2, 2-10,
more than 10 years.
Results: The patients with longer DM2 duration received more intensi-
fied treatment, with almost 50% taking insulin after 10 years of diabetes
(Table). In the whole group HbA1c less than 7% was achieved in 30% of
those treated with oral monotherapy, in 46% - dual oral therapy, in 62% -
insulin only and in 69% - metformin + insulin. Among cardiovascular
risk related therapies only statins and ACE inhibitors were used with
increased frequency over time. Less than 10% of the patients achieved
all main therapeutic targets (HbA1c lower than 7%, total cholesterol less
than 175 mg/dl, HDL cholesterol over 40 (men) or 50 mg/dl (women),
LDL cholesterol less than 100 mg or 70 mg/dl in patients with CVD,
triglycerides less than 150mg/dl, blood pressure less than 140/90mmHg),
while 20-25% failed to achieve any of them.
Conclusion: Despite widely accepted need for progressive and multifac-
torial treatment of DM2, still many patients are not treated intensively
enough, even with older and inexpensive therapies.
Supported by: TEVA Pharmaceuticals
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Quality of diabetes care and gender differences in the Netherlands
(ZODIAC-45)
S.H. Hendriks1, K.J.J. van Hateren1, K.H. Groenier2, S.T. Houweling1,
A.H.E. Maas3, N. Kleefstra1,4, H.J.G. Bilo1,4;
1Diabetes Centre, Isala Clinics, Zwolle, 2Department of General Practice,
University of Groningen and University Medical Center Groningen, 3De-
partment of Cardiology, Radboud University Medical Center, Nijmegen,
4Department of Internal Medicine, University of Groningen and Univer-
sity Medical Center Groningen, Netherlands.
Background and aims: The risk of cardiovascular disease and mortality
increases by about two times in men and about four times in women with
type 2 diabetes mellitus (T2DM) compared to men and women without
T2DM. Poorer control of cardiovascular risk factors in women has been
described as a possible explanation for this difference. Aim of the current
study was to investigate whether trends in quality of diabetes care differ
between sexes in the Netherlands from 1998 till 2013.
Materials and methods: This is a prospective observational cohort
study (ZODIAC) using data from patients with T2DM treated in
primary care. Information about HbA1c, blood pressure, BMI,
lipid profile, renal function, foot and eye examination and medi-
cation use was collected annually. Target values for clinical pa-
rameters were defined according to national guidelines. Linear
time trends form 1998 to 2013 were estimated using linear mixed
models, adjusted for gender and age. Differences in trends be-
tween genders were investigated by adding sex as an interaction
term to the model and by performing stratified analyses. Absolute
differences between gender were visually investigated and by
adding gender as a confounder to the model for the whole study
group.
Results: The number of participating patients increased in the period
1998 to 2013 from 2644 to 62,230. Trend differences between sexes over
time were observed for systolic blood pressure and smoking (figure 1).
Throughout the whole study period the target value for systolic blood
pressure was achieved more often in men and the cut-off value for
cholesterol-HDL ratio was achievedmore often in women. The difference
between sexes concerning the percentage of smokers decreased to a 5%
difference, still in favor of women. The prevalence of albuminuria de-
creased from 48% to 24% in men and from 38% to 16% in women. In the
group of patients with a BMI >25 kg/m2, men were more overweight and
women were more obese. Antihypertensive drugs and insulin were pre-
scribed more often in women and lipid lowering drugs more often inmen.
No relevant absolute gender differences were found for HbA1c, neurop-
athy and diabetic retinopathy.
Conclusion: The quality of care for patients with T2DM has im-
proved considerably in the period 1998-2013 in both sexes. In all
years, absolute gender differences were observed for systolic
blood pressure, cholesterol-HDL ratio, smoking and BMI. Rele-
vant trends differences in the improvement of the quality of care
between sexes were only observed for systolic blood pressure and
smoking, with women reaching target values of blood pressure
almost as much as men and with men smoking less every year
while smoking in women has plateaued.
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Treatment of patients with type 2 diabetes mellitus with HbA1c levels
above target; the follow up of the Diabetes Care System (DCS) cohort
R. Mast1, A.A. van der Heijden2, P.J.M. Elders2, R.J. Heine3, J.M. Dek-
ker2, J.G. Hugtenburg1, G. Nijpels2;
1Department of Clinical Pharmacology and Pharmacy, EMGO Institute
for Health and Care Research, 2Department of General Practice and El-
derly Care Medicine, EMGO Institute for Health and Care Research,
Amsterdam, Netherlands, 3Eli Lilly and Company, Indianapolis, USA.
Background and aims: Because of the progressive nature of the type 2
diabetes (T2DM), many patients show a pattern of so-called ‘serial fail-
ure’ as a result of sequential addition of glucose lowering drugs including
insulin as the final step. The determinants and the sustainability of good
glycemic control following the initiation of insulin therapy have not been
described. The aim of this study was to assess the patient characteristics
and the treatment responses to the initiation of insulin therapy in a large
cohort of T2DM patients.
Materials and methods: The study was performed in the population
based diabetes cohort of the Diabetes Care System (DCS) responsible
for the quality of T2DM care and uses a managed care plan for almost
all T2DM patients in the region, in collaboration with contracted general
practices (GP’s). The managed care plan encompasses the care provided
by patient’s GP, according to the Dutch College of GPs’ treatment guide-
lines for T2DM and a standardised annual assessment organised centrally
since 1998 by the DCS in the Netherlands. Of a total of 9849 type 2
diabetes patients, 1203 T2DM patients initiated insulin. ‘Serial failure’,
compared to ‘good response’, was defined as HbA1c levels of 53 mmol/
mol or higher (7%) at more than 1/3 of the time points during the mean
5.6 year (SD 2.8) follow-up. Differences of the demographic characteris-
tics, HbA1c, BMI, and diabetes duration at baseline between the ‘serial
failure’ group and ‘good response’ group were tested with ANOVA and
post hoc Bonferroni tests for mean levels, with Chi-square tests for pro-
portions and Kruskal - Wallis test for median levels.
Results: Of the 1203 patients initiating insulin therapy 294 patients
(24.4%) showed a ‘good response’, whereas 909 patients (75.6%)
showed a ‘serial failure’ response with an equal follow-up of 5.5 year.
Patients in the ‘serial failure’ group were significantly younger, and had
higher HbA1c and glucose levels at the initiation of insulin. More patients
in the ‘serial failure’ group were using a combination of metformin and
sulfonylureas (SU) (table 1). There was no difference in total mortality
between serial failure (14.0%) and good response (16.0%).
Conclusion: Less than a quarter of the patients showed sustained glucose
control after the start of insulin treatment. Those with ‘good response’
were characterised by lower HbA1c level and higher age at the start of
insulin therapy. The ‘good responders’ may represent a subgroup of pa-
tients with a less progressive disease. Alternatively, it may be speculated
that initiating insulin earlier, increases the likelihood of achieving and
sustaining glycemic control by preserving beta-cell function.
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Identification of key success factors in type 2 diabetes care in Sweden
S. Ekeblad Lien1, L. Odevall1, T. Holm2, M. Bojestig3, S.
Gudbjörnsdottir4,5, C.-G. Östenson6;
1Health Navigator, 2Swedish Association of Local Authorities and Re-
gions, Stockholm, 3Region Jönköping county, 4Institute of Medicine,
Sahlgrenska University Hospital, University of Gothenburg, 5National
Diabetes Register, Centre of Registers, Gothenburg, 6Department of Mo-
lecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Background and aims: In Sweden, the National Diabetes Register
(NDR) has shown differences in treatment outcomes for diabetes patients
in primary care, both between and within the 21 county counties (CCs).
This study of the structure and provision of diabetes care was conducted
to identify factors associated with high performance in type 2 diabetes
(T2D) primary care, based on glycemic (HbA1c) and blood pressure
control, and use of lipid-lowering medication.
Materials and methods: 4 CCs with high performance, and 4 with low
performance, as well as 4 high performing and 6 low performing primary
care centers (PCCs) were selected based on 2011 NDR outcome data.
Differences in the provision of T2D care were explored using a combi-
nation of quantitative and qualitative analysis. Semi-structured in-depth
interviews were conducted with 66 selected individuals with professional
key roles in diabetes care, either as PCC managers, members of the
commissioning organisation or political leadership, including 22 in-
depth interviews with PCC clinical staff. In addition, steering documents,
guidelines, staffing levels and diabetic medication use were analysed.
Results: Comparing high and low performing CCs no systematic differ-
ences were identified in tender documents or reimbursement models.
Different reimbursement models and care requirements were used, but
no apparent pattern distinguishing high and low performing CCs could be
identified. The number of listed patients per full-time specialist ranged
from 1955 to 2275 (median=2048) and 1755 to 2181 (median=1840), in
high and low performing CCs respectively. No clear differences were
seen regarding insulin use. The average number of defined daily doses
of insulin per diabetes patient ranged from 212 to 281 (median=227) and
209 to 244 (median=219), and the proportion of the total number of
diabetes patients using insulin ranged from 45 to 53% (median=47%)
and 45 to 51% (median=46%) in high and low performing CCs respec-
tively. The interview analysis did however show large differences in the
structure and provision of diabetes care between high and low performing
CCs and PCCs. Systematic differences, where CCs and PCCs with better
outcomes stand out, were described in terms of seven success factors
relating to PCC design and delivery of healthcare (1. Focus on quickly
achieving target values for each patient; 2. Systematic targeted efforts to
help patients with suboptimal outcomes; 3 Own results always on the
agenda of both clinical staff and management), CC leadership and
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management of care (4. Easily accessible evidence-based guidelines, and
expectation of adherence to recommendations; 5. Follow-up and feed-
back on results; 6. Continuous improvement efforts in diabetes care),
and the culture that permeates the organisation as a whole (7. Ownership
of results and focus on secondary prevention).
Conclusion: Comparison of high and low performers, based on national
register data fromSweden, yielded insight into key success factors in T2D
care. The factors can serve as a basis for discussion and improvement
initiatives striving toward evidence-based and equal care.
Supported by: Swedish Association of Local Authorities and Regions
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Real-life practice glycaemic control in patients with latent
autoimmune diabetes of the adult and type 2 diabetes
C. Lopez1, L. Gutierrez1, J. Valls2, E. Rubinat2, M. Granado2, M.D.
Santos1, F. Rius1, A. Betriu3, D. Mauricio4, A. Lecube1, M. Hernandez1;
1Endocrinology and Nutrition, Hospital Universitari Arnau Vilanova,
lerida, 2Institut de recerca biomedica, Hospital Universitari Arnau
Vilanova, lerida, 3Nephrology, Hospital Universitari Arnau Vilanova,
lerida, 4Endocrinology and Nutrition, Hospital Universitari Germans
Trias i Pujol, Barcelona, Spain.
Background and aims: The objective of our study was to compare the
glycemic control before and after initiation of insulin therapy between
type 2 diabetes patients and patients with latent autoimmune diabetes in
adults (LADA).
Materials and methods: We restrospectively assessed previous glyce-
mic control in a case-control study on cardiovascular risk in 189 patients
with type 2 diabetes and 66 patients with LADA. All the HbA1c deter-
minations from primary and specialized care during the period 2004-2014
and time of insulin initiation were recorded. Differences in raw Area
Under the Curve (AUC) of HbA1c and HbA1c-weighted by the follow-
up time were assessed with a Mann-Whitney test. All analyses were
obtained using R, setting a threshold for significance at 5% (α=0.05)
Results: Patients with type 2 diabetes and LADA were similar in age
(58.4±10.1 vs. 58.3±12.1 yr), gender distribution (55% vs. 48% male
participants), prevalence of retinopathy (19% vs.18%) and albumin-to-
creatinine ratio (14.5±32.9 vs. 19.7±71.6 mg/g) respectively. Type 2
diabetic patients exhibited higher body mass index (31.2±5 vs. 27.5±
5.6 Kg/m2) andwaist circumference (104.5±11.7 vs. 95.5±14.9 cm), and
shorter diabetes duration (8.8±7.9 vs. 12±8.8 years), respectively (P≤
0.01 for all comparisons). Frequency of insulin treatment was 19% in type
2 diabetes and 86% in LADA (P <0.001). Mean day-weighted HbA1c
AUC was higher in LADA than in patients with type 2 diabetes (7.9%±1
vs 7.3%±1, P &lt 0.001). Patients with type 2 diabetes were exposed for a
longer period to values of HbA1c &gt 7.5% than LADA patients before
insulin iniciation (527.9±699.6 vs 197.7±361, P &lt 0.001). However,
LADA patients were exposed to HbA1c &gt 7.5% for an overall longer
period than type 2 diabetic patients (1232±834 vs 735±821 days, days, p
<0.001)
Conclusion: Despite earlier initiation of insulin therapy for poor glyce-
mic in patients with LADA,they were exposed to higher burden of hy-
perglycemia than type 2 diabetes patients.
PS 077 Burden of diabetes: economic
and otherwise
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Humanistic and economic outcomes of people with type 1 diabetes in
Europe with various degrees of complications
C. Sternhufvud1, E. Sörstadius1, K. Bergenheim1, A. Romanovschi2, F.
Thorén1, E.A. Witt3, A. Rydén1;
1AstraZeneca, Mölndal, Sweden, 2AstraZeneca, London, UK, 3Kantar
Health, Princeton, USA.
Background and aims: Following the limited research on Type 1 diabe-
tes (T1DM) regarding burden of the disease, aim of this study was to
estimate the impact of complications on health-related quality of life,
work productivity, and healthcare resource use.
Materials and methods: The 5EU NHWS is a proprietary survey of
adults (≥18 years) where respondents complete a suite of demographic,
clinical and healthcare utilization questions, as well as standardized PROs
to assess health-related quality of life (SF-36) and work impairment
(WPAI) approximately every 18 months. Data from the SF-36, WPAI
and healthcare resource use items from the 2013 survey were evaluated
for patients indicating a diagnosis of T1DM.Within this sample, data was
compared between those with no diabetes-related micro or macro-
vascular complications, 1 complication or 2 or more complications using
one-way ANOVAs with a significance level of p<0.05.
Results: The T1DM sample comprised 402 people. Mean time since
T1DMdiagnosis was 21.7 years. 67.2% of patients had no complications,
18.9% had one complication, and 13.9% had 2 or more complications.
Groups were similar in terms of age, gender, marital status, working
status, education, smoking status and income. Significant differences
were observed in BMI, such that the proportion of those who were obese
was higher in the ≥2 complications group relative to the other two groups,
19.6% vs. 5.6% and 5.3%, respectively. This group was also less likely to
report that they had exercised in the past month, 42.9% vs. 65.6% and
61.8%. In general, as the number of complications increased (0, 1, ≥2)
overall health-related quality of life and health utility scores, as reported
by the SF-36 decreased; see Table. On the WPAI, there were significant
differences such that those with 1 complication and those with ≥2 com-
plications were significantly more likely to report impairment in the form
of Presenteeism, Work Productivity, and Activity Impairment than those
with no complications. Those with 1 complication did not differ signifi-
cantly from those with ≥2 complications on all work productivity and
activity impairment measures; see Table. Patients with ≥2 complications
reported significantly more ER Visits, number of hospitalizations, and
visits to healthcare providers than those patients with no complications.
Those with 1 complication did not differ significantly from either those
with no complications or those with ≥2 complications.
Conclusion: Diabetes-related complications can have a significant hu-
manistic burden on patients with T1DM, and a significant economic
impact on the healthcare system. Patients should be educated beyond
the incidence of complications to understand the humanistic and econom-
ic burden.
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The humanistic and economic burden of type 1 diabetes in Europe
A. Rydén1, E. Sörstadius1, K. Bergenheim1, A. Romanovschi2, F.
Thorén1, E.A. Witt3, C. Sternhufvud1;
1AstraZeneca, Mölndal, Sweden, 2AstraZeneca, London, UK, 3Health
Outcomes Research, Kantar Health, Princeton, USA.
Background and aims: Following the limited research on Type 1 diabe-
tes mellitus (T1DM) regarding burden of the disease, aim of this study
was to estimate the humanistic and economic burden of T1DM regarding
health-related quality of life, work productivity, and healthcare resource
use.
Materials and methods: The 5EU NHWS is a proprietary survey of
adults (≥18 years) where respondents complete a suite of demographic,
clinical and healthcare utilization questions, as well as standardized PROs
to assess health-related quality of life (SF-36) and work impairment
(WPAI) approximately every 18 months. Data from the SF-36, WPAI
and healthcare resource use items from the 2013 survey were compared
between patients indicating a diagnosis of Type 1 diabetes and those who
indicated no diabetes diagnosis (thereby excluding type 2 diabetes from
the comparator group) via one-way ANOVAs with a significance level of
p<0.05.
Results: The sample comprised 402 patients with T1DM and 57,912
people without diabetes (non-diabetes). Mean time since T1DM diagno-
sis was 21.7 years. Two thirds of the T1DM respondents had no diabetes-
related micro or macro-vascular complications. T1DM respondents re-
ported lower income, lower BMI scores, and higher Charlson comorbid-
ity index scores relative to non-diabetes respondents. With regard to de-
mographics, a higher proportion of T1DM patients were male and a
higher proportion were current smokers when compared with non-
diabetes respondents. Age, marital status, working status, education and
exercise frequency was similar between the cohorts. 83.1% of T1DM
respondents reported experiencing hypoglycaemia; 62.7% in the past
month. T1DM respondents reported significantly worse health-related
quality of life, with lower SF-36 scores on all domains as well as mental
component and physical component scores compared to non-diabetes
respondents; see Table. The utility values were also lower for the
T1DM patients and they reported significantly more Presenteeism
(27.94 vs. 16.35, p<.001), work productivity loss (30.91 vs. 19.74, p
<.001), and activity impairment (36.29 vs. 23.95, p<.001) on the WPAI
compared to non-diabetes respondents, but nomore absenteeism (7.22 vs.
5.45, p .154). Furthermore, T1DM patients reported significantly more
healthcare resource use than non-diabetes respondents: ERVisits 0.38 vs.
0.19 (p<.001); Days of hospitalization 0.30 vs. 0.12 (p .001); HCP visits
7.86 vs. 4.43 (p<.001).
Conclusion: There is a significant humanistic and economic burden of
T1DM. Treatment strategies for T1DM should seek to balance the clini-
cal, humanistic and economic outcomes to achieve the greatest value to
the healthcare system and to individual patients.
Supported by: AstraZeneca
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Post-prandial hyperglycaemic episodes (PPH): impact on healthcare
resource use among people with type 1 and type 2 diabetes in the US,
UK and Germany
K.M. Pfeiffer1, A. Nikolajsen2, J. Weatherall3, M. Brod1;
1The Brod Group, Mill Valley, USA, 2Novo Nordisk A/S, Søborg, Den-
mark, 3Novo Nordisk, Inc., Plainsboro, USA.
Background and aims: Post-prandial hyperglycaemic episodes (PPH)
among people with diabetes are a well-known clinical challenge to dia-
betes management. While the impact of post-prandial hypoglycaemia on
healthcare resource use has been well studied, little is known about the
impacts of PPH episodes on healthcare resource use. The purpose of this
study was to assess the impact of respondent-reported PPH on healthcare
resource use among people with type 1 (T1DM) and type 2 (T2DM)
diabetes treated with meal-time bolus insulin.
Materials and methods: Data were collected in a web-survey of 906
adults diagnosed with T1DM (39%) and T2DM (61%) and treated with
self-administered bolus insulin therapy, but not using pre-mixed insulin or
GLP-1 analogues (with or without OADs), in the US (40%), UK (26%),
and Germany (34%). Respondent experience of PPH was self-reported.
Results: Analyses demonstrated that inadequate post-prandial glucose
control was prevalent among people with diabetes. Sixty-six percent of
respondents reported difficulty getting blood glucose (BG) stable after
eating during the past week. Thirty-six percent of respondents indicated
that they experienced post-prandial hypoglycaemia in the past week, and
62% reported experiencing PPH in the past week. A total of 11% of
respondents experienced post-prandial hypoglycaemia 3 or more times
in the previous week, and 30% experienced PPH episodes 3 or more
times in the previous week. Further, respondents who experienced PPH
episodes in the past week called or emailed their physicians or other
healthcare professionals about their diabetes an average of 2.7 times in
the previous year compared to an average of 1.4 times for those who did
not experience PPH episodes in the previous week (p<.001). Respon-
dents who experienced PPH in the past week made an average of 5.5
diabetes-related visits to their physicians or healthcare professionals in the
past year, compared to an average of 4.4 visits for those who did not
experience PPH episodes (p<.001). The associations between PPH and
contact with healthcare professionals were significant among those with
T2DM, but not for those with T1DM. Of those who experienced PPH
episodes during the past week, 72% reported at least one medical com-
plication related to diabetes, compared to 55% of those who did not
experience PPH episodes (p<.001). More specifically, compared to those
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without PPH in the past week, respondents who experienced PPH in the
previous week were significantly more likely to report being diagnosed
with high blood pressure (41% vs. 29%, p<.001), eye problems (33% vs.
21%, p<.001), and nerve damage (neuropathy) (28% vs. 21%, p<.05)
related to their diabetes. Respondents who experienced PPH episodes
during the previous week reported measuring their BG 1.9 additional
times on days they experienced symptoms of PPH compared to their
usual BG measurement on an average day.
Conclusion: These results indicate that PPH episodes among adults with
diabetes are common and are significantly associated with greater use of
healthcare resources, including increased communication and contact
with physicians and other healthcare professionals and greater incidence
of one or more medical complications related to diabetes, as well as more
frequent BG measurement. The additional use of healthcare resources
associated with PPH may increase the costs of diabetes management for
both T1DM and T2DM.
Supported by: Novo Nordisk
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Economic impact and associations of recurrent diabetic ketoacidosis
in type 1 diabetes
M.L. Byrne1, C. Garrett2, J. Collins3, S.A. Amiel1, K. Ismail2, S. Thom-
as3, D. Hopkins1;
1Diabetes Research Group, 2Diabetes and Psychiatry Research Group,
King's College London, 3Dept of Diabetes & Endocrinology, Guy's and
St Thomas' Hospital, London, UK.
Background and aims: For a small, but high risk sub-population of type
1 diabetes (T1D) patients, self-management is extremely difficult and
characterised by recurrent admissions with diabetic ketoacidosis (rDKA).
Economic studies demonstrate T1D patients experiencing DKA incur
1.4-2.2 times the cost of a non-DKAT1D patient, with further increases
with rDKA. There are currently no UK studies that have analysed the
healthcare cost burden of patients with rDKA admissions. To understand
the reasons for rDKA and its economic impact we have reviewed data on
all individuals with rDKA admissions over 8-years at two inner-city
teaching hospitals.
Materials and methods: Retrospective analysis of combined biochemi-
cal (HbA1c), demographic (age, sex, ethnicity and socio-economic sta-
tus) and health resource utilisation data (outpatient and inpatient activity)
collected between 2006-2014 for T1D patients with rDKA in a defined
geographical catchment area of London, UK. rDKA patients were iden-
tified by ≥3 DKA admissions and compared with the local T1D popula-
tion. Costs were calculated using the UKNational Schedule of Reference
costs (2010-2011) and NHS best practice tariffs for DKA episodes post
April 2013.
Results: 68 patients, mean age 27.8 (±12.5) years, had a total of 407
DKA admissions (mean 6.0 admissions/patient, range 3-24) with total
bed day occupancy for DKA of 1,373 days (mean 3.4 days/admission).
rDKA admission tended to ‘cluster’ with 43.2% occurring ≤3 months
from the previous episode. The total cost of DKA admissions was
£360,093 [€493,829] (£5,295/patient [€7,262]). Additionally, other
diabetes-related and non-diabetes related inpatient visits cost £227,640
[€312,184] and £171,581 [€235,305] respectively for this group. These
patients were also high users of diabetes outpatient services (mean 5.4
diabetes clinic appointments/year) but were poor attenders, with 34.8% of
appointments being missed. Total annualised cost of ‘routine’ diabetes
care was £317,565 [€435,507] (£584/patient/year [€801]). Use of non-
diabetes appointments was too high totaling £264,595 [€362,864]. Com-
pared to the local T1D cohort, rDKAwas associated with greater socio-
economic deprivation (mean index of multiple deprivation score 32.9±
10.5 vs. 29.5±9.8; p=0.01) and ethnic minority status (62% vs. 27% non-
white ethnicity, p<0.01). For those with complete medical history data
(n=37) glycaemic control was consistently poor, with mean HbA1c 101
(±30.6)mmol/mol and 92 (±20.7) mmol/mol (p=0.10) at the start and end
of the 8-year period. Only 16.7% had attended structured diabetes edu-
cation, 88.9% had noted issues with compliance and 30.6% had a clinical
diagnosis of depression.
Conclusion: These data demonstrate that rDKA patients incur extremely
high healthcare costs. DKA episodes have a tendency to ‘cluster’ but
occur on a background of long-term non-compliance and outpatient
non-attendance. This behaviour suggests a long-term relational psycho-
logical difficulty and would fit with acute admissions related to affect
regulation. Therefore, specific psychological and social interventions ca-
pable of even a modest decrease in DKA frequency would have a signif-
icant economic impact.
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Risk factor and economic burden of hypoglycaemia in elderly
patients with type 2 diabetes mellitus initiating Basal Insulin (BI) in
a US medicare advantage population
L. Liao1, H. Wang1, C. Pan2, M. Bala3, J. Escalada4;
1Sanofi, Bridgewater, 2ProUnlimited, Boca Raton, 3Sanofi, Cambridge,
4Department of Endocrinology and Nutrition, Clinica Universidad de
Navarra, Pamplona, Spain.
Background and aims: Insulin treatment is an essential tool in diabetes
management and hypoglycaemic (HG) remains a barrier for optimal
glycaemic control. Older patients are at increased risk of experiencing
severe HG events compared with other age groups with Type 2 diabetes.
We present a retrospective US health insurance claims database study to
assess risk factors for HG and its cost burden in elderly patients with
T2DM who initiated BI on top of OADs/GLP-1 s (2007-2013).
Materials and methods: The Clinformatics® Data Mart Medicare Ad-
vantage database was used to identify patients with T2DM who initiated
Basal insulin (BI) between January 2007 and December 2013. All pa-
tients had a minimum of one year continuous medical and pharmacy
coverage prior to (baseline period) and after (follow-up period) BI initial-
ization. Logistic regression was used to identify risk factors of HG oc-
curred during 1-year follow-up, adjusting baseline patient characteristics
that include age, gender, comorbidities, prescriptions, HG and healthcare
utilization. The economic burden of HG was evaluated accounting for
baseline patient characteristics with a generalized linear model assuming
gamma distribution with log link for healthcare costs to accommodate its
skewed distribution.
Results: There were 31,035 patients included in the study (mean age:
72 years). Of these patients, during the one year follow up period, 3,066
(9.9%) patients experienced one or more episodes of medically attended
HG (HG group) and 27,969 patients did not experience HG (non-HG
group). At baseline, the HG group were more likely to have general
comorbid conditions (Charlson Comorbidity Index excluding diabetes
2.6 vs 1.7, p<0.001) and incurred higher total annual healthcare costs
($54,057 vs $30,249, p<0.001) than the non HG group. The HG group
were also more strongly associated with baseline macrovascular (OR=
1.23, 95%CI: 1.12-1.34) and microvascular (OR=1.50, 95%CI: 1.38-
1.63) complications, mental illness (OR=1.24, 95%CI: 1.15-1.35) and
foot disease (OR=2.32, 95%CI: 2.08-2.59). In the one year follow up
period, percentage of patients with such conditions increased from base-
line by 8.0-9.3% for HG group and was lower or stable in the non-HG
group. After BI initiation, average annual healthcare costs slightly fell,
from $32,601 at baseline to $32,460. However, there was a 8.3%decrease
in non-HG while 39% increase in HG group. After adjusting for baseline
characteristics, the HG group was associated with substantially higher
annual healthcare expenditure ($53,375 vs $25,881) and diabetes-
related costs ($19,938 vs $8539) compared with non-HG group, mainly
driven by inpatient and outpatient services. The HG group also incurred
$5337 HG-related annual costs.
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Conclusion: Elderly T2DM patients with comorbidities are at increased
risk of HG after BI initiation and patients experiencing HG are associated
with substantially higher healthcare utilization and costs, highlighting the
need for a BI with a reduced risk of HG that can further improve
glycaemic control.
Supported by: Sanofi
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Investigating sickness absence as a pathway behind labor market
consequences of childhood onset type 1 diabetes mellitus
S. Persson1, G. Dahlquist2, U. Gerdtham1,3, K. Steen Carlsson1;
1Health Economics Unit, Department of Clinical Sciences, Lund, 2Pedi-
atrics Unit, Department of Clinical Sciences, Umeå, 3Department of Eco-
nomics, Lund University, Sweden.
Background and aims: Earlier studies from our research group show
that childhood onset of type 1 diabetes mellitus (T1DM) negatively im-
pacts employment and earnings from labor market entrance and onwards.
Less is however known to what extent these differences are directly
related to indicators of adult health and what is explained by other factors.
This study analyzed sickness absence as a mediator explaining the nega-
tive impact on employment and earnings in adults with childhood onset of
T1DM.
Materials and methods: We selected all individuals born 1962-1977
(n=3,507) with onset of T1DM before age 15 and registered in the na-
tional Swedish Childhood Diabetes Register (SCDR) which covers inci-
dent cases of T1DM since 1977. The impact of T1DM was investigated
using a matched case-control design where Statistics Sweden identified
controls matched for year of birth and residency (n=14,029). The SCDR
has been linked to national health and labourmarket registers and we used
information on sickness absence including sickness benefits (shorter du-
ration) and sickness compensation (long duration or permanent; full or
part time) as indicators of health in ages 30-33 and 40-43 years old,
respectively. First, we investigated the absolute and relative risks of sick-
ness absence in people with T1DM compared to controls. Secondly, we
added the sickness absence as a control variable in regression analyses of
employment and earnings to explore the robustness of the basic T1DM
effect shown in previous work. The analyses used logistic and panel data
regression methods, controlling for calendar year, demographic and so-
cioeconomic background.
Results: Men and women with childhood onset of T1DM were more
likely to have been on sickness benefits at least once in ages 30-
33 years (men 31% vs 19% (OR 1.94, 1.71-2.19); women 64% vs 46%
(OR 2.09, 95% CI 1.85-2.35)) and in ages 40-43 years (men 33% vs 22%
(OR 1.80, 1.30-2.50); women 53% vs 33% (OR 2.40, 1.71-3.36)). Addi-
tionally, the length of the sickness period was longer, statistically signif-
icantly for women with T1DM (men 14 days more (p=0.209); women
21 days more (p=0.007) in age 33). The likelihood of long-term/perma-
nent sickness compensation was also higher (≤ age 33; men 5% vs 3%
(OR 1.98, 1.49-2.64), women 10% vs 4% (OR 2.84, 2.27-3.55) and≤age
43; men 12% vs 5% (OR 2.64, 1.53-4.56), women 28% vs 8% (OR 4.20,
2.71-6.50)). In ages 30-33 years, T1DM had a negative effect on employ-
ment (menOR 0.63, 0.51-0.77; womenOR 0.56, 0.44-0.70) and earnings
if employed (men -9.4%, p<0.001; women -7.3%, p=0.004) and
remained or slightly increased in age 40-43 years. Adding sickness ab-
sence to the regression analyses slightly decreased the estimated effect of
T1DM on employment and earnings but T1DM in itself remained nega-
tive and significant.
Conclusion:While childhood onset of T1DM significantly increased the
risk of sickness absence early in adulthood, particularly among women, it
accounted for only a small part of the diabetes related difference in em-
ployment and earnings we have shown earlier.
Supported by: The Swedish Council forWorking Life and Social Research
(FAS)
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Type 1 diabetes with early onset and educational field at upper
secondary and university level: Is own experience an asset for a
health care carrier?
K. Steen Carlsson, I. Lovén, for the Swedish Childhood Diabetes Reg-
ister StudyGroup;
Lund University, Sweden.
Background and aims: Earlier work from our group on long-term con-
sequences of type 1 diabetes with early onset has shown small but signif-
icant negative impact on school grades, final educational level and earn-
ings. Less is known about other aspects of consequences, such as choices
of educational field. We analyzed the probability of having a health-
related education at upper secondary and university level, comparing
people with type 1 diabetes onset before age 15 and matched population
controls.
Materials andmethods: From the Swedish ChildhoodDiabetes Register
we retrieved all incident cases of childhood-onset type 1-diabetes from
1977-1990 for people born 1962-1975 and their four population controls
matched for year of birth and municipality of residence at the time of
diabetes onset. Themain outcome variable, health-oriented educationwas
defined using the SUN-classification in the SwedishNational Educational
Register for vocational and theoretical programmes at the upper second-
ary level and at university level using the last available registration up to
year 2010. These educations thus ranged from nursing assistant exam
from the vocational programmes at upper secondary level to physician
exam at the university level. The hypothesis of no systematic differences
between people with diabetes and population controls was tested using
regression analyses (multinomial and standard logit regression) for wom-
en and men separately, and controlling for demographic and socio-
economic background obtained from the Longitudinal Integration Data-
base for Health Insurance and Labour Market Studies (LISA) at Statistics
Sweden.
Results: From the selected years, 2,756 people had onset of diabetes in
ages 2-15 years (mean age at diagnosis 10.9 (SD 2.9); 53% boys) and
there were 11,020 population controls (51% boys). The majority of the
included subjects completed upper secondary school (girls/ boys: 90.5/
88.1%, with no significant differences between people with diabetes and
population controls. Women with type 1 diabetes were more likely to
complete health-oriented education at the upper secondary level (+
5.3%, p<0.01 vocational health; +1.4%, p=0.08 theoretical health) com-
pared to vocational non-health programme (reference category), but less
likely to complete a theoretical non-health oriented programme (-6.4%, p
<0.01). Men were more likely to complete a vocational health pro-
gramme (+3.2%, p<0.01) but less likely to complete both types of theo-
retical programmes (health -0.7%, p=0.01; non-health -4.1%, p<0.01).
People with type 1 diabetes were less likely to have a university exam
(women 40% vs 46%; -6.4% p<0.01; men 30% vs 35%;-5.7% p<0.01),
but among people with a university exam, women were more likely to
have a health orientated exam (+7.4%, p<0.01), while no significant
difference was found for men. The effect was consistent at all levels for
womenwith diabetes, adding to the population based differences between
men and women as regards field of education. The significant pro-health
orientation was robust in sub-group analysis and remained when control-
ling for school grades at previous level.
Conclusion: We rejected the hypothesis of no systematic differences in
choice of educational field between people with type 1 diabetes onset up
to age 15 and population controls. People with diabetes were more likely
to complete health-oriented educational programmes, both at upper sec-
ondary and university levels.
Supported by: VR dnr 2008-3802, 2011-2502, 2014-2072; FAS dnr.
2009-0768
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Education level, occupational status and quality of life in adults with
type 1 diabetes and in the general population: a comparative study
L.L. Ovesen1, H.B. Nielsen1, L.H.Mortensen2, C.J. Lau3, L.E. Joensen1;
1Patient Education Research, Health Promotion Research, StenoDiabetes
Center A/S, Gentofte, 2University of Copenhagen, 3Research Center for
Prevention and Health, Glostrup, Denmark.
Background and aims: Type 1 diabetes is a complex disease, demand-
ing a high degree of self-care throughout life. Few studies have examined
how adults with type 1 diabetes differ from the general popula-tion re-
garding education level, occupational status and self-rated quality of life.
Research in this field has shown inconsistent results and is characterized
by small samples and poor clas-sification of type 1 diabetes. Furthermore
most studies are published before 2005. The aim of this study is to com-
pare adults with type 1 diabetes and the general population in terms of
education level, occupational status and self-rated quality of life.
Materials and methods: This study compared 2.415 adults with type 1
diabetes and 48.511 adults from the general population. Data were col-
lected in 2010 and 2011 from two cross-sectional surveys of Danish
adults living in the capital region. One survey from a specialist diabetes
clinic targeting type 1 diabetes patients and one from the capital region of
Denmark representing the general popu-lation. Validated questions mea-
sured education level, occupational status, working hours, sick leave per
year and self-rated quality of life. Self-rated quality of life was assessed
with eight domains of health scored with SF-12. Data were sex- and age
standardized. Mean difference and risk difference (RD) were calculat-ed
as outcome measures. For each outcome we used stepwise addition of
covariates in a mul-tivariable linear regression model to identify potential
confounding (partner, children living at home, education, occupational
status and self-rated quality of life). Further, we analysed the difference
between education level, occupational status and self-rated quality of life
in subgroups by age and sex. A sensitivity analysis excluding individuals
participating in both surveys from the general population was conducted.
Results: Compared to the general population, a larger proportion of the
diabetes population were male (52% vs. 44%) and between 30-59 years
old (58% vs. 52%). After taking age and sex into account, adults with
type 1 diabetes, on average, reported a higher education level (RD be-
tween 0.2 - 1.6, p<.0001), lower level of employment (RD=7.69, p
<.0001), more sick leave per year (mean difference=0.71 days, P=
0.0027) and lower scores on all domains of self-rated quality of life
(RD between 3 - 8, p<.0001) compared to the gen-eral population. No
difference was found in working hours per week (mean difference=
0.06 hours, p=0.6). Yet, after adjusting for education, the results sug-
gested that adults with type 1 diabetes worked fewer hours a week
(0.28 hours, P=0,0119) compared to the general population. Covariates
explained only a small proportion of the overall difference. Results
remained the same in the sensitivity analysis.
Conclusion:Our findings indicate differences between adults with type 1
diabetes and the general popula-tion in relation to education level, occu-
pational status and self-rated quality of life. Further research into the
mechanisms is needed in order to develop interventions supporting adults
with type 1 diabetes.
PS 078 Double trouble: depression
and diabetes
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A trial to decrease diabetes distress in diabetic persons with
depression
B. Potter van Loon1, C. Schmidt1, I. de Vlieger2, E. Kilic1, F.J. Snoek3,
A. Honig4,5;
1Internal Medicine, OLVG-Sint Lucas Andreas, 2Psychology, OLVG-
Sint Lucas Andreas, 3Psychology, VU Medical Centre, 4Psychiatry,
OLVG-Sint Lucas Andreas, 5Psychiatry, VU Medical Centre, Amster-
dam, Netherlands.
Background and aims: Screening for depression is recommended annu-
ally. We set up a programme to screen for diabetesdistress (DD), depres-
sive symptoms ( Depr), and hypoglycaemia fear burden ( Hypo). If Depr
was detected in combination with DD, DDwas discussed with the patient
in 2 structured meetings in order to reduce the burden and influence both
DD and Depr.
Materials and methods: DD was measured bij PAID-5; cutoff value 8
for distress; Depr was measured by Extended Kessler -10 ( EK-10) ;
cutoff value 20; Hypo was determined by both dutch 33-item
Hypoglycaemia Fear Survey (HFS-AHV) and 3-item questionnaire ( 3I-
S); non-parametric statistics ( Wilcoxon, spearman correlation and chi
square).
Results:Out of 810 patients screened 73 ( 9%) had bothDepr and DD. 61
patients were invited for structured discussing; 20 completed the inter-
vention, 30 started the intervention but failed to complete. No show was
50% in the total group. In Completers PAID-5 score decreased from 11,
2(SD 2,5) to 8,9(3,8)( p<0.05) and EK-10 score decreased from 24,2(8,6)
to 20,8 (6,9)( p<0.05). In a subset of 410 insulin treated patients DD was
present in 52% of those with Hypo ( n=95) and in 9%without Hypo ( P<
0.001). Also, HbA1c was higher (71 mmol/mol) in those with Hypo than
without (62 mmol/mol; P<0.001). HFS-AHV score correlated with 3I-S (
rs=0,65, p<0.001); Sensitivity of 3I-S in detecting fear of hypoglycaemia
was 90% and specificity was 98%. PPV was 57% and NPV was 95%
Conclusion: In patients with Depression and DiabetesDistress a struc-
tured intervention aimed at reducing DiabetesDistress reduces both.
Hypoglycaemia fear burden is an important determinant of diabetes dis-
tress and can be measured by a 3- item questionnaire. Longer duration
follow up is warranted.
Supported by: InnovationFund SLAZ, Amsterdam
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Association of anxiety, stress and depression with demographic,
anthropometric, socioeconomic glycaemic and cardiometabolic risk
factors in patients with type 2 diabetes
A. Sereti, A. Angelidi, C. Verras, S. Vrakas, A. Papazafiropoulou, A.
Foutris, K. Charpidis, V. Liosi, V. Gkizlis, A. Melidonis;
Diabetes Center, Tzanio General Hospital, Piraeus, Greece.
Background and aims: Depression is a serious mental disease quite
prevalent. Surveys have shown a strong association between depression,
anxiety and stress with diabetes mellitus. These disorders can negatively
affect disease control. The purpose of this study is to explore possible
correlations between demographic, anthropometric, socioeconomic and
cardiometabolic parameters with the presence and severity of depression,
anxiety and stress in people with type 2 diabetes.
Materials andmethods: 391 patients (193males, aged 64.9±10.3 years)
with type 2 diabetes were included in the study. Information regarding
demographic characteristics, socioeconomic status, anthropometric and
metabolic parameters, glycemic control, type of antidiabetic treatment
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and the presence of complications of diabetes were collected from all
patients. The questionnaire DASS-21 is widely used and it is a set of
three self-report scales designed to measure the emotional states of de-
pression, anxiety and stress. It consists of 21 questions each answer being
scored on a scale value of 0 to 3. The higher total scores indicate more
severe symptoms. Statistical analysis was performed using STATA 9.0
software.
Results: Severity of stress showed a statistically significant association
with the following parameters: sex(p=0.020), age(p=0.002), marital
status(p=0.045) and insulin treatment(p=0.032), regarding anxiety:
sex(p=0.002), age(p=0.022) and insulin treatment (p<0.001) while de-
pression was associated with: sex(p=0.004), age(p=0.007), educational
level(p=0.043), marital status(p=0.004), ΒΜΙ (p=0.012) and insulin
treatment (p=0.01). On multivariate analysis, insulin treatment showed
significant positive association with stress and anxiety (Coefficient=4.56,
95%CI:0.61-8.52, p=0.024 and Coefficient=6.46, 95%CI:3.02-9.9, p<
0.001, respectively), while BMI showed significant positive association
with the severity of depression (Coefficient=0.27, 95%CI:0.03-0.51, p=
0.028). Moreover, further analysis regarding insulin treatment revealed
that when the number of insulin injections per day was increased from
two injections to three or four per day, a strong association with the
severity of stress was observed (p=0.007 and p=0.019, respectively).
Conclusion:Obesity appears to act adversely to the presence and severity
of depression, giving further emphasis on the importance of adopting a
healthy lifestyle of living and weight loss in people with type 2 diabetes.
Insulin treatment (especially when more than two injections per day are
performed) is accompanied by increased stress and anxiety levels in peo-
ple with type 2 diabetes.
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Glycaemic control and diabetes mellitus duration are associated with
geriatric depressive scale in elderly male people with type 2 diabetes
mellitus
S.-Y. An1, H. Kim2, S. Han2, Y. Kim3, D. Shin3, N. Kim4, J. Seo4, Y.
Ahn5, S. Ko5, Y. Cho6, S. Park6, S. Kim6, K. Kim7, C. Kim8, K.-W. Lee2;
1Endocrinology and metabolism, Hongik Hospital, Seoul, 2Endocrinolo-
gy and metabolism, Ajou University School of Medicine, Suwon, 3Inter-
nal Medicine, Bundang Jesaeng Hospital, Seongnam, 4Internal Medicine,
Korea University Ansan Hospital, College of Medicine, 5Internal Medi-
cine, St. Vincent's Hospital, The Catholic University of Korea College of
Medicine, Suwon, 6Internal Medicine, CHA Bundang Medical Center,
CHA University, Seongnam, 7Internal Medicine, Dongtan jeil Women’s
Hospital, Hwaseong, 8InternalMedicine, HallymUniversity SacredHeart
Hospital, Hallym University College of Medicine, Anyang, Republic of
Korea.
Background and aims: The prevalence of depression and Type 2 Dia-
betes Mellitus (T2DM) are increasing in the elderly population of Korea
and these are known to be related with each other. We evaluated the
relationship between T2DM related factors and the degree of depression
using the Korean Geriatric Depressive Scale (K-GDS) in elderly Type 2
DM subjects.
Materials and methods: This study was based on data from seven hos-
pitals in Korea. To assess the status of depressive symptoms, the K-GDS
was used. High GDS meant high probability of depression. DM related
factors were the duration of T2DM, HbA1c, and the existence of T2DM
complications.
Results:A total of 154 subjects (55 male and 99 female) with a mean age
of 71.3 years, and a mean HbA1c of 7.6% were included. In males, the
well-controlled (HbA1c<7%) T2DM group showed low GDS compared
to the less-controlled T2DM group (1.94±2.59 vs. 4.54±3.57, p=0.016).
The mean GDS of well/less controlled T2DM groups did not show any
significant difference in females. The mean GDS was higher in the group
with a longer duration (10 years and more) of T2DM in both gender
groups, but this trend showed significance only in the male group. Com-
pared to the subjects with no complications or micro-vascular complica-
tions, the subjects with micro- and macro-vascular complications showed
high GDS in males (p=0.029). In a multiple linear regression analysis,
DM duration and HbA1c were independently associated with GDS in the
male group.
Conclusion: Greater depression was associated with poorer glycemic
control and longer diabetic duration in elderly male subjects with T2DM.
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The temporal relationship between diagnosis of diabetes and
depression
B. Cleal1, U.H. Nielsen2, I. Willaing1, R.I.G. Holt3;
1Health Promotion Research, Steno Diabetes Center, Copenhagen, 2In-
centive A/S, Holte, Denmark, 3Human Development and Health Aca-
demic Unit, Faculty of Medicine, University of Southampton, UK.
Background and aims: The purpose of this study was to investigate the
temporal relationship between diagnosis with diabetes (Source: Danish
National Diabetes Register) and first purchase of prescribed antidepres-
sants (Source: Register Medicinal Product Statistics) in a working-age
population.
Materials and methods:We included all Danish adults aged 18-59 who
were diagnosed with diabetes in the study period (01/01/96 - 31/12/10)
We ceased inclusion after 31/12/05 in order to ensure all subjects could be
followed for five years after diagnosis. We excluded individuals who
purchased antidepressants at any time within, and up to, a year prior to
their inclusion in the data-set. Subjects were stratified according to the
highest occupational category they attained in study period. For those
who purchased antidepressants in the study period, we calculated the time
elapsed from their diabetes diagnosis to the point at which they first
purchased antidepressants. We calculated the percentage of people with
diabetes who purchased antidepressants within one and five years post-
diagnosis. Furthermore, we calculated the proportion who purchased an-
tidepressants within one year post-diagnosis among all those who pur-
chased antidepressants within five years. P-values for between-group
differences were calculated using two sided Fisher’s exact tests.
Results:Of those who develop depression within five years, 25.3% do so
in the first year. Thus, more develop depression within the first year than
if the likelihood was the same in all five years of follow-up. Of the
individuals who go on to purchase antidepressants within five years of
diagnosis, a greater proportion from the higher occupational groups did so
within the first year (e.g. Employee at highest level 29.7%: Employee at
basic level 24.2%). In contrast, overall incidence after five years is sig-
nificantly greater in the lower occupational groups (e.g. Employee at
highest level 9.7%: Employee at basic level 11.9%). Likewise, men as a
whole were more liable to purchase antidepressants within one year of
their diagnosis (Men: 27.1%: Women: 23.5%), whereas the incidence
among men after five years is significantly lower than that of women
(Men: 9.7%: Women: 13.5%).
Conclusion: The data indicate that diagnosis of diabetes precipitates
depression across the workforce. Of those who purchase antidepressants
within five years of diagnosis, both men and individuals with higher
occupational status are more likely to do so within the first year. With
previous research indicating purchase of antidepressants is more preva-
lent among women and lower occupational groups in the general popu-
lation, our results suggest that it is in the period immediately after diag-
nosis that people with diabetes least resemble the general population in
terms of their propensity to purchase antidepressants, with the impact
dissipating over time.
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Depression and anxiety among young adults with type 1 diabetes
K.-M. Roelver1, S. Matthaei1, A. Lueg2, B. Lutze3, K. Lange3;
1Diabetes-Zentrum, Christliches Krankenhaus Quakenbrück,
2Diabetologische Schwerpunktpraxis, Hameln, 3Medical Psychology,
Hannover Medical School, Germany.
Background and aims: Data on prevalence of depression and anxiety
among young adults with type 1 diabetes are heterogeneous. Most studies
report a high rate of comorbidity. In a representative sample of young
adults with type 1 diabetes in Lower-Saxony (Germany) the prevalence of
both mental disorders and the association with critical life events and
quality of metabolic control were assessed.
Materials and methods: In 26 specialized diabetes out-patient units all
patients (19-30 yrs.) diagnosed with type 1 diabetes in childhood or ad-
olescence were invited to complete a questionnaire on their psychosocial
and diabetes status, diabetes specific distress (PAID), critical life-events,
and depression and anxiety (HADS-D).
Results: 306 patients (47% female, mean age 24.1±3.5 yrs., mean dia-
betes duration 11.7±5.8 yrs.; 43% CSII; HbA1c: 8.3±1.6% (67.2±
6.0 mmol/mol)) participated (additional 12 patients refused). HADS-
score >10 indicating clinical relevant anxiety was seen in 6.1% of the
participants, symptoms of depression in 4.0% (HADS-D score >10).
These prevalence data correspond to published prevalence data of the
background population. On the other hand 25% of the participants report-
ed a high level of diabetes specific distress (PAID score >39; mean score:
26.8±19.8). Diabetes distress was mainly connected to the items “worry-
ing about future” and “feeling guilty”. Sum scores of HADS-D and PAID
were both associated with HbA1c (r=-0.14; r=0.23; each p<0.01). Crit-
ical life events during the last 12 months were reported by 33.2% of the
patients with negative impact onmetabolic control (HbA1c 8.8±1.8% vs.
8.0±1.5%; p<0.001)
Conclusion:Despite several challenges of diabetes the majority of young
adults were able to cope successfully with age specific developmental
tasks without suffering from mental disorder (anxiety and depression).
In contrast they report of a high level of diabetes specific distress, mainly
associated with fear of late complication and feelings of guilt. A regular
assessment of diabetes specific burden and critical life events is recom-
mended to suggest a personalized insulin therapy regimen and psychoso-
cial support.
Supported by: Deutsche Diabetes Stiftung
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Undiagnosed cognitive impairment, health status and depressive
symptoms in patients with type 2 diabetes
P.S. Koekkoek1, G. Biessels2, M. Kooistra1, J. Janssen1, L. Kappelle2,
G.E.H. Rutten1;
1Julius Center for Health Sciences and Primary Care, 2Neurology, Uni-
versity Medical Center Utrecht, Netherlands.
Background and aims: Type 2 diabetes is associated with cognitive
impairment. We aimed to examine whether undiagnosed cognitive im-
pairment in patients with type 2 diabetes is associated with a reduced
health status and depressive symptoms.
Materials and methods: 225 primary care patients aged ≥70 years with
type 2 diabetes were examined, both at their homes and at a memory
clinic, for undiagnosed cognitive impairment (dementia or mild cognitive
impairment [MCI]). Dementia and MCI were defined according to inter-
nationally accepted criteria. Questionnaires assessing health status (SF-
36, EQ-5D and EQ-VAS) and depressive symptoms (CES-D) were filled
out. Health status and depressive symptoms were compared between
patients with and without cognitive impairment.
Results: Patients with cognitive impairment (n=57) showed significantly
lower scores on the SF-36 on six out of the eight domains, on the physical
and mental summary scores, and on both the EQ-5D and the EQ-VAS
scores. CES-D scores were significantly higher in patients with cognitive
impairment (9.2±7.1 versus 12.7±8.5; p=0.009). Depression (CES-D≥
16) occurred almost twice as often in patients with cognitive impairment
(RR 1.8; 95%-CI: 1.1-3.0).
Conclusion: Undiagnosed cognitive impairment in patients with type 2
diabetes is associated with a reduced health status and more depressive
symptoms. Detection of cognitive impairment in type 2 diabetes patients
identifies a vulnerable group of patients that could benefit from integrated
and tailored treatment.
Supported by: EFSD/Lilly
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Female sex, age (<50 and ≥70 years), northern German residency,
high HbA1c and insulin use predict depressed mood in 35,691 type 2
diabetes patients
N. Scheuing1, S. Ebner2, A. Grünerbel3, U. Henkelüdecke4, N.
Hermanns5, M. Hummel6, C. Schäfer7, C. Wagner8, J. Weiland9, R.
Welp10, R.W. Holl1, for the DPV initiative;
1ZIBMT, University of Ulm and German Center for Diabetes Research
(DZD), Germany, 22nd Medical Department, General Hospital Linz,
Austria, 3Specialized practice for diabetes and nutritional medicine, Mu-
nich, 4Internal Medicine, Hospital Malteser St. Johannes-Stift, Duisburg,
5Diabetes Centre Mergentheim, Bad Mergentheim, 6Specialized diabetes
practice, Rosenheim, 7Internal Medicine, Hospital Neumarkt, 8Special-
ized diabetes practice, Saaldorf-Surheim, 9Internal Medicine, Hospital
Bad Reichenhall, 10Internal Medicine, Knappschafts-Krankenhaus, Bot-
trop, Germany.
Background and aims: A bidirectional relationship between type 2 di-
abetes (T2D) and depressive symptoms has been reported. The primary
aim was to analyze predictors of depressed mood in T2D. Secondly, the
odds ratio of developing a clinically recognized depression in patients
with conspicuous screening result was evaluated.
Materials and methods: 35,691 T2D patients aged ≥18 years (median
[IQR]: 68.9 [59.2-76.5] years) from the German/Austrian multicenter
prospective diabetes follow-up registry (DPV) were analyzed. All pa-
tients had completed the WHO-5 questionnaire, a reliable and validated
5-item screening tool for depression (score ≤7: likely depression). Logis-
tic regression modeling (SAS 9.4) was applied to study potential predic-
tors (e.g. demographics, regional aspect, diabetes therapy, glycemic
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control) for depressed mood as well as the risk of developing clinically
recognized depression.
Results: Depressed mood was present in 11.2% (n=4,000) of patients
screened and thereby significantly more prevalent compared to the adult
German population (DEGS study: 8.1%, p<0.001). Patients with likely
depression had a later diabetes onset (60.5 [49.6-70.2] vs. 58.3 [49.1-
67.7] years, p<0.001) and were more often female (54.0 vs. 48.0%, p<
0.001) compared to patients with inconspicuous results. Duration of dia-
betes did not differ significantly between groups (7.6 [2.4-12.9] vs. 7.0
[2.1-13.5] years, p=0.76). Young and very old age as well as female sex
were associated with depressedmood (table 1, model 1). Moreover, living
in northern federal states of Germany, poor glycemic control (HbA1c
≥58 mmol/mol) and insulin treatment were significantly related to de-
pressed mood in T2D (table 1). Overall, the odds of developing a clinical
diagnosis of depression was 1.95 (95%CI: 1.66-2.29) times higher in
patients scored ≤7 in the WHO-5 questionnaire.
Conclusion: Depressed mood is a frequent psychological comorbidity in
adult T2D patients. In clinical care, routinely screening for psychological
problems as recommended by guidelines is absolutely advisable, espe-
cially in high-risk patients.
Supported by: EFSD/AatraZeneca, German Competence Net Diabetes,
DZD, DDG
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The synergistic effect of depression and diabetes on cognitive func-
tion in a community sample of older adults
A. Nouwen1, P. Demakakos2;
1Department of Psychology, Middlesex University, 2Department of Epi-
demiology and Public Health, University College London, London, UK.
Background and aims: Diabetes and depression are independently as-
sociatedwith increased risk of cognitive decline. But the synergistic effect
of depression and diabetes on cognitive function has yet to be studied in
the general population. We used a nationally representative sample of
community-dwelling individuals aged ≥50 years to investigate whether
patients with diabetes and depression are at greater risk of cognitive
decline compared with patients with either depression or diabetes.
Materials and methods: Our sample comprised 10,812 individuals
(45.5% male) from the English Longitudinal Study of Ageing (mean
age 65.0 years; SD±10.1). Diabetes was defined by self-reported diagno-
sis and depression by a score of ≥4 symptoms on the 8-item Centre for
Epidemiological Studies-Depression scale. We measured two domains of
cognitive function, memory and verbal fluency. We estimated OLS re-
gression models of change in the summary score of immediate and de-
layed recall (range 0-20 words) over a 10-year follow-up (2002-2012)
and change in the animal naming score (range at baseline 0-50) over an 8-
year follow-up (2002-10). Age, sex, marital status, education, occupa-
tional class, BMI, physical activity levels, smoking, and alcohol use were
assessed at baseline and used as covariates. We also used six repeated
measurements of the word recall score and five of the animal naming
score to estimate lagged GEE models of the average 2-year change in
these two cognitive function domains.
Results: At baseline, 616 individuals had T2DM, 1,574 had depression,
and 188 individuals both. In OLS regression models adjusted for baseline
cognition, age, sex, and marital status, individuals with diabetes, depres-
sion, or both experienced a significant decline in both memory and verbal
fluency compared with individuals free of both conditions. In the fully
adjusted model, individuals with diabetes but without depression no lon-
ger scored significantly lower on the word recall score compared with
individuals free of both diabetes and depression (β coeff -0.31; -0.70 to
0.85), but those with depression (-0.42; -0.68 to -0.14) or with depression
and diabetes (-1.25; -2.1 to -0.46) did. Similarly, in the fully adjusted
model, individuals with depression (β coeff -0.64; -1.11 to -1.81) and
those with both diabetes and depression (-1.87; -3.27 to -0.46) scored
significantly lower on the animal naming test compared with individuals
free of both conditions; this did not apply to individuals with diabetes (-
0.54; -1.27 to 0.18). The GEE models indicated that, on average, com-
pared with individuals without diabetes and depression, those with either
condition or both conditions experienced a significant decline on both
domains of cognitive function on a 2-year basis.
Conclusion: Depression and diabetes are associated with an increased
risk of cognitive decline in a large community cohort of older adults. The
effect of diabetes and depression on cognitive function appears to be
multiplicative. The effects are seen over a 10-year period, but are evident
also over repeated 2-year assessments. In most cases, the risk of cognitive
decline was independent of sociodemographic, lifestyle, and clinical risk
factors. Cognitive decline was more pronounced in depressed individuals
than in diabetes patients. The consequences of depression, especially in
individuals with diabetes, are serious; regular monitoring of depression in
clinical practice is required.
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PS 079 Recognising and treating
hypoglycaemia
864
Nocturnal hypoglycaemia can be predicted by retrospective analysis
of glucose variability in elderly type 2 diabetic patients treated by
insulin
N.E. Myakina, V.V. Klimontov;
Laboratory of Endocrinology, Institute of Clinical and Experimental
Lymphology, Novosibirsk, Russian Federation.
Background and aims: Nocturnal hypoglycemia (NH) is
underestimated complication of insulin therapy, especially in elderly sub-
jects. We aimed to determine the applicability of glucose variability (GV)
indices, calculated from continuous glucose monitoring (CGM) data, for
prediction of NH in elderly type 2 diabetic patients treated with insulin.
Materials and methods:We analyzed blinded CGM data for 176 nights
generated by 83 in-patients, aged 65-80 years, HbA1c 7.8, 6.9-8.2%
(median, 25th-75th percentile). Patients were treated with basal insulin
(n=17), premixed insulin (n=24), or basal-bolus insulin therapy (n=42).
The values of standard deviation (SD), continuous overlapping net gly-
cemic action (CONGA), lability index (LI), M-value, J-index, mean ab-
solute glucose (MAG), high blood glucose index (HBGI), low blood
glucose index (LBGI), mean amplitude of glucose excursions (MAGE)
and average daily risk range (ADRR) were estimated. Most of GV pa-
rameters were computed for nocturnal hours, daytime hours and one-hour
pre-midnight interval. The values of MAGE and ADRR were calculated
for the whole recordings, in accordance with computational algorithms
for these indices. Bedtime glucose trend was evaluated as difference
between glucose values at 11 p.m. and at midnight (deltaG). Hypoglyce-
mia was defined as glucose level ≤3.9 mmol/L.
Results: At least one episode of non-severe CGM-defined NH was re-
corded in 39 (47%) patients. The NH was present in 68 out of 176
analyzed nights (39%). Subjects with detected NH did not differ signifi-
cantly from those without by age, body mass index, diabetes duration,
total and basal insulin dose and HbA1c levels (all p>0.05). None of these
parameters was significant predictor for NH in univariate logistic regres-
sion model. Lower daytime mean glucose, CONGA, J-index (all p<0.02)
and higher MAG and LBGI (both p<0.0001) values were found in pa-
tients with NH as compared to those without. Bedtime mean glucose and
J-index was lower (p<0.0001), while bedtimeM-value, deltaG and LBGI
was higher (all p<0.01) in patients with NH. The value of ADRR was
higher in patients with NH as compared to those without (p=0.003),
meanwhile the differences in MAGE did not reach statistical significance
(p=0.07). Antecedent daytime hypoglycemia increased the risk of NH (p
<0.0001). In multivariate logistic regression analysis the combination of
three bedtime parameters (mean glucose, LBGI and deltaG) was the most
reliable predictor of subsequent NH (accuracy 93.5%%, p<0.0001).
Conclusion: The retrospective analysis of CGM-derived GV indices
could improve prediction of NH in elderly type 2 diabetic patients treated
with insulin.
Supported by: RSF (14-15-00082)
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Prevention of hypoglycaemia by the predictive low glucose
management feature in a user evaluation study
I. Conget1, P. Choudhary2, B.S. Olsen3, L. Vorrink4, J. Shin5, S. Liabat4;
1Endocrinology Unit, Hospital Clinic i Universitari, Barcelona, Spain,
2King's College London, UK, 3Herlev Hospital, Denmark, 4Medtronic
plc, Tolochenaz, Switzerland, 5Medtronic plc, Northridge, USA.
Background and aims: Automated suspension of insulin delivery in
response to hypoglycaemia detected by continuous glucose monitoring
(CGM) sensors has been shown to reduce severity and duration of hypo-
glycemic events. Suspending insulin delivery earlier, in response to pre-
dicted hypoglycaemia, may allow patients with type 1 diabetes to further
reduce or avoid hypoglycaemia entirely. Performance of a predictive low
glucose management feature in a commercially-available sensor-aug-
mented pump system was evaluated in a user evaluation study.
Materials andmethods:Three study sites in Europe enrolled 40 subjects
(18 female, ages 9-65 years) with type 1 diabetes whosemean (±SD) A1C
was 7.6±0.87%. The pumps were programmed to suspend insulin deliv-
ery if the sensor glucose (SG) value was predicted to be at or below the
programmed threshold with a +20 mg/dL offset within 30 min and to
restart when the SG value was at least 20 mg/dL above the threshold
value and predicted to be at least 40 mg/dL above it within 30 min.
Subjects wore the pumps and sensors for 4 weeks, after which data were
downloaded and questionnaires were completed.
Results: The pump suspension feature was activated 2417 times, or 2.1
times per subject-day. The median duration of pump suspensions was
57.8 (interquartile range [IQR], 49.2-63.3) min. The median minimum
SG value during the suspensions was 3.85 (IQR, 3.67-4.15) mmol/l
(69.3 mg/dL), and the median SG value was 8.95 (IQR, 8.04-9.27)
mmol/l (161.1 mg/dL) 2 h after restart. Most (70.5%) pump suspensions
were terminated automatically; 29.5% were terminated manually. The
Figure shows median and IQR of SG values surrounding the activations;
the dotted line at 3 mmol/l represents the most-commonly chosen thresh-
old value. The mean and median absolute relative differences (ARDs)
between 5195 pairs of SG and contemporaneous blood glucose values
were 9.5% and 5.6%, respectively. Of the 2401 evaluable activations,
2327 (96.9%) were not followed by any SG value(s) below the pre-
specified threshold value. Based on mean questionnaire responses, sub-
jects found the system’s low glucose management features easy to set up
and beneficial with respect to managing hypoglycaemia, and almost all
(97%) expressed a preference for it compared to the system they had been
using before the study.
Conclusion: Insulin pump suspension in advance of predicted
hypoglycaemia helped subjects with type 1 diabetes avoid
hypoglycaemia in 97% of the occasions when it was predicted. These
data show that predictive low glucose management was effective in
preventing hypoglycaemia and well accepted by patients.
Clinical Trial Registration Number: NCT01726621
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Detecting hypoglycaemia in breath-exhaled isoprene and acetone as
biomarkers of blood glucose
S. Neupane1, G. Richmond2, T. Blaikie2, R. Peverall2, D. Taylor2, I.
Campbell2, G. Hancock2,3, M.L. Evans1;
1Wellcome Trust-MRC Institute of Metabolic Science, University of
Cambridge, 2Oxford Medical Diagnostics (OMD), 3Department of
Chemistry, University of Oxford, UK.
Background and aims: Despite decades of research, no viable non-
invasive alternatives to capillary blood glucose testing currently exist.
Given reports of rescue dogs responding to changes in glycaemia, partic-
ularly alerting of hypoglycaemia, we hypothesized that volatile com-
pounds (VOCs) in exhaled breath might change with blood glucose of-
fering biomarkers for non-invasively monitoring glycaemia
Materials and methods: 8 female non-smoking patients with type 1
diabetes (age 46±14, duration of diabetes 23±20 years) attended on 2
occasions. After an overnight fast, we used a 220 min stepped insulin
clamp technique (actrapid 0.3 mU/kg/min for 2 h then increased to
1.5 mU/kg min) with variable 20% dextrose. On one occasion,
arterialised plasma glucose was adjusted stepwise to 7.1+0.8, 8.7+0.4,
10.7+0.1, 4.3+0.3 and 2.8+0.1 mM (40 min steps). On the other day,
glucose was maintained throughout at 6.2+0.1 mM (CON) with STEP
and CON studies performed in random order at least 1 week apart (single
blinded). Thus, the study design allowed us to examine the relationship
between VOCs and glucose independent of insulin which was infused
identically on both study days. At 20 minute intervals, 1.1 L of exhaled
breath samples were collected in Fischer Analysen Instrumente GmbH
bags and analysed using V&FAirsense Compact Ion-Molecule-Reaction
Mass Spectrometer. VOCs (acetone, isoprene, methyl nitrate, ethyl ben-
zene, ethanol and propane) were standardised for exhaled CO2. We
subtracted CON from STEP values for VOCs and glucose and examined
using Pearson Correlation with IBM SPSS Statistics 21. Looking specif-
ically for a biomarker of hypoglycaemia, we also compared VOC values
during final 2.8 mM step with those from non-hypoglycaemia range.
Results: (1) Exhaled breath isoprene increased significantly at glucose of
2.8 mM compared to non hypoglycaemia range (85±15 vs 34±13 parts
per billion (ppb), p<0.05- see figure). (2) We found a linear correlation
across study glucose values between exhaled acetone and plasma glucose
with higher acetone at higher glucose values (r=0.25, p<0.05). (3) There
was no obvious correlation for other measured VOCs.
Conclusion: Our data suggest that exhaled breath VOCs might offer an
alternative non-invasivemethod formonitoring changes in blood glucose,
including detecting hypoglycaemia, in diabetes.
Supported by: NIHR Cambridge Biomedical Research Centre
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Needle-free nasal delivery of glucagon is superior to injectable
delivery in simulated hypoglycaemia rescue
J. Yale1, C. Piche2, M. Lafontaine2, R. Margolies3, E. Dissinger3, A.
Shames3, N. Fink3, M. Egeth3, H. Dulude2;
1McGill University, 2Locemia Solutions, Montreal, Canada, 3CORE Hu-
man Factors, Philadelphia, USA.
Background and aims: Injecting glucagon to treat severe hypoglycemia
(SH) can be difficult for caregivers of persons with diabetes (PWDs). This
study evaluated the ability of people to use injectable glucagon (Glucagon
Emergency Kit - GEK) and needle-free Glucagon Nasal Powder (GNP)
devices to treat a simulated episode of SH.
Materials andmethods: The Caregiver arm included 16 pairs each com-
posed of an adult with diabetes (PWD) and their caregiver. PWDs, who
were taught how to use 1 of the devices in random order, then instructed
their caregivers on device use. Approx. 1 wk later, caregivers treated a
manikin during a simulated episode of SH. The procedure was repeated
with the other product. The Acquaintance arm had 15 adults, not associ-
ated with any particular PWD, who said they were willing to assist some-
one in distress. Acquaintances were not trained on device use but were
shown the device prior to the simulation. Acquaintances treated 2 epi-
sodes of SH, in random order, with a delay of about 10min between each.
A fully clothed adult manikin represented a PWD in the simulation.
Participants were told the manikin was in SH and that they had to admin-
ister the rescue glucagon as quickly as possible. They were told to find the
PWD’s glucagon rescue kit in the PWD’s backpack. The backpack
contained the glucagon rescue kit being evaluated in that episode and
the PWD’s diabetes supply pouch (glucometer and strips, alcohol swabs,
lancing device, insulin syringe and a vial of insulin). Sound effects and
distractions created a sense of urgency.
Results: Fifteen of 16 caregivers and 14 of 15 acquaintances adminis-
tered a full dose of GNP (avg. time 0.27 and 0.44 min, respectively; see
table below). The 2 participants who failed to fully depress the plunger on
the GNP device also failed to inject GEK. With GEK, only 8 of 16
caregivers injected glucagon (avg. time 1.89 min) of which 2 gave a full
dose. Failures included injection of diluent only (n=4) and bent needle
(n=1). Three caregivers administered insulin instead of glucagon; when
then prompted to use GEK, 2 injected only diluent. Only 3 of 15 acquain-
tances injected glucagon (avg. time 2.4 min); none gave a full dose.
Failures included injection of diluent only (n=9), refusal to attempt to
inject (n=1) and injection with an empty syringe (n=1). One acquain-
tance injected insulin instead of glucagon; when then prompted to use
GEK, only diluent was injected.
Conclusion:Under conditions that simulate some of the stress associated
with real episodes of SH, Caregivers and Acquaintances injected gluca-
gon with a very low success rate and numerous errors; however, the same
people used GNP successfully in less time. The data indicate that delivery
of GNP is easier for non-medical third parties to administer successfully
and suggest administering glucagon using a different route and dosage
form than those used for insulin may also reduce the risk of accidental
delivery of insulin.
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Subcutaneous low-dose glucagon bolus in the treatment of mild
hypoglycaemia in insulin pump treated patients with type 1 diabetes
A. Ranjan1,2, S. Schmidt1,2, S. Madsbad1, J.J. Holst3, K. Nørgaard1;
1Department of Endocrinology, Copenhagen University Hospital
Hvidovre, 2Danish Diabetes Academy, Odense, 3Department of Biomed-
ical Sciences, Endocrinology Research Section, University of Copenha-
gen, Hvidovre, Denmark.
Background and aims: Hypoglycaemia is a common side effect to in-
sulin treatment in patients with type 1 diabetes (T1D). Dual-hormone
treatment with combined subcutaneous (s.c.) infusion of insulin and glu-
cagon, has potential to improve glucose control without inducing
hypoglycaemia. However, in order to use glucagon in a dual-hormone
approach, the dose-response relationship of exogenous glucagon on plas-
ma glucose (PG) is a prerequisite.
Materials and methods: We carried out a single-blinded, randomized,
placebo-controlled four-way crossover study to determine the dose-
response relationship of s.c. glucagon to increase PG during mild
hypoglycaemia in 8 T1D insulin-pump treated patients (5 females, medi-
an (range) age 47 (19-64) years, HbA1c 52 (43-57) mmol/mol, BMI 24
(20-25) kg/m2, C-peptide 3 (3-30) ρmol/l, no autonomic neuropathy and
no hypoglycaemia unawareness). Each patient underwent 4 study visits.
In fasting state, an s.c. insulin bolus expected to reduce PG to 3.0 mmol/l
was given, however, when PG reached 3.9 mmol/l (t=0 min), 1 of 3
different low-doses of s.c. glucagon or saline was given as a bolus. A
repeated measurement linear mixed model was applied and results
expressed as absolute change (95% CI).
Results:Mean (95% CI) PG peak increased with 2.3 (1.7-3.0), 4.2 (3.5-
4.8) and 5.0 (4.3-5.6) mmol/l after 100, 200 and 300 μg glucagon, re-
spectively, compared with saline (all p<0.001) (figure 1). Time to peak
was 30 (27-39), 40 (32-44) and 50 (43-55) min after glucagon. Within
15 min each glucagon dose significantly increased PG with 1.4 (0.4-2.5),
2.1 (1.1-3.2), and 2.0 (1.0-3.0) mmol/l. The PG values were significantly
higher compared with the saline day until 120 (83-156), 189 (152-225)
and 195 (185-257) min after glucagon bolus. The incremental areas under
the curve (iAUC) for glucagon were 894, 1148, and 1354 mmol/l x min
and for saline 550 mmol/l x min (all p<0.001 compared to saline).There
was no significant difference between 200 and 300 μg glucagon doses in
regard to iAUC (p=0.13) or PG values at any time points. Mean peak
plasma glucagon response above baseline occurred 10min after glucagon
administration and was 100 (47-152), 217 (118-317), and 358 (190-526)
ρmol/l (p<0.001). However, 45 min after saline administration a PG of
3.2 (2.9-3.4) mmol/l increased plasma peak endogenous glucagon con-
centration with 4.5 (1.7-7.3) ρmol/L above baseline (p<0.01).
Conclusion: Low-dose s.c. glucagon bolus significantly elevates plasma
glucose in case of relative insulin over-bolusing. Low dose s.c. glucagon
is an alternative to oral glucose in the treatment of mild hypoglycaemia in
insulin pump treated patients.
Clinical Trial Registration Number: NCT02232971
Supported by: Danish Diabetes Academy
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Targeted photodynamic therapy of insulinomas and congenital
hyperinsulinism by exendin-700DX
S. Ekim, D. Bos, M. Brom, M. Gotthardt;
Department of Radiology and Nuclear Medicine, Radboud University
Medical Centre, Nijmegen, Netherlands.
Background and aims: Insulinomas are tumors of the pancreas that are
derived from beta cells. Because the tumor produces excess amounts of
insulin, it can lead to hypoglycemia. Congenital hyperinsulinism is a
disease that causes high levels of insulin. People with this condition have
frequent episodes of hypoglycemia which can cause complications such
as breathing difficulties, seizures, brain damage, and coma. Currently,
treatment options are limited and there is an urgent need for novel ther-
apeutic options. Exendin is a peptide which can specifically bind to the
glucagon-like peptide 1 receptor (GLP-1R) which is expressed in the beta
cells in the pancreas. Photosensitizing fluorescent dyes as 700DX can
create free radicals and singlet oxygen that can be fatal to the cells, when
they are subjected to laser irradiation. Labeling Exendin with 700DX can
be a promising way to produce a new agent for laser induced photody-
namic therapy (PDT) of insulinomas in adults and congenital
hyperinsulinism in children, aimed at selective destruction of diseased
beta cells. With this therapy, it would be possible to treat insulinomas or
destroy diseased beta cells in a specific area of pancreas and leave a
sufficient amount of beta cells to prevent diabetes. The aim of the study
is development of a new agent and method for laser induced photody-
namic therapy of insulinomas and congenital hyperinsulinism.
Materials and methods: Exendin-3 (Ex-3) and 700DX coupled
Exendin(Ex-700DX)were used in the experiments. The therapeutic effect
of the compound was examined on islets isolated from C3H mice, a rat
insulinoma cell line (INS-1E) and GLP-1R expressing CHL cells. In vitro
PDT experiments, were performed by incubating islets with 165 nM Ex-
700DX, 165 nM Ex-3 and medium only (control) for 3 hours at 37°C.
The islets and cells were irradiated for 30min at 60Watt, with a LED laser
system that emits radiation in the 690 nm spectral band while the control
plate was not laser irradiated. An hour after the PDT, cell titer glo assay
was performed to detect the islet death in both plates. The effect of inter-
nalization of Ex-700DX was examined using CHL-GLP1R(+) cells by
incubation at 0°C (no internalization) or 37°C (internalization).
Results: Nearly 60% islet death was detected after the targeted PDT, on
the Ex-700DX treated group of islets. No significant islet death was
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observed with Ex-3 and vehicle incubated groups after PDT, which
proves that the compound and laser irradiation itself does not cause any
islet death. (Figure) The percentage of cell death after PDTwas calculated
as 44% when Ex-700DX internalized into the cells, while 21% cell death
was observed when Ex-700DX was only bound to GLP-1 receptors on
the cells.
Conclusion: First trials on mice islets and GLP-1R positive tumor cells
showed that targeted PDTwith Ex-700DX efficiently destroys the target
cells. For efficient PDT, Ex-700DX should be at least bound to GLP-1
receptor and the efficiency of the therapy increases nearly 2 times when
Ex-700DX is internalized into the cells.
Supported by: BetaCure (EU Project), BetaTrain (EU Project)
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Factors associated with post-prandial hypoglycaemia in patients with
remission of type 2 diabetes after bariatric surgery
G. Nosso1, G. Saldalamacchia1, M. Cotugno1, E. Griffo1, L. Angrisani2,
G. Riccardi1, B. Capaldo1;
1Clinical Medicine and Surgery, Federico II University of Naples, 2Gen-
eral and Endoscopic Surgery Unit, S. Giovanni Bosco Hospital, Naples,
Italy.
Background and aims: Post-prandial hypoglycemia (P-HYPO) occurs
in a significant proportion of patients who achieve remission of type 2
diabetes (DM2) after bariatric surgery (BS). Aim of this study is to eval-
uate the factors associated with P-HYPO in patients with remission of
DM2 (HbA1c <6.5%, fasting glucose <125 mg / dl in the absence of
hypoglycemic therapy) after gastric bypass (BPG) or sleeve gastrectomy
(SG).
Materials andmethods:All participants underwent a 75 g-OGTT before
and 2 years after BS. A mixed meal test and a continuous glucose mon-
itoring (CGM) for 7 days by Dexcom G4 PLATINUM were performed
after surgery. In fourteen patients (BPG / SG: 8/6, age: 49±7 years, BMI:
32±6 kg / m2, diabetes duration: 3±5 years) with evidence of P-HYPO
(blood glucose <70 mg / dl) and in 5 patients (BPG / SG: 1/4, age: 45±
10 years, BMI: 31±6 kg / m2, diabetes duration: 7±3 years) without P-
HYPO (NO-HYPO) changes in insulin sensitivity (OGIS), insulin secre-
tion (IGI) and the meal response of the entero-hormones were evaluated.
Results: The two groups were similar for age, duration of DM2 and
postoperative BMI. Patients with P-HYPO showed a greater decrease in
weight (ΔBMI: 13±6 vs 7±4 kg / m2, p=0.042), a greater improvement
in insulin sensitivity (ΔOGIS: 158±54 vs 29±22 ml min -1 ml-2 , p=
0.001), a higher postprandial GLP-1 peak (32±31 vs 7±2 pmol/L, p=
0.031) and a lower GIP meal response (GIP peak: 209±120 vs 371±
27 pg/ml, p=0.009) than NO-HYPO.
Conclusion: In patients with remission of DM2 after BS, P-HYPO is
associated with greater weight loss, more marked increase in insulin sen-
sitivity and distinct entero-hormone profile, suggesting that this complica-
tion can reflect an "extreme" form of improvement of the metabolic status.
871
Impact of early and late dumping syndrome on weight loss after
bariatric surgery
E. Rebelos1, M. Seghieri1, V. Siciliano2, D. Guarino1, L. Fortunato2, S.
Molinaro2, F. Denoth2, M. Anselmino3, E. Ferrannini2, M. Nannipieri1;
1Department of Clinical and Experimental Medicine, University of Pisa,
2Institute of Clinical and Experimental Physiology, CNR, 3Unit of Bar-
iatric Surgery, AOUP, Pisa, Italy.
Background and aims: It has been postulated that weight loss after
RYGB could be in part attributed to dumping syndrome following sweet
ingestion with a consequent aversion for such foods. However, no study
has shown a correlation between dumping syndrome and weight loss. On
the other hand, other investigators have hypothesised that increased inter-
meal hunger, due to reactive hypoglycaemia, could reduce weight loss.
We analyzed an integrated database on bariatric subjects, asking the ques-
tion if there was any correlation between reported early dumping syn-
drome (ED), or late dumping syndrome (LD) (i.e., reactive
hypoglycaemia) and body weight change.
Materials and methods: 136 morbidly obese subjects, who had under-
gone bariatric surgery and have been followed for at least 30months were
evaluated. After surgery, during regular follow-up visits, a standardized
questionnaire (Sigstaad and Arts questionnaires) was administered to
each subject in order to diagnose ED/LD. In this dataset, ED/LD was
detected 10-20 months after surgery; BMI values were recorded over
the ensuing 10 months. A control group (ND) of bariatric subjects not
reporting ED/LD was evaluated at the same time intervals. Once ED/LD
was detected, patients were advised to change eating habits; in some
cases, an OGTTwas performed to confirm diagnosis.
Results: In the whole cohort, there was no significant difference in age
among the 3 groups (52±10 years for the ND group, 48±11 years for the
ED group and 49±11 years for the LD group, p=ns). RYGB was per-
formed in the 72% of ND, 100% ED and 79% LD (p=ns). ED was
reported in 19% of the patients and LD in 27%. LD was significantly
more frequent in subjects that had undergone RYGB than in those who
underwent sleeve gastrectomy (79% vs 21%, p=0.007). The prevalence
of type 2 diabetes mellitus was higher in the ND compared to other
groups (55, 25, 22%, p=0.01, in ND, ED and LD group, p=0.01 respec-
tively). The ND group had higher BMIs at 10-20 months and 30 months
compared to the ED and LD group (p=0.006); however the data show
that ND continued to lose weight throughout the 30 months of follow-up,
whereas this was not true for the LD and ED groups: once LD or ED
disturb came up, subjects on these groups stopped losing weight. In total
the ND group lost more weight than the LD and ED group (p=0.009).
BMIs and body weights of the 3 groups at 10-20 months and 30 months
are reported in table 1.
Conclusion: Patients present ED after RYGB but not sleeve gastrectomy,
while LD occurs after both RYGB and sleeve gastrectomy, with a higher
prevalence in the former (≈80%). LD/ED occurs more frequently in glu-
cose tolerant than in diabetic subjects. When ED/LD occurs, subjects stop
losing weight.
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Impaired awareness of hypoglycaemia and peripheral autonomic
neuropathy in type 1 diabetes
S.E. Olsen1, M.R. Bjørgaas1, B.O. Åsvold2, T. Sand3, M. Stjern3, K.B.
Nilsen3;
1Department of Cancer Research and Molecular Medicine, 2Department
of Public Health, 3Department of Clinical Neurosciences, Norwegian
University of Science and Technology, Trondheim, Norway.
Background and aims: Impaired awareness of hypoglycaemia (IAH)
implies many-fold increased risk of severe hypoglycaemia in type 1 dia-
betes mellitus (T1DM). Peripheral autonomic neuropathy has been sug-
gested as a mechanism for the development of IAH. The aim of the
present study was to evaluate the association between IAH and the pres-
ence of peripheral autonomic neuropathy.
Materials and methods:We included 33 subjects with T1DM and IAH
(Gold score≥4) and 33 with normal awareness (NAH; Gold score≤2),
matched for age, gender and diabetes duration. A thorough clinical and
laboratory evaluation including extensive cardiovascular and
pupillometric autonomic function testing, nerve conduction studies as
well as quantitative sensory testing was performed. Composite abnormal-
ity Z-scores were used for group comparisons. Investigators were blinded
as to the hypoglycaemia awareness status of the participants.
Results: The IAH and NAH group had similar age, diabetes duration and
HbA1c (Table 1). The autonomic composite score was not different be-
tween the IAH and NAH groups (mean difference - 0.15 (95%CI -0.46 to
0.16; p=0.33), and neither were the thermal detection or nerve conduc-
tion scores (mean difference 0.15( -0.31 to 0.61; p=0.51) and 0.03 (-0.43
to 0.49; p=0.89), respectively.
Conclusion: Sensitive and extensive measures of autonomic neuropathy
were similar in closely matched IAH and NAH participants, indicating
that peripheral autonomic neuropathy is not a likely mechanism for the
development of IAH in subjects with T1DM.
Supported by: NTNU and Norwegian Extra Foundation for Health and
Rehabilitation.
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Sulphonylurea induced hypoglycaemia: How often are we really
seeing it?
C. McQuillan1, M. Abouzaid1, S. Kassim2;
1NHSCT, 2Diabetes and Endocrinology, NHSCT, Coleraine, UK.
Background and aims: Sulphonylureas are oral medications used to
reduce blood glucose levels in Type II Diabetes. The current National
Institute for Health and Care Excellence (NICE) guidelines recommend
their prescription as second line oral hypoglycaemic agents where blood
glucose control is suboptimal despite treatment with metformin. While
effective at lowering blood glucose levels, sulphonylureas are associated
with serious adverse effects especially in the elderly population. These
include hypoglycaemia and increased cardiovascular risk. The ultimate
outcome can result in falls, fractures, psychological fear and frequent
hospital admissions. The authors suspected that the prevalence of
sulphonylurea induced hypoglycaemia was higher than anticipated based
on in hospital observation and volume of referrals to the diabetic team.
The aim of this audit was to ascertain the commonest cause of
hypoglycaemia in hospitalised patients. Secondary review points includ-
ed reviewing the investigations and contributing factors to
hypoglycaemia as well as treatment by staff. The data collected would
be used to discourage the prescription of sulphonylureas in the elderly
population.
Materials and methods: Retrospective data was collected on all patients
who sustained an episode of hypoglycaemia while admitted in a district
general hospital over a 6 month period. The inclusion criteria required
hypoglycaemia to be coded somewhere in the patient’s discharge. This
included patients admitted with hypoglycaemia and those where
hypoglycaemia was a secondary diagnosis during admission. Particular
focus was applied to medication prescription and contributing factors
such as alcohol excess and prescription errors. The results were collated
and statistically analysed for comparative purposes
Results: Analysis revealed the commonest cause of hypoglycaemia in
hospitalised patients to be insulin related. In total 14.3% of cases were
related to sulphonylureas, much higher than anticipated from the UKPDS
study where sulphonylurea associated hypoglycaemia is quoted at ap-
proximately 1.8%. Contributing factors played a relatively modest role
in this subset of data. Acute kidney injury and liver failure played impor-
tant roles in two patients. One elderly patient self administered twice the
usual dose of insulin. The treatment in all cases was reviewed and deemed
appropriate for the level of hypoglycaemia and patients clinical status.
Conclusion: Sulphonylureas are contributing to a higher than expected
percentage of hypoglycaemia in hospitalised patients. There are often
contributing factors as identified with this audit: A relatively small num-
ber of patients were used in the audit and the district general hospital is
located near a seaside resort with a predominately retired population.
Regardless of this the rate of hypoglycaemia caused by sulphonylureas
is significantly higher than expected. It is also likely that we are
underestimating the impact and frequency of hypoglycaemia as patients
are treated by ambulance services, emergency departments and general
practitioners. From this data we recommend avoiding sulphonylurea pre-
scription in elderly patients. We also recommend discontinuing them
where patients are at risk of falls, isolation and acute kidney injury. NICE
guidelines recommend the use of dipeptidyl peptidase 4 (DPP-4) inhibi-
tors and Thiazolidineiones as alternatives. This data is being used to raise
awareness with GP's in the local area.
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Brain lactate concentration is not increased during hypoglycaemia in
non-diabetic subjects and patients with type 1 diabetes, as measured
with 1H-MRS
H.M.M. Rooijackers1, E.C. Wiegers2, C.J. Tack1, A. Heerschap2, M.
van der Graaf2,3, B.E. de Galan1;
1Internal Medicine, 2Radiology and Nuclear Medicine, 3Pediatrics,
Radboud University Medical Center, Nijmegen, Netherlands.
Background and aims: Iatrogenic hypoglycemia is the most frequent
acute complication of insulin therapy in patients with type 1 diabetes
(T1DM), and limits glycemic management. Recurrent hypoglycemia ini-
tiates a process of habituation, characterized by suppression of hypogly-
cemic symptoms and impaired hypoglycemic awareness. Recent evi-
dence suggests a role for increased brain lactate transport as underlying
mechanism. The aim of our study was to investigate the effect of hypo-
glycemia on both plasma and brain lactate content in non-diabetic sub-
jects and in T1DM patients.
Materials and methods: After an overnight fast, 5 non-diabetic subjects
(2 males, mean age: 29±7 yrs, BMI 23.2±1.7 kg/m2) and 10 T1DM
patients (6 males, mean age 27±7 yrs, BMI 24.4±2.5 kg/m2 ) underwent
a stepped hyperinsulinemic (60 mU m2 m-1) euglycemic-hypoglycemic
clamp. Arterial plasma glucose and lactate levels were determined every
5 minutes. Cerebral 1H-MRS data were acquired with a J-editing semi-
LASER sequence (TE 144 ms, TR 3000 ms, 32 averages) at 3.0 T (Sie-
mens, Trio) from a 31.25 cm3 voxel placed in the supraventricular cortex,
and lactate signals were quantified using the AMARES algorithm in
jMRUI.
Results: Plasma glucose levels were similar in patients and controls, both
during the euglycemic and the hypoglycemic phase (euglycemia: 5.01±
0.18 versus 4.92±0.20 mmol/L, hypoglycemia: 2.84±0.04 versus 2.86±
0.08 mmol/L, p=NS for all). In non-diabetic subjects, plasma lactate
levels increased from 0.87±0.22 mmol/L during euglycemia to 1.31±
0.33 mmol/L during hypoglycemia (p=0.010). Conversely, plasma lac-
tate levels dropped from 1.16±0.12 mmol/L to 0.92±0.14 mmol/L in
T1DM patients (p=0.001). Brain lactate levels did not differ between
the eu- and hypoglycemic condition, neither in non-diabetic subjects,
nor in T1DM patients (controls: 0.50±0.06 versus 0.45±0.04 μmol/g,
and T1DM: 0.48±0.07 versus 0.43±0.06 μmol/g, p=NS for all). In ad-
dition, brain lactate levels did not differ between patients and controls (p=
0.69 for euglycemia, p=0.51 for hypoglycemia).
Conclusion: These data show divergent responses in plasma lactate
levels during hypoglycemia between non-diabetic subjects and T1DM
patients, which are not accompanied by changes in lactate content in
the brain. This could indicate that during hypoglycemia (excess) lactate
is either not taken up in the brain or that lactate is immediately utilized as a
fuel, potentially to a greater extent in T1DM patients than in controls.
Clinical Trial Registration Number: NCT02146404
Supported by: EFSD and the Dutch Diabetes Research Foundation
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Recovery of cognitive function following brief exposure to
hypoglycaemia in adults with type 1 diabetes
S. Mathur1, N. Zammitt1, B. Frier2, I. Deary2;
1Edinburgh Centre for Endocrinology and Diabetes, Royal Infirmary of
Edinburgh, 2University of Edinburgh, UK.
Background and aims:Recovery of cognitive function after one hour of
hypoglycaemia is delayed for a protracted period in adults. Whether a
shorter period of exposure to hypoglycaemia can cause a similar delay in
cognitive recovery is unknown. The aim of this study was to determine
whether the duration of hypoglycaemia affects the time of recovery of
cognitive function in adults with type 1 diabetes and intact
hypoglycaemia awareness.
Materials and methods: A hyperinsulinaemic hypoglycaemic clamp
was used to lower blood glucose to 2.5 mmol/L (45 mg/dL)
(hypoglycaemia) for 20 minutes or to maintain blood glucose at
4.5 mmol/L (81 mg/dL) (euglycaemia) on two separate occasions at least
two weeks apart. The order of exposure to each experimental condition
was randomised and counterbalanced. A hypoglycaemia symptom ques-
tionnaire (HSQ) and cognitive test battery (Digit Symbol Substitution
Test (DSST) and Four Choice Reaction Time (CRT)) were completed
before, and during each experimental condition, and repeated at 10 to
15 minute intervals for 90 minutes during the recovery period. Perfor-
mance on the two experimental conditions was compared using repeated
measures ANOVA. A p value of <0.05 is considered significant.
Results: Eighteen adults (5 female) participated in the study (median age
28.5 years (IQR 23.75-33.25), median duration of type 1 diabetes
15.5 years (IQR 12.25-22.00) and median HbA1c 63 mmol/mol (IQR
59-74.25)).
Table 1 shows mean (SD) test scores and scores corrected for baseline
performance. HSQ, DSST and CRT deteriorated during hypoglycaemia
(p=0.009, <0.001 and 0.001 respectively) with an immediate improve-
ment following restoration of euglycaemia. CRT deteriorated again 20
and 70 minutes into recovery (p=0.016 and 0.032 respectively) while the
DSST score also deteriorated 70 minutes (p=0.006) into recovery but
both scores had improved by the final time point (85 minutes after
euglycaemia was restored).
Conclusion: Following brief hypoglycaemia, although cognitive func-
tion recovered immediately once euglycaemia was restored, subsequently
a transient deterioration in reaction time was observed in a similar pattern
to that observed in previous studies in which the duration of
hypoglycaemia was longer. Both DSSTand CRT deteriorated 70 minutes
into the recovery period but were restored within 15 minutes. This could
suggest an effect of boredom or fatigue rather than a direct consequence
of hypoglycaemia. However, as the counterbalanced study design should
ensure equal levels of ennui during both study conditions, hypoglycaemia
may be affecting the ability to sustain attention for mundane, repetitive
tasks during the recovery period, even after brief exposure to a low blood
glucose. This has practical implications for the time required for recovery
of cognitive function following hypoglycaemia in relation to activities
such as driving.
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The combined effects of sleep deprivation and insulin-induced
hypoglycaemia on cognitive function in adults with type 1 diabetes
B. Inkster1, N.N. Zammitt1, I.J. Deary2, B.M. Frier1;
1Diabetes and Endocrinology, Royal Infirmary of Edinburgh, 2Depart-
ment of Psychology, University of Edinburgh, UK.
Background and aims: To test the hypothesis that when hypoglycemia
is induced during a state of sleep deprivation the severity of cognitive
dysfunction would be greater than with hypoglycemia alone, and that
recovery following restoration of normoglycemia would be delayed.
Materials and methods: Fourteen adults with type 1 diabetes underwent
a hyperinsulinaemic, hypoglycemic clamp on two occasions, separated
by at least two weeks. Before one glucose clamp the subjects were sleep
deprived overnight. Subjects were randomized and counterbalanced to
the experimental condition. Cognitive function tests were performed be-
fore and during hypoglycemia, and for 90 minutes following recovery of
euglycemia.
Results: Performance in cognitive tests assessed during hypoglycemia
did not differ significantly between the sleep-deprived and non-sleep-
deprived conditions. Digit symbol substitution scores and choice reaction
times were consistently poorer during recovery in the sleep-deprived
state, but the difference was only significant at the final time point (p=
0.01) for digit symbol, and at 20 and 40 minutes into recovery for choice
reaction time(p=0.02 and 0.03 respectively). Hypoglycemia symptom
scores were significantly higher in the sleep-deprived state during all
stages of recovery (p=0.002).
Conclusion: Hypoglycemia per se produced a profound deficit in cogni-
tive function and co-existing sleep deprivation did not have an additive
effect. However, during restoration of normoglycemia, sleep-deprived
subjects remained more symptomatic and performed more poorly on
cognitive testing for the full 90 minute recovery period.
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Hypoglycaemia-induced changes in cerebral metabolic and reward
processing: a non-invasive imaging investigation using arterial spin
labelling
M. Nwokolo1, P. Choudhary1, F.O. Zelaya2, S.A. Amiel1;
1Division of Diabetes and Nutritional Sciences, Faculty of Life Sciences
and Medicine, 2Department of Neuroimaging, Institute of Psychiatry,
Psychology and Neuroscience, King's College London, UK.
Background and aims: Impaired awareness of hypoglycaemia (IAH)
affects 30% of people with longstanding type 1 diabetes, increasing risk
of severe hypoglycaemia 6-fold. Attenuated neuroendocrine responses to
hypoglycaemia are well-described; the central correlates of symptomatic
counterregulatory actions are less well understood. To explore the brain
responses to hypoglycaemia and the complex interplay between the re-
gions involved we used 3D pseudo-continuous arterial spin labelling (3D
pcASL) functional magnetic resonance imaging (fMRI). This approach
allowed us to measure regional variation in cerebral perfusion as a surro-
gate marker of changes in brain activity in non-diabetic volunteers.
Materials and methods: 14 healthy, right-handed volunteers, (mean age
± SD, 40±10 years, 6 male) underwent a two-step hyperinsulinaemic
(1.5 mU kg-1 min-1) clamp in a 3 Tesla MR scanner after an overnight
fast. Two 3D pcASL scans were obtained at euglycaemia (5 mmol/L) and
2 further scans at established hypoglycaemia (2.6 mmol/L). After each
scan subjects quantified autonomic symptoms using a visual analogue
scale (VAS). Each pcASL scan (5 min) provided a whole brain cerebral
blood flow (CBF) map with a spatial resolution of 2×2×3 mm. Statistical
parametric analysis of these images was performed using SPM-8; and a
voxel-wise paired t-test was employed to examine the effect of
hypoglycaemia. Only those clusters that remained statistically significant
(p<0.05 from a cluster-forming threshold of Z>2.31) after family-wise
error correction for multiple comparisons are reported here.
Results: During hypoglycaemia, autonomic symptom scores increased
significantly (mean symptom score±SD, euglycaemia 12.39±4.97,
hypoglycaemia 21.75±8.44 p<0.001 ). A significant increase in CBF
occurred in the left thalamus (a brain region associated with arousal,
vigilance and recognition of stressful stimuli), right inferior orbitofrontal
cortex and dorsolateral prefrontal cortex (associated with executive func-
tion, decision making and complex motivation and reward pathways).
Significant decreases were detected in the right hippocampus and superior
temporal cortex bilaterally (regions associated with memory and process-
ing sensory input).
Conclusion: The cerebral response to acute hypoglycaemia reflects the
activation of stress pathways but also encompasses brain regions involved
in reward salience, executive function and memory. Recruitment of these
higher cortical areas suggest their involvement in the behavioural re-
sponse to hypoglycaemia. These networks may also influence the re-
sponse to the repeat stimulus of future hypoglycaemia. Their investiga-
tion in people with type 1 diabetes and different degrees of
hypoglycaemia awareness and risk will inform future therapies to reduce
severe hypoglycaemia.
Supported by: DUK Project Grant
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Hypoglycaemia and QTC prolongation in patients with type 2
diabetes
K. Makrilakis1, C. Stathi1, I. Vlahodimitris2, N. Katsilambros1, S.
Liatis1;
1First Department of Propaedeutic Medicine, Athens University Medical
School, 2Department of Cardiology, Laiko General Hospital, Athens,
Greece.
Background and aims: Hypoglycaemia has been associated with in-
creased risk of death, mainly attributed to lethal arrhythmias and QTc
prolongation, both in Type 1 and Type 2 diabetes (T2D) patients. Very
few studies have been performed under real-life conditions though. The
aim of the present study was to examine the relationship between
hypoglycaemic episodes (examined during continuous glucose monitor-
ing subcutaneously [CGMS]) and QTc prolongation (measured by con-
tinuous ECGmonitoring) in patients with T2D, during routine every-day
life.
Materials and methods: A total of 40 (50% males) patients with T2D
(mean age [±SD]: 68.3±6.9 years, HbA1c: 7.45±0.91%, diabetes dura-
tion 17.7±8.7 years, BMI: 29.9±1.3 kg/m2, treated with insulin with or
without oral hypoglycaemicmedications) were studiedwith simultaneous
CGMS and 24-hour ECGmonitoring. Hypoglycaemia was defined as an
episode of blood glucose <70 mg/dl (3.9 mmol/L), lasting for ≥20 mi-
nutes. The mean QTc during these episodes was compared with the mean
QTc during the period preceding the episode. Hypoglycaemia during day-
and night-time was also evaluated separately.
Results:A total of 26 non-severe hypoglycaemic episodes were recorded
in 16 patients. Half of these episodes occurred during the night. Mean
QTc during hypoglycaemia was significantly longer than during
normoglycaemia (443.38±51.38 vs. 424.46±61.49 msec, p=0.012). In-
terestingly, only the night-time hypoglycaemic QTc differed significantly
from the preceding period’s one (459.62±55.65 vs. 417.62±86.13 msec,
p=0.003), while, during the day-time, no significant difference was ob-
served (427.15±42.81 vs. 431.31±18.91 msec, p=0.58)
Conclusion: Hypoglycaemia in patients with T2D is associated with
prolongation of the QTc interval, especially during the night, and may
contribute to the increased adverse outcomes seen with intensive treat-
ment of the disease.
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Hypoglycaemia reduces cognitive performance and affects cerebral
blood flow in subjects with type 1 diabetes
A. Gjedde1, M. Gejl2, B. Brock2, A. Møller2, E. van Duinkerken3, K.
Stender-Petersen4, C.T. Hansen4, P.-L. Chu5, H. Haahr4, J. Rungby6;
1Dept of Neuroscience and Pharmacology, University of Copenhagen,
2Aarhus University and Aarhus University Hospital, Denmark, 3VU Uni-
versity Medical Center, Amsterdam, Netherlands, 4Novo Nordisk A/S,
Søborg, Denmark, 5Novo Nordisk Inc., Plainsboro, USA, 6Gentofte Uni-
versity Hospital, Copenhagen, Denmark.
Background and aims: This randomised single-blinded, two-period
cross-over trial investigated cognitive performance and associated region-
al cerebral blood flow (rCBF) during hypoglycaemia.
Materials and methods: Subjects (n=26) with type 1 diabetes
underwent a hypoglycaemic and euglycaemic clamp (target plasma glu-
cose 2.8±0.2 mmol/L and 5.5±0.55 mmol/L, respectively). Cognitive
performance (workingmemory) was assessed by a modified digit symbol
substitution test (DSST), adjusted for sight and finger movements (con-
trol DSST [cDSST]), at both visits. During DSST and cDSST, rCBF was
measured in 19 pre-specified brain regions using 15O-labelled water pos-
itron emission tomography. DSST scores and response time were
analysed using a linear mixed-effect model with condition and period as
fixed factors and subject as a random factor. All rCBF values were nor-
malised to grey matter and analysed using an ANOVA with condition,
period and subject as fixed factors.
Results: The DSST score was significantly lower (estimated treatment
difference [ETD]: –0.63 [–1.13; –0.14], p=0.014) and the response time
significantly longer (ETD: 2.86 s [0.67; 5.05], p=0.013) during
hypoglycaemia vs euglycaemia. During DSST, rCBF was significantly
decreased (p<0.05) in medial temporal lobe (MTL) and hippocampus,
and increased (p<0.05) in dorsolateral prefrontal cortex (DPC), middle
and inferior frontal gyrus (MFG/IFG), superior parietal lobe (SPL) and
thalamus during hypoglycaemia vs euglycaemia. During cDSST, rCBF
was significantly decreased (p<0.05) in hippocampus, MTL,
parahippocampal gyrus and striatum, and increased (p<0.05) in DPC,
IFG, MFG, orbitofrontal cortex, superior frontal gyrus, ventromedial pre-
frontal cortex, SPL and thalamus during hypoglycaemia vs euglycaemia.
When performing the DSST adjusted for cDSST (DSST-cDSST), rCBF
was relatively increased in the striatum during hypoglycaemia vs
euglycaemia.
Conclusion: Hypoglycaemia reduced cognitive performance, accompa-
nied by significant changes of rCBF, indicating raised activity in the
attentional mode network at the expense of the default mode network.
Clinical Trial Registration Number: NCT01789593
Supported by: Novo Nordisk
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‘It makes a difference, coming here’: a qualitative exploration of
clinic attendance among young adults with type 1 diabetes
L. Hynes1, M. Byrne1, S.F. Dinneen2, D. Casey3, M. O'Hara4;
1School of Psychology, 2School of Medicine, 3School of Nursing and
Midwifery, National University of Ireland, Galway, 4Endocrinology and
Diabetes Centre, Galway University Hospitals, Ireland.
Background and aims: Young adulthood is a time of challenges
and risks for people with type 1 diabetes. Thus, appropriate sup-
port and education from a diabetes clinic is of particular impor-
tance. However, poor outpatient clinic attendance is common
among young adults with type 1 diabetes. A significant gap exists
in the research related to clinic non-attendance among young
adults. The aim of this qualitative study was to develop a theory
explaining attendance at a hospital-based diabetes clinic.
Materials and methods: Using a grounded theory methodology, data
were collected through semi-structured qualitative interviews. Twenty
nine people (21 young adults with type 1 diabetes and 8 service providers)
from one hospital-based diabetes clinic were interviewed. Interviews
were recorded, transcribed and analysed according to the grounded theory
methodology.
Results: Relationships between young adults and service providers
is the core category of this theory. Collaborative relationships
between young adults and service providers increased the per-
ceived value of attendance and reduced the vulnerability of young
adults to the barriers within the existing service, such as meeting
unfamiliar service providers. Relationships between young adults
and service providers were developed following opportunities for
contact (e.g. experiencing a crisis of diabetes or attending a struc-
tured education programme), and facilitated engagement with the
service and further attendance. Relationships developed outside
clinic appointments due to clinic-related barriers such as short,
impersonal consultations. Barriers to clinic attendance included
young adults’ negative perceptions of their self-management and
a lack of value associated with attending. Young adults who were
engaged with the service were more likely to attend, despite bar-
riers to attendance, due to the knowledge and confidence they had
that they would benefit from attending.
Conclusion: The diabetes clinic was described as an important and
valued resource by young adults and service providers. Collabo-
rative relationships between young adults and service providers
enhanced service provision in this study. Young adults gain the
motivation and confidence to engage with diabetes services by
experiencing collaboration with service providers. According to
the results of this study, clinic attendance may be improved by
increasing opportunities for relationship development between ser-
vice providers and young adults. A focus on relationship devel-
opment may result in more effective use of limited clinic re-
sources by increasing engagement and reducing non-attendance.
Supported by: a Galway Doctoral Research Scholarship
Diabetologia (2015) 58 (Suppl 1):S1–S607 S423
881
Dysregulated IGF-system in type 1 diabetes on subcutaneous insulin
therapy. Need for a change?
H.J. Arnqvist1, K. Gutefeldt2, A. Spångeus2, C.A. Hedman2, T.
Lindström2;
1Department of Endocrinology and Department of Clinical and Experi-
mental Medicine, Linköping University, Linköping, 2Department of En-
docrinology and Department of Medical and Health Sciences, Linköping
University, Sweden.
Background and aims: Under physiological conditions insulin reaches
the liver through the portal vein and the liver is exposed to a several fold
higher insulin concentration than the rest of the body. In Type 1 diabetes
(T1D) treated with subcutaneous insulin high IGFBP-1 and low IGF1
have been reported and this may be due to insufficient insulin delivery
to the liver. Our aim was to characterize associations of IGFBP-1 and
IGF1 levels to metabolic variables in a largematerial of patients with T1D
of long duration in comparison to matched controls without diabetes.
Materials and methods: Patients diagnosed before 35 years of age,
diabetes duration >20 years and not older than 65 years were invited to
participate. Controls matched for age were obtained from a national pop-
ulation registry. IGF1 was measured by Immulite® and IGFBP1 by an
ELISA. C-peptide was analyzed with a high sensitive ELISA. Blood
samples were obtained after fasting overnight
Results:Altogether 773 patients and 708 controls participated. Mean age
for the patients was 50.5±9.5 (±SD) and for controls 54.1±9.3. In spite of
a long diabetes duration 80 of 578 patients were C-peptide positive and 30
had values>100 pmol/l. IGFBP-1 was 68.1 (36.0 - 159.0) μg/l (median;
interquartile range) in T1D and 20.0 (11.0-34.0 in controls) p<0.0001
while IGF1 was 112±44 μg/l (mean ± SD) in T1D and 151±60 in con-
trols p<0.0001.
IGFBP-1 was strongly associated with fasting P-glucose (r=0.405; p<
0.0001) but not with HbA1c. No associations were found between P-
glucose or HbA1c with IGF1. In Spearmans correlation there was a neg-
ative association between C-peptide and IGFBP-1 (p=0.011) and a pos-
itive with IGF1 (p=0.001).
Conclusion: There are pronounced changes in the IGF-system in T1D on
subcutaneous insulin administration counteracted by persistent endoge-
nous insulin secretion. Although the clinical consequences of the dysreg-
ulated IGF-system is still unclear the results raises the question of the
possible advantages of intraperitoneal insulin administration.
Supported by: FORSS and County of Östergötland
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Predicting complications and long-term outcomes in type 1 diabetes:
the PRIME Diabetes Model
W.J. Valentine1, R.F. Pollock1, R. Saunders1, J.P. Bae2, K. Norrbacka3,
B.H. Curtis2, K.S. Boye2;
1Ossian Health Economics and Communications, Basel, Switzerland,
2Eli Lilly and Company, Indianapolis, USA, 3Eli Lilly Finland, Helsinki,
Finland.
Background and aims: Health economic models are important for
informing healthcare policy that directly affects patients with diabetes.
The utility of a model is inherently linked to its accuracy and representa-
tiveness. To date, several models of type 1 diabetes mellitus (T1DM) have
been published, but often rely on historical data and/or data derived from
populations without T1DM. Recent publications describing long-term
follow-up from landmark trials and diabetes registries represent an oppor-
tunity to revisit T1DMmodeling options. Our objective was to develop a
new, product-independent model of T1DM, using data from T1DM pop-
ulations to estimate complication risk, capable of predicting long-term
clinical and cost outcomes.
Materials and methods: Following a systematic literature review to
identify large-scale clinical trials in populations with T1DM, a model
was developed (the PRIME Diabetes Model) to simulate disease progres-
sion and the risk of complications. Written in Java and externally audited,
the model is structured such that individual, simulated patients are follow-
ed over time analogous to a clinical trial. At the start of a simulation,
patient characteristics are assigned using a covariance matrix to ensure
realistic risk profiles. Each patient is then passed to individual controllers
to evaluate the risk of complications (myocardial infarction, stroke, angi-
na, heart failure, nephropathy, retinopathy, macular edema, neuropathy,
amputation, hypoglycemia and ketoacidosis), mortality and progression
of risk factors such as glycated hemoglobin (HbA1c). Several approaches
novel to T1DM modeling are utilized, including covariance of patient
characteristics and risk factors, an HbA1c progression model derived
from patient-level data, a weighted model averaging approach to estimate
cardiovascular risk, and model combination to more accurately assess
microvascular complication risk.
Results:Validation analysis comparing outcomes predicted by the model
with those of clinical studies has shown that the PRIME Diabetes Model
can project long-term patient outcomes that are consistent with those
reported for a number of long-term studies in T1DM. Macrovascular
endpoint data have been reliably reproduced from the EURODIAB study,
the FinnDiane Registry, the Diabetes Control and Complications Trial
(DCCT), the Swedish National Diabetes Registry (SNDR), and Wiscon-
sin Epidemiologic Study of Diabetic Retinopathy study (WESDR). Sim-
ilarly, macrovascular complication risk is accurately reflected in the mod-
el based on comparisons with the DCCT and the Epidemiology of Dia-
betes and its Complications (EDIC) study, the SNDR, EURODIAB and
WESDR.
Conclusion: The PRIME Diabetes Model is product-independent, avail-
able online for academic use and has been developed in line with good
practice guidelines. Validation has indicated that outcomes from long-
term T1DM trials can be reliably reproduced. The model offers new
approaches to long-standing challenges in T1DM modeling and may be
a valuable tool for informing healthcare policy in T1DM.
Supported by: Eli Lilly
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Diet management, lifestyle factors and education needs by target
attainment in Italian youth with type 1 diabetes from the Global
TEENs study
C. Maffeis1, S. Toni1, D. Iafusco1, A. La Loggia1, I. Rabbone1, S.
Tumini1, S. Waldron2, C. Domenger3, F. Calvi-Gries4, A. Scaramuzza1,
TEENs investigator group of ISPED;
1Italian Society for Pediatric Endocrinology and Diabetology (ISPED/
SIEDP), Torino, Italy, 2National Children and Young People's Diabetes
Network, London, UK, 3Sanofi, Paris, 4AtlanStat, Nantes, France.
Background and aims: TEENs is an international, cross-sectional ob-
servational study, conducted in 20 countries in order to assess T1D man-
agement and psychosocial parameters in 8-25-year-olds (y/o). Data on
diet management, lifestyle factors and education needs by target HbA1c
attainment from the Italian cohort are reported.
Materials and methods:Data were collected at 23 centres by participant
interview, medical record review and participant/parent survey from 1,
009 Italian youth (46% female) in three age groups: 8-12 y/o (n=330),
13-18 y/o (n=490), and 19-25 y/o (n=189). HbA1c was measured uni-
formly using A1cNow™with target HbA1c defined as <7.5% (58mmol/
mol) for ≤18 y/o (ISPAD) and <7% (53 mmol/mol) for >18 y/o (ADA).
Results: Overall, 40% of participants met HbA1c targets. Measuring
food intake based on experience was the most common method used by
all age groups, followed by carbohydrate counting (Table). Of the partic-
ipants who used carbohydrate counting, a higher percentage met target
HbA1c than did not in all age groups, with a significant effect on target
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attainment due to carbohydrate counting compared with other methods
observed in 13-18 y/o (p=0.035). Avoiding sugars was the least common
method used in all age groups. Across all age groups, participants who did
not undertake any exercise were numerically less likely to reach HbA1c
target; on the contrary, participants who exercised 1-2 days/week were
numerically more likely to reach HbA1c target (Table). Performing exer-
cise had a significant effect on target HbA1c attainment in 8-12 y/o (p=
0.012). Themajority of participants were in the underweight/normal body
mass index (BMI) category in all age groups, with no clear pattern be-
tween BMI class and the proportion of patients reaching HbA1c target.
Participants of all ages commonly requested education on diet, carbohy-
drate counting, how to manage T1D during illness, and how to manage
blood glucose levels with exercise.
Conclusion: Carbohydrate counting and exercising at least twice per
week help to attain HbA1c target across all age groups. Assessment of
lifestyle factors suggests that efforts targeting carbohydrate counting and
exercise could promote successful health outcomes and help more pa-
tients with T1D to reach the recommended HbA1c target.
Supported by: Sanofi
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Freedom for life: 13 years of experience from an accredited patients'
education course for type 1 diabetes. Review of long-term outcomes
K. Gkastaris, S. Wylie, N. Hillier, B. Hall, A. Carling, A.M. Robinson;
Diabetes department, Royal United Hospital, Bath, UK.
Background and aims: The Freedom for Life course is the accredited
patients' education course for type 1 diabetes in the catchment area of
Bath, UK. It is similar in principle to the DAFNE (Dose Adjustment For
Normal Eating) course but with a different structure. It consists of one
session a week (3 hours) for five weeks with follow up at 3 months,
6 months and 1 year (2 hours). The aim of our work was to review the
long-term outcomes of the course 12 years after its introduction in eleven
centres in the Bath catchment area.
Materials and methods: Using the hospital's research diabetes database
(DIAMOND), records of 211 adults with Type 1 diabetes (65.5% female)
were examined (baseline mean ± SD: age 45.28±12.94 years,duration of
diabetes 19.29±13.21 years). Biomedical data for HbA1c and body mass
index (BMI) were collected before and then every 12 months after pa-
tients completed the education. Additionally, data for proportion of pa-
tients progressing to insulin pump were collected.
Results: At one year follow-up HbA1c had greatly decreased from 76±
15.7 to 66±12.3(p<0.001). The results for the years following the
Freedom for Life course showed an improved HbA1c compared to the
baseline: 67±13.6 at 24 months, 69±13.6 at 36 months, 70±12.1 at
48 months, 71±13.2 at 60 months, 71±10 at 72 months, 72±12.3 at
84 months, 72±11.4 at 96 months and 73±13.4 at 108 months. Further
review of the outcomes excluding patients who had insulin pump therapy
revealed a significant reduction in HbA1c which remained statistically
significant for 6 years following the course. The mean BMI had not
significantly changed before (24.35) and after (25.11) the course. Lastly
47 patients (22.27%) progressed to insulin pump with a mean interval of
2.25 years between the course and the initiation of insulin pump
treatment.
Conclusion: The impact of a single Freedom for Life course on
glycaemic control remains apparent in the long term. The improvement
in the HbA1c at 108 months compared to the baseline one remained
significant (76±15 to 71±13.4 of 6.57%) even though it had deteriorated
from 12 months (66±12.3 or 13.15%). Analysis of the outcomes for
patients who didn't have insulin pump revealed that the reduction in
HbA1c remains significant for 6 years after the course. 22.3% of the
patients who participated in the Freedom for Life course progressed to
insulin pump treatment with a mean interval of 2.25 years. The effect of a
single Freedom for Life course on glycaemic control seems to be superior
to the outcomes of the other educational programmes for people with type
1 DM (both the traditional programmes and the DAFNE 5×1 day trial).
This is likely due to the fact that the Freedom for Life course offers
follow-up sessions at 3, 6 and 12 months. Repeat training sessions have
been shown to have better outcomes in educational trials and other chron-
ic health conditions and also lead to a better relationship between the
patients and healthcare professionals.
885
Predictors of hospital admission in patients with type 1 diabetes
following participation in the structured education programme, Dose
Adjustment For Normal Eating (DAFNE)
P.R.E. Cliff1, B. Hudson2;
1College of Medical and Dental Sciences, University of Birmingham,
2University Hospitals Birmingham NHS Foundation Trust, UK.
Background and aims: Diabetes-related hospital admissions are not
only costly to the NHS in the UK but are distressing for patients involved.
Structured education programmes such as DAFNE encourage self-
management and participation has been shown to reduce hospital admis-
sions post-course. However, there continues to be some patients who are
admitted despite training. We aimed to determine the rate of hospital
admissions in patients with type 1 diabetes prior to and post DAFNE
and examine predictors for admission post course.
Materials andmethods:Using clinical case records from the PIC patient
database, anonymised data from 99 adults with type 1 diabetes (T1D)
who participated in DAFNE between January 2012 and September
2013, was collected and examined. Records were reviewed for evidence
of hospital admission for severe hypoglycaemia, hyperglycaemia and
diabetic ketoacidosis in the 12 months prior to and 12 months following
course participation. Case notes were reviewed for those admitted to
hospital and follow-up attendance recorded. HbA1c results for all were
recorded 1 year before and after DAFNE training.
Results: In the year before the course, 14 patients were admitted to
hospital with a total number of 15 admissions. In the year following
DAFNE, 5 patients were admitted with a total of 6 admissions. Of the
94 avoiding admission in the year following DAFNE, 83 attended at least
one DAFNE review or diabetes clinic in this time (88% attendance)
compared to 2 patients (40%, p<0.05) for those admitted. Evidence of
poor blood glucose monitoring was recorded in the notes for 5 of the 5
patients (100%) and HbA1c values increased in 3 of the 5 (60%).
Conclusion:As has been previously demonstrated, we show that hospital
admissions for severe hypoglycaemia and diabetic ketoacidosis are
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reduced in the year following the DAFNE structured education course. A
predictive factor reported for ketoacidosis is a higher HbA1c concentra-
tion and our findings are consistent with this. In addition, we also dem-
onstrate that lack of engagement with diabetes services is a further pre-
dictor of hospital admission in the year following the course. We suggest
that patients such as these could be identified, monitoredmore closely and
offered extra support to improve outcomes following programmes such as
DAFNE. Whilst some participants will benefit from group follow-up,
these results and indeed, previous studies suggest that there is a need
for ongoing individualised support and follow-up. In this way, DAFNE
principles are more likely to be reinforced andmaintained, and this in turn
contributing to reducing hospital admissions, emergency treatment costs,
and improving psychosocial outcomes for patients with type 1 diabetes.
Structured education remains an important part of the management of
type 1 diabetes and is recommended for all adults with the condition.
Gaining a more thorough understanding of what factors influence adher-
ence to DAFNE principles will allow for more focused care.
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Partial remission period based on insulin dose-adjusted HbA1c in 3,
661 German and Austrian children and adolescents with type 1
diabetes
K. Nagl1, J.M. Hermann2, M. Plamper3, C. Schröder4, A. Dost5, O.
Kordonouri6, R.W. Holl2, on behalf of the DPV initiative;
1Department of Pediatrics and Adolescent Medicine, Medical University
Vienna, Austria, 2Epidemiology and med. Biometry, German Center for
Diabetes Research (DZD), University of Ulm, 3Department of Pediatrics,
University of Bonn, 4Department of Pediatrics, University of Greifswald,
5Department of Pediatrics, University Hospital Jena, 6Children’s Hospital
Auf der Bult, Hannover, Germany.
Background and aims: Occurrence of partial remission (PR) period
shortly after onset of type 1 diabetes (T1D) might be due to amelioration
of insulin sensitivity, but also due to a temporary restoration of pancreatic
beta cells affecting insulin dosage. Insulin dose adjusted A1C (IDAA1C)
combines required insulin dosage with HbA1c and correlates with stim-
ulated c-peptide. Applying IDAA1c, we studied PR in a large group of
children and adolescents with T1D.
Materials and methods: Data of 3,661 patients with T1D (<18 years at
diabetes onset, continuous follow-up) from the DPV (Diabetespatienten
Verlaufsdokumentation) database were analysed. IDAA1C was calculat-
ed as HbA1c (%) + 4 × [insulin dosage (Units per kilogram bodyweight
per day)] at 1, 3, 6, 12, 18, 24, 36, 48, 60 and 72 months after T1D onset.
We evaluated duration of PR (IDAA1c≤9, based on the first period with-
out and the last period with PR) using Kruskal-Wallis tests and hierarchi-
cal linear regression models with random effects accounting for differ-
ences between treatment centres.
Results:Median PR period was 9 (0;21) months. After 3 months, 61% of
patients had PR. In 4.7% of patients, PR even lasted until 72 months after
onset. Median PR duration was lowest in patients aged<5 years at T1D
onset (4.5 (0;30) months), whereas it was highest in patients older than
15 years at T1D onset (21 (9;72) months). In those>15 years, 21% still
had PR 5 years after T1D onset. Duration of PR showed significant
negative correlations with initial HbA1c (R=-0.15, p=<0.001), positivity
for islet-autoantibodies at T1D onset (R=-0.06, p=0.003) and year of
diagnosis (R=-0.05, p=0.004). Duration of PR was longer in boys than
in girls (9 (2;21) vs. 4.5 (0;15) months, p<0.001). This difference
remained significant after adjustment for age, HbA1c, ketoacidosis,
auto-antibody-positivity at T1D onset and year of diagnosis (p=0.01).
Subsequently, linear regression revealed that age at T1D onset>15 years,
lower initial HbA1c, and negativity for islet-auto-antibodies were signif-
icantly associated with longer duration of PR. Though patients with dia-
betic ketoacidosis at T1D onset had a significantly shorter PR than pa-
tients without, this difference did not remain significant after adjustment.
Conclusion: As IDAA1c does not discriminate between insulin sensitiv-
ity and insulin secretion, available data did not allow resolving whether
the sex-difference in PR duration reflects an innate higher insulin resis-
tance in girls, or a better beta-cell recovery in boys. Hence, the weighting
of HbA1c in the IDAA1c definition could cause underreporting of PR
duration in girls. Yet, ketoacidosis at T1D onset, which is strongly asso-
ciated with initial HbA1c and has been discussed as a main risk factor for
a short PR, does not show statistical significance in our regression model
with adjustment for age and gender. Further research is needed to clarify
the usefulness and performance of IDAA1c in clinical practice.
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Understanding patient and clinician glucose reporting preferences in
type 1 diabetes: Ambulatory Glucose Profile (AGP)
D. Mullen, S. Richter, R. Bergenstal, AGP Work Flow Study Group;
International Diabetes Center, Minneapolis, USA.
Background and aims: A lack of a standardized glucose report and
streamlined data acquisition across glucose monitoring devices has cre-
ated frustration in clinics and reduced the use of glucose data in clinical
encounters. Device specific reports are unique to each glucose monitoring
device, are complex and not able to incorporate devices from different
manufacturers into a single view. The AGP is simple one page report with
3 components: glucose metrics, graphic summary visualization of a
2 week glucose profile and a calendar view the glucose profiles from
each of the days making up the summary profile view. The purpose of
this novel research is to evaluate both patient (aim 1) and clinician (aim 3)
utility and preference of streamlined standardized glucose reporting using
Ambulatory Glucose Profile (AGP) reports. The first two sites participat-
ed in Time in Motion (TIM) evaluation as well as work flow mapping to
determine an idealized glucose reporting work flow (aim 2).
Materials and methods: Seven geographically and demographically di-
verse clinics with large patient populations with type 1 diabetes were
selected. Twenty patients per clinic and up to four clinicians per clinic
utilized a device download station to create a standardized SMBG or
CGM AGP report. Both the patients and clinicians reviewed the report
then responded to a survey about the AGP reports utility and their pref-
erences when compared with their usual glucose reports.
Results: Patients or their parents have reported a significantly higher
preference for the AGP report than logbooks, device specific reports or
from device displays (see Table). Patients and parents report significantly
higher amounts of information, better information to support health rou-
tine changes, better understanding of their glucose patterns, more confi-
dence in managing their glucose levels and seeing new trends from the
AGP (see Table). Clinicians reported significantly higher preference of
the AGP over other methods for seeing glucose trends and helping to
educate patients about trends. TIM portions of the study showed signif-
icant savings in staff time (on average 4 to 15 minutes) per patient from
this streamlined reporting system.
Conclusion: This novel approach to glucose reporting has the ability to
save staff time, improve patient and clinician interactions through shared
understanding of the patient’s glucose profile and lead to more in depth
individualized support for medication adjustment and health related be-
havior changes. Compared to the use of an HbA1c and inconsistent pa-
tient reporting of adverse glucose related events, the standardized use of a
one page comprehensive glucose report (AGP) resulted in more person-
alized clinical decision making and significantly improved clinic
workflow.
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Where do SGLT2 inhibitors fit in treating my patients with diabetes?
Effect of online CME and need for further education
A. Larkin, M. LaCouture, A. Csicseri, A. Le;
Medscape Education, New York, USA.
Background and aims: Successful implementation of new standards of
care begins with a thorough understanding of the mechanisms of action of
newer agents, and where these agents fit into modern type 2 diabetes
(T2D) treatment algorithms. We sought to determine if online continuing
medical education (CME) could improve the clinical knowledge and
competence of primary care physicians (PCPs) regarding the use of
SGLT2 inhibitors in T2D management.
Materials and methods: The effect of two educational interventions on
the role of the kidney and SGLT2 in the treatment of T2Dwas analyzed to
determine efficacy of online education presented in the form of a video
lecture and interactive case-based text activity. The activities launched
online in November or December, 2014 and data were collected through
January, 2015. The effects of education were assessed using knowledge-
and case-based matched pre-assessment/post-assessments. The effect size
was calculated with Cohen’s d (>0.8 are large, 0.8-0.4 are medium, and<
0.4 are small).
Results: In total, 1566 PCPs participated. Significant overall improve-
ments were seen for both the video lecture (n=455; large effect d=0.98)
and case-based text activity (n=1111; large effect d=1.238). Specific
areas of improvements seen include:
•Compared with baseline, 43%more PCPs (P<.0005) correctly identified
the rationale for glomerular filtration rate (GFR) limits when considering
use of SGLT2 inhibitors
•Compared with baseline, 33% more pulmonologists (P<.05) correctly
identified a strategy for combating hypotension in patients on SGLT2
inhibitor therapy
•In a patient with T2D, more physicians appropriately identified themajor
pathological contributor to the patient’s T2D after the education (47%
increase, P<.05)
•In a patient with T2D who is starting on an SGLT2 inhibitor, more
physicians appropriately educated the patient on genital mycotic
infections as the most common side effect associated with this class of
antihyperglycemic agents (44% increase, P<.05)
Conclusion: This study demonstrates the success of a targeted education-
al intervention with multiple educational components (serial learning) on
improving knowledge and competence of PCPs regarding the use of
SGLT2 inhibitors in the treatment of T2D. Additional studies are needed
to assess if improved knowledge and competence translates into im-
proved appropriate use of these therapeutic options.
Supported by: Independent educational grants from Janssen Pharmaceu-
ticals, Inc.
Diabetologia (2015) 58 (Suppl 1):S1–S607 S427
PS 082 Perceptions, communications
and patient outcomes in diabetes care
889
Change in HbA1c associated with adherence to newly initiated
metformin therapy
G.A. Nichols1, K. Tunceli2, A.G. Rosales1, K. Kurtyka2, P. Mavros2;
1Kaiser Permanente Center for Health Research, Portland, 2Merck & Co,
Inc, Kenilworth, USA.
Background and aims: Adherence to newly prescribed anti-
hyperglycemic agents is essential for the attainment of glycemic goals
but the association between changes in adherence and glycemic control
has not been reported. We studied the association between metformin
adherence and change in A1C from pre- to post-treatment levels, and
the association between change in adherence and change between 2
post-treatment A1C measures.
Materials and methods: First, we analyzed 2,844 patients who newly
initiated metformin monotherapy to estimate the effect of adherence on
change in A1C that occurred as a result of initiating metformin. A1C
change was calculated as the difference between pre-metformin A1C
and the first A1C measured 6-12 months following their first metformin
dispense. We used a modification of the proportion of days covered
(PDC) method to estimate adherence over the 90-day period preceding
each A1C to produce a “biologic response based” PDC (BRB-PDC). We
categorized BRB-PDC into 4 levels: 0% (no refill of initial dispense), 1-
49%, 50-79%, and >80%. Change in A1C was modeled as a function of
BRB-PDC category. Next, we evaluated change in A1C among 2,416
patients who had at least two post-metformin A1C values. Change in
A1C was calculated as the difference between the first and last post-
treatment values. We estimated BRB-PDC for each A1C value and
modeled change in A1C as a function of change in BRB-PDC category.
Analyses were adjusted for age, sex, the first A1C value used in the
relevant change calculation, and metformin dose.
Results: There was a graded relationship between adherence and change
in A1C following metformin initiation. Relative to the non-adherent
group, BRB-PDC 50-79% was associated with a change of -0.45%
(95% CI -0.65, -0.26; p<0.001), and BRB-PDC >80% was associated
with an A1C change of -0.73% (-0.90, -0.55; p<0.001). In addition,
change in BRB-PDC was associated with a significant change in A1C.
Among patients with at least some initial adherence (1-79%), change to
total non-adherence (BRB-PDC=0%) at the 2nd A1C measure was asso-
ciated with 0.25% (0.07, 0.42; p=0.005) increase in A1C, while change
from some to full adherence (BRB-PDC >80%) was associated with an
A1C decrease of 0.15% (-0.28, -0.02; p=0.027). These results were mag-
nified when limited to the 861 patients whose 1st A1C was >7%. Change
from some to no adherence was associated with an A1C increase of
0.63% (0.27, 0.99; p<0.001) while change from some to full adherence
was associated with an A1C decrease of 0.40% (-0.67, -0.14; p=0.003).
Conclusion: Estimating adherence over a biologically relevant time pe-
riod produces a stronger association with glycemic control than has been
previously reported. Changes in adherence were inversely associated with
changes in glycemic control and were especially important among pa-
tients not at optimal glycemic goal.
Supported by: Merck and Co.
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Perceptions of diabetes control among physicians and patients with
uncontrolled type 2 diabetes using basal insulin
M. Brod1, K.M. Pfeiffer1, A.H. Barnett2, K. Berntorp3, T. Vilsbøll4, B.
Weissenberger5;
1The Brod Group, Mill Valley, USA, 2University of Birmingham, UK,
3Lund University, Malmö, Sweden, 4University of Copenhagen,
Hellerup, Denmark, 5Praxis Hardhof, Basel, Switzerland.
Background and aims:While clinical definitions of diabetes control are
well established, there is limited understanding of how patients perceive
control and whether it differs from perceptions of control among physi-
cians. The purpose of the study was to investigate how physicians and
patients with uncontrolled type 2 diabetes (T2D) using basal insulin per-
ceive diabetes control.
Materials andmethods:Aweb survey of 1,012 adults with uncontrolled
T2D (physician confirmed HbA1c>8% (64 mmol/mol)) and treated with
basal insulin and 300 physicians was conducted in Sweden (n=240 pa-
tients and 100 physicians), Switzerland (n=152 patients and 100 physi-
cians), and the UK (n=620 patients and 100 physicians).
Results: Analyses revealed significant differences between physicians
and patients with uncontrolled T2D in their perceptions of control. In
defining control, physicians were significantly more likely than patients
to indicate that HbA1c (85% vs. 79%, p<.05), complications from dia-
betes (89% vs. 75%, p<.001), and frequency/severity of hypoglycaemia
(93% vs. 69%, p<.001) were very/extremely important for deciding
whether or not diabetes is well-controlled. Patients, on the other hand,
were significantly more likely than physicians to report that a wide range
of other factors were very/extremely important, including energy levels
(75% vs. 33%, p<.001), insulin units/day (78% vs. 29%, p<.001), how
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predictable life is (72% vs. 29%, p<.001), and howmuch one has to think
about diabetes (68% vs. 31%, p<.001). The time period for thinking
about control also differed; physicians were significantly more likely than
patients to think about the last three months (60% vs. 19%, p<.001) and
less likely than patients to consider the last week or more recently (7% vs.
51%, p<.001). Patients also saw more obstacles making control
very/extremely difficult compared to physicians, including stress (75%
vs. 54%, p<.001), medicine side effects (70% vs. 56%, p<.001), other
health issues (71% vs. 45%, p<.001), family obligations (61% vs. 33%, p
<.001), and lack of patient support groups (56% vs. 11%, p<.001). Pa-
tients were significantly more likely than physicians to see uncontrolled
diabetes as very/extremely interfering in different aspects of their lives,
including general health (70% vs. 51%, p<.001), energy level (71% vs.
36%, p<.001), mood/emotions (63% vs. 33%, p<.001), how much one
accomplishes during the day (62% vs. 23%, p< .001), keeping
appointments/commitments (63% vs. 17%, p<.001), making plans
(62% vs. 16%, p<.001), completing daily chores (60% vs. 21%, p
<.001), and family responsibilities (60% vs. 18%, p<.001).
Conclusion: Results revealed a significant disconnect between physi-
cians and patients with uncontrolled T2D in their perceptions of diabetes
control, including how they define control, obstacles to control, and the
impact of uncontrolled T2D. While physicians generally expressed a
more focused and clinical view of diabetes control, patients had a much
broader view, considering many different factors in their perceptions of
control. The findings suggest that educating physicians about how pa-
tients’ perceptions of control may differ from theirs could benefit
physician/patient communication and improve diabetes management.
Supported by: Novo Nordisk
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Discussing the need for additional oral drugs in type 2 diabetes: link
between perceived physician empathy, patient bargaining and
self-reported outcomes in the IntroDia™ study
A. Belton1,2, M. Capehorn3, S. Down4, A. Alzaid5, V. Gamerman6, F.
Nagel7, J. Lee7, S. Edelman8, W.H. Polonsky9;
1International Diabetes Federation, Brussels, Belgium, 2The Michener
Institute for Applied Health Sciences, Toronto, Canada, 3National Obesi-
ty Forum and Clifton Medical Centre, Rotherham, 4Somerset Partnership
NHS Foundation Trust, Bridgwater, UK, 5Prince SultanMilitary Medical
City, Riyadh, Saudi Arabia, 6Boehringer Ingelheim Pharmaceuticals Inc.,
Ridgefield, USA, 7Boehringer Ingelheim Pharma GmbH & Co. KG,
Ingelheim, Germany, 8Division of Endocrinology and Metabolism, Uni-
versity of California San Diego and Veterans Affairs Medical Center,
9Department of Psychiatry, University of California San Diego and Be-
havioral Diabetes Institute, San Diego, USA.
Background and aims: IntroDia™ is investigating physician-patient
communication during early treatment of type 2 diabetes (T2D); at diag-
nosis and at the time, often months or years post-diagnosis, when an
additional medication is added (“add-on”). Here we examine the issue
of patient bargaining (to delay additional medication) and its association
with self-reported outcomes.
Materials and methods: As part of IntroDia™, 4235 T2D patients from
26 countries (median age, 46 years; male gender, 52%) were surveyed
about their experience with their physician during oral medication add-on
conversations (which had occurred, on average, 7.4 months ago). Patients
were asked whether, during these conversations, they tried to convince
their physician to postpone the additional medication. Perceived physi-
cian empathy (PPE) (using elements from CAHPS, TIPS and IPC) was
measured as well as current psychosocial status (DDS and WHO-5) and
self-care behaviours (SDSCA).
Results: At add-on, 80% of patients did not bargain (DNB), while 20%
did bargain (DB). Of note, within theDBgroup, 60% of patients managed
to delay initiating additional medication, while 40% did not. There were
no clinically relevant differences between DNBs and DBs on key demo-
graphic variables. The mean PPE score (scale 1=poor to 4=high [SD])
was significantly higher (p<0.001) for DNBs vs. DBs (3.25 [0.71] vs.
3.01 [0.68]). DNBs were significantly less distressed by diabetes (DDS
emotional score 2.63) than DBs (3.45) (p<0.001). In addition, well-being
(WHO-5: 63% vs. 54%) and self-care scores (SDSCA general diet: 4.8
vs. 4.1; SDSCA medication: 5.9 vs. 4.8) were significantly higher for
DNBs vs. DBs, respectively (in all cases, p<0.001).
Conclusion: These data show that at least 20% of patients are reluctant to
start an additional medication and actively bargain with their physicians
to avoid doing so. Those who bargain report poorer PPE, greater diabetes
distress, and poorer well-being and self-care than those who do not
bargain.
Supported by: Boehringer Ingelheim/Eli Lilly
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An informed shared decision making programme on the prevention
of myocardial infarction for patients with type 2 diabetes:
randomised, controlled trial
S. Buhse1, I. Mühlhauser1, T. Heller2, J. Kasper3, N. Kuniss2, U.A. Müll-
er2, T. Lehmann4, M. Lenz1;
1Health Sciences and Education, University of Hamburg, 2Endocrinology
and Metabolic Diseases, University Hospital Jena, Germany, 3Faculty of
Health Sciences, University of Tromsø, Norway, 4Centre for Clinical
Studies, University Hospital Jena, Germany.
Background and aims: EASD/ADA and the German national guideline
committee explicitly recommend the implementation of shared decision
making (SDM) in diabetes care. SDM is a complex approach requiring
evidence-based patient information and health professionals willing and
capable to share decisions with patients. We have developed an informed
shared decision making (ISDM) programme on the prevention of myo-
cardial infarction. Diabetes educators teach patients to understand risk
information including probabilities of benefits and harms of preventive
options, and to set individual treatment goals. We evaluated the efficacy
of this programme within a single centre study in the setting of an outpa-
tient diabetes clinic in Germany.
Materials and methods: Patients with type 2 diabetes, 40 to 69 years,
without diagnosis of ischemic heart disease or stroke were randomly
assigned to the ISDM programme or control intervention. Follow-up
was 6 months. The ISDM programme consisted of a patient decision
aid, a 90 minutes teaching session provided by diabetes educators, and
provider training. The control intervention was structurally identical but
addressed lifestyle topics. Primary endpoint was the level of risk knowl-
edge after teaching when patients define their individual treatment goals.
Secondary outcomes were sufficient risk knowledge, realistic expecta-
tions, prioritisation of treatment goals, knowledge at follow-up, and
achievement of treatment goals. Analyses were on intention-to-treat basis.
ISDM sessions were video-taped to monitor intervention fidelity.
Results: A total of 154 patients (mean HbA1c 7.0%, blood pressure 145/
82 mmHg) were randomised; 72/77 patients in the ISDM group, and 71/
77 in the control group attended the teaching sessions and completed the
knowledge test (score 0-12). Mean score was 8.25 for ISDM, and 2.62 for
the control group (difference 5.63 [95% CI 4.82 to 6.44]; p<0.001).
Sufficient risk knowledge (9 correct answers) was achieved by 35/72
patients in ISDM, but no one in the control group. Mean score of realistic
expectations (six questions) was 4.51 for ISDM, and 0.85 for the control
group (difference 3.67 [95% CI 3.23 to 4.11]; p<0.001). In the ISDM
group more patients prioritised blood pressure control (51.4% vs. 25.7%;
p=0.002), whereas fewer prioritised glucose control (33.3% vs. 60%; p=
0.002). At follow-up the risk knowledge score was 3.68 for ISDM (n=71)
and 2.70 for controls (n=70) (difference 0.98 [95% CI 0.15 to 1.80]; p=
0.021). More ISDM patients achieved their HbA1c goals (81.7% vs.
65.7%; p=0.036). There was no difference with respect to other treatment
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goals. In both groups, most patients achieved their prioritised goals. Anal-
ysis of the video-taped ISDM teaching sessions documented that the
curriculum was properly implemented.
Conclusion: This study shows that the informed and shared decision
making programme is effective under high fidelity conditions. Patients
in the ISDM group demonstrated better understanding of risk informa-
tion, more realistic expectations, and more patients achieved individual
HbA1c goals. Involvement of diabetes educators may be essential to
implement SDM.
Clinical Trial Registration Number: ISRCTN84636255
Supported by: European Foundation for the Study of Diabetes
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Physician-patient communication at type 2 diabetes diagnosis and its
links to physician empathy and patient outcomes: new results from
the global IntroDia™ study
W.H. Polonsky1,2, A. Belton3, S. Down4, M. Capehorn5, A. Alzaid6, V.
Gamerman7, F. Nagel8, J. Lee8, S. Edelman9;
1Department of Psychiatry, University of California San Diego, 2Behav-
ioral Diabetes Institute, San Diego, USA, 3International Diabetes Feder-
ation, Brussels, Belgium and The Michener Institute for Applied Health
Sciences, Toronto, Canada, 4Somerset Partnership NHS Foundation
Trust, Bridgwater, 5National Obesity Forum and Clifton Medical Centre,
Rotherham, UK, 6Prince Sultan Military Medical City, Riyadh, Saudi
Arabia, 7Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, USA,
8Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany,
9Division of Endocrinology and Metabolism, University of California
San Diego,USA and Veterans Affairs Medical Center, San Diego, USA.
Background and aims: Effective communication between physicians
and type 2 diabetes (T2D) patients may improve patient self-care and
outcomes. IntroDia™ is a global study investigating physician-patient
communication at the time of T2D diagnosis and during early treatment,
and the possible impact of early conversations on patient self-care and
self-reported outcomes.
Materials and methods: As part of IntroDia™, 3628 T2D patients from
26 countries (48% male, median age 51 years) were surveyed about
conversations with physicians at diagnosis. Parameters examined includ-
ed the conversation’s content (via a 43-item version of PACIC modified
for T2D diagnosis), conversation quality (using CAHPS, TIPS and IPC
scale items to ascertain perceived physician empathy [PPE]), current psy-
chosocial status (WHO-5, DDS) and self-care behaviour (SDSCA).
Results:Using factor analysis, we identified 4 types of physician action -
Collaborative (e.g. “Gave me choices about treatment to think about”),
Encouraging (e.g. “Told me that a lot can be done to control my diabe-
tes”), Discouraging (e.g. “Told me that diabetes gets harder…”) and
Recommending Other Resources (ROR) (e.g. “Referred me to a dietician,
health educator, nurse or counselor”). PPE was positively associated with
Collaborative (β=0.44, p<0.001) and Encouraging (β=1.69, p<0.001),
negatively associated with Discouraging (β=-1.24, p<0.001) and unre-
lated to ROR (β=0.09, p=0.078). In turn, PPE was also linked to less
diabetes distress (DDS: β=-0.37, p<0.001), greater well-being (WHO-5:
β=0.39, p<0.001), and greater adherence to self-care behaviour (SDSCA
- exercise: β=0.70, p<0.001; diet: β=1.09, p<0.001; medication taking:
β=0.91, p<0.001).
Conclusion: Physicians’ use of collaborative and encouraging conversa-
tion elements at T2D diagnosis may improve physicians’ communication
with patients, leading to better self-care and enhanced quality of life.
Conversations using discouraging elements, however, may be
counterproductive.
Supported by: Boehringer Ingelheim/Eli Lilly
894
Physician-patient communication at prescription of an additional
oral agent for type 2 diabetes: link between conversation elements,
physician empathy and patient outcomes
S. Edelman1,2, M. Capehorn3, A. Belton4, S. Down5, A. Alzaid6, V.
Gamerman7, F. Nagel8, J. Lee8, W.H. Polonsky9;
1Division of Endocrinology and Metabolism, University of California
San Diego, 2Veterans Affairs Medical Center, San Diego, USA, 3National
Obesity Forum, UK and Clifton Medical Centre, Rotherham, UK, 4Inter-
national Diabetes Federation, Brussels, Belgium and The Michener Insti-
tute for Applied Health Sciences, Toronto, Canada, 5Somerset Partnership
NHS Foundation Trust, Bridgwater, UK, 6Prince SultanMilitary Medical
City, Riyadh, Saudi Arabia, 7Boehringer Ingelheim Pharmaceuticals Inc.,
Ridgefield, USA, 8Boehringer Ingelheim Pharma GmbH & Co. KG,
Ingelheim, Germany, 9Department of Psychiatry, University of California
San Diego Behavioral Diabetes Institute, San Diego, USA.
Background and aims: The global IntroDia™ study is investigating
physician-patient communication during the early treatment of type 2
diabetes (T2D) and how such conversations may be linked to critical
patient outcomes. Here we investigate patient experiences of the “add-
on” moment, i.e. the consultation when, typically months or years after
the T2D diagnosis, another oral agent is first prescribed, and how this
conversation is associated with patient self-care and quality of life
outcomes.
Materials andmethods:A total of 4235 patients from 26 countries (52%
male, median age 46 years) completed a self-report survey examining the
content of the conversation with their physicians at add-on (via a 27-item
scale of conversation elements specific for add-on). Perceived physician
empathy (PPE) was measured with CAHPS, TIPS and IPC items. Current
psychosocial status (WHO-5, DDS) and self-care behaviour (SDSCA)
were also evaluated.
Results: Three key elements of the physician-patient conversation were
identified by factor analysis - Collaborative (e.g. “Encouraged me to ask
him/her questions”), Encouraging (e.g. “Told me that the new medication
would improve my quality of life”) and Discouraging (e.g. “Told me that
my diabetes was getting worse”). PPE was positively associated with
Collaborative (β=1.16, p<0.001) and Encouraging (β=1.39, p<0.001)
and negatively linked with Discouraging (β=-0.92, p<0.001). Further,
PPEwas associatedwith less diabetes distress (DDS:β=-0.39, p<0.001),
greater well-being (WHO-5: β=0.54, p<0.001) and better self-care
(SDSCA - exercise: β=0.56, p<0.001; diet: β=0.94, p<0.001; medica-
tion taking: β=0.76, p<0.001).
Conclusion: Physician use of collaborative/encouraging conversation el-
ements when prescribing an additional oral agent may enhance commu-
nication with T2D patients and lead to better self-care and quality of life.
Conversely, discouraging elements may have the opposite effect.
Supported by: Boehringer Ingelheim/Eli Lilly
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Hypoglycaemia contributes to insulin discontinuation in US patients
newly-initiated on basal insulin: a real-world analysis study
M.R. Dalal1, F. Ye1, L. Xie2, M. Kazemi1;
1Sanofi US, Inc., Bridgewater, 2STATinMED Research, Ann Arbor,
USA.
Background and aims: Hypoglycaemia and fear of hypoglycaemia re-
main major barriers to persistence with insulin therapy among patients
with type 2 diabetes mellitus (T2DM). This study examined if US patients
with T2DM who experience hypoglycaemia soon after insulin initiation
are at a greater risk of insulin discontinuation.
Materials and methods: This was a retrospective cohort study using
claims data from the IMPACT™medical and pharmacy claims database.
Patients (aged≥18 years) with T2DM were identified if they initiated
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basal insulin therapy (defined as having no prescription of basal insulin≥
12 months before initiating insulin glargine, insulin detemir, or NPH
insulin) between January 2007 and March 2013. Hypoglycaemic events
were identified by health care encounters with an ICD-9-CM diagnosis
code of 250.8× during the first 6 months of basal insulin use. Discontin-
uation was defined as gaps of longer than 45, 60, or 90 days in any insulin
prescription coverage. A baseline was established using 12-months pa-
tient-level data prior to insulin initiation; follow-up periods of 12 and
24 months were considered. Data were adjusted for confounders using
Cox regression analysis.
Results: Among 71,470 patients identified, 3,301 (4.6%) experienced
hypoglycaemia within the first 6 months of insulin use. These patients
were on average older than those without hypoglycaemia (56 vs 54 years;
P<0.0001), and were more likely to discontinue insulin use within
12 months of initiation (45-day gap: 79% vs 74%; P<0.001). Data ad-
justed for confounders showed that patients with hypoglycaemia had a
higher risk of discontinuation over 12 months (hazard ratio 1.16; 95% CI
1.03-1.32). Similar results were seen at 12- and 24-months follow-up, or
when using prescription gaps of 60 or 90 days. Furthermore, patients who
experienced hypoglycaemia, versus those who did not, were more likely
to have a hospitalization (41% vs 23%) or an emergency department visit
(56% vs 35%) (both P<0.001) during the first 12 months.
Conclusion: In conclusion, in a US setting, patients with T2DM who
experienced hypoglycaemia within the first 6 months after initiating basal
insulin use were more likely to discontinue insulin therapy and had great-
er annual health care use.
Supported by: Sanofi US, Inc.
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Factors influencing remission phase in type 1 diabetic children
C.A. Buyukgebiz, S. Yuksel;
Pediatric Endocrinology, 0 18 klinik, Istanbul, Turkey.
Background and aims: To evaluate factors influencing the natural
course and characteristics of the remission phase while residual beta cell
function preservation is important.
Materials and methods: 120 patients with type 1 diabetes under the age
of 18 enrolled in the study in 3 years period. Data were collected by
reviewing the hospital records of patients from the time of diagnosis
through the firs 24 hours after diagnosis. Duration of symptoms,history
of prior infection, ketoasidosis at diagnosis,length of hospitalization, ini-
tial glucose level, basal C peptide levels at diagnosis and daily insulin
requirement per kg/body weight and HbA1C in each visit were recorded.
Results: 68 patients (56.5%)entered partial remission.We observed sim-
ilar remission rates in those aged 10 years at diagnosis and in boys and
girls.History of infection and presentation with ketoasidosis were associ-
ated with a lower rate of remission(p<0.001,p<0.0001 respectively) and
were commonly observed under the age of 10 years(p<0.001 and p<
0.0001 respectively). The average insulin requirements per kg at diagno-
sis decreased with increasing age(r:-0.31,p<0.012).The length of time
until remission was 1.36+/-1.03 months and positively correlated with
insulin requirements at discharge from the hospital(p<0.0001). Mean
duration of remission was 11.67+/-5.82 months and was longer in boys
than girls(p<0.05). 8 patients,all boys, entered total remission for 3.80+/-
3.73 months. HbA1C levels were 7.31+/-1.24% in the first year in remis-
sion patients with respect to 8.24+/-1.47 in non remission patients(p<
0.05).
Conclusion: History of infection prior to presentation and diabetic
ketoacidosis at diagnosis were associated with young age and were the
most important factors negatively influencing the remission rate in newly
diagnosed type 1 diabetics.Boys had a longer length of remission, and
especially in puberty, had lower insulin requirement than girls. It is im-
portant to provide close follow up for patients in remission, since HbA1C
levels may become elevated and remain unrecognised for a while in these
patients when the remission phase is over.
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Management and mortality in very old patients with type 2 diabetes
S. Hamada, M.C. Gulliford;
Primary Care and Public Health Sciences, King's College London, UK.
Background and aims: Less stringent treatment goals for intermediate
outcome measures such as HbA1c are sometimes proposed for older
patients with diabetes according to characteristics and health status of
individual patients, but the appropriate ranges for the intermediate out-
comes are still unclear. This study aimed to evaluate the management of
very old patients with type 2 diabetes, and to explore associations of
HbA1c, blood pressure (BP) and total cholesterol (TC) with all-cause
mortality.
Materials and methods: A population-based cohort aged 80 years or
older, diagnosed with type 2 diabetes, and registered at family practices in
the UKClinical Practice Research Datalink at 1 April 2011 was analysed.
The intermediate outcomes were measured between 1 April 2011 and 31
March 2012. Patients were followed up for all-cause mortality from 1
April 2012 to death, the end of their record, or the last data collection
date (31 March 2014). Associations of HbA1c, BP and TC with all-cause
mortality were estimated in the Cox proportional hazards model,
adjusting for age, sex, duration of diabetes, BMI, smoking status, history
of coronary heart diseases and stroke, and medications including
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antidiabetic, antihypertensive, lipid-lowering and antiplatelet drugs, and
clustering by general practice.
Results: Data for 29,909 patients, including 16,739 (56%) of females,
were analysed. During the 2-year follow-up period (median 1.8 years,
IQR 1.3 to 1.9 years), there were 5,016 deaths (11.1 per 100 person-year).
Mortality was higher for HbA1c <6.0% [42mmol/mol] HR 1.33 (95%CI
1.18 to 1.50); 6.0-6.4% [42-47mmol/mol] 1.16 (1.03 to 1.30); and ≥8.5%
[69 mmol/mol] 1.49 (1.31 to 1.69); BP <130/80 mmHg 1.49 (1.38 to
1.60); and TC <4.0 mmol/L 1.20 (1.11 to 1.29). There was evidence of
interaction between HbA1c and prescriptions of antidiabetic drugs (P for
interaction <0.05), with low HbA1c only associated with mortality in
patients on antidiabetic medications. In patients receiving no antidiabetic
drugs, HbA1c 8.0-8.4% (64-68 mmol/mol) was associated with higher
mortality (HR 2.07, 95% CI 1.28 to 3.33). However, in patients pre-
scribed antidiabetic drugs, HRs for HbA1c <6.0% (42 mmol/mol), 6.0-
6.4% (42-47 mmol/mol) and ≥8.5% (69 mmol/mol) were 1.42 (95% CI
1.23 to 1.64), 1.21 (95%CI 1.06 to 1.38), and 1.52 (95%CI 1.33 to 1.74),
respectively. There were no interactions between BP and prescriptions of
antihypertensive drugs or TC and prescriptions of lipid-lowering drugs.
Conclusion: In very old people with type 2 diabetes, stringent targets for
metabolic and BP control may not be advisable, but control of the inter-
mediate outcomes within appropriate ranges may be required.
Supported by: Guy’s and St Thomas’ NHS Foundation Trust and King’s
College London
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Clinical inertia affects younger and older adults with type 2 diabetes
mellitus equally, with or without CKD
W.D. Strain1, P.M. Paldánius2;
1University of Exeter Medical School, UK, 2Novartis Pharma AG, Basel,
Switzerland.
Background and aims: Clinical inertia (CI) is often defined as a failure
to escalate treatment in order to achieve appropriate treatment goals in
management of type 2 diabetes mellitus (T2DM). There is no single
identifiable fault in CI; rather, it is a multifactorial condition, with con-
tributory factors from the people with diabetes, the physicians and the
system inwhich they operate. The Time2DoMore inDiabetes programme
suggested that physicians believe older adults with diabetes and those
with chronic kidney disease (CKD) are more susceptible to CI than youn-
ger patients with few or no comorbidities, resulting in lower expectations
for concordance and adherence to lifestyle changes in the older or multi-
morbid people with diabetes. It is widely accepted that CI affects less
clinical trials, presumably due to the placebo effect. The difference be-
tween routine care and this placebo effect in trials represents a correction
of non-pharmacological aspects of CI. We used this concept to explore
the pre-existing CI by targeting placebo-treated patients from the large
vildagliptin clinical trial programme and using CKD as a proxy of diabe-
tes complications in general; comparing the glycaemic outcomes after a
placebo intervention in older patients with or without CKD, to those in a
younger population, with or without CKD.
Materials and methods:We stratified all placebo-treated subjects, both
treatment-naïve or with multiple antidiabetes background medications,
from the vildagliptin clinical trial programme, in a factorial design by
age (<70 or >70 years) and with or without CKD (impaired renal function
defined as eGFR <60ml/min). Least Square (LS) mean change in HbA1c
was assessed at 24 weeks (ANCOVA) and predictors of any differences
were explored from the available baseline characteristics.
Results: Our cohort comprised 3081 placebo-treated patients from 25
studies. 80% of patients included in the analysis were <70 years old
and 45% of all patients were women. As expected, the duration of
T2DMwas longer in patients with CKD in both younger and older groups
(table), and the renal function was reduced in patients with CKD inde-
pendent of their age; corresponding stage 3B in both CKD groups. The
mean baseline HbA1c was comparable across the groups independent of
age or CKD status. The overall mean placebo effect, with or without
adjustment for baseline HbA1c value, was similar between all groups
(adjusted LS mean HbA1c reductions between -0.23 and -0.32). There
was no between-group difference when the HbA1c reductions from base-
line were adjusted for CKD status (p=ns, for all comparisons).
Conclusion: In this exploratory analysis we were able to demonstrate a
consistent placebo effect across age groups in presence or absence of
CKD. This suggests that the non-pharmacological component of CI in
patients with diabetes may be independent of age and comorbidities.
Supported by: Novartis
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Impact of socioeconomic status and ethnicity on risk of stroke,
hospitalisation for heart failure and death in 371,092 individuals with
type 2 diabetes
B. Zethelius1, A. Rawshani2, A.-M. Svensson3, B. Eliasson4, A.
Rosengren4, S. Gudbjörnsdottir4;
1Dept of Public Health and Caring Sciences/Geriatrics, Institute of Clin-
ical Sciences, Uppsala, 2Inst of Medicine, 3Dept of Molecular and Clin-
ical Medicine, Inst of Medicine, 4Clinical and Molecular Medicine, Inst
of Medicine, Gothenburg, Sweden.
Background and aims: Socioeconomic status (SES) and ethnicity are
powerful predictors of coronary heart disease in diabetes, but whether this
association extends to heart failure and stroke is unknown. We examined
the impact of SES and ethnicity on the risk of stroke, hospitalization for
heart failure (HF) and overall mortality in type 2 diabetes.
Materials and methods: We included 371,092 patients (contributing 2,
766,349 appointments) with type 2 diabetes in the Swedish National
Diabetes Register (NDR) during 2004-2012. Clinical data from the
NDR was linked to national registers, whereby information on income,
education, marital status, country of birth, comorbidities and events was
obtained. Swedish natives were used as the reference group for ethnicity.
Patients were followed until a first incident event (hospitalization for heart
failure and fatal/nonfatal stroke), death or end of follow-up. The associ-
ation between socioeconomic variables and the outcomes was modeled
using Cox regression. Twomodels were computed for each outcome. The
first model was adjusted for demographic and diabetes-related covariates.
The second model was additionally adjusted for outcome specific
covariates.
Results: Mean (SD) follow-up was 4.7 (2.5) years. HF occurred in 26,
448 (7.1%) persons. Fatal/nonfatal stroke occurred in 38,480 (10.1%)
persons and 49,829 died (13.4%). Immigrants from Nordic countries
had 9% and 14% elevated risk of HF (Figure 1). Immigrants from the
Middle East and North Africa had 22% to 50% lower risk of all outcomes.
Immigrants from the Mediterranean Basin had 23% lower risk of stroke.
Latin Americans had 50% lower risk of HF and 40% lower risk of overall
mortality. East Asians had 60% lower risk of HF and 50% lower risk of
overall death. As compared with having 9 years or less education, having
a college/university degree was associated with 20% lower risk of both
HF and overall mortality. Those with 10 to 12 years of education had 10%
lower risk of both death and HF, compared with having 9 years or less
education. Income was inversely associated with the outcomes. As com-
pared with the highest income quintile, those in the two lowest quintiles
had 50% higher risk of all outcomes. As compared with being single,
beingmarriedwas associated with 12% lower risk of HF. Individuals who
were widowed had 10% higher risk of HF.
Conclusion: There are marked socioeconomic disparities in the risk of
HF, stroke and overall mortality despite equitable access to universal
health care. We find indications of a healthy immigrant phenomenon, as
non-Western immigrants frequently had lower risk than native Swedes.
Socioeconomic status and ethnicity are independent predictors of stroke,
HF and death in type 2 diabetes.
900
Exploring the distribution of cardiovascular disease and risk factors
amongst patients with diabetes on sulfonylurea in a Canadian
primary care dataset
P. Farahani1, S. Khan2, M. Oatway3, A. Dziarmaga3;
1Department of Medicine - Division of Endocrinology, 2CPCSSN -
Queen's University, Kingston, 3AstraZeneca Canada Inc., Mississauga,
Canada.
Background and aims: A growing body of evidence generated from
observational studies and meta-analyses has begun to illustrate the poten-
tial adverse cardiovascular (CV) risk profile associated with sulfonylurea
(SU) use. Studies reported an increased risk of death with SU drugs. The
use of SU was associated with increased mortality and a higher risk of
stroke. Also, more CV events with SU use have been reported in sub-
groups of patients with history of CV disease, elderly and higher body
mass index. The objective of this study was to explore the distribution of
CV disease and CVrisk factors amongst patients with diabetes on SU in a
Canadian primary care dataset for 2013 calendar year.
Materials and methods: The Canadian Primary Care Sentinel Surveil-
lance Network (CPCSSN), which is a multi-disease surveillance system
based on primary care electronic medical record data, was utilized for this
research study. Patients with a diagnosis of type 2 diabetes and exposure
to SUwere identified. Distribution/prevalence of CVrisk profile amongst
this sub-cohort was explored.
Results: Through database for 2013 calendar year there were 6146 pa-
tients who had diabetes, had at least one visit with their family doctor, and
were on SU. For this sub-cohort demographic data included: age [mean
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(SD)] 65.4(12.8) years-old; 56.4% male and mean BMI 31.3(10.0).
Established CV disease was found in 16% of the patients with the fol-
lowing distribution: 13% had ischemic heart disease/myocardial infarc-
tion or coronary artery disease; 2% had stroke; and 2% had peripheral
vascular disease. Regarding aggregation of CV risk factors a very signif-
icant proportion (65%) of patients without established atherosclerotic CV
disease had 2 or more CV risk factors including: hypertension (62%),
dyslipidemia (33%), active smoking (13%), and obesity (43%). Almost
half of the cohort (45%) were males older than 55 years of age or females
more than 60 years of age with at least one of the following risk factors:
dyslipidemia, hypertension or current smoking, but without established
cardiovascular disease. A large proportion of patients (19.5%) had a di-
agnosis of cardiac specific issues including ischemic heart disease, heart
failure or arrhythmia. Almost 82% of patients had established atheroscle-
rotic CV disease or 2 or more CV risk factors without established athero-
sclerotic CV disease.
Conclusion: This study illustrated that in this dataset a significant pro-
portion of patients with diabetes on SU in 2013 had established CV
disease and/or aggregation of multiple CV risk factors. In light of recent
data on association between SU utilization and CV events and increased
mortality, pharmacovigilance programs should actively monitor SU utili-
zation in patients with diabetes and high risk CV profile in real world
clinical settings.
Supported by: AstraZeneca Canada Inc.
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LEADER-8: Type 2 diabetes patients at high cardiovascular risk: a
comparison of Eastern and Western European participants in the
trial
E. Franek1, M. Haluzik2, on behalf of the LEADER investigators;
1Polish Academy of Sciences, Warsaw, Poland, 2Charles University,
Prague, Czech Republic.
Background and aims: The prevalence of type 2 diabetes (T2D) may
reach 600 million patients worldwide in 2035. There are many regional
and national differences in incidence and prevalence for the disease itself
as well as its complications. The 45 years of separation between Western
and Eastern Europe may have resulted in some of these differences, but
also in distinct differences in the cardiovascular disease (CVD) epidemi-
ology. It is unknown how the baseline demographics and anthropometric
differences for patients with T2D and high risk of CVD vary between
these two regions.
Materials and methods: This study compares metabolic control, diabetic
risk factors and treatment at baseline between regions (Western EU (WEU),
Eastern EU (EEU) and Russia/Serbia (Ru/Se)) in a subpopulation of sub-
jects with T2D and high cardiovascular risk (n=2845) enrolled in the
Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular
outcome Results (LEADER) trial. We performed descriptive statistics to
describe the differences in baseline characteristics among the regions.
Results: HbA1c levels were similar between WEU and EEU, 8.3±1.3%
and 8.3±1.3%, respectively. Western patients were older (65.9 years vs.
62.1, p<0.0001) and had longer diabetes duration (12.4±7.7 years vs 9.5
±6.5, p<0.0001). Mean systolic blood pressure (BP) was lowest for par-
ticipants from Ru/Se (137±14 mmHg), whereas diastolic BP was lowest
in WEU (81.3±9.5 mmHg). Control of dyslipidaemia was best in WEU,
and worst in Ru/Se. The percentage of patients meeting all three guideline
targets for Hba1c (<7%), BP (140/80 mmHg), and LDL cholesterol
(70 mg/dL) was 9.7%, 6.4% and 3.2% (p<0.05) in WEU, EEU and Ru/
Se, respectively. For antidiabetic treatment, metformin and sulphonylurea
treatment was more frequent in the EEU than in WEU. Insulin was used
less frequently in EEU than in WEU and Ru/Se. Statins were used most
frequently in the WEU countries and least frequently in Ru/Se.
Conclusion: In spite of longer diabetes duration and higher age, patients
with T2D and high CV risk from WEU had lower BMI, better blood
pressure and lipid control than those in the EEU. The differences, how-
ever, were small and the percentage of subjects meeting all the three
targets of treatment was low in all regions of Europe, suggesting that
despite socioeconomic differences patients recruited in Europewere over-
all comparable at baseline.
Clinical Trial Registration Number: NCT01179048
Supported by: Novo Nordisk
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LEADER-7: US and European participants in the trial are different:
implications for the interpretation of the trial results
G. Rutten, on behalf of the LEADER investigators;
University Medical Center, Utrecht, Netherlands.
Background and aims: The usefulness of trial results for a particular
clinician depends on how well the trial population mirrors the population
of patients in that clinician’s practice. When participants differ with re-
spect to attributes that modify treatment, the results will be less applica-
ble. We examined whether there are important differences in cardiovas-
cular risk factors among LEADER participants enrolled in the US and in
Europe.
Materials and methods: The Liraglutide Effect and Action in Diabetes:
Evaluation in cardiovascular outcome Results (LEADER) trial in 9340
patients with type 2 diabetes mellitus (T2DM) will provide data on the
cardiovascular safety of liraglutide compared to placebo. Baseline data
from US (n=2488) and European (n=3521) participants were compared,
and stratified for prior cardiovascular disease (CVD). Multivariable lo-
gistic regression analyses were used to determine whether region was an
independent determinant of achieved targets for HbA1c, blood pressure
and LDL-cholesterol.
Results: Irrespective of CVD history, US participants were more often of
non-white origin, had a longer history of T2DM and a higher bodyweight
(Table). They had a 0.5% higher baseline HbA1c and a substantially
lower blood pressure, but were less often at target for their ‘region-spe-
cific’ blood pressure target (OR 0.60; 95% CI 0.42-0.87). They had a
marginally lower LDL-cholesterol level. In the group of patients with
prior CVD less US participants had a prior myocardial infarction
(15.5% vs 19.4%). ‘Region’ was independently associated with partici-
pants being at the HbA1c, BP and LDL-targets, likely partially due to
different diabetes guidelines in Europe and the US.
Conclusion: The differences between US and EU participants and the
role of the region might cause clinically important heterogeneity in treat-
ment effects across regions and subgroups. These differences should be
taken into account in the analysis and reporting of the results.
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Effectiveness and feasibility of a computerised prompt for primary
and secondary care physicians to refer or refer back type 2 diabetes
patients
M.C.M. Ronda1, L.-T. Dijkhorst-Oei2, G.E.H. Rutten1;
1Julius Center for Health Sciences and Primary Care, University Medical
Center Utrecht, 2Internal Medicine, Meander Medical Center, Amers-
foort, Netherlands.
Background and aims: Patients with type 2 diabetes mellitus (T2DM)
are treated according to clear guidelines. However, guidelines on treat-
ment setting (primary or outpatient clinic based care) are mostly lacking.
In the Netherlands, ~85% of T2DM patients are treated by general prac-
titioners in primary care and clear guidelines exist when to refer a patient.
However, many patients are not treated in the correct setting. We intro-
duced an automated signal in the Electronic Medical Record (EMR) of
general practitioners and internists that warns if a patient should be treated
in another setting, i.e. be referred or referred back. This signal gives a
recommendation according to guidelines. We hypothesize that this can
create a shift from primary to secondary care and vice versa in such a way
that only individuals who need intensive diabetes treatment will be of-
fered hospital based diabetes care.
Materials and methods: In a cluster randomized trial general practices
and practices of hospital based specialists who all share a common EMR
were randomized. In the intervention group an automated message in the
EMR popped up to physicians during a consultation if their patients were
not treated in the correct setting; it also recommended the preferred allo-
cation of care. The signal was based onHbA1c, blood pressure, lipids and
end organ damage. In the general practices 3 types of recommendations
were provided: 1. e-consultation with a specialist; 2. referral to specialist;
3. decrease consultation frequency combined with self-monitoring by the
patient. A single patient could be treated according to both recommenda-
tions 1. and 2, depending on treatment values. In the outpatient clinic
specialists could receive only one signal to refer a patient back to the
general practitioner. At the same time, we asked physicians if they would
follow the recommendation and if not, why. The control group provided
care as usual. Follow-up: 12 months. The primary outcome is the change
in proportion of patients who are treated in the right care setting.
Results:We included 38 primary care and 10 specialist practices. Togeth-
er they included 2779 patients (1418 intervention, 1361 control group).
At the start, in the intervention group there were 818 patients (57.7%)
with one or more recommendations to change treatment setting (559 for
e-consult; 451 for referral to specialist care; 53 for self-monitoring and 30
for referral back). In the control group there were 764 patients (56.1%)
who qualified for another treatment setting (501 for e-consult; 417 for
change to specialist care; 49 for self-monitoring and 39 for change to
primary care). After one year, in the intervention group 542 of these
individuals (66.3%) and in the control group 552 (72.3%) still were not
treated in the correct setting (p=0.29). The main reasons for not adhering
to the guideline-based recommendation were: 1) at patient’s request and
2) the current leading physician would like to adjust treatment first.
Conclusion: Over half of T2DM patients are not treated in the correct
treatment setting as stipulated in the DutchNational Guidelines. After one
year this situationwas unchanged in over two-thirds of these patients. The
signal to the treating physician in the EMR had no added value to improve
triage and change treatment setting in this population.
Clinical Trial Registration Number: NCT02229110
Supported by: Stichting Diamuraal and UMC Utrecht
904
Blood glucose and blood pressure related treatment target
achievement: results of the prospective DIALOGUE registry
D. Tschöpe1, R.E. Schmieder2, P. Bramlage3, C. Koch4, T. Ouarrak5,
A.K. Gitt6;
1Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen,
2Schwerpunkt Nephrologie / Hypertensiologie, Universitätsklinikum Er-
langen, 3Institute for Pharmacology and Preventive Medicine, Mahlow,
4Novartis Pharma GmbH, Nürnberg, 5Stiftung „Institut für
Herzinfarktforschung“, Ludwigshafen, 6Herzzentrum Ludwigshafen,
Germany.
Background and aims: Individualized treatment target achievement is
difficult to predict, based on patient characteristics at baseline. Therefore,
we analyzed the baseline characteristics of 6,092 patients included into
the prospective, observational, multi-center DIALOGUE registry in Ger-
many which had a 12 months follow-up to identify patients with good
treatment outcomes.
Materials and methods: A total of 8,594 patients with type-2 diabetes
and hypertension were included of which 6,092 had a 12 months follow-
up and complete data to assess treatment target achievement. Treatment
targets were individually assigned by the physicians to strict, moderate or
loose blood glucose (BG) targets (HbA1c <6.5%; 6.5-<7.0%; 7.0-<
7.5%) and blood pressure (BP) targets (sBP <130 mmHg; 130-<
135 mmHg; 135-140 mmHg).
Results: Out of 6,092 patients 32.3% (n=1,967) had both their blood
pressure (BP) and glucose (BG) controlled at 12 months according to
their prespecified individualized goals. 24.6% (n=1,500) missed their
BG goal, 20.8% (n=1,267) missed their BP goal and 22.3% (n=1,358)
missed both treatment targets. Patients who achieved their individual BP
and BG targets (BP+/BG+) were older, had a shorter diabetes duration
and a lower BMI compared to the other patient groups (p<0.0001). With
a mean admission HbA1c of 7.5±1.3% in this group, 30.4% had a strict
treatment target of HbA1c ≤6.5% assigned which were fewer patients
compared to the other groups (p<0.0001). For this purpose less
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antidiabetic drugs were needed in this group after baseline. The same
pattern was seen for blood pressure targets. With a mean admission BP
of 137.5±14.0 which was less than in the other groups, less stringent
treatment targets were pursued (p<0.0001). On the other hand there
was no difference in the number of antihypertensive drugs used.
Conclusion: In this observational study, blood pressure and blood glu-
cose treatment targets were achieved in a substantial portion of patients
associated with being older, having a shorter diabetes duration and lower
weight.
Supported by: Novartis Pharma GmbH
PS 084 Diabetes devices
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GLP-1 receptor agonist device- and regimen-related features
important to injection-experienced and injection-naïve patients with
type 2 diabetes mellitus: a multinational interview study
S. Grandy1, S. Chen1, E. Flood2, B. Romero2, K. Bergenheim3, A.
Rydén3;
1AstraZeneca, Gaithersburg, , 2ICON, Bethesda, USA, 3AstraZeneca,
Mölndal, Sweden.
Background and aims:GLP-1 receptor agonist injectable treatments for
type 2 diabetes mellitus (T2DM) varywith respect to device and regimen-
related features. The objective of the study was to examine importance
and acceptability of GLP-1 receptor agonist treatment features among
injection-experienced and injection-naïve patients.
Materials and methods: One-on-one interviews were performed with
injection-experienced and injection-naïve patients with T2DM in 5 coun-
tries: Brazil, China, Germany, Japan, and the UK. Interviews were con-
ducted in the patients’ native language by trained interviewers using a
semi-structured interview guide. All patients ranked the importance of 5
device- and regimen-related attributes: dosing frequency, preparation
method, needle size, device size, and need for refrigeration. Injection-
naïve patients also were asked both open-ended and prompted questions
about the acceptability of an injectable medication and the most important
aspects of injection treatment. Interviews were audio-recorded and tran-
scribed into English. A thematic and content analysis was performed
using MaxQDA 11 software.
Results: Fifty patients, 10 in each target country, were interviewed and
included injection-experienced patients (n=28, 56%; n=9, 18%
exenatide QWusers and n=19, 38% liraglutide users) and injection-naïve
patients on oral anti-diabetic medications (n=22, 44%). Mean age was
52.8+12.5 years (range 21 to 79), and 54% (n=27) were male. The 3
most important attributes were the same for both the injection-
experienced and injection-naïve patients; dosing frequency (experienced:
n=23, 82%; naïve: n=18, 82%), needle size (experienced: n=19, 68%,
naïve: n=15, 68%), and injection preparation (experienced: n=16, 57%;
naïve: n=11, 50%). For the remaining two attributes, need for refrigera-
tion was ranked as more important than device size for the injection-naïve
patients. Almost two-thirds of the injection-naïve patients (n=14; 64%)
reported that they would be hesitant to use an injectable treatment. Top
concerns regarding injectable treatment were related to self-injection,
such as knowing how and where to inject, (n=7, 32%), side effects (n=
6, 27%), dosing frequency (n=4, 18%) and preparation involved, includ-
ing amount and ease of preparation (n=4, 18%). Injection-naïve patients
identified important aspects of injectable treatment as needle size (n=13,
59%), the frequency of dosing (n=11, 50%), injection preparation (n=9,
41%), efficacy (n=5, 23%) and device size (n=5, 23%).
Conclusion: Injection-experienced and injectable-naïve patients both
identified dosing frequency, needle size and preparation as the most im-
portant device- and regimen-related attributes. Injection-naïve T2DM pa-
tients have concerns about injectable treatments and are hesitant to begin
this type of therapy. Comprehensive education and support by healthcare
providers on the preparation and proper use of injectable diabetes treat-
ments would be important in relieving patients’ fears and concerns about
self-preparation and administration.
Supported by: AstraZeneca
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Sustained effects of duodenal-jejunal bypass liner on weight loss and
glycaemic control
L.M. Kaplan1, D. Maggs2, A. Liao2, E. Chiquette2;
1Massachusetts General Hospital and Harvard Medical School, Boston,
2GI Dynamics, Lexington, USA.
Background and aims: Behavioral and pharmacologic interventions in
patients with obesity and type 2 diabetes (T2DM) have a poor record of
sustainable efficacy in a real world setting. This has been thought to result
from advancing disease, waning therapeutic potency and progressive
non-adherence to therapy. The safety and efficacy of the duodenal-
jejunal bypass liner (DJBL) for the treatment of patients with obesity
and T2DM has been established during the intended 12-month implanta-
tion period. Possible longer-term effects of DJBL onweight and glycemic
control, after device removal, are not well characterized.We examined the
effects of DJBL on weight and hemoglobin A1c at 12 months of implan-
tation and 6 months after removal.
Materials and methods: Data were extracted from one controlled and
five single-arm clinical studies, involving subjects who completed a 12-
month DJBL implantation period and a 6-month post-explantation fol-
low-up. Data are presented as mean±standard error of the mean.
Results: 56 subjects (aged 51.4±1.0 years; 54% male) with obesity (100
±2.6 kg, BMI 36.1±0.8 kg/m2) and T2DM (A1c 8.4±0.15%) were in-
cluded. The mean implant duration was 368±0.6 days. The mean change
in weight from baseline to 12 months was -10.4±0.96 kg and from
12 months to 6 months post-explantation was 4.75±0.55 kg. The overall
weight change from baseline to 6 months post-explantation was -5.6±
1.01 kg. The percent weight change was -10.3±0.89% at 12 months and -
5.5±0.95% at 6 months after explantation. Themean change in A1c was -
1.05±0.2% from baseline to 12months and 0.19±0.15% from 12months
to 6 months after explantation. The overall A1c change from baseline to
6 months post-explantation was -0.86±0.18%. At 12 months, 43/56
(76.8%) achieved≥5% weight loss. Of these “responders,” 13/43 (30%)
exhibited≤25%weight regain 6 months after explantation. Among the 13
subjects who did not achieve≥5% weight loss at 12 months, 8 (62%)
nonetheless exhibited≥0.5% reduction in A1c at 12 months. Similarly,
38/56 (67%) achieved≥0.5% reduction in A1c at 12 months, and of these
responders, 25/38 (66%) maintained at least 75% of this reduction
6 months after explantation (Figure 1).
Conclusion: DJBL was associated with a significant decline in both
weight and A1c during the 12-month implantation period. At 6 months
after device removal, there was a surprisingly modest increase in weight
and A1c overall. Following a 12-month implantation with DJBL, 30% of
subjects maintained their weight loss and 66% maintained their A1c
6 months after device removal. These observations, if confirmed by lon-
ger post-explantation follow-up, suggest that device may influence the
underlying pathogenesis and progression of obesity and diabetes.
Clinical Trial Registration Number: 00985491, 00985114, 00986349,
01114438, 00985491, 01372501
Supported by: GI Dynamics
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The EndoBarrier® gastrointestinal liner reduces food intake in obese
subjects and improves postprandial glucose metabolism acutely in
obese patients with type 2 diabetes
U. Rohde1, C.A. Federspiel1, E. Langholz1, P. Vilmann2, S.U. Friis1, T.
Vilsbøll1, F.K. Knop1;
1Center for Diabetes Research, Gentofte Hospital, University of Copen-
hagen, Hellerup, 2GastroUnit, Department of Surgery, Herlev Hospital,
University of Copenhagen, Denmark.
Background and aims: The EndoBarrier® gastrointestinal liner is an
endoscopic deployable (and removable) duodenal-jejunal bypass sleeve
(DJBS) developed to treat obesity and type 2 diabetes (T2D). To evaluate
the acute effect of the EndoBarrier® gastrointestinal liner on appetite,
food intake, gallbladder emptying and postprandial glucose excursions
we investigated obese subjects with normal glucose tolerance (NGT) and
obese patients with T2D before and one week after DJBS implantation.
Materials and methods: Eleven obese metformin-treated T2D patients
(diabetes duration: 40±18 months; age: 51±12 years; body weight 108±
18 kg; BMI: 36.6±3.3 kg/m2; fasting plasma glucose (FPG): 9.3±
2.8 mmol/l; HbA1c: 49±11 mmol/mol) and 12 gender, age and BMI-
matched NGT subjects (age: 45±12 years; body weight 102±10 kg;
BMI: 34.3±2.1 kg/m2; FPG: 5.5±0.5 mmol/l; HbA1c: 32±5 mmol/mol)
underwent a standardised 4-hour liquid mixed meal test during which
blood samples were collected, gallbladder emptying measured via ultra-
sound and appetite evaluated using visual analogue scales, and a subse-
quent ad libitum meal before and one week after DJBS implantation.
Results: Postprandial glucose excursions declined significantly after one
week of implantation in obese patients with T2D (AUC: 638±115 vs.
431±83 min×mmol/l, p=0.02), but did not change in the NGT subjects.
NGT subjects experienced significantly greater fullness and satiety and
less hunger and thirst and T2D patients reported less thirst after DJBS
implantation. Food intake during the ad libitum meal decreased signifi-
cantly and similarly in both groups after implantation (NGT: 393±42 vs.
261±34 g, p=0.002; T2D: 463±64 vs. 269±33 g, p=0.02). Gallbladder
emptying did not change in any of the groups.
Conclusion: After only one week of implantation, DJBS improves post-
prandial glucose tolerance in obese patients with T2D and alters satiety
sensation and reduces food intake in obese patients with or without T2D.
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Gallbladder emptying was left intact despite lining of the duodenal mu-
cosa by the device.
Clinical Trial Registration Number: NCT02360878
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Ten months of treatment with endoscopic duodeno-jejunal bypass
liner reduce glycaemic variability and partially restore the incretin
effect in obese type 2 diabetic subjects
M. Mraz1, P. Kavalkova1, P. Trachta1, D. Haluzikova2, Z. Lacinova1, J.
Krizova1, M. Benes3, Z. Vlasakova4, V. Burda5, D. Novak5, T.
Pelikanova4, S. Svacina1, M. Haluzik1;
13rd Department of Medicine, 2Department of Sports Medicine, Charles
University, 3Department of Gastroenterology, Institute of Clinical and
Experimental Medicine, 4Department of Diabetology, Institute of Clinical
and Experimental Medicine, 5Faculty of Electrical Engineering, Czech
Technical University, Prague, Czech Republic.
Background and aims: Duodenal-jejunal by-pass liner (DJBL) is an
endoscopically implantable device designed to non-invasively mimic
the effects of surgical gastrointestinal by-pass operations. The aim of
our study was to comprehensively assess the effects of DJBL on body
composition, glucose control and metabolic and hormonal profile of sub-
jects with obesity and type 2 diabetes mellitus (T2DM).
Materials and methods: Thirty obese patients with T2DM (22 males,
age 51.8±1.8 years) underwent the implantation of the EndoBarrier
DJBL (GI Dynamics, USA). Anthropometric, biochemical and hormonal
parameters were measured before and 1, 6 and 10 months after the im-
plantation of DJBL. Glycemic variability was assessed using continuous
glucose monitoring (CGM). Postprandial effects of DJBLwere evaluated
during a 2-hour liquid meal test (LMT).
Results: Over 10 months the implantation of EndoBarrier lead to a
sustained decrease in body weight (BMI 42.7±1.2 vs. 38.4±1.2, p<
0.05) and body fat (40.2±1.2 vs. 30.5±2.6%, p<0.05) and improvement
in glucose control (fasting blood glucose 12.3±0.7 vs. 9.1±0.7 mmol/l, p
<0.05; HbA1C 75.0±3.4 vs. 55.4±3.8 mmol/mol, p<0.05) accompanied
by reduction of glycemic variability as calculated from a 7-day CGM (SD
2.5±0.2 vs. 1.8±0.2, p<0.05). Conversely, the levels of fibroblast growth
factor 19 (FGF-19), a potent regulator of bile acid synthesis, markedly
increased after implantation (80.3±9.8 vs. 154.4±26.1 pg/ml, p<0.05).
Moreover, EndoBarrier also partially restored the incretin effect 1 month
after insertion (serum GLP-1 at 15 min of LMT 129.7±17.0 vs. 105.8±
12.0 pg/ml, p<0.05).
Conclusion: The implantation of EndoBarrier DJBL leads to a lasting
reduction of body weight and improvement of all measures of glycemic
control. Changes in the incretin system and the increase of FGF19 might
be at least partially responsible for these effects.
Supported by: RVO-VFN64165, SVV260019/2014
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Advanced correction of marked hyperglycaemia with insulin
administered by needle-free jet injection in patients with
insulin-treated diabetes
H.M. de Wit, E.E. Engwerda, C.J. Tack, B.E. de Galan;
Internal medicine, Radboud university medical center, Nijmegen, Neth-
erlands.
Background and aims: Rapid correction of marked hyperglycaemia in
patients with insulin-treated diabetes is important to reduce symptoms
and revert the risk of progression to ketoacidosis or hyperosmolar
hyperglycaemic states. Insulin administered by jet injection may more
rapidly correct marked hyperglycaemia than injectionwith a conventional
pen, because insulin is dispensed over a larger subcutaneous area, facil-
itating faster absorption, especially in patients with body weights above
normal.We compared the pharmacologic properties of the jet injector and
conventional pen for the correction of marked hyperglycaemia by rapid-
acting insulin.
Materials and methods: Adult, overweight or obese (BMI ≥25 and
≤40 kg/m2) patients with type 1 diabetes (n=10) or insulin-treated type
2 diabetes (n=10) were enrolled in a randomized, controlled, cross-over
study. On two separate occasions, after reaching hyperglycaemia (18-
23 mmol/l) by decreasing prior insulin use, they were injected with insu-
lin aspart by jet injection or by conventional pen, in a dose based on an
estimate of their individual insulin sensitivity. Pharmacologic profiles
were derived from plasma glucose and insulin levels, measured for six
hours after injection.
Results: Insulin administered by jet injection resulted in faster correction
of hyperglycaemia (fig 1). Plasma glucose values dropped with
≥10 mmol/l after 147.9±14.4 minutes with jet injection versus 192.5±
13.6 minutes after conventional administration (difference 44.6 [95% CI
4.3- 84.8]; P=0.03). After one hour, plasma glucose had dropped with
4.4±0.3 mmol/l versus 3.0±0.2 mmol/l (P=0.001). The hyperglycaemic
burden was significantly reduced during the first two hours (2041±37.2
versus 2167±26.1 mmol ·min-1 · l-1; P=<0.012). The risk for late
hypoglycaemia was not increased after insulin administration by jet in-
jection. The jet injector performed better in patients with a higher BMI.
Conclusion: Administration of insulin aspart by jet injection resulted in
faster correction of marked hyperglycaemia compared to administration
by conventional pen. The jet injector provided the most benefit in obese
patients who needed high insulin doses.
Clinical Trial Registration Number: NCT01947556
Supported by: European Pharma Group
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Lipohypertrophy: prevalence, risk factors, clinical characteristics,
and economic burden of insulin-requiring patients in China
Z. Sun1, Q. Li2, L. Ji3, G. Qin4, L. Hirsch5, Z. Wei6, J. Liu6, L. Luan6, D.
Wang6, A. Chandran5;
1Endocrinology, Southeast University Zhongda Hospital, Nanjing, 2En-
docrinology, Chongqing MU Affiliated No. 1 Hospital, Chongqing, 3En-
docrinology, Peking University People’s Hospital, Beijing, 4Endocrinol-
ogy, The First Affiliated Hospital of Zhengzhou University, China, 5Di-
abetes Care, BD, Franklin Lakes, USA, 6BD and Company, Beijing,
China.
Background and aims: Lipohypertrophy (LH) is a poorly studied com-
plication of insulin injection/infusion therapy that impairs insulin
absorption/glycemic control. This study aims to understand the preva-
lence, risk factors, clinical characteristics and economic burden associated
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with LH to provide optimal patient care as the insulin-requiring popula-
tion in China grows.
Materials and methods: Prevalence, risk factors and clinical features of
LH patients were evaluated in 4 Chinese cities. Adult patients injecting
insulin by pen ≥1 yr provided detailed information on diabetes/injection
history, injection technique/training, pen needle (PN) reimbursement, and
insulin doses, followed by physical exam and HbA1c testing. Differences
from those without LH were evaluated by Student’s t-test or Wilcoxon
rank sum test. P-values<0.05 were considered significant.
Results: The 401 patients were mean(SD) 59.6(11.5) yrs; BMI 25.4(3.2)
kg/m2; 50% male; 93.5% T2DM. HbA1c=8.0(1.7)%; total daily insulin
dose=33.0(18.4) U with 2.1(1.0) injections daily. Durations of diabetes
and of insulin therapy=11.9(7.6) and 5.6(4.6) yrs, respectively; 95% of
patients reused PNs median 10 (max 360) times; 35.6% had PN reim-
bursement. LH prevalence was 53% overall (range 38-76%), mostly ab-
dominal. Patients with LH had higher BMI and HbA1c, took 11 U
(0.13U/kg or 31.7%) more insulin daily, took more injections, reused
PNs more times and had less PN reimbursement (all p≤0.003) versus
those without LH. LH patients rotated injection sites less and had slightly
more injection training, but these were marginally significant (see Table).
BMI and # daily injections remained significantly associated with LH
prevalence by logistic regression (p≤0.01). Based on an estimated 8.4
million insulin injectors, the cost of excess insulin use associated with LH
is estimated at RMB 3,892,593,600 ($630 million) per year.
Conclusion: LH was present in over half of insulin-requiring patients in
China. LH is associated with worse glycemic control despite higher in-
sulin consumption. Needle reuse frequency, # daily injections, BMI and
lack of PN reimbursement are risk factors, suggesting local tissue trauma
and/or insulin exposure as important contributors to LH development.
Additionally, patients with LH contribute to a significant and avoidable
economic burden in China of up to RMB 3.9 billion due to excess insulin
consumption.
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Insulin injection into regions with lipohypertrophy worsens
postprandial blood glucose versus injections into normal adipose
tissue
L. Hirsch1, U. Hövelmann2, S. Famulla2, L. Hermanski2, A. Fischer2, L.
Heinemann2, M. Kaltheuner3, T. Heise2;
1BD (Becton Dickinson) Diabetes Care, Franklin Lakes, USA, 2Profil,
Neuss, 3Gemeinschaftspraxis Kaltheuner, Leverkusen, Germany.
Background and aims: Lipohypertrophy (LHT) is a common side effect
of long-standing insulin therapy, however, the impact of LHT on insulin
absorption and blood glucose variability has not been investigated sys-
tematically yet. Therefore we compared the effects of subcutaneous insu-
lin (INS) injection into LHT and regions with normal adipose tissue
(NAT) on postprandial blood glucose (BG) control and INS absorption
in 13 patients with type 1 diabetes (mean ± SD age: 50.1±10.1 years,
HbA1c: 7.55±1.15%) during a mixed meal tolerance test.
Materials and methods: Patients received two identical standardised
mixed meals (75 g CHO) separated by at least 6 h, each covered with a
single dose of 0.15 U/kg insulin lispro injected at meal start into LHT or
NAT, in randomised order. LHTwas assessed and confirmed by physical
examination and ultrasound. Pre-meal BG was adjusted to 100±20 mg/
dL. BG and INS (lispro-specific radioimmunoassay) were measured over
5 hours after each mixed meal test.
Results: Injection into LHT led to reduced INS exposure (AUCINS 0-5h
46% lower, p=0.053), which was in line with a less pronounced maxi-
mum exposure versus injection into NAT (Cmax-Ins. 42% lower, p=0.72).
Mean postprandial BG concentrations were significantly increased (17%
higher in the first 2 hours, 58% higher from 2 to 5 h, 39% higher over 5 h,
all p<0.05) after injection into LHT resulting in a 25% increase in max-
imum BG (193 vs. 154 mg/dL, p=0.043) (Figure). In addition maximum
BG concentrations were reached 15 min later after injection into LHT
(TBG-max: 60 min vs. 45 min, p<0.05). Postprandial hypoglycemia (BG≤
50 mg/dL) occurred slightly less frequently with LHT injection (2 vs. 6
patients, p=0.20), whereas postprandial hyperglycaemia (BG≥300 mg/
dL) occurred only with LHT injection (2 patients).
Conclusion: Insulin injection into LHT regions leads to a pronounced
impairment in insulin absorption leading to a deterioration in postprandial
blood glucose control compared with injection into NAT. These results
reinforce the importance of good injection technique, particularly site
rotation, and provide the rationale for patients to avoid injecting insulin
into areas with LHT.
Clinical Trial Registration Number: NCT02221323
Supported by: Becton Dickinson Diabetes Care
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Lipohypertrophy leads to blunted, more variable insulin absorption
and action in patients with type 1 diabetes
S. Famulla1, U. Hövelmann1, A. Fischer1, H.-V. Coester1, L.
Heinemann1, L. Kaltheuner2, L. Hirsch3, T. Heise1;
1Profil, Neuss, 2Gemeinschaftspraxis Kaltheuner, Leverkusen, Germany,
3BD (Becton Dickinson) Diabetes Care, Franklin Lakes, USA.
Background and aims: Lipohypertrophy (LHT) is a common side effect
of long-standing insulin therapy; however, the impact of LHT on insulin
(INS) absorption and efficacy has not yet been investigated using a so-
phisticated method such as the euglycaemic clamp technology. Therefore,
we compared the pharmacokinetics (PK) and pharmacodynamics (PD) of
subcutaneous injection of insulin lispro into abdominal areas with LHT
and normal adipose tissue (NAT) in 13 patients with type 1 diabetes
(T1D) under automated glucose clamp conditions.
Materials and methods: Patients (mean ± SD age: 50.1±10.5 years,
BMI: 26.7±2.2 kg/m2, HbA1c: 7.6±1.2%) received 4 single doses of
0.15 U/kg insulin lispro approximately every 6 hours, twice into a region
with LHT and twice into NAT in random order. LHT was assessed and
confirmed by physical examination and ultrasound. The clamp target
level after dosing was 100 mg/dL and the glucose infusion rate (GIR)
and serum insulin concentration were measured for 5 hours post-dosing.
Results: Mean INS profiles are shown in the figure. Comparing LHT
with NAT injection, LS-mean INS concentrations were comparable dur-
ing the first 30 min (AUCINS0-0.5h 8.8 vs. 9.4 h*mU/L), but significantly
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lower thereafter (AUCINS0-1h 29.3 vs. 41.5 h*mU/L, AUCINS.0-4h 97 vs.
154 h*mU/L, all p<0.02). Maximum INS exposure was reduced by 34%
(CINSmax 49.7 vs. 75.4 mU/L, p<0.002). These differences were reflected
in the GIR profiles: The PD effect in the first 30 min was comparable
between LHT and NAT (AUCGIR0-0.5h 25 vs. 23 mg//kg, p=0.273) but
was significantly and nearly 30% lower after 4 to 5 hours with LHT
injection (AUCGIR0-4h 529 vs. 720 mg/kg, AUCGIR0-5h 576 vs.
803 mg/kg, all p<0.05). Maximum GIR was also reduced with LHT
injection but this did not reach statistical significance (GIRmax 5.5 vs.
6.0 mg/kg/min, p=0.378). Intra-subject variability was substantially
higher after dosing into LHT compared to NAT (coefficients of variation
52 vs. 11% [AUCINS0-4h], 55 vs. 15% [Cmax], and 57 vs. 23% [AUCGIR0-
4h], all p<0.01).
Conclusion: This first glucose clamp study in patients with LHTexplains
clinical experience that both insulin absorption and action are substantial-
ly blunted and considerably more variable when insulin is injected into
areas with LHT. These findings likely also apply to subcutaneous insulin
infusion and warrant further study.
Clinical Trial Registration Number: NCT02221323
Supported by: BD (Becton Dickinson) Diabetes Care
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User interaction are associated with glycaemic control in regular-use
of real-time CGM
L. Bohnett, T. Kent, T. Hall, K. Nakamura;
Dexcom, Inc, San Diego, USA.
Background and aims: The clinical benefit from real-time CGM (RT-
CGM) in the management of diabetes has been demonstrated in many
studies. However, there is limited information reported regarding the
everyday use of RT-CGM. This study was to evaluate relationships be-
tween user interaction, demographics,and glycemic control in real-life
patient daily use.
Materials andmethods: The RT-CGMdatawas voluntarily uploaded by
users seeking diagnostic technical support. The Dexcom G4 Platinum
CGM system records the interaction users have with their alert settings
and logs screen views. The alert settings are a customizable threshold for
when to sound a hypoglycemia or hyperglycemia alarm, while screen
views are button pushes that result in the display of glucose and/or glu-
cose trend information. RT-CGM users’ most common alert settings, the
frequency of their average daily screen views (repeated screen views
within a minute were counted as one view), and their overall glucose
average and standard deviation were compared with age by grouping into
four categories:Seniors (50 YO+), Adults (18 to 49 YO), Adolescents
(12-17 YO) and Children (2-11 YO).
Results: A total of 229 (~50% male) users provided their CGM data and
their demographics. There were ~4.6 M records of CGM data and the
average time of CGM use was 77±68 (mean±s.d.) days. As age in-
creased, average CGM glucose decreased; the highest average glucose
was 9.6±1.9 mmol/l in Children and the lowest of that was 8.1±
1.5 mmol/l in Seniors. The average standard deviations of CGM glucose
were 4.2 mmol/l in Children, 4.1 mmol/l in Adolescents, 3.6 mmol/l in
Adults and 3.3 mmol/l in Seniors. There was a consistent decrease in both
average standard deviation of glucose from one age group to the next. The
majority used the manufacturer default glucose alert settings of 4.4 mmol/
l (for low) and 11.1 mmol/l (for high), 70% and 75% of users, respective-
ly. However, as users increased their low glucose alert settings the average
CGM glucose did as well. There was a positive correlation between the
low glucose alert setting and the average glucose (r=0.313, p<.0001,
displayed in Figure 1). The same relationship was noted between the high
glucose alert setting and the average glucose (r=0.299, p<.0001). Fur-
thermore, an examination of daily average screen views by subject within
age group revealed that Children interacted with their CGM receiver the
most with an average of 59±22 views per day. The next closest group was
Adolescents with an average of 54±48 views per day. On average, Adults
and Seniors viewed their receivers 36 times per day.
Conclusion: This study found an inverse relationship between age and
average glucose, and also found that the older age groups had tighter
glycemic control. Furthermore, CGM alert settings are associated with
glucose levels and variability. Although younger populations interact
with their RT-CGM more frequently, this study suggests there may be
other factors preventing them from tighter glycemic control. The impacts
of user interaction in glycemic control should be evaluated further within
patient age population in a larger scale study.
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Resolution of the main indication and sustainability of long-term
glycaemic control in type 1 diabetes with continuous subcutaneous
insulin infusion
C. Quirós, M. Giménez, R. Paola, D. Roca, M. Vidal, I. Conget;
Diabetes Unit, Hospital Clínic de Barcelona, Spain.
Background and aims: The effectiveness of continuous subcutaneous
insulin infusion (CSII) in Type 1 diabetes (T1D) has been established in
the short-term. However, less information is available regarding the im-
pact on solving main indications for initiating CSII and whether good
control can be maintained over several years. Our objective was to assess
the resolution of the main indication and sustainability of long-term
glycaemic control in T1D using CSII.
Materials and methods: Retrospective observational study including
178 T1D patients who started CSII treatment in our Center (2003-
2008). All patients were followed in our CSII program for outpatients
for at least 5 years. Data on annually HbA1c was collected and the reso-
lution of the main indication for starting CSII was analysed.
Results: 27 out of 178 patients were excluded because of loss of follow-
up or withdrawal fromCSII. 151 patients (37.4±10.5 years, 64%women)
were analysed. The main indications to start CSII were suboptimal met-
abolic control (SMC-group, 60.9%), severe hypoglycaemia/
hypoglycaemia unawareness (H-group, 25.5%) and other (13.6%).
HbA1c at the start of CSII was 8.0±1.2 and 7.8±1.2 after 5 years in the
total cohort (p<0.05). In the SMC-group HbA1c dropped from 8.37±
1.09% to 8.04±1.33% (p=0.016) and 37.4% of patients in this group had
an HbA1c≤7.5% after 5 years. The resolution of the main indication was
obtained in 64% of the SMC-group and 93% in H-group.
Conclusion: CSII therapy maintains long term glycaemic benefits after
5 years of follow up. In addition, themain indication for this treatment can
be resolved in two thirds of T1D patients.
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Optimal glucose control during insulin pump therapy requires self-
monitoring of blood glucose at least six times daily
E. Szymanska-Garbacz, J. Loba, L. Czupryniak;
Medical University of Lodz, Poland.
Background and aims: Due to economical reasons sensor-augmented
pumps are not in common use among type 1 diabetes patients in many
European countries. Subsequently, the subjects treated with continuous
subcutaneous insulin infusion (CSII) are strongly advised to measure
blood glucose (self-monitoring of blood glucose, SMBG) at least four
times a day. However, the minimal frequency of SMBG required for
having optimal glucose control remains unknown. Optimally, individuals
with type 1 diabetes should maintain their HbA1c<6.5%, which is equiv-
alent to the average blood glucose (BG) <140 mg/dl [7.8 mmol/l]. We
conducted a study aiming at identifying minimal frequency of SMBG
which would allow type 1 diabetes patients achieving good metabolic
control.
Materials and methods: The group comprised 40 type 1 diabetes pa-
tients (mean age 27±8 years, diabetes duration 9±8 years, CSII duration
3.1±2.5 years, bodyweight 70±12 kg, BMI 24.2±3.7 kg/m2, HbA1c 7.7
±1.9%, average BG 155±56 mg/dl, number of SMBG 5.7±3.7/day).
Data from 2 last weeks before the study visit were analysed. All subjects
were treated with CSII for at least for 6 months, thus they had obtained
sufficient knowledge about this therapy mode. The pump settings (basal
rate, bolus wizard) were assessed with standard tests.
Results: A negative correlation between the frequency of SMBG and the
average number of capillary BGmeasurements (figure) was revealed (r=-
0.37; p<0.05); the recommended target ofmetabolic control was obtained
in subjects who had performed SMBG at least six times a day.
Conclusion: In conclusion, CSII therapy may lead to good metabolic
control, but the acceptance and willingness of a patient to measure blood
glucose six or more times a day is crucial.
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Continuous subcutaneous insulin infusion in patients with type 1
diabetes: results of a prospective study with three years of follow up
A.Kamaratos, A. Angelidi, S. Vrakas, E. Fousteris, C. Verras, I. Bakalis,
C. Sagia, E. Efstratiadi, A. Bilis, S. Iraklianou, A. Melidonis;
Diabetes Center, Tzanio General Hospital, Piraeus, Greece.
Background and aims: Several studies have found improved glycemic
control with continuous subcutaneous insulin infusion compared with
multiple daily insulin injections for patients with type 1 diabetes albeit
for a relatively short-period of follow-up. This prospective study presents
for the first time the optimization of glycemic control with insulin pumps
in a cohort of Greek patients with type 1 diabetes during a 3-year follow-
up period.
Materials andmethods: Seventy-nine patients (30males), previously on
intensified basal-bolus insulin therapy with poor glycemic control, were
recruited. HbA1c, hypoglycemic and diabetic ketoacidosis episodes,
pump related side effects, lipidemic profile, 24-hour urine albumin excre-
tion, body mass index, blood pressure, total daily insulin requirements
(bolus and basal) were recorded during the 3-year follow-up. Statistical
analysis was initially conducted for the entire study population. Statistical
analysis was performed using STATA 9.0 software.
Results: A statistically significant decrease during the 3 year period of
study was noted for the following parametres: HbA1c (p<0.001), basal
rate (p<0.001), basal/bolus ratio (p<0.001), hypoglycemic episodes (p=
0.007) and total/HDL-cholesterol ratio (p=0.01). On multivariate analy-
sis, an independent and significant association was observed for hypo-
glycemic episodes (95%CI: -0.014 - -0.0038, p=0.001), basal rate
(95%CI: -0.0322 - -0.0148, p<0.001) and total/HDL-cholesterol ratio
(95%CI: -0.1222 - 0.0078, p=0.026). Insulin pump treatment was not
accompanied with weight changes across all body mass index strata.
Conclusion: Continuous subcutaneous insulin infusion achieved almost
optimal glycemic control, reduced hypoglycemic episodes without
weight gain and was well tolerated for the whole study period. Finally,
this therapeutic approach was accompanied with lower daily insulin re-
quirements.
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Long-term glycaemic remission of type 2 diabetes mellitus with
insulin pump therapy regardless of disease duration
S. Choi1, E. Hong1, E. Jeon2, K. Kim2, H. An2, Y. Noh3;
1Internal Medicine, Konkuk University, 2Konkuk University, Chungju,
3Biochemistry, Konkuk University, Seoul, Republic of Korea.
Background and aims: Intensive insulin therapy (IIT) is known to im-
prove β-cell function and induce glycemic remission in newly diagnosed
type 2 diabetes mellitus (T2DM) patients. However, it is not known
whether IIT can induce long-term remission in patients with long
T2DM duration. We aimed to analyze T2DM remission cases achieved
by insulin pumps.
Materials andmethods: The patients who experienced T2DM remission
were included betweenMarch and July in 2014.We collected the medical
records retrospectively and prospectively. Remission is defined as main-
taining normal fasting and postprandial glucose levels for 6 months after
discontinuation of all anti-diabetic medications. Blood samplings were
performed at fasting and 120 minutes after ingestion of a mixed meal
(500 kcal), at baseline and 6 month intervals during the treatment and
follow-up periods. Vales are presented as median (minimum-maximum)
or mean±standard deviation.
Results:Nineteen patients (9 males, 10 females) were enrolled during the
5 months [age at diagnosis, 49 (32-57) years; duration of T2DM, 1.0 (0.0
- 23.0) years]. Two patients (11%) had been newly diagnosed and 17
patients (89%) were on oral anti-diabetic medications before insulin
pump therapy. Baseline HbA1c level was 7.4±2.0%, and total daily in-
sulin dose at the initiation of insulin pump therapy was 50 (22 - 344) IU.
The time to remission was 23 (5 - 108) months and the duration of
remission was 38 (12 - 108) months. During the follow-up of 5.0 (2.3 -
10.4) years, 5 subjects had T2DM relapse. After restart of insulin pump
therapy, 3 subjects had remission again by 4 (3 - 8) months. In 17 patients
with sustained remission, the latest HbA1c level was significantly lower
than the initial level (6.1±0.4 vs. 7.4±2.1%, p=0.017) and their latest
body mass index was not significantly changed (24.7±3.6 vs. 25.7±
4.0 kg/m2, p=0.053). Their disposition index increased from 0.14±0.09
(initial) to 0.34±0.15 (maximum) (p=0.001).
Conclusion: In conclusion, insulin pump therapy improved β-cell
function and induced long-term glycemic remission regardless of
T2DM duration.
918
Glycaemic control in a large cohort of patients with type 1 diabetes
treated with continuous subcutaneous insulin infusion
K. Markakis1, P. Jinadev1, A. Chapman1, A. Urwin1, J. Morris1, A.J.M.
Boulton1,2, M.K. Rutter1,2, L. Leelarathna1,2;
1Manchester Diabetes Centre, 2University of Manchester & Manchester
Academic Health Science Centre, UK.
Background and aims:There is limited data describing glycemic control
in patients with type 1 diabetes (T1DM) treated with continuous subcu-
taneous insulin infusion (CSII) during routine care. In a tertiary referral
center we undertook one of the largest studies of the effectiveness of CSII
in adults with T1DM.
Materials and methods: In T1DM patients with at least 12 months of
CSII therapy we obtained demographic and HbA1c data from hospital
records and central laboratory. For each patient the average post-CSII
HbA1c was computed from results obtained over 30 months since
June 2012. We also compared pre- and average post-CSII HbA1c in the
subgroup with paired data.
Results:We analysed 2079 HbA1c results from 484 patients (% females
57; mean (SD) ; age: 45 (13) years, CSII duration: 4.4 (2.5) years; HbA1c
tests per patient: 4.3 (2.5); time between pump start and average HbA1c
40.4 (27.5) months). Insulin pumps used were: Medtronic: 43%;
Omnipod: 29%; Animas: 14%; Accu-Chek: 13%. There were no differ-
ences in HbA1c comparing different pump users (p=0.65, ANOVA) or
those using catheter pump vs. Omnipod (66 (15) vs. 68 (16) mmol/mol,
p=0.34). CSII therapy was associated with a significant improvement in
glycemic control (N=422 with paired data; mean (SD), pre vs. average
post-CSII HbA1c: 73 (19) vs. 66 (15) mmol/mol, p <0.001, mean (SD)
change -7 (15) mmol/mol). For those with a pre-CSII HbA1c more than
69 mmol/mol, improvements in glycemic control were even larger (N=
224, pre- vs. average post-CSII HbA1c, 86 (16) vs.74 (15), p <0.001,
mean (SD) change -12 (17) mmol/mol) (Figure). Despite improvements
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only 30% of patients achieved good glycaemic control (HbA1c<or=
58 mmol/mol) and 39% of patients had a HbA1c more than 69 mmol/
mol. We found a negative correlation between post-CSII HbA1c and age
(r=-0.17, p=0.001) and diabetes duration (r=-0.23, p=0.001) but no
association with CSII duration (p=0.30). In contrast no demographic
factors were associated with improvements in HbA1c with CSII therapy.
Conclusion: We found significant improvements in glycaemic control
with CSII particularly in those with a higher pre-CSII HbA1c under
routine care conditions. Despite improved control, a large proportion of
T1DM patients treated with CSII have poor glycaemic control, highlight-
ing the challenges of managing T1DM under real-life conditions. Further
work is required to understand the factors associated with poor control.
919
Diabetes distress and fear of hypoglycaemia: What are the psycho-
logical benefits of insulin pump therapy?
C. Shaban, J. Knott, E. Jenkins, M. Weiss, J. Ryder, J. Charman, H.
Partridge;
Diabetes and Endocrine Centre, Royal Bournemouth Hospital, UK.
Background and aims: Living with Type 1 diabetes imposes a consid-
erable burden on the individual to continuously self-manage their condi-
tion. As part of on-going audit the psychological outcomes of insulin
pump therapy were evaluated over a 3 year period.
Materials and methods: Adult patients completed self-report question-
naires at initiation and after 12 months of pump therapy. Diabetes emo-
tional distress was assessed using the Problem Areas in Diabetes Scale
(PAID) and cognitive and behavioural aspects of fear of hypoglycaemia
using the Hypoglycaemia Fear Survey (HFS-W, HFS-B). HbA1c and
demographic data were obtained from the clinical record. Data were
analysed using Predictive Analytic Software (PASW) Version 19.
Results: Data were collected from 142 adults, mean age 40 years (range
15-72), mean duration of diabetes 22 years (range 3-57). Outcomes im-
proved significantly from baseline to 12 months for all variables (mean
(sd)): HbA1c mmol/mol 73.7 (15.6), 63.2 (12.6) p<0.001; PAID 24.6
(15.7), 16.7 (13.22) p<0.001; HFS-W 24.9 (15.9), 16.4 (13.0) p<
0.001; HFS-B 19.1 (10.0), 13.8 (8.9) p<0.001. Paired data analysis did
not indicate an association between HbA1c reduction and reduced PAID
and HFS scores. There was no between group difference in baseline
psychological variables above and below HbA1c <70 mmol/mol and >-
70 mmol/mol.
Conclusion: Pump therapy is associated with improvements in medical
and psychological variables. Whilst a reduction in both diabetes emotion-
al distress, and worries and behaviours related to fear of hypoglycaemia
appear to be unrelated to improvements a reduction in HbA1c, the overall
burden of diabetes indicated by diabetes distress and fear of
hypoglycaemia is reduced significantly 12 months after initiation of in-
sulin pump therapy.
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Is the pump bolus calculator a useful tool or the man behind the
curtain?
E. Omura1, K.M. Miller2, D.M. Maahs3, J.C. Wong4, S. Adi4, R.W.
Beck2, A.L. Peters1;
1Keck School of Medicine of the Unversity of Southern California, Los
Angeles, 2Jaeb Center for Health Research, Tampa, 3Barbara Davis Cen-
ter for Childhood Diabetes, Aurora, 4University of California San
Francisco, , USA.
Background and aims: Currently, little data exist on the utility of bolus
calculators included in insulin pumps. It is unclear if this feature is a
crucial part of pump management, a reflection of user ability, or simply
a device of the program. Their utility depends on multiple factors_how
well they are set up and adjusted by the provider and the patient, whether
or not carb counting is done accurately and if a blood glucose level is
entered into the pump so dose adjustments can be made. The aim of this
analysis is to assess the frequency of bolus calculator use and determine if
there are associations with demographic and clinical characteristics/
outcomes among T1D Exchange clinic registry participants.
Materials and methods: Analysis included data from 1,944 T1D Ex-
change registry participants using an insulin pump who were age≥
13 years with type 1 diabetes (T1D) duration≥1 year (mean age 33.1 years
[range 13.0-83.7], duration 18.8 years [2.2-71.7], 60% female, 93% non-
Hispanic white). Participants who self-reported using a bolus calculator
most of the time or always were counted as frequent users. The most
recent HbA1c from the medical record was used for analysis and frequen-
cies of≥1 diabetic ketoacidosis (DKA) and severe hypoglycemic (SH),
defined as seizure/loss of consciousness, events in the past 3 months were
self-reported. Chi-square tests and t-tests were performed and adjusted
models were conducted using logistic and linear regression.
Results: Among the 1,944 participants, 1532 (79%) reported frequently
using a pump bolus wizard/calculator and 412 (21%) did not. Bolus
calculator use wasmore common among adolescent participants, females,
and participants with shorter duration of T1D and a lower education level
(Table). Use of a bolus calculator was reported by 82% of participants
who frequently check their blood glucose prior to giving a bolus for a
meal vs. 66% among those who infrequently check (P<0.001). Bolus
calculator use was similar among participants who reported giving a bolus
prior to a meal vs. during or after a meal (80% vs. 76%, P=0.06). There
were no significant differences between frequent vs. infrequent use of a
bolus calculator in # of boluses per day (5.4 vs. 5.3, P=0.23), HbA1c
(adjusted HbA1c 8.0% vs. 8.1%, P=0.04), occurrence of DKA in the
prior 3 months (2% vs. 1%, P=0.18), and occurrence of SH in the prior
3 months (6% vs. 7%, P=0.56).
Conclusion: The majority of T1D patients using an insulin pump report
frequently using a bolus wizard/calculator. Yet, in this study frequent use
of the wizard/calculator was not a significant factor in the safe and effec-
tive use of insulin pumps. Common use of the bolus calculator should
drive the development of further technology, as well as support the need
for automatic entry of blood glucose values into the pump.
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Elastargene 3C helps to improve glycated haemoglobin in children
and adolescents with type 1 diabetes using insulin pump therapy
A.E. Scaramuzza1, M. Ferrari1, G. Zuccotti2;
1Paediatrics, University of Milano - Luigi Sacco Hospital, 2Paediatrics,
University of Milano - Ospedale dei Bambini V. Buzzi, Italy.
Background and aims: Elastargene 3C is a cream specifically designed
to improve lipoatrophy in patients with diabetes. It is made by many
ingredients; themost important ones are elastin, arnica, collagen, caffeine,
and L-carnitine. We started a 6-month, double-blind, randomized trial to
test the efficacy of elastargene 3C in children with type 1 diabetes using
insulin pump, in whom infusion set usually left little withe scars.
Materials and methods: Forty children and adolescents using insulin
pump therapy, were randomized into 2 arms: a) n=20 elastargene 3C
once a day on the skin of abdomen or other sites where infusion sets have
been placed, administered before sleeping; b) n=20 placebo once a day
on the skin of abdomen or other sites where infusion sets have been
placed, administered before sleeping. BMI, HbA1c, insulin requirement,
were determined in each child before staring the study and after 6 months.
Results: At the end of the study, 5 patients dropped using the elastargene
cream or placebo and were excluded from the analysis. In elastargene
group, 18 patients with type 1 diabetes were evaluated: age 15.2±
4.8 yrs, diabetes duration 8.0±5.3, time using a pump 4.1±3.0; in the
placebo group, 17 patients with type 1 diabetes were evaluated: age 15.1
±5.7 yrs, diabetes duration 8.3±5.8, time using a pump 4.7±3.0. No
significant difference has been observed for age, disease duration and
time since insulin pump started. HbA1c significantly improved in patients
using elastargene 3C (baseline 8.08±0.80%, after 6 month 7.51±0.53%,
p=0.005, delta -0.53%), but not in placebo group (baseline 7.98±0.74%,
after 6 month 7.76±0.79%, p=0.19, delta -0.22%). No difference has
been observed regarding BMI or insulin requirement. In the elastargene
3C group, withe scars completely disappeared in 8 patients and improved
in 10; in the placebo group withe scars did not change in any of the
patients.
Conclusion: To our knowledge this is the first time that a direct effect of
elastargene 3C have been shown in improving little withe scars that ap-
pear on the skin after infusion set removal in children with type 1 diabetes
using insulin pump therapy. Moreover, HbA1c significantly improved
only in the elastargene 3C group, probably because improved insulin
absorption.
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Effects of advanced carbohydrate counting guided by an automated
bolus calculator in type 1 diabetes (ABC): a 12-month, randomised
clinical trial
E.E. Hommel1, S. Smidt2, D. Vistisen1, M. Gribhild1, K. Neergaard1, T.
Almdal3, K. Nørgaard2;
1Steno Diabetes Center, Gentofte, 2Hvidovre University Hospital, 3Gen-
tofte University Hospital, Denmark.
Background and aims: Advanced carbohydrate counting (ACC) im-
proves metabolic control in patients with type 1 diabetes (T1D). We
studied whether concomitant use of an automated bolus calculator
(ABC) results in further improvement in HbA1c.
Materials andmethods: The study was a 12-month randomised, parallel
group, open-label, single-centre, investigator-initiated clinical trial. ACC-
naïve and poorly controlled T1D adults on multiple daily insulin injec-
tions therapy and HbA1c 64-100 mmol/mol were recruited from a spe-
cialized diabetes centre. Between August 2012 and September 2013, 168
participants (96 men, 72 women) were enrolled and randomly assigned to
receive training in either ACC using mental calculations (MC-group, n=
84) or ACC using an ABC (ABC-group, n=84). All patients received a
3.5-hour group training course in general T1Dmanagement guidelines as
well as theoretical and hands-on training in ACC. The patients were
subsequently followed in routine clinical practice for 12 months. The
primary outcome was change in HbA1c from baseline to 12 months.
Results: Baseline HbA1c was 75.0±8.9 mmol/mol in the MC-group and
73.7±8.1 mmol/mol in the ABC-group. Drop-out rates were similar,
23.8% and 21.4%, respectively (p=0.712); 130 patients completed the
study. At 12months, change inHbA1cwas significant within both groups;
MC-group -2.1 mmol/mol/year (95%CI -3.8 to -0.5, p=0.017) and ABC-
group -4.6 mmol/mol/year (95%CI -6.2 to -3.0, p<0.0001). The decrease
in HbA1c was significantly greater in the ABC-group (p=0.033). No
participants experienced a severe hypoglycaemic episode during the
study. Patients wore a continuous glucose monitoring (CGM) device for
6 days before the intervention and for 6 days after the intervention. Glu-
cose levels were categorized as below, within and above target, using a
target range 3.9-10.0 mmol/l. We compared the distribution of CGM
measurements between the two study groups. At baseline, there was no
difference in time spent in the different target ranges between patients in
the MC-group and the ABC-group. At 12 months, ABC-patients spent a
larger amount of time within target compared with MC-patients (50% vs.
41%, p<0.001) and a smaller amount of time above target (45% vs. 55%,
p=0.002). There was no difference in time spent below target (p=0.902).
Overall, weight increased significantly (p=0.045) but with no indication
of a difference in weight development between the ABC-group and the
MC-group (0.67 vs. 0.24 kg/year, p=0.353).
Conclusion: Twelve months after training poorly controlled adult T1D
patients in advanced carbohydrate counting, patients using an automated
bolus calculator achieved significantly greater improvements in HbA1c
and spent more time in the glycaemic target range.
Clinical Trial Registration Number: NCT02084498
Supported by: Roche; Steno Diabetes center
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Efficacy and safety of standardised glycaemic control in adult and
geriatric hospitalised patients with type 2 diabetes mellitus
K.M. Neubauer1, J.K. Mader1, F. Aberer1, L. Schaupp1, K. Donsa2, T.
Augustin2, P. Beck2, T.R. Pieber1, J. Plank1;
1Division of Endocrinology and Metabolism, Medical University of
Graz, 2HEALTH, Joanneum Research Forschungsgesellschaft mbH,
Graz, Austria.
Background and aims: Insulin therapy as the preferred method is rec-
ommended to achieve glycaemic control in non-critically ill hospitalized
patients with hyperglycaemia. The aim of the study was to investigate the
efficacy and safety of a standardized insulin therapy supported by a com-
puterized algorithm (GlucoTab) in adult (<70 years) and geriatric
(≥70 years) hospitalized patients with diabetes mellitus type 2 (T2DM).
Materials andmethods:The GlucoTab system provided automated dos-
ing for basal-bolus insulin therapy for health care professionals in 191
non-critically ill hospitalized patients with T2DM for 8.3 days. Insulin
therapy was started with a total daily dose (TDD) of 0.5 units per kg
bodyweight in adult patients (<70 years) and 0.3 units per kg bodyweight
in geriatric patients (≥70 years) or in patients with a creatinine value
≥2 mg/dl.
Results: 97 adult patients (30 female, age 60±7 years, BMI 31±7 kg/m2,
creatinine 1.7±1.4 mg/dl, HbA1c 72±26 mmol/mol; mean ± SD) and 94
geriatric patients (48 female, age 77±5 years, BMI 29±6 kg/m2, creati-
nine 1.5±0.9 mg/dl, HbA1c 64±19 mmol/mol) were treated with the
standardized insulin therapy using the GlucoTab system. First provided
TDD was 0.49±0.16 vs. 0.37±0.24 units per kg bodyweight in adult and
geriatric patients, respectively. The overall mean daily blood glucose
value (BG) was 155±33 mg/dl (adult patients) and 157±31 mg/dl (geri-
atric patients). 69.6% vs. 71.8% of BG values were in the range 70-<
180 mg/dl for adult and geriatric patients, respectively. In the range
<70 mg/dl 2.5% vs. 1.3% of BG values occurred in adult and geriatric
patients. In both groups no BG value <40 mg/dl was detected. 25.1% vs.
25.2% and 2.8% vs. 1.7% of BG values were in the hyperglycaemic
ranges of 180-<300 mg/dl and ≥300 mg/dl in adult and geriatric patients,
respectively.
Conclusion: The standardized insulin starting dose suggested by the
GlucoTab with 0.5 and 0.3 units per kg bodyweight supported an effica-
cious and safe glycaemic control for adult and geriatric hospitalized
patients.
Clinical Trial Registration Number: NTC01932775, NCT01766752,
NCT02053077
Supported by: FB7 248590, FFG 844737
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An individualised calculation of insulin dose to correct marked
hyperglycaemia in adult patients with insulin-treated diabetes
E.E.C. Engwerda1, H.M. de Wit2, B.E. de Galan1, C.J. Tack1;
1Internal medicine, Radboudumc, Nijmegen, 2Internal medicine,
Universiteit van Amsterdam, Netherlands.
Background and aims: Marked hyperglycaemia frequently occurs in
patients with diabetes, the correction of which may be difficult because
of glucose toxicity induced insulin resistance and fear that too aggressive
correction may lead to hypoglycaemia. Usually, standard sliding scale
insulin regimens, barely adjusted to and often underestimating individual
needs, are applied both in outpatient and in-patient settings. We tested a
simple formula based on the insulin sensitivity factor (ISF, calculated by
dividing 100 by the total daily insulin dose [TDID]) for the estimation of
the individual insulin dose needed to correct substantial hyperglycaemia
in patients with insulin-treated diabetes.
Materials and methods: This analysis was part of a randomised con-
trolled cross-over trial, comparing the efficacy of two insulin pens to
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correct hyperglycaemia with the rapid-acting insulin analogue aspart.
Adult patients with type 1 or type 2 diabetes on basal-bolus injection or
pump therapy were instructed to decrease insulin doses in order to reach
morning hyperglycaemia (18-23 mmol/l). Subsequently, aspart insulin
was administered subcutaneously in a dose calculated as follows: 1.5
times the difference between the initial and target glucose value (set at
6 mmol/l) divided by the ISF. Plasma glucose levels were determined
during 6 hours thereafter. The primary endpoint was the time in minutes
until plasma glucose concentration had dropped by at least 10 mmol/l.
Results: 20 patients (10 type 1 diabetes, 10 type 2 diabetes, mean age
53.4 years, HbA1c 70 mmol/mol, TDID 96.1 U/day) underwent 40 ex-
periments. Glucose values dropped from 21.3±0.4 to 7.3±0.4 mmol/l
after injection of 21.7±1.9 (range, 8-40) insulin units (figure 1). After
196.2±11.7 minutes, plasma glucose levels dropped below 10 mmol/l.
the fall in plasma glucose was about similar in patients with type 1 com-
pared to those with type 2 diabetes. On 6 (15%) occasions the formula
under-predicted insulin needs, and glucose values dropped to 12.3±
0.5 mmol/l, whereas in 7 (17.5%) occasions over-prediction required
some exogenous glucose administration to prevent hypoglycaemia.
Conclusion: This easy-to-use formula was fairly accurate in calculating
individualized insulin doses to correct marked hyperglycaemia in patients
with insulin-treated diabetes. In the majority of patients, much larger
insulin doses are required than usually recommended.
Clinical Trial Registration Number: NCT01947556
Supported by: europharma group
925
Evaluation of accuracy of continuous glucose monitoring when using
capillary compared to venous samples as reference
M. Andelin1, J. Kropff2, V. Matuleviciene3, J.I. Joseph4, S. Attvall3, S.
Dahlqvist1, H. Imberg5, J. DeVries2, M. Lind3;
1NU-Hospital Organization, Institute of Medicin, Uddevalla, Sweden,
2Department of Internal Medicine, Academic Medical Center, Amster-
dam, Netherlands, 3University of Gothenburg, Sweden, 4Department of
Anesthesiology, Jefferson Medical College of Thomas Jefferson Univer-
sity, Philadelphia, USA, 5Statistiska Konsultgruppen, Gothenburg, Swe-
den.
Background and aims: Accuracy of continuous glucose monitoring
(CGM) is generally evaluated using venous reference samples even
though CGM-systems are calibrated with capillary glucose samples. Ve-
nous glucose might be assessed with higher accuracy and reliability than
capillary samples and can be taken more frequently, and have therefor
become a prerequisite from regulatory perspective. However, capillary
and venous glucose levels differ, and using venous reference could thus
affect measured sensor accuracy. The aim was to evaluate the impact of
using either capillary or venous samples as reference when evaluating
accuracy of CGM calibrated with capillary values.
Materials and methods: We evaluated 41 patients with type 1 diabetes
examined in Sweden. All patients used the DexcomG4 during 6 days and
calibrated their CGM by capillary values (HemoCue meter). At one oc-
casion during days 1-3 and 1 occasion during days 4-6 the patients visited
the research unit for measuring both capillary and venous samples at the
same time using the HemoCue meter. The Mean Absolute Relative Dif-
ference (MARD) and correlation coefficient were used to estimate accu-
racy of CGM in relation to capillary and venous samples. The Wilcoxon
Signed Rank test was used in statistical comparisons.
Results: Mean age was 51 years, 14 (34%) were women, and 31 (76%)
were treated with multiple daily insulin injections (MDI). Mean HbA1c
was 59.3mmol/mol, diabetes duration 23 years and BMI 24.9 kg/m2. The
venous samples were overall 0.83 mmol/l lower than capillary values
(8.15 vs. 8.98), p<0.0001. In values below 4 mmol/l (22 values from
14 individuals) the difference was 1.25 mmol/l, p=0.0001, in the range
4-10 mmol/l (153 values from 38 individuals) 0.67 mmol/l, p<0.0001
and above 10 mmol/l (60 values from 24 individuals) 0.95 mmol/l differ-
ence, p<0.0001. The MARD using capillary values as reference was
11.7% compared to 13.7% for venous samples as reference, p=0.037.
Below 4 mmol/l the MARD was 16.6% and 31.8% respectively, p=
0.048, at 4-10 mmol/ 12.1% and 12.6%, p=0.32, and above 10 mmol/l
8.7% and 9.2% respectively, p=0.82. The correlation coefficient did not
differ using capillary and venous samples, 0.84 and 0.85 respectively, p=
0.75.
Conclusion: Measured CGM accuracy is significantly affected by the
used referencemethod.MARD in the hypoglycaemic range is significant-
ly lower with capillary values as reference as compared to venous sam-
ples as reference. We recommend taking capillary reference values when
evaluating CGM accuracy in the hypoglycaemic range.
Clinical Trial Registration Number: NCT02159638
Supported by: The Region of Västra Götaland, Swedish state, Swedish
Society for Physicians
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Point-of-care assessment of salivary protein glycosylation as a short-
term glycaemic index
C.T. Roberts1, E.S. Bean1, P.V. Rao2, S.R. Nagalla1;
1DiabetOmics, Inc., Hillsboro, USA, 2Nizam's Institute of Medical Sci-
ences, Hyderabad, India.
Background and aims: Assessment of short-term (2 to 3-week) glyce-
mia can complement daily self-monitoring of blood glucose and long-
term (3-month) average blood glucose estimation based onHbA1c levels.
Short-term glycemic monitoring can be particularly useful in individuals
with type-2 diabetes, where occasional HbA1c resultsmay not adequately
reveal significant glycemic fluctuations and the potential for adverse ef-
fects of glycemic variability. A short-term index is also useful in deter-
mining response therapy, where a more rapid determination of efficacy
can enable more efficient treatment regimes. Ideally, a short-term glyce-
mia test would be simple, non-invasive, and feasible in a point-of-care
(POC) format. We have recently described salivary protein glycosylation
(SPG) as a non-invasive biomarker for assessment of glycemia over the
previous 2-3 weekswith performance superior to that of fructosamine and
1,5-anhydroglucitol in comparison to continuous glucose monitoring ref-
erence values. We have now expanded the validation of SPG as a glyce-
mia biomarker in a larger population and have developed a prototype
POC device (Salivary GlyChek).
Materials and methods: One hundred and thirty-two subjects (47 con-
trols with HbA1c less than 5.7 and 85 type 2 diabetes (T2D) subjects with
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HbA1c greater than 6.5) participated in a 4-week study with daily 6-point
capillary blood sugar monitoring (pre and post meal). Fasting and post-
breakfast saliva and serum samples were collected weekly. HbA1c levels
were determined at baseline and at the end of the study. Salivary protein
glycosylation (SPG) was measured using a microplate assay involving
sample oxidation, neutralization, and color development with a chemical
reagent under conditions optimized for detection of fucose and sialic acid
residues. Serum fructosamine was measured using an automated chemis-
try analyzer. The SPG plate assay chemistry was also adapted to a POC
format comprised of a lateral-flow test strip containing multiple zones for
glycoprotein oxidation, neutralization, and color development. A propri-
etary hand-held reader was also developed that utilizes colorimetric dif-
fuse reflectance for quantitative test results.
Results: Classification performance analyses demonstrated mean SPG
levels of 6.3 ug/ml and 9.5 ug/ml in controls and T2D, respectively with
p<0.0001. Mean fructosamine values were 284 umol/L and 480 umol/l in
controls and T2D, respectively with p<0.0001. Baseline fasting blood
glucose correlated better with SPG than with with fructosamine (r=
0.61, p<0.0001 vs r=0.51, p<0.0001). There were no significant differ-
ences between fasting and post-prandial sampling. 7 and 14-day mean
BG measures were strongly correlated with SPG (r=0.82 and 0.88, re-
spectively, p<0.0001). The microplate and POC tests for SPG demon-
strated similar performance (r=0.89), and the prototype POC device ex-
hibited a cv of 8% across the dynamic range of the assay.
Conclusion: The non-invasive GlyChek POC test, in conjunction with
the hand-held reader, can greatly facilitate self-monitoring of T2D by
patients and their clinical management by healthcare providers.
Supported by: R43 DE020973
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Which principles patients with diabetes type 2 and flexible insulin
therapy use for self-adjustment of insulin dose?
G. Kramer1, N. Kuniss1, C. Kloos1, N. Müller1, B. Sanow1, G. Wolf2,
U.A. Müller1;
1Endocrinology and Metabolic Diseases, Internal Medicine III, 2Internal
Medicine III, Jena University Hospital, Germany.
Background and aims:Multiple insulin injection therapy is increasingly
used in the treatment of people with diabetes type 2 (DM2) to improve
metabolic control and reduce hypoglycaemia. Structured treatment and
education programmes for people with flexible preprandial insulin thera-
py provide rules for self-adjustment of insulin dose according to carbo-
hydrate amount of the meal, current blood glucose level, physical activity,
stress or illness, which are extensively trained. The aim of this study was
to analyze current principles and frequency of self-adjustment of insulin
dose and the association with metabolic control in people with DM2.
Materials and methods: In a large university outpatient department for
endocrinology and metabolic diseases over a period of three months 149
people with DM2 with flexible or intensive insulin therapy (mean HbA1c
7.1%, age 65y, diabetes duration 19.0y, female 38.9%, BMI 33.8 kg/m2)
were interviewed. 147 (98.7%) of 149 participants had participated in a
therapy specific structured education programme. Self-adjustment of in-
sulin dose was defined as each change of insulin dosage compared with
the same time the previous day. Additional and skipped injections were
counted as dose adjustments. The type of insulin adjustment, insulin-to-
carbohydrate ratio (insulin units per 10 g of carbohydrate) and the factor
for correction (e.g. 1 insulin unit lowers plasma glucose by 1.5 mmol/l)
were assessed by a structured interview. Two principles for insulin dose
adjustment were set: firstly the use of adjustment patterns/rules, e.g.
insulin-to-carbohydrate ratio and secondly use of personal experience
without a nameable rule. The frequency of insulin dose adjustments
was drawn from the last 28 days of the patients' diary.
Results: Insulin dose adjustment by pattern/rule was used in 33 people
(22.1%) and by personal experience in 111 of 149 participants (74.5%).
People adjusting by rule/pattern were younger (60.9±9.8 vs. 65.7±9.2,
p=0.011) and performedmore insulin dose adjustments per 28 days (50.0
±31.0 vs. 33.4±23.5, p=0.016). HbA1c and incidence of hypoglycaemia
were comparable at time of data collection. People adjusting by pattern/
rule had on average lower HbA1c three years prior to the survey than
people adjusting by personal experience (6.8±0.9 vs. 7.2±0.9%, p=
0.026). Moreover, no differences regarding satisfaction of treatment,
quality of life as well as current well-being was found between the two
groups. In case of high premeal blood glucose levels 77 of 149 partici-
pants (51.6%) reported to use a higher insulin dosage, 30 (20.2%) de-
crease their carbohydrate intake and 42 (28.2%) correct with increased
physical activity.
Conclusion: Patients with DM2 and flexible preprandial insulin therapy
in Germany are specifically trained to adjust their insulin dose using an
insulin-to-carbohydrate factor respectively a factor for correction. Only
22% use this trained concept in daily life. The majority of the patients
adjust their insulin dose by personal experience or feeling. Although
people using insulin-to-carbohydrate ratio adjust their insulin dose more
frequently, HbA1c and incidence of hypoglycaemia is similar compared
to those using personal experience. The importance and effectiveness of
self adjustment of insulin dose by rules has to be examined in a RCT.
928
Two-year clinical study of a mHealth remote diabetes care system:
interim results
K. Brismar1, J. Öhrvik2;
1Department of Molecular Medicine and Surgery, 2Department of Med-
icine, Karolinska Institutet, Stockholm, Sweden.
Background and aims: There is a lack of long-term clinical data from
mHealth interventions in diabetes management. The objective of this
study is to evaluate the clinical and economical effects of Triabetes, a
smartphone and online based decision support tool for coaching of pa-
tients with type 2 diabetes. The system coaches patients on a daily basis
and remotely monitors their progress.
Materials and methods: In a two-year, open-label, parallel-group, mul-
ticenter study, nine private care clinics were randomized in clusters with
healthcare professionals and adult patients (n=225) with type 2 diabetes
(≥6 months) and HbA1c≥53 mmol/mol to usual quarterly follow-up or
use of the smartphone based system with quarterly follow-ups. The pri-
mary endpoint was changes in HbA1c after 6, 12 and 24 months. The
study further measures other clinical biomarkers and patient-reported
health, prescription use and disease progression.
Results: Population characteristics are shown in Table 1. The six-month
median HbA1c change was significantly larger in the intervention group
than in the control group, with a 5.3 mmol/mol reduction (95% CI: -8.5 -
(-2.7); p-value<0.001). A total of 197 patients were included in the anal-
ysis. There were no significant differences in the secondary endpoints.
The study is currently awaiting 12 months results.
Conclusion: Using the Triabetes software in type 2 diabetes treatment
helps reduce long-term blood glucose levels with clinically relevant effects.
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Which mean absolute relative difference is acceptable with respect to
ISO 15197 system accuracy limits?
S. Pleus, G. Freckmann, D. Rittmeyer, T. Leucht, C. Haug;
I n s t i t u t f ü r D i a b e t e s - Te c h n o l o g i e F o r s c h u n g s - u n d
Entwicklungsgesellschaft mbH, Ulm, Germany.
Background and aims: In the literature, the analytical quality of a blood
glucose (BG) monitoring system (BGMS) is often described with respect
to the system accuracy criteria of the international standard ISO 15197.
Sometimes, the mean absolute relative difference (MARD) between the
results of the BGMS and a comparison method is used as well; however,
MARD is more commonly used to describe the analytical quality of
continuous glucose monitoring systems. With regard to BGMS the ques-
tion arises: which MARD corresponds to the system accuracy limits of
ISO 15197?
Materials and methods: In this retrospective analysis, data from system
accuracy evaluations of 69 different BGMS types (96 different test strip
lots) were used to calculate the MARD between the BGMS results and
the corresponding results obtained with the manufacturer’s comparison
method. Additionally, the same data were used to calculate the percentage
of BGMS results within the system accuracy limits of ISO 15197:2003
(±15 mg/dL for BG concentrations below 75 mg/dL, ±20% for BG con-
centrations equal to or above 75 mg/dL) and ISO 15197:2013 (±15 mg/
dL for BG concentrations below 100 mg/dL, ±15% for BG concentra-
tions equal to or above 100 mg/dL), respectively. The system accuracy
data were then used to establish which MARD result will likely lead to
having at least 95% of results within ISO 15197:2003/2013 accuracy
limits.
Results: The MARD results for these 96 test strip lots ranged from 2.8%
to 16.4%. The lowest MARD of a test strip lot that showed <95% of
results within ISO 15197:2003 accuracy limits was 7.5%, whereas the
highest MARD of a test strip lot that showed ≥95% of results within ISO
15197:2003 accuracy limits was 10.2%. For the ISO 15197:2013 accu-
racy limits, the corresponding MARD values were 6.5% and 7.6%, re-
spectively (see Figure).
Conclusion: Based on our analysis we conclude that a BGMS likely has
acceptable analytical quality with respect to ISO 15197:2003, if its
MARD result is below 7.5%. If the BGMS’MARD result is even below
6.5%, the BGMS is likely to have ≥95% of results within ISO
15197:2013 system accuracy limits, thus reaching an acceptable analyti-
cal quality with respect to ISO 15197:2013.
930
Long-term accuracy surveillance of a system for self-monitoring of
blood glucose
G. Freckmann, A. Baumstark, N. Jendrike, T. Leucht, P. Wintergerst, D.
Rittmeyer, S. Pleus;
I n s t i t u t f ü r D i a b e t e s - Te c h n o l o g i e F o r s c h u n g s - u n d
Entwicklungsgesellschaft mbH, Ulm, Germany.
Background and aims: Systems for self-monitoring of blood glucose
(SMBG) require a CE mark to be distributed in the EU. A one-time
conformity assessment, e. g. according to ISO 15197, is sufficient to
obtain such a CE mark. While ISO 15197:2013 was released in 2013,
ISO 15197:2003 is still valid throughout a transition period of 3 years that
ends in 2016. In this study, a CE-marked SMBG system was monitored
over a period of 1.5 years by repeatedly evaluating system accuracy of
different test strip lots.
Materials and methods: A total of 11 test strip lots were evaluated in 4
individual studies between August 2013 and February 2015. System ac-
curacy assessments were performed following procedures described in
ISO 15197 and values obtained with the SMBG system were compared
to a laboratory glucose oxidase method, which is also the manufacturer’s
comparison method. All materials were purchased from pharmacies; stor-
age conditions were controlled and evaluations were performed prior to
the labelled expiration dates. Results were analyzed by applying accuracy
criteria of ISO 15197:2003 and criterion A of ISO 15197:2013 for every
test strip lot individually. ISO 15197:2003 states that for acceptable sys-
tem accuracy at least 95% of results have to fall within ±15 mg/dL at BG
concentrations below 75 mg/dL and within ±20% at BG concentrations
equal to or above 75 mg/dL. Criterion A of ISO 15197:2013 has more
stringent criteria: at least 95% of results have to fall within ±15mg/dL and
±15% for BG concentrations below and equal to or above 100 mg/dL,
respectively.
Results: Out of 11 test strip lots, 9 lots fulfilled the criteria of ISO
15197:2003 with ≥95% of the results within the stipulated limits (see
table). The more stringent criteria of ISO 15197:2013 were fulfilled by
5 test strip lots. The relative bias was between 0.2% and 10.7%. No clear
trend in accuracy could be observed, but lot-to-lot variations between lots
evaluated at the same time seemed to have decreased over time.
Conclusion: This long-term surveillance indicates variations in system
accuracy of a CE-marked SMBG system after market-release. Getting a
CE mark for an SMBG system is a one-time process with long-term
surveillance of system accuracy by manufacturers not being required.
However, consistent acceptable system accuracy of SMBG systems is
an important prerequisite of adequate insulin-based diabetes therapy.
Therefore, regular post-marketing evaluations are important to identify
outliers (such as lot 4) and to ensure continuing compliance with the
respective standards, thus providing people with diabetes the opportunity
of properly managing their diabetes.
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Ultra-rapid BioChaperone insulin Lispro (BC-LIS): linear
dose-response and faster absorption than insulin Lispro (LIS)
G. Andersen1, B. Alluis2, G. Meiffren2, A. Ranson2, C. Seroussi2, M.
Gaudier2, O. Soula2, A. Fischer1, L. Nosek1, T. Heise1;
1Profil, Neuss, Germany, 2Adocia, Lyon, France.
Background and aims: We investigated dose-response and dose-
exposure relationship of BC-LIS, a novel, ultra-rapid formulation of the
insulin analogue lispro using the BioChaperone technology, and LIS.
Materials and methods: Thirty-eight patients with type 1 diabetes
mellitus (age 47.0±11.7 years, BMI 24.7±1.9 kg/m2, HbA1c 7.5±0.8%
[mean ± SD]) were included in this double-blind, randomised, four period
crossover phase IIa study. They received single doses of 0.1, 0.2 or 0.4
U/kg of BC-LIS or 0.2 of LIS under automated euglycaemic clamp con-
ditions (target blood glucose 100 mg/dL, clamp duration 12 h post-
dosing).
Results: Mean baseline adjusted Insulin profiles are given in the figure.
Ultra-rapid properties of 0.2 U/kg BC-LIS were demonstrated with sig-
nificantly earlier time to maximum (tmax) and time to half-maximum
insulin levels (t50% Cmax early), (median tmax 40 vs. 60 min, t50% Cmax early
14 vs. 27 min, both comparisons p<0.0001), greater early exposure up to
2 h (AUC
Ins(0-30min
) 23.2 vs. 9.2 h*mU/L, p<0.0001; AUCIns(0-2 h) 132.3
vs. 122.6 h*mU/L, p=0.0057) and lower late exposure (AUCIns(2-8h) 69.0
vs. 87.6 h*mU/L, p <0.0001) than 0.2 U/kg LIS. BC-LIS had significant-
ly earlier time to half-maximum GIR and time to maximal GIR
(t0.5(GIRmax) 32 vs. 42 min, p <0.0001; tGIRmax 86 vs. 117 min, p=
0.0005), stronger early metabolic effect up to 3 h post-dosing
(AUCGIR(0-3h) 952.8 vs. 812.9 mg/kg, p=0.0090) and lower late metabol-
ic effect (AUCGIR(3-8h) 357 vs. 446 mg/kg, p=0.0115). Total exposure
and total metabolic effect were similar with either BC-LIS or LIS. Dose-
proportionality was established for early and total exposure of BC-LIS
(AUCIns(0-12h) 102 vs 205 vs 444 h*mU/kg, 0.1 vs 0.2 vs 0.4 U/kg) and
dose-linearity for early and total metabolic effect (AUCGIR(0-12h) 726,
1357 and 2422 mg/kg for 0.1, 0.2 and 0.4 U/kg). Ultra-rapid properties
were preserved between doses as shown by unchanged tmax and t50% Cmax
early. Both insulin formulations were well tolerated and no injection site
reactions were observed with BC-LIS.
Conclusion: BC-LIS presents ultra-rapid, dose-proportional absorption,
resulting in significantly improved glucose-lowering effect and dose-
linear gluco-dynamic activity in subjects with type 1 diabetes. In addition,
ultra-rapid properties are preserved at clinically relevant doses of up to 0.4
U/kg. Therefore, BC-LIS has the potential to improve postprandial glu-
cose control versus currently available fast-acting insulin analogues such
as LIS.Dose-proportional early and total exposures of clinically relevant
doses (0.1, 0.2, and 0.4 units/kg) was established for BC-LIS
Clinical Trial Registration Number: NCT02146651
Supported by: Adocia
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Reduced hypoglycaemia is observed with inhaled insulin versus
subcutaneous insulin aspart in patients with type 1 diabetes mellitus
E. Nikonova1, B. Bode2, J. Gill1, J. Stewart3, L. Blonde4;
1Sanofi US, Inc., Bridgewater, 2Atlanta Diabetes Associates, USA,
3Sanofi Canada, Lavalle, Canada, 4Ochsner Medical Center, New
Orleans, USA.
Background and aims: Technosphere Insulin Inhalation Powder (TI) is
a dry powder formulation of regular human insulin adsorbed onto
Technosphere microparticles for oral inhalation in patients with diabetes.
We conducted a post hoc analysis of hypoglycaemia rates from a 24-
week, phase 3 randomized study of prandial TI (N=172) versus insulin
aspart (IA; N=167) added to basal insulin in patients with type 1 diabetes
mellitus (T1DM).
Materials and methods: Annualised hypoglycaemia event rates were
determined in the overall study population, patients taking≥1 postmeal
supplemental dose (TI, n=111; IA, n=91), and patients not taking a
supplemental dose (TI, n=61; IA, n=76). Hypoglycaemia rates during
study weeks 0-12 (dose adjustment) and 12-24 (stable dosing) were
assessed. Hypoglycaemia was defined as total (all events), confirmed
(blood glucose<49 mg/dL), nocturnal (0:00−6:00 AM), and severe (as-
sistance required). Data were adjusted for baseline HbA1c level.
Results: There was no significant difference in the mean number of
supplemental doses taken between the TI and IA arms (34.1 vs 26.6,
respectively; P=0.1907). Significantly higher hypoglycaemia rates
(events per patient/year) were seen for IA versus TI in the overall study
population (total 81.1 vs 55.2; confirmed 15.0 vs 9.0; nocturnal 8.8 vs
5.9; and severe 0.9 vs 0.5; all P<0.05) and patients taking≥1 supplemen-
tal dose (total 96.3 vs 60.9; confirmed 18.6 vs 9.8; nocturnal 11.5 vs 6.5;
and severe 1.1 vs 0.6; all P<0.05). In patients not taking a supplemental
dose, a significantly higher total hypoglycaemia rate was seen with IA
versus TI (64.9 vs 46.0 events per patient/year; P=0.0160). Within each
arm there was a trend for higher total hypoglycaemia rates≥1 hour after
supplemental dosing (events per patient/year) in patients with a higher
supplemental dose frequency (TI vs IA: 0.4 vs 0.4; 1.7 vs 2.2; and 4.9 vs
6.6 for patients receiving 1-5, 6-20, and 21-60 supplemental doses during
the study); there was no significant difference between the TI and IA
arms. In the overall study population, within both treatments arms there
was a trend for a higher rate of all types of hypoglycaemia during weeks
0-12 (titration) versus 12-24 (stable dosing). In patients taking a supple-
mental dose, a similar trend was seen in the IA arm only. In patients not
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taking a supplemental dose, there was a trend for higher total, confirmed,
and nocturnal hypoglycaemia rates during weeks 0-12 versus 12-24 for
IA; and total, confirmed, and severe hypoglycaemia for TI.
Conclusion: These data show that the more rapid onset and offset of
action with TI versus IA was not associated with greater supplemental
dosing. There was a consistently lower hypoglycaemia rate in patients
with T1DM treated with TI versus IA, including those taking supplemen-
tal doses, and during dose adjustment and stable dosing. These data show
that supplemental TI dosing does not result in an increased
hypoglycaemia risk.
Clinical Trial Registration Number: NCT01445951
Supported by: Study funding MannKind Corp/Sanofi US Inc. Editorial
support Sanofi US Inc.
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Higher early insulin exposure and greater early glucose-lowering
effect with faster-acting insulin aspart vs insulin aspart in elderly
and younger adults with type 1 diabetes
U. Hövelmann1, E. Zijlstra1, K. Stender-Petersen2, J.B. Jacobsen2, T.
Heise1, H. Haahr2;
1Profil, Neuss, Germany, 2Novo Nordisk A/S, Søborg, Denmark.
Background and aims: Faster-acting insulin aspart (faster aspart) is a
new formulation of insulin aspart (IAsp), with initial faster absorption
following subcutaneous (s.c.) injection. This single-dose, double-blind,
two period, cross-over trial compared the pharmacokinetic (PK) and phar-
macodynamic (PD) profiles of faster aspart vs IAsp in elderly and youn-
ger adults with type 1 diabetes (T1D).
Materials and methods: Sixty-seven patients (n=37 aged 18-35 years;
n=30 aged ≥65 years) received a single dose (0.2 U/kg body weight s.c.)
of faster aspart or IAsp in a euglycaemic glucose clamp setting (blood
glucose target 5.5 mmol/L (100 mg/dL;duration 12 h post-dose).
Results: For both age groups, onset of appearance with faster aspart
occurred twice as fast (relative difference: 55%, elderly, 47%, younger
adults; Table) than with IAsp (mean difference [95% CI]: elderly, -
2.88 min [-3.83; -1.94]; younger adults, -2.78 min [-4.21; -1.35]), with
a greater early insulin exposure during the first 1 h; total exposure was
similar in both groups (Table). Earlier onset of action with faster aspart vs
IAsp (relative difference: 35%, elderly, 33% younger adults; Table) oc-
curred in both age groups (elderly, -10.17 min [-15.29; -5.06]; younger
adults, -8.70 min [-15.07; -2.34]) and was supported by shorter
t50%GIRmax vs IAsp (elderly, -5.58 min [-8.99; -2.17]; younger adults,
-10.28 min [-15.41; -5.15]). Faster aspart also had a greater early glucose-
lowering effect within 2 h post-dose vs IAsp (greatest [i.e., 2-fold] differ-
ence within the first 30 min; LSmean, mg/kg: elderly, 44.72 vs 21.41;
younger adults, 42.83 vs 20.52); total glucose-lowering effect was similar
[Table]). Treatment effects did not differ significantly between age
groups. Both treatments were well tolerated and no safety issues were
identified, including no injection-site reactions.
Conclusion: Earlier onset and greater early insulin exposure with faster
aspart led to a greater early glucose-lowering effect vs IAsp, which was
retained in both elderly and younger adults with T1D.
Clinical Trial Registration Number: NCT02003677
Supported by: Novo Nordisk
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Insulin degludec/insulin aspart lowers fasting plasma glucose and
rates of confirmed and nocturnal hypoglycaemia independent of
baseline HbA1c levels
J.S. Christiansen1, G. Fulcher2, M. Haluzik3, T.R. Pieber4, H. Rodbard5;
1Aarhus University Hospital, Denmark, 2Royal North Shore Hospital,
Sydney, Australia, 3Charles University, Prague, Czech Republic, 4Medi-
cal University of Graz, Austria, 5Endocrinology and Metabolic Consul-
tants, Rockville, USA.
Background and aims: Individual patient characteristics can influence
the selection of appropriate glycaemic targets by clinicians. The availabil-
ity of individual patient data, including baseline HbA1c levels may im-
prove the achievement of individualised glycaemic targets. IDegAsp, a
novel co-formulation of 70% insulin degludec (IDeg) and 30% insulin
aspart (IAsp) has been previously shown to provide effective glycaemic
control in individuals with type 2 diabetes mellitus (T2DM). This post-
hoc, pooled analysis evaluated the efficacy of IDegAsp vs BIAsp 30 and
IDeg OD + IAsp in adequately controlling glycaemic parameters and
lowering hypoglycaemia in subjects with T2DM stratified according to
baseline HbA1c.
Materials and methods: Data were pooled from five 26-week treat-to-
target phase 3a/b clinical trials in subjects with T2DM in the IDegAsp
clinical development programme. Comparators from the individual trials
were pooled and included biphasic insulin aspart 30 (BIAsp 30) twice-
daily (BID) or IDeg OD + IAsp (2-4 injections). End of trial (EOT)
HbA1c, confirmed and nocturnal confirmed hypoglycaemia, and insulin
dose were stratified according to four baseline HbA1c categories: <7.5%
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(n=263), ≥7.5-<8.5% (n=760), ≥8.5-<9.0% (n=309), ≥9.0% (n=476).
EOT fasting plasma glucose (FPG) was stratified according to baseline
FPG: 5.5-7.0-10.0 (n=523). For each separate group, continuous vari-
ables were analysed using ANOVA and event rates were analysed using
negative binomial regression.
Results: There was no difference in HbA1c EOTacross HbA1c categories
between IDegAsp (n=1111) and the comparator group (n=697). FPG
EOTwas significantly lower in subjects in three baseline FPG categories
(>5.5-7.0-10.0, n=523) with IDegAsp vs comparator (Table 1). Episodes
of confirmed hypoglycaemia were significantly lower with IDegAsp (p<
0.05) (Table 1) as were episodes of nocturnal confirmed hypoglycaemia
in all four HbA1c categories (Table 1). IDegAsp BID vs BIAsp 30 BID
achieved a significant reduction in total daily insulin dose at EOT in
subjects with baseline HbA1c ≥7.5-<8.5% and ≥9.0 (p<0.0001). Similar-
ly, when compared with IDeg OD+ IAsp, IDegAspwas associated with a
significant reduction in EOT daily insulin dose in subjects with baseline
HbA1c ≥7.5-<8.5% (p<0.05).
Conclusion:Nodifferences in EOTHbA1c levels were observed between
IDegAsp and comparator in any of the baseline HbA1c categories.
IDegAsp significantly lowered FPG, particularly when baseline FPG
exceeded 5.5 mmol/L. IDegAsp was associated with significantly lower
rates of confirmed hypoglycaemia and nocturnal confirmed
hypoglycaemia compared with BIAsp 30 and IDeg OD + IAsp, indepen-
dent of baseline HbA1c.
Supported by: Novo Nordisk A/S
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A novel once weekly combination of a long-acting GLP-1R agonist
and an insulin analogue (LAPSInsulin Combo) offers favourable PK/
PD and mitogenic properties
J. Kim1, Y. Park1, C. Lim1, I. Choi1, S. Lee1, Y. Kim1, J. Kang1, M.
Trautmann2, M. Homepesch2, S. Kwon1;
1Hanmi Parmaceutical, Seoul, Republic of Korea, 2Profil institute, Chula
Vista, USA.
Background and aims: Developments of a basal insulin and a GLP-1
agonist combination have received great interest due to greater efficacy
and fewer side effects. However, recently developed combination prod-
ucts still require a once-daily administration, which may negatively affect
treatment adherence. We have developed a long-acting basal insulin and
an exendin-4 analog, LAPSInsulin 115 (HM12470) and LAPSCA-Exendin-
4 (efpeglenatide) with PK indicating that once-weekly administration
would achieve continuous therapeutic plasma levels. This study investi-
gated the PK/PD and mitogenic properties of LAPSInsulin Combo
(HM14220: LAPSInsulin 115 and efpeglenatide combination) in vitro
and in vivo.
Materials and methods: Serum concentration of LAPSInsulin 115 and
efpeglenatide were quantified after single administration of LAPSInsulin
115 and/or efpeglenatide in various species. The Human PK profile of
LAPSInsulin 115 was predicted using WajimaCss-MRT method. A thymi-
dine incorporation assay was performed to evaluate the mitogenic effect
of LAPSInsulin Combo on SaOS2, MCF7, and COLO205 cells. DIO/STZ
rats were chronically treated with LAPSInsulin 115 and/or efpeglenatide.
Blood glucose and weight changes were monitored throughout the study.
At the end of treatment, HbA1c levels were determined. Various dosing
regimens were investigated,including a forced flexible regimen (10 to
50 hr delayed administration at every other dosing).The effect on β-cell
preservation was evaluated by insulin staining of pancreas of db/db mice
after 12 weeks treatment of LAPSInsulin 115 and/or efpeglenatide. A
switching study, with initial administration of either insulin glargine or
liraglutide for 2 weeks, followed by administration of LAPSInsulin Combo
for another 4 weeks in db/db mice was conducted.
Results: After single administration, LAPSInsulin 115 and efpeglenatide
showed harmonized PK without drug to drug interaction. The half-life of
LAPSInsulin 115 and efpeglenatide was determined as 32.2~106.8 h and
38.4~79.6 h, respectively, in rodents and cynomolgus monkeys. Based
on these results, LAPSInsulin 115 half-life in human was predicted as
132 h which was similar to that of efpeglenatide (~140 h).The addition
of efpeglenatide did not alter the low mitogenicity of LAPSInsulin 115
(~5% vs.rh-Insulin) in all cell systems tested. Combined administration
(Q3D) in DIO/STZ rats mimicked human once-weekly administration of
LAPSInsulin 115 and efpeglematide achieved significantly greater HbA1c
reductions (endpoint HbA1c: 4.8±0.25%) relative to the groups treated
with the individual compounds (6.3±0.28% for LAPSInsulin 115; 5.4±
1.3% for efpeglenatide). The improved efficacy was maintained even
after forced-flexible dosing without fluctuation in blood glucose profile.
Moreover, switching from either insulin glargine or liraglutide to
LAPSInsulin Combo led to additional HbA1c reduction. Finally, insulin
staining indicated that LAPSInsulin Combo showed an increased β-cell
mass compared the groups treated with the individual compounds.
Conclusion: LAPSInsulin Combo may offer the convenience of once-
weekly regimen with a potential for flexible dosing together with im-
proved effects on blood glucose for the management of diabetic patients.
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Faster-acting insulin aspart by continuous subcutaneous insulin
infusion: earlier exposure and greater early pharmacokinetic /
pharmacodynamic effects vs insulin aspart
E. Zijlstra1, T. Heise1, T. Rikte2, L. Thorsson2, L. Nosek1, H. Haahr2;
1Profil, Neuss, Germany, 2Novo Nordisk A/S, Søborg, Denmark.
Background and aims: Faster-acting insulin aspart (faster aspart) is in-
sulin aspart (IAsp) in a new formulation with a faster initial absorption
after subcutaneous injection. The aims of this study were to evaluate the
pharmacokinetic (PK) and pharmacodynamic (PD) properties of faster
aspart during continuous subcutaneous insulin infusion (CSII).
Materials and methods: PK/PD properties were investigated in a
randomised, double-blind, crossover trial in 48 patients with type 1 dia-
betes mellitus (mean ± SD age: 46.3±8.6 years; HbA1c: 7.4±0.6% [57±
6 mmol/mol]). Patients received faster aspart or IAsp as a CSII bolus dose
(0.15 U/kg) on top of basal CSII (0.02 U/kg/h) under glucose clamp
conditions (ClampArt; target 5.5 mmol/l [100 mg/dl]; duration 27 h,
13 h run-in, 14 h post bolus dosing).
Results: After the bolus dose, t50% Cmax and tmax (Table) occurred 36%
(12 min [95% CI 9;14]) and 31% (26 min [17;34]) earlier, respectively,
with faster aspart compared to IAsp. Moreover, early insulin exposure in
the first 2 h was greater with faster aspart than IAsp; for example, expo-
sure was threefold greater in the first 30 min for faster aspart (AUCIAsp, 0-
30 min, Table), whereas total exposure was similar (AUCIAsp, Total, Table).
Faster aspart had earlier t50% GIRmax (21%; 11 min [7;15]) and tGIRmax
(14%; 19 min [3;34]) and a greater glucose-lowering effect during the
first 2 h after bolus dosing vs IAsp; whereas total glucose-lowering effect
was similar (AUCGIR, Total, Table). Both treatments were well tolerated.
Conclusion: In summary, faster aspart showed enhanced early exposure
and action compared with IAsp in CSII. Improvements in onset of expo-
sure and action were more pronounced than those previously reported for
subcutaneous injection of faster aspart.
Clinical Trial Registration Number: NCT01992588
Supported by: Novo Nordisk
937
Cardiovascular events and all-cause mortality: effects of dual
therapy intensification with insulin vs glucagon-like peptide-1
analogue
U. Anyanwagu1, J. Mamza1, R. Mehta2, R. Donnelly1, I. Idris1, I. Idris1;
1Division of Medical Sciences and Graduate Entry Medicine, 2Trent Re-
search Design Services, University of Nottingham, UK.
Background and aims: Recent observational studies have raised con-
cerns about the CV safety of insulin therapy in type 2 diabetes (T2DM)
after monotherapy with metformin (MET) has failed to maintain
glycaemic control. We therefore analysed the time to non-fatal acute
myocardial infarction, non-fatal stroke or all-cause mortality in patients
with T2DM who had their treatment intensified with insulin or a
Glucagon like peptide-1 (GLP-1) analogue following dual therapy failure
with MET and SU.
Materials and methods: A retrospective cohort study was conducted in
2003 patients who were newly treated with a GLP-1 or insulin following
dual therapy (MET + SU) failure between 2006 and-2014. Data was
sourced from UK General Practices via The Health Initiative Network
(THIN) database. The risk of the composite outcome (CV events) was
compared between 2 treatment groups: MET+SU+Insulin (N=1584) and
MET+SU+GLP-1 (N=419). Follow-up was 5 yrs (total of 6614 person-
yrs), and propensity score matching analysis and Cox proportional hazard
models were employed.
Results: Mean age was 52.8±14.1 years. Overall, the number of CV
events was 231 vs 11 for patients who added insulin vs GLP-1 respec-
tively, (44.5 vs 7.7 per 1000 person-years adjusted Hazard Ratio (aHR):
0.27; 95%CI: 0.14-0.53; p<0.0001). Insulin was associated with signif-
icant increase in weight compared with GLP-1; (1.78 vs -3.93 kg; p
<0.0001) but HbA1c reduction was similar between both treatment
groups; (-1.29 vs -0.98; p=0.156). In a subgroup analysis of obese pa-
tients, (BMI>30 kg/m2) there were 84 vs 11 composite outcomes (38.6 vs
8.1 per 1000 person-years; aHR: 0.31; 95%CI: 0.16-0.61; p=0.001) in the
Insulin and GLP-1 groups respectively.
Conclusion: Therefore, in this large cohort study tracking outcomes in
routine clinical practice, intensification of dual oral therapy by adding
insulin is associated with a higher risk of CV events, irrespective of
weight compared with adding a GLP-1 therapy as the third oral agent.
938
Rapid-acting insulin lispro products SAR342434 and US-and EU-
approved insulin lispro solution show similar pharmacokinetics and
pharmacodynamics in subjects with type 1 diabetes mellitus
C.Kapitza1, I. Nowotny2, A. Lehmann2, H. Khatami3, K. Bergmann2, B.
Rotthaeuser2, R. Becker2;
1Profil, Neuss, 2Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany,
3Sanofi, Bridgewater, USA.
Background and aims: SAR342434 solution and US- and EU-approved
insulin lispro solution are rapid-acting insulin lispro products. Despite
identical amino sequences, protein-based therapeutics must be shown to
be pharmacologically similar to be approved as biosimilars.We compared
the pharmacokinetics (PK) and pharmacodynamics (PD) of SAR342434
(T) and US-approved (R1) and EU-approved (R2) insulin lispro in a
single-centre, randomized, double-blind, 3-treatment, 3-period, 6-se-
quence, crossover, euglycaemic clamp study.
Materials and methods: 30 male subjects with T1DM (20-59 years)
were randomized to receive 0.3 U.kg-1 T, R1 and R2 in separate periods;
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28 subjects completed all 3 treatment periods. PK and PD (Glucose In-
fusion Rate, GIR) by euglycaemic clamp were assessed up to 12 hours.
Results:Mean concentration and GIR vs time profiles for T, R1 and R2
were similar. Exposure to and activity of T, R1 and R2 were similar
between treatments, with the 90% CI for the ratios of geometric least
squares means contained in the pre-specified bioequivalence limit of
0.80 to 1.25, and non-significant differences in time related parameters
(Table). The within-subject variability of exposure and activity across the
3 clamps was low: 6.8% (90% CI 5.9 to 8.1) for INS-AUC; 15.6% (13.5
to 18.6) for INS-Cmax, 16.7% (14.4 to 19.9) for GIR-AUC0-12; and 15.2%
(13.1 to 18.1) for GIRmax, indicating high day-to-day reproducibility in
clamp performance, regardless of the product. Adverse events were sim-
ilar for T, R1 and R2. No safety concerns were noted in laboratory, vital
signs, or ECG data.
Conclusion: This study demonstrated a similar insulin lispro exposure
profile, PK and PD activity for SAR342434 solution compared to both
US- and EU-approved insulin lispro solution, and between both US- and
EU-approved insulin lispro, rendering SAR342434 a biosimilar candi-
date.
Clinical Trial Registration Number: NCT02273258
Supported by: Sanofi
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Exploratory study of a dose-response curve for basal insulin
C. Shaefer1, L. Traylor2, L. Gao3, T. Dex2, P. Sepe4, N. Skolnik4;
1Georgia Health Sciences University, Augusta, 2Sanofi US, Inc., Bridge-
water, 3Analystat, Somerset, 4Abington Family Medicine, USA.
Background and aims:Many primary care physicians (PCPs) are chal-
lenged by decisions on transitioning their patients with type 2 diabetes
mellitus (T2DM) from basal insulin alone to basal insulin plus prandial
therapy. PCPs often continue to titrate basal insulin beyond a point of
optimal efficacy and, for many patients, this results in inadequate HbA1c
control and increased risk of hypoglycaemia and weight gain. With the
aim of guiding PCPs in utilizing basal insulin properly, we assessed if
there is a diminishing response to increasing basal insulin by performing a
post hoc analysis of 3 insulin glargine titration studies of≥24 weeks
among patients with T2DM.
Materials andmethods:A total of 458 patients were included; mean age
56 years, half were male, mean BMI 33 kg/m2, mean HbA1c 8.7%, and
mean fasting plasma glucose (FPG) 199.6 mg/dL. Ratios for FPG
change:insulin dose change were calculated and plotted at various time
points.
Results: We observed that with increasing dose of basal insulin, FPG
reduction becomes proportionally smaller, levelling at around 0.5 IU/kg
(Figure).
Conclusion: Basal insulin shows a dose-response curve; as the basal
insulin dose approaches 0.5 IU/kg, there is little incremental benefit of
further increasing the basal insulin dose. Therefore, at basal insulin
doses>0.5 IU/kg it may be advisable for PCPs to consider initiating
prandial therapy. In patients requiring high basal insulin doses, decreasing
glucose-lowering responses may be indicative of either a dose-response
curve or a greater degree of insulin resistance. However, despite a dose-
response curve seen at a population level, it is important to stress that
appropriate treatment decisions for patients with T2DM should be based
on individualization of therapy and response.
Supported by: Sanofi US, Inc.
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Excessive daytime sleepiness, daytime napping, and risk of type 2
diabetes: a meta-analysis
T. Yamada, N. Shojima, K. Hara, T. Yamauchi, T. Kadowaki;
Department of Diabetes and Metabolic Diseases, University of Tokyo,
Japan.
Background and aims: Sleep is an important component of a healthy
life, along with a good diet and appropriate physical activity. Excessive
daytime sleepiness is widely prevalent around the world and so is the
habit of napping. Daytime naps are usually brief, but can range from a
few minutes to a few hours. The frequency varies from taking an occa-
sional nap to planned rest periods several times daily for habitual nappers.
Some individuals take a nap because they are excessively sleepy during
the daytime as a result of a sleep disorder. We performed a meta-analysis
to investigate the association between daytime sleepiness or napping and
the risk of type 2 diabetes.
Materials and methods: We searched Medline, the Cochrane Library,
andWeb of Science for articles published up to November 2014 using the
keywords daytime sleepiness, nap, and diabetes. To ascertain the validity
of the eligible studies, the quality of each report was appraised with
reference to the STROBE statement. In addition, the Newcastle-Ottawa
Scale for assessing the quality of observational studies in meta-analyses
was used to quantify the validity of each study. The adjusted relative risk
and 95% confidence interval were calculated with the random effect
model. Dose-response relations were also evaluated. Two observers in-
dependently assessed eligibility, extracted data, and assessed possible
bias. Sex was employed as an independent category for comparison.
Publication bias was evaluated by the funnel plot, Begg’s test, and
Egger’s test.
Results:Among 683 studies initially identified, 261,365 Asian andWest-
ern subjects stratified into 13 categories (reports) were selected. In each
study, analyses were well adjusted for several confounders for diabetes.
Pooled analysis revealed that excessive daytime sleepiness and a longer
nap (≥60 min/day) each significantly increased the risk of type 2 diabetes
by about 50% comparted with the absence of these factors. The relative
risk was 1.56 (95% CI 1.13-2.14, p=0.006) for excessive daytime sleep-
iness, while the relative risk was 1.46 (1.23-1.74, p<0.001) for a longer
nap. In contrast, a shorter nap (<60 min/day) did not increase the risk of
diabetes (0.95 (0.75-1.21, p=0.68)). A dose-response meta-analysis using
the cubic spline model showed a J-shaped relation between nap time and
the risk of diabetes (p for non-linearity=0.003), with no effect of napping
up to about 40 minutes/day followed by a sharp increase in the risk of
diabetes at longer times. Analyses stratified by study location, study qual-
ity, and study type also yielded similar results. Moreover, the funnel plot,
Begg’s test, and Egger’s test did not suggest any evidence of publication
bias.
Conclusion: Excessive daytime sleepiness and taking longer naps were
associated with increased risk of type 2 diabetes, with a short nap not
increasing this risk.
941
Curvilinear associations of irregular sleep patterns during weekends
with glycaemic control in type 2 diabetes: the Hong Kong Diabetes
Registry
A.P.S. Kong1, J. Zhang2, K. Choi3, Y. Zhang1, W. So1, R.C.W. Ma1, Y.
Wing2, J.C.N. Chan1;
1Medicine and Therapeutics, 2Psychiatry, 3Nethersole School of Nursing,
The Chinese University of Hong Kong, China.
Background and aims: Both long and short duration of sleep are asso-
ciated with hyperglycemia. Nonetheless, the associations between glyce-
mia and sleep duration during weekdays and weekends are less well
studied. We examined the associations of glycemic control with sleep
patterns during weekdays and weekends in patients with type 2 diabetes.
Materials and methods: A consecutive cohort of 2,531 type 2 diabetic
patients was studied between July 2010 and February 2013.Wemeasured
indices of glycemic control including glycated hemoglobin (HbA1c) and
fasting plasma glucose (FPG), and sleep parameters including sleep du-
ration during weekdays and weekends, chronotype (a construct capturing
an individual’s preference for being a “morning” or “evening” person)
and social jetlag (a measure of misalignment between biological and
social clocks). Restricted cubic spline (RCS) regressions were used to
examine the relationships between the parameters of glycemic control
and sleep pattern in the present study.
Results: In this cohort, mean age was 54.6 (standard deviation, SD 8.6)
years and mean disease duration of diabetes was 7.9 (SD 7.0) years.
59.5% were men with 60.7% reported to have full or part-time employ-
ment. 4.5% were regular shift-workers. The mean sleep duration was 7.8
±1.4 and 8.4±1.5 hours during weekdays and weekends respectively.
After adjustment for potential confounders including employment and
shift work, we found that chronotype and social jetlag had a significant
U-shaped and J-shaped like relationship with HbA1c and FPG respective-
ly (p for non-linear association=0.002 and<0.001 respectively).
Conclusion: In type 2 diabetes, irregular sleep patterns with excessive
and insufficient sleep compensation during weekends are associated with
poor glycemic control. These novel data underpinned the importance of
regularity of sleep habits and circadian influences in glucose metabolism.
Supported by: Research Grants Council, Hong Kong (CUHK 466711)
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Serum insulin degrading enzyme level and other factors in type 2
diabetic patients with mild cognitive impairment
J. Sun1, B. Zhang2, J. Han1, Y. Yuan1, R. Cai1, P. Wang1, R. Huang1, W.
Xia1, H. Sun1, S. Wang1;
1Department of Endocrinology, The Affiliated ZhongDa Hospital of
Southeast University, 2Department of Medicine, Panda Group Commu-
nity Health Service Centre, Nanjing, China.
Background and aims: Insulin degrading enzyme (IDE) contributes to
the degradation process of insulin and Aβ. We aimed to investigate the
role of IDE in patients with type 2 diabetes patients with mild cognitive
impairment (MCI).
Materials and methods: A total of 146 individuals with type 2 diabetes
were enrolled, including 75 patients with MCI and 71 patients without
MCI. Demographic characteristics, cognitive function and serum IDE
level were examined.
Results: Among patients with MCI, the Montreal Cognitive Assessment
(MoCA) score was positively correlated with serum IDE (r=0.906; p<
0.001) but negatively correlated with fasting blood glucose (FBG) (r=
−0.314; p=0.026), glycosylated hemoglobin (HbAlc) (r=−0.349; p=
0.003), homeostasis model assessment of insulin resistance (HOMA-
IR) (r=−0.619; p<0.001) and glucose fluctuation (r=−0.508; p<0.001).
Spearman rank correlation analysis demonstrated that IDE was positively
correlated with MoCA score (r=0.847; p<0.001) but negatively
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correlated with Trail Making Test B (r=−0.413; p<0.001), FBG (r=
−0.372; p<0.001), HbAlc (r=−0.214; p=0.015), HOMA-IR (r=−0.582;
p<0.001) and glucose fluctuation (r=−0.551; p<0.001) in all subjects. In
logistic regression analysis for MCI, only fasting C-peptide (FCP) (p=
0.003), HbAlc (p=0.056), and IDE (p=0.010) were independent
variables.
Conclusion: This study demonstrated greater likelihood of MCI with
decreasing serum IDE in patients with type 2 diabetes.
Clinical Trial Registration Number: ChiCTR-OCC-15006060
943
Mental disorders, suicidal ideation and diabetes mellitus: data from
primary care
J. Peceliuniene1, N. Mickuviene2, V. Kasiulevicius1, A. Norkus3, R.
Bunevicius2;
1Clinic of Internal Diseases, Family Medicine and Oncology, Vilnius
University Faculty of Medicine, 2Behavioral Medicine Institute of Lith-
uanian University of Health Sciences, Palanga, 3Institute of Endocrinol-
ogy of the Medical Academy of Lithuanian University of Health Sci-
ences, Kaunas, Lithuania.
Background and aims:Data onmental disorders and suicidal ideation in
relation to diabetes mellitus in primary care (PC) are scarce. The aim of
the study was to evaluate the rate and association of depressive, anxiety
disorders, and suicidal ideation in relation to diabetes mellitus (DM) in
PC.
Materials and methods: A cross-sectional study was performed. 1170
adult consecutive patients approached; the final study group consisted of
998 patients. Mental status was evaluated by standard method, by using
MINI International Neuropsychiatric Interview (MINI), performed by
trained investigator (JP). Information on the clinical diagnoses was ob-
tained from patients’ medical records.
Results:Most commonly detected mental disorders were: major depres-
sive episode (MDE) - 15.2%, anxiety disorders - 26.3% (generalized
anxiety disorder (GAD) - 18.1%), alcohol misuse/probable alcohol abuse
- 34.8%. 6.1% of the sample had suicial ideation, according to the MINI.
DM was not the main reason of the visit of the primary care patients to
contact their general practitioner (1.9%). When the probability of having
mood or anxiety disorders amongmales and females according to somatic
diagnosis was calculated, GAD but not MDE had significant association
with both DM and suicidality in all patients (odds ratio (OR) (95% con-
fidence interval (CI)=3.49 (1.35-9.19) and OR (95% CI) =3.26 (1.89-
5.60)), and both were found higher in men, respectively (OR (95% CI)=
6.88 (1.98-23.8) and OR (95% CI)=3.7 (1.2-11.4)). Neurotic illness had
significant association with DM (OR (95% CI)=2.7 (1.09-6.96)) and
suicidality (OR (95%CI)=3.01 (1.76-5.12)) in all patients, andwas found
significantly higher in men with diabetes, and inmenwith suicidality (OR
(95% CI)=5.54 (1.60-19.18) and OR (95% CI)=2.96 (1.60-5.47)) in PC.
The differences of clinic variables between suicidal and non-suicidal pa-
tients were evaluated. Subjects with type 2 DM were at the greatest risk
for suicidality (OR (95% (CI)=4.3 (1.38-13.4), p=0.012), and the risk
was greater than this of both GAD and MDE diagnoses taken together
(OR (95% CI)=3.32 (1.97-5.6), p<0.001).
Conclusion: The rate of depressive, anxiety disorders and suicidal idea-
tion is prevalent in PC. Psychiatric disorders are associated with DM,
especially inmen. Suicidal ideation is associated withmale gender, mood,
anxiety disorders and their coexistence, as well DM in PC. Primary care
patients with type 2 DM have very high risk for suicidal ideation. General
practitioners should be recommended to screen patients with diabetes for
mental disorders and suicidal ideation in their routine practice.
Supported by: The Research Council of Lithuania grant #LIG-03/2011
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Screening for sexual problems among type 2 diabetes patients in
primary care
A. Rutte1, A.M.J. Braamse2, P.J.M. Elders1, P. Van Oppen2, G. Nijpels1;
1General practice and elderly care medicine, 2Psychiatry, VU University
medical center, Amsterdam, Netherlands.
Background and aims: Although sexual problems are prevalent among
men and women with type 2 diabetes, these problems receive little atten-
tion in diabetes care. To identify patients who are dissatisfied about their
sexual functioning, routine screening was performed in primary care as
part of a randomized clinical trial. The aim of this study was to determine
the prevalence of sexual dissatisfaction, sexual problems and need for
help among men and women with type 2 diabetes in primary care.
Materials and methods:Data was collected from January - March 2015
by practice nurses from 40 general practices in the Netherlands. The Brief
Sexual Symptom Checklist for men (BSSC-M) and women (BSSC-W)
was used to screen among 40-75 year old men and women with type 2
diabetes. The BSSC identifies men and women with self-reported dissat-
isfaction about sexual functioning, among who the self-reported type of
sexual problem and need for help is further screened.
Results: In total, 251 patients with type 2 diabetes (61.4% men) were
screened. Mean age did not differ between men and women: 63.2 versus
61.4 years. The prevalence of sexual dissatisfaction was 33.1%, and was
significantly higher among men (39.0%) than among women (23.7%).
Moreover, dissatisfied men were significantly older than satisfied men
(65.1 vs. 61.9 years), yet no significant age difference was observed
among women. Dissatisfied men most often reported erectile dysfunction
(76.7%), low sexual desire (31.7%) and ejaculatory problems (31.7%).
Among dissatisfied women, lubrication problems (52.2%), low sexual
desire (39.1%), and dyspareunia (34.8%) were common. Furthermore,
significantly more men (70.0%) than women (39.1%) wanted to talk
about their sexual problems with their general practitioner.
Conclusion: Preliminary findings suggest that the majority of sexually
dissatisfied men with type 2 diabetes would like help for their sexual
problems in primary care, as well as over a third of dissatisfied women.
Research should further look into the gender differences and their possi-
ble implications for care.
Clinical Trial Registration Number: NTR4807
Supported by: Dutch Diabetes Research Foundation (Grant:
2012.00.1554)
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Living without a spouse/partner and psychosocial health: results of
the second Diabetes Attitudes, Wishes and Needs (DAWN2) study
L.E. Joensen1, I. Willaing1, R.I.G. Holt2, S. Skovlund3, J. Wens4, M.
Peyrot5;
1Health Promotion Research, Steno Diabetes Center, Gentofte, Denmark,
2University of South Hampton, UK, 3Novo Nordisk, Copenhagen, Den-
mark, 4University of Antwerp, Belgium, 5Loyola University Maryland,
Baltimore, USA.
Background and aims: Research has shown that people living without a
partner have lower quality of life compared to people living with a part-
ner. Few studies have explored the association between living without a
partner and poor psychological health in people with diabetes (PWD).
The aim of the current study was to compare PWD living without a
partner to those living with a partner regarding psychosocial health across
countries.
Materials and methods: The present study is part of the DAWN2 study,
a multinational, interdisciplinary and multi-stakeholder study conducted
in 17 countries across four continents. The population comprised 8596
PWD, approximately 500 PWD from each country. Measures included
cohabitation status (living with a partner or not), patient characteristics
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(age, gender, complications, education and diabetes type/treatment and
duration), social support provision (who and how many supports), social
support level (what is the level of the support), and psychological health
(wellbeing, diabetes distress, diabetes impact, worries of hypoglycaemia
and diabetes empowerment). Analyses used multiple regression (linear
and binary) to control for potential confounding with patient characteris-
tics. The analyses examined whether associations between cohabitation
status and psychological outcomes were mediated by social support.Mul-
tilevel regression models were applied to adjust for clustering within
countries. Data were weighted in comparison with the general population
in each country by age, gender, region and level of education.
Results: About one third of PWD lived without a partner, and there were
significant country differences in the proportion of PWD living without a
partner. Compared to PWD living with a partner, PWD living without a
partner more often had type 1 diabetes than type 2 diabetes (p=0.004),
more frequently were women (p<0.0001), had higher rates of complica-
tions (p<0.0001), were younger (p=0.002) but had longer diabetes dura-
tion (p=0.014). There was no significant association between cohabita-
tion status and education. PWD living without a partner more frequently
experienced lack of social support (p<0.01), were less empowered (p=
0.001) and the proportion with high depressive symptom scores was
larger (18% vs. 12%, p<0.0001) compared to PWD living with a partner.
Significant differences with regards to diabetes distress and worrying
about night time hypoglycaemia were found, however, these differences
were small and probably clinically insignificant. There was no significant
difference between PWD living with or without a partner on overall
diabetes impact. Overall, the associations between cohabitation status
and different psychological outcomes were not fully mediated by social
support. The associations between cohabitation status and poor psycho-
logical health varied by (interacted with) age, diabetes type and country.
Conclusion: The study indicates social and psychological vulnerability
of PWD living without a partner. Further research is needed into the
mechanisms underlying this association. In order to enhance psycholog-
ical health in PWD living without a partner appropriate support interven-
tions have to be developed and tested.
Supported by: Novo Nordisk A/S
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Development and evaluation of a psychometric instrument to assess
problems related to illness acceptance in diabetes: the Denial versus
Integration of Diabetes Scale (DIDS)
A. Schmitt, A. Reimer, D. Ehrmann, B. Kulzer, T. Haak, N. Hermanns;
Research Institute of the Diabetes AcademyMergentheim, Diabetes Cen-
ter Mergentheim, Bad Mergentheim, Germany.
Background and aims: Insufficient diabetes acceptance has been asso-
ciated with reduced self-care and glycaemic control. However, satisfac-
tory tools to measure diabetes acceptance are lacking. Therefore, the
Denial versus Integration of Diabetes Scale (DIDS) was developed. This
report presents its development and preliminary evaluation.
Materials and methods: 56 items were generated and revised based on
patient feedback and expert reviews (27 directed towards acceptance/
integration, e. g. ‘I accept diabetes as a part of my life’, 29 towards
denial/non-acceptance/avoidance, e. g. ‘I often push diabetes to the back
ofmymind’). A four-point Likert scale (3 - ‘applies tome verymuch’ to 0
- ‘does not apply to me’) was used for responses. Negatively keyed items
were reverse-scored; hence, higher scores indicate higher acceptance. The
items were tested in a pilot study with 222 patients (age 49±16 y.; 49%
female; BMI 30±7; 64% type 1 DM; duration 17±11 y.; HbA1c 8.5±
1.7%) to exclude unsatisfactory items and define the scale. A subsequent
validation study is recruiting; at the time of this report, 66 patients (age 48
±13 y.; 46% female; BMI 28±5; 62% type 1 DM; duration 14±10 y.;
HbA1c 8.0±1.0%) had been included, providing data on diabetes non-
acceptance (AADQ), self-care (DSMQ), treatment satisfaction (DTSQ),
diabetes distress (PAID), depression (PHQ-9) and HbA1c (central lab).
Analyses comprised item and scale properties, exploratory factor analyses
(EFA), correlations and t-Test.
Results: Item selection: Initially, 5 items were excluded for psychometric
problems. Through EFA, 8 items were excluded for loadings on non-
interpretable factors, finally yielding an interpretable four-factor structure.
Based on this, 11 items were excluded for poor statistical or semantic fit
and 4 for redundancy, leading to the final 28-item scale. Scales/reliability:
EFA of the selected items yielded four factors (71% explained variance),
interpreted as ‘acceptance/integration’ (7 items, Cronbach’s α=0.93),
‘treatment motivation’ (7 items, α=0.93), ‘denial/defence’ (7 items, α=
0.91) and ‘emotional suffering’ (7 items, α=0.92). The derived subscales
were highly correlated, providing summing to a reliable total score (α=
0.97). Reliability was again tested on the validation sample, yielding the
followingα coefficients (scales in above order): 0.91, 0.91, 0.90, 0.87 and
0.96. Validity: A correlation of -0.76 (P<0.01) was found with the
AADQ, a measure of diabetes non-acceptance. The correlation with
HbA1c was -0.45 (P<0.01). Patients with higher DIDS scores (suggesting
higher acceptance; n=34) compared to those with lower ones (n=32;
median split) reported better self-care, particularly regarding diet (6.4±
1.9 vs. 4.0±2.0, P<0.01), glycaemic self-management (8.7±1.9 vs. 7.1±
2.3, P<0.01) and physician visiting (9.2±1.3 vs. 7.9±3.3, P<0.01), and
showed better glycaemic control (HbA1c: 7.6±1.1 vs. 8.3±1.1%,
P<0.05). They also reported higher treatment satisfaction (30±4 vs. 24
±6), less diabetes distress (21±15 vs. 37±16) and less depressive symp-
toms (6±4 vs. 9±6); all P<0.01.
Conclusion: The DIDS appears reliable and valid in assessing problems
related to illness acceptance in both major types of diabetes. It may help
explain inadequate self-care and suboptimal glycaemic control. Further
data to expand these initial findings are being collected.
Supported by: ‘Competence Network for Diabetes mellitus’ (FKZ
01GI1107)
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Sleep and health-related quality of life in adults with type 2 diabetes
S.T. Johnson1, W. Qiu2, C. Mundt2, F. Al Sayah3, J.A. Johnson4;
1Centre for Nursing & Health Studies, Athabasca University, 2Alliance
for Candian Health Outcomes in Diabetes, University of Alberta, Edmon-
ton, 3Alliance for Candian Health Outcomes in Diabetes, University of
Alberta, Athabasca, 4School of Public Health, University of Alberta, Ath-
abasca, Canada.
Background and aims: Sleep is becoming recognized as an important
behavior for metabolic control and mental health. The aim of this study
was to examine the relationship between objective estimates of sleep
quantity and quality and health-related quality of life (HRQL) in adults
with type 2-diabetes (T2DM).
Materials and methods: Adults with T2DM were recruited as a sub-
sample of a large ongoing cohort study in Alberta, Canada. Participants
completed an extensive survey of health status and health-related behav-
iours. HRQL was measured with the SF-12 version 2, which provides
Physical and Mental Composite Summary (PCS and MCS) scores, and
the EQ-5D (5-Level) index score. Participants also wore an accelerometer
(Actigraph GT3X+; 60-epochs @ 30Hz) on their wrist during sleep pe-
riods over 7 consecutive days, to derive nightly estimates of total sleep
time (TST), sleep latency (SLAT) and sleep efficiency (SEFF) calculated
using total number of sleep minutes divided by self-reported number of
minutes in bed. Multivariate linear regression models, adjusting for age,
sex, diabetes duration, BMI, depressive symptoms, medical comorbidi-
ties and household income, were used to examine the association between
accelerometer-derived TST, SLAT and SEFF and the PCS, MCS or EQ-
5D index scores.
Results: Average age of participants (N=168) was 65 years (SD 10),
BMI 31(6.5) kg/m2, 46% female, with a diabetes duration 13(9) years.
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Average TST and SLATwere 451.1 (59.1) and 9.9(7.6) minutes, respec-
tively and SEFFwas 82.7 (6.1)%.Multivariate regressionmodels showed
an inverse association between TST and PCS where every additional
60 min of sleep was associated with a 1.31 unit lower PCS (p=0.036);
there was no relationship between TST and MCS (p=0.86). SEFF was
positively associated with both PCS and MCS, where a 10% greater
SEFFwas associated with 2.73 units higher PCS (p=0.005) and 1.77 unit
higher MCS (p=0.056). SLAT was not associated with either PCS or
MCS, and there were no significant relationships with any sleep variable
and the EQ-5D Index.
Conclusion: Among adults with T2DM, both sleep quantity and quality
are important contributors to HRQL. An inverse relationship was ob-
served between the quantity of sleep and physical health in this sample,
but the magnitude of this difference was quite small. Regardless of the
quantity of sleep, better sleep quality (efficiency) was associated with
better physical and mental health.
Supported by: Alberta Health
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Coping skills and quality of life of adolescents with type 1 diabetes
A. Lukács1, V. Bánóczki1, A. Nagy2, K. Mayer1, L. Barkai1,3;
1Faculty of Health Care, University of Miskolc, 2Faculty of Health Sci-
ences, Semmelweis University, Budapest, 3Velkey László Center for
Child Health, Miskolc, Hungary.
Background and aims:Biological-psychological changes of puberty are
a major challenge in the treatment and care of diabetic patients. In these
ages, the adolescents develop various coping strategies that determine
stress tolerance, quality of life (QoL) in their later life. The ultimate goal
of diabetes management is to achieve good QoL perception. In our re-
search, we compared the coping skills (resilience level) (RL), QoL and
glycemic control (GC) in patients with type 1 diabetic adolescents; and
we also aimed to examine the effect of regular exercise and use of insulin
pump.
Materials and methods: Two hundred and twenty-nine patients with
type 1 diabetes (118 males and 111 females) participated in the study.
Their mean age was 15.38±2.37 years. Diabetic young people were re-
cruited from 3 Diabetes Outpatient Clinics of the country. QoL was
assessed with the Pediatric Quality of Life Inventory 3.0 Diabetes Mod-
ule. Coping skills were evaluated with the Resilience Scale-15 that was
completed with an additional question regarding the regular exercise. GC
was indicated with the HbA1c measured during the assessment. Data
were analyzed with F-probe and regression analysis using the SPSS
22.0 statistical software.
Results: Regular exercise had a positive impact both on RL (F(2,225)=
8.627, p<.001) and QoL (F(2,223)=6.476, p=.002), whereas the use of
insulin pump positively affected QoL (F(1,225)=14.502, p<.001) and
tended to affect the GC (F(1,222)=2.948, p=.087). In our regression
model, RS was predicted by regular exercise (β=-.207, t=-3.395,
p=.001) and QoL (β=.374, t=6.153, p<.001) (R=.476, R2=.226).
QoL was predicted by gender (β=-.148, t=-2.482, p= .014), RL
(β=.383, t=6.381, p<.001) and intensive insulin therapy modality
(β=-.209, t=-3.389, p=.001) (R=.472, R2=.223). GC was significantly
predicted by QoL (β=-.138, t=-2.102, p=.037) and family background
(β=-.187, t=-2.852, p=.005) (R=.239, R2=.057). Independent predic-
tors were age, gender, diabetes duration, HbA1c, intensive insulin therapy
modality (1=CSII, 2=MDI), RS, QoL, family background (1=1 parent,
2=2 parents, 3=other), and financial background (1=below average, 2=
average, 3=above average)
Conclusion: In addition to the healthy physical development, regular
exercise can positively affect the diabetic adolescents’ coping skills and
QoL. Treatment with insulin pump therapy, male gender and higher RL
seemed to be determining factors of better QoL. Favorable GC showed
relationship with better QoL and living in intact family. The main goals in
diabetes treatment and care are to achieve as good GC and QoL as pos-
sible. Some factors cannot be controlled as gender, family and financial
background, but improving and developing coping skills, treating with
insulin pump therapy and encourage patients to exercise regularly seems
effective way to achieve the aims.
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Incidence of hypoglycaemia in patients with type 2 diabetes mellitus
recently initiating basal insulin in a real-world US setting
M. Kazemi, F. Ye, M.R. Dalal;
Sanofi US, Inc., Bridgewater, USA.
Background and aims: Hypoglycaemia and fear of hypoglycaemia re-
main major barriers to persistence with insulin therapy. This retrospective
cohort study of electronic medical record (EMR) data examined the inci-
dence of hypoglycaemia soon after insulin initiation in US patients with
type 2 diabetes mellitus (T2DM) and if they are at a greater risk of insulin
discontinuation.
Materials and methods: The Predictive Health Intelligence diabetes
dataset integrates anonymous de-identified EMR patient-level data from
20 Integrated Delivery Networks in the USA, with>325 hospitals and
300,000 providers (including some of the largest integrated delivery net-
works in the US). This was used to identify adult patients with T2DM
who initiated basal insulin therapy (defined as having no prescription of
basal insulin≥12 months before initiating insulin glargine, insulin
detemir, or NPH insulin) between January 2008 and March 2013.
Hypoglycaemic events were identified by health care encounters with
ICD-9-CM diagnosis codes for hypoglycaemia, or blood glucose
values≤70 mg/dL (≤3.89 mmol/L) during the first 6 months of basal
insulin use. Discontinuation was defined as a gap of>45 days in insulin
prescription coverage. A baseline was established using 12-month pa-
tient-level data prior to insulin initiation and the follow-up period was
6-24 months; all data were reported descriptively. Data were adjusted for
confounders using Cox regression analysis for time to basal insulin
discontinuation.
Results: Of 49,062 patients with T2DM identified, 5,159 (10.5%) expe-
rienced hypoglycaemia within the first 6 months of insulin use; 44%were
identified using ICD-9-CMdiagnosis codes and the remaining 56% using
blood glucose values. Patients experiencing hypoglycaemia, versus those
without hypoglycaemia, were older (mean age: 63 vs 60 years; P<
0.0001) with 49% aged≥65 years; had more comorbidities (Charlson
Comorbidity Index: 1.21 vs 0.67; P<0.0001); had more experience of
hypoglycaemia during the baseline period (18.9% vs 4.5%; P<0.0001);
and a greater proportion had a health care utilization during the baseline
period (inpatient visits: 20.1% vs 8.7%; P<0.0001). During the follow-up
period, 68.1% of patients with hypoglycaemia experienced their first
event in the first 3 months of treatment. In patients experiencing
hypoglycaemia, versus those without hypoglycaemia, discontinuation
of insulin therapy was higher at 6 months (58.7% vs 45.5%; P<0.0001)
and at 12 months (68.1% vs 53.9%; P<0.0001). Data adjusted for con-
founders showed that patients with hypoglycaemia had almost twice the
risk of discontinuation over 12 months compared with those without
hypoglycaemia (hazard ratio 1.90; 95% CI 1.82-1.98; P<0.0001).
Conclusion: This study illustrates an incidence of hypoglycaemia as high
as 10% in a US setting of patients with T2DM initiating basal insulin, and
that these patients are at greater risk of discontinuation of their basal
insulin therapy.
Supported by: Sanofi US, Inc.
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Comparison of findings from the HAT study, the largest global
hypoglycaemia study to date, with prior large real-world studies
U. Pedersen-Bjergaard1, S. Alsifri2, R. Aronson3, M. Cigrovski
Berković4, G. Galstyan5, M. Goldfracht6, H. Gydesen7, R. Kapur7, N.
Lalic8, B. Ludvik9, E. Moberg10, A. Ramachandran11, K. Khunti12;
1Endocrinology Section, Hillerød Hospital, Denmark, 2Al Hada Military
Hospital, Taif, Saudi Arabia, 3LMC Diabetes and Endocrinology, Toron-
to, Canada, 4University Hospital 'Sestre Milosrdnice', Zagreb, Croatia,
5Endocrinology Research Centre, Moscow, Russian Federation, 6The
Technion, Haifa, Israel, 7Novo Nordisk A/S, Søborg, Denmark, 8Clinic
for Endocrinology, Diabetes and Metabolic Diseases, University of Bel-
grade, Serbia, 9Medical University of Vienna, Austria, 10Karolinska
Institutet, Stockholm, Sweden, 11India Diabetes Research Foundation,
Chennai, India, 12University of Leicester, UK.
Background and aims: HAT (Hypoglycaemia Assessment Tool) was a
non-interventional, 6-month retrospective and 1-month prospective real-
world study to determine the extent of hypoglycaemia in 27, 585 people
from 24 countries. The study outcomes were compared with similarly
designed large real-world studies.
Materials and methods: A systematic literature search of PubMed
(1995-2014) for population-based studies of people treated with insulin,
excluding clinical trials and reviews, identified comparable reports of
proportions of people experiencing hypoglycaemia or rates of events
experienced. The study results that met the inclusion criteria were com-
pared with prospective HAT data (see Table).
Results: Overall, severe and nocturnal hypoglycaemia rates varied wide-
ly between the studies identified and the HAT study (see Table). Estimat-
ed annual hypoglycaemia rates for Northern Europe and Canada in the
HAT study (91.6 [T1DM]; 18.1 [T2DM]) were similar to or slightly
higher than comparable studies identified in the search. However, in the
HAT study, rates for overall hypoglycaemia in T2DM were higher for
Latin America, Eastern Europe and Russia than for Northern Europe/
Canada and lower for the Middle East and South East Asia. Rates for
overall hypoglycaemia in T1DM in the HAT study were highest in Latin
America and much lower in South East Asia. Similarly, severe and noc-
turnal hypoglycaemia rates for Northern Europe/Canada in the HATstudy
were comparable with other studies but differed from other regions in the
HAT study. Comparable data from prior studies in non-US/European
regions are sparse.
Conclusion: Findings from the HAT study revealed that more evidence
from large, international, non-US/Europe-based real-world studies is
needed, and highlighted that the rates of hypoglycaemia in some regions
of the world may be higher than previously suggested by Europe and US-
based studies. Reasons for these variations and optimisation of diabetes
care in these regions are needed.
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Clinical Trial Registration Number: NCT01696266
Supported by: Novo Nordisk A/S
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Seasonal variations of severe hypoglycaemia in patients with type 1
diabetes and type 2 diabetes in a German population
T. Wohland1, O.-M. Patzer2, T. Tiemann3, J. Holstein4, P. Kovacs1, A.
Holstein2;
1IFB AdiposityDiseases Leipzig, University of Leipzig, 21st Department
of Medicine, Lippe-Detmold Hospital, 3Outpatient Diabetes Center,
Rinteln, 4Medical Department, Division of Nephrology and Internal In-
tensive Care Medicine, Charité University Medicine Berlin, Germany.
Background and aims: Severe hypoglycemia (SH) is associated with a
critical prognosis. In addition to its acute life-threatening potential, SH
may increase cardiovascular and all-cause mortality irrespective of dia-
betes type. Our aim was to highlight seasonal changes in SH and the
corresponding clinical circumstances in patients with type 1 diabetes
(T1DM) and type 2 diabetes (T2DM) in a German population under the
conditions of real life.
Materials and methods: Prospective population-based observational tri-
al. All SH occurred between 2007 and 2014 in a large tertiary care hos-
pital in a rural area (200.000 inhabitants) were captured. SH was defined
as a symptomatic event requiring treatment with intravenous glucose or
administration of glucagon and being confirmed by a blood glucose mea-
surement of <50 mg/dl. Seasons were scaled according to meteorological
conditions. Statistical significant differences between diabetes groups
were calculated using the Student’s t-test and chi-square test. Furthermore
one-way anovawith post-hoc LSD-test was used to investigate significant
differences between the seasons within a diabetes group.
Results: A total of 1080 episodes of SH in 747 patients were registered:
37.5% of cases were related to T1DM, 51.7% to T2DM, 3.2% to
pancreoprivic diabetes and 7.6% occurred in non-diabetic individuals.
The 405 cases of SH in T1DM comprised 206 subjects. The 558 cases
of SH in T2DM occurred in 453 subjects. In T1DM 50.1% and in T2DM
16.1% of hypoglycemic episodes were related to only 31 respectively to
23 patients who experienced ≥3 SH. Most tested basic parameters (e.g.
age, HbA1c, Charlson comorbidity index, creatinine-clearance, impaired
awareness of hypoglycaemia) between patients with T1DM and T2DM
were statistically significant (all p<0.001). In cases with T1DM we ob-
served significantly increased prevalence of SH in spring (27.7%) and
summer (28.6%) vs. autumn (21.5%; p=0.04 and p=0.02 respectively)
and winter (22.2%; p=0.04 vs. summer). In contrast, there was a more
balanced and not significant seasonal distribution of SH in subjects with
T2DM (winter 25.3%, spring 26.0%, summer 25.1%, autumn 23.5%).
Surprisingly, we found no significant variation in seasonal HbA1c and
insulin dose in subjects with T1DM. However, at the scene of emergency
there were significant lower initial blood glucose levels in spring (29.2±
11.1 mg/dl) vs. autumn (32.7±10.1 mg/dl) and a significant lower fre-
quency of blood glucose self-measurement per week in spring (30.1±
11.4) vs. summer (33.0±12.9). In cases with T2DM we revealed a sig-
nificant higher HbA1c in spring (7.0±1.6) compared to autumn (6.6±
1.0).
Conclusion: Individuals with T1DM and SH clearly distinguish from
those with T2DM and SH. We found an increased frequency of SH in
patients with T1DM in spring and summer which was probably due to
short-term impacts like more physical activity or possibly higher alcohol
consumption during these warmer seasons. Better seasonal adaptation of
insulin therapy in subjects with T1DM could be an appropriate approach
to prevent SH. For the cohort of mostly multimorbid geriatric patients
with T2DM there was no seasonal effect for the risk of SH.
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Incidence, predictive factors and direct costs of severe
hypoglycaemia: results from the prospective HYPO.15 study
N.S. Chevalier1, P. Böhme2, A.-S. Durand-Lugger3, A. Bassand2, J.
Vouillarmet4, N. Marchant4, C. Maisondieu5, S. Fontaine6, B.
Nicolascu-Catargi7, F.-L. Velayoudom-Céphise8, V. Chingan-Martino8,
I. De Lameth9, R. Desailloud9, P. Hanon10, GEODE Group;
1Endocrinologie-Diabétologie, CHU de Nice, 2CHU de Nancy, 3CH
d'Epinal, 4Hospices Civils de Lyon, 5SAMU 75 - Hôpital Lariboisière,
Paris, 6Hôpital Joseph Ducuing, Toulouse, 7CHU de Bordeaux, 8CHU de
Pointe-à-Pitre, 9CHU d'Amiens, 10Lifescan, Issy-les-Moulineaux,
France.
Background and aims: Severe hypoglycaemia (SH) is the most serious
side effect of insulin therapy and has been associated with an increased
risk ofmortality. However, few data are available concerning its incidence
and/or its direct cost. The observational, prospective, multicenter, French
HYPO.15 study assessed the incidence of SH in patients with type 1 or
type 2 diabetes.
Materials and methods: Emergency care units of 9 French University
Hospital consecutively enrolled all patients with SH (diagnosed accord-
ing to ADA criteria) during at least 3 months. The primary endpoint was
frequency of confirmed SH. Secondary endpoints included predictive
factors of SH and estimation of direct costs, including costs of emergency
care and hospitalizations' costs.
Results: We included a total of 811 patients. Incidence of SH was esti-
mated to 0,63 SH/100 patients/year (20 433 SH/year in France). Charac-
teristics of the 811 patients were: median age 61,3±21,1 years (59,3 years
in men vs. 64,0 years in women; p=0,002); duration of diabetes<5 years
for 10,3% and duration of diabetes>10 years for 75,9%; previous history
of SH during the past year in 62%. SH happened at home for 86,4% of the
patients, during the morning (7 h-13 h) for 31,8% of them (23,8% in the
afternoon; 22,7% in the evening and 21,7% during the night). 92,4% of
the patients used insulin therapy, alone in 82,3% and together with oral
anti-diabetics (OAD) in 10,1%. Patients with insulin therapy alone were
younger (58,1 yrs vs 72,7 yrs for OAD + insulin and 76,1 yrs for OAD
alone; p<0,0001). Sulfonylureas were used by 51% of patients with OAD
alone, but only in 20% of patients with OAD + insulin (p=0,0005),
whereas use of repaglinide was similar in both groups (38%). Median
glycemia was 37±17 mg/dL. Fasting (43%), infection (26%) and treat-
ment misuse (17%) were the most frequent etiologies of SH in our cohort.
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55,5% of patients stayed at home after intervention of emergency care
unit, 25,6%were brought to the hospital for a short monitoring and 15,6%
were hospitalized for more than one night. Rate of hospitalization de-
pends of treatment and was increased for patients with OAD alone (44,
8% vs 16,9% for OAD + insulin and 10,4% for insulin alone; p<0,05).
Direct cost of SHwas estimated to 47 834 978 € for 20 433 SH per year in
France, which represents a mean cost by SH of 2 341 €.
Conclusion: HYPO.15 is the first prospective study giving the high in-
cidence and the direct costs of confirmed SH in patients with type 1 and
type 2 diabetes in France, underlying the importance of optimizing pa-
tients’ treatment regimens and education. Previous history of SH and
male gender appears to be the main predictive factors for SH.
Supported by: Lifescan, a Johnson & Johnson company
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Regional variation in patient definitions and rates of hypoglycaemia:
findings from the HATstudy of 27,585 people with type 1 and type 2
diabetes on insulin
K. Khunti1, M. Cigrovski Berković2, P. Geelhoed-Duijvestijn3, B.
Ludvik4, E. Moberg5, J. Barner Lekdorf6, H. Gydesen6, U. Pedersen-
Bjergaard7;
1Diabetes Research Unit, University of Leicester, UK, 2University Hos-
pital 'Sestre Milosrdnice', Zagreb, Croatia, 3Medical Centre Haaglanden,
The Hague, Netherlands, 4Medical University of Vienna, Austria,
5Karolinska Institutet, Stockholm, Sweden, 6Novo Nordisk A/S, Søborg,
Denmark, 7Nordsjællands Hospital Hillerød, Denmark.
Background and aims: Hypoglycaemia is an important concern for
people with diabetes, but how individuals understand and define
hypoglycaemia remains unclear. The Hypoglycaemia Assessment Tool
(HAT) study was a non-interventional assessment of self-reported
hypoglycaemia. This post-hoc analysis aimed to determine patient knowl-
edge of hypoglycaemia and associated reporting.
Materials and methods: HAT was conducted in 24 countries using
questionnaires and diaries (28-day prospective period) in 27, 585 adults
with type 1 (T1DM) or type 2 diabetes (T2DM) using insulin for
≥12 months. The patient diary defined confirmed hypoglycaemia as a
blood glucose (BG) level <3.9 mmol/L. Patients recorded in the diary if
hypoglycaemia was based on BG levels, symptoms of hypoglycaemia or
both.
Results: Most respondents (96.8% and 85.6% of patients with T1DM
and T2DM, respectively) knew the ADA/EASD hypoglycaemia defini-
tion (see Table). However, in some regions, many patients actually iden-
tified hypoglycaemic events from symptoms alone. Reported
hypoglycaemia rates varied substantially between regions, with SE Asia
having a relatively high rate of unconfirmed symptomatic
hypoglycaemia. Rates of severe hypoglycaemia also varied widely be-
tween regions, both for T1DM and T2DM, with lower rates in N Europe
and Canada.
Conclusion: Regional variations in patient definition of hypoglycaemia
may contribute to the global variations in rates of hypoglycaemia reported
in the HAT study. Discrepancies between patient definitions in different
countries and guidelines may highlight a need to redefine the criteria of
hypoglycaemia.
Clinical Trial Registration Number: NCT01696266
Supported by: Novo Nordisk A/S
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Self-reported hypoglycaemia and mortality in type 2 diabetes
patients treated with insulin in the diabetes care system West-
Friesland, Netherlands
S.P. Rauh, F. Rutters, G. Nijpels, A.A. van der Heijden, I. Walraven, P.J.
Elders, M.W. Heymans, J.M. Dekker;
VU University Medical Center, Amsterdam, Netherlands.
Background and aims: Tight glucose control trials and observational
studies based on medical records have suggested that objectively mea-
sured hypoglycaemic events are associated with cardiovascular events
and mortality in patients with type 2 diabetes (T2D). However, little is
known about self-reported hypoglycaemia, as experienced in everyday
life, and the associated risk on mortality in the general T2D population in
usual care. Further, no observational studies have focused on the associ-
ation between hypoglycaemia and mortality in insulin users. Our aim was
to study the association between self-reported mild and severe
hypoglycaemia and mortality in T2D patients in usual care treated with
insulin.
Materials andmethods:Demographics, clinical characteristics and mor-
tality data were obtained from 1,667 T2D patients treated with insulin in
the Diabetes Care System West-Friesland, the Netherlands.
Hypoglycaemia was self-reported, including complaints like dizziness,
dreaming, feeling restless, headache when getting out of bed, hunger,
mood swings, palpitations, snoring, night sweats, tingling sensations
around the mouth, and trembling. Mild hypoglycaemia was defined as
events not requiring help from others, while severe hypoglycaemia was
defined as events requiring help from other persons (either medical or
non-medical). Logistic regression analysis was used to analyse the asso-
ciation between hypoglycaemia and mortality during follow-up. In addi-
tion, generalized linear models with an offset variable were used to allow
for differences in follow-up duration.
Results: During a median follow-up of 1.9 years, 804 participants (48%)
reported no hypoglycaemia, 744 (45%) reported only mild and 119 (7%)
reported severe hypoglycaemia. During follow-up, 98 patients (5.9%)
died. Reporting only mild hypoglycaemia was significantly associated
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with lower mortality risk during follow-up (OR: 0.48, 95%CI 0.29-0.81),
while reporting severe hypoglycaemia was not significantly associated
with mortality (OR: 0.77, 95%CI: 0.33-1.80), compared to reporting no
hypoglycaemia. These results were adjusted for age, sex, diabetes dura-
tion, HbA1c levels, hypertension, smoking, sulfonylurea use, and micro-/
macro-vascular complications. Sensitivity analyses showed an OR of
1.38 (95%CI 0.31-6.11) for patients reporting severe hypoglycaemia re-
quiring medical assistance, and 0.57 (0.23-1.46) for patients reporting
severe hypoglycaemia, but not requiring medical assistance. Further, no
significant interaction was found between mild and severe
hypoglycaemia during follow-up. Finally, allowing for differences in
follow-up duration did not lead to different results.
Conclusion: We observed that insulin-treated type 2 diabetes patients
reporting mild hypoglycaemia had a lower mortality risk during a median
follow-up of 2 years compared to patients reporting no hypoglycaemia. A
possible explanation for this finding might be the concept of hypo-un-
awareness. If this finding is confirmed in other studies, it may be
reassuring for T2D patients and their physicians to know that experienc-
ing hypoglycaemic sensations not requiring medical help is associated
with reduced short-term mortality risk.
Supported by: Novo Nordisk A/S
955
Increase in hospital admissions, length of hospital stay and outpatient
visits in diabetes patients one month and one year following severe
hypoglycaemic events events
A. Karasik1, D. Goldstein2, V. Shalev2, B.L. Thorsted3, L. Elliott4, G.
Chodick2;
1Institute of Endocrinology, Sheba Medical Center, Tel-Hashomer,
2Maccabitech, Maccabi Healthcare Services, Tel Aviv, Israel, 3Epidemi-
ology, Novo Nordisk A/S, 4Market Access, Novo Nordisk A/S, Søborg,
Denmark.
Background and aims: Severe hypoglycaemia is a burden for the patient
and payer alike. In this study, we aimed to quantify the resource use
associated with a severe hypoglycaemic event (SHE) in patients with
diabetes using the database of Maccabi Healthcare Services (MHS), a
large Health Management Organization in Israel.
Materials and methods: This retrospective, non-interventional study
compared resource use 1 month and 1 year pre and post SHE. Data
collected by the MHS database included overall as well as detailed health
utilisation data per patient. Patients were included if they had a diagnosis
of diabetes and experienced a SHE, as identified by diagnosis codes in the
MHS database, from 2005-2014.
Results: From 2005-2014, a total of 4376 patients were eligible for in-
clusion in the study, out of approximately 100,000 patients with diabetes
in theMHS registry. The study population consisted of 6.4%T1D, 75.2%
T2D and 18.4%with diabetes type undefined. Mean characteristics of the
study population were age 64.5 years, HbA1c 7.4%, BMI 29.5 kg/m2,
47.9% male, 42.9% insulin-treated and 60.5% were treated with oral
drugs that may cause hypoglycaemia (sulphonylureas or meglitinides).
Diabetes duration (years) was <5 in 20.4%, 5-9 in 45.2% and 10+ in
34.4% of cases. At baseline (time of SHE), 42% of patients had a cardiac
comorbidity and 73% had hypertension. Hospital admissions increased
significantly (P<0.001) in the month following a SHE (Figure). Of those
admitted to hospital (n=1418), the mean duration of stay was significant-
ly (P<0.001) longer during the month post (5.59 days) vs pre SHE
(4.37 days). In this period, outpatient visits increased by 46% (12557 vs
18441, P<0.001). The greatest increases were in visits to endocrinolo-
gists (+169%), nurses (+70%) and dieticians (+66%). The number of
hospital admissions also increased in the 1 year post vs the 1 year pre
SHE (Figure), corresponding to a 38% increase in hospitalisations (P<
0.001), and there was a 13% increase in outpatient visits (P<0.001) dur-
ing this period. The mean duration of hospital stay increased from 4.81 to
6.82 days during the 1 year pre vs post SHE (P<0.001), however it is
recognised that other factors could influence the data over the 1 year time
period.
Conclusion: This real-world data analysis indicates an increased use of
healthcare services, including more frequent and prolonged hospital ad-
missions and outpatient visits after a SHE.
Supported by: Novo Nordisk A/S
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Incidence of severe hypoglycaemia in 2006 and 2011 in consideration
of the medication in Germany: analysis based on health insurance
data
N. Müller1, C. Kloos1, B. Gerste2, M. Hartmann3, U.A. Müller1;
1Endocrinology andMetabolic Diseases, Internal Medicine III, Jena Uni-
versity Hospital, 2Wissenschaftliches Institut der AOK (WIdO), Berlin,
3Department of Pharmacy, Jena University Hospital, Germany.
Background and aims: New antihyperglycaemic agents are advertised
to offer effective glycaemic control while reducing the risk of
hypoglycaemia. The aim of this study was to analyze the development
of the incidence of severe hypoglycaemia from 2006 to 2011 in
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consideration of the medication, based on AOK (largest health insurance
in Germany) routine data.
Materials and methods:All adult insured persons with diabetes mellitus
type 2 (extrapolated to the German population: 6.6 million in 2006 and
7.9 million in 2011) were screened for severe hypoglycaemia (identified
by ICD 10 coding) which requires hospitalization or emergency use.
Antihyperglycaemic agents were identified by ATC-Code and Defined
Daily Dose (DDD) of the respective medication was calculated.
Results: There was a slight increase in the incidence of severe
hypoglycaemia in 2006 (0.04%, n=28.892) to 2011 (0.05%, n=
33.741). Persons with severe hypoglycaemia were older (69.7y vs.
73.8y in 2006 and 70.1y vs. 74.4y in 2011) and 46.5% in 2006 and
56.2% in 2011 had nephropathy. In 2006 8.3% (n=2.412 of 28.892) of
all persons with severe hypoglycaemia had sulfonylureas as monotherapy
and 8.9% (n=565.862 of 6.3 Mio.) of the persons without severe
hypoglycaemia (DDD 214 with vs. 248 without severe hypoglycaemia).
In 2011 the prescription of sulfonylureas as monotherapy was significant-
ly lower, 4.4% (n=1.471 of 33.741) of persons with as well as without
severe hypoglycaemia (n=330.175 of 7.5 Mio.) (DDD 252 with vs. 309
without severe hypoglycaemia). A combination therapy of biguanides
and sulfonylureas had 17% (n=4.926 of 28.892) of the persons with
and 12.7% (n=804.757 of 6.3 Mio.) of the persons without severe
hypoglycaemia in 2006 (DDD of this combination therapy was 480 with
vs. 577 without severe hypoglycaemia). In 2011 this combination therapy
applied 14.2% (n=4791 of 33.741) of the persons with severe
hypoglycaemia and 10% (n=749.878 of 7.5 Mio.) of the persons without
severe hypoglycaemia (DDD 518 vs. 664). A combination therapy of
short and long acting human insulin used 17.1% (n=4.941 of 28.892)
of the persons with and 4% (n=254.588 of 6.3 Mio.) of the persons
without severe hypoglycaemia in 2006 (DDD 481 vs. 563) and 14.4%
(n=4.851 of 33.741) of the persons with and 3.4% (n=257.357 of
7.5 Mio.) of the persons without severe hypoglycaemia in 2011 (DDD
491 vs. 592). A combination therapy of short and long acting analogue
insulin was present in 6.1% (n=1.761 of 28.892) of the persons with and
1.3% (n=81.898 of 6.3 Mio.) of the persons without severe
hypoglycaemia in 2006 (DDD 558 vs. 589) and 12.4% (n=4.200 of
33.741) of the persons with and 2% (n=153.014 of 7.5 Mio.) of the
persons without hypoglycaemia in 2011 (DDD 570 vs. 628).
Conclusion: Comparing 2006 to 2011 showed a significant reduced pre-
scription of sulfonylureas as monotherapy, a slightly reduced use of hu-
man insulin and a significantly increased prescription of analogue insulin.
Despite the changes in drug prescription there was a slight increase in
overall incidence of severe hypoglycaemia from 2006 to 2011.
PS 090 Hypoglycaemia: recognition
and avoidance
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Continuous Subcutaneous Insulin Infusion (CSII) and fear of
hypoglycaemia in patients with type 1 diabetes: five years of study
M. Carreira1, M.S. Ruiz de Adana2, A. Orozco3, F. Linares2, M.
Fontalba2, M. Guerrero2, M.T. Anarte1;
1Department of Personality, Assessment and Psychological Treatment,
University of Malaga. Instituto de Investigación Biomédica de Málaga
(IBIMA), 2Unidad de Diabetes. Servicio de Endocrinología y Nutrición.
Hospital Regional Universitario, Málaga. Biomedical Research Centre in
Diabetes and AssociatedMetabolic Disorders (CIBERDEM). Instituto de
Investigación Biomédica de Málaga (IBIMA), 3Department of Personal-
ity, Assessment and Psychological Treatment, University of Malaga,
Spain.
Background and aims: Fear of hypoglycemia is one of the factors as-
sociated with poor adherence to diabetologic treatment. 1) To assess the
effect of CSII in fear of hypoglycemia in patients with type 1 diabetes
(DM1) after 5 years of treatment. 2) Analyze the relationship of fear of
hypoglycemia with other variables.
Materials and methods: The sample consisted of 72 patients with DM1
and CSII. Patients were evaluated clinically, metabolic and psychologi-
cally at baseline, 6 months and annually. Fear of hypoglycemia was
assessed with the Fear of Hypoglycemia Scale (FH-15). In addition, qual-
ity of life (DQOL), depressive symptoms (BDI-II) and anxiety (STAI)
were assessed. The analyses were performed using Student's t test and the
relationship between variables was analyzed with the Pearson correlation
coefficient. SPSS version 15.0 was used.
Results:At baseline, 66.7% of the sample showed fear of hypoglycemia.
In fact, a significant decrease in prevalence from baseline score at
6 months (p <0.001) and a year of treatment (p <0.001) occurs. Over
5 years of treatment, there is a statistically significant decrease in scores
of fear of hypoglycemia in all assessments made with respect to the initial
score, except for two years. A significant negative relationship between
fear of hypoglycaemia and number of self-controls (p=0.008) at 5 years
was found. On the other hand, between fear of hypoglycaemia and quality
of life was found a positive and significant correlation at baseline (p
<0.001) at 6 months (p <0.001), 1 year (p <0.001), 2 years (p=0.025),
3 years (p <0.001), 4 years (p <0.001) and 5 years (p <0.001). There is
also a significant positive correlation between fear of hypoglycaemia and
depressive symptoms at baseline (p=0.019), at 3 years (p=0.005) and
4 years (p <0.001).
Conclusion: Preliminary results of this study show some evidence of
improvement experienced by patients with DM1 treated with CSII for
5 years in the fear of hypoglycemia. Also found relationships between
this variable, greater depressive symptoms, poorer quality of life and
fewer self-monitoring. The results of this study have demonstrated the
importance of this variable and suggest that it is necessary to assess the
fear of hypoglycemia in these patients by specific protocols.
Supported by: PSI2011-27820 MINECO
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Insulin degludec/insulin aspart lowers fasting plasma glucose and
rates of confirmed and nocturnal confirmed hypoglycaemia
independent of disease duration
M. Haluzik1, J.S. Christiansen2, G. Fulcher3, T.R. Pieber4, H. Rodbard5;
1Charles University, Prague, Czech Republic, 2Aarhus University Hospi-
tal, Denmark, 3Royal North Shore Hospital, Sydney, Australia, 4Medical
University of Graz, Austria, 5Endocrinology and Metabolic Consultants,
Rockville, USA.
Background and aims: Longer diabetes duration is linked with the need
for intensification of insulin therapy. The novel co-formulation of 70%
insulin degludec (IDeg) and 30% insulin aspart (IAsp) has been shown to
provide effective glycaemic control with reduced rates of hypoglycaemia
in individuals with type 2 diabetes (T2D). This post-hoc pooled analysis
evaluated the efficacy of IDegAsp vs biphasic insulin aspart 30 (BIAsp
30) and IDeg OD + IAsp in improving glycaemic control and reducing
risk of hypoglycaemia in subjects with T2D stratified according to disease
duration (≤10 or >10 years).
Materials and methods: Data were pooled from five 26-week treat-to-
target and phase 3a/b clinical trials in subjects with T2D in the IDegAsp
clinical development programme. Baseline HbA1c was similar between
all five studies. Comparators from individual trials were pooled and in-
cluded BIAsp 30 twice-daily (BID) or IDeg OD + IAsp (2-4 injections).
End of trial (EOT) HbA1c, fasting plasma glucose (FPG) and rates of
confirmed and nocturnal confirmed hypoglycaemia and insulin dose were
stratified according to disease duration (≤10 years or >10 years). For each
separate group, continuous variables were analysed using ANOVA and
event rates were analysed using negative binomial regression.
Results: There was no difference in EOT HbA1c between IDegAsp and
comparator in subjects with disease duration of ≤10 years (IDegAsp, n=
430; comparator [BIAsp 30 and IDeg OD + IAsp], n=298) or >10 years
(IDegAsp, n=681; comparator [BIAsp 30 and IDeg OD + IAsp], n=399)
(Table 1). Significant reductions in EOT FPG were observed with
IDegAsp vs comparator (BIAsp 30 and IDeg OD + IAsp) in subjects with
a disease duration of ≤10 years (6.1 vs 6.9 mmol/L, respectively,
>10 years (5.8 vs 6.9 mmol/L, respectively, p<0.0001). IDegAsp vs
comparator (BIAsp 30 and IDeg OD + IAsp) was associated with greater
reductions in rates of confirmed hypoglycaemia (p<0.05) and nocturnal
confirmed hypoglycaemia (p<0.0001) in subjects with T2D, independent
of disease duration. EOT total daily insulin dose was significantly lower
for IDegAsp BID vs BIAsp30 BID (60.4 vs 73.8 U, p<0.0001) and
IDegAsp BID vs IDeg OD + IAsp (93.8 vs 123.3 U, p10 years but not
in the subjects with T2D duration ≤10 years.
Conclusion: No differences were observed in HbA1c when stratified
according to disease duration. IDegAsp was associated with significant
reductions in FPG and rates of confirmed- and nocturnal confirmed
hypoglycaemia. IDegAsp improves glycaemic control at a significantly
lower total daily insulin dose irrespective of disease duration. The lower
total daily insulin dose in subjects with T2D duration >10 years treated
with IDegAsp vs comparators warrants further investigation.
Supported by: Novo Nordisk A/S
959
Sustained glycaemic control and less hypoglycaemia over 1y with
new insulin glargine 300 U/ml vs glargine 100 U/ml in Japanese type
2 diabetes mellitus people on basal insulin +OAD(s) (EDITION JP 2)
Y. Terauchi1, M. Koyama2, X. Cheng3, M. Sumi2, T. Hirose4, on behalf
of the EDITION JP 2 Study Group;
1Yokohama City University School of Medicine, 2Sanofi, Tokyo, Japan,
3Sanofi, Beijing, China, 4Toho University School of Medicine, Japan.
Background and aims: In EDITION JP 2, Japanese people with T2DM
managed with basal insulin plus OAD(s) receiving new insulin glargine 300
U/ml (Gla-300) achievedcomparableglycaemiccontrolwith lesshypoglycaemia
over 6 months when compared with glargine 100 U/ml (Gla-100).
Materials and methods: Participants continued Gla-300 or Gla-100 for
an additional 6 months.
Results: 222 participants completed the 12-month study (107 [88.4%]
with Gla-300 and 115 [95.8%] with Gla-100). From baseline tomonth 12,
HbA1c and FPG decreased with both Gla-300 (mean [SD] change −0.28
[0.84] % and −0.7 [3.1] mmol/l) and Gla-100 (mean [SD] change −0.33
[0.79] % and −1.0 [2.4] mmol/l). At month 12, the mean daily Gla-300
dose was 25 U/day (0.36 U/kg/day) and mean daily Gla-100 dose was 21
U/day (0.30 U/kg/day), with no change in dose observed betweenmonths
6 and 12. Over 12 months, the percentage of participants experiencing ≥1
nocturnal confirmed (≤3.9 mmol/l [≤70 mg/dl]) or severe hypoglycaemic
event was lower with Gla-300 compared with Gla-100 (38.3% vs 52.5%;
relative risk 0.73; 95% CI: 0.55 to 0.97). Consistently fewer nocturnal
confirmed (≤3.9 mmol/l [≤70mg/dl]) or severe hypoglycaemic events per
participant-year were seen with Gla-300 compared with Gla-100 (2.09 vs
5.30; rate ratio 0.41; 95% CI: 0.18 to 0.92). Severe hypoglycaemia was
rare, with only 3 and 2 events reported with Gla-300 and Gla-100, re-
spectively. Mean (SE) weight change over the 12-month period was −0.7
(0.2) kg with Gla-300 and 0.5 (0.2) kg with Gla-100. No between-
treatment differences in the number of adverse events were seen.
Conclusion: Japanese people with T2DM managed with basal insulin
plus OAD(s) showed sustained glycaemic control with less nocturnal
confirmed (≤3.9 mmol/l [≤70 mg/dl]) or severe hypoglycaemia over
12 months with Gla-300 compared with Gla-100. Gla-300 was well tol-
erated over the 12-month study period.
Clinical Trial Registration Number: NCT01689142
Supported by: Sanofi
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The efficacy of degludec in improving hypoglycaemia in type 1
diabetic patients
Y.W. Yap, A. Robinson, A. Basu, H. Bharaj, R. Prajapati;
Department of Endocrinology and Diabetes, Royal Bolton Hospital,
Manchester, UK.
Background and aims: Insulin Degludec (Tresiba) is a recently
launched ultra-long acting insulin with a steady and stable pharmokinetic
profile with minimal intra and inter-day variability, with a glucose low-
ering effect. Over 1,578 patients have been treated in phase three trials but
there are few data available relating to the real world benefits in clinical
practice.
Materials andmethods:Data from patients attending our diabetes centre
between 07/02/2013 and 09/10/2013 who were switched from their usual
basal insulin to insulin Degludec were included in this study. Laboratory
results, together with clinical notes from general practice and outpatient
clinic correspondence were reviewed.
Results: 57 patients were analysed with 40% ofmales & 60% of females.
Basal insulin that had been used pre-Degludec includes Glargine in
77.1% & Detemir in 15.8%. Hypurin, Insulatard, Insulin Pump &
Glimepiride, each represented 1.8%. In the graph as illustrated, a trend
of improvement in hypoglycaemia had been observed in the mean HbA1c
values between the 60-90 mmol/l. A more significant improvement in
both the mean HbA1c values and percentage of patients with improve-
ments in their hypogycaemic controls were observed in the group of
patients with initial mean HbA1c of 100-140 mmol/l. In the initial pre-
degludec group of 100-120 mmol/l, improvements of 100% of
hypoglycaemic events and reduction of an average of 17 mmol/l, sug-
gested that perhaps Tresiba is ideal in improving the glycaemic control
and also in reducing hypoglycaemic events in this group of patients.
Degludec that had been initiated for the group of both mixed
hyperglycaemia and hypoglycaemia were noted in 3 patients. The mean
initial HbA1c for this group was at 89mmol/l. This increased to 96mmol/
l with no further reported improvements in hypoglycaemia in this group.
The number of patients in this group was small and in addition, other
factors need to be considered for this rise in HbA1c in this particular
group of patients.
Conclusion: Our results confirms the benefits of Degludec over previ-
ously available basal insulin being translated into clinical practice, where-
by modest improvements in glycaemic control are associated with signif-
icant reduction in hypoglycaemia rates. Thus, Degludec is a useful new
addition to the basal insulin range & is most useful in Type 1 diabetes
with hypoglycaemia as a frequent problem.
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Glycaemic control and hypoglycaemia burden in patients with type 2
diabetes initiating basal insulin in Europe
D. Mauricio1, L. Liao2, H. Wang2, A. Cali3, P. Stella3, P. Carita3, K.
Khunti4;
1Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 2Sanofi,
Bridgewater, USA, 3Sanofi, Paris, France, 4University of Leicester, UK.
Background and aims: Many patients with T2DM fail to achieve the
ADA/EASD recommended target of HbA1c ≤7%, despite numerous treat-
ment options. Hypoglycaemia (HG) is the main barrier to effective glu-
cose control for people on insulin, impacting long-term treatment adher-
ence/persistence. This study evaluated short- and long-term glycaemic
target attainment and HG incidence, specifically in patients with T2DM
initiating insulin using a basal insulin (BI)-only regimen.
Materials and methods: This was an observational, retrospective longi-
tudinal analysis of electronic medical records (EMRs) from five European
countries (Germany, Italy, France, Spain and UK) extracted from the
Cegedim Strategic Data Longitudinal Patient Database. Insulin-naïve pa-
tients aged ≥30 years with T2DM initiating BI with or without OADs
between Jan 2007 and Sep 2014 were included. Patients had ≥1 HbA1c
measurement pre- and post BI initiation and data available for ≥1 year
pre- and ≥2 years post BI initiation. Occurrence of HG was defined either
as a recorded diagnosis of HG or a fasting plasma glucose of ≤3.9 mmol/l
(70 mg/dl) during an office visit. A multivariate logistic regression model
assessed baseline characteristics, 3-month glycaemic control (for patients
with an HbA1c value 2-4 months post BI initiation) and HG for long-term
(3-24 months post BI initiation) glycaemic control and HG.
Results:A total of 12,141 patients were included (mean age across coun-
tries: 65-69 years). Most patients did not achieve HbA1c target ≤7%, at
both 3 months (range not at target: 70.2-91.9%) and 24months (range not
at target: 66.4-82.7%) post BI initiation. Those with suboptimal control at
3 months were less likely to reach target at 24 months (p≤0.001). A
similar proportion of patients experienced HG over 24 months in Germa-
ny, Spain and France (~8-9%); HG was higher in Italy (~16%) and lower
in the UK (~4%). HG during the initial 3-month period was predictive
(p≤0.02) of longer-term risk (between 3-24 months) (Table).
Conclusion: Across five European countries, a consistent pattern of
short- and long-term suboptimal glycaemic control emerged: the majority
of patients initiating BI failed to reach HbA1c target ≤7% in the first
3 months, or after 2 years’ follow up. Pre- and post-index glycaemic
control varied between countries. Approximately 9% of patients in all
countries experienced HG in the first 2 years of initiating BI, with the
exception of a higher rate in Italy and a lower rate in the UK. Treatment
response and HG incidence by 3 months post BI initiation are predictive
of longer-term glycaemic control and HG risk, respectively. The true
burden of HG is likely underestimated because only EMR-captured epi-
sodes or HG during an office visit were analysed. These results support
the need for interventions that both improve glycaemic control and reduce
the risk of HG.
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Silent hypoglycaemic episodes among well controlled type 2 diabetic
patients treated with sulfonylureas
G. Simonyi1, G. Csitári1, R. Gasparics1, R. Kollár1, Á. Hegedűs1, Z. Pál1,
K. Gencsiova1, P. Kempler2;
1Metabolic Center, St Imre University Teaching Hospital, 21st Depart-
ment of Internal Medicine, Semmelweis University, Budapest, Hungary.
Background and aims:Hypoglycaemia is a relevant cardiovascular risk
factor. The aim of our study was to assess the frequency of silent
hypoglycaemic episodes among well-controlled type 2 diabetic patients
treated with sulfonylurea.
Materials andmethods: 29 type 2 diabetic patients (16 men, 13 women)
with HbA1c ≤7% treated with sulfanylurea and/or metformin without
manifest symptoms of hypoglycaemia during the past two year were
involved in the study (mean age: 70.94±8.92 years, mean duration of
diabetes mellitus 13.88±8.42 years, mean HbA1c was 5.48±0.82%). A
120-hour long (5 days) glucose monitoring using a Continuous Glucose
Monitor System (CGMS) device (Medtronic iPro2®) was performed.
Patients were asked to document four self-monitored capillary blood glu-
cose levels each day for calibration of the monitor, as well as to record
meal times and exercise. Hypoglycaemia symptoms were also recorded.
According to the EASD/ADA recommendation, glucose concentration of
≤3.9 mmol/l were classified as hypoglycaemia. The number of
hypoglycaemic events ≤3.9 mmol/l and, additionally, the number of
hypoglycaemic episodes <3.1 mmol/l were determined. Hypoglycaemic
episodes were defined as a glucose value that persisted for at least 15 mi-
nutes with or without symptoms.
Results: Twenty nine patients were monitored for a mean period of
5744.72±1406.28 min. The mean interstitial glucose (IG) concentration
was 7.07±1.12 mmol/l. The minimal IG was 2.2 mmol/l, while the max-
imal IG concentration was 19.3 mmol/l. 18/29 (62.01%) patients had a
total number of 65 silent hypoglycaemic episodes (interstitial glucose
≤3.9 mmol/l), the mean 3.88±2.05 episodes per patients. The total dura-
tion of these hypoglycemic episodes was 374.5±462.97 min. 8/29
(27.6%) patients had hypoglycaemic episodes of interstitial glucose
≤3.1 mmol/l. The mean frequency of these episodes was 0.88±1.01 per
patient. The total number of episodes was 15. The total duration of hy-
poglycemic episodes with glucose values ≤3.1 mmol/l was 72.5±
120.04 min. None of our patients recorded symptoms of hypoglycaemia.
CGMS measurements were generally well tolerated.
Conclusion:We demonstrated that silent hypoglycemia is quite common
inwell-controlled patients with type 2 diabetes treated with a sulfonylurea
with or without metformin. As a key finding, all registered
hypoglycaemic episodes were silent. CGMS is a useful clinical tool for
detecting silent hypoglycaemia.
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Effects of liraglutide as add-on to insulin on counter-regulatory
hormone responses, gastric emptying and glycaemic recovery during
hypoglycaemia
L. Østergaard1, C.S. Frandsen1, T.F. Dejgaard2, J.J. Holst3, H.U. Ander-
sen2, B. Thorsteinsson4, S. Madsbad1;
1Dept. of Endocrinology, Hvidovre University Hospital, 2Steno Diabetes
Center, Gentofte, 3Novo Nordisk Foundation Center for Basic Metabolic
Research, Copenhagen, 4Dept. of Cardiology, Nephrology and Endocri-
nology, Nordsjællands Hospital, Hillerød, Denmark.
Background and aims: There is a growing body of evidence that GLP-1
receptor agonists (GLP-1 RA) could be beneficial as add-on to insulin in
patients with type 1 diabetes (T1D). GLP-1 inhibits glucagon secretion
and delays gastric-emptying (GE) during euglycaemia; however, these
effects have not been fully elucidated during hypoglycaemia. The aim
of this study was to investigate the counter-regulatory hormone responses
and GE rate during hypoglycaemia in patients with T1D treated with
liraglutide 1.2 mg or placebo for 12 weeks
Materials and methods: In total 20 T1D patients were randomized to
12 weeks treatment with once-daily liraglutide 1.2 mg or placebo as add-
on to pre-existing insulin treatment. Before and after 12 weeks of treat-
ment a hyperinsulinemic hypoglycaemic clamp was performed (figure).
Before both experimental days glucose was monitored using continuous
glucose monitor (CGM). In case of glucose measurements <3.5 mmol/l
(CGM or glucose meter) within 24 hours of the study, study procedures
were postponed. On both occasions patients were studied at
normoglycaemia (plasma glucose target: 5-6 mmol/l), followed
hypoglycaemia (approx. 2.0 mmol/l) and during glycaemic recovery after
a liquid meal (containing 600 kcal and 1.5 g of acetaminophen) served at
hypoglycaemia (figure). Blood samples for analysis of counter-regulatory
hormone responses, p-glucose, and p-acetaminophen were drawn.
Results: Baseline characteristics were similar between groups:
(liraglutide; placebo, mean±sem): HbA1c 77±4; 71±2 mmol/mol, BMI
24.9±0.8; 23.2±0.7 kg/m2, diabetes duration 20±3; 22±2 years, age 36
±3; 37±2. In the liraglutide group, no counter-regulatory differences
between experimental days were seen in change in cortisol, glucagon or
growth hormone (GH) from normoglycaemia to maximum response fol-
lowing hypoglycaemia. However, at 12 weeks change from baseline in
glucagon secretion tended to lower with liraglutide compared with place-
bo (liraglutide vs. placebo, iAUC0-240:1862±967 to 1290±993 vs. 2435
±1239 to 2311±1295 pmol/l×min, p=0.4). The acetaminophen absorp-
tion test assessing rate of gastric emptying displayed no differences be-
tween treatments. Glycaemic recovery from hypoglycemia did not differ
between groups
Conclusion: In patients with T1D liraglutide as add-on to insulin do not
affect the counter-regulatory hormone responses during hypoglycaemia.
However, a trend toward lower glucagon secretion was seen after
liraglutide treatment. Foremost, gastric emptying was not delayed during
hypoglycaemia and glycaemic recovery from hypoglycaemia was unaf-
fected with liraglutide adjunct to insulin treatment in T1D
Diabetologia (2015) 58 (Suppl 1):S1–S607 S465
Clinical Trial Registration Number: NCT02092896
Supported by: Novo Nordisk
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Similar counter-regulatory hormone responses to hypoglycaemia
with Basal Insulin peglispro (BIL) versus insulin Glargine (GL) in
type 1 diabetes
T. Heise1, C. Kapitza1, L. Nosek1, E. Lam2, S. Choi2, P. Garhyan3, S.J.
Jacober3, N. Porksen3, M.J. Prince3, H. Linnebjerg3;
1Profil, Neuss, Germany, 2Lilly-NUS Centre for Clinical Pharmacology
Pte Ltd, Singapore, 3Eli Lilly and Company, Indianapolis, USA.
Background and aims: BIL is a novel PEGylated basal insulin with a
flat pharmacokinetic and glucodynamic profile which has a hepato-
preferential action resulting from reduced peripheral effects. This study
assessed the effects of BIL and GL on the counter-regulatory response to
and recovery from hypoglycaemia induced by human insulin infusion. In
patients with type 1 diabetes, the glucagon response to hypoglycaemia is
reduced over time and the glucose counter-regulatory response depends
mainly on epinephrine. For this reason, the primary objective of the study
was to assess the counter-regulatory response of epinephrine.
Materials and methods: This was an open-label, randomised, 2-period,
crossover study. After once-daily, individualised, subcutaneous doses of
BIL or GL for ≥14 days, 13 patients (mean [±SD] age, 41.0±10.4 years;
duration of diabetes, 19.0±8.7 years) underwent a hypoglycaemic clamp
by infusion of human insulin (0.5 mU/kg/min) to achieve sequential
blood glucose (BG) targets of 72, 58 and 45 mg/dL (BG nadir) (4.0, 3.2
and 2.5 mmol/L). The amount of glucose infusion required to recover
from 45 to 72 mg/dL (2.5 to 4.0 mmol/L) was also compared.
Results: There was no statistically significant difference between treat-
ments in the counter-regulatory response of epinephrine (Table; see also
norepinephrine, cortisol and growth hormone data). Mean baseline glu-
cagon was higher following BIL than GL; this statistically significant
difference was maintained during the clamp. There were no statistically
significant differences between BIL and GL in the mean amount of glu-
cose required to reach a BG concentration of 72 mg/dL (4.0 mmol/L)
from 45 mg/dL (2.5 mmol/L).
Conclusion:BIL and GL showed similar counter-regulatory responses to
and recovery from hypoglycaemia, indicating that the hepato-preferential
action of BIL does not impair counter-regulation.
Clinical Trial Registration Number: NCT01769404
Supported by: Eli Lilly and Company
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Good glycaemic control with low incidence of hypoglycaemia:
complete evaluation of data of routine care by electronic patient file
C. Kloos, D. Askitis, N. Müller, B. Milke, G. Kramer, U.A. Müller;
Endocrinology and Metabolic Diseases, Internal Medicine III, Jena Uni-
versity Hospital, Germany.
Background and aims: Regular assessments of treatment quality is only
practicable with easy data handling from routine-care integrating existing
processes and treatment structures and replace paper documents and files.
Since 1997 we conceived and continuously improved an electronic data-
base and patient file, which is easy to use, and can locally be adapted to
specific needs and pre-existing software structure. Exemplarily the qual-
ity of care of all patients with diabetes mellitus cared for at the outpatient
department in the year 2011 is shown.
Materials and methods: A total of 1411 people with DM were seen in
our outpatient department. DM1 292 (49,5% females, 50,2y, time since
diagnosis 21,5y, BMI 27,2 kg/m2) and DM2 1118 (with insulin n=730,
43,6% females, age 68,5y, time since diagnosis 18,4y, BMI 33,69 kg/m2;
without insulin n=388, 48,6% females, age 64,6y, time since diagnosis 8,
4y, BMI 30,75 kg/m2). HbA1c was DCCT adjusted (mean of healthy
persons 5,05%). All patients took part in a structured patient education
programme in 2011 or earlier.
Results:All people with DM1 had an intensified insulin therapy with the
basal-bolus schema (74%) or a therapy with insulin pump (26%). 50%
used short-acting human insulin and 50% short-acting insulin analogues,
NPH-insulin 30,5%, long-acting insulin analogues 31,8% and combined
human insulin 5,5%. Mean blood pressure office was 135/81 and patient
self 130/77, mean HbA1c 7,5%. The incidence of severe hypoglycaemia
(glucose or glucagone injection) was 0,11/pat/y and the frequency of
non-severe hypoglycaemia was 1,76/pat/wk. 316 (44%) of the people
with DM2 on insulin had a conventional therapy (CT) with human insulin
and 404 (56%) a multiple injection therapy (MIT) with human or ana-
logue insulin. The therapy was combined with metformin in 42,2% of the
cohort, in 0,4% with sulfonylureas, 2,7% with DPP4-inhibitors and 1,9%
with other medications. Mean blood pressure office was 145/83 mmHg
and patient self 135/77, mean HbA1c 7,5%. The incidence of severe
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hypoglycaemia (glucose or glucagone injection) was 0,02/pat/y and the
frequency of non-severe hypoglycaemia was 0,21/pat/wk. People with
DM2 without insulin were treated in 71% with oral antidiabetic agents
(58% metformin, 22% sulfonylureas, 7% DDP4-inhibitors, 4% other
drugs (glinides, GLP1-analogues)). Mean blood pressure office was
144/88 and patient-self 133/78, mean HbA1c 6,6%. The incidence of
severe hypoglycaemia was 0% and non-severe hypoglycaemia 0,05/
pat/wk.
Conclusion: The easily retrieved data from routine care of a tertiary
university outpatient clinic displayed a very good metabolic control with-
in the target of near normoglycaemia. The incidence of severe
hypoglycaemias under insulin therapy was low, even in the group of
DM1. Severe hypoglycaemias in patients with DM2 on insulin were very
rare, subjects without insulin did not report severe hypoglycaemic events.
Mild hypoglycaemias occurred rarely in peoplewith DM1 and very rarely
in people with DM2, even on insulin therapy. Blood pressure self-control
is considerably lower than office blood pressure well in the target range.
PS 091 Basal insulin therapy
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A single dose study in healthy subjects demonstrating
pharmacokinetic and pharmacodynamic equivalence between MK-
1293 and EU- and US-approved innovator insulin glargine
M. Hompesch1, J. Palcza2, K.Mostoller2, C. Mahon2, A.M. Barbour2, Y.
Xu2, E. Mangin2, P. Algatt-Bergstrom2, L. Morrow1, M. Crutchlow2;
1Profil Institute for Clinical Research, Inc., Chula Vista, 2Merck & Co.,
Inc., Kenilworth, USA.
Background and aims: MK-1293 is a follow-on/biosimilar insulin
glargine under development using EU- and US-approved innovator insu-
lin glargine as the benchmark comparator.
Materials and methods: This double-blind, randomized, three-period
balanced crossover euglycemic clamp study in healthy male subjects
(age: 18-45 yrs; BMI: 18.5-25.0 kg/m2) was conducted to demonstrate
pharmacokinetic (PK) and pharmacodynamic (PD) equivalence between
MK-1293, innovator insulin glargine procured in the US (‘US-approved
innovator insulin glargine’) and EU (‘EU-approved innovator insulin
glargine’). In each treatment period, subjects received single 0.4 units/
kg S.C. doses of MK-1293, US-approved innovator insulin glargine, or
EU- approved innovator insulin glargine in random sequence followed by
a 24-hour assessment period for PK sampling and euglycemic clamping
(clamp target 80 mg/dL [4.44 mmol/L]). An LC-MS/MS assay was used
to quantify concentrations of the major circulating active glargine metab-
olite (M1) as well as parent glargine and the M2 metabolite.
Results: Data for the primary PK and PD endpoints are presented in the
table. For all three treatment comparisons, the 90% confidence intervals
for the geometric mean ratios for the primary PK endpoints and the
arithmetic mean ratios for the primary PD endpoints were within 0.80
to 1.25, which was the pre-specified equivalence criterion for both PK
and PD endpoints. All treatments were well tolerated.
Conclusion: This study demonstrated PK and PD equivalence between
MK-1293, US-approved innovator insulin glargine, and EU-approved
innovator insulin glargine, thereby supporting the potential for MK-
1293 as a follow-on/biosimilar insulin glargine.
Supported by: Merck & Co., Inc.
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Superior reduction of HbA1c in a double-blind, randomised study of
basal insulin peglispro (BIL) vs insulin glargine (GL) in patients with
type 1 diabetes: IMAGINE 3
H. Lunt1, R.M. Bergenstal2, E. Franek3, F. Travert4, J. Mou5, M.L.
Hartman5,M. Rosilio6, E.J. Bastyr III5, for the IMAGINE 3 Study Group;
1Christchurch Hospital Diabetes Centre, New Zealand, 2International Di-
abetes Center, Minneapolis, USA, 3Centralny Szpital Kliniczny MSW,
Warszawa, Poland, 4Hopital Bichat Claude Bernard, Paris, France, 5Eli
Lilly and Company, Indianapolis, USA, 6Lilly France, Neuilly sur Seine,
France.
Background and aims: Basal insulin peglispro (BIL) is a novel basal
insulin with a flat pharmacokinetic profile which has a hepato-preferential
action resulting from reduced peripheral effects.
Materials and methods: In this Phase 3, 52-week, blinded study of BIL
vs GL, 1114 adults with T1D (39% female) and HbA1c <12%
(<108 mmol/mol) (mean 7.9% [62 mmol/mol]) were randomised 3:2 to
bedtime BIL or GL with prandial insulin lispro. An electronic diary fa-
cilitated data capture and insulin dosing decisions.
Results: At 52 weeks, BIL vs GL provided superior reduction of HbA1c
(difference -0.22% [-2.42 mmol/mol]; 95% CI: -0.32%, -0.12% [-3.47, -
1.36 mmol/mol]). More patients on BIL achieved HbA1c <7%
(<53 mmol/mol). With BIL, patients had less glucose variability, a 47%
lower rate of nocturnal hypoglycaemia (SMBG ≤3.9 mmol/l [70 mg/dl]),
and weight loss. The total hypoglycaemia rate was 11% higher with BIL
and may be associated with daytime bolus insulin dosing; severe
hypoglycaemia rates were similar. While total insulin dose was similar,
BIL patients used more basal and less bolus insulin. With BIL, LDL-C
and triglycerides (TG) increased and HDL-C decreased. More BIL pa-
tients had ALT ≥3×ULN (4.8% vs 2.0%, p=0.021) with no cases of Hy’s
law. Liver fat content (LFC, %), assessed by MRI in 182 patients from 2
studies of BIL vs GL in T1D, increased with BIL (5.7±0.3 vs 3.5±0.4, p
<0.001). Patients on BIL were more likely to have injection site reactions
(13.3% vs 0.2%, p<0.001).
Conclusion: In T1D, treatment with BIL vs GL gave superior HbA1c
reduction, lower nocturnal hypoglycaemia, and weight loss, with in-
creases in ALT, TG, LFC, and injection site reactions.
Clinical Trial Registration Number: NCT01454284
Supported by: Eli Lilly and Company
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Efficacy, patient-reported outcomes and safety of insulin degludec
U200 compared with insulin glargine in patients with type 2 diabetes
requiring high-dose insulin
M.Warren1, L.B. Chaykin2, S. Jabbour3, M. Sheikh-Ali4, C.T. Hansen5,
T.S.S. Nielsen5, P. Norwood6;
1Physicians East, Greenville, 2Meridien Research, Bradenton, 3Jefferson
University Hospitals, Philadelphia, 4University of Florida Health, Jack-
sonville, USA, 5Novo Nordisk A/S, Søborg, Denmark, 6Endocrinolgy,
Valley Research, Fresno, USA.
Background and aims:This was a 32-week, open-label, crossover, treat-
to-target trial that compared the efficacy, patient-reported outcomes and
safety of insulin degludec (IDeg) 200 U/mL with insulin glargine (IGlar)
100 U/mL, administered once daily (OD) after 16 weeks’ run-in.
Materials and methods: Adults aged ≥18 years with type 2 diabetes
(T2D) for ≥6 months, receiving IGlar OD (≥65-≤100 U/day) + metfor-
min ± one other oral antidiabetic drug for ≥3 months, with a HbA1c
≥7.5% who required ≥81U insulin after a 16-week run-in were
randomised 1:1 to IDeg/IGlar or IGlar/IDeg (Figure).
Results: After 16 weeks, noninferiority of IDeg to IGlar with respect to
change in HbA1c was confirmed. Mean fasting plasma glucose was sig-
nificantly reduced with IDeg vs. IGlar (-0.82 vs. -0.05 mmol/L; estimated
treatment difference [ETD]: -0.77 mmol/L, p<0.05). For IDeg vs. IGlar,
the rate of confirmed hypoglycaemia was significantly lower (estimated
rate ratio [ERR]: 0.59, p<0.05) while nocturnal hypoglycaemia was nu-
merically lower (ERR: 0.66, p=NS). Mean weight change was 0.42 kg
(IDeg) vs. 1.04 kg (IGlar), p=NS. The IDeg delivery device was rated
significantly better for function (ETD: 8.40, p<0.05) and less bother
(ETD: 6.01, p<0.05) compared with the IGlar device, and more patients
preferred IDeg treatment (54.5%) vs. IGlar (20.0%); 15.9% no preference
and 2.8% didn’t know.
Conclusion: IDeg U200 was effective in regulating glycaemic control as
measured by HbA1c (noninferiority to IGlar confirmed) and is preferred
by a numerically higher proportion of patients with T2D requiring high-
dose insulin.
Clinical Trial Registration Number: NCT01570751
Supported by: Novo Nordisk A/S
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The efficacy and safety of LY2963016 insulin glargine in patients
with type 1 and type 2 diabetes previously treated with insulin
glargine
I. Hadjiyianni1, A. Asaro-Harris2, D. Dahl3, L.B. Lacaya1, R.K.
Pollom1, L.L. Ilag1, J.S. Zielonka1;
1Eli Lilly and Company, Indianapolis, USA, 2Eli Lilly and Company,
Basingstoke, UK, 3Gemeinschaftspraxis für Innere Medizin und
Diabetologie, Hamburg, Germany.
Background and aims: LY2963016 insulin glargine (LY IGlar) and
insulin glargine (IGlar) are insulin glargine products with identical prima-
ry amino acid sequences as well as similar pharmacokinetic and pharma-
codynamic profiles. In 2 prospective, global, parallel, Phase 3 trials, LY
IGlar had a similar efficacy and safety profile to IGlar with no clinically
meaningful differences. To further assess the treatment effect and similar-
ity of LY IGlar to IGlar, additional analyses were done in the subgroup of
patients with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus
(T2DM) who reported prestudy treatment with IGlar (prior IGlar) in these
52-week open-label (ELEMENT-1) and 24-week double-blind
randomised (ELEMENT-2) studies, respectively.
Materials and methods: In both studies, unit-to-unit dose conversions
were used from prestudy IGlar to study LY IGlar or IGlar followed by
treat-to-target titration (eg, HbA1c <7.0%). The efficacy and safety of LY
IGlar and IGlar were compared in the prior IGlar subgroup. Primary
efficacy was defined as change in HbA1c from baseline to the 24-week
endpoint. Continuous data were analysed using ANCOVA. Treatment
comparisons for hypoglycaemia rate were done using the Wilcoxon test.
Fisher’s exact test or chi-square test was used for categorical data.
Results: No significant treatment differences were observed for primary
and other efficacy outcomes, including proportion of patients achieving
endpoint HbA1c targets, fasting plasma glucose, basal insulin dose, and
prandial insulin dose (T1DM only) (Table), except for a significantly
greater weight change from baseline observed in the LY IGlar group of
patients with T1DM, which was not consistently observed in patients
with T2DM and in the total T1DM population. For safety outcomes, a
significant difference in the proportion of patients with detectable insulin
antibodies at any time point of the study (overall) was noted in patients
with T2DM but not for patients with T1DM. No significant difference
was observed at the 52-week (T1DM) or 24-week (T2DM) endpoint
(LOCF); median insulin antibody levels were low (<5%) and similar in
the 2 treatment groups. Significantly fewer patients with T2DM treated
with LY IGlar reported ≥1 serious adverse event, which was not seen in
patients with T1DM and no treatment differences were observed for pre-
ferred terms. No significant treatment differences were observed for other
safety outcomes, including total and nocturnal hypoglycaemia rates and
incidences (endpoint and overall; blood glucose ≤3.9mmol/l if available),
incidence of treatment-emergent antibody response, and treatment-
emergent adverse events.
Conclusion: In patients who reported prestudy treatment with IGlar in
these 2 Phase 3 trials, patients randomised to LY IGlar had similar effi-
cacy and safety outcomes as those randomised to IGlar.
Clinical Trial Registration Number: NCT01421147, NCT01421459
Supported by: Eli Lilly and Company and Boehringer-Ingelheim
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Adherence to initiated basal insulin analogue treatment in type 1 and
2 diabetes
J. Westerbacka1, H. Mihailov2, T. Valle3, S. Jääskeläinen1, J. Kaukua1;
1Sanofi Finland, Helsinki, 2Department of Health Policy and Manage-
ment, Health Economics, University of Eastern Finland, Kuopio,
3Mehiläinen Diabetes Clinic, Helsinki, Finland.
Background and aims: Poor medication adherence is common in dia-
betes potentially causing poor health outcomes and complications. The
aim of this study was to analyze the discontinuation rate of initiated basal
insulin analog in type 1 and type 2 diabetic patients in Finland.
Materials and methods: The data was obtained from the national reim-
bursement registry. Study population consisted of 14 462 diabetic patients
(18% had type 1 diabetes) who started basal insulin analogs (insulin
glargine or insulin detemir) in 2012. Patients were followed by their
insulin purchases for 18months after the initiation. The data was analysed
with χ2-test and logistic regression analysis. Logistic regression analysis
was used to find out what variables (age, gender, type of diabetes, type of
insulin analog) explain patient staying in the treatment.
Results: Type of insulin, gender, age and type of diabetes had statistically
significant influence on patients’ treatment adherence (p<0.001 for all).
Overall 47% of patients starting insulin detemir and 39% starting insulin
glargine patients discontinued their basal insulin treatment within
18 months of the initiation. Most of the patients stopped treatment within
first 6 months after the initiation. In type 1 diabetic patients, 42% of
insulin glargine patients and 57% of insulin detemir patients stopped
the initiated treatment. In type 2 diabetic patients, 35% stopped insulin
glargine and 38% insulin detemir. In only 15% of the patients
discontinuing the initiated basal insulin, death or switch to other insulin
or GLP-1RA explained the discontinuation suggesting non-adherence to
insulin therapy from other reasons.
Conclusion: There is a considerable proportion of diabetic patients
discontinuing their initiated basal insulin analog. Future studies are war-
ranted to examine the detailed reasons for discontinuation.
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Superior HbA1c reduction with Basal Insulin peglispro (BIL) vs
insulin glargine in patients with type 2 diabetic patients previously
treated with basal insulin: IMAGINE 5
C. Trescoli Serrano1, J.B. Buse2, H.W. Rodbard3, J. Luo4, T. Ivanyi4, J.
Bue-Valleskey4, M.L. Hartman4, M.A. Carey5, A.M. Chang4;
1Diabetes Unit, Hospital de la Ribera, Valencia, Spain, 2University of
North Carolina School of Medicine, Chapel Hill, 3Endocrine and Meta-
bolic Consultants, Rockville, 4Eli Lilly and Company, Indianapolis,
5inVentiv Health Clinical, Blue Bell, USA.
Background and aims: Basal insulin peglispro (BIL) is a novel basal
insulin with a flat profile which has a hepato-preferential action resulting
from reduced peripheral effects.
Materials and methods: This Phase 3, open-label, treat-to-target 52-
week study in patients with type 2 diabetes (T2D) (HbA1c ≤9%) on basal
insulin alone or with up to 3 oral antihyperglycaemic medications
(OAMs), assessed noninferiority of BIL to insulin glargine (GL) in re-
ducing HbA1c at 26 weeks (margin=0.4%) when added to prestudy
OAMs. Patients were randomised 2:1 to BIL (N=307) or GL (N=159);
162 patients underwent MRI to assess liver fat content (LFC).
Results: Superiority of BIL vs GL was demonstrated for change in
HbA1c at 26 and 52 weeks. In addition, more BIL patients reached
HbA1c <7% and lab FSG was lower with BIL. BIL patients had a 60%
rate reduction vs GL in nocturnal hypoglycaemia and more patients
reaching HbA1c <7% without nocturnal hypoglycaemia over 52 weeks.
BIL-treated patients had a lower total hypoglycaemia rate, higher basal
insulin dose. BIL patients had higher triglycerides (TGs), lower LDL-C
and HDL-C, no difference in non-HDL-C, and higher ALT and AST.
More BIL patients had ALT≥3×ULN (2.3 vs 0%, p=.101), with no cases
of Hy’s law. LFC increased from baseline in patients on BIL vs GL with
stable LFC from weeks 26 to 52.
Conclusion: In summary, in patients previously treated with convention-
al basal insulins, BIL provided superior reduction in HbA1c, less noctur-
nal and total hypoglycaemia, and higher TGs, ALT, and LFC compared to
GL.
Clinical Trial Registration Number: NCT01582451
Supported by: Eli Lilly and Company
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Superior HbA1c reduction with basal insulin peglispro (BIL) vs
insulin glargine (GL) and preprandial insulin lispro in a
double-blind study in type 2 diabetes patients: IMAGINE 4
A.M. Chang1, T. Blevins2, T.R. Pieber3, G. Colón Vega4, S. Zhang1, E.J.
Bastyr III1;
1Eli Lilly and Company, Indianapolis, 2Texas Diabetes and Endocrinol-
ogy, Austin, USA, 3Division of Endocrinology and Metabolism, Medical
University of Graz, Austria, 4American Telemedicine Center, San Juan,
USA.
Background and aims: Basal insulin peglispro (BIL) is a novel basal
insulin with a flat activity profile which has a hepato-preferential action
resulting from reduced peripheral effects.
Materials and methods: In this 26-week, Phase 3, blinded, treat-to-
target trial, 1369 patients with T2D (HbA1c ≥53 mmol/mol [>7.0%]
and <108 mmol/mol [<12.0%] on ≥1 insulin injection/day) were
randomised to bedtime BIL (N=691) or GL (N=678). Patients could
continue metformin. A wireless electronic diary system facilitated com-
munication of SMBG, hypoglycaemia, and insulin dosing.
Results: At Week 26, patients on BIL vs GL demonstrated superior
HbA1c reduction (baseline: 69 mmol/mol [8.4%]; Week 26: 50 vs
53 mmol/mol [6.8% vs 7.0%]; treatment difference -2.30 mmol/mol [-
0.21%], p<.001). BIL-treated patients had lower FSG (7.0 vs 7.3 mmol/l
[125 vs 132 mg/dl], p=.015), and more reached HbA1c <7% (63% vs
53%, p<.001). The improved glycaemic control with BIL vs GL was
achieved with a 45% lower rate of nocturnal hypoglycaemia and more
patients reaching HbA1c <53 mmol/mol (<7%) without nocturnal
hypoglycaemia over 26 weeks (24% vs 12%, p< .001). Total
hypoglycaemia relative rate was 1.10 (BIL/GL, p=.053); severe
hypoglycaemia rate and incidence did not differ between treatments.With
BIL, basal insulin dose was 11% higher, but bolus and total insulin doses
were similar at 26 weeks. The BIL group had greater reduction in within-
day and between-day fasting and 9-point SMBG variability, and less
weight gain (change from baseline, 1.3 vs 2.2 kg, p<.001). BIL treatment
was associated with higher triglycerides (TG, change from baseline: 0.27
vs -0.04 mmol/l [24 vs -3 mg/dl], p<.001), lower HDL-C (change from
baseline: -0.04 vs -0.01 mmol/l [-2 vs 0 mg/dl], p<.001), and similar
LDL-C, with no difference in cardiovascular or other serious adverse
events. At Week 26, ALT mean change from baseline was 7.6 vs -
0.6 IU/l (p<.001); more BIL patients had ALT ≥3× ULN (1.9% vs
0.9%, p=0.16), with no cases of Hy’s law. There were no significant
differences in efficacy or safety in patients with anti-BIL treatment-emer-
gent antibody responses.
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Conclusion: In patients with T2D, BIL vs GL, in combination with
insulin lispro, provided improved glycaemic control with less nocturnal
hypoglycaemia, less weight gain, and increases in TG and ALT.
Clinical Trial Registration Number: NCT01468987
Supported by: Eli Lilly and Company
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Liver enzyme and Liver Fat Content (LFC) results from Basal
Insulin peglispro (BIL) clinical trials in type 1 and type 2 diabetes
M.L. Hartman, S. Zhang, E.J. Bastyr III, A.M. Chang, S.J. Jacober, A.
Haupt, M.J. Prince;
Eli Lilly and Company, Indianapolis, USA.
Background and aims: BIL, a basal insulin analog with a flat pharma-
cokinetic profile, has reduced peripheral activity resulting in hepato-
preferential action. To monitor hepatic safety, liver enzymes and LFC
were measured in patients (pts) with T1D and T2D during BIL trials.
Materials andmethods:Alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), alkaline phosphatase (ALP), and total bilirubin
(TBL) were measured at 0, 4, 8, 12, 16, 26, 39, 52, 65, and 78 weeks
(wks), depending on study duration, and 4 wks following study basal
insulin withdrawal. Data were integrated for studies comparing BIL with
insulin glargine (GL) in pts with T1D (1 Phase 2 and 2 Phase 3 trials;
1026BIL and 676GL) and T2D (1 Phase 2 and 3 Phase 3 trials; 2194BIL
and 1464 GL). LFC was measured via magnetic resonance imaging
(MRI) in 3 subsets of pts (N given in table) at 0, 26, and 52 wks: 1)
T1D, 2) insulin naïve (IN) T2D pts, and 3) T2D pts previously treated
with insulin (PTI). A small number of T1D pts had MRI at 78 wks (26
BIL, 11 GL).
Results: In T1D and T2D pts, mean ALT increased from baseline in BIL
pts and was higher than in GL pts at all time points to 78 wks (all p<.001)
and decreased after discontinuation of BIL. Similar results were observed
for AST, but no clinically meaningful changes in mean TBL or ALP
occurred. More pts taking BIL had ALT≥3X upper limit of normal
(ULN) than GL but TBL≥2X ULN was similar for BIL vs GL. AST≥
3X ULN was more common in BIL than GL pts for T2D (1.2% vs 0.4%,
p=.009) but not for T1D. No patient had ALT≥3XULNwith a TBL≥2X
ULN that could not be attributed to another cause; thus Hy’s Law criteria
were not met. Of the pts taking BIL with ALT≥3X ULN (44 in T1D, 44
in T2D), all pts with T1D and 40 (90.9%) with T2D returned to or trended
toward baseline while continuing BIL (37 in T1D, 22 in T2D) or after
discontinuing BIL (7 in T1D, 18 in T2D), consistent with hepatic adap-
tation. Four T2D pts had insufficient follow-up to adequately assess the
ALT trend. In T2D IN pts, LFC did not change with BIL but decreased
significantly with GL. In T1D and T2D PTI pts, LFC increased signifi-
cantly with BIL but no change occurred with GL. In T1D pts at 78 wks,
LFC remained higher in BIL than GL (6.1%±0.5% in BIL, 2.9%±0.8%
in GL; p=.001). More BIL than GL pts had LFC≥6% (ULN). The cor-
relation between the change in ALT and change in LFC at 52 wks was
statistically significant in T1D, T2D IN, T2D PTI pts taking BIL (R=0.37
to 0.47; all p<.001); it was also significant in pts taking GL in T2D IN
(R=0.29; p=.029) but not in T1D or T2D PTI pts.
Conclusion: No acute, severe, hepatocellular drug-induced liver injury
was apparent with BIL treatment for up to 78 wks. LFC was significantly
higher in T1D and T2D pts treated with BIL compared to GL for treat-
ment up to 78 wks. In T2D IN pts, this difference was due to a decrease in
LFCwith GL. In T1D and T2D PTI pts, the difference was the result of an
increase in LFC with BIL. Further research is needed to understand and
characterize the potential effects, if any, of changes in LFC observed with
BIL treatment in Phase 3 trials.
Clinical Trial Registration Number: NCT01027871, NCT01049412,
NCT01435616, NCT01468987, NCT0141779, NCT01454284,
NCT01582451
Supported by: Eli Lilly and Company
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Is hypoglycaemia a modifiable patient risk in type 2 diabetes: A
pooled analysis of insulin glargine 300 U/mL (Gla-300) vs 100U/mL
(Gla-100) trials?
Q. Zhang1, J. Rosenstock2, C. Gerrits3, L. Liao3, P. Chew3;
1Rutgers University, Piscataway, 2Dallas Diabetes and Endocrine Center,
Dallas, 3Sanofi, Bridgewater, USA.
Background and aims: Repeated episodes of hypoglycemia are associ-
ated with an increased risk of adverse clinical outcomes. Underlying
patient characteristics may predispose to repeated hypoglycemia.
Materials andmethods:We evaluated potential patient predisposition to
documented hypoglycemia in pooled data (N=2488) from 3 T2DM clin-
ical trials of Gla-300 vs Gla-100 and their 6-month extensions (N=1994).
Study populations for the three studies are as follows: DIV>14 patients
were removed due to missing baseline data. Monthly study data were
analyzed with general estimating equations (GEE) to assess the impact
of patient characteristics on risk of repeated hypoglycemic events over
12 months.
Results:Baseline characteristics were comparable between groups: mean
age 59 years, BMI 35 kg/m2, A1C 8.3%, diabetes duration 13 years, and
Charlson Comorbidity Index (CCI) 0.56 for Gla-300 vs 0.60 for Gla-100.
Less documented (≤70 mg/dL) symptomatic hypoglycemia was noted
with Gla-300 vs Gla-100 (57.0% vs 63.3%, odds ratio=0.77, 95% CI:
0.65-0.90, P=0.001). Female gender (P<0.001), BMI ≤35 kg/m2
(P<0.001), CCI >0.60 (P=0.017), and diabetes duration >10 years (P=
0.001) were associated with an increased number of documented, symp-
tomatic hypoglycemia events. Poisson regression showed a lower event
rate for Gla-300 vs Gla-100 (4.4 vs. 5.2 events/year; rate ratio 0.84, 95%
CI: 0.76-0.92, P<0.001) independent of patient characteristics. Further-
more, monthly percentage of patients experiencing documented hypogly-
cemia increased in Gla-100 but stayed unchanged in Gla-300 over CCI
(PInteraction=0.017).
Conclusion: Repeated episodes of documented hypoglycemia in T2DM
are reflective of such patient characteristics as gender, BMI, diabetes
duration and comorbidity. Gla-300 is associated with a lower event rate
than Gla-100 through the 12 months period. In particular, increasing
hypoglycemia risk due to patient burden of comorbidity appears to be
mitigated with Gla-300 compared to Gla-100.
Supported by: Sanofi
975
Patient-level meta-analysis of 1y phase 3a EDITION type 2 diabetes
mellitus studies: glycaemic control and hypoglycaemia with insulin
glargine 300 U/ml (Gla-300) vs glargine 100 U/ml (Gla-100)
R.A. Ritzel1, R. Roussel2, A. Giaccari3, J. Vora4, M.-L. Grisoni5, C.
Brulle-Wohlhueter6, S. Glezer6, H. Yki-Järvinen7;
1Klinikum Schwabing, Städtisches Klinikum München GmbH, Germa-
ny, 2Assistance Publique Hôpitaux de Paris, Bichat Hospital, France,
3Endocrino-Metabolic Diseases Unit, Università Cattolica del Sacro
Cuore, Rome, Italy, 4Royal Liverpool University Hospital, UK,
5AIXIAL, Levallois-Perret, France, 6Sanofi, Paris, France, 7University
of Helsinki, Finland.
Background and aims: EDITION 1, 2 and 3 assessed Gla-300 vs Gla-
100 in people with type 2 diabetes (T2DM).
Materials and methods: A patient-level meta-analysis of 1-year data
was conducted.
Results: Glycaemic control was sustained in both groups, with more
sustained HbA1c reduction for Gla-300 at 1 year. LS mean (SE) change
from baseline in HbA1c was −0.91 (0.03) % for Gla-300 and −0.80 (0.03)
% for Gla-100 (LS mean difference [95% CI] between groups −0.10
[−0.18 to −0.02] %; p=0.0174). There was a reduced risk of confirmed
(≤3.9 mmol/l [≤70 mg/dl]) or severe hypoglycaemia at any time (24 h)
and during the night with Gla-300 vs Gla-100. Weight gain was less with
Gla-300 vs Gla-100. The slight insulin dose difference at 6 months
remained at 1 year.
Conclusion:Gla-300 was associated withmore sustained glycaemic con-
trol, with greater up-titration of insulin dose, primarily in the first weeks,
and without increased risk of any time and nocturnal hypoglycaemia or
weight gain at 1 year vs Gla-100.
Clinical Trial Registration Number: NCT01499082, NCT01499095,
NCT01676220
Supported by: Sanofi
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Sustainable effects of basal insulin have favourable outcomes on
fasting blood glucose control in patients with type 2 diabetes
S. Kaneko, R. Adachi, Y. Ueda, Y. Tahara;
Diabetes, Endocrinology and Life-related Disease, Takatsuki Red Cross
Hospital, Japan.
Background and aims: Recently, basal insulin formulations of longer
effect have been developed. We investigated the difference in the sustain-
able effect of longer acting formulations on blood glucose control in
patients with Type 2 diabetes. We compared insulin degludec (IDeg)
therapy which has the longest effect of 42 hours with a conventional basal
insulins (NPH, ditemir or glargine (IGla)) therapies of which the effect is
less than 24 hours.
Materials and methods:We conducted two different retrospective anal-
yses, namely; 1) A comparison study of the newly introduced IDeg versus
conventional insulin, the duration needed to achieve the target FPG and
the quantity of insulin needed in both groups were analysed. and 2) In
substitution study of IDeg for conventional insulin, the average and var-
iability (SD) of FPG for 14 days prior to and after both switches were
analysed.
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Results: 1) Out of 332 patients with T2DM, 114 patients (60 males, 64.4
±9.8 years old, disease duration of 7.6±7.4 years, HbA1c 10.1±2.1%,
BMI 26.7±3.7, FPG 201±52 mg/dl) were newly administered IDeg
once-daily, and 218 patients (95 males, 57.4±13.0 years old, disease
duration of 5.6±5.6 years, HbA1c 10.4±1.8%, BMI 27.1±4.6, FPG
200±56 mg/dl) were newly administered conventional therapy once-
daily or twice a day. Patients newly treated with IDeg achieved the target
FPG earlier (6.7±6.9 days) than those with conventional insulin IGla (8.9
±11.7 days) (p<0.01). Total doses of insulin IDeg (104.4±75.3 unit)
needed to achieve the target FPG tended to be less than those of IGla
(122.5±93.4 unit) (NS).2) Sixty-nine patients undergoing conventional
therapy were switched to IDeg for more than 30 days and then switched
back to conventional therapy. For the 14 days before and after both
switches, the average variability (SD) of FPG were analyzed. After
switching from conventional therapy to IDeg therapy, both the average
and SD of FPG decreased in 47.8% of patients (the average decreased in
72.4% and the SD of FPG decreased in 68.1%), and the amount of insulin
was reduced by 10%. Nocturnal hypoglycemia occurred in 1% and 5% of
patients undergoing IDeg and conventional therapy,repectively.
Conclusion: Longer active basal insulin therapy, i.e. IDeg, provides more
effective and safer control of blood glucose in T2DM. It might also be
expected to reduce medical costs.
Supported by: JAPAN VASCULAR DISEASE RESEARCH FOUNDA-
TION
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Older people with type 2 diabetes: glycaemic control and
hypoglycaemia risk with new insulin glargine 300 U/ml (Gla-300)
P. Stella1, V. Aroda2, B. Charbonnel3, R. Ritzel4, A. Merino-Trigo1, M.-
L. Grisoni5, A.J. Sinclair6, J.-F. Yale7;
1Sanofi, Paris, France, 2MedStar Health Research Institute, Hyattsville,
USA, 3Nantes University, France, 4Klinikum Schwabing, Städtisches
Klinikum München GmbH, Germany, 5AIXIAL, Levallois-Perret,
France, 6Foundation for Diabetes Research in Older People, Diabetes
Frail Ltd, Droitwich Spa, UK, 7McGill University, Montreal, Canada.
Background and aims: In people with T2DM, a patient-level meta-anal-
ysis of EDITION 1, 2 and 3 has shown Gla-300 provides comparable
glycaemic control with less hypoglycaemia over 6 months vs insulin
glargine 100 U/ml (Gla-100).
Materials and methods: In this post hoc analysis, we investigated these
outcomes, as well as an extended and clinically defined window of noc-
turnal hypoglycaemia (22:00 h to pre-breakfast SMPG) and composite
endpoints, in those aged ≥65 years (n=659).
Results: Gla-300 showed comparable glycaemic control to Gla-100 (LS
mean [95% CI] difference in HbA1c change from baseline to month 6:
0.00 [−0.14 to 0.15] %). There was less confirmed (≤3.9 mmol/l [≤70mg/
dl]) or severe hypoglycaemia during the night irrespective of the noctur-
nal window analysed and a trend towards fewer any time (24 h) events for
Gla-300 vs Gla-100. More Gla-300-treated participants reached HbA1c
targets or had HbA1c reduction ≥0.5% without confirmed (≤3.9 mmol/l
[≤70 mg/dl]) or severe nocturnal hypoglycaemia. Those on Gla-300 were
55-70% more likely to achieve HbA1c <7% with no nocturnal
hypoglycaemia (significant using both windows).
Conclusion: The comparable glycaemic control plus hypoglycaemia
benefit of Gla-300 is confirmed in a potentially more vulnerable subgroup
aged ≥65 years, with more people reaching HbA1c targets without
hypoglycaemia on Gla-300 vs Gla-100. The nocturnal hypoglycaemia
benefit of Gla-300 was also confirmed when an extended window
(22:00 h to pre-breakfast SMPG) was considered.
Clinical Trial Registration Number: NCT01499082, NCT01499095,
NCT01676220
Supported by: Sanofi
978
Comparison of glycaemic variations in Japanese patients with type 1
diabetes receiving insulin detemir vs insulin degludec as assessed by
Continuous Glucose Monitoring (CGM)
H. Takahashi, R. Nishimura, Y. Onda, D. Tsujino, K. Ando, K.
Utsunomiya;
The Jikei University School of Medicine, Tokyo, Japan.
Background and aims: Japanese patients with type 1 diabetes receiving
the long-acting soluble insulin preparations insulin degludec (Deg) and
insulin detemir (Det) were compared for glycemic variation by using
continuous glucose monitoring (CGM).
Materials and methods: A total of 12 patients with type 1 diabetes
(males/females, 4/8) were enrolled in the study (mean age, 51.8±12.0
(SD) years; BMI, 22.1±2.5 kg/m2; and HbA1c, 7.8±0.6%). The patients
received one insulin preparation and were crossed over to the other for
comparison. Of these, 2 patients received 1 Det injection, and 10 received
2 Det injections per day. The timing of Deg injection was set to fit the
lifestyle of each patient and the amount administered was determined by
Diabetologia (2015) 58 (Suppl 1):S1–S607 S473
each patient in consultation with their doctors. Each patient was fitted
with a CGM device in the outpatient clinic and 24-hour data were col-
lected for comparison after they had had the same test meals. During each
period, blood glucose levels were monitored with the CGM for at least
3 days. Mean glucose levels, standard deviations of glucose (SD), time in
hypoglycemia ( 200 mg/dL), range of postprandial glucose increase, time
to peak glucose values (time to peak glucose values after each meal and
mean time to peak glucose values after 3 meals), and area under the
concentration-time curve for glucose (AUC, > 200 mg/dL) were com-
pared between those given Det and those given Deg by using paired t-test.
All statistical analyses were performed by using SPSS 22.0. The present
study was approved by the Ethics Committee of our university.
Results: Those receiving Det versus Deg had a mean glucose level of
183.3±46.2 mg/dL versus 144.5±37.2 mg/dL (P=0.025) and an SD of
77.4±20.6 mg/dL versus 59.6±17.5 mg/dL (P=0.004), indicating that
the glucose values were significantly lower during degludec administra-
tion. Those receiving Det versus Deg had a SD during nighttime (mid-
night to 6:00 AM) was 34.5±27.6 mg/dL versus 16.5±10.4 mg/dL, with
their nighttime SD being significantly lower while onDeg (P=0.048). No
significant differences were seen in time in hypoglycemia ( 200 mg/dL)
while on Det versus Deg. Their mean preprandial blood glucose level
before breakfast was 165.3±83.6 mg/dL versus 102.3±72.3 mg/dLwhile
onDet versus Deg (P=0.010) and their mean postprandial peak level after
breakfast was 284.5±60.6mg/dL versus 200.3±48.2 mg/dLwhile onDet
versus Deg (P=0.004), with the values significantly lower while on Deg.
No significant differences were seen at lunch or dinner times. Their AUC
(>200 mg/dL) was 44836±36118 versus 16993±18932 while on Det
versus Deg, with the AUC being significantly lower while on Deg (P=
0.007).
Conclusion: Type 1 diabetic patients receiving insulin detemir or insulin
deguldec were compared for glycemic variability by using CGM. Results
suggested that insulin deguldec appears to be superior to insulin detemir
in stabilizing blood glucose levels from late at night through breakfast.
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Similar HbA1c reduction and hypoglycaemia with variable time and
fixed time dosing of basal insulin peglispro (BIL) in type 1 diabetes:
IMAGINE 7
N.C. Schloot1, S. Garg2, J.-L. Selam3, A. Bhargava4, J. Luo5, Q. Zhang5,
J.G. Jacobson5, B.J. Hoogwerf5;
1Lilly Deutschland GmbH, Bad Homburg, Germany, 2Barbara Davis
Center for Diabetes, University of Colorado Denver, 3Diabetes Research
Center, Tustin, 4Iowa Diabetes & Endocrinology Center, Des Moines,
5Eli Lilly and Company, Indianapolis, USA.
Background and aims: Basal insulin peglispro (BIL) is a novel basal
insulin with a flat profile which has a hepato-preferential action resulting
from reduced peripheral effects. The flat profile suggests some variation
in dosing intervals will not affect measures of glycaemic control. This
Phase 3 crossover study was designed to assess whether variable dose
timing was noninferior (margin=.4%) to fixed dose timing for HbA1c
after 12 weeks of BIL treatment in patients with type 1 diabetes.
Materials and methods:During the lead-in phase, 212 patients received
BIL (evening dosing) for 12 weeks. Of those patients, 182 completed the
lead-in phase and were randomised to two 12-week crossover treatment
periods comparing fixed time dosing (evening) and variable time dosing
(dosing intervals were 8±2 hours to 40±2 hours, with morning dosing on
Monday, Wednesday, Friday, and evening dosing on Tuesday, Thursday,
Saturday, Sunday).
Results: Patients were mostly Caucasian (96%), approximately 43 years
old with diabetes duration of about 20 years. During the 12-wk lead-in,
mean ± SD HbA1c decreased from 7.5%±.8 to 6.8%±.7; fasting serum
glucose (FSG) decreased from 9.0±3.9 mmol/L (162±69mg/dL) to 6.9±
3.3 mmol/L (123±59 mg/dL). During the randomised phase, variable
timing and fixed timing groups had similar HbA1c, FSG, glucose vari-
ability, total and nocturnal hypoglycaemia, and basal and bolus insulin
doses (Table). Self-monitored fasting blood glucose was .46 mmol/L
(8 mg/dL) lower (LS mean difference) with fixed time dosing compared
to variable time dosing (p=.014). Treatment-emergent adverse events
(AEs) and serious AEs were similar for both groups. Over 36 weeks,
LS mean weight decreased 1.2±.3 kg (p<.001) and mean triglycerides,
ALT, and AST increased significantly (all p<.001) but trended toward
baseline levels by 4 weeks after BIL discontinuation. No patients met
criteria for Hy’s law. Twenty patients (9.4%) experienced injection site
reactions including injection site swelling and lipohypertrophy.
Conclusion: We conclude that BIL allows 8±2 to 40±2 hour dosing
intervals with similar HbA1c compared to fixed time dosing in patients
with type 1 diabetes.
Clinical Trial Registration Number: NCT01792284
Supported by: Eli Lilly and Company
980
Reduced nocturnal hypoglycaemia with basal insulin peglispro (BIL)
compared to insulin glargine (GL): pooled analyses of 5 randomised
controlled trials
M. Marre1, J. Rosenstock2, Y. Qu3, S.J. Jacober3, M.J. Prince3, A.M.
Chang3, E.J. Bastyr III3;
1Hopital Bichat Claude Bernard, Paris, France, 2Dallas Diabetes and En-
docrine Center, 3Eli Lilly and Company, Indianapolis, USA.
Background and aims: Nocturnal hypoglycaemia is a significant safety
concern and limits optimisation of basal insulin dosing to achieve
glycaemic goals.
Materials and methods: We compared the novel basal insulin analog
BIL, with its flat pharmacokinetic profile and hepato-preferential action,
to GL for glucose control in 5 international studies in 3 patient groups
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(type 2 diabetes [T2D] basal only, T2D basal-bolus, and type 1 diabetes
[T1D]). We conducted integrated analyses to assess HbA1c change and
hypoglycaemia events (SMBG ≤53 mmol/l [≤70 mg/dL]) across studies.
Results: Patients (N=4927) were randomised to bedtime BIL or GL in
26-, 52- and 78-week treat-to-target trials. In all patient groups, patients
treated with BIL met statistical superiority in the primary outcome of
reduction in HbA1c, and had 36%–45% lower nocturnal hypoglycaemia
rates. Total hypoglycaemia rates were not significantly different in T2D
patients. In T1D patients, total hypoglycaemia rates were higher with BIL
and associated with higher rates of daytime hypoglycaemia following
bolus insulin administration. There were no statistically significant treat-
ment differences in severe hypoglycaemia rates in the integrated analyses.
For symptomatic hypoglycaemia events, the mean SMBG values were
not different with BIL vs GL. Continuous glucose monitoring in a subset
of T1D and T2D patients showed similar mean duration of individual
hypoglycaemia events by treatment groups.
Conclusion: Treatment with BIL compared to GL was associated with
greater HbA1c reductions and fewer nocturnal hypoglycaemia events in
patients with T1D or T2D.
Clinical Trial Registration Number: NCT01435616, NCT01468987,
NCT01481779, NCT01454284, NCT01582451
Supported by: Eli Lilly and Company
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Basal Insulin peglispro (BIL) provides better HbA1c control with less
nocturnal hypoglycaemia than NPH when used in combination with
oral agents in type 2 diabetic patients: IMAGINE 6
G. Grunberger1, L. Chen2, Á. Rodríguez3, F.J. Tinahones4, S.J.
Jacober2, J. Bue-Valleskey2;
1Grunberger Diabetes Institute, Bloomfield Hills, 2Eli Lilly and Compa-
ny, Indianapolis, USA, 3Eli Lilly and Company, Alcobendas, 4Hospital
Virgen de la Victoria, Malaga, Spain.
Background and aims: Basal insulin peglispro (BIL) is a novel basal
insulin with a flat profile which has a hepato-preferential action resulting
from reduced peripheral effects.
Materials and methods: This Phase 3, open-label, treat-to-target (TTT)
study assessed if BIL was non-inferior (margin=0.4%) to NPH in reduc-
ing HbA1c in insulin naïve patients with type 2 diabetes when added to
prestudy oral agents (26-week endpoint).
Results: Patients were randomised to bedtime NPH (n=213) or BIL (n=
428; n=213 morning and n=215 bedtime dosing). HbA1c at endpoint
was lower for BIL vs NPH (6.8 vs 7.1%; treatment difference [95% CI]: -
0.37% [-0.50, -0.23%]; p<0.001). A greater proportion of BIL patients
achieved HbA1c <7% (66.3 vs 44.7%; p<0.001) and HbA1c <7% with-
out nocturnal hypoglycaemia (39.1 vs 12.6%; p<0.001). Weight gain did
not differ between groups; insulin doses were higher in BIL patients (BIL:
0.40 vs NPH: 0.35 U/kg; p=0.015). Nocturnal hypoglycaemia rates
(events/patient/30 d) were lower for BIL vs NPH (0.31 vs 0.61; p<
0.001) and total hypoglycaemia rates were similar (BIL: 1.46 vs NPH:
1.73; p=0.092). No significant differences between groups were ob-
served at endpoint for any lipid variables. At endpoint, ALT increased
with BIL, but patients with ALT ≥3XULN did not differ between groups,
with no cases of Hy’s law. Injection site reactions were infrequent.
Conclusion: In this TTT study, BIL treatment showed clinically relevant
improvements in glycaemic control and a significant reduction in noctur-
nal hypoglycaemia compared to NPH, consistent with a hepato-
preferential action and reduced peripheral activity.
Clinical Trial Registration Number: NCT01790438
Supported by: Eli Lilly and Company
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Clinical performance of a new integrated insulin pump system in
adult patients with type 1 diabetes
R. Bilous1, R. Prager2, T.R. Pieber3, S. Ramtoola4, P. Narendran5, K.D.
Barnard6, K. Köhler7, U. Gelchsheimer8, B. Petersen8, L. Amstutz9, I.
Schütz-Fuhrmann2;
1James Cook University Hospital, Middlesbrough, UK, 2Hospital
Hietzing, Vienna, 3Medical University of Graz, Austria, 4Royal Black-
burn Hospital, 5University Hospital Birmingham, 6University of South-
ampton, UK, 7Premier Research Germany Limited, Darmstadt, 8Roche
Diagnostics GmbH, Mannheim, Germany, 9Roche Diabetes Care, Inc.,
Indianapolis, USA.
Background and aims: The Accu-Chek® Insight diabetes therapy sys-
tem combines a glucose meter with integrated bolus advice and extended
data management capabilities with an insulin pump. The use of the new
system was evaluated in a multicenter clinical trial conducted in Austria
and the United Kingdom.
Materials and methods: Individuals with type 1 (T1) or type 2 (T2)
diabetes mellitus (DM) >18 years of age, and for >6 months on intensive
insulin therapy were eligible for this 6-month study of the new system.
All individuals received training on the use of the new system. HbA1c
results were evaluated in a central laboratory. Pump signals were captured
through data uploads using engineering software. User acceptance of the
new systemwas assessed bymeans of a self-report questionnaire using an
11-point Likert Scale.
Results: 90 individuals with T1DM were included in the intention-to-
treat analyses: age 41.8 (18-75) years, BMI 27.1 (19-41) kg/m2, HbA1c
7.8 (5.8 - 10.8) %, T1DM since 23 (1-49) years. 76 individuals had been
previously on insulin pump therapy, and 14 on multiple daily injection
(MDI) therapy. 81 individuals completed the study, 9 individuals
discontinued the study or were withdrawn. Insulin pump experienced
users maintained their mean
baseline HbA1c levels (7.76+1.00%) at Month 3 (7.58+0.93%) and
Month 6 (7.73+0.96) after switching from other insulin pump systems,
most often the Accu-Chek® Combo system, to the Accu-Chek® Insight
system. Mean HbA1c levels decreased in previous MDI users from 7.96+
1.20% at baseline to 7.45+1.22% at Month 3 and 7.46+1.08% at Month
6. At month 6, the mean change from baseline was significantly different
from 0: -0.50, 95% CI [-0.94; -0.06]. Two episodes each of severe hypo-
glycemia and diabetic ketoacidosis were reported. Most frequently re-
corded errors were electronic for the pump, and battery life time related
for the meter. User acceptance of the new system was high, with highest
ratings given for the ease of use of the insulin pump.
Conclusion: In adults with type 1 diabetes, the new Accu-Chek® Insight
diabetes therapy system was effective and safe to use under routine prac-
tice conditions. Glycemic control improved when switching from MDI
therapy, and was maintained in previous insulin pump users. User accep-
tance of the new system was high.
Clinical Trial Registration Number: NCT02105103
Supported by: Roche Diagnostics
983
Continuous glucose monitoring improved glycaemic control in
patients with type 1 diabetes during 52 weeks of insulin pump ther-
apy as well as with basal-bolus insulin regimen
J. Šoupal1, M. Flekač1, L. Petruželková2, J. Škrha jr.1, J. Škrha1, M.
Prázný1;
13rd Department of Internal Medicine, 1st Faculty of Medicine, 2Depart-
ment of Paediatrics, 2nd Faculty ofMedicine, Charles University, Prague,
Czech Republic.
Background and aims: Insulin pump therapy (CSII) improves glycemic
control of patients with diabetes, both individually and in combination
with continuous glucose monitoring (SAP - Sensor Augmented Pump).
However, the efficacy of long-term use of real-time continuous glucose
monitoring (RT-CGM) in patients on multiple daily injections (MDI) is
less described. The aim of the study was to compare the efficacy of long-
term use of RT-CGM on glycemic control in patients treated with CSII or
MDI in comparison to more common schemes based on classical self-
monitoring of blood glucose (SMBG).
Materials and methods: In this prospective study, 52 patients with type
1 diabetes were followed up for 1 year (age 36±13 years, diabetes dura-
tion 15±8 years, HbA1c 68±10 mmol/mol). Patients were divided into 3
groups with comparable baseline parameters. 17 patients started to use
RT-CGM. 18 patients initiated insulin pump therapy alone (without RT-
CGM) and 17 patients in a control group continued on MDI and SMBG
only. In the first group with RT-CGM, 10 patients started to use insulin
pump and sensors (SAP) and the remaining 7 continued with MDI (MDI
+ RT-CGM). Prerequisite for participation in the first group was the
willingness to use sensors>70% of the time. At the baseline, all 52 pa-
tients were monitored by blinded CGM and underwent a structured edu-
cation according to type of their future treatment. In addition, groups of
patients without RT-CGM were monitored for a week by blinded CGM
every 3 months and at the end of the study. The main endpoints were
reduction of HbA1c, glycemic variability expressed by the standard de-
viation of blood glucose (SDT) and the incidence of hypoglycemia (% of
time below 3.9 mmol/L). Statistical analysis was performed by nonpara-
metric tests (Kruskal-Wallis and ANOVA-repeated measurement).
Results:After a year, the group of patients on RT-CGM had significantly
lower HbA1c (67±11 vs. 55±11 mmol/mol; p<0.0001), and both sub-
groups of patients, with SAP and with MDI + RT-CGM, showed compa-
rable improvement in HbA1c. Insulin pump therapy alone (without RT-
CGM) also led to reduction of HbA1c (68±9 vs. 63±8 mmol/mol; p<
0.05), while in the control group just on MDI significant decrease of
HbA1c was not reached (67±9 vs. 64±10 mmol/mol; NS). Importantly,
any treatment strategy using RT-CGMwas superior to insulin pump ther-
apy alone (HbA1c: 55±11 vs 63±8 mmol/mol; p<0.05). As compared to
the baseline, glycemic variability was lower both, in the group with RT-
CGM (SDT: 4.0±0.7 vs. 3.0±0.5; p<0.0001) as well as in patients with
insulin pumps alone (SDT 3.8±0.7 vs. 3.4±0.6; p<0.01). Moreover,
reduction of time spent in hypoglycemia was observed only in patients
with RT-CGM (8±4 vs. 6±3%; p<0.01).
Conclusion: The usage of RT-CGM for 70% of the time or more resulted
in significant HbA1c reduction in patients with insulin pumps as well as
in patients onMDI. This improvement was greater than the improvement
with insulin pumps alone. The combination of RT-CGM and MDI can be
a suitable alternative to the SAP system for some patients.
Supported by: The research project of Charles University (Prvouk 25)
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Diabetes control in type 1 diabetes mellitus patients treated with
continuous subcutaneous insulin infusion vs multiple daily insulin
injections in short and long term follow up
K. Chantziara, S. Koutroumpi, A. Tsartsalis, E. Souvatzoglou, G.
Ioannidis, B. Vlassopoulou, V. Tsimihodimos, S. Tsagarakis, C.
Vasilopoulos;
Department of Endocrinology, Diabetes & Metabolism, Evangelismos
Hospital, Athens, Greece.
Background and aims: Type 1 Diabetes Mellitus (T1DM) is a chronic
disease that requires continuous training of patients in order to optimize
their blood glucose levels and achieve the goals set for glycated hemo-
globin A1c (HbA1c). Patients are often treated with either Continuous
Subcutaneous Insulin Infusion (CSII) or Multiple Daily Insulin
Injections(MDII). The aim of this study was to investigate the outcome
in lowering HbA1c and fasting blood glucose (FBG), as well as the result
in body weight (BW) of T1DM patients treated with either CSII or MDII.
Materials and methods: A retrospective cohort including 291 T1DM
patients who were followed in the Diabetes Center of our Department
between 2008 and 2014. Two groups were included: 196 patients started
on treatment with CSII and 95 treated with MDII. All CSII patients were
previously treated with MDII. Both groups received intensive training on
how to monitor their blood glucose and how to control both hyper and
hypoglycemia.Wilcoxon test was used to calculate each group at baseline
vs. one-year (FU1, short-term) and five-year (FU5, long-term) follow up
and Mann-Whitney test was used to compare CSII vs. MDII at baseline,
one-year and five-year follow up due to not normally distributed vari-
ables. Statistical significance was defined when p<0.05.
Results: The patients’ age ranged from 20 to 68 years old; diabetes
duration since diagnosis ranged from 4 to 48 years. At baseline, there
was a statistically significant difference in BW between the two groups,
CSII 74.0 kg (64.0-82.5) andMSII 69.0 kg (58.0-78.5), p=0.043. HbA1c
was significantly reduced from baseline both at one-year as well as at
five-years follow up in patients on CSII (p<0.001 for both). HbA1c was
reduced significantly in patients on MDII at one-year follow up 7.1%
(6.3-8.3), compared to the baseline value 8.0% (6.9-9.3),p=0.013, but
not at five-year follow up 7.1% (6.5-7.9), p=0.181.All other variables
were not significantly different. The reduction of HbA1c, FBG and the
BW difference between the two groups were not significantly different
(Table 1).
Conclusion:Our study demonstrates that both CSII andMDII have com-
parable results in improving diabetes control both in short and long-term
follow up, which could be attributed to the intensive training program
applied in this T1DM patient cohort.
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Cost savings associated with CSII therapy compared to MDI in a
Swedish setting
A.-S. Brandt1, S. de Portu2, J. Hellman3;
1Medtronic Danmark A/S, Copenhagen, Denmark, 2Medtronic Interna-
tional Sàrl, Tolochenaz, Switzerland, 3Uppsala University Hospital, Swe-
den.
Background and aims: The aim was to estimate the potential clinical
and economic benefits of insulin pump therapy (CSII) compared to mul-
tiple daily injection (MDI) therapy in a real life setting in Sweden.
Materials and methods: The model used a Markov framework based on
a recent meta-analysis where real life data from Uppsala Academic Hos-
pital was used to define baseline cohort characteristics. A 100 patient
cohort was modelled over a four year period. Key events modelled were:
Severe Hypoglycemic events (SH), Diabetic Ketoacidosis (DKA) and
death. Cost of treatment and the costs associated to address acute com-
plications in the Swedish health care setting were retrieved from pub-
lished literature.
Results: The total cost of CSII for the patient population (including
societal cost) over 4 years was 21 365 608 SEK and the total cost of
MDI treatment was 44 042 816 SEK. This suggests a total cost saving
of 22 677 208 SEK when CSII is selected vs MDI. By avoiding events
such as DKA and SH followed associated benefits with the mortality risk
of these specific events. In the 4 year time horizon selected, 8 deaths were
avoided by using CSII therapy.
Conclusion: The greater cost of the CSII treatment is offset by the re-
duced costs related to acute complications being avoided due to better
control compared to MDI treatment.
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Efficacy and safety after 1 year of insulin pump therapy in type 2
diabetes: the OpT2mise Study continuation phase
Y. Reznik1, R. Aronson2, I. Conget3, S. Runzis4, A.-S. Racault4, J.
Castaneda5, S.W. Lee6, O. Cohen7;
1Department of Endocrinology, University of Caen Côte de Nacre Re-
gional Hospital Center, France, 2LMCDiabetes & Endocrinology, Toron-
to, Canada, 3Endocrinology and Nutrition Department, University Hos-
pital Clinic, Barcelona, Spain, 4Medtronic International Trading Sàrl,
Tolochenaz, Switzerland, 5Medtronic Bakken Research Center, Maas-
tricht, Netherlands, 6Medtronic Diabetes, Northridge, USA, 7Chaim She-
ba Medical Center, Tel Hashomer, Israel.
Background and aims: The impact of continuous subcutaneous insulin
infusion (CSII) administered to type 2 diabetes patients failing to respond
to multiple daily injections (MDI) is still debated. The OpT2mise study
was a multicenter, randomized, controlled trial comparing CSII vsMDI in
insulin-using patients with T2D.
Materials and methods: Subjects using MDI basal bolus regimen with
rapid and slow-acting insulin analogs at a total daily dose (TDD)>0.7
U/kg/d, with persistent hyperglycemia (A1c ≥8%) after a 8-week optimi-
zation period, were randomly assigned to CSII or to continue MDI in the
“study phase” (SP) of 6 months. In another 6-month “continuation phase”
(CP), CSII patients continued pump therapy while MDI subjects crossed
to CSII. Of 331 subjects randomized in the study phase (45.6% women,
age 56.0±9.6 yr, BMI 33.4±7.3 kg/m2, diabetes duration 15.1±8.0 yr,
A1c 9.0±0.8%), 291 completed the 12 months study.
Results: At 6 months, CSII subjects had achieved significantly greater
A1c reduction than MDI subjects (-1.1±1.2% vs. -0.4±1.1%, p<0.001)-
and this effect was maintained until 12 months in the CSII subjects. MDI
subjects crossing to CSII after the 6-month SP showed during the CP a -
0.8% A1c reduction, with a final A1c similarly dropping at 7.8% in both
arms. SP response rate (A1c <8.0%) was higher in the CSII arm (CSII
55% vs. MDI 28%) but by end of the CP, both groups had achieved
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similar response rates of 57%. In the overall patient population, the de-
crease in A1c at 12 months was independent of diabetes duration, body
mass index (BMI), education level, MoCA score, and number of blood
glucose self-assessment(SMBG) performed per day. Frequency of SMBG
declined similarly in both groups throughout both study phases from a
mean of 4.0/day to the 12-month result of 3.4/day for MDI and 3.6/day
for CSII subjects. At the end of the SP, TDDwas 20.4% lower in the CSII
subjects compared to the MDI subjects. During the CP, MDI subjects
crossing to CSII showed a 19.0% TDD reduction and finally TDD was
equivalent in both groups. There was no between-groups difference in
weight gain during the whole study period (CSII : +2.1±5.2 and MDI : +
2.3±4.9 kg). No ketoacidosis occurred during the whole study period in
both groups. One patient in the CSII subjects and 2 in the MDI subjects
experienced severe hypoglycemia during the whole study phase.
Conclusion: OPT2MISE demonstrates that CSII provides a significant
advantage in glycemic control over MDI with a safe and consistent effect
in long-term treatment, proving the durability of CSII impact on glucose
control during a 1 year period of treatment.
Clinical Trial Registration Number: NCT01182493
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Twelve-week unsupervised day-and-night closed loop insulin
delivery during free daily living in adults with type 1 diabetes: a
multicentre randomised cross-over study
H. Thabit1,2, L. Leelarathna1,2, S. Dellweg3, J.K.Mader4, S. Hartnell2, C.
Benesch3, H. Kojzar4, M. Holzer4, L. Heinemann3, M.E. Wilinska1, T.R.
Pieber4, S. Arnolds3, M.L. Evans1,2, R. Hovorka1, AP@Home
consortium;
1University of Cambridge, 2Department of Diabetes and Endocrinology,
Addenbrookes Hospital, Cambridge, UK, 3Profil Institut, Neuss, Germa-
ny, 4Division of Endocrinology and Metabolism, Department of Internal
Medicine, Medical University of Graz, Austria.
Background and aims: Closed loop studies in outpatient settings have
shown promising results in an up to one week day-and-night application.
Prolonged day-and-night home use has not been investigated. In a 12-
week open-label prospective multinational three-centre randomised
crossover study, we evaluated the efficacy and safety of unsupervised
day and night closed-loop insulin delivery compared to sensor augmented
pump (SAP) therapy at home settings under free living conditions.
Materials and methods: Twenty-five adults with type 1 diabetes on
insulin pump therapy (13 male, age 40.0±9.4 years, HbA1c 8.5±0.6%,
duration of diabetes 20.9±9.3 years) underwent 5 weeks of training and
optimisation on SAP, followed by two 12-week periods of SAP and day-
and-night closed-loop utilising a model predictive control algorithm to
direct insulin delivery overnight and between meals and prandial insulin
delivery based on standard bolus wizard. The order of interventions was
random with a 4 week washout between study periods. The primary
outcome was time when sensor glucose were in the target range between
3.9 and 10.0 mmol/l. Analyses were by intention to treat.
Results: The proportion of time when sensor glucose was in target range
between 3.9 and 10.0 mmol/l was significantly increased during closed-
loop compared to SAP (P<0.001; Table). Mean glucose and time spent
above target range were significantly reduced during closed loop, while
time spent below target was low and comparable during both interven-
tions. Hypoglycaemia exposure measured by AUC <3.5 mmol/l was
reduced during closed loop (P=0.004). Glycaemic variability measured
by standard deviation of sensor glucose was modestly reduced during
closed-loop (P=0.001). Reduction in mean glucose and time spent above
target range during closed loop was brought about without changing the
total daily insulin delivery (P=0.44).
Conclusion: Prolonged home use of unsupervised day-and-night closed
loop under free living conditions in adults with type 1 diabetes is feasible
demonstrating improved glucose control and reduced exposure to
hypoglycaemia without increasing total daily insulin requirements.
Clinical Trial Registration Number: NCT01961622
Supported by: Seventh Framework Programme of the EU, NIHR Cam-
bridge BRC, and JDRF
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Psychological aspects of evening and night closed-loop insulin
delivery under free living conditions: a 2 months cross-over trial
J. Kropff1, J. DeJong1, S. del Favero2, J. Place3, M. Messori4, B.
Coestier3, A. Farret3, F. Boscari5, S. Galasso5, D. Bruttomesso5, C.
Cobelli2, E. Renard3, L. Magni4, J.H. DeVries1, AP@home consortium;
1Internal Medicine, Academic Medical Center, Amsterdam, Netherlands,
2Information Engineering, University of Padova, Italy, 3Endocrinology,
Diabetes, Nutrition, Montpellier University Hospital, France, 4Civil En-
gineering and Architecture, 5Internal Medicine, University of Padova,
Italy.
Background and aims: Closed-loop glucose control or Artificial Pan-
creas (AP) research is currently at a level that allows assessment of psy-
chological aspects and patients’ perspective. In this study we aimed to
assess the acceptance of long-term use of a current AP system and its
impact on fear for hypoglycaemia and treatment satisfaction.
Materials and methods: In a multicentre, randomized cross-over trial,
35 adults with Type 1 Diabetes using an insulin pump were included.
Sensor Augmented Pump (SAP) therapy was used day and night during
the control period, while SAP was replaced by closed-loop glucose con-
trol from dinner until wake-up in the intervention period. Both interven-
tion periods lasted 8 weeks, were preceded by a run-in and divided by
4 weeks wash-out. The AP acceptance questionnaire, Hypoglycaemia
Fear Survey II (HFS-II) and Diabetes Treatment Satisfaction Question-
naire (DTSQs) were administered throughout the study and semi struc-
tured interviews were conducted after study completion in a subset of
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patients (n=8). Normality of data distribution was confirmed, paired t-
tests were used for analysis.
Results: Three drop-outs resulted in 32 patients available for analysis,
56.3% female, mean age 48, mean pump treatment duration 10.2 years
and a total daily insulin dose of 0.54 u/kg/day. The total AP perspective
score was 69.14 (SD 14.71 [95% CI 63.54, 74.73], 76.82% of 90 points
max score), indicating a positive attitude towards the AP. Perceived use-
fulness (42.10, SD 8.73 [95% CI 38.78, 45.42], 77.97% of max score of
54) and perceived ease of use (9.62, SD 2.03 [95% CI 8.85, 10.39],
80.17% of max score of 12) were the highest scoring items in the AP
questionnaire. Themes frequently mentioned by patients in the interview
were ‘positive effects at work’, ‘improved blood glucose’, ‘less worries
about blood glucose’, but also ‘frequent alarms, interferingwith sleep and
social life’, ‘technological issues’, mainly connectivity problems and ‘de-
mand for an all-in-one device’. No significant difference between AP and
SAP was found in fear of hypoglycaemia (as reflected by the HFS-II
mean total score, range 0-4, reduction 0.15 vs. 0.06, p 0.32, difference
0.09 [95% CI -0.09, 0.27]) or worries about hypoglycaemia (as reflected
by the HFS-II worry subscale, range 0-4, reduction 0.19 vs. 0.12, p 0.53,
difference 0.07 [95% CI -0.15, 0.28]). DTSQs results showed similar
treatment satisfaction scores (range 0-36) for the AP and SAP of 28.01
(SD 7.06 [95% CI 25.40, 30.67]) and 28.17 (SD 5.19 [95% CI 26.23,
30.10]).
Conclusion: Our data indicates that current acceptance of the AP is
reasonably good. Positive effects of the AP include perceived improved
blood glucose and better performance at work, shadowed by frequent
technological hassles impacting factors such as nocturnal usability. Pa-
tients are equally satisfied with AP and SAP use, without difference in
improvement of fear for hypoglycaemia. Current AP technology is prom-
ising but diminishing the frequent hassles is needed.
Clinical Trial Registration Number: NCT02153190
Supported by: FP7-ICT-2009-4 grant number 247138
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Evaluation of HbA1c in subjects with type 1 diabetes with and
without insulin pump transferred from paediatric to adult diabetes
care through an adolescence unit between 2002 and 2014
M.Wittrup, E.E. Hommel, S. Hangaard, L. Jelstrup, H.-C. Andersen,M.
Hviid, S. Wulff, L. Vinther, M. Ridderstråle;
Steno Diabetes Center, Gentofte, Denmark.
Background and aims:We wanted to evaluate the HbA1c development
in adolescent patients with type 1 diabetes (T1D) transferring from a
paediatric to an adolescence clinic between 2002 and 2014 with a partic-
ular focus on the use of insulin pumps; continuous subcutaneous insulin
infusion (CSII). Over time we have observed a decrease in HbA1c at the
service and wanted to investigate to what extent this decrease was due to
the increased use of CSII in children and adolescents with T1D.
Materials and methods: We included adolescent patients transferred
from paediatric departments to our adolescence clinic between 2002
and 2014; in total 480 subjects, 253 males and 227 females in the study.
Average age at transfer was (mean ± SD): 18.6±1.5 and 18.8±1.6 years,
and diabetes duration 6.6±4.8 and 7.9±5.0 years for males and females,
respectively. We divided the cohort into three groups: CSII at transfer (C,
n=96), receiving CSII during follow-up (R, n=53) and multiple daily
injections (M, n=331).
Results: The HbA1c level of patients transferring from pediatric services
to our adolescence center has successively and significantly decreased
since 2005 up until today (e.g. from 81,1±25,5 mmol/mol in 2005 (n=
53) to 69,0±18,4 in 2014 (n=54); p<0.001 for the whole study period by
One Way Anova.In parallel, the use of CSII has increased from 0 to 40%
of patients during the study period (p<0.0001). Baseline HbA1c was
significantly lower in the C compared to the R and M groups (66.1±
2.2, 74.9±2.9, and 75.9±1.2, respectively; p=0.001). Patients already
on CSII were older at transfer (19.3±0.2, 18.8±0.2, and 18.5±0.1, re-
spectively; p<0.0001), and had a significantly longer duration of diabetes
(9.8±0.5, 8.4±0.7, and 6.3±0.3 years, respectively; p<0.0001). The 53
patients receiving CSII during follow-up were characterized by a signif-
icant decrease in Hb1Ac between the first and forth year after transfer
(from 78,5+22.9 to 72,8+22,4 mmom/mol; p=0.04 (n=27). The HbA1c
development as a function of time after transfer is illustrated in Figure 1.
Over the five year follow-up period there was a non-significant decrease
in the HbA1c of patients already on CSII at transfer. Among the other
patients there was a slight increase in HbA1c in those subsequently put on
pump. Their HbA1c levels decreased parallel to the other patients during
the follow-up. Patients considered not in need of CSII either before or
after transfer were characterized by a continuous decrease in HbA1c
which was significant after five years (p=<0.01).
Conclusion: Adolescence patients on CSII transitioning from paediatric
to adult diabetes care appear to have a lower HbA1c compared to patients
on MDI. CSII users trended towards being female and having a longer
duration of diabetes. Patients put on CSII post-transition also experience
benefits in terms of HbA1c lowering.
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The impact of hypoglycaemia on health care use and costs in US
patients with type 2 diabetes mellitus newly-initiated on basal insulin
F. Ye1, M.R. Dalal1, M. Kazemi1, L. Xie2;
1Sanofi US, Inc., Bridgewater, USA, 2STATinMED Research, Ann Ar-
bor, USA.
Background and aims: Insulin use is associated with an increase in
hypoglycaemia, which may have a negative impact on insulin therapy
persistence, target HbA1c achievement, and health care costs. This retro-
spective cohort study, of US patients, assessed health care use and costs in
those with type 2 diabetes mellitus (T2DM) who experience
hypoglycaemia after initiating insulin.
Materials and methods: The MarketScan™ claims databases were used
to identify adult patients with T2DM who initiated basal insulin therapy
(defined as having no insulin prescription≥12 months before starting
insulin glargine, insulin detemir, or NPH insulin) between January 2007
and March 2013. Hypoglycaemic events were identified by health care
encounters with an ICD-9-CM diagnosis code of 250.8× during the first
6 months of basal insulin use. Data were assessed for 12 months prior
(baseline) and 12 months after insulin initiation. Differences in baseline
demographic and clinical characteristics between patients who had
hypoglycaemia during the first 6 months following initiation with basal
insulin therapy and those who did not were compared using t-tests for
continuous variables, and Chi-squared tests for dichotomous variables.
Outcomes were adjusted for differences in demographics, clinical char-
acteristics and baseline health care utilization, and were adjusted using
regression analyses. Logistic regression was used to model inpatient ad-
missions and visits to the emergency department (ED). Health care costs
were modelled with a generalized linear model.
Results: Of the 134,934 patients identified, 7,371 (5.5%) had
hypoglycaemia during the first 6 months; there were significant differ-
ences in baseline characteristics between patients (Table). At 12 months,
more patients with hypoglycaemia, versus those without, had hospitali-
zations and ED visits, and greater total and diabetes-related health care
costs (Table).
Conclusion: Hypoglycaemia was seen in 5.5% of US patients with
T2DM within 6 months after basal insulin initiation, and was associated
with greater costs and health care resource use.
Supported by: Sanofi US, Inc.
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Health economic impact of hypoglycaemia in a global population of
patients with insulin-treated diabetes
L. Elliott1, R. Aronson2, G. Galstyan3, M. Goldfracht4, S.N. Alsifri5,
R.A. Kapur6, K. Khunti7;
1Market Access, Novo Nordisk A/S, Copenhagen, Denmark, 2LMC Di-
abetes & Endocrinology, Toronto, Canada, 3Endocrinology Research
Center, Moscow, Russian Federation, 4Clalit Health Services, Tel Aviv,
Israel, 5Al Hada Military Hospital, Taif, Saudi Arabia, 6Novo Nordisk
A/S, Søborg, Denmark, 7University of Leicester, UK.
Background and aims: HAT (Hypoglycaemia Assessment Tool) was a
non-interventional, multicentre, 6-month retrospective and 1-month pro-
spective study of hypoglycaemic events in 24 countries.
Materials and methods: Questionnaires and patient diaries (28-day
prospective period) were completed by adults with type 1 (T1DM) or
type 2 diabetes (T2DM) and using insulin for ≥12 months (N=27,585).
Results: Patient responses to hypoglycaemia had both direct and indirect
economic impact with regional variations in their extent. Direct economic
impact included more frequent blood glucose self-monitoring (reported
by 69.7% [T1DM] and 60.9% [T2DM] of patients), increased
hospitalisation (T1DM 2.1%; T2DM 3.4% of patients) and increased
medical contact in the month following hypoglycaemia (T1DM 3.8%;
T2DM 6.8% of patients). Indirect economic impact included loss of pro-
ductivity due to absence from work or study; 3.9% (T1DM) and 6.2%
(T2DM) of patients took leave from work following hypoglycaemia.
Regional differences included higher hospital admissions in Latin Amer-
ica vs global data (5.2 and 6.8% vs 2.1 and 3.4% of patients for T1DM
and T2DM, respectively) and more clinic visits for southeast (SE) Asia vs
global data (5.7 and 12.6% vs 3.8 and 6.8%). However, increased blood
glucose monitoring was lower for SEAsia vs global data (53.2 and 37.5%
vs 69.7 and 60.9% for T1DM and T2DM, respectively).
Conclusion: This study shows that hypoglycaemia has a significant but
variable impact on the economics of diabetes healthcare globally.
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Impact of the Framingham Offspring Study (FOS) vs Kaiser
Permanente NorthWest (KPNW) prediction equations for diabetes
mellitus in economic modelling of type 2 diabetes mellitus
C. Asseburg, P. Johansen, A. Nilsson, M. Willis;
The Swedish Institute for Health Economics, Lund, Sweden.
Background and aims:The short- and intermediate-run consequences of
overweight and obesity patterns are well-known, including elevated risk
of T2DM, micro- and macrovascular complications, and premature mor-
tality. Given worrisome population weight trends in most western coun-
tries, estimation of long-term consequences is necessary to allocate health
care resources for primary and secondary intervention efficiently. Be-
cause trial data of sufficient duration are seldom available, allocation of
economic resources is often based on economic simulation modelling.
Prediction equations for developing T2DM are a key driver of model
outcomes, but the impact of choice of equation is unknown. The aim of
this study is to evaluate the performance of two published risk equations
in predicting outcomes in the data they were estimated with and in an
external study and to compare predictions over the long horizons typical
of health economic modelling.
Materials and methods: The Economic and Health Outcomes Model of
Weight Management (ECHO-WM), a long-term stochastic
microsimulation model, was used to estimate the conversion rate to
T2DM for three cohorts of non-T2DM patients matching baseline char-
acteristics of the FraminghamOffspring Study (FOS), Kaiser Permanente
Northwest (KPNW), and the Diabetes Prevention Study (DPP). ECHO-
WM includes both the FOS and the KPNW T2DM equations, yielding
six simulations. Key outcomes included the cumulative incidence of
T2DM at 8 years for the FOS and KPNW patient cohorts and 10 years
for the DPP patient cohort and 25-year cumulative incidences of T2DM
and micro- and macrovascular events.
Results: The FOS equation better matched the observed FOS cumulative
incidence of 5.1% (5.5% vs. 13.1%) and the KPNW risk equation better
matched the observed KPNW cumulative incidence of 16.5% (16.6% vs.
7.2%). The differences were maintained at 25-years. The incidence of
microvascular complications followed differences in predicted T2DM,
though predicted rates of macrovascular events and life-years were sim-
ilar. Quality-Adjusted Life-Years were lower with the KPNW equations.
Both risk equations underestimated the ~51.8% incidence of T2DM over
10-years in the placebo arm of the enriched (impaired glucose tolerance)
DPP cohort (13.8% and 28.4% incidence rates when using the FOS and
KPNWequations, respectively).
Conclusion: Simulations using an economic model support the internal
validity of the FOS and KPNW equations. External validity, however,
was limited and the simulations lend support to concerns that recalibra-
tion of the FOS (and by extension the KPNW) equations is necessary for
extrapolation to different patient populations. The FOS and KPNW risk
equations provide accurate predictions of the risks in patient populations
similar to that which they were estimated from, but may be inaccurate
when applied to different patients. Until more accurate prediction equa-
tions are available, it is advisable to include multiple risk equations in
economic models and use the most appropriate in any given application.
993
Vildagliptin is cost-effective in real-world: economic evaluation
evidence from EDGE study
G. Partha1, R. Agrawal1, P.M. Paldánius2, R. Viana2;
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharma AG,
Basel, Switzerland.
Background and aims: Therapeutic benefits of vildagliptin have been
extensively studied and characterised in randomised controlled trials
(RCTs). It is also commonly accepted that RCTs are largely unable to
reproduce real-life observations. Therefore, evaluation of outcomes in
real-world clinical practice would allow a full understanding of
vildagliptin usefulness as an oral antidiabetes therapy alternative. EDGE
(Effectiveness of Diabetes control with vildaGliptin and vildagliptin/mEt-
formin) was a worldwide prospective, non-interventional, ‘real-life’ ob-
servational study that compared the effectiveness and tolerability of
vildagliptin-based dual combinations with other oral antidiabetes drugs
in patients uncontrolled with monotherapy. Unlike sulphonylureas (SUs),
vildagliptin was able to provide glycaemic control targets at the same
levels as observed in RCTs. However, if this translates to cost-
effectiveness in real-world, is yet to be established. Therefore, the objec-
tive of this study is to evaluate the cost-effectiveness of vildagliptin+
metformin compared with generic SUs+metformin in patients with type
2 diabetes mellitus (T2DM) uncontrolled with metformin, from a real-life
perspective.
Materials and methods: Cost-effectiveness was assessed by building a
patient-level simulation model based on risk equations from the United
Kingdom Prospective Diabetes Study Outcomes (UKPDS) model. The
results were generated by simulating a cohort of 10,000 patients for a
lifetime time horizon. The model predicted micro- and macro-vascular
complications and mortality in yearly cycles. The base case compared
metformin+vildagliptin with metformin+SUs. The patients could move
on to metformin+basal insulin if they had inadequate glycaemic control
(using a threshold of HbA1c >7.5%). Effectiveness parameters for the
two strategies were derived from the EDGE study. Cost estimates were
based on UK direct medical costs. Both costs and benefits were
discounted at 3.5%. The annual therapy costs used were: £110.51,
£410.53 and £806.84 for metformin+SUs, metformin+vildagliptin and
insulin glargine+metformin, respectively. Hypoglycaemia rates and utili-
ty decrements were derived from the literature.
Results: Over the lifetime time horizon, fewer non-fatal diabetes-related
adverse events (AEs) were observed in patients treated with metformin+
vildagliptin compared to metformin+SUs treated patients that led to a
differential AE cost of £190 (£783 versus £973). Nonetheless, addition
of vildagliptin compared with SUs led to increased drug acquisition costs
that were counter-balanced with reduced costs of AEs, managing mor-
bidities, and monitoring patients. Metformin+vildagliptin yielded an in-
cremental gain of 0.03 quality-adjusted life years (QALYs) and a mean
per patient increase in total cost of £548, giving an incremental cost-
effectiveness ratio (ICER) of £18,801 per QALY.
Conclusion: In clinical practice, treatment with metformin+vildagliptin
resulted in lower incidence of diabetes-related AEs compared to metfor-
min+SUs. Additionally, an increase in health benefits was also observed.
Together, these results demonstrate that metformin+vildagliptin is a cost-
effective treatment strategy for T2DM in real-life setting.
Supported by: Novartis
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Cost-effectiveness of metformin plus vildagliptin versus metformin
plus sulphonylurea for the treatment of type 2 diabetes: a real-life
perspective
R. Viana1, R. Agrawal2, S.-H. Ong1, P.M. Paldánius1, G. Partha2;
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Healthcare Pvt.
Ltd., Hyderabad, India.
Background and aims:Metformin plus vildagliptin has been previously
shown to be cost-effective when compared with metformin plus
sulphonylurea (SU) in the Portuguese setting. However, the cost-
effective analysis was based on data from a head-to-head randomised
controlled trial (RCT) thereby, potentially limiting the external validity
and generalisability. EDGE (Effectiveness of Diabetes control with
vildaGliptin and vildagliptin/mEtformin) was a worldwide, prospective,
non-interventional, real-life observational study that compared the effec-
tiveness and tolerability of vildagliptin-based dual combinations with
other oral antidiabetes drugs in patients with type 2 diabetes mellitus
uncontrolled on monotherapy. Unlike SUs, vildagliptin was able to pro-
vide glycaemic control targets at the same levels as observed in RCTs.
However, the cost-effectiveness of vildagliptin in the real-world is yet to
be established. Therefore, the aim of this analysis was to determine the
cost-effectiveness of metformin plus vildagliptin using the EDGE data
and to compare these estimates with the previously published cost-
effectiveness results based on the RCT data in the Portuguese setting.
Materials and methods: Cost-effectiveness was assessed by building a
patient-level simulation model based on risk equations from the United
Kingdom Prospective Diabetes Study Outcomes (UKPDS) model. The
results were generated by simulating a cohort of 10,000 patients for a
lifetime time horizon. The model predicted microvascular and
macrovascular complications and mortality in yearly cycles. The base
case compared metformin plus vildagliptin with metformin plus SU.
The patients could move on to metformin plus basal insulin if they had
inadequate glycaemic control (HbA1c >7.5%). Effectiveness parameters
for the two strategies were derived from the EDGE study. Cost estimates
were based on direct medical costs only. Costs and benefits were
discounted at 5.0%. The annual therapy costs used were: €76.70 and
€662.74 for metformin plus SU and metformin plus vildagliptin, respec-
tively. Hypoglycaemia rates and utility decrements were derived from the
literature.
Results: Compared with the cost-effectiveness estimates based on the
RCT data, average quality adjusted life years (QALYs) increased from
5.63 to 5.73 for metformin plus vildagliptin and 5.74 to 5.77 for metfor-
min plus SU. Average total costs decreased from €13,052 to €12,073 for
metformin plus vildagliptin and from €14,310 to €12,544 for metformin
plus SU. The decrease in cost for metformin plus vildagliptin was mainly
driven by reduction in costs due to complications and adverse events,
namely hypoglycaemia. Overall, based on the EDGE data, treatment with
metformin plus vildagliptin yielded an incremental cost-effectiveness ra-
tio (ICER) of €11,072 per QALY. This value is within the same range
observed for cost-effectiveness assessment based on the RCT data.
Conclusion: This analysis confirms that the cost-effectiveness of metfor-
min plus vildagliptin extends beyond controlled clinical trials, and con-
tinues to be cost-effective in real-life settings.
Supported by: Novartis
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Cost-effectiveness of second-line therapies in real-world setting: an
economic evaluation of the EDGE study using patient level data
P. McEwan1, M. Evans2, V. Foos3, P.M. Paldánius4;
1Health Economics & Outcomes Research, 2University Hospital
Llandough, Cardiff, UK, 3IMS Health, Health Economics & Outcomes
Research, 4Novartis Pharma AG, Basel, Switzerland.
Background and aims: The observational, non-interventional EDGE
study showed that a DPP-4 inhibitor, vildagliptin, is efficacious in pa-
tients with type 2 diabetes mellitus who have suboptimal glycaemic con-
trol on metformin monotherapy in the real-world setting, confirming the
results of previous randomised clinical trials (RCTs). Simultaneously the
effectiveness of second-line sulphonylurea (SU)-based regimens was de-
creased in EDGE vs. the results attained in RCTs. Cost-effectiveness
evaluations are typically pharmaco-economic modelling based on RCT
data, however, there is a growing trend towards the complementary use of
real-world patient level data (PLD). Consequently, we sought to perform
a health economic evaluation based on data from EDGE study using an
established diabetes outcomes model and PLD drawn from the cohort
worldwide.
Materials and methods: The IMS Core Diabetes Model (CDM) was
used to evaluate the lifetime costs and outcomes of two different regi-
mens: metformin+vildagliptin compared to metformin+SU. Annual ther-
apy costs applied were for metformin+SU: £106.79 (year 1), then
£110.51 (year 2+) and for metformin+vildagliptin: £410.53 (year 1), then
£412 (year 2+). Therapy escalation at HbA1c of 8.5% was modeled
assuming insulin glargine+metformin (cost £899.51; year1, then
£806.84; year 2+). Published network meta-analysis data were used to
populate the CDM with hypoglycaemia rates. Multivariate regression
analysis of PLD output from CDM was undertaken using R version
2.15.2. UK costs (£UK) and health benefits were discounted at 3.5%.
Results: Overall predicted life expectancy (LE) and quality-adjusted life
expectancy (QALE) were 16.24 and 11.01, respectively. In multivariate
analysis, adjusting for baseline characteristics, metformin+vildagliptin
was associated with an increase in LE (0.8 years, p<0.001) and QALE
(0.12 years, p<0.001) compared to metformin+SU. Gains in LE and
QALE favouring metformin+vildagliptin were driven by an 8.6% and
6.8% reduction in the cumulative incidence of major microvascular and
cardiovascular complications. Total costs were £28,512 (metformin+SU)
and £27,507 (metformin+vildagliptin); this cost saving favouring metfor-
min+vildagliptin driven by reduced complications and a longer time to
insulin intensification compared to metformin+SU.
Conclusion: In the real-world setting, compared to SUs, vildagliptin was
estimated to be associated with lower overall costs and additional health
benefits. To our knowledge, this is the first report showing the potential of
cost savings achievement with use of vildagliptin in detriment of low
acquisition cost SUs. These data further highlight the potential role of
real-world observational data in assessing health economic value.
Supported by: Novartis
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Healthcare utilisation and costs following initiation of insulin
treatment in type 2 diabetes: a long-term follow-up in clinical
practice
A. Kalkan1, J. Bodegard1, J. Sundström2, B. Svennblad2, C. Östgren3,
P.M. Nilsson4, G. Johansson2, M. Ekman1;
1AstraZeneca, Södertälje, 2Uppsala University, 3Linköping University,
4Lund University, Malmö, Sweden.
Background and aims: Initiation of insulin is often chosen in type 2
diabetes mellitus (T2DM) patients when blood glucose control with other
antidiabetics fail. However, long term changes in resource use and costs
in primary and hospital care have not been reported before, important
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when planning type 2 diabetes health care utilization. The aim of this
study was to describe how T2DM patients were initiated on insulin, and
describe long-term changes in healthcare utilization and costs before and
after insulin initiation.
Materials and methods: T2DM patients newly initiated on insulin were
identified in primary health care records from 84 primary care centers
(almost 10% of all primary care centers in Sweden), between 1999-2009.
The index-date was set to date of first prescription with insulin and pa-
tients and at least a second insulin prescription within the following
15 months. Healthcare resource use data, excluding pharmaceuticals,
were extracted from electronic primary care medical records in primary
care and mandatory national patient register covering in- and outpatient
care. The mean healthcare costs per patient are reported as annual and
cumulative costs. Patients had to be on insulin treatment during follow-up
and were censored when no renewed prescription of insulin was regis-
tered within one year.
Results:During a median of 3 years (maximum9 years) follow-up; 6,213
T2DM patients (18,639 patientyears) were initiated, in combination or as
monotherapy, on short-, medium-, mixed medium long and long acting
insulin, 3%, 51%, 27% and 19% respectively. Patients initiated on insulin
were on average 64 years, 59%men, had HbA1c 7.6%, bodymass index,
29 kg/m2, blood pressure 140/80 mmHg and LDL 2.7 mmol/l. Mean per
patient annual healthcare costs were € 3,519 (95% CI 3,342-3,713) the
first year after insulin initiation, € 2,783 (95% CI 2621-2955) the second
year, and € 3,539 (95% CI 3,042-4,111) in year 9 (2012 unit cost values),
see figure. Mean per patient cumulative healthcare costs were € 29,316
(95% CI 27,833-31,106) at 9 years of follow-up. Higher costs were seen
in primary care compared with hospital care, € 15,245 (95% CI 14,122-
16,578) and € 14,071 (95% CI 13,226-15,043) respectively. The 2,776
patients with HbA1c >7.5% at insulin initiation had lower mean per
patient healthcare costs before insulin start compared with the 2,770 pa-
tients with HbA1c ≤7.5%, € 2,325 (95% CI 2,189-2,482) and € 2,931
(95% CI 2,717-3,168) respectively.
Conclusion: Initiation of insulin in type 2 diabetes patients were followed
by increased costs in both primary and hospital care and higher costs were
generated in primary care. Patients with lower HbA1c at insulin start had
surprisingly higher initial costs compared to those with higher HbA1c,
indicating two different clinical situations when the treatment decision
was made.
Supported by: AstraZeneca
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Cost-effectiveness of simple insulin infusion: Sweden
O. Henriksen1, M. Dall2, J. Warner3, C. Parkin4;
1Last Mile P/S, 2CeQur SA., Copenhagen, Denmark, 3CeQur SA.,
Marlborough, 4Cgparkin communications, inc, Boulder City, USA.
Background and aims: Continuous subcutaneous insulin infusion
(CSII) in people with type 2 diabetes (T2DM) has proven to improve
glycemic control (HbA1c) and reduce insulin dosage compared to multi-
ple daily injections (MDI). However, CSII has not been widely adopted in
T2DM due to costs, complexity and training requirements. New devices
that provide simple CSII reduce complexity and training requirements.
This analysis assessed the cost effectiveness in Sweden of simple insulin
infusion (SII) compared to MDI in people with T2DM not in glycemic
control.
Materials and methods: The UKPDS Outcomes Model was used to
project long-term cost-effectiveness over 40 years, based on results of
recently published studies and direct costs for Sweden. Costs and out-
comes were discounted at 3%. Cost-effectiveness was pre-defined in
relation to per capita gross domestic product (GDP) with Incremental
Cost Effectiveness Ratios (ICERs) below 1X, respectively 3X GDP per
capita per life year gained, defined as highly ‘cost-effective’, respectively
‘cost-effective’.
Results: Our analysis showed discounted 0.3 life year gained on average
and lifetime discounted savings on complication costs and insulin reduc-
tions of SEK 88,352. Based on projected direct costs and life expectancy,
a simple CSII device will be highly cost-effective in Sweden at a price of
SEK 36 per day and cost-effective at a price up to SEK 77. This implied
an ICER at 1, 3 times per capita GDP per life year gained for the two
cases, respectively. Cost effectiveness would be further supported if indi-
rect costs (i.e. costs of premature mortality and sick leave) were included.
These estimates were very robust to sensitivity analyses on both reduc-
tions in HbA1c and dose effects.
Conclusion: For people with T2DM not in glycemic control on MDI,
simple CSII is highly cost-effective at a daily cost in Sweden of SEK 36
or less and cost-effective at a daily cost of SEK 77 or less in Sweden.
Supported by: CeQur SA.
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The relative importance of maternal body mass index and glucose
levels for the prediction of large for gestational age births
R. Claesson1, E. Anderberg2, C. Ignell1, K. Källén2, K. Berntorp1;
1Department of Clinical Sciences, Lund University, Malmö, 2Department
of Clinical Sciences, Lund University, Lund, Sweden.
Background and aims: The risk of gestational diabetes mellitus (GDM)
increases substantially with increasing maternal body mass index (BMI).
GDM and maternal obesity are independently associated with adverse
neonatal outcomes, in particular large for gestational age (LGA) births,
which in turn increase the risk of complications among both the new-
borns and the mother. The aims of the present study were to evaluate the
relative contribution of maternal body mass index and glucose levels on
the prediction of LGA births in women giving birth in southern Sweden
during 2003-2005, and to investigate whether the prediction could be
further improved by adding information on maternal characteristics.
Materials and methods: Information on 10 974 pregnancies was re-
trieved from a population-based perinatal register. A 75-g oral glucose
tolerant test (OGTT) was performed in the 28th week of pregnancy for
determination of the 2-h plasma glucose concentration. Maternal BMI
was calculated fromweight and height measured during the first trimester.
The prediction of LGAwas assessed by receiver-operating characteristic
(ROC) curves, with LGA defined as birth weight>+2 SD of the mean.
The data set was divided into a development and a validation set. Using
the development set, predictive maternal variables were identified by
multiple logistic regression analysis. The predictive ability of the model
was then validated in the test sample.
Results:Based on the total data set, the area under the ROC curve (AUC)
of the 2-h glucose level to predict LGAwas 0.54 (95% confidence inter-
val (CI) 0.48-0.60), indicating poor performance. Factors associated with
LGA in the final multiple regression analyses were BMI (per 1-step
increase), 2-h glucose concentration (per 1 mmol/L increase), smoking
and parity 1 (less than 2-3 reference): odds ratio (OR) (95%CI) were 1.10
(1.08-1.13), 1.09 (1.01-1.18), 0.29 (0.16-0.52) and 0.51 (0.40-0.67), re-
spectively. Using the validation data base, the AUC for the developed
model was 0.69 (95% CI 0.66-0.72), which was identical to the AUC
retrieved from a model not including 2-h glucose, and larger than a model
including 2-h glucose but not BMI (AUC 0.63, 95% CI 0.60-0.67).
Conclusion: Both the 2-h glucose level of the OGTT and maternal BMI
had a significant impact on the risk of LGA births but the relative contri-
bution was higher for BMI. The data support the importance of targeting
healthy body weight in young women and to closer monitor weight dur-
ing pregnancy as a strategy in reducing the risk of excessive fetal growth.
Supported by: Malmö University Hospital and Skåne Research and De-
velopment Foundation
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Gestational weight gain is associated with obstetric and neonatal
outcome in morbid obese mothers with gestational diabetes
B. Barquiel, J.L. Bartha, L. Herranz, D. Meneses, M.A. Burgos, N.
Hillman, L.F. Pallardo;
Diabetes and Pregnancy Unit, Hospital Universitario La Paz, Madrid,
Spain.
Background and aims: To study the effect of gestational weight gain
(GWG) on pregnancy-induced hypertensive disorders (PIHD), caesarean
deliveries, neonatal ponderal index (NPI) and macrosomia in morbid
obese women with gestational diabetes (GDM) and to evaluate the best
upper limit of weight gain in these women.
Materials and methods: Observational retrospective study in 2747
women with GDM (NDDG criteria) between 1986 and 2012. Multiple
pregnancies, pregestational diabetes and secondary causes of
hyperglycaemia were excluded. A number of 118 (4.3%) consecutive
GDM women being morbidly obese pre-pregnancy (BMI≥35 kg/m2)
were included. GWG was measured as the difference between last prena-
tal weight and self-reported pre-pregnancy weight. Associations between
GWG and PIHD (140 and/or 90mmHg±proteinuria ≥300mg/24 hours at
>20 weeks’ gestation), caesarean deliveries, NPI (neonatal birthweight /
p50 for gestational age and sex) and macrosomia (neonatal birthweight
≥4000 g) were assessed. Spearman correlations or MannWhitney U tests
were used in bivariable comparisons. The effect of GWG on the associ-
ated outcomes (p <0.05) was adjusted for pre-pregnancy BMI and
glycaemic control (average of monthly HbA1c) in multiple stepwise for-
ward linear or binary logistic regression models. For each model con-
structed, GWG threshold values to predict an outcome were examined
on the basis of sensitivity (S) and specificity (E) values under the ROC
curve.
Results: Median GWG was 4.5 (IQ 1.3-8.2) (range -18 to 17.5) kg.
Median pre-pregnancy BMI was 37.4 (IQ 35.8-40.4) (range 35.0 to
52.1) kg/m2. Concerning other risk factors for GDM, mean age was 32
±5 yr, 80 (67.8%) women had family history of diabetes, 12 (10.2%) had
GDM in a previous pregnancy and 15 (12.7%) previous macrosomia.
Forty three (36.4%) women were nulliparous. Gestational age at GDM
diagnosis was 19.8±6.0 weeks (in 48 (40.7%) cases before 24 weeks).
GDM class was A1 in 71 (60.1%) and A2 in 47 (39.9%). Mean average
HbA1c was 5.3±0.5%. PIHD occurred in 41 (34.7%) women and cae-
sarean delivery in 49 (41.5%). Mean NPI was 1.03±0.17 and the rate of
macrosomia was 12 (10.2%) of the newborns. GWG was 6.5 (IQ 2.7-11)
in PIHD vs. 4.0 (0.9-6.6) kg in non-PIHD women (p=0.027). GWG
≥8 kg was very specific to predict PIHD (S=40.0%, E=90.0%). GWG
was not associated with caesarean delivery. GWG and NPI were positive-
ly correlated (r=0.227, p=0.017). GWG was related to macrosomia: 7.2
(4.4-14.0) vs. 4.4 (1.0-7.5) kg (p=0.044). GWG ≥5.5 kg correctly classi-
fied macrosomic newborns (S=77.8%, E=61.5%) and GWG≥11 kg was
highly specific (S=44.0%, E=99.0%) to detect macrosomia.
Conclusion:Morbid obese women with GDM and GWG ≥8 kg are at a
high risk of PIHD. We suggest an upper GWG threshold of 5.5 kg in
morbid obese women in order to reduce macrosomia.
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Triglyceride-glucose index is related to neonatal overgrowth in
mothers with gestational diabetes
D. Meneses1, O. Moreno1, B. Barquiel1, M.A. Burgos2, N. Hillman1, L.
Herranz1;
1Diabetes, 2Obstetrics, Hospital Universitario La Paz, Madrid, Spain.
Background and aims: Diabetes during pregnancy is associated with
abnormalities in protein and lipid metabolism in addition to those of
glucose metabolism. A positive correlation between maternal serum tri-
glyceride (TG) level and newborn birthweight has been reported. The
TyG index, the product of fasting plasma glucose (FPG) and TG has been
suggested as a surrogate of insulin resistance in healthy subjects. Our
objective is to determine whether maternal TyG index is associated with
newborn birthweight at term.
Materials and methods: A number of 223 consecutive women diag-
nosed with gestational diabetes mellitus (GDM) between 2009 and
2015 were followed. Multiple pregnancies were excluded. FPG and se-
rum TG concentrations were determined at 27±5 (1) and 34±2 (2) weeks
of gestation. The TyG index was calculated as Ln[Fasting TG (mg/
dL)*FPG (mg/dL)]/2. At term, neonatal weight was registered and fetal
ponderal index (FPI) calculated. Infants with birthweight above the
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90thpercentile were classified as LGA, based on gestational age and sex-
adjusted birthweight from Spanish neonatal growth charts. Pearson’s cor-
relation coefficients between TyG index, birthweight and FPI were com-
puted, respectively. T-test were applied to calculate TyGmean differences
between LGA and non-LGA neonates. A p-value <0.100 was considered
statistically significant.
Results: Women’s mean age was 35.1±4.6 years. Pre-pregnancy BMI
was 25.8±5.4 kg/m2. Gestational weight gain was 9.2±5.7 kg. Gesta-
tional age at diagnosis was 24.9±4.7 weeks. Mean FPG of oral glucose
tolerance test and HbA1c were 90.5±13.2 mg/dl and 5.2±0.4%, respec-
tively. FPG1 was 85.2±15.9 mg/dL, median TG1 175 (144-227) mg/dL
and TyG1 4.8±0.2; FPG2 was 82.0±10.9 mg/dL, TG2 205 (150-254)
mg/dL and TyG2 4.6±0.2 (p =0.000, 0.001 and 0.008, respectively).
Gestational age at delivery was 38±1 weeks with a birthweight of 3126
±504 g and a FPI 0.98 (0.92-1.06), identifying 17 (7.6%) newborns as
LGA. Maternal TG1, TG2 and TyG1 levels were not correlated with
birthweight and FPI and were not different in LGA newborns. TyG2
index was positively correlated with birthweight (r=0.221, p=0.023)
and FPI (r=0.219, p=0.027). Mean TyG2 index was higher in LGA
newborns (4.9±0.2 vs. 4.8±0.2, p=0.073).
Conclusion: The TyG index is a simple parameter of insulin resistance
that can be calculated from routine laboratory data and, according to our
results, it is related with birthweight. Even in well-controlled GDM preg-
nancies, this index at 32-36 weeks of gestation is related to neonatal
overgrowth.
1001
Differences in characteristics and pregnancy outcomes between
insulin- and diet-treated women with gestational diabetes
K. Robyns1, F. Nobels2, P. Van Crombrugge2, N. Deprez2, B. Seynhave3,
R. Devlieger4, J. Verhaeghe4, C. Mathieu1, K. Benhalima1;
1Endocrinology, UZ Gasthuisberg, KU Leuven, 2Endocrinology, OLV
ziekenhuis Aalst-Asse-Ninove, Aalst, 3Obstetrics and Gynecology,
OLV ziekenhuis Aalst-Asse-Ninove, Aalst, 4Obestetrics & Gynecology,
UZ Gasthuisberg, KU Leuven, Belgium.
Background and aims: The predictors for insulin use and the difference
in pregnancy outcomes between insulin- and diet-treated women with
gestational diabetes (GDM) remain unclear in different populations.
Our aim was to evaluate the difference in characteristics and pregnancy
outcomes between insulin- and diet-treated women with GDM in Belgian
patients.
Materials andmethods:Retrospective analysis of the medical files from
01-01-2010 till 31-12-2013 of women with GDM diagnosed with the
Carpenter & Coustan criteria attending two large obstetrical clinics, one
in a university and another in a non-university hospital. The prevalence of
GDM in these centers at the time of the study was respectively 3.3% and
5.1%. Clinical and biochemical characteristics associated with insulin use
were analyzed. Multivariable logistic regression was used to adjust for
confounders such as age, BMI, weight gain, ethnicity andmultiparity. For
women attending the university hospital, indices of insulin sensitivity (the
Matsuda index and the reciprocal of the homeostasis model assessment of
insulin resistance, 1/HOMA-IR) and an index of beta-cell function, the
Insulin Secretion-Sensitivity Index-2 (ISSI-2) were calculated.
Results: Over a 4 year period, 601 women were identified with GDM,
with a mean age of 31.9±4.8 years and of whom 32.2% were overweight
and 22.9% were obese at first prenatal visit. 24.2% needed insulin. Com-
pared to diet-treated women, women on insulin more often had an ethnic
minority background (33.3% vs. 21.6%, p=0.004), more often had a
history of GDM (21.5% vs. 10.4%, p=0.002), were more often multipa-
rous (59.3% vs. 47.6%, p=0.044) and were diagnosed with GDM earlier
in pregnancy (weeks 25.3±4.9 vs. 27.1±3.7, p<0.0001). When undergo-
ing an oral glucose tolerance test (100 g OGTT) women treated with
insulin had a higher fasting glycaemia (97.6±18.8 vs.87.7±10.3, p<
0.0001), a higher 1 hour glycaemia (197.7±30.1 vs.184.5±25.8, p<
0.0001), a higher 2 hour glycaemia (185.2±28.5 vs. 175.0±22.8, p<
0.0001) and more often 3 and 4 abnormal values (58.1% vs. 37.8%, p<
0.0001 and 24.8% vs. 7.7%, p<0.0001), with higher HbA1c levels at the
time of the OGTT (5.5±0.6 vs 5.2±0.5, p<0.0001). ISSI-2 (1.3±0.5 vs.
1.7±0.5, p<0.0001) and 1/HOMA-IR [0.01 (0.001-0.002) vs. 0.02 (0.01-
0.03), p=0.027] were significantly lower in women on insulin. Women
on insulin more often received corticoids in preparation of preterm deliv-
ery (11.0% vs. 2.4%, p<0.0001). Insulin did not prevent adverse out-
comes, as women on insulin had higher rates of large-for-gestational
age infants (LGA) (28.5% vs. 13.1%, p<0.0001) and more cesarean
sections (44.1% vs. 27.0%, <0.0001), remaining significant after adjust-
ment for confounders.
Conclusion: Compared to diet-treated women with GDM, women treat-
ed with insulin have a higher metabolic risk profile, impaired beta-cell
function and lower insulin sensitivity. Rates of LGA and cesarean sec-
tions were higher in insulin-treated women.
Supported by: Scholarship of ‘FWO Vlaanderen’ for KB and RD
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How to improve worse pregnancy outcomes in immigrant pregnant
women such as in comparable Italian ones by insulin treatment and/
or education
G. Silvani1, A. Albonetti2, S. Acquati3, P. Zanasi2, H.N. Inostroza
Velozo2;
1Primus Forlì Medical Center, Villa Maria Hospital, 2Woman Health Ser-
vice, AUSL of Forlì, 3Endocrinology and Metabolic Diseases, G.B.
Morgagni - L. Pierantoni Hospital, Forlì, Italy.
Background and aims: Immigration of foreign workers and families to
northern Italy increased more and more in the past three decades: at the
same time a growing incidence of gestational diabetes (GDM) has been
detected in our Diabetes Unit, owing to immigrant pregnant womenmore
than to italian ones. Pregnancies have been more frequent in foreign
women (29.7% while foreigners percentage is only 9.6% of the whole
population) and the overall incidence of GDM in the last five years has
been much higher in the immigrant (22.4%) than in the italian pregnant
women (10.6%). Aim of this study was to compare maternal features and
pregnancy outcsomes in 2 cohorts of immigrant and italian pregnant
women with GDM, according to diagnostic criteria of IADPSG (Interna-
tional Workshop Conference on Gestational Diabetes) Consensus Panel
(2008), enrolled from july 2010 to december 2014. Moreover we inves-
tigated whether an insulin treatment or an intensive educational program
could improve the outcomes in two subgroups of immigrant women.
Materials andmethods: 182 immigrant and 168 italian pregnant women
were compared for age, body mass index (BMI) before pregnancy, ges-
tational age at diagnosis of GDM, HbA1c at diagnosis and before deliv-
ery, need of insulin treatment, weight gain, timing and mode of delivery
and, as fetal outcomes, birth weight and number of LGA (Large for
Gestational Age) infants. The immigrant pregnant women were a multi-
ethnic population, to which an iso- or slightly hypocaloric diet was pre-
scribed and training to self blood monitoring performed. Eventually two
subgroups of immigrant pregnant women, 48 and 51 respectively, were
randomly allocated to insulin treatment, analogue aspart in three doses
before meals, or to an intensive educational program for six weeks,
HbA1c and weight gain being evaluated.
Results: Immigrant and italian pregnant women were well-matched for
age (33.2+/-5.8 vs 39.2+/-4.8 years, p=ns) and pre-pregnancy BMI
(28.6+/-5.5 vs 27.7+/-6.4 kg/sq.m, p=ns). No difference was found in
HbA1c at diagnosis, need of insulin treatment (21.4 vs 19.7%, p=ns) and
mode of delivery: cesarean section 44.9 vs 43.8%, p=ns (currently per-
formed in 28.3% of pregnancies in our country). The immigrant women
had a more advanced gestational age at diagnosis (27.5+/-5.1 vs 24.3+/-
4.8 weeks, p<0.01) but an earlier one at delivery (38.3+/-1.6 vs 39.5+/-
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1.7 weeks, p<0.05), a higher pre-delivery HbA1c (5.8+/-0.4 vs 5.2+/-
0.4%, p=0.03) and a greater weight gain (12.14+/-3.87 vs 8.57+/-3.68 kg,
p<0.01). Birth weight (3676+/-652 vs 3423+/-455 g, p<0.01) and rate of
LGA infants (8.1 vs 12.3%, p<0.05) were higher in newborns of immi-
grant women. The outcomes of two subgroups on insulin or intensive
education did not show any significant difference after six weeks: a com-
parable decrease of HbA1c (-1.1+/-0.3 vs -0.9+/-0.2%, p=ns)) and a
similar weight gain (2.1+/-0.4 vs 2.0+/-0.5 kg, p=ns).
Conclusion: The immigrant pregnant women and the comparable italian
ones had similar pre-pregnancy features but different outcomes, likely
due to socio-economic factors and cultural barriers, in spite of the same
given access to our health care system. In the two random subgroups on
insulin therapy or intensive education, we surprisingly found the two
treatments being both and likewise effective.
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Gestational diabetes mellitus after gastric bypass surgery
C. Nilsson1, D. Ursing2, H. Strevens3, M. Hillman4, J. Dereke4, M.
Landin-Olsson2;
1Department of Pediatrics, 2Department of Endocrinology, 3Department
of Obstetrics and Gynecology, 4Diabetes Research Laboratory, Institution
of Clinical Science, Lund University, Sweden.
Background and aims:The number of obese women in childbearing age
is increasing and the most common and effective weight loss treatment is
gastric bypass (GBP). Overweight is a risk for developing Gestational
Diabetes Mellitus (GDM) and therefore all pregnant women who have
undergone GBP are screened for GDM in our region. The aim of this
study was to compare eventual differences in demographics and pregnan-
cy outcome among women who had undergone a GBP and developed
GDM during pregnancy against those who did not develop GDM.
Materials and methods: Since 2012 all women in our region who have
undergone GBP are screened for GDM with a three day plasma glucose
profile. The regular oral glucose tolerance test is not performed because of
the risk for dumping symptoms. During 2012-2014 there were 73 preg-
nant women who had undergone a GBP earlier and not developed GDM
during pregnancy and these were compared against 11 women who had
undergone a GBP and also developed GDM.
Results: When comparing pregnant women who had undergone GBP
against the other pregnant women who had undergone GBP and also
developed GDM, there was no significant difference between the groups
regarding age of themother, ethnicity, family history of diabetes, smoking
habits, education level, years after GBP surgery, first weight/height/BMI
of the mother during pregnancy, the mother’s weight gain during preg-
nancy and weight at delivery, gestational length, birth weight/length of
the child, Apgar score at 1, 5 and 10 minutes of the child, weight of
placenta and number of caesarian deliveries.
Conclusion: No characteristic pattern was found for those who devel-
oped GDMduring pregnancy after GBP surgery. Due to the small number
of observations it is important to continue screening all pregnant women
who have undergone GBP for GDM.
PS 096Gestational diabetes: predictors
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Gestational diabetes: metabolic risks of adult women in respect to
birth weight
D. Vejrazkova1, P. Lukasova1, M. Vankova1, O. Bradnova1, G.
Vacinova1, J. Vcelak1, V. Cirmanova1, K. Andelova2, H. Krejci3, B.
Bendlova1;
1Institute of Endocrinology, Prague 1, 2Department of Mother and Child
Care, Prague 4, 31st Faculty of Medicine of Charles University and Gen-
eral University Hospital, Prague 2, Czech Republic.
Background and aims: Metabolic disorders such as obesity, insulin
resistance and other components of metabolic syndrome (MetS) are as-
sociated with birth weight (BW). Low BW is associated with higher risk
of developing type 2 diabetes mellitus, the mechanism is not clear. In this
study, we evaluated the association between BW and anthropometric as
well as biochemical components of MetS in women with a history of
special diabetic condition - gestational diabetes mellitus (GDM). In part
of the tested women, we evaluated metabolic changes over the years.
Materials andmethods:All 456 women involved in the study gave birth
at least once. Depending on the course of pregnancy, they were divided
into gestational diabetics (GDM, n=376) and controls (C, n=80). An-
thropometric characteristics of BMI, WHR, waist, hips, and abdomen
circumferences were evaluated. Glucose metabolism was defined by bas-
al glucose, insulin, proinsulin, C-peptide and glucagon. These parameters
were also monitored 7 times during the 3-hour oGTT. Lipid profile in-
cluded total cholesterol, HDL-CH, LDL-CH, TG and FFA. Furthermore,
blood pressure, uric acid, thyroid hormones, and liver enzymes were
assessed. 150 women from this cohort (100 GDM and 50 C) were
completely re-examined after at least 5 years. Statistical analysis:
Mann-Whitney test, Repeated Measures ANOVA (NCSS 2004).
Results: From all the components of MetS tested in the study, BW was
systematically associated solely with glucose metabolism: In GDM
group, low BW (below 25th percentile) was associated with higher
postchallenge insulinemia during oGTT (AUC I7 p=0.002), C-peptide
levels (AUC C-pep7 p=0.0001), and with lower indices of insulin sensi-
tivity (Matsuda p=0.02, Cederholm p=0.002) compared to medium
(25th-75th percentile) and high (above 75th percentile) BW categories.
Re-examinations in the GDM group indicate this association lasts over
the years. Repeated measures ANOVA confirms BW as a significant
factor for glucose processing. In the group of controls only borderline
significance between low BW and higher postchallenge glucose levels
(AUC Glc7 p=0.04) was found.
Conclusion: From the evaluated biochemical and anthropometric com-
ponents of MetS in adult women we proved the association of low BW
with glucose processing, in particular among women with a history of
GDM. Low BW GDM women reveal significantly higher postchallenge
insulin secretion and, accordingly, lower peripheral insulin sensitivity.
This association persists long after delivery.
Supported by: IGA MH CR NT/13544-4, MH CR 00023761
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Hypovitaminosis D in 1st trimester may predict gestational diabetes
P. Khandavalli, R. Chawla, H. Punyani, S. Gupta;
Diabetes, Maharaja Agrasen Hospital Punjabi bagh, New Delhi, India.
Background and aims: Pregnancy is nature’s gift that should be nurtured
over ninemonths with no adverse outcome. Gestational DiabetesMellitus
affects 3 to 10% of pregnancies, depending on the population studied.
The progressive increase of insulin resistance observed in pregnancy
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contributes to the pathophysiology of gestational diabetes mellitus
(GDM). There is controversy whether vitaminD deficiency contributes
to abnormal glycemic regulation in pregnancy
Materials and methods:We tested the associations between first trimes-
ter 25-hydroxyvitamin D3(25OHD3) levels and the risk of developing
GDM in a large hospital-based prospective cohort of pregnant women.
Participants (n=200) were seen at first (6-13 weeks) and second (24-
28 weeks) trimesters for blood samples. Each participant was selected
in their first trimester and demographic parameters were recorded. Height
in cms, weight was measured in kg’s. BMI was calculated as weight (kg)/
height (m2). Family history of Diabetes, Obstetric score for gravidity,
history of previous abortion and previous history of GDM was recorded.
Fasting blood sugar wasmeasured and in those >92 mg/dl HbA1c is done
and those with >6.5% were excluded. Those with FBS value of 140 mg/
dl, Oral Glucose tolerance test (OGTT) was done and diagnosed as GDM
or NGT based on ACOG criteria.
Results:Based on ACOG criteria, 18 participants (9%) developed GDM.
25(OH) Vitamin D level was deficient in 190 participants (95%) and sub
group analysis revealed 25(OH) Vitamin D3 level of <20 nmol/l in 48%
of participants. On logistic regression analysis for GDM risk factors,
Advancing age, Increased BMI and 25(OH) Vitamin D3 level of
<20 nmol/l were significantly associated with risk of GDM. 25(OH)
Vitamin D3 level <20 nmol/l was found to be significantly associated
with increased risk of GDM however our study found this risk was evi-
dent only in advanced maternal age (29.07±1.68).
Conclusion: Severe Hypovitaminosis D was present in 48% of study
participants. Pregnant females with very low vitamin D (<20 nmol/l)
are at odds of 2.45 in relation to increased risk of development of Gesta-
tional Diabetes mellitus. In our study we found that advanced maternal
age in parallel with simultaneous very low vitamin D level may contribute
to insulin resistance and increased risk of GDM.
1006
Maternal stress predicts insulin resistance in pregnancy
G. Valsamakis1, D. Papatheodorou1, N. Chalarakis1, E. Kapantais2, A.
Mantzou3, A. Margeli4, I. Papassotiriou4, G. Mastorakos1;
1Endocrine Unit, 2nd Department Obs&Gynae, Athens Medical School,
2Diabetes Obesity Metabolism, Metropolitan Hospital, 3Paidon Aghia
Sofia Hospital, 4Biochemistry, Paidon Aghia Sofia Hospital, Athens,
Greece.
Background and aims: Endometrial environment affects maternal me-
tabolism and fetal growth during pregnancy.It is not known yet to what
extent maternal stress could affect maternal glucose metabolism and fetal
growth. Aim was to investigate the association of maternal stress and
fasting stress hormones (CRH and cortisol) with insulin resistance and
fetal growth.
Materials and methods: The investigation was approved by the local
ethical committee and it has been performed in accordance with the eth-
ical standards laid down in the Helsinki Declaration. Consent has been
obtained from each patient after full explanation of the purpose and nature
of all procedures used. Eighty five pregnant, with no history of diabetes
mellitus, primigravidae Caucasian women (mean ± SD); age: 27.7±
3.6 years; pre-pregnancy BMI 26±2.1 kg/m2 were recruited during the
second trimester of pregnancy from an Obstetrics and Gynecology out-
patient clinic of a university hospital.Women were seen randomly in the
clinic at the second and third trimester and had their weight measured, a
75gr OGTT with insulin and glucose measured, HOMAR values were
estimated and fasting (9:00 am) serum CRH, cortisol and IL6 were mea-
sured. Three women were diagnosed with gestational diabetes and were
withdrawn from the study. During the visits they had fetal ultrasound
(US) measurements of abdominal and head circumference. A specialist
clinical psychiatrist interviewed them with STAI state and trait stress
questionnaires and scored them.The STAI state questionnaire is com-
posed of 20 questions about how the individual feels at that particular
period. The STAI trait questionnaire is composed of 20 questions about
how the person usually feels.A p-value of <0.05 was considered to be
statistically significant.
Results: In the second trimester maternal cortisol (r=0.53), CRH (r=
0.35) and STAI state score (r=0.82) were positively associated with
HOMAR (p<0.05). Best predictor of HOMAR was STAI state score
(p=0.01, beta=0.88) among STAI trait score, CRH, IL6 and cortisol
levels and maternal weight. Best predictor of US fetal abdominal circum-
ference was serum cortisol (p=0.028, beta=0.638) among STAI state and
trait scores, CRH and IL6 levels and maternal weight. In the third trimes-
ter cortisol (r=0.65) and STAI state score (r=0.35) were asssociated with
HOMAR and the latter was its best predictor (p=0.013, beta=0.83)
among STAI trait score, maternal weight and CRH, IL6, cortisol levels.
Conclusion: Maternal stress, as assessed by STAI state score which
shows how the woman feels at that particular period studied, seems to
affect insulin resistance during pregnancy. The stress hormone cortisol is
associated with fetal abdominal circumference. Stress assessment by
STAI state score at initial stages of pregnancy could be a potential risk
factor tool of insulin resistance and possibly fetal growth in the outpatient
clinic.
1007
Selective screening for gestational diabetes development based on
risk factors
M. Vladimirova, T. Tankova, I. Atanasova;
Clinical Center of Endocrinology, Sofia, Bulgaria.
Background and aims:Gestational diabetes (GDM) development is one
of themost common complications during pregnancy. It is speculated that
OGTTshould be performed only on womenwith high risk for GDM. The
aim of the present study was to assess the predictive value of risk factors
for GDM established by selective screening and to identify subgroups of
women at a higher risk of developing GDM.
Materials and methods: 1300 pregnant women between 24 and
28 weeks of gestation were recruited for the purposes of the study. They
have undergone standard OGTTas part of screening program for GDM in
Clinical Center of Endocrinology. For GDM diagnosis we have use the
IADPSG criteria and logistic regression analysis for identifying signifi-
cant risk factors.
Results:We found 29.1% (378) prevalence of GDM. The application of
the selective screening criteria would result in the execution of an oral
glucose tolerance test (OGTT) in 55.1% of women and 24 (24.0%) cases
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of GDMwould not be detected due to the absence of any risk factors. The
presence of relatives with diabetes type 2 increase 1,394 (р<0,034) risk
for GDM development. Furthemore, the presence of I and II line relatives
with diabetes type 2 additionally increase the risk (OR 2.523 (р<0.001).
Body mass index (BMI) between 25 and 29.9 kg/m2 before pregnancy
increases the risk 1.629 (р30kg/m2 4,162 (р<0.0001). Women above
30 years of age have significantly higher risk (OR 2.245, р0.371). Other
significant risk factors were higher random blood sugar (OR 3,883 (р<
0.0001) and the need of assisted reproduction as method for conception
(OR 2.123, p<0.001).
Conclusion: The lack of established national screening program neces-
sitates the active search for pregnant women at high risk for GDM devel-
opment. Identifying major risk factors will categorize the women, who
will benefit from performing OGTT and thus how reducing their risks, if
having GDM.
Supported by: Ministry of Education
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The growth patterns in children born to mothers with gestational
diabetes mellitus
J. Rutkowska, E. Bandurska-Stankiewicz, D. Wiatr-Bykowska, K.
Myszka-Podgórska, E. Kuglarz, W. Matuszewski;
Endocrinology, Diabetology and Internal Medicine, University of Varmia
and Masuria, Olsztyn, Poland.
Background and aims: The aim of the study was to assess if gestational
diabetes mellitus (GDM) influences the pregnancy outcomes and the
growth patterns in children.
Materials and methods: Our prospective study cohort consisted of 261
children born tomothers with GDMand 153 control children born to non-
diabetic mothers. In both groups children’s birth weight, and length were
assessed. Children were matched for large for gestational age (LGA)
(birth weight >90th percentile for gestational age), appropriate for gesta-
tional age (AGA) (birth weight between the 10th and 90th percentile for
gestational age ), small for gestational age (SGA) (birth weight <10th
percentile for gestational age) status. Children anthropometric measure-
ments were made at 12, 18, 24, and 30 months after their birth. BMI was
calculated. The overweight was diagnosed at BMI between 90-96 per-
centile, obesity between 97-100 percentile. The WHO child growth stan-
dards were implemented. The bioethics committee agreement was
obtained.
Results: Among 261 children born to mothers with GDM, 80.5% were
AGA, 10%SGA, 9.6%LGA; in control group - 75.2%AGA, 5.9%SGA,
and 19% LGA. Birth weight of the children in GDM pregnancies was
3.30±0.53 kg comparing to the control children 3.42±0.54 kg, p=0.01.
No weight and BMI differences were found between groups in the 12th
month of life. The weight >90 percentile at this period was observed in
37.7% GDM children, comparing to 32.4% in control group. BMI be-
tween 90-96 percentile was found in 15.63% and between 97-100 per-
centile in 15.63%GDM children comparing to 18.6% and 18.6% respec-
tively in control group. At the age of 18 months the weight of children
born to GDM mothers was >90 percentle in 54.8% comparing to the
control group in 29%, p=0.04; No changes were found in BMI. At the
age of 24 and 30 months we found no differences in BMI between both
groups.
Conclusion: We found that children who were LGA at birth were less
often born to GDM mothers after implementation of dietary regiment
comparing to general population. GDM did not influence the growth
pattern in first 36 months of live.
Supported by: NN404 521938
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A randomised trial of the effects of prenatal education of overweight
or obese pregnant women to prevent childhood overweight: the
ETOIG study
S. Parat1, V. Negre2, A. Baptiste1, M.-T. Tauber3, P. Valensi4, A.-M.
Bertrand5, M. Dabbas6, C. Elie1, F. Lorenzini3, E. Cosson4;
1AP-HP, PARIS, 2Hôpital Saint Jacques, RePPOP-FC, Besançon, 3CHU,
TOULOUSE, 4AP-HP, BONDY, 5CHRU, BESANCON, 6AP-HP,
RePPOP-IDF, PARIS, France.
Background and aims:We aimed to evaluate whether pre and perinatal
education of overweight or obese pregnant women would reduce child-
hood overweight.
Materials and methods: Four French centers included before 20 weeks
of gestation 268 pregnant women who were overweighed or obese before
pregnancy (BMI 32.5±5.4 kg/m2, obesity 62%, age 30.4±5.0 years).
They were randomized in a control group (n=136: routine care including
at least one dietary visit) and an interventional group (n=132). This in-
tervention which included 2 individual and 4 collective dietary counsel-
ing at 18, 26, 33 weeks of gestation and 2 months after delivery aimed to
educate the future mother for infant and maternal nutritional aspects,
without weight objectives. The primary objective was postnatal catch-
up growth from birth to two years (>0.67 DS), which is associated with
obesity in childhood.
Results: Events during pregnancy were similar in both groups, including
incident gestational diabetes mellitus, maternal gestational weight gain
and birth weight. The rate of postnatal catch-up growth was similar in
interventional and control groups: in intention to treat (59.1 vs 60.3%
respectively, p=0.84), in available data (AD n=206) and in per-protocol
population (PP n=177). Disappearance of maternal overweight 2 years
after delivery was more frequent in the interventional group (AD, n=149:
12.9 vs 3.8%, p=0.04; PP, n=128: 10.7 vs 4.2%, p=0.18). The children
were less likely with BMI>19 kg/m2 (corresponding to the 97eme per-
centile) when theywere 2 years old (AD, n=204: 0 vs 6.8%, p=0.014; PP,
n=176: 0 vs 6.4%, p=0.03).
Conclusion: Intervention based on education and nutritional counseling
in womenwith overweight / obesity, starting at more than three months of
gestation, has no effect on postnatal catch-up growth but appears to pre-
vent overweight in mothers and obesity in children two years after
delivery.
Clinical Trial Registration Number: NCT00804765
1010
ShouldHbA1c be used for the diagnosis of glucose tolerance disorders
in women with a history of gestational diabetes mellitus?
E. Anastasiou, M. Apostolakis, A. Papadimitriou, E. Zapanti, V.
Vasiliou, A. Saltiki, M. Alevizaki;
Alexandra Hospital, Athens, Greece.
Background and aims: Women with a history of Gestational Diabetes
Mellitus (GDM) present an increased risk for Diabetes Mellitus 2 (DM2).
Thus it is recommended to perform an oral glucose tolerance test (OGTT)
after delivery. Recently use of A1C has been proposed as a simpler and
faster method to diagnose glucose tolerance disorders. The aim of this
study is to investigate whether A1C measurement can replace OGTT in
the detection of pre-diabetes and diabetes in women with a history of
GDM.
Materials and methods: 1336 women with a history of GDM after
delivery were studied. All women had been evaluated through an OGTT
and a simultaneous A1C measurement. ADA criteria were used for the
assessment of dysglycemia. Sensitivity and specificity of A1C were mea-
sured for the prediction of diabetes and pre-diabetes; Cohen’s coefficient
of agreement (k) was also calculated. ROC analysis was performed to
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evaluate the sensitivity and specificity of A1C for detection of abnormal
glucose tolerance.
Results: Based on OGTT, 725 (54.3%) women were normal, Impaired
Fasting Glucose (IFG)=406(30.4%), Impaired Glucose Tolerance
(IGT)=48(3.6%), IFG+IGT=74 (5.5%) and 83 women presented with
DM2 (6.2%). On the contrary, using A1C as a criterion of dysglycemia
1150 (94.1%) women were normal, while 49 (4.0%) had an impaired
A1C and 23 (1.9%) were diagnosed as DM2. Sensitivity of A1C for the
diagnosis of pre-diabetes was 5.3% in comparison to OGTT, specificity
was 99.2%, while for the diagnosis of DM2 the percentages were 29.6%
and 100% respectively. The consistency in classifying abnormal glucose
tolerance between A1C and OGTT was 59.7% (Cohen’s coefficient of
agreement k=0.116). Performing a ROC curve, the optimal value of
discriminating ability of A1C was 5% for the prediction of pre-diabetes
and diabetes.
Conclusion: The study showed that A1C measurement has a very low
sensitivity in detecting pre-diabetes and diabetes in women with a history
of GDM. Hence, we suggest that the ADA proposed thresholds cannot be
used as an alternative to OGTT in this regard.
1011
A model for individual prediction of diabetes up to five years after
gestational diabetes mellitus
C. Ignell1, E. Anderberg2, M. Ekelund1, K. Berntorp1;
1Department of Clinical Sciences, Malmö, 2Department of Clinical Sci-
ences, Lund, Lund University, Sweden.
Background and aims: Gestational diabetes mellitus (GDM) is a major
risk factor for subsequent diabetes. A cumulative diabetes incidence of
30-50% within five to ten years after GDM has been described. In south-
ern Sweden universal screening with a 75-g OGTT during pregnancy has
been applied since 1995. Using the WHO criteria from 1999 to define
GDM we have previously reported a diabetes incidence of 6% 1-2 years
after delivery. The aim of the present study was to identify risk factors
associated with diabetes development based on a 5-year follow-up of
these women and to develop a prediction model to be used on an indi-
vidual basis when counselling women after GDM.
Materials and methods: Five years after GDM a 75-g OGTT was per-
formed in 362women, excludingwomen already diagnosedwith diabetes
at the 1-2 year follow-up visit or later (n=45). All but 21 women had
results from follow-up at 1-2 years, while 84 women were lost from that
point. Predictive variables were identified by multiple logistic regression
analysis. The performance of the developed model was assessed in re-
ceiver operating characteristic (ROC) curves.
Results: Five years after GDM, 28/362 (8%) women were diagnosed
with diabetes whereas 187/362 (52%) had normal glucose tolerance
(NGT). Among the latter, 139/187 (74%) also had NGT at 1-2 year fol-
low-up. In univariate regression analysis, using NGTat 1-2 and 5 years as
the reference, diabetes at 1-2 year follow-up or later (n=73) was clearly
associated with easily assessable clinical variables, such as BMI at 1-
2 year follow-up, 2-h OGTT glucose concentration during pregnancy
and non-European ethnicity (p<0.001). A prediction model based on
these variables, resulting in 86% correct classifications with an area under
the ROC curve of 0.91 (95% CI 0.86-0.95), was applied in a function
sheet line diagram illustrating the individual effect of weight on diabetes
risk.
Conclusion: The results highlight the importance of BMI as a potentially
modifiable risk factor of diabetes after GDM. For motivational purposes,
a patient information function sheet illustrating the effects of weight ver-
sus diabetes risk is proposed as a model to be used on an individual basis,
see Figure. As an example, a European woman with a height of 1.75 m, a
2-h OGTT plasma glucose concentration in pregnancy of 9.8 mmol/l and
a weight of 90 kg one year after pregnancy would have a 60% risk of
diabetes, declining to 20% with a weight loss of 20 kg.
Supported by: Skåne Research and Development Foundation, the
Gorthon Foundation.
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Metabolic changes during oral glucose tolerance test in healthy
pregnancy and gestational diabetes mellitus revealed by LC-MS-
based metabolomics
B.A. Raczkowska1, M. Ciborowski2, J. Godzien3, B. Telejko1, C.
Barbas3, A. Kretowski1,2, M. Gorska1;
1Department of Endocrinology, Diabetology and Internal Medicine,
2Clinical Research Centre, Medical University of Bialystok, Poland,
3Centre of Metabolomics and Bioanalysis (CEMBIO), Universidad
CEU San Pablo, Madrid, Spain.
Background and aims: Gestational diabetes mellitus (GDM) is mani-
fested by changes in such metabolites as lysophospholipids, bile acids,
fatty acids and amino acids. However, its pathogenesis and mechanisms
responsible for complications caused by GDM are still not entirely clear.
In order to evaluate which metabolic pathways are affected by glucose
load metabolomics was applied. Serum samples obtained during oral
glucose tolerance test (OGTT) were fingerprinted by LC-QTOF-MS.
Among different tools used in metabolomics, LC-MS is characterized
by the highest sensitivity and dynamic range therefore this method was
chosen to perform the experiment. The aim of the present study was to
examine serum metabolic changes in response to glucose load in patients
with GDM and healthy pregnant women.
Materials and methods: The study group contained 129 pregnant wom-
en who underwent a 75 g-OGTT between 24-28 weeks of gestation.
Fasting, 1 h and 2 h serum samples were collected from each participant
during OGTT. Patients were divided into two groups: primary set (n=67)
and validation set (62), both consisted of GDM and healthy pregnant
women (control). Serum samples were fingerprinted using LC-QTOF-
MS. Data was collected in ESI (+) and ESI (-) mode (50-1,000 m/z).
Prior to statistical analysis, quality assurance protocol was applied to keep
only metabolic features with good repeatability. Statistical analysis was
performed independently in both sets and afterward only statistically
significant metabolites (p-value <0.05), common in both sets, were se-
lected for MS/MS analysis to confirm their identification. Depending on
the data distribution, paired t-test or Wilcoxon signed rank test were used
and obtained p-values were corrected by application of Benjamini-
Hochberg false discovery rate test.
Results: Around 140 metabolic features changed significantly after glu-
cose load. The differences concerning about a hundred of them were
observed irrespective of the presence of GDM, while other changes were
significant only in the control group or patients with GDM. The list of
metabolites that differed significantly at 2 h of OGTT in comparison to
the fasting state in both groups included dicyclohexylurea (+85%, p<10-
7) and several fatty acids (e.g. eicosadienoic +120%, p<10-4; stearolic -
48%, p<10-4; oleic -55%, p<10-8). A significant decrease (14-21%, p<
0.03) in phosphatidylethanolamine and sphingomyelin at 2 h of OGTT
was observed only in patients with GDM. On the other hand, in the GDM
group we did not observe any significant changes in several metabolites,
which increased markedly at 2 h of OGTT in the control group (e.g.
lysophospholipids [12-20%, p<0.01] and choline [58%, p<0.01]).
Conclusion: Our results suggest that glucose load causes mainly the
derangement of lipid metabolism. The changes in fatty acids were ob-
served irrespective of the presence of GDM, whereas choline containing
lipids and choline itself were affected in a different way in control and
GDM samples. However, further investigations are needed to evaluate the
role of observed changes in the metabolism of choline and choline con-
taining lipids in the development of GDM and its complications.
Supported by: Polish Ministry of Science and Higher Education (KNOW
2012-2017)
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Testing for genetic associations in gestational diabetes mellitus
(GDM): preliminary results from the EFSD New Horizons study
K. Rosta1, Z. Al-Aissa2, O. Hadarits3, J. Harreiter4, A. Zoka2, D.
Bancher-Todesca1, L. Nemeth5, J. Rigo6, A. Kautzky-Willer4, G.
Firneisz7;
1Department of Obstetrics and Fetomaternal Medicine, Medical Univer-
sity Vienna, Austria, 22nd Department of Internal Medicine, 31st Depart-
ment of Obstetrics and Gynecology, Semmelweis University, Buadpest,
Hungary, 4Department of Internal Medicine 3, Medical University Vien-
na, Austria, 5Department of Probability Theory and Statistics, Eötvös
Loránd University, Budapest, Hungary, 6Department of Obstetrics and
Gynecology, 72nd Department of Internal Medicine, Semmelweis Uni-
versity, Hungary, Budapest, Hungary.
Background and aims: To identify maternal single nucleotide gene
polymorphisms (SNPs) associated with GDM or influencing fasting
and 2 hours glucose levels at OGTT.
Materials and methods: A set of 77 SNPs was selected based on their
previously reported contribution to beta-cell dysfunction or genesis,
incretin effect, K+-channel function, amyloid formation, zinc transport,
insulin resistance, obesity, IGF system, glucose homeostasis, neuronal
regulation of appetite, energy balance or immunoregulation. The majority
of these SNPs were previously reported to be associated with either type 2
diabetes or with a metabolic trait. Thus far 149 pregnant women with
GDM, 269 non-diabetic pregnant women and 154 neonates born to
mothers with GDM and 274 neonates born to non-diabetic mothers were
enrolled. This study was conducted in two Hungarian and one Austrian
centers. Genomic DNAwas isolated from a total of 846 samples using a
magnetic bead based robotized approach (Hamilton Robotics, Magna
Starlet). PCR-based KASP™ genotyping (FRET based) assay (LGC Ge-
nomics) was used for the bi-allelic discrimination of SNPs. Logistic re-
gression (logit) risk model and subsequent algorithms written in "R"
statistical programming language were used to assess Odds Ratios, p-
values and to detect potential gene-gene interactions. Maternal gene var-
iants were also assessed for association with fasting and 2 hours plasma
glucose levels at routine OGTT (24-28th gestational week).
Results: Carrying a G allele of the rs10830963 of the melatonin receptor
1B (MNTR1B) or a G allele of the rs6832769 of the clock circadian
regulator (CLOCK) genes were most significantly associated with the
binary trait of GDM (OR=1.708-1.56, p<10-5). In qualitative trait anal-
ysis we found that the rs10830963 in MTNR1B was consistently associ-
ated with increased fasting and 2 hours glucose levels. The rs10871777
(G allele) of the melanocortin 4 receptor (MC4R) was associated with an
increase in 2 hours plasma glucose values at OGTT. In contrast, the A
allele of the rs1143634 of the interleukin 1 beta (IL1B) gene was associ-
ated with decreased fasting glucose levels.We identified significant gene-
gene interactions betweenMC4R andCLOCK gene variants (rs1087177-
rs6832769 and rs17782313-rs6892769 with OR=2.09, p=1.4×10-3 and
OR=2.11, p=1.1×10-3, respectively) and between rs10830963 of
MNTR1B and rs4712526 of the CDK5 regulatory subunit associated
protein 1-like 1 (CDKAL1) gene (OR=2.17, p=1.7×10-3) when interac-
tions were analyzed for GDM binary trait.
Conclusion: Our preliminary data suggest that a few SNPs could be
associated with GDM or qualitative traits. Surprisingly, the identified
gene polymorphisms are likely to participate in neuronal regulation of
appetite, circadian rhythm, energy balance, immunoregulation or are with
unknown function.
Supported by: EFSD
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The role of hepassocin in gestational diabetes mellitus
H.-T. Wu1,2, M.-T. Su3, P.-Y. Tsai3, H.-Y. Ou4, C.-J. Chang1, C.-L. Wu5,
P. Wu6;
1Department of Family Medicine, 2Research Center of Herbal Medicine,
New Drugs, and Nutritional Supplements, National Cheng Kung Univer-
sity, 3Departments of Obstetrics and Gynecology, 4Department of Internal
Medicine, College of Medicine, 5Department of Biochemistry and Mo-
lecular Biology National Cheng Kung University Medical College, Na-
tional Cheng Kung University and Hospital, Tainan, Taiwan, 6Institute of
Institute for Science & Technology in Medicine, Keele University, UK.
Background and aims: Gestational diabetes mellitus (GDM) is hyper-
glycemia that is first detected during pregnancy and does not meet the
criteria for manifest diabetes. GDM is associated with the development of
preeclampsia, the birth of a big baby, emergency cesarean section, birth
trauma, and neonatal hypoglycemia. In addition, it is a risk factor for
obesity, type 2 diabetes and cardiovascular diseases in the mother and
her offspring. However, there is no suitable biomarker for the screening of
GDM that leads to the diagnosis of this condition is delayed. Recently, a
novel physiological function of hepassocin was found that increased
hepassocin levels activated ERK1/2 to induce insulin resistance; howev-
er, the role of hepassocin in GDM is still unknown. Thus, the aim of this
study is to investigate the role of hepassocin in GDM.
Materials and methods: Fifteen subjects for each group including nor-
mal control and GDM groups were enrolled. GDMwas diagnosed by 75-
g oral glucose challenge test screening at 24-28 weeks of gestation. The
plasma samples were collected to examine hepassocin concentrations by
enzyme-linked immunosorbent assay. In addition, the placenta was also
collected for the expression of hepassocin by reverse transcriptase-
polymerase chain reaction, and western blots, as well as
immunoflurorescent staining. 3A-sub-E trophoblasts were used to evalu-
ate the physiological effect of hepassocin in placenta. The effect of
hepassocin on insulin-induced glucose uptake was determined by L6
myoblasts.
Results: The expression of hepassocin was detected in the placenta, and
the placental expression level of hepassocin was increased in GDM as
compared with control group. The result from immunoflurorescent stain-
ing indicated that hepassocin was mainly expressed in the trophoblasts of
placenta. In addition, interleukin-6 treatment induced the expression of
hepassocin in 3A-sub-E trophoblasts. The serum concentrations of
hepassocin were significantly increased in patients with GDM (N=15
for each group) (P<0.01). Treatment with hepassocin in trophoblasts
significantly increased the migration of trophoblast through an ERK1/2-
dependent pathway. In addition, hepassocin disrupted insulin signaling to
decrease insulin-induced glucose uptake in L6 myoblasts.
Conclusion: Inflammation in the placenta of GDM increased the expres-
sion of hepassocin and the elevated hepassocin in circulation further led
to the insulin resistance in skeletal muscle, and affected glucose utility. In
addition, hepassocin increased the migration of trophoblasts and this ef-
fect might be correlated with the increased weight of placenta in GDM.
Thus, we provided a novel mechanism in the development of GDM by
hepassocin.
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Oxidative stress and gestational diabetes: the impact on placenta,
perinatal outcomes and postpartum evolution
C. López-Tinoco1, M.M. Roca-Rodríguez2, F. Visiedo-García3, C.
Rosendo3, R.M. Mateos-Bernal3, M. Aguilar-Diosdado1;
1Endocrinology, Hospital Puerta del Mar, Cádiz, 2Endocrinology, Hospi-
tal Virgen de la Victoria, Málaga, 3Investigation Unit, Hospital Puerta del
Mar, Cádiz, Spain.
Background and aims: The simultaneous existence of a placental oxi-
dative stress and maternal-placental interactions during Gestational Dia-
betes Mellitus [GDM] are still not well understood. The aim of the study
was to evaluate the levels of oxidative stress markers and antioxidants in
women con GDM, and to assess the impact on the placenta oxidative
status and perinatal outcomes.
Materials and methods: One hundred twenty six pregnant women (63
with GDM, 63 controls) were enrolled and 41 cases and 21 controls were
recruited for the following-up study. Markers oxidative stress and antiox-
idants status were measured during 24th and 29th week of gestation and
twelvemonths after delivery; moreover, 6 placenta from healthy pregnant
women and 6 from women with GDM were studied.
Results: In the postpartum period, we found significant increases of
levels of Lipoperoxides [LPO] (p=<0,001) and catalase (p=<0,001)
and significant declines of levels of glutathione peroxidase [GPX] (p=
0,003) in both (GDM and controls). In addition, in cases had lower levels
of glutathione transferase [GST] (p=0,003) and in controls had lower
levels of superoxide dismutase [SOD] (p=<0,001), respectively. In order
to investigate the influence of clinical and metabolic variables on post-
partum period, multiple regression analysis was performed and the levels
of oxidative stress and antioxidant markers postpartum were significantly
associated with the GDM.We observed that the levels of GPX (p=0.012)
and LPO (p=0.04) were significantly related to the percentage of Caesar-
ean deliveries, while the percentage of macrosomia was related to the
levels of GPX (p=0.01). In GDM placenta a significant increase was
noted in the levels of carbonyl protein (p=<0,05), LPO (p<0,05) and
reduced antioxidants enzymatic activities of SOD (p=<0,05) and catalase
(p=<0,05) compared to controls.
Conclusion:We concluded that increased oxidative stress and reduction
in antioxidant defense mechanisms appeared in the mother and GDM
placenta. These maternal and placental oxidant/ antioxidant imbalances
could lead to maternal and fetal complications and should be carefully
considered.
1016
Pregnancy induces an insulin resistance promotin hepatic ceramide
phenotype in mice
L.I. Hellgren, C. Ingvorsen;
DTU Systems Biology, Technical University of Denmark, Kgs. Lyngby,
Denmark.
Background and aims: Temporary insulin resistance (IR) develops in
women during pregnancy, in order to ensure appropriate supply of nutri-
ents to the growing fetus. This physiological adaptation can develop into
a pathological insulin resistance and overt gestational-diabetes mellitus
(GDM). Understanding the mechanism behind the normal pregnancy-
induced IR is an important tool to elucidate key molecular mechanisms
leading to GDM. Altered ceramide-metabolism has been implicated in
the development of type-2 diabetes mellitus (T2DM). In particular cer-
amide species produced by ceramide synthase 6 (CS6) have been identi-
fied as potential inducers of hepatic IR. We therefore hypothesise that
pregnancy induced IR is caused by altered ceramide metabolism, with a
higher flux through CS6 and increased production of ceramide species
with the ability to induce IR.
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Materials and methods: Fasting glucose and insulin was analysed in
age-matched non-pregnant (n=12) and pregnant mice (gestations day
18, n=10). Hepatic lipids were extracted and fractionated into different
lipid classes. Ceramide content and composition was analysed using liq-
uid chromatography-MS. Ceramide species were identified based on ex-
act mass, fragmentation pattern and retention time. Quantification was
performed using internal standard and external standard curves. Pairwise
comparisons were performed using Mann-Whitney U-test. Ceramide
composition was assessed by principal component analysis (PCA) and
differences between principal components for pregnant (P) and non-
pregnant (NP) dams was also analysed using Mann-Whitney U-test.
Results: Fasting insulin (NP: 0.18±0.13 ng/mL, P: 0.45±0.13 ng/mL, p
<0.01), but not fasting glucose (NP: 7.7±1.1 mM, P: 8.4±0.9 mM, p=
0.19), was increased at gestation day 18, compared to the non-pregnant
dams. Total hepatic ceramide concentration was elevated in pregnant
dams (NP: 4.9±0.6 mg/g tissue, P: 8.1±0.9 mg/g tissue, p<0.0001),
while hepatic TAG-levels were unaffected. The PCA analysis of ceramide
profile strongly separated the pregnant from the non-pregnant dams along
PC1 (p<0.0001), which explained 46% of thevariation in the data. The
loading plot revealed that ceramide in pregnant dams were characterized
by relatively shorter saturated acyl groups (C16:0 and C18:0), i. e. those
synthesized by CS6, while the non-pregnant dams were characterized by
the longer-chained, C22:0, C24:0 and C24:1, ceramides, synthesized by
ceramide synthase 2. Total hepatic ceramide correlated to QUICKI
(Spearman r=0.-57, p=0.03), but the correlation to ceramide composition
(given as PC1) was stronger (Spearman r=-0.70, p=0.003.
Conclusion: In late stage of pregnancy, the hepatic ceramide profile is
characterized by ceramide species that are known drivers of insulin resis-
tance, while it in the non-pregnant state is characterized by ceramide
structures that have been shown to attenuate IR in high-fat fed mice. This
suggests that pregnancy-induced IR can partly be explained by altered
metabolic fluxes through the different ceramide synthases pathways,
resulting in altered ceramide composition. This interpretation is supported
by the strong the correlation between ceramide composition and
QUICKI.
Supported by: Danish Strategic Research Council Grant no 09-067124
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A role for kisspeptin in regulating beta cell mass during pregnancy
J. Bowe, T. Hill, S. Persaud, P. Jones;
King's College London, UK.
Background and aims: Whilst effects of kisspeptin on islet function
have previously been studied the physiological role remains unclear.
The extremely high levels of kisspeptin released by the placenta suggest
a possible role during pregnancy, characterised in the islets by a rapid and
reversible increase in beta-cell mass. This study therefore examined the
effects of kisspeptin on beta cell mass in pregnant and non-pregnant mice.
Materials and methods: Control or pregnant mice were implanted with
subcutaneous osmotic minipumps containing either saline, kisspeptin
(50 nmol/day) or the kisspeptin antagonist kisspeptin-234 (200 nmol/
day) and were given water containing 1 mg/ml BrdU for 10 days (from
day 8-18 of pregnancy). Immunohistochemical staining of pancreas sec-
tions for BrdU and insulin followed by morphometric analysis was used
to assess beta-cell proliferation, beta-cell hypertrophy and islet mass.
Results:Kisspeptin administration in non-pregnant mice had no effect on
beta-cell proliferation, assessed by the extent of BrdU labelling, com-
pared to untreated non-pregnant mice (non-pregnant: 7.83±0.72%, non-
pregnant + kisspeptin: 8.65±1.18%, percentage of BrdU positive beta-
cells, n=6). Kisspeptin also had no significant effect on beta-cell hyper-
trophy in non-pregnant mice (non-pregnant: 107.8±12.3 μm2/cell, non-
pregnant + kisspeptin: 116.3±8.9 μm2/cell, beta-cell size, n=6). Howev-
er, administration of kisspeptin-234 in pregnant mice significantly atten-
uated the increased beta-cell proliferation associated with pregnancy
(pregnant: 21.42±1.19%, pregnant + kisspeptin-234: 16.91±1.07%, per-
centage of BrdU positive beta-cells, n=6, p<0.05). Similarly, blocking
endogenous placental kisspeptin attenuated pregnancy related beta-cell
hypertrophy (pregnant: 194.3±11.5 μm2/cell, pregnant + kisspeptin-
234: 162.7±13.1 μm2/cell, beta-cell size, n=6, p<0.05).
Conclusion: These data indicate that endogenous kisspeptin increases
beta-cell proliferation and hypertrophy, supporting a role for placental
kisspeptin in regulating the increase in beta-cell mass during pregnancy.
The lack of significant effect of kisspeptin on beta-cell mass in non-
pregnant mice suggests that this is likely to be an effect specific to the
pregnant environment and may involve other factors.
Supported by: DRWF
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The role of long non-coding RNAs in beta cell mass expansion during
mouse pregnancy
A. Zhou1, G. Sisino1, B. Tyrberg1, M. Soundarapandian2, M. Althage1,
E.-M. Andersson1, N. Dahr3, E. Larsson3;
1AstraZeneca R&D Mölndal, Sweden, 2Sanford-Burnham Medical Re-
search Institute, Orlando, USA, 3University of Gothenburg, Sweden.
Background and aims: Pregnancy is accompanied by a remarkable pan-
creatic islet β-cell mass expansion, whereas progression of type 2 diabe-
tes (T2D) correlates with β-cell mass loss. Long non-coding RNA
(lncRNA) is a novel RNA species with emerging evidence highlighting
its multiple regulatory functions in biology and diseases. Strikingly,
lncRNA tissue distribution suggests a higher degree of specificity com-
pared to coding genes in particular cell types, such as in human islets. The
aim of this study is to identify functionally important lncRNAs in β-cell
expansion during pregnancy that are β-cell specific, and therefore, puta-
tive candidate drug targets or biomarkers.
Materials and methods: We performed a microarray analysis on islets
isolated from non-pregnant and pregnant mice at gestational day 14.5
(peak β-cell proliferation). Bioioinformatic approaches were applied to
compare a public RNA-seq dataset with our microarray data to identify
differentially expressed lncRNAs during pregnancy. The differential ex-
pression of candidate lncRNAswere verified using real time RT-PCR in a
mouse beta-cell line (MIN6c4) and isolated primary mouse islets treated
with prolactin to mimic pregnancy and induce β-cell proliferation.
Results: We identified a small number of lncRNAs that were differen-
tially expressed in pancreatic islets during pregnancy from RNA-seq
analysis (P<0.01). Most of them displayed a similar expression pattern
in the microarray analysis. As an initial approach, we validated the ex-
pression of 5 novel lncRNAs in prolactin-treated MIN6c4 cells and
mouse islets. Mn-Lnc03 and Mn-Lnc04 were markedly induced by pro-
lactin in both MIN6c4 cells and mouse islets: Mn-Lnc03 expression was
dose-dependently induced by 24-hour treatment of prolactin 200 ng/mL
(P<0.05) and 500 ng/mL (P<0.001) inMIN6c4 cells and by 24-hour (P<
0.01) and 48-hour (P<0.001) treatment of prolactin 500 ng/mL in mouse
islets; similarly, Mn-Lnc04 expression was dose-dependently induced by
24-hour treatment of prolactin 200 ng/mL (P<0.001) and 500 ng/mL (P<
0.001) in MIN6c4 cells and by treatment of prolactin 200 and 500 ng/mL
for 24 hours (P<0.05) and 48 hours (P<0.01) in mouse islets.
Conclusion: These findings suggest that pregnancy is associated with an
altered expression of specific lncRNAs in islets, which may play a regu-
latory role inβ-cell mass expansion. Although their functions in beta-cell
proliferation and human relevance are currently not known, our data
suggests that novel lncRNAs that could be drug targets or biomarkers
are indeed regulated by pregnancy-induced adaptation in the islet.
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INSC93S transgenic pigs: a novel large animal model for gestational
diabetes
A. Martins1,2, C. Braun2, E. Streckel2, A. Blutke3, N. Klymiuk2, A.
Bähr2, B. Rathkolb4, R. Wanke3, M. Hrabe de Angelis4, E. Wolf1,2, S.
Renner2;
1MWMBiomodels, Tiefenbach, 2Gene Center, LMU, 3Institute of Veter-
inary Pathology, LMU, Munich, 4Institute of Experimental Genetics,
Helmholtz Zentrum, Munich, Germany.
Background and aims: The prevalence of gestational diabetes mellitus
(GDM) is steadily increasing. GDM has a negative impact on foetal
development and can trigger intrauterine programming of diseases like
obesity or diabetes in the offspring’s later life. Due to major differences in
foetal development, mouse models are not sufficient to address these
questions. In contrast, prenatal development of pigs mimics the human
situation more closely. We evaluated INSC93S transgenic pigs
characterised by a pre-diabetic condition (i.e. fasting normoglycaemia,
reduced glucose tolerance and decreased beta cell mass) as a novel model
of GDM.
Materials and methods: INSC93S transgenic pigs express the INSC93S
coding sequence under the control of porcine INS regulatory sequences.
INSC93S transgenic (n=3) and wild-type (WT) sows (n=4) were oestrus
synchronized and artificially inseminated with sperm of the same boar.
Hyperinsulinaemic-euglycaemic clamps (HIC) were performed within
the third trimester of pregnancy. At gestation day 98±1.5, sows were
necropsied and foetuses were recovered. From all foetuses blood samples
were taken, and body weight (BW) and crown-rump length (CRL) data
were recorded. In addition, pancreas was sampled from a random subset
of foetuses of both groups of pregnant sows and processed for stereolog-
ical analysis. From INSC93S transgenic sows only the WT foetuses were
studied. Effects on foetal outcomes were analysed using the General
Linear Models (GLM) procedure (SAS), taking sow genotype and fetal
sex as fixed effects, and sow body weight and litter size as covariates into
account. Data are presented as mean ± SEM.
Results: HIC showed a 35% reduced insulin sensitivity in pregnant (n=
4) compared to non-pregnant (n=3) WT sows (p=0.028), and insulin
sensitivity of pregnant INSC93S transgenic sows was reduced to the same
extent. While fasting blood glucose (FBG) levels were not different be-
tween the two sow groups at the beginning of pregnancy, INSC93S trans-
genic sows exhibited significantly higher FBG levels at gestation day 50
(71±2.3 vs. 50.3±3.3 mg/dl, p<0.01) and even more at gestation day 95
(106.7±9.7 vs. 55.5±4.3 mg/dl, p<0.001) compared to pregnant WT
sows. WT foetuses (n=14) recovered from INSC93S transgenic dams re-
vealed significantly higher blood glucose levels than those (n=44) from
WT sows (45.4±3.9 vs. 33.7±1.1 mg/dl, p<0.01). While foetal BW was
not significantly affected by maternal GDM, the relative CRL (CRL/
BW0.33) was significantly increased in foetuses from INSC93S transgenic
vs. WT sows (2.75±0.08 vs. 2.68±0.03; p<0.01). Additional analyses of
foetal insulin and metabolite levels as well as pancreas stereology are
ongoing.
Conclusion: Like humans, pigs develop reduced insulin sensitivity in the
late gestational period. In pre-diabetic INSC93S transgenic sows
pregnancy-induced metabolic stress resulted in a gradual elevation of
blood glucose levels to a clinically relevant extent which also projected
to the corresponding fetuses. The increased relative CRL in fetuses from
INSC93S transgenic sows suggests effects on foetal growth which deserve
organ specific analysis in future studies. This model is an important tool
to systematically analyse the molecular and biochemical changes induced
by GDM in the mother, fetuses and offspring.
Supported by: The Federal Ministry of Education and Research (German
Center)
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Haemoglobin A1c levels in the periconception period with type 1
diabetes and the risk of adverse neonatal outcomes: a systematic
review and dose-response meta-analysis
Y. Ding1, X. Zheng1, J. Yan1, S. Luo1, D. Yang1, L. Qiu1, W. Bao2, B.
Yao1, W. Xu1, J. Weng1,3;
1Endocrinology and Metabolic Disease, the Third Affiliated Hospital of
Sun Yat-sen University, 2School of Public Health, the Sun Yat-sen Uni-
versity, 3Guangdong Provincial Key Laboratory of Diabetology, Guang-
zhou, China.
Background and aims: Poor peri-conceptional (i.e., in the preconception
period or during first trimester of pregnancy) glycemic control signifi-
cantly increased adverse neonatal pregnancy outcomes in type 1 diabetes
mellitus (T1DM). Glycemic target in this period is controversial. We
aimed to evaluate and quantify the potential dose-response association
between peri-conceptional hemoglobin A1c (HbA1c) levels and the rel-
ative risk (RR) of congenital malformations and fetal loss in women with
T1DM.
Materials and methods: A systematic review and dose-response meta-
analysis of prospective cohort studies or nested case-control studies were
performed. Relevant articles in English were identified through searching
PubMed and EMBASE databases up to November 2014. The references
of relevant articles were reviewed to identify potential publications. Stud-
ies that were stratified by HbA1c with measures of RR, and 95% confi-
dence intervals (CI) for congenital malformations or fetal loss in T1DM
compared with non-diabetes were included.
Results:We reviewed 3958 abstracts and extracted 7 articles with data for
4153 individuals. A total of 124 congenital malformations events from 6
prospective cohort trials, and 88 fetal loss events from 5 prospective
cohort trials were observed. There was a linear dose-response relationship
between the peri-conceptional HbA1c of women with T1DM and the
relative risk of congenital malformations and fetal loss as shown in figure
1. The RR of congenital malformations was 1.61[0.58-4.49], 2.14[0.55-
8.32], 3.07[1.23-7.65] and 3.29[0.58-18.71], and the RR of fetal loss was
1.54[0.61-3.91], 2.09[0.48-9.11], 3.54[0.94-13.33] and 6.23[1.65-23.47],
when the maternal HbA1c during periconception was 5.5%, 5.9%, 7%
and 10%, respectively.
Conclusion: The risk of congenital malformation and fetal loss both
increased with maternal HbA1c level. If it is achievable without signifi-
cant hypoglycemia, HbA1c levels should be maintained as close to nor-
mal as possible in the periconception period.
Supported by: Sun Yat-sen University Clinical Research 5010 Program
(2007030)
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Lower levels of placental growth hormone in early pregnancy in type
1 diabetic women with large for gestational age infants
L. Ringholm1,2, A. Juul3, U. Pedersen-Bjergaard4, B. Thorsteinsson4, P.
Damm5, E.R. Mathiesen1;
1Endocrinology, University Hospital of Copenhagen Rigshospitalet,
2Steno Diabetes Center, Gentofte, 3Growth and Reproduction, University
Hospital of Copenhagen Rigshospitalet, 4Endocrinology Section,
Nordsjællands Hospital, Hillerød, 5Obstetrics, University Hospital of Co-
penhagen Rigshospitalet, Denmark.
Background and aims: Early growth delay may occur in the first trimes-
ter of pregnancy in women with diabetes. Insulin-like Growth Factor-I
(IGF-I) levels are higher in women with fetuses smaller than expected
from gestational age compared with women with normal-size fetuses.
Placental growth hormone (GH) levels in late pregnancy have previously
been reported to be associated with fetal growth. We evaluated whether
levels of placental GH and IGF-I are associated with development of large
for gestational age (LGA) infants in pregnant women with type 1
diabetes.
Materials and methods: Observational study of 107 consecutive preg-
nant women with type 1 diabetes (median duration 16 years (range 1-36),
HbA1c 6.6% (4.9-10.5) in early pregnancy). At 8, 14, 21, 27 and 33weeks
blood was sampled for measurements of placental GH, IGF-I and HbA1c.
Weight gain in early pregnancy was calculated as the difference between
weight at 14 weeks and pre-pregnancy weight. Total gestational weight
gain was calculated as the difference between the last weight measured
before delivery and the self-reported pre-pregnancy weight. LGA was
defined as birth weight >90th percentile.
Results: Throughout pregnancy the levels of placental GH were similar
in 51 (48%) women delivering LGA infants (birth weight 3930 g (3295-
5620)) compared with the remaining women (3198 g (2040-3880)) ex-
cept at 8 weeks where placental GH levels were lower in the women with
LGA infants (1.1 ng/ml (0.1-4.3) vs. 1.7 (0.3-11.7), p=0.02). IGF-I levels
during pregnancy were similar (p=0.61) in women with and without
LGA infants. Gestational age at first blood sampling was similar in wom-
en with and without LGA (60 days (37-89) vs. 62.5 (42-94), p=0.26).
Placental GH levels at 14 weeks correlated negatively with weight gain in
early pregnancy (r=-0.29, p=0.006). Total gestational weight gain corre-
lated positively with birth weight (r=0.28, p=0.003). LGA was more
frequent in women with parity ≥1 (34 (67%) vs. 17 (33%), p=0.001),
but was not associated with pre-pregnancy BMI. As predictors of LGA
infants multivariate logistic regression analysis identified placental GH
levels at 8 weeks (OR 0.4 (95% CI: 0.2-0.9), p=0.03; i.e. a doubling of
placental GH levels implied a 60% lower risk of having an LGA infant),
total gestational weight gain (1.7 (1.1-2.7), p=0.04; i.e. a 5 kg increase in
gestational weight gain implied a 70% higher risk of having an LGA
infant) and parity ≥1 (3.5 (1.5-8.3), p=0.004; i.e. parity ≥1 implied a
3.5 fold risk of having an LGA infant compared with primiparous
women).
Conclusion: Unexpectedly, elevated levels of placental GH or IGF-I
were not associated with the development of LGA infants in this cohort
of women with type 1 diabetes. Women delivering LGA infants had
lower placental GH levels in early pregnancy. Growth factors and mater-
nal weight gain in early pregnancy may play an important role for healthy
fetal growth.
1022
Maternal lipids are associated with large for gestational birth weight
in women with type 1 diabetes: results from a prospective single-
center study
P. Gutaj, E. Wender-Ozegowska, J. Brazert;
Dept. of Obstetrics andWomen's Diseases, Poznan University ofMedical
Sciences, Poland.
Background and aims: Despite improvement in diabetes care over the
years, incidence of large for gestational age (LGA) is still very high even
in a well controlled type 1 diabetic mothers. Aside from the already
studied effects of glycemia, it has been suggested that maternal lipids also
play an important role in influencing fetal growth. However, data on the
association of lipids and LGA in womenwith T1DM is scarce. Therefore,
the aim of our study was to determine whether changes in maternal lipids
might contribute to high rates of LGA in this population.
Materials and methods: Prospective single-center study on a population
of 171 women with T1DM admitted to the perinatal center for women
with diabetes between June 2012 and December 2014. Anthropometric,
clinical and laboratory data (HbA1C, total cholesterol, HDL, LDL, tri-
glycerides) were collected during 3 planned hospitalizations: in the first
trimester (<12th week), in mid-pregnancy (20th-24th weeks) and before
delivery (34th-39th weeks). All multivariate models were adjusted for
maternal age, duration of diabetes, BMI, gestational weight gain, parity
(mulitpara vs. primipara), mode of insulin therapy (CSII vs. MDI) and
HbA1c.
Results: Fifty- seven women were excluded from the study group due the
following: multiple pregnancy, spontaneous abortions, preeclampsia, and
delivery in a different hospital/loss of follow-up, giving a group of 114
women included in the final analysis (LGA=30; AGA=84). In the mul-
tivariate logistic regression analysis lower HDL concentration in the first
trimester was significantly associated with LGA (p=0.01). Similar asso-
ciation was observed for the HDL concentrations in mid-pregnancy (p=
0.04) and before delivery (p=0.03). Higher triglycerides concentrations
in the first trimester (p=0.02) and before delivery (p=0.008) were asso-
ciated with increased risk of LGA. There was no association between
second trimester TG and LGA. Both total cholesterol and LDL were
not associated with LGA. Higher HbA1c was associated with LGA in
the second trimester (p=0.01) and before delivery (p=0.02). There was
no association between first trimester HbA1c and LGA.
Conclusion:Decreased HDL and increased triglycerides during pregnan-
cy might contribute to the development of LGA in women with type 1
diabetes. HbA1c seems to be a significant predictor of LGA, however,
only in the second part of pregnancy.
Supported by: PUMS Young Researchers' Grant/ PDA Scientific Grant
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Diabetic autonomic neuropathy in type 1 diabetic pregnant women
L. Mattei, O. Bitterman, C. Festa, A. Napoli;
Clinical Sciences, Sapienza University of Rome, Italy.
Background and aims: Pregnant women undergo several metabolic and
circulatory changes to meet fetal needs. Diabetic autonomic neuropathy
(DAN) is a common complication of type 1 diabetes, involving cardio
vascular system. Primary aim: To evaluate the pregnancy outcome of two
groups of women with type 1 diabetes with and without autonomic dia-
betic neuropathy. Secondary aim: Longitudinal evaluation of time and
frequency domain indexes and 24 h ambulatory blood pressure monitor-
ing (24hABPM) in pregnancy.
Materials and methods:Diabetic autonomic neuropathy was diagnosed
before pregnancy, according to ‘SID diabetic neuropathy study group’
reccomandations. 22 normotensive type 1diabetic women at enrollment,
7 with DAN (N+) e 15without DAN (N-) underwent 24 hour Holter ECG
recording ( 24 h ECG) and 24hABPM at the 1st and the 3rd trimester. We
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analyzed time ( SDNN, SDANN, SDNN INDEX, PNN50%) and fre-
quency (LF, HF and LF- HF ratio) domain indexes derived from 24 h
ECG and 24 hour blood pressure profiles. Statistics: IBM SPPS ver.20 t
test, chi square and Mann Whitney.
Results: N+ showed a longer diabetes duration than N- (N+=20.2±3,9
vs N- =12.7±5,8 years , p=0.007) with a higher prevalence of
microalbuminuria ( N+=28.5% vs N-=0%, p=0,04) and retinopathy
(N+=100% vs N-=6,6%, p=0,01). Despite HbA1c levels were similar
during pregnancy, post prandial blood glucose levels were higher at lunch
time in N+ at the 1st trimester (N+=150,6±45,9 vs N-=112,9±26,5 mg/
dl, p=0,04). The prevalence of hypertension during pregnancy was not
significantly higher in neuropathic women (N+= 42,8% vs N-=33,3%,
p=0,66) even though two cases of pre-eclampsia were only observed in
N+ with microalbuminuria. At 1st and 3rd trimester, 24 hour systolic and
diastolic blood pressure values were not significantly higher in N+. At 3rd
trimester N+ were all ‘non dipper’ with a systolic delta day-night lower
than N- (N+=4 (3-5) vs N-=8,0 (5-9) mmHg, p=0,04). Time domain
indexes were lower in N+ at the 1st (SDNN index N+=78,2±21,5 vs N-=
102,6±18,8 milliseconds, p=0,01, SDANN index N+=69,4±23,4 vs
N-=94,1±22,7 milliseconds, p=0,04, PNN50 (N+=3,5 vs N-=11,1%,
p=0,04) and at the 3rd trimester ( SDNN index N+=69,7±25,1 vs N-=
95,4±31,7 milliseconds, p=0,04, SDANN index N+=61,7±27,2 vs N-
81,4±30,2 milliseconds, p=0,04, PNN50 index N+ =2,5 vs N-=6,0%,
p=0,04).We did not find any difference in frequency domain indexes. N+
women delivered not significantly earlier than N-.
Conclusion: Diabetic autonomic neuropathy is associated with higher
post prandial blood glucose values at the first trimester and worse blood
pressure levels throughout gestation. Differences in vagal indexes be-
tween neuropatic and non neuropatic women were definitely unmasked
in late pregnancy.
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Diabetic ketoacidosis in type 1 diabetic pregnancy: a case series
review
J. Bujanova, E.J. Nicholson, M.H. Cummings, A. Going, C. Hall;
Department of Diabetes and Endocrinology, Portsmouth Hospitals NHS
Trust, UK.
Background and aims: Diabetic ketoacidosis (DKA) in pregnancy is a
rare but serious medical and obstetrics emergency associated with a high
risk of fetal demise (9-35%) and maternal mortality (4-15%). Factors
predisposing to development of DKA in pregnancy include reduced buff-
ering bicarbonate capacity due to hyperventilation in 2nd and 3rd trimes-
ter, increased insulin resistance induced by pregnancy hormones, in-
creased insulin requirements in later stages of pregnancy, emesis
gravidarum and increased carbohydrate absorption due to progesterone
effect on gut mobility. The most common precipitants include infection,
first presentation of type 1 diabetes (T1DM), omission of insulin,
hyperemesis gravidarum, steroids for fetal lung maturation or severe
emotional stress. Ketonaemia, dehydration and acidosis cause reduced
utero-placental blood flow and increased affinity of maternal
haemoglobin to oxygen which can lead to fetal hypoxia. The aim of this
case series was to review the presentations of DKA in pregnancy in
patients with T1DM in our institution over the last 5 years.
Materials and methods: The electronic notes of 87 women with T1DM
seen in local antenatal service with 96 separate pregnancies between 1/4/
2010 to 31/3/2015 were reviewed. 5 of 87 (5.75%) women had 7 distinct
episodes of DKA in pregnancy. Demographic data on each woman was
collected alongside information on pre-pregnancy HbA1c, diabetes com-
plications, degree of metabolic derangement on admission, DKA trigger
and outcomes of pregnancy.
Results: 7 episodes of DKA occurred in 5 women in 6 pregnancies over
5 year period. One woman had 2 episodes of DKA in each of the 1st and
2nd trimesters of her pregnancy. Average pre-pregnancy HbA1c was
103mmol/mol. 3/5 women had pre-pregnancy retinopathy and one wom-
an had overt diabetic nephropathy. The majority of pregnancies (4/6)
were unplanned and 4/6 women did not attend pre-pregnancy counselling
clinic. DKA precipitants were influenza, mumps, dental abscess, UTI,
vomiting, gastritis and omission of insulin. DKAs occurred with equal
frequency in 1st trimester (3 episodes) and 3rd trimester (3 episodes) and
one DKA occurred in 2nd trimester. Average blood glucose at presenta-
tion was 17 mmol/l with two DKA episodes presented with only mildly
elevated glucose levels (12.7 and 8.9mmol/l). Average pH at presentation
was 7.23. Those who had blood ketones measured on admission had
levels ranging between 3.7-6.9 mmol/l. In one woman the DKA episode
was associated with fetal demise on admission at 9 weeks gestation. 4
women delivered by emergency caesarean section and their babies re-
quired admission to neonatal intensive care unit due to prematurity or
neonatal hypoglycaemia.
Conclusion:Higher risk ofDKA in pregnancy despite intensive antenatal
input seems to be associated with suboptimal HbA1c prior conception
and past history of DKA admissions prior to pregnancy. Our case review
demonstrated that pregnant women with DKA presented predominantly
to medicine. Cases presented with lower than expected glucose levels
with one woman presenting with a level of 8.9 mmol/l, which might
present a diagnostic challenge. One woman presented with fetal death
on admission but no fetal deaths occurred after treatment of DKA was
initiated which highlights importance of rapid diagnosis and rigorous
treatment. All babies were delivered via emergency caesarean section
and required specialist baby unit care which would suggest that DKA in
pregnancy is a risk factor for these outcomes.
1025
The clinical significance of overt diabetes diagnosed in pregnancy
L. Mañé1, D. Benaiges1, J. Pedro-Botet1, M. Prados2, A. Payà3, J.J.
Chillarón1, A. goday1, R. Carreras3, R. Carreras3, J.A. Flores-LE Roux1;
1ENDOCRINOLOGY, Hospital Del Mar, 2ENDOCRINOLOGY, Hospi-
tal De Martorell, 3Ginecology, Hospital Del Mar, Barcelona, Spain.
Background and aims: To analyze maternal characteristics, pregnancy
and neonatal outcomes in women diagnosed of overt diabetes (ODM)
during pregnancy and to compare these results with those of women
diagnosed with gestational diabetes mellitus (GDM)
Materials and methods: A prospective study of women who gave birth
in our hospital between January 2011 and October 2014 was carried out.
All women underwent screening for GDM using the two-step approach
between the 24th and the 28th week of pregnancy. Those with risk factors
for GDM underwent testing during the first trimester. The diagnosis of
GDM was based on the recommendations of the National Diabetes Data
Group. A1c levels were determined in those diagnosed of GDM. ODM
was diagnosed in those who met the ADA criteria for diabetes (fasting
glucose ≥126 mg/dl and/or a glycosylated hemoglobin≥6.5%) but who
had not a previous diagnosis of diabetes mellitus.
Results: During the study period 567 women were diagnosed of GDM
and 40 fulfilled the criteria for ODM. Maternal, gestational and newborn
characteristics of both study groups are shown in the Table.
Conclusion: In this patient cohort, overt diabetes in pregnancy signifi-
cantly increased the risk of adverse pregnancy outcomes such as prema-
ture birth, induced delivery, caesarean section and large for gestational
age babies, when compared with GDM. The majority of women diag-
nosed of ODM belong to ethnic minority groups and so special attention
to these women should be paid in order to achieve early detection and
treatment.
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The prevalence of early somatic neuropathy in children and
adolescents with type 1 diabetes and its association with the persis-
tence of GAD-65 and IA-2 autoantibodies
F. Karachaliou1, M. Louraki2, M. Katsalouli3, C. Kanaka-Gantenbein4,
E. Critselis5, N. Kafasi6, D. Kallinikou2, C. Tsentidis2, K. Karavanaki2;
1Endocrine Department, “P&AKyriakou” Children’s Hospital, 2Diabetic
Clinic, Second Pediatric Department University of Athens, “P&A
Kyriakou” Children’s Hospital, 3Neurologic Department, “Aghia
Sophia” Children’s Hospital, 4Diabetes Center, First Department of Pedi-
atrics University of Athens, “Aghia Sophia”Children’s Hospital, 5Second
Pediatric Department University of Athens, “P&A Kyriakou” Children’s
Hospital, 6Department of Immunology, ‘Laiko’ General Hospital, Ath-
ens, Greece.
Background and aims: Diabetic neuropathy (DN) is a complication of
type 1 diabetes mellitus (T1D) with somewell established risk factors and
others that remain to be identified. We tried to evaluate the prevalence of
early somatic neuropathy in children and adolescents with T1D and its
association with the persistence of autoantibodies against glutamic acid
decarboxylase (GADA) and islet antigen-2 (IA-2A).
Materials and methods: A cross-sectional study was conducted in a
hospital-based cohort of pediatric T1D patients (n=85, mean (SD) age:
12.3±3.4 years). Peripheral neuropathy was assessed with nerve conduc-
tion studies (NCS). GADA and IA-2A titers were measured in samples
collected prior to electrophysiological testing.
Results: Among the study population, 34.1% had at least one abnormal
electrophysiological parameter in NCS, although usually asymptomatic.
The highest rates of abnormalities were detected in the sensory fibers of
the peroneal nerve. These patients were not different from the rest of the
study group in terms of age, diabetes duration or glycaemic control.
Among our patients with a mean (SD) T1DM duration of 5.4±3.3 years,
62.4% had positive GADA, 58.8% positive IA-2A and 41.2% double
antibody positivity. Abnormal NCS correlated neither with GADA nor
with IA-2A levels. However lower sensory nerve action potential (SNAP)
in the peroneal nerve, which was indicative of early axonal dysfunction,
was observed in patients with GADA (8.3±3.0 mV vs 10.2±4.2 mV, p=
0.046) or IA-2A (7.8±3.9 mV vs 10.6±4.0 mV, p=0.002) positivity.
Conclusion: Impaired indices of subclinical peripheral sensory neuropa-
thy were present among one third of the T1DM children and adolescents,
with no difference in diabetes duration or glycaemic control. GADA and
IA-2A seem to be involved in the development of axonal degeneration, in
a pathway which remains to be identified.
1027
Is IGT-associated sensory neuropathy driven only by glycaemia?
Z. Putz1, N. Nemeth1, I. Istenes1, O. Vagi1, A. Korei1, T. Martos1, S.
Kempler1, R. Gandhi2, S. Tesfaye2, G. Jermendy3, A. Tabak1, P.
Kempler1;
1Ist Dep. of Int. Med., Semmelweis University, Budapest, Hungary,
2Royal Hallamshire Hospital, Sheffield, UK, 3Bajcsy Zsilinszky Hospital,
Budapest, Hungary.
Background and aims: Traditional cardiovascular risk factors play an
important role in the development of neuropathy in diabetes. In the pres-
ent study, we aimed to investigate risk factors of sensory neuropathy in
patients with impaired glucose tolerance (IGT) and healthy volunteers.
Materials and methods: Seventy-five people with impaired glucose tol-
erance and 40 age and gender matched healthy volunteers underwent a
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detailed clinical examination and neurological assessment. Sensory nerve
function was assessed by using Neurometer (current perception threshold
[CPT]) and Medoc devices. Autonomic neuropathy was detected by the
five standard cardiovascular autonomic tests. Mean 24-h systolic and
diastolic blood pressures were assessed by 24-hour ambulatory blood
pressure monitoring.
Results: The prevalence of sensory neuropathy was 58% in subjects with
impaired glucose tolerance. The Odds ratio (OR) was 11.23 (CI: 3.57-
35.35). This association was independent from the presence of autonomic
neuropathy or the measure of BMI, HbA1c, BP and HR. However, ad-
justment for fasting plasma glucose attenuated the association notably
(OR: 6.75; CI: 1.33-34.27), and the significance was lost after adjustment
for 120 min glucose level (OR: 3.76; CI: 0.26-54.10). Sensory neuropa-
thy in patients with IGT showed a strong association with 120 min glu-
cose level (OR: 1.78; CI: 1.20-2.63) in the entire population studied.
Conclusion: Our data suggest that glycemia (120 min glucose level) is a
risk factor for sensory neuropathy in subjects with IGTwhich is indepen-
dent of all other known cardiovascular risk factors. This new knowledge
may be an important addition to risk reduction strategies.
1028
Reduced sudomotor function in adult patients with long lasting type
1 diabetes and peripheral neuropathy
A. Gandecka, A. Araszkiewicz, S. Pilacinski, B. Wierusz-Wysocka, D.
Zozulinska-Ziolkiewicz;
Department of Internal Medicine and Diabetology, Poznan University of
Medical Sciences, Poland.
Background and aims:Diabetic neuropathy is the most common chron-
ic complication of diabetes. It often remains undiagnosed for a long time
and usually leads to chronic pain and foot ulcerations. Therefore, new
accurate and noninvasive methods are needed for its early diagnosis.
Sweat glands are innervated by small C-fibers. Dysfunction of the sweat
glands is very early clinical manifestation of diabetic neuropathy.
SUDOSCAN+ device is used to noninvasively assess the function of
the sweat glands, measuring electrochemical skin conductance (ESC)
through reverse iontophoresis. The aim of this study was to evaluate the
sudomotor function in patients with long lasting type 1 diabetes.
Materials and methods: The study included 381 adult patients with type
1 diabetes (185 women and 196 men) aged 41 years (IQR: 32-51), with
disease duration of 23 (IQR: 18-30) years. The study group was
subdivided into two groups depending on the presence of peripheral
neuropathy identified by standard methods. Neuropathy was diagnosed
in patients with two or more of the following five elements: the presence
of symptoms, lack of ankle reflexes, impaired sensation of touch, tem-
perature and/or vibration. We measured ESC with SUDOSCAN+ on feet
(Feet ESC) and hands (Hands ESC) in the study group and in the control
group of 63 healthy volunteers sex and age matched. We also evaluated
metabolic control of diabetes using HbA1c value and skin autofluores-
cence (AF) measured with AGE-Reader as well as the presence of late
diabetic complications.
Results: Peripheral neuropathy was diagnosed in 45% of patients. Pa-
tients with peripheral neuropathy, compared to those without it, had lower
Feet ESC [68 (IQR: 46-81) vs 83 (IQR: 76-87)μS; p<0.001] and lower
Hands ESC [56 (IQR: 39-69) vs 69 (IQR: 59-77)μS, p<0.001].We found
a negative correlation between the result of ESC on feet and hands and
patients’ age (Rs=-0.41, p<0.0001; Rs=-0.40, p<0.0001), duration of
diabetes (Rs=-0.33, p<0.0001, Rs=-0.31, p<0.0001), HbA1c level
(Rs=-0.12, p=0.015, Rs=-0.12, p=0.017), skin AF (Rs=-0.33, p<
0.0001, Rs=-0.30, p<0.0001) and positive correlation with the eGFR
(Rs=0.36, p<0.0001, Rs=0.30, p<0.0001). Feet ESC and Hand ESC
did not differ between patients with diabetes without neuropathy and
controls [83 (IQR: 76-87) vs 82 (IQR: 78-86) μS), p<0.94 and 69 (59-
77) vs 69 (60-79)μS, p=0.57]. In a multivariate logistic regression model
electrochemical skin conductance was independently associated with the
presence of peripheral neuropathy (Feet ESC OR 0.96; 95%CI: 0.95-
0.98, p<0.0001 and Hands ESC OR 0.97; 95%CI: 0.95-0.98, p=
0.0001). This association was independent from age, sex, duration of
diabetes, HbA1c, skin AF and eGFR.
Conclusion: In adults with type 1 diabetes and peripheral neuropathy
sudomotor function is markedly reduced. The longer duration of diabetes,
worse metabolic control or reduced renal function, the greater sudomotor
dysfunction is.
Supported by: Diabetes Poland
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Sudoscan as a tool for early screening of diabetic microvascular
complications: experience of a French hospital
L. Bordier, C. Garcia, M. Dolz, B. Bauduceau, H. Mayaudon;
Endocrinology Department, Hospital Bégin, Saint-Mandé, France.
Background and aims:The screening ofmicrovascular complications in
patients with type 2 diabetes is not optimal, especially for neuropathy at
early stage. As sweat glands are innervated by small autonomic C-fibers
the measurement of sweat function has been proposed to evaluate periph-
eral small fiber neuropathy, whichmay occur very early. This study aimed
to evaluate SUDOSCAN, an easy, fast, non-invasive and quantitative
measurement of sweat function for the detection and follow-up of micro-
vascular complications of diabetes.
Materials and methods: During this study involving 189 patients with
type 2 diabetes, the following tests were performed: a clinical examina-
tion including monofilament testing (n=154), blood tests including
MDRD clearance (Modification of the Diet in Renal Disease) measure-
ment, ophthalmologic examination (n=113), SUDOSCAN with hands
and feet conductance measurements (μS). A general risk score for auto-
nomic neuropathy based on previous studies was also calculated. Results
were expressed as mean ± SD and comparisons were made by a Student
test.
Results: The population had a mean age of 60±16 years, 49% were men,
HbA1c 9.0±1.3%. Feet conductances of patients having Fasting blood
glucose>7.2 mmol/L were significantly lower (70±15 vs 74±16 μS, p=
0.03). Patients with MDRD clearance<90 ml/min had significant lower
conductances for hands and feet (Figure). Patients with urinary albumin
excretion (UAE)≥15 mg/L had significant lower feet conductances (69±
17 vs 75±14 μS, p=0.002). Lastly, patients who presented abnormalities
to monofilament testing had lower conductances for hands (57±16 vs 65
±16 μS, p=0.004), and feet (65±20 vs 75±11 μS, p=0.003). Same
tendency was observed in patients with retinopathy as compared to pa-
tients without (69±16 vs 74±14 μS, p=0.13). Global autonomic risk
score using 35 as threshold had a sensitivity of 78% and a specificity of
54% to detect at least one microvascular complication. No adverse event
or discomfort has been reported during or following SUDOSCAN
recording.
Conclusion: This study showed lower conductances values for diabetic
patients who presented abnormalities to monofilament test, assessing big
myelinisated fibers. These data also suggest that the conductances mea-
sured by the device correlate well with renal microvascular alterations as
represented by both decreased MDRD clearance and increased UAE.
These results indicate that SUDOSCAN device could be used for early
detection and monitoring of both diabetic neuropathy and nephropathy.
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Thalamic γ-aminobutyric acid in diabetic neuropathy
I.D. Wilkinson1, P. Shillo2, M. Greig2, R.A. Edden3, D. Selvarajah4, S.
Tesfaye2;
1Academic Radiology, University of Sheffield, 2Academic Department of
Diabetes and Endocrinology, Sheffield Teaching Hospitals NHS Founda-
tion Trust, UK, 3JohnHopkins University School ofMedicine, Baltimore,
USA, 4Human Metabolism, University of Sheffield, UK.
Background and aims: The thalamus forms a major component of the
ascending sensory pathway to the brain, the function of which may play
an important role in patients with diabetic neuropathy (DN). Previous
Magnetic Resonance (MR) studies have demonstrated thalamic metabo-
lite involvement on Proton MR Spectroscopy (H-MRS). One such me-
tabolite, γ-Aminobutyric acid (GABA), is an inhibitory neurotransmitter.
This study assessed thalamic GABA in-vivo using specialised novel H-
MRS editing techniques in patients with and without DN.
Materials and methods: 44 type 2 diabetes (T2DM) Caucasian subjects
(14 Painful-DPN, 15 Painless-DPN and 15 No-DPN) and 15 healthy
volunteers without diabetes (HV) underwent detailed clinical and neuro-
physiological assessments. T2DM subjects were divided into three
groups based on the neuropathy composite score [NIS(LL)+7 and
Douleur Neuropathique 4 score(DN4). All groups were age-matched.
Subjects underwent localised H-MRS at 3 Tesla to assess GABA relative
to unsuppressed water and creatine using a single-voxel, spin-echo, spec-
tral editing technique (MEGA-PRESS; echo time=68 ms) centred over
thalami. GABA resonance signal was obtained relative to that of paren-
chymal water
Results: Analysis of Variance revealed differences in group mean
GABA/H20 ratios [ANOVA p<0.01; Painless-DPN 1.47(sd=0.23),
Painful-DPN 1.61(0.33), HV 1.75(0.25) and T2DM with No-DPN
1.84(0.38)]. Post-hoc comparisons indicated significantly lower mean
GABA/H20 in Painless-DPN compared to No-DPN (p<0.005) and sig-
nificantly lower mean GABA/H20 in Painless-DPN compared with HV
(p<0.05).
Conclusion: This study containing a well-sized, well-characterised co-
hort clearly demonstrates lower relative levels of the ‘H-MRS-visible’
inhibitory neurotransmitter GABA in the thalamus of patients with
DPN. Previous published pilot data from 7 diabetics with neuropathy
and 7 non-diabetics reported lower GABA in the posterior insula in the
context of DN. Our current larger sample size indicates significantly
lower GABAwithin the thalamus often considered the sensory gateway
to the brain. A further understanding of the cerebral neuronal excitatory/
inhibitory balance inferred from this H-MRS technique may help deter-
mine the mechanistic basis of central nervous system involvement in pain
perception associated with DN.
Supported by: STH15701
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Neuroinflammation and neurodegeneration in the prefrontal cortex
during diabetic neuropathic pain
J. Pereira, S. Oliveira, I. Tavares, C. Morgado;
Experimental Biology Department, Faculty of Medicine of Porto & I3S -
Institute for Innovation and Health Research, University of Porto,
Portugal.
Background and aims: Diabetic neuropathy (DN) is associated with
structural and functional changes of nervous system, including areas in-
volved in central pain control system, as the prefrontal cortex (PFC),
which can lead to chronic excruciating pain. Neuroinflammation and
synaptic plasticity have been associated to chronic pain conditions, with
interplay between increased glial activation, pro-inflammatory mediators
overexpression and neurodegeneration. Whether such factors contribute
in the impairments detected in PFC in painful DN is still unknown. This
study intended to evaluate neuroinflammation and neurodegeneration in
PFC using an animal model of diabetic neuropathic pain - the
streptozotocin (STZ)-diabetic rat.
Materials and methods: Rats were rendered diabetic by an intraperito-
neal injection of streptozotocin (STZ). Control (CTR) rats were received
vehicle solution. Ten weeks post-induction, the animals were sacrificed
and the interest brain areas were removed and processed by western blot
to quantify expression of Iba1 (microglial activity marker), IL1β and
TNFα (pro-inflammatory factors) and synaptophysin (synaptic integrity
marker). Volumes and neuronal density was determined by stereological
methods in PFC areas, namely in the anterior cingulated cortex (ACC),
prelimbic cortex (PL) and infralimbic cortex (IL). Glycaemic values and
behaviour pain responses to mechanical stimuli were evaluated before
sacrifice in order to confirm the diabetic neuropathic pain condition. Data
were compared by independent sample t test and presented as mean ±
SEM. Statistical significance was settled as p<0.05.
Results: The STZ-diabetic rats presented hyperglycaemia (CTR: 151.3±
43.8; STZ: 580.5±19.5; mgdl-1, p<0.05) and decreased mechanical
thresholds (CTR: 14.8±0.5; STZ: 8.5±0.2; grams, p=0.002). We ob-
served an increase of Iba1 expression in STZ-diabetic rats (CTR: 0.8±
0.1; STZ: 2.3±0.2; optical units, p=0.002), which was accompanied by
an increase of IL1β (CTR: 1.2±0.1; STZ: 2.0±0.3; optical units, p=
0.041) and TNFα (CTR: 0.8±0.1; STZ: 1.2±0.05; optical units, p=
0.048) levels. Synaptophysin expression was significantly decreased
(CTR: 1.0±0.04; STZ: 0.7±0.07; optical units, p=0.009). A significant
reduction was observed in the estimated volume of ACC in diabetic
animals (CTR: 3.3×10^7±1.3×10^6; STZ: 2.8×10^7±6.0×10^5;
μm3, p=0.007) accompanied by a clear reduction in neuronal density
(CTR: 14.8×10^10±2.1×10^10; STZ: 8.1×10^10±3.8×10^10; neu-
rons/μm2), albeit non-significant (p>0.05).
Conclusion: Diabetes induces neuroinflammation and neurodegenera-
tion in PFC. These changes may contribute to diabetic neuropathic pain,
point for the need of strategies to prevent it.
Supported by: Grant: Dr. Pedro Eurico Lisboa SPP/Bayer 2012; FPF7
EU Project REDDSTAR
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GLP-1 analogue has anti-inflammatory effects at the spinal cord of
diabetic rats
C. Morgado, L. Lopes, J. Pereira, S. Oliveira, I. Tavares;
Department of Experimental Biology, Faculty of Medicine & I3S- Insti-
tute for Innovation and Health Research, University of Porto, Portugal.
Background and aims: Diabetic neuropathy is a common complication
of diabetes, often associated with chronic pain. Several studies pointed to
changes at the spinal cord as possible mechanisms underlying the diabetic
neuropathic pain (DNP). Neuroinflammation emerges as a possible cause
of diabetes-induced spinal dysfunction. Incretin drugs, namely glucagon-
like peptide 1 (GLP1) analogues, emerge as promising drugs as they were
shown to present anti-inflammatory and neuroprotective effects in neuro-
degenerative diseases. Moreover, the GLP1 receptor was shown to be
expressed by CNS immune cells, the microglia, at the spinal dorsal horn,
reinforcing the possible effect of GLP1 in mediating spinal inflammatory
responses. The aim of present study was to evaluate the anti-
inflammatory effects of Liraglutide (LIRA, GLP1 analogue) in the spinal
cord of rats with DNP.
Materials and methods: Diabetes was induced by injection of
streptozotocin (i.p., STZ), whereas control rats (CTR) received vehicle
solution. One week after diabetes induction, STZ-injected rats initiated a
treatment with LIRA (1 g/kg s.c.) (STZ+LIRA) or were maintained un-
treated for 10 weeks (STZ-untreated). Blood glucose and mechanical
hypersensitivity were evaluated after injections and at 4 and 10 weeks
post-injections. The L4-L5 spinal segments were removed and processed
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for western blot to quantify Iba1 (microglial activation marker), GFAP
(astroglial activation marker) and interleukin 1β (IL1β) and tumor necro-
sis factor alpha (TNFα). Behavioral data was compared by Two Way
ANOVA with repeated measures and molecular data was compared by
One Way ANOVA, followed by Tukey post-hoc test for multiple com-
parisons. Statistical significance was settled as p<0.05. Results are pre-
sented as mean ± SEM.
Results: All STZ animals presented increased blood glucose concentra-
tion at 4 (CTR: 106.3±9.7; STZ-untreated: 462.0±37.2; STZ+LIRA:
378.0±20.5, mg/dl) and at 10 weeks post-induction (CTR: 151.3±43.8;
STZ-untreated: 580.5±19.5; STZ+LIRA: 574.9±84.1, mg/dl). The treat-
ment with LIRA significantly reduced mechanical hypersensitivity at
10 weeks of diabetes (STZ-untreated: 9.8±0.4; STZ+LIRA: 11.9±0.7,
grams), but the mechanical hypersensitivity thresholds were maintained
significantly lower than in control animals (CTR: 14.9±0.5; STZ+LIRA:
11.9±0.7, grams). A significant increase in the expression of IL1β (CTR:
0.8±0.1; STZ-untreated: 1.9±0.5, optical units) and TNFα (CTR: 0.9±
0.1; STZ-untreated: 2.9±0.9, optical units) was detected in the spinal cord
of STZ-untreated rats. The levels of IL1β were significantly reduced by
the treatment with LIRA (STZ+LIRA: 0.5±0.1, optical units), whereas a
non-significant decrease in TNFα expression was detected (STZ+LIRA:
1.6±0.6, optical units). The STZ+LIRA rats presented increased expres-
sion of Iba1 (CTR:0.8±0.1; STZ-untreated: 0.9±0.1; STZ+LIRA: 1.2±
0.2, optical units). The expression ofGFAPwas dramatically decreased in
STZ-untreated rats (CTR: 0.9±0.1; STZ-untreated: 0.2±0.1, optical
units) and was not affected by the treatment with LIRA(STZ+LIRA:
0.3±0.1, optical units).
Conclusion: This study shows that diabetes induces neuroinflammation
in the spinal cord, which may be reduced by the treatment with LIRA.
The anti-inflammatory effects of LIRA at the spinal cord may concur for
the attenuation of diabetes-induced mechanical hypersensitivity.
Supported by: Grant SPP/Bayer 2012 and FPF7 EUProject REDDSTAR
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AICAR-transformylase/ cyclohydrolase mediates glucotoxic
complications in C. elegans and can be treated in an AMP-kinase
dependent manner
C. Riedinger, M. Mendler, P.P. Nawroth;
Innere Medizin I, Medizinische Klinik Heidelberg, Germany.
Background and aims: As the expression atic-1, which codes for an
enzyme that catalyzes the last two steps of purine de-novo synthesis
(AICAR-transformylase/ cyclohydrolase) was found to be upregulated
under high-glucose conditions in C. elegans, it was hypothesized that
ATIC itself might be causally involved in mediating glucotoxic effects.
Materials and methods: Nematodes were cultured under standard and
high glucose (HG) conditions, leading to glucose concentrations in whole
animal extract of 5.5 mM and 13 mM, respectively, and treated with
1 mMAICAR. The dependency of ATIC was evaluated by using specific
ATIC RNAi. Further, AMPK (aak-2), iron/ manganese superoxide dis-
mutase (sod-3) and glyoxalase-1 (glod-4) mutant strains were used to
evaluate downstream mechanisms. Life span, neuronal structure (micros-
copy of the pan neuronal GFP-expressing strain NW1229) and neuronal
function (video analysis) were determined as well as accumulation of
reactive oxygen species (ROS) and advanced glycation end-products
(AGEs). Furthermore, concentrations of AICAR were measured.
Results: Under high glucose conditions the expression of atic-1 is in-
creased 3.1-fold (p=0.006) compared to standard conditions. If the ex-
pression of atic-1 is abrogated by specific RNAi, which leads to an in-
crease of its substrate AICAR (16-fold), HG mediated shortening of
lifespan (from 11.0±0.5 days to 14.4±0.9 days, p<0.0001) as well as
structural and functional neuronal damage (from 0.12±0.02 mm/s to
0.24±0.01 mm/s, p=0.012) are prevented. This goes along with a nor-
malization of ROS and AGEs. The normalization of mean lifespan (and
neuronal function?) by atic-1 RNAi is dependent on AMP-K as this effect
is not seen in aak-2 mutant animals (life span from 9.5±0.3 days to 9.6±
0.4 days). Conversely, ATIC overexpression shortens lifespan (from
36 days to 30 days) and negatively affects neuronal structure (0.25 dam-
age scores to 0.75 damage scores). Corresponding to the effect of ATIC
RNAi, exogenous AICAR treatment could prevent deleterious effects on
neuronal structure (from 1.76±0.2 damage scores to 0.84±0.13 damage
scores, p=0.016) and function (from 0.09±0.04 mm/s to 0.25 mm/s, p=
0.03) and lifespan (from 14.8±0.9 days to 19.9±0.7 days) in high glucose
cultured C. elegans. Additional treatment with the antioxidant butylated
hydroxyanisole (BHA) and the complex-1 inhibitor rotenone could not
further improve the effect of AICAR treatment on normalizing lifespan (+
AICAR: 16.9±0.8 days, +BHA: 16.5±1.1 days and +rotenone: 16.3±
1.1 days). Finally, the life prolonging effect of AICAR under HG condi-
tions is independent on glod-4 (from 13.8±0.3 days to 18.3±0.9 days, p=
0.001) and sod-3 (from 14.4±0.6 days to 17.9±0.6 days, p=0.0012) but
dependent on AMP-K (aak-2) (from 13.8±0.5 days to 14.0±0.8 days, p=
0.438).
Conclusion: The overexpression of atic-1 seen under high glucose con-
ditions in C. elegans is contributing to the deleterious effects on lifespan
and the neuronal system. This can be reversed by the use of specific atic-1
RNAi or treatment with AICAR in an AMP-K dependent manner.
Supported by: DFG NA 138/7-1; Dietmar-Hopp-Stiftung; SFB 1118
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Validation of Neuropathy Symptoms Score (NSS) and Neuropathy
Disability Score (NDS) in clinical evaluation of peripheral
neuropathy in diabetes mellitus
A. Chawla, A. Chawla, R. Chawla, G. Bhasin;
Diabetes, North Delhi Diabetes Centre, New Delhi, India.
Background and aims: About one third of diabetic people are at risk of
foot ulceration because of loss of protective sensation due to peripheral
Neuropathy. The symptoms of neuropathy& the conventional assessment
of it with Cotton wool, Vibrating tuning fork, pin prick and hot and cold
sensation can give a qualitative diagnosis. Biothesiometer can quantify &
pick up early cases of DPN & is an important diagnostic tool in clinical
practice
Materials and methods: Present pilot study was designed to find out the
prevalence of Diabetic peripheral neuropathy (DPN) incidence by bed
side evaluation using NDS & NSS as per “Young et al” criterion & then
to study its co-association with other diabetic complications 855 Type -2
diabetes patients who got newly enrolled at our Diabetes Centre” between
July 2013 to Dec 2014 were evaluated clinically by neuropathy symptom
score (NSS) & Neuropathy Disability score (NDS) as suggested by
“Young et al”. Peripheral Neuropathy was diagnosed clinically if sum
of NDS + NSS was >10 135 patients out of total 855 patients who had
NSS 5-6 (mild symptoms) or NDS 5-6 but if sum of NDS +NSSwas>10
were then evaluated by biothesiometry to validate this score . VPT>15
volts was taken as cut off for mild DPN&VPT >25 volts was considered
as significant DPN. Detailed Diabetes Profile including their clinical pro-
file namely Age, Sex, Mean duration of Diabetes, their personal habits
smoking, dietary habits were evaluated. These patients were also evalu-
ated for presence of Microabluminuria, Retinopathy, PVD and
Dyslipidaemia etc.
Results: 86 patients had monofilament impairment, 49 patients had nor-
mal monofilament test. 96 patients were detected to have DPN by VPT
(60 severe, 36 mild to Moderate). Hence, applying NDS+NSS >10 as per
” Young et al criterion “ could pick up early DPN in 96 out of 135 (
sensitivity of 71.1% & specificity of 90% ) This has a +ve predictive
value of 57.14% & –ve predictive value of 94.32% as validated & doc-
umented by biothesiometer. Prevalence of DPN in total 855 patients
evaluated clinically by NSS & NDS later tested by biothesiometry was
found to be 15.4%.
Conclusion: Neurological examination like NSS & NDS can be an im-
portant bed side tool in the clinics for early diagnosis of DPN with a
sensitivity of 71.1% & specificity of 90%. It is simple, acceptable, repro-
ducible & validated as per our study. DPN has a strong co-association
with other complications like DR (44.1% Vs 19.2%) and
Microalbuminuria 61.3% Vs 38%.
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Can a nurse successfully diagnose distal diabetic polyneuropathy?
A. Zielinska, E. Szymanska-Garbacz, J. Loba, L. Czupryniak;
Medical University of Lodz, Poland.
Background and aims: Distal symmetrical polyneuropathy (DPN) is
one of the most frequent chronic complications of diabetes. Early diag-
nosis of DPN is of paramount importance for the prevention of diabetic
foot syndrome.We conducted a study aiming at assessingwhether a nurse
using a Diabetic Neuropathy Symptom (DNS) score can accurately diag-
nose DPN. DNS is a simple 4-item questionnaire evaluating the 14-day
frequency of gait abnormalities and sensory disturbances (pain, tingling
and numbness) in lower limbs; answering ‘yes’ to one of the questions
reflects the presence of DPN.
Materials and methods: In a single outpatient diabetes clinic 118 pa-
tients (21 with type 1, and 97 with type 2 diabetes) were first met by
nurse, who administered DNS. Then they were seen by a diabetologist
who performed thorough medical examination aiming at assessing the
presence of DPN. The specialist was blinded to the results of nurse-
conducted DNS.
Results: 71 (60%) patients replied positively to at least one of four ques-
tions in DNS, while the diabetologist confirmed the presence of DPN in
80 (68%) patients, including all who were tested positive by a nurse.
Thus, the sensitivity of DNS was 0.89 (95%CI 0.84-0.89), and specificity
reached 1.00 (0.95-1.00). According to the results of the nurse-conducted
DNS, the most frequent complaint was tingling (31%), then numbness
(27%), pain (24%) and gait abnormalities (18%). The significant risk
factors for positive DNS result were disease duration, HbA1c, smoking,
and recent (in the previous 3 months) change in diabetes treatment. DPN
was confirmed by a diabetologist in 71% of the patients with diabetes
duration >15 years and in 42% of those who had diabetes for less than
5 years, in 90% patients with HbA1c >9.0% and in 34% of those with
HbA1c <7%, in 69% of ever smokers and in 46% of those who never
smoked, and in 84% of those whose diabetes therapy was modified in
previous 3 months and in 17% of those whose treatment remained stable
recently (all differences p<0.05). Interestingly, self-declared alcohol in-
take level was not related to DNS results.
Conclusion: In conclusion, DNS can be a very effective tool to diagnose
DPN when used by a nurse working on her own. Engaging nursing staff
into DPN assessment may help diagnose the condition at its early stage.
S500 Diabetologia (2015) 58 (Suppl 1):S1–S607
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The first demonstration that the Norfolk QOL-DN scale establishes
safety in painful diabetic peripheral neuropathy
F. van Nooten1, C. Poole2, M. Stoker1, R. Snijder1, F. Lewis3, E.J.
Vinik4, A.I. Vinik1;
1Astellas Pharma Europe B.V., Leiden, Netherlands, 2Astellas Pharma
Europe, Chertsey, 3Office of Health Economics, London, UK, 4Eastern
Virginia Medical School, Norfolk, USA.
Back ground and aims: PACE was a Phase III, randomised, controlled,
open-label, 52-week, safety study that assessed the safety and efficacy of
repeat treatment with the capsaicin 8% patch plus standard of care (SOC),
versus SOC alone in patients with painful diabetic peripheral neuropathy
(PDPN) (N=468). The Norfolk QOL-DN scale was the primary safety
endpoint and it was used to assess patient-reported functional conse-
quences of potential impairment in small-fibre nerve function that may
be due to capsaicin treatment. Secondary safety endpoints included an
objective utilization of the Utah Early Neuropathy Scale (UENS) and
quantitative sensory perception testing.
Materials andmethods:As PACE is the first study in which the Norfolk
QOL-DN scale was a safety endpoint, patient level analyses were per-
formed to determine correlation with other safety endpoints. An additive
(Gaussian) regression model, adjusted for repeated measures using an
AR(1) error structure, including additional random effects and covariates
was utilised. Relationship strength was assessed using F-tests.
Results: Treatment with capsaicin improved quality of life in parallel
with improved UENS and sensory function. This relationship between
change in Norfolk QOL-DN total and UENS total scores was observed in
patients in all treatment arms (p<0.0001), with a 1.0 unit decrease in
UENS corresponding to a 0.4 unit decrease in Norfolk. In all treatment
arms, improvement in sharp, heat, cold and vibration sensation scores
were correlated with improvement in Norfolk total (p≤0.01 for all) and
UENS total (p≤0.0006 for all) scores, but there were no relationships
with deep-tendon reflex. Improvement in the Norfolk small fibre subscale
score was correlated with improvement in UENS pinprick subscale and
sharp sensation score in patients in all treatment arms (p<0.001 for both).
In addition, improvement in Norfolk large fibre subscale score was cor-
related with improvement in UENS total (p<0.0001), UENS large fibre
subscale (p=0.0025) scores, as well as improved cold, heat and sharp
sensation scores (p≤0.004 for all) in all arms. In contrast, deterioration
in Norfolk total and small fibre subscale, UENS total and sharp sensation
scores were all found if an increase in average daily pain occurred in
patients in any arm (p≤0.001 for all).
Conclusion: In patients with PDPN treated with either capsaicin 8%
patch plus SOC or SOC alone, a consistent correlation was observed
between assessments with the Norfolk QOL-DN scale, UENS scale and
sensory perception testing. These findings suggest that the Norfolk QOL-
DN scale is sensitive to changes in small-fibre nerve function and is a
relevant safety endpoint in treating neuropathic pain in PDPN.
Clinical Trial Registration Number: NCT01478607
Supported by: Astellas Pharma Europe B. V.
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One-leg standing time correlates with peripheral and cardiac
autonomic nerve function in Japanese patients with type 2 diabetes
K. Sugimoto1, T. Hoshino2, A. Tamura1, R. Yabe1, T. Yamazaki1, S.
Suzuki1;
1Diabetes Center, 2Department of Physical Training and Science, Ohta
Nishinouchi Hospital, Koriyama, Japan.
Background and aims: Patients with diabetes show impaired physical
functional capacity and peripheral nerve function. Some evidence sug-
gests that exercise may prevent and improve peripheral nerve dysfunction
in diabetic patients. However, information is lacking regarding the
relationship between poor physical fitness and peripheral nerve dysfunc-
tion, along with possible risk factors for diabetic neuropathy, in Japanese
patients with type 2 diabetes.
Materials and methods: The current study analyzed data collected from
299 Japanese patients with type 2 diabetes: 212 males (71%); mean age,
51±14 years; mean duration of diabetes, 8±8 years; hemoglobin (Hb)
A1c, 10.4±2.5%; and normal cardiovascular response to exercise as de-
termined by the double Master two-step test. Patients were excluded if
they had a history of coronary heart disease, cerebrovascular disease,
peripheral artery disease or psychiatric disorder. Peripheral sensory and
motor nerve functions were evaluated by nerve conduction studies on the
sural sensory nerve and tibial motor nerve, respectively. The coefficient of
variation for normal R-R intervals (CVRR) at rest and during deep breath-
ing was also used to assess cardiac autonomic nerve function. Further-
more, we examined body composition, muscle strength (knee extension),
leg muscle quality (knee extension strength per unit leg muscle mass),
functional balance (one-leg standing time with eyes open), agility perfor-
mance (whole-body reaction time) and cardiopulmonary fitness (maximal
oxygen uptake) in these patients. To identify independent correlates of
peripheral nerve dysfunction, stepwise multiple regression analysis was
performed. Covariates were age, sex, duration of diabetes, height, total
body mass, fat mass, skeletal muscle mass, weight loss rate (maximal
body weight minus body weight at entry divided by maximal body
weight), blood pressure, brachial-ankle pulse wave velocity, ankle brachi-
al index, carotid plaque, retinopathy, insulin use and levels of HbA1c,
fasting plasma glucose, serum C-peptide, lipids, albumin and creatinine
as well as urinary excretion of albumin and C-peptide. Highly skewed
data were log-transformed.
Results:Multiple regression analysis showed that one-leg standing time
correlated independently with sural sensory nerve conduction velocity,
sural sensory nerve action potential, tibial motor nerve conduction veloc-
ity, minimal F-wave latency, compound muscle action potential and
CVRR during deep breathing. Whole-body reaction time also correlated
with sensory nerve conduction velocity and sensory nerve action poten-
tial. In addition, knee extension strength as percentage of bodyweight and
in kilograms and leg muscle quality were related to motor nerve conduc-
tion velocity, minimal F-wave latency and CVRR at rest, respectively.
Conclusion: Based on these results, poor physical fitness as indicated by
decreased one-leg standing time, increased whole-body reaction time and
decreased knee extension strength correlated with impaired peripheral
and cardiac autonomic nerve function in Japanese patients with type 2
diabetes. In particular, decreased one-leg standing time was most predic-
tive of peripheral nerve dysfunction and thus offers a novel risk factor for
diabetic neuropathy in these patients.
Supported by: Ely Lilly & Company
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Atrophy of both extensor digitorum brevis muscle may be a useful
sign for diagnosis of diabetic symmetric polyneuropathy in Japanese
diabetic men
H. Sasaki1, K. Ogawa1, H. Tanaka1, S. Kurisu1,2, H. Furuta2, M. Nishi2,
T. Akamizu2, K. Nanjo3;
1Department of Medicine, Wakayama Medical University, Katsuragi
Cho, 2First Department of Medicine, Wakayama Medical University,
3Wakayama Rosai Hospital, Japan.
Background and aims: Though atrophy of small muscles of feet has
been known as a cause of diabetic foot lesions, diagnostic significance of
small muscles atrophy on diabetic symmetric polyneuropathy (DPN) has
not been established. We aimed to evaluate the validity and reliability of
observation of typical small muscle as extensor digitorum brevis muscle
(EDB) EDB atrophy for diagnosis of DPN. Firstly, we examined the
relations between EDB atrophy and neurological findings in the regional
population-based Japanese subjects (Study I). Secondly, we investigated
Diabetologia (2015) 58 (Suppl 1):S1–S607 S501
the relations between EDB atrophy and quantitative neurological findings
in the hospital-based diabetic patients (Study II).
Materials and methods: Study I. 367 non diabetic persons (128 male,
239 female) who received medical screening program of Katsuragi-Town
were subjected. Subjective symptoms (numbness in toes and sole, pain in
feet, paresthesia in feet), vibratory perception at both medial malleolus
(VP; using C-128 tuning fork), bilateral Achilles tendon reflexes (ATR)
and EDB atrophy were evaluated. We judged EDB atrophy as positive
when both EDB could not be identified by inspection and palpation in the
position of toe extension. We also interviewed about Seiza habit (Japa-
nese sit-down style with the buttocks on top of the ankles). Study II. In
193 diabetic patients (109 male, 84 female), neurological examination as
same as Study I were examined. Additional 8 objective nerve function
tests such as: 4 parameters of nerve conduction study, 2 parameters of
coefficient of variation of ECG R-R intervals, fall in systolic blood pres-
sure during head-up tilt and quantitative vibratory perception threshold
were evaluated. The relationships among these findings were analyzed.
Results: Study I. Prevalence (%) of EDB atrophy and Seiza habit in
female (46, 67) were significantly higher than those in male (14, 26),
respectively. Prevalence of EDB atrophy in positive Seiza habit subjects
was significantly higher than that in Seiza habit negative subjects (53 vs
29, p=0.001). Therefore, female and male were separately analyzed. On-
ly in male, EDB atrophy was significantly associated with ATR reduction
and VP impairment. Study II. EDB atrophy was observed in 49% of
women and in 27% of men. Only in male, EDB atrophy was significantly
more prevalent in diabetic compared to non-diabetic subjects (27 vs 14,
p=0.011). In male diabetic patients, all items of 8 quantitative nerve tests
were significantly associated with EDB atrophy. In female, only 4 items
were associated with EDB atrophy. We evaluated the predictive power of
EDB atrophy for diagnosing the probable DSPN of Toronto consensus in
diabetic men. The sensitivity, specificity and positive predictive value of
EB atrophy to determine probable DSPN were 48%, 92% and 83%,
respectively.
Conclusion: EDB atrophy was also seen in non-diabetic subjects, but
EDB atrophy was significantly associated with peripheral neuropathy.
EDB atrophy was more frequent in female than male. The gender differ-
ence seemed to depend the lifestyle such as Seiza habit. In diabetic men,
EDB atrophy clearly reflected the DPN and EDB atrophy indicated the
presence of DPN in approximately 90% of probability.
1039
Initial findings in the relationship between diabetic peripheral
neuropathy and microvascular reactivity in the foot
A. Barwick1, J. Tessier2, X. Janse de Jonge3, V. Chuter1;
1Podiatry, University of Newcastle, Ourimbah, 2Medical Radiation Sci-
ence, University of Newcastle, Callaghan, 3Exercise Science, University
of Newcastle, Ourimbah, Australia.
Background and aims:Microvascular dysfunction is common in people
with diabetes resulting in diabetic nephropathy, retinopathy and neurop-
athy of both the large and small fibre nerves. In the periphery it contrib-
utes to diabetic ulceration via both peripheral neuropathy and changes to
microvascular function. Post-occlusive reactive hyperaemia is a measure
of microvascular reactivity (vasodilation capacity) that has been implicat-
ed in the diabetic foot complications. This study aimed to investigate the
relationship between large and small fibre neuropathy and the post-
occlusive reactive hyperaemia response in the diabetic foot.
Materials and methods: Diabetic participants were recruited from podi-
atry clinics for this cross-sectional study. They underwent testing for large
fibre neuropathy (vibration perception threshold and monofilament de-
tection), small fibre neuropathy (temperature and pain perception) as well
as post occlusive reactive hyperaemia at the hallux (using laser Doppler).
Correlations between presence of large and small fibre neuropathy, post-
occlusive reactive hyperaemia parameters (time to peak and peak as a %
of baseline) and demographics characteristics including sex, HbA1c, age,
height, weight and duration of diabetes were performed. Binary logistic
regressions were performed on factors associated with the presence of
large fibre neuropathy and small fibre neuropathy.
Results: Eighty-eight participants were included in the analysis. Signifi-
cant but weak correlations were observed between presence of large fibre
neuropathy and age (r=0.20; p<0.05), height (r=-0.35.; p<0.05), and
time to peak (r=-0.21; p<0.05). Correlations were observed between
small fibre neuropathy and height (r=0.34; p<0.05), and time to peak
(r=0.24; p<0.05). Binary logistic regression analyses demonstrated pres-
ence of large fibre neuropathy was associated with several demographic
factors including increasing age (OR of 1.08 (95%CI: 1.02-1.15, p<0.05)
and greater height (OR of 1.1 (95%CI: 1.04-1.15, p<0.05) and time to
peak perfusion after occlusion (OR of 1.02 (95%CI: 1-1.04, p<0.05).
Presence of small fibre neuropathy in taller people (OR of 1.09 (95%CI
of 1.03-1.15, p<0.05) and those with an increased time to peak perfusion
after occlusion (OR1.02, 95%CI 1-1.03).
Conclusion: Greater height is associated with increased likelihood of the
presence of both large and small fibre peripheral neuropathy. An in-
creased time to peak following occlusion was also associated with in-
creased likelihood of both types of neuropathy suggesting microvascular
dysfunction measured by post occlusive reactive hyperaemia (specifically
increased time to peak) is associated with higher likelihood of the pres-
ence of peripheral neuropathy.
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Association between biomarkers of subclinical inflammation and
nerve conduction in individuals with newly diagnosed diabetes:
German Diabetes Study
C. Herder1,2, I. Schamarek1,2, B. Nowotny1,2, K. Straßburger3,2, M.
Carstensen-Kirberg1,2, P. Nowotny1,2, A. Strom1,2, S. Püttgen1,2, K.
Müssig1,2, J. Szendroedi1,2, D. Ziegler1,2, M. Roden1,2;
1Institute for Clinical Diabetology, German Diabetes Center, 2German
Center for Diabetes Research (DZD e.V.), 3Institute for Biometrics and
Epidemiology, German Diabetes Center, Düsseldorf, Germany.
Background and aims: Biomarkers of subclinical inflammation are as-
sociated with distal sensorimotor polyneuropathy, but their relationship to
electrophysiological measures has not been assessed. Therefore, the aim
of this study was to investigate associations between inflammation-
related biomarkers and nerve conduction velocity (NCV) in the German
Diabetes Study (GDS).
Materials and methods: Motor and sensory NCV was assessed in 513
patients with newly diagnosed type 1 and type 2 diabetes (161 T1D and
352 T2D; mean age 47±14 years, 64.5% male, BMI 29.5±6.4 kg/m2,
time since diagnosis of diabetes 6±3 months). NCV sum scores were
calculated using z-transformed NCV for motor (N. medianus, N. ulnaris,
N. peronaeus) and sensory (N. medianus, N. ulnaris, N. suralis) conduc-
tion. Associations between biomarkers of subclinical inflammation (C-
reactive protein [CRP], interleukin [IL]-6 and IL-18, total and high-
molecular-weight [HMW] adiponectin) and NCV sum scores were esti-
mated using multiple linear regression models adjusted for time since
diagnosis of diabetes, HbA1c, waist circumference, height, hypertension,
cholesterol, smoking, physical activity, medication and history of myo-
cardial infarction and/or stroke.
Results: In persons with T2D serum IL-6 and CRP were inversely asso-
ciated with motor NCV (p=0.011 and p=0.052, respectively), and both
total and HMW adiponectin were inversely associated with motor and
sensory NCV (p between 0.001 and 0.033). In persons with T1D, total
and HMW adiponectin showed positive associations with motor NCV
(both p=0.02), but not with sensory NCV. Serum IL-18 was neither
associated with motor nor sensory NCV in T1D and T2D.
Conclusion: Our results indicate that IL-6 may play a role in slowed
motor NCV, but not in slowed sensory NCV in individuals with recent-
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onset T2D. The lack of associations for CRP and IL-18, in contrast to IL-
6, points to a differential rather than general association between
inflammation-related biomarkers and NCV. The fact that associations
between adiponectin and NCV appear to depend on diabetes type is in-
triguing and may reflect differences in the pathogenesis of both diabetes
types.
Clinical Trial Registration Number: NCT01055093
Supported by: German Center for Diabetes Research (DZD e.V.)
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The centre of sub-basal corneal nerve fibres can best reflect
alterations in the blood glucose concentrations in diabetes mellitus
J. Leckelt1, A. Kott1, O. Stachs2, S. Baltrusch1;
1Institute of Medical Biochemistry and Molecular Biology, 2Department
of Ophthamology, University of Rostock, Germany.
Background and aims: Small fibre neuropathy belongs to one of the
most common long-term complications of diabetes mellitus (DM). In the
assessment of diabetic neuropathy (DN), visualization and quantification
of small nerve fibre damage is hitherto only possible by skin biopsy, thus,
an invasive diagnostic tool. Another method, in vivo corneal confocal
microscopy (IVCCM) is currently a matter of investigation to be
established as a non-invasive procedure. The aim of this study was to
elucidate the impact of streptozotocin (STZ) induced hyperglycaemia and
subsequent insulin treatment on corneal und intraepidermal nerve fibre
changes in thy1-YFP mice.
Materials andmethods:Neuronal yellow fluorescent protein expressing
B6.Cg-Tg(Thy1-YFP)16Jrs/J mice were injected by multiple low-dose
injection of STZ (diabetic group n=15) or an equal volume of sodium
citrate buffer (control group n=10). After induction of DM at day 20, half
of the diabetic animals were treated with insulin releasing pellets. By
using IVCCM, the subbasal nerve plexus in the centre of the cornea
was examined at day 10, 20, 40 and 80. Corneal nerve fibre length (CNFL
inmm/mm2) was quantified byNeuronJ. At the endpoints, day 20 and 80,
mice were euthanized for tissue extractions. Using fluorescence micros-
copy ex vivo, the nerve fibres from the periphery and the centre of the
cornea were examined as well as skin biopsies taken from the plantar
surface of the hind paw. Intraepidermal nerve fibre density (IENFD in
number/mm) was determined according to the guidelines of the European
Federation of Neurological Societies (EFNS).
Results: STZ-treatedmice showed hyperglycaemia (23.87±0.87 vs. 8.36
±0.44 mmol/l; p<0.0001), a significant increase in HbA1c values (46.89
±1.36 vs. 22.09±1.42 mmol/mol; p<0.0001) and a decrease in body
weight. Insulin treatment resulted in a normalization of blood glucose
concentration (8.24±1.72 vs. 6.26±0.29mmol/l; p<0.29), HbA1c values
(26.78±1.94 vs. 20.00±1.17mmol/mol; p<0.02) and bodyweight. How-
ever, higher levels of advanced glycation end products (AGEs) (24.62±
1.32 vs. 16.07±1.73 ng/ml; p<0.005) were observed at day 80. At day
20, the decrease of in vivo CNFL inversely correlated with
hyperglycaemia. Ex vivo analyses revealed changes in the centre of the
cornea, but not in peripheral parts. At day 80, in insulin treated mice
recovery of central CNFL was observed. IENFD showed no significant
changes to the diabetic group or age-matched controls at any time point.
Conclusion: Our study demonstrated that acute hyperglycaemia triggers
subbasal corneal nerve fibre damage, whereas intraepidermal nerves
remained unaffected.We hypothesize a higher susceptibility of the cornea
to advanced glycation end products. However, after insulin therapy and
blood glucose normalization, corneal nerve fibres start to regenerate. Ad-
ditionally, it could be shown by ex vivo fluorescence analyses that nerve
fibre damage and repair in DM take place from the centre of the cornea
with a tendency to the inferior whorl. Integration of IVCCM in the diag-
nosis of DN in addition to quantitative sensory tests seems to be helpful,
but needs further investigation to be a valuable tool.
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Nocturnal antihypertensive treatment restores 24 hour blood
pressure profile in type 1 diabetic patients with autonomic
neuropathy
H.Ø. Hjortkjær1, T. Jensen1, K.F. Kofoed2, U.M. Mogensen2, L.
Køber2, K. Hilsted1, H. Corinth1, S. Theilade3, J. Hilsted1;
1Endocrinology, 2Cardiology, Rigshospitalet, Copenhagen University
Hospital, 3Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Cardiac autonomic neuropathy (CAN) and ele-
vated nocturnal blood pressure are independent risk factors for cardiovas-
cular disease in patients with diabetes and associations between CAN,
non-dipping of nocturnal blood pressure and coronary artery disease have
been demonstrated. The objective of the present study was to test the
efficacy of bedtime dosing (BD) versus morning dosing (MD) of the
angiotensin converting enzyme (ACE) inhibitor enalapril on 24 h blood
pressure profile in patients with type 1 diabetes.
Materials and methods: In a randomised, double-blind, two-way cross-
over study, 24 normoalbuminuric patients with long-term type 1 diabetes
with CAN were treated for 12 weeks with either MD or BD of 20 mg
enalapril, followed for 12 weeks of switched treatment regimen. During
each treatment period, two 24 hour ambulatory blood pressure measure-
ments were performed. The systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were measured automatically every 20 min during
daytime (between 07 and 23 h) and once every hour during nighttime
(between 23 and 07 h). SBP, DBP and mean arterial pressure (MAP)
during daytime and nighttime and the dipping percentage was calculated
using Spacelabs Healthcare Ambulatory Blood Pressure Report Manage-
ment System version 3.0.0.9. Furthermore two computed tomography
(CT) scans were performed after each treatment period measuring the left
ventricle mass (LVM) and the left ventricle volume (LVV). Themean age
of the patients were 60 +/- 7 (SD) years, 40% were males, BMI was 24.5
+/- 4.0 (SD), HbA1C was 62 +/- 7 (SD) mmol/mol, creatinine was 66 +/-
13 (SD) μmol/L and the diabetes duration was 36 +/- 11 (SD) years. Sixty
percent of the patients were treated with antihypertensive drugs (median 2
drugs) before the study.
Results: Nighttime SBP dipping increased 2.4 (0.03 - 4.9) % (p<0.05)
with BD of enalapril compared with MD. Also, there was seen a trend
towards a MAP dipping increase of 2.2 (-0.1 - 4.5) % (p=0.07) and a
nighttime MAP reduction of 1.7 (-3.6 - 0.2) mmHg (p=0.07) with BD
compared with MD. Daytime SBP and DBP were not significantly dif-
ferent between the two treatment regimens. A small, but insignificant
reduction in pulse pressure was observed. No significant difference was
found on LVM or LVV between the two treatment regiments. No adverse
events were registered during nighttime treatment of blood pressure and
no drop outs occurred during the study.
Conclusion:This study demonstrates for the first time that high risk long-
term type 1 diabetic patients with autonomic neuropathy favourably and
without risk can be treated with an ACE inhibitor during night. The
potentially beneficial effect on long-term cardiovascular risk remains to
be determined.
Clinical Trial Registration Number: 2012- 002136-90
Supported by: Arvid Nilssons Foundation
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Diabetic nephropathy lesions associate with cardiovascular
autonomic neuropathy in Pima Indians with type 2 diabetes
K.M. Wheelock1, M. Jaiswal2, C.L. Martin2, G.D. Fufaa1, J.E. Weil1, E.
Feldman3, F.C. Brosius2, W.C. Knowler1, R.G. Nelson1, R. Pop-Busui2;
1Phoenix Epidemiology and Clinical Research Branch, 2Department of
Internal Medicine, 3Department of Neurology, University of Michigan
Medical School, Ann Arbor, USA.
Background and aims: Cardiovascular autonomic neuropathy (CAN)
and diabetic kidney disease (DKD) are thought to be linked. The associ-
ation of CAN with renal structure is unknown. To identify the renal
lesions that associate with CAN in Pima Indians with type 2 diabetes
(T2D).
Materials and methods: Sixty-three Pima Indians (27% men) with T2D
underwent kidney biopsy at baseline. Masked unbiased random sampling
morphometric methods were used to measure renal structural parameters
of DKD. Glomerular filtration rate (GFR; iothalamate), urinary albumin/
creatinine ratio (ACR), and other clinical variables were measured at an
examination within a median of 46 days of the biopsy. CANwas assessed
after a mean follow-up of 9 years by standard cardiovascular reflex testing
(deep-breathing test) and heart rate variability studies. Measures of CAN
analyzed, included the expiration/inspiration ratio (E/I) and the standard
deviation of the normal R-R intervals (sdNN). Associations of CAN with
structural variables were assessed by Spearman’s correlations and by
multiple linear regression after adjusting for age, sex, diabetes duration,
HbA1c, ACR and GFR. E/I and sdNN were log-transformed for linear
regression modeling due to skewed distributions.
Results: Mean age at kidney biopsy was 46±9 years, diabetes duration
16±6 years, mean HbA1c 9.1±1.9%, mean GFR 156±57 ml/min, and
median ACR 25 mg/g (IQR=9-68 mg/g). At follow-up, 95% of partici-
pants had CAN (E/I<1.17, median=1.04, IQR=1.03-1.08). E/I correlat-
ed positively with percentage of fenestrated endothelium (FE; r=0.26, p=
0.040) and negatively with mesangial fractional volume (VvMes; r=-
0.39, p=0.002) and glomerular basement membrane (GBM) width (r=-
0.40, p=0.001). sdNN (median=18 ms, IQR=11-27 ms) correlated pos-
itively with glomerular filtration surface density (Sv; r=0.35, p=0.005)
and negatively with VvMes (r=-0.34, p=0.007) and GBM width (r=-
0.42, p=0.001). Neither E/I nor sdNN correlated with ACR or GFR. In
linear regression analyses adjusted for age, sex, diabetes duration,
HbA1c, ACR, and GFR, E/I was positively associated with FE (r=0.33,
p=0.011) and negatively associated with VvMes (r=-0.32, p=0.018) and
GBMwidth (r=-0.28, p=0.034). sdNNwas positively associated with FE
(r=0.31, p=0.019) and Sv (r=0.41, p=0.001) and negatively associated
with VvMes (r=-0.28, p=0.035) and GBM width (r=-0.42, p=0.001).
Adjusted associations between sdNN and morphometric variables are
shown in Figure
Conclusion: Pima Indians with T2D and DKD have a high prevalence of
CAN, which is more severe in those with more severe renal structural
damage.
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Hypoxia as a reversible cause of cardiovascular autonomic
dysfunction in patients type 2 diabetes and impaired renal function
L. Bernardi1, P. Esposito2, L. Bianchi1, R. Mereu1, G. DeBarbieri1, A.
Dal Canton2, P.-H. Groop3;
1Department of Internal Medicine, 2Department of Nephrology, Pavia
University, Italy, 3Nephrology and Folkhälsan Research Center, Univer-
sity of Helsinki, Finland.
Background and aims: Cardiovascular autonomic dysfunction, charac-
terized by an imbalance between sympathetic and parasympathetic activ-
ities, is common in patients with diabetes mellitus. Although this is con-
ventionally considered to be an organic, irreversible disorder, it has al-
ready been demonstrated in patients with type 1 diabetes that baroreflex
sensitivity (BRS) could be corrected by deep breathing, thus suggesting a
functional component to the disorder. In this study we tested this hypoth-
esis in the type 2 diabetic patients with or without renal impairment.
Materials and methods: Twenty-six patients affected by type 2 diabetes
were enrolled (age 61.1±0.8 years, Mean±SEM; diabetic duration 10.5±
2 years, BMI 29.9±0.7 kg/m2, GFR, [CKD-EPI formula]: 68.1±5.5 ml/
min (range 18-105 ml/min). Six patients presented microalbuminuria and
five macroalbuminuria. Twenty-four healthy subjects (age 58.5±
1.0 years) were enrolled as controls. BRS was obtained from recordings
of RR interval and systolic blood pressure fluctuations during spontane-
ous and slow, deep (6 breaths/min) controlled breathing. Then, the entire
protocol was repeated in hyperoxia (breathing 5 L/min oxygen).
Results: During normal breathing diabetic patients presented higher HR
and lower BRS compared with the control participants (5.5±0.6 vs 11.8±
2.0 ms/mmHg, p<0.005). Deep breathing and oxygen administration
significantly increased arterial saturation, reduced HR and increased
BRS in both the diabetic patients and the control group and (to 9.6±1.9
and 15.3±2.3 ms/mmHg, respectively, P<0.05, hyperoxia vs normoxia).
Twelve diabetic patients presented chronic kidney disease (CKD), de-
fined by the presence of proteinuria and reduced GFR. CKD patients
compared with non-CKD subjects showed a longer duration of diabetes
and a poorer glycaemic control, with a significant inverse correlation
between diabetes duration and GFR values (r2=0.20, p=0.02). However,
also this group of patients presented a significant improvement of BRS
during slow breathing and hyperoxia (p<0.05 vs spontaneous breathing
in normoxia).
Conclusion:Our results show that autonomic dysfunction present in type
2 diabetic patients is further aggravated in CKD. However, this condition
can be partially reversed by increasing oxygen supply, suggesting a pos-
sible role of hypoxia in the origin of diabetic complications. This finding
supports the hypothesis that interventions known to relieve tissue hypox-
ia, like physical activity, may be useful in the prevention andmanagement
of complications in diabetic patients. The severity of autonomic dysfunc-
tion and response to oxygen seen in CKD call attention on hypoxia as a
reversible pathogenic factor of the renal damage in diabetic patients.
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Erectile dysfunction among Bangladeshi diabetic men
S. Selim1, M.A.J. Chowdhury2, M.N. Karim3;
1Endocrinology, 2Internal Medicine, Bangabandhu Sheikh Mujib Medi-
cal University, Dhaka, Bangladesh, 3Department of Epidemiology and
Preventive Medicine Faculty of Medicine Nursing and Health Science,
Monash University, Melbourne, Australia.
Background and aims: Erectile dysfunction (ED) is an important im-
pediment to quality of life of men. ED is approximately, three times more
common in diabetic than non-diabetic men, and diabetic men develop ED
earlier than age matched non-diabetic subjects. Glycemic control and
other factors may contribute in developing and or deteriorating ED. The
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aim of the study was to determine the prevalence of ED and its risk factors
in type 2 diabetic (T2DM) men in Bangladesh.
Materials andmethods:During 2013-2014, 3980 diabetic men aged 30-
69 years were interviewed at the out-patient departments of seven diabetic
centers in Dhaka by using the validated Bengali version of the question-
naire of the international index of erectile function (IIEF) for evaluation of
baseline erectile function (EF). The indexes indicate a very high correla-
tion between the items and the questionnaire is consistently reliable. Data
were analyzed with Chi-squared (χ2) test using SPSS software. P≤0.05
was considered significant.
Results: Out of 3790, ED was found in 2046 (53.98%) of T2DM men.
The prevalence of ED was increased with age from 10.5% in men aged
30-39 years to 33.6% in those aged over 60 years (P<0.001). In compar-
ison with patients with reported diabetes lasting≤5 years (26.4%), the
prevalence of ED was less than in those with diabetes of 6-11 years
(35.3%) and of 12-30 years (42.5%, P <0.001). ED increased significant-
ly in those who had poor glycemic control. The prevalence of ED in
patients with good, fair and poor glycemic control was 22.8%, 42.5%
and 47.9% respectively (P=0.004). Treatment modalities (medical nutri-
tion therapy, oral agents, insulin and insulin plus oral agents) had signif-
icant association with ED and its severity (P<0.001).
Conclusion: Prevalence of ED is very high among T2DM men in Ban-
gladesh and can be reduced the burden by improving glycemic status.
Glycemic control, duration of diabetes, treatment modalities, increasing
age are associated with ED.
1046
Low gastrointestinal symptom burden in a Swedish population based
cohort with insulin dependent diabetes mellitus
J.E.A. Brun, H. Törnblom, G. Ringström, E. Olausson, M. Simrén;
Gastroenterology&Hepatology, Internal Medicine, Gothenburg, Sweden.
Background and aims: Long-standing diabetes mellitus (DM) is
afflicted with a wide variety of complications that may cause symptoms
frommultiple organ systems including the gastrointestinal (GI) tract. Data
from other centers have claimed that autonomic neuropathy affects up to
30-40% of patients with long-standing disease and as many as 75% of
patients attending DM clinics report significant GI symptoms The aim of
our study was to understand the extent to which a defined cohort of
Swedish patients with DM suffers from GI symptoms.
Materials and methods: Patients with insulin dependent DM type 1
(IDDM1) and type 2 (IDDM2) who attended the diabetic outpatient
clinics at two county hospitals were included in the study. They were sent
the Patient Assessment of upper GastroIntestinal Symptom Severity In-
dex (PAGI-SYM) questionnaire for assessment of GI symptom severity
which consists of 20 questions answered by use of a six-point Likert
response scale, ranging from 0 (none) to 5 (very severe). The
Gastroparesis Cardinal Symptom Index (GCSI) can be calculated by
use of the first nine questions of PAGI-SYM resulting in scores for total
symptomburden, nausea/vomiting, postprandial fullness/early satiety and
bloating. Hospital anxiety and depression (HAD) scale was used for
psychological assessment and the short form (SF) 36 questionnaire sum-
mary measures for physical and mental health. For those who answered
the questionnaires (one reminder to non-responders), clinical information
was retrieved from medical records regarding complications related to
long-standing DM such as manifestations from large vessel atherosclero-
sis (ischemic heart disease and stroke), peripheral neuropathy, retinopathy
and nephropathy.
Results:We included 754 patients (mean age 48 years (range18-82 years).
The questionnaire was answered by 436 patients (response rate 57.8%),
and 363 (83.3%) of these had IDDM1 and 73 (16.7%) had IDDM2. The
duration of insulin treatment was 21±13 years. The mean GCSI total
score in the cohort was 0.7±0.8. Females with IDDM had significantly
higher GCSI total score (0.853 vs. .622; p=0.003), GCSI nausea/
vomiting score (0.42 vs. 0.28; p=0.019) and GCSI bloating score (1.2
vs. 0.81; p=0.001) compared to males. There was a strong correlation(p=
0.001) between SF-36,HAD and the GCSI total, nausea/vomiting and
bloating scores. There was no significant difference between sexes for
GCSI postprandial fullness/early satiety score. There was no significant
difference in GCSI scores comparing patients with IDDM1 and IDDM2,
also not within sexes. Patients with one or more complications related to
long-standing DM reported GI symptoms to the same extent as those with
no complications and more complications was not associated with higher
GCSI scores.
Conclusion: Females with IDDM reported more GI symptoms compared
with males. Although the total GI symptom burden in our study
corresponded to “very mild” there was a highly significant correlation
between the GCSI subscores; total, nausea/vomiting, bloating and mental
and physical health and anxiety and depression. Furthermore it appears
that the number complications to long standing DM do not per se imply
an increase in reported GI symptoms.
1047
Cardiovascular autonomic neuropathy predicts development of
diabetic foot ulcer in patients with type 2 diabetes mellitus
S.-A. Cha1, T.-S. Lim1, J.-S. Yun1, S.-D. Moon2, H. Seok3, Y.-B. Ahn1,
S.-H. Ko1;
1Internal Medicine, The Catholic University of Korea, St. Vincent’s hos-
pital, Suwon, 2Internal Medicine, The Catholic University of Korea, In-
cheon St. Mary's Hospital, 3InternalMedicine, The Catholic University of
Korea, Uijeongbu St. Mary's Hospital, Republic of Korea.
Background and aims:We investigated potential risk factors that might
influence the development of diabetic foot ulcers in patients with type 2
diabetes.
Materials and methods: From January 2003 to December 2004, a total
of 1,534 patients with type 2 diabetes were consecutively enrolled. Sig-
nificant diabetic foot ulcer was defined as a full-thickness break in the
epithelium with a minimum width of 5 mm. Patients were checked every
3-6 months for status of diabetic foot ulcer, or amputation during the
follow-up periods. A cardiovascular autonomic function test (AFT) was
performed to diagnose cardiovascular autonomic neuropathy (CAN)
using heart rate variability parameters. We used a Cox proportional haz-
ard regression analysis to test associations between diabetic foot ulcer and
potential explanatory variables.
Results: The median follow-up time was 9.7 years. The mean age was
55.6±10.8 years, and the duration of diabetes was 8.3±7.0 years. During
the follow-up periods, 135 patients (8.8%) developed new ulcer, and 26
patients (1.7%) underwent an amputation. The patients in the diabetic foot
ulcer group had a longer duration of diabetes (p<0.001), higher baseline
HbA1c levels (p<0.001), higher rates of smoking (p=0.001), albuminuria
(p<0.001), retinopathy (p<0.001), and received more insulin treatment
(p<0.001). A Cox hazard regression analysis revealed that the develop-
ment of diabetic foot ulcer was significantly associated with the presence
of cardiovascular autonomic dysfunction (normal vs early CAN, HR
2.06, 95% CI 0.95-4.45; p=0.066; normal vs definite CAN, HR 2.50,
95% CI 1.18-5.26; p=0.010) after adjusting for sex, age, diabetic dura-
tion, mean HbA1c, albuminuria, retinopathy, and treatment of insulin.
Conclusion: The development of diabetic foot ulcers was independently
associated with cardiovascular autonomic dysfunction in patients with
type 2 diabetes.
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Short-term beat-to-beat QT-interval variability in patients with
impaired glucose tolerance
C. Lengyel1, A. Orosz2, S. Nyiraty1, N. Németh3, Z. Putz3, R. Takács1,
A. Nemes4, T.T. Várkonyi1, I. Baczkó2, G. Ábrahám1, P. Kempler3, J.G.
Papp2,5, A. Varró2,5;
11st Department of Medicine, 2Department of Pharmacology and Phar-
macotherapy, University of Szeged, 32nd Department of Medicine,
Semmelweis University, Budapest, 42nd Department of Medicine and
Cardiology Centre, University of Szeged, 5MTA-SZTE Research Group
of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Sze-
ged, Hungary.
Background and aims: Determination of short-term QT-interval vari-
ability (QTV) is a non-invasive method for assessment of proarrhythmic
risk. The aim of the present study was to evaluate the QTV in patients
with impaired glucose tolerance (IGT).
Materials and methods: 18 IGT patients (age: 63.0±2.7 years, BMI:
31.4±1.5 kg/m2, fasting glucose: 6.0±0.1 mmol/l, 120 min postload
glucose: 9.0±0.2 mmol/l, HbA1c: 5.9±0.1%; mean±SEM) and 18
healthy controls (age: 56.1±2.2 years, BMI: 27.3±1.3 kg/m2, fasting
glucose: 5.2±0.1 mmol/l, 120 min postload glucose: 5.5±0.3 mmol/l,
HbA1c: 5.4±0.1%) were enrolled into the study. ECGs were recorded,
processed, stored and analyzed off-line using a computer based analyzing
system. The RR and QT intervals were expressed as the average of 31
consecutive beats. The ventricular repolarization was characterized by
uncorrected QT-interval and QT intervals corrected by Bazett (QTc-b),
Fridericia (QTc-f) and Hodges (QTc-h) formula. The spatial repolariza-
tion inhomogenity was specified byQT dispersion (QTd). To evaluate the
short-term temporal instability of beat-to-beat repolarization, Poincare’
plots of the QT intervals were constructed, where each QT value is plotted
against its former value. QTV was calculated using the following formu-
la: QTV=∑|QTn+1-QTn| (30×√2)-1. Autonomic function was assessed
by means of five standard cardiovascular reflex tests using the same
analyzing system.
Results: Comparison of the two groups (IGT vs control) revealed no
difference in the uncorrected QT (410±10.2 ms vs 409±11.5 ms), QTc-
b (431±5.8 ms vs 427±6.8 ms), QTc-f (424±6.3 ms vs 421±7.8 ms), or
QTc-h (424±6.9 ms vs 420±8.2 ms) intervals. There was no difference in
the QTd between IGT and control individuals (43.8±3.0 ms vs 43.1±
5.6 ms). The QTV, however, was increased in the IGT patients relative to
those for the control group (4.95±0.16 ms vs 3.82±0.23, p=0.0004).
Conclusion: The short-term QT variability may be elevated in patients
with impaired glucose tolerance. This enhanced temporal QT variability
may early indicate the increased instability of cardiac repolarization.
Supported by: TÁMOP-4.1.2.E-13/1/KONV-2013-0011, GOP-1.1.1-11-
2011-0081
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Changes in vago-sympathetic activity and its influence on heart rate
and insulin response to oral glucose load
S. Bathaei, C. Cussac-Pillegand, S. Chiheb, R. Dutheil, M. Fysekidis, E.
Cosson, P. Valensi;
Department of Endocrinology Diabetology Nutrition, Jean Verdier hos-
pital,AP-HP, CRNH-IdF, CINFO, Bondy, France.
Background and aims:We showed that cardiac parasympathetic activity
is often altered in non diabetic obese patients and similarly in metaboli-
cally healthy obese patients. The aim of this study was in obese patients
with a metabolically healthy phenotype to examine the influence of the
changes in vago-sympathetic activity on heart rate and insulin response to
oral glucose load (OGTT).
Materials and methods: We recruited 24 patients, aged 34±13 years,
BMI 42.2+/-6.9 kg/m2, with only one criterion of themetabolic syndrome
(hyperglycemia in only one patient) in addition to large waist circumfer-
ence. An oral glucose tolerance test (OGTT, 75 g) was performed. Com-
posite indexes of insulin secretion (insulinogenic index=IGI=
Δinsulinemia(T0-T30)/Δglycemia(T0-T30), and oral disposition index=
ODI=IGI/insulinemia) were calculated. Cardiac parasympathetic activity
(HF-HR), sympatho-vagal balance (LF/HF-HR), and vascular sympathet-
ic activity (LF-SBP) were evaluated by spectral analysis of heart rate and
systolic blood pressure (SBP) variations (Finapress®), and plasma epi-
nephrine and norepinephrine levels were measured at fasting and during
the OGTT.
Results: Patients were separated in two groups according to cardiac para-
sympathetic activity at fasting: high or low (HF-HR>or<median value:
2.78). During OGTT the patients with high parasympathetic activity at
fasting maintained a higher HF-HR (p<0.001) despite a transient de-
crease after insulin peak. These patients had lower LF/HF-HR at fasting
which remained lower during OGTT (p=0.019). Epinephrine and norepi-
nephrine response did not differ significantly between the two groups. A
significant acceleration of heart rate occurred during OGTT in the two
groups (p=0.002) but heart rate was lower both at fasting and during
OGTT in the patients with high parasympathetic activity (p=0.03). High
parasympathetic activity was associated with higher ODI (p=0.035).
Conclusion: Among obese patients with metabolically healthy pheno-
type those with a higher parasympathetic activity keep a higher parasym-
pathetic activity after glucose intake. This profile accounts for a lower
heart rate at fasting and after glucose load and seems to contribute to a
greater insulin secretion.
1050
Why not to use the handgrip test in the assessment of cardiovascular
autonomic neuropathy?
A.E. Körei1, Z. Putz1, I. Istenes1, M. Kempler1, O. Vági1, R. Nagy1, K.
Keresztes1, V. Spallone2, P. Kempler1;
11st Department of Medicine, Semmelweis University, Budapest, Hunga-
ry, 2Department of Systems Medicine, University of Rome Tor Vergata,
Italy.
Background and aims: The cardiovascular autonomic reflex tests
(CARTs) have been considered as gold standard in the assessment of
cardiovascular autonomic neuropathy (CAN). However, only four of
the five tests have been currently suggested to be performed - sympathetic
function should be evaluated by the orthostatic hypotension (OHT) test
while measuring diastolic blood pressure (BP) response to sustained
handgrip is omitted in recent guidelines. Aim of our study was to assess
the relationship of handgrip test with the other tests in detecting CAN as
well as to identify the factors having impact on the handgrip test results in
diabetic patients.
Materials and methods: Our study involved 353 patients with diabetes
(age: 60,2±7,4 years; female: 57,2%; BMI: 29,3±2,1 kg/m2; diabetes
duration: 15,6±9,9 years; HbA1c: 8,2±1,9%; with type 1 diabetes: 18,
1%). CANwas assessed by five CARTs: the deep breathing test, Valsalva
ratio, 30/15 ratio, handgrip and OHT test. CARTs based on heart rate
changes mainly reflect parasympathetic while those based on BP re-
sponse tomanoeuvres explore sympathetic function. Connection between
results of the handgrip and the other CARTs as well as clinical parameters
of the study population were analysed using Kendall monotony coeffi-
cient (γ) and Spearman’s correlation (ρ). Dichotomous variables were
analysed using χ2-test.
Results: Definite diagnosis of CAN according to recent guidelines as
well as abnormal results of the deep breathing, Valsalva ratio, 30/15 ratio,
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handgrip test and OHT test were present in 49,3%, 86,1%, 35,1%, 4,5%,
22%, and 32,3%, respectively. Results of the handgrip test did not show
any association with results of the deep breathing test (p=0,897) and 30/
15 ratio (p=0,357), as they did not do with the results of the partially
sympathetically controlled Valsalva ratio, either (p=0,781). An associa-
tion between handgrip and OHT failed to be proven (p=0,833). Sensitiv-
ity, specificity, positive and negative predictive value of the handgrip test
versus definite diagnosis of CAN were 22,9%, 78,8%, 51% and 51,3%,
respectively. The results of handgrip test did actually show a significant
negative association with the presence of hypertension (γ=-0,315, p=0,
009), whereas the diastolic BP elevation during the manoeuvre was in-
versely related to the baseline diastolic BP (ρ=-0,283, p=0,013). In mul-
tiple logistic regression analysis, the significant inverse association be-
tween abnormality of the handgrip test and hypertension was independent
of age, gender, BMI, diabetes duration, type of antihypertensive medica-
tion, insulin treatment as well as presence of sensory loss and neuropathic
pain medication. OHT was associated with the severity of the parasym-
pathetic impairment (γ=0,303, p<0,0001) and with Valsalva ratio abnor-
mality (γ=0,342, p<0,0001). Presence of hypertension had no effect on
the results of OHT test (p=0,97).
Conclusion:Our data may provide evidence that the handgrip test should
no longer be part of the cardiovascular autonomic testing being highly
dependent of the hypertensive status and baseline blood pressure. The
putative mechanism for the inverse association between abnormal results
of the handgrip test and hypertension could be an exaggerated exercise
pressor reflex related to increased sympathetic cardiovascular activation
in patients with diabetes and hypertension.
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Integrated cardiovascular/respiratory control in type 1 diabetes
L. Bianchi1, C. Porta1, A. Rinaldi1, C. Gazzaruso2, P. Fratino3, P.
DeCata2, P. Protti1, R. Paltro1, L. Bernardi1,4;
1Department of Internal Medicine, University of Pavia, 2Department of
Internal Medicine and Endocrinology, IRCCS Fondazione S.Maugeri,
Pavia, 3ASL Pavia, Italy, 4Folkhälsan Institute of Genetics, Folkhälsan
Research Center, University of Helsinki, Finland.
Background and aims: Diabetic autonomic dysfunction and ventilatory
control abnormalities both increase cardiovascular risk. Cardiovascular
(baroreflex) and respiratory (chemoreflex) control mechanisms were
studied separately in diabetes, but their reciprocal interaction had never
been assessed. We hypothesized that prevalent autonomic neuropathy
would depress both chemoreflexes and the arterial baroreflex mecha-
nisms, whereas prevalent autonomic imbalance through sympathic acti-
vation would depress the baroreflex but enhance chemoreflex
mechanisms.
Materials and methods: In 46 type-1 diabetic subjects (33±1 yr, 22
female) and in 103 age-matched controls we measured RR interval, con-
tinuous noninvasive blood pressure (Colin®), minute ventilation, oxygen
saturation (SaO2) and end-tidal carbon dioxide (CO2) at rest and during
progressive normoxic hypercapnia (from baseline to 55 mmHg) and pro-
gressive isocapnic hypoxia (from baseline down to 80% SaO2). Barore-
flex sensitivity was estimated by a battery of 6 standardized methods
(based on spectral analysis and spontaneous sequences of RR interval
and Systolic Blood pressure variabilities), hypercapnic and hypoxic
chemoreflex sensitivities were obtained by the slopes of the linear regres-
sions linking minute ventilation to CO2 increase and to SaO2 decrease,
respectively. Autonomic neuropathy was evaluated by a standard battery
of cardiovascular reflex tests (deep breathing, lying-to-standing, hand-
grip, Valsalva manoeuvre, blood pressure changes to tilting).
Results:Mild signs of autonomic neuropathy were present in 26/46 dia-
betics (average score 1.42±0.14, group N+), and absent in 20/46 patients
(group N-). Baroreflex sensitivity was reduced in the entire diabetic group
(9.8±0.9 vs controls: 13.4±0.8 ms/mmHg, p<0.01), and particularly in
group N+ (8.5±0.9 ms/mmHg, p<0.01), whereas although reduced, it
was not significantly different in N- diabetics (11.7±1.6 ms/mmHg,
p:ns). The hypercapnic chemoreflex was significantly increased in the
entire diabetic group (1.86±0.19 vs 1.41±0.13 L/min/mmHgCO2 in con-
trols, p<0.05), and particularly in N+ diabetics (2.18±0.28 L/min/
mmHgCO2, p<0.05). Conversely, the hypoxic chemoreflex was slightly
depressed in the entire diabetic group (0.73±0.9 vs controls: 0.91±
0.07 L/min/%SaO2, p:ns), and equally reduced in N+ and N- groups.
Conclusion: Thus, a reduced sensitivity to hypoxia seems a primary
factor leading to reflex sympathetic activation (enhanced hypercapnic
chemoreflex and depression of baroreflex), hence suggesting a functional
origin of autonomic abnormalities in initial diabetes.
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Parasympathetic autonomic dysfunction rather than central afferent
impairment is the early sign of neuropathy in recently diagnosed type
2 diabetes
T.T. Várkonyi1, S. Nyiraty1, K. Fehértemplomi1, R. Takács1, A. Orosz2,
F. Tóth3, L. Rovó3, C. Lengyel1, J. Kiss3, P. Kempler4, G. Ábrahám1;
11st Department of Medicine, 2Department of Pharmacology and Phar-
macotherapy, 3Department of Oto-Rhino-Laringology, University of Sze-
ged, 41st Department of Medicine, Semmelweis University, Budapest,
Hungary.
Background and aims: It is well known that hyperglycemia has a long-
term harmful effect on nerve fibres, but the shortest period of diabetic
exposure leading to the appearance of different neuronal dyfunctions is
poorly documented. The aim of this study was to characterize the pres-
ence and severity of autonomic and central nerve function in patients with
recently diagnosed type 1 or type 2 diabetes (DM).
Materials and methods: 40 patients with type 1 or type 2 DM were
involved (type 1: n=21, age: 28.8±2 years, duration of DM: 2.1±
0.5 months; type 2 DM: n=19, age: 48.4±3.9 years, duration of DM:
3.3±0.8 months; mean±SE). Age and sex matched subjects served as
controls. Cardiovascular reflex tests (CRT) were applied for the assess-
ment of autonomic neuropathy (AN). The afferent central pathways were
measured by analysis of the latencies of the four waves (I-IV/V) of
brainstem auditory-evoked potentials (BAEP).
Results: The results of the CRT-s and the latencies of BAEP did not differ
from controls among recently diagnosed type 1 DM patients. The overall
AN score was higher in recently discovered type 2 DM than in controls
(AN score: 2.16±0.5 vs 0.33±0.1, p<0.01; diabetic vs control). The heart
rate response to breathing was lower in type 2 DM patients than in con-
trols (17±2.1 vs 23.1±2.3 min., p<0.05) and a negative correlation was
found between Valsalva ratio and the wave V. latency of BAEP (r=-0.61,
p<0.01). There was a non-significant tendency of longer latencies of all
BAEP waves in type 2 DM patients than in controls.
Conclusion: The autonomic and central neuronal function seems to be
intact among type 1 diabetic patients with short duration. Early to mod-
erate impairment of parasympathetic cardiovascular autonomic function
was found in patients with recently diagnosed type 2 diabetes. The more
abnormal values of a parasympathetic test correlated with the latency of a
wave of the auditory-evoked potentials. Our data support that autonomic
parasympathetic dysfunction rather than central afferent impairment
should be considered as the early sign of neuropathy in recently diag-
nosed type 2 diabetes.
Diabetologia (2015) 58 (Suppl 1):S1–S607 S507
1053
Main determinants of autonomic dysfunction in subjects with
normoglycaemia and newly-diagnosed type 2 diabetes
R. Dimova, T. Tankova, N. Chakarova, L. Dakovska, G. Grozeva;
Department of Diabetology, Clinical Centre of Endocrinology, Medical
University, Sofia, Bulgaria.
Background and aims:Cardiovascular autonomic dysfunction (CAD) is
a serious and common complication of diabetes associated with increased
cardiovascular morbidity and mortality. As it occurs even at the early
stages of glucose intolerance and insulin resistance the present study aims
to outline main predictors of CAD in subjects with normal glucose toler-
ance (NGT) and newly-diagnosed type 2 diabetes (NDT2D) with or
without metabolic syndrome (MetS).
Materials and methods: A total of 200 subjects - 108 females and 92
males (mean age 49.8±10.3 years, mean BMI 31.1±5.8 kg/m2), divided
into two age- and BMI-matched groups according to their glucose toler-
ance: 100 with NGTand 100 with NDT2D, and subdivided into 4 groups
according to the presence of MetS; and into two groups according to the
presence of CAD - 42 with CAD and 158 controls, were enrolled. Glu-
cose tolerance was studied during OGTT. Anthropometric indices, blood
pressure (BP), HbA1c, serum lipids and hsCRP were measured. ECG for
calculating QTc interval was performed. AGEs were evaluated by skin
autofluоrescence (AGE-Reader). Body composition was estimated by
impedance analysis (InBody 720). Cardiovascular autonomic function
(CAF) was assessed by ANX-3.0 using frequency-domain analysis at rest
and during deep breathing, Valsalva and standing from a seated position.
Statistical analysis was performed using SPSS v.20.0.
Results: A higher prevalence of CAD in NDT2D as compared to NGT -
27/100 (64.3%) vs 15/100 (35.7%), OR 1.4 (95%CI: 1.05 to 1.84), p=
0.037 was observed. Despite the trend toward lower autonomic power in
the subgroups with MetS, the difference was not statistically significant.
CAF showed a significant negative correlation with age, visceral fat area,
total body fat, systolic BP, AGEs, and QTc interval in both groups with
NDT2D andNGT. Although significantly elevated levels of triglycerides,
total cholesterol, BP, HbA1c, fasting glucose, AGEs, QTc interval and
age were found in the group with CAD in comparison to controls, after
performing logistic regression analysis, χ2(4)=26.385, p<0.0001 with
R2 of 0.021, correctly classifying 81.0% of cases, only increasing age -
OR 1.06 (95%CI: 1.02 to 1.1), p=0.005 and the presence of hypertension
- OR 2.8 (95%CI: 1.2 to 6.7), p=0.019 were associated with an increased
likelihood of CAD - AUC 0.762 (95%CI: 0.682 to 0.842), p<0.0001.
Conclusion: Our results demonstrate increased frequency of CAD in
NDT2D independently of the presence of metabolic syndrome. Hyper-
tension and age seem to be the main predictors of CAD in the early stages
of impaired glucose metabolism.
Supported by: Grant№19-D/2012
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Vitamin B12 deficiency is associated with cardiovascular autonomic
neuropathy in patients with type 2 diabetes
C.S. Hansen1, M. Ridderstråle2, J. Fleischer3, D. Vistisen1, M.E.
Jørgensen1;
1dept. of epidemiology 469, Steno Diabetes Center, Gentofte, Denmark,
2Outpatient clinic, Steno Diabetes Center, Gentofte, 3Medical Research
Laboratories, Clinical Institute of Medicine, Aarhus University, Den-
mark.
Background and aims: Cardiovascular autonomic neuropathy (CAN) is
a severe diabetic complication associated with increased cardiovascular
mortality. The risk of CAN in diabetes 2 patients could be additionally
increased by vitamin B12 deficiency which is known to be a risk factor
for peripheral neuropathy and has also been associated with markers of
CAN in non-diabetic patients. Type 2 diabetes patients are prone to B12
deficiency by the use of metformin and possibly proton pump inhibitors
(PPIs). We aim to be the first to investigate the possible cross-sectional
association between serum levels of Vitamin B12 and CAN in patients
with type 2 diabetes.
Materials and methods: 512 type 2 diabetes patients (mean diabetes
duration 10.0 years, mean age 58.7 year, 34.9% men, 14.5% with
CAN) had serum vitamin B12 measured and were screened for CAN
using 3 standard cardiovascular reflex tests (CARTS): deep breathing test
(E:I-ratio), lying-to-standing test (30/15) and the Valsalva maneuver.
5 minute resting heart rate (5 min RHR) was also measured. CAN was
diagnosed if at least 2 of 3 CARTSwere abnormal. Associations between
vitamin B12 and outcomes were assessed by using logistic and linear
regression models adjusting for age and sex.
Results:We found associations between levels of serum vitamin B12 and
the E:I-ratio, an early marker of CAN. A 25 pmol/l increase of vitamin
B12 was associated with an increase in E:I-ratio of 0.22% (P=0.038,
95%Cl 0.01-0.43) . No significant associations between 5 min RHR,
the 30/15 test, the Valsalva maneuver or the CAN diagnosis were found
possibly be due to lack of statistical power.
Conclusion: Serum vitamin B12 is associated with early CAN in patients
with type 2 diabetes prompting the need for annual vitamin B12 screening
in high risk patients e.g. those treated with metformin and/or PPIs.
Supported by: The Danish Ministry of Higher Education and Science.
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Patients and health care provider related delay in the treatment of
diabetic foot ulcers
A. Rasmussen, K. Engelhard, A. Pedersen, N. Bonnichsen, M.
Ridderstråle;
Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Diabetic foot ulcer is a life threatening compli-
cation and very costly both for the health care system and the patient.
Prompt treatment is necessary to reduce the risk of deep infections and
amputations. Time from ulcer to treatment is an important determinant of
treatment outcome. The aim was to study factors that influence healing
time in patients with diabetic foot ulcers seen in a multidisciplinary out-
patient clinic.
Materials and methods: Newly referred patients between Sep. 9th 2013
and March 9th 2014 were identified and primarily analysed for time
between ulcer to contact, and contact to appointment in relation to various
baseline and outcome variables. Data are shown as mean±standard devi-
ation (SD). Non-parametric statistical analyses were used, and a p-value
below 0.05 was considered statistically significant.
Results: 118 patients presenting 193 ulcers were identified: Age 65.9±
1.1 years (89 [75%] males), diabetes duration 27.8±1.3 years (47 type 1
diabetes [40%]), BMI 29.8±0.5 kg/m2, HbA1c 66.9±1.4 mmol/mol,
total cholesterol 4.6±0.1 mmol/L, LDL-cholesterol 2.3±0.1 mmol/L,
HDL-cholesterol 1.3±0.05 mmol/L, triglycerides 2.3±0.2 mmol/L, and
blood pressure 137±1.8/74±1 mm Hg. 21% were smokers and 29% had
a previous history of amputation; more common amongmales (35%) than
females (10%), p=0.01. Total loss of vibration sense >50 volt was seen in
right 59% and left foot 66%, and only 17% showed no signs of retinop-
athy. 29 patients were normoalbuminuric (26%), 47 micro- (42%) and 37
had macro-albuminuria (33%). 45% had lacking palpable peripheral
pulses.Time before contacting the service (contact delay time) was 17±
2 days, and wound healing time was 8±0.6 weeks (n=164). Patients were
offered an appointment within 24 hours for 165 of the wounds (86%), and
within a week for another 11%. There was no difference in contact delay
time between males and females (p=0.6). Wound healing time was pos-
itively correlated with contact delay time (r=0.2, p=0.01) which was also
the only independent predictor of wound healing time as judged by a
multiple regression analysis including relevant co-variates such as age,
gender, diabetes duration, metabolic control, co-morbidities and compli-
cations, although the model explained less than 10% of the variability in
healing time (r2=0.09, p=0.02).
Conclusion: Diabetic foot ulcer healing in a multidisciplinary setting is
dependent on patient lag time to contact the clinic. Further investigation
as to the underlying reasons and remedies for this delay is warranted in
order to further improve the long term prognosis of diabetic foot ulcers.
1056
Patients' adherence to customised diabetic insoles as objectively
assessed by a temperature sensor
D. Ehrmann1, M. Spengler2, M. Jahn2, H. Siebert3, D. Niebuhr3, T.
Haak1, B. Kulzer1, N. Hermanns1;
1Research Institute Diabetes AcademyMergentheim (FIDAM), BadMer-
gentheim, 2IETEC orthopaedic insoles, Kuenzell, 3University of Applied
Sciences, Fulda, Germany.
Background and aims: Customized diabetic insoles reduce the mechan-
ical stress by re-distributing pressure to the plantar tissue. Thus, custom-
ized diabetic insoles are an effective means to prevent the reoccurrence of
neuropathic diabetic foot ulcerations. However, the efficacy of these in-
soles is highly dependent on patients’ adherence. By recommendation,
patients should wear their customized diabetic insoles asmuch as possible
for the prevention of diabetic foot problems. However, adherence data
often rely on self-report since objective parameters are not available. The
aim of this study was to objectively assess patients’ adherence with a
temperature sensor directly incorporated into their insoles.
Materials and methods: In a pilot study, the cut-off value for optimal
temperature was determined that differentiates between wearing and not
wearing footwear. For this purpose, a ROC analysis was conducted that
yielded an area under the curve of .996 (p<.0001). A cut-off value of
25°Celsius was determined that achieved a sensitivity of 95.3%, a specific-
ity of 99.8%, a positive predictive value of 98.7%, and a negative predictive
value of 99.2%. In the main study, temperature sensors were incorporated
into the specialized diabetic insoles of 26 patients with type-2-diabetes and
diabetic foot syndrome (age: 67.5±10.8 yrs.; 35% female; BMI: 30.3±
4.7 kg/m2; diabetes duration: 10.4±6.8 yrs.; HbA1c: 7.7±0.6%).
Results:On average, data from 133.5 days per patient could be analysed.
Patients wore their diabetic footwear (temperature>25°C) on an average
(median) of 3.4 hours per day (inter-quartile-range (IQR): 0.5 - 6.9 hours/
per day). On an average (median) of 51% of days, patients did not wear
their diabetic footwear (IQR: 16.9 - 81.8%).
Conclusion: Wearing time of diabetic insoles and other specialized dia-
betic footwear can be objectively and validly assessed by temperature
sensors. This study offers objective data regarding patients’ adherence
to their customized diabetic insoles. Nearly every second day, patients
did not wear their insoles at all. Results of this study indicate that the
utilization of specialized diabetic footwear is suboptimal in order to pre-
vent re-ulcerations and other diabetes foot problems. Future studies
should examine how the adherence of patients with a high risk for foot
ulcerations can be enhanced, e.g. by patient education or technological
assistance or reminders.
Supported by: LOEWE Offensive for the Development of Scientific and
Economic Excellence
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The ABCDEF classification of perfusion in the diabetic foot
C.A. Manu1, M. Bates1, N. Petrova1, A. Donaldson2, M. Simmgen3, P.
Vas3, K. Winkley4, H. Rashid5, M. Edmonds3;
1Diabetic Foot Clinic, King's College Hospital, Croydon - London, 2Bio-
statistics, Diabetic Foot Clinic, King's College Hospital, 3Diabetic Foot
Clinic, King's College Hospital, 4Diabetes Research Group, King's Col-
lege London, 5Vascular Surgery, King's College Hospital, London, UK.
Background and aims: The diabetic ischaemic foot is difficult to assess
and treatment is often delayed. There is no consensus on a standardised
assessment of foot perfusion in patients presenting with diabetic foot
ulceration. A new classification system that grades the varying degrees
of perfusion in the diabetic foot is needed to match assessment with
management in individual patients. The aim was to create a new classifi-
cation that reflects the spectrum of perfusion.
Materials and methods:We recruited consecutive patients attending the
diabetes foot clinic with an ulcer in one or both feet. We measured bra-
chial and toe blood pressure (TBP) and derived the toe brachial index
(TBPI) in both feet. We then measured transcutaneous oxygen tension
(TcP02), at the dorsum of both feet in the supine position and on the
forearm, and derived the baseline TcP02 Index as a ratio of TcP02 on
the foot compared to the arm. If the foot TcP02 was ≥40 mmHg, we then
measured it after a provocation test of 30o leg elevation for 5 minutes. If
the supine TcP02 was <40 mmHg, we measured it after an oxygen chal-
lenge (inhalation of 100% oxygen for 10 min), to assess the restoration of
the TcPO2 Index after oxygen inhalation. All measurements were done
with the PeriFlux System 5000.
Results:We studied 236 limbs in 130 patients. Hundred and seven limbs
had a TBPI of ≥0.7 and baseline TcP02 Index of 0.84±0.19 (Mean ± SD),
indicating that these limbs had good perfusion and were graded as Group
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A. There were 129 limbs with TBPI <0.7 of which 91 had TcPO2≥
40 mmHg; 46/91 of these limbs had a sustained TcPO2 that did not fall
on leg elevation andwere graded as Group B, but 45/91 limbs had a fall of
≥10 mmHg on elevation and were graded as Group C. TBP was signif-
icantly greater at 75±25mmHg inGroup B comparedwith 56±18mmHg
in Group C [p<0.001]. Thirty eight of the 129 limbs with TBPI <0.7 had
TcPO2<40 mmHg. Eleven of the 38 limbs responded to the oxygen
challenge, with restoration of their TcP02 Index (1.06±0.15) and were
graded as Group D, but 27/38 did not respond to oxygen challenge.
Sixteen of the 27 were graded as Group E, with a baseline TcPO2≥
10 mmHg but <40 mmHg and the remaining 11 were graded as Group
F, having a baseline TcPO2<10 mmHg. TBP were not significantly dif-
ferent between Group E and F, 48±21 vs 40±28 mmHg respectively [p=
0.203], but Groups E and F were distinguished by their response to
oxygen inhalation, the TcPO2 Index after oxygen inhalation being 0.55
±0.15 in Group E vs 0.26±0.25 in Group F [p<0.001].
Conclusion: We have classified 6 grades of perfusion, using a 3 step
approach of TBPI, TcPO2 and a provocation test. Group A: TBPI ≥0.7,
Group B: TBPI <0.7 TcPO2≥40 mmHg sustained on elevation, Group C:
TBPI <0.7, TcPO2≥40 mmHg falling on elevation, Group D: TBPI <0.7,
TcPO2<40mmHgwith restoration of TcPO2 Index on oxygen challenge,
Group E: TBPI <0.7, TcPO2<40 mmHg but >10 mmHg with failure to
restore TcPO2 Index and Group F: TBPI <0.7, with failure to restore
TcPO2 Index and TcPO2<10 mmHg. This study has derived a novel
classification of diabetic foot perfusion, namely the ABCDEF classifica-
tion, which objectively stratifies the diabetic foot into 6 groups, thus
facilitating the standardisation of assessment and management of the
diabetic foot.
Supported by: King's College Charitable Trust
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Toe-brachial index is associated more strongly with outcome of
chronic diabetic foot ulcers than ankle-brachial index in patients with
type 2 diabetes
D.-H. Cho, J.-O. Chung, D.-J. Chung, M.-Y. Chung;
Chonnam National University Hospital, Gwangju, Republic of Korea.
Background and aims: Chronic diabetic foot ulcers remain a significant
problem in individuals with diabetes and precede 84% of all diabetes-
related lower-leg amputations. Such ulcers are responsible for a
prolonged period of hospitalization and co- morbidities caused by infect-
ed diabetic foot ulcers. Both micro- and macroangiopathy strongly con-
tribute to the development and delayed healing of diabetic wounds. Pe-
ripheral arterial disease (PAD) can be diagnosed noninvasively by seg-
mental blood pressure measurement and calculating an ankle-brachial
index (ABI) or toe-brachial index (TBI). The toe vessels are less suscep-
tible to vessel stiffness, which makes the TBI useful. The objective of this
study was to determine whether ankle-brachial index or toe-brachial in-
dex can influence outcome of chronic diabetic foot ulcers in patients with
type 2 diabetes.
Materials and methods: We recruited a total of 89 type 2 diabetic pa-
tients (58 men and 31 women) with chronic nonhealing diabetic foot
ulcers with Wagner grade 1 or 2 ulcers that are ≥2 cm in largest diameter
at diagnosis for more than 1-month duration. The age was 67.4±
15.9 years, and the diabetes duration was 15.8±12.3 years. Anthropomet-
ric, clinical, and laboratory data were measured. All patients were seen bi-
weekly for debridement, offloading, and other treatments during the ini-
tial 8 weeks. All patients subsequently underwent ABI and TBI testing.
ABI and TBI measurements were performed with the subject in a supine
position, and were determined as the ratio of ankle or toe systolic blood
pressure to the brachial systolic blood pressure, with both determined
using an automatic device.
Results: At 8 weeks, 56 of the 89 ulcers had completely healed. The
patients were assigned into healed group (n=56) or unhealed group (n=
33) according to clinical outcome of ulcer healing at 8 weeks. There were
not significantly different in age, duration of diabetes, HbA1c, or initial
wound size in diameter of the ulcer between the healed and unhealed
groups. The healing time of foot ulcers in healed group was 4.3±
3.1 weeks (range 2.1-7.8). The TBI was significantly (P<0.05) lower in
the unhealed group (0.58±0.21 cm/s) as compared with the healed group
(0.71±0.19 cm/s). ABI was not significantly different between unhealed
and healed group. Age (r=0.533; p<0.01), duration of diabetes (r=0.459;
p<0.05) and ABI (r=0.725; p<0.001) were significantly correlated with
TBI. But BMI, cholesterol levels, HbA1c, and systolic and diastolic BP
were not correlated with TBI. Univariate analysis revealed that TBI was
significantly correlated with healing rate of diabetic ulcers (r=0.296, p<
0.05) and duration of diabetes (r=0.403, p<0.05).
Conclusion: This study demonstrated that toe-brachial index is more
strongly associated with the healing time of diabetic ulcers than ankle-
brachial index. We suggest that the measurement of toe-brachial index
may help to identify ulcers at risk of poor healing in chronic diabetic foot
ulcers in patients with type 2 diabetes.
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Do ulcer characteristics and cardiovascular risk factors predict
healing and mortality in people with diabetic foot ulcers in northern
England?
N. Holman1, P. Chadwick2, J. McAdam2, S. Haycocks2, B. Young2;
1Institute of Cardiovascular and Medical Sciences, University of Glas-
gow, 2Salford Royal Foundation NHS Trust, UK.
Background and aims: This population based study examines foot dis-
ease and non-foot disease associations with ulcer healing and mortality
among people with incident diabetic foot ulcers in a ‘real world’ longitu-
dinal cohort.
Materials and methods: In the city of Salford routine electronic clinical
records are kept by podiatrists for all people with an incident diabetic foot
ulcer. Where possible these records have been linked to complementary
primary and secondary care electronic health records to identify patient
characteristics, cardiovascular risk factors and death registrations to
June 2013. Regression and survival models were created to examine
factors associated with ulcer healing and mortality.
Results: The foot care records of 1728 out of 2977 Salford residents
presenting with foot ulcers between 2001 and 2012 could be linked to
their general health record to provide sufficient data for analysis. 55.1%of
ulcers healed within 90 days. Age (OR 0.99 per additional year of age,
95% CI 0.98-0.99) and being male (OR 0.74 95% CI 0.60-0.92), in-
creased depth (probing to bone) (OR 0.22 95% CI 0.08-0.60), rear foot
location (OR 0.68 95% CI 0.49-0.92), peripheral vascular disease (OR
0.52 95% CI 0.39-0.69) and blood pressure below the current NICE
recommended target for people with vascular disease (130/80) (OR
0.64 95% CI 0.51-0.79) were associated with a lower chance of healing
in 90 days. Total cholesterol below 5 mmol/l was linked with ulcer
healing (OR 1.20 95% CI 1.01-1.41) in 90 days, whereas kidney function
was inversely related to the chance of healing in 90 days (OR compared to
eGFR 90+ for eGFR 60-89 1.27 95% CI 1.01-1.60, eGFR 30-59 1.71 95
CI 1.19-2.47, eGFR <30 4.57 95% 0.52-39.92). Cellulitis, type of diabe-
tes, HbA1c, bodymass index and smoking were not associated with ulcer
healing rates at 90 days. In this cohort mortality one year from initial
presentation was 13.1% and 19.5% at two years. Increasing age (HR
1.10 per additional year of age, 95% CI 1.09-1.11) and being male (HR
1.31 95% CI 1.08-1.60) were associated with shorter survival. Peripheral
vascular disease (HR 1.61 95% CI 1.30 - 1.99) and rear foot ulcers (HR
1.72 95% CI 1.35 - 2.20) were associated with shorter survival. Smokers
had significantly higher mortality than those who had never smoked (HR
1.71 95% CI 1.30 - 2.25) whilst ex-smokers showed a non-significant
raised risk of dying (HR 1.19 95% CI 0.97 - 1.47). Blood pressure below
130/80 was associated with higher mortality (HR 1.39 95% CI 1.15 -
S510 Diabetologia (2015) 58 (Suppl 1):S1–S607
1.69). Poor kidney function was associated with higher mortality but only
reached statistical significance with very advanced disease (eGFr <15
(OR 9.71 95% 2.38-39.64). The depth of the incident ulcer and cellulitis,
type of diabetes, HbA1c, body mass index and lipid profile were not
significantly associated with differential mortality.
Conclusion: High risk characteristics for poor healing of diabetic foot
ulcers identified in this record linkage extend beyond the well-recognised
age, male sex, ulcer location and depth and peripheral vascular disease to
dyslipidaemia, low blood pressure and chronic kidney disease. Similar
factors plus smoking were associated with early mortality. In this analysis
HbA1c, weight and cellulitis were not related to healing or death. More
intensive vascular and renal management may be necessary to improve
outcomes in people with diabetic foot ulcers.
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Prolonged hospital stay and increased readmission of lower limb
cellulitis in type 2 diabetes patients
F. Wu1,2, S. Wijayaratna1, S. Sehgal1, T. Cundy2, G. Gamble2, S.
Wijayaratna2, P.L. Drury1;
1Auckland District Health Board, 2Auckland University, New Zealand.
Background and aims: Incidences of soft tissue infections in people
with and without diabetes are increasing. Cellulitis, perhaps by damaging
the lymphatic vessels, is prone to recur. However, there is little data on
hospitalization rates of lower limb (LL) cellulitis, specifically in the dia-
betes population. We quantify the impact of this condition and assess the
factors associated with prolong stay and readmissions.
Materials and methods: Retrospective case-control study conducted in
an urban hospital, servicing a multi-ethnic population of nearly 0.4 mil-
lion adults, including ~27000 (7%) with known type 2 diabetes (T2DM).
Adults with T2DM and those without diabetes admitted with LL cellulitis
between 2008-2013 were identified from discharge coding and medical
records. Length of stay, patient demographics, HbA1c, presence of LL
ulceration, and subsequent readmission with LL cellulitis >1 month from
the index admission were recorded.
Results: T2DM patients were over-represented, with 719 patients ac-
counting for 22% of the 4600 LL cellulitis admissions in the 6 year
period. ~3% of the estimated T2DM population were admitted at least
once during that time, compared to 0.8% of the non-diabetic population
(p<0.0001). T2DM was associated with a significantly longer length of
stay (median 5.3 vs 3.0 days, p<0.001), regardless of age, ethnicity and
despite relatively good glycaemic control (mean HbA1c 61 mmol/mol).
Ulceration commonly accompanied LL cellulitis, particularly in T2DM
subjects (52% vs 18%, p<0.001), and increased the length of stay
(T2DM: ulcer vs no ulcer: 7.9 vs 3.7 days, P<0.0001; control: ulcer vs
non ulcer: 5.9 vs 2.9 days, p<0.0001). Amputation was almost exclusive-
ly performed in patients with ulceration, more commonly in T2DM pa-
tients (10% vs 0.1%, p<001), particularly in those with HbA1c
>89 mmol/mol. The risk of readmission during the mean 37 months of
follow-up was increased in the T2DM group compared with control (HR
1.73, 95% CI 1.4-2.4, p<0.001) and remained elevated even in the ab-
sence of ulceration (HR 1.67, 95% CI 1.2-2.4, p<0.01). Non-diabetic
patients without ulceration were at the least risk of readmission (Figure).
Ethnicity, age, HbA1c, and length of index admission were unrelated to
the risk of readmission. We estimate that 3% of the total T2DM patients
account for 1/3 of the 26364 cellulitis-related bed days and the average
annual cost of €3.4 million during the study period.
Conclusion: This study highlights the huge economic and social burden
of LL cellulitis admissions and its recurrent nature, posed by a small
proportion of the population. Patient demographics and chronic
glycaemic control do not predict readmission risk. Exploring other clin-
ical factors that may influence recurrence and response to antibiotic pro-
phylaxis in the T2DM population will enable targeting of high risk
patients.
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Diabetic foot disease, self-care, and clinical monitoring in adults with
type 2 diabetes: the Alberta's Caring for Diabetes (ABCD) cohort
study
J.A. Johnson1, F. Al Sayah2, A. Soprovich2, W. Qiu2, A.L. Edwards3;
1School of Public Health, University of Alberta, 2University of Alberta,
Edmonton, Canada, 3Department of Medicine, University of Calgary,
Canada.
Background and aims: Diabetic foot disease is a major cause of mor-
bidity, disability and mortality, and contributes to increased healthcare
cost. Throughout the world, up to 70% of leg amputations are performed
on people with diabetes, the majority of which are preceded by a foot
ulcer and considered preventable. Our aim was to examine the prevalence
and predictors of foot disease, self-care and clinical monitoring in adults
with type 2 diabetes (T2D) in Alberta, Canada.
Materials and methods: We used data from the baseline survey of a
large prospective cohort of adults with T2D. Data were collected via a
mailed self-administered questionnaire. Assessment of foot disease in-
cluded self-reported peripheral neuropathy, peripheral vasculopathy, foot
or leg ulcer/infection or gangrene/amputation. Foot self-care was assessed
using the Summary of Diabetes Self-Care Activities, and clinical moni-
toring was assessed by patient-report of having feet checked for lesions or
sensory loss by a health professional. Multivariable logistic regression
was used to estimated odds ratios (OR) and 95% confidence intervals
(CI) for potential predictors of diabetic foot disease, good foot self-care
and clinical monitoring.
Results: Mean age of respondents (N=2040) was 64 (SD 10.6) years,
45%were female, and 91%Caucasian. Peripheral neuropathywas report-
ed by 18% of the respondents, peripheral vasculopathy by 28%, ulcer/
infection by 6%, and gangrene/amputation by 1.4%. Only 14% of respon-
dents performed recommended foot self-care behaviours≥6 days/week,
and only 41% and 34% had their feet clinically checked for lesions or
sensory loss respectively. Predictors of increased risk of diabetic foot
disease included longer diabetes duration, history of smoking, depressive
symptoms, low self-efficacy, and a history of cardiovascular diseases.
Predictors of good foot self-care included older age (OR 1.8; 95%CI
1.0, 3.1), female sex (1.4; 1.1, 1.8), longer diabetes duration (1.7; 1.3,
2.3), inadequate health literacy (1.4; 1.0, 2.0), and presence of hyperlip-
idemia (0.6; 0.5, 0.8). Predictors of clinical monitoring included female
sex (0.8; 0.7, 0.9), residing in urban areas (1.6; 1.3, 2.0), longer diabetes
duration (1.5; 1.2, 1.8), current smoking (0.7; 0.5, 0.9), presence of heart
disease (1.4; 1.1, 1.8) or hyperlipidemia (1.2; 1.1, 1.5).
Conclusion: Peripheral neuropathy and vasculopathy were the most
commonly reported foot problems in this population. Recommended foot
self-care is generally infrequent, and clinical monitoring is performed for
less than half of these patients, with significant variations by patient
demographics and clinical presentation. We found it particularly interest-
ing that smokers, who have a higher risk of developing foot disease, were
less likely to receive a clinical foot exam compared to non-smokers. Our
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results underline the importance of a detailed exploration of clinical mon-
itoring of diabetic foot disease by care providers, and the development of
standards, resources and tools for health care providers to enhance these
preventive services.
Supported by: Alberta Health and CIHR
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Long-term follow-up of a cohort with a history of diabetic foot ulcer
in Austria
A. Ribitsch, W. Haas, J.K. Mader, J. Samonigg, K. Horvath, G. Köhler,
H. Sourij, T.R. Pieber, J. Plank;
Internal Medicine / Endocrinology and Metabolism, Medical University
of Graz, Austria.
Background and aims: Patients with previous diabetic foot ulcer are
prone to re-ulceration and (re-)amputation. To evaluate the rate of foot
related complications and mortality in a high-risk population of patients
with diabetic foot syndrome over a decade.
Materials and methods: A cohort of 91 patients with recently healed
diabetic foot ulcer were invited for follow-up 1, 6 and 11 years after
inclusion. Patient characteristics at inclusionwere: 65±11 years, 44wom-
en, diabetes type 1 (n=6) or 2 (n=85), BMI 28.5±4.4 kg/m2, and HbA1c
8.4±1.6%. Patients presented with clinical signs of neuropathy (n=91),
peripheral vascular disease (n=42), history of minor (n=25) or major (n=
5) amputation, nephropathy (n=40) and retinopathy (n=53).
Results: Over the follow-up period ulceration recurred in 71 (78%) pa-
tients, time to first recurrence was 1.8±2.4 years (mean ± SD). 21 patients
(23%) had to undergo a new amputation (minor n=19, major n=2), time
to new amputation was 3.6±1.9 years. Over time 3 further major ampu-
tations were required in patients with an initial minor amputation. 33 of
the initially included patients completed the follow-up period of 11.0±
0.6 years. 58 (64%) patients died during the observational period, time
until exitus was 5±3 years in this group. Causes of death were the fol-
lowing: 56.9% cardiovascular, 17.2% infections, 6.9% cancer, 19% other
causes. Microvascular complications were not predictive for a composite
of amputation or death, while peripheral artery disease was significantly
predictive (p<0.0001).
Conclusion: Our data highlights the high recurrence rate of ulcerations
and the poor longterm prognosis in high-risk patients with a diabetic foot
syndrome. More research is urgently needed to improve the outcome of
this patient cohort.
PS 104 Treating and salvaging the
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Inflammatory cytokines role in extracellular matrix turnover
induces in human skin fibroblasts by AGEs exposure
A.I. Serban1, L. Stanca1, O.I. Geicu2,1, A. Dinischiotu2;
1Preclinical Sciences, University of Agronomic Sciences and Veterinary
Medicine, Faculty of Veterinary Medicine, 2Biochemistry and Molecular
Biology, University of Bucharest, Faculty of Biology, Bucharest, Romania.
Background and aims: AGEs accumulation in the skin affects extracel-
lular matrix (ECM) turnover and triggers diabetes associated skin condi-
tions and skin ageing. The receptor of AGEs (RAGE) has an essential
contribution to cellular dysfunction driven by chronic inflammatory re-
sponses. TGF-β1 is also critical in dermal homeostasis and inflammation.
We investigated the contribution of RAGE and TGF-β1 to the modula-
tion of inflammatory response and EMC turnover in AGEs milieu, and
the effects generated by their blockade in order to delineate a potential
therapeutic strategy.
Materials and methods: Human skin fibroblasts (CCD-1070Sk) were
exposed for 12 and 24 h to 50, 100 and 200 μg/ml glycated BSA (AGEs-
BSA) and unglycated BSA (control). Anti-RAGE and anti-TGF-β1
blocking antibodies were applied to the 200 μg/ml AGEs exposed cells
for 24 h. Secreted TGF-β1, IL-2, IL-4, IL-6, IL-8, granulocyte-
macrophage colony-stimulating factor (GM-CSF), IFN-γ and TNF-α
were determined by multiplex immunoassay, while RAGE, TGF-β1,
collagen I and III and metalloproteinase (MMPs) protein levels were
evaluated by western blot. The gene expression was quantified by real-
time RT-PCR, and activity of MMPs was evaluated by gelatin
zymography.
Results: The 12 h exposure to AGEs-BSA induced a dose dependent
upregulation of RAGE, TGF-β1, collagen I and III, increasing the rela-
tive gene expression ratio (R) to 4.1, 3.1, 5.9, and 2.7, after exposure to
200μg/ml AGEs-BSA, whereas their protein expressionwas affected to a
lesser extent. Notably, after 24 h, the increases of collagen III gene and
protein expression exceeded those of collagen I. MMP-2 was activated
after 12 h of AGEs-BSA exposure, while MMP-9 activity was not de-
tected. MMP-2 protein expression was induced in a dose dependent man-
ner by AGEs-BSA exposure, with a maximal 2 fold increase after 12 and
24 h. While RAGE blockade diminished MMP-2 activation, TGF-β1
didn't significantly inhibit it. All cytokine levels increased after 12 h of
exposure to AGEs-BSA in a dose dependent manner; IL-8 and TNF-α
had the highest expression levels and increased over 1.7 fold, while after
24 h, TGF-β1, IL-6, GM-CSM and TNF-α increased over 2 fold. R of
collagen I and III decreased after RAGE blockade to 0.14 and 0.52 com-
pared to 200 μg/ml AGEs-BSA exposed cells, while TGF-β1 blockade
only inhibited collagen III expression. IL-2, IL-8, and TNF-α protein
levels were diminished by RAGE blockade, which also mildly decreased
active TGF-β1 secretion. TGF-β1 blockade diminished IL-6 and GM-
CSF levels in AGEs milieu, as opposed to IL-8 and TNF-α which were
additionally increased.
Conclusion: The pro-inflammatory effect of AGEs on human skin fibro-
blasts involved both the activation of TGF-β1 and RAGE-NF-κB-TNF-α
signaling axes. The activation ofMMP-2 and over-expression of collagen I
and III probably prompted an increased ECM turnover. Additionally, after
24 h, collagen III expression ratio dominance over collagen I could suggest
diminished ECM mechanical stability. RAGE blockade markedly de-
creased collagen I level, and inhibited MMP-2 activation, while TGF-β1
blockade decreased collagen III expression and mildly inhibited MMP-2
activity, as it induced IL-8 expression. TGF-β1 blockade overall effect
could contribute to restore the collagen I/III ratio, in favor of the former.
Supported by: CNCS –UEFISCDI, project no. PN-II-RU-TE-2012-3-0034
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Direct revascularisation based on angiosome model reduces major
amputations and increases life expectancy in diabetic patients with
critical limb ischaemia and diabetic foot
E. Iacopi1, A. Coppelli1, I. Bargellini2, C. Goretti3, A. Cicorelli2, A.
Lunardi2, R. Cioni2, S. Del Prato1, A. Piaggesi3;
1Diabetology Unit - Medicine Department, University of Pisa, 2Interven-
tional Radiology Department - Pisa University Hospital, 3Diabetic Foot
Section - Medicine Department, University of Pisa, Italy.
Background and aims: The role of AM to guide revascularization pro-
cedures is debated. We evaluated whether direct or indirect revasculari-
zation, based on Angiosome model (AM), affects clinical outcomes in
type 2 diabetic patients (T2DM) with critical limb ischemia (CLI) under-
going percutaneous trans-luminal angioplasty (PTA).
Materials and methods: We retrospectively evaluated 445 consecutive
successful lower limb PTA performed in 370 T2DM patients (M/F: 257/
113; age: 73.5±9.3 yrs; BMI: 27.4±4.8 Kg/m2; diabetes duration: 21.4±
12.8 yrs; HbA1c 7.8±1.6%) because of CLI and diabetic foot ulceration
(DFU). Patients were divided into 2 groups: direct (DG - 266 pts, 72%) or
indirect (IG - 104 pts, 28%) depending on whether the flow to the artery
directly feeding the site of ulceration, as determined by AM, was success-
fully identified or not. No significant difference was apparent between
groups regarding main clinical characteristics. Ulcer healing (HR), major
amputation (MA) and death (D) rates were compared in the 2 groups
during a follow-up of 18.9±12.4 months (range 0.7-43.2).
Results: HR was achieved in 68% of DG vs. 52% of IG (χ2=9.6; p<
0.05). MA was needed in 11% of DG vs. 4% of IG (χ2=9.4; p<0.02).
Cumulative mortality rate during follow-up was 14% in DG and 27% in
IG (χ2=8.7; p<0.02).
Conclusion: Our data show that direct revascularization of arteries sup-
plying the DFU site by means of AM is associated with higher rate of
healing and lower risk of amputation and mortality as compared to indi-
rect PTA procedure. These results support use of AM for PTA guiding in
diabetic patients with DFU.
1065
Trends in lower extremity amputations over 5 years at a tertiary
hospital
T. Macriyiannis, J.T. Dales, D. Tesh, M.-F. Kong;
Department of Diabetes, University Hospitals of Leicester NHS Trust,
UK.
Background and aims:Around 6000 people with diabetes have leg, foot
or toe amputation each year in England. Up to 80% people die within
5 years of having an amputation. Amputations remain a common out-
come of diabetic foot disease and have an impact on individuals econom-
ically, socially and psychologically. It has been estimated that a reduction
of 50% late referrals to specialist foot teams could save £34 million (47
million Euros) a year by a reduction in amputations. We analysed all
lower extremity amputations between 2009 and 2013 in our tertiary re-
ferral hospital and evaluated patient characteristics and trends in
amputations.
Materials andmethods:We performed a retrospective review of data on
hospital discharges of patients who were coded as having had a lower
extremity amputation from 2009 to 2013 in our hospitals which cover a
relatively static population. Data were collected from the hospital coding
activities from 1 January 2009 to 31 December 2013. For each amputa-
tion, diabetes status was ascertained by looking through our diabetes
register and the pathology system. The demographic, admission details
and relevant medical history were also collected.
Results: 30-40% of amputations occurred in patients with diabetes, com-
parable with other series. The total number of patients with diabetes in the
region in 2011 was 49,645, 52,428 in 2012 and 59,611 in 2013, with a
calculated mean incidence of 0.56/1000 diabetic population in 2011,
0.53/1000 diabetic population in 2012 and 0.55/1000 diabetic population
in 2013 for major amputations. The figures for minor amputations were
1.13/1000, 1.28/1000 and 1.16/1000 diabetic population respectively. In
our local population, the mean incidence over the 3 years was 1.74/1000
diabetic population for all foot amputations, 0.55/1000 for major ampu-
tations and 1.19/1000 diabetic population for minor amputations. The
amputation rate per 1000 diabetic population in England over the same
3 year period was 2.6 for all amputations, 0.9 for major foot amputations
and 1.7 for minor foot amputations.
Conclusion: Increasing numbers of people with diabetes in the popula-
tion area is expected to lead to a rise in the number of lower extremity
amputations. Our major and minor amputation rates have remained un-
changed from 2011 to 2013. The trend is an increase in the number of
minor amputations from 2009-2010 to 2011-2013. An early minor am-
putation can prevent a later major amputation. . Thus, minor amputations
may reflect improved quality of care with earlier intervention; conse-
quently preventing the progression from minor to major amputation.
1066
Nationwide lower extremity amputation rates in patients with
diabetes in secondary care in the Netherlands (DUDE-7)
L. Nijenhuis - Rosien1,2, S. Hendriks1, N. Kleefstra1,3, H.J.G. Bilo1,3,
G.W.D. Landman1,4;
1Diabetes Centre Isala, 2Innofeet Footcentre Nijenhuis, Zwolle, 3Depart-
ment of Internal Medicine, University of Groningen, University Medical
Centre Groningen, 4Department of Internal Medicine, Gelre Hospital,
Apeldoorn, Netherlands.
Background and aims: Patients with diabetes are at increased risk for
lower extremity amputation as a consequence of micro- and microvascu-
lar complications. Almost one in five European patients with a diabetic
foot ulcer ends up with a below knee amputation (Eurodiale). The esti-
mated amputation rate estimates from the general diabetes population in
the UKwere 0.25% and in the Netherlands between 0.36 and 0.55% in at
the end of the last century, treated in both primary and secondary care.
The primary aim of this study was to estimate the annual incidence rate of
amputations in secondary care treated patients with diabetes. The second-
ary aim was to estimate the amputation rate in secondary care treated
patients diagnosed with diabetic retinopathy.
Materials and methods: The study population consisted of all patients
for whom an insurance claim was made for treatment of diabetes in
secondary care. Patients were selected from a nationwide database that
collects data on insurance claims. Physicians are required to record
Diagnosis-treatment-codes (DTC) for receiving reimbursement of hospi-
tal care using. Each DTC code contains information about the specialism
that recorded the DTC, the diagnosis and type of treatment. From this
database, patients with diabetes were selected and incidence rates of non-
traumatic lower extremity amputation and retinopathy were selected be-
tween 2007 and 2011. The percentage of claims for amputations was
identified for the whole study group and for the subgroup with
retinopathy.
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Results: Total number of secondary care treated patients with diabetes in
the Netherlands increased from 132.499 to 137.049 between 2007 and
2011 (table 1). The annual rate of total non-traumatic lower-extremity
amputation was 0,5% and remained stable over the years. The percentage
of patients diagnosed with retinopathy by an ophthalmologist ranged
from 13,7%% to 15,0%. Annual rate of lower extremity amputations
was 1.2% for those with retinopathy, see table 1.
Conclusion: The Dutch annual incidence rates of non-traumatic lower
extremity amputations in the Netherlands in secondary care patients with
diabetes between 2007 and 2011 were comparable to the rates 20 years
ago and higher compared to data from the UK (2005-2008), although the
most recent UK data concerned primary and secondary care treated pa-
tients. The annual amputation rate in patients with retinopathywas higher,
indicating a higher risk on lower extremity amputation when (other) mi-
crovascular complications are present.
1067
Efficacy, quality of life and treatment satisfaction with capsaicin 8%
patch versus standard of care in painful diabetic peripheral
neuropathy
S. Perrot1,2, E. Ortega3, E.J. Vinik4, L. Pazdera5, M. Stoker6, F. van
Nooten6, R. Snijder6, C. Poole7, F. Lewis8, N. Katz9, A.I. Vinik4;
1Hôpital Hôtel Dieu, Paris, 2Paris Descartes University, France, 3Hôpital
Rio Hortega, Valladolid, Spain, 4Eastern Virginia Medical School, Nor-
folk, USA, 5Vestra Clinics, Rychnov nad Kneznou, Czech Republic,
6Astellas Pharma Europe B. V., Leiden, Netherlands, 7Astellas Pharma
Europe, Chertsey, 8Office of Health Economics, London, UK, 9Analgesic
Solutions and Tufts University, Boston, USA.
Background and aims: PACE was a Phase III, randomised, controlled,
open-label, 52-week, safety study that assessed the safety and efficacy of
repeat treatment with the capsaicin 8% patch plus standard of care (SOC)
versus SOC alone in painful diabetic peripheral neuropathy (PDPN).
Secondary efficacy, quality of life (QoL) and treatment satisfaction results
are presented.
Materials and methods: Patients (N=468) with mean [SD] duration of
PDPN 4.4 [3.6] years, glycosylated haemoglobin 7.4% [1.0], average
daily pain 5.6 [1.3] and European quality of life in 5 dimensions visual
analogue scale (EQ-5D VAS) 54.6 [14.7], were randomised (1:1:1) to
capsaicin 8% patch 30 min plus SOC (n=156), capsaicin 8% patch
60 min plus SOC (n=157), or SOC alone (n=155). Capsaicin arms re-
ceived 1-7 treatments with at least 8-week intervals. Results for the sec-
ondary endpoints BPI-DN pain severity index, BPI-DN pain interference
index, EQ-5D dimensions, VAS and utility, and self-assessment of treat-
ment (SATII) are presented. No formal statistical testing was performed
and treatment deltas were compared with a 90% CI in this safety study.
Results: Regarding pain severity index, the mean [SD] change from
baseline to end of study (EoS) was -1.9 [1.8], -2.2 [1.9] and -0.9 [1.7]
with capsaicin 30 min, capsaicin 60 min and SOC, respectively; mean
difference [90% CI] with capsaicin 30 min and 60 min versus SOC was -
0.9 [-1.3, -0.6] and -1.2 [-1.6, -0.9], respectively. With pain interference
index, the mean change from baseline to EoS was -1.9 [2.1], -2.0 [2.3]
and -0.8 [1.9] with capsaicin 30 min, capsaicin 60 min and SOC, respec-
tively; mean difference for capsaicin 30 min and 60 min versus SOC was
-1.0 [-1.4, -0.6] and -1.2 [-1.6, -0.8], respectively. A greater mean
improvement in EQ-5D utility index of 0.07 was observed in both cap-
saicin arms versus SOC from baseline to Month 12. Regarding EQ-5D
items, a greater proportion of patients at EoS in both capsaicin arms
versus SOC had no problems with mobility, self-care, usual activities,
pain or discomfort and anxiety or depression. Regarding EQ-5D VAS,
the mean change from baseline to EoS was 10.4 [18.5], 11.2 [21.4] and
5.5 [18.1] with capsaicin 30 min, capsaicin 60 min and SOC; mean
difference with capsaicin 30 min and 60 min versus SOC was 4.9 [1.1,
8.6] and 5.7 [2.0, 9.4], respectively. With SATII at EoS, a greater propor-
tion of patients in both capsaicin arms versus SOC reported improve-
ments in pain level, activity level, quality of life, willingness to undergo
treatment again, and also preferred treatment compared with their previ-
ous treatment.
Conclusion:Repeat treatment with the capsaicin 8% patch in PDPN over
52 weeks was associated with improvements in pain severity and inter-
ference, QoL and treatment satisfaction compared with SOC alone, fur-
ther supporting the broad effectiveness of capsaicin treatment in PDPN.
Clinical Trial Registration Number: NCT01478607
Supported by: Astellas Pharma Europe B. V.
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Capsaicin 8% patch repeat treatment versus standard of care in
painful diabetic peripheral neuropathy: a randomised, open-label,
52-week study
A.I. Vinik1, S. Perrot2, E.J. Vinik1, L. Pazdera3, H. Jacobs4, M. Stoker4,
S. Long4, R. Snijder4, M. van der Stoep4, E. Ortega5, N. Katz6;
1Eastern Virginia Medical School, Norfolk, USA, 2Hôpital Hôtel Dieu,
Paris, France, 3Vestra Clinics, Rychnov nad Kneznou, Czech Republic,
4Astellas Pharma Europe B. V., Leiden, Netherlands, 5Hôpital Rio
Hortega, Valladolid, Spain, 6Analgesic Solutions and Tufts University
School of Medicine, Boston, USA.
Background and aims: PACE assessed the safety and efficacy of repeat
treatment over 52 weeks with the capsaicin 8% patch plus standard of
care (SOC) versus SOC alone in painful diabetic peripheral neuropathy
(PDPN). The Norfolk QOL-DN scale was utilised to assess any patient-
reported functional consequences of potential small-fibre dysfunction that
may be induced by capsaicin treatment. Sensory testing, including the
Utah Early Neuropathy Scale (UENS), was also performed to assess
capsaicin safety.
Materials and methods: PACE was a Phase III, randomised, controlled,
open-label, 52-week, safety study. Patients with painful, distal, symmet-
rical, sensorimotor diabetic polyneuropathy, glycosylated haemoglobin
≤9% and average daily pain ≥4, were randomised (1:1:1) to capsaicin
8% patch 30 min plus SOC, capsaicin 8% patch 60 min plus SOC, or
SOC alone. Capsaicin arms received 1-7 treatments with at least 8-week
intervals. The primary endpoint was percentage change from baseline to
end of study (EoS) in Norfolk QOL-DN total score. Secondary endpoints
were UENS score, ratings of evoked sensations, average daily pain,
≥30% pain response and patient global impression of change (PGIC).
No formal statistical testing was performed and treatment deltas were
compared with a 90% CI in this safety study.
Results: In total, 468 patients with mean [SD] duration of PDPN 4.4 [3.6]
years, glycosylated haemoglobin 7.4% [1.0], average daily pain 5.6 [1.3],
Norfolk QOL-DN total score 41.4 [18.7] and UENS total score 16.4 [6.9],
were randomised to capsaicin 30min (n=156), capsaicin 60min (n=157)
or SOC alone (n=155). A greater improvement from baseline to EoS in
mean Norfolk QOL-DN total score was observed with capsaicin 30 min
versus SOC (mean difference [90% CI]: -20.9% [-31.7, -10.1]) and cap-
saicin 60 min versus SOC (-26.1% [-36.8, -15.4]). Subscale scores for
symptoms, physical functioning/large fibre, small fibre, autonomic and
activities of daily living improved with capsaicin over SOC. Mean [SD]
changes in UENS total score from baseline to EoS also showed improve-
ment and were -2.1 [5.0], -3.0 [5.1] and -1.2 [4.2] in capsaicin 30 min,
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capsaicin 60 min and SOC arms, respectively. A greater reduction in
average daily pain score from baseline to EoS was observed with capsa-
icin 30 min versus SOC (-1.0 [-1.4, -0.6]) and capsaicin 60 min versus
SOC (-1.2 [-1.6, -0.9]). The 30% responder rate by EoS was 67.3%,
67.5% and 40.6% in the capsaicin 30 min, capsaicin 60 min and SOC
arms, respectively. With regard to PGIC at EoS, a very much improved or
much improved general state of health since study start was reported by
24.2%, 24.5% and 9.5% of patients in the capsaicin 30 min, capsaicin
60 min and SOC arms, respectively.
Conclusion: Repeat treatment with capsaicin 8% patch over 52 weeks in
patients with PDPNwas well tolerated, not associated with any functional
consequences arising from potential impaired small-fibre function, or any
sensory deterioration, and pain relief was sustained and progressively
improved compared with SOC.
Clinical Trial Registration Number: NCT01478607
Supported by: Astellas Pharma Europe B. V.
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Capsaicin 8% patch versus standard of care in painful diabetic
peripheral neuropathy: efficacy of seven consecutive treatments over
52 weeks versus SOC
R. Snijder1, E. Ortega2, S. Perrot3,4, E.J. Vinik5, L. Pazdera6, H. Jacobs1,
S. Long1, M. Stoker1, M. van der Stoep1, N. Katz7,8, A.I. Vinik5;
1Astellas Pharma Europe B. V., Leiden, Netherlands, 2Hôpital Rio
Hortega, Valladolid, Spain, 3Hôpital Hôtel Dieu, Paris, 4Paris Descartes
University, France, 5Eastern Virginia Medical School, Norfolk, USA,
6Vestra Clinics, Rychnov nad Kneznou, Czech Republic, 7Analgesic So-
lutions, Natick, USA, 8Tufts University School of Medicine, Boston,
USA.
Background and aims: PACE was a Phase III, randomised, controlled,
open-label, 52-week, safety study that assessed the safety and efficacy of
repeat treatment with the capsaicin 8% patch plus standard of care (SOC),
versus SOC alone in painful diabetic peripheral neuropathy (PDPN).
Efficacy results in patients who received seven consecutive capsaicin
8% patch treatments versus SOC are presented.
Materials and methods: Patients (N=468) with painful, distal, symmet-
rical, sensorimotor diabetic polyneuropathy, glycosylated haemoglobin
≤9% and average daily pain ≥4, were randomised (1:1:1) to capsaicin
8% patch 30 min plus SOC, capsaicin 8% patch 60 min plus SOC, or
SOC alone. Capsaicin arms received 1-7 treatments with at least 8-week
intervals. Efficacy endpoints were average daily pain, Brief Pain
Inventory-Diabetic Neuropathy (BPI-DN) pain severity index, BPI-DN
pain interference index and patient global impression of change (PGIC).
No formal statistical testing was performed and treatment deltas were
compared with a 90% CI in this safety study.
Results: The SOC arm comprised 155 patients and seven treatments were
received by 84/156 (53.8%) and 83/157 (52.9%) patients in the capsaicin
30min and 60min arms, respectively. Baseline mean [SD] daily pain was
5.6 [1.3], 5.7 [1.4] and 5.7 [1.3] in the capsaicin 30 min subset, 60 min
subset and SOC arm, respectively. From baseline to end of study (EoS),
the mean change in average daily pain was -2.4 [1.7], -2.6 [2.1] and -1.1
[2.0] in capsaicin 30 min subset, 60 min subset and SOC arm, respective-
ly; mean difference [90% CI] between capsaicin 30 min and 60 min
versus SOC was -1.3 [-1.8, -0.9] and -1.5 [-2.0, -1.1], respectively. Re-
garding pain severity index, the mean change from baseline to EoS was -
2.3 [1.6], -2.4 [1.8] and -0.9 [1.7] in capsaicin 30 min subset, 60 min
subset and SOC arm, respectively; mean difference between capsaicin
30 min and 60 min versus SOC was -1.4 [-1.8, -1.0] and -1.5 [-1.9, -
1.1], respectively. The mean change in pain interference index from base-
line to EoS was -2.2 [1.7], -2.5 [2.0] and -0.8 [1.9] in capsaicin 30 min
subset, 60 min subset and SOC arm, respectively; mean difference be-
tween capsaicin 30 min and 60min versus SOCwas -1.4 [-1.8, -0.9] and -
1.6 [-2.1, -1.2], respectively. With regard to PGIC at EoS, a very much
improved or much improved general state of health since study start was
reported by 22.6%, 27.7% and 9.5% of patients in the capsaicin 30 min
subset, 60 min subset and SOC arm, respectively. Compared with obser-
vations in the total capsaicin arms who received 1-7 treatments, numeri-
cally similar or larger improvements in all efficacy endpoints versus SOC
were observed following seven consecutive capsaicin treatments.
Conclusion: In patients with PDPN, seven consecutive treatments with
the capsaicin 8% patch over 52 weeks were associated with sustained and
progressively improved pain relief, reduced pain severity and pain inter-
ference indices, as well as an improved global impression of change
compared with SOC treatment.
Clinical Trial Registration Number: NCT01478607
Supported by: Astellas Pharma Europe B. V.
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Capsaicin 8% patch versus standard of care in painful diabetic
peripheral neuropathy: safety of seven consecutive treatments over
52 weeks
H. Jacobs1, S. Perrot2,3, E.J. Vinik4, L. Pazdera5, M. Stoker1, R. Snijder1,
S. Long1, M. van der Stoep1, E. Ortega6, N. Katz7,8, A.I. Vinik4;
1Astellas Pharma Europe B. V., Leiden, Netherlands, 2Hôpital Hôtel
Dieu, Paris, 3Paris Descartes University, France, 4Eastern Virginia Med-
ical School, Norfolk, USA, 5Vestra Clinics, Rychnov nad Kneznou,
Czech Republic, 6Hôpital Rio Hortega, Valladolid, Spain, 7Analgesic
Solutions, Natick, USA, 8Tufts University School of Medicine, Boston,
USA.
Background and aims: PACE was a Phase III, randomised, controlled,
open-label, 52-week, safety study that assessed the safety and efficacy of
repeat treatment with the capsaicin 8% patch plus standard of care (SOC),
versus SOC alone in painful diabetic peripheral neuropathy (PDPN). The
Norfolk QOL-DN scale was utilised to assess any patient-reported func-
tional consequences of potential small-fibre nerve dysfunction that may
be due to capsaicin treatment. Sensory testing, including the Utah Early
Neuropathy Scale (UENS), was also performed to assess capsaicin safety.
Safety results in patients who received seven consecutive capsaicin 8%
patch treatments versus SOC are presented.
Materials and methods: Patients (N=468) with painful, distal, symmet-
rical, sensorimotor diabetic polyneuropathy, glycosylated haemoglobin
≤9% and average daily pain ≥4, were randomised (1:1:1) to capsaicin
8% patch 30 min plus SOC, capsaicin 8% patch 60 min plus SOC, or
SOC alone. Capsaicin arms received 1-7 treatments with at least 8-week
intervals. The primary endpoint was percentage change from baseline to
end of study (EoS) in Norfolk QOL-DN total score. Secondary safety
endpoints were UENS score and ratings of evoked sensations (warm,
cold, sharp and vibration), plus assessment of deep-tendon reflexes.
Results: The SOC arm comprised 155 patients and seven treatments were
received by 84/156 (53.8%) and 83/157 (52.9%) patients in the capsaicin
30min and 60min arms, respectively. Baseline mean [SD] daily pain was
5.6 [1.3], 5.7 [1.4], 5.7 [1.3], and Norfolk QOL-DN total score was 41.5
[20.1], 42.4 [19.8], 41.0 [18.5], in capsaicin 30 min subset, 60 min subset
and SOC arm, respectively. The mean percentage reduction
(improvement) from baseline to EoS in Norfolk QOL-DN total score
was -31.2% [50.9], -40.5% [38.8] and -6.7% [54.1] in capsaicin 30 min
subset, 60 min subset and SOC arm, respectively. Regarding UENS total
score, the mean reduction (improvement) from baseline to EoS in capsa-
icin 30 min subset, 60 min subset and SOC arm was -2.3 [4.8], -4.1 [5.3]
and -1.2 [4.2], respectively. Ratings of evoked sensation for warm, cold
and sharp at EoS compared with baseline indicated that fewer patients
within all three treatment arms reported no sensation and a numerically
greater proportion reported slightly diminished or normal sensation by
EoS. Ratings for vibration followed a similar trend from baseline to EoS
within the capsaicin 30 min and 60 min subsets, but no noticeable chang-
es were observed within the SOC arm. There were no noticeable
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differences from baseline to EoS within all three treatment groups for
ratings of deep-tendon reflexes. All safety observations in the capsaicin
subsets were consistent with the total capsaicin arms.
Conclusion: In patients with PDPN, seven consecutive treatments with
the capsaicin 8% patch over 52 weeks were well tolerated and not asso-
ciated with any functional consequences from potential impaired small-
fibre function, or adverse sensory effects.
Clinical Trial Registration Number: NCT01478607
Supported by: Astellas Pharma Europe B. V.
PS 105 Mechanisms of diabetic
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Hyperglycaemia and hypoxia induce overexpression of GLUT1 in
models of diabetic retinopathy
S.M. Calado1,2, L.S. Alves1,3, S. Simão1, G.A. Silva1,4;
1University of Algarve, Centre for Biomedical Research, 2PhD Program
in Biomedical Sciences, 3Masters in Biomedical Sciences, Department of
Biomedical Sciences andMedicine, Faro, 4Universidade Nova de Lisboa,
CEDOC, NovaMedical School/ Faculdade de Ciências Médicas, Lisbon,
Portugal.
Background and aims: Diabetes mellitus is a group of metabolic dis-
eases characterized by high blood glucose that leads to several complica-
tions, including diabetic retinopathy (DR). DR is a blinding disease char-
acterized by retinal microvascular changes caused by chronic exposure to
hyperglycemia leading to low tissue oxygenation and ultimately to neo-
vascularization. It has been hypothesized that an increase in glucose
transporters such as GLUT1 is responsible for increased glucose levels
in retinal cells. In the retina, glucose is the only fuel source for the cells
and its cellular intake occurs exclusively through GLUT1. GLUT1 ex-
pression is also controlled by HIF-1, a key player in neovascularization.
To understand the role of GLUT1 in DR, we have characterized the
GLUT1 expression in both in vitro and in vivo models of DR.
Materials andmethods:Retinal epithelium cells (D407), subjected to
normoxia and hypoxia were cultured in DMEM with different glu-
cose concentrations, corresponding to non-diabetic (5 mM of glu-
cose) and diabetic conditions (25 mM of glucose). GLUT1 expres-
sion and localization were analyzed by Western Blot and immunoflu-
orescence. Analysis of GLUT1 in vivo was performed using retinas
of 6 month-old Ins2Akita diabetic mice by western blot and immu-
nofluorescence and compared with the retinas of age-matched non-
diabetic mice (C57Bl6 WT).
Results: Our in vitro results show an increase in GLUT1 expression
in a glucose-dependent manner, under hypoxia conditions. This in-
crease is associated to the translocation and stabilization of GLUT1
in the cell membrane, as observed by immunofluorescence. In vivo,
GLUT1 was overexpressed in the retina of Ins2Akita mice com-
pared with the non-diabetic mice. The immunofluorescence analysis
of the retina of diabetic mice shows an accumulation of GLUT1 in
the cell membrane of the innermost layers of the retina, such as the
photoreceptors’ layer, which is avascular and known to be under
hypoxic conditions in diabetic environment. As expected, this was
not observed in the retina of the WT mice, corroborating our in vitro
results.
Conclusion: In this study the expression of GLUT1was analyzed in vitro
in conditions simulating DR and in vivo in a mouse model of DR. The
results show an overexpression of GLUT1 induced by hyperglycemia and
low oxygen supply. This overexpression was associated to an increase of
GLUT1 in the cell membrane of the cells, which points to a significant
contribution of GLUT1 to the progression of DR.
Supported by: Portuguese Foundation for Science and Technology (FCT)
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High glucose-induced metabolic and structural changes in
mitochondria promote retinal Müller cell loss associated with
diabetic retinopathy
J. Zhang, D. Kim, S. Roy;
Ophthalmology and Medicine, Boston University School of Medicine,
USA.
Background and aims: Müller cells are the principal glial cells in the
retina located in the inner nuclear layer with processes extending toward
the outer limiting membrane and in the opposite direction toward the
inner limiting membrane. These processes come in frequent contact with
retinal blood vessels allowing coupling betweenMüller cells and vascular
cells necessary for cell survival and retinal vascular homeostasis. Müller
cell loss in the diabetic retina can have a profound effect on retinal dys-
function associated with diabetic retinopathy. However, it is currently
unclear how high glucose promotes Müller cell loss in diabetes. In this
study, we determined whether high glucose compromises mitochondrial
structure and function, and thereby promotes apoptosis in rat retinal Müll-
er cells (rMC-1).
Materials and methods: To determine if high glucose (HG) induces
changes to mitochondrial metabolic function, rat retinal Müller cells
(rMC-1) were grown in normal (N, 5 mM glucose) or HG (30 mM)
medium for 7 days and subjected to bioenergetic assay using the XF24
analyzer. In particular, altered mitochondrial metabolic function under
HG was assessed by measuring oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR). In parallel, differential staining
method was performed to identify cells undergoing apoptosis, and digital
images of mitochondria stained with MitoTracker Red were captured
through live cell imaging under confocal microscopy. Images were ana-
lyzed for mitochondrial morphology changes based on Form Factor (FF)
and Aspect Ratio (AR).
Results: rMC-1 grown in HG showed a significant decrease in steady
state OCR (100.5±23 vs. 155±6 pmol O2/min in normal; p<0.05) and
maximum OCR (85.5±26 vs. 171.5±16 pmol O2/min in normal; p<
0.05), compared to those in cells grown in N medium. Similarly, ECAR
was significantly decreased in cells grown under HG condition compared
to those grown in Nmedium (40±4% of normal; p<0.05). Cells grown in
HG exhibited significant increase in the number of apoptotic cells (202±
29% of control; p<0.05), and the mitochondria became fragmented and
punctate compared to the long, tubular mitochondrial networks seen in
cells grown in normal medium.
Conclusion: Findings from this study indicate that HG induces changes
to mitochondrial metabolic function by altering OCR and ECAR while
inducing mitochondrial morphology and structural changes in retinal
Müller cells. Such changes are likely contributing to retinal Müller cell
loss associated with diabetic retinopathy.
1073
Hydroquinone-damaged human retinal pigment epithelial cell
proliferation by advanced glycation end-products via up-regulation
of VEGF gene
H. Tsujinaka1, A. Itaya-Hironaka1, A. Yamauchi1, S. Sakuramoto-
Tsuchida1, H. Ota1, T. Fujimura1, R. Shobatake1, N. Ogata2, S.
Takasawa1;
1Department of Biochemistry, 2Department of Ophthalmology, Nara
Medical University, Kashihara, Japan.
Background and aims:Age-related macular degeneration (AMD) is the
important cause of irreversible blindness in elderly patients. The disease
has been classified into dry and wet forms. The dry form AMD was
defined as progressive destruction of retinal pigment epithelial (RPE)
cells. While, exudative form AMD is characterized by choroidal neovas-
cularization, which is led by some angiogenic cytokines such as vascular
endothelial growth factor (VEGF). Although recent research showed that
advanced glycation endproduct (AGE), which is accumulated by the
history of diabetes mellitus, and hydroquinone (HQ), which is generated
by the smoking, are strongly correlated to the pathogenesis of AMD, the
mechanism how AGE and HQ induce or accelerate AMD remains elu-
sive. In the study, we investigated effects of AGE on RPE cell prolifera-
tion and VEGF expression in HQ-damaged human RPE cells.
Materials and methods: ARPE-19 and h1RPE7 cells, human RPE cell
lines, were treated HQ (20-40 μM), AGEs (300 μg/ml), and HQ+AGE
for 12 h. After the treatment, viable cell numbers, apoptosis, and replica-
tive DNA synthesis was measured byWST-8 cleavage, TUNEL method,
and 5’-iodo-2’-deoxyuridine (IdU) incorporation, respectively. VEGF
mRNA was measured by real-time RT-PCR and VEGF, secreted into
culture medium, was measured by ELISA. Reporter plasmids containing
several length of VEGF promoter and mutants of potential binding sites
for SP1 (GC box) were constructed on pGL4.17 vector and introduced
them into RPE cells. After 12 h incubation with HQ and/or AGE, cells
were recovered and promoter activity was determined.
Results: The viable cell numbers of ARPE-19 and h1RPE7 were
markedly reduced by HQ (P<0.0001). The addition of AGE to the
HQ-treated cells increased cell numbers (P<0.002). HQ significant-
ly increased apoptosis (P=0.0002). AGE alone did not change ap-
optosis and the addition of HQ+AGE did not prevent the HQ-
induced apoptosis. Replicative DNA synthesis was increased by
the addition of AGE in HQ-treated cells (No addition vs HQ+
AGE, P=0.0013; HQ vs HQ+AGE, P=0.0001), indicating that
AGE increases cell number by activating HQ-treated cell replica-
tion. Real-time RT-PCR revealed that VEGF mRNA was increased
by the combined addition of HQ+AGE. The increase of VEGF in
the HQ+AGE treated cell culture medium was confirmed by ELISA
(P=0.0064 vs no addition, P=0.0433 vs HQ, P=0.0063 vs AGE).
Inhibitors for VEGF/VEGF receptor (sulochrin, Ki8751, and CBO-
P11) as well as siVEGF attenuated the HQ+AGE-induced increases
in RPE cell numbers (P<0.05). Introduction of siRNA for receptor
of AGE (RAGE) into RPE cells attenuated the HQ+AGE-induced
increase in RPE cell numbers (P=0.0175). Deletion analysis of
VEGF promoter revealed that GC boxes in the -102~-43 region
were essential for the VEGF promoter activation. Site-directed
mutaions of the GC boxes in the VEGF promoter and knockdown
experiment using SP1 siRNA revealed that SP1 is an essential tran-
scription factor for VEGF expression in RPE cells.
Conclusion: HQ induces RPE cell apoptosis and leads to dry AMD.
AGE stimulation enhancesVEGF transcription via the AGE-RAGE path-
way in HQ-damaged cells. As a result, the secreted VEGF acts as an
autocrine/paracrine growth factor for RPE and/or adjacent vascular cells,
causing wet AMD.
1074
The role of erythropoietin in physiological angiogenesis of mouse
retina
J. Lin, J. Wang, S. Wetzel, H.-P. Hammes;
University of Heidelberg, 5th Medical Department, Mannheim, Germany.
Background and aims: Diabetic retinopathy (DR) is a prevalent micro-
vascular complication and it is characterized by increased vascular per-
meability, ischemia and neovascularization. Angiogenesis is modulated
by growth factors such as vascular endothelial growth factor and
angiopoietin-2. Recently, it has been found that erythropoietin, besides
neuroprotection, has angiogenic effects and its level is highly elevated in
vitreous fluids of patients with proliferative diabetic retinopathy. Howev-
er, the role of erythropoietin in physiological angiogenesis of the retina
and its cooperation with angiopoietin 2 remains unclear. This study in-
vestigated the effects of erythropoietin on the physiological angiogenesis
of the mouse retina.
Materials and methods: C57Bl/6 wild type and angiopoietin 2 trans-
genicmice were intraperitoneally injected at postnatal days P1, P3, P5, P7
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and P9 with human recombinant erythropoietin at doses of 256 IU/kg.
Retinae at P10 were stained with isolectin B4, NG2 and Iba1 antibodies,
respectively. Angiogenic parameters of retinal vasculatures were ana-
lyzed using a Leica confocal microscope TCS SP2 system.
Results: Erythropoietin promoted the outgrowth of the deep vessels by
21% (*p<0.05) and increased pericytes recruitment in the superficial and
deep layer by 23% and by 42%, respectively (*p<0.05). The microglial
number was reduced in the superficial layer of retinal vessels (27%, *p<
0.05), but increased in the deep layer (60%, ***p<0.001).Microglia were
located in front of tip cells and acted as a bridge to connect neighboring
sprouts. Angiogenic activity was elevated in the deep layer of the retinal
vascular plexus, especially with cooperation of angiopoietin 2.
Conclusion: Erythropoietin promotes angiogenesis and the maturation of
the vascular plexus in the mouse retina.
Supported by: EFSD/Novartis
1075
Identification of pro-apoptotic markers responsible for hypoxia and
hyperglycaemia-induced pericyte apoptosis
E. Beltramo1, A.I. Arroba2, A. Mazzeo1, R. Simò3,4, M. Porta1, A.M.
Valverde2;
1Dept Medical Sciences, University of Turin, Italy, 2Instituto de
Investigaciones Biomédicas Alberto Sols, Madrid, 3Vall d'Hebron Re-
search Institute (VHIR), Universitat Autònoma de Barcelona,
4CIBERDEM, Barcelona, Spain.
Background and aims: Loss of pericytes is the key-event in the patho-
genesis of microvascular diabetic retinopathy. We have previously dem-
onstrated that human retinal pericytes (HRP) are more vulnerable to in-
termittent than stable high glucose concentrations, with an increase in
their apoptosis. Somatostatin, a well-known neuroprotective drug, may
protect retinal cells, both microvascular and neuronal, from stress condi-
tions. The aim of the present study was to investigate the effects of
hypoxia combined with high glucose on HRP and explore the expression
of molecules involved in the pro-apoptotic and survival pathways. This
research will further clarify the mechanisms of action of these diabetic-
like stress stimuli.
Materials and methods: HRP were exposed intermittently at 48 hr-
intervals to high (28 mM)/physiological (5.6 mM) glucose for 8 days
(intHG) and/or hypoxia for the last 48 hrs, with or without the addition
of somatostatin. Cell proliferation was assessed by cell counting and
BrdU incorporation, and apoptosis as DNA fragmentation (ELISA).
The expression of pro-apoptotic (FasL, pro-caspase-8, active-caspase-8,
Bid, t-Bid, Bax, calpain-2) and anti-apoptotic (PCNA, p-Akt) molecules
were evaluated by Western blot.
Results: Hypoxia, alone and combined with intHG, is able to increase
HRP apoptosis (+27 and +34%, respectively, p<0.05 vs ctrl) and de-
crease their proliferation (-28 and -31% vs ctrl, p<0.005). Pro-apoptotic
molecules (FasL, active caspase-8, t-Bid, Bax) were significantly in-
creased in HRP cultured in hypoxic conditions, both in physiological
and intHG conditions, while no significant differences, but a trend to-
wards decrease, were observed in the expression of survival markers
(PCNA, p-Akt).
Conclusion: Diabetic-like conditions (intHG and hypoxia) are able to
stimulate pericyte apoptosis through activation of pro-apoptotic mole-
cules, thus leading to an imbalance between pro-apoptotic and survival
signaling pathways. Our identification of such intermediates could help
finding new therapeutic approaches for the prevention of DR.
Supported by: EU-FP7-EUROCONDOR
1076
Decreasing diabetes-induced overexpression of lysyl oxidase prevents
development of retinal vascular lesions associated with diabetic
retinopathy
D. Kim1, S. Amin1, E. Bae1, S. Wong1, J. Zhang1, R.P. Mecham2, S.
Roy1;
1Ophthalmology and Medicine, Boston University School of Medicine,
2Cell Biology and Physiology, Washington University School of Medi-
cine, St. Louis, USA.
Background and aims: Retinal capillary basement membrane (BM)
thickening is closely associated with the development of vascular lesions
in diabetic retinopathy (DR). Thickened capillary BM has been shown to
compromise blood-retinal-barrier (BRB) characteristics and thereby con-
tribute to retinal vascular permeability, a significant clinical manifestation
of DR.We have previously shown that high glucose increases the expres-
sion and activity of lysyl oxidase (LOX), a cross-linking enzyme, in
retinal endothelial cells. Additionally, concomitant with overexpression
of LOX, increased vascular permeability was observed in streptozotocin
(STZ)-induced diabetic rat retinas. However, it is unknown whether de-
creased LOX expressionmay have beneficial effects against development
of retinal vascular lesions in diabetes.
Materials and methods: To examine whether reduced LOX expression
has protective effects against diabetes-induced development of retinal
vascular lesions characteristic of DR, four groups of mice: wild type
(WT) control mice, STZ-induced diabetic mice, LOX +/- mice, and
STZ-induced diabetic LOX +/- mice were used for this study. Diabetes
was induced via STZ andmaintained for 3 months; at the end of the study,
retinas were assessed for LOX protein level by Western Blot (WB) anal-
ysis. Retinal capillary networks were isolated from the four groups of
animals and retinal trypsin digest (RTD) was performed with
hematoxylin/periodic acid Schiff staining. Digital images of the stained
retinal capillary networks were captured to assess the number of acellular
capillaries (AC) and pericyte loss (PL). In parallel, retinal vascular per-
meability was determined in retinal whole mounts following FITC-
dextran injection.
Results:WB analysis showed significant increase in LOX expression in
the diabetic retinas (135.13±23.6% ofWT) compared to those of theWT
control retinas, and a significant decrease in LOX expression in the dia-
betic LOX +/- retinas (105.29±9.8% of WT) compared to those of the
diabetic retinas. RTD images exhibited a significant increase in the num-
ber of AC (197±52%of control; p<0.05) and PL (566±26% of control; p
<0.05) in the retinas of diabetic mice compared to those of theWTcontrol
mice. Interestingly, the number of AC and PLwas significantly decreased
in the retinas of the diabetic LOX +/- mice compared to those of the
diabetic mice (42%, p<0.05; 19%, p<0.05, respectively). Additionally,
retinal vascular permeability was decreased in the retinas of the diabetic
LOX +/- mice compared to those of the diabetic mice.
Conclusion: Findings from this study suggest that reducing diabetes-
induced LOX overexpression may have beneficial effects against the
development of retinal vascular lesions characteristic of DR. Therefore,
LOX overexpression may be a potential therapeutic target in preventing
retinal vascular cell loss and excess permeability associated with DR.
Supported by: R01-EY-14702
S518 Diabetologia (2015) 58 (Suppl 1):S1–S607
1077
Deficiency in nucleoside diphosphate kinase B aggravates the
development of diabetic retinopathy through upregulation of
angiopoietin-2 via FOXO1
Y. Qiu1, D. Zhao1, E.Y. Skolnik2, H.-P. Hammes3, T. Wieland1, Y. Feng1;
1Institute for Experimental and Clinical Pharmacology and Toxicology,
Medical Faculty Mannheim, Heidelberg University, Mannheim, Germa-
ny, 2Division of Nephrology, New York University Langone Medical
Center, New York, USA, 3Fifth Medical Department, Medical Faculty
Mannheim, Heidelberg University, Mannheim, Germany.
Background and aims:Nucleoside diphosphate kinase B (NDPKB) is a
ubiquitous enzyme required for the synthesis of nucleoside triphosphates.
It is thus involved in many cellular functions. Based on its role in endo-
thelial cells and glucose metabolism, we hypothesize that NDPKB may
play a role in diabetic retinopathy (DR).
Materials and methods: Diabetes was induced in NDPKB knockout
(KO) and wild type (WT) mice with streptozotocin. Pericyte (PC) cover-
age and acellular capillary (AC) formation were evaluated in the retina
6 month after diabetes induction. The expression of angiopopietin-2
(Ang2) and forkhead box protein O1 (FOXO1) was assessed by western
blotting and/or immunofluorescence staining in the diabetic retinas
in vivo, and in NDPKB knockdown human umbilical vein endothelial
cells (HUVEC) as well as in Müller cells isolated from NDPKB KO
retinas and stimulated with high glucose (HG) in vitro. The knockdown
of NDPKB and FOXO1 was performed by transfection with specific
siRNAs.
Results: The number of PCs in the non-diabetic (NC) NDPKB KO ret-
inas (1542/mm2 capillary area) was significantly decreased compared to
WT NC retinas (1741/mm2 capillary area, P<0.01) and similar to diabet-
ic (DC) WT retinas (1586/mm2 capillary area, p<0.05 vs. WT NC).
Diabetic conditions further decreased PC number in NDPKB KO retinas
(1400/mm2 capillary area) comparedwith KONC andWTDC (p<0.05).
Additionally, diabetes significantly enhanced the formation of AC inWT
retinas (DC: 34/mm2 retinal area, NC: 25/mm2 retinal area, p<0.05). The
number of AC in NDPKB KO NC retinas (28/mm2 retinal area) was
similar to WT NC retinas. However, NDPKB KO DC retinas displayed
a significant enhancement in AC formation (44/mm2 retinal area) com-
pared with WT DC retinas and KO NC retinas (p<0.05). Concerning the
essential role of Ang2 in pericyte loss in diabetic retinopathy, we deter-
mined the Ang2 levels in the NDPKB KO retinas. Compared to WT NC
retinas, the expression pf Ang2 was significantly upregulated in NDPKB
KO NC retinas (p<0.05 vs. WT NC) and to a similar extent in WT DC
retinas (p<0.05 vs. WT NC). No difference in Ang2 expression was
detected between NDPKB KO DC and NDPKB KO NC retinas. Endo-
thelial and Müller cells are the main source of Ang2 in the retina. As
shown by western blotting and immunofluorescence in HUVEC as well
as in Müller cells, HG and NDPKB depletion similarly increased Ang2
expression, which was paralleled by enhanced FOXO1 levels and activ-
ity. Conversely, Ang2 expression was dramatically suppressed in the
NDPKB- and FOXO1- double depleted HUVEC.
Conclusion: Our data indicate that NDPKB deficiency aggravates the
development of diabetic retinopathy through an upregulation of Ang2
in endothelial and Müller cells. The NDPKB-dependent expression and
activity of the transcription factor FOXO1 likely regulates Ang2 levels.
Supported by: EFSD/Novartis, DFG (GRK1874)
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Mechanism of action of calcium dobesilate in the early stages of
diabetic retinopathy
C. Sola-Adell1,2, P. Bogdanov1,2, L. Corraliza1,2, C. Hernandez1,2, S.
Ballarini3, C. Pasquali3, R. Simo1,2;
1Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de
Recerca, 2Centro de Investigacion Biomedica en Red de Diabetes y
Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain,
3Vifor Pharma/OM Pharma, Geneva, Switzerland.
Background and aims: Calcium Dobesilate (CaD) has been prescribed
to prevent the progression of diabetic retinopathy (DR). However, its
clinical efficacy is still a matter of controversy. Recently, it has been
reported that administration of the CaD in patients with DR may reduce
the serum levels of endothelin-1 (ET-1). It should be noted that ET-1, a
potent vasoconstrictor, is involved in the development of DR and also
contributes to retinal neurodegeneration. The aim of the present study was
to determine the effect of CaD in preventing retinal neurodegeneration
and early microvascular abnormalities induced by diabetes in a murine
model (db/db mouse). In addition, the effect of CaD on ET-1 and its
receptors were also assessed.
Materials and methods: For this purpose we evaluated a total of 24
diabetic mice (db/db) aged 8 weeks that were randomly assigned to daily
oral treatment with CaD (200 mg/kg/day) (n=12) or vehicle (n=12) for
two weeks. Twelve non-diabetic mice (db/+) were used as control group.
Retinal neurodegeneration was evaluated by measuring glial activation
(GFAP immunofluorescence) and apoptosis (TUNEL, cell count in gan-
glion cell layer). Glutamate excitotoxicity, ET-1 pathway and VEGF ex-
pression were assessed by immunohistochemistry and Western blotting
analysis. Functional retinal abnormalities were measured by focal elec-
troretinography (fERG). Statistical analysis was performed by unpaired t-
student test and results were expressed as mean±SEM.
Results: In summary, we found that CaD significantly decreases the main
hallmarks of retinal neurodegeneration (glial activation and apoptosis). In
addition, a significant improvement of ERG parameters was observed.
CaD also reduces glutamate excitotoxicity induced by diabetes. Further-
more, CaD prevented the up-regulation of ET-1 and its cognate receptors
in diabetic retinas. Finally, we have found that CaD treatment reduces the
expression of VEGF and preserves the sealing function of the blood
retinal barrier (BRB).
Conclusion: Our results suggest that CaD treatment could be effective in
preventing neurodegeneration and microvascular abnormalities (disrup-
tion of BRB) in early DR. Better understanding of the mode of action of
CaD could be important to guide physicians in targeting the treatment
more appropriately.
Supported by: SAF2012-3556 and BES-2013-064944 and Vifor Pharma/
OM Pharma
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Prevalence and progression of diabetic retinopathy in people with
type 2 diabetes dependent on the duration of diabetes
M. Voigt1, S. Schmidt1, N. Müller1, B. Milke1, U.A. Voigt2, G. Wolf3,
U.A. Müller1;
1Endocrinology and Metabolic Diseases, Internal Medicine III, 2Dept. of
Ophthalmology, 3InternalMedicine III, Jena University Hospital, Germany.
Background and aims:At present the guideline for diabetic retinopathy
of the DDG (German diabetes association) and the NVL (national guide-
line for diabetic eye disease) recommend annual screening of patients
with type 2 diabetes and no prior retinopathy. It is because the onset of
diabetes complications under good glycaemic control is a matter of years
that this practice presumably leads to frequent superfluous examinations.
The aim of our investigation was to examine the prevalence of retinopa-
thy dependent on the diabetes duration in order to assess the probability of
the disease progressing.
Materials and methods: In a retrospective database analysis from a
university outpatient department for endocrinology and metabolic dis-
eases we analyzed 17461 consultations of 4513 patients with type 2
diabetes (age 64,5 years, duration of diabetes 12,8 years, BMI 31,4 kg/
m2, HbA1c DCCT adjusted 7,4% / 51,9 mmol/mol, blood pressure 146/
82 mmHg, 50,3% women). The obtained data included clinical evidence
from 1987 to 2014. 50,5% of the patients (n=2279) had at least one
documented result of fundoscopy and were enclosed in the analysis
(age 65,4 years, duration of diabetes 14,9 years, BMI 31,6 kg/m2, HbA1c
DCCT adjusted 7,25% / 52,2 mmol/mol, blood pressure 145/80 mmHg,
47,3% women).
Results: 25,8% of the patients had retinopathy (20,2% non-proliferative,
4,7% proliferative, 0,7% were not classified, 0,1% blindness). The prev-
alence of retinopathy dependent on the duration of diabetes was 1,1% at
diagnosis, 6,6% after 0<5 years, 12% after 5<10 years, 24% after 10<
15 years, 39,9% after 15<20 years, 52,7% after 20<25 years, 58,7% after
25<30 years and 63% after ≥30 years. From 586 (25,7%) patients retinal
photography of three consecutive years could be obtained and evaluated.
Out of these 7,3% showed deterioration after one year and 13% after two
years. On the other hand 3,4% improved after one year and 3,6% after
two years. 201 (34,3%) of these patients had less than 10 years diabetes
and showed an even lower tendency of deterioration (4,5% worsened
after one and 9,5% after two years). Notably these patients mainly trans-
formed from no retinopathy at all to non-proliferative retinopathy. Only
four patients (2%) developed a proliferative retinopathy within this
period.
Conclusion:The prevalence of the diabetic retinopathy increases with the
duration of diabetes. Within the first ten years of diabetes the prevalence
of retinopathy is low and the progression of the disease infrequent. Most
patients have a non-proliferative form which can be reversible and re-
quires no intervention in most cases. In patients with type 2 diabetes and
no prior retinopathy as well as good glycaemic control, intervals of fun-
doscopy could be widened from annual to two yearly screenings within
the first five years of diabetes duration given that an initial examination of
the eyes has been obtained.
1080
Lipoprotein(a) predicts development of diabetic retinopathy in
patients with type 2 diabetes mellitus
Y.-B. Ahn1, T.-S. Lim1, J.-S. Yun1, S.-A. Cha1, H. Seok2, S.-D. Moon3,
S.-H. Ko1;
1Internal Medicine, The Catholic University of Korea, Suwon, 2Internal
Medicine, The Catholic University of Korea, Uijeongbu, 3Internal Med-
icine, The Catholic University of Korea, Incheon, Republic of Korea.
Background and aims:We investigated factors that might influence the
development of diabetic retinopathy (DR) in patients with type 2 diabetes.
Materials and methods: From January 2003 to December 2004, a total
of 767 patients with type 2 diabetes without diabetic retinopathy were
consecutively enrolled. The serum lipoprotein(a) [Lp(a)] concentration
was measured by a one-step sandwich enzyme-linked immunoassay,
and a standardized clinical examination and retinal photographs were
checked annually by opthalmologist. We used a Cox proportional hazard
regression analysis to test the associations between diabetic retinopathy
and Lp(a).
Results:Of the 765 patients who were enrolled in this study, 483 (63.1%)
completed the follow-up evaluation. The median follow-up time was
10.3 years. The mean age was 53.9±10.6 years, and the duration of
diabetes was 6.4±5.6 years. During the follow-up period, 225 patients
(46.6%) developed DR. The patients in the DR group had a longer dura-
tion of diabetes (p<0.001), higher baseline HbA1C levels (p<0.001),
received more insulin treatment (p<0.001) and a higher level of Lp(a)
(12.6 [Interquartile range 7.9-24.0] vs 15.2 [9.2-29.7] mg/dl; p=0.010). A
Cox hazard regression analysis revealed that the development of DR was
significantly associated with the high level of serum Lp(a) level (hazard
ratio 1.13; 95% CI 1.03-1.24; p=0.008) per 10 mg/dl Lp(a) increase after
adjusting for sex, age, diabetic duration, mean HbA1c, treatment of insu-
lin, ACE inhibitor/angiotensin receptor blocker and lipid lowering agents.
Conclusion: The development of DR was independently associated with
serum Lp(a) level in patients with type 2 diabetes.
1081
Cognitive function may be a predictor of retinopathy progression in
patients with type 2 diabetes
L. Borio1, M. Salassa1, A. Baltatescu2, V. Paganin1, P. Passera1, L.
Charrier3, F. Cavallo3, M. Porta2, M. Trento1;
1Medical Sciences, Laboratory of Clinical Pedagogy, 2Medical Sciences,
Center of Diabetic Retinopathy, 3Public Health and Pediatric Sciences,
University of Turin, Italy.
Background and aims: Cognitive function,depression and anxiety may
be associated with type 2 diabetes(T2DM) and its complications. In par-
ticular diabetic retinopathy (DR) is a complication that affects peoplewith
diabetes.
In an observational prospective study of a cohort of T2DM patients
followed for 8 years,we monitored a number of clinical, psychological
and cognitive variables to identify possible predictors of progression of
DR.
Materials andmethods: Patients (n=498) with T2DM, of which 249 not
treated by insulin (NIT) and 249 on insulin treatment (IT), were enrolled
at baseline. The following variables were recorded: age, gender, diabetes
duration, schooling, occupation, social status, smoking, self-monitoring
of blood glucose, hypertension, menopausal status, fasting blood glucose,
HbA1c, BMI, total and HDL cholesterol, triglyceride, retinopathy grad-
ing, presence of foot ulcers, depression and anxiety scores (Zung ques-
tionnaire) and cognitive function (Minimal Mental State Examination,
MMSE). The same variables were collected again after 4 (JEI 37,79-85,
2014) and 8 years. DR assessment was by grading of digital 45° photo-
graphs of the macular and nasal areas. Grading of the worst eye was
considered.
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Results:Out of 477 patients for whom fundus evaluationwas available at
baseline, 240 (160 ITand 80NIT) had noDR, 110 (48NITand 62 IT) had
mild non proliferative DR and 127 (24 NIT and 103 IT) had moderate or
more severe DR.After 8 years, 357 patients were available for analysis, of
whom 191 had remained with no or mild DR and 166 had developed
moderate or more severe DR. Patients who had moderate or more severe
DR at baseline were not included in the follow-up analysis. On multivar-
iate analysis, being on insulin treatment (OR 1.90, 95%CI 1.02;3.55, p=
0.043) and having mild vs no DR at baseline (OR 4.51, 2.44;8.31, p<
0.0001)were associated with progression to moderate/more severe DR,
whereas male gender (OR 0.49, 0.26;0.92, p=0.028) and a higherMMSE
score (indicative of better cognitive ability) (OR 0.90 per scoring point;
0.83;0.99, p=0.026) were protective. None of the other baseline variables
was associated with progression of DR in this cohort.
Conclusion: Lower MMSE score may represent a novel risk factor for
progression of DR, on top of other known determinants. Microangiopa-
thy might develop at both brain and retinal level and manifest itself with
changes in cognitive function and retinopathy.
Supported by: Ricerca Sanitaria Finalizzata Regione Piemonte
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Evaluation of medically treatable risk factors in subjects with
significant diabetic retinopathy from a local health economy area in
the UK
W.J. Fusi-Rubiano1, G. Ramsamy1, S. Gillani1, A. Bhatnagar2, B.
Singh1, R. Raghavan1;
1Diabetes, 2Ophthalmology, New Cross Hospital, Wolverhampton, UK.
Background and aims: Diabetic retinopathy is the leading cause of
blindness in people of working age in the western world. People with
high risk retinopathy are also at risk of other diabetes and vascular com-
plications. The aim of this study was to categorize and evaluate people
with high risk diabetic retinopathy within our local health economy. We
aimed to assess HbA1c and four other key risk factors in this group to
develop an understanding of the current provision of care.
Materials andmethods: People with high-risk diabetic retinopathy (DR)
were identified from our local health economy centralized electronic di-
abetes register and ophthalmic laser register. All known subjects with
either currently active or previously treated significant diabetic retinopa-
thy were included. People who were out of area or who had laser treat-
ment for non-diabetic reasons were excluded. Prevalence was ascertained
for each stage of DR. Data was derived from local IT systems for HbA1c
and four other important medically manageable risk factors- Blood pres-
sure (BP), Creatinine, albumin/creatinine ratio (ACR) and cholesterol.
These were then classified into good or poor control in accordance with
internationally recognized standards such as BHS and NICE. Glycaemic
control was assessed according to HbA1c (%) categories as denoted:
HbA1c<7=A; 7.0-8.5=B; 8.5-10=C; HbA1c>10=D. Number of risk
factors not controlled were then assessed and analyzed for different
grades of retinopathy and correlated against HbA1c and other risk factors.
Results: Of 16,693 people with diabetes, 1440 (8.6%) were identi-
fied to have high-risk current or previously treated diabetic retinop-
athy (age range 20-94). 32 subjects were excluded from analysis due
to incomplete dataset. Mean age was 63.2±14.6 and M:F ratio 1.5:1
(F=571). 1095 (78%) subjects had type 2 diabetes. 868 subjects
(61.6%) were insulin treated. Breakdown of retinopathy grading:
R1 940 (67%), R2 231 (16%), R3 239 (17%); M1 952 (67.6%).
HbA1c categories: A=529 (38%), B=317 (23%), C=330 (23%),
D=234 (16%). BP of <140/80 mm Hg was achieved in 922 (65%)
and Cholesterol of <4 mmol/l in 570 (40%). Diabetic Nephropathy
(microalbuminuria and Creatinine>120) was seen in 392 (27%). All
risk factors were controlled in 60 females (4.2%) and 64 males
(4.5%). 845 (60%) subjects had 2 or more risk factors uncontrolled.
For subjects with HbA1c categories A,B,C positive correlation found
between proportion of people with R3 and increase in number of
risk factors above defined threshold. Significant positive correlation
(p=<0.01) was also found between retinal score and HbA1c and
ACR on individual variate analysis.
Conclusion: Available retinopathy grades and risk factor data suggests
that this group of high risk individuals have accessed local healthcare
services within the recent past in the majority of cases (>97%). Despite
this over one third of subjects with significant diabetic retinopathy had
poor or very poor glucose control & suboptimal blood pressure control.
Nearly two thirds of these subjects had 2 or more risk factors which were
above a significant threshold. A correlation between degree of retinopa-
thy and HbA1c and ACR underlines the significance of managing micro-
vascular risk factors in this cohort. Overall this study suggests that it is the
service element that needs to be addressed in this group to target data
driven care & improve outcomes.
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Multiparametric in-vivo imaging in degenerative retinopathy
M. Kolibabka1, Y. Feng1,2, S. Hoffmann3, N. Gretz3, H.-P. Hammes1;
15th Medical Department, 2Institute of Experimental and Clinical Phar-
macology and Toxicology, 3Medical Research Center, Medical Faculty
Mannheim, University of Heidelberg, Mannheim, Germany.
Background and aims: The transgenic polycystic-kidney-disease rat
(PKD) develops neurodegeneration and subsequent vasoregression mor-
phologically similar to diabetic retinopathy. The neurodegeneration over
time has already been characterized using different parameters that are the
in-vivo measurements of electroretinograms and the ex-vivo quantified
retinal thickness histologically measured in retinal sections. In this study
we analyzed the timecourse of the neurodegeneration with a multi-
parametric in-vivo imaging device to establish a method allowing us to
monitor structural and functional changes over time and to identify spe-
cific sets of markers suitable to define the outcome of possible
therapeutics.
Materials and methods: PKD rats were analyzed at different timepoints
(1, 2, 3, 5, 7 and 12months of age) matching our previously published ex-
vivo results. Age matched Sprague Dawley (SD) rats served as controls.
All measurements were performed using the RETImap multi-parametric
imaging device. Retinal thickness was measured with the optical coher-
ence tomography (OCT) module quantifying the thickness in five loca-
tions at the border of the central and peripheral retina equivalent to the
area measured histologically. For the determination of the retinal function
the multifocal electroretinography (mfERG) module with a seven frame
focal algorithm centered on the optic nerve head was used. The groups
were compared to each other and the retinal thickness was compared to
our already published histological analysis.
Results: The in-vivo analysis showed a similar timecourse of disease
progression as the histological data with a significantly decreased retinal
thickness from one month on in PKD rats compared to SD rats (p<
0.001). Comparing the OCT-data to the histological data we achieve a
Pearson Correlation Coefficient of R2=0.97 for SD and R2=0.87 for
PKD rats (both p<0.05). For the retinal function the A-wave amplitude,
reflecting the function of photoreceptors, revealed no significant differ-
ence between SD and PKD, the B-wave amplitude, reflecting the function
of interneurons but also of glial cells, is decreased from two months on in
PKD (p<0.01). In order to identify a functional parameter reflecting also
the structural changes, we correlated them with the OCT-data showing a
Pearson Correlation Coefficient for the B-wave amplitude of R2=0.88 in
SD and R2=0.83 in PKD rats (both p<0.05).
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Conclusion: In this study we demonstrate the suitability of the multi-
parametric in-vivo imaging device RETImap to detect andmonitor retinal
pathological changes affecting structure and neuroretinal function. By
using this device it is possible to check the outcome of therapeutic inter-
ventions and to dramatically reduce the number of animals needed to
perform this kind of studies. We also are able to show that the B-wave
amplitude measured by mfERG is the most suitable parameter to deter-
mine early changes in neuroretinal function as it adequately takes the
structural changes into account. This again suggests an impact of Müller
cell function on the development of degenerative retinopathies.
Supported by: DFG
1084
Genome-wide association study of severe diabetic retinopathy in type
1 diabetes
N. Vuori1,2, N. Sandholm1,2, I. Toppila1,2, K. Hietala3,1, C. Forsblom1,2,
P. Summanen3, P.-H. Groop1,2;
1Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki,
2Abdominal Center Nephrology, University of Helsinki and Helsinki
University Hospital, 3Department of Ophthalmology, Helsinki University
Central Hospital, Finland.
Background and aims: The aim of the study is to find genetic risk
factors for severe diabetic retinopathy (SDR) in type 1 diabetes with
genome-wide association studies (GWAS) in the Finnish Diabetic Ne-
phropathy (FinnDiane) Study. We also estimated the heritability of SDR.
Materials andmethods:The patient population in the FinnDiane GWAS
consisted of 1518 cases with SDR and 1622 controls without SDR. Type
1 diabetes was defined as being diagnosed <39 years of age and insulin
treatment started within 1 year of diagnosis or if not available, a basal C-
peptide level ≤0.2 pmol/ml. Patients were not excluded based on duration
of diabetes. SDR was defined at baseline visit as presence of severe non-
proliferative diabetic retinopathy or worse in ophthalmic exam/fundus
photography or a history of scatter laser treatment (panretinal photocoag-
ulation). This is equivalent to an ETDRS-score of 50 or worse in
FinnDiane. Participants with mild or no retinopathy were considered as
controls (ETDRS-score 45 or lower). The GWAS in FinnDiane was ge-
notyped using Illumina 610Quad chip and SNP imputation was per-
formed with HapMap II CEU reference population. The GWAS was
performed using multiple logistic regression model with SDR status as
the dependent variable and allele dosage as the independent variable
(PLINK). Covariates in the analysis included age, gender, HbA1c mea-
sured at baseline, diabetes duration, and quadratic transformation of du-
ration (duration2) all of which were significantly associated with retinop-
athy. The heritability estimation of SDR was calculated using GCTA
(Genome-wide Complex Trait Analysis) with and without the covariates.
A prevalence of 30% was used and samples with estimated relatedness of
0.025 or higher were excluded.
Results: 14 SNPs showed a p-value of <10-5. The lowest p-value for SDR
was found for a SNP on chromosome 1p13.3 with an odds ratio of 0.72
(95% confidence interval 0.707-0.819) and a p-value of 1.1×10-6 on
AKNAD1 gene. The results from the heritability estimation show herita-
bility of SDR of <1% (heritability: 1×10-6, standard error (S.E.) =0.130,
p=0.5) without covariates. However, when including covariates (age,
sex, HbA1c, duration, duration
2) the heritability was estimated to 18%
(S.E. =0.158, p=0.119).
Conclusion: Although no locus reached genome-wide significance, our
finding show suggestive evidence of an association on chr1 to SDR in
patients with type 1 diabetes. The heritability of SDR in our study is
~18% when the major covariates such as age, sex, HbA1c, duration and
duration2 are considered.
Supported by: Folkhälsan Research Foundation, Stockmann Foundation,
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Implication of genetic loci identified in genome-wide association
studies of diabetic retinopathy in Chinese patients with
type 2 diabetes
C.Y.Y. Cheung1, E.Y.L. Hui1, K.H.M. Kwok1, Y.C. Woo1, P.C.H. Lee1,
W.S. Chow1, C.H.Y. Fong1, M.M.A. Yuen1, R.L.C. Wong1, A. Xu1,2,
D.S.H. Wong3,2, P.C. Sham4,5, K.S.L. Lam1,2;
1Department of Medicine, The University of Hong Kong, 2Research
Centre of Heart, Brain, Hormone and Healthy Aging, HKU, Hong Kong,
3Department of Ophthalmology, 4Department of Psychiatry, The Univer-
sity of Hong Kong, 5Centre for Genomic Sciences, HKU, Hong Kong,
China.
Background and aims: Diabetic retinopathy (DR), a leading cause of
blindness, is the most common microvascular complication of type 2 dia-
betes (T2DM). Recent genome-wide association studies (GWAS) had iden-
tified novel DR-susceptibility genetic loci in various populations. If validat-
ed, these genetic markers may be utilised for risk profiling of DR in patients
with diabetes and facilitate their early diagnosis. This study aimed to ex-
amine the association of the newly identified DR-associated single nucleo-
tide polymorphisms (SNPs) with severe DR in Chinese T2DM patients.
Materials and methods: We conducted a cross-sectional case-control
study on sight-threatening DR (STDR) based on Chinese subjects of
the Hong Kong West Diabetes Registry. STDR cases were T2DM pa-
tients with either proliferative DR (PDR) or pre-PDR, or clinically signif-
icant macular oedema, or with photo-coagulation (with laser photocoag-
ulation marks). Non-STDR controls were T2DM patients with no reti-
nopathy. The grading of retinopathy was based on 2-field fundal photo-
graphs, according to the United KingdomNational Screening Committee
(NSC) classification. A total of 36 SNPs showing top association signals
with DR in previous GWAS were genotyped in 567 STDR cases, includ-
ing 309 subjects with PDR, and 1490 non-STDR controls. Multiple lo-
gistic regression models with adjustment for confounding factors, includ-
ing age, gender, duration of diabetes, and presence of hypertension, were
employed.
Results: The strongest association was found at rs2115386, an intronic
SNP in the insulin receptor gene INSR : adjusted P=9.13×10-4
(OR[95%CI]: 1.28[1.11-1.48]) for STDR, and adjusted P=1.12×10-4
(OR: 1.44[1.20-1.74]) for PDR. rs599019 located downstream of
COLEC12 (adjusted P=0.019; OR: 1.19[1.03-1.38]) and rs4462262 lo-
cated at an intergenic region between ZWINT and MRPS35P3 (adjusted
P=0.041; OR: 1.38[1.01-1.89]) were also found to be significantly asso-
ciated with STDR, but not with PDR alone. On the other hand,
rs10199521 (MYT1L-LOC729897; adjusted P=0.022; OR: 1.25[1.03-
1.51]), and rs899036 (API5; adjusted P=0.049; OR: 1.36[1.00-1.85])
showed significant independent associations only with PDR. Similar re-
sults were obtained when glycated hemoglobin (HbA1c) was also includ-
ed in the adjustment models. The combined genetic risk score constructed
of the significant SNPs showed an OR of 1.24 (adjusted P=1.20×10-5)
and 1.35 (adjusted P=2.00×10-6) for each additional risk allele with
STDR and PDR, respectively, in the combined genetic risk analyses.
Conclusion:We have successfully confirmed the significant independent
associations of several SNPs identified in previous GWAS with severe
DR (STDR and/or PDR) in our Chinese T2DM patients. Their highly
significant combined genetic risk scores suggest potential applications in
risk stratification for enhanced DR screening. Our findings on rs2115386
of the insulin receptor gene INSR are supportive of the role of insulin
resistance, or the compensatory hyperinsulinaemia, in the pathogenesis of
DR.
Supported by: Seed Funding Programme for Basic Research grant of
HKU
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Hyperglycaemia down-regulates levels ofmiR-126 in endothelial cells
R. Sanguineti1, A. Puddu1, C.E. Traverso2, M. Nicolò2, G.L. Viviani1;
1Department of Internal Medicine and Medical Specialites, 2Department
of Neuroscience, Ophthalmology and Genetics, University of Genova,
Italy.
Background and aims:MicroRNAs have been implicated in the epige-
netic regulation of key pathways in many diseases including type 2 dia-
betes (DM). miR-126, a microRNA expressed in endothelial cells, regu-
lates expression of genes involved in neovascularization and vascular
permeability, including Vascular Endothelial Growth Factor-A (VEGF-
A) and hypoxia-inducible factor-1α (HIF-1α). VEGF-A has a pathologic
role in microvascular diabetic complication, such as Diabetic retinopathy
(DR) and diabetic macular edema (DME) which are the leading causes of
blindness in the working-age population. Since levels of miR-126 are
significantly lower in T2DM patients than in healthy controls, the aim
of this study is to investigate whether hyperglycemia affects expression of
miR-126 in a model in vitro of blood retinal barrier.
Materials and methods:We used commercially available human retinal
pigment epithelial cells (ARPE-19) and endothelial cells (HECV). HECV
cells were seeded in transwell inserts, let adhere for 24 hours and then co-
cultured for 24 hours with ARPE-19 cells in DMEM normal glucose
(5.5 mmol/Ll; CTR) or DMEM high glucose (25 mmol/L; HG) supple-
mented with 10% FBS. Total RNAwas extracted from HECV cells and
levels of miR-126 were detected using quantitative real-time PCR. Then
mRNA expression of the miR-126 targets VEGF-A and HIF-1α was
evaluated by quantitative real-time PCR. Another set of cells was lysed
in RIPA buffer and HIF-1α protein expression was evaluated byWestern
blot.
Results: Levels of miR-126 were strongly decreased in HECV cells
cultured with HG compare to CTR (-62.5%±10.61%, p<0.001 vs
CTR). Lowered levels of miR-126 in HG condition are associated with
increased mRNA expression of VEGF-A and HIF-1α (respectively +
30%±11.79%, p<0.05 vs CTR; and +33.3%±10.26%, p<0.01 vs
CTR). In addition HIF-1α protein levels was up-regulated in HECV cells
cultured under hyperglycemic condition (+51.7%±8.622%, p<0.001 vs
CTR).
Conclusion: Here we show evidence that hyperglycemia directly lowers
levels of miR-126 in endothelial cells. These results suggest that HG
enhanced VEGF-A and HIF-1α mRNA expression by down-regulating
miR-126. Furthermore the increased expression of VEGF-A induced by
HG may be due to the synergic effect of miR-126 down-regulation and
HIF-1α protein stabilization. These findings suggest that hyperglycemia
may contribute to microvascular complication of diabetes by impairing
levels of miR-126.
Supported by: Novartis Farma S.p.A.
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miR-126 is downregulated in pericytes following exposure to
mesenchymal stem cell-derived extracellular vesicles
obtained in diabetic-like conditions
A. Mazzeo, E. Beltramo, A. Iavello, S. Grimaldi, A. Carpanetto, M.
Porta;
Dept of Medical Sciences, University of Turin, Italy.
Background and aims: Loss of pericytes in the early phases of diabetic
retinopathy (DR) may disrupt their stable association with endothelial
cells (EC), leading to EC proliferation and, eventually, angiogenesis.
We have recently shown that extracellular vesicles (EV) derived from
mesenchymal stem cells (MSC) in diabetic-like conditions may play a
role in vessel destabilization by interfering with the strict EC/pericyte/
extracellular matrix interactions. Thus they might contribute to angiogen-
esis through paracrine signalling; in particular, a role forMMP-2 has been
described. MicroRNAs (miR) are short RNA sequences acting as gene
modulators and playing important roles in angiogenesis and inflamma-
tion. MiR-126 is secreted mostly by the endothelium and controls vascu-
lar integrity and regeneration after injury. A down-regulation of miR-126
was observed in experimental models of DR, in diabetic retina extracts
and in chorioretinal EC in hypoxic conditions, correlating with an in-
crease in VEGF and MMP. Our aim in this study was therefore to inves-
tigate miR-126 expression in pericytes and the possible influence of EV
derived by MSC cultured in diabetic-like conditions.
Materials and methods: Pericytes (HRP) were cultured in physiological
(NG), stable high (HG) and intermittent high (intHG) glucose conditions
for 8 days. In other experiments, EV were extracted from the supernatant
of MSC cultured in hypoxic (hypo) and/or HG conditions and added to
HRP cultured in NG for 6, 24 and 48 hrs. Real-Time PCR for miR-126
was performed on RNA extracts.
Results:HRP express miR-126 and this expression is down-regulated by
20% in intHG. miR-126 expression is not significantly modified by 6 and
24 hr exposure of HRP to EV. After 48 hrs, miR-126 is up-regulated by
exposure to NG-EV (+62% vs ctrl). HG-EV and NG-hypo-EV do not
influence significantly miR-126 expression, while EVobtained by MSC
cultured in HG + hypoxia (HG-hypo) down-regulate miR-126 (-41% vs
ctrl and -64% vs NG-EV, p<0.05).
Conclusion: We show for the first time in our knowledge that HRP
express miR-126 and that its expression is down-regulated in diabetic-
like conditions. Moreover, exposure of HRP to EVobtained in diabetic
conditions is able to decrease miR-126 expression, consistently with pre-
vious observations of its involvement in DR and providing further in-
sights for our findings of EV contribution to vessel destabilization.
Supported by: EFSD/Novartis
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Retinopathy in children with diabetes: When should they be
screened?
I.M. Stratton, S.J. Aldington, P.H. Scanlon;
Gloucestershire Diabetic Retinopathy Research Group, Gloucestershire
Hospitals, Cheltenham, UK.
Background and aims: Current advice in the UK is to commence
screening for diabetic retinopathy with digital retinal photography at
twelve years of age. Here we report on the relationships between age at
diagnosis of diabetes, age at diabetic eye screening and severity of Dia-
betic Retinopathy (DR) in children aged 12 or 13.
Materials and methods: Data were extracted from 6 UK screening
programmes. Time from diagnosis of diabetes to first screening and age
at diagnosis were calculated.
Results: Data were available for 2125 children screened for the first time
at age 12 or 13 and diagnosed with diabetes before the age of 13. The
proportion with any retinopathy decreased monotonically from 20% in
those diagnosed at age of 2 years or below to 8% in those diagnosed at 12
(p<0.0001). The proportion with mild non-proliferative retinopathy in
both eyes decreased from 11% in those diagnosed at 2 or below and
2% those diagnosed at 12. Only 3 children (aged 8, 10 and 11 respectively
at time of diagnosis of diabetes) had images graded with referable reti-
nopathy and of these 2 had non-referable DR at all subsequent screenings.
Of 1703 children with subsequent images 25 were graded with referable
DR over a mean follow-up of 3 years, incidence rate of 5 per 1,000 per
year. Those with longer duration of diabetes at age 12 were at higher risk
of progression to referable DR with hazard ratio of 1.3 per year (95% CI
1.18 to 1.50)
Conclusion:Although the rate of retinopathy in children below the age of
13 at first screening in the UK is significantly higher in those diagnosed
with diabetes in early childhood, the rate is low and few children progress
to referable DR. In this large cohort there is no evidence to suggest that
earlier screening or more frequent screening is needed in this age group.
1089
Automated screening of diabetic retinopathy is safe and effective: a
large-scale study on 55,074 diabetic patients
K.M. Solanki, M. Bhaskaranand, S.K. Bhat, C. Ramachandra;
Eyenuk, Inc., Woodland Hills, USA.
Background and aims:Diabetic retinopathy (DR) is the leading cause of
new-onset blindness in working-age adults in the industrialized world
today. Fully-automated screening solutions are indispensable to screen
the large and ever-increasing number of diabetic patients for preventable
vision loss due to DR. EyeArt is a computerized, high diagnostic efficacy,
cloud-based DR screening system that can screen thousands of patient
images in just a few hours and thus enables seamless, large-scale screen-
ing deployment to aid triage of DR patients in most need of eye-care. The
aim of this study is to validate EyeArt for detecting referable DR defined
to be moderate non-proliferative DR (NPDR) or higher on the Interna-
tional Clinical Diabetic Retinopathy (ICDR) severity scale and assess its
ability to reduce the workload of retina experts.
Materials and methods: A total of 440,072 color retinal fundus images
of 55,074 diabetic patient visits or encounters were obtained from the
EyePACS database without any patient identification data. Each of these
encounters had 2-24 images including external lens-shots. These
deidentified images were captured between April 2006 and December
2013 at various DR screening centers that use the EyePACS professional
image grading services. The DR severity on the ICDR scale provided by
human graders at EyePACS were also made available and considered to
be the gold standard. The images were analyzed by EyeArt. External lens-
shots and images of inadequate quality that were ungradable due to fac-
tors like poor focus or poor illumination were automatically flagged by
the EyeArt system and were not further analyzed for detecting referable
DR. A “refer” recommendation was provided for patients with apparent
signs of moderate NPDR or higher on the ICDR scale and a “no refer”
recommendation was provided for patients with no apparent signs of DR
or signs of mild DR. EyeArt’s referral recommendation performance was
evaluated by using sensitivity, specificity, and area under the receiver
operating characteristic curve (AUROC).
Results: Among the 55,074 encounters, prevalence of encounters with
moderate NPDR or higher was 14.7% and prevalence of encounters with
potentially treatable DR (severe NPDR or proliferative DR) was 3.5%.
EyeArt’s screening sensitivity was 90% (95% CI: 89.3% - 90.6%) and
specificity was 47.5% (95% CI: 47.1% - 48.0%). This corresponds to 31,
926 “refer” recommendations and 809 false negatives out of which 766 did
not meet the general treatment criteria (i.e. had moderate NPDR). The
AUROC was 0.847 (95% CI: 0.842 - 0.852). EyeArt’s sensitivity for de-
tecting potentially treatable DR was 97.8% (1878/1921 encounters). If the
23,148 encounters with “no refer” recommendations and 4,512 encounters
with confident “refer” recommendations (operating point at 98% specific-
ity) are not seen by graders, the graders need to grade only 49.8% of the
total encounters with EyeArt. Therefore, in this mode of operation, EyeArt
can help reduce the workload of graders by a factor of about 2.
Conclusion: EyeArt has high sensitivity and specificity for identifying
patients with referable DR, making it safe and effective for integration
into DR screening workflow. It can help save costs by greatly reducing
the workload of image graders.
Supported by: EB013585 and TR000377 from NIH (NIBIB and NCATS)
USA
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Stratification of screening intervals for diabetic retinopathy based on
one versus two consecutive negative screening events
R.L. Thomas1, S.D. Luzio1, A. Crowder2, R.McPherson2, D.R.Owens1;
1Diabetes Research Unit, Cymru, Swansea University, 2Cardiff and Vale
University Health Board, Diabetic Retinopathy Screening Service for
Wales, Cardiff, UK.
Background and aims: There is ongoing debate about the appropriate
interval for diabetic retinopathy (DR) screening. It has been proposed that
persons with diabetes without evidence of DR at two consecutive nega-
tive screening events are at low risk of developing referable DR (RDR)
and can safely be screened bi or triennially. The question remains whether
one screening event with no evidence of DR is adequate to similarly
extend the screening interval. The aim of this study was to compare the
incidence of RDR in persons without evidence of DR at either one or two
prior consecutive screening events.
S524 Diabetologia (2015) 58 (Suppl 1):S1–S607
Materials and methods: The diabetic retinopathy screening service for
Wales (DRSSW) screens annually all persons with diabetes within Wales
over the age of 12 years. The service utilises standardised image capture
i.e. 2× 45 degree digital retinal per eye using Canon DgI cameras and
grading according to a nationally agreed protocol (DRSSW protocol). All
persons included in the analysis were identified as having no DR, back-
ground DR or referable DR (RDR) i.e. pre-proliferative, proliferative DR
or exudative maculopathy. Kaplan Meier survival estimates were obtain-
ed for the population undergoing screening and the incidence rates of
RDR over 5 years were compared between those with one or two prior
consecutive negative screening events for type 1 and type 2 diabetes
separately.
Results: 1,338 persons with type 1 diabetes and 48,908 type 2 diabetes
without evidence of DR at their first screening event between 2000 and
2013 were included in the analysis. There were 39 and 506 new cases of
RDR over 5 years in those with type 1 and type 2 diabetes, respectively,
with the 5 years cumulative incidence of RDR being 3.7% and 1.3%
respectively. Of those with no DR at first screening 879 (65.7%) persons
with type 1 diabetes and 37,958 (77.6%) persons with type 2 diabetes
remained without DR at their second screening event which occurred at a
mean of 606.7 (304.4) days and 574.8 (267.2) days respectively after the
initial screening event. There were 10 and 146 new cases of RDR respec-
tively within this group at 5 years, with the cumulative incidence of RDR
being 5.1% and 1.3% respectively. The 1-5 year cumulative incidence of
RDR for persons with type 1 diabetes was 0, 0.5, 0.7, 1.9 and 3.7% for
those with 1 negative screening event and 0, 0.2, 1.2, 2.7 and 5.1% for
those with 2 consecutive negative screening events without DR. The 1-
5 year cumulative incidence of RDR for persons with type 2 diabetes was
0, 0.2, 0.5, 0.8 and 1.3% for those with 1 negative screening event without
DR and 0, 0, 0.3, 0.7 and 1.3% for those with 2 negative consecutive
screening events without DR.
Conclusion: There appears to be little added benefit of needing 2 con-
secutive annual negative screening events in order to safely extend the
interval of screening to biennial in those persons considered to be at low
risk as the incidence of RDR was 0%with 1 or two subsequent screening
events. If screening intervals were extended to triennial then the incidence
of RDR was slightly lower in those persons with 2 prior consecutive
negative screening events at 0.2% compared to 0.5% for type 1 diabetes
with 1 screening event and 0% compared to 0.2% respectively for type 2
diabetes.
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Diabetic retinopathy severity grading using digital image processing
algorithms
C. Valverde1, M. Garcia2, R. Hornero2, M.I. López3,1;
1Universidad de Valladolid, 2Biomedical Engineering Group, Depart-
ment TSCIT, ETS. Ingenieros de Telecomunicación, Universidad de Val-
ladolid, 3Hospital Clinico Universitario de Valladolid, Spain.
Background and aims:Diabetic retinopathy (DR) is an important cause
of visual impairment. To ensure early detection and treatment, patients
should undergo periodic eye examinations. In them, retinal images of the
patient are usually captured using digital fundus cameras. Ophthalmolo-
gists further review these images to determine the degree of DR and
establish the follow-up period accordingly. However, with the growing
incidence of diabetes, the number of images to be examined can be pro-
hibitively large. For this reason, automatic methods to detect DR severity
level could be helpful to reduce the workload of ophthalmologists.
Materials and methods: We analysed 249 images from 18 diabetic pa-
tients without DR and 35 diabetic patients with different degrees of DR.
Images were divided in a training set with 81 images and a test set of 168
images (96 without DR lesions and 72 with DR lesions). An ophthalmol-
ogist manually marked the location of hard exudates (EXs) and red le-
sions (RLs) in these images and classified the severity of DR for each
patient. Besides, an automatic method for the location of EXs and RLs in
the images was developed using digital image processing algorithms
based on neural-networks (NNs). Three different types of NNs were
analysed: multilayer perceptron (MLP), radial basis function (RBF) net-
works and support vector machine (SVM). The level of DR severity for a
patient was subsequently established according to the number of lesions
located in each image of the patient.
Results: The best results on the location of EXs and RLs were obtained
with MLP. Using a lesion-based criterion, we achieved a mean sensitivity
(SEl) of 60.0% and a mean positive predictive value (PPVl) of 50.0% for
EXs. For RLs we obtained SEl =51.9% and PPVl =50.5%. With an
image-based criterion, a mean sensitivity (SEi) of 76.4%, a mean speci-
ficity (SPi) of 55.2% and a mean accuracy (ACi) of 62.9% were obtained
for EXs. For RLs we achieved SEi =71.2%, SPi =50.0% and ACi
=58.5%. In a second phase, we assessed the usefulness of the proposed
method for DR severity grading according to the detected lesions. Our
results show that we were able to detect the correct DR severity grade in
65.7% of the patients. In 97.1% of the incorrectly classified cases, the
automatic method provided the grade immediately above that given by
the ophthalmologist. Besides, we reached an accuracy of 77.1% in
distinguishing referable DR from non-referable DR.
Conclusion:Automatic methods for DR lesion detection and DR severity
grading could be an important aid for ophthalmologists in the screening
and evaluation of DR. Our results show that, in most cases, the frequency
of revisions given by the automatic method would be equal or lower than
that indicated by the ophthalmologist. However, further efforts should be
directed to improve our results in the location of DR lesions and classifi-
cation of DR severity grade, by improving the different stages of the
algorithm and revising the definition of DR grades for automatic
methods.
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Validation of an algorithm to predict the risk of sight threatening
retinopathy in a multi-ethnic patient group treated in a Dutch
hospital
K.M. Holtzer-Goor1,2, A.A. van der Heijden2,3, M. Jonker1, E. Stolk1,
G. Nijpels2,3;
1iBMG/iMTA, Erasmus University Rotterdam, 2EMGO Institute for
Health and Care Research, 3Department of General Practice and Elderly
CareMedicine, VUUniversityMedical Center, Amsterdam, Netherlands.
Background and aims: The majority of guidelines recommend a bien-
nial fundoscopy to monitor retinopathy for all persons with type 2 diabe-
tes mellitus (T2DM) free of elevated risk factors, and an annual fundos-
copy for all other persons with T2DM. Only a minority of this population
develops sight threatening retinopathy (STR). Recent studies indicate that
it is possible to estimate STR risk based on individual patient character-
istics and calculate a screening interval accordingly. In persons with a low
STR risk, the screening frequency could be reduced, where it could be
increased in the small high risk group. This personalized screening meth-
odwould probably reduce the total number of fundoscopies, which would
contribute to issues of the high and rising costs of T2DM care, the in-
creasing demand for health care, and the limited eye care capacity. The
algorithm developed in Iceland proved to predict the STR risk quit well in
a mainly Caucasian population treated in a Primary Care Diabetes centre.
However, it is yet unknown how the algorithm acts in a multi-ethnic
patient group treated in secondary care, which was the aim of this study.
Materials and methods: Data of 888 persons with T2DM, treated in a
hospital in the Netherlands were analysed. Using the Icelandic model,
STR risk and an accompanying screening interval ranging from 6 to
60 months were calculated for each person based on gender, diabetes
duration, HbA1c, systolic blood pressure and presence of retinopathy.
In patients who developed STR during follow-up, we checked whether
STR occurred before or after the model-recommended time of screening.
Outcomes of omitted fundus photographs according to the model and
potentially missed cases of STR were checked.
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Results: The persons in this study had a Caucasian (n=403 (45.4%)),
Hindustan-Surinam (n=178 (20.0%)), Negroid (n=33 (3.7%)), unknown
(n=246 (27.7%), or other background. During the average follow-up
duration of 40 months, 47 patients (5.3%) developed STR, of which 15
(31.9%) in the Hindustan-Surinam group. In 7 patients (15.2%) STR had
developed before the recommended date of screening. Of these, 4 patients
(57.1%) had a Caucasian background, 1 patient (14.3%) had a Hindustan-
Surinam background and 2 patients (28.6%) had an unknown ethnic
background. Using the algorithm, 50% of the fundoscopies would be
omitted.
Conclusion: The model was less accurate in a multi-ethnic population of
T2DM patients treated in secondary care. It remains to be determined
whether this lower accuracy is caused by the multi-ethnic background
of the population or the secondary care setting. Nevertheless, the number
ofmissed cases of STR suggests that there is room for improvement of the
current model for this multi-ethnic population treated in secondary care.
Supported by: ZonMW, SAG
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Screening for diabetic retinopathy: a collaborative model in Italy
M. Porta1, F. Boscia2, P. Lanzetta3, E. Mannucci4, U. Menchini5, F.
Simonelli6;
1Medical Sciences, University of Turin, 2Department of surgical, micro-
surgical and medical sciences, University of Sassari, 3Department of
Medical and Biological Sciences – Ophthalmology, University of Udine,
4Diabetology, Careggi Hospital, Florence, Italy, 5Ophthalmology, Uni-
versity of Florence, 6Department of Medical, Surgical and Dental Sci-
ences - Eye Clinic, 2nd University of Naples, Italy.
Background and aims: Systematic screening for diabetic retinopathy
(DR) is not centrally organized in Italy, where screening is performed
mostly on an opportunistic basis. The REaD (REtina and Diabetes) pro-
gramme was launched in April 2013 to establish a network of screening
centres where diabetes and eye specialists work in the same settings. This
paper reports on the results obtained up to December 2014.
Materials and methods: Screening was conducted in 33 diabetes clinics
by non-mydriatic digital fundus cameras (DRS, Centervue, Padua, Italy)
connected to ophthalmology units within the same health structures in
Italy. Two partially overlapping non-stereoscopic 45 degree fields (central
and nasal) of each eye were obtained by trained operators and sent via
web to partnering eye units. Images were then evaluated by an ophthal-
mologist to assess the presence of diabetic retinopathy (DR) and/or mac-
ular oedema (DMO) according to a severity scale with standardized re-
ferral guidelines.
Results: In total, 16,275 patients were screened, of which 53.0% were
male; 51.3% were≤64 years old and 48.7% were≥65 years old. Out of
77,309 images collected, 22 centres collected approximately 2,000 each
and 11 collected more than 2000. In total, 87.2% of patients could be
properly assessed. The percentage of ungradable images decreased from
14% (November 2013) to 9.5% (December 2014). Most ungradable im-
ages (57% of those obtained with mydriasis and 62% without mydriasis)
were observed in patients aged 61 to 80. Of the 14,185 patients with
gradable images, 3,260 (23%) had diabetic retinopathy and were referred
for further assessment and treatment.
Conclusion: The REaD programme is the largest screening campaign
conducted in Italy in a setting where screening is mostly performed on
an opportunistic basis. Non-mydriatic digital fundus cameras may be a
cost-containing screening tool for DR. The number of ungradable images
was a main limitation, at its maximum when the programme started,
possibly due to operator-related factors, then stabilized around 10%. It
appeared mainly related to patient age and non-induction of mydriasis.
Systematic screening for DR with non-mydriatic digital cameras allows
diabetes specialists to obtain a basic fundus evaluation directly in their
units and to promptly organize referrals to ophthalmic centers in case of
abnormal findings.
Supported by: Novartis Pharma, Italy
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Regional differences in macular thickness in the early stages of
diabetic retinopathy in type 2 diabetes
K.M. Gooding1, A.C. Shore1, R. Ling2, F. Casanova1, H.C. Looker3, E.
Agardh4;
1Diabetes and Vascular Medicine, University of Exeter Medical School,
2West of England Eye Unit, Royal Devon and Exeter NHS Foundation
Trust, 3Medical Research Institute, University of Dundee, UK, 4Depart-
ment of Clinical Sciences, Ophthalmology, Lund University, Malmö,
Sweden.
Background and aims: Following the advent of optical coherence to-
mography (OCT) for the measurement of macular thickness there has
been interest in the relationship between macular thickness and diabetic
retinopathy (DR). Research to date has focussed on fovea thickness with
conflicting results. The variations in the observationsmay reflect different
grading systems utilised to assess retinopathy status. As part of the SUM-
MITconsortium this study aims to examine the relationship between early
stages of DR andmacular thickness in all subdivision of the OCTETDRS
grid.
Materials and methods: 780 participants with type 2 diabetes (461, 162
and 157 with no, microaneurysms only or mild background DR respec-
tively) were recruited across two centres. DR was graded from two-field
retinal photography. Macular thickness (inner limiting membrane to the
mid-point of the retinal pigment epithelium) was measured in both eyes
using a standard OCT 512×128 scanning protocol. Participant character-
istics were recorded. The eye with the worse retinopathy and its corre-
sponding OCT data were utilised in the analysis. If retinopathy was the
same in both eyes the data from the right eye was utilised. The relation-
ship between retinal thicknesses in each ETDRS region with DR (entered
as no DR, microaneurysms only and mild background DR) was investi-
gated using regression analysis, adjusting for age, gender and centre.
Results: There was no relationship between the thickness of the fovea or
inner quadrants with DR. In the outer quadrants there was a significant
positive association between thickness in the temporal region and DR
(unstandardised β (standard error): 1.639(0.648)μm; standardised β=
0.092, p=0.012). This association remained when further adjusted for
glycaemic control (HbA1c) and duration of diabetes (unstandardised β
(standard error): 1.655(0.709)μm; standardisedβ=0.093, p=0.020). This
association was not present in the nasal, superior or inferior outer
quadrants.
Conclusion: This study suggests that there are small differences in the net
thickness in the outer temporal region in the early stages of DR. An
attractive explanation is that in the early stages of DR there is thinning
of the retinal nerve fibre layer (RNFL) accompanied by thickening of
another retinal layer, resulting in no net change in thickness in the major-
ity of the ETDRS grid. As the outer temporal region has minimal RNFL
there is net thickening in this region.
Supported by: SUMMIT Consortium IMI-2008/115006
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Cataract associated with diabetes and diabetic retinopathy in type 2
diabetes
M. Tomić, R. Vrabec, Ž. Rogulja Pepeonik, S. Ljubić, T. Bulum, K.
Blaslov, L. Duvnjak;
Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Meta-
bolic Diseases, Merkur University Hospital, Zagreb, Croatia.
Background and aims: Cataract is the commonest cause of preventable
blindness worldwide. In patients with diabetes, cataract occurs at a youn-
ger age and progresses more rapidly than senile cataract, resulting in
higher rates of cataract surgery at a quite young age and poorer vision
outcomes especially in operated eyes with active proliferative retinopathy
and/or preexisting macular edema. The exact pathogenesis that leads to
lens opacification in diabetes is still insufficiently understood and pre-
sumed to involve diabetic complications risk factors. The aim of this
study was to investigate the role of diabetes duration, metabolic risk
factors, diabetic retinopathy (DR) and nephropathy in cataract develop-
ment in type 2 diabetes.
Materials and methods: This was a cross-sectional study including 107
type 2 diabetic patients (67 male / 40 female, mean age 66.74±8.01 years,
mean diabetes duration 15.05±5.69 years). Metabolic risk factors:
glycated hemoglobin (HbA1c), total cholesterol, HDL cholesterol, LDL
cholesterol and triglycerides were determined using routine laboratory
methods. Blood pressure was measured with a mercury sphygmomanom-
eter after a 10-minute resting period. Serum creatinine, creatinine clear-
ance and albumin/creatinine (A/C) ratio were used to determine the pres-
ence of nephropathy. Ophthalmologic examination included best
corrected visual acuity (BCVA), biomicroscopy of the lens, binocular
indirect slit lamp fundoscopy and color fundus photography of two fields
(macular field, disc/nasal field) of both eyes according to the
EURODIAB retinal photography methodology. Lens opacity was graded
according to the Lens Opacity Classification System version III
(LOCSIII).
Results: According to the 4 grading scales of the LOCSIII patients were
divided into three groups: group 1 - patients with clear crystalline lens
(n=16), group 2 - patients with initial cataract (NO1-NO2, NC1-NC2,
C1-C2, P1-P2; n=74), and group 3 - patients with immature cataract
(NO3-NO4, NC3-NC4, C3-C4, P3-P4; n=17). The three groups did not
differ in age, gender, diabetes treatment, SBP and DBP, total cholesterol,
HDL, LDL and triglycerides. Group 3 had significantly longer diabetes
duration (17.12±6.38 years vs. 10.81±4.09 years; p<0.001) and margin-
ally higher HbA1c (7.11±1.06 vs. 6.38±0.82; p=0.052) than group 1.
DR was significantly more severe (35/29/36% vs. 82/6/12%; p=0.047)
and creatinine clearance significantly lower (1.53±0.25 vs. 1.90±0.72;
p=0.017) in group 3 than in group 1. Cataract was positively correlated
with DBP (p=0.002), DR (p=0.009) and A/C ratio (p=0.004). DR was
positively correlated with HbA1c (p=0.018), triglycerides (p=0.041) and
A/C ratio (p=0.007). Multiple regression analysis showed that diabetes
duration (β coefficient=0.365; p<0.001), SBP (β coefficient=0.379; p=
0.003), DBP (β coefficient=0.503; p<0.001) and DR (β coefficient=
0.243; p=0.013) were the main predictors of cataract development in type
2 diabetic patients.
Conclusion: This study showed that diabetes duration, poor glycemic
control, blood pressure, retinopathy and nephropathy play an important
role in the cataract development in type 2 diabetes. These findings point
to the need for even more reducing risk factors as a means of preventing
not only retinopathy but also cataract in order to improve the quality of
life of diabetics and reduce the economic burden due to disability and
surgery related to cataract.
PS 108 Diabetic nephropathy:
pathogenesis and predictors
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Genetic exploration of a causal role of dyslipidaemia on diabetic
nephropathy in type 1 diabetes
E.H. Dahlström1,2, J. Todd3,4, N. Sandholm1,2, R. Salem3,4, C.
Forsblom1,2, N. Tolonen1,2, V. Harjutsalo1,2, J. Hirschorn3,4, J.C.
Florez5,6, P.-H. Groop1,2;
1Folkhälsan Institute of Genetics, 2Abdominal Center Nephrology, Hel-
sinki, Finland, 3Division of Endocrinology, Boston Children’s Hospital,
4Department of Pediatrics, HarvardMedical School, 5Program inMedical
and Population Genetics, Broad Institute, 6Department ofMedicine, Cen-
ter for Human Genetic Research and Diabetes Unit, Massachusetts Gen-
eral Hospital, USA.
Background and aims:Dyslipidemia has been suggested as a risk factor
for diabetic nephropathy (DN), but epidemiologic studies do not reveal
whether these associations are causal. Genome-wide association studies
have uncovered a number of single nucleotide polymorphisms (SNPs)
affecting plasma lipid fractions. In three cohorts participating in the Ge-
netics of Nephropathy-An International Effort (GeNIE) cohort, we tested
if genetic risk scores (GRS) for LDL cholesterol, HDL cholesterol, total
cholesterol and triglycerides were associated with DN in 6126 adult pa-
tients with type 1 diabetes.
Materials and methods: We created weighted GRS constructed from
established variants for HDL cholesterol (71 SNPs), LDL cholesterol
(58 SNPs), triglycerides (40 SNPs) and total cholesterol (74 SNPs)
weighting each risk allele by its published effect size, in each of 3 cohorts.
DN was defined as having macroalbuminuria or end-stage renal disease
(ESRD). Controls with normal albumin excretion rate were required to
have a diabetes duration of more than 15 years. Association results from
each cohort were combined in a meta-analyses using a fixed effect model.
Results: Genetic risk scores for lipid fractions (LDL cholesterol, HDL
cholesterol, triglycerides, and total cholesterol) were not significantly
associated with DN inmeta-analyses. However, there was a trend towards
increased odds of DN with a higher LDL cholesterol GRS (OR=1.048
per 1 SD of GRS [95% CI, 0.994 -1.105], P=0.085) and a trend towards
decreased odds of DN with a higher HDL cholesterol GRS (OR=0.954
per 1 SD of GRS [95% CI, 0.904-1.006], P=0.080). We also investigated
the impact of GRS lipid fractions onDN subtypes; macroalbuminuria and
ESRD. We found that a higher HDL cholesterol GRS was significantly
associated with decreased odds of macroalbuminuria (OR=0.936 per 1
SD of GRS [95% CI, 0.879-0.996], P=0.036) and a higher triglyceride
GRS with increased odds of macroalbuminuria (OR=1.069 per 1 SD of
GRS [95% CI, 1.005-1.138], P=0.034). None of the GRS lipid fractions
were significantly associated with ESRD.
Conclusion: In conclusion, genetic factors associated with increased
HDL and TG are associated with macroalbuminuria in patients with
T1D suggesting that these lipids have a causal role on development of
diabetic nephropathy. Further research is needed to verify these findings.
Supported by: NIDDK R01, Folkhälsan, Nylands Nation
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Long-term high level of LDL cholesterol associated with a new onset
of chronic kidney disease in patients with type 2 diabetes mellitus
T.-S. Lim1, J.-S. Yun1, S.-A. Cha1, S.-D.Moon2, H. Seok3, S.-H. Ko1, Y.-
B. Ahn1;
1Internal Medicine, The Catholic University of Korea, St. Vincent’s hos-
pital, Suwon, 2Internal Medicine, The Catholic University of Korea, In-
cheon St. Mary's Hospital, 3InternalMedicine, The Catholic University of
Korea, Uijeongbu St. Mary's Hospital, Republic of Korea.
Background and aims:We investigated factors that might influence the
development of chronic kidney disease (CKD) in patients with type 2
diabetes.
Materials and methods: From January 2003 to December 2004, a total
of 861 patients with type 2 diabetes without CKD (estimated glomerular
filtration rate [GFR]≥60 ml/min/1.73 m2) were consecutively enrolled.
The blood lipid concentrations for total cholesterol, triglycerides, high-
density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, and the estimated GFR were measured annually and mean
LDL cholesterol level was calculated from annual LDL cholesterol data
during the study. The new onset CKD was defined as estimated GFR<
60 ml/min/1.73 m2 using a Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) equation. We used a Cox proportional hazard re-
gression analysis to test the associations between new onset CKD and
potential explanatory variables.
Results: Of the 861 patients enrolled in this study, 582 (67.6%) complet-
ed the follow-up evaluation. The median follow-up time was 10.1 years.
The mean age was 55.0±10.0 years, and the duration of diabetes was 8.0
±6.6 years. The baseline estimated GFR was 95.2±15.1 ml/min/1.73 m2.
The patients who developed a new onset of CKD had higher level of
mean LDL level (2.67±0.56 vs 2.85±0.58 mmol/l; p=0.004) than those
who did not develop CKD. During the follow-up period, 184 patients
(31.6%) progressed to chronic kidney disease. The hazard ratio of CKD
development was 1.61 (95% CI 1.14-2.26; p for trend=0.006) per
1.0 mmol/l mean LDL cholesterol level increase after adjusting for sex,
age, diabetic duration, mean HbA1c, albuminuria, treatment of insulin,
ACE inhibitor/angiotensin receptor blocker and lipid lowering agents.
Conclusion: The development of CKD was independently associated
with serum LDL cholesterol level in patients with type 2 diabetes. Thus,
in addition to strict glycemic control, constant long term management of
dyslipidemia is important to prevent development of CKD.
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Association of monocyte-to-HDL-cholesterol ratio with
microalbuminuria in patients with type 2 diabetes mellitus
R. Emral, A.G. Canpolat, Ç. Keskin, S. Canlar, Ö. Demir, D.
Çorapçıoğlu;
Endocrinology and Metabolic Diseases, Ankara University Faculty of
Medicine, Turkey.
Background and aims: Chronic kidney disease (CKD) due to diabetes
mellitus is a growing health problem worldwide. Chronic proinflamma-
tory state exists in adults with CKD. Previous studies have demonstrated
that monocyte count to high density lipoprotein cholestrol (HDL-C) ratio
(MHR) is one of the indicators of oxidative stress and systemic inflam-
mation and showed that renal dysfunction was associated with both a
reduction in serum HDL-C level and increased circulating monocyte
count. Thus, we aimed to evaluate the relationship
Materials andmethods:Between June 2014 and January 2015 a total of
80 patients with type 2 DM (n=34 with microalbuminuria and n=46
without microalbuminuria) who admitted to our outpatient clinic were
enrolled. 24-h urine analysis for microalbuminuria, calculation of MHR
and serum C-reactive protein (CRP) were performed for each patient.
Patients with malignancy or acute/chronic infectious/inflammatory state
were excluded.
Results: Patients with microalbuminuria were older, with higher glyco-
sylated hemoglobin levels (HbA1c). The MHR and CRP levels were also
significantly higher in patients with microalbuminuria (p=0.002 and p<
0.001, respectively). There was a positive correlation between MHR and
serum CRP (r=0.462, p<0.001). In multivariate logistic regression anal-
ysis, MHR was found as independent predictor for the presence of
microalbuminuria in patients with diabetes (OR: 1.44, p<0.001).
Conclusion: Higher MHR which indicates an enhanced inflammation
and oxidative stress was significantly and independently associated with
the presence of microalbuminuria in patients with diabetes. Besides,
MHR was positively correlated with serum CRP level as a conventional
marker for systemic inflammation.
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Functional polymorphisms in the promoter region of heme
oxygenase-1 and susceptibility to diabetic nephropathy in type 2
diabetes
H. Won1, Y. Lee2, E. Lee3, B. Kim2, C. Nam4, B. Lee2, E. Kang2, B.
Cha2, H. Lee2;
1Department of Internal medicine, Konyang University College of Med-
icine, Daejeon, 2Department of Internal medicine, Yonsei University Col-
lege of Medicine, 3Department of Internal medicine, The Catholic Uni-
versity of Korea, 4Department of Preventive Medicine, Yonsei University
College of Medicine, Seoul, Republic of Korea.
Background and aims: Heme oxygenase (HO)-1 is a key enzyme in
cytoprotective mechanisms against oxidative stress in the cardiovascular-
renal system. The T(-413)A single nucleotide polymorphism (SNP) and
(GT)n microsatellite polymorphism in the HO-1 gene promoter modulate
the HO-1 gene transcriptional activity and these polymorphisms are as-
sociated with various human diseases. We investigated the association
between HO-1 promoter polymorphisms and nephropathy in type 2 dia-
betes and assessed the effect of SNP on promoter activity in kidney cell-
lines in vitro.
Materials and methods: We sequenced the T(-413)A SNP and (GT)n
repeat segments of the HO-1 gene promoter in 536 patients with type 2
diabetes. (GT)n alleles were divided into 2 groups: short (S, ≤25 GT
repeats) and long (L, >25 GT repeats) alleles. Diabetic nephropathy was
defined as follows: urinary albumin/creatinine ratio≥30 mg/mg or albu-
min excretion≥30 mg/day in a 24 h urine analysis. The regulatory effects
of SNPs in the HO-1 promoter were explored in two kidney cell-lines
using luciferase assay after site-specific mutagenesis of HO-1 promoter.
Results: Patients with the TT genotype in the T(-413)A SNP were sig-
nificantly more susceptible to diabetic nephropathy than those carrying
the A allele, with an odds ratio (OR) of 1.577 (95% confidence interval,
1.088−2.285; P=0.016). Subgroup analysis showed that patients carry-
ing the TT genotype with long duration of diabetes (≥20 years, OR=
3.325, P<0.05), poor glycemic control (HbA1c>7.4%, OR=1.780, P<
0.05), and male gender (OR=2.043, P<0.05) had higher odds ratios for
the development of diabetic nephropathy. Regarding to the (GT)n repeats,
the LL genotype showed a higher odds ratio for the development of
diabetic nephropathy only in patients with hypertension when compared
to the S allele. In vitro experiments, promoter activity of the T(-413)A
SNP was higher with A allele than T allele in human embryonic kidney
cells and mesangial cells.
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Conclusion: In conclusion, the T(-413)A SNP in the HO-1 promoter is
significantly associated with diabetic nephropathy development in type 2
diabetes patients, especially with longer duration and poor glycemic control.
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T-cadherin gene (CDH13) polymorphisms and nephropathy in
subjects with type 1 diabetes
A. Nicolas1,2, K. Mohammedi3, N. Bellili-Muñoz1, R. Roussel1,3, S.
Hadjadj4, M. Marre1,3, G. Velho1, F. Fumeron1,5;
1Inserm UMRS1138, 2Université Pierre et Marie Curie, Sorbonne
Universités, 3Diabetology, Endocrinology and Nutrition, Bichat Hospital,
APHP, Paris, 4Diabetology and Endocrinology, University Hospital of
Poitiers, 5Université Paris Diderot, Sorbonne Paris Cité, France.
Background and aims: T-cadherin is a receptor for the active forms of
adiponectin, and variants in the T-cadherin gene (CDH13) have been
associated with adiponectin levels. Plasma adiponectin levels are associ-
ated with diabetic nephropathy (DN). We investigated associations of
CDH13 allelic variations with kidney complications in subjects with type
1 diabetes.
Materials and methods: Three CDH13 polymorphisms (rs11646213,
rs3865188, rs4783244) were genotyped in 1297 Caucasian type 1 diabet-
ic patients from SURGENE (n=340), GENESIS (n=501) and
GENEDIAB (n=456) studies. Follow-up data were available for all
SURGENE participants and for 462 GENESIS and 283 GENEDIAB
participants. Duration of follow-up was 10, 9 and 5 years, respectively.
Renal events were defined as new cases of DN or progression to a more
severe stage of DN.We used ANCOVA to compare means of clinical and
biological parameters between genotypes. Odds-ratios (OR) and hazard-
ratios (HR) were estimated for the prevalence and incidence of DN using
logistic regression and Cox model analyses, respectively. GENEDIAB
and GENESIS data were pooled for the analyses. All analyses were
adjusted for sex, age, duration of diabetes, body mass index, retinopathy
stages and cohort membership (when adequate).
Results: In the SURGENE study, the variants rs11646213 (HR 1.69; CI
95% 1.01-2.71; p=0.04) and rs3865188 (HR 0.74; CI 95% 0.55-0.99; p=
0.04) were associated with the incidence of renal events during follow-up.
At the end of the study, these variants were associated with the prevalence
of DN (OR 3.30; CI 95% 1.28-8.38; p=0.01 for rs11646213 and OR
0.54; CI 95% 0.30-0.93; p=0.03 for rs3865188). In the pooled analysis
of GENEDIAB and GENESIS studies, the AA genotype of rs11646213
was associated with the prevalence of established/advanced DN (OR
1.47; CI 95% 1.18-1.85; p=0.0009), with higher urinary albumin excre-
tion (p=0.01) and diastolic blood pressure (p=0.01). The same genotype
was associated with higher incidence of end-stage renal disease (ESRD)
during follow-up (HR 1.96; CI 95% 1.06-3.51; p=0.03). Furthermore, the
minor alleles A and T of rs3865188 and rs4783244, respectively, were
also associated with the prevalence of established/advanced DN (OR
0.71; CI 95% 0.57-0.90; p=0.004 for rs3865188 and OR 0.79; CI 95%
0.63-0.99; p=0.05 for rs4783244) and the incidence of ESRD (HR 0.47;
CI 95% 0.27-0.84; p=0.01 for rs3865188 and HR 0.44; CI 95% 0.25-
0.79; p=0.006 for rs4783244).
Conclusion: In subjects with type 1 diabetes, CDH13 polymorphisms
were associated with the prevalence of established and advanced diabetic
nephropathy, as well as with the incidence of renal events and ESRD. The
genotypes at risk have been previously associated with lower plasma
adiponectin levels. Further investigations are needed to determine wheth-
er the variations in plasma adiponectin and/or t-cadherin levels can ex-
plain these associations.
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Markers of chronic kidney disease - albuminuria and glomerular
filtration rate encoded by different genetic determinants in type 2
diabetes
A.V. Zheleznyakova1, O.K. Vikulova1, V.V. Nosikov2, M.V.
Shestakova1;
1Endocrinology research centre, 2National Research Center
“GosNIIgenetika”, Moscow, Russian Federation.
Background and aims: The major markers of chronic kidney disease
(CKD) - albuminuria (AU) and glomerular filtration rate (GFR) have the
different clinical pattern due to diabetes type: in type 1 diabetes AU is a
predictor of subsequent GFR decrease, in type 2 diabetes (T2D) it might
develop in parallel or after GFR decrease may be due to different genetic
determinants. The aim of our study was to assess the association of can-
didate genes polymorphisms encoding the key mediators of kidney dam-
age with AU and GFR in T2D patients.
Materials andmethods:We enrolled 262 patients with T2D divided into
groups due to the rate of AU>/<30 mg/per 24H (AU+/-, n=128/134) and
GFR≥/<60 ml/min/1.73 m2 estimated by MDRD (CKD+/CKD-, n=86/
176) and analyzed a complex of 6 pm in genes involved in coding of
major mediators of kidney injury: endothelial dysfunction [nitric oxide
synthase-3 (ecNOS4a/4b in NOS3), angiotensin I-converting enzyme
(I/D in ACE)]; lipids metabolism [apolipoprotein B (I/D in APOB), apo-
lipoprotein E (e2/e3/e4 in APOE)]; insulin secretion and sensitivity
(rs5219 in KCNJ11 coding protein Kir6.2 subunits of potassium
inwardly-rectifying channel, rs7903146 in TCF7L2 coding transcription-
al factor 7-like 2). Statistic analysis was assessed by χ2, OR, p<0.05. The
study was approved by local ethical committee; informed concern was
obtained from all the patients.
Results: Significant association with AU showed one of the studied pm:
4a/4b in NOS3 gene: we observed excess of 4a allele and 4a4a genotype
in group with AU did as risk factors [4a: OR=1.7; 95%CI 1,1-2,5, 4aa:
OR=9.89; 95%CI 2,05-47,72]. Significant association with GFR de-
crease showed pm in 4 genes. NOS3 gene: the prevalence of 4b/4bb in
CKD- group [OR=0.45/0.45; 95%CI 0,2-0,7/0,26-0,77, respectively];
while allele 4a and genotype 4a/4a did as risk factors [OR=2,2/9,9;
95%CI 1,4-3,6/2,1-47.7, respectively]. APOB gene: genotype DD
protected from CKD [OR=0,2; 95%CI 0,05-0,8, р=0,04] in dominant
inheritance model compared with carriers of II and ID genotypes that did
as risk factors [OR=5.00; 95%CI 1,1-21, р=0,02]. KCNJ11 gene: an
excess of allele T facilitate to CKD existence [OR=2,4 95%CI 1,4-4,1],
allele C/genotype CC were protective [OR=0,52/0,44, 95%CI 0,3-0,8/0,
2-0,8 respectively]. TCF7L2 gene: genotype TT [OR=0,12, 95%CI 0,03-
0,53] had a protective role. We didn’t find a variant association of pm’s in
ACE and APOE with CKD. CKD risk highly depended on the amount
and combination of risk/protective genotypes (r=0,971, p<0,05). The
absence of any risk genotypes protected from CKD [RR=0], if one of
risk genotypes detected RR=0,86, if any 2 of them RR=1,7, any 3 risk
genotypes increased CKD risk with RR=2,2 and RR=3,27 was the
highest in carriers of 4 predisposing variants of studied pm.
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Conclusion: The CKD development might have genetic susceptibility
with different genetic determinants for AU and GFR in T2D patients.
Risk of AU is associated with polymorphism of NOS3 gene; risk of
GFR decline - with pm in NOS3, APOB, KCNJ11 and TCF7L2 genes.
CKD risk was highly depended on the amount of risk genotypes with
highest risk in carriers of 4 predisposing variants. The data obtained allow
offering these pm as diagnostic panel for allocation of high-risk patients,
which require more frequent screening and active prevention for this
complication.
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Uric acid contributes to the faster progression of diabetic kidney
disease and higher incidence of major cardiovascular event in type
2 diabetic patients
L. Pacal1, V. Bartakova1, K. Kuricova1, Z. Nova1, V. Dvorakova1, M.
Svrckova1, D. Maluskova2, J. Rehorova3, J. Svojanovsky4, J. Olsovsky4,
J. Belobradkova3, D. Krusova4, K. Kankova1;
1Department of Pathophysiology, 2Institute of Biostatistics and analyses,
Faculty of Medicine, Masaryk University, 3Clinic of Internal Medicine -
Gastroenterology, University Hospital, 4Clinic of Internal Medicine, Di-
abetes and Nephrology Centres, St. Anne's University Hospital, Brno,
Czech Republic.
Background and aims: Recent evidence suggests that increased serum
uric acid (SUA) is associated with increased risk of diabetic kidney dis-
ease (DKD) development in patients with type 1 diabetes. Data on the role
of SUA in the progression of DKD in type 2 diabetes (T2DM) are lack-
ing. Polymorphisms in genes encoding for uric acid transporters in the
kidney (SLC2A9, ABCG2) and gut (ABCG2) affect SUA and were as-
sociated with hyperuricaemia and gout but were not studied with respect
to DKD yet. The aims of the study were to assess (i) the prognostic value
of baseline SUA and (ii) variability in selected genes involved in the
regulation of uric acid metabolism for DKD progression in T2DM.
Materials and methods: 422 patients with T2DM and different stage of
DKD (defined asmacroalbuminuria or ESRD and/or CKD III and higher)
at baseline were included in the prospective study. Median follow-up was
47 [IQR 27-79] months. Hyperuricaemia was defined as initial SUA≥
420 μmol/l in men and ≥360 μmol/l in women or as a treatment with
allopurinol at the inception in the study. Following endpoints were de-
fined: 1) DKD progression (i.e. the decline of GFR<60 ml/min per
1.73 m2 during the follow-up period for those with GFR≥60 ml/min
per 1.73 m2 at baseline or achieving ESRD, or the development of overt
proteinuria in normo- and microalbuminuric subjects at baseline or the
progression of CKD by at least stage for those with CKD III and IV at
baseline) with all-cause mortality as a competing risk and 2) major car-
diovascular event (MACE - i.e. fatal or non-fatal myocardial infarction or
cerebrovascular event, limb amputation, revascularization) with non-
CVD death as a competing risk. Using PCR-based methodology we
detected 5 SNPs in the genes formerly associated with hyperuricaemia/
gout (4 in SLC2A9 and 1 in ABCG2). Statistical analysis involved sur-
vival analysis, competing risk analysis and Cox regression.
Results: Cumulative incidence of DKD progression was 54.4%, MACE
32.2% and total mortality 43.8%. Initial hyperuricaemiawas confirmed as
a significant risk factor for both DKD progression and MACE (P<
0.00001 and P=0.0021, log-rank test). Allopurinol treatment did not have
protective effect with respect to DKD progression. Patients with and
without initial hyperuricaemia did not differ in the frequency of risk
genotype in any of studied SNPs. Allele T of SLC2A9 rs16890979 was
marginally associated with faster DKD progression (P=0.05, Kaplan-
Meier).
Conclusion: Our results suggest that hyperuricaemia significantly con-
tributes to the progression of DKD and to the higher incidence of MACE
in patients with T2DM. The effect of studied genetic variants appears to
be minor.
Supported by: IGA MZ CR NT13198
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Uric acid associated with decline of GFR in diabetic nephropathy
S. Pilemann-Lyberg1,2, M. Lindhardt1, F. Persson1, S. Andersen3, P.
Rossing1,4;
1Diabetes complications research, Steno Diabetes Center, Gentofte,
2Danish Diabetes Academy and Aarhus University, Aarhus, 3Department
of Cardiology, Endocrinology and Nephrology, Nordsjællands Hospital,
Hillerød, 4Aarhus University, Denmark.
Background and aims: Diabetes is the major cause of chronic kidney
disease (CKD). Evidence from epidemiological and prospective studies
indicates that serum uric acid (UA) is a risk factor for development and
progression of CKD and loss of kidney function. We evaluated the effect
of serum UA on change in GFR in patients with type 1 diabetes (T1DM)
in a previous conducted clinical trial.
Materials and methods: Post hoc analysis of a prospective, double-
blinded, clinical intervention trial of the long-term renoprotective effect
of AT1 receptor blockade (losartan 100 mg) on progression of diabetic
nephropathy in T1DM homozygous for the I (n=26 ) or D (n=27) allele
of the ACE/ID polymorphisms. Mean follow-up time was 3 years (range
1.5 - 3.5). Serum UAwas measured at baseline. Primary end-point was
GFR measured with Cr51-clearance every 6 month. Effect of UA was
tested in a linear regressionmodel with andwithout adjustment for known
progression factors (Gender, HbA1c, systolic blood pressure, cholesterol,
baseline GFR and baseline urinary albumin excretion rate (UAER)) .
Results: Mean baseline UAwas 0.339 mmol/L (SD ±0.1), GFR 87 ml/
min/ 1.73 m2 (SD ±23), Geometric mean of UAER 1023 mg/ 24 h (IQR,
631 - 1995). Similar association between UA and change in GFR was
present for the two ACE/ID polymorphisms. In an unadjusted linear
model UA was positively associated with decline in GFR (r2=0.06, p=
0.09). After adjustment for known progression factors the association
increased to a significant level (r2=0.35, p=0.011). In the backward elim-
ination UA remained in the model, together with baseline UAER and
baseline GFR (r2=0.26, p=0.0031).
Conclusion: Uric acid was positively associated with decline in GFR in
type 1 diabetic patients with nephropathy. UAwas a significant predictor
together with UAER and baseline GFR. The clinical significance ofUA is
currently investigated in a multicenter clinical trial (PERL Study).
Supported by: DDA and AU
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The effect of sensor augmented insulin pump treatment versus
multiple daily injections on albuminuria: a one year randomised
controlled study
S. Rosenlund1, T.W. Hansen1, P. Rossing1, S. Andersen2;
1Steno Diabetes Center, Gentofte, 2Nordsjaellands Hospital, Hilleroed,
Denmark.
Background and aims: The effect of tight glycaemic control on
persisting albuminuria remains unclear. Insulin delivery methodmay play
an important part by affecting HbA1c and/or glucose variability. We
investigated the effect of 1 year sensor augmented insulin pump treatment
(SAP) versus multiple daily injections (MDI) on albuminuria in type 1
diabetes patients with a history of elevated urinary albumin excretion.
Materials and methods: In a randomized controlled open-label parallel
trial 60 type 1 diabetes patients were randomized to 1 year SAP or MDI
treatment. At screening patients had urinary albumin creatinine ratio
(UACR) ≥10 mg/g in 2 out 3 morning urines. All were on stable RAS
inhibition 4 weeks prior to screening and throughout the study. UACR
was measured in 3 morning urines at all visits. Glucose variability (CGM)
and glomerular filtration rate (51Cr-EDTA GFR) was measured at begin-
ning and end of study. Changes in UACR between treatment groups were
analysed using a mixed linear model including all measurements during
the study and adjustment for HbA1c.
Results: 57 patients (SAP: n=28; MDI: n=29) completed the study. At
baseline 86% had UACR ≥30 mg/g. Age was (mean ± SD) 51±10 years,
duration of diabetes was 33±12 years. UACR was (geometric mean,
IQR) 99 (37-235) mg/g. GFR: 94±22 ml/min/1.73 m2, HbA1c: 75±
12 mmol/mol, glucose variability (given as SD): 4.0±1.0 mmol/mol
and systolic blood pressure (SBP): 143±17 mmHg; no difference be-
tween groups (P≥0.08 for all). After 1 year, HbA1c decreased 14±11
vs. 6±11 mmol/mol (P=0.013), glucose variability decreased 0.9±1.1
vs. 0.3±1.0 mmol/mol (P=0.037), GFR declined 5.6±9.6 vs. 3.4±
13 ml/min/1.73 m2 (P=0.50), SBP decreased 1.6±17 vs. 3.6±17 mmHg
(P=0.68) in SAP vs.MDI treatment, respectively. UACR (mean(95%CI))
decreased 13 (-39-22)% with SAP vs. 30 (-12-92)% increase on MDI
(unadjusted: P=0.052; adjusted for HbA1c: P=0.042). In the subgroup
of patients with UACR ≥30mg/g at baseline (n=48) UACR decreased 18
(-44-20)% in the SAP treatment group (n=24) while MDI treated patients
(n=24) had an increase of 38 (-11-71)% (unadjusted: P=0.01; adjusted
for HbA1c: P=0.01).
Conclusion: In conclusion, sensor augmented insulin pump treatment
tended to reduce UACR in a randomized controlled trial in type 1 diabetes
patients with a history of albuminuria on stable RAS inhibition. Signifi-
cance was reached after adjustment for HbA1c. In the subgroup with
albuminuria at baseline, SAP treatment reduced UACR significantly.
SAP treatment reduced glucose variability and HbA1c and might have
a beneficial effect on diabetic nephropathy.
Clinical Trial Registration Number: NCT01454700
Supported by: Medtronic
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Effect of different types of insulin therapy on transplant state,
metabolic and haemodynamic factors control in patients with type 1
diabetes after kidney transplantation
A. Glazunova1, M. Arutyunova1, E. Tarasov1, G. Musaeva2, M.
Shestakova1,2, Y. Moysyuk3;
1Research Centre of Endocrinology, 2I.M. Sechenov First Moscow State
Medical University, 3Academician V.I. Shumakov federal research center
of transplantology and artificial organs, Moscow, Russian Federation.
Background and aims: To evaluate the impact of different types of
insulin therapy (continuous subcutaneous insulin infusion (CSII) using
insulin pump or multiple insulin injections (MII)) on carbohydrate me-
tabolism, the state of the transplant, cardiovascular system, calcium and
phosphorus metabolism in patients with type 1 diabetes (DM1) after
kidney transplantation (KT).
Materials and methods: The study included two groups of patients with
DM1 after transplantation: 1) 17 patients treated with CSII 2) 10 with
MII. Mean duration of diabetes in the first group was 25 years [20,5;34,
5], the second group - 24,5 years [20;30]. Posttransplantation period in
both groups was comparable - 8,0 [7,0;36,0] and 7,5 [7,0:19,0] months.
Results: The mean level of glycated hemoglobin (HbA1c) in groups
before the study did not differ: 9.0% [8.0;9.6] and 9.0% [8,7; 9.8], re-
spectively. When patients were transfer into CSII - HbA1c was signifi-
cantly lower in this group after 3-6-9months -7,4% [7,4; 8,6 ](p<0,0005),
while in the MII group - 8,1% [7,5;8,7] (p<0,026). Recurrent diabetic
nephropathy at the stage of microalbuminuria was diagnosed in 2 patient
(20%) in the MII group with continuing poor glycemic control (the level
of albuminuria was 35-65 mg/l, reanalysis - 68-85 mg/l). All patients,
treated CSII had normal albuminuria. Glomerular filtration rate (GFR)
(CKD-EPI) in both groups was comparable: 67 ml/min/1,73 m2 [65,86]
and 65ml/min/1,73 m2 [60,0;75,0], respectively. Stabilization of diabetic
retinopathy (proliferative stage mainly) was observed in all patients after
repeated laser photocoagulation. Positive of hemoglobin, parathyroid hor-
mone, calcium phosphorus product and blood pressure dynamics did not
differ in the groups after KT.
Conclusion: The CSII using insulin pump allows to reach target values
faster and more efficiently, CSII seems to be more effective than MII in
reducing glycemic variability (tabl.1), and this improving the control of
complications and overall prognosis in patients with DM1 after KT.
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The effects of vildagliptin added-on insulin therapy in well-controlled
type 2 diabetic patients onmarkers of glomerular and tubular kidney
injury
V. Bayrasheva1,2, A. Babenko1, S. Chefu1, Y. Dmitriev1, I. Shatalov3, E.
Grineva1;
1Institute of Endocrinology, Federal North-West Medical Research Cen-
tre, 2Pavlov First Saint Petersburg State Medical University,
3St.Petersburg national research University of Information, Technologies,
Mechanics and Optics, Saint-Petersburg, Russian Federation.
Background and aims: Several recent experimental studies have dem-
onstrated beneficial effects of dipeptidyl peptidase 4 inhibitor vildagliptin
on certain processes associated with reduced renal function in diabetes,
but its renal effects in patients with type 2 diabetes (T2D) have still
remained unclear. The study aimed to assess the effects of vildagliptin
added-on insulin therapy on kidney dysfunction markers in type 2 dia-
betic patients.
Materials and methods: The study aimed to assess the effects of
vildagliptin added-on insulin therapy on kidney dysfunction markers in
type 2 diabetic patients.In a single-center, unblinded, randomized com-
parative clinical study we investigated the dynamic of serum (estimate
GFR using creatinine (eGFRcr) and cystatin C (eGFRcys)) and twice-
measured urinary markers of renal dysfunction, based on a first morning
urine spot (indicators of glomerular injury - albuminuria, and excretion of
collagen type IV; proximal tubular (neutrophil gelatinase-associated
lipocalin (NGAL)), and distal tubular (liver fatty acid-binding protein
(L-FABP)) damage markers in forty three well-controlled insulin-treated
patients with T2D randomized either to continue insulinotherapy (insulin-
treated group (IG), n=22), or to receive 6-month vildagliptin treatment in
daily dose 50 mg added-on insulin (vildagliptin/insulin-treated group
(VIG),n=21). Non-inclusion criteria were severe micro- and
macrovascular diabetic complication, uncontrolled hypertension, inflam-
matory and oncological conditions, nephrotoxic drugs using, and renal
disease other than diabetic nephropathy.
Results: Studying groups were comparable on the basis of sex and age
(from 54 to 67 years) , and duration of T2D ranged from 5 to 17 years. At
baseline, in VIG eGFRcr was 76,7±7,8 ml/min/1.73 m2, eGFRcys 84,2±
10,2 ml/min/1.73 m2, albuminuria 37±11,4 mg/l, excretion of collagen
type IV 3,98±1,16 μg/l, urinary NGAL 46,7±16,8 ng/ml, and urinary L-
FABP was 848±87,8 ng/ml, and these parameters didn’t statistically dif-
fer compared to IG. Although there were no comparable changes in
eGFRcr, albuminuria, and NGAL in both studying groups, eGFRcys,
and excretions of collagen type IV were significantly improved in VIG
after 6-month vildagliptin treatment (89,6±8,7 ml/min/1.73 m2, 3,46±1,
1 μg/l, (respectively, p≤0,5). Also the tendency to lowering urinary L-
FABP was observed (805,6±66,8 ng/ml, P=0,052).
Conclusion: The results of the study showed that 6-month vildagliptin treat-
ment in daily dose 50 mg added-on insulin therapy in well-controlled type 2
diabetic patients could result in amelioration of glomerular dysfunction.
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Urinary albumin excretion with sitagliptin compared to sulfonylurea
as add on to metformin in patients with type 2 diabetes and albumin-
uria: a real-world evidence study
H.L. Katzeff1, I. Goldshtein2, K. Tunceli1, G. Chodik2, L. Radican1, V.
Shalev2, N. Gadir1, S. Yu1, S.S. Engel1, E.S. Ommen1, O. Sharon1, A.
Karasik3;
1Merck &Co., Inc., Kenilworth, USA, 2Maccabi Healthcare Services, Tel
Aviv, 3Sheba Medical Center, Tel Hashomer, Israel.
Background and aims:We compared the change in urinary albumin to
creatinine ratio (UACR) in patients with type 2 diabetes (T2DM) and
albuminuria who initiate sitagliptin to those who initiate sulfonylurea
(SU) as add-on to metformin monotherapy.
Materials and methods: A cohort of T2DM patients with albuminuria
(UACR >30 mg/g), who initiated sitagliptin or SU as add-on therapy to
metformin from 2008-2014, was extracted from the computerized medi-
cal records of a large managed care organization in Israel. Patients with
available UACR measurements at treatment initiation and 120-365 days
afterwards were included. A propensity score matching with a 1:1 ratio
and 17 matching factors including demography, comorbidities, baseline
levels of HbA1c, UACR, BMI, eGFR, and ACE/ARB use, was imple-
mented. The changes in UACR were compared between the matched
pairs using generalized estimating equations.
Results: A total of 282 eligible pairs were identified. During a mean
follow-up of 9 months, median UACR changes were -35% (IQR=-73%
to 5%) and -31% (IQR=-72% to 21%) in the sitagliptin and SU groups,
respectively. Mean absolute HbA1c reductions among sitagliptin and SU
groups were 0.9% and 1.0%, respectively. The magnitude of UACR
reduction generally increased with greater magnitude of HbA1c reduction
in both treatment groups. After controlling for HbA1c reduction and the
interaction between HbA1c reduction and UACR reduction, sitagliptin
users demonstrated a trend toward a greater reduction in UACR com-
pared to SU users (odds ratio=1.20; 95% confidence interval: 0.99-1.47,
P=0.063).
Conclusion: Our results suggest that both sitagliptin and SU reduce al-
buminuria as an add-on therapy to metformin, but sitagliptin may provide
greater reductions in albuminuria per improvement in glycemic control
when compared to SU. We could not rule out chance in our study, how-
ever, and a larger population study is required to explore this further.
Supported by: Merck & Co., Inc.
1108
Glucagon-like peptide-1 receptor agonists decreases albuminuria in
overweight patients with type 2 diabetes
T. Bulum, K. Blaslov, M. Tomić, L. Duvnjak;
Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Dis-
eases, University Hospital Merkur, Zagreb, Croatia.
Background and aims: Glucagon-like peptide-1 (GLP-1) is a gut
incretin hormone that stimulates insulin secretion from pancreatic β-cell
in a glucose-dependent manner. In kidney, the GLP-1 receptors are
expressed in glomerular capillary and vascular walls. Oxidative stress
produced by chronic hyperglycemia has a central role in the development
and progression of diabetic nehropathy. Activation of GLP-1 receptor
stimulates the production of cAMP and subsequent activation of protein
kinase A (PKA) and contributes to various physiological actions includ-
ing insulin secretion and antioxidative effects that protect various tissues
from oxidative injury. GLP-1 receptor agonists exenatide and liraglutide
have structural similarity and bind to the GLP-1 receptor displaying a
similar broad range of activities relevant to improving glycemic control
and antioxidative effects. The aim of this study was to investigate the
effects of GLP-1 receptor agonists exenatide and liraglutide on metabolic
and renal function parameters in overweight patients with type 2 diabetes
(T2DM).
Materials andmethods:A total of 75 overweight T2DMwith normal or
mildly decreased (estimated GFR≥60 mlmin-11.73 m2) renal function
were included in this study and followed for 17 months (age 58±8 years,
33 M/42 F, body mass index (BMI) 39±5 kg/m2, weight 112±20 kg,
HbA1c 8.4±1.2%, duration of diabetes 12±6 years, serum creatinine 73±
20 umol/L, estimated GFR 89±16 mlmin-11.73 m2, urinary albumin
excretion rate (UAE) 184.8±560.1 mg/24 h, exenatide/liraglutide group
36/39 patients). UAEwas measured from at least two 24-h urine samples.
Estimated GFR was calculated using the Chronic Kidney Disease Epide-
miology Collaboration (CKD-EPI) formula. Microalbumin was mea-
sured spectrophotometrically by turbidimetric immuno-inhibition.
Liraglutide was started as 0.6 mg once daily dose and increased up to
1.8 mg once daily. Exenatide was started as 5 μg twice daily dose and
increased to 10 μg twice daily.
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Results: Treatment with GLP-1 receptor agonists caused a significant
decrease in HbA1c from 8.4±1.2 to 8.0±1.3% (p=0.03), BMI from 39
±5 to 36±5 kg/m2 (p<0.001), and weight from 112±20 to 103±20 kg (p
<0.001). However, the 17-months administration of GLP-1 receptor ag-
onists caused a significant decrease in UAE from 184.8±560.1 to 82.8±
268.9 mg/24 h (p=0.04), while serum creatinine (from 73±20 to 73±22
umol/L (p=0.4)) and estimated GFR (from 89±16 to 89±19 mlmin-
11.73 m2 (p=0.4)) did not significantly changed. The effects of GLP-1
receptor agonists onmetabolic and renal function parameters were similar
in both exenatide/liraglutide groups (data not shown) and were not sig-
nificantly different compared to presented combination results.
Conclusion: The results of our study suggest that therapy with GLP-1
receptor agonists liraglutide and exenatide may significantly reduce UAE
in overweight T2DM. It has been suggested that GLP-1 receptor agonists
has a crucial role in protection against increased renal oxidative stress
under chronic hyperglycemia via inhibition of NAD(P)H oxidase and
PKA activation which resulted in reduced albuminuria and mesangial
expansion.
1109
Primary prevention of albuminuria using renin-angiotensin system
inhibitors in patients with type 2 diabetes: a systematic review
F. Persson1, B. Hemmingsen2, M.K. Lindhardt1, P. Rossing1,3, H.-H.
Parving4,5;
1Steno Diabetes Center, Gentofte, 2Cardiology, Nephrology and Endocri-
nology, Nordsjællands University Hospital, Hillerød, 3NNF Center for
Basic and Metabolic Research, 4Medical Endocrinology, Rigshospitalet,
Copenhagen, 5Health, Aarhus University, Denmark.
Background and aims: Early prevention of diabetic nephropathy by
way of blocking the renin angiotensin system (RAS) in patients with
normoalbuminuria seems rational, but trials have so far shown conflicting
results. The present meta-analysis was undertaken to investigate if such
treatment can prevent development of microalbuminuria and to assess
whether available trials can provide sufficient information for such
conclusions.
Materials and methods: We searched MEDLINE, EMBASE and the
Cochrane Library for double-blinded randomised controlled trials, with
a population of patients with type 2 diabetes and normoalbuminuria,
comparing angiotensin enzyme inhibitors (ACEi) or angiotensin receptor
blockers (ARB) to placebo. At least one year of follow-up was required,
and trials had to have at least 50 participants in each arm. Random effects
and fixed effect models were performed as well as trial sequential
analysis.
Results: Six trials (Ravid et al, BENEDICT, MICRO-HOPE, AD-
VANCE, DIRECT, ROADMAP) were identified and included in the
analysis (n=16921). Overall risk of bias was low. In a fixed effects model
analysis ACE or ARB treatment was superior to placebo in relation to
development of microalbuminuria, relative risk 0.84 (95% CI 0.79, 0.88)
p<0.001, I2 23%, risk difference -4% (-5%, -3%), p=0.001. Similar
results were seen with the random effects model. Trial sequential analysis
confirmed a 16% RRR for development of microalbuminuria suggesting
sufficient trial data are available to draw a conclusion.
Conclusion: Sufficient trial data are available for the meta-analysis to
conclude that in patients with type 2 diabetes and normoalbuminuria,
ACEinhibitors or ARBs reduces the risk for development of
microalbuminuria.
1110
Patiromer lowers serum potassium in patients with elevated
potassium and diabetes and advanced CKD on RAAS inhibitors:
Results from OPAL-HK and AMETHYST-DN
M. Weir1, D. Bushinsky2, M. Mayo3, D. Garza3, Y. Stasiv3, S. Arthur3,
B. Schreiber3, L. Berman3, G. Bakris4;
1University of Maryland, Baltimore, 2University of Rochester, 3Relypsa,
Inc., Redwood City, 4University of Chicago, USA.
Background and aims:Albuminuria and decreased glomerular filtration
rate (GFR) are associated with increased risk of end stage renal disease
and cardiovascular events in patients (pts) with diabetes (DM). Guide-
lines recommend renin-angiotensin-aldosterone system inhibitors
(RAASi) for the management of micro- and macro-vascular complica-
tions of DM and advanced chronic kidney disease (CKD), however such
pts are at high risk for development of hyperkalemia, which may limit or
prevent RAASi use. We evaluated the effect of patiromer, a novel inves-
tigational potassium (K+)-binder, on serum K+ in DM pts with advanced
CKD on RAASi.
Materials and methods: OPAL-HK was a 12-week, 2-part (Part A,
treatment phase; Part B, randomized withdrawal phase), single-blind
study (n=243); AMETHYST-DN was a 52-week, randomized, open-
label study (n=304). Eligible pts had estimated GFR (eGFR) 15-
59 mL/min/1.73 m2, were on ≥1 RAASi and, in AMETHYST-DN, had
Type 2 (T2) DM. Entry serum K+ was 5.1-<6.5 mEq/L (OPAL-HK) and
>5.0-<6.0 mEq/L (AMETHYST-DN). In a post-hoc subgroup analysis,
efficacy data were pooled to determine the change from baseline in serum
K+ during the first 4 weeks of patiromer treatment (primary endpoint in
both studies) in pts with hyperkalemia, T2DM and eGFR <60 mL/min/
1.73 m2. Pts were stratified by baseline serum K+: >5.0-5.5 (mild) and
>5.5-<6.0 mEq/L (moderate) in AMETHYST-DN; 5.1-<5.5 (mild) and
5.5-<6.5 mEq/L (moderate-severe) in OPAL-HK.
Results: The pooled analysis includes 386 pts with T2DM and advanced
CKD and hyperkalemia on stable doses of ≥1 RAASi, who then received
patiromer at a starting dose of 4.2 or 8.4 g twice daily, respectively, for
mild or moderate-severe hyperkalemia for 4 weeks. For pts with mild and
moderate-severe hyperkalemia, respectively, mean (SD) time since
T2DM diagnosis was 13±8 and 14±9 yr, mean (SD) eGFR was 38±12
and 32±12 mL/min/1.73 m2, and mean (SE) serum K+ was 5.2±
0.02 mEq/L and 5.7±0.03 mEq/L at baseline (Day 1). With patiromer
mean serumK+was reduced to <5.0 mEq/L by the first post-baseline visit
(Day 3, approx. 48 hr after first dose) in mild hyperkalemia pts and by
Week 1 in moderate-severe hyperkalemia pts and continued to improve
(Fig). By week 4, mean (95% CI) serum K+ change from baseline was -
0.58 mEq/L (-0.65,-0.51) in mild hyperkalemia and -1.12mEq/L (-1.20, -
1.04) in moderate-severe hyperkalemia pts (both p<0.001). Adverse
events in these pts were predominately mild-to-moderate gastrointestinal
complaints. Adverse events led to patiromer discontinuation in 10.5% of
pts over 52 weeks in AMETHYST-DN and in 5.0% of pts in Part A (first
4 weeks) and 0% in Part B (weeks 5-12) in OPAL-HK.
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Conclusion: Patiromer significantly reduced serum K+ in hyperkalemic
pts with T2DM and advanced CKD over 4 weeks. Patiromer may be an
option for hyperkalemia treatment in pts with T2DM and advanced CKD.
Clinical Trial Registration Number: NCT01810939, NCT01371747
Supported by: Relypsa, Inc.
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Death, cardiovascular and renal events in type 2 diabetic patients
with proteinuria followed by nephrologists: results of the 2-year
ALICE PROTECT study
B. Fiquet1, J.-M. Halimi2, G. Choukroun3, C. Combe4, B. Dussol5, J.-P.
Fauvel6, S. Quéré7, D. Joly8;
1Medical affairs, Novartis Pharma SAS, Rueil-Malmaison, 2Nephrology
unit, CHU Université François Rabelais, Tours, 3Nephrology unit, CHU
Université Picardie Jules Verne, Amiens, 4Nephrology unit, CHU
Université Bordeaux Segalen, 5Nephrology unit, CHU Aix-Marseille
université, 6Nephrology hypertension unit, CHU Université Claude Ber-
nard, Lyon, 7Biostatistic, Novartis Pharma SAS, Rueil-Malmaison, 8Ne-
phrology unit, Hôpital Necker Université Paris-Descartes, Paris, France.
Background and aims: Type 2 diabetes (T2DM) is the leading cause of
chronic kidney disease (CKD) in western countries. The combination of
T2DM and CKD increases the risk of end stage renal disease (ESRD),
cardiovascular events and all-cause mortality. UKPDS study showed that
the risk of death was higher than the risk of renal disease progression.
Early control of blood pressure (BP) and proteinuria (Pu) is crucial to
slow down the progression of the CKD and prevent cardiovascular events
and mortality.
Materials and methods: Prospective, multicenter, observational study
conducted from 2010 to 2013. Overall, 153 French nephrologists includ-
ed 986 T2DM patients with Pu (≥0.5 g/day) and an eGFR>15 ml/min/
1.73 m2. Data from 729 patients were available after a 2-year follow-up.
The primary objective was to assess the proportion of patients reaching
the BP (<140/90 mmHg) and Pu targets (<0.5 g/day) at the end of the
study. We also looked at renal (doubling of plasma creatinine and/or
ESRD) and cardiovascular events.
Results: At baseline, 74% of the patients were male, mean age was
70 years. The mean T2DM duration was 17 years with a mean HbA1c
of 7.4%. All were treated for hypertension and 33% had a controlled BP;
81% had dyslipidemia and LDLc was <1 g/L for 54%; 44% had retinop-
athy, 40% macrovascular complications and 12% heart failure. Mean Pu
was 2 g/day and eGFR 40±20mL/min/1.73m2, with 13%,18%, 32% and
37% of the patients in respectively stage 2, 3a, 3b and 4 CKD. After two
years, 21% reached the Pu target and 39% the BP target. The mean eGFR
of 40±20.3 ml/min/1.73m2 at baseline dropped to 36.5±20.9 by year one
and to 33.9±22.6 ml/min/1.73 m2 by year two (p<0.001).This
corresponded to a mean annual eGFR reduction of 3.2 ml/min/1.73 m2.
118 patients presented a renal event (16.2%): doubling of serum creati-
nine for 86 patients (11.8%) and start of dialysis for 72 (9.9%); 176
patients (24.1%) developed at least one cardiovascular complication dur-
ing the follow-up period, and among these, 50 had also developed renal
complications. Overall, 61 patients (8.4%) had a coronary event, 25 pa-
tients had a stroke (3.4%), 32 patients underwent a lower limb
revascularisation procedure (4.4%), 17 patients required amputation
(2.3%) and 80 patients were hospitalised with heart failure (11%). Sixty
patients died, i.e. 8.2%, 26 patients from cardiovascular causes.
Conclusion: Our study highlights that achieving BP and Pu targets re-
mains a major challenge in patients with T2DM and nephropathy, even in
a nephrology environment. In contrast to older studies, renal failure is
more frequent than death.
Supported by: Novartis
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Triglyceride variation and renal function in type 2 diabetes
R. Fonseca, C. Tavares Bello, C. Barreiros, C. Moniz, C. Limbert, J.
Sequeira Duarte, M. Oliveira, J. Azinheira, C. Vasconcelos;
Endocrinology, Hospital de Egas Moniz, Lisboa, Portugal.
Background and aims: Diabetic nephropathy progression is linked to
glycemic and blood pressure control. The effect of lipid metabolism is not
totally understood. Hypertriglyceridemia is thought to be a risk factor to
renal failure progression. The author's objective was to investigate the
association between triglyceride variation (Δ TG), renal function and
metabolic control in type 2 diabetic patients (T2D).
Materials and methods: Retrospective cohort observational study of
T2D patients, followed between 2005 and 2014, for at least two years.
Secondary forms of diabetes, children and renal transplant patients were
excluded.Δ TG was determined by calculating the mean of yearly stan-
dard deviation of triglyceride levels per patient and compared to eGFR
(obtained by CKD-EPI formula), glycemic control, blood pressure and
drugs. We used descriptive statistical methods, Pearson’s correlation, stu-
dent t-test and ANOVA for continuous and chi-square for categorical
variables.
Results: There were 2322 patients (38% males) with a median follow-up
time of 6.9±4.9 years. Initial median GFRe was 71 (7-138)ml/min/1,
73 m2 and the final 63 ml/min/1,73 m2. Δ TG was strongly correlation
withGFReworsening (p=0,002). Higher fasting plasma glucose, HbA1c,
albuminuria and uric acid were also associated to TG variation (p<0,
001). A modest correlation was obtained between Δ TG and weight
(p=0.045), but not significantly with BMI. There was not an impact of
Δ TG in inflammatory markers, hepatic function and systolic blood
pressure.
Conclusion: Triglyceride variation was significantly associated with re-
nal function worsening, but also with worse glycemic control (higher fast
plasma glucose and HbA1c) and hyperuricemia. Hypertriglyceridemia
control may be an important factor to slow the diabetic nephropathy
progression.
1113
Evolution of albuminuria depending on HbA1c in diabetes mellitus
type 1 patients. 20-year follow-up study
L.L. Bolotskaya1, M.Y. Kutuzova1, M.S. Shamkhalova1, M.V.
Shestakova2;
1Diabetic Nephropathy, 2Diabetology, FSBU Endocrinology Research
Center, Moscow, Russian Federation.
Background and aims: To investigate the rate of albuminuria (AU)
according to changes of glycated hemoglobin (HbA1c) in patients with
debut of diabetes mellitus type 1 (DMT1) in their childhood during
20 year observational period.
Materials and methods: 256 patients with DMT1 (girls-143, boys-113)
took part in the follow-up study from 1994 to 2014. Average age of
DMT1manifestation was 9.95±3.01 years. HbA1cwasmeasured 4 times
a year. Complications screening was done at least once a year.
Results: AU was diagnosed in 44 patients (17.2%) at the age of 15.53±
3.93 years after 5.6±2.76 years from beginning of DMT1 in accordance
with categories A2 (30-300 mg/L) and A3 (>300 mg/L) with average
level of HbA1c 9.57±2.32%. Correlation between changes in the rate
of AU and annual fluctuation of HbA1c level was established in 37
patients (84%). All measurements of HbA1c were conditionally divided
into 2 groups: 1) HbA1c<9%; 2) HbA1c≥9%. We determined annual
crucial changes of HbA1c level, which were associated with
manifestation of AU or its progression: in the group of HbA1c<9%
average yearly fluctuation of HbA1c was -1.92±1.08÷1.59±1.09; in the
group of HbA1c≥9% - -1.39±1.4÷1.41±1.3. The difference between
negative average values of the HbA1c crucial interval in two groups
was statistically significant (p<0.01). The safe interval of annual HbA1c
level changes leading to AU reduction or even regression to the category
A1 (<30 mg/L) was established: in the group of HbA1c<9% - -0.78±
0.78÷0.76±0.74; in the group of HbA1c≥9% - -0.98±0.88÷0.94±0.94.
The divergence between negative average values of HbA1c changes in
both groups was estimated with p=0.05.
Conclusion: In our study the correlation between AU and HbA1c fluc-
tuation rates was established.We also determined safe HbA1c fluctuation
rate interval as renal dysfunction risk factor in patients with DMT1 debut
in childhood.
1114
The association between glycaemia, blood pressure, and lipidaemia
control and the risk of renal function progression in type 2 diabetes
patients
P.-Y. Chang1, L.-N. Chien2, Y.-W. Chang3, Y.-F. Lin4, K.-X. Ho5, W.-T.
Chiu6, H.-Y. Chiou1;
1School of Public Health, 2School of Health Care Administration, Taipei
Medical University, Taiwan, 3Department of Information Management,
China Jiliang University, Hangzhou, China, 4Graduate Institute of Clini-
cal Medicine, Taipei Medical University, Taipei, 5Department of Nursing,
Hsin Sheng College of Medical Care and Management, Taoyuan, 6Grad-
uate Institute of Injury Prevention and Control, Taipei Medical Universi-
ty, Taiwan.
Background and aims: Studies have demonstrated that the intensive
control of glycemia, blood pressure, or lipidemia can slow progression
of kidney outcomes. In addition to glycemia control of patients with
diabetes, blood pressure and hyperlipidemia should also be managed.
However, there is no study to discuss the association between simulta-
neous control of diabetes mellitus, hypertension, and hyperlipidemia and
renal function. Thus, this study was to examine the interactive effects of
the intensive control of three diseases on rapid progression of renal
function.
Materials and methods: This prospective cohort study enrolled 2768
adult patients with type 2 diabetes from eight hospitals in Taiwan in
October, 2008 to September, 2014. Demographic characteristics was col-
lected using structured questionnaires. Clinical examination was obtained
using medical chart reviews. Rapid progression of renal function was
defined as a continued decline in eGFR of more than 5 ml/min/1.73 m
−2/year. The poor control of diabetes mellitus, hypertension and hyper-
lipidemia was defined as if a patient had a HbA1C ≧7%, MAP
>100 mmHg, and total cholesterol≧200 mg/dl and triglyceride≧150 mg/
dl, respectively. Cox proportional hazard regression models were used to
study the associated between interactive effects of diabetes, hypertension
and hyperlipidemia controls and the rapid progression of renal function.
Covariates included age, sex, stroke, CVD, anemia, CKD, BMI, baseline
eGFR, BUN, smoking, alcohol, and Chinese herb drug.
Results: A total of 27.1% (751/2768) had rapid progression of renal
function during a mean follow-up of 2.4 years (SD: ±1.16). The mean
age of the cohort was 62.9±11.5 years, and male gender accounted for
53.6%.
When considered the single effect of the control of diabetes, hypertension
and hyperlipidemia, the poor control of glycemia had the highest risk of
the increase risk of rapid progression of renal function, with an adjusted
HR of 1.41 (95% CI: 1.22-1.64). The poor control of hypertension and
hyperlipidemia was also associated the increase risk of rapid progression
of renal function, with an adjusted HR of 1.27 (95% CI: 1.03-1.56) and
1.25 (95% CI: 1.01-1.56), respectively. When considered the interactive
effect of the poor control of all three diseases, we treated the patients with
an intensive control of all three disease as the reference group. Compared
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to the reference group, the poor control of all three diseases had the
highest risk of rapid progression of renal function, with an adjusted HR
of 2.84 (95%CI, 1.80-4.47). Even if the patients with an intensive control
of glycemia, the result showed the poor control of both hypertension and
hyperlipidemia was associated with the increased risk of rapid progres-
sion of renal function, with adjusted HR of 1.92 (95% CI of 1.11-3.29)
than the reference group.
Conclusion: A poor control of glycemia, blood pressure, and lipidemia
were found to be associated with the increased risk of declining renal
function.
Supported by: TMU-Joint Institutional Review Board (Approval No:
201204036), Health Promotion Administration, Ministry of Health and
Welfare, Taiwan
1115
Decline in renal function was not associated with steatosis evaluated
by proton-spectroscopy in a population of people with type 2 diabetes
J.-M. Petit, C. Fourmont, B. Guiu, B. Bouillet, M.-C. Brindisi, E.
Crevisy, P. Buffier, S. Baillot-Rudoni, J. Cercueil, B. Verges;
diabetologie, CHU du Bocage, Dijon, France.
Background and aims:Data regarding the link between hepatic steatosis
and renal function in people with type 2 diabetes are controversial. Liver
fat content was associated with the development of diabetic nephropathy
in cross-sectional studies but not in one longitudinal study. We aimed to
determine whether liver fat content was associated with a decline in renal
function in patients with type 2 diabetes.
Materials and methods: Two hundred and twenty-three patients with
type 2 diabetes were included in the study. Liver fat content was measured
by proton spectroscopy at inclusion. Steatosis was defined by liver fat
content greater than 5.5%. The decline in renal function was assessed by
changes in the estimated glomerular filtration rate (eGFR), (MDRD for-
mula) over time. Diabetic nephropathy at inclusion was defined by the
presence of microalbuminuria or macroproteinuria.
Results: One hundred and thirty-four (60.1%) patients had steatosis.
Those with steatosis had higher BMI (p=0.0003), lower diabetes duration
(p=0.005) and a lower frequency of diabetic nephropathy at inclusion
(12.6% vs 24.7%, p=0.03). Age, HbA1c and eGFR at inclusion were not
statistically different between groups. The median follow up was
4.4 years. Hepatic steatosis was not associated with the rate of decline
in renal function calculated by year, but the difference was borderline
significant (Patients with steatosis had a lower annual renal decline than
those without steatosis (+0.48 vs. -0.98 ml/min per year, p=0.06). In
multivariate analysis, steatosis was associated with BMI, but not with
age, diabetes duration, diabetic nephropathy at inclusion, eGFR at inclu-
sion, renal decline per year or gender.
Conclusion: When we used an accurate method to evaluate liver fat
content, the presence of steatosis was not associated with the decline in
renal function in our cohort of patients with type 2 diabetes. Our study
suggests that early identification of hepatic steatosis in people with type 2
diabetes may not be useful to identify people at the highest risk of renal
decline.
1116
The risk of incident chronic kidney disease in a Koreanmetabolically
healthy obese population
C. Jung1, Y. Kang1, K.-U. Lee1,2, J. Jang1,2, I.-K. Lee3, M. Rhee4;
1Department of Internal Medicine, Asan Medical Center, University of
Ulsan College ofMedicine, 2Metabolism Reserch Unit, Asan Institute for
Life Sciences, Seoul, 3Department of Internal Medicine, Kyungpook Na-
tional University School of Medicine, Daegu, 4Department of Internal
Medicine, Division of Endocrinology and Metabolism, Department of
Internal Medicine, Korea University, Seoul, Republic of Korea.
Background and aims: Obesity is considered to be an important risk
factor for chronic kidney disease (CKD).The metabolically healthy obese
(MHO) phenotype refers to obese individuals with a favorable metabolic
profile. Its prognostic value remains controversial and may depend on the
health outcome being investigated. We examined the risk of MHO phe-
notype with incident CKD in a Korean population.
Materials and methods: The study population comprised 40,579 Ko-
reans without CKD. Participants were stratified by body mass index
(BMI) (cut-off value, 25.0 kg/m2) and metabolic health state (assessed
using Adult Treatment Panel-III criteria). Incident CKD was assessed by
the Modification of Diet in Renal Disease (MDRD) study equation and
defined by a glomerular filtration rate (GFR) less than 60ml/min/1.73 m2
during the follow-up period.
Results: Over the median follow-up period of 39.0 months (range, 4.8-
83.8 months), 315 of the 40,579 individuals (0.8%) developed incident
CKD. Compared with the metabolically healthy nonobese (MHNO)
group, the MHO group showed increased risk of incident CKD with a
multivariate-adjusted hazard ratio (HR) of 1.52 (95% confidence interval
[CI], 1.10-2.11). Nonobese but metabolically unhealthy individuals were
at an increased risk of incident CKD (multivariate-adjusted HR, 1.44
[95% CI, 1.01-2.00]) than the MHNO group.
Conclusion: Metabolically unhealthy obese individuals were at the
highest risk of incident CKD.A healthymetabolic profile does not protect
obese adults from incident CKD. Thus, it is important to consider meta-
bolic health and obesity when evaluating CKD risk.
1117
The prevalence of diabetic nephropathy in patients with type 2
diabetes mellitus in Slovakia: the NEFRITI Study
E. Martinka1, P. Pontuch2;
1Diabetes, National Institute of Endocrinology and Diabetology,
Lubochna, 24th Department of Internal Medicine, St. Cyril and
Methodius Hospital, Bratislava, Slovakia.
Background and aims:To assess: 1) the prevalence of diabetic nephrop-
athy (DNeF), 2) proportion of patients with complications and accompa-
nying diseases, according to the stage of chronic kidney disease (CKD)
and albuminuria, and 3) the proportion of patients with GFR<60 ml/min/
1,73 m2 with normal creatinine values.
Materials and methods: Randomized, multicentric, epidemiological
survey in cohort of 1831 patients with type 2 diabetes mellitus. Urinary
albumin was determined by turbidimetric method, GFR was calculated
by CKD-EPI formula.
Results: Male 46,5%, age 63,85±9,48 years (y), duration of diabetes 9,
29±7,21 y, HbA1c 7,5±1,6 median 7,2% (DCCT), BMI 31,5±5,6 kg.m-
2, hypertension 82,1%, dyslipidemia 76,8%, serum creatinine 80,3±44,0
umol/l, GFR 87,2±27,7 ml/min/1,73 m2, UACR 8,1±36,0 median 1,
41 mg/mmol. Proportions of patients with normoalbuminuria (nA) resp.
microalbuminuria (miA) resp. macroalbuminuria (maA) were 67,7%
resp. 25,2% resp. 5,01%. Proportion of patients with CKD stage 1
(CKD1) 42,9% CKD2 42,8%, CKD3a 9,4% CKD3b 3,3%, CKD4 1,
2% CKD5 0,39%. The prevalence of DNeF based on a presence of
maA or miA, eGFR>30 ml/min/1,73 m2 and diabetic retinopathy was
12,7%. The prevalence of DNeFwas increasing with duration of diabetes:
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less than 5y / 5-10y / 10-15y / 15y and more was 4,8 / 9,9 / 15,9 / 26,8%.
Chronic renal failure (CKD5 and/or dialysis) was found in 0,45%. The
proportion of patients with complications of diabetes and accompanying
diseases were rapidly increasing with both increasing stage of CKD and
albuminuria (Tab. 1).
Conclusion: The prevalence of DNeF in patients with Type 2 diabetes in
Slovakia was 12,3%. Both, increase in stage of CKD and albuminuria
were associated with increase in all complications of diabetes and accom-
panying diseases. Normal serum creatinine values were found in 35,4%
of patients with eGFR<60 ml/min/1,73 m2. Namely in elderly
women.The study has been reviewed by the Local Ethics Committee
and therefore it been been performed in accordance with the ethical stan-
dards laid down in the Helsinki Declaration.
1118
Frailty and the relationship between albuminuria and renal function
in elderly patients with type 2 diabetes (ZODIAC)
K.J.J. van Hateren, L.C. Hartog, G.W.D. Landman, K.H. Groenier,
H.J.G. Bilo, N. Kleefstra;
Diabetes Centre, Zwolle, Netherlands.
Background and aims: In elderly patients with type 2 diabetes mellitus
(T2DM), a moderate reduced renal function (eGFR between 45 and
60 ml/min) is not related to mortality. Other cardiovascular risk factors,
such as blood pressure, also have different consequences in old age.
Previous studies showed that frailty influences the relationship between
several risk factors, e.g. blood pressure, and mortality in old age. We
hypothesized that the relationship between renal function and mortality
may also be influenced by the level of frailty.
Materials and methods: Patients with T2DM participating in a prospec-
tive observational cohort study (ZODIAC) in the Netherlands were in-
cluded. Patients aged 60 years and older were selected from this cohort of
primary care treated patients. Frailty was defined as a score less than 80
on the subscale ‘physical functioning’ of the RAND-36 questionnaire.
After median follow-up for 14 years, multivariate Cox regression analy-
ses were performed to evaluate the association between albuminuria/renal
function and (cardiovascular) mortality. Analyses were performed in stra-
ta according to the frailty level (‘physical functioning’ score 80). We
adjusted for age, gender, BMI, duration of diabetes, systolic blood pres-
sure, serum creatinine level (for model with albuminuria), total
cholesterol-HDL ratio, HbA1c, macrovascular complications, albumin-
uria (for model with eGFR), lipid lowering drugs and the use of antihy-
pertensive drugs. Renal function was estimated by the Modification of
Diet in Renal Disease equation (MDRD).
Results: Approximately 60% of our study population was female. Median
age (interquartile range) was 72 (67-77) years and median diabetes duration
was 6 (3-12) years. Frailty was highly prevalent in our study population; 629
out of 858 patients (73%) fulfilled the criterion. Albuminuria was related to
increased all-cause and cardiovascular mortality in both frail and non-frail
patients (table 1). Every 10 ml/min decrease in eGFR was related to a 41%
(95% confidence interval (CI): 12-76%) and 18% (95% CI: 8-27%) higher
cardiovascular mortality risk in non-frail and frail patients, respectively. No
significant associationswere observed between eGFR and all-causemortality.
Conclusion: The presence of albuminuria and decreased eGFR were
related to cardiovascular mortality in both frail and non-frail elderly pa-
tients with T2DM. However, the associations were the strongest for non-
frail patients. Therefore, we conclude that frailty seems to attenuate the
relationship between renal function and cardiovascular mortality, but not
for all-cause mortality.
1119
Albumin- and haemoglobin- corrected HbA1c detects uncontrolled
diabetic patients on haemodialysis better than glycated serum
protein: a continuous glucose monitoring study
F. Iliadis1, M. Divani1, T. Didangelos1, C. Margaritidis1, A. Makedou2,
V. Liakopoulos3, A. Hatzitolios1, D. Grekas1;
1First Propedeutic Department of Internal Medicine, 2Laboratory of
Lipids, 2nd Paediatric Department, 3First Department of Internal Medi-
cine, AXEPA Hospital, Aristotle University of Thessaloniki, Greece.
Background and aims: It is reported that HbA1c is unreliable in hemo-
dialysis patients, underestimating the level of glycemic control. Anemia
and administration of erythropoietin are the primary factors that influence
its validity. Alternatively the glycated serum protein (GSP) has been
proposed as a more reliable marker of glycemic control in these patients.
The aim of the studywas to compare these twomarkers of glucose control
estimation in hemodialysis patients with diabetes.
Materials and methods:We studied 38 hemodialysis patients with dia-
betes (36 type 2), sex: 22 male, age: 62.8 (16.2) years, BMI: 27.0 (3.9)
Kg/m2, serum albumin (Alb): 4.0 (0.3) g/dl, hemoglobin (Hb): 10.9 (1.4)
g/dl, HbA1c: 6.5 (1.3)% and GSP: 622.8 (184.3) μmol/L. A 7-day con-
tinuous glucose monitoring system was used (iPro2 CGM) in order to
measure the average glucose (mAG: 162.5±35.3 mg/dl) and the standard
deviation of mAG (mSDG: 49.1±17,0 mg/dl). The predicted HbA1c
(preHbA1c) according to mAG was calculated, based on equation:
preHbA1c=mAG+46.7 / 28.7.Moreover we estimated the AG according
to HbA1c, based on equation for patients in hemodialysis: eAG=104.8+
(29.7 X HbA1c) - (18.4 X Alb) - (4.7 X Hb) and thereafter we estimated
the corrected HbA1c (corHbA1c=eAG+46.7 / 28.7). ROC analysis was
performed to determine which of the three markers (HbA1c, corHbA1c
and GSP) could predict better mAG≥184 mg/dl, which in patients with
normal renal function corresponds to HbA1c≥8% and detects the uncon-
trolled diabetic patients in hemodialysis. Statistical analysis was per-
formed with SPSS 18.0. P value<0.05 was considered statistically
significant.
Results: preHbA1c and corHbA1c were 7.3 (1.2)% and 7.6 (1.4)% re-
spectively. There was a significant difference betweenHbA1c, preHbA1c
and corHbA1c (p=0.001). HbA1c was statistically significantly lower
compared to preHbA1c (p=0.033) and to corHbA1c (p=0.001). There
was no statistically significant difference between preHbA1c and
corHbA1c (p=0.509). The mAG and the mSDAG were significantly
correlated with HbA1c, corHbA1c and GSP (p>0.001). The area under
receiver-operating characteristic curve (AUC) for HbA1c, corHbA1c and
GSP to detect mAG≥184 mg/dl was 0.786 (0.623-0.902), 0.771 (0.606-
0.891) and 0.694 (0.523-0.832) respectively. There was no significant
statistical difference between the AUCs. The sensitivity of HbA1c≥8%,
corHbA1c≥8% and GSP≥650.0 μmol/L to detect mAG≥184 mg/dl was
36.4%, 72.7% and 81,8% respectively. The specificity of HbA1c≥8%,
corHbA1c≥8% and GSP≥650.0 μmol/L to detect mAG≥184 mg/dl was
85.2%, 85.2% and 63.0% respectively. In total, the false negative and
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false positive values of HbA1c≥8%, corHbA1c≥8% and GSP≥
650.0 μmol/L to detect mAG≥184 mg/dl were 11 (28.9%), 7 (18.4%)
and 12 (31.5%) respectively.
Conclusion: In hemodialysis diabetic patients, HbA1c should be
corrected according to serum albumin and hemoglobin. The albumin-
and hemoglobin- corrected HbA1c seems to detect uncontrolled diabetic
patients on hemodialysis better than glycated serum protein.
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High glucose induces membrane-bound transcription factor pepti-
dase site1 via carbohydrate response element binding protein tomod-
ulate ER stress in mesangial cells
Y. Makino, K.K. Atageldiyeva, H. Kitsunai, K. Mizumoto, T.
Yanagimachi, Y. Fujita, A. Abiko, Y. Takiyama, M. Haneda;
Department of Medicine, Asahikawa Medical University, Japan.
Background and aims: High glucose (HG) evokes a variety of gene
expressions in mesangial cells (MC) that alter cellular functions respon-
sible for the development of diabetic glomerulopathy. We previously
reported that HG activates hypoxia-inducible factor-1α and its target
genes expression in MC, leading to an extracellular matrix expansion in
diabetic glomeruli. A glucose responsive transcription factor, carbohy-
drate response element binding protein (ChREBP), plays a pivotal role
in such derangement of gene regulation. To provide more insight into
glucose-mediated gene regulation at genome-wide level, we performed
chromatin immunoprecipitation with anti-ChREBP antibodies followed
by DNA microarray analysis (ChIP-chip) and identified membrane-
bound transcription factor peptidase site1 (MBTPS1) as a novel target
gene of ChREBP in MC. MBTPS1 proteolytically activates a class of
transmembrane transcription factors at the endoplasmic reticulum (ER)
and participates in the regulation of cellular events such as response to ER
stress; however the role of MBTPS1 in MC under diabetic circumstances
is largely unknown. In the present study, we examined the mechanism by
whichMBTPS1 is induced by HG inMC, and the role of MBTPS1 in the
regulation of cellular function.
Materials and methods: Cultured human MC were incubated in HG
(25 mM glucose) and normal glucose (NG; 5.6 mM glucose), and the
gene and protein expression were analyzed. Gene expressions in the
kidney of diabetic model mice were determined by real time PCR.
Results:ChIP-chip assay revealed binding of ChREBP toMBTPS1 gene
at 2.5 kb in 3’-flanking region. In validation analyses, exposure to HG for
24 h enhanced MBTPS1 mRNA expression in cultured MC (2.4±0.43
fold, compared to NG). Knock-down of ChREBP abrogated this induc-
tion response. MBTPS1 is known for the proteolytic activation of acti-
vating transcription factor-6 (ATF6), which is involved in the adoptive
response to ER stress. In support of these issues, HG induced the activa-
tion of ATF6 in MC and the inhibitor of MBTPS1 cancelled this activa-
tion. Interestingly, the target genes of ATF6 were not universally induced
by HG; C/EBP homologous protein, a critical determinant of ER stress-
induced apoptosis, was induced by 4.8±1.1 fold (p<0.05), whereas X-
box-binding protein 1 was induced by 1.8±0.2 fold (p<0.05) of and
glucose-regulated protein-78 was not induced, indicating that MBTPS1
may participate in the control of the fate of MC exposed to HG. More-
over, the expression of MBTPS-1 mRNAwas upregulated in the kidney
of streptozotocin-induced diabetic model mice compared to control mice
(1.36 fold).
Conclusion: HG-mediated induction of MBTPS1 via ChREBP operates
in response to ER stress inMC, which may provide novel insights into the
pathogenesis and therapeutic intervention of diabetic nephropathy.
Supported by: JSPS KAKENHI
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Advanced Glycation End products (AGEs) increase human renal
tubular foam cell formation by endoplasmic reticulum stress
Y. Yuan, H. Sun, Z. Sun;
Department of Endocrinology, ZhongDa Hospital, SouthEast University,
Nanjing, China.
Background and aims: Diabetic nephropathy caused by advanced
glycation end products (AGEs) is associated with lipid accumulation in
renal tubule. This study was designed to investigate whether
Nε-(carboxymethyl) lysine (CML) (one of AGEs family) increase lipid
accumulation in human renal tubular epithelial cell line (HK-2) via in-
creasing cholesterol synthesis and uptake, reducing cholesterol efflux
though endoplasmic reticulum stress (ERS).
Materials and methods:HK-2 were incubated with CML. Cell viability
was evaluated through the CCK-8 assay, and cell apoptosis was evaluated
by Annexin V-FITCKit. Intracellular cholesterol content was assessed by
Oil Red O staining and cholesterol enzymatic assay. Expression of
mRNA and protein of molecules controlling cholesterol homeostasis in
the treated cells was examined by real-time quantitative PCR and western
blotting, respectively.
Results: CML reduced the cell viability and increased the cell apoptosis
of HK-2 cells, which could be inhibited by anti-RAGE (RAGE, receptor
of AGEs). CML increased cholesterol accumulation in HK-2 cells, how-
ever anti-RAGE reduced the lipid content. Exposure to CML increased
expression of 78-kDa glucose-regulated protein (GRP78) and C/EBP
homologous protein (CHOP), which up-regulated transcription factor
SREBP-2 to the Golgi for activation by cleavage enhanced gene tran-
scription of HMGCoA reductase and LDL receptor, down-regulated
adenosine triphosphate-binding cassette transporter A1 (ABCA1) and
Liver X receptor (LXR), which were reversed by anti-RAGE. The effects
of CML were blocked by 4-PBA(4-PBAwas used to inhibit ERS).
Conclusion: CML increased HMG-CoAR-mediated cholesterol synthe-
sis and LDLr-mediated cholesterol uptake, reduced ABCA1-mediated
cholesterol efflux though ERS, ultimately, caused lipid accumulation in
HK-2 cells. These data imply that inhibiting ERS might have a potential
renal protective role in prevention of renal tubular foam cell formation.
1122
Effects of high free fatty acids on human kidney epithelial cells
G. Li1, X.-F. Khew1, S. Meng1, C.-S. Yap1, M.-M. Tong1, Y.-M. Bee2;
1Clinical Research, 2Endocrinology, Singapore General Hospital, Singa-
pore.
Background and aims: Diabetes is an epidemic metabolic syndrome,
becoming one of the most common causes of kidney diseases leading to
the end stage renal failure and dialysis requirement. Several factors in-
cluding hyperglycemia and dyslipidemia have been identified as risk
factors for diabetic nephropathy. Also, an elevation of free fatty acids
(FFA) level is commonly observed in diabetic patients. This study exam-
ined potential adverse effects of high FFA on kidney epithelial cells and
investigated relevant signaling pathways.
Materials and methods: RC124 cells (a human kidney epithelial cell
line) were treated with high concentrations (0.5 and 1 mM) of the satu-
rated palmitic acid (PA) alone, or a mixture of equal amount of PA and the
monounsaturated oleic acid (OA), for 12, 24 or 48 hours, followed by
assessments of cell viability and various signaling pathways using
immuno-blotting and assay kits run on Muse Cell Analyzer.
Results: Morphological changes occurred after kidney epithelial cells
were exposure to high FFA, displaying coarse surface and membrane
blebbing. When OA was present, cell confluence was higher than that
by high PA treatment alone. High PA treatment reduced (up to by 80%)
viability of kidney epithelial cells in both time- and dose- dependent
manner. By contrast, co-treatment with equal amount of OAwas able to
block such adverse effects by PA to a large degree. The underlying
mechanisms for high FFA effects on renal cell viability were studied by
examining related signaling events. High PA treatment activated caspase-
3 and induced apoptotic cell death at 24 h. In addition, PA treatment
evoked endoplasmic reticulum (ER) stress (as indicated by increased
phosphorylation of eIF2α) and induction of autophagy (assessed by
detection of LC3-II) in renal cells. Both high PA-induced ER stress and
autophagy occurred at 12 h, a time point prior to apoptosis occurrence,
suggesting their possible causative relationship in the course of injuring
cells. On the other hand, co-treatment with OA abolished such PA-
induced ER stress, autophagy and apoptosis of renal cells.
Conclusion: High PA may exert lipotoxicity effects on kidney epithelial
cells via induction of ER stress, autophagy and apoptosis, which may
contribute to the development of renal diseases in diabetes. OA appears
capable of antagonizing high PA’s adverse action and potential for devel-
opment of targeting drugs.
Supported by: Singapore National Kidney Foundation
1123
The function of ELMO1 in renal development under diabetic condi-
tions within zebrafish and in human diabetic nephropathy
K.R. Sharma1, K. Heckler1, S.J. Stoll1, J.-L. Hillebrands2, J. Kroll1;
1Department of Vascular Biology and Tumor Angiogenesis, Center for
Biomedicine and Medical Technology Mannheim (CBTM), Germany,
2Department of Pathology and Medical Biology, University Medical
Center Groningen, Netherlands.
Background and aims: Although the engulfment and cell motility 1
(ELMO1) protein functions as a guanine exchange factor for Rac1, reg-
ulating cell migration and early vascular development within the
zebrafish (ZF); recently, it was found to protect endothelial cells from
apoptosis via activation of the Rac1/PAK/AKT signalling cascade
in vitro and in vivo. GWAS data suggests that polymorphisms in different
regions of human ELMO1 acts as a potential contributing factor for the
development of diabetic nephropathy (DN). However, the function and
altered expression of ELMO1 remains unclear with respect to the devel-
opment of DN and this study thus aims to illustrate the role played by
ELMO1 in renal development in ZF, under diabetic conditions, and DN
patients.
Materials and methods: ELMO1 expression within the Wt1B:GFP
transgenic zebrafish line was knocked out using the CRISPR:Cas9 tech-
nology. The renal system in Wt1B:GFP fish line is tagged with GFP and
hence was used to observe developmental changes within the
pronephron. ZF embryos were rendered diabetic via the knockdown of
PDX1 using specific splice blocking morpholinos. Nephron functional
assays were carried out with the help of TexasRed labelled Dextran to
observe leakage via the pronephron. TUNEL assay was used to measure
increase in apoptosis within the ZF embryos. Lastly, human kidney par-
affin sections from controls and DN human patients suffering from Type
1 and Type 2 DM were stained to observe and compare ELMO1 expres-
sion within the glomeruli.
Results: It was observed that a knockout of ELMO1 within ZF embryos
leads to pathophysiological changes within the pronephron, adversely
affecting pronephric structure and appropriate ultrafilteration. Subse-
quently, renal structure and function is restored in rendered diabetic ZF
embryos upon over-expression of ELMO1. ZF embryos upon loss of
ELMO1 showed a significant increase of apoptosis within the ZF
pronephron, which consequently lead to the renal pathophysiological
effects. Lastly, expression of ELMO1 within kidney samples of human
patients suffering from Type 1 and Type 2 DM was greatly reduced as
compared to control samples.
Conclusion: Collectively, the results indicate that ELMO1 is extremely
important for glomerular protection and renal cell survival via decreasing
apoptosis, especially within the diabetic diseased renal conditions.
Supported by: DIAMICOM, SFB1118
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Defining the role of pyroptosis and apoptosis in diabetic nephropathy
K. Shahzad1, F. Bock1,2, M. Al-DABET1, H.Wang1, I. Gadi1, S. Kohli1,
J. Wolter1, M. Thati1, B. isermann1;
1Uniklinikum Magdeburg, Institute for Clinical Chemistry and, 2Depart-
ment of Internal Medicine I and Clinical Chemistry, University of Hei-
delberg, Germany.
Background and aims: Cell death and inflammation are both associated
with the progression of diabetic nephropathy (dNP). Glomerular cell ap-
optosis is thought to contribute to diabetic nephropathy. However, direct
experimental evidence supporting a causative role of apoptosis is lacking.
Of note, common cell death assays like TUNEL fail to distinguish apo-
ptosis from other cell death forms, leaving the question open, whether
apoptosis has a prevailing role for establishing dNP. To evaluate the role
of apoptosis for experimental diabetic nephropathy we used various phar-
macological and genetic approaches.
Materials and methods:Murine models of type 2 (db/db mice) and type
1 (Streptozotocin [STZ] -uninephrectomized mice) diabetes were ana-
lyzed. dNP was quantified based on albuminuria and histological chang-
es. Expression levels of cleaved caspase-1 (Casp1), Casp3, and IL1β
were determined by immunoblotting and immunohistochemistry. A sub-
set of mice was injected with M-920 (a pan caspases inhibitor targeting
Casp1, 3, 4, 5, 6, 7) and CIX (an inhibitor of Casp3, 6, 7, 8, 10). Further-
more, Casp3 and Casp1 deficient micewere used to distinguish the role of
apoptosis and pyroptosis.
Results:Of the two pharmacological approaches used in db/db mice only
one (M-920, targeting also Casp1) efficiently ameliorated diabetic ne-
phropathy. Furthermore, Casp1 inhibitor, but not CIX, prevented glucose
induced Nlpr3 expression as well as IL-1β and caspase-1 cleavage in
podocyte in vitro and in vivo. Importantly, while Casp1 deficient mice
with STZ induced persistent hyperglycemia were protected from diabetic
nephropathy, Casp3 deficient mice were not. Hence, manifestation of
dNP is independent of caspase-3, but requires caspase-1 in mice.
Conclusion: Taken together, these studies question the role of Casp3
dependent cell death while emphasizing the role of inflammasome and
Casp1 activation and potentially of pyroptosis for diabetic nephropathy.
Therefore, we propose that inflammasome inhibition is a more feasible
therapeutic approach to successfully target dNP than apoptosis inhibition.
Supported by: EFSD/Sanofi
1125
The antifibrotic microRNA crosstalk in the action of N-acetyl-seryl-
aspartyl-lysyl-proline on kidney fibrosis in diabetes
D. Koya, S.P. Srivastava, M. Kanasaki, T. Nagai, S. Shi, K. Kanasaki;
Endocrinology & Metabolism, Kanazawa Medical University,
Kahokugun, Ishikawa, Japan.
Background and aims:N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP)
is an endogenous peptide and provides renal-protective effects by
inhibiting renal fibrosis.
Materials and methods:We found that the suppression of AcSDKP and
concomitant induction of dipeptidyl peptidase-4 (DPP-4) were connected
with insufficient levels of antifibrotic microRNAs in the kidney of
streptozotocin (STZ)-induced diabetic CD-1 mice, considering the possi-
ble collaborations among these molecular defects in the onset of kidney
fibrosis of diabetes.
Results: By the comparative studies using streptozotocin (STZ)-induced
diabetic non-fibrotic (129Sv) kidneys, we found that diabetic CD-1 mice
with fibrotic kidney was differentiated from non-fibrotic diabetic 129SV
mice by the suppression of AcSDKP, prominent induction of DPP-4
protein expression/activity, endothelial to mesenchymal transition
(EndMT), and the suppression of anti-fibrotic microRNAs (miRs) such
as miR-29 s and miR-let-7 s. These alterations in diabetic CD-1 mice
were all reversed by AcSDKP treatment. Transfection studies in human
microvascular endothelial cells revealed that miR-29 s andmiR-let-7 s are
bidirectionally regulated each other against EndMT program, and such
regulation of miR-29 s and miR-let-7 s played an essential role in main-
taining the antifibrotic program in AcSDKP action. The suppressed level
of AcSDKP in diabetic CD-1 mice also induced inflammatory responses
by enhancing both IFN-γ and TGF-β signaling, resulting in inhibition of
antifibrotic miRs crosstalk.
Conclusion: In conclusion, the present study provides new insight into
the physiologically relevant antifibrotic actions of AcSDKP via restora-
tion of antifibrotic miRs, and such anti-fibrotic programs mediated by
AcSDKP would have potential utility in combating diabetic nephropathy.
Supported by: Japan Society for the Promotion of Science to DK and KK
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High levels of fasting plasma pro-enkephalin predict deterioration of
kidney function and incidence of chronic kidney disease
C.-A. Schulz1, U. Ericson1, G. Hindy1, P. Almgren1, A. Bergman2, O.
Melander1, M. Orho-Melander1;
1Lund University, Malmoe, Sweden, 2SphingoTec GmbH, Hohen
Neuendorf, Germany.
Background and aims: Recently, high levels of pro-enkephalin A (p-
ENK) have been associated with decreased estimated glomerular filtra-
tion rate (eGFR) in an acute setting. Here we examined, if plasma levels
of p-ENK may predict chronic kidney disease (CKD), a decline of eGFR
or increase of cystatin C, and analyzed the genetic determinants of p-ENK
using a genome-wide association study (GWAS).
Materials and methods: The study included 2568 individuals, aged 46-
68 years, without CKD (eGFR≥60 ml/min/m2), and with measured
fasting plasma p-ENK at baseline (1991-1994). Incidence of CKD was
defined as≤eGFR 60 ml/min/m2 at follow-up re-examination (2007-
2012). Logistic regression was used to calculate the odds ratio (OR) of
CKD according to tertiles of fasting plasma concentrations of p-ENK
adjusting for sex, age, eGFR, fasting glucose, systolic blood pressure,
anti-hypertensive medication, BMI at baseline and follow-up time. Fur-
ther, we conducted a GWAS for p-ENK levels in 4150 participants and
tested if the genetic markers identified genome wide significantly associ-
ated with p-ENK may prospectively predict incidence of CKD from
baseline to follow-up re-examination.
Results:During a mean follow-up time of 16.6 years we observed a CKD
incidence rate of 32%. Among participants in the highest tertile of p-ENK
concentration at baseline the OR for CKD was increased to 1.51 (95% CI
1.18-1.94) compared to participants within the lowest p-ENK tertile. The
yearly mean decline of eGFRwas significantly higher (P=0.0002) among
participants with high levels of p-ENK and likewise did cystatin C (P=
0.005) and creatinine (P=0.000003) increase in individuals with high p-
ENK concentrations. In GWAS we identified 19 SNPs up- and 5 SNPs
down-stream of the PENK locus that altered p-ENK concentration on a
GWAS significant level. Per copy of the p-ENK increasing minor alleles
of the lead SNP rs1012178 (P: 4.666-21) the risk for incidence of CKD
was significantly increased (OR: 1.19; 95% CI 1.02-1.38). The mean
decline of eGFR per year was significantly higher (P=0.0007) and creat-
inine (P=0.002) and cystatin C (P=0.031) levels increased more com-
pared to homozygote major allele carriers.
Conclusion: Our large prospective study suggest circulating p-ENK as a
potential biomarker to predict incidence of CKD. GWAS followed by
analyses for the lead SNP provided evidence for that increased risk for
CKD observed in participants with high p-ENK concentrations may be
partially genetically determined.
Supported by: VR, HLF, Novo Nordic Foundation, Swedish Diabetes
Found, Påhlsson Found
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Increased copeptin in plasma predicts mortality and renal outcome
in patients with type 1 diabetes
S. Theilade1, S. Rosenlund1, T.W. Hansen1, J. Gøtze2,3, F. Persson1, P.
Rossing1,4;
1520, Steno Diabetes Center, Gentofte, 2Rigshospitalet, Copenhagen,
3Aarhus University, 4University of Copenhagen, Denmark.
Background and aims:Copeptin is a surrogatemarker for vasopressin in
plasma and associated with cardiovascular disease (CVD) and renal dis-
ease in patients with type 2 diabetes. Here, we examined the association
between copeptin concentrations and cardiorenal disease in patients with
type 1 diabetes.
Materials and methods: Baseline complications were defined as albu-
minuria (n=358) (urinary albumin excretion rate (UAER) ≥30 mg/24 h)
and CVD (n=143) (myocardial infarction, revascularisation, stroke or
peripheral arterial disease). Adjustments in the regression model included
gender, age, diabetes duration, eGFR, UAER, HbA1c, cholesterol, systol-
ic blood pressure, insulin dose, sodium excretion, BMI, smoking and
antihypertensive treatment. During follow up we assessed 1) the devel-
opment of a combined endpoint including end stage renal disease (ESRD)
(dialysis, renal transplantation), doubling of baseline creatinine and all-
cause mortality, and 2) annual change in eGFR.
Results: In 665 patients with type 1 diabetes (age (mean ± SD) 55±
13 years, 301(45%) females), the median (interquartile range) copeptin
concentration was 5.5 (3.3-10.9) pmol/L. In multivariate analysis,
copeptin concentrations were higher in males and correlated positively
with UAER and HbA1c and, inversely with eGFR and systolic blood
pressure (p≤0.008). Moreover, copeptin concentrations were higher in
patients with albuminuria than in patients without (8.0 (3.8-16.0) vs. 4.4
(2.8-6.8) pmol/L; adjusted p=0.035). During a follow up of median [in-
terquartile range] 3.9 [0.16-5.0] years, the mean ± SD, annual eGFR
decline was 0.30±4.1 ml/min/1.73 m2. Increased copeptin concentrations
predicted the combined endpoint (n=47) with a hazard ratio of 3.5 (1.6-
7.7) (per doubling in ln-copeptin; p=0.002) adjusted for gender, age,
systolic blood pressure, eGFR and previous CVD, and was associated
with a larger annual decline in eGFR (adjusted p=0.02).Conclusion:
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Increased copeptin concentrations were associated with impaired renal
function and larger decline in eGFR. Moreover, increased copeptin con-
centration independently predicted the combined endpoint. Copeptinmay
thus be a useful cardiorenal risk marker in patients with type 1 diabetes.
Clinical Trial Registration Number: NCT01171248
1128
Serum adiponectin and glomerular filtration rate in patients with
type 2 diabetes
L. Ortega Moreno1, O. Lamacchia2, L. Salvemini1, S. De Cosmo3, M.
Cignarelli4, V. Trischitta5, C. Menzaghi1;
1Research Unit of Endocrinology, IRCCS, San Giovanni Rotondo, 2Uni-
versity of Foggia, 3IRCCS, San Giovanni Rotondo, 4University of Fog-
gia, San Giovanni Rotondo, 5Sapienza University, Rome, Italy.
Background and aims:High serum adiponectin has been associated with
decreased renal function in the general population. Only sparse and con-
flicting results, all derived from small studies mainly carried out in non-
European populations, have been reported in patients with type 2 diabetes
(T2D), a subgroup of individuals who are at high risk of renal dysfunction.
The aim of this study was to fill up this gap of knowledge by investigating
such association among diabetic patients of European ancestry.
Materials and methods: The association between serum adiponectin
levels and estimated glomerular filtration rate (eGFR by Modification
of Diet in Renal Disease equation) was investigated in 1,212 patients with
T2D from two different Italian samples: 847 patients from San Giovanni
Rotondo (SGR) and 365 patients from Foggia.
Results: Serum adiponectin was inversely associated with eGFR in SGR
[β (SE) for 1 SDof adiponectin=-2.53 (0.69), p=2.0*10-4] and in Foggia
[β (SE)=-5.63 (1.66), p=0.001] samples, as well as in the two studies
combined [β (SE)=-3.46 (0.69), p=6.0*10-7]. The association was
somehow reduced but still significant after adjusting for sex, smoking
habits, BMI, diabetes duration, HbA1c, anti-diabetic, anti-hypertensive
and anti-dyslipidemic treatments [β (SE)=-1.79 (0.73), p=0.015]. For
each adiponectin SD increment, the odds of having eGFR<60 ml/min/
1.73m2 increased by 46% (OR=1.46; 95%CI 1.24-1.71; p=3.2*10-6) in
SGR sample, 52% (OR=1.52; 95% CI 1.19-1.94; p=0.001) in Foggia
sample, and 47% (OR=1.47; 95% CI 1.29-1.68; p=8.7*10-9) in the two
studies considered together. Further adjustment for the above mentioned
covariates did not change the observed association (OR=1.36; 95% CI
1.16-1.59; p=9.6*10-5).
Conclusion: This is the first report of an association between high serum
adiponectin and low eGFR in a large study of patients with T2D of
European ancestry. Such counterintuitive, paradoxical association de-
serve further attempts to be deeper understood.
1129
Associations of serum N-glycans with glycaemic control and albu-
minuria in type 1 diabetes
M. Colombo1, F. Vučković2, M. Pučić Baković2, H.C. Looker3, F.
Agakov4, G. Lauc2, P.M. McKeigue1, H.M. Colhoun3, on behalf of the
SDRN Type 1 Bioresource Investigators;
1Usher Institute of Population Health Science and Informatics, University
of Edinburgh, UK, 2Genos Glycoscience Reseach Laboratory, Zagreb,
Croatia, 3Population Health Sciences, University of Dundee, 4Pharmatics
Ltd, Edinburgh, UK.
Background and aims: Higher glycaemia levels leading to altered flux
through the hexosamine pathway is considered to be a pivotal pathway in
diabetic complications, as this produces UDP-N-acetylglucosamine
(UDP-GlcNAc), the substrate for N-linked glycosylation. The N-glycan
profile reflects oligosaccharide modifications on secreted proteins
resulting from N-linked glycosylation. We tested whether in people with
type 1 diabetes the N-glycans profile in serum differs by glycaemic con-
trol and albuminuria status.
Materials and methods: Study participants comprised 744 people with
T1D recruited from diabetes clinics and primary care into the Scottish
Diabetes Research Network Type 1 Bioresource. The N-glycan profile in
non-fasting serum samples were analysed using hydrophilic interaction
ultra performance liquid chromatography (HILIC-UPLC) and divided
into 39 glycan groups (GP1-GP39). We investigated associations with
HbA1c adjusted for age and sex, through linear regression where the
relative quantity of each N-glycan was evaluated independently and then
further adjusted for diabetes duration. We also examined associations
with 14 summary variables reflecting the ratios of different branching
patterns and levels of sialylation and galactosylation. We used a
Bonferroni adjusted p-value to consider significance of associations. We
used a cross-validated forward selection to define a set of N-glycans
associated with HbA1c and used it to compute an N-glycan-based score
for glycaemia and tested it for association with albuminuria status adjust-
ed for age, sex, diabetes, duration and HbA1c.
Results:At baseline median (inter-quartile range) for age was 43.6 (31.4,
54.8) years, duration 20.6 (11.0, 30.2) years, HbA1c 75.7 (63.0, 85.9)
mmol/mol, eGFR 108.1 (66.6, 135.6) ml/min/1.73 m2, 23.7% of the
subjects had micro- or macroalbuminuria (13.2% and 10.5% respective-
ly). Of the 39 N-glycans and 14 summary measures, 16 showed strong
associations in either direction with HbA1c at p<0.0001 (Fig 1). The
proportion of N-glycans that were tri-antennary glycans was higher with
poorer glycaemic control and the level of non-sialylated glycans was
decreased. Further adjustment for diabetes duration did not alter these
associations. The N-glycan-based score was associated with albuminuria
status adjusted for age, sex, diabetes duration and HbA1c (regression
coefficient=0.06, 95% CI: (0.02, 3.52), p=0.0005).
Conclusion: In type 1 diabetes the serum N-glycan profile shows strong
associations with glycaemic control in a pattern consistent with increased
hexosamine flux. Further studies are needed to evaluate whether the cross
sectional association with albuminuria is found in prospective studies.
Supported by: Chief Scientist Office, Diabetes UK, JDRF
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Arterial stiffness is an independent predictor of renal function decline
and stroke in patients with type 2 diabetes with preserved renal
function
N. Fountoulakis, K. Patel, C. Thakrar, A. Smith, G. Viberti, L. Gnudi, J.
Karalliedde;
Diabetes, King's College London, UK.
Background and aims: Aortic pulse wave velocity (Ao-PWV) the gold
standard measure of arterial stiffness is an independent predictor of car-
diovascular disease (CVD) in T2DM patients with advanced renal dis-
ease. The role of Ao-PWV as a predictor of glomerular filtration rate
(GFR) decline in T2DM patients with relatively preserved renal function
is unclear.
Materials and methods: In a prospective, observational study of 119
T2DM consecutive patients (81 males) attending a diabetes clinic in a
university hospital, we evaluated if Ao-PWV measured (by applanation
tonometry (AtCor Medical, Sydney, NSW, Australia) at baseline, was a
predictor of renal function decline, CVD or cerebrovascular events
(CVA). Patients were followed at least annually with standardized clinical
and laboratory assessments. CVD and CVA events were obtained from
hospital records.
Results:Median duration of follow upwas 9 yrs (range 3-11). At baseline
mean age was 60 yrs (range 34 to 80), duration of diabetes 9 yrs (range 4-
28), mean ± SD estimated GFR (Modification of Diet in Renal Disease
equation) 85±24 ml/min, Ao-PWV 10.1±2.6 m/s, urine albumin to cre-
atinine ratio (median 1.3 mg/mmol, interquartile range 0.6-4.7) and
HbA1c 7.9±1.5%. Patients were divided into two groups above (n=72)
or below (n=47) 60 yrs of age. Patients below 60 yrs reaching an eGFR
value below the median for this group at the end of the observation period
had a higher Ao-PWV value at baseline (9.2 vs. 7.9 m/s, mean difference
1.3 m/s 95% CI 0.2-2.4 p=0.02) and a higher rate of GFR decline (-
3.3 ml/min/yr, 95% CI -5.0 to -1.5 p=0.001). Ao-PWV was an indepen-
dent risk factor for decline of renal function after adjustment for age, pulse
pressure, gender, baseline eGFR, and albuminuria. In those above 60 yrs
baseline Ao-PWV was similar (11.6 vs. 11.1 m/s) in patients above or
below final median eGFR for this group. During the follow up there were
4 (3.3%) CVA events and 17(14%) CVD events. Ao-PWV was an inde-
pendent predictor of CVA events (p=0.015, odds ratio=2.5) but not CVD
after adjustment for conventional risk factors.
Conclusion: In ‘younger’ T2DM subjects with preserved renal function
Ao-PWV is an independent predictor of renal function decline. In the
whole cohort, Ao-PWV predicted CVA independent of traditional risk
factors. Treatments that target Ao-PWV reduction may delay the progres-
sion of renal function decline in T2DM.
1131
Microalbuminuria, but not mildly reduced eGFR, predicts cardio-
vascular outcomes in patients with type 2 diabetes
P. Sjöblom1,2, F.H. Nystrom1, T. Länne1, J. Engvall1,3, C.J. Östgren1;
1Department ofMedical andHealth Sciences, LinköpingUniversity, 2De-
partment of Local Care Finspång, County Council of Östergötland, 3De-
partment of Endocrinology and Metabolism, Linköping University Hos-
pital, Sweden.
Background and aims: A growing body of evidence emphasizes the
importance of albuminuria as a predictor for cardiovascular disease and
mortality in patients with type 2 diabetes. However, it is still a matter of
controversy if mild renal impairment is an independent risk factor for
macrovascular complications. Thus, the aim of this study was to explore
the impact from microalbuminuria and mild renal impairment on cardio-
vascular events in patients with type 2 diabetes.
Materials and methods: Data were analyzed from 706 patients from
baseline in the Cardiovascular Risk factors in Patients with Diabetes - a
Prospective study in Primary care (CARDIPP). The participants were
consecutively recruited 2005-2008, at an age of 55-65 years from 22
primary health care centers in Sweden. The mean age of the patients
was 60.7 years. At baseline, urine and blood samples for standardized
laboratory analyses were taken in the morning following at least 10 hours
fasting. Presence of microalbuminuria was defined as a u-albumin/creat-
inine ratio (uACR) ≥3.0 mg/mmol. Estimated Glomerular Filtration Rate
(eGFR) was calculated by use of the MDRD formula and reduced renal
function was defined as level of eGFR<60 ml/min/1.73 m2. Cardiovas-
cular disease and death data were retrieved from the hospital discharge
register and the cause of death register in Sweden until 31st December
2012. The primary endpoint was a composite endpoint of the first non-
fatal or fatal event of hospitalization for acute myocardial infarction or
stroke or cardiovascular mortality diagnosed according to ICD-10, I00-
99. The relations of microalbuminuria and renal impairment to risk of the
outcomes were investigated using Cox proportional hazard models.
Results: When uACR was used as a continuous variable, covariates in
the final model were age, sex, smoking status, previous MI, LDL-choles-
terol, triglycerides, HbA1c, mean 24-h systolic blood pressure and use of
ACE inhibitors, ARB, beta-blockers and statins in Cox proportional haz-
ard models. There was a strong association between uACR and the end-
point, P=0.001 HR: 1.03; CI 1.01-1.04. When uACR was replaced by
eGFR in the analysis there were no significant association between eGFR
and the primary endpoint crude or in any model of adjustments of covar-
iates. The association between uACR and eGFR and the primary end-
point are further illustrated in the Figure by Kaplan-Meier curves with
uACR dichotomized at ≥3.0 mg/mmol and eGFR<60 ml/min/1.73 m2 .
Conclusion: Our study confirms that microalbuminuria defined as
uACR, but not renal impairment defined by eGFR, predicts cardiovascu-
lar complications in middle-aged patients with type 2 diabetes.
Clinical Trial Registration Number: Dnr M26-05
Supported by: King Gustaf Vand Queen Victoria Freemason Foundation
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Albuminuria is positively associated with elevated numbers of circu-
lating endothelial pre- andmature cells, but inversely associated with
circulating fibrocytes
A. Rosendahl1, B. von Scholten2, R. Bergholdt3, P. Rossing2, T.
Hansen2;
1BiopharmQC New Haemophilia, Novo Nordisk A/S, 2Steno Diabetes
Center, 3Diabetes Complications Biology, Novo Nordisk A/S, Gentofte,
Denmark.
Background and aims: Diabetic nephropathy is characterized as a mi-
crovascular disease with enhanced vascular leakiness in the diabetic
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kidney together with aberrant tissue remodelling. Abnormal number and
function of endothelial cells, stem cells and activation of leukocytes is
considered as contributing mechanisms to the “kidney-micro”-vascular
leaky syndrome. We aim to determine if circulating endothelial pre- and
mature cells, fibrocytes or monocyte sub-populations are abnormally reg-
ulated in type 2 diabetic patients with albuminuria.
Materials and methods: Cross-sectional study of 37 type 2 diabetic
patients, 18 with normoalbuminuria (<30 mg/24 h) and 19 with albumin-
uria (≥30 mg/24 h) randomly selected from our outpatient clinic. 8-color
flow cytometry (FACS analysis) of peripheral blood was performed.
Analysis of covariance compared -expression of cell markers as well as
absolute number of specific cell populations in patients with
normoalbuminuria vs. albuminuria. Adjustment included age, sex, body
mass index, total cholesterol, 24 h systolic blood pressure, smoking,
Hba1c and eGFR.
Results: The cohort included 30% women, mean ± SD age was 62.4±
9.4 years, and median (interquartile range) UACRwas 61.5 (10-234) mg/
24 h. Expression of VEGFR2 was significantly enhanced in patients with
albuminuria compared to normoalbuminuria (p=0.009). Also, the total
number of circulating mature endothelial cells (CEC) was significantly
enhanced in patients with albuminuria (p<0.001). Moreover, the circu-
lating fibrocyte number and collagen-1 expression was inversely associ-
ated with presence of albuminuria (p≤0.037 for both). The TGFbeta
stabilizing and M2-associated galectin-3 expression on M1 and M0-M2
macrophages was positively associated with presence of albuminuria (p≤
0.029 for all). In contrast, the expression of the M1-like marker CD11c
(p=0.042) was inversely associated with presence of albuminuria on all
macrophages and particularly on the M0-like macrophages (p=0.014).
Conclusion: The enhanced number of CEC together with elevated ex-
pression of VEGFR2 may indicate an aberrant function of the CEC with
reduced capacity to heal the kidney microvascular disease. The imbal-
anced M2-polarization of macrophages may favour improper repair lead-
ing to excessive tissue fibrosis. Hence therapeutic approaches addressing
migratory pattern of CEC, providing adjuvant activating signals and re-
storing immune balance might provide novel individualized treatment
regimes.
1133
Systemic inflammation and glucose variability in type 2 diabetic pa-
tients with and without chronic kidney disease
V.V. Klimontov, N.E. Myakina, N.V. Tyan;
Scientific Institute of Clinical and Experimental Lymphology, Novosi-
birsk, Russian Federation.
Background and aims: A growing body of evidence indicates that
chronic macrophage-mediated inflammation is involved in the pathogen-
esis of diabetic kidney disease. Furthermore, it was demonstrated that
increased glucose variability (GV) can enhance the systemic inflamma-
tory response in diabetes. The aim of our study was to assess the relation-
ship between acute-phase and macrophage-related inflammatory markers
and GV parameters in type 2 diabetic patients with and without chronic
kidney disease (CKD).
Materials and methods:We observed 211 insulin-treated patients, 47 M/
164 F, 43-70 years of age, HbA1c 8.4, 7.2-9.6% (median, 25th-75th per-
centile). Sixty four patients had estimated glomerular filtration rate (eGFR)
<60 mL/min/1.73 m2. The serum levels of high-sensitivity C-reactive pro-
tein (hsCRP), alpha1-acid glycoprotein (AGP), macrophage colony stimu-
lating factor (M-CSF), macrophage inflammatory protein 1alpha (MIP-1al-
pha), macrophage migration inhibiting factor (MIF), as well as urinary
albumin and type IV collagen were determined by ELISA and compared
to control (30 healthy subjects). The parameters of GV were derived from
the blinded continuous glucose monitoring (CGM) recordings. The values
of nine GV indices were estimated, including lability index, M-value, J-
index, continuous overlapping net glycemic action, mean absolute glucose,
high blood glucose index, low blood glucose index, mean amplitude of
glucose excursions and average daily risk range.
Results: The increased serum levels of hsCRP, AGP, M-CSF, MIP-
1alpha and MIF were found in observed diabetic patients as compared
to control (p<0.0001, p<0.0001, p<0.0001, p=0.03 and p=0.0006 re-
spectively). The concentration of hsCRP correlated positively with AGP
and M-CSF (r=0.44 and r=0.37, both p<0.01), AGP demonstrated cor-
relations with M-CSF and MIP-1alpha (r=0.51 and r=0.4, both p<0.01).
Concentrations of hsCRP, M-CSF and MIP-1alpha, as well as urinary
type IV collagen, were higher in patients with reduced eGFR as compared
to those without (p=0.04, p=0.02, p=0.02 and p=0.01 respectively).
Serum AGP and M-CSF correlated positively with urinary albumin/
creatinine ratio (r=0.39 and r=0.37 respectively, p<0.0001), meanwhile
hsCRP, M-CSF and MIP-1alpha demonstrated weak relationships with
type IV collagen excretion (r=0.31, r=0.37, r=0.4, all p<0.01). Subjects
with reduced GFR did not differ from those without by mean monitored
glucose and all investigated GV parameters. No relationships were found
between concentrations of inflammatory markers and GV indices.
Conclusion: The serum levels of acute-phase and macrophage-related
inflammatory proteins are associated with CKD in type 2 diabetic pa-
tients. The parameters of GV seem to be not related to inflammatory
markers in these patients.
Supported by: RSF (14-15-00082)
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Type 2 diabetes is associated with greater carotid stiffness and great-
er pressure-dependency of carotid stiffness: The Maastricht Study
M.G.J. Veugen, R.M.A. Henry, T.T. van Sloten, E. Hermeling, H.-P.
Brunner-La Rocca, M.T. Schram, P.C. Dagnelie, C.D.A. Stehouwer,
K.D. Reesink; on behalf of The Maastricht Study group; Cardiovascular
Research Institute Maastricht (CaRIM); MUMC+, Netherlands.
Background and aims: Arterial remodeling is considered an adaptive
process aimed at maintaining mechanical arterial integrity under altered
arterial environmental conditions, e.g. hypertension and hyperglycemia.
This process has been shown operative in both impaired glucose metab-
olism and type 2 diabetes, but eventually may even become maladaptive
leading to excessive arterial stiffening. A specific marker of arterial re-
modeling, hypothesized to be closely linked to structural alterations of the
arterial wall itself, we propose is the pressure-dependency of arterial
stiffness. The pressure-dependency of arterial stiffness is quantified as
the systolic-diastolic difference in pulse wave velocity (δPWV), with
greater δPWV signifying greater pressure dependency.Thus far, the rela-
tionship between arterial stiffness pressure dependency with deteriorating
glucose metabolism status (GMS) has not been investigated. Therefore,
we investigated in The Maastricht Study the associations of carotid arte-
rial stiffness (cPWV) and the pressure-dependency of carotid arterial
stiffness (δPWV) with deteriorating GMS. Additionally, we investigated
the interdependency of cPWV and δPWV to evaluate whether arterial
remodeling may act differentially upon cPWVand δPWV.
Materials and methods: The study population consisted of 746 individ-
uals (415 normal glucose metabolism [NGM], 126 impaired glucose
metabolism [IGM] and 205 type 2 diabetes [T2D]). Each participant
underwent carotid ultrasonography and tonometry to determine cPWV
and δPWV. Linear regression analyses were used to investigate the asso-
ciations of cPWVand δPWVwith deteriorating GMS (NGM as reference
category). Models were adjusted for age, sex, mean arterial pressure
(MAP), anti-hypertensive medication, prior cardiovascular disease,
eGFR, BMI and smoking and δPWVor cPWVas appropriate.
Results: After adjustment for age, sex and MAP, T2D was associated
with greater cPWV (β (95% CI; 0.377 (0.124; 0.629) and δPWV (0.311
(0.027;0.595)). Further adjustments did not change these associations
materially. After additional adjustment for δPWVor cPWV the associa-
tions of T2D with cPWV and δPWV were attenuated (0.292 (0.051;
0.534) and 0.182 (-0.090; 0.454), respectively). IGM was not associated
with either cPWVor δPWV.
Conclusion: In T2D, but not in IGM, both cPWV and δPWV were
increased. These associations were only partially interdependent which
suggests that the process of arterial remodeling may act differentially on
carotid arterial stiffness and the pressure dependency of carotid arterial
stiffness. This study hereby provides a pathophysiological framework to
understand how arterial remodeling may shift from being adaptive to
maladaptive with deteriorating GMS.
Supported by: EFRO, MUMC+
1135
Hypertension among urban and rural type 2 diabetic subjects in
Bangladesh
P.C. Banik1, M. Moniruzzaman2, F. Zaman3, L. Ali1;
1Nonommunicable Diseases, Bangladesh University of Health Sciences
(BUHS), 2Injury Prevention and Disability, Country Office for Bangla-
desh,World Health Organization, 3Epidemiology, Bangladesh University
of Health Sciences (BUHS), Dhaka, Bangladesh.
Background and aims: Hypertension is known to be more common
among people with type 2 diabetes mellitus (T2DM), but the prevalence
and risk factors of the comorbidity vary from population to population.
The present study was undertaken to estimate the proportion of hyperten-
sion among urban and rural Bangladeshi Type 2 diabetic subjects.
Materials and methods: An analytical cross-sectional study was con-
ducted among 640 urban (M/F, 244/396; age in years, 52.23±11.8; BMI,
25.95±3.9 Kg/m2) and 560 rural (M/F, 244/396; age in years, 50.89±
11.9; BMI, 24.13±4.6) subjects, selected purposively from various health
care facilities in Dhaka and Northern Districts of Bangladesh. The World
Bank criteria were followed for the selection of the urban and rural areas.
Diagnosis of T2DM and hypertension was done by WHO Study Group
Criteria (following a 2-sample OGTT) and WHO/ISH Guideline
respectively.Data were collected by face-to-face interview and by physi-
cal examinations through interviewer administered pretested semi-
structured questionnaire and check-list. Data were analyzed by univariate,
bivariate and multivariate statistics as appropriate.
Results: Hypertension was present among 45.5% urban (95% CI,41.6-
49.4) and 43.6% rural (CI,39.5-47.7) subjects. There was no significant
difference in the proportion of hypertension between the two demograph-
ic locations. Males and females did not differ in the proportion of hyper-
tension either in the urban or in the rural region. The trend in the propor-
tion did not vary when the data were analyzed for systolic and diastolic
hypertension separately. Urban hypertensive subjects had higher age
compared to their normotensive counterparts (age in years, 53.85±10.5
vs 50.88±12.7; p<0.001). The rural hypertensive subjects showed simi-
lar difference in age (54.69±11.4 vs 47.95±11.5; p<0.001). The BMI of
the hypertensive subjects (25.56±4.1 Kg/m2) was higher compared to
normotensive (24.73±4.4 Kg/m2) and the difference was significant (p<
0.001). The waist circumference (WC) of the hypertensive subjects
(90.11±13.1 cm) was similarly higher compared to normotensive sub-
jects (86.30±14.2 cm)and difference was significant (p<0.001). Physical
activity was significantly less in hypertensive compared to the normoten-
sive subjects (p=0.032). On Pearson correlation analysis hypertension
correlated positively with WC (r=0.092, p<0.001), and duration of DM
(r =0.122, p<0.001). On multiple regression analysis higher age (p<
0.001, OR=1.036, CI,1.025-1.048), greater WC (p<0.001, OR=1.014,
CI,1.004-1.025) and less physical activity (p<0.001, OR=1.396, CI,
1.098-1.775) were found as the main predictors of hypertension.
Conclusion: A large proportion of Type 2 diabetic subjects in Bangla-
desh, both males and females, irrespective of urban or rural origin, suffer
from hypertension. Higher age, central obesity and reduced physical ac-
tivity are the major predictors of hypertension in this population.Only an
appropriate lifestyle intervention can minimize the risk of hypertension
among T2DM subjects.
1136
Diastolic but not systolic orthostatic hypotension is associated with
organ damage and with increased risk for cardiovascular complica-
tions in type 2 diabetes
M. Wijkman1, T. Lindström2, T. Länne2, C. Östgren2, F.H. Nystrom2;
1Department of Internal Medicine and Department ofMedical and Health
Sciences, Linköping University, Norrköping, 2Department of Medical
and Health Sciences, Linköping University, Linköping, Sweden.
Background and aims: Orthostatic hypotension (OH) is a marker for
increased cardiovascular risk, and is common in patients with diabetes. It
is likely that the diastolic and systolic components of OH represent two
different clinical entities, but their respective impacts on cardiovascular
prognosis have not been compared in patients with diabetes. The aim of
this study was to determine the association between diastolic and systolic
OH, respectively, with markers of macrovascular atherosclerosis and with
subsequent cardiovascular prognosis, in a cohort of patients with type 2
diabetes.
Materials and methods: Office blood pressures were measured in the
sitting and in the standing position in 749 patients with type 2 diabetes, as
part of the baseline examination of the observational cohort study
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CARDIPP (Cardiovascular Risk factors in Patients with Diabetes - a
Prospective study in Primary care). Systolic OH was defined as a systolic
blood pressure drop≥20 mmHg, and diastolic OH was defined as a dia-
stolic blood pressure drop≥10 mmHg when rising from sitting to stand-
ing. Aortic pulse wave velocity (PWV) and carotid intima media thick-
ness (IMT) measurements were performed at baseline. Patients were
treated in usual care at their primary health care centers, and were follow-
ed until any of the primary endpoint events (fatal or non-fatal myocardial
infarction or stroke, or cardiovascular death) occurred or until 31 Decem-
ber 2012.
Results: Among the 749 study participants, 18 had systolic OH only, 25
had diastolic OH only, and 6 had combined systolic and diastolic OH.
Patients with diastolic OH had significantly higher PWV than patients
without diastolic OH (11.3 m/s vs. 10.3 m/s, P=0.030), but there was no
significant difference between patients with systolic OH and patients
without systolic OH (11.0 m/s vs. 10.4 m/s, P=0.145). Likewise, carotid
IMTwas significantly higher in patients with diastolic OH than in patients
without diastolic OH (0.83 mm vs. 0.73 mm; P=0.002), but did not differ
significantly between patients with systolic OH and patients without sys-
tolic OH (0.74 mm vs. 0.79 mm, P=0.138). During a median follow-up
time of 5.9 years, there were 48 primary endpoint events. The presence of
diastolic OH was a significant predictor of cardiovascular complications
(crude hazard ratio: 3.321; 95% CI: 1.412 - 7.815; P=0.006), but the
presence of systolic OH was not (crude hazard ratio: 0.636; 95% CI:
0.088 - 4.609, P=0.654). When treated as a continuous variable, diastolic
blood pressure drop from sitting to standing was significantly associated
with increased risk for cardiovascular complications (crude hazard ratio
per 1 mmHg: 1.048; 95% CI: 1.007 - 1.091; P=0.020), but systolic blood
pressure drop was not (crude hazard ratio per 1 mmHg: 1.002; 95% CI:
0.976 - 1.028; P=0.894).
Conclusion: In patients with type 2 diabetes, diastolic OH is associated
with more severe atherosclerosis, and with an increased risk for
macrovascular diabetes complications. On the contrary, we found no
significant associations between systolic OH and degree of atherosclero-
sis or prognosis. Diastolic OH is easily diagnosed in the usual clinical
setting, and our data suggest that it is a useful marker to detect patients at
higher risk for macrovascular diabetes complications.
Clinical Trial Registration Number: NCT01049737
1137
Baroreceptor stimulation enhanced vessel sensitivity to nitric oxide-
mediated vasodilation, implications for treatment of diabetes and the
metabolic syndrome
J. Gmitrov;
National Institute of Public Health, Tokyo, Japan. Pro Vitae and
Krompachy Hospital Agel SK Inc., Gelnica, Slovakia.
Background and aims: Increasing evidence suggests endothelial nitric
oxide (NO) deficit and baroreflex dysfunction to be characteristic for
diabetic and cardiovascular conditions ranging from arterial hypertension
to stroke and coronary heart disease with deleterious impact on morbidity
and mortality. To test the hypothesis that arterial baroreflex has a modu-
latory effect on NO-dependent vasodilation the magnitude of the cutane-
ous vasodilator response to sodium nitroprusside (SNP), a spontaneous
NO donor, was determined in relation to increase in baroreflex sensitivity
(BRS) generated by carotid baroreceptor magnetic activation and poten-
tial implementation in NO deficiency states.
Materials and methods: Mean femoral artery blood pressure (MAP),
heart rate (HR) and ear lobe skin microcirculatory blood flow, measured
by microphotoelectric plethysmogram (MPPG), were simultaneously re-
corded in conscious rabbits before and after 40-min sinocarotid barore-
ceptor exposure to 350 mTstatic magnetic field (SMF), generated by Nd-
Fe-B alloy (n=8) or sham magnets (n=8, controls). Arterial baroreflex
sensitivity (BRS) was measured by changes in HR and MAP (ΔHR /
ΔMAP) after intravenous bolus injections of SNP and phenylephrine.
Results: SMF sinocarotid baroreceptor exposure significantly increased
BRS, HR variability and decreased phenylephrine MAP ramps. The
vasodilatory effect of SNP was markedly enhanced after SMF exposure
(MPPGbeforeSMF: 2.57±0.81 V vs. MPPGafterSMF: 7.82±1.61 V, p<
0.0001), Figure 1, and positively correlated with increase in BRS (r=
0.51, p=0.01).
Conclusion: The important and novel findings demonstrated in this study
are that arterial baroreflex modulates NO-mediated vasodilation and that
sinocarotid baroreceptormagnetic stimulation improved vessel sensitivity
to NO vasodilatory effect. These may synergistically reinforce the recip-
rocal cross-talk relationship between insulin resistance and NO deficit
arguing for baroreceptor stimulation in cardiometabolic conditions such
as diabetes and the metabolic syndrome where unresponsiveness of vas-
cular smooth muscle cells to NO amplifies deleterious consequences of
the reduced endothelial NO availability importantly contributing to auto-
nomic dysfunction, arterial hypertension and the non-lipid residual car-
diovascular risk.
Figure 1. Segments of five experimental recordings after local exposure
of sham magnets (SHAM, control experiment) or static magnetic field
(SMF) to sinocarotid baroreceptors. (Ni3, 10.0; Ni4, 30.0) and (Ph3, 3.0),
doses of sodium nitroprusside and phenylephrine (μg/kg), respectively,
given by intravenous bolus injections for BRS testing. CONT, initial
readings.
A notable increase of the vasodilation in response to same dose sodium
nitroprusside after sinocarotid baroreceptor magnetic stimulation is obvi-
ous.
1138
LEADER-4: blood pressure control in patients with type 2 diabetes
and high cardiovascular risk: baseline data from the trial
J.R. Petrie, on behalf of the LEADER investigators;
University of Glasgow, UK.
Background and aims: Blood pressure (BP) control is a key strategy for
reducing cardiovascular (CV) and renal complications in patients with
type 2 diabetes mellitus (T2DM). As a result, treatment guidelines include
disease-specific targets but these can be difficult to achieve even with
multiple antihypertensive agents. For patients with T2DM who are also
obese, there is limited knowledge about the percentage whose BP reaches
target and the factors associated with non-achievement of target.
Materials and methods: We collected data on BP control at baseline
(2010-2012) and demographic/anthropometric characteristics from the
Liraglutide Effect and Action in Diabetes; Evaluation in Cardiovascular
outcomes Results (LEADER) trial. LEADER is an ongoing Phase 3B
randomized, double-blind, placebo-controlled CVoutcome trial examin-
ing the safety and efficacy of the GLP-1 receptor agonist liraglutide in
9340 people with T2DM from 32 countries (including USA, Europe,
Asia and other countries). Mean (±SD) age was 64±7.2 years; BMI
32.5±6.3 kg/m2; duration of diabetes 12.7±8.0 years; 81% had suffered
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a previous CV event. We analysed factors associated with BP control
usingmultiple logistic regressionmodels in order to assess the association
between dichotomized ‘off-target’ hypertension endpoints and predefined
explanatory factors.
Results: 91% of participants had a history of hypertension but only 51%
were treated to a target BP of <140/85 mmHg [European Society of
Hypertension (ESH)/ European Society of Cardiology (ESC) 2013] and
only 26% to the predefined BP target of <130/80 mmHg (ESH/ ESC
guideline 2007). This was despite prescription of multiple antihyperten-
sive agents: 61% of patients were on two or more agents and 19% on
three or more. Those with a previous CVevent had lower BP than those
without (137±18.8/78±10.6 mmHg vs. 140±17.7/80±9.9 mmHg; p<
0.001) and were prescribed more antihypertensive agents (p<0.001).
BP control was better in the US than Europe with a higher proportion
achieving a BP target of 140/85 mmHg (63% vs. 42%, p<0.0001) and a
BP target of <130/80 mmHg (37% vs. 20%, p<0.0001); this was not
readily explained by baseline demographics or the intensity of antihyper-
tensive therapy. In multifactorially adjusted logistic regression analyses,
principal characteristics associatedwith poorer BP control were: region of
residence, smoking status, and number of antihypertensive agents
(Figure).
Conclusion: These data confirm that even with modern antihypertensive
agents, BP is frequently poorly controlled in individuals with long-
standing T2DM, including individuals who are also obese. The LEADER
trial will provide important information on the effects of the GLP-1 re-
ceptor agonist liraglutide on BP and other CV risk factors in relation to
CV safety and outcomes in this patient population.
Clinical Trial Registration Number: NCT01179048
Supported by: Novo Nordisk
1139
Remodelling of the aorta and kidney in L-NAME-induced hyperten-
sion in rats: comparison of the protective effect of ivabradine with
captopril and melatonin
F. Simko, K. Repova, K. Krajcirovicova, S. Aziriova, L. Paulis, T. Baka;
Institute of Pathophysiology, School of Medicine, Comenius University,
Bratislava, Slovakia.
Background and aims: Ivabradine was recently proven to reduce mor-
bidity and mortality in patients with heart failure. It is supposed that its
benefit is achieved through the reduction of heart rate via blockade of the
If-channel in sinoatrial node. Besides the heart rate reduction, ivabradine
seems to reduce afterload potentially through its antiproliferative effect on
the aorta. The aim of our experiment was to show the effect of ivabradine
on morphometry of the aorta and kidney and to compare ivabradine with
well established protectives - agiotensin converting enzyme (ACE) inhib-
itor captopril and melatonin.
Materials and methods: 72maleWistar rats were divided into 6 groups:
controls (C), ivabradine (10 mg/kg/day) (Iv), Nω-Nitro-L-arginine meth-
yl ester (40 mg/kg/day) (L-NAME), L-NAME+ivabradine (L-NAME+
Iv), L-NAME+captopril (100 mg/kg/day) (L-NAME+Cap), L-NAME+
melatonin (10 mg/kg/day) (L-NAME+Mel). Drugs were administered in
drinking water for 4 weeks. Systolic blood pressure (SBP) and heart rate
(HR) were measured (by tail-cuff method) once a week. After 4 weeks of
the therapy rats were killed and organs (heart, aorta, kidney) were re-
moved and processed for morphometric and biochemical investigation.
One-way analysis of variance (ANOVA) and the Bonferroni test were
used for statistical analysis. Differences were considered significant if
the p value <0.05.
Results: Ivabradine significantly (p<0,05) reduced SBP in Iv (by 21%)
and in L-NAME (by 19%) and markedly reduced HR in both Iv and L-
NAME (by 26% and 21%, respectively). Ivabradine did not affect the
wall thickness (WT) and cross-sectional area (CSA) of the aorta in neither
controls nor in L-NAME. Captopril reduced SBP and WT in L-NAME
but HR and CSA remained unchanged. Melatonin reduced both SBP (by
14%) andHR (by 10%)without any effects onWTor CSA. Enhancement
of glomerular tuft area (AG) in L-NAME was decreased by ivabradine
(by 8%) and captopril (by 7%). Density of glomeruli was decreased by
ivabradine (16%), captopril (19%) and melatonin (14%).
Conclusion: Ivabradine reduced HR, SBP and modified kidney remod-
elling in L-NAME-induced hypertension, without influencing the remod-
elling of the aorta.
Supported by: VEGA No 1/0227/12 and 2/0183/12
1140
Sitagliptin and risk of hypertension in patients with type 2 diabetes
mellitus: meta-analysis of randomised trials
B. Zhang, Z. Lu;
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen
University, Guangzhou, China.
Background and aims: Recent reports of sitagliptin use have raised
questions about whether the sitagliptin have beneficial effect on blood
pressure of type 2 diabetes mellitus (T2DM) patients. The aim of this
meta-analysis was to evaluate the effect of sitagliptin on hypertension.
Materials and methods:We searched PubMed, MEDLINE, EMBASE,
the Cochrane Central Register of Controlled Trials, and product informa-
tion sheets for randomized controlled trials, systematic reviews, and
meta-analyses published through December 2012. Studies were included
if theywere randomized controlled trials of sitagliptin vs placebo or active
comparator for T2DM patients also monitored hypertension. Relative
risks of hypertension events were estimated using a fixed-effects meta-
analysis.
Results: We analyzed 8 randomized controlled trials. Compared with
placebo therapy and control therapy, sitagliptin had no significant in-
crease in risk of hypertension (n=46/2381 vs 39/2224; RR 0.99; 95%
CI, 0.65 - 1.52; P=0.97). The risk of hypertension was slightly lower in
the sitagliptin group than in the placebo group, but the difference was not
statistically significant (n=27/1459 vs 19/694; RR 0.72; 95% CI, 0.40 -
1.29; P=0.27). Conversely, the risk of hypertension was slightly higher in
the sitagliptin group than in the control therapy group, but the difference
was not statistically significant (n=19/922 vs 20/1530; RR 1.48; 95% CI,
0.76 - 2.86; P=0.25). There was no evidence of substantial heterogeneity
among the trials (I2=41%, I2=28%, and I2=46%, respectively).
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Conclusion: Sitagliptin has no beneficial or harmful effect on hyperten-
sion in the treatment of T2DM. PS 114 Diabetic complications:
beyond the vasculature
1141
The changes of the mitochondria in the lung parenchyma in
streptozotocin-induced diabetes
O. Pivovarova1, E. Rozova2, B. Mankovsky3;
1Kyiv Medical University of UAFM, 2Bogomoletz Institute of Physiolo-
gy, 3P.L. Shupyk National Medical Academy of PostGraduate Education,
Kyiv, Ukraine.
Background and aims: There is growing body of evidence that lungs
represent another target for diabetic complications. However, the patho-
genetic mechanisms of lung damage in diabetes mellitus remain not fully
understood. The damage of mitochondria can be one of the underlying
mechanisms of the development of this complication. Therefore, the aim
of this study was to investigate ultrastructural features of mitochondria in
pulmonary tissue in the streptozotocin (STZ)-induced diabetes.
Materials and methods: The study was performed on 47 STZ-induced
diabetic and 43 control male Wistar rats. Diabetes was induced by single
intraperitoneal injection of STZ 60 mg/kg in 0.1 M citrate buffer, pH-4.5.
The tissue for the further evaluation was collected after 18 weeks of
diabetes. The diabetic rats were not treated with insulin. The morphomet-
ric assessment was performed using the electron microscope PEM-125 K
and the data were analyzed using the software Image Tool Version 3
(USА).
Results:We found swelling and clarification of the mitochondrial matrix,
the intercrystaline intervals enlargement without change of the space be-
tween the internal and external membranes which corresponded to a
reduced generation of adenosine triphosphate, fragmentation and
decondensation of the mitochondrial membrane in the lung tissue in
STZ-induced diabetic rats compared to non-diabetic rats. The total num-
ber of mitochondra in the lung tissue was not significantly different in
STZ-induced diabetic rats compared to control group - 10,1±0,4 U/μm2
and 9,6±0,3 U/μm2, respectively, p>0.05. However, it was found an
increased number of structurally damaged mitochondria per μm2 of the
lung parenchyma - 15,3±0,8% and 4,6±0,4%, in STZ-induced diabetic
rats and control group respectively, р<0,001. There were no signs of
morphogenesis activation. Also, it was an increase of the average diam-
eter of the of mitochondria in the diabetic rats compared to controls - 0,64
±0,05 μm and 0,39±0,04 μm, respectively, p<0,01.
Conclusion: Experimental STZ-induces diabetes mellitus leads to the
morphological changes of mitochondria in the lung parenchyma. The
revealed mitochondrial dysfunction could be one of the possible mecha-
nisms of the lung damage observed in diabetes mellitus.
1142
Carbon monoxide in exhaled air and the development of vascular
complications in type 2 diabetes
V.I. Tkachenko;
Department of Family Medicine, Shupyk National Medical Academy of
Postgraduate Education, Kiev, Ukraine.
Background and aims: Decompensated diabetes leads to high levels of
glycosylated hemoglobin (HbA1c), which forms close bond with oxygen
and cause tissue hypoxia. On the other hand the catabolism of heme-
containing compounds and proteins, lipid peroxidation, cetogenesis and
other metabolic transformations lead to formation of endogen carbon
monoxide (CO) that form carboxyhemoglobin and exacerbates tissue
hypoxia and development of angiopathy in diabetes. The aim of our
research is to study the level of CO in exhaled air and the development
of vascular complications in patients with type 2 diabetes.
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Materials and methods:We examined 53 patients with type 2 diabetes
(age 57,5±1,18 years, 39 women and 14 men, diabetes duration 6,1±2,
1 years) and 26 patients without diabetes (age 59,5±2,18 years, 18 wom-
en and 8 men) who did not smoke and have no respiratory or blood
diseases. All patients underwent clinical and laboratory examination:
HbA1c levels, lipid profile, C-reactive protein, urinary albumin/
creatinine ratio. CO in exhaled air was performed using Smokelyzer
Bedfont Scientific Micro +. Doppler of carotid arteries was done to reg-
ister diabetes complications. Statistical analysis - using Excell 2007,
SPSS.
Results: The patients with type 2 diabetes had significantly higher fasting
glucose (9,4±0,5 mmol/l, p<0,01) and HbA1c (7,6±0,4%, p<0.05) in
contrast to comparison group (glucose=5,3±0,4 mmol/l, HbA1c=5,5±0,
1%). Violation of lipid metabolism was also confirmed by significant
differences in triglyceride levels (1,08±0,07 mmol/l) and levels of very
low-density lipoproteins (VLDL=0,5±0,03 mmol/l) in patients with di-
abetes, in contrast to comparison group (triglyceride=0,8±0,1 mmol/l,
VLDL=0,4±0,03 mmol/l, p<0,01). The level of urinary albumin/
creatinine ratio was significantly higher in diabetes patients (2,9±0,
6 mg/mmol),in contrast to comparison group (1,1±0,2 mg/mmol, p<0,
05) that shows endothelial dysfunction, the initial glomerular and vascu-
lar changes, and is known marker of atherosclerosis and cardiovascular
events. In this situation, patients with diabetes had significantly higher
CO levels in exhaled air (1,9±0,2 ppm, p<0,05), in contrast to compar-
ison group (1,5±0,1 ppm), which had significantly direct correlation with
urinary albumin/creatinine ratio (p<0,01), HbA1c (p<0,05) and confirms
direct relationship of hyperglycemia, endothelial dysfunction and CO
levels in exhaled air. Significant thickening of intima/media in patients
with type 2 diabetes was determined by Doppler of carotid artery, which
has direct correlation with total cholesterol (p<0,05), LDL (p<0,05),
HbA1c (p<0,05) and was inversely related to HDL level (p<0,01); ath-
erosclerotic plaques with restriction of blood flow were identified in 21%
of diabetes patients. Our data confirm the significant relationship between
glucose metabolism, endothelial dysfunction, microvascular and
macrovascular complications, atherosclerosis and level of CO in exhaled
air.
Conclusion: Defined in patients with type 2 diabetes significantly higher
glucose levels, HbA1c level, urinary albumin/creatinine ratio, which cor-
related with significantly higher CO levels in exhaled air, suggests a direct
relationship between hyperglycemia, endothelial dysfunction and CO
levels in exhaled air. Determination of CO in exhaled air is composed
of non-invasive method and can be used to analyze the development
angiopathy and cardiovascular complications in general practice.
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Prevalence, associates and prognostic significance of abnormal pul-
monary function in type 2 diabetes: the Fremantle Diabetes Study
Phase II
T.M.E. Davis, J. Drinkwater, W.A. Davis;
School of Medicine and Pharmacology, University of Western Australia,
Fremantle, Australia.
Background and aims: We found previously that type 2 diabetes
(T2DM) was associated with reduced pulmonary function in the
community-based observational Fremantle Diabetes Study Phase I
(FDS1) in patients recruited between 1993 and 1996. Since clinical man-
agement, complications and methods of spirometric data assessment have
changed over the last two decades, we re-examined the prevalence, asso-
ciates and prognostic significance of abnormal pulmonary function in a
larger, contemporary sample of community-based patients with T2DM
from the same geographical area as FDS1.
Materials and methods: We used baseline data including spirometry
from the FDS Phase II (FDS2) collected between 2008 and 2011. Mor-
tality data were available through validated health service linkage to end-
June 2013. The highest forced expiratory volume in the first second
(FEV1) and forced vital capacity (FVC) from three recordings/patient
were used in analyses. Predicted values and lower limits of normal
(LLN; z-score<-1.96) were determined using Quanjer Global Lungs Ini-
tiative 2012 reference equations which are based on sex, age, height and
ethnicity. Multivariable linear regression was used to assess independent
associates of lung function measures. Cox proportional hazard modelling
was used to determine whether FEV1 and FVC predicted mortality.
Results:Of 1,551 participants, 1,393 (89.8%) performed acceptable lung
function tests. Of these patients, 109 (7.8%) died during a mean ± SD of
3.7±1.0 years (5,106 patient-years) of follow-up. The mean ± SD FEV1
and FVC as percentage predicted were 82.6±18.9% and 85.7±17.4%,
respectively, and 294 (21.1%) and 238 (17.1%), respectively, had FEV1
and FVC values below the LLN. After adjusting for other variables in-
cluding a history of respiratory disease, body mass index and smoking,
the diabetes-related independent inverse predictors of both FEV1 and
FVC were diabetes duration, HbA1c, ln(urinary albumin:creatinine),
self-reported ischaemic heart disease, and peripheral arterial disease
(ankle:brachial index ≤0.90) (P≤0.037 in each case). Although FEV1
and FVC as percentages of predicted were bivariately associated with
mortality (P≤0.001), neither variable was an independent predictor of
death in a fully adjusted model.
Conclusion: These spirometric data, derived from contemporary validat-
ed predictive equations, confirm that T2DM is associated with a restric-
tive lung defect, especially in those patients with long duration of disease,
poor glycaemic control, and both micro- and macrovascular complica-
tions of diabetes. Abnormal pulmonary function is not an independent
predictor of short-term mortality in T2DM.
Supported by: National Health and Medical Research Council of
Australia
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Metformin protects against homocysteine-induced apoptosis of
osteocytic MLO-Y4 cells by activation of AMP-activated protein
kinase
I. Kanazawa, A. Takeno, K.-I. Tanaka, M. Notsu, M. Yokomoto, T.
Yamaguchi, T. Sugimoto;
Internal Medicine 1, Shimane University Faculty of Medicine, Izumo,
Japan.
Background and aims:Homocysteine (Hcy) is a sulfur-containing ami-
no acid formed by the demethylation of methionine. Hcy is reported to be
significantly increased in patients with diabetes mellitus, and it is an
emerging risk factor for diabetic complications such as diabetic nephrop-
athy and cardiovascular disease. On the other hand, accumulating evi-
dence has shown that the risk of osteoporotic fractures is increased in type
2 diabetes mellitus. Previous studies have shown that elevated plasma
Hcy level is associated with the risk of osteoporotic fracture. Osteocytes
are the most abundant cells in the bone, and they play important roles in
coordinating the functions of osteoblasts and osteoclasts. However, to our
best knowledge, no study has described the effects of Hcy on osteocytes.
While Hcy increases oxidative stress, AMP-activated protein kinase
(AMPK) activation ameliorates it, suggesting that an AMPK activator,
metformin, may rescue the adverse effects of Hcy on osteocytes. This
study aimed to investigate whether Hcy induces apoptosis of osteocytes
through regulating expressions of oxidant and anti-oxidant enzymes and
determine the effects of AMPK activation by metformin and 5-
aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) on the
Hcy-induced apoptosis of the cells.
Materials and methods: MLO-Y4, a murine long bone-derived
osteocytic cell line, was used. DNA fragment ELISA and TUNEL stain-
ing assays were performed to detect the apoptosis of the cells. Real-time
PCR and western blot analysis were performed to examine the expression
of NADPH (Nox) oxidase and superoxide dismutase (SOD).
Results:DNA fragment ELISA and TUNEL staining assays showed that
Hcy treatments (0.1-5.0 mM) induced apoptosis of MLO-Y4 cells in a
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dose-dependent manner. The detrimental effect of Hcy was partly but
significantly reversed by an antioxidant (N-acetylcysteine) and NADPH
oxidase (Nox) inhibitors (apocynin and diphenyleneiodonium). In addi-
tion, metformin (10-100 μM) and treatment with AICAR (0.05-0.1 mM)
ameliorated Hcy-induced apoptosis of the cells. The favorable effect of
metformin on Hcy-induced apoptosis was completely cancelled by an
AMPK inhibitor Ara-A. Hcy increased the expression levels of Nox1
and Nox2, while it had no effects on the expressions of Nox4 or the
anti-oxidant enzymes, SOD1 and SOD2. Hcy-induced increases in the
expressions of Nox1 andNox2 decreased significantly by treatments with
AICAR.
Conclusion: These findings suggest that Hcy induces apoptosis of oste-
ocytes by increasing the expression of Nox1 and Nox2, and metformin
effectively prevents the detrimental reactions via AMPK activation.
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Wnt/b-catenin pathway downregulation, indicated by increased
dickkopf-1 in type 1 diabetes, is probably associated with lower bone
mineral density
K. Karavanaki1, C. Tsentidis1, L. Kossiva1, A. Marmarinos2, A.
Doulgeraki3, D. Gourgiotis2;
1Diabetic clinic, 2nd dept. of paediatrics, 2Biochemistry Laboratory, 2nd
dept. of paediatrics, Athens University, 3Department of Bone andMineral
Metabolism, Institute of Child Health, Athens, Greece.
Background and aims:Diabetes Mellitus disrupts many bone metabolic
pathways, predisposing to reduced bone mass. Increased fracture risk and
elevated Dickkopf-1 and sclerostin levels, which are inhibitors of Wnt/β-
catenin pathway, have been documented in adult patients with T2DM;
however no relevant data exist on childhood T1DM. We aimed to study
plasma Dickkopf-1 and sclerostin concentrations in children and adoles-
cents with T1DM and controls and to correlate them with metabolic bone
markers and bone mineral density(BMD).
Materials and methods:We evaluated 40 children and adolescents with
T1DM (mean ± SD age:13.04±3.53 years, T1DM duration:5.15±
3.33 years), along with 40 healthy matched controls (age 12.99±
3.3 years). Dickkopf-1, Sclerostin, Receptor Activator of Nuclear
factor-KappaB Ligand(s-RANKL), Osteoprotegerin, Osteocalcin, C-
telopeptide crosslinks-CTX, electrolytes, PTH, total 25(OH) Dwere mea-
sured and lumbar spine and total body BMD were evaluated.
Results:BMDwas found lower andDickkopf-1 levels were found higher
(13.56±5.34 vs 11.35±3.76 pmol/L, p=0.0194) in T1DM patients than
controls. A trend for lower values was found in girls (13.36±4.04 vs
11.72±5.14 pmol/L, p=0.06) and in pubertal children (13.61±4.87 vs
11.83±4.56 pmol/L, p=0.054). Dickkopf-1 correlated with Sclerostin
and L1-L4 BMD z-score only in controls and with Osteoprotegerin and
i-Phosphorus only in patients, while in both groups a significant correla-
tion with log(CTX) and √ALP was documented. A significant correlation
of Dickkopf-1 with IGF-1 and insulin dose was also found in patients.
Conclusion: Higher levels of Dickkopf-1 were found in T1DM children
and adolescents, indicating a downregulated Wnt signaling system and
possible lower osteoblast activation that could be associated with T1DM
osteopathy.
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FGF-23 in type 1 diabetes: the potential role of mineral metabolism
in arterial stiffness
G. Llaurado1,2, A. Megia3,2, A. Cano4, O. Giménez-Palop4, I. Simón3,2,
M. González-Sastre5, E. Berlanga6, J. Vendrell3,2, J.-M. González-
Clemente4,2;
1Department of Endocrinology and Nutrition, Hospital del Mar. IMIM
(Hospital del Mar Medical Research Institute), Barcelona, 2Centro de
Investigación Biomédica en Red de Diabetes y Enfermedades
Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 3En-
docrinology and Nutrition Unit, Hospital Universitari Joan XXIII de Tar-
ragona. Institut d’Investigacions Sanitàries Pere Virgili (IISPV).
Universitat Rovira i Virgili, 4Department of Endocrinology and Nutrition,
Hospital de Sabadell. Corporació Sanitària i Universitària Parc Taulí
(Universitat Autònoma de Barcelona), 5Department of Ophthalmology,
Hospital de Sabadell. Corporació Sanitària i Universitària Parc Taulí
(Universitat Autònoma de Barcelona), 6Biochemistry Department,
UDIAT. Corporació Sanitària i Universitària Parc Taulí (Universitat
Autònoma de Barcelona), Sabadell, Spain.
Background and aims: Existing evidence suggests that an abnormal
mineral metabolism, and particularly vitamin D deficiency, may promote
atherosclerosis. However, the discovery of fibroblast growth factor 23
(FGF-23) has introduced a new perspective linking vitamin Dmetabolism
and cardiovascular (CV) disease. FGF-23 is an endocrine peptide that
regulates mineral metabolism and is directly associated with adverse
CVoutcomes. Our aim was to investigate the likely relationship between
FGF-23 and vitamin D with arterial stiffness (AS), as an early sign of
atherosclerosis, in a group of subjects with type 1 diabetes (T1DM) with-
out previous clinical cardiovascular disease.
Materials and methods: 68 T1DM patients and 68 age- and sex-
matched controls were evaluated for: 1) age, sex, diabetes duration, phys-
ical activity, smoking, alcohol intake, BMI, BP, fasting plasma glucose,
HbA1c, estimated glomerular filtration rate (eGFR) and lipid profile, 2)
microvascular complications, 3) concentrations of FGF-23 and mineral
metabolism parameters (calcium, phosphate, parathyroid hormone (PTH)
and 25-hydroxy-vitamin D (25(OH)D)), 4) AS, assessed as aortic pulse
wave velocity (aPWV), and 5) low-grade inflammation (hsCRP, IL-6,
sTNFαR1, sTNFαR2) and endothelial dysfunction (ED) markers
(ICAM-1, VCAM-1, E-Selectin).
Results: Subjects with T1DM had higher aPWV compared with healthy
controls (6.8(6.0-7.9)m/s vs. 6.1(5.5-6.7)m/s; p<0.001), but they did not
present differences in 25(OH)D (28.3(23.9-33.3)ng/mL vs. 28.1(20.2-
34.5)ng/mL; p=0.462) and in FGF-23 plasma concentrations
(70.1(38.4-151.9)RU/ml vs. 77.6(51.8-113.9)RU/ml; p=0.329). In pa-
tients with T1DM, higher concentrations of FGF-23 were positively as-
sociated with aPWVafter adjusting for eGFR and classical cardiovascular
risk factors (model 1: ß=0.202, p=0.026), other mineral metabolism
parameters (model 2: ß=0.214, p=0.015), microvascular complications,
low-grade inflammation and ED markers (model 3: ß=0.170, p=0.045).
Lower 25(OH)D concentrations were also associated with higher aPWV
after adjusting for FGF-23 and all the above-mentioned factors (model 3:
ß=-0.241, p=0.015).
Conclusion: We conclude that both FGF-23 plasma concentrations
(positively) and 25(OH)D serum concentrations (negatively) are associ-
ated with AS in subjects with T1DM and no previous clinical cardiovas-
cular disease.
Supported by: PS09/01360 (ISCIII), Marató TV3 (081410). GL
CM12/00444 (ISCIII)
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Impaired balance ability, particularly one-leg stand evaluation, is
associated with diabetic complications even in younger adults with
type 2 diabetes
D. Kukidome1, M. Sato1, S. Shimoda1, T. Nishikawa1,2, E. Araki1;
1METABOLIC MEDICINE, FACULTY OF LIFE SCIENCES, 2Com-
munity medicinec, KUMAMOTO UNIVERSITY SCHOOL OF MEDI-
CINE, Kumamoto, Japan.
Background and aims: Elderly individuals with diabetes were at greater
falls risk, but probability for falls among younger adults with diabetes is
unknown. Several clinical balance tests have been reported to be a useful
predictor of falls among older adults. Our aims of this study are 1) to
characterize the balance ability of subjects aged 30 and older with type 2
diabetes (T2D) compared with non-diabetic control subjects, 2) to inves-
tigate the relevance between the balance ability and diabetic complica-
tions among subjects with T2D.
Materials and methods: Two static balance tests, one-leg stand (OLS)
and outer area of postural sway while standing (OAPS), and two dynamic
balance tests, timed up and go test (TUG) and functional reach test (FR),
were measured in 115 T2D subjects and 51 non-diabetic subjects. All
subjects were interviewed for a history of falls, and were divided into
six groups with age: younger (60 years) T2D (n=55), or older control (n=
15). In comparison of balance ability among the different groups, Mann-
Whitney test or Kruskal-Wallis test were used.
Results: T2D subjects had significantly lower balance ability compared
with non-diabetic subjects in all four balance measures (OLS; 44.8 vs
60.0 sec, OAPS; 1.83 vs 1.25 cm2, TUG: 7.3 vs 5.8 sec, FR 0.189 vs
0.230, all P<0.01). In subjects with T2D, the balance ability assessed by
measuring OLS and OAPS decreased gradually with retinopathy progres-
sion (OLS; 52.9, 42.8, 10.3 sec, P<0.01, OAPS; 1.67, 1.94, 3.08 cm2, P<
0.01 in no retinopathy, simple retinopathy, or either preoproliferative or
proliferative retinopathy, respectively). Subjects with diabetic neuropathy
showed a lower balance ability assessed by OLS (30.0 vs 57.5 sec, P<
0.01), OAPS (1.65 vs 2.11 cm2, P<0.05) and TUG (6.7 vs 7.5 sec, P<
0.05) compared with those without diabetic neuropathy. Furthermore,
T2D subjects with a falls history (n=9) had a longer duration of diabetes
(18.3 vs 9.7 years, P<0.05), a shorter time of OLS (6.1 vs 46.6 sec, P<
0.01) and a longer time of TUG (9.7 vs 7.2 sec, P<0.01) compared with
those without a falls history. Even in younger and middle-aged T2D
subjects, the OLS, TUG and FR evaluation showed lower balance ability,
compared with those of age-matched non-diabetic subjects (in younger
OLS; 52.7 vs 60.0 sec, TUG; 6.8 vs 5.3 sec, FR; 0.197 vs 0.240, in
middle-aged OLS; 57.5 vs 58.1 sec, TUG; 6.9 vs 5.8 sec, FR; 0.192 vs
0.238, all P<0.01, respectively).
Conclusion: Subjects with T2D, even in younger adults, had impaired
balance ability. OLS was closely associated with the severity of diabetic
neuropathy and retinopathy in every aged group, and the previous falls
history. Therefore OLSmay be themost suitable clinical measurement for
evaluating balance ability and falls risks among subjects with T2D.
Clinical Trial Registration Number: UMIN 000008698
Supported by: Manpei Suzuki Diabetes Foundation
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Severe vertebral fracture and low osteocalcin level increase the mor-
tality in postmenopausal women with type 2 diabetes mellitus
H. Miyake, I. Kanazawa, T. Sugimoto;
Internal Medicine 1, Shimane University Faculty of Medicine, Izumo,
Japan.
Background and aims: Accumulating evidence has shown that patients
with type 2 diabetes mellitus (T2DM) have an increased risk of osteopo-
rotic fracture independently of bone mineral density. Although osteopo-
rotic fractures such as hip fracture and vertebral fracture (VF) are known
to increase mortality in general population, there are no studies
investigating whether the fractures influence the mortality of patients with
T2DM. On the other hand, previous studies have shown that osteocalcin,
which is secreted from osteoblasts, has a hormonal function improving
glucose tolerance by increasing insulin secretion and sensitivity. Because
serum osteocalcin levels are decreased in diabetic patients, we hypothe-
sized that serum osteocalcin may be associated with the mortality. There-
fore, the aim of this study was to examine whether the presence of VF and
bone turnover markers including osteocalcin were associated with the
mortality in postmenopausal women with T2DM.
Materials and methods: This is a historical cohort study with the end-
point of all-cause mortality in postmenopausal women with type 2 diabe-
tes.We recruited 190 postmenopausal womenwith T2DMwho previous-
ly underwent lateral X-ray examination of thoracic and lumbar spine to
check VF from 1993 to 2009 at Shimane University Hospital. AVF was
diagnosed if at least one of three height measurements along the length of
the same vertebrae had decreased by >20% compared to the height of the
nearest uncompressed vertebral body. VFs were classified as follows;
grade 1 (G1), a reduction of 20-25%; G2, 25-40%; G3, more than 40%.
The participants were observed up to 7 years, and the association between
VF and bone turnover markers versus all-cause mortality was explored
using Kaplan-Meier method, logrank test, and Cox regression analysis.
Results: At the entry of this study, mean age and duration of diabetes
were 67.5 and 12.3 years, respectively. Mean serum osteocalcin level was
6.9 ng/mL, and 54 patients (28.4%) had vertebral fractures. Of 190 sub-
jects, 19 patients died during the observation period. Logrank tests
showed that lower serum osteocalcin (<6.5 ng/mL), multiple and G3
VFs were associated with higher mortality compared to higher
osteocalcin (≥6.5 ng/mL) or non VFs, respectively (at least p<0.01).
Moreover, age-adjusted Cox regression analyses showed that G3 VF
was significantly associated with the mortality [relative risk (RR)=3.7,
95% confidence interval (CI)=1.1-13.0, p=0.04] and multiple VFs were
marginally with it (RR=2.8, 95%CI=0.9-8.7, p=0.08) compared to non
VFs, and that serum osteocalcin was significantly associated with age-
adjusted mortality (Hazard ratio (HR)=0.36, 95%CI=0.16-0.80 per SD
increase, p=0.012). Moreover, the association of osteocalcin and mortal-
ity was still significant even after additional adjustment for duration of
diabetes mellitus, body mass index, HbA1c, and serum creatinine (HR=
0.30, 95%CI=0.11-0.80 per SD increase, p=0.02).
Conclusion: The present study for the first time showed that severe VF
and low serum osteocalcin were associated with all-cause mortality in
postmenopausal women with T2DM.
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Relation of 25OHD3 availability to VDR expression and NF-κB-
dependent proinflammatory signalling pathway in diabetes-induced
liver failure
D. Labudzynskyi1, I. Shymanskyy1, S. Savosko2, V. Dosenko3, M.
Veliky1;
1Laboratory of Medicine biochemistry, Palladin Institute of Biochemistry
of NAS of Ukraine, 2Department of Histology and Embryology, O.O
Bogomolets Kiev National Medical university, 3Genaral and Molecular
Patophysiology, Bogomoletz Institute of Physiology of NAS of Ukraine,
Kyiv, Ukraine.
Background and aims: Diabetes is known to be characterized with
upregulation of pro-inflammatory factors in various tissues. It is known
that nuclear factor kappa B (NF-κB) is a key regulator of inflammatory
process and its activation leads to increased expression of inducible nitric
oxide synthase (iNOS) and vascular permeability factor (VPF) involved
in inflammation. Vitamin D3 (D3) is currently recognized as a potent
immunomodulator affecting various inflammatory and autoimmune dis-
eases. Importantly, hormonally active form of vitaminD3 (1,25(OH)2D3)
binds to vitamin D3 receptors (VDR) functioning as transcription factor
to modulate gene expression. However, precise mechanisms of vitamin
D3 influence on immune regulation has not been clearly established. We
therefore investigated the hepatoprotective role of vitamin D3 in VDR-
mediated regulation of pro-inflammatory factors (p65 NF-κB, VPF,
iNOS) expression in diabetic liver.
Materials and methods: Type 1 diabetes was induced in male C57BL/J6
mice (24.0±1.6 g) by i.p. injection of high-dose STZ (150mg/kg b.w.). After
2 weeks of STZ-induced diabetes mice were treated with or without vitamin
D3 (15 IU/mouse per os, for 8 weeks). Serum 25OHD3 was assessed by
ELISA. The expression of phosphorylated NF-κB/p65 (Rel A), VPF, iNOS
and VDR mRNA were measured by RT-PCR and Western-blot analysis.
Histological features were assessed using H&E staining.
Results: Serum level of 25OHD3 was shown to be reduced to 27.4±2.0
in diabetes vs. 41.6±2.9 nmol/L in control, indicative of diabetes-induced
D3 deficiency (p<0.05). These changes were accompanied by 1.3-fold
overexpression of VDR mRNA, that can be a compensatory mechanism
in response to D3 deficiency. It should be noted, that diabetes was asso-
ciated with 2.4-fold augmentation of RelA expression in hepatic tissue of
diabetic mice. NF-κB overexpression was accomponied by 1.53- and
1.28-fold increase in VPF and iNOS mRNA levels in liver. The results
of RT-PCR correlated with results of Western blot analysis that showed a
1.21- , 2.04- , 1.62- and 1.32-fold elevation of liver tissue protein contents
of VDR, NF-κB p65, VPF and iNOS respectively. Diabetes also caused
structural lesions in liver, which were characterized by altered blood
microcirculation (dilated microvessels), degenerative changes in cytolog-
ical structure of hepatocytes and their mitotic activity. Full restoration of
25OHD3 content and partial normalization of liver tissue structure were
achieved by D3 treatment. Vitamin D3 administration caused a partial
normalization of mRNA expression and protein contents of VDR,
pNF-κB/p65, VPF and iNOS in liver tissue. It can be suggested that D3
prevents overexpression of pNF-κB/p65 and nuclear translocation of
phosphorylated p65 in hepatocytes and its effect is mediated through 1,
25(OH)2D3 and VDR.
Conclusion: The study confirmed that diabetes-induced liver abnormal-
ities are associated with upregulation of VDR and inflammatory markers
NF-κB/p65, VPF and iNOS expression that correlated with insufficient
vitamin D3 availability. Our results can explain protective VDR-mediated
effects of vitamin D3 action against diabetes-induced liver cells injury.
Supported by: Personal scholarship of Palladin Bioch. Inst. Board of
directors (2013)
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Metformin attenuates hepatitis C virus-induced hepatic fibrosis
through up-regulation of AMPK and orphan nuclear receptor SHP
J.-H. Jeon1, G.-S. Jung1, Y.-K. Choi1, K.-H. Bae1, A. Khang1, M.-K.
Kim2, E.-H. Kim3, I.-K. Lee1, K.-G. Park1;
1Department of Internal Medicine, Kyungpook National University
School of Medicine, 2Department of Internal Medicine, Keimyung Uni-
versity School of Medicine, 3Department of Internal Medicine, Daegu
Fatima Hospital, Daegu, Republic of Korea.
Background and aims: Metformin, a commonly prescribed oral hypo-
glycemic agent, has pleiotropic benefits including lowering cancer devel-
opment and cancer mortality in patients with type 2 diabetes. Metformin
was also independently associated with a reduction in hepatitis C virus
(HCV)-induced cirrhosis in patients with type 2 diabetes. Mounting evi-
dence suggests that the potential beneficial effects of metformin are asso-
ciated with AMPK and SHP activation. However, little is known about
the protective effects exerted by metformin induced AMPK and SHP
activation against HCV-induced hepatic fibrosis.
Materials and methods: Levels of SHP, p-AMPK and fibrotic markers
in HCV-infected human liver and in Huh-7.5 cells infected with HCV
genotype 2a (JFH-1) were investigated. The effect of adenovirus-
mediated overexpression of SHP (Ad-SHP) and AMPK activation by
metformin on fibrotic gene expression was evaluated in HCV-infected
cells. Finally, we examined the effect of Ad-SHP and metformin on in-
vasion and activation of LX2 human hepatic stellate cells induced by
conditioned media (CM) from HCV-infected hepatocyte.
Results: In human livers infected with HCV and Huh-7.5 cells infected
with JFH-1, SHP mRNA and protein levels were diminished compared
with control livers and Huh-7.5 cells, respectively, whereas profibrotic
factors, including TGF-β, were increased. In addition, levels of phosphor-
ylated p38mitogen-activated protein kinase, c-Jun N-terminal kinase, and
Smad3 were also increased. Metformin-induced AMPK activation recov-
ered HCV-suppressed SHP expression, and Ad-SHP inhibited mRNA
and protein levels of profibrotic factors and fibrotic genes. SHP overex-
pression also inhibited HCV-stimulated nuclear factor-kappa B activa-
tion, which led to decreased TGF-β production. CytoSelect invasion
assay revealed that increased activity and invasiveness of HSCs induced
by CM from HCV-infected Huh-7.5 cells were attenuated by treatment
with metformin or Ad-SHP.
Conclusion: These results demonstrate that metformin-induced activa-
tion of AMPK and SHP reverses profibrogenic features of HCV-infected
cells by overcoming HCV-induced diminution of AMPK and SHP ex-
pression, and concomitantly decreasing TGF-β and fibrotic gene expres-
sion. These findings provide a rationale for metformin as a possible ther-
apeutic agent against HCV-induced hepatic fibrosis, especially when ac-
companied by type 2 diabetes.
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Non-alcoholic fatty liver disease is associated with vascular inflam-
mation: analysis by 18 F-fluorodeoxyglucose positron emission
tomography
R. Min Jung1, H. Choi1, J. Ryu1, H. Hong1, H. Yoo1, J. Seo2, N. Kim3,
H. Kim3, S. Kim3, N. Kim2, S. Baik1, D. Choi3, K. Choi1;
1Division of Endocrinology and Metabolism, Department of Internal
Medicine, Korea University GuroHospital, 2Department of InternalMed-
icine, Korea University Ansan Hospital, 3Department of Internal Medi-
cine, Korea University Anam Hospital, Seoul, Republic of Korea.
Background and aims: Growing evidence suggests that non-alcoholic
fatty liver disease (NAFLD) is associated with cardiovascular disease as
well as metabolic syndrome. FDG-PET is a novel imaging technique that
detects vascular inflammation, which may reflect rupture-prone vulnera-
ble atherosclerotic plaques.
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Materials and methods: Vascular inflammation was measured as the
maximum target-to-background ratio (maxTBR), along with various car-
diometabolic risk factors in 51 subjects with NAFLD, and compared
them with 100 age- and gender-matched subjects without NAFLD. The
liver attenuation index (LAI), which was measured using computed to-
mography, was used as a parameter for the diagnosis of NAFLD.
Results: After adjusting for age and sex, both maxTBR and LAI values
were associated with several cardiometabolic risk parameters. Further-
more, there was a significant inter-relationship between LAI and
maxTBR values (r=-0.227, P=0.005). Individuals with NAFLD had
higher maxTBR values than those without NAFLD (P=0.026), although
their carotid intima-media thickness values did not differ. The proportion
of subjects with NAFLD showed a step-wise increment following the
tertiles of maxTBR values (P for trend=0.015). In multiple logistic re-
gression analysis, maxTBR tertiles were independently associated with
NAFLD after adjusting for age, gender, systolic blood pressure, triglyc-
erides, HDL-cholesterol, glucose, BUN, creatinine and homeostasis mod-
el assessment of insulin resistance (HOMA-IR) (P=0.030). However,
their relationship was attenuated after further adjustment for waist circum-
ference, LDL-cholesterol or high sensitive C-reactive protein.
Conclusion: The present study first shows that patients with NAFLD
have an increased risk for vascular inflammation as measured via FDG-
PET/CT.
Clinical Trial Registration Number: NCT01958411
Supported by: K.M.C. 2012006363, K.M.C. and S.H.B. HI10V-0007-
010013
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The hepatic protective effect of hepassocin on hyperglycaemic crisis
H.-Y. Ou1, H.-T. Wu2, C.-H. Lin1, Y.-F. Du1, F.-H. Lu3, J.-S. Wu3, H.-C.
Hung1, Y.-C. Yang3, C.-J. Chang3;
1Department of Internal Medicine, 21. Research Center of Herbal Medi-
cine, New Drugs, and Nutritional Supplements, 3Department of Family
Medicine, National Cheng-Kung University, Tainan, Taiwan.
Background and aims: Hyperglycemic crisis is a metabolic emergency
associated with uncontrolled diabetes that may result in morbidity. Al-
though it is known that reactive oxygen species (ROS) production by
hyperglycemia leads to hepatic dysfunction, only a mild increase of as-
partate aminotransferase (AST) and/or alanine aminotransferase (ALT)
level is observed in patients with hyperglycemic crisis, and the exact
mechanisms were still undefined. Hepassocin is a hepatokine that plays
as a mitogen for hepatocytes and exerts a hepatic protection action against
chemical-induced liver injury. However, the effect of hepassocin in
hyperglycemia-induced hepatic dysfunction remains obscure. Thus, the
aim of this study is to investigate the role of hepassocin in hyperglycemia-
induced hepatic dysfunction.
Materials and methods: Thirty patients with hyperglycemic crisis, in-
cluding diabetic ketoacidosis and hyperosmolar hyperglycemic state,
without obvious infection were enrolled at our university hospital. Stan-
dard treatment of hyperglycemic crisis including insulin, hydration, and
correction of electrolyte imbalance were given. After resolution of hyper-
glycemia, the blood samples were collected to examine hepassocin con-
centrations by enzyme-linked immunosorbent assay. In addition,
streptozotocin-induced hyperglycemic mice and HepG2 cell models were
used to evaluate the role of hepassocin in hyperglycemic crisis.
Results: The serum concentrations of hepassocin were significantly in-
creased in patients with hyperglycemic crisis. After treatment to relieve
hyperglycemic status, hepassocin levels were significantly reduced (P<
0.01). In addition, we found a dose-dependent increase in the hepassocin
expression of HepG2 cells exposed to high glucose condition. In
streptozotocin-induced hyperglycemic mice, treatment with hepassocin
significantly decreased the levels of AST and ALT without affecting the
concentrations of blood glucose and insulin in circulation (P<0.001). In
addition, the hepatic SOD1 expression was increased after the hepassocin
treatment. Furthermore, we found that hepassocin increased the activity
of ERK1/2, Nf-E2 related factor-2 (NRF2) translocation to nuclear, as
well as SOD1 expression. Blockade of ERK1/2 by U0126 inhibited
NRF2 translocation and SOD1 expression, indicating hepassocin in-
creased SOD1 through an ERK1/2-NRF2-SOD1 dependent pathway.
As a result of increased SOD1 expression, HepG2 hepatocytes were
protected by hepassocin from ketone body (acetoacetate)-induced ROS
production and cell death.
Conclusion: Hepassocin plays a protective role in hyperglycemia-
induced hepatic dysfunction by regulating ERK1/2 activity. Hepassocin
induced SOD1 expression through an ERK1/2-NRF2-SOD1 dependent
pathway, and this effect further decreased ROS production and protects
hepatocytes from hyperglycemia-induced hepatocyte injury.
Supported by: MOST; NCKUH
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Liver proteome and microRNAs in insulin receptor knockout mice
reveal novel molecules involved in the diabetes pathophysiology
B. Capuani1, D. Della Morte1, S. Caratelli2, D. Pastore1, A. Coppola1, F.
Pacifici1, R. Arriga1, A. Bellia1, M. Federici1, P. Sbraccia1, M. Romano3,
A. Galli3, G. Donadel1, G. Sconocchia2, D. Lauro1;
1Systems Medicine, University of Rome, 2Institute of Translational Phar-
macology Council National Research, 3Unit of Endocrinology,
Diabetology and Metabolic Diseases, University Hospital Fondazione
Policlinico Tor Vergata, Rome, Italy.
Background and aims: Type 2 Diabetes Mellitus (T2DM) is a disease
characterized by alteration of insulin signaling in specific target tissues,
such as skeletal muscle, adipose tissue, and liver. Dysfunction and later
failure of insulin-producing pancreatic beta cells (β-cells) and peripheral
insulin resistance induce hyperglycemia in pre-diabetes conditions. Fun-
damental is discovering early biomarkers to delay or prevent onset of
T2DM. Recently, some studies are seeking for biomarkers through pro-
teomic and microRNA (miRNA) approaches, but none identified specific
hepatic proteins which trigger early stages of T2DM. Therefore we are
reaching the goal to reveal new proteins involved in the onset of diabetes
and/or its relative complications.
Materials and methods:miRNAs were extracted from ten mice for each
genotype (IR+/+, IR+/-, and IR-/- its integrity assayed on Nano Chip and
Small ChipAgilent, and then hybridised with miRNAMicroarray System
with miRNA Complete Labeling and Hyb kit (Agilent) for expression
profiling. Expression levels of specific miRNAs were validated by qRT
PCR using TaqMan assay. We used miR-Walk algorithm to determine
miRNA targets and mRNAs expression were validated by qRT PCR.
Different protein profiles of IR+/+, IR+/-, and IR-/- were analyzed by
2D PAGE and nLC MS/MS analysis. HMGB1 acetylation and SIRT1
expression were analyzed by Immunoprecipitation and Western Blot,
while HMGB1 secretion was studied by ELISA kit (Shino Test), and
immunofluorence microscopy.
Results: We analyzed protein and miRNA patterns by proteomic and
miRNA arrays in insulin receptor knockout (IR-/-) and heterozygous
(IR+/-) mice as a murine model of liver metabolic dysfunction associated
with diabetic ketoacidosis and insulin resistance. We evaluated protein
expressions by using protein 2-DE MALDI-TOF/TOF and peptic nLC-
MS/MS shotgun profiling. Twenty-eight proteins identified by 2-DE
analysis and 24 identified by nLC-MS/MS shotgun, were differentially
expressed among the 3 genotypes. Bioinformatic analysis revealed a cen-
tral role of High Mobility Group Box 1/2 and huntigtin (HTT) never
reported to be associated with metabolic and related liver disease.
MiRNAs array identified only 4 miRNA differently expressed between
IR+/+, IR+/- and IR-/- miR-376b, miR-154, miR-543, and miR-199b.
Quantitative Real time polymerase reaction (qRTPCR) confirmed these
results, and bioinformatic analysis reveals interesting mRNA targets in-
volved in metabolic pathways linked with proteomic analysis. Among
these targets, the most interesting is SIRT1, a deacytetilase involved in
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HMGB1 translocation, and then, in the activation of inflammatory state
mediated by HMGB1.
Conclusion: These results provide new insight into pathophysiology of
T2DM and non alcoholic fatty liver disease, and should be useful to be
confirmed as novel biomarkers to predict risk for diabetes and its com-
plications.
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Tissue-specific effects on mitochondrial dysfunction in type 1 and 2
diabetic mouse models
N. Volk, T.H. Fleming, E. Kliemank, P.P. Nawroth;
Department of Medicine I and Clinical Chemistry, University of Heidel-
berg, Germany.
Background and aims: During diabetes, increased hyperglycemic flux
is considered to raise the production of reactive oxygen species (ROS).
However, it remains under debate whether this increase is due to or
causing functional changes of the mitochondria. Several studies have
been published to determine the effect of diabetes on the function of the
mitochondria. Yet, the results are contradictory. Here, we present a screen
analyzing the effects of diabetes on the mitochondria of heart, kidney and
liver using low-dose streptozotocin (STZ)-induced wild-type mice as a
model for type 1 diabetes (T1D) and db/db mice as a model for type 2
diabetes (T2D).
Materials and methods:Mitochondria were isolated by differential cen-
trifugation and purity was determined using FACS. Functionality of the
mitochondria was analyzed using fluorescence-photometric and spectro-
photometric assays. Gene expression profiles were analyzed using quan-
titative PCR. Data was expressed as fold change to control (mean +/- SD)
and statistical significance was calculated using students t-test.
Results: After 3 months of diabetes (3 M) oxygen consumption was
decreased (0.11 +/- 0.09, P-value<0.001) and ATP production showed
a tendency to decrease in heart-derived mitochondria of T1D mice. In
T2D oxygen consumption (0.68 +/- 0.07, P-value<0.01), ATP (0.71 +/-
0.20, P-value=0.03) and superoxide (0.78 +/- 0.01, P-value=0.02) pro-
duction were decreased in cardiac mitochondria. In the mitochondrial
fraction of T1D kidneys increased ATP production (1.25 +/- 0.15, P-
value<0.01) and a tendency of increased oxygen consumption was mea-
sured. In T2D oxygen consumption (0.31 +/- 0.23, P-value<0.01) was
decreased whereas ATP and superoxide production remained unchanged.
In T1D increased superoxide production (1.31 +/- 0.28, P-value=0.04)
and a tendency of increased oxygen consumption and ATP production
was measured in the liver. In T2D superoxide production (1.48 +/- 0.17,
P-value<0.01) was increased in the same extent as in T1D. However,
ATP and oxygen consumption (10.29 +/- 5.40, P-value=0.02) increased
to a higher extent in T2D. Besides the comparison of T1D and T2D,
mitochondrial changes were also analyzed during the progression of di-
abetes using the T1D model. 6 months after the induction of diabetes
(6 M) ATP and superoxide production were unchanged compared to
3 M. In the heart- and liver-derived mitochondria oxygen consumption
remained unchanged as well. However, oxygen consumption in the kid-
ney increased in 6M compared to 3M. Gene expression analysis showed
a decrease in mitochondrial complexes and antioxidative enzymes in the
diabetic kidney in 3 M and 6 M. In the heart and liver changes in the
expression were first detected in 6 M and less pronounced than in the
kidney.
Conclusion: In this study it was found that the effect of diabetes on
mitochondrial dysfunction depends on the tissue and model studied and
that results obtained from one organ and model cannot be applied to
another. Furthermore, the kidney was found to be the organ which was
affected first and most severe in T1D, suggesting that tissues which are
highly susceptible to chronic hyperglycaemia are likely to be the most
affected with respect to mitochondrial properties.
Supported by: GRK 1874/1, SFB 1118
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Long-term clinical outcomes in patients with acute coronary
syndrome and dysglycaemia
J. Kuhl, G. Jörneskog, M. Bengtsson, P. Lundman, M. Kalani;
Department of Clinical Sciences, Karolinska Institutet, Stockholm, Swe-
den.
Background and aims: Diabetes and impaired glucose tolerance (IGT)
are major risk factors for atherosclerosis including coronary artery disease
(CAD). The aim of the present study was to investigate the importance of
glucose tolerance for long term clinical outcome in patients with acute
coronary syndrome (ACS).
Materials and methods: 1062 consecutive patients, 781 men and 281
women, aged 32-80 years, admitted to the coronary care unit at a Univer-
sity Hospital, for ACS from year 2006 to 2008. At discharge, the patients
were categorized according to an OGTT as having normal glucose toler-
ance (NGT); n=295 (28%), impaired glucose tolerance (IFG) and im-
paired glucose tolerance (IGT); n=299 (28%), diabetes discovered by
OGTT; n=156 (15%) or known diabetes at admission to the hospital;
n=312 (29%). Mortality and reinfarction rates were studied during a
mean follow-up time of 4.0 (±0.8) years. Clinical outcome data were
obtained from the Swedish Coronary Angiography and Angioplasty Reg-
istry and the Swedish National Registry.
Results: Patients with known diabetes at admission had compared to
patients with dysglycaemia discovered by OGTT and NGT a significant
increase (p<0.001) in death within 14 days (2.9% vs 0.2% and 0%),
30 days (4.8% vs 0.2% and 0%), 6 month (9% vs 1% and 0%), 1 year
(12% vs 2% and 0%) and 3 years (25% vs 5% and 3%). During the
follow-up, reinfarction was significantly higher (p<0.001) in patients
with known diabetes compared to patients with dysglycaemia discovered
by OGTT and NGT (28% vs 17% and 12%). The composite endpoint of
mortality and reinfarction was significantly higher (p<0.001) in patients
with known diabetes compared to patients with dysglycaemia discovered
by OGTT and NGT (44% vs 22% and 15%). Furthermore, it was also a
significant difference (p<0.001) between patients with dysglycaemia dis-
covered by OGTT as compared to patients with NGT.
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Conclusion: A majority of patients admitted for ACS have disturbed
glucose metabolism including diabetes with high prevalence of previous-
ly undiagnosed dysglycaemia. Both known diabetes and dysglycaemia
discovered by OGTT are associated with poor clinical prognosis in these
patients.
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HbA1c and risk of stroke in 33,414 type 1 diabetes patients compared
to 166,097 controls from the general population
A. Rosengren1, C.H. Stahl1, S. Gudbjornsdottir2, A.-M. Svensson2, M.
Kosiborod3, M. Clements4, M. Lind5;
1Molecular and Clinical Medicine, Institute of Medicine, University of
Gothenburg, 2Center of Registers in Region Västra Götaland, Gothen-
burg University, Sweden, 3Saint Luke’s Mid America Heart Institute,
University of Missouri–Kansas City School of Medicine, 4University of
Missouri–Kansas City School of Medicine and Children’s Mercy Hospi-
tal, the University of Kansas School of Medicine, Kansas City, USA,
5Department of Medicine, NU-Hospital Organization, University of
Gothenburg, Uddevalla, Sweden.
Background and aims: Earlier studies have found patients with type 1
diabetes at increased risk of stroke compared to the general population. In
this study we estimated the risk of stroke among individuals with type 1
diabetes according to HbA1C level, and compared it to the risk in the
general population.
Materials and methods: We included 33,414 individuals with type 1
diabetes, aged 18 years or older (mean 35.5 years), registered in the
Swedish National Diabetes Register 1998 to 2011 and 166,097 age, sex
and county matched controls from the general population. The endpoints
all stroke, ischemic stroke and hemorragisk stroke were captured using
ICD-10 codes I61, I62.9, I63, I64 and I67.9 from the Swedish Inpatient
and Cause of Death Registers. The risk of stroke for patients with type 1
diabetes were estimated in 5 different HbA1C categories by Cox hazard
regression analysis adjusted for age, sex, diabetes duration, born in Swe-
den, highest education level and baseline comorbidities with controls
from the general population as reference.
Results:Medium follow-up was 8.6 years and 9.0 years for patients with
type 1 diabetes and controls respectively. Among patients with type 1
diabetes 759 (2.3%) received a non-fatal or fatal stroke diagnosis com-
pared to 1425 (0.9%) among the controls. Unadjusted incidence values of
all stroke expressed as cases per 1000 person years were 2.86 (2.66 - 3.08)
for patients with type 1 diabetes and 1.04 (0.99 - 1.10) for controls. The
risk for all and ischemic stroke was significantly increased for patients
with type 1 diabetes in all HbA1C categories. The risk rose gradually by
each HbA1C category from a HR of 1.56 (95% CI 1.21 - 2.01) for all
stroke in the lowest category (≤6.9% (≤52 mmol/mol)) to a more than 7
times increased risk for patients with type 1 diabetes in the highest HbA1c
category (HR for all stroke 7.52 (95% CI 6.10 - 9.26) in HbA1c category
≥9.7% (≥83 mmol/mol )). For hemorrhagic stroke the risk for patients
with type 1 diabetes was increased in all but the lowest HbA1C category
compared to the controls. After a gradual increase in risk over the HbA1c
categories, patients with type 1 diabetes in the highest HbA1C category
≥9.7% (≥83 mmol/mol) had a HR of 7.74 (4.74 - 12.62) for hemorrhagic
stroke.
Conclusion: Individuals with type 1 diabetes experience a considerably
higher risk for stroke compared to the general population. The risk in-
creases gradually with worse glycemic control from a 50% higher risk in
the lowest HbA1C category to more than 700% higher risk in the highest
HbA1c category.
Supported by: Swedish Scientific Council, Swedish Heart and Lung
Found, Diab. Wellness
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Blood pressure and stroke risk in 408,076 type 2 diabetes patients
compared to 1,913,507 controls from the general population
C.H. Stahl1, M. Lind2, S. Gudbjornsdottir3, A.-M. Svensson3, M.
Kosiborod4, M. Clements5, A. Rosengren1;
1Molecular and Clinical Medicine, Gothenburg University, 2NU-Hospital
Organization, Gothenburg University, Uddevalla, 3Center of Registers in
Region Västra Götaland, Gothenburg University, Göteborg, Sweden,
4University of Missouri, Saint Luke’s Mid America Heart Institute, 5the
University of Kansas School of Medicine, Kansas City School of Medi-
cine and Children’s Mercy Hospital, Kansas City, USA.
Background and aims: Patients with type 2 diabetes have an elevated
risk of stroke. In this study we estimated the risk of stroke among patients
with type 2 diabetes at different blood pressure levels compared to the risk
in the general population in Sweden.
Materials and methods: This case-control study was based on 408,076
individuals with type 2 diabetes, 18 years or older, registered in the
Swedish National Diabetes Register 1998-2011 and 1,913,507 age- and
sex matched controls from the general population. Stroke diagnoses were
retrieved by ICD-10 codes I61, I62.9, I63, I64 and I67.9 from the Swed-
ish Inpatient and Cause of Death Registers. Cox hazard ratios (HRs) and
95% confidence intervals (CIs) adjusted for age, sex, diabetes duration,
born in Sweden, highest education level and baseline comorbidities were
estimated at 6 different blood pressure levels (<110/<65, 110-119/65-69,
120-129/70-79, 130-139/80-89, 140-159/90-99, >160/>100 mm Hg)
Results: During a median follow up of 4.0 years for patients with type 2
diabetes and 4.1 years for controls, 19,548 (4.8%) patients with type 2
diabetes and 61,690 (3.2%) controls were diagnosed with non-fatal or
fatal stroke. Corresponding unadjusted incidence values for any stroke
as cases per 1000 person years were 10.63 (10.48-10.78) for patients with
type 2 diabetes and 6.80 (6.75-6.86) for controls. Multivariable adjusted
Cox regression analysis, using controls as reference, yielded a significant-
ly increased risk of any stroke for patients with type 2 diabetes in blood
pressure categories above 130-139/80-89 mm Hg (hazard ratio HR of
1.11 (95% CI 1.07-1.15)), with gradually increasing HR to 1.80 (95%
CI 1.73-1.86) in the highest blood pressure category (>160/>100 mm
Hg). A similar pattern was observed for ischemic stroke. The association
was more complex for hemorrhagic stroke with a significant reduced risk
for patients with type 2 diabetes compared to controls in lower blood
pressure categories and significantly increased only in blood pressure
category >160/>100 mmHg (HR 1.49 (95% CI 1.33-1.68)).
Conclusion: Individuals with type 2 diabetes and blood pressure below
130/80mmHg have a risk of all stroke and ischemic stroke comparable to
that of the general population.
Supported by: Swedish Scientific Council, Swedish Heart and Lung
Foundation, Diabetes Wellness
Diabetologia (2015) 58 (Suppl 1):S1–S607 S555
1158
Remnant cholesterol predicts cardiovascular event risk in patients
with type 2 diabetes independently from the baseline coronary artery
disease state
H. Drexel1,2, C.H. Saely3,1, D. Zanolin4, P. Rein1, A. Vonbank1, A.
Leiherer4, A. Muendlein4;
1Academic Teaching Hospital Feldkirch, Austria, 2Drexel University,
Philadelphia, USA, 3Private University of the Principality of Liechten-
stein, Triesen, Liechtenstein, 4VIVIT Institute, Feldkirch, Austria.
Background and aims:Remnant cholesterol, which is calculated as total
cholesterol minus LDL cholesterol minus HDL cholesterol recently has
attracted interest as a marker of cardiovascular event risk. We aimed at
investigating the power of remnant cholesterol to predict cardiovascular
events in patients with type 2 diabetes (T2DM) as well as in non-diabetic
patients in whom the baseline coronary artery disease (CAD) state was
verified angiographically.
Materials and methods: We enrolled 1774 consecutive patients under-
going coronary angiography for the evaluation of established or suspected
stable CAD. Prospectively, cardiovascular events were recorded over a
mean follow-up period of 7.5±2.9 years. Diabetes was diagnosed accord-
ing to ADA criteria.
Results:During follow-up, 32.5% of our patients suffered cardiovascular
events; the event rate was significantly higher in patients with T2DM (n=
513) than in nodiabetic subjects (40.5 vs. 29.3%; p<0.001). Remnant
cholesterol significantly predicted cardiovascular events in the total study
population, among patients with T2DM, as well as among non-diabetic
subjects both univariately (HR 1.18 [1.10-1.27], p<0.001, 1.20 [1.05-
1.38], p=0.008 and 1.19 [1.09-1.30], p<0.001, respectively) and after
multivariate adjustment including presence as well as extent of baseline
CAD (HR 1.15 [1.07-1.24], p<0.001, 1.21 [1.05-1.39], p=0.009 and
1.15 [1.05-1.25], p=0.002, respectively).
Conclusion: Fromour data we conclude that remnant cholesterol predicts
cardiovascular event risk in patients with type 2 diabetes aswell as in non-
diabetic patients independently from the baseline CAD state.
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Contrasting eight cardiovascular risk equations for use in type 2
diabetes cohorts using the CORE Diabetes Model
M. Lamotte1, V. Foos2, P. McEwan3;
1IMS Health, Vilvoorde, Belgium, 2IMS Health, Basel, Switzerland,
3Health Economics & Outcomes Research Ltd, Cardiff, UK.
Background and aims: Within health economic evaluations concern
persists regarding the generalizability of cardiovascular (CV) risk equa-
tions (REs) and their impact upon cost-effectiveness predictions. The
IMS CORE Diabetes Model (CDM) is a widely published and validated
decision support tool that has been recently updated to include eight sets
of CV risk equations derived from European, American, Asian and Glob-
al cohorts. The objective of this study was to compare and contrast car-
diovascular incidence and predicted quality adjusted life expectancy
(QALE) across these REs.
Materials and methods: Lifetime analyses comparing outcomes for
metformin+ sulphonylurea (M+S) versus metformin + DPP-4 (M+D)
were undertaken using the CDMwith basal insulin rescue therapy applied
to both arms at an HbA1c threshold level of 7.5%. Baseline characteris-
tics and treatments effects from the published EDGE study were utilised:
mean age 57.8 years, duration diabetes 5.5 years, 54.8% male, HbA1c
8.2% and BMI 29 kg/m2. HbA1c reductions applied were -0.99% and -
1.19% for M+S and M+D respectively with a -0.3 kg and -1.6 kg change
in body weight for M+S and M+D respectively. A comparison of cumu-
lative incidence (CI) of myocardial infarction (MI) and stroke, QALE and
incremental cost effectiveness ratio (ICER) was made for the following
risk equations Swedish-National Diabetes Registry (S-NDR); UKPDS 68
(UK); UKPDS 82 (UK); ADVANCE (Global); FREMANTLE
(Australian); ARIC (US); HONG KONG (Asia) and PROCAM (Euro-
pean). UK 2013 costs were applied; costs and health benefits were
discounted at 3.5%.
Results: Across all REs, overall mean (standard error [SE]) predicted CI
of MI and stroke were 23.9% (4.1) and 35.7% (4.6) respectively. Aver-
aged across treatment arms, the Swedish-NDRRE predicted highest CI of
stroke (58.3%) and ARIC the lowest (4.3%); PROCAM the highest CI of
MI (69.7%) and ARIC lowest (9.8%). Mean (SE) predicted QALE across
all RE was 9.2 (0.2) with the highest (10.4) from ARIC and lowest (7.8)
from PROCAM. The overall mean (SE) ICER across all RE was £8,569
(£280) with the lowest (£6,980) from UKPDS 68 and highest (£10,964)
from PROCAM (range £3,984).
Conclusion: There was a noteworthy difference in predicted CI of CV
events across the eight RE and therefore economic assessments should
utilise RE from the most representative population. Importantly, estimat-
ed QALE and ICERs were relatively stable. Nevertheless, choice of RE
may have a significant impact on cost-effectiveness evaluations, particu-
larly where results lie close to the willingness-to-pay threshold.
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Testosterone in patients with acutemyocardial infarction and glucose
abnormalities and in matched controls: a report from the GAMI
study
A. Wang1, S. Arver2, J. Flanagan2, L.G. Mellbin1, V. Gyberg1, K.
Malmberg1, A. Norhammar1, P. Näsman3, V. Ritsinger1, L. Rydén1;
1Cardiology Unit, Department of Medicine Solna, Karolinska Institutet,
Stockholm, 2Center for Andrology and Sexual Medicine, Department of
Medicine, Karolinska University Hospital, Huddinge, 3Center for Safety
Research, KTH Royal Institute of Technology, Stockholm, Sweden.
Background and aims: Low levels of testosterone are prevalent in men
with diabetes and have been associated with impaired cardiovascular
health. A potential relationship between testosterone, diabetes and cardio-
vascular disease needs to be further elucidated. The present aims were to
investigate the prevalence of low testosterone (<350 ng/dl) and the dy-
namic of levels over time in patients with acute myocardial infarction
(AMI) with or without newly detected glucose abnormalities and in con-
trols. Further, the study explored the relation between testosterone and
cardiovascular prognosis.
Materials andmethods:Thematerial comprisesmale patients with AMI
without known diabetes (n=123) and age-matched controls without AMI
(n=124). Testosterone levels were measured at baseline for controls and
at the first morning after admission, at discharge, and 3 and 12 months
post-discharge for patients. Study participants were categorized as having
normal or abnormal glucose tolerance (NGT or AGT=diabetes or im-
paired glucose tolerance) by means of an oral glucose tolerance test.
The prognostic impact of testosterone was studied by Cox regression
hazard analyses (by +1 SD) with major cardiovascular events (cardiovas-
cular death, non-fatal MI, non-fatal stroke or severe heart failure) as
primary endpoint during 11 years follow-up.
Results:At the first morning after admission, 76% of the patients had low
testosterone (vs. 43% in controls) and their median testosterone levels
were significantly lower than among controls (Table 1). Testosterone
was lower in patients with AGT than NGT during hospitalization. The
prevalence of low testosterone was 83% in AGT vs. 65% in NGT pa-
tients, and 57% in AGT vs. 34% in NGT controls. Testosterone did not
predict cardiovascular events in patients (events=50) or controls
(events=27). Subgroups analyses were not performed due to limited
number of events.
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Conclusion: Low testosterone levels are common in patients with AMI,
especially in combination with AGT. Over time, the difference in testos-
terone levels between patients with or without glucose abnormalities di-
minished. The results raise questions on the proposed causal relationship
between testosterone and glucose abnormalities. Also, it indicates that
testosterone substitution should not be instituted based on samples taken
during hospitalization for AMI.
Supported by: Bayer AG
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Myo-inoisitol and d-chiro-inositol prevent palmitate-induced autoph-
agy and senescence in human cardiac progenitor cells
R. D'Oria1, L. Laviola1, A. Leonardini1, M. Incalza1, C. Caccioppoli1, P.
Nigro1, M. Scioscia2, A. Natalicchio1, S. Perrini1, F. Giorgino1;
1Endocrinology & Metabolic Diseases, University of Bari, 2Obstetrics
and Gynecology, Sacro Cuore Don Calabria, Verona, Italy.
Background and aims: Supplementation with myo-inositol and D-
chiro-inositol has been shown to induce insulin-mimetic effects in
humans and to improve cardiac performance in experimental heart fail-
ure. The aim of this study was to evaluate the effects of myo-inositol and
D-chiro-inositol on lipotoxicity-induced autophagy and senescence in
human cardiac progenitor cells (CPC).
Materials and methods: Human CPC were isolated from right auricle
biopsies of patients undergoing elective heart surgery and exposed to
palmitate (0.25 mM up to 16 h). Autophagy was evidenced by
monodansylcadaverine and autophagolysosome labeling, and by immu-
noblotting of microtubule-associated protein 1 light chain 3 (LC3)-II and
beclin1. Cellular senescence was detected by evaluation of senescence-
associated β-galactosidase activity, p21(WAF1/Cip1) and p16(Ink4a)
gene and protein expression. Protein expression and phosphorylation
were detected by immunoblotting.
Results: Incubation of CPC with 0.25 mmol/Lpalmitate for 16 h in-
creased cell autophagy, evidenced by monodansylcadaverine staining
and confirmed by increased levels of LC3-II and beclin-1, respectively
(p<0.05). Palmitate also induced cellular senescence, demonstrated by
increased senescence-associated β-galactosidase activity. Cellular senes-
cence was confirmed by the detection of increased p21(WAF1/Cip1) gene
and protein expression (p<0.05), whereas the p16(Ink4a) pathway ap-
peared to be unaffected. Chemical inhibition of autophagy with 3-
methyladenine resulted in reduced β-galactosidase staining, suggesting
that increased autophagy mediates palmitate-induced cellular senescence
in human CPC.When cells were pretreated with myo-inositol or D-chiro-
inositol (1-1000 micromol/L), both the palmitate-induced
autophagosome formation and increase in LC3-II were abrogated (p<
0.05), and so was the increase in p21 protein levels (p<0.05). Increased
Akt and p42/p44MAPK phosphorylation (p<0.05) was observed in CPC
exposed to myo-inositol or D-chiro-inositol for up to 30 min.
Conclusion: Palmitate increases both autophagy and senescence in hu-
man CPC. Both myo-inositol and D-chiro-inositol activate survival ki-
nases and counteract the effects of palmitate. Inositols may thus protect
the myocardium from lipotoxic damage by preserving the CPC pool in
type 2 diabetic and/or obese subjects with elevated free fatty acid levels.
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ApoA-I glycation; linking diabetes and CVD
J. Domingo-Espin1, J. Dalla-Riva1, K. Bernfur2, O. Wolanin1, M.
Lindahl1, J. Lagerstedt1;
1Department of Experimental Medical Science, 2Department of Bio-
chemistry and Structural Biology, Lund University, Lund, Sweden.
Background and aims: Diabetic patients have an increased risk of suf-
fering from atherosclerosis. Apolipoprotein A-I (ApoA-I) function and
metabolism in high-density lipoprotein (HDL) is closely linked to diabe-
tes. Recognized positive qualities of ApoA-I in HDL include removal of
cholesterol from macrophage-derived foam cells at the vascular wall in
the reverse cholesterol transport pathway, as well as anti-inflammatory
and anti-thrombotic functions, all leading to reduced development of
atherosclerosis and cardiovascular disease. Importantly, novel features
of this lipoprotein have recently emerged describing ApoA-I/HDL as
regulator of glucose homeostasis (insulin secretion and glucose disposal
in target tissues), thus suggesting dysfunctional ApoA-I/HDL as a con-
tributing factor to the development of type 2 diabetes. In support of this,
our recent in vivo data show massive impact (increase) on glucose dis-
posal capacity following acute ApoA-I injections. Intensive glycemic
control management reduces CVD events with the most significant re-
duction related to HbA1c. Hyperglycemia results in increased non-
enzymatic reaction of sugars with proteins to form advanced glycation
end products (AGEs). Taking all this information into account we hy-
pothesize that the glycation of ApoA-I structurally and functionally mod-
ifies the protein and it has an important impact in the impairment of its
ability to control glucose homeostasis and cholesterol efflux thus leading
to the increase of diabetes and CVD complications. The aim of this study
is to elucidate the role of hyperglycemia/glycation of ApoA-I/HDL in its
loss of functionality, especially related to its impact on glucose
homeostasis.
Materials and methods: Recombinant ApoA-I is in vitro glycated with
glycolaldehyde (GA) or methylglyoxal (MG) and modifications of the
protein are determined by mass spectrometry analysis. Functional modi-
fication of the protein are tested by acute injections of ApoA-I (modified
and non-modified) in diet-induced obese (DIO) and insulin resistant mice
followed by a glucose tolerance test (GTT) and insulin concentration
determination (ELISA), lipid clearance assay (LCA), HDL formation
assay and finally cholesterol efflux experiments.
Results: Glucose clearance in a glucose tolerance test is markedly im-
proved by the injection of non-modified ApoA-I. When the protein is
glycated by MG, a less efficient glucose clearance can be observed, es-
pecially in the first 15 minutes of the test (n=15, p<0,05). The capacity of
ApoA-I to form HDL particles is clearly reduced when it is modified as
seen by the LCA and also, cholesterol efflux from macrophages is re-
duced. Mass spectrometry studies revel a different modification pattern
for each of the reactive carbonyls used (GA or MG).
Conclusion: Non-enzymatic glycation of ApoA-I partially impairs the
capacity of the protein to form HDL particles leading to reduced glucose
clearance in DIO mice. Different reactive carbonyls lead to different
profiles in glucose clearance suggesting that there are specific residues
in the protein implicated in the glucose homeostasis functions.
Supported by: Swedish Research Council (K2014-54X-22426-01-3)
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Glycation as an atherogenic modification of lipoproteins, and the
contribution of copper
J.D. Schofield1,2, Y. Liu1, T. Siahmansur1, M.W. France3, P.N.
Durrington1, G.J. Cooper4, H. Soran1,2;
1Lipoprotein Research Group, University of Manchester, 2University De-
partment of Medicine, Central Manchester University Hospitals NHS
Trust, 3Department of Clinical Biochemistry, Central Manchester Univer-
sity Hospitals NHS Trust, 4Centre for Advanced Discovery & Experi-
mental Therapeutics, University of Manchester, UK.
Background and aims: Cardiovascular disease is the leading cause of
death and disability in diabetes. Low-density lipoprotein (LDL) is the
permissive factor in the development of atherosclerosis. LDL must un-
dergo oxidation and / or glycation to participate in atherogenesis.
Glycated LDL is present in the circulation under physiological conditions
and at higher concentrations in diabetes and in those destined to experi-
ence myocardial infarction, but LDL glycation in vitro requires
supraphysiological glucose concentrations. Protection against glycation
is a recognised function of high-density lipoprotein (HDL). The role of
copper in promoting in vitro glycation requires further investigation as it
may be possible to manipulate this process therapeutically with a copper
chelating agent to protect lipoproteins against glycation.
Materials and methods: LDL (1.019-1.063 g/ml) and HDL (1.063-
1.21 g/ml) were isolated from human serum using sequential preparative
ultracentrifugation before incubation of LDL at a concentration of
1 mg/ml with glucose and copper at physiological concentrations (5-25
mMol/l and 1.25-5 umol/l respectively) for 3 days. The ability of HDL
and the divalent copper-selective chelator triethylenetetramine to protect
against glycation were also assessed. Glycated lipoproteins were separat-
ed from non-glycated lipoproteins usingm-aminophenylboronate affinity
chromatography. Apolipoprotein B (apoB) was measured
immunoturbidimetrically and glycated apoB by a validated in-house
high-sensitivity ELISA. Lipid hydroperoxide (LPO) formed during
glycation was measured by a cholesterol oxidase colorimetric assay.
The cholesterol efflux capacity of HDL in vitro was determined by a
previously validated assay.
Results: In vitro glycation occurs more readily in the presence of phys-
iological concentrations of copper. Incubation with 10mMol/l glucose
and 1.25umol/l and 2.5umol/l copper sulphate for 3 days significantly
increased the proportion of glycated apoB (P=0.003 and 0.01 respective-
ly). Similar effects were observed in the presence of copper chloride (P=
0.05) but not copper-histidine complex (P=0.28) or ferrous sulphate (P=
0.18). Addition of HDL prevented glycation of apoB (P=0.02). We also
for the first time report a potential therapeutic role for copper-selective
chelation in the protection of lipoproteins against glycation. Glycation
also appears to impair the capacity of HDL to promote cholesterol efflux
(P=0.36), with a further reduction in the presence of 1.25umol/l copper
sulphate (P=0.21).
Conclusion: This work offers insight into HDL functionality in diabetes
and supporting evidence for the emerging link between copper dysregu-
lation and the accumulation of advanced glycation end-products, and a
potential role for copper in lipoprotein glycation.
Supported by: NIHR/Wellcome Trust Manchester CRF
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Unravelling the methylglyoxal effect on the angiogenic process
C. Nigro1, A. Leone1, F. Fiory1, P. Mirra1, I. Prevenzano1, T.H. Fleming2,
P.P. Nawroth2, T. Procopio1, A. Volpe1, R. Falco1, F. Beguinot1, C.
Miele1;
1DiSMeT& IEOS-CNR, Federico II University of Naples, Italy, 2Depart-
ment of Medicine I and Clinical Chemistry, University Hospital Heidel-
berg, Germany.
Background and aims:Much of the morbidity and mortality associated
with diabetes mellitus (DM) reflects its deleterious effects on micro and
macrocirculation. DM impairs physiological angiogenesis by molecular
mechanisms that are not fully understood. Generation of Advanced
Glycation End-products (AGEs) has an important role in the development
of hyperglycaemia-induced endothelial damage. The highly reactive
dicarbonyl methylglyoxal (MG) is the most reactive AGE precursor in
endothelial cells. It is a potent dicarbonyl glycating agent formed from
glycolysis intermediates of in cells and degraded by the glyoxalase sys-
tem (Glo). Glo1 activity prevents the accumulation of MG, thereby sup-
pressing dicarbonyl-mediated glycation reactions and cellular damage.
The concentration of MG is increased 2 to 5-fold in plasma of diabetic
patients. Recent experimental evidence indicate that MG is implicated in
the pathogenesis of diabetic complications, however, the mechanisms by
which MG accumulation leads to endothelial dysfunction and possibly to
the vascular complications associated with DM need to be clarified. Ho-
meobox (Hox) genes and miRNAs-mediated epigenetic regulation have a
crucial role in the neovascularization both in physiological and patholog-
ical conditions. This work aims at elucidating the MG effect on the an-
giogenic ability of endothelial cells and the molecular mechanisms
involved.
Materials and methods: Proliferation and migration were evaluated by
cell-growth curves, scratch and transwell migration assays on mouse
aortic endothelial cells isolated from heterozygous mice for glo1 deletion
(Glo-/+ MAEC) and their wild type littermates (WT MAEC). Glo1,
HoxA5 and miRNAs expression levels were measured by Real-time
PCR and MG intracellular concentrations by HPLC.
Results: Glo1-/+ MAEC show a 50% reduction of Glo1 mRNA levels
and a 5-fold increase of MG intracellular concentrations compared toWT
MAEC (p=0.0001). Cell-growth curves reveal that Glo1-/+MAEC grow
slower than WTMAEC (Glo1-/+ MAEC 106833±15610 vsWTMAEC
202733±62699 cells at 24 h, p=0.002). Preliminary data indicate that
Glo1-/+ MAEC have a delayed wound healing upon VEGF stimulation
even when the proliferation is inhibited by mitomycin C (Glo1-/+ MAEC
55.1±13% vs WT MAEC 100% of wound closure at 12 h) and an im-
paired migration capacity (Glo1-/+ MAEC 0.062±0.008 vs WT MAEC
0.09±0.024 OD) compared to WT MAEC. To investigate the molecular
mechanisms by which angiogenic function may be compromised by MG
inMAEC, HoxA5 and vascular function-related miRNAs expression has
been evaluated. mRNA levels of the anti-angiogenic gene HoxA5 are 2-
fold increased in Glo1-/+ MAEC compared to WT MAEC (Glo1-/+
MAEC 1.98±0.48 vs WT MAEC 1 REU, p=0.01). Moreover,
miRNA126 and miRNA503 levels are 0.5-fold reduced and 2-fold in-
creased, respectively, in Glo1-/+ MAEC compared to WT MAEC.
Conclusion: These results suggest that MG accumulation impairs the
angiogenic ability of Glo1-/+ MAEC. This effect is associated to the
overexpression of the anti-angiogenic HoxA5 and the altered levels of
miRNA-126 and miRNA-503, found to be modified in vascular dysfunc-
tion. A better understanding of the molecular mechanisms by which MG
alters the angiogenic process may allow to identify novel approaches in
the prevention and treatment of diabetes vascular disease.
Supported by: SID-FO.DI.RI.
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Fructose-derived advanced glycation end-products induce a negative
crosstalk between lipogenesis and muscle reprogramming in mice
through SREBP-1c
R. Mastrocola1, M. Collino2, D. Nigro1, C. Medana3, F. Dal Bello3, F.
Chiazza2, G. Boccuzzi4, M. Aragno1;
1Clinical and Biological Sciences, 2Drug Science and Technology, 3Mo-
lecular Biotechnology and Health Sciences, 4Medical Sciences, Univer-
sity of Turin, Italy.
Background and aims:AdvancedGlycation End-Products (AGEs) have
been recently linked to the onset of obesity, adiposity, and insulin-resis-
tance. AGEs can endogenously be formed by dietary sugars, in particular
fructose, which is widely used as added sweetener in foods and drinks.
We previously reported that chronic fructose exposure generates AGEs in
mice plasma and liver at higher level than glucose. Recently we docu-
mented that AGEs accumulate in gastrocnemius muscle in obese mice
and that this is associated to activation of the SCAP/SREBP-1c
lipogenetic pathway. We have now investigated whether mice skeletal
muscle structure and metabolism can be affected by chronic exposure to
a high-fructose diet and we have better characterized the causal role of
fructose-derived AGEs by using the glycation inhibitor pyridoxamine.
Materials and methods:C57Bl/6J mice were fed a standard diet (SD) or
a 60% fructose diet (HFRT) for 12 weeks. Two subgroups of SD and
HFRT mice received the anti-glycative compound pyridoxamine
(120 mg/kg/day) in the drinking water.
Results: At the end of protocol HFRT mice showed increased plasma
glucose (P<0.05 vs SD), insulin (P<0.05 vs SD), triglycerides (P<0.05
vs SD) and cholesterol (P<0.001 vs SD), and impairedOGTTcurve. Very
high levels of AGEs were detected both in plasma and gastrocnemius
muscle (P<0.001 vs SD). We found that AGEs enhanced the activation
of SREBP-1c through either downregulation of the SREBP-inihibiting
enzyme SIRT-1 and increased glycation of the SREBP-activating protein
SCAP. Interestingly, the AGEs-induced SREBP-1c activation also had
dramatic repercussions onmyogenic regulatory factors and myosin heavy
chain isoforms expression, paralleled by depletion ofmuscle strength (P<
0.05 vs SD) and increased fatigability (P<0.05 vs SD). This could be
related to the impaired individual oxidative activity of myofibers, and
oxidative stress increase. The use of pyridoxamine almost completely
counteracted not only AGEs generation, but all the fructose-inducedmus-
cle alterations.
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Conclusion: The present data indicate for the first time that fructose-
derived AGEs exert a multiple interference on SREBP-1c activity which
in turn enhances fatty acids synthesis and impairs muscle proteins expres-
sion, leading to a negative crosstalk between lipogenesis and muscle
reprogramming. Thus, these findings revealed an unsuspected involve-
ment of AGEs in muscle derangements that could contribute to further
progression of insulin resistance and obesity.
Supported by: ex-60% University of Turin
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Lens autofluorescence relates to skin autofluorescence but poorly to
glycated haemoglobin in patients with diabetes
J. Skrha jr., J. Soupal, M. Prazny, J. Skrha;
Third Department of Medicine, First Faculty of Medicine, Charles Uni-
versity in Prague, General University Hospital, Czech Republic.
Background and aims: Advanced glycation endproducts (AGEs) play
an essential role in the pathophysiology of diabetes and its complications.
Their accumulation in the lens reflects the intensity of glycation process
and it is demonstrated by specific lens autofluorescence. Recently, a new
confocal biomicroscope ClearPath DS-120 easily measuring lens autoflu-
orescence (LAF) has been developed. The aim of this study was to com-
pare lens autofluorescence (LAF) in diabetic and non-diabetic subjects
with their skin autofluorescence (SAF) and parameters of glucose control.
Materials and methods: LAF was measured in the left eye in 126 dia-
betic patients (55 Type 1 /T1DM/ aged 42±14 yrs, 71 Type 2 /T2DM/
aged 61±10 yrs) and 59 healthy controls (aged 47±13 yrs) by ClearPath
DS-120 (Freedom Meditech, US). SAF was measured on forearm by
AGE-Reader (Diagnoptics BV, Netherlands) in subgroup with 116 sub-
jects (32 T1DM, 35 T2DM and 49 controls). Results were expressed in
arbitrary units (AU) and compared with age, anthropometrical data, cur-
rent glycated hemoglobin HbA1c (in IFCC units) and mean HbA1c in the
last 2 years, renal function (using MDRD formula) and albuminuria.
Results: In both T1DM and T2DM LAF was significantly higher as
compared to healthy controls (0.26±0.09, 0.23±0.06 vs 0.17±0.04 AU,
p<0.0001). Similar results were found in SAF (2.01±0.45, 2.28±0.57 vs
1.78±0.33 AU, p<0.0001). Significantly higher mean current HbA1c
found in T1DM and T2DM as compared to controls (65±16; 58±18 vs
34±5 mmol/mol, p<0.0001) was related to LAF only in T2DM (T1DM:
r=0.19, NS; T2DM: r=0.37, p<0.01; controls: r=0.28, NS). The same
was true for the two-year HbA1c. LAF was inversely related to glomer-
ular filtration in T1DM (r=-0.34, p<0.05) and controls (r=-0.29, p<
0.05), but not in T2DM (r=-0.10, NS). No significant difference of
LAF was observed in diabetic patients with or without positive albumin-
uria (0.27±0.08 vs 0.24±0.07 AU, NS). Significant relationship of LAF
and SAF was found in all groups (T1DM: r=0.53, p<0.005, T2DM: r=
0.36, p<0.05; controls: r=0.30, p<0.05).
Conclusion: Our study demonstrates significant association of lens and
skin autofluorescence in subjects with or without diabetes. It confirms
similar effect of non-enzymatic glycation in two different tissues. LAF is
elevated in diabetes, but is not entirely related to current or average two-
year HbA1c, since LAF is likely a very-long-term glycation marker in-
dependent on HbA1c variability. On the other hand, LAF does not reflect
more advanced changes as it was not significantly different in patients
with or without albuminuria or with normal or decreased MDRD. A
follow-up study will be necessary to evaluate the usefulness of LAF in
clinical practice.
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Synergistic effects of transplanted endothelial progenitor cells and
RWJ67657 in diabetic ischaemic stroke models
Y.-Y. Bai;
Jiangsu Key Laboratory of Molecular and Functional Imaging, Depart-
ment of Radiology, Zhongda Hospita, Nanjing, China.
Background and aims: An immature vascular phenotype in diabetes
may cause more severe vascular damage and poorer functional outcomes
after stroke, and it would be feasible to repair damaged functional vessels
using endothelial progenitor cell (EPC) transplantation. However, high
glucose induces p38 mitogen-activated protein kinase (MAPK) activa-
tion, which can accelerate the senescence and apoptosis of EPCs. The aim
of this study was to investigate the combined effects of EPC transplanta-
tion and p38MAPK inhibitor administration on diabetic stroke outcomes.
Materials and methods: Bone marrow-derived EPCs, labeled with a
multi-functional nanoprobe modified with paramagnetic chelators and
fluorophores, were injected intra-arterially into wild-type and db/db mice
after ischemic stroke induction. RWJ 67657 (RWJ), a p38 MAPK inhib-
itor, was administered orally into db/db mice for 7 consecutive days, with
the first dose given 30 min before stroke induction.
Results: The signal on magnetic resonance (MR) and optical imaging of
diabetic stroke models was significantly lower than that of wild-type
controls (P<0.001, n=4 to 6 per group). However, the signal intensity
of diabetic stroke models significantly increased after oral administration
of RWJ (P<0.05, n=4 or 5 per group), indicating that more transplanted
EPCs migrated to the ischemic brain. Neither EPC transplantation nor
RWJ administration alone significantly improved diabetic stroke out-
come, althoughRWJ displayed a potent anti-inflammatory effect. By both
improving the functioning of EPCs and reducing inflammation, EPC
transplantation plus RWJ administration in vivo synergistically promoted
angiogenesis (P<0.05, n=4 per group) and neurogenesis (P<0.05, n=6
or 7 per group) after diabetic stroke . In addition, fractional anisotropy
value and number of fibers in the ispileasional internal capsule derived
fromMR diffusion tensor imaging (MR-DTI), together with myelin basic
protein-positive cells were significantly increased in the combination
group, indicatingmore white matter remodeling. Furthermore, behavioral
scores, infarct volume reduction, and expressions of VEGF and BDNF
were significantly increased in diabetic mice treated with both EPCs and
RWJ.
Conclusion: The dual-modal imaging strategy suggested that diabetes
reduced the number of transplanted EPCs homing to the ischemic area,
while consecutive intragastric administration of RWJ could protect EPC
from being damaged in diabetic mice. The combination of EPC
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transplantation and RWJ administration accelerated recovery from dia-
betic stroke, which might have been caused by increased levels of pro-
angiogenic and neurotrophic factors.
Supported by: NSFC
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A novel role for the Krüppel-like factor 14, klf14, on macrophage
inflammatory response and atherosclerosis development
Y. Jia1,2, L. Li1,2, G. Yang3;
1Key Laboratory of Diagnostic Medicine (Ministry of Education) & De-
partment of Clinical Biochemistry, 2College of Laboratory Medicine,
3Department of Endocrinology,the Second Affiliated Hospital, Chong-
qing Medical University, China.
Background and aims: Genome-wide association studies have shown
that Krüppel-like factor 14(KLF14) is associated with both Type 2 dia-
betes mellitus (T2DM) and lipid metabolism. However, its role in chronic
inflammatory responses and the pathogenesis of atherosclerosis remains
unknown. The present study was designed to investigate in both vivo and
vitro the impact of KLF14 on chronic inflammatory responses and
atherosclerosis.
Materials andmethods: In vivo, KLF14-knockdownApoEKOmice by
a adenovirus-mediated RNAi was used to assessed the effects of KLF14
knockdown onmetabolic parameters and the formation of atherosclerosis
on a high fat diet. Atherosclerotic lesions in the aorta were analyzed
by en face analysis of the spread total aorta and analysis of
cross sections of the aortic sinus with oil red O staining. The circulating
levels of pro-inflammatory cytokine in ApoE KO mice were detected by
ELISA. In vitro, Both the effects of up-regulation and down-regulation of
KLF14 on the ac-LDL-induced cholesterol accumulation in macrophage
were evaluated. Effects of KLF14 on the expressions of cytokines and the
activities of mitogen-activated protein kinases (MAPKs) were detected
by real time-PCR and western blot, respectively. The specify inhibitors of
MAPKs were used to analyze the mechanisms bywhich KLF14 regulates
the accumulation of cholesterol and cholesterol ester.
Results: Here, we have shown that in ApoE KO mice, a well established
animal model of atherosclerosis, fed with both high fat diet (HFD) and
standard chow diet (SCD), expression of KLF14 in aortas tissues was
higher than in C57BL/6J mice. Consistent with this, adenovirus-
mediated KLF14 knockdown markedly reduced the circulating levels of
pro- inflammatory cytokine and the formation of atherosclerotic lesions in
HFD-fed ApoE KO mice. In RAW264.7 macrophages, KLF14 overex-
pression significantly increased ac-LDL induced expressions of inflam-
matory cytokine and further strengthened ac-LDL-induced increase in
total cholesterol (TC), cholesteryl ester (CE) and the ratios of CE to TC.
Conversely, KLF14 knockdown in these cells remarkably attenuated ac-
LDL-induced increase in TC, CE and the ratios of CE to TC and the
expressions of inflammatory cytokine. KLF14 overexpression remark-
ably elevated the phosphorylation levels of p38 MAPK and ERK1/2 in
ac-LDL- stimulated RAW264.7 macrophages. Importantly, treatment
with a p38 MAPK (PD098059) and ERK1/2 inhibitors (SB203580) sig-
nificantly nullified the ability of KLF14 to promote inflammatory cyto-
kine expressions in these cells.
Conclusion: These data demonstrate an important role for KLF14 ex-
pression in atherosclerotic lesion formation. Thus, KLF14 may be a po-
tential target for therapy of atherosclerosis.
Supported by: NSFC of China (81270913,81070640,81100567)
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Increased infiltration of inflammatory immune-cells in sciatic nerves
but not in dorsal root ganglions in late diabetic neuropathy in the
murine STZ model of diabetes
A.S. Hidmark, T.H. Fleming, S. Vittas, P.P. Nawroth;
Innere Medizin I und klinische Chemie, Heidelberg, Germany.
Background and aims: The diabetic condition is associated with a pro-
inflammatory phenotype of immune-cells infiltrating into different organs
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where inflammatory macrophages contribute to the pathogenesis of the
disease and impair tissue re-generation. Infiltrating immune-cells into the
peripheral nervous system during DN, in absence of an injury, has not yet
been demonstrated in the streptozotocin (STZ) mouse model of diabetes.
The aim of this study is to investigate changes to immune-cell population
in sciatic nerve (SN) and dorsal root ganglion (DRG) in late diabetic
neuropathy.
Materials andmethods:Diabetes was induced inWTC56BL/6, mice or
in mice lacking T-cells (RAG2-/-) by STZ (50 mg/kg/day i.p. for 5 days).
At 6 months, thermal hypoalgesia was assessed by hotplate and Har-
greave’s and neuronal blood flow of SN by laser-doppler. Peritoneal
cavity lavage was collected and SN and DRGs were digested and stained
with antibodies against CD45, CD68 and CD206. The cells were ana-
lyzed by flow cytometry. Statistical significance was tested with two-
tailed student’s T-test.
Results: At 6 months of STZ-induced diabetes, WT mice showed signif-
icant hypoalgesia, as compared to the age-matched WTcontrols; hotplate
response times were increased by 6.5 secs on average (p <0.002) and 2.8
secs by Hargreave’s (p<0.0001). SN blood-flow was significantly re-
duced in WT diabetic mice (74% as compared to controls, p<0.01, n=
5). In contrast, the diabetic RAG2-/- mice showed no significant differ-
ences either in measurements of thermal hypoalgesia or SN-blood flow.
In the SN of theWT diabetic mice, a 2-fold increase of infiltrating CD45+
leukocytes was observed by flow cytometry (from 4,5% of all nucleated
cells to 9,3%, p<0.001, n=11), but no significant increase in infiltration
was observed in the DRGs. These findings were confirmed by immuno-
histochemistry stainings of SN and DRGs cryosections. No increase in
infiltrating leukocytes was observed in the SN of the RAG2-/- diabetic
mice, as compared to the control RAG2-/- mice. In SN of both the control
and diabetic WT mice, 50-70% of the infiltrating CD45+ cells expressed
the macrophage marker CD68. However, fewer of the SN CD68+ mac-
rophages in the WT diabetic mice expressed the M2 marker, CD206
(reduced from 70% of macrophages in control to 58% in diabetic mice,
p<0.01). The proportion of macrophages in peritoneal cavity lavage ex-
pressing CD206 was reduced from 10% inWTcontrol mice to 4% inWT
diabetic mice (p<0.05).
Conclusion: Late diabetic neuropathy is associated with increased infil-
tration of leukocytes in SN but not DRG of STZ-induced diabetic mice.
Leukocyte infiltration into SN and neuropathic symptoms, such as ther-
mal hypoalgesia and reduced SN blood-flow, were reduced in mice lack-
ing T and B cells. We conclude that late diabetic neuropathy is associated
with changes of macrophage populations in peripheral nerves, which
require the adaptive immune system.
Supported by: SFB1118, DZD/BMBF
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New insights for an old marker: TGF-beta, diabetic nephropathy
and metabolic memory
A.A.F. Oliveira1, L.L. Bobadilla1, T.F. Oliveira1, M.H.G. Medeiros2, P.
Di Mascio2, A.M. Loureiro1;
1Department of Clinical and Toxicological Analysis, 2Department of Bio-
chemistry, University of São Paulo, Brazil.
Background and aims: Metabolic memory has been pointed out as an
important phenomenon to explain the increasing incidence of diabetic
nephropathy (DN) and other diabetes complications even by patients
under intensive glycemic control. TGF-β is thought to play a key role
in mediating major kidney alterations due to diabetes, such as hypertro-
phy and fibrosis. Although the mechanisms bywhich TGF-β causes renal
fibrosis are well characterized, the relationship between TGF-β and met-
abolic memory remains unexplored, which is the purpose of this study.
Materials andmethods:MaleWistar rats weremade diabetic by a single
injection of streptozotocin. After 4 or 12 weeks of diabetes induction,
animals were kept under intensive glycemic control for the same period,
until 8 or 24 weeks, respectively. Treatments were performed with insulin
alone or combined with metformin (100 mg/kg). For the 24 weeks study,
a group treated with insulin plus N-acetylcysteine (NAC, 750mg/kg) was
included. Control groups consisted of non-diabetic and diabetic animals
after 8, 12 and 24weeks. Bodyweight and blood glucose were monitored
weekly, while HbA1c and renal function were assessed at different time
points along the study. Renal expression of TGF-β was analyzed by
western blotting, and intracellular metabolites related to glycolytic path-
way and tricarboxylic acid cycle were quantified in kidney tissue by
reverse phase ion pair HPLC-ESI-MS/MS.
Results: High levels of HbA1c were detected after 4 weeks of diabetes,
but the decline of renal function started just after 8 weeks, as evidenced by
increased proteinuria, albuminuria and kidney/body weight ratio. This
impairment on renal function occurred in parallel to the raise of TGF-β
expression (p=0.0018), ATP (p=0.0039), and fumarate (p=0.0103)
levels, compared to non-diabetic animals. Treatments with either insulin
alone or combined withmetformin recovered all of these early alterations.
After 12 weeks of diabetes, the decline of renal function was more pro-
nounced, including tubular injury, assessed by KIM-1 quantification in
urine (p=0.0003). TGF-β expression remained elevated (p=0.0040), as
well as glutamine (p=0.0024) and glutamate (p=0.0043), in comparison
to non-diabetic rats. At the end of 24 weeks, when diabetic animals
presented a clear impairment of glomerular and tubular function, renal
expression of TGF-β was even higher (p=0.0198) and none of the treat-
ment strategies were able to normalize it. Concomitantly, greater levels of
pyruvate (p=0.001), lactate (p=0.0002), malate (p=0.0464), succinate
(p=0.0166), glutamine (p=0.0051), and glutamate (p=0.0211) were de-
tected in diabetic kidneys, suggesting the occurrence of tricarboxylic acid
cycle changes.
Conclusion: Increased TGF-β expression is an early alteration related to
DN, which is just normalized by early, but not late, glycemic control,
even though renal function is re-established. This uncontrolled TGF-β
expression may lead to mitochondrial damage and mediate other long-
termmodifications related to the occurrence of metabolic memory, which
deserves more investigation.
Supported by: FAPESP, CNPq, CAPES, PRP/USP, CEPID Redoxoma
(2013/07937–8)
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Impaired cytokine responses from circulating monocytes in type 2
diabetes mellitus
F. Kousathana1, M. Georgitsi2, V. Lambadiari3, E.J. Giamarellos-
Bourboulis2, G. Dimitriadis3, M. Mouktaroudi2;
12nd Department of Internal Medicine, Research Unit and Diabetes Cen-
ter, University of Athens, Medical School, Attikon University Hospital,
24th Department of Internal Medicine, University of Athens, Medical
School, 32nd Department of Internal Medicine, Research Unit and Dia-
betes Center, University of Athens, Medical School, Attikon University
Hospital, Greece.
Background and aims: Although type 2 diabetes mellitus (T2DM) is
associated with predisposition to infection, the mechanism is poorly stud-
ied.We explored the impairment of innate immune responses to microbial
antigens as part of the mechanism underlying infection predisposition.
Materials and methods: Peripheral blood mononuclear cells were iso-
lated from 20 healthy controls and 34 treatment-naïve patients (HbA1c
9.64±1.48%) and stimulated with each of the following six stimuli: a) the
purified Toll-like receptor (TLR)- 4 ligand lipopolysaccharide (LPS) of
Escherichia coli O55:B5; b) the TLR2 ligand Pam3Cys; c) the lympho-
cyte mitogen phytohemmaglutin (PHA); and d) heat-killed isolates of
Pseudomonas aeruginosa (PA), Staphylococcus aureus (SA) and Candida
albicans (CA). TNFα and IL-1β were measured in cell supernatants.
Stimulations were repeated after 3 and 6 months of treatment and related
with the level of glycemic control. Any less than 5-fold increase of cyto-
kine production to at least four stimuli compared to medium-treated cells
was considered appropriate response. HbA1c below 7% was considered
proper glycemic control.
Results: All healthy controls (100%) had appropriate cytokine responses
compared to only 18 (52.9%) of T2DM patients (p<0.0001). This was
predominantly shown for IL-1β after stimulation with LPS, PA and CA
(Figure). In treatment month 3, IL-1β produced after LPS stimulation of
cells of patients with proper glycemic control was 5277.6±1262.0 pg/ml
compared with 1235.8±488.8 pg/ml of cells of patients with improper
glycemic control (p<0.0001).
Conclusion: T2DM is characterized by impaired cytokine production
from circulating monocytes. This is pronounced for LPS that is a ligand
of the cell wall of Gram-negative bacteria and it is partly restored after
proper glycemic control. Results provide insight into the mechanism of
predisposition for Gram-negative infections in T2DM and of the impor-
tance of proper glycemic control for prevention.
Supported by: Sanofi SA Hellas and the Hellenic Institute for the Study of
Sepsis
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IL-1beta, a novel predictive factor of cardiovascular disease in
patient with newly diagnosed, drug-naïve type 2 diabetes mellitus
K. Joung, H. Kim, B. Ku;
Internal Medicine, Endocrinology, Chungnam National University, Dae-
jeon, Republic of Korea.
Background and aims: Cardiovascular disease (CVD) is a major cause
of death in patients with type 2 diabetes mellitus (T2DM). So develop-
ment of markers to detect earlier and prevent CVD in patients with T2DM
is very important. Chronic activation of innate immune system through
the nucleotide binding and oligomerization domain-like receptor family
pyrin domain-containing 3 (NLRP3) inflammasome leads to the matura-
tion and secretion of proinflammatory cytokines such as IL-1beta and 18
and plays an essential role in the pathogenic mechanism of T2DM and
CVD. In our previous study, NLRP3 inflammasome activation is elevated
in myeloid cells from drug-naïve, newly diagnosed type 2 diabetic pa-
tients and antidiabetic treatment with metformin contributes to modula-
tion of inflammasome activation. However, the study whether the NLRP3
inflammasome activation and its products in diabetic patients can predict
the risk of CVD has not been reported. Therefore, we examined the
association of CVD risk using the Framingham risk equation with the
NLRP3 inflammasome activation in two group; patents with newly diag-
nosed, drug-naïve T2DM (New-DM) vs with patients taking anti-diabetic
drug over one year (Old-DM).
Materials and methods:We used the serum, cultured monocyte-derived
macrophages (MDMs) and their supernatants for measuring the mRNA
expression and secreted maturation form of IL-1beta in New-DM (n=44)
and Old-DM (n=16). Statistical analyses were completed using unpaired
t-test, Pearson correlation, and one-way ANOVA.
Results: Although the mean values of Framingham 10-year CVD risk
score were not significantly different between two groups (8.9±7.1 vs 9.3
±7.4, p=0.863), the serum value of IL-1beta showed the positive linear
correlation with Framingham 10-year CVD risk score only in New-DM
(r=0.314, p=0.038), not in Old-DM (r=-0.083, p=0.760). To evaluate
whether IL-1beta and NLRP3 inflammasome activation were different
between the low risk group (10-year CVD risk score<5%) and the inter-
mediate to high risk group (10-year CVD risk score≥10%), we compared
the values of mean ± SD between two groups in New-DM and Old-DM.
The serum value of IL-1beta showed the significantly increase in the
intermediate to high risk group compared to the low risk group only in
New-DM (18.03±15.36 vs 28.41±10.65, p=0.046), not in Old-DM
(23.25±13.43 vs 21.47±8.99, p=0.960) as expected. In addition, the
intermediate to high risk group compared to the low risk group had
significantly elevated levels of IL-1beta in LPS-primedMDMs after treat-
ment with different “danger signal” molecules, such as ATP (349.35±
141.32 vs 383.17±157.60, p=0.017), monosodium uric acid crystals
(MUS) (262.94±69.98 vs 283.30±82.68, p=0.003) and free fatty acids
(FFAs) (384.41±127.11 vs 392.55±141.60, p=0.004) only in New-DM,
not in Old-DM.
Conclusion: In conclusion, serum IL-1beta was positively correlated
with CVD risk score using Framingham risk equation only in New-
DM. The serum value of IL-1beta also increased significantly in the
intermediate to high risk group compared to the low risk group only in
New-DM. Our study suggests that serum IL-1beta might be used as a
marker for prediction of CVD in newly diagnosed type 2 diabetic
patients.
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Glycaemic variability correlates with 1.5-AHG but not with markers
of oxidation, inflammation and endothelial function: baseline results
of the CAROLINA® CGM substudy
R. Mazze1, R. Bergenstal1, E. Strock1, X. Min1, K. Thompson1, S.
Borgman1, M. Mattheus2, K. Hermansson3, H. Woerle4, O. Johansen5;
1International Diabetes Center, Minneapolis, USA, 2Global biometrics,
Boehringer-Ingelheim, Ingelheim, Germany, 3Boehringer-Ingelheim,
Stockholm, Sweden, 4Therapeutic area metabolism, Boehringer-
Ingelheim, Ingelheim, Germany, 5Medical department, Boehringer-
Ingelheim, Asker, Norway.
Background and aims:DPP4-inhibitors enhance glucose-induced insulin
secretion, decreases glucagon secretion and might effectively reduce blood
glucose variability. This is investigated in the CGM substudy of CAROLI-
NA®,an ongoing, cardiovascular outcome trial assessing potential differing
impact of linagliptin or glimepiride predominantly when given as second
line therapy in patients with relatively early type 2 diabetes (T2D).
Materials and methods: To explore potential relationships between gly-
cemic variability (assessed with CGM, Dexcom SEVEN PLUS) and
circulating markers of glucose variability (1.5 - anhydroglucitol [1.5-
AHG]), oxidative stress (8 isoprostane prostaglandin F2α) endothelial
function (asymmetric dimethylarginine and Endothelin-1) and systemic
inflammation (interleukin-6) we analyzed the baseline glucose excursion
patterns and assessed whether glycemic variability was correlated with
five vascular markers. Specifically, we characterized the baseline ambu-
latory glucose profiles (AGP) with glucose exposure (by total area under
the curve), glucose variability (by inter-quartile range) and glucose sta-
bility (by the average hourly absolute change) of all CGM readings over a
2-week period. We also calculated the mean amplitude of glycemic ex-
cursions (MAGE).
Results:Mean ± SD age of the 44 patients (91%males) with T2Dwas 66
±9 years and HbA1c 7.0±0.4%. Median (min, max) diabetes duration
was 11.0 (4.0, 29.0) years and 43% had a history of vascular complica-
tions. 79.5% were treated with metformin (66% in monotherapy), 34.1%
received a sulfonylurea (34% as monotherapy)and 11.4% did not receive
and treatment. As indicated in the table, a modest, significant negative
correlation between glycemic variability and 1.5 AHG was observed, but
no significant correlations between the vascular markers and glucose
variability were seen.
Conclusion: A modest, significant negative correlation between glyce-
mic variability and 1.5 AHG was observed indicating a potential appli-
cability of this marker to identify patients with excess glucose
pertubations. We found no significant correlations between glycaemic
variability and the vascular markers (Table). Future analysis of the pro-
spective CAROLINA® CGM substudy will determine if glimepiride and
linagliptin have differing impact on glycemic excursions patterns.
Clinical Trial Registration Number: NCT01243424
Supported by: Boehringer-Ingelheim and Eli Lilly
1174
Role of SGK-1 in regulating eNOS activity in human coronary artery
endothelial cells
D. Pastore1, D. Della Morte1, B. Capuani1, F. Pacifici1, A. Coppola1, R.
Arriga1, A. Bellia1, A. Galli2, M. Romano2, P. Sbraccia1, M. Tesauro1, G.
Sconocchia3, D. Lauro1;
1University of Rome Tor Vergata, 2University Hospital ‘Fondazione
Policlinico di Tor Vergata’, 3Institute of Translational Pharmacology, Na-
tional Research Council, Roma, Italy.
Background and aims: Cardiovascular diseases (CVD) are the leading
cause of death globally and especially in patients with diabetes. CVD is a
class of diseases that involve the blood vessels, in fact the initial step in
development of CVD is the impairment in endothelial homeostasis,
which is modulated by nitric oxide (NO) production. Important studies
performed in endothelial cells recognized some signaling, such as the
activation of PI3K-AKT-1 pathway, that improves endothelial nitric oxide
synthase (eNOS) activation as a result of insulin stimulation. While it is
known that Akt-1 directly phosphorylates human eNOS at Ser1177
resulting in an increase of eNOS activity, on the contrary the role of
Serum and glucocorticoid-inducible kinase (SGK)-1 in modulation of
eNOS activity is still sparse. In this study, we analyzed the role of
SGK-1 in regulating eNOS activation in a cell model of human coronary
artery endothelial cells (HCAEC).
Materials and methods:A retrovirus system was used to infect HCAEC
with different constructs such as SGK-1wt, SGK-1Δ60 (lacking of the
N-60 amino acids, not ubiquitinated and more active construct), and
SGK-1Δ60KD (kinase dead constructs). eNOS phosphorylation at
Ser1177 was measured in cells infected with different SGK-1 constructs
in diverse experimental conditions: 1. insulin stimulation alone (10-7 M
for 1 h); 2. SGK1 inhibitor (GSK650394, 103 nM, added 30 min before
insulin); 3. AKT-1 inhibitor (iAKT, 10 μM, added 18 h before insulin) in
presence or absence of insulin.
Results: AKT-1 inhibitor completely inhibited phosphorylation and acti-
vation of AKT-1 in Ser473 in all constructs, but inhibited only partially
eNOS phosphorylation in Ser1177. In a similar way, SGK-1 inhibitor,
inhibited only partially eNOS activity and phosphorylation but this inhi-
bition was significantly less (p<0.05) in SGK-1Δ60 cells than other
constructs, probably due to an increased activity of SGK-1 in this cells.
Conclusion: These results demonstrated that SGK-1 and AKT-1 may
have a synergistic and compensatory effect in inducing eNOS phosphor-
ylation in Ser1177 modulating NO production in HCAEC cells. Further
studies in different cellular systems and in vivo are needed to better define
the role of SGK-1 in diabetic cardiovascular diseases.
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Previously unknown glucose abnormalities are common in
individuals with periodontitis, especially in those with a previous
myocardial infarction
A. Norhammar1, B. Kjellström1, N. Habib1, P. Näsman2, A.
Gustafsson3, L. Rydén1, for the PAROKRANK Study Group;
1Karolinska Institute, Department of Medicine, Cardiology Unit,
Karolinska University Hospital, 2Royal Institute of Technology (KTH),
3Karolinska Institute, Dental Medicine, Stockholm, Sweden.
Background and aims: Periodontal disease (PD) is more common in
diabetes (DM) and is suggested as a risk factor for myocardial infarction
(MI) as well as for dysglycaemia. The prevalence of unknown abnormal
glucose tolerance (AGT) in people with PD and if this is more common in
MI patients with PD has not been investigated.We studied the prevalence
of AGT in different grades of PD in patients with a first MI and controls.
Materials and methods: Patients (n=805) <75 years with a first MI in
Sweden 2010-2014 and age and gender matched controls (n=805) were
examined for risk factors, including an oral glucose tolerance test
(OGTT). Dental bone loss was examined by panoramic radiographs
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and PD classified as healthy (≥80% remaining bone), mild to moderate
(79-66%) or severe (<66%). Known diabetes was present if reported by
the participant. AGT was based on OGTT according to WHO (DM=F-
glucose: ≥7.0 mmol/l and or F-glucose<7.0 and 2-h above 11.0 mmol/l,
impaired glucose tolerance (IGT); F-glucose <7.0 and 2-h glucose ≥7.8 -
11.0 mmol/l).
Results:Mean age was 62±8 years (81% males). Previously known DM
was present in 10% of patients and 8% of controls, newly detected DM in
9 and 5% (p=0.002) and new IGT in 20% and 12% (p<0.0001) respec-
tively. AGT (new DM +IGT) was present in 29% of patients and 17% of
controls (p<0.0001). Among study participants with signs of PD (mod-
erate + severe) 62% of patients and 37% of controls had unknown AGT.
Newly detected DM (Figure) was more common in patients with severe
PD than in those without PD (18% vs. 9%) and more common than in
controls (9% vs. 4%).
Conclusion:Unknown AGT is more common among patients with a first
MI than in controls and especially apparent in the presence of PD. Newly
detected DM is particularly apparent in patients with severe PD. This
indicates that PD may induce a chronic inflammatory condition and pro-
voke glucose abnormalities as well as MI supporting the assumption of a
two-way relationship between dysglycaemia and PD.
Supported by: AFA insurance, Swedish Heart Lung Foundation, Swedish
Society of Medicine
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The relationship between LDL-c reduction during statin therapy and
the risk of new-onset diabetes: a meta-analysis
R. Cai1, Y. Yuan1, S. Wang1, X. Ruan2;
1Affiliated ZhongDa Hospital of Southeast University, Nanjing, China,
2JohnMoorhead Research Laboratory, Centre for Nephrology, University
College London (UCL) Medical School, UK.
Background and aims: Recent studies demonstrated that lower target
LDL-c level of statin use is associated with excess risk of diabetes. This
study is to investigate under what circumstances we should focus on
statin-induced diabetes according to the new ACC-AHA cardiovascular
prevention guidelines.
Materials and methods: We searched Pubmed, Embase, and the
Cochrane Central Register of Controlled Trials, with no time constraints,
for randomized placebo and standard care-controlled endpoint trials of
statins. According to the new ACC-AHA cardiovascular prevention
guidelines, the included trials were stratified by the relative LDL-c reduc-
tion of 10% to 20%; 20% to 30%; 30% to 40%; or 40% to 50%. We
calculated an overall odds ratio (OR) with a random-effect model.
Results: Totally, 4559 patients developed diabetes during duration in 14
trials. The risks of incident diabetes elevate by 13% and 29% when
relative LDL-c reduction were 30-40% and 40-50%, respectively. How-
ever, incident diabetes did not increase when relative LDL-c reduction
were <20% and between 20-30%. In absolute terms, one additional case
of diabetes is diagnosed per 137 patients and per 108 patients whose
relative LDL-c reduction were 30-40% andwithin 40%-50%when taking
statin therapy for 4 years.
Conclusion: LDL-c reduction is positive related with new-onset diabetes
risk. We should pay close attention to incident diabetes among the "major
statin benefit groups", especially when LDL-c reduction more than 30%
during the process of lipid lowering.
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Effects of lipid drugs on glycaemic control in type 2 diabetes
G. Bardini1, S. Giannini2, B. Cresci2, L. Pala2, C.M. Rotella1;
1Obesity Agency, 2Diabetology and Endocrinology Unit, University of
Florence, Italy.
Background and aims: Several studies showed that statins increase the
risk of incident diabetes; however, the relationship between statins and
glycemic control in subjects with established diabetes has not been well
characterized. Aim of this study was to evaluate the effect of lipid drugs,
statins, ezetimibe and fenofibrate, on glycemic control in patients with
type 2 diabetes (DM2).
Materials and methods: In a retrospective study, a consecutive series of
423 (210 F, 213 M) DM2 clinic outpatients, aged 67.7±8.8 years, were
consecutively examined for HbA1c levels before starting lipid drugs and
after 6, 12 and 18 months with lipid therapies. All patients studied
remained with unchanged diabetes therapies for all the study duration.
Subjects with current corticosteroids drugs and chronic kidney disease
were excluded. Statins were subdivided by pharmachological potency,
based on their low density lipoprotein-cholesterol reduction below 40%
(low-potency statins: atorvastatin 10 mg, simvastatin 10 mg, 20 mg and
40 mg, fluvastatin, pravastatin and lovastatin at all doses) and upper 40%
(high-potency statins: rosuvastatin all doses, atorvastatin 20 mg and
40 mg and simvastatin+ezetimibe all doses). We compared HbA1c levels
modifications during the 18 months of follow-up in subjects with or
without lipid drugs.
Results: The patients studied showed HbA1c 7.0±1.1% (53±12 mmol/
mol) with 13.8±7.1 years duration of diabetes. 90.6% patients assumed
oral hypoglycemic agents, 9.4% insulin, and 88.0% lipid drugs. Among
these, 96.0%were treated with statins and 4.0%with fenofibrate. Among
subjects with statins therapy, 50.8% patients assumed high-potency
statins and 49.2% low-potency statins. No statistical difference was found
inHbA1c baseline levels between subjects with or without lipid therapies.
During the follow-up, we observed a significant increase of HbA1c levels
in patients treated with lipid drugs compared to subjects without any lipid
therapy: 6.9±0.9% vs 6.5±0.8% (p=0.004) at 6 months, 6.88±0.8% vs
6.46±0.7% (p=0.003) at 12 months and 6.9±0.8% vs 6.4±0.8% (p=
0.002) at 18 months. Considering the effects of statins potency on HbA1c
variation, we observed an increase of 0.5% at 6months (p=0.022), 0.45%
at 12 months (p=0.003) and 0.53% (p=0.001) at 18 months in HbA1c by
high-potency statins. Low-potency statins were associated to an incre-
ment of HbA1c levels 0.31% (p=0.025) at 6 months, 0.36% (p=0.03)
at 1 year and 0.48% (p=0.001) at 18 months. Fenofibrate showed an
increase of HbA1c 0.5% (p=0.021) at 6 months, 0.76% (p=0.002) at
1 year and 0.78% (p=0.001) at 18 months.
Conclusion: In DM2 patients, lipid therapies are associated with a mod-
est, but significant decrease in glycemic control. This fact should not be
relevant in clinical setting in the choice of lipid drugs considering their
positive effects on cardiovascular protection.
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High adherence to dietary recommendations associates with lower
risk of developing high triglycerides and LDL during 16 years of
follow-up
S. Hellstrand1, I. Drake2, U. Ericson1, J. Hlebowicz3, B. Gullberg2, B.
Hedblad4, G. Engström4, M. Orho-Melander1, E. Sonestedt1;
1Diabetes and Cardiovascular Disease - Genetic Epidemiology, Clinical
Sciences, 2Nutritional Epidemiology, Clinical Sciences, 3Experimental
Cardiovascular Research, Clinical Sciences, 4Cardiovascular Epidemiol-
ogy, Clinical Sciences, Lund University, Malmö, Sweden.
Background and aims: A high diet quality according to the Swedish
nutrition recommendations associates with reduced risk of mortality and
cardiovascular disease in the Malmö Diet and Cancer cohort. To further
clarify this protective association we examined its relation to change in
standard blood lipids during 16 years of follow-up. In addition, because
genetic variation could influence the response to certain diets we exam-
ined if genetic risk scores composed of 80 validated lipid-associated
genetic variants modify this association.
Materials and methods: We included 3,145 individuals from the
population-based Malmö Diet and Cancer cohort study that had standard
lipid concentrations (triglycerides, HDL and LDL) measured both at
baseline examination (1992-1994) and after an average of 16 years of
follow-up. Dietary intakes at baseline were measured using a modified
diet history method, and a diet quality index was constructed based on
adherence to recommended intakes for saturated fat, polyunsaturated fat,
sucrose, fiber, fruit and vegetables, and fish.
Results: A high compared with a low diet quality index was associated
with higher HDL concentrations at baseline and lower risk of developing
high triglycerides and high LDL during follow-up. We found an inverse
association between diet quality and HDL change during follow-up only
among those with lower genetic risk for low HDL but not among those
with higher genetic risk (p-interaction=0.04). Among those with low
genetic risk for low HDL, low diet quality was associated with decreased
HDL during follow-up.
Conclusion: Individuals with high adherence to the Swedish nutrition
recommendation had lower risk of developing high triglycerides and
LDL during 16 years of follow-up. We found no strong evidence that
genetic risk for dyslipidemia modified the association between diet qual-
ity index and change in standard blood lipids.
Supported by: SMRC, SSMR, SH-L Foundation, SUH, Albert Påhlsson
RF, Crafoord Foundation
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Rosuvastatin 5 mg improved carotid atherosclerotic changes
regardless of LDL cholesterol level in Japanese diabetic patients:
a 2-year prospective study
R. Saiki, H. Imai, M. Hashizume, Y. Kigawa, G. Koizumi, R. Tadokoro,
S. Sato, F. Otsuka, M. Taniyama;
Endocrinology and Metabolism, Showa University Fujigaoka Hospital,
Yokohama, Japan.
Background and aims:A new AHA guideline on the treatment of blood
cholesterol recommends moderate-intensity statin therapy (MIST) for
diabetic patients regardless of LDL-C levels. In Japan, we set the targeted
values for lipid level in detail based on medical conditions. However, the
dosage of strong statin is generally less than western countries due to size
of physique. Therefore, no enough evidences using MIST exist for Asian
people. In this study, we had assessed the effectiveness of rosuvastatin
5 mg as MIST on carotid atherosclerotic changes for Japanese diabetic
patients.
Materials and methods: Ninety-nine diabetic outpatients (59.6% male;
mean age=55.8±8.0 years; average diabetic duration=9.4±6.5 years;
mean HbA1c=7.26±1.3%; 33% statin-naive) were enrolled who also
meet the following requirements; Age≦65 years, with hyper lipidemia,
found max carotid intima media thickness (CIMT)≧1 mm or plaques in
carotid ultra sound (US). 33 patients had already received statin therapy
before the study. Daily oral administration of 5 mg rosuvastatin was
started or switched from other statins and the fasting blood samples were
collected (including TC, HDL-C, triglyceride and LDL-C was estimated
by Friedwald method) every 1 to 3 months, then carotid US had been
performed 1 to 2 years later. We had assessed the mean CIMT(mm)
including no plaques, max CIMT(mm) and stenosis(%) using ECST
measurement method and the course of primary lesion area of max CIMT
and stenosis was followed. In addition, we assessed the change of US
findings depending on reduced LDL-C levels.
Results: Mean levels of LDL-C were reduced from 100.4±28.4(mg/dl)
to 71.5±23.7 (after 1-2 years). There were no significant changes in
HbA1c levels for 2 years (mean HbA1c: 7.26→7.26→7.27%). The sig-
nificant improvement was not accepted after 1 year, but accepted after
S566 Diabetologia (2015) 58 (Suppl 1):S1–S607
2 years through the observation of carotid US findings: mean CIMT 0.76
±0.16→0.72±0.16 (p=0.02), max CIMT 2.0±0.9→1.8±0.8 (p=
0.0002), stenosis 22.9±9.2→20.2±8.3 (p<0.0001) (by using Student’s
t test). Based on the levels of LDL-C after 1-2 years of administration, we
divided participants into 2 groups by referring to the ESC/EAS dyslipid-
emia guideline recommendation for diabetic patients [LDL-C<70 mg/
dl=group A (n=51; mean age=56.5 years; 63% male; mean LDL-C=
55.1 mg/dl; mean HbA1c=7.2%); 70≦LDL-C=group B (n=48; mean
age=55.0 years; 56% male; mean LDL-C=89.6 mg/dl; mean HbA1c=
7.4%)]. Both groups had significant amelioration of max CIMT (A: p=
0.016; B: p=0.001) and stenosis (A: p<0.0001; B: p=0.002) but mean
IMTwas improved only in group A (p=0.01) (by usingWilcoxon signed-
rank test). There were no significant differences within 2 groups in the
result of 2 years changing rate of each US findings (by using Mann-
Whitney U test) with no significant differences in age, sex, diabetic du-
ration and HbA1c. Mean changing rates of US findings in each group
were as follows: mean CIMT [-5.6 vs -1.1(p=0.14)]; maxCIMT [-9.31 vs
-3.22(p=0.81)]; stenosis [-6.9 vs -12.9(p=0.95)] (%).
Conclusion: This result shows that rosuvastatin 5 mg (as MIST) admin-
istration for Japanese diabetic patients for 2 years improves carotid ath-
erosclerotic change regardless of maintained LDL-C levels without dete-
rioration in HbA1c.
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Does diagnosis of diabetes mellitus among patients surviving an ACS
event affect lipid control measures? Results from the Dyslipidaemia
International Study (DYSIS) II ACS
D. Lautsch1, A.K. Gitt2, J. Ferrieres3, M. Horack4, V. Ashton1, P. Brudi1,
B. Ambegaonkar1, DYSIS II study investigators;
1Merck & Co., Inc., Kenilworth, USA, 2Stiftung Institut fur
Herzinfarktforschung,Herzzentrum Ludwigshafen, Ludwigshafen am
Rhein, Germany, 3Toulouse University School of Medicine, Rangueil
Hospital, France, 4Stiftung Institut fur Herzinfarktforschung,
Ludwigshafen am Rhein, Germany.
Background and aims: Patients suffering an acute coronary syndrome
(ACS) event with concomitant diabetes mellitus (DM) remain at very
high risk for future cardiovascular complications. Current ESC guidelines
recommend an LDL-C target of <70mg/dl for very high risk patients. We
aimed to determine LDL-C target achievement rates among post-ACS
patients with DM and how this differs from patients without DM. We
further evaluated lipid management and in those not reaching target, the
distance to LDL-C <70 mg/dl.
Materials and methods: DYSIS II ACS, a multicountry observational
cross sectional study, enrolled ACS patients from May 2013-October
2014 in 18 countries from Asia-Pacific, Europe, and Middle East/Africa
regions. Eligible adult patients were hospitalized for an ACS event, had
documented DM (previously diagnosed, fasting plasma glucose≥
126 mg/dl, or currently receiving treatment for DM), full lipid profile
available within 24 hours of hospital admission, on lipid lowering therapy
(LLT)≥3 months or not at all, alive at discharge, and not participating in
clinical trials involving medication. Patient follow-up interviews were
conducted 4 months after ACS hospital admission date to capture details
on recurrent events, current symptoms, laboratory values, LLT, and qual-
ity of life.
Results:Among 3855 enrolled ACS patients (mean age 62.3±12.1 years;
76.4% male), 36.9% had DM, with 23.8% of DM patients having an
LDL-C <70 mg/dl versus 16.0% of patients without DM (p <0.0001).
Median distance to LDL-C target at enrollment was 38.0 (16.0,66.0) mg/
dl amongDMpatients and 48.0 (24.0,77.0) mg/dl among patients without
DM (p <0.0001). Seventy-seven percent of DM patients and 58.5% of
patients without DM were currently receiving LLTwhen admitted to the
hospital. Approximately ninety-one percent of ACS patients (n=3496)
had 4 month follow-up data available, with 37.5% having DM. Lipid
results available for 1040 patients at follow-up showed that 38.8% of
DM patients versus 28.1% of patients without DM (p <0.001) achieved
an LDL-C <70 mg/dl. Median distance to LDL-C target was 21.5 (9.0,
42.0) mg/dl for DM patients and 21.0 (6.0,37.0) mg/dl for patients with-
out DM (p=0.16). Differences in LLT management 4 months after an
ACS event are shown in Table 1.
Conclusion: LLT was used the same way in both patient groups, with
concomitant DM having no influence on the physicians’ prescribing be-
havior. LDL-C was lower in patients with DM indicating towards a dif-
ferent lipid profile containing smaller lipoprotein particles. Additional
effective lipid lowering strategies are needed among these very high
cardiovascular risk patients in order to further reduce CVevents.
Supported by: Merck & Co., Inc.
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Target value attainment among treated ACS and CHD patients with
concomitant type 2 diabetes mellitus in 21 countries: the
Dyslipidaemia International Study (DYSIS) II results
A.K. Gitt1, J. Ferrieres2, D. Lautsch3, M. Horack4, V. Ashton3, P. Brudi3,
B. Ambegaonkar3, DYSIS II study investigators;
1Stiftung Institut fur Herzinfarktforschung, Herzzentrum Ludwigshafen,
Ludwigshafen am Rhein, Germany, 2Toulouse University School of
Medicine, Rangueil Hospital, France, 3Merck & Co., Inc., Kenilworth,
USA, 4Stiftung Institut fur Herzinfarktforschung, Ludwigshafen am
Rhein, Germany.
Background and aims: ESC guidelines set target LDL-C values for
patients suffering from diabetes or CHD at <70 mg/dl. The condition of
concomitant CHD and diabetes puts patients at very high risk for cardio-
vascular events, specifically recurrent infarctions. We aimed to determine
target value attainment in 2 cohorts: stable CHD patients and post-acute
coronary syndrome (ACS) patients respectively, both with concomitant
type 2 diabetes mellitus (T2DM). Further, we evaluated lipid manage-
ment and in those not reaching the target, the distance to LDL-C <70 mg/
dl.
Materials and methods: DYSIS II, a multicountry observational cross
sectional study enrolled stable CHD and ACS patients in 21 countries
fromAsia-Pacific, Europe, andMiddle East/Africa regions. Eligible adult
patients were hospitalized for an ACS event or had a documented history
of CHD, documented T2DM (previously diagnosed, fasting plasma glu-
cose≥126 mg/dl, or currently receiving treatment for diabetes), full lipid
profile available within 24 hours of hospital admission for ACS patients
and 0-12 months prior to enrollment for CHD patients, on lipid lowering
therapy (LLT)≥3 months or not at all, and not participating in clinical
trials involving medication.
Results:Overall, 1346 patients with ACS and T2DMwere enrolled, with
77.4% (n=1042) currently on LLT when admitted to the hospital. Only
28.3% of patients on LLT had an LDL-C <70mg/dl (mean LDL-C 94.2±
40.2 mg/dl), with median distance to LDL-C target being 32.0 (14.0,
57.0) mg/dl. Mean atorvastatin equivalent dose was 23±16 mg/day, with
themajority of patients on statinmonotherapy (91.4%), followed by 3.6%
statin + other non-statin (fibrates or omega 3 fatty acids), 3.2% statin +
ezetimibe, and 1.8% non-statin monotherapy when admitted to the hos-
pital. Among 2620 enrolled stable CHD patients with T2DM, 94.6% (n=
2479) were currently on LLT, with 36.3% achieving an LDL-C <70mg/dl
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(mean LDL-C 82.4±41.0 mg/dl). Median distance to target LDL-C was
21.0 (9.0, 38.0) mg/dl. Mean atorvastatin equivalent dose was 25±18mg/
day, with 81.9% currently on statin monotherapy followed by 10.4%
statin + ezetimibe, 6.5% statin + other non-statin (fibrates, nicotinic acid,
or omega 3 fatty acids), and 1.2% non-statin monotherapy.
Conclusion: Approximately two-thirds of treated ACS and stable CHD
patients with concomitant T2DM were not at the recommended LDL-C
target while receiving primarily statin monotherapy. DYSIS II confirms
that patients at highest CV risk are treated mainly with moderate statin
doses. Switching to higher statin doses, and the addition of ezetimibe, will
further reduce the risk of future cardiovascular events.
Supported by: Merck & Co., Inc.
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The abruptness of terminating nicotinic acid delivery has a profound
effect on free fatty acid and insulin rebound in rats
T. Kroon1,2, J. Gabrielsson2, N.D. Oakes1;
1iMed CVMD, AstraZeneca, Mölndal, 2Swedish University of Agricul-
tural Sciences (SLU), Uppsala, Sweden.
Background and aims:Amajor factor thought to drive insulin resistance
is ectopic lipid accumulation. Reducing circulating lipids including free
fatty acids (FFA) may offer an approach to ameliorate insulin resistance.
Acute nicotinic acid (NiAc) infusion results in rapid reduction of plasma
FFA concentrations. However, this tends to be offset following infusion
cessation, by a FFA rebound, which overshoots pre-treatment levels. One
possible explanation is that this is a consequence of the very short plasma
NiAc half life (~3 min in the rat). The aim of this study was to determine
whether a slow step-down NiAc infusion protocol (Step-Down group) vs.
simply turning the infusion off (On/Off group) could attenuate the FFA
rebound development and maximize NiAc induced FFA lowering.
Materials and methods: FFA lowering was assessed in obese Zucker
rats following a 12 hr constant rate NiAc infusion with corresponding
saline infused controls.
Results: It was found that, following a 12 hr constant rate NiAc infusion
the On/Off group exhibited a FFA rebound and a remarkable insulin
rebound. To our surprise the Step-Down group did not succeed in im-
proving FFA control. In fact the area under the FFA curve during the 5 hr
step-down phase was greater than for the corresponding period in the On/
Off group (5.70 vs. 4.96 mM hr, P<0.05) despite substantially higher
plasma levels of NiAc in the Step-Down group. The higher FFA levels
were associated with, and may have been caused by, a markedly blunted
insulin rebound in the Step/Down versus On/Off group possibly due to
NiAc-induced inhibition of insulin secretion.
Conclusion: In conclusion, these results show that the time dependence
of the infusion profile of the anti-lipolytic agent NiAc has a very signif-
icant impact on control of plasma FFA levels. Specifically, gradual step-
down reduction of NiAc infusion actually degraded the anti-lipolytic
effectiveness of NiAc compared to abrupt withdrawal possibly due to a
NiAc induced blunting of insulin secretion.
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Down-regulation of vascular GLP-1 receptor expression in subjects
with obesity
T. Kimura1, M. Shimoda1, S. Okauchi1, A. Obata1, H. Hirukawa1, K.
Kohara1, A. Hiraoka2, K. Tamura2, G. Chikazawa2, H. Yoshitaka2, I.
Shimizu2, K. Kaku1, H. Kaneto1;
1Diabetes, Endocrinology and Metabolism, Kawasaki Medical School,
Kurashiki, 2Sakakibara Heart Institute, Okayama, Japan.
Background and aims: It is known that incretin signaling improve vas-
cular relaxation response through eNOS expression and/or activity in
endothelial cells. In addition, it has been shown that incretin has anti-
atherosclerotic effects in vascular smoothmuscle cells. On the other hand,
although it has been reported that GLP-1 receptor expression in pancre-
atic β-cells is reduced under diabetic conditions, it remains unknown
whether vascular GLP-1 receptor expression is altered under some con-
ditions and which factor could influence vascular GLP-1 receptor expres-
sion. The aim of this study was to reveal the alteration of vascular GLP-1
receptor expression and the factors affecting its expression in human
artery.
Materials and methods: We examined the subjects having artery sur-
gery. Excised diseased artery was mechanically separated into the intima
and tunica. Gene expression of various factors in the intima and tunica
was analyzed by real time RT-PCR. Primer pairs encoding genes associ-
ated with GLP-1 receptor and factors related to arteriosclerosis were
prepared, and real-time RT-PCR with Sybr Green was performed. Each
gene expression was semi-quantified by the comparative Ct method with
each result in β-actin as a control. Subjects were divided into obesity
(BMI≥25 kg/m2) and non-obesity group (BMI<25 kg/m2) and compar-
ison of the clinical parameters and various gene expression levels in the
intima and tunica was performed. The results were expressed as mean±
SE. AWilcoxon test was used to test the difference between obesity and
non-obesity group with p<0.05 regarded as significant.
Results: Subjects were 36 patients (male / female=26 / 10, abdominal or
thoracic aortic aneurysm / aortic dissection / arteriosclerosis obliterans /
other=11 / 17 / 6 / 2, diabetic / non-diabetic=11 / 23, age 67.3±2.3 years
old, BMI 23.7±0.8 kg / m2, HbA1C 6.3±0.3%). BMI in obese and non-
obese group was 28.6±0.7 kg/m2 and 20.2±0.6 kg/m2, respectively (p<
0.05). Between the obesity and non-obesity group, there was no signifi-
cant difference in FBG (121.2±8.9 mg/dl vs 119.6±6.3 mg/dl). Plasma
insulin level in obesity group was higher compared to that in non-obesity
group (29.2±11.0 μU/ml vs 6.5±1.3 μU/ml) (p<0.05). And there was no
significant difference in HbA1c (5.9±0.2% vs 6.6±0.5%), triglyceride,
HDL-cholesterol, LDL-cholesterol between the 2 groups. GLP-1 receptor
gene expression in the intima and tunica was significantly lower in obe-
sity group compared to that in non-obesity group (p<0.05). In spearman's
rank correlation coefficient test, there was significantly negative correla-
tion between GLP-1 receptor gene expression and BMI, LDL-cholesterol
in the intima and tunica.
Conclusion:GLP-1 receptor gene expression in human artery was down-
regulated in subjects with obesity. The present results suggest that obesity
and hyperinsulinemia down-regulate GLP-1 receptor gene expression in
human artery.
Supported by: KMS1933
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Resistance to theGLP-1 effects on platelets in type 2 diabetes mellitus
C. Barale, F. Cavalot, C. Frascaroli, L. Mattiello, A. Guerrasio, I. Russo;
Internal Medicine and Metabolic Disease Unit, Department of Clinical
and Biological Sciences, San Luigi Gonzaga Hospital, University of Tu-
rin, Orbassano, Italy.
Background and aims: Glucagon-like peptide 1 (GLP-1) shows pleio-
tropic benefits on cardiovascular system: its influence on platelets - deep-
ly involved in the pathogenesis of diabetic vascular diseases - is poorly
investigated. The GLP-1 active form is GLP-1 (7-36), rapidly degraded to
GLP-1 (9-36).We previously showed that, in platelets, both GLP-1 (7-36)
and GLP-1 (9-36) and the analogue Liraglutide similarly increase the
sensitivity to the antiaggregating nitric oxide (NO) and decrease the
agonist-induced activation of the signalling pathways PI-3Kinase (PI-
3 K) and MAP-Kinase (MAPK) and reactive oxygen species (ROS)
production. The GLP-1 influence on platelet response in Type 2 Diabetes
Mellitus (T2DM) is not known. Aim of this study was to verify whether
the GLP-1 effects observed in healthy subjects were preserved in T2DM.
Materials and methods: In platelets from 20 T2DM patients (M/F: 9/11;
age 56.1±1.9 years; BMI:32.6±1.1 kg/m2; HbA1C:8.0±0.2%) and 12
healthy control subjects (M/F:6/6; age:48.2±3.4 years; BMI: 24.0±
0.7 kg/m2) we evaluated the ability of GLP-1(7-36), GLP-1(9-36) and
Liraglutide (100 nmol/l) to influence: the antiaggregating effects of the
nitric oxide donor Na-nitroprusside (SNP) (Born’s method), the phos-
phorylation levels of AKT (pAKT) and ERK-1/2 (pERK-1/2)(Western
Blot) and ROS synthesis (DCF-DA fluorescence assay) in the presence of
the agonists ADP (10 micromol/l), Collagen (4 mg/L) and Na-
Arachidonate (NaA) (100 micromol/l).
Results: The effects of GLP-1 (7-36), GLP-1 (9-36) and Liraglutide,
were lower in T2DM compared with healthy subjects. In particular, in
the presence of GLP-1 (7-36): the percent (%) increases of the
antiaggregating effects of SNP were 4.0±1.8 vs 28.2±4.8 (p<0.0001)
with ADP, and 17.0±5.2 vs 36.8±5.1 (p<0.02) with Collagen; the%
reductions of pAKT were 3.2±4.2 vs 43.1±3.5 (p<0.0001) with Colla-
gen, and 5.4±5.2 vs 32.1±6.8 (p<0.004) with NaA; the % reductions of
pERK-2 were 3.5±2.2 vs 25±8.2 (p<0.004) with Collagen, and 10.5±
8.6 vs 40.2±9.5 (p<0.03) with NaA; the% reductions of ROS production
were 15.1±5.2 vs 41.2±7.5 (p<0.006) with NaA. In the presence of
GLP-1 (9-36): the % increases of the antiaggregating effects of SNPwere
6.1±1.9 vs 25.6±3.0 (p<0.0001) with ADP, and 18.5±3.8 vs 32.7±4.1
(p<0.02) with Collagen; the % reductions of pAKTwere 4.8±3.1 vs 45.3
±4.6 (p<0.0001) with Collagen, and 6.1±3.3 vs 35.9±7.3 (p<0.0001)
with NaA; the % reductions of pERK-2 were 4.9±2.0 vs 28±9.1 (p<
0.004) with Collagen, and 12.6±8.1 vs 44.0±9.8 (p<0.02) with NaA; the
% reductions of ROS production were 17.1±8.3 vs 45.9±7.9 (p<0.03)
with NaA. In the presence of Liraglutide: the % increases of the
antiaggregating effects of SNPwere 5.7±2.5 vs 30.1±7.8 (p<0.001) with
ADP, and 15.5±3.5 vs 33.5±4.4 (p<0.003) with Collagen; the % reduc-
tions of pAKTwere 15.9±5.7 vs 39.1±9.0 (p<0.03) with Collagen, and
20.1±5.7 vs 36.2±5.8 (ns) with NaA; the % reductions of pERK-2 were
4.0±2.5 vs 27.9±8.8 (p<0.003) with Collagen, and 24.3±7.7 vs 39.2±
6.8 (ns) with NaA; the% reductions of ROS production were 26.1±5.4 vs
56.8±6.3 (p<0.001) with NaA.
Conclusion: T2DM is characterized by a resistance to the effects of the
native GLP-1 (7-36), truncated GLP-1 (9-36) and GLP-1 analogue
Liraglutide to increase the antiaggregating effects of NO, to reduce plate-
let activation of signalling pathways PI-3 K and MAPK and oxidative
stress stimulated by platelet agonists.
Supported by: A "PRIN" grant of MIUR
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The DPP-4 enzyme correlates with plasma triglycerides in non-obese
subjects andmediates palmitate-induced apoptosis in human cardiac
progenitor cells
M. Incalza, L. Laviola, C. Caccioppoli, A. Leonardini, R. D'Oria, A.
Cignarelli, V. Andrulli Buccheri, A. Natalicchio, S. Perrini, F. Giorgino;
Endocrinology & Metabolic Diseases, University of Bari, Italy.
Background and aims: Hypertriglyceridemia is an independent risk
factor for cardiovascular disease, and chronic exposure to elevated satu-
rated fatty acids (SFA) leads to cardiomyocyte dysfunction and death,
both in vivo and in vitro. Circulating levels of dipeptidyl peptidase-4
(DPP-4) have been shown to correlate with cardiovascular disease in
humans. Thus, we investigated the potential link between plasma DPP-
4 levels, triglyceridemia and the activation of apoptotic pathways in hu-
man cardiac progenitor cells (CPC).
Materials and methods: Plasma DPP-4 levels were determined with an
ELISA assay. DPP-4 activity was measured by a colorimetric assay. Hu-
man CPC isolated from right auricle biopsies were exposed to 0.25 mM
palmitate up to 24 h. Cell apoptosis was detected by caspase-3 cleavage
and cytosolic release of oligosomes. Expression and phosphorylation
levels of the proteins under investigation were evaluated by immunoblot-
ting techniques.
Results: In 20 non-diabetic subjects (M/F 9/11, age 47±11 y, BMI 33±9,
triglycerides 135±99mg/dL), plasmaDPP-4 levels were found to positive-
ly correlate with BMI (r=0.485, p<0.05). In addition, DPP-4 levels were
significantly and positively associated with plasma triglycerides in non-
obese (r=0.847, p<0.05) but not in obese (r=0.02) individuals. Then,
primary cultures of CPC were obtained from right auricle biopsies of pa-
tients undergoing elective heart surgery. When CPC were exposed to the
SFA palmitate (0.25 mmol/L, up to 16 h), DPP-4 levels and activity in the
culture medium were found to be increased 2- to 4-fold (p<0.05), and this
was associated with increased phosphorylation of the stress kinase JNK
and the JNK substrate c-Jun (p<0.05). In addition, exogenous DPP-4 (up
to 500 ng/ml) activated the JNK pathway, inducing a 2.5 fold increase in c-
Jun phosphorylation (p<0.05). Finally, palmitate augmented CPC apopto-
sis, evaluated by measuring cytoplasmic oligosomes and Caspase-3 cleav-
age, (p<0,05), but DPP-4 silencing with a specific siRNA prevented CPC
apoptosis, as well as c-Jun phosphorylation (p<0.05).
Conclusion: The DPP-4 enzyme correlates with plasma triglycerides
in vivo in non-obese subjects, is released from CPCs in response to
palmitate in vitro, and contributes to SFA-triggered stress signals leading
to cardiac cell dysfunction and death.
1186
Correlation of SDF-1a levels and left ventricular diastolic dysfunc-
tion in type 2 diabetes patients according to treatment with or with-
out DPP4-inhibitors
S. Iraklianou1, A. Papazafiropoulou1, E. Fousteris1, E. Trikkalinou1, V.
Gkizlis1, A. Ganotopoulou1, A. Theodosis-Georgilas2, C. Tountas2, S.
Matsagos3, P. Spyropoulou3, S. Foussas2, A. Melidonis1;
1Diabetes Center, 2Cardiology Department, 3Blood Bank Service, Tzanio
General Hospital of Piraeus, Greece.
Background and aims: Recent studies have shown that stromal derived
factor-1α (SDF-1α) is a substrate of dipeptidyl-peptidase-4 (DPP-4) in-
hibitors. SDF-1α is a small cytokine that belongs to the chemokine family
and can stimulate endothelial progenitor cells. It has, also, been shown
that SDF-1α shares antiapoptotic as well as nephroprotective properties
and it has a beneficial effect in the cardiovascular system. Therefore, the
aim of the present study was to estimate the effect of the treatment with
DDP-4 inhibitors to SDF-1α levels according to the presence of diastolic
dysfunction of left ventricle (DDLV) in subjects with type 2 diabetes
(T2D)
Materials and methods: 32 participants (16 males) with T2D, mean age
(±SD) 67.2±8.3 years, HbA1c 6.4±0.5%, body-mass index (BMI) 29.1±
4.9 Kg/m2, duration of diabetes 8.5±4.0 years receiving antidiabetic
treatment with metformin only (17 participants) or metformin plus
DPP-4 inhibitors (14 participants) without known cardiovascular disease
were enrolled into the study. All study participants underwent fully clin-
ical examination and ultrasound examination of the heart while a blood
sample was taken at fasting state for the estimation of SDF-1α levels.
Results: Study participants receiving metformin plus DPP-4 inhibitors
had higher plasma levels of SDF-1α compared to participants on metfor-
min therapy only (19.6±4.1 versus 6.9±1.3 pg/ml, respectively, p=0.01).
14 participants had DDLV, while SDF-1α levels did not differ according
to the presence or not of DDLV (12.0±1.8 versus 9.1±0.1 pg/ml, respec-
tively, p=0.65). 61.3% of participants had arterial hypertension, 77.4%
dyslipidemia while 12.9% were current smokers. Multivariate regression
analysis (backward), after controlling for age, sex, BMI, smoking, history
of arterial hypertension and dyslipidemia, DDLV, white blood cells count,
C-reactive protein, creatinine clearance, uric acid, LDL-cholesterol and
triglycerides, showed that SDF-1α levels were positive related with treat-
ment with DPP-4 inhibitors (beta=0.91, p=0.001), and negative with
duration of T2D (beta=-0.42, p=0.05), ΗDL-cholesterol levels (beta=-
0.46, p=0.02) and HbA1c (beta=-0.41, p=0.05).
Conclusion: The results of the present study showed that treatment with
DDP-4 inhibitors has a favorable effect to SDF-1α levels. On the con-
trary, no statistical significant relation was found between SDF-1α levels
and DDLV. Finally, long duration of diabetes is related with lower levels
of SDF-1α, confirming the detrimental effects of diabetes per se.
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LEADER-5: prevalence and cardiometabolic impact of obesity in
cardiovascular high-risk patients with type 2 diabetes: baseline data
from the trial
L. Masmiquel1, S.C. Bain2, on behalf of the LEADER investigators;
1University Insitute of Health Science Research, Palma de Mallorca,
Spain, 2University of Swansea, UK.
Background and aims: The association between anthropometric mea-
sures of adiposity and cardiovascular (CV) risk in patients with
established type 2 diabetes mellitus (T2DM) and high CV risk has not
been well studied. Some longitudinal cohort studies have shown reduced
mortality with higher body mass index (BMI) in patients with T2DM and
coronary artery disease, suggesting an “obesity paradox”. However, this
is not well-established and additional data in this patient group are
needed.
Materials and methods: We used baseline data from the Liraglutide
Effect and Action in Diabetes: Evaluation of cardiovascular outcome
Results (LEADER) trial, which enrolled 9340 patients with T2DM, at
high-risk for CVD, across 32 countries. We used cross-sectional data to
investigate (1) the prevalence of overweight and obesity; (2) the associ-
ation of cardiometabolic risk factors withmeasures of adiposity (BMI and
waist circumference (WC)); and (3) the cardiometabolic risk factors af-
fecting treatment intensity. Lipids and blood pressure measurements were
considered on target according to ADA 2014 criteria. Descriptive statis-
tics and multivariable logistic regression analyses were used.
Results: Mean BMI was 32.5±6.3 kg/m2, with only 9.1% of patients
having normal weight. The prevalence of normal WC was also low
(6.4% according to harmonized criteria). The percentage of patients with
LDL-cholesterol <2.6 mmol/L (100 mg/dl), triglycerides (TG)
<1.7 mmol/L (150 mg/dl), and blood pressure (<140/80 mmHg) at target
was generally lower for individuals with a BMI >40 kg/m2 compared to
individuals with a BMI <25 kg/m2 (37.6% vs. 36.9%, 63.1% vs. 45.9%,
44.9%vs. 38.2%, respectively). A similar trendwas observed forWC. No
differences were detected for HbA1c and LDL-cholesterol. Insulin, statin,
and antihypertensive agent use was more frequent at higher BMI and
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WC.Multivariable adjusted logistic regression analyses yielded that obe-
sity was mainly associated with female gender (p<0.0001), with not
smoking (p<0.0001), race and region of living (p<0.0001 for both) (Ta-
ble), as well as triglyceride level and hypertension (data not shown).
Conclusion:Overweight and obesity are extremely prevalent in high-risk
patients with T2DM. BMI and WC are associated with cardiometabolic
risk factors and treatment intensity is higher in patients who are over-
weight or obese; however, a high percentage of these patients were not at
target for HbA1c, BP, and lipids at baseline. The LEADER trial will
provide important information on the effects of the GLP-1 receptor ago-
nist liraglutide on CVoutcomes in this patient population.
Clinical Trial Registration Number: NCT01179048
Supported by: Novo Nordisk
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Health-related quality-of-life (HRQoL) implications of cardiovascu-
lar and hypoglycaemic events in type 2 diabetes mellitus
A.H. Briggs1, D.L. Bhatt2, B.M. Scirica2, O. Mosenzon3, K. Johnston4,
S.M. Szabo5, K. Bergenheim6, J. Mukherjee7, B. Hirshberg8, I. Raz3;
1University of Glasgow, UK, 2Harvard Medical School, Boston, USA,
3Hadassah Medical Center, Jerusalem, Israel, 4ICON Epidemiology,
5Redwood Outcomes, Vancouver, Canada, 6AstraZeneca, Molndal, Swe-
den, 7Bristol-Myers Squibb, Wallingford, 8AstraZeneca, Gaithersburg,
USA.
Background and aims: The Saxagliptin Assessment of Vascular Out-
comes Recorded in Patients with Diabetes Mellitus (SAVOR) -TIMI 53
trial was a multicenter randomized controlled phase IV trial of clinical and
HRQoL outcomes in 16,492 T2DM patients with a previous cardiovas-
cular event, or multiple risk factors for vascular disease. The analysis
quantified the impact of major non-fatal clinical events on HRQoL (as
measured by EQ5D utilities); and compared utilities over time according
to whether patients experienced clinical events of interest.
Materials and methods: During the trial, EQ5D utility values were
elicited annually and following a non-fatal clinical event, including hos-
pitalizations for hypoglycemia, heart failure (hHF) and major cardiovas-
cular events (myocardial infarction and stroke). Utilities were analyzed
using linear mixed effects regression, adjusting for baseline characteris-
tics (including EQ5D utility) and a time-dependent variable describing
prior cardiovascular events.
Results: Most patients completed the EQ5D survey at baseline,
12 months, and closeout; 1,973 also completed the EQ5D after a clinical
event. The mean EQ5D utility of the overall sample was 0.78 at baseline
and all subsequent time points and did not vary by treatment arm. Despite
no observed difference in mean HRQoL utility between treatment arms at
planned observation points, an impact of cardiovascular events was ob-
served: mean baseline, month 12, and closeout utilities among those with
a cardiovascular event were 0.75, 0.72, and 0.71, respectively. After a
cardiovascular event, mean utilities were 0.69, 0.69, and 0.72 (within
3 months, 3-6 months, and 6-12 months after the event, respectively).
In the regression analysis adjusting for age, sex, treatment arm, and base-
line HRQoL, utility decrements associated with cardiovascular events
were -0.059, -0.045, and -0.037 over the same time periods; all coeffi-
cients were statistically significant. Utility decrements for specific cardio-
vascular events (MI, stroke and hHF) will be presented. Among 96 indi-
viduals who experienced a hospitalized hypoglycemic event, mean time
between the event and next utility elicitation was 175 days; the adjusted
utility decrement following the hypoglycemic event was 0.026, although
this difference was not statistically significant.
Conclusion: In a large clinical trial T2DM population, no significant
impact was observed by treatment arm for HRQoL, consistent with re-
sults reported elsewhere for clinical outcomes. However, cardiovascular
events were associated with a significant decrease in HRQoL, most sub-
stantial in the initial post-event period. These data also suggest a potential
relationship between hypoglycemic events and HRQoL; investigating
this association would be best addressed by a study designed to include
a sufficient number of hypoglycemic events. The temporal relationship
observed between major cardiovascular events and utility trajectories
highlights the need to elicit utilities proximal to occurrence of events of
interest, in order to accurately and comprehensively quantify HRQoL
burden.
Clinical Trial Registration Number: NCT01107886
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Insulin-like factor 5: a novel orexigenic hormone in humans is dys-
regulated in obesity
I.V. Wagner1,2, G. Flehmig3, K. Scheuermann4, D. Löffler4, A. Körner4,
2, W. Kiess4,2, M. Stumvoll3,2, A. Dietrich2, M. Blueher3,2, N. Klöting3,2,
O. Söder1, K. Svechnikov1;
1Womens and Childrens Health, Karolinska Institutet, Stockholm, Swe-
den, 2Integrated Research and Treatment Center (IFB Adiposity Dis-
eases), 3Division of Endocrinology, Department ofMedicine, 4University
Hospital for Children and Adolescents, Center for Pediatric Research
Leipzig, Germany.
Background and aims: Insulin-like factor 5 (INSL5), a member of the
insulin superfamily, is expressed in the colorectum and hypothalamus.
INSL5 deficient mice display impaired fertility and dysregulated glucose
homeostasis. Based on the observation that INSL5 was elevated by
prolonged calorie restriction and declined with feeding, it was suggested
that INSL5 might be an orexigenic hormone. Our aim was to explore the
relationship between circulating levels of INSL5 and different metabolic
parameters in lean and obese subjects and to identify possible links be-
tween INSL5 and the development of metabolic disorders such as obesity
and diabetes.
Materials and methods: INSL5 was measured in serum samples by
ELISA (Cloud clone corp.). 20 lean females and males and 20 obese
females and males were included. Furthermore 15 morbidly obese pa-
tients were tested before and six months after they underwent bariatric
surgery. In addition we measured INSL5 levels in 10 lean and obese
individuals after an overnight fasting, after a meal and during an oral
glucose tolerance test (OGTT). For all groups, correlations between
INSL5 concentrations and anthropometric, metabolic and hormonal mea-
sures were investigated.
Results: We found gender specific differences in INSL5 after fasting.
INSL5 was significantly higher (by 25.5%, p<0.05) in healthy lean fe-
males than males but this gender specific difference was not observed in
obese subjects. Basal INSL5 was significantly lower in the obese group
(by 28.6%, p<0.05). Correlation analysis revealed that INSL5 was neg-
atively correlated to testosterone in both lean and obese males (p=0.001,
r=-0.58; p=0.02, r=-0.52) and to insulin in both genders. Six months
after bariatric surgery 15 males lost 25% of their body weight that was
associated with significant (by 97%) increase in serum testosterone and
marked (by 17.4%) decline in serum INSL5. Obese subjects with type 2
diabetes (T2DM) had lower INSL5 before and after surgery compared to
obese persons without T2DM. In patients without T2DM INSL5 levels
decreased more (20.7%) compared to T2DM patients (14.8%). After a
meal INSL5 decreased by 21.8% and 20.8% in lean females and males,
respectively, while interestingly this effect was not observed in obese
individuals of both genders. During an OGTT, after a pure sugar load,
there was no significant effect in the lean group but a decrease in INSL5
in the obese subjects with insulin resistance.
Conclusion: Altogether, our data indicate that the gender-related differ-
ence in INSL5 was observed only in healthy lean but not in obese indi-
viduals. Thus suggesting that the regulation of INSL5 is dependent on the
metabolic state in humans. Negative influence of insulin resistance and
T2DM on serum levels of INSL5 in obese individuals may indicate a link
between beta cell function and INSL5 regulation. Our finding that INSL5
levels were restored after weight loss let us to suggest a negative effect of
fat tissue on the biosynthesis of this hormone in obesity. Therefore,
INSL5 may become an interesting target for the development of new
therapeutic agents to treat metabolic disorders in humans.
Supported by: ESPE Research Fellowship, IFB Adiposity Diseases
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Secretory products from epicardial adipose tissue from patients with
type 2 diabetes impair mitochondrial respiration in cardiac myocytes
via upregulation of miR-208a
M. Blumensatt1, D. Herzfeld de Wiza1, H. Mueller1, D.M. Ouwens1,2;
1German Diabetes Center, Institute for Clinical Biochemistry and
Pathobiochemistry, Duesseldorf, Germany, 2Ghent University Hospital,
Department of Endocrinology, Belgium.
Background and aims: Alterations in cardiac energy substrate metabo-
lism contribute to the development of diabetic cardiomyopathy. We have
recently found that secretory products from epicardial adipose tissue
(EAT) from patients with type 2 diabetes impair cardiac myocyte function
as illustrated by the induction of insulin resistance, contractile dysfunc-
tion, and changes in microRNA expression, including miR-208a, a key
regulator of energy metabolism. The present study examines whether
EAT affects mitochondrial respiration in cardiac myocytes and whether
this can be ascribed to the induction of miR-208a by angiotensin II.
Materials and methods: Biopsies from EAT from were collected from
patients with and without type 2 diabetes and used to generate condi-
tioned media (CM). Levels of angiotensin II in CM were determined by
enzyme-linked immunosorbent assay. Mitochondrial respiration was
measured in primary adult rat cardiac myocytes exposed to CM using a
Seahorse XF96e analyzer. Gene and miRNA-expression as well as
mtDNA copy number were measured by qRT-PCR. The cardiac mouse
cell line HL-1 was used for transfection with precursor-miRNAs to in-
vestigate the impact of miRNAs on mitochondrial respiration and fatty
acid oxidation. Protein expression and phosphorylation was measured by
Western blot analysis.
Results:CM from EATand from patients with type 2 diabetes (CM-EAT-
T2D) increased the levels of miR-208a in both primary adult rat (1.8-fold,
p<0.05) and primary human cardiac myocytes (1.6-fold, p<0.05) as
compared to cells exposed to CM from patients without type 2 diabetes
(CM-EAT-ND). The effects of CM-EAT-T2D on miR-208a induction
were abolished by the angiotensin II receptor antagonist, losartan. Higher
levels of angiotensin II were identified in CM-EAT-T2D compared to
CM-EAT-ND (2-fold, p<0.05). Furthermore, CM-EAT-T2D reduced
maximal mitochondrial respiration by 20% and spare respiratory capacity
by 40% in primary adult rat cardiac myocytes. Accordingly, expression of
the precursor for miR-208a reduced maximal mitochondrial respiration
by 19% and spare respiratory capacity by 25% inHL-1 cardiac myocytes.
Moreover, miR-208a reduced palmitate-induced maximal respiration by
22%. This decrease in mitochondrial function associated with a reduced
phosphorylation of the regulatory beta subunit of AMP-activated protein
kinase, and its substrate acetyl-CoA carboxylase. Finally, higher levels of
miR-208a reduced mtDNA copy number and the expression of carnitine
palmitoyltransferase 1, a regulator of mitochondrial β-oxidation.
Conclusion: Secretory products from epicardial adipose tissue from pa-
tients with type 2 diabetes impair mitochondrial respiration in cardiac
myocytes via upregulation of miR-208a. This miRNA inhibits myocar-
dial energy metabolism via the down-regulation of mitochondrial β-ox-
idation. Finally, the induction of miR-208a is prevented by the angioten-
sin II receptor antagonist losartan.
Supported by: German Center for Diabetes Research
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The effect of a fat-rich mixed meal on metabolic and hormonal pa-
rameters, postprandial lipaemia as well as endothelial function in
women with polycystic ovary syndrome
G. Argyrakopoulou1,2, E. Diamanti-Kandarakis3, K. Makrilakis1, N.
Tentolouris1, A. Kokkinos1, D. Perrea4, N. Katsilambros1,4, S. Raptis5,2;
1First Department of Propaedeutic and Internal Medicine, Athens Univer-
sity Medical School, 2Athens Medical Center, 3Third Department of In-
ternal Medicine, Endocrine Unit, 4Laboratory of Experimental Surgery
and Surgical Research, Athens University Medical School, 5Hellenic Na-
tional Center for Research, Prevention and Treatment of Diabetes
Mellitus and its Complications, Athens, Greece.
Background and aims: Polycystic ovary syndrome (PCOS) is charac-
terized by hyperandrogenism, chronic anovulation, and metabolic disor-
ders like insulin resistance, glucose intolerance, dyslipidaemia and im-
paired endothelial function. No studies have yet investigated the meta-
bolic response of these patients in the postprandial state. The aim of this
study was to investigate the effect of consumption of a fat-rich mixed
meal on metabolic and hormonal parameters as well as endothelial func-
tion in women with PCOS and to compare them with healthy controls.
Materials and methods:We studied 55 women with PCOS (age 26.0±
6.1 years; BMI 27.6±6.9 kg/m2), and 20 age and BMI matched healthy
controls (age 26.5±4.3 years; BMI 25.15±7.76 kg/m2) who consumed a
fat-rich mixed meal (783 kcal; 27.5% carbohydrates 52.5% fat, 20%
protein). Sex hormones at times 0' and 6 h after the meal as well as
glucose, insulin, total cholesterol, HDL, LDL and triglycerides at times
0’, 2 h, 4 h and 6 hwere measured. Additionally, all patients underwent an
oGTT in a separate session, for the detection of insulin resistance using
the HOMA, QUICKI, and MATSUDA indices. A subset of women
(nPCOS=46 and nControls=12) underwent an endothelial function test
using flow-mediated dilation and assessment of skin microcirculation
using laser Doppler flowmetry.
Results: In the postprandial state, PCOS patients showed a significant
reduction ofΔ4-androstenedione (p<0.001) and a trend for reduction of
free testosterone levels (p=0.052), a significant increase of dehydroepi-
androsterone sulfate (p=0.016) and a trend for increase of sex hormone-
binding globulin levels (p=0.086). We also found a trend for the triglyc-
eride concentrations expressed as area under the curve (AUC) to be
higher (464.79±158.55 vs. 587.72±287.81, p=0.073) and the AUC of
insulin to be significantly higher (97.06±62.24 vs. 147.08±94.85, p=
0.014) in womenwith PCOS compared to controls. Furthermore, patients
with PCOS had worse endothelial function (brachial artery dilation of
8.52±5.80% vs. 4.78±6.42%, p=0.036) while skin microcirculation
and insulin resistance indices were not different between the two groups.
Conclusion: In the postprandial state women with PCOS exhibited sig-
nificant changes in their hormonal profile. In addition, PCOS compared
to controls had a trend for higher postprandial lipaemia and worse endo-
thelial function. These findings suggest that young women with PCOS
have detrimental hormonal, metabolic and endothelial alterations. There-
fore, they seem to be more susceptible to cardiovascular disease.
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Microvesicles from activated endothelial cells are decreased by
weight loss and correlate with dyslipidaemia and cardiovascular risk
in severe obesity
A. Handberg1,2, M.H. Christensen1, M.H. Nielsen1, S.B. Thomsen3, H.
Vestergaard3;
1Dept. of Clinical Biochemistry, Aalborg University Hospital, 2Clinical
Institute, Aalborg University, 3Center for BasicMetabolic Research, Uni-
versity of Copenhagen, Denmark.
Background and aims: Obesity, elevated triglycerides (TG) and low
HDL-cholesterol are all factors related to the metabolic syndrome
(MetSy), a state that includes increased cardiovascular risk. Endothelial
CD36 is involved in TG clearance from TG-rich lipoproteins and up-
regulated by oxidative stress, both potentially activating endothelial cells.
Microvesicles (MVs) may be markers and mediators of endothelial dys-
function having impact on the cardiovascular state during obesity. The
aim of this studywas to evaluate the effect of weight loss on levels of total
MV number, activated endothelial MVs (EMVs), and CD36 positive
EMVs, and their correlation to HDL, TG, and MetSy.
Materials and methods: Twenty obese individuals (BMI of 43.0±
5.4 kg/m2) were included. Informed consent was obtained and the study
was approved by the local ethical committee. Fasting blood samples were
collected at baseline and three months after weight loss. Plasma MV
profile was analyzed in accordance to a published flow cytometric meth-
od by this group that includes the whole MV size range of 100-1000 nm.
MVs were stained with Lactadherin-FITC, CD62e-PE, and CD36-APC
antibodies. Statistical analysis included theWilcoxon signed rank test and
Spearman’s Correlation test.
Results: Gastric bypass reduced BMI with 20% (p<0.001). Total MV
number decreased by 39% (p=0.025), total EMV number by 47% (p=
0.002), and CD36 positive EMVs by 73% (p=0.004). At baseline, total
MV count correlated with TG (rho =0.5, p=0.015) and TG/HDL ratio
(rho=0.6, p=0.009). Total EMVs correlated with HDL (rho=-0.6, p=
0.005), TG (rho=0.5, p=0.02) and TG/HDL ratio (rho =0.8, 0.001).
When data from baseline and after weight loss were pooled, total MV
number was increased by 1.7 (p<0.012), total EMV by 1.74 (p<0.067),
and CD36+EMV by 3.45 fold (p<0.01) in participants with MetSy.
Conclusion: Significant weight loss in extremely obese individuals leads
to a decrease in total MV number. The decrease in EMVs and CD36+
EMVs may reflect reduced endothelial dysfunction and lower cardiovas-
cular risk.
Supported by: The Novo Nordisk Foundation
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Cardiovascular safety of liraglutide: meta-analysis of major adverse
cardiovascular events across weightmanagement and type 2 diabetes
development programmes
S.C. Bain1, I.D. Caterson2, J.L. Gross3, C.B. Svendsen4, C.B. Jensen4,
S.P. Marso5;
1Department of Medicine, Abertawe Bro Morgannwg University NHS
Trust, Swansea, UK, 2University of Sydney, Australia, 3Universidade
Federal do Rio Grande do Sul, Porto Alegre, Brazil, 4Novo Nordisk,
Søborg, Denmark, 5University of Texas Southwestern Medical Center,
Dallas, USA.
Background and aims: The cardiovascular safety of liraglutide among
overweight/obese individuals and those with type 2 diabetes (T2D) is
unknown. We therefore performed a meta-analysis of all available indi-
viduals from five phase 2/3 liraglutide weight management trials, includ-
ing follow-up through a 120-Day Safety Update. A meta-analysis of 21
trials from T2D development programmes, in which liraglutide was used
as a treatment, provided further supportive information. The maximum
dose of liraglutide investigated in the weight management programme
was 3.0 mg, whereas the maximum dose was 1.8 mg in the T2D trials.
Materials and methods: The primary endpoint was first occurrence of
adjudicated major adverse cardiovascular events (MACE) (non-fatal
myocardial infarction, non-fatal stroke or CV death) on liraglutide (any
dose) or pooled comparator (placebo, active) and was analysed using a
Cox proportional hazards model stratified by trial. Prospective adjudica-
tion (blinded, independent) was implemented in three of the weight man-
agement trials; post-hoc adjudication was conducted for all other trials.
Individuals who did not experience an event during the treatment period
or within 30 days after last dose were censored at last treatment date plus
30 days. Multiple sensitivity analyses were conducted to confirm the
robustness of the primary analysis. Across weight management trials
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(liraglutide: n=3,872; comparator: n=2,036), baseline characteristics
were: 71%women; history of CV disease, 9%; mean age, 47 years; mean
BMI, 38 kg/m2. Across T2D trials (liraglutide: n=5,511; comparator: n=
2,748): 43% women; history of CV disease, 13%; mean age, 56 years;
mean BMI, 30 kg/m2.
Results: In the weight management trials, the overall number of adjudi-
cated MACE was low and numerically lower with liraglutide (any dose:
10 events, frequency 0.2%, 0.2 events/100 patient-years of exposure
[PYE]; liraglutide 3.0 mg: 7 events, 0.2%, 0.2 events/100 PYE) than with
comparator (total comparator: 10 events, 0.5%, 0.4 events/100 PYE; pla-
cebo: 10 events, 0.5%, 0.4 events/100 PYE). Hazard ratios (HR) and 95%
confidence intervals (CI)] for liraglutide (any dose) vs. total comparator:
0.40 [0.16; 1.01]; liraglutide 3.0 mg vs. placebo: 0.33 [0.12; 0.90]. As
expected, higher event rates were observed across T2D trials: (liraglutide
[any dose]: 26 events, 0.5%, 0.6 events/100 PYE vs. total comparator: 23
events, 0.8%, 1.3 events/100 PYE vs. total comparator): HR [95% CI]:
0.6 [0.35, 1.15].
Conclusion: Based on these data, there was no indication of an increased
risk of MACE with liraglutide up to doses of 3.0 mg once-daily in
overweight/obese individuals, or in those with T2D.
Supported by: Novo Nordisk
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Discrepancies in the relationship of BMI and traditional cardiovas-
cular risk factors in subjects with different levels of obesity
S.R. van Mil1, A. van Huisstede2, B. Klop3, G.J.M. van de Geijn4, G.J.
Braunstahl2, E. Birnie5, G.H.H. Mannaerts1,6, L.U. Biter1, M. Castro
Cabezas3;
1Surgery, 2Pulmonology, 3Internal Medicine, 4Clinical Chemistry, 5Sta-
tistics and Education, Sint Franciscus Vlietland Gasthuis, Rotterdam,
Netherlands, 6Tawam Hospital, Al Ain, United Arab Emirates.
Background and aims: Obesity is related to increased cardiovascular
risk. This relationship is based on the negative effects of body weight
on several traditional risk factors. It remains unknown whether this asso-
ciation also holds at higher levels of obesity. The purpose of this study
was to investigate this relation in a cohort with wide ranges of BMI.
Materials and methods: Lean subjects participating in observational
studies in our out-patient clinic and obese subjects scheduled for bariatric
surgery were included. Baseline characteristics and laboratory values
were collected according to a standard protocol. Both, the group of lean
subjects (i.e. BMI<30) and the group of obese subjects (i.e. BMI≥30)
were categorized in quintiles according to BMI. The relation between
BMI and cardiovascular risk factors were analyzed using ANOVA.
Results: The cohort consisted of 953 subjects (591 women, 362 men;
mean age±SD, 49.9±14.8 years). The lean group consisted of 377 sub-
jects, with a mean BMI of 25.0±2.81 kg/m2. 576 Subjects were included
in the obese group, with a mean BMI of 43.8±7.58 kg/m2. The obese
group included significantly more women, more T2DM, more HT and
more smokers than the lean group.Mean values of LDLC, apolipoprotein
B, systolic en diastolic blood pressure were significantly higher in the
obese group and HDLC was significantly lower in the obese group.
Diastolic blood pressure, apolipoprotein B and LDLC showed a signifi-
cant dose-response relationship with increasing BMI in the lean group
(p=0.002, p=0.005 and p=0.034, respectively), but this association was
not observed in the obese group. In the lean group, triglycerides increased
with increasing BMI (p=0.001) but decreased in the obese group (p=
0.009). HDLC decreased with higher BMI in both groups, but the asso-
ciation was weaker in the obese. Inflammatory markers like CRP, leuko-
cyte count and C3 increased with increasing BMI in the obese group (p<
0.001 for all markers). In the lean subjects this association with BMI was
also observed for C3 (p<0.001), but not for CRP and leukocytes.
Conclusion: Lipid associated risk factors showed a significant dose-
response relationship with increasing BMI especially in lean subjects,
but this association was weaker in obese subjects. The association with
inflammatory markers and BMI was strongest in obese subjects. The
relationship between cardiovascular risk factors and BMI is lost in higher
levels of obesity. In that case, inflammation seems to be clinically more
prevalent.
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Type 1 diabetes as a coronary disease equivalent: an analysis of 33,
886 individuals with type 1 diabetes and 169,223 controls from the
Swedish National Diabetes Registry
V. Matuleviciene1,2, A. Rosengren1, S. Gudbjörnsdottir1, A.-M.
Svensson3, A. Mårtensson4, H. Wedel5, S. Dahlqvist6, M. Kosiborod7,
M. Lind1;
1Department of Molecular and Clinical Medicine, Universityof Gothen-
burg, 2Department of EmergencyMedicine, Solna, Karolinska University
Hospital, Stockholm, 3Center of Registers in Region Västra Götaland,
Gothenburg, 4Statistiska Konsultgruppen, Gothenburg, 5Nordic School
of Public Health, Gothenburg, 6Department of Medicine, NU Hospital
Organization, Uddevalla, Sweden, 7Saint Luke’s Mid America Heart In-
stitute and University of Missouri, Kansas City, USA.
Background and aims: Few studies have been performed on the con-
temporary incidence of myocardial infarction (MI) among patients with
type 1 diabetes (T1D) in comparison to the general population. Whether
diabetes represents a coronary artery disease equivalent remains contro-
versial, and has not been specifically examined in patients with T1D.
Materials and methods: Individuals with T1D registered in the Swedish
National Diabetes Register (NDR) after January 1st, 1998 (n=33,886)were
included. For each patient registered in the NDR, 5 controls matched ac-
cording to age, gender, and county were randomly selected from the gen-
eral population (n=169,223). T1D individuals without history of MI were
compared to controls with and without history of MI. Endpoints included
MI, cardiovascular death and all-cause mortality. T1D individuals and
controls were studied until occurrence of an endpoint or December 31st,
2011, through the Swedish In-hospital and Cause of death Registries. Anal-
yses were performed with Cox regression adjusting for age and gender.
Results: Themean age of individuals with T1D and no history of MI (n=
33142) was 35.3 years and 35.6 years in corresponding controls (n=
168257). The mean age of controls with history of MI (n=966) was
62.5 years. Themean follow up period in T1D individuals without history
of MI was 7.9 years. Mean follow up was 8.2 years and 6.8 years, re-
spectively, in controls with and without history of MI. Hazard ratios
(HRs) for MI and cardiovascular death for individuals with T1D and no
history of MI versus corresponding controls were 4.6 (95% CI 4.31 to
4.95) and 3.09 (95% CI 2.78 to 3.42), respectively. The HR for all-cause
mortality was 2.70 (95% CI 2.56 to 2.86). The corresponding age-
adjusted HRs for T1D individuals without history of MI versus controls
with history ofMI were 1.20 (95% CI 1.02 to 1.42), 0.93 (95%CI 0.75 to
1.14) and 1.29 (95% CI 1.12 to 1.50).
Conclusion: Individuals with T1D without history of MI had greater risk
of futureMI and all-causemortality but had similar risk for cardiovascular
death compared with controls with history of MI. These results support
the notion that T1D is a coronary disease equivalent.
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Decreased eGFR as a risk factor for heart failure in 13,781 patients
with type 1 diabetes
D. Vestberg1,2, A. Rosengren1, M. Olsson3, S. Gudbjörnsdottir1,4, B.
Haraldsson1, A.-M. Svensson4, M. Lind1,2;
1Molecular and Clinical Medicine, Medicine, Sahlgrenska Academy,
Gothenburg, 2Medicine, NU-Hospital Organisation, Trollhättan, 3Mathe-
matical Sciences, Chalmers University of Technology, 4Centers of Reg-
isters in Region Västra Götaland, Gothenburg, Sweden.
Background and aims: Heart failure (HF) is a disease with poor long
time prognosis and is more prevalent among patients with type 1 diabetes.
Decreased kidney function is a well-known risk factor in the general
population but little is known of its importance in type 1 diabetes. This
study investigates the association of eGFR (estimated GFR) and
hospitalisation for heart failure in patients with type 1 diabetes
Materials and methods: Data were obtained from the Swedish National
Diabetes Registry (NDR), a nationwide quality-assurance instrument for
diabetes care, in conjunction with outcomes data from the Swedish hos-
pital discharge and cause-specific death registries. A cohort of patients
18 years or older who had type 1 diabetes mellitus and no known HF and
registred with at least one creatine value in the NDR between January
1998 and December 2003 was identified (N=13,718). Three equations
were used to calculate eGFR and proportional hazards regression models
were constructed to evaluate the association between eGFR and hospital-
ization for HF.
Results:Among 13,781 patients (mean age 41.1 (SD 13.3) years at base-
line), 330 (2.4%) were hospitalised for HF over median follow-up of
7.0 years. Renal function was normal (eGFR >90 mL/min/1.73 m2) in
67% of patients according to the Cockcroft-Gault formula, compared to
51% and 41% according to the Chronic Kidney Disease Epidemiology
(CKD-EPI) and Modification of Diet in Renal Disease (MDRD) formu-
las. For eGFR 45-60 ml/min/1.73 m2, hazard ratios (HRs) for
hospitalisation (reference >90 mL/min/1.73 m2) were 3.18(95% CI
2.17;4.65), 2.12 (1.16;3.08), and 2.44 (1.69;3.55) using the Cockcroft-
Gault, MDRD, and CKD-EPI formulas. In the group with even worse
kidney function (eGFR <30 mL/min/1.73 m2) the HRs (95% CI) were
respectively 3.78(2.15;5.91), 3.44(2.14;5.51) and 3.51(2.21;5.58)
Conclusion: In patients with type 1 diabetes, risk of hospitalisation for
heart failure was over two times greater at eGFR 45-60 ml/min/1.73 m2
and more than 3 times greater at <30 ml/min/1.73 m2 when compared to
normal eGFR
Supported by: ALF-agreement
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Incidence of atrial fibrillation in 33442 individuals with type 1 dia-
betes from the National Diabetes Registry compared to 167930
matched controls in Sweden from 2001-2011
S. Dahlqvist1, A. Rosengren2,3, S. Gudbjörnsdottir2, A.-M. Svensson4,
A. Mårtensson5, H. Wedel6, M. Kosiborod7,8, M. Lind1,2;
1Department of Medicine, NU Hospital Group, Uddevalla, 2Department
of Molecular and Clinical Medicine, University of Gothenburg,
3Sahlgrenska University Hospital, Gothenburg, 4Centre of Registers in
Region Västra Götaland, 5Statistiska Konsultgruppen, 6Nordic School of
Public Health, Gothenburg, Sweden, 7University of Missouri, 8Saint
Luke’s Mid America Heart Institute, Kansas City, USA.
Background and aims: Atrial fibrillation (AF) is a condition that sub-
stantially increases the risk of stroke. Diabetes is a risk factor for many
cardiovascular conditions, and studies of type 2 diabetes have shown that
diabetes is associated with higher prevalence and incidence of AF. How-
ever the relation between type 1 diabetes (T1D) and AF has not been
studied. The aim of this study was, therefore, to evaluate the relation
between type 1 diabetes and atrial fibrillation.
Materials and methods: Individuals with T1D registered in the Swedish
National Diabetes Registry (NDR) after January 1, 1998 were included in
the study. For each individual with T1D, 5 controls matched on age, sex
and county were randomly selected from the general population at time of
registration in NDR. Because the diagnosis of AF was only available in
the Outpatient Registry from 2001, evaluations were performed from
January 1, 2001, and onwards. At baseline 253 (0.8%) individuals with
T1D and 998 (0.6%) controls were excluded from further analysis due to
previous AF diagnosis. After these exclusions, 33442 individuals with
T1D and 167930 controls were followed using the Inpatient Registry and
the Outpatient Registry with regards to AF until December 31, 2011.
Mortality was assessed using the Cause of Death Registry.
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Results:Mean age at baseline was 36.3 in individuals with T1D and 36.4
in controls, and 45.3% and 45.2% were women, respectively. During an
average follow up of 7.37 years in the T1D group and 7.61 years in the
control group, 578 (1.7%) individuals with T1D and 2353 (1.4%) con-
trols were diagnosed with AF. The incidence rate per 1000 years was 2.35
and 1.84 in individuals with T1D and controls, respectively. The overall
Hazard Ratio (HR) for individuals with T1D versus controls after
adjusting for age and sex was 1.43 (95% CI, 1.31 to 1.57). When addi-
tionally adjusting for myocardial infarction (MI) and hospitalization for
heart failure (HF) at baseline, the HR decreased to 1.29 (95% CI, 1.18 to
1.42). The HRs for individuals with T1D versus controls when adjusting
for age was 2.66 (95% CI, 1.94 to 3.65) in women ≤50 years old, 1.56
(95% CI, 1.32 to 1.85) in women >50 years old, 1.64 (95% CI, 1.35 to
1.99) in men ≤50 years old and 1.13 (95% CI, 0.98 to 1.31) in men
>50 years old. Notably, men older than 50 years had similar risk as
controls, with no significant difference. The corresponding HRs with
respect to age groups and sex when additionally adjusting for MI and
HF was 2.66 (95% CI, 1.94 to 3.65), 1.40 (95% CI, 1.18 to 1.68), 1.61
(95% CI, 1.33 to 1.96) and 1.04 (95% CI, 0.90 to 1.20), respectively.
Conclusion: Type 1 diabetes is associated with a higher risk of AF in
women all ages and inmen 50 years or younger, but not in men older than
50 years. Further research is needed to confirm and explore reasons for
this increased risk.
Supported by: Swedish Research Council, Swedish State, Swedish Society
of Medicine + more
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Features of coronary artery disease in 2776 type 1 diabetes patients
undergoing coronary angiography
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A.-M. Svensson5, A. Norhammar2;
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Background and aims: Individuals with diabetes have more widespread
coronary artery disease (CAD) than those without which partly can ex-
plain their increased risk for cardiovascular death. However few studies
have addressed type 1 diabetes in this context. The aim of this study was
to assess features of coronary artery disease in type 1 diabetes undergoing
coronary angiography.
Materials and methods: All patients undergoing coronary angiography
during the years 2001-2012 included in the Swedish Coronary Angiog-
raphy and Angioplasty Registry (SCAAR) as well in the Swedish Na-
tional Diabetes Registry (NDR) with type 1 diabetes were included and
followed for mortality until 31 December 2012. Type 1 diabetes was
defined bothwith an epidemiological definition (onset age before 30 years
and insulin treatment alone) and using the clinicians’ diagnosis of type 1
diabetes and onset age before 50 years. The coronary angiogram was
visually judged by the local coronary interventionist and divided into
normal (atheromatosis/stenosis<50%), one-, two-, three- and left main-
vessel disease.
Results: Of 2776 individuals with type 1 diabetes (58% male) and com-
plete data on coronary angiogram, mean age was 57 years (SD 11), mean
diabetes duration 35 years (SD 14, range 0-76) and mean HbA1c
67 mmol/mol (SD 14). The indications for coronary angiography were
stable CAD (31%), unstable acute CAD (38%) and ST-elevation myocar-
dial infarction (STEMI; 10%), heart failure (4%), atypical chest pain
(5%), silent ischemia (3%) and other rare reasons. Coronary angiography
revealed 21% without significant stenosis, 23% had one-vessel, 18% had
two-vessel and 29% had three-vessel disease. Left main stem disease was
present in 9%. Among those with stable CAD 15% had a normal angi-
ography and 21% had one-vessel disease. The corresponding figures for
unstable acute CAD were 13% and 23% (Figure).
Conclusion: In patients with type 1 diabetes the coronary angiogramwas
normal more often than expected or with only one-vessel affected despite
a long diabetes duration. These findings might be encouraging for those
who are involved in type 1 diabetes care.
Figure: Percentage of coronary artery disease by indication for the coro-
nary angiography
Supported by: Swedish Heart-Lung Fdn., Dep. of Research and Devel-
opment, Region Kronoberg
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Accelerated decline in brachial distensibility in women with type 1
diabetes: a cross sectional study
P. Ljunggren1,2, P. Johansson1,2, L. Pyle2, D. Maahs2, R. Sippl2, J.
Ludvigsson1, P. Wadwa2, J. Snell-Bergeon2;
1Linköping University, Sweden, 2Barbara Davis Center, Denver, USA.
Background and aims: In patients with type 1 diabetes mellitus (T1D),
cardiovascular disease (CVD) events are more common and occur earlier
in life than in non-diabetics. Reduced brachial artery distensibility
(BrachD), a non-invasive measure of vascular stiffness and early athero-
sclerosis, is an independent risk factor for development of CVD. A lower
BrachD indicates increased arterial stiffness. Our aim was to determine if
adults with T1D have lower BrachD compared to adults without diabetes
and also to determine how age and gender affect the relationship of
BrachD with T1D status. We also investigated the association of BrachD
with coronary artery calcium (CAC), a marker of subclinical CVD.
Materials and methods: BrachD was measured using the Dynapulse
instrument (PulseMetric, San Diego, CA) in 829 participants (352 with
T1D, diabetes duration 29.4±8.8 years, age 43±9 years, range 25-
63 years; 477 non-diabetics age 47±9, range 26-62 years) as part of the
Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. CAC
was measured twice within 5 minutes and averaged, and CAC volume
was square root transformed (CVS) for linear regression analysis. An
ANCOVA model was used to test the association of BrachD with age,
sex, and T1D, and the significance of an age*sex*T1DM interaction. The
correlation of BrachD with CAC was investigated with Spearman corre-
lation coefficients, linear models, and logistic regression.
Results: Mean BrachD was lower in T1D patients vs. controls (6.43±
1.46 vs. 7.16±1.48% change per mmHg, p<0.0001), indicating higher
arterial stiffness. In a model adjusted for age, T1D, and sex, the interac-
tion of age*T1D*sex was significant (p=0.0045). Younger women both
with and without T1D had higher BrachD than men with and without
T1D, but older women had lower BrachD compared to older men. Wom-
en with T1D had a steeper decline than nondiabetic women (Figure 1).
BrachD was correlated with CAC score (r=-0.17, p<0.0001), but after
adjusting for age and sex, neither CAC score nor CVS were associated
with BrachD (p=0.95 and p=0.23, respectively).
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Conclusion: BrachD is lower in T1D patients indicating increased vas-
cular stiffness. Younger females have higher BrachD than males but the
decline with age in BrachD is steeper for women and even greater in
women with T1D. This greater change in BrachD with age seen in wom-
en with T1D is consistent with the increase in other CVD risk factors in
women with T1D. BrachD may be an inexpensive, non-invasive method
to ascertain increased CVD risk in this population. CAC was not associ-
ated with BrachD after adjusting for age and sex, suggesting that these
markers of subclinical atherosclerosis may have different pathophysio-
logic pathways.
Supported by: NHLBI, JDRF
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Use of statins and risk of cardiovascular disease and death in type 1
diabetes: a report from Swedish NDR
S. Gudbjörnsdottir1,2, C. Hero2, A. Rawshani2, A.-M. Svensson1, S.
Franzén1, B. Eliasson2, K. Eeg-Olofsson2;
1The National Diabetes Register, Gothenburg, 2Depatment of Medicin,
University of Gothenburg, Sweden.
Background and aims: Individuals with type 1 diabetes (T1D) are at
higher risk of cardiovascular disease (CVD) and death than the general
population. Risk factor control is crucial and statin treatment is advocated
by guidelines. Recommendations for persons with T1D proceed largely
from extrapolation from other patient populations. The effect of statins in
primary prevention among persons with T1D without previous CVD is
unknown. Our aim was to examine the effect of statins on major cardio-
vascular events and death in T1D.
Materials and methods: We used the Swedish National Diabetes Reg-
ister (NDR) to perform a propensity score based study. A total of 24,230
individuals (included during 2006-2008) with T1D without history of
CVD were followed until 31/12/2012; 18,843 (53% male) were un-
treated and 5387 (57% male) treated with statins. Mean follow-up was
6.0 years with 146,553 person-years of follow-up. A propensity score for
treatment with statins was estimated using 32 baseline variables, includ-
ing socioeconomic factors, and used to balance the covariates in the two
groups. Cox regression analysis was performed by stratifying (eight stra-
ta) on the propensity score, with and without censoring at cross-over (i.e.
switching treatment group by starting or ending medication with statins).
Results: Unadjusted differences were marked at baseline between the
groups but the propensity score allowed for balancing of all 32 covariates;
there were no differences between treated and untreated after accounting
for the propensity score. Figure 1 compares numbers of events and ad-
justed hazard ratios (HR) with 95% confidence intervals (CI) for CVD
death, total death, for fatal/non-fatal acute myocardial infarction (AMI),
coronary heart disease (CHD), stroke and CVD in patients with and
without statin treatment in the overall cohort and in the cohort with cen-
soring at cross-over.
Conclusion: This large observational study shows that treatment with
statins reduces the risk of CVD death and total death as well as stroke
in individuals with T1D without history of CVD.
1201
Mortality by affected coronary artery vessels in 2776 patients with
type 1 diabetes undergoing coronary angiography
K. Eeg-Olofsson1, V. Ritsinger2,3, C. Hero1, N. Saleh2, B. Lagerqvist4,
A.-M. Svensson5, A. Norhammar2;
1Department ofMedicine, SahlgrenskaUniversity Hospital, University of
Gothenburg, 2Department of Medicine, Karolinska University Hospital,
Karolinska Institute, Stockholm, 3Department of Research and Develop-
ment, RegionKronoberg, Växjö, 4Department ofMedical Sciences, Upp-
sala University Hospital, 5The National Diabetes Register, Centre of Reg-
isters, Region of Västra Götaland, Gothenburg, Sweden.
Background and aims: Individuals with diabetes mellitus have more
widespread coronary artery disease (CAD) than those without which
partly can explain their increased risk for cardiovascular death. However
few studies have addressed type of diabetes in this context and rarely type
1 diabetes. The aim of this study was to assess long-term mortality by
affected coronary vessels in type 1 diabetes undergoing coronary
angiography.
Materials and methods: All patients undergoing coronary angiography
during the years 2001-2012 included in the Swedish Coronary Angiog-
raphy and Angioplasty Registry (SCAAR) as well as in the Swedish
National Diabetes Registry (NDR) with type 1 diabetes were included
and followed for mortality until 31 December 2012. Type 1 diabetes was
defined bothwith an epidemiological definition (onset age before 30 years
and insulin treatment alone) and using the clinicians’ diagnosis of type 1
diabetes and onset age before 50 years. The coronary angiogram was
visually judged by the local coronary interventionist and divided into
normal (atheromatosis/stenosis<50%), one-, two-, three- and left main-
vessel disease.
Results: Of 2776 individuals with type 1 diabetes (58% male); mean age
was 57 years (SD 11), mean diabetes duration 35 years (SD 14, range 0-
76) and mean HbA1c 67 mmol/mol (SD 14). Mean follow-up time was
7.2 years (SD 2.2). The most common indications for coronary angiog-
raphy were stable CAD (31%), unstable acute CAD (38%) and ST-
elevation myocardial infarction (STEMI) (10%). Patients with three-
compared to one-vessel disease had longer diabetes duration (39 vs.
33 years) and lower onset age of diabetes (21 vs. 23 years) while actual
HbA1c did not differ (67.2 vs. 66.8 mmol/mol). Mortality (Figure) was
similar in those with normal and one-vessel diseases while those with
two-vessel almost had comparable mortality rate to those with three-
vessel disease.
Conclusion: In patients with type 1 diabetes admitted for coronary angi-
ography mortality is increased by numbers of affected coronary vessels.
Duration of diabetes seems more important than actual HbA1c for
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numbers of affected coronary arteries. Figure: Time to mortality by af-
fected coronary vessels after coronary angiography. Log-rank p=
<0.0001.
Supported by: Swedish Heart-Lung Fdn., Dep. of Research and Devel-
opment Region Kronoberg
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Cumulative smoking and the risk of acute myocardial infarction and
stroke in patients with type 1 diabetes
M. Feodoroff1,2, V. Harjutsalo1,3, C. Forsblom1,2, P.-H. Groop1,2,
FinnDiane Study Group;
1Folkhälsan Institute of Genetics, 2Abdominal Center Nephrology, 3Na-
tional Institute for Health and Welfare, Helsinki, Finland.
Background and aims: Previous studies addressing the association be-
tween smoking and cardio vascular disease (CVD) in patients with dia-
betes have mainly been focused on the CVD mortality and only few of
them have included patients with type 1 diabetes. Our aim was to study
the effect of cumulative smoking in pack-years on the risk of acute myo-
cardial infarction (AMI) and stroke in patients with type 1 diabetes.
Materials and methods: The study included 3,545 patients with type 1
diabetes participating the FinnDiane (Finnish Diabetic Nephropathy)
study. The smoking status was based on baseline questionnaires and
patients were considered as current, ex- or nonsmokers and the amount
of cumulative smoking was calculated in pack-years. The follow-up data
for the development of AMI or stroke was based on The Care Register for
Health Care and Causes of Death Register until the end of year 2012. The
overall follow-up time was 39,481 person years and themedian follow-up
time was 12.0 (9.2-13.9) years. Cox-regression analyses providing HRs
were used to estimate the risk for the development of AMI or stroke per
each pack-year as continuous variable. Sex, duration of diabetes, systolic
blood pressure, HbA1c andHDL cholesterol were used as covariates. The
14-year cumulative risk of combined AMI and stroke in current, ex- and
nonsmokers was estimated with Kaplan-Meier analyses and log-rank test
was used for comparison between the groups.
Results: One pack-year increased the risk of incident AMI with a HR of
1.027 (95% CI 1.016-1.037, p<0.0001) in current smokers and 1.032
(1.023-1.041, p<0.0001) in ex-smokers, compared with nonsmokers. In
the multivariate model the HR of AMI was 1.011 (0.001-1.022, p<0.05)
for current smokers and 1.009 (0.996-1.021, p=NS) for ex-smokers. The
results were similar in stroke and the HRs were 1.029 (1.017-1.042, p<
0.0001) in current smokers and 1.035 (1.025-1.045, p<0.0001) in ex-
smokers compared with nonsmokers in the unadjusted model. In the
adjusted model the HRs were 1.015 (1.001-1.028, p<0.05) and 1.019
(1.005-1.032, p<0.01) respectively. The combined 14-year cumulative
risk of AMI and stroke was 17.1% (14.7-19.3, p=0.011) in current
smokers and 21.4% (18.8-23.9, p<0.0001) in ex-smokers compared with
12.3% (10.9-13.7) in nonsmokers.
Conclusion: Smoking is a significant risk factor for CVD in patients with
type 1 diabetes and the risk of developing CVD depends on the cumula-
tive amount of smoked cigarettes. After the adjustments for other CVD
riskfactors the risk for AMI in ex-smokers approaches the risk seen in
nonsmokers. However, the risk for stroke is the highest in ex-smokers
also after the adjustments.
Supported by: Folkhälsan RF, Stockmann F, Diabetes RF
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Adipose-specific Dipeptidyl Peptidase 4 (DPP4) knockout mice dis-
play improved fasting insulin and smaller adipocytes on High Fat
Diet (HFD)
T. Romacho1, D. Röhrborn1, I. Indrakusuma1, T. Jelenik2, T.R.
Castañeda3, H. Al-Hasani3, M. Roden2,4, H. Sell1, J. Eckel1;
1Paul Langerhans Group for Integrative Physiology, 2Institute for Clinical
Diabetology, 3Institute for Clinical Biochemistry and Pathobiochemistry,
German Diabetes Center, 4Department of Endocrinology and
Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf,
Germany.
Background and aims:DPP4 is an important therapeutic target for type
2 diabetes mellitus. Our group has recently characterized this serine pro-
tease as a novel adipokine potentially linking obesity to the metabolic
syndrome. By using a unique adipose-tissue (AT) specific DPP4 KO
mouse model, we aimed to elucidate the role of adipose DPP4 in high
fat diet-induced obesity.
Materials and methods: The AT-specific DPP4 KO mouse was gener-
ated using a Cre-lox strategy under control of the aP2 promoter on the
C57BL/6J background. Metabolic phenotyping of mice on both chow
and HFD (60% kcal fat) over 24 weeks was performed using
Phenomaster metabolic cages, MRT, glucose and insulin tolerance tests
(ipGTT, ipITT), as well as euglycemic-hyperinsulinemic clamps. DPP4
concentration and DPP4 activity in serum, DPP4 expression in mature
adipocytes and stroma-vascular fraction (SVF) as well as plasma levels of
glucose, insulin, triglycerides and cholesterol were measured. Adipocyte
size was quantified by immunohistochemistry in subcutaneous (sWAT)
and epididymal white adipose tissue (eWAT). Furthermore, gene expres-
sion was assessed in both depots by qRT-PCR.
Results: DPP4 expression in mature adipocytes from KO mice was re-
duced up to 65% (p<0.01) with unchanged expression in the SVF. Serum
DPP4 was significantly lower in KO animals on both diets. KO mice
gained significantly more weight, fat and lean mass on HFD. However,
body fat percentage and length remained similar. The genotype exerted
no effect on energy expenditure, respiratory quotient and spontaneous
physical activity. ipGTT, ipITT and clamps were affected by HFD but
not by genotype. On the other hand, fasting insulin and HOMA-IR were
significantly lower in KO mice on HFD despite unchanged insulin sen-
sitivity. Cholesterol was reduced in both KO mice on chow and on HFD
compared to WT but triglycerides were similar. Within the HFD group,
the KO mice showed a marked shift in the adipocyte size distribution
towards smaller adipocytes. In both fat depots, differentiation markers
remained similar whereas theM2macrophage markers macrophage man-
nose receptor 1 and interleukin (IL)-10 were significantly upregulated in
KO animals compared to WT under HFD. In eWAT, IL-6 and monocyte
chemotactic protein 1 were significantly increased in KO mice. Serum
DPP4 correlated significantly with adipocyte size in both subcutaneous
and epigonadal AT while negatively with serum adiponectin.
Conclusion: This model proves that AT is an important source of DPP4
in mice. Although KO animals gained more weight and fat mass under
HFD challenge, this is not followed by decreased glucose tolerance .
Taken into account that KO animals display smaller adipocytes under
HFD, these findings point towards a beneficial role for DPP4 deletion
in adipose tissue remodeling during HFD. Nevertheless, how DPP4 de-
letion in adipose tissue translates into impaired metabolic performance in
this mouse model must be further clarified.
Supported by: EFSD/MSD and FP7-EU-Marie Curie-IEF (ADDIO-
PIEF-2012-328793)
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Spontaneous high fat diet overeating and body weight gain in selec-
tively bred mice for diet-induced glucose intolerance: possible role of
leptin
A. Asai, M. Nagao, H. Sugihara, S. Oikawa;
Department of Endocrinology, Diabetes and Metabolism, Nippon Medi-
cal School, Tokyo, Japan.
Background and aims: Selective breeding is a powerful approach for
studying the polygenic etiology of lifestyle-related diseases, such as type
2 diabetes and obesity. To investigate the pathogenesis of type 2 diabetes
under high fat diet (HFD) conditions, we recently established 2 lines of
mice with distinctively different susceptibilities to HFD-induced glucose
intolerance by selective breeding; designated selectively bred diet-in-
duced glucose intolerance-prone (SDG-P) and -resistant (SDG-R). In
addition to the obvious glucose intolerance, SDG-P mice showed greater
body weight gain, adiposity, and insulin resistance after HFD feeding as
compared to SDG-R mice. Here, we investigated the differences in feed-
ing behavior between the 2 lines of mice and further explored the mech-
anism underlying the different feeding behavior.
Materials and methods: Male SDG-P and SDG-R mice fed a HFD
(32% energy fat) for 5 weeks (5-10 weeks of age). In a pair-feeding
experiment, daily food intake of some SDG-P mice (pair-fed SDG-P)
was kept the same amount of SDG-R mice during the HFD feeding
period. Glucose tolerance was assessed before and after the HFD feeding
by OGTT. Plasma leptin concentration was measured by ELISA. Leptin
gene expression in epididymal adipose tissue was assessed by quantita-
tive real-time PCR. Data are expressed as mean±SEM. Values of p<0.05
were considered statistically different between groups by Student’s t test
or ANOVAwith Tukey’s multiple comparisons.
Results: At 5 weeks of age (before the HFD feeding), no significant
differences were shown in body weight, adipose tissue mass, locomotor
activity, and oxygen consumption between SDG-P and SDG-R. In ad
libitum feeding condition, SDG-P mice showed higher HFD intake and
greater body weight gain than SDG-R [SDG-P (n=14) vs SDG-R (n=
15): food intake, 4.3±0.4 vs 3.4±0.2 g/day (p<0.001); body weight after
the 5-weekHFD feeding, 36.8±4.3 vs 27.3±2.5 g (p<0.001)]. In the pair-
feeding experiment, body weight gain of pair-fed SDG-P mice was
completely suppressed to the level of SDG-R [27.1±1.5 g (n=14, p=
0.991 vs SDG-R)]. Furthermore, HFD-induced deterioration of glucose
intolerance in SDG-P mice was largely abrogated by the pair feeding.
Despite the no significant differences in body weight and adipose tissue
mass at 5 weeks of age, plasma leptin concentration of SDG-P mice was
significantly lower than that of SDG-R mice [SDG-P (n=12) vs SDG-R
(n=11): 1.7±0.7 vs 2.7±1.4 ng/ml (p=0.039)]. Leptin gene expression
level was also lower in SDG-P mice [~50% of SDG-R (normalized to
Gapdh), p=0.016]. In addition, exogenous leptin injections (50μg/mouse
twice daily for 3 days, i.p.) effectively reduced HFD intake in both lines
of mice and the body weight gain of SDG-P mice was suppressed to the
same level of SDG-R mice by the injections.
Conclusion: The present results demonstrate that the HFD-induced de-
terioration of glucose intolerance in SDG-P mice is the result of sponta-
neous overeating. The lower leptin levels before HFD feeding in SDG-P
mice suggest a possible role of leptin as a determinant of later overeating,
obesity, and the development of type 2 diabetes under HFD conditions.
Supported by: JSPS KAKENHI
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Methylglyoxal impairs high-fat diet-induced adipose tissue expan-
sion causing systemic dysmetabolism
T. Rodrigues1, J.P. Almeida1, J. Sereno2, J. Castelhano2, C. Neves1, R.
Fonseca1, S. Gonçalves2, L. Gamas1, M. Castelo-Branco2,3, P.
Matafome1,4, R. Seiça1;
1Laboratory of Physiology, Institute of Biomedical Imaging and Life
Sciences (IBILI), Faculty of Medicine, 2Institute for Nuclear Sciences
Applied to Health (ICNAS), 3Laboratory of Visual Neuroscience, IBILI,
Faculty of Medicine, University of Coimbra, 4Coimbra Health School
(ESTeSC), Department of Complementary Sciences, Instituto Politécnico
de Coimbra, Portugal.
Background and aims: Adipose tissue dysfunction is known to trigger
systemic dysmetabolism in obesity and type 2 diabetes. The use of obese
models consistently has shown hypoxia in adipose tissue, but previous
studies did not fully explored the mechanisms involved. Many of them
suggested adipocyte hypertrophy as the cause for hypoxia and
dysmetabolism, due to lower oxygen diffusion. However, recent data
supported the idea that instead of simple adipocyte hypertrophy, micro-
vascular dysfunction could be the trigger for hypoxia and dysmetabolism.
We previously demonstrated that methylglyoxal (MG), a byproduct of
glucose metabolism, is able to induce glycation, microvascular dysfunc-
tion and inflammation, as well as impaired adaptation to decreased blood
supply. This study investigates the role of MG-induced microvascular
dysfunction in a context of high-fat diet-induced adipocyte hypertrophy
and tissue expansion.
Materials and methods: We used animal models fed a high-fat diet
(HFD), with MG-induced glycation (MG) or both (HFDMG) during
4 months, separating both variables in the experimental design, as well
as a group of control (Ct) and diabetic Goto-Kakizaki (GK) rats fed a
standard diet (n=6/ group). Animals were submitted to functional mag-
netic resonance imaging (fMRI) in order to assess tissue irrigation. Sub-
sequently, animals were injected i.p. with the hypoxia probe
pimonidazole (60 mg/Kg) and epididymal adipose tissue was collected
for biochemical analyses.
Results: Rats submitted to MG administration (MG and HFDMG)
showed h ighe r a ccumul a t i on o f the MG-de r i ved AGE
N(epsilon)-(carboxyethyl) lysine (CEL) in adipose tissue, similarly to
diabetic rats. Using fMRI imaging, lower accumulation of the contrast
product was observed in high-fat diet-fed (HFD) and GK rats, but mostly
in rats treated with MG alone (MG) and in HFD rats supplemented with
MG (HFDMG). Moreover, pimonidazole adducts were significantly in-
creased in the epididymal adipose tissue of HFDMG and GK rats, but not
HFD or MG. In addition, decreased Perilipin A, a marker of adipocyte
dysfunction, was observed in HFDMG rats. Regarding insulin signaling,
despite no differences were observed in phosphorylated Akt, the HFD fed
rats with MG supplementation (HFDMG) and GK rats, but not the HFD
nor the MG groups, showed a significant decrease of the active form of
insulin receptor (Tyr1163). These data were in accordance with the i.p.
glucose tolerance test (IPGTT), where higher glucose intolerance (higher
area under the curve) and hyperinsulinemia were observed in HFDMG
rats.
Conclusion: Altogether, our results show that glycation induced by
methylglyoxal conduces to microvascular dysfunction that impairs adi-
pose tissue expansibility. In a context of diet-induced hypertrophy and
adipose tissue expansion, such events lead to hypoxia, adipocyte dysfunc-
tion and insulin resistance, that have systemic repercussions in the glu-
cose metabolism.
Supported by: FCT (Pest-C/SAU/UI3282/2011). Project DoIT –
Diamarker (QREN- COMPETE)
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Glycation and high-fat diet trigger distinct functional consequences
in the heart: an MRI study
P.Matafome1,2, J. Sereno3, J. Castelhano3, T. Rodrigues1, S. Gonçalves3,
C. Neves1, C. Marques4, R. Seiça1, M. Castelo-Branco3;
1Laboratory of Physiology, Institute of Biomedical Imaging and Life
Sciences (IBILI), Faculty of Medicine, University of Coimbra, 2Coimbra
Health School (ESTeSC), Department of Complementary Sciences,
Instituto Politécnico de Coimbra, 3Institute for Nuclear Sciences Applied
to Health (ICNAS), 4Center of Ophthalmology, IBILI, Faculty of Medi-
cine, University of Coimbra, Portugal.
Background and aims: Cardiovascular diseases are one of the main
consequences of obesity and type 2 diabetes. Among other factors, alter-
ations of lipid metabolism and glucotoxicity are known to be involved in
heart disease and decreased ability to adapt to an ischemic event. In the
past, we showed that glucose-derived methylglyoxal (MG) is able to
decrease the activation of survival pathways during heart ischemia, sim-
ilarly to diabetic rats. More, we observed that such effects were specifi-
cally inhibited by the dicarbonyl scavenger drug pyridoxamine. More-
over, we described that diabetic rats fed a high-fat diet showed impaired
response to ischemia. Thus, our goal was to investigate the mechanisms
of heart dysfunction in diabetes and obesity, using a magnetic resonance
imaging device specially designed for laboratory animals.
Materials and methods: Rats were maintained during 4 months with
MG supplementation (100 mg/Kg/day) (MG), a high-fat diet rich in tri-
glycerides (HFD) or both (HFDMG) and compared with controls feeding
a standard diet (n=6/ group). The effects of MG-induced glycation and a
high-fat diet regimen in several cardiac functional parameters were
assessed using magnetic resonance imaging (MRI).
Results: High-fat diet-fed rats (HFD group) showed no significant alter-
ations in heart function parameters, despite a trend to increased end-
diastolic volume and end-systolic volume and heart weight was observed.
On the other hand, accumulation of glycated products induced by MG
supplementation (MG group) resulted in decreased stroke volume and
cardiac output, as well as decreased peak filling rate. Interestingly, MG
supplementation to high-fat diet-fed rats (HFDMG group) produced
many of the functional consequences of MG and further decreased the
peak ejection rate.
Conclusion: Using magnetic resonance imaging, our results suggest that
moderate ventricular hypertrophy caused by the consumption of a high-
fat diet is not associated with impaired heart functional parameters. On the
other hand, the accumulation of MG-derived advanced glycation end
products impairs filling and ejection rates, conducing to decreased cardiac
output and stroke volume. This study sheds light on the mechanisms
governing heart failure in obesity and type 2 diabetes, which may con-
duce to better therapeutic approaches in the future.
Supported by: FCT (Pest-C/SAU/UI3282/2011). Project DoIT –
Diamarker (QREN- COMPETE)
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PAR2 is upregulated by adipocyte-derived factors and high fat diet in
the vascular wall
I. Indrakusuma, T. Romacho, J. Eckel;
Paul Langerhans Group for Integrative Physiology, German Diabetes
Center, Düsseldorf, Germany.
Background and aims: Obesity is associated with impaired vascular
function. However, the underlying mechanisms linking obesity and car-
diovascular diseases are not fully understood. Protease activated receptor-
2 (PAR2) is a G protein coupled receptor that can be activated by prote-
ases as well as other activating peptides. Under physiological conditions,
PAR2 exerts multiple functions such as controlling vascular tone and
coagulation. In pathological conditions, PAR2 is upregulated in athero-
sclerotic lesions and promotes vasoconstriction. However, little is known
about the impact of obesity on PAR2 in the vasculature. Our group has
recently proposed that the adipokine soluble DPP4 (sDPP4) acts as an
agonist for PAR2 leading to pro-atherogenic effects in human vascular
smooth muscle cells (SMC). Thus, we aimed to investigate the impact of
adipocyte-derived factors on the expression and function of PAR2 in the
context of obesity-related vascular dysfunction.
Materials and methods: SMC were treated with conditioned medium
(CM) from in vitro differentiated primary human adipocytes, IL-1β
(10 ng/ml) or YKL-40 (100 ng/ml) for 24 h. Additionally, a time course
with CM treatment was performed in SMC. In parallel, human coronary
artery endothelial cells (HCAEC) were incubated with CM for 4 h. Pro-
tein and mRNA expressionwere assessed byWestern Blot and qRT-PCR,
respectively. BrdU incorporation was analyzed to determine SMC prolif-
eration. Furthermore, C57BL/6 mice were fed with either a chow or a
60% high fat diet (HFD) for 24 weeks prior to isolation and subsequent
mRNA extraction from aortas. DPP4 activity of serum samples frommice
were analyzed with a DPP4 activity kit.
Results: We observed that CM treatment significantly enhanced PAR2
protein expression in both SMC and HCAEC (1.4-, 1.5- fold, respective-
ly). Interestingly, PAR2 mRNA level in SMC showed a peak (1.7 fold)
after 1 h of CM exposure. PAR2 protein level was increased in SMC by
the adipokines IL-1β (1.8 fold) or YKL-40 (1.4 fold). Moreover, CM
exerted a pro-atherogenic action on SMC since it promoted proliferation
at 24 h. This observation was a PAR2-specific effect abrogated in the
presence of the PAR2 antagonist GB83 (10 μM). In vivo, aortas of
HFD-fed mice expressed significantly more PAR2 mRNA (1.5 fold)
compared to aortas from lean mice. PAR2 upregulation in aortas was in
parallel with an increase in the enzymatic activity of DPP4 in the serum of
the animals treated with HFD (1.8 fold).
Conclusion: We showed that PAR2 is upregulated in two different vas-
cular cell types in response to CM and in response to specific adipocyte-
derived factors, leading to a pro-atherogenic effect. PAR2 expression
levels were also elevated by HFD in murine aortas. In conclusion, under
obesogenic conditions, where circulating levels of adipokines, such as IL-
1β, YKL40 or sDPP4, are elevated, PAR2 arises as an important player
linking obesity-related adipose tissue inflammation with atherogenesis.
Supported by: FP7-EU-Marie Curie-IEF (ADDIO-PIEF-2012-328793)
1208
Irisin improves endothelial function in obese mice through the
AMPK-eNOS pathway
X. Sun1, F. Han2, N. Hou1;
1Department of Endocrinology, 2Department of Pathology, Affiliated
Hospital of Weifang Medical University, China.
Background and aims: Irisin is a novel hormone secreted by myocytes
and has been proposed to mediate the beneficial effects of exercise on
metabolism. Some studies reported that circulating irisin levels were pos-
itively associated with endothelium-dependent vasodilation in obese
subjects and irisin may be involved in the regulation of endothelial func-
tion in obesity. Therefore, the objectives of this study were to explore
whether irisin could improve endothelial function in obesity.
Materials andmethods:C57BL/6mice were given chow or high fat diet
with or without treatment with irisin. Aortic endothelial function was
determined by measuring endothelium-dependent vasodilatation (EDV).
Nitric oxide (NO) in the aorta was determined. The effect of irisin on the
level of phosphorylation of AMP kinase (AMPK), Akt and endothelial
nitric-oxide synthase (eNOS) in endothelial cells were determined. Hu-
man umbilical vein endothelial cells (HUVECs) were used to study the
role of irisin on AMPK-eNOS pathway.
Results: Treatment of obese mice with irisin improved glucose and lipids
metabolism (glucose, 88.2±5.4 mg/dl vs 99.0±5.4 mg/dl; triglycerides,
83.54±12.60 mg/dl vs 124.54±16.83 mg/dl; NEFA 0.73±0.26 mmol/L
vs 1.09±0.22 mmol/L; P<0.01), reduced serum levels of TNF-α (20.34
±4.24 pg/ml vs 32.45±5.84 pg/ml, P<0.01), high sensitivity C-reactive
protein (1.47±0.55 vs 2.84±0.83 mg/L, P<0.01), malondialdehyde (3.16
±0.45 umol/L vs 5.33±0.72 umol/L, P<0.01) and increased serum
adiponectin levels (16.65±1.13 ug/ml vs 14.35±1.16 ug/ml, P<0.01).
Acetylcholine-stimulated EDVwas significantly lower in obese mice com-
pared with control mice (maximum vasodilatation rate, 39.01%±7.96% vs
82.31%±5.18%, P<0.05). Treatment of obese mice with irisin significant-
ly enhanced EDV and improved endothelial function (63.23%±7.97% vs
39.01%±7.96%, P<0.05). This beneficial effect of irisin was partly atten-
uated in the presence of compound C (AMPK inhibitor), API-2/triciribine
(Akt inhibitor) and L-NAME (eNOS inhibitor). Treatment of obese mice
with irisin enhanced NO production (19.40±3.20 umol/L vs 10.24±2.30
umol/mg, P<0.01), phosphorylation of AMPK, Akt and eNOS in endo-
thelial cells (P<0.05). Incubation of the HUVECs with irisin induced NO
production in a dose- dependent and time-dependent manner (P<0.05) and
also enhanced phosphorylation of AMPK, Akt and eNOS (P<0.05). Treat-
ment with L-NAME abolished irisin-induced NO production (P<0.05).
Suppression of AMPK expression by siRNA blocked irisin-induced Akt
and eNOS phosphorylation and abolished irisin-induced NO production
(92.40±12.30 umol/L vs 162.3±13.20 umol/L, P<0.01).
Conclusion: We have provided the first evidence that irisin improved
endothelial function in aortas of high-fat diet induced obese mice. The
mechanism for this protective effect is related to the activation of the
AMPK-eNOS signaling pathway.
Supported by: NSFC (NO. 81300688 and NO. 81400829).
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Olfactory-bulbar prokineticin-2 is involved in the regulation of food
intake and energy homeostasis, and proceeds through a GLP-1R
dependent mechanism
M. Mortreux1, N. Kassis1, R. Burcelin2, D.J. Drucker3, C. Magnan1, S.
Migrenne-Li1;
1University Paris Diderot CNRS UMR 8251, 2INSERM UMR 1048,
Toulouse, France, 3Mount Sinai Hospital Lunenfeld-Tanenbaum Re-
search Institute, Toronto, Canada.
Background and aims: Food intake is influenced by olfactory cues and
metabolic status can affect the olfactory function of animals and regulate
feeding behavior. Prokineticin-2 (PK2) is a hypothalamic anorectic neu-
ropeptide that is also highly expressed in the olfactory bulb (OB) as well
as GLP-1 receptor (GLP-1R). Our study was aimed to assess the role of
olfactory-bulbar PK2 in regulation of food intake and energetic homeo-
stasis, in relation with GLP-1R signaling pathway.
Materials and methods: To that end, expression of both PK2 and GLP-
1R mRNAwas measured in fed or fasted mice either under control diet
(CD) or high fat diet (HFD). In another serial, spontaneous food intake
was measured in fasted mice injected with recombinant PK2 (rPK2) +/-
Exendin9 (Ex9) in the OB.Energetic homeostasis was assessed after
5 weeks of down-regulation of OB-PK2 using a specific shRNA.
Diabetologia (2015) 58 (Suppl 1):S1–S607 S581
Results:We first evidenced that PK2 mRNA levels in the OB of C57Bl/
6j mice depend on both the nutritional (fed vs fasted) and the metabolic
(lean vs obese) status of the animal. Indeed, fasting resulted in a decrease
of PK2 mRNA in lean mice and a significant increase of PK2 mRNA in
obese mice. Moreover, we confirmed that GLP-1R mRNA was present
within the OB and increased by fasting. Injection of rPK2 in the OB
significantly decreased food intake during 24 h post-surgery compared
to control animals, in both mice fed with CD or HFD. Inhibitory effect of
rPK2 injected in the OBwas lost when Ex9 was co-infused. Additionally,
we injected rPK2 in the OB of GLP-1R-KO mice and could not detect
any anorectic effect. Moreover, a chronic down-regulation ofOB-PK2 led
to variations of GLP-1R mRNAs in both the OB and the HT, and also
altered energy homeostasis of animals.
Conclusion:We conclude that olfactory-bulbar PK2 reduces food intake
through a GLP-1R dependent mechanism.
Supported by: CORDDIM
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